P00001606T0076|0 10|Comparison
P00001606T0076|16 37|alkaline phosphatases
P00001606T0076|42 56|5-nucleotidase
P00008171T0000|14 21|aspects
P00008171T0000|34 52|hyperbilirubinemia
P00008997A0472|5 8|CSF
P00008997A0472|10 14|HCO3
P00008997A0472|31 39|function
P00008997A0472|43 51|CSF PCO2
P00008997A0472|56 60|data
P00008997A0472|75 79|rats
P00008997A0472|121 129|controls
P00008997A0472|169 174|slope
P00010943A0733|0 10|Flurazepam
P00010943A0733|52 56|drug
P00010943A0733|74 78|dose
P00010943A0733|83 86|use
P00010943A0733|98 106|practice
P00010943A0733|116 118|mg
P00010943A0733|122 127|night
P00012653T0045|0 4|Beta
P00012653T0045|14 20|agents
P00013683A0210|20 31|CO2 removal
P00013683A0210|45 59|CO2 production
P00013683A0210|61 65|VCO2
P00013683A0210|77 88|ventilation
P00015731A0090|12 26|administration
P00015731A0090|31 36|mg/kg
P00015731A0090|50 70|anhydrase inhibitors
P00015731A0090|72 85|acetazolamide
P00015731A0090|87 100|methazolamide
P00015731A0090|102 118|dichlorphenamide
P00015731A0090|120 129|sulthiame
P00015731A0090|158 162|rise
P00015731A0090|175 176|p
P00015731A0090|207 215|increase
P00015731A0090|219 220|p
P00015731A0090|228 233|p CO2
P00015731A0090|238 246|decrease
P00015731A0090|250 252|pH
P00015731A0090|265 270|blood
P00022143T0000|14 19|study
P00022143T0000|23 34|etoperidone
P00022143T0000|42 45|rat
P00022143T0000|50 56|rabbit
P00023348A0601|11 17|polyps
P00024600A0522|13 31|HMG dosage regimen
P00024600A0522|54 64|advantages
P00024600A0522|103 117|dosage regimen
P00025557A0100|9 20|CO2 content
P00025557A0100|34 35|%
P00025557A0100|40 47|animals
P00025557A0100|72 83|body weight
P00027739T0000|0 31|Serum gamma glutamyltransferase
P00027739T0000|39 48|diagnosis
P00027739T0000|52 65|liver disease
P00027739T0000|69 75|cattle
P00027967A0207|3 11|contrast
P00027967A0207|23 36|HI antibodies
P00027967A0207|66 71|onset
P00027967A0207|75 82|illness
P00027967A0207|97 105|patients
P00027967A0207|117 126|formation
P00027967A0207|149 159|antibodies
P00027967A0207|176 182|levels
P00027967A0207|192 196|days
P00027967A0207|203 208|onset
P00027967A0207|212 219|illness
P00029555A0861|9 18|exception
P00029555A0861|22 33|virus assay
P00029555A0861|38 50|quantitation
P00029555A0861|58 65|methods
P00029555A0861|122 157|shellfish microbiology laboratories
P00029953T0045|0 15|Characteristics
P00029953T0045|19 34|lipase activity
P00030183T0000|0 8|Takayasu
P00030183T0000|11 18|disease
P00030183T0000|20 31|association
P00030183T0000|37 43|HLA-B5
P00030937A0119|0 4|SGPT
P00030937A0119|6 10|SGOT
P00030937A0119|16 51|alkaline phosphatase concentrations
P00030937A0119|83 91|subjects
P00033873T0001|0 29|Gamma glutamyl transpeptidase
P00033873T0001|31 35|GGTP
P00033873T0001|37 45|activity
P00033873T0001|61 66|fluid
P00034935A0545|0 8|Patients
P00034935A0545|14 23|Parkinson
P00034935A0545|26 33|disease
P00034935A0545|59 68|incidence
P00034935A0545|72 81|psychoses
P00034935A0545|89 103|drug treatment
P00034935A0545|110 111|%
P00038408T0000|10 21|stimulation
P00038408T0000|33 52|alpha-autoreceptors
P00038408T0000|63 72|treatment
P00038408T0000|78 94|alpha-methyldopa
P00038408T0000|99 102|FLA
P00039271T0000|13 19|action
P00039271T0000|23 31|diazepam
P00039271T0000|55 66|application
P00039271T0000|74 77|rat
P00041512T0067|0 9|Abstracts
P00048373A0377|0 7|Removal
P00048373A0377|38 44|mucoas
P00048373A0377|72 79|absence
P00048373A0377|92 102|epithelium
P00050628A0202|3 6|IgG
P00050628A0202|18 28|gammopathy
P00050628A0202|48 53|serum
P00050628A0202|59 67|patients
P00050628A0202|85 96|proteinuria
P00050628A0202|112 119|patient
P00052597T0000|0 7|Studies
P00052597T0000|11 27|immunoglobulin E
P00052597T0000|33 39|impact
P00052597T0000|45 52|sojourn
P00052597T0000|58 74|Professor Dan H.
P00054900A0226|11 26|reaction stains
P00054900A0226|56 64|esterase
P00055040A0000|4 16|out-patients
P00055040A0000|22 41|pustulosis palmaris
P00055040A0000|81 99|immunofluorescence
P00055040A0000|105 114|technique
P00055040A0000|119 129|deposition
P00055040A0000|133 143|fibrinogen
P00055040A0000|159 179|degradation products
P00055040A0000|181 191|FR-antigen
P00055040A0000|220 224|skin
P00055040A0000|261 269|fraction
P00055040A0000|271 274|HPF
P00055040A0000|277 289|cryoglobulin
P00055040A0000|300 317|plasma fibrinogen
P00055040A0000|325 330|blood
P00056837A0000|7 24|mediastinoscopies
P00056837A0000|89 100|operability
P00056837A0000|116 125|carcinoma
P00056901A0308|2 9|mixture
P00056901A0308|19 26|albumin
P00056901A0308|28 29|%
P00056901A0308|34 54|hydroxy-ethyl-starch
P00056901A0308|69 77|solution
P00056901A0308|82 90|dilution
P00060529A0695|15 28|control group
P00060529A0695|33 49|acquisition-rate
P00060529A0695|87 98|0acteriuria
P00060529A0695|110 111|%
P00060529A0695|115 121|figure
P00060529A0695|137 147|percentage
P00060529A0695|151 156|women
P00060529A0695|172 191|practice population
P00060529A0695|203 207|year
P00060529A0695|252 256|A.B.
P00061478T0000|5 18|complications
P00061478T0000|22 37|catheterisation
P00061478T0000|54 63|nutrition
P00063680T0000|9 18|diagnosis
P00063680T0000|22 35|galactosaemia
P00064414A1098|0 5|Sings
P00064414A1098|42 56|erythropoiesis
P00066874T0000|24 54|fluid alpha fetoprotein levels
P00066874T0000|70 83|contamination
P00066874T0000|95 100|blood
P00066874T0000|102 109|results
P00066874T0000|116 126|experiment
P00072928T0000|0 14|Serum-ferritin
P00072928T0000|18 27|diagnosis
P00072928T0000|31 47|haemochromatosis
P00073344A0367|5 13|subjects
P00073344A0367|18 41|phytomitogen reactivity
P00073344A0367|49 60|lymphocytes
P00073344A0367|80 89|treatment
P00074758T0000|0 8|Patients
P00074758T0000|12 16|risk
P00074758T0000|20 34|hypothyroidism
P00083846T0000|0 7|Albumin
P00083846T0000|19 29|AMP levels
P00083846T0000|44 50|fluids
P00083846T0000|58 63|child
P00084275T0063|0 7|Preface
P00086313A0000|12 19|strains
P00086313A0000|23 35|Legionnaires
P00086313A0000|37 53|disease bacteria
P00086313A0000|102 108|groups
P00086313A0000|116 121|basis
P00086313A0000|125 133|findings
P00086313A0000|167 183|antibody testing
P00088391A0181|13 24|hand factor
P00088391A0181|28 36|activity
P00088391A0181|53 71|coumarin treatment
P00088391A0181|77 83|factor
P00088391A0181|87 94|antigen
P00089778A0000|4 17|concentration
P00089778A0000|21 42|alpha 2-macroglobulin
P00089778A0000|44 63|alpha 1-antitrypsin
P00089778A0000|65 76|plasminogen
P00089778A0000|78 91|C3-complement
P00089778A0000|93 124|fibrinogen degradation products
P00089778A0000|126 129|FDP
P00089778A0000|148 156|activity
P00089778A0000|186 192|humour
P00089778A0000|197 202|serum
P00089778A0000|213 221|patients
P00089778A0000|227 232|Fuchs
P00089778A0000|246 255|dystrophy
P00089778A0000|260 268|patients
P00089778A0000|295 303|cataract
P00089778A0000|342 359|cataract patients
P00092689A0352|7 8|%
P00092689A0352|16 24|patients
P00092689A0352|44 49|times
P00094639A0313|0 8|Prazosin
P00094639A0313|32 38|volume
P00094639A0313|50 58|patients
P00094639A0313|64 68|dose
P00094639A0313|82 84|mg
P00096241A0087|0 2|T4
P00096241A0087|7 11|FT4I
P00096241A0087|30 37|courses
P00096241A0087|46 52|groups
P00096241A0087|74 78|days
P00096241A0087|93 99|values
P00096241A0087|138 145|infants
P00096241A0087|155 160|weeks
P00096241A0087|162 165|EGA
P00096241A0087|174 186|term infants
P00096241A0087|188 189|P
P00097989A0106|15 23|analysis
P00097989A0106|27 42|treatment plans
P00097989A0106|50 58|patients
P00100540T0000|0 19|Aspirin intolerance
P00100540T0000|31 45|susceptibility
P00100540T0000|49 73|platelet cyclo-oxygenase
P00100540T0000|77 87|inhibition
P00100540T0000|91 98|aspirin
P00100791A0425|6 13|results
P00100791A0425|28 46|cynomolgus monkeys
P00100791A0425|101 115|rhesus monkeys
P00100791A0425|147 154|effects
P00100791A0425|158 168|norcocaine
P00101300A0257|3 8|cases
P00101300A0257|34 41|cancers
P00101300A0257|43 45|T1
P00101300A0257|47 49|T2
P00101300A0257|51 53|T3
P00101300A0257|55 57|N0
P00101300A0257|59 61|N1
P00101300A0257|77 85|followup
P00101300A0257|93 98|years
P00101300A0257|110 115|years
P00101300A0257|122 128|months
P00105401A0635|4 10|effect
P00105401A0635|14 17|CBZ
P00105401A0635|22 25|DPH
P00105401A0635|46 58|interference
P00105401A0635|64 87|thyroid hormone binding
P00105401A0635|91 94|TBG
P00105401A0635|144 158|clearance rate
P00105401A0635|162 178|thyroid hormones
P00105401A0635|199 210|maintenance
P00105401A0635|214 234|premedication levels
P00105401A0635|238 241|FT4
P00105401A0635|246 249|FT3
P00105903A0288|12 20|research
P00105903A0288|35 46|possibility
P00105903A0288|52 71|polyethylene glycol
P00105903A0288|77 80|PEG
P00111174A0351|30 40|properties
P00111174A0351|52 59|neurons
P00111174A0351|86 93|neurons
P00111174A0351|108 115|stimuli
P00111174A0351|125 129|eyes
P00111174A0351|135 142|neurons
P00111174A0351|171 178|stimuli
P00111174A0351|184 191|neurons
P00111174A0351|212 219|stimuli
P00112627A0542|0 13|Pentobarbital
P00112627A0542|34 39|mg/kg
P00112627A0542|60 71|combination
P00112627A0542|93 98|doses
P00112627A0542|102 115|normeperidine
P00112627A0542|122 127|mg/kg
P00112627A0542|130 141|anileridine
P00112627A0542|146 151|mg/kg
P00112627A0542|154 166|alphaprodine
P00112627A0542|171 176|mg/kg
P00112627A0542|183 191|fentanyl
P00112627A0542|197 202|mg/kg
P00113657A0628|0 7|Pb foil
P00113657A0628|14 19|gcm-2
P00113657A0628|47 58|improvement
P00114144A0189|32 37|study
P00114144A0189|67 82|result emphasis
P00114144A0189|102 112|hypotheses
P00114144A0189|136 148|similarities
P00114144A0189|154 158|Type
P00114144A0189|162 186|glycogen storage disease
P00114144A0189|188 196|Andersen
P00114144A0189|199 206|disease
P00114144A0189|258 271|enzyme defect
P00115974A0576|4 10|groups
P00115974A0576|42 46|maze
P00115974A0576|71 75|days
P00115974A0576|79 82|age
P00117748T0000|0 12|Erythromycin
P00117748T0000|17 39|clindamycin resistance
P00117748T0000|43 70|Corynebacterium diphtheriae
P00117748T0000|76 88|skin lesions
P00118044A0000|16 29|displacements
P00118044A0000|33 39|monkey
P00118044A0000|42 47|wrist
P00118044A0000|68 73|peaks
P00118044A0000|77 85|activity
P00118044A0000|87 95|terms M1
P00118044A0000|97 99|M2
P00118044A0000|105 113|M3 peaks
P00118044A0000|137 149|EMG activity
P00118044A0000|167 174|muscles
P00118810T0001|10 17|disease
P00119339A0400|8 14|animal
P00119339A0400|92 107|T. cruzi stocks
P00119339A0400|115 121|strain
P00119339A0400|144 155|myocarditis
P00119339A0400|171 183|degeneration
P00119339A0400|189 196|lesions
P00119339A0400|204 214|oesophagus
P00122718A0500|4 12|majority
P00122718A0500|16 25|MRF units
P00122718A0500|89 93|case
P00122718A0500|101 109|activity
P00122718A0500|141 149|behavior
P00129659T0000|0 11|Variability
P00129659T0000|19 23|Down
P00129659T0000|26 34|syndrome
P00129659T0000|36 46|trisomy-21
P00129659T0000|70 85|sex differences
P00129659T0000|89 92|IQs
P00130573T0054|0 3|VII
P00131739T0001|20 27|indices
P00131739T0001|40 51|populations
P00131739T0001|55 65|Uzbekistan
P00133214T0064|4 12|concepts
P00133214T0064|31 39|function
P00133214T0064|47 51|USSR
P00136175A1137|4 15|maintenance
P00136175A1137|50 57|density
P00136175A1137|77 83|amount
P00136175A1137|87 95|exercise
P00136175A1137|112 113|h
P00136175A1137|117 125|exercise
P00136175A1137|133 137|week
P00136175A1137|168 179|enlargement
P00136175A1137|183 186|ECA
P00137671A0896|6 18|observations
P00137671A0896|60 70|VIII-ratio
P00137671A0896|91 100|indicator
P00137671A0896|118 129|coagulation
P00139624A0318|6 11|hours
P00139624A0318|22 36|administration
P00139624A0318|40 50|colchicine
P00139624A0318|56 81|serum ceruloplasmin level
P00139624A0318|112 116|rats
P00139624A0318|134 138|rats
P00139827A0000|0 17|Radioimmunoassays
P00139827A0000|21 33|pregnenolone
P00139827A0000|35 47|progesterone
P00139827A0000|49 71|dehydroepiandrosterone
P00139827A0000|73 76|DHA
P00139827A0000|81 98|alpha-hydroxy-DHA
P00139827A0000|100 107|estriol
P00139827A0000|113 121|cortisol
P00139827A0000|142 147|total
P00139827A0000|155 157|ml
P00139827A0000|168 174|plasma
P00139827A0000|197 203|course
P00139827A0000|222 230|delivery
P00142718A0156|12 20|patients
P00142718A0156|49 56|changes
P00142718A0156|81 91|metastases
P00142718A0156|111 121|99mTc-EHDP
P00142718A0156|137 154|chest radiographs
P00146327A0147|4 12|majority
P00146327A0147|16 22|tumors
P00146327A0147|45 53|cavities
P00146327A0147|76 86|incidences
P00146327A0147|110 116|larynx
P00146327A0147|118 125|trachea
P00146327A0147|130 142|stem bronchi
P00149899T0001|0 10|Prediction
P00149899T0001|18 23|times
P00149899T0001|35 46|development
P00150066A0100|13 23|fibrinogen
P00150066A0100|39 50|coagulation
P00150066A0100|61 69|thrombin
P00150066A0554|18 30|haemorrhages
P00150066A0554|40 50|prostheses
P00154430A0906|4 22|Southern technique
P00154430A0906|41 53|localization
P00154430A0906|61 67|region
P00154430A0906|86 99|transcription
P00154430A0906|109 111|kb
P00154430A0906|126 134|fragment
P00155973A0387|29 35|limits
P00155973A0387|49 55|errors
P00155973A0387|65 66|%
P00155973A0387|95 101|system
P00155973A0387|140 168|carbon dioxide concentration
P00155973A0387|183 186|vol
P00155973A0387|187 188|%
P00155973A0387|206 220|gas flow rates
P00155973A0387|233 238|min-1
P00155973A0387|248 253|range
P00155973A0387|257 275|minute ventilation
P00155973A0387|285 290|min-1
P00159600A0871|0 2|SV
P00159600A0871|21 24|SHR
P00159600A0871|66 76|compliance
P00159600A0871|98 101|SHR
P00159600A0871|107 116|ventricle
P00159600A0871|146 151|shift
P00159600A0871|174 179|curve
P00163384A0000|4 11|carcass
P00163384A0000|30 33|owl
P00163384A0000|35 51|Bubo virginianus
P00163384A0000|96 103|Ontario
P00163384A0000|123 131|necropsy
P00167544A0067|10 14|ears
P00167544A0067|31 46|microdissection
P00167544A0067|75 82|regions
P00167544A0067|131 150|electron microscopy
P00167544A0067|185 211|surface specimen technique
P00168176A0000|0 7|Patulin
P00168176A0000|26 46|apple butter samples
P00168176A0000|52 65|ethyl acetate
P00168176A0000|74 81|extract
P00168176A0000|101 118|silica gel column
P00168176A0000|140 147|acetate
P00168176A0000|163 169|eluant
P00168431T0000|0 20|Steroid glucuronides
P00168431T0000|33 38|fluid
P00168431T0000|42 46|term
P00172199A0270|4 10|matrix
P00172199A0270|27 35|clusters
P00172199A0270|59 69|morphology
P00172199A0270|87 97|appearance
P00172199A0270|118 134|cross striations
P00173860A0475|0 10|Riboflavin
P00173860A0475|30 40|percentage
P00173860A0475|62 69|animals
P00173860A0475|92 110|excretion patterns
P00173860A0475|133 142|magnitude
P00173860A0475|150 162|disturbances
P00173860A0475|166 177|elimination
P00173860A0475|207 212|acids
P00176742T0000|0 11|Polyglactin
P00176742T0000|16 33|suture absorption
P00176742T0000|42 46|role
P00176742T0000|59 66|enzymes
P00183063A0300|4 13|incidence
P00183063A0300|17 31|DNCB reactions
P00183063A0300|43 47|cent
P00183063A0300|52 57|Stage
P00183063A0300|67 74|cancers
P00183063A0300|79 87|patinets
P00183063A0300|97 101|cent
P00183063A0300|117 122|Stage
P00183063A0300|127 133|cancer
P00183063A0300|138 146|patients
P00183063A0300|160 164|cent
P00183063A0300|168 176|patients
P00183063A0300|209 214|Stage
P00183063A0300|219 225|cancer
P00188387A0975|0 7|Studies
P00188387A0975|11 23|lipoproteins
P00188387A0975|52 60|children
P00188387A0975|66 74|families
P00188387A0975|89 91|FH
P00188387A0975|110 123|heart disease
P00193088A0196|21 29|subjects
P00193088A0196|37 38|g
P00193088A0196|42 52|Metyrapone
P00193088A0196|62 71|responses
P00193587T0000|0 15|EEG theta waves
P00193587T0000|34 43|phenomena
P00193587T0000|47 53|review
P00193587T0000|58 66|analysis
P00196255A0000|0 17|REM dream content
P00196255A0000|33 43|categories
P00196255A0000|71 80|influence
P00196255A0000|93 103|hemisphere
P00196255A0000|116 119|ego
P00196255A0000|133 146|verbalization
P00196255A0000|161 171|hemisphere
P00196255A0000|179 184|music
P00196255A0000|194 202|salience
P00196255A0000|204 215|bizarreness
P00198510T0000|0 11|Innervation
P00198510T0000|27 36|diaphragm
P00198510T0000|44 50|locust
P00198510T0000|52 70|Locusta migratoria
P00199012T0000|8 21|ACTH syndrome
P00199012T0000|36 53|thyroid carcinoma
P00201881A0487|11 18|finding
P00201881A0487|33 40|studies
P00201881A0487|56 67|correlation
P00201881A0487|76 83|PI ACTH
P00201881A0487|88 100|MSH contents
P00205074A0000|8 24|hypophosphatemia
P00205074A0000|44 48|type
P00205074A0000|64 71|rickets
P00209664A0836|13 24|correlation
P00209664A0836|33 41|serum LH
P00209664A0836|63 71|bone age
P00209664A0836|80 89|age group
P00209664A0836|115 126|correlation
P00209664A0836|159 177|parallel phenomena
P00210220X0000|10 24|neurochemistry
P00210220X0000|38 43|drugs
P00211881A0602|0 7|Efforts
P00211881A0602|35 41|amount
P00211881A0602|45 49|time
P00211881A0602|63 77|kidney lesions
P00211881A0602|134 138|site
P00211881A0602|142 148|action
P00211881A0602|152 155|PBB
P00216939T0001|0 6|Effect
P00216939T0001|10 18|succimer
P00216939T0001|26 35|intensity
P00216939T0001|53 81|acid dehydrogenase reactions
P00216939T0001|89 94|brain
P00216939T0001|98 102|rats
P00216939T0001|126 134|chloride
P00219533T0001|0 12|Distribution
P00219533T0001|17 29|correlations
P00219533T0001|33 48|serum uric-acid
P00219533T0001|69 80|populations
P00219533T0001|89 92|men
P00219533T0001|103 108|women
P00219565A0172|4 13|incidence
P00219565A0172|17 36|hepatitis B antigen
P00219565A0172|47 58|transfusion
P00219565A0172|77 81|cent
P00219674A0000|0 14|Technetium-99m
P00219674A0000|24 37|pyrophosphate
P00219674A0000|49 60|scintigrams
P00219674A0000|100 108|patients
P00219674A0000|123 128|weeks
P00219674A0000|130 135|range
P00219674A0000|169 179|infarction
P00221136A0984|10 20|phenomenon
P00221136A0984|48 54|humans
P00221725A0523|4 11|decline
P00221725A0523|19 27|activity
P00221725A0523|31 49|cytochrome oxidase
P00221725A0523|51 61|peroxidase
P00221725A0523|73 86|lipid content
P00221725A0523|101 112|neutrophils
P00221725A0523|131 139|decrease
P00221725A0523|158 166|activity
P00222102A0227|0 9|Treatment
P00222102A0227|15 23|patients
P00222102A0227|29 58|pseudohypoparathyroidism type
P00222102A0227|66 77|vitamin-D-3
P00222102A0227|84 112|alpha-Hydroxycholecalciferol
P00222102A0227|152 160|response
P00222102A0227|166 172|regard
P00222102A0227|180 193|normalisation
P00222102A0227|197 210|serum-calcium
P00222827A0000|0 7|Workers
P00222827A0000|14 25|sensitivity
P00222827A0000|38 50|diisocyanate
P00222827A0000|52 55|TDI
P00222827A0000|68 73|depth
P00222827A0000|80 87|attempt
P00222827A0000|101 111|mechanisms
P00222827A0000|125 140|hyperreactivity
P00224013A0661|6 9|VO2
P00224013A0661|32 38|groups
P00224013A0661|53 60|hypoxia
P00224013A0661|65 73|limb VO2
P00224013A0661|107 112|group
P00224013A0661|114 124|beta-Block
P00224013A0661|139 143|fall
P00224013A0661|157 161|limb
P00224013A0661|173 183|resistance
P00224013A0661|199 206|hypoxia
P00224013A0661|257 268|utilization
P00224013A0661|281 289|delivery
P00224013A0661|303 307|limb
P00224013A0661|311 321|comparison
P00224013A0661|335 339|body
P00224013A0661|353 370|extraction ratios
P00224013A0661|391 399|pressure
P00224013A0661|401 427|beta-Vasodilator receptors
P00224013A0661|455 459|part
P00224013A0661|467 481|vasodilatation
P00224013A0661|501 508|hypoxia
P00225352T0000|22 33|alterations
P00225352T0000|41 51|metabolism
P00225352T0000|56 58|3H
P00225352T0000|59 69|vitamin D3
P00225352T0000|95 104|rat liver
P00227393T0000|0 10|Modulation
P00227393T0000|14 49|25-hydroxyvitamin D3-24-hydroxylase
P00227393T0000|53 66|aminophylline
P00227393T0000|70 107|cytochrome P-450 monooxygenase system
P00227610A1593|14 22|respects
P00227610A1593|37 45|DBP mRNA
P00227610A1593|65 75|messengers
P00227610A1593|79 83|SV40
P00227610A1593|88 103|polyoma viruses
P00231555T0001|0 6|Effect
P00231555T0001|50 67|combination drugs
P00231555T0001|82 86|ACTH
P00231555T0001|91 110|cortisol production
P00232354A0286|0 10|Serum ACTH
P00232354A0286|30 37|insulin
P00232354A0286|42 52|metyrapone
P00232456T0000|0 7|Anatomy
P00232456T0000|15 18|RNA
P00232456T0000|23 36|gene products
P00232456T0000|40 44|MC29
P00232456T0000|49 52|MH2
P00232456T0000|74 87|tumor viruses
P00232456T0000|102 110|leukemia
P00232456T0000|115 124|carcinoma
P00232456T0000|126 134|evidence
P00232456T0000|145 150|class
P00232456T0000|167 172|genes
P00234206T0000|0 8|Bertioga
P00234206T0000|10 21|Guama group
P00234206T0000|27 34|Anhembi
P00234206T0000|36 52|Bunyamwera group
P00234206T0000|63 74|arboviruses
P00234206T0000|87 96|Sao Paulo
P00234206T0000|98 104|Brazil
P00234264A0164|0 38|Gamma glutamyl transpeptidase activity
P00234264A0164|62 67|times
P00234264A0164|91 96|limit
P00234264A0164|100 108|children
P00234264A0164|123 134|aminopyrine
P00234264A0164|143 148|weeks
P00234626T0036|0 3|XXI
P00239014A0000|29 35|method
P00239014A0000|44 57|determination
P00239014A0000|88 92|CPIB
P00239014A0000|94 98|acid
P00239014A0000|102 114|blood plasma
P00239169T0000|0 26|Dopamine receptor blockade
P00239169T0000|35 47|neuroleptics
P00239169T0000|68 73|study
P00240016T0033|0 2|V.
P00240518A0000|21 30|procedure
P00240518A0000|39 52|determination
P00240518A0000|60 86|fungicide 5-fluorocytosine
P00240518A0000|90 95|serum
P00242427T0001|5 10|field
P00242427T0001|14 20|stress
P00242427T0001|41 46|nurse
P00254537T0000|7 16|graduates
P00254537T0000|30 35|types
P00254537T0000|39 47|programs
P00254537T0000|59 71|state boards
P00261981A0434|20 39|serum somatomedin A
P00261981A0434|69 73|rats
P00261981A0434|88 95|litters
P00264240A1843|4 13|sequences
P00264240A1843|28 46|X. borealis oocyte
P00264240A1843|59 67|5S genes
P00264240A1843|104 112|residues
P00264240A1843|137 147|T clusters
P00264240A1843|175 181|region
P00264240A1843|185 208|X. laevis oocyte 5S DNA
P00265964A0562|5 14|mechanism
P00265964A0562|42 56|grain boundary
P00267764A0651|5 11|report
P00267764A0651|37 44|reasons
P00267764A0651|49 67|treatment failures
P00267764A0651|88 98|philosophy
P00267764A0651|109 119|management
P00294502T0001|0 9|Diagnosis
P00294502T0001|14 32|treatment planning
P00294502T0001|36 44|Class II
P00294502T0001|46 54|division
P00300314A0132|19 29|infections
P00300314A0132|31 36|fever
P00300314A0132|65 88|degrees F. granulocytes
P00300314A0132|105 107|mm
P00300314A0132|115 130|hospitalization
P00300314A0132|138 148|drug death
P00300314A0132|164 172|patients
P00300314A0132|179 197|calcium leucovorin
P00300314A0132|208 213|mg/m2
P00300314A0132|234 238|days
P00300314A0132|245 257|methotrexate
P00300314A0132|272 288|treatment cycles
P00303189A0247|18 21|way
P00303189A0247|31 36|drugs
P00303189A0247|46 53|patient
P00303189A0247|56 71|serum chemistry
P00303189A0247|98 106|efficacy
P00303189A0247|148 155|process
P00304240A0369|22 27|tests
P00304240A0369|51 59|presence
P00304240A0369|77 84|disease
P00304310A0000|4 13|end-stage
P00304310A0000|30 35|phase
P00304310A0000|62 73|retinopathy
P00304310A0000|88 101|stabilization
P00304310A0000|105 111|vision
P00304310A0000|121 128|periods
P00304310A0000|132 136|time
P00304806A0760|7 12|basis
P00304806A0760|16 43|serum alpha1AT quantitation
P00304806A0760|53 60|infants
P00304806A0760|87 93|groups
P00304806A0760|125 139|concentrations
P00304806A0760|159 162|mg%
P00313766A0666|3 11|patients
P00313766A0666|63 73|depression
P00313766A0666|77 85|function
P00313766A0666|95 96|%
P00313766A0666|100 107|control
P00313766A0666|109 114|range
P00313766A0666|122 123|%
P00313766A0666|125 126|p
P00316723A0558|0 7|Changes
P00316723A0558|11 22|body weight
P00316723A0558|37 45|behavior
P00321261A0104|12 20|response
P00321261A0104|24 40|prostaglandin E2
P00321261A0104|42 46|PGE2
P00321261A0104|52 73|prostaglandin F2alpha
P00321261A0104|120 126|routes
P00321261A0104|159 165|phases
P00321261A0104|183 188|cycle
P00321261A0104|220 225|women
P00330364A0132|2 7|total
P00330364A0132|14 25|BCG strains
P00330364A0132|55 62|strains
P00330364A0132|78 86|cultures
P00330364A0132|90 93|BCG
P00330364A0132|107 112|batch
P00330364A0132|116 123|strains
P00330364A0132|138 147|abscesses
P00330364A0132|151 159|children
P00330364A0132|166 181|BCG-vaccination
P00330364A0132|188 195|strains
P00330364A0132|207 212|cases
P00330364A0132|219 234|BCG-vaccination
P00330364A0132|243 250|strains
P00330364A0132|273 285|laboratories
P00331128A0000|5 11|levels
P00331128A0000|15 31|serum calcitonin
P00331128A0000|46 54|patients
P00331128A0000|74 81|failure
P00331936T0000|0 9|Detection
P00331936T0000|29 39|antibodies
P00331936T0000|50 87|immunoperoxidase antiglobulin technic
P00336354A0543|4 12|response
P00336354A0543|16 24|serum GH
P00336354A0543|28 45|arginine infusion
P00336354A0543|88 100|hypoglycemia
P00336547A0000|4 18|mortality rate
P00336547A0000|41 49|features
P00336547A0000|53 72|Nocardia asteroides
P00336547A0000|77 109|Nocardia brasiliensis infections
P00336547A0000|141 145|mice
P00336547A0000|149 152|ICR
P00336547A0000|157 171|C3H/eB origins
P00336547A0000|228 232|mice
P00336547A0000|250 263|mouse strains
P00336547A0000|273 282|C57/BL/6J
P00336547A0000|284 301|New Zealand Black
P00336547A0000|303 309|BALB/c
P00336547A0000|311 318|CBA/LAC
P00336547A0000|324 330|C3H/eB
P00337102T0058|0 8|Williams
P00337102T0058|12 18|August
P00339289T0049|0 3|Use
P00339289T0049|19 27|isotopes
P00339289T0049|35 44|chemistry
P00339289T0049|48 56|proteins
P00340692T0033|1 9|Emeritus
P00340692T0033|11 42|John Henri Roosegaarde Bisschop
P00342623A0228|10 18|vaccines
P00342623A0228|23 43|whole-virus vaccines
P00342623A0228|55 69|type B antigen
P00342623A0228|101 111|reactivity
P00350465T0000|10 19|diagnosis
P00350465T0000|38 47|disorders
P00352569A0000|8 21|oxygen supply
P00352569A0000|35 51|blood parameters
P00352569A0000|81 86|rates
P00352569A0000|100 105|mg/kg
P00352569A0000|123 132|endotoxin
P00354315T0000|8 19|dysfunction
P00354315T0000|23 31|patients
P00354315T0000|37 58|ataxia telangiectasia
P00358945A0225|12 18|period
P00358945A0225|22 31|treatment
P00358945A0225|83 88|weeks
P00361059T0000|2 7|study
P00361059T0000|27 35|efficacy
P00361059T0000|39 62|diflucortolone valerate
P00361059T0000|66 76|% ointment
P00361059T0000|81 102|clobetasol propionate
P00361059T0000|107 117|% ointment
P00361340A0529|12 21|phenomena
P00361340A0529|35 49|osteodystrophy
P00361340A0529|76 96|vitamin D deficiency
P00361340A0529|109 118|condition
P00361340A0529|120 130|deficiency
P00361340A0529|134 163|1,25-dihydroxycholecalciferol
P00361340A0529|182 194|significance
P00361340A0529|216 235|hyperparathyroidism
P00361340A0529|245 252|failure
P00369397A0280|6 9|FSH
P00369397A0280|14 23|LH levels
P00369397A0280|52 59|addicts
P00369397A0280|67 83|GnRH stimulation
P00369397A0280|88 95|addicts
P00369397A0280|97 100|FSH
P00369397A0280|105 114|LH values
P00369397A0280|159 167|controls
P00369683T0000|0 10|Adriamycin
P00369683T0000|12 22|comparison
P00369683T0000|35 43|schedule
P00369683T0000|58 66|schedule
P00369683T0000|74 83|treatment
P00369683T0000|87 100|breast cancer
P00377466A0188|10 18|controls
P00377466A0188|34 41|hormone
P00377466A0188|43 45|LH
P00377466A0188|48 76|follicle stimulating hormone
P00377466A0188|78 81|FSH
P00377466A0188|84 93|prolactin
P00377466A0188|95 99|HPRL
P00377466A0188|102 112|oestradiol
P00377466A0188|114 116|E2
P00377466A0188|119 131|progesterone
P00377466A0188|133 134|P
P00377466A0188|140 152|testosterone
P00377466A0188|154 155|T
P00377466A0188|164 173|catabolic
P00377466A0188|178 191|healing phase
P00377466A0188|200 207|disease
P00378492A0475|0 13|Renin studies
P00378492A0475|43 51|patients
P00378492A0475|61 74|control group
P00378492A0475|81 91|recipients
P00378492A0475|104 113|elevation
P00378492A0475|117 138|plasma renin activity
P00378492A0475|146 170|plasma aldosterone level
P00378492A0475|237 252|artery stenosis
P00378735A0000|22 27|trial
P00378735A0000|47 55|patients
P00378735A0000|79 84|fever
P00378735A0000|96 101|blood
P00378735A0000|106 120|marrow culture
P00378735A0000|134 145|amoxycillin
P00378735A0000|151 166|dosage schedule
P00378735A0000|172 173|g
P00378735A0000|203 207|days
P00378735A0000|224 239|chloramphenicol
P00378735A0000|245 251|regard
P00378735A0000|268 288|temperature response
P00378735A0000|296 303|respect
P00378735A0000|307 315|carriers
P00378735A0000|320 333|relapse rates
P00381783T0000|0 32|Bone marrow transplantation-1979
P00383169A0000|8 15|article
P00383169A0000|30 37|actions
P00383169A0000|55 72|dopamine receptor
P00383169A0000|85 91|agents
P00383169A0000|93 104|apomorphine
P00383169A0000|113 124|derivatives
P00383169A0000|126 135|piribedil
P00383169A0000|137 158|rye-ergot derivatives
P00383169A0000|181 186|basis
P00383169A0000|228 238|properties
P00384744T0000|26 38|hypofunction
P00385457A0187|10 20|inhibition
P00385457A0187|24 30|pepsin
P00385457A0187|48 53|juice
P00385457A0187|86 95|influence
P00385457A0187|103 110|healing
P00385457A0187|123 128|ulcer
P00386251A0899|4 23|IDF standard method
P00386251A0899|32 41|detection
P00386251A0899|45 55|penicillin
P00386251A0899|59 63|milk
P00386251A0899|88 97|detection
P00386251A0899|101 122|sulphonamide residues
P00386251A0899|126 130|milk
P00390932T0001|9 17|antigens
P00393598A0198|4 10|course
P00393598A0198|14 29|endotoxin fever
P00393598A0198|55 58|ALS
P00397806T0039|6 20|Algerian cases
P00401521A0138|12 19|percent
P00401521A0138|23 31|patients
P00401521A0138|45 56|ticarcillin
P00401676A0414|20 27|staging
P00401676A0414|39 47|patients
P00401676A0414|81 93|radiotherapy
P00406585T0001|9 19|hematology
P00406585T0001|27 30|age
P00409927A0570|0 8|Neomycin
P00409927A0570|37 50|staphylococci
P00409927A0570|75 87|streptococci
P00409927A0570|143 152|organisms
P00411465A0142|34 41|section
P00411465A0142|52 56|cent
P00411465A0142|64 74|trabeculae
P00411465A0142|83 90|contact
P00411465A0142|105 113|cavities
P00413854A0958|0 7|Changes
P00413854A0958|11 22|tissue PCO2
P00413854A0958|103 108|blood
P00414575T0000|11 21|evaluation
P00414575T0000|31 38|calculi
P00415543A0320|0 11|Recognition
P00415543A0320|15 24|emphysema
P00415543A0320|39 50|radiographs
P00415543A0320|65 72|quality
P00415543A0320|104 109|films
P00415543A0320|113 118|films
P00415543A0320|124 132|patients
P00415543A0320|155 167|lung disease
P00416758T0001|0 9|Isolation
P00416758T0001|13 33|T. gambiense strains
P00416758T0001|37 42|Zaire
P00416758T0001|53 63|adaptation
P00416758T0001|67 85|laboratory animals
P00417166T0000|16 23|profile
P00417166T0000|27 37|clonazepam
P00417166T0000|41 55|rhesus monkeys
P00417301T0001|12 22|mechanisms
P00417301T0001|34 45|brucellosis
P00417301T0001|49 55|humans
P00418341T0000|11 21|adaptation
P00418341T0000|36 41|parts
P00420460A0291|3 11|patients
P00420460A0291|41 55|drug treatment
P00420460A0291|57 91|log baseline plasma renin activity
P00420460A0291|96 102|change
P00420460A0291|111 125|blood pressure
P00420460A0291|132 134|SQ
P00420460A0291|167 168|r
P00420460A0291|178 179|P
P00423649A0259|6 16|techniques
P00423649A0259|40 46|people
P00423649A0259|56 61|years
P00423649A0259|69 74|claim
P00423649A0259|97 107|innovation
P00423649A0259|116 122|regard
P00425547A0000|3 11|patients
P00425547A0000|25 38|osteomyelitis
P00425547A0000|56 58|os
P00425547A0000|104 114|cephalexin
P00425547A0000|130 135|weeks
P00427715A0000|2 7|total
P00427715A0000|14 22|patients
P00427715A0000|28 35|Hodgkin
P00427715A0000|38 45|disease
P00427715A0000|67 76|diaphragm
P00427715A0000|78 84|Stages
P00427715A0000|101 102|B
P00427715A0000|122 139|radiation therapy
P00427715A0000|153 163|University
P00427715A0000|167 174|Florida
P00429151T0000|0 4|Year
P00429151T0000|30 42|practitioner
P00429151T0000|51 55|unit
P00429151T0000|71 83|Glasgow area
P00429893A0000|24 29|array
P00429893A0000|34 46|round window
P00429893A0000|56 68|implantation
P00429893A0000|91 97|system
P00429893A0000|115 117|mm
P00429893A0000|128 141|scala tympani
P00429893A0000|149 156|minimum
P00429893A0000|160 166|trauma
P00429893A0000|195 206|stimulation
P00429949A0000|21 46|World Health Organization
P00429949A0000|52 68|Expert Committee
P00429949A0000|72 98|Biological Standardization
P00429949A0000|104 115|preparation
P00429949A0000|125 134|prolactin
P00429949A0000|138 146|ampoules
P00429949A0000|188 223|International Reference Preparation
P00429949A0000|225 228|IRP
P00429949A0000|239 248|prolactin
P00429949A0000|253 264|immunoassay
P00430889T0001|16 24|fistulas
P00431832T0001|0 18|Plasma ion changes
P00431832T0001|29 34|blood
P00431832T0001|50 72|beta receptor blockers
P00432615A0541|12 23|differences
P00432615A0541|54 64|literature
P00432615A0541|66 88|heterophile antibodies
P00432615A0541|104 117|gammaglobulin
P00432615A0541|154 166|interference
P00432615A0541|174 189|Sephadex system
P00432615A0541|193 197|RIST
P00435187T0000|17 30|flowers bloom
P00437749A0242|8 28|treatment modalities
P00437749A0242|49 56|context
P00437749A0242|64 74|psychology
P00437749A0242|90 100|physiology
P00437749A0242|123 127|pain
P00439618T0001|0 17|Lethal Tachmalcor
P00439618T0001|25 39|diethylamino-2
P00439618T0001|41 54|hydroxypropyl
P00439618T0001|56 64|ajmaline
P00439618T0001|66 75|poisoning
P00439618T0001|79 88|childhood
P00439716T0001|21 31|evaluation
P00439716T0001|35 54|blood flow velocity
P00439716T0001|75 82|fistula
P00445259T0000|0 28|Serum ferritin concentration
P00445259T0000|33 56|bone marrow iron stores
P00445720A0263|13 30|pressure gradient
P00445720A0263|32 35|SPG
P00445720A0263|54 63|ventricle
P00445720A0263|65 67|LV
P00445720A0263|78 84|atrium
P00445720A0263|86 88|LA
P00445720A0263|108 142|high-fidelity pressure transducers
P00450367T0000|14 19|trail
P00450367T0000|30 42|hysterectomy
P00450367T0000|44 56|hysterectomy
P00450367T0000|70 76|radium
P00450367T0000|90 96|radium
P00450367T0000|102 114|hysterectomy
P00450367T0000|118 123|stage
P00450367T0000|138 147|carcinoma
P00450559A0269|7 12|basis
P00450559A0269|18 25|patient
P00450559A0269|28 34|report
P00450559A0269|53 62|Clinitemp
P00450559A0269|96 104|accuracy
P00450559A0269|113 124|thermometer
P00450760T0001|0 16|Cryoglobulinemia
P00450760T0001|20 27|Raynaud
P00450760T0001|30 38|syndrome
P00451192A0248|0 4|Data
P00451192A0248|42 58|computer program
P00451192A0248|93 98|curve
P00451192A0248|116 137|LV region-of-interest
P00453780A0430|17 35|serum IgA response
P00453780A0430|52 70|patient population
P00453780A0430|115 121|tissue
P00453780A0430|138 142|lung
P00453780A0430|159 165|source
P00453780A0430|181 184|IgA
P00454780A0340|0 19|Ultimate strengthes
P00454780A0340|43 61|cast cobalt alloys
P00454780A0340|71 86|titanium alloys
P00454780A0340|96 98|Ta
P00454780A0340|101 102|V
P00454780A0340|122 135|fatigue limit
P00454780A0340|142 151|corrosion
P00456424A0000|4 11|effects
P00456424A0000|30 39|injection
P00456424A0000|41 47|i.c.i.
P00456424A0000|52 61|clonidine
P00456424A0000|65 79|microgram kg-1
P00456424A0000|84 98|blood pressure
P00456424A0000|103 113|heart rate
P00456424A0000|140 147|rabbits
P00456424A0000|166 174|catheter
P00456424A0000|182 196|cisterna magna
P00463973A0000|0 15|Platelet number
P00463973A0000|20 29|life span
P00463973A0000|58 67|trimester
P00463973A0000|71 80|pregnancy
P00463973A0000|87 92|women
P00463973A0000|137 140|age
P00463973A0000|142 145|SGA
P00463973A0000|147 154|infants
P00463973A0000|165 170|women
P00463973A0000|176 183|infants
P00463973A0000|198 211|birth weights
P00464387A1185|7 19|measurements
P00464387A1185|29 38|serum IgE
P00464387A1185|62 67|index
P00464387A1185|71 87|disease activity
P00464387A1185|91 95|ABPA
P00465223A0373|9 17|patients
P00465223A0373|22 41|difference betweent
P00465223A0373|60 66|values
P00465223A0373|70 78|delta PU
P00465223A0373|83 91|delta PM
P00465223A0373|112 114|SD
P00465223A0373|116 120|mmHg
P00465681A0000|2 6|rise
P00465681A0000|10 34|hemoglobin concentration
P00465681A0000|53 61|increase
P00465681A0000|75 79|iron
P00465681A0000|87 98|blood serum
P00465681A0000|108 112|mice
P00465681A0000|129 144|oxygen pressure
P00465681A0000|150 153|atm
P00465681A0000|161 165|hour
P00465681A0000|181 186|state
P00465681A0000|194 197|atm
P00465681A0000|210 215|state
P00465829T0000|0 6|Nernst
P00465829T0000|8 31|Planck analog equations
P00465829T0000|47 61|state membrane
P00465829T0000|71 81|potentials
P00473229T0000|0 7|Effects
P00473229T0000|11 29|methylene chloride
P00473229T0000|31 46|trichloroethane
P00473229T0000|48 65|trichloroethylene
P00473229T0000|67 86|tetrachloroethylene
P00473229T0000|91 98|toluene
P00473229T0000|106 117|development
P00473229T0000|121 134|chick embryos
P00473249T0000|0 6|Effect
P00473249T0000|27 41|administration
P00473249T0000|45 59|streptolysin O
P00473249T0000|67 87|electroencephalogram
P00473249T0000|91 98|rabbits
P00474064A0205|8 17|situation
P00474064A0205|22 42|convlusion threshold
P00474064A0205|53 63|substances
P00474064A0205|79 88|pethidine
P00474064A0205|92 104|mg.kg-1 I.V.
P00474064A0205|106 117|piritramide
P00474064A0205|122 130|morphine
P00474064A0205|136 149|phenoperidine
P00474064A0205|153 154|R
P00474064A0205|165 173|fentanyl
P00474064A0205|177 187|sufentanil
P00474064A0205|194 195|R
P00474064A0205|214 218|I.V.
P00476020T0000|4 16|biochemistry
P00476020T0000|29 34|fluid
P00476020T0000|51 57|growth
P00476572A0139|26 32|lesion
P00476572A0139|109 114|cases
P00476572A0139|132 144|radiodensity
P00476572A0139|148 153|cases
P00477794T0000|0 7|Effects
P00477794T0000|30 40|tractotomy
P00477794T0000|48 65|response patterns
P00477794T0000|69 76|neurons
P00477794T0000|95 113|nuclei principalis
P00477794T0000|118 124|oralis
P00478714T0000|0 8|Efficacy
P00478714T0000|40 65|alcohol treatment program
P00479222A0682|0 10|Resistance
P00479222A0682|40 51|environment
P00479222A0682|75 84|retention
P00479222A0682|99 109|properties
P00479222A0682|116 131|immersion times
P00479222A0682|156 161|fluid
P00479222A0682|163 167|PECF
P00479222A0682|175 184|degrees C
P00479222A0682|206 211|years
P00479246T0000|31 44|osteomyelitis
P00481612A1121|28 37|receptors
P00481612A1121|68 77|ventricle
P00481612A1121|118 124|action
P00481612A1121|128 136|fentanyl
P00483716A0366|3 7|case
P00483716A0366|48 55|carotid
P00483716A0366|67 81|carotid artery
P00483716A0366|114 125|anastomosis
P00484177A0242|5 15|expression
P00484177A0242|31 51|laminar flow regimen
P00484177A0242|59 69|expiration
P00484177A0242|90 98|CT value
P00484177A0242|108 113|range
P00484177A0242|117 120|VT.
P00485615A0935|6 10|data
P00485615A0935|23 32|existence
P00485615A0935|59 65|crisis
P00485615A0935|80 86|entity
P00485615A0935|106 116|importance
P00485615A0935|137 145|syndrome
P00485615A0935|149 154|order
P00485615A0935|168 178|occurrence
P00485615A0935|188 200|pancreatitis
P00485615A0935|209 220|performance
P00485615A0935|260 267|surgery
P00488534A0308|3 11|addition
P00488534A0308|26 56|Treatment X Strain interaction
P00488534A0308|79 97|defecation numbers
P00488534A0308|132 139|MR rats
P00488534A0308|172 179|MR rats
P00490336A0181|6 25|conduction velocity
P00490336A0181|51 56|m/sec
P00490336A0181|58 65|group C
P00493818A0422|4 12|failures
P00493818A0422|40 59|patient intolerance
P00493818A0422|79 82|fit
P00493818A0422|113 117|days
P00493818A0422|131 137|months
P00493818A0422|144 153|insertion
P00494659A0391|18 29|metabolites
P00494659A0391|38 53|3-carboxyphenyl
P00494659A0391|57 86|hydroxymethyl-2-oxazolidinone
P00494659A0391|93 104|glucuronide
P00494659A0391|108 118|toloxatone
P00495097A0663|6 21|characteristics
P00495097A0663|47 55|activity
P00495097A0663|71 86|fiber synthesis
P00495097A0663|95 101|matrix
P00495097A0663|117 123|tissue
P00497494A0112|4 15|ventilation
P00497494A0112|38 43|PACO2
P00499588T0000|0 23|Carbohydrate metabolism
P00499588T0000|32 45|semen profile
P00499588T0000|47 54|glucose
P00499588T0000|56 63|insulin
P00499588T0000|69 82|sperm studies
P00503336A0285|21 25|CAEC
P00503336A0285|37 39|CC
P00503336A0285|44 48|CIEC
P00503336A0285|58 65|attacks
P00503336A0285|77 82|fever
P00503336A0285|92 98|levels
P00503336A0285|102 122|alkaline phosphatase
P00503336A0285|127 140|transaminases
P00503336A0285|148 153|serum
P00503336A0285|170 178|findings
P00503336A0285|196 205|diagnosis
P00506559A0000|14 33|inhalation toxicity
P00506559A0000|37 45|furfural
P00506559A0000|75 83|hamsters
P00506649T0000|0 7|Changes
P00506649T0000|22 46|serum protein components
P00506649T0000|66 72|stress
P00509703A0581|6 17|differences
P00509703A0581|63 72|textbooks
P00510341T0036|2 7|study
P00510341T0036|15 25|E.O.R.T.C.
P00512215A0000|12 17|study
P00512215A0000|31 41|dependence
P00512215A0000|45 66|difference tone level
P00512215A0000|68 69|L
P00512215A0000|70 75|f2-f1
P00512215A0000|95 105|parameters
P00512215A0000|122 127|input
P00512215A0000|129 131|f1
P00512215A0000|133 138|f2/f1
P00512215A0000|140 142|f2
P00512215A0000|156 158|f1
P00512215A0000|161 163|L1
P00512215A0000|165 167|L2
P00512215A0000|173 175|L1
P00512215A0000|178 180|L2
P00513284A0000|15 26|preparation
P00513284A0000|30 41|doxycycline
P00513284A0000|43 47|DOTC
P00513284A0000|49 59|Vibramycin
P00513284A0000|61 67|Pfizer
P00513284A0000|86 98|tetracycline
P00513284A0000|127 140|drip infusion
P00513284A0000|147 153|series
P00513284A0000|157 162|study
P00513284A0000|170 186|pediatrics field
P00513284A0000|196 203|results
P00513284A0000|224 228|DOTC
P00513284A0000|234 236|mg
P00513284A0000|261 263|ml
P00513284A0000|267 283|glucose solution
P00513284A0000|293 298|mg/kg
P00513284A1255|18 22|days
P00513284A1255|29 42|DOTC infusion
P00513284A1255|44 60|laboratory tests
P00513284A1255|65 70|liver
P00513284A1255|81 90|functions
P00513284A1255|95 100|blood
P00516545T0001|11 26|characteristics
P00516545T0001|34 54|erythrocyte membrane
P00516545T0001|56 78|peroxidation processes
P00516545T0001|95 103|function
P00516545T0001|107 115|children
P00516545T0001|129 147|glomerulonephritis
P00517890A0468|12 17|route
P00517890A0468|35 39|mode
P00517890A0468|43 55|transmission
P00517890A0468|60 71|hepatitis A
P00517890A0468|85 91|levels
P00517890A0468|95 122|hepatitis A virus excretion
P00517890A0468|140 145|onset
P00517890A0468|149 157|jaundice
P00519173A0126|7 15|patients
P00519173A0126|34 42|evidence
P00519173A0126|46 58|oesophagitis
P00521732T0000|8 17|excretion
P00521732T0000|21 29|oestrone
P00521732T0000|31 49|oestradiol-17 beta
P00521732T0000|54 62|oestriol
P00521732T0000|66 77|pregnancies
P00521732T0000|93 122|steroid sulphatase deficiency
P00524451A0136|25 43|locomotor activity
P00524451A0136|47 51|mice
P00524451A0136|73 78|death
P00524451A0136|84 95|amphetamine
P00524451A0136|104 112|toxicity
P00524451A0136|124 137|hexobarbitone
P00524451A0136|147 151|time
P00524451A0136|165 174|depletion
P00524451A0136|178 192|catecholamines
P00524451A0136|206 212|organs
P00524451A0136|220 223|rat
P00528144T0000|7 11|role
P00528144T0000|15 26|transferrin
P00528144T0000|34 40|uptake
P00528144T0000|44 51|gallium
P00528144T0000|55 66|tumor cells
P00534613A0000|0 11|Irradiation
P00534613A0000|21 36|blood platelets
P00534613A0000|42 46|UV-A
P00534613A0000|70 77|ability
P00534613A0000|81 90|aggregate
P00534613A0000|97 106|challenge
P00534613A0000|112 120|collagen
P00535520A0239|13 23|exceptions
P00535520A0239|28 34|method
P00535520A0239|86 101|cholangiography
P00540707A0255|27 34|results
P00540707A0255|51 58|account
P00540707A0255|68 81|complications
P00540707A0255|108 112|rate
P00540707A0255|119 124|cases
P00540707A0255|130 146|tip displacement
P00540707A0255|151 166|pouch haematoma
P00540707A0255|195 202|Authors
P00540707A0255|224 230|method
P00540707A0255|241 249|approach
P00540707A0255|254 270|PMK implantation
P00540707A0255|293 296|use
P00540707A0255|304 318|vena cephalica
P00541752A1032|9 23|determinations
P00541752A1032|45 52|samples
P00541752A1032|56 62|plasma
P00541752A1032|81 87|adults
P00541752A1032|91 98|October
P00541752A1032|104 110|values
P00541752A1032|147 151|mean
P00541752A1032|156 158|SD
P00541752A1032|160 165|ng/ml
P00550399A0615|18 24|causes
P00550399A0615|28 33|death
P00550399A0615|61 67|groups
P00553858A0000|9 14|Grice
P00553858A0000|17 26|operation
P00553858A0000|54 59|world
P00553858A0000|75 82|account
P00553858A0000|111 121|literature
P00553858A0000|133 145|publications
P00553858A0000|159 168|technique
P00553858A0000|192 197|terms
P00553858A0000|231 241|principles
P00553858A0000|255 264|operation
P00555492A1034|7 14|changes
P00555492A1034|51 61|blood flow
P00555492A1034|88 97|injection
P00555492A1034|101 111|cimetidine
P00555492A1034|126 135|injection
P00555492A1034|145 149|flow
P00555492A1034|181 195|blood pressure
P00555495T0000|0 5|Study
P00555495T0000|9 25|re-establishment
P00555495T0000|29 38|ovulation
P00555495T0000|45 56|termination
P00555495T0000|74 83|treatment
P00555495T0000|100 113|re-appearance
P00555495T0000|117 126|ovulation
P00555495T0000|133 141|abortion
P00555495T0000|156 164|delivery
P00555583T0000|0 16|Pharmacokinetics
P00555583T0000|20 33|Carbamazepine
P00555583T0000|37 40|man
P00555583T0000|44 50|review
P00557559A0170|7 16|compounds
P00557559A0170|25 30|alpha
P00557559A0170|57 84|N-methylnitrone 1,4-dioxide
P00557559A0170|109 114|agent
P00557559A0170|171 180|organisms
P00564032A0724|0 7|Changes
P00564032A0724|17 24|content
P00564032A0724|64 74|mechanisms
P00564032A0724|82 90|pressure
P00564032A0724|108 112|duct
P00564032A0724|120 125|gland
P00564943A0444|0 6|Calves
P00564943A0444|11 19|MCT-milk
P00564943A0444|44 61|blood cholesterol
P00564943A0444|67 73|calves
P00564943A0444|78 79|T
P00564943A0444|84 92|SBO-milk
P00565136T0000|8 17|mortality
P00565136T0000|21 25|mice
P00565136T0000|36 46|inhalation
P00565136T0000|56 61|doses
P00565136T0000|65 69|CH2O
P00565136T0000|71 77|SO2Cl2
P00565136T0000|83 86|Br2
P00565314A0293|0 11|Guinea pigs
P00565314A0293|43 44|g
P00569989A0239|6 26|halothane anesthesia
P00569989A0239|32 53|flow pneumocardiogram
P00569989A0239|55 59|PnCG
P00569989A0239|69 73|time
P00569989A0239|86 115|acceleration pneumocardiogram
P00569989A0239|119 125|dPn/dt
P00569989A0239|150 155|apnea
P00569989A0239|177 193|pneumotachograph
P00574222T0000|8 16|kindling
P00574222T0000|18 30|implications
P00574222T0000|35 46|development
P00574222T0000|58 68|prostheses
P00574956A0304|21 31|stereotypy
P00574956A0304|58 62|case
P00574956A0304|94 98|tone
P00574956A0304|141 152|equilibrium
P00574956A0304|194 201|systems
P00574956A0304|232 240|dopamine
P00574956A0304|269 280|development
P00574956A0304|300 313|manifestation
P00575231A0422|0 4|None
P00575231A0422|12 27|cystometrograms
P00575231A0422|47 68|detrusor contractions
P00577440A0298|7 15|duodenum
P00577440A0298|24 28|part
P00577440A0298|49 53|dose
P00577440A0298|73 95|3H-alpha-acetyldigoxin
P00578648T0048|11 18|effects
P00578648T0048|38 52|administration
P00580106T0000|0 9|Treatment
P00580106T0000|13 19|Graves
P00580106T0000|21 28|disease
P00580151A0706|74 86|testosterone
P00580151A0706|99 110|se-T levels
P00580151A0706|130 135|range
P00580151A0706|141 152|convenience
P00580151A0706|160 167|patient
P00580151A0706|197 201|cost
P00580151A0706|220 227|effects
P00580151A0706|241 246|doses
P00583004A0445|12 36|1,8-dihydroxy-9-anthrone
P00583004A0445|38 64|1,8,9-triacetoxyanthracene
P00583004A0445|69 93|1,8-diacetoxy-9-anthrone
P00583004A0445|126 133|lesions
P00583004A0445|155 168|inflammations
P00583004A0445|176 180|skin
P00583522T0001|33 41|problems
P00583522T0001|59 71|inflammation
P00587791T0054|0 7|Nursing
P00587791T0054|11 19|patients
P00587791T0054|39 47|diseases
P00589073A0000|18 49|plasma prolactin concentrations
P00589073A0000|54 61|samples
P00589073A0000|99 104|phase
P00589073A0000|120 127|control
P00589073A0000|129 134|women
P00589073A0000|152 157|group
P00589073A0000|164 172|patients
P00589073A0000|194 201|history
P00589073A0000|205 216|infertility
P00590594T0000|8 27|allotransplantation
P00592887T0000|9 17|reaction
P00592887T0000|21 39|Patent Blue Violet
P00592887T0000|47 59|lymphography
P00593119T0001|0 9|Screening
P00593119T0001|13 28|asthma patients
P00593119T0001|32 45|determination
P00593119T0001|49 52|IgE
P00593119T0001|60 73|comprehension
P00593119T0001|77 85|spectrum
P00593119T0001|105 119|IgE antibodies
P00594466T0001|4 13|induction
P00594466T0001|17 25|seizures
P00594466T0001|30 41|Papio papio
P00594466T0001|53 65|allylglycine
P00594466T0001|78 89|combination
P00594466T0001|115 126|stimulation
P00594617A0192|21 32|correlation
P00594617A0192|55 63|presence
P00594617A0192|80 100|degradation products
P00594617A0192|102 105|FDP
P00594617A0192|115 124|incidence
P00594617A0192|128 139|nephropathy
P00594617A0192|150 163|insufficiency
P00594617A0192|188 196|presence
P00594617A0192|207 215|monomers
P00594617A0192|217 222|Godal
P00594617A0192|225 250|ethanol-gelification test
P00594617A0192|270 275|signs
P00594617A0192|291 298|disease
P00594617A0192|300 305|fever
P00594617A0192|319 322|ESR
P00597715A0256|0 9|One-third
P00597715A0256|17 20|men
P00597715A0256|26 37|azoospermia
P00597715A0256|47 60|sperm density
P00597715A0256|96 109|FSH elevation
P00597715A0256|118 128|experience
P00597715A0256|142 146|work
P00597715A0256|150 156|others
P00597715A0256|184 193|prognosis
P00598012A0174|3 25|girls prolactin levels
P00598012A0174|34 39|stage
P00598012A0174|64 72|menarche
P00598012A0174|77 81|boys
P00598012A0174|94 100|change
P00598012A0174|104 120|prolactin levels
P00599601A0260|45 55|procedures
P00599601A0260|77 89|pinealectomy
P00599601A0260|122 133|alterations
P00599601A0260|154 164|physiology
P00599601A0260|193 196|rat
P00600943T0001|2 7|cases
P00600943T0001|17 36|lymphomononucleosis
P00601401A0181|8 27|hemoglobin solution
P00601401A0181|56 64|affinity
P00601401A0181|69 75|oxygen
P00601401A0181|86 97|Bohr effect
P00601401A0181|117 145|delta log Po2/delta pH ratio
P00602622A0362|11 24|ulcer therapy
P00602622A0362|30 38|atropine
P00602622A0362|43 50|Vikalin
P00602622A0362|52 57|Roter
P00602622A0362|81 82|p
P00602622A0362|99 108|reduction
P00602622A0362|138 146|activity
P00602702A0309|7 14|patient
P00602702A0309|27 35|diarrhea
P00602702A0309|40 61|estriol concentration
P00602702A0309|65 70|serum
P00602702A0309|100 108|function
P00602702A0309|128 149|estriol concentration
P00602702A0309|175 183|diarrhea
P00603783A0647|0 12|Serum levels
P00603783A0647|16 19|IgG
P00603783A0647|24 27|IgM
P00603783A0647|66 74|findings
P00603783A0647|84 104|observers IgA levels
P00606849T0000|22 35|heart disease
P00606849T0000|47 61|thromboxane A2
P00606849T0000|65 72|rabbits
P00614915T0001|0 10|Vitrectomy
P00614915T0001|21 33|traumatology
P00616575A0000|13 24|sensitivity
P00616575A0000|41 57|brain structures
P00616575A0000|65 71|action
P00616575A0000|94 99|field
P00616575A0000|103 118|decimeter waves
P00616575A0000|120 123|EMF
P00616575A0000|127 129|DW
P00616575A0000|141 154|investigation
P00616575A0000|165 178|unit activity
P00617815A0215|14 29|L-R differences
P00618078A0367|2 10|decrease
P00618078A0367|18 35|lysozyme activity
P00618078A0367|64 75|improvement
P00618078A0367|93 103|meningitis
P00619305A0759|22 28|groups
P00619305A0759|58 67|dimension
P00619305A0759|85 95|dimensions
P00619782A0058|5 9|tans
P00619782A0058|32 37|backs
P00619782A0058|41 51|volunteers
P00619782A0058|66 74|exposure
P00619782A0058|87 108|ultraviolet radiation
P00619782A0058|110 114|UV-A
P00619948A0000|6 13|effects
P00619948A0000|24 32|subjects
P00619948A0000|50 54|dose
P00619948A0000|58 65|Motival
P00619948A0000|71 77|tablet
P00619948A0000|90 102|fluphenazine
P00619948A0000|107 109|mg
P00619948A0000|114 127|nortriptyline
P00619948A0000|131 133|mg
P00619948A0000|162 171|variation
P00619948A0000|173 176|CNV
P00619948A0000|179 192|reaction time
P00619948A0000|194 204|heart rate
P00619948A0000|206 220|blood pressure
P00619948A0000|237 243|scales
P00619948A0000|248 257|alertness
P00619948A0000|259 266|anxiety
P00619948A0000|268 275|tension
P00619948A0000|277 287|detachment
P00619948A0000|292 302|depression
P00619948A0000|331 339|diazepam
P00619948A0000|343 345|mg
P00619948A0000|354 356|mg
P00619948A0000|362 369|placebo
P00619948A0000|373 384|propranolol
P00619948A0000|389 391|mg
P00621626T0000|0 14|Stress effects
P00621626T0000|18 41|affiliation preferences
P00621626T0000|48 56|subjects
P00621626T0000|72 76|type
P00621626T0000|94 110|behavior pattern
P00622556A0111|20 28|collagen
P00622556A0111|37 43|tissue
P00622556A0111|78 84|tendon
P00623361A0221|0 7|Smoking
P00623361A0221|34 46|contribution
P00623361A0221|60 71|dysfunction
P00626014T0001|4 13|malignity
P00626014T0001|24 31|lentigo
P00627039T0000|0 11|Elimination
P00627039T0000|15 25|bagassosis
P00627039T0000|29 72|Louisiana paper manufacturing plant workers
P00627129A0944|6 15|responses
P00627129A0944|35 41|others
P00627129A0944|54 62|subjects
P00627129A0944|78 88|conditions
P00627129A0944|136 142|effect
P00627129A0944|146 155|labetalol
P00627129A0944|183 191|blockade
P00627129A0944|205 223|beta-adrenoceptors
P00627202T0000|0 9|Diuretics
P00627202T0000|26 38|pharmacology
P00627202T0000|55 58|use
P00628990A0000|6 14|patients
P00628990A0000|38 43|units
P00628990A0000|72 86|reconstruction
P00628990A0000|97 116|ureteroureterostomy
P00628990A0000|133 153|ureteroneocystostomy
P00628990A0000|174 178|loop
P00628990A0000|189 201|ureterostomy
P00630713T0000|0 10|Evaluation
P00630713T0000|18 47|Du Pont aca ammonia procedure
P00633909A0000|20 28|patients
P00633909A0000|30 36|scores
P00633909A0000|40 46|Rotter
P00633909A0000|49 72|Internal-External Locus
P00633909A0000|76 89|Control Scale
P00633909A0000|113 122|treatment
P00633909A0000|156 164|patients
P00633909A0000|197 204|control
P00635143T0001|0 6|Action
P00635143T0001|10 22|strontium-90
P00635143T0001|27 35|metaphos
P00635143T0001|39 54|Cyprinus carpio
P00635194A0093|0 15|Kodak XV-2 film
P00635194A0093|77 94|dose distribution
P00636526T0033|0 9|Diagnosis
P00636526T0033|27 36|diagnosis
P00637637T0000|13 20|factors
P00637637T0000|31 52|plasma renin activity
P00637637T0000|66 78|hypertension
P00639410T0000|0 9|Cortisone
P00639410T0000|18 30|bone changes
P00639410T0000|39 47|response
P00639410T0000|51 72|lipid clearing agents
P00640584A0250|20 29|principle
P00640584A0250|55 64|stability
P00641395A0441|5 18|blood samples
P00641395A0441|22 30|patients
P00641395A0441|36 54|hyperbilirubinemia
P00641395A0441|77 88|measurement
P00641395A0441|92 95|ZPP
P00641395A0441|104 115|fluorimeter
P00641395A0441|145 151|levels
P00641395A0441|174 191|extraction method
P00644314T0000|8 24|hypersensitivity
P00644314T0000|28 31|man
P00644314T0000|33 40|effects
P00644314T0000|53 68|anticoagulation
P00644539A0783|23 33|inhalation
P00644539A0783|39 41|ml
P00644539A0783|49 55|saline
P00644539A0783|65 69|FEV1
P00644539A0783|81 82|%
P00644539A0783|88 89|%
P00644539A0783|133 140|subject
P00644539A0783|143 152|reactions
P00644539A0783|160 174|test solutions
P00646023T0058|13 20|studies
P00646023T0058|24 39|virus excretion
P00646023T0058|58 70|transmission
P00646193T0000|0 7|Potency
P00646193T0000|11 20|enflurane
P00646193T0000|24 28|dogs
P00646193T0000|30 40|comparison
P00646193T0000|46 55|halothane
P00646193T0000|60 70|isoflurane
P00656008T0000|0 10|Prevention
P00656008T0000|20 37|paraquat toxicity
P00656008T0000|41 45|rats
P00656008T0000|49 69|superoxide dismutase
P00657551T0000|0 11|Measurement
P00657551T0000|15 35|magnesium absorption
P00657551T0000|39 42|man
P00657551T0000|56 60|26Mg
P00657551T0000|66 72|tracer
P00659962T0000|18 38|riboflavin excretion
P00659962T0000|60 74|acid ingestion
P00663166A0000|13 24|angiography
P00663166A0000|42 54|body imaging
P00663166A0000|93 105|particulates
P00663166A0000|143 151|shunting
P00663166A0000|155 163|patients
P00663166A0000|169 193|patent ductus arteriosus
P00663166A0000|195 198|PDA
P00663166A0000|205 227|Eisenmenger physiology
P00664320T0000|8 17|detectors
P00664320T0000|38 45|pathway
P00665053A0276|39 43|type
P00665053A0276|45 50|06a6b
P00665053A0276|52 55|K13
P00665053A0276|57 59|H1
P00665053A0276|80 95|group affection
P00665214A0374|4 10|method
P00665214A0374|54 64|physiology
P00665214A0374|78 83|cycle
P00665336A0908|12 16|time
P00665336A0908|51 66|EEG-information
P00668122A0414|0 8|Analysis
P00668122A0414|12 34|liver biopsy specimens
P00668122A0414|40 48|patients
P00668122A0414|54 63|hepatitis
P00668122A0414|79 88|variation
P00668122A0414|96 113|mean iron content
P00668122A0414|121 145|liver ferritin molecules
P00669800A0579|7 11|mice
P00669800A0579|49 58|infection
P00669800A0579|64 69|males
P00676416A0320|27 32|years
P00676416A0320|50 64|liver biopsies
P00676790T0000|0 18|Angiotensin effect
P00676790T0000|32 38|kidney
P00681550A0000|0 7|Procion
P00681550A0000|59 74|auditory fibers
P00681550A0000|78 86|goldfish
P00681550A0000|107 119|relationship
P00681550A0000|132 145|response type
P00681550A0000|155 161|fibers
P00681550A0000|172 176|site
P00681550A0000|180 191|termination
P00681550A0000|208 214|macula
P00681571T0028|11 19|findings
P00681571T0028|27 36|epidermis
P00681571T0028|63 87|eccrine sweat duct units
P00682762T0001|0 19|Silicosis mortality
P00685922A0451|31 41|strictures
P00685922A0451|77 81|tree
P00685922A0451|83 86|IHB
P00686836A0000|0 7|Pentane
P00686836A0000|12 18|ethane
P00686836A0000|39 57|lipid peroxidation
P00686836A0000|84 102|gas chromatography
P00686836A0000|106 120|breath samples
P00686836A0000|124 128|rats
P00686836A0000|139 144|weeks
P00686836A0000|147 154|vitamin
P00686836A0000|167 171|diet
P00686836A0000|209 229|IU vitamin E acetate
P00686836A0000|234 236|kg
P00693987T0001|0 14|Thromboplastic
P00693987T0001|32 40|activity
P00693987T0001|48 53|blood
P00693987T0001|60 74|administration
P00693987T0001|78 88|intralipid
P00693987T0001|92 95|men
P00693987T0001|101 108|history
P00693987T0001|123 133|infarction
P00693987T0001|143 147|year
P00693987T0001|151 155|life
P00696680A0000|4 11|authors
P00696680A0000|41 49|findings
P00696680A0000|58 63|cases
P00696680A0000|73 78|women
P00696680A0000|84 101|rhabdomyosarcomas
P00696680A0000|125 136|endometrium
P00696680A0000|140 146|cervix
P00696858A0000|4 10|effect
P00696858A0000|27 43|porcine secretin
P00696858A0000|47 56|endocrine
P00696858A0000|81 90|secretion
P00696858A0000|136 152|porcine pancreas
P00701144T0000|10 18|analysis
P00701144T0000|34 44|lens power
P00701144T0000|65 75|emmetropia
P00701144T0000|77 84|results
P00701144T0000|92 100|implants
P00701462A0722|0 16|Urine antibodies
P00701462A0722|56 61|cases
P00702773A0327|0 11|Althoug RBF
P00702773A0327|41 48|therapy
P00702773A0327|89 95|change
P00702773A0327|99 102|RBF
P00702773A0327|104 107|GFR
P00702773A0327|120 126|output
P00703350A0418|0 13|99mTc phytate
P00703350A0418|15 28|198Au colloid
P00703350A0418|34 39|99mTc
P00703350A0418|49 56|sulfide
P00703932A0000|4 12|patients
P00703932A0000|18 36|glomerulonephritis
P00703932A0000|40 51|association
P00703932A0000|78 83|shunt
P00703932A0000|114 119|modes
P00703932A0000|123 130|therapy
P00704675A0199|4 8|mass
P00704675A0199|12 15|UO2
P00704675A0199|38 45|bronchi
P00704675A0199|56 67|bifurcation
P00704675A0199|100 101|d
P00704675A0199|108 118|inhalation
P00704675A0199|142 146|mass
P00704675A0199|154 161|trachea
P00710217T0001|9 14|cysts
P00710217T0001|22 31|hip joint
P00710372A0302|25 36|dysfunction
P00710372A0302|71 79|function
P00710372A0302|94 107|GH deficiency
P00710372A0302|143 151|features
P00712117A0521|8 16|outbreak
P00712117A0521|20 31|influenza A
P00712117A0521|48 52|base
P00712117A0521|60 68|February
P00712117A0521|88 97|A/Texas/1
P00712117A0521|106 111|virus
P00712117A0521|115 122|variant
P00712117A0521|130 142|A/Victoria/3
P00712117A0521|146 155|prototpye
P00713525A0268|8 17|decreases
P00713525A0268|25 41|disfluency rates
P00713525A0268|45 55|stutterers
P00713525A0268|81 93|presentation
P00713525A0268|107 121|stimulus words
P00713525A0268|127 131|data
P00713525A0268|162 167|model
P00715180T0074|0 6|Effect
P00715180T0074|10 14|time
P00715180T0074|19 23|dose
P00715180T0074|27 38|alterations
P00715180T0074|49 59|inhalation
P00715180T0074|63 92|plutonium-239 dioxide aerosol
P00715180T0074|96 99|rat
P00715753A0241|3 26|biopsies CK-MB fraction
P00715753A0241|47 50|CPK
P00715753A0241|57 58|%
P00715753A0241|64 82|total-CPK activity
P00715753A0241|101 108|muscles
P00715753A0241|124 134|% fraction
P00715753A0241|138 143|CK-MB
P00716366T0001|0 5|Value
P00716366T0001|9 22|determination
P00716366T0001|26 57|alkaline phosphatase isoenzymes
P00716366T0001|75 84|diagnosis
P00716366T0001|100 108|jaundice
P00716366T0001|121 136|liver cirrhosis
P00722298A0619|10 18|analysis
P00722298A0619|22 30|variance
P00722298A0619|57 60|men
P00722298A0619|65 70|women
P00722298A0619|75 86|differences
P00722298A0619|110 116|groups
P00722298A0619|121 137|field dependence
P00722298A0619|146 158|significance
P00722298A0619|160 163|rho
P00722298A0619|187 194|females
P00722298A0619|205 211|famale
P00722298A0619|235 240|field
P00722298A0619|281 287|groups
P00722298A0619|305 310|males
P00722652A0118|13 37|2nd-generation schizonts
P00722652A0118|55 63|diameter
P00722652A0118|80 90|micrometer
P00722652A0118|121 128|surface
P00722652A0118|136 141|cecum
P00725257A0452|15 25|pD2 values
P00725257A0452|39 40|E
P00725257A0452|50 53|DHE
P00725257A0452|66 68|M.
P00725336T0000|0 36|Newcastle disease virus surveillance
P00725336T0000|40 49|Hong Kong
P00725336T0000|72 79|poultry
P00725534A0888|34 43|challenge
P00725534A0888|47 56|M. leprae
P00725534A0888|64 72|antigens
P00725534A0888|80 95|IgA immunocytes
P00725534A0888|114 124|epithelium
P00725534A0888|144 153|tolerance
P00725534A0888|165 179|IgA deficiency
P00725534A0888|204 211|atrophy
P00725534A0888|230 235|villi
P00725534A0888|243 251|patients
P00725534A0888|269 276|leprosy
P00725752T0001|0 9|Treatment
P00725752T0001|13 25|hypertension
P00725752T0001|33 44|combination
P00725752T0001|63 86|beta receptor blockader
P00725752T0001|88 95|obsidan
P00725752T0001|105 116|vasodilator
P00725752T0001|118 126|apressin
P00726581T0122|0 6|Orthop
P00728718T0000|0 15|Thyroid disease
P00728718T0000|20 29|pregnancy
P00729003A1182|0 8|Residues
P00729003A1182|22 33|transcripts
P00729003A1182|37 45|splicing
P00733067A0188|12 18|reflux
P00733067A0188|34 38|loop
P00733067A0188|42 48|number
P00733067A0188|62 67|steps
P00733067A0188|108 115|section
P00733067A0188|131 136|stump
P00733067A0188|156 168|construction
P00733067A0188|176 187|anastomosis
P00733067A0188|214 222|creation
P00733067A0188|245 257|valve system
P00733067A0188|276 287|anastomosis
P00733067A0188|291 310|spiral introflexion
P00733067A0188|318 324|mucosa
P00733067A0188|342 350|stitches
P00733067A0188|391 396|lumen
P00736376A0371|8 13|stage
P00736376A0371|33 42|mortality
P00736376A0371|52 60|ischemia
P00736376A0371|89 96|urgency
P00736376A0371|104 113|operation
P00736376A0371|121 126|skill
P00737422A0832|0 9|Pathogens
P00737422A0832|50 57|bacilli
P00737422A0832|87 93|member
P00737422A0832|97 102|staff
P00737422A0832|112 119|numbers
P00737422A0832|156 163|numbers
P00737422A0832|169 177|patients
P00740409A0000|4 18|histochemistry
P00740409A0000|23 37|ultrastructure
P00740409A0000|51 70|cerebellar deposits
P00740409A0000|84 89|Tonge
P00741476A0000|14 19|woman
P00741476A0000|30 49|Ergotamine Tartrate
P00741476A0000|54 61|mg p.d.
P00741476A0000|75 79|days
P00741476A0000|90 98|abortion
P00741476A0000|108 113|birth
P00743335T0001|0 14|Reaction times
P00743335T0001|47 54|stimuli
P00743335T0001|58 67|diabetics
P00745775A0170|16 24|patients
P00745775A0170|53 66|arteriography
P00745775A0170|100 113|complications
P00745775A0170|125 134|injection
P00745775A0170|138 147|Urografin
P00745775A0170|152 154|M.
P00747722A0486|4 8|data
P00747722A0486|32 40|reaction
P00747722A0486|47 59|B1 injection
P00747722A0486|62 67|Phase
P00747722A0486|85 94|injection
P00747722A0486|106 110|drop
P00747722A0486|118 128|parameters
P00747722A0486|144 147|sec
P00748978T0000|0 20|Serum relaxin levels
P00748978T0000|24 40|prostaglandin E2
P00748978T0000|49 58|abortions
P00753237A0000|25 35|phenomenon
P00753237A0000|44 49|level
P00753237A0000|57 61|ends
P00753237A0000|77 81|arcs
P00753237A0000|92 103|body weight
P00753237A0000|108 112|PAIN
P00753237A0000|123 127|role
P00753237A0000|131 140|outsentry
P00753237A0000|142 145|fig
P00753237A0000|156 157|B
P00753237A0000|159 166|Plantar
P00753237A0000|179 189|ulceration
P00753237A0000|191 194|PPU
P00753237A0000|211 222|combination
P00753237A0000|226 239|INSENSITIVITY
P00753237A0000|244 253|TRAUMATIS
P00753237A0000|259 260|C
P00753237A0000|266 273|patient
P00753237A0000|287 298|body weight
P00753237A0000|300 310|traumatism
P00753237A0000|312 319|effects
P00753237A0000|345 352|process
P00753237A0000|377 378|D
P00753237A0000|380 396|PNEUMATIC INSOLE
P00753237A0000|432 443|compression
P00753237A0000|451 455|ends
P00753237A0000|471 475|arcs
P00753237A0000|485 494|attrition
P00753237A0000|509 526|blood circulation
P00753237A0000|539 543|cure
P00753237A0000|548 559|prophylaxis
P00753237A0000|563 566|PPU
P00753237A0000|568 571|fig
P00755245A0000|0 6|Effect
P00755245A0000|10 19|indoramin
P00755245A0000|29 34|doses
P00755245A0000|50 64|vasomotor loci
P00755245A0000|85 95|chloralose
P00755245A0000|109 113|cats
P00755245A0000|146 151|sites
P00755671A0485|17 24|heparin
P00755671A0485|47 68|recalcification times
P00755671A0485|77 88|development
P00755671A0485|116 125|hematomas
P00755869A0216|0 23|Contingency contracting
P00755869A0216|32 39|clients
P00755869A0216|50 68|parents/caregivers
P00755869A0216|89 101|consequences
P00755869A0216|112 127|self-monitoring
P00755869A0216|145 151|intake
P00755869A0216|153 164|weight loss
P00755869A0216|170 178|exercise
P00756511T0036|0 9|Dietetics
P00756511T0036|13 22|childhood
P00756511T0036|37 45|diabetes
P00757244A0000|4 11|results
P00757244A0000|30 35|study
P00757244A0000|56 65|membranes
P00757244A0000|73 82|placentas
P00759049A0185|4 15|micromethod
P00759049A0185|21 34|microcuvettes
P00759049A0185|51 60|ferrozine
P00759049A0185|69 98|bathophenanthroline chromogen
P00759049A0185|106 110|ICSH
P00759400T0000|0 18|Platelet serotonin
P00759400T0000|20 24|5-HT
P00759400T0000|30 34|5-HT
P00759400T0000|45 51|factor
P00759400T0000|55 61|plasma
P00759400T0000|76 84|patients
P00762763A0253|12 21|incidence
P00762763A0253|25 29|SIDS
P00762763A0253|54 60|births
P00764737X0000|4 18|vigilance task
P00764737X0000|27 38|measurement
P00764737X0000|54 62|deficits
P00767155T0001|4 12|December
P00767155T0001|19 25|revolt
P00767155T0001|29 35|Moscow
P00767155T0001|56 65|personnel
P00767161A0837|12 21|increases
P00767161A0837|30 52|serum E2 concentration
P00767161A0837|65 70|pg/ml
P00767161A0837|94 99|hours
P00767161A0837|106 120|administration
P00767161A0837|124 127|day
P00767161A0837|139 144|hours
P00767161A0837|148 151|day
P00768220X0000|4 14|motor unit
P00771729X0000|19 25|system
P00771729X0000|33 43|variations
P00771729X0000|47 56|responses
P00771729X0000|60 68|hormones
P00775582T0000|11 21|properties
P00775582T0000|25 34|sumithion
P00779272T0001|12 19|studies
P00779272T0001|23 33|antibodies
P00779272T0001|50 55|virus
P00779272T0001|70 83|mononucleosis
P00780639X0000|17 24|antigen
P00780639X0000|26 29|CEA
P00780639X0000|31 41|procedures
P00780639X0000|55 65|evaluation
P00792847A0000|25 48|antilymphocyte globulin
P00792847A0000|50 53|ALG
P00792847A0000|85 90|agent
P00792847A0000|94 100|humans
P00799988A0554|7 12|basis
P00799988A0554|25 44|assessment patients
P00799988A0554|73 83|preference
P00799988A0554|88 98|imipramine
P00799988A0554|113 120|placebo
P00799988A0554|135 142|therapy
P00803867A0315|0 8|Patients
P00803867A0315|45 51|groups
P00803867A0315|73 79|cancer
P00803867A0315|96 102|cancer
P00803867A0315|121 129|patients
P00803867A0315|151 158|disease
P00803867A0315|174 180|months
P00806295A0193|0 10|Absorption
P00806295A0193|40 44|cent
P00806295A0193|58 68|absorption
P00806295A0193|79 83|cent
P00806295A0193|119 127|subjects
P00807356T0001|33 41|activity
P00807356T0001|45 66|hydroxy-9 ellipticine
P00808266T0000|0 8|Advances
P00808266T0000|16 26|management
P00808266T0000|42 48|cancer
P00808266T0000|50 67|radiation therapy
P00808898A0000|25 29|data
P00808898A0000|37 44|patient
P00808898A0000|81 88|failure
P00808898A0000|90 94|IPRF
P00811852T0001|9 21|satisfaction
P00811852T0001|25 32|nursing
P00811852T0001|37 46|encounter
P00811852T0001|70 78|patients
P00812183T0000|11 26|transfer factor
P00818380A0239|11 17|factor
P00818380A0239|34 48|antibody tests
P00818380A0239|79 88|reactions
P00818380A0239|92 104|gold therapy
P00818380A0239|149 160|populations
P00819176T0001|4 10|effect
P00819176T0001|26 34|pressure
P00819176T0001|42 59|swimming activity
P00819176T0001|83 92|crustacea
P00819176T0001|94 115|Anomalocera patersoni
P00819176T0001|117 138|Pontella mediterranea
P00819176T0001|140 161|Labidocera wollastoni
P00821833A0000|5 11|report
P00821833A0000|24 32|analysis
P00821833A0000|46 56|repertoire
P00821833A0000|60 74|howler monkeys
P00821833A0000|76 93|Alouatta palliata
P00821833A0000|113 124|field study
P00821833A0000|141 147|Panama
P00822611A0467|14 20|number
P00822611A0467|24 32|patients
P00822611A0467|71 78|persons
P00822611A0467|93 106|binephrectomy
P00823087A0608|0 8|Deflunia
P00823087A0608|34 42|patients
P00825571T0031|0 3|III
P00827364A0000|6 16|instrument
P00827364A0000|39 56|freeze-fracturing
P00827364A0000|71 79|material
P00827364A0000|83 88|ultra
P00827364A0000|94 100|vacuum
P00830568A0000|23 32|secretion
P00830568A0000|45 59|emptying rates
P00830568A0000|72 81|test meal
P00830568A0000|83 86|LTM
P00830568A0000|114 121|persons
P00830568A0000|126 134|patients
P00830568A0000|149 160|gastrectomy
P00830568A0000|166 184|gastroduodenostomy
P00830568A0000|186 192|STG-BI
P00830568A0000|202 219|gastrojejunostomy
P00830568A0000|221 228|STG-BII
P00830568A0000|238 246|patients
P00830568A0000|260 268|vagotomy
P00830568A0000|273 285|pyloroplasty
P00830568A0000|287 290|V&P
P00832096T0000|9 27|calcium metabolism
P00832096T0000|46 57|sarcoidosis
P00833472A0907|20 27|patient
P00833472A0907|42 52|gallstones
P00833472A0907|63 74|institution
P00833472A0907|78 88|colestipol
P00833472A0907|90 100|saturation
P00833472A0907|104 120|gallbladder bile
P00833472A0907|126 137|cholesterol
P00833472A0907|173 177|drug
P00836637A0000|13 23|experiment
P00836637A0000|75 90|music-listening
P00836637A0000|106 116|reinforcer
P00836637A0000|129 151|arithmetic performance
P00836637A0000|155 167|EMR children
P00836637A0000|200 213|reinforcement
P00836637A0000|227 237|preference
P00836637A0000|247 257|reinforcer
P00837262A0000|4 18|responsiveness
P00837262A0000|29 35|cortex
P00837262A0000|37 39|VC
P00837262A0000|54 64|colliculus
P00837262A0000|66 68|SC
P00837262A0000|108 120|conditioning
P00837262A0000|122 124|ON
P00837262A0000|130 133|OFF
P00837262A0000|135 146|stimulation
P00837262A0000|155 161|rabbit
P00837811A0675|2 11|diagnosis
P00837811A0675|15 17|MS
P00837811A0675|54 59|signs
P00837811A0675|68 99|fluid gamma globulin elevations
P00837811A0675|105 118|abnormalities
P00837811A0675|141 148|testing
P00838152A0863|17 38|mean temperature rise
P00838152A0863|56 65|degrees C
P00838152A0863|74 83|degrees C
P00838152A0863|93 102|selection
P00838152A0863|131 144|disappearance
P00838152A0863|159 173|qualifications
P00838152A0863|181 195|triplet groups
P00838152A0863|208 220|predominance
P00838152A0863|241 255|qualifications
P00838152A0863|269 275|groups
P00839378A0649|13 19|Viso V
P00839378A0649|27 36|RDS group
P00839378A0649|49 57|increase
P00839378A0649|67 84|airway resistance
P00839378A0649|102 109|disease
P00839378A0649|120 127|therapy
P00842406A0771|18 23|tests
P00842406A0771|51 55|task
P00842406A0771|59 63|test
P00842406A0771|68 91|visuomotor coordination
P00842406A0771|98 114|recognition task
P00842522T0000|20 30|intubation
P00842522T0000|38 48|management
P00842522T0000|86 95|emphysema
P00843232A0100|4 14|background
P00843232A0100|54 60|factor
P00843232A0100|69 78|character
P00843232A0100|82 88|lesion
P00843232A0100|96 106|epithelium
P00843670T0000|4 9|sense
P00843670T0000|13 17|self
P00846559A0000|7 14|strains
P00846559A0000|18 31|Fusarium poae
P00846559A0000|36 55|F. sporotrichioides
P00846559A0000|65 73|U.S.S.R.
P00846559A0000|80 87|strains
P00846559A0000|97 104|species
P00846559A0000|116 139|F. sporotrichioides var
P00846559A0000|141 151|tricinctum
P00846559A0000|157 163|U.S.A.
P00846559A0000|168 174|France
P00846559A0000|206 214|capacity
P00846559A0000|224 233|T-2 toxin
P00847967T0000|19 23|uses
P00847967T0000|40 50|tomography
P00847967T0000|63 71|medicine
P00851041A0000|12 17|study
P00851041A0000|24 32|patients
P00851041A0000|38 45|Ebstein
P00851041A0000|48 55|anomaly
P00851286A0375|0 6|Deaths
P00851286A0375|18 23|hours
P00851286A0375|30 51|copper concentrations
P00851286A0375|72 75|ppm
P00851286A0375|80 85|signs
P00851286A0375|89 97|distress
P00851286A0375|146 151|hours
P00851286A0375|167 172|death
P00857024A0888|0 10|Recurrence
P00857024A0888|14 28|bladder tumors
P00857024A0888|50 55|cases
P00857024A0888|92 108|properdin levels
P00857024A0888|128 134|median
P00863184T0043|0 10|Adaptation
P00863184T0043|27 44|transport maximum
P00863184T0043|68 72|load
P00863184T0043|80 83|rat
P00863773T0000|0 7|Dangers
P00863773T0000|11 14|use
P00863773T0000|18 37|live-virus vaccines
P00866577A0579|0 9|Treatment
P00866577A0579|15 22|heparin
P00866577A0579|24 46|plasminogen activators
P00866577A0579|68 74|agents
P00866577A0579|108 116|function
P00866577A0579|139 146|patient
P00866577A0579|155 159|term
P00866577A0579|179 186|therapy
P00868301A0043|3 25|diethyl ether solution
P00868301A0043|35 39|peak
P00868301A0043|51 83|2-benzylidenamio-1-phenylpropane
P00868301A0043|97 111|retention time
P00868301A0043|120 127|minutes
P00868301A0043|138 147|condition
P00868903A0000|0 8|Amikacin
P00868903A0000|25 34|treatment
P00868903A0000|63 73|infections
P00868903A0000|80 88|patients
P00870859A0121|4 8|data
P00870859A0121|57 64|account
P00870859A0121|72 81|direction
P00870859A0121|85 98|recirculation
P00870859A0121|127 133|factor
P00871237A0601|7 15|activity
P00871237A0601|25 32|patient
P00871237A0601|43 49|angina
P00872442T0000|0 10|Estimation
P00872442T0000|14 23|L-alanine
P00872442T0000|27 32|serum
P00872442T0000|36 42|plasma
P00872442T0000|53 79|LKB reaction rate analyser
P00872922A0204|4 9|acids
P00872922A0204|27 37|hydrolysis
P00872922A0204|59 65|esters
P00872922A0204|95 103|activity
P00874942T0000|13 23|amnionitis
P00874942T0000|28 39|prematurity
P00874942T0000|55 61|report
P00875778T0000|0 10|Evaluation
P00875778T0000|22 45|Gravigard IUCD inserter
P00876722T0000|10 20|meningitis
P00876722T0000|34 41|abscess
P00876722T0000|55 61|septum
P00877857A0763|0 13|Serum amylase
P00877857A0763|46 55|CU/100 ml
P00877857A0763|69 78|serum FFA
P00877857A0763|86 95|mEq/liter
P00879329A0176|7 26|control preparation
P00879329A0176|34 40|weight
P00879329A0176|91 99|pressure
P00879329A0176|101 104|Pci
P00879329A0176|117 121|mmHg
P00879329A0176|133 140|colloid
P00879329A0176|149 157|pressure
P00879329A0176|165 171|plasma
P00879329A0176|173 176|IIp
P00879829A0564|0 7|Infants
P00879829A0564|33 38|hours
P00879829A0564|45 48|IVH
P00879829A0564|75 89|birth asphyxia
P00879829A0564|127 134|symptom
P00879829A0564|149 155|apnoea
P00881630A0000|18 25|effects
P00881630A0000|33 45|snake venoms
P00881630A0000|47 54|N. naja
P00881630A0000|59 72|A. piscivorus
P00881630A0000|98 104|Factor
P00881630A0000|109 124|Phospholipase-A
P00881630A0000|126 135|compounds
P00881630A0000|150 157|N. naja
P00881630A0000|164 169|venom
P00881630A0000|192 196|lung
P00881630A0000|201 218|cremaster vessels
P00881630A0000|222 226|rats
P00885562A0281|6 10|GAGs
P00885562A0281|19 29|components
P00885562A0281|33 49|cartilage matrix
P00885562A0281|55 64|depletion
P00885562A0281|93 107|osteoarthrosis
P00885562A0281|111 117|method
P00885562A0281|142 155|GAG synthesis
P00885562A0281|159 166|culture
P00890028A0507|4 17|length scales
P00890028A0507|25 35|turbulence
P00890028A0507|62 77|Reynolds number
P00890028A0507|93 103|macroscale
P00890028A0507|118 120|mm
P00890028A0507|126 143|Taylor microscale
P00890028A0507|158 160|mm
P00890028A0507|170 187|Kolmogoroff scale
P00890028A0507|202 204|mm
P00891370A0000|16 28|arteriograms
P00891370A0000|36 41|limbs
P00891370A0000|61 76|xeroradiography
P00891370A0000|96 105|injection
P00891370A0000|109 124|contrast-medium
P00891370A0000|133 141|arm vein
P00891370A0000|165 173|patients
P00892353A0686|3 14|hypotension
P00892353A0686|28 36|patients
P00892353A0686|42 49|toxemia
P00892353A0686|67 72|fever
P00892353A0686|84 94|degrees C.
P00898500A0246|4 8|sera
P00898500A0246|19 29|secretions
P00898500A0246|37 45|patients
P00898500A0246|68 70|HD
P00898500A0246|74 89|mites skin test
P00898500A0246|131 135|test
P00898500A0246|137 141|RAST
P00898500A0246|171 192|IgE antibody activity
P00898500A0246|196 201|mites
P00903772A0359|0 8|Wherever
P00903772A0359|13 17|site
P00903772A0359|25 49|conditioning stimulation
P00903772A0359|57 70|modifications
P00903772A0359|89 98|ischaemia
P00903772A0359|106 109|leg
P00909114A0000|0 18|Diallylnitrosamine
P00909114A0000|20 23|DAN
P00909114A0000|41 53|nitrosamines
P00909114A0000|91 100|neoplasms
P00909114A0000|104 108|rats
P00909114A0000|124 133|incidence
P00909114A0000|149 161|tract tumors
P00909114A0000|179 187|hamsters
P00909114A0000|196 198|sc
P00909114A0000|221 226|doses
P00909114A0000|234 242|compound
P00910823A0196|5 9|term
P00910823A0196|30 40|conditions
P00910823A0196|61 72|blood gases
P00910823A0196|74 76|pH
P00910823A0196|78 85|uterine
P00910823A0196|100 111|blood flows
P00911590T0000|13 22|responses
P00911590T0000|26 36|antagonism
P00911590T0000|40 56|bocurarine block
P00911590T0000|62 90|atropine-neostigmine mixture
P00911590T0000|94 102|children
P00913623A0242|4 13|mechanism
P00913623A0242|29 38|molecules
P00913623A0242|52 65|diphosphonate
P00913623A0242|80 84|EHDP
P00913623A0242|102 115|pyrophosphate
P00913623A0242|117 121|pass
P00913623A0242|130 141|capillaries
P00913623A0242|145 149|bone
P00913623A0242|156 173|passive diffusion
P00915090A0536|12 16|days
P00915090A0536|23 32|injection
P00915090A0536|40 43|mCi
P00915090A0536|47 53|Tc-99m
P00915090A0536|70 74|rads
P00915090A0536|82 88|testis
P00915090A0536|94 100|number
P00915090A0536|104 114|sperm hads
P00915090A0536|130 131|%
P00915090A0536|135 142|control
P00916099A0000|0 17|Self-emasculation
P00916099A0000|25 35|end result
P00916099A0000|62 70|disorder
P00916099A0000|106 115|treatment
P00917572T0001|0 11|Possibility
P00917572T0001|31 37|method
P00917572T0001|42 51|detection
P00917572T0001|55 69|hypothyroidism
P00917721A0484|5 13|analysis
P00917721A0484|36 44|evidence
P00917721A0484|60 80|presleep suggestions
P00917721A0484|106 119|dream content
P00918556A0000|4 14|prevalence
P00918556A0000|18 45|hepatitis B surface antigen
P00918556A0000|47 52|HBsAg
P00918556A0000|58 66|anti-HBs
P00918556A0000|113 140|radio-immunoassay technique
P00918556A0000|146 152|series
P00918556A0000|156 164|patients
P00918556A0000|178 192|liver diseases
P00918965A0728|22 30|patients
P00918965A0728|54 61|failure
P00918965A0728|83 94|ventilation
P00918965A0728|104 116|componenents
P00918965A0728|134 139|shunt
P00918965A0728|145 153|parallel
P00918965A0728|200 204|PAO2
P00920381T0000|18 26|glycogen
P00920381T0000|48 57|injection
P00920381T0000|107 111|rats
P00921032T0000|11 21|evaluation
P00921032T0000|25 35|mibolerone
P00921032T0000|50 56|Beagle
P00921911A0159|0 6|Levels
P00921911A0159|15 18|PGF
P00921911A0159|23 27|PGFM
P00921911A0159|79 85|labour
P00921911A0159|101 111|dilatation
P00921911A0159|127 129|cm
P00921911A0159|147 152|onset
P00921911A0159|156 162|labour
P00926272A0000|16 21|cause
P00926272A0000|31 44|deterioration
P00926272A0000|59 63|cord
P00926272A0000|72 79|patient
P00926272A0000|111 117|reflux
P00926604A0504|0 11|Propranolol
P00926604A0504|13 20|Inderal
P00926604A0504|40 44|dose
P00926604A0504|78 87|apparatus
P00926604A0504|95 100|heart
P00926604A0504|114 125|development
P00926604A0504|152 158|effect
P00926604A0504|174 179|doses
P00926604A0504|183 197|strophanthin K
P00926604A0504|232 242|myocardium
P00926751A0000|7 14|studies
P00926751A0000|30 40|rat larynx
P00926751A0000|60 65|organ
P00926751A0000|73 83|evaluation
P00926751A0000|87 96|irritancy
P00926751A0000|108 117|materials
P00927633T0001|9 17|electron
P00927633T0001|30 44|investigations
P00927633T0001|52 61|formation
P00927633T0001|65 73|Reissner
P00927633T0001|76 81|fiber
P00927633T0001|85 98|Rattus rattus
P00928529T0001|0 16|Feeding behavior
P00928529T0001|29 40|body weight
P00928529T0001|45 64|hibernation rhythms
P00928529T0001|77 85|hamsters
P00928529T0001|126 133|bundles
P00929418T0001|0 4|Role
P00929418T0001|12 41|infectious-disease specialist
P00929418T0001|74 83|incidence
P00929418T0001|100 108|diseases
P00930947A0629|15 32|drug interactions
P00930947A0629|49 55|effect
P00930947A0629|59 69|probenecid
P00930947A0629|79 88|secretion
P00930947A0629|92 95|PZA
P00930947A0629|137 143|effect
P00930947A0629|155 160|drugs
P00930947A0629|193 199|effect
P00930947A0629|208 212|drug
P00931089T0001|12 18|arrest
P00931089T0001|26 40|operating room
P00932738A0116|14 28|blood pressure
P00932738A0116|30 32|BP
P00932738A0116|40 44|mmHg
P00932738A0116|46 64|C02 responsiveness
P00932738A0116|109 115|levels
P00932738A0116|119 121|BP
P00932817A0499|0 10|Iodine-123
P00932817A0499|51 54|MEC
P00932817A0499|59 78|pinhole collimators
P00932817A0499|89 93|turn
P00932817A0499|102 112|MTF values
P00932817A0499|146 151|99mTc
P00933251T0000|8 18|meningioma
P00933251T0000|22 28|plaque
P00933251T0000|58 67|ear tumor
P00935526A0000|4 16|difficulties
P00935526A0000|28 42|prostaglandins
P00935526A0000|44 46|PG
P00935526A0000|62 76|chromatography
P00935526A0000|99 103|lack
P00935526A0000|107 118|sensitivity
P00935526A0000|168 170|ng
P00935526A0000|188 198|resolution
P00935526A0000|213 220|columns
P00938594A0149|3 12|cessation
P00938594A0149|16 31|steroid therapy
P00938594A0149|36 43|patient
P00938594A0149|73 87|manifestations
P00938594A0149|104 120|osteoarthropathy
P00938594A0149|122 125|HOA
P00938594A0149|151 170|laboratory features
P00938594A0149|185 194|arthritis
P00938594A0149|196 198|RA
P00941050T0000|4 10|effect
P00941050T0000|14 18|food
P00941050T0000|22 45|procainamide absorption
P00947327A0000|15 21|survey
P00947327A0000|29 38|situation
P00947327A0000|53 63|resistance
P00947327A0000|71 77|region
P00947327A0000|90 97|Bavaria
P00947327A0000|131 139|activity
P00947327A0000|145 161|sulfamethoxazole
P00947327A0000|163 166|SMZ
P00947327A0000|168 180|trimethoprim
P00947327A0000|182 185|TMP
P00947327A0000|187 198|combination
P00947327A0000|222 233|antibiotics
P00947327A0000|255 261|agents
P00947327A0000|267 274|results
P00947327A0000|278 283|tests
P00947327A0000|297 308|combination
P00947327A0000|312 314|N1
P00947327A0000|341 354|sulfanilamide
P00947327A0000|357 368|sulfamoxole
P00947327A0000|374 387|2,4-diamino-5
P00947327A0000|389 412|3,4,5-trimethoxy-benzyl
P00947327A0000|414 424|pyrimidine
P00947327A0000|426 438|trimethoprim
P00947327A0000|445 450|ratio
P00947327A0000|459 461|CN
P00947327A0000|468 473|Nevin
P00947327A0000|475 484|Supristol
P00947327A0000|511 516|tests
P00947327A0000|522 529|TMP/SMZ
P00947834X0000|0 7|RESULTS
P00947834X0000|15 25|IgE levels
P00947834X0000|35 43|tendency
P00951909X0001|14 27|loop syndrome
P00951909X0001|46 52|author
P00951909X0001|55 62|opinion
P00951909X0001|68 77|diagnosis
P00951909X0001|95 108|loop syndrome
P00951909X0001|139 147|patients
P00951909X0001|161 184|Billroth-II gastrectomy
P00952734T0000|0 6|Letter
P00952734T0000|27 33|damage
P00952734T0000|48 53|cause
P00952734T0000|76 87|elastolysis
P00952734T0000|92 102|cutis laxa
P00952734T0000|104 108|PECL
P00954819A1041|6 10|data
P00954819A1041|36 44|recovery
P00954819A1041|68 76|function
P00954819A1041|83 95|intoxication
P00954819A1041|101 106|Soman
P00954819A1041|110 115|Sarin
P00954819A1041|142 148|return
P00954819A1041|152 165|AChE activity
P00956364A0138|0 14|Batch cultures
P00956364A0138|18 36|S. mutans serotype
P00956364A0138|55 61|growth
P00956364A0138|65 73|MSB agar
P00956554A0414|6 13|samples
P00956554A0414|17 22|serum
P00956554A0414|54 75|solid-phase allergens
P00956554A0414|84 94|reactivity
P00956554A0414|112 126|IgE antibodies
P00958550T0001|0 6|Crisis
P00958550T0001|26 35|community
P00958550T0001|45 52|Britain
P00959656A0250|9 14|women
P00959656A0250|18 22|term
P00959656A0250|38 44|levels
P00959656A0250|48 60|antithrombin
P00961711T0000|0 18|Hematology problem
P00961711T0000|26 31|month
P00961711T0000|33 37|band
P00961711T0000|41 44|seg
P00962222A0633|27 37|variations
P00962222A0633|41 54|heme turnover
P00962222A0633|70 77|changes
P00962222A0633|81 108|erythrocyte characteristics
P00962222A0633|120 138|progesterone phase
P00962277T0000|0 13|Haemodilution
P00962277T0000|33 39|bypass
P00962277T0000|48 67|gelatine derivative
P00962277T0000|72 79|priming
P00964758T0001|15 27|plasmacytoma
P00964758T0001|35 48|parotid gland
P00967223T0059|0 2|I.
P00968181A0264|14 20|calves
P00968181A0264|37 45|immunity
P00968181A0264|67 76|challenge
P00968181A0264|87 91|days
P00968181A0264|108 117|infection
P00970320A0000|4 15|performance
P00970320A0000|39 69|chemical cartridge respirators
P00970320A0000|74 77|SO2
P00970320A0000|105 115|conditions
P00970320A0000|121 135|copper smelter
P00970488A0105|24 32|increase
P00970488A0105|44 55|DA turnover
P00970488A0105|60 69|indicator
P00970488A0105|78 84|degree
P00970488A0105|88 108|DA receptor blocking
P00970488A0105|169 175|effect
P00970488A0105|179 191|neuroleptics
P00970488A0105|200 211|development
P00970488A0105|233 241|symptoms
P00970839A0118|0 13|Rainbow trout
P00970839A0118|46 56|trout farm
P00970839A0118|74 79|water
P00970839A0118|84 91|feeding
P00970839A0118|108 115|pellets
P00970839A0118|127 132|weeks
P00974901A0080|0 11|Stimulation
P00974901A0080|15 34|macrophage function
P00974901A0080|45 71|Bordetella pertussis cells
P00974901A0080|100 106|effect
P00974901A0080|123 137|susceptibility
P00975314T0001|8 19|amenorrhoea
P00975314T0001|65 74|karyotype
P00975314T0001|79 81|xy
P00975314T0001|96 110|gonadoblastoma
P00975540T0000|16 23|methods
P00975540T0000|36 45|chemistry
P00975540T0000|47 58|application
P00975540T0000|62 82|mass fragmentography
P00975540T0000|86 108|high-accuracy analyses
P00980255T0000|0 11|Application
P00980255T0000|19 43|2-deoxy-D-glucose method
P00980255T0000|51 59|coupling
P00980255T0000|72 82|metabolism
P00980255T0000|87 97|blood flow
P00984209A0614|0 20|Serum gastrin levels
P00984209A0614|46 51|group
P00984209A0614|62 101|background serum gastrin concentrations
P00984209A0614|133 145|V&P patients
P00984209A0614|151 163|V&A patients
P00984209A0614|179 184|study
P00985110T0001|9 20|projections
P00985110T0001|36 43|portion
P00985110T0001|51 58|putamen
P00985110T0001|97 104|regions
P00985110T0001|112 115|cat
P00985110T0001|125 131|cortex
P00985276A0000|0 9|Preflight
P00985276A0000|11 19|inflight
P00985276A0000|25 59|postflight exercise response tests
P00985276A0000|82 92|astronauts
P00985276A0000|107 121|Skylab mission
P00985276A0000|123 129|Skylab
P00985276A0000|136 140|part
P00985276A0000|147 157|evaluation
P00985276A0000|175 185|adaptation
P00985276A0000|199 213|weightlessness
P00985279A0493|0 4|Mean
P00985279A0493|17 42|hemoglobin concentrations
P00985279A0493|66 67|h
P00985279A0493|95 101|groups
P00985279A0493|107 116|CO2 group
P00985279A0493|136 144|decrease
P00986800A0325|4 13|Cu values
P00986800A0325|32 38|organs
P00986800A0325|66 82|saturation level
P00986800A0325|88 101|mug Cu/g diet
P00986800A0325|111 120|exception
P00986800A0325|128 134|values
P00986800A0325|139 146|body Cu
P00986800A0325|160 164|dams
P00986800A0325|189 192|day
P00986800A0325|196 204|delivery
P00986925A0002|4 10|effect
P00986925A0002|14 24|calcitonin
P00986925A0002|34 40|amount
P00986925A0002|44 51|calcium
P00986925A0002|66 78|pentagastrin
P00986925A0002|83 91|glucagon
P00986925A0002|95 127|plasma 47Ca radioactivity curves
P00986925A0002|131 139|subjects
P00986925A0002|156 160|47Ca
P00987649T0001|0 5|State
P00987649T0001|13 17|body
P00987649T0001|21 30|disorders
P00987649T0001|56 63|rhythms
P00987649T0001|78 89|hypokinesia
P00988572A0000|0 14|Oxygen tension
P00988572A0000|28 41|lymph vessels
P00988572A0000|43 47|PLO2
P00988572A0000|56 72|rabbit hind limb
P00988572A0000|117 124|chamber
P00988572A0000|145 174|catheter-tip oxygen electrode
P00988572A0000|198 202|data
P00988572A0000|210 216|source
P00988572A0000|220 226|oxygen
P00988572A0000|234 239|lymph
P00989973A0000|4 12|response
P00989973A0000|20 43|plasma fibrinogen level
P00989973A0000|65 74|injection
P00989973A0000|78 88|turpentine
P00989973A0000|112 121|injection
P00989973A0000|125 134|endotoxin
P00989973A0000|158 165|rabbits
P00989973A0000|173 180|rabbits
P00989973A0000|229 237|busulfan
P00992316A0178|23 38|pressure curves
P00992316A0178|55 65|activities
P00992316A0178|112 120|criteria
P00992316A0178|144 153|gravidity
P00993176A0066|6 15|myoglobin
P00993176A0066|41 51|hemoglobin
P00993176A0066|59 72|heme pigments
P00993176A0066|94 101|portion
P00993176A0066|109 116|extract
P00993176A0066|138 148|hemoglobin
P00993176A0066|157 158|%
P00993176A0066|160 163|NH4
P00993176A0066|164 177|2SO4 solution
P00996272A0397|18 25|sources
P00996272A0397|29 34|error
P00996272A0397|47 58|variability
P00996272A0397|74 87|investigation
P00996272A0397|119 131|instructions
P00996364X0000|0 1|E
P00999494A0000|4 12|patients
P00999494A0000|22 31|diagnosis
P00999494A0000|41 46|mania
P00999494A0000|70 75|doses
P00999494A0000|108 125|agent propranolol
P01000378T0000|0 6|Effect
P01000378T0000|10 16|trauma
P01000378T0000|20 35|plasma glucagon
P01000378T0000|40 62|insulin concentrations
P01000378T0000|66 71|sheep
P01003819A0498|9 13|help
P01003819A0498|19 31|nomogram one
P01003819A0498|49 59|refraction
P01003819A0498|66 77|axis length
P01003819A0498|82 99|corneal curvature
P01004298A0744|5 15|up-grading
P01004298A0744|29 34|score
P01004298A0744|42 54|CA component
P01004298A0744|70 71|%
P01004298A0744|90 98|students
P01004298A0744|104 110|scores
P01004298A0744|126 131|level
P01009451A0728|12 20|controls
P01009451A0728|27 29|UB
P01009451A0728|34 42|OCS rats
P01009451A0728|89 98|reduction
P01009451A0728|106 118|nocturnality
P01009451A0728|122 130|drinking
P01009739T0001|0 6|Effect
P01009739T0001|10 22|indomethacin
P01009739T0001|35 46|circulation
P01009739T0001|48 54|effect
P01009739T0001|58 61|ECG
P01009841T0001|5 16|innervation
P01009841T0001|25 31|fibers
P01009841T0001|35 48|trunk muscles
P01009841T0001|52 66|lamprey larvae
P01010638A0161|4 8|feed
P01010638A0161|41 42|%
P01012640T0001|8 23|characteristics
P01012640T0001|27 38|eye changes
P01012640T0001|42 50|patients
P01012640T0001|56 72|pheochromocytoma
P01012640T0001|83 89|Sipple
P01012640T0001|92 100|syndrome
P01012904A0333|15 34|interference effect
P01012904A0333|67 78|populations
P01012904A0333|94 105|Stroop test
P01012904A0333|141 147|sample
P01012904A0333|164 170|format
P01019207A0232|37 47|conditions
P01019207A0232|57 67|dependence
P01019207A0232|87 99|betaI% value
P01019207A0232|104 107|lgC
P01019207A0232|119 124|range
P01019207A0232|136 150|mug ruscogenin
P01021091T0000|4 13|influence
P01021091T0000|28 34|nerves
P01021091T0000|42 50|response
P01021091T0000|54 67|blood vessels
P01021091T0000|75 85|rabbit ear
P01021091T0000|115 126|vasopressin
P01021091T0000|128 139|Octapressin
P01027644T0001|11 15|test
P01030985T0090|0 2|I.
P01035457A0623|7 13|tumour
P01035457A0623|25 41|nipple discharge
P01035457A0623|55 65|importance
P01035457A0623|74 83|diagnosis
P01035457A0623|88 97|treatment
P01036714A0072|0 7|Studies
P01036714A0072|41 48|changes
P01036714A0072|77 84|animals
P01036714A0072|96 106|chrysotile
P01036714A0072|118 126|increase
P01036714A0072|134 138|lung
P01036714A0072|144 159|cell population
P01036714A0072|185 191|levels
P01044338A0240|9 21|measurements
P01044338A0240|25 44|temperature changes
P01044338A0240|49 58|estimates
P01044338A0240|66 73|heating
P01047417T0000|10 37|National Health Dis-service
P01047895T0001|3 12|criticism
P01047895T0001|16 28|patient care
P01047895T0001|68 73|value
P01047895T0001|75 83|Patients
P01047895T0001|85 94|criticism
P01047895T0001|119 131|patient care
P01048020T0000|0 8|Critique
P01048020T0000|25 32|Effects
P01048020T0000|36 48|Test Anxiety
P01048020T0000|53 69|Credit/No Credit
P01048020T0000|73 92|A-F Grade Condition
P01048020T0000|133 151|Course Information
P01048968A0152|6 13|studies
P01048968A0152|34 42|majority
P01048968A0152|53 66|staphylococci
P01048968A0152|85 97|penicillin G
P01048968A0152|99 111|erythromycin
P01048968A0152|126 140|beta-lactamase
P01050144A0297|20 28|decrease
P01050144A0297|36 42|number
P01050144A0297|46 53|strains
P01050144A0297|81 92|antibiotics
P01050144A0297|121 128|strains
P01050144A0297|136 147|83A complex
P01050400T0000|0 11|Improvement
P01050400T0000|15 34|nursing instruction
P01050400T0000|54 58|time
P01050400T0000|62 71|discharge
P01050400T0000|81 85|ward
P01050400T0000|100 107|infants
P01057137A0192|3 13|difference
P01057137A0192|30 43|acceptability
P01057137A0192|81 87|groups
P01064124A0560|9 10|d
P01064124A0560|13 23|subsurface
P01064124A0560|49 55|lesion
P01064124A0560|76 85|specimens
P01067493A0119|18 25|pattern
P01067493A0119|33 38|women
P01067493A0119|61 68|percent
P01067493A0119|92 99|methods
P01071715A0903|17 26|technique
P01071715A0903|40 65|blood pressure recordings
P01075075T0038|0 2|I.
P01078982A0227|62 78|cyclophosphamide
P01078982A0227|81 104|antilymphocyte globulin
P01078982A0227|106 109|ALG
P01078982A0227|111 120|treatment
P01078982A0227|127 145|ALG administration
P01078982A0227|166 172|dosage
P01078982A0227|176 192|cyclophosphamide
P01080374A0709|0 8|Evidence
P01080374A0709|27 32|Leber
P01080374A0709|44 62|aneurysm retinitis
P01080374A0709|81 87|entity
P01080374A0709|102 106|form
P01080374A0709|110 115|Coats
P01080374A0709|117 124|disease
P01081904A0198|26 34|catheter
P01081904A0198|51 59|patients
P01081904A0198|71 93|pull-out arteriography
P01081904A0198|129 137|symptoms
P01082726A0248|4 13|influence
P01082726A0248|26 31|pupil
P01082726A0248|39 47|response
P01082726A0248|55 61|DC-ERG
P01082833A0000|38 43|agent
P01082833A0000|45 51|Y-8004
P01082833A0000|75 85|inhibition
P01082833A0000|95 107|indomethacin
P01082833A0000|109 111|IM
P01082833A0000|130 138|response
P01082833A0000|159 167|erythema
P01082833A0000|171 182|guinea pigs
P01082833A0000|184 201|carrageenin edema
P01082833A0000|238 247|pleuritis
P01082833A0000|272 283|peritonitis
P01082833A0000|287 291|rats
P01083321X0000|3 9|stands
P01083321X0000|21 30|dominance
P01083321X0000|53 56|age
P01083321X0000|58 71|subalpine fir
P01083321X0000|114 119|rates
P01083321X0000|136 148|productivity
P01083321X0000|155 161|stands
P01083321X0000|185 190|years
P01083375T0000|0 19|Alpha-1 antitrypsin
P01083375T0000|31 50|childhood cirrhosis
P01083784T0000|0 25|Lymphocyte subpopulations
P01083784T0000|27 36|serum IgE
P01083784T0000|47 64|eosinophil counts
P01083784T0000|68 76|patients
P01083784T0000|92 98|asthma
P01084413A0271|2 7|range
P01084413A0271|30 42|measurements
P01084413A0271|51 54|EMI
P01087288T0000|2 12|comparison
P01087288T0000|41 50|estimates
P01087288T0000|54 68|radiation dose
P01087288T0000|72 80|patients
P01087288T0000|94 104|iodine-131
P01087288T0000|109 126|thyroid carcinoma
P01088654T0001|0 9|Technique
P01088654T0001|32 40|ceramics
P01088654T0001|52 56|mass
P01090210A0417|0 4|Mean
P01090210A0417|11 24|lung capacity
P01090210A0417|46 54|capacity
P01090210A0417|69 75|volume
P01090210A0417|109 128|mean closing volume
P01090210A0417|134 145|lung volume
P01090210A0417|161 167|volume
P01090210A0417|177 182|phase
P01090210A0417|226 232|cm H20
P01090210A0417|253 268|airway pressure
P01090210A0417|270 281|differences
P01090210A0417|287 293|cm H20
P01092248T0000|8 14|status
P01092248T0000|18 33|zinc deficiency
P01092248T0000|41 53|pathogenesis
P01092248T0000|106 115|disorders
P01093055T0000|0 7|Calcium
P01093055T0000|12 33|phosphorus metabolism
P01093055T0000|45 51|uremia
P01093845A0208|0 14|Modern studies
P01093845A0208|31 42|Delta-9-THC
P01093845A0208|55 66|voluntaries
P01093845A0208|86 96|comparison
P01093845A0208|109 117|identity
P01093845A0208|125 138|modifications
P01093845A0208|149 157|cannabis
P01093845A0208|163 168|sleep
P01093845A0208|173 178|dream
P01093847A0000|15 21|action
P01093847A0000|25 50|tropatepine hydrochloride
P01093847A0000|75 82|effects
P01093847A0000|94 106|neuroleptics
P01093847A0000|146 152|states
P01096741X0000|11 17|growth
P01096741X0000|34 41|animals
P01096741X0000|63 77|chickpea haulm
P01096741X0000|96 111|supplementation
P01097100A0217|4 12|patients
P01097100A0217|36 44|regimens
P01098179A0167|0 7|Results
P01098179A0167|48 60|preparations
P01098179A0167|85 103|dissolution curves
P01098179A0167|118 124|assays
P01098179A0167|142 157|chloramphenicol
P01098179A0167|175 182|release
P01098179A0167|194 202|activity
P01098179A0167|209 215|creams
P01098179A0167|237 246|ointments
P01098592A0567|0 10|IgG levels
P01098592A0567|57 64|samples
P01098592A0567|78 82|days
P01098592A0567|102 107|onset
P01099693T0000|0 6|Letter
P01099693T0000|8 20|Perspectives
P01099693T0000|24 51|bone marrow transplantation
P01101272T0000|0 10|Assessment
P01101272T0000|18 33|carcinogenicity
P01101272T0000|51 60|sweetners
P01101272T0000|65 75|Cyclamates
P01101272T0000|80 95|cyclohexylamine
P01103390A0149|15 24|behaviour
P01103390A0149|44 48|mice
P01103390A0149|64 74|occurrence
P01103390A0149|83 90|animals
P01103390A0149|103 108|phase
P01103390A0149|123 131|increase
P01103390A0149|139 150|parasitemia
P01107226A0808|9 23|amphotericin B
P01107226A0808|44 49|feces
P01107226A0808|57 61|mice
P01107226A0808|101 117|mg/ml dose level
P01113908A0475|19 27|increase
P01113908A0475|37 48|transferrin
P01113908A0475|51 53|hr
P01113908A0475|62 68|tablet
P01113908A0475|73 79|values
P01113908A0475|109 119|experiment
P01116254A0000|22 36|administration
P01116254A0000|53 66|concentration
P01116254A0000|70 89|tracer thallium-201
P01116254A0000|91 103|potassium-43
P01116254A0000|109 120|rubidium-81
P01116254A0000|140 144|mice
P01116254A0000|146 154|thallium
P01116254A0000|183 196|concentration
P01116254A0000|204 214|myocardium
P01116254A0000|220 221|%
P01116254A0000|235 236|%
P01116254A0000|241 250|potassium
P01116254A0000|259 260|%
P01116254A0000|265 273|rubidium
P01116254A0000|280 287|minutes
P01116466A0185|0 19|Thromboplastin time
P01116466A0185|29 48|thromboplastin time
P01116466A0185|50 63|thrombin time
P01116466A0185|80 86|fibrin
P01116466A0185|88 103|clot retraction
P01116466A0185|109 125|clotting factors
P01116466A0185|130 131|V
P01116466A0185|133 137|VIII
P01116466A0185|143 144|X
P01116466A0185|154 168|platelet count
P01118293A0150|4 8|data
P01118293A0150|21 27|notion
P01118293A0150|33 44|suppression
P01118293A0150|48 54|images
P01118293A0150|72 79|rivalry
P01118293A0150|103 107|eyes
P01119586A0337|0 20|Glycogen utilization
P01119586A0337|40 53|tissue levels
P01119586A0337|57 75|creatine phosphate
P01119586A0337|77 80|ATP
P01119586A0337|86 93|lactate
P01119586A0337|119 125|hearts
P01119586A0337|143 147|flow
P01119658A0000|4 11|records
P01119658A0000|63 71|patients
P01119658A0000|86 100|cell carcinoma
P01119658A0000|113 119|cavity
P01119658A0000|121 131|oropharynx
P01119658A0000|146 152|larynx
P01119658A0000|157 168|hypopharynx
P01119658A0000|206 227|lymph node metastases
P01119658A0000|235 237|N1
P01119658A0000|239 242|N2A
P01119658A0000|247 250|N2B
P01119658A0000|270 284|neck treatment
P01119658A0000|307 324|radiation therapy
P01122015A0467|9 12|vol
P01122015A0467|14 15|%
P01122015A0467|35 41|values
P01122015A0467|51 58|mumol/1
P01122015A0467|65 74|mg/100 ml
P01122015A0467|84 91|mumol/1
P01122015A0467|98 107|mg/100 ml
P01123658A0000|4 11|authors
P01123658A0000|25 34|technique
P01123658A0000|55 65|tomography
P01123658A0000|73 78|spine
P01123658A0000|99 110|description
P01123658A0000|124 131|anatomy
P01123658A0000|153 158|spine
P01123658A0000|164 167|L-4
P01123658A0000|175 181|sacrum
P01124944A0830|18 26|attitude
P01124944A0830|34 46|protein diet
P01124944A0830|52 56|g/kg
P01125117A0183|3 7|none
P01125117A0183|18 22|type
P01125117A0183|25 32|attacks
P01125117A0183|40 44|type
P01125117A0183|48 55|attacks
P01125117A0183|92 99|changes
P01125117A0183|138 144|groups
P01128985A0000|31 37|method
P01128985A0000|88 95|periods
P01128985A0000|99 104|apnea
P01128985A0000|118 126|patients
P01130186A0568|24 31|patient
P01130186A0568|54 69|insulin release
P01130186A0568|73 81|response
P01130186A0568|85 96|tolbutamide
P01130531A0224|0 17|Nerve stimulation
P01130531A0224|26 34|cycles/s
P01130531A0224|65 75|reductions
P01130531A0224|79 82|CBF
P01130531A0224|86 94|decrease
P01130531A0224|101 108|percent
P01130531A0224|136 145|frequency
P01131946T0001|0 6|Effect
P01131946T0001|10 19|ingestion
P01131946T0001|23 33|Norbiogest
P01131946T0001|55 61|period
P01131946T0001|77 83|organs
P01138215T0001|0 4|Risk
P01138215T0001|8 17|infection
P01138215T0001|25 34|treatment
P01138215T0001|38 47|fractures
P01138330A0204|7 14|pouches
P01138330A0204|34 43|solutions
P01138330A0204|50 57|% Na C1
P01138330A0204|63 68|N HC1
P01138330A0204|72 81|% glucose
P01138330A0204|85 91|% NaC1
P01138330A0204|99 108|% peptone
P01138330A0204|120 131|% solutions
P01138330A0204|135 157|acetylcholine chloride
P01140184A0342|0 16|Liver microsomes
P01140184A0342|50 51|%
P01140184A0342|59 83|epoxide hydrase activity
P01140184A0342|103 104|%
P01140184A0342|126 134|capacity
P01140184A0342|138 154|liver microsomes
P01140184A0342|164 167|rat
P01141114A0188|16 20|work
P01141114A0188|33 41|increase
P01141114A0188|68 72|mmHg
P01141114A0188|84 87|P50
P01141114A0188|94 98|PH-v
P01141114A0188|103 114|degrees C-v
P01141114A0188|123 129|Pv-CO2
P01141114A0188|161 168|effects
P01141114A0188|189 200|temperature
P01141114A0188|206 207|H
P01145884T0028|39 44|study
P01147436T0000|13 38|Burkitt Lymphoma Registry
P01147436T0000|42 57|progress report
P01147502T0000|0 10|Vitrectomy
P01147502T0000|31 48|instrument system
P01148868A0284|14 28|clearance rate
P01148868A0284|32 44|progesterone
P01148868A0284|61 65|S.E.
P01148868A0284|67 72|1/day
P01150658A0683|5 13|sequence
P01150658A0683|65 72|hormone
P01150658A0683|74 80|Sairam
P01150658A0683|82 84|M.
P01156631A0658|4 36|mean plasma sodium concentration
P01156631A0658|59 61|SD
P01156631A0658|68 74|mEq/kg
P01156631A0658|91 100|treatment
P01156631A0658|136 145|treatment
P01156631A0658|161 163|SD
P01156631A0658|170 176|mEq/kg
P01156631A0658|178 179|P
P01156814T0000|0 9|Editorial
P01156814T0000|20 27|heparin
P01156814T0000|36 46|prevention
P01156814T0000|57 79|thromboembolic disease
P01157191A0536|17 28|dose levels
P01157191A0536|35 51|sodium saccharin
P01157191A0536|56 72|sodium cyclamate
P01157191A0536|92 103|carcinogens
P01157191A0536|130 145|bladder tumours
P01157191A0536|183 190|tumours
P01157191A0536|223 228|weeks
P01157614T0000|0 7|Effects
P01157614T0000|22 30|salience
P01157614T0000|38 61|matrix task performance
P01157614T0000|88 96|children
P01158512T0000|20 33|dehydrogenase
P01158512T0000|35 41|G-6-PD
P01158512T0000|43 53|deficiency
P01158838A0438|57 66|flow rate
P01158838A0438|74 80|ml/min
P01159822A0353|14 23|epithelia
P01159822A0353|45 52|animals
P01159822A0353|82 96|ultrastructure
P01159822A0353|104 117|invaginations
P01159822A0353|119 123|tilt
P01159822A0353|135 139|axes
P01159822A0353|144 152|increase
P01159822A0353|160 166|number
P01159822A0353|171 175|size
P01159822A0353|179 188|lysosomes
P01159822A0353|210 216|bodies
P01159822A0353|232 239|numbers
P01159822A0353|271 279|granules
P01168607A0672|12 26|administration
P01168607A0672|42 50|vitamins
P01168607A0672|100 116|prothrombin time
P01168607A0672|121 135|serum vitamins
P01168607A0672|142 143|E
P01168607A0672|147 156|intervals
P01168908A0000|0 16|Prostaglandins F
P01168908A0000|18 21|PGF
P01168908A0000|48 52|vein
P01168908A0000|62 68|artery
P01168908A0000|82 93|vein plasma
P01168908A0000|117 124|tissues
P01168908A0000|136 141|times
P01168908A0000|168 173|cycle
P01168908A0000|207 233|plasma progesterone levels
P01168956A0552|12 16|date
P01168956A0552|22 26|drug
P01168956A0552|51 62|weight gain
P01168956A0552|76 87|sensitivity
P01168956A0552|95 103|placenta
P01168956A0552|125 128|day
P01168956A0552|145 168|maximum weight decrease
P01168956A0552|177 182|organ
P01168956A0552|186 187|h
P01170143A0247|0 6|Groups
P01170143A0247|32 43|saline mice
P01170143A0247|86 96|conditions
P01170143A0247|121 130|cylinders
P01171020A0711|4 11|effects
P01171020A0711|31 54|nucleus accumbens septi
P01171935A0313|4 14|appearance
P01171935A0313|29 47|movement disorders
P01171935A0313|51 57|humans
P01171935A0313|80 83|use
P01171935A0313|87 95|levodopa
P01171935A0313|99 110|amphetamine
P01171935A0313|120 133|manifestation
P01171935A0313|157 191|dopamine receptor site sensitivity
P01171935A0313|203 211|striatum
P01172734T0035|0 11|Association
P01172734T0035|22 26|W-27
P01172917T0000|0 6|Letter
P01172917T0000|8 31|Lactose tolerance tests
P01172917T0000|37 46|predictor
P01172917T0000|50 64|milk tolerance
P01174873T0000|0 14|Retinoblastoma
P01174873T0000|18 23|study
P01174873T0000|35 42|history
P01174873T0000|47 56|prognosis
P01174873T0000|64 69|cases
P01176905A0094|12 21|melatonin
P01176905A0094|23 38|serum melatonin
P01176905A0094|51 59|mid-dark
P01176905A0094|71 80|mid-light
P01178153A0056|0 2|D.
P01178637T0001|0 15|Atherosclerosis
P01185956A0722|4 11|authors
P01185956A0722|38 58|Doppler-cardiography
P01185956A0722|98 105|changes
P01185956A0722|113 126|stroke volume
P01186344A0303|4 14|attainment
P01186344A0303|25 33|maturity
P01186344A0303|37 42|terms
P01186344A0303|63 78|characteristics
P01186344A0303|84 94|production
P01186344A0303|98 109|spermatozoa
P01186344A0303|117 121|male
P01186344A0303|147 154|pattern
P01186344A0303|160 167|release
P01186344A0303|171 174|ova
P01186344A0303|179 189|end-points
P01186344A0303|211 218|process
P01190120A0832|17 30|% lengthening
P01190120A0832|46 65|thromboplastin time
P01190120A0832|86 91|hours
P01190120A0832|95 102|storage
P01190251A0335|0 7|Caution
P01190251A0335|35 38|use
P01190251A0335|48 52|dyes
P01190251A0335|57 68|lymphograms
P01191955A0077|19 23|test
P01191955A0077|44 56|incompetence
P01191955A0077|79 83|cent
P01191955A0077|87 94|varices
P01191955A0077|124 130|reflux
P01191964A0000|6 12|groups
P01191964A0000|16 24|patients
P01191964A0000|52 65|thyroidectomy
P01191964A0000|70 76|Graves
P01191964A0000|79 86|disease
P01191964A0000|107 113|goitre
P01191964A0000|141 147|goitre
P01191964A0000|157 162|years
P01191964A0000|191 206|serum thyroxine
P01191964A0000|208 211|T-4
P01191964A0000|213 218|level
P01191964A0000|256 265|subgroups
P01191964A0000|273 278|basis
P01191964A0000|303 335|serum thyrotrophin concentration
P01193458T0001|8 27|isotope cystography
P01193458T0001|38 55|Tc sulfur colloid
P01193458T0001|60 69|detection
P01193458T0001|74 83|follow-up
P01193458T0001|103 109|reflux
P01193770T0000|0 14|Air ion action
P01193770T0000|18 26|bacteria
P01194673A0652|3 11|evidence
P01194673A0652|43 54|chemography
P01201977T0000|4 18|interpretation
P01201977T0000|33 51|disc sensitivities
P01202616A0466|10 23|retransfusion
P01202616A0466|49 55|lining
P01202616A0466|103 117|lamina propria
P01202616A0466|140 144|loss
P01202616A0466|159 165|detail
P01206772T0000|2 7|study
P01206772T0000|11 22|chromosomes
P01206772T0000|26 37|lymphocytes
P01206772T0000|43 51|patients
P01206772T0000|65 75|hycanthone
P01206896T0001|0 15|Characteristics
P01206896T0001|19 29|anesthesia
P01206896T0001|34 47|resuscitation
P01206896T0001|51 73|emergency lung surgery
P01208811T0001|0 5|Study
P01208811T0001|30 35|state
P01208811T0001|39 52|plutonium-239
P01208811T0001|58 87|citrate solution-blood system
P01209618A0409|0 10|Tobramycin
P01209618A0409|14 16|mg
P01209618A0409|45 51|effect
P01209618A0409|57 66|dibecacin
P01209618A0409|71 73|mg
P01209618A0409|92 111|potentiating effect
P01209618A0409|119 125|action
P01209618A0409|129 143|d-tubocurarine
P01211754A0192|26 31|cases
P01211754A0192|37 46|operation
P01211754A0192|74 85|improvement
P01211754A0192|90 98|patients
P01211754A0192|137 145|deafness
P01215067A0000|24 34|resistance
P01215067A0000|56 61|fluid
P01215067A0000|78 83|means
P01215067A0000|87 100|conductometry
P01215067A0000|107 112|cases
P01215067A0000|116 136|meningitis purulenta
P01215067A0000|141 146|cases
P01215067A0000|150 167|meningitis serosa
P01215067A0000|172 177|cases
P01215067A0000|181 193|encephalitis
P01215067A0000|212 220|subjects
P01217450A0295|4 22|Chemical occlusion
P01217450A0295|64 69|block
P01217450A0295|93 97|dogs
P01224116A0576|23 31|patients
P01224116A0576|42 63|serum immunoglobulins
P01224116A0576|73 76|IgG
P01224116A0576|87 92|Russe
P01224116A0576|94 99|Busey
P01224116A0576|104 111|Barbeau
P01224116A0576|152 158|family
P01225339A0590|21 31|occlusions
P01225339A0590|48 52|time
P01225339A0590|60 70|infarction
P01228258A0000|14 25|preparation
P01228258A0000|27 33|OK-432
P01228258A0000|42 46|type
P01228258A0000|62 67|agent
P01228258A0000|86 94|patients
P01228258A0000|109 115|cancer
P01228258A0000|119 130|combination
P01228258A0000|136 147|Mitomycin-C
P01228258A0000|149 153|5-FU
P01228258A0000|158 178|Cytosine arabinoside
P01228882A0437|13 24|correlation
P01228882A0437|54 68|concentrations
P01228882A0437|72 91|CSF immunoglobulins
P01228882A0437|96 102|degree
P01228882A0437|129 137|response
P01228882A0437|158 167|component
P01228882A0437|190 198|diseases
P01233561T0001|9 18|lactation
P01235347T0001|13 27|cardiotoxicity
P01235347T0001|31 41|adriamycin
P01236224T0001|9 18|pathology
P01237206A0199|0 13|Demonstration
P01237206A0199|21 26|agent
P01237206A0199|66 74|day p.i.
P01237206A0199|97 104|methods
P01237206A0199|106 111|Stamp
P01237206A0199|116 133|auramine staining
P01237206A0199|147 165|antibody technique
P01237206A0199|172 188|Coxiella content
P01237206A0199|207 216|titration
P01237206A0199|232 235|hen
P01237206A0199|238 242|eggs
P01241437A0152|4 12|patients
P01241437A0152|33 39|groups
P01241437A0152|50 56|NLA II
P01241437A0152|73 83|nalorphine
P01241437A0152|85 93|morphine
P01241437A0152|97 104|Micoren
P01241588A1470|4 15|alterations
P01241588A1470|19 23|5-HT
P01241588A1470|28 41|5-HIAA levels
P01241588A1470|53 60|regions
P01241588A1470|68 73|brain
P01241588A1470|84 94|conditions
P01241588A1470|122 126|IDPN
P01241588A1470|129 142|neurotoxicity
P01241588A1470|177 185|neurones
P01241866A0682|7 15|increase
P01241866A0682|19 35|leukocyte-counts
P01241866A0682|52 66|administration
P01241866A0682|70 75|serum
P01241866A0682|90 96|rabbit
P01241866A0682|104 111|phase-2
P01242636A0678|4 11|results
P01242636A0678|64 70|system
P01242636A0678|94 113|beryllium retention
P01243628A0286|8 13|cases
P01243628A0286|22 25|end
P01243628A0286|29 37|exposure
P01243628A0286|47 52|level
P01243628A0286|56 79|blood carboxyhemoglobin
P01243628A0286|81 85|COHb
P01243628A0286|96 97|%
P01244236A1122|4 11|results
P01244236A1122|46 56|blood flow
P01244236A1122|90 100|resistance
P01244236A1122|116 125|gestation
P01244236A1122|140 148|increase
P01244236A1122|162 168|number
P01244236A1122|172 179|vessels
P01244236A1122|194 214|vasomotor reactivity
P01244236A1122|232 240|increase
P01244236A1122|254 260|amount
P01244236A1122|271 277|muscle
P01244236A1122|288 297|thickness
P01244236A1122|301 307|muscle
P01244236A1122|322 329|vessels
P01245162A0262|0 9|Reduction
P01245162A0262|13 19|dosage
P01245162A0262|36 47|taste sense
P01245162A0262|77 81|drug
P01245162A0262|132 151|transaminase levels
P01246210A0648|4 17|calcium ratio
P01246210A0648|18 28|mean ratio
P01246210A0648|58 62|TBCa
P01246210A0648|67 70|men
P01246210A0648|88 89|%
P01246210A0648|97 102|women
P01246210A0648|116 117|%
P01247475A0000|7 16|diagnosis
P01247475A0000|20 34|retinoblastoma
P01247475A0000|56 60|fact
P01247475A0000|77 83|growth
P01247475A0000|99 112|deterioration
P01247475A0000|120 127|outlook
P01248124A0281|6 17|cholesterol
P01248124A0281|43 49|fluids
P01248124A0281|73 79|stages
P01248124A0281|83 92|gestation
P01249198A1097|4 27|serum FT3 concentration
P01249198A1097|63 69|ranges
P01249198A1097|80 89|pregnancy
P01249198A1097|96 108|GTD patients
P01249198A1097|126 141|hyperthyroidism
P01252223A0347|4 11|authors
P01252223A0347|34 38|fear
P01252223A0347|43 52|pugnacity
P01252223A0347|70 88|trait correlations
P01252223A0347|107 115|contrast
P01252223A0347|119 124|Winch
P01252223A0347|127 136|principle
P01252223A0347|140 144|type
P01252223A0347|147 162|complementarity
P01253191T0000|2 6|note
P01253191T0000|14 50|phase-plane technique representation
P01253191T0000|62 79|action potentials
P01256410T0001|2 12|activities
P01256410T0001|20 26|factor
P01256410T0001|30 38|molecule
P01256410T0001|54 60|infant
P01256410T0001|64 68|term
P01259027A0416|4 11|concept
P01259027A0416|27 42|identifiability
P01259027A0416|64 72|analysis
P01259027A0416|92 108|model parameters
P01259027A0416|182 186|data
P01259027A0416|203 212|procedure
P01259027A0416|225 234|extension
P01259027A0416|243 250|concept
P01259027A0416|289 297|approach
P01259027A0416|318 332|design problem
P01261005A0711|34 43|variation
P01261005A0711|48 59|differences
P01261005A0711|63 74|performance
P01261005A0711|90 98|bandpass
P01261005A0711|108 135|bandpass spectrophotometers
P01262596T0000|13 23|compromise
P01264640T0028|2 6|case
P01264640T0028|19 25|Saigon
P01265443A0159|11 18|glucose
P01265443A0159|50 71|Heidenhain pouch dogs
P01265443A0159|93 103|inhibition
P01265443A0159|128 142|acid secretion
P01265443A0159|152 157|pouch
P01265443A0159|171 178|stomach
P01265443A0159|199 205|saline
P01265443A0159|213 219|effect
P01265887T0001|9 30|factor VIII inhibitor
P01265887T0001|49 57|patients
P01267446A0210|0 16|Biohydrogenation
P01267446A0210|29 33|acid
P01267446A0210|52 56|acid
P01272816A0000|4 9|study
P01272816A0000|13 31|calcium metabolism
P01272816A0000|52 60|children
P01272816A0000|80 88|controls
P01272816A0000|100 114|administration
P01272816A0000|118 122|47Ca
P01272816A0000|155 165|absorption
P01275335A0158|11 17|agents
P01275335A0158|41 46|semen
P01275335A0158|56 59|end
P01275335A0158|79 84|phase
P01275541A0405|25 37|CPK activity
P01275541A0405|54 62|newborns
P01275541A0405|101 110|dystrophy
P01275541A0405|141 146|weeks
P01275541A0405|153 161|delivery
P01276105A0313|3 11|contrast
P01276105A0313|17 33|insulin response
P01276105A0313|67 72|value
P01276105A0313|87 90|day
P01276105A0313|98 108|puerperium
P01278251A0000|4 11|authors
P01278251A0000|23 30|results
P01278251A0000|36 42|series
P01278251A0000|60 65|tests
P01278251A0000|87 96|materials
P01278251A0000|98 110|polyethylene
P01278251A0000|127 147|tetraphenylbutadiene
P01278251A0000|149 152|TPB
P01278251A0000|189 199|sensitizer
P01278251A0000|234 243|materials
P01279197T0000|11 19|analysis
P01279197T0000|33 48|homology region
P01279197T0000|52 77|Mason-Pfizer monkey virus
P01279197T0000|81 84|use
P01279197T0000|88 110|saturation mutagenesis
P01279352A0297|4 8|site
P01279352A0297|10 13|PAL
P01279352A0297|36 58|bp sequence GGGGAGGAGG
P01279352A0473|8 16|extracts
P01279352A0473|58 68|cell lines
P01279352A0473|70 81|mouse brain
P01279352A0473|87 98|mouse liver
P01279352A0473|107 115|proteins
P01279352A0473|147 151|PROX
P01279352A0473|156 169|PAL sequences
P01279352A0473|186 194|proteins
P01279352A0473|215 231|target sequences
P01279352A1197|20 22|NF
P01279352A1197|23 24|H
P01279352A1197|26 34|promoter
P01279352A1197|57 63|tissue
P01279352A1197|73 79|manner
P01279352A1197|87 98|development
P01279352A1197|110 114|mice
P01279352A1197|130 145|promoter region
P01279352A1197|158 190|beta-galactosidase reporter gene
P01279374A0396|38 43|genes
P01279374A0396|74 85|suppressors
P01279374A0396|123 133|truncation
P01279374A0396|137 143|PET122
P01279696A0862|9 16|studies
P01279696A0862|29 37|Hisanaga
P01279696A0862|39 41|S.
P01279696A0862|43 51|Kusubata
P01279696A0862|53 55|M.
P01279696A0862|57 64|Okumura
P01279696A0862|66 68|E.
P01279696A0862|71 80|Kishimoto
P01279696A0862|82 84|T.
P01280413T0001|0 9|Treatment
P01280413T0001|14 22|staining
P01280413T0001|26 32|smears
P01280413T0001|37 45|sections
P01280413T0001|50 59|detection
P01280413T0001|63 77|microorganisms
P01280807A0575|13 15|Kd
P01280807A0575|23 49|MetRS/CAU operator complex
P01280807A0575|57 72|order magnitude
P01280807A0575|97 123|ThrRS/CGU operator complex
P01281322A0604|21 33|relationship
P01281322A0604|59 79|percent area density
P01281322A0604|90 96|muscle
P01281322A0604|105 119|percent change
P01281322A0604|136 145|flow rate
P01281472T0000|0 6|Rabbit
P01281472T0000|16 33|muscle glycogenin
P01281771T0000|0 16|Characterization
P01281771T0000|30 34|gene
P01281771T0000|44 55|cytokeratin
P01281771T0000|67 85|expression pattern
P01282014A0275|0 7|Animals
P01282014A0275|22 27|DSP-4
P01282014A0275|59 73|motor recovery
P01282014A0275|92 104|saline group
P01282638A0934|4 20|prophylactic use
P01282638A0934|28 38|medication
P01282638A0934|43 51|patients
P01282638A0934|81 86|cycle
P01282638A0934|90 102|chemotherapy
P01282638A0934|107 116|agreement
P01282638A0934|126 135|estimates
P01282638A0934|162 179|health care costs
P01282638A0934|200 207|quality
P01282638A0934|211 215|life
P01282638A0934|225 233|patients
P01282638A0934|249 261|continuation
P01282638A0934|279 287|schedule
P01282638A0934|296 308|interruption
P01282638A0934|331 346|life expectancy
P01282638A0934|354 361|patient
P01284032A0213|0 2|AP
P01284032A0213|30 38|infusion
P01284032A0213|56 70|concentrations
P01284032A0213|91 95|acid
P01284032A0213|97 101|GDOC
P01284032A0213|105 109|mmol
P01284032A0213|117 121|mmol
P01284595A0102|4 13|isolation
P01284595A0102|22 26|gene
P01284595A0102|44 58|identification
P01284595A0102|66 78|Y-231 cosmid
P01284595A0102|93 96|CpG
P01284595A0102|102 111|sequences
P01284595A0102|113 124|HTF islands
P01284595A0102|139 145|insert
P01284828T0001|0 28|Tissue plasminogen activator
P01284828T0001|34 43|inhibitor
P01284828T0001|54 64|parameters
P01284828T0001|68 80|fibrinolysis
P01284828T0001|84 89|blood
P01284828T0001|93 101|patients
P01284828T0001|120 131|hypertrophy
P01284828T0001|139 147|prostate
P01285009A0000|0 15|Gene constructs
P01285009A0000|36 50|growth hormone
P01285009A0000|52 55|hGH
P01285009A0000|57 61|gene
P01285009A0000|92 100|sequence
P01285009A0000|104 125|mouse metallothionein
P01285009A0000|127 130|mMT
P01285009A0000|139 155|thymidine kinase
P01285009A0000|157 160|vTK
P01285009A0000|163 182|rat cholecystokinin
P01285009A0000|184 188|rCCK
P01285009A0000|194 212|chicken beta-actin
P01285009A0000|214 217|cBA
P01285009A0000|219 223|gene
P01285009A0000|247 256|cytoplasm
P01285009A0000|271 282|medaka eggs
P01285009A0000|291 300|micropyle
P01285358A0396|0 13|Serum gastrin
P01285358A0396|18 28|AFP levels
P01285358A0396|42 51|evolution
P01285358A0396|80 88|interest
P01285358A0396|103 109|course
P01285358A0396|117 124|disease
P01285554T0000|0 9|Prospects
P01285554T0000|34 41|systems
P01285807A0365|4 8|mean
P01285807A0365|14 16|SD
P01285807A0365|18 22|PaO2
P01285807A0365|52 56|mmHg
P01285807A0365|81 85|mmHg
P01285807A0365|96 104|infusion
P01285807A0365|106 107|P
P01285807A0365|124 129|PaCO2
P01285807A0365|174 178|mmHg
P01285807A0365|180 181|P
P01286732A0572|7 19|hepatomegaly
P01286732A0572|29 38|elevation
P01286732A0572|42 49|enzymes
P01286732A0572|83 93|proportion
P01286732A0572|97 105|patients
P01286732A0572|107 118|involvement
P01286732A0572|122 127|liver
P01286732A0572|145 154|hepatitis
P01286732A0572|158 177|liver cell necrosis
P01286732A0572|203 215|complication
P01286732A0572|219 240|P. falciparum malaria
P01287197A0761|14 19|group
P01287197A0761|33 41|decrease
P01287197A0761|45 61|plasma potassium
P01287197A0761|74 84|salbutamol
P01287197A0761|137 143|mmol/l
P01287197A0761|164 169|group
P01287197A0761|179 188|decrement
P01287197A0761|241 247|mmol/l
P01287197A0761|256 258|iv
P01287197A0761|260 262|po
P01292230A0283|8 13|drugs
P01292230A0283|27 31|rate
P01292230A0283|51 58|filling
P01294345A0591|28 39|improvement
P01294345A0591|51 65|administration
P01294345A0591|69 78|Bromergon
P01294345A0591|95 103|symptoms
P01294345A0591|120 136|overreactiveness
P01294345A0591|147 163|prolactin levels
P01294345A0591|180 187|tension
P01294345A0591|189 194|edema
P01294345A0591|196 207|weight gain
P01294345A0591|212 229|breast tenderness
P01295373A0651|4 13|magnitude
P01295373A0651|27 35|response
P01295373A0651|50 51|%
P01295373A0651|55 56|A
P01295373A0651|58 71|% baseline RL
P01295373A0651|73 77|mean
P01295373A0651|82 84|SE
P01295373A0651|113 114|B
P01295373A0651|124 125|%
P01295373A0651|131 132|C
P01295373A0651|143 144|%
P01295373A0651|147 148|p
P01295500A0366|12 20|patients
P01295500A0366|55 62|Attacks
P01295500A0366|66 67|%
P01295500A0366|103 111|Deficits
P01295500A0366|115 116|%
P01296815A0059|26 30|gene
P01296815A0059|39 43|LD78
P01296815A0059|52 62|LD78 gamma
P01296815A0059|71 88|sequence analysis
P01296815A0059|122 132|pseudogene
P01297332A0983|5 13|analysis
P01297332A0983|31 44|consideration
P01297332A0983|52 56|SCBs
P01297332A0983|98 103|genes
P01297332A0983|118 126|proposal
P01297332A0983|140 158|consensus sequence
P01297332A0983|189 196|element
P01297332T0000|11 19|analysis
P01297332T0000|25 37|DNA sequence
P01297332T0000|58 73|gene expression
P01297332T0000|81 91|cell cycle
P01298173A0153|12 19|history
P01298173A0153|29 36|lesions
P01298173A0153|51 61|efficiency
P01298173A0153|79 89|treatments
P01298173A0153|100 104|part
P01298173A0153|115 127|chemotherapy
P01298173A0153|129 137|survival
P01298173A0153|149 154|death
P01298173A0153|171 181|modalities
P01298173A0153|197 204|measure
P01298398A0461|4 10|method
P01298398A0461|31 44|determination
P01298398A0461|48 66|nadolol racemate A
P01298398A0461|72 78|change
P01298398A0461|89 106|phase composition
P01299489A0788|26 31|study
P01299489A0788|48 56|evidence
P01299489A0788|64 70|effect
P01299489A0788|74 89|supplementation
P01299489A0788|102 113|performance
P01299489A0788|118 126|athletes
P01299489A0788|149 153|RDIs
P01300914A1066|7 14|absence
P01300914A1066|31 39|criteria
P01300914A1066|76 80|view
P01300914A1066|88 99|variability
P01300914A1066|103 110|results
P01300914A1066|125 132|dangers
P01300914A1066|151 157|biopsy
P01300914A1066|202 207|walls
P01300914A1066|213 222|diagnosis
P01300914A1066|226 230|ACRV
P01300914A1066|261 270|existence
P01300914A1066|300 308|criteria
P01300914A1066|322 333|arrhythmias
P01300914A1066|372 374|VT
P01300914A1066|396 403|feature
P01300914A1066|419 425|degree
P01300914A1066|429 440|sensitivity
P01300914A1066|455 466|stimulation
P01300914A1066|468 476|exercise
P01300914A1066|483 492|existence
P01300914A1066|501 511|potentials
P01300914A1066|524 541|amplification ECG
P01300914A1066|561 565|sign
P01300914A1066|596 607|sensitivity
P01300914A1066|621 626|froms
P01300914A1066|713 729|RV abnormalities
P01300914A1066|797 805|vaulting
P01300914A1066|812 818|stasis
P01301171A0979|10 15|cases
P01301171A0979|21 29|enhancer
P01301171A0979|46 69|c-myc bearing sequences
P01301171A0979|73 83|chromosome
P01302765A0999|6 16|components
P01302765A0999|35 37|R2
P01302765A0999|66 69|R2s
P01302765A0999|119 121|ad
P01302765A0999|130 140|components
P01304515A0178|13 20|results
P01304515A0178|40 53|control group
P01304515A0178|65 75|volunteers
P01304809T0001|4 9|years
P01304809T0001|13 22|dentistry
P01304809T0001|30 59|Friedrich Schiller University
P01304809T0001|63 67|Jena
P01309244A0798|4 10|target
P01309244A0798|29 38|positions
P01309244A0798|53 57|acts
P01309244A0798|75 86|orientation
P01309244A0798|101 111|cell types
P01309244A0798|116 123|species
P01309244A0798|136 143|context
P01309244A0798|162 170|promoter
P01309587A0715|12 27|transactivation
P01309587A0715|35 49|BMRF1 promoter
P01309587A0715|57 76|Z/c-myb combination
P01309587A0715|103 110|binding
P01309587A0715|118 127|Z protein
P01309587A0715|140 153|c-myb protein
P01309593A0095|4 21|UCR core sequence
P01309593A0095|23 32|CGCCATTTT
P01309593A0095|61 67|factor
P01309593A0095|90 100|regulation
P01309593A0095|104 126|MuLV promoter activity
P01309593A1092|6 13|studies
P01309593A1092|24 29|UCRBP
P01309593A1092|47 60|target motifs
P01309593A1092|88 97|UCR motif
P01309593A1092|120 137|virus P5 promoter
P01309593A1092|142 150|elements
P01309593A1092|158 178|immunoglobulin light
P01309593A1092|196 201|genes
P01309593A1092|214 222|elements
P01309593A1092|236 249|protein genes
P01309815A0972|14 29|scr1-1 mutation
P01309815A0972|46 64|signal recognition
P01309815A0972|82 88|arrest
P01309815A0972|112 123|maintenance
P01309815A0972|141 147|arrest
P01309815A0972|151 164|AEP synthesis
P01309860A0559|13 22|sequences
P01309860A0559|39 55|integration site
P01309860A0559|74 84|% identity
P01309860A0559|96 105|sequences
P01309860A0559|123 138|mouse L1 family
P01309860A0559|171 180|sequences
P01309894A0807|5 10|Rep78
P01309894A0807|15 20|Rep68
P01309894A0807|38 50|AAV sequence
P01309894A0807|63 67|site
P01309894A0807|69 79|nucleotide
P01309910A0428|0 28|Nucleotide sequence analysis
P01309910A0428|55 62|protein
P01309910A0428|86 99|CREB2 protein
P01310154A0879|6 13|results
P01310154A0879|33 34|N
P01310154A0879|51 60|mutations
P01310154A0879|85 100|transrepression
P01310154A0879|104 115|FBR protein
P01310154A0879|145 154|mutations
P01310154A0879|188 208|protein modification
P01310154A0879|215 230|gene regulation
P01310154A0879|234 245|FBR protein
P01310178A0876|4 32|JS78 mutation changes Gln243
P01310178A0876|36 39|gp0
P01310178A0876|48 59|amber codon
P01310178A0876|80 90|production
P01310178A0876|130 141|polypeptide
P01310178A0876|180 186|domain
P01310178A0876|190 217|host transcription shut-off
P01310879A0000|2 19|patient suffering
P01310879A0000|44 60|thrombocytopenia
P01310879A0000|62 65|HAT
P01310879A0000|78 95|arteriothromboses
P01310879A0000|113 120|failure
P01310879A0000|127 136|treatment
P01310879A0000|151 158|heparin
P01310899A0339|14 32|receptor structure
P01310899A0339|72 78|domain
P01310899A0339|101 121|transmembrane domain
P01310899A0339|151 181|serine/threonine kinase domain
P01310935T0000|11 16|UbcD1
P01310935T0000|66 72|enzyme
P01310935T0000|95 114|protein degradation
P01312005A0600|0 8|Analysis
P01312005A0600|31 40|mt genome
P01312005A0600|59 63|MDP1
P01312005A0600|73 81|cleavage
P01312005A0600|85 96|chick mtDNA
P01312005A0600|115 116|H
P01312005A0600|153 165|target sites
P01312005A0600|189 190|A
P01312005A0600|208 213|tract
P01312005A0600|265 275|structures
P01312005A0600|295 300|bases
P01312005A0600|328 334|origin
P01312005A0600|336 338|OH
P01312005A0600|343 354|replication
P01313715A0461|4 8|goal
P01313715A0461|24 29|study
P01313715A0461|51 62|feasibility
P01313715A0461|66 76|retrovirus
P01313715A0461|86 96|expression
P01313715A0461|100 108|rp47phox
P01313715A0461|116 120|HL60
P01313715A0461|125 129|U937
P01313715A0461|150 160|cell lines
P01313715A0461|185 190|virus
P01313715A0461|203 225|B-lymphocyte cell line
P01313715A0461|227 234|EBV-BCL
P01313715A0461|269 280|CGD patient
P01313846A0850|0 10|Comparison
P01313846A0850|20 38|sequence databanks
P01313846A0850|49 56|Tactile
P01313846A0850|62 68|member
P01313846A0850|76 107|immunoglobulin gene superfamily
P01313846A0850|114 124|similarity
P01313846A0850|152 170|melanoma Ag MUC-18
P01313846A0850|172 179|members
P01313846A0850|204 213|Ag family
P01313846A0850|219 238|poliovirus receptor
P01313846A0850|255 277|cell adhesion molecule
P01313894A1179|17 24|pattern
P01313894A1179|28 35|results
P01313894A1179|54 61|respect
P01313894A1179|65 86|LMP2B mRNA expression
P01313894A1179|93 104|transcripts
P01313894A1179|132 138|subset
P01313894A1179|142 148|tumors
P01313894A1179|177 183|levels
P01313909A0526|4 14|phenotypes
P01313909A0526|22 43|ICP0 nonsense mutants
P01313909A0526|93 98|virus
P01313909A0526|137 145|sequence
P01313909A0526|167 182|nonsense mutant
P01313909A0526|216 225|phenotype
P01314457T0000|0 8|Analysis
P01314457T0000|12 31|nucleotide sequence
P01314457T0000|52 55|kbp
P01314457T0000|59 78|herpesvirus saimiri
P01314457T0000|80 83|HVS
P01314457T0000|85 90|L-DNA
P01314457T0000|100 112|conservation
P01314457T0000|124 136|organization
P01314457T0000|145 148|HVS
P01314457T0000|166 171|virus
P01314841A0724|0 9|Treatment
P01314841A0724|15 21|MK-801
P01314841A0724|32 49|burst suppression
P01314841A0724|57 60|EEG
P01314841A0724|77 81|drop
P01314841A0724|96 101|mm Hg
P01314841A0724|110 114|mean
P01314841A0724|124 132|pressure
P01314953A1266|3 11|contrast
P01314953A1266|13 43|gel mobility shift experiments
P01314953A1266|71 75|HAP2
P01314953A1266|79 83|HAP3
P01314953A1266|93 99|domain
P01314953A1266|110 124|hap3 mutations
P01314953A1266|136 145|complexes
P01315706A0000|9 24|differentiation
P01315706A0000|49 71|adenovirus E1a protein
P01315706A0000|79 102|rat L6 muscle cell line
P01316125A0176|4 14|experiment
P01316125A0176|44 47|1O2
P01316125A0176|63 71|radicals
P01316125A0176|79 81|OH
P01316125A0176|86 90|YHPD
P01316125A0176|115 118|aid
P01316125A0176|122 126|YHPD
P01316125A0176|147 154|ability
P01316125A0176|168 171|1O2
P01316125A0176|173 177|YHPD
P01316125A0176|188 192|BHPD
P01316125A0176|225 227|OH
P01316125A0176|229 233|YHPD
P01316125A0176|247 251|BHPD
P01316125A0382|4 10|points
P01316125A0382|53 59|damage
P01316125A0382|63 67|YHPD
P01316125A0382|96 99|1O2
P01316125A0382|115 123|radicals
P01316125A0382|131 133|OH
P01316125A0382|138 142|YHPD
P01316125A0382|147 153|second
P01316125A0382|184 190|damage
P01316125A0382|194 198|YHPD
P01316125A0382|224 228|BHPD
P01316125A0382|254 260|damage
P01316125A0382|293 298|yield
P01316125A0382|302 305|1O2
P01316125A0382|353 355|OH
P01316459A0311|0 4|Acad
P01316461A1083|26 36|S2 protein
P01316461A1083|51 59|peptides
P01316461A1083|77 79|S2
P01316461A1083|115 119|sera
P01316461A1083|148 154|horses
P01316461A1083|183 191|evidence
P01316461A1083|195 205|expression
P01316461A1083|214 221|protein
P01316461A1083|234 241|animals
P01316476A0842|15 29|TATA sequences
P01316476A0842|62 65|VZV
P01316476A0842|82 93|start sites
P01316476A1428|4 7|ORF
P01316476A1428|10 14|gene
P01316476A1428|49 52|ORF
P01316476A1428|56 60|gene
P01316476A1428|74 83|induction
P01316476A1428|90 95|genes
P01316476A1428|128 137|induction
P01316680A0643|19 26|IR5 ORF
P01316680A0643|30 35|EHV-1
P01316680A0643|48 56|sequence
P01316680A0643|63 74|amino acids
P01316680A0643|76 89|CAYWCCLGHAFAC
P01316680A0643|109 114|match
P01316680A0643|122 149|consensus zinc finger motif
P01316680A0643|151 167|C-X2-4-C-X2-15-C
P01316680A0643|168 176|H-X2-4-C
P01316680A0643|177 178|H
P01316900A0000|4 16|DNA sequence
P01316900A0000|24 48|sulfate activation locus
P01316900A0000|71 75|K-12
P01316903A0296|21 25|form
P01316903A0296|29 43|RNA polymerase
P01316903A0296|61 64|IIA
P01316903A0296|93 97|form
P01316903A0296|112 115|IIO
P01316903A1040|0 18|RNA polymerase IIA
P01316903A1040|61 70|complexes
P01316903A1040|74 83|reactions
P01316903A1040|97 109|input enzyme
P01316903A1040|114 132|RNA polymerase IIA
P01317376A0981|0 21|Fructokinase activity
P01317376A0981|53 63|Z. mobilis
P01317376A0981|77 85|fructose
P01317376A0981|97 104|glucose
P01317376A0981|131 139|increase
P01317376A0981|143 158|frk mRNA levels
P01318310A0000|0 16|Plasma membranes
P01318310A0000|29 34|cells
P01318310A0000|48 66|affinity receptors
P01318310A0000|76 95|density lipoprotein
P01318310A0000|97 100|HDL
P01318310A0000|125 132|removal
P01318310A0000|157 168|cholesterol
P01318739A0410|19 39|patients vincristine
P01318739A0410|56 66|teniposide
P01318739A0410|68 73|VM-26
P01318739A0410|82 95|neurotoxicity
P01320255A0795|6 13|results
P01320255A0795|46 53|element
P01320255A0795|89 100|L1 sequence
P01320255A0795|117 131|factor binding
P01320255A0795|139 146|element
P01320255A0795|162 166|role
P01320255A0795|174 187|transcription
P01320255A0795|197 199|L1
P01320640A0336|0 11|Tumor cells
P01320640A0336|60 67|enolase
P01320640A0336|69 76|insulin
P01320640A0336|78 86|glucagon
P01320640A0336|91 94|VIP
P01321277A0342|24 27|end
P01321277A0342|33 36|src
P01321277A0342|46 49|end
P01321277A0342|55 58|ros
P01321277A0342|67 70|SRC
P01321277A0342|73 76|ROS
P01321277A0342|90 116|chicken embryo fibroblasts
P01321277A0342|118 121|CEF
P01321277A0342|128 152|spindle shape morphology
P01321277A0342|172 175|UR2
P01321277A0664|0 3|ROS
P01321277A0664|6 9|SRC
P01321277A0664|11 12|R
P01321277A0664|39 47|deletion
P01321277A0664|95 101|domain
P01321277A0664|105 108|ros
P01321280A0494|14 20|number
P01321280A0494|25 31|nature
P01321280A0494|39 41|E6
P01321280A0494|46 62|E7 gene products
P01321280A0494|94 99|cells
P01321280A0494|114 145|immunoprecipitation experiments
P01321280A0494|151 159|antisera
P01321280A0494|192 200|BPV-1 E6
P01321280A0494|205 223|E7 fusion proteins
P01321332A0970|10 29|transfection assays
P01321332A0970|42 48|site A
P01321332A0970|81 84|RXR
P01321332A0970|100 115|transactivation
P01321332A0970|123 133|apoAI gene
P01321332A0970|140 148|promoter
P01321332A0970|158 178|hepatoma HepG2 cells
P01321332A0970|186 194|presence
P01321332A0970|198 200|RA
P01321332A0970|215 230|transactivation
P01321332A0970|258 265|amounts
P01321332A0970|283 288|ARP-1
P01321336A0000|4 19|enhancer region
P01321336A0000|23 26|Akv
P01321336A0000|34 48|leukemia virus
P01321336A0000|62 85|sequence motif ACAGATGG
P01321336A0731|4 19|splice variants
P01321336A0731|23 32|ALF1 cDNA
P01321336A0731|71 80|insertion
P01321336A0731|102 110|proteins
P01321336A0731|126 137|amino acids
P01321337A0318|18 27|component
P01321337A0318|50 54|mass
P01321337A0318|58 61|kDa
P01321337A0318|80 90|properties
P01321337A0318|102 109|ability
P01321337A0318|118 123|45Ca2
P01321337A0318|169 170|B
P01321337A0318|172 179|subunit
P01321337A0318|193 204|calcineurin
P01321337A0318|230 239|antiserum
P01321337A0318|262 273|calcineurin
P01321337A1161|31 45|MATa cna1 cna2
P01321337A1161|53 60|mutants
P01321337A1161|62 79|MATa cnb1 mutants
P01321337A1161|104 111|ability
P01321337A1161|149 162|growth arrest
P01324172A0880|0 10|Antibodies
P01324172A0880|33 40|protein
P01324172A0880|50 54|RIM1
P01324172A0880|58 70|mitochondria
P01324385A0329|0 7|METHODS
P01324385A0329|9 23|IgG antibodies
P01324385A0329|27 32|HHV-6
P01324385A0329|34 48|anti-HHV-6-IgG
P01324385A0329|78 96|immunofluorescence
P01324385A0329|104 108|IVDA
P01324385A0329|113 125|seronegative
P01324385A0329|150 155|HIV-1
P01324385A0329|176 181|stage
P01324385A0329|195 200|IV-C1
P01324385A0329|204 207|CDC
P01324385A0329|235 243|subjects
P01324385A0329|257 260|age
P01324385A0329|262 275|control group
P01324404A0813|23 40|activation domain
P01324404A0813|67 74|regions
P01324404A0813|108 125|carboxyl terminus
P01324404A0813|133 151|HNF-3 beta protein
P01324404A0813|153 164|amino acids
P01324404A1208|0 10|HNF-3 beta
P01324404A1208|26 35|sequences
P01324404A1208|57 63|region
P01324404A1208|87 102|transactivation
P01324404A1208|108 114|region
P01324404A1208|118 126|activity
P01324404A1208|140 153|participation
P01324404A1208|161 181|region II-III domain
P01324406A1250|9 14|roles
P01324406A1250|18 22|RAD5
P01324406A1250|32 60|ATPase/DNA helicase activity
P01324406A1250|64 74|DNA repair
P01324406A1250|86 97|maintenance
P01324406A1250|111 116|rates
P01324406A1250|120 131|instability
P01324406A1250|153 162|sequences
P01324639T0000|0 16|Susceptibilities
P01324639T0000|48 55|bacilli
P01324639T0000|59 70|amoxicillin
P01324639T0000|72 87|amoxicillin-BRL
P01324639T0000|95 118|amoxicillin-clavulanate
P01324639T0000|120 132|temafloxacin
P01324639T0000|138 149|clindamycin
P01325221A0870|11 17|arrest
P01325221A0870|21 32|DU249 cells
P01325221A0870|55 64|detection
P01325221A0870|89 99|MBP kinase
P01325221A0870|123 137|p41 MAP kinase
P01325221A0870|157 171|chromatography
P01325386A0766|4 19|hit1-1 mutation
P01325386A0766|29 35|defect
P01325386A0766|39 48|synthesis
P01325386A0766|60 78|heat shock protein
P01326329A0703|8 24|base pair region
P01326329A0703|53 61|CAP site
P01326329A0703|86 90|lack
P01326329A0703|105 113|TATA box
P01326329A0703|122 130|presence
P01326329A0703|134 143|sequences
P01326329A0703|155 163|GC boxes
P01326329A0703|165 176|CACCC boxes
P01326329A0703|178 189|CCAAT boxes
P01326329A0703|191 208|activator protein
P01326329A0703|212 216|Ap-2
P01326329A0703|218 223|sites
P01326329A0703|233 265|glucocorticoid response elements
P01326329A0703|267 271|GREs
P01326329A0703|293 314|AMP response elements
P01326329A0703|316 320|CREs
P01326557T0000|0 7|Cloning
P01326557T0000|20 29|structure
P01326557T0000|33 41|neurocan
P01326557T0000|84 116|chondroitin sulfate proteoglycan
P01326557T0000|120 125|brain
P01327280A0000|3 7|rats
P01327280A0000|29 39|chloralose
P01327280A0000|44 51|changes
P01327280A0000|69 71|pH
P01327280A0000|76 77|K
P01327280A0000|89 105|cord dorsal horn
P01327280A0000|125 127|pH
P01327280A0000|132 133|K
P01327280A0000|149 159|electrodes
P01327758A0000|0 11|Replication
P01327758A0000|22 38|papillomavirus-1
P01327758A0000|40 45|BPV-1
P01327758A0000|47 50|DNA
P01327758A0000|70 83|gene products
P01327758A0000|89 99|E1 protein
P01327758A0000|120 130|E2 protein
P01327967A0668|12 24|inactivation
P01327967A0668|28 31|sms
P01327967A0668|49 60|sensitivity
P01327967A0668|79 108|agent methylmethane sulfonate
P01327967A0668|123 134|requirement
P01327967A0668|139 145|serine
P01327967A0668|155 166|metabolites
P01328197A0985|6 14|findings
P01328197A0985|32 70|MAP kinase activator/MAP kinase system
P01328197A0985|93 103|components
P01328197A0985|107 139|ras signal transduction pathways
P01328219A1397|0 6|NSCL-1
P01328219A1397|32 38|number
P01328219A1397|48 58|cell lines
P01328681A0149|19 27|proteins
P01328681A0149|55 76|c-myc hyperexpression
P01328681A0149|102 115|transcription
P01328681A0149|124 134|activities
P01328681A0149|150 158|proteins
P01328681A0149|192 202|inhibition
P01328681A0149|206 223|protein synthesis
P01328681A0149|225 227|A.
P01328681A0348|0 7|Ruddell
P01328681A0348|9 11|M.
P01328854T0000|9 19|MEF-2 site
P01328854T0000|51 58|element
P01328854T0000|72 85|transcription
P01328854T0000|109 116|subunit
P01328854T0000|130 158|phosphoglycerate mutase gene
P01328854T0000|183 195|muscle cells
P01328884T0000|0 19|Truncation variants
P01328884T0000|23 31|peptides
P01328884T0000|46 55|MHC class
P01328884T0000|59 68|molecules
P01328884T0000|77 92|sequence motifs
P01329039A0239|13 28|E-box consensus
P01329039A0239|53 59|CANNTG
P01329039A0239|74 85|nucleotides
P01329039A0239|100 107|E-boxes
P01329039A0239|125 130|genes
P01329039A0239|153 161|proteins
P01329039A0951|0 19|Intermediate levels
P01329039A0951|23 36|gene activity
P01329039A0951|55 68|TnI enhancers
P01329039A0951|80 87|E-boxes
P01329039A0951|105 108|MCK
P01329039A0951|114 124|E-box site
P01329039A0951|137 154|Ig kappa E2 E-box
P01330077A0000|0 20|T-cell receptor beta
P01330077A0000|22 30|TCR beta
P01330077A0000|32 51|gene rearrangements
P01330077A0000|78 84|B-cell
P01330077A0000|105 114|leukemias
P01330077A0000|116 120|ALLs
P01330309A1134|4 17|CANNTG motifs
P01330309A1134|37 41|MyoD
P01330309A1134|46 70|myogenin fusion proteins
P01330309A1134|92 100|proteins
P01330309A1134|112 120|extracts
P01330309A1134|135 143|myotubes
P01330975T0000|11 25|polyneuropathy
P01330975T0000|51 58|myeloma
P01331057A0000|29 34|COX12
P01331057A0000|48 52|gene
P01331057A0000|57 68|subunit VIb
P01331057A0000|97 117|cytochrome c oxidase
P01331060A0768|4 13|structure
P01331060A0768|21 39|calcineurin A gene
P01331060A0768|58 68|comparison
P01331060A0768|88 102|cDNA sequences
P01331086T0000|10 27|promoter elements
P01331086T0000|38 66|cytochrome c oxidase subunit
P01331086T0000|70 74|gene
P01331086T0000|106 116|ets motifs
P01331086T0000|143 164|transcription factors
P01331292A1425|27 36|instances
P01331292A1425|52 67|oligonucleotide
P01331292A1425|75 82|repeats
P01331292A1425|91 97|region
P01331292A1425|117 124|variola
P01331292A1425|128 142|vaccinia virus
P01331501A0397|34 42|peptides
P01331501A0397|70 79|sequences
P01331501A0397|83 86|E1A
P01331501A0397|106 117|interaction
P01331501A0397|123 127|p107
P01331501A0397|129 137|cyclin A
P01331501A0397|143 147|p130
P01331516A0103|6 13|mutants
P01331516A0103|31 57|3T6 mouse fibroblast cells
P01331516A0103|100 105|virus
P01331516A0103|109 132|coinfection experiments
P01331516A0103|136 148|C2 myoblasts
P01332589A0666|4 8|MICs
P01332589A0666|17 25|compound
P01332589A0666|36 37|%
P01332589A0666|47 56|organisms
P01332589A0666|91 100|S. aureus
P01332589A0666|150 163|micrograms/ml
P01332964A0247|12 20|promoter
P01332964A0247|28 41|RII beta gene
P01332964A0247|82 90|elements
P01333035T0000|0 7|Mapping
P01333035T0000|12 46|cAMP receptor protein contact site
P01333035T0000|54 67|alpha subunit
P01333035T0000|88 102|RNA polymerase
P01333047A0404|28 41|growth factor
P01333047A0404|62 87|growth factor stimulation
P01333047A0404|114 119|cells
P01333047A0404|129 144|phosphorylation
P01333047A0404|148 159|Nck protein
P01333047A0404|163 171|tyrosine
P01333047A0404|173 179|serine
P01333047A0404|185 203|threonine residues
P01333053A0110|8 17|mechanism
P01333053A0110|26 64|steroid hydroxylase gene transcription
P01333053A0110|93 99|cortex
P01333053A0110|123 138|peptide hormone
P01333053A0110|140 144|ACTH
P01333053A0110|161 165|cAMP
P01333125A0000|2 13|combination
P01333125A0000|29 46|sequence analysis
P01333125A0000|65 72|methods
P01333125A0000|85 97|conservation
P01333125A0000|110 128|structure elements
P01333125A0000|152 158|region
P01333125A0000|160 163|UTR
P01333125A0000|174 187|enteroviruses
P01333125A0000|192 204|rhinoviruses
P01333317A1008|12 18|region
P01333317A1008|44 47|Sp1
P01333317A1008|68 75|protein
P01333317A1008|76 77|s
P01333317A1008|100 106|factor
P01333317A1008|107 108|s
P01333317A1008|113 118|PRF-I
P01334428A1102|0 2|Km
P01334428A1102|7 11|Vmax
P01334428A1102|20 30|substrates
P01334428A1102|44 51|peptide
P01334428A1102|56 60|poly
P01334428A1102|61 64|Glu
P01334428A1102|66 69|Tyr
P01334428A1102|87 89|mM
P01334428A1102|98 114|mumol min-1 mg-1
P01334428A1102|124 126|mM
P01334428A1102|135 151|mumol min-1 mg-1
P01334493A0289|13 17|form
P01334493A0289|25 29|HGFr
P01334493A0289|31 36|sHGFr
P01334493A0289|44 47|HGF
P01334493A0289|56 64|affinity
P01334493A0289|119 127|receptor
P01334518T0000|0 10|Strategies
P01334518T0000|15 30|blood screening
P01334518T0000|39 56|hepatitis C virus
P01334518T0000|75 97|immunodeficiency virus
P01334518T0000|106 117|risk groups
P01337142A2043|16 51|glycoprotein alpha-subunit promoter
P01337142A2043|75 78|FSK
P01337142A2043|82 89|GH4 rat
P01337142A2043|100 105|cells
P01337142A2043|107 115|ABSTRACT
P01337142A2043|133 138|WORDS
P01338867A0503|0 10|Comparison
P01338867A0503|14 18|data
P01338867A0503|37 44|results
P01338867A0503|56 65|treatment
P01338867A0503|82 92|antagonist
P01338867A0503|130 138|blockade
P01338867A0503|153 166|fatiguability
P01338867A0503|178 184|extent
P01338867A0503|198 208|activation
P01338867A0503|219 225|system
P01339125A0153|0 18|Laboratory studies
P01339125A0153|25 29|Ca45
P01339125A0153|38 43|teeth
P01339125A0153|69 74|teeth
P01339125A0153|94 104|dentifrice
P01339125A0153|123 129|enamel
P01339125A0153|133 145|bleach teeth
P01339373T0000|0 9|Structure
P01339373T0000|14 24|expression
P01339373T0000|30 34|gene
P01339373T0000|40 60|Arabidopsis thaliana
P01339373T0000|72 79|protein
P01339373T0000|91 110|SNF1 protein kinase
P01339391A0000|41 47|region
P01339391A0000|51 72|DNA surrounding HRAS1
P01339468A0272|4 16|ORF1 protein
P01339468A0272|67 92|potexvirus RNA replicases
P01339468A0272|94 98|ORF2
P01339468A0272|114 122|proteins
P01339468A0272|133 142|analogues
P01339468A0272|153 158|potex
P01339468A0272|186 194|proteins
P01339773A0000|2 7|total
P01339773A0000|15 23|patients
P01339773A0000|42 48|groups
P01339773A0000|77 86|diagnosis
P01339773A0000|111 122|capnography
P01339773A0000|124 134|spirometry
P01339773A0000|149 157|analysis
P01339773A0778|4 17|relationships
P01339773A0778|38 47|pressures
P01339773A0778|58 61|CO2
P01339773A0778|87 96|gradients
P01339773A0778|123 131|increase
P01339773A0778|139 166|ventilation-perfusion ratio
P01339815A1545|15 27|correlations
P01339815A1545|31 39|peak VO2
P01339815A1545|68 73|tests
P01340470A0000|15 27|protein gene
P01340470A0000|29 33|rbp1
P01340470A0000|77 98|RNA recognition motif
P01340470A0000|106 113|Arg-Ser
P01340470A0000|120 122|RS
P01340470A0000|124 130|domain
P01341119A0450|5 21|research studies
P01341119A0450|40 44|kind
P01341119A0450|48 54|tumors
P01341119A0450|70 79|ingestion
P01341119A0450|83 96|H2 inhibitors
P01341119A0450|101 115|others antacid
P01346262A0377|14 19|study
P01346262A0377|33 49|protein profiles
P01346262A0377|63 81|S. entomophila UC9
P01346262A0377|93 97|UC21
P01346262A0377|154 161|protein
P01346262A0377|204 211|protein
P01346534T0000|0 16|Characterization
P01346534T0000|24 31|regulon
P01346534T0000|80 87|protein
P01347476T0000|0 7|Mapping
P01347476T0000|15 30|mouse ornithine
P01347476T0000|53 68|sequence family
P01347664A1026|5 13|mutation
P01347664A1026|49 55|levels
P01347664A1026|59 67|CAD mRNA
P01347664A1026|72 79|protein
P01347664A1026|87 93|mutant
P01347908T0000|4 13|rationale
P01347908T0000|42 53|stimulation
P01347908T0000|57 65|patients
P01347908T0000|71 80|Parkinson
P01347908T0000|83 90|disease
P01347944A0964|11 18|studies
P01347944A0964|44 68|homeodomain binding site
P01347944A0964|72 80|sequence
P01347944A0964|108 118|regulation
P01348504A0757|10 35|pol alpha-primase complex
P01348504A0757|81 89|distance
P01348508A0313|19 28|positions
P01348508A0313|38 45|introns
P01348508A0313|69 79|comparison
P01348508A0313|89 94|genes
P01348508A0313|130 140|activities
P01348508A0313|158 168|literature
P01348508A0313|178 187|TGM1 gene
P01348508A0313|228 232|date
P01348508A0313|245 252|introns
P01348590A0000|19 27|analysis
P01348590A0000|31 35|data
P01348590A0000|44 49|cases
P01348590A0000|65 73|lymphoma
P01348590A0000|81 87|cohort
P01348590A0000|109 117|patients
P01348590A0000|123 128|stage
P01348590A0000|132 143|HIV-disease
P01348590A0000|149 152|CD4
P01348590A0000|167 171|time
P01348590A0000|175 184|diagnosis
P01348590A0000|194 197|use
P01348590A0000|216 222|agents
P01348590A0000|226 238|radiotherapy
P01348590A0000|260 267|outcome
P01349705T0000|0 7|Effects
P01349705T0000|11 18|dioxins
P01349705T0000|22 38|thyroid function
P01349705T0000|50 56|babies
P01349837T0000|0 11|cDNA clones
P01349837T0000|21 41|Arabidopsis thaliana
P01349837T0000|46 54|Zea mays
P01349837T0000|69 85|chaperonin HSP60
P01349837T0000|90 105|gene expression
P01349837T0000|113 129|seed germination
P01349837T0000|134 144|heat shock
P01350780A0184|0 30|Amino acid sequence comparison
P01350780A0184|52 60|homology
P01350780A0184|73 78|yeast
P01350780A0184|100 122|gamma-glutamyl kinases
P01350780A0184|140 147|lengths
P01350932A1123|11 15|site
P01350932A1123|19 32|glycosylation
P01350932A1123|53 63|C-terminus
P01350932A1123|71 93|N-glycosylation sequon
P01350932A1123|95 106|Asn-Cys-Ser
P01350932A1123|117 120|Cys
P01350932A1123|127 131|part
P01350932A1123|137 154|disulphide bridge
P01352113A0002|20 26|events
P01352113A0002|44 60|nitrogen dioxide
P01352113A0002|62 64|NO
P01352113A0002|67 75|exposure
P01352113A0002|96 99|rat
P01352113A0002|114 130|inhalation model
P01352113A0002|158 166|measures
P01352113A0231|14 21|effects
P01352113A0231|71 89|NO2 concentrations
P01352113A0231|118 121|ppm
P01352113A0231|125 132|ppm NO2
P01352113A0231|140 150|mg m-3 NO2
P01352113A0231|156 170|exposure times
P01352113A0231|188 191|min
P01353478T0000|0 11|Interaction
P01353478T0000|15 20|H-2Eb
P01353478T0000|29 48|IAP retrotransposon
P01353478T0000|56 78|A20/2J B cell lymphoma
P01354506T0000|26 34|diseases
P01354506T0000|43 51|advances
P01354506T0000|59 72|understanding
P01354506T0000|76 88|cytogenetics
P01354506T0000|90 104|histopathology
P01354506T0000|118 125|history
P01357190A0726|9 18|exception
P01357190A0726|22 29|mutants
P01357190A0726|46 68|membrane anchor domain
P01357190A0726|88 101|glycoproteins
P01357190A0726|115 122|ability
P01357190A0726|132 138|fusion
P01357190A0726|154 159|cells
P01357528A0084|4 19|subunit protein
P01357528A0084|23 28|curli
P01357528A0084|58 72|amino terminus
P01357528A0084|76 82|SEF-17
P01357528A0084|88 103|subunit protein
P01357528A0084|125 133|fimbriae
P01357528A0084|166 175|strain 3b
P01357528A0084|199 205|fibres
P01357528A0084|219 224|class
P01357528A0084|228 246|surface organelles
P01357528A0084|250 264|enterobacteria
P01358190A0654|0 12|Substitution
P01358190A0654|20 34|DR1 beta chain
P01358190A0654|40 51|H-2E beta k
P01358190A0654|70 74|loss
P01358190A0654|78 89|recognition
P01358190A0654|91 115|alpha chain substitution
P01358190A0654|134 140|effect
P01358592A0752|25 32|pathway
P01358592A0752|66 75|cell fate
P01358592A0752|104 109|state
P01358592A0752|133 139|region
P01358592A0752|147 153|embryo
P01358758A0000|11 18|portion
P01358758A0000|26 44|rat insulin I gene
P01358758A0000|57 60|DNA
P01358758A0000|74 91|sequence elements
P01358758A0000|97 100|Far
P01358758A0000|105 118|FLAT elements
P01358758A0000|141 152|combination
P01358758A0000|214 222|enhancer
P01358880A0251|12 31|amino acid sequence
P01358880A0251|44 54|% identity
P01358880A0251|77 102|transglutaminase sequence
P01359588A0375|5 16|computation
P01359588A0375|44 51|network
P01359588A0375|85 93|elements
P01360180A0513|9 16|efforts
P01360180A0513|40 53|baculoviruses
P01360180A0513|77 83|kinase
P01360180A0513|100 112|recombinants
P01360180A0513|140 146|kinase
P01360180A0513|164 170|domain
P01360180A0513|174 182|mutation
P01360180A1568|32 50|P68 amino terminus
P01360180A1568|97 102|dsRNA
P01360180A1568|145 155|properties
P01360180A1568|161 182|reporter gene product
P01360180A1568|209 212|RNA
P01360294A0000|5 11|August
P01360294A0000|20 27|October
P01360294A0000|54 59|women
P01360294A0000|69 77|subjects
P01360294A0000|96 102|levels
P01360294A0000|106 112|plasma
P01360294A0000|124 136|antithrombin
P01360294A0000|150 158|activity
P01363080A0710|7 13|acuity
P01363080A0710|44 51|changes
P01363080A0710|66 71|error
P01363080A0710|82 94|sulfonamides
P01363080A0710|111 130|agent metronidazole
P01363080A0710|141 150|diuretics
P01363080A0710|165 185|anhydrase inhibitors
P01363166T0001|0 16|Currents aspects
P01363166T0001|20 43|H2 receptor antagonists
P01363166T0001|51 60|treatment
P01363166T0001|64 70|ulcers
P01364100A0377|3 11|addition
P01364100A0377|22 41|subrepeat structure
P01364100A0377|66 70|unit
P01370281A0461|0 10|Sequencing
P01370281A0461|35 48|reading frame
P01370281A0461|67 74|protein
P01370446A0818|6 11|sites
P01370446A0818|31 63|keratan sulfate attachment sites
P01371181A0688|16 24|plasmids
P01371181A0688|32 43|pLS1 family
P01371181A0688|45 50|pE194
P01371181A0688|52 59|pADB201
P01371181A0688|65 69|pLB4
P01371181A0688|71 76|share
P01371181A0688|103 118|characteristics
P01371181A0688|127 137|regulation
P01371181A0688|147 159|copy numbers
P01371272A1167|0 12|Perturbation
P01371272A1167|16 26|dNTP pools
P01371272A1167|45 64|frameshift fidelity
P01371272A1167|84 110|yeast DNA polymerase alpha
P01371275T0000|13 23|expression
P01371275T0000|32 33|B
P01371275T0000|35 42|subunit
P01371275T0000|59 60|H
P01371275T0000|64 70|ATPase
P01371275T0000|81 88|tissues
P01371413A0742|3 11|addition
P01371413A0742|17 28|hGCSFR gene
P01371413A0742|60 82|Southern blot analysis
P01371413A0742|90 109|segregation pattern
P01371413A0742|115 120|panel
P01371413A0742|124 148|rodent-human hybrid DNAs
P01371413A0742|172 182|cDNA probe
P01371863A0000|62 73|gene family
P01371863A0000|81 110|protozoan parasite Leishmania
P01372365A1202|8 13|sites
P01372365A1202|15 17|%T
P01372365A1202|42 44|Cl
P01372365A1202|46 60|concentrations
P01372365A1202|69 70|M
P01372365A1202|87 95|sites %T
P01372365A1202|130 140|conditions
P01372456A0426|0 8|Necrosis
P01372456A0426|19 20|h
P01372456A0426|27 38|TA infusion
P01372456A0426|50 51|%
P01372456A0426|55 61|extent
P01372456A0426|71 72|h
P01372456A0426|78 79|%
P01372456A0426|89 90|h
P01372456A0426|95 102|animals
P01372456A0426|115 119|area
P01372456A0426|127 137|% necrosis
P01372802A1481|3 10|summary
P01372802A1481|16 24|segments
P01372802A1481|28 30|C3
P01372802A1481|46 65|amino acid residues
P01372802A1481|124 126|C3
P01372802A1481|127 128|D
P01372802A1481|130 138|epitopes
P01372802A1481|179 191|C3 fragments
P01372802A1481|222 242|fluid-phase fragment
P01372802A1481|256 264|segments
P01372802A1481|274 282|residues
P01372802A1481|314 316|C3
P01372802A1481|317 318|D
P01372802A1481|320 328|epitopes
P01372802A1481|371 373|C3
P01372802A1481|412 421|fragments
P01372802A1481|429 436|protein
P01372900A0448|6 11|exons
P01372900A0448|35 40|exons
P01372900A0448|79 98|amino acid residues
P01372900A0448|110 135|alpha s1-casein variant A
P01372900A0448|159 161|F.
P01372900A1017|44 56|organization
P01372900A1017|64 103|goat alpha s1-casein transcription unit
P01372900A1017|118 155|polymerase chain reaction experiments
P01373374A0735|0 10|Homodimers
P01373374A0735|24 32|proteins
P01373374A0735|60 71|G-box motif
P01373374A0735|78 82|GBF1
P01373374A0735|87 99|GBF3 binding
P01373374A0735|134 142|sequence
P01374331A0636|8 12|gene
P01374331A0636|50 60|start site
P01374331A0636|73 93|nuclease S1 analysis
P01374392A0341|4 23|hydrophobicity plot
P01374392A0341|27 32|NHE-3
P01374392A0341|60 65|NHE-1
P01374392A0341|70 75|NHE-2
P01374398A0951|12 31|translation protein
P01374398A0951|47 51|cDNA
P01374398A0951|62 65|kDa
P01374398A0951|94 116|amino acid composition
P01374398A0951|131 135|acid
P01374398A0951|149 150|%
P01374398A0951|164 183|amino acid residues
P01374688A0471|5 10|group
P01374688A0471|23 28|ml/kg
P01374688A0471|40 55|% pentafraction
P01374688A0471|58 71|% pentastarch
P01374688A0471|76 82|plasma
P01374688A0471|96 101|hours
P01374688A0471|115 130|micrograms/kg/0
P01374688A0471|133 138|hr E.
P01375224A0152|24 32|evidence
P01375224A0152|47 52|v-Crk
P01375224A0152|64 78|transformation
P01375224A0152|82 108|chicken embryo fibroblasts
P01375224A0152|128 136|activity
P01375224A0152|149 157|proteins
P01375224A0152|170 187|growth regulation
P01375913A0484|37 57|DNA oligonucleotides
P01375913A0484|61 75|U14 snRNA gene
P01375913A0484|111 142|T7 RNA polymerase promoter site
P01375913A0484|168 175|plasmid
P01376319T0000|0 4|Gene
P01376319T0000|9 19|pseudogene
P01376319T0000|27 32|mouse
P01376319T0000|50 78|mannose 6-phosphate receptor
P01377696A0000|4 9|chick
P01377696A0000|26 58|surface glycoprotein neurofascin
P01377696A0000|83 89|growth
P01377696A0000|94 107|fasciculation
P01377696A0000|123 156|antibody perturbation experiments
P01377764A0309|4 13|carcinoma
P01377764A0309|40 50|epithelium
P01377764A0309|71 76|layer
P01377764A0309|105 110|layer
P01377818A0468|3 11|addition
P01377818A0468|13 23|C/EBP beta
P01377818A0468|28 39|C/EBP gamma
P01377818A0468|95 106|C/EBP alpha
P01377962A1012|3 11|contrast
P01377962A1012|13 25|tobacco GS-2
P01377962A1012|41 49|subunits
P01377962A1012|63 67|size
P01377962A1012|75 81|organs
P01378052A0594|8 12|acoR
P01378052A0594|17 24|acoXABC
P01378052A0594|40 45|types
P01378052A0594|49 58|sequences
P01378052A0594|80 88|symmetry
P01378052A0594|90 93|CAC
P01378052A0594|95 98|N11
P01378052A0594|102 105|N18
P01378052A0594|107 110|GTG
P01378052A0594|115 118|TGT
P01378052A0594|120 123|N10
P01378052A0594|127 130|N14
P01378052A0594|132 135|ACA
P01378052A0594|155 164|sequences
P01378052A0594|180 184|NtrC
P01378052A0594|189 193|NifA
P01378052A0594|203 222|activator sequences
P01378127A0841|13 20|effects
P01378127A0841|28 46|calcium supplement
P01378127A0841|50 68|calcium antagonist
P01378127A0841|110 119|responses
P01378431A0202|0 2|C.
P01378431A0202|4 7|Sun
P01378431A0202|9 11|J.
P01378431A0202|13 16|Hsu
P01378431A0202|18 23|M.-Y.
P01378431A0202|25 40|Vallejo-Ramirez
P01378431A0202|42 44|J.
P01378431A0202|46 52|Inouye
P01378431A0202|54 56|S.
P01378431A0202|62 68|Inouye
P01378431A0202|70 72|M.
P01378506A0884|18 38|full-deletion mutant
P01378506A0884|55 60|block
P01378506A0884|64 77|virus release
P01378506A0884|95 97|NC
P01378506A0884|113 127|virus assembly
P01378526A0535|34 53|FK506 plasma levels
P01378526A0535|78 88|appearance
P01378526A0535|97 103|effect
P01379032A0495|7 14|percent
P01379032A0495|18 26|patients
P01379032A0495|48 56|steroids
P01379032A0495|74 86|steroid dose
P01379032A0495|94 99|group
P01379032A0495|113 121|steroids
P01379032A0495|130 132|mg
P01379032A0495|136 146|prednisone
P01379032A0495|151 154|day
P01379150A0996|6 17|cibenzoline
P01379150A0996|49 54|agent
P01379150A0996|89 96|profile
P01379150A0996|131 136|class
P01379150A0996|139 144|drugs
P01379150A0996|148 156|patients
P01379150A0996|167 174|therapy
P01379150A0996|184 200|risk arrhythmias
P01380062A0097|0 9|T antigen
P01380062A0097|51 63|T lymphocyte
P01380062A0097|65 68|CTL
P01380062A0097|70 90|recognition epitopes
P01380062A0097|100 107|targets
P01380062A0097|112 126|CTL clones Y-1
P01380062A0097|128 131|Y-2
P01380062A0097|133 136|Y-3
P01380062A0097|142 145|Y-5
P01380076A0165|4 10|method
P01380076A0165|37 43|column
P01380076A0165|50 70|paired-ion technique
P01380076A0165|83 98|docusate sodium
P01380076A0165|110 120|components
P01380454A0451|29 44|protein product
P01380454A0451|52 62|ref-1 gene
P01380454A0451|78 98|DNA binding activity
P01380454A0451|102 122|Fos-Jun heterodimers
P01380454A0451|124 142|Jun-Jun homodimers
P01380454A0451|147 170|Hela cell AP-1 proteins
P01380454A0451|204 225|transcription factors
P01380454A0451|236 246|NF-kappa B
P01380454A0451|248 251|Myb
P01380454A0451|256 263|members
P01380454A0451|271 286|ATF/CREB family
P01380716A0174|11 18|tissues
P01380716A0174|47 53|molars
P01380716A0174|91 106|calcium hydrate
P01380825A0622|0 22|Northern blot analyses
P01380825A0622|60 65|mRNAs
P01380825A0622|87 91|cDNA
P01380825A0622|112 119|tissues
P01380825A0622|150 157|protein
P01380825A0622|193 201|function
P01383690A1023|4 18|ARG SH2 domain
P01383690A1023|45 53|affinity
P01383690A1023|58 61|BCR
P01383690A1023|126 140|ABL SH2 domain
P01383695A0100|15 31|EBV B-cell clone
P01383695A0100|33 38|E29.1
P01383695A0100|68 74|embryo
P01383695A0100|95 104|IgM kappa
P01383695A0100|109 119|IgM lambda
P01384040A1043|20 30|activation
P01384040A1043|54 61|regions
P01384040A1043|95 106|orientation
P01384040A1043|140 145|pCF10
P01384165A0000|3 7|rats
P01384165A0000|25 31|effect
P01384165A0000|38 45|omentum
P01384165A0000|62 77|vascularization
P01384165A0000|85 92|trachea
P01384165A0000|100 112|regeneration
P01384165A0000|128 138|epithelium
P01384165A0000|157 162|stage
P01384165A0000|174 191|tracheal grafting
P01384229A0175|31 35|role
P01384229A0175|53 64|chicken ICS
P01384229A0175|69 84|oligonucleotide
P01384229A0175|107 116|sequences
P01384229A0175|124 134|BF-IV gene
P01384229A0175|180 186|copies
P01384229A0175|198 216|herpes TK promoter
P01384229A0175|233 267|chloramphenicol acetyl transferase
P01384229A0175|269 272|CAT
P01384229A0175|274 278|gene
P01384229A0175|280 287|pBLCAT2
P01385462A0151|65 69|runs
P01385462A0151|117 135|acid determination
P01385462A0151|152 165|determination
P01385462A0151|173 183|monoamines
P01386210A0293|25 28|use
P01386210A0293|50 57|therapy
P01386210A0293|62 71|treatment
P01386210A0293|82 92|depression
P01386210A0293|104 107|man
P01386210A0293|119 137|GM2 gangliosidosis
P01386897A0000|0 5|Entry
P01386897A0000|9 20|yeast cells
P01386897A0000|38 48|cell cycle
P01386897A0000|50 55|Start
P01386897A0000|68 72|form
P01386897A0000|80 92|CDC28 kinase
P01386897A0000|126 133|cyclins
P01386897A0000|145 149|CLN1
P01386897A0000|154 158|CLN2
P01386897A0000|160 163|ref
P01387105A0933|8 30|Southern blot analyses
P01387105A0933|34 37|DNA
P01387105A0933|43 52|backcross
P01387105A0933|65 69|mice
P01387105A0933|90 97|strains
P01387105A0933|111 123|cell hybrids
P01387105A0933|137 141|loci
P01387105A0933|159 165|cyclin
P01387105A0933|177 186|sequences
P01387105A0933|199 213|loci Cycb1-rs1
P01387105A0933|217 226|Cycb1-rs9
P01387105A0933|243 260|mouse chromosomes
P01387105A0933|285 286|X
P01388160A1102|6 21|residue Glu-381
P01388160A1102|25 29|beta
P01388160A1102|65 72|residue
P01388160A1102|82 97|epsilon peptide
P01388160A1102|127 143|peptide sequence
P01388160A1102|165 172|choices
P01388160A1102|176 183|Ser-106
P01388160A1102|185 192|Ser-107
P01388160A1102|197 204|Ser-108
P01389362T0000|0 9|Porcelain
P01389362T0000|20 33|bond strength
P01389362T0000|41 56|dentin adhesive
P01389573A1071|0 4|TBPf
P01389573A1071|21 29|quotient
P01389573A1071|37 47|difference
P01389573A1071|76 87|measurement
P01389573A1071|89 93|TBPf
P01389573A1071|97 99|P1
P01389573A1071|102 104|P2
P01389573A1071|107 109|A1
P01389573A1071|112 114|A2
P01389585A0825|22 32|Scotchbond
P01389585A0825|39 60|Prisma Universal Bond
P01389585A0825|89 111|dentine bonding agents
P01389585A0825|115 121|choice
P01391001A0583|30 44|yeasts species
P01391001A0583|48 53|total
P01391001A0583|59 60|%
P01391001A0583|80 90|ATB method
P01391001A0583|117 124|methods
P01392012A0228|21 32|vasopressin
P01392012A0228|37 53|oxytocin content
P01392012A0228|72 86|pressor effect
P01392012A0228|97 105|Dekanski
P01392012A0228|123 131|activity
P01392012A0228|151 161|van Dongen
P01392012A0228|166 170|Hays
P01392277A0000|0 8|Comments
P01392277A0000|34 40|status
P01392277A0000|44 55|regulations
P01392277A0000|67 72|water
P01392277A0000|76 90|swimming pools
P01392277A0000|95 100|baths
P01392277A0000|112 122|connection
P01392277A0000|132 147|KOK regulations
P01392277A0000|178 186|standard
P01392277A0000|188 191|DIN
P01392277A0000|193 196|No.
P01392358A0389|6 11|reply
P01392358A0389|26 43|telephone contact
P01392358A0389|47 58|home visits
P01394200A0592|4 19|treatment group
P01394200A0592|40 57|T-cell activation
P01394200A0592|74 85|lymphopenia
P01394200A0592|100 121|rebound lymphocytosis
P01394200A0592|126 138|upregulation
P01394200A0592|146 165|subset markers CD25
P01394200A0592|167 178|interleukin
P01394200A0592|181 189|receptor
P01394200A0592|195 201|CD45RO
P01394200A0592|212 217|cells
P01394655A0615b|0 15|Urease activity
P01394655A0615b|31 37|amount
P01394655A0615b|41 59|ammonia production
P01394655A0615b|65 69|urea
P01394655A0615b|95 97|ng
P01394655A0615b|102 106|tube
P01394655A0615b|108 111|S/N
P01394655A0615b|124 145|Jack bean meal urease
P01395755A1023|26 37|differences
P01395755A1023|74 81|methods
P01395755A1023|96 109|oxygen uptake
P01395755A1023|122 128|ml/min
P01395755A1023|143 149|ml/min
P01395755A1023|151 152|p
P01395755A1023|163 178|oxygen delivery
P01395755A1023|192 198|ml/min
P01395755A1023|214 220|ml/min
P01395755A1023|222 223|p
P01395755A1023|246 252|output
P01395755A1023|266 271|L/min
P01395755A1023|287 292|L/min
P01395755A1023|294 295|p
P01396432A0388|16 21|range
P01396432A0388|35 44|functions
P01396432A0388|74 81|seizure
P01396432A0388|98 108|assessment
P01396432A0388|112 130|memory performance
P01396444A0934|4 15|experiments
P01396444A0934|36 47|micromilieu
P01396444A0934|55 62|alveoli
P01396444A0934|71 80|condition
P01396444A0934|88 90|AM
P01396444A0934|114 131|activation states
P01396444A0934|152 160|activity
P01396444A0934|193 199|degree
P01396444A0934|203 211|recovery
P01396572A0320|23 36|plasmid pUC19
P01396572A0320|85 98|plasmid pUC19
P01396572A0320|99 101|CG
P01396572A0320|123 128|dG-dC
P01396572A0320|131 138|segment
P01396572A0320|146 152|Z-form
P01396572A0320|170 180|competitor
P01396583A0204|2 14|cDNA library
P01396583A0204|18 30|tumour cells
P01396583A0204|52 63|interleukin
P01396583A0204|80 85|probe
P01396592A1113|4 15|experiments
P01396592A1113|33 41|SCL gene
P01396592A1113|51 57|target
P01396592A1113|76 103|transcription factor GATA-1
P01396592A1113|117 133|SCL gene product
P01396592A1113|155 164|regulator
P01396592A1113|178 193|differentiation
P01396601A0986|3 11|contrast
P01396601A0986|25 32|domains
P01396601A0986|36 42|Sec12p
P01396601A0986|44 49|Stl1p
P01396601A0986|54 59|Stl2p
P01396601A0986|82 86|size
P01396601A0986|119 127|homology
P01398068A0948|0 9|Complexes
P01398068A0948|42 48|his175
P01398068A0948|52 58|his273
P01398068A0948|66 78|p53 proteins
P01398068A0948|116 132|RGC DNA sequence
P01398071A0526|6 17|temperature
P01398071A0526|38 45|strains
P01398071A0526|67 75|extracts
P01398071A0526|89 102|BRF1 activity
P01398071A0526|139 147|activity
P01398071A0526|151 166|RNA polymerases
P01398071A0526|178 181|III
P01398073A0986|6 13|results
P01398073A0986|64 77|TFIID protein
P01398073A0986|103 114|stimulation
P01398073A0986|126 144|activation domains
P01398073A0986|166 174|promoter
P01398074A0697|4 17|gene sequence
P01398074A0697|51 54|RNA
P01398074A0697|64 73|yeast RNA
P01398074A0697|90 119|RNase MRP enzyme preparations
P01398074A1081|4 22|RNase MRP RNA gene
P01398074A1081|50 61|replacement
P01398074A1081|101 110|viability
P01398074A1081|142 146|role
P01398074A1081|151 160|RNase MRP
P01398098A0770|0 20|Clone pSRc200 hybrid
P01398098A0770|33 37|mRNA
P01398098A0770|56 67|translation
P01398098A0770|86 97|polypeptide
P01398104A0834|11 18|results
P01398104A0834|20 25|CBF-A
P01398104A0834|37 45|CArG box
P01398104A0834|48 53|ssDNA
P01398104A0834|71 78|protein
P01398104A0834|120 126|factor
P01398106A0754|0 8|Cleavage
P01398106A0754|31 37|enzyme
P01398106A0754|39 45|I-CreI
P01398106A0754|56 58|bp
P01398106A0754|65 67|bp
P01398106A0754|78 99|intron insertion site
P01398106A0754|111 115|exon
P01398106A0754|124 127|top
P01398106A0754|136 142|bottom
P01398106A0754|147 154|strands
P01398106A0754|204 213|overhangs
P01398106A0754|222 232|OH termini
P01398140A0488|18 33|Xenopus U7 gene
P01398140A0488|72 78|motifs
P01398140A0488|102 104|bp
P01398140A0488|123 126|PSE
P01398140A0488|149 157|location
P01398140A0488|173 175|bp
P01399206A0375|4 11|results
P01399206A0375|28 35|reports
P01399206A0375|41 63|collagenase inhibitors
P01399206A0375|90 107|blister formation
P01399206A0375|132 153|epidermolysis bullosa
P01400217T0000|11 19|analysis
P01400217T0000|33 71|IncP alpha plasmid transfer genes traF
P01400217T0000|76 80|traG
P01400217T0000|85 96|involvement
P01400217T0000|100 104|traF
P01400217T0000|108 125|phage sensitivity
P01400396A1265|4 12|promoter
P01400396A1265|41 55|phorbol esters
P01400396A1265|111 121|activation
P01400396A1265|125 146|protein kinase C beta
P01400401A0065|3 9|humans
P01400401A0065|16 38|AMP deaminase variants
P01400401A0065|47 48|M
P01400401A0065|50 56|muscle
P01400401A0065|59 60|L
P01400401A0065|62 67|liver
P01400401A0065|70 72|E1
P01400401A0065|78 80|E2
P01400401A0065|82 93|erythrocyte
P01400401A0065|121 128|variety
P01400401A0065|162 170|criteria
P01400401A0854|0 21|Western blot analyses
P01400401A0854|45 61|immunoreactivity
P01400401A0854|83 91|extracts
P01400401A0854|119 129|expression
P01400401A0854|145 155|AMPD3 cDNA
P01400775A0435|6 13|results
P01400775A0435|42 55|N-methylation
P01400775A0435|59 69|salsolinol
P01400775A0435|75 93|N-methylsalsolinol
P01400775A0435|108 113|brain
P01402647A0114|0 13|DR1 molecules
P01402647A0114|49 59|cell lines
P01402647A0114|93 110|peptide sequences
P01402647A0114|128 141|phage surface
P01403222A0391|5 12|article
P01403222A0391|41 45|care
P01403222A0391|53 58|woman
P01403222A0391|85 99|blood donation
P01403222A0391|117 128|transfusion
P01403391T0000|8 19|hepatitis B
P01403391T0000|40 48|children
P01404401A0740|11 25|ATPase cluster
P01404401A0740|36 50|reading frames
P01404401A0740|102 118|chloroplast gene
P01404612A0303|29 32|Ads
P01404612A0303|60 63|HIV
P01404612A0303|83 91|proteins
P01404612A0303|107 125|vaccine candidates
P01406630A0545|0 9|Alignment
P01406630A0545|26 35|sequences
P01406630A0545|60 78|consensus sequence
P01406630A0545|83 90|binding
P01406630A0545|133 141|proteins
P01406630A0545|159 175|binding analysis
P01406630A0545|192 205|DNA sequences
P01406630A0545|215 235|sequence specificity
P01406630A0545|243 251|proteins
P01406630A0965|15 18|p50
P01406630A0965|36 49|kappa B motif
P01406630A0965|80 87|binding
P01406630A0965|93 100|respect
P01406630A0965|114 121|protein
P01406630A0965|136 143|binding
P01406630A0965|180 198|NF-kappa B complex
P01406656A1075|18 23|clone
P01406656A1075|46 57|mouse alpha
P01406656A1075|63 67|gene
P01406656A1075|83 85|kb
P01406656A1075|99 101|kb
P01406656A1075|117 120|DNA
P01406656A1075|147 153|levels
P01406656A1075|157 168|fibroblasts
P01406656A1075|194 197|ras
P01406677A0000|26 42|control elements
P01406677A0000|75 85|expression
P01406677A0000|99 113|myoglobin gene
P01406677A0000|139 147|analysis
P01406677A0000|160 169|sequences
P01406677A0000|171 191|nucleotide positions
P01406677A0000|235 245|start site
P01406677A0000|267 282|luciferase gene
P01406688A0898|0 19|Sequencing analysis
P01406688A0898|40 52|rap1t allele
P01406688A0898|64 81|nonsense mutation
P01406688A0898|100 106|region
P01406688A0898|115 126|amino acids
P01406703A1435|15 35|Y1 cell cDNA library
P01406703A1435|57 63|region
P01406703A1435|71 79|H-2RIIBP
P01406703A1435|88 109|hormone receptor cDNA
P01406703A1435|125 129|cDNA
P01406703A1435|177 182|cells
P01407286A0427|0 7|Autopsy
P01407286A0427|26 34|survival
P01407286A0427|55 60|cells
P01407286A0427|71 82|integration
P01407286A0427|92 97|brain
P01407286A0427|119 125|traces
P01407286A0427|157 165|reaction
P01407286A0427|170 190|tyrosine hydroxylase
P01408090A0572|4 13|technique
P01408090A0572|21 38|TEE visualization
P01408090A0572|64 72|arteries
P01408137A0974|4 12|sequence
P01408137A0974|21 27|region
P01408137A0974|39 50|G+C content
P01408137A0974|54 55|%
P01408137A0974|102 104|bp
P01408137A0974|123 133|mRNA start
P01408137A0974|137 142|% G+C
P01408219A0670|13 21|patients
P01408219A0670|50 66|lymph-adenopathy
P01408219A0670|68 71|PGL
P01408219A0670|77 86|nontender
P01408219A0670|101 106|nodes
P01408219A0670|119 127|analysis
P01408219A0670|146 157|hyperplasia
P01408474A0531|0 14|PaO2 threshold
P01408474A0531|41 51|indwelling
P01408474A0531|55 70|sensor catheter
P01409581A0206|23 26|E26
P01409581A0206|41 46|v-ets
P01409581A0206|79 88|factor PU
P01409581A0206|116 120|site
P01409643A0618|9 31|lambda gt11 expression
P01409643A0618|45 61|oligonucleotides
P01409643A0618|89 111|immunodeficiency virus
P01409643A0618|114 126|TATA element
P01409643A0618|142 156|identification
P01409643A0618|171 178|protein
P01409643A0618|207 211|mass
P01409643A0618|219 222|kDa
P01409643A0618|241 253|TATA element
P01409643A0618|265 271|factor
P01409643A0618|273 276|TMF
P01410071T0000|0 12|Blood levels
P01410071T0000|16 25|melatonin
P01410071T0000|27 36|serotonin
P01410071T0000|38 46|cortisol
P01410071T0000|52 61|prolactin
P01410071T0000|65 73|relation
P01410071T0000|91 97|rhythm
P01410071T0000|101 126|platelet serotonin uptake
P01413984A0737|23 29|effect
P01413984A0737|37 55|FA supplementation
P01413984A0737|65 76|cholesterol
P01413984A0737|78 93|HDL cholesterol
P01413984A0737|95 110|LDL cholesterol
P01413984A0737|112 118|apo A1
P01413984A0737|120 122|Lp
P01413984A0737|127 132|HbA1C
P01413984A0737|134 141|glucose
P01413984A0737|143 153|fibrinogen
P01413984A0737|155 166|factor VIII
P01413984A0737|168 180|antithrombin
P01413984A0737|186 217|plasminogen activator inhibitor
P01413984A0737|219 247|tissue plasminogen activator
P01413984A0737|252 287|von Willebrand factor concentration
P01413984A0737|301 305|time
P01413984A0737|334 348|blood pressure
P01414219A0319|13 23|volunteers
P01414219A0319|50 61|differences
P01414219A0319|65 68|AUC
P01414219A0319|70 96|peak plasma concentrations
P01414219A0319|100 104|time
P01414219A0319|113 126|concentration
P01414219A0319|132 135|OXC
P01414219A0319|176 179|ERY
P01418272A1072|8 13|ng/mL
P01418272A1072|21 27|cutoff
P01418272A1072|33 44|sensitivity
P01418272A1072|48 51|CEA
P01418272A1072|58 59|%
P01418494T0000|9 15|spikes
P01418494T0000|30 38|function
P01418542A0000|4 10|effect
P01418542A0000|14 20|sodium
P01418542A0000|24 42|beta-glycyrrhetate
P01418542A0000|44 47|SGA
P01418542A0000|65 75|arrhythmia
P01418834A0987|14 33|hematocrit decrease
P01418834A0987|45 46|H
P01418834A0987|50 51|P
P01418834A0987|78 82|fall
P01418834A0987|86 100|blood pressure
P01418834A0987|155 160|mm Hg
P01418834A0987|176 177|P
P01418860A0797|4 11|effects
P01418860A0797|15 24|diltiazem
P01418860A0797|56 68|potentiation
P01418860A0797|86 95|diltiazem
P01418860A0797|129 134|cases
P01418860A0797|162 171|diltiazem
P01418860A0797|193 217|calcium channel blockade
P01418860A0797|226 230|role
P01418860A0797|240 252|interactions
P01419945A1386|0 12|Localization
P01419945A1386|29 35|plexus
P01419945A1386|45 61|nerve stimulator
P01419945A1386|90 102|interscalene
P01419945A1386|134 139|sites
P01420177A1065|0 12|Substitution
P01420177A1065|23 28|Val33
P01420177A1065|33 36|Gly
P01420177A1065|41 46|Gly28
P01420177A1065|51 54|Ser
P01420177A1065|83 91|residues
P01420177A1065|99 114|protein kinases
P01420177A1065|128 134|enzyme
P01420177A1065|162 170|activity
P01420223T0000|0 12|Significance
P01420223T0000|20 31|biopsy site
P01420223T0000|39 62|latissimus dorsi muscle
P01420223T0000|67 79|fiber typing
P01420363A0818|4 8|TIMP
P01420363A0818|18 26|AP1 site
P01420363A0818|44 49|motif
P01420363A0818|61 76|c-Fos/c-Jun AP1
P01420363A0818|117 127|competitor
P01420363A0818|132 139|binding
P01420363A0818|151 162|AP1 factors
P01420363A0818|170 183|consensus TRE
P01420363A0818|192 200|addition
P01420363A0818|210 217|factors
P01420363A0818|249 262|consensus TRE
P01420363T0000|0 11|Involvement
P01420363T0000|15 18|AP1
P01420363T0000|23 41|PEA3 binding sites
P01420363T0000|49 59|regulation
P01420363T0000|70 86|tissue inhibitor
P01420363T0000|90 110|metalloproteinases-1
P01420363T0000|112 118|TIMP-1
P01420363T0000|120 133|transcription
P01420579A0292|7 25|serum neutralizing
P01420579A0292|27 29|SN
P01420579A0292|31 39|antibody
P01420579A0292|49 55|calves
P01420579A0292|60 61|%
P01420579A0292|78 79|%
P01420579A0292|98 109|SN antibody
P01420579A0292|112 117|month
P01420579A0292|153 164|vaccination
P01421145A1190|0 13|Fractionation
P01421145A1190|31 39|extracts
P01421145A1190|43 73|heparin-agarose chromatography
P01421145A1190|89 95|PCAT-1
P01421145A1190|117 125|extracts
P01421145A1190|154 165|leaf tissue
P01421390T0000|13 18|trial
P01421390T0000|82 88|factor
P01421390T0000|101 117|body irradiation
P01421390T0000|129 141|chemotherapy
P01421390T0000|158 185|bone marrow transplantation
P01421390T0000|210 218|leukemia
P01421390T0000|232 240|lymphoma
P01421609A1067|6 10|data
P01421609A1067|28 32|DMVA
P01421609A1067|64 70|trauma
P01421609A1067|76 79|CPB
P01421609A1067|127 134|support
P01422265A0263|4 24|IgG subclass profile
P01422265A0263|38 53|coeliac disease
P01422265A0263|93 101|controls
P01422265A0263|103 107|IgG1
P01422265A0263|122 126|IgG2
P01422265A0263|129 133|IgG3
P01422265A0263|136 140|IgG4
P01422265A0263|157 166|magnitude
P01422265A0263|185 203|subclass responses
P01422265A0263|223 239|coeliac patients
P01423454A0309|0 11|Examination
P01423454A0309|15 19|ANCA
P01423454A0309|46 58|contribution
P01423454A0309|83 92|diagnosis
P01423454A0309|102 112|vasculitis
P01423454A0309|126 135|indicator
P01423454A0309|143 151|activity
P01423454A0309|159 166|disease
P01423454A0309|183 196|effectiveness
P01423454A0309|218 227|treatment
P01423738A0639|13 17|hand
P01423738A0639|25 37|pinealectomy
P01423738A0639|80 87|rabbits
P01423738A0639|121 133|deceleration
P01423738A0639|141 148|rhythms
P01423738A0639|150 164|mean delta tau
P01423738A0639|173 174|h
P01424674A0000|12 22|pemphigoid
P01424674A0000|49 56|disease
P01424674A0000|95 108|cicatrization
P01425653T0000|4 11|effects
P01425653T0000|19 25|levels
P01425653T0000|29 47|caffeine ingestion
P01425653T0000|71 89|oxygen consumption
P01425653T0000|103 108|women
P01425921A1286|19 27|features
P01425921A1286|43 61|amino acid changes
P01425921A1286|82 97|lysine deletion
P01425921A1286|120 138|consensus sequence
P01425921A1286|176 182|region
P01425921A1286|186 190|V1J1
P01426635A0496|12 19|profile
P01426635A0496|23 28|ZFH-2
P01426635A0496|43 46|CNS
P01426635A0496|77 80|DDC
P01426635A0496|93 102|serotonin
P01426635A0496|107 123|dopamine neurons
P01427034A0440|11 18|introns
P01427034A0440|49 62|protein genes
P01427034A0440|105 114|S13 genes
P01427034A0440|141 154|DNA sequences
P01427034A0440|168 170|bp
P01427034A0440|174 180|length
P01427034A0440|194 201|introns
P01427457A0000|38 43|trial
P01427457A0000|60 68|efficacy
P01427457A0000|88 90|SC
P01427457A0000|114 115|h
P01427457A0000|117 132|calcium heparin
P01427457A0000|153 167|sodium heparin
P01427457A0000|175 184|treatment
P01427457A0000|207 217|thrombosis
P01427457A0000|219 222|DVT
P01428490A0671|12 22|prevalence
P01428490A0671|35 46|pet allergy
P01428490A0671|56 61|cough
P01428490A0671|63 69|wheeze
P01428490A0671|71 78|attacks
P01428490A0671|82 91|shortness
P01428490A0671|95 101|breath
P01428490A0671|138 144|asthma
P01428490A0671|158 166|children
P01428490A0671|175 179|pets
P01428490A0671|187 191|past
P01428513A0440|53 60|persons
P01429596A1669|7 12|basis
P01429596A1669|29 39|properties
P01429596A1669|65 78|hemagglutinin
P01429596A1669|103 139|18K agglutination-aggregation factor
P01429596A1669|141 148|18K-LAF
P01429624A0328|4 9|shift
P01429624A0328|31 42|temperature
P01429624A0328|65 69|loss
P01429624A0328|73 79|guanyl
P01429624A0328|101 109|activity
P01429624A0328|113 128|adenylylcyclase
P01429714A0730|0 4|Clin
P01429724A0664|4 8|data
P01429724A0664|45 51|domain
P01429724A0664|55 60|Nmt1p
P01429724A0664|80 85|Ile59
P01429724A0664|88 93|Phe96
P01429724A0664|98 104|Gly451
P01429724A0664|107 113|Leu455
P01429740A1065|45 56|presequence
P01429740A1065|80 86|domain
P01429740A1065|107 112|exons
P01429740A1065|144 151|E2 gene
P01429768T0000|6 25|neutrophil response
P01429768T0000|40 48|exposure
P01429768T0000|52 56|F-75
P01429768T0000|70 75|alloy
P01429836A0457|0 10|Disruption
P01429836A0457|14 26|microtubules
P01429836A0457|46 54|fidelity
P01429836A0457|58 66|kinetics
P01429836A0457|79 94|protein sorting
P01429836A0457|112 126|Vps1p function
P01429836A0457|147 159|microtubules
P01429836A1205|9 13|form
P01429836A1205|17 22|Vps1p
P01429836A1205|54 60|domain
P01429836A1205|86 101|protein sorting
P01429836A1205|115 120|cells
P01431380A0244|17 31|field research
P01431380A0244|37 47|tick fauna
P01431380A0244|78 82|area
P01431380A0244|127 132|ticks
P01431380A0244|140 147|vectors
P01431380A0244|177 194|group rickettsiae
P01431380A0244|196 200|SFGR
P01431380A0244|202 210|antibody
P01431380A0244|214 218|mice
P01431380A0244|240 254|tick emulsions
P01431380A0244|256 264|findings
P01431380A0244|268 279|rickettsiae
P01431380A0244|292 304|patient sera
P01431380A0244|338 346|antibody
P01431380A0244|350 354|JSFR
P01431380A0244|362 377|hemolymph cells
P01431380A0244|386 391|ticks
P01431380A0244|397 405|electron
P01431380A0244|420 432|observations
P01431380A0244|436 440|SFGR
P01431380A0244|461 467|organs
P01431380A0244|491 496|gland
P01431380A0244|500 505|ticks
P01431602A0229|11 17|method
P01431602A0229|24 29|macro
P01431602A0229|31 36|assay
P01431602A0229|44 61|sensitivity range
P01431602A0229|74 95|micrograms phosphorus
P01431602A0229|109 126|microliters HClO4
P01431809T0000|0 19|Nucleotide sequence
P01431809T0000|40 48|analysis
P01431809T0000|56 71|polyhedrin gene
P01431809T0000|75 92|Spodoptera exigua
P01431809T0000|101 119|polyhedrosis virus
P01432453T0000|0 10|Validation
P01432453T0000|24 31|systems
P01432453T0000|33 50|system definition
P01433391A0594|5 16|consequence
P01433391A0594|25 32|rearing
P01433391A0594|48 55|density
P01433391A0594|68 75|neurons
P01433391A0594|79 83|area
P01433391A0594|119 124|value
P01433391A0594|153 160|kittens
P01433391A0594|198 202|area
P01433502A1163|6 13|results
P01433502A1163|37 42|class
P01433502A1163|45 62|enhancer activity
P01433502A1163|83 88|cells
P01433502A1163|106 110|part
P01433502A1163|133 139|levels
P01433502A1163|164 170|factor
P01433502A1163|193 202|repressor
P01433524A0788|9 15|domain
P01433524A0788|47 58|amino acids
P01433524A0788|62 65|IE1
P01433524A0788|110 120|activities
P01435698A0000|3 8|order
P01435698A0000|28 47|blood compatibility
P01435698A0000|62 72|vein graft
P01435698A0000|74 77|AVG
P01435698A0000|80 87|changes
P01435698A0000|91 103|prostacyclin
P01435698A0000|105 109|PGI2
P01435698A0000|111 121|production
P01435698A0000|132 142|harvesting
P01435698A0000|156 168|implantation
P01436261A0145|0 27|Subcutaneous administration
P01436261A0145|35 56|somatostatin analogue
P01436261A0145|58 68|octreotide
P01436261A0145|74 84|micrograms
P01436261A0145|123 134|improvement
P01436261A0145|138 147|diarrhoea
P01436261A0145|152 165|disappearance
P01436261A0145|176 188|incontinence
P01436261A0145|206 223|calcitonin levels
P01437562A0462|9 19|antibodies
P01437562A0462|35 42|protein
P01437562A0462|46 54|extracts
P01437562A0462|58 71|C.fasciculata
P01437562A0462|75 84|agreement
P01437562A0462|94 98|size
P01437562A0462|118 137|nucleotide sequence
P01437562A0462|152 156|gene
P01438224A0749|57 59|J.
P01438287T0000|15 30|vaccinia vector
P01438287T0000|65 70|genes
P01441120T0000|0 3|Use
P01441120T0000|19 27|minerals
P01441818T0001|0 15|Interferon type
P01441818T0001|32 46|body reactions
P01441818T0001|66 86|Klebsiella infection
P01443047A0773|9 16|changes
P01443047A0773|34 56|differentiation status
P01443047A0773|74 85|association
P01443047A0773|91 108|Id-SCL expression
P01443745T0000|12 23|interaction
P01443745T0000|37 47|anesthesia
P01443745T0000|52 60|sedation
P01443745T0000|66 75|midazolam
P01443748A1190|4 12|pressure
P01443748A1190|30 37|atm abs
P01443748A1190|52 64|excitability
P01443748A1190|72 80|tadpoles
P01443748A1190|151 160|movements
P01446132A0328|4 16|air embolism
P01446132A0328|45 51|filter
P01446132A0328|74 86|complication
P01446828A1088|7 13|region
P01446828A1088|17 21|ADH5
P01446828A1088|31 54|consensus binding sites
P01446828A1088|90 98|proteins
P01446828A1088|100 103|Sp1
P01446828A1088|105 108|AP2
P01446828A1088|110 115|LF-A1
P01446828A1088|117 121|NF-1
P01446828A1088|123 128|NF-A2
P01446828A1088|134 139|NF-E1
P01447139A0208|0 2|V.
P01447189A1546|6 10|data
P01447189A1546|25 34|RNK-Met-1
P01447189A1546|40 55|serine protease
P01447189A1546|68 76|activity
P01447189A1546|102 110|granules
P01447189A1546|129 140|lymphocytes
P01447189T0000|0 12|Purification
P01447189T0000|17 24|cloning
P01447189T0000|36 51|serine protease
P01447189T0000|53 62|RNK-Met-1
P01447189T0000|73 81|granules
P01447189T0000|87 90|rat
P01447189T0000|99 119|killer cell leukemia
P01448107A0361|29 43|GCN2 mutations
P01448107A0361|57 69|derepression
P01448107A0361|73 88|GCN4 expression
P01448107A0361|96 103|absence
P01448107A0361|107 128|amino acid starvation
P01448806A0135|0 14|Administration
P01448806A0135|18 32|growth hormone
P01448806A0135|49 55|growth
P01448806A0135|73 88|bone maturation
P01448917A0775|0 11|Comparisons
P01448917A0775|31 49|amino acid residue
P01448917A0775|51 53|aa
P01448917A0775|55 75|sequence information
P01448917A0775|94 102|CPMV RNA
P01448917A0775|105 113|sequence
P01448917A0775|130 138|sequence
P01448917A0775|146 169|clover mottle virus RNA
P01448917A0775|185 194|CPSMV RNA
P01448917A0775|220 223|set
P01448917A0775|239 247|proteins
P01448917A0775|253 272|proteinase cofactor
P01448917A0775|274 277|58K
P01448917A0775|287 295|helicase
P01448917A0775|297 300|VPg
P01448917A0775|311 318|protein
P01448917A0775|334 338|RNAs
P01448917A0775|340 354|24K proteinase
P01448917A0775|360 363|87K
P01448917A0775|373 383|polymerase
P01448917A0775|403 417|cleavage sites
P01448932T0000|0 47|Rice dwarf phytoreovirus segment S12 transcript
P01449183A0795|3 11|addition
P01449183A0795|17 24|utility
P01449183A0795|28 32|beta
P01449183A0795|35 52|transferrin assay
P01449183A0795|60 69|diagnosis
P01449183A0795|87 101|fluid otorrhea
P01449301A0710|0 17|Cold cardioplegia
P01449301A0710|41 46|mm Hg
P01449301A0710|56 63|minutes
P01449301A0710|70 75|hours
P01450815A0337|4 12|addition
P01450815A0337|16 27|diatrizoate
P01450815A0337|35 39|IPRK
P01450815A0337|73 79|change
P01450815A0337|83 86|RPF
P01450815A0337|91 94|GFR
P01450815A0337|133 141|increase
P01450815A0337|177 185|decrease
P01451771A0619|15 23|analyses
P01451771A0619|33 49|family variables
P01451771A0619|79 83|data
P01451771A0619|112 131|components analysis
P01451771A0619|133 136|PCA
P01451771A0619|159 175|scaling analysis
P01451771A0619|177 180|MDS
P01451771A0619|202 215|health scores
P01451771A0619|220 228|husbands
P01451771A0619|237 242|wives
P01452037A0000|15 20|genes
P01452037A0000|30 70|glyceraldehyde-3-phosphate dehydrogenase
P01452037A0000|72 77|GAPDH
P01452037A0000|99 105|kinase
P01452037A0000|107 110|PGK
P01452037A0000|131 135|part
P01452037A0000|139 164|triosephosphate isomerase
P01452037A0000|166 169|TIM
P01452037A0000|187 213|Bacillus megaterium DSM319
P01452037A0000|236 248|gene cluster
P01452037A0000|250 260|gap operon
P01452037A0000|265 280|complementation
P01452037A0000|304 320|gap amber mutant
P01452584T0000|23 33|exotoxin A
P01452584T0000|39 43|role
P01452584T0000|47 58|retardation
P01452584T0000|62 75|wound healing
P01452584T0000|86 100|Lindberg Award
P01452703A0782|0 18|Laboratory studies
P01452703A0782|63 67|kits
P01452703A0782|101 105|case
P01452703A0782|153 159|bodies
P01452703A0782|164 166|ml
P01452703A0782|179 189|ELISA kits
P01452703A0782|230 236|bodies
P01452703A0782|241 243|ml
P01454518A0336|13 25|significance
P01454518A0336|35 42|domains
P01454518A0336|72 84|conservation
P01454518A0336|92 96|gene
P01454518A0336|102 109|homolog
P01454518A0336|159 184|stringency hybridizations
P01454518A0336|204 210|probes
P01454518A0336|224 234|ERCC3 cDNA
P01454819A0000|0 21|Mono-ADP-ribosylation
P01454819A0000|38 50|modification
P01454819A0000|54 62|proteins
P01454819A0000|69 72|NAD
P01454819A0000|73 105|arginine ADP-ribosyltransferases
P01454819A0000|107 109|EC
P01454819A0000|144 154|hydrolases
P01454819A0000|156 158|EC
P01454819A0000|193 202|reactions
P01454819A0000|209 231|ADP-ribosylation cycle
P01456888A0074|9 15|reason
P01456888A0074|21 29|particle
P01456888A0074|38 46|capacity
P01456888A0074|50 61|derivatives
P01456888A0074|69 80|HIV-1 group
P01456888A0074|90 110|core antigen p55 gag
P01456888A0074|157 175|expression systems
P01456888A0074|189 197|bacteria
P01456888A0074|199 207|vaccinia
P01456888A0074|213 226|baculoviruses
P01456888A0074|264 280|core protein p55
P01456888A0074|305 313|sequence
P01456888A0074|329 359|myristylation consensus signal
P01457380A0000|4 13|tramtrack
P01457380A0000|15 18|ttk
P01457380A0000|20 24|gene
P01457380A0000|65 73|proteins
P01457380A0000|94 102|splicing
P01457380A0000|118 132|ttk transcript
P01457695T0000a|0 7|Removal
P01457695T0000a|11 31|beta 2-microglobulin
P01457695T0000a|35 47|hemodialysis
P01457695T0000a|52 66|hemofiltration
P01457695T0000a|75 79|year
P01457695T0000b|0 7|Removal
P01457695T0000b|11 31|beta 2-microglobulin
P01457695T0000b|35 47|hemodialysis
P01457695T0000b|52 66|hemofiltration
P01457695T0000b|75 79|year
P01458170A0155|0 10|Adapromine
P01458170A0155|38 46|decrease
P01458170A0155|54 63|amplitude
P01458170A0155|80 84|peak
P01458170A0155|98 112|theta-activity
P01458170A0155|116 129|power spectra
P01458170A0155|137 140|EEG
P01458170A0155|148 154|cortex
P01458170A0155|159 168|hippocamp
P01458170A0155|178 186|increase
P01458170A0155|196 209|wave activity
P01458170A0155|217 221|beta
P01458170A0155|224 229|range
P01458170A0155|243 249|cortex
P01458170A0155|254 263|hippocamp
P01459447A0484|6 15|sequences
P01459447A0484|34 39|clone
P01459447A0484|56 61|genes
P01459447A0484|69 74|yeast
P01459447A0484|83 90|library
P01459451A0478|19 33|antirepression
P01459451A0478|56 62|factor
P01459451A0478|77 93|co-antirepressor
P01459451A0478|140 147|embryos
P01459885A0705|9 13|days
P01459885A0705|17 38|haloperidol treatment
P01459885A0705|48 55|changes
P01459885A0705|74 79|delta
P01459885A0705|98 106|increase
P01459885A0705|110 115|alpha
P01459885A0705|125 133|decrease
P01459885A0705|142 146|beta
P01459921A0000|41 58|Hampshire wethers
P01459921A0000|93 103|experiment
P01459921A0000|125 145|linoleoyl methionine
P01459921A0000|150 167|calcium linoleate
P01459921A0000|192 196|flow
P01459921A0000|218 223|acids
P01459921A0000|225 230|C18:2
P01459921A0000|233 240|cis C18
P01460054A0478|10 15|ICSBP
P01460054A0478|52 63|amino acids
P01460054A0478|85 88|ICS
P01460054A0478|115 119|part
P01460054A0478|127 145|DNA binding domain
P01460054A0478|183 197|amino terminus
P01460054A0968|11 16|ICSBP
P01460054A0968|75 83|activity
P01460054A0968|101 106|genes
P01460054A0968|124 129|cells
P01460772T0001|2 6|case
P01460772T0001|18 29|hepatitis C
P01460772T0001|43 57|hypothyroidism
P01460772T0001|76 96|interferon treatment
P01462786T0000|0 23|Dynamic decision making
P01462786T0000|31 38|control
P01462786T0000|42 57|complex systems
P01464329T0000|22 29|protein
P01464329T0000|52 59|regions
P01464329T0000|71 91|prophase chromosomes
P01464606A0344|11 18|amounts
P01464606A0344|22 27|alpha
P01464606A0344|30 34|beta
P01464606A0344|37 45|integrin
P01464606A0344|71 76|cells
P01464606A0344|80 94|chromatography
P01464606A0344|98 116|detergent extracts
P01464606A0344|122 133|fibronectin
P01464606A0344|147 171|fragment affinity column
P01464606A0344|176 183|elution
P01464606A0344|189 193|EDTA
P01467088T0075|0 9|Abstracts
P01467828A0542|6 13|results
P01467828A0542|34 45|involvement
P01467828A0542|60 75|opioid peptides
P01467828A0542|91 98|effects
P01467828A0542|117 126|ischaemia
P01467828A0542|131 142|reperfusion
P01467828A0542|163 172|receptors
P01467828A0542|188 198|antagonism
P01468625A0282|10 17|library
P01468625A0282|19 23|LEU2
P01468625A0282|28 38|HIS3 cDNAs
P01468625A0282|59 68|frequency
P01468625A0282|109 114|cases
P01468625A0282|161 167|manner
P01468625A1080|13 17|ACT1
P01468625A1080|36 41|times
P01468625A1080|47 51|NSR1
P01468625A1080|58 63|times
P01469042A0355|6 17|CENP-B gene
P01469042A0355|44 51|species
P01469042A0355|56 68|CENP-B boxes
P01469042A0355|87 117|mouse centromere satellite DNA
P01469042A0355|125 134|satellite
P01469042A0355|172 183|interaction
P01469042A0355|210 214|kind
P01469042A0355|225 244|centromere function
P01469047A1606|17 24|portion
P01469047A1606|32 43|tail domain
P01469047A1606|45 47|aa
P01469047A1606|62 68|shares
P01469047A1606|71 101|% amino acid sequence identity
P01469047A1606|116 123|protein
P01469047A1606|129 140|mouse brain
P01469047A1606|167 185|acid decarboxylase
P01470243A0871|16 24|subgroup
P01470243A0871|37 39|Ht
P01470243A0871|48 51|l/l
P01470243A0871|53 54|n
P01470243A0871|86 95|reduction
P01470243A0871|97 98|p
P01470243A0871|114 123|mortality
P01470243A0871|132 138|months
P01470243A0871|142 143|%
P01470243A0871|150 151|%
P01470243A0871|174 182|increase
P01470243A0871|186 198|independence
P01470243A0871|202 206|home
P01470243A0871|210 211|%
P01470243A0871|218 219|%
P01470243A0871|244 253|reduction
P01470243A0871|261 270|viscosity
P01470243A0871|274 279|means
P01470243A0871|283 296|haemodilution
P01470243A0871|302 309|albumin
P01470243A0871|322 338|viscosity effect
P01470243A0871|360 365|group
P01470741T0062|0 12|Distribution
P01470741T0062|40 46|course
P01471602A0362|16 19|use
P01471602A0362|24 32|benefits
P01471602A0362|36 58|bile acid sequestrants
P01471602A0362|70 74|acid
P01471602A0362|83 88|acids
P01471602A0362|117 127|coenzyme A
P01471602A0362|129 136|HMG-CoA
P01471602A0362|138 158|reductase inhibitors
P01471602A0362|164 172|probucol
P01471602A0362|226 236|approaches
P01471602A0362|245 256|conjunction
P01471602A0362|266 271|drugs
P01473196A1016|24 36|reabsorption
P01473196A1016|61 70|clearance
P01473207A0582|23 31|findings
P01473207A0582|39 47|placenta
P01473207A0582|53 66|prematuration
P01473207A0582|71 81|hypoplasia
P01473234A1001|0 12|Green pepper
P01473234A1001|70 84|acid formation
P01473234A1001|106 110|acid
P01474990A0000|10 15|clone
P01474990A0000|17 22|pTt21
P01474990A0000|35 38|DNA
P01474990A0000|78 89|Trypanosoma
P01474990A0000|96 111|trypomastigotes
P01474990A0000|164 171|library
P01474990A0000|177 191|trypomastigote
P01474990A0000|196 213|epimastigote cDNA
P01475381T0001|0 11|Brucellosis
P01476376T0000|0 5|Assay
P01476376T0000|9 13|urea
P01476376T0000|29 35|urease
P01476376T0000|62 70|pH-meter
P01477021A0394|0 7|RESULTS
P01477021A0394|16 25|AGA group
P01477021A0394|51 80|serum prolactin concentration
P01477021A0394|110 119|gestation
P01477021A0394|121 122|P
P01477021A0394|135 136|P
P01478672A0795|4 15|phage clone
P01478672A0795|27 35|junction
P01478672A0795|44 63|alpha satellite DNA
P01478672A0795|94 102|sequence
P01480183A0000|16 22|region
P01480183A0000|36 52|lactoferrin gene
P01480183A0000|97 104|library
P01480183A1689|25 35|mechanisms
P01480183A1689|43 58|estrogen action
P01480183A1689|75 102|lactoferrin gene expression
P01480183A1689|118 123|mouse
P01480470A0323|0 6|BiP670
P01480470A0323|25 28|Ca2
P01480470A0323|30 39|ionophore
P01480470A0323|57 67|activities
P01482912A0617|4 7|CEM
P01482912A0617|17 37|registration updates
P01482912A0617|45 56|HL7 message
P01482912A0617|71 88|data dependencies
P01482912A0617|92 97|rules
P01482912A0617|105 114|interface
P01482912A0617|122 141|relational database
P01483755A0000|9 31|resonance spectroscopy
P01483755A0000|33 36|MRS
P01483755A0000|42 49|imaging
P01483755A0000|51 54|MRI
P01483755A0000|81 91|techniques
P01483755A0000|100 105|study
P01483755A0000|118 128|metabolism
P01483755A0000|139 148|structure
P01483755A0000|152 158|muscle
P01483771A1335|25 27|NA
P01483771A1335|46 52|change
P01483771A1335|56 83|plasma epinephrine response
P01485648A0000|31 36|value
P01485648A0000|55 59|test
P01485648A0000|61 81|Pharmacia CAP System
P01485648A0000|83 107|Pharmacia Diagnostics AB
P01485648A0000|109 116|Uppsala
P01485648A0000|118 124|Sweden
P01485648A0000|148 159|measurement
P01485648A0000|181 195|IgE antibodies
P01485648A0000|199 209|comparison
P01485648A0000|215 219|RAST
P01485648A0000|225 231|groups
P01485648A0000|235 243|patients
P01486836A0774|0 8|Patients
P01486836A0774|19 22|VPA
P01486836A0774|30 41|differences
P01486836A0774|45 54|attention
P01486836A0774|56 78|visuomotor performance
P01486836A0774|87 91|span
P01486836A0774|104 124|discrimination tasks
P01486836A0774|128 130|T1
P01486836A0774|135 157|visuomotor performance
P01486836A0774|161 163|T2
P01486836A0774|179 183|span
P01486836A0774|187 189|T3
P01486836A0774|202 213|differences
P01486836A0774|231 233|T4
P01487144A0505|18 30|gene segment
P01487144A0505|46 55|mu m poly
P01487144A0505|56 57|A
P01487144A0505|59 66|signals
P01487144A0505|83 85|bp
P01487144A0505|109 117|sequence
P01487144A0505|130 154|transcription terminator
P01487144A0505|163 176|myeloma cells
P01487144A0505|181 199|L cell fibroblasts
P01490493A0416|5 9|part
P01490493A0416|21 32|examination
P01490493A0416|49 66|serum cholesterol
P01490493A0416|74 79|lipid
P01490493A0416|84 103|triglyceride levels
P01492463T0001|0 5|Alena
P01492463T0001|11 16|nurse
P01492463T0001|20 26|Prague
P01492463T0001|49 54|wages
P01492463T0001|61 65|trip
P01492463T0001|77 82|ocean
P01493864A0619|0 16|Dopamine neurons
P01493864A0619|20 28|subjects
P01493864A0619|43 49|6-OHDA
P01493864A0619|68 81|pre-treatment
P01493864A0619|87 96|GBR-12909
P01495069A0392|0 4|DIBA
P01495069A0392|61 66|value
P01495069A0392|94 104|percentage
P01495069A0392|110 114|DFAT
P01496348A0000|0 6|Caries
P01496348A0000|11 23|parodontitis
P01496348A0000|57 65|diseases
P01496348A0000|69 76|mankind
P01496784A0939|4 11|results
P01496784A0939|20 25|study
P01496784A0939|43 59|strongyloidiasis
P01496784A0939|68 73|cause
P01496784A0939|84 89|death
P01497582A0593|15 20|group
P01497582A0593|24 33|disorders
P01497582A0593|37 46|pregnancy
P01497582A0593|60 67|effects
P01497582A0593|71 81|infections
P01497582A0593|89 95|mother
P01497582A0593|104 113|pathogens
P01497582A0593|139 145|embryo
P01497582A0593|153 161|placenta
P01498607A0000|11 31|nucleotide sequences
P01498607A0000|33 38|boxes
P01498607A0000|72 86|responsiveness
P01498607A0000|94 128|parsley chalcone synthase promoter
P01499213A0185|4 8|case
P01499213A0185|44 47|man
P01499213A0185|53 63|ochronosis
P01499213A0185|79 100|hyperextension injury
P01499213A0185|108 113|spine
P01499213A0185|119 123|fall
P01499213A0185|140 148|fracture
P01499213A0185|170 186|L2-L3 disk space
P01499616A0136|9 19|blood flow
P01499616A0136|34 42|foreskin
P01499616A0136|77 78|g
P01499616A0136|106 107|%
P01499616A0136|118 127|induction
P01499616A0136|131 141|anesthesia
P01499616A0136|167 168|%
P01499616A0136|176 179|tip
P01499616A0136|206 219|foreskin flap
P01502157A0000|0 5|ME1a1
P01502157A0000|30 49|factor binding site
P01502157A0000|71 79|c-MYC P1
P01502157A0000|84 117|P2 transcription initiation sites
P01502157A0000|135 146|P2 activity
P01504178T0000|16 21|years
P01504178T0000|25 35|prevention
P01504178T0000|46 53|country
P01504178T0000|55 64|visionary
P01504178T0000|66 73|complex
P01504853A0299|10 14|LHRH
P01504853A0299|43 58|mating behavior
P01504853A0299|70 77|species
P01505488A0231|26 34|patients
P01505488A0231|48 51|EVL
P01505488A0231|63 69|period
P01505488A0231|75 81|August
P01505488A0231|91 95|July
P01505516A0928|23 27|acid
P01505516A0928|35 41|lysine
P01505516A0928|58 65|alanine
P01505516A0928|69 83|valine residue
P01505516A0928|92 101|formation
P01505516A0928|122 128|dimers
P01506705A0282|7 17|V-A bypass
P01506705A0282|19 31|hemodynamics
P01506746A0476|0 21|Greater rupture force
P01506746A0476|48 52|pigs
P01506746A0476|71 75|pigs
P01509798A0520|3 11|rest AFF
P01509798A0520|40 42|UT
P01509798A0520|46 47|%
P01509798A0520|64 66|AT
P01509798A0520|70 71|%
P01509798A0520|77 80|UEA
P01509798A0520|84 85|%
P01511231A0085|20 34|smoking habits
P01511231A0085|38 47|relapsers
P01511231A0085|50 54|year
P01511231A0085|75 98|smoking cessation trial
P01511231A0085|105 113|nicotine
P01511231A0085|117 132|placebo patches
P01511950T0000|0 8|Exposure
P01511950T0000|12 29|hepatitis B virus
P01511950T0000|45 55|population
P01511950T0000|59 67|Hisayama
P01511950T0000|69 74|Japan
P01511950T0000|76 88|significance
P01511950T0000|101 109|antibody
P01511950T0000|113 140|hepatitis B surface antigen
P01511950T0000|152 162|population
P01512259A0867|23 33|phenomenon
P01512259A0867|73 87|cysteine motif
P01512259A0867|115 120|times
P01512259A0867|124 131|Dfurin2
P01512259A0867|168 173|furin
P01512654A0503|13 17|hand
P01512654A0503|27 36|phosphate
P01512654A0503|46 62|saline injection
P01512654A0503|72 74|ES
P01512654A0503|87 101|KLH challenges
P01512654A0503|109 111|ES
P01512654A0503|142 157|threshold level
P01512654A0503|175 182|latency
P01512941A0000|50 62|levofloxacin
P01512941A0000|64 68|LVFX
P01512941A0000|70 77|DR-3355
P01512941A0000|118 128|comparison
P01512941A0000|134 147|ciprofloxacin
P01512941A0000|149 153|CPFX
P01512941A0000|156 165|ofloxacin
P01512941A0000|167 171|OFLX
P01512941A0000|177 188|norfloxacin
P01512941A0000|190 194|NFLX
P01513114A1133|9 32|serum creatinine levels
P01513114A1133|53 57|year
P01513114A1133|59 62|SPK
P01513114A1133|68 71|KTA
P01513114A1133|76 80|mg/d
P01513114A1133|83 91|ABSTRACT
P01513114A1133|109 114|WORDS
P01513213A0231|0 17|Model predictions
P01513213A0231|26 32|accord
P01513213A0231|52 71|survival experience
P01513213A0231|75 80|women
P01513213A0231|88 97|HIP trial
P01513213A0231|113 122|exception
P01513213A0231|126 131|women
P01513213A0231|138 143|years
P01513213A0231|154 162|HIP data
P01513213A0231|174 182|survival
P01516427T0000|25 35|tomography
P01516427T0000|43 52|diagnosis
P01516427T0000|64 76|tuberculosis
P01516829A0113|27 31|SNF2
P01516829A0113|33 37|SNF5
P01516829A0113|43 56|SNF6 function
P01516829A0113|93 103|activation
P01516829A0113|136 143|complex
P01516829A0460|13 22|LexA-GAL4
P01516829A0460|39 54|fusion proteins
P01516829A0460|77 81|SNF2
P01516829A0460|83 87|SNF5
P01516829A0460|93 97|SNF6
P01516829A0460|102 112|activation
P01516829A0460|116 128|target genes
P01516829A0460|156 170|lexA operators
P01518396T0000|0 9|George T.
P01518833A0397|2 26|lambda gt10 cDNA library
P01518833A0397|48 52|poly
P01518833A0397|53 54|A
P01518833A0397|57 60|RNA
P01518833A0397|76 82|leaves
P01518833A0397|86 93|spinach
P01518849A0165|0 2|NE
P01518849A0165|7 10|PR3
P01518849A0165|25 36|destruction
P01518849A0165|53 67|microorganisms
P01518849A0165|108 123|protein elastin
P01518849A0165|150 160|activities
P01518849A0165|172 210|alpha 1-proteinase inhibitor complexes
P01518849A0165|215 231|elastin peptides
P01518926T0000|9 15|topics
P01518926T0000|29 44|ultrasonography
P01522699A0092|0 7|Methods
P01522699A0092|33 39|recall
P01522699A0092|41 53|menu weights
P01522699A0092|59 74|recipe analysis
P01523111A0769|0 7|Factors
P01523111A0769|24 33|afterdrop
P01523111A0769|43 46|age
P01523111A0769|63 74|temperature
P01523111A0769|97 106|body mass
P01524549A0241|5 18|GH deficiency
P01524549A0241|39 45|growth
P01524549A0241|66 73|stature
P01524549A0241|87 97|occurrence
P01524549A0241|107 114|puberty
P01524549A0241|118 129|association
P01524549A0241|135 148|GH deficiency
P01524549A0241|161 165|time
P01524549A0241|180 190|GH therapy
P01525153A0359|3 11|contrast
P01525153A0359|13 14|d
P01525153A0359|15 21|T2AG3T
P01525153A0359|27 28|d
P01525153A0359|29 34|T2G4T
P01525153A0359|36 40|form
P01525153A0359|63 81|monomer structures
P01525153A0359|97 119|K cation concentration
P01525153A0359|144 147|Sen
P01525153A0359|149 151|D.
P01525153A0359|155 162|Gilbert
P01525153A0359|164 166|W.
P01525966T0000|28 34|stones
P01526658A0454|0 3|IFI
P01526658A0454|7 11|mRNA
P01526658A0454|65 70|cells
P01526658A0454|78 88|cell lines
P01526658A0454|101 102|T
P01526658A0454|107 117|B lineages
P01526690T0000|19 25|action
P01526690T0000|29 37|warfarin
P01526690T0000|41 52|lymphocytes
P01527020A0511|12 21|junctions
P01527020A0511|39 69|rat AdoMet decarboxylase genes
P01527020A0511|88 97|positions
P01527020A0511|110 115|exons
P01527020A0511|137 141|gene
P01527020A0511|158 162|exon
P01527020A0511|170 178|rat gene
P01529530T0000|25 40|gene expression
P01529530T0000|42 50|evidence
P01529530T0000|67 73|effect
P01529530T0000|77 84|ouabain
P01529530T0000|88 98|activation
P01529530T0000|106 133|ISGF3 transcription complex
P01531086A0127|4 8|cDNA
P01531086A0127|21 34|reading frame
P01531086A0127|42 53|amino acids
P01531086A0127|83 90|protein
P01531214A0885|10 14|LD50
P01531214A0885|18 22|mice
P01531214A0885|26 32|RP-170
P01531214A0885|38 42|g/kg
P01531214A0885|46 50|i.v.
P01531214A0885|73 77|g/kg
P01531214A0885|86 100|administration
P01531632A0000|14 22|proteins
P01531632A0000|41 50|nucleolus
P01531632A0000|86 94|proteins
P01531632A0000|96 105|nucleolin
P01531632A0000|107 118|fibrillarin
P01531632A0000|120 124|SSB1
P01531632A0000|129 133|NSR1
P01531632A0000|163 168|motif
P01531632A0000|174 184|GAR domain
P01531632A0000|203 210|glycine
P01531632A0000|215 232|arginine residues
P01532229A1264|11 16|study
P01532229A1264|26 34|evidence
P01532229A1264|60 66|factor
P01532229A1264|68 73|HF-1a
P01532229A1264|81 94|muscle factor
P01532229A1264|96 101|HF-1b
P01532229A1264|102 107|MEF-2
P01532229A1264|145 152|pathway
P01532229A1264|173 183|expression
P01532229A1264|207 219|muscle cells
P01532796A0107|0 9|Mutations
P01532796A0107|20 24|gene
P01532796A0107|49 53|step
P01532796A0107|57 65|assembly
P01532796A0107|69 71|F1
P01532796A0107|85 90|alpha
P01532796A0107|95 108|beta subunits
P01532796A0107|126 138|mitochondria
P01532796A0107|151 161|aggregates
P01532796A0107|163 171|Ackerman
P01532796A0107|173 175|S.
P01532914A0067|0 7|Expense
P01532914A0067|19 22|use
P01532914A0067|26 46|hepatitis B vaccines
P01532914A0067|73 85|immunization
P01532914A0067|122 130|strategy
P01532914A0067|143 150|studies
P01533760T0000|0 28|Estrogen replacement therapy
P01533760T0000|33 37|risk
P01533760T0000|41 54|breast cancer
P01533760T0000|56 63|results
P01533760T0000|71 84|meta-analyses
P01535242A0557|10 16|FDC-P1
P01535242A0557|17 26|MAC cells
P01535242A0557|32 38|growth
P01535242A0557|42 47|M-CSF
P01535242A0557|51 57|GM-CSF
P01535242A0557|79 90|degradation
P01535242A0557|94 104|c-fms mRNA
P01535242A0557|114 115|h
P01535242A0557|122 138|factor switching
P01536153A0574|34 44|difference
P01536153A0574|52 62|prevalence
P01536153A0574|86 94|symptoms
P01536153A0574|103 122|animal food workers
P01536153A0574|150 160|skin tests
P01536153A0574|170 174|dust
P01536153A0574|181 191|fish flour
P01536153A0574|232 235|IgE
P01536153A0574|248 255|dyspnea
P01536575A1213|14 21|finding
P01536575A1213|30 38|presence
P01536575A1213|42 50|position
P01536575A1213|78 84|dioxin
P01536575A1213|96 103|element
P01536575A1213|107 115|sequence
P01536575A1213|148 157|induction
P01536575A1213|161 174|transcription
P01536575A1213|182 205|cytochrome P450IA1 gene
P01536575A1213|207 213|CYPIA1
P01536575A1213|225 230|genes
P01536575A1213|243 268|detoxification/activation
P01536575A1213|292 304|hydrocarbons
P01537334A0507|4 8|gene
P01537334A0507|18 28|TRP-2 maps
P01537334A0507|32 48|mouse chromosome
P01537334A0507|60 66|region
P01537334A0507|74 100|coat colour mutation slaty
P01537845A0571|24 36|c-myb clones
P01537845A0571|41 47|change
P01537845A0571|55 59|rate
P01537845A0571|63 87|c-myb gene transcription
P01537845A0571|91 105|mRNA stability
P01537845A0571|130 140|cell cycle
P01538401A1244|5 30|base-pair oligonucleotide
P01538401A1244|40 51|nucleotides
P01538401A1244|72 82|S RNA gene
P01538401A1244|119 126|binding
P01538401A1244|141 147|latter
P01538401A1244|187 200|DNA fragments
P01538403A1058|14 28|reconstitution
P01538403A1058|32 36|eUSF
P01538403A1058|56 79|transcription complexes
P01538403A1058|94 111|protein fractions
P01538403A1058|138 143|TFIID
P01538403A1058|153 157|eUSF
P01538403A1058|186 203|complex formation
P01538403A1058|212 233|H5 promoter mutations
P01538403A1058|246 254|TATA-box
P01539996A0588|2 12|comparison
P01539996A0588|20 39|amino acid sequence
P01539996A0588|47 69|T. thermophilus enzyme
P01539996A0588|104 110|enzyme
P01539996A0588|126 127|%
P01539996A0588|136 146|similarity
P01539996A0588|157 169|conservation
P01539996A0588|177 188|Ser residue
P01539996A0588|241 247|enzyme
P01539996A0588|272 280|sequence
P01539996A0588|296 304|presence
P01539996A0588|318 326|residues
P01539996A0588|334 344|C terminus
P01539996A0588|352 374|T. thermophilus enzyme
P01541556A1040|14 23|palmitate
P01541556A1040|62 69|protein
P01541556A1040|84 102|lipid modification
P01541556A1040|117 131|Cys-22 residue
P01541577A0000|3 12|volunteer
P01541577A0000|18 20|Ss
P01541577A0000|43 63|volunteer hearing Ss
P01541577A0000|71 88|Stanford Hypnotic
P01541577A0000|98 103|Scale
P01541577A0000|105 109|SHCS
P01541577A0000|114 120|Morgan
P01541577A0000|125 127|J.
P01542565A0220|7 26|tobacco L12 protein
P01542565A0220|33 54|% amino acid identity
P01542565A0220|70 84|protein L7/L12
P01542565T0000|38 49|protein L12
P01542565T0000|53 70|Nicotiana tabacum
P01542565T0000|72 88|characterization
P01542565T0000|99 106|protein
P01542565T0000|111 120|isolation
P01542565T0000|125 142|sequence analysis
P01542565T0000|146 157|cDNA clones
P01542565T0000|183 192|precursor
P01542667A0125|4 8|gene
P01542667A0125|18 27|IFN-gamma
P01542667A0125|72 88|enhancer element
P01542667A0125|125 133|activity
P01542667A0125|158 168|expression
P01542667A0125|202 206|gene
P01542686A0000|10 17|cloning
P01542686A0000|25 46|polypeptide component
P01542686A0000|72 97|p75 nucleoprotein complex
P01542686A0000|115 123|identity
P01542686A0000|141 144|p65
P01542686A0000|146 153|subunit
P01542686A0000|157 168|NF-kappa B.
P01542730A1982|44 50|pacing
P01542730A1982|62 69|patient
P01542730A1982|85 89|risk
P01542730A1982|100 111|development
P01542730A1982|115 123|AV block
P01542730A1982|128 138|DDD pacing
P01542730A1982|169 176|support
P01542730A1982|218 230|dual-chamber
P01542730A1982|232 236|DDDR
P01542730A1982|238 245|devices
P01542730A1982|276 282|number
P01542730A1982|292 300|patients
P01542730A1982|302 310|ABSTRACT
P01542730A1982|328 333|WORDS
P01543909A0787|34 44|K562 cells
P01543909A0787|51 53|Lg
P01543909A0787|62 67|clone
P01543909A0787|136 151|characteristics
P01543909A0787|167 177|pseudogene
P01543909A0787|213 217|gene
P01543909A0787|236 252|ferritin subunit
P01544854A0699|7 12|drugs
P01544854A0699|34 43|WR-168643
P01544854A0699|57 66|protector
P01544854A0699|74 77|DMF
P01544918A1240|0 16|Characterization
P01544918A1240|26 36|R subunits
P01544918A1240|46 81|8-azido-cAMP photoaffinity labeling
P01544918A1240|86 102|immunoreactivity
P01544918A1240|146 160|mobility shift
P01544918A1240|164 178|sodium dodecyl
P01544918A1240|202 221|gel electrophoresis
P01544918A1240|223 231|SDS-PAGE
P01544918A1240|244 257|subunit sizes
P01544918A1240|261 269|RII beta
P01544918A1240|274 277|kDa
P01544918A1240|292 315|RII alpha dephosphoform
P01544918A1240|320 323|kDa
P01544918A1240|338 346|RI alpha
P01544918A1240|351 354|kDa
P01544928A1252|0 10|Comparison
P01544928A1252|26 38|DNA sequence
P01544928A1252|71 76|mRNAs
P01544928A1252|98 109|transcripts
P01544928A1252|138 146|splicing
P01544928A1252|161 169|pre-mRNA
P01544928A1252|185 199|cassette model
P01545523A0000|19 34|quantifications
P01545523A0000|56 64|testings
P01545523A0000|77 78|C
P01545523A0000|88 95|protein
P01545523A0000|108 114|factor
P01545523A0000|119 137|antistreptolysin O
P01545787A0345|17 25|enhancer
P01545787A0345|37 42|sites
P01545787A0345|85 90|DNase
P01545787A0345|93 103|footprints
P01545787A0345|105 111|NFAT-1
P01545787A0345|116 123|NFIL-2B
P01545792A0000|12 32|myosin light chain-2
P01545792A0000|34 39|MLC-2
P01545792A0000|41 54|gene promoter
P01545792A0000|105 114|sequences
P01545792A0000|140 150|regulation
P01545792A0000|158 168|expression
P01545792A0492|0 20|Deletion mutagenesis
P01545792A0492|49 57|elements
P01545792A0492|87 97|regulation
P01545792A0492|101 125|MLC-2 gene transcription
P01545797A0587|0 20|Disruption mutations
P01545797A0587|50 59|SLK1 gene
P01545797A0587|61 65|slk1
P01545797A0587|71 78|mutants
P01545797A0587|97 106|degrees C
P01545797A0587|117 122|cells
P01545797A0587|150 160|degrees C.
P01545806T0000|22 30|analysis
P01545806T0000|38 43|yeast
P01545806T0000|58 84|recombination genes REC102
P01545806T0000|89 100|REC107/MER2
P01545818A0696|4 8|p130
P01545818A0696|13 16|p62
P01545818A0696|41 49|proteins
P01545818A0696|65 74|v-Src SH2
P01545818A0696|105 110|v-Src
P01545818A0696|132 143|Rat-2 cells
P01545818A0696|158 165|binding
P01545818A0696|187 203|v-Src SH2 domain
P01546522A0000|0 8|Probable
P01546522A0000|32 51|leukoencephalopathy
P01546522A0000|53 56|PML
P01546522A0000|79 84|basis
P01546522A0000|97 104|picture
P01546522A0000|118 135|resonance imaging
P01546522A0000|153 156|man
P01546522A0000|173 182|remission
P01546522A0000|202 210|lymphoma
P01547775A1024|6 10|data
P01547775A1024|41 53|significance
P01547775A1024|61 71|frameshift
P01547775A1024|89 97|position
P01547775A1024|145 148|RNA
P01547775A1024|166 170|site
P01547775A1024|178 192|PLRV replicase
P01547775A1024|200 230|ORF2a/ORF2b transframe protein
P01547787A0548|0 21|Proprotein processing
P01547942A0120|14 17|LAP
P01547942A0120|34 53|dimerization domain
P01547942A0120|55 67|zipper probe
P01547942A0120|91 96|clone
P01547942A0120|133 140|protein
P01547942A0120|142 149|CHOP-10
P01547957A1083|19 43|oligodeoxyribonucleotide
P01547957A1083|76 87|aa sequence
P01547957A1083|138 144|region
P01547957A1083|156 163|portion
P01547957A1083|167 171|CYP1
P01547957A1083|176 180|CYP2
P01547957A1083|210 216|genome
P01547957A1083|234 246|DNA fragment
P01547957A1083|268 293|polymerase chain reaction
P01547957A1083|295 298|PCR
P01547957A1083|306 310|GL81
P01547957A1083|319 322|DNA
P01547957A1083|328 337|substrate
P01548756A1102|10 23|hybridization
P01548756A1102|27 32|EHS-1
P01548756A1102|57 60|DNA
P01548756A1102|84 94|EHS-1 loci
P01548756A1102|111 114|DNA
P01548756A1102|129 141|band pattern
P01548756A1102|145 159|chimpanzee DNA
P01548756A1102|174 179|locus
P01548756A1102|183 200|rhesus monkey DNA
P01548891A0635|4 9|level
P01548891A0635|43 50|hormone
P01548891A0635|58 66|patients
P01548891A0635|72 89|thyroid carcinoma
P01548891A0635|118 126|patients
P01548891A0635|135 152|thyroid carcinoma
P01548891A0635|154 155|P
P01549118A0000|4 45|Caenorhabditis elegans vitellogenin genes
P01549118A0000|61 64|sex
P01549118A0000|67 72|stage
P01549118A0000|95 105|regulation
P01549118A0000|146 169|hermaphrodite intestine
P01549123A0480|4 13|MET4 gene
P01549123A0480|34 42|sequence
P01549123A0480|69 76|protein
P01549123A0480|92 98|family
P01549123A0480|106 110|bZIP
P01549123A0480|127 137|activators
P01549125A0140|4 13|functions
P01549125A0140|26 34|portions
P01549125A0140|42 49|insulin
P01549125A0140|51 55|IAPP
P01549125A0140|61 78|beta GK promoters
P01549125A0140|111 121|expression
P01549125A0140|126 144|DNA binding assays
P01549129A0356|26 33|domains
P01549129A0356|87 99|interactions
P01549129A0356|125 136|functioning
P01549129A0356|140 143|Src
P01549346A0000|4 23|c-Ets-1 oncoprotein
P01549346A0000|29 52|transcription activator
P01549346A0000|80 83|DNA
P01549465A0122|9 36|transactivation experiments
P01549465A0122|58 69|amino acids
P01549465A0122|87 93|region
P01549465A0122|95 98|Gly
P01549465A0122|100 103|Ser
P01549465A0122|108 111|Val
P01549465A0122|151 165|discrimination
P01551176A0000|0 8|GR63178A
P01551176A0000|28 36|analogue
P01551176A0000|40 51|mitoquidone
P01551176A0000|67 81|pyrroloquinone
P01551568A1476|0 22|Marker rescue analysis
P01551568A1476|37 40|ts8
P01551568A1476|62 69|segment
P01551568A1476|73 77|rpoB
P01551568A1476|95 105|Rif domain
P01551898A1084|5 11|vector
P01551898A1084|33 38|yeast
P01551898A1084|72 82|expression
P01551898A1084|104 111|protein
P01551898A1084|115 121|levels
P01551898A1084|132 134|mg
P01551898A1084|138 148|LAPP/liter
P01551898A1084|152 166|culture medium
P01551910A0313|0 20|Competition analysis
P01551910A0313|24 58|gel mobility shift electrophoresis
P01551910A0313|91 102|interaction
P01551910A0313|136 157|transcription factors
P01551910A0978|5 14|DNA motif
P01551910A0978|50 58|sequence
P01552052A0139|0 9|OBJECTIVE
P01552052A0139|15 20|study
P01552052A0139|53 62|frequency
P01552052A0139|66 77|alterations
P01552052A0139|81 97|serum creatinine
P01552052A0139|101 109|patients
P01552052A0139|115 124|psoriasis
P01552052A0139|137 146|mg/kg/day
P01552052A0139|150 162|cyclosporine
P01552457T0000|0 24|Intrapocket chemotherapy
P01552457T0000|34 47|periodontitis
P01552457T0000|79 85|insert
P01552457T0000|97 106|ofloxacin
P01552457T0000|108 113|PT-01
P01552662A0398|16 26|blood flow
P01552662A0398|28 30|BF
P01552662A0398|32 37|probe
P01552662A0398|82 88|artery
P01552662A0398|90 93|LAD
P01552853A1377|6 17|temperature
P01552853A1377|22 26|virF
P01552853A1377|53 62|induction
P01552853A1377|70 81|yop regulon
P01553407T0000|0 8|Problems
P01553407T0000|38 42|area
P01553407T0000|59 74|risk assessment
P01554334A0000|23 39|gamma-interferon
P01554334A0000|41 50|IFN-gamma
P01554334A0000|52 64|assay system
P01554334A0000|73 82|diagnosis
P01554334A0000|93 105|tuberculosis
P01554334A0000|109 115|cattle
P01554334A0000|152 161|Committee
P01554334A0000|165 176|Agriculture
P01554334A0000|181 184|use
P01554334A0000|188 197|Australia
P01555556A0565|0 15|Control Tmuscle
P01555556A0565|33 42|degrees C
P01555556A0565|49 59|control Wi
P01555556A0565|60 63|max
P01555556A0565|76 78|SD
P01555556A0565|84 90|W.kg-1
P01556068A0000|4 34|Klebsiella aerogenes gene maoA
P01556068A0000|61 70|synthesis
P01556068A0000|74 91|monoamine oxidase
P01556068A0000|108 116|tyramine
P01556068A0000|133 142|compounds
P01556068A0000|157 167|catabolite
P01556068A0000|172 195|ammonium ion repression
P01556111A0241|15 22|regions
P01556111A0241|30 37|plasmid
P01557217A0272|39 46|lesions
P01557217A0272|88 94|h p.i.
P01557411A1282|16 24|D1A gene
P01557411A1282|40 48|category
P01557411A1282|79 84|genes
P01557411A1282|113 122|promoters
P01558942A1369|8 20|observations
P01558942A1369|57 62|genes
P01559209T0000|0 13|Preceptorship
P01559209T0000|17 29|CNS students
P01559209T0000|46 51|study
P01560021A0379|25 30|basis
P01560021A0379|39 50|differences
P01560021A0379|75 93|brain AE3 variants
P01560021A0379|129 137|rat gene
P01560774A0885|8 10|kb
P01560774A0885|18 26|fragment
P01560774A0885|73 82|fliA gene
P01562659A0676|0 11|Institution
P01562659A0676|51 65|administration
P01562659A0676|69 83|amphotericin B
P01562659A0676|121 135|administration
P01562659A0676|139 152|dexamethasone
P01562659A0676|173 183|situations
P01562659A0676|197 208|association
P01562659A0676|212 222|C. immitis
P01562659A0676|228 242|CNS vasculitis
P01562659A0676|246 258|encephalitis
P01562659A0676|303 315|confirmation
P01562659A0676|319 339|C. immitis infection
P01562659A0676|354 357|CNS
P01563343A0548|0 13|Lac operators
P01563343A0548|43 52|positions
P01563343A0548|64 76|CAB promoter
P01563343A0548|95 102|plasmid
P01563343A0548|115 122|control
P01563635T0000|0 14|Overproduction
P01563635T0000|16 28|purification
P01563635T0000|33 49|characterization
P01563635T0000|53 78|M.HinfI methyltransferase
P01563635T0000|87 102|deletion mutant
P01564653A0307|8 17|companies
P01564653A0307|31 35|type
P01564653A0307|39 43|lens
P01565093A0179|5 10|March
P01565093A0179|21 28|October
P01565093A0179|45 52|persons
P01565093A0179|82 99|blood lead levels
P01565093A0179|101 105|BLLs
P01565093A0179|118 126|hospital
P01565093A0179|163 190|disease surveillance system
P01565093A0179|209 227|Alabama Department
P01565093A0179|231 244|Public Health
P01565093A0179|246 250|ADPH
P01565882A0737|17 24|changes
P01565882A0737|28 45|perfusion defects
P01565882A0737|58 60|RD
P01565882A0737|65 75|ReI images
P01565882A0737|105 110|types
P01565882A0737|112 116|Type
P01565882A0737|120 136|perfusion defect
P01565882A0737|144 152|RD image
P01565882A0737|174 179|image
P01565882A0737|183 184|%
P01565882A0737|186 190|Type
P01565882A0737|212 221|subgroups
P01565882A0737|230 246|perfusion defect
P01565882A0737|268 270|Ia
P01565882A0737|274 275|%
P01565882A0737|290 292|Ib
P01565882A0737|296 297|%
P01565882A0737|306 314|RD image
P01566576A0605|0 4|Keck
P01566576A0605|6 10|C.J.
P01567649A0139|17 18|%
P01567649A0139|20 27|infants
P01567649A0139|52 62|hemorrhage
P01567649A0139|104 109|palsy
P01567649A0139|132 142|evaluation
P01567649A0139|152 159|infancy
P01568960A1129|11 20|mechanism
P01568960A1129|47 55|pressure
P01568960A1129|78 84|output
P01568960A1129|95 105|blood flow
P01568960A1129|111 125|corner vessels
P01568960A1129|147 159|VA/Q regions
P01569015A0120|16 21|FRAME
P01569015A0120|23 31|analysis
P01569015A0120|60 74|reading frames
P01569015A0120|76 80|ORFs
P01569015A0120|96 105|direction
P01569015A0120|130 139|direction
P01569102A0708|0 6|Domain
P01569102A0708|38 50|LDL receptor
P01569102A0708|69 76|repeats
P01569102A0708|90 102|conservation
P01569102A0708|124 133|cysteines
P01569344A0404|8 14|cities
P01569344A0404|26 36|prevalence
P01569344A0404|66 69|age
P01569344A0404|79 94|New Orleans age
P01569344A0404|113 133|HTLV-I/II prevalence
P01569344A0404|172 181|Baltimore
P01569344A0404|183 184|P
P01569581A0482|17 25|evidence
P01569581A0482|32 37|model
P01569581A0482|47 51|mRNA
P01569581A0482|79 90|nucleotides
P01569581A0482|111 122|start codon
P01569581A0482|130 134|fold
P01569581A0482|144 153|base-pair
P01569581A0482|165 194|translation initiation region
P01569581A0482|219 251|translation initiation frequency
P01569584A0672|0 18|Hybridization data
P01569584A0672|33 38|6F6.2
P01569584A0672|83 98|m6F6 cDNA clone
P01569584A0672|108 113|6F6.1
P01569584A0672|118 123|6F6.3
P01569584A0672|133 138|6F6.2
P01569584A0672|167 172|genes
P01569945A0529|4 13|SEN1 gene
P01569945A0529|45 58|reading frame
P01569945A0529|89 96|protein
P01569945A0529|108 112|mass
P01569945A0529|118 121|kDa
P01572549A0000|0 24|Protein tyrosine kinases
P01572549A0000|26 30|PTKs
P01572549A0000|54 61|control
P01572549A0000|65 76|cell growth
P01572549A0000|80 86|virtue
P01572549A0000|105 115|appearance
P01572549A0000|119 127|products
P01572549A0000|142 151|oncogenes
P01572549A0000|170 188|signal transducers
P01572549A0000|197 220|growth factor receptors
P01572549A0000|224 234|components
P01573270A0000|4 11|IA4 mAb
P01573270A0000|35 41|series
P01573270A0000|45 55|antibodies
P01573270A0000|66 77|BALB/c mice
P01573270A0000|84 96|immunization
P01573270A0000|107 116|HLA class
P01573270A0000|151 157|killer
P01573270A0000|159 162|LAK
P01573270A0000|176 197|EBV-B lymphocyte line
P01577056A0178|40 45|study
P01577056A0178|51 59|subjects
P01577056A0178|69 81|theophylline
P01577056A0178|84 91|mg.kg-1
P01577056A0178|96 99|day
P01577056A0178|105 115|omeprazole
P01577056A0178|119 121|mg
P01577056A0178|126 129|day
P01577056A0178|143 150|placebo
P01577056A0178|162 169|periods
P01577056A0178|181 185|days
P01577056A0178|202 216|washout period
P01577056A0178|222 226|days
P01577740A1111|0 16|Primer extension
P01577740A1111|21 30|mung bean
P01577740A1111|35 54|S1 nuclease mapping
P01577740A1111|74 104|transcription initiation sites
P01577740A1111|130 147|Northern analyses
P01577819A0709|12 33|PRP-precursor alleles
P01577819A0709|69 75|number
P01577819A0709|79 86|repeats
P01577819A0709|90 99|domain C.
P01579472A1018|19 35|enhancer element
P01579472A1018|42 48|region
P01579472A1018|87 93|manner
P01579537A0000|15 20|years
P01579537A0000|38 42|uses
P01579537A0000|46 61|botulinum toxin
P01579537A0000|72 82|neurotoxin
P01580738T0001|0 9|Allagille
P01580738T0001|12 20|syndrome
P01580738T0001|47 54|ascites
P01581409A0398|0 11|Sensitivity
P01581409A0398|16 27|specificity
P01581409A0398|52 72|Pharmacia CAP System
P01581409A0398|81 99|DPC AlaSTAT System
P01581409A0398|103 113|comparison
P01581409A0398|119 126|results
P01581409A0398|134 138|skin
P01581409A0398|145 149|test
P01581577A1186|0 5|PSI-G
P01581577A1186|10 15|PSI-K
P01581577A1186|45 61|gene duplication
P01581577A1186|78 82|gene
P01581965A0388|7 17|C-terminus
P01581965A0388|25 32|protein
P01581965A0388|38 44|domain
P01581965A0388|59 68|sequences
P01581965A0388|104 142|breakpoint cluster region gene product
P01581965A0388|144 154|n-chimerin
P01581965A0388|160 167|rho GAP
P01581965A0388|219 231|GAP activity
P01581965A0388|241 248|GTPases
P01582413A0192|14 25|mutagenesis
P01582413A0192|44 52|clusters
P01582413A0192|62 73|amino acids
P01582413A0192|99 105|region
P01582413A0192|126 133|helices
P01582413A0192|158 164|domain
P01582413A0192|201 212|DNA binding
P01582413A0192|217 239|hetero-oligomerization
P01582413A0759|0 12|Dimerization
P01582413A0759|16 21|Myf-5
P01582413A0759|59 70|protein E12
P01582413A0759|94 102|affinity
P01582413A0759|107 110|DNA
P01582413A0759|131 146|transactivation
P01582413A0759|164 175|DNA binding
P01582500A0178|14 25|rhythmicity
P01582500A0178|29 34|sleep
P01583819A0377|0 3|SEA
P01583819A0377|36 43|filters
P01583819A0377|54 56|HZ
P01583819A0377|68 70|Hz
P01583819A0377|77 90|Simson method
P01584812T0000|16 26|expression
P01584812T0000|36 45|structure
P01584812T0000|63 75|localization
P01584812T0000|83 87|gene
P01584812T0000|113 140|transcription factor NGFI-C
P01585014A0000|3 13|experiment
P01585014A0000|27 34|effects
P01585014A0000|38 47|treatment
P01585014A0000|53 66|gonadotrophin
P01585014A0000|77 84|hormone
P01585014A0000|90 105|micrograms GnRH
P01585014A0000|118 119|h
P01585014A0000|126 152|progestagen sponge removal
P01585014A0000|155 161|season
P01585014A0000|165 174|treatment
P01585014A0000|176 182|autumn
P01585014A0000|186 192|spring
P01585014A0000|199 205|effect
P01585014A0000|236 247|lupin grain
P01585014A0000|252 258|autumn
P01585014A0000|273 277|days
P01585014A0000|293 297|days
P01585014A0000|304 318|sponge removal
P01585014A0000|327 331|time
P01585014A0000|335 344|ovulation
P01585014A0000|359 370|Merino ewes
P01585014A0000|392 403|combination
P01585014A0000|411 415|I.U.
P01585014A0000|425 449|mare serum gonadotrophin
P01585014A0000|451 455|PMSG
P01585014A0000|464 495|mg follicle stimulating hormone
P01585014A0000|497 502|FSH-P
P01586901A0000|10 22|interactions
P01586901A0000|51 59|patients
P01586901A0000|79 90|medications
P01586901A0000|100 105|drugs
P01586901A0000|137 143|window
P01587267A1144|4 17|sequence data
P01587267A1144|40 54|interpretation
P01587267A1144|62 67|X-ray
P01587267A1144|85 94|structure
P01587267A1144|102 108|enzyme
P01587267A1144|117 124|cloning
P01587267A1144|129 139|expression
P01587267A1144|159 163|gene
P01587267A1144|194 205|mutagenesis
P01587763A0402|6 22|body irradiation
P01587763A0402|70 76|scheme
P01587763A0402|83 92|fractions
P01587763A0402|109 112|day
P01587763A0402|115 117|hr
P01587763A0402|130 134|days
P01588270A1029|2 11|reduction
P01588270A1029|15 29|blood pressure
P01588270A1029|55 58|end
P01588270A1029|66 71|study
P01588270A1029|118 120|.9
P01588270A1029|129 133|mmHg
P01588270A1029|135 136|P
P01588270A1029|156 159|DBP
P01588315A0356|0 6|AgMNPV
P01588315A0356|11 36|Orgyia pseudotsugata MNPV
P01588315A0356|38 44|OpMNPV
P01588315A0356|61 66|terms
P01588315A0356|70 88|promoter structure
P01588315A0356|93 103|polyhedrin
P01588315A0356|112 120|sequence
P01588315A0356|130 145|polyhedrin gene
P01588315A0356|154 161|viruses
P01588315A0356|199 208|direction
P01588315A0356|212 220|relation
P01588315A0356|239 243|maps
P01588913A0000|2 6|gene
P01588913A0000|42 51|dnaA gene
P01588913A0000|97 110|transcription
P01588913A0000|153 162|P. putida
P01588961A0000|0 4|STP1
P01588961A0000|23 33|yeast gene
P01588961A0000|50 57|removal
P01588961A0000|73 82|sequences
P01588961A0000|107 115|families
P01588961A0000|151 160|pre-tRNAs
P01588963A1153|12 22|antibodies
P01588963A1153|51 61|conditions
P01588963A1153|91 104|Cdc25 protein
P01588965A0000|0 18|GCR1 gene function
P01588965A0000|57 72|gene expression
P01589576A0170|4 16|decay curves
P01589576A0170|20 44|chlorophyll fluorescence
P01589576A0170|54 67|superposition
P01589576A0170|100 110|components
P01589576A0170|116 130|time constants
P01589576A0170|134 136|T1
P01589576A0170|147 149|ps
P01589576A0170|151 153|T2
P01589576A0170|164 166|ps
P01589576A0170|171 173|T3
P01589576A0170|184 186|ns
P01592545A0726|24 38|blood pressure
P01592545A0726|47 54|average
P01592545A0726|60 61|%
P01592545A0726|65 73|patients
P01592545A0726|100 101|p
P01592545A0726|123 124|%
P01592545A0726|148 156|patients
P01594554A0845|6 13|results
P01594554A0845|38 43|roles
P01594554A0845|49 52|CCK
P01594554A0845|57 75|trypsin inhibitors
P01594554A0845|113 129|feedback control
P01594554A0845|153 161|function
P01596007A0908|12 18|events
P01596007A0908|35 41|Stages
P01596007A0908|56 59|REM
P01596007A0908|70 80|proportion
P01596007A0908|101 115|gamma OH study
P01596007A0908|129 130|%
P01596007A0908|148 163|control studies
P01596007A0908|194 195|%
P01596007A0908|227 230|SWS
P01596007A0908|236 244|gamma OH
P01596007A0908|246 254|ABSTRACT
P01596007A0908|272 277|WORDS
P01597170A0000|6 13|rabbits
P01597170A0000|42 51|mg/m3 Co2
P01597170A0000|56 61|CoCl2
P01597170A0000|78 87|mg/m3 Cr3
P01597170A0000|92 94|Cr
P01597170A0000|95 98|NO3
P01597170A0000|102 110|group Co
P01597170A0000|113 115|Cr
P01597170A0000|139 148|mg/m3 Co2
P01597170A0000|151 159|group Co
P01597170A0000|184 187|air
P01597170A0000|189 202|control group
P01597170A0000|211 217|months
P01597170A0000|221 230|days/week
P01597170A0000|238 244|hr/day
P01597272A0077|3 8|women
P01597272A0077|27 36|methadone
P01597272A0077|48 67|withdrawal symptoms
P01597462A0457|0 10|Disruption
P01597462A0457|29 34|CDC14
P01597462A0457|51 55|gene
P01600531A0483|9 13|flow
P01600531A0483|31 32|%
P01600531A0483|40 55|phosphocreatine
P01600531A0483|65 66|%
P01600531A0483|74 87|control group
P01601181A0842|4 19|60A transcripts
P01601181A0842|24 31|protein
P01601181A0842|58 63|onset
P01601181A0842|67 79|gastrulation
P01601181A0842|98 106|mesoderm
P01601181A0842|124 133|germ band
P01601869A1389|9 16|segment
P01601869A1389|36 42|region
P01601869A1389|70 75|E-box
P01601869A1389|124 130|region
P01601869A1389|174 184|activation
P01601869A1389|202 217|BC3H1 myoblasts
P01603088A1121|6 13|results
P01603088A1121|50 52|TR
P01603088A1121|78 88|activation
P01603088A1121|93 103|repression
P01603088A1121|127 133|manner
P01605038T0001|0 9|Influence
P01605038T0001|20 30|regulation
P01605038T0001|50 57|effects
P01605038T0001|61 65|GABA
P01605038T0001|69 73|rats
P01607223A0000|7 21|investigations
P01607223A0000|52 69|release technique
P01607223A0000|81 86|pulse
P01607223A0000|90 101|laser light
P01607223A0000|114 121|release
P01607223A0000|170 179|liposomes
P01607223A0000|207 218|vasculature
P01608239T0001|16 24|barriers
P01611699A0000|6 28|pyridoxine derivatives
P01611699A0000|63 72|stem bark
P01611699A0000|76 103|Albizzia julibrissin DURAZZ
P01612085A0624|4 24|serum erythropoietin
P01612085A0624|26 29|EPO
P01612085A0624|31 45|concentrations
P01612085A0624|57 68|triathletes
P01612085A0624|75 81|U.ml-1
P01612085A0624|130 146|distance runners
P01612085A0624|153 159|U.ml-1
P01612085A0624|161 162|P
P01613640A0158|4 21|coating materials
P01613640A0158|27 37|poloxamine
P01613640A0158|43 53|poloxamine
P01613640A0158|59 69|poloxamine
P01613640A0158|76 85|poloxamer
P01613640A0158|95 99|Brij
P01615049A0000|4 10|eating
P01615049A0000|15 32|drinking patterns
P01615049A0000|42 47|goats
P01615049A0000|52 58|ad lib
P01615049A0000|76 88|h light/12 h
P01615049A0000|94 99|cycle
P01615182A0206|12 17|study
P01615182A0206|33 44|improvement
P01615182A0206|48 66|sputum amoxycillin
P01615182A0206|68 73|amoxy
P01615182A0206|75 81|levels
P01615182A0206|89 107|combination tablet
P01615182A0206|109 114|amoxy
P01615182A0206|119 121|mg
P01615182A0206|127 138|bromhexeine
P01615182A0206|141 143|mg
P01615182A0206|182 187|amoxy
P01615182A0206|192 194|mg
P01615493A0408|4 6|HC
P01615493A0408|10 18|activity
P01615493A0408|23 37|antigen levels
P01615493A0408|45 46|%
P01615493A0408|53 54|%
P01615493A0408|78 86|daughter
P01615493A0408|111 117|levels
P01615493A0975|0 10|Argatroban
P01615493A0975|43 45|HC
P01615493A0975|49 59|conditions
P01615493A0975|82 92|inhibition
P01615493A0975|96 113|thrombin activity
P01615493A0975|117 122|sites
P01615493A0975|135 146|wall damage
P01616475A0756|6 13|results
P01616475A0756|37 45|validity
P01616475A0756|49 53|NFPD
P01616475A0756|57 72|CP/NCA patients
P01616475A0756|87 95|patients
P01616475A0756|102 116|family history
P01616475A0756|120 134|panic disorder
P01616475A0756|146 154|patients
P01616475A0756|177 204|panic disorder presentation
P01617242T0000|0 15|FDA regulations
P01617242T0000|20 34|growth factors
P01617242T0000|47 55|products
P01617776A0343|31 37|system
P01617776A0343|57 68|arrhythmias
P01617776A0343|84 94|infarction
P01617776A0343|127 138|innervation
P01617776A0343|146 151|heart
P01617776A0343|173 177|role
P01617776A0343|205 211|system
P01617776A0343|215 222|reentry
P01617776A0343|237 242|heart
P01617776A0343|245 249|days
P01617776A0343|256 266|infarction
P01617801A0088|0 6|DESIGN
P01617801A0088|8 25|Serum aldosterone
P01617801A0088|30 51|plasma renin activity
P01617801A0088|66 72|supine
P01617801A0088|98 105|minutes
P01617801A0088|117 126|captopril
P01617801A0088|131 133|mg
P01618027A1108|16 27|transcripts
P01618027A1108|40 44|size
P01618027A1108|79 86|profile
P01618027A1108|123 135|E10 fragment
P01618027A1108|155 161|probes
P01618027A1108|175 184|remainder
P01618027A1108|199 205|region
P01618243T0000|12 31|amine pressor tests
P01618243T0000|43 53|volunteers
P01618256A0521|4 8|mean
P01618256A0521|30 43|concentration
P01618256A0521|59 66|regimen
P01618256A0521|71 85|micrograms.l-1
P01618256A0521|93 94|%
P01618256A0521|127 133|regime
P01618256A0521|138 152|micrograms.l-1
P01619114A0383|14 19|study
P01619114A0383|24 35|performance
P01619114A0383|43 47|SMSP
P01619114A0383|83 104|Mini Speech Processor
P01619114A0383|106 109|MSP
P01619642A0131|5 12|parents
P01620118A0470|13 21|proteins
P01620118A0470|35 42|ability
P01620118A0470|68 73|kappa
P01620118A0470|101 111|activation
P01620118A0470|125 147|immunodeficiency virus
P01620118A0470|162 168|repeat
P01620118A0470|205 212|chicken
P01620118A0470|222 227|cells
P01620129A0417|22 33|interaction
P01620129A0417|45 58|factor HiNF-D
P01620129A0417|82 98|promoter element
P01620129A0417|106 119|H4-FO108 gene
P01620129A0417|123 133|cell cycle
P01620129A0417|162 167|cells
P01620129A0417|169 171|J.
P01620610A1070|3 13|conclusion
P01620610A1070|37 39|TI
P01620610A1070|53 72|expression problems
P01620610A1070|120 126|vector
P01620610A1070|149 158|mutations
P01620610A1070|185 194|sequences
P01620610A1070|201 205|rule
P01620610A1070|217 230|MTI subregion
P01620781A0611|19 27|subjects
P01620781A0611|49 58|sequences
P01620781A0611|77 84|control
P01620781A0611|92 97|words
P01620781A0611|105 107|A1
P01620781A0611|111 113|B2
P01620781A0611|117 119|A3
P01620781A0611|123 125|B4
P01620781A0611|129 131|A5
P01620781A0611|140 148|reversal
P01620781A0611|170 177|stimuli
P01620781A0611|202 210|position
P01620781A0611|219 227|sequence
P01620781A0611|233 240|members
P01620781A0611|253 258|class
P01621584A0183|0 6|UF-021
P01621584A0183|18 26|solution
P01621584A0183|40 41|%
P01621584A0183|74 78|eyes
P01621584A0183|82 89|rabbits
P01621584A0183|113 126|IOP reduction
P01621584A0183|139 143|mmHg
P01621584A0183|164 172|IOP rise
P01623900A0670|6 20|blood pressure
P01623900A0670|39 47|activity
P01623900A0670|61 68|changes
P01623900A0670|76 89|plasma levels
P01623900A0670|102 111|excretion
P01623900A0670|115 129|norepinephrine
P01623900A0670|158 166|Pl group
P01623900A0670|182 186|drop
P01623900A0670|194 200|supine
P01623900A0670|224 239|blood pressures
P01623900A0670|274 294|norepinephrine level
P01623900A0670|310 334|norepinephrine excretion
P01623900A0670|361 366|month
P01623900A0670|370 387|dF administration
P01624425A0907|10 17|protein
P01624425A0907|44 51|mutants
P01624425A0907|57 70|substitutions
P01624425A0907|78 99|consensus amino acids
P01624425A0907|120 129|azido-ATP
P01625131A0452|18 24|biopsy
P01625131A0452|34 44|stoma site
P01625131A0452|56 60|risk
P01625131A0452|78 87|rejection
P01625527A0000|6 28|blood serotonin levels
P01625527A0000|52 65|control group
P01625527A0000|67 68|n
P01625527A0000|84 89|group
P01625527A0000|107 123|failure patients
P01625527A0000|125 126|n
P01625527A0000|145 162|treatment regimen
P01625527A0000|181 190|treatment
P01625527A0000|192 193|n
P01625527A0000|201 226|maintenance haemodialysis
P01625527A0000|228 229|n
P01625527A0000|252 267|transplantation
P01625527A0000|269 270|n
P01626372T0000|0 7|Tissues
P01626372T0000|12 20|exudates
P01626372T0000|40 49|thymidine
P01626372T0000|54 60|growth
P01626372T0000|74 82|bacteria
P01626372T0000|90 98|presence
P01626372T0000|113 119|levels
P01626372T0000|123 152|trimethoprim-sulfamethoxazole
P01626430A1112|4 14|homologies
P01626430A1112|23 28|RAD16
P01626430A1112|30 35|RAD54
P01626430A1112|40 44|SNF2
P01626430A1112|102 107|yeast
P01626430A1112|112 128|Drosophila genes
P01626440A0449|8 29|application solutions
P01626440A0449|33 57|instrument disinfectants
P01626440A0449|93 96|day
P01626631A0557|7 20|Rett syndrome
P01626631A0557|54 66|disturbances
P01626631A0557|74 84|brain stem
P01626631A0557|144 150|system
P01626631A0557|171 180|elevation
P01626631A0557|198 203|level
P01627106A0320|13 23|experiment
P01627106A0320|38 66|nitrofurazone administration
P01627106A0320|71 95|S. enteritidis challenge
P01627106A0320|123 134|differences
P01627106A0320|138 140|S.
P01627106A0320|153 172|isolation frequency
P01627828A0475|3 12|agreement
P01627828A0475|32 40|blotting
P01627828A0475|44 53|mouse DNA
P01627828A0475|59 69|SmN probes
P01627828A0475|78 83|bands
P01627828A0475|122 132|pseudogene
P01627828A0475|183 191|SmN gene
P01627830A0000|4 9|cDNAs
P01627830A0000|19 34|casein kinase-1
P01627830A0000|61 79|yeast cDNA library
P01627830A0000|91 95|CKI1
P01627830A0000|100 104|CKI2
P01628201A0824|0 14|Incidence rate
P01628201A0824|43 47|year
P01628201A0824|64 68|year
P01628201A0824|81 88|minimum
P01628201A0824|108 116|datasets
P01628806A1347|13 31|sequence variation
P01628806A1347|51 54|ORF
P01628806A1347|63 64|Y
P01628806A1347|92 95|ORF
P01628806A1347|119 134|helicase region
P01628904A0386|10 19|screening
P01628904A0386|30 35|clone
P01628904A0386|51 59|kilobase
P01628904A0386|61 63|kb
P01628904A0386|65 71|insert
P01629768A0131|0 7|Lesions
P01629768A0131|21 39|pressure injection
P01629768A0131|50 54|acid
P01629768A0131|64 67|SOC
P01629768A0131|105 123|glass micropipette
P01630454A0635|8 12|poly
P01630454A0635|13 18|dA-dT
P01630454A0635|20 26|region
P01630454A0635|54 63|regulator
P01630454A0635|67 89|Act1 promoter activity
P01630455A0448|16 23|protein
P01630455A0448|32 45|NFIL-1 beta A
P01630455A0448|47 56|NF beta A
P01630455A0448|98 110|DNA sequence
P01630455A0448|148 162|TATA box motif
P01630455A0448|192 207|IL-1 beta genes
P01630569A0605|9 23|amphotericin B
P01630569A0605|25 28|AmB
P01630569A0605|35 44|remission
P01630569A0605|52 57|tumor
P01631229T0000|0 13|Cutis aplasia
P01633435A0743|4 9|DRF-2
P01633435A0743|18 25|protein
P01633435A0743|30 45|characteristics
P01633435A0743|97 103|factor
P01633435A0743|105 110|MEF-2
P01633435A0743|112 118|Buskin
P01633435A0743|123 131|Hauschka
P01633435A0743|138 145|Gossett
P01633816A0667|15 20|clone
P01633816A0667|28 42|EcoRI fragment
P01633816A0667|68 73|exons
P01633816A0667|82 84|kb
P01633816A0667|104 110|region
P01633816A0667|118 126|opn gene
P01633816A0667|166 176|start site
P01633816A0667|191 216|primer extension analysis
P01633816A0667|221 240|S1 nuclease mapping
P01634308A0191|0 27|Cardiovascular risk factors
P01634308A0191|58 68|techniques
P01634400A1101|0 16|Production costs
P01634400A1101|26 30|feed
P01634400A1101|41 50|operating
P01634400A1101|63 86|replacement stock costs
P01634464A0163|12 19|patient
P01634464A0163|31 51|factor VII inhibitor
P01634464A0163|66 74|reaction
P01634464A0163|78 103|penicillin administration
P01634464A0163|113 117|rise
P01634464A0163|127 138|haemorrhage
P01634861A1336|11 19|contrast
P01634861A1336|40 62|oxygen debt hypothesis
P01634861A1336|87 98|oxygen debt
P01634861A1336|103 120|lactate clearance
P01636339A0200|0 7|Account
P01636339A0200|46 54|elements
P01636339A0200|62 68|smears
P01636339A0200|84 89|mucus
P01636339A0200|106 114|crystals
P01636339A0200|116 129|pollen grains
P01636339A0200|139 148|fragments
P01636339A0200|153 158|fungi
P01636714A0845|4 11|results
P01636714A0845|46 51|areas
P01636714A0845|56 59|MBF
P01636714A0845|67 72|liver
P01636714A0845|80 86|cortex
P01636714A0845|88 94|spleen
P01636714A0845|117 123|serosa
P01636714A0845|130 133|MBF
P01636714A0845|161 162|h
P01636714A0845|169 172|CLP
P01637758A0532|3 11|addition
P01637758A0532|22 32|proportion
P01637758A0532|36 41|women
P01637758A0532|58 63|group
P01637758A0532|79 89|dilatation
P01637758A0532|95 97|cm
P01637758A0532|127 138|examination
P01637758A0532|146 157|labour ward
P01637758A0532|168 169|%
P01637758A0532|182 183|%
P01637758A0532|186 188|OR
P01637758A0532|197 201|% CI
P01637758A0532|217 218|P
P01639092A0776|0 5|Lewis
P01639092A0776|7 9|N.
P01639724A0452|2 15|control group
P01639724A0452|24 29|women
P01639724A0452|31 34|age
P01639724A0452|41 46|years
P01639724A0452|56 70|contraceptives
P01639724A0452|72 83|Nordette-28
P01639724A0452|107 112|times
P01639724A0452|122 132|pill cycle
P01640778A0485|24 30|method
P01640778A0485|41 50|MLPA test
P01640778A0485|89 98|screening
P01641628A0869|4 14|modalities
P01641628A0869|25 41|reference values
P01641628A0869|57 65|subjects
P01641628A0869|81 87|groups
P01641628A0869|120 126|points
P01641628A0869|130 138|research
P01641628A0869|188 204|reference values
P01642060A0471|13 24|application
P01642060A0471|50 64|Phthalocyanine
P01642060A0471|84 92|patients
P01642060A0471|128 137|carcinoma
P01642060A0471|139 147|FIGO III
P01643943A0300|14 33|lung cancer tissues
P01643943A0300|46 50|67Ga
P01643943A0300|66 69|TFR
P01644751A0590|10 23|reading frame
P01644751A0590|79 96|sequence analysis
P01644751A0590|117 134|msgB gene product
P01644796A0374|8 13|study
P01644796A0374|61 66|furin
P01644796A0374|88 94|medium
P01644796A0374|104 109|cells
P01644814A0068|4 9|virus
P01644814A0068|27 34|protein
P01644814A0068|36 39|tax
P01644814A0068|67 82|immortalization
P01644814A0068|86 93|T cells
P01644821A1259|9 17|butyrate
P01644821A1259|68 80|CAT activity
P01644821A1259|84 96|fusion genes
P01644821A1259|117 126|sequences
P01644821A1259|173 182|sequences
P01644821A1259|214 221|regions
P01644821A1259|229 240|PSG1-I gene
P01644821A1259|258 275|butyrate response
P01644831A0824|3 14|examination
P01644831A0824|22 26|role
P01644831A0824|34 51|carboxyl terminus
P01644831A0824|66 72|NGFI-B
P01644831A0824|89 97|activity
P01644831A0824|116 126|accordance
P01644831A0824|146 155|receptors
P01644831A0824|157 164|mutants
P01644831A0824|173 181|portions
P01644831A0824|189 206|carboxyl terminus
P01644831A0824|229 237|activity
P01645902A1462|17 24|results
P01645902A1462|43 46|Syn
P01645902A1462|49 54|locus
P01645902A1462|75 79|gene
P01645902A1462|91 93|gH
P01645902A1462|100 106|region
P01645902A1462|120 128|portions
P01645902A1462|136 138|TK
P01645902A1462|143 145|UL
P01645902A1462|149 154|genes
P01645902A1462|169 181|syn mutation
P01645902A1462|202 212|expression
P01645902A1462|216 224|activity
P01645902A1462|228 230|TK
P01645905A0341|0 13|Nucleoprotein
P01645905A0341|15 16|N
P01645905A0341|48 62|vaccinia virus
P01645905A0341|67 71|TGEV
P01645905A0341|97 101|mass
P01645905A0341|103 105|Mr
P01645905A0341|140 151|degradation
P01645905A0341|159 169|C-terminus
P01645905A0341|188 206|breakdown products
P01646157A0414|33 59|alpha-GalNAc cDNA sequence
P01646157A0414|102 112|nucleotide
P01646157A0414|127 146|amino acid homology
P01646157A0414|161 162|%
P01646157A0414|193 214|alpha-galactosidase A
P01646157A0414|216 227|alpha-Gal A
P01646157A0414|229 233|cDNA
P01646487A0874|0 8|Patients
P01646487A0874|27 35|activity
P01646487A0874|42 43|X
P01646487A0874|60 68|decrease
P01646487A0874|76 83|content
P01646487A0874|87 90|IgA
P01646487A0874|92 95|IgG
P01646487A0874|97 100|IgM
P01646487A0874|102 103|T
P01646487A0874|108 121|B lymphocytes
P01646487A0874|141 149|activity
P01646487A0874|153 164|neutrophils
P01646487A0874|180 188|patients
P01646487A0874|217 225|activity
P01646753A0336|4 10|reason
P01646753A0336|24 29|oxide
P01646753A0336|47 64|hydroxyl radicals
P01646753A0336|104 122|reduction proceeds
P01646753A0336|134 137|N2O
P01646753A0336|194 196|EO
P01646753A0336|198 205|N2O/N2O
P01646753A0336|215 217|V.
P01647070A0232|11 25|JCV T antigens
P01647070A0232|35 38|JCV
P01647070A0232|43 55|SV40 origins
P01647070A0232|59 74|DNA replication
P01647656A0000|4 12|relation
P01647656A0000|48 56|receptor
P01647656A0000|79 81|LV
P01647656A0000|83 91|function
P01647656A0000|110 118|patients
P01647656A0000|134 139|years
P01647656A0000|159 177|LV volume overload
P01647656A0000|207 220|regurgitation
P01647813A0512|11 21|transcript
P01647813A0512|49 56|protein
P01647813A0512|63 73|complexity
P01647813A0512|90 94|need
P01647813A0512|145 152|control
P01647813A0512|156 166|expression
P01648142A1170|3 11|patients
P01648142A1170|25 32|disease
P01648142A1170|38 46|survival
P01648142A1170|66 69|arm
P01648142A1170|104 112|survival
P01648142A1170|120 127|CAV arm
P01648142A1170|129 130|P
P01648142A1170|146 154|survival
P01648142A1170|162 168|PE arm
P01648142A1170|170 171|P
P01648530A0000|17 25|M region
P01648530A0000|50 57|Xenopus
P01648530A0000|66 85|actin gene promoter
P01648530A0000|135 145|expression
P01648530A0000|159 190|actin-beta-globin reporter gene
P01648530A0000|216 220|eggs
P01649173A0160|3 11|addition
P01649173A0160|59 69|attenuator
P01649173A0160|84 95|nucleotides
P01649173A0160|127 151|transcription start site
P01649173A0160|162 172|attenuator
P01649173A0160|174 184|attenuator
P01649173A0160|200 211|nucleotides
P01649318A0734|0 6|EBNA-2
P01649318A0734|26 38|CD23 element
P01649318A0734|61 65|mRNA
P01649318A0734|88 145|herpes simplex virus TK promoter transcription start site
P01649318A1222|6 17|experiments
P01649318A1222|56 73|cell DNA fragment
P01649318A1222|91 99|evidence
P01649318A1222|105 111|EBNA-2
P01649318A1222|127 140|transcription
P01649318A1222|144 154|cell genes
P01649539T0000|0 16|Plasma vitamin E
P01649539T0000|24 30|lipids
P01649539T0000|35 57|myeloperoxidase levels
P01649539T0000|72 79|surgery
P01649835A0822|31 43|PBR/IBP cDNA
P01649835A0822|49 60|COS-7 cells
P01649835A0822|84 92|increase
P01649835A0822|100 107|density
P01649835A0822|116 124|affinity
P01649835A0822|126 128|3H
P01649835A0822|129 131|PK
P01649835A0822|138 151|binding sites
P01649835A0822|171 179|affinity
P01649835A0822|184 192|Ro5-4864
P01650524A0837|12 17|phase
P01650524A0837|40 52|permeability
P01650524A0837|71 77|cavity
P01650524A0837|82 97|LTB4 production
P01650524A0837|102 106|dose
P01650524A0837|136 161|5-LO inhibitors phenidone
P01650524A0837|163 169|BW A4C
P01650524A0837|171 177|A63162
P01650524A0837|183 186|ICI
P01650524A0837|206 219|dexamethasone
P01650524A0837|223 233|colchicine
P01650557T0000|11 18|results
P01650557T0000|26 50|latex agglutination test
P01650557T0000|58 68|assessment
P01650557T0000|72 103|cytomegalovirus antibody status
P01650557T0000|115 132|transplant donors
P01651232A0152|5 9|mRNA
P01651232A0152|41 57|uridine residues
P01651232A0152|90 97|mixture
P01651232A0152|101 104|UTP
P01651232A0152|109 117|thio-UTP
P01651918A0000|47 61|cDNA fragments
P01651918A0000|94 113|amino acid sequence
P01651918A0000|117 148|rat testis fructose-6-phosphate
P01651918A0000|151 157|kinase
P01651918A0000|158 168|fructose-2
P01651918A0000|171 185|bisphosphatase
P01652372A0153|19 23|SWI5
P01652372A0153|34 53|localization signal
P01652372A0153|55 58|NLS
P01652372A0153|88 92|cell
P01652372A0153|117 122|entry
P01652372A0153|141 148|protein
P01652515A0379|3 11|contrast
P01652515A0379|26 35|deviation
P01652515A0379|41 63|avoidance conditioning
P01652515A0379|75 86|haloperidol
P01652515A0379|101 116|microinjections
P01652515A0379|136 138|DA
P01652515A0379|148 153|level
P01652515A0379|165 176|neostriatum
P01652755A1492|21 45|transfection experiments
P01652755A1492|49 59|HeLa cells
P01652755A1492|61 75|overexpression
P01652755A1492|92 134|retinoblastoma susceptibility gene product
P01652755A1492|136 138|RB
P01652755A1492|179 183|IL-6
P01652755A1492|199 204|c-fos
P01652755A1492|224 234|beta-actin
P01652755A1492|251 260|promoters
P01652755A1492|285 289|IL-6
P01652755A1492|325 328|MHC
P01652755A1492|343 352|promoters
P01653173A0619|5 15|repression
P01653173A0619|37 44|binding
P01653173A0619|52 54|E2
P01653173A0619|67 71|site
P01653173A0619|100 122|P105 promoter TATA box
P01653173A0619|149 162|preincubation
P01653173A0619|170 199|HPV-18 P105 promoter template
P01653173A0619|217 224|extract
P01653173A0619|238 247|formation
P01653173A0619|255 276|preinitiation complex
P01653236A0895|18 21|p50
P01653236A0895|25 36|association
P01653236A0895|49 72|glucocorticoid receptor
P01653236A0895|76 83|L cells
P01653236A0895|110 133|glucocorticoid receptor
P01653236A0895|145 164|hamster ovary cells
P01653238A1062|13 50|12-O-tetradecanoyl-phorbol-13-acetate
P01653238A1062|52 55|TPA
P01653238A1062|57 74|response elements
P01653238A1062|104 109|sites
P01653238A1062|118 143|transcription factor AP-1
P01653238A1062|150 168|consensus sequence
P01653238A1062|187 205|growth factor beta
P01653238A1062|209 217|TGF-beta
P01653238A1062|232 239|element
P01653238A1062|258 273|promoter region
P01653238A1715|0 3|TPA
P01653238A1715|8 16|TGF-beta
P01653238A1715|47 57|activities
P01653238A1715|72 78|enzyme
P01653918A0286|38 46|pressure
P01653918A0286|66 72|cornea
P01653918A0286|84 91|corneas
P01653918A0286|97 105|strength
P01653918A0286|127 149|corneal pain threshold
P01654349A0327|0 11|Feed intake
P01654349A0327|40 43|KCl
P01654349A0327|47 69|NaHCO3 supplementation
P01654349A0327|89 93|gain
P01654349A0327|119 120|K
P01654349A0327|157 163|NaHCO3
P01655126T0000|0 20|Extraction procedure
P01655126T0000|29 40|measurement
P01655126T0000|44 62|butyltin compounds
P01655126T0000|77 84|tissues
P01655126T0000|91 98|toluene
P01655126T0000|100 103|HBr
P01655126T0000|109 118|tropolone
P01655713A0294|8 13|study
P01655713A0294|32 38|region
P01655713A0294|82 91|phenotype
P01655713A0294|95 101|strain
P01655713A0294|106 110|exs1
P01655713A0294|112 115|Tn1
P01655713A0294|131 134|Tn1
P01655713A0294|147 155|mutation
P01656220T0000|0 3|axl
P01656220T0000|20 24|gene
P01656220T0000|61 75|leukemia cells
P01656220T0000|93 117|receptor tyrosine kinase
P01656221A1319|0 9|Alignment
P01656221A1319|17 37|amino acid sequences
P01656221A1319|50 57|Tyr-766
P01656221A1319|77 84|regions
P01656221A1319|94 99|FGFRs
P01656221A1319|119 136|tyrosine residues
P01656221A1319|150 157|members
P01656221A1319|165 176|FGFR family
P01656235A0946|26 33|element
P01656235A0946|54 62|analysis
P01656235A0946|75 81|region
P01656235A0946|98 109|CCAAT motif
P01656675A0236|0 18|Capnography curves
P01656675A0236|25 37|HVS patients
P01656675A0236|50 58|patients
P01656675A0236|79 89|complaints
P01656675A0236|105 113|controls
P01657246A0325|4 33|transcription initiation site
P01657246A0325|61 63|bp
P01657246A0325|91 94|Met
P01657249A1019|22 24|CA
P01657249A1019|47 50|VH4
P01657249A1019|57 63|chains
P01657249A1019|78 80|CA
P01657249A1019|114 117|VH4
P01657249A1019|139 157|region determinant
P01657249A1019|166 174|VH4-HV2a
P01657415A0837|0 16|Intron K1 cox1.2
P01657415A0837|72 80|location
P01657415A0837|84 93|K. lactis
P01657594A0472|28 35|mutants
P01657594A0472|47 69|complementation groups
P01657594A0472|82 86|cgs1
P01657594A0472|92 96|cgs2
P01657969A1420|9 20|alterations
P01657969A1420|54 66|interactions
P01657969A1420|88 112|amino acid substitutions
P01657969A1420|140 146|change
P01657969A1420|154 160|enzyme
P01657969A1420|181 199|calmodulin binding
P01658356A1369|4 11|results
P01658356A1369|23 35|coexpression
P01658356A1369|65 75|generation
P01658356A1369|79 96|FeLV recombinants
P01658356A1369|102 108|FeLV-C
P01658356A1369|139 154|3201B cell line
P01658356A1369|190 196|levels
P01658356A1369|225 230|mRNAs
P01658356T0000|0 13|Recombination
P01658356T0000|29 54|leukemia virus subgroup B
P01658356T0000|58 59|C
P01658356T0000|75 87|env elements
P01658356T0000|119 129|activities
P01658356T0000|137 144|viruses
P01658375A0854|4 24|nucleotide sequences
P01658375A0854|42 46|ends
P01658375A0854|56 63|introns
P01658375A0854|94 105|transcripts
P01658375A0854|139 144|genes
P01658375A0854|167 177|difference
P01658375A0854|192 195|end
P01658375A0854|203 213|LAT intron
P01658375A0854|217 219|GC
P01658375A0854|235 256|consensus sequence GT
P01658468A0123|15 21|months
P01658468A0123|36 45|isolation
P01658468A0123|49 61|C. kutscheri
P01658468A0123|76 82|cavity
P01658468A0123|84 92|hamsters
P01658468A0123|116 124|attempts
P01658468A0123|138 145|culture
P01658468A0123|178 183|sites
P01658741A1047|4 12|strategy
P01658741A1047|44 53|kilobases
P01658741A1047|57 76|nucleotide sequence
P01658741A1047|109 112|ADE
P01658741A1047|115 120|locus
P01659685T0000|16 25|promoters
P01659685T0000|53 60|regions
P01659685T0000|70 87|Dd ras expression
P01659685T0000|91 104|Dictyostelium
P01660486A1756|4 11|results
P01660486A1756|47 56|cell type
P01660486A1756|58 73|gene cotransfer
P01660486A1756|80 105|aminoglycoside resistance
P01660486A1756|122 128|marker
P01660486A1756|170 188|control mechanisms
P01660486A1756|201 212|PKC pathway
P01660486A1756|224 234|activation
P01660486A1756|238 253|gene expression
P01660925T0000|0 18|Transfer RNA genes
P01660925T0000|24 48|Dictyostelium discoideum
P01660925T0000|91 99|elements
P01660925T0000|112 127|consensus boxes
P01660925T0000|156 163|regions
P01661369A0825|15 19|strD
P01661369A0825|24 34|strE genes
P01661369A0825|60 66|probes
P01661369A0825|85 93|presence
P01661369A0825|110 118|capacity
P01661369A0825|137 145|moieties
P01662609A0398|8 13|genes
P01662609A0398|23 35|polypeptides
P01662609A0398|43 54|amino acids
P01662609A0398|56 63|M.HgiCI
P01662609A0398|73 84|amino acids
P01662609A0398|86 93|R.HgiCI
P01662794A0640|0 10|Expression
P01662794A0640|18 26|wt1 gene
P01662794A0640|41 53|transfection
P01662794A0640|57 68|COS-1 cells
P01662794A0640|83 94|kDa protein
P01662794A0640|172 180|antisera
P01662807A1182|4 10|factor
P01662807A1182|30 41|TR promoter
P01662807A1182|61 77|SV40 chromosomes
P01662807A1182|96 105|infection
P01662884A1029|0 12|Temafloxacin
P01662884A1029|17 26|mg b.i.d.
P01662884A1029|54 58|days
P01662884A1029|91 100|treatment
P01662884A1029|123 134|prostatitis
P01664192A1577|18 25|effects
P01664192A1577|50 59|ED90 dose
P01664192A1577|63 73|vecuronium
P01669611A0142|4 11|patient
P01669611A0142|29 34|fever
P01669611A0142|56 64|aneurysm
P01669611A0142|72 77|aorta
P01669611A0142|86 101|pleuropneumonia
P01669611A0142|118 126|diseases
P01671675A0483|14 25|clone pKB11
P01671675A0483|49 53|pair
P01671675A0483|55 57|bp
P01671675A0483|59 70|cDNA insert
P01671675A0483|84 91|pCAD142
P01671675A0483|99 101|bp
P01671675A0483|121 142|hybridization methods
P01671675A0483|147 164|sequence analysis
P01671675A0483|197 210|cDNA sequence
P01671675A0483|219 228|amino end
P01671675A0483|236 251|CAD polypeptide
P01671675A0905|5 15|conclusion
P01671675A0905|33 59|Northern blotting analysis
P01671675A0905|79 85|region
P01671675A0905|89 97|CAD gene
P01673220A0578|14 23|isolation
P01673220A0578|39 50|cDNA clones
P01673220A0578|76 78|Sn
P01673220A0578|80 91|bol3 allele
P01674177T0001|0 20|Histamine-2 blockade
P01674177T0001|24 33|psoriasis
P01674242A0358|4 13|clearance
P01674242A0358|68 69|%
P01674242A0358|97 109|erythromycin
P01674242A0358|111 125|troleandomycin
P01674242A0358|127 148|triacetyloleandomycin
P01674242A0358|151 164|roxithromycin
P01674242A0358|166 174|enoxacin
P01674242A0358|176 189|ciprofloxacin
P01674242A0358|191 201|pefloxacin
P01674242A0358|203 214|norfloxacin
P01674242A0358|216 225|ofloxacin
P01674242A0358|243 249|T-3262
P01674242A0358|261 265|acid
P01674242A0358|267 277|cimetidine
P01674242A0358|279 289|etintidine
P01674242A0358|291 302|propranolol
P01674242A0358|304 313|verapamil
P01674242A0358|315 324|diltiazem
P01674242A0358|326 336|nifedipine
P01674242A0358|338 348|furosemide
P01674242A0358|350 359|frusemide
P01674242A0358|386 392|agents
P01674242A0358|394 404|viloxazine
P01674242A0358|406 417|allopurinol
P01674242A0358|419 430|ticlopidine
P01674242A0358|432 444|idrocilamide
P01674242A0358|446 459|thiabendazole
P01674242A0358|461 471|disulfiram
P01674242A0358|473 482|influenza
P01674242A0358|488 503|BCG-vaccination
P01674242A0358|505 515|interferon
P01674242A0358|521 529|caffeine
P01674242A0358|531 549|half-life increase
P01674369A0417|21 28|element
P01674369A0417|64 80|restriction site
P01674369A0417|90 97|cloning
P01674662A0000|38 52|heroin addicts
P01674662A0000|73 80|disease
P01674662A0000|82 83|n
P01674662A0000|121 136|lymphadenopathy
P01674662A0000|138 139|n
P01674662A0000|164 169|study
P01674662A0000|191 202|progression
P01674662A0000|206 210|AIDS
P01674662A0000|219 226|complex
P01674662A0000|228 231|ARC
P01674662A0000|236 240|AIDS
P01674662A0000|257 264|factors
P01674662A0000|288 297|relevance
P01674817A0862|3 11|homology
P01674817A0862|30 35|RNA14
P01674817A0862|40 45|RNA15
P01674817A0862|57 62|RNA14
P01674817A0862|73 81|proteins
P01674817A0862|95 105|data banks
P01674817T0000|0 9|Mutations
P01674817T0000|17 28|yeast RNA14
P01674817T0000|33 44|RNA15 genes
P01674817T0000|67 82|mRNA decay rate
P01674817T0000|84 101|sequence analysis
P01674817T0000|125 131|domain
P01674817T0000|139 152|RNA15 protein
P01675154T0000|11 21|infarction
P01675154T0000|25 33|patients
P01675154T0000|48 62|bypass surgery
P01675424A0991|18 28|difference
P01675424A0991|42 45|NAD
P01675424A0991|46 47|P
P01675424A0991|48 61|H-NR sequence
P01675424A0991|65 75|comparison
P01675424A0991|79 96|NADH-NR sequences
P01675424A0991|123 142|pyridine nucleotide
P01675424A0991|151 155|site
P01675637T0033|9 30|amino acid difference
P01675637T0033|49 55|region
P01675637T0033|85 93|activity
P01675637T0033|98 122|receptor dimer formation
P01675763A1389|8 16|benefits
P01675763A1389|31 39|children
P01675763A1389|45 48|CD4
P01675763A1389|79 84|liter
P01675763A1389|88 93|entry
P01678287A1308|18 44|Antp TATAA binding protein
P01678287A1308|92 97|cells
P01678287A1308|120 133|homeobox gene
P01678287A1308|188 196|function
P01678287A1308|218 223|cells
P01678392A0648|6 25|% confidence values
P01678392A0648|27 30|2SD
P01678392A0648|40 46|change
P01678392A0648|50 53|Ros
P01678392A0648|82 93|variability
P01678392A0648|119 130|cmH2O l-1 s
P01679068A0000|10 17|infants
P01679068A0000|33 43|care units
P01679068A0000|55 56|%
P01679068A0000|65 70|value
P01679068A0000|72 77|range
P01679068A0000|155 162|strains
P01679068A0000|184 194|Klebsiella
P01679068A0000|198 214|Enterobacter spp
P01679124A1368|12 19|studies
P01679124A1368|42 46|loss
P01679124A1368|50 63|ChAT activity
P01679124A1368|71 77|dorsal
P01679124A1368|90 100|hippocampi
P01679124A1368|113 120|animals
P01679124A1368|141 147|levels
P01679124A1368|151 165|norepinephrine
P01679124A1368|167 169|NE
P01679124A1368|178 196|dorsal hippocampus
P01679124A1368|200 214|MS/HSI animals
P01679124A1368|216 224|ABSTRACT
P01679124A1368|242 247|WORDS
P01679749A1171|4 16|localization
P01679749A1171|25 43|proteoglycan locus
P01679749A1171|57 63|genome
P01679749A1171|72 84|availability
P01679749A1171|92 97|RFLPs
P01679749A1171|110 115|tools
P01679749A1171|127 134|studies
P01679749A1171|144 152|diseases
P01679749A1171|163 186|HSPG2 proteoglycan gene
P01681075A0429|8 11|min
P01681075A0429|15 35|dobutamine injection
P01681075A0429|49 52|min
P01681075A0429|56 76|pimobendan injection
P01681075A0429|82 92|myocardium
P01681075A0429|119 132|determination
P01681075A0429|140 153|tissue levels
P01681075A0429|157 168|metabolites
P01681075A0429|172 178|energy
P01681075A0429|183 206|carbohydrate metabolism
P01682484A0680|16 24|stenosis
P01682484A0680|33 41|contrary
P01682484A0680|57 67|procaterol
P01682484A0680|80 84|dose
P01682484A0680|132 143|dysfunction
P01682484A0680|161 169|LCX flow
P01682484A0680|178 190|hemodynamics
P01682484A0680|203 221|lactate metabolism
P01682509A0539|16 24|evidence
P01682509A0539|39 52|proteins IE86
P01682509A0539|54 58|IE72
P01682509A0539|64 68|IE55
P01682509A0539|105 112|HIV LTR
P01682509A0539|118 129|T-cell line
P01682509A0539|131 137|HUT-78
P01682542A0690|5 12|country
P01682542A0690|27 41|HIV prevalence
P01682542A0690|54 62|strategy
P01682542A0690|85 93|location
P01682542A0690|98 109|counselling
P01682542A0690|138 149|individuals
P01684791A0000|15 22|element
P01684791A0000|33 60|glucocorticoid inducibility
P01684791A0000|68 101|chicken glutamine synthetase gene
P01686909A0299|13 21|increase
P01686909A0299|33 42|excretion
P01686909A0299|78 89|elimination
P01686909A0299|93 102|bretylium
P01686909A0299|122 126|acid
P01686909A0299|135 141|kidney
P01687050T0000|11 16|value
P01687050T0000|34 56|fluid immunoglobulin G
P01687050T0000|58 61|IgG
P01687050T0000|89 97|diseases
P01688841A0430|0 10|Expression
P01688841A0430|18 23|genes
P01688841A0430|25 29|ipaB
P01688841A0430|31 35|ipaC
P01688841A0430|37 41|invE
P01688841A0430|43 47|invG
P01688841A0430|49 53|invJ
P01688841A0430|59 63|invK
P01688841A0430|106 120|regulator virF
P01688972A0803|10 12|VT
P01688972A0803|44 51|patient
P01690703A0285|0 10|Venkatesan
P01690703A0285|16 18|D.
P01690728A1166|4 12|presence
P01690728A1166|41 57|mRNA transcripts
P01690728A1166|67 81|kilobase pairs
P01690728A1166|83 85|kb
P01690728A1166|96 107|fibroblasts
P01690728A1166|121 148|Northern blot hybridization
P01690728A1166|150 178|S1 nuclease protection assay
P01690728A1166|188 213|polymerase chain reaction
P01690812A0000|16 17|%
P01690812A0000|35 38|DNA
P01690812A0000|40 44|rDNA
P01690812A0000|46 51|units
P01690812A0000|115 120|S RNA
P01690812A0000|131 146|gene insertions
P01690812A0000|148 152|type
P01690812A0000|159 163|type
P01691184A0995|0 6|Gap b3
P01691184A0995|23 41|polypeptide chains
P01691184A0995|43 45|Mr
P01691184A0995|98 115|cleavage products
P01691184A0995|129 144|disulfide bonds
P01691184A0995|152 169|precursor protein
P01692135A0783|13 42|rtFc gamma R alpha cDNA clone
P01692135A0783|92 97|mRNAs
P01692135A0783|111 124|CRNK-16 cells
P01692135A0783|149 157|Fc gamma
P01692135A0783|168 180|mRNA species
P01692135A0783|204 209|mouse
P01692135A0783|218 230|killer cells
P01692837A0390|5 10|genes
P01692837A0390|26 31|exons
P01692837A0390|37 44|introns
P01692837A0390|83 89|region
P01692837A0390|95 109|kilobase pairs
P01692837A0390|127 131|mRNA
P01692837A0390|153 162|kilobases
P01692962A0980|7 17|expression
P01692962A0980|34 39|alpha
P01692962A0980|46 59|s polypeptide
P01692962A0980|71 84|hamster ovary
P01692962A0980|86 89|CHO
P01692962A0980|91 96|cells
P01692962A0980|127 141|cAMP synthesis
P01692962A0980|161 184|protein kinase activity
P01694009A0112|5 9|exon
P01694009A0112|22 26|exon
P01694009A0112|67 73|region
P01694009A0112|93 108|signal sequence
P01694009A0112|116 127|polypeptide
P01694014A0716|0 9|Treatment
P01694014A0716|27 43|cell lines HL-60
P01694014A0716|48 52|U937
P01694014A0716|58 89|phorbol 12-myristate 13-acetate
P01694014A0716|91 94|PMA
P01694014A0716|115 116|h
P01694014A0716|126 132|levels
P01694014A0716|140 156|RNA hybridizable
P01694014A0716|160 169|LD78 cDNA
P01694280A0000|27 42|ventriculoscope
P01694280A0000|47 58|observation
P01694280A0000|66 76|ventricles
P01694280A0000|87 95|cisterns
P01694525A0000|0 25|Isopenicillin N isomerase
P01694525A0000|27 36|epimerase
P01694525A0000|96 115|amino acid sequence
P01694525A0000|123 133|N-terminus
P01695098A1116|0 9|Serum IgG
P01695098A1116|38 46|patients
P01695116A0078|4 11|patient
P01695116A0078|40 49|remission
P01695116A0078|51 54|CR1
P01695116A0078|74 86|chemotherapy
P01695116A0078|108 114|months
P01695314A0762|11 16|mg/dl
P01695314A0762|18 20|NS
P01695314A0762|23 37|glucose levels
P01695314T0000|0 20|Platelet aggregation
P01695314T0000|35 42|control
P01695314T0000|63 91|calcium antagonist treatment
P01695314T0000|95 99|type
P01695314T0000|103 120|diabetes mellitus
P01695322A0000|0 5|Wnt-1
P01695322A0000|7 12|int-1
P01695322A0000|28 36|oncogene
P01695322A0000|56 65|insertion
P01695322A0000|78 81|DNA
P01695322A0000|89 94|mouse
P01695322A0000|103 114|tumor virus
P01695378A1406|0 9|Induction
P01695378A1406|13 19|Jurkat
P01695378A1406|29 36|T cells
P01695378A1406|42 73|phorbol 12-myristate 13-acetate
P01695378A1406|78 87|ionomycin
P01695378A1406|107 112|level
P01695378A1406|116 125|FKBP mRNA
P01695905A0480|0 10|GLUT5 mRNA
P01695905A0480|35 41|levels
P01695905A0480|51 60|intestine
P01695905A0480|79 85|levels
P01695905A0480|89 95|kidney
P01695905A0480|106 112|muscle
P01695905A0480|118 132|adipose tissue
P01697611A0738|24 30|tumors
P01697611A0738|70 77|growths
P01697683T0000|0 14|Identification
P01697683T0000|19 35|characterization
P01697683T0000|43 51|promoter
P01697683T0000|60 75|cytotactin gene
P01697928A1214|26 43|sequence homology
P01697928A1214|57 63|region
P01697928A1214|67 72|Ly-6E
P01697928A1214|93 102|consensus
P01697928A1214|133 149|response element
P01697928A1214|227 237|alpha/beta
P01697928A1214|259 268|promoters
P01698761A1059|17 35|DNA rearrangements
P01698761A1059|49 55|region
P01698761A1059|75 82|repeats
P01698761A1059|113 120|histone
P01698761A1059|129 138|structure
P01698761A1059|142 146|AlgP
P01698761A1059|172 179|strains
P01698761A1059|185 195|conversion
P01698761A1059|205 211|mucoid
P01698761A1059|229 238|phenotype
P01698772A0238|7 9|J.
P01699944A1538|6 13|results
P01699944A1538|69 94|CArG box binding proteins
P01699944A1538|136 152|promoter element
P01699944A1538|160 164|VLC1
P01699944A1538|174 185|alpha-actin
P01699944A1538|191 202|c-fos genes
P01700272A0838|0 15|Polyadenylation
P01700272A0838|19 25|B4 RNA
P01700272A0838|58 68|maturation
P01700272A0838|88 96|residues
P01700272A0838|113 119|number
P01700272A0838|151 162|recruitment
P01701088A1335|0 12|Co-existence
P01701088A1335|33 41|elements
P01701088A1335|53 61|elements
P01701088A1335|75 87|AP-2 element
P01701088A1335|91 100|CCAAT box
P01702361A0621|10 17|studies
P01702361A0621|21 27|agents
P01702361A0621|41 59|collagen synthesis
P01702361A0621|64 74|deposition
P01702361A0621|100 123|angiogenesis inhibitors
P01702426A0196|22 28|region
P01702426A0196|37 41|gene
P01702426A0196|73 83|regulation
P01702426A0196|91 101|expression
P01702426A0196|163 181|acid synthase gene
P01702426A1006|6 9|set
P01702426A1006|13 24|cDNA clones
P01702426A1006|52 54|kb
P01702426A1006|75 110|lambda-ZAP goose liver cDNA library
P01702426A1006|145 153|fragment
P01702426A1006|177 186|DNA clone
P01702432A1296|0 26|Northern blotting analysis
P01702432A1296|42 52|expression
P01702432A1296|60 65|genes
P01702432A1296|89 95|clones
P01702432A1296|111 124|pollen tissue
P01702972A0613|8 26|cDNA hybridization
P01702972A0613|38 47|DNA blots
P01702972A0613|66 75|subfamily
P01702972A0613|79 90|G0S19 genes
P01702972A0613|99 107|patterns
P01702972A0613|111 116|bands
P01702972A0613|137 142|cDNAs
P01702972A0613|154 164|G0S30 cDNA
P01702972A0613|194 199|genes
P01703335T0000|20 29|disorders
P01703335T0000|44 61|immunosuppression
P01703335T0000|67 69|FK
P01703335T0000|83 95|observations
P01703335T0000|107 128|transplant population
P01703632T0000|15 25|suppressor
P01703632T0000|35 39|gene
P01703632T0000|50 61|polypeptide
P01703632T0000|67 74|regions
P01703632T0000|107 115|proteins
P01707659A0458|64 68|gene
P01707659A0458|70 77|HLA-5.4
P01707659A0458|90 105|chimpanzee gene
P01707659A0458|107 111|Ch28
P01707800A0354|13 39|N13-N20 interpeak interval
P01707800A0354|71 85|parallel shift
P01707800A0354|95 100|peaks
P01707800A0354|114 129|conduction time
P01707800A0354|144 159|onset latencies
P01707800A0354|163 166|N11
P01707800A0354|171 174|N20
P01708098A0922|20 46|complex DNA binding assays
P01708098A0922|50 56|series
P01708098A0922|72 100|alpha promoter DNA sequences
P01708098A0922|120 129|basepairs
P01708098A0922|167 169|GR
P01708098A0922|181 192|control GRE
P01708098A0922|206 214|receptor
P01708771A1215|0 22|Sequence determination
P01708771A1215|35 43|peptides
P01708771A1215|59 65|Asn120
P01708771A1215|83 88|Asn65
P01708771A1215|93 99|Asn109
P01708771A1215|121 130|molecules
P01708771A1215|142 148|others
P01708771A1215|154 159|Asn72
P01708774A0203|4 16|DNA sequence
P01708774A0203|28 41|AP-1 activity
P01708774A0203|70 85|promoter region
P01709486A0000|11 19|mutation
P01709486A0000|45 46|W
P01709486A0000|58 72|proto-oncogene
P01709486A0000|74 79|c-kit
P01709933T0000|0 9|Isolation
P01709933T0000|14 30|characterization
P01709933T0000|38 41|rat
P01709933T0000|54 58|gene
P01709933T0000|65 76|polypeptide
P01709933T0000|78 81|pS1
P01709933T0000|108 114|statin
P01710766A0349|4 12|proteins
P01710766A0349|27 35|presence
P01710766A0349|39 46|absence
P01710766A0349|66 74|sequence
P01710766A0349|86 108|amino acids C terminal
P01710766A0349|130 146|initiation codon
P01710768A1172|4 11|results
P01710768A1172|30 39|existence
P01710768A1172|43 52|sequences
P01710768A1172|73 75|kb
P01710768A1172|100 107|pattern
P01710768A1172|127 137|expression
P01710768A1172|145 156|HLA-B7 gene
P01710768A1172|165 172|ability
P01710768A1172|181 185|gene
P01710768A1172|200 216|gamma interferon
P01710979T0000|4 7|SH2
P01710979T0000|12 23|SH3 domains
P01710979T0000|27 34|pp60src
P01710979T0000|49 60|association
P01710979T0000|66 74|tyrosine
P01710979T0000|90 103|proteins p130
P01710979T0000|108 112|p110
P01710985A0315|0 4|Chem
P01711041A0348|6 12|clones
P01711041A0348|53 57|gene
P01711041A0348|80 94|C5 alpha-chain
P01711041A0348|101 102|%
P01711041A0348|110 120|beta-chain
P01711041A0962|4 18|C5 alpha-chain
P01711041A0962|37 46|kilobases
P01711041A0962|61 66|exons
P01711041A0962|72 82|beta-chain
P01711041A0962|101 110|kilobases
P01711041A0962|125 130|exons
P01711048T0000|13 21|mutation
P01711048T0000|29 30|G
P01711048T0000|33 41|position
P01711048T0000|45 51|intron
P01711048T0000|62 71|pro-alpha
P01711048T0000|77 81|gene
P01711048T0000|83 89|COL1A2
P01711048T0000|112 124|RNA splicing
P01711048T0000|136 159|osteogenesis imperfecta
P01712296A0157|4 24|nucleotide sequences
P01712296A0157|34 39|genes
P01712296A0157|60 69|positions
P01712296A0157|90 112|amino acid differences
P01713213A0000|4 11|protein
P01713213A0000|29 37|sequence
P01713213A0000|51 78|pim-1 proto-oncogene shares
P01713213A0000|89 97|homology
P01713213A0000|109 141|serine/threonine protein kinases
P01713213A0000|161 173|Pim-1 enzyme
P01713213A0000|214 246|protein tyrosine kinase activity
P01713213A0488|20 30|pim-1 cDNA
P01713213A0488|64 78|vector pGEX-2T
P01713213A0488|87 100|Pim-1 protein
P01713213A0488|116 130|fusion product
P01713213A0488|146 171|glutathione S-transferase
P01713213A0488|173 176|GST
P01714322A0969|5 11|report
P01714322A0969|54 62|kDa hsps
P01714322A0969|66 71|maize
P01714322A0969|76 84|products
P01714322A0969|110 115|genes
P01714358A0990|7 22|kDa polypeptide
P01714358A0990|65 90|wheat etioplast membranes
P01714358A0990|97 106|gamma 32P
P01714358A0990|108 111|ATP
P01714452A0559|0 8|Homology
P01714452A0559|24 31|protein
P01714452A0559|42 43|%
P01714452A0559|58 71|repeat domain
P01714452A0559|88 100|conservation
P01714452A0559|104 111|serines
P01714452A0559|116 126|threonines
P01714452A0559|137 142|sites
P01714452A0559|155 178|carbohydrate attachment
P01714902A0221|3 11|addition
P01714902A0221|45 96|Ti alpha-beta CD3 gamma delta epsilon TCR complexes
P01714902A0221|104 116|cell surface
P01714902A0221|118 126|CD3 zeta
P01714902A0221|155 179|interleukin-2 production
P01714902A0221|186 201|TCR stimulation
P01714902A0221|221 247|histocompatibility complex
P01715593A0838|5 16|desipramine
P01715593A0838|33 36|hrs
P01715593A0838|43 63|fluoxetine injection
P01715593A0838|65 77|brain levels
P01715593A0838|81 92|desipramine
P01715975A0885|9 16|effects
P01715975A0885|20 24|CYP1
P01715975A0885|66 71|cells
P01716292A0000|12 20|analysis
P01716292A0000|32 39|regions
P01716292A0000|43 50|HLA-DR1
P01716292A0000|64 86|T cell allorecognition
P01716292A0000|112 118|series
P01716292A0000|134 144|cell lines
P01716292A0000|160 168|products
P01716292A0000|184 189|DRB/H
P01716292A0000|191 199|Eb genes
P01716292A0000|220 228|DR alpha
P01716292A0000|232 242|H-2E alpha
P01716629A0000|17 28|cDNA clones
P01716629A0000|60 87|matrix glycoprotein undulin
P01717718A1255|14 29|point mutations
P01717718A1255|37 54|Gag-Pol PR domain
P01717718A1255|65 75|activation
P01717718A1255|79 81|RT
P01717718A1255|106 108|PR
P01717718A1255|138 150|conformation
P01717718A1255|158 167|PR domain
P01717718A1255|171 178|Gag-Pol
P01717718A1255|182 194|prerequisite
P01717718A1255|199 209|activation
P01717718A1255|213 215|RT
P01717833A1223|4 26|alpha inhibin promoter
P01717833A1223|48 51|CRE
P01717833A1223|73 82|forskolin
P01717833A1223|86 101|granulosa cells
P01717833A1223|123 135|CREB protein
P01717833T0000|0 10|Regulation
P01717833T0000|18 36|alpha inhibin gene
P01717833T0000|47 56|adenosine
P01717833T0000|63 76|monophosphate
P01717833T0000|83 95|transfection
P01717833T0000|101 120|rat granulosa cells
P01717925A0477|0 10|Comparison
P01717925A0477|18 38|nucleotide sequences
P01717925A0477|68 71|DNA
P01717925A0477|88 107|sequence similarity
P01717925A0477|122 124|bp
P01717925A0477|152 158|region
P01717994T0000|0 7|Cloning
P01717994T0000|19 23|cDNA
P01717994T0000|48 54|kinase
P01717994T0000|58 73|complementation
P01717994T0000|87 92|yeast
P01717994T0000|99 107|mutation
P01718043A0384|3 11|patients
P01718043A0384|17 30|osteomyelitis
P01718043A0384|41 48|empyema
P01718043A0384|50 51|n
P01718043A0384|58 70|PMN elastase
P01718043A0384|77 88|sensitivity
P01718043A0384|94 95|%
P01718043A0384|147 177|erythrocyte sedimentation rate
P01718043A0384|179 190|sensitivity
P01718043A0384|193 194|%
P01718983A1640|0 2|E.
P01718983A1640|4 11|Hession
P01718983A1640|13 15|C.
P01718983A1640|17 21|Goff
P01718983A1640|23 25|D.
P01718983A1640|27 36|Griffiths
P01718983A1640|38 40|B.
P01718983A1640|42 48|Tizard
P01718983A1640|50 52|R.
P01718983A1640|54 60|Newman
P01718983A1640|62 64|B.
P01718983A1640|66 75|Chi-Rosso
P01718983A1640|77 79|G.
P01718983A1640|85 89|Lobb
P01718983A1640|91 93|R.
P01718983A1640|102 106|Cell
P01719684A0494|10 17|results
P01719684A0494|32 40|increase
P01719684A0494|61 70|receptors
P01719684A0494|81 89|prostate
P01719684A0494|171 189|sphincter function
P01720555A1087|28 41|B2 transcript
P01720555A1087|63 77|alfalfa organs
P01720843A1506|6 13|results
P01720843A1506|32 48|sulfhydryl group
P01720843A1506|60 71|angiotensin
P01720843A1506|83 100|enzyme inhibitors
P01720843A1506|122 128|effect
P01720843A1506|147 168|nitrovasodilator EDRF
P01721261T0000|0 16|Pharmacokinetics
P01721261T0000|20 22|FK
P01721261T0000|30 49|transplant patients
P01721884A0962|31 36|match
P01721884A0962|53 59|region
P01721884A0962|88 102|ribonuclease H
P01721884A0962|104 111|RNase H
P01721884A0962|113 119|domain
P01721884A0962|152 158|region
P01721884A0962|193 206|investigators
P01721884A0962|224 231|RNase H
P01721884A0962|249 252|Pol
P01721884A0962|255 264|helices O
P01721884A0962|269 270|P
P01721884A0962|289 296|helices
P01721884A0962|303 304|D
P01721884A0962|312 337|RNase H crystal structure
P01722319A0849|0 8|Analysis
P01722319A0849|24 43|amino acid sequence
P01722319A0849|58 72|CHIP28 protein
P01722319A0849|103 110|domains
P01722319A0849|136 157|N-glycosylation sites
P01722319A0849|177 178|N
P01722319A0849|183 192|C termini
P01722479A0302|16 30|concentrations
P01722479A0302|34 37|HCG
P01722479A0302|44 55|sensitivity
P01722479A0302|63 64|%
P01722479A0302|71 82|specificity
P01722479A0302|89 90|%
P01723619A0766|12 16|rate
P01723619A0766|20 32|F absorption
P01723619A0766|44 48|rise
P01723619A0766|52 74|plasma F concentration
P01723619A0766|104 112|emptying
P01723619A0766|127 134|passage
P01723619A0766|138 139|F
P01723619A0766|155 164|intestine
P01723619A0766|178 184|factor
P01723619A0766|194 206|F absorption
P01723962A0165|4 12|activity
P01723962A0165|16 28|serum lipase
P01723962A0165|33 40|amylase
P01723962A0165|67 68|h
P01723962A0165|88 95|maximum
P01723962A0165|102 103|h
P01723962A0165|110 119|injection
P01723962A0165|123 128|Na-Tc
P01724982A0237|50 61|HCV EIA kit
P01724982A0237|63 74|Abbott Lab.
P01724982A0237|76 89|North Chicago
P01724982A0237|91 93|IL
P01725547A0354|0 9|Diltiazem
P01725547A0354|36 44|increase
P01725547A0354|59 67|diameter
P01725547A0354|72 73|%
P01725547A0354|75 76|p
P01725547A0354|102 112|blood flow
P01725547A0354|114 117|CBF
P01725547A0354|123 124|%
P01725547A0354|126 127|p
P01725622A0292|10 21|transfusion
P01725622A0292|36 54|platelet increment
P01725622A0292|61 66|Gpt/l
P01725622A0292|68 71|CCI
P01726211A0502|6 18|risk factors
P01726211A0502|41 47|groups
P01726211A0502|55 61|vessel
P01726211A0502|75 82|factors
P01726211A0502|101 107|action
P01726211A0502|118 125|factors
P01726631T0001|0 12|Epidemiology
P01726631T0001|17 27|prevention
P01726631T0001|31 50|hospital infections
P01726631T0001|58 75|Local Health Unit
P01726631T0001|79 86|Sassari
P01726631T0001|88 95|profile
P01726631T0001|109 119|resistance
P01726631T0001|138 144|agents
P01726631T0001|154 159|usage
P01727488A1146|18 23|cDNAs
P01727488A1146|42 53|stimulation
P01727488A1146|95 110|gene expression
P01727494A0000|0 14|Vaccinia virus
P01727494A0000|16 18|VV
P01727494A0000|32 41|immunogen
P01727494A0000|51 57|nature
P01727494A0000|61 72|VV proteins
P01727494A0000|89 99|activation
P01727494A0000|114 122|response
P01727494A0000|130 134|host
P01730412T0000|0 3|Max
P01730412T0000|16 23|domains
P01730412T0000|28 39|interaction
P01730412T0000|45 50|c-Myc
P01730747A0205|18 20|G1
P01730747A0205|24 31|S phase
P01730747A0205|33 39|Reilly
P01730747A0205|41 43|C.
P01731107A0928|0 13|Substitutions
P01731107A0928|28 33|bases
P01731107A0928|50 60|ICR2 motif
P01731107A0928|69 75|levels
P01731107A0928|79 95|pRNA replication
P01731107A0928|128 139|maintenance
P01731107A0928|167 176|structure
P01731107A0928|193 199|strand
P01731107A0928|213 219|genome
P01731933T0000a|0 2|Zn
P01731933T0000a|7 34|coordination domain mutants
P01731933T0000a|38 45|T4 gene
P01731933T0000a|49 56|protein
P01731933T0000b|0 2|Zn
P01731933T0000b|7 34|coordination domain mutants
P01731933T0000b|38 45|T4 gene
P01731933T0000b|49 56|protein
P01731979A1408|4 22|tissue specificity
P01731979A1408|26 41|gene expression
P01731979A1408|93 127|CaMV 35S domain B enhancer element
P01732033A0000|4 19|pathophysiology
P01732033A0000|33 43|management
P01732033A0000|53 65|brain injury
P01732033A0000|69 76|infancy
P01732033A0000|81 90|childhood
P01732033A0000|127 139|brain injury
P01732033A0000|145 150|model
P01732736A1076|0 11|Transcripts
P01732736A1076|26 41|POU-domain gene
P01732736A1076|43 49|Oct-25
P01732736A1076|71 77|levels
P01732736A1076|81 88|oocytes
P01732736A1076|99 106|embryos
P01732736A1076|154 166|gastrulation
P01732752A0156|14 21|B cells
P01732752A0156|26 33|Abelson
P01732752A0156|41 49|leukemia
P01732752A0156|68 84|pre-B-cell lines
P01732752A0156|86 93|LT mRNA
P01733105A0127|4 10|genome
P01733105A0127|14 27|Thogoto virus
P01733105A0127|42 50|segments
P01733105A0127|80 89|sense RNA
P01733358A0240|6 12|tumors
P01733358A0240|46 52|groups
P01733358A0240|57 68|cystadenoma
P01733358A0240|74 92|cystadenocarcinoma
P01733358A0240|98 101|III
P01733358A0240|103 117|adenocarcinoma
P01733358A0240|123 139|mucin production
P01733358A0240|157 161|cyst
P01734020A1318|0 14|Immunostaining
P01734020A1318|18 23|cells
P01734020A1318|47 57|constructs
P01734020A1318|116 123|mutants
P01734020A1318|142 148|nuclei
P01734020A1318|168 177|PKC alpha
P01734283A0817|32 45|RAP74 protein
P01734283A0817|60 70|HeLa cells
P01734283A0817|97 100|DNA
P01734283A0817|120 139|translation product
P01734283A0817|158 163|RAP30
P01734570T0000|0 7|Effects
P01734570T0000|11 44|thromboxane synthetase inhibition
P01734570T0000|77 87|resistance
P01734570T0000|96 100|rate
P01734570T0000|114 127|translocation
P01734570T0000|141 154|porcine model
P01735347A0482|23 29|insult
P01735347A0482|61 70|treatment
P01735347A0482|92 96|rise
P01735347A0482|100 113|plasma lipase
P01735347A0482|122 133|development
P01735347A0482|137 144|ascites
P01735347A0482|152 161|extension
P01735347A0482|180 188|necrosis
P01735447A0271|4 8|size
P01735447A0271|23 31|molecule
P01735447A0271|75 84|precursor
P01735447A0271|86 103|pre-super-pro-PrB
P01735447A0271|121 134|sec61 mutants
P01735447A0271|141 154|translocation
P01735447A0271|176 185|reticulum
P01735447A0833|10 30|active-site mutation
P01735447A0833|54 64|processing
P01735447A0833|94 103|precursor
P01735447A0833|107 110|PrB
P01735447A0833|123 134|kDa pro-PrB
P01735447A0833|154 163|reticulum
P01735721A0185|14 33|amino acid sequence
P01735721A0185|46 56|% identity
P01735721A0185|68 101|Bacillus stearothermophilus TyrTS
P01735721A0185|108 118|% identity
P01735721A0185|138 143|TyrTS
P01735721A0185|151 159|identity
P01735721A0185|180 202|B. subtilis TyrTS gene
P01735721A0185|215 219|tyrZ
P01735721A0185|232 233|%
P01736093A0731|15 27|CAT activity
P01736093A0731|59 68|sequences
P01736093A0731|85 93|promoter
P01736093A0731|111 122|CCAAT boxes
P01736093A0731|136 139|HSE
P01736093A0731|160 173|constructions
P01736651A0104|9 14|Women
P01736651A0104|16 23|Infants
P01736651A0104|29 45|Children clinics
P01736651A0104|49 60|Minneapolis
P01736651A0104|62 67|Minn.
P01736844T0000|0 12|Testosterone
P01736844T0000|19 31|testosterone
P01736844T0000|72 84|testosterone
P01736844T0000|95 109|androgen index
P01736844T0000|117 141|testosterone measurement
P01736844T0000|186 194|function
P01736844T0000|198 201|men
P01736844T0000|207 215|epilepsy
P01737741A0000|0 10|BACKGROUND
P01737741A0000|16 29|effectiveness
P01737741A0000|33 61|monoamine oxidase inhibitors
P01737741A0000|63 68|MAOIs
P01737741A0000|93 103|depression
P01737741A0000|148 153|study
P01737789A0800|25 35|breakpoint
P01737789A0800|61 68|repeats
P01737789A0800|76 96|acceptor splice site
P01737789A0800|110 144|down-stream alpha-delta breakpoint
P01737789A0800|172 178|intron
P01738470A0441|0 8|Patients
P01738470A0441|23 28|PDDAT
P01738470A0441|57 66|positions
P01738470A0441|84 89|order
P01738470A0441|102 120|recognition memory
P01738653T0014|0 4|Bone
P01738653T0014|9 14|bones
P01738936A0292|4 12|patients
P01738936A0292|17 33|plasma C-peptide
P01738936A0292|49 51|pM
P01738936A0292|84 92|analysis
P01739439A0257|0 7|Complex
P01739439A0257|19 29|discharges
P01739439A0257|47 54|muscles
P01739439A0257|58 66|mdx mice
P01739439A0257|74 81|complex
P01739439A0257|93 103|discharges
P01739439A0257|113 126|abnormalities
P01739439A0257|144 151|muscles
P01739439A0257|162 174|control mice
P01739956A0638|0 10|Management
P01739956A0638|26 30|beta
P01739956A0638|36 51|calcium channel
P01739956A0638|61 66|drugs
P01739956A0638|70 77|type IC
P01739956A0638|93 98|drugs
P01740121A0136|17 24|problem
P01740121A0136|48 53|Kex2p
P01740121A0136|64 105|baculovirus/insect cell expression system
P01740330A0329|0 2|J.
P01740437A0851|17 29|core protein
P01740437A0851|37 59|liver HSPG preparation
P01740437A0851|91 99|antibody
P01740437A0851|145 151|domain
P01740437A0851|155 166|fibroglycan
P01740448A1735|17 38|transmembrane regions
P01740448A1735|82 102|amino acid stretches
P01740448A1735|155 161|region
P01740448A1735|196 206|attachment
P01740448A1735|210 220|precursors
P01740448A1735|224 233|membranes
P01740682A0703|0 8|Toxicity
P01740682A0703|40 46|emesis
P01740682A0703|50 51|%
P01740682A0703|59 67|patients
P01740682A0703|71 72|%
P01740682A0703|80 87|courses
P01740682A0703|90 100|leukopenia
P01740682A0703|104 129|World Health Organization
P01740682A0703|136 141|grade
P01740682A0703|152 153|%
P01740682A0703|161 169|patients
P01740682A0703|173 174|%
P01740682A0703|182 189|courses
P01740682A0703|196 212|thrombocytopenia
P01740682A0703|216 217|%
P01740682A0703|225 233|patients
P01740682A0703|236 237|%
P01740682A0703|245 252|courses
P01741249A0177|0 4|W.G.
P01742341A0499|5 10|study
P01742341A0499|41 49|reaction
P01742341A0499|75 89|transportation
P01742341A0499|102 110|stressor
P01742341A0499|115 126|Beagle dogs
P01742606A0000|2 27|mouse brain beta-spectrin
P01742606A0000|31 35|cDNA
P01742606A0000|60 90|lambda Gt11 expression library
P01742606A0000|100 108|antibody
P01742606A0000|147 172|kDa spectrin beta-subunit
P01742879A0471|0 7|RESULTS
P01742879A0471|9 29|Plasma AVP responses
P01742879A0471|41 52|stimulation
P01742879A0471|70 80|inhibition
P01742879A0471|84 92|drinking
P01742879A0471|109 117|patients
P01742879A0471|134 148|water drinking
P01744039A0511|4 13|fragments
P01744039A0511|22 28|region
P01744039A0511|47 72|polymerase chain reaction
P01744039A0511|89 108|gel electrophoresis
P01744039A0511|133 158|conformation polymorphism
P01744042A1355|4 15|csbA fusion
P01744042A1355|64 69|phase
P01744042A1355|73 78|cells
P01744042A1355|88 99|Luria broth
P01744042A1355|112 121|% glucose
P01744042A1355|129 140|% glutamine
P01744119A0757|4 15|constraints
P01744119A0757|19 48|primase recognition sequences
P01744119A0757|50 83|nucleotide substrate requirements
P01744119A0757|93 100|effects
P01744119A0757|115 123|proteins
P01744119A0757|127 156|oligoribonucleotide synthesis
P01744119A0757|171 175|gene
P01744119A0757|178 185|protein
P01744119A0757|211 220|templates
P01744119A0757|232 240|sequence
P01747972T0000|13 20|therapy
P01747972T0000|45 62|artery dissection
P01748067A0000|14 19|trial
P01748067A0000|54 62|patients
P01748067A0000|67 70|men
P01748067A0000|77 80|age
P01748067A0000|86 91|years
P01748067A0000|97 102|women
P01748067A0000|109 112|age
P01748067A0000|118 123|years
P01748067A0000|149 152|hip
P01748067A0000|159 170|replacement
P01748067A0000|211 220|arthritis
P01748067A0000|224 232|fracture
P01748067A0000|240 244|neck
P01748067A0000|252 257|femur
P01748194A0767|10 17|lesions
P01748194A0767|40 52|hemisections
P01748194A0767|93 101|recovery
P01748194A0767|143 159|cord transection
P01748194A0767|161 162|N
P01748287T0000|18 26|proteins
P01748287T0000|40 50|properties
P01748287T0000|76 83|targets
P01748292A0000|17 22|cDNAs
P01748292A0000|29 33|gene
P01748292A0000|47 70|G protein alpha subunit
P01748292A0000|76 82|tomato
P01748292A0000|84 107|Lycopersicon esculentum
P01748292A0000|109 111|cv
P01748630A0125|0 25|Growth factor stimulation
P01748630A0125|29 34|cells
P01748630A0125|46 61|phosphorylation
P01748630A0125|69 74|c-Myc
P01748630A0125|91 108|activation domain
P01748630A0125|112 117|Ser62
P01748630A0125|140 146|region
P01748630A0125|178 185|members
P01748630A0125|193 203|Myc family
P01748630A0125|205 212|Alvarez
P01748630A0125|214 216|E.
P01748630A0125|218 227|Northwood
P01748630A0125|229 233|I.C.
P01748630A0125|235 243|Gonzalez
P01748630A0125|245 247|F.
P01751163A0000|4 11|authors
P01751163A0000|26 35|potential
P01751163A0000|51 64|complications
P01751163A0000|78 90|implantation
P01751163A0000|115 121|device
P01751163A0000|123 135|Sarns/3M-VAD
P01751163A0000|145 151|calves
P01751255A0529|8 14|output
P01751255A0529|16 18|CO
P01751255A0529|46 47|p
P01751255A0529|73 83|MBBF group
P01751970A0209|0 19|Amino acid residues
P01751970A0209|55 63|sequence
P01751970A0209|84 92|residues
P01752441A0000|16 26|activation
P01752441A0000|34 51|HIV-1 Tat protein
P01752441A0000|70 78|residues
P01752441A0000|86 105|hexanucleotide loop
P01752441A0000|110 129|trinucleotide bulge
P01752441A0000|137 164|TAR RNA stem-loop structure
P01752441A0000|194 200|leader
P01752441A0000|214 225|transcripts
P01752792A0000|25 33|evidence
P01752792A0000|41 47|coding
P01752792A0000|62 78|time differences
P01752792A0000|80 84|ITDs
P01752792A0000|95 102|stimuli
P01752792A0000|116 123|neurons
P01752792A0000|140 146|cortex
P01752792A0000|163 174|albino rats
P01753317A0879|6 13|results
P01753317A0879|52 55|TTC
P01753317A0879|59 70|combination
P01753317A0879|76 80|FDBA
P01753317A0879|94 108|bone formation
P01753317A0879|134 146|bone defects
P01754381A0000|14 18|step
P01754381A0000|31 47|characterization
P01754381A0000|63 78|DNA polymerases
P01754381A0000|82 94|trypanosomes
P01754381A0000|139 149|expression
P01754381A0000|157 168|Trypanosoma
P01754381A0000|170 181|Trypanozoon
P01754381A0000|197 201|gene
P01754381A0000|219 239|DNA polymerase alpha
P01754381A0000|250 254|core
P01754381A0000|256 265|pol alpha
P01756195A1117|3 11|addition
P01756195A1117|37 45|increase
P01756195A1117|76 90|concentrations
P01756195A1117|96 99|age
P01756195A1117|101 102|p
P01756195A1117|119 120|r
P01756539A0354|10 22|hypertension
P01756539A0354|58 67|narrowing
P01756539A0354|82 91|condition
P01756539A0354|119 129|infarction
P01757341A0591|4 19|volume fraction
P01757341A0591|21 23|Vv
P01757341A0591|29 39|number/mm2
P01757341A0591|41 43|Na
P01757341A0591|52 63|capillaries
P01757341A0591|102 106|area
P01757341A0591|110 115|brain
P01757341A0591|151 171|alkaline phosphatase
P01758750A0000|0 15|Airway pressure
P01758750A0000|20 28|air flow
P01758750A0000|63 67|tube
P01758750A0000|74 82|children
P01758750A0000|88 95|variety
P01758750A0000|99 110|ventilators
P01759052A0786|0 4|Appl
P01759282A0000|0 6|Issues
P01759282A0000|10 22|distribution
P01759282A0000|34 40|energy
P01759282A0000|57 63|object
P01759282A0000|74 93|contact interaction
P01759282A0000|99 103|head
P01759282A0000|111 117|impact
P01759282A0000|137 145|position
P01759282A0000|149 161|biomechanics
P01760166A0963|0 10|CONCLUSION
P01760166A0963|23 27|SpO2
P01760166A0963|41 52|septum site
P01760166A0963|96 107|finger site
P01760166A0963|123 131|patients
P01761736A0158|0 9|Diltiazem
P01761736A0158|30 44|body clearance
P01761736A0158|79 85|mL/min
P01761736A0158|87 88|P
P01761736A0158|123 144|elimination half-life
P01761736A0158|179 184|hours
P01761736A0158|186 187|P
P01761736A0158|206 216|antipyrine
P01761736A0158|229 236|changes
P01761736A0158|240 246|volume
P01761736A0158|250 262|distribution
P01762053A0557|4 12|granules
P01762053A0557|32 40|material
P01762053A0557|64 69|space
P01762053A0557|88 97|particles
P01762914A1218|11 23|uPA promoter
P01762914A1218|58 66|elements
P01762914A1218|88 90|kb
P01762914A1218|101 123|translation start site
P01762917A0615|15 18|Ser
P01762917A0615|23 28|Gly69
P01762917A0615|34 37|Glu
P01762917A0615|42 45|Lys
P01762917A0615|66 83|TGEK tetrapeptide
P01762917A0615|87 93|finger
P01762917A0615|100 106|TFIIIA
P01762917A0615|123 127|loss
P01762917A0615|131 142|DNA binding
P01763065A0913|0 2|P.
P01763106A0070|20 28|behavior
P01763106A0070|42 46|hole
P01763106A0070|58 68|locomotion
P01763106A0070|99 111|test session
P01764899A0399|4 9|model
P01764899A0399|40 46|effect
P01764899A0399|50 68|water fluoridation
P01764899A0399|72 89|caries prevalence
P01764899A0399|114 120|caries
P01764899A0399|137 149|cavity level
P01765095A0680|0 36|12-O-Tetradecanoylphorbol 13-acetate
P01765095A0680|83 93|expression
P01765095A0680|97 102|mRNAs
P01765095A0680|127 142|regulators CMD1
P01765095A0680|147 155|myogenin
P01765266A0000|3 17|Xenopus laevis
P01765266A0000|23 27|gene
P01765266A0000|41 66|elongation factor 1-alpha
P01765266A0000|75 87|EF-1 alpha O
P01765266A0000|95 96|O
P01765266A0000|108 114|oocyte
P01765266A0000|132 139|oocytes
P01765266A0000|150 157|embryos
P01765269A0308|6 13|introns
P01765269A0308|28 33|class
P01765269A0308|45 61|pre-mRNA introns
P01765269A0308|93 112|consensus sequences
P01765269A0308|132 140|features
P01765375A0290|4 8|mRNA
P01765375A0290|38 47|rat cells
P01765375A0290|63 77|clathrin clone
P01765375A0290|87 98|transcripts
P01765375A0290|120 122|kb
P01765375A0290|167 170|kDa
P01765375A0290|181 187|weight
P01765375A0290|195 203|clathrin
P01765375A0290|210 215|chain
P01765386A0305|8 14|report
P01765386A0305|25 27|kb
P01765386A0305|31 43|DNA sequence
P01765386A0305|73 75|bp
P01765386A0305|86 90|gene
P01765386A0305|99 101|kb
P01765386A0305|105 109|exon
P01765386A0305|126 135|junctions
P01765386A0305|145 147|bp
P01765386A0305|158 162|gene
P01765407A0866|7 15|exposure
P01765407A0866|22 32|mg DMEA/m3
P01765407A0866|63 83|plasma concentration
P01765407A0866|92 104|postexposure
P01765407A0866|113 122|excretion
P01765407A0866|130 137|mumol/l
P01765407A0866|145 164|mmol/mol creatinine
P01766666A0788|0 10|Antibodies
P01766666A0788|23 27|rE12
P01766666A0788|32 39|rNFIL-6
P01766666A0788|48 71|nucleoprotein complexes
P01766666A0788|95 100|sites
P01766666A0788|117 128|interaction
P01766666A0788|147 154|factors
P01766876A0000|2 8|method
P01766876A0000|45 51|events
P01766876A0000|59 61|mu
P01766876A0000|68 78|chain gene
P01766876A0000|95 108|co-conversion
P01766876A0000|113 124|co-exchange
P01766876A0000|131 145|point mutation
P01766876A0000|164 170|marker
P01766876A0000|186 204|replacement vector
P01766999A0000|11 19|activity
P01766999A0000|23 56|allergen extract Ambrosia elatior
P01766999A0000|58 60|AE
P01766999A0000|84 94|volunteers
P01766999A0000|122 130|allergen
P01767060A0000|5 10|study
P01767060A0000|42 62|c-DDP administration
P01767060A0000|82 94|radiotherapy
P01767060A0000|110 119|frequency
P01767060A0000|124 132|duration
P01767060A0000|146 155|responses
P01767060A0000|168 176|survival
P01767060A0000|181 189|patients
P01767060A0000|221 227|stages
P01767060A0000|240 250|carcinomas
P01767060A0000|258 262|head
P01767060A0000|267 271|neck
P01767592A0682|25 34|sequences
P01767592A0682|39 59|DNA binding proteins
P01767592A0682|92 98|region
P01767592A0682|102 142|HAP2/HAP3 consensus recognition sequence
P01767592A0682|146 160|nucleotide-154
P01767592A0682|167 202|BAF1 consensus recognition sequence
P01767592A0682|206 220|nucleotide-136
P01767899A0136|7 23|thrombocytopenia
P01767899A0136|25 34|depletion
P01767899A0136|38 54|serum fibrinogen
P01767899A0136|69 80|prothrombin
P01767899A0136|103 122|thromboplastin time
P01767899A0136|162 169|minutes
P01767899A0136|188 200|envenomation
P01768648A0853|15 25|properties
P01768648A0853|29 49|LexA fusion proteins
P01768648A0853|63 75|dimerization
P01768648A0853|95 102|domains
P01768648A0853|106 110|cRel
P01769189A0000|0 12|Plasma lipid
P01769189A0000|17 37|lipoprotein profiles
P01769189A0000|70 77|runners
P01769189A0000|79 81|RU
P01769189A0000|83 84|n
P01769189A0000|105 110|years
P01769189A0000|112 116|body
P01769189A0000|129 130|%
P01769189A0000|132 149|training distance
P01769189A0000|160 169|km week-1
P01769189A0000|171 177|VO2max
P01769189A0000|187 200|ml kg-1 min-1
P01769189A0000|202 206|mean
P01769189A0000|211 213|SD
P01769189A0000|241 246|women
P01769189A0000|248 250|UT
P01769189A0000|252 253|n
P01769189A0000|269 274|years
P01769189A0000|276 280|body
P01769189A0000|293 294|%
P01769189A0000|296 302|VO2max
P01769189A0000|312 325|ml kg-1 min-1
P01769919A0393|9 25|threshold shifts
P01769919A0393|62 80|brainstem response
P01769919A0393|122 125|kHz
P01770651T0001|25 35|evaluation
P01770651T0001|39 59|equilibrium dialysis
P01770651T0001|61 84|radioimmunoassay system
P01770651T0001|89 100|measurement
P01770651T0001|104 109|serum
P01770651T0001|115 124|thyroxine
P01771593A1152|17 19|TA
P01771593A1152|38 46|decrease
P01771593A1152|50 53|AGD
P01771593A1152|57 59|GD
P01771593A1152|92 95|PCD
P01771593A1232|17 23|adults
P01771593A1232|27 32|weeks
P01771593A1232|52 61|genitalia
P01771593A1232|76 85|offspring
P01771959A0442|6 10|PTCA
P01771959A0442|12 29|ejection fraction
P01771959A0442|53 54|%
P01771959A0442|66 67|%
P01771959A0442|69 70|p
P01771959A0442|100 108|function
P01771959A0442|150 159|deviation
P01771959A0442|167 171|PTCA
P01771959A0442|192 196|PTCA
P01771959A0442|211 219|segments
P01771959A0442|245 254|deviation
P01771959A0442|262 266|PTCA
P01771959A0442|285 289|PTCA
P01772201T0001|14 21|patient
P01772201T0001|27 31|work
P01772201T0001|40 52|subjectivity
P01772201T0001|60 66|period
P01772341A0852|6 10|data
P01772341A0852|37 46|treatment
P01772341A0852|54 86|thromboxane synthetase inhibitor
P01772341A0852|93 124|thromboxane receptor antagonist
P01772341A0852|143 153|protection
P01772341A0852|162 182|digoxin intoxication
P01772341A0852|200 205|agent
P01774062A0257|9 12|YAC
P01774062A0257|14 20|A148A7
P01774062A0257|39 53|HLA-DQA1 locus
P01774062A0257|66 73|Y3/Ring
P01774062A0257|76 81|locus
P01774062A0257|108 110|kb
P01774062A0257|126 135|YAC B1D12
P01774063A0161|14 32|backcross analysis
P01774063A0161|39 46|progeny
P01774063A0161|60 67|matings
P01774063A0161|72 94|C57BL/6J x Mus spretus
P01774063A0161|96 98|F1
P01774063A0161|101 114|C57BL/6J mice
P01774063A0161|134 153|thrombospondin gene
P01774063A0161|179 183|Fshb
P01774063A0161|185 190|Actcl
P01774063A0161|192 195|Ltk
P01774063A0161|201 209|B2M loci
P01774063A0161|220 230|chromosome
P01774093T0000|15 22|outcome
P01774093T0000|35 38|IgM
P01774093T0000|48 79|Chlamydia trachomatis infection
P01774093T0000|83 92|pregnancy
P01774822A0289|26 34|computer
P01774822A0289|45 67|LV time-density curves
P01774822A0289|101 106|cycle
P01776306A0572|12 19|patient
P01776306A0572|24 26|VT
P01776715A0489|3 8|delay
P01776715A0489|30 44|centrifugation
P01776715A0489|53 64|measurement
P01776715A0489|86 90|loss
P01776715A0489|94 97|CO2
P01776715A0489|99 112|equilibration
P01776715A0489|120 126|sample
P01776715A0489|134 145|gas mixture
P01776715A0489|163 167|PCO2
P01776715A0489|174 177|kPa
P01776715A0489|191 202|measurement
P01777841A0744|13 23|mechanisms
P01777841A0744|35 46|differences
P01777841A0744|63 70|effects
P01777841A0744|76 82|muscle
P01777841A0744|97 106|afferents
P01777841A0744|110 116|adults
P01777841A0744|121 129|neonates
P01779299A0000|23 34|alterations
P01779299A0000|48 57|cockroach
P01779299A0000|59 78|Periplaneta brunnea
P01779299A0000|98 113|acanthocephalan
P01779299A0000|115 140|Moniliformis moniliformis
P01779433A0694|11 18|finding
P01779433A0694|34 51|Alu family repeat
P01779433A0694|59 67|junction
P01779433A0694|88 95|block I
P01779433A0694|100 108|homology
P01779433A0694|115 116|Y
P01779433A0694|124 129|alpha
P01779433A0694|148 152|unit
P01779433A0694|156 162|rhesus
P01779433A0694|197 214|Alu family repeat
P01779433A0694|216 219|Alu
P01779433A0694|242 250|position
P01779433A0694|277 286|insertion
P01779433A0694|302 319|Alu family repeat
P01779433A0694|332 335|end
P01779433A0694|359 376|Alu family repeat
P01779769A0000|4 12|sequence
P01779769A0000|20 35|repressor locus
P01779769A0000|37 38|c
P01779769A0000|47 59|Streptomyces
P01779769A0000|70 75|phage
P01779769A0000|77 84|phi C31
P01779769A0000|126 139|reading frame
P01779769A0000|154 165|kDa protein
P01780235A0094|4 14|EPO levels
P01780235A0094|48 59|transfusion
P01780235A0094|106 117|transfusion
P01781923A0744|18 29|sensitivity
P01781923A0744|33 35|DB
P01781923A0744|60 73|concentration
P01781923A0744|77 79|DB
P01781923A0744|93 97|loss
P01781923A0744|101 109|righting
P01781923A0744|113 115|LS
P01781923A0744|145 149|rate
P01781923A0744|167 197|barbiturate brain distribution
P01781923A0744|202 213|elimination
P01781923A0744|225 230|lines
P01782424A0278|4 13|existence
P01782424A0278|17 41|threshold concentrations
P01782424A0278|63 72|phenomena
P01782424A0278|100 104|role
P01782424A0278|108 117|sentinels
P01782669A0496|36 48|temperatures
P01782669A0496|55 63|addition
P01782669A0496|67 73|A23187
P01782982A0155|0 10|Felodipine
P01782982A0155|29 42|baseline FEV1
P01782982A0155|86 92|effect
P01782982A0155|98 107|histamine
P01782982A0155|112 115|AMP
P01782982A0155|124 143|bronchoconstriction
P01783088A1136|14 22|patients
P01783088A1136|40 47|disease
P01783088A1136|52 62|mast cells
P01783088A1136|91 92|%
P01783088A1136|94 104|hyaluronan
P01783088A1136|133 147|micrograms.l-1
P01783088A1136|152 163|fibronectin
P01783088A1136|193 207|micrograms.l-1
P01783088A1136|236 244|patients
P01783088A1136|271 278|disease
P01783088A1136|280 288|ABSTRACT
P01783088A1136|306 311|WORDS
P01783375A1066|4 11|mapping
P01783375A1066|36 47|involvement
P01783375A1066|56 60|gene
P01783375A1066|90 99|disorders
P01783375A1066|133 158|translocation breakpoints
P01784589A0000|41 45|role
P01784589A0000|49 72|5-HT2 receptor activity
P01784589A0000|81 84|rat
P01784589A0000|92 100|behavior
P01785749A0695|6 13|changes
P01785749A0695|44 49|group
P01785749A0695|59 67|children
P01785749A0695|84 90|weight
P01786094T0001|8 16|contents
P01786094T0001|27 33|copper
P01787085A0331|13 24|experiments
P01787085A0331|47 59|control rats
P01787085A0331|74 81|colloid
P01788002T0001|0 14|Magnetotherapy
P01788002T0001|18 29|hepatitis A
P01788002T0001|34 35|B
P01788002T0001|39 47|children
P01791363A0208|6 13|results
P01791363A0208|43 51|patients
P01791363A0208|81 88|sutures
P01791363A0208|101 108|testing
P01791754T0000|11 19|analysis
P01791754T0000|31 35|role
P01791754T0000|60 68|features
P01791754T0000|87 103|secretion signal
P01791754T0000|124 134|haemolysin
P01792580A0198|6 18|blood donors
P01792580A0198|26 34|Republic
P01792580A0198|38 44|Serbia
P01792580A0198|61 67|number
P01792580A0198|71 86|blood donations
P01792580A0198|92 102|percentage
P01792580A0198|113 119|donors
P01792580A0198|159 169|percentage
P01792580A0198|178 190|blood donors
P01792914T0000|15 22|relapse
P01792914T0000|26 44|childhood leukemia
P01797459A0103|0 10|Mycoplasma
P01797459A0103|52 57|fluid
P01797459A0103|66 73|patient
P01797467A0000|0 5|RU486
P01797467A0000|10 13|ONO
P01797467A0000|21 32|combination
P01797467A0000|74 85|termination
P01797467A0000|89 98|pregnancy
P01798407A1011|4 12|presence
P01798407A1011|22 35|abnormalities
P01798407A1011|44 52|patients
P01798407A1011|69 79|hypothesis
P01798407A1011|89 95|cortex
P01798407A1011|133 137|lobe
P01798407A1011|158 164|origin
P01798407A1011|172 189|laughing seizures
P01804671A1001|3 7|line
P01804671A1001|23 29|values
P01804671A1001|34 39|QS/QC
P01804671A1001|45 52|results
P01804671A1001|111 121|air spaces
P01804671A1001|129 133|lung
P01804671A1001|167 201|ventilation/perfusion distribution
P01804671A1001|222 230|gas data
P01804671A1001|236 242|CDCSF6
P01804671A1001|255 263|ml.min-1
P01804671A1001|264 270|mmHg-1
P01806314A0322|5 10|cells
P01806314A0322|46 53|markers
P01806314A0322|90 98|antibody
P01806314A0322|107 119|muscle actin
P01808049A0262|0 16|CT abnormalities
P01808049A0262|26 37|term babies
P01808049A0262|47 57|hemorrhage
P01808049A0262|75 76|%
P01808049A0262|96 97|%
P01808049A0262|100 111|hypodensity
P01808049A0262|122 123|%
P01808049A0262|138 139|%
P01808049A0262|150 151|%
P01808049A0262|154 165|hypodensity
P01808049A0262|171 181|hemorrhage
P01808049A0262|185 186|%
P01808049A0262|200 207|atrophy
P01808049A0262|211 212|%
P01808136T0000|4 11|effects
P01808136T0000|15 29|contrast media
P01808136T0000|33 55|coagulation factor XII
P01808186A0984|0 4|Pigs
P01808186A0984|53 57|diet
P01808186A0984|71 73|kg
P01808186A0984|77 80|Exp
P01808602A0000|11 19|patients
P01808602A0000|44 56|hypertension
P01808602A0000|61 68|effects
P01808602A0000|79 99|nifedipine treatment
P01808602A0000|103 108|serum
P01808602A0000|114 118|acid
P01808602A0000|129 138|excretion
P01808602A0000|147 151|acid
P01808829A0510|0 4|TPTA
P01808829A0510|14 30|brain congestion
P01808829A0510|84 95|hemorrhages
P01809854A0106|0 8|Examples
P01809854A0106|24 32|subjects
P01809854A0106|48 63|research design
P01809854A0106|76 96|consensus statements
P01809854A0106|106 119|meta-analysis
P01810108A0000|6 21|phase slug flow
P01810108A0000|30 44|heat exchanger
P01810108A0000|70 82|inactivation
P01810108A0000|86 108|Listeria monocytogenes
P01810108A0000|129 133|milk
P01810108A0000|145 149|cows
P01810154A0491|10 18|children
P01811243A0000|0 8|Regional
P01811243A0000|18 28|blood flow
P01811243A0000|30 34|rCBF
P01811243A0000|36 48|measurements
P01811243A0000|65 72|ratings
P01811243A0000|111 119|patients
P01811243A0000|126 129|age
P01811243A0000|137 142|years
P01811243A0000|169 174|years
P01811243A0000|191 196|study
P01811243A0000|227 234|ratings
P01811243A0000|252 266|rCBF technique
P01811948A0289|15 20|study
P01811948A0289|69 76|element
P01811948A0289|84 86|bp
P01811948A0289|94 96|bp
P01811948A0289|104 122|LpS1 beta promoter
P01811948A0289|132 140|sequence
P01811948A0289|142 143|G
P01811948A0289|173 184|cis-element
P01811948A0289|193 195|bp
P01811948A0289|204 206|bp
P01812102A0101|12 25|study reports
P01812102A0101|50 59|responses
P01812102A0101|63 79|pattern reversal
P01812102A0101|81 86|VEP-P
P01812102A0101|101 110|trimester
P01812102A0101|120 125|women
P01812102A0101|130 137|changes
P01812102A0101|141 148|latency
P01812102A0101|152 163|NPN complex
P01812102A0101|189 198|responses
P01812102A0101|219 224|state
P01812690A0475|3 7|case
P01812690A0475|11 14|SMF
P01812690A0475|47 53|growth
P01814182A0000|10 15|doses
P01814182A0000|19 39|15-methyl-PGF2 alpha
P01814182A0000|50 52|mg
P01814182A0000|74 84|luteolysis
P01814182A0000|89 96|oestrus
P01814182A0000|102 109|heifers
P01814182A0000|118 128|treatments
P01814182A0000|132 135|day
P01814182A0000|157 162|cycle
P01816655T0000|0 6|Review
P01816655T0000|14 24|literature
P01816655T0000|29 35|report
P01816655T0000|41 45|case
P01816655T0000|59 63|cyst
P01817497A0715|0 10|Resolution
P01817497A0715|28 37|asymmetry
P01817497A0715|45 53|decrease
P01817497A0715|57 64|Delta T
P01817497A0715|101 102|%
P01817497A0715|125 135|population
P01822581A0533|7 16|instances
P01822581A0533|30 47|alcohol responses
P01822581A0533|85 92|reading
P01822581A0533|98 113|microgram/100ml
P01822581A0533|118 132|breath samples
P01822995T0000|0 28|Maize rbcS promoter activity
P01822995T0000|40 57|sequence elements
P01822995T0000|71 91|dicot rbcS promoters
P01823520A0183|0 12|Measurements
P01823520A0183|41 70|haematofluorometer Buchler ZF
P01823520A0183|107 124|haematocrit value
P01823524A0238|22 28|number
P01823524A0238|32 40|examples
P01823524A0238|74 81|variety
P01823524A0238|86 96|complexity
P01823524A0238|109 117|exposure
P01823524A0238|154 161|factors
P01823524A0238|180 189|influence
P01823524A0238|209 220|differences
P01823524A0238|224 238|susceptibility
P01823524A0238|242 262|xenobiotics toxicity
P01824713A0964|4 19|12S E1A product
P01824713A0964|40 52|TRE sequence
P01824713A0964|58 72|cotransfection
P01824713A0964|78 83|c-jun
P01824713A0964|101 105|lack
P01824713A0964|109 120|stimulation
P01824944A0988|6 15|treatment
P01824944A0988|21 32|tunicamycin
P01824944A0988|38 51|transfectants
P01824944A0988|83 95|polypeptides
P01824944A0988|118 121|IgE
P01825027T0000|0 4|PAS1
P01825027T0000|8 18|yeast gene
P01825027T0000|32 53|peroxisome biogenesis
P01825027T0000|65 71|member
P01825027T0000|83 89|family
P01825027T0000|102 109|ATPases
P01826003A0694|4 8|gene
P01826003A0694|18 28|base pairs
P01826003A0694|30 32|bp
P01826003A0694|56 63|members
P01826003A0694|71 81|SIG family
P01826003A0694|87 99|beta TG gene
P01826003A0694|118 123|exons
P01826043A0431|4 35|pp90rsk-protein kinase activity
P01826043A0431|52 62|rsk-kinase
P01826043A0431|106 140|signal transducing protein kinases
P01826043A0431|174 189|protein kinases
P01826043A0431|191 198|members
P01826043A0431|206 229|protein kinase C family
P01826043A0431|240 243|Ca2
P01826043A0431|257 272|protein kinases
P01827068T0000|6 12|GATA-3
P01827068T0000|35 55|transcription factor
P01827068T0000|75 85|expression
P01827068T0000|93 119|T cell receptor alpha gene
P01827203A0136|21 42|transcription factors
P01827203A0136|50 58|proteins
P01827203A0136|67 70|DNA
P01827203A0136|74 80|dimers
P01828248A0189|17 29|UvrA protein
P01828248A0189|49 61|UvrB protein
P01828248A0189|78 88|activities
P01828248A0189|98 106|solution
P01828248A0189|114 125|association
P01828248A0189|131 134|DNA
P01828248A0189|146 159|UvrAB complex
P01828248A0189|172 189|helicase activity
P01829060A0649|4 15|ED30 values
P01829060A0649|33 38|mg/kg
P01829060A0649|69 75|values
P01829060A0649|79 89|nifedipine
P01829060A0649|91 93|ED
P01829060A0649|105 110|mg/kg
P01829460A0329|0 26|Southwestern blot analysis
P01829460A0329|50 64|phosphoprotein
P01829460A0329|78 93|kappa B element
P01830114A1587|19 25|effect
P01830114A1587|29 32|NS1
P01830114A1587|53 59|levels
P01830114A1587|63 77|P4 transcripts
P01830114A1587|93 106|amplification
P01830114A1587|110 126|gene copy number
P01830114A1587|135 144|integrity
P01830114A1587|161 168|repeats
P01830928A0361|23 41|microtubule motors
P01830928A0361|47 54|dyneins
P01830928A0361|78 89|superfamily
P01830928A0361|110 118|proteins
P01830928A0361|133 151|attachment domains
P01832019A0265|77 84|animals
P01832019A0265|102 107|weeks
P01832152A0000|4 39|incompatibility group W plasmid pSa
P01832152A0000|51 89|Agrobacterium tumefaciens oncogenicity
P01832152A0000|91 93|J.
P01832152A0902|24 37|start signals
P01832152A0902|54 58|ORF1
P01832152A0902|63 67|ORF2
P01832197T0001|0 7|Imaging
P01832197T0001|11 31|D2 dopamine receptor
P01833185A0547|4 22|Thr161Val mutation
P01833185A0547|39 48|phenotype
P01833185A0547|56 69|fission yeast
P01833185A0547|103 114|replacement
P01833185A0547|118 124|Thr161
P01833185A0547|139 143|acid
P01833185A0547|167 182|phosphorylation
P01833185A0547|191 205|uncoordination
P01833185A0547|209 216|mitosis
P01833185A0547|230 241|cytokinesis
P01833637A0531|4 13|abundance
P01833637A0531|17 28|transcripts
P01833637A0531|52 57|genes
P01833637A0531|74 81|cdc68-1
P01833637A0531|89 94|cells
P01833637A0531|101 109|transfer
P01833637A0531|129 140|temperature
P01833637A0531|161 171|transcript
P01833637A0531|182 192|HSP82 gene
P01833637A0531|218 225|fashion
P01833716A0990|0 12|Deregulation
P01833716A0990|22 32|expression
P01833716A0990|61 75|transformation
P01833716A0990|92 108|HTLV-1 infection
P01837787T0000|11 22|Mov-34 gene
P01837787T0000|36 40|cDNA
P01837787T0000|53 65|organization
P01837842A1410|0 4|CREB
P01837842A1410|34 52|protein components
P01837842A1410|71 90|gel shift complexes
P01837842A1410|115 118|CRE
P01839414T0000|4 12|spectrum
P01839414T0000|51 60|neoplasms
P01839414T0000|64 69|Sabah
P01840513A1019|33 43|SL-2 cells
P01840513A1019|45 57|pCAT plasmid
P01840513A1019|75 77|bp
P01840513A1019|93 99|region
P01840513A1019|125 133|increase
P01840513A1019|137 179|chloramphenicol acetyltransferase activity
P01840513A1019|186 195|induction
P01840513A1019|210 214|acid
P01840513A1019|222 234|8-bromo-cAMP
P01840607A0294|29 33|UTRs
P01840607A0294|46 50|type
P01840607A0294|57 61|type
P01840607A0294|81 83|bp
P01840607A0294|126 129|PFP
P01840608A0823|4 14|N-terminus
P01840608A0823|31 44|reading frame
P01840608A0823|63 67|nifA
P01840608A0823|98 102|nifB
P01840608A0823|106 136|amino acid sequence comparison
P01840711A0000|4 14|RNA genome
P01840711A0000|18 24|rabbit
P01840711A0000|37 50|disease virus
P01840711A0000|52 56|RHDV
P01840902A1089|31 37|system
P01840902A1089|68 74|plants
P01840902A1089|113 132|transport machinery
P01840902A1089|147 155|monocots
P01840902A1089|160 166|dicots
P01842498A0000|8 18|cDNA clone
P01842498A0000|26 28|R2
P01842498A0000|57 70|hybridization
P01842498A0000|76 88|cDNA library
P01842498A0000|92 110|phytohemagglutinin
P01842498A0000|112 115|PHA
P01842498A0000|117 134|phorbol myristate
P01842498A0000|154 166|Jurkat cells
P01842498A0000|188 200|cDNA library
P01842498A0000|230 247|blood lymphocytes
P01842867A0696|3 13|conclusion
P01842867A0696|35 55|regeneration ability
P01842867A0696|77 83|injury
P01842867A0696|97 103|mucosa
P01844017A0410|24 36|relationship
P01844017A0410|49 53|drop
P01844017A0410|57 101|glucose-6-phosphatase dehydrogenase activity
P01844017A0410|109 124|vitamin E level
P01844017A0410|133 137|hand
P01844017A0410|147 155|duration
P01844017A0410|159 168|poisoning
P01844017A0410|174 188|sodium nitrite
P01844878A0000|2 8|vector
P01844878A0000|49 76|neomycin phosphotransferase
P01844878A0000|80 84|gene
P01844878A0000|104 122|promoter sequences
P01844878A0000|130 134|pool
P01844878A0000|153 166|DNA fragments
P01844982A0324|0 6|Chagas
P01844982A0324|8 15|disease
P01844982A0324|26 39|leishmaniasis
P01844982A0324|54 60|factor
P01844982A0324|62 77|schistosomiasis
P01844982A0324|90 96|factor
P01844982A0324|108 116|controls
P01845829A0158|9 17|analysis
P01845829A0158|31 39|sequence
P01845829A0158|79 86|domains
P01845829A0158|118 125|factors
P01845829A0158|143 154|brain cells
P01845885A1003|27 31|unit
P01845885A1003|44 48|UL26
P01845885A1003|75 82|protein
P01845885A1003|90 101|amino acids
P01845885A1003|115 121|family
P01845885A1003|125 133|proteins
P01845885A1003|159 163|mRNA
P01845885A1003|221 255|UL26 transcription initiation site
P01845885A1003|283 310|methionine initiation codon
P01845885A1003|322 330|position
P01845885A1003|344 348|UL26
P01845885A1003|365 369|unit
P01845899A0000|21 26|virus
P01845899A0000|28 31|AAV
P01845899A0000|33 41|rep gene
P01845899A0000|55 63|proteins
P01845899A0000|65 70|Rep78
P01845899A0000|72 77|Rep68
P01845899A0000|79 84|Rep52
P01845899A0000|90 95|Rep40
P01845899A0000|110 129|AAV DNA replication
P01845899A0000|134 153|AAV gene regulation
P01846206A0665|9 15|region
P01846206A0665|34 41|CMV dbp
P01846206A0665|56 67|replication
P01846206A0665|81 87|assays
P01846489A1119|40 55|protease domain
P01846489A1119|76 92|protease domains
P01846491A0459|22 31|positions
P01846491A0459|39 47|VV genes
P01846491A0459|49 68|genus Orthopoxvirus
P01846491A0459|116 120|ORFs
P01846491A0459|124 127|SFV
P01846491A0459|129 149|genus Leporipoxvirus
P01846491A0459|163 185|complex rearrangements
P01846491A0459|189 192|DNA
P01846491A0459|200 206|genome
P01846491A0459|231 238|viruses
P01846491A0459|259 269|divergence
P01846491A0459|284 292|ancestor
P01846803A0688|5 11|result
P01846803A0688|26 41|phosphorylation
P01846803A0688|45 48|Thr
P01846803A0688|59 62|Tyr
P01846803A0688|75 98|p34cdc2 kinase activity
P01846803A0688|103 107|line
P01846803A0688|117 125|location
P01846803A0688|135 143|residues
P01846803A0688|164 180|ATP binding site
P01846803A0688|188 194|kinase
P01847464A0856|14 29|cotransfections
P01847464A0856|33 49|pFRTK-CAT target
P01847464A0856|76 81|sites
P01847464A0856|91 101|EBV origin
P01847464A0856|105 124|plasmid replication
P01847464A0856|126 131|ori-P
P01847464A0856|174 193|EBNA-1 construction
P01847464A0856|195 206|amino acids
P01847464A0856|239 244|c-myc
P01847464A0856|253 272|localization signal
P01847665A1079|4 12|findings
P01847665A1079|37 41|idea
P01847665A1079|51 56|genes
P01847665A1079|66 80|PDGF receptors
P01847665A1079|84 96|glioma cells
P01847665A1079|114 121|concert
P01847665A1079|133 138|genes
P01847665A1079|144 154|expression
P01847665A1079|194 201|program
P01847665A1079|212 230|glia cell lineages
P01848300A0910|11 19|evidence
P01848300A0910|38 42|cstA
P01848300A0910|58 77|peptide utilization
P01848871A0392|5 10|study
P01848871A0392|22 32|hypothesis
P01848871A0392|38 52|sodium channel
P01848871A0392|62 67|drugs
P01848871A0392|97 106|potential
P01848871A0392|124 140|amplitude signal
P01848871A0392|142 149|portion
P01848871A0392|173 184|QRS complex
P01848871A0392|194 206|prolongation
P01848871A0392|219 228|potential
P01848871A0392|250 257|slowing
P01848871A0392|273 284|tachycardia
P01849509T0000|0 14|Identification
P01849509T0000|19 38|nucleotide sequence
P01849509T0000|42 85|Rhizobium meliloti insertion sequence ISRm3
P01849509T0000|87 97|similarity
P01849509T0000|119 130|transposase
P01849509T0000|142 147|ISRm3
P01849509T0000|191 196|IS256
P01849509T0000|201 231|Thiobacillus ferrooxidans IST2
P01849675A0167|17 29|relationship
P01849675A0167|39 46|viruses
P01849675A0167|61 73|DNA sequence
P01849675A0167|77 79|KV
P01849675A0167|99 101|bp
P01849734A1063|10 30|PR55 beta transcript
P01849734A1063|44 46|kb
P01849734A1063|68 74|levels
P01849734A1063|82 95|neuroblastoma
P01849734A1063|104 120|cell line LA-N-1
P01849734A1063|126 131|level
P01849734A1063|139 143|mRNA
P01849734A1063|176 186|cell lines
P01850096A0662|0 12|Heterodimers
P01850096A0662|16 24|myogenin
P01850096A0662|29 32|E12
P01850096A0662|37 41|MyoD
P01850096A0662|46 49|E12
P01850096A0662|72 92|restriction fragment
P01850096A0662|137 142|start
P01850096A0662|154 179|alpha-actin transcription
P01850105A1093|4 11|effects
P01850105A1093|15 20|c-myc
P01850105A1093|60 65|c-myc
P01850105A1093|78 93|differentiation
P01850105A1093|111 113|Id
P01850105A1093|126 135|regulator
P01850105A1093|139 161|muscle differentiation
P01850127A0000|7 18|association
P01850127A0000|22 30|U2 snRNP
P01850127A0000|40 60|branchpoint sequence
P01850127A0000|74 83|pre-mRNAs
P01850127A0000|93 100|binding
P01850127A0000|116 123|protein
P01850127A0000|131 151|polypyrimidine tract
P01850893A0286|19 29|antibodies
P01850893A0286|56 63|rabbits
P01850893A0286|83 88|farms
P01851386T0092|12 34|Lung Cancer Task Force
P01851386T0092|36 43|FONICAP
P01851527T0000|4 21|promoter activity
P01851527T0000|29 33|gene
P01851527T0000|43 83|Alzheimer beta-amyloid precursor protein
P01851527T0000|85 88|APP
P01851527T0000|110 116|blocks
P01851527T0000|129 138|sequences
P01851756A0743|0 4|Biol
P01851862A0273|0 20|Nucleotide sequences
P01851862A0273|33 41|env gene
P01851862A0273|50 53|LTR
P01851862A0273|57 62|SFV-1
P01851876A0129|5 12|element
P01851876A0129|35 46|EMBL3 mouse
P01851876A0129|55 62|library
P01852438A0928|4 13|MVV-value
P01852438A0928|37 42|level
P01852438A0928|50 54|case
P01852438A0928|64 71|percent
P01852603A0000|4 8|rad9
P01852603A0000|13 30|DNA repair mutant
P01852603A0000|40 53|fission yeast
P01852603A0000|103 105|UV
P01852603A0000|119 128|radiation
P01853796T0000|0 6|Review
P01853796T0000|8 21|deterioration
P01853796T0000|25 42|glucose tolerance
P01853796T0000|48 51|age
P01853796T0000|57 61|role
P01853796T0000|65 83|insulin resistance
P01854339A0221|7 13|region
P01854339A0221|27 46|sequence similarity
P01854339A0221|67 86|consensus promoters
P01854339A0221|108 117|sequences
P01854339A0221|134 140|levels
P01854339A0221|144 154|expression
P01855255T0000|10 20|initiation
P01855255T0000|24 31|mitosis
P01855255T0000|35 40|yeast
P01855255T0000|49 53|RCC1
P01855255T0000|72 78|GTPase
P01856021A0577|4 10|method
P01856021A0577|42 52|laboratory
P01856021A0577|59 63|year
P01856021A0577|96 105|procedure
P01856021A0577|125 132|control
P01856021A0577|149 157|exposure
P01856021A0577|161 168|toluene
P01856021A0577|176 182|xylene
P01857143A0351|4 11|patient
P01857143A0351|30 34|male
P01857143A0351|43 55|skin lesions
P01857143A0351|69 78|diagnosis
P01857143A0351|82 95|myelofibrosis
P01857326A0160|0 10|Oculus-500
P01857326A0160|16 21|group
P01857326A0160|30 55|resolution imaging boards
P01857326A0160|60 63|use
P01857326A0160|69 75|IBM-AT
P01857326A0160|91 100|computers
P01860846A0663|10 14|cDNA
P01860846A0663|44 71|tumor necrosis factor-alpha
P01860846A0663|96 121|MARCKS gene transcription
P01860846A0663|149 172|leukemia cell line HL60
P01861034A0798|6 15|resection
P01861034A0798|32 40|fragment
P01861034A0798|55 67|contact area
P01861034A0798|72 80|pressure
P01861034A0798|104 121|scaphoid fragment
P01861188A0000|0 12|Plate luting
P01861188A0000|16 25|technique
P01861188A0000|60 64|PMMA
P01861188A0000|89 94|plate
P01861188A0000|103 107|bone
P01861188A0000|132 143|screw heads
P01861188A0000|152 157|plate
P01861188A0000|174 183|stability
P01861188A0000|196 204|fixation
P01861188A0000|265 270|bones
P01861188A0000|291 302|osteotomies
P01861188A0000|330 353|ASIF compression plates
P01862027A0212|6 14|features
P01862027A0212|49 58|diagnosis
P01862027A0212|62 87|Rothmund-Thomson syndrome
P01862455T0000|0 16|Thyroid lymphoma
P01862455T0000|25 35|management
P01863768A0649|4 11|protein
P01863768A0649|23 29|ORF113
P01863768A0649|55 61|domain
P01863887A0174|0 17|Space limitations
P01863887A0174|40 46|review
P01863887A0174|63 78|pharmaceuticals
P01863887A0174|88 106|tissue plasminogen
P01863887A0174|118 127|substance
P01863887A0174|129 137|hormones
P01863887A0174|145 152|thyroid
P01863887A0174|154 161|insulin
P01863887A0174|163 177|growth hormone
P01863887A0174|179 193|erythropoietin
P01863887A0174|196 212|clotting factors
P01863887A0174|218 232|blood products
P01864510A0946|0 10|Dd PK1 RNA
P01864510A0946|29 30|h
P01864510A0946|34 44|starvation
P01864510A0946|71 76|cells
P01864821A0000|12 17|forms
P01864821A0000|28 40|cell disease
P01864821A0000|58 65|feature
P01864821A0000|81 93|globin chain
P01864821A0000|114 124|conditions
P01864821A0000|133 140|hypoxia
P01864821A0000|157 165|sickling
P01864821A0000|173 184|blood cells
P01864821A0000|189 200|obstruction
P01864821A0000|204 217|blood vessels
P01864837A1029|12 21|structure
P01864837A1029|43 51|proteins
P01864837A1029|64 74|% homology
P01864837A1029|88 104|mouse contrapsin
P01864837A1029|109 117|contrast
P01864837A1029|126 136|% homology
P01864837A1029|150 180|rat alpha 1-protease inhibitor
P01865010A0000|0 8|Patterns
P01865010A0000|12 23|connections
P01865010A0000|50 61|integration
P01865010A0000|116 123|tracers
P01865010A0000|125 136|Fluoro-Gold
P01865010A0000|141 150|diamidino
P01865010A0000|171 177|manner
P01865010A0000|201 216|representations
P01865010A0000|245 253|auditory
P01865010A0000|271 277|cortex
P01865010A0000|285 288|rat
P01867069A0000|6 15|CD-1 mice
P01867069A0000|19 23|days
P01867069A0000|43 61|% nicotine sulfate
P01867069A0000|77 81|days
P01867069A0000|116 120|pups
P01867069A0000|133 136|age
P01867069A0000|154 160|effect
P01867069A0000|168 179|development
P01867069A0000|200 206|molars
P01869565A1254|0 3|USF
P01869565A1254|31 44|transcription
P01869565A1254|49 67|translation system
P01869565A1254|86 98|ADH promoter
P01869565A1254|117 120|MLP
P01869907A2146|4 24|across-fiber pattern
P01869907A2146|32 41|responses
P01869907A2146|55 69|NaCl solutions
P01869907A2146|120 123|H2O
P01869907A2146|125 133|ABSTRACT
P01869907A2146|151 156|WORDS
P01869968A0000|9 30|radioactivity content
P01869968A0000|53 67|administration
P01869968A0000|71 76|HMPAO
P01869968A0000|92 100|subjects
P01869968A0673|7 26|regression analysis
P01869968A0673|59 65|result
P01869968A0673|80 89|clearance
P01869968A0673|91 96|HMPAO
P01869968A0673|114 118|rCBF
P01869968A0673|131 143|significance
P01869968A0673|145 146|p
P01870194A0302|6 33|immunodeficiency virus type
P01870194A0302|37 42|HIV-1
P01870194A0302|100 111|homogeneity
P01870428A0677|0 11|Thigh girth
P01870428A0677|39 42|HDL
P01870428A0677|47 53|HDL2-C
P01870428A0677|58 62|mass
P01870428A0677|73 90|LDL particle size
P01870428A0677|97 102|women
P01870500A0276|0 13|Contributions
P01870500A0276|19 24|pairs
P01870500A0276|28 34|source
P01870500A0276|39 61|target volume elements
P01870500A0276|81 89|S values
P01870500A0276|102 107|tumor
P01870500A0276|150 160|host organ
P01870500A0276|189 194|tumor
P01870500A0276|221 231|host organ
P01870500A0276|242 261|reciprocity theorem
P01871033A0434|0 5|Tests
P01871033A0434|29 39|impression
P01871033A0434|47 52|force
P01871033A0434|86 107|laboratory simulation
P01871033A0434|118 133|clearing cement
P01871033A0434|138 152|testing cement
P01871033A0434|179 185|method
P01871135A0295|4 8|cDNA
P01871135A0295|27 40|reading frame
P01871135A0295|49 51|bp
P01871135A0295|69 76|protein
P01871135A0295|84 95|amino acids
P01871135A0295|112 116|mass
P01871135A0295|123 126|kDa
P01871135A0295|133 140|protein
P01871135A0295|147 157|% identity
P01871135A0295|161 182|rat liver glucokinase
P01871971A0836|0 8|Analysis
P01871971A0836|18 25|mutants
P01871971A0836|56 65|NFIII/OCT
P01871971A0836|68 80|binding site
P01871971A0836|97 106|ATF motif
P01871971A0836|142 148|growth
P01872856A0277|0 8|Recovery
P01872856A0277|26 28|BA
P01872856A0277|37 42|urine
P01872856A0277|46 47|%
P01872856A0277|53 59|faeces
P01872856A0277|63 64|%
P01872856A0277|75 78|hrs
P01872856A0277|90 91|%
P01872856A0277|110 123|radioactivity
P01872856A0277|127 132|liver
P01872856A0277|137 143|testis
P01872856A0277|158 166|recovery
P01872856A0277|172 173|%
P01872856A0277|187 194|animals
P01873999A0000|56 68|model system
P01873999A0000|124 131|details
P01873999A0000|135 150|gene expression
P01873999A0000|159 176|secretion process
P01873999A0000|187 191|host
P01873999A0000|200 210|production
P01873999A0000|227 235|proteins
P01873999A0000|256 264|interest
P01874195A0139|28 39|GH receptor
P01874195A0139|52 57|liver
P01874195A0139|70 89|sequence similarity
P01874195A0139|93 102|receptors
P01874195A0139|114 144|signal transduction mechanisms
P01874195A0139|190 214|tyrosine kinase activity
P01874752A0948|47 66|conditions cdc2/p58
P01874752A0948|71 79|cdc2/p62
P01874752A0948|97 108|differences
P01874752A0948|128 136|activity
P01875922A0770|0 17|Mutation analysis
P01875922A0770|38 46|segments
P01875922A0770|70 76|region
P01875922A0770|111 117|effect
P01876836T0000|0 14|Identification
P01876836T0000|18 21|Ets
P01876836T0000|41 49|subunits
P01876836T0000|53 71|GA binding protein
P01878489A0959|14 22|response
P01878489A0959|26 37|neutrophils
P01878489A0959|42 51|monocytes
P01878489A0959|77 86|magnitude
P01878489A0959|94 116|NADPH oxidase activity
P01878489A0959|145 156|neutrophils
P01878489A0959|165 174|monocytes
P01878755A0496|7 12|ileum
P01878755A0496|14 25|enterotoxin
P01878755A0496|48 61|disappearance
P01878755A0496|63 64|P
P01878755A0496|96 112|blood appearance
P01878755A0496|114 115|P
P01878755A0496|136 147|chloroquine
P01881595A0476|0 8|Formalin
P01881595A0476|24 30|SNO NS
P01881595A0476|35 47|NnS neurones
P01881595A0476|75 86|NS neurones
P01881595A0476|88 89|n
P01881595A0476|117 122|phase
P01881595A0476|126 134|activity
P01881595A0476|141 153|NnS neurones
P01881595A0476|173 174|n
P01881595A0476|188 194|phases
P01881595A0476|196 197|n
P01881671T0001|0 6|Uptake
P01881671T0001|10 19|ofloxacin
P01882240A0526|21 30|attention
P01882240A0526|40 46|issues
P01882240A0526|77 84|quality
P01882240A0526|88 96|research
P01882240A0526|100 104|AIDS
P01882240A0526|113 122|behaviors
P01882240A0526|132 143|communities
P01882386A0000|4 17|effectiveness
P01882386A0000|21 40|alpha-mercapto-beta
P01882386A0000|42 49|2-furyl
P01882386A0000|58 62|acid
P01882386A0000|64 67|MFA
P01882386A0000|73 109|N-benzyl-N-dithiocarboxy-D-glucamine
P01882386A0000|111 114|NaB
P01882386A0000|125 136|combination
P01882386A0000|145 157|mobilization
P01882386A0000|162 171|excretion
P01882386A0000|175 179|lead
P01882386A0000|200 204|rats
P01883992A0922|6 13|results
P01883992A0922|27 33|beta-1
P01883992A0922|77 86|regulator
P01883992A0922|94 104|expression
P01883992A0922|112 126|beta-zein gene
P01883992A0922|141 156|maize endosperm
P01884435A0088|5 10|study
P01884435A0088|24 31|effects
P01884435A0088|35 46|hypovolemia
P01884435A0088|68 72|ptO2
P01884435A0088|77 94|ptH distributions
P01884435A0088|107 119|tissue sites
P01884435A0088|158 172|microelectrode
P01884435A0088|201 213|measurements
P01884435A0088|217 221|ptO2
P01884435A0088|226 229|ptH
P01884998A1135|4 11|members
P01884998A1135|51 64|transcription
P01884998A1135|70 79|promoters
P01884998A1135|109 113|site
P01885006A0995|4 11|domains
P01885006A0995|24 39|superactivation
P01885006A0995|55 61|subset
P01885006A0995|104 114|activation
P01885613A1298|0 11|Information
P01885613A1298|35 44|sequences
P01885613A1298|58 65|studies
P01885613A1298|73 83|regulation
P01885613A1298|91 100|pro alpha
P01885613A1298|107 120|collagen gene
P01885752A0198|0 21|Chlamydia trachomatis
P01885752A0198|26 44|Chlamydia psittaci
P01885752A0198|66 83|methanol fixation
P01885915A0000|15 25|infections
P01885915A0000|31 42|bacteraemia
P01885915A0000|50 71|Pasteurella multocida
P01885915A0000|90 102|endocarditis
P01885915A0000|119 133|P. haemolytica
P01886043A0380|4 7|SMX
P01886043A0380|11 13|pH
P01886043A0380|25 32|complex
P01886043A0380|51 53|pH
P01886043A0380|58 62|HPCD
P01886043A0380|74 80|effect
P01886043A0380|88 98|solubility
P01886043A0380|121 124|SMX
P01886043A0380|159 168|molecules
P01886043A0380|178 197|inclusion complexes
P01886043A0380|207 211|HPCD
P01886368A0000|0 16|PO2 measurements
P01886368A0000|42 69|recess type microelectrodes
P01886368A0000|97 107|nerve head
P01886368A0000|121 125|pigs
P01886368A0000|129 137|normoxia
P01886368A0000|142 151|hyperoxia
P01886774A0000|27 34|domains
P01886774A0000|38 42|Oct3
P01886774A0000|60 75|Echerichia coli
P01886774A0000|80 96|characterization
P01886774A0000|100 111|DNA binding
P01886774A0000|119 135|octamer sequence
P01888896A0505|2 17|deletion series
P01888896A0505|37 43|region
P01888896A0505|61 69|position
P01888896A0505|115 130|initiation site
P01888896A0505|168 175|tobacco
P01889753A0441|4 14|nucleotide
P01889753A0441|16 18|nt
P01889753A0441|20 29|sequences
P01889753A0441|37 42|exons
P01889753A0441|56 66|boundaries
P01889753A0441|95 102|regions
P01890362A0305|10 18|patients
P01890362A0305|47 64|eye complications
P01890362A0305|72 79|leprosy
P01890362A0305|84 92|patients
P01890362A0305|122 127|years
P01890989A1392|36 44|elements
P01890989A1392|65 83|estrogen induction
P01890989A1392|95 100|genes
P01890989A1392|104 112|chickens
P01890989A1392|117 127|amphibians
P01892680A0907|0 8|Toxicity
P01892680A0907|33 41|regimens
P01892680A0907|52 60|sedation
P01892680A0907|89 94|arm B
P01892680A0907|96 97|p
P01893195A0000|24 31|monkeys
P01893195A0000|40 48|hamsters
P01893195A0000|59 63|mice
P01893195A0000|68 75|authors
P01893195A0000|99 109|properties
P01893195A0000|119 134|virus Issyk-Kul
P01893927A0704|25 33|pressure
P01893927A0704|37 59|phenylephrine infusion
P01893927A0704|63 69|levels
P01893927A0704|100 103|NMA
P01893927A0704|108 111|NNA
P01893927A0704|130 140|reductions
P01893927A0704|152 158|output
P01894696A0301|0 2|J.
P01895358A0000|0 6|Limits
P01895358A0000|10 25|energy turnover
P01895358A0000|29 37|relation
P01895358A0000|50 61|performance
P01895358A0000|80 85|terms
P01895358A0000|105 110|limit
P01895358A0000|112 119|changes
P01895358A0000|129 147|training programme
P01895358A0000|168 182|energy balance
P01895358A0000|197 212|energy turnover
P01895370A0199|14 24|reductions
P01895370A0199|28 32|flow
P01895370A0199|38 42|peak
P01895370A0199|44 45|S
P01895370A0199|51 57|trough
P01895370A0199|59 60|D
P01895370A0199|62 68|points
P01895370A0199|76 110|maximum shifted-frequency envelope
P01895370A0199|119 127|parallel
P01895370A0199|140 147|fashion
P01895370A0199|154 155|D
P01895384A0746|4 20|IE0 gene product
P01895384A0746|45 57|IE1 promoter
P01895384A0746|77 87|expression
P01895384A0746|101 109|promoter
P01895393A0745|10 19|promoters
P01895393A0745|33 41|TATA box
P01895393A0745|49 56|absence
P01895393A0745|60 69|Sp1 sites
P01895393A0745|73 82|Sp1 sites
P01895393A0745|90 97|absence
P01895393A0745|103 111|TATA box
P01895393A0745|155 169|RNA polymerase
P01895393A0745|174 182|promoter
P01895555T0001|0 10|Evaluation
P01895555T0001|31 39|function
P01895555T0001|70 77|imaging
P01895555T0001|83 94|Tc-99m-MIBI
P01896777T0000|0 17|Ivermectin uptake
P01896777T0000|22 34|distribution
P01896777T0000|42 48|plasma
P01896777T0000|53 59|tissue
P01896777T0000|84 92|patients
P01896777T0000|107 126|Onchocerca volvulus
P01897515A0348|0 25|Bone marrow abnormalities
P01897515A0348|29 36|Hodgkin
P01897515A0348|39 46|disease
P01897515A0348|76 89|understanding
P01897515A0348|110 120|mechanisms
P01897515A0348|141 147|anemia
P01898113A0265|12 23|uptake rate
P01898113A0265|35 49|clearance rate
P01898113A0265|72 75|BCF
P01898113A0265|80 93|SWA killifish
P01898164A0839|37 43|repair
P01898164A0839|77 82|group
P01898164A0839|86 93|infants
P01898164A0839|117 121|arch
P01898164A0839|135 156|aorta diameter ratios
P01898164A0839|158 170|arch indices
P01898928A0260|0 26|DNA hybridization analysis
P01898928A0260|73 78|cells
P01898928A0260|82 84|Y.
P01898928A0260|102 111|DNA locus
P01898928A0260|147 155|fur gene
P01899209A0883|0 9|Increases
P01899209A0883|17 31|perfusate PCO2
P01899209A0883|47 58|perfusate H
P01899209A0883|88 97|decreases
P01899209A0883|117 130|contractility
P01899209A0883|135 153|oxygen consumption
P01899209A0883|155 157|r2
P01899287A0726|0 10|Expression
P01899287A0726|15 25|cell cycle
P01899287A0726|56 66|RNA levels
P01899287A0726|133 138|cells
P01899409T0000a|0 12|Determinants
P01899409T0000a|26 35|ischaemia
P01899409T0000a|40 68|revascularisation procedures
P01899409T0000a|75 87|thrombolysis
P01899409T0000a|105 133|tissue plasminogen activator
P01899409T0000a|154 163|occlusion
P01899846A0862|15 30|rbcL-rbcS locus
P01899846A0862|77 86|condition
P01899846A0862|108 114|growth
P01900194T0000|0 12|Relationship
P01900194T0000|35 60|NADH-ubiquinone reductase
P01900194T0000|90 101|hydrogenase
P01901405A0694|0 8|Analysis
P01901405A0694|12 27|mRNA expression
P01901405A0694|39 45|AT-BP1
P01901405A0694|50 56|AT-BP2
P01901405A0694|82 89|tissues
P01901443A0297|14 22|patients
P01901443A0297|33 54|maintenance valproate
P01901443A0297|81 92|hepatitis C
P01901443A0297|131 142|hepatitis C
P01901443A0297|175 184|steatosis
P01901443A0297|209 217|O stains
P01901664T0064|2 7|cases
P01901859A0000|0 7|UDP-Gal
P01901859A0000|8 16|Gal beta
P01901859A0000|22 35|4GlcNAc alpha
P01901859A0000|41 64|3-galactosyltransferase
P01901859A0000|79 98|glycosyltransferase
P01901859A0000|129 136|variety
P01901859A0000|150 157|species
P01901859A0000|176 185|exception
P01901859A0000|189 192|man
P01901859A0000|194 198|apes
P01901859A0000|204 221|Old World monkeys
P01901946A0243|12 27|oligonucleotide
P01901946A0243|43 55|SRE sequence
P01901946A0243|65 90|mouse c-fos gene promoter
P01901946A0243|143 148|probe
P01901946A0243|157 177|mobility shift assay
P01901946A0243|182 194|Southwestern
P01901946A0243|196 207|DNA-protein
P01901946A0243|209 217|blotting
P01901946A0243|255 278|affinity chromatography
P01901950T0000|0 21|Sequence requirements
P01901950T0000|36 56|transcription arrest
P01901950T0000|74 80|intron
P01901950T0000|88 104|mouse c-fos gene
P01903404A0688|17 34|ejection fraction
P01903404A0688|59 60|%
P01903404A0688|84 91|studies
P01903404A0688|117 123|artery
P01903404A0688|128 134|patent
P01903404A0688|153 154|%
P01903404A0688|175 176|p
P01903404A0688|187 194|changes
P01903404A0688|229 246|ejection fraction
P01903404A0688|276 292|perfusion status
P01903841A0125|11 26|lysine residues
P01903841A0125|42 52|spermidine
P01903841A0125|61 69|hypusine
P01903841A0125|91 103|modification
P01903841A0125|114 120|eIF-5A
P01903841A1449|4 29|plasmid shuffle technique
P01903841A1449|64 68|gene
P01903841A1449|85 89|form
P01903841A1449|104 111|failure
P01903841A1449|119 130|yeast cells
P01904154A0164|15 19|case
P01904154A0164|21 35|identification
P01904154A0164|40 56|characterization
P01904154A0164|60 71|transcripts
P01904154A0164|81 88|Ig loci
P01904154A0164|112 125|understanding
P01904154A0164|133 159|gene rearrangement process
P01904437A0000|0 13|Transcription
P01904437A0000|21 30|metH gene
P01904437A0000|109 126|metR gene product
P01904437A0000|130 149|DNA binding protein
P01904546A0671|0 10|Disruption
P01904546A0671|30 39|AAR1 gene
P01904546A0671|43 48|alpha
P01904546A0671|53 66|a/alpha cells
P01904546A0671|91 100|phenotype
P01904546A0671|110 126|a/alpha diploids
P01905199A0210|4 10|effect
P01905199A0210|14 22|ICRF-187
P01905199A0210|30 48|antitumor response
P01905199A0210|64 75|combination
P01905199A0210|79 82|ADR
P01905199A0210|87 90|WBH
P01905199A0210|116 121|order
P01905199A0210|132 143|alterations
P01905199A0210|163 168|index
P01905199A0210|198 216|modality treatment
P01905517A1076|4 7|ORF
P01905517A1076|46 54|features
P01905517A1076|64 83|sequence data bases
P01905517A1076|102 112|homologies
P01906111A1295|5 10|study
P01906111A1295|44 51|regimen
P01906111A1295|94 97|use
P01906111A1295|108 114|marrow
P01906111A1295|135 151|toxicity profile
P01906166A0119|0 11|Mitomycin-C
P01906166A0119|29 37|necrosis
P01906166A0119|42 52|ulceration
P01906166A0119|90 94|skin
P01906166A0119|104 111|tissues
P01906166A0119|125 144|drug administration
P01906509A0072|8 13|study
P01906509A0072|46 52|region
P01906509A0072|66 78|nidogen gene
P01906692A0321|0 13|INTERVENTIONS
P01906692A0321|15 23|Patients
P01906692A0321|33 38|rt-PA
P01906692A0321|40 47|heparin
P01906692A0321|53 60|aspirin
P01907265A0670|28 34|result
P01907265A0670|56 69|endonucleases
P01907265A0670|83 95|cell extract
P01907265A0670|126 147|DNA cleavage activity
P01907941A0275|14 28|I kappa B beta
P01907941A0275|38 53|I kappa B alpha
P01907941A0275|74 81|binding
P01907941A0275|85 88|Rel
P01907941A0275|96 108|kappa B site
P01909027A0922|0 17|Sequence analysis
P01909027A0922|35 53|DNA binding domain
P01909027A0922|57 60|ILF
P01909027A0922|72 80|homology
P01909027A0922|107 135|fork head DNA binding domain
P01909027A0922|169 186|protein fork head
P01909027A0922|193 199|family
P01909027A0922|203 213|hepatocyte
P01909027A0922|222 229|factors
P01909027A0922|231 236|HNF-3
P01909621A0119|21 33|hemodialyses
P01909621A0119|57 65|lithemia
P01909621A0119|78 84|ranges
P01909960A0134|14 23|injection
P01909960A0134|43 48|mg/kg
P01909960A0134|62 75|noradrenaline
P01909960A0134|77 79|NA
P01909960A0134|81 93|biosynthesis
P01909960A0134|105 106|%
P01909960A0134|127 140|concentration
P01909960A0134|144 159|normetanephrine
P01909960A0134|161 164|NMN
P01909960A0134|169 170|%
P01909960A0134|186 195|NA levels
P01909960A0134|199 200|%
P01910505A0000|7 25|wuzi yanzong pills
P01910505A0000|49 55|effect
P01910505A0000|59 75|cyclophosphamide
P01910505A0000|84 94|leukopenia
P01910505A0000|98 102|mice
P01911767T0000|0 9|Mutations
P01911767T0000|23 30|subunit
P01911767T0000|34 66|ribulosebisphosphate carboxylase
P01911767T0000|74 89|subunit binding
P01911767T0000|94 103|catalysis
P01913955A0177|15 22|changes
P01913955A0177|39 45|artery
P01913955A0177|70 78|increase
P01913955A0177|82 88|number
P01913955A0177|101 107|artery
P01913955A0177|123 138|muscularization
P01913955A0177|142 157|precursor cells
P01913955A0177|159 168|pericytes
P01913955A0177|186 191|cells
P01913955A0177|252 256|wall
P01913955A0177|267 278|muscle cell
P01913955A0177|298 302|wall
P01913955A0177|320 331|hypertrophy
P01913955A0177|336 347|hyperplasia
P01913955A0177|358 370|muscle cells
P01913955A0177|382 394|accumulation
P01913955A0177|406 412|amount
P01913955A0177|416 424|collagen
P01913955A0177|441 445|type
P01913955A0177|448 456|collagen
P01915580A0889|6 13|results
P01915580A0889|27 33|NZ-107
P01915580A0889|50 54|drug
P01915580A0889|63 72|treatment
P01915580A0889|86 92|asthma
P01915580A0889|116 132|airway responses
P01915580A0889|137 159|airway hyperreactivity
P01916168A0969|3 8|study
P01916168A0969|16 40|correlation coefficients
P01916168A0969|53 70|ISO2 measurements
P01916168A0969|87 99|ulcer margin
P01916168A0969|127 133|mucosa
P01916168A0969|139 149|delta ISO2
P01916168A0969|178 186|observer
P01916168A0969|208 216|learners
P01916405A0242|10 26|mucosa tattooing
P01916405A0242|30 37|persons
P01916405A0242|70 78|aerosols
P01916405A0242|101 106|forms
P01916405A0242|110 112|PC
P01916405A0242|114 116|DB
P01916405A0242|125 133|diseases
P01916405A0242|135 141|stages
P01916632A0431|9 19|production
P01916632A0431|23 27|PBMC
P01916632A0431|60 64|case
P01917943A0621a|0 17|Sequence analysis
P01917943A0621a|25 30|sMtCK
P01917943A0621a|48 57|sequences
P01917943A0621a|76 85|TATAA box
P01917943A0621a|100 110|base pairs
P01917943A0621a|112 114|bp
P01917943A0621a|125 149|transfection experiments
P01917943A0621a|177 187|expression
P01917943A0621a|200 208|plasmids
P01917943A0621a|218 260|chloramphenicol acetyltransferase reporter
P01917943A0621b|0 17|Sequence analysis
P01917943A0621b|25 30|sMtCK
P01917943A0621b|48 57|sequences
P01917943A0621b|76 85|TATAA box
P01917943A0621b|100 110|base pairs
P01917943A0621b|112 114|bp
P01917943A0621b|125 149|transfection experiments
P01917943A0621b|177 187|expression
P01917943A0621b|200 208|plasmids
P01917943A0621b|218 260|chloramphenicol acetyltransferase reporter
P01917962A0152|4 16|cDNA segment
P01917962A0152|35 85|immunoglobulin gene recombination signal sequences
P01917962A0152|98 110|cDNA segment
P01917962A0152|136 149|IL-2R L chain
P01917962A0152|186 193|control
P01917962A0152|201 214|SV40 promoter
P01918010A0000|0 18|Lipoprotein lipase
P01918010A0000|20 23|LPL
P01918010A0000|32 38|enzyme
P01918010A0000|49 71|lipoprotein metabolism
P01918010A0000|87 94|pattern
P01918010A0000|98 108|regulation
P01918010A0000|129 139|expression
P01918010A1730|0 8|Deletion
P01918010A1730|25 45|octanucleotide motif
P01918010A1730|55 62|plasmid
P01918010A1730|83 91|fragment
P01918010A1730|99 111|LPL promoter
P01918010A1730|136 146|% decrease
P01918010A1730|154 159|level
P01918010A1730|163 173|expression
P01918010A1730|189 206|3T3-L1 adipocytes
P01918010A1730|211 228|HepG2 hepatocytes
P01918070A0281|16 23|binding
P01918070A0281|36 53|T3 receptor alpha
P01918070A0281|55 64|T3R alpha
P01918070A0281|131 140|mutations
P01918070A0281|148 156|rGH T3RE
P01918070A0281|193 200|potency
P01918070A0281|217 224|changes
P01918070A0281|228 239|T3R binding
P01918073A0150|0 10|Comparison
P01918073A0150|39 70|TnIcardiac amino acid sequences
P01918073A0150|82 95|TnI sequences
P01918073A0150|118 126|presence
P01918073A0150|144 162|extension sequence
P01918073A0150|179 223|protein kinase A phosphorylation target site
P01918073A0150|253 260|segment
P01918073A0150|292 299|feature
P01918073A0150|303 306|TnI
P01918073A0150|354 364|divergence
P01918073A0150|406 416|troponin C
P01918073A0150|418 421|TnC
P01918073A0150|431 444|site sequence
P01918073A0150|470 480|adaptation
P01918073A0150|484 487|TnI
P01918073A0150|492 495|TnC
P01918073A0150|519 529|TnIcardiac
P01918073A0150|539 556|actin/TnC-binding
P01918073A0150|558 579|actomyosin-inhibitory
P01918073A0150|581 587|domain
P01918073A0150|606 625|sequence divergence
P01918073A0150|641 661|TnIcardiac sequences
P01918073A0150|677 684|absence
P01918073A0150|690 718|protein kinase C target site
P01918073A0150|747 754|feature
P01918073A0150|758 761|TnI
P01918073A0150|765 772|mammals
P01919831T0000|12 31|management casebook
P01921463T0000|3 20|ASSEMBLER routine
P01921463T0000|41 48|display
P01921463T0000|53 62|averaging
P01921463T0000|66 70|data
P01921463T0000|94 107|microcomputer
P01922082A0149|0 10|Expression
P01922082A0149|18 37|mouse TSH beta gene
P01922082A0149|56 60|rise
P01922082A0149|73 78|mRNAs
P01922082A0149|115 121|region
P01922734T0000|0 11|Habituation
P01922734T0000|35 42|neurons
P01922734T0000|57 62|snail
P01922734T0000|77 88|stimulation
P01922739A0336|22 26|ROSP
P01922739A0336|39 45|number
P01922739A0336|49 61|fluctuations
P01922739A0336|91 101|directions
P01922739A0336|130 139|amplitude
P01922739A0336|147 153|course
P01922739A0336|162 166|days
P01922739A0336|181 190|operation
P01922739A0336|231 237|values
P01922739A0336|245 249|ROSP
P01922739A0336|273 280|average
P01922739A0336|284 294|electrodes
P01922739A0336|312 317|level
P01922739A0336|325 335|dura mater
P01922739A0336|350 356|values
P01922739A0336|360 370|electrodes
P01922739A0336|388 393|level
P01922739A0336|401 410|pia mater
P01923167A0000|0 29|Blood flow velocity waveforms
P01923167A0000|54 73|Doppler examination
P01923167A0000|96 103|carotid
P01923167A0000|124 132|arteries
P01923167A0000|170 175|route
P01923167A0000|206 214|approach
P01923628T0001|13 21|analysis
P01923628T0001|25 28|DNA
P01923628T0001|35 49|flow cytometry
P01923628T0001|73 81|findings
P01923628T0001|88 93|cases
P01923628T0001|105 112|myxomas
P01923766A0485|0 17|Sequence analysis
P01923766A0485|35 43|addition
P01923766A0485|63 70|variant
P01923766A0485|81 93|mRNA species
P01923766A0485|124 132|splicing
P01923766A0485|150 159|exclusion
P01923766A0485|189 200|nucleotides
P01923766A0485|202 204|nt
P01923766A0485|226 230|exon
P01923803A0609|0 8|Position
P01923803A0609|18 28|isoleucine
P01923803A0609|45 68|SsoL12 protein sequence
P01923803A0609|82 91|AUA codon
P01923985A0111|0 8|Symptoms
P01923985A0111|20 26|action
P01923985A0111|30 49|mastocyte mediators
P01924315A0158|7 12|yeast
P01924315A0158|39 52|copper levels
P01924315A0158|64 71|control
P01924315A0158|81 86|level
P01924315A0158|90 105|SOD1 expression
P01924920A0115|13 20|samples
P01924920A0115|22 35|Mobiluncus SP
P01924920A0115|60 61|%
P01924920A0115|69 82|Gram staining
P01924920A0115|98 99|%
P01924920A0115|106 119|microorganism
P01924920A0115|136 144|agar RLK
P01924920A0115|159 169|atmosphere
P01925092A0000|9 22|investigators
P01925092A0000|54 59|blood
P01925092A0000|72 78|retina
P01925092A0000|82 86|part
P01925092A0000|115 123|meshwork
P01925092A0304|12 17|hours
P01925092A0304|29 36|animals
P01925092A0304|67 76|treatment
P01925092A0304|86 96|micrograms
P01925092A0304|100 128|tissue plasminogen activator
P01925092A0304|142 148|volume
P01925092A0304|164 170|saline
P01927421A0181|17 29|examinations
P01927421A0181|60 69|nystagmus
P01927421A0181|86 95|nystagmus
P01927421A0181|108 117|nystagmus
P01927845A0107|10 20|morphology
P01927845A0107|28 35|lesions
P01927845A0107|70 79|disorders
P01927845A0107|81 86|Bowen
P01927845A0107|89 96|disease
P01928923A0000|0 13|Equine amnion
P01928923A0000|23 44|yeast cell derivative
P01928923A0000|102 118|wound medicament
P01928923A0000|140 149|treatment
P01928923A0000|165 171|wounds
P01928923A0000|186 193|portion
P01928923A0000|201 206|limbs
P01928923A0000|210 216|horses
P01930470A0337|26 35|incidence
P01930470A0337|52 55|PTH
P01930470A0337|70 90|American Association
P01930470A0337|94 105|Blood Banks
P01930470A0337|107 111|AABB
P01930470A0337|125 132|testing
P01930470A0337|170 177|markers
P01930470A0337|193 198|units
P01930470A0337|202 207|blood
P01930660T0000|13 26|growth factor
P01930660T0000|30 35|IGF-1
P01930660T0000|45 53|patients
P01931966A0490|0 6|Fusion
P01931966A0490|10 19|ubiquitin
P01931966A0490|23 29|pADPRP
P01931966A0490|44 49|yield
P01931966A0490|53 59|pADPRP
P01931966A0490|114 120|enzyme
P01932650A0435|3 8|group
P01932650A0435|14 22|patients
P01932650A0435|59 73|drainage blood
P01932650A0435|86 91|hours
P01932650A0435|98 107|operation
P01932650A0435|115 128|concentration
P01932650A0435|146 150|MBRS
P01932695A1155|4 15|suppression
P01932695A1155|53 69|expression assay
P01932695A1155|93 110|barley endosperms
P01933614A0406|4 10|effect
P01933614A0406|14 31|salmon calcitonin
P01933614A0406|38 43|spray
P01933614A0406|47 52|women
P01933614A0406|70 82|osteoporosis
P01934378A1219|9 40|muscle metaboreceptor responses
P01934378A1219|57 70|heart failure
P01934378T0000|9 49|muscle metaboreceptor exercise responses
P01934378T0000|68 81|heart failure
P01936213T0000|0 10|Evaluation
P01936213T0000|28 39|drug effect
P01936213T0000|43 60|membrane fluidity
P01936348A0155|4 16|examinations
P01936348A0155|39 45|groups
P01936348A0155|59 67|AmF/SnF2
P01936348A0155|71 75|resp
P01936997A0795|0 19|RNA gel retardation
P01936997A0795|24 44|competition analyses
P01936997A0795|59 74|TRP-185 binding
P01936997A0795|104 126|TAR RNA loop sequences
P01937790A0292|4 11|vaccine
P01937790A0292|55 63|children
P01937790A0292|68 74|adults
P01937989A0383|5 11|groups
P01937989A0383|36 45|induction
P01937989A0383|65 69|test
P01937989A0383|77 79|R2
P01938178T0000|0 12|Applications
P01938178T0000|34 42|analysis
P01938178T0000|59 63|P300
P01939131A0871|4 13|construct
P01939131A0871|34 40|BW2001
P01939131A0871|42 48|xth-11
P01939131A0871|50 55|nfo-2
P01939131A0871|57 69|strain cells
P01939199A0588|18 23|TFIID
P01939199A0588|45 58|transcription
P01939199A0588|83 91|extracts
P01939199A0588|121 135|TFIID fraction
P01939199A0588|141 151|HeLa cells
P01939199A0588|176 181|level
P01939199A0588|185 198|transcription
P01939827A0150|13 25|pretreatment
P01939827A0150|50 69|oxide surface layer
P01939827A0150|74 89|titanium powder
P01939827A0150|114 127|precipitation
P01939827A0150|133 142|solutions
P01939827A0150|156 168|mmol/L CaCl2
P01939827A0150|172 185|mmol/L KH2PO4
P01939827A0150|190 202|mmol/L Hepes
P01939827A0150|204 206|pH
P01939827A0150|226 239|precipitation
P01939827A0150|256 265|solutions
P01939827A0150|281 293|mmol/L CaCl2
P01939827A0150|299 312|mmol/L KH2PO4
P01939827A0150|317 329|mmol/L Hepes
P01939827A0150|331 333|pH
P01939827A0150|345 355|degrees C.
P01939878A0765|17 31|solidification
P01939878A0765|68 74|casein
P01939878A0765|126 134|patients
P01939878A0765|158 165|acidity
P01939899A2043|8 13|model
P01939899A2043|51 58|account
P01939899A2043|66 73|effects
P01939899A2043|86 95|variables
P01939899A2043|99 105|number
P01939899A2043|109 114|tones
P01939899A2043|119 125|amount
P01939899A2043|129 141|perturbation
P01939899A2043|143 151|ABSTRACT
P01939899A2043|169 174|WORDS
P01939906A0233|5 19|generalization
P01939906A0233|23 26|MFP
P01939906A0233|76 89|cost function
P01939906A0233|109 121|search space
P01939906A0233|129 140|environment
P01939906A0233|145 151|source
P01939906A0233|166 175|solutions
P01939906A0233|183 196|wave equation
P01939906A0233|224 243|optimization method
P01939906A0233|258 277|parameter landscape
P01939906A0233|293 300|minimum
P01939906A0233|308 321|cost function
P01942033T0000|0 13|Determination
P01942033T0000|20 33|RNA structure
P01942033T0000|46 65|splicing inhibition
P01942033T0000|87 91|exon
P01943184A1050|12 17|cells
P01943184A1050|30 40|University
P01943184A1050|44 62|Wisconsin solution
P01943184A1050|72 78|trypan
P01943184A1050|95 96|%
P01943184A1050|104 111|% cells
P01943184A1050|121 122|p
P01945430A0660|13 22|technique
P01945430A0660|72 81|ear fluid
P01945430A0660|98 107|procedure
P01945430A0660|126 140|labyrinthotomy
P01945430A0660|154 170|neuroma suspects
P01947449A0191|4 10|effect
P01947449A0191|14 34|diffusion limitation
P01947449A0191|53 58|terms
P01947449A0191|66 71|ratio
P01947449A0191|75 96|uptake/O2 requirement
P01947449A0191|100 108|fraction
P01947449A0191|128 132|area
P01947449A0191|170 181|requirement
P01947449A0191|186 197|unit volume
P01947449A0191|232 235|PO2
P01947449A0191|239 242|PO2
P01947449A1082|4 24|Diffusion limitation
P01947449A1082|46 56|model sets
P01947449A1082|74 91|requirement value
P01947449A1082|141 152|requirement
P01947449A1082|192 198|models
P01947449A1082|221 238|cylinder diameter
P01948783A0000|21 27|effect
P01948783A0000|31 38|Estulic
P01948783A0000|73 79|period
P01948783A0000|100 108|patients
P01952827A0215|7 11|time
P01952827A0215|19 26|seizure
P01952827A0215|32 39|patient
P01952827A0215|60 71|test phrase
P01954355A0997|0 19|Monitoring patients
P01954355A0997|31 39|leukemia
P01954355A0997|44 48|IL-1
P01954355A0997|53 63|TNF levels
P01954355A0997|88 94|course
P01954355A0997|98 105|disease
P01954355A0997|127 133|causes
P01954355A0997|145 153|episodes
P01954835A0000|0 23|Echinococcus granulosus
P01954835A0000|53 72|aspiration cytology
P01954835A0000|78 87|lung cyst
P01954835A0000|108 114|female
P01954835A0000|126 134|Missouri
P01956285A0000|4 12|sequence
P01956285A0000|36 47|nucleotides
P01956285A0000|65 74|bet genes
P01956285A0000|127 158|choline-glycine betaine pathway
P01956491A0095|8 17|treatment
P01956491A0095|21 35|amphotericin B
P01956491A0095|39 48|mg/kg/day
P01956491A0095|92 107|filtration rate
P01956491A0095|109 112|GFR
P01956491A0095|134 143|clearance
P01956491A0095|148 168|creatinine clearance
P01956491A0095|202 208|ml/min
P01956491A0095|227 237|comparison
P01956491A0095|257 261|rats
P01956491A0095|295 301|ml/min
P01958368A0556|0 9|Evolution
P01958368A0556|13 20|lesions
P01958368A0556|58 69|progression
P01958368A0556|88 94|stages
P01958368A0556|102 128|vitelliform classification
P01958821T0000|9 32|fluorescence microscopy
P01958821T0000|43 55|cell biology
P01960974A0000|0 7|Toluene
P01960974A0000|15 23|chemical
P01960974A0000|51 56|cases
P01960974A0000|76 84|solvents
P01961213A0150|27 37|HCB-levels
P01961213A0150|51 62|breast milk
P01961213A0150|79 84|years
P01961747A0000|2 33|herpesvirus proteinase activity
P01961747A0000|102 108|enzyme
P01961747A0000|113 128|substrate genes
P01961747A0000|142 161|transfection assays
P01961996A0522|0 7|Adult H
P01961996A0522|17 18|R
P01961996A0522|45 55|preference
P01961996A0522|77 88|opportunity
P01963419A0501|9 30|silver liquid chamber
P01963419A0501|57 68|MeV protons
P01963419A0501|72 77|water
P01963419A0501|113 116|13N
P01963419A0501|124 127|16O
P01963419A0501|128 129|p
P01963419A0501|131 136|alpha
P01963419A0501|137 149|13N reaction
P01963419A0501|154 157|18F
P01963419A0501|158 170|fluoride ion
P01963419A0501|178 181|18O
P01963419A0501|182 183|p
P01963419A0501|185 186|n
P01963419A0501|187 199|18F reaction
P01963438T0000|14 31|electron transfer
P01963438T0000|35 47|cytochrome c
P01963438T0000|63 74|polypyrrole
P01963438T0000|79 88|methylene
P01963438T0000|94 110|polypyrrole film
P01963438T0000|120 130|electrodes
P01963858T0001|10 20|activation
P01963858T0001|24 44|adrenaline secretion
P01963858T0001|52 55|rat
P01963858T0001|67 82|neuroglycopenia
P01963858T0001|96 109|microdialysis
P01964989A0145|0 15|Urine specimens
P01964989A0145|34 47|phencyclidine
P01964989A0145|49 52|PCP
P01964989A0145|106 110|acid
P01964989A0145|112 122|9-THC-COOH
P01964989A0145|146 161|sodium chloride
P01964989A0145|163 169|bleach
P01964989A0145|171 178|vinegar
P01964989A0145|180 199|potassium hydroxide
P01964989A0145|208 212|soap
P01964989A0145|214 224|2-propanol
P01964989A0145|230 237|ammonia
P01967130A0645|14 28|pair EFIA cDNA
P01967130A0645|49 61|acid protein
P01967130A0645|122 142|DNA binding proteins
P01968043A0908|23 34|cDNA clones
P01968043A0908|66 72|insert
P01968043A0908|74 80|pASB-1
P01968043A0908|104 116|orientations
P01968061A0371|0 3|Sci
P01968156T0000|0 20|Dose standardisation
P01968156T0000|24 39|botulinum toxin
P01968224A0119|4 19|coding sequence
P01968224A0119|41 60|residue polypeptide
P01968224A0119|95 101|intron
P01968224A0119|108 118|base pairs
P01968224A0119|120 122|bp
P01968224A0119|137 138|%
P01968224A0119|154 173|amino acid sequence
P01968224A0119|192 196|PCNA
P01968224A0119|218 221|rat
P01968224A0119|232 249|PCNA polypeptides
P01968224A0119|273 280|repeats
P01968224A0119|284 291|leucine
P01968224A0119|310 316|region
P01970560A1024|14 21|fusions
P01970560A1024|29 33|aroF
P01970560A1024|45 52|regions
P01970560A1024|56 60|lacZ
P01970560A1024|108 112|copy
P01970560A1024|130 140|chromosome
P01970560A1024|142 167|beta-Galactosidase assays
P01970560A1024|186 196|regulation
P01970560A1024|200 220|aroF-lacZ expression
P01970560A1024|247 261|TyrR repressor
P01970560A1024|288 297|operators
P01970560A1024|306 315|organisms
P01970560A1024|333 343|efficiency
P01970801A0925|29 34|genes
P01970801A0925|45 49|Ly-1
P01970801A0925|54 58|CD20
P01970801A0925|60 64|OSBP
P01970801A0925|98 103|group
P01970801A0925|116 119|arm
P01970801A0925|123 133|chromosome
P01970801A0925|167 170|end
P01970801A0925|174 184|chromosome
P01970801A0925|195 200|mouse
P01970926A0000|7 17|exercise K
P01970926A0000|48 54|muscle
P01970926A0000|59 67|plasma K
P01970926A0000|69 88|concentration rises
P01970984A0668|10 19|treatment
P01970984A0668|21 43|serum estradiol levels
P01970984A0668|59 67|groups E
P01970984A0668|70 71|T
P01970984A0668|76 77|E
P01970984A0668|86 94|group C.
P01971191A1271|37 44|agonist
P01971191A1271|46 59|isoproterenol
P01971191A1271|72 81|influence
P01971191A1271|94 105|capacitance
P01971191A1271|109 121|liver volume
P01971191A1271|125 129|dogs
P01971191A1271|150 168|outflow resistance
P01971191A1271|184 190|agents
P01971191A1271|199 208|histamine
P01972379T0042|0 12|DNA sequence
P01972379T0042|17 26|evolution
P01972379T0042|34 44|CPS domain
P01972379T0042|59 66|hamster
P01972379T0042|83 94|protein CAD
P01973384A0206|34 47|binding sites
P01973384A0206|84 91|ability
P01973384A0206|103 116|transcription
P01973384A0206|145 152|embryos
P01974550A0362|16 19|CBF
P01974550A0362|37 58|hexamethonium bromide
P01974550A0362|62 70|mg/kg iv
P01974550A0362|73 92|ipratropium bromide
P01974550A0362|98 113|microgram/kg iv
P01974550A0362|116 128|indomethacin
P01974550A0362|132 140|mg/kg iv
P01974550A0362|161 169|% saline
P01974876A1051|17 57|restriction fragment length polymorphism
P01974876A1051|77 80|DNA
P01974876A1051|99 110|individuals
P01974876A1051|121 133|enzyme BglII
P01975157A0836|12 26|transformation
P01975157A0836|30 32|pH
P01975157A0836|53 60|results
P01975428A0151|0 9|Telomeres
P01975428A0151|29 36|fusions
P01975428A0151|56 67|degradation
P01975428A0151|80 83|end
P01975428A0151|98 110|DNA molecule
P01975428A0151|129 137|function
P01975428A0151|141 154|cell division
P01976638A1135|47 53|region
P01976638A1135|81 90|sequences
P01977585A0222|11 17|enzyme
P01977585A0222|70 75|cells
P01977585A0222|121 129|subunits
P01977585A0222|153 167|protein kinase
P01977856A1036|5 10|study
P01977856A1036|25 30|BSPMs
P01977856A1036|49 59|assessment
P01977856A1036|63 66|AMI
P01977856A1036|70 75|terms
P01977856A1036|79 88|diagnosis
P01977856A1036|90 98|location
P01977856A1036|103 109|extent
P01977856A1036|124 131|infarct
P01978834A0076|9 42|abomasum lambda gt11 cDNA library
P01978834A0076|74 82|antibody
P01978834A0076|102 132|rabbit H,K-ATPase beta subunit
P01978857A0504|10 13|use
P01978857A0504|17 35|laboratory testing
P01978857A0504|47 57|monitoring
P01978857A0504|61 76|CD4 cell counts
P01982061A0615|12 20|TATA box
P01982061A0615|60 89|transcription initiation site
P01982061T0000|0 16|Characterization
P01982061T0000|27 30|end
P01982061T0000|62 78|hamster CAD gene
P01982190T0001|6 15|cirrhosis
P01982190T0001|26 34|modality
P01982190T0001|42 51|evolution
P01982190T0001|61 70|hepatitis
P01982997A1104|0 11|Examination
P01982997A1104|31 62|transcription factor expression
P01982997A1104|74 85|MDI regimen
P01982997A1104|100 102|RA
P01982997A1104|135 145|expression
P01982997A1104|149 159|c-Jun mRNA
P01982997A1104|186 196|expression
P01982997A1104|200 205|c-Fos
P01982997A1104|210 221|Jun-B mRNAs
P01983026A0483|9 19|heart rate
P01983026A0483|34 42|pressure
P01983026A0483|56 62|degree
P01983026A0483|65 68|min
P01983026A0483|75 85|intubation
P01983026A0483|102 119|CA concentrations
P01983026A0483|144 156|study period
P01984665T0000|0 10|Processing
P01984665T0000|12 21|secretion
P01984665T0000|27 43|immunoreactivity
P01984665T0000|47 54|carboxy
P01984665T0000|76 108|dengue-2 virus envelope proteins
P01984665T0000|129 134|cells
P01984665T0000|150 163|baculoviruses
P01985301T0000|9 16|therapy
P01985301T0000|22 28|MK-801
P01985301T0000|33 43|nimodipine
P01985301T0000|48 58|protection
P01985301T0000|71 83|brain damage
P01985920A0156|8 17|screening
P01985920A0156|23 45|rat liver cDNA library
P01985920A0156|54 75|oligonucleotide probe
P01985920A0156|93 118|rat SCP2 protein sequence
P01985920A0156|140 155|pair cDNA clone
P01985920A0156|180 201|SCP2 protein sequence
P01985920T0000|0 7|Cloning
P01985920T0000|9 19|expression
P01985920T0000|25 44|nucleotide sequence
P01985920T0000|48 80|rat liver sterol carrier protein
P01985920T0000|83 88|cDNAs
P01985924A0554|4 12|addition
P01985924A0554|29 36|complex
P01985924A0554|71 79|subunits
P01985924A0554|95 98|pol
P01985924A0554|102 112|holoenzyme
P01985924A0554|129 143|chromatography
P01985924A0554|151 159|presence
P01985924A0554|163 167|urea
P01985924A0554|196 215|initiation activity
P01985924A0554|219 222|pol
P01985924A0554|226 231|delta
P01986225A0250|19 33|identification
P01986225A0250|37 40|HSF
P01986225A0250|48 61|fission yeast
P01986241A0117|0 9|Induction
P01986241A0117|23 40|ACE1 gene product
P01986241A0117|66 71|sites
P01986241A0117|79 94|promoter region
P01986241A0117|102 111|CUP1 gene
P01986254A0452|0 25|Gel mobility shift assays
P01986254A0452|44 52|E6 motif
P01986254A0452|80 87|complex
P01986254A0452|91 99|addition
P01986254A0452|116 120|band
P01986254A0452|135 142|T cells
P01986254A0452|147 157|HeLa cells
P01986360A0000|6 12|clones
P01986360A0000|22 65|interferon response element binding factors
P01986360A0000|92 133|mouse fibroblast lambda gt11 cDNA library
P01986360A0000|145 148|32P
P01986360A0000|168 174|trimer
P01986360A0000|182 187|mouse
P01986360A0000|195 253|oligoadenylate synthetase gene interferon response element
P01986360A0000|259 264|probe
P01988041A0281|4 12|sequence
P01988041A0281|21 27|clones
P01988041A0281|66 84|BAL cDNA structure
P01989561A0100|4 15|application
P01989561A0100|25 36|instruments
P01989561A0100|44 53|occlusion
P01989561A0100|71 76|aorta
P01989561A0100|94 111|perfusion cannula
P01989561A0100|145 149|apex
P01989561A0100|157 162|heart
P01989561A0100|204 211|venting
P01989999A0000|17 27|synthetase
P01989999A0000|29 32|IMP
P01989999A0000|33 51|L-aspartate ligase
P01989999A0000|53 56|GDP
P01989999A0000|59 61|EC
P01989999A0000|90 94|role
P01989999A0000|98 117|purine biosynthesis
P01989999A0000|147 157|conversion
P01989999A0000|161 164|IMP
P01989999A0000|168 171|AMP
P01990254A0791|0 17|Immunophenotyping
P01990254A0791|26 31|cases
P01990254A0791|59 70|cell origin
P01990254A0791|90 101|cell origin
P01990266A0678|12 36|UV cross-linking studies
P01990266A0678|52 57|UHF-1
P01990266A0678|81 89|mobility
P01990266A0678|93 107|sodium dodecyl
P01990266A0678|127 131|gels
P01990266A0678|152 155|kDa
P01990266A0678|186 194|proteins
P01990266A0678|213 221|promoter
P01990266A0678|236 240|site
P01991521A0481|4 11|results
P01991521A0481|27 37|conclusion
P01991521A0481|65 73|activity
P01991521A0481|88 98|G4 content
P01991521A0481|125 132|muscles
P01992459A0000|13 24|interaction
P01992459A0000|54 61|element
P01992459A0000|75 102|immunodeficiency virus mRNA
P01992459A0000|104 107|RRE
P01992459A0000|113 133|Rev response element
P01992459A0000|157 168|protein Rev
P01992459A0000|196 206|regulation
P01992459A0000|214 220|export
P01992459A0000|252 256|mRNA
P01992459A0000|266 273|nucleus
P01992459A0000|281 290|cytoplasm
P01992742A0000|16 23|records
P01992742A0000|31 39|patients
P01992742A0000|51 59|neuritis
P01992742A0000|88 94|period
P01992953A0247|8 14|levels
P01992953A0247|27 38|abnormality
P01992953A0247|83 94|specificity
P01992953A0247|102 106|test
P01992953A0247|129 137|patients
P01992953T0000|0 24|Alanine aminotransferase
P01992953T0000|37 45|practice
P01993181T0000|0 28|Nucleotide sequence analysis
P01993181T0000|55 87|PpG7 salicylate hydroxylase gene
P01993181T0000|89 93|nahG
P01993181T0000|115 121|region
P01993656A1860|8 17|ARF cDNAs
P01993656A1860|84 91|guanine
P01993656A1860|111 119|proteins
P01995951A0000|18 24|repeat
P01995951A0000|26 29|LTR
P01995951A0000|44 66|immunodeficiency virus
P01995951A0000|68 71|HIV
P01995951A0000|96 101|sites
P01995951A0000|126 136|factor Sp1
P01996312A0454|0 3|DNA
P01996312A0454|9 12|PCR
P01996312A0454|53 76|lambda gt11 cDNA clones
P01996312A0454|109 120|Dd kinase-2
P01997465A0276|18 25|changes
P01997465A0276|33 37|area
P01997465A0276|41 48|alveoli
P01997465A0276|53 58|septa
P01997465A0276|70 86|collagen content
P01997465A0276|100 105|weeks
P01997465A0276|112 123|irradiation
P01999035A0383|10 19|follow-up
P01999035A0383|45 53|interval
P01999035A0383|61 66|years
P01999035A0383|70 80|Caerphilly
P01999035A0383|89 94|years
P01999035A0383|98 107|Speedwell
P01999035A0383|119 129|IHD events
P01999459A0795|0 2|A.
P01999999T0001|10 18|luxation
P01999999T0001|31 37|injury
P01999999T0001|70 79|treatment
P02000093A0794|0 9|Landsberg
P02000093A0794|11 15|La-O
P02000093A0794|21 23|cv
P02001033A1907|3 10|summary
P02001033A1907|30 44|concentrations
P02001033A1907|46 56|desflurane
P02001033A1907|61 71|isoflurane
P02001033A1907|101 108|effects
P02001033A1907|126 133|absence
P02001033A1907|137 142|drugs
P02001033A1907|166 174|reflexes
P02001033A1907|176 186|desflurane
P02001033A1907|215 223|activity
P02001033A1907|242 250|decrease
P02001033A1907|263 271|pressure
P02002051A0276|19 28|isolation
P02002051A0276|46 56|cDNA clone
P02002051A0276|92 99|isoform
P02002051A0276|114 123|C-subunit
P02002051T0000|0 14|Isoform C beta
P02002051T0000|29 33|form
P02002051T0000|58 65|subunit
P02002051T0000|84 98|protein kinase
P02002511A0637|8 20|applications
P02002511A0637|24 38|PB-PK modeling
P02002511A0637|56 64|problems
P02002511A0637|86 94|examples
P02004521A0266|0 8|Patients
P02004521A0266|31 47|CT abnormalities
P02004521A0266|78 85|disease
P02004705A0686|4 17|cdr1 sequence
P02004705A0686|45 56|amino acids
P02004705A0686|75 83|fragment
P02004705A0686|98 105|product
P02004705A0686|119 121|Mr
P02005547A0121|19 32|understanding
P02005547A0121|57 65|pathways
P02005547A0121|106 117|development
P02005547A0121|134 152|hyperbilirubinemia
P02005547A0121|172 180|jaundice
P02005547A0121|186 198|practitioner
P02005547A0121|233 239|family
P02005547A0121|257 262|child
P02005547A0121|265 272|illness
P02006558A0000|0 23|Displacement thresholds
P02006558A0000|38 43|sites
P02006558A0000|63 69|vision
P02007045A0092|4 11|authors
P02007045A0092|21 25|case
P02007045A0092|48 58|irrigation
P02007045A0092|64 74|brain cyst
P02007045A0092|118 126|distress
P02008982A0463|0 5|ELISA
P02008982A0463|26 38|contribution
P02008982A0463|46 55|diagnosis
P02008982A0463|59 71|tuberculosis
P02008982A0463|91 103|sputum smear
P02010912A0366|8 13|paper
P02010912A0366|36 41|study
P02010912A0366|49 58|structure
P02010912A0366|78 82|role
P02010912A0366|90 108|MalT binding sites
P02010912A0366|147 152|pulAp
P02010912A0366|157 172|pulCp promoters
P02011924A0729|18 24|number
P02011924A0729|28 36|patients
P02011924A0729|45 50|basis
P02011924A0729|59 65|report
P02011924A0729|91 97|MU/day
P02011924A0729|101 110|alpha-IFN
P02011924A0729|126 135|treatment
P02011924A0729|140 148|patients
P02011924A0729|160 173|cell leukemia
P02012097T0000|11 23|fluctuations
P02012097T0000|36 47|parasitemia
P02012097T0000|51 80|Plasmodium falciparum malaria
P02012789A0051|12 26|family history
P02014928T0000|13 19|asthma
P02014928T0000|24 43|rhinoconjunctivitis
P02014928T0000|49 59|inhalation
P02014928T0000|82 102|serum albumin powder
P02015921A0523|10 21|subdivision
P02015921A0523|25 37|Category pN1
P02015921A0523|43 47|pN1a
P02015921A0523|49 59|metastasis
P02015921A0523|70 74|node
P02015921A0523|80 84|pN1b
P02015921A0523|98 103|nodes
P02016053A0752|0 31|Amino acid sequence comparisons
P02016053A0752|39 51|E74A protein
P02016053A0752|89 95|region
P02016053A0752|118 137|amino acid residues
P02016053A0752|195 215|DNA binding activity
P02016769A0720|27 36|strengths
P02016769A0720|44 53|promoters
P02016769A0720|80 88|contexts
P02017159A0646|0 6|Grasso
P02017159A0646|12 14|A.
P02017271A0502|8 14|months
P02017271A0502|25 36|improvement
P02017271A0502|40 48|strength
P02017271A0502|86 94|patients
P02017271A0502|102 106|none
P02017271A0502|112 120|controls
P02017414A0307|0 3|Age
P02017414A0307|7 10|POI
P02017414A0307|15 24|asymptote
P02017414A0307|49 58|Line RBC2
P02017414A0307|68 75|Line F.
P02019572A0000|16 29|DNA sequences
P02019572A0000|52 62|expression
P02019572A0000|70 95|rat liver pyruvate kinase
P02019572A0000|103 108|genes
P02019572A0000|112 118|series
P02019572A0000|122 132|constructs
P02019572A0000|146 194|chloramphenicol acetyltransferase reporter genes
P02019572A0000|224 233|fragments
P02019572A0000|246 256|base pairs
P02019572A0000|258 260|bp
P02019572A0000|283 296|gene cap site
P02019572A0000|329 339|expression
P02019572A0000|346 358|introduction
P02019572A0000|364 384|hepatoma HepG2 cells
P02019572A0000|386 401|rat hepatocytes
P02019572A0000|413 420|culture
P02019572A0000|422 436|fibroblast LTK
P02019572A0000|438 443|cells
P02019572A0000|454 465|C2C12 cells
P02019572A0000|471 480|CHO cells
P02020082A0356|4 15|disturbance
P02020082A0356|29 41|gas exchange
P02020082A0356|67 72|value
P02020082A0356|76 81|AaDO2
P02020082A0356|116 127|dysfunction
P02020082A0356|133 138|AaDO2
P02020082A0356|158 170|relationship
P02020082A0356|199 209|parameters
P02020082A0356|224 234|difference
P02020082A0356|243 257|plasma colloid
P02020082A0356|266 274|pressure
P02020082A0356|279 282|PCW
P02020314A1290|2 6|dose
P02020314A1290|18 42|micrograms/kg/day GM-CSF
P02020314A1290|55 63|severity
P02020314A1290|67 78|neutropenia
P02020314A1290|83 99|thrombocytopenia
P02020314A1290|106 147|carboplatin-cyclophosphamide chemotherapy
P02020314A1290|182 194|chemotherapy
P02020314A1290|207 213|cancer
P02020314A1290|221 227|future
P02021630A1104|6 17|differences
P02021630A1104|52 64|interactions
P02021630A1104|77 84|protein
P02021630A1104|89 92|DNA
P02021630A1104|104 120|guanine N7 sites
P02021630A1104|134 140|groove
P02021630A1104|144 147|DNA
P02021630A1104|153 164|alterations
P02021630A1104|168 199|DNA phosphodiester conformation
P02021630A1104|211 226|protein binding
P02022188A0112|12 20|analysis
P02022188A0112|43 54|BJ1 protein
P02022188A0112|74 85|nucleosomes
P02022188A0112|107 116|chromatin
P02022188A0112|120 126|agents
P02022188A0112|150 153|DNA
P02022188A0112|188 211|mobility group proteins
P02022188A0112|213 217|HMGs
P02022188A1463|21 34|gene products
P02022188A1463|47 56|chromatin
P02022188A1463|98 113|order structure
P02022188A1463|119 131|prerequisite
P02022188A1463|148 163|gene expression
P02022920A0334|4 19|C4BP alpha gene
P02022920A0334|55 65|exon codes
P02022920A0334|84 95|nucleotides
P02022920A0334|106 109|UTR
P02023097A0000|10 37|immunodeficiency virus type
P02023097A0000|41 46|HIV-1
P02023097A0000|48 59|Rev protein
P02023097A0000|94 103|regulator
P02023097A0000|124 139|gene expression
P02023097A0000|158 175|virus replication
P02023421A0343|9 22|proliferation
P02023421A0343|26 37|fibroblasts
P02023421A0343|42 60|collagen synthesis
P02023421A0343|75 83|increase
P02023421A0343|98 106|strength
P02023421A0343|120 126|effect
P02023421A0343|130 143|wound healing
P02023421A0343|197 203|agents
P02023904A0120|4 13|CDC7 gene
P02023904A0120|31 41|AUG codons
P02023904A0120|54 77|translation start sites
P02023904A0120|114 122|proteins
P02024252A0000|11 16|years
P02024252A0000|27 32|total
P02024252A0000|40 47|persons
P02024252A0000|57 76|disability pensions
P02024252A0000|84 96|municipality
P02024252A0000|100 109|Nordreisa
P02024252A0000|122 128|Norway
P02024488A0506|0 4|HeLa
P02024488A0506|9 26|Jurkat cell lines
P02024488A0506|40 48|nef gene
P02024488A0506|63 75|CMV promoter
P02024488A0506|83 92|HIV-1 LTR
P02024488A0506|110 121|coselection
P02024488A0506|126 145|neomycin resistance
P02024625A0202|0 11|Differences
P02024625A0202|28 40|presentation
P02024625A0202|55 65|appearance
P02024625A0202|77 82|cases
P02024625A0202|102 114|similarities
P02024625A0202|134 142|features
P02024791A0582|0 12|MEASUREMENTS
P02024791A0582|17 29|MAIN RESULTS
P02024791A0582|39 45|groups
P02024791A0582|62 67|entry
P02024791A0582|77 82|study
P02024791A0582|99 116|FEV1 measurements
P02024791A0582|123 135|L atropine/0
P02024791A0582|139 155|L metaproterenol
P02024791A0582|157 158|P
P02024816A0521|9 14|ELISA
P02024816A0521|41 50|protein A
P02024816A0521|52 56|SP-A
P02024816A0521|87 105|pneumonia patients
P02025515A0979|3 7|view
P02025515A0979|21 25|t1/2
P02025515A0979|41 50|doses/day
P02026144A0741|9 16|control
P02026144A0741|20 34|GUS expression
P02026144A0741|80 89|sequences
P02026144A0741|91 95|NRS1
P02026144A0741|115 119|NRS2
P02026144A0741|160 171|domain UAS1
P02026147A0000|14 17|Ca2
P02026147A0000|19 29|calmodulin
P02026147A0000|31 34|CaM
P02026147A0000|46 60|protein kinase
P02026147A0000|62 72|CaM kinase
P02026147A0000|83 88|yeast
P02026147A0000|119 129|properties
P02026147A0000|151 155|type
P02026147A0000|159 170|CaM kinases
P02026461A0760|8 13|cases
P02026461A0760|49 60|individuals
P02026461A0760|89 94|panel
P02026461A0760|98 104|probes
P02026491A0399|4 12|patients
P02026491A0399|35 42|effects
P02026491A0399|48 51|NMF
P02026491A0399|73 80|seizure
P02026491A0399|122 126|pain
P02027839A0250|4 11|muscles
P02027839A0250|30 35|group
P02027839A0250|61 62|P
P02027839A0250|78 84|values
P02027839A0250|99 106|density
P02027839A0250|111 120|capillary
P02027839A0250|124 135|fiber ratio
P02027839A0250|176 184|distance
P02027839A0250|212 217|group
P02028125A0101|4 14|prevalence
P02028125A0101|32 41|infection
P02028125A0101|58 71|AIDS patients
P02028125A0101|80 91|probability
P02028125A0101|104 119|tumour response
P02028125A0101|130 144|cancer therapy
P02028125A0101|180 188|examples
P02028125A0101|197 206|functions
P02029468A0296|0 24|Serum TNF concentrations
P02029468A0296|42 51|diagnosis
P02029468A0296|87 103|reference limits
P02029468A0296|107 111|week
P02030910A0000|8 14|clones
P02030910A0000|38 47|ETS1 gene
P02030910A0000|99 111|organization
P02030910A1070|0 34|Polymerase chain reaction analysis
P02030910A1070|38 47|ETS1 cDNA
P02030910A1070|77 85|products
P02030910A1070|110 118|splicing
P02033038A0309|28 43|E3 polypeptides
P02033038A0309|50 55|bands
P02033038A0309|85 91|pellet
P02033038A0309|127 129|E3
P02033038A0309|155 163|fraction
P02033062A1169|8 25|promotor function
P02033062A1169|36 41|genes
P02033062A1169|67 76|fragments
P02033062A1169|80 93|chicken IGF-I
P02033062A1169|106 109|DNA
P02033062A1169|128 144|reporter plasmid
P02034655A1224|4 9|alpha
P02034655A1224|12 16|gene
P02034655A1224|29 35|region
P02034655A1224|47 55|promoter
P02034655A1224|59 78|transfection assays
P02034655T0000|0 16|Characterization
P02034655T0000|24 29|alpha
P02034655T0000|32 54|integrin gene promoter
P02034669A0293|16 26|transcript
P02034669A0293|49 56|tissues
P02034669A0293|68 78|expression
P02034669A0293|136 142|system
P02034676A0267|4 14|homologues
P02034676A0267|22 36|rhombotin gene
P02035805T0000|0 28|Angina haemorrhagica bullosa
P02035805T0000|49 60|obstruction
P02036066A0000|16 23|effects
P02036066A0000|37 46|perfusion
P02036066A0000|66 102|hemoglobin polyoxyethylene conjugate
P02036066A0000|104 107|PHP
P02036066A0000|109 117|solution
P02036066A0000|129 137|function
P02036066A0000|150 160|rat hearts
P02038293A0919|0 10|Conclusion
P02038293A0919|12 26|inlet type VSD
P02038293A0919|46 54|type TOF
P02038293A0919|69 77|features
P02038293A0919|104 110|bundle
P02038293A0919|151 162|VSD closure
P02038326A0538|4 21|gcd2-503 mutation
P02038326A0538|47 53|runoff
P02038326A0538|55 67|accumulation
P02038326A0538|80 83|80S
P02038326A0538|94 101|couples
P02038326A0538|107 119|accumulation
P02038326A0538|143 151|subunits
P02038326A0538|167 196|translation initiation factor
P02038326A0538|200 211|eIF-2 alpha
P02038326A0538|216 233|43S-48S particles
P02038326A0538|246 251|shift
P02038326A0538|271 282|temperature
P02038784A0317|6 14|patients
P02038784A0317|20 23|ARC
P02038784A0317|34 41|failure
P02041088A1053|15 32|enhancer activity
P02041088A1053|36 40|DR60
P02041088A1053|44 60|reporter plasmid
P02041088A1053|92 96|DR60
P02041088A1053|120 167|reporter chloramphenicol acetyltransferase gene
P02041088A1053|178 185|control
P02041088A1053|207 219|39K promoter
P02044785A0000|9 13|case
P02044785A0000|20 34|adenocarcinoma
P02044785A0000|49 64|retroperitoneal
P02044785A0000|78 82|cyst
P02044785A0000|119 123|cyst
P02044950A0258|10 35|polymerase chain reaction
P02044950A0258|53 65|U6 RNA genes
P02044950A0258|72 81|organisms
P02044975A0380|10 16|volume
P02044975A0380|26 30|flow
P02044975A0380|63 64|P
P02044975A0380|100 101|h
P02044975A0380|108 120|instillation
P02044975A0380|144 147|min
P02044975A0380|154 165|application
P02044975A0380|172 178|volume
P02044975A0380|183 184|%
P02044975A0380|191 195|flow
P02044975A0380|200 201|%
P02045366A1149|0 23|Hydrophobicity analysis
P02045366A1149|43 47|KlaA
P02045366A1149|52 69|KlaB polypeptides
P02045366A1149|108 124|KlaC polypeptide
P02045366A1149|180 187|domains
P02045524A0000|18 30|availability
P02045524A0000|60 66|agents
P02045524A0000|72 76|Food
P02045524A0000|81 100|Drug Administration
P02045524A0000|102 105|FDA
P02045524A0000|114 123|mid-1970s
P02045524A0000|152 159|ratings
P02045524A0000|183 188|drugs
P02045524A0000|201 213|end-of-phase
P02045524A0000|217 228|conferences
P02045524A0000|234 247|drug sponsors
P02045809A0331|3 11|contrast
P02045809A0331|21 26|rates
P02045809A0331|30 52|B. sphaericus products
P02045809A0331|54 62|ABG-6184
P02045809A0331|73 79|powder
P02045809A0331|84 89|BSP-2
P02045809A0331|99 110|concentrate
P02045809A0331|136 145|reduction
P02046202A0625|4 13|remainder
P02046202A0625|19 20|%
P02046202A0625|31 46|IgA nephropathy
P02047597A0149|26 34|vulvitis
P02047597A0149|56 71|field condition
P02047597A0149|77 85|bacteria
P02047597A0149|124 131|strains
P02052544A0641|17 31|DNA polymerase
P02052544A0641|35 42|complex
P02052544A0641|72 78|dpb2-1
P02052544A0641|86 91|cells
P02052544A0641|118 132|DNA polymerase
P02052544A0641|136 143|complex
P02052544A0641|153 157|DPB2
P02052544A0641|191 202|replication
P02052592A0000|33 37|cell
P02052592A0000|48 56|products
P02052592A0000|75 82|changes
P02052592A0000|86 99|bone turnover
P02052592A0000|122 133|development
P02052592A0000|152 164|osteoporosis
P02052592A0000|183 190|effects
P02052592A0000|194 206|oophorectomy
P02052592A0000|222 242|estrogen replacement
P02052592A0000|262 271|secretion
P02052592A0000|275 286|interleukin
P02052592A0000|290 294|IL-1
P02052592A0000|300 327|tumor necrosis factor alpha
P02052592A0000|329 338|TNF-alpha
P02052592A0000|351 369|phytohemagglutinin
P02052592A0000|380 389|secretion
P02052592A0000|435 441|factor
P02052592A0000|443 449|GM-CSF
P02052592A0000|467 472|blood
P02052592A0000|485 490|cells
P02053289A0701|20 34|nt differences
P02053289A0701|70 76|groups
P02053289A0701|102 116|nt differences
P02053289A0701|138 145|strains
P02054754A0919|13 23|principles
P02054754A0919|36 46|management
P02054754A0919|77 88|Sandostatin
P02054754A0919|98 106|patients
P02054754A0919|118 127|disorders
P02055484A0538|12 24|PCR products
P02055484A0538|35 44|mutations
P02055484A0538|48 52|ATG1
P02055484A0538|60 64|ATG2
P02056553T0000|12 17|shock
P02056553T0000|32 45|translocation
P02056553T0000|51 62|swine model
P02060052A0954|6 10|data
P02060052A0954|28 34|levels
P02060052A0954|38 44|oxygen
P02060052A0954|50 58|radicals
P02060052A0954|77 88|hepatocytes
P02060052A0954|93 105|mitochondria
P02061282A0447|4 12|sequence
P02061282A0447|20 33|pMxL1 plasmid
P02061282A0447|60 66|region
P02061282A0447|93 99|repeat
P02061282A0447|106 108|bp
P02061282A0447|116 127|orientation
P02061282A0447|143 153|pilin gene
P02061282A0447|161 167|middle
P02061282A0447|175 202|recombination junction site
P02061333A0784|3 11|evidence
P02061333A0784|20 28|presence
P02061333A0784|32 39|introns
P02061333A0784|51 60|acvA gene
P02061333A1359|6 18|observations
P02061333A1359|38 48|occurrence
P02061333A1359|64 99|phosphopantetheine-attachment sites
P02061333A1359|115 132|thioesterase site
P02061333A1359|153 162|reference
P02061333A1359|170 187|reaction sequence
P02061333A1359|199 209|production
P02061333A1359|217 231|ACV tripeptide
P02062116A0688|0 9|Pargyline
P02062116A0688|13 40|monoamine oxidase inhibitor
P02062116A0688|70 73|max
P02062933A0738|15 21|choice
P02062933A0738|41 47|female
P02062933A0738|70 74|male
P02062933A0738|82 85|AOF
P02062933A0738|87 104|flutamide females
P02062933A0738|117 125|controls
P02062933A0738|146 153|partner
P02064119A1172|20 29|responses
P02064119A1172|50 55|L/min
P02064119A1172|56 62|% SaO2
P02064119A1172|70 79|relatives
P02064119A1172|99 104|L/min
P02064119A1172|105 111|% SaO2
P02064119A1172|127 135|subjects
P02064119A1172|137 145|ABSTRACT
P02064119A1172|163 168|WORDS
P02065022A0747|11 20|deletions
P02065022A0747|42 48|region
P02065022A0747|70 91|transforming activity
P02065022A0747|95 98|dbl
P02065022A0747|116 124|deletion
P02065022A0747|141 147|region
P02065022A0747|155 161|effect
P02066246A0258|18 22|list
P02066246A0258|49 54|files
P02066246A0258|62 91|Massachusetts Cancer Registry
P02066246A0258|96 101|cases
P02068085A1273|16 24|evidence
P02068085A1273|51 58|element
P02068085A1273|78 84|region
P02068085A1273|92 95|Mlu
P02068085A1273|107 126|activation sequence
P02069738A0000|2 8|method
P02069738A0000|26 42|stimulus control
P02069738A0000|46 53|ethanol
P02069873X0000|0 9|Mechanism
P02069873X0000|13 23|activation
P02069873X0000|31 48|vav protooncogene
P02069873X0000|50 53|vav
P02069873X0000|65 70|locus
P02069873X0000|116 121|cells
P02069873X0000|139 145|origin
P02069873X0000|166 189|differentiation lineage
P02070227T0000|12 24|cell seeding
P02072238T0000|0 17|Menetrier disease
P02072238T0000|23 28|child
P02072798A0330|18 31|stabilization
P02072798A0330|37 41|goal
P02072798A0330|45 52|therapy
P02072798A0330|72 78|chance
P02072798A0330|87 92|ulcer
P02073222A0269|13 21|patients
P02073222A0269|23 38|amitriptyline n
P02073222A0269|45 58|moclobemide n
P02073222A0269|83 96|week protocol
P02073222A0269|137 147|conditions
P02075876A0408|4 22|stimulus threshold
P02075876A0408|27 30|EER
P02075876A0408|56 65|variation
P02075876A0408|71 80|amplitude
P02075876T0001|0 8|Analysis
P02075876T0001|32 40|response
P02075876T0001|42 45|EER
P02075876T0001|50 58|relation
P02075876T0001|81 88|pathway
P02075876T0001|96 99|cat
P02076620A0548|13 37|plasma fibrinogen levels
P02076620A0548|53 57|mean
P02076620A0548|65 66|%
P02076620A0548|90 96|effect
P02076620A0548|100 111|gemfibrozil
P02076620T0000|0 11|Gemfibrozil
P02076620T0000|31 39|patients
P02076620T0000|65 72|disease
P02076620T0000|92 99|actions
P02076816T0000|20 27|pathway
P02076816T0000|32 51|sporulation control
P02076816T0000|93 121|IME1 transcript accumulation
P02077560T0000|4 8|role
P02077560T0000|28 37|profiling
P02077560T0000|41 58|safety assessment
P02078080T0040|4 15|application
P02078080T0040|19 29|Madagascar
P02078080T0040|31 41|advantages
P02078080T0040|46 59|disadvantages
P02078570A0287|7 12|cases
P02078570A0287|25 35|expression
P02078570A0287|59 68|integrins
P02079811A0407|4 11|authors
P02079811A0407|34 42|efficacy
P02079811A0407|46 53|EMB AZS
P02079811A0407|67 72|ulcer
P02079811A0407|79 88|operation
P02079811A0407|96 103|stomach
P02079811A0407|121 126|level
P02079811A0407|130 145|acid production
P02079811A0407|176 184|bleeding
P02080902A0183|3 12|adulthood
P02080902A0183|19 23|rats
P02080902A0183|64 82|avoidance response
P02080902A0183|98 106|controls
P02081463A0110|19 29|regulation
P02081463A0110|33 51|Spec gene activity
P02081463A0110|57 63|region
P02081463A0110|75 80|Spec1
P02081463A0110|97 112|initiation site
P02081463A0110|130 135|sites
P02081463A0110|151 162|interaction
P02083199A1175|0 22|Phosphopeptide mapping
P02083199A1175|41 66|autophosphorylation sites
P02083199A1175|79 86|EGFR-IC
P02083199A1175|120 124|EGFR
P02083230A0938|12 20|sequence
P02083230A0938|40 54|signal peptide
P02083230A0938|88 113|amino acid residue domain
P02083230A0938|121 142|N-glycosylation sites
P02083230A0938|160 166|domain
P02083230A0938|185 191|domain
P02083230A0938|198 209|amino acids
P02083253A1512|4 28|TCF-1 alpha binding site
P02083253A1512|51 78|TCR alpha enhancer activity
P02083253A1512|107 115|extracts
P02083253A1512|121 127|Jurkat
P02083253A1512|136 146|HeLa cells
P02083253A1512|164 175|TCF-1 alpha
P02083253A1512|197 217|transcription factor
P02083546A0000|21 27|method
P02083546A0000|62 68|uptake
P02083546A0000|107 118|amine oxime
P02083546A0000|120 131|99mTc-HMPAO
P02083546A0000|159 184|photon emission tomograms
P02083546A0000|199 207|subjects
P02083546A0000|212 220|patients
P02083546A0000|226 235|Alzheimer
P02083546A0000|238 245|disease
P02083546A0000|250 258|patients
P02083546A0000|264 272|dementia
P02083546A0000|284 293|lobe type
P02083546A0000|300 308|patients
P02083546A0000|314 322|dementia
P02083546A0000|328 349|motor neurone disease
P02088781A0653|4 11|results
P02088781A0653|24 27|fog
P02088781A0653|37 42|level
P02088781A0653|46 50|base
P02088781A0653|56 59|fog
P02088781A0653|75 88|density units
P02088781A0653|97 106|influence
P02088781A0653|125 133|accuracy
P02088781A0653|141 148|absence
P02088781A0653|156 168|compensation
P02089054A0121|0 3|IdB
P02089054A0121|32 54|liquid-solid partition
P02089054A0121|63 71|extracts
P02089054A0121|121 127|column
P02089054A0121|144 154|conditions
P02089054A0121|193 204|UV detector
P02091890A0614|8 13|model
P02091890A0614|15 26|eltoprazine
P02091890A0614|73 80|profile
P02091890A0614|93 103|aggression
P02091890A0614|117 128|interaction
P02091890A0614|133 144|exploration
P02091890A0614|182 192|inactivity
P02091890A0614|196 203|measure
P02091890A0614|208 216|sedation
P02092131T0000|6 12|method
P02092131T0000|30 38|transfer
P02092131T0000|50 66|hypersensitivity
P02092131T0000|79 94|transfer factor
P02093033T0001|0 6|Effect
P02093033T0001|32 39|effects
P02093033T0001|43 56|plutonium-239
P02093033T0001|58 77|hexachlorobutadiene
P02093033T0001|82 100|tributyl phosphate
P02093033T0001|108 120|thymus gland
P02093033T0001|124 128|rats
P02093741A0211|0 15|Data collection
P02093741A0211|32 46|query language
P02093741A0211|52 65|data analysis
P02093741A0211|124 128|tool
P02093741A0211|130 137|MAXITAB
P02093741A0211|172 190|analysis technique
P02093888A0293|0 5|ARPIA
P02093888A0293|49 53|DBMS
P02093888A0293|98 107|computers
P02094221A0247|0 8|Diuresis
P02094221A0247|34 42|drinking
P02094221A0247|46 49|tea
P02094221A0247|55 59|ml/h
P02094257T0000|11 16|value
P02094257T0000|20 48|adenosine deaminase activity
P02094257T0000|64 73|effusions
P02095150T0000|8 25|strain adaptation
P02095150T0000|38 53|hip replacement
P02095150T0000|57 67|comparison
P02095150T0000|91 110|ingrowth components
P02095150T0000|114 121|canines
P02099622A1046|0 20|Immuno-cytochemistry
P02099622A1046|28 36|antisera
P02099622A1046|45 65|Campylobacter jejuni
P02099622A1046|92 100|staining
P02099622A1046|123 128|cells
P02099622A1046|162 171|organisms
P02099622A1046|181 190|structure
P02099622A1046|202 219|Campylobacter spp
P02102823A0492|0 19|Promoter activities
P02102823A0492|41 59|beta-glucuronidase
P02102823A0492|64 91|neomycin phosphotransferase
P02102823A0492|95 116|reporter gene systems
P02102831A1282|7 14|regions
P02102831A1282|28 47|soybean actin genes
P02102831A1282|69 77|features
P02102831A1282|89 91|CT
P02102831A1282|93 100|repeats
P02102831A1282|110 119|stretches
P02102831A1282|139 142|DNA
P02103140A1088|10 11|%
P02103140A1088|13 21|patients
P02103140A1088|45 52|failure
P02103140A1088|66 72|grafts
P02103140A1088|125 131|grafts
P02103140A1088|173 190|retransplantation
P02103403A0149|3 10|patient
P02103403A0149|17 24|history
P02103403A0149|35 49|alcohol intake
P02103403A0149|64 70|intake
P02103403A0149|86 91|drugs
P02103403A0149|96 104|steroids
P02105497A1092|16 26|comparison
P02105497A1092|30 50|amino acid sequences
P02105497A1092|57 71|HSP70 proteins
P02105497A1092|80 87|species
P02105497A1092|102 111|BiP genes
P02105497A1092|127 135|ancestor
P02105497A1092|163 174|HSP70 genes
P02105497A1092|184 188|time
P02105497A1092|194 204|eukaryotes
P02106287A0478|0 13|Spore inocula
P02106287A0478|35 41|coupon
P02106287A0478|59 65|0.5-in
P02107073A0584|9 23|overexpression
P02107073A0584|36 40|STE4
P02107073A0584|45 59|STE18 proteins
P02107073A0584|88 106|pheromone response
P02107073A0584|112 126|overexpression
P02107073A0584|130 134|STE4
P02107073A0584|142 150|presence
P02107073A0584|164 170|levels
P02107073A0584|174 179|STE18
P02107548A0727|8 25|transcription-PCR
P02107548A0727|43 48|clone
P02107548A0727|60 64|poly
P02107548A0727|65 66|A
P02107548A0727|69 72|RNA
P02107548A0727|77 81|cDNA
P02107548A0727|113 120|homolog
P02107548A0727|124 131|psi ARF
P02107548A0727|156 159|ARF
P02109544A0000|16 20|cost
P02109544A0000|25 33|benefits
P02109544A0000|37 52|screening tests
P02109544A0000|57 78|Chlamydia trachomatis
P02109544A0000|93 98|males
P02109544A0000|115 138|decision analysis model
P02109544A0000|156 194|leukocyte esterase urine dipstick test
P02109544A0000|200 207|culture
P02109544A0000|239 247|antibody
P02109544A0000|249 252|DFA
P02109544A0000|268 274|option
P02109544A0000|281 290|screening
P02109544A0000|295 304|treatment
P02110145T0000|0 10|Sequencing
P02110145T0000|15 19|gene
P02110145T0000|58 64|enzyme
P02110145T0000|66 70|CfiA
P02110145T0000|77 88|Bacteroides
P02110145T0000|98 105|TAL2480
P02110145T0000|121 131|similarity
P02110145T0000|140 144|CfiA
P02110145T0000|149 179|Bacillus cereus beta-lactamase
P02110148A0423|11 27|HindIII fragment
P02110148A0423|48 69|DNA sequence analysis
P02110148A0423|95 99|half
P02110148A0423|107 130|B. subtilis IF2 protein
P02110148A0423|139 141|kb
P02110148A0423|163 171|sequence
P02110148A0423|202 207|probe
P02110148A0423|211 216|clone
P02110148A0423|240 244|ClaI
P02110148A0423|257 265|fragment
P02110148A0423|288 291|IF2
P02110148A0423|303 307|gene
P02111015A0574|19 30|amino acids
P02111015A0574|68 74|domain
P02111015A0574|96 115|sequence similarity
P02111015A0574|134 154|IFN response factors
P02111015A0574|156 161|IRF-1
P02111015A0574|166 171|IRF-2
P02113015A0295|9 17|seizures
P02113015A0295|38 47|pregnancy
P02113015A0295|58 62|cent
P02113174A0064|13 20|protein
P02113174A0064|32 44|zinc fingers
P02113174A0064|69 93|transcription factor Sp1
P02113174A0957|0 7|Krox-24
P02113174A0957|57 66|activator
P02113455A0207|20 31|variability
P02113455A0207|39 49|parameters
P02113455A0207|64 77|consideration
P02113455A0207|111 127|threshold levels
P02113699A0372|4 12|patients
P02113699A0372|33 42|subgroups
P02113699A0372|50 51|N
P02113699A0372|53 61|patients
P02113699A0372|80 85|spots
P02113699A0372|104 105|N
P02113699A0372|107 109|IM
P02113699A0372|118 119|N
P02113699A0372|121 129|patients
P02113699A0372|146 151|spots
P02113699A0372|179 180|N
P02113699A0372|193 194|N
P02113699A0372|196 204|patients
P02113699A0372|221 226|spots
P02113699A0372|254 255|N
P02113901A0000|9 12|CO2
P02113901A0000|21 28|changes
P02113901A0000|34 38|hypo
P02113901A0000|43 54|normocapnia
P02113901A0000|104 111|tension
P02113901A0000|113 117|PaO2
P02113901A0000|154 164|difference
P02115111T0000|0 10|Expression
P02115111T0000|12 31|nucleotide sequence
P02115111T0000|47 55|analysis
P02115111T0000|68 82|reading frames
P02115111T0000|90 105|nif gene region
P02115111T0000|109 120|Anabaena sp
P02115111T0000|122 136|strain PCC7120
P02115115A1053|38 48|suggestion
P02115115A1053|54 59|sites
P02115115A1053|78 86|CAR1 URS
P02115115A1053|122 129|regions
P02115115A1053|152 163|yeast genes
P02115116A1137|4 11|results
P02115116A1137|27 41|sequence match
P02115116A1137|50 59|enhancers
P02115116A1137|72 89|promoter elements
P02115118A0565|5 7|Mr
P02115118A0565|44 56|smg p25A GDI
P02115118A0565|70 84|sodium dodecyl
P02115118A0565|108 127|gel electrophoresis
P02115118A0565|132 176|sucrose density gradient ultracentrifugation
P02115121A0000|0 13|Yeast mutants
P02115121A0000|30 60|pet complementation group G104
P02115121A0000|100 122|dehydrogenase activity
P02115121A0000|128 134|result
P02115121A0000|138 147|mutations
P02115121A0000|155 185|dihydrolipoyl transsuccinylase
P02115121A0000|187 190|KE2
P02115121A0000|192 201|component
P02115121A0000|209 216|complex
P02115122A0562|9 17|residues
P02115122A0562|31 41|repression
P02115122A0562|79 90|amino acids
P02115122A0562|94 99|c-Fos
P02115122A0562|107 112|v-Fos
P02115122A0562|128 139|truncations
P02115122A0562|143 148|c-Fos
P02115572A1323|21 40|V lambda pseudogene
P02115572A1323|49 61|psi V lambda
P02115572A1323|67 69|kb
P02115572A1323|86 102|U266 lambda gene
P02115889A0436|8 13|paper
P02115889A0436|36 45|structure
P02115889A0436|55 59|gene
P02115889A0436|64 72|Gx alpha
P02115889A0436|99 108|kilobases
P02116071A0000|17 22|study
P02116071A0000|50 64|stage children
P02116071A0000|80 87|potency
P02116071A0000|109 139|type hypersensitivity reaction
P02116071A0000|143 151|exposure
P02116071A0000|160 167|antigen
P02116071A0000|181 186|titer
P02116071A0000|204 207|IgE
P02116071A0000|217 221|sera
P02116071A0000|256 263|attacks
P02116071A0000|279 288|reduction
P02116071A0000|296 302|amount
P02116071A0000|311 318|antigen
P02116071A0000|326 330|body
P02116071A0000|348 357|reduction
P02116071A0000|365 371|amount
P02116071A0000|389 392|IgG
P02116537A1237|7 16|influence
P02116537A1237|39 53|concentrations
P02116537A1237|63 66|MIC
P02116537A1237|70 73|AMK
P02117799T0000a|0 4|Uses
P02117799T0000a|8 23|orthoclone OKT3
P02117799T0000a|28 39|prophylaxis
P02117799T0000a|43 52|rejection
P02117799T0000a|57 66|induction
P02117799T0000a|78 89|nonfunction
P02117799T0000a|93 115|kidney transplantation
P02117799T0000b|0 4|Uses
P02117799T0000b|8 23|orthoclone OKT3
P02117799T0000b|28 39|prophylaxis
P02117799T0000b|43 52|rejection
P02117799T0000b|57 66|induction
P02117799T0000b|78 89|nonfunction
P02117799T0000b|93 115|kidney transplantation
P02118519A0516|37 53|consensus motifs
P02118519A0516|92 101|positions
P02118519A0516|109 114|genes
P02118519A0516|123 151|nerve growth factor receptor
P02118519A0516|167 188|neurofilament protein
P02118525A0737|3 11|addition
P02118525A0737|29 37|fragment
P02118525A0737|45 57|CCK promoter
P02118525A0737|85 93|enhancer
P02118525A0737|115 128|transcription
P02118525A0737|138 184|herpes simplex virus thymidine kinase promoter
P02118525A0737|190 198|position
P02118525A0737|228 234|manner
P02118612A0629|7 14|minutes
P02118612A0629|18 34|supine restraint
P02118612A0629|45 65|DOPAC concentrations
P02118612A0629|80 88|eminence
P02118612A0629|99 103|rats
P02118612A0629|146 154|exposure
P02118612A0629|158 163|ether
P02118612A0629|178 184|effect
P02119530T0000|0 9|Influence
P02119530T0000|13 33|metoprolol treatment
P02119530T0000|54 64|activation
P02119530T0000|68 80|fibrinolysis
P02119626A0471|11 16|scars
P02119626A0471|46 47|%
P02119626A0471|58 68|dimensions
P02119946T0000|9 18|dysphagia
P02119946T0000|32 44|care setting
P02119946T0000|49 61|introduction
P02120707A0594|19 25|assays
P02120707A0594|45 49|Raji
P02120707A0594|58 66|proteins
P02120707A0594|81 82|W
P02120707A0594|87 97|V elements
P02120707A0594|123 152|HLA-DRA X-box oligonucleotide
P02120833A0000|3 10|Denmark
P02120833A0000|20 25|cases
P02120833A0000|52 66|hepatitis NANB
P02120833A0000|68 76|TAH-NANB
P02120833A0000|113 117|case
P02120833A0000|130 135|units
P02121371T0000|4 13|NF1 locus
P02121371T0000|24 31|protein
P02121371T0000|66 69|GAP
P02121371T0000|74 92|yeast IRA proteins
P02122454A1042|11 22|replacement
P02122454A1042|26 32|Phe-62
P02122454A1042|38 41|Ser
P02122454A1042|65 76|determinant
P02122454A1042|84 90|lambda
P02122454A1042|99 104|chain
P02122454A1042|145 154|transport
P02122454A1042|163 171|molecule
P02123029A0478|9 16|isotype
P02123029A0478|20 39|Raja immunoglobulin
P02123029A0478|46 57|chain genes
P02123029A0478|91 110|spleen cDNA library
P02123029A0478|127 134|Raja VH
P02123029A0478|153 159|probes
P02123029A0478|189 196|regions
P02123029A0478|212 219|isotype
P02123293A0227|0 5|Petko
P02123293A0227|11 13|S.
P02123295A0645|0 10|Disruption
P02123295A0645|14 18|ARF2
P02123295A0645|40 49|phenotype
P02123300T0000|45 51|factor
P02123300T0000|53 59|factor
P02123300T0000|73 82|treatment
P02123300T0000|86 99|hemophilia A.
P02123300T0000|112 135|Factor VIII Study Group
P02123466A0272|11 18|members
P02123466A0272|27 33|family
P02123466A0272|39 43|AP-4
P02123466A0272|48 53|motif
P02123466A0272|77 83|domain
P02123466A0272|137 148|DNA binding
P02123467A0811|13 23|expression
P02123467A0811|31 39|promoter
P02123467A0811|77 82|cells
P02123467A0811|93 98|MyoD1
P02123467A0811|103 106|Sp1
P02123467A0811|142 147|sites
P02123467A0811|176 184|presence
P02123467A0811|209 212|Sp1
P02123467A0811|217 222|MyoD1
P02123820A0000|0 7|Effects
P02123820A0000|23 40|monoamine oxidase
P02123820A0000|42 45|MAO
P02123820A0000|50 59|inhibitor
P02123820A0000|61 71|clorgyline
P02123820A0000|85 100|MAO-B inhibitor
P02123820A0000|102 110|deprenyl
P02123820A0000|132 145|MAO inhibitor
P02123820A0000|147 156|nialamide
P02123820A0000|197 207|aggression
P02123820A0000|209 212|FIA
P02123820A0000|224 228|rats
P02123875A0223|23 31|features
P02123875A0223|35 43|residues
P02123875A0223|57 65|c-region
P02123875A0223|85 93|fidelity
P02123875A0223|98 108|efficiency
P02123875A0223|112 137|signal peptidase cleavage
P02123875A0223|166 179|translocation
P02123875A0223|199 223|amino acid substitutions
P02123875A0223|233 246|COOH terminus
P02123875A0223|266 270|core
P02123875A0223|281 294|substitutions
P02123875A0223|302 314|NH2 terminus
P02123875A0223|329 335|region
P02123875A0223|341 352|+1 position
P02123875A0223|359 364|model
P02123875A0223|397 406|delta pro
P02123875A0223|407 414|apoA-II
P02123877A1452|23 28|c-fos
P02123877A1452|33 44|egr-1 mRNAs
P02123877A1452|71 77|levels
P02123877A1452|92 103|liver cells
P02123877A1452|105 110|fos-B
P02123877A1452|112 117|fra-1
P02123877A1452|123 128|egr-2
P02123877A1452|158 165|factors
P02123877A1452|169 177|addition
P02123877A1452|185 206|serum response factor
P02123877A1452|226 236|regulation
P02123877A1452|256 270|gene induction
P02124433A0235|7 15|patients
P02124433A0235|21 26|cases
P02124433A0235|41 52|description
P02124433A0235|56 63|patient
P02124433A0235|66 76|background
P02124433A0235|93 100|Group A
P02124433A0235|102 109|surgery
P02124433A0235|112 115|MMC
P02124433A0235|118 122|5-FU
P02124433A0235|123 135|chemotherapy
P02124433A0235|141 146|cases
P02124433A0235|148 155|group B
P02124433A0235|157 164|surgery
P02124433A0235|167 170|MMC
P02124433A0235|173 177|5-FU
P02124433A0235|180 186|OK-432
P02124433A0235|190 193|PSK
P02124433A0235|194 212|immunochemotherapy
P02124433A0235|222 229|group C
P02124433A0235|231 238|surgery
P02124710A0193|12 20|proteins
P02124710A0193|36 41|c-fos
P02124710A0193|46 66|c-jun protooncogenes
P02124710A0193|92 112|proliferation period
P02124710A0193|116 148|osteoblast phenotype development
P02124710A1624|5 10|model
P02124710A1624|35 42|binding
P02124710A1624|50 65|Fos-Jun complex
P02124710A1624|72 81|AP-1 site
P02124710A1624|89 99|type alpha
P02124710A1624|102 119|collagen promoter
P02124710A1624|170 174|VDRE
P02125016A0145|0 4|PBSX
P02125016A0145|19 25|agents
P02125016A0145|43 55|SOS response
P02125153A0410|18 25|relapse
P02125153A0410|36 45|treatment
P02125153A0410|60 65|years
P02125153A0410|73 74|%
P02125153A0410|82 84|R3
P02125153A0410|89 90|%
P02125153A0410|97 99|R5
P02125153A0410|109 110|%
P02125153A0410|118 129|Z5 patients
P02125153A0410|135 144|organisms
P02125153A0410|158 170|streptomycin
P02125153A0410|175 184|isoniazid
P02126417A0408|7 15|controls
P02126417A0408|81 97|control subjects
P02126417A0408|113 116|VHF
P02126417A0408|129 139|hemisphere
P02126417A0408|141 150|advantage
P02126504A0602|12 25|Rh-antibodies
P02126504A0602|55 64|mechanism
P02126504A0602|91 100|Rh-system
P02129338A0568|12 31|amino acid sequence
P02129338A0568|49 57|homology
P02129338A0568|61 62|%
P02129338A0568|77 114|alga Scenedemus obliquus plastocyanin
P02131652A0883|15 42|serum gastrin concentration
P02131652A0883|75 81|ng.l-1
P02131652A0883|109 124|gastrin release
P02131652A0883|126 134|AUC0-120
P02131652A0883|169 179|ng.l-1 min
P02131652A0883|201 207|VTP-HM
P02131652A0883|219 226|VTP-Cas
P02131666A0483|17 22|group
P02131666A0483|39 59|examinees class II/2
P02131666A0483|72 81|anomalies
P02131902A0000|5 10|study
P02131902A0000|40 48|location
P02131902A0000|89 92|TEE
P02131902A0000|94 104|transducer
P02131902A0000|135 139|view
P02131902A0000|152 161|ventricle
P02131902A0000|163 167|S-LV
P02132636A0188|0 8|Subjects
P02132636A0188|30 44|schizophrenics
P02132636A0188|61 76|DST suppressors
P02132636A0188|83 97|nonsuppressors
P02133731A1572|5 7|S3
P02133731A1572|9 12|CBF
P02133731A1572|19 20|%
P02133731A1572|25 27|S5
P02133731A1572|29 32|CBF
P02133731A1572|38 39|%
P02133731A1572|42 46|%WTh
P02133731A1572|48 53|1/TPC
P02133731A1572|58 61|1/T
P02133731A1572|109 123|control levels
P02133731A1572|129 130|p
P02135343A0131|8 15|article
P02135343A0131|43 53|percentage
P02135343A0131|64 73|occlusion
P02135343A0131|82 94|distribution
P02135343A0131|98 110|maloclusions
P02135343A0131|145 157|relationship
P02135343A0131|177 182|archs
P02135343A0131|198 219|ANGLE3 classification
P02135536A0621|8 12|case
P02135536A0621|18 23|ratio
P02135536A0621|27 41|brush abrasion
P02135536A0621|80 88|strength
P02135536A0621|105 108|MPa
P02135536A0621|123 131|hardness
P02135536A0621|138 140|Hk
P02135536A0621|142 158|water absorption
P02135536A0621|164 178|micrograms/mm3
P02135536A0621|191 212|expansion coefficient
P02135536A0621|228 238|degrees C.
P02137704A0000|19 24|group
P02137704A0000|48 56|patients
P02137704A0000|79 87|strength
P02137704A0000|91 102|association
P02137704A0000|119 146|blood pressure measurements
P02137704A0000|151 152|h
P02137704A0000|182 196|blood pressure
P02137704A0000|200 201|h
P02137704A0000|223 230|morning
P02137704A0000|239 253|blood pressure
P02137704A0000|264 276|office visit
P02137704A0000|285 299|blood pressure
P02137704A0000|314 326|office visit
P02137704A0000|335 349|blood pressure
P02137704A0000|381 388|indices
P02137704A0000|413 432|target organ damage
P02137704A0000|446 454|diameter
P02137704A0000|473 476|end
P02137704A0000|487 495|diameter
P02137704A0000|507 521|wall thickness
P02137704A0000|532 546|wall thickness
P02137704A0000|557 571|wall thickness
P02137704A0000|590 594|mass
P02137704A0000|599 609|mass index
P02137704A0000|624 643|wall thickness/left
P02137704A0000|666 680|diameter ratio
P02138707A0198|46 76|lambda gt11 expression library
P02138707A0198|85 97|protein mXBP
P02138707A0198|116 124|sequence
P02138707A0198|147 150|end
P02138707A0198|165 170|class
P02138707A0198|180 225|histocompatibility complex A alpha gene X box
P02138707A0198|239 260|transcription element
P02138707A0198|283 288|class
P02138707A0198|292 297|genes
P02138915A1060|4 12|p36 gene
P02138915A1060|28 30|kb
P02138915A1060|34 40|length
P02138915A1060|58 66|sequence
P02138915A1060|86 88|kb
P02138915A1060|111 112|%
P02138915A1060|120 124|gene
P02138915A1060|126 134|ABSTRACT
P02138915A1060|152 157|WORDS
P02138992A0911|19 28|treatment
P02138992A0911|62 68|tumors
P02138992A0911|91 103|modification
P02138992A0911|119 123|work
P02138992A0911|139 147|approach
P02139473A1603|61 65|site
P02139473A1603|69 73|entC
P02139473A1603|98 116|Fur concentrations
P02139473A1603|142 148|region
P02139473A1603|187 210|Shine-Dalgarno sequence
P02139891A0532|10 18|promoter
P02139891A0532|60 74|activators EIA
P02139891A0532|79 82|EIV
P02139891A0532|101 109|elements
P02139891A0532|113 123|TAGA motif
P02139891A0532|141 149|TATA box
P02139891A0532|155 165|EIIF sites
P02139891A0532|189 200|orientation
P02139891A0532|209 222|ATF/CREB site
P02141425A0175|18 36|fingertip-to-floor
P02141425A0175|38 42|MFTF
P02141425A0175|44 50|method
P02141425A0175|52 60|patients
P02141425A0175|72 77|stool
P02141425A0175|103 115|measurements
P02141425A0175|132 140|patients
P02141425A0175|167 172|floor
P02141425A0175|193 198|level
P02141425A0175|206 211|floor
P02142240A0506|15 26|differences
P02142240A0506|44 58|response rates
P02142240A0506|76 89|concentration
P02142240A0506|93 111|estrogen receptors
P02142240A0506|115 123|presence
P02142240A0506|127 148|progesteron receptors
P02142240A0506|157 162|group
P02142240A0506|166 174|patients
P02142486A0367|0 11|Teicoplanin
P02142486A0367|55 60|fever
P02142486A0367|86 97|bacteraemia
P02142486A0367|107 116|one-third
P02142486A0367|126 131|cases
P02142921T0000|12 52|hormone-releasing hormone analog therapy
P02142921T0000|64 71|fibroid
P02142921T0000|73 81|analysis
P02142921T0000|85 92|results
P02142921T0000|107 116|buserelin
P02142921T0000|147 156|goserelin
P02142921T0000|198 203|depot
P02142955A0248|3 14|Experiments
P02142955A0248|24 31|infants
P02142955A0248|38 44|adults
P02142955A0248|74 81|objects
P02142955A0248|89 94|basis
P02142955A0248|107 117|appearance
P02142955A0248|153 162|exemplars
P02142955A0248|170 176|delays
P02142955A0248|188 192|days
P02142993A0176|13 20|picture
P02142993A0176|28 35|disease
P02142993A0176|93 106|leishmaniasis
P02142993A0176|117 127|L. tropica
P02142993A0176|153 161|patterns
P02142993A0176|172 183|L. infantum
P02142993A0176|206 213|pattern
P02142993A0176|230 236|France
P02143023A0729|22 38|octamer elements
P02143023A0729|46 63|adenovirus genome
P02143023A0729|99 112|transcription
P02143023A0729|124 140|octamer elements
P02143023A0729|163 179|repeat sequences
P02143186A0867|3 13|comparison
P02143186A0867|26 33|introns
P02143186A0867|46 50|AHA3
P02143186A0867|52 56|AHA2
P02143186A0867|72 78|intron
P02143186A0867|102 108|region
P02143186A0867|122 128|intron
P02143186A0867|147 160|coding region
P02143186A1306|0 22|Northern blot analysis
P02143186A1306|38 47|AHA2 mRNA
P02143186A1306|75 78|RNA
P02143186A1306|116 122|levels
P02143186A1306|126 137|root tissue
P02143186A1306|155 167|shoot tissue
P02143768T0000|0 9|Impaction
P02143768T0000|13 29|gastrostomy tube
P02143768T0000|47 51|wall
P02143961A0400|5 20|antidepressants
P02143961A0400|34 48|pain threshold
P02143961A0400|64 76|pretreatment
P02143961A0400|82 86|pCPA
P02143961A0400|107 116|analgesia
P02144290A1444|0 3|Sci
P02144558A1022|2 18|needs assessment
P02144558A1022|28 36|families
P02144610A1306|0 9|TCR alpha
P02144610A1306|14 34|beta gene expression
P02144610A1306|64 67|set
P02144610A1306|71 77|T-cell
P02144610A1306|86 94|proteins
P02144610A1306|107 113|T beta
P02144610A1306|116 123|element
P02144610A1306|134 137|set
P02144610A1306|148 160|AMP response
P02144610A1306|177 185|proteins
P02144610A1306|213 220|T alpha
P02144610A1306|223 230|element
P02144610A1306|244 262|TCR alpha enhancer
P02144610A1306|271 286|decamer element
P02144610A1306|306 312|number
P02144610A1306|333 351|TCR beta promoters
P02145195A0253|7 16|stem-loop
P02145195A0253|40 49|structure
P02145195A0253|56 63|species
P02145195A0253|101 113|binding site
P02145195A0253|118 129|Sm proteins
P02145268A0746|12 31|nucleotide sequence
P02145268A0746|48 57|sequences
P02145268A0746|67 74|analogy
P02145268A0746|82 94|organization
P02145268A0746|102 106|type
P02145268A0746|109 123|collagen genes
P02145268A0746|156 160|exon
P02145268A0746|171 182|COL3A1 gene
P02145268A1454|6 12|losses
P02145268A1454|29 39|resistance
P02145268A1454|43 58|EDS-IV collagen
P02145268A1454|62 78|cyanogen bromide
P02145268A1454|93 114|collagenase digestion
P02146266A0000|15 37|BamHI-HindIII fragment
P02146266A0000|58 106|Neurospora crassa CuZn superoxide dismutase gene
P02146266A0000|126 131|sod-1
P02146266A0000|161 168|library
P02146266A0000|187 214|deoxyoligonucleotide probes
P02146266A0000|246 275|N. crassa amino acid sequence
P02146495A0706|10 18|peptides
P02146495A0706|66 72|region
P02146495A0706|100 121|leucine zipper domain
P02146495A0706|136 142|dimers
P02146495A0706|166 169|CRE
P02147223A1047|3 11|contrast
P02147223A1047|17 20|CRE
P02147223A1047|34 48|c-fos promoter
P02147223A1047|86 90|cAMP
P02147223A1047|95 98|E1a
P02147223A1047|107 111|HeLa
P02147223A1047|116 126|PC12 cells
P02147422A0000|35 39|gene
P02147422A0000|59 79|U1-70K snRNP protein
P02148219A0508|22 32|hypothesis
P02148219A0508|73 78|facts
P02148219A0508|92 100|rigidity
P02148219A0508|113 121|extensor
P02148219A0508|126 132|flexor
P02148219A0508|154 161|muscles
P02148291A0173|28 48|HSE oligonucleotides
P02148291A0173|56 61|types
P02148291A0173|65 71|clones
P02148291A0173|87 106|HSE binding domains
P02148291A0173|128 165|tomato lambda gt11 expression library
P02148291A0173|180 189|screening
P02148508A0374|0 5|Fluid
P02148508A0374|7 11|AVLF
P02148508A1478|4 11|results
P02148508A1478|38 47|principle
P02148508A1478|51 54|TCM
P02148508A1478|65 73|patients
P02148508A1478|112 120|patterns
P02148799A0000|4 12|nmr gene
P02148799A0000|46 50|gene
P02148799A0000|58 82|nitrogen control circuit
P02148799A0000|86 103|Neurospora crassa
P02148799A0000|146 151|genes
P02148799A0000|165 175|expression
P02148799A0000|208 213|genes
P02148799A0000|221 228|circuit
P02149487A0348|6 41|days dexamethasone suppression test
P02149487A0348|61 74|% suppression
P02149487A0348|78 109|dehydroepiandrosterone-sulphate
P02149487A0348|131 132|%
P02149487A0348|134 143|reduction
P02149487A0348|147 159|testosterone
P02149487A0348|164 186|androstenedione levels
P02149566A0478|4 9|ratio
P02149566A0478|13 23|P-31 NMR-S
P02149566A0478|42 52|phosphates
P02149566A0478|54 56|Pi
P02149566A0478|61 76|phosphocreatine
P02149566A0478|78 81|PCr
P02149566A0478|112 116|rest
P02149566A0478|120 131|LVH baboons
P02149566A0478|180 181|P
P02149570T0000|10 18|necrosis
P02149570T0000|35 55|protein S deficiency
P02150473T0067|9 14|study
P02151229A0000|0 8|Regional
P02151229A0000|18 28|blood flow
P02151229A0000|48 80|N-isopropyl-123I-iodoamphetamine
P02151229A0000|100 108|emission
P02151229A0000|118 128|tomography
P02151229A0000|130 132|CT
P02151229A0000|145 153|patients
P02151229A0000|180 197|diabetes mellitus
P02151229A0000|199 204|NIDDM
P02151229A0000|214 217|age
P02151229A0000|223 228|years
P02151229A0000|238 260|fasting plasma glucose
P02151229A0000|265 271|mmol/L
P02151229A0000|293 301|subjects
P02151229A0000|308 313|years
P02151229A0000|319 325|mmol/L
P02151229A0921|0 18|Mean ROI-A/B ratio
P02151229A0921|35 36|%
P02151229A0921|53 58|group
P02151229A0921|101 102|%
P02151229A0921|122 127|group
P02151229A0921|129 130|p
P02153243A0965|6 10|data
P02153243A0965|41 48|product
P02153243A0965|56 66|int-2 gene
P02153243A0965|92 123|fibroblast growth factor family
P02153243A0965|143 149|factor
P02153243A0965|177 183|tumors
P02153683A1579|5 11|result
P02153683A1579|36 45|complexes
P02153683A1579|63 70|ankyrin
P02153683A1579|75 81|fodrin
P02153683A1579|94 104|uvomorulin
P02153683A1579|108 110|Na
P02153683A1579|112 113|K
P02153683A1579|115 121|ATPase
P02153977A0364|6 11|genes
P02153977A0364|39 44|hours
P02153977A0364|52 62|initiation
P02153977A0364|66 77|development
P02153977A0364|85 90|mRNAs
P02153977A0364|107 111|peak
P02153977A0364|118 120|hr
P02153977A0364|139 150|culmination
P02154467A0709|4 15|PC2 protein
P02154467A0709|33 43|similarity
P02154467A0709|75 83|sequence
P02154467A0709|97 115|furin gene product
P02154467A0709|160 168|molecule
P02154474A1504|25 34|sequences
P02154474A1504|46 65|cAMP responsiveness
P02154474A1504|91 99|P-450scc
P02154474A1504|128 139|P-450 genes
P02154599A0382|8 13|study
P02154599A0382|23 35|footprinting
P02154599A0382|40 71|gel mobility retardation assays
P02154599A0382|111 130|Zta fusion proteins
P02154599A0382|166 172|motifs
P02154599A0382|180 183|DSL
P02154599T0000|4 22|zta transactivator
P02154599T0000|35 44|induction
P02154599T0000|54 75|cycle gene expression
P02154599T0000|107 118|lymphocytes
P02154599T0000|133 137|AP-1
P02154599T0000|142 151|ZRE sites
P02154599T0000|155 170|target promoter
P02154599T0000|175 191|enhancer regions
P02154602A0092|16 23|homolog
P02154602A0092|31 47|mouse Mx protein
P02154602A0092|60 70|resistance
P02154602A0092|74 89|influenza virus
P02154686A0185|0 9|Fragments
P02154686A0185|38 51|repeat region
P02154686A0185|57 65|enhancer
P02154686A0185|76 81|virus
P02154686A0185|113 141|beta-galactosidase synthesis
P02154686A0185|153 162|fragments
P02154686A0185|172 200|polyomavirus enhancer region
P02154686A0185|221 227|levels
P02154885A0153|4 9|sites
P02154885A0153|23 34|mutagenesis
P02154885A0153|36 44|residues
P02154885A0153|99 113|loop structure
P02154885A0153|139 160|substrate recognition
P02154885A0153|168 174|enzyme
P02155017A1106|13 21|benefits
P02155017A1106|25 36|LMW heparin
P02155017A1106|46 55|frequency
P02155017A1106|59 67|bleeding
P02155017A1106|69 80|alleviation
P02155017A1106|84 104|hypertriglyceridemia
P02155017A1106|165 183|observation period
P02155017A1106|196 205|incidence
P02155017A1106|221 234|complications
P02155017A1106|246 254|dialyses
P02156828A0164|12 31|amino acid sequence
P02156828A0164|35 42|destrin
P02156828A0164|50 58|residues
P02156828A0164|87 88|%
P02156828A0164|111 118|cofilin
P02156828A0164|172 179|protein
P02157067A0610|0 7|Summers
P02157067A0610|9 17|Virology
P02157141A0923|19 28|T antigen
P02157141A0923|36 44|presence
P02157141A0923|48 61|topoisomerase
P02157141A0923|83 86|DNA
P02157141A0923|102 111|sequences
P02157141A0923|153 156|DNA
P02157141A0923|172 179|changes
P02157141A0923|217 227|base pairs
P02157764A1115|2 18|rabbit antiserum
P02157764A1115|50 57|peptide
P02157764A1115|89 96|portion
P02157764A1115|122 135|cDNA sequence
P02157882T0000|0 12|Conservation
P02157882T0000|16 24|function
P02157882T0000|52 55|abl
P02157882T0000|73 81|proteins
P02157882T0000|85 99|transformation
P02157882T0000|113 118|cells
P02158099A0487|13 34|cotransfection assays
P02158099A0487|41 58|Chang liver cells
P02158099A0487|60 63|CCL
P02158099A0487|69 76|pM1 DNA
P02158099A0487|117 123|effect
P02158099A0487|131 141|expression
P02158099A0487|149 173|pSV2CAT reporter plasmid
P02158927A0000|23 33|nucleotide
P02158927A0000|35 37|nt
P02158927A0000|39 47|sequence
P02158927A0000|62 73|COR segment
P02158927A0000|93 100|cluster
P02158927A0000|108 113|genes
P02158927A0000|115 119|CYC1
P02158927A0000|121 125|UTR1
P02158927A0000|127 131|UTR3
P02158927A0000|133 137|OSM1
P02158927A0000|139 143|tRNA
P02158927A0000|144 147|Gly
P02158927A0000|153 157|RAD7
P02158927A0000|170 182|chromosome X
P02158927A0000|190 195|yeast
P02159470A1432|9 16|binding
P02159470A1432|24 39|protein factors
P02159470A1432|47 52|sites
P02159470A1432|76 88|Mt sequences
P02159470A1432|112 116|role
P02159470A1432|135 145|regulation
P02159470A1432|153 166|transcription
P02159470A1432|178 183|genes
P02159470A1432|193 201|subunits
P02159470A1432|242 257|phosphorylation
P02159559A0779|26 38|interference
P02159559A0779|56 73|DNA amplification
P02160502A0471|3 33|recombination signal sequences
P02160502A0471|68 87|recombination point
P02160622A0000|20 30|properties
P02160622A0000|51 61|tail-flick
P02160622A0000|66 81|hot-plate tests
P02160622A0000|91 104|motor effects
P02160622A0000|138 170|benzodiazepine agonist midazolam
P02160622A0000|186 197|combination
P02160622A0000|203 211|morphine
P02160622A0000|229 233|rats
P02160955A0899|0 10|Constructs
P02160955A0899|33 39|AATAAA
P02160955A0899|56 62|region
P02160955A0899|89 98|distances
P02160955A0899|120 122|bp
P02162049A0291|16 21|issue
P02162049A0291|27 31|gene
P02162049A0291|36 44|factor Y
P02162049A0291|81 93|DNA sequence
P02162103A0000|28 33|cDNAs
P02162103A0000|50 53|RNA
P02162103A0000|58 62|mRNA
P02162103A0000|67 81|phosphoprotein
P02162103A0000|83 84|P
P02162103A0000|95 113|parainfluenza type
P02162103A0000|116 121|virus
P02162103A0000|123 128|PIV-2
P02162103A0000|131 141|cDNA clone
P02162103A0000|155 158|RNA
P02162103A0000|168 179|nucleotides
P02162103A0000|183 189|length
P02162103A0000|200 204|poly
P02162103A0000|205 206|A
P02162103A0000|245 259|reading frames
P02162103A0000|269 277|proteins
P02162103A0000|293 304|amino acids
P02162467A0311|13 28|cytR expression
P02162467A0311|61 73|CytR protein
P02162467A0311|105 121|cAMP/CAP complex
P02162754A0339|18 23|sites
P02162754A0339|37 56|amino acid sequence
P02162754A0339|64 97|3T3-L1 adipocyte insulin receptor
P02162754A0339|105 110|mouse
P02162754A0801|0 3|PAO
P02162754A0801|11 19|turnover
P02162754A0801|27 43|phosphoryl group
P02162754A0801|47 51|pp15
P02162754A0801|65 77|accumulation
P02162754A0801|112 131|signal transmission
P02162754A0801|141 149|receptor
P02162754A0801|157 181|glucose-transport system
P02162835A0989|22 43|sequence similarities
P02162835A0989|71 83|architecture
P02162835A0989|95 113|heme binding sites
P02162835A0989|123 142|copper binding site
P02162835A0989|152 159|enzymes
P02163347A0472|4 17|cDNA sequence
P02163347A0472|37 50|reading frame
P02163347A0472|52 55|ORF
P02163347A0472|73 92|amino acid sequence
P02163347A0472|100 101|%
P02163347A0472|140 151|amino acids
P02163347A0472|165 178|ets-1 protein
P02163382A0169|20 33|O7-LPS region
P02163382A0169|51 66|cosmids pJHCV31
P02163382A0169|71 78|pJHCV32
P02163382A0169|99 121|transposon mutagenesis
P02163382A0169|127 135|Tn3HoHo1
P02163382A0169|166 176|lac operon
P02163382A0169|204 208|lacZ
P02163382A0169|225 232|fusions
P02163382A0169|238 258|target DNA sequences
P02163394T0000|4 13|sacT gene
P02163394T0000|29 41|sacPA operon
P02163394T0000|45 69|Bacillus subtilis shares
P02163394T0000|77 85|homology
P02163394T0000|107 122|antiterminators
P02164585A0416|4 16|TraD protein
P02164585A0416|25 27|Da
P02164585A0416|56 63|regions
P02164585A0416|114 120|region
P02164585A0814|4 19|protein product
P02164585A0814|23 27|orfD
P02164585A0814|53 61|tra gene
P02164585A0814|69 73|traX
P02164585A0814|87 88|%
P02164585A0814|101 112|amino acids
P02164585A0814|133 140|alanine
P02164585A0814|145 152|leucine
P02164588A0266|15 23|HN genes
P02164588A0266|56 60|role
P02164588A0266|64 72|residues
P02164588A0266|100 106|domain
P02164588A0266|134 138|tail
P02164588A0266|143 151|assembly
P02164588A0266|170 179|transport
P02164588A0266|187 202|HN glycoprotein
P02164604A0399|4 11|studies
P02164604A0399|25 33|findings
P02164604A0399|52 75|E2 transactivation gene
P02164604A0399|103 112|promoters
P02164604A1574|13 21|analysis
P02164604A1574|29 40|E2 proteins
P02164604A1574|60 70|cell lines
P02164604A1574|90 103|BPV-1 mutants
P02164604A1574|124 139|acceptor mutant
P02164604A1574|163 168|modes
P02164604A1574|172 185|E2 expression
P02164637A0515|0 10|Disruption
P02164637A0515|18 27|IRA2 gene
P02164637A0515|54 65|sensitivity
P02164637A0515|69 79|heat shock
P02164637A0515|84 103|nitrogen starvation
P02164637A0515|110 129|sporulation defects
P02164637A0515|141 152|suppression
P02164637A0515|160 169|lethality
P02164637A0515|177 189|cdc25 mutant
P02165181A0299|5 11|cohort
P02165181A0299|15 23|patients
P02165181A0299|44 49|basis
P02165181A0299|62 67|stage
P02165589A0000|2 6|gene
P02165589A0000|61 66|2C1-3
P02165589A0000|81 88|portion
P02165589A0000|96 108|X-chromosome
P02165589A0000|119 125|member
P02165589A0000|149 177|hormone receptor superfamily
P02165589A0888|2 9|portion
P02165589A0888|13 22|Region II
P02165589A0888|38 42|part
P02165589A0888|56 73|c-jun oncoprotein
P02165589A0888|76 90|leucine zipper
P02165589A0888|101 105|turn
P02165589A0888|139 162|heterodimerization site
P02165589A0888|175 178|jun
P02165589A0888|183 199|fos oncoproteins
P02166040A0385|21 29|vanadate
P02166040A0385|44 68|PEPCK gene transcription
P02166040A0385|72 78|series
P02166040A0385|91 96|genes
P02166040A0385|116 125|deletions
P02166040A0385|149 171|carboxykinase promoter
P02166040A0385|222 227|genes
P02166040A0385|256 274|phosphotransferase
P02166040A0385|276 279|neo
P02166040A0385|284 317|chloramphenicol acetyltransferase
P02166040A0385|338 352|hepatoma cells
P02166040A0385|365 372|methods
P02166040A0385|378 387|infection
P02166040A0385|395 402|Moloney
P02166040A0385|410 418|leukemia
P02166040A0385|431 441|retrovirus
P02166040A0385|447 459|transfection
P02166040A0385|471 480|selection
P02166040A0385|485 499|neo expression
P02166040A0385|518 528|expression
P02166040A0385|532 566|chloroamphenicol acetyltransferase
P02166416A0419|4 13|diagnosis
P02166416A0419|25 37|tuberculosis
P02166416A0419|77 81|ARDS
P02166416A0419|93 99|origin
P02166825A0198|3 8|order
P02166825A0198|40 48|elements
P02166825A0198|56 64|promoter
P02166825A0198|78 81|way
P02166825A0198|115 122|signals
P02166825A0198|126 132|number
P02166825A0198|136 154|promoter mutations
P02166825A0198|185 188|set
P02166825A0198|208 217|mutations
P02166825A0198|236 251|promoter region
P02167321T0000|2 11|DNA motif
P02167321T0000|43 50|element
P02167321T0000|71 90|activator protein-2
P02167321T0000|99 103|site
P02167321T0000|117 164|tissue-type plasminogen activator gene promoter
P02167321T0000|184 194|expression
P02167321T0000|206 216|activation
P02167321T0000|220 233|phorbol ester
P02167321T0000|238 242|cAMP
P02167467T0000|4 20|26S rRNA binding
P02167467T0000|31 49|protein equivalent
P02167467T0000|63 74|protein L11
P02167467T0000|110 115|genes
P02167784A0109|18 26|subjects
P02167784A0109|36 39|air
P02167784A0109|47 50|min
P02167784A0109|61 62|%
P02167784A0109|69 70|%
P02167784A0109|81 84|min
P02167784A0109|108 111|min
P02167784A0109|157 172|CO2 measurement
P02168640A0268|12 24|correlations
P02168640A0268|47 54|changes
P02168640A0268|58 62|SSEP
P02168640A0268|66 74|response
P02168640A0268|89 97|presence
P02168640A0268|127 139|disturbances
P02168640A0268|152 158|ground
P02168640A0268|175 184|disorders
P02169887A0360|4 15|transcripts
P02169887A0360|68 80|capstructure
P02169887A0360|100 108|EMCV-RNA
P02169887A0360|123 128|mRNAs
P02169887A0360|149 159|initiation
P02170687A0000|4 18|E6/E7 promoter
P02170687A0000|40 56|papillomaviruses
P02170687A0000|76 86|expression
P02170687A0000|100 118|transforming genes
P02172672T0001|2 6|case
P02172672T0001|10 21|Goodpasture
P02172672T0001|24 32|syndrome
P02173399A0333|27 35|controls
P02173399A0333|53 59|blocks
P02173399A0333|76 94|tissue radiographs
P02173399A0333|96 100|STRs
P02173399A0333|124 135|specificity
P02173399A0333|140 141|%
P02173399A0333|143 154|sensitivity
P02173399A0333|158 159|%
P02173405A0270|15 26|abnormality
P02173405A0270|58 64|period
P02173405A0270|88 102|calcifications
P02174105A1232|20 28|analysis
P02174105A1232|40 50|rat organs
P02174105A1232|63 71|staining
P02174105A1232|86 91|cells
P02174427A1574|5 12|strains
P02174427A1574|64 78|carbon sources
P02174427A1574|109 110|%
P02174427A1574|124 170|ubiquinol-cytochrome c oxidoreductase activity
P02174861A0736|0 10|Regulation
P02174861A0736|14 18|irgA
P02174861A0736|22 26|iron
P02174861A0736|30 41|V. cholerae
P02174861A0736|72 77|level
P02174861A0736|107 111|dyad
P02174861A0736|122 130|sequence
P02174861A0736|138 146|vicinity
P02174861A0736|154 162|promoter
P02174861A0736|185 188|Fur
P02174861A0736|197 202|sites
P02174974A0000|0 13|Transcription
P02174974A0000|27 33|operon
P02174974A0000|64 71|enzymes
P02174974A0000|79 90|TOL plasmid
P02174974A0000|133 150|xylR gene product
P02174974A0000|158 166|presence
P02174974A0000|170 178|m-xylene
P02175433A0575|36 54|beta A-globin gene
P02175433A0575|67 71|gene
P02175433A0575|76 96|Ylp vector sequences
P02175433A0575|113 119|copies
P02175908A0805|12 21|mutations
P02175908A0805|48 52|copy
P02175908A0805|60 75|Ulysses element
P02175908A0805|90 95|locus
P02175908A0805|138 145|element
P02175908A0805|173 181|mutation
P02176021T0000|0 13|Determination
P02176021T0000|17 23|diquat
P02176021T0000|38 47|materials
P02176021T0000|51 87|electron spin resonance spectroscopy
P02176152A0896|18 20|RA
P02176152A0896|51 59|activity
P02176152A0896|65 78|reporter gene
P02176152A0896|92 95|TPA
P02176152A0896|107 123|AP1 binding site
P02176152A0896|136 151|HSV tk promoter
P02176209A0954|23 26|EFI
P02176209A0954|28 32|NF-Y
P02176209A0954|37 45|CBF DNAs
P02176209A0954|51 55|rise
P02176209A0954|69 93|gel retardation patterns
P02176209A0954|97 105|extracts
P02176209A0954|113 120|variety
P02176209A0954|134 144|cell types
P02176232T0001|0 12|Risk factors
P02176232T0001|25 47|lymph nodes metastasis
P02176232T0001|51 62|lung cancer
P02176232T0001|68 73|stage
P02176232T0001|83 87|IIIA
P02176822A0000|16 30|protein kinase
P02176822A0000|32 36|MFPK
P02176822A0000|65 70|lyase
P02176822A0000|74 83|peptide B
P02176822A0000|91 96|sites
P02176822A0000|98 100|BT
P02176822A0000|105 107|BS
P02176822A0000|112 121|threonine
P02176822A0000|126 132|serine
P02176822A0000|148 157|inhibitor
P02176822A0000|174 181|residue
P02176822A0000|187 204|glycogen synthase
P02176822A0000|208 213|sites
P02179052A1044|18 19|Y
P02179052A1044|30 47|sequence families
P02179052A1044|72 78|system
P02179052A1044|97 118|sequence interactions
P02179052A1044|134 143|evolution
P02179188A1223|25 41|motile responses
P02179188A1223|69 77|presence
P02179188A1223|81 94|dinitrophenol
P02179188A1223|98 113|cytochalasin B.
P02179815A0582|7 15|p59v-rel
P02179815A0582|36 43|protein
P02179815A0582|47 50|CEF
P02179815A0582|61 79|immunofluorescence
P02179815A0582|92 100|p68c-rel
P02179815A0582|124 127|CEF
P02179815A0582|158 167|cytoplasm
P02179815A0582|177 182|cells
P02179815A0582|200 208|sequence
P02179815A0582|212 220|p68c-rel
P02179815A0582|266 274|sequence
P02179815A0582|321 329|p59v-rel
P02180935A0535|8 19|experiments
P02180935A0535|44 47|min
P02180935A0535|66 83|precursor protein
P02180935A0535|101 112|HL-60 cells
P02180935A0535|121 123|Mr
P02180935A0535|146 191|chondroitin sulfate proteoglycan intermediate
P02181760A0311|0 10|Blood flow
P02181760A0311|15 23|velocity
P02181760A0311|40 58|Doppler ultrasound
P02181760A0311|87 95|diastole
P02181760A0311|123 132|direction
P02181760A0311|136 156|cotyledon resistance
P02181760A0311|180 184|fold
P02182240A0355|2 7|total
P02182240A0355|15 23|patients
P02182240A0355|33 45|anistreplase
P02182240A0355|63 70|heparin
P02182240A0355|85 91|period
P02182240A0355|106 109|min
P02182240A0355|124 129|onset
P02182240A0355|133 141|symptoms
P02182323A0121|17 28|transcripts
P02182323A0121|42 46|tRNA
P02182323A0121|47 50|Val
P02182323A0121|52 55|UAC
P02182323A0121|57 61|gene
P02182323A0121|102 119|growth conditions
P02182323A0121|124 133|degrees C
P02182323A0121|174 180|region
P02182618A0168|4 21|promoter activity
P02182618A0168|50 60|expression
P02182618A0168|66 99|chloramphenicol acetyltransferase
P02182618A0168|101 104|CAT
P02182618A0168|106 110|gene
P02182618A0168|137 153|deletion mutants
P02182618A0168|173 179|region
P02183467A0668|19 23|ORFs
P02183467A0668|39 45|region
P02183467A0668|49 52|BIV
P02183467A0668|77 85|location
P02183467A0668|101 111|similarity
P02183467A0668|144 149|genes
P02183467A0668|151 154|vif
P02183467A0668|156 159|tat
P02183467A0668|165 168|rev
P02183467A0668|179 191|lentiviruses
P02183467A0668|223 227|ORFs
P02183467A0668|236 237|W
P02183467A0668|242 243|Y
P02183467A0668|264 269|exons
P02183467A0668|280 285|genes
P02185140A0000|29 38|14DM gene
P02185140A0000|49 75|cytochrome P450 lanosterol
P02185140A0000|79 96|alpha-demethylase
P02185140A0000|98 102|14DM
P02185140A0000|148 155|strains
P02185140A0000|166 173|control
P02185140A0000|203 232|yeast transcription promoters
P02185140A0000|234 239|pADC1
P02185140A0000|241 245|pGPD
P02185140A0000|247 252|pPHO5
P02185140A0000|268 275|control
P02185140A0000|287 295|promoter
P02185250A0726|0 11|Truncations
P02185250A0726|34 45|amino acids
P02185250A0726|87 105|reticulum membrane
P02185250A0726|111 124|translocation
P02187091A0721|19 29|resistance
P02187091A0721|47 64|ejection fraction
P02187091A0721|99 116|relaxation period
P02187091A0721|167 168|P
P02187871T0000|4 14|ANB1 locus
P02187871T0000|55 97|protein synthesis initiation factor eIF-4D
P02188096A0955|4 16|contribution
P02188096A0955|34 49|splicing events
P02188096A0955|53 69|c-myb expression
P02188096A0955|82 96|c-myb function
P02188168A0000|0 10|Serum beta
P02188168A0000|27 33|levels
P02188168A0000|35 43|beta-2-M
P02188168A0000|65 77|drug addicts
P02188168A0000|103 111|carriers
P02188168A0000|120 136|HIV-1 antibodies
P02188168A0000|153 161|carriers
P02188168A0000|190 205|lymphadenopathy
P02188168A0000|207 213|P.G.L.
P02188168A0000|222 227|serum
P02188168A0000|237 245|patients
P02188168A0000|278 287|community
P02188168A0000|303 308|years
P02190122A0633|5 17|emancipation
P02190122A0633|25 32|ability
P02190122A0633|59 68|influence
P02190122A0633|89 99|motivation
P02190122A0633|112 121|regulator
P02190122A0633|125 131|mating
P02190122A0633|135 143|primates
P02190134A0572|3 10|therapy
P02190134A0572|34 45|progression
P02190134A0572|53 60|disease
P02190134A0572|79 88|exception
P02190134A0572|92 124|laser photocoagulation treatment
P02190134A0572|163 172|membranes
P02190134A0572|179 186|attempt
P02190134A0572|196 209|complications
P02190134A0572|224 235|hemorrhages
P02193033A0195|0 2|R.
P02194273A0913|9 30|hyperimmune globulins
P02194273A0913|34 43|pathogens
P02194273A0913|64 74|influenzae
P02194273A0913|79 92|Streptococcus
P02194972T0000|12 19|effects
P02194972T0000|23 32|cefpirome
P02194972T0000|34 36|HR
P02194972T0000|64 74|infections
P02194972T0000|80 101|Enterococcus faecalis
P02194972T0000|126 130|mice
P02195025T0000|0 10|Regulation
P02195025T0000|14 24|yeast LEU2
P02195715A0143|11 22|individuals
P02195715A0143|39 56|purpura fulminans
P02195715A0143|60 68|newborns
P02195715A0143|83 90|protein
P02195715A0143|103 114|individuals
P02195715A0143|132 136|risk
P02195715A0143|148 158|thrombosis
P02195715A0143|173 181|embolism
P02195715T0000|9 15|stroke
P02195715T0000|23 43|protein C deficiency
P02196176A0749|0 5|TREB7
P02196176A0749|10 16|TREB36
P02196176A0749|37 44|repeats
P02196176A0749|55 57|bp
P02196176A0749|63 68|TREB5
P02196176A0749|95 101|repeat
P02196311A1034|6 13|results
P02196311A1034|29 37|KE X 3/W
P02196311A1034|57 64|regimen
P02196311A1034|80 98|antitumor immunity
P02196311A1034|102 105|RNL
P02196450A0870|0 8|Analysis
P02196450A0870|20 36|deletion mutants
P02196450A0870|56 77|sequence requirements
P02196450A0870|82 89|binding
P02196450A0870|93 96|QBP
P02196450A0870|153 163|Q activity
P02196450A0870|198 201|QBP
P02196450A0870|222 230|function
P02196450A0870|256 264|promoter
P02196565A0606|25 33|factor I
P02196565A0606|35 39|GRFI
P02196565A0606|41 81|repressor/activator site binding protein
P02196565A0606|85 89|RAP1
P02196565A0606|91 102|translation
P02196565A0606|112 118|factor
P02196565A0606|120 123|TUF
P02196565A0606|146 155|activator
P02196565A0606|159 179|MAT alpha expression
P02196565A0606|201 205|PYK1
P02196565A0606|241 254|GRFI/RAP1/TUF
P02196565A0606|280 294|gal11 mutation
P02196565T0000|0 19|Yeast Gal11 protein
P02196565T0000|49 66|activation signal
P02196565T0000|96 103|factors
P02196565T0000|105 109|Gal4
P02196565T0000|133 196|factor I/repressor/activator site binding protein 1/translation
P02196565T0000|206 212|factor
P02198259A0685|0 8|Deletion
P02198259A0685|25 26|N
P02198259A0685|42 46|ends
P02198259A0685|50 54|repA
P02198259A0685|66 72|codons
P02198259A0685|114 127|reading frame
P02198259A0685|142 151|initiator
P02198259A0685|175 183|activity
P02198289A0436|15 23|peptides
P02198289A0436|40 51|amino acids
P02198289A0436|83 94|amino acids
P02198289A0436|110 116|dimers
P02198289A0436|120 128|solution
P02198289A0436|139 142|DNA
P02198289A0436|161 166|dimer
P02199311A0620|9 31|transcription extracts
P02199311A0620|37 49|ret1-1 cells
P02199311A0620|85 118|transcription termination signals
P02199311A0620|135 145|RET1 cells
P02199311A0620|155 162|variety
P02199311A0620|166 180|tRNA templates
P02200150A1381|8 16|patients
P02200150A1381|24 32|decision
P02200150A1381|68 72|team
P02200150A1381|96 106|oncologist
P02200150A1381|108 118|geneticist
P02200150A1381|120 131|pathologist
P02200150A1381|133 148|psychotherapist
P02200150A1381|153 168|plastic surgeon
P02200315A0278|0 3|IgG
P02200315A0278|8 29|IgM antibody activity
P02200315A0278|63 71|dilution
P02200315A0278|75 80|serum
P02200315A0278|84 90|plates
P02200315A0278|103 114|A60 antigen
P02200736A1003|6 13|factors
P02200736A1003|26 29|set
P02200736A1003|54 63|molecules
P02200736A1003|75 79|AP-4
P02200736A1003|84 88|MLTF
P02200736A1003|107 121|CACCTGTC motif
P02200736A1003|133 142|sequences
P02201770A0188|12 23|flea larvae
P02201770A0188|29 48|genus Anomiopsyllus
P02201770A0188|50 65|Anomiopsyllinae
P02201770A0188|67 81|Anomiopsyllini
P02201770A0188|111 115|form
P02201770A0188|127 133|adults
P02201901A0229|28 36|antibody
P02201901A0229|70 82|SSN6 protein
P02201905A1004|13 20|results
P02201905A1004|37 49|ABFI protein
P02201905A1004|60 72|RAP1 protein
P02201905A1004|80 89|sequences
P02201905A1004|132 142|regulation
P02201905A1004|146 161|gene expression
P02202496T0000|9 18|nutrition
P02202496T0000|28 34|horses
P02203672A1542|24 38|cytocentrifuge
P02204029A0184|0 23|RNase protection assays
P02204029A0184|41 45|gene
P02204029A0184|47 50|unr
P02204029A0184|79 88|direction
P02204029A0184|92 97|N-ras
P02204029A0184|114 117|end
P02204029A0184|138 148|base pairs
P02204029A0184|163 168|point
P02204029A0184|184 197|transcription
P02204621T0000|0 9|Isolation
P02204621T0000|37 43|mutant
P02204621T0000|60 87|tRNA nucleotidyltransferase
P02204621T0000|92 99|cloning
P02204621T0000|107 111|gene
P02204621T0000|121 148|tRNA nucleotidyltransferase
P02204621T0000|156 161|yeast
P02204623A0000|4 24|juxtamembrane region
P02204623A0000|32 48|insulin receptor
P02204623A0000|50 52|IR
P02204623A0000|54 66|beta-subunit
P02204623A0000|96 111|tyrosyl residue
P02204623A0000|113 119|Tyr960
P02204623A0000|162 185|tyrosyl phosphorylation
P02204623A0000|205 215|substrates
P02204623A0000|239 248|responses
P02204623A0000|250 255|White
P02204623A0000|257 261|M.F.
P02204623A0000|263 273|Livingston
P02204623A0000|275 279|J.N.
P02204623A0000|281 287|Backer
P02204623A0000|289 293|J.M.
P02204623A0000|295 301|Lauris
P02204623A0000|303 305|V.
P02204623A0000|307 311|Dull
P02204623A0000|313 317|T.J.
P02204623A0000|319 326|Ullrich
P02204623A0000|328 330|A.
P02204623A0000|336 340|Kahn
P02204623A0000|342 346|C.R.
P02204625A1130|5 9|gene
P02204625A1130|20 25|group
P02204625A1130|29 34|genes
P02204625A1130|41 48|members
P02204625A1130|76 84|response
P02204625A1130|88 95|insulin
P02204625A1130|106 114|mitogens
P02204810A1080|7 13|region
P02204810A1080|15 18|GA2
P02204810A1080|45 55|expression
P02206430A0197|0 4|Pups
P02206430A0197|27 38|environment
P02206430A0197|50 57|mothers
P02206430A0197|84 89|level
P02206430A0197|93 104|DA turnover
P02206789A0002|4 12|efficacy
P02206789A0002|17 23|safety
P02206789A0002|48 71|anaesthetic preparation
P02206789A0002|81 92|amethocaine
P02206789A0002|142 153|environment
P02206858A0000|11 20|protein C
P02206858A0000|22 24|PC
P02206858A0000|26 36|deficiency
P02206858A0000|56 64|siblings
P02206858A0000|66 70|girl
P02206858A0000|75 78|boy
P02206858A0000|106 115|diagnoses
P02206858A0000|123 127|ages
P02206858A0000|149 154|years
P02208762A0228|4 15|grandfather
P02208762A0228|24 37|granddaughter
P02208762A0228|47 55|microtia
P02208762A0228|67 74|atresia
P02208762A0228|88 96|daughter
P02208762A0228|116 119|ear
P02208762A0228|140 146|meatus
P02208762A0228|161 171|appendages
P02209237A0239|24 32|shunting
P02209237A0239|34 37|IPS
P02209237A0239|62 67|cases
P02209237A0239|95 103|scanning
P02209237A0239|109 118|99mTc-MAA
P02209237A0239|146 151|cause
P02209237A0239|155 163|cyanosis
P02209237A0239|167 182|liver cirrhosis
P02209243A0237|12 19|protein
P02209243A0237|21 34|serum albumin
P02209243A0237|36 39|BUN
P02209243A0237|44 47|SCr
P02209243A0237|73 84|improvement
P02209540A1362|16 20|Ets1
P02209540A1362|25 29|Ets2
P02209540A1362|45 58|transcription
P02209540A1362|71 76|genes
P02209605A0510|12 20|sequence
P02209605A0510|25 34|MSAS gene
P02209605A0510|73 86|reading frame
P02209605A0510|100 107|protein
P02209605A0510|116 127|amino acids
P02209605A0510|140 142|Da
P02209605A0510|153 157|mass
P02209811T0000|12 22|peroxidase
P02209811T0000|28 47|permeability marker
P02209811T0000|59 69|rat caudal
P02209811T0000|74 88|iliac arteries
P02212540A0473|21 35|wall specimens
P02212540A0473|45 49|area
P02212540A0473|68 74|ulcers
P02212540A0473|118 134|light microscopy
P02212540A0473|142 174|transmission electron microscopy
P02213566A0000|4 11|effects
P02213566A0000|15 27|coenzyme Q10
P02213566A0000|29 32|CoQ
P02213566A0000|38 47|captopril
P02213566A0000|62 70|capacity
P02213566A0000|72 84|hemodynamics
P02213566A0000|89 97|survival
P02213566A0000|118 122|rats
P02213566A0000|168 178|infarction
P02217307T0000|0 8|Evidence
P02217307T0000|26 37|alterations
P02217307T0000|53 59|rhythm
P02217307T0000|72 89|emptying response
P02217741T0001|4 17|interrelation
P02217741T0001|25 31|levels
P02217741T0001|35 50|glucocorticoids
P02217741T0001|55 62|insulin
P02217741T0001|70 75|blood
P02217741T0001|90 97|animals
P02218094A0395|19 25|tissue
P02218094A0395|29 37|transfer
P02218094A0395|39 41|Ft
P02218094A0395|65 76|utilization
P02218094A0395|78 80|Fm
P02219751A0517|10 18|saccades
P02219751A0517|63 67|FEMs
P02219751A0517|75 80|basis
P02219751A0517|84 89|speed
P02220102A0271|0 9|Incidence
P02220102A0271|30 35|grade
P02220102A0271|44 55|hygiene und
P02220102A0271|68 75|disease
P02220304A0501|4 9|study
P02220304A0501|25 29|area
P02220304A0501|33 38|Alcoy
P02220304A0501|44 65|medium MS risk region
P02220304A0501|83 89|thesis
P02220304A0501|93 99|Kurzke
P02220304A0501|115 123|MS areas
P02220304A0501|159 174|MS distribution
P02220304A0501|187 193|Europe
P02223652A0939|6 29|antithrombin unit basis
P02223652A0939|31 33|CY
P02223652A0939|42 44|CY
P02223652A0939|86 88|UH
P02223773A0000|0 39|Chick brain actin depolymerizing factor
P02223773A0000|41 44|ADF
P02223773A0000|58 65|protein
P02223773A0000|78 93|actin filaments
P02223773A0000|104 118|actin monomers
P02223928T0069|8 18|experience
P02223928T0069|26 43|serotonin agonist
P02225687A0546|0 18|Comprehensive care
P02225687A0546|26 33|patient
P02225687A0546|53 62|teratogen
P02225687A0546|80 90|discussion
P02225687A0546|114 124|procedures
P02225687A0546|135 163|pregnancy management options
P02227438A0492|0 25|Primer extension analysis
P02227438A0492|30 44|RNA sequencing
P02227438A0492|67 92|transcription start point
P02227438A0492|96 108|rat ODC mRNA
P02227438A0492|124 126|nt
P02227438A0492|145 154|A residue
P02227438A0492|162 173|start codon
P02228615A0974|4 8|85Sr
P02228615A0974|31 56|distribution coefficients
P02228615A0974|78 100|desorption experiments
P02228615A0974|105 115|indication
P02228615A0974|136 145|formation
P02228615A0974|149 168|metal-oxyhydroxides
P02228615A0974|183 191|reaction
P02229068A0156|0 15|Gene constructs
P02229068A0156|40 43|tat
P02229068A0156|45 48|rev
P02229068A0156|50 53|tat
P02229068A0156|55 58|rev
P02229068A0156|65 74|env genes
P02229068A0156|105 116|COS-1 cells
P02229068A0156|120 135|precursor SU-TM
P02229068A0156|137 142|gp160
P02229068A0156|145 147|SU
P02229068A0156|148 150|TM
P02229068A0156|152 159|gp120 x
P02229068A0156|179 190|rev protein
P02229072A1012|5 18|growth arrest
P02229072A1012|51 57|medium
P02229072A1012|67 77|conditions
P02229072A1012|91 96|cells
P02229072A1012|133 143|metabolism
P02229282A0454|0 8|Patients
P02229282A0454|25 41|serum TNF levels
P02229282A0454|66 89|serum T3 concentrations
P02229282A0454|126 132|levels
P02229541T0000|0 5|Giant
P02229541T0000|17 26|carcinoma
P02229541T0000|28 34|report
P02229541T0000|39 45|review
P02229541T0000|53 63|literature
P02231162T0000|8 15|studies
P02231162T0000|30 38|movement
P02231162T0000|50 63|tooth contact
P02231479A0585|5 11|parent
P02231479A0585|51 54|son
P02231479A0585|58 66|daughter
P02231479A0585|82 95|conversations
P02231479A0585|118 130|conversation
P02231479A0585|148 161|task activity
P02233626T0000|34 42|symptoms
P02233626T0000|70 88|strabismus surgery
P02233680A1115|6 13|results
P02233680A1115|47 55|elements
P02233680A1115|83 90|control
P02233680A1115|98 122|HaG3-A helianthinin gene
P02233680A1115|144 146|kb
P02233680A1115|156 162|region
P02233680A1115|171 175|gene
P02233715A0914|4 13|induction
P02233715A0914|17 35|pseudorabies virus
P02233715A0914|42 56|IL-6 construct
P02233715A0914|72 85|IL-6 TATA box
P02233715A0914|94 108|RNA start site
P02233715A0914|111 120|initiator
P02233715A0914|129 136|element
P02233715A0914|150 160|MRE region
P02233715A0914|183 186|Dex
P02233715A0914|194 202|presence
P02233715A0914|216 218|GR
P02233729A1065|5 14|mutations
P02233729A1065|24 28|Dhfr
P02233729A1065|46 52|manner
P02233729A1065|78 88|startpoint
P02233729A1065|109 125|Dhfr transcripts
P02233729A1065|151 160|abundance
P02233729A1065|178 194|Dhfr transcripts
P02234345A0215|10 19|cyst wall
P02234345A0215|33 37|part
P02234345A0215|63 73|epithelium
P02234731A0503|17 22|class
P02234731A0503|35 41|smears
P02234731A0503|66 78|inflammation
P02234731A0503|102 110|findings
P02234731A0503|114 125|condylomata
P02234731A0503|139 148|dysplasia
P02236002A0958|6 13|mammals
P02236002A0958|28 48|nucleotide diversity
P02236002A0958|69 78|junctions
P02236002A0958|96 105|diversity
P02236002A0958|119 127|elements
P02236002A0958|131 153|chicken TCR beta cDNAs
P02236022A0000|4 23|protooncogene c-myb
P02236022A0000|42 62|transcription factor
P02236022A0000|77 80|DNA
P02236022A0000|104 110|manner
P02236022A0000|130 143|transcription
P02236022A0000|174 179|genes
P02236060A1671|0 12|Modification
P02236060A1671|28 36|compound
P02236060A1671|63 69|amount
P02236060A1671|109 116|protein
P02236064A1178|0 20|S6 kinase activation
P02236064A1178|30 42|displacement
P02236064A1178|62 69|segment
P02236064A1178|125 140|phosphorylation
P02236276T0000|0 4|Rats
P02236276T0000|24 28|bulb
P02236276T0000|59 64|naris
P02236276T0000|83 88|odors
P02237431A0000|0 10|Expression
P02237431A0000|24 39|T cell receptor
P02237431A0000|41 44|TCR
P02237431A0000|46 56|alpha gene
P02237431A0000|75 76|T
P02237431A0000|107 115|enhancer
P02237431A0000|136 145|kilobases
P02237431A0000|147 149|kb
P02237431A0000|161 181|C alpha gene segment
P02237431A0833|4 22|Ets-1 binding site
P02237431A0833|50 54|pair
P02237431A0833|56 58|bp
P02237431A0833|60 66|region
P02237431A0833|79 82|end
P02237431A0833|86 93|T alpha
P02241742A0766|9 13|flow
P02241742A0766|18 28|resistance
P02241742A0766|42 52|reductions
P02241742A0766|58 60|HD
P02241892A0681|0 11|Utilization
P02241892A0681|27 50|polyadenylation signals
P02241892A0681|100 105|mRNAs
P02241892A0681|121 123|kb
P02241892A0681|145 151|length
P02241892A0681|177 184|regions
P02242222T0000|13 20|address
P02242222T0000|46 50|cold
P02243093A0000|6 32|T-cell leukemia virus type
P02243093A0000|36 42|HTLV-I
P02243093A0000|69 76|protein
P02243093A0000|78 81|Tax
P02243093A0000|100 113|transcription
P02243093A0000|133 137|pair
P02243093A0000|139 141|bp
P02243093A0000|143 150|repeats
P02243093A0000|158 167|U3 region
P02243386A0113|33 39|serial
P02243386A0113|50 58|passages
P02243386A0113|62 65|MHV
P02243386A0113|75 81|DI RNA
P02243386A0113|83 88|DIssF
P02243386A0113|125 132|virions
P02246362T0000|4 27|Jenkins Activity Survey
P02246362T0000|57 65|evidence
P02246362T0000|94 98|type
P02246362T0000|101 107|traits
P02246447A0460|10 18|evidence
P02246447A0460|33 50|regression slopes
P02246447A0460|81 94|portion sizes
P02246447A0460|111 122|food groups
P02246447A0460|133 142|r2 values
P02246447A0460|160 173|portion sizes
P02246803A0692|4 10|result
P02246803A0692|43 53|TTD method
P02246803A0692|126 132|output
P02247069A0261|4 13|TUP1 gene
P02247069A0261|32 38|screen
P02247069A0261|43 48|genes
P02247069A0261|63 74|mating type
P02247069A0261|76 80|V.L.
P02247072A0794|4 29|SUP44 suppressor mutation
P02247072A0794|44 50|region
P02247072A0794|58 65|protein
P02247072A0794|96 105|positions
P02247072A0794|109 120|alterations
P02247072A0794|135 148|ram mutations
P02247081A0223|15 25|disruption
P02247081A0223|33 44|VPS34 locus
P02247081A0223|81 94|growth defect
P02247081A0223|116 126|VPS34 gene
P02247081A0223|155 161|growth
P02247081A0223|179 198|growth temperatures
P02247924A0078|14 18|case
P02247924A0078|36 43|abscess
P02247924A0078|57 71|amphotericin B
P02247924A0078|76 87|nephrectomy
P02248732A1113|24 28|data
P02248732A1113|43 54|haloperidol
P02248732A1113|80 88|increase
P02248732A1113|96 107|firing rate
P02248732A1113|111 119|LC cells
P02248732A1113|125 126|%
P02248732A1113|170 178|turnover
P02248732A1113|182 184|NA
P02248732A1113|201 214|DOPAC changes
P02249872A1051|5 16|interaction
P02249872A1051|36 41|range
P02249872A1051|50 60|parameters
P02249872A1051|66 80|charge density
P02249872A1051|105 115|microC/cm2
P02249872A1051|125 131|charge
P02249872A1051|136 141|phase
P02249872A1051|169 175|microC
P02249872A1051|180 185|phase
P02250919A0404|0 11|Perceptions
P02250919A0404|15 36|illness intrusiveness
P02250919A0404|73 85|muscle cramp
P02250919A0404|90 107|headache symptoms
P02250919A0404|136 156|assessment intervals
P02250919A0404|177 190|muscle cramps
P02250919A0404|194 203|headaches
P02251119A0319|0 7|Results
P02251119A0319|39 47|presence
P02251119A0319|57 60|U14
P02251119A0319|78 85|regions
P02251119A0319|104 111|introns
P02251119A0319|131 136|mouse
P02251119A0319|145 166|hsc70 heat shock gene
P02252891T0000|14 21|protein
P02252891T0000|40 51|interleukin
P02252891T0000|54 65|stimulation
P02252891T0000|99 104|sites
P02252891T0000|129 134|sites
P02252953A0300|22 27|girls
P02252953A0300|55 64|EAT score
P02252953A0300|89 94|girls
P02252953A0300|118 125|mothers
P02252953A0300|128 142|susceptibility
P02252953A0300|164 171|effects
P02252953A0300|184 195|mood states
P02252953A0300|205 221|eating behaviour
P02253274A0000|4 16|Mauriceville
P02253274A0000|21 27|Varkud
P02253274A0000|42 50|plasmids
P02253274A0000|88 92|DNAs
P02253274A0000|106 108|kb
P02253274A0000|134 149|characteristics
P02253274A0000|153 166|mtDNA introns
P02253274A0000|179 187|elements
P02253663A0687|14 20|rhythm
P02253663A0687|56 66|difference
P02253663A0687|75 82|minimum
P02253663A0687|90 91|h
P02253663A0687|97 104|maximum
P02253663A0687|112 113|h
P02253663A0687|115 135|serum concentrations
P02253663A0687|144 145|%
P02254282T0000|0 8|Sequence
P02254282T0000|21 33|organization
P02254282T0000|39 69|Zymomonas mobilis gene cluster
P02254282T0000|91 98|enzymes
P02254282T0000|102 120|glucose metabolism
P02254418A0641|5 12|strains
P02254418A0641|16 17|%
P02254418A0641|22 36|S. lugdunensis
P02254418A0641|48 63|delta hemolysin
P02254418A0641|95 102|species
P02254418A0641|106 109|CNS
P02254749A0133|10 15|cDNAs
P02254749A0133|31 34|60K
P02254749A0133|36 39|87K
P02254749A0133|41 45|110K
P02254749A0133|50 62|170K protein
P02254749A0133|70 79|sequences
P02254749A0133|107 122|ATG start codon
P02254749A0133|131 135|cDNA
P02254749A0133|151 154|60K
P02254749A0133|162 170|sequence
P02254749A0133|178 181|TAA
P02254749A0133|187 192|codon
P02254749A0133|230 238|sequence
P02256678A1224|25 46|footprinting analysis
P02256678A1224|63 69|region
P02256678A1224|102 112|HSC82 gene
P02256678A1224|125 133|presence
P02256678A1224|152 169|protein complexes
P02257251T0000|0 15|Pathophysiology
P02257251T0000|19 28|bone loss
P02257251T0000|42 49|animals
P02257899T0000|16 27|interaction
P02257899T0000|35 45|generation
P02257899T0000|49 57|saccades
P02257899T0000|61 64|man
P02258918A0242|12 16|lung
P02258918A0242|30 36|slices
P02258918A0242|57 66|disectors
P02258918A0242|108 125|sampling fraction
P02259334A0205|13 21|promoter
P02259334A0205|51 59|sequence
P02259334A0205|75 79|gene
P02259334A0205|93 100|protein
P02259334A0205|104 106|Mr
P02259334A0205|110 113|kDa
P02259334A0205|125 133|function
P02259795A0570|12 23|consumption
P02259795A0570|40 44|skin
P02259795A0570|68 80|calculations
P02259795A0570|98 107|water PO2
P02259795A0570|122 127|mm Hg
P02259795A0570|138 139|%
P02259795A0570|162 168|uptake
P02259795A0570|189 193|skin
P02261254A0168|0 11|Experiments
P02261254A0168|34 40|arrest
P02261254A0168|54 65|circulation
P02261254A0168|72 82|conditions
P02261254A0168|101 112|circulation
P02261254A0168|132 143|development
P02261254A0168|147 155|ischemia
P02261254A0168|185 191|tissue
P02262439A0508|0 12|MCh infusion
P02262439A0508|46 54|increase
P02262439A0508|58 75|airway resistance
P02262439A0508|88 91|QBA
P02264601A0000|0 22|Taste reactivity tests
P02264601A0000|58 67|responses
P02264601A0000|71 78|alcohol
P02264601A0000|91 92|P
P02264601A0000|94 98|rats
P02264601A0000|103 124|alcohol nonpreferring
P02264601A0000|126 128|NP
P02264601A0000|130 134|rats
P02264601A0000|142 147|taste
P02264601A0000|151 158|alcohol
P02265055A0417|0 21|Plasma concentrations
P02265055A0417|25 35|atracurium
P02265055A0417|40 51|laudanosine
P02265055A0417|67 82|micrograms ml-1
P02265055A0417|97 112|micrograms ml-1
P02265055A0417|128 145|CSF concentration
P02265055A0417|149 160|laudanosine
P02265055A0417|172 179|ng ml-1
P02266679A0740|0 9|Plasma Al
P02266679A0740|35 43|baseline
P02266679A0740|48 59|drug course
P02268461A0224|4 12|survival
P02268461A0224|20 24|case
P02268461A0224|34 42|patients
P02268461A0224|60 65|years
P02269281A1276|4 14|occurrence
P02269281A1276|16 27|maintenance
P02269281A1276|41 52|involvement
P02269281A1276|71 80|sequences
P02269281A1276|118 128|structures
P02269281A1276|147 155|relation
P02269281A1276|165 173|location
P02269281A1276|181 187|region
P02269281A1276|191 206|control signals
P02269426A0428|0 3|IST
P02269426A0428|15 25|RNA target
P02269426A0428|27 30|TAR
P02269426A0428|36 56|Tat trans-activation
P02269426A0428|106 113|factors
P02269426A0428|118 126|activity
P02269426A0428|128 131|IST
P02269426A0428|162 173|RNA targets
P02269426A0428|178 198|Tat trans-activation
P02269426A0428|209 220|requirement
P02269426A0428|243 258|mRNA expression
P02270096T0000|10 18|activity
P02270096T0000|41 52|nitrosamine
P02270587A0000|15 29|treatment need
P02270587A0000|58 63|order
P02270587A0000|67 76|magnitude
P02270834A0123|9 15|method
P02270834A0123|26 36|HML method
P02272095A0832|6 13|results
P02272095A0832|26 37|involvement
P02272095A0832|52 63|enkephalins
P02272095A0832|67 82|pain modulation
P02272095A0832|86 94|patients
P02272095A0832|109 125|cluster headache
P02273690T0001|0 7|Effects
P02273690T0001|11 20|cisapride
P02273690T0001|47 55|motility
P02273690T0001|70 78|hormones
P02274343A0064|7 23|foot pathologies
P02274343A0064|28 37|heel pain
P02274343A0064|39 52|metatarsalgia
P02274343A0064|54 64|hammertoes
P02274343A0064|69 77|clawtoes
P02274343A0064|79 86|bunions
P02274343A0064|88 102|hallux rigidus
P02274343A0064|104 109|corns
P02274343A0064|114 122|calluses
P02274343A0064|124 140|nail pathologies
P02274343A0064|142 151|arthritis
P02274343A0064|157 169|neuropathies
P02274509A0623|0 17|Liver dysfunction
P02274509A0623|25 33|presence
P02274509A0623|55 64|reactions
P02274509A0623|89 97|activity
P02274509A0623|105 116|blood serum
P02274509A0623|120 143|indicator liver enzymes
P02274509A0623|177 185|function
P02276891T0000|0 12|Coenzyme Q10
P02276891T0000|14 26|blood levels
P02276891T0000|41 47|demand
P02277005A0227|4 22|CT characteristics
P02277005A0227|52 62|literature
P02277319A0211|21 34|preservatives
P02277319A0211|75 81|assays
P02277319A0211|100 117|product sterility
P02277319A0211|121 137|bioburden levels
P02277452A0116|6 14|patients
P02277452A0116|20 35|angina pectoris
P02277452A0116|41 48|changes
P02277452A0116|52 56|LVEF
P02277452A0116|58 63|LVESV
P02277452A0116|68 77|PSP/LVESV
P02277452A0116|106 115|detection
P02277452A0116|136 144|ischemia
P02277452A0116|154 164|appearance
P02277452A0116|168 178|chest pain
P02277452A0116|187 194|changes
P02277452A0116|198 201|ECG
P02278217A0372|8 14|groups
P02278217A0372|28 46|management failure
P02278217A0372|50 57|therapy
P02278217A0372|79 89|medication
P02278217A0372|104 116|section lead
P02278217A0372|120 128|delivery
P02278474A0000|0 33|Serum Fibrin Degradation Products
P02278474A0000|35 38|FDP
P02278474A0000|67 82|cancer patients
P02278474A0000|97 108|individuals
P02278474A0000|122 126|kind
P02278474A0000|130 139|treatment
P02280777T0000|4 24|uteroglobin promoter
P02280777T0000|49 57|estrogen
P02280777T0000|69 76|element
P02281118A1191|0 34|Prostaglandin synthesis inhibitors
P02281118A1191|60 67|healing
P02281118A1191|71 75|bone
P02281118A1191|96 107|limitations
P02281118A1191|117 120|use
P02281118A1191|140 150|situations
P02281330A0556|16 36|oxygen concentration
P02281330A0556|45 49|FiO2
P02281330A0556|59 76|Horowitz quotient
P02281330A0556|110 116|manner
P02281330A0556|138 141|day
P02281330A0556|148 154|trauma
P02281948A0245|4 8|corn
P02281948A0245|13 34|mineral oil emulsions
P02281948A0245|63 67|milk
P02281948A0245|92 99|sucrose
P02281948A0245|104 105|M
P02281948A0245|122 131|ingestion
P02282815T0000|0 12|Significance
P02282815T0000|32 50|basement membranes
P02282815T0000|64 72|children
P02283148T0000|0 12|Significance
P02283148T0000|16 35|cytokine production
P02283148T0000|40 58|adhesion molecules
P02283148T0000|71 86|immunopathology
P02283378A0385|11 20|procedure
P02283378A0385|114 134|ultrafiltration tube
P02283378T0000|7 13|method
P02283378T0000|18 31|determination
P02283378T0000|39 60|cephalosporin DQ-2556
P02283378T0000|75 81|fluids
P02283378T0000|109 123|chromatography
P02283873A0308|10 15|group
P02283873A0308|19 30|adolescents
P02283873A0308|75 88|parents smoke
P02283873A0308|99 110|involvement
P02283873A0308|114 132|smoking prevention
P02283873A0308|151 159|enhancer
P02284393A0751|8 16|research
P02284393A0751|48 61|coping styles
P02284393A0751|87 120|EE/low EE research classification
P02284573A0943|17 21|MoAB
P02284573A0943|31 40|BAL fluid
P02284573A0943|91 111|methenamine staining
P02284573A0943|115 118|BAL
P02284573A0943|120 123|TBB
P02284573A0943|128 145|brushing material
P02287860T0001|33 38|study
P02287860T0001|54 70|parenchyma cells
P02287860T0001|74 78|mice
P02287860T0001|95 109|X-ray exposure
P02289102A0114|9 27|audiotape cassette
P02289102A0114|32 42|headphones
P02289102A0114|47 55|duration
P02289102A0114|63 77|hallucinations
P02289639A0989|9 15|change
P02289639A0989|19 23|HbA1
P02289639A0989|50 55|value
P02289639A0989|65 66|%
P02289639A0989|95 96|%
P02289639A0989|104 117|control group
P02289639A0989|119 120|p
P02290216T0001|0 6|Effect
P02290216T0001|18 29|obstruction
P02290216T0001|34 45|cholangitis
P02290216T0001|49 67|serum SPan-1 level
P02291144A0493|10 18|accuracy
P02291144A0493|20 21|r
P02291144A0493|72 73|H
P02291144A0493|91 98|machine
P02291144A0493|107 124|reference methods
P02291144A0493|137 142|MCHCH
P02291144A0493|147 161|basophil count
P02291628A0264|11 15|part
P02291628A0264|24 29|paper
P02291628A0264|49 61|applications
P02291628A0264|75 82|aspects
P02291628A0264|86 89|NMR
P02291628A0264|96 100|help
P02291628A0264|109 117|examples
P02291628A0264|134 144|literature
P02291628A0264|182 195|endocrinology
P02292272T0000|0 22|Interlimb coordination
P02292272T0000|38 48|locomotion
P02292272T0000|65 68|cat
P02293019A0000|0 19|Antileukoproteinase
P02293019A0000|21 24|ALP
P02293019A0000|35 38|mol
P02293019A0000|60 67|protein
P02293019A0000|84 91|tissues
P02293019A0000|106 116|activities
P02293019A0000|132 138|serine
P02293019A0000|149 169|proteinases elastase
P02293019A0000|174 185|cathepsin-G
P02293664A0946|17 23|series
P02293664A0946|27 36|deletions
P02293664A0946|44 61|vimentin promoter
P02293664A0946|89 98|sequences
P02293664A0946|105 115|base pairs
P02293664A0946|145 155|base pairs
P02293664A0946|172 185|mRNA cap site
P02294048A0881|24 58|% amino acid sequence similarities
P02294048A0881|80 85|hsp70
P02294048A0881|110 129|Bacillus megaterium
P02295521A0922|10 19|relations
P02295521A0922|45 56|correlation
P02295521A0922|69 74|level
P02295521A0922|78 96|trapezius activity
P02295521A0922|101 111|complaints
P02295521A0922|138 148|individual
P02295521A0922|162 186|muscle activity patterns
P02295521A0922|215 226|risk factor
P02295521A0922|231 242|development
P02295521A0922|263 273|complaints
P02296509A0997|21 38|household members
P02296509A0997|53 65|seronegative
P02296509A0997|95 112|serum p24 antigen
P02298741A0809|0 8|Analysis
P02298741A0809|38 48|antibodies
P02298741A0809|62 67|alpha
P02298741A0809|69 73|beta
P02298741A0809|78 87|gamma PKC
P02298741A0809|113 118|types
P02298741A0809|122 125|PKC
P02298741A0809|143 151|JK cells
P02298741A0809|162 172|JKPE cells
P02298741A0809|203 206|kDa
P02298741A0809|232 239|protein
P02298741A0809|265 279|alpha antibody
P02299543A0317|54 61|outlook
P02300541A0000|17 24|effects
P02300541A0000|42 49|barrier
P02300541A0000|61 68|surface
P02300541A0000|76 82|agents
P02300541A0000|86 92|series
P02300541A0000|104 117|dose inhalers
P02300541A0000|119 123|MDIs
P02300541A0000|150 154|dose
P02300541A0000|167 177|surfactant
P02300541A0000|185 192|airways
P02300541A0000|214 223|rat lungs
P02300577A0852|4 14|beta chain
P02300577A0852|48 67|glycosylation sites
P02300577A0852|73 98|endoglycosidase digestion
P02300577A0852|118 128|beta chain
P02300577A0852|148 155|complex
P02300577A0852|169 180|side chains
P02300759A0000|16 25|protocole
P02300759A0000|38 62|Gustave Roussy Institute
P02300759A0000|76 87|epithelioma
P02300759A0000|103 109|cervix
P02300759A0000|129 134|forms
P02300759A0000|136 142|T1B-T2
P02300759A0000|166 175|radiology
P02300759A0000|180 187|surgery
P02303158T0000|20 30|expression
P02303158T0000|36 40|gene
P02303158T0000|57 64|protein
P02303158T0000|80 92|trk oncogene
P02303470A0242|4 11|introns
P02303470A0242|24 27|kbp
P02303874A1643|17 33|titration period
P02303874A1643|38 48|adjustment
P02303874A1643|68 72|dose
P02303874A1643|89 94|doses
P02303874A1643|115 132|micrograms/24 hrs
P02303874A1643|134 138|mean
P02303874A1643|143 160|micrograms/24 hrs
P02305014A0226|13 19|series
P02305014A0226|23 34|experiments
P02305014A0226|56 60|rats
P02305014A0226|94 108|guide cannulas
P02305014A0226|130 139|ventricle
P02306539T0000|0 3|Use
P02306539T0000|7 32|Selenastrum capricornutum
P02306539T0000|37 47|Microfeast
P02306539T0000|51 55|food
P02306539T0000|60 73|Daphnia pulex
P02307067A1348|4 15|persistence
P02307067A1348|19 26|members
P02307067A1348|47 64|families Tydeidae
P02307067A1348|66 80|Nanorchestidae
P02307067A1348|85 97|Tarsonemidae
P02307067A1348|126 127|%
P02307067A1348|128 152|concentration treatments
P02307067A1348|171 179|evidence
P02307067A1348|183 194|adaptations
P02307067A1348|216 224|habitats
P02307371A0263|14 23|mechanism
P02307371A0263|44 48|loss
P02307371A0263|52 85|transcription elongation blockage
P02307371A0263|100 118|c-myc deregulation
P02307371A0263|122 129|Burkitt
P02307371A0263|132 140|lymphoma
P02307371A0263|154 176|transcription patterns
P02307371A0263|183 191|transfer
P02307371A0263|206 213|Burkitt
P02307371A0263|216 238|lymphoma c-myc alleles
P02307371A0263|251 256|cells
P02307371A0263|261 275|Xenopus oocyte
P02307371A0263|285 293|vesicles
P02307613A0783|0 40|Erythrocyte protoporphyrin concentration
P02307613A0783|66 67|P
P02307613A0783|90 94|days
P02307613A0783|98 102|dogs
P02307613A0783|117 121|diet
P02307613A0783|175 179|dogs
P02307613A0783|201 207|groups
P02307613A0783|216 225|remainder
P02307613A0783|233 238|study
P02307848A0347|11 20|sequences
P02307848A0347|28 37|Crry gene
P02307848A0347|56 58|kb
P02307848A0347|62 65|DNA
P02307848A0347|87 96|sequences
P02307848A0347|133 148|Eco-R1 fragment
P02307848T0042|32 42|complexity
P02307848T0042|50 54|Crry
P02307848T0042|67 72|genes
P02307850A0000|8 34|RNK-16 lambda-gt11 library
P02307850A0000|75 100|cDNA rat NK cell protease
P02307850A0000|104 110|RNKP-1
P02307850A0000|121 136|characteristics
P02307850A0000|147 163|serine proteases
P02307850A1197|4 13|induction
P02307850A1197|17 34|RNKP-1 expression
P02307850A1197|42 45|Con
P02307850A1197|57 69|spleen cells
P02307850A1197|88 97|increases
P02307850A1197|106 108|NK
P02307850A1197|134 162|killer lymphocyte activities
P02308496A0000|4 9|paper
P02308496A0000|32 36|data
P02308496A0000|40 46|change
P02308496A0000|54 65|blood level
P02308496A0000|69 73|ACTH
P02308496A0000|75 78|STH
P02308496A0000|80 83|TSH
P02308496A0000|85 93|cortisol
P02308496A0000|95 97|T3
P02308496A0000|99 106|insulin
P02308496A0000|108 117|C-peptide
P02308496A0000|137 144|session
P02308496A0000|148 159|respiration
P02308496A0000|184 191|mixture
P02308496A0000|199 207|% oxygen
P02308496A0000|209 215|GHM-10
P02310261A0115|4 11|abscess
P02310261A0115|33 39|septum
P02310261A0115|66 71|layer
P02310261A0115|86 97|pericardium
P02310300A0298|5 19|% lymphography
P02310300A0298|45 47|CT
P02310350A0221|12 17|study
P02310350A0221|31 37|effect
P02310350A0221|41 50|intensity
P02310350A0221|52 56|rate
P02310350A0221|62 70|polarity
P02310350A0221|87 94|content
P02310350A0221|98 102|ABRs
P02310350A0221|124 132|subjects
P02310496X0000|8 26|memory impairments
P02310496X0000|68 72|band
P02310496X0000|76 81|Broca
P02310496X0000|86 101|nucleus basalis
P02310496X0000|111 115|rats
P02310496X0000|121 135|memory defects
P02310496X0000|147 170|nucleus basalis lesions
P02310496X0000|186 192|degree
P02310496X0000|221 230|cell loss
P02310496X0000|236 244|function
P02310496X0000|248 263|nucleus basalis
P02310496X0000|265 267|NB
P02310496X0000|305 309|band
P02310496X0000|313 318|Broca
P02310496X0000|320 327|MS-VDBB
P02310496X0000|334 355|place navigation task
P02310496X0000|366 382|reference memory
P02311544A0086|0 7|Studies
P02311544A0086|31 43|relationship
P02311544A0086|56 65|MSMR cyst
P02311544A0086|78 83|signs
P02311544A0086|87 95|symptoms
P02311544A0086|99 106|disease
P02312470A0774|4 17|BAL-to-plasma
P02312470A0774|27 35|activity
P02312470A0774|39 43|urea
P02312470A0774|68 70|Na
P02312470A0774|89 93|urea
P02312470A0774|112 115|ELF
P02312470A0774|134 136|Na
P02312470A0774|152 153|s
P02312470A0774|179 183|time
P02312470A0774|200 204|urea
P02312470A0774|209 211|Na
P02312470A0774|236 247|circulation
P02312470A0774|256 260|time
P02312470A0774|266 272|lavage
P02312689A0360|4 21|kappa coefficient
P02312689A0360|25 34|agreement
P02312689A0360|47 59|Patho Dx Kit
P02312689A0360|68 83|standard method
P02315151T0020|7 14|systems
P02315151T0020|27 33|health
P02315151T0020|38 45|illness
P02315151T0020|53 56|age
P02315472A0583|20 32|imaging time
P02315472A0583|38 48|parameters
P02315472A0583|79 83|RASE
P02315472A0583|92 95|C/A
P02315472A0583|100 109|unit time
P02315472A0583|122 123|%
P02317413A0364|0 8|Patients
P02317413A0364|31 41|infarction
P02317413A0364|53 74|plasma concentrations
P02317413A0364|78 97|neutrophil elastase
P02317413A0364|119 124|diene
P02317413A0364|136 142|isomer
P02317413A0364|155 159|acid
P02317413A0364|172 182|volunteers
P02317413A0364|186 194|patients
P02317413A0364|217 230|heart disease
P02317554T0000|0 13|Determination
P02317554T0000|35 53|imaging properties
P02317554T0000|65 82|microscope system
P02318208A0817|15 22|element
P02318208A0817|38 49|CACGTGACCCG
P02318208A0817|65 67|bp
P02318208A0817|86 115|transcription initiation site
P02318208A0817|134 147|core sequence
P02318208A0817|164 181|promoter sequence
P02318208A0817|185 191|Ad2MLP
P02319610A1527|13 22|relevance
P02319610A1527|32 40|findings
P02319610A1527|64 75|observation
P02319610A1527|89 96|results
P02319610A1527|116 121|P.HCl
P02319610A1527|151 156|route
P02320008A0651|0 6|TMBr-1
P02320008A0651|32 56|muscle alpha-tropomyosin
P02320008A0651|62 73|amino acids
P02320008A0651|123 129|region
P02320008A0651|135 146|amino acids
P02320999A0606|4 13|procedure
P02320999A0606|40 49|materials
P02320999A0606|51 65|particle board
P02320999A0606|71 77|carpet
P02320999A0606|79 91|gypsum board
P02320999A0606|97 106|wallpaper
P02320999A0606|112 119|plywood
P02320999A0606|125 145|polyurethane lacquer
P02320999A0606|174 190|emission factors
P02320999A0606|192 202|mg m-2 h-1
P02320999A0606|215 224|compounds
P02322535A0658|0 6|Intron
P02322535A0658|16 18|kb
P02322535A0658|41 46|sizes
P02322535A0658|50 57|introns
P02322535A0658|89 91|kb
P02323517A0557|8 9|h
P02323517A0557|11 18|lesions
P02323517A0557|36 40|part
P02323517A0557|48 55|stomach
P02323517A0557|80 106|prostaglandin E2 synthesis
P02323517A0557|137 171|prostaglandin generation technique
P02324102A1157|0 10|Comparison
P02324102A1157|14 27|transmembrane
P02324102A1157|44 51|domains
P02324102A1157|76 88|proteoglycan
P02324102A1157|90 94|48K5
P02324102A1157|106 122|lung fibroblasts
P02324102A1157|124 131|Marynen
P02324102A1157|133 135|P.
P02324102A1157|137 142|Zhang
P02324102A1157|144 146|J.
P02324102A1157|148 156|Cassiman
P02324102A1157|158 160|J.
P02324102A1157|162 175|Vanden Berghe
P02324102A1157|177 179|H.
P02324102A1157|185 190|David
P02324102A1157|192 194|C.
P02324104A0151|16 17|%
P02324104A0151|46 73|phosphotransferase activity
P02324104A0151|102 111|fractions
P02324104A0151|115 126|homogenates
P02324104A0151|154 165|populations
P02324104A0151|169 179|C. elegans
P02324104A0516|5 11|levels
P02324104A0516|15 25|C subunits
P02324104A0516|78 84|stages
P02324104A0516|88 99|development
P02324104A0929|16 25|C subunit
P02324104A0929|27 38|CeCAT alpha
P02324104A0929|45 53|residues
P02324104A0929|97 103|region
P02324104A0929|141 149|splicing
P02324104A0929|157 167|C pre-mRNA
P02324104A1195|16 20|exon
P02324104A1195|42 59|carboxyl terminus
P02324104A1195|70 93|translation stop signal
P02324104A1195|138 146|sequence
P02324104A1195|172 180|residues
P02324104A1195|184 195|CeCAT alpha
P02324104A1195|217 228|nucleotides
P02325208A0209|0 6|French
P02325208A0209|8 10|M.
P02325895T0000b|16 20|type
P02325895T0000b|23 48|mechanoreceptor discharge
P02325895T0000b|54 62|function
P02325895T0000b|74 79|force
P02325895T0000b|95 107|displacement
P02325895T0000b|120 124|skin
P02325895T0000b|128 135|raccoon
P02325895T0000b|140 160|squirrel monkey hand
P02326716A0139|0 7|Methods
P02326716A0139|21 31|Cobb angle
P02326716A0139|48 58|evaluation
P02326716A0139|60 66|T7-T12
P02326716A0139|79 85|convex
P02326716A0139|90 117|concave rib-vertebra angles
P02326716A0139|119 123|RVAs
P02326716A0139|139 156|angle differences
P02326716A0139|158 163|RVADs
P02326716A0139|176 184|rotation
P02326716A0139|186 190|tilt
P02326716A0139|195 207|displacement
P02326946T0000|0 43|Plasma lecithin/cholesterol acyltransferase
P02326946T0000|45 49|LCAT
P02326946T0000|51 59|activity
P02326946T0000|78 84|donors
P02326946T0000|88 97|predictor
P02326946T0000|101 120|allograft viability
P02326946T0000|133 154|liver transplantation
P02327159T0001|0 4|Lars
P02327159T0001|9 13|AIDS
P02327159T0001|32 36|life
P02327159T0001|42 46|care
P02327159T0001|50 54|home
P02328328A0419|15 21|status
P02328328A0419|23 58|tumour progesterone receptor status
P02328328A0419|64 70|season
P02328328A0419|74 90|tumour detection
P02328328A0419|116 124|survival
P02328328A0419|156 159|yrs
P02328328A0419|187 190|yrs
P02328328A0419|192 200|patients
P02329840A0383|4 15|application
P02329840A0383|25 40|microelectrodes
P02329840A0383|48 59|measurement
P02329840A0383|80 87|changes
P02329840A0383|100 101|K
P02329840A0383|103 104|o
P02330041A0335|0 10|Expression
P02330041A0335|21 33|localization
P02330041A0335|47 68|transcription studies
P02330041A0335|91 95|hUBF
P02330041A0335|116 122|factor
P02330041A0335|163 178|control element
P02330041A0335|183 187|core
P02330041A0335|195 213|rRNA gene promoter
P02330041A0335|226 239|transcription
P02330041A0335|245 252|binding
P02330041A0335|268 274|manner
P02330110A1085|19 37|laboratory studies
P02330110A1085|48 53|value
P02330110A1085|85 92|outcome
P02330333A0325|0 13|Accumulations
P02330333A0325|17 21|Tl+1
P02330333A0325|23 34|202Tl label
P02330333A0325|43 48|times
P02330333A0325|59 61|Ga
P02330333A0325|75 80|brain
P02330333A0325|85 92|muscles
P02330333A0325|101 106|times
P02330333A0325|110 116|plasma
P02331361A0268|20 28|increase
P02331361A0268|36 52|myocyte diameter
P02331361A0268|66 69|age
P02331361A0268|77 83|biopsy
P02331361A0268|88 105|autopsy specimens
P02332018A0538|12 19|absence
P02332018A0538|40 46|asthma
P02332018A0538|48 51|EIA
P02332018A0538|69 75|WH air
P02332018A0538|87 95|patients
P02332018A0538|127 145|mean GH increments
P02332018A0538|158 166|subjects
P02332018A0538|179 184|ng/ml
P02332018A0538|186 187|P
P02332798A0725|4 13|afferents
P02332798A0725|15 20|phase
P02332798A0725|24 32|response
P02332798A0725|62 77|EVS stimulation
P02333239T0000|11 14|age
P02333239T0000|19 26|problem
P02333545A0313|4 16|distribution
P02333545A0313|26 43|fibrinogen levels
P02333545A0313|87 99|distribution
P02333545A0313|114 122|controls
P02333749A0411|23 42|regression analysis
P02333749A0411|46 49|SPT
P02333749A0411|54 63|RAST data
P02333749A0411|69 79|occurrence
P02333749A0411|83 103|serum IgE antibodies
P02333749A0411|107 120|P. orbiculare
P02333749A0411|149 154|value
P02333749A0411|167 173|eczema
P02334972A0145|4 15|examination
P02334972A0145|31 41|assessment
P02334972A0145|55 60|types
P02334972A0145|64 70|drusen
P02334972A0145|75 85|evaluation
P02334972A0145|93 104|development
P02334972A0145|109 118|incidence
P02334972A0145|122 134|risk factors
P02334972A0145|146 159|complications
P02334972A0145|164 168|loss
P02334972A0145|180 186|vision
P02335034A0584|39 50|heat stress
P02335034A0584|67 72|suits
P02335034A0584|85 92|minutes
P02335034A0584|96 100|LBNP
P02335521T0000|15 45|vitellogenin activator element
P02335521T0000|55 68|transcription
P02335521T0000|97 133|Xenopus laevis vitellogenin promoter
P02335713A0905|7 18|correlation
P02335713A0905|45 48|PbB
P02335713A0905|53 66|ALAD activity
P02335713A0905|74 90|stearate workers
P02335815A0530|7 24|carboxyl terminus
P02335815A0530|26 34|deletion
P02335815A0530|45 52|residue
P02335815A0530|81 84|TRF
P02335815A0530|85 95|C assembly
P02335815A0530|123 131|activity
P02336338A0931|4 11|effects
P02336338A0931|15 29|mean luminance
P02336338A0931|63 73|expression
P02336338A0931|100 107|account
P02339005T0000|0 6|Effect
P02339005T0000|10 23|hyperglycemia
P02339005T0000|27 41|pain threshold
P02339005T0000|62 66|rats
P02339447A0162|21 28|7,7-2H2
P02339447A0162|33 36|OHA
P02339447A0162|47 64|deuterium content
P02339447A0162|85 92|7,7-2H2
P02339447A0162|93 94|A
P02339447A0162|100 108|9,11-2H2
P02339447A0162|109 116|estrone
P02339447A0162|118 120|E1
P02339447A0162|153 158|assay
P02339447A0162|162 180|serum level 19-OHA
P02339447A0162|182 183|A
P02339447A0162|189 191|E1
P02339447A0162|202 266|gas chromatography/mass spectrometry-mass fragmentography method
P02339447A0162|289 297|subjects
P02339447A0162|309 318|pregnancy
P02340595A0124|0 17|Sequence analysis
P02340595A0124|27 32|genes
P02340595A0124|55 64|sequences
P02340595A0124|109 119|tRNA genes
P02340595A0124|125 143|plant mitochondria
P02341669A0000|0 11|Experiments
P02341669A0000|36 46|brain-stem
P02341669A0000|63 72|responses
P02341669A0000|74 79|BAERs
P02341669A0000|102 107|types
P02341669A0000|111 136|pseudorandom pulse trains
P02341669A0000|138 162|maximum length sequences
P02341669A0000|164 167|MLS
P02341669A0000|173 191|Legendre sequences
P02341669A0000|193 196|LGS
P02342477A1292|10 14|UfAP
P02342477A1292|19 23|UTMP
P02342477A1292|63 71|features
P02342477A1292|85 89|site
P02342477A1292|93 105|biosynthesis
P02342477A1292|113 124|endometrium
P02342477A1292|126 143|P4-responsiveness
P02342477A1292|149 157|presence
P02342477A1292|165 172|mannose
P02342477A1292|195 213|recognition marker
P02342477A1292|232 251|sequence similarity
P02342477A1292|257 261|UfAP
P02342477A1292|270 274|UTMP
P02342477A1292|295 303|function
P02343033A0000|8 13|light
P02343033A0000|18 31|dates infants
P02343033A0000|42 51|placentae
P02343033A0000|83 90|infants
P02343033A0000|101 110|placentae
P02344529T0000|15 22|anaemia
P02344529T0000|46 60|erythropoietin
P02347102A0000|4 27|pseudolymphoma syndrome
P02347102A0000|53 62|condition
P02347102A0000|77 82|fever
P02347102A0000|84 99|lymphadenopathy
P02347102A0000|116 120|rash
P02347407A0217|25 30|field
P02347407A0217|36 43|animals
P02347407A0217|58 67|SE-sector
P02347655A0193|18 22|lung
P02347655A0193|44 48|lung
P02347655A0193|64 71|tissues
P02347655A0193|73 86|gas exchanges
P02347655A0193|105 115|parameters
P02347655A0193|117 139|blood inlet conditions
P02347655A0193|141 156|blood flow rate
P02347655A0193|158 169|temperature
P02347655A0193|171 182|composition
P02347655A0193|190 201|gas mixture
P02347655A0193|211 222|ventilation
P02347655A0193|224 246|blood tissue perfusion
P02347655A0193|251 262|consumption
P02348225A0192|0 4|Mean
P02348225A0192|10 12|SE
P02348225A0192|14 26|measurements
P02348225A0192|30 39|clearance
P02348225A0192|71 80|mL/min/m2
P02348225A0192|83 92|half-life
P02348225A0192|120 125|hours
P02348225A0192|132 138|volume
P02348225A0192|142 154|distribution
P02348225A0192|184 188|L/m2
P02348225A0192|226 234|patients
P02348225A0192|240 248|jaundice
P02348225A0192|268 276|controls
P02348408A0126|0 9|Attitudes
P02348408A0126|58 68|dimensions
P02348408A0126|94 101|samples
P02348728A1153|17 27|DNA ploidy
P02348728A1153|60 66|factor
P02348728A1153|83 94|determinant
P02348728A1153|111 120|carcinoma
P02349827A0193|24 30|system
P02349827A0193|32 41|Videoplan
P02349942A0287|14 21|factors
P02349942A0287|55 62|cohorts
P02349942A0287|97 103|recall
P02349998A0297|0 21|Dopamine SERS spectra
P02349998A0297|33 43|electrodes
P02349998A0297|86 96|electrodes
P02351239A0693|6 14|findings
P02351239A0693|29 45|hypergastrinemia
P02351239A0693|66 73|removal
P02351239A0693|92 98|mucosa
P02351239A0693|106 109|rat
P02351239A0693|123 130|effects
P02351239A0693|152 164|HDC activity
P02351239A0693|166 189|histamine concentration
P02351239A0693|194 210|ECL cell density
P02351239A0693|214 230|hypergastrinemia
P02351239A0693|253 269|gastrin infusion
P02351239A0693|286 295|treatment
P02351239A0693|311 328|antisecretagogues
P02351297A0000|23 40|toxicity research
P02351297A0000|76 113|atmosphere metal corrosion inhibitors
P02351297A0000|127 131|cent
P02351297A0000|171 175|cent
P02351297A0000|185 190|level
P02351297A0000|205 212|percent
P02351297A0000|237 241|cent
P02353453A1249|4 9|order
P02353453A1249|17 31|helicase motif
P02353453A1249|40 60|nsP3 homology region
P02353453A1249|68 78|RUB genome
P02353453A1249|96 103|respect
P02353453A1249|111 128|alphavirus genome
P02353453A1249|155 168|rearrangement
P02353453A1249|193 202|evolution
P02353453A1249|212 219|viruses
P02353875A0800|4 11|results
P02353875A0800|20 30|followings
P02353875A0800|40 51|eosinophils
P02353875A0800|56 67|neutrophils
P02353875A0800|83 97|hypersecretion
P02353875A0800|101 108|type Ib
P02353875A0800|119 124|cases
P02353875A0800|135 146|eosinophils
P02353875A0800|161 166|cases
P02354381A0207|13 23|treatments
P02354381A0207|25 32|control
P02354381A0207|34 35|C
P02354381A0207|68 74|corner
P02354381A0207|82 86|cage
P02354381A0207|88 89|S
P02354381A0207|94 113|fiberglass rollaway
P02354381A0207|133 139|corner
P02354381A0207|147 151|cage
P02354381A0207|153 154|H
P02354381A0207|182 185|H/S
P02354381A0207|190 198|nest box
P02354381A0207|215 219|back
P02354381A0207|227 231|cage
P02354381A0207|254 255|N
P02355293A0749|21 32|differences
P02355293A0749|48 57|responses
P02355293A0749|61 84|failure characteristics
P02355293A0749|129 135|grafts
P02355293A0749|143 147|drip
P02355293A0749|156 172|bath environment
P02355293A0749|191 198|tissues
P02355293A0749|211 219|strength
P02355293A0749|224 231|modulus
P02355765A0220|4 11|patient
P02355765A0220|29 50|benzathine penicillin
P02355765A0220|62 70|U weekly
P02355765A0220|81 86|weeks
P02355920A0681|2 24|consensus binding site
P02355920A0681|33 57|transcription factor SP1
P02355920A0681|76 82|intron
P02355920A0681|104 143|proenkephalin germ cell cap site region
P02356823A0063|14 20|method
P02356823A0063|35 44|principle
P02356823A0063|52 66|sets technique
P02356823A0063|109 113|time
P02356823A0063|117 133|alarm properties
P02357537A0451|4 11|effects
P02357537A0451|22 31|latencies
P02357537A0451|43 48|paCO2
P02357537A0451|52 55|pHa
P02357537A0451|72 80|naloxone
P02357537A0451|84 89|mg/kg
P02357537A0451|134 141|animals
P02358975A0709|70 78|symptoms
P02358975A0709|108 121|gluten intake
P02358975A0709|142 156|IgA deficiency
P02360336A0574|0 4|Drug
P02360336A0574|9 24|personnel costs
P02360336A0574|43 62|batch manufacturing
P02360336A0574|74 89|multidose vials
P02360336A0574|150 155|vials
P02361008T0000|0 7|Changes
P02361008T0000|11 20|prognosis
P02361008T0000|29 35|births
P02361008T0000|44 49|years
P02361575T0000|7 15|toxicity
P02361575T0000|20 35|carcinogenicity
P02361575T0000|61 70|diepoxide
P02361575T0000|74 86|Fischer rats
P02361575T0000|91 102|B6C3F1 mice
P02361812A1110|4 14|kg FFM SMR
P02361812A1110|38 53|baseline values
P02361812A1110|62 70|EX group
P02361812A1110|99 107|subjects
P02361812A1110|131 137|values
P02361812A1110|139 141|EX
P02361812A1110|150 154|cent
P02361812A1110|159 160|D
P02361812A1110|163 165|DE
P02361812A1110|175 179|cent
P02361812A1110|198 207|treatment
P02361812A1110|209 210|P
P02362161T0000|0 6|MK-927
P02362161T0000|55 74|anhydrase inhibitor
P02362803A0608|12 21|fragments
P02362803A0608|35 41|probes
P02362803A0608|50 59|isolation
P02362803A0608|67 81|U3 snRNA genes
P02362803A0608|97 104|library
P02362803A0608|108 119|Arabidopsis
P02368931A0587|3 36|addition serum IgE concentrations
P02370571A0663|4 12|findings
P02370571A0663|36 53|iodine deficiency
P02370571A0663|75 80|cause
P02370571A0663|84 90|goiter
P02370571A0663|97 107|immigrants
P02370571A0663|120 126|cohort
P02370571A0663|145 155|population
P02370571A0663|175 178|men
P02370571A0663|183 188|women
P02370571A0663|214 220|factor
P02370571A0663|221 222|s
P02371273A0144|20 24|unit
P02371273A0144|45 51|region
P02371273A0144|64 78|kilobase pairs
P02371273A0144|80 83|kbp
P02371517A0747|11 19|patients
P02372496A0782|0 17|Co-administration
P02372496A0782|21 24|5FU
P02372496A0782|26 37|angiotensin
P02372496A0782|45 57|microspheres
P02372496A0782|74 80|artery
P02372496A0782|92 105|drug exposure
P02372496A0782|122 133|compartment
P02372496A0782|177 182|ratio
P02372496A0782|186 204|5FU administration
P02372496A0782|221 227|artery
P02372712A0002|4 11|effects
P02372712A0002|15 18|tap
P02372712A0002|20 22|TW
P02372712A0002|39 41|CW
P02372712A0002|43 48|water
P02372712A0002|61 63|pH
P02372712A0002|73 81|pressure
P02372712A0002|85 99|carbon dioxide
P02372712A0002|101 105|PCO2
P02372712A0002|111 125|plasma lactate
P02372712A0002|159 167|broilers
P02373686T0000|10 20|expression
P02373686T0000|34 64|chicken progesterone receptors
P02373686T0000|108 118|initiation
P02373686T0000|133 137|mRNA
P02373686T0000|145 154|mechanism
P02373686T0000|170 187|receptor isoforms
P02373810A1118|3 11|contrast
P02373810A1118|22 23|%
P02373810A1118|41 53|risk factors
P02373810A1118|63 67|risk
P02373810A1118|83 84|%
P02373810A1118|95 100|weeks
P02373810A1118|102 103|p
P02374886A0305|4 30|Community Adjustment Scale
P02374886A0305|40 52|outcome data
P02374886A0305|68 76|subjects
P02374886A0305|78 84|degree
P02374886A0305|88 100|productivity
P02374886A0305|102 109|ability
P02374886A0305|128 141|relationships
P02374886A0305|147 163|presence/absence
P02374886A0305|167 181|symptomatology
P02374886A0305|185 192|average
P02374886A0305|199 204|years
P02374886A0305|219 228|admission
P02376023A0307|15 21|months
P02376023A0307|25 28|age
P02376023A0307|51 57|levels
P02376023A0307|61 65|IgG1
P02376023A0307|67 68|P
P02376023A0307|92 96|IgG4
P02376023A0307|98 99|P
P02376023A0307|130 137|infants
P02376023A0307|155 158|IgE
P02376023A0307|189 193|kU/l
P02376023A0307|222 227|level
P02378615A0807|4 20|protein sequence
P02378615A0807|55 74|glycosylation sites
P02378615A0807|103 109|region
P02378615A0807|131 135|site
P02378615A0807|140 150|attachment
P02378615A0807|163 175|carbohydrate
P02378945A0487|5 15|adaptation
P02378945A0487|35 41|stress
P02378945A0487|70 76|effect
P02378945A0487|111 121|vagal tone
P02383693A0301|20 26|column
P02383693A0301|63 71|solution
P02383693A0301|83 92|lucigenin
P02383693A0301|97 109|Triton X-100
P02383693A0301|121 135|M KOH solution
P02383693A0301|139 144|pumps
P02383693A0301|164 190|chemiluminescence detector
P02383771A0544|14 25|examination
P02383771A0544|39 49|epithelium
P02383771A0544|64 72|membrane
P02383771A0544|111 121|epithelium
P02383771A0544|135 147|distribution
P02383771A0544|160 166|nuclei
P02383771A0544|185 194|cytoplasm
P02384265A0947|6 13|results
P02384265A0947|35 39|risk
P02384265A0947|54 60|cancer
P02384265A0947|67 81|polyp patients
P02384265A0947|90 101|possibility
P02384265A0947|105 124|prophylactic effect
P02384265A0947|128 139|polypectomy
P02384265A0947|159 165|cancer
P02384389A0854|9 14|trend
P02384389A0854|33 35|YG
P02384389A0854|40 47|heifers
P02384389A0854|52 54|YG
P02384389A0854|92 102|deposition
P02384389A0854|106 114|seam fat
P02384389A0854|118 128|fed cattle
P02386485A0554|4 23|nucleotide sequence
P02386485A0554|39 41|bp
P02386485A0554|63 69|region
P02386485A0554|76 78|bp
P02386485A0554|89 95|region
P02386485A0554|104 106|bp
P02386485A0554|128 134|region
P02386485A0554|150 157|bp poly
P02386485A0554|158 159|A
P02386485A0554|161 165|tail
P02386895A0496|0 10|Toxicities
P02386895A0496|21 36|nausea/vomiting
P02386895A0496|40 41|%
P02386895A0496|44 52|headache
P02386895A0496|56 57|%
P02386895A0496|60 66|chills
P02386895A0496|70 71|%
P02386895A0496|74 78|pain
P02386895A0496|82 93|tumor sites
P02386895A0496|97 98|%
P02386895A0496|101 112|hypotension
P02386895A0496|116 117|%
P02386895A0496|124 136|hypertension
P02386895A0496|140 141|%
P02388685A0577|4 11|results
P02388685A0577|38 66|oyster shell supplementation
P02388685A0577|87 116|alkaline phosphatase activity
P02388685A0577|118 137|bone mineralization
P02388685A0577|187 199|coefficients
P02388685A0577|203 212|variation
P02388685A0577|214 216|CV
P02388685A0577|230 231|%
P02388685A0577|245 246|%
P02388685A0577|251 258|calcium
P02388685A0577|263 281|phosphorus content
P02388685A0577|289 294|femur
P02388685A0577|299 304|tibia
P02390538A0000|11 18|infants
P02390538A0000|38 43|weeks
P02390538A0000|47 56|gestation
P02390538A0000|94 103|anomalies
P02390538A0000|111 118|airways
P02390538A0000|160 170|fiberscope
P02390538A0000|172 186|Olympus PF18 S
P02390538A0000|192 194|mm
P02390633T0000|6 18|encephalitis
P02390633T0000|24 31|patient
P02390633T0000|63 70|disease
P02390989A0745|16 27|counterpart
P02390989A0745|35 43|GPB gene
P02390989A0745|45 49|exon
P02390989A0745|59 67|GPE gene
P02390989A0745|85 100|point mutations
P02390989A0745|105 114|insertion
P02390989A0745|121 123|bp
P02390989A0745|131 141|stop codon
P02390989A0745|161 174|reading frame
P02391344T0000|10 17|cloning
P02391344T0000|23 27|cDNA
P02391344T0000|37 69|rat NADH-cytochrome b5 reductase
P02391344T0000|92 96|gene
P02392032A0657|4 11|results
P02392032A0657|28 32|idea
P02392032A0657|42 51|structure
P02392032A0657|55 72|relaxation curves
P02392032A0657|82 93|information
P02392032A0657|101 115|distance scale
P02392032A0657|127 139|architecture
P02392032A0657|147 157|pore space
P02392032A0657|205 216|ambiguities
P02392511T0000|0 32|Serotonin 5-HT2 receptor binding
P02392511T0000|36 51|blood platelets
P02392511T0000|57 62|state
P02392511T0000|73 79|marker
P02392511T0000|99 107|disorder
P02393001A0324|9 12|%BF
P02393001A0324|41 45|BMIs
P02393001A0324|47 48|r
P02393001A0324|82 93|definitions
P02393001A0324|97 104|obesity
P02393001A0324|114 118|BMIs
P02393001A0324|122 125|%BF
P02393001A0324|129 141|densitometry
P02393001A0324|169 176|results
P02393895A0918|4 13|RF values
P02393895A0918|69 74|scale
P02393895A0918|78 86|severity
P02393895A0918|97 110|insufficiency
P02393895A0918|112 113|r
P02393895A0918|123 124|p
P02393895A0918|169 176|authors
P02393895A0918|200 215|differentiation
P02393895A0918|243 257|regurgitations
P02393895A0918|284 288|ones
P02394707A0789|0 17|Promoter elements
P02394707A0789|38 46|TATA box
P02394707A0789|48 52|GTTA
P02394707A0789|59 68|CCAAT box
P02394707A0789|91 106|initiation site
P02394707A0789|122 133|compliments
P02394707A0789|137 142|CCAAT
P02394707A0789|144 149|ATTGG
P02394707A0789|176 196|nucleotide stretches
P02394718A0130|11 16|genes
P02394718A0130|44 53|libraries
P02394718A0130|57 80|hybridization screening
P02394718A0130|92 119|deoxyoligonucleotide probes
P02394718A0130|154 173|amino acid sequence
P02394718A0130|190 196|enzyme
P02395868A0322|4 11|pattern
P02395868A0322|26 36|zinc sites
P02395868A0322|50 57|ligands
P02395868A0322|67 75|sequence
P02395868A0322|96 102|ligand
P02395868A0322|121 134|hydrogen bond
P02395868A0322|147 154|ligands
P02396415T0001|0 7|Results
P02396415T0001|25 36|observation
P02396415T0001|41 50|treatment
P02396415T0001|54 62|patients
P02396415T0001|77 89|hypertension
P02398897A0000|11 32|transcription factors
P02398897A0000|48 62|RNA polymerase
P02398897A0000|84 94|efficiency
P02398897A0000|98 108|elongation
P02398897A0000|147 157|RNA chains
P02399053A0153|23 27|rats
P02399053A0153|29 30|n
P02399053A0153|49 57|% oxygen
P02399053A0153|66 74|room air
P02399053A0153|76 78|RA
P02399053A0153|99 103|days
P02399053A0153|107 111|life
P02399053A0153|122 124|RA
P02399053A1032|4 6|Lm
P02399053A1032|25 36|alveoli/mm2
P02399053A1032|49 64|recoil pressure
P02400070T0000|0 10|Comparison
P02400070T0000|14 22|propofol
P02400070T0000|27 38|thiopentone
P02400070T0000|54 60|agents
P02400070T0000|83 90|therapy
P02400457A0469|3 13|Experiment
P02400457A0469|41 55|supine cycling
P02400457A0469|59 68|% VO2 max
P02400457A0469|77 84|minutes
P02400457A0469|99 114|LBNP conditions
P02400457A0469|130 135|women
P02400457A0469|181 188|manners
P02400457A0469|211 222|adjustments
P02400457A0469|238 244|phases
P02400457A0469|254 267|Experiment I.
P02402678A0463|23 35|formulations
P02402678A0463|42 43|%
P02402678A0463|49 68|% lambdacyhalothrin
P02402678A0463|96 101|water
P02402678A0463|106 109|ULV
P02402678A0463|115 137|aerosol space-spraying
P02402678A0463|146 161|diesel/kerosene
P02402678A0463|174 181|fogging
P02402678A0463|197 214|application rates
P02402678A0463|224 231|g ai/ha
P02402678A0463|236 252|mosquito control
P02402678A0463|259 266|g ai/ha
P02402678A0463|271 287|housefly control
P02403035A0621|11 24|reading frame
P02403035A0621|53 62|precursor
P02403035A0621|80 88|fumarase
P02403634A0788|0 17|Sequence analysis
P02403634A0788|36 44|addition
P02403634A0788|51 54|ATA
P02403634A0788|59 65|GC box
P02403634A0788|72 78|region
P02403634A0788|88 95|domains
P02403634A0788|129 139|regulation
P02403634A0788|165 170|genes
P02403634A0788|174 182|CArG box
P02403634A0788|190 192|bp
P02403634A0788|236 242|factor
P02403634A0788|245 268|binding site homologies
P02403634A0788|292 294|bp
P02403634A0788|302 332|muscle-CAAT consensus sequence
P02403634A0788|341 343|bp
P02403634A0788|360 368|cap site
P02403926A0000|4 19|trk-2h oncogene
P02403926A0000|45 78|breast carcinoma cell line MDA-MB
P02403926A0000|94 110|DNA-transfection
P02403926A0000|116 128|NIH3T3 cells
P02403926A0000|146 187|trk proto-oncogene receptor kinase domain
P02403926A0000|213 223|amino acid
P02403926A0000|235 243|sequence
P02403926A0000|245 250|Kozma
P02403926A0000|252 256|S.C.
P02403926A0000|258 265|Redmond
P02403926A0000|267 273|S.M.S.
P02403926A0000|275 285|Xiao-Chang
P02403926A0000|287 289|F.
P02403926A0000|291 297|Saurer
P02403926A0000|299 303|S.M.
P02403926A0000|305 311|Groner
P02403926A0000|313 315|B.
P02403926A0000|320 325|Hynes
P02403926A0000|327 331|N.E.
P02403926A0307|0 10|Antibodies
P02403926A0307|49 92|beta gal-trk receptor kinase fusion protein
P02403926A0307|109 126|kd phosphoprotein
P02403926A0307|145 151|serine
P02403926A0307|153 162|threonine
P02403926A0307|167 175|tyrosine
P02403926A0307|179 187|extracts
P02403926A0307|210 222|NIH3T3 cells
P02404451A1532|18 44|scanning-deletion analysis
P02404451A1532|80 86|region
P02404451A1532|91 99|activity
P02404451A1532|105 112|Cys-118
P02404451A1532|122 129|Cys-118
P02404451A1532|155 163|activity
P02404451A1532|186 201|Cys-118 residue
P02404451A1532|226 239|glycosylation
P02404451A1532|261 269|activity
P02404451A1532|273 279|GM-CSF
P02405393T0000|25 41|characterization
P02405393T0000|49 57|promoter
P02405393T0000|61 65|ETS2
P02405393T0000|77 89|c-ets-2 gene
P02405589A0000|0 11|Information
P02405589A0000|30 47|drug interactions
P02405589A0000|61 72|pharmacists
P02405589A0000|90 108|drug-use decisions
P02405818A0550|0 16|Branch occlusion
P02405818A0550|20 27|Heubner
P02405818A0550|30 36|artery
P02405818A0550|41 52|perforators
P02405818A0550|99 107|arteries
P02405818A0550|125 134|mechanism
P02405818A0550|138 148|infarction
P02406570A0466|17 22|sites
P02406570A0466|38 44|origin
P02406570A0466|60 63|UAS
P02406570A0466|98 111|test plasmids
P02406570A0898|3 14|examination
P02406570A0898|22 32|properties
P02406570A0898|36 45|sequences
P02406570A0898|58 62|ARS1
P02406570A0898|77 88|possibility
P02406570A0898|94 98|ABFI
P02406570A0898|112 122|initiation
P02406570A0898|126 141|DNA replication
P02406570A0898|145 149|ARS1
P02406570A0898|169 179|activation
P02406992A0192|38 47|disorders
P02406992A0192|74 89|amaurosis fugax
P02406992A0192|109 118|algorithm
P02406992A0192|123 133|evaluation
P02406992A0192|161 172|examination
P02406992A0192|174 192|laboratory studies
P02406992A0192|210 232|carotid artery studies
P02408248A0414|41 47|action
P02408248A0414|62 79|enzyme inhibitors
P02409297A0984|11 20|antiserum
P02409297A0984|38 52|fusion protein
P02409297A0984|100 112|polypeptides
P02409297A0984|118 133|virus particles
P02409297A0984|140 152|polypeptides
P02409297A0984|180 198|HBsAg determinants
P02411513A0667|6 21|characteristics
P02411513A0667|25 32|N22/P22
P02411513A0667|88 93|event
P02411513A0667|121 127|dipole
P02411513A0667|133 150|dorsal negativity
P02411513A0667|179 189|positivity
P02417023T0001|0 4|Role
P02417023T0001|8 28|superoxide dismutase
P02417023T0001|51 60|processes
P02417023T0001|65 71|method
P02417023T0001|79 92|determination
P02417023T0001|107 116|materials
P02417669A0218|3 27|maximum photosensitivity
P02417669A0218|43 54|amino acids
P02417669A0218|74 78|acid
P02417669A0218|83 90|taurine
P02417669A0218|116 126|asparagine
P02417669A0218|128 138|metabolite
P02417669A0218|157 177|amino acid aspartate
P02417669A0218|206 213|animals
P02418701A0000|17 27|likelihood
P02418701A0000|31 38|tissues
P02418701A0000|75 82|antigen
P02418701A0000|91 100|intensity
P02418701A0000|121 137|antigen staining
P02418701A0000|141 150|specimens
P02418701A0000|162 170|adenomas
P02418701A0000|178 186|polypoid
P02418701A0000|195 203|adenomas
P02418701A0000|214 222|adenomas
P02418701A0000|228 242|diverticulitis
P02418701A0000|279 288|technique
P02419327A0998|4 20|priming activity
P02419327A0998|24 27|DNA
P02419327A0998|64 71|enzymes
P02419327A0998|115 125|incubation
P02419327A0998|193 196|DNA
P02419327A0998|207 211|side
P02419327A0998|227 231|site
P02419588A0284|0 2|A.
P02420432A1060|14 25|conjunction
P02420432A1060|42 56|pregnancy test
P02420432A1060|65 72|patient
P02420432A1060|84 91|history
P02420432A1060|124 142|serum PAPP-A level
P02420432A1060|158 167|diagnosis
P02420432A1060|184 193|pregnancy
P02423533A1314|4 10|levels
P02423533A1314|51 56|mRNAs
P02423533A1314|93 98|brain
P02423533A1314|104 109|level
P02423533A1314|127 131|mRNA
P02423533A1314|159 173|rat PC12 cells
P02423533A1314|179 187|exposure
P02423533A1314|191 210|nerve growth factor
P02423533A1790|4 9|cDNAs
P02423533A1790|39 48|sequences
P02423533A1790|52 55|rat
P02423533A1790|68 79|chicken DNA
P02423533A1790|94 97|DNA
P02423533A1790|103 107|frog
P02423533A1790|124 134|sea urchin
P02423773T0001|13 19|method
P02423773T0001|35 43|glycerin
P02423773T0001|51 56|blood
P02423850A0292|0 17|Deletion analysis
P02423850A0292|43 47|part
P02423850A0292|67 73|region
P02423850A0292|82 90|homology
P02423850A0292|107 113|region
P02423850A0292|121 136|yeast CYC1 gene
P02424743A0280|4 6|N1
P02424743A0280|11 13|P2
P02424743A0280|33 42|amplitude
P02424743A0280|77 84|periods
P02427024X0000|0 9|Tolerance
P02427024X0000|13 34|fenfluramine anorexia
P02427024X0000|36 40|fact
P02427024X0000|44 51|fiction
P02427024X0000|60 68|findings
P02427024X0000|77 87|laboratory
P02427024X0000|93 99|regard
P02427024X0000|103 112|tolerance
P02427024X0000|116 137|fenfluramine anorexia
P02427024X0000|156 163|respect
P02427024X0000|167 177|generality
P02427024X0000|197 207|phenomenon
P02427797A0199|6 10|dogs
P02427797A0199|20 24|limb
P02427797A0199|26 30|tail
P02427797A0199|39 47|pancreas
P02427797A0199|86 92|cavity
P02427797A0199|99 108|cessation
P02427797A0199|112 122|blood flow
P02427797A0199|139 147|ischemia
P02427797A0199|168 171|min
P02427797A0199|176 180|dogs
P02427797A0199|189 199|time point
P02427797A0199|233 240|Ringers
P02427797A0199|242 249|lactate
P02427797A0199|280 287|vessels
P02427812A0865|6 13|results
P02427812A0865|26 30|view
P02427812A0865|36 45|clonidine
P02427812A0865|50 56|6-OHDA
P02427812A0865|66 74|alpha-MD
P02427812A0865|89 104|pressor actions
P02427812A0865|112 115|rat
P02427812A0865|151 157|action
P02427869A0939|13 17|beta
P02427869A0939|33 44|sensitivity
P02427869A0939|72 75|BHT
P02431314A0834|17 23|Hansel
P02431314A0834|59 70|recognition
P02431314A0834|74 88|eosinophiluria
P02431314A0834|106 112|Wright
P02436005A0707|6 13|results
P02436005A0707|50 56|action
P02436005A0707|60 70|nicorandil
P02436005A0707|84 94|inhibition
P02436005A0707|98 107|Ca influx
P02436005A0707|126 138|mobilization
P02436005A0707|142 144|Ca
P02437625A0197|4 9|study
P02437625A0197|23 27|eyes
P02437625A0197|49 72|histoplasmosis syndrome
P02437625A0197|74 78|POHS
P02437625A0197|104 116|degeneration
P02437625A0197|118 121|AMD
P02437792T0000|0 10|Comparison
P02437792T0000|14 24|elastase-1
P02437792T0000|30 37|amylase
P02437792T0000|39 45|lipase
P02437792T0000|64 80|immunoreactivity
P02437792T0000|88 97|diagnosis
P02437792T0000|107 119|pancreatitis
P02437895A0000|2 7|probe
P02437895A0000|15 35|potentials procedure
P02437895A0000|68 78|engagement
P02437895A0000|96 107|hemispheres
P02437895A0000|117 130|language task
P02437895A0000|153 159|groups
P02437895A0000|171 177|adults
P02437895A0000|184 194|hemisphere
P02437895A0000|196 198|LH
P02437895A0000|208 216|aphasics
P02437895A0000|233 239|stroke
P02437895A0000|241 252|dysarthrics
P02437895A0000|260 270|hemisphere
P02437895A0000|272 274|RH
P02437895A0000|295 303|patients
P02437895A0000|324 332|subjects
P02438637T0000|0 18|Mucolipidosis type
P02438637T0000|32 40|spectrum
P02438637T0000|53 60|history
P02442837A0060|17 23|groups
P02442837A0060|42 51|dauricine
P02442837A0060|62 85|calcium channel blocker
P02442837A0060|91 100|verapamil
P02442837A0060|128 151|calcium channel blocker
P02442837A0060|175 182|minutes
P02442837A0060|201 204|end
P02442837A0060|212 228|bypass procedure
P02442837A0060|232 238|period
P02442837A0060|245 252|minutes
P02443028A0695|3 9|reflow
P02443028A0695|39 46|percent
P02443028A0695|54 77|muscle microvasculature
P02443028A0695|83 94|reperfusion
P02443924A0083|8 16|patients
P02443924A0083|81 87|cancer
P02443924A0083|104 112|survival
P02444507A0240|0 17|Lysozyme activity
P02444507A0240|77 81|sera
P02444507A0240|100 108|patients
P02445751A0925|19 31|measurements
P02445751A0925|46 58|state levels
P02445751A0925|62 67|mRNAs
P02445751A0925|72 79|subunit
P02445751A0925|85 103|cytochrome oxidase
P02445751A0925|112 124|beta subunit
P02445751A0925|128 137|F1 ATPase
P02445751A0925|146 150|type
P02445751A0925|160 171|hem2 mutant
P02446871A1021|12 21|structure
P02446871A1021|56 62|region
P02446871A1021|97 106|LSU rRNAs
P02446871A1021|111 119|contrast
P02446871A1021|134 143|structure
P02446871A1021|165 168|end
P02446871A1021|178 187|molecules
P02449431A1121|0 22|ATP gamma S inhibition
P02449431A1121|47 61|concentrations
P02449431A1121|65 68|ATP
P02449431A1121|70 74|dATP
P02449431A1121|76 82|araATP
P02449431A1121|87 92|ddATP
P02451872A0391|4 12|recovery
P02451872A0391|25 40|methoxydextrane
P02451872A0391|52 53|%
P02452313A0114|0 8|ASL-8123
P02452313A0114|59 76|blocking activity
P02452313A0114|89 111|guinea pig right atria
P02452313A0114|119 122|pA2
P02452313A0114|157 165|activity
P02452313A0114|187 193|tissue
P02452313A0114|197 211|concentrations
P02452313A0114|215 223|ASL-8123
P02452313A0114|231 232|X
P02452313A0114|245 246|X
P02452313A0114|254 256|M.
P02454390T0000|0 8|Enhancer
P02454390T0000|13 30|promoter elements
P02454390T0000|41 51|activation
P02454390T0000|56 81|glucocorticoid repression
P02454390T0000|89 113|alpha 1-fetoprotein gene
P02454390T0000|117 128|hepatocytes
P02454976A0944|15 22|results
P02454976A0944|26 34|relation
P02454976A0944|47 54|systems
P02454976A0944|98 103|gyrus
P02454976A0944|111 114|cat
P02454976A0944|132 143|possibility
P02454976A0944|149 158|divisions
P02454976A0944|195 200|gyrus
P02454976A0944|224 229|areas
P02454976A0944|262 267|gyrus
P02454976A0944|271 279|primates
P02455821A0099|4 8|gene
P02455821A0099|44 83|AccI-EcoRI restriction fragment mapping
P02455821A0099|87 90|map
P02455821A0099|125 134|UL region
P02455821A0099|142 154|EHV-1 genome
P02455821A0099|179 184|right
P02456827A0899|4 8|4-AP
P02456827A0899|15 17|mM
P02456827A0899|19 25|effect
P02456827A0899|40 48|decrease
P02456827A0899|64 72|activity
P02456827A0899|102 105|TEA
P02456827A0899|109 112|Ba2
P02457922A0991|0 13|Hybridization
P02457922A0991|19 24|probe
P02457922A0991|35 41|region
P02457922A0991|61 66|blots
P02457922A0991|70 74|RNAs
P02457922A0991|96 103|tissues
P02457922A0991|125 137|2.8-kilobase
P02457922A0991|139 141|kb
P02457922A0991|143 150|message
P02457922A0991|173 178|bands
P02457922A0991|191 193|kb
P02457922A0991|197 201|size
P02458080T0000|0 9|Prognosis
P02458080T0000|35 42|myeloma
P02458234T0000|6 12|method
P02458234T0000|34 42|analysis
P02458234T0000|46 60|sleep spindles
P02458234T0000|89 103|EEG recordings
P02458699A0650|0 8|Svensson
P02459309T0000|11 18|release
P02459309T0000|31 40|serotonin
P02459309T0000|67 71|acid
P02459309T0000|79 94|caudate-putamen
P02459309T0000|102 105|rat
P02459309T0000|135 143|dialysis
P02459309T0000|179 193|chromatography
P02459309T0000|212 221|detection
P02461368A0162|8 14|report
P02461368A0162|41 45|time
P02461368A0162|67 76|structure
P02461368A0162|80 95|type X collagen
P02461368A0162|106 113|cloning
P02461368A0162|118 128|sequencing
P02461368A0162|132 136|cDNA
P02461368A0162|149 152|DNA
P02462047A0208|7 17|flap areas
P02462047A0208|54 70|pedicle ligation
P02462047A0208|77 84|vessels
P02462047A0208|93 99|artery
P02462047A0208|103 107|vein
P02462047A0208|123 126|day
P02462047A0208|133 150|flap replantation
P02462047A0208|159 165|island
P02462047A0208|175 180|flaps
P02462305A1071|4 20|size discrepancy
P02462305A1071|35 48|glycosylation
P02462305A1071|52 67|phosphorylation
P02462305A1071|71 75|Ag35
P02462305A1071|111 119|sequence
P02462305A1071|141 152|polypeptide
P02462523A0394|9 27|KpnI-SalI fragment
P02462523A0394|43 54|DNA changes
P02462523A0394|71 73|su
P02462523A0394|74 76|Hw
P02462523A0394|78 87|mutations
P02462523A0394|124 126|su
P02462523A0394|127 129|Hw
P02462523A0394|138 147|phenotype
P02462523A0394|173 197|germ-line transformation
P02463050A0514|4 49|corticosterone synthesis inhibitor metyrapone
P02463050A0514|54 59|mg/kg
P02463050A0514|93 97|rise
P02463050A0514|101 115|corticosterone
P02463050A0514|121 126|level
P02463050A0514|147 152|males
P02464097T0000|4 11|effects
P02464097T0000|15 19|L655
P02464097T0000|37 48|thromboxane
P02464097T0000|53 90|prostaglandin endoperoxide antagonist
P02464097T0000|95 103|ischemia
P02464097T0000|137 148|arrhythmias
P02466414A0000|24 28|dogs
P02466414A0000|30 46|plasma viscosity
P02466414A0000|48 50|Ep
P02466414A0000|87 102|blood viscosity
P02466414A0000|104 106|Ea
P02466414A0000|139 144|steps
P02466414A0000|148 168|exchange transfusion
P02466414A0000|176 178|ml
P02466414A0000|182 188|plasma
P02466414A0000|194 200|plasma
P02466414A0000|227 241|weight dextran
P02466414A0000|243 246|mol
P02466414A0000|261 269|% wt/vol
P02466665A0202|22 29|protein
P02466665A0202|60 65|fluid
P02468795A1086|0 5|Serum
P02468795A1086|16 39|acid phosphatase levels
P02468795A1086|70 81|correlation
P02468795A1086|87 100|cancer volume
P02468795A1086|102 103|r
P02468795A1086|146 155|parameter
P02469451A0239|4 17|investigation
P02469451A0239|54 61|fashion
P02469451A0239|91 98|mg dose
P02469451A0239|106 130|MAO-B inhibitor deprenyl
P02469451A0239|143 151|subjects
P02470955A0101|6 13|studies
P02470955A0101|43 51|increase
P02470955A0101|55 70|CSF AP activity
P02470955A0101|83 95|meningitides
P02470955A0101|114 126|meningitides
P02473156A0000|2 6|cDNA
P02473156A0000|28 60|lymphocyte cell surface molecule
P02473156A0000|110 116|member
P02473156A0000|142 148|family
P02473156A0000|152 169|adhesion proteins
P02473198A0613|0 8|Dopamine
P02473198A0613|28 44|potassium efflux
P02473198A0613|57 61|86Rb
P02473198A0613|63 69|efflux
P02473198A0613|83 89|glands
P02473198A0613|107 113|effect
P02473198A0613|128 134|glands
P02473619A0202|12 25|sensitization
P02473619A0202|44 53|chemicals
P02473619A0202|59 69|proportion
P02473619A0202|73 88|control animals
P02473619A0202|141 154|sensitization
P02473619A0202|158 166|patients
P02473619A0202|186 195|reactions
P02473619A0202|213 221|blockers
P02473619A0202|231 239|exposure
P02473619A0202|253 267|IgE antibodies
P02473693A0174|5 13|approach
P02473693A0174|47 54|protein
P02473693A0174|56 62|HGB F.
P02473718A0000|4 17|investigation
P02473718A0000|42 54|relationship
P02473718A0000|71 82|metabolites
P02473718A0000|86 95|serotonin
P02473718A0000|100 113|catecholamine
P02473718A0000|115 121|5-HIAA
P02473718A0000|126 129|VMA
P02473718A0000|132 139|T-cells
P02473718A0000|141 145|OKT3
P02473718A0000|149 157|T-helper
P02473718A0000|159 163|OKT4
P02473718A0000|167 179|T-suppressor
P02473718A0000|181 185|OKT8
P02473718A0000|192 199|B-cells
P02473718A0000|221 226|cells
P02473718A0000|242 250|subjects
P02473718A0000|254 260|female
P02473718A0000|264 268|male
P02473718A0000|270 273|age
P02473718A0000|283 288|years
P02473718A0000|294 300|stress
P02473718A0000|314 322|subjects
P02473718A0000|327 335|subjects
P02473718A0000|339 345|female
P02473718A0000|350 354|male
P02473718A0000|356 359|age
P02473718A0000|369 374|years
P02473907A1338|8 13|C mAb
P02473907A1338|27 31|site
P02473907A1338|35 38|IgE
P02473907A1338|79 91|Fc epsilon R
P02473907A1338|100 104|site
P02473907A1338|128 132|site
P02473907A1338|136 139|IgE
P02473907A1338|183 195|Fc epsilon R
P02473907A1338|204 208|site
P02473942A1207|18 23|plots
P02473942A1207|76 84|segments
P02473942A1207|115 137|transmembrane segments
P02474093T0000|0 11|Angiotensin
P02474093T0000|23 40|enzyme inhibitors
P02474093T0000|70 78|efficacy
P02474093T0000|82 91|diuretics
P02474093T0000|131 138|effects
P02474110A1039|3 11|addition
P02474110A1039|31 40|reduction
P02474110A1039|44 58|blood pressure
P02474110A1039|64 75|angiotensin
P02474110A1039|87 93|enzyme
P02474110A1039|95 98|ACE
P02474110A1039|100 118|inhibitor ramipril
P02474110A1039|140 150|regression
P02474110A1039|182 193|hypertrophy
P02474110A1039|219 236|resonance imaging
P02474110A1039|241 257|echocardiography
P02474204A0105|10 15|cells
P02474204A0105|32 37|means
P02474204A0105|41 50|Grimelius
P02474204A0105|59 67|staining
P02474204A0105|72 86|immunostaining
P02474204A0105|91 103|chromogranin
P02474204A0105|115 121|marker
P02474204A0105|135 140|cells
P02474356A0559|4 9|ratio
P02474356A0559|13 26|radioactivity
P02474356A0559|30 36|tumour
P02474356A0559|58 64|tissue
P02474356A0559|66 67|T
P02474356A0559|68 75|N ratio
P02474356A0559|123 135|microspheres
P02474356A0559|145 151|portal
P02474356A0559|165 176|circulation
P02474356A0559|185 191|animal
P02475506A0878|4 8|mRNA
P02475506A0878|26 30|cDNA
P02475506A0878|52 87|polymerase chain reaction technique
P02475717A0565|0 15|Tissue necrosis
P02475717A0565|36 65|triphenyltetrazolium staining
P02475717A0565|95 114|baseline predictors
P02475717A0565|118 130|infarct size
P02475717A0565|141 155|risk zone size
P02475717A0565|169 184|collateral flow
P02476030A0000|21 28|surface
P02476030A0000|42 45|eye
P02476030A0000|69 75|states
P02476030A0000|84 109|laser scanning tomography
P02476664A0563|28 36|sequence
P02476664A0563|44 48|gene
P02476664A0563|64 67|K14
P02476664A0563|69 71|D.
P02477373A0930|12 20|TATA box
P02477373A0930|35 45|base pairs
P02477373A0930|68 97|transcription initiation site
P02479635A0659|0 14|Cotransfection
P02479635A0659|25 34|construct
P02479635A0659|40 48|plasmids
P02479635A0659|58 61|PKI
P02479635A0659|111 118|phorbol
P02479635A0659|136 146|expression
P02479823A0727|0 17|Sequence analysis
P02479823A0727|37 43|region
P02479823A0727|61 69|GC boxes
P02479823A0727|90 98|TATA box
P02480419A0735|15 24|cirrhosis
P02480419A0735|50 51|%
P02480419A0735|76 77|%
P02480419A0735|84 95|hepatitis B
P02480419A0735|104 113|infection
P02480419A0735|132 133|%
P02480959A0470|5 18|P-450scc mRNA
P02480959A0470|35 46|consequence
P02480959A0470|61 66|surge
P02480959A0470|113 118|cells
P02480959A0470|132 136|days
P02480959A0470|156 160|days
P02480959A0470|169 176|absence
P02480959A0470|180 193|gonadotropins
P02480959A0470|213 223|modulation
P02480959A0470|227 236|prolactin
P02480959A0470|267 271|cAMP
P02481230A1258|29 51|bovine alpha transgene
P02481230A1258|69 77|placenta
P02481230A1258|92 96|mice
P02481429T0000|8 26|staining technique
P02481429T0000|31 51|Leishmania parasites
P02481429T0000|72 78|smears
P02481779A0213|0 7|NIK-244
P02481779A0213|28 36|ligation
P02481779A0213|60 71|arrhythmias
P02481779A0213|99 120|plasma concentrations
P02481779A0213|125 136|arrhythmias
P02481779A0213|171 179|ligation
P02481779A0213|184 193|digitalis
P02481779A0213|219 229|mg/kg i.v.
P02481779A0213|252 262|mg/kg i.v.
P02481779A0213|291 301|mg/kg i.v.
P02481779A0213|303 315|microgram/ml
P02481779A0213|331 335|mean
P02481779A0213|340 342|SD
P02481779A0213|350 354|mean
P02481779A0213|356 357|n
P02482293A1518|17 44|T24 bladder carcinoma cells
P02482293A1518|46 49|TNF
P02482293A1518|66 104|EGF-R tyrosine protein kinase activity
P02482293A1518|119 122|EGF
P02482293A1518|127 140|phorbol ester
P02482293A1518|178 186|activity
P02482293A1518|194 202|receptor
P02482293A1518|212 217|cells
P02482511A0860|6 34|phosphodiesterase inhibitors
P02482511A0860|75 83|syndrome
P02482511A0860|109 116|stimuli
P02482511A0860|121 132|weight loss
P02482511A0860|153 172|withdrawal syndrome
P02482511A0860|189 199|naltrexone
P02482511A0860|222 226|rats
P02483210A0000|15 20|value
P02483210A0000|24 35|blood serum
P02483210A0000|48 55|amylase
P02483210A0000|57 63|lipase
P02483210A0000|69 76|trypsin
P02483210A0000|80 93|exacerbations
P02483210A0000|105 127|relapsing pancreatitis
P02483438A0498|7 12|basis
P02483438A0498|20 29|mechanism
P02483438A0498|33 39|action
P02483438A0498|45 51|groups
P02483438A0498|55 66|inodilators
P02483438A0498|90 118|phosphodiesterase inhibitors
P02483438A0498|140 146|agents
P02484714T0000|11 23|organization
P02484714T0000|28 38|expression
P02484714T0000|46 69|mouse estrogen receptor
P02484994T0001|12 27|gamma globulins
P02485188A0415|10 27|chondroitinase AC
P02485188A0415|32 45|ABC digestion
P02485188A0415|56 65|reactions
P02485188A0415|93 99|levels
P02485188A0415|103 119|dermatan sulfate
P02485188A0415|132 140|diabetes
P02485188A0415|151 156|group
P02485188A0415|158 159|p
P02485188A0415|198 199|p
P02485188A0415|228 236|diabetes
P02485188A0415|260 266|levels
P02485188A0415|270 290|chondroitin sulfates
P02485188A0415|303 311|diabetes
P02485188A0415|318 323|group
P02485188A0415|325 326|p
P02486634A0632|11 20|perfusion
P02486634A0632|59 64|level
P02486634A0632|71 89|contrast injection
P02486634A0632|99 104|level
P02486634A0632|127 137|morphology
P02486634A0632|142 148|degree
P02486634A0632|152 174|collateral development
P02487898A0315|5 23|NGF administration
P02487898A0315|87 91|ways
P02487898A0315|95 113|NGF administration
P02488148A1156|11 18|program
P02488148A1156|21 24|use
P02488148A1156|32 44|RSNA meeting
P02488148A1156|50 57|program
P02488148A1156|79 88|diagnosis
P02488148A1156|107 108|%
P02488148A1156|116 120|time
P02489032A0000|0 14|Immunoglobulin
P02489032A0000|21 26|chain
P02489032A0000|28 31|IgL
P02489032A0000|33 42|diversity
P02489032A0000|63 70|chicken
P02489032A0000|74 87|recombination
P02489032A0000|118 126|variable
P02489032A0000|128 130|VL
P02489032A0000|145 147|JL
P02489032A0000|149 162|gene segments
P02489032A0000|186 201|diversification
P02489032A0000|220 229|VL region
P02489753A0581|4 11|results
P02489753A0581|49 61|EMG activity
P02489753A0581|65 73|FB group
P02489753A0581|114 122|position
P02489753A0581|140 142|CG
P02489753A0581|147 155|GF group
P02489753A0581|168 176|position
P02489753A0581|180 188|position
P02489895T0001|0 13|Muscle action
P02489895T0001|40 46|rhythm
P02489895T0001|81 88|muscles
P02489895T0001|92 100|children
P02489895T0001|105 111|adults
P02492111A0670|5 6|%
P02492111A0670|24 32|children
P02492111A0670|34 50|bone lead values
P02492111A0670|63 67|LXRF
P02492111A0670|148 154|adults
P02492111A0868|42 49|effects
P02492111A0868|53 61|children
P02492111A0868|70 76|levels
P02492111A0868|81 89|exposure
P02492111A0868|105 112|results
P02492111A0868|160 166|margin
P02492111A0868|170 176|safety
P02492111A0868|193 199|safety
P02492111A0868|223 238|U.S. guidelines
P02492111A0868|267 291|blood lead concentration
P02492111A0868|298 311|micrograms/dl
P02493644A0588|11 20|3T3 cells
P02493644A0588|22 27|jun-D
P02493644A0588|53 58|level
P02493644A0588|71 76|c-jun
P02493644A0588|81 86|jun-B
P02493644A0588|96 109|transcription
P02493644A0588|141 161|serum growth factors
P02495745T0000|17 24|effects
P02495745T0000|35 68|tissue-type plasminogen activator
P02495745T0000|70 76|AK-124
P02495745T0000|110 120|thrombosis
P02496090A0252|7 10|CO2
P02496090A0252|18 35|tracheostomy tube
P02496090A0252|67 84|mass spectrometry
P02496090A0252|126 144|sampling technique
P02496100T0000|28 33|assay
P02496100T0000|48 60|aflatoxin B1
P02496100T0000|64 83|cottonseed products
P02496100T0000|94 98|feed
P02496100T0000|114 119|study
P02496109A0754|9 20|experiments
P02496109A0754|26 36|S1 mapping
P02496109A0754|48 59|transcripts
P02496109A0754|61 77|gene disruptions
P02496109A0754|85 97|alpha region
P02496109A0754|133 146|fusion vector
P02496109A0754|181 190|promoters
P02496109A0754|232 238|growth
P02496109A0754|255 263|promoter
P02496109A0754|272 284|alpha operon
P02496109A0754|307 313|region
P02496109A0754|335 340|genes
P02496109A0754|348 351|IF1
P02496109A0754|355 367|L17 interval
P02497340A0989|22 36|antibody genes
P02497340A0989|56 58|JH
P02497340A0989|63 65|VH
P02497340A0989|72 84|chain probes
P02497340A0989|94 96|Jk
P02497340A0989|101 103|Vk
P02497340A0989|110 122|chain probes
P02498322A0226|25 34|complexes
P02498322A0226|54 76|gel retardation assays
P02498322A0226|83 92|HeLa cell
P02498322A0226|101 109|extracts
P02498322A0226|117 138|oligonucleotide probe
P02498322A0226|164 170|region
P02498652A0460|6 18|transfection
P02498652A0460|29 55|TSH beta promoter activity
P02498652A0460|109 112|GH3
P02498652A0460|135 148|cell cultures
P02500432A1416|37 51|CAT expression
P02500432A1416|88 96|kilobase
P02500432A1416|100 103|DNA
P02500432A1416|116 119|end
P02500432A1416|140 147|segment
P02500432A1416|175 186|orientation
P02500432A1416|190 195|front
P02500432A1416|203 211|CAT gene
P02502096A0462|22 32|blood flow
P02502096A0462|67 86|excretion processes
P02502602A0323|0 9|Tonometry
P02502602A0323|13 26|blood samples
P02502602A0323|32 40|patients
P02502602A0323|65 78|determination
P02502602A0323|82 102|acid-base quantities
P02502602A0323|125 133|affinity
P02502602A0323|139 142|p50
P02502960A0762|11 13|p.
P02504603T0000|0 9|Isolation
P02504603T0000|13 29|Weeksella virosa
P02504603T0000|40 53|CDC group IIf
P02504603T0000|70 76|sample
P02505087A1037|19 43|dimerization specificity
P02505087A1037|47 50|Fos
P02505087A1037|78 92|leucine zipper
P02505087A1037|108 112|GCN4
P02506390T0001|0 6|Growth
P02506390T0001|19 30|anastomoses
P02506390T0001|42 49|animals
P02506740A0742|34 39|hours
P02506740A0742|43 51|recovery
P02506740A0742|80 86|effect
P02506740A0742|98 105|hypoxia
P02506740A0742|118 128|blood flow
P02507523A0791|4 16|ORF1 product
P02507523A0791|34 44|competence
P02507523A0791|52 56|ORF2
P02507523A0791|87 91|ORF1
P02507523A0791|116 123|protein
P02507523A0791|131 142|amino acids
P02507815A0000|0 8|Kindling
P02507815A0000|31 37|cortex
P02507815A0000|39 41|VC
P02507815A0000|73 81|amygdala
P02507815A0000|85 89|cats
P02508306A0528|9 21|infiltration
P02508306A0528|25 36|lymphocytes
P02508306A0528|41 53|plasma cells
P02508306A0528|87 96|carcinoma
P02508306A0528|133 142|follicles
P02508726A0498|6 18|case reports
P02508726A0498|35 43|evidence
P02508726A0498|49 54|LiCO3
P02508726A0498|71 81|medication
P02508726A0498|89 98|treatment
P02508726A0498|113 121|behavior
P02508726A0498|136 147|instability
P02508726A0498|154 166|brain injury
P02508726A0498|196 205|potential
P02508726A0498|210 223|neurotoxicity
P02508726A0498|232 242|population
P02508726A0498|270 281|conjunction
P02508726A0498|299 305|agents
P02509123A0371|7 15|sessions
P02509123A0371|22 25|IFN
P02509123A0371|31 38|latency
P02509123A0371|46 60|P100 component
P02509123A0371|68 71|VEP
P02509123A0371|101 120|baseline conditions
P02510242A0313|10 15|cases
P02510242A0313|36 45|hepatitis
P02510242A0313|65 82|hepatitis B virus
P02510242A0313|103 109|search
P02510242A0313|114 120|HBs Ag
P02510242A0313|160 167|viruses
P02510242A0313|208 213|tests
P02510242A0313|232 239|viruses
P02510242A0313|251 254|CMV
P02511069A0532|17 26|mutations
P02511069A0532|52 59|failure
P02511069A0532|88 97|lethality
P02511069A0532|101 103|Df
P02511069A0532|104 106|3L
P02511069A0532|107 110|RR2
P02511069A0532|114 122|deletion
P02511069A0532|130 140|DRE region
P02511069A0532|160 185|polytene chromosome bands
P02511150T0025|8 14|status
P02511150T0025|26 38|perspectives
P02511207A0282|0 2|K.
P02511430A0000|17 19|bp
P02511430A0000|21 27|region
P02511430A0000|35 45|mouse MOPC
P02511430A0000|49 54|kappa
P02511430A0000|67 95|immunoglobulin gene enhancer
P02511430A0000|127 134|binding
P02511430A0000|171 178|factors
P02511898A0000|5 10|paper
P02511898A0000|24 31|reasons
P02511898A0000|36 45|countries
P02511898A0000|55 69|Chagas disease
P02511898A0000|111 119|research
P02512010A0801|4 22|PETCO2 measurement
P02512010A0801|41 52|compression
P02512010A0801|67 74|success
P02512010A0801|78 92|defibrillation
P02512010A0801|98 104|return
P02512010A0801|120 131|circulation
P02514498A0000|8 16|CO2/HCO3
P02514498A0000|35 42|absence
P02514498A0000|59 69|inhibition
P02514498A0000|73 87|acid secretion
P02514498A0000|91 96|intra
P02514498A0000|115 135|pCO2/pH measurements
P02514498A0000|142 149|persons
P02514498A0000|175 183|equation
P02514498A0000|187 208|Henderson-Hasselbalch
P02514498A0000|210 214|pCO2
P02514498A0000|233 236|use
P02514498A0000|246 255|electrode
P02515953A0459|10 15|study
P02515953A0459|25 26|%
P02515953A0459|36 44|patients
P02515953A0459|50 63|effectiveness
P02517008A0481|10 18|patients
P02517008A0481|33 38|trial
P02517008A0481|57 62|doses
P02517008A0481|66 77|monotherapy
P02518645T0001|9 23|Chagas disease
P02518645T0001|25 45|laboratory diagnosis
P02518645T0001|63 67|year
P02518645T0001|71 75|life
P02518691A0251|14 44|IL2R alpha promoter constructs
P02518691A0251|58 70|transfection
P02518691A0251|75 93|DNA binding assays
P02518691A0251|119 128|sequences
P02518691A0251|180 196|kappa B enhancer
P02518691A0251|220 230|regulation
P02518691A0251|234 260|IL2R alpha gene expression
P02519327T0001|12 22|rheumatism
P02519679T0000|0 10|Inefficacy
P02519679T0000|14 34|phosphine fumigation
P02519679T0000|43 48|ticks
P02520622A0200|6 14|patients
P02520622A0200|74 87|transit times
P02520622A0200|103 111|symptoms
P02520622A0200|131 150|cimetropium bromide
P02520622A0200|154 163|mg t.d.s.
P02520622A0200|167 174|placebo
P02520622A0200|181 186|month
P02520622A0200|225 237|group design
P02521217A1035|27 34|protein
P02521217A1035|51 59|ribosome
P02521217A1035|64 82|membrane fractions
P02521217A1035|86 98|mitochondria
P02521674T0000|0 7|Mapping
P02521674T0000|11 14|RNA
P02521674T0000|38 45|mutants
P02521674T0000|57 62|virus
P02521674T0000|64 95|complementation group F mutants
P02521674T0000|101 108|lesions
P02521674T0000|112 116|nsP4
P02522297A0000|4 10|effect
P02522297A0000|18 32|thromboxane A2
P02522297A0000|34 38|TXA2
P02522297A0000|40 86|prostaglandin endoperoxide receptor antagonist
P02522297A0000|88 90|SQ
P02522297A0000|116 124|ischemia
P02522297A0000|167 171|dogs
P02523800A1178|27 35|sequence
P02523800A1178|43 52|CHS1 gene
P02523800A1178|59 67|fragment
P02523800A1178|82 89|repeats
P02523800A1178|95 121|TGAAACA consensus sequence
P02523800A1178|174 187|BAR1 promoter
P02523800A1178|189 197|Kronstad
P02523800A1178|199 201|J.
P02525044A1026|4 18|recovery index
P02525044A1026|20 27|T25-T75
P02525044A1026|39 47|infusion
P02525044A1026|71 79|patients
P02525044A1026|93 103|mivacurium
P02525044A1026|127 140|suxamethonium
P02526165X0000|4 8|sign
P02526165X0000|12 24|Leser-Trelat
P02526165X0000|45 49|sign
P02526165X0000|53 65|Leser-Trelat
P02526165X0000|110 116|marker
P02526165X0000|129 139|malignancy
P02527365T0000|0 15|Xenopus homolog
P02527365T0000|23 40|mos protooncogene
P02527365T0000|62 73|fibroblasts
P02527365T0000|86 96|maturation
P02527365T0000|100 115|Xenopus oocytes
P02527745A0865|0 22|Southern blot analyses
P02527745A0865|58 69|copy number
P02527745A0865|79 83|gene
P02527745A0865|88 100|conservation
P02527745A0865|109 115|domain
P02527745A0865|125 136|vertebrates
P02528329A0000|6 22|missense mutants
P02528329A0000|26 33|subunit
P02528329A0000|60 71|F1F0-ATPase
P02528329A0000|110 135|hydroxylamine mutagenesis
P02528329A0000|141 148|plasmid
P02528329A0000|162 166|uncB
P02528329A0000|168 175|subunit
P02528329A0000|179 183|gene
P02528730A1073|10 18|exons 2a
P02528730A1073|26 31|share
P02528730A1073|44 52|sequence
P02528730A1073|87 90|use
P02528730A1073|107 125|donor splice sites
P02528730A1073|130 132|bp
P02528730A1073|146 150|gene
P02529378A0536|0 20|S1 nuclease analysis
P02529378A0536|24 27|RNA
P02529378A0536|43 55|transfection
P02529378A0536|65 79|HIV constructs
P02529378A0536|85 95|HeLa cells
P02529378A0536|120 130|adenovirus
P02529378A0536|150 158|enhancer
P02529378A0536|160 163|SP1
P02529378A0536|165 169|TATA
P02529378A0536|177 184|portion
P02529378A0536|219 226|element
P02529378A0536|276 286|activation
P02529378A0536|294 301|HIV LTR
P02530413A0195|3 18|supine position
P02530413A0195|20 37|plasma ANP levels
P02530413A0195|53 58|pg/ml
P02530413A0195|67 72|pg/ml
P02530413A0195|90 95|level
P02530413A0195|113 118|pg/ml
P02530470A0604|12 22|prevalence
P02530470A0604|26 37|HBV markers
P02530470A0604|55 68|staff members
P02530470A0604|81 93|blood donors
P02530470A0604|101 105|area
P02531203A0241|13 24|predictions
P02531203A0241|56 65|responses
P02531203A0241|83 92|negatives
P02531203A0241|114 124|SSTS model
P02532032A0385|0 21|Plasma concentrations
P02532032A0385|25 28|ANF
P02532032A0385|30 34|pANF
P02532032A0385|37 48|aldosterone
P02532032A0385|50 53|PAC
P02532032A0385|59 64|renin
P02532032A0385|66 69|PRC
P02532032A0385|112 122|parameters
P02532210A0000|4 23|adenovirus E1A gene
P02532210A0000|34 41|protein
P02532210A0000|87 92|genes
P02534067A0316|0 14|Administration
P02534067A0316|18 31|dexamethasone
P02534067A0316|64 69|rises
P02534067A0316|73 79|plasma
P02534067A0316|83 104|alpha OH progesterone
P02534067A0316|109 128|beta-desoxycortisol
P02534067A0316|130 143|DHEA sulphate
P02534067A0316|145 160|androstenedione
P02534067A0316|165 177|testosterone
P02534067A0316|211 220|excretion
P02534067A0316|224 236|androsterone
P02534067A0316|241 261|beta OH androsterone
P02534067A0316|263 278|etiocholanolone
P02534067A0316|280 284|DHEA
P02534067A0316|293 306|alpha OH DHEA
P02535460A1443|0 15|RNA transcripts
P02535460A1443|57 61|gene
P02536096A0327|3 13|HeLa cells
P02536096A0327|28 41|transcription
P02536096A0327|51 76|herpes simplex virus type
P02536096A0327|79 104|thymidine kinase promoter
P02536096A0327|119 157|chloramphenicol acetyltransferase gene
P02536096A0327|183 194|orientation
P02536096A0327|211 236|thymidine kinase promoter
P02536096A0327|258 296|chloramphenicol acetyltransferase gene
P02536096A0327|304 312|sequence
P02536160A0518|26 35|condition
P02536160A0518|37 42|Ren1d
P02536160A0518|55 63|sequence
P02536160A0518|71 88|sense orientation
P02536160A0518|105 119|CAT expression
P02536160A0518|129 140|TK promoter
P02536160A0518|144 151|pUTKAT1
P02536160A0518|170 178|sequence
P02536160A0518|196 207|orientation
P02537441A0231|0 4|None
P02537441A0231|35 41|duties
P02537441A0231|54 70|varicella-zoster
P02537441A0231|78 86|globulin
P02537441A0231|101 108|disease
P02537485A0841|7 20|formalin test
P02537485A0841|31 39|naloxone
P02537485A0841|51 69|morphine analgesia
P02537485A0841|83 88|doses
P02537485A0841|102 107|mg/kg
P02537485A0841|125 143|morphine analgesia
P02537485A0841|159 163|dose
P02537485A0841|168 173|mg/kg
P02538450A0000|17 28|cDNA clones
P02538450A0000|34 43|rat brain
P02538450A0000|54 59|liver
P02538450A0000|80 87|isoform
P02538450A0000|95 119|Na,K-ATPase beta subunit
P02538656A0172|32 42|E1 mutants
P02538656A0172|63 64|M
P02538656A0172|69 78|R regions
P02538656A0172|92 98|mutant
P02538656A0172|126 132|region
P02538656A0172|147 168|transforming activity
P02538656A0172|172 188|mouse C127 cells
P02538656A0172|208 214|genome
P02538720A0582|0 4|UbiA
P02538720A0582|32 51|polyubiquitin genes
P02538720A0582|83 90|introns
P02538720A0582|109 117|sequence
P02541251A1327|12 19|T2 gene
P02541251A1327|48 53|sites
P02541251A1327|80 104|transcription factor SP1
P02541251A1327|113 117|TATA
P02541251A1327|121 136|CCAAT sequences
P02541251A1327|164 167|end
P02541251A1327|191 199|features
P02541251A1327|230 237|T1 gene
P02541882A0251|0 17|Radiation therapy
P02541882A0251|59 69|metastasis
P02541882A0251|83 91|patients
P02542194A1496|6 13|results
P02542194A1496|28 36|patients
P02542194A1496|63 74|irradiation
P02542194A1496|83 88|grade
P02542194A1496|96 108|astrocytomas
P02542194A1496|130 141|ependymomas
P02542194A1496|160 168|survival
P02542270A0000|4 15|methylation
P02542270A0000|31 47|chloroplast DNAs
P02542270A0000|69 77|relation
P02542270A0000|104 114|expression
P02542270A0000|118 141|C4 photosynthesis genes
P02542270A0000|149 162|bundle sheath
P02542270A0000|167 182|mesophyll cells
P02542270A0000|197 205|greening
P02542270A0000|223 228|maize
P02542612A0530|0 20|S1 nuclease analysis
P02542612A0530|24 27|RNA
P02542612A0530|52 63|B95-8 cells
P02542612A0530|73 83|Vero cells
P02542612A0530|103 127|NotI repeat promoter-CAT
P02542612A0530|132 133|Z
P02542612A0530|146 163|Z transactivation
P02542612A0530|178 183|level
P02542612A0530|215 230|RNA transcripts
P02543226A1559|25 35|likelihood
P02543226A1559|49 58|carcinoma
P02543226A1559|71 82|hyperplasia
P02543226A1559|102 126|adipose tissue component
P02543226A1559|145 160|breast biopsies
P02543226A1559|213 219|method
P02543226A1559|223 231|sampling
P02543226A1559|247 262|breast biopsies
P02543226A1559|298 305|maximum
P02543226A1559|312 318|blocks
P02543226A1559|330 340|parenchyma
P02543226A1559|350 354|case
P02543226A1559|385 391|tissue
P02543226A1559|415 424|carcinoma
P02543226A1559|437 448|hyperplasia
P02543226A1559|470 476|blocks
P02543621A0788|0 8|Analysis
P02543621A0788|16 19|DNA
P02543621A0788|28 33|cases
P02543621A0788|59 64|Wilms
P02543621A0788|66 71|tumor
P02543621A0788|91 98|changes
P02543621A0788|120 144|translocation breakpoint
P02543621A0788|169 173|gene
P02543679A1291|16 24|evidence
P02543679A1291|42 50|lambda O
P02543679A1291|55 67|P initiators
P02543679A1291|84 88|DnaJ
P02543679A1291|93 117|DnaK heat shock proteins
P02543679A1291|132 136|role
P02543679A1291|144 155|propagation
P02543679A1291|159 177|lambda replication
P02543734A0414|10 26|oligonucleotides
P02543734A0414|47 61|bp repeat unit
P02543734A0414|83 91|activity
P02543734A0414|99 122|IE1/2 enhancer/promoter
P02543734A0414|126 147|cotransfection assays
P02543734A0414|164 174|expression
P02544059A0377|0 7|Effects
P02544059A0377|11 19|nitrogen
P02544059A0377|21 24|PN2
P02544059A0377|35 38|MPa
P02544059A0377|44 50|helium
P02544059A0377|52 55|PHe
P02544059A0377|67 70|MPa
P02545357A0000|4 34|mustard chloroplast gene rps16
P02545357A0000|54 62|bp group
P02545357A0000|75 81|intron
P02545903A0639|0 10|Antibodies
P02545903A0639|35 38|NS3
P02545903A0639|42 54|immunization
P02545903A0639|58 62|mice
P02545903A0639|77 80|NS3
P02545903A0639|85 89|NS3A
P02545903A0639|109 118|BHK cells
P02545903A0639|139 161|BTV-10 virus particles
P02546234A1382|28 39|tachycaydia
P02546234A1382|64 71|efforts
P02546234A1382|114 121|outcome
P02547079A0910|13 28|calcium balance
P02547079A0910|34 54|hyperparathyroidemia
P02547079A0910|86 100|administration
P02547079A0910|104 106|Cd
P02547079A0910|143 152|excretion
P02547079A0910|156 163|calcium
P02547611A0318|0 8|Clone 4c
P02547611A0318|15 17|bp
P02547611A0318|32 38|region
P02547611A0318|60 69|clone 22c
P02547611A0318|97 103|intron
P02547611A0318|111 113|bp
P02547706A0928|4 15|application
P02547706A0928|19 22|ISH
P02547706A0928|27 30|IHC
P02547706A0928|83 97|classification
P02547706A0928|101 111|pneumonias
P02547706A0928|117 123|CMV-IP
P02547706A0928|128 131|IIP
P02547706T0001|0 8|Validity
P02547706T0001|12 27|immunohistology
P02547706T0001|40 53|hybridization
P02547706T0001|74 83|diagnosis
P02547706T0001|87 112|cytomegalovirus pneumonia
P02547706T0001|141 150|pneumonia
P02547706T0001|167 194|bone marrow transplantation
P02547778A0786|11 17|nature
P02547778A0786|22 33|arrangement
P02547778A0786|41 45|ANT1
P02547778A0786|62 78|control elements
P02547778A0786|113 123|expression
P02548683T0001|8 15|account
P02548683T0001|28 35|seminar
P02548683T0001|39 47|Shanghai
P02548683T0001|57 68|hepatitis A
P02549036A0000|4 31|Bacillus subtilis phage phi
P02549036A0000|36 45|repressor
P02549036A0000|49 55|lambda
P02549036A0000|98 105|protein
P02549036A0000|165 176|homogeneity
P02549036A0000|180 185|order
P02549036A0000|222 232|properties
P02549343A1008|3 14|consequence
P02549343A1008|20 23|gpI
P02549343A1008|37 42|cells
P02549343A1008|57 61|mO74
P02549343A1008|79 94|characteristics
P02549343A1008|115 118|gpI
P02549343A1008|137 142|cells
P02549343A1008|166 193|immunoprecipitation pattern
P02549343A1008|218 224|weight
P02549343A1008|233 244|polypeptide
P02549343A1008|264 272|antibody
P02549343A1008|285 292|rabbits
P02549343A1008|319 324|virus
P02549343A1008|336 357|neutralizing activity
P02549343A1008|368 376|reaction
P02549343A1008|396 406|complement
P02549417A0000|13 19|stages
P02549417A0000|42 51|parasites
P02549417A0000|60 82|acristate mitochondria
P02549417A0000|89 98|functions
P02550118A0610|37 50|infiltrations
P02550118A0610|64 68|days
P02550682A0411|13 22|incidence
P02550682A0411|28 46|type IIc carcinoma
P02550682A0411|55 56|%
P02550682A0411|71 74|IIc
P02550682A0411|81 85|type
P02550682A0411|94 95|%
P02551886A0332|0 16|Restriction maps
P02551886A0332|31 39|plasmids
P02551886A0332|72 79|inserts
P02551886A0332|105 114|fragments
P02552143A0748|0 3|VP5
P02552143A0748|29 43|capsid protein
P02552143A0748|63 101|chloramphenicol acetyltransferase gene
P02552316A0526|30 40|caretakers
P02552316A0526|58 65|average
P02552316A0526|73 77|days
P02552316A0526|82 87|woman
P02552316A0526|122 141|seroconversion rate
P02552316A0526|148 155|percent
P02554310A0419|3 11|contrast
P02554310A0419|23 31|fragment
P02554310A0419|57 63|region
P02554310A0419|88 94|effect
P02555177A0488|9 14|pet54
P02555177A0488|16 20|LEU2
P02555177A0488|67 73|genome
P02555177A0488|90 112|COX1 introns aI5 alpha
P02555177A0488|117 125|aI5 beta
P02555177A0488|147 167|COX3 gene expression
P02555177A0488|179 197|COX1 mRNA splicing
P02555177A0488|201 217|mRNA translation
P02555418A0973|0 7|Insert2
P02555418A0973|43 52|sequences
P02555418A0973|76 84|sequence
P02555519A0798|19 29|variations
P02555519A0798|33 39|length
P02555519A0798|52 60|sequence
P02555519A0798|68 72|CDR3
P02555519A0798|74 108|complementarity determining region
P02555519A0798|110 118|peptides
P02555519A0798|130 138|H-chains
P02555519A0798|152 164|conservation
P02555519A0798|172 190|D-region structure
P02555519A0798|237 251|hapten binding
P02555703T0000|0 25|Tyrosine kinase oncogenes
P02555703T0000|35 59|interleukin-3 dependence
P02555703T0000|78 83|cells
P02555703T0000|92 110|signaling pathways
P02555703T0000|121 126|c-myc
P02555703T0000|140 150|regulation
P02555703T0000|154 173|c-myc transcription
P02555703T0000|199 204|v-abl
P02556264A0278|5 19|TC-II enhanson
P02556264A0278|47 60|kappa B motif
P02556264A0278|70 90|kappa chain enhancer
P02556264A0278|137 142|cells
P02556264A0278|198 214|cell specificity
P02556264A0278|222 235|kappa B motif
P02556269A0187|4 13|DNA helix
P02556269A0187|40 54|13mer sequence
P02556269A0187|102 118|hypersensitivity
P02556269A0187|145 153|nuclease
P02556269A0187|182 189|plasmid
P02556269A0187|218 221|DNA
P02556269A0187|259 278|gel electrophoresis
P02556269A0187|282 293|topoisomers
P02556603A0606|23 34|improvement
P02556603A0606|75 81|cancer
P02556603A0606|83 101|gallbladder cancer
P02556603A0606|119 135|bile duct cancer
P02557217A0000|0 14|Beta-endorphin
P02557217A0000|16 20|ACTH
P02557217A0000|25 43|cortisol secretion
P02557217A0000|82 87|males
P02557217A0000|100 120|spray administration
P02557217A0000|125 145|IU salmon calcitonin
P02557217A0398|4 8|data
P02557217A0398|23 33|calcitonin
P02557217A0398|59 67|increase
P02557217A0398|92 123|corticotrophin-cortisol release
P02557350A0632|4 17|DNA sequences
P02557350A0632|26 34|proteins
P02557350A0632|39 46|SRP54sc
P02557350A0632|51 58|SRP54sp
P02557350A0632|70 71|%
P02557350A0632|78 79|%
P02557350A0632|93 101|SRP54mam
P02559630A0270|17 23|values
P02559630A0270|57 77|thromboplastin times
P02559630A0270|79 96|prothrombin times
P02559630A0270|98 112|thrombin times
P02559630A0270|114 124|fibrinogen
P02559630A0270|126 141|platelet counts
P02559630A0270|147 185|fibrin/fibrinogen degradation products
P02560415T0012|16 21|tumor
P02560415T0012|27 37|metastasis
P02560415T0012|41 46|mouth
P02560415T0012|48 51|jaw
P02560415T0012|56 68|face regions
P02562787A0637|23 30|protein
P02562787A0637|41 44|NBP
P02562787A0637|47 51|CNBP
P02562825A0413|0 14|Responsiveness
P02562825A0413|18 40|beta-2 agonist therapy
P02562825A0413|64 70|agents
P02562825A0413|72 73|p
P02565405T0000|0 8|Drug use
P02565405T0000|12 26|trauma victims
P02565683A0841|11 21|heart rate
P02565683A0841|53 58|state
P02565683A0841|84 93|instances
P02565683A0841|97 106|reentrant
P02565683A0841|127 138|tachycardia
P02565683A0841|163 174|tachycardia
P02565807A1198|3 11|contrast
P02565807A1198|17 35|neu proto-oncogene
P02565807A1198|49 64|kinase activity
P02565807A1198|81 91|properties
P02565807A1198|118 124|levels
P02565807A1198|128 141|NIH 3T3 cells
P02565807A1198|143 151|ABSTRACT
P02565807A1198|169 174|WORDS
P02566613A0831|10 18|sequence
P02566613A0831|58 66|enhancer
P02566613A0831|68 71|CRE
P02566613A0831|73 81|TGACGTCA
P02566613A0831|83 94|nucleotides
P02566613T0000|0 28|Somatostatin gene expression
P02566613T0000|43 54|islet cells
P02566613T0000|84 104|DNA control elements
P02566613T0000|121 129|proteins
P02566680A0820|3 11|contrast
P02566680A0820|32 49|agonists fentanyl
P02566680A0820|51 59|morphine
P02566680A0820|61 72|I-methadone
P02566680A0820|77 88|levorphanol
P02566680A0820|100 101|%
P02566680A0820|137 142|doses
P02566680A0820|160 165|times
P02566680A0820|206 220|response rates
P02566680A0820|226 227|%
P02567030A0482|35 49|discrimination
P02567030A0482|55 63|controls
P02567030A0482|82 92|difficulty
P02567030A0482|115 123|reversal
P02568930T0000|0 9|Isolation
P02568930T0000|14 30|characterization
P02568930T0000|36 40|cDNA
P02568930T0000|61 69|cytokine
P02568930T0000|90 101|stimulation
P02568930T0000|110 123|CD2 structure
P02568930T0000|133 146|T lymphocytes
P02569411A0151|6 17|termination
P02569411A0151|21 31|medication
P02569411A0151|36 43|animals
P02569411A0151|77 93|nucleus amygdala
P02571924A0000|8 13|cells
P02571924A0000|17 30|mating type A
P02571924A0000|54 85|yeast Rhodosporidium toruloides
P02571924A0000|96 112|mating pheromone
P02571924A0000|114 129|rhodotorucine A
P02571924A0000|143 156|undecapeptide
P02571924A0000|168 187|S-farnesyl cysteine
P02571924A0000|195 211|carboxy terminus
P02572777T0000|0 22|Tumour necrosis factor
P02572777T0000|45 62|distress syndrome
P02572928T0000|0 10|Monitoring
P02572928T0000|25 34|arthritis
P02573303A0000|4 12|decrease
P02573303A0000|34 36|LV
P02573303A0000|38 51|stroke volume
P02573303A0000|83 91|pressure
P02573303A0000|93 97|PEEP
P02573303A0000|130 132|LV
P02573303A0000|157 174|contractile state
P02573336A0000|3 13|experiment
P02573336A0000|37 40|ROF
P02573336A0000|64 69|snake
P02573336A0000|88 96|subjects
P02573336A0000|100 105|order
P02573336A0000|139 144|event
P02573336A0000|172 178|retest
P02573336A0000|194 203|magnitude
P02573336A0000|211 214|ROF
P02573829T0000|13 25|conservation
P02573829T0000|49 54|sites
P02573829T0000|65 74|sequences
P02573829T0000|105 123|transcription unit
P02573829T0000|142 159|segmentation gene
P02573836A0244|25 35|importance
P02573836A0244|45 48|NBS
P02573836A0244|64 89|drug resistance phenotype
P02573836A0244|103 107|mdr1
P02573836A0244|123 147|amino acid substitutions
P02573836A0244|155 178|core consensus sequence
P02573836A0244|183 201|nucleotide binding
P02573836A0244|203 209|GXGKST
P02574016A0428|25 28|TOF
P02574016A0428|58 59|%
P02574016A0428|63 76|control value
P02574016A0428|78 89|neostigmine
P02574016A0428|107 120|micrograms/kg
P02574016A0428|124 130|adults
P02574016A0428|135 148|micrograms/kg
P02574016A0428|152 159|infants
P02574016A0428|164 172|children
P02574052A0910|15 26|differences
P02574052A0910|41 49|relation
P02574052A0910|53 69|Type A behaviour
P02574052A0910|74 100|beta-adrenoceptor blockade
P02574193A0663|0 9|Selection
P02574193A0663|20 25|items
P02574193A0663|42 89|Institute Withdrawal Assessment-Benzodiazepines
P02574193A0663|91 97|CIWA-B
P02574193A0663|138 149|differences
P02574193A0663|158 166|baseline
P02574193A0663|180 198|withdrawal periods
P02574193A0663|212 220|subjects
P02574193A0663|233 241|symptoms
P02574193A0663|258 265|placebo
P02574193A0663|270 278|diazepam
P02574193A0663|291 299|subjects
P02574193A0663|307 325|contingency tables
P02574193A0663|339 358|regression analysis
P02574551T0000|0 14|Antihistamines
P02574551T0000|18 24|asthma
P02575174A0229|32 40|efficacy
P02575174A0229|45 51|safety
P02575174A0229|55 64|doxazosin
P02575174A0229|96 101|alpha
P02575174A0229|104 111|blocker
P02575174A0229|116 124|patients
P02575174A0229|139 151|hypertension
P02575174A0229|169 187|airflow limitation
P02575490A1021|0 22|Northern blot analysis
P02575490A1021|41 59|oIGF-I transcripts
P02575490A1021|71 75|band
P02575490A1021|89 100|nucleotides
P02575490A1021|111 122|transcripts
P02575490A1021|143 149|weight
P02575490A1021|153 158|liver
P02575567T0001|0 25|Materials science studies
P02575567T0001|68 73|wires
P02575959A0643|4 16|latency time
P02575959A0643|25 46|lactate concentration
P02575959A0643|64 70|values
P02575959A0643|94 102|training
P02575959A0643|104 106|T2
P02576405A0223|3 11|patients
P02576405A0223|25 28|VAD
P02576405A0223|40 49|therapies
P02576405A0223|67 76|melphalan
P02576405A0223|80 95|CBV combination
P02576405A0223|97 124|cyclophosphamide-BCNU-VP-16
P02576405A0223|132 144|EDAP regimen
P02576405A0223|146 151|VP-16
P02576405A0223|153 161|platinum
P02576405A0223|172 181|responses
P02576405A0223|193 194|%
P02576405A0223|198 206|patients
P02577458A0412|4 14|discussion
P02577458A0412|46 51|drugs
P02577458A0412|57 68|angiotensin
P02577458A0412|80 97|enzyme inhibitors
P02577458A0412|116 133|receptor blockers
P02577458A0412|139 158|calcium antagonists
P02577867T0000|19 26|homolog
P02577867T0000|34 47|oncogene jun.
P02580830A1131|9 17|sequence
P02580830A1131|37 43|region
P02580830A1131|60 68|cap site
P02580830A1131|82 90|AFP gene
P02580830A1131|101 113|% similarity
P02580830A1131|137 143|region
P02580830A1131|151 165|mouse AFP gene
P02582240A1009|5 19|ATP/GTP ratios
P02582240A1009|29 39|initiation
P02582240A1009|43 63|RNA primer synthesis
P02582240A1009|70 81|dCTTT sites
P02582240A1009|95 109|ATP/GTP ratios
P02582240A1009|119 129|initiation
P02582240A1009|136 146|dCCC sites
P02582918A0000|6 38|hepatitis B vaccine immunization
P02582918A0000|40 63|serum antibody response
P02582918A0000|79 83|type
P02582918A0000|90 95|cases
P02582918A0000|101 109|anti-HBs
P02582918A0000|124 127|S/N
P02582918A0000|129 143|S/N Ratio Unit
P02582918A0000|148 150|T0
P02582918A0000|174 178|rate
P02582918A0000|187 188|%
P02582918A0000|194 195|%
P02582918A0000|201 202|%
P02582918A0000|211 212|%
P02582918A0000|216 218|T1
P02582918A0000|220 222|T2
P02582918A0000|224 226|T0
P02582918A0000|231 234|T12
P02584969A0119|17 23|design
P02584969A0119|48 64|regression model
P02584969A0119|77 87|treatments
P02584969A0119|107 116|end point
P02584969A0119|120 121|%
P02584969A0119|127 142|protection time
P02585492A1005|14 35|complementation tests
P02585492A1005|52 63|P7 proteins
P02585492A1005|89 96|P1 parA
P02585492A1005|100 112|parB mutants
P02585492A1005|122 133|P1 proteins
P02585492A1005|157 169|P7 mutations
P02586485A0511|0 5|GN101
P02586485A0511|7 14|YC819-9
P02586485A0511|20 23|SB3
P02586513A0622|0 8|Analysis
P02586513A0622|39 52|ama-1 product
P02586513A0622|73 81|identity
P02586513A0622|99 106|subunit
P02586513A0622|110 114|RNAP
P02586513A0622|129 138|organisms
P02586513A0622|154 162|presence
P02586513A0622|168 185|zinc finger motif
P02586513A0622|195 209|amino terminus
P02586513A0622|235 241|domain
P02586513A0622|268 277|heptamers
P02586513A0622|287 304|consensus Tyr Ser
P02586513A0622|309 316|Thr Ser
P02586513A0622|321 324|Ser
P02590097A0093|8 19|involvement
P02590097A0093|32 36|lung
P02590097A0093|41 53|infiltration
P02590097A0093|61 67|mucosa
P02590097A0093|86 99|lobe bronchus
P02590097A0093|141 151|gammopathy
P02590097A0093|153 156|IgA
P02590097A0093|158 168|Type Kappa
P02590391A0442|0 4|None
P02590391A0442|21 31|parameters
P02590391A0442|33 47|heart contents
P02590391A0442|59 65|lipids
P02590391A0442|73 86|phospholipids
P02590391A0442|88 107|phosphatidylcholine
P02590391A0442|109 133|phosphatidylethanolamine
P02590391A0442|135 157|diphosphatidylglycerol
P02590391A0442|159 172|sphingomyelin
P02590391A0442|183 199|acid composition
P02590391A0442|208 226|phospholipid class
P02590391A0442|260 267|grading
P02590391A0442|275 282|lesions
P02590540A0741|7 12|women
P02590540A0741|32 41|diagnoses
P02590540A0741|48 49|%
P02590540A0741|55 57|CA
P02590540A0741|62 68|levels
P02590540A0741|72 78|excess
P02590540A0741|85 89|U/ml
P02590540A0741|98 99|%
P02590540A0741|117 121|U/ml
P02590615A0636|27 32|state
P02590615A0636|37 43|timing
P02590615A0636|55 59|meal
P02590615A0636|109 115|manner
P02590615A0636|120 136|pharmacokinetics
P02590615A0636|140 150|nifedipine
P02590615A0636|176 183|tablets
P02590869A0743|16 22|calves
P02590869A0743|37 46|serum IgG
P02590869A0743|48 58|lavage IgG
P02590869A0743|63 66|IgA
P02590869A0743|81 91|LNA titers
P02590869A0743|100 113|lavage fluids
P02590869A0743|118 123|serum
P02590869A0743|138 145|SC dose
P02590869A0743|156 164|bacteria
P02591078A0000|7 21|investigations
P02591078A0000|38 48|Grenz rays
P02591078A0000|75 102|contact dermatitis reaction
P02591078A0000|123 139|Langerhans cells
P02591078A0000|155 170|OKT6 antibodies
P02591078A0000|175 194|electron microscopy
P02591078A0000|215 224|epidermis
P02591078A0000|237 241|time
P02591969A0961|4 12|elements
P02591969A0961|29 55|glucocorticoid stimulation
P02591969A0961|59 81|ADH gene transcription
P02591969A0961|115 121|region
P02592543A0106|12 19|studies
P02592543A0106|44 59|characteristics
P02592543A0106|61 89|Kanagawa hemolysin reactions
P02592543A0106|95 111|plasmid profiles
P02592543A0106|118 125|patient
P02592543A0106|148 156|isolates
P02592543A0106|164 172|organism
P02592640A0466|5 11|values
P02592640A0466|20 27|retinol
P02592640A0466|32 45|beta-carotene
P02592640A0466|69 76|cheeses
P02592640A0466|90 95|cream
P02592640A0466|109 115|cheese
P02592640A0466|152 153|g
P02592640A0466|164 169|cream
P02592640A0466|186 192|cheese
P02592640A0466|229 230|g
P02592640A0466|241 246|cream
P02592640A0466|262 269|retinol
P02592640A0466|280 293|beta-carotene
P02592961A0327|0 6|COGLAB
P02592961A0327|16 24|measures
P02592961A0327|73 96|psychomotor performance
P02595451A1136|6 10|data
P02595451A1136|22 35|aniridia gene
P02595451A1136|37 40|AN2
P02595451A1136|58 84|T-cell leukemia breakpoint
P02595451A1136|86 90|TCL2
P02595451A1136|99 114|marker sequence
P02595451A1136|128 133|sides
P02595451A1136|137 141|MIC1
P02595451T0000|17 29|deletion map
P02595451T0000|39 53|chromosome 11p
P02595451T0000|55 63|analysis
P02595451T0000|67 84|J1 series hybrids
P02597484A0624|5 12|respect
P02597484A0624|26 37|diffusivity
P02597484A0624|41 50|platelets
P02597484A0624|52 54|De
P02597484A0624|64 82|surface reactivity
P02597484A0624|93 94|K
P02597484A0624|114 125|differences
P02597484A0624|154 163|materials
P02597549A0964|20 28|patients
P02597549A0964|41 45|days
P02597549A0964|66 78|dipyridamole
P02597549A0964|83 93|mg X 3/day
P02597549A0964|99 106|aspirin
P02597549A0964|111 117|mg/day
P02597549A0964|135 150|recovery period
P02597549A0964|161 165|days
P02597549A0964|188 199|prothrombin
P02597549A0964|212 232|thromboplastin times
P02598034A0000|0 23|Middle-latency auditory
P02598034A0000|31 41|potentials
P02598034A0000|43 48|MAEPs
P02598034A0000|67 75|controls
P02598034A0000|80 88|patients
P02598034A0000|100 107|lesions
P02598034A0000|135 141|cortex
P02598745A0251|30 45|Sylvius fissure
P02598745A0251|50 55|cases
P02599995A1031|14 30|activity studies
P02599995A1031|54 63|times MBC
P02599995A1031|70 80|penicillin
P02599995A1031|101 109|activity
P02599995A1031|132 145|staphylococci
P02599995A1031|156 164|survival
P02599995A1031|170 171|%
P02600306A0140|55 64|detection
P02600306A0140|68 92|envelope phase disparity
P02600306A0140|113 123|processing
P02600306A0140|140 147|channel
P02600306A0140|161 169|AM tones
P02601707A0986|0 22|Gel retardation assays
P02601707A0986|37 42|DNase
P02601707A0986|45 57|footprinting
P02601707A0986|62 96|diethyl pyrocarbonate interference
P02601707A0986|119 125|factor
P02601707A0986|146 157|C2 myotubes
P02601707A0986|162 176|BC3H1 myocytes
P02601707A0986|200 201|A
P02601707A0986|211 219|sequence
P02601707A0986|253 259|region
P02602150A0993|16 22|plants
P02602150A0993|61 69|analysis
P02602150A0993|73 90|sequence elements
P02602150A0993|102 127|replication origin region
P02602150A0993|142 154|construction
P02602150A0993|164 174|generation
P02602150A0993|178 185|vectors
P02602150A0993|190 208|gene amplification
P02602150A0993|212 218|plants
P02602150A0993|239 253|virus replicon
P02603374A0383|8 17|rhinotomy
P02603374A0383|44 60|dorsal rhinotomy
P02603374A0383|71 88|patient morbidity
P02603374A0383|113 126|complications
P02603923A0220|20 34|skin incisions
P02603923A0220|52 56|back
P02603923A0220|70 74|pigs
P02603923A0220|96 99|day
P02603923A0220|107 111|days
P02603923A0220|119 121|ml
P02603923A0220|135 148|growth factor
P02603923A0220|154 159|ng/ml
P02603923A0220|166 168|ml
P02603923A0220|172 178|Ringer
P02603923A0220|181 197|lactate solution
P02603923A0220|228 235|fashion
P02604420A0234|7 16|challenge
P02604420A0234|18 26|rebiopsy
P02604420A0234|41 61|reticulin antibodies
P02604420A0234|88 93|years
P02604420A0234|95 100|range
P02604420A0234|106 108|.0
P02604420A0234|120 123|end
P02604420A0234|135 145|year study
P02605160A0000|4 10|effect
P02605160A0000|14 25|iron intake
P02605160A0000|29 44|59Fe absorption
P02605160A0000|56 65|pregnancy
P02605160A0000|93 102|Fe status
P02605160A0000|115 118|end
P02605160A0000|122 131|pregnancy
P02605160A0000|153 157|rats
P02605182A0936|12 28|protein sequence
P02605182A0936|86 100|signal peptide
P02605182A0936|145 156|polypeptide
P02605679A0306|0 8|Analysis
P02605679A0306|16 30|rate constants
P02605679A0306|50 72|isomerization rate k12
P02605679A0306|113 129|degradation rate
P02605679A0306|137 142|delta
P02605679A0306|145 155|ester kdeg
P02605679A0306|177 192|hydrolysis rate
P02605679A0306|200 205|delta
P02605679A0306|208 217|ester k24
P02607766A0000|2 10|protocol
P02607766A0000|33 44|preparation
P02607766A0000|49 65|characterization
P02607766A0000|71 95|quality control material
P02607766A0000|97 100|QCM
P02607766A0000|123 136|concentration
P02607766A0000|140 147|cadmium
P02607766A0000|149 151|Cd
P02607766A0000|158 169|microgram/L
P02607766A0000|175 179|lead
P02607766A0000|181 183|Pb
P02607766A0000|191 204|micrograms/dL
P02607766A0000|218 223|blood
P02607766A0000|240 243|QCM
P02607766A0000|255 257|Cd
P02607766A0000|263 275|micrograms/L
P02607766A0000|278 285|mercury
P02607766A0000|287 289|Hg
P02607766A0000|297 309|micrograms/L
P02607766A0000|316 318|Pb
P02607766A0000|325 338|micrograms/dL
P02607766A0000|352 357|blood
P02607766A0000|378 395|spiking-solutions
P02607766A0000|410 415|salts
P02607766A0000|419 421|Cd
P02607766A0000|423 425|Hg
P02607766A0000|431 433|Pb
P02609112A0000|0 14|Reagent strips
P02609112A0000|42 50|practice
P02609112A0000|54 73|laboratory medicine
P02609112A0000|110 122|laboratories
P02614668A0971|22 35|concentration
P02614668A0971|44 49|ng/ml
P02614668A0971|57 62|serum
P02615078A0283|14 24|antibodies
P02615078A0283|42 55|actinomycetes
P02615078A0283|60 64|M.f.
P02617623A0740|0 6|LON-72
P02617623A0740|11 19|isolates
P02617623A0740|22 28|LON-73
P02617623A0740|34 40|LON-71
P02617623A0740|49 55|LON-10
P02617623A0740|74 83|altitudes
P02617623A0740|96 97|m
P02617623A0740|121 128|village
P02620085A0656|0 6|Animal
P02620085A0656|33 45|applications
P02620085A0656|49 55|plates
P02620085A0656|57 63|screws
P02620085A0656|85 105|replacement implants
P02620085A0656|129 137|material
P02620085A0656|154 161|results
P02621983T0001|0 12|Significance
P02621983T0001|37 50|acid analysis
P02621983T0001|63 68|tests
P02623038A0632|3 10|changes
P02623038A0632|39 50|performance
P02623038A0632|54 62|controls
P02623038A0632|83 100|saline injections
P02627159A0899|21 34|IgG4 antibody
P02627159A0899|50 55|index
P02627159A0899|70 83|immunotherapy
P02629109A0000|13 30|fertility decline
P02629109A0000|44 54|population
P02629109A0000|62 79|Mississippi Delta
P02629109A0000|167 177|population
P02629109A0000|245 256|1880 levels
P02630543A0210|19 36|staining affinity
P02630543A0210|48 58|antibodies
P02630543A0210|74 86|tissue cells
P02630543A0210|106 107|T
P02630543A0210|110 111|T
P02630543A0210|114 115|T
P02630543A0210|123 124|T
P02630543A0210|140 147|changes
P02630543A0210|155 162|numbers
P02630543A0210|172 188|cell populations
P02630543A0210|208 214|volume
P02630543A0210|241 247|tissue
P02631505A0382|0 10|Ampicillin
P02631505A0382|12 15|AMP
P02631505A0382|34 48|aminoglycoside
P02631505A0382|50 53|AMI
P02631505A0382|63 72|treatment
P02631505A0382|85 90|cases
P02631566A0151|0 14|Alkoxymetgyl-3
P02631566A0151|17 45|dimethylpyridinium chlorides
P02631566A0151|75 95|3,4-dimethylpyridine
P02631566A0151|101 126|chloromethyl alkyl ethers
P02631566A0151|180 189|chlorides
P02631566A0151|207 216|reactions
P02631566A0151|220 244|1-ethyloxymethylimidazol
P02631566A0151|250 277|chloromethyl alkyl sulfides
P02631743A0275|20 29|incidence
P02631743A0275|44 60|color deficiency
P02631743A0275|67 74|Koreans
P02631743A0275|82 85|use
P02631743A0275|89 94|H-R-R
P02631743A0275|114 120|plates
P02631887A0000|7 15|patients
P02631887A0000|30 34|HGGM
P02631887A0000|54 63|lymphomas
P02632904A0619|4 12|relation
P02632904A0619|21 27|VE/VO2
P02632904A0619|32 37|Q/VO2
P02632904A0619|68 79|correlation
P02632904A0619|81 82|r
P02632904A0619|92 93|p
P02634490A0186|17 26|diagnosis
P02634490A0186|35 45|affections
P02634490A0186|71 77|course
P02634490A0186|79 90|sialography
P02634490A0186|95 109|CT examination
P02634490A0186|134 147|ATB treatment
P02634490A0186|192 199|therapy
P02634872A0000|0 10|Retrograde
P02634872A0000|39 57|endodontics system
P02634872A0000|81 85|zone
P02634872A0000|101 109|approach
P02636920T0001|14 19|study
P02636920T0001|32 79|Pharmacopoeia Heparin Sodium Reference Standard
P02637597A0362|12 19|studies
P02637597A0362|33 46|relapse stage
P02637597A0362|55 62|disease
P02637597A0362|80 89|serum ANA
P02637597A0362|91 94|IgA
P02637597A0362|99 108|IgM level
P02637597A0362|121 124|IgG
P02637597A0362|129 137|decrease
P02637597A0362|141 143|C3
P02637597A0362|148 150|C4
P02638964A0372|4 18|maximum stress
P02638964A0372|42 53|examination
P02638964A0372|61 70|composite
P02638964A0372|80 86|kg/mm2
P02638964A0372|90 101|equilibrium
P02638964A0372|109 114|water
P02638964A0372|131 140|composite
P02641762T0001|9 22|heart disease
P02641762T0001|36 64|exercise stress thallium-201
P02641762T0001|76 88|scintigraphy
P02641762T0001|92 102|comparison
P02641762T0001|106 111|SPECT
P02641762T0001|116 120|bull
P02641762T0001|123 134|eye display
P02642466T0000|0 17|Sequence analysis
P02642466T0000|54 72|membrane immunogen
P02642976A1474|10 29|consensus sequences
P02642976A1474|60 68|elements
P02644735A0427|3 12|FP mutant
P02644735A0427|14 23|AcFP875-2
P02644735A0427|39 48|insertion
P02644735A0427|52 69|S. frugiperda DNA
P02644735A0427|82 85|end
P02644735A0427|95 106|transcripts
P02644735A0427|116 127|S1 analysis
P02644735A0427|162 180|host cell sequence
P02645276T0088|0 12|Construction
P02645276T0088|18 38|RIP1 deletion strain
P02645276T0088|43 52|isolation
P02645276T0088|78 85|mutants
P02645431A1562|6 10|data
P02645431A1562|24 38|hypocitraturia
P02645431A1562|42 46|type
P02645431A1562|63 71|acidosis
P02645431A1562|88 94|defect
P02645431A1562|114 122|function
P02646007T0000|32 40|leukemia
P02646007T0000|56 64|leukemia
P02646007T0000|70 80|thrombosis
P02646007T0000|86 106|protein C deficiency
P02647403A0000|13 27|hallucinations
P02647403A0000|42 57|psychopathology
P02647403A0000|97 102|years
P02647918A0423|13 18|group
P02647918A0423|26 28|GH
P02647918A0423|33 53|somatomedin-C levels
P02647918A0423|71 75|mean
P02647918A0423|90 95|error
P02647918A0423|103 107|mean
P02647918A0423|142 147|ng/ml
P02647918A0423|184 188|U/ml
P02647918A0588|0 11|Application
P02647918A0588|25 33|criteria
P02647918A0588|37 41|cure
P02647918A0588|59 67|patients
P02647918A0588|71 72|%
P02647918A0588|84 93|GH levels
P02647918A0588|102 107|ng/ml
P02647918A0588|112 120|patients
P02647918A0588|124 125|%
P02647918A0588|138 158|somatomedin-C values
P02647918A0588|163 171|patients
P02647918A0588|175 176|%
P02647918A0588|191 205|GH suppression
P02647918A0588|219 224|ng/ml
P02647918A0588|233 237|OGTT
P02647918A0588|246 254|patients
P02647918A0588|258 259|%
P02647918A0588|285 293|criteria
P02647918A0588|299 312|disappearance
P02647918A0588|332 343|GH response
P02647918A0588|347 360|TRH/GnRH test
P02647937A0191|14 22|sequence
P02647937A0191|35 43|planning
P02647937A0191|82 86|ways
P02647937A0191|107 115|problems
P02648396A0565|3 15|Rat-1a cells
P02648396A0565|20 30|expression
P02648396A0565|40 50|c-jun mRNA
P02648396A0565|75 82|ability
P02648396A0565|86 91|clone
P02648396A0565|100 107|agarose
P02648396A0565|112 123|form tumors
P02648396A0565|132 136|mice
P02648396A1033|13 22|formation
P02648396A1033|26 30|foci
P02648396A1033|46 50|RECs
P02648396A1033|68 79|combination
P02648396A1033|108 159|tumor promoter phorbol 12-tetradecanoate 13-acetate
P02648646A0216|0 26|Platelet activating factor
P02648646A0216|44 49|doses
P02648646A0216|56 72|minute intervals
P02648646A0216|77 92|airway response
P02648646A0216|105 111|change
P02648646A0216|123 138|expiratory flow
P02648646A0216|144 145|%
P02648646A0216|155 163|capacity
P02648646A0216|165 169|Vp30
P02648646A0932|25 36|correlation
P02648646A0932|45 71|baseline PC40 methacholine
P02648646A0932|88 92|fall
P02648646A0932|96 100|Vp30
P02648646A0932|128 138|micrograms
P02648646A0932|154 158|dose
P02648646A0932|163 173|micrograms
P02648646A0932|178 204|platelet activating factor
P02649445A0412|5 7|BG
P02649445A0412|12 30|IRI concentrations
P02649445A0412|42 46|OGTT
P02649445A0412|66 79|body builders
P02649445A0412|81 87|medium
P02649445A0412|91 99|controls
P02649445A0412|126 129|men
P02649811T0000|11 24|contraception
P02649811T0000|28 49|family planning study
P02650663A0178|6 12|rating
P02650663A0178|42 50|subjects
P02650663A0178|74 84|impairment
P02650663A0178|99 107|dementia
P02650663A0178|115 129|Alzheimer type
P02650663A0178|168 174|degree
P02650663A0178|188 197|diagnosis
P02650663A0178|210 218|dementia
P02651448A0000|25 29|drug
P02651448A0000|40 49|diffusion
P02651448A0000|66 77|dissolution
P02651448A0000|103 111|material
P02651448A0000|120 136|depolymerization
P02651448A0000|138 144|Type A
P02651448A0000|152 162|bioerosion
P02651448A0000|173 189|depolymerization
P02651448A0000|191 197|Type B
P02651487A0000|31 55|calcium channel blockers
P02651487A0000|70 81|contraction
P02651487A0000|101 107|muscle
P02651487A0000|123 132|knowledge
P02651487A0000|140 146|effect
P02651487A0000|150 181|excitation contraction coupling
P02651487A0000|199 205|glands
P02651487A0000|231 238|insulin
P02651487A0000|243 259|glucagon release
P02655381A0000|5 12|studies
P02655381A0000|34 45|possibility
P02655381A0000|66 73|factors
P02655381A0000|86 95|impotence
P02655381A0000|116 121|means
P02655381A0000|125 150|laboratory investigations
P02655381A0000|157 169|hypogonadism
P02655381A0000|171 189|hyperprolactinemia
P02655381A0000|191 201|occlusions
P02655381A0000|229 233|site
P02655381A0000|248 256|arteries
P02655381A0000|265 277|incompetence
P02655381A0000|291 303|neuropathies
P02656257A0000|18 42|DNA inversion system Cin
P02656257A0000|58 74|bacteriophage P1
P02656257A0000|89 100|recombinase
P02656257A0000|115 134|crossing-over sites
P02656257A0000|157 165|enhancer
P02657388A1011|4 21|terminator region
P02657388A1011|32 43|termination
P02657388A1011|47 58|transcripts
P02657388A1011|72 88|RNA polymerase I
P02657883A0000|0 10|US-Doppler
P02657883A0000|31 40|attention
P02657883A0000|58 64|method
P02657883A0000|84 94|evaluation
P02657883A0000|112 120|fistulas
P02657883A0000|122 125|FAV
P02657883T0001|0 7|Doppler
P02657883T0001|41 49|fistulae
P02657883T0001|54 62|dialysis
P02664229A0138|9 17|cosmesis
P02664229A0138|19 28|extension
P02664229A0138|36 41|scope
P02664229A0138|49 57|problems
P02664229A0138|90 96|repair
P02664229A0138|108 117|treatment
P02664229A0138|147 154|fistula
P02664229A0138|164 168|ease
P02664229A0138|184 198|Arap procedure
P02664229A0138|224 234|advantages
P02664229A0138|245 254|operation
P02664229A0138|285 304|hypospadias repairs
P02666034A1520|14 22|patients
P02666034A1520|32 38|course
P02666034A1520|42 49|therapy
P02666034A1520|67 97|vasodilator calcium antagonist
P02666034A1520|126 138|vasodilation
P02666034A1520|198 212|placebo course
P02666034A1520|216 223|therapy
P02666404A0220|4 25|galactose transporter
P02666404A0220|37 45|sequence
P02666404A0220|61 69|homology
P02666404A0220|77 88|superfamily
P02666404A0220|92 110|sugar transporters
P02666404A0220|136 153|HepG2-erythrocyte
P02666404A0220|164 191|muscle glucose transporters
P02666404A0220|197 206|rat brain
P02666404A0220|211 237|liver glucose transporters
P02666404A0220|260 266|xylose
P02666404A0220|271 290|arabinose permeases
P02666404A0220|314 321|glucose
P02666404A0220|323 330|maltose
P02666404A0220|336 358|galactose transporters
P02666568A0000|28 36|patients
P02666568A0000|57 62|study
P02666568A0000|66 81|protocol TCL821
P02667259A0331|25 29|cent
P02667259A0331|39 48|reactions
P02667259A0331|50 54|ADRs
P02667259A0331|65 69|case
P02667259A0331|78 84|nausea
P02667259A0331|86 95|dizziness
P02667259A0331|120 124|flow
P02668691A0570|5 9|mRNA
P02668691A0570|27 31|nagB
P02668691A0570|36 40|nagA
P02668691A0570|91 96|genes
P02668691A0570|98 102|nagC
P02668691A0570|107 111|nagD
P02669199A0000|0 21|Tumor necrosis factor
P02669199A0000|23 26|TNF
P02669199A0000|51 65|shock syndrome
P02669199A0000|94 103|endotoxin
P02669199A0000|105 108|LPS
P02670457T0000|4 23|calcium requirement
P02670457T0000|40 47|storage
P02670457T0000|63 70|explant
P02674141A1202|12 28|cysteine residue
P02674141A1202|32 36|CTSE
P02674141A1202|59 84|activation peptide region
P02674141A1202|92 101|proenzyme
P02674327A0493|4 7|p34
P02674327A0493|10 14|gene
P02674327A0493|28 44|codon usage bias
P02674327A0493|92 107|polyhedrin gene
P02674671A0601|23 40|DNA transformants
P02674671A0601|44 45|%
P02674671A0601|60 71|replacement
P02674671A0601|88 101|met2 mutation
P02674671A0601|129 135|allele
P02674674A1308|4 11|results
P02674674A1308|33 39|notion
P02674674A1308|62 67|sites
P02674674A1308|76 88|OBF1 protein
P02674674A1308|114 126|ARS function
P02674674A1308|133 139|origin
P02674674A1308|143 154|replication
P02674679A1237|7 12|basis
P02674679A1237|16 47|S1 nuclease protection analysis
P02674679A1237|51 67|RNA preparations
P02674679A1237|81 94|mouse tissues
P02674679A1237|101 105|dhfr
P02674679A1237|120 125|genes
P02674679A1237|141 147|levels
P02674679A1237|151 161|expression
P02674679A1237|180 191|specificity
P02674679A1237|195 217|start site utilization
P02675492A0806|15 23|patients
P02675492A0806|40 51|improvement
P02675492A0806|65 78|Ritchie-Index
P02675492A0806|80 90|pain score
P02675492A0806|92 95|ESR
P02675492A0806|100 103|CRP
P02677002A0205|35 42|enzymes
P02677002A0205|44 47|ATP
P02677002A0205|64 67|14C
P02677002A0205|68 71|Asp
P02677002A0205|75 109|equilibrium N-carbamyl-L-aspartate
P02677002A0205|111 116|C-Asp
P02677002A0205|127 130|32P
P02677002A0205|131 149|carbamyl phosphate
P02677002A0205|151 154|C-P
P02677002A0205|159 183|equilibrium Pi exchanges
P02677429A0366|0 14|Survival rates
P02677429A0366|32 47|treatment group
P02677429A0366|57 58|%
P02677429A0366|67 68|%
P02677429A0366|82 88|months
P02677429A0366|120 135|treatment group
P02677429A0366|141 142|%
P02677429A0366|151 152|%
P02677429A0366|166 172|months
P02677429A0366|196 197|%
P02677429A0366|206 207|%
P02677429A0366|221 227|months
P02677429A0366|250 258|subjects
P02677429A0366|264 268|AIDS
P02677429A0366|277 278|%
P02677429A0366|287 288|%
P02677429A0366|311 319|subjects
P02677429A0366|338 345|complex
P02677429A0366|362 377|treatment group
P02677666A0356|0 7|Mapping
P02677666A0356|35 56|complementation group
P02677666A0356|77 84|mutants
P02677666A0356|103 111|ag alpha
P02677666A0356|114 122|mutation
P02679804A2000|4 12|products
P02679804A2000|16 27|genes ura10
P02679804A2000|32 36|ura3
P02679804A2000|72 82|channeling
P02679804A2000|86 109|orotidine monophosphate
P02680843A0724|10 21|application
P02680843A0724|25 27|RS
P02680843A0724|32 43|REM latency
P02680843A0724|65 71|groups
P02680843A0724|78 91|investigation
P02684159A0870|0 22|Hybridization analysis
P02684159A0870|39 43|size
P02684159A0870|51 55|mRNA
P02684159A0870|69 78|kilobases
P02684585T0001|0 25|Agranulocytosis treatment
P02684585T0001|31 39|rhGM-CSF
P02685331A0523|4 29|R. meliloti nifH promoter
P02685331A0523|42 44|K.
P02685331A0523|56 69|nifH promoter
P02685331A0523|77 82|sigma
P02685331A0523|96 118|methylation protection
P02685331A0523|122 138|guanine residues
P02685331A0523|179 190|nucleotides
P02685331A0523|209 214|sigma
P02685331A0523|228 237|promoters
P02685461A0380|15 23|symptoms
P02685461A0380|31 38|disease
P02685461A0380|60 65|group
P02685461A0380|69 77|patients
P02685565A0165|35 39|form
P02685565A0165|57 61|mRNA
P02685565A0165|92 97|cells
P02685565A0165|137 148|c-myb genes
P02686588A0592|17 25|analysis
P02686588A0592|41 51|hematocrit
P02686588A0592|56 66|hemoglobin
P02686588A0592|81 84|BUN
P02686588A0592|89 109|alkaline phosphatase
P02686588A0592|125 130|group
P02686749A0000|14 33|health significance
P02686749A0000|53 60|changes
P02686749A0000|75 83|exposure
P02686749A0000|87 94|cadmium
P02686749A0000|99 106|workers
P02686749A0000|120 128|exposure
P02686749A0000|144 153|discovery
P02686749A0000|178 187|excretion
P02686749A0000|191 211|beta 2-microglobulin
P02686749A0000|215 238|retinol binding protein
P02686749A0000|275 279|year
P02686749A0000|289 294|years
P02686980A0000|3 8|order
P02686980A0000|48 60|organization
P02686980A0000|79 88|nucleolus
P02686980A0000|144 154|components
P02686980A0000|162 167|yeast
P02686985A0811|2 38|transcription factor exclusion assay
P02686985A0811|65 78|PCF1 mutation
P02686985A0811|100 106|stages
P02686985A0811|110 123|transcription
P02686985A0811|159 176|complex formation
P02686985A0811|193 200|effects
P02686985A0811|219 228|component
P02686985A0811|243 250|complex
P02688772T0000|0 10|Psychiatry
P02688772T0000|19 23|skin
P02689136A1851|14 21|effects
P02689136A1851|41 45|time
P02689439A0000|14 40|glutathione S-transferases
P02689439A0000|42 46|GSTs
P02689439A0000|48 50|EC
P02689439A0000|67 78|superfamily
P02689439A0000|90 100|isoenzymes
P02689439A0000|120 131|conjugation
P02689439A0000|149 159|substrates
P02689439A0000|165 176|glutathione
P02689439A0402|33 40|regions
P02689439A0402|44 50|pmGT10
P02689439A0402|68 74|degree
P02689439A0402|78 86|homology
P02689439A0402|97 103|region
P02689439A0402|111 123|rat Yb1 gene
P02689439A0402|136 142|region
P02689439A0402|146 151|pmGT2
P02689439A0402|168 176|homology
P02689439A0402|198 204|region
P02689439A0402|212 224|rat Yb2 gene
P02689544A0456|0 5|Model
P02689544A0456|18 27|abutments
P02689544A0456|45 52|incisor
P02689544A0456|87 96|abutments
P02691557A0273|4 13|incidence
P02691557A0273|23 42|breathing movements
P02691557A0273|56 57|h
P02691557A0273|97 100|age
P02691557A0273|122 136|concentrations
P02691557A0273|140 150|plasma PGE
P02691557A0273|189 195|period
P02691557A0273|199 208|gestation
P02691811A0355|19 22|min
P02691811A0355|26 34|recovery
P02691811A0355|36 52|plasma potassium
P02691811A0355|69 74|spite
P02691811A0355|95 109|blood acidosis
P02691811A0355|151 164|concentration
P02691998A0672|12 16|data
P02691998A0672|74 77|bed
P02691998A0672|102 105|bed
P02691998A0672|128 148|bolus administration
P02691998A0672|152 156|ET-1
P02692881A0354|3 13|comparison
P02692881A0354|35 40|women
P02692881A0354|65 70|women
P02692881A0354|72 77|women
P02692881A0354|83 86|PIH
P02692881A0354|97 105|increase
P02692881A0354|109 119|heart rate
P02692881A0354|168 172|tone
P02692881A0354|189 200|derangement
P02692881A0354|210 218|function
P02692881A0354|235 243|increase
P02692881A0354|247 252|serum
P02692881A0354|258 262|acid
P02692881A0354|267 276|reduction
P02692881A0354|280 296|sodium excretion
P02692881A0354|301 306|total
P02692881A0354|322 339|calcium excretion
P02692881A0354|353 358|level
P02692881A0354|362 378|sodium excretion
P02693208A0166|21 25|role
P02693208A0166|33 46|recombination
P02693208A0166|69 78|mutations
P02693208A0166|80 84|rad1
P02693208A0166|89 94|rad52
P02693208A0166|106 126|repeat recombination
P02693208A0166|168 177|sequences
P02693593A0866|12 19|protein
P02693593A0866|26 41|leader sequence
P02693593A0866|48 59|amino acids
P02694731A0241|13 17|hand
P02694731A0241|19 28|knowledge
P02694731A0241|36 48|epidemiology
P02694731A0241|52 61|Parkinson
P02694731A0241|64 71|disease
P02694731A0241|109 119|hypotheses
P02694731A0241|132 142|hypotheses
P02694731A0241|179 186|profile
P02694731A0241|203 210|testing
P02695914T0000|4 21|stereoselectivity
P02695914T0000|25 36|drug action
P02700977A0444|0 10|Scotchbond
P02700977A0444|34 45|penetration
P02700977A0444|82 95|XR bond/Silus
P02700977A0444|101 112|combination
P02702566A0000|2 13|combination
P02702566A0000|17 26|cisplatin
P02702566A0000|31 45|5-fluorouracil
P02702566A0000|67 71|days
P02702566A0000|88 96|infusion
P02702566A0000|123 127|head
P02702566A0000|132 143|neck cancer
P02702849A0418|0 31|Metformin plasma concentrations
P02702849A0418|62 70|patients
P02702849A0418|99 100|g
P02702849A0418|114 116|mg
P02702849A0418|139 169|patients plasma concentrations
P02702849A0418|216 228|micrograms/l
P02702849A0418|230 231|p
P02703121T0000|0 9|Diagnosis
P02703121T0000|21 43|sclerosing cholangitis
P02703121T0000|49 60|blood donor
P02703121T0000|75 105|serum alanine aminotransferase
P02703925A0359|39 51|subgroupings
P02703925A0359|74 100|sedimentation coefficients
P02703925A0359|105 128|polydispersity profiles
P02703925A0359|153 164|conclusions
P02703925A0359|170 174|loss
P02703925A0359|178 202|proteoglycan aggregation
P02703925A0359|207 222|sedimentability
P02703925A0359|252 256|sign
P02703925A0359|260 288|cartilage matrix degradation
P02703925A0359|301 309|S values
P02703925A0359|314 327|proteoglycans
P02703925A0359|340 346|weight
P02703925A0359|348 350|HW
P02703925A0359|360 365|areas
P02703925A0359|376 382|values
P02703925A0359|404 410|weight
P02703925A0359|412 414|LW
P02703925A0359|424 429|areas
P02703925A0359|445 452|finding
P02703925A0359|463 480|cartilage samples
P02703925A0359|486 495|inversion
P02703925A0359|504 511|pattern
P02703925A0359|530 548|matrix degradation
P02703925A0359|570 580|HW regions
P02703925A0359|619 624|areas
P02703925A0359|642 662|S value distribution
P02703925A0359|670 689|cartilage thickness
P02703925A0359|727 747|proteoglycan content
P02703925A0359|755 763|distance
P02703925A0359|779 786|surface
P02703925A0359|808 823|cartilage layer
P02703925A0359|837 842|cases
P02703925A0359|857 863|amount
P02703925A0359|867 877|aggregates
P02703925A0359|904 919|sedimentability
P02703925A0359|947 951|zone
P02703925A0359|966 973|samples
P02704579A1078|14 26|relationship
P02704579A1078|46 55|evolution
P02704579A1078|63 70|disease
P02704579A1078|79 85|CRS/BW
P02704579A1078|90 113|gas exchange parameters
P02704579A1078|115 119|FIO2
P02704579A1078|124 135|a/AO2 ratio
P02704579A1078|138 139|P
P02704579A1078|161 173|gas exchange
P02704579A1078|196 210|lung mechanics
P02705072A0464|0 10|End points
P02705072A0464|59 69|infarction
P02705072A0464|71 73|MI
P02705072A0464|75 79|rate
P02705072A0464|84 89|death
P02705296A0231|24 30|weight
P02705296A0231|38 49|polyprotein
P02705296A0231|61 65|ORF1
P02705296A0231|72 83|kilodaltons
P02705296A0231|85 88|kDa
P02705556A1049|5 7|RV
P02705556A1049|11 17|demand
P02705556A1049|28 30|RC
P02705556A1049|34 40|supply
P02705556A1049|65 77|flow reserve
P02707909A0209|3 21|alternative method
P02707909A0209|25 28|UKM
P02707909A0209|69 77|fraction
P02707909A0209|87 101|dialysate flow
P02707909A0209|120 128|dialyses
P02708288A0139|0 21|Liquid chromatography
P02708288A0139|40 49|detection
P02708288A0139|51 56|LC/AD
P02708288A0139|89 93|acid
P02708288A0139|112 122|metabolism
P02708288A0139|126 141|base hydrolysis
P02708288A0139|145 160|fluazifop-butyl
P02708288A0139|164 172|soybeans
P02708288A0139|177 188|soybean oil
P02708288A0621|4 19|dichloromethane
P02708288A0621|39 44|phase
P02708288A0621|67 75|aliquots
P02708288A0621|96 108|PRP-1 liquid
P02708288A0621|125 131|column
P02708288A0621|143 147|acid
P02708288A0621|178 187|compounds
P02708288A0621|215 224|potential
P02708288A0621|235 236|V
P02708288A0621|276 284|detector
P02708288A0621|292 306|oxidation mode
P02708353A1080|0 28|Primer extension experiments
P02708353A1080|48 77|transcription initiation site
P02708353A1080|90 98|position
P02708353A1080|102 106|gene
P02708353A1080|175 186|P-450e gene
P02708353A1452|19 44|polymerase chain reaction
P02708353A1452|71 75|gene
P02708353A1452|79 90|transcripts
P02708353A1452|120 138|polysome fractions
P02708353A1452|164 175|utilization
P02708353A1452|184 190|tissue
P02709081T0000|0 10|Validation
P02709081T0000|18 24|survey
P02709081T0000|28 39|work styles
P02709081T0000|43 58|profile measure
P02709081T0000|66 90|type A behaviour pattern
P02709819A0495|9 12|ADR
P02709819A0495|39 60|ciprofloxacin therapy
P02711145T0000|0 18|HIV infectiousness
P02711145T0000|27 31|AIDS
P02711167A0818|5 8|day
P02711167A0818|18 25|turnout
P02711167A0818|31 40|PFB-group
P02711167A0818|65 88|serum pepsinogen levels
P02711167A0818|113 119|degree
P02711167A0818|132 138|damage
P02711167A0818|148 155|animals
P02711601A0601|18 28|inhibition
P02711601A0601|32 57|acid phosphatase activity
P02711601A0601|61 68|control
P02711601A0601|85 96|guinea pigs
P02711601A0601|106 107|%
P02711601A0601|117 118|%
P02712246T0042|33 48|characteristics
P02712450A0989|13 18|PACO2
P02712450A0989|24 29|mm Hg
P02712450A0989|43 48|drive
P02712450A0989|74 75|p
P02712450A0989|99 107|subjects
P02712450A0989|109 113|Type
P02712450A0989|116 124|response
P02712450A0989|161 167|others
P02712450A0989|169 173|Type
P02712450A0989|176 184|response
P02712450A0989|192 203|hypercapnia
P02712450A0989|209 216|changes
P02712450A0989|220 225|drive
P02712450A0989|250 256|groups
P02713310T0000|0 14|Fundus changes
P02713310T0000|19 23|type
P02713310T0000|46 64|glomerulonephritis
P02713310T0000|76 82|drusen
P02713310T0000|104 110|report
P02713520T0000|8 20|dose effects
P02713520T0000|24 40|methyl parathion
P02713520T0000|44 54|nuthatches
P02713520T0000|56 70|cholinesterase
P02713520T0000|75 90|ptilochronology
P02713994A0482|4 9|titer
P02713994A0482|18 26|HSV type
P02713994A0482|38 46|HSV type
P02713994A0482|49 59|antibodies
P02713994A0482|67 74|mothers
P02713994A0482|80 90|cord blood
P02714525A0529|0 13|Kidney weight
P02714525A0529|33 45|weight ratio
P02714525A0529|89 99|dose level
P02714525A0529|109 114|weeks
P02714525A0529|137 148|dose levels
P02714525A0529|158 163|weeks
P02714525A0529|167 175|exposure
P02714852T0000|8 17|variation
P02714852T0000|21 26|HLA-B
P02714852T0000|31 46|HLA-C sequences
P02714852T0000|55 64|evolution
P02714852T0000|72 85|HLA-B alleles
P02717133T0001|2 8|method
P02717133T0001|33 55|development conditions
P02717133T0001|59 85|summary oxygen consumption
P02717349A0311|0 3|Men
P02717349A0311|44 51|fitness
P02717349A0311|57 62|women
P02718683A0142|0 20|Handgrip dynamometry
P02718683A0142|56 64|patients
P02720966A0455|17 22|fluid
P02720966A0455|27 30|ADA
P02720966A0455|41 54|concentration
P02720966A0455|66 74|mu kat/L
P02720966A0455|105 115|meningitis
P02720966A0455|119 127|patients
P02720966A0455|141 146|years
P02720966A0455|148 159|sensitivity
P02720966A0455|166 177|specificity
P02720966A0455|187 197|efficiency
P02721169A0171|0 9|NERVTRACK
P02721169A0171|35 45|data items
P02721169A0171|70 76|manner
P02721169A0171|114 127|relationships
P02723503T0000|0 9|Swim-over
P02723503T0000|14 32|alternative method
P02723503T0000|55 66|spermatozoa
P02724227T0000|0 17|Perfusion washout
P02724227T0000|51 65|flap tolerance
P02724227T0000|69 77|ischemia
P02725495A0929|15 23|sequence
P02725495A0929|31 44|U2 RNA region
P02725495A0929|69 101|pre-mRNA branchpoint recognition
P02725495A0929|105 110|yeast
P02725495A0929|137 153|metazoan U2 RNAs
P02725495A0929|180 192|trypanosomes
P02725513A0617|31 50|CHO spacer promoter
P02725513A0617|84 88|rule
P02725513A0617|94 117|metazoan RNA polymerase
P02725513A0617|120 129|promoters
P02725513A0617|141 150|G residue
P02725513A0617|154 162|position
P02727909A0383|9 18|amplitude
P02727909A0383|26 37|aggregation
P02727909A0383|41 47|plates
P02727909A0383|54 62|decrease
P02727909A0383|70 79|threshold
P02727909A0383|89 100|sensitivity
P02727909A0383|104 107|ADP
P02727909A0383|132 139|persons
P02727909A0383|145 154|types IIa
P02727909A0383|159 166|IIb HLP
P02727909A0383|174 177|CHD
P02727909A0383|186 189|HLP
P02729666A0267|12 34|intergroup differences
P02729666A0267|69 82|dentoskeletal
P02729666A0267|92 116|tissue profile variables
P02731611A0134|4 10|author
P02731611A0134|22 31|rationale
P02731611A0134|53 57|view
P02731611A0134|73 77|case
P02731611A0134|101 108|hiccups
P02731611A0134|142 152|principles
P02731611A0134|170 195|Mental Research Institute
P02731671A0000|13 21|toxicity
P02731671A0000|25 37|nickel oxide
P02731671A0000|39 42|NiO
P02731671A0000|45 71|nickel sulfate hexahydrate
P02731671A0000|73 78|NiSO4
P02731671A0000|80 83|H2O
P02731671A0000|90 107|nickel subsulfide
P02731671A0000|109 114|Ni3S2
P02731671A0000|131 142|F344/N rats
P02731671A0000|147 158|B6C3F1 mice
P02731671A0000|165 184|inhalation exposure
P02731671A0000|191 197|hr/day
P02731671A0000|201 210|days/week
P02731671A0000|219 224|weeks
P02732341A0000|52 59|studies
P02732341A0000|74 82|neoplasm
P02732341A0000|91 95|year
P02732341A0000|100 105|woman
P02732341A0000|140 148|lymphoma
P02732341A0000|168 176|staining
P02732341A0000|181 203|chloroacetate esterase
P02732341A0000|228 237|diagnosis
P02733116T0000|9 28|National Institutes
P02733116T0000|32 38|Health
P02733690T0000|10 17|cloning
P02733690T0000|22 38|characterisation
P02733690T0000|61 66|genes
P02733690T0000|86 95|reductase
P02733690T0000|99 106|tobacco
P02735364A1330|13 18|model
P02735364A1330|20 25|grade
P02735364A1330|27 28|p
P02735364A1330|61 68|results
P02735364A1330|70 71|p
P02735364A1330|83 111|progesterone receptor status
P02735364A1330|113 114|p
P02735364A1330|129 132|age
P02735364A1330|149 157|variable
P02735364A1330|159 160|p
P02735364A1330|217 225|survival
P02736482A0550|3 11|contrast
P02736482A0550|30 47|radiation therapy
P02736482A0550|49 65|brain metastases
P02739739T0000|0 25|COUP transcription factor
P02739739T0000|31 37|member
P02739739T0000|45 73|steroid receptor superfamily
P02740196A0704|3 13|Experiment
P02740196A0704|31 45|classification
P02740196A0704|61 69|standard
P02740196A0704|88 94|center
P02740196A0704|102 107|range
P02740196A0704|111 125|target numbers
P02740347A0644|0 13|Cosmid clones
P02740347A0644|30 44|VNTR sequences
P02740347A0644|66 85|restriction mapping
P02740347A0644|117 119|kb
P02740627A0137|4 17|oxygen uptake
P02740627A0137|19 22|VO2
P02740627A0137|25 46|carbon dioxide output
P02740627A0137|48 52|VCO2
P02740627A0137|67 71|rate
P02740627A0137|73 75|fR
P02740627A0137|78 96|minute ventilation
P02740627A0137|98 100|VE
P02740627A0137|112 123|ventilation
P02740627A0137|125 127|VA
P02740627A0137|139 154|oxygen pressure
P02740627A0137|156 160|PAO2
P02740627A0137|167 179|VE/VO2 ratio
P02740627A0137|199 203|cows
P02740627A0137|221 227|volume
P02740627A0137|229 231|VT
P02740627A0137|256 261|space
P02740627A0137|263 265|VD
P02740627A0137|286 292|horses
P02740874A0957|11 17|damage
P02740874A0957|42 50|controls
P02740874A0957|66 73|tissues
P02740874A0957|85 88|SO2
P02740955A0333|13 21|patients
P02740955A0333|35 49|mortality rate
P02740955A0333|78 86|patients
P02740955A0333|102 112|deliveries
P02743842A0000|12 17|study
P02743842A0000|39 53|prostaglandins
P02743842A0000|55 66|cytoprotect
P02743842A0000|80 86|mucosa
P02743842A0000|114 131|stress ulceration
P02743842A0000|149 158|influence
P02743842A0000|177 193|prostaglandin E2
P02743842A0000|204 208|PGE2
P02743842A0000|235 251|lesion formation
P02743842A0000|266 275|tissue pH
P02743842A0000|277 278|H
P02743842A0000|280 294|back-diffusion
P02743842A0000|308 318|blood flow
P02743842A0000|322 325|rat
P02743842A0000|334 340|mucosa
P02743842A0000|360 364|acid
P02743842A0000|370 376|mM HCl
P02743842A0000|397 402|shock
P02743842A0000|407 412|ml/kg
P02743842A0000|420 423|min
P02743981A0347|0 11|Transcripts
P02743981A0347|61 65|L11e
P02743981A0347|83 108|L1e-L10e-L12e transcripts
P02743981A0347|141 149|NAB-L11e
P02743981A0347|168 183|NAB transcripts
P02743981A0347|206 209|ORF
P02743981A0347|224 234|transcript
P02744123A0237|19 26|results
P02744123A0237|51 58|species
P02744123A0237|65 78|rhesus monkey
P02744123A0237|83 86|man
P02744123A0237|114 122|branches
P02744123A0237|162 166|time
P02744123A0237|209 229|background luminance
P02744490A0894|0 8|Evidence
P02744490A0894|18 27|structure
P02744490A0894|33 39|number
P02744490A0894|43 54|cDNA clones
P02744490A0894|67 78|S1 nuclease
P02744490A0894|83 107|primer extension studies
P02744490A0894|121 131|hypothesis
P02744490A0894|141 151|PTHrP gene
P02744490A0894|174 205|mRNA transcription start points
P02744490A0894|242 249|domains
P02745280A0276|8 13|level
P02745280A0276|17 21|PaO2
P02745280A0276|47 55|measures
P02745280A0276|79 90|blood gases
P02745280A0276|99 120|lactate concentration
P02745280A0276|126 133|changes
P02745280A0276|150 164|concentrations
P02745280A0276|178 187|phosphate
P02745280A0276|189 204|phosphocreatine
P02745280A0276|210 213|ATP
P02745280A0276|228 231|31P
P02745280A0276|241 263|resonance spectroscopy
P02745444A0391|4 33|transcription initiation site
P02745444A0391|52 71|S1 nuclease mapping
P02745666A0000|12 20|biopsies
P02745666A0000|25 42|plasma oestradiol
P02745666A0000|44 46|E2
P02745666A0000|52 64|progesterone
P02745666A0000|66 68|P4
P02745666A0000|70 76|levels
P02745666A0000|83 91|patients
P02745666A0000|117 143|replacement therapy cycles
P02745666A0000|166 173|failure
P02746099A0000|4 12|mobility
P02746099A0000|36 45|premolars
P02746099A0000|52 56|load
P02746099A0000|77 85|relation
P02746099A0000|107 114|contact
P02746099A0000|128 134|facets
P02747653A0910|22 29|protein
P02747653A0910|59 67|staining
P02747653A0910|71 76|serum
P02747653A0910|80 88|tadpoles
P02747653A0910|100 109|beginning
P02747653A0910|113 126|metamorphosis
P02747653A0910|130 135|stage
P02748188A0091|30 35|group
P02748188A0091|37 39|PT
P02748188A0091|45 47|Ss
P02748188A0091|76 80|test
P02748188A0091|82 87|means
P02748188A0091|100 103|sec
P02748188A0091|129 134|group
P02748188A0091|136 138|PS
P02748188A0091|144 146|Ss
P02748188A0091|178 181|sec
P02748188A0091|202 206|test
P02748188A0091|208 209|t
P02748188A0091|219 220|P
P02748188A0091|264 271|studies
P02748595A0492|20 38|baboon liver class
P02748595A0492|41 44|ADH
P02748595A0492|70 77|lineage
P02748595A0492|91 99|ADH-beta
P02749215A0000|9 20|proteinuria
P02749215A0000|35 44|hematuria
P02749215A0000|52 58|pyuria
P02749215A0000|74 81|finding
P02751080A0176|16 20|shot
P02751080A0176|24 31|bullets
P02751080A0176|43 50|minutes
P02751080A0176|58 73|intensity level
P02751080A0176|92 94|dB
P02752303A0000|0 14|Lithium delays
P02752303A0000|29 35|rhythm
P02752303A0000|63 71|hamsters
P02752303A0000|75 96|plasma concentrations
P02752303A0000|108 110|mM
P02752303A0000|134 145|weight loss
P02752629A0163|0 7|Dynamic
P02752629A0163|19 30|scintigrams
P02752629A0163|52 75|methylene diphosphonate
P02752629A0163|112 117|weeks
P02752629A0163|124 132|fracture
P02752651A0480|3 12|admission
P02752651A0480|20 30|department
P02752651A0480|34 43|September
P02752651A0480|55 62|patient
P02752651A0480|89 100|paraparesis
P02752651A0480|106 116|impairment
P02752651A0480|132 142|modalities
P02752651A0480|153 158|level
P02752651A0480|162 164|Th
P02752651A0480|180 191|disturbance
P02756731T0001|0 14|Prostaglandins
P02756731T0001|19 29|gallstones
P02756878A0075|4 10|nature
P02756878A0075|18 25|process
P02756878A0075|51 62|occurrences
P02756878A0075|71 81|arrhythmia
P02756878A0075|99 107|patients
P02756878A0075|115 122|history
P02756878A0075|149 151|AF
P02757033A0905|24 30|effect
P02757033A0905|50 55|genes
P02757033A0905|78 81|arm
P02757033A0905|110 125|heterochromatin
P02757033A0905|151 166|position effect
P02757033A0905|171 184|transcription
P02757033A0905|194 199|genes
P02757862T0000|8 18|experience
P02757862T0000|26 40|microprocessor
P02757862T0000|66 79|defibrillator
P02758382A0478|0 7|Obesity
P02758382A0478|41 52|proportions
P02758382A0478|91 100|estradiol
P02758382A0478|132 160|sex hormone binding globulin
P02758382A0478|162 166|SHBG
P02758382A0478|168 174|levels
P02758382A0478|183 193|proportion
P02758382A0478|208 217|estradiol
P02760922A0000|22 39|ribonucleoprotein
P02760922A0000|41 46|hnRNP
P02760922A0000|48 63|core protein A1
P02760922A0000|75 84|component
P02760922A0000|98 103|hnRNP
P02760922A0000|107 118|S particles
P02761008X0000|0 29|Brain cholinesterase activity
P02761008X0000|48 54|egrets
P02761008X0000|62 68|egrets
P02761008X0000|87 99|night-herons
P02761008X0000|101 111|inhibition
P02761008X0000|115 135|brain cholinesterase
P02761008X0000|137 140|ChE
P02761008X0000|142 150|activity
P02761008X0000|154 159|birds
P02761008X0000|186 194|exposure
P02761008X0000|198 203|death
P02761008X0000|209 225|organophosphorus
P02761008X0000|229 249|carbamate pesticides
P02761150A0000|4 10|effect
P02761150A0000|14 29|zinc deficiency
P02761150A0000|33 45|trace metals
P02761150A0000|53 58|liver
P02761150A0000|60 66|spleen
P02761150A0000|68 74|kidney
P02761150A0000|76 84|pancreas
P02761150A0000|89 97|duodenum
P02761150A0000|122 129|control
P02761150A0000|149 153|rats
P02761150A0000|160 164|days
P02761150A0000|172 176|days
P02761150A0000|180 189|pregnancy
P02761492A0124|4 12|findings
P02761492A0124|25 29|view
P02761492A0124|50 57|genesis
P02761492A0124|73 84|involvement
P02761492A0124|95 103|patients
P02761537A0168|0 13|Heating cells
P02761537A0168|20 29|degrees C
P02761537A0168|44 50|amount
P02761537A0168|72 76|rRNA
P02761537A0168|91 92|%
P02761537A0168|100 113|control level
P02761537A0168|140 152|% inhibition
P02761537A0168|156 181|transcription termination
P02761537A0168|187 193|region
P02761537A0168|205 216|nucleotides
P02761537A0168|238 241|end
P02761537A0168|245 253|28S rRNA
P02761537A0168|260 271|readthrough
P02761537A0168|297 315|transcription unit
P02761540A0873|0 17|Deletion analysis
P02761540A0873|34 40|NF-4FA
P02761540A0873|42 48|NF-4FB
P02761540A0873|54 68|AP-1 sequences
P02761540A0873|97 114|enhancer activity
P02762006A0071|0 4|Cord
P02762006A0071|32 40|patients
P02762006A0071|64 71|lesions
P02762198T0001|0 4|Reye
P02762198T0001|7 15|syndrome
P02762198T0001|17 24|reports
P02762198T0001|30 35|cases
P02762198T0001|43 49|period
P02763467A0903|21 39|polyacrylamide gel
P02763467A0903|56 64|patterns
P02763467A0903|69 72|35S
P02763467A0903|92 100|proteins
P02763467A0903|115 120|cells
P02763467A0903|160 167|viruses
P02763467A0903|185 189|spot
P02763467A0903|262 267|point
P02763467A0903|297 304|N1L ORF
P02764797A0182|0 5|PULSE
P02764797A0182|26 29|NMR
P02764797A0182|44 54|parameters
P02764797A0182|62 67|delay
P02764797A0182|72 80|duration
P02764797A0182|84 86|rf
P02764797A0182|108 113|gates
P02764797A0182|115 123|rf phase
P02764797A0182|125 139|sampling times
P02764797A0182|150 168|imaging parameters
P02764797A0182|172 186|rf pulse shape
P02764797A0182|191 209|gradient waveforms
P02765001A0105|9 13|JPsA
P02765001A0105|18 26|patients
P02765001A0105|43 52|arthritis
P02765001A0105|122 126|rash
P02765001A0105|131 140|arthritis
P02765001A0105|168 176|criteria
P02765001A0105|178 188|dactylitis
P02765001A0105|190 194|nail
P02765001A0105|219 223|rash
P02765001A0105|228 242|family history
P02765001A0105|246 255|psoriasis
P02765214A0486|14 19|Kurti
P02765214A0486|22 28|demand
P02765214A0486|53 63|importance
P02765214A0486|71 80|arguments
P02766330A0779|4 10|author
P02766330A0779|20 27|account
P02766330A0779|88 95|effects
P02766330A0779|104 123|calcium antagonists
P02766330A0779|144 155|application
P02766508A0421|2 25|correlation coefficient
P02766508A0421|53 63|similarity
P02766508A0421|72 83|map pattern
P02766508A0421|100 114|mean IQRST map
P02766745T0000|17 22|study
P02766745T0000|30 42|relationship
P02766745T0000|60 68|placenta
P02766745T0000|73 81|mastitis
P02766745T0000|85 95|dairy cows
P02767166A0368|20 38|lipid peroxidation
P02767166A0368|62 73|development
P02767166A0368|84 92|cataract
P02767166A0368|110 121|consequence
P02767166A0368|133 139|damage
P02767166A0368|153 165|pathogenesis
P02767166A0368|169 177|cataract
P02767166A0368|181 189|diabetes
P02767166A0368|204 210|myopia
P02767733A0690|17 24|grading
P02767733A0690|45 50|cases
P02767733A0690|55 57|G1
P02767733A0690|62 64|G2
P02767733A0690|69 71|G3
P02767733A0690|87 93|spread
P02767733A0690|113 118|cases
P02767733A0690|122 123|%
P02772495A0641|0 6|Asthma
P02772495A0641|52 61|ASA group
P02772495A0641|65 66|%
P02772495A0641|73 74|%
P02772495A0641|78 80|AT
P02772495A0641|95 96|%
P02772495A0641|100 110|INTR group
P02773507A0750|2 7|value
P02773507A0750|15 19|l/kg
P02773507A0750|33 34|V
P02773507A0750|61 77|sample estimates
P02773507A0750|81 90|clearance
P02773507A0750|92 94|CL
P02773507A0750|103 108|value
P02773507A0750|116 120|l/kg
P02773507A0750|150 166|sample estimates
P02773507A0750|170 179|clearance
P02773507A0750|183 189|plasma
P02773507A0750|198 202|drug
P02773507A0750|204 209|CLunb
P02773930T0000|13 19|kidney
P02773930T0000|23 28|model
P02773930T0000|40 55|hyperfiltration
P02773930T0000|59 65|humans
P02774271A0000|0 9|Halothane
P02774271A0000|41 48|pathway
P02774271A0000|72 84|end products
P02774271A0000|102 106|acid
P02774271A0000|108 112|TFAA
P02774271A0000|118 125|bromide
P02774271A0000|127 129|Br
P02774271A0000|150 158|pathways
P02774271A0000|179 187|fluoride
P02774271A0000|189 190|F
P02774808A0194|4 10|values
P02774808A0194|36 37|P
P02774808A0194|61 67|summer
P02774808A0194|83 100|micrograms/100 ml
P02774808A0194|118 124|winter
P02775136A1151|6 13|results
P02775136A1151|27 35|HAPE-S-S
P02775136A1151|69 87|breathing patterns
P02775136A1151|96 104|altitude
P02775136A1151|135 146|development
P02775136A1151|150 153|AMS
P02775136A1151|215 233|breathing patterns
P02775136A1151|240 245|cause
P02775136A1151|252 258|effect
P02775136A1151|262 265|AMS
P02775333A1137|0 10|Buflomedil
P02775333A1137|12 16|i.v.
P02775333A1137|43 51|increase
P02775333A1137|63 69|output
P02775333A1137|83 88|mg/kg
P02775333A1137|99 106|changes
P02775333A1137|124 129|mg/kg
P02775333A1137|143 151|decrease
P02775333A1137|174 182|increase
P02775333A1137|194 198|dose
P02775333A1137|207 212|mg/kg
P02776471A0235|32 39|animals
P02776471A0235|58 68|responders
P02776471A0235|86 93|pattern
P02776471A0235|112 120|response
P02776742A0000|0 10|Heart rate
P02776742A0000|12 14|HR
P02776742A0000|24 35|temperature
P02776742A0000|37 40|Tre
P02776742A0000|43 57|blood pressure
P02776742A0000|59 70|temperature
P02776742A0000|84 100|humidity changes
P02776742A0000|108 116|clothing
P02776742A0000|150 157|firemen
P02776742A0000|164 167|age
P02776742A0000|181 183|yr
P02776742A0000|185 192|VO2 max
P02776742A0000|204 217|ml kg-1 min-1
P02776742A0000|227 239|fire fighter
P02776742A0000|242 250|uniforms
P02776742A0000|252 254|SU
P02776742A0000|271 275|fire
P02776742A0000|299 307|clothing
P02776742A0000|313 317|self
P02776742A0000|328 347|breathing apparatus
P02776742A0000|349 351|FE
P02776823A0000|13 22|tolerance
P02776823A0000|27 43|pharmacokinetics
P02776823A0000|47 50|FCE
P02776823A0000|58 64|sodium
P02776823A0000|66 68|5R
P02776823A0000|70 72|6S
P02776823A0000|78 80|1R
P02776823A0000|82 94|hydroxyethyl
P02776823A0000|98 138|carbamoyloxymethyl-2-penem-3-carboxylate
P02776823A0000|147 152|penem
P02776823A0000|205 214|i.v. dose
P02776823A0000|220 227|mg.kg-1
P02776823A0000|248 258|volunteers
P02777797A0720|0 22|DNA blot hybridization
P02777797A0720|41 51|rat genome
P02777797A0720|78 82|gene
P02777797A0720|92 115|PtdIns transfer protein
P02778237A0585|11 15|term
P02778237A0585|41 43|IA
P02778237A0585|68 75|problem
P02778237A0585|87 89|IA
P02778237A0585|100 130|maintenance prednisone therapy
P02778873A0761|8 15|segment
P02778873A0761|19 23|CRL3
P02778873A0761|56 73|enhancer function
P02778873A0761|101 110|sequences
P02778873A0761|112 117|DR-A1
P02778873A0761|122 127|DR-A2
P02779752A0000|3 13|1-Naphthyl
P02779752A0000|14 24|piperazine
P02779752A0000|26 30|1-NP
P02779752A0000|58 89|serotonin antagonist properties
P02779752A0000|97 110|5-HT2 subtype
P02779752A0000|114 122|receptor
P02779752A0000|167 182|agonist actions
P02779752A0000|190 200|5-HT1 site
P02779752A0776|3 17|m-Chlorophenyl
P02779752A0776|18 28|piperazine
P02779752A0776|30 34|mCPP
P02779752A0776|44 49|mg/kg
P02779752A0776|58 81|m-trifluoromethylphenyl
P02779752A0776|82 92|piperazine
P02779752A0776|94 99|TFMPP
P02779752A0776|109 114|mg/kg
P02779752A0776|150 161|5-HT1 sites
P02779752A0776|198 204|effect
P02779752A0776|220 232|methysergide
P02779752A0776|240 244|1-NP
P02779752A0776|257 267|ketanserin
P02780157A0576|19 26|feature
P02780157A0576|30 35|liver
P02780157A0576|40 58|spleen MP function
P02780157A0576|62 70|patients
P02780157A0576|76 79|VHA
P02780157A0576|96 113|HBsAg carriership
P02780157A0576|131 135|lack
P02780157A0576|156 164|reaction
P02780157A0576|172 176|part
P02780157A0576|180 189|spleen MP
P02780157A0576|229 239|overstrain
P02780157A0576|248 256|standing
P02780157A0576|261 270|depletion
P02780157A0576|278 287|MP system
P02780157A0576|315 326|stimulation
P02780157A0576|330 335|HBsAg
P02781495T0001|0 7|Changes
P02781495T0001|11 36|xanthine oxidase activity
P02781495T0001|40 48|patients
P02781495T0001|66 73|failure
P02781567A0544|2 6|soap
P02781567A0544|11 16|water
P02781567A0544|23 26|v/v
P02781567A0544|28 36|solution
P02781567A0544|73 88|stratum corneum
P02783181A0000|33 43|activities
P02783181A0000|51 69|antacid magaldrate
P02783181A0000|71 80|ES Riopan
P02783181A0000|97 104|effects
P02783181A0000|124 134|blood flow
P02783181A0000|139 155|mucus secretions
P02783181A0000|180 183|rat
P02784507A0000|10 37|immunodeficiency virus type
P02784507A0000|41 46|HIV-1
P02784507A0000|71 74|CD4
P02784507A0000|76 89|T lymphocytes
P02784507A0000|116 124|provirus
P02784507A0000|138 143|cells
P02784507A0000|157 164|periods
P02787430A0124|12 24|panniculitis
P02787430A0124|41 57|biopsy specimens
P02787430A0124|63 79|cytophagocytosis
P02789062A0000|27 30|4F2
P02789062A0000|37 42|chain
P02789062A0000|44 49|4F2HC
P02789062A0000|51 55|gene
P02789062A0000|61 73|model system
P02789062A0000|77 84|studies
P02789062A0000|121 127|events
P02789062A0000|161 176|gene expression
P02789062A0000|197 214|T-cell activation
P02789062A1420|2 6|cDNA
P02789062A1420|20 51|NF-4FB enhancer binding protein
P02789062A1420|83 107|lambda gt11 cDNA library
P02789062A1420|129 144|oligonucleotide
P02789062A1420|166 193|NF-4FB recognition sequence
P02789180A0407|39 50|hypertrophy
P02789180A0407|84 95|hypertrophy
P02789180A0407|101 109|patients
P02789217A1323|8 24|IL6 mRNA species
P02789217A1323|54 69|polyadenylation
P02789217A1323|73 78|sites
P02789217A1323|94 102|distance
P02789217A1323|110 119|kilobases
P02790009A0375|0 19|Sequencing analysis
P02790009A0375|55 64|fragments
P02790009A0375|94 105|nucleotides
P02790009A0375|124 130|region
P02790009A0375|145 153|fragment
P02790009A1052|11 18|protein
P02790009A1052|69 75|region
P02790009A1052|104 130|serine protease inhibitors
P02790009A1052|132 140|residues
P02792270A1220|14 29|EPSP components
P02792270A1220|91 100|responses
P02792270A1220|104 122|flexor motoneurons
P02792270A1220|149 158|amplitude
P02792270A1220|170 183|flexion phase
P02792430A0000|0 11|Experiments
P02792430A0000|24 28|rats
P02792430A0000|36 47|guinea pigs
P02792430A0000|99 109|inhibition
P02792430A0000|113 137|prostaglandins synthesis
P02792430A0000|148 159|development
P02792430A0000|173 179|oedema
P02792430A0000|204 209|serum
P02792430A0000|213 217|rats
P02792430A0000|225 233|vagotomy
P02792430A0000|237 248|guinea pigs
P02793216A0876|13 17|hand
P02793216A0876|19 23|lack
P02793216A0876|27 39|conservation
P02793216A0876|47 75|membrane attachment sequence
P02793216A0876|102 106|acid
P02793216A0876|137 147|importance
P02793216A0876|151 154|CgA
P02793620A0214|24 28|cows
P02793620A0214|63 74|parturition
P02793620A0214|78 87|Charolais
P02793620A0214|92 106|Red Poll bulls
P02793620A0214|124 132|pastures
P02793753A0354|12 16|lobe
P02793753A0354|22 35|PA dispersion
P02793753A0354|49 54|cmH2O
P02793753A0354|58 61|CFV
P02793753A0354|68 73|l/min
P02793753A0354|80 84|flow
P02793753A0354|96 98|PA
P02793753A0354|106 111|sites
P02793753A0354|145 155|dispersion
P02794828A0214|4 10|system
P02794828A0214|42 47|heart
P02794828A0214|63 76|microcomputer
P02794828A0214|121 130|pacemaker
P02795923A0000|3 8|order
P02795923A0000|44 58|CT appearances
P02795923A0000|75 84|pneumonia
P02795923A0000|121 126|study
P02795923A0000|166 171|lungs
P02795923A0000|177 184|autopsy
P02795923A0000|189 196|surgery
P02796216A0063|4 11|disease
P02796216A0063|28 34|course
P02796216A0063|47 64|jaundice syndrome
P02796216A0063|73 86|enterorrhagia
P02796216A0063|96 106|appearance
P02796216A0063|110 117|roseola
P02796988A0735|4 28|transcription factor Sp1
P02796988A0735|44 49|sites
P02796988A0735|70 89|footprinting assays
P02796988A0735|94 112|gel shift analysis
P02796988A0735|127 130|Sp1
P02797877A0475|4 19|combination PIP
P02797877A0475|23 33|micrograms
P02797877A0475|36 39|PEF
P02797877A0475|42 52|micrograms
P02797877A0475|85 93|regrowth
P02797877A0475|107 112|hours
P02797877A0475|122 133|antibiotics
P02798953A0307|7 13|sample
P02798953A0307|17 24|mothers
P02798953A0307|36 43|infants
P02798953A0307|55 64|subscales
P02798953A0307|80 90|instrument
P02798953A0307|92 97|WPL-R
P02798953A0307|114 120|levels
P02798953A0307|133 144|consistency
P02798953A0307|162 177|days postpartum
P02798953A0307|183 192|stability
P02798953A0307|200 215|administrations
P02799892A0154|16 19|use
P02799892A0154|41 46|cells
P02799892A0154|48 53|WRBCs
P02799892A0154|86 95|hemolysis
P02799892A0154|102 113|transfusion
P02799892A0154|117 125|patients
P02799892A0154|131 134|PNH
P02800417A0332|7 12|group
P02800417A0332|16 26|asthmatics
P02800417A0332|53 64|correlation
P02800417A0332|83 98|PC20 PGF2 alpha
P02800417A0332|103 119|histamine values
P02800417A0332|121 122|r
P02800417A0332|132 133|p
P02800435A0000|6 17|experiments
P02800435A0000|43 47|cats
P02800435A0000|52 57|mg/kg
P02800435A0000|92 98|effect
P02800435A0000|104 105|T
P02800435A0000|125 130|field
P02800435A0000|132 135|PMF
P02800435A0000|154 160|system
P02800435A0000|168 171|leg
P02802280A0495|15 26|differences
P02802280A0495|50 52|TS
P02802280A0495|61 64|PTS
P02805945A0000|4 15|percentages
P02805945A0000|26 31|cysts
P02805945A0000|36 48|growth rates
P02805945A0000|106 113|cosinor
P02805945A0000|127 135|cultures
P02805945A0000|139 167|Scripsiella trochoidea Stein
P02805945A0000|180 185|years
P02805945A0000|192 213|laboratory conditions
P02805945A0000|255 265|view point
P02805945A0000|283 294|temperature
P02805945A0000|305 313|degree C
P02805945A0000|316 324|lighting
P02805945A0000|329 345|microEin m-2 s-1
P02805945A0000|363 371|seawater
P02806916A0000|10 19|DNA clone
P02806916A0000|29 42|oryzacystatin
P02806916A0000|44 46|Oc
P02806916A0000|51 80|cysteine proteinase inhibitor
P02806916A0000|82 90|cystatin
P02806916A0000|95 99|rice
P02806916A0000|121 147|lambda EMBL3 phage library
P02806916A0000|165 171|Sau3AI
P02806916A0000|180 187|digests
P02806916A0000|191 195|rice
P02806916A0000|208 211|DNA
P02806916A0000|234 241|oc cDNA
P02806916A0000|247 252|probe
P02807780A0143|4 7|use
P02807780A0143|26 34|solution
P02807780A0143|38 52|methylene blue
P02807780A0143|57 58|%
P02807780A0143|66 72|M NaCl
P02807780A0143|80 83|min
P02807780A0143|97 105|staining
P02807780A0143|122 127|areas
P02807780A0143|132 135|CIS
P02807780A0143|153 162|diagnosis
P02808232A0681|6 12|limits
P02808232A0681|20 33|micrograms/kg
P02808232A0681|67 78|reliability
P02808232A0681|82 83|%
P02809116A0237|29 36|effects
P02809116A0237|74 81|effects
P02809116A0237|85 93|husbands
P02809116A0237|95 105|retirement
P02809116A0237|121 133|satisfaction
P02809116A0237|146 151|wives
P02809651A0492|8 12|turn
P02809651A0492|38 42|role
P02809651A0492|46 59|meta-analysis
P02809651A0492|71 81|clinicians
P02809651A0492|86 99|policy makers
P02809651A0492|116 125|questions
P02809722A0926|19 26|patient
P02809722A0926|34 45|improvement
P02809722A0926|78 90|GH secretion
P02809831A0799|3 11|contrast
P02809831A0799|17 21|PPSF
P02809831A0799|24 32|DBP side
P02809831A0799|46 53|amounts
P02809831A0799|57 71|bone formation
P02809831A0799|77 81|bone
P02810911A0372|4 14|accuracies
P02810911A0372|18 26|presence
P02810911A0372|30 37|absence
P02810911A0372|41 54|neuroblastoma
P02810911A0372|77 94|131I-MIBG imaging
P02810911A0372|107 120|tumor markers
P02811378A0250|15 20|forms
P02811378A0250|24 29|cases
P02811378A0250|54 61|infants
P02811378A0250|79 85|mucosa
P02811378A0250|116 121|ridge
P02811378A0250|129 136|maxilla
P02811378A0250|144 152|mandible
P02811378A0379|20 27|studies
P02811378A0379|46 54|staining
P02811378A0379|59 71|S100 protein
P02811378A0379|92 103|cell tumors
P02811378A0379|124 128|none
P02811378A0379|156 169|cell epulides
P02813369A0390|28 33|males
P02813369A0390|57 62|years
P02813369A0390|75 86|territories
P02813369A0390|113 119|harems
P02813369A0390|127 132|years
P02813369A0390|151 160|neighbors
P02813404T0000|14 26|antigen gene
P02813404T0000|79 85|stages
P02813404T0000|89 104|spermatogenesis
P02814182A1211|3 7|rats
P02814182A1211|42 47|4-EPI
P02814182A1211|63 71|ABSTRACT
P02814182A1211|89 94|WORDS
P02814820A0967|11 20|Roux limb
P02814820A0967|43 53|pacemakers
P02814820A0967|73 81|emptying
P02814820A0967|85 92|liquids
P02814820A0967|111 115|rate
P02814820A0967|129 142|Billroth dogs
P02814820A0967|144 148|t1/2
P02814820A0967|156 160|Roux
P02814820A0967|172 179|minutes
P02814820A0967|181 189|Billroth
P02814820A0967|200 207|minutes
P02814820A0967|209 210|p
P02814820A0967|261 267|solids
P02815229A0139|4 14|treatments
P02815229A0139|23 32|mg t.i.d.
P02815229A0139|41 50|mg t.i.d.
P02815229A0139|61 65|days
P02815229A0139|67 76|treatment
P02815229A0139|92 96|dose
P02815229A0139|114 117|MBq
P02815229A0139|119 122|14C
P02815229A0139|123 132|diltiazem
P02816251A0397|28 39|capillaries
P02816251A0397|113 120|network
P02816251A0397|152 159|surface
P02816251A0397|168 178|ventricles
P02817724A0075|4 15|examination
P02817724A0075|29 31|T1
P02817724A0075|36 48|T2 sequences
P02817724A0075|53 58|scans
P02817724A0075|68 74|planes
P02818122A0000|8 12|deal
P02818122A0000|16 27|information
P02818122A0000|48 58|morphology
P02818122A0000|66 75|claustrum
P02818122A0000|87 101|animal species
P02818122A0000|130 142|distribution
P02818122A0000|147 160|relationships
P02818122A0000|179 185|cortex
P02818122A0000|196 202|nuclei
P02818260T0000|10 16|glioma
P02820128A1333|3 8|terms
P02820128A1333|12 32|sequence repetitions
P02820128A1333|58 64|copies
P02820128A1333|72 93|hexanucleotide ATTGTT
P02820128A1333|113 120|regions
P02820128A1333|124 137|dyad symmetry
P02820128A1333|160 167|ORF T3C
P02820128A1670|4 16|significance
P02820128A1670|38 45|domains
P02820128A1670|54 57|ORF
P02820128A1670|77 88|coincidence
P02820128A1670|96 99|end
P02820128A1670|114 124|palindrome
P02820128A1670|134 137|end
P02820128A1670|156 172|protein sequence
P02820128A1670|182 190|homology
P02820128A1670|200 207|B chain
P02820128A1670|211 218|insulin
P02820128A1670|237 248|palindromes
P02820128A1670|264 274|T2 protein
P02820128A1670|299 304|units
P02821340A0434|19 27|exercise
P02821340A0434|29 32|DCR
P02821340A0434|40 47|UT dogs
P02821340A0434|73 78|value
P02821340A0434|96 116|mm Hg X ml-1 X min-1
P02821340A0434|134 154|mm Hg X ml-1 X min-1
P02821340A0434|160 168|workload
P02821340A0434|176 179|kph
P02821340A0434|181 186|speed
P02821340A0434|190 191|%
P02821340A0434|193 198|grade
P02824334A0972|6 10|data
P02824334A0972|28 49|G-protein gene family
P02824334A0972|93 104|chromosomes
P02825139A0661|19 22|DNA
P02825139A0661|42 50|homology
P02825139A0661|78 92|acid sequences
P02825750A0260|16 24|patients
P02825750A0260|29 42|response rate
P02825750A0260|49 50|%
P02825750A0260|70 78|response
P02826127A0709|37 48|interaction
P02826127A0709|61 79|SV40 octamer motif
P02826127A0709|111 125|protein oct-B2
P02826127A0709|156 165|component
P02826127A0709|189 197|extracts
P02826127A0709|220 230|cell lines
P02826717A0179|0 6|Anoxia
P02826717A0179|39 43|gill
P02826717A0179|49 54|water
P02826717A0179|67 73|oxygen
P02826717A0179|92 102|water flow
P02826717A0179|110 114|gill
P02826729A0790|0 6|Growth
P02826729A0790|8 12|4-PA
P02826729A0790|17 34|14C turnover data
P02826729A0790|50 52|WB
P02826729A0790|68 78|B-6 intake
P02826729A0790|88 92|rats
P02828926A1870|24 31|factors
P02828926A1870|135 143|programs
P02828926A1870|147 168|actin gene expression
P02828926A1870|193 215|muscle differentiation
P02829183A0117|0 21|DNA sequence analysis
P02829183A0117|42 48|clones
P02829183A0117|69 74|forms
P02829183A0117|78 89|translocase
P02830214A0000|4 10|effect
P02830214A0000|14 27|acetazolamide
P02830214A0000|29 32|ACZ
P02830214A0000|37 41|HCO3
P02830214A0000|47 49|Cl
P02830214A0000|51 61|activities
P02830214A0000|71 80|ear fluid
P02830214A0000|115 137|microelectrode methods
P02830265A0341|0 6|RPA190
P02830265A0341|17 34|polypeptide chain
P02830265A0341|46 53|daltons
P02830265A0341|79 92|reading frame
P02830282A0155|16 26|A1 protein
P02830282A0155|47 55|fragment
P02830282A0155|61 72|UP1 protein
P02830282A0155|114 126|V-8 protease
P02830282A0155|142 154|polypeptides
P02830282A0155|161 172|amino acids
P02831398A0346|0 7|Irmiere
P02831398A0346|13 15|W.
P02831556A0173|6 15|offspring
P02831556A0173|23 32|alpha-MSH
P02831556A0173|41 48|mothers
P02831556A0173|72 76|pain
P02831556A0173|84 90|adults
P02831556A0173|118 126|response
P02831556A0173|130 138|morphine
P02831796A0000|7 29|immunodeficiency virus
P02831796A0000|31 34|SIV
P02831796A0000|41 51|lentivirus
P02831796A0000|85 97|similarities
P02831796A0000|107 129|immunodeficiency virus
P02831796A0000|145 150|agent
P02831796A0000|163 188|immunodeficiency syndrome
P02831796A0000|190 194|AIDS
P02831796A0000|199 205|humans
P02832149A1009|4 8|lack
P02832149A1009|12 18|change
P02832149A1009|26 31|ratio
P02832149A1009|51 59|products
P02832149A1009|114 117|myb
P02832149A1009|145 154|insertion
P02832149A1009|173 184|amino acids
P02832149A1009|199 214|myb transcripts
P02832149A1009|224 235|consequence
P02832149A1009|254 264|activation
P02832149A1009|272 290|mouse myb oncogene
P02832293T0000|4 7|use
P02832293T0000|11 17|CRF-41
P02832293T0000|38 47|diagnosis
P02832293T0000|51 58|Cushing
P02832293T0000|61 69|syndrome
P02832293T0000|74 81|obesity
P02832744A0403|12 27|mos transcripts
P02832744A0403|31 39|Northern
P02832744A0403|41 44|RNA
P02832744A0403|46 54|analyses
P02832744A0403|58 61|RNA
P02832744A0403|76 83|chicken
P02832744A0403|88 101|quail ovaries
P02832744A0403|106 112|testes
P02833012A0428|14 20|L mRNA
P02833012A0428|30 41|nucleotides
P02833012A0428|75 88|reading frame
P02833012A0428|109 118|L protein
P02833012A0428|137 148|amino acids
P02833012A0428|156 158|MW
P02833021A1185|4 11|results
P02833021A1185|29 41|organization
P02833021A1185|56 61|units
P02833021A1185|75 81|repeat
P02833021A1185|111 122|enhancement
P02833021A1185|136 144|promoter
P02833021A1185|186 203|promoter function
P02833049A0630|0 10|Variations
P02833049A0630|29 31|U3
P02833049A0630|54 64|insertions
P02833049A0630|69 78|deletions
P02833049A1041|3 11|analysis
P02833049A1041|26 42|state RNA levels
P02833049A1041|57 67|cell lines
P02833049A1041|125 136|transcripts
P02833049A1041|155 163|products
P02833049A1041|176 184|majority
P02833049A1041|198 209|RD-114 mRNA
P02833049A1041|268 272|loci
P02833049A1041|343 353|cell types
P02833101T0000|9 15|crisis
P02833101T0000|26 40|cell disorders
P02833101T0000|42 62|bone marrow necrosis
P02833101T0000|73 93|parvovirus infection
P02833517A0467|29 38|sequences
P02833517A0467|51 59|cleavage
P02833517A0467|73 80|element
P02834478A0000|14 29|weight heparins
P02834478A0000|51 59|interest
P02834478A0000|103 109|action
P02834478A0000|113 122|Xa factor
P02834843A0000|17 25|activity
P02834843A0000|37 58|rifamycin derivatives
P02834843A0000|60 69|rifabutin
P02834843A0000|71 74|RBU
P02834843A0000|77 80|FCE
P02834843A0000|88 91|F22
P02834843A0000|94 105|rifapentine
P02834843A0000|107 110|RPE
P02834843A0000|113 116|CGP
P02834843A0000|124 127|C29
P02834843A0000|130 133|CGP
P02834843A0000|140 143|C70
P02834843A0000|149 152|CGP
P02834843A0000|160 163|C27
P02834843A0000|169 179|rifampicin
P02834843A0000|181 184|RMP
P02834843A0000|214 223|log phase
P02834843A0000|241 245|test
P02834843A0000|261 269|activity
P02834843A0000|290 304|phase cultures
P02834843A0000|308 334|Mycobacterium tuberculosis
P02834843A0000|336 341|H37Rv
P02836623A1094|0 2|Mo
P02836623A1094|5 7|SV
P02836623A1094|26 33|animals
P02836623A1094|61 83|months postinoculation
P02836623A1094|93 101|delta Mo
P02836623A1094|104 106|SV
P02836623A1094|125 132|animals
P02836623A1094|160 182|months postinoculation
P02837575A0979|0 14|Sodium dodecyl
P02837575A0979|32 40|cleavage
P02837575A0979|55 68|topoisomerase
P02837575A0979|89 95|enzyme
P02837575A0979|130 133|end
P02837575A0979|141 144|DNA
P02837763A0259|0 19|Amino acid sequence
P02837763A0259|33 44|liver clone
P02837763A0259|46 51|HL-14
P02837763A0259|74 80|rabbit
P02837763A0259|90 116|muscle phosphatase 2A cDNA
P02837763A0259|125 146|% nucleotide identity
P02838246A0225|0 22|Herpes virus infection
P02838246A0225|44 53|inversion
P02838246A0225|61 72|T4/T8 ratio
P02838246A0225|84 95|sensitivity
P02838246A0225|98 99|%
P02838246A0225|101 112|specificity
P02838246A0225|115 116|%
P02838246A0225|129 142|proliferation
P02838246A0225|150 166|T8 subpopulation
P02838246A0225|193 201|findings
P02838246A0225|205 213|patients
P02838246A0225|219 235|rejection crises
P02838246A0225|263 264|P
P02838319A0527|0 4|RVEF
P02838319A0527|9 13|LVEF
P02838319A0527|40 41|%
P02838319A0527|43 44|p
P02838319A0527|64 65|p
P02838710A0299|4 10|levels
P02838710A0299|14 20|NPY-ir
P02838710A0299|28 31|rat
P02838710A0299|101 110|treatment
P02839488A1314|13 19|assays
P02839488A1314|33 41|activity
P02839488A1314|59 68|alpha s-1
P02839488A1314|115 136|erythrocyte type-1 Gs
P02839488A1314|161 169|products
P02839488A1314|201 207|margin
P02839488A1314|211 216|error
P02839716A0673|9 14|cells
P02839716A0673|16 27|E2 proteins
P02839716A0673|57 63|effect
P02839716A0673|87 95|activity
P02839716A0673|103 132|HPV-11 enhancer-SV40 promoter
P02839716A1907|4 13|mechanism
P02839716A1907|23 27|E2-C
P02839716A1907|51 68|enhancer activity
P02839716A1907|90 101|competition
P02839716A1907|107 109|E2
P02839716A1907|161 165|site
P02839716A1907|167 175|ABSTRACT
P02839716A1907|193 198|WORDS
P02840034A1266|9 19|evaluation
P02840034A1266|27 36|treatment
P02840034A1266|61 81|lung cancer patients
P02840034A1266|114 121|factors
P02840034A1266|127 134|account
P02840376A0461|1 9|anti-IIa
P02840376A0461|15 21|Holmer
P02843495A0544|0 12|Introduction
P02843495A0544|16 21|v-fms
P02843495A0544|29 34|CSF-1
P02843495A0544|52 72|macrophage cell line
P02843495A0544|81 100|factor independence
P02843495A0544|105 119|tumorigenicity
P02843495A0544|138 147|mechanism
P02843694T0001|8 27|E-B virus infection
P02843694T0001|52 60|lymphoma
P02843694T0001|64 75|case report
P02844767A0191|12 21|structure
P02844767A0191|26 41|cotranscription
P02844767A0191|49 60|petCA genes
P02844767A0191|74 84|Rieske-FeS
P02844767A0191|105 111|plants
P02844767A0191|117 130|apocytochrome
P02844767A0191|133 141|proteins
P02844767A0191|173 179|Kallas
P02844767A0191|181 183|T.
P02844767A0191|185 192|Spiller
P02844767A0191|194 196|S.
P02844767A0191|202 208|Malkin
P02844767A0191|210 212|R.
P02844767A0596|4 22|Nostoc petBD genes
P02844767A0596|53 62|psbB gene
P02844767A0596|84 95|photosystem
P02844767A0596|99 110|polypeptide
P02844767A0596|131 138|introns
P02844767A0596|165 182|chloroplast genes
P02844767A1022|0 23|RNA blot hybridizations
P02844767A1022|45 49|mRNA
P02844767A1022|60 73|cytochrome b6
P02844767A1022|78 85|subunit
P02844767A1022|126 130|mRNA
P02844767A1022|147 154|subunit
P02844767A1022|158 168|gene probe
P02844797A1225|12 26|muscle isoform
P02844797A1225|43 54|amino acids
P02844797A1225|79 103|sequence Ala-Ile-Leu-Glu
P02844797A1225|116 123|isoform
P02844797A1225|132 143|amino acids
P02844797A1225|147 153|length
P02844797A1225|165 176|replacement
P02844797A1225|193 204|amino acids
P02844797A1225|221 234|acid sequence
P02844797A1225|261 281|transmembrane domain
P02844797A1225|296 314|consensus sequence
P02844797A1225|331 349|glycosylation site
P02845654A0510|0 12|Substitution
P02845654A0510|18 35|threonine residue
P02845654A0510|42 57|alanine residue
P02845654A0510|61 69|position
P02845654A0510|74 76|P2
P02845654A0510|86 99|cleavage site
P02845654A0510|110 118|cleavage
P02845654A0510|128 140|substitution
P02845654A0510|146 162|tyrosine residue
P02845654A0510|168 189|phenylalanine residue
P02845654A0510|193 212|amino acid position
P02845654A0510|217 219|P1
P02845654A0510|228 241|cleavage site
P02845654A0510|260 270|processing
P02846640A0643|28 36|bacteria
P02846640A0643|44 63|indoxyl phosphatase
P02846640A0643|71 73|pI
P02846852A1459|4 10|number
P02846852A1459|14 25|polymerases
P02846852A1459|49 66|E strand promoter
P02846852A1459|86 92|number
P02846852A1459|96 107|polymerases
P02846852A1459|115 132|L strand promoter
P02848842A0643|2 8|family
P02848842A0643|12 25|RNA molecules
P02848842A0643|38 40|.2
P02848842A0643|41 55|kilobase range
P02848842A0643|74 79|probe
P02848842A0643|90 94|gene
P02848842A0643|130 135|cells
P02849100A0441|21 29|sequence
P02849100A0441|65 74|extremity
P02849100A0441|82 90|molecule
P02849100A0441|119 125|anchor
P02849100A0441|133 148|plasma membrane
P02849759A0865|4 17|SV40 enhancer
P02849759A0865|28 39|replication
P02849759A0865|47 51|fold
P02850472A0112|18 29|origin core
P02850472A0112|52 67|DNA replication
P02850967T0000|0 9|Induction
P02850967T0000|13 45|proto-oncogene fos transcription
P02850967T0000|58 83|adenylate cyclase pathway
P02850967T0000|85 101|characterization
P02850967T0000|123 130|element
P02850971A0180|9 29|oligodeoxynucleotide
P02850971A0180|50 56|region
P02850971A0180|64 88|VtHb amino acid sequence
P02850971A0180|103 122|hybridization probe
P02850971A0180|135 147|Vitreoscilla
P02850971A0180|156 163|library
P02850971A0180|196 216|cosmid vector pVK102
P02852805A0216|15 21|solids
P02852805A0216|40 55|characteristics
P02852805A0216|66 75|influence
P02852805A0216|89 99|treatments
P02852894T0000|0 6|Causes
P02852894T0000|10 15|death
P02852894T0000|44 49|study
P02852894T0000|60 68|chickens
P02852894T0000|72 85|Thai villages
P02853799T0001|4 15|progression
P02853799T0001|19 24|non-A
P02853799T0001|32 41|hepatitis
P02853799T0001|53 61|diseases
P02853799T0001|71 85|transformation
P02853799T0001|104 113|carcinoma
P02853922A0596|9 12|IOP
P02853922A0596|29 37|patients
P02853922A0596|42 46|eyes
P02853922A0596|59 64|study
P02856622T0001|0 3|Use
P02856622T0001|7 40|serum thyroglobulin determination
P02856622T0001|48 57|follow-up
P02856622T0001|76 86|carcinomas
P02856622T0001|94 101|thyroid
P02859434T0000|0 13|Poor response
P02859434T0000|19 29|laboratory
P02859434T0000|42 47|range
P02859434T0000|52 65|serum lithium
P02861067A0000|4 7|aim
P02861067A0000|16 21|study
P02861067A0000|45 52|effects
P02861067A0000|66 77|ipratropium
P02861067A0000|81 89|patients
P02861067A0000|101 107|asthma
P02861067A0000|111 116|order
P02861067A0000|154 175|bronchodilator effect
P02861067A0000|181 198|beta agonist drug
P02861144A0242|8 16|analysis
P02861144A0242|25 37|DNA fragment
P02861144A0242|55 60|genes
P02861144A0242|73 90|encoding proteins
P02861144A0242|114 118|kDal
P02861238T0000|8 13|virus
P02862656T0000|0 7|Changes
P02862656T0000|11 40|dopamine receptor sensitivity
P02862656T0000|44 50|humans
P02862656T0000|63 77|alcohol intake
P02863492A0544|15 26|differences
P02863492A0544|43 59|treatment groups
P02863492A0544|82 92|responders
P02863492A0544|107 111|mean
P02863492A0544|140 149|IgG index
P02863492A0544|227 237|responders
P02863747T0000|0 11|Replacement
P02863747T0000|20 33|histone genes
P02863747T0000|54 63|sequences
P02865502T0000|24 29|trial
P02865502T0000|45 78|tissue-type plasminogen activator
P02865502T0000|86 93|placebo
P02865502T0000|114 124|infarction
P02868446A0184|15 22|domains
P02868446A0184|24 28|CTDs
P02868446A0184|37 55|RPase beta subunit
P02868446A0184|60 71|DNA primase
P02868446A0184|73 85|dnaG protein
P02868446A0184|175 186|RPase alpha
P02868446A0184|207 212|alpha
P02868446A0184|226 232|enzyme
P02868446A0184|270 290|core enzyme subunits
P02868446A0184|295 302|primase
P02868848A0167|9 19|vancomycin
P02868848A0167|24 34|fosfomycin
P02868848A0167|84 92|activity
P02868848A0167|119 131|penicillin G
P02868848A0167|136 144|imipenem
P02868848A0167|164 168|mode
P02868848A0167|179 191|gas gangrene
P02869125A0120|0 8|Fentanyl
P02869125A0120|33 49|receptor agonist
P02869125A0120|90 98|syndrome
P02869125A0120|123 132|analgesia
P02869125A0120|137 158|locomotor stimulation
P02869125A0120|170 181|tachycardia
P02869125A0120|183 193|tachypnoea
P02869125A0120|210 217|arousal
P02870249T0000|13 25|chemotherapy
P02870720A0188|0 10|Bisoprolol
P02870720A0188|40 68|beta-adrenoceptor antagonist
P02870720A0188|74 84|pA2 values
P02870720A0188|104 116|isoprenaline
P02870720A0188|120 136|guinea pig atria
P02870720A0188|141 156|tracheal muscle
P02870851A0349|0 6|Output
P02870851A0349|10 18|99mTcO-4
P02870851A0349|26 39|parotid gland
P02870851A0349|57 69|fluctuations
P02870851A0349|73 97|parotid saliva flow rate
P02872786A0147|21 29|equation
P02872786A0147|52 59|effects
P02872786A0147|72 81|parasites
P02872786A0147|89 96|foregut
P02872786A0147|120 129|sandflies
P02872786A0147|133 143|blood flow
P02873593A0581|13 17|rats
P02873593A0581|98 104|reward
P02873593A0581|106 109|BZP
P02873593A0581|138 147|frequency
P02873593A0581|171 177|reward
P02873593A0581|195 215|5-HT uptake blockers
P02873593A0581|235 242|effects
P02874078A0252|15 38|luteal phase deficiency
P02874078A0252|61 62|%
P02874078A0252|76 84|patients
P02874635T0000|9 17|exposure
P02874635T0000|25 42|fungicide dinocap
P02874635T0000|61 72|torticollis
P02874635T0000|74 84|ballooning
P02874635T0000|89 101|cleft palate
P02874635T0000|105 109|mice
P02874635T0000|119 123|rats
P02874635T0000|127 135|hamsters
P02875224A1059|0 11|Reperfusion
P02875224A1059|24 29|blood
P02875224A1059|37 44|beating
P02875224A1059|54 60|hearts
P02875224A1059|89 95|damage
P02875224A1059|105 111|reflow
P02875224A1059|135 148|contractility
P02875224A1059|156 164|instance
P02875224A1059|169 170|%
P02875224A1059|192 193|p
P02875967A0377|4 15|sensitivity
P02875967A0377|39 49|adrenaline
P02875967A0377|80 91|guinea pigs
P02875967A0377|115 129|fertility rate
P02876820A0841|13 21|acidosis
P02876820A0841|41 52|stimulation
P02876820A0841|81 83|mV
P02876899A0568|3 7|Days
P02876899A0568|41 49|subjects
P02876899A0568|76 83|decline
P02876899A0568|87 119|bevantolol plasma concentrations
P02876899A0568|126 142|absorption phase
P02877124A0000|15 20|B6AF1
P02877124A0000|25 36|B6D2F1 mice
P02877124A0000|58 67|tap water
P02877124A0000|71 87|promethazine HCl
P02877124A0000|91 104|phenothiazine
P02877124A0000|110 139|H1 receptor blocking activity
P02877124A0000|142 158|chlorpheniramine
P02877124A0000|163 173|H1 blocker
P02877124A0000|178 193|trifluoperazine
P02877124A0000|197 210|phenothiazine
P02877124A0000|219 239|H1 blocking activity
P02877124A0000|250 264|drinking water
P02877124A0000|274 281|effects
P02877124A0000|291 297|agents
P02877124A0000|301 321|bone mineral content
P02877124A0000|379 393|body retention
P02877124A0000|397 399|Tc
P02877124A0000|404 427|methylene diphosphonate
P02877124A0000|429 431|Tc
P02877124A0000|436 439|MDP
P02877124A0000|444 453|indicator
P02877124A0000|457 472|bone metabolism
P02877124A0000|485 488|end
P02877124A0000|496 503|studies
P02877124A0000|523 530|weights
P02877124A0000|534 539|femur
P02877124A0000|541 546|ilium
P02877124A0000|551 557|sacrum
P02878100A0674|8 15|results
P02878100A0674|45 55|inhibition
P02878100A0674|70 82|transmission
P02878100A0674|86 95|diltiazem
P02878100A0674|114 123|diltiazem
P02878100A0674|158 166|activity
P02878100A0674|203 215|transmission
P02879906A0000|0 7|Studies
P02879906A0000|46 51|veins
P02879906A0000|61 72|rabbit face
P02879906A0000|88 100|relationship
P02879906A0000|109 147|beta adrenoceptor subtype distribution
P02879906A0000|168 172|tone
P02879906A0000|189 206|nerve innervation
P02879951T0000|0 7|Effects
P02879951T0000|34 39|agent
P02879951T0000|41 49|SGB-1534
P02879951T0000|54 78|rat platelet aggregation
P02880841A0313|10 19|stability
P02880841A0313|23 26|TF1
P02880841A0313|50 59|structure
P02880841A0313|73 77|gene
P02880841A0313|89 92|TF1
P02880841A0313|110 119|structure
P02880841A0313|127 139|beta subunit
P02880841A0313|161 180|nucleotide sequence
P02880841A0313|188 192|gene
P02880841A0313|208 216|sequence
P02880841A0313|231 235|beta
P02880841A0313|253 263|categories
P02880841A0313|267 269|F1
P02880841A0313|285 294|membranes
P02880841A0313|296 308|chloroplasts
P02880841A0313|314 326|mitochondria
P02882893A0301|0 16|Body temperature
P02882893A0301|29 40|conductance
P02882893A0301|83 98|P. s. campbelli
P02882893A0301|118 120|sp
P02883327A0413|4 25|polyadenylation sites
P02883327A0413|48 51|end
P02883327A0413|66 67|E
P02883327A0413|69 75|region
P02883327A0413|89 92|DNA
P02883327A0413|111 114|end
P02883327A0413|128 129|L
P02883327A0413|131 137|region
P02883871A1075|2 6|drug
P02883871A1075|12 15|ISA
P02883871A1075|33 47|beta receptors
P02883871A1075|64 68|drug
P02883871A1075|113 134|drug hypersensitivity
P02883871A1075|138 146|contrast
P02883871A1075|150 156|agents
P02883871A1075|165 168|ISA
P02883963A0000|4 12|patients
P02883963A0000|24 30|T-cell
P02883963A0000|44 54|virus type
P02883963A0000|58 64|HTLV-I
P02883963A0000|77 87|myelopathy
P02883963A0000|89 92|HAM
P02883963A0000|129 136|methods
P02884860A0329|0 9|Terazosin
P02884860A0329|24 30|analog
P02884860A0329|34 42|prazosin
P02884860A0329|58 63|alpha
P02884860A0329|66 79|adrenoceptors
P02884860A0329|122 129|therapy
P02885517T0000|8 20|blood donors
P02885517T0000|25 30|non-A
P02885517T0000|38 47|hepatitis
P02889352A0000|5 13|patients
P02889352A0000|24 38|blood pressure
P02889352A0000|40 42|BP
P02889352A0000|77 84|classes
P02889352A0000|88 97|compounds
P02889352A0000|111 123|beta blocker
P02889352A0000|136 152|enzyme inhibitor
P02889352A0000|156 174|calcium antagonist
P02889495A0000|29 34|study
P02889495A0000|45 67|episode schizophrenics
P02889495A0000|79 87|pimozide
P02889495A0000|91 103|flupenthixol
P02889495A0000|116 121|weeks
P02889495A0000|138 142|dose
P02889495A0000|150 153|end
P02889495A0000|163 174|mg pimozide
P02889495A0000|182 197|mg flupenthixol
P02890200T0001|44 49|tumor
P02890200T0001|53 67|Recklinghausen
P02890200T0001|70 87|neurofibromatosis
P02892762A0296|20 35|repeat elements
P02892762A0296|62 73|nucleotides
P02892762A0296|75 77|nt
P02892762A0296|89 102|promoter site
P02894689A0000|34 47|DNA fragments
P02894689A0000|55 60|bases
P02894689A0000|64 79|chromatin loops
P02894689A0000|89 93|help
P02894689A0000|105 125|extraction procedure
P02894689A0000|135 144|lithium-3
P02894689A0000|149 165|diiodosalicylate
P02894741A0000|26 31|doses
P02894741A0000|35 45|vecuronium
P02894741A0000|60 77|muscle relaxation
P02894741A0000|97 115|NLA II anaesthesia
P02894789A0954|13 29|recovery indexes
P02894789A0954|49 54|times
P02894789A0954|68 73|T1/T0
P02894789A0954|78 83|T4/T1
P02894789A0954|99 100|%
P02894789A0954|106 107|%
P02895472A0178|22 30|colonies
P02895472A0178|61 69|plasmids
P02895472A0178|81 85|cDNA
P02895472A0178|97 100|BiP
P02895472A0178|120 136|mRNA translation
P02895566A0187|0 3|DPA
P02895566A0187|19 27|increase
P02895566A0187|35 44|intensity
P02895566A0187|65 89|pressure pain components
P02895566A0187|106 123|ischemia duration
P02895566A0187|138 144|effect
P02895566A0187|152 175|pressure pain component
P02895754A0000|10 31|percent isoproterenol
P02895754A0000|39 47|presence
P02895754A0000|55 95|phosphodiesterase inhibitor theophylline
P02895754A0000|115 122|ability
P02895754A0000|140 144|rate
P02895754A0000|156 166|humor flow
P02895754A0000|188 195|chamber
P02895754A0000|260 263|eye
P02895754A0000|265 271|Horner
P02895754A0000|274 282|syndrome
P02897651A0000|0 15|Hyperthyroidism
P02897651A0000|39 45|causes
P02897651A0000|49 60|infertility
P02897651A0000|75 83|abortion
P02898752A0683|9 20|correlation
P02898752A0683|40 47|numbers
P02898752A0683|51 57|CFU-GM
P02898752A0683|77 81|rate
P02898752A0683|85 97|granulocytes
P02898752A0683|102 120|platelets recovery
P02899177A0605|20 29|technique
P02899177A0605|33 55|low-frequency kindling
P02899177A0605|81 86|model
P02899177A0605|104 111|effects
P02899177A0605|146 151|drugs
P02899177A0605|159 171|excitability
P02899177A0605|186 193|regions
P02899792T0000|0 9|Oestrogen
P02899792T0000|18 26|overdose
P02900760A0073|6 23|sequence elements
P02900760A0073|76 101|transcription termination
P02900760A0073|105 121|RNA polymerase I
P02900760A0073|123 128|pol I
P02900760A0073|158 178|transcription system
P02900760A0073|197 209|transfection
P02900760A0073|213 237|rDNA minigene constructs
P02900760A0073|243 252|3T6 cells
P02901498A0354|4 16|biosynthesis
P02901498A0354|21 30|stability
P02901498A0354|51 59|proteins
P02901498A0354|99 111|erbB protein
P02901498A0354|140 147|ability
P02901498A0354|161 187|chicken embryo fibroblasts
P02901763A0977|0 11|Codon usage
P02901763A0977|15 42|C. reinhardtii mitochondria
P02901763A0977|72 78|codons
P02901763A0977|119 124|genes
P02901763A0977|147 158|codon usage
P02901763A0977|190 210|C. reinhardtii mtDNA
P02901763A0977|237 243|number
P02901763A0977|247 252|tRNAs
P02901763A0977|285 302|protein synthesis
P02902615A0000|25 34|treatment
P02902615A0000|50 63|polyarteritis
P02902615A0000|76 84|advances
P02902615A0000|92 101|treatment
P02902615A0000|120 131|hepatitis B
P02902615A0000|148 156|patients
P02902656A0481|13 19|testes
P02902656A0481|33 39|testes
P02902656A0481|45 56|hypointense
P02902656A0481|60 63|fat
P02902656A0481|67 76|sequences
P02902656A0481|90 105|repetition time
P02902656A0481|107 109|TR
P02902656A0481|120 124|time
P02902656A0481|126 128|TE
P02902656A0481|137 142|cases
P02902656A0481|148 160|hyperintense
P02902656A0481|164 174|isointense
P02902656A0481|178 181|fat
P02902656A0481|190 205|TR/TE sequences
P02902656A0481|221 226|cases
P02902844A1219|14 18|gene
P02902844A1219|36 40|gene
P02902844A1219|72 79|protein
P02902844A1219|120 131|atp operons
P02902844A1219|144 157|bacterium PS3
P02902844A1219|162 175|cyanobacteria
P02902927A0145|22 31|isolation
P02902927A0145|46 67|rat GHF-1 cDNA clones
P02903500A0278|26 36|properties
P02903500A0278|44 51|protein
P02903500A0278|63 66|neu
P02903500A0278|81 92|fusion gene
P02903500A0278|120 126|domain
P02903500A0278|130 133|neu
P02903500A0278|155 162|portion
P02903500A0278|169 183|immunoglobulin
P02903500A0278|190 195|chain
P02904322A0002|25 33|antelope
P02904322A0002|57 71|model ruminant
P02904322A0002|88 95|studies
P02906027A0553|3 22|sequence comparison
P02906027A0553|27 33|blocks
P02906027A0553|37 45|homology
P02906027A0553|77 83|region
P02906027A0553|111 121|CpG island
P02906027A0553|153 170|CpG dinucleotides
P02906027A1156|14 22|features
P02906027A1156|49 50|G
P02906027A1156|70 79|sequences
P02906027A1156|101 107|intron
P02906249A1195|13 18|group
P02906249A1195|24 34|% Prazosin
P02906249A1195|40 45|mg/kg
P02906249A1195|86 91|hours
P02906249A1195|103 114|application
P02906249A1195|118 124|Oxy-Hb
P02906249A1195|128 138|PGF2 alpha
P02906673T0000|0 8|Efficacy
P02906673T0000|13 29|field evaluation
P02906673T0000|33 55|Bacillus thuringiensis
P02906673T0000|57 61|H-14
P02906673T0000|67 80|B. sphaericus
P02906673T0000|89 110|floodwater mosquitoes
P02906673T0000|114 124|California
P02907308T0001|2 7|cases
P02907308T0001|11 15|type
P02907308T0001|19 30|tyrosinosis
P02907308T0001|32 56|Richner-Hanhart syndrome
P02907533A0362|5 9|loss
P02907533A0362|29 47|drug concentration
P02907533A0362|54 71|correction factor
P02907533A0362|112 134|diazepam concentration
P02907533T0000|0 7|Effects
P02907533T0000|31 47|blood substitute
P02907533T0000|51 67|diazepam binding
P02907533T0000|77 84|albumin
P02909528A1081|9 26|promoter activity
P02909528A1081|49 55|region
P02909528A1081|94 105|start sites
P02910496A0583|2 18|decamer sequence
P02910496A0583|23 36|CGA-CCCCUCC-3
P02910496A0583|68 76|sequence
P02910496A0583|103 116|cleavage site
P02910496A0583|138 151|RNA substrate
P02910496A0583|171 185|RNAase MRP RNA
P02910989T0000|0 7|Effects
P02910989T0000|11 16|aging
P02910989T0000|21 45|beta-adrenergic-blockade
P02910989T0000|66 80|QT/QS2 changes
P02911540A0478|2 9|patient
P02911540A0478|27 32|wound
P02911540A0478|53 57|area
P02911540A0478|59 64|hands
P02911540A0478|66 70|feet
P02911540A0478|72 76|face
P02911540A0478|81 89|perineum
P02911540A0478|136 140|care
P02913368A1037|0 20|Pharmacology studies
P02913368A1037|26 44|potassium chloride
P02913368A1037|49 62|acetylcholine
P02913368A1037|76 83|raveron
P02913368A1037|94 112|calcium antagonist
P02913368A1037|129 135|influx
P02913368A1037|153 160|calcium
P02914422A0409|0 17|Computer analysis
P02914422A0409|35 44|averaging
P02914422A0409|89 104|frequency bands
P02914422A0409|108 113|order
P02914422A0409|131 146|frequency range
P02914422A0409|164 171|notches
P02914422A0409|176 181|slurs
P02914492A0183|3 12|admission
P02914492A0183|20 23|ICU
P02914492A0183|29 37|patients
P02914492A0183|42 49|percent
P02914492A0183|55 69|hypomagnesemia
P02914492A0183|71 79|serum Mg
P02914492A0183|94 100|mEq/dl
P02914492A0183|106 114|patients
P02914492A0183|119 126|percent
P02914492A0183|132 147|normomagnesemia
P02914492A0183|160 166|mEq/dl
P02914492A0183|177 185|patients
P02914492A0183|189 196|percent
P02914492A0183|202 217|hypermagnesemia
P02914492A0183|236 242|mEq/dl
P02916764A0253|4 16|risk factors
P02916764A0253|35 38|sex
P02916764A0253|40 52|hypertension
P02916764A0253|54 71|diabetes mellitus
P02916764A0253|73 93|hypercholesterolemia
P02916764A0253|95 112|cigarette smoking
P02916764A0253|124 134|life-style
P02916764A0253|140 154|family history
P02918474A0817|8 17|verapamil
P02918474A0817|22 32|nifedipine
P02918474A0817|41 51|collateral
P02918474A0817|63 73|blood flow
P02918474A0817|100 114|subendocardium
P02918474A0817|133 141|ml/min/g
P02918474A0817|149 162|subepicardium
P02919483A0091|14 18|boys
P02919483A0091|26 31|girls
P02919483A0091|45 48|age
P02919483A0091|63 73|half years
P02919530A0000|31 42|reperfusion
P02919530A0000|55 65|myocardium
P02919530A0000|94 110|artery occlusion
P02919530A0000|140 146|effect
P02919530A0000|171 182|wall motion
P02919530A0000|210 221|alterations
P02919832A0144|8 15|disease
P02919832A0144|38 44|M-mode
P02919832A0144|85 109|Doppler echocardiography
P02920591A0251|12 22|assessment
P02920591A0251|57 71|administration
P02920591A0251|75 82|digoxin
P02920591A0251|86 99|micrograms/kg
P02920591A0251|106 114|dopamine
P02920591A0251|124 141|micrograms/kg/min
P02923687A0218|21 33|relationship
P02923687A0218|46 50|side
P02923687A0218|54 63|sinusitis
P02923687A0218|72 82|cleft side
P02923687A0218|86 94|patients
P02923687A0218|111 123|cleft palate
P02925013A1112|30 36|levels
P02925013A1112|46 54|aluminum
P02925013A1112|81 87|tissue
P02925013A1112|103 115|accumulation
P02925013A1112|131 145|citrate ligand
P02925568A0460|10 17|effects
P02925568A0460|21 35|father absence
P02925568A0460|50 60|conditions
P02925568A0460|83 90|samples
P02925568A0460|116 123|effects
P02925568A0460|151 167|family stressors
P02925568A0460|180 195|psychopathology
P02926499A0340|35 47|analog model
P02926499A0340|51 60|heat flow
P02926499A0340|72 77|brain
P02926499A0340|111 121|expression
P02926499A0340|126 129|CBF
P02926499A0340|148 151|CBF
P02926499A0340|154 156|Cb
P02926499A0340|166 167|c
P02926499A0340|175 178|tau
P02926499A0340|194 199|decay
P02926499A0340|210 213|rho
P02926499A0340|221 228|density
P02926499A0340|232 237|blood
P02926499A0340|243 244|c
P02926499A0340|261 265|heat
P02927391A0238|26 36|proviruses
P02927391A0238|58 81|founder SWR/J-RF/J mice
P02927391A0238|120 129|germ line
P02927391A0238|159 166|tissues
P02927391A0238|193 204|integration
P02927391A0238|225 234|germ line
P02927391A0238|266 274|lineages
P02928112T0000|10 17|cloning
P02928112T0000|25 29|cDNA
P02928112T0000|44 46|U2
P02928112T0000|62 63|A
P02928112T0000|65 72|protein
P02928376A0312|16 20|work
P02928376A0312|29 34|water
P02928376A0312|58 65|mixture
P02928376A0312|69 71|H2
P02928376A0312|79 84|gases
P02928376A0312|100 111|heat defect
P02928376A0312|136 137|%
P02929056T0000|11 14|use
P02929056T0000|18 42|transureteroureterostomy
P02929056T0000|54 74|ureterosigmoidostomy
P02929056T0000|93 100|failure
P02930623A0404|7 23|flexion whiplash
P02930623A0404|29 35|torque
P02930623A0404|53 60|condyle
P02930623A0404|74 83|direction
P02930623A0404|96 98|ms
P02930623A0404|105 111|impact
P02934778A0702|4 8|data
P02934778A0702|23 31|presence
P02934778A0702|35 40|5-HT2
P02934778A0702|54 63|receptors
P02934778A0702|81 87|artery
P02934778A0702|97 104|species
P02934889A0558|0 11|Oxfendazole
P02934889A0558|47 51|time
P02934889A0558|62 66|days
P02934889A0558|77 82|start
P02934889A0558|86 93|grazing
P02934889A0558|95 98|May
P02934889A0558|123 137|cent reduction
P02934889A0558|141 159|Ostertagia species
P02934889A0558|176 190|cent reduction
P02934889A0558|194 205|D viviparus
P02934891A0845|14 20|method
P02934891A0845|55 63|extracts
P02934891A0845|67 70|ner
P02934891A0845|85 90|cells
P02934891A0845|139 144|sites
P02934891A0845|165 176|nucleotides
P02934891A0845|200 202|Mu
P02934891A0845|208 211|end
P02935638A0000|41 50|structure
P02935638A0000|58 68|Spec1 gene
P02935638A0000|76 116|sea urchin Strongylocentrotus purpuratus
P02936163T0000|0 17|Platelet function
P02936163T0000|60 71|interaction
P02936163T0000|75 83|patients
P02936163T0000|99 129|platelet lipoxygenase activity
P02936284A0357|12 23|degradation
P02936284A0357|27 37|atracurium
P02936284A0357|41 47|plasma
P02936284A0357|61 66|route
P02936284A0357|70 81|elimination
P02936284A0357|85 88|man
P02936284A0357|116 137|elimination half-life
P02936284A0357|158 161|min
P02938185A0223|12 22|cell lines
P02938185A0223|41 44|E1a
P02938185A0223|48 51|E1a
P02938185A0223|56 73|E1b gene products
P02938185A0223|93 100|viruses
P02938185A0223|140 146|growth
P02938185A0223|153 162|degrees C
P02938185A0223|173 182|degrees C
P02938185A0223|210 222|architecture
P02938185A0223|261 271|CREF cells
P02939260A1553|19 47|amino acid sequence analysis
P02939260A1553|64 67|43K
P02939260A1553|72 86|42K T antigens
P02939260A1553|95 105|methionine
P02939260A1553|109 117|residues
P02939260A1553|149 161|DNA sequence
P02939260A1553|174 184|methionine
P02939260A1553|207 220|39K T antigen
P02939260A1553|242 248|cycles
P02939260A1553|252 269|Edman degradation
P02940334A0141|0 7|Group A
P02940334A0141|39 44|doses
P02940334A0141|48 59|hepatitis B
P02940334A0141|67 75|globulin
P02940334A0141|77 81|HBIG
P02940334A0141|109 118|schedules
P02941237A0160|14 22|instance
P02941237A0160|27 35|addition
P02941237A0160|39 52|serum calcium
P02941237A0160|57 87|phosphorous ion concentrations
P02941237A0160|89 98|tissue pH
P02941237A0160|100 112|blood supply
P02941237A0160|114 122|hormones
P02941237A0160|130 139|vitamin D
P02941237A0160|141 150|vitamin A
P02941237A0160|164 171|enzymes
P02941237A0160|179 199|alkaline phosphatase
P02941237A0160|204 219|pyrophosphatase
P02941237A0160|298 303|roles
P02943562T0000|0 24|Penicillinase production
P02943562T0000|50 57|strains
P02943562T0000|70 80|importance
P02947866A1416|19 27|analysis
P02947866A1416|31 50|thallium-201 uptake
P02947866A1416|55 62|washout
P02947866A1416|82 90|evidence
P02947866A1416|115 124|perfusion
P02947866A1416|140 151|angioplasty
P02949170A0184|5 10|study
P02949170A0184|23 30|effects
P02949170A0184|36 47|preparation
P02949170A0184|56 84|micrograms ethinyl estradiol
P02949170A0184|91 113|mg cyproterone acetate
P02949170A0184|117 130|gonadotropins
P02949170A0184|132 141|prolactin
P02949170A0184|143 155|testosterone
P02949170A0184|157 185|sex hormone binding globulin
P02949170A0184|187 191|SHBG
P02949170A0184|194 209|androstenedione
P02949170A0184|231 249|testosterone index
P02949170A0184|271 277|months
P02949170A0184|281 290|treatment
P02950216A0084|11 15|flow
P02950216A0084|36 59|laser Doppler flowmetry
P02950216A0084|61 64|LDF
P02950216A0084|81 94|output signal
P02950216A0084|96 111|blood cell flux
P02950216A0084|113 116|BCF
P02950216A0084|135 140|terms
P02950216A0084|144 149|volts
P02957125A0601|8 16|patients
P02957125A0601|28 35|failure
P02957125A0601|44 57|haemodialysis
P02957125A0601|86 100|cent reduction
P02957125A0601|104 128|plasma ANP concentration
P02958204A0175|19 26|effects
P02958204A0175|30 42|isotretinoin
P02958204A0175|46 49|HDL
P02958204A0175|63 68|HDL-C
P02958204A0175|70 87|HDL phospholipids
P02958204A0175|89 95|HDL-PL
P02958204A0175|98 111|apoprotein A1
P02958204A0175|113 120|apo A-1
P02958204A0175|127 145|HDL-C subfractions
P02958204A0175|147 153|HDL2-C
P02958204A0175|158 164|HDL3-C
P02958204A0175|186 194|patients
P02958204A0175|215 221|course
P02958204A0175|225 237|isotretinoin
P02958204A0175|243 252|mg/kg/day
P02958204A0175|258 267|treatment
P02958204A0175|278 291|acne vulgaris
P02958233A0123|13 20|picture
P02958233A0123|25 46|laboratory parameters
P02958233A0123|70 93|serum sickness reaction
P02958660A1094|4 8|data
P02958660A1094|39 48|existence
P02958660A1094|54 71|conversion factor
P02958660A1094|76 86|LDF signal
P02958660A1094|99 110|flow values
P02958660A1094|116 126|experiment
P02958660A1094|130 140|experiment
P02959089T0000|11 17|effect
P02959089T0000|21 29|ONO-3708
P02959089T0000|33 43|thrombosis
P02959089T0000|48 58|vasospasms
P02960012A0838|4 13|frequency
P02960012A0838|17 29|PPNG strains
P02960012A0838|48 49|%
P02960012A0838|64 65|%
P02962859A0276|13 23|antibodies
P02962859A0276|41 74|beta-galactosidase fusion protein
P02962859A0276|85 90|clone
P02962859A0276|108 110|U1
P02962859A0276|126 135|A antigen
P02963517A0453|13 21|analysis
P02963517A0453|38 46|stenosis
P02963517A0453|77 81|PTCA
P02963517A0453|91 101|dilatation
P02963517A0453|117 125|increase
P02963517A0453|161 165|area
P02963517A0453|198 201|mm2
P02964329A0000|4 16|pathogenesis
P02964329A0000|28 42|Joint Mobility
P02964329A0000|44 47|LJM
P02964329A0000|52 60|diabetes
P02964329A0000|81 92|abnormality
P02964329A0000|136 145|incidence
P02964329A0000|149 164|microangiopathy
P02965149A0727|14 19|study
P02965149A0727|21 27|Brandl
P02965149A0727|29 31|C.
P02966671A0151|17 27|end points
P02966671A0151|37 41|time
P02966671A0151|63 69|tumors
P02966671A0151|81 86|times
P02966671A0151|93 107|treatment size
P02966671A0151|113 121|survival
P02966671A0151|125 135|stem cells
P02966671A0151|152 158|crypts
P02966671A0151|168 182|breathing rate
P02966671A0151|205 210|weeks
P02966671A0151|228 233|weeks
P02966671A0151|241 250|treatment
P02966671A0551|0 8|Schedule
P02966671A0551|25 36|mg/kg c-DDP
P02966671A0551|73 78|X-ray
P02966671A0551|96 100|days
P02966671A0551|122 128|degree
P02966671A0551|132 143|enhancement
P02966671A0551|147 163|radiation effect
P02966671A0551|190 196|factor
P02966671A0551|221 232|enhancement
P02966671A0551|252 263|mg/kg c-DDP
P02966671A0551|280 281|h
P02966671A0551|293 298|start
P02966671A0551|321 333|radiotherapy
P02967496A0182|18 28|transcript
P02967496A0182|49 63|reading frames
P02967496A0182|112 126|leader segment
P02967496A0182|141 146|cpc-1
P02967496A0182|154 160|region
P02967915A0000|17 49|hormone 1,25-dihydroxyvitamin D3
P02967915A0000|73 83|expression
P02967915A0000|89 112|calcium binding protein
P02967915A0000|120 134|calbindin-D28K
P02967915A0000|140 147|variety
P02967915A0000|151 165|target tissues
P02967915A0968|3 11|addition
P02967915A0968|17 40|calbindin-D28K promoter
P02967915A0968|58 65|variety
P02967915A0968|85 94|sequences
P02967915A0968|114 124|components
P02967915A0968|148 155|signals
P02968055A0984|4 7|HOI
P02968055A0984|34 42|increase
P02968055A0984|46 49|ANF
P02969316A0002|14 21|ability
P02969316A0002|29 34|atria
P02969316A0002|56 77|plasma concentrations
P02969316A0002|100 107|peptide
P02969316A0002|109 112|ANP
P02969316A0002|128 135|changes
P02969316A0002|139 164|plasma ANP concentrations
P02969316A0002|212 216|dogs
P02969316A0002|226 227|h
P02969316A0002|255 261|pacing
P02969819A0814|0 22|Ig D-JH recombinations
P02969819A0814|35 57|TcR gene recombination
P02969819A0814|73 85|T cell lines
P02969819A0814|124 139|Cmu transcripts
P02970061A0271|4 14|RAD18 gene
P02970061A0271|20 33|reading frame
P02970061A0271|44 51|protein
P02970061A0271|59 70|amino acids
P02970061A0271|100 106|weight
P02970640A0341|7 35|absorption spectrophotometry
P02970640A0341|69 81|E1A proteins
P02970640A0341|110 122|acid protein
P02970640A0341|133 141|zinc ion
P02970640A0341|165 177|acid protein
P02970640A0341|187 191|zinc
P02971603A0883|5 13|patients
P02971603A0883|24 31|tablets
P02971603A0883|35 44|injection
P02971603A0883|53 56|day
P02971710A0734|0 5|Plots
P02971710A0734|9 11|RV
P02971710A0734|13 15|LV
P02971710A0734|18 19|S
P02971710A0734|24 33|2A weight
P02971710A0734|42 52|hematocrit
P02971710A0734|73 84|inflections
P02971710A0734|93 103|hematocrit
P02971710A0734|106 107|%
P02971710A0734|131 135|role
P02971710A0734|149 158|viscosity
P02971710A0734|162 164|CO
P02971710A0734|192 202|hematocrit
P02971957A0287|27 31|mesh
P02971957A0287|48 59|improvement
P02971957A0287|73 78|cases
P02971957A0287|100 110|techniques
P02971957A0287|133 141|bleeding
P02973304A0000|15 21|course
P02973304A0000|25 45|Budd-Chiari syndrome
P02973304A0000|62 72|thrombosis
P02973304A0000|87 91|vein
P02973304A0000|127 144|patient suffering
P02973304A0000|166 181|cardiosclerosis
P02975680A0000|10 29|accommodation night
P02975680A0000|31 51|sleep EEG recordings
P02975680A0000|92 98|nights
P02975680A0000|116 126|inpatients
P02975680A0000|150 166|anxiety disorder
P02975680A0000|168 171|GAD
P02975680A0000|190 200|depression
P02975680A0000|218 221|age
P02975680A0000|239 244|group
P02975680A0000|248 256|patients
P02975680A0000|262 265|GAD
P02975680A0000|272 277|group
P02975680A0000|306 314|disorder
P02975680A0000|316 319|MDD
P02975680A0000|321 329|patients
P02975753A1333|0 27|Oligonucleotide mutagenesis
P02975753A1333|37 52|binding domains
P02975753A1333|69 79|importance
P02975753A1333|103 113|regulation
P02975753A1333|121 132|E3 promoter
P02975753A1333|136 147|yeast cells
P02976332A1277|4 17|concentration
P02976332A1277|21 25|PGI2
P02976332A1277|54 61|surface
P02979426T0000|0 21|Organ transplantation
P02979426T0000|25 32|Denmark
P02979834T0000|0 7|Effects
P02979834T0000|31 67|maltose tetrapalmitate immunotherapy
P02979834T0000|69 98|cyclophosphamide chemotherapy
P02979834T0000|103 115|radiotherapy
P02979834T0000|119 134|ethyl carbamate
P02979834T0000|155 166|lung cancer
P02979834T0000|170 178|A/J mice
P02981457A0368|0 2|D.
P02981840A0907|11 24|pair sequence
P02981840A0907|70 81|nucleotides
P02981840A0907|102 103|d
P02981840A0907|104 106|AC
P02981840A0907|108 115|repeats
P02982332T0001|0 5|Phase
P02982332T0001|9 14|study
P02982332T0001|18 23|VP-16
P02982332T0001|25 32|capsule
P02982332T0001|43 49|tumors
P02983316A0310|16 24|segments
P02983316A0310|41 50|framework
P02983316A0310|55 90|complementarity-determining regions
P02983316A0310|101 106|genes
P02983316A0310|122 137|probe sequences
P02983316A0310|161 169|analysis
P02983316A0310|195 207|caiman genes
P02983316A0310|275 283|sequence
P02983316A0310|313 325|preservation
P02983316A0310|329 348|nucleotide sequence
P02983316A0310|366 372|period
P02983316A0310|389 393|time
P02983331T0000|0 8|Evidence
P02983331T0000|15 19|role
P02983331T0000|58 64|factor
P02983331T0000|74 79|ether
P02983331T0000|81 95|immobilization
P02983331T0000|111 117|stress
P02985812A0984|11 18|feature
P02985812A0984|40 45|genes
P02985812A0984|66 70|mRNA
P02985812A0984|97 110|reading frame
P02985812A0984|125 129|mRNA
P02985820A1287|10 27|sequence elements
P02985820A1287|51 58|vectors
P02985820A1287|67 77|c-myc gene
P02985820A1287|96 103|genesis
P02985820A1287|124 141|retroviruses CMII
P02985820A1287|143 147|MC29
P02985820A1287|152 155|MH2
P02986279A0000|3 15|milk samples
P02986279A0000|34 40|donors
P02986279A0000|43 47|days
P02986279A0000|53 59|months
P02986279A0000|66 74|delivery
P02986279A0000|97 107|occurrence
P02986279A0000|111 126|cytomegalovirus
P02986279A0000|128 131|CMV
P02987220A0472|0 10|Subcloning
P02987220A0472|14 27|DNA fragments
P02987220A0472|51 53|kb
P02987220A0472|55 61|insert
P02987220A0472|65 70|pAVO4
P02987220A0472|86 98|DNA fragment
P02987220A0472|130 133|FBP
P02987220A0472|135 139|gene
P02987220A0472|159 165|region
P02987777A0000|6 11|cases
P02987777A0000|35 49|cell carcinoma
P02987777A0000|57 63|rectum
P02988457A0650|4 8|data
P02988457A0650|52 64|potentiality
P02988457A0650|68 86|Bestatin treatment
P02988457A0650|97 102|types
P02988457A0650|106 116|malignancy
P02989637A0671|6 10|data
P02989637A0671|37 47|regulation
P02989637A0671|59 90|zona glomerulosa corticosteroid
P02989637A0671|101 116|renin secretion
P02989637A0671|130 138|patients
P02989637A0671|156 173|cord transections
P02989637A0671|205 213|pathways
P02989637A0671|239 245|system
P02989637A0671|264 290|metoclopramide stimulation
P02989637A0671|294 305|aldosterone
P02989637A0671|310 325|renin secretion
P02989637A0671|329 332|men
P02989786A0328|7 14|absence
P02989786A0328|18 36|enhancer sequences
P02989786A0328|42 61|adenovirus E1A gene
P02989786A0328|80 96|CATase synthesis
P02991060A0465|6 20|IgG antibodies
P02991060A0465|28 34|babies
P02991060A0465|60 68|delivery
P02991060A0465|100 105|cases
P02991060A0465|121 127|months
P02991060A0465|131 135|ages
P02991060A0465|146 152|babies
P02991060A0465|162 168|months
P02993630A1190|5 13|analysis
P02993630A1190|21 37|nucleotide level
P02993630A1190|51 57|events
P02993630A1190|65 74|digestion
P02993630A1190|80 91|nuclease S1
P02993630A1190|107 121|enzyme attacks
P02993630A1190|141 149|sequence
P02993630A1190|151 154|G-A
P02993630A1190|165 172|message
P02993630A1190|187 193|strand
P02994253A0482|6 13|dosages
P02994253A0482|29 46|mean NTE activity
P02994253A0482|57 61|cord
P02994253A0482|89 90|%
P02994253A0482|95 100|brain
P02994253A0482|128 129|%
P02994253A0482|133 147|control values
P02994253A0482|158 173|hr postexposure
P02994253A0482|197 211|cord pathology
P02994253A0482|215 232|days postexposure
P02994253A0482|263 264|%
P02994253A0482|284 291|animals
P02994336A0864|0 2|FK
P02994336A0864|35 43|analogue
P02994336A0864|56 67|plasma ACTH
P02994336A0864|73 74|%
P02994336A0864|84 89|level
P02994336A0864|97 110|bromocriptine
P02994336A0864|112 118|CB-154
P02994336A0864|142 148|change
P02995967T0000|17 30|protooncogene
P02995967T0000|32 40|c-erbB-2
P02995967T0000|63 71|c-erbB-1
P02995967T0000|82 109|growth factor-receptor gene
P02995967T0000|147 167|gland adenocarcinoma
P02995999A0000|4 21|sequence analysis
P02995999A0000|30 38|products
P02995999A0000|53 56|phi
P02995999A0000|74 94|recombination events
P02995999A0000|114 127|recombination
P02995999A0000|145 155|attachment
P02995999A0000|157 160|att
P02995999A0000|162 166|site
P02995999A0000|201 207|joints
P02995999A0000|226 234|position
P02995999A0000|240 259|recombination event
P02995999A0000|281 299|base-pair deletion
P02995999A0000|314 334|recombination events
P02995999A0000|368 391|base-pair substitutions
P02997622A0916|11 19|sequence
P02997622A0916|52 71|SCLC cell line DNAs
P02997622A0916|83 103|SCLC tumour specimen
P02997622A0916|126 133|patient
P02997777A0609|18 29|experiments
P02997777A0609|56 61|cells
P02997777A0609|67 82|delta top1 top2
P02997777A0609|106 108|ts
P02997777A0609|141 155|top2 ts strain
P02997777A0609|183 189|blocks
P02997777A0609|202 209|killing
P02997777A0609|217 224|top2 ts
P02997777A0609|251 262|temperature
P02997777A0609|273 283|treatments
P02997777A0609|314 324|cell death
P02997777A0609|332 350|delta top1 top2 ts
P02998016A0527|4 12|homology
P02998016A0527|16 21|v-mil
P02998016A0527|47 55|sequence
P02998016A0527|59 63|exon
P02998016A0527|102 108|region
P02998016A0527|112 116|exon
P02998016A0527|124 135|nucleotides
P02998016A0527|156 170|nonsense codon
P02998016A0527|198 211|reading frame
P02998016A0527|227 232|c-mil
P02998016A0527|237 242|v-mil
P02998043A1199|0 11|Examination
P02998043A1199|19 27|sequence
P02998043A1199|35 60|Punta Toro M gene product
P02998043A1199|73 81|presence
P02998043A1199|106 115|sequences
P02998043A1199|137 141|acid
P02998043A1199|143 159|carboxy-proximal
P02998043A1199|173 179|region
P02998043A1199|181 183|G2
P02999267A0606|10 13|FAP
P02999267A0606|27 38|amyloidosis
P02999267A0606|79 86|uptakes
P02999267A0606|96 105|intensity
P02999267A0606|132 139|sternum
P02999267A0885|4 13|intensity
P02999267A0885|28 34|uptake
P02999267A0885|38 48|Tc-99m-PYP
P02999267A0885|52 60|patients
P02999267A0885|101 112|hypertrophy
P02999267A0885|149 155|echoes
P02999267A0885|186 196|appearance
P02999267A0885|198 200|GS
P02999267A0885|236 244|patients
P02999267A0885|269 280|hypertrophy
P02999267A0885|285 287|GS
P03000457A1554|8 21|kDa precursor
P03000457A1554|43 44|t
P03000457A1554|53 54|h
P03000457A1554|71 81|processing
P03000457A1554|93 96|kDa
P03000457A1554|98 103|alpha
P03000457A1554|113 116|kDa
P03000457A1554|118 122|beta
P03000457A1554|125 132|species
P03000489A0822|9 20|lymphocytes
P03000489A0822|57 65|patients
P03000489A0822|71 75|AIDS
P03000489A0822|77 81|mean
P03000489A0822|95 96|%
P03000489A0822|98 103|range
P03000489A0822|108 109|%
P03000489A0822|115 118|CGL
P03000489A0822|120 124|mean
P03000489A0822|138 139|%
P03000489A0822|141 146|range
P03000489A0822|151 152|%
P03000489A0822|159 167|criteria
P03000489A0822|171 181|activation
P03000489A0822|203 220|blood lymphopenia
P03001054A0703|30 35|nicks
P03001054A0703|79 84|sites
P03001084A0406|4 12|sequence
P03001084A0406|44 48|pair
P03001084A0406|50 52|bp
P03001084A0406|54 61|segment
P03001084A0406|84 86|bp
P03001084A0406|97 105|cap site
P03001084A0406|109 114|alpha
P03001084A0406|124 126|bp
P03001084A0406|133 142|psi alpha
P03001086A0587|14 33|amino acid sequence
P03001086A0587|50 58|homology
P03001086A0587|82 87|hsp70
P03001086A0587|89 100|trout hsp70
P03001086A0587|102 115|Xenopus hsp70
P03001086A0587|117 128|yeast hsp70
P03001086A0587|139 147|homology
P03001086A0587|170 187|dnaK gene product
P03001110A0546|5 20|phosphorylation
P03001110A0546|34 52|peptide substrates
P03001110A0546|71 79|function
P03001110A0546|83 112|receptor self-phosphorylation
P03001110A0546|114 138|tyrosine kinase activity
P03001110A0546|188 191|mol
P03001110A0546|195 204|phosphate
P03001110A0546|209 212|mol
P03001110A0546|216 224|receptor
P03001353A0146|3 15|temperatures
P03001353A0146|31 45|transformation
P03001353A0146|47 56|6m2 cells
P03001353A0146|65 71|P58gag
P03001353A0146|104 106|kb
P03001353A0146|114 124|RNA genome
P03001353A0146|129 139|P85gag-mos
P03001353A0146|173 177|mRNA
P03001645A0785|4 9|pet56
P03001645A0785|14 24|his3 genes
P03001645A0785|58 74|initiation sites
P03001645A0785|106 108|bp
P03001705T0000|10 24|transformation
P03001705T0000|36 45|fragments
P03001705T0000|49 74|herpes simplex virus type
P03001705T0000|77 80|DNA
P03001705T0000|92 98|region
P03001705T0000|107 119|gene product
P03001952A0958|24 32|patients
P03001952A0958|59 65|herpes
P03001952A0958|71 75|type
P03001952A0958|79 82|HSV
P03001952A0958|105 116|determinant
P03001952A0958|131 142|recurrences
P03001952A0958|164 173|acyclovir
P03001952A0958|185 191|effect
P03001952A0958|206 217|recurrences
P03002501A1327|0 10|Comparison
P03002501A1327|14 23|sequences
P03002501A1327|45 48|rat
P03002501A1327|53 85|guinea-pig alpha s1-casein mRNAs
P03002501A1327|109 117|homology
P03002501A1327|157 164|regions
P03002786A0143|4 9|group
P03002786A0143|11 12|n
P03002786A0143|40 49|midazolam
P03002786A0143|55 62|mg kg-1
P03002786A0143|68 76|atropine
P03002786A0143|85 92|mg i.m.
P03003695A0395|0 10|Comparison
P03003695A0395|37 53|c-sis cDNA clone
P03003695A0395|55 62|Collins
P03003695A0395|71 77|Nature
P03003695A0395|121 135|kbp DNA region
P03003695A0395|157 167|c-sis exon
P03003695A0395|185 187|bp
P03004364A0775|42 52|activities
P03004364A0775|56 60|5-FU
P03004364A0775|62 65|ADM
P03004364A0775|70 73|MMC
P03004364A0775|77 83|FAMLIP
P03004364A0775|99 104|FULIP
P03004364A0775|106 112|ADRLIP
P03004364A0775|117 123|MMCLIP
P03004739A0753|16 17|C
P03004739A0753|21 35|G transversion
P03004739A0753|49 56|residue
P03004739A0753|64 83|CAT pentanucleotide
P03004739A0753|112 120|activity
P03004739A0753|129 138|promoters
P03004739A0753|160 168|affinity
P03004739A0753|176 195|CAT binding protein
P03004982A0199|4 23|nucleotide sequence
P03004982A0199|32 34|bp
P03004982A0199|45 59|R. sphaeroides
P03004982A0199|72 75|DNA
P03004982A0199|108 118|genes fbcF
P03004982A0199|120 124|fbcB
P03004982A0199|129 133|fbcC
P03004982A1094|15 23|sequence
P03004982A1094|43 50|peptide
P03004982A1094|58 69|FeS protein
P03004982A1094|108 126|fbcF reading frame
P03005231A0649|27 36|sequences
P03005231A0649|60 69|sequences
P03005231A0649|95 105|initiation
P03005231A0649|110 121|termination
P03005231A0649|125 138|transcription
P03005231A0649|163 172|promoters
P03005231A0649|219 228|sequences
P03006066A0653|7 22|P135gag-myb-ets
P03006066A0653|31 33|Mr
P03006066A0653|41 60|translation product
P03006066A0653|64 69|c-myb
P03006066A0653|71 79|P75c-myb
P03006066A0653|100 108|proteins
P03006066A0653|110 118|P54c-ets
P03007281A0905|4 16|Dox-A2 locus
P03007281A0905|38 40|kb
P03007281A0905|48 50|Df
P03007281A0905|51 53|2L
P03007281A0905|54 69|OD15 breakpoint
P03007281A0905|97 101|loci
P03007281A0905|111 118|maximum
P03007281A0905|127 129|kb
P03008094A0697|15 18|end
P03008094A0697|27 38|polypeptide
P03008094A0697|53 58|types
P03008094A0697|71 80|sequences
P03008405A0532|8 17|outbreaks
P03008405A0532|28 35|disease
P03008405A0532|50 61|deer calves
P03008405A0532|72 77|HVC-1
P03009366A0438|41 48|studies
P03009366A0438|69 73|Type
P03009366A0438|77 88|pneumocytes
P03009366A0438|102 108|target
P03009366A0438|112 121|radiation
P03009366A0438|130 137|release
P03009366A0438|141 151|surfactant
P03009366A0438|184 192|exposure
P03009366A0438|206 210|days
P03009366A0438|215 220|weeks
P03009826A0201|14 20|clones
P03009826A0201|46 66|base-pair dimer unit
P03009826A0201|74 80|repeat
P03010281A0220|4 10|copies
P03010281A0220|24 30|repeat
P03010281A0220|50 60|activation
P03010281A0220|64 79|gene expression
P03011793A0582|9 23|reading frames
P03011793A0582|27 31|rbsD
P03011793A0582|33 37|rbsA
P03011793A0582|43 47|rbsC
P03011793A0582|55 63|proteins
P03011793A0582|85 104|amino acid residues
P03013477A0000|3 8|order
P03013477A0000|22 31|influence
P03013477A0000|35 48|iron overload
P03013477A0000|74 83|leucocyte
P03013477A0000|85 88|PMN
P03013477A0000|90 100|metabolism
P03013477A0000|104 112|patients
P03013477A0000|124 136|hemodialysis
P03013477A0000|138 148|generation
P03013477A0000|152 168|superoxide anion
P03013477A0000|178 181|PMN
P03013477A0000|191 196|blood
P03013477A0000|217 223|groups
P03013477A0000|240 248|patients
P03013477A0000|250 255|group
P03013477A0000|282 293|individuals
P03013477A0000|299 320|serum ferritin levels
P03013477A0000|332 337|ng/ml
P03013477A0000|342 349|group B
P03013477A0000|362 373|individuals
P03013477A0000|379 400|serum ferritin levels
P03013477A0000|412 417|ng/ml
P03013841A0207|0 8|Cattaneo
P03013841A0207|14 16|J.
P03014515T0000|6 27|alpha-galactosidase A
P03014515T0000|29 48|nucleotide sequence
P03014515T0000|54 64|cDNA clone
P03014515T0000|85 91|enzyme
P03014593A0681|0 8|Diazepam
P03014593A0681|12 17|mg/kg
P03014593A0681|34 36|Ro
P03014593A0681|78 87|Ro 5-4864
P03014593A0681|91 96|mg/kg
P03014593A0681|104 109|mg/kg
P03015611A0331|4 23|amino acid sequence
P03015611A0331|45 53|residues
P03015611A0331|72 86|lysine residue
P03015611A0331|125 129|site
P03015628A1078|0 11|Osteocalcin
P03015628A1078|25 39|hydroxyproline
P03015628A1078|71 91|hyperphosphatasaemia
P03015628A1078|109 119|mechanisms
P03015628A1078|141 154|bone turnover
P03015628A1078|193 228|serum alkaline phosphatase activity
P03015628A1078|238 246|subjects
P03015953T0000|0 8|Analysis
P03015953T0000|12 26|glucocorticoid
P03015953T0000|40 53|cell variants
P03015953T0000|62 91|mouse glucocorticoid receptor
P03015953T0000|106 115|DNA clone
P03016301A0605|10 22|v-myc codons
P03016301A0605|70 78|terminus
P03016301A0605|93 103|c-myc exon
P03016301A0605|113 119|codons
P03016301A0605|138 143|c-myc
P03016301A0605|151 157|region
P03016506A0611|14 20|vector
P03016506A0611|22 26|p410
P03016506A0611|71 79|fragment
P03016506A0611|81 92|nucleotides
P03016506A0611|117 129|B95-8 strain
P03016506A0611|167 181|antigen EBNA-1
P03016506A0611|199 207|sequence
P03016506A0611|217 233|BamHI-C fragment
P03016506A0611|261 272|marker gene
P03016506A0611|282 298|G-418 resistance
P03016506A0611|302 314|animal cells
P03016883A0000|3 6|men
P03016883A0000|14 21|history
P03016883A0000|43 68|herpes simplex virus type
P03016883A0000|72 77|HSV-2
P03016883A0000|79 88|infection
P03016883A0000|115 120|weeks
P03016883A0000|126 133|samples
P03016883A0000|149 156|urethra
P03016883A0000|161 176|virus isolation
P03017225A0706|11 20|carcinoma
P03017225A0706|34 48|leather bottle
P03017225A0706|50 71|linitis plastica type
P03017225A0706|80 87|stomach
P03017225A0706|100 112|II c portion
P03017225A0706|120 127|stomach
P03017225A0706|148 154|glands
P03017225A0706|173 182|carcinoma
P03017225A0706|209 214|focus
P03017225A0706|226 234|Nakamura
P03017225A0706|237 243|theory
P03017996A0731|11 23|biosynthesis
P03017996A0731|44 56|polypeptides
P03017996A0731|62 76|signal peptide
P03017996A0731|132 139|protein
P03017996A0731|156 166|mutants X2
P03017996A0731|171 173|X3
P03017996A0731|178 191|cleavage site
P03018491A0840|4 18|hexanucleotide
P03018491A0840|22 30|TGTCCT-3
P03018491A0840|61 73|GRE activity
P03018491A0840|102 110|sequence
P03018491A0840|134 140|region
P03018491A0840|179 182|end
P03018491A0840|190 194|gene
P03018491A0840|222 238|receptor binding
P03019505A0390|5 13|patients
P03019505A0390|35 41|spread
P03019505A0390|67 72|tumor
P03020001A0781|20 36|mini-Mu elements
P03020001A0781|49 63|kilobase pairs
P03020001A0781|83 90|cloning
P03020001A0781|94 107|DNA fragments
P03020001A0781|122 136|kilobase pairs
P03020001A0781|170 184|kilobase pairs
P03020001A0781|201 207|clones
P03020001A0781|214 224|insertions
P03020001A0781|243 257|kilobase pairs
P03020513T0000|15 22|subunit
P03020513T0000|26 46|T4 DNA topoisomerase
P03020513T0000|68 80|gyrA-protein
P03020513T0000|84 90|gyrase
P03021050A0501|26 31|peaks
P03021050A0501|39 51|quantitation
P03021050A0501|55 64|sulbactam
P03021088A0135|11 18|periods
P03021088A0135|35 44|exclusion
P03021088A0135|52 62|occurrence
P03021088A0135|78 84|ulcers
P03021088A0135|102 113|gastrectomy
P03021088A0135|119 127|Billroth
P03021088A0135|130 134|type
P03021088A0135|138 152|reconstruction
P03021088A0135|171 175|days
P03021088A0135|182 187|years
P03021088A0135|197 204|average
P03021088A0135|212 217|years
P03022129A0842|16 22|arrays
P03022129A0842|35 43|MPE X Fe
P03022129A0842|44 46|II
P03022129A0842|85 89|loss
P03022129A0842|93 99|detail
P03022129A0842|127 140|accessibility
P03022129A0842|146 152|extent
P03022129A0842|194 212|transcription rate
P03022129A0842|221 225|gene
P03023067A0779|0 11|Translation
P03023067A0779|33 38|genes
P03023067A0779|72 83|transcripts
P03023679A0624|14 20|weight
P03023679A0624|40 48|proteins
P03023679A0624|103 111|proteins
P03023679A0624|149 161|modification
P03023682A0271|0 9|Insertion
P03023682A0271|15 17|bp
P03023682A0271|26 30|SV40
P03023682A0271|56 89|chloramphenicol acetyltransferase
P03023682A0271|91 94|CAT
P03023682A0271|96 106|expression
P03023859A0000|7 11|DNAs
P03023859A0000|51 68|leukemia patients
P03023859A0000|80 84|date
P03023859A0000|88 98|breakpoint
P03023859A0000|102 112|chromosome
P03023859A0000|121 135|Ph1 chromosome
P03023859A0000|164 169|probe
P03023859A0000|179 182|bcr
P03023859A0000|184 209|breakpoint cluster region
P03023887A0470|0 21|Nuclease footprinting
P03023887A0470|45 68|glucocorticoid receptor
P03023887A0470|96 101|sites
P03023887A0470|120 127|borders
P03023887A0470|153 167|sequence motif
P03023887A0470|181 183|Sa
P03023970A0922|10 16|insert
P03023970A0922|29 47|termination signal
P03023970A0922|75 86|termination
P03023970A0922|94 101|protein
P03023970A0922|118 128|generation
P03023970A0922|134 145|p53 product
P03023970A0922|148 159|amino acids
P03024343A0372|4 10|tumors
P03024343A0372|39 53|neuroendocrine
P03024343A0372|57 63|origin
P03024703A1036|11 17|region
P03024703A1036|26 37|nucleotides
P03024703A1036|55 72|polypeptide chain
P03024703A1036|80 91|amino acids
P03024703A1036|112 118|weight
P03024703A1036|137 151|hsp108 protein
P03025606T0000|16 31|control signals
P03025606T0000|37 62|herpes simplex virus type
P03025606T0000|71 76|gamma
P03025606T0000|80 88|gene lie
P03025606T0000|96 101|bases
P03025606T0000|133 141|terminus
P03025606T0000|149 153|mRNA
P03025655T0000|15 21|domain
P03025655T0000|67 74|kinases
P03025655T0000|88 103|kinase function
P03025655T0000|108 129|transforming activity
P03025655T0000|133 167|Fujinami sarcoma virus P130gag-fps
P03025661A0260|0 7|Gluzman
P03025661A0260|9 16|EMBO J.
P03025862A0860|9 13|exon
P03025862A0860|47 58|amino acids
P03025862A0860|66 75|ssd chain
P03025862A0860|100 106|region
P03025862A0860|114 118|mRNA
P03025862A0860|134 138|poly
P03025862A0860|139 140|A
P03025862A0860|142 155|addition site
P03026915A1024|21 30|sequences
P03026915A1024|35 40|parts
P03026915A1024|55 64|sequences
P03026915A1024|76 87|yeast genes
P03026915A1024|125 144|lacZ fusion vectors
P03027661A0000|4 14|activities
P03027661A0000|22 31|D protein
P03027661A0000|39 52|miniF plasmid
P03027779A0000|0 17|SPECT examination
P03027779A0000|25 28|TMJ
P03027779A0000|39 45|Tc-MDP
P03027779A0000|66 74|patients
P03027779A0000|114 125|dislocation
P03027779A0000|133 137|disc
P03027779A0000|148 155|normals
P03027905A0632|0 21|Plasma renin activity
P03027905A0632|35 59|plasma aldosterone level
P03027905A0632|78 88|lisinopril
P03029111A0155|4 11|mutants
P03029111A0155|18 32|representative
P03029111A0155|47 72|pet complementation group
P03031602A1001|11 16|group
P03031602A1001|31 39|elements
P03031602A1001|67 73|region
P03031602A1001|82 87|genes
P03032143A0218|2 12|centromere
P03032143A0218|44 50|region
P03032143A0218|54 57|DNA
P03032143A0218|77 79|bp
P03032143A0218|83 89|length
P03032143A0218|118 135|sequence elements
P03032143A0218|159 167|proteins
P03032143A0218|184 196|conformation
P03032143A0218|204 213|chromatin
P03032143A0218|219 236|yeast kinetochore
P03032964T0000|13 21|function
P03032964T0000|48 56|promoter
P03032964T0000|69 78|sequences
P03032964T0000|93 101|activity
P03033283A0837|25 29|loci
P03033283A0837|64 73|IE68 gene
P03033283A0837|77 81|HCMV
P03033283A0837|82 87|Towne
P03033283A0837|89 92|DNA
P03033283A0837|106 110|case
P03033283A0837|115 127|DNA sequence
P03033283A0837|132 170|competition filter binding experiments
P03033283A0837|183 190|maximum
P03033283A0837|212 235|consensus binding sites
P03033283A0837|271 277|region
P03033283A1415|30 34|sets
P03033283A1415|71 86|repeat elements
P03033283A1415|155 163|strength
P03033283A1415|177 188|arrangement
P03033283A1415|239 244|sites
P03033283A1415|301 311|host range
P03033283A1415|316 326|expression
P03033283A1415|330 339|SCMV IE94
P03033283A1415|354 363|HCMV IE68
P03034570A0943|12 17|genes
P03034570A0943|21 34|gene segments
P03034570A0943|41 45|code
P03034570A0943|64 97|chloramphenicol acetyltransferase
P03034570A0943|113 117|gene
P03034570A0943|129 139|resistance
P03034570A0943|148 158|hygromycin
P03034570A0943|168 174|ORF E7
P03034570A0943|188 207|papillomavirus type
P03034570A0943|222 229|vectors
P03034956A0666|3 11|contrast
P03034956A0666|33 48|androgen levels
P03034956A0666|106 114|subjects
P03034956A0666|127 130|day
P03034956A0666|142 145|day
P03034956A0666|150 160|prednisone
P03034956A0666|162 163|P
P03035056T0000|7 13|lambda
P03035056T0000|18 51|kappa antibody gene rearrangement
P03035056T0000|55 62|Abelson
P03035056T0000|70 78|leukemia
P03035056T0000|103 113|cell lines
P03035218T0000|0 14|Identification
P03035218T0000|45 54|sequences
P03035218T0000|72 98|T-cell leukemia virus type
P03035218T0000|115 121|repeat
P03035658A0355|21 31|anesthesia
P03035658A0355|43 46|VO2
P03035658A0355|56 65|ml/kg/min
P03035658A0355|87 98|epinephrine
P03035658A0355|104 108|dose
P03035658A0355|119 125|manner
P03035658A0355|129 150|plasma concentrations
P03035658A0355|163 168|ng/ml
P03035658A0355|170 173|VO2
P03035658A0355|181 190|ml/kg/min
P03035658A0355|201 206|ng/ml
P03035658A0355|208 211|VO2
P03035658A0355|219 228|ml/kg/min
P03036415T0000|0 9|Influence
P03036415T0000|13 39|cyclo-oxygenase inhibition
P03036415T0000|47 76|leukotriene receptor blockade
P03036415T0000|99 135|pressure/cardiac index relationships
P03036415T0000|164 168|dogs
P03036817A0213|25 36|mutagenesis
P03036817A0213|59 80|NdeI restriction site
P03036817A0213|96 99|ATG
P03036817A0213|107 115|yeast R.
P03036933A0774|0 12|ACTH release
P03036933A0774|47 55|children
P03036933A0774|72 86|ACTH treatment
P03037334A0932|39 55|promoter element
P03037334A0932|63 79|yeast RP39A gene
P03037334A0932|108 123|sequence motifs
P03038643A1374|6 10|data
P03038643A1374|44 58|alpha-spectrin
P03038643A1374|70 81|duplication
P03038643A1374|92 102|divergence
P03038643A1374|139 143|gene
P03038891A0935|0 17|Northern analyses
P03038891A0935|21 25|RNAs
P03038891A0935|31 44|mouse tissues
P03038891A0935|49 59|cell lines
P03038891A0935|75 90|p11 mRNA levels
P03039177A0503|4 9|group
P03039177A0503|17 28|cDNA clones
P03039177A0503|67 77|transcript
P03039177A0503|93 111|IR2 repeat element
P03039177A0503|123 152|restriction site polymorphism
P03039177A0503|161 172|enzyme SmaI
P03039387A0920|33 49|cyclophosphamide
P03039387A0920|55 58|BCG
P03039387A0920|73 84|enhancement
P03039387A0920|102 108|effect
P03039387A0920|144 155|combination
P03039387A0920|159 171|methotrexate
P03039387A0920|177 180|BCG
P03039387A0920|185 201|cyclophosphamide
P03039387A0920|207 217|levamisole
P03040023A0113|0 8|Morphine
P03040023A0113|35 46|bradycardia
P03040023A0113|59 70|tachycardia
P03040403A0155|4 12|PSS gene
P03040403A0155|41 49|fragment
P03040403A0155|57 66|yeast DNA
P03040403A0155|74 86|YEp13 vector
P03041046A0127|8 14|A-MuLV
P03041046A0127|37 44|viruses
P03041046A0127|58 70|Moloney MuLV
P03041046A0127|121 127|A-MuLV
P03041046A0127|151 158|viruses
P03041046A0127|172 178|BALB/c
P03041046A0127|199 203|MuLV
P03041046A0127|248 257|potential
P03041046A0127|259 261|N.
P03041802A0975|4 12|presence
P03041802A0975|28 47|platelet aggregates
P03041802A0975|61 67|levels
P03041802A0975|71 87|fibrinopeptide A
P03041802A0975|91 107|cleavage product
P03041802A0975|133 152|platelet activation
P03041802A0975|164 174|deposition
P03041802A0975|186 190|role
P03041802A0975|198 210|pathogenesis
P03041802A0975|219 227|disorder
P03042778A0643|4 8|gene
P03042778A0643|26 31|yeast
P03042778A0643|43 49|growth
P03045117A0936|16 22|values
P03045117A0936|43 50|methods
P03045117A0936|59 68|agreement
P03045117A0936|78 85|species
P03045117A0936|99 112|growth factor
P03045117A0936|130 135|order
P03045117A0936|142 146|type
P03045117A0936|160 165|Glu24
P03045117A0936|186 191|Asp27
P03045117A0936|225 228|Thr
P03045117A0936|242 247|Tyr29
P03045117A0936|268 273|Leu47
P03045725A0872|21 32|suppression
P03045725A0872|45 61|prolactin levels
P03045725A0872|88 110|breast cancer patients
P03045725A0872|141 158|tumor sensitivity
P03045725A0872|162 174|chemotherapy
P03046655A0000|12 28|prevalence study
P03046655A0000|48 54|acuity
P03046655A0000|71 74|eye
P03046655A0000|91 99|patients
P03046655A0000|114 123|keratitis
P03046655A0000|147 153|period
P03046931A0247|17 23|eIF-4A
P03046931A0247|35 45|retroposon
P03046931A0247|74 78|cDNA
P03046931A0247|98 119|nucleotide difference
P03048024A0418|14 21|culture
P03048024A0418|36 42|tissue
P03048024A0418|63 65|IB
P03048024A0418|75 83|NIB rats
P03048024A0418|85 86|p
P03049570A1242|6 18|similarities
P03049570A1242|38 49|E2 proteins
P03050147A0896|6 15|infection
P03050147A0896|23 28|cells
P03050147A0896|58 75|E1a-E1b functions
P03050147A0896|83 90|viruses
P03050147A0896|106 113|amounts
P03050147A0896|130 148|mRNA transcription
P03050147A1520|5 16|observation
P03050147A1520|44 58|scanning model
P03050147A1520|73 83|initiation
P03050147A1520|102 111|ribosomes
P03050147A1520|151 160|mRNA site
P03050147A1520|176 195|initiator AUG codon
P03050147A1520|204 213|C protein
P03052327A1474|3 7|view
P03052327A1474|17 24|results
P03052327A1474|39 70|pancreas-kidney transplantation
P03052327A1474|89 98|treatment
P03052327A1474|102 108|choice
P03052327A1474|113 117|Type
P03052327A1474|129 137|patients
P03052641A0204|17 26|compounds
P03052641A0204|41 49|vehicles
P03052641A0204|70 75|gases
P03053713A0752|0 14|DNA sequencing
P03053713A0752|22 31|DPM1 gene
P03053713A0752|49 62|reading frame
P03053713A0752|70 75|bases
P03057259A0514|4 16|relationship
P03057259A0514|43 51|lymphoma
P03057259A0514|59 66|thyroid
P03057259A0514|79 90|thyroiditis
P03059171A1232|0 14|Administration
P03059171A1232|18 32|anticoagulants
P03059171A1232|40 47|heparin
P03059171A1232|49 65|prostaglandin E1
P03059171A1232|70 81|ticlopidine
P03059171A1232|119 127|symptoms
P03059171A1232|154 167|deterioration
P03060846T0000|11 19|analysis
P03060846T0000|27 42|L1 binding site
P03060846T0000|46 54|23S rRNA
P03060953A0481|0 7|Animals
P03060953A0481|33 44|vaccination
P03060953A0481|58 68|mechanisms
P03060953A0481|93 102|outbreaks
P03061301A0624|0 22|Prostacyclin formation
P03061301A0624|41 55|excretion rate
P03061301A0624|70 110|metabolite 6-keto-prostaglandin F1 alpha
P03061301A0624|128 133|means
P03061301A0624|137 153|radioimmunoassay
P03061301A0624|164 179|urine specimens
P03061301A0624|211 217|period
P03061301A0624|228 240|participants
P03061301A0624|253 258|smoke
P03061301A0624|283 293|cigarettes
P03061301A1409|9 18|excretion
P03061301A1409|43 51|F1 alpha
P03061301A1409|79 86|smokers
P03061301A1409|101 115|contraceptives
P03061301A1409|140 145|ng/gm
P03061301A1409|149 159|creatinine
P03061301A1409|161 162|p
P03061383A0000|13 21|activity
P03061383A0000|25 35|mecillinam
P03061383A0000|63 67|acid
P03061383A0000|93 100|strains
P03061383A0000|111 126|beta-lactamases
P03061383A0000|134 139|TEM-1
P03061383A0000|141 146|Oxa-1
P03061383A0000|163 167|type
P03061383A0000|191 196|broth
P03061383A0000|201 224|agar dilution technique
P03062370A0000|0 4|GCN4
P03062370A0000|31 40|activator
P03062370A0000|44 54|amino acid
P03062370A0000|68 73|genes
P03062370A0384|6 13|results
P03062370A0384|29 41|GCN3 product
P03062370A0384|61 71|repression
P03062370A0384|75 85|activation
P03062370A0384|89 104|GCN4 expression
P03062370A0384|118 141|amino acid availability
P03064524A0160|4 12|efficacy
P03064524A0160|40 45|drugs
P03064811A0485|4 23|amino acid sequence
P03064811A0485|31 48|S. aureus peptide
P03064811A0485|62 78|phosphoryl group
P03064811A0485|168 171|Asp
P03065140A0273|6 15|mutations
P03065140A0273|26 33|regions
P03065140A0273|37 49|GAL4 protein
P03065140A0273|55 73|DNA binding domain
P03065140A0273|83 114|transcription activation domain
P03065141A0448|4 11|results
P03065141A0448|31 36|genes
P03065141A0448|38 42|citA
P03065141A0448|47 51|citB
P03065141A0448|67 76|promoters
P03065141A0448|86 94|location
P03065141A0448|102 110|promoter
P03065141A0448|119 128|citB gene
P03065141A0448|136 162|Tn3411 nucleotide sequence
P03065141A0448|190 196|pMS185
P03065610A0375|4 12|rci gene
P03065610A0375|28 32|lacZ
P03065610A0375|41 53|gene product
P03065610A0375|72 93|Western blot analysis
P03065621T0000|0 9|Structure
P03065621T0000|14 24|regulation
P03065621T0000|38 42|gene
P03065621T0000|86 91|MRP13
P03065621T0000|95 102|protein
P03065621T0000|116 123|subunit
P03065621T0000|145 153|ribosome
P03066131A0000|8 14|survey
P03066131A0000|51 56|basis
P03066131A0000|70 79|treatment
P03066131A0000|83 102|behaviour disorders
P03066131A0000|119 126|lesions
P03066131A0000|134 142|amygdala
P03066131A0000|168 180|hypothalamus
P03066131A0000|185 191|author
P03066131A0000|210 221|experiences
P03066131A0000|231 241|operations
P03066131A0000|246 253|control
P03066131A0000|284 298|aggressiveness
P03066208A0310|13 24|examination
P03066208A0310|55 59|cyst
P03066208A0310|82 96|cell carcinoma
P03066625A0756|29 36|studies
P03066625A0756|76 89|contributions
P03066625A0756|102 114|risk factors
P03066625A0756|143 155|risk factors
P03066625A0756|161 168|studies
P03066625A0756|207 216|questions
P03067505A0688|6 18|prostacyclin
P03067505A0688|47 55|property
P03067505A0688|69 80|ear vessels
P03069046A0126|4 10|method
P03069046A0126|34 43|precision
P03069046A0126|57 68|sensitivity
P03069980T0000|0 7|Factors
P03069980T0000|24 37|bond strength
P03069980T0000|46 65|glass polyalkenoate
P03069980T0000|67 74|ionomer
P03069980T0000|76 83|cements
P03069980T0000|88 95|dentine
P03072021A0696|4 24|amino acid sequences
P03072021A0696|32 37|yeast
P03072021A0696|66 85|targeting sequences
P03072021A0696|131 143|polypeptides
P03072580A0455|0 12|Van der Ende
P03072580A0455|14 16|R.
P03073091A0338|7 23|insulin infusion
P03073091A0338|29 48|% dextrose solution
P03073091A0338|66 75|Biostator
P03073091A0338|79 84|order
P03073091A0338|101 108|patient
P03073091A0338|111 119|glycemia
P03073091A0338|126 131|mg/dl
P03073091A0449|0 7|Amounts
P03073091A0449|11 18|glucose
P03073091A0449|46 49|min
P03073091A0449|60 81|hour insulin infusion
P03073091A0449|131 140|treatment
P03073091A0449|142 143|K
P03073091A0449|151 157|mmol/l
P03073091A0449|172 181|mg/kg/min
P03073091A0449|189 203|spironolactone
P03073091A0449|205 206|K
P03073091A0449|214 220|mmol/l
P03073091A0449|236 245|mg/kg/min
P03073091A0449|253 266|indomethacine
P03073091A0449|268 269|K
P03073091A0449|277 283|mmol/l
P03073091A0449|295 304|mg/kg/min
P03073091A0449|320 325|drugs
P03073091A0449|327 328|K
P03073091A0449|336 342|mmol/l
P03073091A0449|357 366|mg/kg/min
P03073192T0000|0 53|Mycobacterium avium-intracellulare complex infections
P03073192T0000|70 95|immunodeficiency syndrome
P03075154T0000|0 10|Recurrence
P03075154T0000|14 32|oxalate deposition
P03075154T0000|44 54|transplant
P03075154T0000|62 83|ciclosporin A therapy
P03076124A0496|4 26|bile acid sequestrants
P03076124A0496|28 42|cholestyramine
P03076124A0496|47 57|colestipol
P03076124A0496|70 74|acid
P03076124A0496|76 87|fenofibrate
P03076124A0496|92 102|inhibitors
P03076124A0496|106 138|hydroxymethylglutaryl coenzyme A
P03076124A0496|140 147|HMG CoA
P03076124A0496|149 158|reductase
P03076124A0496|165 175|lovastatin
P03076124A0496|179 190|simvastatin
P03076124A0496|215 220|drugs
P03076124A0496|225 228|use
P03076124A0496|232 240|patients
P03076124A0496|254 275|hypercholesterolaemia
P03076124A0496|283 289|agents
P03076124A0496|297 318|plasma concentrations
P03076124A0496|322 327|total
P03076124A0496|332 347|LDL-cholesterol
P03076124A0496|359 360|%
P03078268A0529|32 39|aspects
P03078268A0529|51 64|acidification
P03078268A0529|106 121|acidosis models
P03078268A0529|134 141|maleate
P03078268A0529|146 170|amphotericin B treatment
P03078268A0529|191 201|mechanisms
P03078268A0529|218 222|role
P03078268A0529|234 242|steroids
P03078268A0529|254 267|acidification
P03079276T0029|0 8|Analysis
P03079276T0029|14 20|groups
P03079276T0029|24 32|patients
P03079276T0029|85 94|flare-ups
P03080793T0000|0 9|Statement
P03080793T0000|17 28|development
P03080793T0000|32 42|guidelines
P03080793T0000|51 61|prevention
P03080793T0000|65 82|AIDS transmission
P03080793T0000|90 99|workplace
P03083441T0000|0 13|Modifications
P03083441T0000|33 48|postcontraction
P03083441T0000|61 67|people
P03088643A0000|16 20|rats
P03088643A0000|32 42|preference
P03088643A0000|77 84|stimuli
P03088643A0000|86 88|CS
P03088643A0000|118 130|control rats
P03090237A0202|12 21|schedules
P03090237A0202|36 48|response run
P03090237A0202|94 99|times
P03090237A0202|107 119|response key
P03090237A0202|121 129|work key
P03090237A0202|168 180|response key
P03090237A0202|193 196|key
P03090372A0607|12 35|glucose tolerance tests
P03090372A0607|58 67|operation
P03090372A0607|85 88|CyA
P03090372A0607|101 106|weeks
P03091849A0000|4 11|effects
P03091849A0000|15 29|glutaraldehyde
P03091849A0000|33 43|dimensions
P03091849A0000|48 62|ultrastructure
P03091849A0000|80 84|beds
P03091849A0000|88 101|rat mesentery
P03091849A0000|122 127|kinds
P03091849A0000|131 141|experiment
P03091849A0000|161 169|fixative
P03091849A0000|188 197|perfusion
P03091849A0000|203 211|pressure
P03091849A0000|218 223|mm Hg
P03091849A0000|231 242|superfusion
P03091849A0000|274 282|membrane
P03097509A0654|10 14|rise
P03097509A0654|18 31|RNA molecules
P03097509A0654|53 60|regions
P03097509A0654|90 100|base pairs
P03097643A1357|10 21|BALB/c gene
P03097643A1357|40 52|substitution
P03097643A1357|68 84|octamer sequence
P03097643A1357|112 123|nucleotides
P03097643A1357|147 153|region
P03097643A1357|178 188|expression
P03098018A0139|9 17|findings
P03098018A0139|24 30|height
P03098018A0139|35 37|cm
P03098018A0139|39 45|weight
P03098018A0139|49 51|kg
P03098018A0139|63 69|length
P03098018A0139|79 84|limbs
P03098018A0139|86 100|P2-A2 pilosity
P03098018A0139|105 115|micropenis
P03102289A0786|4 8|data
P03102289A0786|58 76|hCG administration
P03102289A0786|80 88|midcycle
P03102289A0786|108 114|number
P03102289A0786|118 127|follicles
P03102289A0786|143 145|cm
P03102289A0786|149 159|ultrasound
P03102289A0786|163 172|cycle day
P03102289A0786|193 196|hCG
P03102289A0786|202 217|serum E2 levels
P03102289A0786|237 243|pmol/l
P03102289A0786|248 256|follicle
P03104245A0402|6 14|patients
P03104245A0402|25 30|Ir192
P03104245A0402|42 50|addition
P03104245A0402|63 72|radiation
P03104245A0402|90 91|p
P03104245A0402|100 108|survival
P03104245A0402|162 168|months
P03104245A0402|170 175|range
P03104245A0402|185 191|months
P03104245A0402|202 208|months
P03104245A0402|210 215|range
P03104245A0402|223 229|months
P03104248A0322|7 15|Stage IA
P03104248A0322|21 29|patients
P03104248A0322|54 59|tumor
P03104248A0322|61 63|G1
P03104248A0322|104 109|tumor
P03104248A0322|111 113|G2
P03104248A0322|123 131|patients
P03104248A0322|159 161|G3
P03104914T0000|0 9|Mechanism
P03104914T0000|17 18|t
P03104914T0000|38 51|translocation
P03104914T0000|64 72|analysis
P03104914T0000|113 121|partners
P03104982A0690|6 9|age
P03104982A0690|19 36|hemoglobin levels
P03104982A0690|41 44|men
P03104982A0690|80 85|women
P03104982A0690|104 118|sex difference
P03104982A0690|139 144|years
P03104982A0690|148 151|age
P03108171A0088|0 10|Ritanserin
P03108171A0088|20 29|substance
P03108171A0088|52 69|blocking activity
P03108171A0088|73 85|S2 receptors
P03108171A0088|90 94|5-HT
P03108171A0088|118 124|system
P03109147A0000|0 15|Ethylene glycol
P03109147A0000|20 37|diethylene glycol
P03109147A0000|91 97|groups
P03109147A0000|112 121|NMRI mice
P03109147A0000|127 134|dosages
P03109147A0000|143 146|und
P03109147A0000|149 151|mg
P03109147A0000|159 163|dose
P03109147A0000|168 173|mouse
P03109147T0127|0 8|Research
P03109147T0127|12 27|ethylene glycol
P03109147T0127|32 49|diethylene glycol
P03109147T0127|67 74|effects
P03109954A0945|4 11|results
P03109954A0945|48 57|influence
P03109954A0945|78 85|ethinyl
P03109954A0945|107 109|OC
P03109954A0945|122 132|inhibition
P03109954A0945|145 167|artery atherosclerosis
P03109954A0945|207 215|lowering
P03109954A0945|219 255|plasma HDL cholesterol concentration
P03109954A0945|284 291|balance
P03109954A0945|310 319|influence
P03109954A0945|327 339|relationship
P03109954A0945|348 361|plasma lipids
P03109954A0945|366 379|atherogenesis
P03110119A0267|7 9|BH
P03110119A0267|14 24|ventilator
P03110119A0267|48 57|bias flow
P03110119A0267|63 64|%
P03110119A0267|75 80|l/min
P03110119A0267|107 117|side ports
P03110119A0267|129 137|catheter
P03110119A0267|144 147|tip
P03110119A0267|165 176|cm cephalad
P03110119A0267|184 190|carina
P03110678A0702|0 10|Comparison
P03110678A0702|14 18|beta
P03110678A0702|35 42|removal
P03110678A0702|58 79|polysulphone membrane
P03110678A0702|84 97|haemodialysis
P03110678A0702|102 117|haemofiltration
P03110678A0702|129 149|beta 2-microglobulin
P03110678A0702|181 191|convection
P03110678A0702|200 209|diffusion
P03110678A0702|220 235|treatment modes
P03110678A0702|252 262|blood flow
P03110678A0702|267 281|urea clearance
P03110692A0156|14 18|mg/l
P03110692A0156|20 22|SD
P03110692A0156|41 42|P
P03110692A0156|60 67|beta 2m
P03110692A0156|100 108|patients
P03110692A0156|114 124|bone cysts
P03110692A0156|140 144|mg/l
P03110692A0156|175 183|duration
P03110692A0156|187 195|dialysis
P03110692A0156|215 216|P
P03110692A0156|243 251|patients
P03110692A0156|257 267|bone cysts
P03110692A0156|278 284|months
P03110692A0156|287 294|beta 2m
P03110692A0156|308 316|patients
P03110692A0156|331 339|dialysis
P03110692A0156|356 360|year
P03110692A0156|380 392|urine volume
P03110692A0156|414 419|litre
P03110692A0156|424 427|day
P03110746A0146|9 19|percentage
P03110746A0146|32 36|acid
P03110746A0146|44 57|triglycerides
P03110746A0146|78 92|adipose tissue
P03110746A0146|94 100|PLASAT
P03110746A0146|111 119|subjects
P03110746A0146|168 173|group
P03110794A0991|3 12|overdoses
P03110794A0991|21 34|g fluvoxamine
P03110794A0991|52 59|effects
P03110801A0532|25 50|plasma prolactin response
P03110801A0532|59 69|micrograms
P03111946A0309|3 9|effect
P03111946A0309|32 40|behavior
P03112028A0404|18 26|patients
P03112028A0404|51 52|n
P03112028A0404|69 70|n
P03112028A0404|84 94|parameters
P03112412A0985|3 11|addition
P03112412A0985|25 31|strain
P03112412A0985|81 100|synthetase mutation
P03112412A0985|118 139|thr operon expression
P03112412A0985|162 173|temperature
P03112412A0985|183 187|none
P03112412A0985|195 202|mutants
P03112412A0985|214 220|change
P03114188A0907|30 38|problems
P03114188A0907|66 72|decade
P03114188A0907|78 86|patients
P03114188A0907|102 120|chest wall sarcoma
P03114188A0907|135 143|patients
P03114188A0907|169 171|Gy
P03114188A0907|175 181|breast
P03114188A0907|201 206|areas
P03114829T0000|24 34|correlates
P03114829T0000|38 50|panic states
P03114995T0000|0 7|Effects
P03114995T0000|32 41|nutrition
P03114995T0000|45 60|gastrin release
P03114995T0000|64 68|dogs
P03115087A0515|9 15|weight
P03115087A0515|20 37|height velocities
P03115087A0515|46 47|%
P03115087A0515|55 56|%
P03115087A0515|64 72|standard
P03115787A0633|5 13|patients
P03115787A0633|27 43|cyclophosphamide
P03115787A0633|45 63|hexamethylmelamine
P03115787A0633|65 75|adriamycin
P03115787A0633|80 89|cisplatin
P03115787A0633|91 97|CHAP-5
P03115787A0633|117 124|disease
P03115787A0633|146 154|response
P03115787A0633|167 176|responses
P03115787A0633|192 198|months
P03115787A0633|213 222|responses
P03115787A0633|238 244|months
P03117046T0000|0 9|Isolation
P03117046T0000|14 30|characterization
P03117046T0000|36 49|vinculin cDNA
P03117046T0000|68 79|fibroblasts
P03117147A1059|16 21|study
P03117147A1059|38 47|agreement
P03117147A1059|56 63|surface
P03117147A1059|68 84|oesophageal EMGd
P03117147A1059|107 119|surface EMGd
P03117147A1059|146 150|tool
P03117147A1059|164 177|investigation
P03118631A0140|3 14|differences
P03118631A0140|18 34|fixation quality
P03118631A0140|57 65|cochleas
P03118631A0140|89 98|perfusion
P03118631A0140|103 111|cochleas
P03118631A0140|139 148|perfusion
P03119227A0079|4 16|DNA sequence
P03119227A0079|27 34|protein
P03119227A0079|43 54|amino acids
P03119227A0079|60 77|sequence homology
P03119227A0079|91 119|c-abl proto-oncogene product
P03119227A0079|138 152|amino terminus
P03119227A0079|171 182|amino acids
P03119227A0079|195 201|region
P03119227A0079|216 240|tyrosine kinase activity
P03119485A0476|4 15|requirement
P03119485A0476|45 50|acids
P03119485A0476|54 62|patients
P03119485A0476|85 94|nutrition
P03119485A0476|107 113|injury
P03119485A0476|128 136|interest
P03119485A0476|142 149|respect
P03119485A0476|157 168|development
P03119485A0476|173 182|prognosis
P03119485A0476|186 191|shock
P03119485A0476|193 199|sepsis
P03119485A0476|221 238|distress syndrome
P03120334A0893|5 6|%
P03120334A0893|23 27|vein
P03120334A0893|52 58|origin
P03120334A0893|79 83|vein
P03120334A0893|95 101|system
P03120334A0893|122 127|veins
P03123310A0000|28 37|Gart gene
P03123310A0000|62 72|activities
P03123310A0000|80 87|pathway
P03123310A0000|92 98|purine
P03123310A0000|107 116|synthesis
P03123983T0000|4 8|role
P03123983T0000|12 27|neuroplasticity
P03123983T0000|35 43|response
P03123983T0000|47 52|drugs
P03125420A0421|0 4|Biol
P03125422A0202|4 11|results
P03125422A0202|21 32|experiments
P03125422A0202|69 88|activator sequences
P03125422A0202|90 93|UAS
P03125422A0202|111 120|induction
P03125422A0202|124 133|galactose
P03126531T0000|0 8|Reversal
P03126531T0000|16 24|increase
P03126531T0000|48 58|stereotypy
P03126531T0000|63 73|aggression
P03126531T0000|77 86|REM sleep
P03126531T0000|96 100|rats
P03126531T0000|104 134|dopamine agonist pretreatments
P03127034A0591|4 14|heart rate
P03127034A0591|28 32|rate
P03127034A0591|68 78|resistance
P03127463A1017|6 11|rIL-3
P03127463A1017|25 35|COS7 cells
P03127463A1017|55 67|CSF activity
P03127463A1017|81 89|cultures
P03127463A1017|93 110|bone marrow cells
P03127463A1017|140 153|proliferation
P03127463A1017|157 162|My-10
P03127463A1017|164 170|marrow
P03127463A1017|174 190|cord blood cells
P03127463A1017|201 209|cultures
P03132498A0730|6 14|patients
P03132498A0730|21 26|PaCO2
P03132498A0730|59 63|torr
P03132498A0730|65 70|range
P03132498A0730|80 84|torr
P03132498A0730|99 111|asthma score
P03132498A0730|130 135|PaCO2
P03132498A0730|148 152|mean
P03132498A0730|161 165|torr
P03132498A0730|175 179|mean
P03132498A0730|187 192|hours
P03133250A0000|26 31|study
P03133250A0000|65 76|stimulation
P03133250A0000|99 111|gonadotropin
P03133250A0000|113 116|hMG
P03133250A0000|149 156|hormone
P03133250A0000|158 162|hFSH
P03133250A0000|179 192|fertilization
P03133250A0000|197 212|embryo transfer
P03133250A0000|214 220|IVF-ET
P03133250A0000|222 229|program
P03133360A1215|4 12|findings
P03133360A1215|30 41|mtr product
P03133360A1215|54 79|transcription attenuation
P03133360A1215|84 94|inhibition
P03133360A1215|98 109|translation
P03133360A1215|113 122|trpE mRNA
P03134872T0029|0 7|Apropos
P03134872T0029|13 17|case
P03137105A0146|2 24|prostaglandin analogue
P03137105A0146|40 49|pregnancy
P03137105A0146|70 82|gonadotropin
P03137105A0146|98 101|end
P03137105A0146|128 133|phase
P03137105A0146|177 182|cycle
P03137105A0146|191 208|oocyte collection
P03137105A0146|232 238|cycles
P03137105A0146|242 255|oocyte donors
P03137105A0146|260 277|embryo recipients
P03137346A0319|4 18|nucleolin gene
P03137346A0319|37 47|base-pairs
P03137346A0319|69 74|exons
P03137346A0319|95 114|amino acid residues
P03137346A0319|122 129|protein
P03137601A0212|9 38|L-threo-dihydroxyphenylserine
P03137601A0212|40 44|DOPS
P03137601A0212|61 75|norepinephrine
P03137601A0212|77 79|NE
P03137601A0212|81 90|precursor
P03137601A0212|107 117|immobility
P03137601A0212|128 132|mice
P03137601A0212|134 138|DOPS
P03137601A0212|161 171|immobility
P03137601A0212|175 179|mice
P03137601A0212|210 228|NE neurotoxin DSP4
P03138190A0347|12 19|amounts
P03138190A0347|33 43|ampicillin
P03138190A0347|73 86|Kupffer cells
P03138190A0347|92 104|target cells
P03138190A0347|143 154|inoculation
P03138449A0759|20 25|delta
P03138449A0759|32 37|delta
P03138449A0759|40 63|desaturation activities
P03138449A0759|84 94|conditions
P03138449A0759|105 108|C18
P03138449A0759|110 119|w6 supply
P03139750A0000|12 17|basis
P03139750A0000|26 36|expression
P03139750A0000|49 60|VH allotype
P03139750A0000|68 74|rabbit
P03142875A0366|28 52|6-kilobase cDNA sequence
P03142875A0366|66 71|chain
P03142875A0366|80 91|amino acids
P03142875A0366|116 125|structure
P03143048A1091|0 15|HDL-cholesterol
P03143048A1091|19 20|%
P03143048A1091|22 23|P
P03143048A1091|43 61|apolipoprotein A-I
P03143048A1091|65 66|%
P03143048A1091|68 69|P
P03143048A1091|85 99|concentrations
P03143485A0366|4 11|Euglena
P03143485A0366|22 42|protein gene cluster
P03143485A0366|72 86|protein operon
P03143485A0366|110 127|gene organization
P03143485A0366|157 162|order
P03143485A0366|180 185|genes
P03143485A0366|193 200|tobacco
P03143485A0366|205 234|liverwort chloroplast genomes
P03144705A0859|4 16|distribution
P03144705A0859|24 29|sites
P03144705A0859|49 59|resolution
P03144705A0859|101 109|gradient
P03144705A0859|113 132|sequence divergence
P03144705A0859|159 160|%
P03144705A0859|168 169|X
P03144705A0859|219 220|X
P03144705A0859|247 265|Alu family repeats
P03146017A0983|4 23|nucleotide sequence
P03146017A0983|31 37|region
P03146017A0983|52 54|M.
P03146017A0983|62 69|ORFtrpA
P03146017A0983|102 110|presence
P03146017A0983|117 120|ORF
P03146017A0983|129 140|nucleotides
P03146017A0983|142 149|ORFtrpB
P03146017A0983|166 188|amino acid polypeptide
P03146017A0983|192 195|mol
P03146150T0000|0 12|Potentiation
P03146150T0000|33 41|efficacy
P03146150T0000|58 67|urokinase
P03146150T0000|69 82|Pro-urokinase
P03146150T0000|87 94|heparin
P03146784A0158|6 15|receptors
P03146784A0158|31 36|phase
P03146784A0158|42 53|ventilation
P03146784A0158|108 125|stretch receptors
P03146784A0158|171 188|stretch receptors
P03146784A0158|190 193|PSR
P03146784A0158|243 257|chemoreceptors
P03146784A0158|259 262|IPC
P03147912A0422|12 28|hyperventilators
P03147912A0422|42 48|number
P03147912A0422|52 57|sighs
P03147912A0422|78 90|fluctuations
P03147912A0422|94 102|baseline
P03147912A0422|119 123|time
P03147912A0422|136 140|time
P03147912A0422|146 152|PETCO2
P03149774A0173|7 14|IA task
P03149774A0173|46 56|injections
P03149774A0173|60 70|picrotoxin
P03149774A0173|75 86|bicuculline
P03149774A0173|112 123|enhancement
P03149774A0173|127 136|retention
P03149774A0173|149 150|h
P03149774A0173|161 169|training
P03149774A0173|177 186|retention
P03149774A0173|207 229|bicuculline methiodide
P03149774A0173|233 257|GABA receptor antagonist
P03149774A0173|302 309|barrier
P03150015T0001|9 17|research
P03150015T0001|21 26|non-A
P03150015T0001|51 60|hepatitis
P03150296A0594|25 28|use
P03150296A0594|43 63|creatinine clearance
P03150296A0594|91 106|filtration rate
P03150296A0594|108 111|GFR
P03150296A0594|122 129|caution
P03150296A0594|138 149|recognition
P03150296A0594|157 168|limitations
P03150296A0594|176 182|method
P03150296A0594|201 211|techniques
P03150296A0594|213 229|serum creatinine
P03150296A0594|254 274|creatinine clearance
P03150296A0594|302 310|practice
P03154072A0862|4 20|protein mixtures
P03154072A0862|24 36|sesame flour
P03154072A0862|41 54|soybean flour
P03159903A0352|7 10|end
P03159903A0352|25 31|region
P03159903A0352|79 98|amino acid sequence
P03159903A0352|124 143|amino acid sequence
P03159903A0352|147 150|IHF
P03166458A1356|2 19|protein footprint
P03166458A1356|46 60|GC box element
P03166458A1356|64 75|nucleotides
P03167060A0000|13 26|growth factor
P03167060A0000|31 36|IGFII
P03167060A0000|53 64|polypeptide
P03167060A0000|70 75|mRNAs
P03167060A0000|109 114|forms
P03167060A0000|124 134|derivation
P03167060A0000|149 153|gene
P03168709A0000|19 25|fields
P03168709A0000|49 62|glaucoma eyes
P03168709A0000|85 94|threshold
P03168709A0000|103 126|suprathreshold strategy
P03171221A0531|4 15|variability
P03171221A0531|33 39|result
P03171221A0531|55 63|splicing
P03171221A0531|67 72|exons
P03171221A0531|90 109|elastin transcripts
P03171279A0158|16 26|conclusion
P03171279A0158|47 53|artery
P03171279A0158|73 79|toe MP
P03171279A0158|86 92|grafts
P03171279A0158|130 136|artery
P03171279A0158|153 160|toe PIP
P03171279A0158|167 173|grafts
P03171279A0158|204 210|dorsal
P03171279A0158|221 225|vein
P03172863T0000|0 6|Effect
P03172863T0000|18 32|undernutrition
P03172863T0000|36 50|susceptibility
P03172863T0000|59 65|stress
P03172863T0000|90 94|rats
P03175942A0706|5 11|effect
P03175942A0706|20 24|fact
P03175942A0706|40 45|doses
P03175942A0706|64 68|dams
P03175942A0706|92 102|experiment
P03175942A0706|127 132|doses
P03178097A0000|4 22|CHARGE association
P03178097A0000|28 38|collection
P03178097A0000|42 53|multisystem
P03178097A0000|65 74|anomalies
P03178097A0000|93 100|atresia
P03178161A0000|11 16|brush
P03178161A0000|29 38|screening
P03178161A0000|58 78|blood concentrations
P03178161A0000|82 96|micronutrients
P03178161A0000|98 107|vitamin A
P03178161A0000|109 110|E
P03178161A0000|112 115|B12
P03178161A0000|123 127|acid
P03178161A0000|132 142|methionine
P03178161A0000|160 166|adults
P03178161A0000|170 174|risk
P03178161A0000|190 199|carcinoma
P03178161A0000|201 203|EC
P03178161A0000|208 216|Transkei
P03178161A0000|221 227|Ciskei
P03178161A0000|229 244|Southern Africa
P03178626A0137|0 8|Aviators
P03178626A0137|24 35|Attack Wing
P03178626A0137|37 44|Pacific
P03178626A0137|67 74|results
P03178626A0137|95 108|aircraft type
P03179496T0000|0 10|Evaluation
P03179496T0000|31 59|modified-hemoglobin solution
P03179496T0000|79 84|fluid
P03179496T0000|89 113|blood volume replacement
P03180595A1040|8 33|gallbladder visualization
P03180595A1040|38 47|reduction
P03180595A1040|51 68|ejection fraction
P03180595A1040|100 110|indicators
P03180595A1040|122 129|disease
P03181276A0422|3 17|micrograms PAF
P03181276A0422|21 28|placebo
P03181276A0422|57 63|cavity
P03181276A0422|66 67|h
P03181276A0422|74 75|h
P03181276A0422|91 109|allergen challenge
P03182802A0278|0 3|Sci
P03182872A1122|0 4|Chem
P03183103A0000|11 26|MR examinations
P03183103A0000|40 46|cavity
P03183103A0000|61 68|sinuses
P03183103A0000|97 105|h period
P03183103A0000|121 131|volunteers
P03183127A0068|0 10|Comparison
P03183127A0068|49 67|imaging modalities
P03183127A0068|78 80|CT
P03183127A0068|82 93|myelography
P03183127A0068|95 114|CT ventriculography
P03183127A0068|120 142|CT myelocisternography
P03184267A0000|4 8|feed
P03184267A0000|24 40|broiler chickens
P03184267A0000|99 107|serotype
P03184267A0000|141 151|infections
P03184267A0000|175 183|chickens
P03184267A0000|188 202|food poisoning
P03184267A0000|206 212|humans
P03185322A1305|7 18|correlation
P03185322A1305|82 88|result
P03185322A1305|90 95|class
P03185322A1305|125 134|diagnosis
P03185322A1305|138 139|%
P03185322A1305|143 157|class-2 smears
P03185322A1305|191 200|dysplasia
P03185540T0000|0 7|Factors
P03185540T0000|29 42|transcription
P03185540T0000|56 70|RNA polymerase
P03185540T0000|75 87|purification
P03185540T0000|97 108|specificity
P03185540T0000|114 144|TATA box-promoter interactions
P03185540T0000|148 153|TFIID
P03186091T0000|0 6|Change
P03186091T0000|10 38|plasma cystyl aminopeptidase
P03186091T0000|40 51|oxytocinase
P03186091T0000|67 72|weeks
P03186091T0000|74 83|gestation
P03186091T0000|89 98|predictor
P03186091T0000|120 132|hypertension
P03186270T0001|13 22|diagnosis
P03190481A0292|4 8|test
P03190481A0292|28 36|esterase
P03190481A0292|41 53|quantitation
P03190481A0292|57 68|macrophages
P03190481A0292|79 85|number
P03190481A0292|91 113|infiltration area unit
P03190481A0292|130 137|abscess
P03190481A0292|155 166|correlation
P03190481A0292|188 194|number
P03190481A0292|198 209|macrophages
P03190481A0292|218 223|width
P03190481A0292|231 238|capsule
P03190914A0149|14 37|migration differentials
P03190914A0149|68 82|responsiveness
P03190914A0149|122 127|group
P03192537A0370|23 33|amino acid
P03192537A0370|41 49|sequence
P03192537A0370|64 69|HMG-I
P03192537A0370|70 71|Y
P03192537A0370|73 77|cDNA
P03192537A0370|110 129|amino acid sequence
P03192537A0370|139 144|HMG-I
P03192537A0370|179 190|amino acids
P03192537A0370|213 220|protein
P03192724A0000|14 31|style differences
P03192724A0000|38 50|drug abusers
P03192724A0000|71 75|Ryan
P03192724A0000|97 103|system
P03192724A0000|107 128|FIRO-B interpretation
P03192799T0000|0 9|Statement
P03192799T0000|17 33|American Academy
P03192799T0000|37 54|Implant Dentistry
P03192950A0566|0 4|Sera
P03192950A0566|48 53|women
P03192950A0566|62 72|TSH levels
P03192950A0566|91 96|range
P03194410A0771|3 14|UOxase mRNA
P03194410A0771|45 52|tissues
P03194410A0771|56 59|rat
P03194410A0771|72 90|tissue specificity
P03194410A0771|94 104|expression
P03194410A0771|113 124|UOxase gene
P03195167A0104|4 26|platelet adhesion rate
P03195167A0104|36 42|layers
P03195167A0104|70 79|valuation
P03195167A0104|87 105|haemocompatibility
P03195167A0104|113 140|basic-polymers polyurethane
P03195167A0104|142 145|PUR
P03195167A0104|148 165|polyvinylchloride
P03195167A0104|167 170|PVC
P03195167A0104|177 188|polystyrene
P03195167A0104|190 192|PS
P03195167A0104|218 231|test chambers
P03198436T0000|13 22|treatment
P03198436T0000|26 43|bladder carcinoma
P03198436T0000|55 65|cystectomy
P03198436T0000|83 90|iridium
P03198525A0164|11 24|feedlot trial
P03198525A0164|30 37|heifers
P03198525A0164|55 60|light
P03198525A0164|62 68|medium
P03198525A0164|79 85|weight
P03198525A0164|101 111|treatments
P03198525A0164|121 124|MGA
P03198525A0164|129 136|mg.hd-1
P03198525A0164|137 140|d-1
P03198525A0164|143 150|control
P03198525A0164|155 158|MGA
P03198525A0164|163 171|DEPO-MGA
P03198525A0164|175 176|d
P03198525A0164|197 202|ml/hd
P03198525A0164|217 226|mg MGA/hd
P03199043A0248|0 9|Existence
P03199043A0248|14 24|uniqueness
P03199043A0248|28 37|solutions
P03199043A0248|57 80|boundary value problems
P03199043A0248|105 109|case
P03199043A0248|119 144|permeability coefficients
P03199043A0248|149 164|transport rates
P03199043A0248|175 197|diffusion coefficients
P03199043A0248|208 218|resistance
P03199043A0248|227 236|constants
P03199436A1060|11 24|gene clusters
P03199436A1060|34 59|photosynthesis components
P03199436A1060|72 91|psbB-psbH-petB-petD
P03199436A1060|100 118|psbE-psbF clusters
P03200488A0439|4 11|results
P03200488A0439|35 38|TIQ
P03200488A0439|51 64|turnover rate
P03200488A0439|86 102|dopamine neurons
P03200488A0439|118 132|administration
P03200488A0439|144 150|period
P03200488A0439|154 158|mice
P03200844A1211|12 20|sequence
P03200844A1211|43 60|pore glycoprotein
P03200844A1211|74 84|similarity
P03200844A1211|108 116|proteins
P03200844A1211|143 151|features
P03200844A1211|157 163|member
P03200844A1211|171 177|family
P03200844A1211|189 207|pore glycoproteins
P03207975A0709|12 17|hours
P03207975A0709|24 38|administration
P03207975A0709|42 52|vitamin K1
P03207975A0709|54 75|plasma concentrations
P03207975A0709|83 90|vitamin
P03208493A0849|15 30|filtration rate
P03208493A0849|50 67|lithium clearance
P03208493A0849|78 79|%
P03209019A0662|17 35|promotion bioassay
P03209019A0662|37 43|groups
P03209019A0662|55 64|CD-1 mice
P03209019A0662|91 101|microliter
P03209019A0662|112 116|DMBA
P03209019A0662|122 127|mg/ml
P03209019A0662|132 139|acetone
P03209019A0662|154 159|weeks
P03209019A0662|188 192|week
P03209019A0662|198 211|test material
P03209019A0662|233 238|weeks
P03212551T0001|4 16|pathogenesis
P03212551T0001|20 29|Dupuytren
P03212551T0001|32 43|contracture
P03212929A0000|3 18|ELISA procedure
P03212929A0000|61 73|IgE response
P03212929A0000|77 81|dogs
P03212929A0000|85 114|Dirofilaria immitis infection
P03214709A0559|6 9|min
P03214709A0559|16 23|release
P03214709A0559|29 35|stress
P03214709A0559|50 78|plasma corticosterone levels
P03214709A0559|90 96|stress
P03214709A0559|121 126|group
P03214709A0559|163 168|group
P03216131A0559|9 16|isolate
P03216131A0559|20 40|Aeromonas hydrophila
P03216131A0559|60 71|enterotoxin
P03218714A0000|16 20|girl
P03218714A0000|36 61|Dandy-Walker malformation
P03218714A0000|63 66|DWM
P03218714A0000|84 93|tetralogy
P03218714A0000|97 103|Fallot
P03218714A0000|105 108|TOF
P03219107A0212|4 13|incidence
P03219107A0212|32 43|convulsions
P03219107A0212|55 61|babies
P03219107A0212|80 86|births
P03220077A0274|11 19|survival
P03220077A0274|59 63|time
P03220077A0274|71 76|years
P03223123T0001|9 19|evaluation
P03223123T0001|31 38|methods
P03223123T0001|54 61|markers
P03223123T0001|71 79|maturity
P03223123T0001|92 97|fluid
P03227288A0542|10 17|infants
P03227288A0542|36 40|loss
P03227288A0542|69 75|months
P03227288A0542|86 89|age
P03227568T0001|0 7|Variety
P03227568T0001|11 15|cows
P03227568T0001|20 25|sires
P03227568T0001|39 44|types
P03227568T0001|48 63|dermatoglyphics
P03227568T0001|65 73|patterns
P03227568T0001|94 100|mirror
P03227568T0001|104 110|cattle
P03228518A0339|44 51|samples
P03228518A0339|63 71|Academic
P03228518A0339|73 96|Personal Responsibility
P03228518A0339|123 133|dimensions
P03228785A1047|0 8|Recovery
P03228785A1047|36 47|improvement
P03228785A1047|71 81|parameters
P03228785A1047|98 102|week
P03228785A1047|139 143|area
P03228785A1047|175 180|weeks
P03228785A1047|191 194|cm2
P03228785A1047|196 197|p
P03228785A1047|220 227|control
P03228785A1047|230 238|ABSTRACT
P03228785A1047|256 261|WORDS
P03229917A0099|30 39|resection
P03229917A0099|65 82|remnant infection
P03232410A1467|40 45|cases
P03232410A1467|49 60|lung cancer
P03232410A1467|83 87|year
P03232410A1467|109 116|smoking
P03233862T0000|0 20|Neuromyelitis optica
P03233862T0000|30 38|syndrome
P03233862T0000|61 70|sclerosis
P03234790T0001|0 6|Effect
P03234790T0001|14 21|methods
P03234790T0001|35 49|administration
P03234790T0001|53 75|methyl isobutyl ketone
P03234790T0001|83 91|toxicity
P03235487A0404|0 13|Incorporation
P03235487A0404|28 57|M sodium dihydrogen phosphate
P03235487A0404|65 80|sugar solutions
P03235487A0404|95 103|decrease
P03235487A0404|111 121|shelf-life
P03235487A0404|125 134|diltiazem
P03237446A0377|0 4|None
P03237446A0377|16 23|history
P03237446A0377|41 51|infections
P03237446A0377|74 85|lymphopenia
P03239106A0856|15 33|phosphorus content
P03239106A0856|41 45|diet
P03239106A0856|59 71|reabsorption
P03239106A0856|75 82|calcium
P03239106A0856|87 96|magnesium
P03243027T0000|21 31|regulation
P03243027T0000|45 68|protein gene expression
P03243027T0000|76 87|development
P03243027T0000|91 115|Dictyostelium discoideum
P03243920A0591|24 65|plasma concentration-effect relationships
P03243920A0591|100 108|modeling
P03243920A0591|120 130|regression
P03246999A0483|4 12|increase
P03246999A0483|16 26|amplitudes
P03246999A0483|34 40|b-wave
P03246999A0483|52 69|adaptation period
P03246999A0483|105 113|subjects
P03246999A0483|122 130|controls
P03249792A0241|9 16|factors
P03249792A0241|25 36|development
P03249792A0241|50 64|symptomatology
P03249792A0241|72 88|group activities
P03249792A0241|97 101|role
P03249792A0241|105 119|group dynamics
P03249792A0241|130 144|stress factors
P03249792A0241|170 179|psychoses
P03249792A0241|200 214|manifestations
P03249840A0411|0 21|Baseline measurements
P03249840A0411|43 49|volume
P03249840A0411|55 56|s
P03249840A0411|58 62|FEV1
P03249840A0411|74 92|airway conductance
P03249840A0411|94 98|SGaw
P03249840A0411|120 124|dose
P03249840A0411|128 137|carbachol
P03249840A0411|150 161|% reduction
P03249840A0411|165 169|SGaw
P03249840A0411|171 175|PD35
P03249840A0411|186 197|% reduction
P03249840A0411|201 205|FEV1
P03249840A0411|207 211|PD20
P03249840A0411|233 238|entry
P03249840A0411|250 257|subject
P03249840A0411|268 275|smoking
P03251210A0981|5 13|children
P03251210A0981|19 22|BGC
P03251210A0981|44 55|development
P03251210A0981|61 75|calcifications
P03251210A0981|113 118|forms
P03251210A0981|133 144|dysfunction
P03253219T0000|7 14|voltage
P03253219T0000|39 44|leads
P03253219T0000|48 76|anthracycline cardiomyopathy
P03253219T0000|89 94|study
P03256150A1866|4 11|results
P03256150A1866|38 50|requirements
P03256150A1866|55 59|task
P03257146A1037|6 13|results
P03257146A1037|28 33|CSFHU
P03257146A1037|47 64|neutrophil counts
P03257146A1037|83 89|number
P03257146A1037|94 102|maturity
P03257146A1037|110 138|marrow neutrophil precursors
P03257146A1037|147 152|types
P03257146A1037|156 165|childhood
P03257146A1037|174 185|neutropenia
P03258069A0000|4 12|purposes
P03258069A0000|21 26|study
P03258069A0000|50 56|effect
P03258069A0000|65 74|intensity
P03258069A0000|80 89|frequency
P03258069A0000|116 133|nerve stimulation
P03258069A0000|147 165|acupuncture points
P03258069A0000|182 196|pain threshold
P03258069A0000|213 218|wrist
P03258069A0000|243 250|changes
P03258069A0000|254 260|effect
P03258069A0000|266 270|time
P03259437A0140|16 50|neonates serum alpha-amylase value
P03259437A0140|78 91|starch method
P03259437A0140|104 105|%
P03259437A0140|122 130|controls
P03259437A0140|141 146|value
P03259437A0140|165 169|IU/l
P03259437A0140|182 190|neonates
P03259437A0140|217 218|p
P03259437A0140|246 251|value
P03259437A0140|269 273|IU/l
P03259437A0140|291 299|neonates
P03261005A0216|0 7|Records
P03261005A0216|14 22|children
P03261005A0216|28 32|AIDS
P03261005A0216|49 56|complex
P03261005A0216|93 102|care unit
P03261005A0216|125 132|failure
P03261005A0216|155 161|period
P03261223A0644|9 17|patients
P03261223A0644|41 54|disease group
P03261223A0644|76 81|SPECT
P03261223A0644|92 95|TCT
P03261331A0563|0 5|SPECT
P03261331A0563|22 25|aid
P03261331A0563|33 42|diagnosis
P03261331A0563|46 67|AIDS dementia complex
P03261331A0563|91 104|understanding
P03261331A0563|131 141|mechanisms
P03261331A0563|150 158|disorder
P03263357A0112|35 47|relationship
P03263357A0112|70 76|rhythm
P03263357A0112|80 96|body temperature
P03263357A0112|106 116|variations
P03263357A0112|120 141|plasma concentrations
P03263357A0112|145 149|iron
P03263357A0112|151 155|zinc
P03263357A0112|169 185|leukocyte counts
P03263357A0112|191 209|plasma interleukin
P03263357A0112|213 217|IL-1
P03263357A0112|219 227|activity
P03263465T0000|11 20|MHC class
P03263465T0000|23 28|genes
P03263465T0000|30 35|H-2Dq
P03263465T0000|40 45|H-2Lq
P03263465T0000|88 93|H-2Ld
P03263465T0000|103 108|genes
P03263465T0000|143 151|antigens
P03264073A0224|11 22|derivatives
P03264073A0224|38 44|series
P03264073A0224|82 90|activity
P03264073A0224|129 140|albino mice
P03264073A0224|157 165|activity
P03264073A0224|169 180|albino rats
P03264299A0679|13 17|mice
P03264299A0679|32 40|activity
P03264299A0679|55 66|macrophages
P03264299A0679|86 89|day
P03264299A0679|95 99|days
P03264299A0679|106 118|ip injection
P03264886A0000|8 18|population
P03264886A0000|29 37|children
P03264886A0000|46 51|years
P03264886A0000|55 58|age
P03264886A0000|62 68|medium
P03264886A0000|75 80|towns
P03264886A0000|91 96|areas
P03264886A0000|114 121|Germany
P03264886A0000|131 132|%
P03264886A0000|134 139|cases
P03264886A0000|143 148|croup
P03264886A0000|177 190|months period
P03264886A0000|211 221|physicians
P03267732A0788|18 37|Ga-fbg scintigraphy
P03267732A0788|55 61|method
P03267732A0788|124 131|thrombi
P03267732A0788|155 161|effect
P03267732A0788|179 186|therapy
P03268555T0000|9 19|assessment
P03268555T0000|27 43|biocompatibility
P03268555T0000|54 63|materials
P03268555T0000|69 92|millipore filter method
P03270085A0382|0 14|Hypomagnesemia
P03270085A0382|26 43|magnesium wasting
P03270085A0382|51 57|kidney
P03274204A0642|0 12|Dentalplaque
P03274204A0642|49 54|index
P03274204A0642|68 77|dentition
P03274204A0642|111 130|cent alkaline fuxin
P03275867A0187|0 4|GRFI
P03275867A0187|14 23|sequences
P03275867A0187|51 59|elements
P03275867A0187|61 70|silencers
P03275867A0187|86 108|mating type loci HML E
P03275867A0187|113 118|HMR E
P03275867A0187|150 158|sequence
P03275867A0187|160 163|UAS
P03275867A0187|178 191|transcription
P03275867A0187|199 214|MAT alpha genes
P03275873A0379|4 11|effects
P03275873A0379|21 30|mutations
P03275873A0379|34 48|RNA polymerase
P03275873A0379|52 60|activity
P03275873A0379|91 98|ability
P03275873A0379|109 114|genes
P03275873A0379|140 150|resistance
P03275873A0379|157 169|transfection
P03275873A0379|192 197|cells
P03276246A0037|14 17|use
P03276246A0037|50 57|colloid
P03276246A0037|64 74|blood cell
P03276246A0037|76 83|TAC-WBC
P03276246A0037|97 107|evaluation
P03276246A0037|111 123|appendicitis
P03276924A0090|16 22|tumors
P03276924A0090|36 49|rearrangement
P03276924A0090|69 78|insertion
P03276924A0090|92 107|MoMuLV provirus
P03278829A0082|4 15|indications
P03278829A0082|24 27|use
P03278829A0082|76 85|candidate
P03278829A0082|93 103|tip grafts
P03278829A0082|126 133|tension
P03278829A0082|144 153|deformity
P03280021A1615|13 15|dT
P03280021A1615|17 25|affinity
P03280021A1615|52 59|buffers
P03280021A1615|78 84|M NaCl
P03280021A1615|106 112|M NaBr
P03280021A1615|117 150|measure alpha log Kobsd/alpha log
P03280021A1615|152 156|NaBr
P03280021A1615|187 192|value
P03280021A1615|202 205|T/O
P03280807A0000|0 9|Mutations
P03280807A0000|17 28|suf12 locus
P03280807A0000|85 96|suppressors
P03280807A0000|103 123|frameshift mutations
P03280807A0000|127 134|glycine
P03280807A0000|136 139|GGX
P03280807A0000|145 152|proline
P03280807A0000|154 157|CCX
P03280807A0000|159 165|codons
P03280807A0000|178 181|UGA
P03280807A0000|186 208|UAG nonsense mutations
P03280807A1447|4 12|behavior
P03280807A1447|16 32|suf12-null/SUF12
P03280807A1447|34 47|heterozygotes
P03280807A1447|63 68|suf12
P03280807A1447|114 119|suf12
P03280807A1447|136 147|suppression
P03280807A1447|193 201|proteins
P03280807A1447|214 223|variation
P03280807A1447|246 251|SUF12
P03280807A1447|253 261|activity
P03280912T0000|0 23|Antituberculosis agents
P03280946A0375|13 29|immunity protein
P03280946A0375|54 57|35S
P03280946A0375|78 86|proteins
P03280946A0375|99 108|minicells
P03280946A0375|118 121|cni
P03280946A0375|135 155|lac promoter control
P03280946A0375|170 174|gene
P03280946A0375|194 212|expression vectors
P03280946A0375|223 230|control
P03280946A0375|236 261|bacteriophage T7 promoter
P03282232A0743|0 10|Antibodies
P03282232A0743|24 38|fusion protein
P03282232A0743|55 65|DP1A clone
P03282232A0743|92 96|DP-I
P03282232A0743|108 119|immunoblots
P03282813A0794|24 29|range
P03282813A0794|33 36|QO2
P03282813A0794|38 55|oxygen extraction
P03282813A0794|71 79|patients
P03282813A0794|85 89|ARDS
P03282813A0794|102 110|patients
P03282813A0794|137 144|failure
P03282813A0794|146 147|r
P03282813A0794|160 165|slope
P03282813A0794|177 178|r
P03282813A0794|191 196|slope
P03282813A0794|206 207|p
P03283881A0216|7 15|patients
P03283881A0216|28 42|hypersecretion
P03283881A0216|54 62|evidence
P03283881A0216|72 84|inflammation
P03285764A0675|0 19|Hyperprolactinaemia
P03285764A0675|30 42|hypogonadism
P03285764A0675|58 70|neuropathies
P03285764A0675|81 89|stenoses
P03285764A0675|110 118|leakages
P03285764A0675|142 146|role
P03285764A0675|169 177|cofactor
P03285764A0675|190 202|consequences
P03285764A0675|243 250|factors
P03285764A0675|291 299|failures
P03286611A1198|0 4|Yang
P03286611A1198|9 11|H.
P03287597T0000|10 18|function
P03287597T0000|26 40|prostate gland
P03292076A0820|8 19|endotoxemia
P03292076A0820|86 98|permeability
P03292076A0820|105 113|tendency
P03292076A0820|136 147|circulation
P03292076A0820|172 178|degree
P03292076A0820|182 196|refractoriness
P03292076A0820|222 234|hemodynamics
P03292076A0820|239 262|eicosanoid biosynthesis
P03292082A0486|3 11|contrast
P03292082A0486|30 44|concentrations
P03292082A0486|57 65|patients
P03292082A0486|71 77|tumors
P03292082A0486|101 107|system
P03292082A0486|123 133|meningioma
P03292082A0486|141 153|glioblastoma
P03292082A0486|166 175|neurinoma
P03293844T0000|0 4|Diet
P03293844T0000|16 22|eczema
P03296019T0000|0 18|Time delay effects
P03296019T0000|34 47|bond strength
P03296019T0000|65 75|Silicoater
P03296212A0603|4 10|future
P03296212A0603|14 22|research
P03296212A0603|28 38|interferon
P03296212A0603|65 70|areas
P03296212A0603|72 79|Efforts
P03296212A0603|141 148|synergy
P03296212A0603|176 181|terms
P03296212A0603|186 191|order
P03296212A0603|215 224|potential
P03296212A0603|228 231|IFN
P03296212A0603|233 241|research
P03296212A0603|270 275|agent
P03296212A0603|287 294|disease
P03296212A0603|323 338|tumor debulking
P03296212A0603|356 365|diagnosis
P03296212A0603|379 388|community
P03296212A0603|414 421|history
P03296212A0603|430 438|diseases
P03296212A0603|460 469|potential
P03296212A0603|486 492|agents
P03296212A0603|537 543|agents
P03296254A0556|6 17|differences
P03296254A0556|34 43|latamoxef
P03296254A0556|70 79|elevation
P03296254A0556|83 99|prothrombin time
P03296254A0556|129 139|depression
P03296254A0556|143 149|factor
P03296254A0556|157 167|factor VII
P03297181A0127|17 25|subjects
P03297181A0127|47 52|doses
P03297181A0127|64 71|release
P03297181A0127|73 75|RR
P03297181A0127|77 94|quinidine sulfate
P03297181A0127|106 113|release
P03297181A0127|115 117|SR
P03297181A0127|119 138|quinidine bisulfate
P03297181A0127|152 156|dose
P03297181A0127|167 174|product
P03297181A0127|180 184|food
P03297181A0127|186 190|SR-F
P03298134A0000|5 11|report
P03298134A0000|32 36|work
P03298134A0000|42 60|interferon alfa-2b
P03298134A0000|62 70|Intron A
P03298134A0000|72 87|Schering-Plough
P03298134A0000|96 105|treatment
P03298134A0000|115 128|cell leukemia
P03298134A0000|130 133|HCL
P03300118A0392|0 15|Oxygen delivery
P03300118A0392|20 31|base excess
P03300118A0392|65 69|pigs
P03304015T0000|9 18|chemistry
P03304866T0001|0 17|Revascularization
P03304866T0001|58 67|osteotomy
P03305875T0000|7 15|orthoses
P03305875T0000|24 34|management
P03305875T0000|38 49|microstomia
P03306340A0537|20 26|spread
P03306340A0537|34 43|carcinoma
P03306340A0537|67 75|invasion
P03306340A0537|79 88|carcinoma
P03306340A0537|90 98|hardness
P03306340A0537|106 110|body
P03306340A0537|115 119|tail
P03306340A0537|121 132|obstruction
P03306340A0537|152 156|duct
P03306340A0537|171 186|pancreaticogram
P03308909A0485|10 17|enzymes
P03308909A0485|31 40|cartilage
P03309892A0637|16 27|observation
P03309892A0637|44 46|S.
P03309892A0637|53 58|genes
P03309892A0637|86 91|yeast
P03309892A0637|110 131|actin gene transcript
P03309892A0637|148 159|nucleotides
P03309892A0637|176 197|initiation start site
P03309892A0637|221 226|yeast
P03311954A0000|14 19|study
P03311954A0000|40 52|institutions
P03311954A0000|84 92|efficacy
P03311954A0000|97 103|safety
P03311954A0000|107 117|ranitidine
P03311954A0000|122 131|mg b.i.d.
P03311954A0000|136 146|ranitidine
P03311954A0000|151 159|mg nocte
P03311954A0000|167 176|treatment
P03311954A0000|180 199|reflux oesophagitis
P03312033A0501|0 11|Monotherapy
P03312033A0501|17 28|ceftazidime
P03312033A0501|84 103|combination therapy
P03312033A0501|109 118|cefazolin
P03312033A0501|123 133|tobramycin
P03312514A0756|4 11|N3 wave
P03312514A0756|19 23|SSEP
P03312514A0756|84 92|recovery
P03312514A0756|108 109|%
P03312514A0756|116 117|%
P03312514A0756|125 146|preischemia amplitude
P03312514A0756|170 177|animals
P03312514A0756|193 194|%
P03312514A0756|201 202|%
P03312514A0756|217 222|group
P03312514A0756|229 230|%
P03312514A0756|237 238|%
P03312514A0756|246 261|control animals
P03315359A0732|0 11|Proctoscopy
P03315359A0732|33 40|studies
P03315359A0732|61 65|part
P03315359A0732|69 79|evaluation
P03315359A0732|95 103|patients
P03315359A0732|130 141|suppuration
P03315359A0732|143 149|masses
P03315359A0732|159 167|fissures
P03317796A0853|7 20|control group
P03317796A0853|38 45|picture
P03317796A0853|56 70|osteoarthritis
P03319621A0707|3 11|contrast
P03319621A0707|20 24|mRNA
P03319621A0707|28 29|%
P03319621A0707|33 38|alpha
P03319621A0707|43 59|beta actin mRNAs
P03319621A0707|84 93|myoblasts
P03319621A0707|98 106|myotubes
P03319646T0000|0 21|Plasma renin activity
P03319646T0000|60 68|efficacy
P03319646T0000|72 86|chlorthalidone
P03319912A0000|0 10|Cephradine
P03319912A0000|15 17|mg
P03319912A0000|21 26|night
P03319912A0000|34 40|months
P03319912A0000|56 76|prophylactic measure
P03319912A0000|90 98|patients
P03319912A0000|102 110|mean age
P03319912A0000|116 121|years
P03319912A0000|133 140|history
P03319912A0000|161 167|months
P03319912A0000|193 199|median
P03319912A0000|205 213|episodes
P03319912A0000|217 226|frequency
P03319912A0000|234 241|dysuria
P03320875A2090|29 37|Supramid
P03320875A2090|51 57|record
P03320875A2090|67 87|tissue compatibility
P03320875A2090|92 102|resistance
P03320875A2090|106 115|infection
P03322829A0952|4 8|size
P03322829A0952|16 21|group
P03322829A0952|44 63|compliance category
P03322829A0952|71 74|use
P03322829A0952|82 96|digoxin marker
P03322829A0952|115 119|size
P03322829A0952|125 130|group
P03322829A0952|134 142|patients
P03322829A0952|172 173|%
P03322829A0952|194 198|dose
P03322829A0952|213 222|deviation
P03322829A0952|237 238|%
P03322829A0952|250 262|prescription
P03325081A0524|8 19|keratopathy
P03325081A0524|43 49|origin
P03325081A0524|95 106|keratopathy
P03325081A0524|108 111|PBK
P03325081A0524|133 138|cause
P03325081A0524|150 161|keratopathy
P03326381A0423|20 28|findings
P03326381A0423|53 72|C-peptide excretion
P03326381A0423|102 109|effects
P03326381A0423|154 160|action
P03326381A0423|168 173|drugs
P03326381A0423|196 204|pancreas
P03329716A0187|4 12|activity
P03329716A0187|20 41|EGF receptor promoter
P03329716A0187|62 73|E1A protein
P03329716A0187|78 97|receptor RNA levels
P03329716A0187|111 122|stimulation
P03329716A0187|128 141|phorbol ester
P03329716A0187|151 161|calf serum
P03330711T0000|22 30|activity
P03330711T0000|34 38|neem
P03330711T0000|40 61|Azadirachta indica A.
P03331525T0001|11 16|study
P03331525T0001|20 35|dentin adhesion
P03331525T0001|39 48|adhesives
P03331525T0001|59 77|urethane molecules
P03331525T0001|88 94|groups
P03331525T0001|98 108|isocyanate
P03331933T0048|3 17|Felix Lagrange
P03332022A1094|11 37|cysteine clustering region
P03332022A1094|55 61|region
P03332022A1094|69 74|c-raf
P03332022A1094|79 86|product
P03332022A1094|104 123|nucleotide sequence
P03332022A1094|134 160|cysteine clustering region
P03332022A1094|228 234|region
P03332022A1094|238 254|protein kinase C
P03332022A1094|280 297|cysteine clusters
P03332848A0000|27 41|Doppler probes
P03332848A0000|71 79|analysis
P03332848A0000|106 129|carotid artery stenosis
P03334950A0000|4 18|German Society
P03334950A0000|22 40|Pediatric Oncology
P03334950A0000|63 80|Cooperative Ewing
P03334950A0000|83 96|Sarcoma Study
P03334950A0000|98 102|CESS
P03334950A0000|125 136|combination
P03334950A0000|140 152|chemotherapy
P03334950A0000|179 186|control
P03334950A0000|192 199|surgery
P03334950A0000|207 216|radiation
P03335127A0176|4 11|program
P03335127A0176|42 47|BASIC
P03335127A0176|51 56|order
P03335127A0176|69 78|procedure
P03335398A0568|11 17|levels
P03335398A0568|21 37|immunoglobulin G
P03335398A0568|68 75|surface
P03335398A0568|83 86|NVS
P03335398A0568|93 105|immunization
P03335398A0568|107 135|passive transfer experiments
P03335444A0000|2 7|study
P03335444A0000|33 37|male
P03335444A0000|56 63|mixture
P03335444A0000|67 72|241Am
P03335444A0000|77 79|Pu
P03335651A0000|12 18|method
P03335651A0000|35 54|parameter weighting
P03335651A0000|67 76|resonance
P03335651A0000|78 80|MR
P03335651A0000|82 89|imaging
P03335651A0000|119 126|concept
P03335651A0000|142 153|sensitivity
P03335651A0000|165 173|approach
P03335651A0000|203 210|indexes
P03335651A0000|215 217|T1
P03335651A0000|219 221|T2
P03335651A0000|227 245|hydrogen weighting
P03335923A0257|11 19|patients
P03335923A0257|38 44|groups
P03335923A0257|73 85|presentation
P03335923A0257|106 116|volunteers
P03335923A0257|121 129|patients
P03335923A0257|152 170|reflux gastropathy
P03335923A0257|172 175|DRG
P03335923A0257|181 189|patients
P03335923A0257|205 211|ulcers
P03335923A0257|228 232|bulb
P03335923A0257|234 237|RUD
P03335923A0257|247 255|patients
P03335923A0257|261 269|Moynihan
P03335923A0257|272 279|disease
P03337024A0000|12 19|studies
P03337024A0000|40 57|pharmaco-dynamics
P03337024A0000|73 85|procainamide
P03337024A0000|109 113|dose
P03337024A0000|120 125|mg/kg
P03337024A0000|135 139|rate
P03337024A0000|146 152|mg/min
P03337024A0000|167 175|practice
P03337024A0000|204 211|testing
P03338154T0000|5 19|concentrations
P03338154T0000|40 57|trypsin inhibitor
P03338154T0000|74 82|patients
P03340548A1018|7 20|chicken liver
P03340548A1018|22 28|levels
P03340548A1018|32 47|chicken MT mRNA
P03340548A1018|72 78|metals
P03340548A1018|80 83|Cd2
P03340548A1018|86 89|Zn2
P03340548A1018|92 95|Cu2
P03340548A1018|99 114|glucocorticoids
P03340548A1018|119 137|lipopolysaccharide
P03340726A1103|5 14|histology
P03340726A1103|19 24|Evans
P03340726A1103|30 40|injections
P03340726A1103|54 73|barrier alterations
P03340726A1103|98 102|days
P03340726A1103|111 115|dose
P03340726A1103|122 124|Gy
P03340774A0328|11 20|estimates
P03340774A0328|31 37|organs
P03340774A0328|71 74|rad
P03340774A0328|88 90|Gy
P03340774A0328|125 133|estimate
P03340774A0328|142 145|rad
P03340774A0328|152 154|Gy
P03343730A0486|14 25|association
P03343730A0486|36 50|family history
P03343730A0486|72 74|pH
P03343730A0486|105 127|calcium stone patients
P03344586T0000|0 16|New technologies
P03344586T0000|20 29|diagnosis
P03344586T0000|34 48|classification
P03344586T0000|52 62|malignancy
P03344812A0924|17 21|data
P03344812A0924|40 42|BP
P03344812A0924|47 62|HR measurements
P03344812A0924|106 113|factors
P03344812A0924|151 158|factors
P03344812A0924|192 197|state
P03344812A0924|212 214|BP
P03344812A0924|219 228|HR values
P03344812A0924|256 261|cycle
P03344812A0924|266 272|animal
P03344812A0924|297 306|influence
P03344812A0924|326 333|ranking
P03344812A0924|341 351|individual
P03344812A0924|354 356|BP
P03344812A0924|361 370|HR levels
P03344812A0924|382 392|population
P03345706A0561|4 15|correlation
P03345706A0561|24 29|PaCO2
P03345706A0561|34 39|PtcO2
P03345706A0561|43 46|RDS
P03345706A0561|81 90|judgement
P03346157A0000|18 23|times
P03346157A0000|42 51|ABCC/RERF
P03346157A0000|65 77|examinations
P03346157A0000|83 101|Adult Health Study
P03346157A0000|103 106|AHS
P03346157A0000|108 116|subjects
P03346157A0000|156 165|exposures
P03346157A0000|177 183|x-rays
P03346157A0000|204 216|institutions
P03346157A0000|228 232|RERF
P03346157A0000|236 241|order
P03346157A0000|258 265|numbers
P03346157A0000|269 281|examinations
P03346157A0000|300 305|doses
P03346210A0000|14 27|growth factor
P03346210A0000|29 32|EGF
P03346210A0000|34 42|receptor
P03346210A0000|69 101|protein tyrosine kinase activity
P03346210A0000|137 166|self-phosphorylation reaction
P03346210A0000|177 191|EGF activation
P03348382A0785|15 22|ouabain
P03348382A0785|48 52|HCO3
P03348382A0785|54 63|secretion
P03351478A0371|10 17|regions
P03351478A0371|28 32|runs
P03351478A0371|44 47|% C
P03351478A0371|53 65|% G residues
P03352254A0203|18 27|structure
P03352254A0203|38 48|prediction
P03352254A0203|76 82|vowels
P03352254A0203|95 104|syllables
P03352439T0000|6 35|cord abduction rehabilitation
P03352439T0000|57 68|anastomosis
P03352727T0000|0 2|UK
P03352727T0000|5 18|biotechnology
P03352727T0000|27 38|specialists
P03352947T0001|2 6|case
P03352947T0001|23 30|complex
P03352947T0001|32 39|ARC/LAS
P03352947T0001|46 59|health worker
P03354295A0157|8 14|spread
P03354295A0157|31 39|patients
P03354295A0157|43 44|%
P03354295A0157|62 70|serum Tg
P03354295A0157|87 99|micrograms/l
P03354341A0177|15 30|filtration rate
P03354341A0177|51 62|plasma flow
P03354341A0177|93 109|clearance method
P03354341A0177|132 140|infusion
P03354341A0177|144 150|inulin
P03354341A0177|174 178|acid
P03355122A0238|10 14|meal
P03355122A0238|26 32|potato
P03355122A0238|34 55|plasma glucose levels
P03355122A0238|86 89|min
P03355122A0238|113 119|levels
P03355122A0238|127 128|h
P03359860A0000|4 13|relations
P03359860A0000|62 77|characteristics
P03359860A0000|85 95|aggression
P03359860A0000|97 104|anxiety
P03359860A0000|106 121|undercompliance
P03359860A0000|134 138|mood
P03359860A0000|144 154|adjustment
P03359860A0000|177 180|use
P03359860A0000|184 188|data
P03359860A0000|210 237|New York Longitudinal Study
P03360667A0000|16 22|effect
P03360667A0000|26 34|altitude
P03360667A0000|49 55|growth
P03360667A0000|60 71|development
P03360667A0000|79 85|groups
P03360667A0000|113 118|youth
P03360667A0000|144 150|status
P03360667A0000|162 170|grouping
P03360667A0000|186 195|sea level
P03360667A0000|197 198|n
P03360667A0000|206 214|subjects
P03360667A0000|217 229|mid-altitude
P03360667A0000|231 232|n
P03360667A0000|240 248|subjects
P03360667A0000|260 268|altitude
P03360667A0000|270 271|n
P03360667A0000|279 287|subjects
P03360948A0477|12 15|CAP
P03360948A0477|25 34|variables
P03360948A0477|57 65|behavior
P03360948A0477|81 93|relationship
P03360948A0477|119 122|CAP
P03360948A0477|131 139|MHI Loss
P03360948A0477|143 177|Behavioral/Emotional Control scale
P03361653A0459|21 27|system
P03361653A0459|40 60|contour digitization
P03361653A0459|92 103|limitations
P03361653A0459|131 138|objects
P03366720A1335|7 13|change
P03366720A1335|44 55|utilization
P03366720A1335|87 91|acid
P03366720A1335|106 116|metabolism
P03366720A1335|120 127|glucose
P03366720A1335|132 142|glycolysis
P03366864A0099|4 13|skin site
P03366864A0099|54 62|segments
P03366864A0099|70 78|catheter
P03366864A0099|94 99|blood
P03368701A0113|21 32|reliability
P03368701A0113|47 60|arteriography
P03368701A0113|72 77|place
P03368701A0113|81 87|choice
P03368701A0113|106 124|imaging techniques
P03370815T0000|6 15|detection
P03370815T0000|50 60|test serum
P03370815T0000|68 78|radioassay
P03370815T0000|82 93|vitamin B12
P03371139A0829|11 16|group
P03371139A0829|44 52|material
P03371139A0829|76 82|groups
P03371806A0000|11 26|data processing
P03371806A0000|28 31|EDP
P03371806A0000|33 50|latex immunoassay
P03371806A0000|76 92|acid phosphatase
P03371806A0000|112 117|serum
P03371806A0000|138 145|species
P03371806A0000|150 170|organ identification
P03371806A0000|188 194|stains
P03371894A0355|0 19|Vimentin positivity
P03371894A0355|71 81|components
P03372422A0558|4 23|maximum deflections
P03372422A0558|27 32|phase
P03372422A0558|40 42|Ar
P03372422A0558|47 49|N2
P03372422A0558|68 73|phase
P03372422A0558|78 84|slopes
P03372422A0558|111 119|position
P03372422A0558|145 170|tracer gas concentrations
P03372422A0558|182 187|lungs
P03373755T0001|7 19|developments
P03373755T0001|23 28|drugs
P03373755T0001|45 52|factors
P03373755T0001|68 73|ulcer
P03373755T0001|84 92|efficacy
P03373755T0001|97 105|problems
P03373755T0001|107 134|gastrin receptor blockaders
P03375184A0000|4 26|spermicide nonoxynol-9
P03375184A0000|32 38|member
P03375184A0000|55 61|series
P03375184A0000|65 88|alkylphenol-ethoxylates
P03375184A0000|90 108|polyethoxyethanols
P03375184A0000|121 141|formula C9H19-C6H6-O
P03375184A0000|143 150|CH2CH2O
P03375184A0000|151 163|n-1 CH2CH2OH
P03377864A0000|16 22|fields
P03377864A0000|34 43|diffusion
P03377864A0000|58 67|particles
P03377864A0000|71 80|solutions
P03377864A0000|93 106|Lorentz force
P03377864A0000|111 125|Maxwell stress
P03377891A0652|14 25|disturbance
P03377891A0652|50 67|life stress group
P03377891A0652|96 106|elevations
P03377891A0652|121 135|severity index
P03377891A0652|143 163|Symptom Checklist-90
P03377891A0652|168 178|elevations
P03377891A0652|182 194|somatization
P03377891A0652|232 243|sensitivity
P03377891A0652|245 255|depression
P03377891A0652|257 264|anxiety
P03377891A0652|269 291|psychoticism subscales
P03378994T0000|8 22|administration
P03378994T0000|26 40|sodium cyanate
P03378994T0000|54 70|extraction ratio
P03378994T0000|74 78|dogs
P03379058A0188|0 21|Nucleotide sequencing
P03379058A0188|42 61|E1 alpha cDNA clone
P03379058A0188|70 80|base pairs
P03379058A0188|82 84|bp
P03379058A0188|89 95|length
P03379058A0188|109 122|reading frame
P03379058A0188|131 133|bp
P03379058A0188|156 162|region
P03379058A0188|170 172|bp
P03380547A0169|0 3|SPA
P03380547A0169|9 18|PAG sites
P03380547A0169|39 47|aversion
P03381039A0364|3 11|contrast
P03381039A0364|17 20|MAN
P03381039A0364|47 59|distribution
P03381039A0364|68 73|range
P03381039A0364|101 107|micron
P03381039A0364|114 121|maximum
P03381039A0364|129 135|micron
P03382310A0903|9 22|technetium Tc
P03382310A0903|37 42|scans
P03382310A0903|46 54|patients
P03382310A0903|83 98|polyarthralgias
P03382310A0903|122 133|arthropathy
P03382310A0903|149 169|management decisions
P03382310A0903|197 205|outcomes
P03382772A0319|0 18|Practical interest
P03382772A0319|27 34|studies
P03382772A0319|72 82|parameters
P03382772A0319|115 118|man
P03382772A0319|126 131|phase
P03382772A0319|134 140|trials
P03382855A0368|4 15|artery cuff
P03382855A0368|49 53|wrap
P03382855A0368|84 93|adhesions
P03382855A0368|120 127|picture
P03383897A0189|18 24|action
P03383897A0189|32 49|radiation therapy
P03383897A0189|89 95|effect
P03383897A0189|99 111|leukopoiesis
P03383897A0189|147 157|conditions
P03383897A0189|165 173|patients
P03383897A0189|177 183|course
P03383897A0189|187 196|treatment
P03384033A0155|10 15|units
P03384033A0155|41 47|motion
P03384033A0155|56 58|Hz
P03384033A0155|64 68|cm/s
P03384033A0155|77 78|%
P03384033A0155|102 115|otolith input
P03384033A0155|130 131|%
P03384033A0155|163 168|input
P03384033A0155|186 187|%
P03384033A0155|207 217|modalities
P03384272A0145|17 25|location
P03384272A0145|30 34|size
P03384272A0145|42 46|mass
P03384272A0145|55 60|range
P03384272A0145|73 86|presentations
P03384272A0145|110 116|lesion
P03387665A0000|4 15|development
P03387665A0000|20 32|distribution
P03387665A0000|36 47|Trypanosoma
P03387665A0000|60 67|T vivax
P03387665A0000|72 80|T brucei
P03387665A0000|88 92|skin
P03387665A0000|96 101|goats
P03387665A0000|125 132|animals
P03387665A0000|157 185|Glossina morsitans centralis
P03390074A0000|0 19|Electroglottography
P03390074A0000|46 55|technique
P03390074A0000|79 89|assessment
P03390074A0000|104 115|dysfunction
P03395009A1750|12 20|analysis
P03395009A1750|28 35|degrees
P03395009A1750|56 72|cord compression
P03395009A1750|90 102|group-1 dogs
P03395009A1750|130 136|ratios
P03395009A1750|171 180|diameters
P03395009A1750|206 219|cord sections
P03395009A1750|225 234|locations
P03395009A1750|243 246|T12
P03395009A1750|250 252|L1
P03395009A1750|266 269|T11
P03395009A1750|271 277|T11-12
P03395009A1750|279 283|L1-2
P03395009A1750|289 291|L2
P03395009A1750|297 303|region
P03395009A1750|316 328|intervention
P03395164A0000|20 27|effects
P03395164A0000|41 53|compound WEB
P03395164A0000|59 61|FU
P03395249A1044|18 29|examination
P03395249A1044|52 65|proliferation
P03395249A1044|69 73|type
P03395249A1044|77 88|pneumocytes
P03395249A1044|92 96|dams
P03395249A1044|101 114|proliferation
P03395249A1044|131 136|cells
P03395249A1044|166 177|development
P03395249A1044|181 189|neonates
P03395249A1044|191 199|ABSTRACT
P03395249A1044|217 222|WORDS
P03396437A0321|10 18|problems
P03396437A0321|43 50|strains
P03396628A0207|11 29|observation period
P03396628A0207|40 45|weeks
P03396628A0207|61 66|spots
P03396628A0207|80 89|ventricle
P03396628A0207|93 104|BALB/c mice
P03396628A0207|134 139|weeks
P03396628A0207|149 153|mice
P03396628A0207|157 158|%
P03396628A0207|177 186|incidence
P03396628A0207|204 209|spots
P03396628A0207|231 236|weeks
P03396628A0207|247 251|mice
P03396628A0207|255 256|%
P03398433T0001|4 9|state
P03398433T0001|17 22|liver
P03398433T0001|38 43|forms
P03398433T0001|61 70|infection
P03398714A0594|15 17|RH
P03398714A0594|27 28|%
P03398714A0594|41 50|solvation
P03398714A0594|58 72|peroxy radical
P03398714A0594|99 106|radical
P03398714A0594|125 153|propagation transition state
P03398823A0459|4 11|effects
P03398823A0459|29 43|administration
P03398823A0459|51 65|mg/kg p-xylene
P03398823A0459|69 76|toluene
P03398823A0459|95 97|hr
P03398823A0459|109 115|effect
P03398823A0459|127 135|p-xylene
P03398823A0459|157 160|min
P03398823A0459|164 171|removal
P03398823A0459|181 189|exposure
P03400694A0245|0 8|PATIENTS
P03400694A0245|13 20|METHODS
P03400694A0245|22 34|Thallium-201
P03400694A0245|46 58|scintigraphy
P03400694A0245|76 80|rest
P03400694A0245|96 101|mg/kg
P03400694A0245|114 126|dipyridamole
P03400694A0245|139 146|minutes
P03400694A0245|153 161|patients
P03400694A0245|167 178|sarcoidosis
P03401060A0000|5 14|melanomas
P03402183A0171|4 13|TA muscle
P03402183A0171|35 40|forms
P03402183A0171|63 75|contractions
P03402183A0171|99 111|contractions
P03402183A0171|113 116|MVC
P03402183A0171|123 126|MVC
P03402183A0171|132 143|circulation
P03402183A0171|178 190|contractions
P03402183A0171|199 201|Hz
P03402183A0171|215 234|voltage stimulation
P03402183A0171|263 275|contractions
P03402183A0171|281 292|circulation
P03403313A0298|20 33|control rates
P03403313A0298|40 45|years
P03403313A0298|60 76|treatment groups
P03403313A0298|103 111|excision
P03403313A0298|121 122|%
P03403313A0298|133 141|excision
P03403313A0298|161 178|radiation therapy
P03403313A0298|182 183|%
P03403313A0298|195 203|excision
P03403313A0298|213 214|%
P03403412A0000|4 11|effects
P03403412A0000|24 32|implants
P03403412A0000|36 40|rate
P03403412A0000|42 53|composition
P03403412A0000|68 78|efficiency
P03403412A0000|82 88|growth
P03403412A0000|115 124|fed diets
P03403412A0000|136 142|forage
P03403412A0000|147 160|grain content
P03403480A0299|10 20|suspension
P03403480A0299|43 49|change
P03403480A0299|67 80|configuration
P03403480A0299|88 106|femur middiaphysis
P03403480A0299|133 141|diameter
P03403480A0299|145 146|%
P03403480A0299|172 183|alterations
P03403480A0299|196 200|area
P03403480A0299|202 209|density
P03403480A0299|211 218|mineral
P03403480A0299|224 247|collagen concentrations
P03403826T0000|86 98|measurements
P03403826T0000|102 119|stenosis severity
P03403826T0000|123 133|comparison
P03403826T0000|150 158|analysis
P03403826T0000|175 188|cineangiogram
P03403826T0000|212 224|flow reserve
P03403826T0000|229 278|exercise/redistribution thallium-201 scintigraphy
P03404334T0000|0 13|Water content
P03404334T0000|18 45|equilibrium water partition
P03404334T0000|58 67|cartilage
P03404495A0172|0 22|Thyroid function tests
P03404495A0172|45 55|admissions
P03406054A0351|0 4|Data
P03406054A0351|12 32|line spread function
P03406054A0351|34 37|LSF
P03406054A0351|62 67|image
P03406054A0351|77 79|mm
P03406054A0351|85 89|slit
P03406054A0351|98 106|tungsten
P03406054A0351|142 151|isocentre
P03406054A0351|155 160|front
P03406054A0351|166 177|polystyrene
P03407676A0585|8 17|infection
P03407843T0000|0 6|Papers
P03407843T0000|14 21|Society
P03407843T0000|44 51|Surgery
P03413681A0659|9 22|heart disease
P03413681A0659|24 27|age
P03413681A0659|44 49|years
P03413681A0659|59 63|fact
P03413681A0659|73 80|patient
P03413681A0659|87 92|woman
P03413681A0659|110 120|predictors
P03413681A0659|137 145|function
P03413890T0001|0 9|Prognosis
P03413890T0001|13 18|Bowen
P03413890T0001|21 28|disease
P03413890T0001|58 64|region
P03417104A0536|20 27|results
P03417104A0536|41 57|chlorphentermine
P03417104A0536|91 107|stimulus effects
P03417104A0536|111 118|animals
P03417588T0000|0 6|Liquid
P03417588T0000|23 29|method
P03417588T0000|34 47|determination
P03417588T0000|51 64|citreoviridin
P03417588T0000|68 72|corn
P03417588T0000|77 81|rice
P03417668A1233|6 14|findings
P03417668A1233|29 48|autophosphorylation
P03417668A1233|52 58|Thr286
P03417668A1233|60 73|alpha subunit
P03417668A1233|79 85|Thr287
P03417668A1233|87 99|beta subunit
P03417668A1233|120 130|transition
P03417668A1233|134 147|CaM-kinase II
P03417668A1233|155 158|Ca2
P03417668A1233|172 176|form
P03418727A0992|25 36|penetration
P03418727A0992|67 79|chemotherapy
P03418727A0992|90 97|insight
P03418727A0992|107 117|myelopathy
P03418727A0992|138 148|treatments
P03420266A0000|4 15|interaction
P03420266A0000|19 28|radiation
P03420266A0000|33 45|hyperthermia
P03420266A0000|80 94|Dunning R3327G
P03420266A0000|105 119|adenocarcinoma
P03420266A0000|136 148|animal model
P03420266A0000|169 175|cancer
P03420324A0178|9 13|rats
P03420324A0178|41 50|following
P03420324A0178|58 59|%
P03420324A0178|66 68|N2
P03420324A0178|75 76|%
P03420324A0178|86 90|days
P03420324A0178|104 107|day
P03420324A0178|128 137|pregnancy
P03420324A0178|145 146|%
P03420324A0178|153 155|N2
P03420324A0178|162 163|%
P03420324A0178|174 189|h/day beginning
P03420324A0178|193 196|day
P03420324A0178|212 213|%
P03420324A0178|220 222|N2
P03420324A0178|249 252|day
P03420324A0178|261 264|day
P03420466A0000|4 13|incidence
P03420466A0000|17 34|cryptosporidiosis
P03420466A0000|44 52|children
P03420466A0000|71 79|staining
P03420466A0000|90 99|specimens
P03420466A0000|116 123|Kinyoun
P03421425A0878|6 14|patients
P03421425A0878|20 27|percent
P03421425A0878|40 54|hypothyroidism
P03421425A0878|83 97|determinations
P03423732A0341|0 8|Addition
P03423732A0341|12 22|sucralfate
P03423732A0341|26 32|De-Nol
P03423732A0341|45 55|increments
P03423732A0341|67 81|HCO3 secretion
P03423732A0341|100 101|%
P03423732A0341|108 109|%
P03423732A0341|140 153|HCO3 response
P03423732A0341|172 176|PGE2
P03423732A0341|178 184|dmPGE2
P03427474A0853|17 29|control rats
P03427474A0853|39 46|animals
P03427474A0853|60 68|aversion
P03427474A0853|84 98|concentrations
P03427474A0853|102 121|saccharin solutions
P03427613A0659|35 41|system
P03427613A0659|52 59|vessels
P03427613A0659|89 101|pineal organ
P03427613A0659|112 120|portions
P03427613A0659|128 133|brain
P03428084A0430|6 21|degrees stimuli
P03428084A0430|43 62|scalp distributions
P03428084A0430|71 92|pattern reversal P100
P03428084A0430|101 117|pattern onset C1
P03428084A0430|134 141|striate
P03428084A0430|175 182|origins
P03428274A0000|8 14|factor
P03428274A0000|20 25|NFIII
P03428274A0000|32 39|protein
P03428274A0000|45 55|HeLa cells
P03428274A0000|76 86|initiation
P03428274A0000|90 105|adenovirus type
P03428274A0000|109 112|Ad2
P03428274A0000|114 129|DNA replication
P03428274A0000|155 174|nucleotide sequence
P03428274A0000|182 188|origin
P03428274A0000|214 220|factor
P03428274A0000|223 239|recognition site
P03429306T0000|2 13|Golgi study
P03429306T0000|27 32|layer
P03429306T0000|49 55|cortex
P03429371A1051|17 38|cephalothin clearance
P03429371A1051|59 63|site
P03429371A1051|78 88|phagocytes
P03429371A1051|143 147|site
P03430221A1236|4 12|findings
P03430221A1236|34 41|context
P03430221A1236|51 61|properties
P03430221A1236|78 87|detectors
P03434347A0358|0 9|Mean rCBF
P03434347A0358|28 36|patients
P03434347A0358|41 46|weeks
P03434347A0358|53 60|surgery
P03434347A0358|80 84|side
P03436119A0000|22 32|tomography
P03436119A0000|57 77|bone mineral content
P03436119A0000|90 101|sensitivity
P03436119A0000|106 121|reproducibility
P03436529A1066|4 13|structure
P03436529A1066|21 29|enhancer
P03436529A1066|61 65|pair
P03436529A1066|93 114|oligodeoxynucleotides
P03436529A1066|137 143|region
P03436529A1066|152 164|nt positions
P03436529A1066|196 204|template
P03436529A1066|222 230|enhancer
P03436877A0950|0 2|Kf
P03436877A0950|3 4|c
P03436877A0950|9 11|CT
P03436877A0950|39 48|lung mass
P03436877A0950|74 84|reductions
P03436877A0950|88 108|lung mass % delta Kf
P03436877A0950|109 110|c
P03436877A0950|122 128|% mass
P03436877A0950|138 139|r
P03436877A0950|148 149|P
P03436877A0950|170 180|% delta CT
P03436877A0950|193 199|% mass
P03436877A0950|209 210|r
P03436877A0950|219 220|P
P03436877A0950|237 250|relationships
P03436877A0950|276 296|blocker pretreatment
P03436877A0950|298 306|ABSTRACT
P03436877A0950|324 329|WORDS
P03439248A0000|18 25|methods
P03439248A0000|35 47|dipyridamole
P03439248A0000|52 73|exercise thallium-201
P03439248A0000|85 102|perfusion imaging
P03439248A0000|136 151|artery stenosis
P03439248A0000|172 180|patients
P03439248A0000|205 219|artery disease
P03440780A0779|11 18|results
P03440780A0779|41 45|EDLF
P03440780A0779|56 82|vasoconstrictor properties
P03440780A0779|118 142|calcium entry mechanisms
P03440780A0779|162 173|differences
P03440780A0779|181 204|vasoconstrictor effects
P03440780A0779|208 213|EDLFs
P03440780A0779|219 226|respect
P03440780A0779|249 253|beds
P03441587A0000|0 8|Research
P03441587A0000|43 50|factors
P03441587A0000|58 63|serum
P03441587A0000|71 79|patients
P03441587A0000|83 88|means
P03441587A0000|96 101|tests
P03441587A0000|113 124|polystyrene
P03441587A0000|138 150|erythrocytes
P03441587A0000|160 167|results
P03441587A0000|199 205|method
P03441587A0000|209 218|reference
P03443144A0409|6 31|aspirin esterase activity
P03443144A0409|54 60|factor
P03443144A0409|84 91|aspirin
P03443144A0409|102 111|reactions
P03443566A0675|8 19|experiments
P03443566A0675|35 39|gain
P03443566A0675|44 62|gain-to-feed ratio
P03443566A0675|80 82|TR
P03443566A0675|87 89|CR
P03443573A0329|8 21|least-squares
P03443573A0329|52 70|longissimus muscle
P03443573A0329|88 91|fat
P03443573A0329|120 122|mg
P03443573A0329|142 143|g
P03443573A0329|147 153|tissue
P03443609A0000|4 8|role
P03443609A0000|26 46|fluid chromatography
P03443609A0000|48 51|SFC
P03443609A0000|65 74|technique
P03443609A0000|102 110|products
P03443609A0000|160 178|column methodology
P03446332A0831|0 13|Nitrofurazone
P03446332A0831|40 44|rise
P03446332A0831|48 50|LH
P03446332A0831|62 66|LHRH
P03448035T0000|8 14|tumors
P03448035T0000|18 27|pregnancy
P03449358T0001|16 21|study
P03449358T0001|25 38|polyarteritis
P03450438A0446|0 7|X2 test
P03450438A0446|14 30|Yates correction
P03450438A0446|34 38|need
P03450438A0446|65 71|method
P03451761A0215|8 22|baseline study
P03451761A0215|24 36|WPW syndrome
P03451761A0215|54 65|stimulation
P03451761A0215|85 90|sites
P03451761A0215|102 106|base
P03451761A0215|114 124|ventricles
P03451761A0215|130 133|RNV
P03452920T0001|0 3|Man
P03452920T0001|8 14|insect
P03452920T0001|16 20|past
P03457330A0271|4 12|patients
P03457330A0271|21 23|CA
P03457330A0271|28 33|assay
P03457330A0271|55 59|week
P03457330A0271|85 94|operation
P03459385T0000|0 7|Allergy
P03459385T0000|12 20|Tourette
P03459385T0000|23 31|syndrome
P03459736A0184|4 13|criterion
P03459736A0184|36 44|sessions
P03459736A0184|49 63|generalization
P03459736A0184|69 76|variety
P03459736A0184|80 85|pills
P03459736A0184|90 98|capsules
P03463537T0001|9 15|method
P03463537T0001|24 33|treatment
P03463537T0001|37 42|Class
P03463537T0001|55 64|anomalies
P03463537T0001|75 79|bite
P03463543A1613|0 8|Enoxacin
P03463543A1613|43 52|treatment
P03463543A1613|68 71|UTI
P03465957A1008|0 21|Mean fluorosis scores
P03466730A0210|10 22|dysfunctions
P03466730A0210|48 54|pupils
P03473253A0000|31 53|cohort mortality study
P03473253A0000|77 93|chemical workers
P03473253A0000|142 172|chloromethyl ether manufacture
P03473253A0000|184 198|U.S. companies
P03473379A0183|4 13|diagnosis
P03473379A0183|17 28|amyloidosis
P03473379A0183|67 79|gland biopsy
P03476002A0148|0 4|Hair
P03476002A0148|9 22|blood samples
P03476002A0148|41 50|vitamin C
P03476002A0148|54 77|placebo supplementation
P03476002A0148|105 114|intervals
P03476002A0148|136 142|months
P03478354A0436|11 16|herds
P03478354A0436|18 22|cows
P03478354A0436|36 48|d postpartum
P03478354A0436|56 69|corpus luteum
P03478354A0436|79 101|prostaglandin F2 alpha
P03479897A0961|13 17|hand
P03479897A0961|35 44|angle ANB
P03479897A0961|76 81|angle
P03479897A0961|96 104|relation
P03479897A0961|108 117|Class III
P03484075T0001|0 19|Emergency treatment
P03484075T0001|55 63|injuries
P03484894A0782|6 11|cases
P03484894A0782|13 21|isolates
P03484894A0782|56 63|biotype
P03484894A0782|78 85|biotype
P03484894A0782|109 117|biotypes
P03484894A0782|125 127|V.
P03485064A0135|2 7|total
P03485064A0135|15 29|EVS treatments
P03485064A0135|51 59|patients
P03486405A0341|23 30|portion
P03486405A0341|38 59|precursor polypeptide
P03486405A0341|89 94|exons
P03486405A0341|111 115|form
P03486405A0341|119 129|IL-1 alpha
P03486405A0341|164 169|exons
P03487348A0000|13 20|version
P03487348A0000|24 31|Kernell
P03487348A0000|47 52|model
P03487348A0000|69 91|afterhyperpolarization
P03487348A0000|93 96|AHP
P03488532A0235|22 28|report
P03488532A0235|50 60|resolution
P03488532A0235|64 80|dermatomal signs
P03488532A0235|85 93|symptoms
P03488532A0235|99 118|acyclovir treatment
P03491190A0233|4 17|detectability
P03491190A0233|25 32|defects
P03491190A0233|36 39|RCA
P03491190A0233|43 53|LAD region
P03491190A0233|60 61|%
P03491190A0233|81 86|scans
P03491190A0233|90 104|stress studies
P03493240T0000|14 24|properties
P03493240T0000|41 47|agents
P03493240T0000|67 72|drugs
P03494649A0472|23 32|challenge
P03494649A0472|49 57|increase
P03494649A0472|61 64|CBF
P03494649A0472|72 79|absence
P03494649A0472|87 93|change
P03494649A0472|97 101|MABP
P03499608A1054|6 10|data
P03499608A1054|42 50|reagents
P03499608A1054|55 77|heterozygote detection
P03499608A1054|91 100|diagnosis
P03499608A1054|107 134|beta-hydroxylase deficiency
P03499608A1054|161 166|cause
P03499608A1054|189 200|hyperplasia
P03499657A0000|0 11|Osteocalcin
P03499657A0000|13 35|serum bone-Gla protein
P03499657A0000|37 41|sBGP
P03499657A0000|44 70|serum alkaline phosphatase
P03499657A0000|72 75|sAP
P03499657A0000|89 120|hydroxyproline/creatinine ratio
P03499657A0000|122 141|uOH-Prol/creatinine
P03499657A0000|168 176|patients
P03499657A0000|190 209|hyperparathyroidism
P03499657A0000|211 215|PHPT
P03499657A0000|229 237|patients
P03499657A0000|243 257|hypercalcaemia
P03499657A0000|261 271|malignancy
P03499657A0000|273 275|HM
P03499822A0182|22 41|regression analysis
P03499822A0182|57 71|seropositivity
P03499822A0182|105 115|prevalence
P03499822A0182|119 130|hepatitis B
P03499822A0182|137 145|employee
P03499822A0182|148 155|country
P03499822A0182|159 164|birth
P03499822A0182|174 177|age
P03504971A0000|0 6|Hexsyn
P03504971A0000|14 27|Goodyear Tire
P03504971A0000|32 56|Rubber Company tradename
P03504971A0000|63 80|polyolefin rubber
P03504971A0000|115 132|% methylhexadiene
P03504971A0000|140 146|source
P03504971A0000|166 171|bonds
P03504971A0000|176 189|vulcanization
P03507689A0000|9 41|phage-plasmid expression vectors
P03507689A0000|64 81|pUC18/19 plasmids
P03507689A0000|111 114|DNA
P03507689A0000|116 121|ssDNA
P03507689A0000|123 129|origin
P03507689A0000|133 144|replication
P03507689A0000|150 166|bacteriophage f1
P03507689A0000|183 208|bacteriophage T7 promoter
P03507689A0000|220 243|beta-galactosidase gene
P03508698A0535|3 8|order
P03508698A0535|23 27|rate
P03508698A0535|29 43|finger flexors
P03508698A0535|45 48|jaw
P03508698A0535|58 67|adductors
P03508698A0535|73 89|triceps reflexes
P03508698A0535|128 134|groups
P03510185A0187|0 5|Natl.
P03513989A0580|8 15|ethanol
P03513989A0580|20 28|estrogen
P03513989A0580|53 68|UROD-deficiency
P03513989A0580|72 79|animals
P03513989A1149|25 33|disorder
P03513989A1149|67 78|disturbance
P03513989A1149|82 102|porphyrin metabolism
P03513989A1149|111 120|countries
P03513989A1149|134 141|insight
P03513989A1149|159 171|pathogenesis
P03513989A1149|200 207|effects
P03513989A1149|227 233|agents
P03515840A0000|30 35|cases
P03515840A0000|49 57|symptoms
P03515840A0000|72 81|granuloma
P03515840A0000|112 125|histiocytosis
P03515840A0000|139 146|sarcoma
P03515840A0000|163 169|months
P03515840A0000|175 180|years
P03515840A0000|188 202|generalization
P03515840A0000|207 212|death
P03516189A0406|4 12|patients
P03516189A0406|27 40|suxamethonium
P03516189A0406|45 57|mg kg-1 i.v.
P03517388A0763|26 37|CK-MB level
P03517388A0763|53 55|BC
P03517388A0763|57 59|BC
P03517388A0763|71 74|U/L
P03517388A0763|76 78|CC
P03517388A0763|90 93|U/L
P03517388A0763|95 96|p
P03520729A0381|12 19|changes
P03520729A0381|23 33|heart rate
P03520729A0381|35 46|body weight
P03520729A0381|52 65|plasma levels
P03520729A0381|69 83|renin activity
P03520729A0381|88 113|aldosterone concentration
P03522105A1011|5 36|trough serum TOB concentrations
P03522105A1011|58 63|death
P03522105A1011|77 83|levels
P03522105A1011|89 97|recovery
P03526279T0000|15 22|schools
P03526279T0000|26 38|nursing R.N.
P03528748A0414|5 20|maxicell system
P03528748A0414|23 30|protein
P03528748A0414|61 67|weight
P03531317A0930|20 24|loss
P03531317A0930|28 38|recessives
P03531317A0930|69 83|hypergeometric
P03531317A0930|103 108|model
P03531317A0930|112 118|Fisher
P03534581A0976|4 13|incidence
P03534581A0976|34 43|neoplasms
P03534581A0976|58 59|%
P03534581A0976|68 73|group
P03534581A0976|87 101|5-fluorouracil
P03534581A0976|103 114|doxorubicin
P03534581A0976|120 136|cyclophosphamide
P03534581A0976|160 173|control group
P03534581A0976|178 179|%
P03536682A0572|0 9|Ovulation
P03536682A0572|32 33|%
P03536682A0572|35 43|patients
P03536864A0000|12 16|work
P03537686A0099|10 14|size
P03537686A0099|19 28|placement
P03537686A0099|36 54|mutagenesis marker
P03537686A0099|60 85|supF suppressor tRNA gene
P03537686A0099|120 126|vector
P03537686A0099|153 162|frequency
P03537686A0099|178 187|mutations
P03537686A0099|212 224|transfection
P03537686A0099|238 243|cells
P03537686A0099|249 260|plasmid DNA
P03537686A0099|280 289|mutations
P03537686A0099|335 345|background
P03537711A0181|0 2|W.
P03537721A0491|7 15|analysis
P03537721A0491|28 53|recombination experiments
P03537721A0491|68 77|PEP4 gene
P03537721A0491|90 94|GAL4
P03537721A0491|98 112|chromosome XVI
P03537721A0876|13 25|observations
P03537721A0876|40 45|model
P03537721A0876|63 82|precursor molecules
P03537721A0876|101 124|PEP4 gene self-activate
P03537721A0876|136 149|yeast vacuole
P03537721A0876|191 201|hydrolases
P03537727A0243|4 8|poly
P03537727A0243|9 10|A
P03537727A0243|12 19|segment
P03537727A0243|27 30|RNA
P03537727A0243|91 98|protein
P03537727A0243|104 111|protein
P03540591A0330|9 20|translation
P03540591A0330|24 27|RNA
P03540591A0330|56 61|cDNAs
P03540591A0330|76 90|P0 transcripts
P03540591A0330|135 142|protein
P03540591A0330|175 188|reading frame
P03540853A0652|15 34|amino acid sequence
P03540853A0652|38 41|Mop
P03540853A0652|46 63|sequence homology
P03540853A0652|69 89|DNA binding proteins
P03541263A0368|12 22|techniques
P03541263A0368|52 59|control
P03541263A0368|63 71|diabetes
P03542945T0000|0 13|Ciprofloxacin
P03542945T0000|18 26|overview
P03542945T0000|38 49|experiences
P03543485A0069|22 32|mechanisms
P03543485A0069|48 55|changes
P03543485A0069|59 67|response
P03543485A0069|71 91|space flight effects
P03543936A0000|4 13|rho genes
P03543936A0000|51 57|family
P03543936A0000|75 83|homology
P03543936A0000|91 110|ras oncogene family
P03544858A0374|6 15|component
P03544858A0374|56 63|insulin
P03544858A0374|68 75|VO2 max
P03544858A0374|85 90|sexes
P03544858A0374|106 116|metabolism
P03544858A0374|121 136|HDL-cholesterol
P03544858A0374|141 148|females
P03544858A0374|153 158|males
P03545955A0751|4 17|glucose areas
P03545955A0751|32 41|ingestion
P03545955A0751|49 54|foods
P03545955A0751|61 66|Study
P03545955A0751|70 77|glucose
P03545955A0751|91 96|juice
P03545955A0751|102 109|sucrose
P03545955A0751|115 122|glucose
P03545955A0751|125 133|fructose
P03545955A0751|143 151|fructose
P03545955A0751|156 166|mmol X h/l
P03545955A0751|168 173|Study
P03545955A0751|177 184|glucose
P03545955A0751|198 203|juice
P03545955A0751|209 215|apples
P03545955A0751|225 236|apple juice
P03545955A0751|241 251|mmol X h/l
P03545955A0751|253 258|Study
P03545955A0751|262 269|glucose
P03545955A0751|276 285|ice cream
P03545955A0751|291 295|milk
P03545955A0751|305 312|lactose
P03545955A0751|317 327|mmol X h/l
P03545955A1378|4 26|serum insulin response
P03549045A0878|0 3|SCL
P03549045A0878|29 38|verapamil
P03549045A0878|44 56|sinus arrest
P03549045A0878|80 85|group
P03549045A0878|104 109|group
P03549045A0878|112 119|animals
P03550444T0000|0 11|Development
P03550444T0000|17 29|yeast system
P03550444T0000|33 38|assay
P03550444T0000|50 61|specificity
P03552363A0568|12 32|serum insulin levels
P03552363A0568|55 67|correlations
P03552363A0568|95 116|blood pressure levels
P03552363A0568|120 123|men
P03552363A0568|165 173|subjects
P03552363A0568|186 198|correlations
P03552363A0568|238 258|blood pressure level
P03553149A0299|33 44|mutagenesis
P03553149A0299|56 60|site
P03553149A0299|64 68|MucA
P03553149A0299|95 108|cleavage site
P03553149A0299|112 116|LexA
P03553439A0404|4 10|latter
P03553439A0404|38 42|Type
P03553439A0404|51 63|tumor tissue
P03553439A0404|104 115|tumor cells
P03553439A0404|117 121|Type
P03553439A0404|131 143|tumor tissue
P03553439A0404|180 191|tumor cells
P03553439A0404|193 197|Type
P03553439A0404|211 222|tumor cells
P03555318T0000|4 16|pharmacology
P03555318T0000|20 29|carnitine
P03556834T0000|6 25|inhalation toxicity
P03556834T0000|29 42|T-2 mycotoxin
P03556834T0000|46 50|mice
P03559193A0000|12 25|investigation
P03559193A0000|59 69|dimensions
P03559193A0000|77 92|Framingham Type
P03559193A0000|95 100|scale
P03559193A0000|102 106|FTAS
P03559193A0000|166 176|correlates
P03559232T0000|14 19|study
P03559232T0000|32 41|arthritis
P03559287T0000|0 10|Legionella
P03559287T0000|22 29|ecology
P03559287T0000|49 60|consumption
P03561036T0000|0 10|Lymphatics
P03561036T0000|18 23|aorta
P03561036T0000|27 31|rats
P03561036T0000|56 67|oil extract
P03561036T0000|69 79|lipofundin
P03561622A0659|10 16|resort
P03561622A0659|51 58|patient
P03561622A0659|62 70|dialysis
P03561622A0659|85 91|health
P03561622A0659|99 126|DiaTAP button graft complex
P03561622A0659|194 208|blood cultures
P03561622A0659|220 243|term vancomycin therapy
P03563399A0534|4 20|signal durations
P03563399A0534|34 36|ms
P03563399A0534|51 55|SoNo
P03563399A0534|60 77|S pi No threshold
P03563399A0534|120 130|difference
P03563604A1075|4 15|spleen rate
P03563604A1075|29 38|villagers
P03563604A1075|42 44|RK
P03563604A1075|64 65|%
P03563604A1075|74 87|parasite rate
P03563604A1075|92 93|%
P03563604A1075|105 122|drug intervention
P03567017A0000|9 15|dosing
P03567017A0000|21 26|times
P03567017A0000|39 43|days
P03567017A0000|47 57|indoprofen
P03567017A0000|62 64|mg
P03567017A0000|100 104|drug
P03567017A0000|118 127|half-life
P03567017A0000|129 133|t1/2
P03567017A0000|145 162|drug accumulation
P03567017A0000|180 188|subjects
P03568311A0273|6 14|patients
P03568311A0273|37 46|tamponade
P03568311A0273|58 72|wedge pressure
P03568311A0273|74 77|PWP
P03568311A0273|80 83|RAP
P03568311A0273|89 92|IPP
P03568311A0273|118 125|indexes
P03568311A0273|138 146|function
P03568311A1361|13 22|tamponade
P03568311A1361|27 50|pericardiocentesis data
P03568311A1361|69 86|stroke work index
P03568311A1361|103 114|correlation
P03568311A1361|120 125|TMFP1
P03568311A1361|127 128|r
P03568311A1361|140 145|TMFP2
P03568311A1361|147 148|r
P03568311A1361|169 174|TMFP3
P03570455A0433|0 7|Rabbits
P03570455A0433|27 39|hypocalcemia
P03570455A0433|46 52|levels
P03570455A0433|94 99|mg/dl
P03570455A0433|110 119|influence
P03570455A0433|123 129|TSST-1
P03571135T0000|7 12|value
P03571135T0000|25 33|features
P03571135T0000|37 45|language
P03571135T0000|90 98|children
P03572706A0329|21 36|interpretations
P03572706A0329|52 61|protocols
P03572706A0329|99 109|therapists
P03572706A0329|139 158|treatment condition
P03572706A0329|163 172|elevation
P03572706A0329|180 181|F
P03572706A0329|186 197|F-K indices
P03572706A0329|211 223|MMPI profile
P03575656A0120|30 43|chemical form
P03575656A0120|45 49|90Sr
P03575656A0120|80 84|lung
P03575656A0120|88 92|bone
P03575656A0120|113 120|portion
P03575656A0120|145 151|period
P03575656A0120|155 159|time
P03577670A0102|4 9|study
P03577670A0102|32 39|atrophy
P03577670A0102|68 88|matter hypodensities
P03577670A0236|4 13|diagnosis
P03577670A0236|31 45|leukodystrophy
P03577670A0236|47 50|MLD
P03577670A0236|73 80|finding
P03577670A0236|88 103|arylsulfatase A
P03577670A0236|105 108|ASA
P03577670A0236|110 116|levels
P03577670A0236|129 140|fibroblasts
P03577670A0236|149 156|sisters
P03578948A0448|11 22|ventilation
P03578948A0448|51 57|volume
P03578948A0448|64 73|ml X kg-1
P03578948A0448|80 84|rate
P03578948A0448|97 106|c X min-1
P03581160A0583|20 41|heart rate reactivity
P03581160A0583|90 122|artery pulse amplitude responses
P03581160A0583|151 162|TH subjects
P03581160A0583|171 179|controls
P03582149T0001|19 25|survey
P03582149T0001|39 52|valve disease
P03582149T0001|67 72|fever
P03582149T0001|98 113|school students
P03582149T0001|117 133|Jiangxi Province
P03582184A0448|0 5|Drugs
P03582184A0448|31 36|phase
P03582184A0448|40 49|reactions
P03582184A0448|73 90|dosage adjustment
P03582982A0000|2 7|study
P03582982A0000|17 22|genes
P03582982A0000|34 36|U4
P03582982A0000|51 54|RNA
P03583001A0111|22 31|procedure
P03583001A0111|46 59|gas injection
P03583001A0111|63 69|bubble
P03583001A0111|145 153|drainage
P03583001A0111|168 173|fluid
P03583001A0111|177 187|vitrectomy
P03584426A0706|17 28|enterotoxin
P03584426A0706|30 32|LT
P03584426A0706|59 73|stool isolates
P03584426A0706|77 78|%
P03584426A0706|104 112|isolates
P03584426A0706|115 116|%
P03584426A0706|143 151|activity
P03584426A0706|155 168|suckling mice
P03584426A0706|172 173|%
P03584426A0706|201 208|strains
P03584426A0706|234 242|material
P03586925T0001|0 11|Development
P03586925T0001|51 70|descriptor language
P03586925T0001|76 111|Roentgenology and Medical Radiology
P03586925T0001|117 120|use
P03586925T0001|128 144|Medinform system
P03590911T0001|24 34|dermatosis
P03590911T0001|50 67|light sensitivity
P03591464A0840a|17 21|test
P03591464A0840a|45 61|disease activity
P03591464A0840a|69 77|efficacy
P03591464A0840a|81 109|calcium antagonist treatment
P03591464A0840b|17 21|test
P03591464A0840b|45 61|disease activity
P03591464A0840b|69 77|efficacy
P03591464A0840b|81 109|calcium antagonist treatment
P03592297A0138|0 17|Dorsal foot TcpO2
P03592297A0138|55 65|electrodes
P03592297A0138|71 91|surface temperatures
P03592297A0138|98 107|degrees C
P03592297A0138|115 124|degrees C
P03592297A0138|129 135|theory
P03592297A0138|137 144|changes
P03592297A0138|160 168|activity
P03592297A0138|183 197|vasomotor tone
P03592297A0138|202 207|TcpO2
P03592297A0138|211 215|skin
P03592297A0138|227 236|electrode
P03592297A0138|243 252|degrees C
P03592297A0138|265 277|vasodilation
P03592297A0138|294 303|degrees C
P03592297A0138|313 325|vasodilation
P03592297A0679|3 11|subjects
P03592297A0679|13 14|n
P03592297A0679|25 37|quadriplegia
P03592297A0679|62 66|tone
P03592297A0679|89 100|cord trauma
P03592297A0679|102 107|TcpO2
P03592297A0679|114 123|degrees C
P03592297A0679|128 146|vasodilation index
P03592297A0679|168 172|mmHg
P03592297A0679|184 189|TcpO2
P03592297A0679|196 205|degrees C
P03595418A0688|4 24|nucleotide sequences
P03595418A0688|49 78|ornithine decarboxylase mRNAs
P03595418A0688|90 100|% homology
P03595418A0688|129 136|regions
P03597218A0901|13 27|concentrations
P03597218A0901|31 36|alpha
P03597218A0901|47 56|inhibitor
P03597218A0901|58 79|alpha 2-macroglobulin
P03597218A0901|85 97|antithrombin
P03597218A0901|117 125|exercise
P03597218A0901|131 132|P
P03597218A0901|160 174|concentrations
P03597218A0901|200 206|shifts
P03597218A0901|210 222|plasma water
P03597218A0901|230 238|exercise
P03597218A0901|244 252|quantity
P03597218A0901|262 272|inhibitors
P03597218A0901|297 298|P
P03597269A0409|10 15|model
P03597269A0409|33 44|exponential
P03597269A0409|50 58|constant
P03597269A0409|66 73|form La
P03597269A0409|81 82|b
P03597269A0409|83 86|exp
P03597269A0409|87 91|cVO2
P03600633A1069|0 4|Cell
P03600705T0000|0 6|Timing
P03600705T0000|10 18|symptoms
P03600705T0000|23 39|oocyst excretion
P03600705T0000|49 66|cryptosporidiosis
P03601275A0601|6 23|dopamine infusion
P03601275A0601|27 32|women
P03601275A0601|55 63|syndrome
P03601275A0601|79 87|controls
P03601275A0601|96 108|state levels
P03601275A0601|112 127|plasma dopamine
P03601275A0601|129 143|norepinephrine
P03601275A0601|153 158|ratio
P03601275A0601|162 185|dopamine/norepinephrine
P03601275A0601|210 216|groups
P03601533T0001|11 21|importance
P03601533T0001|41 64|complement constituents
P03601533T0001|68 76|children
P03601533T0001|93 104|thyroiditis
P03602261A0238|36 45|condition
P03602261A0238|72 84|correlations
P03602261A0238|86 87|p
P03602261A0238|128 142|blood pressure
P03602261A0238|147 155|dopamine
P03602261A0238|157 158|r
P03602261A0238|168 182|norepinephrine
P03602261A0238|184 185|r
P03602261A0238|198 209|epinephrine
P03602261A0238|211 212|r
P03602261A0238|249 261|correlations
P03602261A0238|270 279|melatonin
P03602261A0238|284 292|dopamine
P03602261A0238|294 295|r
P03602261A0238|306 320|norepinephrine
P03602261A0238|322 323|r
P03602261A0238|337 351|growth hormone
P03602261A0238|353 354|r
P03605895A0888|6 14|patients
P03605895A0888|20 44|carboxyhemoglobin levels
P03605895A0888|48 54|excess
P03605895A0888|60 61|%
P03605895A0888|83 108|carbon monoxide poisoning
P03605895A0888|117 127|population
P03607109A0370|10 19|processes
P03607109A0370|57 62|month
P03607109A0370|66 75|pregnancy
P03607109A0370|95 102|picture
P03607109A0370|110 118|controls
P03607961T0001|13 19|action
P03607961T0001|33 47|zhuang qi gong
P03607961T0001|57 66|mechanism
P03607961T0001|70 87|diabetes mellitus
P03608916A0790|3 8|cases
P03608916A0790|14 25|degrees HPT
P03608916A0790|31 37|plasma
P03608916A0790|44 46|OH
P03608916A0790|47 55|2D level
P03608916A0790|82 87|cases
P03608916A0790|89 90|P
P03608916A0790|121 128|pattern
P03608916A0790|136 144|increase
P03608989A0668|5 11|region
P03608989A0668|18 29|amino acids
P03608989A0668|61 73|interactions
P03608989A0668|111 129|filament formation
P03608989A0668|137 147|rod region
P03610663A0201|5 13|approach
P03610663A0201|26 33|sources
P03610663A0201|37 42|error
P03610663A0201|50 61|calculation
P03610663A0201|65 85|nutrient utilization
P03610663A0201|122 128|effect
P03610663A0201|132 141|precision
P03610663A0201|196 202|states
P03610674T0000|4 10|effect
P03610674T0000|22 37|zinc deficiency
P03610674T0000|51 69|fiber zinc content
P03610674T0000|77 92|rat hippocampus
P03612316A0102|7 11|rats
P03612316A0102|30 34|diet
P03612316A0102|40 51|low-protein
P03612316A0102|64 68|diet
P03612316A0102|88 94|saline
P03612316A0102|98 107|thyroxine
P03612316A0102|126 130|g BW
P03612316A0102|139 143|days
P03612648A0085|27 46|lupus anticoagulant
P03612648A0085|79 98|thromboplastin time
P03612648A0085|107 115|antibody
P03612648A0085|119 130|cardiolipin
P03615550A0000|4 11|effects
P03615550A0000|30 38|agonists
P03615550A0000|54 73|antagonist naloxone
P03615550A0000|91 95|rats
P03615550A0000|115 139|fixed-consecutive-number
P03615550A0000|141 144|FCN
P03615550A0000|146 154|schedule
P03615550A1094|20 27|effects
P03615550A1094|31 39|morphine
P03615550A1094|44 50|U50488
P03615550A1094|94 104|mg/kg dose
P03615550A1094|108 116|naloxone
P03615763A0170|0 4|Data
P03615763A0170|14 17|men
P03615763A0170|25 30|women
P03615763A0170|51 62|angiography
P03615763A0170|74 85|opportunity
P03615763A0170|103 115|associations
P03615763A0170|119 127|relation
P03615763A0170|155 162|measure
P03615763A0170|166 181|atherosclerosis
P03615763A0170|204 207|age
P03615763A0170|209 212|sex
P03615763A0170|214 220|income
P03615763A0170|222 234|hypertension
P03615763A0170|236 253|serum cholesterol
P03615763A0170|255 262|smoking
P03615763A0170|264 270|angina
P03615763A0170|272 280|diabetes
P03615763A0170|282 296|family history
P03615763A0170|300 313|heart disease
P03615763A0170|315 338|Type A behavior pattern
P03615763A0170|344 353|hostility
P03616174A1069|14 20|change
P03616174A1069|24 35|temperature
P03616174A1069|54 63|degrees C
P03616174A1069|99 109|blood flow
P03616174A1069|133 143|blood flow
P03616174A1069|160 167|tissues
P03616174A1069|214 225|circulation
P03616237T0001|11 29|status epilepticus
P03616237T0001|36 44|infusion
P03616237T0001|48 57|cisplatin
P03618039A0126|4 12|presence
P03618039A0126|21 29|patients
P03618039A0126|33 43|antibodies
P03618039A0126|47 57|adrenaline
P03618039A0126|62 75|noradrenaline
P03618039A0126|106 116|disruption
P03618039A0126|120 151|catecholamine biotransformation
P03619249A0428|14 21|markers
P03619249A0428|45 50|serum
P03619249A0428|52 56|skin
P03619249A0428|61 66|liver
P03619249A0428|74 82|patients
P03619249A0428|96 105|hepatitis
P03619249A0428|107 110|HBV
P03619249A0428|112 118|HBs Ag
P03619249A0428|123 129|HBe Ag
P03619249A0428|131 139|anti-HBs
P03619249A0428|170 175|serum
P03619249A0428|177 180|HBs
P03619249A0428|185 191|HBc Ag
P03619249A0428|199 204|liver
P03619249A0428|233 235|Ag
P03619249A0428|240 248|antibody
P03619249A0428|261 267|non-Bc
P03619249A0428|275 280|serum
P03619249A0428|282 287|non-A
P03619249A0428|296 298|Ag
P03619249A0428|306 311|liver
P03622423A0000|0 6|Groups
P03622423A0000|10 14|male
P03622423A0000|26 33|Fischer
P03622423A0000|38 42|rats
P03622423A0000|44 55|B6C3F1 mice
P03622423A0000|61 80|Hartley guinea pigs
P03622423A0000|105 107|hr
P03622423A0000|116 130|concentrations
P03622423A0000|161 168|control
P03622423A0000|170 173|ppm
P03622423A0000|177 194|methyl isocyanate
P03622423A0000|196 199|MIC
P03622423A0000|201 206|vapor
P03622571A0208|0 18|Radionuclide study
P03622571A0208|38 44|biopsy
P03622571A0208|65 77|degeneration
P03622571A0208|81 91|myocardium
P03625688A0372|0 14|Immobilization
P03625688A0372|22 30|fracture
P03625688A0372|36 42|collar
P03625688A0372|47 57|cuff sling
P03625688A0372|93 100|methods
P03625762A0308|0 10|Comparison
P03625762A0308|14 22|patients
P03625762A0308|33 42|phenytoin
P03625762A0308|93 98|serum
P03625762A0308|133 142|phenytoin
P03625762A0308|173 183|difference
P03625762A0308|196 206|sub-groups
P03625762A0308|212 219|respect
P03625762A0308|223 234|vitamin B12
P03625762A0308|238 262|behaviour problem rating
P03626129T0001|0 7|Effects
P03626129T0001|24 34|laser beam
P03626129T0001|42 47|cells
P03626129T0001|60 66|embryo
P03627720A0196|30 38|features
P03627720A0196|56 64|sac cyst
P03628532A0000|4 8|role
P03628532A0000|12 18|saliva
P03628532A0000|27 43|taste perception
P03628532A0000|66 72|series
P03628532A0000|78 89|experiments
P03628596A0000|0 7|Samples
P03628596A0000|31 39|patients
P03628596A0000|74 79|value
P03628596A0000|83 108|acid alpha 1-glycoprotein
P03628596A0000|137 142|fluid
P03628713A0961|9 20|experiments
P03628713A0961|30 33|AIB
P03628713A0961|38 51|86RbCl uptake
P03628713A0961|55 67|36B-10 cells
P03628713A0961|85 89|days
P03628713A0961|103 117|Gy irradiation
P03628713A0961|141 155|radiation dose
P03628713A0961|168 176|capacity
P03628713A0961|180 191|tumor cells
P03628713A0961|195 203|trap AIB
P03628713A0961|207 209|Rb
P03628794A0648|4 12|patients
P03628794A0648|42 49|disease
P03628794A0648|55 59|data
P03628794A0648|73 96|I-131 MIBG scintigraphy
P03628794A0648|104 115|examination
P03628794A0648|119 125|choice
P03629973A0240|0 2|W.
P03629974A1468|0 10|Comparison
P03629974A1468|18 37|amino acid sequence
P03629974A1468|45 58|M RNA product
P03629974A1468|62 77|Uukuniemi virus
P03629974A1468|91 101|Punta Toro
P03629974A1468|106 131|Rift Valley fever viruses
P03629974A1468|147 152|cases
P03629974A1468|160 168|homology
P03629974A1468|202 210|proteins
P03629974A1468|240 243|end
P03629974A1468|251 260|precursor
P03632739T0000|0 22|Cyclosporine treatment
P03632739T0000|39 51|polymyositis
P03635597A0377|3 11|addition
P03635597A0377|20 26|Cohler
P03635597A0377|38 43|scale
P03635597A0377|52 59|mothers
P03635597A0377|85 92|infants
P03635597A0377|101 108|passive
P03635597A0377|137 144|mothers
P03635597A0377|150 151|P
P03637037T0000|15 31|teaching booklet
P03637037T0000|46 54|patients
P03645733T0001|0 15|Hyperthyroidism
P03649340A1119|35 45|precursors
P03649340A1119|73 79|choice
P03649340A1119|83 95|splice sites
P03649340A1119|109 123|exon sequences
P03649340A1119|164 180|splicing process
P03651330T0000|24 31|lesions
P03651840A0266|8 27|MAO inhibition data
P03651840A0266|38 44|DPGPEA
P03651840A0266|54 63|inhibitor
P03651840A0266|67 72|MAO-B
P03651840A0266|87 93|effect
P03651840A0266|125 140|tranylcypromine
P03651840A0266|144 153|pargyline
P03652083A0720|13 19|region
P03652083A0720|27 46|vessel pyridinoline
P03652083A0720|80 89|crosslink
P03652083A0720|93 101|collagen
P03653226A0833|25 50|tissue-distribution study
P03653226A0833|103 107|fate
P03653226A0833|111 122|perhexiline
P03658866A0081|9 28|lupus erythematosus
P03659603A0797|7 14|evening
P03659603A0797|20 29|amplitude
P03659603A0797|37 46|responses
P03659603A0797|62 65|CO2
P03659603A0797|84 92|increase
P03659603A0797|96 111|CO2 sensitivity
P03659805A0404|16 28|significance
P03659805A0404|36 53|prognosis factors
P03659805A0404|69 72|uni
P03659805A0404|93 100|methods
P03659805A0404|119 124|model
P03659805A0404|128 131|Cox
P03659805A0404|142 146|help
P03659805A0404|153 165|IMB computer
P03659994A0150|6 13|changes
P03659994A0150|21 25|site
P03659994A0150|29 38|injection
P03659994A0150|58 69|abnormality
P03659994A0150|96 104|increase
P03659994A0150|108 124|signal intensity
P03659994A0150|128 130|T1
P03659994A0150|140 146|images
P03659994A0150|170 186|signal intensity
P03659994A0150|190 192|T2
P03659994A0150|202 208|images
P03663789A0568|6 13|results
P03663789A0568|49 57|activity
P03663789A0568|61 65|RHAL
P03663789A0568|86 90|test
P03663789A0568|124 134|conversion
P03663789A0568|138 142|RHAL
P03663789A0568|146 149|HAL
P03664038A0000|4 11|purpose
P03664038A0000|20 25|study
P03664038A0000|64 68|form
P03664038A0000|76 107|Gudjonsson Suggestibility Scale
P03664038A0000|109 112|GSS
P03664038A0000|114 118|Form
P03664038A0000|148 161|reliabilities
P03664038A0000|179 193|suggestibility
P03666957A0219|0 9|Organisms
P03666957A0219|34 45|conjunctiva
P03666957A0219|58 63|weeks
P03666957A0219|109 118|infection
P03666957A0219|149 158|infection
P03666957A0219|167 171|cats
P03668003T0000|24 34|microscopy
P03668003T0000|48 60|skin lesions
P03668396A0171|6 27|equilibrium solutions
P03668396A0171|61 69|vertices
P03668396A0171|86 103|convex polyhedron
P03668736A0177|12 22|deviations
P03668736A0177|30 42|X-ray counts
P03668736A0177|59 67|elements
P03668736A0177|77 83|series
P03668736A0177|124 129|count
P03668736A0177|146 153|element
P03668736A0177|162 167|block
P03672532A1111|26 33|effects
P03672532A1111|48 53|doses
P03673640A0533|4 16|MAO subjects
P03673640A0533|26 33|pattern
P03673640A0533|44 50|scores
P03673640A0533|54 71|KSP Impulsiveness
P03673640A0533|73 88|EPQ Neuroticism
P03673640A0533|94 97|KSP
P03673640A0533|106 113|Anxiety
P03673640A0533|118 130|Irritability
P03673640A0533|141 147|scores
P03673640A0533|151 168|KSP Socialization
P03673640A0533|173 177|line
P03673640A0533|183 203|personality profiles
P03673640A0533|213 223|alcoholics
P03673640A0533|225 236|psychopaths
P03673640A0533|242 260|suicide attempters
P03673640A0533|287 308|platelet MAO activity
P03673881A0000|25 33|accuracy
P03673881A0000|48 52|wave
P03673881A0000|54 56|CW
P03673881A0000|67 93|pulse repetition frequency
P03673881A0000|95 99|HPRF
P03673881A0000|101 108|Doppler
P03673881A0000|145 163|pressure gradients
P03673881A0000|165 185|Doppler examinations
P03673881A0000|196 203|devices
P03673881A0000|236 244|patients
P03673881A0000|257 270|valve disease
P03676054A0865|3 8|group
P03676054A0865|12 15|Paw
P03676054A0865|17 24|delta V
P03676054A0865|26 30|PaO2
P03676054A0865|32 36|Vinj
P03676054A0865|41 43|VT
P03676054A0865|86 94|pressure
P03676054A0865|99 100|E
P03676054A0865|143 151|diameter
P03676054A0865|159 175|injector cannula
P03676174A0730|3 9|calves
P03676174A0730|36 41|diets
P03676174A0730|60 67|g DM/kg
P03676174A0730|69 81|milk intakes
P03676174A0730|106 107|%
P03676174A0730|119 122|day
P03676174A0730|128 134|calves
P03678269A0633|0 5|Today
P03678269A0633|18 23|doubt
P03678269A0633|38 63|plasma cholesterol levels
P03678269A0633|99 111|modification
P03678269A0633|126 135|childhood
P03678269A0633|154 157|age
P03678269A0633|165 170|years
P03678372A0170|4 10|number
P03678372A0170|20 27|pellets
P03678372A0170|54 59|weeks
P03678372A0170|68 79|pellets/day
P03678372A0170|122 129|pellets
P03678372A0170|136 141|weeks
P03678372A0170|151 158|pellets
P03678372A0170|166 171|weeks
P03679407A0556|6 13|results
P03679407A0556|27 46|N-nitroso compounds
P03679407A0556|85 92|bladder
P03679407A0556|118 129|association
P03679407A0556|152 162|infections
P03679407A0556|177 181|risk
P03679407A0556|186 200|bladder cancer
P03679756A0830|11 30|nerve fiber defects
P03679756A0830|40 47|absence
P03679756A0830|61 73|architecture
P03679756A0830|98 104|plexus
P03679756A0830|126 135|terminals
P03680791A0230|15 20|grade
P03680791A0230|43 47|site
P03680791A0230|61 67|hearts
P03680791A0230|97 102|sites
P03680791A0230|115 120|heart
P03682805A0375|0 12|Serum levels
P03682805A0375|16 23|albumin
P03682805A0375|25 33|globulin
P03682805A0375|39 67|coagulation protein activity
P03682805A0375|82 90|preshock
P03682805A0375|92 101|postshock
P03682805A0375|119 123|days
P03682805A0375|125 142|skin lymph levels
P03682805A0375|160 163|Day
P03684378A0653|14 18|milk
P03684378A0653|43 54|correlation
P03684378A0653|58 68|vitamin K1
P03684378A0653|72 83|cholesterol
P03684378A0653|85 86|r
P03684378A0653|112 117|lipid
P03684378A0653|147 151|role
P03684378A0653|156 167|cholesterol
P03684378A0653|175 184|secretion
P03684378A0653|188 198|vitamin K1
P03684378A0653|214 218|milk
P03684517A0462|10 18|training
P03684517A0462|34 42|increase
P03684517A0462|46 55|stiffness
P03684517A0462|74 82|decrease
P03684517A0462|86 90|type
P03684517A0462|94 100|fibers
P03685073A0200|18 22|dose
P03685073A0200|26 39|physostigmine
P03685073A0200|44 74|acetylcholinesterase inhibitor
P03685073A0200|91 102|combination
P03685073A0200|112 117|range
P03685073A0200|121 135|atropine doses
P03687078T0001|0 10|References
P03687078T0001|28 35|fitness
P03687078T0001|39 50|adolescents
P03687078T0001|56 64|diseases
P03687078T0001|84 89|tract
P03687078T0001|94 99|lungs
P03687148T0187|0 8|Salzburg
P03687148T0187|15 24|September
P03687313A0000|8 30|glucosidase inhibitors
P03687313A0000|32 37|BAY m
P03687313A0000|47 52|BAY o
P03687313A0000|75 85|volunteers
P03687313A0000|90 94|type
P03687313A0000|98 107|diabetics
P03687313A0000|122 132|conditions
P03688202A0377|4 10|models
P03688202A0377|43 53|boundaries
P03688202A0377|66 69|PBB
P03688202A0377|74 76|CN
P03688301A0129|17 22|cases
P03688301A0129|38 44|spread
P03688301A0129|61 69|invasion
P03688301A0129|71 77|type A
P03688301A0129|99 104|cases
P03688301A0129|124 133|extension
P03688301A0129|135 141|type B
P03688301A0129|164 174|carcinomas
P03688301A0129|182 189|bladder
P03688676A0487|9 20|conversions
P03688676A0487|27 29|mm
P03688676A0487|65 71|result
P03688676A0487|82 88|spread
P03688676A0487|92 101|infection
P03690262A0428|4 21|maximum amplitude
P03690262A0428|32 41|responses
P03690262A0428|70 75|trunk
P03690262A0428|98 100|T2
P03690262A0428|107 112|ramus
P03690262A0428|173 184|stimulation
P03690262A0428|188 190|T1
P03690262A0428|192 194|T3
P03690262A0428|196 198|T4
P03690262A0428|203 205|T5
P03690262A0428|212 216|rami
P03691316A0560|21 36|contact allergy
P03691316A0560|40 44|K-CG
P03692331A0000|4 10|effect
P03692331A0000|34 44|antagonist
P03692331A0000|46 54|pindolol
P03692331A0000|74 80|muscle
P03692331A0000|84 88|term
P03692331A0000|98 103|women
P03692331A0000|154 159|women
P03693543A0405|39 58|Rhodococcus species
P03693543A0405|82 90|patterns
P03693543A0405|121 134|elution times
P03693543A0405|140 148|patterns
P03693543A0405|152 171|Nocardia asteroides
P03693543A0405|173 192|N. otitidiscaviarum
P03693543A0405|198 213|N. brasiliensis
P03693543A0405|230 236|number
P03693543A0405|240 245|peaks
P03693543A0405|258 265|species
P03693543A0405|271 281|separation
P03693543A0405|294 300|genera
P03694102A0000|4 15|development
P03694102A0000|21 30|data base
P03694102A0000|72 81|reference
P03694102A0000|86 107|ECG computer programs
P03694102A0000|151 156|leads
P03696899T0001|0 32|Blood serum erythropoietin level
P03696899T0001|57 64|indices
P03696899T0001|76 86|adaptation
P03696899T0001|106 113|infants
P03697587T0000|4 28|XXXXY chromosome anomaly
P03697587T0000|41 48|variant
P03697587T0000|52 63|Klinefelter
P03697587T0000|66 74|syndrome
P03697798T0001|0 11|Contraction
P03697798T0001|28 34|muscle
P03697798T0001|43 51|activity
P03697798T0001|55 72|stretch receptors
P03697798T0001|80 87|trachea
P03697971A0311|4 18|selenium level
P03697971A0311|23 54|glutathione peroxidase activity
P03697971A0311|62 67|blood
P03697971A0311|69 74|liver
P03697971A0311|80 94|stomach mucosa
P03697971A0311|142 152|diet group
P03697971A0311|178 188|diet group
P03698251T0000|0 15|Oxygen delivery
P03698251T0000|20 31|consumption
P03698251T0000|36 39|P50
P03698251T0000|43 51|patients
P03698251T0000|74 84|infarction
P03700952A0273|0 7|Infants
P03700952A0273|16 22|sample
P03700952A0273|37 39|PL
P03700952A0273|47 55|acuities
P03700952A0273|88 96|McDonald
P03700952A0273|109 127|laboratory setting
P03701640A1178|6 13|results
P03701640A1178|32 38|effect
P03701640A1178|46 53|isomers
P03701640A1178|96 106|FR30 FI600
P03701640A1178|174 182|ABSTRACT
P03701640A1178|200 205|WORDS
P03703493A0654|4 10|number
P03703493A0654|26 34|deposits
P03703493A0654|68 73|areas
P03703493A0654|81 109|RPE-choriocapillaris complex
P03704087A0394|7 15|subjects
P03704087A0394|40 51|instruments
P03704087A0394|74 84|components
P03704087A0394|88 93|anger
P03704087A0394|98 105|anxiety
P03704087A0394|107 118|Spielberger
P03704087A0394|121 154|State-Trait Personality Inventory
P03704087A0394|160 182|Anger Expression Scale
P03704087A0394|192 218|State Anger Reaction Scale
P03709191A0125|37 43|cortex
P03709191A0125|51 54|rat
P03709191A0125|74 80|volume
P03709191A0125|95 104|asymmetry
P03709191A0125|114 130|side differences
P03709191A0125|138 144|number
P03709191A0125|148 155|neurons
P03709627A0247|4 12|subjects
P03709627A0247|35 42|mg dose
P03709627A0247|46 64|acetaminophen i.v.
P03709627A0247|69 83|concentrations
P03709627A0247|87 93|plasma
P03709627A0247|116 123|minutes
P03709627A0247|131 136|urine
P03709627A0247|144 145|h
P03709627A0247|149 154|order
P03709627A0247|171 181|production
P03709627A0247|185 196|metabolites
P03710973A0817|0 4|Mean
P03710973A0817|14 30|skin temperature
P03710973A0817|32 35|Tsk
P03710973A0817|48 49|P
P03710973A0817|76 87|acclimation
P03710973A0817|105 116|acclimation
P03710973A0817|139 140|P
P03710973A0817|157 176|Tre-to-Tsk gradient
P03712050T0000|0 28|Indium-111 leukocyte imaging
P03712050T0000|32 40|patients
P03712050T0000|57 66|arthritis
P03712106A0000|4 10|effect
P03712106A0000|14 42|L-methionine supplementation
P03712106A0000|50 61|utilization
P03712106A0000|67 86|soy protein isolate
P03712106A0000|88 91|SPI
P03712106A0000|121 145|nitrogen balance studies
P03712106A0000|155 160|women
P03712153T0000|17 54|Haemophilus influenzae type b disease
P03712153T0000|75 85|assessment
P03712153T0000|89 101|risk factors
P03713187A0691|9 16|lesions
P03713187A0691|39 53|lamina propria
P03713187A0691|79 88|frequency
P03713187A0691|92 102|occurrence
P03713187A0691|115 122|lesions
P03713187A0691|149 155|muscle
P03713187A0691|166 176|carcinomas
P03713187A0691|198 203|sites
P03713187A0691|221 230|frequency
P03713187A0691|254 261|lesions
P03713187A0691|265 275|comparison
P03713187A0691|296 303|lesions
P03714348A0833|0 7|Factors
P03714348A0833|32 43|correlation
P03714348A0833|56 59|CIC
P03714348A0833|85 92|portion
P03714348A0833|100 114|CIC population
P03714348A0833|125 134|NIH score
P03714348A0833|146 157|patient age
P03714348A0833|163 188|peak expiratory flow rate
P03714348A0833|209 218|serum IgG
P03714473A0496|0 9|Induction
P03714473A0496|28 39|transcripts
P03714473A0496|48 58|heat shock
P03717475A0208|0 3|New
P03717475A0208|19 24|steps
P03717475A0208|43 60|immunodiagnostics
P03717475A0208|62 75|immunotherapy
P03717475A0208|81 98|immunoprophylaxis
P03717475A0208|130 141|infertility
P03717936A0252|0 8|Amikacin
P03717936A0252|33 43|tobramycin
P03717936A0252|65 79|aminoglycoside
P03717936A0252|90 100|conditions
P03720615A0434|20 24|part
P03720615A0434|35 40|trend
P03720615A0434|57 68|birthweight
P03720615A0434|73 82|gestation
P03720615A0434|94 101|infants
P03720966A1043|18 35|acid N absorption
P03720966A1043|42 43|%
P03720966A1043|47 55|N intake
P03721594A0000|0 8|Adhesion
P03721594A0000|10 22|phagocytosis
P03721594A0000|47 56|migration
P03721594A0000|68 79|tetrazolium
P03721594A0000|84 93|reduction
P03721594A0000|108 127|exudate neutrophils
P03721594A0000|132 143|macrophages
P03721594A0000|145 161|fibrinogen level
P03721594A0000|163 171|gelation
P03721594A0000|201 232|dilution protamine sulfate test
P03721594A0000|258 269|New Zealand
P03721594A0000|276 283|rabbits
P03721594A0000|312 333|Shwartzman phenomenon
P03721594A0000|341 346|colon
P03721594A0000|363 370|animals
P03721666A0000|0 6|Nickel
P03721666A0000|26 31|cause
P03721666A0000|44 62|contact dermatitis
P03721666A0000|66 75|Singapore
P03721666A0000|99 108|reactions
P03721666A0000|112 123|patch tests
P03721666A0000|140 141|%
P03722016A0797|4 14|FFA levels
P03722016A0797|34 35|P
P03722016A0797|56 69|meal interval
P03728230A0104|15 23|hospital
P03728230A0104|48 52|cyst
P03732252A0556|17 25|analyses
P03732252A0556|33 37|data
P03732252A0556|63 66|VO2
P03732252A0556|71 72|r
P03732252A0556|82 83|P
P03732252A0556|112 118|VO2max
P03732252A0556|120 121|r
P03732252A0556|168 186|m race performance
P03732252A0556|199 205|extent
P03732252A0556|229 235|amount
P03732252A0556|239 245|change
P03732252A0556|247 252|delta
P03732252A0556|268 278|m run time
P03732252A0556|306 317|combination
P03732252A0556|321 330|delta VO2
P03732252A0556|338 343|delta
P03732252A0556|350 360|m run time
P03733563A0716|14 39|herd X period interaction
P03733563A0716|52 60|liver TG
P03733563A0716|65 78|serum dextran
P03733563A0716|92 118|cholesterol concentrations
P03733563A0820|0 8|Liver TG
P03733563A0820|13 38|serum NEFA concentrations
P03734641A0203|4 11|results
P03734641A0203|22 27|nerve
P03734641A0203|32 37|roots
P03734641A0203|70 75|force
P03734641A0203|96 103|failure
P03734641A0203|121 133|biomechanics
P03736081A0465|18 32|sinus pressure
P03736081A0465|44 48|torr
P03736081A0465|74 82|decrease
P03736081A0465|94 99|index
P03736081A0465|130 138|L/min/m2
P03736081A0465|140 141|p
P03736081A0465|169 179|blood flow
P03736081A0465|209 215|ml/min
P03736081A0465|217 218|p
P03736081A0465|237 241|rate
P03736081A0465|245 249|rise
P03736081A0465|270 278|pressure
P03736081A0465|312 313|p
P03736081A0465|338 346|increase
P03736081A0465|373 383|difference
P03736081A0465|389 390|%
P03736081A0465|398 399|%
P03736081A0465|407 408|%
P03736081A0465|416 428|% saturation
P03736081A0465|430 431|p
P03738919A0000|0 14|Calcifications
P03738919A0000|31 36|aorta
P03738919A0000|44 49|level
P03738919A0000|84 93|vertebrae
P03738919A0000|101 104|men
P03738919A0000|113 118|women
P03738919A0000|147 157|tomography
P03743683A0000|5 11|series
P03743683A0000|31 40|autopsies
P03743683A0000|59 66|plaques
P03743683A0000|68 70|PP
P03743683A0000|89 100|individuals
P03743683A0000|110 115|years
P03743683A0000|119 122|age
P03743702A0158|16 17|%
P03743702A0158|21 32|cell bodies
P03743702A0158|44 51|neurons
P03743702A0158|68 73|intra
P03743702A0158|87 97|structures
P03743702A0158|119 127|alveolar
P03743702A0158|129 136|lingual
P03743702A0158|157 163|nerves
P03743702A0158|176 181|range
P03743702A0158|202 208|micron
P03743702A0158|230 234|area
P03743702A0158|236 240|mean
P03743702A0158|245 247|SD
P03743702A0158|260 266|micron
P03743702A0158|282 288|micron
P03743702A0158|304 310|micron
P03743702A0158|330 336|micron
P03744168T0001|16 22|action
P03744168T0001|26 36|eptazocine
P03744168T0001|38 41|l-1
P03744168T0001|76 87|hexahydro-1
P03744168T0001|90 115|methano-1H-4-benz azonine
P03745833A0258|3 13|transition
P03745833A0258|31 38|voltage
P03745833A0258|63 67|fall
P03745833A0258|80 88|pressure
P03745833A0258|91 92|%
P03745833A0258|101 109|increase
P03745833A0258|113 117|flow
P03745833A0258|124 125|%
P03745833A0258|130 135|areas
P03745833A0258|143 148|brain
P03745833A0258|170 182|arborization
P03745833A0258|200 209|formation
P03745833A0258|230 238|cerebrum
P03745833A0258|243 253|cerebellum
P03746053A0670|0 8|Findings
P03746053A0670|21 31|potentials
P03746053A0670|44 46|N1
P03746053A0670|65 69|area
P03746053A0670|86 92|matter
P03746053A0670|120 126|column
P03746053A0670|131 133|N2
P03746053A0670|146 159|dorsal column
P03746107A0192|29 33|cent
P03746107A0192|50 57|tumours
P03746508A0390|0 8|Failures
P03746508A0390|25 35|additivity
P03746508A0390|61 71|conditions
P03746601A0299|21 29|problems
P03746601A0299|31 44|extravasation
P03746601A0299|58 64|sepsis
P03746601A0299|72 80|hematoma
P03746601A0299|93 98|total
P03746601A0299|108 112|days
P03746601A0299|116 124|exposure
P03746896A0890|27 34|results
P03746896A0890|61 72|possibility
P03746896A0890|88 93|means
P03746896A0890|127 141|susceptibility
P03746896A0890|158 165|effects
P03746896A0890|169 184|Type A behavior
P03746906A0000|4 11|studies
P03746906A0000|25 30|types
P03746906A0000|34 45|reliability
P03746906A0000|53 84|student Jenkins Activity Survey
P03746906A0000|86 89|JAS
P03746906A0000|93 114|questionnaire measure
P03746906A0000|118 133|Type A behavior
P03747493A0000|15 23|patients
P03747493A0000|81 91|infections
P03749226A0506|5 18|phencyclidine
P03749226A0506|51 64|response rate
P03749226A0506|87 93|errors
P03749226A0506|120 125|doses
P03750700T0001|0 13|Possibilities
P03750700T0001|18 25|outlook
P03750700T0001|30 35|wrist
P03750700T0001|42 56|endoprosthesis
P03751308T0001|0 5|Study
P03751308T0001|13 30|energy metabolism
P03751308T0001|38 55|sensomotor cortex
P03751308T0001|60 71|hippocampus
P03751308T0001|80 83|14C
P03751308T0001|84 105|2-deoxyglucose method
P03751308T0001|117 128|development
P03751308T0001|144 150|states
P03753022A0000|10 18|lymphoma
P03753022A0000|44 49|terms
P03753022A0000|68 76|behavior
P03755623A1233|8 22|investigations
P03755623A1233|84 94|properties
P03755623A1233|98 102|DLIS
P03755673A0054|15 20|cases
P03757294A0414|7 12|cases
P03757294A0414|18 21|PLD
P03757294A0414|25 26|%
P03757294A0414|48 53|cysts
P03757294A0414|60 61|%
P03757294A0414|69 74|cases
P03757294A0414|80 84|APCD
P03757294A0414|100 111|liver cysts
P03758250A0000|29 38|movements
P03758250A0000|58 67|extremity
P03758250A0000|115 121|bursts
P03758250A0000|125 137|EMG activity
P03758250A0000|154 161|muscles
P03759330A0713|4 15|combination
P03759330A0713|19 21|F1
P03759330A0713|26 28|F2
P03759330A0713|48 57|predictor
P03759330A0713|61 64|CHD
P03759330A0713|73 83|population
P03759330A0713|85 87|G1
P03759330A0713|124 139|trunk adiposity
P03759731A0992|6 15|clearance
P03759731A0992|39 47|ml/min/1
P03759731A0992|51 53|m2
P03759731A0992|55 60|group
P03759731A0992|79 87|ml/min/1
P03759731A0992|91 93|m2
P03759731A0992|95 100|group
P03761122T0000|4 13|relations
P03761122T0000|22 37|type A behavior
P03761122T0000|59 67|behavior
P03761122T0000|78 89|achievement
P03761122T0000|95 97|IQ
P03761122T0000|101 109|children
P03761523A0000|4 8|rats
P03761523A0000|27 32|study
P03761523A0000|40 47|effects
P03761523A0000|51 57|sepsis
P03761523A0000|65 76|utilization
P03761523A0000|94 102|emulsion
P03763241A0446|20 28|weakness
P03763241A0446|42 53|extremities
P03763836T0001|0 7|Results
P03763836T0001|11 27|electron therapy
P03763836T0001|31 37|tumors
P03763836T0001|51 56|sites
P03765552A0582|4 13|mechanism
P03765552A0582|17 23|action
P03765552A0582|44 50|detail
P03765552A0582|102 108|system
P03765552A0582|110 113|RES
P03765552A0582|115 135|Fc receptor blockade
P03765552A0582|140 151|suppression
P03765552A0582|168 186|antibody synthesis
P03765731A0918|0 10|Incidences
P03765731A0918|23 29|stroke
P03765731A0918|42 52|infarction
P03765731A0918|54 73|angina pectoris und
P03765731A0918|91 102|hypertrophy
P03766370A0546|12 20|r values
P03766370A0546|41 51|deviations
P03766370A0546|76 78|LV
P03766370A0546|111 118|regions
P03768208A0879|6 13|results
P03768208A0879|35 44|pregnancy
P03768208A0879|55 64|increases
P03768208A0879|68 88|bone formation rates
P03768208A0879|109 118|increases
P03768208A0879|131 135|mass
P03769224A0000|12 16|data
P03769224A0000|25 33|patients
P03769224A0000|48 67|Lupus Erythematosus
P03769224A0000|69 72|SLE
P03769224A0000|88 96|biopsies
P03770143A1209|4 15|possibility
P03770143A1209|32 40|disorder
P03770143A1209|60 66|defect
P03770143A1209|78 93|fibre structure
P03770143A1209|141 148|lesions
P03771670T0058|0 10|Prevention
P03771670T0058|16 36|heparin-antithrombin
P03771670T0058|41 52|combination
P03771703A0000|14 38|trimethylsilylcarbamates
P03771703A0000|67 75|reagents
P03771703A0000|80 83|gas
P03771703A0000|100 108|analysis
P03771749A0465|0 4|MICs
P03771749A0465|24 30|agents
P03771749A0465|32 48|5-fluorocytosine
P03771749A0465|50 60|miconazole
P03771749A0465|62 74|ketoconazole
P03771749A0465|80 94|amphotericin B
P03771749A0465|112 120|isolates
P03771749A0465|132 147|Candida species
P03771749A0465|179 184|media
P03771749A0465|188 201|agar dilution
P03771749A0465|206 239|microtiter broth dilution systems
P03772471A1054|14 22|patients
P03772471A1054|28 36|Group II
P03772471A1054|40 46|tumors
P03772471A1054|57 69|tumor biopsy
P03772471A1054|116 125|diagnosis
P03772471A1054|133 137|time
P03772471A1054|141 148|surgery
P03772471A1054|170 174|case
P03774111T0000|0 8|Evidence
P03774111T0000|21 30|addiction
P03774111T0000|37 41|part
P03774111T0000|52 60|response
P03776080A0400|16 39|post-mortem examination
P03776080A0400|60 67|animals
P03776080A0400|105 112|animals
P03776080A0400|118 121|E/S
P03776080A0400|126 138|CWE antigens
P03776438A0000|0 14|Glucocorticoid
P03776438A0000|23 35|hypertension
P03776438A0000|72 78|sodium
P03776438A0000|80 82|Na
P03776438A0000|88 96|contrast
P03776438A0000|100 117|mineralocorticoid
P03776438A0000|126 138|hypertension
P03776438A0000|149 151|Na
P03776779A0238|26 35|treatment
P03776779A0238|50 58|steroids
P03777398A0156|0 8|Examples
P03777398A0156|16 19|use
P03777398A0156|37 49|therapy unit
P03779182A0370|12 24|drug problem
P03779182A0370|61 67|number
P03779182A0370|71 76|cases
P03779182A0370|80 91|hepatitis B
P03779182A0370|112 118|deaths
P03779205A0459|11 19|patients
P03779205A0459|50 57|disease
P03779205A0459|80 85|years
P03779205A0459|98 110|presentation
P03779205A0459|117 125|patients
P03779205A0459|143 154|secondaries
P03779205A0459|170 175|years
P03780248A0274|9 20|differences
P03780248A0274|43 50|infants
P03780248A0274|71 76|group
P03780248A0274|86 93|changes
P03780248A0274|124 135|ventilation
P03780248A0274|137 140|IMV
P03780248A0274|142 150|settings
P03780248A0274|158 167|transport
P03780248A0274|183 190|infants
P03780248A0274|216 224|hospital
P03780248A0274|241 243|pH
P03780248A0274|248 259|PCO2 values
P03780371A0792|11 20|sequences
P03780371A0792|51 58|introns
P03780371A0792|66 91|cytochrome P-450PBc2 gene
P03780371A0792|104 109|exons
P03780371A0792|129 135|region
P03780704A0573|8 16|increase
P03780704A0573|20 33|serum ketones
P03780704A0573|53 63|conditions
P03780704A0573|73 81|exercise
P03780704A0573|94 102|quotient
P03780704A0573|118 126|increase
P03780704A0573|134 145|utilization
P03780704A0573|147 149|WW
P03780704A0573|165 167|CW
P03780704A0573|178 180|CC
P03781000A0101|5 9|lack
P03781000A0101|13 24|correlation
P03781000A0101|39 49|variations
P03781000A0101|67 75|activity
P03781000A0101|97 105|implants
P03781000A0101|127 133|stages
P03781000A0101|141 148|disease
P03781948T0000|12 22|adaptation
P03781948T0000|34 41|hypoxia
P03781948T0000|53 57|rats
P03783160A0285|0 8|Compound
P03783160A0285|21 34|21-O-angeloyl
P03783160A0285|49 62|R1-barrigenol
P03783160A0285|67 79|21-O-tigloyl
P03783160A0285|95 108|R1-barrigenol
P03785212A0091|18 47|hamster S14 protein sequences
P03785212A0091|65 70|cDNAs
P03785212A1128|0 13|RPS14 introns
P03785212A1128|35 48|Alu sequences
P03788231A0802|25 32|aspects
P03788231A0802|61 69|survival
P03788231A0802|76 82|animal
P03788231A0802|111 123|implantation
P03788231A0802|146 151|heart
P03788231A0802|197 206|placement
P03788231A0802|221 231|ventricles
P03788231A0802|243 248|chest
P03789052A0527|15 30|tissue response
P03789052A0527|47 65|cyanoacrylate site
P03789052A0527|94 102|chemical
P03789052A0527|114 122|reaction
P03789052A0527|140 155|tissue adhesive
P03789052A0527|174 182|evidence
P03789052A0527|205 212|effects
P03791645A1124|6 14|findings
P03791645A1124|43 55|relationship
P03791645A1124|68 80|pathogenesis
P03791645A1124|84 87|MAL
P03791645A1124|89 99|narcolepsy
P03791645A1124|105 108|OSA
P03795488A0487|21 28|lesions
P03795488A0487|88 90|PR
P03795488A0487|99 112|response rate
P03795488A0487|120 121|%
P03799323A0501|15 25|hematocrit
P03799323A0501|30 45|flow conditions
P03799323A0501|51 55|rate
P03799323A0501|59 85|oxygen saturation decrease
P03799323A0501|119 131|sickle cells
P03799323A0501|148 153|cells
P03799790A0146|10 18|examiner
P03799790A0146|32 40|interior
P03799790A0146|48 51|eye
P03799790A0146|66 80|ophthalmoscopy
P03799790A0146|86 98|point source
P03799790A0146|102 107|light
P03799790A0146|128 138|light pipe
P03799790A0146|159 166|margins
P03799790A0146|185 191|plaque
P03802195A0481|6 21|fusion proteins
P03802195A0481|39 51|localization
P03802195A0481|75 85|activation
P03802195A0481|90 109|DNA binding domains
P03802195A0481|117 129|ToxR protein
P03802195A0481|172 179|portion
P03805090A0645|16 24|analyses
P03805090A0645|34 42|patients
P03805090A0645|66 75|incidence
P03805090A0645|89 103|chondrosarcoma
P03805090A0645|107 115|patients
P03805090A0645|132 139|disease
P03805090A0645|156 160|cent
P03805090A0645|168 171|age
P03805090A0645|181 186|years
P03805090A0645|207 219|degeneration
P03805090A0645|232 241|certainty
P03805090A0645|245 253|patients
P03805090A0645|263 280|Maffucci syndrome
P03806696A0000|11 19|toxicity
P03806696A0000|34 39|HgCl2
P03806696A0000|54 61|CH3HgCl
P03806696A0000|63 79|mercury chloride
P03806696A0000|97 105|Coturnix
P03806696A0000|107 121|Japanese quail
P03806696A0000|123 140|Coturnix japonica
P03806696A0000|155 159|ages
P03806696A0000|165 170|hatch
P03806696A0000|179 188|adulthood
P03806696A0000|233 243|injections
P03806696A0000|265 270|trial
P03810361A0576|33 59|plasma cortisol estimation
P03810361A0576|92 96|mean
P03810361A0576|109 135|plasma cortisol estimation
P03810361A0576|159 166|adjunct
P03810361A0576|174 183|diagnosis
P03810361A0576|187 194|Cushing
P03810361A0576|197 205|syndrome
P03810867A0305|12 20|patients
P03810867A0305|42 49|lesions
P03810867A0305|54 58|T3-4
P03810867A0305|64 65|%
P03810867A0305|92 102|TNM system
P03810867A0305|104 121|Lederman-Gadeberg
P03810867A0305|123 135|Sisson-Jesse
P03811852A0109|4 8|risk
P03811852A0109|19 32|complications
P03811852A0109|63 70|factors
P03811852A0109|81 90|gestation
P03811852A0109|96 107|combination
P03811852A0109|111 128|magnesium sulfate
P03811852A0109|149 156|agonist
P03811852A0109|166 169|use
P03811852A0109|173 195|adrenocortico-steroids
P03811852A0109|222 230|maturity
P03814493T0000|0 12|Chlorambucil
P03814493T0000|17 27|interferon
P03814493T0000|36 41|grade
P03814493T0000|56 64|lymphoma
P03818467A0180|0 8|Selenium
P03818467A0180|13 16|ppm
P03818467A0180|22 23|E
P03818467A0180|28 33|IU/kg
P03818467A0180|35 50|supplementation
P03818467A0180|58 62|diet
P03818467A0180|84 101|plasma tocopherol
P03818467A0180|106 123|Se concentrations
P03818467A0180|146 175|plasma glutathione peroxidase
P03818467A0180|177 183|GSH-Px
P03818467A0180|185 193|activity
P03818866A0116|0 15|Framingham Type
P03818866A0116|18 26|behavior
P03818866A0116|68 82|blood pressure
P03818866A0116|84 85|r
P03818866A0116|94 95|p
P03818866A0116|122 127|women
P03820222A0203|27 34|potency
P03820222A0203|142 147|group
P03824908A0116|4 19|M reading frame
P03824908A0116|47 55|sequence
P03824908A0116|68 78|nucleotide
P03824908A0116|111 117|lysine
P03824908A0116|121 153|arginine amino acid substitution
P03824908A0116|163 179|carboxy-terminus
P03824908A0116|200 210|M proteins
P03824908A0116|214 229|paramyxoviruses
P03826871A0000|3 6|ion
P03826871A0000|23 29|method
P03826871A0000|52 58|Br ion
P03826871A0000|66 71|urine
P03826871A0000|75 85|Greyhounds
P03827071T0040|0 2|II
P03828209T0000|15 22|changes
P03828209T0000|46 56|intubation
P03828209T0000|60 66|adults
P03828500T0001|0 15|Intensification
P03828500T0001|36 56|contractile activity
P03828500T0001|72 83|blood serum
P03829848T0001|0 19|Autotransplantation
P03829848T0001|25 37|vein segment
P03829848T0001|43 48|valve
P03829848T0001|56 65|treatment
P03829848T0001|74 78|vein
P03829848T0001|88 101|insufficiency
P03829848T0001|115 124|extremity
P03830147A0000|4 17|relationships
P03830147A0000|29 40|descriptors
P03830147A0000|44 60|lactate increase
P03830147A0000|62 79|lactate threshold
P03830147A0000|81 83|LT
P03830147A0000|90 93|VO2
P03830147A0000|103 130|blood lactate concentration
P03830147A0000|168 173|level
P03830147A0000|196 209|exercise test
P03830147A0000|212 215|LT1
P03830147A0000|221 224|VO2
P03830147A0000|234 247|blood lactate
P03830147A0000|260 262|mM
P03830147A0000|281 286|level
P03830147A0000|289 292|LT2
P03830147A0000|298 301|VO2
P03830147A0000|311 338|blood lactate concentration
P03830147A0000|355 360|value
P03830147A0000|366 368|mM
P03830147A0000|371 376|onset
P03830147A0000|380 406|blood lactate accumulation
P03830147A0000|408 412|OBLA
P03830147A0000|418 421|VO2
P03830147A0000|431 444|blood lactate
P03830147A0000|455 468|concentration
P03830147A0000|474 476|mM
P03830147A0000|506 514|capacity
P03830147A0000|516 522|VO2max
P03830147A0000|531 534|min
P03830147A0000|543 554|performance
P03830147A0000|578 586|students
P03830255A0074|64 76|distribution
P03835413A0616|4 15|observation
P03835413A0616|24 31|effects
P03835413A0616|38 50|irradiations
P03835413A0616|60 73|space flights
P03835413A0616|83 95|difficulties
P03835413A0616|131 136|risks
P03835413A0616|149 171|duration space flights
P03836777T0001|0 13|Practical use
P03836777T0001|18 32|interpretation
P03836777T0001|42 61|hepatitis B markers
P03836777T0001|74 80|biopsy
P03836777T0001|84 99|HBs Ag carriers
P03836777T0001|119 134|hepatitis stage
P03836853A0204|18 37|year survival rates
P03836853A0204|45 46|%
P03836853A0204|50 51|%
P03836853A0204|55 56|%
P03836853A0204|63 64|%
P03836854T0000|0 10|Inhibition
P03836854T0000|42 51|secretion
P03836854T0000|62 64|RP
P03836854T0000|106 111|agent
P03837609T0000|22 27|study
P03837609T0000|48 59|blood cells
P03837609T0000|74 87|mononucleosis
P03838797A0903|0 17|Northern blotting
P03838797A0903|39 54|oligonucleotide
P03838797A0903|72 79|absence
P03838797A0903|94 102|sequence
P03838797A0903|110 114|mRNA
P03838797A0903|130 142|cDNA library
P03838797A0903|150 154|rise
P03838797A0903|169 173|cDNA
P03840480T0000|16 24|families
P03840480T0000|52 69|peptide sequences
P03841627T0001|0 12|Chemotherapy
P03841627T0001|30 43|breast cancer
P03843496A0919|10 15|years
P03843496A0919|42 48|models
P03843496A0919|75 82|variety
P03843496A0919|111 120|chemicals
P03843496A0919|132 139|ability
P03843496A0919|155 169|extrapolations
P03843496A0919|180 195|risk assessment
P03843676A0381|7 20|extrapolation
P03843676A0381|52 56|data
P03843676A0381|107 111|risk
P03843676A0381|119 124|doses
P03848527T0020|0 13|Hisako Minowa
P03848527T0020|46 56|counsellor
P03848527T0020|60 68|industry
P03848527T0020|85 90|years
P03857577A0413|0 24|Deletion mapping studies
P03857577A0413|52 65|DNA sequences
P03857577A0413|114 133|level transcription
P03857577A0413|137 147|HeLa cells
P03857577A0413|177 190|transcription
P03860162A0000|0 13|Incorporation
P03860162A0000|21 28|polyene
P03860162A0000|40 54|amphotericin B
P03860162A0000|56 59|AMB
P03860162A0000|64 73|liposomes
P03860162A0000|94 103|reduction
P03860162A0000|107 120|drug toxicity
P03860162A0000|129 133|loss
P03860162A0000|148 155|potency
P03861687A0000|29 34|males
P03861687A0000|73 77|care
P03861687A0000|100 109|treatment
P03861687A0000|135 146|alterations
P03861687A0000|150 158|response
P03861687A0000|192 210|system stimulation
P03862898A0563|0 9|Serum IgM
P03862898A0563|14 32|IgE concentrations
P03862898A0563|52 62|IgE scores
P03862898A0563|72 88|tumor E2R status
P03862898A0563|130 149|risk classification
P03862898A0563|202 212|components
P03863231A0530|4 15|M-3 subtype
P03863231A0530|42 48|factor
P03863561A0405|11 16|Strep
P03863561A0405|18 30|mutans group
P03863561A0405|62 72|difference
P03863561A0405|81 86|Strep
P03863561A0405|88 100|mutans/Strep
P03863561A0405|102 110|cricetus
P03863561A0405|112 113|p
P03863561A0405|135 142|respect
P03863561A0405|151 161|clump size
P03865743A0859|6 13|results
P03865743A0859|28 32|T.C.
P03865743A0859|34 40|LDL-C.
P03865743A0859|42 48|HDL-C.
P03865743A0859|50 57|HDL2-C.
P03865743A0859|59 64|apo B
P03865743A0859|66 81|apo A-I/B ratio
P03865743A0859|86 102|apo A-II/B ratio
P03865743A0859|118 130|risk factors
P03865743A0859|147 160|heart disease
P03866085A0795|32 55|suppository formulation
P03866085A0795|59 64|CZX-S
P03866085A0795|82 91|treatment
P03866085A0795|95 105|infections
P03866085A0795|109 117|children
P03866085A0795|147 156|disorders
P03866085A0795|164 172|children
P03866085A0795|194 199|drugs
P03866085A0795|218 226|vomiting
P03869442A0223|3 11|addition
P03869442A0223|20 32|hypertension
P03869442A0223|50 58|disorder
P03869442A0223|67 80|abnormalities
P03869442A0223|96 108|hypertension
P03869442A0223|147 166|vasopressin therapy
P03871298A0217|7 22|photon emission
P03871298A0217|36 46|tomography
P03871298A0217|48 53|SPECT
P03871298A0217|87 101|representation
P03871298A0217|116 122|Tl-201
P03871298A0217|131 138|promise
P03871298A0217|152 164|localization
P03871298A0217|168 171|CAD
P03871445T0000|0 8|Computer
P03871445T0000|18 25|mapping
P03871445T0000|42 50|analysis
P03871445T0000|63 90|positron emission tomograms
P03873141A0304|6 23|patients vagotomy
P03873141A0304|44 52|bleeding
P03873141A0304|77 84|therapy
P03873141A0304|86 92|Visick
P03873141A0304|102 110|patients
P03873141A0304|117 131|mortality rate
P03873141A0304|134 135|%
P03874921A0862|0 13|Documentation
P03874921A0862|43 56|fertilization
P03874921A0862|62 70|delivery
P03874921A0862|76 85|term baby
P03874921A0862|111 122|feasibility
P03874921A0862|130 132|EP
P03874921A0862|143 154|anovulation
P03874921A0862|171 180|procedure
P03874921A0862|205 213|drawback
P03875231A0627|0 3|MRI
P03875231A0627|43 56|abnormalities
P03875231A0627|66 67|%
P03875231A0627|83 90|kidneys
P03875231A0627|96 100|loss
P03875231A0627|121 136|differentiation
P03875231A0627|152 157|fluid
P03875231A0627|175 183|hematoma
P03875231A0627|189 199|hemorrhage
P03875231A0627|213 217|cyst
P03875231A0627|239 252|abnormalities
P03877298A0718|4 11|results
P03877298A0718|70 91|Cremophor formulation
P03877298A0718|109 120|variability
P03877298A0718|124 133|induction
P03877298A0718|138 152|recovery times
P03877298A0718|172 192|emulsion formulation
P03878585A0507|4 28|percentage RFR reduction
P03878585A0507|36 39|end
P03878585A0507|43 46|CPB
P03878585A0507|66 77|correlation
P03878585A0507|86 98|CPB duration
P03878585A0507|100 101|r
P03878585A0507|114 136|oxygen flow rate index
P03878585A0507|138 142|OFRI
P03878585A0507|166 190|bubble oxygenator/m2 bsa
P03878585A0507|192 193|r
P03878585A0507|210 231|blood flow rate index
P03878585A0507|233 237|BFRI
P03878585A0507|253 259|volume
P03878585A0507|263 268|blood
P03878585A0507|299 326|machine/min CPB time/m2 bsa
P03878585A0507|328 329|r
P03880838T0000|0 9|Diagnosis
P03880838T0000|30 44|artery lesions
P03880838T0000|51 75|captopril administration
P03881260A0000|2 20|yeast DNA fragment
P03881260A0000|34 44|gene CP A1
P03881260A0000|64 71|subunit
P03881260A0000|79 126|arginine pathway carbamoyl-phosphate synthetase
P03882029A0000|16 21|study
P03882029A0000|32 36|sera
P03882029A0000|45 49|cats
P03882029A0000|72 89|granuloma complex
P03882029A0000|106 107|%
P03882029A0000|120 124|cats
P03882029A0000|141 151|antibodies
P03882029A0000|155 165|components
P03882029A0000|176 190|cat epithelium
P03883052T0001|3 9|memory
P03883052T0001|13 32|Magdelaine Comtesse
P03883541A0200|4 27|H2 receptor antagonists
P03883541A0200|32 47|sucralfate cost
P03883541A0200|81 88|effects
P03885983A0254|6 13|results
P03885983A0254|27 36|indoramin
P03885983A0254|46 55|Class III
P03885983A0254|71 79|activity
P03887085A0000|7 15|efficacy
P03887085A0000|32 35|use
P03887085A0000|48 53|doses
P03887085A0000|61 76|pharmaceuticals
P03887085A0000|78 87|cystamine
P03887085A0000|92 97|mg/kg
P03887085A0000|103 111|mexamine
P03887085A0000|116 121|mg/kg
P03887085A0000|133 143|conditions
P03887085A0000|168 175|hypoxia
P03887085A0000|180 181|%
P03887085A0000|200 211|CBA X C57Bl
P03887085A0000|212 219|F1 mice
P03887769A0093|4 8|Mean
P03887769A0093|27 44|micrograms J/g Cr
P03887769A0093|60 77|micrograms J/g Cr
P03887769A0584|7 13|region
P03887769A0584|49 59|population
P03887769A0584|63 80|iodine deficiency
P03887769A0584|98 99|%
P03887769A0584|107 124|iodine deficiency
P03887769A0584|133 134|%
P03888621A0185|15 19|gene
P03888621A0185|24 35|hydrogenase
P03888621A0185|46 61|protein product
P03888621A0185|75 79|mass
P03888621A0185|86 88|Da
P03890486A0000|20 42|lymph node enlargement
P03890486A0000|58 63|cause
P03890486A0000|76 82|source
P03890486A0000|86 103|imaging confusion
P03890486A0000|119 129|propensity
P03890486A0000|150 160|malignancy
P03890486A0000|183 194|obstruction
P03891766A1473|0 12|Interference
P03891766A1473|29 35|factor
P03891766A1473|61 66|ELISA
P03891766A1473|80 84|sera
P03891766A1473|110 126|latex adsorbents
P03894482A0549|4 12|patients
P03894482A0549|26 32|levels
P03894482A0549|36 56|serum IgE antibodies
P03894482A0549|70 85|soybean extract
P03894482A0549|87 101|binding values
P03894482A0549|126 131|times
P03894482A0549|151 164|control serum
P03896991T0000|0 14|New techniques
P03896991T0000|23 40|mass spectrometry
P03896991T0000|52 60|products
P03898382A0000|18 37|subtraction imaging
P03898382A0000|45 51|spleen
P03898382A0000|58 70|67Ga citrate
P03898382A0000|75 80|99mTc
P03898382A0000|114 121|lesions
P03898382A0000|162 181|radiogallium survey
P03898382A0000|203 217|sulfur colloid
P03898382A0000|231 236|image
P03904004A1577|31 37|energy
P03904004A1577|41 66|medium energy collimation
P03904004A1577|73 79|window
P03904004A1577|100 118|keV 123I photopeak
P03904004A1577|146 166|breakthrough signals
P03904004A1577|184 199|Compton scatter
P03904004A1577|208 222|energy photons
P03904004A1577|238 242|124I
P03904952T0000|0 17|Nursing education
P03904952T0000|23 42|computer obligation
P03908196T0000|0 19|Shear bond strength
P03908196T0000|35 40|resin
P03908196T0000|54 67|glass ionomer
P03908493A0246|14 23|advantage
P03908493A0246|36 41|resin
P03908493A0246|65 91|immunoperoxidase technique
P03908493A0246|112 120|sections
P03910310A0666|7 14|concept
P03910310A0666|33 46|understanding
P03910310A0666|54 63|pathology
P03911052A0909|17 23|DIL-CP
P03911052A0909|48 50|CP
P03911052A0909|54 66|CABG surgery
P03911052A0909|97 99|CP
P03911052A0909|107 115|patients
P03911052A0909|126 138|CABG surgery
P03911702A0530|40 45|model
P03911702A0530|49 54|means
P03911702A0530|89 111|microembolism syndrome
P03911702A0530|164 170|trauma
P03911702A0530|174 178|pigs
P03911702A0530|204 214|anesthesia
P03911702A0530|234 244|conditions
P03911965A0513|24 36|significance
P03911965A0513|91 96|trend
P03911965A0513|105 116|superiority
P03911965A0513|120 132|Galphimia D6
P03911965A0513|143 161|Galphimia dilution
P03911965A0513|211 218|placebo
P03912247A0282|4 10|volume
P03912247A0282|14 19|blood
P03912247A0282|27 31|flap
P03912247A0282|51 57|ml/min
P03912247A0282|59 81|collateral circulation
P03912247A0282|89 93|flap
P03912247A0282|141 147|change
P03912247A0282|165 175|blood flow
P03912247A0282|183 192|flap ages
P03913522A0000|5 10|aging
P03913522A0000|17 24|aspects
P03913522A0000|35 50|function change
P03914875T0001|5 16|candidiasis
P03915540A0863|3 11|addition
P03915540A0863|17 34|gcd1-101 mutation
P03915540A0863|68 78|efficiency
P03915540A0863|82 96|GCN4-lacZ mRNA
P03915540A0863|109 113|gcn2
P03915540A0863|119 123|gcn3
P03915540A0863|125 130|cells
P03920700A0491|53 67|responsiveness
P03920700A0491|99 104|alpha
P03920700A0491|107 120|adrenoceptors
P03921727A0523|4 18|concentrations
P03921727A0523|22 29|apo A-I
P03921727A0523|34 42|apo A-II
P03921727A0523|46 56|abstainers
P03921727A0523|113 120|changes
P03921727A0523|124 132|controls
P03922116A0197|4 16|distribution
P03922116A0197|20 28|patients
P03922116A0197|45 50|group
P03922116A0197|62 75|gamma-therapy
P03922116A0197|80 85|cases
P03922116A0197|88 93|group
P03922116A0197|105 118|gamma-therapy
P03922116A0197|130 145|lymphadenectomy
P03922116A0197|150 155|cases
P03922116A0197|161 166|group
P03922116A0197|178 197|radiation treatment
P03922116A0197|203 211|megavolt
P03922116A0197|227 231|beam
P03922116A0197|241 262|luc type installation
P03922116A0197|267 288|iliac lymphadenectomy
P03922116A0197|293 298|cases
P03923828A1031|4 16|availability
P03923828A1031|20 35|cryoprecipitate
P03923828A1031|40 45|DDAVP
P03923828A1031|82 91|treatment
P03923828A1031|110 118|reversal
P03923828A1031|129 137|bleeding
P03923828A1031|141 149|patients
P03923828A1031|178 188|procedures
P03923976T0001|0 16|Thrombophlebitis
P03923976T0001|31 39|embolism
P03923976T0001|54 75|factor XII deficiency
P03925712A0229|0 8|Biopsies
P03925712A0229|24 30|mucosa
P03925712A0229|51 66|enzyme activity
P03925712A0229|70 82|deficiencies
P03925712A0229|86 106|transport mechanisms
P03928357A0340|0 20|Laboratory pyrolyses
P03928357A0340|44 48|PCBs
P03928357A0340|66 72|yields
P03928357A0340|76 81|PCDFs
P03928357A0340|87 101|chlorobenzenes
P03928357A0340|112 117|PCDFs
P03928357A0340|122 127|PCDDs
P03928442A0463|14 20|degree
P03928442A0463|24 32|homology
P03928442A0463|60 65|genes
P03928442A0463|74 84|Mtase gene
P03928442A0463|96 105|phage SPR
P03928442A0463|126 132|enzyme
P03928442A0463|148 172|modification specificity
P03928678T0000|38 49|contraction
P03928678T0000|53 61|urethral
P03928678T0000|74 80|muscle
P03929486A0309|22 27|trial
P03929486A0309|32 40|patients
P03929486A0309|46 50|COCM
P03929486A0309|52 63|NYHA II-III
P03929486A0309|70 82|sinus rhythm
P03929486A0309|106 123|ejection fraction
P03929486A0309|125 130|LV-EF
P03929486A0309|147 148|%
P03929486A0309|172 173|D
P03929486A0309|184 188|mg/d
P03929486A0309|191 198|placebo
P03929486A0309|200 204|PLAC
P03929486A0309|207 208|P
P03929486A0309|215 223|releases
P03929486A0309|226 228|SR
P03929486A0309|234 241|mg/d SR
P03929486A0309|252 257|drugs
P03929486A0309|281 286|doses
P03929610A0268|13 23|discomfort
P03929610A0268|41 49|patients
P03930549A0209|4 10|sample
P03930549A0209|38 52|centrifugation
P03930549A0209|62 66|acid
P03930549A0209|74 85|supernatant
P03930549A0209|110 114|form
P03930549A0209|125 134|injection
P03930549A0209|144 161|gas chromatograph
P03930894T0000|0 7|Changes
P03930894T0000|22 45|acetylcholine receptors
P03930894T0000|60 64|lung
P03930894T0000|66 73|effects
P03930894T0000|77 82|aging
P03930894T0000|84 94|inhalation
P03930894T0000|101 109|allergen
P03930894T0000|111 125|administration
P03930894T0000|129 134|drugs
P03930894T0000|140 148|vagotomy
P03931293A0437|7 14|absence
P03931293A0437|24 35|stabilizers
P03931293A0437|47 54|sucrose
P03931293A0437|77 93|thermoresistance
P03931293A0437|101 106|virus
P03931293A0437|113 122|% albumin
P03931797A0134|12 22|prevalence
P03931797A0134|26 35|psoriasis
P03931797A0134|44 45|%
P03931797A0134|49 52|men
P03931797A0134|61 62|%
P03931797A0134|66 71|women
P03933232T0000|6 16|classicism
P03933232T0000|27 36|structure
P03933232T0000|53 61|pathways
P03933232T0000|65 82|animal morphology
P03933784A0420|13 19|origin
P03933784A0420|24 28|role
P03933784A0420|32 45|CSF prolactin
P03934667A0124|18 32|crsA mutations
P03934667A0124|34 39|crsA1
P03934667A0124|41 46|crsA4
P03934667A0124|52 58|crsA47
P03934667A0124|85 100|gene conversion
P03934667A0124|102 109|process
P03934667A0124|113 139|B. subtilis plasmid pRPD11
P03934667A0124|180 184|rpoD
P03934667A0124|192 200|sequence
P03934667A0124|221 226|sigma
P03934667A0124|230 236|factor
P03934667A0124|240 266|B. subtilis RNA polymerase
P03934667A0124|272 278|pUB110
P03935117T0000|10 16|effect
P03935117T0000|30 36|oedema
P03935117T0000|40 73|prostaglandin E2 pharmacokinetics
P03935117T0000|77 85|rat lung
P03935375A0414|5 12|article
P03935375A0414|47 51|data
P03935375A0414|59 69|morphology
P03935375A0414|71 79|function
P03935375A0414|85 97|biochemistry
P03935375A0414|118 125|medulla
P03935375A0414|134 143|pathology
P03935375A0414|160 163|RPN
P03935375A0414|193 200|changes
P03935375A0414|212 216|rise
P03935375A0414|229 241|degeneration
P03935375A0414|256 265|carcinoma
P03935797A0183|4 8|data
P03935797A0183|70 88|sry messenger RNAs
P03935797A0183|109 116|embryos
P03935797A0183|149 154|sites
P03935797A0183|216 223|regions
P03935797A0183|249 254|order
P03935797A0183|256 260|beta
P03935797A0183|262 267|alpha
P03935797A0183|272 277|delta
P03936828T0000|8 19|thyroiditis
P03936828T0000|25 36|risk factor
P03936828T0000|40 55|B-cell lymphoma
P03936828T0000|63 76|thyroid gland
P03937294A0404|0 22|Plasma secretin levels
P03937294A0404|48 62|administration
P03937294A0404|66 83|ethanol solutions
P03937294A0404|92 97|delay
P03937294A0404|111 115|hour
P03937294A0404|126 131|onset
P03937294A0404|135 149|acid secretion
P03937481T0001|19 32|microanalysis
P03937481T0001|62 66|acid
P03937481T0001|85 97|preparations
P03939317A0352|2 12|comparison
P03939317A0352|35 42|regions
P03939317A0352|72 83|HS promoter
P03939317A0352|91 115|soybean HS-protein genes
P03939317A0352|134 140|region
P03940426A0618|0 7|Results
P03940426A0618|16 21|study
P03940426A0618|36 39|GLC
P03940426A0618|49 54|chain
P03940426A0618|61 66|acids
P03940426A0618|79 90|agar medium
P03940426A0618|94 103|anaerobes
P03940426A0618|126 131|tests
P03940426A0618|140 144|Gram
P03940426A0618|166 176|morphology
P03940426A0618|188 191|fir
P03940426A0618|211 231|genus identification
P03940426A0618|253 265|agar culture
P03940733A0755|11 17|method
P03940733A0755|31 41|absorption
P03940733A0755|49 54|doses
P03940733A0755|58 67|vitamin A
P03940733A0755|108 116|approach
P03940733A0755|120 130|assessment
P03940733A0755|138 151|malabsorption
P03940818T0000|10 21|hepatitis A
P03940818T0000|33 44|HBV carrier
P03944212A0166|0 15|Tissue pressure
P03944212A0166|17 21|rCBF
P03944212A0166|27 40|water content
P03944212A0166|65 71|matter
P03944212A0166|87 91|core
P03944212A0166|111 117|margin
P03944212A0166|125 138|MCA territory
P03944212A0166|146 147|h
P03944212A0166|154 158|MCAO
P03944239A0780|12 16|time
P03944239A0780|22 30|patients
P03944239A0780|58 88|plasma thyroid hormone changes
P03944239A0780|105 123|amiodarone therapy
P03944239A0780|140 142|T4
P03944239A0780|149 151|T4
P03944239A0780|157 160|rT3
P03944239A0780|175 177|T3
P03946125T0000|0 4|Drug
P03946125T0000|9 30|nutrient interactions
P03952387A0336|8 19|compartment
P03952387A0336|41 48|tissues
P03952387A0336|63 71|reaction
P03952387A0336|78 83|place
P03952387A0336|99 112|oxyhemoglobin
P03952387A0336|114 118|HbO2
P03953361A0000|16 23|effects
P03953361A0000|27 38|propranolol
P03953361A0000|53 63|metabolism
P03953361A0000|79 90|reperfusion
P03953361A0000|92 111|serial measurements
P03953361A0000|126 141|creatine kinase
P03953361A0000|143 145|CK
P03953361A0000|151 158|calcium
P03953361A0000|160 162|Ca
P03953361A0000|164 172|contents
P03953361A0000|177 179|CK
P03953361A0000|184 195|lactic acid
P03953361A0000|197 199|LA
P03953361A0000|201 215|concentrations
P03953361A0000|228 239|sinus blood
P03953361A0000|274 278|dogs
P03956647A1063|0 11|Dissolution
P03956647A1063|24 46|%Ir microelectrode tip
P03956647A1063|63 91|scanning electron microscopy
P03956647A1063|95 111|charge densities
P03956647A1063|126 141|microC/cm2 X ph
P03956647A1063|145 150|A/cm2
P03956647A1063|161 168|erosion
P03956647A1063|182 205|iridium microelectrodes
P03956647A1063|235 241|charge
P03956647A1063|254 263|densities
P03956647A1063|270 285|microC/cm2 X ph
P03956647A1063|290 295|A/cm2
P03956695A0617|0 18|Cortisol excretion
P03956695A0617|60 66|season
P03956695A0617|82 89|factors
P03956695A0617|123 129|stress
P03959045A0000|4 11|studies
P03959045A0000|19 31|relationship
P03959045A0000|60 75|coaching course
P03959045A0000|80 91|performance
P03959045A0000|99 129|Medical College Admission Test
P03959045A0000|131 135|MCAT
P03963860A0137|2 7|total
P03963860A0137|14 22|patients
P03963860A0137|60 64|MY-1
P03963860A0137|89 94|group
P03964489A1195|8 18|% decrease
P03964489A1195|22 26|PaO2
P03964489A1195|28 32|NADH
P03964855A0254|0 11|Angiography
P03964855A0254|40 50|rCBF study
P03964855A0254|59 65|degree
P03964855A0254|69 78|vasospasm
P03964855A0254|99 109|angiograms
P03965012A0163|4 11|results
P03965012A0163|32 37|years
P03965012A0163|84 93|mortality
P03965012A0163|118 132|heart diseases
P03965012A0163|134 145|ICD A83-A84
P03965012A0163|174 190|reference cohort
P03965012A0163|194 212|paper mill workers
P03966687A0000|14 20|impact
P03966687A0000|24 40|childhood asthma
P03966687A0000|69 74|Vance
P03966687A0000|79 85|Taylor
P03966687A0000|101 105|data
P03966687A0000|109 115|Annals
P03966687A0000|119 126|Allergy
P03966687A0000|130 135|years
P03967144T0001|0 13|Hypersplenism
P03970191A0275|11 19|activity
P03970191A0275|60 78|electrocorticogram
P03970191A0275|80 84|ECoG
P03970191A0275|103 105|DC
P03970191A0275|113 122|potential
P03970191A0275|128 133|sites
P03972038A0000|4 14|topography
P03972038A0000|19 31|trajectories
P03972038A0000|39 57|commissural fibers
P03972038A0000|83 89|region
P03972038A0000|91 94|STR
P03972038A0000|135 144|technique
P03972185A0137|13 18|state
P03972185A0137|45 63|insulin deficiency
P03972185A0137|65 78|plasma levels
P03972185A0137|87 88|%
P03972185A0137|92 100|controls
P03972185A0137|111 124|hyperglycemia
P03972185A0137|142 163|plasma glucose levels
P03972185A0137|171 176|times
P03974790A0053|12 23|CT findings
P03974790A0053|49 62|brain infarct
P03974790A0053|77 83|tumour
P03976323A0821|14 25|correlation
P03976323A0821|34 55|blood pressure change
P03976323A0821|60 70|SCR-change
P03977577T0000|0 24|Shoulder forearm support
P03977577T0000|42 50|shoulder
P03977603A0326|0 9|Piroxicam
P03977603A0326|27 36|incidence
P03977603A0326|48 54|ulcers
P03977603A0326|71 76|doses
P03977603A0326|80 92|indomethacin
P03978045A0857|6 14|findings
P03978045A0857|46 52|stages
P03978045A0857|54 56|0T
P03978045A0857|58 60|0N
P03978045A0857|81 87|stages
P03978045A0857|91 94|VWF
P03978045A0857|96 102|stages
P03978045A0857|121 136|hyperreactivity
P03978045A0857|152 159|vessels
P03978045A0857|164 171|Raynaud
P03978045A0857|174 182|syndrome
P03978045A0857|196 205|disorders
P03978045A0857|220 226|origin
P03978045A0857|263 274|alterations
P03978132A0108|3 17|MCCP functions
P03978132A0108|25 40|source emission
P03978132A0108|42 60|surface reflection
P03978132A0108|62 87|photoacceptor sensitivity
P03978132A0108|119 138|distribution curves
P03979084A1019|9 16|kidneys
P03979084A1019|33 35|hr
P03979084A1019|68 77|functions
P03979084A1019|100 104|IMPK
P03979084A1019|108 112|IBPK
P03980386A0000|14 21|effects
P03980386A0000|34 41|hypoxia
P03980386A0000|46 57|angiotensin
P03980386A0000|61 69|infusion
P03980386A0000|73 85|distribution
P03980386A0000|89 99|blood flow
P03980386A0000|107 111|lung
P03980386A0000|125 139|perfusion lung
P03980386A0000|186 191|lambs
P03981421A0246|2 11|flow rate
P03981421A0246|26 30|mL/h
P03981421A0246|55 63|receptor
P03981421A0246|65 71|volume
P03981421A0246|77 79|mL
P03981421A0246|94 101|results
P03981640A0168|27 31|ends
P03981640A0168|58 63|mRNAs
P03981952T0000|4 12|efficacy
P03981952T0000|45 63|chloride titrators
P03981952T0000|71 81|estimation
P03981952T0000|91 102|salt intake
P03982288T0000|0 15|Doctor Berglund
P03982288T0000|22 29|members
P03982288T0000|33 47|union pitfalls
P03984683A0000|6 16|appearance
P03984683A0000|20 31|hemiparesis
P03984683A0000|35 45|hemiplegia
P03984683A0000|66 76|spasticity
P03984683A0000|95 110|stroke patients
P03985849A0221|16 30|rhinosinusitis
P03985849A0221|50 56|groups
P03985849A0221|60 68|patients
P03985849A0221|78 89|development
P03985849A0221|101 115|rhinosinusitis
P03985849A0221|134 142|patients
P03985849A0221|148 152|CVID
P03985849A0221|181 187|nature
P03985849A0221|196 205|condition
P03985849A0221|230 244|IgA deficiency
P03987818A0440|6 10|data
P03987818A0440|24 28|AP-A
P03987818A0440|62 72|management
P03987818A0440|76 89|heart failure
P03987857A0733|12 19|muscles
P03987857A0733|34 46|floor region
P03987857A0733|103 112|mass unit
P03987857A0733|130 139|intensity
P03987857A0733|143 154|stimulation
P03988001A0227|26 53|rat blood chloroform levels
P03988001A0227|89 98|treatment
P03988001A0227|104 108|ClO2
P03989827T0000|4 13|frequency
P03989827T0000|17 35|lactase phenotypes
P03989827T0000|39 54|Aymara children
P03992022A0330|0 10|Activities
P03992022A0330|22 32|cytochrome
P03992022A0330|62 69|enzymes
P03992022A0330|78 89|aminopyrine
P03992022A0330|95 112|TMO N-demethylase
P03992022A0330|117 145|aniline hydroxylase activity
P03992022A0330|164 176|pretreatment
P03992022A0330|180 184|rats
P03992022A0330|190 200|cimetidine
P03992022A0330|217 221|rats
P03992022A0330|238 248|ranitidine
P03992022A0330|256 273|enzyme activities
P03995513T0000|0 11|Doxorubicin
P03995513T0000|13 24|dacarbazine
P03995513T0000|26 37|vincristine
P03995513T0000|43 59|cyclophosphamide
P03995513T0000|67 76|treatment
P03995513T0000|106 120|leiomyosarcoma
P03997467A0000|4 10|effect
P03997467A0000|25 44|antagonist naloxone
P03997467A0000|76 84|patients
P03997467A0000|99 107|ischemia
P03998071T0000|0 25|Electrochemical detection
P03998071T0000|51 57|levels
P03998071T0000|61 71|vitamin K1
P03998071T0000|75 87|osteoporosis
P03998813A0406|15 26|experiments
P03998813A0406|47 51|role
P03998813A0406|75 82|pattern
P03998813A0406|93 101|activity
P03998813A0406|113 121|ontogeny
P03998813A0406|125 141|frequency tuning
P03998813A0406|149 154|mouse
P03998813A0406|172 178|system
P03999219A0463|0 14|Ultrastructure
P03999219A0463|22 27|tumor
P03999219A0463|33 40|patient
P03999219A0463|63 72|resection
P03999219A0463|89 94|weeks
P03999219A0463|101 116|alum irrigation
P03999219A0463|149 158|chromatin
P03999219A0463|191 198|changes
P03999219A0463|211 226|alum irrigation
P04000347A0442|22 30|criteria
P04000347A0442|65 72|persons
P04000347A0442|94 100|groups
P04000347A0442|133 136|BEN
P04000347A0442|168 171|BEN
P04000347A0442|181 192|individuals
P04000347A0442|201 206|signs
P04000347A0442|218 225|disease
P04001413A0093|9 16|purpose
P04001413A0093|47 53|device
P04001413A0093|90 97|patient
P04001413A0093|109 123|breath-holding
P04001413A0093|142 147|scans
P04001490T0001|4 18|POEMS syndrome
P04001490T0001|20 34|Polyneuropathy
P04001490T0001|36 48|Organomegaly
P04001490T0001|50 64|Endocrinopathy
P04001490T0001|77 86|component
P04001490T0001|88 92|Skin
P04002131A0506|9 26|disease remission
P04002131A0506|40 48|increase
P04002131A0506|52 65|GAG secretion
P04002131A0506|71 76|urine
P04002131A0506|90 106|hyperheparinuria
P04002131A0506|119 120|P
P04002667A0181|19 27|patients
P04002667A0181|38 45|results
P04002667A0181|65 80|tumor diameters
P04002667A0181|89 91|cm
P04002667A0181|112 124|localization
P04002667A0181|128 139|lung tissue
P04002667A0181|156 165|cm tumors
P04002667A0181|178 193|lung parenchyma
P04004168A0000|4 12|siblings
P04004168A0000|28 34|anemia
P04004168A0000|45 81|triosephosphate isomerase deficiency
P04004168A0000|119 127|syndrome
P04004168A0000|147 156|movements
P04004168A0000|158 164|tremor
P04004168A0000|176 187|tract signs
P04004168A0000|193 201|evidence
P04004168A0000|212 236|motor neuron involvement
P04005190A1288|4 11|extract
P04005190A1288|28 39|PCA content
P04011338A0620|10 18|patients
P04011338A0620|38 44|degree
P04011338A0620|48 59|steatorrhea
P04011338A0620|64 72|decrease
P04011338A0620|80 84|loss
P04011338A0620|98 99|%
P04011338A0620|112 124|relationship
P04011338A0620|136 137|r
P04011338A0620|146 147|p
P04011338A0620|176 182|extent
P04011338A0620|196 205|acid loss
P04011338A0620|209 216|placebo
P04011338A0620|225 233|decrease
P04011338A0620|242 246|loss
P04011338A0620|250 257|taurine
P04011466T0000|7 16|diameters
P04011466T0000|20 27|infants
P04011466T0000|38 46|children
P04011466T0000|71 75|data
P04013576A0981|12 25|investigation
P04013576A0981|48 60|distribution
P04013576A0981|79 84|acids
P04013576A0981|88 112|Leptospira phospholipids
P04013576A0981|133 145|distribution
P04013576A0981|149 159|Leptospira
P04013576A0981|168 174|lipids
P04013576A0981|184 193|exception
P04013576A0981|215 219|acid
P04013576A0981|228 240|carbon atoms
P04013576A0981|262 275|phospholipids
P04013604A0412|15 24|frequency
P04013604A0412|46 56|ulceration
P04013604A0412|73 78|cases
P04013604A0412|91 104|patient-years
P04013604A0412|108 131|slow-release tablet use
P04014833A0400|0 14|Hydrocortisone
P04014833A0400|22 33|lymphopenia
P04014833A0400|64 72|response
P04014833A0400|87 104|blood lymphocytes
P04014833A0400|108 126|phytohemagglutinin
P04014833A0400|131 143|concanavalin
P04014833A0400|146 154|mitogens
P04014861A0000|12 23|feasibility
P04014861A0000|33 42|liposomes
P04014861A0000|66 72|agents
P04014861A0000|80 85|lungs
P04014861A0000|91 97|effect
P04014861A0000|123 143|superoxide dismutase
P04014861A0000|145 148|SOD
P04014861A0000|153 161|catalase
P04014861A0000|175 190|oxygen toxicity
P04014861A0000|206 210|rats
P04015988T0000|0 20|Marrow cell necrosis
P04015988T0000|24 40|anorexia nervosa
P04015988T0000|57 67|starvation
P04017295A0139|4 14|comparison
P04017295A0139|28 35|heparin
P04017295A0139|55 63|dialyses
P04017295A0139|76 84|patients
P04018444A0000|17 21|acid
P04018444A0000|23 28|cheno
P04018444A0000|50 54|acid
P04018444A0000|56 60|urso
P04018444A0000|71 93|cholesterol gallstones
P04018444A0000|97 100|man
P04019066A0000|15 31|field potentials
P04019066A0000|79 88|formation
P04019066A0000|90 93|MRF
P04019066A0000|110 112|CG
P04019066A0000|132 138|cortex
P04019066A0000|140 143|SCX
P04019066A0000|168 173|doses
P04019066A0000|177 186|halothane
P04019066A0000|204 208|rats
P04021281T0001|0 14|Ultrastructure
P04021281T0001|22 34|heart muscle
P04021281T0001|62 69|infarct
P04021281T0001|89 97|training
P04021305A0530|16 32|desympathization
P04021305A0530|46 57|development
P04021305A0530|61 77|hyper-reactivity
P04021305A0530|90 100|pacemakers
P04021305A0530|104 117|noradrenaline
P04021305A0530|122 130|dopamine
P04021305A0530|148 155|changes
P04021305A0530|163 173|regulation
P04021305A0530|190 198|activity
P04021305A0530|208 213|cells
P04021305A0530|217 231|catecholamines
P04021431A0000|0 4|OODG
P04021431A0000|21 27|method
P04021431A0000|39 49|assessment
P04021431A0000|60 72|pulse curves
P04021431A0000|87 100|determination
P04021431A0000|104 119|blood pressures
P04021431A0000|150 156|system
P04021431A0000|187 202|blood pressures
P04021431A0000|228 232|eyes
P04021431A0000|242 252|dilatation
P04021431A0000|260 266|pupils
P04021437A0000|6 16|infections
P04021437A0000|58 64|agents
P04021437A0000|70 76|number
P04021437A0000|86 102|ear dysfunctions
P04024685A0650|9 10|%
P04024685A0650|23 33|parameters
P04024685A0650|55 63|increase
P04024685A0650|65 73|RS index
P04024685A0650|86 91|mVolt
P04024685A0650|107 112|mVolt
P04024685A0650|114 115|p
P04024685A0650|133 136|EDD
P04024685A0650|164 166|cm
P04024685A0650|168 169|p
P04024685A0650|188 190|HV
P04024685A0650|204 206|ml
P04024685A0650|223 225|ml
P04024685A0650|227 228|p
P04024685A0650|246 249|EDV
P04024685A0650|262 264|ml
P04024685A0650|280 282|ml
P04024685A0650|284 285|p
P04024685A0650|304 307|RBV
P04024685A0650|319 321|ml
P04024685A0650|336 338|ml
P04024685A0650|340 341|p
P04025178A0126|14 22|analyses
P04025178A0126|31 36|death
P04025178A0126|60 68|decrease
P04025178A0126|94 96|LV
P04025178A0126|112 124|volume index
P04025178A0126|126 130|EDVI
P04025178A0126|138 143|ml/m2
P04025178A0126|147 148|%
P04025179A0955|3 8|group
P04025179A0955|11 17|adults
P04025179A0955|32 41|variables
P04026903A0512|0 11|Polysorbate
P04026903A0512|37 46|stimulant
P04026903A0512|50 65|relaxant effect
P04026903A0512|76 92|guinea pig ileum
P04026903A0512|96 106|rat uterus
P04026903A0512|136 148|contractions
P04026903A0512|160 173|acetylcholine
P04026903A0512|175 184|histamine
P04026903A0512|186 192|barium
P04026903A0512|194 213|5-hydroxytryptamine
P04026903A0512|218 227|carbachol
P04026903A0512|248 254|manner
P04026972T0000|11 36|alcohol reaction profiles
P04027182T0000|0 8|Vitiligo
P04027182T0000|12 29|diabetes mellitus
P04028871A0133|4 20|pharmacokinetics
P04028871A0133|29 41|tetracycline
P04028871A0133|45 50|serum
P04028871A0133|71 84|blister fluid
P04028871A0133|112 117|doses
P04028871A0133|125 139|mg lymecycline
P04028871A0133|147 161|mg doxycycline
P04028871A0133|173 176|day
P04031488A1091|7 13|degree
P04031488A1091|17 28|correlation
P04031488A1091|36 41|sense
P04031488A1091|57 67|conception
P04031488A1091|71 89|brain localization
P04031488A1091|112 121|syndromes
P04032268A0358|9 20|UV detector
P04032268A0358|32 34|nm
P04032268A0358|58 60|EC
P04032268A0358|62 70|detector
P04032268A0358|80 89|potential
P04032268A0358|98 99|V
P04032268A0358|108 124|Ag/AgCl/3 M NaCl
P04032268A0358|150 154|drug
P04032349A0000|3 11|patients
P04032349A0000|32 42|occlusions
P04032349A0000|52 68|graft thromboses
P04032349A0000|108 116|ischemia
P04032349A0000|147 154|therapy
P04032349A0000|156 165|Urokinase
P04032349A0000|173 186|units/kg/hour
P04032349A0000|192 207|Lys Plasminogen
P04032716A0299|4 24|mean transfer ratios
P04032716A0299|32 36|drug
P04032716A0299|54 61|tissues
P04032716A0299|69 82|concentration
P04032716A0299|107 112|blood
P04032716A0299|132 146|transfer ratio
P04032716A0299|214 220|cervix
P04032716A0299|229 239|myometrium
P04032716A0299|259 266|oviduct
P04033402A1112|28 36|hormones
P04033402A1112|44 74|HDL-cholesterol concentrations
P04033402A1112|83 111|HDL2-cholesterol subfraction
P04033402A1112|143 171|triglyceride lipase activity
P04034220A0205|20 28|spectrum
P04034220A0205|32 40|activity
P04034220A0205|62 72|ampicillin
P04034220A0205|83 90|strains
P04034220A0205|94 107|H. influenzae
P04034220A0205|132 150|tolerance Cefaclor
P04034220A0205|169 178|treatment
P04034220A0205|194 210|tract infections
P04034220A0205|214 222|children
P04034666T0000|6 30|extremity weight bearing
P04034666T0000|45 64|standing conditions
P04034666T0000|93 101|patients
P04034666T0000|107 118|hemiparesis
P04036838A0918|6 12|factor
P04036838A0918|46 50|data
P04036838A0918|55 60|RV/LV
P04036838A0918|70 85|pressure ratios
P04036838A0918|87 88|r
P04036838A0918|97 98|p
P04036838A0918|148 168|pressure differences
P04036838A0918|170 171|r
P04036838A0918|181 182|p
P04037809A0964|28 42|dose schedules
P04037809A0964|46 53|KW-2083
P04038454A0984|25 45|plasma retinol level
P04038454A0984|49 60|conjunction
P04038454A0984|66 69|RBP
P04038454A0984|103 111|patients
P04038454A0984|118 133|micrograms dl-1
P04038454A0984|139 146|mg dl-1
P04038454A0984|169 186|cancer recurrence
P04038454A0984|231 237|cancer
P04038454A0984|244 259|micrograms dl-1
P04038454A0984|265 272|mg dl-1
P04038702A0768|4 11|results
P04038702A0768|42 50|response
P04038702A0768|54 63|tethering
P04038702A0768|93 100|penning
P04038702A0768|114 124|experience
P04038702A0768|152 158|rhythm
P04038702A0768|162 170|cortisol
P04038702A0768|210 216|estrus
P04038702A0768|223 234|disruptions
P04038702A0768|258 262|type
P04038702A0768|288 294|stalls
P04038702A0768|320 343|cortisol concentrations
P04038702A0768|347 352|gilts
P04039109A0139|5 10|laser
P04039109A0139|31 36|power
P04039109A0139|52 64|fluid medium
P04039109A0139|86 93|vessels
P04039109A0139|108 110|mm
P04039109A0139|114 122|diameter
P04039109A0139|132 139|seconds
P04039109A0139|145 158|power density
P04039109A0139|167 172|W/cm2
P04039307A0613|3 4|d
P04039307A0613|10 22|progesterone
P04039307A0613|35 36|P
P04039307A0613|71 78|heifers
P04039307A0613|93 109|treatment groups
P04039439A0000|14 19|quail
P04039439A0000|53 66|ppm manganese
P04039439A0000|68 70|Mn
P04039439A0000|87 102|manganese oxide
P04039439A0000|104 109|Mn3O4
P04039439A0000|120 124|diet
P04039439A0000|145 149|days
P04039439A0000|153 156|age
P04039439A0842|5 10|study
P04039439A0842|39 44|quail
P04039439A0842|79 93|Mn3O4 exposure
P04039439A0842|99 106|rodents
P04039525A0475|0 6|Plasma
P04039525A0475|11 41|bladder platinum concentration
P04039525A0475|79 82|DDP
P04039525A0475|111 122|examination
P04039525A0475|124 134|urinalysis
P04039525A0475|145 156|blood count
P04039525A0475|161 176|blood chemistry
P04039525A0475|195 200|order
P04039525A0475|213 221|toxicity
P04039525A0475|238 241|DDP
P04039667T0000|14 27|visualisation
P04039667T0000|31 51|Walker carcinoma-256
P04039667T0000|55 74|Sprague-Dawley rats
P04039667T0000|78 83|means
P04039667T0000|102 111|monocytes
P04039744A0141|6 13|results
P04039744A0141|52 61|D mothers
P04039744A0141|66 70|pups
P04039744A0141|89 96|mothers
P04039744A0141|105 115|supplement
P04039744A0141|120 139|i.u. vitamin D3/day
P04039744A0141|152 158|period
P04039744A0141|162 171|lactation
P04039744A0141|176 180|days
P04040083A0000|0 11|Rabbit eyes
P04040083A0000|59 67|chambers
P04040083A0000|87 93|saline
P04040307A0145|7 12|birth
P04040307A0145|55 61|nerves
P04040307A0145|94 103|NE levels
P04040339T0001|0 18|Monitoring changes
P04040339T0001|26 36|heart rate
P04040339T0001|54 59|fetus
P04040339T0001|67 76|tocolysis
P04040339T0001|106 117|partusisten
P04040339T0001|122 129|Pre-par
P04040858A0000|6 15|September
P04040858A0000|24 28|June
P04040858A0000|53 61|patients
P04040858A0000|75 81|cancer
P04041307A0614|4 11|results
P04041307A0614|29 47|calcium antagonist
P04041307A0614|49 58|diltiazem
P04041307A0614|75 82|effects
P04041307A0614|86 96|isoflurane
P04041307A0614|111 119|function
P04041346T0000|17 28|arrhythmias
P04041346T0000|30 37|digoxin
P04041346T0000|42 51|quinidine
P04043489A0648|0 7|Visidex
P04043489A0648|28 35|storage
P04043489A0648|40 50|re-reading
P04048245A0331|0 9|Treatment
P04048245A0331|15 32|oxyphenylbutazone
P04048245A0331|37 51|hydrocortisone
P04048245A0331|81 97|serum CPN levels
P04050771A0474|4 7|Cox
P04050771A0474|21 34|hazards model
P04050771A0474|54 58|data
P04050771A0474|62 67|order
P04050771A0474|96 103|factors
P04050771A0474|118 126|survival
P04050821A0531|19 29|mechanisms
P04050821A0531|54 62|increase
P04050821A0531|77 90|oxygen demand
P04050821A0531|123 131|episodes
P04050821A0531|154 162|hospital
P04051521T0001|0 8|Duration
P04051521T0001|12 21|remission
P04051521T0001|42 57|cancer patients
P04051521T0001|83 87|dose
P04051521T0001|91 94|MTX
P04051521T0001|99 103|5-FU
P04052919A0205|6 10|data
P04052919A0205|24 46|progesterone secretion
P04052919A0205|81 93|luteal phase
P04052919A0205|108 117|frequency
P04052919A0205|136 141|phase
P04052919A0205|170 175|phase
P04052919A0205|181 189|subjects
P04052919A0205|194 213|progesterone levels
P04052919A0205|264 274|thresholds
P04052919A0205|280 283|use
P04052919A0205|296 307|measurement
P04052919A0205|311 323|progesterone
P04052919A0205|342 347|phase
P04052919A0205|373 382|indicator
P04052919A0205|386 395|ovulation
P04052919A0205|399 408|threshold
P04052919A0205|425 431|nmol/l
P04052919A0205|458 464|number
P04052919A0205|483 490|results
P04055593A0523|27 37|processing
P04055593A0523|45 47|N2
P04055593A0523|52 64|flow signals
P04055593A0523|95 107|compensation
P04055593A0523|113 124|corrections
P04055593A0523|133 140|effects
P04055593A0523|144 151|changes
P04055593A0523|155 170|gas composition
P04055593A0523|175 186|temperature
P04056218A0463|5 10|slope
P04056218A0463|50 55|dB/dB
P04056218A0463|61 63|L1
P04056218A0463|66 68|L2
P04056218A0463|85 87|dB
P04056256A0416|0 20|Histamine reactivity
P04056256A0416|57 75|nifedipine aerosol
P04056256A0416|91 95|mean
P04056256A0416|108 121|concentration
P04056256A0416|134 140|% fall
P04056256A0416|153 171|airway conductance
P04056256A0416|197 202|mg/ml
P04056256A0416|206 215|histamine
P04056256A0416|217 218|p
P04058985A0000|14 19|doses
P04058985A0000|23 33|vitamin B6
P04058985A0000|60 65|women
P04058985A0000|97 113|plasma prolactin
P04061342A0512|36 45|elevation
P04061342A0512|49 53|mean
P04061342A0512|57 63|uptake
P04061342A0512|74 90|min postexercise
P04061342A0512|98 99|%
P04061342A0512|120 121|p
P04061342A0512|147 152|state
P04061342A0512|154 155|p
P04062128T0028|0 19|National Institutes
P04062128T0028|23 72|Health Consensus Development Conference Statement
P04063732A0509|3 11|controls
P04063732A0509|25 31|output
P04063732A0509|41 48|conduit
P04063732A0509|65 69|type
P04063732A0509|72 80|activity
P04063732A0509|91 92|%
P04066194A0163|0 19|Greater attenuation
P04066194A0163|27 32|N1-P2
P04066194A0163|37 58|baseline-P2 amplitude
P04066194A0163|66 75|probe EPs
P04066194A0163|98 112|probe stimulus
P04066194A0163|140 143|ear
P04066194A0163|159 167|material
P04066194A0163|190 193|ear
P04066194A0163|217 240|stimulation arrangement
P04066274A0265|12 20|patients
P04066274A0265|26 27|%
P04066274A0265|40 49|neoplasms
P04066274A0265|89 102|parotidectomy
P04066274A0265|104 110|T.C.P.
P04066274A0265|119 120|%
P04066274A0265|125 129|S.P.
P04066274A0265|140 141|%
P04066274A0265|146 148|En
P04067540A0413|4 15|comparisons
P04067540A0413|54 66|perpetrators
P04067540A0413|113 120|victims
P04067540A0413|139 144|homes
P04067540A0413|157 162|lover
P04067540A0413|166 174|ex-lover
P04067540A0413|187 192|crime
P04067540A0413|226 238|suicide note
P04067540A0413|250 257|weekend
P04067540A0413|326 333|victims
P04067540A0413|349 355|spouse
P04068663A0452|10 17|rabbits
P04068663A0452|24 39|mouse CRF-flora
P04068663A0452|47 53|values
P04068663A0452|83 90|animals
P04068663A0452|100 110|parameters
P04068663A0452|123 136|unsuitability
P04068663A0452|140 155|mouse CRF flora
P04068663A0452|171 178|rabbits
P04068774A1292|9 22|relationships
P04068774A1292|31 32|F
P04068774A1292|37 39|Zn
P04068774A1292|43 45|Mg
P04068774A1292|74 80|effect
P04068774A1292|88 96|contents
P04068774A1292|106 114|elements
P04068774A1292|118 122|bone
P04068969A0300|0 5|L3-L4
P04068969A0300|18 22|load
P04068969A0300|46 51|model
P04068969A0300|59 66|anatomy
P04068969A0300|74 79|trunk
P04068969A0300|96 102|system
P04069756T0025|0 9|Diagnosis
P04069756T0025|34 53|leukoencephalopathy
P04070725A0442|0 14|Component P100
P04070725A0442|45 55|negativity
P04070725A0442|67 74|latency
P04070725A0442|88 98|hypothesis
P04070725A0442|122 131|generator
P04071063A0863|12 23|differences
P04071063A0863|42 50|decrease
P04071063A0863|54 69|platelet counts
P04071063A0863|86 92|groups
P04071063A0863|94 111|fibrinogen levels
P04071063A0863|116 121|alpha
P04071063A0863|136 142|levels
P04071063A0863|197 202|group
P04073848T0000|0 7|Failure
P04073848T0000|11 33|stapedius reflexometry
P04073848T0000|41 50|diagnosis
P04073848T0000|54 71|myasthenia gravis
P04074214A0000|0 7|Factors
P04074214A0000|20 41|semen characteristics
P04074214A0000|51 56|boars
P04074214A0000|81 92|environment
P04075021T0000|1 4|14C
P04075021T0000|6 25|beta-phenethylamine
P04075021T0000|31 43|distribution
P04075021T0000|50 64|administration
P04075021T0000|76 82|routes
P04075021T0000|86 90|cats
P04075021T0000|100 107|effects
P04075021T0000|111 139|monoamine oxidase inhibitors
P04075061A0355|4 11|runners
P04075061A0355|20 25|total
P04075061A0355|33 34|L
P04075061A0355|38 43|water
P04075061A0355|55 59|race
P04079738A0677|4 9|rates
P04079738A0677|19 29|energy use
P04079738A0677|31 35|mean
P04079738A0677|40 42|SD
P04079738A0677|74 84|kJ X min-1
P04079738A0677|86 87|P
P04079738A0677|137 146|degrees C
P04079738A0677|158 168|degrees C.
P04081425T0016|9 16|aspects
P04081425T0016|21 28|therapy
P04082267A0720|16 20|days
P04082267A0720|22 32|incubation
P04082267A0720|44 53|degrees C
P04082267A0720|61 70|degrees C
P04082267A0720|72 74|Ae
P04082267A0720|76 82|vexans
P04082267A0720|120 125|virus
P04082592T0000|0 17|Blood eosinophils
P04082592T0000|21 29|patients
P04082592T0000|35 41|Taenia
P04084607A0663|4 16|imino proton
P04084607A0663|20 22|T3
P04084607A0663|30 35|O6meG
P04084607A0663|36 37|T
P04084607A0663|49 51|G3
P04084607A0663|59 64|O6meG
P04084607A0663|65 66|N
P04084607A0663|74 79|helix
P04084607A0663|111 128|modification site
P04084607A0663|157 162|field
P04084607A0663|175 178|ppm
P04084607A0663|192 205|imino protons
P04084607A0663|209 232|Watson-Crick base pairs
P04084607A0663|247 250|ppm
P04084896A0569|4 18|recommendation
P04084896A0569|41 51|sub-groups
P04084896A0569|55 65|attempters
P04084896A0569|116 139|intervention strategies
P04085589A0264a|13 24|correlation
P04085589A0264a|33 48|secretor status
P04085589A0264a|62 68|status
P04085589A0264a|70 93|spirometry measurements
P04085589A0264a|108 129|serum lysozyme levels
P04085589A0264a|133 138|rates
P04085589A0264a|154 172|tract colonization
P04085589A0264b|13 24|correlation
P04085589A0264b|33 48|secretor status
P04085589A0264b|62 68|status
P04085589A0264b|70 93|spirometry measurements
P04085589A0264b|108 129|serum lysozyme levels
P04085589A0264b|133 138|rates
P04085589A0264b|154 172|tract colonization
P04086403A1016|0 5|Gains
P04086403A1016|19 20|%
P04086403A1016|22 23|P
P04086403A1016|43 58|feed conversion
P04086403A1016|71 72|%
P04086403A1016|74 75|P
P04086403A1016|101 104|fed
P04086403A1016|108 116|% AS-VFA
P04086403A1016|131 135|gain
P04086403A1016|140 155|feed conversion
P04086403A1016|163 170|control
P04086657T0000|21 32|development
P04086657T0000|51 57|cortex
P04086657T0000|65 68|rat
P04086993T0000|0 5|Daily
P04086993T0000|19 30|rhythmicity
P04086993T0000|38 49|methylation
P04086993T0000|53 59|pineal
P04086993T0000|68 77|compounds
P04086993T0000|99 107|hamsters
P04086993T0000|128 138|conditions
P04088233A0309|4 16|transit time
P04088396A0145|10 31|patients grades 1-2-3
P04088396A0145|35 36|%
P04088396A0145|82 93|abnormality
P04088396A0145|105 113|patients
P04088396A0145|133 134|%
P04088733T0001|0 8|Activity
P04088733T0001|12 27|acid hydrolases
P04088733T0001|42 58|blood leukocytes
P04088733T0001|82 91|pneumonia
P04088733T0001|95 103|children
P04088936T0001|12 19|studies
P04088936T0001|27 39|antithrombin
P04088936T0001|44 49|level
P04088936T0001|54 84|plasminogen activator activity
P04088936T0001|88 96|patients
P04088936T0001|102 118|thrombophlebitis
P04093211A0560|37 44|ability
P04093211A0560|61 70|attitudes
P04093211A0560|75 87|orientations
P04101003T0001|0 9|Relations
P04101003T0001|38 46|activity
P04101003T0001|70 78|activity
P04101003T0001|82 85|man
P04101003T0001|91 94|dog
P04101003T0001|103 109|rabbit
P04102280T0000|0 9|Treatment
P04102280T0000|13 18|Paget
P04102280T0000|21 28|disease
P04103248T0000|0 11|Improvement
P04103248T0000|19 30|CRT display
P04103248T0000|37 45|averager
P04113011T0000|4 19|desensitization
P04113011T0000|25 42|ragweed hay fever
P04114211T0000|6 15|excretion
P04114211T0000|19 33|sulphadimidine
P04114211T0000|56 64|subjects
P04115870T0000|0 11|Experiences
P04115870T0000|47 50|use
P04115870T0000|54 73|Urat-I lithotriptor
P04123217T0000|0 9|Formation
P04123217T0000|13 19|hyphae
P04123217T0000|24 38|chlamydospores
P04123217T0000|42 64|Cryptococcus laurentii
P04123662T0000|0 10|Evaluation
P04123662T0000|14 30|thyroid function
P04138224T0095|4 10|effect
P04138224T0095|16 31|tissue emulsion
P04138224T0095|33 42|vitamin A
P04138224T0095|59 73|gamma-globulin
P04138224T0095|81 96|blood clearance
P04138224T0095|100 107|rabbits
P04139081T0001|5 15|antibodies
P04139081T0001|34 42|patients
P04139943T0001|0 13|Demonstration
P04139943T0001|22 31|structure
P04139943T0001|39 55|guinea pig organ
P04139943T0001|59 64|Corti
P04139943T0001|71 79|electron
P04139943T0001|92 107|silver staining
P04140567T0001|0 20|Histamine metabolism
P04140567T0001|48 53|shock
P04143528A0394|31 43|nomenclature
P04145244T0000|0 10|Relaxation
P04145244T0000|14 19|catch
P04145244T0000|42 48|muscle
P04152725T0001|0 7|Studies
P04152725T0001|21 33|liver injury
P04160980T0000|13 20|control
P04160980T0000|33 44|circulation
P04160980T0000|52 55|dog
P04164595T0020|0 8|Evidence
P04164595T0020|74 79|types
P04164595T0020|83 92|infection
P04164669T0000|26 41|kinin formation
P04164669T0000|51 55|skin
P04172166T0000|0 13|Poliomyelitis
P04172166T0000|21 28|vaccine
P04175007T0001|7 14|problem
P04175007T0001|22 33|stimulation
P04175007T0001|41 47|growth
P04175007T0001|66 72|tumors
P04175007T0001|76 83|animals
P04175007T0001|123 134|antibiotics
P04176249T0001|0 10|Assessment
P04176249T0001|23 28|media
P04176249T0001|36 45|diagnosis
P04176249T0001|49 58|diptheria
P04176268T0000|0 15|Aluminium resin
P04176268T0000|24 33|treatment
P04176268T0000|41 53|hyperkalamia
P04176268T0000|63 70|failure
P04176625T0000|0 5|Value
P04176625T0000|13 16|EMG
P04176625T0000|24 33|diagnosis
P04176625T0000|39 53|cardiomyopathy
P04176625T0000|81 89|myopathy
P04179445T0036|0 2|D.
P04189158T0000|0 10|Prevention
P04189158T0000|23 39|Rh sensitization
P04189158T0000|56 64|globulin
P04194466T0000|0 16|Serotonin levels
P04194466T0000|20 41|infant hypothyroidism
P04196986T0000|14 31|fluid transferrin
P04196986T0000|35 42|studies
P04196986T0000|55 64|disorders
P04196986T0000|88 94|system
P04213917T0001|5 12|dosages
P04213917T0001|16 31|D-penicillamine
P04213917T0001|45 53|fibroses
P04214345T0000|8 16|relation
P04214345T0000|25 48|serum IgG concentration
P04214345T0000|53 60|glucose
P04214345T0000|65 82|xylose absorption
P04214345T0000|86 108|Zambian African adults
P04226360T0001|0 9|Disorders
P04226360T0001|13 30|platelet function
P04226360T0001|50 59|leukemias
P04239041T0045|4 10|effect
P04239041T0045|14 29|anticonvulsants
P04239041T0045|60 66|ATPase
P04239041T0045|68 74|sodium
P04239041T0045|80 88|potassim
P04239041T0045|92 98|cortex
P04246054T0028|0 6|Effect
P04246054T0028|17 28|lymphocytes
P04246054T0028|36 67|rabbit-anti-lymphocyte globulin
P04246054T0028|69 74|RAMLG
P04246054T0028|88 99|macrophages
P04246054T0028|121 143|incubation temperature
P04247472T0001|7 12|cycle
P04247472T0001|22 26|rats
P04247472T0001|47 56|mountains
P04247472T0001|60 69|Kirghizia
P04247966T0000|0 9|Lactation
P04247966T0000|13 20|baboons
P04247966T0000|31 55|protein maintenance diet
P04262268T0001|0 7|Studies
P04262268T0001|23 29|matrix
P04262268T0001|39 51|ear ossicles
P04263748T0042|23 29|review
P04281856T0001|0 3|Age
P04281856T0001|8 21|sex structure
P04281856T0001|37 47|population
P04281856T0001|51 77|Ornithodoros tatarovski Ol
P04282315T0001|0 13|Sensitization
P04282315T0001|17 32|hyperlactatemia
P04282315T0001|44 54|phenformin
P04282315T0001|70 78|ablation
P04282315T0001|86 94|pancreas
P04284435T0000|0 10|Vitamin D3
P04284435T0000|15 33|calcium absorption
P04284435T0000|41 46|chick
P04289156T0000|4 13|incidence
P04289156T0000|17 24|tumours
P04289156T0000|34 42|chickens
P04291759T0048|0 18|Laboratory aspects
P04291759T0048|35 44|reference
P04291759T0048|48 60|chemotherapy
P04291759T0048|65 72|control
P04295031T0062|6 12|effect
P04295031T0062|20 30|guinea pig
P04305850T0000|0 9|Androgens
P04305850T0000|14 20|growth
P04308979T0000|0 6|Effect
P04308979T0000|10 20|variations
P04308979T0000|24 37|time interval
P04308979T0000|46 55|treatment
P04308979T0000|61 64|BCG
P04308979T0000|69 80|quartz dust
P04308979T0000|84 97|translocation
P04308979T0000|101 112|quartz dust
P04308979T0000|122 127|lungs
P04308979T0000|146 157|lymph nodes
P04311951T0001|12 18|action
P04311951T0001|49 60|association
P04311951T0001|70 83|instillations
P04311951T0001|87 94|otology
P04315233T0128|22 32|experiment
P04316696T0001|0 6|Enzyme
P04316696T0001|21 29|findings
P04316696T0001|53 57|body
P04316696T0001|65 70|horse
P04321861T0001|9 41|glutathione reductase deficiency
P04321861T0001|46 54|disorder
P04321861T0001|58 79|glutathione synthesis
P04321861T0001|87 98|erythrocyte
P04323641T0000|0 7|Studies
P04323641T0000|11 30|swine enteroviruses
P04325736T0001|0 13|Serodiagnosis
P04325736T0001|17 27|ectromelia
P04325736T0001|31 46|laboratory mice
P04328746T0073|0 17|Ultrasound effect
P04328746T0073|25 52|cytochrome oxidase activity
P04335965T0000|0 10|Metastasis
P04335965T0000|14 29|colon carcinoma
P04335965T0000|37 40|lip
P04350410T0000|0 7|Genesis
P04350410T0000|11 21|foam cells
P04350410T0000|23 28|study
P04350410T0000|32 36|rats
P04350410T0000|43 57|administration
P04350410T0000|61 69|Cloforex
P04364369T0000|0 22|Pre-beta-1 lipoprotein
P04364369T0000|33 42|detection
P04364369T0000|46 58|risk factors
P04364369T0000|72 85|heart disease
P04369884T0000|0 10|Conditions
P04369884T0000|23 33|inhibitors
P04369884T0000|60 66|factor
P04369884T0000|68 71|CSF
P04371279T0000|0 7|Absence
P04371279T0000|11 28|action potentials
P04371279T0000|32 36|frog
P04371279T0000|42 55|muscle fibres
P04371279T0000|69 84|botulinum toxin
P04377003A0000|13 19|method
P04377003A0000|41 49|analysis
P04377003A0000|57 78|polyamines putrescine
P04377003A0000|80 90|spermidine
P04377003A0000|95 103|spermine
P04377003A0000|121 126|fluid
P04377003A0000|128 131|CSF
P04377003A0000|153 164|CSF samples
P04377003A0000|173 181|patients
P04377003A0000|203 209|system
P04377003A0000|211 214|CNS
P04377003A0000|216 222|tumors
P04377003A0000|235 243|patients
P04377003A0000|252 258|tumors
P04377328T0027|0 2|I.
P04385060T0000|0 10|Disulfiram
P04385060T0000|32 39|effects
P04385060T0000|43 51|motility
P04387103T0000|0 9|Particles
P04387103T0000|21 32|microbodies
P04387103T0000|67 73|glands
P04387103T0000|77 81|dogs
P04392584T0000|20 28|malarias
P04392584T0000|40 58|hemisphere monkeys
P04394290T0000|2 7|study
P04394290T0000|30 39|receptors
P04394290T0000|47 53|rectum
P04394290T0000|78 87|sphincter
P04394290T0000|95 98|cat
P04407649T0000|13 27|arachnoid cyst
P04407649T0000|42 47|fossa
P04407649T0000|73 96|99mTc brainscintigraphy
P04418687T0000|0 7|Effects
P04418687T0000|11 19|estrogen
P04418687T0000|24 39|glucocorticoids
P04418687T0000|55 66|development
P04418687T0000|74 79|fetus
P04423347T0001|0 6|Copper
P04423347T0001|11 32|ceruloplasmin content
P04423347T0001|45 50|women
P04423347T0001|58 63|women
P04423347T0001|91 99|diseases
P04428800T0001|0 6|Effect
P04428800T0001|10 15|noise
P04428800T0001|30 39|increases
P04428800T0001|43 46|LAP
P04428800T0001|51 63|GPT activity
P04428800T0001|71 77|plasma
P04428800T0001|81 85|rats
P04428981T0000|0 8|Kinetics
P04428981T0000|12 30|calcium metabolism
P04429269T0000|7 16|transport
P04429269T0000|20 25|mucus
P04429269T0000|44 53|simulants
P04429269T0000|66 73|systems
P04437406T0000|15 26|description
P04437406T0000|42 64|reflection coefficient
P04437406T0000|70 81|application
P04437406T0000|89 100|pore theory
P04437406T0000|119 127|exchange
P04445874T0001|0 9|Pathology
P04445874T0001|13 21|neuritis
P04445874T0001|44 49|horse
P04446923T0001|9 24|characteristics
P04446923T0001|29 43|verticillation
P04446923T0001|47 68|Platynothrus peltifer
P04460692T0000|9 15|topics
P04460692T0000|19 45|laboratory animal medicine
P04468264T0053|0 8|Problems
P04468264T0053|19 29|pediatrics
P04468264T0053|34 48|anesthesiology
P04482661T0001|9 15|course
P04482661T0001|20 32|nursing care
P04482661T0001|36 44|patients
P04482661T0001|50 65|decubitus ulcer
P04482661T0001|67 70|use
P04482661T0001|74 81|pillows
P04482661T0001|95 110|buckwheat chaff
P04487835T0001|3 10|parents
P04487920T0001|9 39|Icelandic Red Cross activities
P04488232T0001|0 7|Effects
P04488232T0001|11 21|alcoholism
P04488232T0001|29 35|family
P04488271T0001|0 9|Treatment
P04488271T0001|14 18|care
P04488271T0001|28 45|diabetes mellitus
P04488271T0001|54 58|coma
P04495034T0000|13 26|methylbenzene
P04495034T0000|28 35|toluene
P04495034T0000|42 51|treatment
P04495034T0000|56 76|Ancylostomum caninum
P04506738T0000|0 9|Junctions
P04506738T0000|18 23|cells
P04506738T0000|37 49|enamel organ
P04510102T0000|0 18|Electrocardiograms
P04510102T0000|26 31|month
P04511139T0001|0 10|Composites
P04511139T0001|14 35|restoration materials
P04512496T0000|0 7|Hodgkin
P04512496T0000|10 17|disease
P04515631T0000|0 5|Value
P04515631T0000|9 18|Normotest
P04515631T0000|23 35|antithrombin
P04515631T0000|45 55|assessment
P04515631T0000|59 73|liver function
P04518624T0000|0 22|Glutathione peroxidase
P04518624T0000|36 41|cells
P04518624T0000|45 51|health
P04518624T0000|56 63|disease
P04524081T0000|16 24|response
P04524081T0000|37 44|tissues
P04524081T0000|48 56|hemodent
P04524081T0000|61 88|aluminum chloride solutions
P04524081T0000|92 121|tissue displacement materials
P04533208T0083|0 7|Changes
P04533208T0083|30 37|surgery
P04536964T0000|14 16|pH
P04536964T0000|18 28|H ion flux
P04536964T0000|33 63|H ion permeability coefficient
P04536964T0000|67 86|bullfrog toe muscle
P04539552T0001|14 21|studies
P04539552T0001|25 31|SF-837
P04543036T0001|0 10|Directives
P04543036T0001|30 34|care
P04544430T0001|0 11|Proceedings
P04544430T0001|33 44|heart block
P04544430T0001|55 62|surgery
P04544430T0001|77 90|heart defects
P04544704T0001|0 6|Method
P04544704T0001|10 19|synthesis
P04544704T0001|38 44|factor
P04544704T0001|70 77|studies
P04546974T0000|0 10|Variations
P04546974T0000|18 24|timing
P04546974T0000|28 39|deflections
P04546974T0000|51 68|bundle recordings
P04547933T0000|14 30|fibril formation
P04547933T0000|45 50|cells
P04547933T0000|72 80|junction
P04547933T0000|94 97|eye
P04548483T0001|0 15|Blood platelets
P04548483T0001|17 36|coagulation factors
P04548483T0001|53 66|organ changes
P04548483T0001|86 91|shock
P04548483T0001|95 109|rhesus monkeys
P04551650T0001|0 14|Cell viability
P04551650T0001|29 36|enzymes
P04552263T0000|15 22|schools
P04552263T0000|26 33|nursing
P04552263T0000|35 39|R.N.
P04562038T0001|8 21|investigation
P04562038T0001|41 50|influence
P04562038T0001|61 68|hormone
P04562038T0001|72 83|lymphocytes
P04563045T0000|0 7|1,3-bis
P04563045T0000|8 21|2-chloroethyl
P04563045T0000|25 36|nitrosourea
P04563045T0000|38 42|bcnu
P04563045T0000|54 66|nitrosoureas
P04563045T0000|70 86|cancer treatment
P04563045T0000|90 96|review
P04578686T0000|0 12|Pneumothorax
P04578686T0000|23 35|lung abscess
P04578686T0000|49 67|transplant patient
P04579436T0000|26 40|colour changes
P04579436T0000|44 65|Brevibacterium linens
P04579436T0000|109 116|pigment
P04580044T0047|9 22|relationships
P04580044T0047|31 48|development phase
P04583791T0000|8 15|history
P04583791T0000|19 30|dermatology
P04583791T0000|34 39|Lagos
P04583791T0000|41 48|Nigeria
P04598670T0000|6 23|graft irradiation
P04598670T0000|30 37|adjunct
P04598670T0000|55 72|immunosuppression
P04600603T0001|0 6|Letter
P04600603T0001|19 28|detection
P04613073T0001|0 4|Role
P04613073T0001|8 18|biocenosis
P04613073T0001|26 39|manifestation
P04613073T0001|43 61|Shigella virulence
P04615525T0001|4 10|effect
P04615525T0001|29 33|sera
P04615525T0001|37 46|formation
P04615525T0001|50 65|transplantation
P04615525T0001|85 93|immunity
P04615525T0001|97 101|mice
P04615828T0001|5 13|birthday
P04615828T0001|17 43|colonel prof. e.cerny m.d.
P04621188T0000|0 10|Morphology
P04621188T0000|14 28|bacteriophages
P04621188T0000|32 50|Klebsiella bacilli
P04622430T0000|9 18|afferents
P04622430T0000|37 43|cortex
P04622430T0000|51 64|Rhesus monkey
P04624863T0001|0 9|Mechanism
P04624863T0001|13 26|immunogenesis
P04624863T0001|30 41|vaccination
P04624863T0001|70 77|mutants
P04624863T0001|81 92|salmonellae
P04624863T0001|97 106|shigellae
P04627477T0001|0 18|Resistance pattern
P04627477T0001|22 48|Mycobacterium tuberculosis
P04627477T0001|50 51|H
P04627477T0001|55 57|Rv
P04627477T0001|80 91|lividomycin
P04632967T0000|19 27|pressure
P04632967T0000|32 41|structure
P04632967T0000|49 61|patas monkey
P04632967T0000|78 92|administration
P04632967T0000|96 113|aminorex fumarate
P04638365T0001|0 6|Effect
P04638365T0001|10 19|triftazin
P04638365T0001|24 32|aminazin
P04638365T0001|60 68|activity
P04640155T0045|0 9|Sex ratio
P04640155T0045|13 18|birth
P04645078T0001|13 22|processes
P04645078T0001|30 42|cervix uteri
P04646045T0001|18 24|tumors
P04646045T0001|32 41|esophagus
P04653144T0000|0 16|General formulae
P04653144T0000|32 44|heritability
P04653144T0000|50 60|population
P04653144T0000|74 81|parents
P04654249T0000|0 11|Measurement
P04654249T0000|25 34|responses
P04654249T0000|49 60|stimulation
P04654249T0000|74 78|bulb
P04654249T0000|82 85|cat
P04656185T0000|0 26|Glucose disappearance rate
P04656185T0000|31 38|changes
P04656185T0000|42 58|plasma nutrients
P04656185T0000|87 94|glucose
P04656185T0000|143 151|newborns
P04661961T0001|7 13|values
P04661961T0001|33 38|blood
P04661961T0001|43 54|bone marrow
P04661961T0001|78 85|hamster
P04676734T0000|4 16|relationship
P04676734T0000|56 69|plasma levels
P04676734T0000|73 88|corticosteroids
P04676734T0000|104 107|age
P04679438T0001|11 17|effect
P04679438T0001|25 28|mud
P04679438T0001|34 39|heviz
P04679807T0000|9 27|acid concentration
P04679807T0000|45 65|breathalyzer ampules
P04704137T0001|0 4|Role
P04704137T0001|22 29|studies
P04704137T0001|37 48|prophylaxis
P04704137T0001|64 73|abortions
P04704186T0000|0 14|Range behavior
P04704186T0000|18 26|Hereford
P04704186T0000|28 36|Hereford
P04704186T0000|39 47|Holstein
P04704186T0000|52 60|Holstein
P04704186T0000|75 82|heifers
P04712626T0000|0 21|Chemical constituents
P04712626T0000|29 43|gentianaceae V
P04712626T0000|61 70|xanthones
P04712626T0000|74 99|Swertia chirata Buch.-Ham
P04718233T0000|0 27|Methyl mercury intoxication
P04718233T0000|31 42|rat kidneys
P04727344T0000|0 18|Microdetermination
P04727344T0000|37 45|steroids
P04727344T0000|56 70|isotope method
P04729063T0000|13 20|justice
P04729063T0000|31 41|investment
P04729063T0000|71 78|Koreans
P04730467T0000|0 7|Effects
P04730467T0000|11 20|cortisone
P04730467T0000|22 32|starvation
P04730467T0000|38 45|rickets
P04730467T0000|59 76|enzyme activities
P04730467T0000|80 100|epiphyseal cartilage
P04730467T0000|106 110|rats
P04733391T0000|0 28|Metal coordination compounds
P04733391T0000|32 45|thiabendazole
P04746559T0053|0 10|Estimation
P04746559T0053|14 34|renin secretion rate
P04746559T0053|45 56|plasma flow
P04746559T0053|83 100|vein renin levels
P04752455T0000|0 20|Disability insurance
P04752455T0000|34 42|security
P04753073T0000|0 6|Choice
P04753073T0000|10 16|vessel
P04753286T0000|0 11|Suppression
P04753286T0000|15 26|food intake
P04753286T0000|34 37|rat
P04753286T0000|41 49|tung oil
P04757217T0000|0 7|Studies
P04757217T0000|11 24|lipoprotein-X
P04757217T0000|26 30|LP-X
P04757217T0000|36 46|bile acids
P04757217T0000|59 74|LCAT deficiency
P04758799T0000|0 12|Pneumothorax
P04758799T0000|36 53|steroid treatment
P04759722T0000|0 17|Polycythemia-1973
P04760826T0000|9 16|anxiety
P04760826T0000|20 37|Vietnam returnees
P04760826T0000|42 56|undergraduates
P04764049T0001|18 34|nephronophthisis
P04766888T0000|6 21|heparin therapy
P04766888T0000|28 36|children
P04766888T0000|48 63|meningococcemia
P04778129T0000|0 18|9,11-Seco steroids
P04778129T0000|32 56|estradiol 3-methyl ether
P04782788T0001|14 26|examinations
P04782788T0001|30 38|patients
P04782788T0001|52 72|kidney insufficiency
P04784432T0001|0 13|Possibilities
P04784432T0001|28 42|administration
P04784432T0001|54 64|substances
P04784432T0001|68 75|animals
P04787472T0001|0 6|Change
P04787472T0001|14 20|makeup
P04787472T0001|28 33|blood
P04787472T0001|63 69|action
P04787472T0001|94 99|field
P04787472T0001|113 117|body
P04787716T0000|0 12|Observations
P04787716T0000|20 37|flight activities
P04787716T0000|41 63|Chrysops caecutiens L.
P04788701T0001|0 11|Combination
P04788701T0001|55 61|tumors
P04788701T0001|69 76|breasts
P04788701T0001|81 87|uterus
P04789916T0001|0 8|Analysis
P04789916T0001|12 27|clearance curve
P04789916T0001|36 48|bengal-I-131
P04791420T0000|0 11|Proceedings
P04791420T0000|13 20|Barrels
P04791420T0000|25 35|somatotopy
P04791420T0000|39 40|S
P04791420T0000|43 52|neocortex
P04791420T0000|73 79|possum
P04794218T0001|12 20|K agents
P04796997T0000|7 19|reproduction
P04796997T0000|21 28|effects
P04796997T0000|41 50|injection
P04796997T0000|54 81|medroxyprogesterone acetate
P04796997T0000|102 108|organs
P04796997T0000|116 121|bitch
P04801663T0049|30 40|properties
P04803629T0001|14 20|system
P04803629T0001|38 45|allergy
P04810131T0000|0 6|Letter
P04810131T0000|8 36|Aryl hydrocarbon hydroxylase
P04810131T0000|41 48|smoking
P04813394T0000|0 10|Evaluation
P04813394T0000|14 33|1,10-phenanthroline
P04813394T0000|39 46|reagent
P04813394T0000|58 77|acid determinations
P04820791T0001|21 25|acid
P04820791T0001|43 53|conditions
P04820791T0001|63 71|diseases
P04820791T0001|75 83|children
P04824747T0000|0 17|Nonteratogenicity
P04824747T0000|21 25|rats
P04824747T0000|38 46|potatoes
P04824747T0000|51 60|compounds
P04826272T0074|0 3|VII
P04828587T0000|0 9|Isolation
P04828587T0000|13 16|tha
P04828587T0000|43 48|virus
P04828587T0000|50 58|strain T
P04837183T0000|0 12|Observations
P04837183T0000|16 24|saccules
P04837183T0000|28 32|rats
P04837183T0000|54 66|hypergravity
P04839176T0001|0 6|Effect
P04839176T0001|27 36|SHF field
P04839176T0001|44 68|blood coagulation system
P04843031T0000|4 10|levels
P04843031T0000|14 44|galactosyltransferase activity
P04843031T0000|48 52|sera
P04843031T0000|65 73|children
P04843031T0000|78 86|patients
P04843031T0000|99 107|fibrosis
P04852635T0000|0 4|Lack
P04852635T0000|8 14|effect
P04852635T0000|22 50|appetite stimulant pizotifen
P04852635T0000|52 54|BC
P04852635T0000|67 77|absorption
P04852635T0000|81 102|isonicotinylhydrazine
P04863895T0000|0 12|Relationship
P04863895T0000|27 34|lesions
P04863895T0000|56 65|serotypes
P04863895T0000|89 96|disease
P04863895T0000|98 101|CRD
P04863895T0000|106 113|poultry
P04871589T0001|8 16|solution
P04871589T0001|20 25|elbow
P04871589T0001|32 41|ankylosis
P04871589T0001|74 78|flap
P04878680T0000|0 7|Effects
P04878680T0000|20 29|radiation
P04878680T0000|48 54|cavity
P04878680T0000|59 69|oropharynx
P04878680T0000|71 78|results
P04878680T0000|84 90|survey
P04884060T0000|4 25|Twentieth Anniversary
P04884060T0000|33 59|Pomeranian Medical Academy
P04890336T0001|21 28|pattern
P04890336T0001|32 49|Wassermann reagin
P04890336T0001|54 64|comparison
P04890336T0001|72 87|appearance time
P04890336T0001|96 100|RPCF
P04890336T0001|105 119|FTA antibodies
P04909355T0000|17 32|Actinomycetales
P04911925T0001|0 34|Electrocardiographic QRS complexes
P04911925T0001|59 67|QRS loop
P04919613T0001|0 5|Study
P04919613T0001|21 35|autoantibodies
P04919613T0001|39 65|immunofluorescence technic
P04919613T0001|69 86|collagen diseases
P04921762T0000|8 20|preservation
P04925617T0000|7 10|bar
P04941419T0000|0 28|Yusuf Dawood Docrat L.R.C.P.
P04941951T0000|0 3|Dr.
P04942414T0000|4 14|metabolism
P04942414T0000|19 31|pharmacology
P04942414T0000|35 49|5-fluorouracil
P04947347T0000|0 13|Spleen weight
P04947347T0000|17 21|rats
P04947347T0000|29 42|tumour growth
P04947347T0000|50 69|homograft rejection
P04948325T0000|0 9|Isolation
P04948325T0000|13 20|Proteus
P04948325T0000|30 35|MC-63
P04948325T0000|41 50|carcinoma
P04948325T0000|72 78|effect
P04948325T0000|82 97|Crocker sarcoma
P04948325T0000|106 123|Ehrlich carcinoma
P04959816T0000|15 20|fluid
P04959816T0000|22 31|detection
P04959816T0000|41 50|component
P04967824T0000|0 7|Effects
P04967824T0000|11 22|temperature
P04967824T0000|36 41|cycle
P04967824T0000|45 62|melanin synthesis
P04967824T0000|70 74|newt
P04970131T0001|5 23|reflexions apropos
P04970131T0001|50 55|study
P04970131T0001|72 81|embolisms
P04970918T0069|0 10|LA-3848-MS
P04973523T0000|15 22|studies
P04973523T0000|37 45|antigens
P04975676T0000|29 40|alterations
P04975676T0000|53 59|baboon
P04975676T0000|66 85|allotransplantation
P04976988T0000|0 13|Heterogeneity
P04976988T0000|23 36|serum albumin
P04989251T0000|0 8|Analysis
P04989251T0000|12 27|corticosteroids
P04990556T0000|0 12|Reactivities
P04990556T0000|16 21|horse
P04990556T0000|38 46|globulin
P04992478T0000|0 18|Plasma histaminase
P04992478T0000|22 30|patients
P04992478T0000|44 50|asthma
P04992478T0000|59 65|effect
P04992478T0000|82 96|administration
P04999086T0001|14 19|study
P04999086T0001|36 39|end
P04999086T0001|56 64|analyzer
P04999086T0001|82 93|ontogenesis
P04999086T0001|103 110|monkeys
P04999086T0001|115 118|man
P05000171T0000|4 10|effect
P05000171T0000|22 26|flow
P05000171T0000|34 46|distribution
P05000171T0000|50 72|horseradish peroxidase
P05000171T0000|98 104|spaces
P05000171T0000|108 131|toad bladder epithelium
P05005311T0000|0 14|Immunogenicity
P05005311T0000|26 38|mycobacteria
P05005311T0000|61 67|levels
P05005311T0000|71 87|cross-protection
P05005311T0000|106 113|species
P05012220T0000|9 19|experience
P05012220T0000|35 50|proctocolectomy
P05012220T0000|60 69|ileostomy
P05015678T0000|18 29|tautomerism
P05015678T0000|33 43|porphyrins
P05015678T0000|48 56|chlorins
P05020660T0000|0 7|Factors
P05020660T0000|22 32|inhibition
P05020660T0000|36 48|phagocytosis
P05020660T0000|52 66|chlorpromazine
P05021912T0000|18 29|sensitivity
P05021912T0000|74 84|pigeon eye
P05025918T0000|0 11|Angiography
P05025918T0000|26 35|bone cyst
P05027295T0034|0 14|Cholinesterase
P05027799T0000|0 18|Sodium restriction
P05027799T0000|30 37|failure
P05028628T0001|26 38|examinations
P05028628T0001|42 59|occlusion disease
P05028628T0001|84 92|arteries
P05031074T0001|0 19|Serum lipid changes
P05031074T0001|27 36|pregnancy
P05031074T0001|49 71|calcium administration
P05031659T0000|11 20|treatment
P05031659T0000|24 35|candidiasis
P05031659T0000|41 56|transfer factor
P05034373T0000|11 15|role
P05034373T0000|30 60|function oxidase enzyme system
P05034373T0000|68 79|requirement
P05034373T0000|84 92|selenium
P05034373T0000|100 103|rat
P05045351T0000|9 18|breathing
P05045351T0000|23 28|apnea
P05045351T0000|40 47|infants
P05049711T0000|8 22|session report
P05049711T0000|41 50|screening
P05060388T0000|18 25|studies
P05060388T0000|40 46|tumors
P05060388T0000|54 59|ovary
P05065548T0075|7 19|constituents
P05065548T0075|23 43|Dryopteris polylepis
P05066316T0001|0 8|Relation
P05066316T0001|24 29|ratio
P05066316T0001|37 46|materials
P05066316T0001|51 62|composition
P05066316T0001|66 74|products
P05066316T0001|82 91|synthesis
P05066316T0001|95 111|aluminosilicates
P05068271T0000|0 9|Influence
P05068271T0000|13 17|diet
P05068271T0000|29 42|VMA excretion
P05075857T0000|0 31|Oscilloscope triggering circuit
P05075857T0000|51 61|transients
P05075857T0000|70 82|sweep speeds
P05081814T0000|0 11|Derivatives
P05081814T0000|25 30|acids
P05083872T0000|4 10|status
P05083872T0000|14 23|education
P05083872T0000|28 45|training programs
P05083872T0000|49 65|speech pathology
P05083872T0000|70 79|audiology
P05087496T0000|9 17|arteries
P05091970T0000|10 16|agents
P05093030T0001|0 10|Separation
P05093030T0001|33 42|compounds
P05093030T0001|46 51|urine
P05093030T0001|68 75|methods
P05093030T0001|79 106|medium-tension intophoresis
P05093030T0001|111 135|partition chromatography
P05095988T0001|13 22|treatment
P05095988T0001|42 57|system injuries
P05101762T0000|0 14|Spasmus nutans
P05101762T0000|18 26|syndrome
P05110049T0001|4 8|data
P05110049T0001|34 41|therapy
P05110049T0001|45 56|scleroderma
P05114515T0000|17 31|enzyme release
P05114515T0000|40 53|normalization
P05114515T0000|57 62|drugs
P05114515T0000|83 96|polyarthritis
P05119546T0001|0 9|Treatment
P05119546T0001|21 30|neoplasms
P05120197T0000|13 25|pancreatitis
P05120197T0000|29 33|pigs
P05123884T0000|10 20|metabolism
P05123884T0000|24 46|4-chlorophenoxyacetate
P05124707T0001|0 8|Dynamics
P05124707T0001|12 25|hospital stay
P05124707T0001|36 50|ulcer patients
P05124972T0042|0 2|I.
P05128149T0001|0 18|Surgical treatment
P05128149T0001|33 38|scars
P05128149T0001|53 60|infarct
P05132558T0000|4 15|interaction
P05132558T0000|19 27|caffeine
P05132558T0000|29 41|theophylline
P05132558T0000|46 57|theobromine
P05132558T0000|63 91|monoamine oxidase inhibitors
P05133723T0000|0 6|Effect
P05133723T0000|10 20|phenformin
P05133723T0000|24 39|gluconeogenesis
P05133723T0000|52 61|rat liver
P05135168T0000|0 13|New alkaloids
P05135168T0000|19 23|bark
P05135168T0000|27 49|Erythrophleum ivorense
P05138738T0001|2 6|case
P05138738T0001|10 26|M hemoglobinosis
P05145925T0000|15 21|nature
P05145925T0000|59 68|potential
P05145925T0000|81 93|spleen cells
P05152314T0001|11 23|oscillations
P05152314T0001|29 51|gas dilution indicator
P05154132T0000|4 9|value
P05154132T0000|23 30|sources
P05154132T0000|34 42|nitrogen
P05154132T0000|46 51|diets
P05154132T0000|73 77|calf
P05162342T0001|10 16|tumors
P05162342T0001|20 29|childhood
P05170106T0034|0 7|Results
P05170106T0034|24 34|inspection
P05170106T0034|71 90|enzyme preparations
P05170106T0034|102 114|chymotrypsin
P05170106T0034|119 126|trypsin
P05170106T0034|130 135|means
P05170106T0034|148 150|NF
P05170106T0034|154 161|methods
P05172320T0001|0 7|Studies
P05172320T0001|26 32|nature
P05172320T0001|41 47|prints
P05172320T0001|62 71|reference
P05172320T0001|75 87|interdigital
P05172320T0001|92 100|triradii
P05172970T0001|4 11|problem
P05172970T0001|15 26|disablement
P05172970T0001|44 56|tuberculosis
P05172970T0001|65 70|basis
P05172970T0001|77 85|analysis
P05172970T0001|93 100|history
P05172970T0001|108 113|cases
P05172970T0001|129 135|Gdansk
P05172970T0001|143 148|years
P05174753T0001|14 24|dysostosis
P05177935T0001|0 9|Proposals
P05177935T0001|13 26|authorization
P05177935T0001|33 38|group
P05177935T0001|42 48|nurses
P05177935T0001|66 75|hospitals
P05203499T0001|21 34|scintillation
P05203499T0001|53 56|BSP
P05203499T0001|58 69|description
P05203499T0001|77 90|thyroid gland
P05203499T0001|92 98|kidney
P05203499T0001|103 109|spleen
P05203499T0001|111 121|comparison
P05203499T0001|127 135|131-I-RB
P05210791T0001|0 9|Pneumonia
P05210791T0001|13 21|children
P05253274T0001|0 12|Osteosarcoma
P05253274T0001|23 38|3,4-benzopyrene
P05274128T0001|4 11|content
P05274128T0001|15 26|glucosamine
P05274128T0001|31 44|galactosamine
P05274128T0001|48 54|tartar
P05274526T0000|0 7|Relapse
P05274526T0000|11 19|leukemia
P05274526T0000|36 45|remission
P05276380T0000|0 9|Influence
P05276380T0000|13 30|cigarette smoking
P05276380T0000|39 62|blood coagulation tests
P05284310T0000|16 24|fluoride
P05284310T0000|32 39|control
P05284310T0000|43 57|plasma calcium
P05284310T0000|86 89|rat
P05285978T0076|7 13|report
P05285978T0076|31 45|Cancer Society
P05299993T0000|0 12|Modification
P05299993T0000|20 26|growth
P05299993T0000|30 41|Tetrahymena
P05299993T0000|45 54|compounds
P05299993T0000|83 92|mechanism
P05303700T0066|0 12|SAM-TR-68-54
P05305671T0000|8 18|discussion
P05305671T0000|22 40|color deficiencies
P05308271T0000|0 3|BIM
P05309471T0000|0 8|Problems
P05309471T0000|16 29|determination
P05309471T0000|47 54|content
P05309471T0000|58 76|influenza vaccines
P05316745T0000|0 13|Aedes aegypti
P05316745T0000|15 17|L.
P05316745T0000|23 39|Aedes albopictus
P05316745T0000|41 46|Skuse
P05316745T0000|51 65|Singapore City
P05322558T0000|0 18|Homograft response
P05322558T0000|23 47|hemagglutinin production
P05322558T0000|93 97|mice
P05322747T0034|12 17|study
P05322747T0034|32 40|overload
P05322747T0034|47 58|tolbutamide
P05322747T0034|63 73|tolazamide
P05322747T0034|97 105|subjects
P05340801T0000|0 10|Mycotoxins
P05340801T0000|24 29|foods
P05344097T0000|0 7|Factors
P05344097T0000|29 64|skin permeability factor production
P05344097T0000|68 83|Vibrio cholerae
P05353667T0000|7 26|cord representation
P05353667T0000|34 45|micturition
P05356107T0001|11 17|action
P05356107T0001|22 30|kinetics
P05356107T0001|38 49|elimination
P05356107T0001|53 66|tritium oxide
P05356107T0001|70 74|dogs
P05357390T0001|0 4|Auto
P05357390T0001|10 17|isotopy
P05357390T0001|25 36|conjunctiva
P05359464T0000|0 8|Pitfalls
P05359464T0000|16 19|use
P05359464T0000|23 53|chromosome aberration analysis
P05359464T0000|69 88|radiation dosimetry
P05362866T0000|0 15|Renin secretion
P05362866T0000|45 57|hypertension
P05363816T0001|4 8|need
P05363816T0001|40 49|expertise
P05363816T0001|57 61|list
P05363816T0001|95 102|actions
P05364951T0001|0 14|Histopathology
P05364951T0001|19 31|pathogenesis
P05364951T0001|49 56|viroses
P05368978T0000|0 11|CNS effects
P05368978T0000|21 32|anesthetics
P05368978T0000|70 86|amine mechanisms
P05372511T0105|0 18|Diethylene benzene
P05379901T0000|0 13|Midge control
P05379901T0000|17 31|flood channels
P05388567T0000|4 11|effects
P05388567T0000|15 25|taloximine
P05388567T0000|30 43|aminophylline
P05388567T0000|69 75|muscle
P05389125T0000|16 25|behaviour
P05389125T0000|51 55|mice
P05394352T0000|0 12|Genitography
P05394352T0000|28 34|states
P05394461T0001|0 14|Tolerance test
P05394461T0001|18 20|HB
P05394461T0001|28 46|animal experiments
P05410590T0000|4 8|role
P05410590T0000|21 25|acid
P05410590T0000|33 43|prevention
P05410590T0000|47 70|bladder tumor formation
P05410641T0000|8 15|percent
P05410641T0000|17 29|Venturi mask
P05410641T0000|45 59|airway disease
P05412122T0000|3 9|Methyl
P05412122T0000|11 19|8-methyl
P05412122T0000|25 45|8-phenyl derivatives
P05412122T0000|63 65|,7
P05412122T0000|66 79|benzomorphans
P05412687T0000|11 19|invasion
P05412687T0000|23 31|impulses
P05412687T0000|46 67|collateral inhibition
P05412687T0000|81 95|tract neurones
P05413428T0000|4 16|distribution
P05413428T0000|20 31|body fluids
P05413428T0000|42 52|hemorrhage
P05413428T0000|57 70|resuscitation
P05413428T0000|74 91|combat casualties
P05414186T0001|10 29|Hong Kong influenza
P05414186T0001|37 48|Netherlands
P05417431T0001|6 16|disagnosis
P05417431T0001|20 26|cancer
P05417431T0001|35 39|cent
P05417431T0001|47 55|patients
P05421537T0001|0 12|Difficulties
P05421537T0001|35 51|sputum viscosity
P05424220T0001|0 19|Lipid concentration
P05424220T0001|24 39|lipase activity
P05424220T0001|47 56|epiphysis
P05424220T0001|77 81|rats
P05424220T0001|92 96|food
P05424220T0001|112 126|sodium content
P05425195T0001|0 8|Behavior
P05425195T0001|12 38|aspartate aminotransferase
P05425195T0001|40 42|EC
P05425195T0001|56 80|alanine aminotransferase
P05425195T0001|82 84|EC
P05425195T0001|97 106|rat serum
P05425195T0001|118 124|course
P05425195T0001|134 152|radiation syndrome
P05425195T0001|169 187|body X-irradiation
P05437405T0000|11 18|forearm
P05437405T0000|30 46|dilator capacity
P05437405T0000|85 99|salt retention
P05437405T0000|103 106|man
P05441564T0001|0 7|Studies
P05441564T0001|15 28|pathogenicity
P05441564T0001|32 36|ECHO
P05441564T0001|40 44|HILL
P05441564T0001|46 51|virus
P05441564T0001|60 67|mutants
P05441564T0001|72 85|suckling mice
P05445187T0000|16 29|heat exchange
P05445187T0000|49 57|passages
P05445187T0000|59 65|effect
P05445187T0000|69 74|water
P05445187T0000|79 91|heat balance
P05451324T0000|0 11|Calibration
P05451324T0000|18 28|correction
P05451324T0000|32 37|blood
P05451324T0000|41 48|content
P05451324T0000|61 64|Po2
P05451324T0000|69 82|CO saturation
P05456002T0000|0 8|Mae West
P05456002T0000|17 32|doctor shortage
P05460466T0001|0 11|Elimination
P05460466T0001|15 32|gamma-irradiation
P05460466T0001|41 50|oxidation
P05460466T0001|62 79|drug preparations
P05463837T0023|13 26|configuration
P05463837T0023|30 33|C-2
P05463837T0023|50 54|acid
P05466177T0001|12 19|effects
P05466177T0001|23 36|actinomycin D
P05466177T0001|40 44|rats
P05471866T0000|4 39|plasma growth hormone concentration
P05471866T0000|54 58|lamb
P05472485T0000|8 32|cochlear response curves
P05472485T0000|36 43|rodents
P05474466T0001|6 27|hemagglutination test
P05474466T0001|45 50|assay
P05474466T0001|65 71|factor
P05488121T0000|0 16|CO2 assimilation
P05488121T0000|20 32|chloroplasts
P05488121T0000|48 60|filter paper
P05492285T0000|4 11|biology
P05492285T0000|15 35|Hyostrongylus ruidus
P05496619T0000|8 16|profiles
P05496619T0000|20 52|air pollution control activities
P05497793T0000|0 7|Effects
P05497793T0000|19 40|metaraminol treatment
P05497793T0000|60 68|activity
P05497793T0000|104 108|rats
P05497793T0000|130 142|environments
P05500957T0001|4 15|association
P05500957T0001|19 28|clopamide
P05500957T0001|33 42|hydergine
P05500957T0001|44 53|Brinedine
P05500957T0001|62 71|treatment
P05500957T0001|93 102|syndromes
P05500957T0001|106 115|pregnancy
P05501347T0001|4 10|effect
P05501347T0001|18 34|dosage radiation
P05501347T0001|38 48|metabolism
P05501347T0001|53 61|function
P05501347T0001|69 79|rat kidney
P05501347T0001|91 99|ischemia
P05502054T0000|0 8|Leukemia
P05502054T0000|12 17|twins
P05502054T0000|30 36|review
P05502054T0000|49 54|cases
P05525652T0064|12 18|report
P05529283T0000|0 12|Quantitation
P05529283T0000|25 28|IgA
P05529283T0000|38 43|serum
P05529283T0000|47 53|health
P05529283T0000|58 65|disease
P05532854T0001|17 31|manifestations
P05532854T0001|44 53|sclerosis
P05533214T0001|0 17|Iodine metabolism
P05533214T0001|29 40|thyroiditis
P05536803T0001|6 16|body water
P05536803T0001|18 33|rhodanide space
P05536803T0001|52 57|space
P05536803T0001|74 80|effect
P05536803T0001|84 94|furosemide
P05544291T0031|0 2|V.
P05552149T0000|0 3|18F
P05552149T0000|8 24|85Sr scintimetry
P05552149T0000|32 37|study
P05552149T0000|49 62|arthropathies
P05552642T0000|0 11|Propagation
P05552642T0000|16 34|hormone production
P05552642T0000|65 76|trophoblast
P05552642T0000|80 84|rats
P05553261T0000|0 6|Health
P05553261T0000|23 32|reticulum
P05555149T0001|23 29|method
P05555149T0001|46 48|SH
P05555149T0001|54 64|S-S-groups
P05556977T0001|0 13|Morphogenesis
P05556977T0001|21 31|trochanter
P05556977T0001|52 64|regeneration
P05556977T0001|72 100|phasmid Carausius morosus Br
P05560428T0001|30 40|expression
P05560428T0001|52 57|sleep
P05560428T0001|62 73|wakefulness
P05560428T0001|77 85|reptiles
P05567721T0000|0 13|Sensitivities
P05567721T0000|17 32|thromboplastins
P05567721T0000|36 57|factor VII deficiency
P05572662T0000|0 7|Central
P05572662T0000|15 23|catheter
P05572662T0000|56 73|electrocardiogram
P05574818T0000|4 7|Lab
P05574818T0000|10 29|computer programmes
P05574818T0000|34 37|use
P05574818T0000|45 50|study
P05574818T0000|81 108|contractile characteristics
P05574818T0000|121 127|muscle
P05593469T0001|16 24|injuries
P05594277T0051|4 16|modification
P05594277T0051|20 30|P32 uptake
P05594277T0051|40 54|Jensen sarcoma
P05594277T0051|77 85|peroxide
P05594277T0051|103 109|medium
P05595036T0001|0 8|Students
P05595036T0001|10 17|parents
P05595036T0001|19 27|teachers
P05595036T0001|40 49|disorders
P05621339T0001|24 29|doses
P05621339T0001|33 50|Cs137 irradiation
P05627251T0000|9 15|shifts
P05627251T0000|25 40|skin potentials
P05627251T0000|54 59|sleep
P05642051T0000|19 40|department management
P05671267T0000|3 22|Dimethylaminopropyl
P05671267T0000|30 46|dihydro-5H-benzo
P05671267T0000|51 57|pyrido
P05671267T0000|64 71|azepine
P05672903T0001|0 23|Osteogenesis imperfecta
P05683363T0001|0 13|Investigation
P05683363T0001|21 29|exchange
P05683363T0001|33 37|Ca45
P05683363T0001|59 63|rats
P05683363T0001|79 94|analysis method
P05683809T0000|0 6|Effect
P05683809T0000|40 45|drugs
P05683809T0000|53 83|surface charge characteristics
P05683809T0000|94 107|blood vessels
P05683809T0000|130 137|studies
P05684081T0001|0 12|Measurements
P05684081T0001|16 24|activity
P05684081T0001|50 66|chamber VA-K-254
P05684081T0001|74 89|osimeter VA-J18
P05689427T0052|3 37|N-Alkyl-N-2-chloroethylaminomethyl
P05689427T0052|61 62|b
P05689427T0052|72 86|hydrochlorides
P05692759T0001|0 11|Nephrectomy
P05692759T0001|23 29|cattle
P05693602T0001|0 10|Evaluation
P05693602T0001|24 43|blood cell counters
P05693605T0001|0 13|Determination
P05693605T0001|17 30|transaminases
P05693605T0001|39 51|autoanalyzer
P05715613T0000|0 7|Sterols
P05715613T0000|11 17|pollen
P05718386T0001|8 12|cyst
P05718386T0001|23 32|skin flap
P05718386T0001|40 52|complication
P05718386T0001|59 68|treatment
P05718386T0001|82 88|hernia
P05718500T0001|13 25|observations
P05718500T0001|33 40|decidua
P05718500T0001|55 59|half
P05718500T0001|63 72|pregnancy
P05718994T0000|12 27|fibro-elastosis
P05718994T0000|36 48|incompetence
P05718994T0000|54 65|coarctation
P05718994T0000|79 84|aorta
P05719031T0000|0 7|Studies
P05719031T0000|15 21|method
P05719031T0000|25 39|size reduction
P05719031T0000|53 62|compounds
P05719746T0001|0 8|Children
P05719746T0001|24 30|vision
P05722341T0000|0 14|Identification
P05722341T0000|19 29|estimation
P05722341T0000|33 48|monosaccharides
P05722341T0000|53 66|disaccharides
P05722341T0000|70 75|urine
P05722341T0000|90 104|chromatography
P05725509T0000|0 8|Steroids
P05725509T0000|12 20|germfree
P05725509T0000|38 42|rats
P05727222T0000|4 11|effects
P05727222T0000|39 44|pumps
P05727222T0000|52 70|oxygen consumption
P05727222T0000|74 90|Callionymus lyra
P05732641T0001|0 6|Trials
P05732641T0001|10 25|sevine activity
P05732641T0001|34 49|mosquito larvae
P05733952T0001|4 16|significance
P05733952T0001|31 40|integrity
P05733952T0001|53 59|tissue
P05733952T0001|64 83|antibody production
P05733952T0001|87 94|culture
P05733953T0001|4 10|effect
P05733953T0001|34 39|field
P05733953T0001|58 66|activity
P05733953T0001|70 79|Paramecia
P05734847T0000|0 7|Studies
P05734847T0000|29 54|Glossina morsitans colony
P05734847T0000|58 64|Lisbon
P05740389T0001|0 9|Relations
P05740389T0001|29 39|mechanisms
P05740389T0001|54 61|effects
P05742879T0000|0 15|Transformations
P05742879T0000|23 38|morphine series
P05749438T0001|13 24|anesthetics
P05749438T0001|28 42|o-chlorophenyl
P05749438T0001|46 74|methyl-amino cyclohexane HCL
P05749438T0001|76 82|CI-581
P05750950T0001|0 6|Estrus
P05750950T0001|22 31|abilities
P05750950T0001|55 59|rats
P05751819T0000|4 11|bearing
P05751819T0000|15 21|season
P05751819T0000|26 34|sequence
P05751819T0000|38 45|calving
P05751819T0000|49 58|frequency
P05751819T0000|62 66|male
P05751819T0000|85 93|calvings
P05751819T0000|97 109|Hariana cows
P05758469T0001|0 20|Hemodynamics changes
P05758469T0001|24 27|man
P05758469T0001|35 41|flight
P05760665T0000|0 17|Caries prevention
P05760665T0000|32 38|office
P05763287T0063|0 2|I.
P05763347T0000|9 21|applications
P05763347T0000|25 35|inhibition
P05763347T0000|55 64|receptors
P05763347T0000|70 81|propranolol
P05769307T0000|0 18|Automatic view box
P05774062T0000|0 11|Measurement
P05774062T0000|23 37|acid secretion
P05774062T0000|41 53|conductivity
P05779953T0000|0 6|Effect
P05779953T0000|10 20|castration
P05779953T0000|38 46|serum LH
P05779953T0000|51 54|FSH
P05779953T0000|82 86|rats
P05781385T0000|4 16|significance
P05781385T0000|24 55|phenolphthalein sulphatase test
P05781385T0000|64 79|differentiation
P05781385T0000|84 98|identification
P05781385T0000|102 118|Nocardia species
P05782943T0001|0 12|Relationship
P05782943T0001|16 26|mast cells
P05782943T0001|30 51|sarcoidosis granuloma
P05782943T0001|59 63|skin
P05787318T0000|10 17|effects
P05787318T0000|21 31|clofibrate
P05787318T0000|33 42|Atromid-S
P05787318T0000|47 59|serum lipids
P05787318T0000|63 66|man
P05789870T0001|0 42|Phosphate glucose dehydrogenase deficiency
P05789870T0001|51 69|hyperbilirubinemia
P05792868T0000|0 37|Evidence forthe electroosmosis theory
P05792868T0000|41 50|transport
P05792868T0000|58 64|phloem
P05792911T0000|0 7|Effects
P05792911T0000|27 44|receptor blockade
P05792911T0000|48 66|airway conductance
P05792911T0000|71 82|lung volume
P05792911T0000|107 115|subjects
P05794247T0000|0 6|Effect
P05794247T0000|10 17|heparin
P05794247T0000|25 37|inactivation
P05794247T0000|41 65|serum lipoprotein lipase
P05794247T0000|73 78|liver
P05794247T0000|97 101|dogs
P05796272T0000|13 37|chlorpromazine cataracts
P05797287T0069|0 2|I.
P05798063T0000|0 10|Specialist
P05798063T0000|14 29|family practice
P05798063T0000|31 40|prototype
P05798063T0000|46 52|doctor
P05799686T0001|4 15|possibility
P05799686T0001|29 41|chemotherapy
P05799686T0001|75 84|carcinoma
P05799686T0001|94 97|aid
P05799686T0001|101 114|cytodiagnosis
P05799686T0001|119 132|incorporation
P05799686T0001|143 154|idoxuridine
P05805644T0001|0 9|Variation
P05805644T0001|34 46|distribution
P05805644T0001|50 55|228Ra
P05805644T0001|60 65|224Ra
P05805644T0001|73 76|RES
P05805644T0001|93 101|skeleton
P05805644T0001|108 121|incorporation
P05805644T0001|125 139|colloidal ThO2
P05806615T0001|10 21|degradation
P05806615T0001|25 45|adrenaline solutions
P05806615T0001|47 52|study
P05806615T0001|73 79|stages
P05806615T0001|99 104|value
P05806615T0001|113 120|control
P05806615T0001|129 135|solute
P05806936T0000|0 10|Absorption
P05806936T0000|14 26|electrolytes
P05806936T0000|36 41|colon
P05806936T0000|45 50|cases
P05806936T0000|65 72|colitis
P05806936T0000|88 96|subjects
P05807222T0052|0 13|Ion injection
P05810259T0001|0 17|Polyvinyl alcohol
P05810259T0001|23 40|solution mediator
P05819249T0000|0 6|Mining
P05819249T0000|22 30|iron ore
P05822499T0034|4 13|structure
P05822499T0034|17 29|digiprogenin
P05823624T0031|4 8|need
P05823624T0031|22 30|hospital
P05826818T0098|0 2|I.
P05833022T0001|7 16|character
P05833022T0001|20 27|changes
P05833022T0001|35 50|enzyme activity
P05833022T0001|58 70|brain tissue
P05833022T0001|85 93|epilepsy
P05836483T0000|17 25|teratoma
P05836483T0000|29 34|liver
P05836483T0000|38 47|childhood
P05837169T0001|0 14|Methoxyflurane
P05837169T0001|25 33|function
P05839844T0000|0 14|Histochemistry
P05839844T0000|19 38|electron microscopy
P05839844T0000|48 61|liver lesions
P05839844T0000|73 85|Aflatoxin B1
P05839844T0000|89 98|ducklings
P05847772T0001|11 20|disorders
P05847772T0001|28 34|ureter
P05847772T0001|57 64|surgery
P05850652T0001|0 5|Study
P05850652T0001|13 24|alterations
P05850652T0001|39 49|absorption
P05850652T0001|54 59|means
P05850652T0001|63 77|I-131-triolein
P05850652T0001|92 96|body
P05850652T0001|108 111|rat
P05857301T0000|0 8|Chemical
P05857301T0000|36 45|responses
P05857301T0000|49 53|rats
P05857301T0000|57 62|CC1-4
P05857301T0000|76 82|routes
P05857301T0000|86 100|administration
P05858571T0000|9 15|trials
P05858571T0000|21 28|1,3-bis
P05858571T0000|29 42|2-chloroethyl
P05858571T0000|46 57|nitrosourea
P05858571T0000|59 69|NSC-409962
P05859016T0000|0 26|Hydroxypropyl methacrylate
P05859016T0000|49 65|embedding medium
P05859016T0000|70 89|electron microscopy
P05879595T0094|0 10|Statistics
P05879595T0094|25 30|years
P05881833T0001|7 16|diagnosis
P05881833T0001|27 35|leucosis
P05881833T0001|44 51|control
P05881833T0001|64 76|Lower Saxony
P05884183T0001|0 10|Experience
P05884183T0001|20 31|restoration
P05884183T0001|35 59|agglutination properties
P05884183T0001|93 101|cultures
P05884183T0001|111 114|use
P05884183T0001|118 127|Rzhaninov
P05884183T0001|130 136|method
P05890093T0000|0 5|Study
P05890093T0000|9 20|micromelias
P05890093T0000|28 39|mouse fetus
P05890093T0000|50 61|x-radiation
P05890093T0000|63 70|hypoxia
P05890093T0000|72 78|trypan
P05890093T0000|84 93|injection
P05890093T0000|97 115|hypervitaminosis-A
P05890093T0000|121 135|mother animals
P05890093T0000|143 152|pregnancy
P05890351T0001|6 23|antitetanus serum
P05890351T0001|35 41|wealth
P05893495T0001|0 7|Studies
P05893495T0001|30 39|infection
P05893495T0001|43 50|rabbits
P05896996T0001|3 13|catabolism
P05896996T0001|17 29|aminoketones
P05896996T0001|45 48|age
P05901778T0000|4 10|effect
P05901778T0000|22 30|patterns
P05901778T0000|38 48|deposition
P05901778T0000|52 56|mice
P05902458T0001|0 11|Naphthalene
P05902458T0001|16 35|paradichlorobenzene
P05902458T0001|48 58|toxicology
P05909034T0000|0 7|Studies
P05909034T0000|20 32|preparations
P05917315T0026|2 13|case report
P05917315T0026|42 47|study
P05919308T0001|0 12|Interactions
P05919308T0001|21 32|adrenergics
P05919308T0001|34 46|adrenolytics
P05919308T0001|51 79|monoamine oxidase inhibitors
P05930797T0000|8 15|studies
P05930797T0000|33 53|isoprecipitin system
P05930797T0000|55 72|Australia antigen
P05933228T0000|11 18|rhythms
P05933228T0000|22 32|indicators
P05933228T0000|36 50|neurosecretion
P05938720T0000|0 5|Story
P05938720T0000|11 19|hospital
P05938720T0000|36 64|employee orientation program
P05939748T0000|18 27|Pap smear
P05942953T0049|0 2|I.
P05947377T0001|11 22|test iodine
P05947377T0001|24 29|I-132
P05947377T0001|31 37|uptake
P05947377T0001|45 52|thyroid
P05947377T0001|56 64|children
P05947377T0001|70 87|growth deficiency
P05949971T0000|0 11|Persistence
P05949971T0000|15 24|toxaphene
P05949971T0000|36 41|lakes
P05959588T0000|0 7|Studies
P05959588T0000|11 27|Coxsackie B Type
P05959588T0000|30 46|virus infections
P05960999T0001|0 5|Value
P05960999T0001|13 19|method
P05960999T0001|23 47|passive hemagglutination
P05960999T0001|53 69|polysaccharide C
P05960999T0001|94 101|protein
P05960999T0001|117 130|precipitation
P05960999T0001|134 145|capillaries
P05960999T0001|150 166|slide latex test
P05960999T0001|181 186|serum
P05967610T0000|11 25|nerve function
P05967610T0000|27 46|noradrenaline level
P05967610T0000|51 71|noradrenaline uptake
P05967610T0000|75 78|cat
P05967610T0000|91 99|membrane
P05967610T0000|106 125|reserpine treatment
P05969185T0001|0 10|Concussion
P05969185T0001|25 29|cord
P05982700T0000|0 5|Study
P05982700T0000|13 24|evagination
P05982700T0000|28 50|Cysticercus pisiformis
P05985275T0000|14 23|substance
P05985275T0000|41 54|acorn extract
P05992157T0001|4 17|pathogenicity
P05992157T0001|21 43|Achromobacter puntatum
P05992157T0001|53 60|blooded
P05992157T0001|78 85|animals
P05994421T0045|0 13|Consanguinity
P05994421T0045|18 27|migration
P05994421T0045|35 44|marriages
P05994421T0045|52 58|region
P05994421T0045|62 67|Nunoa
P05994421T0045|69 77|Santiago
P05995140T0001|7 13|amount
P05995140T0001|18 30|significance
P05995140T0001|48 61|glucose level
P05995140T0001|65 71|tumors
P05999607T0001|0 7|Studies
P05999607T0001|11 22|lipogenesis
P05999607T0001|35 45|precursors
P05999607T0001|62 65|rat
P06012827T0000|16 23|studies
P06012827T0000|46 52|system
P06012827T0000|83 87|rats
P06027841T0000|8 12|spin
P06027841T0000|16 21|249Bk
P06027841T0000|31 50|hyperfine structure
P06027841T0000|58 75|emission spectrum
P06035001T0000|8 20|observations
P06035001T0000|24 34|resorption
P06035001T0000|38 49|guinea pigs
P06035001T0000|60 70|injections
P06035001T0000|74 85|trypan blue
P06048505T0000|0 11|Derivatives
P06048505T0000|15 23|fluorene
P06051644T0000|8 12|Slot
P06051644T0000|15 21|method
P06051644T0000|39 52|determination
P06051644T0000|56 66|creatinine
P06054411T0000|0 18|Retention behavior
P06054411T0000|22 30|steroids
P06054411T0000|34 52|gas chromatography
P06054411T0000|60 66|series
P06054411T0000|70 89|combination columns
P06065507T0000|19 30|hypertrophy
P06065507T0000|45 49|rats
P06070204T0025|0 3|XXI
P06072512T0000|9 19|evaluation
P06072512T0000|37 43|action
P06072512T0000|47 51|urea
P06073427T0001|16 32|characteriaztion
P06073427T0001|50 60|interferon
P06073427T0001|68 73|blood
P06073427T0001|78 83|urine
P06073427T0001|87 94|rabbits
P06074093T0001|0 4|Iron
P06074093T0001|9 26|folate deficiency
P06074093T0001|30 39|pregnancy
P06074640T0001|0 9|Symposium
P06074640T0001|30 46|encephalopathies
P06084279A0218|21 29|patients
P06084279A0218|36 40|rise
P06084279A0218|54 67|serum amylase
P06084279A0218|78 82|ERCP
P06084810A0169|20 24|mRNA
P06084810A0169|32 48|polysome complex
P06084810A0169|69 73|cDNA
P06084810A0169|96 98|D.
P06084810A0169|120 127|library
P06084864T0001|18 36|alpha fetoproteins
P06084864T0001|41 52|oligoamnios
P06084864T0001|60 69|prognosis
P06085839A0721|22 33|possibility
P06085839A0721|74 82|etiology
P06088722A0171|0 7|Courses
P06088722A0171|35 43|recovery
P06088722A0171|47 63|myelosuppression
P06089575A0464|0 11|Stimulation
P06089575A0464|17 20|MCh
P06089575A0464|55 64|elevation
P06089575A0464|68 78|cGMP level
P06089575A0464|93 103|fmol/gland
P06089575A0464|120 123|min
P06089575A0464|151 156|level
P06089575A0464|162 165|min
P06090369A0000|24 32|patients
P06090369A0000|47 54|WR-2721
P06090369A0000|58 63|Phase
P06090369A0000|69 76|studies
P06090458A0407|4 27|PEPCK promoter fragment
P06090458A0407|64 75|orientation
P06090458A0407|80 93|transcription
P06090458A0407|101 108|TK gene
P06090458A0407|128 139|orientation
P06091914A0000|13 19|tumors
P06091914A0000|31 36|mouse
P06091914A0000|45 56|tumor virus
P06091914A0000|58 62|MMTV
P06091914A0000|74 82|provirus
P06091914A0000|95 101|region
P06091914A0000|119 125|genome
P06091914A0000|138 148|expression
P06091914A0000|172 180|oncogene
P06091914A0000|188 193|int-1
P06092048A1111|9 14|cases
P06092048A1111|16 24|asbestos
P06092048A1111|44 50|burden
P06092048A1111|63 71|fibrosis
P06092588T0000|0 17|Hepatitis B virus
P06092588T0000|22 30|hepatoma
P06093354A0000|18 28|DNA clones
P06093354A0000|50 64|leukemia virus
P06093354A0000|66 70|MuLV
P06093354A0000|80 93|DNA sequences
P06093354A0000|140 147|library
P06093354A0000|151 167|Balb/c mouse DNA
P06093363A0612|0 3|USA
P06093363A0612|27 35|proteins
P06093363A0612|43 55|% identities
P06093363A0612|65 84|amino acid sequence
P06093363A0612|92 101|alignment
P06093363A0612|116 120|gaps
P06094591A0000|4 26|envelope glycoproteins
P06094591A0000|30 48|Rous sarcoma virus
P06094591A0000|50 53|RSV
P06094591A0000|56 60|gp85
P06094591A0000|65 69|gp37
P06094591A0000|91 99|membrane
P06094591A0000|114 118|acid
P06094591A0000|132 138|domain
P06094591A0000|172 176|acid
P06094591A0000|190 196|domain
P06094591A0000|204 220|carboxy terminus
P06094591A0000|224 228|gp37
P06095372A0435|4 8|drug
P06095372A0435|35 39|dose
P06095372A0435|47 51|g/m2
P06095372A0435|57 58|h
P06095372A0435|73 92|radiation treatment
P06095774T0001|13 20|aspects
P06095774T0001|36 44|nephroma
P06096246T0000|0 6|Effect
P06096246T0000|40 46|stress
P06096246T0000|87 95|hormones
P06096246T0000|104 108|rats
P06096380A0662|7 11|mRNA
P06096380A0662|26 59|phosphoenolpyruvate carboxykinase
P06096380A0662|67 74|chicken
P06096380A0662|82 91|kilobases
P06096380A0662|95 101|length
P06096380A0662|140 144|mRNA
P06096380A0662|165 171|enzyme
P06096380A0662|179 182|rat
P06096863T0000|9 25|activation sites
P06096863T0000|33 42|CYC1 gene
P06096863T0000|135 143|TATA box
P06097027A0000|17 25|provirus
P06097027A0000|39 65|erythroblastosis virus E26
P06097027A0000|98 109|comparisons
P06097027A0000|121 141|myeloblastosis virus
P06097027A0000|143 146|AMV
P06097027A0000|164 177|tumor viruses
P06097285A1077|21 32|haloperidol
P06097285A1077|57 63|animal
P06097285A1077|66 74|capacity
P06097285A1077|111 126|motor behaviour
P06098719A0369|13 19|effect
P06098719A0369|33 52|laboratory findings
P06098719A0369|65 69|drug
P06098828A0352|4 11|results
P06098828A0352|30 36|report
P06098828A0352|54 58|SV40
P06098828A0352|68 77|sequences
P06098828A0352|106 120|RNA polymerase
P06098828A0352|148 156|elements
P06099656T0000|0 12|Construction
P06099656T0000|22 32|cell lines
P06099656T0000|63 98|adenovirus DNA binding protein gene
P06099656T0000|102 118|cotransformation
P06099656T0000|128 141|HSV-1 tk gene
P06101359T0000|0 9|Diagnosis
P06101359T0000|14 23|treatment
P06101359T0000|45 52|tumours
P06108610A0518|0 8|Theories
P06108610A0518|38 59|modality shift effect
P06109017A0000|4 11|effects
P06109017A0000|31 37|beta-1
P06109017A0000|49 56|agonist
P06109017A0000|61 77|4-hydroxyphenoxy
P06109017A0000|79 104|isopropylamino-2-propanol
P06109017A0000|113 124|prenalterol
P06109017A0000|165 177|measurements
P06109017A0000|199 201|LV
P06109017A0000|203 211|pressure
P06109017A0000|213 221|diameter
P06109017A0000|223 228|dP/dt
P06109017A0000|230 238|velocity
P06109017A0000|263 271|pressure
P06109017A0000|279 289|blood flow
P06109017A0000|294 304|heart rate
P06109017A0000|321 325|dogs
P06110026T0000|0 10|Endorphins
P06110026T0000|18 26|approach
P06110026T0000|30 35|death
P06111283T0032|0 15|Trial treatment
P06111283T0032|19 32|schizophrenia
P06111283T0032|38 61|des-Tyr-gamma-endorphin
P06113084T0000|8 22|taurine levels
P06113084T0000|39 63|calcium binding activity
P06113084T0000|88 102|cardiomyopathy
P06113443T0000|0 10|Separation
P06113443T0000|31 43|erythrocytes
P06113443T0000|55 60|blood
P06113443T0000|62 65|use
P06113443T0000|104 124|separation technique
P06119262T0000|4 18|roll-over test
P06119262T0000|30 37|toxemia
P06119262T0000|41 50|pregnancy
P06120429T0000|4 23|thyroglobulin assay
P06120429T0000|40 51|radioiodine
P06120429T0000|61 69|patients
P06120429T0000|90 104|thyroid cancer
P06121577A0280|14 24|reductions
P06121577A0280|48 62|blood pressure
P06121577A0280|88 93|doses
P06121577A0280|101 103|mg
P06121577A0280|108 109|%
P06121577A0280|116 118|mg
P06121577A0280|124 125|%
P06121577A0280|135 137|mg
P06121577A0280|143 144|%
P06121577A0280|184 193|decreases
P06121577A0280|197 207|heart rate
P06121577A0280|212 233|plasma renin activity
P06130348T0000|0 9|Isolation
P06130348T0000|13 22|Aeromonas
P06130348T0000|28 34|faeces
P06131038A0000|0 6|Plasma
P06131038A0000|11 35|erthrocyte lipid profile
P06131038A0000|40 67|lipoprotein lipase activity
P06131038A0000|71 89|postheparin plasma
P06131038A0000|106 113|rabbits
P06131038A0000|140 149|incidence
P06131038A0000|153 168|atherosclerosis
P06131038A0000|191 195|beds
P06131378A0818|10 14|mRNA
P06131378A0818|52 61|sequences
P06131378A0818|72 75|end
P06131378A0818|83 92|DHFR cDNA
P06131378A0818|109 132|polyadenylation signals
P06131378A0818|153 162|DHFR cDNA
P06136374A0151|8 26|water temperatures
P06136374A0151|28 31|VO2
P06136374A0151|67 84|swimming velocity
P06137028A0624|0 11|Propranolol
P06137028A0624|53 59|tremor
P06138015T0114|6 12|report
P06138313A0948|4 22|distribution phase
P06138313A0948|41 58|elimination phase
P06138313A0948|78 87|half-life
P06138313A0948|89 99|mean value
P06138313A0948|104 107|min
P06138313A0948|115 121|volume
P06138313A0948|125 137|distribution
P06141764A0339|0 28|Hybrid-selection experiments
P06141764A0339|56 59|RNA
P06141764A0339|80 91|plasmid DNA
P06141764A0339|105 111|clones
P06141764A0339|137 148|information
P06142279T0000|0 4|Risk
P06142279T0000|8 22|HTLV infection
P06142279T0000|26 34|patients
P06142279T0000|38 51|haemodialysis
P06143734T0000|9 19|metabolism
P06143734T0000|23 35|progesterone
P06143734T0000|61 67|testis
P06147504A0086|4 12|patients
P06147504A0086|27 34|therapy
P06147504A0086|53 60|reasons
P06147504A0086|90 94|mass
P06150069A0422|4 12|patients
P06150069A0422|22 25|VCR
P06150069A0422|30 35|mg/m2
P06150069A0422|49 54|weeks
P06150069A0422|60 77|dose modification
P06150069A0422|82 95|neurotoxicity
P06151518A0000|9 13|acid
P06151518A0000|19 23|dose
P06151518A0000|40 44|LD50
P06151518A0000|65 69|form
P06151518A0000|73 84|sodium salt
P06151518A0000|113 117|rats
P06151518A0000|124 128|days
P06151518A0000|149 159|injections
P06151518A0000|163 171|dexazone
P06151942A0235|0 5|Serum
P06151942A0235|15 19|acid
P06151942A0235|53 64|association
P06151942A0235|79 93|blood pressure
P06151942A0235|104 116|risk factors
P06151942A0235|127 141|blood pressure
P06151942A0235|149 160|cholesterol
P06151942A0235|162 174|triglyceride
P06151942A0235|176 185|gamma-GTP
P06151942A0235|190 197|obesity
P06152670T0000|0 15|Plasma secretin
P06152670T0000|17 29|pancreozymin
P06152670T0000|53 60|hormone
P06152670T0000|78 94|failure patients
P06152844T0000|0 6|Effect
P06152844T0000|10 20|bromazepam
P06152844T0000|24 38|growth hormone
P06152844T0000|43 62|prolactin secretion
P06152844T0000|73 81|subjects
P06153936A0784|11 16|cases
P06153936A0784|29 32|SjS
P06153936A0784|50 68|gland examinations
P06153936A0784|91 104|year interval
P06153936A0784|127 136|occasions
P06153936A0784|177 184|changes
P06155967A1132|4 16|radiologists
P06155967A1132|27 34|machine
P06155967A1132|50 68|reporting terminal
P06155967A1132|117 130|abnormalities
P06155967A1132|151 157|effort
P06155967A1132|176 180|time
P06158844A0000|0 11|Thalamotomy
P06158844A0000|26 39|CM-Pf complex
P06158844A0000|63 80|gamma irradiation
P06158844A0000|105 111|series
P06158844A0000|118 126|patients
P06158844A0000|139 143|pain
P06158844A0000|151 161|malignancy
P06161823A0129|11 19|capsules
P06161823A0129|43 45|mg
P06161823A0129|49 66|ethinyl estradiol
P06161823A0129|102 105|men
P06161823A0129|128 139|hypertrophy
P06162419A0118|45 52|maximum
P06162419A0118|63 68|doses
P06162419A0118|98 109|development
P06162419A0118|113 132|lymphadenosis NK/Li
P06162419A0118|150 154|cent
P06163433T0000|0 6|Effect
P06163433T0000|13 27|p-chlorophenyl
P06163433T0000|28 44|cyclopropylamine
P06163433T0000|64 77|concentration
P06163433T0000|82 108|monoamine oxidase activity
P06163433T0000|112 121|rat brain
P06165068A0547|22 27|juice
P06165068A0547|49 57|duodenum
P06165132A0000|3 13|experiment
P06165132A0000|42 47|fowls
P06165132A0000|52 60|broilers
P06165132A0000|79 84|farms
P06165132A0000|102 113|spray lento
P06165132A0000|128 136|vaccines
P06165132A0000|155 163|immunity
P06165132A0000|172 182|pseodopest
P06165132A0000|191 195|RIHA
P06165132A0000|210 222|pseudoplague
P06165132A0000|241 246|virus
P06165551A0793|8 25|inappropriateness
P06165551A0793|38 50|segmentation
P06165551A0793|59 68|isolation
P06165551A0793|72 78|spikes
P06165551A0793|89 94|waves
P06165551A0793|126 130|view
P06165551A0793|144 152|duration
P06165551A0793|161 171|transients
P06165551A0793|175 183|relation
P06165551A0793|191 197|length
P06165551A0793|205 211|window
P06165551A0793|217 220|sec
P06165551A0793|235 250|autocorrelation
P06165551A0793|277 299|segmentation algorithm
P06167806A0000|4 11|ability
P06167806A0000|23 29|UM-272
P06167806A0000|31 50|dimethylpropranolol
P06167806A0000|52 61|treatment
P06167806A0000|77 86|induction
P06167806A0000|112 128|tachyarrhythmias
P06167806A0000|159 162|dog
P06167806A0000|205 216|stimulation
P06167806A0000|220 224|days
P06167806A0000|247 257|infarction
P06173032T0000|4 10|effect
P06173032T0000|14 27|echothiophate
P06173032T0000|44 52|response
P06173032T0000|56 62|rabbit
P06173032T0000|70 78|pressure
P06173032T0000|82 92|dipivefrin
P06173860A0000|8 13|cases
P06173860A0000|34 44|infarction
P06173860A0000|64 83|segment depressions
P06173860A0000|96 115|contralateral leads
P06173860A0000|152 170|segment elevations
P06175691T0000|0 31|Bacillus cereus cross-infection
P06175691T0000|37 51|maternity-unit
P06181216A0070|38 46|patients
P06181216A0070|60 84|serum IgA concentrations
P06181216A0070|93 98|years
P06182979A0807|14 22|category
P06182979A0807|34 42|emphasis
P06182979A0807|66 89|anthracycline analogues
P06182979A0807|93 104|doxorubicin
P06182979A0807|109 118|analogues
P06182979A0807|122 153|cisplatinum diammine dichloride
P06184276T0001|8 14|course
P06184276T0001|18 31|plasmocytosis
P06184487A1485|5 9|mRNA
P06184487A1485|24 28|cDNA
P06184487A1485|47 71|HindIII-P/EcoRI-B region
P06184487A1485|79 88|AcNPV map
P06184487A1485|102 111|synthesis
P06184487A1485|115 118|31K
P06184487A1485|123 135|30K proteins
P06184487A1485|162 165|31K
P06184487A1485|170 182|30K proteins
P06184487A1485|199 202|RNA
P06184487A1485|219 248|HindIII-A/EcoRI-C/SstI-G cDNA
P06185014A0642|21 42|complement factor C3c
P06185014A0642|58 59|%
P06185014A0642|67 86|alpha 1-antitrypsin
P06185014A0642|113 121|increase
P06185014A0642|127 128|%
P06185493A0468|2 19|polypeptide chain
P06185493A0468|26 34|residues
P06185493A0468|50 75|yeast amino acid sequence
P06185493A0468|96 112|peptide sequence
P06185493A0468|120 136|ADP binding site
P06185493A0468|147 169|muscle pyruvate kinase
P06189698A0246|4 18|P165 component
P06189698A0246|72 82|components
P06189698A0246|105 114|amplitude
P06189698A0246|130 142|task demands
P06189698A0246|153 155|N2
P06189698A0246|160 173|P3 amplitudes
P06191243T0000|13 25|drawing size
P06191243T0000|53 65|brain damage
P06193351A1010|18 32|administration
P06193351A1010|41 46|drugs
P06193351A1010|68 77|incidence
P06193351A1010|81 83|VF
P06193351A1010|99 106|release
P06193351A1010|128 144|artery occlusion
P06198241A0209|6 13|fusions
P06198241A0209|31 39|plasmids
P06198241A0209|56 61|yeast
P06198241A0209|74 93|replication origins
P06198241A0209|109 116|markers
P06198241A0209|165 170|yeast
P06198241A0209|182 187|cells
P06198532A0982|44 52|tendency
P06198532A0982|74 82|patients
P06198532A0982|88 90|MS
P06198532A0982|118 121|RHD
P06198532A0982|149 155|causes
P06198532A0982|182 191|incidence
P06198532A0982|195 210|thromboembolism
P06198532A0982|214 224|comparison
P06198532A0982|234 237|RHD
P06199132A0179|0 8|Toxicity
P06199132A0179|37 42|cases
P06199132A0179|50 58|patients
P06199132A0179|69 72|WBC
P06199132A0179|117 125|patients
P06199132A0179|136 142|sepsis
P06200300A0409|9 19|electrodes
P06200300A0409|37 51|VEP amplitudes
P06200300A0409|57 62|skull
P06200300A0409|66 82|scalp electrodes
P06203843A0757|0 8|Products
P06203843A0757|19 24|cells
P06203843A0757|33 48|transfer factor
P06203843A0757|53 64|lymphokines
P06203843A0757|108 113|group
P06203843A0757|136 142|agents
P06204120T0001|0 3|Use
P06204120T0001|11 36|immunofluorescence method
P06204120T0001|41 55|identification
P06204120T0001|59 72|enteroviruses
P06204120T0001|76 89|cell cultures
P06208024A0168|5 13|fraction
P06208024A0168|30 40|digestions
P06208024A0168|44 49|DNase
P06208024A0168|56 64|RNase T1
P06208024A0168|103 113|hydrolysis
P06208477A0000|4 16|construction
P06208477A0000|28 35|library
P06208477A0000|39 44|mouse
P06208477A0000|56 59|DNA
P06208477A0000|90 97|Pietras
P06208477A0000|114 123|Acids Res
P06209403A0562|10 17|repeats
P06209403A0562|28 38|pseudogene
P06209403A0562|46 56|U2/4 locus
P06209499A0682|11 18|effects
P06209499A0682|22 41|transmitter release
P06209499A0682|60 64|fall
P06209499A0682|68 71|MAP
P06209499A0682|91 105|pressor effect
P06209499A0682|124 135|bradycardia
P06209499A0682|155 166|tachycardia
P06212776A0000|3 9|Cabras
P06212776A0000|11 19|Oristano
P06212776A0000|24 28|town
P06212776A0000|53 62|incidence
P06212776A0000|66 78|thalassaemia
P06212776A0000|83 98|G6PD deficiency
P06212776A0000|118 124|people
P06212776A0000|155 164|knowledge
P06212776A0000|176 184|diseases
P06212776A0000|198 208|prevention
P06214605A0123|4 10|number
P06214605A0123|14 22|elements
P06214605A0123|33 38|sizes
P06214605A0123|55 68|configuration
P06214605A0123|86 92|series
P06214605A0123|101 112|experiments
P06216125A0470|3 11|addition
P06216125A0470|25 31|chance
P06216125A0470|39 46|patient
P06216125A0470|61 63|ET
P06216125A0470|81 86|cycle
P06216125A0470|110 118|follicle
P06216125A0470|122 124|mm
P06216125A0470|160 165|cycle
P06216125A0470|190 198|follicle
P06217859T0000|0 10|Experience
P06217859T0000|20 26|tensor
P06217859T0000|46 50|flap
P06218005A0948|12 20|patients
P06218005A0948|36 44|L-L size
P06218005A0948|58 70|A-P diameter
P06223586A0000|0 18|Immunochemotherapy
P06223586A0000|24 37|schizophyllan
P06223586A0000|39 42|SPG
P06223586A0000|75 81|agents
P06223586A0000|113 122|tumor-C3H
P06223586A0000|126 139|mouse systems
P06223586A0460|28 39|mitomycin C
P06223586A0460|63 71|interval
P06223586A0460|88 102|administration
P06223586A0460|106 109|SPG
P06223586A0460|138 147|life-span
P06223586A0460|169 173|mice
P06224974A0833|0 4|Data
P06224974A0833|39 51|beta-hydroxy
P06224974A0833|54 64|metabolite
P06224974A0833|68 71|CPA
P06224974A0833|112 117|agent
P06225279A0498|14 21|surface
P06225279A0498|68 73|layer
P06225279A0498|99 105|tissue
P06227570A0523|3 11|contrast
P06227570A0523|16 27|LL patients
P06227570A0523|35 38|ENL
P06227570A0523|56 75|suppressor response
P06229542T0045|11 27|characterization
P06229542T0045|33 41|fraction
P06229542T0045|60 68|activity
P06229542T0045|81 102|template rescue assay
P06230499A0128|42 53|irradiation
P06230499A0128|61 65|form
P06230499A0128|73 86|fractionation
P06230499A0128|105 109|dose
P06230499A0128|115 117|Gy
P06230499A0128|130 133|day
P06230499A0128|139 151|summary dose
P06230499A0128|158 160|Gy
P06230499A0128|173 177|days
P06230499A0128|190 197|surgery
P06230499A0128|202 206|days
P06230499A0128|213 224|irradiation
P06230499A0128|256 267|performance
P06230499A0128|275 281|course
P06230499A0128|303 309|period
P06230499A0128|343 350|results
P06230499A0128|383 401|dose fractionation
P06233924T0000|0 11|Fibrin gels
P06233924T0000|31 42|implication
P06233924T0000|47 67|surface hemorheology
P06233924T0000|71 77|health
P06233924T0000|82 89|disease
P06234369T0000|12 23|vaccination
P06234786A0606|0 20|Radiogallium imaging
P06234786A0606|40 43|use
P06234786A0606|47 57|evaluation
P06234786A0606|77 88|cell tumors
P06234786A0606|92 96|bone
P06237518A0117|14 30|coupling reagent
P06237518A0117|42 46|acid
P06237518A0117|91 95|acid
P06237518A0117|97 101|CNCl
P06237518A0117|121 125|flow
P06237518A0117|134 140|system
P06237518A0117|155 158|KCN
P06237518A0117|163 173|chloramine
P06238540A0798|12 28|volume stiffness
P06238540A0798|37 66|mean wall stress relationship
P06238540A0798|70 73|LVH
P06238540A0798|113 134|wall muscle stiffness
P06238540A0798|143 172|mean wall stress relationship
P06238540A0798|176 179|LVH
P06238540A0798|197 202|slope
P06238704T0001|0 9|Synthesis
P06238704T0001|26 43|acid diethylamide
P06239545A0649|0 11|Weight loss
P06239545A0649|29 37|pressure
P06239545A0649|43 51|decrease
P06239545A0649|69 75|volume
P06239545A0649|88 94|output
P06239545A0649|113 117|fall
P06239545A0649|133 141|activity
P06240448A0652|4 10|effect
P06240448A0652|14 23|treatment
P06240448A0652|58 64|phases
P06240448A0652|77 82|phase
P06240448A0652|90 99|reduction
P06240448A0652|103 110|LV mass
P06240448A0652|117 126|reduction
P06240448A0652|138 144|output
P06240448A0652|152 158|change
P06240448A0652|179 189|resistance
P06240448A0652|204 209|phase
P06240448A0652|226 233|LV mass
P06240448A0652|241 249|increase
P06240448A0652|261 267|output
P06240448A0652|275 293|pretreatment level
P06240448A0652|318 326|decrease
P06240448A0652|347 357|resistance
P06241900A0000|5 10|study
P06241900A0000|40 47|effects
P06241900A0000|51 62|hypothermia
P06241900A0000|67 88|chemical cardioplegia
P06241900A0000|107 115|recovery
P06241900A0000|145 155|rat hearts
P06241900A0000|181 187|period
P06241900A0000|198 207|ischaemia
P06241980A0855|0 15|Oxygen profiles
P06241980A0855|35 46|Krogh model
P06241980A0855|62 71|diffusion
P06241980A0855|114 120|models
P06241980A0855|135 144|diffusion
P06242113T0001|0 20|Cultivation technics
P06242113T0001|25 44|Codonopsis pilosula
P06244732T0000|0 16|Radioimmunoassay
P06244732T0000|20 53|serum creatine kinase B isoenzyme
P06244732T0000|61 70|diagnosis
P06244732T0000|91 101|infarction
P06245672T0000|10 31|macrophage inhibition
P06245672T0000|59 68|reduction
P06245672T0000|72 82|metastasis
P06246254A0676|0 18|Restriction enzyme
P06246254A0676|23 44|heteroduplex analyses
P06246254A0676|60 69|sequences
P06246254A0676|80 84|FeSV
P06246254A0676|86 99|src sequences
P06246254A0676|120 126|center
P06246254A0676|134 145|FeSV genome
P06246254A0676|172 186|kilobase pairs
P06246254A0676|190 196|length
P06251469A0830|20 36|library isolates
P06251469A0830|61 70|IAP units
P06251469A0830|77 94|restriction sites
P06251469A0830|125 131|others
P06251469A0830|147 157|occurrence
P06251469A0830|162 170|position
P06252520T0000|0 14|Catecholamines
P06252520T0000|28 36|learning
P06252520T0000|40 46|review
P06252883A0100|29 35|strain
P06252883A0100|48 52|O149
P06252883A0100|53 56|K88
P06252883A0100|57 60|H10
P06252883A0100|91 98|piglets
P06252883A0100|104 107|PWD
P06252883A0100|114 123|rotavirus
P06252883A0100|146 152|number
P06252883A0100|156 165|occasions
P06254403A0000|4 18|antibody titer
P06254403A0000|26 34|chickens
P06254403A0000|38 53|SA-11 rotavirus
P06254403A0000|100 114|blocking assay
P06254973A1757|0 4|Poly
P06254973A1757|5 7|dT
P06254973A1757|23 38|calf thymus DNA
P06254973A1757|75 90|polynucleotides
P06254973A1757|111 123|accumulation
P06254973A1757|130 133|HDP
P06254973A1757|137 139|dT
P06254973A1757|174 183|molecules
P06254973A1757|188 190|dT
P06254973A1757|191 192|n
P06254973A1757|199 201|dT
P06254973A1757|209 211|dT
P06254973A1757|260 272|binding site
P06254973A1757|288 291|HDP
P06254973A1757|293 305|accumulation
P06254973A1757|330 338|residues
P06254973A1757|343 345|dT
P06254973A1757|346 348|n.
P06258699T0000|15 20|trial
P06258699T0000|38 49|Polybactrin
P06258699T0000|58 79|GU bladder irrigation
P06258699T0000|83 93|cystoscopy
P06258806A0963|21 30|insertion
P06258806A0963|49 56|element
P06258806A0963|69 77|terminus
P06258806A0963|96 100|gene
P06258806A0963|126 136|expression
P06258806A0963|169 175|enzyme
P06259220A0000|5 16|experiments
P06259220A0000|30 39|influence
P06259220A0000|50 61|antagonists
P06259220A0000|95 103|reaction
P06259220A0000|117 120|min
P06259220A0000|127 135|exposure
P06259220A0000|151 156|shock
P06259220A0000|185 193|reaction
P06259220A0000|210 220|reexposure
P06259220A0000|224 229|shock
P06259220A0000|233 235|hr
P06259220A0000|254 268|shock exposure
P06259220A0464|0 10|Experiment
P06259220A0464|49 57|reaction
P06259220A0464|83 97|administration
P06259220A0464|101 111|naltrexone
P06259220A0464|121 131|reexposure
P06259220A0464|135 140|shock
P06259389A0000|11 17|period
P06259389A0000|23 26|May
P06259389A0000|30 36|August
P06259389A0000|59 63|hand
P06259389A0000|65 69|foot
P06259389A0000|74 87|mouth disease
P06259389A0000|89 93|HFMD
P06259389A0000|107 122|Gifu prefecture
P06270347A0740|2 17|22K polypeptide
P06270347A0740|36 55|translation product
P06270347A0740|64 67|RNA
P06270347A0740|92 104|DNA fragment
P06272844A0000|19 24|virus
P06272844A0000|29 33|SV40
P06272844A0000|35 46|chromosomes
P06272844A0000|92 103|chromosomes
P06272844A0000|116 120|rate
P06272844A0000|125 131|extent
P06272844A0000|147 155|nuclease
P06272844A0000|157 162|MNase
P06272844A0000|164 173|digestion
P06272844A0000|236 250|SV40 chromatin
P06277159T0033|2 12|hypothesis
P06278424A0145|25 37|requirements
P06278424A0145|45 59|CH gene switch
P06278424A0145|94 108|gamma 2b genes
P06278424A0145|116 124|gamma 2b
P06278424A0145|135 148|mouse myeloma
P06278424A0145|150 156|MPC-11
P06278544T0027|0 10|Physiology
P06278544T0027|15 30|Physiopathology
P06279309A0000|4 10|genome
P06279309A0000|20 42|erythroblastosis virus
P06279309A0000|88 92|loci
P06279309A0000|94 100|v-erbA
P06279309A0000|105 111|v-erbB
P06279309A0000|119 129|activities
P06279309A0000|159 170|oncogenesis
P06279309A0000|178 183|virus
P06281759A1086|8 13|RNase
P06281759A1086|18 30|host mutants
P06281759A1086|48 62|sib regulation
P06281759A1086|64 74|processing
P06281759A1086|82 89|PL mRNA
P06281759A1086|93 96|sib
P06281759A1086|105 121|endoribonuclease
P06281759A1086|132 146|int mRNA decay
P06281759A1086|160 173|int synthesis
P06281786A1222|13 18|clone
P06281786A1222|20 30|lambda HHG
P06281786A1222|48 56|addition
P06281786A1222|64 77|histone genes
P06281786A1222|81 87|region
P06281786A1222|123 126|RNA
P06281786A1222|145 156|nucleotides
P06281786A1222|160 166|length
P06281891A0399|25 33|pathways
P06281891A0399|64 74|substances
P06281891A0399|80 85|roles
P06281891A0399|93 111|complex modulation
P06281891A0399|115 132|pain transmission
P06286191T0000|0 11|Restoration
P06286191T0000|31 40|functions
P06286191T0000|50 57|animals
P06286443A0498|14 31|serum ACTH levels
P06286549A0000|0 7|WR-2721
P06286549A0000|9 12|S-2
P06286549A0000|16 32|aminopropylamino
P06286549A0000|55 59|acid
P06286549A0000|91 98|ability
P06286549A0000|110 113|gut
P06286549A0000|115 119|lung
P06286549A0000|125 131|testis
P06286549A0000|144 156|fibrosarcoma
P06286549A0000|158 161|FSa
P06286549A0000|163 176|tumor nodules
P06286549A0000|185 190|lungs
P06286549A0000|194 198|mice
P06286549A0000|204 226|gamma-radiation injury
P06287212A1352|3 7|fact
P06287212A1352|9 17|families
P06287212A1352|21 33|polypeptides
P06287212A1352|51 61|initiation
P06287212A1352|65 76|translation
P06287212A1352|80 90|AUG codons
P06287212A1352|98 107|sequences
P06287212A1352|119 122|VP1
P06287212A1352|127 128|T
P06287212A1352|146 152|result
P06287212A1352|156 187|transcription initiation events
P06287212A1352|243 247|AUGs
P06287231A0914|3 11|addition
P06287231A0914|13 31|TRP1 RI Circle DNA
P06287231A0914|50 61|nucleosomes
P06287231A0914|68 72|size
P06287231A0914|77 84|spacing
P06287231A0914|120 140|bulk yeast chromatin
P06287737A0477|4 13|frequency
P06287737A0477|26 37|transfusion
P06287737A0477|49 58|hepatitis
P06287737A0477|60 69|cirrhosis
P06287737A0477|89 98|carcinoma
P06287737A0477|102 111|type NANB
P06287737A0477|135 136|%
P06287737A0477|164 173|incidence
P06287737A0477|183 208|posttransfusion hepatitis
P06287737A0477|229 230|%
P06287737A0477|257 271|liver diseases
P06287737A0477|279 286|history
P06287737A0477|290 298|jaundice
P06287737A0477|306 315|hepatitis
P06287737A0477|326 338|transfusions
P06287737A0477|375 384|type NANB
P06287737A0477|395 409|type B disease
P06290859A0426|7 27|hepatitis B patients
P06290859A0426|39 45|months
P06290859A0426|48 49|%
P06290859A0426|62 87|hepatitis Bs antigenaemia
P06290859A0426|91 92|%
P06290859A0426|116 126|antibodies
P06290859A0426|135 136|%
P06290859A0426|156 170|liver function
P06290899T0000|0 6|Survey
P06290899T0000|10 18|antibody
P06290899T0000|27 55|egg drop syndrome-1976 virus
P06290899T0000|62 76|chicken flocks
P06290899T0000|80 85|Japan
P06291369A0000|6 14|patients
P06291369A0000|29 57|equilibrium ventriculography
P06291369A0000|70 85|catheterization
P06291369A0000|112 124|day interval
P06291369A0000|147 155|portions
P06291369A0000|197 214|ejection fraction
P06291369A0000|216 220|RVEF
P06291369A0000|271 279|pressure
P06295429A0412|4 15|combination
P06295429A0412|19 23|MISO
P06295429A0412|28 35|WR-2721
P06295429A0412|57 65|response
P06295429A0412|87 91|drug
P06295429A0412|122 135|sensitization
P06295429A0412|148 153|doses
P06295429A0412|169 179|protection
P06295429A0412|200 205|doses
P06296833A0000|4 13|mutations
P06296833A0000|33 64|cuticle protein gene expression
P06296833A0000|108 114|strain
P06298014A0647|4 13|ensembles
P06298014A0647|46 51|forms
P06298014A0647|55 63|activity
P06298014A0647|108 113|units
P06298014A0647|124 131|columns
P06298720A0893|11 23|conservation
P06298720A0893|49 64|repeat sequence
P06298720A0893|86 107|integration mechanism
P06298720A0893|112 125|VL30 elements
P06298720A0893|130 145|MuLV proviruses
P06300662T0000|2 21|cDNA cloning vector
P06300662T0000|35 45|expression
P06300662T0000|49 61|cDNA inserts
P06300662T0000|75 80|cells
P06300836A0285|0 13|Hybridization
P06300836A0285|54 66|RR1 colonies
P06300836A0285|90 101|genome RNAs
P06300836A0285|119 127|presence
P06300836A0285|131 156|DNA clones representative
P06300836A0285|175 188|reovirus RNAs
P06300836A0285|206 226|constituent segments
P06300836A0285|234 250|rotavirus genome
P06304771A1284|8 16|sequence
P06304771A1284|18 26|GGGXGGAG
P06304771A1284|54 59|times
P06304771A1284|68 82|polyomaviruses
P06304771A1284|87 99|adenoviruses
P06304771A1284|132 136|role
P06304771A1284|140 155|DNA replication
P06304771A1284|163 176|transcription
P06304771A1284|198 210|JCV sequence
P06306342A1156|3 13|conclusion
P06306342A1156|21 28|studies
P06306342A1156|43 47|LiCl
P06306342A1156|91 105|acid secretion
P06306342A1156|139 149|disruption
P06306342A1156|173 180|barrier
P06306342A1156|195 211|Heidenhain pouch
P06307099A1005|0 12|Lung density
P06307099A1005|74 81|animals
P06308536T0001|4 30|hepatitis A virus antibody
P06308536T0001|32 40|anti-HAV
P06308536T0001|61 75|liver diseases
P06308607A0375|4 13|junctions
P06308607A0375|41 50|sequences
P06308607A0375|70 91|DNA sequence analysis
P06308607A0375|102 113|nucleotides
P06308607A0375|123 135|p30 sequence
P06308607A0375|146 157|nucleotides
P06308607A0375|167 186|polymerase sequence
P06309020A0473|0 8|Naloxone
P06309020A0473|12 23|mg/kg bolus
P06309020A0473|28 43|mg X kg-1 X h-1
P06309020A0473|75 80|doses
P06309020A0473|88 106|lipopolysaccharide
P06309855T0000|0 21|Gel route preparation
P06309855T0000|29 35|fusing
P06309855T0000|43 57|porcelain frit
P06309969T0055|0 2|I.
P06310159A0000|6 9|RNA
P06310159A0000|39 42|DNA
P06310159A0000|63 70|protein
P06310159A0000|80 94|retrovirus MH2
P06310457A0000|14 24|recordings
P06310457A0000|53 59|tectum
P06310457A0000|67 71|carp
P06310553T0000|10 19|structure
P06310553T0000|37 43|origin
P06310553T0000|61 78|muscle actin gene
P06310608A0749|4 11|mutants
P06310608A0749|29 41|substitution
P06310608A0749|59 64|clone
P06310608A0749|68 78|M-MuLV DNA
P06310608A0749|82 85|DNA
P06310608A0749|116 123|viruses
P06310608A0749|125 137|Ableson MuLV
P06310608A0749|139 146|Ab-MuLV
P06310608A0749|152 159|Moloney
P06310608A0749|167 180|sarcoma virus
P06310608A0749|182 187|M-MSV
P06314276T0000|0 8|Plasmids
P06314276T0000|17 24|cloning
P06314276T0000|29 39|expression
P06314276T0000|71 76|cDNAs
P06314276T0000|83 90|control
P06314276T0000|98 102|SV40
P06314276T0000|117 130|gene promoter
P06314312A0359|16 31|soybean protein
P06314312A0359|50 54|diet
P06314312A0359|60 66|levels
P06314312A0359|86 89|ppm
P06314312A0359|122 129|sources
P06314312A0359|154 162|purities
P06314312A0359|173 184|weight gain
P06314312A0359|188 194|chicks
P06314312A0359|198 205|average
P06314312A0359|211 212|%
P06314312A0359|226 241|feed efficiency
P06314312A0359|245 252|average
P06314312A0359|258 259|%
P06314312A0359|274 280|levels
P06314312A0359|286 287|P
P06316347A0852|4 13|dnaQ-lacZ
P06316347A0852|22 30|rnh-lacZ
P06316347A0852|37 42|genes
P06316347A0852|71 79|proteins
P06316347A0852|85 112|beta-galactosidase activity
P06316623A0188|8 19|prevalences
P06316623A0188|23 31|antibody
P06316623A0188|44 48|cent
P06316623A0188|52 58|cattle
P06316623A0188|67 71|cent
P06316623A0188|75 80|sheep
P06316623A0188|92 96|cent
P06316623A0188|100 105|goats
P06316623A0188|124 144|immunodiffusion test
P06318078T0000|0 10|Expression
P06318078T0000|14 39|herpes simplex virus beta
P06318078T0000|44 55|gamma genes
P06318078T0000|80 85|cells
P06318078T0000|96 105|induction
P06318078T0000|112 130|alpha gene product
P06318091A0395|4 24|splice acceptor site
P06318322A0350|26 31|model
P06318322A0350|47 50|SSV
P06318322A0350|68 81|recombination
P06318322A0350|99 102|DNA
P06318322A0350|115 122|sarcoma
P06318322A0350|134 139|virus
P06318322A0350|144 153|proto-sis
P06318322A0350|163 170|introns
P06318322A0350|224 237|messenger RNA
P06319040A1627|41 56|system activity
P06319040A1627|65 86|carotid chemoreceptor
P06319040A1627|94 104|activation
P06319040A1627|128 136|reflexly
P06319040A1627|146 155|reduction
P06319040A1627|168 178|blood flow
P06319040A1627|204 207|dog
P06319040A1627|220 228|increase
P06319040A1627|241 249|pressure
P06319071A0173|7 15|subjects
P06319071A0173|39 47|subjects
P06319071A0173|63 84|calcium stone-formers
P06319071A0173|113 123|AMP levels
P06319071A0173|140 152|counterparts
P06319071A0173|163 173|difference
P06319071A0173|209 212|AMP
P06319071A0173|233 246|units mumol/g
P06319071A0173|250 260|creatinine
P06319072A0711|22 33|morning dip
P06319072A0711|57 65|patients
P06319072A0711|96 103|changes
P06319072A0711|107 127|cell receptor number
P06319072A0711|131 139|affinity
P06319072A0711|148 155|results
P06319072A0711|174 180|groups
P06319072A0711|193 219|beta-adrenoceptor function
P06319421A0937|4 10|effect
P06319421A0937|14 25|desipramine
P06319421A0937|46 56|inhibition
P06319421A0937|69 75|uptake
P06319421A0937|88 101|amitriptyline
P06319421A0937|106 124|mianserin blockade
P06319421A0937|137 143|uptake
P06319421A0937|162 185|alpha 2-adrenoreceptors
P06319740A1331|21 25|gp54
P06319740A1331|37 41|gene
P06319740A1331|58 68|initiation
P06319740A1331|72 85|amplification
P06319740A1331|101 125|erythroblast hyperplasia
P06319740A1331|162 167|phase
P06319740A1331|171 187|Rauscher disease
P06320380T0001|0 18|Surgical treatment
P06320380T0001|32 42|metastases
P06321505A0401|2 19|promoter sequence
P06321505A0401|21 37|Goldberg-Hogness
P06321505A0401|41 49|TATA box
P06321505A0401|66 76|base pairs
P06321505A0401|95 100|point
P06321505A0401|104 114|initiation
P06321505A0401|118 131|transcription
P06321505A0401|151 170|S1 nuclease mapping
P06321505A0401|209 222|transcription
P06321505A0401|226 238|rat PTH mRNA
P06321634A0123|22 27|mRNAs
P06321634A0123|48 63|leader sequence
P06321634A0123|71 76|bases
P06321634A0123|90 96|intron
P06321634A0123|118 123|bases
P06321634A0123|160 177|TRs/IRs sequences
P06321770A1353|4 14|expression
P06321770A1353|18 51|chloramphenicol acetyltransferase
P06321770A1353|74 75|h
P06321770A1353|82 91|infection
P06321770A1353|95 100|cells
P06321770A1353|118 123|virus
P06321770A1353|146 152|nature
P06321770A1353|160 169|promoters
P06322183A1070|0 16|NPT II synthesis
P06322183A1070|30 47|agar plate assays
P06322183A1070|51 71|kanamycin resistance
P06322183A1070|79 98|immunoprecipitation
P06322183A1070|106 120|NPT II protein
P06322183A1070|143 151|presence
P06322183A1070|155 163|cysteine
P06322183A1070|187 194|absence
P06323556A0126|11 22|tomographic
P06323556A0126|43 58|EOE-13 infusion
P06323556A0126|81 98|perfusion pattern
P06323556A0126|116 124|catheter
P06324089A0453|12 21|structure
P06324089A0453|29 33|GAL7
P06324089A0453|46 52|region
P06324089A0453|62 70|features
P06324089A0453|115 120|genes
P06324121A0256|11 13|MW
P06324121A0256|15 18|12K
P06324121A0256|23 34|polypeptide
P06324121A0256|46 54|IEmRNA-5
P06324121A0256|80 85|codon
P06324121A0256|91 104|reading frame
P06324121A0256|121 125|base
P06324121A0256|144 150|region
P06325415A0757|13 23|difference
P06325415A0757|36 39|Ad7
P06325415A0757|44 52|Ad5 DBPs
P06325415A0757|60 67|absence
P06325415A0757|76 87|Ad7 protein
P06325415A0757|95 106|amino acids
P06325415A0757|142 149|domains
P06325415A0757|157 168|Ad5 protein
P06325415A0757|170 181|amino acids
P06327039A0743|15 26|correlation
P06327039A0743|45 48|LVM
P06327039A0743|52 66|wall thickness
P06327039A0743|71 88|body surface area
P06327039A0743|90 93|age
P06327039A0743|95 109|blood pressure
P06327039A0743|111 121|heart rate
P06327039A0743|131 137|output
P06327039A0743|156 166|resistance
P06327039A0743|197 208|wall stress
P06327039A0743|218 222|CD25
P06327039A0743|251 265|catecholamines
P06327039A0743|287 295|patients
P06327039A0743|297 298|r
P06327039A0743|308 309|p
P06327292A0846|16 40|Shine-Dalgarno sequences
P06327292A0846|92 104|start codons
P06327638A0155|4 15|gene cat-86
P06327638A0155|54 87|chloramphenicol acetyltransferase
P06327638A0155|107 119|1.1-kilobase
P06327638A0155|127 130|DNA
P06328002A0000|23 36|sarcoma virus
P06328002A0000|38 42|MPSV
P06328002A0000|59 66|passage
P06328002A0000|70 91|Moloney sarcoma virus
P06328002A0000|93 100|Mo-MuSV
P06328002A0000|111 115|mice
P06328012A0549|15 27|EBNA protein
P06328012A0549|66 78|transfection
P06328012A0549|84 91|BamHI-K
P06328012A0549|97 111|kilobase pairs
P06328012A0549|113 116|kbp
P06328012A0549|126 141|I1f subfragment
P06328012A0549|147 150|kbp
P06328485A0277|28 47|nucleotide sequence
P06328485A0277|55 57|kb
P06328485A0277|70 73|end
P06328485A0277|77 86|delta gag
P06328485A0277|97 100|end
P06328485A0277|132 139|MH2 DNA
P06328485A0277|144 149|order
P06328485A0277|175 184|structure
P06328485A0277|192 197|virus
P06328485A0277|227 230|mht
P06328485A0277|262 269|viruses
P06328485A0277|290 312|chicken proto-myc gene
P06328504A0161|0 3|USA
P06328504A0161|47 65|clone lambda PGK-1
P06328504A0161|79 86|portion
P06328504A0161|103 108|locus
P06328504A0161|113 136|phosphoglycerate kinase
P06328504A0161|138 141|PGK
P06330082A0329|0 2|A.
P06330478A0304|4 12|patients
P06330478A0304|22 32|cimetidine
P06330478A0304|37 46|mg q.i.d.
P06330478A0304|71 73|mg
P06330478A0304|98 103|doses
P06331684A0607|15 19|test
P06331684A0607|26 33|stomach
P06331684A0607|38 52|tumor antigens
P06331684A0607|57 66|screening
P06331684A0607|84 88|risk
P06331684A0607|93 107|stomach cancer
P06333433A0000|7 15|isolates
P06333433A0000|31 48|influenzae type b
P06333433A0000|73 81|outbreak
P06333433A0000|94 122|H. influenzae type b disease
P06333433A0000|166 173|profile
P06333433A0000|183 201|lipopolysaccharide
P06333433A0000|203 206|LPS
P06333878T0000|12 25|acid overdose
P06336045A0261a|0 9|Frog type
P06336045A0261a|13 17|Ft I
P06336045A0261a|23 32|frog type
P06336045A0261a|37 39|Ft
P06336045A0261a|61 63|SA
P06336045A0261a|65 70|units
P06336045A0261a|80 86|spikes
P06336045A0261a|99 116|indentation phase
P06336045A0261a|126 150|threshold response phase
P06336045A0261a|152 155|TRP
P06336045A0261a|168 173|phase
P06336045A0261a|187 192|spike
P06336045A0261b|0 9|Frog type
P06336045A0261b|13 17|Ft I
P06336045A0261b|23 32|frog type
P06336045A0261b|37 39|Ft
P06336045A0261b|61 63|SA
P06336045A0261b|65 70|units
P06336045A0261b|80 86|spikes
P06336045A0261b|99 116|indentation phase
P06336045A0261b|126 150|threshold response phase
P06336045A0261b|152 155|TRP
P06336045A0261b|168 173|phase
P06336045A0261b|187 192|spike
P06340643A0598|0 4|DMCM
P06340643A0598|18 27|extension
P06340643A0598|35 48|possibilities
P06340643A0598|80 92|donor organs
P06340703A0324|0 9|Grimelius
P06340703A0324|30 44|Masson Fontana
P06341139A0213|0 13|Blood glucose
P06341139A0213|18 32|plasma insulin
P06341139A0213|55 59|time
P06341139A0213|95 98|min
P06341139A0213|105 114|ingestion
P06341139A0213|121 130|g glucose
P06341139A0213|132 140|fructose
P06341139A0213|144 151|lactose
P06341139A0213|159 166|g honey
P06341139A0213|171 172|g
P06341139A0213|179 184|bread
P06341139A0213|190 191|g
P06341139A0213|198 202|rice
P06341139A0213|206 214|potatoes
P06341139A0213|220 228|g apples
P06341139A0213|236 245|g carrots
P06341661T0001|9 12|use
P06341661T0001|40 51|acid suture
P06341661T0001|55 70|Blalock-Taussig
P06341661T0001|73 82|operation
P06342141A0226|41 54|understanding
P06342141A0226|58 80|family pathophysiology
P06342141A0226|89 100|sensitivity
P06342141A0226|105 116|specificity
P06342141A0226|131 141|techniques
P06342141A0226|153 159|safety
P06342141A0226|164 172|efficacy
P06342141A0226|188 198|modalities
P06342141A0226|212 230|family health care
P06342141A0226|253 257|type
P06342141A0226|261 265|care
P06342141A0226|291 296|needs
P06342141A0226|304 310|family
P06342141A0226|330 337|members
P06342141A0226|346 362|value judgements
P06342141A0226|389 399|importance
P06342141A0226|422 434|consequences
P06342141A0226|443 470|health care delivery system
P06342141A0226|479 483|type
P06342141A0226|487 491|care
P06342141A0226|506 523|literature review
P06342141A0226|538 545|attempt
P06342141A0226|562 569|queries
P06342141A0226|582 591|questions
P06342141A0226|604 609|study
P06345840A0348|3 11|patients
P06345840A0348|15 22|group A
P06345840A0348|33 35|CI
P06345840A0348|42 44|CI
P06345840A0348|46 56|heart rate
P06345840A0348|65 69|mean
P06345840A0348|86 91|fiber
P06345840A0348|103 111|velocity
P06345840A0348|113 117|mVCF
P06345840A0348|140 143|TPR
P06346427A0000|25 39|insulin levels
P06346427A0000|80 84|rats
P06346427A0000|109 119|test-meals
P06349364A1051|6 13|results
P06349364A1051|56 63|passive
P06349364A1051|81 95|serum globulin
P06349364A1051|97 107|antibodies
P06349364A1051|111 115|type
P06349364A1051|120 149|group B Streptococcus antigen
P06349364A1051|198 207|infection
P06350092A0916|20 25|phase
P06350092A0916|29 32|AMI
P06350092A0916|48 52|CCHD
P06350092A0916|58 68|occurrence
P06350092A0916|83 87|VPBs
P06350092A0916|120 127|degrees
P06350092A0916|166 173|disease
P06350092A0916|189 200|possibility
P06350092A0916|226 231|death
P06354594A0114|6 13|oranges
P06354594A0114|15 23|mandarin
P06354594A0114|25 35|grapefruit
P06354594A0114|48 52|lime
P06354594A0114|76 86|processing
P06355483A0134|4 9|genes
P06355483A0134|18 23|locus
P06355483A0134|67 76|sequences
P06355483A0134|98 108|base-pairs
P06355483A0134|116 121|locus
P06355483A0134|130 140|base-pairs
P06360426A0501|12 22|hydrolysis
P06360426A0501|26 30|urea
P06360426A0501|40 47|ammonia
P06360426A0501|86 99|colour change
P06360426A0501|107 119|pH indicator
P06361318A0440|13 27|efficacy rates
P06361318A0440|45 50|cases
P06361318A0440|52 63|KS-R1 group
P06361318A0440|70 75|cases
P06361318A0440|82 87|group
P06361318A0440|94 99|cases
P06361318A0440|113 121|criteria
P06361318A0440|125 142|committee members
P06361318A0440|152 153|%
P06361318A0440|162 173|KS-R1 group
P06361318A0440|182 183|%
P06361318A0440|197 202|group
P06361318A1127|0 11|Side effect
P06361318A1127|47 55|symptoms
P06361318A1127|87 92|cases
P06361318A1127|94 105|KS-R1 group
P06361318A1127|112 117|cases
P06361318A1127|124 129|group
P06361318A1127|136 141|cases
P06361318A1127|152 166|incidence rate
P06361318A1127|181 182|%
P06361318A1127|191 202|KS-R1 group
P06361318A1127|211 212|%
P06361318A1127|226 231|group
P06361318A1127|254 264|difference
P06362143A0565|0 21|Plasma renin activity
P06362143A0565|40 48|response
P06362143A0565|60 64|tilt
P06362143A0565|68 89|isoprenaline infusion
P06362143A0565|97 105|patients
P06362239T0001|0 13|Martin Luther
P06362239T0001|22 32|physicians
P06362602T0001|0 11|Enhancement
P06362602T0001|26 34|response
P06362602T0001|48 54|action
P06362602T0001|58 75|vaccine additives
P06362602T0001|93 105|immunization
P06362602T0001|109 114|swine
P06362602T0001|123 128|swine
P06364265T0062|8 30|gamma-ray spectroscopy
P06367414A0000|0 8|Bepridil
P06367414A0000|12 30|calcium antagonist
P06367414A0000|38 47|half-life
P06367414A0000|68 73|hours
P06367414A0000|93 100|placebo
P06367414A0000|132 147|crossover trial
P06369355A0834|0 8|Analysis
P06369355A0834|12 20|proteins
P06369355A0834|36 44|plasmids
P06369355A0834|64 69|forms
P06369355A0834|77 88|trfA region
P06369355A0834|108 118|A2 protein
P06369355A0834|149 168|replication protein
P06369355A0834|172 183|plasmid RK2
P06369954T0000|0 7|Effects
P06369954T0000|28 36|pressure
P06369954T0000|57 69|hemodynamics
P06370553A0444|8 29|plasma norepinephrine
P06370553A0444|31 33|NE
P06370553A0444|39 50|epinephrine
P06370553A0444|52 53|E
P06370553A0444|55 61|levels
P06370553A0444|87 94|therapy
P06370553A0444|102 104|wk
P06370553A0444|111 121|withdrawal
P06370553A0444|123 133|guanfacine
P06370553A0444|138 145|control
P06370553A0444|147 156|plasma NE
P06370553A0444|186 191|ng/ml
P06370553A0444|193 201|plasma E
P06370553A0444|231 236|ng/ml
P06372563T0000|6 14|response
P06372563T0000|18 27|captopril
P06372563T0000|38 51|heart failure
P06372563T0000|53 57|role
P06372563T0000|61 71|furosemide
P06372563T0000|75 86|natriuresis
P06372563T0000|91 99|reversal
P06372563T0000|103 115|hyponatremia
P06373409A1163|0 9|Lauciello
P06373409A1163|22 31|technique
P06373409A1163|40 49|placement
P06373409A1163|76 83|amalgam
P06373409A1163|93 105|restorations
P06373409A1163|132 137|teeth
P06373855A0000|7 23|biopsy specimens
P06373855A0000|30 37|papules
P06373855A0000|46 51|dusky
P06373855A0000|63 70|lesions
P06373855A0000|82 90|patients
P06373855A0000|96 118|pityriasis lichenoides
P06373855A0000|136 141|acuta
P06373855A0000|144 149|PLEVA
P06373855A0000|175 193|immunofluorescence
P06373855A0000|198 223|immunoperoxidase technics
P06374369A1112|6 10|data
P06374369A1112|32 36|part
P06374369A1112|44 53|reduction
P06374369A1112|57 68|food intake
P06374369A1112|84 88|rats
P06374369A1112|118 122|diet
P06374369A1112|149 155|events
P06374418A0877|4 12|aspirate
P06374418A0877|32 36|cyst
P06374418A0877|73 79|amount
P06374418A0877|95 102|hormone
P06376227A0217|0 3|EGV
P06376227A0217|22 28|effect
P06376227A0217|32 44|PP secretion
P06376227A0217|71 81|conditions
P06379363A0415|13 18|tests
P06379363A0415|40 46|HDL-2M
P06379363A0415|92 99|therapy
P06379363A0415|121 138|diabetes mellitus
P06379363A0415|151 159|practice
P06381438A1280|0 28|Lung prostacyclin production
P06382374A0206|17 20|min
P06382374A0206|31 53|insulin administration
P06382374A0206|59 63|rate
P06382374A0206|67 73|change
P06382374A0206|77 91|glucose levels
P06382374A0206|125 133|patients
P06382374A0206|156 164|disorder
P06382374A0206|187 195|patients
P06382374A0206|211 219|disorder
P06382374A0206|234 250|control subjects
P06384983T0000|0 10|Management
P06384983T0000|14 26|hypertension
P06385474T0001|9 18|treatment
P06385474T0001|22 30|children
P06385474T0001|48 55|allergy
P06388189T0001|0 15|Transplantation
P06388189T0001|19 26|kidneys
P06388189T0001|39 45|donors
P06388189T0001|55 65|recipients
P06388818A0000|4 12|patients
P06388818A0000|36 43|Hodgkin
P06388818A0000|64 73|lymphomas
P06388818A0000|128 149|chemotherapy regimens
P06388818A0000|180 192|chemotherapy
P06388818A0000|194 197|HDC
P06388818A0000|211 217|rescue
P06388818A0000|245 265|bone marrow infusion
P06388818A0000|267 271|ABMT
P06391496T0000|0 6|Effect
P06391496T0000|22 29|enzymes
P06391496T0000|34 46|polypeptides
P06391496T0000|54 70|antacid activity
P06391496T0000|74 82|almagate
P06391496T0000|93 101|antacids
P06394228T0073|0 7|Results
P06394228T0073|24 29|study
P06394347A1024|0 12|Hydrallazine
P06394347A1024|34 42|increase
P06394347A1024|46 67|plasma renin activity
P06394347A1024|80 89|excretion
P06394347A1024|93 106|noradrenaline
P06395804A0382|0 15|Urease activity
P06395804A0382|21 22|%
P06395804A0382|32 41|organisms
P06395804A0382|67 70|min
P06397009A0204|6 17|description
P06397009A0204|31 35|life
P06397009A0204|43 54|explanation
P06397009A0204|68 85|conductor Bozzini
P06397009A0204|88 93|merit
P06397009A0204|116 125|invention
P06397009A0204|135 144|physician
P06397009A0204|172 180|medicine
P06397009A0204|203 216|possibilities
P06401749T0000|4 10|effect
P06401749T0000|14 21|lithium
P06401749T0000|29 43|osmoregulation
P06401749T0000|47 77|arginine vasopressin secretion
P06402480A0373|4 18|susceptibility
P06402480A0373|26 38|PPNG strains
P06402480A0373|62 73|antibiotics
P06402480A0373|90 105|plasmid pattern
P06402480A0373|125 134|necessity
P06402480A0373|148 160|surveillance
P06402480A0373|175 185|infections
P06402480A0373|201 211|evaluation
P06402480A0373|219 234|recommendations
P06402480A0373|253 262|treatment
P06402859A0000|0 16|Antithrombin III
P06402859A0000|31 45|plasma protein
P06402859A0000|74 83|inhibitor
P06402859A0000|87 95|thrombin
P06402859A0000|111 120|modulator
P06402859A0000|138 149|coagulation
P06404842A0127|9 17|patients
P06404842A0127|64 73|treatment
P06404842A0127|79 97|depot testosterone
P06404842A0127|102 104|mg
P06404842A0127|131 136|weeks
P06404842A0127|152 160|duration
P06404842A0127|168 173|years
P06406060A0000|15 24|cisplatin
P06406060A0000|42 44|iv
P06406060A0000|49 51|ip
P06406060A0000|63 67|mice
P06406060A0000|75 79|mice
P06406060A0000|88 95|Sarcoma
P06407348A0516|0 3|New
P06407348A0516|18 23|drugs
P06407348A0516|92 102|situations
P06407348A0516|135 143|blockade
P06407348A0516|159 168|receptors
P06407348A0516|170 175|beta1
P06407348A0516|198 214|muscle receptors
P06407348A0516|216 221|beta2
P06411659A0264|3 13|facilities
P06411659A0264|18 30|measurements
P06411659A0264|37 48|consumption
P06411659A0264|69 73|rate
P06411659A0793|24 37|energy intake
P06411659A0793|52 57|times
P06411659A0793|62 80|energy expenditure
P06411659A0793|89 97|N intake
P06411659A0793|112 121|mg/kg/day
P06412385A0356|10 18|patients
P06412385A0356|27 39|lung disease
P06412385A0356|52 67|muscle weakness
P06412385A0356|99 108|decreases
P06412385A0356|118 126|capacity
P06412385A0356|134 147|lung capacity
P06412385A0356|153 160|maximum
P06412385A0356|171 182|ventilation
P06412385A0356|199 208|increases
P06412385A0356|221 227|volume
P06412385A0356|241 263|carbon dioxide tension
P06412385A0356|265 270|PaCO2
P06412385A0356|285 295|likelihood
P06412385A0356|299 309|dependence
P06412385A0356|313 324|ventilators
P06412385A0356|326 337|atelectasis
P06412385A0356|343 352|pneumonia
P06413492A0990|0 6|Commun
P06414990A0057|16 24|analysis
P06414990A0057|28 32|data
P06414990A0057|36 44|TRH test
P06414990A0057|50 56|sample
P06414990A0057|71 81|volunteers
P06414990A0057|99 109|evaluation
P06414990A0057|123 129|limits
P06414990A0057|144 164|thyrotropin response
P06414990A0057|180 184|area
P06415299A0233|17 22|doses
P06415299A0233|26 37|doxorubicin
P06415299A0233|61 63|mg
P06415299A0233|65 67|m.
P06419251T0000|0 20|Movement programming
P06419251T0000|32 45|understanding
P06419251T0000|60 72|requirements
P06426493A0331|13 16|min
P06426493A0331|27 44|state anaesthesia
P06426493A0331|58 70|measurements
P06426493A0331|74 77|IOP
P06426493A0331|88 96|pressure
P06426493A0331|98 108|heart rate
P06426493A0331|110 114|FIO2
P06426493A0331|116 121|FE'CO
P06426493A0331|127 130|CVP
P06426493A0331|150 155|group
P06426493A0331|159 167|patients
P06426493A0331|177 187|atracurium
P06426493A0331|193 200|mg kg-1
P06426493A0331|215 226|pancuronium
P06426493A0331|231 238|mg kg-1
P06428116T0000|37 51|hypothyroidism
P06428116T0000|59 65|course
P06428116T0000|78 89|thyroiditis
P06429992T0000|0 19|Gonadotropin levels
P06429992T0000|23 30|mothers
P06429992T0000|48 52|sets
P06429992T0000|56 64|DZ twins
P06433442T0000|0 8|Freezing
P06433442T0000|12 18|plasma
P06433442T0000|36 41|yield
P06433442T0000|45 51|factor
P06433442T0000|57 59|C.
P06434572A0157|6 14|children
P06434572A0157|49 59|categories
P06434572A0157|75 88|GH deficiency
P06434572A0157|90 91|n
P06434572A0157|110 125|hypopituitarism
P06434572A0157|127 128|n
P06434572A0157|151 169|growth retardation
P06434572A0157|171 172|n
P06434572A0157|201 206|delay
P06434572A0157|210 216|growth
P06434572A0157|239 246|stature
P06434572A0157|248 249|n
P06434572A0157|278 286|criteria
P06434572A0157|325 330|tests
P06434572A0157|334 344|GH reserve
P06434587A0551|5 12|patient
P06434587A0551|28 30|LH
P06434587A0551|35 45|FSH levels
P06434587A0551|69 78|secretion
P06434587A0551|93 95|LH
P06434587A0551|100 113|FSH responses
P06434587A0551|117 120|LRH
P06435565A0648|6 13|changes
P06435565A0648|23 29|result
P06435565A0648|35 43|decrease
P06435565A0648|47 56|afterload
P06435565A0648|70 78|pressure
P06435565A0648|116 120|mmHg
P06435565A0648|122 123|p
P06435565A0648|162 172|resistance
P06435565A0648|214 222|dynes/cm
P06435565A0648|234 235|p
P06437579A0727|0 10|Cimetidine
P06437579A0727|15 17|mg
P06437579A0727|27 32|night
P06437579A0727|56 58|mg
P06437579A0727|83 95|dose regimen
P06437579A0727|108 126|patient compliance
P06437579A0727|146 155|treatment
P06439114A0677|0 11|Ceftazidime
P06439114A0677|18 25|promise
P06439114A0677|42 49|therapy
P06439114A0677|86 96|infections
P06439135A0250|0 12|Regional CBF
P06439135A0250|31 40|clearance
P06439135A0250|44 49|xenon
P06439135A0250|60 68|patients
P06439135A0250|89 95|bypass
P06439135A0250|105 115|procedures
P06441624A0263|4 11|results
P06441624A0263|26 35|serum BGP
P06441624A0263|50 61|measurement
P06441624A0263|65 80|bone metabolism
P06443550T0000|4 14|management
P06443550T0000|32 39|patient
P06443639T0001|0 5|Study
P06443639T0001|19 27|motility
P06443639T0001|32 36|rate
P06443639T0001|40 48|movement
P06443639T0001|64 82|circuit television
P06443714T0001|11 33|Rhodnius prolixus Stal
P06443714T0001|44 62|babassu palm trees
P06444119A0340|15 23|organism
P06444119A0340|47 57|preference
P06444119A0340|62 73|requirement
P06444119A0340|78 89|temperature
P06444119A0340|91 99|salinity
P06444119A0340|101 103|pH
P06444119A0340|115 124|nutrients
P06444119A0340|130 144|growth factors
P06444119A0340|154 169|toxin formation
P06444119A0340|205 212|factors
P06446048A0356|37 44|by-pass
P06446048A0356|57 65|solution
P06446048A0356|119 126|problem
P06451557A0777|0 11|Deformities
P06451557A0777|19 22|tip
P06451557A0777|30 39|olecranon
P06451557A0777|60 67|process
P06451557A0777|88 96|De Palma
P06451557A0777|103 109|Jordan
P06451557A0777|116 123|Ahlberg
P06451557A0777|130 137|Weseloh
P06452461A0930|22 33|correlation
P06452461A0930|37 43|LVM/M2
P06452461A0930|48 52|PWVn
P06452461A0930|57 64|pre-AVR
P06452461A0930|69 85|post AVR studies
P06452827T0001|18 27|recording
P06452827T0001|31 49|Huntington choreas
P06453290A0000|4 15|development
P06453290A0000|36 48|organization
P06453290A0000|73 78|ducts
P06453290A0000|115 123|material
P06453290A0000|132 137|weeks
P06454625A0000|24 41|animal experiment
P06454625A0000|47 58|alterations
P06454625A0000|72 83|vasculature
P06454625A0000|88 98|parenchyma
P06454625A0000|105 115|hemostasis
P06454625A0000|129 157|Infrared-Contact-Coagulation
P06454625A0000|187 212|magnification angiography
P06454625A0000|214 234|magnification factor
P06459831T0001|0 14|Cardiovascular
P06459831T0001|47 56|reactions
P06459831T0001|66 83|tobacco poisoning
P06460889A0111|12 22|injections
P06460889A0111|26 31|SG-75
P06460889A0111|40 45|mg/kg
P06460889A0111|66 80|blood pressure
P06460889A0111|82 85|SBP
P06460889A0111|154 164|blood flow
P06460889A0111|166 169|PBF
P06460889A0512|3 8|doses
P06460889A0512|18 31|.3 mg/kg i.v.
P06460889A0512|33 38|SG-75
P06460889A0512|68 82|pulse pressure
P06460889A0512|84 94|heart rate
P06460889A0512|103 113|blood flow
P06460889A0512|132 140|pressure
P06460889A0512|142 145|LVP
P06460889A0512|151 162|LVdP/dt max
P06463429A0414|8 10|VE
P06463429A0414|25 30|phase
P06463429A0414|38 39|%
P06463429A0414|76 81|phase
P06466804A0686|0 8|Exposure
P06466804A0686|12 23|endothelium
P06466804A0686|37 51|shear stresses
P06466804A0686|68 82|tape recording
P06466804A0686|100 114|flow waveforms
P06466804A0686|132 141|flowmeter
P06466804A0686|163 169|injury
P06466804A0686|173 183|denudation
P06466804A0686|199 204|shear
P06466804A0686|219 227|dyne/cm2
P06467241A0000|0 21|Modern cancer therapy
P06467241A0000|35 42|surgery
P06467241A0000|44 56|radiotherapy
P06467241A0000|58 70|chemotherapy
P06467241A0000|91 104|immunotherapy
P06467241A0000|109 121|hyperthermia
P06467797A0233|18 29|correlation
P06467797A0233|38 54|plasma clearance
P06467797A0233|58 60|NT
P06467797A0233|64 80|10-hydroxylation
P06467797A0233|89 90|D
P06467797A0233|101 106|ratio
P06467797A0233|108 116|D/4-OH-D
P06467797A0233|120 125|urine
P06467797A0233|134 143|Ghanaians
P06467797A0233|145 147|rs
P06467797A0233|157 158|P
P06467797A0233|179 185|Swedes
P06467797A0233|187 189|rs
P06467797A0233|199 200|P
P06468565A0000|4 23|response properties
P06468565A0000|27 30|cat
P06468565A0000|42 57|canal afferents
P06468565A0000|59 60|N
P06468565A0000|95 105|parameters
P06468565A0000|118 132|time constants
P06468565A0000|134 137|tau
P06468565A0000|144 168|frequency gain constants
P06468565A0000|170 172|G1
P06468565A0000|186 210|frequency gain constants
P06468565A0000|212 214|Gm
P06468632A0135|0 11|Endothelium
P06468632A0135|27 37|ear artery
P06468632A0135|57 63|rabbit
P06468632A0135|86 100|artery forceps
P06468632A0135|108 111|ear
P06468632A0135|130 136|vessel
P06468673A0358|25 42|E2 concentrations
P06468673A0358|62 74|mucus scores
P06468673A0358|120 125|group
P06468673A0358|127 128|P
P06468694A0441|0 11|Stimulation
P06468694A0441|19 34|caudate nucleus
P06468694A0441|55 61|system
P06468694A0441|65 69|dogs
P06468694A0441|73 78|means
P06468694A0441|82 96|administration
P06468694A0441|100 109|dophamine
P06468694A0441|114 124|micrograms
P06468694A0441|130 139|phenamine
P06468694A0441|147 160|deterioration
P06468694A0441|194 204|components
P06468694A0441|216 225|behaviour
P06473219T0000|0 5|Value
P06473219T0000|9 28|urine glucose tests
P06473219T0000|36 46|management
P06473219T0000|50 54|type
P06473219T0000|58 75|diabetes mellitus
P06473252A1073|5 15|experiment
P06473252A1073|50 53|sex
P06473252A1073|64 78|egg production
P06473252A1073|97 103|factor
P06473252A1073|105 113|ABSTRACT
P06473252A1073|131 136|WORDS
P06479362A0680|0 14|Hydrocortisone
P06479362A0680|48 71|postdenervation changes
P06479362A0680|79 94|muscle membrane
P06479362A0680|108 113|doses
P06479362A0680|121 128|hormone
P06479362A0680|148 155|changes
P06479362A0680|163 178|muscle membrane
P06479976A0386|21 32|differences
P06479976A0386|45 53|patients
P06479976A0386|79 82|AMB
P06479976A0386|95 108|survival time
P06479976A0386|119 128|diagnosis
P06479976A0386|132 139|illness
P06479976A0386|141 142|P
P06479976A0386|185 196|nerve signs
P06479976A0386|212 220|patients
P06479976A0386|222 223|P
P06480542A0000|18 23|study
P06480542A0000|27 37|apalcillin
P06480542A0000|58 66|patients
P06480542A0000|88 92|unit
P06482179A0497|0 15|Catch-up growth
P06482179A0497|49 55|period
P06482179A0497|61 69|children
P06482179A0497|77 85|bone age
P06482179A0497|96 101|years
P06482318A0117|0 20|Thrombocyte function
P06482318A0117|41 49|patients
P06482318A0117|81 102|platelet shape change
P06482665A0735|4 12|findings
P06482665A0735|30 49|AMPH administration
P06482665A0735|72 80|increase
P06482665A0735|88 94|height
P06482665A0735|120 124|peak
P06482665A0735|132 147|caudate nucleus
P06482665A0735|151 166|pigtail monkeys
P06482665A0735|210 219|increases
P06482665A0735|282 287|state
P06482665A0735|295 301|animal
P06483863A0000|7 18|experiments
P06483863A0000|36 46|BALB/cCrgl
P06483863A0000|50 69|BALB/cfC3HCrgl mice
P06483863A0000|94 104|injections
P06483863A0000|110 120|micrograms
P06483863A0000|124 138|beta-estradiol
P06483863A0000|149 152|oil
P06483863A0000|169 173|days
P06483863A0000|177 181|life
P06483863A0000|212 216|days
P06483863A0000|220 223|age
P06483863A0000|234 238|time
P06483863A0000|247 258|concretions
P06483863A0000|260 271|Experiments
P06483863A0000|285 291|silica
P06483863A0000|293 303|Experiment
P06486932A0000|15 21|deaths
P06486932A0000|25 26|%
P06486932A0000|28 37|occurring
P06486932A0000|51 57|people
P06486932A0000|67 70|age
P06486932A0000|78 93|Malumfashi area
P06486932A0000|106 113|Nigeria
P06486932A0000|115 119|data
P06486932A0000|138 146|symptoms
P06486932A0000|164 169|death
P06487290A0000|9 18|estradiol
P06487290A0000|22 26|beta
P06487290A0000|28 38|E2-17 beta
P06487290A0000|44 56|progesterone
P06487290A0000|58 59|P
P06487290A0000|86 113|radioimmunoassay techniques
P06487290A0000|129 136|females
P06487290A0000|168 178|trimesters
P06487290A0000|209 217|controls
P06487290A0000|236 241|phase
P06487290A0000|259 264|cycle
P06492188A0615|11 12|d
P06492188A0615|41 47|effect
P06492188A0615|55 61|number
P06492188A0615|65 73|implants
P06493655A0415|9 26|FHR decelerations
P06493655A0415|30 42|bradycardias
P06493655A0415|66 81|nonstress tests
P06493655A0415|87 88|%
P06493655A0415|101 102|%
P06493655A0415|113 121|patients
P06494215A0248|4 18|response chain
P06494215A0248|27 36|component
P06494215A0248|55 72|food presentation
P06494215A0248|93 101|schedule
P06494297A0939|4 11|results
P06494297A0939|23 31|kindling
P06494297A0939|66 72|effect
P06494297A0939|76 87|acquisition
P06494297A0939|91 97|HPC SS
P06494297A0939|123 129|effect
P06494297A0939|137 148|stimulation
P06494766A0241|21 31|dispersion
P06494766A0241|45 66|Hiss bundle fragments
P06494766A0241|90 96|septum
P06494766A0241|123 134|explanation
P06495195A0536|29 34|tests
P06495195A0536|41 49|activity
P06495195A0536|60 63|U/l
P06495195A0536|68 88|alkaline phosphatase
P06495195A0536|117 125|patients
P06495195A0536|164 176|liver damage
P06497671T0001|0 7|Changes
P06497671T0001|11 32|plasma cortisol level
P06497671T0001|51 60|responses
P06501086A0165|12 23|alterations
P06501086A0165|44 48|rats
P06501086A0165|54 63|sham rats
P06501086A0165|100 111|hypertrophy
P06501086A0165|113 122|formation
P06501086A0165|137 160|vas deferens granulomas
P06501086A0165|178 191|serum protein
P06501086A0165|216 222|levels
P06501086A0165|235 256|serum electrophoresis
P06501086A0165|272 304|sperm agglutinin antibody titers
P06503132A0784|0 3|SFP
P06503132A0784|34 36|Hn
P06503132A0784|38 39|s
P06503329A0588|12 22|birth mass
P06503329A0588|32 40|newborns
P06503329A0588|58 60|SD
P06503329A0588|67 68|g
P06503329A0588|85 98|control group
P06503329A0588|113 115|SD
P06503329A0588|122 123|g
P06503329A0588|125 126|P
P06503885A0342|5 18|machine drift
P06503885A0342|52 56|rise
P06503885A0342|60 65|water
P06503885A0342|74 85|temperature
P06503885A0342|136 151|x-ray tube heat
P06503885A0342|183 197|overestimation
P06503885A0342|219 229|blood flow
P06503885A0342|231 235|rCBF
P06503885A0342|243 265|xenon/CT rCBF protocol
P06503885A0342|291 296|scans
P06503885A0342|315 334|interscan intervals
P06505014A1192|6 19|uncertainties
P06505014A1192|27 36|dosimetry
P06505014A1192|40 44|Y-12
P06505014A1192|49 54|Vinca
P06506074A0456|0 13|E2 treatments
P06506074A0456|23 36|hen plasma TG
P06506074A0456|40 41|X
P06506074A0456|43 45|PL
P06506074A0456|49 50|X
P06506074A0456|56 57|C
P06506074A0456|61 62|X
P06506074A0456|75 84|plasma TG
P06506074A0456|88 89|X
P06506074A0456|91 93|PL
P06506074A0456|97 98|X
P06506074A0456|104 105|C
P06506074A0456|109 111|X.
P06507629A0717|3 11|contrast
P06507629A0717|13 20|kidneys
P06507629A0717|26 30|rats
P06507629A0717|54 62|acidosis
P06507629A0717|91 94|NH3
P06507629A0717|111 117|groups
P06507629A0717|133 152|mumol X min-1 X g-1
P06508393T0000|0 13|Serodiagnosis
P06508393T0000|17 32|trypanosomiasis
P06508393T0000|46 52|camels
P06508393T0000|61 88|card agglutination test set
P06508393T0000|90 102|Testryp CATT
P06513456T0001|0 23|Adenyl cyclase activity
P06513456T0001|35 41|mucosa
P06513456T0001|45 53|patients
P06513456T0001|68 73|ulcer
P06513456T0001|91 100|treatment
P06516369T0001|0 11|Proteinuria
P06516369T0001|54 62|problems
P06516847A0393|37 48|pneumococci
P06516847A0393|62 71|mortality
P06516847A0393|77 88|pneumococci
P06516977T0000|0 8|Reaction
P06516977T0000|18 26|organism
P06516977T0000|30 38|exercise
P06517816A0388|0 2|HA
P06517816A0388|26 27|p
P06517816A0388|44 47|Tre
P06517816A0388|53 62|degrees C
P06517816A0388|68 70|HR
P06517816A0388|75 84|b X min-1
P06517816A0388|102 103|p
P06517816A0388|120 123|Msw
P06517816A0388|128 141|g X m-2 X h-1
P06517816A0388|154 172|saline experiments
P06520418A0325|4 11|results
P06520418A0325|49 67|valve orifice area
P06520418A0325|69 72|MVA
P06520418A0325|103 111|patients
P06520418A0325|117 121|type
P06520418A0325|133 159|LVIT flow velocity pattern
P06520418A0325|168 176|patients
P06520418A0325|182 186|type
P06520418A0325|190 191|p
P06521802A0251|0 22|Scientific cooperation
P06521802A0251|26 47|CMEA member countries
P06521802A0251|90 101|sponsorship
P06521802A0251|109 134|Cancer Research Institute
P06521802A0251|136 150|Slovak Academy
P06521802A0251|154 162|Sciences
P06521802A0251|164 178|Czechoslovakia
P06521802A0251|191 200|framework
P06521802A0251|204 208|CMEA
P06521999A0677|27 34|results
P06521999A0677|54 63|melanomas
P06521999A0677|75 86|enucleation
P06524202A0167|6 13|variant
P06524202A0167|21 35|EMG-BFB method
P06524202A0167|37 49|multichannel
P06524202A0167|100 106|method
P06524202A0167|120 128|training
P06524202A0167|138 145|muscles
P06524202A0167|159 169|spasticity
P06524202A0167|179 190|antagonists
P06524202A0167|214 232|motor coordination
P06524727A0601|0 11|Lymphocytes
P06524727A0601|23 30|species
P06524727A0601|47 56|responses
P06524727A0601|72 80|prelabel
P06524727A0601|96 100|hour
P06524727A0601|111 128|incubation period
P06524727A0601|135 136|C
P06524727A0601|146 160|blood dilution
P06524761A0596|21 31|difference
P06524761A0596|39 46|quality
P06524761A0596|50 58|immunity
P06524761A0596|60 65|fever
P06524761A0596|70 86|body weight loss
P06524761A0596|100 108|hamsters
P06524761A0596|129 154|killed-toxoplasma vaccine
P06524761A0596|171 180|challenge
P06524761A0596|194 204|T-1 strain
P06524761A0596|220 227|changes
P06524761A0596|248 256|hamsters
P06524761A0596|267 290|live-toxoplasma vaccine
P06524761A0596|300 309|challenge
P06524761A0596|323 332|RH strain
P06527379T0044|12 36|proline/alanine sequence
P06527379T0044|40 55|beta B1 subunit
P06527379T0044|85 97|DNA sequence
P06527872T0000|27 38|projections
P06527872T0000|82 88|nerves
P06527872T0000|96 117|substantia gelatinosa
P06527872T0000|132 136|cord
P06527872T0000|140 144|rats
P06527872T0000|162 167|study
P06527872T0000|171 176|means
P06527872T0000|183 199|acid phosphatase
P06527872T0000|201 204|ACP
P06527872T0000|206 212|method
P06531286A0382|0 7|Removal
P06531286A0382|11 26|lipid fractions
P06531286A0382|30 47|plant extractions
P06531286A0382|53 59|hexane
P06531286A0382|84 90|damage
P06531286A0382|98 109|HPLC column
P06535384A1115|18 25|subtest
P06535384A1115|37 42|items
P06535384A1115|62 72|difficulty
P06535384A1115|106 111|items
P06535384A1115|130 141|possibility
P06535384A1115|145 152|success
P06535384A1115|161 169|subjects
P06535384A1115|171 179|ABSTRACT
P06535384A1115|197 202|WORDS
P06539738T0000|18 28|evaluation
P06539738T0000|32 50|chlorofluorocarbon
P06539738T0000|55 58|CFC
P06541019A0555|4 12|patients
P06541019A0555|32 40|toxicity
P06541019A0555|51 59|response
P06541932A0000|0 7|Methods
P06541932A0000|37 48|algesimetry
P06541932A0000|95 102|effects
P06541932A0000|140 150|analgesics
P06542372A0159|12 17|paper
P06542372A0159|42 55|discrepancies
P06542372A0159|81 92|terminology
P06542372A0159|117 122|terms
P06542372A0159|127 137|additivity
P06542372A0159|141 153|potentiation
P06542372A0159|168 178|similarity
P06542918A1131|30 44|discrimination
P06542918A1131|64 68|time
P06542918A1131|81 91|evaluation
P06542918A1131|135 147|P3 latencies
P06545651A0346|0 21|Ammonia concentration
P06545651A0346|51 61|treatments
P06545651A0346|65 72|finding
P06545651A0346|101 107|effect
P06545651A0346|111 139|protein nitrogen degradation
P06545651A0346|155 163|nitrogen
P06545651A0346|165 168|NH3
P06546392A0542|8 17|respect C
P06546392A0542|27 49|protein concentrations
P06546392A0542|72 82|cell count
P06546392A0542|84 114|erythrocyte sedimentation rate
P06546392A0542|120 131|temperature
P06546392A0542|140 154|concentrations
P06546392A0542|158 171|antiproteases
P06548953T0001|6 24|thyroid stimulator
P06548953T0001|26 29|HTS
P06548953T0001|34 50|thyroid diseases
P06555107A1227|17 31|administration
P06555107A1227|39 67|calcium antagonist Verapamil
P06555107A1227|88 93|value
P06555107A1227|107 116|treatment
P06555107A1227|122 135|beta-mimetics
P06568939A0000|0 9|Brainstem
P06568939A0000|26 35|responses
P06568939A0000|37 42|BAERs
P06568939A0000|70 90|eye movement studies
P06568939A0000|99 110|information
P06568939A0000|118 127|integrity
P06568939A0000|131 139|pathways
P06568939A0000|155 164|brainstem
P06571587T0000|0 7|Effects
P06571587T0000|11 19|ketamine
P06571587T0000|39 48|functions
P06571587T0000|53 76|body tissue oxygenation
P06571587T0000|80 84|dogs
P06571587T0000|114 124|conditions
P06579147A0060|21 29|features
P06579147A0060|35 43|problems
P06579147A0060|47 57|management
P06579147A0060|73 83|approaches
P06579147A0060|91 105|reconstruction
P06579147A0060|116 127|deformities
P06579147A0060|141 148|disease
P06579152A1061|36 39|NPF
P06579152A1061|53 57|tool
P06579152A1061|62 72|activation
P06579152A1061|76 99|velopharyngeal activity
P06579152A1061|103 106|way
P06579152A1061|117 134|feed-back control
P06582285A0222|28 34|safety
P06582285A0222|38 41|U-P
P06582285A0222|46 49|D&E
P06582285A0222|69 72|U-P
P06582285A0222|83 96|D&E abortions
P06582285A0222|119 124|weeks
P06582285A0222|126 135|gestation
P06584416A0157|6 18|radiologists
P06584416A0157|27 36|knowledge
P06584416A0157|40 48|patients
P06584416A0157|50 54|data
P06584416A0157|59 68|treatment
P06584416A0157|81 91|angiograms
P06584416A0157|104 116|examinations
P06584416A0157|125 128|PGF
P06585277A0000|5 8|man
P06585277A0000|29 37|leukemia
P06585277A0000|43 54|association
P06585277A0000|78 103|acid phosphatase activity
P06585277A0000|107 112|serum
P06585277A0000|121 129|presence
P06585277A0000|141 153|bone lesions
P06585277A0000|157 172|roentgenography
P06585277A0000|187 196|existence
P06585277A0000|223 232|carcinoma
P06588306A0076|21 43|prophylactic treatment
P06588306A0076|49 56|therapy
P06588306A0076|64 76|meningopathy
P06588306A0076|81 84|AIL
P06588306A0076|86 101|AIEOP protocols
P06588501T0059|26 31|study
P06591992A0569|3 15|anisotropism
P06591992A0569|50 58|solution
P06593862T0001|0 19|Hepatitis B vaccine
P06594105A0560|15 21|values
P06594105A0560|25 34|lambda tb
P06594105A0560|41 50|degrees C
P06594105A0560|62 78|cent haematocrit
P06594105A0560|98 102|pulp
P06594105A0560|118 124|tongue
P06594105A0560|154 159|gland
P06594105A0560|178 185|gingiva
P06594105A0560|193 196|dog
P06594105A0560|198 207|lambda cp
P06594105A0560|222 231|lambda tp
P06594105A0560|249 260|temperature
P06594105A0560|286 296|degrees C.
P06597709A0596|42 52|asbestosis
P06597709A0596|71 83|lung volumes
P06597709A0596|92 97|ratio
P06597709A0596|101 116|transfer factor
P06597709A0596|139 145|volume
P06597709A0596|151 158|results
P06597709A0596|168 180|measurements
P06597709A0596|207 212|cases
P06599282T0001|13 20|pattern
P06599282T0001|33 47|cell carcinoma
P06599282T0001|66 73|gingiva
P06600533T0000|0 11|Azygos vein
P06600533T0000|35 39|wall
P06600533T0000|68 80|lobe bronchi
P06600533T0000|91 101|CT variant
P06602580A0664|13 20|history
P06602580A0664|37 50|complications
P06602580A0664|56 68|otitis media
P06602580A0664|87 96|frequency
P06602580A0664|106 117|individuals
P06602580A0664|123 153|alpha 1-antitrypsin deficiency
P06602580A0664|169 176|normals
P06602600A0582|4 13|Sarns 51F
P06602600A0582|25 32|cannula
P06602600A0582|57 63|system
P06602600A0582|99 107|cannulas
P06606043A0598|10 17|changes
P06606043A0598|37 48|6-positions
P06606043A0598|65 76|replacement
P06606043A0598|84 96|phenyl group
P06606043A0598|100 108|position
P06606043A0598|128 136|decrease
P06606043A0598|140 148|activity
P06607427A0000|6 17|experiments
P06607427A0000|33 40|effects
P06607427A0000|70 77|lesions
P06607427A0000|111 117|dorsal
P06607427A0000|132 143|projections
P06607427A0000|162 174|hypothalamus
P06607427A0000|179 185|cortex
P06607427A0000|206 225|body weight changes
P06607427A0000|243 252|behaviour
P06607427A0000|260 263|rat
P06607714T0000|0 15|Limb allografts
P06607714T0000|19 23|rats
P06607714T0000|46 60|cyclosporin A.
P06609166A0209|4 10|method
P06609166A0209|35 42|samples
P06609166A0209|52 59|volumes
P06609166A0209|63 75|acetonitrile
P06609166A0209|88 97|injection
P06609166A0209|103 114|microliters
P06609166A0209|151 176|C18 reversed-phase column
P06610347A0581|11 18|periods
P06610347A0581|26 37|AV junction
P06610347A0581|67 74|fashion
P06610347A0581|78 88|conduction
P06610347A0581|101 108|AV node
P06612373A0000|5 10|paper
P06612373A0000|27 31|data
P06612373A0000|49 56|variety
P06612373A0000|60 67|sources
P06612373A0000|76 82|extent
P06612373A0000|86 98|prescription
P06612373A0000|103 106|use
P06612373A0000|123 128|drugs
P06612373A0000|141 146|1960s
P06612373A0000|157 162|1970s
P06615053A0202|8 16|patients
P06615053A0202|40 45|hours
P06615053A0202|49 62|resuscitation
P06615053A0202|106 114|ejection
P06615053A0202|116 120|RVEF
P06615053A0202|156 162|volume
P06615053A0202|164 170|RVEDVI
P06615403A0718|16 29|LAD occlusion
P06615403A0718|41 48|minutes
P06615403A0718|50 56|series
P06615403A0718|60 61|n
P06615403A0718|70 81|microns TMs
P06615403A0718|114 121|minutes
P06615403A0718|128 136|ligation
P06615403A0718|141 152|microns TMs
P06615403A0718|179 186|minutes
P06625058A0666|4 14|population
P06625058A0666|71 75|cost
P06625058A0666|80 86|capita
P06627123A0000|7 18|Wistar rats
P06627123A0000|37 41|diet
P06627123A0000|43 51|Sustacal
P06627123A0000|69 76|ethanol
P06627123A0000|80 81|%
P06627123A0000|85 93|calories
P06627123A0000|109 116|sucrose
P06627569T0001|0 2|HL
P06627569T0001|6 32|type oculomotor stimulator
P06629370A0252|5 13|patients
P06629370A0252|15 20|group
P06629370A0252|28 32|type
P06629370A0252|35 64|basement membrane nephropathy
P06629370A0252|105 116|lamellation
P06629370A0252|124 141|basement membrane
P06629370A0252|147 154|pattern
P06629370A0252|174 180|Alport
P06629370A0252|183 191|syndrome
P06630319A0244|0 8|Brain pH
P06630319A0244|21 22|h
P06630319A0244|41 49|ischemia
P06630319A0244|72 77|value
P06630319A0244|103 110|animals
P06630319A0244|125 136|barbiturate
P06630319A0244|141 161|halothane anesthesia
P06634712A0557|4 11|results
P06634712A0557|28 38|importance
P06634712A0557|42 51|phosphate
P06634712A0557|56 63|calcium
P06634712A0557|83 92|secretion
P06634712A0557|96 99|PTH
P06634712A0557|104 106|CT
P06634712A0557|110 116|uremia
P06643612A0000|27 34|methods
P06643612A0000|69 76|studies
P06643612A0000|80 90|imipramine
P06643612A0000|94 100|plasma
P06643612A0000|105 110|urine
P06648156T0034|13 20|remarks
P06652293A0353|23 28|point
P06652293A0353|43 52|responses
P06652293A0353|67 78|sensitivity
P06652293A0353|84 85|%
P06652293A0353|104 115|specificity
P06652293A0353|121 122|%
P06653755A0192|6 29|clofelin administration
P06653755A0192|34 56|autoregulation borders
P06653755A0192|78 83|i. e.
P06653755A0192|99 108|AP levels
P06654047A0694|5 15|phenomenon
P06654047A0694|37 44|variant
P06654047A0694|69 79|cell death
P06654047A0694|106 115|apoptosis
P06654047A0694|161 165|case
P06654047A0694|179 195|rhabdomyosarcoma
P06654686T0001|0 11|Combination
P06654686T0001|17 35|Shwachman syndrome
P06654686T0001|50 79|granulocyte function disorder
P06654686T0001|85 89|girl
P06655634A0195|11 17|series
P06655634A0195|21 29|patients
P06655634A0195|44 47|TOL
P06655634A0195|75 94|cesarean deliveries
P06655634A0195|100 104|rate
P06655634A0195|116 124|delivery
P06655634A0195|131 132|%
P06655634A0195|161 170|morbidity
P06656249T0000|0 23|Nursing home discharges
P06656249T0000|36 44|practice
P06657559A0489|0 5|Trial
P06657559A0489|8 24|broiler chickens
P06657559A0489|44 56|control feed
P06657559A0489|78 83|weeks
P06657559A0489|87 90|age
P06657559A0489|100 104|time
P06657559A0489|128 132|feed
P06657559A0489|141 143|hr
P06657559A0489|170 182|control feed
P06657559A0489|186 190|feed
P06657559A0489|206 222|ppm ochratoxin A
P06657559A0489|228 238|heart rate
P06657559A0489|243 257|blood pressure
P06657559A0489|278 287|half hour
P06657559A0489|298 300|hr
P06658029A0086|4 23|carcinogen bioassay
P06658029A0086|54 63|component
P06658029A0086|71 78|battery
P06658029A0086|96 101|tests
P06658029A0086|110 127|hazard evaluation
P06658445A0140|8 15|effects
P06658445A0140|19 26|animals
P06658445A0140|31 34|man
P06658445A0140|79 86|amounts
P06658445A0140|90 96|intake
P06658586T0001|0 23|Angionephroscintigraphy
P06658586T0001|31 40|diagnosis
P06658586T0001|44 52|diseases
P06658586T0001|60 66|kidney
P06659982A0231|4 12|analysis
P06659982A0231|20 29|structure
P06659982A0231|37 49|sleep period
P06659982A0231|97 100|age
P06659982A0231|116 121|stage
P06659982A0231|123 125|DS
P06659982A0231|134 136|QS
P06659982A0231|172 182|parameters
P06659982A0231|184 193|increases
P06659982A0231|217 222|phase
P06659982A0231|226 231|sleep
P06659982A0231|233 235|PS
P06659982A0231|253 259|change
P06659982A0231|303 309|months
P06659982A0231|333 337|ones
P06659982A0231|351 355|year
P06659982A0231|363 367|life
P06662623A0124|1 5|82Br
P06662623A0124|6 10|MISO
P06662623A0124|39 46|samples
P06662623A0124|50 57|Br-MISO
P06662623A0124|63 79|SLOWPOKE reactor
P06662623A0124|86 87|h
P06662623A0124|101 113|neutron flux
P06662623A0124|124 134|n cm-2 s-1
P06667015A0832|12 20|findings
P06667015A0832|37 48|sensitivity
P06667015A0832|71 75|wall
P06667015A0832|79 88|ischaemia
P06667015A0832|96 103|surgery
P06667015A0832|123 131|recovery
P06667015A0832|155 172|serum CK-MB level
P06667868T0001|17 23|status
P06667868T0001|38 46|elements
P06667868T0001|54 59|blood
P06667868T0001|63 67|rats
P06667868T0001|91 99|variants
P06667868T0001|125 133|exposure
P06667868T0001|137 149|BR-1 benzene
P06668316A0178|21 42|reversed-phase column
P06668316A0178|50 66|phosphate buffer
P06668316A0178|68 80|acetonitrile
P06668316A0178|88 93|phase
P06668316A0178|95 114|baseline separation
P06668316A0178|118 128|antipyrine
P06668316A0178|134 145|metabolites
P06668316A0178|229 237|standard
P06668316A0178|239 249|phenacetin
P06668316A0178|273 276|min
P06669864T0001|4 9|liver
P06670732A0000|16 21|study
P06670732A0000|29 37|patients
P06670732A0000|39 42|ASA
P06670732A0000|57 66|induction
P06670732A0000|70 81|anaesthesia
P06670732A0000|87 94|effects
P06670732A0000|98 106|Fentanyl
P06670732A0000|112 114|mg
P06670732A0000|121 132|combination
P06670732A0000|136 144|Fentanyl
P06670732A0000|150 152|mg
P06670732A0000|158 168|Droperidol
P06670732A0000|172 174|mg
P06670732A0000|177 184|Innovar
P06670732A0000|186 196|Thalamonal
P06670732A0000|202 210|Atropine
P06670732A0000|217 227|mg/kg b.w.
P06670732A0000|256 266|parameters
P06671047A1124|6 13|results
P06671047A1124|34 42|validity
P06671047A1124|46 49|NOM
P06671047A1124|61 65|test
P06671047A1124|73 82|diagnosis
P06671047A1124|114 120|states
P06671047A1124|143 152|responses
P06671047A1124|156 161|CD/LD
P06671047A1124|163 165|LD
P06671047A1124|170 173|DOM
P06671047A1124|192 201|existence
P06671047A1124|207 216|sub-group
P06671047A1124|220 233|Prolactinomas
P06671047A1124|264 266|DA
P06671047A1124|275 280|tonus
P06671047A1124|296 307|possibility
P06671047A1124|340 347|factors
P06671047A1124|390 396|states
P06671065A0000|0 12|Serum lipids
P06671065A0000|17 29|lipoproteins
P06671065A0000|36 43|insulin
P06671065A0000|63 71|children
P06671065A0000|122 128|status
P06671065A0000|136 144|patients
P06671385A0856|4 6|NA
P06671385A0856|11 12|A
P06671385A0856|45 66|plasma renin activity
P06671385A0856|76 78|PA
P06671385A0856|137 156|body sodium content
P06671925T0000|0 23|Amikacin concentrations
P06671925T0000|27 32|serum
P06671925T0000|37 50|blister fluid
P06671925T0000|62 72|volunteers
P06671925T0000|80 88|patients
P06671925T0000|100 110|impairment
P06672094A0390|4 12|subgroup
P06672094A0390|36 42|rectus
P06672094A0390|77 81|face
P06672094A0390|89 107|oculomotor nucleus
P06672094A0390|126 133|neurons
P06672094A0390|161 171|fasciculus
P06672094A0390|201 208|mammals
P06674374T0000|0 32|Hepatitis B vaccination strategy
P06674374T0000|37 56|health-care workers
P06674374T0000|62 69|country
P06674374T0000|86 108|hepatitis B endemicity
P06674516A0350|15 28|drip infusion
P06674516A0350|32 35|AMK
P06674516A0350|48 54|dosage
P06674516A0350|106 114|diseases
P06674516A0350|139 144|field
P06674977A1181|13 21|families
P06674977A1181|26 27|%
P06674977A1181|41 50|pregnancy
P06674977A1181|52 57|table
P06674977A1181|67 68|%
P06674977A1181|93 102|diagnosis
P06674977A1181|104 112|table VI
P06675047A0000|4 11|authors
P06675047A0000|28 40|interference
P06675047A0000|48 58|hemoglobin
P06675047A0000|74 81|methods
P06675047A0000|84 93|Berthelot
P06675047A0000|106 115|Berthelot
P06675047A0000|134 147|determination
P06675047A0000|161 165|urea
P06683807A0160|13 21|patients
P06683807A0160|48 58|prevalence
P06683807A0160|62 73|alcohol use
P06683876A0244|6 11|cells
P06683876A0244|24 31|microns
P06683876A0244|35 43|diameter
P06683876A0244|62 69|fission
P06683876A0244|79 87|clusters
P06683876A0244|103 117|daughter cells
P06684624A0298|20 31|mortalities
P06684624A0298|71 75|rats
P06684624A0298|95 103|diet 41B
P06684624A0736|8 40|N-acetylglucosaminidase activity
P06684624A0736|45 58|mg creatinine
P06684624A0736|96 102|groups
P06685004A0000|4 16|associations
P06685004A0000|45 62|globulin capacity
P06685004A0000|64 68|SHBG
P06685004A0000|71 74|age
P06685004A0000|76 91|body mass index
P06685004A0000|93 96|BMI
P06685004A0000|112 119|fitness
P06685004A0000|144 147|men
P06685004A0000|155 160|women
P06685177T0000|0 12|Dipetalonema
P06685177T0000|14 24|Alafilaria
P06685177T0000|26 45|hydrochoerus subgen
P06685177T0000|54 56|n.
P06685536A0502|10 15|years
P06685536A0502|38 45|control
P06685536A0502|51 55|ewes
P06685536A0502|90 101|enucleation
P06685643A0179|4 18|concentrations
P06685643A0179|22 24|C4
P06685643A0179|29 35|C1-INH
P06685643A0179|61 66|stage
P06685643A0179|70 77|disease
P06685643A0179|100 111|mean values
P06685643A0179|119 125|stages
P06686454A0585|19 27|activity
P06686454A0585|63 70|bacilli
P06686454A0585|91 114|Klebsiella-Enterobacter
P06686454A0585|116 124|Shigella
P06686454A0585|144 163|Serratia marcescens
P06686454A0585|168 175|Proteus
P06687953T0000|12 28|defence capacity
P06687953T0000|49 66|leukocyte enzymes
P06689413A0174|4 13|apparatus
P06689413A0174|29 35|Am-241
P06689413A0174|45 51|source
P06689413A0174|56 59|mCi
P06689413A0174|70 81|Ge detector
P06689413A0174|85 90|mm2 X
P06689413A0174|93 95|mm
P06689413A0174|111 118|K alpha
P06689413A0174|131 137|x-rays
P06689413A0174|152 155|KeV
P06689413A0174|177 183|iodine
P06689513T0001|16 23|studies
P06689513T0001|27 38|retinopathy
P06689513T0001|52 59|infants
P06691304A0284|4 9|range
P06691304A0284|13 33|serum concentrations
P06691304A0284|40 46|values
P06691304A0284|55 61|values
P06691304A0284|76 86|deviations
P06691304A0284|96 103|analyte
P06691304A0284|121 126|males
P06691304A0284|131 138|females
P06691304A0284|153 163|age groups
P06692517T0000|4 11|effects
P06692517T0000|30 35|drugs
P06692517T0000|39 47|patients
P06692517T0000|70 77|thrombi
P06692517T0000|79 89|assessment
P06692517T0000|95 122|indium-111 platelet imaging
P06692517T0000|143 159|echocardiography
P06692631A0129|9 18|interface
P06692631A0129|38 44|stress
P06692631A0129|49 73|microstress distribution
P06692631A0129|81 85|bone
P06692631A0129|111 115|bone
P06694380A1483|0 9|Plasma NE
P06694380A1483|39 44|group
P06694380A1483|50 58|mg/liter
P06694380A1483|70 72|SD
P06694380A1483|90 91|P
P06694380A1483|111 119|ABSTRACT
P06694380A1483|137 142|WORDS
P06694778A0000|13 34|hemodialysis patients
P06694778A0000|53 80|redistribution thallium-201
P06694778A0000|92 99|imaging
P06694778A0000|118 124|course
P06694778A0000|128 140|hemodialysis
P06698047A0445|4 20|Prolactin levels
P06698047A0445|51 56|norms
P06698047A0445|62 71|responses
P06698047A0445|75 78|TRH
P06698047A0445|119 124|cases
P06700231A0259|14 29|tumor resection
P06700231A0259|56 69|tumor nodules
P06700231A0259|81 86|sizes
P06700231A0259|115 121|months
P06700231A0259|130 134|year
P06700469T0000|8 30|hospital accreditation
P06702257T0001|0 16|Antithrombin III
P06702257T0001|20 31|hip surgery
P06702643A0000|12 25|infant hearts
P06702643A0000|29 30|%
P06702643A0000|44 61|arch interruption
P06702643A0000|86 93|carotid
P06702643A0000|114 122|arteries
P06702643A0000|124 130|type B
P06702643A0000|134 141|Celoria
P06702643A0000|146 152|Patton
P06702643A0000|176 182|artery
P06702643A0000|184 186|SA
P06704467A0539|16 27|sensitivity
P06704467A0539|31 42|photoperiod
P06704467A0539|53 57|bats
P06704467A0539|79 86|mammals
P06704467A0539|107 119|pineal gland
P06705456A0346|0 10|Absorption
P06705456A0346|34 38|time
P06705456A0346|42 46|peak
P06705456A0346|53 56|min
P06707357A0180|14 26|observations
P06707357A0180|32 40|patients
P06707357A0180|67 80|regurgitation
P06707357A0180|104 121|valve replacement
P06707357A0180|135 146|differences
P06707357A0180|186 191|types
P06707357A0180|195 210|volume overload
P06709310A0000|2 6|case
P06709310A0000|26 35|nystagmus
P06709310A0000|44 49|onset
P06709310A0000|67 71|girl
P06709700A0230|11 22|compartment
P06709700A0230|26 35|dimension
P06709700A0230|39 47|severity
P06709700A0230|51 61|depression
P06709700A0230|64 72|subscale
P06709700A0230|80 105|Hamilton Depression Scale
P06709700A0230|114 131|Melancholia Scale
P06709700A0230|175 185|perfection
P06709700A0230|198 213|outcome measure
P06709700A0230|232 241|treatment
P06711642A0093|12 30|immunoglobulinuria
P06711642A0093|54 65|development
P06711642A0093|69 77|azotemia
P06711642A0093|103 123|creatinine clearance
P06711642A0093|137 148|proteinuria
P06711642A0093|178 186|dipstick
P06711642A0093|217 219|gm
P06711642A0093|232 248|urine collection
P06711642A0093|254 262|oliguria
P06712314A0148|8 14|number
P06712314A0148|23 28|cases
P06712314A0148|61 73|institutions
P06713200A0630|0 21|Epileptiform activity
P06713200A0630|48 55|laminae
P06713200A0630|66 71|layer
P06713200A0630|90 95|layer
P06713200A0630|108 119|projections
P06713200A0630|163 172|phenytoin
P06713204A0867|4 17|AD components
P06713204A0867|64 69|state
P06713204A0867|77 80|rat
P06713204A0867|94 106|V1 component
P06714298X0000|52 59|preload
P06714298X0000|81 85|pigs
P06714298X0000|87 98|nisoldipine
P06714298X0000|104 129|micrograms X kg-1 X min-1
P06714298X0000|134 157|calcium channel blocker
P06714298X0000|182 192|nifedipine
P06714298X0000|228 236|pressure
P06714298X0000|240 241|%
P06714298X0000|265 275|resistance
P06714298X0000|279 280|%
P06714298X0000|291 301|maxLVdP/dt
P06714298X0000|317 318|%
P06714298X0000|331 337|output
P06714354A0194|0 7|Monkeys
P06714354A0194|72 79|removal
P06714354A0194|101 107|cortex
P06715792A0295|0 17|HBB concentration
P06715792A0295|25 32|fetuses
P06715792A0295|58 70|accumulation
P06716977A0136|4 11|samples
P06716977A0136|24 31|decline
P06716977A0136|35 56|ethanol concentration
P06716977A0136|68 74|losses
P06716977A0136|112 121|mg% range
P06718064T0001|0 18|Plasma lactoferrin
P06718064T0001|27 38|blood count
P06718064T0001|54 65|neutrophils
P06719057A0181|4 14|importance
P06719057A0181|34 51|vein phlebography
P06719057A0181|59 69|evaluation
P06719057A0181|85 94|hematuria
P06719057A0181|99 113|filing defects
P06719057A0181|131 138|urogram
P06720371T0000|0 11|Pilot study
P06720371T0000|15 32|blood coagulation
P06720371T0000|36 49|gout patients
P06721188A0200|16 24|analysis
P06721188A0200|40 46|F test
P06721188A0200|59 67|Snedecor
P06721188A0200|71 84|contrast test
P06723849A0197|14 19|tract
P06723849A0197|48 57|Formation
P06723849A0197|59 62|MRF
P06723849A0197|101 112|transection
P06726257A1179|13 22|reduction
P06726257A1179|26 45|5-hydroxytryptophan
P06726257A1179|47 52|5-HTP
P06726257A1179|54 66|accumulation
P06726257A1179|70 73|LSD
P06726257A1179|90 101|differences
P06726257A1179|105 115|inhibition
P06726257A1179|119 131|methiothepin
P06726257A1179|133 145|hypothalamus
P06726257A1179|159 165|cortex
P06726257A1179|179 187|striatum
P06726257A1179|210 242|autoreceptor antagonist activity
P06726257A1179|246 258|methiothepin
P06726257A1179|269 277|ABSTRACT
P06726257A1179|295 300|WORDS
P06726257T0000|0 7|Effects
P06726257T0000|11 23|methiothepin
P06726257T0000|37 54|acid diethylamide
P06726257T0000|58 75|serotonin release
P06726257T0000|89 108|serotonin synthesis
P06726257T0000|127 135|relation
P06726257T0000|139 170|serotonin autoreceptor function
P06728580A0291|12 19|measles
P06728580A0291|32 39|El Paso
P06728580A0291|42 44|TX
P06728580A0291|54 61|records
P06728580A0291|88 96|criteria
P06728580A0291|107 113|result
P06728580A0291|121 129|students
P06731302A0930|3 10|patient
P06731302A0930|16 31|bradyarrhythmia
P06731302A0930|41 44|SCD
P06731302A0930|75 80|block
P06731302A0930|91 103|branch block
P06732946A0281|4 15|measurement
P06732946A0281|23 28|areas
P06732946A0281|43 49|tissue
P06732946A0281|54 66|fibrinolysis
P06732946A0281|91 96|times
P06732946A0281|128 141|magnification
P06732946A0281|146 147|X
P06732946A0281|155 169|image analyser
P06732946A0281|171 180|Videoplan
P06732946A0281|182 187|scale
P06734713T0000|0 10|Diclofenac
P06734713T0000|32 41|poisoning
P06735247A0803|13 48|plasma enteroglucagon concentration
P06735247A0803|58 65|minutes
P06735247A0803|79 87|patients
P06735247A0803|128 137|excretion
P06735247A0803|139 140|r
P06735247A0803|149 150|p
P06738410T0000|0 14|Blood pressure
P06738410T0000|18 26|children
P06740373A0891|8 13|study
P06740373A0891|33 40|captive
P06740373A0891|46 56|cynomolgus
P06740373A0891|97 103|rhesus
P06740373A0891|123 141|drug testing model
P06740697A0318|4 11|results
P06740697A0318|28 39|sensitivity
P06740697A0318|55 73|guinea pig strains
P06740919A0162|6 23|Amblyomma lepidum
P06740919A0162|37 43|nymphs
P06740919A0162|52 56|goat
P06740919A0162|69 79|heartwater
P06740919A0162|95 98|Bos
P06740919A0162|107 111|calf
P06743061A0239|11 18|percent
P06743061A0239|28 36|patients
P06743061A0239|52 59|disease
P06743061A0239|100 108|tinnitus
P06744024A0000|0 8|Morphine
P06744024A0000|35 44|ventricle
P06744024A0000|52 55|rat
P06744024A0000|76 85|analgesia
P06744024A0000|93 106|formalin test
P06744024A0000|144 148|pain
P06748227A0423|4 8|maps
P06748227A0423|12 16|Case
P06748227A0423|33 40|maximum
P06748227A0423|69 74|right
P06748227A0423|110 114|side
P06748227A0423|132 138|thorax
P06749072A0116|8 23|urate excretion
P06749072A0116|31 40|clearance
P06749072A0116|57 66|excretion
P06749072A0116|70 75|urate
P06749072A0116|111 126|water immersion
P06749072A0116|149 153|hour
P06749072A0116|164 179|water immersion
P06750608A1442|0 9|Mutations
P06750608A1442|25 34|lts genes
P06750608A1442|56 59|mak
P06750608A1442|61 70|phenotype
P06751455A0117|30 40|gallstones
P06751455A0117|65 74|remainder
P06751455A0117|79 87|patients
P06751455A0117|97 105|glucagon
P06751455A0117|113 120|placebo
P06753902A0437|7 15|patients
P06753902A0437|32 37|month
P06753902A0437|41 50|captopril
P06753902A0437|83 89|months
P06753902A0437|121 130|class IIM
P06753902A0437|142 145|IIS
P06753902A0437|153 158|death
P06754662T0001|8 33|angiolymphoid hyperplasia
P06754662T0001|39 51|eosinophilia
P06755468A0180|0 7|Regions
P06755468A0180|31 45|reading frames
P06755468A0180|49 53|cobA
P06755468A0180|68 74|intron
P06755468A0180|82 90|cob gene
P06755468A0180|94 99|yeast
P06755468A0180|110 129|amino acid homology
P06755986A0382|15 22|strains
P06755986A0382|37 43|humans
P06755986A0382|55 72|toxico-infections
P06755986A0382|94 98|mice
P06755986A0382|120 127|strains
P06755986A0382|140 159|hospital infections
P06760394T0001|7 24|tooth replacement
P06760394T0001|34 37|aid
P06760394T0001|45 48|ITI
P06760394T0001|50 86|International Team fur Implantologie
P06760394T0001|88 94|type F
P06762025A0171|4 37|13,14-dihydro-15-keto-metabolites
P06762025A0171|41 45|PGE2
P06762025A0171|50 60|PGF2 alpha
P06762025A0171|109 115|effect
P06762321T0000|0 19|Nucleotide sequence
P06762321T0000|23 49|DNA controlling expression
P06762321T0000|53 58|genes
P06762321T0000|63 90|maltosaccharide utilization
P06762321T0000|94 107|Streptococcus
P06763897A0216|4 16|hypertension
P06763897A0216|31 34|PRA
P06763897A0216|66 77|angiotensin
P06763897A0216|82 85|AII
P06763897A0216|87 93|analog
P06763897A0216|95 99|Sar1
P06763897A0216|101 105|Ile8
P06763897A0216|107 110|ALL
P06764669T0001|13 26|determination
P06764669T0001|38 42|iron
P06764669T0001|58 72|deferoxamine B
P06764669T0001|89 96|reagent
P06767648A0734|0 12|Measurements
P06767648A0734|16 25|perfusion
P06767648A0734|59 65|values
P06767648A0734|79 86|therapy
P06772370A0342|0 6|Volume
P06772370A0342|10 22|distribution
P06772370A0342|32 36|DMDZ
P06772370A0342|38 43|range
P06772370A0342|58 62|l/kg
P06772370A0342|79 83|DMDZ
P06772370A0342|90 100|correction
P06772370A0342|105 120|protein binding
P06772370A0342|122 127|range
P06772370A0342|139 143|l/kg
P06772370A0342|159 164|women
P06772370A0342|173 176|men
P06772370A0342|184 188|ages
P06772612A0000|0 7|Effects
P06772612A0000|11 19|dopamine
P06772612A0000|42 49|blocker
P06772612A0000|51 62|haloperidol
P06772612A0000|71 80|responses
P06772612A0000|84 111|carotid body chemoreceptors
P06772612A0000|115 122|hypoxia
P06772612A0000|127 138|hypercapnia
P06772612A0000|176 180|cats
P06775834A0000|0 5|HLA-A
P06775834A0000|10 22|B phenotypes
P06775834A0000|30 38|patients
P06775834A0000|64 73|melanomas
P06775834A0000|104 110|regard
P06775834A0000|126 130|form
P06775834A0000|134 141|relapse
P06776918T0000|0 17|Trypanosoma cruzi
P06777229A0243|4 12|subjects
P06777229A0243|20 25|study
P06777229A0243|41 49|subjects
P06777229A0243|57 65|patients
P06777229A0243|86 93|disease
P06781339A0501|5 10|study
P06781339A0501|52 61|follow-up
P06781339A0501|77 81|mode
P06781339A0501|85 94|treatment
P06781339A0501|98 106|patients
P06781339A0501|121 136|hypoventilation
P06781728A0690|4 15|alterations
P06781728A0690|19 34|differentiation
P06781728A0690|38 59|osteoprogenitor cells
P06781728A0690|79 86|failure
P06781728A0690|90 104|mineralization
P06781728A0690|138 143|rates
P06781728A0690|147 161|bone formation
P06781728A0690|178 199|fluorochrome labeling
P06781728A0690|228 232|rats
P06782612A0142|13 20|measure
P06782612A0142|29 39|impairment
P06782612A0142|66 71|ratio
P06782612A0142|75 87|urine volume
P06782612A0142|89 90|V
P06782612A0142|103 120|lithium clearance
P06782612A0142|122 125|CLi
P06782869A0263|0 16|Nitrogen balance
P06782869A0263|45 58|complications
P06782869A0263|88 91|BUN
P06782869A0263|93 109|serum creatinine
P06782869A0263|111 131|creatinine clearance
P06782869A0263|133 142|serum CO2
P06782869A0263|144 148|SGOT
P06782869A0263|150 154|SGPT
P06782869A0263|156 165|serum LDH
P06782869A0263|171 197|serum alkaline phosphatase
P06784123A0286|0 10|Production
P06784123A0286|14 23|C mu RNAs
P06784123A0286|32 40|mu mRNAs
P06784123A0286|59 72|recombination
P06784123A0286|90 96|region
P06784123A0286|98 100|JH
P06784123A0286|102 107|locus
P06784123A0771|11 19|C mu RNA
P06784123A0771|36 59|sequence characteristic
P06784123A0771|72 80|mu chain
P06784123A0771|101 108|species
P06784123A0771|137 144|mu chin
P06784123T0000|0 11|Transcripts
P06784123T0000|19 43|immunoglobulin C mu gene
P06784123T0000|52 61|structure
P06784123T0000|66 74|splicing
P06784123T0000|91 102|development
P06785113A0337|44 52|activity
P06785113A0337|87 92|mucus
P06785113A0337|104 112|patients
P06786756T0000|4 8|role
P06786756T0000|12 29|DNA rearrangement
P06786756T0000|46 60|RNA processing
P06786756T0000|68 78|expression
P06786756T0000|82 108|immunoglobulin delta genes
P06788388A0000|13 22|mechanism
P06788388A0000|26 32|action
P06788388A0000|36 44|ICRF-159
P06788388A0000|138 145|studies
P06788388A0000|157 166|compounds
P06788388A0000|174 182|interest
P06790572A0330|7 15|isolates
P06790572A0330|34 44|lincomycin
P06790572A0330|46 54|colistin
P06790572A0330|56 64|nystatin
P06790572A0330|66 80|amphotericin B
P06790572A0330|82 102|trimethoprim lactate
P06790572A0330|104 115|polymyxin B
P06790572A0330|121 131|anisomycin
P06791500A0622|4 14|evaluation
P06791500A0622|27 44|fluid delta OD450
P06791500A0622|69 80|cornerstone
P06791500A0622|93 103|management
P06793764T0001|0 11|Host lipids
P06793764T0001|27 36|infection
P06794480A0785|29 39|difference
P06794480A0785|48 57|age group
P06794480A0785|70 76|others
P06794480A0785|78 79|p
P06794666A0208|16 39|neuroeffector influence
P06794666A0208|47 57|myocardium
P06794666A0208|63 67|ATCI
P06794666A0208|87 94|measure
P06794666A0208|102 111|intensity
P06794666A0208|119 148|neurotransmitter biosynthesis
P06794666A0208|153 161|function
P06794666A0208|165 194|cardiomyocyte adrenoreceptors
P06795119T0000|0 21|Lens aldose reductase
P06795119T0000|51 60|cataracts
P06795654A0434|0 12|Fenfluramine
P06795654A0434|17 22|doses
P06795654A0434|47 61|mg/kg/infusion
P06795654A0434|80 108|self-administration behavior
P06795654A0434|125 144|minimum requirement
P06795654A0434|146 148|FR
P06795832A0148|7 13|course
P06795832A0148|17 28|Hepatitis A
P06795832A0148|38 49|HBe-antigen
P06795832A0148|61 64|HBc
P06795832A0148|65 68|IgM
P06795832A0148|73 76|IgG
P06795832A0148|89 103|HBe-antibodies
P06795900A0000|4 10|effect
P06795900A0000|24 67|acid cyclo-oxygenase inhibitor indomethacin
P06795900A0000|80 90|blood flow
P06795900A0000|92 95|CBF
P06795900A0000|115 119|rate
P06795900A0000|124 130|oxygen
P06795900A0000|132 137|CMRO2
P06795900A0000|192 196|rats
P06795971A0000|4 15|rat incisor
P06795971A0000|32 44|model system
P06795971A0000|63 74|amelgenesis
P06796300A0759|21 37|prolactin levels
P06796300A0759|41 54|nursing women
P06796300A0759|86 111|oestradiol administration
P06797063A0000|0 6|Factor
P06797063A0000|12 33|procoagulant activity
P06797063A0000|35 56|antigen concentration
P06797063A0000|61 84|von Willebrand activity
P06797063A0000|88 107|ristocetin cofactor
P06797063A0000|132 137|times
P06797063A0000|144 152|patients
P06797063A0000|158 161|DIC
P06798609A0000|31 35|rats
P06798609A0000|59 67|protocol
P06798609A0000|86 102|gamma-vinyl GABA
P06798609A0000|104 107|GVG
P06798609A0000|126 134|mg/kg IP
P06798609A0000|142 146|days
P06798609A0000|169 176|periods
P06801778T0001|0 12|Significance
P06801778T0001|30 51|gas exchange reaction
P06801778T0001|64 71|loading
P06801778T0001|90 103|effectiveness
P06801778T0001|114 128|commissurotomy
P06802500T0001|0 18|Thyreoliberin VUFB
P06802500T0001|22 41|thyroid gammagraphy
P06803634A0810|3 12|silicosis
P06803634A0810|26 39|relationships
P06803634A0810|48 56|patients
P06803634A0810|61 65|sons
P06803634A0810|85 92|respect
P06803634A0810|105 129|blood gas determinations
P06803634A0810|146 155|responses
P06803634A0810|167 172|Paco2
P06803634A0810|176 184|patients
P06803634A0810|213 222|responses
P06803634A0810|226 230|sons
P06805504A0629|23 31|N values
P06805504A0629|49 57|mg/kg W0
P06805504A0629|76 78|kg
P06805504A0629|84 90|weight
P06805504A0629|114 125|N excretion
P06805504A0629|143 144|N
P06805504A0629|161 169|mg/kg W0
P06805537T0001|0 8|Advances
P06805537T0001|12 32|hemophilia treatment
P06805537T0001|51 57|factor
P06805537T0001|63 74|concentrate
P06807149A0222|5 10|study
P06807149A0222|50 57|ability
P06807149A0222|77 82|forms
P06807149A0222|86 89|DSG
P06807149A0222|99 102|EIB
P06807149T0000|0 10|Comparison
P06807149T0000|30 42|preparations
P06807149T0000|46 67|disodium cromoglycate
P06807149T0000|75 85|prevention
P06807149T0000|106 118|bronchospasm
P06807149T0000|135 140|study
P06807192A0312|0 4|LCBF
P06807192A0312|27 34|puppies
P06807192A0312|70 89|glucose utilization
P06807192A0312|91 95|LCGU
P06807192A0312|134 144|conditions
P06807192A0312|146 151|Duffy
P06807659T0001|0 12|Phagocytosis
P06807659T0001|25 32|bacilli
P06807659T0001|36 47|macrophages
P06808287T0001|0 9|Detection
P06808287T0001|13 34|hemophilia A carriers
P06808529A0167|4 13|stability
P06808529A0167|17 36|isoniazid solutions
P06808529A0167|72 75|NTA
P06808529A0167|79 97|EDTA concentration
P06808529A0167|106 112|mmol/l
P06809474A1156|0 14|Bile bilirubin
P06809474A1156|38 39|h
P06809474A1156|46 59|haem infusion
P06809474A1156|62 69|finding
P06809474A1156|93 106|investigation
P06809586T0000|0 28|Autoimmune manipulation aids
P06809586T0000|38 57|diabetes management
P06810070A0502|6 16|properties
P06810070A0502|20 22|Hg
P06810070A0502|28 37|Cd-spores
P06810070A0502|63 77|control spores
P06810694A0328|4 12|decrease
P06810694A0328|16 31|HDL-cholesterol
P06810694A0328|48 66|VLDL-triglycerides
P06810694A0328|115 123|decrease
P06810694A0328|127 134|apo A-I
P06810694A1000|0 13|Apo A-I level
P06810694A1000|31 34|age
P06810694A1000|55 74|ethanol consumption
P06810694A1000|94 103|adiposity
P06812389A0658|0 5|TEMTU
P06812389A0658|10 14|DPTU
P06812389A0658|36 46|teratogens
P06815368A0203|21 29|mannitol
P06815368A0203|53 61|patients
P06816053A0849|7 15|patients
P06816053A0849|34 48|drug reactions
P06816053A0849|62 66|cent
P06816053A0849|84 92|response
P06816053A0849|100 114|mast cell test
P06816123A0526|0 8|Selenium
P06816123A0526|15 26|constituent
P06816123A0526|30 52|glutathione peroxidase
P06816123A0526|62 66|role
P06816123A0526|86 101|defense systems
P06816123A0526|109 113|body
P06816123A0526|135 140|roles
P06816123A0526|145 153|selenium
P06816442T0001|11 16|value
P06816442T0001|20 35|serum myoglobin
P06816442T0001|39 44|cases
P06816442T0001|62 69|disease
P06816609A0639|5 31|% blood pressure reduction
P06816609A0639|33 37|PCO2
P06816609A0639|51 54|kPa
P06816609A0639|58 66|decrease
P06816609A0639|104 112|CBF fall
P06816609A0639|118 119|%
P06817410A0982|18 24|months
P06817410A0982|32 37|study
P06817410A0982|49 55|change
P06817410A0982|59 71|epidemiology
P06817410A0982|83 94|hepatitis A
P06817410A0982|134 142|increase
P06817410A0982|150 159|incidence
P06817410A0982|168 172|type
P06817410A0982|176 185|hepatitis
P06817410A0982|192 204|drug addicts
P06818113A0384|10 18|patients
P06818113A0384|34 43|responses
P06818113A0384|52 62|parameters
P06818113A0384|66 76|adrenaline
P06818113A0384|82 90|controls
P06818113A0384|117 141|corticosteroid treatment
P06818113A0384|161 170|responses
P06818113A0384|174 195|plasminogen activator
P06818113A0384|200 215|clotting factor
P06818113A0384|235 243|infusion
P06821147A0468|0 19|Sulphur amino acids
P06821147A0468|26 29|g N
P06821147A0468|50 58|isolates
P06821147A0468|71 77|flours
P06822645T0039|0 4|Time
P06822645T0039|12 43|increase growth hormone release
P06823837A0562|38 48|wavefronts
P06823837A0562|110 116|groove
P06823837A0562|121 134|outflow tract
P06825641A0076|14 33|landfill operations
P06825641A0076|85 94|knowledge
P06825641A0076|128 139|containment
P06825641A0076|147 152|waste
P06826813A0264|0 8|Vesicles
P06826813A0264|45 54|exposures
P06826813A0264|58 61|UVA
P06828396A0095|4 9|level
P06828396A0095|13 26|contamination
P06828396A0095|34 39|wound
P06828396A0095|73 98|biopsy fixation technique
P06829082A0187|24 35|hypothermia
P06829082A0187|40 49|degrees C
P06829082A0187|73 81|increase
P06829082A0187|89 123|brain tissues glutaminase activity
P06829082A0187|139 162|incubation temperatures
P06829082A0187|182 191|degrees C
P06829082A0187|216 220|rats
P06829082A0187|225 229|rats
P06829082A0187|236 247|hypothermia
P06830033A0661|8 20|observations
P06830033A0661|47 59|pneumothorax
P06830033A0661|66 71|cmH2O
P06830033A0661|79 82|min
P06830351A0397|13 20|Sugiura
P06830351A0397|23 37|classification
P06830351A0397|57 64|Type Ia
P06830351A0397|70 71|%
P06830351A0397|73 80|Type Ib
P06830351A0397|86 87|%
P06830351A0397|89 93|Type
P06830351A0397|102 103|%
P06830351A0397|109 113|Type
P06830351A0397|123 124|%
P06833047A0000|5 10|study
P06833047A0000|40 49|mechanism
P06833047A0000|70 80|inhibition
P06833047A0000|124 135|ventilation
P06833047A0000|137 141|HFOV
P06833422T0000|0 13|Determination
P06833422T0000|20 40|alpha-hydroxy-9 beta
P06833422T0000|44 58|alpha-pregna-4
P06833422T0000|61 71|dien-3-one
P06833422T0000|75 81|plasma
P06833422T0000|94 108|ion monitoring
P06835516A0000|2 6|case
P06835516A0000|18 33|epidermoid cyst
P06835516A0000|53 60|cistern
P06835914A0192|0 17|Copper treatments
P06835914A0192|58 64|levels
P06835914A0192|68 81|copper intake
P06835914A0192|105 116|differences
P06835914A0192|126 137|feed intake
P06835914A0192|153 161|practice
P06835914A0192|187 195|industry
P06837312A0000|14 21|intimal
P06837312A0000|72 77|aorta
P06837312A0000|85 90|swine
P06837312A0000|102 104|IU
P06837312A0000|108 121|vitamin D3/kg
P06837312A0000|125 129|diet
P06837312A0000|140 155|months duration
P06837312A0000|169 175|months
P06837312A0000|179 200|vitamin D3 withdrawal
P06837312A0000|218 225|lesions
P06838388A0896|19 30|development
P06838388A0896|49 61|tissue scars
P06838388A0896|79 84|place
P06838388A0896|112 128|parenchyma areas
P06838388A0896|142 155|normalization
P06838388A0896|163 168|organ
P06838388A0896|171 180|structure
P06838388A0896|185 193|function
P06838388A0896|205 208|day
P06840803A0397|13 18|signs
P06840803A0397|35 43|reaction
P06840803A0397|70 72|hr
P06840803A0397|79 93|i.v. challenge
P06840803A0397|120 124|days
P06842629A0446|12 27|GMBF reductions
P06842629A0446|46 51|shock
P06842629A0446|60 76|treatment groups
P06848729A0000|7 15|children
P06848729A0000|21 34|neuroblastoma
P06848729A0000|46 49|St.
P06849842T0000|0 33|Penicillin-G degradation products
P06849842T0000|51 65|granulopoiesis
P06851280A0144|0 17|Plasma fibrinogen
P06851280A0144|52 58|method
P06851280A0144|62 67|timol
P06851280A0144|82 87|units
P06851327A0000|5 13|patients
P06851327A0000|19 23|type
P06851327A0000|44 53|infection
P06851327A0000|73 90|Neisseria species
P06851327A0000|123 129|period
P06853042A0282|15 28|acidification
P06853042A0282|37 46|threshold
P06853042A0282|68 92|bicarbonate reabsorption
P06853042A0282|113 118|urine
P06853042A0282|133 141|capacity
P06854957T0066|0 9|Detection
P06854957T0066|30 38|asynergy
P06854957T0066|49 65|echocardiography
P06856306T0000|4 21|Tullio phenomenon
P06856306T0000|23 35|fistula test
P06856306T0000|41 50|Hennebert
P06856306T0000|53 57|sign
P06856306T0000|68 80|significance
P06856669A1004|6 13|results
P06856669A1004|50 60|metabolism
P06856669A1004|64 68|5-HT
P06856669A1004|81 87|efflux
P06856669A1004|91 97|5-HIAA
P06856669A1004|110 116|output
P06856669A1004|143 154|circulation
P06858449A0335|0 12|Disturbances
P06858449A0335|26 36|maturation
P06858640A0262|7 12|basis
P06858640A0262|34 42|findings
P06858640A0262|48 54|origin
P06858640A0262|58 65|amyloid
P06858640A0262|104 115|fibroblasts
P06858805A0314|5 11|groups
P06858805A0314|30 35|tests
P06858805A0314|47 63|hypersensitivity
P06858805A0314|69 77|Candidin
P06858805A0314|79 90|Trycophytin
P06858805A0314|95 105|Tuberculin
P06858967A0167|0 27|Serum lactate dehydrogenase
P06858967A0167|32 50|haptoglobin levels
P06858967A0167|74 83|bilirubin
P06863087A0664|9 10|D
P06863087A0664|20 22|mg
P06863087A0664|28 30|DB
P06863087A0664|40 42|mg
P06863087A0664|76 85|parameter
P06863087A0664|91 98|control
P06864837T0000|0 8|Efficacy
P06864837T0000|21 49|spine immobilization methods
P06864955T0000|15 19|MMWR
P06868345A0000|4 12|presence
P06868345A0000|16 27|visna-maedi
P06868345A0000|31 36|Italy
P06868345A0000|63 67|time
P06869215A0347|5 11|levels
P06869215A0347|15 17|IC
P06869215A0347|42 60|hypocomplementemia
P06869986A0000|12 21|platelets
P06869986A0000|65 73|collagen
P06869986A0000|93 100|lesions
P06869986A0000|117 126|ruminants
P06872800T0000|6 10|type
P06872800T0000|13 22|hepatitis
P06872800T0000|32 40|patients
P06872800T0000|54 67|HBV infection
P06873504T0000|13 26|relationships
P06873504T0000|49 57|acidosis
P06873504T0000|62 91|sodium metabolism alterations
P06873504T0000|95 110|liver cirrhosis
P06875478A0542|2 22|microU/l thyrotropin
P06875478A0542|26 27|%
P06875478A0542|38 39|%
P06875478A0542|53 54|%
P06876006A0930|0 15|Echosismography
P06876006A0930|39 48|diagnosis
P06876006A0930|78 88|sonography
P06876006A0930|100 101|%
P06876006A0930|105 110|cases
P06876317T0033|0 13|Relationships
P06876317T0033|39 58|deficiency syndrome
P06880563A0516|4 14|prevalence
P06880563A0516|18 22|CPAF
P06880563A0516|38 42|type
P06880563A0516|49 53|type
P06880563A0516|56 64|diabetes
P06880563A0516|81 86|women
P06880563A0516|95 98|men
P06880563A0516|145 160|administrations
P06880563A0516|183 197|administration
P06880563A0516|201 215|chlorpropamide
P06880604A0167|2 14|reassessment
P06880604A0167|22 37|prevalence data
P06880604A0167|70 78|province
P06880604A0167|82 89|Uusimaa
P06880604A0167|109 117|province
P06880604A0167|121 126|Vaasa
P06880604A0167|132 146|prevalence day
P06880604A0167|153 160|January
P06880650A0316|4 11|results
P06880650A0316|40 44|work
P06880650A0316|54 65|researchers
P06882578A0464|7 27|ultramarathon runner
P06882578A0464|32 51|testosterone levels
P06882578A0464|72 81|beginning
P06882578A0464|89 105|training session
P06882578A0464|121 126|ng/ml
P06882578A0464|136 141|ng/ml
P06882578A0464|152 160|training
P06882578A0464|197 202|hours
P06882578A0464|209 214|ng/ml
P06882578A0464|227 230|end
P06882578A0464|240 254|hours training
P06882578A0464|261 266|ng/ml
P06883385A0509|3 11|patients
P06883385A0509|37 46|remission
P06883385A0509|54 59|tumor
P06883385A0509|65 85|neopterine excretion
P06883385A0509|104 110|values
P06884450A0234|11 18|tumours
P06884450A0234|28 35|results
P06884450A0234|55 57|FB
P06884450A0234|61 62|%
P06884450A0234|70 73|TBN
P06884450A0234|92 93|%
P06886031A0898|6 16|PGE levels
P06886031A0898|29 34|fluid
P06886031A0898|75 88|patient group
P06886031A0898|96 101|hours
P06886031A0898|119 128|test dose
P06886031A0898|132 140|tolmetin
P06886031A0898|144 147|day
P06886948A0750|7 12|rates
P06886948A0750|16 27|weight gain
P06886948A0750|52 66|energy intakes
P06886948A0750|82 83|%
P06886948A0750|87 99|requirements
P06890622A0067|40 48|platelet
P06890622A0067|61 68|effects
P06890622A0067|115 123|ischemia
P06890622A0067|125 137|hypertension
P06890622A0067|152 163|coagulation
P06890622A0067|181 194|pre-eclampsia
P06890935T0001|0 6|Behcet
P06890935T0001|9 17|syndrome
P06891051A0587|0 8|Survival
P06891051A0587|43 52|platelets
P06891051A0587|70 78|patients
P06891051A0587|85 95|correction
P06891051A0587|99 113|platelet count
P06891270A0000|4 10|effect
P06891270A0000|32 38|stress
P06891270A0000|40 43|EPS
P06891270A0000|59 72|extensibility
P06891270A0000|77 90|contractility
P06891270A0000|118 128|rat atrium
P06895559A0000|0 11|Terbutaline
P06895559A0000|32 39|agonist
P06895559A0000|45 57|aminophyllin
P06895559A0000|61 88|phosphodiesterase inhibitor
P06895559A0000|119 130|combination
P06895559A0000|135 149|rabbit fetuses
P06895559A0000|162 165|day
P06895559A0000|169 178|gestation
P06895663A0810|8 15|therapy
P06895663A0810|40 51|association
P06895663A0810|60 63|RBT
P06895663A0810|68 71|RLF
P06895663A0810|100 112|significance
P06895663A0810|114 115|P
P06897114A0240|15 20|motif
P06897114A0240|59 83|DNA sequence recognition
P06897114A0240|87 90|CAP
P06902722T0000|15 20|phase
P06902722T0000|50 60|infarction
P06911559T0000|0 10|Statistics
P06911559T0000|15 29|nurse managers
P06916588A0304|4 18|infection rate
P06916588A0304|28 33|times
P06916588A0304|45 53|patients
P06916588A0304|59 76|Hickman catheters
P06916588A0304|104 113|catheters
P06916588A0304|115 116|p
P06919347T0001|8 12|year
P06919347T0001|16 24|planning
P06919347T0001|32 53|Laboratory Assistants
P06919347T0001|55 61|School
P06919347T0001|65 74|Stockholm
P06919347T0001|80 89|education
P06919347T0001|94 115|laboratory assistants
P06928974T0000|4 21|electrocardiogram
P06931124A0109|14 19|place
P06931124A0109|28 45|complex formation
P06931124A0109|50 59|NH4Mg PO4
P06931124A0109|61 64|H2O
P06931124A0109|65 66|n
P06931124A0109|75 84|reactants
P06931124A0109|90 95|water
P06935514A0000|4 11|Authors
P06935514A0000|42 50|research
P06935514A0000|63 74|preparation
P06935514A0000|116 128|desametazone
P06935514A0000|133 138|order
P06935514A0000|155 166|alterations
P06935514A0000|174 188|dentinogenesis
P06935514A0000|214 223|component
P06938948T0001|10 13|IgA
P06938948T0001|18 39|serum immunoglobulins
P06938948T0001|43 50|indices
P06938948T0001|64 72|immunity
P06938948T0001|91 97|mucosa
P06938948T0001|107 116|leukemias
P06946314T0000|0 16|Serum IgE levels
P06946314T0000|20 37|Tauranga children
P06946693T0000|0 3|Use
P06946693T0000|7 29|prostaglandin F2 alpha
P06946693T0000|31 41|PGF2 alpha
P06946693T0000|46 52|cattle
P06948398A0523|25 35|management
P06948398A0523|39 44|blood
P06948398A0523|76 86|importance
P06948493T0026|0 5|Range
P06948493T0026|7 17|variations
P06948493T0026|33 42|potential
P06948868A0082|4 10|scores
P06948868A0082|28 32|part
P06948868A0082|40 51|reliability
P06948868A0082|55 74|faculty evaluations
P06950004T0047|0 5|Study
P06950004T0047|9 21|distribution
P06950004T0047|25 30|metal
P06950004T0047|38 43|teeth
P06950004T0047|55 68|iontophoresis
P06950004T0047|86 95|specimens
P06953957A0503|8 32|creatine kinase activity
P06953957A0503|70 74|peak
P06953957A0503|76 85|myoglobin
P06953957A0503|107 115|episodes
P06953957A0503|153 163|peak value
P06953957A0503|193 204|correlation
P06957125T0000|16 26|blood flow
P06957125T0000|35 41|effect
P06957125T0000|45 49|beta
P06957125T0000|65 82|stimulating drugs
P06957633T0001|0 11|Development
P06957633T0001|26 34|leukemia
P06957633T0001|40 47|trisomy
P06957633T0001|63 79|erythroblastosis
P06957633T0001|85 92|patient
P06957633T0001|100 107|history
P06957633T0001|120 126|anemia
P06957633T0001|130 135|years
P06959130A0996|4 25|arginyl peptide bonds
P06959130A0996|50 60|conversion
P06959130A0996|70 76|factor
P06959130A0996|90 93|IXa
P06959130A0996|97 107|factor XIa
P06959130A0996|127 140|Arg145-Ala146
P06959130A0996|145 158|Arg180-Val181
P06962492A0612|9 15|growth
P06962492A0612|42 50|eruption
P06962492A0612|89 99|hypotrophy
P06962492A0612|113 123|bone bases
P06962634A0190|13 20|methods
P06962634A0190|38 49|information
P06962634A0190|56 79|porphyrin binding sites
P06962634A0190|112 131|porphyrin transport
P06962634A0190|136 145|clearance
P06963337T0000|44 55|hyperplasia
P06963337T0000|61 73|hypertension
P06966678A0523|20 24|rate
P06966678A0523|28 37|clearance
P06966678A0523|41 47|tracer
P06966678A0523|67 74|portion
P06966678A0523|100 105|curve
P06966678A0523|117 127|metabolism
P06966678A0523|137 141|acid
P06966678A0523|168 174|lipids
P06966678A0523|209 216|changes
P06966678A0523|233 238|index
P06966678A0523|245 255|injections
P06966678A0523|270 276|atrium
P06966678A0523|278 279|r
P06966678A0523|288 289|n
P06966678A0523|303 309|atrium
P06966678A0523|311 312|r
P06966678A0523|321 322|n
P06966678A0523|334 342|ear vein
P06966678A0523|344 345|r
P06966678A0523|354 355|n
P06969638A0180|5 17|examinations
P06969638A0180|32 42|indicators
P06969638A0180|46 63|CNS abnormalities
P06969638A0180|90 110|meningeal infections
P06969638A0180|129 141|determinants
P06969638A0180|149 156|therapy
P06969638A0180|170 179|prognosis
P06969638A0180|188 201|complications
P06972179A0556|9 19|IgE levels
P06972179A0556|84 89|range
P06972443A0375|17 27|evaluation
P06972443A0375|43 50|carrier
P06972443A0375|70 83|abnormalities
P06972501A0615|0 11|Correlation
P06972501A0615|32 43|involvement
P06972501A0615|57 64|outcome
P06973664A0000|2 6|case
P06973664A0000|19 36|cleavage syndrome
P06973664A0000|61 68|patient
P06975206A0279|10 24|administration
P06975206A0279|28 41|betamethasone
P06975206A0279|52 57|weeks
P06975206A0279|79 89|absorption
P06975206A0279|93 100|calcium
P06975206A0279|105 114|phosphate
P06975206A0279|130 141|growth rate
P06977605T0000|0 10|Endorphins
P06977605T0000|21 27|issues
P06978566A0197|3 11|necropsy
P06978566A0197|15 19|days
P06978566A0197|38 47|F344 rats
P06978566A0197|61 73|lung lesions
P06978566A0197|96 108|maximum dose
P06978566A0197|116 117|X
P06978566A0197|139 144|units
P06978566A0197|148 159|M. pulmonis
P06981991A0756|0 14|Aneurysmectomy
P06981991A0756|23 34|performance
P06981991A0756|38 42|CABG
P06981991A0756|96 107|ECG changes
P06981991A0756|118 131|bypass grafts
P06981991A0756|136 143|patient
P06981991A0756|168 173|group
P06981991A0756|193 204|ECG changes
P06981991A0756|231 245|artery disease
P06981991A0756|273 278|group
P06984225A0367|0 5|REV I
P06984225A0367|11 18|vessels
P06984225A0367|27 28|%
P06984225A0367|45 57|patent graft
P06986168A0304|9 18|sequences
P06986168A0304|62 70|peptides
P06986168A0304|104 112|peptides
P06986168A0304|122 133|V8 protease
P06992600A0405|4 27|extraction measurements
P06992600A0405|64 77|contamination
P06992600A0405|88 95|outflow
P06993660A0000|12 21|responses
P06993660A0000|25 39|norepinephrine
P06993660A0000|41 50|serotonin
P06993660A0000|55 64|potassium
P06993660A0000|66 67|K
P06993660A0000|74 92|relaxant responses
P06993660A0000|96 109|isoproterenol
P06993660A0000|114 124|papaverine
P06993660A0000|181 187|strips
P06993660A0000|222 226|rats
P06993660A0000|228 231|AHR
P06993660A0000|248 252|days
P06993660A0000|326 334|controls
P06994035T0001|3 19|line calculation
P06994035T0001|23 45|steroid concentrations
P06994035T0001|49 65|radioimmunoassay
P06994049T0001|0 9|Detection
P06994049T0001|24 38|hypothyroidism
P06994049T0001|57 64|infants
P06997203A0325|3 19|rubella patients
P06997203A0325|35 47|confirmation
P06997203A0325|51 53|HI
P06997203A0325|62 66|test
P06997203A0325|88 93|rises
P06997203A0325|106 107|%
P06997203A0325|116 124|patients
P06997203A0325|133 141|PHA test
P06997203A0325|151 170|antibody conversion
P06997203A0325|180 181|%
P06997203A0325|189 197|patients
P07004236A0741|4 11|results
P07004236A0741|26 42|folate compounds
P07004236A0741|52 72|formate accumulation
P07004236A0741|79 87|methanol
P07004236A0741|103 120|formate oxidation
P07004236A0741|124 135|utilization
P07004236A0741|159 162|use
P07004236A0741|167 174|folates
P07004236A0741|182 191|treatment
P07004236A0741|203 208|cases
P07004236A0741|218 236|methanol poisoning
P07007181T0000|4 10|effect
P07007181T0000|14 30|sodium saccharin
P07007181T0000|38 42|diet
P07007181T0000|53 63|microflora
P07007591A0324|4 21|residue functions
P07007591A0324|23 24|R
P07007591A0324|25 26|t
P07007591A0324|33 41|C-11 CPZ
P07007591A0324|46 65|In-113m transferrin
P07007591A0324|87 91|time
P07007591A0324|105 110|areas
P07007591A0324|114 122|interest
P07007591A0324|132 135|CPZ
P07007591A0324|150 160|extraction
P07007591A0324|162 163|E
P07007591A0324|164 165|t
P07007591A0324|194 199|areas
P07007591A0324|210 214|msec
P07007591A0324|225 232|formula
P07007591A0324|234 235|E
P07007591A0324|236 237|t
P07007591A0324|242 244|RT
P07007591A0324|245 246|t
P07007591A0324|250 252|RR
P07007591A0324|253 254|t
P07007591A0324|262 264|RR
P07007591A0324|265 266|t
P07007591A0324|276 278|RT
P07007591A0324|283 285|RR
P07007591A0324|305 322|residue functions
P07007591A0324|327 330|CPZ
P07007591A0324|335 346|transferrin
P07015018A0395|12 20|extracts
P07015018A0395|43 63|migration inhibition
P07015018A0395|78 84|assays
P07015262A0396|4 8|days
P07015262A0396|12 30|cefadroxil therapy
P07015262A0396|52 60|children
P07015262A0396|74 89|tract infection
P07015262A0396|94 104|CRP values
P07015262A0396|133 145|microgram/ml
P07015262A0396|160 165|group
P07016141A0238|13 23|blood flow
P07016141A0238|25 28|RBF
P07016141A0238|42 52|blood flow
P07016141A0238|54 57|NBF
P07016141A0238|75 80|Xenon
P07016141A0238|85 94|clearance
P07018810A0002|0 26|Plasma renin concentration
P07018810A0002|77 84|outflow
P07018810A0002|115 121|cortex
P07018810A0002|147 154|outflow
P07018810A0002|179 183|half
P07018810A0002|191 197|cortex
P07018810A0002|202 209|medulla
P07018810A0002|217 227|cat kidney
P07021505A0510|6 17|acclimation
P07021505A0510|27 33|supine
P07021505A0510|46 49|DPB
P07021505A0510|61 62|P
P07021505A0510|90 94|mmHg
P07026328A0369|7 16|diabetics
P07026328A0369|18 21|Ca2
P07026328A0369|23 32|infusions
P07026328A0369|43 47|rise
P07026328A0369|51 61|plasma Ca2
P07026328A0369|81 87|mmol/1
P07026328A0369|94 98|fall
P07026328A0369|114 122|glucagon
P07026328A0369|137 138|%
P07026328A0369|140 141|p
P07026328A0369|163 170|glucose
P07026328A0369|185 186|%
P07026328A0369|188 189|p
P07034479A1050|12 15|RMI
P07034479A1050|34 47|placebo group
P07034479A1050|82 90|AC group
P07034479A1050|92 93|p
P07037479T0000|5 18|cracked-tooth
P07037479T0000|20 28|syndrome
P07038189A2301|14 21|results
P07038189A2301|32 35|CXD
P07038189A2301|45 53|efficacy
P07038189A2301|58 64|safety
P07038189A2301|97 101|drug
P07038189A2301|128 133|field
P07038684A1050|9 33|peptide map similarities
P07038684A1050|58 71|sequence data
P07038684A1050|92 98|origin
P07038684A1050|121 124|p60
P07038684A1050|129 132|p62
P07038684A1050|148 168|amino acid sequences
P07038684A1050|193 217|p60 initiator methionine
P07038684A1050|219 226|residue
P07038684A1050|233 236|p62
P07040659A0212|4 12|patients
P07040659A0212|20 33|control group
P07040659A0212|55 66|improvement
P07040659A0212|76 80|PEFR
P07040659A0212|94 102|patients
P07040659A0212|118 123|group
P07040659A0212|134 145|improvement
P07044389T0000|0 5|Facts
P07044389T0000|13 38|Economic Recovery Tax Act
P07044389T0000|67 79|pathologists
P07044389T0000|84 96|audiologists
P07044562T0000|5 8|Pap
P07044562T0000|12 16|ApUp
P07044842A2062|4 16|relationship
P07044842A2062|34 47|complications
P07044842A2062|72 87|pathophysiology
P07044842A2062|91 98|Bartter
P07044842A2062|101 109|syndrome
P07045156A0204|36 41|assay
P07045156A0204|57 66|rat model
P07045156A0204|70 80|GBS sepsis
P07045156A0204|111 125|immunoglobulin
P07045156A0204|153 161|antibody
P07049690T0000|11 18|lesions
P07049690T0000|28 38|allografts
P07053251A0666|33 40|effects
P07053251A0666|42 53|bone marrow
P07053251A0666|72 77|tract
P07053251A0666|83 88|heart
P07053251A0666|112 117|study
P07061263A0293|14 22|pressure
P07061263A0293|24 28|Pvas
P07061263A0293|65 70|cmH2O
P07061263A0293|74 87|air inflation
P07061263A0293|95 98|min
P07061263A0293|100 102|Px
P07061350A0042|8 15|Science
P07061350A0042|71 77|bundle
P07061350A0042|79 83|COCB
P07061350A0042|100 109|magnitude
P07061350A0042|117 135|distortion product
P07061350A0042|137 142|f2-f1
P07061350A0042|167 175|pressure
P07062036A0072|0 4|Rats
P07062036A0072|29 34|% JIB
P07062036A0072|40 54|sham operation
P07062269A0798|39 47|receptor
P07062269A0798|62 70|naloxone
P07062269A0798|74 83|tolerance
P07062269A0798|104 115|l-methadone
P07062269A0798|139 146|effects
P07062269A0798|162 171|mechanism
P07063606T0000|0 9|Microwave
P07063606T0000|43 62|barrier alterations
P07064662A0222|26 33|lesions
P07064662A0222|48 58|occurrence
P07064662A0222|62 75|target fibres
P07064662A0222|95 102|muscles
P07064662A0222|127 137|neurolysis
P07064662A0222|145 157|dorsal roots
P07064923T0000|0 9|Diagnosis
P07064923T0000|13 49|phenylalanine hydroxylase deficiency
P07064923T0000|51 66|phenylketonuria
P07065206A0398|6 19|control sheep
P07065206A0398|25 50|plasma TXB2 concentration
P07065206A0398|71 86|ng/ml prebypass
P07065206A0398|100 105|ng/ml
P07065206A0398|118 121|min
P07065206A0398|125 131|bypass
P07068493A0414|16 20|rate
P07068493A0414|34 45|breaths/min
P07068493A0414|59 60|%
P07068493A0414|80 85|cycle
P07068493A0414|95 106|inspiration
P07068493A0414|118 130|CO2 pressure
P07068493A0414|156 160|Torr
P07068493A0414|168 172|runs
P07068493A0414|176 179|SIP
P07068493A0636|21 29|increase
P07068493A0636|33 51|oxygen consumption
P07068493A0636|63 71|subjects
P07068493A0636|98 107|pressures
P07068493A0636|114 117|SIP
P07068496A0000|16 22|volume
P07068496A0000|69 80|water space
P07068496A0000|87 93|sodium
P07068496A0000|98 116|sucrose indicators
P07068496A0000|146 158|rabbit lungs
P07068496A0000|175 185|techniques
P07068887A0000|17 28|reliability
P07068887A0000|30 38|validity
P07068887A0000|43 57|dimensionality
P07068887A0000|61 67|scores
P07068887A0000|98 108|inpatients
P07068887A0000|110 111|N
P07068887A0000|126 160|Michigan Alcoholism Screening Test
P07068887A0000|179 187|lifetime
P07068887A0000|200 214|symptomatology
P07072635A0000|9 15|method
P07072635A0000|38 42|iron
P07072635A0000|57 71|administration
P07072635A0000|75 90|desferrioxamine
P07072635A0000|92 94|DF
P07073520A0153|20 34|hemofiltration
P07073520A0153|41 59|substitution fluid
P07073520A0153|67 69|Na
P07073520A0153|71 84|concentration
P07073520A0153|92 97|mEq/L
P07073520A0153|101 109|decrease
P07073520A0153|127 139|fluid volume
P07073520A0153|176 188|fluid volume
P07075024A0540|18 23|cases
P07075024A0540|35 40|fever
P07075024A0540|70 74|CMIR
P07075024A0540|106 111|cases
P07075438T0000|12 34|serial xeroradiography
P07076222A0543|0 15|Recommendations
P07076222A0543|47 53|issues
P07078263T0000|0 3|Use
P07078263T0000|20 32|deferoxamine
P07078263T0000|38 43|child
P07078263T0000|49 64|hemochromatosis
P07078263T0000|110 116|anemia
P07078263T0000|118 125|type I.
P07079595A0848|24 35|correlation
P07079595A0848|52 60|diameter
P07079595A0848|65 68|spg
P07079595A0848|70 71|r
P07079595A0848|80 81|P
P07079595A0848|123 144|diameter measurements
P07079595A0848|161 169|sections
P07079595A0848|195 211|sperm production
P07080496A0097|17 30|investigation
P07080496A0097|34 46|lipoproteins
P07080496A0097|86 97|lipoprotein
P07080496A0097|99 102|HDL
P07080496A0097|104 113|fractions
P07080496A0097|158 165|respect
P07080496A0097|181 193|lipoproteins
P07080496A0097|195 198|LDL
P07080496A0097|212 220|infarcts
P07080496A0097|248 255|attacks
P07081327A0546|23 28|fluid
P07081327A0546|45 59|concentrations
P07081327A0546|63 73|phosphorus
P07081327A0546|78 82|zinc
P07081327A0546|90 101|differences
P07081327A0546|138 145|samples
P07084198T0000|0 15|Selenium status
P07084198T0000|19 32|thoroughbreds
P07084198T0000|40 54|United Kingdom
P07084617A0204|15 24|follow-up
P07084617A0204|26 35|parasites
P07084617A0204|53 61|patients
P07084617A0204|76 80|drug
P07084617A0204|98 100|wk
P07084617A0204|107 116|treatment
P07084814T0000|0 11|Preparation
P07084814T0000|24 44|phospholipid reagent
P07084814T0000|49 67|coagulation assays
P07088195T0019|2 6|note
P07088195T0019|15 27|consequences
P07088195T0019|31 40|UV vision
P07088195T0019|44 49|birds
P07090151A0165|7 14|turnout
P07090151A0165|18 26|morantel
P07090151A0165|37 50|release bolus
P07090151A0165|52 56|MSRB
P07090151A0165|83 89|animal
P07090151A0165|107 115|category
P07094856A0115|18 23|study
P07094856A0115|37 44|fetuses
P07094856A0115|68 77|intervals
P07094856A0115|86 91|weeks
P07094856A0115|95 104|gestation
P07094905A0644|33 43|injections
P07094905A0644|47 49|KA
P07094905A0644|78 82|loss
P07094905A0644|96 101|cells
P07094905A0644|115 124|CA3 field
P07094905A0644|132 143|hippocampus
P07096587A0267|20 28|patients
P07096587A0267|63 79|training program
P07096587A0267|105 110|month
P07096587A0267|147 155|strategy
P07096587A0267|185 193|material
P07097182A0480|4 12|duration
P07097182A0480|21 30|amplitude
P07097182A0480|47 56|potential
P07097182A0480|99 103|ears
P07097182A0480|109 119|overgrowth
P07097182A0480|156 160|ears
P07097182A0480|199 203|ears
P07105635A0412|0 7|Samples
P07105635A0412|29 39|volunteers
P07105635A0412|59 67|majority
P07105635A0412|75 83|patients
P07105635A0412|106 112|asthma
P07105635A0412|121 127|effect
P07105635A0412|139 146|beating
P07106323A0560|6 13|results
P07106323A0560|28 39|possibility
P07106323A0560|49 54|fetus
P07106323A0560|67 71|role
P07106323A0560|79 89|production
P07106323A0560|93 100|E3-16-G
P07106323A0560|110 119|pregnancy
P07106534A0160|8 11|way
P07106534A0160|43 58|growth function
P07106534A0160|78 83|curve
P07106534A0160|91 97|length
P07106534A0160|99 107|increase
P07106534A0160|111 114|man
P07106534A0160|123 128|curve
P07106534A0160|136 140|mass
P07106534A0160|142 150|increase
P07106534A0160|154 157|rat
P07107287A1083|12 17|doses
P07107287A1083|33 40|drivers
P07107287A1083|63 70|numbers
P07107287A1083|74 89|99Mo generators
P07107462A0202|4 13|steepness
P07107462A0202|33 51|dissociation curve
P07107462A0202|79 94|training period
P07107462A0202|96 104|increase
P07107462A0202|108 112|Hill
P07107462A0202|115 116|n
P07107773A0000|41 45|acid
P07107773A0000|50 51|m
P07107773A0000|79 83|acid
P07107773A0000|112 118|plasma
P07107773A0000|138 146|subjects
P07107773A0000|162 173|consumption
P07107773A0000|179 183|meal
P07107773A0000|188 197|ingestion
P07107773A0000|201 210|deuterium
P07107773A0000|220 236|amine precursors
P07107773A0000|257 275|gas chromatography
P07107773A0000|282 310|resolution mass spectrometry
P07107773A0000|325 339|ion monitoring
P07107773A0000|349 396|trifluoroethyl-pentafluoropropionyl derivatives
P07109788A0333|3 10|concept
P07109788A0333|17 25|patients
P07109788A0333|54 62|vagotomy
P07109788A0333|67 79|pyloroplasty
P07110999A0160|30 39|disorders
P07110999A0160|41 53|tetraparesis
P07110999A0160|55 67|incontinence
P07110999A0160|72 92|oculomotor paralysis
P07112320A0086|0 32|CSF adenosine deaminase activity
P07112320A0086|34 37|ADA
P07112320A0086|64 68|time
P07112471A0639|0 20|Histamine reactivity
P07112471A0639|56 63|workers
P07112471A0639|92 101|factories
P07112471A0639|119 125|worker
P07112471A0639|160 167|factory
P07112654A0388|47 57|difference
P07112654A0388|70 80|prevalence
P07112654A0388|90 98|carriage
P07112654A0388|124 138|hospital staff
P07112654A0388|147 155|patients
P07113365A0737|0 5|Ficat
P07113365A0737|10 15|Bizou
P07113365A0737|27 38|depth index
P07113365A0737|62 75|surface angle
P07113365A0737|79 89|Brattstrom
P07113365A0737|129 136|methods
P07113365A0737|140 151|measurement
P07113897A0285|26 37|differences
P07113897A0285|41 43|EF
P07113897A0285|60 67|studies
P07113897A0285|77 81|rest
P07113897A0285|96 97|%
P07113897A0285|114 115|%
P07113897A0285|117 118|p
P07113897A0285|121 123|NS
P07113897A0285|134 142|exercise
P07113897A0285|157 158|%
P07113897A0285|175 176|%
P07113897A0285|178 179|p
P07113897A0285|182 184|NS
P07113897A0285|211 222|correlation
P07113897A0285|249 255|groups
P07113897A0285|259 265|values
P07113897A0285|267 273|rest r
P07113897A0285|282 292|exercise r
P07113897A0285|301 302|p
P07114083A0153|6 18|MOPP therapy
P07114083A0153|29 38|remission
P07114083A0153|42 49|Hodgkin
P07114083A0153|52 59|disease
P07114083A0153|79 92|normalization
P07114083A0153|100 124|glucocerebrosidase level
P07114083A0153|129 142|disappearance
P07114083A0153|146 153|Gaucher
P07114083A0153|156 161|cells
P07116298A1079|21 25|type
P07116298A1079|38 45|therapy
P07116298A1079|71 79|interval
P07116298A1079|84 92|survival
P07116298A1079|98 107|stage IVA
P07116298A1079|115 123|patients
P07116298A1079|134 156|Corynebacterium parvum
P07116298A1079|173 179|months
P07116298A1079|188 196|patients
P07116298A1079|207 210|BCG
P07116298A1079|218 224|months
P07116298A1079|232 238|months
P07116298A1079|247 255|patients
P07116298A1079|266 269|BCG
P07116298A1079|272 276|DTIC
P07116298A1079|293 299|months
P07116298A1079|316 320|DTIC
P07116298A1079|329 337|patients
P07116298A1079|351 357|months
P07116962A0299|4 21|COP-PAWP gradient
P07116962A0299|53 58|shock
P07116962A0299|73 81|patients
P07116962A0299|97 102|edema
P07119890T0000|0 2|Re
P07119890T0000|4 5|A
P07119890T0000|15 21|method
P07119890T0000|38 46|labeling
P07119890T0000|54 65|blood cells
P07119890T0000|71 77|Tc-99m
P07124743A1223|10 15|study
P07124743A1223|21 38|glassware factory
P07124743A1223|40 54|As2O3 exposure
P07124743A1223|70 81|measurement
P07124743A1223|100 107|arsenic
P07124743A1223|113 126|determination
P07124743A1223|138 145|arsenic
P07124743A1223|155 165|evaluation
P07124743A1223|169 173|hand
P07124743A1223|178 197|mouth contamination
P07124743A1223|201 208|arsenic
P07124743A1223|230 239|workshift
P07124743A1223|279 285|levels
P07124743A1223|291 313|microgram/g creatinine
P07124743A1223|366 372|intake
P07124743A1223|391 396|hands
P07124743A1223|418 428|absorption
P07124743A1223|438 443|lungs
P07125064T0000|33 41|findings
P07125064T0000|54 61|monkeys
P07125064T0000|76 97|Schistosoma japonicum
P07125064T0000|101 120|Schistosoma mansoni
P07125238T0000|4 13|pia mater
P07125238T0000|21 25|site
P07125238T0000|33 38|entry
P07125238T0000|42 55|blood vessels
P07125238T0000|81 87|system
P07126067T0000|13 25|reproduction
P07126067T0000|49 54|fever
P07126067T0000|58 69|Bali cattle
P07126413A0000|12 27|delivery system
P07126413A0000|68 73|drugs
P07126413A0000|81 86|colon
P07126413A0000|112 116|site
P07126413A0000|120 127|coating
P07126413A0000|150 155|resin
P07126413A0000|157 167|Eudragit S
P07130335A1081|0 14|Administration
P07130335A1081|22 52|dopamine agonist bromocriptine
P07130335A1081|58 60|mg
P07130335A1081|67 72|times
P07130335A1081|75 78|day
P07130335A1081|85 89|days
P07130335A1081|103 104|P
P07130335A1081|131 151|plasma 18-OHB levels
P07130335A1081|186 191|ng/dl
P07132408A0387|11 15|time
P07132408A0387|36 58|magnesium cardioplegia
P07134924A0640|16 21|types
P07134924A0640|25 38|malformations
P07134924A0640|44 55|eye defects
P07134924A0640|65 72|coeloms
P07135112T0000|0 6|Repair
P07135112T0000|21 27|defect
P07135112T0000|41 44|leg
P07135112T0000|70 74|flap
P07136524A0180|17 27|literature
P07136524A0180|57 64|tumours
P07136524A0180|73 81|contrast
P07136524A0180|97 104|tumours
P07136524A0180|113 125|osteosarcoma
P07136524A0180|140 164|retinoblastoma survivors
P07136569A0000|3 8|Malmo
P07136569A0000|10 16|Sweden
P07136569A0000|25 40|school children
P07136569A0000|53 58|years
P07136569A0000|87 96|scoliosis
P07136569A0000|104 108|year
P07136569A0000|121 125|ages
P07136569A0000|138 143|years
P07137927A0000|7 11|past
P07137927A0000|13 23|immunology
P07137927A0000|27 36|Singapore
P07137927A0000|60 68|serology
P07137927A0000|77 86|diagnosis
P07137927A0000|109 117|diseases
P07140060T0000|16 27|dislocation
P07140060T0000|35 42|patella
P07140493A1045|5 10|study
P07140493A1045|24 33|secretion
P07140493A1045|37 48|bicarbonate
P07140493A1045|62 69|stomach
P07140493A1045|83 87|rate
P07140493A1045|108 109|%
P07140493A1045|119 133|acid secretion
P07141130A0615|13 23|evaluation
P07141130A0615|53 61|increase
P07141130A0615|69 75|number
P07141130A0615|107 112|cells
P07141130A0615|114 115|p
P07141130A0615|144 150|number
P07141130A0615|165 182|cells/100 microns
P07141130A0615|194 200|mucosa
P07141130A0615|209 220|mean height
P07141130A0615|239 244|cells
P07141130A0615|269 275|groups
P07143347T0000|0 6|Cramps
P07143347T0000|25 34|disorders
P07147622T0000|16 31|storage disease
P07147622T0000|35 41|cattle
P07149047A0260|12 23|dog vessels
P07149047A0260|33 37|Q/Dk
P07149047A0260|61 62|X
P07149047A0260|69 77|Torr/cm2
P07149303T0000|16 22|action
P07149303T0000|26 35|lidocaine
P07149303T0000|39 42|CNS
P07149303T0000|54 62|activity
P07149303T0000|67 75|behavior
P07149303T0000|79 83|cats
P07154928T0001|0 12|Modification
P07154928T0001|24 34|resorption
P07154928T0001|49 56|therapy
P07155579T0001|13 28|bacteriospermia
P07155579T0001|33 42|fertility
P07158726T0001|0 7|Triumph
P07158726T0001|29 35|policy
P07160491A0547|15 21|effect
P07160491A0547|78 86|increase
P07160491A0547|90 97|LD50/30
P07160491A0547|107 128|dose reduction factor
P07162146A0000|4 15|application
P07162146A0000|19 34|ultrafiltration
P07162146A0000|38 56|sample preparation
P07162146A0000|64 73|detection
P07162146A0000|78 92|quantification
P07162146A0000|96 111|ethylene glycol
P07162146A0000|115 121|plasma
P07162146A0000|125 143|gas chromatography
P07165767T0000|0 12|Mastocytosis
P07168531T0001|6 24|Onchocerca species
P07168531T0001|28 36|parasite
P07168531T0001|49 55|cattle
P07168531T0001|60 67|Senegal
P07169630A0983|26 33|absence
P07169630A0983|48 59|differences
P07169630A0983|68 78|conditions
P07169630A0983|104 114|complexity
P07169630A0983|122 126|task
P07169630A0983|134 138|type
P07172690A0547|11 17|factor
P07172690A0547|23 35|disturbances
P07172690A0547|43 49|system
P07172690A0547|53 69|energy transport
P07172690A0547|71 89|creatine phosphate
P07172690A0547|91 113|creatine phosphokinase
P07172690A0547|126 138|calcium pump
P07172690A0547|140 142|Ca
P07172690A0547|145 151|ATPase
P07172690A0547|172 181|reticulum
P07172690A0547|183 186|SPR
P07172690A0547|214 222|decrease
P07172690A0547|240 250|properties
P07172690A0547|258 268|myocardium
P07172690A0547|274 287|% restriction
P07172690A0547|300 310|blood flow
P07173729A0000|9 26|penetration tests
P07173729A0000|36 41|sperm
P07173729A0000|56 61|mucus
P07173729A0000|81 86|order
P07173729A0000|100 111|interaction
P07173729A0000|120 125|sperm
P07173729A0000|139 144|mucus
P07174046T0000|0 16|Vibrio fluvialis
P07174046T0000|18 32|group F vibrio
P07174046T0000|37 48|Maharashtra
P07174122A0000|0 21|Serum creatine kinase
P07174122A0000|23 26|SCK
P07174122A0000|48 56|subjects
P07174122A0000|64 74|laboratory
P07174122A0000|96 107|performance
P07174122A0000|111 128|bicycle ergometry
P07174122A0000|135 147|lifting task
P07174437A0181|0 9|Organisms
P07174437A0181|37 44|bobcats
P07174437A0181|64 72|counties
P07175474A0102|4 9|cause
P07175474A0102|13 18|death
P07175474A0102|83 91|findings
P07175474A0102|106 112|manner
P07175474A0102|116 121|death
P07175474A0102|148 156|official
P07175474A0102|162 172|difficulty
P07179412A1131|19 23|cost
P07179412A1131|28 32|head
P07179412A1131|36 46|population
P07179412A1131|51 53|US
P07179412A1131|56 57|X
P07180901A0539|30 40|blood flow
P07180901A0539|74 98|prostaglandin synthetase
P07180901A0539|110 117|effects
P07180901A0539|121 130|ibuprofen
P07180901A0539|152 160|necrosis
P07181985A0107|10 28|mg mitomycin/20 ml
P07181985A0107|39 44|water
P07181985A0107|51 59|mg/40 ml
P07181985A0107|70 75|water
P07181985A0107|107 114|bladder
P07181985A0107|122 130|catheter
P07181985A0107|179 182|min
P07182523A0462|5 11|groups
P07182523A0462|37 40|SOA
P07182523A0462|62 67|times
P07182523A0462|71 88|SOA concentration
P07183576A0157|19 32|concentration
P07183576A0157|36 50|flucloxacillin
P07183576A0157|63 72|operation
P07183576A0157|82 95|micrograms/ml
P07183576A0157|97 99|SD
P07183576A0157|118 123|fluid
P07183576A0157|129 141|micrograms/g
P07183576A0157|143 145|SD
P07183576A0157|155 163|synovium
P07183576A0157|169 181|micrograms/g
P07183576A0157|183 185|SD
P07183576A0157|206 210|bone
P07183576A0157|219 231|micrograms/g
P07183576A0157|233 235|SD
P07183576A0157|254 258|bone
P07184375T0001|14 19|study
P07184375T0001|23 34|vincristine
P07184375T0001|36 48|methotrexate
P07184375T0001|54 66|prednisolone
P07184375T0001|68 70|VM
P07184375T0001|71 72|P
P07184375T0001|74 98|combination chemotherapy
P07184375T0001|132 140|lymphoma
P07184598T0001|9 18|secretion
P07184598T0001|22 37|hyperthyroidism
P07184774T0000|0 14|Re-examination
P07184774T0000|22 32|ED01 study
P07184795A0517|13 27|determinations
P07184795A0517|33 40|control
P07184795A0517|46 64|serum CPK activity
P07184795A0517|81 85|I.U.
P07184795A0517|86 91|liter
P07190627T0000|10 15|study
P07190627T0000|19 48|plasminogen activator release
P07190627T0000|63 69|agents
P07190627T0000|95 102|dog leg
P07190869A0316|0 4|CDDP
P07190869A0316|27 32|agent
P07190869A0316|50 58|lymphoma
P07191183A0505|0 9|Treatment
P07191183A0505|13 24|meat muscle
P07191183A0505|29 30|V
P07191183A0505|38 39|s
P07191183A0505|83 87|rate
P07191183A0505|91 103|autoxidation
P07191183A0505|107 113|lipids
P07191804A0000|13 21|response
P07191804A0000|40 61|bicycle exercise test
P07191804A0000|85 91|cadets
P07191804A0000|105 111|course
P07191804A0000|119 120|h
P07191804A0000|135 143|activity
P07191804A0000|161 168|h sleep
P07191972A0391|14 25|temperature
P07191972A0391|32 41|degrees C
P07191972A0391|47 56|responses
P07191972A0391|67 74|cooling
P07191972A0391|103 108|phase
P07192369T0000|2 8|method
P07192369T0000|47 55|toxicity
P07192369T0000|75 89|administration
P07192369T0000|93 115|l-alpha-acetylmethadol
P07192369T0000|126 130|rats
P07192722A0682|26 43|parathyroidectomy
P07192722A0682|60 68|decrease
P07192722A0682|72 89|serum iPTH levels
P07192722A0682|100 102|CL
P07192722A0682|106 111|group
P07192722A0682|114 118|PMNs
P07192722A0682|127 134|ability
P07192722A0682|138 143|group
P07192722A0682|146 150|sera
P07192722A0682|171 173|CL
P07192722A0682|184 188|PMNs
P07192722A0682|200 201|p
P07194905A0332|0 3|TCZ
P07194905A0332|45 55|indication
P07194905A0332|59 74|tissue necrosis
P07194905A0332|108 118|hemorrhage
P07194905A0332|132 148|brain maturation
P07195615A0087|4 10|number
P07195615A0087|24 28|rats
P07195615A0087|44 52|increase
P07195615A0087|60 68|duration
P07195615A0087|72 89|Cd administration
P07195615A0087|93 104|association
P07195615A0087|118 130|accumulation
P07195615A0087|134 136|Cd
P07195615A0087|154 158|bulb
P07195615A0087|177 183|region
P07195615A0087|191 196|brain
P07195880A0621|5 9|test
P07195880A0621|43 48|means
P07195880A0621|58 65|leprosy
P07202224A0452|4 15|preferences
P07202224A0452|32 41|vis-a-vis
P07202224A0452|52 57|males
P07202224A0452|66 76|injections
P07202224A0452|80 82|TP
P07202224A0452|96 105|castrates
P07202224A0452|107 121|attractiveness
P07202224A0452|129 136|females
P07202525A0200|5 10|trial
P07202525A0200|24 29|light
P07202525A0200|34 40|buzzer
P07202525A0200|50 57|seconds
P07202525A0200|73 80|stimuli
P07202525A0200|94 99|shock
P07202525A0200|109 116|seconds
P07202525A0200|137 145|stimulus
P07202919A0142|0 5|Ulcer
P07202919A0142|22 29|angulus
P07202919A0142|37 44|stomach
P07202919A0142|57 61|week
P07202919A0142|78 88|ulcer scar
P07202919A0142|96 105|42nd week
P07203410T0000|0 13|Family visits
P07203410T0000|18 29|involvement
P07203410T0000|33 42|treatment
P07203410T0000|46 54|patients
P07203410T0000|60 74|state hospital
P07205120T0000|14 21|overlay
P07205120T0000|36 45|amplitude
P07205120T0000|49 63|ECG wave forms
P07205967T0000|8 16|reaction
P07205967T0000|43 50|partner
P07205967T0000|54 62|response
P07205967T0000|66 77|improvement
P07205967T0000|107 114|partner
P07208984A0000|0 5|Brain
P07208984A0000|47 54|albumin
P07208984A0000|56 65|MAA brain
P07208984A0000|85 103|tomography studies
P07208984A0000|105 107|CT
P07208984A0000|130 138|patients
P07208984A0000|157 165|diseases
P07214230T0000|0 10|Inhibition
P07214230T0000|14 38|Fusarium moniliforme var
P07214230T0000|40 52|subglutinans
P07214230T0000|65 70|agent
P07214230T0000|79 91|pitch canker
P07214230T0000|100 130|soil bacterium Arthrobacter sp
P07214665A0000|14 25|combination
P07214665A0000|29 63|fluorouracil imidazole carboxamide
P07214665A0000|73 81|triazeno
P07214665A0000|83 94|vincristine
P07214665A0000|96 123|bis-chloroethyl nitrosourea
P07214665A0000|129 139|prednisone
P07214665A0000|141 145|FIVB
P07214665A0000|148 149|P
P07214665A0000|168 173|women
P07214665A0000|190 203|breast cancer
P07217329A0000|2 8|method
P07217329A0000|43 56|determination
P07217329A0000|63 83|alpha-acetylmethadol
P07217329A0000|85 89|LAAM
P07217329A0000|107 118|metabolites
P07217329A0000|120 137|noracetylmethadol
P07217329A0000|139 158|dinoracetylmethadol
P07217329A0000|160 168|methadol
P07217329A0000|170 181|normethadol
P07217329A0000|187 200|dinormethadol
P07217329A0000|205 214|biofluids
P07217329A0000|242 256|chromatography
P07217329A0000|278 284|column
P07217329A0000|291 302|UV detector
P07217329A0000|310 312|nm
P07217523A0364|0 7|Results
P07217523A0364|15 31|recognition task
P07217523A0364|53 60|effects
P07217523A0364|74 81|voicing
P07217523A0364|83 91|position
P07217523A0364|96 109|vowel context
P07217523A0364|122 133|recognition
P07218008T0000|7 26|response properties
P07218008T0000|30 37|neurons
P07218008T0000|66 71|areas
P07218008T0000|79 89|owl monkey
P07218008T0000|91 108|Aotus trivirgatus
P07218008T0000|126 136|comparison
P07218008T0000|195 200|areas
P07219297T0000|10 18|approach
P07219297T0000|26 41|standardization
P07219297T0000|45 54|allergens
P07219821T0028|24 38|considerations
P07221179A0156|17 21|fall
P07221179A0156|25 37|GABA content
P07221179A0156|52 65|GABA decrease
P07221179A0156|81 84|min
P07221179A0156|95 109|administration
P07221179A0156|123 128|nadir
P07221179A0156|135 138|min
P07221179A0156|162 169|minutes
P07221354T0000|0 6|Theory
P07221354T0000|11 23|applications
P07221354T0000|27 39|pulse dosing
P07221354T0000|43 50|summary
P07221354T0000|58 67|symposium
P07225300A0968|6 13|results
P07225300A0968|28 35|neonate
P07225300A0968|53 58|adult
P07225300A0968|62 69|respect
P07225300A0968|82 88|nature
P07225300A0968|92 99|effects
P07225300A0968|107 111|drug
P07225300A0968|116 127|sensitivity
P07225540A0193|16 19|gas
P07225540A0193|36 69|electron capture detection method
P07225540A0193|92 106|plasma samples
P07225540A0193|134 144|techniques
P07226440T0000|4 16|hemodynamics
P07226440T0000|50 57|failure
P07226440T0000|65 68|rat
P07228955A0000|8 15|authors
P07228955A0000|39 51|interference
P07228955A0000|55 76|theophylline analysis
P07228955A0000|80 92|paraxanthine
P07228955A0000|94 114|1,7-dimethylxanthine
P07228955A0000|130 140|metabolite
P07228955A0000|144 152|caffeine
P07234308A0121|6 19|drug regimens
P07234308A0121|25 31|C-MOPP
P07234308A0121|33 37|CHOP
P07234308A0121|42 47|BACOP
P07234308A0121|60 75|remission rates
P07234308A0121|88 93|cases
P07234308A0121|113 117|cure
P07234308A0121|125 132|disease
P07234755A0838|4 13|monocytes
P07234755A0838|34 42|Hematrak
P07234755A0838|55 56|%
P07234974T0000|14 22|features
P07234974T0000|26 39|Jat dentition
P07235317T0000|9 17|accuracy
P07235317T0000|29 36|version
P07235317T0000|44 62|Phadebas RAST test
P07235355A0462|13 21|subjects
P07235355A0462|27 31|COPD
P07235355A0462|56 64|sequence
P07235355A0462|68 73|tests
P07235355A0462|94 95|%
P07235355A0462|110 116|change
P07235355A0462|120 130|flow rates
P07235355A0462|134 152|density dependence
P07236351A0812|19 27|recovery
P07236351A0812|40 43|EEG
P07236351A0812|82 86|loss
P07236351A0812|90 99|areas CA3
P07236351A0812|104 107|CA4
P07237123T0000|28 42|unit responses
P07237123T0000|56 69|nerve volleys
P07237123T0000|86 92|turtle
P07237123T0000|103 107|bulb
P07237560A1038|10 19|deletions
P07237560A1038|31 39|sequence
P07237560A1038|62 66|tRNA
P07237560A1038|74 84|inactivity
P07237560A1038|100 105|genes
P07237560A1038|107 119|substitution
P07237560A1038|135 142|portion
P07237560A1038|159 175|Hind III linkers
P07237560A1038|185 195|gene units
P07237560A1038|206 219|transcription
P07237817T0000|0 16|Cross reactivity
P07237817T0000|20 40|theophylline RIA kit
P07240343A0000|0 12|Strontium-90
P07240343A0000|24 28|i.v.
P07240343A0000|43 47|rats
P07240343A0000|51 54|day
P07240343A0000|58 73|post conception
P07240343A0000|75 79|p.c.
P07242929T0001|0 9|Recording
P07242929T0001|34 42|activity
P07242929T0001|56 67|extremities
P07242929T0001|116 123|methods
P07243380A0327|6 8|hr
P07243380A0327|12 20|acidosis
P07243380A0327|43 44|P
P07243380A0327|61 69|decrease
P07243380A0327|73 76|P50
P07243380A0327|115 119|torr
P07247059A0775|0 16|Catheter transit
P07247059A0775|27 35|response
P07247059A0775|41 54|step increase
P07247059A0775|58 71|concentration
P07247059A0775|86 87|s
P07247059A0775|101 108|cent-90
P07247059A0775|113 117|cent
P07247059A0775|136 148|transit time
P07247059A0775|161 169|catheter
P07247059A0775|210 211|s
P07247059A0775|222 224|N2
P07249497A0688|6 11|women
P07249497A0688|44 56|estrogen PPI
P07249497A0688|85 90|women
P07249497A0688|98 103|risks
P07249497A0688|117 129|estrogen use
P07249497A0688|133 136|PPI
P07249497A0688|172 180|patients
P07249497A0688|197 204|courses
P07249544A0343|9 20|temperature
P07249544A0343|34 62|serum creatine kinase levels
P07249544A0343|82 90|patients
P07249660T0000|0 13|Determination
P07249660T0000|24 38|distensibility
P07249660T0000|47 57|variations
P07249660T0000|70 82|hypertension
P07249895A0177|15 19|role
P07249895A0177|23 37|prostaglandins
P07249895A0177|54 65|esophagitis
P07249895A0177|85 100|LES hypotension
P07249895A0177|117 126|treatment
P07249895A0177|135 142|animals
P07249895A0177|148 160|indomethacin
P07249895A0177|166 179|micrograms/kg
P07249895A0177|205 214|inhibitor
P07249895A0177|218 241|prostaglandin synthesis
P07249895A0177|257 267|production
P07249895A0177|271 282|esophagitis
P07249895A0177|293 301|recovery
P07251564A0569|13 14|%
P07251564A0569|22 28|sample
P07251564A0569|69 78|diagnosis
P07251564A0569|99 112|ASDC nosology
P07252346A0223|11 20|technique
P07252346A0223|41 48|problem
P07253335T0000|0 7|Effects
P07253335T0000|11 35|prostaglandin inhibitors
P07253335T0000|43 48|onset
P07253335T0000|52 63|proteinuria
P07253335T0000|68 74|stroke
P07253335T0000|78 90|stroke-prone
P07253335T0000|118 122|rats
P07256543A0814|8 13|study
P07256543A0814|36 44|criteria
P07256543A0814|49 66|inhalation injury
P07256543A0814|68 76|presence
P07256543A0814|104 109|burns
P07256543A0814|111 135|carboxyhemoglobin levels
P07256543A0814|150 156|sputum
P07256543A0814|168 180|space injury
P07256543A0814|204 212|patients
P07256543A0814|218 231|airway injury
P07256543A0814|265 271|injury
P07259325A0394|0 8|Survival
P07259325A0394|38 42|date
P07259325A0394|46 51|onset
P07259325A0394|65 69|date
P07259325A0394|73 82|diagnosis
P07260389A0221|0 12|Methisergide
P07260389A0221|18 23|mg/kg
P07260389A0221|34 41|blocker
P07260389A0221|45 64|serotonin receptors
P07260389A0221|80 91|development
P07260389A0221|115 121|effect
P07260389A0221|125 134|serotonin
P07260987A0336|4 20|plasma half-life
P07260987A0336|29 56|disposition phase t1/2 beta
P07260987A0336|78 82|hour
P07260987A0336|86 93|rabbits
P07260987A0336|112 120|function
P07260987A0336|129 134|hours
P07260987A0336|138 145|rabbits
P07260987A0336|164 174|impairment
P07262239T0000|0 7|Effects
P07262239T0000|27 38|deprivation
P07262239T0000|42 53|development
P07262239T0000|76 87|projections
P07262239T0000|95 98|cat
P07262625A0000|0 22|Corticosteroid therapy
P07262625A0000|51 59|patients
P07262625A0000|65 81|occult infection
P07262625A0000|90 99|mechanism
P07262625A0000|113 139|host parasite relationship
P07262625A0000|154 162|steroids
P07262625A0000|203 221|protozoal parasite
P07262625A0000|223 236|Giardia muris
P07262625A0000|253 260|effects
P07262625A0000|264 279|corticosteroids
P07262625A0000|287 293|number
P07262625A0000|297 306|parasites
P07262625A0000|314 323|intestine
P07262625A0000|331 337|course
P07262625A0000|351 360|infection
P07263374T0000|7 20|lung function
P07263374T0000|24 31|puppies
P07263374T0000|38 51|pneumonectomy
P07263421A0351|5 9|Sair
P07263421A0351|14 17|So2
P07263421A0351|30 38|capacity
P07263421A0351|56 57|%
P07263421A0351|63 70|control
P07263745T0000|10 31|Charnley arthroplasty
P07263745T0000|44 53|procedure
P07264787A0351|11 19|patients
P07264787A0351|52 60|evidence
P07264787A0351|72 83|thyroiditis
P07264787A0351|114 115|%
P07264787A0351|121 136|hyperthyroidism
P07264787A0351|147 148|%
P07266969A0246|4 16|relationship
P07266969A0246|36 46|properties
P07266969A0246|50 59|Tamoxifen
P07266969A0246|64 88|breast cancer management
P07267675A0000|28 41|cephalosporin
P07267675A0000|43 46|CGP
P07267675A0000|84 90|number
P07267675A0000|107 115|patients
P07267675A0000|129 139|infections
P07268828A0000|2 19|fluoroimmunoassay
P07268828A0000|28 41|determination
P07268828A0000|45 50|serum
P07268828A0000|54 67|plasma levels
P07268828A0000|71 82|propranolol
P07268828A0000|103 113|antibodies
P07268828A0000|117 128|propranolol
P07268828A0000|153 174|solid-phase particles
P07268828A0000|199 210|propranolol
P07268828A0000|214 220|tracer
P07270163A0684|27 38|projections
P07270163A0684|80 83|CNF
P07270163A0684|99 108|structure
P07270163A0684|130 135|layer
P07270163A0684|143 148|villi
P07270163A0684|157 163|lining
P07270163A0684|188 195|vessels
P07270163A0684|214 217|CNF
P07270163A0684|222 230|controls
P07270991A0149|5 20|pollen allergen
P07270991A0149|32 45|grass species
P07270991A0149|71 78|results
P07270991A0149|109 115|values
P07274042A0249|0 3|DMI
P07274042A0249|17 31|concentrations
P07274042A0249|61 66|group
P07274042A0249|85 93|patients
P07274428A0000|21 32|experiments
P07274428A0000|73 79|anions
P07274428A0000|98 112|contrast agent
P07274428A0000|114 117|RCA
P07274428A0000|119 128|bilignost
P07274428A0000|137 153|cholecystography
P07274428A0000|158 169|Bengal pink
P07274428A0000|179 187|affinity
P07274428A0000|211 224|RCA triombrin
P07274428A0000|245 259|indigo-carmine
P07274428A0000|279 288|membranes
P07274428A0000|290 292|PM
P07274428A0000|297 308|liver cells
P07274482A0000|13 20|neurons
P07274482A0000|28 31|cat
P07274482A0000|50 54|body
P07274482A0000|68 79|selectivity
P07274482A0000|89 104|afterdischarges
P07274482A0000|108 116|movement
P07274482A0000|120 125|sound
P07274482A0000|131 139|velocity
P07274482A0000|147 155|movement
P07274482A0000|179 184|deg/s
P07274505A0660|3 11|controls
P07274505A0660|25 36|differences
P07276210T0000|0 5|Assay
P07276210T0000|9 14|serum
P07276210T0000|30 37|trypsin
P07276210T0000|47 58|blood spots
P07276210T0000|73 82|detection
P07276210T0000|93 101|fibrosis
P07277222A1391|8 13|waves
P07277222A1391|47 57|motor unit
P07277222A1391|77 87|oscillator
P07277222A1391|111 121|occurrence
P07277222A1391|159 168|existence
P07277222A1391|186 198|interactions
P07278104T0001|0 25|Leukocyte enzyme activity
P07278104T0001|30 67|blood lymphocyte blast transformation
P07278104T0001|79 89|bronchitis
P07278578T0001|8 14|status
P07278578T0001|18 30|chemotherapy
P07278578T0001|35 42|Hodgkin
P07278578T0001|45 52|disease
P07280654A0000|3 13|literature
P07280654A0000|19 22|HBE
P07280654A0000|45 56|application
P07280654A0000|64 80|averaging method
P07282444A0075|11 16|cases
P07282444A0075|43 51|approach
P07282444A0075|59 65|tumour
P07282444A0075|77 82|cases
P07282444A0075|108 113|shunt
P07282552A0990|3 10|Group V
P07282552A0990|25 31|tissue
P07282552A0990|86 90|zone
P07282552A0990|103 109|tissue
P07282552A0990|111 116|ratio
P07282552A0990|129 142|subepicardium
P07282552A0990|155 169|subendocardium
P07282943A0097|30 39|decreases
P07282943A0097|43 61|superfusate oxygen
P07282943A0097|70 78|pressure
P07282943A0097|80 83|PO2
P07282943A0097|90 97|control
P07282943A0097|101 102|%
P07282943A0097|106 114|aeration
P07282943A0097|116 119|PO2
P07282943A0097|129 133|mmHg
P07282943A0097|165 172|changes
P07282943A0097|205 212|tension
P07283110A0000|10 12|B1
P07283110A0000|15 25|deficiency
P07283110A0000|49 55|values
P07283110A0000|67 75|exercise
P07286057A0159|9 30|AUC infinity analyses
P07286057A0159|36 52|pharmacokinetics
P07286057A0159|56 66|buflomedil
P07286057A0159|102 106|dose
P07286057A0159|133 135|mg
P07286057A0159|140 142|i.
P07286057A0159|146 155|injection
P07286057A0159|171 173|mg
P07286057A0159|183 197|administration
P07293100T0001|0 17|Gastrin secretion
P07293100T0001|25 41|food stimulation
P07293100T0001|55 70|system diseases
P07293327T0001|0 24|Fibrinogen determination
P07293327T0001|35 46|KZM-1 meter
P07295033A0513|7 13|period
P07295033A0513|20 24|days
P07295033A0513|27 28|%
P07295033A0513|36 40|dose
P07295033A0513|72 78|faeces
P07295033A0513|86 87|%
P07295033A0513|95 100|urine
P07295417A0092|34 41|regions
P07295417A0092|54 63|ventricle
P07295417A0092|106 115|technique
P07295417A0092|117 130|phase imaging
P07296303A0418|0 9|Responses
P07296303A0418|13 22|brainstem
P07296303A0418|26 32|nuclei
P07296303A0418|42 50|dorsalis
P07296303A0418|52 71|lateralis posterior
P07296303A0418|100 107|latency
P07296997A0125|9 17|patients
P07296997A0125|38 49|gallbladder
P07296997A0125|55 58|OCG
P07296997A0125|76 104|Tc-99m-PyG cholescintigraphy
P07297576A0454|22 47|drinking water ad libitum
P07297576A0454|74 81|Aludrox
P07297576A0454|91 105|drinking water
P07297978A0570|11 15|data
P07297978A0570|35 47|case history
P07297978A0570|49 63|smoking habits
P07297978A0570|93 94|A
P07297978A0570|99 101|C.
P07298209A0291|4 17|determination
P07298209A0291|30 50|performance capacity
P07298209A0291|64 68|W170
P07298209A0291|73 74|%
P07298209A0291|92 99|VO2 max
P07298209A0291|138 147|work load
P07298209A0291|153 170|bicycle ergometer
P07298259T0000|0 13|Determination
P07298259T0000|17 21|lead
P07298259T0000|25 30|blood
P07298523T0000|0 6|Effect
P07298523T0000|10 22|indomethacin
P07298523T0000|27 49|prostaglandin F2 alpha
P07298523T0000|53 64|parturition
P07298523T0000|68 73|swine
P07299857A0294|0 11|LD50 values
P07299857A0294|15 20|terms
P07299857A0294|24 26|KP
P07299857A0294|35 40|mg/kg
P07299857A0294|49 53|rats
P07299857A0294|62 67|mg/kg
P07299857A0294|78 82|rats
P07299857A0294|88 94|KP-CMC
P07299857A0294|135 140|mg/kg
P07299857A0294|144 148|male
P07299857A0294|156 161|mg/kg
P07299857A0294|165 171|female
P07299857A0294|177 183|KP-T10
P07299857A0294|201 215|intrarectally.
P07299857A0294|231 245|administration
P07299857A0294|249 255|KP-CMC
P07299857A0294|263 274|LD50 values
P07299857A0294|281 286|mg/kg
P07299857A0294|290 295|males
P07299857A0294|303 308|mg/kg
P07299857A0294|312 319|females
P07299857A0294|323 328|terms
P07299857A0294|332 334|KP
P07304905A0336|0 15|Autotransfusion
P07304905A0336|42 55|Heparin-ACD-B
P07304905A0336|57 68|Heparin-DPD
P07304905A0336|70 88|Heparin-ACD-B etc.
P07306839T0001|0 8|Electron
P07306839T0001|21 28|picture
P07306839T0001|45 51|cortex
P07306839T0001|55 59|rats
P07306839T0001|73 82|degrees C
P07308849A0817|14 25|differences
P07308849A0817|40 43|gut
P07308849A0817|48 70|sham operation animals
P07308849A0817|92 96|data
P07308849A0817|125 131|weight
P07309562T0000|40 53|determination
P07309562T0000|66 70|acid
P07309562T0000|90 95|acids
P07310206A0154|4 16|architecture
P07310206A0154|20 36|microvasculature
P07310206A0154|50 57|regions
P07310206A0154|79 107|scanning electron microscopy
P07310206A0154|119 139|resin casting method
P07311881T0000|0 12|MSMS Council
P07311881T0000|30 45|health director
P07312707T0000|0 8|Chordoma
P07312707T0000|23 27|cord
P07312707T0000|33 41|F344 rat
P07320153T0000|0 5|Micro
P07320153T0000|23 29|liquid
P07320153T0000|46 52|system
P07320153T0000|64 73|precolumn
P07320153T0000|99 107|detector
P07320153T0000|119 137|injection analysis
P07320153T0000|141 155|catecholamines
P07320153T0000|159 170|body fluids
P07323063A0000|63 67|rats
P07323063A0000|99 103|rats
P07323063A0000|105 109|SHRs
P07323063A0000|165 169|dose
P07323063A0000|176 198|mg/kg dl-isoproterenol
P07323063A0000|216 222|degree
P07323063A0000|227 238|time course
P07323063A0000|263 270|failure
P07323063A0000|286 294|recovery
P07323573A0644|9 13|zone
P07323573A0644|31 43|dissociation
P07326596A0061|4 18|IgA deficiency
P07326596A0061|40 43|IgE
P07327097A0647|3 10|PB mice
P07327097A0647|35 42|deficit
P07327097A0647|50 56|number
P07327097A0647|86 93|neurons
P07327097A0647|106 114|controls
P07327097A0647|118 119|%
P07327097A0647|121 122|p
P07327097A0647|147 154|deficit
P07327097A0647|162 175|granule cells
P07328000T0000|0 21|Nutritional cataracts
P07328000T0000|25 38|timber wolves
P07330073T0000|0 10|Prevention
P07330073T0000|14 35|transfusion reactions
P07330073T0000|43 46|use
P07330073T0000|50 56|saline
P07330073T0000|68 79|blood cells
P07337609A0531|14 18|mean
P07337609A0531|47 62|antibody titers
P07337609A0531|64 67|GMT
P07337609A0531|123 131|chickens
P07337609A0531|156 165|intervals
P07337609A0531|184 196|immunization
P07337609A0531|208 220|immunization
P07337609A0531|226 235|challenge
P07340196T0001|17 30|determination
P07340196T0001|34 39|HBSAG
P07340196T0001|52 55|aid
P07340196T0001|74 88|infectiousness
P07340196T0001|92 118|hepatitis B virus carriers
P07341346A0174|19 32|shunt vessels
P07341346A0174|73 81|arteries
P07341346A0174|111 117|system
P07345217A0000|11 24|complications
P07345217A0000|59 68|treatment
P07345217A0000|86 96|malignancy
P07347728T0000|0 14|Arachnoid cyst
P07349416A0337|21 32|summer coat
P07354367A0162|0 11|Hypotension
P07354367A0162|28 32|head
P07354367A0162|36 40|tilt
P07355527A0467|14 23|procedure
P07355527A0467|27 39|Lich-Gregoir
P07355527A0467|68 74|adults
P07356273T0022|27 42|cell carcinomas
P07356273T0022|55 62|tissues
P07365183A0000|7 15|patients
P07365183A0000|42 51|diagnosis
P07365183A0000|66 76|depression
P07365183A0000|95 100|terms
P07365183A0000|104 110|safety
P07365183A0000|115 123|efficacy
P07365183A0000|133 141|response
P07365183A0000|182 189|therapy
P07365183A0000|191 196|MMECT
P07365183A0000|230 237|therapy
P07365183A0000|239 243|SECT
P07369183T0000|8 17|artifacts
P07369183T0000|31 50|coagulation testing
P07369458A0606|44 53|technique
P07369458A0606|72 90|muscle temperature
P07369458A0606|114 121|adjunct
P07369458A0606|138 154|amputation level
P07372433A0000|26 39|relationships
P07372433A0000|43 60|guinea pig ureter
P07372433A0000|86 93|animals
P07372433A0000|96 101|weeks
P07372433A0000|105 111|months
P07372433A0000|119 124|years
P07372433A0000|128 131|age
P07372928A0105|0 5|Tests
P07372928A0105|13 19|method
P07372928A0105|37 53|Mossbauer source
P07372928A0105|83 91|membrane
P07372928A0105|113 143|signal-transmission properties
P07372928A0105|151 158|cochlea
P07372928A0105|172 178|source
P07372928A0105|202 210|membrane
P07375836T0000|13 20|work-up
P07375836T0000|26 33|patient
P07375836T0000|52 62|metastasis
P07375836T0000|76 85|carcinoma
P07375864A0431|4 11|authors
P07375864A0431|26 40|nonspecificity
P07375864A0431|48 60|platelet MAO
P07375864A0431|75 84|correlate
P07375864A0431|106 114|disorder
P07375864A0431|127 140|schizophrenia
P07375864A0431|156 162|burden
P07375864A0431|166 171|proof
P07375864A0431|189 197|findings
P07375864A0431|205 217|platelet MAO
P07376165T0001|0 7|Ecthyma
P07376165T0001|17 24|disease
P07377378A0143|0 20|Estrogen replacement
P07377378A0143|35 49|beta-estradiol
P07377378A0143|53 78|beta-estradiol-3-benzoate
P07377378A0143|105 113|capsules
P07377378A0143|144 149|rates
P07377378A0143|153 168|heat production
P07377378A0143|177 186|heat loss
P07377378A0143|224 232|controls
P07377954A0117|14 21|aspects
P07377954A0117|45 51|effect
P07377954A0117|74 80|system
P07377954A0117|84 89|terms
P07377954A0117|111 119|pressure
P07377954A0117|121 131|pulse rate
P07377954A0117|137 155|oxygen consumption
P07377954A0117|157 160|VO2
P07377954A0117|169 177|exercise
P07377954A0117|183 200|health volunteers
P07377954A0117|206 218|emg activity
P07377954A0117|226 234|tibialis
P07377954A0117|248 269|gastrocnemius muscles
P07377954A0117|277 285|exercise
P07377954A0117|300 310|volunteers
P07377954A0117|320 355|postexercise ankle pressure changes
P07377954A0117|362 370|subjects
P07377954A0117|419 427|diseases
P07377954A0117|441 452|extremities
P07379334A0503|0 7|Changes
P07379334A0503|23 33|reactivity
P07379334A0503|37 45|subjects
P07379334A0503|56 71|transfer factor
P07379334A0503|113 121|subjects
P07379334A0503|132 139|placebo
P07380615A0478|39 50|possibility
P07380615A0478|60 66|nature
P07380615A0478|75 86|collar jobs
P07380615A0478|110 114|loss
P07380615A0478|129 135|tissue
P07380615A0478|192 207|work efficiency
P07380615A0478|249 259|efficiency
P07380615A0478|282 286|jobs
P07380615A0478|296 310|collar workers
P07385543T0001|0 10|Importance
P07385543T0001|30 53|blood sulfhydryl groups
P07385543T0001|57 66|fractures
P07385543T0001|87 92|bones
P07385543T0001|108 117|infection
P07385920A0189|4 11|results
P07385920A0189|31 47|blood lead level
P07385920A0189|74 91|blood haemoglobin
P07385920A0189|114 123|excretion
P07385920A0189|127 138|delta amino
P07385920A0189|149 153|acid
P07385933A0085|10 22|iv injection
P07385933A0085|30 41|g galactose
P07385933A0085|46 60|kg body weight
P07385933A0085|78 83|mu Ci
P07385933A0085|107 116|galactose
P07385933A0085|118 123|14CO2
P07385933A0085|148 157|intervals
P07385933A0085|169 173|hour
P07386500A0174|9 31|clotting factor assays
P07386500A0174|51 61|deficiency
P07386500A0174|65 73|factor X
P07386500A0174|99 103|cent
P07386500A0174|113 127|determinations
P07386864T0000|21 29|dialysis
P07387242A0236|0 15|Blood variables
P07387242A0236|34 43|intervals
P07387242A0236|70 79|operation
P07387242A0236|103 118|plasma proteins
P07387242A0236|125 135|hemoglobin
P07387242A0236|144 152|elements
P07387242A0236|158 176|clotting functions
P07392519T0001|8 15|changes
P07392519T0001|30 41|retinopathy
P07392519T0001|45 53|children
P07393856A0314|5 11|result
P07393856A0314|13 23|beta-apo-8
P07393856A0314|36 52|acid ethyl ester
P07393856A0314|54 60|apo-EE
P07393856A0314|76 94|reference standard
P07393856A0314|98 109|Experiments
P07393976A0000|4 11|ability
P07393976A0000|15 35|sodium phenobarbital
P07393976A0000|40 45|mg/kg
P07393976A0000|51 66|sodium barbital
P07393976A0000|71 76|mg/kg
P07393976A0000|91 105|taste aversion
P07393976A0000|112 120|hr fluid
P07393976A0000|130 134|rats
P07393976A0000|156 170|discrimination
P07393976A0000|178 204|bottle taste aversion task
P07393976A0000|211 238|% sodium saccharin solution
P07393976A0000|242 247|water
P07394364A0738|30 53|gas exchange parenchyma
P07394364A0738|72 79|mammals
P07394364A0738|109 117|organism
P07394364A0738|146 152|levels
P07394364A0738|190 195|rates
P07394364A0738|221 231|adaptation
P07394364A0738|239 243|lung
P07394364A0738|254 257|VO2
P07395750A0294|0 16|Underestimations
P07395750A0294|33 34|%
P07395750A0294|56 64|problems
P07395750A0294|81 94|methodologies
P07396545A0217|0 12|Chemotherapy
P07396545A0217|51 57|course
P07396545A0217|65 73|disorder
P07397066T0000|0 15|Drug inhibition
P07397066T0000|25 47|blood aspirin esterase
P07401318A0823|18 29|temperature
P07401318A0823|43 52|staircase
P07401318A0823|87 96|staircase
P07401318A0823|112 114|Hz
P07405701T0000|23 32|responses
P07405701T0000|37 63|platelet monoamine oxidase
P07405701T0000|67 75|patients
P07405701T0000|91 101|alcoholism
P07406527A0212|7 10|end
P07406527A0212|18 28|experiment
P07406527A0212|41 60|porphyrin excretion
P07406527A0212|69 86|porphyrin content
P07406527A0212|90 96|lijver
P07406527A0212|101 105|skin
P07406527A0212|140 147|animals
P07406527A0212|159 160|%
P07406527A0212|177 189|HCB controls
P07408970A0706|4 9|hours
P07408970A0706|25 39|administration
P07408970A0706|41 47|uterus
P07408970A0706|51 53|Gf
P07408970A0706|58 65|Cv mice
P07408970A0706|71 77|weight
P07408970A0706|84 87|mg%
P07408970A0706|98 101|mg%
P07408970A0706|120 130|difference
P07408970A0706|162 163|p
P07410037A0752|9 22|stone-formers
P07410037A0752|53 61|features
P07410037A0752|65 85|magnesium metabolism
P07410037A0752|124 137|control group
P07410037A0752|159 168|excretion
P07410037A0752|172 181|magnesium
P07410037A0752|185 193|relation
P07410037A0752|197 204|calcium
P07410037A0752|214 220|factor
P07410037A0752|254 264|propensity
P07413144T0018|0 8|Analysis
P07413144T0018|23 33|population
P07413242A0000|20 25|study
P07413242A0000|32 43|paraplegics
P07413242A0000|58 65|lesions
P07413242A0000|71 76|T1-L3
P07413441T0070|17 29|localisation
P07413441T0070|46 58|distribution
P07413441T0070|66 72|kidney
P07413781A0169|12 23|stimulation
P07413781A0169|48 68|stimulus preexposure
P07413781A0169|78 89|attenuation
P07413781A0169|100 110|inhibition
P07413781A0169|119 130|stimulation
P07413781A0169|148 160|conditioning
P07413781A0169|167 178|preexposure
P07413806T0000|17 25|amygdala
P07413806T0000|38 47|pathology
P07413806T0000|51 55|rats
P07414817T0001|0 19|Cataract extraction
P07414817T0001|31 39|glaucoma
P07415340A0280|0 6|Number
P07415340A0280|11 15|size
P07415340A0280|30 40|structures
P07415340A0280|48 63|pneumocytes typ
P07416204A0437|14 20|animal
P07416204A0437|40 52|potentiation
P07416204A0437|75 90|pacing interval
P07416204A0437|92 94|t0
P07416204A0437|104 110|timing
P07416204A0437|118 130|extrasystole
P07416204A0437|132 134|t1
P07416204A0437|141 143|t0
P07416204A0437|166 168|t1
P07416204A0437|184 196|potentiation
P07416204A0437|213 215|t1
P07416204A0437|238 240|t0
P07416204A0437|256 268|potentiation
P07418498A0217|3 8|spite
P07418498A0217|27 40|complications
P07418498A0217|44 59|corticosteroids
P07418498A0217|77 85|recovery
P07418498A0217|102 111|infection
P07418498A0217|122 131|treatment
P07418498A0217|137 151|amphotericin B
P07418498A0217|165 173|excision
P07418498A0217|181 193|lung abscess
P07418829A0191|0 12|Implications
P07418829A0191|21 32|observation
P07418829A0191|37 47|pediatrics
P07419485A0158|8 13|study
P07419485A0158|21 31|transition
P07419485A0158|49 54|waves
P07419485A0158|67 72|waves
P07419485A0158|88 96|solution
P07419485A0158|157 161|cost
P07419485A0158|173 187|simplification
P07423803T0001|0 9|Treatment
P07423803T0001|25 36|peritonitis
P07425838A0182|12 16|case
P07425838A0182|20 36|pheochromocytoma
P07425838A0182|66 75|trimester
P07425838A0182|79 88|pregnancy
P07426101A0124|8 14|plasma
P07426101A0124|19 51|lipoprotein lipid concentrations
P07426101A0124|53 95|adipose tissue lipoprotein lipase activity
P07426101A0124|97 116|anthropometric data
P07426101A0124|118 137|alcohol consumption
P07426101A0124|139 153|smoking habits
P07426101A0124|162 173|mileage run
P07426101A0124|178 189|performance
P07426101A0124|195 212|bicycle ergometer
P07426101A0124|248 263|training period
P07426604A0397|4 9|C18:1
P07426604A0397|11 20|C10 value
P07426604A0397|37 44|measure
P07426604A0397|54 61|changes
P07426604A0397|134 139|acids
P07426745A0177|14 20|growth
P07426745A0177|24 57|blood erythrocyte membrane injury
P07426745A0177|86 90|rats
P07426745A0177|107 123|gamma-irradiaton
P07426745A0177|129 133|dose
P07426745A0177|148 150|Gy
P07428037A0989|26 37|nucleotides
P07428037A0989|43 60|mouse mt 12S rRNA
P07428037A0989|85 105|bp hairpin structure
P07428037A0989|112 120|sequence
P07428037A0989|139 150|nucleotides
P07428037A0989|165 168|RNA
P07428037A0989|192 199|subunit
P07428037A0989|207 214|systems
P07428037A0989|241 258|mRNA binding site
P07428037A0989|260 266|ACCUCC
P07428037A0989|289 311|corn chloroplast rRNAs
P07429009T0121|12 19|anatomy
P07429009T0121|24 48|cell population dynamics
P07431059A0000|7 21|cadaver brains
P07431059A0000|42 43|X
P07431059A0000|52 65|magnification
P07431059A0000|69 74|order
P07431059A0000|103 110|anatomy
P07431059A0000|118 131|pineal region
P07431059A0000|150 162|relationship
P07431059A0000|170 181|pineal body
P07431059A0000|202 208|artery
P07431059A0000|219 236|cerebellar artery
P07431059A0000|238 242|vein
P07431059A0000|246 251|Galen
P07431059A0000|259 263|vein
P07431059A0000|267 276|Rosenthal
P07431059A0000|296 300|vein
P07431059A0000|311 316|sinus
P07431059A0000|327 331|vein
P07431059A0000|337 341|size
P07431059A0000|359 364|notch
P07431059A0000|403 409|nerves
P07432288A0218|0 20|Serum antibody titre
P07432288A0218|63 78|recurrence rate
P07432288A0218|86 94|duration
P07432288A0218|98 107|infection
P07434431A0203|16 25|refeeding
P07434431A0203|46 55|mechanism
P07434431A0203|60 70|activation
P07434431A0203|88 98|infections
P07434431A0203|124 130|famine
P07434456A0286|19 24|units
P07434456A0286|47 58|blood cells
P07434456A0286|70 78|glycerol
P07434456A0286|116 134|% glycerol content
P07434456A0286|140 152|measurements
P07434456A0286|187 192|fluid
P07434456A0286|207 212|index
P07434456A0286|217 226|osmometry
P07435185A0074|4 12|symptoms
P07435185A0074|27 35|findings
P07435185A0074|63 71|lymphoma
P07435185A0074|81 90|diagnosis
P07435185A0074|114 126|drill biopsy
P07436187A0147|4 9|study
P07436187A0147|32 39|studies
P07436187A0147|80 86|entity
P07436187A0147|104 108|time
P07436187A0147|127 132|range
P07436187A0147|160 167|factors
P07436187A0147|171 181|disability
P07436459A0245|67 77|acid ratio
P07436459A0245|108 129|vitamin B6 deficiency
P07436459A0245|162 170|response
P07436459A0245|174 195|tryptophan metabolism
P07436459A0245|199 205|stress
P07436702A0156|4 19|control persons
P07436702A0156|33 41|reaction
P07436702A0156|45 49|DNFB
P07436794A0148|5 18|control group
P07436794A0148|31 47|carotid arteries
P07436794A0148|49 52|CCA
P07438346A0381|3 5|pH
P07438346A0381|20 44|lidocaine concentrations
P07438346A0381|90 91|%
P07438346A0381|94 100|action
P07438346A0381|111 120|amplitude
P07438346A0381|125 126|%
P07438346A0381|132 136|Vmax
P07438346A0381|143 144|%
P07438482A0145|13 18|right
P07438482A0145|51 64|blood samples
P07438482A0145|84 97|determination
P07438482A0145|101 109|oestrone
P07438482A0145|111 113|E1
P07438482A0145|119 129|oestradiol
P07438482A0145|131 133|E2
P07440085T0061|0 18|Arm function tests
P07440430A1074|4 9|lambs
P07440430A1074|15 25|B breeding
P07440430A1074|51 60|Hb levels
P07440430A1074|68 71|end
P07440430A1074|79 89|experiment
P07440430A1074|99 107|NB lambs
P07440430A1074|109 110|b
P07440430A1074|115 126|S x B lambs
P07440430A1074|139 140|P
P07440430A1074|148 157|Hb levels
P07440430A1074|167 178|D x B lambs
P07440430A1074|184 191|B lambs
P07440430A1074|209 210|P
P07440430A1074|235 260|hemoglobin concentrations
P07445971A0241|9 17|response
P07445971A0241|33 43|acrylamide
P07445971A0241|71 85|nerve ligation
P07445971A0241|91 95|week
P07449221A0086|4 13|operation
P07449221A0086|29 37|excision
P07449221A0086|43 45|mm
P07449221A0086|57 61|slip
P07449221A0086|85 91|repair
P07449221A0086|99 105|tendon
P07449253A0411|17 22|group
P07449253A0411|32 40|pressure
P07449253A0411|54 58|mmHg
P07449253A0411|75 76|h
P07449253A0411|111 119|diuresis
P07449253A0411|132 140|decrease
P07449253A0411|144 156|blood volume
P07449253A0411|161 162|%
P07450031A0691|7 24|sedative activity
P07450031A0691|80 96|benzothiazepin-6
P07450031A0691|99 106|dioxide
P07450031A0691|108 112|NF19
P07450031A0691|161 177|benzothiazepin-6
P07450031A0691|180 187|dioxide
P07450031A0691|189 193|NF20
P07450388A0406|3 11|patients
P07450388A0406|17 23|effect
P07450388A0406|27 33|CCK-PZ
P07450388A0406|41 49|movement
P07450388A0406|66 70|part
P07450388A0406|78 87|bile duct
P07450388A0406|108 123|pressure sensor
P07450388A0406|132 149|duodenofiberscope
P07453919A0000|6 14|patients
P07453919A0000|20 26|Horton
P07453919A0000|29 37|headache
P07453919A0000|52 66|investigations
P07453919A0000|87 103|blood cell count
P07453919A0000|120 134|determinations
P07453919A0000|136 144|alkaline
P07453919A0000|149 165|acid phosphatase
P07453919A0000|180 188|esterase
P07453919A0000|212 217|tests
P07453919A0000|219 222|IgM
P07453919A0000|227 238|IgG binding
P07453919A0000|270 287|blood neutrophils
P07453919A0000|306 310|area
P07453919A0000|314 318|pain
P07453919A0000|332 336|area
P07453919A0000|344 348|skin
P07453919A0000|356 360|head
P07453919A0000|382 386|side
P07453919A0000|401 407|finger
P07455042A0457|26 33|imaging
P07455042A0457|61 69|machines
P07455042A0457|82 111|Dynamic Spatial Reconstructor
P07455042A0457|141 159|density resolution
P07455042A0457|178 187|injection
P07455042A0457|191 205|contrast agent
P07455042A0457|221 227|atrium
P07455042A0457|249 253|vein
P07455042A0457|290 302|measurements
P07455521A0414|4 8|ESEG
P07455521A0414|24 30|result
P07455521A0414|38 48|NEXT study
P07456774A0448|29 34|drugs
P07457931A0655|8 14|series
P07457931A0655|18 22|mice
P07457931A0655|43 52|injection
P07457931A0655|56 63|5-OH-DA
P07457931A0655|110 115|study
P07458171A0086|19 26|species
P07458171A0086|34 48|Platyhelmintha
P07458171A0086|54 62|Nematoda
P07458171A0086|72 81|Crustacea
P07461226A0958|3 11|symptoms
P07461226A0958|27 32|flush
P07461226A0958|57 68|correlation
P07461226A0958|74 92|plasma epinephrine
P07461226A0958|96 117|norepinephrine levels
P07461848A0230|4 15|mean values
P07461848A0230|23 37|concentrations
P07461848A0230|45 55|components
P07461848A0230|63 76|tobacco smoke
P07461848A0230|82 84|CO
P07461848A0230|91 94|ppm
P07461848A0230|96 98|NO
P07461848A0230|104 107|ppb
P07461848A0230|109 112|NO2
P07461848A0230|118 121|ppb
P07461848A0230|123 131|nicotine
P07461848A0230|138 151|micrograms/m3
P07461848A0230|165 171|matter
P07461848A0230|178 191|micrograms/m3
P07462481A0422|12 35|backscatter coefficient
P07462481A0422|44 48|time
P07462481A0422|59 66|regions
P07462481A0422|70 77|infarct
P07462481A0422|92 97|weeks
P07462481A0422|104 113|occlusion
P07462481A0422|127 134|regions
P07462481A0422|138 145|infarct
P07462481A0422|159 164|weeks
P07462481A0422|171 180|occlusion
P07463294A1216|5 7|wk
P07463294A1216|17 30|tumor relapse
P07463294A1216|51 56|group
P07463294A1216|59 69|responders
P07463294A1216|83 88|group
P07463294A1216|104 109|group
P07463294A1216|130 135|group
P07463294A1216|138 148|responders
P07463294A1216|150 151|p
P07463294A1216|167 172|group
P07463465A0297|6 15|infection
P07463465A0297|42 55|control women
P07463465A0297|65 70|birth
P07463465A0297|84 90|infant
P07466831A0714|0 17|Pentachlorophenol
P07466831A0714|34 39|onset
P07466831A0714|43 56|HCB porphyria
P07466831A0714|67 72|words
P07466831A0714|104 123|porphyrin excretion
P07466831A0714|146 157|disturbance
P07466831A0714|165 182|porphyrin pattern
P07467975A0316|0 15|Family planning
P07467975A0316|42 46|role
P07467975A0316|66 70|cent
P07467975A0316|78 86|patients
P07467975A0316|109 123|contraceptives
P07467975A0316|146 153|periods
P07467975A0316|157 161|time
P07467975A0316|169 180|percentages
P07467975A0316|184 194|primiparae
P07467975A0316|199 211|secundiparae
P07467975A0316|219 225|births
P07467975A0316|246 256|percentage
P07467975A0316|260 274|multigravidity
P07467975A0316|279 289|parameters
P07467975A0316|303 311|approach
P07467975A0316|315 327|reproduction
P07467975A0316|355 373|behaviour patterns
P07467975A0316|377 383|Europe
P07469692A0000|4 26|term osteomesopycnosis
P07469692A0000|56 68|bone disease
P07469692A0000|83 94|inheritance
P07469692A0000|128 135|members
P07469692A0000|154 162|families
P07471210A0384|4 15|87K protein
P07471210A0384|31 39|proteins
P07471210A0384|62 69|daltons
P07471210A0384|123 137|messenger RNAs
P07471210A0384|174 180|genome
P07471210A0384|189 198|positions
P07472582A0993|4 18|identification
P07472582A0993|29 39|myocardium
P07472582A0993|50 67|99mTc-tetrofosmin
P07472582A0993|72 77|201Tl
P07472582A0993|115 121|degree
P07472582A0993|129 137|severity
P07472582A0993|141 150|reduction
P07472582A0993|154 162|activity
P07472582A0993|184 191|defects
P07472736A0278|13 22|component
P07472736A0278|43 48|fossa
P07472736A0278|70 78|eminence
P07473169A0133|0 5|EUK-8
P07473169A0133|66 73|complex
P07473169A0133|93 113|superoxide dismutase
P07473169A0133|118 137|catalase activities
P07473742A0187|4 17|protein ELT-1
P07473742A0187|44 48|gene
P07473742A0187|67 78|GATA family
P07473742A0187|82 114|vertebrate transcription factors
P07473742A0187|164 171|element
P07474078A0838|12 20|contrast
P07474078A0838|54 73|integration studies
P07474078A0838|75 85|alteration
P07474078A0838|110 125|CA dinucleotide
P07474078A0838|140 146|mutant
P07474078A0838|170 171|%
P07474078A0838|185 205|integration activity
P07474085A0932|14 23|R protein
P07474085A0932|40 46|codons
P07474085A0932|65 80|frameshift site
P07474085A0932|88 97|V protein
P07474085A0932|103 108|codon
P07474124A1360|6 13|results
P07474124A1360|40 43|PI2
P07474124A1360|48 59|PI3 viruses
P07474124A1360|79 104|parainfluenza virus genus
P07474124A1360|112 119|viruses
P07474124A1360|132 143|differences
P07474124A1360|149 156|respect
P07474124A1360|171 183|requirements
P07474124A1360|204 208|tail
P07474124A1360|216 230|F glycoprotein
P07474140A1036|17 28|mutagenesis
P07474140A1036|59 64|ICP27
P07474140A1036|76 95|amino acid residues
P07474140A1036|131 145|ICP27 homologs
P07474140A1036|155 168|herpesviruses
P07474140A1036|170 175|D-357
P07474140A1036|177 182|E-358
P07474140A1036|184 189|H-479
P07474140A1036|191 196|C-400
P07474140A1036|198 203|C-483
P07474140A1036|209 214|C-488
P07474140A1036|250 258|activity
P07474451A0000|9 26|resonance imaging
P07474451A0000|28 31|MRI
P07474451A0000|81 90|pathology
P07474451A0000|94 105|differences
P07474451A0000|109 125|signal intensity
P07474617A1035|0 8|Patients
P07474617A1035|27 32|drugs
P07474617A1035|61 71|PRL levels
P07474772A0274|4 33|Laser Scanning Ophthalmoscope
P07474772A0274|57 68|examination
P07474772A0274|96 106|comparison
P07474772A0274|127 137|appearance
P07474772A0274|156 164|function
P07475733T0000|0 7|Malaria
P07475733T0000|9 16|anaemia
P07475733T0000|22 40|HIV-1 transmission
P07475733T0000|52 58|Africa
P07475793T0000|0 3|BSE
P07475793T0000|8 19|farmworkers
P07476164A1602|3 11|addition
P07476164A1602|46 63|resonance studies
P07476164A1602|69 73|F17A
P07476164A1602|75 79|K13Q
P07476164A1602|81 85|F15Y
P07476164A1602|90 94|F27Y
P07476164A1602|113 120|mutants
P07476164A1602|143 152|structure
P07476164A1602|170 182|CspB protein
P07476701A0654|18 24|levels
P07476701A0654|28 42|IgE antibodies
P07476701A0654|76 83|pollens
P07476701A0654|102 116|correspondence
P07476963A0000|0 10|Peroxisome
P07476963A0000|34 43|receptors
P07476963A0000|45 50|PPARs
P07476963A0000|56 76|retinoid X receptors
P07476963A0000|78 82|RXRs
P07476963A0000|96 113|hormone receptors
P07476963A0000|142 147|acids
P07476963A0000|167 171|acid
P07476971A0381|40 56|SKUT-1B-20 cells
P07476971A0381|66 92|transcription factor Pit-1
P07476975A0492|4 10|number
P07476975A0492|14 25|lactotropes
P07476975A0492|27 39|somatotropes
P07476975A0492|41 52|thyrotropes
P07476975A0492|58 70|gonadotropes
P07476975A0492|101 109|controls
P07476975A0492|140 149|pituitary
P07476975A0492|156 164|products
P07476975A0492|198 210|distribution
P07476975A0492|214 224|cell types
P07477245A0625|5 12|strains
P07477245A0625|16 30|A. parasiticus
P07477245A0625|49 71|aflatoxins B1 B2 G1 G2
P07477245A0625|89 93|ones
P07477245A0625|103 108|AF B1
P07477245A0625|111 113|G1
P07477245A0625|125 139|concentrations
P07477245A0625|143 153|aflatoxins
P07477245A0625|170 175|mg/kg
P07478514A0237|31 34|rat
P07478514A0237|49 54|clone
P07478523A0551|3 11|addition
P07478523A0551|40 56|amino acid forms
P07478523A0551|111 122|amino acids
P07478523A0551|151 170|RET protein isoform
P07478525A1177|5 12|classes
P07478525A1177|16 30|MHBst proteins
P07478525A1177|50 56|dimers
P07478525A1177|96 108|dimerization
P07479004A0421|19 40|mobility shift assays
P07479004A0421|46 50|PERE
P07479004A0421|70 79|complexes
P07479004A0421|81 83|P1
P07479004A0421|85 87|P2
P07479004A0421|92 94|P3
P07479004A0421|101 109|proteins
P07479004A0421|121 129|extracts
P07479004A0421|135 139|HeLa
P07479004A0421|147 152|cells
P07482069A0606|23 26|MTX
P07482069A0606|31 38|mg/week
P07482069A0606|47 53|months
P07482069A0606|69 88|vasculitis symptoms
P07483276A0139|0 8|Analysis
P07483276A0139|16 24|sequence
P07483276A0139|46 60|reading frames
P07483276A0139|62 66|ORFs
P07483276A0139|89 92|UL1
P07483276A0139|94 97|UL2
P07483276A0139|99 102|UL3
P07483276A0139|108 111|UL3
P07483276A0139|129 137|homology
P07483276A0139|143 151|proteins
P07483276A0139|155 177|herpes simplex virus-1
P07483276A0139|179 184|HSV-1
P07483276A0139|187 205|pseudorabies virus
P07483276A0139|207 210|PRV
P07483276A0139|220 233|herpesvirus-1
P07483276A0139|239 261|varicella-zoster virus
P07483285A0322|6 23|HPV16 E6/E7 cDNAs
P07483285A0322|46 68|SV40 enhancer/promoter
P07483285A0322|77 85|MMTV LTR
P07483285A0322|101 111|activities
P07483285A0322|133 147|transformation
P07483285A0322|152 161|induction
P07483285A0322|174 187|DNA synthesis
P07483285A0322|217 232|E7 gene product
P07483857A0350|0 24|Correlation coefficients
P07483857A0350|37 54|reference methods
P07483857A0350|59 62|NIT
P07483857A0350|84 89|water
P07483857A0350|102 109|protein
P07483857A0350|114 157|connective-tissue-protein frei meat protein
P07483857A0350|179 204|connective-tissue-protein
P07487067A0592|4 24|translation products
P07487067A0592|33 39|clones
P07487067A0592|65 69|APS1
P07487067A0592|80 90|% identity
P07487067A0592|124 131|lengths
P07487067A0592|143 148|amino
P07487067A0592|158 167|sequences
P07487067A0592|179 195|transit peptides
P07487067A0592|200 220|plastid localization
P07487363A0447|4 16|serum levels
P07487363A0447|20 23|IgE
P07487363A0447|29 34|asIgE
P07487363A0447|39 44|IgG-4
P07487363A0447|63 77|food allergens
P07487811A0000|4 15|experiments
P07487811A0000|34 41|effects
P07487811A0000|56 67|spaceflight
P07487811A0000|82 95|bone turnover
P07487811A0000|128 148|Systems Experiment-1
P07487811A0000|150 155|PSE-1
P07487811A0000|172 183|spaceflight
P07487811A0000|189 194|PSE-2
P07487811A0000|203 209|flight
P07487908A0230|5 13|sequence
P07487908A0230|36 49|transcription
P07487908A0230|70 102|chloramphenicol acetyltranferase
P07487908A0230|104 107|CAT
P07487908A0230|109 113|gene
P07487908A0230|117 122|cells
P07487908A0230|137 143|origin
P07487908A0230|145 151|AR-42J
P07487908A0230|164 169|cells
P07487908A0230|188 194|origin
P07487908A0230|196 199|Rat
P07487908A0230|206 209|IEC
P07488247T0000|11 19|analysis
P07488247T0000|23 48|aryl hydrocarbon receptor
P07488247T0000|57 82|translocator interactions
P07488247T0000|88 113|aryl hydrocarbon receptor
P07488247T0000|121 126|yeast
P07488247T0000|138 144|system
P07488291A0934|16 28|observations
P07488291A0934|46 58|somatostatin
P07488291A0934|63 86|triamcinolone acetonide
P07488291A0934|112 117|signs
P07488291A0934|131 141|structures
P07488291A0934|152 175|triamcinolone acetonide
P07488959T0000|3 11|approach
P07488959T0000|33 38|model
P07488959T0000|42 59|lymphocytopoiesis
P07489502A0000|4 31|influenza virus NS1 protein
P07489502A0000|64 73|regulator
P07489502A0000|87 97|activities
P07489502A0000|99 109|inhibition
P07489502A0000|125 131|export
P07489502A0000|135 139|poly
P07489502A0000|153 158|mRNAs
P07489502A0000|163 173|inhibition
P07489502A0000|177 194|pre-mRNA splicing
P07490079A0825|14 21|regions
P07490079A0825|41 48|synteny
P07490079A0825|68 76|evidence
P07490079A0825|92 96|STEP
P07490079A0825|107 114|homolog
P07490079A0825|129 138|STEP gene
P07490079T0000|10 17|cloning
P07490079T0000|31 38|homolog
P07490079T0000|62 73|phosphatase
P07490079T0000|75 79|STEP
P07490079T0000|81 85|gene
P07490079T0000|102 109|mapping
P07490079T0000|134 138|loci
P07490083A0000|9 20|anhydrase V
P07490083A0000|22 26|CA V
P07490083A0000|58 64|matrix
P07490083A0000|68 73|liver
P07490083A0000|92 99|tissues
P07490156A0647|0 10|Vitamin D3
P07490156A0647|16 34|nicotine treatment
P07490156A0647|53 62|increases
P07490156A0647|74 78|mass
P07490156A0647|91 98|modulus
P07490156A0647|119 130|correlation
P07490278A0799|11 17|domain
P07490278A0799|54 59|Num1p
P07490278A0799|67 85|mother cell cortex
P07490742A0636|5 12|finding
P07490742A0636|36 42|notion
P07490742A0636|52 73|dsRNA binding domains
P07490742A0636|117 127|subdomains
P07490766T0000|27 35|parallel
P07490766T0000|48 57|formation
P07490766T0000|71 74|Max
P07490766T0000|79 100|c-Myc leucine zippers
P07490766T0000|104 115|description
P07490766T0000|142 154|interactions
P07490766T0000|175 186|specificity
P07490766T0000|190 208|heterodimerization
P07490770A0267|0 10|Comparison
P07490770A0267|20 30|coxI genes
P07490770A0267|49 54|group
P07490770A0267|57 63|intron
P07490770A0267|81 89|homology
P07490770A0267|107 112|yeast
P07490770A0267|118 128|intron aI4
P07490770A0267|181 197|DNA endonuclease
P07491111A0221|15 17|GR
P07491111A0221|21 33|DMS-79 cells
P07491111A0221|76 92|cell lung cancer
P07491305A0102|5 10|study
P07491305A0102|32 44|localization
P07491305A0102|51 68|accessory pathway
P07491305A0102|101 109|polarity
P07491305A0102|117 128|QRS complex
P07491305A0102|136 148|sinus rhythm
P07491305A0102|156 167|surface ECG
P07491305A0102|184 203|delta wave polarity
P07491305A0102|220 227|reports
P07491791A0263|4 21|promoter mutation
P07491791A0263|50 62|E1A products
P07491791A0263|83 105|helper adenovirus type
P07491791A0263|109 112|Ad5
P07493327A0507|49 58|integrity
P07493327A0507|62 64|U2
P07493327A0507|66 68|U4
P07493327A0507|74 83|U6 snRNAs
P07493627A0882|0 9|Treatment
P07493627A0882|13 17|PCC4
P07493627A0882|18 29|aza1R cells
P07493627A0882|52 59|agonist
P07493627A0882|79 89|expression
P07493627A0882|93 102|EC-1 mRNA
P07493627A0882|109 118|treatment
P07493627A0882|141 148|agonist
P07493627A0882|157 172|EC-1 expression
P07494244A0335|7 14|absence
P07494244A0335|18 24|E1A243
P07494244A0335|26 29|YY1
P07494244A0335|54 67|transcription
P07494244A0335|71 76|c-fos
P07494244A0335|108 125|ATF/CREB proteins
P07494244A0335|143 146|CRE
P07494274A1015|11 22|experiments
P07494274A1015|63 72|reduction
P07494274A1015|76 87|virus yield
P07494274A1015|109 120|temperature
P07494274A1015|136 147|disfunction
P07494274A1015|151 160|alpha TIF
P07494274A1015|169 178|infection
P07494274A1015|194 211|virion maturation
P07494293A0585|6 13|results
P07494293A0585|31 34|tip
P07494293A0585|52 57|stage
P07494293A0585|65 99|T-cell signal transduction cascade
P07494293A0585|120 123|Lck
P07494293A0585|156 166|activation
P07494303A0000|6 33|immunodeficiency virus type
P07494303A0000|36 39|Vpr
P07494303A0000|75 82|protein
P07494303A0000|120 131|replication
P07494303A0000|135 156|monocytes/macrophages
P07494306A0240|20 29|potential
P07494306A0240|34 38|VP16
P07494306A0240|55 67|interactions
P07494306A0240|95 100|cells
P07494306A0240|115 119|VP16
P07494306A0240|152 160|fraction
P07494306A0240|181 192|polypeptide
P07494306A0240|243 255|protein VP22
P07494314A1287|22 32|regulation
P07494314A1287|34 42|splicing
P07494314A1287|44 68|kinase interaction sites
P07494314A1287|74 98|tyrosine phosphorylation
P07494314A1287|106 120|LMP2A homologs
P07494314A1287|161 184|sequences heterogeneity
P07494314A1287|204 218|repeat regions
P07494314A1287|255 259|EBVs
P07495059T0078|0 7|Results
P07495059T0078|15 47|ECAT Angina Pectoris Study Group
P07495120A0260|25 30|Phase
P07495120A0260|34 39|trial
P07495120A0260|71 77|safety
P07495120A0260|82 90|efficacy
P07495120A0260|94 105|cryosurgery
P07495120A0260|116 133|radiation therapy
P07495120A0260|137 140|men
P07495120A0260|152 162|recurrence
P07495726A1189|6 12|motifs
P07495726A1189|23 32|Chi motif
P07495726A1189|48 55|element
P07495726A1189|80 108|recombination hotspot region
P07495726A1189|116 136|Bcl-2 proto-oncogene
P07495726A1189|141 146|close
P07495726A1189|162 173|breakpoints
P07495726A1189|177 188|T-ALL lines
P07496184T0001|7 14|history
P07496184T0001|19 28|prospects
P07496184T0001|41 51|gynecology
P07496184T0001|59 66|Charite
P07496184T0001|75 99|Vienna University Clinic
P07496400A0525|3 11|contrast
P07496400A0525|41 51|HMGR1 mRNA
P07496400A0525|53 64|HMGR1S mRNA
P07496400A0525|93 99|levels
P07496400A0525|107 114|tissues
P07496400A0525|122 127|plant
P07496400A0525|129 140|HMGR1L mRNA
P07496400A0525|170 176|levels
P07496400A0525|185 195|expression
P07496400A0525|220 229|seedlings
P07496400A0525|231 236|roots
P07496400A0525|241 255|inflorescences
P07498727A0724|13 24|requirement
P07498727A0724|28 32|rev3
P07498727A0724|41 51|production
P07498727A0724|55 58|G.C
P07498727A0724|61 78|T.A transversions
P07498727A0724|86 99|rad18 mutator
P07498727A0724|126 139|substitutions
P07498727A0724|179 182|G.C
P07498727A0724|185 201|T.A transversion
P07498791A0680|11 19|mutation
P07498791A0680|67 73|allele
P07498791A0680|85 89|gene
P07498791A0680|91 95|PBS2
P07498791A0680|122 136|protein kinase
P07498791A0680|164 189|osmolarity stress pathway
P07499242A0898|9 16|tissues
P07499242A0898|58 74|RAFTK expression
P07499252A0150|3 19|hGM-CSF receptor
P07499252A0150|21 25|hGMR
P07499252A0150|46 64|consensus sequence
P07499252A0150|69 76|binding
P07499252A0150|80 91|PI 3-kinase
P07499252A0150|93 97|hGMR
P07499252A0150|118 127|mechanism
P07499252A0150|136 147|association
P07499252A0150|157 167|activation
P07499252A0150|171 182|PI 3-kinase
P07499394A0187|0 2|J.
P07499401A0444|4 12|identity
P07499401A0444|21 29|hnRNPs H
P07499401A0444|34 35|H
P07499401A0444|42 43|%
P07499401A0444|53 54|H
P07499401A0444|59 60|F
P07499401A0444|63 64|%
P07499401A0444|78 79|H
P07499401A0444|85 86|F
P07499401A0444|89 90|%
P07499409A0367|0 4|TPBF
P07499409A0367|35 42|regions
P07499409A0367|52 58|region
P07499409A0367|75 81|region
P07499409A0367|100 110|N terminus
P07499409A0367|126 144|targeting sequence
P07499421A0237|15 20|study
P07499421A0237|58 66|cultures
P07499421A0237|70 94|rat hepatocytes plasmids
P07499421A0237|109 115|CYP3A1
P07499421A0237|128 137|sequences
P07499421A0237|149 199|chloramphenicol acetyltransferase reporter plasmid
P07499848A0409|13 24|stimulation
P07499848A0409|44 51|B cells
P07499848A0409|74 83|Sf9 cells
P07499848A0409|92 107|germ-line gamma
P07499848A0409|114 133|epsilon transcripts
P07499848A0409|151 160|cytokines
P07500386A0870|15 38|GapIII protein activity
P07500386A0870|40 50|constructs
P07500386A0870|83 90|domains
P07500386A0870|125 130|yeast
P07500386A0870|159 166|ability
P07500386A0870|178 182|IRA1
P07500597A0212|7 11|time
P07500597A0212|29 33|BPVs
P07500597A0212|35 38|age
P07500597A0212|57 61|days
P07500597A0212|70 75|years
P07500597A0212|77 81|mean
P07500597A0212|90 92|SD
P07500597A0212|97 102|years
P07500950A0000|2 19|tobacco homologue
P07500950A0000|21 26|trolC
P07500950A0000|35 44|rolC gene
P07500950A0000|52 87|Agrobacterium rhizogenes Ri-plasmid
P07500950A0000|118 141|Nicotiana tabacum L. cv
P07500953A0305|5 21|ADR1 gene dosage
P07500953A0305|36 49|transcription
P07500953A0305|53 58|genes
P07500953A0305|80 88|proteins
P07500953A0305|108 112|copy
P07500953A0305|120 129|ADR1 gene
P07501016T0000|15 25|giga-maser
P07501016T0000|40 59|galaxy TXFS2226-184
P07501458A0578|19 42|C/EBP family inhibitors
P07501458A0578|44 50|Ig/EBP
P07501458A0578|52 55|LIP
P07501458A0578|60 67|CHOP-10
P07501458A0578|74 80|Ig/EBP
P07501700A0000|4 11|effects
P07501700A0000|31 51|pretreatment regimen
P07501700A0000|57 79|monophosphoryl lipid A
P07501700A0000|81 84|MLA
P07501700A0000|89 107|micrograms/kg i.v.
P07501700A0000|164 174|occlusions
P07501700A0000|213 217|dogs
P07501992A0125|6 14|incisors
P07501992A0125|31 48|scanning electron
P07501992A0125|78 99|spectroscopy analysis
P07501992A0125|101 108|SEM-EDS
P07501992A0125|120 130|microscopy
P07501992A0125|162 167|lines
P07501992A0125|171 180|strontium
P07501992A0125|188 199|rat incisor
P07501992A0125|207 213|dentin
P07504171A0715|19 41|growth factor receptor
P07504171A0715|43 49|PDGF-R
P07504171A0715|51 65|phosphopeptide
P07504171A0715|77 84|Tyr-857
P07504171A0715|118 132|Src SH2 domain
P07504171A0715|159 178|PDGF-R binding site
P07504171A0715|183 186|Src
P07504171A1214|20 35|Src SH2 mutants
P07504171A1214|46 64|binding properties
P07504171A1214|90 97|results
P07504171A1214|101 106|light
P07504171A1214|121 147|crystal structure solution
P07504171A1214|156 170|Src SH2 domain
P07504712A0843|6 18|observations
P07504712A0843|24 45|actin plaque assembly
P07504712A0843|59 82|cell substrate adhesion
P07505349A0702|10 19|lethality
P07505349A0702|38 46|resectio
P07505349A0702|52 53|%
P07505349A0702|76 84|survival
P07505349A0702|91 97|months
P07505798A0000|26 31|sites
P07505798A0000|39 66|type A influenza A/Japan/57
P07505798A0000|68 72|H2N2
P07505798A0000|74 87|hemagglutinin
P07505798A0000|89 91|HA
P07505798A0000|119 124|class
P07505798A0000|133 159|histocompatibility complex
P07505798A0000|161 164|MHC
P07505798A0000|194 207|T lymphocytes
P07505798A0000|209 213|CTLs
P07506253A0742|5 13|enhancer
P07506253A0742|33 36|K19
P07506253A0742|41 43|TK
P07506253A0742|50 59|promoters
P07506253A0742|63 73|HeLa cells
P07507187T0000|0 9|Mechanism
P07507187T0000|13 24|enhancement
P07507187T0000|28 42|DNA expression
P07507187T0000|57 74|cointernalization
P07507187T0000|102 112|adenovirus
P07507187T0000|128 139|plasmid DNA
P07507207A0991|19 35|IRF binding site
P07507207A0991|57 71|IRF-2 promoter
P07507207A0991|77 87|expression
P07507207A0991|95 105|IRF-2 gene
P07507207A0991|148 164|IRF-1 expression
P07507458A0250|43 51|patients
P07507458A0250|61 64|aim
P07507458A0250|84 94|prevalence
P07507458A0250|98 115|hepatitis C virus
P07507458A0250|117 120|HCV
P07507458A0250|122 132|antibodies
P07507458A0250|143 148|ELISA
P07507458A0250|153 165|RIBA methods
P07508082A0821|12 20|decrease
P07508082A0821|34 42|activity
P07508082A0821|71 80|bleaching
P07508082A0821|104 112|chlorine
P07508140A0448|0 27|Hepatitis B surface antigen
P07508140A0448|46 54|patients
P07508140A0448|70 96|hepatitis C virus antibody
P07508250A0537|36 47|correlation
P07508250A0537|62 77|selenium intake
P07508250A0537|82 110|liver selenium concentration
P07508250A0537|112 113|r
P07508250A0537|122 123|p
P07508250A0537|140 142|mo
P07508250A0537|146 155|treatment
P07508250A0537|166 185|time liver selenium
P07508250A0537|206 210|time
P07508250A0537|220 231|correlation
P07508250A0537|275 288|investigation
P07508441A0487|0 10|Antibodies
P07508441A0487|73 80|protein
P07508441A0487|96 111|56K autoantigen
P07508441A0487|117 134|HeLa cell extract
P07508441A0487|136 151|cDNA sequencing
P07508441A0487|170 185|56K cDNA shares
P07508441A0487|193 199|degree
P07508441A0487|203 211|homology
P07508441A0487|220 230|nucleotide
P07508441A0487|234 235|%
P07508441A0487|241 260|amino acid sequence
P07508441A0487|266 267|%
P07508441A0487|281 291|annexin XI
P07508441A0487|313 321|56K cDNA
P07508441A0487|340 349|homologue
P07508441A0487|353 363|annexin XI
P07508441A0487|367 373|member
P07508441A0487|381 383|Ca
P07508441A0487|411 433|binding protein family
P07508954A0000|18 36|complex peroxidase
P07508954A0000|38 43|ABC-P
P07508954A0000|45 51|method
P07508954A0000|71 90|Mycobacterium bovis
P07508954A0000|100 107|results
P07508954A0000|149 162|Ziehl-Neelsen
P07508954A0000|164 166|ZN
P07508954A0000|168 177|technique
P07509053A0139|4 8|role
P07509053A0139|18 27|processes
P07509053A0139|46 54|function
P07509053A0139|58 63|c-Myb
P07509053A0139|94 107|establishment
P07509053A0139|129 136|lineage
P07509449A0000|17 21|gene
P07509449A0000|35 53|sarcoma virus CT10
P07509449A0000|64 78|fusion protein
P07509449A0000|80 90|p47gag-crk
P07509449A0000|94 99|v-Crk
P07509449A0000|118 131|Gag sequences
P07509449A0000|150 159|sequences
P07509449A0000|184 204|Src homology regions
P07509449A0000|214 217|SH2
P07509449A0000|222 235|SH3 sequences
P07509450A0705|14 33|methylation pattern
P07509450A0705|41 53|inactivation
P07509450A0705|61 72|HSV tk gene
P07509450A0705|80 91|methylation
P07509450A0705|99 116|cytosine residues
P07509450A0705|128 147|nucleotide sequence
P07509450A0705|174 180|effect
P07509450A0705|184 204|HSV tk gene activity
P07509472A1320|0 10|CONCLUSION
P07509472A1320|17 32|study documents
P07509472A1320|38 48|regression
P07509472A1320|62 80|neovascularization
P07509472A1320|100 126|alpha interferon treatment
P07509624T0000|11 18|mapping
P07509624T0000|26 38|11q23 region
P07509624T0000|51 73|chromosome aberrations
P07509624T0000|83 89|tumors
P07509624T0000|106 125|gel electrophoresis
P07509624T0000|133 138|yeast
P07509624T0000|150 160|chromosome
P07509811A1357|0 4|GTRE
P07509811A1357|6 9|TRE
P07509811A1357|15 35|CRE oligonucleotides
P07509811A1357|69 84|protein binding
P07509811A1357|102 111|congeners
P07509811A1357|121 136|protein binding
P07509811A1357|168 184|oligonucleotides
P07509811A1357|206 210|GTRE
P07509811A1357|212 215|TRE
P07509811A1357|221 241|CRE oligonucleotides
P07509811A1357|263 267|GTRE
P07509811A1357|269 272|TRE
P07509811A1357|278 298|CRE oligonucleotides
P07509811A1357|334 342|proteins
P07509811A1357|357 364|members
P07509811A1357|372 379|Jun/Fos
P07509811A1357|435 456|transcription factors
P07509811A1357|458 466|CREB/ATF
P07509811A1357|468 476|families
P07509811A1357|480 501|transcription factors
P07509811A1357|506 522|chromaffin cells
P07510461A0731|4 11|patient
P07510461A0731|25 43|test abnormalities
P07510635A0479|4 12|antibody
P07510635A0479|14 20|mAb1C2
P07510635A0479|38 45|peptide
P07510635A0479|61 68|epitope
P07510635A0479|100 113|transcription
P07510635A0479|159 168|promoters
P07510635A0479|219 222|Pol
P07510635A0479|229 232|Pol
P07510724A1208|4 15|lymph nodes
P07510724A1208|32 40|patients
P07510724A1208|57 66|arthritis
P07510724A1208|86 93|sarcoid
P07510724A1208|99 110|granulomata
P07510724A1208|142 153|association
P07510724A1208|162 173|sarcoidosis
P07510724A1208|189 198|arthritis
P07511444A0728|0 13|HCV infection
P07511444A0728|39 42|BMT
P07511444A0728|66 77|hepatitis C
P07511444A0728|107 118|hepatitis C
P07511444A0728|126 133|patient
P07511444A0728|147 152|years
P07511444A0728|159 162|BMT
P07511444T0000|0 27|Hepatitis C virus infection
P07511444T0000|33 44|risk factor
P07511444T0000|49 62|liver failure
P07511444T0000|83 90|disease
P07511444T0000|97 124|bone marrow transplantation
P07511496A1511|5 26|plasma concentrations
P07511496A1511|38 48|E-selectin
P07511496A1511|93 104|dysfunction
P07511496A1511|109 114|death
P07511818A0485|33 49|cell populations
P07511818A0485|84 94|production
P07511818A0485|104 107|IFN
P07511818A0485|132 136|rate
P07511818A0485|170 175|cells
P07511818A0485|183 188|cells
P07511818A0485|210 224|control vector
P07511818A0485|242 259|IFN-beta sequence
P07511818A0485|290 297|protein
P07512159A0992|0 11|Improvement
P07512159A0992|19 39|polypyrimidine tract
P07512159A0992|59 78|splicing efficiency
P07512159A0992|89 95|degree
P07512159A0992|138 158|branchpoint mutation
P07512258A0441|0 21|Liver transplantation
P07512258A0441|29 36|patient
P07512258A0441|56 69|complications
P07512258A0441|90 99|PMN count
P07512258A0441|118 124|status
P07512258A0441|132 143|neutropenia
P07512258A0441|161 166|G-CSF
P07512552A0270|0 4|Joys
P07512552A0270|9 11|F.
P07513703T0000|0 10|Activation
P07513703T0000|33 61|protein tyrosine phosphatase
P07513703T0000|63 70|SH-PTP2
P07513703T0000|102 110|peptides
P07513703T0000|124 152|insulin receptor substrate-1
P07514295A0000|0 24|Tyrosine phosphorylation
P07514295A0000|37 45|proteins
P07514295A0000|75 80|event
P07514295A0000|91 114|T-cell antigen receptor
P07514295A0000|116 119|TCR
P07514295A0000|121 132|stimulation
P07514295A0000|176 195|signaling machinery
P07514301A0000|37 51|protein kinase
P07514301A0000|53 56|PKR
P07514301A0000|93 97|role
P07514301A0000|114 121|defense
P07514301A0000|136 145|infection
P07514301A0000|154 162|addition
P07514301A0000|191 212|tumor suppressor gene
P07514301A0000|247 257|properties
P07516337A1119|10 13|Lck
P07516337A1119|56 62|p95Vav
P07516337A1119|72 85|stoichiometry
P07516337A1119|89 96|binding
P07516337A1119|127 139|Jurkat cells
P07516466A1054|3 11|contrast
P07516466A1054|13 22|injection
P07516466A1054|28 35|plasmid
P07516466A1054|52 57|virus
P07516466A1054|67 76|t antigen
P07516466A1054|99 103|PP2A
P07516466A1054|119 127|activity
P07516466A1054|144 169|phosphoprotein substrates
P07516466A1054|178 184|effect
P07516466A1054|192 213|phosphorylation state
P07516466A1054|217 221|CREB
P07516466A1054|252 265|NIH 3T3 cells
P07516469A1025|8 11|Src
P07516469A1025|24 32|proteins
P07516469A1025|72 77|cells
P07516597A1017|21 27|effect
P07516597A1017|43 53|processing
P07516597A1017|61 64|MVE
P07516597A1017|79 98|polyprotein segment
P07516597A1017|121 135|proteinase NS3
P07516597A1017|139 157|antigen processing
P07516597A1017|162 174|presentation
P07516597A1017|182 185|MVE
P07516597A1017|203 221|T cell determinant
P07516866A0000|14 26|PRL receptor
P07516866A0000|28 32|PRLR
P07516866A0000|48 51|DNA
P07516866A0000|57 64|pigeons
P07516866A0000|91 116|pigeon crop sac libraries
P07516866A0000|132 145|transcription
P07516866A0000|159 184|polymerase chain reaction
P07517544A0515|8 12|days
P07517544A0515|28 38|regression
P07517544A0515|58 69|alterations
P07517544A0515|104 116|pancreatitis
P07517544A0515|134 142|recovery
P07517544A0515|160 168|function
P07517544A0515|176 184|pancreas
P07517544A0515|213 219|period
P07517544A0515|223 227|time
P07517544A0515|233 238|L-364
P07517544A0515|281 290|mg/kg/day
P07517869A0411|17 34|dephosphorylation
P07517869A0411|69 76|ability
P07517869A0411|80 91|C/EBP-delta
P07517869A0411|126 135|increases
P07517869A0411|143 151|presence
P07517869A0411|164 186|phosphatase inhibitors
P07517869A0411|204 208|acid
P07517869A0411|213 233|sodium orthovanadate
P07518257A0351|4 13|promoters
P07518257A0351|33 52|S1 nuclease mapping
P07518257A0351|54 56|P1
P07518257A0351|78 80|bp
P07518257A0351|110 114|gene
P07518257A0351|120 122|P2
P07518257A0351|144 146|bp
P07518426A0000|0 13|Interleukin-8
P07518426A0000|15 19|IL-8
P07518426A0000|46 54|mediator
P07518426A0000|75 81|family
P07518426A0000|85 101|C-X-C chemokines
P07518460A0771|13 17|hand
P07518460A0771|19 24|cells
P07518460A0771|38 43|PTP1C
P07518460A0771|67 71|site
P07518460A0771|101 112|mutagenesis
P07518460A0771|140 151|phosphatase
P07518561A0496|27 57|p72syk protein tyrosine kinase
P07518561A0496|92 107|TCR/CD3 complex
P07518561A0496|123 131|tyrosine
P07518561A0496|164 183|receptor triggering
P07518561A0496|192 199|T cells
P07518561A0496|208 214|p56lck
P07518578A0000|17 24|protein
P07518578A0000|28 46|Rous sarcoma virus
P07518578A0000|48 57|pp60v-src
P07518578A0000|83 90|homolog
P07518578A0000|92 101|pp60c-src
P07518578A0000|172 184|localization
P07518578A0000|202 217|binding ability
P07518578A0000|219 228|pp60v-src
P07518578A0000|304 310|matrix
P07518578A0000|320 329|pp60c-src
P07519447T0000|0 12|Organization
P07519447T0000|27 31|gene
P07519447T0000|64 78|oxide synthase
P07519463A0000|42 57|work efficiency
P07519463A0000|59 80|segment work/regional
P07519463A0000|84 95|consumption
P07519463A0000|139 145|inflow
P07519481A1275|10 12|Sl
P07519481A1275|13 16|pan
P07519481A1275|18 20|Sl
P07519481A1275|21 24|pan
P07519481A1275|26 30|mice
P07519481A1275|40 60|follicle development
P07519481A1275|101 106|stage
P07519481A1275|112 118|result
P07519481A1275|130 143|KL expression
P07519481A1275|147 161|follicle cells
P07519481A1275|176 180|role
P07519481A1275|185 190|c-kit
P07519481A1275|194 207|oocyte growth
P07519606A1269|0 13|Anti-NPROSP-C
P07519606A1269|55 66|appearances
P07519606A1269|79 92|proSP-C forms
P07519606A1269|96 111|lamellar bodies
P07519606A1269|116 127|homogenates
P07520098A0211|18 20|Db
P07520098A0211|28 39|B6.CH-2bm13
P07520098A0211|41 45|bm13
P07520098A0211|47 53|strain
P07520098A0211|55 59|part
P07520098A0211|67 72|class
P07520098A0211|75 77|Db
P07520098A0211|97 103|groove
P07520098A0211|119 124|class
P07520098A0211|138 146|sequence
P07521009A0377|6 13|mutants
P07521009A0377|15 19|pms1
P07521009A0377|21 25|pms2
P07521009A0377|30 34|pms3
P07521009A0377|58 66|MW104-1B
P07521009A0377|110 118|plasmids
P07521009A0377|132 146|DNA mismatches
P07521009A0377|148 151|G/T
P07521009A0377|153 156|A/C
P07521009A0377|158 161|G/G
P07521009A0377|163 167|etc.
P07521009A0377|177 183|Kramer
P07521009A0377|192 197|1989a
P07521285A1109|4 12|findings
P07521285A1109|30 39|frequency
P07521285A1109|52 65|nerve lesions
P07521285A1109|75 78|GBS
P07521285A1109|83 87|CIDP
P07521285A1109|133 163|motor conduction abnormalities
P07521285A1109|182 192|assessment
P07521285A1109|205 222|F wave parameters
P07521285A1109|238 254|chronodispersion
P07521285A1109|261 268|latency
P07521285A1109|278 287|amplitude
P07521285A1109|292 300|addition
P07521285A1109|304 311|absence
P07521285A1109|316 331|minimum latency
P07521285A1109|348 353|yield
P07521285A1109|357 371|F wave studies
P07521601A0000|14 28|growth factors
P07521601A0000|62 70|recovery
P07521601A0000|74 86|myelopoiesis
P07521601A0000|107 119|chemotherapy
P07521601A0000|123 138|cancer patients
P07521916T0000|0 7|Effects
P07521916T0000|11 22|alterations
P07521916T0000|41 55|site sequences
P07521916T0000|65 92|immunodeficiency virus type
P07521916T0000|95 106|replication
P07522163T0000|0 12|Presentation
P07522163T0000|18 44|horse cytochrome c peptide
P07522163T0000|57 67|H-2b class
P07522163T0000|76 102|histocompatibility complex
P07522163T0000|104 107|MHC
P07522163T0000|109 118|molecules
P07522163T0000|122 129|C57BL/6
P07522163T0000|157 170|T lymphocytes
P07522163T0000|172 180|presence
P07522163T0000|193 211|MHC anchor residue
P07522163T0000|250 265|CTL recognition
P07523363A0440|24 29|HpaII
P07523363A0440|35 50|fragment island
P07523363A0440|80 90|base pairs
P07523363A0440|106 138|USF2 translation initiation site
P07523710T0000|0 9|Diagnosis
P07523710T0000|23 32|carcinoma
P07523710T0000|38 43|yield
P07523710T0000|47 61|serum prostate
P07523710T0000|71 78|antigen
P07523710T0000|95 106|examination
P07523710T0000|123 138|ultrasonography
P07524265T0000|29 47|stimulating factor
P07524265T0000|49 54|G-CSF
P07524265T0000|56 62|levels
P07524265T0000|66 74|neonates
P07524265T0000|90 103|complications
P07525548A1380|4 11|results
P07525548A1380|23 32|hierarchy
P07525548A1380|36 53|ligand affinities
P07525548A1380|83 91|activity
P07525548A1380|93 101|rsVCAM-1
P07525548A1380|104 124|fibronectin variants
P07525548A1380|136 139|CS1
P07525548A1380|149 169|fibronectin variants
P07525596A0584|71 75|Fpr3
P07525596A0584|107 113|domain
P07525596A0584|141 156|PPIase activity
P07525843A0859|0 9|Dilutions
P07525843A0859|13 17|H-2b
P07525843A0859|21 37|H-2d NP peptides
P07525843A0859|57 61|logs
P07525843A0859|67 82|H-2b NP peptide
P07525843A0859|119 131|target cells
P07525843A0859|149 154|lysis
P07525843A0859|186 196|affinities
P07525843A0859|200 204|H-2b
P07525843A0859|209 213|H-2d
P07525843A0859|220 256|histocompatibility complex molecules
P07525843A0859|267 275|peptides
P07525843A0859|283 290|account
P07525843A0859|305 312|removal
P07525843A0859|316 322|NP CTL
P07525843A0859|330 339|H-2b mice
P07525843A0859|357 364|removal
P07525843A0859|368 377|H-2d mice
P07525843A0859|401 403|NP
P07526609A0736|9 19|expression
P07526609A0736|23 28|sigma
P07526609A0736|36 38|S4
P07526609A0736|42 48|UTR/S1
P07526609A0736|70 92|PKR activator sequence
P07526609A0736|98 100|S1
P07526609A0736|115 118|UTR
P07526609A0736|122 124|S4
P07526609A0736|164 166|S4
P07527168A0524|0 12|Microvessels
P07527168A0524|31 41|x200 field
P07527168A0524|49 52|mm2
P07527168A0524|61 65|area
P07527168A0524|77 89|angiogenesis
P07528028A1192|26 36|cell lines
P07528028A1192|45 73|FGF-1 cell surface receptors
P07528028A1192|100 107|studies
P07528028A1192|123 136|transfectants
P07528028A1192|165 170|FGF-1
P07528028A1192|191 204|transfectants
P07528028A1192|223 231|ABSTRACT
P07528028A1192|249 254|WORDS
P07528325A0165|7 14|studies
P07528325A0165|52 63|GH receptor
P07528325A0165|78 83|Stat1
P07528325A0165|99 119|transcription factor
P07528325A0165|133 141|tyrosine
P07528325A0165|181 188|nucleus
P07528325A0165|226 239|DNA sequences
P07528325A0165|252 267|gene expression
P07528531A0904|9 19|infections
P07528531A0904|21 26|G-CSF
P07528531A0904|59 64|cells
P07528531A0904|66 68|rs
P07528531A0904|77 78|P
P07528531A0904|94 111|blood cell counts
P07528531A0904|113 115|rs
P07528531A0904|124 125|P
P07528531A0904|135 146|neutrophils
P07528531A0904|148 150|rs
P07528531A0904|159 160|P
P07528531A0904|173 176|CRP
P07528531A0904|178 180|rs
P07528531A0904|189 190|P
P07528667A0834|6 22|initiation sites
P07528667A0834|37 46|positions
P07528746A1049|0 26|Phosphoamino acid analysis
P07528746A1049|43 57|ASGPR subunits
P07528746A1049|69 72|Ser
P07528746A1049|73 74|P
P07528746A1049|112 113|%
P07528746A1049|119 122|Thr
P07528746A1049|123 124|P
P07528746A1049|153 154|%
P07528746A1049|156 173|phosphoamino acid
P07528746A1049|182 193|polypeptide
P07528746A1049|212 220|presence
P07528746A1049|224 227|Tyr
P07528746A1049|228 229|P
P07528746A1049|247 248|%
P07528746A1049|253 257|RHL1
P07528772A0616|33 45|requirements
P07528772A0616|50 68|ZAP-70 interaction
P07528772A0616|78 81|TCR
P07528772A0616|98 111|binding assay
P07528772A0616|130 171|glutathione S-transferase fusion proteins
P07528772A0616|187 190|NH2
P07528772A0616|213 224|SH2 domains
P07528772A0616|228 234|ZAP-70
P07528772A0616|258 266|peptides
P07528772A0616|276 284|sequence
P07528772A0616|304 310|region
P07528772A0616|318 332|TCR zeta chain
P07528772A0616|334 346|TCR zeta cyt
P07528772A0616|362 370|TCR zeta
P07528772A0616|375 397|CD3 epsilon TAM motifs
P07528772A1539|16 24|tyrosine
P07528772A1539|40 52|TAM peptides
P07528772A1539|109 120|SH2 domains
P07528772A1539|124 130|ZAP-70
P07529124A0119|22 31|structure
P07529124A0119|35 37|RT
P07529124A0119|79 90|heterodimer
P07529124A0119|128 136|subunits
P07529124A0119|148 155|weights
P07529124A0119|159 162|kDa
P07529124A0119|170 173|kDa
P07529124A0119|205 225|amino acid sequences
P07529124A0119|227 235|residues
P07529504A0000|36 51|characteristics
P07529504A0000|79 109|X-ray contrast agent iopromide
P07529504A0000|111 120|Ultravist
P07529504A0000|122 125|CAS
P07529504A0000|168 175|studies
P07529516A0474|15 23|patients
P07529516A0474|62 66|dose
P07529516A0474|70 74|EDXR
P07529516A0474|79 88|mg/m2/day
P07530128A0578|41 50|serum PSA
P07530128A0578|59 64|ng/ml
P07530502A0974|0 8|Addition
P07530502A0974|38 41|SLF
P07530502A0974|45 62|SI4-h220 cultures
P07530502A0974|72 81|reduction
P07530502A0974|98 114|c-kit expression
P07530502A0974|123 142|protein degradation
P07530502T0000|15 27|Steel factor
P07530502T0000|52 78|tyrosine kinase activation
P07530502T0000|90 99|life span
P07530502T0000|103 108|c-kit
P07530502T0000|122 129|protein
P07530502T0000|147 151|form
P07530549A0956|0 8|Analysis
P07530549A0956|16 25|sequences
P07530549A0956|35 40|BLAST
P07530549A0956|45 59|GRAIL programs
P07530549A0956|92 100|evidence
P07530549A0956|121 127|clones
P07530549A0956|143 152|sequences
P07530549A0956|173 179|clones
P07530549A0956|202 211|sequences
P07530549A0956|223 231|portions
P07530549A0956|239 244|genes
P07531321A0369|0 8|Patients
P07531321A0369|28 40|PVC/24 hours
P07531321A0369|59 71|distribution
P07531321A0369|75 78|PVC
P07531321A0369|83 96|CI evaluation
P07532278A0833|0 7|Horvath
P07532278A0833|9 11|I.
P07533527A0128|0 10|Cell lines
P07533527A0128|28 34|tumors
P07533527A0128|72 85|hybridization
P07533527A0128|94 100|status
P07533527A0128|126 136|chromosome
P07533527A0128|144 147|PCR
P07533527A0128|152 163|marker loss
P07533758A1038|4 24|amino acid sequences
P07533758A1038|42 46|RfbA
P07533758A1038|51 64|RfbB homologs
P07533758A1038|72 82|identities
P07533758A1038|90 91|%
P07533758A1038|97 98|%
P07533758A1038|105 115|similarity
P07533758A1038|125 126|%
P07533758A1038|132 133|%
P07533758A1038|140 150|similarity
P07533858A1503|18 39|alanine substitutions
P07533858A1503|43 50|proline
P07533858A1503|73 86|substitutions
P07533858A1503|102 117|oligomerization
P07533858A1503|122 131|transport
P07533858A1503|135 143|GP64 EFP
P07533880T0000|4 16|FinO protein
P07533880T0000|20 33|IncF plasmids
P07533880T0000|40 44|FinP
P07533880T0000|55 58|RNA
P07533880T0000|67 73|target
P07533880T0000|75 84|traJ mRNA
P07533880T0000|99 115|duplex formation
P07534285A0155|8 13|paper
P07534285A0155|29 43|ligand binding
P07534285A0155|52 76|tyrosine phosphorylation
P07534285A0155|80 90|BaF3 cells
P07534285A0155|124 136|Mpl receptor
P07534285A0155|138 147|BaF3/mMpl
P07534286A0842|2 23|chicken paxillin cDNA
P07534286A0842|69 76|protein
P07534286A0842|93 94|%
P07534286A0842|114 123|paxil-lin
P07534297A0141|25 50|pair HindIII DNA fragment
P07534297A0141|60 66|region
P07534297A0141|89 109|AP endonuclease gene
P07534297A0141|111 114|APE
P07534297A0141|123 156|chloramphenicol acetyltransferase
P07534297A0141|158 161|CAT
P07534297A0141|163 167|gene
P07534306A0444|30 46|GrsA derivatives
P07534306A0444|89 99|properties
P07534306A0444|107 123|deletion mutants
P07534306A0444|153 160|studies
P07534306A0444|185 206|amino acid activation
P07534306A0444|208 236|carboxyl thioester formation
P07534306A0444|246 253|ability
P07534306A0444|287 300|phenylalanine
P07534306A0444|306 307|L
P07534306A0444|316 324|D-isomer
P07535593A0714|0 3|CD7
P07535593A0714|5 8|CD3
P07535593A0714|10 27|T-cell precursors
P07535593A0714|36 52|V delta 2D delta
P07535593A0714|55 69|rearrangements
P07535768A1076|0 9|HVH2 mRNA
P07535768A1076|20 38|expression pattern
P07535768A1076|53 58|CL100
P07535768A1076|66 75|homologue
P07535768A1076|79 89|mouse MKP1
P07535768A1076|95 99|PAC1
P07535768A1076|127 150|MAP kinase phosphatases
P07537267A2094|6 10|data
P07537267A2094|30 39|sequences
P07537267A2094|70 80|breakpoint
P07537267A2094|88 103|HPFH-3 deletion
P07537267A2094|122 131|structure
P07537267A2094|140 148|function
P07537267A2094|155 163|enhancer
P07537267A2094|198 209|specificity
P07537267A2094|223 241|gamma-globin genes
P07537267A2094|272 282|expression
P07537267A2094|296 300|life
P07537362A1112|8 19|association
P07537362A1112|28 57|Shb-SH3 domain proteins v-Src
P07537362A1112|62 66|Eps8
P07537362A1112|83 104|coimmunoprecipitation
P07537736A0453|4 11|results
P07537736A0453|26 37|interaction
P07537736A0453|46 50|Jak2
P07537736A0453|55 59|PRLR
P07537736A0453|84 92|sequence
P07537736A0453|100 108|membrane
P07537736A0453|118 124|region
P07537736A0453|132 140|receptor
P07537736A0453|181 188|members
P07537736A0453|196 225|cytokine receptor superfamily
P07537851A0000|0 13|Transcription
P07537851A0000|30 52|cell adhesion molecule
P07537851A0000|56 62|VCAM-1
P07537851A0000|64 68|gene
P07537851A0000|84 89|cells
P07537851A0000|104 122|lipopolysaccharide
P07537851A0000|144 172|cytokines interleukin-1 beta
P07537851A0000|177 204|tumor necrosis factor alpha
P07537851A0000|206 215|TNF-alpha
P07537851A0891|0 11|Experiments
P07537851A0891|29 37|proteins
P07537851A0891|50 57|p50/p65
P07537851A0891|82 83|I
P07537851A0891|84 85|Y
P07537851A0891|87 94|protein
P07537851A0891|125 132|binding
P07537851A0891|136 141|IRF-1
P07537851A0891|149 158|VCAM1 IRF
P07537851A0891|167 171|site
P07537851A0891|181 186|IRF-1
P07537851A0891|214 217|p50
P07537851A0891|247 248|I
P07537851A0891|249 250|Y
P07537851A0891|252 259|protein
P07538068A1094|15 22|results
P07538068A1094|35 50|control element
P07538068A1094|52 54|AX
P07538068A1094|84 92|boundary
P07538068A1094|96 110|Hox expression
P07538068A1094|129 144|Hoxa-7 enhancer
P07538122A0800|8 14|report
P07538122A0800|31 40|isolation
P07538122A0800|46 58|Fab fragment
P07538122A0800|60 66|Fab A8
P07538122A0800|92 100|affinity
P07538122A0800|109 117|receptor
P07538122A0800|123 125|nM
P07538173A0307|0 9|MBP-Rep68
P07538173A0307|25 50|DNA-RNA helicase activity
P07538173A0307|60 74|ATP hydrolysis
P07538173A0307|83 91|presence
P07538173A0307|95 98|Mg2
P07538173A0307|100 104|ions
P07538173A0307|137 145|strength
P07538818A0197|21 28|regions
P07538818A0197|39 65|growth signal transduction
P07538818A0197|69 76|hG-CSFR
P07538818A0197|78 87|deletions
P07538818A0197|105 129|amino acid substitutions
P07538818A0197|167 173|domain
P07538818A0197|177 184|hG-CSFR
P07538818A0197|201 206|cDNAs
P07538818A0197|240 253|interleukin-3
P07538818A0197|255 259|IL-3
P07538818A0197|271 276|Ba/F3
P07538818A0197|281 296|FDCP cell lines
P07539119A0291|42 51|mutations
P07539119A0291|59 78|c-abl kinase domain
P07539119A0291|82 94|NH2-terminus
P07539119A0291|100 114|G128R mutation
P07539119A0291|123 137|transformation
P07539119A0291|180 192|G128R mutant
P07539119A0291|217 222|cells
P07539119A0291|235 242|reasons
P07539119A0985|5 14|mutations
P07539119A0985|36 43|binding
P07539119A0985|51 65|Abl SH3 domain
P07539119A0985|82 97|target proteins
P07539119A0985|118 123|assay
P07539314T0000|0 7|Changes
P07539314T0000|23 28|gills
P07539314T0000|49 55|chanos
P07539314T0000|66 77|fingerlings
P07539314T0000|90 98|exposure
P07539314T0000|102 114|nifurpirinol
P07539314T0000|116 124|Furanace
P07539314T0000|126 132|P-7138
P07540607A0709|0 11|Retreatment
P07540607A0709|23 27|dogs
P07540607A0709|64 72|response
P07540607A0709|82 96|immunoglobulin
P07540773A0576|4 10|levels
P07540773A0576|14 17|NSE
P07540773A0576|22 25|MBP
P07540773A0576|33 37|IJVB
P07540773A0576|68 71|PVB
P07540866A1069|17 31|insulin effect
P07540866A1069|44 61|ras GTP formation
P07540866A1069|66 85|MAP kinase activity
P07540866A1069|104 117|A/K1018 cells
P07540866A1069|149 159|Y/F2 cells
P07541589A0652|12 21|variables
P07541589A0652|31 44|cancer volume
P07541589A0652|57 62|grade
P07541589A0652|73 84|penetration
P07541589A0652|94 110|vesicle invasion
P07541589A0652|116 137|lymph node metastasis
P07541912A0485|0 17|Sequence analysis
P07541912A0485|27 34|regions
P07541912A0485|44 52|CAAT box
P07541912A0485|65 72|exon 1a
P07541912A0485|82 101|G-C content regions
P07541912A0485|114 116|P1
P07541912A0485|121 123|P2
P07542577A0438|4 19|fusion proteins
P07542577A0438|35 40|ELISA
P07542577A0438|45 55|reactivity
P07542577A0438|63 68|panel
P07542577A0438|86 90|sera
P07542577A0438|94 99|order
P07542577A0438|114 120|nature
P07542577A0438|128 136|epitopes
P07542616A0313|0 5|GCD10
P07542616A0313|58 67|repressor
P07542616A0313|71 75|GCN4
P07542616A0486|0 5|GCD10
P07542616A0486|12 15|RNA
P07542616A0486|59 67|evidence
P07542616A0486|108 115|subunit
P07542616A0486|119 144|yeast initiation factor-3
P07542616A0486|146 151|eIF-3
P07542616A0486|154 159|eIF-3
P07542616A0486|178 185|complex
P07542616A0486|202 224|translation initiation
P07542616A0486|255 260|steps
P07542698A0137|0 7|Sources
P07542698A0137|11 16|noise
P07542698A0137|26 33|signals
P07542698A0137|52 64|preparations
P07542698A0137|97 109|probe RH-414
P07543592A0624|27 33|mutant
P07543592A0624|54 64|E5 protein
P07543592A0624|76 84|receptor
P07543592A0624|97 130|receptor tyrosine phosphorylation
P07543592A0624|135 150|down-regulation
P07543684A1027|17 21|cAMP
P07543684A1027|38 41|PKA
P07543684A1027|59 68|regulator
P07543684A1027|78 98|CFTR gene expression
P07543684A1027|118 127|induction
P07543684A1027|131 135|CFTR
P07543684A1027|150 160|cell types
P07543868A0414|12 29|restriction sites
P07543868A0414|72 85|cDNA fragment
P07543868A0414|123 131|sequence
P07543868A0414|150 154|poly
P07543868A0414|155 156|A
P07543868A0414|158 162|tail
P07544357A0808|5 10|PPC-1
P07544357A0808|15 28|ALVA-31 cells
P07544357A0808|37 50|tumorigenesis
P07544357A0808|55 67|invasiveness
P07544357A0808|76 80|mice
P07544357A0808|90 101|LNCap cells
P07544357A0808|127 136|phenotype
P07544357A0808|151 162|correlation
P07544357A0808|171 183|CD44 variant
P07544357A0808|185 190|CD44v
P07544357A0808|192 202|expression
P07544357A0808|218 241|prostate tumor behavior
P07545510A0735|4 16|gene product
P07545510A0735|20 24|cotS
P07545510A0735|58 65|Cot40-2
P07545510A0735|69 77|SDS-PAGE
P07545510A0735|82 96|immunoblotting
P07545510A0735|138 145|plasmid
P07545510A0735|161 172|cotS region
P07545920A1336|9 14|genes
P07545920A1336|27 37|hsiggll150
P07545920A1336|42 52|hsiggll295
P07545920A1336|93 96|DNA
P07546256A0000|32 37|study
P07546256A0000|66 74|injuries
P07546256A0000|82 90|children
P07546256A0000|111 115|unit
P07546256A0000|124 128|care
P07546256A0000|132 142|Casablanca
P07546293A0968|4 11|results
P07546293A0968|25 40|protein binding
P07546293A0968|57 66|sequences
P07546293A0968|85 95|expression
P07546294A0000|4 18|RAD6/UBC2 gene
P07546294A0000|81 87|enzyme
P07546294A0000|100 110|DNA repair
P07546294A0000|120 131|mutagenesis
P07546294A0000|137 148|sporulation
P07546794A0100|0 16|Echocardiography
P07546794A0100|54 62|collapse
P07546794A0100|64 68|RVDC
P07546794A0100|87 92|signs
P07546794A0100|104 113|tamponade
P07547220A0229|12 32|screening programmes
P07547220A0229|38 53|Haemoccult test
P07547220A0229|70 76|slides
P07547220A0229|83 87|test
P07547220A0229|127 132|slide
P07547500A0066|28 42|fusion protein
P07547500A0066|44 52|GAL4-p40
P07547500A0066|81 87|domain
P07547500A0066|91 95|GAL4
P07547500A0066|100 109|sequences
P07547500A0066|113 136|chicken l kappa B-alpha
P07547500A0066|138 141|p40
P07547500A0066|152 158|growth
P07547500A0066|166 171|yeast
P07547510A0261|49 54|sites
P07547510A0261|67 86|HNF-3 beta promoter
P07547510A0261|124 131|factors
P07547510A0261|181 185|site
P07547510A0261|203 215|binding site
P07547510A0261|236 242|factor
P07547510A0261|244 254|LF-H3 beta
P07547510A0261|289 315|HNF-3 beta gene expression
P07547510A0261|319 330|hepatocytes
P07548425A0000|16 20|cats
P07548425A0000|26 33|effects
P07548425A0000|46 52|inputs
P07548425A0000|77 83|nerves
P07548425A0000|101 106|nerve
P07548425A0000|108 111|Sur
P07548425A0000|160 183|tail muscle motoneurons
P07548425A0000|221 230|lesioning
P07548425A0000|234 244|S2-3 level
P07548858A0000|4 13|flow rate
P07548858A0000|17 26|phosphate
P07548858A0000|36 42|saline
P07548858A0000|51 57|dermis
P07548858A0000|76 84|function
P07548858A0000|96 104|pressure
P07549005A0530|9 30|parallax measurements
P07549005A0530|52 60|collapse
P07549005A0530|64 77|Epon sections
P07549005A0530|92 97|place
P07550216A0195|23 29|limits
P07550216A0195|31 38|latency
P07551787A0917|4 11|outcome
P07551787A0917|19 31|optimization
P07551787A0917|51 55|plan
P07551787A0917|68 81|investigation
P07551787A0917|96 103|results
P07551787A0917|151 173|radiotherapy technique
P07552974A0217|9 21|requirements
P07552974A0217|41 52|amino acids
P07552974A0217|54 63|glutamine
P07552974A0217|69 77|arginine
P07553942A0810|4 20|pea rps10 intron
P07553942A0810|38 45|introns
P07553942A0810|49 54|rrn26
P07553942A0810|59 63|cox3
P07553942A0810|71 81|Marchantia
P07553942A0810|96 102|genome
P07553942A0810|114 135|Marchantia rps10 gene
P07553942A0810|145 151|intron
P07554541A0587|12 16|care
P07554541A0587|20 31|CHF patient
P07554541A0587|45 56|recognition
P07554541A0587|61 71|management
P07554541A0587|81 105|electrolyte disturbances
P07555373A0000|0 15|Serum magnesium
P07555373A0000|22 30|patients
P07555373A0000|46 55|neoplasms
P07555373A0000|69 78|cisplatin
P07555373A0000|89 97|controls
P07557091A0314|0 7|METHODS
P07557091A0314|9 13|rHb1
P07557091A0314|25 38|serum albumin
P07557091A0314|86 96|volunteers
P07557276A0526|0 24|Alanine aminotransferase
P07557276A0526|26 29|ALT
P07557276A0526|31 37|levels
P07557276A0526|64 70|months
P07557276A0526|78 86|patients
P07557276A0526|91 102|hepatitis B
P07557276A0526|109 118|infection
P07557387A0241|8 13|study
P07557387A0241|39 43|role
P07557387A0241|47 57|C/EBP beta
P07557387A0241|87 94|program
P07557387A0241|113 123|C/EBP beta
P07557387A0241|142 161|NIH-3T3 fibroblasts
P07557424A0124|0 4|XYL1
P07557424A0124|40 52|fusion clone
P07557424A0124|61 65|lacZ
P07557424A0124|80 94|fusion library
P07557446T0000|8 19|transcripts
P07557446T0000|43 53|VCSA1 gene
P07557446T0000|69 77|splicing
P07557446T0000|82 86|poly
P07557446T0000|87 88|A
P07557446T0000|90 100|processing
P07557446T0000|108 111|rat
P07557446T0000|126 131|gland
P07557717A0184|9 17|division
P07557717A0184|25 43|chest wall muscles
P07557717A0184|58 67|diathermy
P07557717A0184|94 98|pain
P07557717A0184|103 112|morbidity
P07558263T0000|0 7|Closure
P07558263T0000|35 62|guillotine amputation wound
P07558263T0000|87 93|device
P07558583A0562|4 9|study
P07558583A0562|31 40|synthesis
P07558583A0562|49 60|derivatives
P07558583A0562|69 77|sequence
P07558583A0562|81 86|order
P07558583A0562|102 120|peptide substrates
P07558583A0562|138 147|detection
P07558583A0562|164 188|tyrosine kinase activity
P07558583A0562|214 224|inhibitors
P07558583A0562|243 248|class
P07558583A0562|252 259|enzymes
P07559233A0534|0 25|Citrate synthase activity
P07559233A0534|54 58|head
P07559233A0534|62 63|%
P07559233A0534|65 66|P
P07559233A0534|93 97|head
P07559233A0534|101 102|%
P07559233A0534|104 105|P
P07559233A0534|122 144|triceps brachii muscle
P07559233A0534|148 154|R rats
P07559233A0534|181 185|head
P07559233A0534|189 190|%
P07559233A0534|192 193|P
P07559347A0000|4 14|expression
P07559347A0000|31 43|operon bglPH
P07559347A0000|47 64|Bacillus subtilis
P07559347A0000|86 90|bglP
P07559347A0000|92 96|lacZ
P07559347A0000|113 120|fusions
P07559355A0066|26 31|genes
P07559355A0066|46 61|urease activity
P07559355A0066|114 126|organization
P07559355A0066|131 141|regulation
P07559355A0066|154 159|genes
P07559355A0066|171 191|Proteus gene cluster
P07559355A0066|221 227|detail
P07559356T0000|4 19|hypBFCDE operon
P07559356T0000|25 62|Rhizobium leguminosarum biovar viciae
P07559356T0000|93 101|promoter
P07559356T0000|115 126|mutagenesis
P07559356T0000|134 143|fnrN gene
P07559402A0622|22 24|VT
P07559402A0622|26 33|peptide
P07559402A0622|69 85|protein kinase C
P07559402A0622|87 90|PKC
P07559402A0622|113 129|protein kinase A
P07559402A0622|131 134|PKA
P07559430A0909|0 2|R.
P07559478A0389|15 22|O'Neill
P07559478A0389|24 26|T.
P07559488A0440|0 19|Control experiments
P07559488A0440|37 51|fusion protein
P07559488A0440|63 84|affinity binding site
P07559488A0440|89 106|estradiol-17 beta
P07559488A0440|143 156|reporter gene
P07559488A0440|160 165|yeast
P07559488A0440|186 193|type ER
P07559510A0000|9 43|Micrococcus luteus UV endonuclease
P07559510A0000|78 84|enzyme
P07559510A0000|99 107|homology
P07559510A0000|122 136|endonuclease V
P07559510A0000|142 158|bacteriophage T4
P07559510A0000|160 166|Gordon
P07559510A0000|168 170|L.
P07559524A0000|18 27|oncogenes
P07559524A0000|32 46|growth factors
P07559524A0000|55 75|G1 phase progression
P07559524A0741|0 27|Cyclin D1 promoter activity
P07559524A0741|46 60|overexpression
P07559524A0741|82 96|protein kinase
P07559524A0741|98 105|p41MAPK
P07559524A0741|110 117|c-Ets-2
P07559524A0741|142 152|base pairs
P07559555A0557|8 11|ERM
P07559555A0557|16 21|c-Jun
P07559555A0557|52 59|EBS-CRE
P07559555A0557|95 102|complex
P07559563A0282|10 18|residues
P07559563A0282|42 45|Ca2
P07559563A0282|61 69|activity
P07559639A0996|3 11|addition
P07559639A0996|17 39|R206S HSF substitution
P07559639A0996|78 88|activation
P07559639A0996|96 109|consensus HSE
P07559639A0996|111 115|HSE2
P07559640A1230|8 13|bases
P07559640A1230|42 45|end
P07559640A1230|53 60|element
P07559640A1230|96 104|function
P07559640A1230|110 121|UAS element
P07559640A1230|137 142|bases
P07559640A1230|170 180|core motif
P07559650A0558|6 13|results
P07559650A0558|32 41|PCNA gene
P07559650A0558|54 65|target gene
P07559650A0558|69 72|E2F
P07560137T0000|13 24|sensitivity
P07560137T0000|32 56|MMPI-2 depression scales
P07560137T0000|61 70|subscales
P07560662A0496|6 14|recovery
P07560662A0496|29 45|saline challenge
P07562775A0596|4 9|range
P07562775A0596|13 24|eosinophils
P07562775A0596|34 35|%
P07562775A0596|43 49|number
P07562775A0596|70 81|blood cells
P07562775A0596|88 93|nadir
P07562775A0596|96 97|%
P07563072A0773|0 11|Comparisons
P07563072A0773|15 38|rrnB P1-lacZ expression
P07563072A0773|52 64|ppGpp levels
P07563072A0773|88 92|rpoD
P07563072A0773|93 98|P504L
P07563072A0773|127 143|hypersensitivity
P07563072A0773|147 152|ppGpp
P07563076A0766|6 21|intron chimeras
P07563076A0766|43 52|sequences
P07563076A0766|61 69|elements
P07563076A0766|86 98|splice sites
P07563076A0766|130 138|activity
P07563076A0766|160 168|portions
P07563076A0766|194 199|cores
P07563076A0766|203 206|ai4
P07563076A0766|211 214|bi4
P07563076A0766|236 241|cores
P07563076A0766|257 264|targets
P07563076A0766|272 289|splicing proteins
P07563090A0124|49 62|DNA synthesis
P07563090A0124|70 87|yeast Ty1 element
P07563090A0124|108 113|sites
P07563090A0124|132 140|boundary
P07563090A0124|165 171|repeat
P07563090A0124|173 177|PPT1
P07563090A0124|192 198|middle
P07563090A0124|206 214|pol gene
P07563090A0124|222 231|integrase
P07563090A0124|239 247|sequence
P07563090A0124|249 253|PPT2
P07563090A0624|0 16|Characterization
P07563090A0624|27 31|ends
P07563090A0624|51 64|DNA fragments
P07563090A0624|95 103|fragment
P07563090A0624|124 128|PPT2
P07563090A0624|177 185|majority
P07563090A0624|213 226|DNA fragments
P07563090A0624|234 238|copy
P07563090A0624|259 278|primer binding site
P07563090A0624|282 291|agreement
P07563090A0624|310 315|model
P07563090A0624|338 363|RNA reverse transcription
P07563994A0488|4 12|patients
P07563994A0488|24 28|VTLB
P07563994A0488|65 70|times
P07563994A0488|72 76|VTLB
P07563994A0488|93 96|min
P07563994A0488|101 104|OLB
P07563994A0488|121 124|min
P07563994A0488|126 127|p
P07563994A0488|145 155|blood loss
P07563994A0488|157 161|VTLB
P07563994A0488|176 178|ml
P07563994A0488|182 185|OLB
P07563994A0488|201 203|ml
P07563994A0488|205 206|p
P07564004A0292|7 14|minutes
P07564004A0292|21 37|Cr2O3 inhalation
P07564004A0292|39 45|FEV1.0
P07564004A0292|65 66|%
P07564210A0557|38 45|regimen
P07564210A0557|56 67|anaesthesia
P07564210A0557|72 81|analgesia
P07564210A0557|85 89|pigs
P07564210A0557|102 103|h
P07564210A0557|129 134|signs
P07565031A0454|7 20|food products
P07565031A0454|44 58|V. cholerae O1
P07565031A0454|60 65|Ogawa
P07565031A0454|95 102|strains
P07565031A0454|104 111|yoghurt
P07565031A0454|113 125|cream cheese
P07565031A0454|127 144|apricot marmelade
P07565031A0454|146 149|hip
P07565031A0454|155 164|marmelade
P07565031A0454|166 176|mayonnaise
P07565031A0454|186 191|pasta
P07565031A0454|197 206|empanadas
P07565031A0454|227 239|meat sausage
P07565031A0454|241 245|meat
P07565031A0454|250 265|spinach ravioli
P07565031A0454|267 276|margarine
P07565031A0454|278 290|milk dessert
P07565031A0454|302 307|cocoa
P07565031A0454|309 323|milk confiture
P07565031A0454|325 331|starch
P07565031A0454|336 345|additives
P07565031A0454|348 355|lettuce
P07565031A0454|357 366|tuna fish
P07565031A0454|368 375|ricotta
P07565031A0454|391 395|milk
P07565049A1032|45 52|outline
P07565049A1032|104 106|NB
P07565049A1032|137 140|age
P07565049A1032|144 148|term
P07565049A1032|183 189|weight
P07565049A1032|210 212|g.
P07565104A0084|4 14|expression
P07565104A0084|22 32|pilin gene
P07565104A0084|34 38|tcpA
P07565104A0084|58 62|ToxR
P07565104A0084|72 76|ToxT
P07565113A0000|31 48|transposon Tn4451
P07565113A0000|79 87|deletion
P07565113A0000|97 118|parent plasmid plP401
P07565113A0000|122 145|Clostridium perfringens
P07565113A0000|170 178|excision
P07565113A0000|194 202|plasmids
P07565669T0000|0 10|Ras p21Val
P07565669T0000|20 30|myogenesis
P07565669T0000|52 63|DNA binding
P07565669T0000|83 93|activities
P07565669T0000|133 140|factors
P07565672A0798|3 8|cells
P07565672A0798|36 46|expression
P07565672A0798|50 55|arg-2
P07565672A0798|60 65|cpc-1
P07565672A0798|81 91|expression
P07565672A0798|95 100|cox-5
P07565672A0798|145 155|components
P07565685A0420|4 21|peptide sequences
P07565685A0420|38 44|factor
P07565685A0420|57 67|GABP alpha
P07565685A0420|72 81|GABP beta
P07565685A0420|89 92|Ets
P07565685A0420|97 109|Notch motifs
P07565688A0797|0 29|Immunofluorescence microscopy
P07565688A0797|34 61|cell fractionation analyses
P07565688A0797|86 93|protein
P07565688A0797|139 146|protein
P07565688A0797|171 180|cytoplasm
P07565688A0797|185 192|nucleus
P07565688A0797|202 207|cells
P07565688T0000|0 10|Expression
P07565688T0000|15 25|regulation
P07565688T0000|29 39|interferon
P07565688T0000|74 93|adenosine deaminase
P07565688T0000|105 110|cells
P07565688T0000|112 120|evidence
P07565688T0000|129 134|forms
P07565688T0000|142 151|deaminase
P07565709A0000|0 17|T-cell hybridomas
P07565709A0000|19 29|thymocytes
P07565709A0000|35 42|T cells
P07565709A0000|79 89|cell death
P07565709A0000|93 103|activation
P07565709A0000|116 131|T-cell receptor
P07565712A0286|0 9|Deletions
P07565712A0286|31 40|LYS2 gene
P07565712A0286|50 53|set
P07565712A0286|71 78|inserts
P07565712A0286|93 100|inserts
P07565712A0286|118 127|potential
P07565712A0286|142 151|structure
P07565712A0286|167 183|quasipalindromes
P07565713A0634|0 14|Overexpression
P07565713A0634|18 22|SCS1
P07565713A0634|47 64|HSP60-null allele
P07565713A0634|82 93|suppression
P07565713A0634|126 140|Hsp60 activity
P07565720A0256|4 22|DNA binding domain
P07565720A0256|26 30|NirA
P07565720A0256|50 64|fusion protein
P07565720A0256|74 99|glutathione S-transferase
P07565720A0256|103 124|Schistosoma japonicum
P07565723A0200|4 10|kinase
P07565723A0200|43 58|phosphorylation
P07565723A0200|66 69|CTD
P07565723A0200|85 91|growth
P07565723A0200|96 111|differentiation
P07565731A1629|10 15|model
P07565731A1629|33 49|mRNA degradation
P07565731A1629|72 76|role
P07565731A1629|111 129|ribonucleoproteins
P07565731A1629|146 154|proteins
P07565736A2134|29 40|C/EBP alpha
P07565736A2134|61 91|GM-CSF receptor alpha promoter
P07565736A2134|106 111|cells
P07565740T0000|0 11|Endocytosis
P07565740T0000|25 36|degradation
P07565740T0000|44 50|plasma
P07565740T0000|70 74|Pdr5
P07565740T0000|87 95|cassette
P07565740T0000|106 117|transporter
P07565775A1265|11 20|mutations
P07565775A1265|24 30|motifs
P07565775A1265|44 45|V
P07565775A1265|62 69|effects
P07565775A1265|77 85|affinity
P07565775A1265|89 95|enzyme
P07565775A1265|100 103|GTP
P07565775A1265|109 113|rate
P07565775A1265|126 135|catalysis
P07565775A1265|137 150|EpG formation
P07565775A1265|160 168|transfer
P07565775A1265|172 175|GMP
P07565775A1265|181 187|enzyme
P07565775A1265|191 194|RNA
P07565775T0000|11 19|analysis
P07565775T0000|23 27|mRNA
P07565775T0000|36 42|enzyme
P07565775T0000|54 65|amino acids
P07565775T0000|78 89|GTP binding
P07565775T0000|108 117|formation
P07565775T0000|123 135|GMP transfer
P07565775T0000|139 142|RNA
P07565776A0612|0 10|Disruption
P07565776A0612|18 22|HOG1
P07565776A0612|27 37|PBS2 genes
P07565776A0612|58 66|decrease
P07565776A0612|74 92|HSP12 inducibility
P07565776A0612|109 114|cells
P07565776A0612|124 138|overproduction
P07565776A0612|142 146|Hog1
P07565776A0612|167 175|increase
P07565776A0612|197 203|levels
P07565776A0612|211 216|shift
P07565776A0612|227 245|salt concentration
P07565797A0116|0 8|Deletion
P07565797A0116|12 24|inactivation
P07565797A0116|28 32|CRY1
P07565797A0116|66 72|levels
P07565797A0116|76 85|CRY2 mRNA
P07567079A0014|7 13|method
P07567079A0014|17 27|separation
P07567079A0014|31 50|Cryptosporidium spp
P07567079A0014|52 59|oocysts
P07567079A0014|65 70|feces
P07567079A0014|82 89|percoll
P07567079A0014|104 120|density gradient
P07567079A0014|132 138|method
P07567079A0014|142 148|choice
P07567079A0014|169 176|numbers
P07567079A0014|180 187|oocysts
P07567079A0014|191 200|C. parvum
P07567079A0014|215 228|contamination
P07567300T0000|15 26|enterotoxin
P07567300T0000|29 40|involvement
P07567300T0000|48 55|illness
P07567300T0000|79 86|patient
P07567830A0072|0 7|METHODS
P07567830A0072|68 74|curves
P07567830A0072|92 100|patients
P07567830A0072|116 122|tremor
P07567830A0072|127 132|males
P07567830A0072|137 144|females
P07567830A0072|146 149|age
P07567830A0072|164 169|years
P07567979A1266|4 12|findings
P07567979A1266|30 35|basis
P07567979A1266|44 55|development
P07567979A1266|59 65|assays
P07567979A1266|84 91|ligands
P07567979A1266|95 110|testis receptor
P07567979A1266|117 122|hERR1
P07567980T0000|5 8|p53
P07567980T0000|21 36|domain peptides
P07567980T0000|63 71|elements
P07567980T0000|85 88|DNA
P07568026A0622|4 15|Stat5b mRNA
P07568026A0622|22 26|size
P07568026A0622|34 36|kb
P07568026A0622|51 58|protein
P07568026A0622|66 77|amino acids
P07568116A0902|4 19|hydropathy plot
P07568116A0902|61 67|region
P07568116A0902|76 83|absence
P07568116A0902|101 115|signal peptide
P07568118A1267|6 13|results
P07568118A1267|27 33|G beta
P07568118A1267|51 70|Shc phosphorylation
P07568118A1267|91 95|step
P07568118A1267|103 110|pathway
P07568118A1267|122 139|p21ras activation
P07568118A1267|156 165|mechanism
P07568118A1267|178 217|growth factor tyrosine kinase receptors
P07568576A0074|5 11|report
P07568576A0074|27 39|relationship
P07568576A0074|48 63|Type A behavior
P07568576A0074|80 98|emotion dimensions
P07568865A0305|4 13|carcasses
P07568865A0305|26 39|contamination
P07568865A0305|64 72|bacteria
P07568865A0305|80 85|range
P07568865A0305|116 122|CFU/ml
P07568865A0305|144 145|%
P07568865A0305|166 174|bacteria
P07568865A0305|180 189|threshold
P07568865A0305|206 212|CFU/ml
P07568865A0305|214 220|Figure
P07569075A0585|10 15|stage
P07569075A0585|21 41|lung cancer patients
P07569075A0585|43 45|CR
P07569075A0585|71 72|%
P07569075A0585|85 87|PR
P07569075A0585|95 96|%
P07569075A0585|102 110|response
P07569075A0585|136 153|chest radiography
P07569075A0585|155 157|CT
P07569075A0585|159 162|FBS
P07569075A0585|164 172|cytology
P07569075A0585|180 189|histology
P07569532T0001|0 9|Pediatric
P07569532T0001|18 29|emergencies
P07569532T0001|44 52|hospital
P07569532T0001|66 72|locale
P07569640A0539|0 23|Protein electrophoresis
P07569640A0539|41 55|albumin levels
P07569640A0539|64 70|groups
P07569640A0539|83 89|values
P07569640A0539|93 95|G2
P07569770A0298|0 7|METHODS
P07569770A0298|22 36|non-responders
P07569770A0298|55 59|dose
P07569770A0298|72 79|vaccine
P07569770A0298|82 88|months
P07569770A0298|103 115|immunization
P07569770A0298|122 134|booster dose
P07569770A0298|156 163|vaccine
P07569770A0298|166 171|years
P07571766A0122|19 29|percentage
P07571766A0122|46 54|patients
P07571766A0122|72 73|%
P07571766A0122|94 109|catheterization
P07571766A0122|129 133|pain
P07571766A0122|158 180|ST-segment depressions
P07571766A0122|218 226|arteries
P07571953T0000|30 42|mycobacteria
P07571953T0000|65 71|smears
P07572582A0000|0 10|Mibefradil
P07572582A0000|12 14|Ro
P07572582A0000|35 53|calcium antagonist
P07572582A0000|65 79|chemical class
P07572582A0000|132 147|calcium channel
P07574064A1416|28 52|concentration anesthesia
P07574064A1416|95 97|VE
P07574064A1416|103 107|PCO2
P07574064A1416|114 118|mmHg
P07574064A1416|152 159|l.min-1
P07574064A1416|185 190|shift
P07574064A1416|198 219|response relationship
P07574682T0000|0 4|cDNA
P07574682T0000|57 77|alkaline phosphatase
P07575416A0000|0 16|Protein kinase C
P07575416A0000|18 21|PKC
P07575416A0000|45 51|enzyme
P07575416A0000|70 80|regulation
P07575416A0000|103 112|processes
P07575416A0000|128 134|family
P07575416A0000|154 164|isoenzymes
P07575416A0000|181 200|tissue distribution
P07575416A0000|214 226|localization
P07575416A0000|239 249|properties
P07575416A1970|5 9|work
P07575416A1970|42 52|importance
P07575416A1970|64 70|choice
P07575416A1970|74 89|oligonucleotide
P07575416A1970|94 105|cDNA probes
P07575416A1970|115 128|PKC zeta mRNA
P07575438A1409|5 11|action
P07575438A1409|45 52|factors
P07575438A1409|66 76|E1 element
P07575947T0000|4 10|debate
P07575947T0000|16 25|electives
P07576178A0000|0 26|Polypeptide growth factors
P07576178A0000|31 40|cytokines
P07576178A0000|67 76|functions
P07576178A0000|102 111|receptors
P07576179A0781|30 39|frequency
P07576179A0781|43 60|CpG dinucleotides
P07576307A0144|23 27|role
P07576307A0144|58 66|cassette
P07576307A0144|78 80|bp
P07576307A0144|89 103|rat enkephalin
P07576307A0144|105 109|rENK
P07576307A0144|111 115|gene
P07576307A0144|137 147|regulation
P07576307A0144|155 175|enkephalin phenotype
P07576307A1654|31 37|motifs
P07576307A1654|86 95|complexes
P07576307A1654|109 117|extracts
P07576307A1654|133 148|tumor cell line
P07576307A1654|150 154|HeLa
P07576307A1654|180 183|ENK
P07577904A0141|16 21|years
P07577904A0141|31 42|persistence
P07577904A0141|66 70|body
P07577904A0141|88 99|dislocation
P07577904A0141|107 120|camera aquosa
P07577904A0141|135 146|buphthalmos
P07577904A0141|159 162|eye
P07577904A0141|167 181|microphthalmos
P07577904A0141|187 198|dislocation
P07577904A0141|234 238|body
P07577904A0141|252 255|eye
P07579023A0214|11 23|dose-finding
P07579023A0214|29 37|patients
P07579023A0214|70 80|medication
P07579023A0214|89 96|patient
P07579023A0214|130 136|levels
P07579023A0214|140 153|liver enzymes
P07579164A0409|3 13|comparison
P07579164A0409|17 21|cDNA
P07579164A0409|34 43|sequences
P07579164A0409|49 67|RNA editing events
P07579164A0409|87 97|atp9 genes
P07579328A0653|0 5|MZF-1
P07579328A0653|16 44|CAT reporter gene expression
P07579328A0653|49 67|GAL4 binding sites
P07579328A0653|92 110|cell lines NIH 3T3
P07579328A1345|25 43|DNA binding domain
P07579328A1345|45 50|MZF-1
P07579328A1345|61 85|reporter gene expression
P07579328A1345|106 116|cell lines
P07579328A1345|131 141|expression
P07579328A1345|159 169|cell lines
P07579683A0660|0 8|Analyses
P07579683A0660|12 37|hGMR beta subunit mutants
P07579683A0660|63 70|regions
P07579683A0660|83 93|activation
P07579683A0660|101 115|c-myc promoter
P07579683A0660|180 188|activity
P07579695A0336|33 43|phenotypes
P07579695A0336|52 61|mutations
P07579695A0336|65 69|MIF2
P07579695A0336|87 96|mutations
P07579695A0336|112 147|yeast centromere protein genes-CEP1
P07579695A0336|148 157|CBF1/CPF1
P07579695A0336|159 169|NDC10/CBF2
P07579695A0336|175 185|CEP3/CBF3B
P07579695A0693|22 26|data
P07579695A0693|44 56|Mif2 protein
P07579695A0693|72 77|Cep1p
P07579695A0693|85 95|centromere
P07579695A0693|109 125|yeast centromere
P07579695A0693|152 157|order
P07579695A0693|170 177|complex
P07579704A0085|20 32|actin cables
P07579704A0085|37 44|patches
P07579704A0085|74 84|cell cycle
P07579704A0085|105 115|components
P07579704A0085|131 136|sites
P07579704A0085|141 152|cell growth
P07580058A0000|4 11|effects
P07580058A0000|15 34|Codonopsis pilosula
P07580058A0000|40 46|liquor
P07580058A0000|48 52|CPOL
P07580058A0000|57 90|tissue-type plasminogen activator
P07580058A0000|92 96|t-PA
P07580058A0000|102 133|plasminogen activator inhibitor
P07580058A0000|135 138|PAI
P07580058A0000|147 153|plasma
P07580058A0000|160 168|patients
P07580058A0000|181 194|heart disease
P07580058A0000|200 212|blood stasis
P07580330A0331|16 23|intakes
P07580330A0331|25 29|EDIs
P07580330A0331|35 41|person
P07580330A0331|52 61|microgram
P07580330A0331|72 75|HCH
P07580330A0331|82 91|microgram
P07580330A0331|96 105|gamma-HCH
P07580330A0331|112 121|microgram
P07580330A0331|126 134|dieldrin
P07580330A0331|141 151|micrograms
P07580330A0331|162 165|DDT
P07580330A0331|176 185|microgram
P07580330A0331|190 193|HCB
P07580782T0000|0 16|Imaging features
P07580782T0000|28 43|epidermoid cyst
P07580782T0000|60 71|correlation
P07581364A0500|15 20|cases
P07581364A0500|26 30|type
P07581364A0500|41 45|type
P07581364A0500|50 53|SMA
P07581364A0500|64 73|deletions
P07581364A0500|86 90|copy
P07581364A0500|94 100|Ag1-CA
P07581364A0500|105 109|C212
P07582316A0696|23 28|pairs
P07582316A0696|32 40|isolates
P07582316A0696|42 46|case
P07582316A0696|62 66|case
P07582316A0696|79 102|IS6110 banding patterns
P07582316A0696|135 146|MTB strains
P07582592A0545|0 4|HRES
P07582592A0545|68 74|damage
P07582592A0545|95 105|dilatation
P07582592A0545|128 131|LES
P07582592A0545|143 157|administration
P07582592A0545|176 201|botulinum toxin injection
P07582592A0545|209 218|treatment
P07582592A0545|222 231|achalasia
P07583190A0306|23 32|processes
P07583190A0306|77 82|parts
P07583190A0306|95 105|hemisphere
P07583190A0306|124 140|brain potentials
P07583190A0306|151 155|area
P07583190A0306|187 214|phrase structure violations
P07583190A0306|250 257|lesions
P07583190A0306|266 275|area lead
P07583190A0306|282 292|impairment
P07583190A0306|319 329|assignment
P07583562A1826|3 6|men
P07583562A1826|12 15|BMI
P07583562A1826|26 28|OR
P07583562A1826|55 57|TG
P07583562A1826|59 60|P
P07583562A1826|95 97|RP
P07583562A1826|99 100|P
P07583562A1826|112 118|models
P07583562A1826|141 143|TG
P07583562A1826|145 150|LDL-C
P07583562A1826|156 168|hypertension
P07585246T0000|0 18|SL1 trans-splicing
P07585246T0000|50 53|RNA
P07585246T0000|73 76|end
P07585246T0000|80 111|Caenorhabditis elegans pre-mRNA
P07585559A0000|21 29|compound
P07585559A0000|31 42|6-methoxy-4
P07585559A0000|48 64|2-hydroxyethoxyl
P07585559A0000|66 71|ethyl
P07585559A0000|72 77|amino
P07585559A0000|81 100|methyl-1M-pyrazo lo
P07585559A0000|102 107|3,4-b
P07585559A0000|108 117|quinoline
P07585559A0000|119 122|SCH
P07585559A0000|159 166|ability
P07585559A0000|193 229|muscle alpha-actin promoter activity
P07585559A0000|249 254|cells
P07586403A0765|7 12|basis
P07586403A0765|22 31|relations
P07586403A0765|35 62|risk factor-selection scale
P07586403A0765|64 68|RFSS
P07586403A0765|71 76|range
P07586403A0765|126 133|weights
P07586403A0765|143 154|risk factor
P07588240A0000|4 52|Caenorhabditis elegans death susceptibility gene
P07588240A0000|54 59|ced-3
P07588240A0000|67 73|number
P07588240A0000|77 85|homologs
P07588240A0000|100 107|species
P07588240A0000|119 137|interleukin-1 beta
P07588240A0000|139 148|IL-1 beta
P07588240A0000|161 167|enzyme
P07588240A0000|169 172|ICE
P07588240A0000|190 195|CPP32
P07588245T0000|0 10|Repression
P07588245T0000|14 28|glucocorticoid
P07588245T0000|63 73|activation
P07588245T0000|88 112|thyroid hormone receptor
P07588245T0000|114 116|TR
P07588245T0000|121 123|TR
P07588603A1054|4 11|results
P07588603A1054|34 45|flexibility
P07588603A1054|53 60|spacing
P07588603A1054|69 71|DH
P07588603A1054|83 88|sites
P07588608A1687|0 11|Obstruction
P07588608A1687|19 41|ERF repressor function
P07588608A1687|65 72|members
P07588608A1687|80 90|ets family
P07588608A1687|94 99|genes
P07588608A1687|101 116|i.e.gag-myb-ets
P07588608A1687|143 150|control
P07588608A1687|154 159|genes
P07588608A1687|172 190|cell proliferation
P07588608A1687|231 238|effects
P07588628A0318|0 14|Overexpression
P07588628A0318|28 31|p53
P07588628A0318|45 54|apoptosis
P07588628A0318|61 64|LCL
P07588633A0362|13 18|c-Fos
P07588633A0362|24 51|c-fos protooncogene product
P07588633A0362|97 104|protein
P07588633A0362|180 190|efficiency
P07588633A0362|194 207|NIH 3T3 cells
P07588633A0362|212 215|Mos
P07588750T0061|0 7|Cloning
P07588750T0061|9 19|sequencing
P07588750T0061|24 34|expression
P07588750T0061|61 72|kinase gene
P07588750T0061|76 93|Pyrococcus woesei
P07588750T0061|118 134|characterization
P07588750T0061|142 149|protein
P07588777A1524|6 18|observations
P07588777A1524|31 39|proposal
P07588777A1524|49 53|RNAP
P07588777A1524|57 60|CTD
P07588777A1524|81 87|target
P07588777A1524|106 113|p42mapk
P07588777A1524|118 137|p44mapk MAP kinases
P07589069A1245|43 48|forms
P07589069A1245|58 66|CD6 cDNA
P07589069A1245|75 84|sequences
P07589069A1245|112 119|regions
P07589069A1245|139 145|domain
P07589069A1245|170 183|reading frame
P07589069A1245|187 194|CD6-PB1
P07590264A0373|36 47|differences
P07590264A0373|51 66|polyadenylation
P07590264A0373|91 97|levels
P07590264A0373|101 105|DHFR
P07590264A0373|110 115|mRNAs
P07590264A0373|138 144|allele
P07590264A0373|168 173|sense
P07590264A0373|190 201|differences
P07590264A0373|208 226|end RNA processing
P07590264A0373|232 236|gene
P07590264A0373|257 261|poly
P07590264A0373|262 263|A
P07590264A0373|265 270|sites
P07590264A0373|289 294|level
P07590264A0373|298 313|gene expression
P07590268A0350|44 46|Dm
P07590268A0350|48 52|cDNA
P07590268A0350|64 75|polypeptide
P07590268A0350|95 114|sequence similarity
P07590268A0350|132 141|MAPKAPK-2
P07590268A0740|9 26|MAPKAPK-2 message
P07590268A0740|51 62|development
P07590268A0740|82 93|transcripts
P07590268A0740|109 111|kb
P07590268A0740|155 163|germline
P07590283A0820|4 11|finding
P07590283A0820|30 33|TdT
P07590283A0820|35 51|Pol beta protein
P07590283A0820|93 112|polymerase activity
P07590283A0820|127 129|aa
P07590283A0820|138 146|Pol beta
P07590283A0820|163 183|template utilization
P07590283A0820|195 218|polymerization reaction
P07590283A0820|249 256|finding
P07590283A0820|283 289|domain
P07590283A0820|293 301|Pol beta
P07590283A0820|326 334|activity
P07590283A0820|336 341|Kumar
P07590283A0820|350 352|J.
P07590525A0811|12 18|values
P07590525A0811|36 48|revertants/g
P07590525A0811|57 67|hamburgers
P07590525A0811|76 80|dogs
P07590657A0624|0 15|Cholangiography
P07590657A0624|37 42|cases
P07590657A0624|71 77|system
P07590657A0624|115 123|patients
P07590744A0829|4 13|integrity
P07590744A0829|21 34|cDNA sequence
P07590744A0829|52 60|analysis
P07590744A0829|92 98|clones
P07590744A0829|113 122|GAR1 gene
P07592072A0217|3 8|Trial
P07592072A0217|39 45|farrow
P07592072A0217|57 58|d
P07592072A0217|64 66|NF
P07592072A0217|104 110|farrow
P07592072A0217|136 145|injection
P07592072A0217|149 171|prostaglandin F2 alpha
P07592072A0217|175 176|d
P07592072A0217|184 193|gestation
P07592220A0846|10 13|PO2
P07592220A0846|22 27|ratio
P07592220A0846|31 49|minute ventilation
P07592220A0846|53 71|oxygen consumption
P07592220A0846|73 79|VE/VO2
P07592220A0846|98 104|PETCO2
P07592220A0846|120 123|Hyp
P07592220A0846|125 126|P
P07592337A0891|6 13|results
P07592337A0891|29 33|NfxB
P07592337A0891|63 73|expression
P07592337A0891|77 81|nfxB
P07592439A0000|0 4|A511
P07592439A0000|37 45|myovirus
P07592439A0000|50 72|Listeria monocytogenes
P07592467A0000|4 13|mechanism
P07592467A0000|17 41|peroxisome proliferation
P07592485A0734|17 32|gene expression
P07592485A0734|60 67|pathway
P07592485A0734|99 103|case
P07592485A0734|114 129|NCR sensitivity
P07592485A0734|135 139|gene
P07592485A0734|142 152|expression
P07592485A0734|178 197|ure2 delta mutation
P07592647A0797|20 53|DNA Pur alpha recognition element
P07592647A0797|69 78|complexes
P07592647T0000|0 11|Association
P07592647T0000|21 30|Pur alpha
P07592647T0000|40 62|retinoblastoma protein
P07592647T0000|64 66|Rb
P07592647T0000|109 142|DNA Pur alpha recognition element
P07592658A0309|32 39|complex
P07592658A0309|62 81|p50/p65 heterodimer
P07592676A0466|14 24|conditions
P07592676A0466|41 50|complexes
P07592676A0466|96 106|NIP region
P07592676A0466|142 160|repressor activity
P07592706A1465|0 8|Exchange
P07592706A1465|16 19|LPL
P07592706A1465|24 31|HL lids
P07592706A1465|46 54|reversal
P07592706A1465|84 96|lipase ratio
P07592706A1465|125 129|role
P07592706A1465|138 144|region
P07592706A1465|168 179|specificity
P07592710T0000|25 43|protein kinase PKR
P07592710T0000|74 84|activation
P07592710T0000|88 113|immunoglobulin kappa gene
P07592711T0000|10 15|forms
P07592711T0000|27 40|yeast protein
P07592711T0000|54 63|lethality
P07592711T0000|69 103|G protein alpha subunit deficiency
P07592711T0000|128 140|beta subunit
P07592721A0827|15 23|mutation
P07592721A0827|33 44|amino acids
P07592721A0827|79 87|contacts
P07592721A0827|93 96|DNA
P07592723A0814|0 14|Phorbol esters
P07592723A0814|26 41|phosphorylation
P07592723A0814|45 61|CSK 35H proteins
P07592723A0814|85 94|sequences
P07592723A0814|117 137|PKC binding activity
P07592723A0814|156 170|PKC substrates
P07592730A0204|0 6|Levels
P07592730A0204|10 24|TSG-14 protein
P07592730A0204|38 43|PTX-3
P07592730A0204|68 73|serum
P07592730A0204|77 81|mice
P07592730A0204|86 92|humans
P07592730A0204|99 108|injection
P07592730A0204|124 142|lipopolysaccharide
P07592730A0204|151 159|contrast
P07592730A0204|182 196|phase proteins
P07592730A0204|202 206|bulk
P07592730A0204|210 226|TSG-14 synthesis
P07592730A0204|241 249|organism
P07592730A0204|269 274|liver
P07592771A0258|4 14|mouse beta
P07592771A0258|28 32|gene
P07592771A0258|40 49|kilobases
P07592771A0258|66 71|exons
P07592771A0258|91 101|homologues
P07592771A0258|123 131|position
P07592771A0258|139 144|alpha
P07592771A0258|158 162|gene
P07592790A1457|15 19|data
P07592790A1457|34 38|PEDF
P07592790A1457|54 62|subgroup
P07592790A1457|80 87|serpins
P07592790A1457|112 118|region
P07592790A1457|147 155|activity
P07592790A1457|163 170|protein
P07592946A0261|19 26|cloning
P07592946A0261|41 55|p44 MAP kinase
P07592946A0261|88 94|kinase
P07592946A0261|98 102|gene
P07592946A0261|108 121|determination
P07592946A0261|129 151|intron/exon boundaries
P07592946A0261|161 177|characterization
P07592946A0261|185 193|promoter
P07592946A0997|27 37|TATA boxes
P07592946A0997|63 81|start sites region
P07592946A0997|87 95|AP-1 box
P07592946A0997|101 109|AP-2 box
P07592946A0997|115 123|Malt box
P07592946A0997|129 137|GAGA box
P07592946A0997|143 147|half
P07592946A0997|165 172|element
P07592946A0997|187 200|binding sites
P07592946A0997|205 208|Sp1
P07592946A0997|225 239|binding factor
P07592946A0997|248 255|CTF-NF1
P07592946A0997|263 266|Myb
P07592946A0997|274 277|p53
P07592946A0997|285 290|Ets-1
P07592946A0997|298 304|NF-IL6
P07592946A0997|312 316|MyoD
P07592946A0997|324 329|Zeste
P07592946A0997|341 351|hepatocyte
P07592946A0997|360 368|factor-5
P07593266A1174|54 60|region
P07593266A1174|86 105|pair stem structure
P07593896A1053|26 47|measurement technique
P07593896A1053|78 94|P0.1 measurement
P07593896A1053|122 131|equipment
P07593896A1053|149 159|lung model
P07594047T0000|0 7|Effects
P07594047T0000|11 20|verapamil
P07594047T0000|25 36|propranolol
P07594047T0000|46 66|afterdepolarizations
P07594047T0000|83 94|arrhythmias
P07594047T0000|106 117|epinephrine
P07594047T0000|137 148|QT syndrome
P07594592A0755|0 8|Deletion
P07594592A0755|16 49|NF-IL6 beta leucine zipper domain
P07594592A0755|78 89|interaction
P07594592A0755|108 116|proteins
P07595221A0733|6 11|cells
P07595221A0733|41 46|CIITA
P07595221A0733|59 68|MHC class
P07595221A0733|72 77|genes
P07595221A0733|113 122|MHC class
P07595221A0733|126 135|promoters
P07595221A0733|150 162|transfection
P07595221A0733|210 215|cells
P07595374A1215|4 11|domains
P07595374A1215|15 20|EBNA2
P07595374A1215|32 40|deletion
P07595374A1215|44 55|amino acids
P07595374A1215|111 121|activation
P07595374A1215|130 139|promoters
P07595374A1215|161 168|domains
P07595374A1215|186 194|residues
P07595374A1215|241 254|LMP1 promoter
P07595857A0521|4 19|peak velocities
P07595857A0521|43 48|waves
P07595857A0521|56 67|transmitral
P07595857A0521|89 104|flow velocities
P07595857A0521|106 107|A
P07595857A0521|112 115|PVA
P07595857A0521|150 154|wave
P07595857A0521|156 160|PVS1
P07595857A0521|182 186|flow
P07595857A0521|188 197|durations
P07595857A0521|222 227|waves
P07595857A0521|233 242|amplitude
P07595857A0521|265 271|motion
P07595857A0521|286 293|systole
P07595857A0521|322 326|days
P07595857A0521|333 346|cardioversion
P07595857A0521|385 388|day
P07595857A0521|392 405|cardioversion
P07595857A0521|413 421|patients
P07595857A0521|435 443|patients
P07595857A0521|457 471|cardiomyopathy
P07596283A0396|18 24|enzyme
P07596283A0396|31 39|activity
P07596283A0396|48 61|triglycerides
P07596283A0396|76 79|oil
P07596283A0396|84 94|tributyrin
P07596283A0396|116 125|emulsions
P07596287A0183|4 23|nucleotide sequence
P07596287A0183|45 49|fimA
P07596287A0183|68 82|reading frames
P07596287A0183|84 88|ORF5
P07596287A0183|93 97|ORF1
P07596287A0183|113 129|protein products
P07596287A0183|148 155|members
P07596287A0183|161 172|superfamily
P07596287A0183|188 224|cassette membrane transport proteins
P07596287A0183|268 274|uptake
P07596287A0183|279 293|export systems
P07596287A1724|4 14|ORF3 probe
P07596287A1724|40 53|bp transcript
P07596287A1724|74 78|size
P07596287A1724|82 86|ORF3
P07596287A1724|115 131|mutagenesis data
P07596558A0824|6 13|results
P07596558A0824|31 45|concentrations
P07596558A0824|49 58|IL-1 beta
P07596558A0824|89 98|treatment
P07596558A0824|117 127|hemorrhage
P07596697A0971|28 39|polypeptide
P07596697A0971|44 61|motilin responses
P07596697A0971|67 71|meal
P07596697A0971|100 108|children
P07596697A0971|117 125|children
P07596697A0971|133 146|control group
P07597030A0260|19 26|cloning
P07597030A0260|28 38|expression
P07597030A0260|56 72|characterization
P07597030A0260|87 94|subunit
P07597030A0260|105 106|h
P07597030A0260|108 113|TFIID
P07597030A0260|122 130|hTAFII32
P07597488T0000|10 18|jaundice
P07597488T0000|26 41|G6PD deficiency
P07597488T0000|50 61|kernicterus
P07597804A1007|4 15|transcripts
P07597804A1007|23 25|kb
P07597804A1007|34 36|kb
P07597804A1007|85 107|glycoprotein gene EUS4
P07598106A0709|0 19|Mean growth changes
P07598106A0709|28 33|Class
P07598106A0709|37 43|sample
P07598106A0709|98 106|subjects
P07598106A0709|112 117|Class
P07598106A0709|120 133|malocclusions
P07598106A0709|148 158|age period
P07598106A0709|173 183|similarity
P07598106A0709|200 211|development
P07598106A0709|230 236|groups
P07598303A1728|17 24|studies
P07598303A1728|52 63|prophylaxis
P07598303A1728|67 94|bone marrow transplantation
P07598303A1728|119 135|survival benefit
P07599449A0445|4 19|fracture groups
P07599449A0445|58 63|years
P07599449A0445|70 79|menopause
P07599449A0445|89 103|control groups
P07599653A0898|3 11|addition
P07599653A0898|22 33|differences
P07599653A0898|41 48|binding
P07599653A0898|60 67|factors
P07599653A0898|73 79|shoots
P07599653A0898|92 97|roots
P07599653A0898|102 111|agreement
P07599653A0898|131 141|activities
P07599653A0898|149 157|promoter
P07599653A0898|171 177|organs
P07600111A0000|4 14|prevalence
P07600111A0000|19 28|incidence
P07600111A0000|38 66|immunodeficiency virus types
P07600111A0000|76 81|HIV-1
P07600111A0000|83 88|HIV-2
P07600111A0000|112 123|virus types
P07600111A0000|134 143|HTLV-I/II
P07600111A0000|161 171|infections
P07600111A0000|180 191|association
P07600111A0000|206 216|infections
P07600111A0000|238 244|cohort
P07600111A0000|248 263|police officers
P07600111A0000|267 280|Guinea-Bissau
P07600986A0605|12 32|immunoprecipitations
P07600986A0605|37 53|gel shift assays
P07600986A0605|73 80|classes
P07600986A0605|89 97|affinity
P07600986A0605|116 121|sites
P07600986A0605|163 182|transcription units
P07601078A1003|0 8|Subjects
P07601078A1003|22 39|postexposure time
P07601078A1003|46 59|dioxin burden
P07601078A1003|66 71|pg/m3
P07601078A1003|99 103|risk
P07601078A1003|107 115|hypoergy
P07601078A1003|131 139|subjects
P07601078A1003|141 151|hypoergy I
P07601078A1003|153 155|OR
P07601078A1003|166 170|% CI
P07601078A1003|185 193|hypoergy
P07601078A1003|198 200|OR
P07601078A1003|211 215|% CI
P07601121A0153|0 8|Analysis
P07601121A0153|17 25|sequence
P07601121A0153|85 91|region
P07601121A0153|117 122|start
P07601121A0153|126 139|transcription
P07601121A0153|177 186|sequences
P07601445A0207|21 45|BAT1 translation product
P07601445A0207|53 60|homolog
P07601445A0207|68 75|rat p47
P07601445A0207|84 91|protein
P07601445A0207|97 124|WM6 Drosophila gene product
P07601445A0207|144 151|Ce08102
P07601445A0207|155 177|Caenorhabditis elegans
P07601445A0207|183 190|members
P07601445A0207|203 217|protein family
P07601445A0207|235 248|RNA helicases
P07601827A0778|9 21|lacZ fusions
P07601827A0778|55 68|DNA sequences
P07601827A0778|97 107|repression
P07601827A0778|115 118|pfl
P07601827A0778|139 145|region
P07601828A0095|8 14|report
P07601828A0095|32 48|characterization
P07601828A0095|62 67|class
P07601828A0095|71 86|flagellar genes
P07601828A0095|104 119|orfX-fliP locus
P07603726T0000|11 31|adaptation exercises
P07603726T0000|36 44|recovery
P07603726T0000|52 57|stage
P07603726T0000|73 90|neuroma resection
P07603956A0115|17 23|design
P07603956A0115|53 64|arrangement
P07603956A0115|68 78|treatments
P07603956A0115|98 104|levels
P07603956A0115|108 121|incorporation
P07603956A0115|125 128|RSB
P07603956A0115|144 145|%
P07603956A0115|152 160|chickens
P07604047A0704|2 12|cDNA clone
P07604047A0704|43 45|GA
P07604047A0704|65 73|sequence
P07604047A0704|107 131|transcription-PCR method
P07604047A0704|141 149|identity
P07604047A0704|157 167|cDNA clone
P07604047A0704|199 209|capability
P07604047A0704|217 231|fusion protein
P07604047A0704|273 277|GA53
P07604047A0704|281 285|GA44
P07604047A0704|290 294|GA19
P07604047A0704|298 302|GA20
P07604783A0952|26 33|changes
P07604783A0952|54 70|acid composition
P07604783A0952|82 90|lecithin
P07604783A0952|101 122|bile acid composition
P07604783A0952|126 130|bile
P07604794A0958|6 17|cholesterol
P07604794A0958|38 42|week
P07604794A0958|53 54|%
P07604794A0958|59 65|mg/day
P07604794A0958|75 76|%
P07604794A0958|84 90|mg/day
P07604794A0958|100 104|week
P07604794A0958|115 116|%
P07604794A0958|128 134|mg/day
P07604794A0958|144 145|%
P07604794A0958|157 163|mg/day
P07605990A1110|17 24|studies
P07605990A1110|63 67|role
P07605990A1110|71 76|PEBP2
P07605990A1110|84 108|GM-CSF promoter activity
P07605990A1110|122 130|findings
P07605990A1110|145 155|importance
P07605990A1110|172 177|ratio
P07605990A1110|191 205|PEBP2 isoforms
P07605990A1110|224 230|levels
P07605990A1110|238 255|promoter activity
P07606548T0000|0 8|Benefits
P07606548T0000|22 41|board certification
P07606548T0000|45 60|pharmacotherapy
P07606587A0266|0 23|Piperacillin-tazobactam
P07606587A0266|44 53|treatment
P07606587A0266|57 67|infections
P07606587A0266|131 139|bacteria
P07607197A1048|6 27|plasma renin activity
P07607197A1048|29 32|PRA
P07607197A1048|63 71|training
P07607197A1048|73 74|P
P07607197A1048|99 107|controls
P07607213A0140|26 57|structure/activity relationship
P07607213A0140|75 81|issues
P07607213A0140|104 113|evolution
P07607213A0140|128 136|peptides
P07607213A0140|145 155|mechanisms
P07607213A0140|175 185|expression
P07607233A0186|15 19|gene
P07607233A0186|51 63|epilancin K7
P07607233A0186|96 98|K7
P07607233A0186|118 137|nucleotide sequence
P07607342A0703|5 10|paper
P07607342A0703|39 47|evidence
P07607342A0703|72 78|trials
P07607342A0703|82 109|aldose reductase inhibitors
P07607342A0703|122 130|patients
P07607342A0703|159 166|results
P07607342A0703|180 191|drug trials
P07607342A0703|201 209|patients
P07607537A0954|4 12|spectrum
P07607537A0954|16 26|phenotypes
P07607537A0954|43 52|mutations
P07607537A0954|83 92|mutations
P07607537A0954|100 107|adaptor
P07607537A0954|116 138|VP16 activation domain
P07607607T0000|0 8|Increase
P07607607T0000|20 27|calcium
P07607607T0000|32 39|oxalate
P07607607T0000|46 63|fructose infusion
P07607669A1112|15 21|region
P07607669A1112|32 34|GC
P07607669A1112|55 67|CpG doublets
P07607669A1112|91 104|binding sites
P07607669A1112|109 112|Sp1
P07608268A0194|25 34|disorders
P07608268A0194|38 53|GnRH deficiency
P07608268A0194|82 110|melatonin secretion profiles
P07608268A0194|140 149|males IGD
P07608268A0194|151 152|n
P07608268A0194|162 164|DP
P07608268A0194|166 167|n
P07608268A0194|197 205|controls
P07608268A0194|207 208|n
P07608649A1429|10 24|blood pressure
P07608649A1429|32 45|CyA treatment
P07608649A1429|77 88|ET-1 levels
P07608968A0836|0 8|Analysis
P07608968A0836|20 31|Tat mutants
P07608968A0836|78 90|core domains
P07608968A0836|99 113|transactivator
P07608968A0836|155 168|transcription
P07608968A0836|174 177|TBP
P07609037A0775|3 11|addition
P07609037A0775|13 22|depletion
P07609037A0775|26 31|Oct-1
P07609037A0775|49 56|extract
P07609037A0775|81 90|antiserum
P07609037A0775|114 132|DNA affinity resin
P07609037A0775|152 165|transcription
P07609037A0775|185 198|MMTV promoter
P07609037A0775|204 209|level
P07609037A0775|244 252|promoter
P07609037A0775|288 297|sequences
P07609079A0387|0 15|Transactivation
P07609079A0387|23 32|HIV-1 LTR
P07609079A0387|36 45|T3R alpha
P07609079A0387|58 74|receptor mutants
P07609079A0387|118 128|A/B region
P07609079A0387|132 141|T3R alpha
P07609079A0387|176 202|transcription factor TFIIB
P07609079A0387|220 230|activation
P07609079A0387|284 293|sequences
P07609079A0387|301 304|LTR
P07609372A0261|0 6|M.M.C.
P07609372A0261|24 31|minutes
P07609372A0261|38 43|cases
P07609372A0261|48 59|HR patients
P07609372A0261|64 75|LR patients
P07609372A0261|88 95|minutes
P07609372A0261|102 107|cases
P07609372A0261|112 123|HR patients
P07609372A0261|128 139|LR patients
P07610052A1064|22 31|complexes
P07610052A1064|47 50|C25
P07610052A1064|52 55|C30
P07610052A1064|60 73|C35 complexes
P07610052A1064|88 98|rat cortex
P07610052A1064|107 115|extracts
P07610052A1064|124 135|SAA element
P07610052A1064|139 155|EMSA experiments
P07610052A1064|172 181|relevance
P07610052A1064|198 210|observations
P07610052A1064|226 237|functioning
P07610052A1064|245 261|rat APP promoter
P07610324A0319|40 47|aspects
P07610324A0319|108 113|years
P07610324A0319|142 156|reconstruction
P07610324A0319|202 209|centers
P07610716A0117|4 12|analysis
P07610716A0117|20 37|prevalence values
P07610716A0117|68 80|MS-frequency
P07610716A0117|141 149|latitude
P07610735A1471|0 9|Diltiazem
P07610735A1471|29 37|decrease
P07610735A1471|57 65|response
P07610735A1471|74 84|conversion
P07610735A1471|88 100|sinus rhythm
P07612174A1064|9 17|primates
P07612174A1064|80 87|effects
P07612174A1064|91 95|PCBs
P07612174A1064|101 107|humans
P07612557A0635|15 23|children
P07612557A0635|49 58|pathology
P07612557A0635|71 76|pairs
P07612557A0635|102 110|children
P07614762A0224|17 29|antigen test
P07614762A0224|55 74|latex agglutination
P07615541T0000|11 19|analysis
P07615541T0000|23 30|DNase-I
P07615541T0000|46 51|sites
P07615541T0000|59 101|mouse porphobilinogen deaminase gene locus
P07615634A0535|6 17|transcripts
P07615634A0535|47 53|region
P07615634A0535|71 79|sequence
P07615634A0535|103 110|protein
P07615634A0535|118 120|kD
P07616056A0278|5 7|mu
P07616056A0278|12 20|gamma 2b
P07616056A0278|27 38|chain genes
P07616056A0278|50 69|feedback inhibition
P07616056A0278|79 103|chain gene rearrangement
P07616563A0532|9 13|CarP
P07616563A0532|36 56|carAB control region
P07616563A0532|78 83|DNase
P07616563A0532|107 109|bp
P07616563A0532|115 124|stretches
P07616563A0532|173 186|GATC sequence
P07616569A0168|13 18|genes
P07616569A0168|34 42|subunits
P07616569A0168|50 68|cytochrome oxidase
P07616569A0168|70 74|cox1
P07616569A0168|82 97|apocytochrome b
P07616569A0168|99 102|cob
P07616569A0168|111 119|subunits
P07616569A0168|127 153|NADH dehydrogenase complex
P07616569A0168|155 159|nad1
P07616569A0168|166 171|nad4L
P07616569A0168|178 193|ATPase subunits
P07616569A0168|195 199|atp6
P07616569A0168|204 208|atp9
P07616569A0168|227 231|RNAs
P07616569A0168|233 237|rrn5
P07616569A0168|239 242|srn
P07616569A0168|247 250|lrn
P07616569A0168|256 261|tRNAs
P07616569A0168|281 289|proteins
P07616569A0168|291 295|rps3
P07616569A0168|297 302|rps11
P07616569A0168|304 309|rps12
P07616569A0168|314 319|rpl16
P07616802A0315|5 8|day
P07616802A0315|27 35|increase
P07616802A0315|39 53|platelet count
P07616802A0315|87 95|patients
P07616802A0315|109 116|heparin
P07616802A0315|118 119|p
P07616802A0315|134 140|return
P07616802A0315|156 161|value
P07616802A0315|168 185|heparin cessation
P07616802A0315|200 210|responders
P07618280A0550|26 36|structures
P07618280A0550|62 93|density gradient centrifugation
P07618548T0000|4 27|Babcock Surgical Clinic
P07620491T0000|0 9|Resources
P07620491T0000|22 30|patients
P07620491T0000|39 46|smoking
P07622058A0411|4 24|PEBP2 alpha proteins
P07622058A0411|51 53|aa
P07622058A0411|55 61|region
P07622058A0411|111 133|segmentation gene runt
P07622060A0967|23 28|cells
P07622060A0967|49 60|ME activity
P07622060A0967|105 121|thyroid hormones
P07622521A0418|18 25|mapping
P07622521A0418|33 60|G beta gamma binding region
P07622521A0418|64 72|beta ARK
P07622521A0418|88 96|residues
P07622521A0418|108 117|PH domain
P07622521A0418|141 147|series
P07622521A0418|151 158|mutants
P07622521A0418|166 183|carboxyl terminus
P07622521A0418|187 195|beta ARK
P07622521A0418|199 204|order
P07622521A0418|228 236|residues
P07622521A0418|249 261|G beta gamma
P07622521A0418|266 278|PIP2 binding
P07622932T0000|18 26|features
P07622932T0000|39 46|leprosy
P07623807A0162|17 27|mechanisms
P07623807A0162|50 64|Raf-1 proteins
P07623807A0162|93 99|system
P07623807A0162|114 130|plasma membranes
P07623807A0162|136 141|v-Ras
P07623807A0162|165 170|cells
P07623807A0162|184 193|membranes
P07623814A1040|3 13|CV-1 cells
P07623814A1040|15 29|cotransfection
P07623814A1040|37 45|retinoid
P07623814A1040|50 68|estrogen receptors
P07623814A1040|83 93|inhibition
P07623814A1040|109 117|activity
P07623814A1040|141 151|inhibition
P07623814A1040|155 166|ER activity
P07623814A1040|183 202|breast cancer cells
P07623821A0649|13 20|factors
P07623821A0649|22 27|HRF-1
P07623821A0649|42 53|cis element
P07623821A0649|92 97|motif
P07623821T0000|0 10|Regulation
P07623821T0000|14 45|Gax homeobox gene transcription
P07623821T0000|51 62|combination
P07623821T0000|75 82|factors
P07623821T0000|110 125|enhancer factor
P07623825T0000|22 44|transactivation domain
P07623825T0000|48 65|heat shock factor
P07623825T0000|96 102|stress
P07623838A1112|0 2|D.
P07623840A0352|44 53|sequences
P07623840A0352|57 61|GCN2
P07623840A0352|76 84|activity
P07623840A0352|92 98|kinase
P07623840A0352|138 142|tRNA
P07623840A0352|167 188|amino acid limitation
P07623844A0639|16 21|Bcl-2
P07623844A0639|30 46|E1B 19K proteins
P07623844A0639|71 80|apoptosis
P07623844A0639|103 116|growth arrest
P07623844A0639|124 134|expression
P07623844A0639|145 158|DNA synthesis
P07623844A0639|163 181|cell proliferation
P07623844A0639|189 197|presence
P07623844A0639|206 212|levels
P07623844A0639|226 229|p53
P07624119A0528|15 19|PAX3
P07624119A0528|33 66|PAX3-FKHR transactivation domains
P07624119A0528|88 102|test fragments
P07624119A0528|123 127|GAL4
P07624119A0528|140 146|domain
P07624119A0528|158 168|activation
P07624119A0528|174 187|reporter gene
P07624119A0528|213 223|cell types
P07624581A0312|4 12|subjects
P07624581A0312|31 34|ECG
P07624581A0312|48 76|blood pressure determination
P07624581A0312|98 101|TSH
P07624581A0312|103 118|thyroid hormone
P07624581A0312|120 123|PRL
P07624581A0312|125 132|glucose
P07624581A0312|134 144|creatinine
P07624581A0312|146 154|nitrogen
P07624581A0312|156 178|glutamine transaminase
P07624581A0312|180 191|cholesterol
P07624581A0312|196 223|triglycerides plasma levels
P07624581A0312|231 238|therapy
P07624581A0312|240 242|T0
P07624581A0312|254 268|treatment days
P07624581A0312|270 273|T30
P07624581A0312|290 302|days washout
P07624581A0312|304 307|T45
P07624615A0267|6 14|decrease
P07624615A0267|18 34|body temperature
P07624615A0267|36 38|TB
P07624615A0267|48 53|PaCO2
P07624615A0267|68 72|mmHg
P07624615A0267|79 83|HCO3
P07624615A0267|93 98|mEq/L
P07624615A0267|108 113|mEq/L
P07624615A0267|126 129|pHa
P07624615A0267|167 169|OH
P07624615A0267|173 174|H
P07624615A0267|177 182|ratio
P07624615A0267|207 213|effect
P07624615A0267|218 221|SID
P07624615A0267|227 231|Atot
P07624615A0267|254 264|phosphorus
P07624615A0267|266 268|PT
P07624615A0267|284 293|phosphate
P07624615A0267|295 297|Pi
P07626378T0000|0 19|Hepatitis B vaccine
P07626378T0000|35 43|problems
P07626469A1341|6 23|promoter activity
P07626469A1341|52 61|M1 domain
P07626469A1341|80 104|mouse Leydig tumor cells
P07626469A1341|106 110|MLTC
P07626469A1341|138 147|CHO cells
P07626806A1098|4 13|RAT3 gene
P07626806A1098|36 48|acid protein
P07626806A1098|57 67|similarity
P07626806A1098|83 91|proteins
P07627317A1502|4 6|Al
P07627317A1502|12 20|exposure
P07627317A1502|29 34|mg/m3
P07627317A1502|46 51|shift
P07627317A1502|78 91|concentration
P07627317A1502|99 102|end
P07627317A1502|110 115|shift
P07627317A1502|123 145|microgram/g creatinine
P07628389A0145|0 27|Tumor necrosis factor-alpha
P07628389A0145|29 38|TNF alpha
P07628389A0145|59 67|cytokine
P07628389A0145|94 117|testosterone production
P07628389A0145|121 139|mouse Leydig cells
P07628438T0000|15 39|insulin receptor homolog
P07628438T0000|43 47|gene
P07628438T0000|72 83|development
P07628438T0000|96 113|receptor isoforms
P07628438T0000|129 148|signaling potential
P07628451A0114|18 20|RA
P07628451A0114|25 28|E1A
P07628451A0114|36 51|phosphorylation
P07628451A0114|78 89|kDa protein
P07628451A0114|91 95|p300
P07628451A0114|108 123|differentiation
P07628451A0114|127 135|F9 cells
P07628456A0000|20 38|RNA binding domain
P07628456A0000|40 45|dsRBD
P07628456A0000|70 86|amino acid motif
P07628456A0000|106 113|variety
P07628456A0000|117 125|proteins
P07628456A0000|166 169|RNA
P07628456A0000|196 201|RNase
P07628456A0000|230 236|kinase
P07628456A0000|238 241|PKR
P07629103T0000|23 44|protein isoforms beta
P07629103T0000|49 54|delta
P07629103T0000|91 96|cells
P07629103T0000|118 123|sites
P07629103T0000|131 156|beta-casein gene promoter
P07629113A0726|0 3|SCA
P07629113A0726|21 31|inhibitors
P07629113A0726|35 41|serine
P07629113A0726|43 51|aspartyl
P07629113A0726|57 73|metalloproteases
P07629113A0726|99 115|N-ethylmaleimide
P07629122A0323|11 19|analysis
P07629122A0323|44 65|phosphorylation sites
P07629122A0323|75 79|NIMA
P07629122A0323|81 86|NIM-1
P07629122A0323|100 115|protein kinases
P07629122A0323|133 137|NIMA
P07629123A0885|19 27|mutation
P07629123A0885|33 48|leucine residue
P07629123A0885|52 60|arginine
P07629123A0885|64 72|position
P07629123A0885|87 97|alteration
P07629123A0885|101 119|heterodimerization
P07629123A0885|121 132|DNA binding
P07629123A0885|153 163|activation
P07629150A0155|0 10|Expression
P07629150A0155|18 30|CYP11A1 gene
P07629150A0155|47 55|hormones
P07629150A0155|65 84|adrenocorticotropin
P07629150A0155|101 108|hormone
P07629150A0155|126 132|number
P07629150A0155|136 150|growth factors
P07629150A0155|172 180|promoter
P07629150A0155|204 212|elements
P07629150A0155|238 266|signal transduction pathways
P07629163A0770|0 3|NH2
P07629163A0770|23 40|deletion analysis
P07629163A0770|64 66|PH
P07629163A0770|80 122|guanine nucleotide exchange factor domains
P07629163A0770|145 159|zinc butterfly
P07629163A0770|180 194|transformation
P07629196A0274|23 33|expression
P07629196A0274|54 61|mutants
P07629196A0274|65 70|alpha
P07629196A0274|75 88|alpha 12Q229L
P07629196A0274|93 98|alpha
P07629196A0274|103 116|alpha 13Q226L
P07629196A0274|134 144|activation
P07629196A0274|152 155|Jun
P07629196A0274|180 194|protein kinase
P07629196A0274|196 204|JNK/SAPK
P07629196A0274|206 213|pathway
P07630687A0010|4 13|objective
P07630687A0010|21 26|study
P07630687A0010|47 50|age
P07630687A0010|52 55|sex
P07630687A0010|66 76|conditions
P07630687A0010|78 92|family history
P07630687A0010|94 98|site
P07630687A0010|100 120|catheter association
P07630687A0010|142 152|evaluation
P07630687A0010|154 165|development
P07630687A0010|179 190|involvement
P07630687A0010|192 202|prevalence
P07630687A0010|206 218|antithrombin
P07630687A0010|224 233|protein C
P07630687A0010|238 260|protein S deficiencies
P07630687A0010|266 286|lupus anticoagulants
P07630687A0010|290 298|children
P07630687A0010|325 330|event
P07630934A0343|0 5|Harel
P07630934A0343|7 11|E.M.
P07631267T0001|0 12|Radiotherapy
P07631267T0001|23 34|orchiectomy
P07631267T0001|38 46|stage D1
P07631267T0001|57 66|carcinoma
P07633444T0000|11 23|organization
P07633444T0000|42 60|expression pattern
P07633444T0000|68 95|mouse WD-repeat gene DMR-N9
P07633444T0000|133 148|dystrophy locus
P07633756A0690|4 25|ARX2 procedure models
P07633756A0690|39 45|signal
P07633756A0690|53 56|sum
P07633756A0690|66 73|signals
P07633756A0690|83 106|background EEG activity
P07633756A0690|138 145|process
P07633756A0690|164 169|noise
P07633756A0690|186 193|version
P07633756A0690|199 215|reference signal
P07633756A0690|237 248|information
P07633756A0690|267 272|sweep
P07633756A0690|280 286|signal
P07633756A0690|305 325|artefact propagation
P07635140A0172|4 14|expression
P07635140A0172|22 26|gene
P07635140A0172|40 46|enzyme
P07635140A0172|48 53|CYP19
P07635140A0172|72 76|part
P07635140A0172|97 106|promoters
P07635140A0172|119 122|use
P07635140A0172|147 157|mechanisms
P07635312A0692|6 17|mutagenesis
P07635312A0692|42 51|mutations
P07635312A0692|80 86|domain
P07635312A0692|114 128|act1 mutations
P07635312A0692|132 140|interest
P07635572A1153|0 10|CIITA mRNA
P07635572A1153|36 45|IFN-gamma
P07635572A1153|49 54|class
P07635572A1153|86 91|lines
P07635572A1153|104 108|line
P07635572A1153|110 123|re-expression
P07635572A1153|127 129|RB
P07635572A1153|137 143|effect
P07635572A1153|147 174|CIITA mRNA induction levels
P07636179A0000|11 21|cell cycle
P07636179A0000|46 55|molecules
P07636179A0000|86 97|protein pRb
P07636179A0000|103 113|G1 cyclins
P07636179A0000|136 143|kinases
P07636179A0000|155 165|inhibitors
P07636187A0585|20 43|protein expression data
P07636187A0585|45 51|V beta
P07636187A0585|56 72|gene transcripts
P07636187A0585|107 112|lines
P07636187A0585|132 140|promoter
P07636337A0687|6 13|results
P07636337A0687|50 55|doses
P07636337A0687|59 67|hormones
P07636337A0687|85 106|serum estradiol level
P07636337A0687|110 113|HRT
P07636337A0687|127 132|women
P07636408T0000|0 10|Comparison
P07636408T0000|18 23|Tesla
P07636408T0000|33 53|Tesla field strength
P07636408T0000|63 80|resonance imaging
P07636408T0000|107 117|evaluation
P07636408T0000|132 155|intervertebral foramina
P07636648A1229|4 9|month
P07636648A1229|20 44|DTaP booster vaccination
P07636648A1229|51 57|groups
P07636648A1229|89 118|serum antibody concentrations
P07636648A1229|126 134|antigens
P07636648A1229|147 161|concentrations
P07636648A1229|180 198|pertussis antigens
P07636648A1229|230 238|children
P07636648A1229|240 241|p
P07636962A1288|35 46|determinant
P07636962A1288|76 89|HSV-alpha TIF
P07636962A1288|136 144|activity
P07636962A1883b|21 28|fusions
P07636962A1883b|38 56|DNA binding domain
P07636962A1883b|60 64|GAL4
P07636962A1883b|71 79|activity
P07636962A1883b|100 113|BHV-alpha TIF
P07636962A1883b|129 134|amino
P07636962A1883b|139 155|carboxyl termini
P07636962A1883b|169 177|activity
P07636984A1349|29 33|role
P07636984A1349|37 40|SP1
P07636984A1349|62 70|extracts
P07636984A1349|90 95|cells
P07637718A0218|18 32|messenger RNAs
P07637718A0218|42 58|trans-sialidases
P07637718A0218|74 81|repeats
P07637718A0218|101 114|epimastigotes
P07637718A0218|135 150|trypomastigotes
P07638517A0000|5 8|May
P07638517A0000|31 41|necropsies
P07638517A0000|64 85|Sao Paulo City Morgue
P07638517A0000|89 97|cadavers
P07638517A0000|101 125|individuals AIDS victims
P07638517A0000|142 148|deaths
P07638517A0000|162 183|police investigations
P07639106A0678|2 7|model
P07639106A0678|13 16|age
P07639106A0678|21 27|weight
P07639106A0678|47 50|fit
P07639106A0678|55 60|TBBMD
P07639106A0678|70 73|age
P07639106A0678|75 81|weight
P07639106A0678|87 93|height
P07639106A0678|113 116|fit
P07639106A0678|127 137|body TBBMC
P07639703A1703|12 16|acid
P07639703A1703|21 36|thyroid hormone
P07639703A1703|89 98|processes
P07639703A1703|125 132|element
P07639703A1703|157 164|process
P07639703A1703|168 194|islet cell differentiation
P07640309A0000|15 32|peptide sequences
P07640309A0000|71 85|mobility group
P07640309A0000|87 90|HMG
P07640309A0000|92 122|box transcription factor TCF-1
P07640309A0000|153 170|splice mechanisms
P07640309A0000|185 190|exons
P07640309A0000|199 201|X.
P07640422A0649|0 14|Thromboxane B2
P07640422A0649|54 59|pg/ml
P07640422A0649|97 104|heparin
P07640422A0649|110 122|hemodialysis
P07640422A0649|135 147|hemodialysis
P07640422A0649|153 160|heparin
P07640422A0649|162 163|p
P07640422A0649|172 180|Wilcoxon
P07640422A0649|189 194|pairs
P07640422A0649|207 211|test
P07642490A0318|6 12|vector
P07642490A0318|14 21|pHBK280
P07642490A0318|55 63|analysis
P07642538A0138|15 24|mechanism
P07642538A0138|28 42|RSK activation
P07642538A0138|59 67|RSK cDNA
P07642538A0138|69 73|RSK3
P07642538A0138|135 146|RSK mutants
P07642538A0138|148 152|K91A
P07642538A0138|154 159|N-Lys
P07642538A0138|186 192|mutant
P07642538A0138|195 200|K444A
P07642538A0138|202 207|C-Lys
P07642538A0138|235 241|mutant
P07642538A0138|244 251|N/C-Lys
P07642538A0138|272 278|mutant
P07642538A0138|280 285|T570A
P07642538A0138|287 292|C-Thr
P07642538A0138|294 300|mutant
P07642538A0138|317 342|MAPK phosphorylation site
P07642538A0138|356 360|VIII
P07642538A0138|368 376|C-domain
P07642538A0138|379 384|S218A
P07642538A0138|386 391|N-Ser
P07642538A0138|393 399|mutant
P07642538A0138|434 441|residue
P07642538A0744|3 11|contrast
P07642538A0744|18 23|C-Lys
P07642538A0744|28 33|C-Thr
P07642538A0744|48 54|levels
P07642538A0744|58 73|kinase activity
P07642538A0744|108 119|stimulation
P07642544A0868|12 21|treatment
P07642544A0868|48 59|phosphatase
P07642544A0868|81 86|cells
P07642544A0868|92 110|phenylarsine oxide
P07642544A0868|120 124|loss
P07642544A0868|145 164|NF-kappa B activity
P07642633T0000|12 20|promoter
P07642633T0000|32 45|binding sites
P07642633T0000|61 82|transcription factors
P07642633T0000|92 96|cell
P07642633T0000|111 121|regulation
P07642633T0000|129 133|gene
P07642633T0000|138 169|transcription enhancer factor-1
P07642633T0000|171 176|TEF-1
P07644127A0000|17 28|stimulation
P07644127A0000|32 40|neurones
P07644127A0000|63 74|cell bodies
P07644127A0000|93 99|fibres
P07644127A0000|106 111|study
P07644127A0000|166 177|stimulation
P07644127A0000|185 210|rat substantia innominata
P07644127A0000|212 214|SI
P07644127A0000|229 243|microinjection
P07644127A0000|247 256|carbachol
P07644127A0000|262 269|effects
P07644127A0000|278 299|acetylcholine agonist
P07644127A0000|319 328|glutamate
P07644466A0578|29 34|assay
P07644466A0578|45 63|NS3-4A polyprotein
P07644466A0578|65 68|NS3
P07644466A0578|74 98|serine proteinase domain
P07644466A0578|119 127|residues
P07644466A0578|131 134|NS3
P07644466A0578|145 158|NS4A cofactor
P07644466A0578|186 197|translation
P07644466A0578|213 229|trans-processing
P07644466A0578|246 256|substrates
P07644503A0729|3 11|contrast
P07644503A0729|13 28|over-expression
P07644503A0729|32 40|RAR beta
P07644503A0729|62 77|differentiation
P07644503A0729|105 114|RAR gamma
P07644503A0729|123 133|activation
P07644503A0729|137 149|target genes
P07646439A0535|17 25|proteins
P07646439A0535|37 55|platelet membranes
P07646439A0535|77 91|chromatography
P07646439A0535|104 135|mAb F11 affinity chromatography
P07647303T0000|4 22|homeobox gene ATK1
P07647303T0000|26 46|Arabidopsis thaliana
P07647303T0000|67 77|shoot apex
P07647303T0000|85 93|seedling
P07647303T0000|101 108|flowers
P07647303T0000|113 126|inflorescence
P07647303T0000|143 149|plants
P07647570A0713|16 27|explanation
P07647570A0713|45 49|gold
P07647570A0713|81 94|Kupffer cells
P07647570A0713|105 111|cortex
P07647570A0713|122 127|cells
P07647570A0713|143 147|Type
P07647570A0713|150 160|deiodinase
P07648338A0815|6 13|results
P07648338A0815|37 43|models
P07648338A0815|58 66|ischemia
P07648338A0815|82 99|cytokine profiles
P07648338A0815|119 131|TNF response
P07648338A0815|148 167|SMA occlusion model
P07648338A0815|192 202|laparotomy
P07649098A0676|4 12|evidence
P07649098A0676|42 54|observations
P07649098A0676|61 83|transfection construct
P07649098A0676|104 115|nucleotides
P07649098A0676|117 119|nt
P07649098A0676|124 132|promoter
P07649098A0676|143 145|nt
P07649098A0676|156 159|UTR
P07649098A0676|190 209|reporter expression
P07649098A0676|234 253|reporter expression
P07649098A0676|267 275|presence
P07649098A0676|279 281|nt
P07649098A0676|296 300|exon
P07649098A0676|326 333|context
P07649098A0676|337 351|IGF-I promoter
P07649098A0676|358 372|cotransfection
P07649098A0676|376 421|IGF-I promoter-luciferase-reporter constructs
P07649098A0676|429 436|plasmid
P07649098A0676|450 463|alpha-isoform
P07649098A0676|481 488|subunit
P07649098A0676|514 528|protein kinase
P07649098A0676|530 533|PKA
P07649098A0676|544 551|results
P07649098A0676|582 596|PGE2 treatment
P07649098A0676|606 620|cotransfection
P07649098A0676|628 635|plasmid
P07649098A0676|665 672|subunit
P07649098A0676|676 679|PKA
P07649098A0676|697 701|cAMP
P07649098A0676|723 742|reporter expression
P07650958A0123|4 11|changes
P07650958A0123|18 27|treatment
P07650958A0123|53 69|electromyography
P07650958A0123|88 105|motor improvement
P07650958A0123|138 148|indicators
P07651131A1407|11 17|assays
P07651131A1407|22 27|DNase
P07651131A1407|30 54|footprinting experiments
P07651131A1407|73 94|kDa repressor isoform
P07651131A1407|110 114|CIRs
P07651131A1407|139 146|targets
P07651131A1407|151 158|binding
P07651131A1407|167 174|protein
P07651141A0265|7 15|terminus
P07651141A0265|23 36|p-gvpF-M mRNA
P07651141A0265|53 64|nucleotides
P07651141A0265|77 83|p-gvpF
P07651141A0265|91 97|p-gvpE
P07651340A0286|0 16|Retransformation
P07651340A0286|20 34|uvsH77 mutants
P07651340A0286|52 59|cosmids
P07651340A0286|83 96|transformants
P07651340A0286|109 120|restoration
P07651340A0286|129 131|UV
P07651340A0286|136 150|MMS resistance
P07651340A0286|164 170|levels
P07651386A0925|18 25|element
P07651386A0925|34 47|p53 induction
P07651386A0925|79 89|adenovirus
P07651386A0925|101 109|promoter
P07651398A0257|3 8|flies
P07651398A0257|14 26|dShc protein
P07651398A0257|68 78|Drosophila
P07651398A0257|89 119|growth factor receptor homolog
P07651398A0257|121 124|DER
P07651398A0257|161 169|tyrosine
P07651398A0257|173 176|DER
P07651398A0803|12 24|binding site
P07651398A0803|33 48|dShc PTB domain
P07651398A0803|63 71|Tyr-1228
P07651398A0803|75 78|DER
P07651398T0000|17 29|gene product
P07651398T0000|47 56|signaling
P07651398T0000|64 92|DER receptor tyrosine kinase
P07651400A0335|5 15|inhibition
P07651400A0335|55 59|exon
P07651400A0335|71 82|splice site
P07651400A0335|134 152|consensus sequence
P07651424A0487|12 20|analysis
P07651424A0487|32 37|Ssm1p
P07651424A0487|54 61|protein
P07651424A0487|73 77|part
P07651424A0487|107 114|subunit
P07651424A0487|142 146|pool
P07651424A0487|155 163|proteins
P07651424A0743|13 18|cells
P07651424A0743|20 37|SSM1b transcripts
P07651424A0743|62 67|level
P07651424A0743|71 88|SSM1a transcripts
P07651424A0743|106 111|SSM1b
P07651424A0743|135 143|majority
P07651424A0743|151 161|Ssm1p pool
P07651734A0961|0 22|Northern blot analysis
P07651734A0961|36 46|expression
P07651734A0961|50 61|LIMK-1 mRNA
P07651734A0961|83 88|brain
P07651734A0961|97 107|expression
P07651734A0961|111 122|LIMK-2 mRNA
P07651734A0961|134 141|tissues
P07651734A0961|149 152|rat
P07651835A0652|22 38|binding affinity
P07651835A0652|47 53|motifs
P07652066A0677|7 12|basis
P07652066A0677|30 37|concept
P07652066A0677|57 66|procedure
P07652066A0677|98 107|anchoring
P07652066A0677|115 123|arm flap
P07652066A0677|140 146|fascia
P07652066A0677|185 198|system repair
P07652066A0677|202 211|incisions
P07652066A0677|226 230|risk
P07652066A0677|246 255|migration
P07652066A0677|259 264|scars
P07652066A0677|279 287|contours
P07652575A0435|13 27|microinjection
P07652575A0435|49 54|forms
P07652575A0435|58 61|Rac
P07652575A0435|66 71|Cdc42
P07652575A0435|82 110|Rho inhibitor C3 transferase
P07652575A0435|133 146|DNA synthesis
P07652582A0000|0 17|INF-alpha therapy
P07652582A0000|35 46|development
P07652582A0000|54 63|treatment
P07652582A0000|67 70|CML
P07653094A0169|2 8|series
P07653094A0169|12 17|amino
P07653094A0169|27 43|deletion mutants
P07653094A0169|45 48|d10
P07653094A0169|50 53|d20
P07653094A0169|55 58|d27
P07653094A0169|60 63|d31
P07653094A0169|65 68|d40
P07653094A0169|70 73|d44
P07653094A0169|79 82|d73
P07653094A0169|102 112|processing
P07653094A0169|114 137|cell surface expression
P07653094A0169|143 154|maintenance
P07653094A0169|175 185|attributes
P07653094A0169|201 211|expression
P07653094A0169|222 227|genes
P07653094A0169|236 250|plasmid vector
P07653094A0169|252 269|pcDL-SR alpha-296
P07653094A0169|274 278|CV-1
P07653094A0169|283 293|HeLa cells
P07653812T0000|12 44|acetyl cholinesterase inhibitors
P07653812T0000|53 62|analgesia
P07653812T0000|88 96|morphine
P07653812T0000|101 110|clonidine
P07653812T0000|114 118|rats
P07653892A0306|18 32|isoflurane MAC
P07653892A0306|36 46|triplicate
P07653892A0306|48 53|birds
P07653892A0306|77 84|agonist
P07653892A0306|86 94|morphine
P07653892A0306|96 97|n
P07653892A0306|121 128|agonist
P07653892A0306|130 137|U50488H
P07653892A0306|139 140|n
P07654239A0698|0 3|Max
P07654239A0698|51 56|level
P07654239A0698|64 86|cell cycle progression
P07654712A0774|4 16|yeast enzyme
P07654712A0774|54 61|enzymes
P07654712A0774|141 149|analysis
P07654712A0774|156 165|degrees C
P07654712A0774|170 172|pH
P07654740A0563|0 9|Key areas
P07654740A0563|17 34|selection process
P07654740A0563|66 78|alternatives
P07654740A0563|82 97|transplantation
P07654740A0563|103 114|composition
P07654740A0563|122 140|transplant work-up
P07654740A0563|151 169|inclusion criteria
P07654740A0563|203 210|factors
P07654740A0563|224 242|disease etiologies
P07654740A0563|247 261|co-morbidities
P07654740A0563|283 300|contraindications
P07655184A0852|4 13|transport
P07655184A0852|51 72|transmembrane protein
P07655184A0852|91 109|ER leader sequence
P07655184A0852|151 158|protein
P07655184A0852|174 185|ER sequence
P07655505A0527|8 14|shoots
P07655505A0527|19 24|roots
P07655505A0527|26 38|GT-2 protein
P07655505A0527|71 77|tissue
P07655505A0527|109 115|stages
P07655505A0527|128 139|development
P07655505A0527|159 163|role
P07655505A0527|187 194|pattern
P07655505A0527|198 227|phytochrome A gene expression
P07655509T0000|24 37|motif signals
P07655509T0000|46 55|targeting
P07655509T0000|81 89|proteins
P07655509T0000|114 117|pea
P07655509T0000|119 132|Pisum sativum
P07656588A0101|12 33|DNA sequence analysis
P07656588A0101|45 76|Genethon microsatellite D19S596
P07656588A0101|86 88|kb
P07656588A0101|114 120|region
P07656588A0101|124 128|FUT1
P07656588A0101|150 157|cluster
P07656588A0101|188 192|FUT1
P07656588A0101|197 207|FUT2 genes
P07656588A0101|221 223|cM
P07656588A0101|234 241|D19S412
P07656588A0101|243 252|lod score
P07656588A0101|265 267|cM
P07656588A0101|280 287|D19S571
P07656588A0101|289 298|lod score
P07657162A1412|17 41|transcription activation
P07657162A1412|45 50|LEF-1
P07657162A1412|85 92|process
P07657162A1412|120 143|trans-activation domain
P07657162A1412|147 155|addition
P07657162A1412|163 173|HMG domain
P07657668A0642|0 14|TH-SH3 binding
P07657668A0642|57 81|amino acid substitutions
P07657668A0642|93 106|Btk TH domain
P07657668A0642|114 128|Fyn SH3 domain
P07657705A1181|6 13|results
P07657705A1181|28 38|K-glypican
P07657705A1181|63 67|HSPG
P07657705A1181|90 101|development
P07658262A0944|0 16|Protein S levels
P07658262A0944|52 56|time
P07658262A0944|60 69|admission
P07658262A0944|95 104|infusions
P07658262A0944|121 127|plasma
P07658262A0944|137 147|correction
P07658262A0944|157 169|procoagulant
P07658262A0944|188 195|factors
P07658471A0000|4 23|plant hormone auxin
P07658471A0000|58 63|genes
P07658777A0400|4 8|test
P07658777A0400|35 43|patients
P07658777A0400|55 72|contraindications
P07659085A1520|15 57|transcription factor Oct-1 forms complexes
P07659085A1520|66 79|octamer motif
P07659085A1520|95 99|FPIV
P07659085A1520|103 121|gel shift analysis
P07659085A1520|127 132|liver
P07659085A1520|137 152|kidney extracts
P07659085A1520|161 166|Oct-1
P07659085A1520|181 190|candidate
P07659085A1520|195 206|partnership
P07659085A1520|210 229|androgen regulation
P07659515T0000|14 29|retrotransposon
P07659515T0000|39 47|evidence
P07659515T0000|84 92|elements
P07659515T0000|96 133|Crithidia fasciculata miniexon arrays
P07659529A0135|8 25|deletion analysis
P07659529A0135|30 49|transfection assays
P07659529A0135|55 79|reporter gene constructs
P07659529A0135|95 125|transcription control elements
P07659529A0135|145 151|region
P07659529A0135|165 174|EpoR gene
P07659746A1464|4 34|CVA16.4 proteolipid transcript
P07659746A1464|68 88|proteolipid messages
P07659746A1464|102 108|ovules
P07659746A1464|122 137|d post-anthesis
P07659757A0191|0 10|Incubation
P07659757A0191|27 42|fusion proteins
P07659757A0191|49 58|gamma-32P
P07659757A0191|59 62|ATP
P07659757A0191|78 83|assay
P07659757A0191|101 109|proteins
P07659757A0191|126 145|autophosphorylation
P07660712A0118|4 13|character
P07660712A0118|33 41|response
P07660712A0118|59 67|children
P07660712A0118|78 84|adults
P07660712A0118|105 115|risk group
P07660712A0118|121 128|respect
P07660712A0118|132 135|VHB
P07663138A0835|6 13|nadolol
P07663138A0835|15 25|heart rate
P07663138A0835|46 47|%
P07663138A0835|61 64|PBV
P07663138A0835|69 72|PBF
P07663160A0287|14 26|DNA sequence
P07663160A0287|64 76|base pairing
P07663160A0287|99 102|16S
P07663160A0287|113 116|RNA
P07663160A0287|118 127|avoidance
P07663160A0287|150 159|structure
P07663160A0287|173 184|codon usage
P07663160A0287|200 218|protein expression
P07663160A0287|222 228|accord
P07663160A0287|244 255|preferences
P07663963A1588|11 28|system activation
P07663963A1588|43 73|metanephrine/epinephrine ratio
P07663963A1588|90 94|time
P07663963A1588|105 110|males
P07663963A1588|134 139|month
P07663963A1588|143 155|cohabitation
P07663963A1588|157 165|turnover
P07663963A1588|178 184|levels
P07663963A1588|207 222|control animals
P07663998T0000|15 21|repair
P07663998T0000|25 29|type
P07663998T0000|58 67|aneurysms
P07664278A0135|0 2|A.
P07665172A0000|0 21|Transcription factors
P07665172A0000|65 70|motif
P07665172A0000|84 94|expression
P07665172A0000|114 119|genes
P07665172A0000|125 131|number
P07665172A0000|156 163|systems
P07665187A0208|0 16|Primer extension
P07665187A0208|21 33|cDNA cloning
P07665187A0208|71 74|end
P07665187A0208|82 93|Nramp1 mRNA
P07665187A0824|0 16|Primer extension
P07665187A0824|21 52|S1 nuclease mapping experiments
P07665187A0824|77 106|transcription initiation site
P07665187A0824|110 116|Nramp1
P07665187A0824|134 142|presence
P07665187A0824|174 190|initiation sites
P07665477A0901|0 4|EsaR
P07665477A0901|25 35|expression
P07665477A0901|66 76|expression
P07665477A0901|80 84|esaI
P07665567A0495|0 17|Sequence analysis
P07665567A0495|37 43|region
P07665567A0495|51 60|CD69 gene
P07665567A0495|74 82|presence
P07665567A0495|98 110|TATA element
P07665567A0495|114 124|base pairs
P07665567A0495|147 176|transcription initiation site
P07665567A0495|198 215|binding sequences
P07665567A0495|230 251|transcription factors
P07665567A0495|253 263|NF-kappa B
P07665567A0495|265 270|Egr-1
P07665567A0495|272 276|AP-1
P07665567A0495|313 323|expression
P07665567A0495|332 336|gene
P07665605A1127|20 21|D
P07665605A1127|46 53|product
P07665605A1127|91 100|DD dimers
P07665633A0284|13 21|isolates
P07665633A0284|51 65|disk diffusion
P07665633A0284|70 94|agar dilution procedures
P07665633A0284|114 132|National Committee
P07665633A0284|146 166|Laboratory Standards
P07665948A0591|0 10|IgE levels
P07665948A0591|25 31|values
P07665948A0591|51 62|individuals
P07665948A0591|67 77|IgE levels
P07665948A0591|93 108|children groups
P07665948A0591|117 123|adults
P07665948A0591|142 151|intensity
P07665948A0591|155 164|infection
P07666414A0614|16 26|expression
P07666414A0614|34 44|tmy-1 gene
P07666414A0614|63 77|microinjection
P07666414A0614|83 108|promoter/lacZ fusion gene
P07666414A0614|118 138|immunohistochemistry
P07666414A0614|182 199|anti-tropomyosins
P07666415A0000|4 23|nucleotide sequence
P07666415A0000|31 42|chloroplast
P07666415A0000|44 46|cp
P07666415A0000|48 51|DNA
P07666415A0000|57 62|maize
P07666415A0000|64 72|Zea mays
P07666523T0000|0 13|Investigation
P07666523T0000|21 28|control
P07666523T0000|32 43|coronavirus
P07666523T0000|55 73|mRNA transcription
P07666523T0000|111 126|RNA transcripts
P07666538A0000|0 10|Initiation
P07666538A0000|14 25|translation
P07666538A0000|39 56|hepatitis C virus
P07666538A0000|58 61|HCV
P07666538A0000|63 73|RNA genome
P07666538A0000|93 107|ribosome entry
P07666538A0000|130 136|region
P07666538A0000|140 143|NCR
P07666538A0000|166 172|manner
P07666966A0207|0 4|Mean
P07666966A0207|18 27|extension
P07666966A0207|44 50|lesion
P07666966A0207|69 77|segments
P07667097A0267|4 15|association
P07667097A0267|19 23|p255
P07667097A0267|29 47|splicing complexes
P07667097A0267|68 75|finding
P07667097A0267|81 88|mAb CC3
P07667097A0267|110 118|splicing
P07667097A0267|123 140|immunoprecipitate
P07667097A0267|155 158|RNA
P07667097A0267|163 180|splicing products
P07667195A0146|0 5|L-735
P07667195A0146|15 19|base
P07667195A0146|23 35|sulfate salt
P07667195A0146|63 73|suspension
P07667195A0146|75 83|solution
P07667195A0146|96 108|dosage forms
P07667195A0146|126 137|Beagle dogs
P07667621T0001|0 26|Doppler ultrasound studies
P07667621T0001|40 49|follow-up
P07667621T0001|53 61|children
P07667621T0001|84 92|syndrome
P07668009A0172|14 24|cumlations
P07668009A0172|28 48|hepatitis A diseases
P07669351A1278|4 14|properties
P07669351A1278|22 25|phi
P07669351A1278|29 46|SSB-ssDNA complex
P07670504A0834|47 62|banding pattern
P07670504A0834|66 71|plant
P07670504A0834|80 88|proteins
P07670504A0834|110 115|G-box
P07670504A0834|138 151|binding assay
P07670504A0834|179 182|GBF
P07670943A0308|15 19|male
P07670943A0308|34 42|patients
P07670943A0308|54 57|CAD
P07670943A0308|105 113|families
P07670943A0308|142 149|sibling
P07670943A0308|160 163|CAD
P07672821A0763|13 20|linkage
P07672821A0763|28 32|FHR2
P07672821A0763|41 55|factor H genes
P07672821A0763|76 84|evidence
P07672821A0763|97 108|relatedness
P07672821A0763|112 131|complement factor H
P07672821A0763|140 146|factor
P07672821A0763|157 165|proteins
P07672822T0000|8 17|structure
P07672822T0000|34 42|location
P07672822T0000|50 55|mouse
P07672822T0000|67 86|receptor alpha gene
P07673128A0989|10 16|domain
P07673128A0989|25 30|motif
P07673128A0989|36 57|cAMP response element
P07673128A0989|59 62|CRE
P07673154A0688|28 33|state
P07673154A0688|37 45|CAK beta
P07673154A0688|65 79|trypsinization
P07673154A0688|97 105|response
P07673154A0688|117 126|3Y1 cells
P07673154A0688|132 143|fibronectin
P07673178A0982|4 11|results
P07673178A0982|36 55|muscle gene E-boxes
P07673178A0982|108 116|spectrum
P07673178A0982|120 143|MDF/bH-L-H heterodimers
P07673178A0982|154 172|MCK-L type E-boxes
P07673178A0982|211 218|factors
P07674649A0508|27 31|ABAB
P07674649A0508|41 56|baseline design
P07674649A0508|82 105|treatment effectiveness
P07675445A0463|6 12|clones
P07675445A0463|42 48|domain
P07675445A0463|60 61|p
P07675445A0463|62 64|CA
P07675445A0463|65 74|n repeats
P07675445A0463|85 113|sequence length polymorphism
P07675445A0463|115 119|SSLP
P07675449A0848|7 29|glioblastoma cell line
P07675449A0848|48 52|p190
P07675449A0848|85 90|PDGFR
P07676492A1000|21 31|comparison
P07676492A1000|35 42|reports
P07676492A1000|54 61|regions
P07676492A1000|82 103|transplant recipients
P07676492A1000|116 120|risk
P07676492A1000|133 136|IHD
P07676587T0000|11 24|certification
P07676587T0000|29 45|livestock export
P07676655A0214|4 23|serum concentration
P07676655A0214|27 29|iP
P07676655A0214|37 45|dialysis
P07676655A0214|47 49|HD
P07676655A0214|82 88|mmol/l
P07676655A0214|93 94|D
P07676655A0214|126 130|mmol
P07677573A0000|14 25|correlation
P07677573A0000|36 42|number
P07677573A0000|57 67|parameters
P07677573A0000|79 88|secretion
P07677573A0000|90 99|incretion
P07677573A0000|117 124|changes
P07677573A0000|136 142|mucosa
P07677573A0000|156 164|patients
P07677573A0000|178 187|gastritis
P07677715A1076|4 14|TAF factor
P07677715A1076|57 60|OCD
P07677836A1356|14 27|matter injury
P07677836A1356|49 58|radiation
P07677836A1356|92 100|deficits
P07677836A1356|106 125|leukoencephalopathy
P07677836A1356|152 159|absence
P07677836A1356|163 175|chemotherapy
P07678006A0472|0 25|RNase protection analyses
P07678006A0472|54 66|CaM PDE mRNA
P07678006A0472|91 102|transcripts
P07678006A0472|122 138|CaM PDE isoforms
P07678006A0472|174 180|manner
P07678006A0901|13 23|protection
P07678006A0901|51 57|cortex
P07678006A0901|67 74|medulla
P07678006A0901|76 81|liver
P07678006A0901|83 96|kidney cortex
P07678006A0901|98 104|spleen
P07678006A0901|109 121|T-lymphocyte
P07678006A0901|128 131|RNA
P07678051A1303|4 17|PDGFR mutants
P07678051A1303|48 57|PLC gamma
P07678051A1303|102 112|production
P07678051A1303|116 135|inositol phosphates
P07678242A0473|18 29|correlation
P07678242A0473|42 48|levels
P07678242A0473|52 65|transcription
P07678242A0473|73 82|acc genes
P07678242A0473|91 95|rate
P07678242A0473|108 114|growth
P07678593A0708|16 21|clone
P07678593A0708|25 38|V. vulnificus
P07678593A0708|51 54|DNA
P07678593A0708|70 92|V. cholerae fur mutant
P07678602A0153|25 49|B lymphoblast cell lines
P07678602A0153|55 63|controls
P07678602A0153|75 83|patients
P07678602A0153|130 137|disease
P07678602A0153|154 161|parents
P07678695A0604|12 22|expression
P07678695A0604|26 31|Oct-3
P07678695A0604|37 49|hybrid cells
P07678695A0604|71 79|promoter
P07678695A0604|114 124|activation
P07678695A0604|149 157|promoter
P07679390A0721|0 16|RNase protection
P07679390A0721|21 44|primer extension assays
P07679390A0721|78 82|exon
P07679390A0721|102 116|DDT1 aFGF mRNA
P07679390A0721|134 158|transcription start site
P07679390A0721|180 182|bp
P07679390A0721|213 228|splice junction
P07679390A0721|237 241|exon
P07679836A0387|6 13|results
P07679836A0387|27 29|FK
P07679836A0387|64 69|agent
P07679836A0387|73 95|kidney transplantation
P07680035A0221|4 9|roles
P07680035A0221|13 27|phorbol esters
P07680035A0221|39 42|AMP
P07680035A0221|60 73|GnRH response
P07680120A1008|0 6|RT-PCR
P07680120A1008|26 33|primers
P07680120A1008|46 52|kidney
P07680120A1008|54 59|brain
P07680120A1008|64 72|prostate
P07680120A1008|90 96|D mRNA
P07680120A1008|109 115|kidney
P07680120A1008|120 125|brain
P07680120A1008|148 154|source
P07680120A1008|159 171|aFGF protein
P07680629T0000|10 17|cloning
P07680629T0000|22 38|characterization
P07680629T0000|46 51|genes
P07680629T0000|61 66|gp138
P07680629T0000|70 95|cell surface glycoprotein
P07680629T0000|119 130|cell fusion
P07680629T0000|134 158|Dictyostelium discoideum
P07681147A1420|31 39|analyses
P07681147A1420|54 69|phosphorylation
P07681147A1420|73 79|Ser-12
P07681147A1420|84 90|Ser-48
P07681147A1420|107 112|cells
P07681147A1420|136 143|ability
P07681147A1420|161 170|pp60c-src
P07681147A1420|201 211|signalling
P07681513A0000|0 10|Piroximone
P07681513A0000|20 37|phosphodiesterase
P07681513A0000|42 51|inhibitor
P07681513A0000|80 102|vasodilator properties
P07681539A0000|12 19|studies
P07681539A0000|38 49|lymphocytes
P07681539A0000|55 71|hospital workers
P07681539A0000|87 92|doses
P07681539A0000|96 105|radiation
P07681539A0000|117 120|mSv
P07682842A0294|13 19|origin
P07682842A0294|33 51|fMLF-R transcripts
P07682842A0294|65 72|linkage
P07682842A0294|88 102|receptor genes
P07682842A0294|112 122|regulation
P07682842A0294|126 148|fMLF-R gene expression
P07682842A0294|168 179|copy number
P07682842A0294|193 201|location
P07682842A0294|214 226|organization
P07682842A0294|244 252|sequence
P07682842A0294|266 277|fMLF-R gene
P07682842A0771|10 14|exon
P07682842A0771|26 28|bp
P07682842A0771|52 60|sequence
P07682842A0771|68 72|exon
P07682842A0771|87 93|coding
P07682842A0771|114 123|sequences
P07683131A0885|12 21|structure
P07683131A0885|30 37|members
P07683131A0885|45 55|SRC-family
P07683131A0885|82 104|exon/intron boundaries
P07683131A0885|126 132|domain
P07683131A0885|141 147|family
P07683375A0000|23 30|effects
P07683375A0000|34 48|growth factors
P07683375A0000|53 57|cAMP
P07683375A0000|69 78|estradiol
P07683375A0000|80 82|E2
P07683375A0000|87 97|regulation
P07683375A0000|101 111|expression
P07683375A0000|120 125|genes
P07683375A0000|144 161|estrogen receptor
P07683375A0000|163 165|ER
P07683375A0000|187 194|studies
P07683375A0000|223 233|activators
P07683375A0000|237 252|protein kinases
P07683375A0000|282 290|activity
P07683375A0000|298 300|ER
P07685263A0503|10 35|polymerase chain reaction
P07685263A0503|54 67|DNA fragments
P07685263A0503|75 85|base pairs
P07685263A0503|95 101|genome
P07685263A0503|109 126|Whipple bacterium
P07685263A0503|128 148|Tropheryma whippelii
P07685823A1234|0 14|RNA polymerase
P07685823A1234|31 41|A promoter
P07685823A1234|66 84|base-pair sequence
P07685823A1234|90 95|DNase
P07685823A1234|98 107|digestion
P07685823A1234|124 134|start site
P07685874A0258|9 15|sodium
P07685874A0258|17 24|calcium
P07685874A0258|30 54|magnesium concentrations
P07685874A0258|88 100|SLE patients
P07685874A0258|115 134|lupus erythematosus
P07685874A0258|144 153|potassium
P07685874A0258|164 186|protein concentrations
P07685874A0258|191 207|amylase activity
P07685874A0258|246 254|controls
P07686619A0704|0 4|Chem
P07687320A0526|12 26|plasmid pFV100
P07687320A0526|60 67|ability
P07687320A0526|71 99|complement B-band expression
P07687320A0526|103 106|ge6
P07687541A0200|49 62|fission yeast
P07687541A0200|82 90|mutation
P07687541A0200|107 111|gene
P07687541A0200|142 157|mtr1/prp20/srm1
P07687541A0200|159 166|mutants
P07687541A0200|186 190|poly
P07687541A0200|191 192|A
P07687541A0200|195 198|RNA
P07687541A0200|205 215|degrees C.
P07687541A0992|6 11|RCC1p
P07687541A0992|20 24|GNRP
P07687541A0992|29 32|Ran
P07687541A0992|50 56|GTPase
P07687541A0992|64 79|ras superfamily
P07687541A0992|104 112|homologs
P07687541A0992|116 119|Ran
P07687541A0992|137 141|CNR1
P07687541A0992|146 150|CNR2
P07687745T0000|22 27|FK506
P07687745T0000|37 54|amino acid import
P07688112A0274|0 8|Prostate
P07688112A0274|18 25|antigen
P07688112A0274|47 52|cases
P07688112A0274|61 71|correction
P07688112A0274|97 113|acid phosphatase
P07689154A0168|0 23|Protein phosphorylation
P07689154A0168|51 55|role
P07689154A0168|59 78|uPA gene expression
P07689154A0168|88 93|cells
P07689154A0168|95 109|protein kinase
P07689154A0168|123 137|phorbol esters
P07689154A0168|153 162|pp60v-src
P07689154A0168|191 199|uPA mRNA
P07689154A0168|216 219|AMP
P07689154A0168|221 225|cAMP
P07689154A0168|237 244|protein
P07689154A0168|263 269|agents
P07689154A0168|285 289|cAMP
P07689154A0168|299 314|uPA mRNA levels
P07689501A0420|9 17|carriers
P07691837A1359|9 11|bp
P07691837A1359|24 32|sequence
P07691837A1359|36 51|K3 keratin gene
P07691837A1359|108 116|promoter
P07691837A1359|131 139|clusters
P07691837A1359|165 171|motifs
P07691837A1359|185 208|NFkB consensus sequence
P07691837A1359|228 234|GC box
P07691885T0000|0 14|Identification
P07691885T0000|18 27|mutations
P07691885T0000|42 50|sequence
P07691885T0000|58 78|proto-oncogene c-kit
P07691885T0000|90 118|mast cell leukemia cell line
P07691885T0000|146 156|activation
P07691885T0000|160 173|c-kit product
P07692366A0000|0 10|BACKGROUND
P07692366A0000|12 23|Delineation
P07692366A0000|43 50|aspects
P07692366A0000|74 86|degeneration
P07692366A0000|88 92|ARMD
P07692366A0000|108 119|correlation
P07692366A0000|138 146|features
P07692366A0000|187 199|pathogenesis
P07692668A0326|47 50|RNA
P07692668A0326|95 99|RNAs
P07692668A0326|126 128|kb
P07692668A0326|162 180|blot hybridization
P07692668A0326|211 233|transcription strategy
P07692668A0326|249 260|arrangement
P07692668A0326|264 268|ORFs
P07692754T0000|0 12|Risk factors
P07692754T0000|36 50|seroprevalence
P07692754T0000|54 81|hepatitis C virus infection
P07692754T0000|94 106|blood donors
P07693132A0100|9 16|cloning
P07693132A0100|31 39|analysis
P07693132A0100|47 56|Zm-ERabp1
P07693132A0100|58 67|Zm-ERabp4
P07693132A0100|73 88|Zm-ERabp5 genes
P07693372A0115|5 10|agent
P07693372A0115|30 36|fungus
P07693372A0115|70 79|mechanism
P07693372A0115|83 89|action
P07693372A0115|109 121|cyclosporine
P07693672A0259|0 5|DNase
P07693672A0259|8 20|footprinting
P07693672A0259|37 45|promoter
P07693672A0259|60 67|regions
P07693672A0259|71 81|protection
P07693699A0831|13 22|stability
P07693699A0831|30 57|nucleotide binding function
P07693699A0831|69 77|proteins
P07693699A0831|104 115|sensitivity
P07693699A0831|119 123|urea
P07693708A0000|13 19|growth
P07693708A0000|35 44|protein-2
P07693708A0000|46 54|IGF-BP-2
P07693708A0000|56 69|transcription
P07693708A0000|73 82|rat liver
P07693708A0000|109 112|age
P07693708A0000|117 124|fasting
P07693967A0905|4 12|presence
P07693967A0905|20 22|RV
P07693967A0905|28 39|SL sequence
P07693967A0905|66 72|effect
P07693967A0905|76 87|translation
P07693975A1418|3 11|contrast
P07693975A1418|17 25|proteins
P07693975A1418|43 53|methionine
P07693975A1418|65 72|residue
P07693975A1418|97 107|N terminus
P07693975A1418|111 113|PR
P07693975A1418|138 149|proteolysis
P07693975T0000|8 21|transcriptase
P07693975T0000|26 45|protease activities
P07693975T0000|55 93|leukosis virus Gag-Pol fusion proteins
P07693975T0000|114 119|cells
P07695629A0489|3 11|addition
P07695629A0489|16 30|mck1 mds1 mrk1
P07695629A0489|38 48|disruptant
P07696183A0567|25 35|properties
P07696183A0567|39 42|Rak
P07696183A0567|75 82|kinases
P07696183A0567|88 98|expression
P07696183A0567|102 105|Rak
P07696183A0567|146 156|cell lines
P07696183A0567|161 168|tissues
P07696183A0567|188 193|liver
P07696183A0567|198 204|kidney
P07696183A0567|210 220|cell lines
P07696183A0567|224 230|breast
P07696183A0567|235 247|colon origin
P07696183A0567|253 256|Rak
P07696183A0567|290 297|glycine
P07696183A0567|312 325|myristylation
P07696183A0567|330 351|membrane localization
P07696183A0567|361 364|Rak
P07696183A0567|404 423|localization signal
P07696183A0567|431 441|SH2 domain
P07696183A0567|459 480|fractionation studies
P07696183A0567|495 501|p54rak
P07696183A0567|531 538|nucleus
P07696450A0271|0 8|PATIENTS
P07696450A0271|13 20|METHODS
P07696450A0271|36 46|experience
P07696450A0271|58 66|children
P07696450A0271|85 96|bowel Crohn
P07696450A0271|99 106|disease
P07696450A0271|139 143|feed
P07696450A0271|152 160|TGF-beta
P07696450A0271|183 187|Diet
P07696450A0271|189 203|Nestle-Clintec
P07696450A0271|205 210|Vevey
P07696450A0271|212 223|Switzerland
P07696450A0271|237 246|nutrition
P07696450A0271|253 258|weeks
P07696878A0222|4 19|leader sequence
P07696878A0222|36 46|cDNA clone
P07696878A0222|75 89|reading frames
P07696878A0222|106 122|initiation codon
P07696878A0222|143 156|reading frame
P07696878A0222|172 191|homeodomain protein
P07697294A0329|8 14|amount
P07697294A0329|18 30|HSP81-1 mRNA
P07697294A0329|52 57|roots
P07698219A0551|0 13|Cell adhesion
P07698219A0551|18 34|migration assays
P07698219A0551|52 57|alpha
P07698219A0551|60 64|beta
P07698219A0551|80 96|laminin receptor
P07698219A0551|117 125|F9 cells
P07698219A0551|148 156|PE cells
P07698727A0386|9 20|destruction
P07698727A0386|24 29|tumor
P07698727A0386|33 42|infection
P07698727A0386|76 89|HIV infection
P07699632A0522|16 28|race persons
P07699632A0522|33 47|Chukcha-Eskimo
P07699632A0522|89 98|arthritis
P07699632A0522|100 103|PsA
P07699632A0715|4 19|data complement
P07699632A0715|26 33|studies
P07699632A0715|49 60|populations
P07699632A0715|93 104|prevalences
P07699632A0715|108 111|SPA
P07699632A0715|116 123|HLA-B27
P07699632A0715|136 147|populations
P07699845A0537|9 23|studies SY5555
P07699845A0537|47 55|patients
P07699845A0537|80 88|diseases
P07699845A0537|103 114|pharyngitis
P07699845A0537|129 140|tonsillitis
P07699845A0537|149 168|lacunar tonsillitis
P07699845A0537|188 198|bronchitis
P07699845A0537|200 209|pneumonia
P07699845A0537|214 223|pertussis
P07699845A0537|240 245|fever
P07699845A0537|254 273|impetigo contagiosa
P07699845A0537|296 312|tract infections
P07699845A0537|321 336|balanoposthitis
P07699845A0537|362 375|lymphadenitis
P07699845A0537|377 385|S.S.S.S.
P07699845A0537|387 395|vulvitis
P07699845A0537|406 413|colitis
P07699845A0537|424 429|doses
P07699845A0537|445 450|mg/kg
P07699845A0537|452 458|t.i.d.
P07699845A0537|469 473|days
P07700361A0125|23 35|interactions
P07700361A0125|64 69|types
P07700361A0125|73 82|molecules
P07700361A0125|131 135|type
P07701266A0808|0 7|RESULTS
P07701266A0808|9 21|Closure time
P07701266A0808|25 33|fistulas
P07701266A0808|37 45|patients
P07701266A0808|56 59|TPN
P07701266A0808|62 74|somatostatin
P07701266A0808|138 142|days
P07701266A0808|168 171|TPN
P07702327T0000|13 33|adhesion prophylaxis
P07702327T0000|51 79|tissue plasminogen activator
P07702378A0668|18 23|sleep
P07702378A0668|27 35|children
P07702378A0668|48 58|dermatitis
P07702378A0668|88 91|VO2
P07702752A0545|19 28|sequences
P07702752A0545|36 56|rat P450c17 promoter
P07702752A0545|106 124|gene transcription
P07702752A0545|126 145|deletion constructs
P07702752A0545|180 190|base pairs
P07702752A0545|206 209|DNA
P07702752A0545|219 235|rat P450c17 gene
P07702752A0545|252 260|plasmids
P07702752A0545|276 300|reporter gene luciferase
P07702752A0545|326 342|mouse cell lines
P07702752A0545|352 361|Y-1 cells
P07702752A0545|378 396|Leydig MA-10 cells
P07702808A0427|15 29|BP differences
P07702808A0427|38 46|fish oil
P07702808A0427|51 69|corn oil treatment
P07702808A0427|87 94|Dinamap
P07702808A0427|120 125|mm Hg
P07702808A0427|140 143|ABP
P07702808A0427|169 174|mm Hg
P07704040A0000|33 48|mouse NMO1 cDNA
P07704040A0000|68 71|NAD
P07704040A0000|72 73|P
P07704040A0000|74 75|H
P07704040A0000|76 100|menadione oxidoreductase
P07704040A0000|114 117|NAD
P07704040A0000|118 119|P
P07704040A0000|120 121|H
P07704040A0000|123 139|quinone acceptor
P07704040A0000|141 155|oxidoreductase
P07704040A0000|157 174|quinone reductase
P07704040A0000|184 193|reductase
P07704040A0000|195 208|DT diaphorase
P07704040A0000|210 212|EC
P07704273A0000|17 23|JRG582
P07704273A0000|30 59|ampD ampE deletion derivative
P07704273A0000|63 74|strain HfrH
P07704273A0000|113 123|expression
P07704273A0000|148 167|beta-lactamase gene
P07704273A0000|171 191|Citrobacter freundii
P07704273A0000|204 218|plasmid pNU305
P07704456A1014|7 16|mechanism
P07704456A1014|27 39|acceleration
P07704456A1014|62 72|conditions
P07704456A1014|108 118|prevalence
P07704456A1014|127 137|conditions
P07704456A1014|148 160|HMS subjects
P07704689T0000|9 23|thyroid nodule
P07704730T0000|5 18|contraception
P07704730T0000|20 25|ideas
P07704730T0000|34 40|future
P07705476A0292|12 23|food intake
P07705476A0292|70 83|protein level
P07705476A0292|85 97|water intake
P07705476A0292|102 114|urine volume
P07705476A0292|153 160|protein
P07705627A1107|16 19|Mad
P07705627A1107|24 29|Medea
P07705627A1107|51 61|components
P07705627A1107|74 86|dpp pathways
P07705627A1107|98 109|development
P07706273T0000|16 26|regulation
P07706273T0000|43 44|H
P07706273T0000|48 70|ATPase B2 subunit gene
P07706273T0000|90 101|THP-1 cells
P07706287A0698|13 22|inability
P07706287A0698|33 36|RNA
P07706287A0698|46 53|nucleus
P07706287A0698|61 70|cytoplasm
P07706287A0698|103 108|phase
P07706287A0698|116 135|cell division cycle
P07706291T0000|3 16|E box element
P07706291T0000|37 47|expression
P07706291T0000|55 65|ad4bp gene
P07706291T0000|79 88|homologue
P07706291T0000|92 103|ftz-f1 gene
P07706291T0000|148 159|development
P07706299A0563|0 17|Inhibition assays
P07706299A0563|100 109|compounds
P07706299A0563|144 150|detail
P07706299A0563|171 179|features
P07706299A0563|192 223|oligosaccharide-protein binding
P07706307A0914|4 23|amino acid sequence
P07706307A0914|31 38|protein
P07706307A0914|46 52|region
P07706307A0914|60 78|specificity pocket
P07706307A0914|101 103|S.
P07706307A0914|112 121|proteases
P07706307A0914|125 126|B
P07706307A0914|132 134|C.
P07706396T0000|0 9|Mutations
P07706396T0000|17 27|VPS45 gene
P07706396T0000|31 45|SEC1 homologue
P07706396T0000|66 73|protein
P07706396T0000|82 89|defects
P07706396T0000|94 106|accumulation
P07706396T0000|110 127|membrane vesicles
P07707523A0704|7 12|cells
P07707523A0704|14 24|expression
P07707523A0704|32 52|NF-kappa B inhibitor
P07707523A0704|54 69|I kappa B-alpha
P07707523A0704|95 103|activity
P07707523A0704|107 110|LMP
P07707531A0550|18 24|design
P07707531A0550|51 57|effect
P07707531A0550|61 73|displacement
P07707531A0550|81 86|alpha
P07707531A0550|91 103|binding site
P07707531A0550|111 121|repression
P07707531A0550|125 130|alpha
P07707531A0550|133 151|gene transcription
P07707531A0550|155 159|ICP4
P07707544T0000|16 29|transcription
P07707544T0000|39 67|channel catfish virus genome
P07707544T0000|69 85|characterization
P07707544T0000|109 120|transcripts
P07708058A0178|4 7|GRE
P07708058A0178|11 21|nucleotide
P07708058A0178|42 45|GRE
P07708058A0178|47 51|cGRE
P07708058A0178|79 98|activator protein-1
P07708058A0178|100 104|AP-1
P07708058A0178|106 111|motif
P07708058A0178|120 135|c-jun homodimer
P07708058A0178|140 163|c-jun/c-fos heterodimer
P07708488A0151|3 11|contrast
P07708488A0151|20 27|results
P07708488A0151|66 82|sequence variant
P07708488A0151|88 91|ref
P07708497A0000|16 26|activation
P07708497A0000|30 45|thyroid hormone
P07708497A0000|47 49|T3
P07708497A0000|60 72|interactions
P07708497A0000|85 96|T3 receptor
P07708497A0000|98 100|TR
P07708497A0000|106 126|T3 response elements
P07708497A0000|128 132|TREs
P07708497A0000|150 156|copies
P07708497A0000|160 169|sequences
P07708497A0000|181 187|AGGTCA
P07711667A0766|15 23|analysis
P07711667A0766|27 39|risk factors
P07711667A0766|44 51|relapse
P07711667A0766|61 64|age
P07711667A0766|66 69|WBC
P07711667A0766|73 82|diagnosis
P07711667A0766|84 95|blast count
P07711667A0766|99 108|diagnosis
P07711667A0766|110 120|percentage
P07711667A0766|124 137|marrow blasts
P07711667A0766|139 150|FAB subtype
P07711667A0766|156 162|number
P07711667A0766|166 193|remission induction courses
P07711667A0766|207 216|remission
P07711667A0766|218 237|maintenance therapy
P07711667A0766|239 260|consolidation therapy
P07711667A0766|262 278|marrow cell dose
P07711667A0766|296 299|sex
P07711667A0766|301 325|GVHD prophylaxis regimen
P07711667A0766|330 339|isolation
P07711667A0766|344 359|decontamination
P07711667A0766|371 384|airflow rooms
P07711730A0000|0 30|Carnitine palmitoyltransferase
P07711730A0000|32 35|CPT
P07711730A0000|40 50|deficiency
P07711730A0000|80 88|disorder
P07711730A0000|92 108|lipid metabolism
P07711730A0000|128 134|muscle
P07713421A1435a|25 49|gain-of-function mutants
P07713421A1435a|79 86|ability
P07713421A1435a|101 125|sex determination signal
P07713421A1435a|132 137|SxlM4
P07713421A1435a|162 167|SxlM1
P07713421A1435b|25 49|gain-of-function mutants
P07713421A1435b|79 86|ability
P07713421A1435b|101 125|sex determination signal
P07713421A1435b|132 137|SxlM4
P07713421A1435b|162 167|SxlM1
P07713936A0393|0 7|Binding
P07713936A0393|11 16|meAda
P07713936A0393|42 55|transcription
P07713936A0393|72 86|response genes
P07713936A0393|110 123|transcription
P07713936A0393|127 131|aidB
P07713936A0393|152 160|presence
P07713936A0393|164 169|meAda
P07714608A1252|15 26|differences
P07714608A1252|51 57|groups
P07714608A1252|62 64|pH
P07714608A1252|66 71|PaCO2
P07714608A1252|86 94|pressure
P07714608A1252|96 106|heart rate
P07714608A1252|108 125|brain temperature
P07714608A1252|130 144|glucose levels
P07714758A1193|0 14|Blood pressure
P07714758A1193|37 46|lidocaine
P07714758A1193|50 57|mg kg-1
P07715200A0000|0 17|Anesthesiologists
P07715200A0000|42 46|drug
P07715200A0000|52 59|patient
P07715200A0000|73 88|target response
P07715200A0000|108 122|blood pressure
P07715602A1088|21 39|gene cluster codes
P07715602A1088|45 50|parts
P07715602A1088|70 93|cytochrome c haem lyase
P07715922A0188|8 13|paper
P07715922A0188|17 27|comparison
P07715922A0188|40 46|number
P07715922A0188|51 56|shape
P07715922A0188|60 67|corneal
P07715922A0188|80 85|cells
P07715922A0188|111 119|patients
P07715922A0188|133 139|months
P07715922A0188|146 149|PRK
P07717823A0328|0 26|Standard reference sources
P07717823A0328|68 73|child
P07717823A0328|88 94|height
P07717823A0328|110 116|kcal/d
P07717823A0328|121 128|support
P07717823A0328|148 157|functions
P07719527T0000|5 18|allergenicity
P07719527T0000|34 45|hirudin CGP
P07719527T0000|53 59|REVASC
P07719527T0000|80 90|volunteers
P07720572A0701|3 11|contrast
P07720572A0701|19 32|myoD promoter
P07720572A0701|38 51|myoD enhancer
P07720572A0701|67 79|conservation
P07720572A0701|88 94|humans
P07720572A0701|99 103|mice
P07720572A0701|116 124|sequence
P07720572A0701|140 148|position
P07720572A1584|17 27|difference
P07720572A1584|43 52|myoblasts
P07720572A1584|57 69|10T1/2 cells
P07720572A1584|92 102|cell types
P07720572A1584|111 130|chromatin structure
P07720572A1584|150 168|myoD core enhancer
P07720572A1584|190 203|myoD enhancer
P07720572A1584|231 241|mechanisms
P07720572A1584|245 257|10T1/2 cells
P07720709A0755|25 34|3T3 cells
P07720709A0755|40 52|model system
P07720709A0755|72 74|RA
P07720709A0755|98 107|retinoids
P07720709A0755|138 156|cell proliferation
P07720709A0755|191 208|growth inhibition
P07720709A0755|227 246|AP1 transrepression
P07720710A0861|4 7|Oct
P07720710A0861|12 25|HMG2 proteins
P07721074A0766|7 17|dermatitis
P07721074A0766|25 29|itch
P07721074A0766|36 42|rashes
P07721074A0766|53 57|rash
P07721074A0766|91 116|patient treatment program
P07721074A0766|136 148|multiplicity
P07721074A0766|162 177|trigger factors
P07721074A0766|196 203|itching
P07721422A0241|0 28|Primer extension experiments
P07721422A0241|55 85|transcription initiation sites
P07721422A0241|89 91|bp
P07721422A0241|105 115|mouse type
P07721422A0241|118 131|receptor gene
P07721878A1163|4 16|beta subunit
P07721878A1163|24 37|Fc epsilon R1
P07721878A1163|50 73|tyrosine phosphoprotein
P07721878A1163|83 86|p33
P07721878A1163|100 107|protein
P07721878A1163|133 139|report
P07721878A1163|151 175|Fc epsilon R1 beta chain
P07721878A1163|184 192|identity
P07723247A0187|13 23|mechanisms
P07723247A0187|35 44|magnitude
P07723247A0187|52 74|transmembrane transfer
P07723247A0187|88 96|products
P07723247A0187|106 115|dialysate
P07723247A0187|132 144|computerized
P07723247A0187|154 168|dialysis model
P07723247A0187|195 213|pressure recording
P07723247A0187|251 257|inflow
P07723247A0187|262 275|outflow ports
P07723247A1161|9 24|hour incubation
P07723247A1161|48 54|IL-1Ra
P07723247A1161|59 68|IL-1 beta
P07723247A1161|95 111|radioimmunoassay
P07724452A0344|13 22|treatment
P07724452A0344|38 41|pen
P07724452A0344|61 67|chicks
P07724452A0344|72 75|pen
P07724452A0344|83 85|d.
P07728201A0660|3 11|contrast
P07728201A0660|20 28|evidence
P07728201A0660|43 51|children
P07728201A0660|57 84|sickle-hemoglobin C disease
P07728201A0660|111 119|asplenia
P07728201A0660|134 139|years
P07728201A0660|143 146|age
P07728201A0660|177 199|penicillin prophylaxis
P07729427A0942|0 17|Deletion analysis
P07729427A0942|33 36|TBP
P07729427A0942|41 49|hTAFII18
P07729427A0942|67 74|domains
P07729427A0942|78 86|hTAFII28
P07729427A0942|88 96|hTAFII18
P07729427A0942|117 120|TBP
P07729427A0942|158 166|hTAFII28
P07729427A0942|171 179|hTAFII30
P07730273A1309|4 8|NarX
P07730273A1309|13 26|NarQ proteins
P07730273A1309|32 56|amino acid substitutions
P07730273A1309|80 98|histidine position
P07730273A1309|135 149|NarL-phosphate
P07730328A0000|21 26|cells
P07730328A0000|44 51|changes
P07730328A0000|66 76|activation
P07730328A0000|87 97|expression
P07730328A0000|103 111|spectrum
P07730328A0000|115 119|cell
P07730328A0000|142 147|genes
P07730336A0606|8 13|ATF-1
P07730336A0606|18 22|CREM
P07730336A0606|44 66|cAMP response elements
P07730336A0606|68 71|CRE
P07730336A0606|90 98|sequence
P07730336A0606|113 121|kappa E3
P07730336A0606|123 126|CRE
P07730337A1439|4 10|Ng/RC3
P07730337A1439|15 30|PKC-gamma genes
P07730337A1439|46 64|expression pattern
P07730337A1439|72 77|brain
P07730337A1439|85 96|development
P07730337T0000|0 9|Structure
P07730337T0000|14 24|regulation
P07730337T0000|32 36|gene
P07730337T0000|66 82|protein kinase C
P07730337T0000|93 104|neurogranin
P07730337T0000|106 117|RC3 protein
P07730795A0104|4 24|amino acid sequences
P07730795A0104|46 54|subunits
P07730795A0104|58 63|DdRPs
P07730795A0104|79 86|species
P07730795A0104|112 119|regions
P07731686A0000|4 14|TTG-2 gene
P07731686A0000|42 46|site
P07731686A0000|62 76|translocations
P07731686A0000|86 101|T-cell leukemia
P07731686A0000|105 110|T-ALL
P07731898A0823|9 16|studies
P07731898A0823|22 33|blood cells
P07731898A0823|49 56|acetate
P07731898A0823|60 76|bicarbonate ions
P07731898A0823|80 94|concentrations
P07731898A0823|130 142|hemodialysis
P07731898A0823|172 176|ions
P07731898A0823|200 228|superoxide anions generation
P07731898A0823|230 247|erythrocyte SOD-1
P07731898A0823|252 271|catalase activities
P07731898A0823|276 315|erythrocyte membrane lipid peroxidation
P07733075A1200|6 13|therapy
P07733075A1200|19 29|omeprazole
P07733075A1200|33 37|mg/b
P07733075A1200|38 42|i.d.
P07733075A1200|44 58|clarithromycin
P07733075A1200|63 67|mg/b
P07733075A1200|68 72|i.d.
P07733075A1200|78 81|CBS
P07733075A1200|86 90|mg/q
P07733075A1200|91 95|i.d.
P07733075A1200|122 133|combination
P07733075A1200|154 172|% eradication rate
P07733075A1200|176 185|H. pylori
P07733075A1200|199 218|ulcer healing rates
P07733075A1200|248 258|omeprazole
P07733075A1200|262 266|mg/d
P07733075A1200|284 286|wk
P07735590A0990|4 17|concentration
P07735590A0990|26 34|allergen
P07735590A0990|59 69|micrograms
P07735590A0990|74 86|p milligrams
P07735590A0990|94 104|house dust
P07735590A0990|123 135|cat allergen
P07735590A0990|148 153|homes
P07735590A0990|161 164|cat
P07735590A0990|171 198|micrograms Fel d milligrams
P07735590A0990|212 217|homes
P07735590A0990|226 229|cat
P07735590A0990|235 262|micrograms Fel d milligrams
P07735833A1078|0 11|CONCLUSIONS
P07735833A1078|15 25|comparison
P07735833A1078|33 55|LysU crystal structure
P07735833A1078|65 75|structures
P07735833A1078|79 84|seryl
P07735833A1078|104 115|synthetases
P07735833A1078|136 140|core
P07737024A1003|6 22|bowel irrigation
P07737024A1003|47 56|technique
P07737024A1003|72 79|passage
P07737024A1003|83 88|drugs
P07737024A1003|108 115|pylorus
P07737118A0317|4 8|MPS1
P07737118A0317|14 27|reading frame
P07737118A0317|68 80|LexA protein
P07737118A0317|88 99|GST protein
P07737118A0317|118 128|constructs
P07737118A0317|141 146|yeast
P07737508A0649|6 8|Tb
P07737508A0649|10 12|U6
P07737508A0649|30 34|gene
P07737508A0649|43 53|tRNA genes
P07737508A0649|55 62|tRNAGln
P07737508A0649|67 74|tRNAIle
P07737508A0649|102 106|gene
P07737944A0000|14 28|growth factors
P07737944A0000|58 64|impact
P07737944A0000|68 88|transfusion practice
P07737944A0000|120 124|need
P07737944A0000|133 156|blood cell transfusions
P07737944A0000|162 169|variety
P07737944A0000|180 186|states
P07737944A0000|228 236|decrease
P07737944A0000|240 254|erythropoietin
P07738026A0216|13 18|mouse
P07738026A0216|67 72|forms
P07738026A0216|76 79|ADH
P07738839A0173|7 17|IC breaths
P07738839A0173|32 34|EC
P07738839A0173|39 49|VC breaths
P07738839A0173|53 57|rest
P07738839A0173|69 81|CO2 pressure
P07738839A0173|83 86|PET
P07738839A0173|87 90|CO2
P07738839A0173|117 121|mmHg
P07739382A0457|13 21|analyses
P07739382A0457|28 48|amino acid sequences
P07739382A0457|62 75|protein types
P07739382A0457|107 115|proteins
P07739382A0457|127 135|gelsolin
P07739382A0457|165 173|ancestor
P07739382A0457|197 205|proteins
P07739520A1250|3 11|homologs
P07739520A1250|21 28|members
P07739520A1250|36 56|Surfeit gene cluster
P07739520A1250|80 89|proximity
P07739520A1250|97 99|D.
P07739520A1250|113 119|Surf-3
P07739520A1250|120 130|rpL7a gene
P07739542A1419|24 32|cyclin E
P07739542A1419|37 45|contrast
P07739542A1419|49 58|cyclin D1
P07739542A1419|81 96|G1/S transition
P07739542A1419|105 110|cells
P07739542A1419|119 150|retinoblastoma protein function
P07739544A0364|14 33|amino acid sequence
P07739544A0364|41 58|SGC1 gene product
P07739544A0364|70 76|region
P07739544A0364|94 104|similarity
P07739544A0364|135 141|domain
P07739544A0364|149 159|Myc family
P07739544A0364|175 183|proteins
P07739566A1076|12 38|Pax-6-BSAP fusion proteins
P07739566A1076|73 91|amino acid stretch
P07739566A1076|110 114|part
P07739566A1076|129 135|domain
P07739566A1076|167 178|differences
P07739566A1076|194 205|specificity
P07740487A0167|24 35|association
P07740487A0167|53 70|dysfibrinogenemia
P07740487A0167|75 88|thrombophilia
P07740487A0167|90 94|data
P07740487A0167|98 103|cases
P07740487A0167|114 124|affections
P07740487A0167|145 150|study
P07740487A0167|162 171|framework
P07740487A0167|179 195|SSC Subcommittee
P07740487A0167|199 209|Fibrinogen
P07740487A0167|217 238|International Society
P07740487A0167|242 252|Thrombosis
P07740487A0167|257 268|Haemostasis
P07740490T0000|11 20|estrogens
P07740490T0000|38 42|time
P07740490T0000|46 53|uraemia
P07740490T0000|66 70|role
P07740490T0000|74 83|serotonin
P07741255A0194|10 19|districts
P07741255A0194|28 32|area
P07741255A0194|43 46|km2
P07741255A0194|58 68|population
P07742024A0121|13 21|symptoms
P07742024A0121|23 28|signs
P07742024A0121|30 46|imaging features
P07742024A0121|48 66|operation findings
P07742024A0121|81 87|places
P07742024A0121|106 116|directions
P07742024A0121|124 129|tumor
P07742024A0121|168 173|types
P07742024A0121|175 181|sellar
P07742024A0121|183 189|clival
P07742024A0121|213 219|extent
P07742363A0135|14 21|enzymes
P07742363A0135|43 52|repressor
P07742363A0135|54 57|HCR
P07742363A0135|97 106|inhibitor
P07742363A0135|108 111|dsI
P07742363A0135|128 134|Ser-51
P07742363A0135|142 155|alpha subunit
P07742363A0135|180 188|exchange
P07742363A0135|198 209|nucleotides
P07742363A0135|227 236|recycling
P07742363A0135|241 246|eIF-2
P07742363A0941|9 12|Ser
P07742363A0941|15 18|Ala
P07742363A0941|26 30|form
P07742363A0941|34 51|yeast eIF-2 alpha
P07742363A0941|110 115|yeast
P07742363A0941|131 155|casein kinase activities
P07742550A0407|4 9|cases
P07742550A0407|49 58|lymphomas
P07742550A0407|60 63|DAL
P07742550A0407|82 92|mixed-cell
P07742550A0407|154 163|lymphomas
P07742550A0407|188 197|lymphomas
P07742550A0407|199 202|TFL
P07742550A0407|228 237|lymphomas
P07742550A0407|239 241|FL
P07742550A0407|247 268|mantle cell lymphomas
P07742550A0407|270 273|MCL
P07742550A0407|300 314|cell lymphomas
P07742550A0407|316 320|SNCL
P07742917T0001|0 7|Icterus
P07742917T0001|12 28|beta-thalassemia
P07742917T0001|42 50|children
P07742917T0001|54 65|Brazzaville
P07743472A0181|7 15|patients
P07743472A0181|21 34|breast cancer
P07743472A0181|70 99|Roswell Park Cancer Institute
P07743472A0181|101 105|RPCI
P07743472A0181|110 117|Buffalo
P07743472A0181|119 127|New York
P07743472A0181|142 153|information
P07743472A0181|163 188|cigarette smoking history
P07743472A0181|196 200|time
P07743472A0181|210 219|diagnosis
P07743515A0223|5 13|analysis
P07743515A0223|21 40|tissue distribution
P07743515A0223|44 48|AAMP
P07743515A0223|103 108|cells
P07743515A0223|110 126|cytotrophoblasts
P07743515A0223|154 180|colon adenocarcinoma cells
P07743515A0223|190 200|lymphatics
P07743697A0703|0 4|Data
P07743697A0703|14 20|V-HeFT
P07743697A0703|44 53|follow-up
P07743697A0703|69 73|rise
P07743697A0703|77 98|plasma norepinephrine
P07743697A0703|120 134|treatment arms
P07743697A0703|152 159|disease
P07743697A0703|179 188|treatment
P07743697A0703|227 243|enzyme inhibitor
P07743697A0703|245 254|enalapril
P07743697A0703|259 278|vasodilator therapy
P07743697A0703|284 316|hydralazine/isosorbide dinitrate
P07744763A0514|0 16|Binding activity
P07744763A0514|20 29|rat liver
P07744763A0514|38 46|extracts
P07744763A0514|62 78|orphan receptors
P07744763A0514|94 132|electromobility supershift experiments
P07744763A0514|142 149|results
P07744763A0514|174 183|receptors
P07744763A0514|198 205|element
P07744763A0514|209 216|CYP2C11
P07744763A0514|230 235|HNF-4
P07744776A0617|0 19|Transcript analysis
P07744776A0617|40 61|B block substitutions
P07744776A0617|69 85|U6 RNA synthesis
P07744846A1006|0 8|Analysis
P07744846A1006|12 17|Bcl-2
P07744846A1006|18 40|Bcl-2 homodimerization
P07744846A1006|61 75|binding assays
P07744846A1006|89 94|yeast
P07744846A1006|106 112|method
P07744846A1006|122 130|evidence
P07744846A1006|134 141|support
P07744846A1006|160 165|model
P07744846A1006|170 175|Bcl-2
P07744846A1006|176 198|Bcl-2 homodimerization
P07744846A1006|217 226|sequences
P07744846A1006|251 259|A domain
P07744846A1006|276 285|structure
P07744846A1006|304 312|presence
P07744846A1006|325 335|carboxyl B
P07744846A1006|340 349|C domains
P07744846A1006|353 364|combination
P07744954A0418|4 11|protein
P07744954A0418|51 58|portion
P07744954A0418|73 80|domains
P07744954A0418|89 92|NH2
P07744954A0418|97 109|COOH termini
P07744954A0418|119 126|epitope
P07744954A0418|145 153|antibody
P07744954A0418|191 196|stalk
P07745008A0892|0 19|Radioligand binding
P07745008A0892|73 83|constructs
P07745311A0264|0 9|Diagnosis
P07745311A0264|13 17|FHCS
P07745311A0264|53 61|findings
P07745684T0000|6 25|papillomavirus type
P07745684T0000|35 50|gene expression
P07745684T0000|72 86|protein kinase
P07745684T0000|98 105|changes
P07745684T0000|109 123|RNA processing
P07745685A1442|15 22|virions
P07745685A1442|46 54|proteins
P07745685A1442|73 83|antibodies
P07745685A1442|101 119|accessory proteins
P07745685A1442|131 133|SN
P07745685A1442|138 157|CAT fusion partners
P07745693A0914|0 7|Studies
P07745693A0914|17 26|inhibitor
P07745693A0914|39 52|Lb proteinase
P07745693A0914|68 79|stimulation
P07745693A0914|95 106|translation
P07745693A0914|123 134|proteolysis
P07745693A0914|152 161|component
P07745693A0914|162 163|s
P07745696A0932|0 28|Restriction mapping analysis
P07745696A0932|44 48|cDNA
P07745696A0932|56 62|HHV-6A
P07745696A0932|63 68|U1102
P07745696A0932|78 94|BamHI G fragment
P07745696A0932|109 112|end
P07745696A0932|132 139|segment
P07745696A0932|147 153|genome
P07745696A0932|165 171|SalI L
P07745696A0932|176 192|SalI O fragments
P07745696A0932|204 208|left
P07745696A0932|235 249|repeat regions
P07745726A0960|4 35|replication reporter constructs
P07745726A0960|42 44|E1
P07745726A0960|49 51|E2
P07745726A0960|92 110|expression vectors
P07745726A0960|112 120|distance
P07745726A0960|133 143|half sites
P07745726A0960|166 170|role
P07745726A0960|188 201|relationships
P07745726A1496|50 60|palindrome
P07745726A1496|81 112|nucleotide sequence information
P07745726A1496|117 127|E1 binding
P07745726A1496|157 177|E1 recognition motif
P07745726A1496|199 208|half site
P07746397A0233|0 7|METHODS
P07746397A0233|20 28|patients
P07746397A0233|39 54|anticoagulation
P07746397A0233|63 67|July
P07746397A0233|77 85|December
P07746397A0233|95 103|patients
P07746397A0233|121 130|embolisms
P07746397A0233|140 147|heparin
P07746397A0233|158 163|hours
P07746397A0233|169 174|onset
P07746397A0233|194 213|thromboplastin time
P07746397A0233|215 219|aPTT
P07746397A0233|225 230|times
P07746397A0233|239 244|value
P07746794A0000|42 53|formulation
P07746794A0000|57 70|Cyclosporin A
P07746794A0000|72 81|Sandimmun
P07746794A0000|101 111|castor oil
P07746794A0000|113 125|Cremophor EL
P07746794A0000|153 158|agent
P07746937A0100|0 19|Lung function tests
P07746937A0100|21 24|EFR
P07746937A0100|50 58|patients
P07746937A0100|65 71|period
P07746937A0100|88 94|months
P07747462A0332|0 20|Sequence comparisons
P07747462A0332|36 50|RCR initiators
P07747462A0332|66 69|set
P07747462A0332|86 92|motifs
P07747462A0332|119 142|metal coordination site
P07747462A0332|172 186|tyrosine motif
P07747462A0332|234 253|replicator proteins
P07748451A0343|4 8|mean
P07748451A0343|18 29|discrepancy
P07748451A0343|45 57|restorations
P07748451A0343|75 87|restorations
P07748451A0343|104 109|stone
P07748451A0343|125 129|poly
P07748451A0343|130 144|vinyl siloxane
P07748451A0343|151 172|medium-viscosity poly
P07748451A0343|173 187|vinyl siloxane
P07748493A1045|18 33|Aplysia Afurin2
P07748493A1045|39 51|candidate PC
P07748493A1045|79 83|role
P07748493A1045|91 101|processing
P07748493A1045|116 123|hormone
P07748493A1045|125 128|ELH
P07748493A1045|138 148|precursors
P07748493A1045|166 171|cells
P07748493A1045|186 191|gland
P07748502A0794|0 4|Rats
P07748502A0794|18 27|8-OH-DPAT
P07748502A0794|55 62|ability
P07748502A0794|81 95|discrimination
P07748502A0794|101 111|water maze
P07748848A0263|4 8|term
P07748848A0263|22 43|papillary haemangioma
P07748952A0462|3 11|addition
P07748952A0462|26 35|promoters
P07748952A0462|37 42|PmiaA
P07748952A0462|47 52|P1hfq
P07748952A0462|95 106|nucleotides
P07748952A0462|136 159|translation start sites
P07748952A1329|6 13|results
P07748952A1329|28 32|mutL
P07748952A1329|34 38|miaA
P07748952A1329|44 58|hfq expression
P07748952A1329|90 100|mechanisms
P07748952A1329|112 118|degree
P07748952A1329|122 137|cotranscription
P07748952A1329|152 157|genes
P07748952A1329|159 169|modulation
P07748952A1329|182 199|promoter strength
P07748952A1329|208 224|RNase E activity
P07749088A0119|9 11|T1
P07749088A0119|16 18|T2
P07749088A0119|28 34|images
P07749461A0632|6 8|kb
P07749461A0632|24 30|region
P07749461A0632|43 45|kb
P07749461A0632|60 78|sGTH alpha subunit
P07749461A0632|86 92|region
P07749461A0632|125 130|clone
P07749461A0632|132 145|sGTH alpha-G1
P07749461A1022|11 19|analysis
P07749461A1022|27 54|sGTH alpha subunit promoter
P07749461A1022|72 84|transfection
P07749461A1022|96 110|sGTH alpha/CAT
P07749461A1022|120 128|plasmids
P07749461A1022|134 147|rainbow trout
P07749461A1022|158 163|cells
P07749461A1022|201 211|expression
P07750217T0000|0 26|Indium-111 OncoScint CR/OV
P07750217T0000|31 39|F-18 FDG
P07750217T0000|66 87|carcinoma recurrences
P07751848A0222|4 34|carnitine palmitoyltransferase
P07751848A0222|36 39|CPT
P07751848A0222|50 60|activities
P07751848A0222|80 99|nmol/min/mg protein
P07751848A0222|125 130|value
P07751848A0222|166 185|nmol/min/mg protein
P07751848A0222|212 220|subjects
P07752223A0960|4 10|Myc LZ
P07752223A0960|44 56|interactions
P07752223A0960|74 87|Myc inability
P07752454A0341|26 29|CNS
P07752454A0341|54 70|resistance rates
P07752454A0341|74 85|methicillin
P07752454A0341|87 92|DMPPC
P07752644A1031|6 8|VF
P07752644A1031|22 36|defibrillation
P07752644A1031|83 100|plasma drug level
P07752644A1031|126 136|conduction
P07752886A0595|20 35|FecR derivative
P07752886A0595|49 68|amino acid residues
P07752886A0595|92 100|residues
P07752886A0595|114 118|FecR
P07753027A0240|4 24|gene pairs psbB-psbT
P07753027A0240|29 38|psbH-psbN
P07753027A0240|71 78|strands
P07753030A0173|0 21|Hybridization signals
P07753030A0173|52 56|DNAs
P07753030A0173|60 86|Rhizobium leguminosarum bv
P07753030A0173|88 96|phaseoli
P07753030A0173|98 120|Rhodobacter capsulatus
P07753030A0173|160 185|Xanthomonas campestris pv
P07753030A0173|187 197|campestris
P07753796A0625|14 33|amino acid sequence
P07753796A0625|43 50|regions
P07753796A0625|68 77|sequences
P07753796A0625|81 89|peptides
P07753796A0625|110 136|liver eIF-2B alpha subunit
P07753796A0743|0 10|Expression
P07753796A0743|19 23|cDNA
P07753796A0743|42 49|peptide
P07753796A0743|80 92|eIF-2B alpha
P07753796A0743|96 119|SDS/polyacrylamide gels
P07753837A0724|5 8|RNA
P07753837A0724|22 33|tail domain
P07753837A0724|37 47|desmoglein
P07753837A0724|68 83|plakoglobin RNA
P07753837A0724|106 112|effect
P07753837A0724|125 137|accumulation
P07753837A0724|141 152|plakoglobin
P07754713A0227|13 17|NUC1
P07754713A0227|19 24|PRP21
P07754713A0227|38 43|SPP91
P07754713A0227|46 50|CDC6
P07754713A0227|52 56|CRY2
P07754713A0227|62 66|gene
P07754713A0227|90 101|protein S24
P07754713A0227|110 114|gene
P07754713A0227|141 148|protein
P07754713A0227|156 167|amino acids
P07755884A0000|14 20|grafts
P07755884A0000|43 50|tissues
P07755884A0000|117 122|motor
P07755884A0000|127 148|sensorimotor deficits
P07755884A0000|165 172|lesions
P07755884A0000|194 209|dopamine system
P07755914A0000|0 9|OBJECTIVE
P07755914A0000|28 34|impact
P07755914A0000|42 54|introduction
P07755914A0000|58 72|clarithromycin
P07755914A0000|77 89|azithromycin
P07755914A0000|97 106|treatment
P07755914A0000|111 119|survival
P07755914A0000|123 131|patients
P07755914A0000|137 141|AIDS
P07755914A0000|159 186|Mycobacterium avium complex
P07755914A0000|188 192|DMAC
P07757315A1227|16 27|aggregation
P07757315A1227|51 58|% value
P07757315A1227|61 62|h
P07757315A1227|69 85|drug application
P07757315A1227|107 112|level
P07757315A1227|124 142|observation period
P07757315A1227|144 152|ABSTRACT
P07757315A1227|170 175|WORDS
P07758167A1488|0 13|Growth curves
P07758167A1488|29 42|proliferation
P07758167A1488|46 55|clone CA9
P07758167A1488|63 71|presence
P07758167A1488|77 84|% serum
P07758167A1488|102 103|%
P07758167A1488|118 128|clone ME10
P07758246A0469|4 11|protein
P07758246A0469|19 25|region
P07758246A0469|33 36|bps
P07758246A0469|60 66|intron
P07758246A0469|76 81|exons
P07758459A1277|4 7|UAS
P07758459A1277|15 24|AAC2 gene
P07758459A1277|56 62|motifs
P07758459A1277|95 105|activators
P07758459A1277|149 176|core HAP2/3/4 binding motif
P07758459A1277|204 235|ABF1 consensus binding sequence
P07758837A1118|13 23|complexity
P07758837A1118|45 51|region
P07758837A1118|59 75|GH receptor gene
P07758837A1118|98 109|observation
P07758837A1118|115 121|probes
P07758837A1118|135 142|exon 1B
P07758837A1118|161 176|intron boundary
P07758837A1118|225 234|sequences
P07758837A1118|264 275|P1 promoter
P07758837A1118|280 284|exon
P07759094A0634|14 26|dinucleotide
P07759094A0634|28 33|GT/CA
P07759094A0634|34 42|n repeat
P07759094A0634|60 71|NHE5 cosmid
P07759094A0634|108 133|microsatellite PCR marker
P07759525A0417|4 12|proteins
P07759525A0417|29 30|%
P07759525A0417|66 87|protein kinase domain
P07759525A0417|102 103|%
P07759525A0417|123 136|casein kinase
P07759525A0417|139 147|isoforms
P07759525A0417|160 166|region
P07759529A0288|12 22|approaches
P07759529A0288|44 51|CDP/cut
P07759529A0288|64 73|repressor
P07759529A0288|77 102|gp91-phox gene expression
P07760790A0327|0 15|Serum induction
P07760790A0327|21 39|MEF2 reporter gene
P07760790A0327|62 66|line
P07760790A0327|70 83|NIH 3T3 cells
P07760790A0327|102 128|MEF2 site binding activity
P07760819A0731|12 22|activation
P07760819A0731|56 65|molecules
P07760819A0731|67 96|PDGF beta receptor activation
P07760819A0731|120 126|effect
P07760819A0731|130 148|cell proliferation
P07760819A0731|152 167|differentiation
P07760841A0221|0 4|UAS1
P07760841A0221|12 24|binding site
P07760841A0221|49 64|regulator Adr1p
P07760841A0647|7 14|context
P07760841A0647|22 26|ADH2
P07760841A0647|47 53|region
P07760841A0647|65 69|UAS1
P07760841A0647|82 89|concert
P07760841A0647|99 103|ADH2
P07760841A0647|110 127|promoter elements
P07760841A0647|144 159|gene activation
P07760841A0647|177 188|orientation
P07760841A0647|190 201|copy number
P07760841A0647|207 218|helix phase
P07760844A0413|0 9|Induction
P07760844A0413|13 29|AP-1 DNA binding
P07760844A0413|60 79|GH trans-activation
P07760844A0413|83 88|c-jun
P07760844A0413|93 104|c-fos genes
P07761091A0294|0 12|Inactivation
P07761091A0294|16 27|MAP kinases
P07761091A0294|50 61|phosphatase
P07761091A0294|63 68|MKP-1
P07761216T0000|13 35|amphotericin B therapy
P07761216T0000|40 50|candidemia
P07761216T0000|64 72|patients
P07761420A0909|26 32|assays
P07761420A0909|47 52|CCaMK
P07761420A0909|68 71|Ca2
P07761434A1084|6 10|AP-1
P07761434A1084|27 35|mediator
P07761434A1084|39 60|tumor promoter action
P07761434A1084|68 76|findings
P07761434A1084|114 122|activity
P07761434A1084|135 147|antioxidants
P07761467A0666|11 18|complex
P07761467A0666|50 68|protein components
P07761467A0666|90 97|protein
P07762431A0356|4 11|protein
P07762431A0356|38 42|cDNA
P07762431A0356|64 78|culture medium
P07762431A0356|83 89|yields
P07762431A0356|102 104|mg
P07762431A0356|109 114|litre
P07762504A0648|4 9|study
P07762504A0648|29 43|administration
P07762504A0648|52 62|amiodarone
P07762504A0648|67 76|mg/kg/day
P07762504A0648|83 87|days
P07762504A0648|101 106|doses
P07762504A0648|113 117|dose
P07762504A0648|130 131|g
P07763727A1035|0 15|Plasmids pAMS12
P07763727A1035|17 23|pAMS13
P07763727A1035|28 34|pAMS14
P07763727A1035|59 76|laboratory strain
P07763727A1035|114 120|pAMS15
P07763727A1035|163 181|wine yeast strains
P07765118A0967|4 21|maximum induction
P07765118A0967|25 48|ACC-oxidase transcripts
P07765118A0967|69 70|h
P07765118A0967|77 85|excision
P07765118A0967|97 120|maximum enzyme activity
P07765118A0967|140 142|h.
P07766885A0405|13 30|polypeptide chain
P07766885A0405|65 73|features
P07766885A0405|88 98|plant CDPK
P07766885A0405|100 106|kinase
P07766885A0405|117 126|sequences
P07766885A0405|170 176|domain
P07766885A0405|187 202|junction region
P07767011A0689|0 6|Repair
P07767011A0689|15 24|insertion
P07767011A0689|39 52|recombination
P07767011A0689|66 74|activity
P07767011A0689|82 92|hprt locus
P07767011A0689|114 118|site
P07767011A0689|122 130|mutation
P07768824A0167|4 10|timing
P07768824A0167|14 33|fla gene expression
P07768824A0167|41 51|cell cycle
P07768824A0167|81 86|forms
P07768824A0167|90 104|RNA polymerase
P07768824A0167|113 123|appearance
P07768824A0167|131 141|activation
P07768824A0167|156 164|proteins
P07768836A1126|0 28|Primer extension experiments
P07768836A1126|47 76|transcription initiation site
P07768836A1126|81 83|bp
P07768836A1126|114 124|start site
P07768848A1880|0 12|Polypeptides
P07768848A1880|34 39|sizes
P07768848A1880|56 62|spores
P07768848A1880|68 72|cotE
P07768848A1880|78 84|mutant
P07768848A1880|95 100|basis
P07768848A1880|119 127|products
P07768848A1880|135 146|cotJ operon
P07768848A1880|175 184|formation
P07768848A1880|198 204|layers
P07768848A1880|212 216|coat
P07768848A1880|246 256|components
P07768848A1880|264 268|coat
P07768898A0492|23 29|values
P07768898A0492|33 43|divergence
P07768898A0492|47 64|apobec1 sequences
P07768898A0492|68 73|terms
P07768898A0492|81 88|numbers
P07768898A0492|122 135|suhstitutions
P07768898A0492|140 144|site
P07768898A0492|160 167|apobec1
P07768898A0492|197 204|protein
P07768953T0039|0 4|EEA1
P07768953T0039|45 61|membrane protein
P07768953T0039|73 81|cysteine
P07768953T0039|83 90|fingers
P07768953T0039|126 134|IQ motif
P07770033A0978|0 20|Nucleotide sequences
P07770033A0978|28 34|clones
P07770033A0978|53 58|clone
P07770033A0978|60 64|cap3
P07770033A0978|84 97|reading frame
P07770033A0978|99 102|ORF
P07770033A0978|135 139|acid
P07770033A0978|155 162|peptide
P07770033A0978|180 188|homology
P07770033A0978|192 232|Neurospora crassa copper metallothionein
P07771671T0000|50 67|carbon electrodes
P07771745A0442|0 9|Elevation
P07771745A0442|17 24|tissues
P07771745A0442|32 36|face
P07771745A0442|77 85|forehead
P07771745A0442|96 102|region
P07771745A0442|113 123|cheekbones
P07772036A1000|5 11|region
P07772036A1000|41 48|factors
P07772036A1000|50 58|USF/MLTF
P07772036A1000|80 115|transcription factor/nuclear factor
P07772036A1000|119 126|CTF/NF1
P07774137A0000|14 20|impact
P07774137A0000|49 53|test
P07774137A0000|55 66|Strep A OIA
P07774137A0000|71 80|detection
P07774137A0000|85 94|treatment
P07774137A0000|98 105|group A
P07774137A0000|136 141|GABHS
P07774137A0000|143 154|pharyngitis
P07774137A0000|198 204|clinic
P07774807A0405|9 17|proteins
P07774807A0405|53 63|activators
P07774807A0405|83 88|genes
P07774807A0405|100 112|heterodimers
P07774807A0405|152 166|family members
P07774925A0084|0 3|YAC
P07774925A0084|8 22|cosmid contigs
P07774925A0084|36 48|BRCA1 region
P07774925A0084|69 80|cDNA clones
P07774925A0084|86 91|pools
P07774925A0084|95 100|cDNAs
P07774925A0084|120 128|placenta
P07774925A0084|130 140|HeLa cells
P07774925A0084|152 159|T cells
P07774925A0084|171 175|head
P07775428A0172|14 20|clones
P07775428A0172|22 27|Ash-m
P07775428A0172|33 34|s
P07775428A0172|40 60|nucleotide sequences
P07775428A0172|76 86|Ash-l cDNA
P07775428A0172|109 115|region
P07776685A0000|5 10|study
P07776685A0000|24 35|feasibility
P07776685A0000|40 48|toxicity
P07776685A0000|61 74|immunotherapy
P07776685A0000|80 85|tumor
P07776685A0000|99 110|lymphocytes
P07776685A0000|127 140|interleukin-2
P07776685A0000|147 155|patients
P07776685A0000|170 179|resection
P07776685A0000|184 189|stage
P07776685A0000|209 220|lung cancer
P07776711A0295|0 8|MATERIAL
P07776711A0295|13 20|METHODS
P07776711A0295|32 35|men
P07776711A0295|43 48|women
P07776711A0295|68 73|years
P07776711A0295|77 80|age
P07776711A0295|100 105|motor
P07776711A0295|118 133|neuropathy type
P07776711A0295|169 183|polyneuropathy
P07776882A0000|12 17|study
P07776882A0000|32 52|cell volume dynamics
P07776882A0000|63 73|rat hearts
P07776882A0000|82 90|ischemia
P07776882A0000|101 112|reperfusion
P07776979A0702|3 11|contrast
P07776979A0702|13 20|COUP-TF
P07776979A0702|34 40|effect
P07776979A0702|62 84|reporter gene activity
P07777518A0483|0 14|DNA sequencing
P07777518A0483|19 41|Southern blot analyses
P07777518A0483|63 74|cDNA clones
P07777518A0483|106 111|genes
P07779558T0000|0 22|Muscle GSH-Px activity
P07779558T0000|39 47|exercise
P07779558T0000|49 57|training
P07779558T0000|63 87|selenium supplementation
P07779811A0901|0 8|Mutation
P07779811A0901|16 27|Sp1 element
P07779811A0901|45 56|Sp1 binding
P07779811A0901|81 90|reduction
P07779811A0901|94 111|reporter activity
P07779812A0000|4 14|c-myc gene
P07779812A0000|37 44|variety
P07779812A0000|48 59|tumor types
P07779812A0000|93 97|role
P07779812A0000|114 120|growth
P07779812A0000|126 132|number
P07779812A0000|136 146|cell types
P07780148A1153|14 17|PML
P07780148A1153|43 48|level
P07780148A1153|52 53|S
P07780148A1153|55 57|G2
P07780148A1153|63 71|M phases
P07780148A1153|102 107|level
P07780148A1153|111 119|G1 phase
P07780525A0495|0 9|Schooling
P07780525A0495|41 47|health
P07780525A0495|75 86|differences
P07780525A0495|101 114|health inputs
P07780719A0477|29 36|driving
P07780738A0091|11 15|Cdks
P07780738A0091|23 25|G1
P07780738A0091|30 38|S phases
P07780738A0091|46 56|cell cycle
P07780738A0091|90 94|cell
P07780738A0091|103 110|antigen
P07780738A0091|112 116|PCNA
P07780738A0091|128 143|DNA replication
P07782087A0559|24 54|transcription initiation sites
P07782087A0559|72 81|positions
P07782087A0559|97 105|position
P07782087A0559|130 141|combination
P07782087A0559|145 168|ribonuclease protection
P07782087A0559|170 186|primer extension
P07782087A0559|195 208|RACE analyses
P07782113A0726|4 23|roxithromycin doses
P07782113A0726|51 58|studies
P07782113A0726|85 97|blood levels
P07782302A0479|30 45|DEDDDL sequence
P07782302A0479|57 60|GDP
P07782302A0479|72 75|Ran
P07782302A0479|90 96|domain
P07782302A0479|118 138|affinity interaction
P07782302A0479|158 165|protein
P07782302A0479|167 179|HTF9A/RanBP1
P07782775A0889|13 17|ORFs
P07782775A0889|21 31|components
P07782775A0889|60 68|proteins
P07782775A0889|81 84|kDa
P07782775A0889|90 94|size
P07782775A0889|102 119|BBTV coat protein
P07783064A0452|16 29|strength data
P07783064A0452|36 44|patients
P07783064A0452|72 89|creatinine kinase
P07783064A0452|91 93|CK
P07783064A0452|95 101|levels
P07783641A0591|0 4|CodY
P07783641A0591|23 33|homologues
P07783641A0591|41 51|data-bases
P07783822A0000|0 9|OBJECTIVE
P07783822A0000|30 39|incidence
P07783822A0000|44 56|presentation
P07783822A0000|92 100|beriberi
P07783822A0000|114 131|district hospital
P07784061A0894|24 34|G proteins
P07784061A0894|69 72|TTF
P07784061A0894|109 114|cells
P07784061A0894|124 137|kb transcript
P07784078A1064|3 14|explanation
P07784078A1064|33 37|lack
P07784078A1064|41 56|gene expression
P07784078A1064|76 82|levels
P07784078A1064|86 95|RAR alpha
P07784078A1064|99 102|PML
P07784078A1064|118 133|APL cell growth
P07784079A1018|0 12|Transfection
P07784079A1018|28 45|expression vector
P07784079A1018|51 63|NIH3T3 cells
P07784079A1018|75 86|acquisition
P07784079A1018|104 112|activity
P07784079A1018|129 133|form
P07784079A1018|137 154|expression vector
P07784079A1018|174 182|activity
P07784079A1018|195 203|presence
P07784079A1018|213 216|FGF
P07784197A0827|10 18|extracts
P07784197A0827|26 33|variety
P07784197A0827|47 57|cell lines
P07784197A0827|59 70|monkey Cos7
P07784197A0827|80 99|mouse fibrosarcomas
P07784197A0827|110 117|HeLa S3
P07784197A0827|140 148|TGF-beta
P07784197A0827|173 184|band shifts
P07784197A0827|188 200|cell extract
P07784197A0827|206 234|BALB/c 3T3 mouse fibroblasts
P07784199A0000|14 21|protein
P07784199A0000|23 25|rp
P07784199A0000|27 41|gene promoters
P07784199A0000|124 129|sites
P07784199A0000|145 165|gene regulator Rap1p
P07784199A0000|181 185|site
P07784199A0000|205 211|factor
P07784199A0000|213 218|Abf1p
P07784870A0119|16 23|reports
P07784870A0119|58 66|findings
P07784870A0119|86 93|reports
P07784870A0119|106 117|information
P07784870A0119|144 158|investigations
P07784870A0119|167 177|microscopy
P07784870A0119|179 193|histochemistry
P07784870A0119|207 226|electron microscopy
P07784870A0119|228 248|immunohistochemistry
P07784870A0119|256 268|microbiology
P07784942T0001|12 26|thrombomodulin
P07784942T0001|36 45|knowledge
P07784942T0001|57 66|prospects
P07786820A0284|0 6|CPT-11
P07786820A0284|39 52|i.v. infusion
P07786820A0284|58 62|dose
P07786820A0284|70 75|mg/m2
P07786820A0284|91 93|ml
P07786820A0284|101 107|saline
P07786820A0284|116 121|weeks
P07786821A2292|0 10|CONCLUSION
P07786821A2292|16 19|MTD
P07786821A2292|24 30|CPT-11
P07786821A2292|51 90|consecutive-days-every-3 weeks schedule
P07786821A2292|99 117|patient population
P07786821A2292|125 134|mg/m2/day
P07787179A0312|5 16|bp fragment
P07787179A0312|18 27|X1 region
P07787179A0312|36 51|PRB-1b promoter
P07787179A0312|69 78|positions
P07787179A0312|119 142|ethylene responsiveness
P07787179A0312|150 163|reporter gene
P07789275A0325|14 22|function
P07789275A0325|23 24|s
P07789275A0325|29 32|E74
P07789275A0325|40 53|metamorphosis
P07789275A0325|100 126|loss-of-function mutations
P07789275A0325|144 162|transcription unit
P07789342A1352|27 33|domain
P07789342A1352|41 46|TSH-R
P07789342A1352|70 86|affinity binding
P07789342A1352|90 93|TSH
P07789342A1352|116 128|hyt mutation
P07789342A1352|143 163|transmembrane domain
P07789342A1352|175 186|TSH binding
P07789396A0504|0 8|Lipiodol
P07789396A0504|40 44|EDTB
P07789809A1246|10 23|Western blots
P07789809A1246|50 55|types
P07789809A1246|59 62|Ypt
P07789809A1246|71 73|Cr
P07789809A1246|78 80|Vc
P07789809A1246|104 107|Ypt
P07789809A1246|121 140|household functions
P07789809A1246|157 174|vesicle transport
P07789809A1246|200 215|differentiation
P07789971A0758|4 11|absence
P07789971A0758|21 28|regions
P07789971A0758|32 45|hybridization
P07789971A0758|89 98|sequences
P07789971A0758|126 137|pseudogenes
P07789971A0758|164 170|genome
P07789971A0758|209 214|genes
P07789971A0758|244 249|GSTT2
P07790271A1185|13 22|lens dose
P07790271A1185|28 43|Gy/25 fractions
P07790271A1185|78 88|techniques
P07790377A0561|0 10|Antibodies
P07790377A0561|24 29|PTS1R
P07790377A0561|45 52|protein
P07790377A0561|63 69|monkey
P07790377A0561|71 74|rat
P07790377A0561|80 93|hamster cells
P07790719A0098|20 26|effort
P07790719A0098|54 62|patients
P07790719A0098|69 84|family violence
P07791760A0424|0 14|GnRH treatment
P07791760A0424|41 56|phosphorylation
P07791760A0424|60 77|tyrosine residues
P07791760A0424|81 85|MAPK
P07791760A0424|102 115|MAPK activity
P07791760A0424|144 164|complex kinase assay
P07791763T0000|10 17|cloning
P07791763T0000|34 60|insulin receptor substrate
P07791763T0000|68 72|cDNA
P07791763T0000|77 88|involvement
P07791763T0000|92 121|phosphatidylinositol 3-kinase
P07791763T0000|141 166|Xenopus oocyte maturation
P07791764A0357|32 46|Jurkat T cells
P07791764A0357|48 51|Cbl
P07791764A0357|75 83|antibody
P07791764A0357|96 116|adapter protein Grb2
P07791768A0930|4 10|effect
P07791768A0930|20 41|cell cycle regulators
P07791768A0930|65 70|rap1s
P07791768A0930|74 94|hmr delta A mutation
P07791768A0930|102 106|swi6
P07791768A0930|108 112|swi4
P07791768A0930|118 132|clb5 mutations
P07791768A0930|147 156|mutations
P07791768A0930|160 164|SIR1
P07791768A0930|174 178|gene
P07791768A0930|197 210|establishment
P07791768A0930|214 223|silencing
P07791769A0826|0 4|ICP4
P07791769A0826|39 48|complexes
P07791769A0826|72 76|TATA
P07791769A0826|89 96|protein
P07791769A0826|101 106|TFIIB
P07791769A0826|110 113|DNA
P07791769A0826|128 145|ICP4 binding site
P07791769A0826|152 160|TATA box
P07791769A0826|162 164|C.
P07791771A0183|0 4|Otte
P07791771A0183|6 9|Mol
P07791776T0000|0 16|Characterization
P07791776T0000|20 24|fus1
P07791776T0000|84 92|function
P07791776T0000|104 115|conjugation
P07791783A0000|12 16|cDNA
P07791783A0000|28 35|protein
P07791783A0000|64 67|HMG
P07791783A0000|69 72|box
P07791783A0000|79 99|leucine zipper motif
P07791783A0000|122 128|SOX-LZ
P07791783A0000|150 183|rainbow trout testis cDNA library
P07793783A0189|0 11|Scalp flaps
P07793783A0189|40 45|point
P07793783A0189|81 86|weeks
P07793783A0189|99 123|scalp flap transposition
P07793783A0189|133 140|closure
P07793783A0189|148 158|donor site
P07794556A0000|7 13|Center
P07794556A0000|24 32|Genetics
P07794556A0000|36 42|Leuven
P07794556A0000|55 66|DNA-testing
P07794556A0000|71 81|Huntington
P07794556A0000|84 91|disease
P07794556A0000|119 126|service
P07794556A0000|133 141|November
P07794556A0000|161 172|DNA-linkage
P07794556A0000|202 219|mutation analysis
P07795104T0000|0 5|Risks
P07795104T0000|9 19|chronicity
P07795104T0000|36 63|hepatitis B virus infection
P07795104T0000|67 73|review
P07795576A0126|0 11|Examination
P07795576A0126|28 35|factors
P07795576A0126|79 85|system
P07795576A0126|93 101|increase
P07795576A0126|105 126|plasma renin activity
P07796935A0284|27 33|effect
P07796935A0284|64 72|hTR beta
P07796935A0284|97 106|hTR alpha
P07796935A0284|109 116|mutants
P07796935A0284|118 130|c-erbA alpha
P07796935A0284|147 157|peroxisome
P07796935A0284|181 189|receptor
P07796935A0284|191 196|hPPAR
P07796935A0284|230 238|elements
P07796935A0284|240 244|TREs
P07796935A0284|247 254|TRE-PAL
P07796935A0284|256 258|DR
P07796935A0284|267 274|TRE-LAP
P07797077A0842|31 37|domain
P07797077A0842|41 44|Pip
P07797077A0842|61 67|degree
P07797077A0842|71 79|homology
P07797077A0842|99 106|domains
P07797077A0842|110 117|members
P07797077A0842|125 135|interferon
P07797077A0842|147 153|factor
P07797077A0842|155 158|IRF
P07797077A0842|160 166|family
P07797077A0842|183 188|IRF-1
P07797077A0842|190 195|IRF-2
P07797077A0842|197 202|ICSBP
P07797077A0842|208 219|ISGF3 gamma
P07797346T0000|3 11|outbreak
P07797346T0000|15 26|hepatitis A
P07797346T0000|44 47|men
P07797346T0000|51 60|Amsterdam
P07797476A1001|4 17|RAP74 subunit
P07797476A1001|21 26|TFIIF
P07797476A1001|59 67|activity
P07797476A1001|84 90|region
P07797476A1001|106 117|stimulation
P07797476A1001|147 155|residues
P07797583A0222|26 44|base substitutions
P07797583A0222|58 67|deletions
P07797583A0222|82 85|DRE
P07797583A0222|87 107|nucleotide positions
P07797583A0222|125 132|respect
P07797583A0222|140 169|transcription initiation site
P07797583A0222|178 187|PCNA gene
P07797583A0222|229 236|effects
P07797583A0222|244 251|binding
P07797583A0222|255 259|DREF
P07797583A0222|273 279|factor
P07797583A0222|285 294|PCNA gene
P07797583A0222|303 311|activity
P07797583A0222|324 343|Drosophila Kc cells
P07797583A0222|365 370|flies
P07798134T0000|4 21|hsp70 gene family
P07798134T0000|25 42|Neurospora crassa
P07798134T0000|44 51|cloning
P07798134T0000|53 70|sequence analysis
P07798134T0000|72 82|expression
P07798134T0000|96 103|mapping
P07798134T0000|134 140|member
P07798207A0759|12 32|amino acid sequences
P07798207A0759|48 65|W3A1 ETF subunits
P07798207A0759|95 105|% identity
P07798207A0759|129 137|subunits
P07798207A0759|145 148|ETF
P07798207A0759|161 164|rat
P07798207A0759|170 194|Paracoccus denitrificans
P07798207A0759|207 212|group
P07798207A0759|232 233|%
P07798217T0000|12 27|phosphorylation
P07798217T0000|31 38|CREB341
P07798217T0000|42 48|Ser129
P07798217T0000|83 90|control
P07798217T0000|94 109|gene expression
P07798217T0095|2 6|role
P07798217T0095|11 37|glycogen synthase kinase-3
P07798217T0095|45 52|control
P07798217T0095|56 71|gene expression
P07798271A0330|10 16|region
P07798271A0330|30 35|sites
P07798271A0330|58 66|proteins
P07798271A0330|78 83|liver
P07798271A0330|92 100|extracts
P07798271A0330|133 146|Ets-1 protein
P07799437A0656|6 12|assays
P07799437A0656|47 58|replication
P07799437A0656|62 72|pNeo.Myc-2
P07799437A0656|95 103|labeling
P07799437A0656|107 123|control plasmids
P07799925A0526|0 14|Reconstitution
P07799925A0526|18 27|complexes
P07799925A0526|39 42|p62
P07799925A0526|51 75|src family kinase p59fyn
P07799925A0526|79 89|HeLa cells
P07799925A0526|108 125|complex formation
P07799925A0526|138 162|tyrosine phosphorylation
P07799925A0526|166 169|p62
P07799925A0526|199 202|SH3
P07799925A0526|207 218|SH2 domains
P07799925A0526|222 228|p59fyn
P07799931A0287|60 67|control
P07799931A0287|75 91|L7 gene insights
P07799931A0287|101 111|mechanisms
P07799931A0287|136 140|fate
P07799931A0287|145 157|organization
P07799931A0287|173 179|system
P07799931A1232|3 11|contrast
P07799931A1232|27 34|protein
P07799931A1232|36 39|Nrl
P07799931A1232|61 74|c-Maf actions
P07799939A0628|12 19|element
P07799939A0628|52 83|serine/threonine phosphoprotein
P07799939A0628|117 124|nucleus
P07799939A0628|141 150|3T3 cells
P07799948A0777|3 11|contrast
P07799948A0777|13 21|deletion
P07799948A0777|42 46|site
P07799948A0777|64 74|activation
P07799948A0777|78 90|Raf-1 kinase
P07799948A0777|94 97|Src
P07799948A0777|113 116|Src
P07799948A0777|121 124|Ras
P07799948A0777|138 143|Raf-1
P07799948A0777|164 174|mechanisms
P07799950A0282|3 10|studies
P07799950A0282|53 58|cells
P07799950A0282|64 67|CRE
P07799950A0282|75 101|somatostatin gene promoter
P07799950A0282|107 116|prototype
P07799950A0282|145 152|element
P07799950A0282|166 170|CREB
P07800479A0201|10 14|gene
P07800479A0201|16 20|NSR1
P07800479A0201|46 50|gene
P07800479A0201|62 69|protein
P07800479A0201|92 106|RNA maturation
P07800479A0201|123 132|transport
P07800479A0201|136 144|proteins
P07800479A0201|154 161|nucleus
P07800505T0000|0 16|Characterization
P07800505T0000|24 32|promoter
P07800505T0000|50 53|kDa
P07800505T0000|64 85|phospholipase A2 gene
P07801180A0197|5 10|paper
P07801180A0197|25 35|advantages
P07801180A0197|40 51|limitations
P07801180A0197|64 80|study approaches
P07802355T0000|12 17|study
P07802355T0000|44 60|blood cell count
P07802355T0000|83 92|analyzers
P07802355T0000|94 106|Coulter STKS
P07802355T0000|108 117|Sysmex NE
P07802355T0000|127 140|Technicon H-1
P07802655T0000|0 16|Characterization
P07802655T0000|20 28|FIII/YY1
P07802655T0000|32 46|Xenopus laevis
P07802655T0000|69 84|protein binding
P07802655T0000|98 102|exon
P07802655T0000|106 108|L1
P07802655T0000|113 116|L14
P07802655T0000|127 140|protein genes
P07803809A1852|8 15|studies
P07803809A1852|48 56|increase
P07803809A1852|60 76|beta-globin mRNA
P07803809A1852|103 138|tyrosine kinase inhibitor genistein
P07803809A1852|147 182|protein kinase C inhibitor Compound
P07803809A1852|186 194|ABSTRACT
P07803809A1852|212 217|WORDS
P07806492A1162|5 14|structure
P07806492A1162|18 27|cucumisin
P07806492A1162|84 93|precursor
P07806507A0121|10 20|dissection
P07806507A0121|39 54|CD3-TCR complex
P07806507A0121|93 105|polypeptides
P07806507A0121|107 115|CD3 zeta
P07806507A0121|120 131|CD3 epsilon
P07806507A0121|163 180|recognition event
P07806507A0121|199 205|events
P07806507A0121|230 248|activation cascade
P07806532A0659|0 13|Protein cHMGI
P07806532A0659|46 49|DNA
P07806532A0659|57 78|half-saturation value
P07806532A0659|86 88|nM
P07806651A0097|5 10|study
P07806651A0097|28 34|degree
P07806651A0097|51 59|identity
P07806651A0097|71 88|Mexican-Americans
P07806651A0097|90 101|performance
P07806651A0097|109 110|L
P07806651A0097|112 113|K
P07806651A0097|119 128|MF scales
P07806651A0097|136 142|MMPI-2
P07806820A0091|42 49|pedicle
P07806820A0091|84 90|artery
P07806820A0091|120 131|fascia flap
P07807002A0500|12 20|segments
P07807002A0500|24 27|DNA
P07807002A0500|40 45|flank
P07807002A0500|53 69|initiation sites
P07807002A0500|74 94|germline epsilon RNA
P07807002A0500|113 137|luciferase reporter gene
P07807002A0500|163 181|mouse B cell lines
P07807002A0500|224 227|IgE
P07808210A1510|24 29|value
P07808210A1510|35 36|%
P07808210A1510|43 44|%
P07808210A1510|53 60|NCEP I.
P07809128T0000|10 18|capacity
P07809128T0000|26 35|E2F1 gene
P07809410A0606|15 20|cases
P07809410A0606|33 39|lesion
P07809410A0606|41 57|serum TSH levels
P07809410A0606|59 85|serum thyroglobulin values
P07809410A0606|91 103|131I protein
P07809410A0606|112 118|iodine
P07809410A0606|120 128|131I-PBI
P07809410A0606|175 186|differences
P07809410A0606|223 230|therapy
P07811639A0222|0 18|Endo16 transcripts
P07811639A0222|58 63|plate
P07811639A0222|76 89|stage embryos
P07811639A0222|94 108|gastrula stage
P07811639A0222|114 118|gene
P07811639A0222|147 158|archenteron
P07811639A0222|182 188|midgut
P07811964A1252|25 39|repeat element
P07811964A1252|76 82|domain
P07811964A1252|86 92|EmBP-1
P07811964A1252|119 123|role
P07811964A1252|142 154|dimerization
P07812450A0849|13 16|ORF
P07812450A0849|43 49|strand
P07812450A0849|70 79|nspC gene
P07813466A0074|4 13|U14 genes
P07813466A0074|17 22|mouse
P07813466A0074|34 37|rat
P07813466A0074|39 46|hamster
P07813466A0074|55 62|Xenopus
P07813466A0074|67 72|trout
P07813466A0074|92 99|introns
P07813466A0074|158 170|protein gene
P07813466A0074|172 177|hsc70
P07813786A0641|12 17|cDNAs
P07813786A0641|44 52|proteins
P07813786A0641|72 89|XMyoDa TATA motif
P07814321A0850|0 8|Deletion
P07814321A0850|17 21|prfA
P07814321A0850|26 30|ponA
P07814321A0850|58 64|growth
P07814321A0850|71 80|reduction
P07814321A0850|84 106|sporulation efficiency
P07814323A0313|0 9|Inclusion
P07814323A0313|18 24|family
P07814323A0313|28 36|proteins
P07814323A0313|51 55|FliQ
P07814323A0313|60 64|FliR
P07814323A0313|87 101|export pathway
P07814323A0313|115 133|flagellum assembly
P07814388A0662|10 26|L-cell membranes
P07814388A0662|43 47|type
P07814388A0662|58 65|M6P/IGF
P07814388A0662|69 78|receptors
P07814388A0662|83 89|nM IGF
P07814388A0662|119 153|pertussis toxin substrate activity
P07814403A0433|0 4|Chem
P07814405A1170|14 18|time
P07814405A1170|31 39|deletion
P07814405A1170|44 59|point mutations
P07814405A1170|71 93|plasma membrane family
P07814405A1170|97 123|guanylyl cyclase receptors
P07814405A1170|143 152|formation
P07814405A1170|184 192|proteins
P07814717A0669|0 8|Increase
P07814717A0669|12 22|blood NEFA
P07814717A0669|48 51|fat
P07814717A0669|57 75|AA supplementation
P07814717A0669|84 91|changes
P07814717A0669|95 109|concentrations
P07814717A0669|113 116|Lys
P07814717A0669|120 123|Met
P07814717A0669|127 132|blood
P07815546A0411|0 5|Virol
P07815811A1487b|9 25|vasoconstriction
P07815811A1487b|36 48|endothelin-1
P07815811A1487b|64 84|ischemia-reperfusion
P07815811A1487b|92 106|norepinephrine
P07815811A1487b|118 132|concentrations
P07815811A1487b|183 189|bypass
P07816025A0196|0 10|Comparison
P07816025A0196|26 45|amino acid sequence
P07816025A0196|49 62|gamma-kafirin
P07816025A0196|82 91|sequences
P07816025A0196|95 110|gamma-prolamins
P07816025A0196|114 119|maize
P07816025A0196|125 129|Coix
P07816025A0196|156 163|domains
P07816049A0686|0 6|Atcys1
P07816049A0686|8 14|Athyp1
P07816049A0686|16 22|AKin10
P07816049A0686|31 34|ORF
P07816049A0686|90 98|polarity
P07816049A0686|122 129|regions
P07816049A0686|169 171|kb
P07816049A0686|192 200|elements
P07816049A0686|221 231|initiation
P07816049A0686|236 247|termination
P07816049A0686|251 264|transcription
P07816049A1157|0 39|Southern blot hybridization experiments
P07816049A1157|52 60|presence
P07816049A1157|68 72|copy
P07816049A1157|76 82|Atcys1
P07816049A1157|84 90|Athyp1
P07816049A1157|95 101|AKin10
P07816049A1157|106 120|haploid genome
P07816049A1157|126 148|Northern blot analysis
P07816049A1157|177 182|genes
P07816049A1157|215 220|roots
P07816617A0763|6 13|results
P07816617A0763|27 31|HAC1
P07816617A0763|63 68|genes
P07816619A0000|23 55|Arabidopsis thaliana cDNA clones
P07816619A0000|86 95|phenotype
P07816619A0000|129 140|pde1 mutant
P07816619A0000|164 186|cAMP phosphodiesterase
P07816619A0872|17 31|identification
P07816619A0872|46 53|protein
P07816619A0872|57 67|A.thaliana
P07816619A0872|92 100|ubiquity
P07816619A0872|109 116|protein
P07816619A0872|134 140|genera
P07816619A0872|161 170|mechanism
P07816619A0872|183 207|transcription initiation
P07816619A0872|222 225|Dr1
P07816630A1333|28 30|bp
P07816630A1333|34 42|sequence
P07816630A1333|61 87|translation terminator TGA
P07816630A1333|95 107|beta-tubulin
P07816630A1333|111 115|BTU2
P07816630A1333|117 121|gene
P07816630A1333|150 156|region
P07816630A1333|164 173|H4-I gene
P07816808A1102|6 10|data
P07816808A1102|32 42|STR family
P07816808A1102|46 51|genes
P07816808A1102|72 80|nematode
P07816808A1102|87 95|ancestor
P07816808A1102|141 145|rise
P07816808A1102|153 163|Arthropoda
P07816808A1102|168 176|Chordata
P07818416A0895|27 53|haemoglobin concentrations
P07818416A0895|72 77|group
P07818416A0895|102 105|g/L
P07818416A0895|135 138|THR
P07818416A0895|149 152|g/L
P07818416A0895|161 170|instances
P07818416A0895|177 189|revision THR
P07819225A1094|4 16|introduction
P07819225A1094|30 37|residue
P07819225A1094|52 56|site
P07819225A1094|75 86|suppression
P07819225A1094|94 110|Asn-285 mutation
P07819225A1094|119 126|Lys-220
P07819225A1094|131 138|Gln-220
P07819225A1094|151 158|mutants
P07819225A1094|166 180|Asn-285 mutant
P07819225A1094|197 220|tetracycline resistance
P07819225A1094|222 230|ABSTRACT
P07819225A1094|248 253|WORDS
P07820057A0000|0 27|Tumor necrosis factor alpha
P07820057A0000|33 41|cytokine
P07820057A0000|77 91|growth control
P07820057A0000|101 114|cell leukemia
P07820057A0000|126 130|bone
P07820057A0000|142 152|properties
P07821790A1084|14 19|UCRBP
P07821790A1084|74 83|repressor
P07821790A1084|103 108|UCRBP
P07821790A1084|136 150|transactivator
P07821790A1084|156 164|reporter
P07821790A1084|175 187|UCR elements
P07821790A1084|201 223|co-transfection assays
P07822161A1172|4 12|sequence
P07822161A1172|16 28|monkey opsin
P07822161A1172|57 65|sequence
P07822161A1172|73 83|nucleotide
P07822161A1172|92 109|amino acid levels
P07822161A1172|141 152|differences
P07822161A1172|164 172|residues
P07822329A0773|4 11|complex
P07822329A0773|62 67|cells
P07822329A0773|87 94|binding
P07822329A0773|118 124|factor
P07822329A0773|152 156|mass
P07822329A0773|177 180|kDa
P07822333A0376|0 4|Chem
P07823919A1422|12 22|activation
P07823919A1422|26 31|Oct-3
P07823919A1422|34 42|promoter
P07823919A1422|46 49|RAR
P07823919A1422|50 66|RXR heterodimers
P07823919A1422|95 100|EAR-3
P07823919A1422|101 109|COUP-TFI
P07823919A1422|117 122|ARP-1
P07823951A1100|6 13|results
P07823951A1100|31 35|EKLF
P07823951A1100|55 79|transactivation function
P07823951A1100|84 101|globin expression
P07823951A1100|128 132|idea
P07823951A1100|138 142|EKLF
P07823951A1100|159 168|regulator
P07823951A1100|172 177|CACCC
P07823951A1100|195 208|transcription
P07823951A1100|222 227|cells
P07823953A0777|8 15|battery
P07823953A0777|19 42|I kappa B alpha mutants
P07823953A0777|63 68|dimer
P07823953A0777|84 108|I kappa B alpha molecule
P07823953A0777|137 143|region
P07823953A0777|147 162|I kappa B alpha
P07823953A0777|199 206|binding
P07823953A0777|220 224|mask
P07823953A0777|237 256|localization signal
P07823953A0777|264 269|dimer
P07823953A0777|297 303|region
P07823953A0777|320 330|inhibition
P07823953A0777|334 345|DNA binding
P07823953A0777|361 371|inhibition
P07823953A0777|402 413|interaction
P07823953A0777|436 442|region
P07823953A0777|463 469|region
P07823953A0777|484 492|subunits
P07823953A0777|500 505|dimer
P07823964A0922|24 32|activity
P07823964A0922|51 57|domain
P07823964A0922|90 97|segment
P07823964A0922|101 107|Pho81p
P07823964A0922|120 125|trans
P07824325A0714|13 18|times
P07824325A0714|35 45|procedures
P07824325A0714|47 61|thorax opening
P07824325A0714|66 73|closure
P07824325A0714|75 81|period
P07824325A0714|101 107|bypass
P07824325A0714|118 119|%
P07824325A0714|127 135|patients
P07824325A0714|139 144|group
P07824325A0714|151 176|vancomycin concentrations
P07824325A0714|192 199|tissues
P07824325A0714|210 213|MIC
P07824325A0714|246 257|microgram/g
P07824325A0714|293 305|micrograms/g
P07824464A0169|20 26|images
P07824464A0169|30 42|tissue flaps
P07824464A0169|59 64|lumen
P07824464A0169|87 94|thrombi
P07824464A0169|96 119|artery wall dissections
P07824464A0169|121 136|plaque ruptures
P07824464A0169|143 155|fissurations
P07824464A0169|172 184|haemorrhages
P07824464A0169|206 212|colour
P07824464A0169|237 247|mechanisms
P07824464A0169|260 275|artery stenosis
P07824657A1456|13 31|cysteine formation
P07824657A1456|37 49|pCSK4F plant
P07824657A1456|64 71|sulfite
P07824657A1456|93 103|leaf discs
P07824726A0454|5 9|type
P07824726A0454|31 40|subgroups
P07824726A0454|48 53|basis
P07824726A0454|69 73|body
P07824726A0454|78 82|tail
P07824726A0454|90 98|pancreas
P07824726A0454|114 131|fatty replacement
P07824726A0454|133 137|type
P07824726A0454|163 180|fatty replacement
P07824726A0454|182 188|type b
P07824726A0454|212 229|fatty replacement
P07825888A0715|12 21|subgroups
P07825888A0715|25 43|dementia disorders
P07825888A0715|70 81|differences
P07825888A0715|91 106|cortisol levels
P07826412T0112|6 16|hypothesis
P07826412T0112|20 30|mechanisms
P07826412T0112|56 64|subunits
P07826412T0112|68 82|gamma-subunits
P07826412T0112|87 97|activation
P07826412T0112|103 113|holoenzyme
P07826412T0112|117 127|transducin
P07826625X0000|6 16|components
P07826625X0000|24 47|transcription apparatus
P07826625X0000|49 63|RNA polymerase
P07826625X0000|81 88|protein
P07826625X0000|98 116|activation domains
P07826625X0000|147 153|domain
P07826625X0000|155 158|CTD
P07826625X0000|163 177|RNA polymerase
P07826625X0000|193 208|enhancer domain
P07826625X0000|211 218|Regions
P07826625X0000|227 233|serine
P07826625X0000|235 244|threonine
P07826625X0000|250 266|proline residues
P07826625X0000|299 317|activation domains
P07826625X0000|348 353|parts
P07826625X0000|380 388|proteins
P07826625X0000|420 443|polyglutamine stretches
P07828584A0681|0 11|Mutagenesis
P07828584A0681|15 18|IM1
P07828584A0681|32 39|ability
P07828584A0681|43 48|c-Fos
P07828584A0681|64 84|AP1 bearing promoter
P07828600A0095|0 7|Binding
P07828600A0095|11 14|SSP
P07828600A0095|22 44|stage selector element
P07828600A0095|46 49|SSE
P07828600A0095|67 88|gamma-globin promoter
P07828600A0095|120 129|silencing
P07828600A0095|142 155|beta-promoter
P07828600A0095|175 196|stage erythroleukemia
P07828600A0095|198 202|K562
P07828600A0095|204 209|cells
P07828811A0556|5 12|failure
P07828811A0556|34 45|G1/S arrest
P07828811A0556|74 91|thermosensitivity
P07828811A0556|110 117|ability
P07828824A0307|0 9|Mutations
P07828824A0307|21 49|photoreceptor cell structure
P07828824A0307|54 65|development
P07828824A0307|110 119|deletions
P07828852A0153|24 33|telomeres
P07828852A0153|45 51|nuclei
P07828852A0153|67 76|functions
P07829057A1097|4 17|marker orders
P07829057A1097|39 46|RH maps
P07829057T0000|0 27|Integrated mapping analysis
P07829057T0000|35 57|Werner syndrome region
P07829057T0000|61 71|chromosome
P07829097A0000|4 10|region
P07829097A0000|19 24|DXS52
P07829097A0000|29 35|Factor
P07829097A0000|41 45|gene
P07829097A0000|59 63|Xq28
P07829097A0000|76 80|band
P07829097A0000|92 95|G+C
P07829097A0000|101 109|isochore
P07829097A0000|124 129|genes
P07829102T0000|0 17|Haplotype mapping
P07829102T0000|22 39|sequence analysis
P07829102T0000|47 63|mouse Nramp gene
P07829102T0000|72 86|susceptibility
P07829102T0000|90 99|infection
P07829102T0000|119 128|parasites
P07829519A1251|5 16|utilization
P07829519A1251|32 52|polyadenylation site
P07829519A1251|73 83|exon usage
P07829519A1251|105 114|mechanism
P07829519A1251|156 161|forms
P07829519A1251|169 186|immunoglobulin mu
P07829519A1251|193 198|chain
P07829519A1251|230 235|locus
P07829554A0257|15 24|knowledge
P07829554A0257|59 74|system response
P07829554A0257|114 132|protein conjugates
P07829554A0257|134 143|corrosion
P07829554A0257|148 161|wear products
P07829554A0257|185 192|devices
P07829554A0257|235 240|assay
P07829554A0257|242 247|ELISA
P07829554A0257|249 255|method
P07829554A0257|260 267|testing
P07829554A0257|272 280|antibody
P07829554A0257|290 298|immunity
P07829554A0257|303 309|metals
P07830112A0532|3 11|contrast
P07830112A0532|13 17|peak
P07830112A0532|26 30|rate
P07830112A0532|32 35|PFR
P07830112A0532|66 72|volume
P07830112A0532|74 77|EDV
P07830112A0532|83 96|stroke volume
P07830112A0532|98 100|SV
P07830112A0532|123 128|ratio
P07830112A0532|132 142|PFR-to-PER
P07830112A0532|156 157|p
P07830112A0532|167 171|time
P07830112A0532|175 178|PFR
P07830112A0532|180 184|TPFR
P07830112A0532|201 202|p
P07830112A0532|251 261|mass index
P07830112A0532|274 275|p
P07830112A0532|288 296|patients
P07830112A0532|302 312|acromegaly
P07830112A0532|325 332|normals
P07831310A0000|10 32|complementation system
P07831310A0000|56 74|tobacco etch virus
P07831310A0000|76 79|TEV
P07831310A0000|81 91|polymerase
P07831310A0000|93 96|NIb
P07831310A0000|120 126|plants
P07831310A0000|130 141|protoplasts
P07831310A0000|177 188|TEV mutants
P07831799T0000|0 19|Nucleotide sequence
P07831799T0000|40 48|analysis
P07831799T0000|56 75|DNA polymerase gene
P07831799T0000|79 85|Bombyx
P07831799T0000|99 117|polyhedrosis virus
P07831829A1324|0 10|Comparison
P07831829A1324|18 25|genomes
P07831829A1324|29 33|PMTV
P07831829A1324|35 40|BNYVV
P07831829A1324|46 51|SBWMV
P07831829A1324|63 74|furoviruses
P07831829A1324|96 109|heterogeneity
P07831829A1324|113 132|genome organization
P07832086A1023|4 20|drug sensitivity
P07832086A1023|28 29|%
P07832086A1023|34 44|vancomycin
P07832086A1023|46 49|VCM
P07832086A1023|54 55|%
P07832086A1023|60 68|imipenam
P07832086A1023|70 73|IMP
P07832086A1023|78 79|%
P07832086A1023|84 93|minomycin
P07832086A1023|95 99|MINO
P07832086A1023|104 105|%
P07832086A1023|110 118|amikacin
P07832086A1023|120 123|AMK
P07832086A1023|131 132|%
P07832086A1023|137 147|fosfomycin
P07832086A1023|149 152|FOM
P07832779A0719|0 15|Deglycosylation
P07832779A0719|21 38|endoglycosidase H
P07832779A0719|62 71|receptors
P07832779A0719|96 118|oligosaccharide chains
P07834582A0115|8 18|supplement
P07834582A0115|24 32|fish oil
P07834582A0115|45 53|n-3 EFAs
P07834582A0115|100 108|property
P07834582A0115|112 119|animals
P07834582A0115|124 130|humans
P07834582A0115|161 173|hypertension
P07835088A0238|4 10|HSD3B1
P07835088A0238|15 27|HSD3B2 genes
P07835088A0238|41 46|types
P07835088A0238|58 77|beta-HSD isoenzymes
P07835088A0238|134 147|hybridization
P07835088A0238|155 179|chromosome 1p13.1 region
P07835214A0603|14 25|prevalences
P07835214A0603|35 43|diabetes
P07835214A0603|48 51|GDM
P07835214A0603|61 62|%
P07835214A0603|71 72|%
P07835273A0000|19 36|glucose transport
P07835273A0000|40 50|adipocytes
P07835273A0000|70 86|insulin receptor
P07835273A0411|6 15|selection
P07835273A0411|20 30|conversion
P07835273A0411|34 44|adipocytes
P07835273A0411|50 55|level
P07835273A0411|59 74|EGFR expression
P07835273A0411|101 111|adipocytes
P07835273A0411|133 137|cell
P07835273A0411|178 195|3T3-L1 adipocytes
P07835273A0411|199 208|5000/cell
P07835710T0000|12 21|structure
P07835710T0000|29 46|porcine I kappa B
P07835710T0000|62 66|gene
P07835826A0195|0 8|Fraction
P07835826A0195|25 27|OH
P07835826A0195|28 40|2-vitamin D3
P07835826A0195|42 52|vitamin D3
P07835826A0195|57 59|OH
P07835826A0195|61 71|vitamin D3
P07835826A0195|84 86|OH
P07835826A0195|87 99|3-vitamin D3
P07835886A0894|4 20|kallistatin gene
P07835886A0894|46 59|hybridization
P07835886A0894|69 89|chromosome 14q31-q32
P07835886A0894|106 118|serpin genes
P07835886A0894|128 152|alpha 1-antichymotrypsin
P07835886A0894|154 173|protein C inhibitor
P07835886A0894|175 194|alpha 1-antitrypsin
P07835886A0894|223 231|globulin
P07835888A0402|4 9|locus
P07835888A0402|23 30|XD gene
P07835888A0402|43 45|Xd
P07835888A0402|72 76|part
P07835888A0402|80 96|mouse chromosome
P07835888A0402|103 121|haplotype analysis
P07835888A0402|143 157|backcross mice
P07836218A0128|5 12|studies
P07836218A0128|16 24|exercise
P07836218A0128|41 63|beta-endorphin release
P07836218A0128|79 94|exertion levels
P07836218A0128|106 114|evidence
P07836218A0128|129 137|acidosis
P07836218A0128|156 163|release
P07836218A0128|167 181|beta-endorphin
P07836228A1052|15 28|communication
P07836228A1052|43 53|impairment
P07836228A1052|57 68|LV function
P07836228A1052|98 102|drop
P07836228A1052|120 128|pressure
P07836364A0000|0 4|Self
P07836364A0000|25 33|proteins
P07836364A0000|42 50|peptides
P07836364A0000|55 67|presentation
P07836364A0000|77 103|histocompatibility complex
P07836364A0000|105 108|MHC
P07836364A0000|110 115|class
P07836364A0000|118 127|molecules
P07836364A0000|135 142|surface
P07836364A0000|146 170|antigen presenting cells
P07836364A0000|172 175|APC
P07836390A1152|4 19|characteristics
P07836390A1152|48 65|cleavage reaction
P07836390A1152|104 115|relaxosomes
P07836390A1152|119 132|IncP plasmids
P07836390A1152|145 155|initiation
P07836390A1152|159 183|transfer DNA replication
P07836390A1152|201 212|conjugation
P07836406A0884|32 40|peptides
P07836406A0884|56 61|MHC-B
P07836406A0884|82 93|cdc2 kinase
P07836406A0884|113 127|phosphopeptide
P07836406A0884|168 179|performance
P07836406A0884|187 201|chromatography
P07836471A0375|12 28|protein sequence
P07836471A0375|35 36|%
P07836471A0375|59 63|hNUC
P07836471A0375|87 105|osteosarcoma cells
P07838156A0789|9 31|cotransfection studies
P07838156A0789|46 49|RVR
P07838156A0789|68 81|transcription
P07838156A0789|92 116|hormone response element
P07838156A0789|132 145|reporter gene
P07838156A0789|186 195|repressor
P07838156A0789|199 217|ROR alpha function
P07840643A1006|2 12|comparison
P07840643A1006|20 55|Flavobacterium glycosylasparaginase
P07840643A1006|73 93|glycosylasparaginase
P07840643A1006|105 106|%
P07840643A1006|118 126|identity
P07840643A1006|133 134|%
P07840643A1006|143 153|similarity
P07840643A1006|193 198|forms
P07840643A1006|206 212|enzyme
P07841230T0000|0 12|Dissociation
P07841230T0000|17 29|complexation
P07841230T0000|53 67|antimicrobials
P07841663A0685|0 20|Superoxide dismutase
P07841663A0685|22 25|SOD
P07841663A0685|27 35|activity
P07841663A0685|63 68|sperm
P07841663A0685|109 119|comparison
P07841663A0685|127 134|control
P07841663A0685|142 148|sample
P07841663A0685|177 183|medium
P07841663A0845|6 13|studies
P07841663A0845|60 71|stimulation
P07841663A0845|90 104|oxygen species
P07841663A0845|116 128|SOD activity
P07841663A0845|139 143|part
P07841663A0845|174 186|sperm motion
P07841663A0845|191 200|viability
P07844142A0640|10 17|cloning
P07844142A0640|22 32|sequencing
P07844142A0640|38 42|cDNA
P07844142A0640|52 59|SR beta
P07844142A0640|74 81|SR beta
P07844142A0640|101 108|protein
P07844142A0640|119 127|SR alpha
P07844142A0640|132 137|SRP54
P07844142A0640|144 150|member
P07844142A0640|158 176|GTPase superfamily
P07844155A0327|18 26|function
P07844155A0327|46 67|tyrosine phosphatases
P07844155A0327|78 89|development
P07844155A0327|113 125|LAR isoforms
P07844155A0327|166 172|system
P07844155A0327|186 195|processes
P07844155A0327|207 210|LAR
P07844155A0327|223 231|splicing
P07844201T0000|0 13|Sex selection
P07844201T0000|18 33|albumin columns
P07844201T0000|38 43|years
P07844201T0000|47 54|results
P07844425A0289|4 12|students
P07844425A0289|19 24|count
P07844425A0289|41 51|eggs/10 ml
P07844425A0289|53 58|urine
P07844425A0289|83 92|eggs/10ml
P07844555A0406|24 34|E mu pim-1
P07844555A0406|46 50|mice
P07844555A0406|76 96|lymphoma development
P07844555A0406|126 132|M-MuLV
P07844555A0406|136 141|birth
P07845672A0368|0 10|Comparison
P07845672A0368|31 44|blk sequences
P07845672A0368|73 94|% amino acid identity
P07845672A0368|115 121|region
P07845672A0368|142 148|domain
P07845672A0368|152 162|% identity
P07846153A0403|0 10|Chrispeels
P07846153A0403|18 24|EMBO J
P07846163A0422|4 9|mRNAs
P07846163A0422|17 26|GRF genes
P07846163A0422|46 51|exons
P07846163A0422|72 79|introns
P07846199A0000|4 10|effect
P07846199A0000|14 21|ethanol
P07846199A0000|31 54|sensorimotor reactivity
P07846199A0000|94 110|startle response
P07846942A0717|0 20|Digitalis glycosides
P07846942A0717|24 49|beta-receptor antagonists
P07846942A0717|73 80|therapy
P07846942A0717|89 93|form
P07846942A0717|104 116|fibrillation
P07846942A0717|125 130|class
P07846942A0717|148 153|drugs
P07846942T0001|7 19|fibrillation
P07846942T0001|46 52|system
P07847036A0353|8 13|doses
P07847036A0353|18 23|times
P07847036A0353|52 65|haemophiliacs
P07847036A0353|74 83|inhibitor
P07848358A0254|2 11|reduction
P07848358A0254|19 54|aspartate aminotransferase activity
P07848358A0254|77 87|mg/kg b.w.
P07848358A0254|88 97|d onwards
P07851643A1365|12 19|studies
P07851643A1365|46 53|isoform
P07851643A1365|77 90|proliferation
P07851643A1365|101 115|germline cells
P07851643A1365|132 154|oocyte differentiation
P07851758A0330|9 27|analysis maps SAL6
P07851758A0330|31 45|chromosome XVI
P07851758A0330|54 58|TPK2
P07851758A0330|63 68|spt14
P07852037A0548|18 35|DCT method yields
P07852037A0548|45 49|data
P07852037A0548|63 66|TBF
P07852361A0868|0 7|Removal
P07852361A0868|11 15|PDMP
P07852361A0868|25 36|cell medium
P07852361A0868|49 57|reversal
P07852361A0868|65 83|cell cycle changes
P07852361A0868|90 95|cells
P07852361A0868|112 119|S phase
P07852400A0519|0 30|Rho GDP/GTP exchange inhibitor
P07852400A0519|32 39|Rho GDI
P07852400A0519|57 61|Rac2
P07852400A0519|66 70|RhoA
P07852400A0519|80 84|Rac1
P07853448A0601|8 12|task
P07853448A0601|17 34|sports scientists
P07853448A0601|68 74|nature
P07853448A0601|92 97|model
P07853448A0601|105 120|sport performer
P07853476A0159|0 7|Schnell
P07853476A0159|9 11|J.
P07853488T0000|0 13|Encapsidation
P07853488T0000|17 37|poliovirus replicons
P07853488T0000|66 93|immunodeficiency virus type
P07853488T0000|96 104|gag gene
P07853488T0000|116 138|complementation system
P07853488T0000|158 175|P1 capsid protein
P07853488T0000|179 184|trans
P07853524A1944|0 7|Removal
P07853524A1944|15 25|GST domain
P07853524A1944|31 38|GST-Tax
P07853524A1944|42 50|thrombin
P07853524A1944|60 63|Tax
P07853524A1944|66 73|ability
P07853524A1944|96 125|Tax-CREB-21-bp-repeat complex
P07853524A1944|127 135|ABSTRACT
P07853524A1944|153 158|WORDS
P07854130A1387|4 15|requirement
P07854130A1387|19 23|PilE
P07854130A1387|27 43|pilus biogenesis
P07854130A1387|92 114|pilE insertion mutants
P07854130A1387|120 125|pilus
P07854130A1387|131 149|twitching-motility
P07854130T0000|4 21|pilE gene product
P07854130T0000|62 78|pilus biogenesis
P07854130T0000|80 115|shares amino acid sequence identity
P07854130T0000|125 134|N-termini
P07854130T0000|138 142|type
P07854130T0000|145 162|prepilin proteins
P07854324A0281|26 38|conservation
P07854324A0281|42 69|cell cycle control elements
P07854324A0281|75 85|expression
P07854324A0281|91 106|vertebrate wee1
P07854324A0281|110 122|mik1 homolog
P07854324A0281|163 172|mutations
P07854324A0281|176 181|yeast
P07854324A0742|4 14|expression
P07854324A0742|23 28|clone
P07854324A0742|61 67|causes
P07854324A0742|81 95|cell phenotype
P07854324A0742|117 134|growth conditions
P07856102A1616|6 10|data
P07856102A1616|25 40|phosphorylation
P07856102A1616|44 53|M protein
P07856102A1616|75 80|sites
P07856102A1616|102 116|virus assembly
P07857086A0949|18 19|%
P07857086A0949|24 31|Insulin
P07857086A0949|60 61|%
P07857086A0949|67 88|Non Insulin Dependent
P07857086A0949|97 98|D
P07857086A0949|100 101|F
P07857086A0949|103 110|H White
P07857086A0949|113 118|Class
P07857163A0551|4 12|activity
P07857163A0551|16 34|6-fluoroquinolones
P07857163A0551|60 71|derivatives
P07857344A0591|7 16|half-life
P07857344A0591|24 32|compound
P07857344A0591|54 55|h
P07857344A0591|61 65|data
P07857344A0591|85 91|change
P07857344A0591|95 128|pidotimod administration schedule
P07857344A0591|142 143|h
P07857762A0611|4 22|MAP kinase cascade
P07857762A0611|50 60|eukaryotes
P07857762A0611|95 104|responses
P07858986A0310|14 19|study
P07858986A0310|35 49|interferometry
P07858986A0310|57 64|porcine
P07858986A0310|79 85|valves
P07858986A0310|93 115|Carpentier-Edwards SAV
P07858986A0310|121 131|BioImplant
P07858986A0310|140 146|Valcor
P07858986A0310|171 177|valves
P07858986A0310|195 219|glutaraldehyde treatment
P07859238A1150|11 23|side effects
P07859301A0325|5 11|region
P07859301A0325|40 46|domain
P07859301A0325|79 100|leucine-zipper motifs
P07859301A0325|102 110|features
P07859301A0325|137 164|transcription factor family
P07859371A1246|9 16|binding
P07859371A1246|62 65|rat
P07859371A1246|69 84|mouse fragments
P07859371A1246|107 115|extracts
P07859665A0498|4 15|mean jitter
P07859665A0498|24 37|fiber density
P07859665A0498|72 75|day
P07859665A0498|92 104|microseconds
P07859665A0498|123 126|day
P07859665A0498|144 156|microseconds
P07859739T0000|0 4|Lack
P07859739T0000|8 30|cyclin D-Cdk complexes
P07859739T0000|46 51|cells
P07859739T0000|73 79|levels
P07859739T0000|83 126|p16INK4/MTS1 tumour suppressor gene product
P07859777A0000|18 31|serum albumin
P07859777A0000|33 37|rHSA
P07859777A0000|60 72|fermentation
P07859777A0000|98 102|form
P07859777A0000|106 119|microcapsules
P07859777A0000|134 141|microns
P07859777A0000|145 153|diameter
P07859777A0000|177 191|technetium-99m
P07859777A0000|202 211|reduction
P07859777A0000|226 234|chloride
P07860208A0000|21 28|release
P07860208A0000|32 50|interleukin-1 beta
P07860208A0000|52 56|IL-1
P07860208A0000|62 90|tumour necrosis factor-alpha
P07860208A0000|92 95|TNF
P07860208A0000|113 122|monocytes
P07860208A0000|127 136|monocytes
P07860208A0000|153 171|lipopolysaccharide
P07860208A0000|173 176|LPS
P07860208A0000|207 212|blood
P07860208A0000|220 228|patients
P07860208A0000|258 276|glomerulonephritis
P07860208A0000|278 281|AGN
P07860208A0000|298 306|controls
P07860646A1363|8 20|intervention
P07860646A1363|44 47|use
P07860646A1363|56 65|treatment
P07860646A1363|92 100|diseases
P07860646A1363|111 116|FGF-2
P07862092A0302|21 26|clone
P07862092A0302|52 63|suppressors
P07862092A0302|72 82|ts mutants
P07862092A0302|84 88|sdp1
P07862092A0302|93 109|mutation pol3-14
P07862092A0302|114 120|sdp5-1
P07862092A0302|125 141|mutation pol3-11
P07862092A0302|175 190|haploid strains
P07862092A0302|199 203|sdp1
P07862092A0302|208 222|pol3-11 sdp5-1
P07862092A0302|246 255|libraries
P07862092A0302|259 269|singlecopy
P07862092A0302|283 290|vectors
P07862108A0987|0 28|UV cross-linking experiments
P07862108A0987|39 42|TEP
P07862108A0987|69 73|mass
P07862108A0987|94 97|kDa
P07862129A1391|15 21|livers
P07862129A1391|46 55|reduction
P07862129A1391|59 81|HNF-3 alpha expression
P07862129A1391|106 114|decrease
P07862129A1391|122 132|expression
P07862129A1391|140 151|target gene
P07862129A1391|157 165|TTR gene
P07862141A0317|32 39|alleles
P07862141A0317|43 48|genes
P07862141A0317|62 71|cAPK lead
P07862141A0317|79 88|inability
P07862141A0317|107 122|differentiation
P07862141A1412|4 10|member
P07862141A1412|19 25|family
P07862141A1412|27 31|RFX1
P07862141A1412|38 58|transcription factor
P07862141A1412|65 72|variety
P07862141A1412|95 100|genes
P07862150A0429|5 11|mutant
P07862150A0429|66 72|vector
P07862150A0429|75 81|series
P07862150A0429|85 94|mink lung
P07862150A0429|106 117|cell clones
P07862150A0429|135 160|TGF-beta binding activity
P07862150A0429|213 222|responses
P07862150A0429|226 234|TGF-beta
P07862154A0340|0 7|Cloning
P07862154A0340|11 26|complementation
P07862154A0340|63 71|analysis
P07862154A0340|97 101|RAF1
P07862162A0408|7 15|presence
P07862162A0408|19 27|inositol
P07862162A0408|32 39|choline
P07862162A0408|58 65|product
P07862162A0408|73 82|OPI1 gene
P07862162A0408|93 106|transcription
P07862162A0408|123 137|UASINO element
P07862165A0184|12 28|monkey COS cells
P07862165A0184|34 50|oligonucleotides
P07862165A0184|61 69|psoralen
P07862165A0184|98 107|mutations
P07862165A0184|120 125|virus
P07862165A0184|130 134|SV40
P07862165A0184|136 142|vector
P07862165A0184|164 169|cells
P07862165A0184|195 210|helix formation
P07862168A0000|4 15|interleukin
P07862168A0000|18 38|receptor alpha-chain
P07862168A0000|40 51|IL-2R alpha
P07862168A0000|53 57|gene
P07862168A0000|93 100|T cells
P07862168A0000|104 112|response
P07862168A0000|126 133|stimuli
P07862533A0000|4 9|Wilms
P07862533A0000|11 36|tumour suppressor protein
P07862533A0000|38 41|WT1
P07862533A0000|84 91|protein
P07862533A0000|102 114|zinc fingers
P07862533A0000|155 172|sequence homology
P07862533A0000|186 203|growth response-1
P07862533A0000|205 210|EGR-1
P07862533A0000|212 219|protein
P07863047A0229|0 10|OBJECTIVES
P07863047A0229|28 46|serum ACE activity
P07863047A0229|50 58|patients
P07863047A0229|64 68|COPD
P07863047A0229|116 130|oxygen therapy
P07863047A0229|132 136|CAOT
P07863047A0229|171 182|correlation
P07863047A0229|191 194|ACE
P07863047A0229|244 253|parameter
P07863619A0098|3 8|order
P07863619A0098|18 23|shape
P07863619A0098|29 36|contour
P07863619A0098|55 61|system
P07863619A0098|89 98|fragments
P07863619A0098|124 130|object
P07863619A0098|145 154|fragments
P07863619A0098|170 177|objects
P07863992A0908|8 13|group
P07863992A0908|16 24|patients
P07863992A0908|41 47|result
P07863992A0908|70 77|testing
P07863992A0908|85 93|evidence
P07863992A0908|108 121|heart disease
P07863992A0908|123 137|mean follow-up
P07863992A0908|142 147|years
P07863992A0908|172 180|episodes
P07863992A0908|184 191|syncope
P07863992A0908|213 223|medication
P07863992A0908|260 268|exercise
P07864652A0753|0 10|Constructs
P07864652A0753|39 43|E2L1
P07864652A0753|51 55|E2L1
P07864652A0753|56 58|H1
P07864652A0753|67 71|E2L2
P07864652A0753|82 86|E2H1
P07864652A0753|87 89|L2
P07864652A0753|103 107|E2L1
P07864652A0753|108 110|H1
P07864652A0753|111 113|L2
P07864652A0753|128 135|numbers
P07864652A0753|139 150|parentheses
P07864652A0753|160 179|amino acid sequence
P07864652A0753|188 196|portions
P07864652A0753|204 216|E2 component
P07864652A0753|237 246|construct
P07864652A1901|30 47|domain constructs
P07864652A1901|93 98|roles
P07864652A1901|102 106|E2L1
P07864652A1901|111 115|E2L2
P07864652A1901|157 166|processes
P07864709A0324|0 7|METHODS
P07864709A0324|13 24|influenza A
P07864709A0324|26 30|H3N2
P07864709A0324|32 39|viruses
P07864709A0324|60 69|outbreaks
P07864709A0324|88 98|resistance
P07864709A0324|102 112|amantadine
P07864709A0324|117 128|rimantadine
P07864709A0324|132 137|means
P07864709A0324|144 162|enzyme immunoassay
P07864709A0324|170 180|sequencing
P07864709A0324|202 206|acid
P07864709A0324|238 244|domain
P07864709A0324|252 262|M2 protein
P07865129A0293|19 26|ATF/CRE
P07865129A0293|31 55|TBP/TATA sequence motifs
P07865129A0293|72 78|region
P07865786A0457|0 15|Gene expression
P07865786A0457|38 44|rhythm
P07865786A0457|60 65|light
P07865786A0457|69 75|leaves
P07865786A0457|92 98|plants
P07865787A1086|4 11|results
P07865787A1086|31 38|hexamer
P07865787A1086|47 61|octamer motifs
P07865787A1086|81 85|role
P07865787A1086|86 87|s
P07865787A1086|92 102|regulation
P07865787A1086|163 173|expression
P07865787A1086|181 202|wheat histone H3 gene
P07865876A1292|20 30|expression
P07865876A1292|34 51|DP family members
P07865876A1292|70 81|combination
P07865876A1292|85 104|DP/E2F heterodimers
P07865876A1292|121 130|DRTF1/E2F
P07865876A1292|152 161|phenotype
P07865876A1292|169 173|cell
P07865888A1309|24 35|cells PBP74
P07865888A1309|56 67|pre-protein
P07865888A1309|82 90|membrane
P07865888A1309|111 117|import
P07865888A1309|123 135|mitochondria
P07865888A1309|144 154|maturation
P07865895A0896|12 22|experiment
P07865895A0896|41 61|lung clearance assay
P07865895A0896|75 78|mAb
P07865895A0896|96 100|rats
P07865895A0896|104 116|LGL/NK cells
P07865895A0896|136 145|rationale
P07865895A0896|150 162|LGL/NK cells
P07865895A0896|191 196|event
P07865895A0896|212 219|absence
P07865895A0896|226 231|event
P07865917A0191|0 9|Treatment
P07865917A0191|23 27|FSGS
P07865917A0191|51 59|steroids
P07865917A0191|71 83|cyclosporine
P07865917A0191|85 88|CSA
P07865917A0191|91 105|plasmapheresis
P07865917A0191|111 125|ACE inhibitors
P07865917A0191|137 144|results
P07867604A1777|4 11|results
P07867604A1777|38 58|inhibin/activin beta
P07867604A1777|69 74|mRNAs
P07867604A1777|107 123|initiation sites
P07867604A1777|133 142|promoters
P07867604A1777|194 202|elements
P07867604A1777|228 237|promoters
P07867604A1777|255 259|cAMP
P07867604A1777|267 281|phorbol esters
P07867604A1777|292 302|conditions
P07867622X0000|0 15|Promoter region
P07867622X0000|39 43|unit
P07867622X0000|54 71|alpha 1-chimaerin
P07867622X0000|109 116|protein
P07867622X0000|121 127|p21rac
P07867622X0000|129 146|alpha 1-chimaerin
P07867622X0000|186 193|protein
P07867622X0000|198 204|p21rac
P07867622X0000|208 215|protein
P07867622X0000|242 248|events
P07867944A0365|0 8|Upstream
P07867944A0365|18 43|transcription start point
P07867944A0365|45 48|tsp
P07867944A0365|53 72|nucleotide sequence
P07867944A0365|98 122|consensus sequence motif
P07867944A0365|131 136|sigma
P07867944A0365|151 160|promoters
P07869721A0000|8 13|paper
P07869721A0000|18 26|analysis
P07869721A0000|34 42|dynamics
P07869721A0000|50 63|closing phase
P07869721A0000|71 79|occluder
P07869721A0000|108 130|heart valve prosthesis
P07869913A1076|7 22|ISO+AT infusion
P07869913A1076|38 48|blood flow
P07869913A1076|100 114|control values
P07869913A1076|133 141|subjects
P07869937A1142|19 39|kilogram body weight
P07869937A1142|46 49|GIT
P07869937A1142|67 75|dF group
P07869937A1142|85 86|%
P07869937A1142|94 95|%
P07869937A1142|102 105|RMR
P07869937A1142|126 134|decrease
P07869937A1142|144 145|%
P07869937A1142|153 154|%
P07869937A1142|162 169|P group
P07870305A1015|3 20|nucleus ventralis
P07870305A1015|30 81|thalami-nucleus ventralis lateralis thalami neurons
P07870305A1015|101 106|input
P07870305A1015|112 136|nucleus entopeduncularis
P07870305A1015|154 164|inhibition
P07870305A1015|198 200|ms
P07870305A1015|202 203|P
P07870305A1015|222 243|haloperidol influence
P07871718A1132|9 18|inclusion
P07871718A1132|38 51|CGGAAR motifs
P07871718A1132|61 74|ICP4 promoter
P07871718A1132|87 105|factors GABP alpha
P07871718A1132|110 114|beta
P07871718A1132|148 158|activation
P07871721A0000|15 28|reading frame
P07871721A0000|46 63|scorch carlavirus
P07871721A0000|65 70|BBScV
P07871721A0000|72 78|genome
P07871721A0000|121 128|protein
P07871721A0000|136 139|kDa
P07871721A0000|141 145|p223
P07871721A0392|5 24|sequence alignments
P07871721A0392|55 62|viruses
P07871721A0392|74 85|tymoviruses
P07871721A0392|105 109|p223
P07871721A0392|134 151|proteinase domain
P07871721A0392|178 189|cysteine994
P07871721A0392|194 207|histidine1075
P07871754A0857|5 12|finding
P07871754A0857|53 62|mechanism
P07871754A0857|72 91|HPV gene expression
P07871754A0857|128 133|model
P07871754A0857|142 147|study
P07871754A0857|167 180|cooperativity
P07871755A0521|11 17|method
P07871755A0521|19 23|VLPs
P07871755A0521|41 51|quantities
P07871755A0521|75 91|characterization
P07871757A0846|0 8|Analysis
P07871757A0846|16 24|sequence
P07871757A0846|42 58|initiation codon
P07871757A0846|71 79|presence
P07871757A0846|85 102|promotor sequence
P07871891A0227|0 5|SUP46
P07871891A0227|23 43|translation fidelity
P07871891A0227|70 81|protein S13
P07872673A0332|26 38|relationship
P07872673A0332|47 52|c-fos
P07872673A0332|57 59|Rb
P07872673A0332|74 92|expression plasmid
P07872673A0332|124 134|c-fos gene
P07872673A0332|141 148|control
P07872673A0332|156 177|SV40 promoter complex
P07872788A1717|9 15|degree
P07872788A1717|19 36|sequence identity
P07872788A1717|40 41|%
P07872788A1717|51 62|hydrolase B
P07872788A1717|67 68|C
P07872788A1717|106 112|region
P07872788A1717|132 137|genes
P07872788A1717|157 174|carboxylesterases
P07872788A1717|186 197|duplication
P07872788A1717|202 212|divergence
P07872788A1717|235 239|gene
P07873631A0114|4 11|regions
P07873631A0114|19 33|tooth fracture
P07873831T0000|21 32|involvement
P07873831T0000|36 53|mycosis fungoides
P07873831T0000|88 92|mass
P07873876A1035|4 14|NR2 hybrid
P07873876A1035|29 33|tool
P07873876A1035|42 49|mapping
P07873876A1035|57 63|probes
P07873876A1035|72 78|region
P07873876A1035|121 127|probes
P07873876A1035|145 153|deletion
P07873876A1035|169 176|cloning
P07873876A1035|184 190|region
P07874060A0810|0 5|TDEYA
P07874060A0810|9 14|doses
P07874060A0810|29 34|mg/kg
P07874060A0810|60 76|xanthine oxidase
P07874060A0810|78 80|XO
P07874060A0810|82 90|activity
P07874060A0810|98 112|stomach tissue
P07874060A0810|132 146|administration
P07875595A0910|5 11|humans
P07875595A0910|17 33|PITSLRE PK genes
P07875595A0910|37 45|chickens
P07875595A0910|99 112|hybridization
P07875595A0910|114 118|FISH
P07875595A0910|120 132|localization
P07875595A0910|142 147|genes
P07875595A0910|160 183|chicken microchromosome
P07876134A0348|20 36|characterization
P07876134A0348|67 71|form
P07876134A0348|75 83|AFAP-110
P07876134A0348|115 124|base pair
P07876134A0348|126 128|bp
P07876134A0348|138 151|reading frame
P07876191A0808|0 10|Expression
P07876191A0808|14 19|class
P07876191A0808|23 31|ADH mRNA
P07876191A0808|54 61|stomach
P07876191A0808|70 75|liver
P07876192A0443|3 12|ICE gamma
P07876192A0443|26 36|propeptide
P07876192A0443|38 49|amino acids
P07876192A0443|111 119|catalyst
P07876192A0443|124 142|ICE autoprocessing
P07876194T0000|0 11|Endocytosis
P07876194T0000|26 35|targeting
P07876194T0000|49 72|growth factor receptors
P07876194T0000|98 107|sequences
P07876194T0000|127 149|tyrosine kinase domain
P07876210A0275|69 74|genes
P07876210A0275|93 100|regions
P07876210A0275|149 157|proteins
P07876210A0275|170 188|Barbie box element
P07876210A0751|0 8|Mutation
P07876210A0751|16 35|P450BM-3 Barbie box
P07876210A0751|64 74|expression
P07876210A0751|83 91|P450BM-3
P07876210A0751|96 101|Bm3P1
P07876210A0751|117 121|gene
P07876210A0751|146 159|P450BM-3 gene
P07876210A0751|202 209|protein
P07876210A0751|214 222|response
P07876210A0751|240 249|induction
P07876210A0751|269 275|levels
P07876300A0994|17 23|nuclei
P07876300A0994|63 77|protein import
P07876562A1646|12 19|outcome
P07876562A1646|41 48|effects
P07876562A1646|73 87|responsiveness
P07876562A1646|100 107|T cells
P07876562A1646|121 132|stimulation
P07876562A1646|149 164|HIV-1 infection
P07877308A1175|9 17|protocol
P07877308A1175|38 46|patients
P07877308A1175|50 51|%
P07877308A1175|64 70|cohort
P07877619A1284|3 11|addition
P07877619A1284|41 52|suppression
P07877619A1284|70 92|zif268 gene expression
P07877619A1284|119 148|base pair nucleotide sequence
P07877619A1284|190 196|region
P07877619A1284|204 215|zif268 gene
P07878029A0721|13 18|CBF-A
P07878029A0721|23 28|CBF-C
P07878029A0721|64 83|CBF-A-CBF-C complex
P07878029A0721|93 98|CBF-B
P07878029A0721|122 127|CBF-A
P07878029A0721|131 136|CBF-C
P07878029A0721|182 201|CBF-A-CBF-C complex
P07878040A0505|25 34|sequences
P07878040A0505|55 69|mouse enhancer
P07878040A0505|102 106|loss
P07878040A0505|110 118|activity
P07878040A0505|146 150|mice
P07879204T0000|0 16|OKT3 prophylaxis
P07879204T0000|42 56|graft survival
P07879204T0000|70 78|patients
P07879204T0000|94 106|cyclosporine
P07879204T0000|117 124|results
P07879204T0000|170 180|US studies
P07880442A0236|10 48|PKC beta transcription initiation site
P07880442A0236|67 83|primer extension
P07880442A0236|88 110|S1 nuclease protection
P07880449A0091|7 13|course
P07880449A0091|19 24|study
P07880449A0091|32 51|dose X-rays effects
P07880449A0091|72 75|ICR
P07880449A0091|88 92|mice
P07880449A0091|111 122|suppression
P07880449A0091|135 143|behavior
P07880449A0091|156 172|body irradiation
P07880449A0091|184 194|cGy X-rays
P07880650A0493|15 23|analysis
P07880650A0493|31 52|diffraction intensity
P07880650A0493|56 64|function
P07880650A0493|84 97|electron dose
P07880650A0493|111 122|possibility
P07880650A0493|146 166|diffraction patterns
P07880650A0493|178 188|resolution
P07880650A0493|203 227|crotoxin complex crystal
P07881077A0195|0 33|Supplementary Phase Contraste RSE
P07881077A0195|53 63|Excitation
P07881077A0195|66 75|sequences
P07881077A0195|99 107|patients
P07883167A0157|3 8|yeast
P07883167A0157|14 22|products
P07883167A0157|30 34|UPF1
P07883167A0157|39 49|UPF3 genes
P07883167A0157|72 85|decay pathway
P07883167A0157|99 105|report
P07883167A0157|122 136|identification
P07883167A0157|141 157|characterization
P07883167A0157|172 179|factors
P07883167A0157|199 204|decay
P07883167A0157|228 233|mRNAs
P07883168A0090|0 9|Mutations
P07883168A0090|13 22|UPF1 lead
P07883168A0090|40 53|stabilization
P07883168A0090|57 62|mRNAs
P07883168A0090|80 98|nonsense mutations
P07883168A0090|121 132|decay rates
P07883168A0090|147 152|mRNAs
P07883193A0000|2 14|DNA fragment
P07883193A0000|40 46|domain
P07883193A0000|48 59|amino acids
P07883193A0000|110 119|regulator
P07883193A0000|140 154|pGEX-KT vector
P07883193A0000|172 177|frame
P07883193A0000|193 197|gene
P07883193A0000|207 232|glutathione S-transferase
P07883754A0993|6 28|gel retardation assays
P07883754A0993|34 39|HepG2
P07883754A0993|48 55|extract
P07883754A0993|77 85|presence
P07883754A0993|100 107|protein
P07883754A0993|127 139|NRE fragment
P07885999A0000|16 23|factors
P07885999A0000|43 52|sequences
P07885999A0000|72 78|region
P07885999A0000|86 107|mouse tyrosinase gene
P07885999A0000|130 140|band shift
P07885999A0000|145 176|methylation interference assays
P07886610A0000|7 17|population
P07886610A0000|56 64|patients
P07886610A0000|70 82|hemophilia A
P07886610A0000|86 91|India
P07886610A0000|103 113|prevalence
P07886610A0000|127 137|population
P07887226A0858|19 33|serum ferritin
P07887226A0858|38 63|hemoglobin determinations
P07887226A0858|69 101|serum transferrin receptor assay
P07887226A0858|116 124|addition
P07887226A0858|142 149|surveys
P07887226A0858|185 192|measure
P07887226A0858|207 222|iron deficiency
P07887226A0858|249 252|IDA
P07887226A0858|262 268|anemia
P07887226A0858|280 287|disease
P07887859A0315|23 31|patients
P07887859A0315|47 53|ulcers
P07887859A0315|58 63|tcPO2
P07887859A0315|97 100|ABI
P07887859A0315|120 123|TBI
P07887859A0315|125 132|indices
P07887859A0998|0 17|TcPO2 measurement
P07887859A0998|43 52|technique
P07887859A0998|82 98|ulcer management
P07888156A0169|15 34|University Hospital
P07888156A0169|38 44|Tromso
P07888156A0169|64 73|hospitals
P07888156A0169|86 92|Norway
P07888156A0169|114 129|section service
P07888156A0169|139 145|access
P07888156A0169|149 166|video conferences
P07888156A0169|175 181|review
P07888156A0169|197 205|findings
P07888156A0169|218 228|discussion
P07888156A0169|249 255|issues
P07888156T0000|8 14|status
P07888156T0000|18 31|telepathology
P07888306A1659|0 10|Expression
P07888306A1659|14 18|h6.1
P07888306A1659|22 33|COS-1 cells
P07888306A1659|45 55|production
P07888306A1659|69 73|type
P07888306A1659|77 89|PDE activity
P07888306A1659|98 102|cAMP
P07888306A1659|112 116|cGMP
P07888306A1659|128 137|substrate
P07888306A1659|146 154|activity
P07888306A1659|181 184|Ca2
P07888306A1659|186 189|CaM
P07888306A1659|193 197|cGMP
P07888306A1659|223 237|concentrations
P07888306A1659|241 249|rolipram
P07888306A1659|251 259|ABSTRACT
P07888306A1659|277 282|WORDS
P07888623A0721|0 14|PMEK1 displays
P07888623A0721|24 34|% identity
P07888623A0721|57 69|tobacco NTF3
P07888623A0721|74 100|Arabidopsis ATMPK1 kinases
P07888623A0721|113 114|%
P07888623A0721|145 168|plant MAP kinase MsERK1
P07888623A0721|174 181|alfalfa
P07888629A0344|0 11|Translation
P07888629A0344|26 33|segment
P07888629A0344|56 62|MsPRP2
P07888629A0344|103 123|Da cell wall protein
P07888629A0344|147 162|signal sequence
P07888629A0344|190 198|sequence
P07888629A0344|238 246|sequence
P07888629A0344|273 296|lipid transfer proteins
P07888788A1010|4 12|presence
P07888788A1010|16 20|type
P07888788A1010|23 39|hypersensitivity
P07888788A1010|45 53|subgroup
P07888788A1010|57 70|aspergillomas
P07888788A1010|98 107|component
P07888788A1010|116 123|disease
P07888788A1010|173 181|response
P07888788A1010|185 196|Aspergillus
P07888788A1010|205 218|aspergillomas
P07888828A0765|5 12|concept
P07888828A0765|33 47|identification
P07888828A0765|59 64|genes
P07888828A0765|78 86|primates
P07890485A0827|12 24|illumination
P07890485A0827|41 54|photoreceptor
P07890485A0827|56 59|QO2
P07890485A0827|85 87|ml
P07890485A0827|96 101|g.min
P07890485A0827|122 125|QO2
P07890485A0827|160 162|ml
P07890485A0827|171 176|g.min
P07890485A0827|181 185|cats
P07890599A0132|21 39|mouse cDNA library
P07890599A0132|46 60|MIN6 cell line
P07890599A0132|86 96|beta cells
P07890599A0132|112 119|isoform
P07890599A0132|142 146|cDNA
P07890599A0132|168 180|acid protein
P07890599A0132|202 212|% identity
P07890599A0132|218 225|munc-18
P07890599A0132|226 232|n-Sec1
P07890599A0132|233 239|rbSec1
P07890599A0132|241 269|Caenorhabditis elegans unc18
P07890599A0132|300 305|Sec1p
P07890674A0916|4 12|catenins
P07890674A0916|21 24|APC
P07890674A0916|29 39|E-cadherin
P07890674A0916|53 60|fashion
P07890674A0916|66 69|APC
P07890674A0916|74 84|E-cadherin
P07890674A0916|132 140|presence
P07890674A0916|144 151|absence
P07890674A0916|155 163|catenins
P07890680A1193|9 17|addition
P07890680A1193|21 40|core DNA polymerase
P07890680A1193|62 69|complex
P07890680A1193|92 102|holoenzyme
P07890680A1193|115 126|replacement
P07890680A1193|130 135|gamma
P07890680A1193|139 144|alpha
P07890680A1193|152 167|primer terminus
P07890740A0997|4 13|PSD2 gene
P07890740A0997|46 55|infection
P07890740A0997|59 76|Sf-9 insect cells
P07890740A0997|94 105|baculovirus
P07890740A0997|130 138|increase
P07890740A0997|142 154|PSD activity
P07891638T0000|13 22|detection
P07891638T0000|35 44|asymmetry
P07891638T0000|56 73|chest radiographs
P07891685A1051|6 13|results
P07891685A1051|41 46|genes
P07891685A1051|68 75|binding
P07891685A1051|79 84|Cat8p
P07891685A1051|92 101|synthesis
P07891685A1051|117 124|release
P07891685A1051|128 133|Cat4p
P07891685A1051|135 140|Mig1p
P07891685A1051|151 164|CAT8 promoter
P07891708A0690|5 8|Epo
P07891708A0690|10 15|HNF-4
P07891708A0690|32 38|kidney
P07891708A0690|40 45|liver
P07891708A0690|51 62|Hep3B cells
P07891708A0690|74 84|HeLa cells
P07891708A1192|30 40|expression
P07891708A1192|59 67|Epo gene
P07891708A1192|99 110|Hep3B cells
P07891708A1192|135 149|HNF-4 delta C.
P07891709A1542|6 18|observations
P07891709A1542|52 62|mechanisms
P07891709A1542|86 96|transcript
P07891709A1542|123 136|deadenylation
P07891713T0000|6 18|Maf proteins
P07891713T0000|39 42|Fos
P07891713T0000|70 80|repressors
P07891713T0000|88 114|NF-E2 transcription factor
P07891720A0818|22 29|binding
P07891720A0818|33 36|C1F
P07891720A0818|66 79|concentration
P07891720A0818|83 95|calcium ions
P07892076A0578|0 8|Survival
P07892076A0578|15 26|development
P07892076A0578|42 51|infection
P07892076A0578|53 56|P-2
P07892076A0578|76 93|transmission mode
P07892353A0667|5 12|factors
P07892353A0667|38 50|correlations
P07892353A0667|56 60|rCBF
P07892353A0667|86 92|cortex
P07892353A0667|111 117|cortex
P07892353A0667|133 139|factor
P07892353A0667|163 171|patterns
P07892353A0667|175 187|correlations
P07892353A0667|203 216|brain regions
P07894021A1130|6 10|data
P07894021A1130|28 36|function
P07894021A1130|44 47|DS2
P07894021A1130|59 69|protection
P07894021A1130|85 88|DNA
P07894021A1130|94 105|desiccation
P07894359T0000|11 23|hemodynamics
P07894359T0000|31 39|abortion
P07894359T0000|51 53|RU
P07894359T0000|62 68|sepsis
P07894359T0000|72 76|rats
P07894761A0000|4 7|aim
P07894761A0000|30 35|study
P07894761A0000|71 76|cases
P07894761A0000|100 110|hemorrhage
P07894761A0000|112 115|ECH
P07894761A0000|128 135|success
P07894761A0000|147 153|vision
P07894761A0000|198 205|surgery
P07896088A0720|4 12|function
P07896088A0720|31 35|tail
P07896088A0720|39 59|telomere maintenance
P07896088A0720|88 92|RAP1
P07896088A0720|105 116|factor RIF1
P07896088A0720|118 130|rap1 alleles
P07896088A0720|164 168|tail
P07896088A0720|173 197|RIF1 interaction domains
P07896088A0720|212 219|effects
P07896088A0720|223 238|telomere length
P07896291A0693|60 63|map
P07896291A0693|78 86|resource
P07896291A0693|95 111|characterization
P07896291A0693|115 120|genes
P07896291A0693|149 162|WAGR syndrome
P07896615A0554|4 16|contribution
P07896615A0554|20 29|skin flow
P07896615A0554|37 44|changes
P07896615A0554|56 69|nm absorption
P07896615A0554|103 114|measurement
P07896615A0554|118 127|skin flow
P07896615A0554|131 149|laser flow Doppler
P07896615A0554|154 168|NIR recordings
P07896615A0554|180 195|water immersion
P07896817A0204|0 8|Proteins
P07896817A0204|33 40|lysates
P07896817A0204|44 51|control
P07896817A0204|73 77|BAEC
P07896817A0204|83 91|antisera
P07896817A0204|95 116|phospholipase C-gamma
P07896817A0204|118 127|PLC-gamma
P07896817A0204|150 188|SDS-polyacrylamide gel electrophoresis
P07896817A0204|208 219|Immobilon-P
P07896846T0000|24 32|isoforms
P07896846T0000|66 73|protein
P07896846T0000|90 107|suppressor region
P07896846T0000|121 132|beta-myosin
P07896846T0000|139 149|chain gene
P07896852T0000|0 11|Involvement
P07896852T0000|21 49|growth response factor Egr-1
P07896852T0000|53 89|apolipoprotein AI gene transcription
P07897359A0354|26 31|forms
P07897359A0354|39 48|F protein
P07897359A0354|67 73|BHK-21
P07897359A0354|78 91|HeLa T4 cells
P07897359A0354|95 98|use
P07897359A0354|118 126|vaccinia
P07897359A0354|142 162|T7 polymerase system
P07897696A0000|0 11|Erythrocyte
P07897696A0000|33 49|acid dehydratase
P07897696A0000|51 55|ALAD
P07897696A0000|57 65|activity
P07897696A0000|67 98|erythrocyte zinc protoporphyrin
P07897696A0000|100 103|ZPP
P07897696A0000|105 115|heme ratio
P07897696A0000|129 143|coproporphyrin
P07897696A0000|145 147|UC
P07897696A0000|149 162|concentration
P07897696A0000|196 206|indicators
P07897696A0000|233 246|lead exposure
P07897696A0000|265 277|blood levels
P07897696A0000|281 287|excess
P07897696A0000|294 307|micrograms/dl
P07897696A0000|318 326|subjects
P07898178A0849|13 17|risk
P07898178A0849|21 31|graft loss
P07898178A0849|38 48|conversion
P07898178A0849|52 64|azathioprine
P07898178A0849|79 89|graft loss
P07898178A0849|96 106|conversion
P07898178A0849|110 122|azathioprine
P07898178A0849|137 160|cyclosporin maintenance
P07898178A0849|199 203|risk
P07898178A0849|207 220|patient death
P07898275A0254|6 13|classes
P07898275A0254|17 29|test objects
P07898275A0254|70 81|test object
P07898275A0254|86 106|31P MRS measurements
P07898275A0254|138 147|sequences
P07898275A0254|171 182|test object
P07898275A0254|204 210|1H MRS
P07898275A0254|236 248|test objects
P07898275A0254|267 278|performance
P07898275A0254|295 302|systems
P07898275A0254|309 313|ISIS
P07898275A0254|317 345|volume localization sequence
P07898275A0254|349 357|31P MRS.
P07898589T0000|5 18|tobacco issue
P07898840X0000|0 19|Pregnancy screening
P07898840X0000|31 57|artery Doppler velocimetry
P07898840X0000|65 74|criterion
P07898840X0000|90 99|OBJECTIVE
P07898840X0000|127 142|Doppler studies
P07898840X0000|165 176|circulation
P07898840X0000|185 194|gestation
P07898840X0000|212 216|test
P07898840X0000|219 224|power
P07898840X0000|258 270|hypertension
P07898840X0000|281 299|growth restriction
P07898840X0000|301 304|FGR
P07898840X0000|319 327|analysis
P07898840X0000|339 350|combination
P07898840X0000|383 394|assessments
P07898840X0000|419 428|waveforms
P07898840X0000|447 454|results
P07898840X0000|460 468|analysis
P07899581A0000|4 10|effect
P07899581A0000|18 47|Ca entry blocker nitrendipine
P07899581A0000|65 85|superoxide dismutase
P07899581A0000|87 90|SOD
P07899581A0000|99 110|combination
P07899581A0000|114 126|nitrendipine
P07899581A0000|131 151|superoxide dismutase
P07899581A0000|174 182|function
P07899581A0000|203 209|groups
P07899581A0000|211 212|n
P07899581A0000|222 226|rats
P07899634A0000|0 7|PURPOSE
P07899634A0000|13 16|aim
P07899634A0000|25 30|study
P07899634A0000|56 65|anchorage
P07899634A0000|98 112|surface effect
P07899634A0000|118 132|alloy Ti Al Va
P07899634A0000|158 160|mu
P07900915A0000|21 25|food
P07900915A0000|33 38|water
P07900915A0000|63 68|tract
P07900915A0000|77 88|restitution
P07900915A0000|92 104|blood volume
P07900915A0000|109 123|plasma protein
P07900915A0000|130 140|hemorrhage
P07900915A0000|142 145|fed
P07900915A0000|168 172|rats
P07900915A0000|187 196|ml.kg-1 x
P07900915A0000|199 215|min-1 hemorrhage
P07900915A0000|221 232|restitution
P07900915A0000|236 248|blood volume
P07900915A0000|265 270|Evans
P07900915A0000|284 292|dilution
P07900915A0000|296 306|hematocrit
P07901121T0000|0 24|Cooperative dimerization
P07901121T0000|35 54|class homeo domains
P07901121T0000|58 61|DNA
P07901125A0416|8 17|advantage
P07901125A0416|30 36|degree
P07901125A0416|40 60|aa sequence homology
P07901125A0416|69 75|DAHPSs
P07901125A0416|89 96|species
P07901125A0416|108 123|ARO3 homologues
P07901125A0416|144 166|yeast Candida albicans
P07902532A0312|8 13|study
P07902532A0312|35 42|BOX DNA
P07902532A0312|52 65|transcription
P07902532A0312|75 91|thymidine kinase
P07902532A0312|93 95|TK
P07902532A0312|97 105|promoter
P07902532A0312|117 125|EC cells
P07902532A1655|0 17|Deletion analyses
P07902532A1655|25 34|construct
P07902532A1655|53 66|transcription
P07902532A1655|70 80|BOXF1 gene
P07902532A1655|97 104|BOX DNA
P07902532A1655|141 149|EC cells
P07902532A1655|172 177|cells
P07902583A0545|0 8|Analysis
P07902583A0545|12 32|disassociation rates
P07902583A0545|52 74|Grf10-Swi5-DNA complex
P07902583A0545|88 97|half-life
P07902583A0545|115 124|complexes
P07902583A0545|143 147|Swi5
P07902583A0545|151 156|Grf10
P07903099A0918|4 12|presence
P07903099A0918|27 37|transcript
P07903099A0918|49 59|IVS2C beta
P07903099A0918|72 80|terminus
P07903099A0918|95 103|cleavage
P07903099A0918|111 126|splice acceptor
P07903670A1202|11 17|allele
P07903670A1202|25 45|alpha 1-tubulin gene
P07903670A1202|61 67|tua1-1
P07905413A0585|15 24|treatment
P07905413A0585|31 52|plasma concentrations
P07905413A0585|77 84|ng.ml-1
P07905413A0585|90 91|h
P07905413A0585|99 106|ng.ml-1
P07905413A0585|113 114|h
P07905413A0585|131 149|segment depression
P07905413A0585|180 188|workload
P07905413A0585|222 223|%
P07905413A0585|238 245|placebo
P07905413A0585|247 248|P
P07905413A0585|266 272|points
P07905413A0585|276 280|time
P07905453A0281|0 7|Results
P07905453A0281|22 56|transcription-translation analysis
P07905453A0281|61 81|maxicell experiments
P07905453A0281|108 111|ORF
P07906265A0897|12 23|experiments
P07906265A0897|69 81|fasD mutants
P07906265A0897|89 97|products
P07906265A0897|129 135|export
P07906265A0897|140 148|assembly
P07906616A0191|25 33|response
P07906616A0191|59 70|stimulation
P07906616A0191|76 78|Hz
P07906616A0191|106 111|goats
P07906616A0191|140 151|anaesthesia
P07907846A0623|0 5|Group
P07907846A0623|18 31|physostigmine
P07907846A0623|37 47|mg/kg i.v.
P07907846A0623|66 92|cholinesterase degradation
P07907846A0623|96 99|min
P07907846A0623|107 133|bupivacaine administration
P07907846A0623|139 144|Group
P07907846A0623|158 169|combination
P07907846A0623|173 199|physostigmine pretreatment
P07907846A0623|221 232|stimulation
P07908012A0678|15 26|possibility
P07908012A0678|32 48|LNNB performance
P07908012A0678|70 76|groups
P07908012A0678|114 124|medication
P07908012A0678|126 134|analyses
P07908012A0678|157 169|relationship
P07908012A0678|178 195|medication levels
P07908012A0678|200 211|LNNB scores
P07908187T0000|0 4|ISIS
P07908187T0000|7 20|possibilities
P07908827A1200|4 7|use
P07908827A1200|20 30|antibodies
P07908827A1200|43 57|identification
P07908827A1200|70 78|RAR beta
P07908827A1200|106 115|complexes
P07908827A1200|135 144|sequences
P07908827A1200|157 161|RARs
P07908827A1200|177 186|COS cells
P07908827A1200|254 257|RAR
P07908827A1200|269 276|element
P07909936A0672|12 30|treatment strategy
P07909936A0672|46 55|disorders
P07909936A0672|93 99|effect
P07909936A0672|113 130|radiochemotherapy
P07909936A0672|143 168|stem-cell transplantation
P07909936A0672|186 189|use
P07909936A0672|193 202|cytokines
P07909936A0672|230 237|factors
P07910716A0359|4 17|study cohorts
P07910716A0359|34 42|patients
P07910716A0359|56 64|SC rIL-2
P07910716A0359|68 73|doses
P07910716A0359|94 103|IU/m2/day
P07910716A0359|109 113|days
P07910716A0359|118 122|week
P07910716A0359|129 134|total
P07910716A0359|140 145|weeks
P07910716A0359|150 158|patients
P07910716A0359|172 185|rIFN-alpha 2b
P07910716A0359|205 220|U/m2/day thrice
P07910716A0359|234 239|total
P07910716A0359|245 250|weeks
P07910716A0359|259 267|patients
P07910716A0359|283 299|SC rIFN-alpha 2b
P07910716A0359|315 330|U/m2/day thrice
P07910716A0359|343 351|SC rIL-2
P07910716A0359|373 382|IU/m2/day
P07910716A0359|386 390|days
P07910716A0359|424 433|IU/m2/day
P07910716A0359|437 441|days
P07910716A0359|446 450|week
P07910716A0359|469 474|weeks
P07910946A0323|0 8|Analysis
P07910946A0323|14 17|set
P07910946A0323|21 40|deletion constructs
P07910946A0323|54 73|transfection assays
P07910946A0323|97 110|reporter gene
P07910946A0323|112 122|luciferase
P07910946A0323|124 132|activity
P07910946A0323|174 180|region
P07910946A0323|195 212|promoter activity
P07910946A0323|232 240|L2 cells
P07911736A1715|7 10|MTD
P07911736A1715|14 23|mg/m2/day
P07911736A1715|44 52|toxicity
P07911736A1715|61 66|agent
P07911736A1715|70 86|myelosuppression
P07912123A0711|16 40|lymphocyte proliferation
P07913080A0564|2 34|decanucleotide promoter sequence
P07913080A0564|64 70|humans
P07913080A0564|75 79|mice
P07913080A0564|115 121|region
P07913080A0564|129 139|horse gene
P07913891A0174|14 21|targets
P07913891A0174|48 57|molecules
P07913891A0174|80 92|interactions
P07913891A0174|105 117|relationship
P07913891A0174|152 161|Hox genes
P07913891A0174|172 193|transcription factors
P07913891A0174|237 255|tissue specificity
P07913926A0878|0 17|Northern analysis
P07913926A0878|21 32|RNA samples
P07913926A0878|62 70|cultures
P07913926A0878|78 89|ntcA mutant
P07913926A0878|105 112|amounts
P07913926A0878|116 128|glnA message
P07913926A0878|137 144|absence
P07913926A0878|157 167|transcript
P07914192A0211|0 25|HER2 overexpressing cells
P07914192A0211|52 57|DNase
P07914192A0211|75 79|site
P07914192A0211|123 143|ets response element
P07914192A0211|145 151|GAGGAA
P07914192A0211|165 182|bases down-stream
P07914192A0211|192 200|CAAT box
P07914192A0211|224 232|TATA box
P07914192A0211|246 259|HER2 promoter
P07914192A0844|0 16|Gel-shift assays
P07914192A0844|30 38|extracts
P07914192A0844|43 68|oligonucleotide sequences
P07914192A0844|91 106|promoter region
P07914192A0844|138 145|complex
P07914192A0844|174 179|cells
P07914192A0844|195 199|HER2
P07914192A0844|221 228|binding
P07914192A0844|245 268|GAGGAA response element
P07914507A1029|0 10|Comparison
P07914507A1029|14 28|cDNA sequences
P07914507A1029|51 63|mRNA species
P07914507A1029|75 81|result
P07914507A1029|95 98|use
P07914507A1029|102 106|poly
P07914507A1029|107 108|A
P07914507A1029|110 124|addition sites
P07914700A0000|4 8|gene
P07914700A0000|31 57|eIF-2 alpha protein kinase
P07914700A0000|59 62|PKR
P07914700A0000|82 87|mouse
P07914700A0000|96 99|DNA
P07915144A0000|0 14|High-frequency
P07915144A0000|26 37|stimulation
P07915144A0000|45 56|hippocampus
P07915144A0000|69 77|increase
P07915144A0000|90 98|efficacy
P07915144A0000|119 124|hours
P07916003A0688|15 25|mouse gene
P07916003A0688|43 49|region
P07916003A0688|59 69|CD79 alpha
P07916003A0688|78 86|TATA box
P07916003A0688|104 120|mouse CD79 alpha
P07916003A0688|134 147|octamer motif
P07916003A0688|185 189|gene
P07916326A0000|19 31|organization
P07916326A0000|39 45|coding
P07916326A0000|70 77|regions
P07916326A0000|115 119|gene
P07916326A0000|121 126|Msx-1
P07916327A0250|19 26|cloning
P07916327A0250|40 54|goosecoid gene
P07916327A0250|56 59|GSC
P07916327A0250|76 83|library
P07916327A0250|92 100|sequence
P07916327A0250|116 123|protein
P07916577A0190|3 8|order
P07916577A0190|29 44|candidate genes
P07916577A0190|59 68|disorders
P07916577A0190|95 110|gene expression
P07916577A0190|140 149|sequences
P07916577A0190|161 165|zinc
P07916577A0190|184 189|cDNAs
P07916588A0471|5 10|virus
P07916588A0471|41 47|strain
P07916588A0471|51 80|passion fruit woodiness virus
P07916588A0471|82 85|PWV
P07916588A0471|100 111|CP sequence
P07916588A0471|141 144|CPs
P07916588A0471|164 171|strains
P07916588A0471|175 178|PWV
P07916588A0471|195 199|part
P07916588A0471|214 222|subgroup
P07916588A0471|226 237|potyviruses
P07916588A0471|249 252|PWV
P07916685A0455|4 9|ratio
P07916685A0455|17 25|activity
P07916685A0455|29 52|arogenate dehydrogenase
P07916685A0455|64 88|prephenate dehydrogenase
P07916685A0455|138 150|purification
P07916685A0455|164 174|activities
P07916689A0312|13 24|POT1 clones
P07916689A0312|45 59|kb RNA species
P07916689A0312|106 112|oleate
P07916689A0312|121 134|carbon source
P07916689A1407|4 17|Y. lipolytica
P07916689A1407|26 35|POT1 gene
P07916689A1407|67 69|bp
P07916689A1407|84 92|sequence
P07916689A1407|102 105|kbp
P07916689A1407|109 112|DNA
P07916689A1407|127 150|Y. lipolytica LEU2 gene
P07916729T0000|2 23|leucine zipper domain
P07916729T0000|31 41|suppressor
P07916729T0000|56 63|protein
P07916729T0000|88 94|effect
P07916729T0000|98 115|enhancer function
P07916983A0623|21 23|CT
P07916983A0623|56 64|patients
P07916983A0623|70 88|N1-N3 neck disease
P07916983A0623|129 141|prescription
P07917016A0581|14 25|DNA-binding
P07917016A0581|27 62|zinc finger domain protein sequence
P07917540A0000|3 11|patients
P07917540A0000|43 48|study
P07917540A0000|59 68|vindesine
P07917540A0000|72 82|mg/m2/week
P07917540A0000|89 108|interferon-alpha 2b
P07917540A0000|112 116|U/m2
P07917540A0000|119 124|times
P07917540A0000|129 133|week
P07917540A0000|138 147|vindesine
P07917540A0000|160 170|interferon
P07917540A0000|185 194|treatment
P07917540A0000|219 227|melanoma
P07918097T0000|10 37|Notch homologue mouse Notch
P07918097T0000|65 86|growth factor-repeats
P07918097T0000|121 136|neuroepithelium
P07918128A0000|0 10|BACKGROUND
P07918128A0000|27 32|phase
P07918128A0000|46 49|MDL
P07918128A0000|56 58|EF
P07918128A0000|68 85|hydroxytryptamine
P07918128A0000|89 94|5-HT3
P07918128A0000|96 115|receptor antagonist
P07918128A0000|123 131|patients
P07918128A0000|153 165|chemotherapy
P07918494A1163|7 15|presence
P07918494A1163|40 46|system
P07918494A1163|48 59|thioredoxin
P07918494A1163|61 82|thioredoxin reductase
P07918494A1163|88 93|NADPH
P07918494A1163|119 126|mutants
P07918494A1163|141 150|formation
P07918494A1163|167 172|dCTPs
P07918494A1163|177 181|mole
P07918494A1163|185 191|enzyme
P07919540A0240|14 25|alterations
P07919540A0240|40 49|synthesis
P07919540A0240|63 76|c-myc protein
P07919540A0240|78 81|p64
P07919540A0240|117 126|AUG codon
P07919540A0240|130 134|exon
P07919540A1119|3 11|addition
P07919540A1119|22 26|exon
P07919540A1119|34 38|exon
P07919540A1119|51 56|forms
P07919540A1119|64 77|c-Myc protein
P07919540A1119|89 102|transcription
P07919540A1119|127 145|reporter construct
P07919540A1119|159 164|level
P07922709T0000|11 21|activities
P07922709T0000|39 53|growth factors
P07922709T0000|83 94|application
P07925022A0285|0 10|Expression
P07925022A0285|41 44|CNS
P07925022A0285|63 69|stages
P07925097A1205|15 25|AR content
P07925097A1205|41 52|COS-1 cells
P07925097A1205|75 83|exposure
P07925097A1205|87 96|8-Br-cAMP
P07925282A0705|0 10|Disruption
P07925282A0705|34 39|genes
P07925282A0705|70 82|SRP proteins
P07925282A0705|99 110|cell growth
P07925282A0705|127 148|protein translocation
P07925282A0705|160 171|ER membrane
P07926729A0000|8 19|alterations
P07926729A0000|23 31|elements
P07926729A0000|42 72|signal transduction mechanisms
P07926729A0000|99 105|events
P07926729A0000|134 144|activation
P07926729A0000|148 156|programs
P07926729A0000|160 178|gene transcription
P07926739A0766|4 22|expression pattern
P07926739A0766|26 29|GL2
P07926739A0766|58 71|hybridization
P07926739A0766|92 96|gene
P07926739A0766|122 138|progenitor cells
P07926739A0766|146 152|stages
P07926739A0766|169 189|trichome development
P07926748A0383|0 4|NOT4
P07926748A0383|20 24|NOT1
P07926748A0383|29 33|NOT3
P07926748A0383|52 57|assay
P07926748A0383|63 77|overexpression
P07926748A0383|81 85|NOT3
P07926748A0383|89 93|NOT4
P07926748A0383|105 109|not1
P07926748A0383|114 128|not2 mutations
P07926749A0471|8 22|site selection
P07926749A0471|50 58|proteins
P07926749A0471|76 85|ROR alpha
P07926749A0471|92 101|ROR alpha
P07926749A0471|104 112|isoforms
P07926749A0471|118 121|DNA
P07926749A0471|125 133|monomers
P07926749A0471|137 162|hormone response elements
P07926749A0471|190 198|sequence
P07926749A0471|221 239|core motif PuGGTCA
P07926749A0471|241 245|RORE
P07926774A0652|4 28|p73pct1/p85cdc10 complex
P07926774A0652|64 67|MCB
P07926774A0652|76 79|SCB
P07926774A0652|83 92|E2F sites
P07926775A0895|20 27|stripes
P07926775A0895|49 52|slp
P07926775A0895|60 67|embryos
P07926775A0895|77 89|slp activity
P07926775A0895|105 116|requirement
P07926775A0895|121 132|maintenance
P07926775A0895|136 149|wg expression
P07926775A0895|162 166|time
P07926775A0895|172 188|wg transcription
P07926775A0895|205 207|hh
P07926789A0960|4 16|DNA sequence
P07926789A0960|33 42|lacZ gene
P07926789A0960|81 93|fusion genes
P07926789A0960|100 108|products
P07926789A0960|160 167|fusions
P07927130A0625|0 33|CMV hyperimmunoglobulin treatment
P07927130A0625|35 43|Cytotect
P07927130A0625|45 52|Biotest
P07927130A0625|69 77|ml/kg bw
P07927130A0625|81 84|day
P07927130A0625|100 105|ml/kg
P07927130A0625|109 113|days
P07927130A0625|144 155|eradication
P07927130A0625|172 182|infiltrate
P07927130A0625|187 194|CMV-DNA
P07927130A0625|202 212|myocardium
P07927267T0000|17 25|drainage
P07927267T0000|43 51|drainage
P07927267T0000|75 87|regeneration
P07927267T0000|103 112|rat liver
P07927267T0000|127 138|hepatectomy
P07927711A0698|0 3|ORF
P07927711A0698|40 47|protein
P07927711A0698|58 60|Da
P07927711A0698|98 105|regions
P07927838A0000|9 15|groups
P07927838A0000|19 27|subjects
P07927838A0000|66 71|tools
P07927838A0000|95 100|years
P07927838A0000|106 122|prevalence rates
P07927838A0000|150 156|finger
P07927838A0000|158 161|VWF
P07927838A0000|167 175|numbness
P07927838A0000|177 181|pain
P07927838A0000|186 195|stiffness
P07927838A0000|219 230|extremities
P07928954A0545|0 21|DNA sequence analysis
P07928954A0545|38 42|gene
P07928954A0545|51 53|bp
P07928954A0545|88 95|protein
P07928954A0545|113 119|weight
P07928954A0545|162 188|lipoprotein signal peptide
P07928954A0545|193 233|consensus prolipoprotein processing site
P07929165T0000|0 12|DNA sequence
P07929165T0000|17 26|functions
P07929165T0000|34 46|actVI region
P07929165T0000|54 66|actinorhodin
P07929165T0000|80 92|gene cluster
P07929165T0000|120 122|A3
P07929238A0734|7 15|Genomics
P07929411A0087|2 12|comparison
P07929411A0087|30 50|polypeptide sequence
P07929411A0087|58 76|Drosophila protein
P07929411A0087|97 105|subunits
P07929411A0087|111 116|mouse
P07929411A0087|121 126|yeast
P07929411A0087|194 201|regions
P07929411A0087|239 254|enzyme activity
P07929431A0949|0 8|Plasmids
P07929431A0949|35 56|mouse promoter region
P07929431A0949|71 118|reporter gene chloramphenicol acetyltransferase
P07929431A0949|120 123|CAT
P07929431A0949|172 183|INS-1 cells
P07929559A0000|12 18|dynein
P07929559A0000|76 82|enzyme
P07929559A0000|123 130|variety
P07929559A0000|148 157|movements
P07929559A0000|188 197|transport
P07929559A0000|201 211|organelles
P07929560T0000|0 14|Identification
P07929560T0000|42 48|domain
P07929560T0000|52 62|desmoglein
P07929560T0000|71 75|role
P07929560T0000|79 94|plaque assembly
P07929560T0000|112 130|filament anchorage
P07931490A0237|0 8|PATIENTS
P07931490A0237|13 20|METHODS
P07931490A0237|65 73|patients
P07931490A0237|94 103|cisplatin
P07931490A0237|115 120|mg/m2
P07931490A0237|161 178|granisetron doses
P07931490A0237|197 210|micrograms/kg
P07931490A0237|232 244|chemotherapy
P07932095A0000|9 20|naphthalene
P07932095A0000|29 38|compounds
P07932095A0000|47 48|V
P07932095A0000|50 57|VII-XII
P07932095A0000|84 93|compounds
P07932095A0000|104 106|VI
P07932095A0000|108 112|XIII
P07932095A0000|137 146|root bark
P07932095A0000|150 171|Oroxylum indicum Vent
P07932943A0113|19 24|study
P07932943A0113|40 49|influence
P07932943A0113|61 79|awareness strategy
P07932943A0113|101 109|strategy
P07932943A0113|117 144|Five-Step Approach strategy
P07932943A0113|155 172|control condition
P07933066T0000|19 30|interaction
P07933066T0000|38 53|adenovirus E4-6
P07933066T0000|56 63|protein
P07933066T0000|72 99|retinoblastoma gene product
P07933066T0000|114 121|domains
P07933066T0000|125 130|E2F-1
P07933066T0000|135 139|DP-1
P07933076A0211|21 26|EBNA2
P07933076A0211|46 55|promoters
P07933076A0211|76 93|membrane proteins
P07933095A0000|26 31|v-Rel
P07933095A0000|37 48|oncoprotein
P07933095A0000|62 78|retrovirus Rev-T
P07933095A0000|93 103|expression
P07933095A0000|109 118|promoters
P07933095A0000|138 143|sites
P07933095A0000|161 185|transcription factor Sp1
P07933095A0000|189 215|chicken embryo fibroblasts
P07933095A0000|217 219|S.
P07933101A0131|9 16|studies
P07933101A0131|44 56|TATA element
P07933101A0131|95 116|HIV-1 gene expression
P07933107A0991|2 12|comparison
P07933107A0991|20 39|nucleotide sequence
P07933107A0991|47 55|p54 gene
P07933107A0991|80 92|ASFV strains
P07933107A0991|94 97|E70
P07933107A0991|102 105|E75
P07933107A0991|131 142|virus Ba71V
P07933107A0991|153 165|% similarity
P07933116A0412|4 12|p55 mRNA
P07933116A0412|49 50|B
P07933116A0412|56 68|T-cell lines
P07933116A0412|92 101|cell line
P07933116A0412|103 107|U937
P07934331T0037|9 21|registration
P07934331T0037|28 37|incentive
P07934331T0037|42 53|improvement
P07934666A0158|15 28|magnetization
P07934666A0158|66 76|components
P07934666A0158|80 82|T2
P07934666A0158|89 92|T2f
P07934666A0158|100 102|T2
P07934666A0158|109 112|T2s
P07934666A0158|114 123|component
P07935094A0516|0 7|RESULTS
P07935094A0516|24 31|quality
P07935094A0516|35 45|FDG images
P07935094A0516|84 103|Tl-201 counterparts
P07935094A0516|115 131|liver background
P07935094A0516|147 156|FDG study
P07935370A0000|16 26|expression
P07935370A0000|30 33|CD4
P07935370A0000|38 41|CD8
P07935370A0000|49 67|T-cell development
P07935370A0000|96 112|maturation state
P07935370A0000|120 126|T cell
P07935375A1197|0 10|Expression
P07935375A1197|34 42|ras gene
P07935375A1197|55 75|TIS10/PGS2 induction
P07935375A1197|79 84|v-src
P07935379A0347|26 31|cells
P07935379A0347|69 76|changes
P07935379A0347|95 100|cells
P07935379A0347|112 121|apoptosis
P07935383A0108|9 14|RNase
P07935383A0108|26 43|mapping technique
P07935383A0108|69 76|subunit
P07935383A0108|80 84|CstF
P07935383A0108|114 123|pre-mRNAs
P07935383A0108|134 141|regions
P07935383A0108|168 181|cleavage site
P07935383A0108|196 201|virus
P07935383A0108|214 237|adenovirus L3 pre-mRNAs
P07935395A0094|4 11|protein
P07935395A0094|27 30|kDa
P07935395A0094|50 68|zinc finger motifs
P07935395A0094|104 112|clusters
P07935395A0094|125 129|ends
P07935395A0094|137 145|molecule
P07935415T0000|16 26|expression
P07935415T0000|51 60|inhibitor
P07935415T0000|89 96|cloning
P07935415T0000|98 107|structure
P07935415T0000|113 125|localization
P07935415T0000|133 137|gene
P07935418A0447|8 20|v-erbA probe
P07935418A0447|36 40|cDNA
P07935418A0447|78 85|protein
P07935418A0447|87 92|RLD-1
P07935418A0447|127 134|domains
P07935418A0447|146 155|receptors
P07935426A0714|16 24|isoforms
P07935426A0714|48 66|zinc finger domain
P07935426A0714|104 124|TdT promoter binding
P07935447A0972|5 10|study
P07935447A0972|27 35|evidence
P07935447A0972|41 44|USF
P07935447A0972|48 54|member
P07935447A0972|85 106|leucine zipper family
P07935447A0972|117 121|MLE1
P07935447A0972|123 128|HF-1a
P07935447A0972|134 145|PRE B sites
P07935447A0972|172 181|component
P07935447A0972|185 202|protein complexes
P07935447A0972|237 247|expression
P07935447A0972|251 257|MLC-2v
P07935447A0972|262 274|alpha-myosin
P07935447A0972|287 292|genes
P07935451T0000|6 32|T-cell leukemia virus type
P07935451T0000|35 49|Tax activation
P07935451T0000|53 67|NF-kappa B/Rel
P07935451T0000|77 92|phosphorylation
P07935451T0000|97 108|degradation
P07935451T0000|112 127|I kappa B alpha
P07935451T0000|132 136|RelA
P07935451T0000|138 141|p65
P07935451T0000|152 161|induction
P07935451T0000|169 179|c-rel gene
P07935468T0000|0 10|Activation
P07935468T0000|14 35|c-fos gene expression
P07935468T0000|68 90|growth factor receptor
P07935471A0613|19 22|HSF
P07935471A0613|35 43|activity
P07935471A0613|66 74|antibody
P07935471A0613|94 105|Xenopus HSF
P07935471A0613|124 130|system
P07935471A0613|135 150|mapping regions
P07935471A0613|154 159|hHSF1
P07935471A0613|186 197|maintenance
P07935471A0613|215 220|state
P07935472A0276|0 9|Enhancers
P07935472A0276|31 36|Ets-1
P07935472A0276|45 50|sites
P07935472A0276|76 93|expression assays
P07935472A0276|108 123|T-cell line EL4
P07935472A0276|124 126|E1
P07935472A0276|128 139|alterations
P07935472A0276|147 158|LVb element
P07935472A0276|181 198|enhancer activity
P07935472A0276|206 214|mutation
P07935472A0276|229 232|LVb
P07935472A0276|236 247|LVc element
P07935472A0276|258 265|phorbol
P07935472A0276|280 297|enhancer activity
P07935472A0790|16 32|binding activity
P07935472A0790|41 46|Ets-1
P07935472A0790|86 95|complexes
P07935472A0790|115 136|mobility shift assays
P07935491A0495|6 18|RZR subtypes
P07935491A0495|29 36|members
P07935491A0495|46 52|family
P07935491A0495|71 80|receptors
P07935491A0495|116 131|gene expression
P07935491A1182|21 38|response elements
P07935491A1182|68 76|affinity
P07935491A1182|90 136|acid receptor-retinoid-X receptor heterodimers
P07935577A0305|0 9|Treatment
P07935577A0305|15 29|amphotericin B
P07935577A0305|34 45|flucytosine
P07935577A0305|53 64|improvement
P07935577A0305|72 80|symptoms
P07935577A0305|107 122|micro-organisms
P07935577A0305|146 151|fluid
P07935577A0305|153 156|CSF
P07935626A1249|15 23|presence
P07935626A1249|31 35|tRNA
P07935626A1249|36 39|trp
P07935626A1249|41 44|CCA
P07935626A1249|46 61|gene transcript
P07935626A1249|65 77|mitochondria
P07935997A0000|4 14|parameters
P07935997A0000|38 46|immunity
P07935997A0000|48 69|serum immunoglobulins
P07935997A0000|81 90|complexes
P07935997A0000|121 126|group
P07935997A0000|130 138|patients
P07935997A0000|152 168|cervix carcinoma
P07935997A0000|170 180|Stages IIB
P07935997A0000|185 189|IIIB
P07935997A0000|203 207|year
P07936635A1134|0 8|Mutation
P07936635A1134|12 16|KRKR
P07936635A1134|20 24|NGER
P07936635A1134|33 37|MO15
P07936635A1134|57 68|compartment
P07936635A1134|91 98|protein
P07936635A1134|130 137|nucleus
P07936640A0900|15 22|binding
P07936640A0900|26 33|protein
P07936640A0900|43 48|sites
P07936640A0900|52 57|cells
P07936640A0900|93 114|footprinting analysis
P07936640A0900|123 130|portion
P07936640A0900|138 156|TGF alpha promoter
P07936640A0900|183 192|rat liver
P07936640A0900|204 214|cell lines
P07936640A0900|243 247|gene
P07936640A0900|259 265|levels
P07936650A0656|17 26|subdomain
P07936650A0656|81 98|activating region
P07936650A0656|102 112|p58c-ets-2
P07936650A0656|132 135|BEC
P07936650A0656|140 150|Ets-1-beta
P07936650A0656|167 175|sequence
P07936650A1752|5 9|work
P07936650A1752|25 30|model
P07936650A1752|39 44|ets-1
P07936650A1752|45 55|ets-2 gene
P07936650A1752|58 67|evolution
P07936650A1752|89 93|time
P07936650A1752|128 137|evidences
P07937106A0100|4 18|v-ets oncogene
P07937106A0100|32 46|retrovirus E26
P07937106A0100|73 94|progenitor p68c-ets-1
P07937106A0100|102 126|amino acid substitutions
P07937106A0100|128 135|alanine
P07937106A0100|144 154|isoleucine
P07937106A0100|162 169|c-ets-1
P07937106A0100|190 196|valine
P07937106A0100|200 205|v-ets
P07937106A0100|207 216|mutations
P07937106A0100|223 224|B
P07937106A0100|264 267|end
P07937106A0100|269 279|mutation C
P07937108A0325|24 29|mRNAs
P07937108A0325|60 77|RNA polymerase I.
P07937112A0220|15 23|subunits
P07937112A0220|27 29|Ku
P07937112A0220|72 77|cells
P07937112A0220|86 98|denaturation
P07937112A0220|146 148|Ku
P07937127A0645|11 17|method
P07937127A0645|63 81|activation domains
P07937127A0645|107 114|regions
P07937127A0645|122 135|herpesviruses
P07937127A0645|144 162|pseudorabies virus
P07937127A0645|174 185|herpesvirus
P07937132A0819|12 15|U21
P07937132A0819|32 39|stretch
P07937132A0819|44 46|nt
P07937132A0819|52 67|complementarity
P07937132A0819|90 98|sequence
P07937132A0819|102 110|28S rRNA
P07937147A0205|10 16|system
P07937147A0205|43 61|pi protein mutants
P07937147A0205|89 91|IR
P07937147A0205|96 98|DR
P07937147A0205|100 104|York
P07937147A0205|113 117|Gene
P07937147A0205|119 123|Amst
P07937147A0205|143 147|York
P07937147A0205|152 162|Filutowicz
P07937147A0205|164 166|J.
P07937656A0182|0 10|Univariate
P07937656A0182|23 31|analysis
P07937656A0182|41 63|Kaplan-Meier-estimates
P07937656A0182|68 81|Log-Rank-Test
P07937656A0182|129 136|factors
P07937656A0182|146 159|disease stage
P07937656A0182|161 162|p
P07937656A0182|173 188|NSE serum level
P07937656A0182|202 214|micrograms/l
P07937656A0182|216 217|p
P07937656A0182|228 254|serum alkaline phosphatase
P07937656A0182|269 272|U/l
P07937656A0182|274 275|p
P07937656A0182|293 306|serum albumin
P07937656A0182|308 309|p
P07937656A0182|323 337|activity index
P07937656A0182|341 348|minimum
P07937656A0182|356 357|p
P07937841A0790|6 13|results
P07937841A0790|22 30|evidence
P07937841A0790|36 42|bypass
P07937841A0790|77 87|cell cycle
P07937841A0790|99 107|pathways
P07937841A0790|113 119|member
P07937841A0790|127 146|myb oncogene family
P07937954A0612|0 3|HBx
P07937954A0612|22 28|levels
P07937954A0612|42 45|Ras
P07937954A0612|76 79|Raf
P07937954A0612|123 133|MAP kinase
P07937965T0000|0 4|Role
P07937965T0000|8 13|c-myc
P07937965T0000|24 29|virus
P07937965T0000|39 44|tumor
P07937965T0000|61 74|DNA synthesis
P07937965T0000|88 112|3T3-L1 mouse fibroblasts
P07938137A0384|4 10|groups
P07938137A0384|45 53|naloxone
P07938137A0384|59 64|mg/kg
P07938137A0384|85 96|environment
P07938137A0384|119 124|signs
P07938137A0384|135 145|withdrawal
P07941174T0001|0 13|Laser therapy
P07941174T0001|24 33|carcinoma
P07941739A0000|7 18|kb fragment
P07941739A0000|26 38|yeast genome
P07941739A0000|72 78|region
P07941739A0000|82 96|chromosome XIV
P07941739A0000|108 115|mapping
P07941750A0344|29 33|half
P07941750A0344|41 47|length
P07941750A0344|67 84|hydantoinase HyuA
P07941750A0344|102 106|half
P07941750A0344|110 126|hydatoinase HyuB
P07942076A0497|18 42|estradiol concentrations
P07942076A0497|58 76|estradiol valerate
P07942076A0497|92 111|estradiol ingestion
P07942076A0497|134 141|patient
P07942076A0497|144 147|age
P07942076A0497|181 185|type
P07942448A1227|13 21|patients
P07942448A1227|25 35|NYHA class
P07942448A1227|49 54|class
P07942448A1227|59 67|ABSTRACT
P07942448A1227|85 90|WORDS
P07942722T0000|0 12|Constipation
P07942722T0000|22 33|risk factor
P07942722T0000|38 49|hemorrhoids
P07942722T0000|66 71|study
P07942722T0000|97 103|agents
P07943556A0694|7 14|persons
P07943556A0694|34 35|%
P07943556A0694|68 79|Og4C3 assay
P07944461A0321|0 6|TG-day
P07944461A0321|11 19|TG-night
P07944461A0321|37 38|%
P07944461A0321|52 53|%
P07944461A0321|60 63|mm3
P07944542T0000|0 20|Vibrio cholerae O139
P07944542T0000|24 32|Calcutta
P07945134A0079|4 14|volunteers
P07945134A0079|37 39|ft
P07945134A0079|47 48|m
P07945134A0079|88 90|ft
P07945134A0079|116 117|m
P07945134A0079|136 142|sounds
P07945134A0079|164 179|head microphone
P07945330A0103|5 20|differentiation
P07945330A0103|35 39|acid
P07945330A0103|41 43|RA
P07945330A0103|46 59|transcription
P07945330A0103|67 77|Rex-1 gene
P07945937A0358|0 17|Sequence analysis
P07945937A0358|25 39|zebrafish egr1
P07945937A0358|47 53|region
P07945937A0358|70 75|level
P07945937A0358|79 87|homology
P07945937A0358|95 100|mouse
P07945937A0358|102 105|rat
P07945937A0358|117 127|Egr1 genes
P07945937A0358|145 154|exception
P07945937A0358|173 207|triplet nucleotide repeat sequence
P07945937A0358|215 221|region
P07945937A0358|237 251|amino terminus
P07945937A0358|259 271|Egr1 protein
P07947930A0499|4 14|fibrinogen
P07947930A0499|16 30|serum proteins
P07947930A0499|32 46|sodium heparin
P07947930A0499|51 59|membrane
P07947930A0499|75 77|Cm
P07947930A0499|83 84|%
P07947930A0499|88 89|%
P07947930A0499|92 93|%
P07947930A0499|100 101|%
P07948129A0297|9 16|vectors
P07948129A0297|44 50|repeat
P07948129A0297|52 57|chLTR
P07948129A0297|70 80|expression
P07948129A0297|88 122|chloramphenicol acetyl transferase
P07948129A0297|124 127|CAT
P07948129A0297|129 142|reporter gene
P07948129A0297|175 185|SV40 virus
P07948129A0297|192 207|region promoter
P07948129A0297|222 249|neomycin phosphotransferase
P07948129A0297|254 257|NEO
P07948129A0297|259 263|gene
P07948921A0051|0 6|Optima
P07948921A0051|16 23|library
P07948921A0051|61 83|stilbene synthase cDNA
P07948921A0051|89 94|probe
P07949137A0000|2 7|total
P07949137A0000|21 29|leukemia
P07949137A0000|36 44|patients
P07949137A0000|67 78|bone marrow
P07949137A0000|80 82|BM
P07949137A0000|94 105|mafosfamide
P07949137A0000|107 113|ASTA Z
P07949137A0000|126 132|period
P07949137A0000|136 143|January
P07949137A0000|152 159|January
P07949137A0532|18 25|regimen
P07949137A0532|39 55|cyclophosphamide
P07949137A0532|61 66|mg/kg
P07949137A0532|78 94|body irradiation
P07949164A0799|18 26|mutation
P07949164A0799|34 47|kappa B motif
P07949164A0799|51 55|IL-6
P07949164A0799|56 67|CAT plasmid
P07949164A0799|93 103|abrogation
P07949164A0799|107 129|IL-6 promoter activity
P07949164A0799|139 144|cells
P07949205A0286|11 25|testololactone
P07949205A0286|64 81|aminoglutethimide
P07949205A0286|103 119|breast carcinoma
P07949551A0000|0 3|Use
P07949551A0000|11 20|vena cava
P07949551A0000|47 51|vein
P07949551A0000|56 79|cadaver transplantation
P07949770T0000|24 34|blood flow
P07949770T0000|46 62|prostaglandin E1
P07949770T0000|73 94|liver transplantation
P07949770T0000|98 102|pigs
P07951235A0277|4 8|gene
P07951235A0277|84 90|muscle
P07951410A0647|4 8|HeLa
P07951410A0647|15 19|U937
P07951410A0647|25 35|A549 cells
P07951410A0647|37 50|participation
P07951410A0647|54 59|E2F-1
P07951410A0647|61 65|DP-1
P07951410A0647|67 75|cyclin A
P07951410A0647|81 83|RB
P07951410A0647|100 109|formation
P07951410A0647|118 127|complexes
P07951410A0647|143 156|participation
P07951410A0647|160 167|factors
P07951410A0647|183 188|E2F-1
P07951410A0647|192 196|DP-1
P07951410A0647|200 206|others
P07951410A1332|0 18|E1A autoactivation
P07951410A1332|37 42|sites
P07951410A1332|86 96|activation
P07951410A1332|124 136|E1A promoter
P07951874A0320|0 16|Cestode invasion
P07951874A0320|31 44|host organism
P07951874A0320|68 74|effect
P07951874A0320|87 96|radiation
P07951874A0320|104 111|hamster
P07951874A0320|119 125|system
P07953785A0648|7 20|heat exposure
P07953785A0648|22 28|chicks
P07953785A0648|64 77|% restriction
P07953785A0648|106 110|food
P07953785A0648|121 131|H/L ratios
P07953785A0648|145 155|resistance
P07953785A0648|159 190|marble spleen disease infection
P07954475A0714|0 8|Analyses
P07954475A0714|23 29|tumors
P07954475A0714|41 45|mice
P07954475A0714|66 73|crosses
P07954475A0714|75 91|A/J x C3H/HeJ F1
P07954475A0714|110 115|AC3F1
P07954475A0714|121 137|C3H/HeJ x A/J F1
P07954475A0714|156 161|C3AF1
P07954475A0714|173 181|evidence
P07954475A0714|190 202|inactivation
P07954475A0714|210 216|allele
P07954475A0714|233 243|chromosome
P07954475A0714|246 267|tumor suppressor gene
P07954891T0000|0 4|ERV1
P07954891T0000|38 43|cycle
P07954891T0000|52 63|maintenance
P07954891T0000|81 88|genomes
P07956578A0851|0 16|Lesion diameters
P07956578A0851|36 38|mm
P07956578A0851|66 80|configurations
P07956578A0851|86 93|factors
P07956578A0851|131 138|removal
P07956869A0000|42 62|breast cancer tissue
P07956869A0000|89 97|archives
P07956869A0000|105 125|Pathology laboratory
P07956869A0000|129 132|Dar
P07956869A0000|149 156|storage
P07956869A0000|168 173|years
P07956869A0000|193 207|flow cytometry
P07956869A0000|212 222|DNA ploidy
P07956869A0000|227 243|S-phase fraction
P07957085A0207|0 4|Cbf3
P07957085A0207|20 28|proteins
P07957085A0207|30 35|Cbf3a
P07957085A0207|37 42|Cbf3b
P07957085A0207|47 52|Cbf3c
P07957106A0471|8 19|interaction
P07957106A0471|46 68|GST-POU fusion protein
P07957106A0471|78 103|glutathione-agarose beads
P07957106A0875|6 15|mutations
P07957106A0875|42 48|region
P07957106A0875|59 82|HSV transactivator VP16
P07957106A0875|120 133|VP16 contacts
P07957158A1532|16 31|filtration rate
P07957158A1532|44 49|areas
P07957158A1532|101 110|parameter
P07957158A1532|186 193|control
P07957158A1532|201 216|Starling forces
P07957243A1316|15 23|residues
P07957243A1316|49 56|domains
P07957559A1557|9 18|rapamycin
P07957559A1557|29 42|proliferation
P07957559A1557|46 58|Ba/F3-EpoRgp
P07957559A1557|72 81|MEL cells
P07957559A1557|90 100|inhibition
P07957559A1557|104 126|p70 S6 kinase activity
P07957559A1557|135 140|cells
P07957632A0000|17 26|injection
P07957632A0000|31 33|2S
P07957632A0000|36 37|R
P07957632A0000|40 41|R
P07957632A0000|44 45|R
P07957632A0000|75 82|glycine
P07957632A0000|84 90|DCG-IV
P07957632A0000|102 109|agonist
P07957632A0000|127 146|glutamate receptors
P07957632A0000|151 155|rats
P07957632A0000|186 194|recovery
P07957632A0000|200 220|halothane anesthesia
P07957632A0000|226 236|dose range
P07957632A0000|252 260|pmol/rat
P07958446A0000|4 14|hepatocyte
P07958446A0000|23 31|factor-3
P07958446A0000|33 38|HNF-3
P07958446A0000|40 48|forkhead
P07958446A0000|50 53|fkh
P07958446A0000|55 63|proteins
P07958446A0000|88 94|family
P07958446A0000|132 147|gene regulators
P07958446A0000|160 168|homology
P07958446A0000|187 210|helix DNA binding motif
P07958865A1152|16 23|embryos
P07958865A1152|39 52|abnormalities
P07958865A1152|56 73|heart development
P07958865A1152|95 105|conclusion
P07958865A1152|111 114|Tek
P07958865A1152|155 167|interactions
P07958865A1152|175 186|development
P07958898A1050|15 25|dTFIIA-L/S
P07958898A1050|80 90|activation
P07958898A1050|103 124|transcription factors
P07958898A1050|135 138|Sp1
P07958898A1050|140 144|VP16
P07958898A1050|150 155|NTF-1
P07958911A0500|9 31|trithorax binding site
P07958911A0500|61 69|location
P07958911A0500|77 91|fork head gene
P07958911A0500|120 124|gene
P07958911A0500|155 162|complex
P07958915A1507|15 22|changes
P07958915A1507|40 43|Ca2
P07958915A1507|97 104|ability
P07958915A1507|108 112|cAMP
P07958915A1507|126 139|transcription
P07958915A1507|158 166|presence
P07958915A1507|179 184|forms
P07958915A1507|188 191|Ca2
P07958915A1507|214 229|protein kinases
P07958920A1157|0 10|Antibodies
P07958920A1157|32 44|SNM1 protein
P07958920A1157|64 77|RNase MRP RNA
P07958920A1157|94 102|extracts
P07958920A1157|167 178|RNase P RNA
P07959011A0379a|0 11|C/EBP alpha
P07959011A0379a|31 39|promoter
P07959011A0379a|47 67|rat class-I ADH gene
P07959011A0379a|91 97|manner
P07959011A0379a|99 105|Potter
P07959011A0379a|114 118|Arch
P07959011A0379b|0 11|C/EBP alpha
P07959011A0379b|31 39|promoter
P07959011A0379b|47 67|rat class-I ADH gene
P07959011A0379b|91 97|manner
P07959011A0379b|99 105|Potter
P07959011A0379b|114 118|Arch
P07959015A0478|4 11|results
P07959015A0478|26 29|ORF
P07959015A0478|33 38|hAMPK
P07959015A0478|51 62|amino acids
P07959015A0478|64 66|aa
P07959015A0478|76 79|kDa
P07959015A0478|110 115|rAMPK
P07959015A0478|121 131|identities
P07959015A0478|146 147|%
P07959015A0478|155 157|aa
P07959015A0478|162 171|nt levels
P07959734A0194|9 14|brain
P07959734A0194|16 25|contactin
P07959734A0194|50 55|amino
P07959734A0194|69 87|peptide sequencing
P07959734A0194|117 135|glycoprotein Gp135
P07959760A0763|16 26|YAC contig
P07959760A0763|61 65|YACs
P07959760A0763|70 76|orders
P07959760A0763|96 101|sites
P07959760A0763|103 107|STSs
P07959760A0763|119 126|minimum
P07959760A0763|134 136|Mb
P07959760A0763|151 175|Ewing sarcoma breakpoint
P07959760A0763|177 182|c-ets
P07959760A0763|189 194|Fli-1
P07959760A0763|200 207|members
P07959760A0763|215 225|ets family
P07959760A0763|255 257|kb
P07959760A0763|273 276|DNA
P07959760A0763|289 295|contig
P07959760A0763|332 346|microsatellite
P07959760A0763|348 355|D11S912
P07959760A0763|357 359|CA
P07959760A0763|360 361|n
P07959760A0763|398 408|Fli-1 gene
P07959952A1446|2 6|cDNA
P07959952A1446|30 40|pseudogene
P07959952A1446|65 89|mouse mast cell chymases
P07959952A1446|106 145|polymerase chain reaction amplification
P07959952A1446|153 158|mouse
P07959952A1446|182 196|mast cell line
P07959953A0423|0 5|IFI16
P07959953A0423|22 27|exons
P07959953A0423|49 56|introns
P07959953A0423|78 87|kilobases
P07959953A0423|89 91|kb
P07959953A0423|96 99|DNA
P07960608A0228|0 7|Courses
P07960608A0228|33 38|weeks
P07960796A0154|0 11|Peter Elfer
P07960796A0154|25 37|implications
P07960796A0154|45 51|ruling
P07961545A1314|14 20|events
P07961545A1314|26 36|incidences
P07961545A1314|68 75|placebo
P07961545A1314|81 90|dizziness
P07961545A1314|92 104|constipation
P07961545A1314|106 114|sweating
P07961545A1314|116 127|nervousness
P07961545A1314|142 153|ejaculation
P07961755A0474|0 8|Homology
P07961755A0474|48 72|transit peptide sequence
P07961755A0474|76 95|cysteine synthase C
P07961755A0474|130 146|leader sequences
P07961957A1565|17 21|data
P07961957A1565|41 49|addition
P07961957A1565|53 58|TEF-1
P07961957A1565|82 88|factor
P07961957A1565|114 139|alpha-MHC gene EM element
P07961958T0000|0 27|Rat kidney carboxylesterase
P07963540A0795|12 27|I-kappa B alpha
P07963540A0795|38 59|kappa B motif binding
P07963540A0795|71 86|factor-kappa B1
P07963540A0795|88 92|RelA
P07963540A0795|98 103|c-Rel
P07963540A0795|120 127|studies
P07963540A0795|134 136|UV
P07963540A0795|164 177|cross-linking
P07963540A0795|213 236|kappa B oligonucleotide
P07963782A0000|26 35|stability
P07963782A0000|41 52|combination
P07963782A0000|56 61|drugs
P07963782A0000|117 122|space
P07963782A0000|131 140|treatment
P07963782A0000|152 156|pain
P07964162A0941|11 21|mechanisms
P07964162A0941|35 45|activation
P07964162A0941|53 71|MAP kinase cascade
P07964162A0941|118 131|specification
P07964162A0941|144 153|responses
P07964458A0179|2 16|candidate gene
P07964458A0179|21 24|Bcg
P07964458A0179|67 85|macrophage protein
P07964458A0179|87 92|Nramp
P07964458A0179|161 177|membrane protein
P07964458A0179|211 218|animals
P07964459A0845|5 10|motif
P07964459A0845|47 57|LIM domain
P07964459A0845|66 84|RING finger family
P07964459A0845|128 135|regions
P07964624A0491|4 12|P131 ORF
P07964624A0491|46 49|ORF
P07964624A0491|89 100|readthrough
P07964624A0491|108 129|UGA termination codon
P07964624A0491|137 145|P131 ORF
P07964624A0491|159 170|polypeptide
P07964624A0491|174 175|M
P07964624A0491|176 177|r
P07964624A0491|187 191|P191
P07964770A0172|18 26|patients
P07964770A0172|46 50|year
P07964770A0172|57 69|arthroplasty
P07964814T0000|18 32|hallucinations
P07964814T0000|36 44|migraine
P07964814T0000|49 57|epilepsy
P07964918A0000|4 13|influence
P07964918A0000|33 40|factors
P07964918A0000|59 70|variability
P07964918A0000|78 88|evaluation
P07964918A0000|105 110|signs
P07965152A0764|0 8|Segments
P07965152A0764|27 39|BMIPP uptake
P07965152A0764|45 56|MIBI uptake
P07965152A0764|58 69|mismatching
P07965152A0764|92 103|wall motion
P07965152A0764|130 137|reserve
P07965152A0764|145 167|dobutamine stimulation
P07966565A0901|12 18|length
P07966565A0901|26 30|mRNA
P07966565A0901|38 49|nucleotides
P07966565A0901|58 67|agreement
P07966565A0901|90 93|RNA
P07966565A0901|119 136|replication cycle
P07966565A0901|160 166|stages
P07966565A0901|170 179|infection
P07966583A1268|10 23|transfections
P07966583A1268|29 38|construct
P07966583A1268|54 68|RNA transcript
P07966583A1268|80 88|clone B1
P07966583A1268|96 105|D17 cells
P07966583A1268|117 127|expression
P07966583A1268|134 142|Env/Mlvi
P07966583A1268|145 159|fusion protein
P07966583A1268|187 191|mass
P07966583A1268|198 201|kDa
P07966602A0130|0 7|Roizman
P07966602A0130|9 11|J.
P07966873A0693|0 8|Articles
P07966873A0693|29 42|heart disease
P07966873A0693|46 59|heart failure
P07966873A0693|90 100|infarction
P07966873A0693|104 110|Chagas
P07966873A0693|112 119|disease
P07967360A1048|12 16|data
P07967360A1048|36 44|patients
P07967360A1048|50 66|TGBM nephropathy
P07967360A1048|90 105|IgA nephropathy
P07967360A1048|134 152|glomerulonephritis
P07967725A0262|12 21|receptors
P07967725A0262|65 72|domains
P07967725A0262|108 114|domain
P07967725A0262|122 143|ligand binding domain
P07967725A0262|151 168|carboxyl terminus
P07967725A0262|176 184|receptor
P07968409A0123|4 10|sample
P07968409A0123|79 97|Outpatient Service
P07968409A0123|116 124|Diseases
P07968409A0123|134 141|Bologna
P07968409A0123|145 162|Ospedale Maggiore
P07968409A0123|164 180|General Hospital
P07968409A0123|198 202|days
P07968409A0123|213 217|July
P07969115A0000|9 37|organello footprint analysis
P07969115A0000|82 94|mitochondria
P07969115A0000|111 116|level
P07969115A0000|132 139|binding
P07969115A0000|160 169|intervals
P07969115A0000|190 196|region
P07969115A0000|221 232|DNA origins
P07969115A0000|241 257|promoter regions
P07969116A0196|4 17|Nur77 protein
P07969116A0196|38 61|transcription activator
P07969116A0196|95 105|expression
P07969116A0196|120 125|genes
P07969116A0196|129 137|response
P07969116A0196|155 162|stimuli
P07969132A0268|4 9|class
P07969132A0268|13 21|plasmids
P07969132A0268|32 36|tRNA
P07969132A0268|42 47|genes
P07969132A0268|72 83|suppression
P07969132A0268|94 99|cells
P07969132A0268|117 126|histidine
P07969132A0268|134 142|plasmids
P07969132A0268|156 169|gcn2 deletion
P07969132A0268|213 221|gcn2-507
P07969135A0913|10 18|presence
P07969135A0913|26 42|Cln2 PEST domain
P07969135A0913|88 95|protein
P07969136A0273|16 37|mobility shift assays
P07969136A0273|57 66|sequences
P07969136A0273|80 89|complexes
P07969136A0273|95 105|mobilities
P07969136A0273|132 147|NF-kappa B site
P07969136A0273|157 162|kappa
P07969136A0273|175 179|gene
P07969152A0721|29 32|HSF
P07969152A0721|49 66|activation domain
P07969152A0721|87 97|activation
P07969152A0721|101 119|CUP1 transcription
P07969152A0721|123 131|response
P07969152A0721|140 157|heat shock stress
P07969152A0721|162 180|glucose starvation
P07969152A0721|187 193|region
P07969152A0721|223 244|heat shock activation
P07969152A0721|261 266|genes
P07969152A0721|276 283|members
P07969152A0721|305 317|hsp70 family
P07969181A0313|31 37|levels
P07969181A0313|41 49|CKB mRNA
P07969181A0313|53 63|HeLa cells
P07969181A0313|77 82|study
P07969181A0313|141 148|amounts
P07969181A0313|152 163|p53 protein
P07969181A0313|175 185|HeLa cells
P07969954T0000|13 34|motor neuron syndrome
P07969954T0000|51 60|serum IgM
P07969954T0000|70 80|antibodies
P07969954T0000|82 93|improvement
P07969954T0000|104 117|immunotherapy
P07969954T0000|131 146|plasma exchange
P07969954T0000|163 179|cyclophosphamide
P07971282A0000|0 10|Regulators
P07971282A0000|70 102|pre-mRNA splicing characteristic
P07971282A0000|106 115|metazoans
P07971709A0907|18 26|response
P07971709A0907|66 73|rhG-CSF
P07971709A0907|82 90|activity
P07971709A0907|104 109|state
P07972012A0956|14 24|cDNA clone
P07972012A0956|41 57|rat lung library
P07972012A0956|91 98|protein
P07972012A0956|117 131|amino terminus
P07972012A0956|144 150|domain
P07972012A0956|169 181|ANP-receptor
P07972012A0956|194 200|domain
P07972012A0956|223 240|carboxyl terminus
P07972012A0956|267 285|phosphatase domain
P07972237A0665|18 33|restriction map
P07972237A0665|46 48|kb
P07972237A0665|63 66|DNA
P07972237A0665|78 83|N-myc
P07972237A0665|106 121|subcloning YACs
P07972237A0665|127 134|cosmids
P07972831A0563|0 12|PAI-1 levels
P07972831A0563|40 48|patients
P07972831A0563|62 69|iohexol
P07972831A0563|100 109|ioxaglate
P07973364A0325|15 22|article
P07973364A0325|28 34|causes
P07973364A0325|38 43|death
P07973364A0325|84 107|carcinogenicity studies
P07973364A0325|111 118|studies
P07973364A0325|129 132|OFA
P07973364A0325|162 173|Wistar rats
P07973364A0325|180 187|studies
P07973364A0325|198 201|OF1
P07973364A0325|206 215|NMRI mice
P07973397T0001|0 13|Determination
P07973397T0001|17 33|potassium iodide
P07973397T0001|51 55|salt
P07973825A0445|4 18|recovery value
P07973825A0445|31 39|pressure
P07973825A0445|66 74|pressure
P07973825A0445|79 93|pulse pressure
P07975763A0000|4 14|importance
P07975763A0000|18 35|hepatitis C virus
P07975763A0000|37 40|HCV
P07975763A0000|42 51|infection
P07975763A0000|57 62|cause
P07975763A0000|74 87|liver disease
P07975763A0000|114 126|introduction
P07975763A0000|140 157|detection methods
P07975882T0000|6 21|adenovirus type
P07975882T0000|38 44|fibers
P07977239A1283|0 19|Outflow obstruction
P07977239A1283|34 39|juice
P07977239A1283|57 65|stenosis
P07977239A1283|79 86|papilla
P07977239A1283|125 133|patients
P07977239A1283|139 143|type
P07977239A1283|147 154|papilla
P07977239A1283|176 184|patients
P07977239A1283|190 194|type
P07977239A1283|198 205|papilla
P07977239A1283|230 242|pancreatitis
P07977239A1283|263 271|drainage
P07977239A1283|286 291|juice
P07977239A1283|306 314|pressure
P07977239A1283|322 333|dorsal duct
P07977648A0880|0 10|Sequencing
P07977648A0880|18 34|TP53 transcripts
P07977648A0880|40 45|exons
P07977648A0880|79 88|mutations
P07977648A0880|106 112|allele
P07977648A0880|129 135|tumors
P07978229T0000|11 23|complication
P07978229T0000|41 48|patient
P07978406A0998|7 16|ISO group
P07978406A0998|21 28|pre-DEX
P07978406A0998|30 33|CBF
P07978406A0998|72 80|mL.min-1
P07978406A0998|85 88|g-1
P07978406A0998|92 100|response
P07978406A0998|104 115|hypercapnia
P07978406A0998|117 121|PCO2
P07978406A0998|139 143|mmHg
P07978406A0998|146 154|ABSTRACT
P07978406A0998|172 177|WORDS
P07979810A0340|20 30|parameters
P07979810A0340|32 39|density
P07979810A0340|41 49|motility
P07979810A0340|60 64|test
P07979810A0340|66 82|penetration test
P07979810A0340|144 153|pregnancy
P07979827A0722|0 7|KRN2391
P07979827A0722|12 22|cromakalim
P07979827A0722|49 57|increase
P07979827A0722|81 91|blood flow
P07980440A0138|3 27|H4IIE rat hepatoma cells
P07980440A0138|29 44|glucocorticoids
P07980440A0138|55 59|acid
P07980440A0138|71 74|AMP
P07980440A0138|76 80|cAMP
P07980440A0138|82 115|increase PEPCK gene transcription
P07980440A0138|124 131|insulin
P07980440A0138|136 150|phorbol esters
P07980440A0138|169 175|effect
P07980468A0298|0 4|Acta
P07980669A0373|6 23|plasma AVP levels
P07980669A0373|28 39|AVP release
P07980669A0373|55 61|change
P07980669A0373|81 98|plasma NPY levels
P07980669A0373|125 132|samples
P07981143A0633|2 9|stretch
P07981143A0633|16 27|nucleotides
P07981143A0633|49 55|IL-4RE
P07981143A0633|71 88|IL-4 inducibility
P07981143A0633|100 123|nucleoprotein complexes
P07981143A0633|142 149|factors
P07981246A0112|13 18|study
P07981246A0112|34 49|pertussis toxin
P07981246A0112|51 54|IAP
P07981246A0112|78 85|protein
P07981246A0112|86 87|s
P07981246A0112|90 99|G-protein
P07981246A0112|120 127|process
P07981246A0112|131 146|differentiation
P07981246A0112|150 163|hormones/IBMX
P07981246A0112|180 195|c-fos induction
P07982964A1017|0 3|ATX
P07982964A1017|10 14|PC-1
P07982964A1017|43 47|type
P07982964A1017|50 103|phosphodiesterase substrate p-nitrophenyl thymidine-5
P07982964A1017|105 118|monophosphate
P07982995A0000|4 10|effect
P07982995A0000|28 37|mutations
P07982995A0000|45 50|mouse
P07982995A0000|68 81|growth factor
P07982995A0000|83 87|PDGF
P07982995A0000|89 102|beta-receptor
P07982995A0000|106 116|activation
P07982995A0000|124 126|Na
P07982995A0000|128 129|H
P07982995A0000|131 140|exchanger
P07982995A0000|179 184|gland
P07982995A0000|197 202|NMuMG
P07982995A0000|216 229|hamster ovary
P07982995A0000|231 234|CHO
P07982995A0000|236 241|cells
P07983011A0617|0 17|Sequence analysis
P07983011A0617|33 39|kinase
P07983011A0617|50 56|domain
P07983011A0617|80 104|serine/threonine kinases
P07983011A0617|109 115|hybrid
P07983011A0617|124 131|members
P07983011A0617|139 145|family
P07983011A0617|172 201|protein kinase kinase kinases
P07983011A0617|210 250|fibroblast growth factor receptor family
P07983011A0617|282 303|leucine zipper motifs
P07983011A0617|328 332|acid
P07983011A0617|354 361|segment
P07983011A0617|396 402|domain
P07983011A0617|455 462|domains
P07983011A0617|477 489|src homology
P07983011A0617|493 496|SH3
P07983011A0617|498 520|domain binding regions
P07983704A0330|0 4|Type
P07983704A0330|7 14|genomes
P07983704A0330|31 39|sequence
P07983704A0330|76 85|structure
P07983704A0330|127 147|retrovirus ancestors
P07983704A0330|155 168|HERV-K family
P07983704A0330|177 181|type
P07983704A0330|184 191|genomes
P07983704A0330|206 214|sequence
P07983712A0914|14 20|domain
P07983712A0914|27 33|domain
P07983712A0914|61 68|plasmid
P07983712A0914|75 81|levels
P07983712A0914|85 96|replication
P07983715A0996|0 15|Point mutations
P07983715A0996|45 52|binding
P07983715A0996|56 60|NF-Y
P07983715A0996|89 92|arm
P07983715A0996|105 113|activity
P07983715A0996|130 141|P4 promoter
P07983715A0996|166 183|complex formation
P07983715A0996|189 192|USF
P07983715A0996|229 246|expression assays
P07983715A0996|257 281|luciferase reporter gene
P07983716A1082|14 22|Northern
P07983716A1082|24 27|RNA
P07983716A1082|29 42|blot analysis
P07983716A1082|55 73|transcriptase-PCRs
P07983716A1082|90 102|transfection
P07983716A1082|106 111|COS-7
P07983716A1082|115 125|HeLa cells
P07983716A1082|143 147|RNAs
P07983716A1082|162 166|Y88S
P07983716A1082|171 180|Y88L RNAs
P07983716A1082|209 215|levels
P07983744A0920|22 27|forms
P07983744A0920|31 36|IE110
P07983744A0920|70 74|form
P07983744A0920|78 83|IE175
P07983744A0920|97 116|punctate structures
P07983744A0920|136 140|form
P07983744A0920|144 149|IE110
P07983744A0920|177 182|forms
P07983744A0920|186 191|IE175
P07983744A0920|207 226|punctate structures
P07984088A0592|0 13|Transcription
P07984088A0592|21 25|gene
P07984088A0592|30 42|ivanolysin O
P07984088A0592|47 57|expression
P07984088A0592|67 72|genes
P07984088A0592|80 102|virulence gene cluster
P07984088A0592|106 117|L. ivanovii
P07984088A0592|136 140|PrfA
P07984105A1509|13 28|complementation
P07984105A1509|36 50|WA fyuA mutant
P07984105A1509|65 74|fyuA gene
P07984105A1509|76 97|yersiniabactin uptake
P07984105A1509|102 117|mouse virulence
P07984261A0536|4 8|ICBF
P07984261A0536|26 32|cortex
P07984261A0536|51 60|reduction
P07984261A0536|80 86|centre
P07984261A0536|106 113|tissues
P07985305T0001|4 13|treatment
P07985305T0001|17 31|hydronephrosis
P07985305T0001|35 43|children
P07987924A0670|4 17|inflation hub
P07987924A0670|25 30|probe
P07987924A0670|68 94|USCI Tuohy-Borst Y adaptor
P07987924A0670|132 146|probe hypotube
P07988559A0836|10 17|element
P07988559A0836|24 35|RBP-J kappa
P07988559A0836|45 53|affinity
P07988730A0220|10 27|promoter strength
P07988730A0220|31 41|constructs
P07988730A0220|57 66|deletions
P07988730A0220|74 83|U5 region
P07988730A0220|91 94|LTR
P07988730A0220|111 144|chloramphenicol acetyltransferase
P07988730A0220|146 149|CAT
P07988730A0220|151 157|assays
P07988730A0220|168 180|transfection
P07988730A0220|184 194|HeLa cells
P07988730A0220|198 212|Jurkat T-cells
P07988730A0220|220 228|presence
P07988730A0220|232 239|absence
P07988730A0220|249 275|transactivator tax protein
P07988731A0002|15 21|number
P07988731A0002|78 87|promoters
P07988731A0002|114 122|presence
P07988731A0002|141 149|elements
P07988731A0002|167 184|promoter activity
P07988731A0002|206 211|G-box
P07988731A0002|213 221|CCACGTGG
P07988731A1301|12 19|protein
P07988731A1301|31 35|GF14
P07988731A1301|82 101|GBF protein complex
P07988945T0000|0 3|New
P07988945T0000|15 25|strategies
P07988945T0000|30 50|lupus anticoagulants
P07988945T0000|72 82|antibodies
P07990136A1124|14 21|ability
P07990136A1124|25 54|selectivity arrest elongation
P07990136A1124|58 64|polIII
P07990136A1124|76 85|positions
P07990136A1124|97 125|tRNA gene transcription unit
P07990136A1124|144 158|identification
P07990136A1124|182 192|properties
P07990136A1124|213 219|polIII
P07990136A1124|228 237|complexes
P07991437A1032|0 11|Propafenone
P07991437A1032|37 45|majority
P07991437A1032|55 63|patients
P07991582A1023b|11 19|analysis
P07991582A1023b|23 33|yeast CEG1
P07991582A1023b|79 85|motifs
P07991582A1023b|112 127|enzyme function
P07992027A0485|2 10|patients
P07992027A0485|14 15|%
P07992027A0485|33 42|morbidity
P07992027A0485|55 59|days
P07992027A0485|79 94|transplantation
P07993559A0233|9 14|index
P07993559A0233|16 36|Fluorosis Risk Index
P07993559A0233|51 58|Pendrys
P07993559A0233|91 97|review
P07994021A1223|12 20|splicing
P07994021A1223|40 44|tail
P07994021A1223|74 90|PECAM-1 isoforms
P07994021A1223|109 124|phosphorylation
P07994021A1223|139 150|association
P07994021A1223|156 175|affinity modulation
P07994021A1223|190 197|protein
P07995173A0585|0 8|Transfer
P07995173A0585|48 56|juice pH
P07995173A0585|58 59|r
P07995173A0585|70 71|P
P07995910A0119|5 14|technique
P07995910A0119|21 32|sensitivity
P07995910A0119|39 50|specificity
P07995910A0119|64 65|%
P07995910A0119|93 96|way
P07995910A0119|115 126|involvement
P07995910A0119|139 149|laparotomy
P07997174A0936|4 8|data
P07997174A0936|32 47|phosphorylation
P07997174A0936|51 58|His-304
P07997174A0936|97 106|functions
P07997174A0936|110 128|A. vinelandii NifL
P07999066A0238|4 8|role
P07999066A0238|12 19|HIV tat
P07999066A0238|39 55|enhancing factor
P07999066A0238|66 69|LTR
P07999066A0238|78 88|regulation
P07999066A0238|92 115|IL-2 gene transcription
P07999066A0238|153 163|expression
P07999066A0238|171 179|tat gene
P07999066A0238|183 196|phorbol ester
P07999066A0238|201 208|calcium
P07999066A0238|229 241|Jurkat cells
P07999066A0238|259 263|IL-2
P07999066A0238|289 326|acetyltransferase reporter constructs
P07999363A0000|7 17|variations
P07999363A0000|21 26|genes
P07999363A0000|42 68|transmembrane FGF receptor
P07999363A0000|70 74|FGFR
P07999363A0000|86 94|isoforms
P07999363A0000|112 122|ectodomain
P07999363A0000|138 158|juxtamembrane domain
P07999363A0000|182 195|kinase domain
P07999604A0139|25 33|patients
P07999604A0139|80 87|lesions
P07999982A0086|10 28|maximum lod scores
P07999982A0086|37 41|FRDA
P07999982A0086|46 50|D9S5
P07999982A0086|63 67|FRDA
P07999982A0086|72 77|D9S15
P07999982A0086|118 140|recombination fraction
P07999982A0086|163 183|recombination events
P07999982A0086|205 211|search
P07999982A0086|219 223|gene
P07999995A0000|16 30|protein kinase
P07999995A0000|32 38|OsPK10
P07999995A0000|61 65|rice
P07999995A0000|67 79|Oryza sativa
P08000074A0162|2 10|sequence
P08000074A0162|32 33|%
P08000074A0162|59 67|sequence
P08000074A0162|84 95|translation
P08000074A0162|112 126|reading frames
P08000074A0162|144 150|kb DNA
P08000074A0162|159 167|fragment
P08000112T0000|0 11|Goodpasture
P08000112T0000|19 27|syndrome
P08000112T0000|32 38|effect
P08000112T0000|57 84|membrane oxygenator support
P08000427A0000|2 17|cDNA clone pCZ1
P08000427A0000|30 39|kb insert
P08000427A0000|74 99|tobacco cell cDNA library
P08000427A0000|142 153|kDa protein
P08000427A0000|159 170|amino acids
P08000427A0000|190 192|pI
P08000497A0179|0 7|METHODS
P08000497A0179|28 38|spirometry
P08000497A0179|44 73|methacholine provocation test
P08000497A0179|86 90|test
P08000497A0179|101 108|airways
P08000497A0179|121 127|volume
P08000497A0179|139 142|gas
P08000497A0179|144 147|VTG
P08001136T0000|0 12|Relationship
P08001136T0000|31 37|kinase
P08001136T0000|42 56|RNA polymerase
P08001136T0000|60 82|CTD kinase TFIIH/TFIIK
P08001792A0284|4 8|git1
P08001792A0284|10 14|git3
P08001792A0284|16 20|git5
P08001792A0284|22 26|git7
P08001792A0284|28 32|git8
P08001792A0284|37 48|git10 genes
P08001792A0284|65 82|adenylate cyclase
P08001792A0284|107 143|adenylate cyclase activation pathway
P08001966A0563|11 18|regions
P08001966A0563|37 45|homology
P08001966A0563|66 74|proteins
P08001966A0563|76 79|CNC
P08001966A0563|84 90|skin-1
P08001966A0563|125 136|development
P08001966A0563|168 190|Caenorhabditis elegans
P08002564A0249|0 21|DNA sequence analysis
P08002564A0249|46 54|mutation
P08002564A0249|78 84|region
P08002564A0249|92 105|alpha subunit
P08002564A0249|118 133|leucine residue
P08002564A0249|137 145|position
P08002564A0249|155 164|histidine
P08002564A0249|166 175|rpoAL290H
P08002857A1070|0 11|CONCLUSIONS
P08002857A1070|19 27|findings
P08002857A1070|48 55|barrier
P08002857A1070|59 81|oesophageal surfactant
P08002857A1070|105 111|degree
P08002857A1070|115 125|protection
P08002857A1070|153 159|reflux
P08002857A1070|199 205|attack
P08002857A1070|209 213|bile
P08003700T0000|13 22|screening
P08003700T0000|40 54|cDNA libraries
P08003700T0000|102 112|sugar-beet
P08003700T0000|121 142|genome rearrangements
P08003700T0000|146 150|atp6
P08003700T0000|155 164|atpA loci
P08004442A0265|4 11|effects
P08004442A0265|22 31|isolation
P08004442A0265|52 70|locomotor activity
P08004442A0265|93 100|animals
P08004442A0265|147 150|HPA
P08004442A0265|152 156|axis
P08004442A0265|163 170|animals
P08004442A0265|195 219|corticosterone secretion
P08004442A0265|235 248|adrenalectomy
P08005230A0222|11 31|reporter gene system
P08005230A0222|71 81|activation
P08005230A0222|89 103|c-fos promoter
P08005230A0222|150 159|elevation
P08005230A0222|172 191|luciferase activity
P08005412A0608|25 40|gene expression
P08005412A0608|46 47|P
P08005412A0608|72 81|formation
P08005412A0608|87 102|protein complex
P08005412A0608|139 147|PS sites
P08005412A0608|166 178|interactions
P08005412A0608|201 204|DNA
P08005438A1185|0 5|SPP41
P08005438A1185|58 63|spp43
P08005438A1185|104 119|suppressor srn1
P08005438A1185|146 155|regulator
P08005438A1185|159 174|gene expression
P08006101A1142|0 39|Standard curve correlation coefficients
P08006101A1142|81 103|validation experiments
P08006101A1142|108 116|analysis
P08006101A1142|120 133|study samples
P08006772A0000|12 26|pulse oximeter
P08006772A0000|43 48|fetus
P08006772A0000|56 62|labour
P08006772A0000|90 95|women
P08006772A0000|120 126|labour
P08006773A0836|13 23|difference
P08006773A0836|27 48|plasma concentrations
P08006773A0836|52 56|PGI2
P08006773A0836|58 64|figure
P08006773A0836|72 76|TxA2
P08006773A0836|80 88|patients
P08006773A0836|101 115|blood pressure
P08006773A0836|122 134|preeclampsia
P08006773A0836|139 150|hypotension
P08006773A0836|170 182|preeclampsia
P08006773A0836|188 208|plasma concentration
P08006773A0836|212 216|PGI2
P08006773A0836|242 243|p
P08006773A0836|260 264|TxA2
P08006773A0836|287 288|p
P08007835A0538|9 17|analysis
P08007835A0538|31 40|variables
P08007835A0538|57 66|formation
P08007835A0538|70 81|FB memories
P08007835A0538|116 121|level
P08007835A0538|125 135|importance
P08007835A0538|152 157|event
P08007835A0538|162 167|level
P08007835A0538|181 189|response
P08007835A0538|197 201|news
P08007954A0374|0 16|Deletion studies
P08007954A0374|37 53|response element
P08007954A0374|82 99|cytokine response
P08007954A0374|108 118|properties
P08007954A0374|151 159|enhancer
P08007975A0000|4 13|IPL1 gene
P08007975A0000|30 66|high-fidelity chromosome segregation
P08007975A0000|82 87|yeast
P08011017A0169|3 7|drop
P08011017A0169|11 28|oxygen saturation
P08011017A0169|30 34|SaO2
P08011017A0169|46 54|evidence
P08011017A0169|93 96|EEG
P08011017A0169|98 106|arousals
P08011017A0169|123 145|repeat polysomnography
P08011166A0207|13 30|gene organization
P08011166A0207|61 68|results
P08011166A0207|76 84|sequence
P08011166A0207|94 100|clones
P08011166A0207|118 134|characterization
P08011166A0207|138 154|polymerase chain
P08011166A0207|182 190|segments
P08012448T0000|0 4|INO2
P08012448T0000|19 23|gene
P08012448T0000|27 32|yeast
P08012448T0000|46 58|biosynthesis
P08012448T0000|76 87|segregation
P08012448T0000|92 113|bud pattern formation
P08012566A0254|4 32|pentafluorobenzyl derivative
P08012566A0254|36 52|clonidine yields
P08012566A0254|64 76|ion fragment
P08012566A0254|80 83|m/z
P08012566A0254|103 108|limit
P08012566A0254|112 121|detection
P08012566A0254|131 136|ng/ml
P08012566A0254|148 161|plasma sample
P08013348A0143|10 14|ABPs
P08013348A0143|19 24|SHBGs
P08013348A0143|30 42|sex steroids
P08013348A0143|53 61|affinity
P08013348A0143|72 90|binding properties
P08013348A0143|104 111|species
P08013457A0342|0 12|Src homology
P08013457A0342|14 16|SH
P08013457A0342|18 24|domain
P08013457A0342|51 63|interactions
P08013457A0342|81 125|tyrosine kinase receptor signal transduction
P08014228A0278|0 16|Sample treatment
P08014228A0278|34 39|order
P08014228A0278|62 72|extraction
P08014228A0278|76 102|labetalol diastereoisomers
P08014228A0278|116 128|racemization
P08014228A0278|136 146|extraction
P08014377A1277|14 24|conditions
P08014377A1277|26 41|activity levels
P08014377A1277|53 58|vagal
P08014377A1277|75 83|outflows
P08014377A1277|128 136|subjects
P08014377A1277|152 163|interaction
P08014377A1277|202 211|divisions
P08014919A0530|41 46|units
P08014919A0530|56 67|progression
P08014919A0530|81 87|fields
P08014919A0530|115 119|body
P08014919A0530|127 134|rostral
P08014919A0530|145 154|direction
P08014919A0530|165 171|length
P08014919A0530|175 178|DGR
P08015672A1282|3 19|control patients
P08015672A1282|21 36|baseline images
P08015672A1282|47 51|Type
P08015672A1282|61 65|Type
P08015672A1282|83 87|Type
P08015672A1282|111 115|Type
P08015672A1282|150 154|Type
P08015672A1282|158 166|baseline
P08015850A1076|16 24|analysis
P08015850A1076|28 41|dose response
P08015850A1076|43 47|time
P08015850A1076|52 56|mode
P08015850A1076|60 77|Ga administration
P08015850A1076|79 88|preinjury
P08015850A1076|92 102|postinjury
P08015850A1076|109 121|availability
P08015850A1076|125 127|Ga
P08015850A1076|151 158|barrier
P08015850A1076|193 201|efficacy
P08015850A1076|210 218|compound
P08016102A1238|4 12|presence
P08016102A1238|27 36|sequences
P08016102A1238|45 52|binding
P08016102A1238|56 77|transcription factors
P08016102A1238|86 96|NF-kappa B
P08016102A1238|101 105|AP-2
P08016102A1238|113 123|activation
P08016102A1238|157 165|response
P08016102A1238|173 177|cell
P08016102A1238|184 190|injury
P08016102A1238|202 212|indication
P08016102A1238|230 234|role
P08016102A1238|241 245|HO-1
P08016102A1238|258 276|defense mechanisms
P08016102A1238|285 298|tissue injury
P08016189A0741|0 11|Granisetron
P08016189A0741|21 27|saline
P08016189A0741|39 47|vomiting
P08016189A0741|52 58|nausea
P08016189A0741|73 85|intervention
P08016189A0741|113 120|regimen
P08017290A1347|28 44|sinus difference
P08017290A1347|48 55|lactate
P08017290A1347|77 79|pH
P08017290A1347|81 85|PCO2
P08017290A1347|90 111|potassium differences
P08017290A1347|125 130|group
P08017290A1347|140 146|pacing
P08018361A0636|35 50|neutron fluency
P08018361A0636|64 69|n/cm2
P08020702A0000|0 11|Endotoxemia
P08020702A0000|37 45|bacteria
P08020702A0000|65 70|shock
P08020702A0000|115 124|component
P08020702A0000|142 146|wall
P08020702A0000|148 156|lipid A.
P08020702A0137|4 9|study
P08020702A0137|29 36|ability
P08020702A0137|40 47|lipid A
P08020702A0137|59 69|antibodies
P08020702A0137|93 105|disturbances
P08020702A0137|113 124|endotoxemia
P08020702A0137|128 143|dog experiments
P08020702A0137|155 163|efficacy
P08020702A0137|171 196|antibodies administration
P08020806A0187|25 30|trial
P08020806A0187|52 60|patients
P08020806A0187|73 78|Crohn
P08020806A0187|81 88|disease
P08020806A0187|126 134|outcomes
P08020806A0187|144 154|amino acid
P08020806A0187|161 165|diet
P08020806A0187|178 183|% fat
P08020806A0187|199 211|feeding tube
P08020806A0187|228 235|peptide
P08020806A0187|242 246|diet
P08020806A0187|260 265|% fat
P08020962A1226|15 21|region
P08020962A1226|29 41|V beta locus
P08020962A1226|62 68|number
P08020962A1226|83 95|DNA elements
P08020962A1226|100 103|Alu
P08020962A1226|111 113|L1
P08020962A1226|121 124|MER
P08020962A1226|155 163|elements
P08020965A0465|22 28|region
P08020965A0465|84 94|transcript
P08020965A0465|100 102|kb
P08020965A0465|126 130|ends
P08020965A0465|139 149|transcript
P08021175A0486|4 8|pexB
P08021175A0486|18 24|region
P08021175A0486|39 50|nucleotides
P08021175A0486|64 73|sequences
P08021175A0486|92 101|consensus
P08021175A0486|113 133|AMP receptor protein
P08021175A0486|138 161|integration host factor
P08021175A0486|170 175|sites
P08021177A0000|4 13|fepA-entD
P08021177A0000|18 34|fes-entF operons
P08021177A0000|42 64|enterobactin synthesis
P08021177A0000|69 85|transport system
P08021177A0000|131 140|promoters
P08021177A0000|172 193|Fur repressor protein
P08021177A0000|213 223|conditions
P08021225A0000|0 17|Sequence analysis
P08021225A0000|39 53|EcoRI-fragment
P08021225A0000|57 78|Alcaligenes eutrophus
P08021225A0000|121 137|dihydrolipoamide
P08021225A0000|161 170|DNA probe
P08021225A0000|172 174|A.
P08022212A0071|29 42|two-frequency
P08022212A0071|44 57|AC excitation
P08022212A0071|75 81|method
P08022212A0071|87 108|admittance locus plot
P08022212A0071|110 113|ALP
P08022212A0071|122 142|low-frequency region
P08022212A0071|151 153|Hz
P08022212A0071|213 217|line
P08022212A0071|266 276|parameters
P08022212A0071|278 300|phase angle alpha pi/2
P08022212A0071|302 313|conductance
P08022212A0071|335 347|frequency G0
P08022212A0071|350 354|1/R0
P08022212A0071|360 383|ion relaxation time tau
P08023662T0000|15 26|measurement
P08023662T0000|48 67|thromboplastin time
P08023662T0000|72 88|prothrombin time
P08023662T0000|108 115|monitor
P08024139A0393|3 11|addition
P08024139A0393|35 45|hypothesis
P08024139A0393|63 70|volumes
P08024139A0393|115 126|differences
P08024139A0393|184 193|solutions
P08024139A0393|212 222|impairment
P08025074A0000|15 20|study
P08025074A0000|27 32|nylon
P08025074A0000|76 96|laser energy density
P08025074A0000|108 120|suture lysis
P08025074A0000|140 144|shot
P08025074A0000|162 168|Dacron
P08025074A0000|177 184|prolene
P08025669A0724|4 12|proteins
P08025669A0724|35 39|rpoN
P08025669A0724|73 78|sigma
P08025669A0724|82 90|activity
P08028671A0687|20 34|microinjection
P08028671A0687|50 59|antiserum
P08028671A0687|65 76|fibroblasts
P08028671A0687|89 102|transcription
P08028671A0687|110 114|cAMP
P08028671A0687|126 134|promoter
P08029001A1020|6 13|results
P08029001A1020|33 38|class
P08029001A1020|55 73|activator proteins
P08029001A1020|78 92|RNA polymerase
P08029001A1020|139 148|component
P08029001A1020|182 188|target
P08029001A1020|204 227|transcription machinery
P08029334T0000|0 7|Cloning
P08029334T0000|18 31|plant omega-3
P08029334T0000|38 54|acid desaturases
P08030239A0833|34 38|form
P08030239A0833|49 60|polypeptide
P08030239A0833|72 91|amino acid residues
P08030239A0833|148 165|activation domain
P08030239A0833|195 212|EHV-1 tk promoter
P08030239A0833|230 237|ability
P08030239A0833|259 276|EHV-1 IE promoter
P08030243A1011|29 46|RNA capture assay
P08030243A1011|52 61|multimers
P08030243A1011|100 108|activity
P08030243A1011|137 141|NS35
P08030704A1503|0 10|CONCLUSION
P08030704A1503|26 31|birth
P08030704A1503|71 108|progesterone/17 beta-estradiol ratios
P08030704A1503|123 128|women
P08030704A1503|134 147|preterm labor
P08030704A1503|161 165|term
P08031424T0000|0 8|Ketamine
P08031424T0000|16 25|treatment
P08031424T0000|29 41|bronchospasm
P08031424T0000|60 71|ventilation
P08033490A0875|3 13|conclusion
P08033490A0875|19 30|disposition
P08033490A0875|34 45|venlafaxine
P08033490A0875|50 72|O-desmethylvenlafaxine
P08033490A0875|102 109|disease
P08033490A0875|121 138|dosage adjustment
P08033490A0875|156 164|patients
P08033490A0875|170 197|creatinine clearance values
P08033490A0875|207 213|ml/min
P08034318A0724|4 16|availability
P08034318A0724|20 28|sequence
P08034318A0724|43 50|species
P08034318A0724|90 98|UBE site
P08034318A0724|109 119|similarity
P08034318A0724|123 129|motifs
P08034318A0724|140 147|members
P08034318A0724|155 166|NF-1 family
P08034318A0724|170 191|transcription factors
P08034486A0579|4 13|incidence
P08034486A0579|17 22|HSV-2
P08034486A0579|32 40|subjects
P08034486A0579|42 47|HSV-2
P08034486A0579|48 68|HSV-1 antibody ratio
P08034486A0579|109 119|population
P08034486A0579|151 156|areas
P08034680A0180|4 13|mechanism
P08034680A0180|22 30|zeta PKC
P08034680A0180|41 51|NF-kappa B
P08034680A0180|79 89|activation
P08034680A0180|104 120|I kappa B kinase
P08034680A0180|134 138|mass
P08034680A0180|156 159|kDa
P08034680A0180|198 208|I kappa B.
P08034682T0000|7 17|expression
P08034682T0000|31 77|inositol 1,4,5-trisphosphate receptor subunits
P08034682T0000|81 96|3T3 fibroblasts
P08034708A0000|14 19|basis
P08034708A0000|24 34|commitment
P08034708A0000|38 49|progenitors
P08034708A0000|57 75|eosinophil lineage
P08034708A0000|80 90|mechanisms
P08034708A0000|120 125|genes
P08034708A0000|161 176|differentiation
P08034741A0000|14 28|identification
P08034741A0000|33 49|characterization
P08034741A0000|53 56|myr
P08034741A0000|60 66|myosin
P08034741A0000|72 75|rat
P08034741A0000|98 106|myosin I
P08034741A0000|144 160|border myosin I.
P08034742A0307|0 2|M.
P08034742A0307|8 10|D.
P08035498A0833|3 11|addition
P08035498A0833|13 30|computer analysis
P08035498A0833|45 54|sequences
P08035498A0833|70 84|A stem element
P08035498A0833|114 134|AAV promoter regions
P08035499A0941|21 31|difference
P08035499A0941|35 44|stability
P08035499A0941|56 61|kinds
P08035499A0941|65 74|complexes
P08035499A0941|90 94|fact
P08035499A0941|104 121|dissociation rate
P08035499A0941|129 145|A stem substrate
P08035499A0941|167 176|complexes
P08035499A0941|237 239|TR
P08035505A0586|0 10|Processing
P08035505A0586|18 21|NS3
P08035505A0586|24 37|B polyprotein
P08035517A0753|14 22|promoter
P08035517A0753|36 41|IEP86
P08035517A0753|78 86|addition
P08035517A0753|90 95|IEP72
P08035796A0890|0 13|32Pi labeling
P08035796A0890|38 46|analysis
P08035796A0890|50 61|eIF-2 alpha
P08035796A0890|79 92|casein kinase
P08035796A0890|96 103|mutants
P08035796A0890|119 134|phosphorylation
P08035796A0890|138 149|eIF-2 alpha
P08035796A0890|183 188|forms
P08035796A0890|192 203|eIF-2 alpha
P08035796A0890|228 235|strains
P08035796A0890|265 282|growth conditions
P08035833A1556|6 10|YMIP
P08035833A1556|27 34|homolog
P08035833A1556|38 42|RMIP
P08035833A1556|64 73|component
P08035833A1556|81 86|yeast
P08035833A1556|101 117|import machinery
P08036004A0292|4 13|R2 region
P08036004A0292|25 30|class
P08036004A0292|33 41|enhancer
P08036004A0292|61 68|element
P08036004A0292|89 94|cells
P08036004A0292|119 135|binding activity
P08036004A0292|187 192|cells
P08036004A0292|219 224|class
P08036004A0292|227 237|expression
P08037338A0000|0 7|PURPOSE
P08037338A0000|25 33|kinetics
P08037338A0000|37 51|erythropoietin
P08037338A0000|53 56|EPO
P08037338A0000|58 68|production
P08037338A0000|85 97|pathogenesis
P08037338A0000|101 107|anemia
P08037338A0000|111 122|prematurity
P08037338A0000|136 146|EPO levels
P08037338A0000|150 157|infants
P08037338A0000|175 179|year
P08037338A0000|183 187|life
P08039422A0000|4 33|nerve growth factor beta gene
P08039422A0000|35 39|NGFB
P08039422A0000|73 78|group
P08039422A0000|88 98|chromosome
P08039422A0000|105 121|mouse Chromosome
P08040336A0435|25 32|element
P08040336A0435|34 50|collagen element
P08040336A0435|79 87|homology
P08040336A0435|97 120|LAP binding cis-element
P08040336A0435|128 144|albumin promoter
P08040336A0435|154 156|bp
P08040391T0000|0 6|Number
P08040391T0000|11 15|size
P08040391T0000|51 59|clusters
P08040391T0000|71 80|seminomas
P08040391T0000|82 93|correlation
P08040391T0000|112 120|features
P08040391T0000|125 141|tumour behaviour
P08040468A0303|18 41|mast cell degranulation
P08040468A0303|65 77|pathogenesis
P08040468A0303|81 92|necrobiosis
P08040468A0303|105 131|fibroblast enzyme activity
P08040468A0303|172 181|reactions
P08041362T0000|10 17|cloning
P08041362T0000|23 45|cysteine synthase cDNA
P08041362T0000|61 69|vulgaris
P08041362T0000|71 81|watermelon
P08041362T0000|94 109|complementation
P08041362T0000|133 136|Cys
P08041362T0000|138 147|auxotroph
P08041793A0242|11 18|studies
P08041793A0242|52 60|elements
P08041793A0242|90 100|activation
P08041793A0242|113 123|repression
P08041793A0242|140 145|genes
P08041793A0242|147 152|COX5b
P08043523A0000|18 30|serum levels
P08043523A0000|34 44|antibodies
P08043523A0000|62 84|acetylcholine receptor
P08043523A0000|86 91|nAChR
P08043523A0000|135 143|patients
P08043523A0000|157 167|dyskinesia
P08043523A0000|174 184|antibodies
P08043523A0000|238 246|patients
P08044794A0000|4 20|tumor suppressor
P08044794A0000|41 51|factor p53
P08044794A0000|72 79|protein
P08044800A0550|5 37|DNA containing promoter activity
P08044800A0550|64 72|entirety
P08044800A0550|123 128|sites
P08044802A0462|9 22|Southern blot
P08044802A0462|27 45|karyotype analyses
P08044802A0462|77 84|changes
P08044802A0462|88 99|copy number
P08044802A0462|109 123|rearrangements
P08044802A0462|131 139|p53 gene
P08044802A0462|154 157|p53
P08044802A0462|159 169|cell lines
P08045431A0894|0 4|HupI
P08045431A0894|19 27|identity
P08045431A0894|31 41|rubredoxin
P08045431A0894|62 70|proteins
P08045431A0894|87 95|bacteria
P08045834A0783|4 24|PCr resynthesis rate
P08045834A0783|26 27|P
P08045834A0783|62 66|rate
P08045834A0783|84 97|ATP synthesis
P08045834A0783|99 100|P
P08046923A0000|3 14|examination
P08046923A0000|35 43|patients
P08046923A0000|73 85|osteomalacia
P08046923A0000|104 113|resection
P08048582A0821|18 22|MVO2
P08048582A0821|51 57|extent
P08048582A0821|65 68|CFX
P08048582A0821|103 120|ml O2.min-1 times
P08048582A0821|125 128|g-1
P08048582A0821|138 148|LAD region
P08048582A0821|183 200|ml O2.min-1 times
P08048582A0821|205 208|g-1
P08048916A0000|0 5|IGF I
P08048916A0000|10 27|insulin receptors
P08048916A0000|43 51|proteins
P08048916A0000|92 100|pathways
P08049401A0428|0 16|Immunodepression
P08049401A0428|39 47|increase
P08049401A0428|51 74|glucocorticoid activity
P08049401A0428|86 92|cortex
P08049401A0428|115 122|changes
P08049401A0428|126 142|thyroid hormones
P08049444A0351|8 16|cleavage
P08049444A0351|21 46|peptide sequence analysis
P08049444A0351|75 82|protein
P08049444A0351|117 124|protein
P08049444A0351|143 158|binding protein
P08049444A0351|162 167|SATB1
P08049444A0351|231 238|regions
P08049444A0351|242 245|DNA
P08049444A0351|247 256|MARs/SARs
P08049521T0000|9 32|protein phosphorylation
P08049521T0000|36 44|tyrosine
P08049521T0000|86 92|action
P08049521T0000|96 105|pp60v-src
P08049521T0000|123 128|yeast
P08049885T0000|6 18|pancreatitis
P08049885T0000|22 41|multisystem disease
P08051019A0365|9 21|biosynthesis
P08051019A0365|60 69|mechanism
P08051059A1000|4 12|sequence
P08051059A1000|29 42|rhlA promoter
P08051059A1000|65 72|repeats
P08051059A1000|95 108|binding sites
P08051059A1000|117 131|RhlR regulator
P08051074A0000|29 41|footprinting
P08051074A0000|44 50|region
P08051074A0000|83 105|immunodeficiency virus
P08051074A0000|107 111|type
P08051074A0000|115 120|HIV-1
P08051074A0000|122 130|promoter
P08051074A0000|161 166|DNase
P08051074A0000|169 178|digestion
P08051102A0532|0 7|Heparin
P08051102A0532|15 21|effect
P08051102A0532|25 38|rAC-st myosin
P08051102A0532|45 71|chain phosphatase activity
P08051102A0532|83 84|B
P08051102A0532|104 109|forms
P08051151A0347|13 22|abundance
P08051151A0347|53 57|mRNA
P08051151A0347|109 123|chain reaction
P08051151A0347|141 148|tissues
P08051151A0347|153 163|cell lines
P08053697A0000|0 10|BACKGROUND
P08053697A0000|15 21|DESIGN
P08053697A0000|46 50|nevi
P08053697A0000|66 70|foci
P08053697A0000|74 91|hyperpigmentation
P08053697A0000|105 109|dots
P08053697A0000|143 145|mm
P08053697A0000|149 157|diameter
P08053697A0000|214 224|correlates
P08053697A0000|237 241|dots
P08054281A0731|4 19|retention index
P08054281A0731|23 34|201Tl SPECT
P08054281A0731|47 56|indicator
P08054281A0731|71 80|potential
P08054281A0731|107 117|prediction
P08054281A0731|121 130|prognosis
P08054281A0731|145 152|insight
P08054281A0731|162 174|relationship
P08054281A0731|183 195|201Tl uptake
P08054281A0731|200 210|malignancy
P08055939A0159|21 27|domain
P08055939A0159|55 62|regions
P08055939A0159|74 86|H1 molecules
P08055939A0159|114 120|domain
P08055939A0159|142 159|hexapeptide motif
P08055939A0159|161 169|variants
P08055939A0159|199 211|H1 molecules
P08055939A0707|4 12|location
P08055939A0707|29 35|length
P08055939A0707|43 49|intron
P08055939A0707|76 82|tomato
P08055939A0707|87 104|Arabidopsis genes
P08055939A0707|115 121|intron
P08055939A0707|138 142|nose
P08055939A0707|144 150|region
P08055939A0707|163 167|exon
P08055939A0707|197 203|domain
P08055939A0707|205 209|exon
P08055941A1264|4 12|topology
P08055941A1264|17 22|chain
P08055941A1264|38 51|beta subunits
P08055941A1264|59 75|artifactual beta
P08055941A1264|79 85|capsid
P08055941A1264|112 117|alpha
P08055941A1264|120 124|beta
P08055941A1264|128 134|enzyme
P08056474A0438|9 13|NMSC
P08056474A0438|33 34|%
P08056474A0438|45 46|%
P08056474A0438|60 61|%
P08056474A0438|74 75|%
P08056474A0438|96 97|%
P08056474A0438|106 107|%
P08057356A0531|22 26|form
P08057356A0531|41 53|substitution
P08057356A0531|55 59|V88A
P08057356A0531|84 102|response regulator
P08057356A0531|104 110|region
P08057356A1824|0 11|Comparisons
P08057356A1824|24 46|operon control regions
P08057356A1824|73 87|NarL heptamers
P08057356A1824|114 126|orientations
P08057356A1824|131 138|spacing
P08057421A1583|7 14|binding
P08057421A1583|19 37|competition assays
P08057421A1583|51 73|oligonucleotide probes
P08057421A1583|102 120|CBF1 binding sites
P08057421A1583|136 140|CBF1
P08057421A1583|171 184|CD23 promoter
P08057421A1583|193 217|EBV LMP-1 promoter sites
P08057421A1583|230 237|Cp site
P08057762A0878|29 44|reproducibility
P08057762A0878|55 57|T1
P08057762A0878|62 63|%
P08057762A0878|65 67|T2
P08057762A0878|72 73|%
P08057762A0878|86 101|reproducibility
P08057762A0878|133 135|T1
P08057762A0878|141 142|%
P08057762A0878|144 146|T2
P08057762A0878|152 153|%
P08057833A0573|8 21|ParA proteins
P08057833A0573|45 51|result
P08057833A0573|67 89|translation initiation
P08057833A0573|107 119|start codons
P08057833A0573|141 154|reading frame
P08058326A0463|15 23|insights
P08058326A0463|43 53|mechanisms
P08058326A0463|67 83|tal-1 expression
P08058326A0463|105 114|sequences
P08058326A0463|129 133|gene
P08058326A0463|167 179|counterparts
P08058948A0810|0 10|CONCLUSION
P08058948A0810|24 35|angiography
P08058948A0810|51 55|role
P08058948A0810|63 72|detection
P08058948A0810|82 89|nodules
P08058948A0810|93 101|patients
P08058948A0810|107 110|CRF
P08062824A0626|15 21|domain
P08062824A0626|34 41|FKBP-33
P08062824A0626|86 104|isomerase activity
P08062824A0626|138 148|activities
P08062824A0626|154 161|FKBP-12
P08062833A0000|13 15|nt
P08062833A0000|32 61|transcription initiation site
P08062833A0000|69 86|mouse desmin gene
P08062833A0000|105 110|E box
P08062833A0000|112 114|E1
P08062833A0000|121 133|binding site
P08062833A0000|167 177|regulators
P08062833A0000|208 213|level
P08062833A0000|230 240|expression
P08063108A0109|4 13|acfD gene
P08063108A0109|30 32|nt
P08063108A0109|80 82|aa
P08063108A0109|84 91|protein
P08063766A0595|13 17|beta
P08063766A0595|21 24|PKC
P08063766A0595|48 64|envelope lamin B
P08063766A0595|74 79|times
P08063766A0595|84 88|rate
P08063766A0595|92 101|alpha PKC
P08063766A0595|116 123|kinases
P08063766A0595|146 153|lamin B
P08063766A0595|165 170|rates
P08063775T0000|0 10|Regulation
P08063775T0000|42 49|protein
P08063775T0000|51 56|PTHrP
P08063775T0000|58 73|gene expression
P08063791A1370|6 13|results
P08063791A1370|41 44|set
P08063791A1370|66 81|sequence motifs
P08063791A1370|104 117|modifications
P08063791A1370|137 149|Ras proteins
P08063791A1370|153 158|yeast
P08063836A0904|17 22|c-Abl
P08063836A0904|33 52|c-myc transcription
P08063836A0904|72 83|requirement
P08063836A0904|88 99|DNA binding
P08063836A0904|103 108|c-Abl
P08064351A1020|0 12|Long-latency
P08064351A1020|21 26|units
P08064351A1020|40 46|shocks
P08064351A1020|59 65|jitter
P08064351A1020|75 82|latency
P08064351A1020|89 91|ms
P08065310A1144|27 33|heptad
P08065310A1144|56 74|heterodimerization
P08065310A1144|125 136|interaction
P08065310A1144|158 167|inhibitor
P08065310A1144|181 187|member
P08065310A1144|195 215|receptor gene family
P08065324A0458|22 32|expression
P08065324A0458|36 47|snRNA genes
P08065324A0458|51 56|maize
P08065324A0458|77 82|plant
P08065324A0458|88 91|USE
P08065324A0458|96 109|TATA elements
P08065324A0458|149 162|transcription
P08065327A0000|10 27|DNA rearrangement
P08065327A0000|46 57|development
P08065327A0000|73 85|macronucleus
P08065327A0000|95 117|germ line micronucleus
P08065327A0000|130 140|protozoans
P08065331A0279|20 44|site selection procedure
P08065331A0279|67 80|DNA sequences
P08065331A0279|115 118|HLF
P08065331A0279|132 148|E2A-HLF proteins
P08065331A0279|171 172|t
P08065331A0279|188 197|leukemias
P08065338T0000|4 9|Oct-2
P08065338T0000|42 60|activation domains
P08065338T0000|94 104|duplicates
P08065338T0000|131 144|transcription
P08065365A0000|0 7|Binding
P08065365A0000|11 13|U2
P08065365A0000|28 45|ribonucleoprotein
P08065365A0000|47 52|snRNP
P08065365A0000|61 69|pre-mRNA
P08065365A0000|96 100|step
P08065365A0000|116 124|assembly
P08065366A0918|20 24|data
P08065366A0918|38 43|Dbf8p
P08065366A0918|63 67|role
P08065366A0918|71 93|chromosome segregation
P08065368A0839|0 5|Ariga
P08065368A0839|7 14|Biochem
P08065901A0997|4 11|results
P08065901A0997|30 41|KRAB domain
P08065901A0997|68 74|region
P08065901A0997|83 92|ZFP genes
P08065901A0997|102 115|transcription
P08065901A0997|157 169|interactions
P08065901A0997|182 195|KRAB-A domain
P08065901A0997|200 210|components
P08065901A0997|243 252|apparatus
P08066094T0000|0 11|Marine oils
P08066094T0000|31 41|reactivity
P08067013T0001|15 27|significance
P08067013T0001|31 64|creatine phosphokinase antibodies
P08067013T0001|80 86|muscle
P08067013T0001|119 127|diseases
P08067123A0248|17 24|results
P08067123A0248|28 34|assays
P08067123A0248|53 56|use
P08067123A0248|60 85|assay systems ORTHO ELISA
P08067123A0248|90 104|ABBOTT HCV EIA
P08067123A0248|106 109|USA
P08067123A0248|116 130|detection rate
P08067123A0248|134 149|anti-HCV-C100-3
P08067123A0248|164 176|blood donors
P08067123A0248|180 186|Moscow
P08067123A0248|195 196|%
P08067123A0248|235 249|HBsAg carriers
P08067123A0248|254 255|%
P08067123A0248|267 273|donors
P08067123A0248|279 294|anti-HCV-C100-3
P08067123A0248|302 307|blood
P08067123A0248|312 313|%
P08067123A0248|316 317|p
P08067546A0000|16 26|hypothesis
P08067546A0000|45 64|vasomotor responses
P08067546A0000|79 82|ETO
P08067546A0000|85 93|propofol
P08067546A0000|105 122|sodium thiopental
P08067546A0000|124 127|STP
P08067546A0000|162 169|effects
P08067546A0000|192 197|oxide
P08067546A0000|199 201|NO
P08067546A0000|213 229|vasodilator tone
P08067546A0000|254 278|vasoconstrictor activity
P08067546A0000|293 296|dog
P08067607A0568|12 23|alterations
P08067607A0568|27 38|CBC results
P08067607A0568|43 66|serum CRP concentration
P08067607A0568|82 97|baseline values
P08067607A0568|115 119|dogs
P08067607A0568|127 140|control group
P08069298A0492|18 33|splice variants
P08069298A0492|51 54|RNA
P08069298A0492|77 84|sources
P08069298A0492|104 125|leptomeningeal tissue
P08069298A0492|145 149|line
P08069298A0492|153 173|leptomeningeal cells
P08069298A0492|175 178|LMC
P08069427T0000|0 27|Roux-en-Y gastroenterostomy
P08069427T0000|46 54|emptying
P08069427T0000|62 73|gallbladder
P08069481A0736|13 24|experiments
P08069481A0736|28 36|phantoms
P08069481A0736|50 62|calf muscles
P08070004A0782|19 28|variation
P08070004A0782|37 54|PCZ plasma levels
P08070004A0782|64 69|ng/ml
P08070004A0782|90 106|plasma half-life
P08070004A0782|108 118|t1/2 alpha
P08070004A0782|143 146|min
P08070004A0782|150 158|patients
P08070004A0782|173 182|mg/m2 PCZ
P08070393A0631|12 18|effect
P08070393A0631|35 44|ng/ml EGF
P08070393A0631|53 61|time lag
P08070393A0631|73 75|h.
P08070654A0000|0 4|KAR1
P08070654A0000|26 35|component
P08070654A0000|43 48|yeast
P08070654A0000|57 66|pole body
P08070654A0000|68 71|SPB
P08070654A0000|94 103|karyogamy
P08070654A0000|108 123|SPB duplication
P08070654A0574|0 5|CDC31
P08070654A0574|22 37|SPB duplication
P08070654A0574|68 75|protein
P08070654A0574|108 126|caltractin/centrin
P08070654A0574|130 137|protein
P08070654A0574|158 171|Chlamydomonas
P08070654A0574|178 182|body
P08071356A0232|7 28|transcript elongation
P08071356A0232|34 39|sizes
P08071356A0232|47 60|DNA footprint
P08071356A0232|85 105|transcription bubble
P08071356A0232|126 149|transcription complexes
P08071356A0232|170 188|template positions
P08071982T0000|36 44|syndrome
P08072352A0567|8 16|patients
P08072352A0567|21 27|polyps
P08072352A0567|35 36|%
P08072352A0567|42 48|asthma
P08072352A0567|56 57|%
P08072352A0567|63 82|aspirin sensitivity
P08072352A0567|90 91|%
P08072352A0567|97 109|eosinophilia
P08072352A0567|120 121|%
P08072352A0567|143 153|IgE levels
P08072547A0690|0 3|Ras
P08072547A0690|33 48|protein kinases
P08072547A0690|68 73|c-Jun
P08072547A0690|77 92|serine residues
P08072547A0690|96 105|positions
P08072547A0690|150 158|activity
P08072547A1009|8 16|sequence
P08072547A1009|39 63|JNK phosphorylation site
P08072547A1009|67 72|c-Jun
P08072547A1009|89 94|c-Fos
P08072547A1009|102 106|part
P08072547A1009|114 131|activation domain
P08072547A1009|149 154|c-Fos
P08072547T0000|0 5|c-Fos
P08072547T0000|22 30|activity
P08072547T0000|61 75|protein kinase
P08072547T0000|90 93|JNK
P08072547T0000|98 101|ERK
P08073505T0000|6 16|generation
P08073505T0000|20 47|information retrieval tools
P08073505T0000|52 62|biologists
P08073505T0000|68 75|example
P08073505T0000|83 100|ExPASy WWW server
P08075070A1632|10 18|features
P08075070A1632|27 32|model
P08075070A1632|52 55|DNA
P08075070A1632|63 68|helix
P08075070A1632|73 80|contact
P08075070A1632|84 98|operator sites
P08075070A1632|104 121|repressor domains
P08075070A1632|130 149|sequence homologies
P08075070A1632|177 180|HTH
P08075070A1632|182 188|motifs
P08075070A1632|210 218|proteins
P08075421A0621a|12 15|ORF
P08075421A0621a|49 59|C terminus
P08075421A0621a|63 68|HrpJ2
P08075421A0621b|12 15|ORF
P08075421A0621b|49 59|C terminus
P08075421A0621b|63 68|HrpJ2
P08076631A0000|4 11|binding
P08076631A0000|15 40|transcription factor AP-1
P08076631A0000|45 63|vitamin D receptor
P08076631A0000|65 68|VDR
P08076631A0000|87 91|AP-1
P08076631A0000|118 133|promoter region
P08076631A0000|135 139|AP-1
P08076631A0000|142 146|VDRE
P08076631A0000|161 177|osteocalcin gene
P08076631A0000|222 227|MG-63
P08076631A0000|255 261|SaOs-2
P08076631A0000|269 292|osteosarcoma cell lines
P08076937A0851|6 15|detection
P08076937A0851|24 32|mutation
P08076937A0851|48 69|restriction digestion
P08076937A0851|95 98|DNA
P08076937A0851|102 117|mismatch primer
P08076937A0851|136 150|point mutation
P08076937A0851|161 183|Tru9I restriction site
P08077236A0243|0 9|Wild type
P08077236A0243|21 30|Epo cDNAs
P08077236A0243|66 72|levels
P08077236A0243|76 80|COS1
P08077236A0243|85 95|COS7 cells
P08078167A0000|0 9|OBJECTIVE
P08078167A0000|25 29|risk
P08078167A0000|33 44|hepatitis A
P08078167A0000|62 71|travelers
P08078167A0000|100 108|measures
P08078416A0581|17 23|effect
P08078416A0581|27 40|disinfectants
P08078416A0581|49 62|biofilm cells
P08078416A0581|119 133|concentrations
P08078416A0581|141 154|disinfectants
P08078473A1107|0 10|Expression
P08078473A1107|14 24|ME31B cDNA
P08078473A1107|28 30|S.
P08078473A1107|52 66|ste13 mutation
P08079268T0028|0 3|Use
P08079268T0028|7 30|Medi-Jector EZ dermojet
P08079268T0028|35 45|anesthesia
P08079268T0028|55 62|surgery
P08082215A0230|11 19|response
P08082215A0230|23 37|past-infection
P08082215A0230|41 56|cytomegalovirus
P08082215A0230|64 72|patients
P08082215A0230|76 80|RTID
P08082286A0748|0 18|Acupuncture effect
P08082286A0748|27 36|receptors
P08082286A0748|60 65|point
P08082286A0748|87 91|area
P08082286A0748|108 114|effect
P08082292T0000|8 19|NK activity
P08082292T0000|43 50|disease
P08082292T0000|54 57|HIV
P08082292T0000|59 67|patients
P08082292T0000|103 115|tuberculosis
P08082360A0411|0 15|Smoking history
P08082360A0411|26 43|oxygen saturation
P08082360A0411|45 49|SaO2
P08082440A0339a|1 5|LH P
P08082440A0339a|14 22|LH/FSH P
P08083011A0584|13 14|R
P08083011A0584|28 35|weights
P08083011A0584|87 103|R-L brain weight
P08083011A0584|116 118|RH
P08083011A0584|126 130|cats
P08083011A0584|136 152|R-L brain weight
P08083011A0584|172 184|testosterone
P08083011A0584|188 193|males
P08083011A0584|195 203|estrogen
P08083011A0584|207 214|females
P08083220A0988|5 9|mode
P08083220A0988|21 38|complex formation
P08083220A0988|45 53|contrast
P08083220A0988|77 85|promoter
P08083220A0988|93 112|c-fos protooncogene
P08083220A0988|120 129|formation
P08083220A0988|145 152|complex
P08083220A0988|179 187|assembly
P08083220A0988|195 209|serum response
P08083220A0988|228 235|complex
P08083963A0795|16 26|activities
P08083963A0795|30 33|VBP
P08083963A0795|35 41|a1/EBP
P08083963A0795|47 53|B-cell
P08083963A0795|62 77|extract protein
P08083963A0795|106 115|gel shift
P08083963A0795|117 122|DNase
P08083963A0795|125 137|footprinting
P08083963A0795|143 174|methylation interference assays
P08083998A1723a|6 13|results
P08083998A1723a|27 45|leader-mRNA fusion
P08083998A1723a|49 74|coronavirus transcription
P08083998A1723a|99 118|RNA-RNA interaction
P08083998A1723a|141 150|sequences
P08083998A1723b|6 13|results
P08083998A1723b|27 45|leader-mRNA fusion
P08083998A1723b|49 74|coronavirus transcription
P08083998A1723b|99 118|RNA-RNA interaction
P08083998A1723b|141 150|sequences
P08083999A0501|0 8|Vaccinia
P08083999A0501|47 53|HPV-16
P08083999A0501|58 75|BPV-1 E2 proteins
P08083999A0501|84 101|consensus E2 site
P08083999A0501|121 131|affinities
P08083999A0501|133 135|Kd
P08083999A0501|159 160|M
P08083999A0501|186 199|transcription
P08084339A0907|27 37|transcript
P08084339A0907|56 69|reading frame
P08084339A0907|98 105|J alpha
P08084339A0907|111 117|region
P08084339A0907|124 135|nucleotides
P08084339A0907|154 163|beginning
P08084339A0907|171 189|TCR C alpha region
P08084339A0907|220 242|amino acid polypeptide
P08084592A0145|3 7|HeLa
P08084592A0145|10 33|fibroblast cell hybrids
P08084592A0145|38 48|expression
P08084592A0145|65 79|tumorigenicity
P08085228A0000|12 27|characteristics
P08085228A0000|32 48|risk factor data
P08085228A0000|60 67|clients
P08085228A0000|101 113|distribution
P08085228A0000|117 126|infection
P08085228A0000|138 160|immunodeficiency virus
P08085228A0000|162 165|HIV
P08085228A0000|175 178|use
P08085228A0000|182 192|counseling
P08085228A0000|197 215|testing facilities
P08085228A0000|219 226|Houston
P08085228A0000|228 232|Tex.
P08085609A0384|0 7|Results
P08085609A0384|22 28|KNM-LU
P08085609A0384|61 75|chimpanzee M1s
P08085609A0384|88 97|distances
P08085609A0384|117 127|dimensions
P08085609A0384|137 158|crown fissure termini
P08085782A0164|15 20|cases
P08085782A0164|36 41|tumor
P08085782A0164|46 48|cm
P08086450A0467|0 10|Comparison
P08086450A0467|27 31|gene
P08086450A0467|60 66|region
P08086450A0467|74 84|hATP1 gene
P08086450A0467|104 120|guanine-cytosine
P08086450A0467|122 124|GC
P08086450A0467|131 137|region
P08086450A0467|157 171|binding motifs
P08086450A0467|191 198|factors
P08086450A0467|208 211|Sp1
P08086450A0467|213 217|AP-2
P08086450A0467|223 226|GCF
P08086453T0000|0 9|Structure
P08086453T0000|11 28|promoter analysis
P08086453T0000|45 55|assignment
P08086453T0000|69 78|APEX gene
P08087887A1067|4 22|polyubiquitin gene
P08087887A1067|54 71|Volvox life cycle
P08087887A1067|77 82|peaks
P08087887A1067|97 108|mRNA levels
P08087887A1067|130 138|cleavage
P08087887A1067|144 158|post-inversion
P08088022A1417|35 42|disease
P08088022A1417|66 79|heart disease
P08088022A1417|103 108|links
P08088022A1417|125 130|heart
P08088022A1417|171 179|ischemia
P08088513A0419|25 33|evidence
P08088513A0419|79 90|interaction
P08088513A0419|103 121|DEAH protein Prp16
P08088513A0419|131 133|U6
P08088513A0419|138 140|U2
P08088513A0419|154 160|snRNAs
P08088777A0754|4 24|consensus gene order
P08088777A0754|46 50|data
P08088777A0754|61 68|crosses
P08088777A0754|72 78|D2Mit1
P08088777A0754|80 83|Dbh
P08088777A0754|84 90|Notch1
P08088777A0754|93 99|Col5a1
P08088777A0754|100 104|Rxra
P08088777A0754|106 116|Spna2-Ab l
P08088777A0754|118 121|Ak1
P08088777A0754|122 126|Fpgs
P08088777A0754|130 135|Grp78
P08088777A0754|136 140|Pbx3
P08088777A0754|147 149|.2
P08088777A0754|150 152|Hc
P08088777A0754|153 156|Gsn
P08088777A0754|158 162|Acra
P08088818A1053|9 14|level
P08088818A1053|44 53|deletions
P08088818A1053|67 71|YACs
P08088818A1053|106 110|host
P08088818A1053|141 147|strain
P08088818A1053|164 174|RAD52 gene
P08089184A0825|3 11|addition
P08089184A0825|17 32|megabase region
P08089184A0825|49 59|dagA locus
P08089834A0561|6 13|mutants
P08089834A0561|18 27|deletions
P08089834A0561|58 66|residues
P08089834A0561|77 95|amino acid residue
P08089887A0742|10 25|OUTCOME MEASURE
P08089887A0742|60 70|evaluation
P08090571T0001|0 11|Elimination
P08090571T0001|23 33|antibodies
P08090571T0001|48 58|xenografts
P08090746A1288|8 16|sequence
P08090746A1288|18 26|ATTTCAAA
P08090746A1288|49 62|region shares
P08090746A1288|75 83|homology
P08090746A1288|89 107|promoter sequences
P08090746A1288|121 144|ethylene responsiveness
P08090746A1288|154 183|tomato fruit-ripening E4 gene
P08090767A0000|11 19|evidence
P08090767A0000|25 45|DNA polymerase delta
P08090767A0000|78 84|enzyme
P08090767A0000|107 116|viability
P08090767A0000|133 144|replication
P08090767A0000|167 187|base excision repair
P08090767A0000|201 223|DNA methylation damage
P08091655A0000|23 28|Marek
P08091655A0000|31 44|Disease Virus
P08091655A0000|46 49|MDV
P08091655A0000|51 56|genes
P08091655A0000|68 84|EcoRI-B fragment
P08091655A0000|88 94|MDV-GA
P08091655A0000|103 106|DNA
P08091665T0000|0 12|Cowpox virus
P08091665T0000|26 32|copies
P08091665T0000|45 49|gene
P08091665T0000|78 82|form
P08091665T0000|90 94|type
P08091665T0000|98 110|TNF receptor
P08091669A0828|21 24|P35
P08091669A0828|44 56|39k promoter
P08091669A0828|64 71|absence
P08091669A0828|75 78|IE1
P08091669A0828|84 87|p35
P08091669A0828|93 106|reading frame
P08091669A0828|128 135|control
P08091669A0828|143 155|ie1 promoter
P08093450A0688|0 11|Mutagenesis
P08093450A0688|20 31|NRF-1 motif
P08093450A0688|39 52|ALAS promoter
P08093450A0688|80 86|levels
P08093450A0688|90 134|chloramphenicol acetyltransferase expression
P08093450A0688|144 155|mutagenesis
P08093450A0688|164 176|NRF-1 motifs
P08093450A0688|209 213|loss
P08093450A0688|217 227|expression
P08093616A1214|0 5|DNase
P08093616A1214|8 29|footprinting analysis
P08093616A1214|45 49|DREF
P08093616A1214|69 79|DRE region
P08093616A1214|87 112|DNA polymerase alpha gene
P08093616A1214|139 148|sequences
P08093616T0000|6 26|8-base pair sequence
P08093616T0000|39 42|DNA
P08093616T0000|63 70|element
P08093616T0000|85 99|binding factor
P08093616T0000|116 126|expression
P08093616T0000|141 146|genes
P08093616T0000|151 171|DNA polymerase alpha
P08093616T0000|190 194|cell
P08093616T0000|203 210|antigen
P08093642A0600|3 11|addition
P08093642A0600|15 49|microsatellite repeat polymorphism
P08093642A0600|57 71|heterozygosity
P08093642A0600|77 78|%
P08093642A0600|86 95|RET locus
P08093642A0600|102 142|restriction fragment length polymorphism
P08093642A0600|150 164|heterozygosity
P08093642A0600|170 171|%
P08093642A0600|186 198|lambda clone
P08093642A0600|208 220|D10S94 locus
P08093642A0600|269 284|linkage mapping
P08093642A0600|311 318|testing
P08094464A0869|9 13|tyrA
P08094464A0869|60 68|promoter
P08094464A0869|104 111|portion
P08094464A0869|115 119|aroF
P08094464A2014|11 15|span
P08094464A2014|19 36|attenuator region
P08094464A2014|66 76|structures
P08094464A2014|80 84|mRNA
P08094464A2014|95 108|configuration
P08094464A2014|114 119|spots
P08094464A2014|123 146|base-residue divergence
P08094464A2014|176 183|regions
P08094498A0614|30 36|spouse
P08094498A0614|46 51|truth
P08094498A0614|63 72|diagnosis
P08094498A0614|77 86|prognosis
P08094927A0311|9 16|studies
P08094927A0311|29 38|mutations
P08094927A0311|46 56|6K protein
P08094927A0311|73 80|release
P08094927A0311|117 124|virions
P08095698T0000|0 10|Metabolism
P08095698T0000|14 21|calcium
P08095698T0000|26 36|vitamin D3
P08095698T0000|40 48|patients
P08095698T0000|79 88|nephritis
P08095698T0000|92 97|study
P08095698T0000|104 112|patients
P08095698T0000|118 140|nephropathia epidemica
P08095872A1672|18 23|study
P08095872A1672|50 58|inotropy
P08095872A1672|64 71|timolol
P08095872A1672|93 104|contraction
P08095872A1672|135 150|LONG/CIRC ratio
P08095872A1672|154 164|transition
P08095872A1672|184 204|contraction efficacy
P08095875T0000|0 7|Effects
P08095875T0000|20 31|hypercapnia
P08095875T0000|35 46|hypothermia
P08095875T0000|63 68|He-O2
P08095875T0000|72 76|rats
P08096066A0623|4 17|RFLP patterns
P08096066A0623|25 33|isolates
P08096066A0623|52 60|patients
P08096066A0623|97 104|strains
P08096066A0623|127 131|band
P08096066A0623|145 156|development
P08096066A0623|160 175|drug resistance
P08096944A0951|26 37|stimulation
P08096944A0951|71 81|indication
P08096944A0951|95 105|assessment
P08096944A0951|113 120|ovaries
P08096944A0951|131 136|women
P08096944A0951|158 169|stimulation
P08097666A1135|0 6|A23187
P08097666A1135|26 39|modifications
P08097666A1135|61 70|potential
P08097666A1135|76 84|ampullar
P08097666A1135|107 116|frequency
P08097666A1135|140 146|spikes
P08097732A0000|0 10|Activation
P08097732A0000|43 54|Spec2a gene
P08097732A0000|73 91|sea urchin embryos
P08097732A0000|124 130|region
P08097732A0000|139 143|part
P08097732A0000|160 176|sequence element
P08097732A0000|178 181|RSR
P08097732A0000|203 220|Spec1/Spec2 genes
P08098228A0625|2 12|transcript
P08098228A0625|24 26|kb
P08098228A0625|48 51|PPO
P08098842A0660|0 9|Mutations
P08098842A0660|15 21|region
P08098842A0660|39 41|bp
P08098842A0660|68 92|transcription start site
P08098842A0660|109 117|homology
P08098842A0660|123 131|sequence
P08098842A0660|145 149|exon
P08098842A0660|153 158|c-fos
P08098842A0660|195 202|element
P08098842A0660|229 237|increase
P08098842A0660|247 262|gene expression
P08098842A0660|282 292|regulation
P08098882T0001|13 28|desensitization
P08098914A0400|7 15|exercise
P08098914A0400|21 37|Pes-Ves relation
P08098914A0400|61 65|left
P08098914A0400|74 79|slope
P08098914A0400|94 103|elastance
P08098914A0400|105 108|Ees
P08098914A0400|155 157|SD
P08098914A0400|159 166|mmHg/ml
P08098914A0400|168 169|P
P08099443A0359|13 16|HRI
P08099443A0359|21 29|dsRNA-PK
P08099443A0359|44 61|yeast eIF-2 alpha
P08099443A0359|115 127|GCN2 protein
P08099443A0359|141 157|GCN4 translation
P08099443A0359|161 166|yeast
P08100057A0577|51 62|populations
P08100057A0577|80 91|macrophages
P08100057A0577|111 122|dendrocytes
P08100765A0361|29 58|transgene expression patterns
P08100765A0361|70 80|cerebellum
P08100765A0361|88 93|lines
P08100765A0361|139 151|compartments
P08100843A0134|0 17|Southern analysis
P08100843A0134|29 32|DNA
P08100843A0134|47 54|tissues
P08100843A0134|59 69|cell lines
P08100843A0134|83 96|mouse strains
P08100843A0134|103 113|mCD22 cDNA
P08100843A0134|136 146|Cd22 locus
P08100843A0134|156 161|mCD22
P08100843A0134|174 183|copy gene
P08100843A0134|197 199|kb
P08101134A0376|4 18|concentrations
P08101134A0376|22 33|plasma ACTH
P08101134A0376|38 46|cortisol
P08101134A0376|62 63|%
P08101134A0376|70 71|%
P08101134A0376|78 92|MPTP treatment
P08101171A0924|13 20|results
P08101171A0924|33 37|idea
P08101171A0924|43 60|Pc group products
P08101171A0924|76 82|memory
P08101171A0924|100 110|boundaries
P08101171A0924|144 147|gap
P08101171A0924|162 172|regulators
P08101839A0000|19 29|regulation
P08101839A0000|33 43|expression
P08101839A0000|57 66|mdr1 gene
P08101839A0000|72 80|response
P08101839A0000|88 101|mdr1 promoter
P08101839A0000|105 112|signals
P08101839A0000|125 143|cell proliferation
P08101843A0151|4 29|tyrosine hydroxylase gene
P08101843A0151|31 33|TH
P08101843A0151|53 57|copy
P08101843A0151|63 76|consensus CRE
P08101843A0151|91 100|base pair
P08101843A0151|102 104|bp
P08101843A0151|122 151|transcription initiation site
P08102364A0000|0 7|Tobacco
P08102364A0000|30 37|tobacco
P08102364A0000|39 60|Nicotiana tabacum var
P08103379A0577|10 17|stretch
P08103379A0577|24 35|amino acids
P08103379A0577|54 65|MADS domain
P08103379A0577|75 83|proteins
P08103379A0577|126 150|amino acid substitutions
P08103935T0000|0 9|Isolation
P08103935T0000|14 30|characterization
P08103935T0000|34 56|SRF accessory proteins
P08104189A1168|6 10|data
P08104189A1168|29 45|proSRIF cleavage
P08104189A1168|66 69|TGN
P08104189A1168|84 92|reaction
P08104189A1168|112 114|pH
P08104189A1168|172 178|ATPase
P08105727A0099|0 10|Fenoldopam
P08105727A0099|14 39|dopamine receptor agonist
P08105727A0099|60 78|animal experiments
P08105727A0099|97 106|perfusion
P08105994T0000|9 16|aspects
P08105994T0000|26 34|increase
P08105994T0000|38 70|serum gamma-glutamyl transferase
P08105994T0000|83 93|infarction
P08106087A0139|19 25|region
P08106087A0139|36 49|kDa zein gene
P08106087A0139|71 80|sequences
P08106087A0139|87 95|sequence
P08106087A0139|129 137|sequence
P08106087A0139|161 182|polyadenylation sites
P08106245A0325|11 30|radon concentration
P08106245A0325|38 44|summer
P08106245A0325|52 58|period
P08106245A0325|83 89|Bq m-3
P08106245A0325|104 110|winter
P08106245A0325|152 158|Bq m-3
P08106245A0325|173 177|year
P08106245A0325|181 193|measurements
P08106245A0325|214 220|Bq m-3
P08106245A0325|228 234|summer
P08106245A0325|242 248|period
P08106245A0325|272 278|Bq m-3
P08106245A0325|286 292|winter
P08106245A0325|320 324|year
P08106245A0325|328 340|measurements
P08106313A1492|4 11|results
P08106313A1492|26 31|hrpRS
P08106313A1492|36 40|hrpL
P08106313A1492|45 49|part
P08106313A1492|66 73|cascade
P08106313A1492|83 87|HrpR
P08106313A1492|92 96|HrpS
P08106313A1492|106 116|expression
P08106313A1492|120 124|hrpL
P08106313A1492|129 133|HrpL
P08106313A1492|146 158|sigma factor
P08106313A1492|168 178|expression
P08106313A1492|198 203|genes
P08106325A0000|0 4|DtxR
P08106325A0000|56 63|protein
P08106325A0000|82 94|tox operator
P08106325A0000|115 134|nucleotide sequence
P08106325A0000|161 182|diphtheria toxin gene
P08106369A0000|0 11|Vasopressin
P08106369A0000|13 16|AVP
P08106369A0000|36 43|hormone
P08106369A0000|57 68|nonapeptide
P08106369A0000|98 99|G
P08106369A0000|125 143|membrane receptors
P08106369A0000|181 189|subtypes
P08106369A0000|191 194|V1a
P08106369A0000|196 199|V1b
P08106369A0000|205 207|V2
P08106369A0000|235 245|messengers
P08106398A1003|6 13|results
P08106398A1003|29 37|cleavage
P08106398A1003|45 59|leader peptide
P08106398A1003|72 76|step
P08106398A1003|80 96|nisin maturation
P08106398A1003|148 155|peptide
P08106512A0522|9 24|promoter region
P08106512A0522|56 69|reporter gene
P08106512A0522|89 104|promoter region
P08106512A0522|126 137|interferons
P08106512A0522|139 155|interferon-alpha
P08106512A0522|161 166|gamma
P08106512A0522|172 182|interferon
P08106512A0522|194 200|factor
P08107167A0222|0 6|Anti-B
P08107167A0222|29 38|turicatae
P08107167A0222|43 49|anti-B
P08107167A0222|51 69|parkeri antibodies
P08107167A0222|112 117|assay
P08107167A0222|119 122|IFA
P08107167A0222|160 161|%
P08107167A0222|169 182|serum samples
P08107167A0222|208 215|IFA-ABS
P08107167A0222|235 236|%
P08107208A0673|4 12|approach
P08107208A0673|47 55|strategy
P08107208A0673|67 79|recombinants
P08107208A0673|102 105|EBV
P08107208A0673|120 124|DNAs
P08107208A0673|126 128|B.
P08108099T0000|0 10|Evaluation
P08108099T0000|14 26|desmopressin
P08108099T0000|38 49|extractions
P08108099T0000|53 61|patients
P08108099T0000|78 87|disorders
P08108343A0000|12 20|analysis
P08108343A0000|42 50|niftolid
P08108343A0000|65 69|GnRH
P08108343A0000|99 107|subjects
P08108343A0000|112 120|patients
P08108343A0000|141 145|ones
P08108343A0000|161 173|hypogonadism
P08108343A0000|184 192|patients
P08108343A0000|207 212|signs
P08108343A0000|224 237|insufficiency
P08108343A0000|250 259|diagnosis
P08108343A0000|263 268|order
P08108343A0000|296 317|gonadotropin reserves
P08108413A0964|58 68|cell lines
P08108413A0964|80 87|tissues
P08108413A0964|106 121|PANG expression
P08108413A0964|137 142|brain
P08108413A0964|175 186|transcripts
P08111035A0098|26 36|properties
P08111035A0098|47 67|bp promoter fragment
P08111035A0098|73 94|B. napus oleosin gene
P08111035A0098|112 120|analysis
P08111035A0098|124 142|beta-glucuronidase
P08111035A0098|144 147|GUS
P08111035A0098|149 159|expression
P08111035A0098|174 188|tobacco plants
P08111035A0098|203 223|oleosin promoter-GUS
P08111035A0098|240 246|fusion
P08111974A1034|24 33|mechanism
P08111974A1034|43 45|CX
P08111974A1034|59 70|degradation
P08111974A1034|74 86|tubulin mRNA
P08111974A1034|127 138|translation
P08111974A1034|156 167|involvement
P08111974A1034|182 194|trans-factor
P08112341A1128|0 2|L.
P08112341A1128|4 9|Greer
P08112341A1128|11 13|J.
P08112341A1128|16 22|Carter
P08112341A1128|24 26|G.
P08112526A0443|29 50|calcium concentration
P08112526A0443|60 82|detrusor contractility
P08112526A0443|103 109|manner
P08112526A0443|118 125|control
P08112526A0443|141 149|bladders
P08112601T0000|11 23|organization
P08112601T0000|31 35|gene
P08112601T0000|55 64|lipocalin
P08112601T0000|85 94|synthesis
P08112601T0000|114 121|protein
P08112611A0404|4 12|sequence
P08112611A0404|32 45|reading frame
P08112611A0404|57 64|protein
P08112611A0404|72 83|amino acids
P08112870A0484|0 16|Western blotting
P08112870A0484|18 32|immunoblotting
P08112870A0484|42 51|antiserum
P08112870A0484|65 68|SOD
P08112870A0484|112 120|proteins
P08112870A0484|146 152|masses
P08112870A0484|166 169|kDa
P08113736A0309|4 21|gene organization
P08113736A0309|25 35|CRSV RNA-1
P08113736A0309|63 69|clover
P08113736A0309|79 85|mosaic
P08113736A0309|87 92|RCNMV
P08113736A0309|104 110|clover
P08113736A0309|120 126|mosaic
P08113736A0309|128 133|SCNMV
P08113736A0309|135 149|dianthoviruses
P08113736A0309|159 168|exception
P08113736A0309|174 184|CRSV RNA-1
P08113736A0309|221 224|ORF
P08114702A0000|0 7|Members
P08114702A0000|49 55|factor
P08114702A0000|59 63|MEF2
P08114702A0000|65 71|family
P08114702A0000|75 96|transcription factors
P08114702A0000|123 131|sequence
P08114702A0000|139 154|control regions
P08114702A0000|183 188|genes
P08114710A0137|30 35|LBP-1
P08114710A0137|46 65|HIV-1 transcription
P08114710A0137|84 91|binding
P08114710A0137|95 100|TFIID
P08114710A0137|108 116|TATA box
P08114745A0953|6 13|results
P08114745A0953|38 42|role
P08114745A0953|47 49|La
P08114745A0953|53 67|RNA production
P08114745A0953|89 96|ability
P08114745A0953|110 127|termination sites
P08114745A0953|131 136|class
P08114745A0953|141 150|templates
P08114745A0953|180 183|use
P08114745A0953|187 210|transcription complexes
P08114745A0953|214 217|pol
P08115744A0462|4 9|films
P08115744A0462|32 40|scanning
P08115744A0462|53 71|laser densitometer
P08115744A0462|85 93|aperture
P08115744A0462|102 109|microns
P08115744A0846|15 21|method
P08115744A0846|61 67|method
P08115744A0846|71 79|analysis
P08115744A0846|120 145|quality assurance program
P08116245A0174|14 17|RNA
P08116245A0174|28 37|reactions
P08116245A0174|71 80|specimens
P08116245A0174|93 104|infant rats
P08118044A0318|0 11|GATA-1 mRNA
P08118044A0318|38 44|levels
P08118044A0318|63 73|cell lines
P08118044A0318|88 93|level
P08118044A0318|97 109|FDC-P1 cells
P08119149A0000|0 27|Tumor necrosis factor-alpha
P08119149A0000|29 38|TNF alpha
P08119149A0000|78 85|factors
P08119149A0000|119 126|effects
P08119149A0000|130 134|bone
P08119907A0000|25 29|role
P08119907A0000|42 56|p21ras protein
P08119907A0000|60 67|insulin
P08119907A0000|85 100|growth factor-I
P08119907A0000|102 107|IGF-I
P08119907A0000|109 127|signaling pathways
P08119958A0273|4 8|lack
P08119958A0273|16 25|C2 domain
P08119958A0273|33 35|Ca
P08119958A0273|50 54|PKCs
P08119958A0273|63 71|presence
P08119958A0273|97 105|sequence
P08119958A0273|123 137|signal peptide
P08119958A0273|158 164|domain
P08119958A0273|178 184|PKC mu
P08119958A0273|196 202|member
P08119958A0273|210 218|subgroup
P08119958A0273|231 235|PKCs
P08119995A0814|31 39|function
P08119995A0814|43 63|T3R-RXR heterodimers
P08119995A0814|67 84|response elements
P08119995A0814|101 111|half-sites
P08119995A0814|135 146|orientation
P08119995A0814|159 170|nucleotides
P08119995A0814|194 199|parts
P08119995A0814|219 227|sequence
P08119995A0814|244 253|half-site
P08120019A1500|15 26|Hm1 mutants
P08120019A1500|73 84|PI turnover
P08120019A1500|102 115|sequestration
P08120019A1500|137 147|mechanisms
P08120029A0864|22 45|decay reaction mixtures
P08120029A0864|74 94|sense RNA transcript
P08120029A0864|107 120|stabilization
P08120029A0864|124 134|R2 message
P08122364A0954|0 17|Deletion analyses
P08122364A0954|25 36|pCD41 ORF-A
P08122364A0954|45 48|use
P08122364A0954|52 71|promoter constructs
P08122364A0954|110 118|promoter
P08122364A0954|130 144|pCD41 sequence
P08122364A0954|165 174|synthesis
P08122364A0954|199 206|protein
P08122370A0331|19 31|counterparts
P08122370A0331|39 41|US
P08122370A0331|45 64|herpes simplex type
P08122370A0331|68 73|HSV-1
P08122370A0331|76 94|pseudorabies virus
P08122370A0331|96 99|PRV
P08122370A0331|113 129|herpesvirus type
P08122370A0331|133 138|EHV-1
P08123787A0554|13 32|amino acid sequence
P08123787A0554|55 67|HemB protein
P08123787A0554|92 102|difference
P08123787A0554|110 136|metal cofactor requirement
P08123787A0554|159 166|enzymes
P08123787A0554|191 205|overexpression
P08123787A0554|222 230|analysis
P08124785A0445|0 7|METHODS
P08124785A0445|12 19|RESULTS
P08124785A0445|27 37|open-chest
P08124785A0445|52 56|dogs
P08124785A0445|70 96|circumflex artery stenosis
P08124785A0445|117 125|decrease
P08124785A0445|140 146|artery
P08124785A0445|169 173|flow
P08124785A0445|184 196|flow reserve
P08124785A0445|223 249|mean transit time Tmicro-1
P08124785A0445|251 252|P
P08124912A0456|11 22|correlation
P08124912A0456|44 53|SF levels
P08124912A0456|57 61|IL-8
P08124912A0456|76 83|lactate
P08124912A0456|85 88|LDH
P08124912A0456|90 110|beta 2-microglobulin
P08124912A0456|115 122|glucose
P08124956T0000|46 58|pancreatitis
P08124956T0000|83 94|oxygenation
P08124956T0000|98 102|pigs
P08125258A0142|21 26|cells
P08125258A0142|40 50|conditions
P08125258A0142|56 65|CHOP gene
P08125258A0142|91 98|variety
P08125258A0142|111 119|stresses
P08125258A0142|140 151|deprivation
P08125258A0142|166 179|perturbations
P08125319A1085|4 14|ipiO genes
P08125319A1085|52 60|proteins
P08125319A1085|83 91|homology
P08125319A1085|97 106|sequences
P08125319A1085|118 132|data libraries
P08125337A0940|0 15|Sterol analysis
P08125337A0940|33 39|mutant
P08125337A0940|57 69|accumulation
P08125337A0940|73 83|ignosterol
P08125337A0940|98 102|loss
P08125337A0940|106 121|Erg24p activity
P08125949A1162|34 45|translation
P08125949A1162|49 65|spinach L12 mRNA
P08125949A1162|86 96|AUG codons
P08125949A1162|120 131|rpl12 genes
P08125949A1162|135 146|Arabidopsis
P08125949A1162|168 178|mechanisms
P08125949A1162|203 209|copies
P08125949A1162|213 237|L12/chloroplast ribosome
P08125949A1162|287 297|eubacteria
P08126096A0478|9 20|experiments
P08126096A0478|53 62|functions
P08126096A0478|70 75|alpha
P08126096A0478|90 96|domain
P08126096A0478|110 120|homologies
P08126096A0478|133 136|rat
P08126096A0478|147 156|sequences
P08126096A0478|173 180|studies
P08126096A0478|207 223|domain antiserum
P08126096A0478|258 263|forms
P08126096A1071|4 21|alpha 7A form RNA
P08126096A1071|49 60|nucleotides
P08126096A1071|77 83|B form
P08126096A1071|98 111|coding region
P08126096A1071|119 120|A
P08126096A1071|125 136|B form RNAs
P08126096A1071|158 172|reading frames
P08127950A0000|3 8|order
P08127950A0000|25 33|function
P08127950A0000|73 76|HPT
P08127950A0000|78 82|axis
P08127950A0000|95 105|depression
P08127950A0000|111 118|authors
P08127950A0000|134 153|0800h plasma levels
P08127950A0000|162 171|thyroxine
P08127950A0000|173 176|FT4
P08127950A0000|184 200|triiodothyronine
P08127950A0000|202 205|FT3
P08127950A0000|212 239|thyroid stimulating hormone
P08127950A0000|241 244|TSH
P08127950A0000|249 254|means
P08127950A0000|282 288|assays
P08127950A0000|290 298|TSH-IRMA
P08127950A0000|314 322|controls
P08127950A0000|381 389|subjects
P08128629A1164|0 12|CRS function
P08128629A1164|32 53|gene expression assay
P08128629A1164|74 81|ability
P08128629A1164|90 96|p60CRS
P08128629A1164|101 107|p40CRS
P08128629A1164|128 135|LTR RNA
P08129955A0572|7 13|levels
P08129955A0572|17 27|troponin T
P08129955A0572|36 44|activity
P08129955A0572|48 53|CK-MB
P08129955A0572|85 86|h
P08129955A0572|100 110|unclamping
P08130942A0051|0 15|Regionalization
P08130942A0051|19 32|drug delivery
P08130942A0051|48 54|method
P08130942A0051|69 76|problem
P08131545A0158|27 32|group
P08131545A0158|39 56|community members
P08131545A0158|61 64|men
P08131545A0158|71 76|women
P08131545A0158|83 86|age
P08131545A0158|96 101|years
P08131545A0158|103 109|living
P08131545A0158|179 184|tests
P08131545A0158|189 199|Mycoplasma
P08131545A0158|212 234|Legionella pneumophila
P08131545A0158|236 251|cytomegalovirus
P08131545A0158|253 263|adenovirus
P08131545A0158|265 282|Coxiella burnetii
P08131545A0158|288 297|Chlamydia
P08131746A0140|0 3|MEK
P08131746A0140|28 50|serine phosphorylation
P08131746A0140|63 80|activator kinases
P08131746A0140|92 97|c-raf
P08131746A0140|99 102|mos
P08131746A0140|107 117|MEK kinase
P08132541A0000|8 18|DNA clones
P08132541A0000|56 64|MAL gene
P08132574A0831|0 7|Members
P08132574A0831|11 14|SVA
P08132574A0831|39 57|complement C2 gene
P08132574A0831|75 84|kilobases
P08132574A0831|97 100|RP1
P08132574A0831|108 111|HLA
P08132574A0831|123 145|cytochrome CYP1A1 gene
P08132667T0000|0 10|Expression
P08132667T0000|26 60|proprotein processing enzyme furin
P08132667T0000|85 94|promoters
P08133502T0105|0 29|European Community Huntington
P08133502T0105|32 65|Disease Collaborative Study Group
P08134108A0277|4 9|c-myc
P08134108A0277|23 49|alpha-actin gene promoters
P08134108A0277|58 75|YY1 binding sites
P08134108A0277|133 141|elements
P08134115A1161|0 6|MSSP-1
P08134115A1161|32 46|fusion protein
P08134115A1161|52 55|GST
P08134115A1161|101 107|TCTTAT
P08134115A1161|114 117|myc
P08134115A1161|118 121|H-P
P08134115A1161|130 137|ACT-ATT
P08134115A1161|148 151|myc
P08134115A1161|152 155|H-P
P08134115A1161|165 174|consensus
P08134115A1161|206 215|A/TCTA/TA
P08134115A1161|216 218|TT
P08136383A0359|10 15|hours
P08136383A0359|22 35|MR tomography
P08136383A0359|40 48|patients
P08138180A0593|8 13|spt10
P08138180A0593|26 33|alleles
P08138180A0593|43 54|suppressors
P08138180A0593|73 84|growth rate
P08138180A0593|106 119|SPT10 protein
P08138180A0593|142 151|functions
P08138364T0000|0 9|Varieties
P08138364T0000|21 31|experience
P08139001A1235|4 11|results
P08139001A1235|31 36|amino
P08139001A1235|41 56|carboxy termini
P08139001A1235|64 84|NS1 protein molecule
P08139001A1235|93 102|cysteines
P08139001A1235|106 114|residues
P08139001A1235|145 161|tubule formation
P08139004A0278|7 10|UTR
P08139004A0278|30 38|hairpins
P08139004A0278|76 79|A/U
P08139004A0278|80 93|UGC sequences
P08139017A1465|20 24|site
P08139017A1465|44 54|initiation
P08139017A1465|79 95|primer extension
P08139017A1465|100 102|bp
P08139017A1465|122 125|end
P08139017A1465|133 149|Ets-1 cDNA clone
P08139017A1465|187 192|cells
P08139017A1465|197 203|tumors
P08139017A1465|215 223|provirus
P08139017A1465|231 242|Tpl-1 locus
P08139031A1168|56 67|mutagenesis
P08139031A1168|95 112|cysteine residues
P08139031A1168|120 136|ORF4 polypeptide
P08139031A1168|143 148|C-421
P08139031A1168|153 158|C-426
P08139031A1168|177 200|transactivator function
P08139031A1168|224 241|cysteine residues
P08139031A1168|286 298|interactions
P08139031A1168|327 344|acid interactions
P08139031A1168|356 373|ORF4 inducibility
P08139539A0446|3 15|Rat 1a cells
P08139539A0446|17 32|m1R stimulation
P08139539A0446|36 56|phospholipase C beta
P08139539A0446|72 76|rise
P08139539A0446|94 101|calcium
P08139539A0446|120 123|AMP
P08139539A0446|125 129|cAMP
P08139539A0446|131 140|synthesis
P08139539A0446|159 169|activation
P08139539A0446|173 190|protein kinase A.
P08139542A1229|4 13|mutations
P08139542A1229|33 43|repression
P08139542A1229|47 51|CPA1
P08139542A1229|55 63|arginine
P08139542T0000|2 9|segment
P08139542T0000|13 17|mRNA
P08139542T0000|31 45|leader peptide
P08139542T0000|53 62|CPA1 gene
P08139542T0000|71 81|repression
P08139542T0000|85 93|arginine
P08139542T0000|112 133|yeast gene transcript
P08139543A0427|14 19|genes
P08139543A0427|43 60|SLK1-SLT2 pathway
P08139543A0427|81 99|suppression screen
P08139543A1520|23 31|analysis
P08139543A1520|47 52|NHP6A
P08139543A1520|57 71|NHP6B function
P08139543A1520|86 90|SLT2
P08139562A0404|8 14|report
P08139562A0404|31 36|lines
P08139562A0404|40 48|evidence
P08139562A0404|58 67|ribosomes
P08139562A0404|85 89|GCN4
P08139562A0404|117 122|uORF1
P08139562A0404|132 140|scanning
P08139562A0404|165 180|GCN4 start site
P08139577T0000|10 20|components
P08139577T0000|24 55|yeast transcription factor IIIB
P08139577T0000|88 101|transcription
P08139577T0000|105 109|TATA
P08139577T0000|139 144|genes
P08139914A0554|36 53|dnHLH protein Id1
P08139914A0554|63 78|differentiation
P08139914A0554|82 88|muscle
P08139914A0554|101 106|cells
P08139928T0000|0 4|RNP1
P08139928T0000|12 34|ribonucleoprotein gene
P08139928T0000|42 47|yeast
P08140847X0001|0 5|Crohn
P08140847X0001|8 15|disease
P08140847X0001|29 38|remission
P08140847X0001|75 81|intake
P08140847X0001|105 113|subjects
P08140847X0001|120 123|aim
P08140847X0001|135 139|year
P08140847X0001|152 157|study
P08140847X0001|188 193|Crohn
P08140847X0001|196 212|disease patients
P08140847X0001|226 235|remission
P08140847X0001|237 241|CDAI
P08140847X0001|253 258|order
P08140847X0001|277 288|body weight
P08140847X0001|351 357|intake
P08140847X0001|408 416|controls
P08142875A0877|20 30|dissection
P08142875A0877|80 84|lens
P08142875A0877|111 123|intervention
P08142875A0877|136 141|cases
P08143198T0001|0 11|Restoration
P08143198T0001|15 23|opponens
P08143198T0001|38 53|transplantation
P08143198T0001|62 95|composites dorsal pedal skin flap
P08143198T0001|107 134|m. extensor hallucis brevis
P08143236A1055|8 23|ethanol regimen
P08143236A1055|45 56|alternation
P08143236A1055|68 82|g ethanol.kg-1
P08143236A1055|85 98|day-1 regimen
P08143236A1055|113 120|percent
P08143236A1055|131 137|trials
P08143667A0222|4 8|mean
P08143667A0222|14 16|sd
P08143667A0222|34 42|pressure
P08143667A0222|44 47|IVP
P08143667A0222|70 87|closure pressures
P08143667A0222|89 93|MUCP
P08143667A0222|136 141|cmH2O
P08143667A0222|165 170|ratio
P08143667A0222|179 183|MUCP
P08143667A0222|188 191|IVP
P08144035A0387|25 32|regions
P08144035A0387|61 71|N terminus
P08144035A0387|84 94|C terminus
P08144037A0000|0 11|Thioredoxin
P08144037A0000|13 15|TR
P08144037A0000|57 63|enzyme
P08144037A0000|84 92|bacteria
P08144037A0000|97 103|plants
P08144470A0711|4 12|mutation
P08144470A0711|24 38|asgB480 allele
P08144470A0711|67 77|transition
P08144470A0711|117 129|substitution
P08144470A0711|147 162|protein product
P08144497T0000|18 24|region
P08144497T0000|28 40|raf-1 kinase
P08144497T0000|50 54|zinc
P08144497T0000|72 81|liposomes
P08144497T0000|104 111|segment
P08144497T0000|123 130|GTP-ras
P08144504T0064|8 16|coupling
P08144504T0064|21 32|requirement
P08144504T0064|37 51|ATP hydrolysis
P08144572A0786|0 3|ATP
P08144572A0786|27 46|polypeptide binding
P08144572A0786|50 57|Ssb1/2p
P08144572A0786|63 68|level
P08144572A0786|121 139|Ssa Hsp70 proteins
P08144572A0786|151 154|BiP
P08144572A0786|159 163|DnaK
P08144615A0533|0 9|Digestion
P08144615A0533|13 19|NF-IL6
P08144615A0533|25 43|endoprotease Asp-N
P08144615A0533|55 61|domain
P08144615A0533|79 82|TCD
P08144615A0533|84 103|NF-IL6 bZIP domains
P08144615A0533|105 109|NFBD
P08144615A0533|125 131|domain
P08144615A0533|157 164|absence
P08144615A0533|172 180|presence
P08144615A0533|184 187|DNA
P08144631A0000|0 9|Signaling
P08144631A0000|13 29|tyrosine kinases
P08144631A0000|46 58|associations
P08144631A0000|67 75|proteins
P08144631A0000|81 93|Src homology
P08144631A0000|97 100|SH2
P08144631A0000|102 109|domains
P08144631A0000|114 119|sites
P08144631A0000|123 147|tyrosine phosphorylation
P08144668A0802|29 35|exon V
P08144668A0802|62 66|exon
P08144668A0802|73 80|exon VI
P08144668A0802|90 95|shift
P08144668A0802|108 121|reading frame
P08144668A0802|139 143|GPHe
P08144668A0802|144 146|P2
P08144668A0802|182 190|sequence
P08144668A0802|195 213|membrane anchoring
P08144852A0000|4 13|responses
P08144852A0000|22 37|stress hormones
P08144852A0000|39 47|cortisol
P08144852A0000|49 65|11-deoxycortisol
P08144852A0000|67 71|ACTH
P08144852A0000|73 84|vasopressin
P08144852A0000|86 89|AVP
P08144852A0000|96 109|corticotropin
P08144852A0000|120 126|factor
P08144852A0000|128 131|CRF
P08144852A0000|158 163|males
P08144852A0000|167 175|response
P08144852A0000|185 204|cortisol deficiency
P08144852A0000|240 249|inhibitor
P08144852A0000|251 261|metyrapone
P08145646T0000|0 9|Structure
P08145646T0000|14 24|expression
P08145646T0000|44 56|sigma factor
P08145646T0000|58 62|RpoN
P08145646T0000|67 89|Rhodobacter capsulatus
P08145646T0000|105 114|relevance
P08145646T0000|135 157|nifU2-rpoN superoperon
P08145770A1078|9 21|observations
P08145770A1078|45 49|link
P08145770A1078|62 65|PKC
P08145770A1078|70 87|retinoid pathways
P08145770A1078|141 151|activities
P08145770A1078|155 180|differentiation processes
P08148463A0000|23 30|factors
P08148463A0000|32 36|CSFs
P08148463A0000|66 76|production
P08148463A0000|80 91|neutrophils
P08148463A0000|96 105|monocytes
P08148463A0000|110 125|granulocyte CSF
P08148463A0000|150 153|CSF
P08148463A0000|155 169|macrophage CSF
P08148463A0000|175 186|interleukin
P08148756A0358|4 10|degree
P08148756A0358|14 30|lung destruction
P08148756A0358|58 68|hemorrhage
P08148756A0358|95 113|hemoglobin content
P08148756A0358|121 126|fluid
P08148756A0358|142 147|lungs
P08149484A0151|0 19|Expression plasmids
P08149484A0151|45 58|kinase domain
P08149484A0151|62 71|PKC alpha
P08149484A0151|76 85|PKC delta
P08149484A0151|87 98|PKC alpha K
P08149484A0151|103 114|PKC delta K
P08149484A1551|6 13|results
P08149484A1551|33 42|PKC alpha
P08149484A1551|44 51|calcium
P08149484A1551|67 76|PKC delta
P08149484A1551|78 85|calcium
P08149484A1551|115 128|transcription
P08149484A1551|146 151|genes
P08149484A1551|165 169|AP-1
P08149484A1551|183 192|sequences
P08150970A0434|7 19|cutoff level
P08150970A0434|24 30|TSST-1
P08150970A0434|48 53|pg/ml
P08150970A0434|58 65|samples
P08150970A0434|83 91|patients
P08150970A0434|110 116|TSST-1
P08151787A0355|0 9|Insertion
P08151787A0355|19 35|oligonucleotides
P08151787A0355|55 88|amino acid motifs 726-GRKRKSP-732
P08151787A0355|94 99|IE175
P08151787A0355|104 119|500-VRPRKRR-506
P08151787A0355|125 130|IE110
P08151787A0355|156 161|forms
P08151787A0355|173 181|proteins
P08151787A0355|207 216|phenotype
P08151787A0355|242 248|motifs
P08151787A0355|302 314|localization
P08151787T0000|0 7|Mapping
P08151787T0000|25 45|localization domains
P08151787T0000|50 58|evidence
P08151787T0000|63 90|colocalization interactions
P08151787T0000|103 108|IE110
P08151787T0000|113 118|IE175
P08151787T0000|127 150|transactivator proteins
P08151787T0000|154 174|herpes simplex virus
P08151790A0354|4 24|revertant TATA boxes
P08151790A0354|41 49|kinetics
P08151790A0354|53 68|HIV replication
P08151790A0354|89 96|context
P08151790A0354|103 106|LTR
P08151790A0354|120 132|Sp1 mutation
P08151790A0354|134 142|deletion
P08151790A0354|146 150|site
P08151790A0354|165 171|effect
P08151790A0354|192 203|infectivity
P08151790A0354|217 220|HIV
P08151980T0001|11 20|emphysema
P08152800A0357|10 20|ETS domain
P08152800A0357|48 55|carboxy
P08152800A0357|65 71|region
P08152800A0357|87 94|protein
P08152800A0357|101 102|%
P08152800A0357|109 110|%
P08152800A0357|132 136|PEA3
P08152800A0357|141 145|ER81
P08152800A0357|179 185|member
P08152800A0357|187 190|Ets
P08152800A0357|199 217|Molecule PEA3-like
P08152800A0357|220 223|ERM
P08152800A0709|0 18|Gel shift analysis
P08152800A0709|50 61|ERM protein
P08152800A0709|97 112|oligonucleotide
P08152800A0709|128 167|consensus nucleotide core sequence GGAA
P08152800A0709|186 198|Ets proteins
P08153130T0000|0 7|Effects
P08153130T0000|11 20|estradiol
P08153130T0000|24 35|worm burden
P08153130T0000|51 61|leukocytes
P08153130T0000|102 106|rats
P08153146A0327|0 10|Dotarizine
P08153146A0327|29 37|dilation
P08153146A0327|69 80|circulation
P08153146A0327|103 113|resistance
P08153146A0327|135 146|artery flow
P08153146A0327|174 185|artery mean
P08153146A0327|200 209|pressures
P08153146A0327|233 242|pressures
P08154171A0649|6 12|issues
P08154171A0649|25 28|use
P08154171A0649|32 37|LMWHs
P08154171A0649|41 49|patients
P08154171A0649|64 74|thrombosis
P08154171A0649|89 99|infarction
P08154171A0649|109 120|conjunction
P08154171A0649|139 148|treatment
P08154171A0649|158 166|patients
P08154171A0649|182 190|embolism
P08154182A0955|4 14|usefulness
P08154182A0955|22 33|lambda PG15
P08154182A0955|42 68|lambda AD5 cloning vectors
P08154182A0955|108 140|Neurospora crassa cDNA libraries
P08156332T0000|25 38|sympathectomy
P08156332T0000|51 60|treatment
P08156332T0000|85 94|ischaemia
P08157009A0264|0 20|Sequence comparisons
P08157009A0264|37 42|Aps1p
P08157009A0264|66 79|sigma subunit
P08157009A0264|113 125|AP-1 complex
P08157009A0264|131 136|Aps2p
P08157009A0264|167 201|plasma membrane AP-2 sigma subunit
P08157009T0000|29 38|APS1 gene
P08157009T0000|49 56|homolog
P08157009T0000|70 77|subunit
P08157009T0000|95 116|clathrin AP-1 complex
P08157009T0000|118 126|evidence
P08157009T0000|142 153|interaction
P08157009T0000|159 167|clathrin
P08157009T0000|175 188|Golgi complex
P08157663A0882|6 13|results
P08157663A0882|58 70|organization
P08157663A0882|76 91|vertebrate gene
P08157663A0882|113 129|membrane protein
P08157663A0882|145 153|envelope
P08157663A0882|168 174|member
P08157663A0882|180 186|family
P08157663A0882|190 202|polypeptides
P08157663A0882|216 225|evolution
P08157674T0000|12 28|characterization
P08157674T0000|51 58|protein
P08157674T0000|62 95|protein tyrosine kinase substrate
P08157674T0000|113 118|cells
P08159174A0581|4 12|presence
P08159174A0581|28 32|gene
P08159174A0581|50 67|Southern analysis
P08160054A0224|4 12|patients
P08160054A0224|18 32|deterioriation
P08160054A0224|43 49|status
P08160054A0224|66 74|increase
P08160054A0224|78 91|liver enzymes
P08160054A0224|93 102|aspartate
P08160054A0224|107 133|alanine aminotransaminases
P08160054A0224|146 158|coagulopathy
P08160387T0000|21 32|development
P08160387T0000|40 43|rat
P08160387T0000|59 65|cortex
P08160387T0000|74 78|role
P08160387T0000|89 99|experience
P08160387T0000|106 113|rearing
P08160387T0000|128 139|deprivation
P08160905A0217|7 15|patients
P08160905A0217|40 67|hepatitis B surface antigen
P08160905A0217|69 74|HBsAg
P08163183T0000|4 10|xylose
P08163183T0000|30 34|gene
P08163183T0000|36 40|xylA
P08163183T0000|45 78|Clostridium thermosaccharolyticum
P08163183T0000|80 87|cloning
P08163183T0000|89 99|sequencing
P08163183T0000|104 113|phylogeny
P08163183T0000|117 129|XylA enzymes
P08163498A0789|4 19|phosphopeptides
P08163498A0789|35 37|RS
P08163498A0789|39 42|32P
P08163498A0789|43 57|SGASGLLTSEHHSR
P08163498A0789|62 63|S
P08163498A0789|65 68|32P
P08163498A0789|69 83|SGASGLLTSEHHSR
P08163498A0789|120 135|phosphorylation
P08163498A0789|140 154|trypsinization
P08163498A0789|162 169|peptide
P08163528T0000|14 43|Mas70p signal anchor sequence
P08163546A1230|18 22|data
P08163546A1230|36 42|Ypt51p
P08163546A1230|44 50|Ypt52p
P08163546A1230|56 62|Ypt53p
P08163546A1230|80 89|transport
P08163546A1230|107 114|pathway
P08163546A1230|131 138|sorting
P08163546A1230|151 161|hydrolases
P08163546A1230|184 196|intersection
P08163546A1230|232 247|sorting pathway
P08164302A0547|17 30|TPN solutions
P08164302A0547|68 88|nutrient composition
P08164302A0547|105 115|difference
P08164302A0547|119 131|energy level
P08164302A0547|157 164|glucose
P08164661A0414|14 26|TFIIIC alpha
P08164661A0414|34 42|homology
P08164661A0414|57 62|yeast
P08164661A0414|70 78|subunits
P08164661A0414|120 126|degree
P08164661A0414|143 153|divergence
P08164661A0414|158 172|RNA polymerase
P08164661A0414|177 184|factors
P08164679A0809|0 22|Transactivation domain
P08164679A0809|67 87|runt homology region
P08164679A0809|108 119|Runt domain
P08164680A1086|21 38|protease activity
P08164680A1086|77 84|B cells
P08164680A1086|99 104|cells
P08164684A1266|4 10|ligand
P08164684A1266|15 18|RXR
P08164684A1266|35 39|acid
P08164684A1266|58 64|effect
P08164684A1266|104 111|complex
P08166402A0631|0 19|Cerebral125 albumin
P08166402A0631|45 56|proportions
P08166402A0631|66 72|groups
P08166402A0631|86 101|hyperosmolality
P08167396A0154|22 29|neurons
P08167396A0154|73 103|substantia nigra pars compacta
P08167555A0972|0 8|Response
P08167555A0972|12 21|treatment
P08167555A0972|36 44|patients
P08167555A0972|55 67|pretreatment
P08167555A0972|83 93|treatments
P08167555A0972|122 126|ones
P08167555A0972|154 162|relation
P08167555A0972|206 207|p
P08169201A0291|30 38|sequence
P08169201A0291|55 67|carA product
P08169201A0291|106 125|nucleotide sequence
P08169201A0291|134 143|organisms
P08169201A0291|180 191|amino acids
P08169709T0000|11 20|bone cyst
P08169709T0000|28 32|jaws
P08169709T0000|34 42|analysis
P08169709T0000|49 54|cases
P08170400T0000|0 8|Location
P08170400T0000|13 24|orientation
P08170400T0000|42 48|region
P08170400T0000|73 93|transcription factor
P08170400T0000|95 98|FNR
P08172416A0860|0 10|Moxidectin
P08172416A0860|17 22|times
P08172416A0860|39 43|dose
P08172416A0860|70 77|effects
P08172416A0860|81 84|cow
P08172416A0860|98 109|performance
P08172416A0860|130 146|folliculogenesis
P08172416A0860|148 157|ovulation
P08172416A0860|183 188|phase
P08172416A0860|192 203|development
P08172598A0237|14 22|analysis
P08172598A0237|26 30|mRNA
P08172598A0237|49 63|N. patriciarum
P08172598A0237|76 80|xynB
P08172598A0237|101 116|kb mRNA species
P08172653A1589|13 20|regions
P08172653A1589|44 56|TnT isoforms
P08172653A1589|80 88|addition
P08172653A1589|93 105|modification
P08172653A1589|117 126|sequences
P08172653A1589|135 139|rise
P08172653A1589|143 150|members
P08172653A1589|158 161|TnT
P08172653A1589|172 178|family
P08172905A0000|4 9|class
P08172905A0000|30 53|alanine tRNA synthetase
P08172905A0000|68 84|RNA miniduplexes
P08172905A0000|108 120|acceptor end
P08172905A0000|124 136|alanine tRNA
P08172905A0000|155 157|G3
P08172905A0000|158 171|U70 base pair
P08173532A0000|7 20|reaction time
P08173532A0000|22 24|RT
P08173532A0000|49 55|target
P08173532A0000|57 59|S2
P08173532A0000|97 100|cue
P08173532A0000|102 104|S1
P08173532A0000|124 135|S2 location
P08173532A0000|144 146|ms
P08173532A0000|154 166|target onset
P08173532A0000|174 186|facilitation
P08173693A0390|9 20|study group
P08173693A0390|42 53|innervation
P08173693A0390|71 79|patients
P08173693A0390|92 113|angina pectoris class
P08173814A0132|6 13|viruses
P08173814A0132|28 47|host cell machinery
P08173814A0132|58 67|existence
P08173814A0132|73 85|interference
P08173814A0132|97 106|processes
P08173814A0132|149 164|host physiology
P08175031A0566|0 9|Treatment
P08175188A0685|2 15|concentration
P08175188A0685|24 31|ppm SO2
P08175188A0685|42 50|decrease
P08175188A0685|56 71|baseline values
P08175188A0685|91 92|%
P08175188A0685|101 104|MCA
P08175188A0685|122 123|%
P08175188A0685|132 135|CBF
P08176742A0190|28 44|assay conditions
P08176742A0190|55 62|studies
P08176742A0190|70 91|transposition pathway
P08177143T0000|6 20|cell carcinoma
P08177143T0000|24 32|children
P08177143T0000|43 54|institution
P08177143T0000|57 67|experience
P08178446A1160|4 8|data
P08178446A1160|22 27|ICP10
P08178446A1160|53 65|ras activity
P08178446A1160|75 85|TM segment
P08178446A1160|103 107|role
P08178446A1160|134 152|signaling pathways
P08178490A0879|28 43|signal function
P08178490A0879|53 68|anchor function
P08178490A0879|79 90|K SA domain
P08178572A1118|5 36|concensus poly A addition sites
P08178572A1118|60 70|base pairs
P08178572A1118|97 104|protein
P08178572A1118|115 121|region
P08179827T0000|0 7|Factors
P08179827T0000|38 50|transmission
P08179827T0000|54 81|hepatitis B virus infection
P08179827T0000|85 90|Korea
P08180129A1256|0 8|Exposure
P08180129A1256|19 37|TPA concentrations
P08180129A1256|52 59|content
P08180129A1256|69 80|transcripts
P08181755A0989|0 17|Northern analysis
P08181755A0989|35 51|pcbAB transcript
P08181755A0989|72 82|transcript
P08181755A0989|115 119|mRNA
P08182041A1067|4 11|results
P08182041A1067|38 50|requirements
P08182041A1067|55 64|induction
P08182041A1067|68 73|PEPCK
P08182041A1067|77 80|PKA
P08182041A1067|85 95|inhibition
P08182041A1067|99 106|insulin
P08182041A1067|123 145|CREB activation domain
P08182041A1067|154 173|PEPCK TATA sequence
P08182041A1067|201 215|hepatoma cells
P08182056A0695|9 15|degree
P08182056A0695|19 31|conservation
P08182056A0695|40 44|NQO2
P08182056A0695|49 71|NQO1 gene organization
P08182056A0695|76 84|sequence
P08182056A0695|100 109|NQO2 gene
P08182056A0695|131 137|member
P08182056A0695|145 160|NQO gene family
P08182171A0000|4 12|efficacy
P08182171A0000|18 49|Propionibacterium acnes product
P08182171A0000|54 63|treatment
P08182171A0000|67 84|coliform mastitis
P08182171A0000|122 130|infusion
P08183552T0000|10 20|eps15 gene
P08183552T0000|33 58|tyrosine kinase substrate
P08183552T0000|76 85|evolution
P08183552T0000|90 94|maps
P08183915A0000|4 8|gene
P08183915A0000|30 37|protein
P08183915A0000|39 43|p105
P08183915A0000|45 54|precursor
P08183915A0000|62 73|p50 subunit
P08183915A0000|77 108|transcription factor NF-kappa B
P08183915A0000|124 145|p70 I kappa B protein
P08183915A0000|147 162|I kappa B gamma
P08183915A0000|205 216|amino acids
P08183915A0000|220 224|p105
P08183915T0000|12 20|splicing
P08183915T0000|24 39|RNA transcripts
P08183915T0000|62 82|p105 NF-kappa B gene
P08183915T0000|93 117|I kappa B gamma isoforms
P08183915T0000|144 154|activities
P08184923A0829|8 13|L-NNA
P08184923A0829|41 49|increase
P08184923A0829|53 57|CoBF
P08184923A0829|69 70|%
P08184923A0829|75 79|CeBF
P08184923A0829|91 92|%
P08184923A0829|106 114|exposure
P08185288A0106|4 14|experiment
P08185288A0106|26 30|male
P08185288A0106|52 60|subjects
P08185288A0106|83 87|stay
P08185288A0106|95 115|respiration chambers
P08185288A0106|135 142|morning
P08185288A0106|147 156|afternoon
P08185288A0106|161 172|min cycling
P08185288A0106|188 192|work
P08185288A0106|202 207|kg m.
P08187085A0086|6 20|rearrangements
P08187085A0086|35 44|formation
P08187085A0086|57 62|genes
P08187085A0086|75 97|tyrosine kinase domain
P08187085A0086|101 104|ret
P08187085A0086|123 136|end sequences
P08187085A0086|150 155|genes
P08187088A0530|9 13|loss
P08187088A0530|17 31|heterozygosity
P08187088A0530|33 36|LOH
P08187088A0530|45 46|%
P08187088A0530|66 71|cases
P08187088A0530|88 102|chromosomes 3p
P08187088A0530|108 109|%
P08187088A0530|112 114|5q
P08187088A0530|120 121|%
P08187088A0530|124 126|6p
P08187088A0530|132 133|%
P08187088A0530|136 138|8p
P08187088A0530|144 145|%
P08187088A0530|148 150|9p
P08187088A0530|156 157|%
P08187088A0530|160 162|9q
P08187088A0530|168 169|%
P08187088A0530|172 175|11p
P08187088A0530|181 182|%
P08187088A0530|185 188|13q
P08187088A0530|194 195|%
P08187088A0530|198 201|17p
P08187088A0530|207 208|%
P08187088A0530|211 214|17q
P08187088A0530|220 221|%
P08187088A0530|224 227|18q
P08187088A0530|233 234|%
P08187088A0530|241 244|19q
P08187088A0530|250 251|%
P08187177A0405|9 26|amino acid change
P08187177A0405|34 37|CPY
P08187177A0405|47 61|sorting signal
P08187177A0405|76 87|interaction
P08188258A0000|14 24|synthetase
P08188258A0000|29 51|prolyl-tRNA synthetase
P08188258A0000|72 79|classes
P08188258A0000|98 109|synthetases
P08188258A0000|174 182|pathways
P08188290A0544|10 23|sequence data
P08188290A0544|48 66|TCRAC/TCRDC region
P08188290A0544|87 103|polymerase chain
P08188290A0544|119 124|assay
P08188290A0544|141 151|expression
P08188290A0544|170 189|TCRAJ gene segments
P08188603A0230|5 13|analysis
P08188603A0230|33 37|gene
P08188603A0230|39 43|arg4
P08188603A0230|60 66|degree
P08188603A0230|70 78|homology
P08188603A0230|113 122|CPA2 gene
P08188603A0230|142 149|subunit
P08188603A0230|173 183|synthetase
P08188603A0230|185 190|CPS-A
P08188606A1034|0 20|Restriction analysis
P08188606A1034|25 47|Southern hybridization
P08188606A1034|61 69|presence
P08188606A1034|73 79|Tn5422
P08188606A1034|143 150|strains
P08188606A1034|169 176|strains
P08188606A1034|186 204|cadmium resistance
P08188606A1034|212 222|chromosome
P08188978A0822|15 22|latency
P08188978A0822|33 43|ECG R-wave
P08188978A0822|62 77|MSNA burst peak
P08188978A0822|114 115|s
P08188978A0822|123 128|sleep
P08188978A0822|146 165|pulse-synchronicity
P08189174A0148|0 6|DESIGN
P08189174A0148|21 26|study
P08189174A0148|48 53|women
P08189174A0148|65 70|years
P08189174A0148|93 116|breast cancer screening
P08189174A0148|121 127|living
P08189174A0148|135 139|city
P08189174A0148|143 150|Utrecht
P08189498T0000|0 14|Identification
P08189498T0000|37 41|gene
P08189498T0000|49 54|Marek
P08189498T0000|57 70|disease virus
P08189498T0000|85 98|repeat region
P08189498T0000|136 147|polypeptide
P08189503A0000|27 37|cDNA clone
P08189503A0000|43 75|mouse hepatitis virus strain A59
P08189503A0000|103 106|RNA
P08189503A0000|108 115|pMIDI-C
P08189503A0000|121 141|cassette mutagenesis
P08189503A0000|155 164|mechanism
P08189503A0000|168 179|coronavirus
P08189503A0000|191 205|mRNA synthesis
P08189533A0203|39 43|gene
P08189533A0203|46 53|product
P08189533A0203|76 81|forms
P08189533A0203|85 89|NS53
P08189533A0203|127 156|baculovirus expression system
P08189533A0203|175 192|vaccinia virus/T7
P08189533A0203|194 200|vTF7-3
P08189533A0203|202 219|expression system
P08189533A0919|0 19|Gel electrophoresis
P08189533A0919|32 51|immunoblot analyses
P08189533A0919|69 78|fractions
P08189533A0919|101 106|cells
P08189533A0919|127 134|amounts
P08189533A0919|138 142|NS53
P08189533A0919|163 170|cytosol
P08189533A0919|178 189|association
P08189533A0919|212 218|matrix
P08190633A0000|4 29|transcription factor AP-2
P08190633A0000|46 50|gene
P08190633A0000|62 72|chromosome
P08190633A0000|84 93|HLA locus
P08190633A0273|11 20|AP-2 mRNA
P08190633A0273|39 44|exons
P08190633A0273|64 70|region
P08190633A0273|77 79|kb
P08190633A0273|88 91|DNA
P08191910A0228|0 10|San Martin
P08191910A0228|27 33|traits
P08191910A0228|49 53|work
P08191910A0228|67 73|lodges
P08191910A0228|106 115|abilities
P08191910A0228|119 129|strategist
P08191910A0228|144 149|ruler
P08192140A0209|4 16|participants
P08192140A0209|33 36|men
P08192140A0209|40 66|hepatitis B vaccine trials
P08192140A0209|70 79|Amsterdam
P08192140A0209|81 82|n
P08192140A0209|90 103|New York City
P08192140A0209|105 106|n
P08192140A0209|119 132|San Francisco
P08192140A0209|134 135|n
P08192451A0885|10 19|treatment
P08192451A0885|34 42|decrease
P08192451A0885|60 66|uptake
P08192451A0885|70 75|Rh123
P08192451A0885|83 91|increase
P08192451A0885|95 105|NAO uptake
P08192795T0000|28 35|purpura
P08192795T0000|48 67|lupus erythematosus
P08193147A0831|0 10|Comparison
P08193147A0831|20 37|crystal structure
P08193147A0831|41 60|Desulfovibrio gigas
P08193147A0831|62 64|Dg
P08193147A0831|66 68|Fd
P08193147A0831|70 79|Kissinger
P08193147A0831|125 133|topology
P08193147A0831|173 181|elements
P08193147A0831|198 200|Pf
P08193147A0831|213 218|Dg Fd
P08194139A0498|0 11|CONCLUSIONS
P08194139A0498|13 43|Serum prolactin concentrations
P08194139A0498|49 52|age
P08194139A0498|61 71|variations
P08194139A0498|94 97|men
P08194549A0000|26 34|kayakers
P08194549A0000|65 77|relationship
P08194549A0000|95 100|power
P08194549A0000|102 104|CP
P08194549A0000|114 119|onset
P08194549A0000|123 149|blood lactate accumulation
P08194549A0000|151 155|OBLA
P08194753A0157|25 33|sequence
P08194753A0157|37 42|rhp51
P08194753A0157|55 59|MluI
P08194753A0157|71 76|boxes
P08194753A0157|92 95|DNA
P08194753A0157|114 121|element
P08194753A0157|138 144|region
P08194970A0000|0 5|Women
P08194970A0000|8 21|opportunities
P08194970A0000|31 35|work
P08194970A0000|48 52|home
P08194970A0000|78 82|role
P08194970A0000|94 99|carer
P08194970A0000|111 117|family
P08194970A0000|126 137|Trudy Wynne
P08195186A0000|10 23|cDNA sequence
P08195186A0000|43 55|T lymphocyte
P08195186A0000|73 77|gene
P08195186A0000|79 82|Tea
P08195186A0000|94 101|protein
P08195186A0000|141 151|retrovirus
P08195186A0000|170 192|amino acid transporter
P08195186A0000|194 203|ecoR/CAT1
P08195186A0000|210 219|RNA blots
P08195186A0000|238 252|Tea expression
P08195186A0000|256 269|T lymphocytes
P08195186A0000|274 279|liver
P08195186A0000|281 288|MacLeod
P08195186A0000|290 294|C.L.
P08195186A0000|296 302|Finley
P08195186A0000|304 306|K.
P08195186A0000|308 314|Kakuda
P08195186A0000|316 318|D.
P08195216A1022|24 28|case
P08195216A1022|33 37|HIS3
P08195216A1022|59 65|subset
P08195216A1022|79 88|sequences
P08195216A1022|102 115|transcription
P08195216A1022|119 130|conjunction
P08195216A1022|136 141|GCN4p
P08195216A1022|168 177|sequences
P08195216A1022|186 202|GCN4p activation
P08195216A1022|206 210|TRP3
P08195217A0799|22 29|protein
P08195217A0799|55 94|reticulocyte lysate translation product
P08195217A0799|132 139|protein
P08195217A0799|143 157|sodium dodecyl
P08195217A0799|181 185|gels
P08195233A0147|3 11|addition
P08195233A0147|18 24|kinase
P08195233A0147|91 96|genes
P08195233A0147|106 114|position
P08195233A0147|124 134|chromosome
P08195233A0147|168 174|stages
P08195233A0147|178 191|tumorigenesis
P08196607A0280|0 17|Deletion analysis
P08196607A0280|25 38|ICL1 promoter
P08196607A0280|50 64|identification
P08196607A0280|91 107|sequence element
P08196607A0280|109 116|UASICL1
P08196607A0280|121 131|CATTCATCCG
P08196607A0280|177 183|carbon
P08196607A0280|201 211|regulation
P08196607A0280|230 243|reporter gene
P08196616A1112|19 30|interaction
P08196616A1112|34 40|ZAP-70
P08196616A1112|50 55|motif
P08196616A1112|77 85|presence
P08196616A1112|94 112|ZAP-70 SH2 domains
P08196616A1112|129 146|tyrosine residues
P08196616A1112|154 159|motif
P08196616A1112|177 183|ZAP-70
P08196616A1112|203 227|phosphotyrosine residues
P08196616A1112|241 248|binding
P08196616A1112|260 271|SH2 domains
P08196618A0473|0 5|PRL-1
P08196618A0473|33 59|phosphotyrosine substrates
P08196618A0473|65 73|mutation
P08196618A0473|93 109|cysteine residue
P08196618A0473|125 133|activity
P08196624A0593|3 13|Mv1Lu lung
P08196624A0593|25 30|cells
P08196624A0593|32 39|ActR-IB
P08196624A0593|44 61|T beta R-I signal
P08196624A0593|71 74|set
P08196624A0593|116 125|responses
P08196624A0593|129 140|association
P08196624A0593|166 173|ligands
P08196624A0593|178 182|type
P08196624A0593|186 195|receptors
P08198524A1134|3 6|kDa
P08198524A1134|19 22|kDa
P08199204A0746|0 3|H-7
P08199204A0746|52 66|PKC activation
P08199204A0746|75 81|effect
P08199204A0746|85 109|tyrosine phosphorylation
P08199204A0746|114 120|PtdIns
P08199204A0746|125 138|P2 production
P08199878T0000|4 11|effects
P08199878T0000|24 45|glucose concentration
P08199878T0000|49 65|brain metabolism
P08199878T0000|85 99|brain ischemia
P08200528A0970|5 13|strategy
P08200528A0970|41 55|Tn903 neo gene
P08200528A0970|64 117|Rhodosporidium toruloides phenylalanine ammonia lyase
P08200528A0970|119 122|PAL
P08200528A0970|133 137|gene
P08200528A0970|164 171|control
P08200528A0970|175 179|pPGK
P08200528A0970|181 185|REP2
P08201352A0239|7 11|case
P08201352A0239|26 46|protein C deficiency
P08201352A0239|48 69|vitamin K antagonists
P08201352A0239|108 112|risk
P08201352A0239|116 129|skin necrosis
P08201758A0125|14 21|patient
P08201758A0125|53 64|obstruction
P08201758A0125|75 85|laparotomy
P08201758A0125|92 97|times
P08201932A0355|12 23|examination
P08201932A0355|43 56|polyarthritis
P08201932A0355|76 82|joints
P08202546A1206|3 11|addition
P08202546A1206|33 58|hUBF-promoter interaction
P08202546A1206|99 106|effects
P08202546A1206|124 131|adducts
P08203260A1204|21 25|SIMV
P08203260A1204|47 55|neonates
P08203260A1204|65 75|ventilator
P08204348T0000|0 5|VP-16
P08204348T0000|7 17|ifosfamide
P08204348T0000|22 31|cisplatin
P08204348T0000|33 36|VIP
P08204348T0000|58 74|cell lung cancer
P08204403A0000|2 7|total
P08204403A0000|16 21|males
P08204403A0000|28 35|females
P08204403A0000|37 45|patients
P08204403A0000|82 87|study
P08204403A0000|105 116|sensitivity
P08204403A0000|120 143|radioimmunoscintigraphy
P08204403A0000|149 154|I-131
P08204403A0000|168 174|CEA/CA
P08204403A0000|191 201|antibodies
P08204426T0001|38 49|ventilation
P08204426T0001|57 73|diaphragm pacing
P08204426T0001|77 86|childhood
P08204426T0001|92 114|implantation technique
P08204426T0001|119 130|indications
P08204824A0000|10 15|clone
P08204824A0000|24 34|cyc07 gene
P08204824A0000|75 82|S phase
P08204824A0000|94 104|cell cycle
P08204824A0000|120 128|cultures
P08204824A0000|132 142|periwinkle
P08204824A0000|144 163|Catharanthus roseus
P08204824A0000|165 170|cells
P08205827A0940|0 11|CONCLUSIONS
P08205827A0940|13 26|Translocation
P08205827A0940|30 38|bacteria
P08205827A0940|42 51|endotoxin
P08205827A0940|78 83|tract
P08205827A0940|93 104|bloodstream
P08205827A0940|123 141|animal experiments
P08205827A0940|152 165|translocation
P08205827A0940|190 198|patients
P08205827A0940|216 221|shock
P08206848A0296|4 8|pyrR
P08206848A0296|13 23|pyrP genes
P08206848A0296|32 44|polypeptides
P08206848A0296|71 77|masses
P08206848A0296|95 98|kDa
P08206867A0874|0 26|Southern blotting analysis
P08206867A0874|39 49|occurrence
P08206867A0874|62 73|COXVb genes
P08206867A0874|81 91|rat genome
P08206991A0466|0 9|Acylation
P08206991A0466|19 35|palmitate analog
P08206991A0466|55 60|Gly-2
P08206991A0466|76 83|alanine
P08206991A0466|99 114|N-myristylation
P08206991A0466|131 144|palmitylation
P08206991A0466|162 167|Cys-3
P08206991A0466|171 176|Cys-6
P08206991A0466|192 198|serine
P08207022T0000|0 19|Subunit composition
P08207022T0000|24 40|domain structure
P08207022T0000|48 86|Spo0A sporulation transcription factor
P08207022T0000|90 107|Bacillus subtilis
P08207232A0503|16 39|mobility shift analysis
P08207232A0503|55 62|NF-IL-6
P08207232A0503|89 96|members
P08207232A0503|105 111|family
P08207232A0503|138 150|NF-IL-6 site
P08207232A0503|158 171|IL-8 promoter
P08207405A0372|0 3|BYV
P08207405A0372|5 26|citrus tristeza virus
P08207405A0372|28 31|CTV
P08207405A0372|34 38|beet
P08207405A0372|46 57|stunt virus
P08207405A0372|59 63|BYSV
P08207405A0372|69 78|carnation
P08207405A0372|88 109|fleck virus templates
P08207405A0372|121 146|kb amplification products
P08207405A0372|168 178|sequencing
P08207405A0372|192 201|fragments
P08207405A0372|220 231|HSP70 genes
P08207795A0409|24 32|location
P08207795A0409|40 60|phosphorylation site
P08207795A0409|75 82|protein
P08207795A0409|99 121|mutagenesis procedures
P08207805A0000|4 37|p53 tumor suppressor gene product
P08207805A0000|71 78|protein
P08207805A0000|123 132|activator
P08207805A0000|137 146|repressor
P08208247T0030|11 19|analysis
P08208247T0030|35 47|segment 64AB
P08208247T0030|51 57|region
P08208247T0030|82 105|acid decarboxylase gene
P08208540A0000|0 14|Rearrangements
P08208540A0000|22 32|NFKB2 gene
P08208540A0000|62 74|malignancies
P08208540A0000|95 107|significance
P08208540A0000|117 128|alterations
P08208540A0417|0 7|Cloning
P08208540A0417|12 22|sequencing
P08208540A0417|44 49|cDNAs
P08208540A0417|82 90|splicing
P08208540A0417|107 117|gene codes
P08208540A0417|126 134|proteins
P08208540A0417|148 150|kD
P08208540A0417|152 158|p84/85
P08208540A0417|189 199|rel domain
P08208540A0417|219 234|ankyrin repeats
P08208540A0417|256 272|carboxy-terminus
P08208540A0417|295 309|ankyrin repeat
P08208540A1114|10 32|co-transfection assays
P08208540A1114|43 67|NFKB2 expression vectors
P08208540A1114|72 77|kappa
P08208540A1114|87 104|reporter plasmids
P08208540A1114|119 128|NFKB2 p85
P08208540A1114|158 177|repressor functions
P08208540A1114|196 205|NFKB2 p52
P08208618A1334|6 12|HR21ap
P08208618A1334|24 31|HR21Xap
P08208618A1334|54 64|inhibition
P08208618A1334|68 79|Sp1 binding
P08209051T0000|23 30|therapy
P08209051T0000|41 49|fibrosis
P08209051T0000|54 62|hospital
P08209051T0000|69 73|home
P08209423T0000|13 19|frames
P08209423T0000|30 49|nucleotide sequence
P08209423T0000|57 83|MDV-1 BamHI-D DNA fragment
P08209423T0000|85 93|evidence
P08209423T0000|98 106|splicing
P08209423T0000|110 114|mRNA
P08209423T0000|132 149|glycoprotein gene
P08209772A0167|4 12|ns2 gene
P08209772A0167|31 44|reading frame
P08209772A0167|46 49|ORF
P08209772A0167|86 88|ns
P08209772A0167|90 97|protein
P08209772A0167|105 116|amino acids
P08209772A0167|144 148|mass
P08212571A0597|0 15|Co-transfection
P08212571A0597|21 24|tat
P08212571A0597|36 43|plasmid
P08212571A0597|55 62|viruses
P08212571A0597|78 95|tat ORF mutations
P08212571A0597|115 121|levels
P08212571A0597|125 141|virus production
P08212571A0597|165 172|effects
P08212571A0597|181 188|mutants
P08212571A0597|193 196|tat
P08212571A0971|0 8|Analysis
P08212571A0971|16 19|gag
P08212571A0971|24 36|rev proteins
P08212571A0971|56 61|cells
P08212571A0971|86 94|proteins
P08212571A0971|118 123|cells
P08212571A0971|145 156|tat mutants
P08212571A0971|196 205|mutations
P08212571A0971|240 261|tat expression vector
P08212897A0404|4 26|hydrophobicity profile
P08212897A0404|34 51|methyltransferase
P08212897A0404|64 72|presence
P08212897A0404|100 121|transmembrane domains
P08213235A1024|0 11|Measurement
P08213235A1024|15 19|SaO2
P08213235A1024|32 40|altitude
P08213235A1024|63 67|care
P08213235A1024|92 100|newborns
P08213235A1024|104 111|infants
P08213747A0000|32 42|prevalence
P08213747A0000|52 79|immunodeficiency virus type
P08213747A0000|83 88|HIV-1
P08213747A0000|90 99|infection
P08213747A0000|103 105|US
P08213747A0000|136 139|men
P08213747A0000|158 161|men
P08213747A0000|182 193|differences
P08213747A0000|214 221|factors
P08213747A0000|223 230|history
P08213747A0000|255 263|diseases
P08213747A0000|288 297|behaviors
P08213747A0000|303 310|authors
P08213747A0000|339 347|analysis
P08213747A0000|351 380|baseline HIV-1 seroprevalence
P08213747A0000|385 403|HIV-1 risk factors
P08213747A0000|481 484|men
P08213747A0000|495 502|centers
P08213747A0000|510 523|United States
P08213747A0000|525 545|Baltimore/Washington
P08213747A0000|547 549|DC
P08213747A0000|551 561|Pittsburgh
P08213747A0000|563 570|Chicago
P08213747A0000|576 587|Los Angeles
P08216115A0158|4 12|patients
P08216115A0158|20 25|group
P08216115A0158|43 52|catheters
P08216115A0158|66 74|oxytocin
P08216115A0158|108 118|percentile
P08216115A0158|130 138|activity
P08216115A0158|170 176|labour
P08216115A0158|190 196|parity
P08217862A1336|10 21|development
P08217862A1336|29 54|rat conditioning paradigm
P08217862A1336|94 101|ability
P08217862A1336|124 138|nerve activity
P08217862A1336|156 164|subjects
P08217862A1336|179 185|number
P08217862A1336|215 222|strains
P08217862A1336|255 261|states
P08218056A0000|4 18|ultrastructure
P08218056A0000|30 37|vessels
P08218056A0000|60 64|eyes
P08218056A0000|79 87|patients
P08218056A0000|96 100|eyes
P08218056A0000|114 122|subjects
P08218230A1505|15 21|region
P08218230A1505|33 41|sequence
P08218230A1505|57 69|binding site
P08218230A1505|91 111|transcription factor
P08218230A1505|113 123|hepatocyte
P08218230A1505|132 138|factor
P08218230A1505|142 147|HNF-1
P08218230A1505|153 162|positions
P08218230A1920|27 30|GRE
P08218230A1920|62 89|glucocorticoid inducibility
P08218230A1920|97 107|HNF-1 site
P08218230A1920|121 129|promoter
P08218230A1920|145 157|determinants
P08218230A1920|177 184|control
P08218230A1920|192 230|Xenopus fibrinogen B beta subunit gene
P08218230A1920|234 239|cells
P08218230A1920|252 264|liver tissue
P08219072A0287|0 4|Acad
P08219081A0000|4 15|PRB-1b gene
P08219081A0000|41 50|component
P08219081A0000|79 98|PR-1 protein family
P08219227A0830|0 11|Replacement
P08219227A0830|19 22|CRE
P08219227A0830|37 41|copy
P08219227A0830|49 58|AP-1 site
P08219227A0830|72 77|level
P08219227A0830|97 105|activity
P08219227A0830|144 152|sequence
P08219227A0830|158 169|replacement
P08219227A0830|177 186|AP-1 site
P08219227A0830|194 197|CRE
P08219227A0830|208 216|activity
P08220494A0231|10 18|promoter
P08220494A0231|42 48|origin
P08220494A0231|62 68|planta
P08220494A0231|80 96|bp cyt-1 element
P08220494A0231|117 123|region
P08220494A0231|152 169|promotor activity
P08220494A0231|173 177|leaf
P08220494A0231|179 183|stem
P08220494A0231|188 198|root cells
P08220494A0231|202 216|tobacco plants
P08220621T0000|10 21|manuscripts
P08220621T0000|47 53|system
P08221251A0239|16 18|CT
P08221251A0239|41 50|diagnosis
P08221251A0239|54 60|tumors
P08221251A0239|69 73|area
P08222384A0455|0 5|SIN-1
P08222384A0455|13 22|influence
P08222384A0455|46 56|parameters
P08222384A0455|64 89|surface electrocardiogram
P08222384A0455|91 94|ECG
P08222384A0455|117 120|ECG
P08222556T0000|0 6|Effect
P08222556T0000|10 15|aging
P08222556T0000|40 47|muscles
P08222618A0000|10 27|computer programs
P08222618A0000|34 54|logit transformation
P08222618A0000|63 71|analysis
P08222618A0000|84 90|curves
P08223425T0000|4 19|yeast SSS1 gene
P08223425T0000|47 68|protein translocation
P08223425T0000|93 100|protein
P08223425T0000|120 129|reticulum
P08223554A0574|4 11|lengths
P08223554A0574|28 45|polypeptide chain
P08223554A0574|65 71|enzyme
P08223554A0574|80 95|transit peptide
P08223554A0574|111 119|residues
P08223576A1261|4 11|absence
P08223576A1261|15 24|H4PteGlun
P08223576A1261|38 47|T protein
P08223576A1261|68 78|conditions
P08223576A1261|97 106|H4PteGlun
P08223576A1261|139 148|T protein
P08223592A0424|0 4|TATA
P08223592A0424|9 20|CCAAT boxes
P08223592A0424|80 104|transcription start site
P08223592A0424|126 132|leader
P08223592A0424|139 150|nucleotides
P08223592A0424|176 180|gene
P08223592A0424|208 229|polyadenylation sites
P08223613A0105|0 4|GGS1
P08223613A0105|17 21|gene
P08223613A0105|25 29|TPS1
P08223613A0105|65 72|subunit
P08223613A0105|102 130|synthase/phosphatase complex
P08223613A0105|156 160|fdp1
P08223613A0105|162 166|byp1
P08223613A0105|168 172|glc6
P08223613A0105|177 191|cif1 mutations
P08223613A0519|21 29|sequence
P08223613A0519|57 65|products
P08223613A0519|87 97|genes TPS2
P08223613A0519|102 106|TSL1
P08223613A0519|133 141|subunits
P08223613A0519|149 175|trehalose synthase complex
P08223613A0519|187 201|TSL1 homologue
P08223613A0519|203 207|TPS3
P08223613A0519|220 228|function
P08223823T0000|0 19|Stroop interference
P08223823T0000|21 34|aging effects
P08223823T0000|53 75|Stroop Color-Word Test
P08223875A0711|0 11|Stimulation
P08223875A0711|16 18|3H
P08223875A0711|19 32|PA production
P08223875A0711|38 55|CD3 cross-linking
P08223875A0711|62 63|%
P08223875A0711|87 91|CD45
P08223875A0711|93 98|cells
P08223875A0711|107 111|CD45
P08223875A0711|113 118|cells
P08223875A0711|148 156|activity
P08223875A0711|160 166|p59fyn
P08223875A0711|170 174|CD45
P08223875A0711|176 181|cells
P08224260A1248|0 10|CONCLUSION
P08224260A1248|16 21|study
P08224260A1248|53 68|ultrasonography
P08224260A1248|76 86|efficiency
P08224260A1248|92 93|%
P08224260A1248|113 126|endometriomas
P08224260A1248|146 152|masses
P08224260A1248|160 171|specificity
P08224260A1248|177 178|%
P08224907A0000|8 30|Southern blot analysis
P08224907A0000|34 42|rat EFIA
P08224907A0000|44 73|gene encoding enhancer factor
P08224907A0000|76 85|subunit A
P08224907A0000|105 117|band pattern
P08224907A0000|123 146|cDNA subfragment probes
P08225657A0000|4 10|effect
P08225657A0000|14 23|ibopamine
P08225657A0000|28 38|furosemide
P08225657A0000|46 54|patients
P08225657A0000|60 72|NYHA Class I
P08225657A0000|77 93|II heart failure
P08225657A0000|112 120|parallel
P08225657A0000|179 184|trial
P08226616A0000|4 14|nit-3 gene
P08226616A0000|34 58|fungus Neurospora crassa
P08226616A0000|75 84|reductase
P08226616A0000|90 96|enzyme
P08226616A0000|123 127|step
P08226616A0000|139 151|assimilation
P08226776A0990|42 49|process
P08226776A0990|58 63|ratio
P08226776A0990|67 72|delta
P08226776A0990|90 99|delta Hva
P08226777A0936|2 28|Dictyostelium transformant
P08226777A0936|44 50|DdPTPa
P08226780A0160|5 10|motif
P08226780A0160|37 57|protein interactions
P08226780A0160|65 69|case
P08226780A0160|73 80|ankyrin
P08226780A0160|121 129|proteins
P08226794A0501|1 6|Ala85
P08226794A0501|7 9|Dk
P08226794A0501|41 49|activity
P08226798A1124|18 29|CaM binding
P08226798A1124|33 54|HIV envelope proteins
P08226798A1124|93 100|effects
P08226798A1124|110 119|mechanism
P08226798A1124|136 148|cytotoxicity
P08226798A1124|165 169|part
P08226798A1124|171 181|inhibition
P08226798A1124|208 217|functions
P08226956A1397|22 28|effect
P08226956A1397|32 50|growth temperature
P08226956A1397|71 77|levels
P08226956A1397|81 90|fad7 mRNA
P08226956A1397|99 110|type plants
P08227129T0000|25 31|domain
P08227129T0000|44 57|muscle MyBP-C
P08227129T0000|59 68|C protein
P08227129T0000|100 123|immunoglobulin C2 motif
P08228805A0540|19 27|molecule
P08228805A0540|31 54|TCR signal transduction
P08228805A0540|62 96|guanine nucleotide binding protein
P08228805A0540|98 104|p21ras
P08228805A0540|130 133|TCR
P08228805A0540|139 162|protein tyrosine kinase
P08228805A0540|173 182|mechanism
P08228997A0866|4 11|results
P08228997A0866|38 56|lipid accumulation
P08228997A0866|80 91|oxygenation
P08229102A0768|21 39|QLMI questionnaire
P08229102A0768|49 58|potential
P08229102A0768|65 75|instrument
P08229102A0768|90 92|QL
P08229102A0768|105 113|patients
P08229330A0000|5 12|smokers
P08229330A0000|34 41|smoking
P08229826A1145|15 23|response
P08229826A1145|27 31|taps
P08229826A1145|103 111|activity
P08229826A1145|131 138|muscles
P08229826A1145|175 182|objects
P08230418A0812|4 10|action
P08230418A0812|14 17|nef
P08230418A0812|38 41|LTR
P08230418A0812|46 56|expression
P08230418A0812|60 63|nef
P08230418A0812|71 77|effect
P08230418A0812|85 93|activity
P08230418A0812|108 113|virus
P08230418A0812|118 123|c-fms
P08230418A0812|125 156|urokinase plasminogen activator
P08230418A0812|161 165|type
P08230418A0812|168 193|acid phosphatase promoter
P08230418A0812|212 220|activity
P08230418A0812|246 256|frameshift
P08230418A0812|293 304|amino acids
P08230418A0812|312 319|protein
P08230445A0000|4 11|product
P08230445A0000|19 22|vpr
P08230445A0000|28 41|reading frame
P08230445A0000|51 78|immunodeficiency virus type
P08230445A0000|82 87|HIV-1
P08230445A0000|116 123|protein
P08230445A0000|143 150|virions
P08230445A0000|160 170|quantities
P08230445A0000|193 196|Gag
P08230452A0551|16 24|vaccinia
P08230452A0551|48 63|P1 polyproteins
P08230452A0551|94 112|processing defects
P08230452A0551|116 121|cells
P08230452A0551|152 166|vaccinia virus
P08230452A0551|168 172|VVP3
P08230452A0551|193 216|poliovirus 3CD protease
P08230452A0551|225 235|processing
P08230452A0551|240 256|assembly defects
P08230452A0551|274 296|complementation system
P08230452A0551|332 348|vaccinia viruses
P08230452A0551|357 373|capsid precursor
P08230452A0551|389 406|poliovirus genome
P08230452A0551|440 455|capsid proteins
P08230452A0551|457 459|D.
P08230452A1489|3 11|contrast
P08230452A1489|13 28|capsid proteins
P08230452A1489|46 58|P1 precursor
P08230452A1489|66 85|valine substitution
P08230452A1489|93 107|amino terminus
P08230452A1489|111 114|VP1
P08230452A1489|116 125|VP1-G001V
P08230452A1489|143 159|capsid particles
P08230452A1489|208 215|virions
P08231398A0802|0 7|RESULTS
P08231398A0802|18 29|moth period
P08231398A0802|43 48|total
P08231398A0802|65 79|blood cultures
P08231398A0802|97 107|isolations
P08231398A0802|112 120|episodes
P08231398A0802|124 134|bacteremia
P08231398A0802|138 153|M. tuberculosis
P08231398A0802|173 188|prison patients
P08231398A0802|213 235|immunodeficiency virus
P08231398A0802|259 276|immunosuppression
P08231398A0802|278 282|mean
P08231398A0802|286 289|CD4
P08231398A0802|306 307|l
P08231577A1027|0 4|Acid
P08231577A1027|22 28|larynx
P08231577A1027|41 48|rabbits
P08231577A1027|105 110|apnea
P08231816A1473|23 31|extracts
P08231816A1473|57 88|penicillin producing conditions
P08231816A1473|120 128|activity
P08231816A1473|156 173|promoter fragment
P08231816A1473|217 225|IPNS tsp
P08232304A1166|2 8|series
P08232304A1166|15 24|deletions
P08232304A1166|43 51|fragment
P08232304A1166|72 75|TSS
P08232304A1166|92 109|promoter activity
P08232304A1166|158 201|chloramphenicol acetyltransferase construct
P08232412A1342|4 15|lemdr1 gene
P08232412A1342|34 59|expression vector pALTNEO
P08232412A1342|91 103|L. enriettii
P08232412A1342|134 139|cells
P08232412A1342|158 169|vinblastine
P08232412A1342|183 189|levels
P08232412A1342|218 223|cells
P08234166A0425|4 19|bioavailability
P08234166A0425|23 31|etodolac
P08234166A0425|37 45|capsules
P08234166A0425|66 76|conditions
P08234166A0425|98 102|dogs
P08234166A0425|107 113|humans
P08234166A0425|117 125|capsules
P08234166A0425|136 149|RT conditions
P08234276A0556|20 30|activation
P08234276A0556|51 64|IL-8 promoter
P08234276A0556|91 97|NF-IL6
P08234276A0556|102 126|NF-kappa B binding sites
P08234308T0000|0 6|Notice
P08234308T0000|10 20|retraction
P08237112A0553|3 11|homology
P08237112A0553|34 45|36K protein
P08237112A0553|56 66|structures
P08237112A0553|70 78|proteins
P08237171A0000|17 21|case
P08237171A0000|32 43|enlargement
P08237171A0000|59 65|recess
P08237171A0000|71 78|patient
P08237171A0000|99 112|hydrocephalus
P08237578A0253|11 27|lipid metabolism
P08237578A0253|33 44|mean values
P08237578A0253|55 68|triglycerides
P08237578A0253|70 81|cholesterol
P08237578A0253|83 98|LDL-cholesterol
P08237578A0253|103 118|HDL-cholesterol
P08237578A0253|131 134|end
P08237578A0253|143 148|years
P08237578A0253|152 170|Norplant-2 rod use
P08237578A0253|179 185|months
P08237578A0253|218 235|preinsertion mean
P08238626A0248|5 10|PaCO2
P08238626A0248|17 21|mmHg
P08238626A0248|23 41|baseline brain pHi
P08238626A0248|90 100|blood flow
P08238626A0248|118 120|ml
P08238626A0248|125 128|g-1
P08238626A0248|129 134|min-1
P08239164A0551|0 4|CPAP
P08239164A0551|13 20|isotime
P08239164A0551|49 55|minute
P08239164A0551|59 67|exercise
P08239164A0551|69 72|VO2
P08239164A0551|77 84|dyspnea
P08239164A0551|94 102|patients
P08239164A0551|120 132|lung disease
P08239164A0551|144 150|values
P08239164A0551|186 194|patients
P08239164A0551|210 222|lung disease
P08239586T0000|0 7|Effects
P08239586T0000|11 20|diltiazem
P08239586T0000|43 57|nephrotoxicity
P08239586T0000|61 68|rabbits
P08240170A0000|5 10|forms
P08240170A0000|14 27|salmonellosis
P08240170A0000|47 55|feedlots
P08240170A0000|67 76|transport
P08240170A0000|80 83|sea
P08241139A0378|8 9|%
P08241139A0378|29 40|DNA binding
P08241139A0378|61 69|presence
P08241139A0378|73 79|MgdTDP
P08241139A0378|85 89|none
P08241139A0378|112 119|absence
P08241139A0378|123 134|nucleotides
P08241656A0189|7 16|knowledge
P08241656A0189|35 39|case
P08241656A0189|60 71|association
P08241656A0189|80 94|cholelithiasis
P08241656A0189|99 110|Wildervanck
P08241656A0189|113 121|syndrome
P08242861A0368|5 16|4,8-DiMeIQx
P08242861A0368|21 30|A alpha C
P08242861A0368|49 55|p.p.b.
P08243476A1177|6 14|cysteine
P08243476A1177|24 43|tryptophan residues
P08243476A1177|102 112|reductases
P08243476A1177|131 148|Paracoccus enzyme
P08244034T0000|12 48|Leishmania surface glycoprotein GP63
P08244034T0000|68 97|baculovirus expression system
P08244034T0000|110 127|metalloproteinase
P08245013A0000|26 31|basis
P08245013A0000|52 67|destabilization
P08245013A0000|71 75|mRNA
P08245013A0000|96 105|receptors
P08245013A0000|126 150|receptor down-regulation
P08245013A0000|173 186|understanding
P08245013A0000|200 210|regulation
P08245013A0000|214 223|receptors
P08245013A0000|227 234|agonist
P08245125A0822|0 8|Addition
P08245125A0822|34 48|F-actin nuclei
P08245125A0822|53 63|phalloidin
P08245125A0822|73 84|L266D actin
P08245125A0822|87 94|ability
P08245125A0822|114 124|degrees C.
P08245456A0501|6 11|cells
P08245456A0501|26 31|level
P08245456A0501|35 39|IL-5
P08245456A0501|61 64|PMA
P08245456A0501|81 83|N6
P08245456A0501|85 102|O2-dibutyryl cAMP
P08245456A0501|104 111|Bt2cAMP
P08245456A0501|117 128|combination
P08245456A0501|134 137|PMA
P08245456A0501|174 189|IL-5 production
P08245456A0501|197 201|mRNA
P08245456A0501|210 224|protein levels
P08245461A0700|0 24|Hu-Met-1 mRNA expression
P08245461A0700|36 42|number
P08245461A0700|52 70|T cell tumor lines
P08245461A0700|109 118|phenotype
P08245461A0700|122 127|stage
P08245461A0700|131 142|development
P08245933A0617|8 19|engorgement
P08245933A0617|38 48|treatments
P08246984A0512|0 8|Northern
P08246984A0512|10 13|RNA
P08246984A0512|15 23|analysis
P08246984A0512|37 47|expression
P08246984A0512|57 68|PI 3-kinase
P08246984A0512|76 83|tissues
P08246984A0512|88 98|cell lines
P08246984A0923|6 13|results
P08246984A0923|30 39|existence
P08246984A0923|53 73|PI 3-kinase isoforms
P08246984A0923|87 93|family
P08246984A0923|97 102|genes
P08246984A0923|121 132|PI 3-kinase
P08246984A0923|143 151|subunits
P08246984A0923|176 179|p85
P08246987A0260|3 11|addition
P08246987A0260|36 49|kinase domain
P08246987A0260|51 57|p56lck
P08246987A0260|68 80|Src homology
P08246987A0260|90 93|SH2
P08246987A0260|98 101|SH3
P08246987A0260|103 110|domains
P08246987A0260|142 148|region
P08247005A0584|0 7|Strains
P08247005A0584|20 41|drs2 mutation process
P08247005A0584|46 59|20S precursor
P08247005A0584|74 82|18S rRNA
P08247005A0584|111 114|40S
P08247005A0584|125 133|subunits
P08247043T0000|0 11|Hepatitis B
P08247043T0000|16 37|liver transplantation
P08248246A0838|4 11|complex
P08248246A0838|34 37|Sp1
P08248246A0838|51 58|complex
P08248246A0838|83 90|binding
P08248246A0838|112 116|role
P08248246A0838|145 163|R1 gene expression
P08248253A1785|15 27|observations
P08248253A1785|37 45|promoter
P08248253A1785|53 61|enhancer
P08248253A1785|70 88|chicken L-CAM gene
P08248688A0726|4 8|rate
P08248688A0726|20 31|stimulation
P08248688A0726|51 58|nitrate
P08248688A0726|87 91|rate
P08248688A0726|104 117|NO production
P08248688A0726|135 143|molecule
P08249319A0578|31 46|mislocalization
P08249319A0578|54 62|position
P08249319A0578|70 74|peak
P08249319A0578|104 109|field
P08249390A0111|4 12|duration
P08249390A0111|16 33|diabetes mellitus
P08249390A0111|43 51|patients
P08249390A0111|63 69|months
P08249390A0111|75 80|years
P08249390A0111|93 101|patients
P08249390A0111|132 142|infarction
P08251506A0503|12 19|complex
P08251506A0503|64 73|complexes
P08251506A0503|103 106|kDa
P08251506A0503|126 134|proteins
P08251506A0503|171 190|DRE oligonucleotide
P08251506A0503|223 232|complexes
P08251506A0503|262 273|cross-links
P08251622A0000|4 12|promoter
P08251622A0000|26 32|region
P08251622A0000|40 83|Brassica napus 2S storage protein napA gene
P08251622A0000|120 129|sequences
P08251622A0000|170 180|expression
P08252067A0917|17 28|comparisons
P08252067A0917|36 43|domains
P08252067A0917|51 54|NH2
P08252067A0917|59 71|COOH termini
P08252067A0917|89 95|degree
P08252067A0917|99 109|similarity
P08252067A0917|132 144|conservation
P08252976A0467|0 5|Rinit
P08252976A0467|29 40|resistances
P08252976A0467|45 50|Rdiff
P08252976A0467|93 114|pressure dissipations
P08252976A0467|122 128|system
P08253386A0800|21 30|mechanism
P08253386A0800|34 40|action
P08253386A0800|48 77|fibronectin splicing enhancer
P08253386A0800|97 107|SE element
P08253386A0800|134 142|assembly
P08253386A0800|152 170|splicing complexes
P08253386A0800|198 209|interaction
P08253386A0800|217 225|U2 snRNP
P08253386A0800|231 252|branch site sequences
P08253387A0801|0 10|Inspection
P08253387A0801|14 30|enhancer mutants
P08253387A0801|45 61|trans-activation
P08253387A0801|65 74|hLEF/GAL4
P08253387A0801|102 107|TCF-2
P08253387A0801|136 143|protein
P08253387A0801|158 167|sequences
P08253387A0801|194 198|site
P08253387A0801|206 214|enhancer
P08253387A1291|17 26|sequences
P08253387A1291|42 54|hLEF HMG box
P08253387A1291|63 67|cell
P08253387A1291|90 100|activation
P08253387A1291|108 126|TCR alpha enhancer
P08253387A1291|146 158|interactions
P08253387A1291|167 171|hLEF
P08253387A1291|198 205|factors
P08253387A1291|223 231|enhancer
P08253777A0301|2 23|cAMP response element
P08253777A0301|25 28|CRE
P08253777A0301|30 46|consensus signal
P08253777A0301|82 88|region
P08253777A0301|90 94|cAMP
P08253777A0301|109 119|expression
P08253777A0301|123 126|Kv1
P08253777A0301|129 133|gene
P08253777A0301|153 159|manner
P08253958A0000|2 8|number
P08253958A0000|24 29|tests
P08253958A0000|44 52|presence
P08253958A0000|56 68|Helicobacter
P08253958A0000|85 107|serum immunoglobulin G
P08253958A0000|109 112|IgG
P08254738A0428|8 14|series
P08254738A0428|25 35|T antigens
P08254738A0428|61 74|baculoviruses
P08254738A0428|78 87|Sf9 cells
P08254738A0428|106 112|origin
P08254738A0428|123 133|activities
P08254738A0428|142 147|TS677
P08254738A0428|156 161|TS677
P08254738A0428|191 207|T-antigen kinase
P08254738A0428|225 234|T antigen
P08255022A0827|4 10|degree
P08255022A0827|14 27|hypoperfusion
P08255022A0827|64 68|FEV1
P08255022A0827|70 71|%
P08255022A0827|73 76|V25
P08255022A0827|81 85|PaO2
P08255022A0827|90 98|increase
P08255022A0827|114 126|blood volume
P08255022A0827|146 163|blood cell counts
P08255341A0554|4 12|patients
P08255341A0554|46 57|combination
P08255341A0554|61 74|metronidazole
P08255341A0554|78 95|tissue amoebicide
P08255341A0554|101 111|diloxanide
P08255341A0554|123 133|amoebicide
P08255758A0000|42 48|region
P08255758A0000|73 88|retrotransposon
P08255758A0000|105 108|LTR
P08255758A0000|112 120|sequence
P08255758A0000|141 151|regulation
P08255758A0000|155 168|homeoproteins
P08257666A0662|15 20|study
P08257666A0662|22 29|lesions
P08257666A0662|37 48|OPT complex
P08257666A0662|63 69|source
P08257666A0662|73 82|afferents
P08257666A0662|86 89|IHA
P08257666A0662|94 96|HD
P08257666A0662|120 126|effect
P08257666A0662|145 165|learning performance
P08257754A0711|11 15|dose
P08257754A0711|35 42|results
P08257754A0711|48 49|%
P08257754A0711|54 65|individuals
P08257754A0711|71 84|HB antibodies
P08257754A0711|104 109|IU/ml
P08257754A0711|126 130|ones
P08257754A0711|135 136|%
P08257754A0711|148 161|HB antibodies
P08257754A0711|176 181|IU/ml
P08258025A1131|0 11|CONCLUSIONS
P08258025A1131|20 28|patients
P08258025A1131|44 49|range
P08258025A1131|53 72|treatment variables
P08258025A1131|82 85|age
P08258025A1131|87 102|Karnofsky index
P08258025A1131|126 133|disease
P08258025A1131|157 164|factors
P08258025A1131|184 193|mortality
P08259650A0640|0 28|Nucleotide sequence analysis
P08259650A0640|36 43|HA gene
P08259650A0640|57 64|mutants
P08259650A0640|79 81|HA
P08259650A0640|83 92|phenotype
P08260635A0926|5 11|intron
P08260635A0926|33 41|position
P08260635A0926|67 73|intron
P08260635A0926|83 105|transit peptide region
P08260635A0926|121 132|GAPDH genes
P08260635A0926|134 138|GapA
P08260635A0926|143 147|GapB
P08260635A0926|159 165|plants
P08261398A0392|19 40|cell lines P388/ADR/3
P08261398A0392|45 55|P388/ADR/7
P08261398A0392|76 80|topo
P08261398A0392|84 105|alpha mRNA transcript
P08261398A0392|109 117|addition
P08261398A0392|132 142|transcript
P08261398A0392|173 189|P388/4 cell line
P08261398A0838|17 30|amplification
P08261398A0838|34 38|cDNA
P08261398A0838|44 52|strategy
P08261398A0838|69 74|cDNAs
P08261398A0838|95 102|termini
P08261398A0838|133 144|transcripts
P08261398A0838|155 165|P388/ADR/3
P08261398A0838|170 186|P388/ADR/7 cells
P08262041A0727|4 18|phi AP3 factor
P08262041A0727|32 46|phosphoprotein
P08262041A0727|52 58|extent
P08262041A0727|66 81|phosphorylation
P08262041A0727|106 116|cell cycle
P08262054A0565|38 44|domain
P08262054A0565|59 78|membrane protein 2A
P08262054A0565|80 85|LMP2A
P08262054A0565|107 112|virus
P08262054A0565|114 117|EBV
P08262054A0565|137 141|copy
P08262054A0565|149 160|Tyr-X-X-Leu
P08262054A0565|176 181|motif
P08262054A0565|210 214|role
P08262054A0565|218 239|B cell transformation
P08262067A1608|15 23|homology
P08262067A1608|27 31|Cwg2
P08262067A1608|37 42|Cdc43
P08262067A1608|77 84|control
P08262067A1608|88 101|cell polarity
P08262067A1608|114 118|link
P08262067A1608|145 151|events
P08262067A1608|160 173|establishment
P08262067A1608|177 190|cell polarity
P08262067A1608|195 217|cell wall biosynthesis
P08263933T0000|10 17|cloning
P08263933T0000|30 41|ATPase gene
P08263933T0000|51 82|cyanobacterium Synechocystis sp
P08264579A1209|4 11|cloning
P08264579A1209|15 19|PTR2
P08264579A1209|41 48|example
P08264579A1209|74 90|characterization
P08264579A1209|107 129|peptide transport gene
P08264582A0750|37 43|domain
P08264582A0750|48 55|mutants
P08264582A0750|90 99|deletions
P08264582A0750|110 119|deletions
P08264582A0750|124 139|point mutations
P08264582A0750|169 188|amino acid residues
P08264582A0750|192 196|LIFR
P08264582A0750|212 218|region
P08264582A0750|233 242|signaling
P08264583A0520|27 32|basis
P08264583A0520|40 43|end
P08264583A0520|61 69|extracts
P08264583A0520|96 103|variety
P08264583A0520|117 127|cell lines
P08264583A0520|149 156|ability
P08264583A0520|165 188|test plasmid substrates
P08264591A1190|6 10|data
P08264591A1190|37 44|subunit
P08264591A1190|48 62|RNA polymerase
P08264591A1190|70 75|TFIIB
P08264591A1190|90 102|determinants
P08264591A1190|106 140|transcription start site selection
P08264591A1190|180 188|function
P08264591A1190|211 222|interaction
P08264591A1190|241 249|proteins
P08264617A0000|12 22|expression
P08264617A0000|37 46|EGFR/ErbB
P08264617A0000|49 57|receptor
P08264617A0000|61 80|NIH 3T3 fibroblasts
P08264617A0000|119 125|events
P08264617A0000|142 168|ErbB-3 signal transduction
P08264617A0000|174 191|ligand activation
P08264628A0418|0 27|Oligonucleotide competitors
P08264628A0418|54 67|accessibility
P08264628A0418|88 92|site
P08264628A0418|96 102|TIF-IB
P08264628A0418|104 109|TFIID
P08264628A0418|115 121|TFIIIB
P08264631A0746|15 21|region
P08264631A0746|30 43|ADR1 activity
P08264631A0746|65 68|TAD
P08264631A0746|80 84|ADR1
P08264631A0746|86 102|ADR1 DNA binding
P08264631A0746|117 140|ADH2 promoter sequences
P08264650A0925|0 8|Analysis
P08264650A0925|12 19|strains
P08264650A0925|33 51|mds1 null mutation
P08264650A0925|70 74|MDS1
P08264650A0925|117 123|growth
P08264650A0925|155 162|meiosis
P08264664A0128|0 8|TGF beta
P08264664A0128|11 21|expression
P08264664A0128|51 69|AP-1 binding sites
P08264664A0128|95 104|promoters
P08264664A0128|113 117|gene
P08265602T0000|0 3|Val
P08265602T0000|6 19|Ala mutations
P08265602T0000|50 57|packing
P08265602T0000|65 86|transmembrane segment
P08265602T0000|90 112|phage M13 coat protein
P08265955T0000|10 16|change
P08265955T0000|24 27|NHS
P08267658A0391|22 30|solution
P08267658A0391|36 38|UW
P08267658A0391|56 57|K
P08267658A0391|61 73|lactobionate
P08267658A0391|75 81|KH2PO4
P08267658A0391|83 88|MgSO4
P08267658A0391|93 102|raffinose
P08267658A0391|133 145|preservation
P08267658A0391|149 164|rat hepatocytes
P08267658A0391|172 174|hr
P08267658A0391|179 201|drug transport studies
P08267667A0748|9 23|administration
P08267667A0748|27 31|GRg2
P08267667A0748|35 40|mg/kg
P08267667A0748|99 107|deficits
P08267667A0748|140 144|rate
P08267667A0748|182 183|d
P08267667A0748|186 206|learning acquisition
P08267667A0748|208 209|F
P08267667A0748|223 224|p
P08267667A0748|274 294|h memory acquisition
P08267667A0748|296 297|F
P08267667A0748|311 312|p
P08267667A0748|365 383|h memory retention
P08267667A0748|385 386|F
P08267667A0748|399 400|p
P08267667A0748|460 478|h memory retrieval
P08267667A0748|480 481|F
P08267667A0748|495 496|p
P08268718A0676|6 18|bcl3 protein
P08268718A0676|43 46|p50
P08268718A0676|53 62|complexes
P08268833T0000|16 22|action
P08268833T0000|26 39|cyclosporin A
P08268833T0000|41 50|Sandimmun
P08268833T0000|57 68|application
P08268833T0000|83 92|arthritis
P08268912A0657|9 32|translation experiments
P08268912A0657|49 53|cDNA
P08268912A0657|62 65|RNA
P08268912A0657|84 91|protein
P08268912A0657|99 107|mobility
P08268912A0657|117 119|kD
P08268912A0657|123 146|SDS polyacrylamide gels
P08269424A0339|17 31|administration
P08269424A0339|40 43|CRF
P08269424A0339|48 51|TRH
P08269424A0339|53 64|ACTH levels
P08269424A0339|98 108|tumor side
P08269424A0339|116 124|patients
P08269439X0000|12 21|analgesia
P08269439X0000|34 39|niche
P08269439X0000|44 53|Talwin Nx
P08269439X0000|55 66|Pentazocine
P08269439X0000|93 98|agent
P08269439X0000|107 117|management
P08269439X0000|134 138|pain
P08270257A0551|2 28|sequence homology analysis
P08270257A0551|43 50|nm23-H1
P08270257A0551|59 71|homolog gene
P08270257A0551|79 82|rat
P08270257A0551|84 94|NDP-K beta
P08270257A0551|119 129|boundaries
P08270257A0551|167 174|species
P08270580A0155|13 21|response
P08270580A0155|42 53|combination
P08270580A0155|57 71|amphotericin B
P08270580A0155|76 89|cotrimoxazole
P08270985A0590|0 18|Response durations
P08273122A0708|0 7|RESULTS
P08273122A0708|16 25|beginning
P08273122A0708|33 46|QA/QI process
P08273122A0708|48 58|monitoring
P08273122A0708|62 92|blood administration practices
P08273122A0708|109 117|variance
P08273122A0708|137 164|blood administration policy
P08273122A0708|184 191|percent
P08273122A0708|195 200|blood
P08273122A0708|205 227|component transfusions
P08274774A0958|3 11|addition
P08274774A0958|13 25|REP21 plants
P08274774A0958|63 68|range
P08274774A0958|72 85|tobamoviruses
P08274774A0958|96 115|tomato mosaic virus
P08274774A0958|117 124|tobacco
P08274774A0958|136 148|mosaic virus
P08274774A0958|150 156|TMV-U5
P08274774A0958|164 170|tomato
P08274774A0958|180 192|mosaic virus
P08274774A0958|198 219|ribgrass mosaic virus
P08275618A0457|0 11|Drug effect
P08275618A0457|64 72|patients
P08275618A0457|78 87|cirrhosis
P08275618A0457|100 108|subjects
P08275618A0457|124 129|ratio
P08275618A0457|133 144|effect area
P08275618A0457|155 160|curve
P08275618A0457|164 182|concentration area
P08275618A0457|193 198|curve
P08275618A0457|202 209|measure
P08275618A0457|213 224|sensitivity
P08275618A0457|267 275|patients
P08275618A0457|281 290|cirrhosis
P08275618A0457|307 315|subjects
P08276234A0119|11 19|evidence
P08276234A0119|25 28|YY1
P08276234A0119|67 74|protein
P08276234A0119|90 98|activity
P08276234A0119|106 120|c-fos promoter
P08276234A0119|142 148|effect
P08276234A0119|152 165|DNA structure
P08276336A0371|19 27|analysis
P08276336A0371|48 61|colonoscopies
P08276336A0371|69 77|patients
P08276336A0371|99 111|relationship
P08276336A0371|149 155|polyps
P08276732A0799|4 8|rate
P08276732A0799|12 21|decrement
P08276732A0799|25 40|DPOAE amplitude
P08276732A0799|59 70|time period
P08276732A0799|89 96|measure
P08276732A0799|100 114|susceptibility
P08276732A0799|131 137|trauma
P08276762T0000|0 6|Effect
P08276762T0000|17 35|base substitutions
P08276762T0000|39 56|glycine-870 codon
P08276762T0000|60 83|gramicidin S synthetase
P08276762T0000|86 90|gene
P08276762T0000|94 112|proline activation
P08276851A0347|14 28|Pay4p sequence
P08276851A0347|63 70|domains
P08276851A0347|92 105|relationships
P08276851A0347|137 145|proteins
P08276851A0347|169 178|processes
P08276851A0347|204 214|biogenesis
P08276851A0347|233 250|protein transport
P08276851A0347|252 270|cell cycle control
P08276851A0347|292 302|regulation
P08276854A1894|4 11|results
P08276854A1894|26 35|structure
P08276854A1894|43 64|decorin gene promoter
P08276854A1894|101 122|proteoglycan promoter
P08276854A1894|166 181|pur/pyr segment
P08276854A1894|190 194|role
P08276854A1894|202 212|regulation
P08276854A1894|216 234|gene transcription
P08276865A1188|4 34|kinase inhibitor staurosporine
P08276865A1188|38 44|microM
P08276865A1188|84 90|growth
P08276865A1188|107 117|activation
P08276865A1188|121 127|p21ras
P08276865A1188|132 142|MAP kinase
P08276865A1188|176 190|protein kinase
P08276865A1188|203 215|LPA receptor
P08276865A1188|219 236|p21ras activation
P08276871A1001|38 46|identity
P08276871A1001|59 60|%
P08276871A1001|92 102|% identity
P08276871A1001|127 140|transmembrane
P08276871A1001|157 164|domains
P08276900A0543|0 2|S.
P08276900A0543|4 6|K.
P08277632A0997|4 17|survival rate
P08277632A0997|27 33|months
P08277632A0997|40 48|patients
P08277632A0997|54 64|N2 disease
P08277632A0997|79 92|R2b operation
P08277632A0997|99 100|%
P08278423A0147|0 7|Mothers
P08278423A0147|31 44|abnormalities
P08278423A0147|54 57|HIV
P08278423A0147|80 82|TB
P08278423A0147|92 100|children
P08278423A0147|125 150|disaccharide intolerances
P08278480T0002|0 2|G.
P08278548A0597|4 8|psaD
P08278548A0597|10 14|psaF
P08278548A0597|16 20|psaH
P08278548A0597|26 39|psaL products
P08278548A0597|49 57|isoforms
P08278548A0597|99 109|mobilities
P08278548A0597|113 147|polyacrylamide gel electrophoresis
P08278548A0597|157 169|psaE product
P08278548A0597|179 187|isoforms
P08278929A0866|12 30|SPF type V embryos
P08278929A0866|59 61|ml
P08278929A0866|64 73|% ethanol
P08278929A0866|77 80|CRS
P08278929A0866|92 98|ml CRS
P08278929A0866|100 108|controls
P08278929A0866|127 134|embryos
P08278929A0866|144 157|VSD incidence
P08278929A0866|165 166|%
P08278929A0866|186 197|% incidence
P08278929A0866|205 213|controls
P08278929A0866|215 216|P
P08279098T0001|31 42|dystrophies
P08279098T0001|46 61|myopia patients
P08280476A0602|7 14|studies
P08280476A0602|28 38|HIV-1 HXB2
P08280476A0602|43 68|HIV-1 Z2Z6 core enhancers
P08280476A0602|81 92|Z2Z6 strain
P08280476A0602|106 120|point mutation
P08280476A0602|152 156|site
P08280925A0261|45 54|responses
P08280925A0261|63 75|C57Bl/6 mice
P08280925A0261|94 98|mice
P08280925A0261|124 128|mice
P08280925A0261|139 145|groups
P08280925A0261|147 158|differences
P08280925A0261|182 185|IgM
P08280925A0261|190 193|IgG
P08280925A0261|203 213|antibodies
P08281153A0543|29 35|degree
P08281153A0543|39 51|conservation
P08281153A0543|55 71|intron sequences
P08281153A0543|98 105|species
P08281536A0626|0 13|Interleukin-6
P08281536A0626|38 48|metastasis
P08281536A0626|60 66|myxoma
P08281634A1801|6 16|parameters
P08281634A1801|20 35|iron metabolism
P08281634A1801|47 55|ferritin
P08281634A1801|93 97|risk
P08281740A0000|0 9|Responses
P08281740A0000|17 45|Plowright Rinderpest vaccine
P08281740A0000|52 58|calves
P08281740A0000|72 78|cattle
P08281740A0000|82 88|Uganda
P08281740A0000|110 120|production
P08281740A0000|124 138|IgG antibodies
P08281740A0000|161 166|weeks
P08281740A0000|177 188|ELISA assay
P08282501A0358|21 27|number
P08282501A0358|40 62|angiography procedures
P08282501A0358|93 104|conclusions
P08282501A0358|130 141|differences
P08282501A0358|169 175|agents
P08282501A0358|186 193|grade-2
P08282501A0358|198 205|grade-3
P08282501A0358|214 220|events
P08282576A0297|0 7|Tumours
P08282576A0297|15 25|cavum oris
P08282576A0297|30 40|oropharynx
P08282576A0297|44 52|T1-stage
P08282576A0297|81 86|cases
P08282749A1474|0 6|Thomas
P08282749A1474|8 25|Hospital solution
P08282749A1474|34 35|%
P08282749A1474|40 45|% CO2
P08282749A1474|70 76|demand
P08282749A1474|94 104|myocardium
P08282749A1474|132 140|duration
P08282749A1474|152 158|arrest
P08283292A0779|0 6|Plasma
P08283292A0779|8 11|LDL
P08283292A0779|16 48|liver cholesterol concentrations
P08283292A0779|83 90|control
P08283292A0779|118 125|control
P08283292A0779|143 149|groups
P08283292A0779|154 159|diets
P08283292A0779|171 177|pectin
P08283292A0779|187 192|fiber
P08283292A0779|220 233|control group
P08283531A0700|4 30|Stryker frame modification
P08283531A0700|47 71|Dornier HM3 lithotriptor
P08283531A0700|92 105|visualization
P08283531A0700|117 129|localization
P08283531A0700|149 156|calculi
P08283531A0700|182 188|gantry
P08284227A0336|21 26|cells
P08284227A0336|53 71|kb mRNA transcript
P08284227A0336|76 79|Id1
P08284227A0336|88 96|contrast
P08284227A0336|106 125|cell types Id1 mRNA
P08284227A0336|157 170|cycling cells
P08284227A0336|204 212|cultures
P08284337A0825|21 30|screening
P08284337A0825|34 46|IHD patients
P08284337A0825|76 81|means
P08284337A0825|94 107|cardiologists
P08284337A0825|112 122|internists
P08284337A0825|146 152|levels
P08284337A0825|156 164|distress
P08284337A0825|177 185|patients
P08285710A0634|16 31|transcript mRNA
P08285710A0634|48 56|Northern
P08285710A0634|58 61|RNA
P08285710A0634|63 76|blot analysis
P08285710A0634|93 97|maps
P08285710A0634|103 111|position
P08285710A0634|115 117|bp
P08285710A0634|136 140|site
P08285710A0634|144 154|initiation
P08285710A0634|158 175|protein synthesis
P08286035A0587|15 35|sequence information
P08286035A0587|41 46|c11/1
P08286035A0587|67 71|cDNA
P08286035A0587|91 95|poly
P08286035A0587|96 97|A
P08286035A0587|99 102|RNA
P08286035A0587|113 118|PMNLs
P08286035A0587|130 143|transcription
P08286035A0587|150 161|combination
P08286035A0587|165 190|polymerase chain reaction
P08286035A0587|192 195|PCR
P08286035A0587|197 204|methods
P08288240A0304|4 23|sequence similarity
P08288240A0304|43 48|SCG10
P08288240A0304|53 61|stathmin
P08288240A0304|125 130|genes
P08288240A1343|6 10|data
P08288240A1343|35 39|idea
P08288240A1343|65 75|SCG10 gene
P08288240A1343|87 98|duplication
P08288240A1343|103 115|modification
P08288240A1343|146 165|stathmin/Lap18 gene
P08288554A0295|12 31|amino acid sequence
P08288554A0295|39 54|mouse HO-1 gene
P08288554A0295|79 82|p32
P08288554A0295|125 132|protein
P08288554A0295|136 157|mouse BALBc/3T3 cells
P08288596A0663|14 16|T3
P08288596A0663|25 26|M
P08288596A0663|51 64|transcription
P08288596A0663|70 77|rGH-TRE
P08288596A0663|83 89|TREpal
P08288596A0663|100 106|ME-TRE
P08288596A0663|112 118|F2-TRE
P08288596A0663|132 141|templates
P08288596A0663|157 161|TREs
P08288596A0663|176 181|front
P08288596A0663|189 192|rGH
P08288596A0663|201 209|promoter
P08288596A0663|230 254|TATA box binding protein
P08288596A0663|283 298|binding protein
P08288596A0663|300 308|sequence
P08288606A0240|8 24|polymerase chain
P08288606A0240|40 48|approach
P08288606A0240|71 84|pair fragment
P08288606A0240|94 104|sialymotif
P08288606A0240|116 129|placenta mRNA
P08288606A0240|156 161|probe
P08288606A0240|165 170|clone
P08288606A0240|184 199|coding sequence
P08288606A0240|221 225|gene
P08288606A0240|233 245|cDNA library
P08288622A0725|15 23|analysis
P08288622A0725|51 64|heterogeneity
P08288622A0725|72 80|HDC mRNA
P08288622A0725|97 106|insertion
P08288622A0725|122 137|intron sequence
P08288622A0725|154 157|use
P08288622A0725|165 187|splicing acceptor site
P08288622A0725|200 204|exon
P08288633A0144|16 19|DNA
P08288633A0144|38 60|Caenorhabditis elegans
P08288633A0144|76 87|polypeptide
P08288633A0144|96 115|amino acid residues
P08288633A0144|117 122|CeGAP
P08288633A0144|141 147|domain
P08288633A0144|153 172|sequence similarity
P08288633A0144|194 201|segment
P08288633A0144|221 235|protein region
P08288633A0144|240 243|Bcr
P08288633A0144|278 286|proteins
P08288633A0144|294 307|Rho subfamily
P08289339A0527|11 22|exonuclease
P08289339A0527|27 37|protection
P08289339A0527|62 73|core region
P08289339A0527|96 101|sides
P08289339A0527|119 121|E1
P08289339A0527|150 159|sequences
P08289341A1202|0 10|Repression
P08289341A1202|43 45|E2
P08289341A1202|61 65|E2-C
P08289341A1202|85 91|copies
P08289341A1202|95 100|E2-RS
P08289342A0931|2 8|mutant
P08289342A0931|16 19|AAV
P08289342A0931|29 44|resolution site
P08289342A0931|46 49|trs
P08289342A0931|69 84|DNA replication
P08289342A0931|101 106|assay
P08289357A0724|4 11|results
P08289357A0724|26 29|rep
P08289357A0724|52 60|function
P08289357A0724|84 92|elements
P08289357A0724|100 103|LTR
P08289593A1404|33 37|rats
P08289593A1404|55 61|MK-801
P08289593A1404|91 103|cocaine dose
P08289593A1404|118 123|mg/kg
P08289593A1404|125 126|n
P08289593A1404|137 144|vehicle
P08289593A1404|156 160|rats
P08289593A1404|177 182|mg/kg
P08289593A1404|184 185|n
P08289593A1404|208 214|MK-801
P08289593A1404|265 273|toxicity
P08289593A1404|277 284|cocaine
P08289593A1404|288 296|urethane
P08289593A1404|310 314|rats
P08289783A0000|4 9|Oct-3
P08289783A0000|12 24|gene product
P08289783A0000|47 57|POU family
P08289783A0000|61 82|transcription factors
P08289783A0000|94 103|candidate
P08289783A0000|127 152|differentiation decisions
P08289783A1476|20 31|mutagenesis
P08289783A1476|50 57|RAREoct
P08289783A1476|93 103|activation
P08289783A1476|107 112|Oct-3
P08289783A1476|115 123|promoter
P08289783A1476|127 136|P19 cells
P08289783A1476|186 196|repression
P08289783A1476|218 226|EC cells
P08289784A0381|19 21|M.
P08289793A1226|42 48|effect
P08289793A1226|52 60|COUP-TFs
P08289793A1226|93 99|effect
P08289793A1226|107 111|Oct4
P08289793A1226|122 126|stem
P08289793A1226|141 149|enhancer
P08289831A0290|0 8|Analysis
P08289831A0290|12 19|mig/CAT
P08289831A0290|29 39|constructs
P08289831A0290|73 76|RAW
P08289831A0290|83 88|mouse
P08289831A0290|99 108|cell line
P08289831A0290|148 155|element
P08289831A0290|157 167|gamma RE-1
P08289834A0341|24 34|test cells
P08289834A0341|36 41|Atr-I
P08289834A0341|60 68|TGF-beta
P08289834A0341|70 77|activin
P08289834A0341|82 86|bone
P08289834A0341|101 108|protein
P08290278A0374|11 15|Mxi1
P08290278A0374|20 23|Mad
P08290278A0374|41 53|Myc function
P08290278A0374|62 94|candidate tumor suppressor genes
P08290421A0165|7 16|knowledge
P08290421A0165|18 22|type
P08290421A0165|40 48|acidosis
P08290421A0165|85 96|association
P08290421A0165|102 108|Alport
P08290421A0165|111 119|syndrome
P08290421A0165|132 139|patient
P08291233A0000|2 12|cDNA clone
P08291233A0000|33 60|chicken embryo cDNA library
P08291233A0000|100 105|probe
P08291233A0000|123 132|U3 region
P08291233A0000|140 162|Rous sarcoma virus LTR
P08291620A0372|10 18|patterns
P08291620A0372|22 40|locomotor behavior
P08291620A0372|59 75|torso morphology
P08291620A0372|95 106|anthropoids
P08291761A0416|0 10|Animal age
P08291761A0416|15 18|sex
P08291761A0416|38 45|effects
P08291761A0416|49 64|CSF composition
P08291761A0416|70 93|serum IgG concentration
P08291761A0416|109 112|age
P08291886T0024|16 25|expansion
P08293412T0000|26 31|study
P08293412T0000|46 54|efficacy
P08293412T0000|59 71|tolerability
P08293412T0000|75 86|tropisetron
P08293412T0000|94 119|5-HT3 receptor antagonist
P08293412T0000|165 173|cocktail
P08293412T0000|181 191|prevention
P08293412T0000|213 219|emesis
P08293992A0432|5 11|repeat
P08293992A0432|27 29|nt
P08293992A0432|57 65|sequence
P08293992A0432|67 73|K/NPAG
P08293993A0948|0 3|ENV
P08293993A0948|27 38|P. pastoris
P08293993A0948|63 99|alpha-factor prepro secretion leader
P08293993A0948|122 147|invertase signal sequence
P08294386A0000|0 10|BACKGROUND
P08294386A0000|29 39|predictors
P08294386A0000|66 76|depression
P08294386A0000|82 89|authors
P08294386A0000|103 110|outcome
P08294386A0000|114 122|patients
P08294386A0000|134 144|depression
P08294386A0000|176 184|hospital
P08294386A0000|202 213|desipramine
P08294386A0000|238 249|blood level
P08294429A0153|0 8|Analysis
P08294429A0153|23 31|hGH gene
P08294429A0153|35 38|hGH
P08294429A0153|51 54|DNA
P08294429A0153|59 61|FR
P08294429A0153|78 86|hGh cDNA
P08294429A0153|90 123|chloramphenicol acetyltransferase
P08294429A0153|127 143|luciferase genes
P08294429A0153|160 164|cAMP
P08294429A0153|186 207|hGH promoter activity
P08294459A0446|14 33|amino acid sequence
P08294459A0446|41 51|SAP-1 cDNA
P08294459A0446|71 76|SAP-1
P08294459A0446|95 106|amino acids
P08294459A0446|132 135|PTP
P08294459A0446|176 182|domain
P08294459A0446|202 208|region
P08294511A0639|14 22|evidence
P08294511A0639|48 55|protein
P08294511A0639|96 103|protein
P08294511A0639|135 155|snRNP core particles
P08294511A0639|175 186|interaction
P08294865A0236|8 16|features
P08294865A0236|28 33|cells
P08294865A0236|51 59|mutation
P08294865A0236|90 99|formation
P08294865A0236|103 123|peptide/DR complexes
P08294906A1315|5 17|distribution
P08294906A1315|40 67|neurotransmitters glutamate
P08294906A1315|72 81|aspartate
P08294906A1315|120 131|amino acids
P08294906A1315|137 146|substrate
P08294906A1315|151 160|transport
P08296434A1141|4 21|Harleco apparatus
P08296434A1141|58 65|adjunct
P08296434A1141|73 82|diagnosis
P08296434A1141|87 96|treatment
P08296434A1141|122 131|condition
P08297376A0236|0 15|Co-transfection
P08297376A0236|19 37|expression vectors
P08297376A0236|42 72|CCAAT/enhancer binding protein
P08297376A0236|74 79|C/EBP
P08297376A0236|81 86|alpha
P08297376A0236|91 101|C/EBP beta
P08297376A0236|122 158|rat uncoupling protein gene promoter
P08297376A0236|166 175|sequences
P08297376A0236|195 201|region
P08298129A0274|33 38|basis
P08298129A0274|59 69|expression
P08298129A0274|78 82|gene
P08298129A0274|96 100|beta
P08298129A0274|103 116|gene promoter
P08298129T0000|0 9|Isolation
P08298129T0000|14 30|characterization
P08298129T0000|46 54|promoter
P08298129T0000|69 73|beta
P08298129T0000|76 89|integrin gene
P08299181A1148|11 16|fluid
P08299181A1148|45 48|eye
P08299181A1148|55 59|eyes
P08299181A1148|65 66|%
P08299181A1148|86 89|eye
P08299181A1148|95 99|eyes
P08299181A1148|105 106|%
P08299568A1401|6 10|data
P08299568A1401|25 35|activation
P08299568A1401|45 52|enzymes
P08299568A1401|85 96|stimulation
P08299568A1401|100 117|glucose transport
P08299725A0724|13 19|region
P08299725A0724|41 47|intron
P08299725A0724|51 56|brain
P08299725A0724|61 67|muscle
P08299725A0724|89 105|tumor cell lines
P08299725A0724|119 130|readthrough
P08299725A0724|132 136|form
P08299725A0724|148 156|residues
P08299725A0724|177 180|end
P08299896A0626|0 11|Concordance
P08299896A0626|15 26|IBDQ scores
P08299896A0626|52 60|subjects
P08299896A0880|0 22|Regression line slopes
P08299896A0880|26 37|IBDQ scores
P08299896A0880|70 78|patients
P08299896A0880|129 130|b
P08299896A0880|140 141|P
P08300463A0581|0 12|Praziquantel
P08300463A0581|17 28|Albendazole
P08300463A0581|57 66|treatment
P08300463A0581|70 88|neurocysticercosis
P08300463A0581|118 125|effects
P08300463A0581|146 151|cases
P08300463A0581|157 162|drugs
P08300463A0581|201 206|cases
P08300527T0000|0 10|Inhibition
P08300527T0000|14 36|erythromycin synthesis
P08300527T0000|40 50|disruption
P08300527T0000|54 96|malonyl-coenzyme A decarboxylase gene eryM
P08300527T0000|100 127|Saccharopolyspora erythraea
P08300601A0745|5 11|region
P08300601A0745|28 38|activation
P08300601A0745|42 53|DNA binding
P08300601A0745|57 61|MyoD
P08300601A0745|66 80|E12 homodimers
P08300601A0745|85 106|E12/MyoD heterodimers
P08300605A0432|16 24|analysis
P08300605A0432|30 36|series
P08300605A0432|40 56|deletion mutants
P08300605A0432|64 68|gene
P08300605A0432|84 92|extracts
P08300605A0432|118 128|silk gland
P08300605A0432|148 161|instar larvae
P08300605A0432|175 183|presence
P08300605A0432|211 219|elements
P08300605A0432|264 279|initiation site
P08300605A0671|13 21|elements
P08300605A0671|47 54|element
P08300605A0671|91 101|regulation
P08300611A0341|14 25|mutagenesis
P08300611A0341|33 37|traI
P08300611A0341|49 53|gene
P08300611A0341|58 69|application
P08300611A0341|89 102|TraI proteins
P08300611A0341|116 122|assays
P08300611A0341|157 167|importance
P08300611A0341|181 200|amino acid residues
P08300611T0000|10 16|action
P08300611T0000|35 42|domains
P08300611T0000|50 53|DNA
P08300611T0000|71 79|reaction
P08300611T0000|93 101|relaxase
P08300611T0000|103 107|TraI
P08300611T0000|124 135|plasmid RP4
P08300625A1352|21 27|codons
P08300625A1352|31 35|slyD
P08300625A1352|71 87|peptide sequence
P08300625A1352|129 142|slyD function
P08300625A1352|157 162|lysis
P08301702A1083|13 23|antibodies
P08301702A1083|39 63|rat cytochrome P-450 1A1
P08301702A1083|77 84|protein
P08301702A1083|100 110|microsomes
P08301702A1083|133 142|cormorant
P08301702A1083|180 185|heron
P08301702A1083|210 224|immunoblotting
P08301841A0000|18 33|enzyme activity
P08301841A0000|37 42|serum
P08301841A0000|66 76|infarction
P08301841A0000|78 81|AMI
P08301841A0000|96 111|angina pectoris
P08301841A0000|113 116|UAP
P08302589A1132|16 29|cell motility
P08302589A1132|87 101|protein kinase
P08302589A1132|115 128|phorbol ester
P08302589A1132|141 144|Ca2
P08302589A1132|146 155|ionophore
P08303233A0313|3 11|addition
P08303233A0313|21 28|priming
P08303233A0313|59 67|identity
P08303233A0313|89 93|text
P08304301A0331|0 7|METHODS
P08304301A0331|20 25|cases
P08304301A0331|53 60|nodules
P08304301A0331|64 67|HCC
P08304301A0331|78 89|examination
P08304301A0331|122 126|HCCs
P08304342A0605|15 21|report
P08304342A0605|26 50|hemochromatosis families
P08304342A0605|64 91|hemochromatosis chromosomes
P08304342A0605|107 118|chromosomes
P08304342A0605|142 149|battery
P08304342A0605|153 159|probes
P08304342A0605|201 208|markers
P08304342A0605|226 236|HLA-F loci
P08304342A0605|257 259|kb
P08304342A0605|273 278|HLA-A
P08305058T0000|0 12|Pneumothorax
P08305058T0000|33 43|dissection
P08305058T0000|65 71|hiatus
P08306356A0000|19 32|malformations
P08306356A0000|50 54|rats
P08306356A0000|67 71|dose
P08306356A0000|75 81|X-rays
P08306356A0000|87 90|cGy
P08306356A0000|111 115|days
P08306356A0000|123 132|gestation
P08306834A0866|0 10|T2 cancers
P08306834A0866|43 50|benefit
P08306834A0866|67 78|irradiation
P08306959A0278|0 9|IFN alpha
P08306959A0278|14 36|IFN gamma inducibility
P08306959A0278|61 68|element
P08306959A0278|77 85|affinity
P08306959A0278|106 113|version
P08306959A0278|121 146|IFN gamma activation site
P08306959A0278|148 151|GAS
P08307338A0227|0 9|Mutations
P08307338A0227|25 34|gene CBP1
P08307338A0227|63 69|result
P08307338A0227|73 84|degradation
P08307338A0227|112 124|cytochrome b
P08307338A0227|126 129|cob
P08307338A0227|131 134|RNA
P08307338A0227|146 151|cells
P08307564A0233|29 34|sites
P08307564A0233|36 40|STSs
P08307564A0233|65 71|contig
P08307564A0233|75 82|density
P08307564A0233|110 112|kb
P08308008A0201|8 13|paper
P08308008A0201|35 42|binding
P08308008A0201|61 68|protein
P08308008A0201|70 74|GABP
P08308008A0201|79 98|ets sequence motifs
P08308008A0201|120 124|unit
P08308008A0201|157 167|activation
P08308008A0201|175 189|COXIV promoter
P08309726A0000|16 23|insight
P08309726A0000|33 45|pathogenesis
P08309726A0000|71 88|distress syndrome
P08309726A0000|90 94|ARDS
P08309726A0000|101 108|authors
P08309726A0000|126 139|relationships
P08309726A0000|150 167|activation status
P08309726A0000|201 212|neutrophils
P08309726A0000|214 217|PMN
P08309726A0000|220 235|cytokine levels
P08309726A0000|245 253|severity
P08309726A0000|257 268|lung injury
P08309726A0000|275 283|patients
P08309726A0000|293 297|ARDS
P08309726A0000|313 322|pneumonia
P08309726A0000|340 344|ARDS
P08309726A0000|376 384|patients
P08309726A0000|398 402|ARDS
P08309726A0000|407 416|pneumonia
P08309912A0306|0 10|Amiodarone
P08309912A0306|38 47|treatment
P08309912A0306|82 86|drug
P08309953A0776|6 13|results
P08309953A0776|31 60|dopamine receptor stimulation
P08309953A0776|74 91|dopamine agonists
P08309953A0776|113 120|pattern
P08309953A0776|124 131|effects
P08309953A0776|139 154|characteristics
P08309953A0776|162 184|reaction time response
P08309957A0000|4 15|experiments
P08309957A0000|52 65|jaw movements
P08309957A0000|77 81|rats
P08309957A0000|91 105|administration
P08309957A0000|133 148|agent reserpine
P08309975A0662|0 9|Depletion
P08309975A0662|13 21|dopamine
P08309975A0662|29 46|nucleus accumbens
P08309975A0662|65 70|shift
P08309975A0662|74 82|behavior
P08309975A0662|116 124|decrease
P08309975A0662|128 133|lever
P08309975A0662|161 169|increase
P08309975A0662|173 184|consumption
P08309975A0662|188 196|lab chow
P08312243A0177|25 34|influence
P08312243A0177|38 43|NaFe3
P08312243A0177|44 48|EDTA
P08312243A0177|76 82|levels
P08312243A0177|86 93|Na2EDTA
P08312243A0177|98 100|Zn
P08312243A0177|102 104|Cu
P08312243A0177|109 122|Ca metabolism
P08312243A0177|126 130|rats
P08312243A0177|138 151|Zn-sufficient
P08312243A0177|193 198|diets
P08314163T0000|0 8|Recovery
P08314163T0000|32 47|agranulocytosis
P08314163T0000|93 118|colony stimulating factor
P08314163T0000|120 128|rhGM-CSF
P08314163T0000|130 144|administration
P08314922A0941|10 16|system
P08314922A0941|57 74|perfusion changes
P08314922A0941|84 97|brain surface
P08314922A0941|111 124|tissue damage
P08316100A0586|4 11|neglect
P08316100A0586|15 23|Richards
P08316100A0586|26 32|theory
P08316100A0586|50 55|range
P08316100A0586|59 66|factors
P08316100A0586|146 155|influence
P08316100A0586|188 194|theory
P08316209A0000|27 33|sulfur
P08316209A0000|45 52|protein
P08316209A0000|54 58|CYS3
P08316209A0000|63 80|Neurospora crassa
P08316209A0000|94 104|expression
P08316209A0000|110 116|family
P08316209A0000|140 145|genes
P08316209A0000|158 165|enzymes
P08316209A0000|169 186|sulfur catabolism
P08316240A1068|0 8|Analysis
P08316240A1068|38 44|region
P08316240A1068|48 53|CHL15
P08316240A1068|67 75|presence
P08316240A1068|83 98|hexamer element
P08316240A1068|100 106|ACGCGT
P08316240A1068|111 132|MluI restriction site
P08316240A1068|164 174|expression
P08316240A1068|190 200|regulation
P08316240A1068|208 227|DNA synthesis genes
P08316240A1068|239 244|yeast
P08317092A0304|15 21|region
P08317092A0304|37 44|protein
P08317092A0304|69 83|helicase motif
P08317092A0304|104 110|region
P08317092A0304|115 135|RNA polymerase motif
P08317092A0304|175 183|proteins
P08317092A0304|196 219|RNA replication complex
P08317092A0304|240 246|tobamo
P08317092A0304|252 264|tobraviruses
P08317094A0778|7 11|ends
P08317094A0778|15 18|F3R
P08317094A0778|24 35|transcripts
P08317094A0778|55 56|A
P08317094A0778|68 76|sequence
P08317094A0778|80 85|TAAAG
P08317094A0778|90 92|nt
P08317094A0778|119 127|promoter
P08317094A0778|135 137|nt
P08317094A0778|156 172|initiation codon
P08319396A0448|3 5|T2
P08319396A0448|15 21|images
P08319396A0448|27 42|intensity areas
P08319396A0448|50 58|thalamus
P08319396A0448|64 72|striatum
P08319396A0448|87 91|limb
P08319396A0448|108 115|capsule
P08319396A0448|121 130|tegmentum
P08319396A0448|149 164|intensity areas
P08319396A0448|175 194|cerebellar peduncle
P08319396A0448|210 214|limb
P08319396A0448|231 238|capsule
P08319396A0448|252 256|part
P08319396A0448|273 281|peduncle
P08319396A0448|306 312|matter
P08319907A0754|10 23|rap1t alleles
P08319907A0754|46 51|cells
P08319907A0754|70 92|telomere tract lengths
P08319907A0754|112 137|telomere position effects
P08319907A0754|162 169|changes
P08319907A0754|177 181|size
P08319907A0754|186 195|structure
P08319907A0754|214 219|tract
P08320120A0361|11 26|microangiopathy
P08320120A0361|54 60|fields
P08320120A0361|84 95|capillaries
P08320120A0361|125 134|diffusion
P08320120A0361|138 156|sodium fluorescein
P08320120A0361|190 194|area
P08320120A0361|202 209|nodules
P08321199T0000|11 20|switching
P08321199T0000|40 46|states
P08321199T0000|48 51|cis
P08321199T0000|70 77|factors
P08321199T0000|88 101|establishment
P08321199T0000|105 114|silencing
P08321199T0000|122 131|HMR locus
P08321203A0840|0 14|NF-kappa B p65
P08321203A0840|16 19|p50
P08321203A0840|25 28|Rel
P08321203A0840|57 68|C/EBP alpha
P08321203A0840|70 80|C/EBP beta
P08321203A0840|86 97|C/EBP delta
P08321227A0854|40 54|culture medium
P08321227A0854|75 84|COS cells
P08321741A0396|10 15|group
P08321741A0396|30 33|BMB
P08321741A0396|55 63|progress
P08321741A0396|67 80|myelofibrosis
P08321741A0396|131 139|Myelosis
P08321741A0396|188 205|Metaplasia-AMM-in
P08321741A0396|210 211|%
P08321741A0396|219 227|patients
P08321741A0396|244 247|CML
P08321741A0396|268 280|increase-CML
P08321741A0396|291 292|%
P08322117A1019|8 15|methods
P08322117A1019|34 42|patients
P08322117A1019|65 74|pressures
P08322117A1019|96 101|cmH2O
P08322117A1019|120 125|cmH2O
P08322117A1019|135 150|Sussett formula
P08322117A1019|179 186|centile
P08322117A1019|188 194|cutoff
P08322823A0839|19 30|correlation
P08322823A0839|43 46|MFA
P08322823A0839|55 63|severity
P08322823A0839|71 84|UTS phenotype
P08323294T0000|0 57|Chicken sterol carrier protein 2/sterol carrier protein x
P08323294T0000|59 71|cDNA cloning
P08323294T0000|93 105|conservation
P08323294T0000|109 118|structure
P08323294T0000|133 143|expression
P08324107A0000|14 35|albumin concentration
P08324107A0000|45 49|g/dl
P08324107A0000|70 71|%
P08324107A0000|85 99|plasma protein
P08324280A0098|6 13|lesions
P08324280A0098|83 93|ulceration
P08324792T0000|21 27|period
P08324792T0000|44 50|pacing
P08324792T0000|66 78|infarct size
P08324792T0000|94 106|rabbit heart
P08325504A0226|8 12|RD19
P08325504A0226|17 36|RD21 mRNA synthesis
P08325504A0226|66 77|heat stress
P08325639A0129|9 16|studies
P08325639A0129|36 50|20S proteasome
P08325639A0129|66 70|core
P08325639A0129|78 81|26S
P08325639A0129|94 101|complex
P08325639A0129|141 160|proteinase activity
P08325639A0129|203 212|breakdown
P08325639A0129|216 224|proteins
P08325639A0129|236 245|ubiquitin
P08325720A0840|7 14|deficit
P08325720A0840|34 47|blood lactate
P08325720A0840|66 74|exercise
P08325720A0840|76 98|muscle enzyme activity
P08325720A0840|100 116|citrate synthase
P08325720A0840|118 149|3-hydroxyacyl-CoA-dehydrogenase
P08325720A0840|151 172|lactate dehydrogenase
P08325720A0840|175 181|number
P08325720A0840|185 203|muscle capillaries
P08325720A0840|205 206|%
P08325720A0840|209 215|fibres
P08325720A0840|219 241|muscle buffer capacity
P08325883A0368|4 12|sequence
P08325883A0368|29 41|RBP1 protein
P08325883A0368|55 61|copies
P08325883A0368|68 89|RNA recognition motif
P08325883A0368|95 114|glutamine stretches
P08325883A0368|135 141|region
P08325883A0368|161 167|region
P08325883A0368|192 205|alpha-helixes
P08327488A0839|14 17|RNA
P08327488A0839|31 39|deletion
P08327488A0839|47 50|p70
P08327488A0839|58 64|region
P08327488A0839|130 143|helper genome
P08327488A0839|202 205|RNA
P08327488A0839|232 235|p70
P08331064A0440|0 7|Release
P08331064A0440|26 34|pressure
P08331064A0440|50 53|way
P08331064A0440|68 78|resolution
P08331064A0440|98 108|structures
P08331067T0000|9 28|nucleotide sequence
P08331067T0000|36 63|bacteriophage K1F tail gene
P08331067T0000|73 97|endo-N-acylneuraminidase
P08331067T0000|99 105|endo-N
P08331067T0000|111 121|comparison
P08331067T0000|135 142|homolog
P08331067T0000|146 164|bacteriophage PK1E
P08331728A0686|0 7|Binding
P08331728A0686|11 13|U2
P08331728A0686|28 45|ribonucleoprotein
P08332033T0000|15 29|quantification
P08332033T0000|33 44|brain edema
P08332033T0000|78 92|micro-infarcts
P08332033T0000|96 100|mice
P08332033T0000|102 112|assessment
P08332033T0000|116 134|neurotropin effect
P08332492A0145|4 10|member
P08332492A0145|29 35|family
P08332492A0145|37 43|GATA-3
P08332492A0145|77 90|T lymphocytes
P08332492A0145|103 109|target
P08332492A0145|120 147|immunodeficiency virus type
P08332492A0145|151 156|HIV-1
P08332492A0145|158 167|infection
P08332492A0145|172 183|replication
P08332495A0408|20 25|level
P08332495A0408|29 41|CAT activity
P08332495A0408|64 83|lung adenocarcinoma
P08332495A0408|85 91|A549-1
P08332495A0408|93 98|cells
P08332495A0408|131 138|complex
P08332495A0408|142 159|T7 RNA polymerase
P08332495A0408|161 176|pT7-EMC-CAT DNA
P08332495A0408|181 188|DC-chol
P08332495A0408|198 207|liposomes
P08333643A0000|0 13|Pneumoscrotum
P08333643A0000|24 33|condition
P08333643A0000|55 65|discussion
P08333643A0000|78 83|texts
P08333643A0000|87 94|urology
P08334158A0660|10 20|gene codes
P08334158A0660|27 34|protein
P08334158A0660|49 65|cystein residues
P08334158A0660|72 83|arrangement
P08334158A0660|96 109|Fe/S proteins
P08334304A0473|17 22|cells
P08334304A0473|32 40|capacity
P08334304A0473|45 55|activation
P08334304A0473|63 70|pathway
P08334304A0473|79 101|peptide growth factors
P08334304A0473|109 117|addition
P08334304A0473|132 144|p21 rasVal12
P08334989A0070|24 33|mechanism
P08334989A0070|46 56|expression
P08334989A0070|65 69|gene
P08334989A0070|95 106|mouse B-myb
P08334989A0070|119 127|sequence
P08334989A0070|155 162|library
P08334989A0070|200 213|transcription
P08334989A0070|219 243|luciferase reporter gene
P08334989A0070|266 284|NIH3T3 fibroblasts
P08335710A0338|4 13|influence
P08335710A0338|30 38|strength
P08335710A0338|46 56|resolution
P08336012A0632|4 10|number
P08336012A0632|14 22|bacteria
P08336012A0632|30 34|lung
P08336012A0632|53 63|blood cell
P08336012A0632|68 82|BAL fluid cell
P08336012A0632|105 119|administration
P08336012A0632|123 125|FN
P08336543A0243|3 7|mice
P08336543A0243|21 29|families
P08336543A0243|33 44|L1 elements
P08336543A0243|54 55|A
P08336543A0243|59 60|F
P08336543A0243|68 69|V
P08336543A0243|97 102|basis
P08336543A0243|110 118|sequence
P08336543A0243|135 143|terminus
P08336698T0000|0 4|TFEC
P08336698T0000|31 38|protein
P08336698T0000|46 58|heterodimers
P08336698T0000|64 68|TFE3
P08336698T0000|97 121|transcription activation
P08336738A1273|4 14|equivalent
P08336738A1273|28 34|ligand
P08336738A1273|36 40|H-87
P08336738A1273|45 49|T-47
P08336738A1273|57 79|PSTAIRE sequence motif
P08337828A0895|8 15|results
P08337828A0895|29 42|Western blots
P08337828A0895|46 73|Autographa californica MNPV
P08337828A0895|75 81|AcMNPV
P08337828A0895|92 119|Spodoptera frugiperda cells
P08337841A0612|22 27|cells
P08337841A0612|33 38|ARV G
P08337841A0612|43 52|GNS genes
P08337841A0612|98 102|mRNA
P08337841A0612|136 154|consensus sequence
P08337841A0612|156 161|AACAG
P08337841A0612|170 175|start
P08337841A0612|183 189|G gene
P08337841A0612|213 235|polyadenylation signal
P08337841A0612|237 241|CATG
P08337841A0612|242 243|A
P08337841A0612|259 270|nucleotides
P08337841A0612|289 318|GNS protein termination codon
P08340400T0000|10 17|cloning
P08340400T0000|22 32|expression
P08340400T0000|36 41|RPE65
P08340400T0000|59 66|pigment
P08340400T0000|98 105|protein
P08342703A0966|9 14|power
P08342703A0966|19 23|mu W
P08342703A0966|58 67|flow rate
P08342703A0966|90 106|outflow pressure
P08342703A0966|114 121|product
P08342703A0966|129 138|flow rate
P08342703A0966|147 155|pressure
P08342703A0966|177 183|vessel
P08343041A0000|19 29|antibodies
P08343041A0000|50 61|infertility
P08343041A0000|68 89|hospital laboratories
P08343041A0000|112 122|antibodies
P08343216A0883|13 35|IgG subclass responses
P08343216A0883|61 75|IgG subclasses
P08343961A0000|0 21|Anterior body pattern
P08343961A0000|63 75|distribution
P08343961A0000|90 97|protein
P08343961A0000|99 102|bcd
P08343961A0000|133 138|genes
P08343961A0000|160 167|domains
P08344248A0910|0 5|GAP-N
P08344248A0910|62 68|growth
P08344248A0910|87 92|cells
P08345191A1140|4 20|peptide sequence
P08345191A1140|32 38|region
P08345191A1140|45 56|amino acids
P08345191A1140|68 78|similarity
P08345191A1140|82 87|bcl-2
P08345191A1140|132 136|gene
P08345191A1140|138 142|MCL1
P08347677A0308|4 30|phosphorylation efficiency
P08347677A0308|61 67|number
P08347677A0308|82 99|arginine residues
P08347677A0308|118 133|arginyl cluster
P08347677A0308|138 145|residue
P08347677A0308|168 174|serine
P08347677A0308|193 196|Arg
P08347677A0308|197 218|4-Ala-Ala-Ser-Val-Ala
P08347677A0308|234 243|substrate
P08347677A0308|264 272|peptides
P08347677A0308|281 283|Km
P08347677A0308|289 295|microM
P08348919T0000|0 15|Botulinum toxin
P08348919T0000|27 36|treatment
P08348919T0000|52 57|spasm
P08349104A0000|29 33|GAL1
P08349104A0000|38 49|GAL10 genes
P08349104A0000|68 76|response
P08349104A0000|84 96|availability
P08349104A0000|100 109|galactose
P08349104A0000|114 121|glucose
P08349104A0000|160 168|proteins
P08349104A0000|202 207|sites
P08349104A0000|211 215|UASG
P08349104A0450|18 25|results
P08349104A0450|37 48|experiments
P08349104A0450|66 75|TSF genes
P08349104A0450|101 108|factors
P08349104A0450|110 114|tsf1
P08349104A0450|118 132|tsf6 mutations
P08349104A0450|145 155|expression
P08349104A0450|161 166|yeast
P08349104A0450|175 191|hybrid promoters
P08349104A0450|202 206|lacZ
P08349104A0450|222 229|variety
P08349104A0450|233 251|operator sequences
P08349104A0450|276 283|defects
P08349104A0450|287 298|cell growth
P08349104A0450|300 306|mating
P08349104A0450|312 323|sporulation
P08349499A1169|0 3|Sex
P08349499A1169|7 11|calf
P08349499A1169|13 20|variate
P08349499A1169|57 62|width
P08349499A1169|66 72|muzzle
P08349499A1169|77 81|head
P08349632A0679|0 19|Sequence comparison
P08349632A0679|35 40|exons
P08349632A0679|44 45|L
P08349632A0679|50 53|L/N
P08349632A0679|57 62|PSG12
P08349632A0679|67 76|PSG12 psi
P08349632A0679|83 84|%
P08349632A0679|112 120|L/N exon
P08349632A0679|128 142|PSG12 psi gene
P08349632A0679|154 164|stop codon
P08350061A0209|4 14|mechanisms
P08350061A0209|31 41|activation
P08350061A0209|45 56|suppression
P08350061A0209|64 72|CD8 gene
P08350061A0209|105 131|T cell development program
P08350398A1616|20 22|ER
P08350398A1616|40 46|domain
P08350398A1616|50 55|gp19K
P08350398A1616|80 89|structure
P08350398A1616|139 144|alpha
P08350398A1616|151 156|alpha
P08350398A1616|159 166|domains
P08350398A1616|170 175|class
P08350398A1616|178 183|heavy
P08350398A1616|185 190|alpha
P08350398A1616|192 198|chains
P08352066A0000|26 40|beta-estradiol
P08352066A0000|42 44|E2
P08352066A0000|66 81|bone resorption
P08352066A0000|102 116|bone formation
P08352066A0000|135 139|bone
P08352066A0000|150 154|rats
P08352268A0000|18 32|erythropoietin
P08352268A0000|34 41|epoetin
P08352268A0000|94 98|i.v.
P08352268A0000|117 119|SC
P08352268A0000|121 126|route
P08355062A0000|14 22|emission
P08355062A0000|32 42|tomography
P08355062A0000|44 49|SPECT
P08355062A0000|56 92|99mTc-hexamethylpropyleneamine oxime
P08355062A0000|94 99|HMPAO
P08355062A0000|125 132|changes
P08355062A0000|145 155|blood flow
P08355062A0000|165 173|patients
P08355062A0000|195 205|impairment
P08355063A0456|4 14|rCBF ratio
P08355063A0456|45 50|lobes
P08355063A0456|54 55|%
P08355539A0133|0 7|METHODS
P08355539A0133|20 28|patients
P08355539A0133|61 69|etiology
P08355539A0133|83 88|study
P08355539A0133|104 114|antibodies
P08355539A0133|118 127|diagnosis
P08355539A0133|135 142|disease
P08355539A0133|172 180|etiology
P08355539A0133|184 187|EAA
P08355539A0133|220 228|etiology
P08355539A0133|232 235|EAT
P08355539A0133|259 264|study
P08355539A0133|297 305|etiology
P08355539A0133|309 312|EAI
P08355680A0824|0 4|2-AP
P08355680A0824|28 33|rises
P08355680A0824|37 54|mRNA accumulation
P08355680A0824|106 122|HIV-1 constructs
P08355680A0824|130 139|increases
P08355680A0824|159 163|gene
P08355680A0824|173 184|gamma-actin
P08355680A0824|188 221|glucose 6-phosphate dehydrogenase
P08355696A0236|4 16|UV induction
P08355696A0236|20 25|c-jun
P08355696A0236|45 65|UV response elements
P08355696A0236|90 99|sequences
P08355696A0236|122 128|region
P08355697A0000|0 29|Protein tyrosine phosphatases
P08355697A0000|31 35|PTPs
P08355697A0000|52 76|protein tyrosine kinases
P08355697A0000|78 82|PTKs
P08355697A0000|105 115|regulation
P08355697A0000|119 134|cell activation
P08355697A0000|136 142|growth
P08355697A0000|148 163|differentiation
P08355857A1293|3 12|elevation
P08355857A1293|25 33|patients
P08355857A1293|39 40|%
P08355857A1293|45 55|subgroup A
P08355857A1293|66 73|patient
P08355857A1293|81 92|subgroup B.
P08356792A1275|15 27|p21X protein
P08356792A1275|40 50|N-terminus
P08356792A1275|54 58|Rex1
P08356792A1275|81 87|levels
P08356792A1275|93 97|data
P08356792A1275|112 116|p21X
P08356792A1275|147 151|mRNA
P08356792A1275|192 202|proviruses
P08356792T0000|0 22|HTLV-1 gene expression
P08356792T0000|36 46|proviruses
P08356792T0000|62 73|T-cell line
P08356944A0589|32 60|sodium lauryl sulfate method
P08356944A0589|75 99|hemoglobin concentration
P08356944A0589|118 129|alternative
P08356944A0589|137 161|cyanmethemoglobin method
P08356944A0589|177 187|generation
P08356944A0589|197 203|wastes
P08357834A0285|2 12|comparison
P08357834A0285|30 50|amino acid sequences
P08357834A0285|68 84|PKC-delta clones
P08357834A0285|94 97|rat
P08357834A0285|102 118|mouse homologues
P08357834A0285|139 145|degree
P08357834A0285|149 168|sequence divergence
P08357834A0285|175 185|% homology
P08357834A0285|208 214|degree
P08357834A0285|218 239|sequence conservation
P08357834A0285|266 284|PKC family members
P08357834A0285|305 317|counterparts
P08360112T0036|0 3|XII
P08360180A1041|19 31|barley PSI-K
P08360180A1041|36 41|PSI-G
P08360180A1041|60 74|PSI-K sequence
P08360180A1041|108 114|degree
P08360180A1041|118 128|similarity
P08360180A1041|168 172|gene
P08360180A1041|210 220|progenitor
P08360180A1041|234 248|cyanobacterial
P08361754A0733|13 17|hand
P08361754A0733|23 33|structures
P08361754A0733|47 53|domain
P08361754A0733|97 105|proteins
P08361755A0734|12 22|conditions
P08361755A0734|24 37|transfections
P08361755A0734|43 48|cDNAs
P08361755A0734|56 70|NF-kappa B p50
P08361755A0734|75 96|serum response factor
P08361755A0734|98 101|SRF
P08361755A0734|114 120|factor
P08361755A0734|121 122|s
P08361755A0734|138 149|Tax binding
P08361755A0734|157 172|NF-kappa B site
P08361755A0734|181 189|CArG box
P08361761A0174|18 23|v-Rel
P08361761A0174|47 57|expression
P08361761A0174|65 81|reporter plasmid
P08361761A0174|102 119|Sp1 binding sites
P08361761A0174|145 171|chicken embryo fibroblasts
P08361761A0174|173 177|CEFs
P08361761A0174|192 197|v-Rel
P08361761A0174|229 234|sites
P08361761A0174|236 241|v-Rel
P08361761A0174|257 267|expression
P08361761A0174|275 291|reporter plasmid
P08361761A0174|311 338|immunodeficiency virus type
P08361761A0174|342 347|HIV-1
P08361761A0174|363 369|repeat
P08361761A0174|371 374|LTR
P08361761A0174|389 410|kappa B binding sites
P08361761A0174|457 474|Sp1 binding sites
P08363332A0365|17 26|recording
P08363332A0365|41 49|activity
P08363332A0365|59 84|surface electrocardiogram
P08363332A0365|104 108|apex
P08363332A0365|114 120|bundle
P08363332A0365|133 139|atrium
P08363332A0365|150 155|sinus
P08363332A0365|182 198|mapping catheter
P08363332A0365|243 262|activation sequence
P08363332A0365|270 275|heart
P08365944A1537|0 10|CONCLUSION
P08365944A1537|31 39|analysis
P08365944A1537|61 69|efficacy
P08365944A1537|77 83|course
P08365944A1537|100 111|Mitomycin-C
P08365944A1537|116 130|5-fluorouracil
P08365944A1537|144 155|association
P08365944A1537|171 183|radiotherapy
P08365944A1537|210 215|boost
P08366034A0637|12 21|existence
P08366034A0637|28 45|cysteine residues
P08366034A0637|47 65|carboxymethylation
P08366034A0637|80 89|formation
P08366034A0637|109 124|disulfide bonds
P08366034A0637|158 163|cells
P08367388T0035|28 36|syndrome
P08367388T0035|51 59|syndrome
P08367487A1014|22 30|addition
P08367487A1014|43 56|17S U2 snRNPs
P08367487A1014|69 82|12S U2 snRNPs
P08367487A1014|87 109|HeLa splicing extracts
P08367487A1014|135 144|U2 snRNPs
P08367487A1014|195 205|antibodies
P08367487A1014|225 247|mRNA-splicing activity
P08367487A1014|255 263|extracts
P08369887A0781|0 11|Differences
P08369887A0781|15 23|profiles
P08369887A0781|27 46|viscosity variables
P08369887A0781|55 64|subgroups
P08369887A0781|68 71|EAD
P08369887A0781|75 86|RA patients
P08370119A0642|31 35|exon
P08370119A0642|53 55|bp
P08370119A0642|86 95|sequences
P08370119A0642|99 107|addition
P08370119A0642|126 139|reading frame
P08370119A0642|183 214|muscle cell AT1a receptor cDNAs
P08370119A1521|0 8|Deletion
P08370119A1521|26 41|promoter region
P08370119A1521|57 81|transcription start site
P08370119A1521|97 105|TATA box
P08370119A1521|131 138|ability
P08370119A1521|151 159|elements
P08370119A1521|169 182|transcription
P08370119A1521|190 205|luciferase cDNA
P08370275A0290|4 14|chimpanzee
P08370275A0290|44 51|numeral
P08370275A0290|61 68|testing
P08370275A0290|88 92|pair
P08370275A0290|106 112|chimps
P08370275A0290|123 133|preference
P08371650T0000|0 11|Dissipation
P08371650T0000|15 32|claudication pain
P08371650T0000|48 60|implications
P08371650T0000|75 83|training
P08371713T0000|12 22|transcript
P08371713T0000|48 67|endothelin receptor
P08371713T0000|73 82|rat brain
P08371936T0000|15 35|Independence Measure
P08371936T0000|51 56|study
P08371936T0000|60 69|clinician
P08371936T0000|74 86|self ratings
P08373274A0546|0 11|Polymyxin B
P08373274A0546|42 55|week postburn
P08373274A0546|59 64|doses
P08373274A0546|100 111|endotoxemia
P08373972A0335|0 4|SvO2
P08374753A0335|15 30|relaxation time
P08374753A0335|32 34|T2
P08374753A0335|49 70|diffusion coefficient
P08374753A0335|74 79|water
P08375651T0000|30 40|chain gene
P08375651T0000|42 59|clathrin function
P08375651T0000|92 100|organism
P08376397A0788|4 23|binding specificity
P08376397A0788|32 39|protein
P08376397A0788|70 73|E2F
P08376397A0788|82 88|number
P08376397A0788|99 108|E2F sites
P08376397A0788|112 123|competitors
P08376796A0172|15 25|VH regions
P08376796A0172|42 52|antibodies
P08376796A0172|70 79|attention
P08376796A0172|109 115|status
P08376796A0172|135 138|IgG
P08376796A0172|146 150|IgG1
P08376796A0172|159 163|IgG3
P08376796A0172|165 168|mAb
P08376796A0172|176 183|B cells
P08376796A0172|199 206|subject
P08376796A0172|210 217|patient
P08376796A0172|241 258|diabetes mellitus
P08376796A0172|265 272|patient
P08376796A0172|278 281|SLE
P08376796A0172|309 321|efficiencies
P08376796A0172|324 330|number
P08376796A0172|344 348|self
P08376796A0172|361 363|Ag
P08377199A1432|24 29|patch
P08377199A1432|52 64|conformation
P08377199A1432|72 76|site
P08377199A1432|104 115|recognition
P08378082A1031|6 14|findings
P08378082A1031|36 46|cross-talk
P08378082A1031|55 65|RB protein
P08378082A1031|70 76|p21ras
P08378082A1031|97 111|cell phenotype
P08378082A1031|143 149|states
P08380736A0895|9 13|mRNA
P08380736A0895|37 45|splicing
P08380736A0895|69 76|protein
P08380736A0895|93 107|amino terminus
P08380896A0938|0 8|Kinetics
P08380896A0938|16 26|inhibition
P08380896A0938|47 64|polymerase domain
P08380896A0938|83 94|replication
P08380896A0938|111 130|preinitiation stage
P08381121A0773|10 31|transmembrane regions
P08381121A0773|61 67|domain
P08382296A0766|0 10|McCann III
P08382296A0766|12 14|F.
P08382300A0341|6 16|cell lines
P08382300A0341|35 42|ability
P08382300A0341|58 69|replication
P08382300A0341|97 107|VP5 mutant
P08382300A0341|130 133|VP5
P08382300A0341|138 142|VP23
P08382300A0341|148 155|mutants
P08382303A0507|4 6|E1
P08382303A0507|15 30|transport motif
P08382303A0507|58 64|animal
P08382303A0507|75 91|papillomaviruses
P08382303A0507|120 126|region
P08382303A0507|142 150|E1 genes
P08382303T0000|4 26|E1 replication protein
P08382303T0000|37 56|papillomavirus type
P08382303T0000|88 107|localization signal
P08382303T0000|124 152|p34cdc2 phosphorylation site
P08382359A0469|3 8|order
P08382359A0469|32 38|extent
P08382359A0469|44 55|interaction
P08382359A0469|76 91|tumor induction
P08382359A0469|99 104|virus
P08382359A0469|139 154|point mutations
P08382359A0469|187 195|sequence
P08382359A0469|205 214|T antigen
P08382359A0469|248 259|experiments
P08382359A0469|282 289|effects
P08382359A0469|318 328|activities
P08382359A0469|341 356|tumor induction
P08382769A0924|21 33|conservation
P08382769A0924|37 48|nucleotides
P08382769A0924|78 89|consequence
P08382769A0924|99 103|role
P08382769A0924|127 146|recognition element
P08382769A0924|155 168|SRP54 protein
P08382778A0891|2 8|region
P08382778A0891|24 38|protein shares
P08382778A0891|49 57|homology
P08382778A0891|75 81|region
P08382778A0891|85 96|Raf kinases
P08382778A0891|100 107|feature
P08382778A0891|125 130|TFIIE
P08382778A0891|137 158|transcription factors
P08383129A0776|18 42|mass polypeptide complex
P08383129A0776|72 92|antigen presentation
P08383129A0776|105 113|peptides
P08383129A0776|129 145|protein antigens
P08383129A0776|193 206|T-lymphocytes
P08383129A0776|214 226|cell surface
P08383214A0389|10 18|cleavage
P08383214A0389|22 24|RT
P08383214A0389|28 43|Trp-595-Tyr-596
P08383214A0389|47 50|Pol
P08383214A0389|70 74|form
P08383214A0389|98 112|RNase H domain
P08383217A0357|32 43|amino acids
P08383217A0357|47 52|Bel-1
P08383217A0357|83 97|Bel-1 activity
P08383217A0357|151 168|activation domain
P08383217A0357|172 176|VP16
P08383287A0611|20 27|element
P08383287A0611|43 51|estrogen
P08383287A0611|56 86|thyroid hormone responsiveness
P08383287A0611|121 145|hormone response element
P08383323A0000|8 18|activation
P08383323A0000|22 29|T cells
P08383323A0000|52 59|signals
P08383492A1205|64 74|aa stretch
P08383492A1205|83 89|region
P08383492A1205|97 108|differences
P08383492A1205|126 131|terms
P08383492A1205|148 156|affinity
P08383492A1205|175 194|cytochrome oxidases
P08383492A1205|206 224|c-type cytochromes
P08383526A0591|16 21|genes
P08383526A0591|37 46|structure
P08383526A0591|57 73|receptor protein
P08383526A0591|94 98|exon
P08383622T0000|0 8|Identity
P08383622T0000|12 16|GABP
P08383622T0000|22 27|NRF-2
P08383622T0000|44 53|activator
P08383622T0000|57 86|cytochrome oxidase expression
P08383622T0000|107 111|role
P08383622T0000|119 139|ETS domain activator
P08383622T0000|149 158|promoters
P08383850A0206|15 20|study
P08383850A0206|22 41|beta-funaltrexamine
P08383850A0206|43 51|beta-FNA
P08383850A0206|57 68|naltrindole
P08383850A0206|70 73|NTI
P08383850A0206|76 93|nonequilibrium mu
P08383850A0206|156 166|withdrawal
P08383850A0206|192 196|rats
P08384309A0000|24 47|region/helix-loop-helix
P08384309A0000|55 70|dioxin receptor
P08384309A0000|80 99|signal transduction
P08384309A0000|103 109|dioxin
P08384309A0000|111 146|2,3,7,8-tetrachlorodibenzo-p-dioxin
P08384309A0000|184 203|DNA binding protein
P08384309A0000|230 242|target genes
P08384309A0000|257 281|dioxin response elements
P08385131A0000|4 9|alpha
P08385131A0000|24 32|receptor
P08385131A0000|34 44|alpha 2AAR
P08385131A0000|62 69|variety
P08385131A0000|73 82|effectors
P08385131A0000|87 96|pertussis
P08385131A0000|125 133|proteins
P08385337A0282|2 21|sequence comparison
P08385337A0282|34 64|CCAAT/enhancer binding protein
P08385337A0282|66 71|C/EBP
P08385337A0282|73 92|consensus sequences
P08385337A0282|100 118|DNA binding region
P08385337A0282|123 138|leucine zippers
P08385337A0282|148 153|bZIP1
P08385337A0282|158 163|bZIP2
P08385337A0282|178 184|region
P08385581A0126|13 18|genes
P08385581A0126|20 26|REC114
P08385581A0126|55 59|data
P08385581A0126|73 79|REC114
P08385581A0126|102 120|recombination gene
P08385581A0126|140 148|function
P08385581A0126|152 159|mitosis
P08386279A1621|4 28|transactivation function
P08386279A1621|32 37|EBNA2
P08386279A1621|63 67|HeLa
P08386279A1621|79 88|cell line
P08386279A1621|110 113|EBV
P08386279A1621|118 133|HIV-1 infection
P08386279A1621|143 148|cells
P08386279A1621|163 188|HIV-1 promoter activation
P08386280T0000|0 8|Mutation
P08386280T0000|16 35|C/EBP binding sites
P08386280T0000|43 61|Rous sarcoma virus
P08386280T0000|76 82|repeat
P08386280T0000|87 100|gag enhancers
P08386317T0000|8 30|protein phosphatase 2A
P08386317T0000|48 62|protein kinase
P08386317T0000|80 84|CREB
P08386317T0000|99 103|CREB
P08386317T0000|120 131|stimulation
P08386318A1102|13 17|IL-6
P08386318A1102|28 35|JRE-IL6
P08386318A1102|60 67|pathway
P08386318A1102|90 106|protein kinase C
P08386318A1102|129 135|kinase
P08386318A1102|137 139|Ca
P08386318A1102|169 176|kinases
P08386318A1102|178 181|Ras
P08386318A1102|183 188|Raf-1
P08386318A1102|193 199|NF-IL6
P08386318A1102|201 211|C/EBP beta
P08386319A1229|0 8|Mutation
P08386319A1229|43 51|tyrosine
P08386319A1229|56 74|threonine residues
P08386319A1229|78 83|Mpk1p
P08386319A1229|100 113|phenylalanine
P08386319A1229|118 125|alanine
P08386319A1229|159 173|Mpk1p function
P08386592A0089|0 25|Growth factor stimulation
P08386592A0089|55 61|change
P08386592A0089|85 93|mobility
P08386592A0089|109 116|complex
P08386592A0089|143 158|phosphorylation
P08386592A0089|166 171|Elk-1
P08386592A0089|183 189|region
P08386592A0089|201 211|activation
P08386592A0089|220 222|kd
P08386592A0089|232 244|Elk-1 kinase
P08386637A1220|3 11|contrast
P08386637A1220|19 28|situation
P08386637A1220|42 47|cells
P08386637A1220|59 67|exposure
P08386637A1220|75 82|agonist
P08386637A1220|87 88|h
P08386637A1220|114 124|regulation
P08386637A1220|144 145|%
P08386637A1220|153 162|receptors
P08387155A1248|17 23|effect
P08387155A1248|50 55|c-Jun
P08387155A1248|78 82|topo
P08387155A1248|98 103|c-Fos
P08387155A1248|125 129|topo
P08387155A1248|149 154|assay
P08387507A1015|4 14|regulation
P08387507A1015|18 23|Myf-5
P08387507A1015|28 41|MyoD function
P08387507A1015|62 69|pathway
P08387507A1015|102 109|signals
P08387507A1015|123 128|serum
P08387507A1015|141 163|peptide growth factors
P08387507A1015|189 196|nucleus
P08387507A1015|225 232|factors
P08387507A1015|258 282|myoblast differentiation
P08387519A0000|38 43|level
P08387519A0000|50 67|desmin expression
P08387519A0000|90 94|pair
P08387519A0000|111 119|enhancer
P08387519A0000|151 159|myotubes
P08387519A0000|183 198|gene expression
P08387519A0000|202 211|myoblasts
P08387662A0302|6 13|surgery
P08387662A0302|15 28|patients self
P08387662A0302|77 88|medications
P08387662A0302|105 112|placebo
P08387662A0302|114 121|codeine
P08387662A0302|125 127|mg
P08387662A0302|133 142|ibuprofen
P08387662A0302|147 149|mg
P08387662A0302|162 166|pain
P08387662A0302|196 205|intensity
P08387743A0624|0 11|Replacement
P08387743A0624|43 49|region
P08387743A0624|69 76|mutants
P08387743A0624|100 107|element
P08387743A0624|134 144|expression
P08387743A0624|155 178|Mn-superoxide dismutase
P08387994A0980|4 22|orf61 gene product
P08387994A0980|57 65|promoter
P08387994A0980|90 101|integration
P08387994A0980|121 130|attB site
P08388496A1117|0 10|Expression
P08388496A1117|26 30|LCLs
P08388496A1117|58 79|virus producer status
P08388496A1117|91 102|consequence
P08388496A1117|125 132|passage
P08388496A1117|162 181|BamHI-A transcripts
P08388496A1117|213 220|B cells
P08388496A1117|230 233|day
P08388496A1117|256 265|infection
P08388496A1117|287 296|BamHI-C/W
P08388496A1117|351 356|mRNAs
P08388510A0891|0 8|Analysis
P08388510A0891|12 43|cell surface immunofluorescence
P08388510A0891|60 69|UL28 gene
P08388510A0891|90 100|expression
P08388510A0891|110 123|glycoproteins
P08388510A0891|131 138|surface
P08388510A0891|151 156|cells
P08388543A1263|22 30|receptor
P08388543A1263|32 43|Y977F/Y989F
P08388543A1263|45 48|PLC
P08388543A1263|63 68|sites
P08388543A1263|92 95|Ras
P08388543A1263|112 122|activation
P08388543A1263|126 142|protein kinase C
P08388543A1263|147 167|calcium mobilization
P08388543A1263|182 188|effect
P08388543A1263|196 209|GDP/GTP state
P08388543A1263|213 216|Ras
P08388543A1263|225 234|cell line
P08388600A0000|0 18|Estrogen treatment
P08388600A0000|27 32|doses
P08388600A0000|64 71|stature
P08388600A0000|97 102|girls
P08389074A1227|0 9|Mutations
P08389074A1227|25 35|C-terminus
P08389074A1227|39 47|EIAV Tat
P08389074A1227|62 73|RNA binding
P08389074A1227|78 105|activation domain functions
P08389074A1227|118 125|effects
P08389074A1227|151 160|structure
P08389365A1344|5 16|observation
P08389365A1344|51 64|repair system
P08389365A1344|87 88|d
P08389365A1344|89 93|GATC
P08389365A1344|95 103|sequence
P08389365A1344|114 124|correction
P08389453A0193|0 22|Uracil DNA glycosylase
P08389453A0193|45 49|step
P08389453A0193|57 71|repair pathway
P08389453A0193|107 113|uracil
P08389453A0193|119 129|duplex DNA
P08390120A0785|17 23|trials
P08390120A0785|42 50|question
P08390120A0785|79 86|options
P08390120A0785|95 102|quality
P08390120A0785|106 110|life
P08390665A0000|0 22|Lithium phthalocyanine
P08390665A0000|24 28|LiPc
P08390665A0000|35 44|prototype
P08390665A0000|56 66|generation
P08390665A0000|112 124|crystallites
P08390665A0000|174 182|electron
P08390665A0000|196 214|resonance oximetry
P08390747A0586|8 14|report
P08390747A0586|32 40|genetics
P08390747A0586|48 54|region
P08390747A0586|65 80|hep syn gB gene
P08390747A0586|105 114|syncytial
P08390747A0586|130 140|phenotypes
P08390747A0586|147 150|syn
P08390831A0143|0 10|Recipients
P08390831A0143|22 31|leukaemia
P08390831A0143|41 50|remission
P08390831A0143|70 79|leukaemia
P08390831A0143|97 102|phase
P08390831A0143|125 129|risk
P08390831A0143|154 160|stages
P08390831A0143|170 183|risk patients
P08391534A0828|0 7|Elledge
P08391534A0828|9 11|P.
P08391748A0452|0 5|Drugs
P08391748A0452|26 27|%
P08391748A0452|63 75|contractions
P08391748A0452|83 91|patients
P08391748A0452|119 135|QRS prolongation
P08391748A0452|162 177|QT prolongation
P08391748A0452|184 185|%
P08391748A0452|189 197|patients
P08391748A0452|217 233|QRS prolongation
P08391748A0452|246 247|%
P08391748A0452|275 290|QT prolongation
P08391748A0452|307 308|%
P08391748A0452|336 352|QRS prolongation
P08391748A0452|379 394|QT prolongation
P08392221A0449|0 6|Losses
P08392221A0449|27 36|procedure
P08392221A0449|73 92|estrogen conjugates
P08392221A0449|110 115|steps
P08392221A0449|156 165|standards
P08392221A0449|173 182|compounds
P08392221A0449|193 205|matairesinol
P08392221A0449|207 217|enterodiol
P08392221A0449|219 232|enterolactone
P08392221A0449|234 242|daidzein
P08392221A0449|244 265|O-desmethylangolensin
P08392221A0449|267 272|equol
P08392221A0449|278 287|genistein
P08392623A1374|0 20|IE2-IE2 interactions
P08392623A1374|38 44|domain
P08392623A1374|84 89|motif
P08392623A1374|107 117|C terminus
P08392623A1374|121 124|IE2
P08392623A1374|134 145|amino acids
P08393143A1281|4 14|Sp1 region
P08393143A1281|63 66|TRE
P08393143A1281|80 90|tat factor
P08394019A0695|0 13|Precipitation
P08394019A0695|20 39|GST fusion proteins
P08394019A0695|51 58|Fyn SH2
P08394019A0695|60 63|SH3
P08394019A0695|69 84|SH2/SH3 domains
P08394019A0695|99 110|PI 3-kinase
P08394019A0695|136 146|SH3 domain
P08394019A0695|150 153|Fyn
P08394255A0000|2 7|sheep
P08394255A0000|19 31|cDNA library
P08394255A0000|47 60|pcDNA1 vector
P08394255A0000|81 86|probe
P08394255A0000|100 125|polymerase chain reaction
P08394255A0000|127 130|PCR
P08394255A0000|159 170|kb fragment
P08394255A0000|178 181|rat
P08394255A0000|194 215|hormone receptor cDNA
P08394464A1080|13 25|Rev proteins
P08394464A1080|50 56|masses
P08394464A1080|70 73|kDa
P08394464A1080|92 96|p2/2
P08394464A1080|101 105|p176
P08394464A1080|113 116|p20
P08394464A1080|141 148|species
P08394862A0565|6 11|group
P08394862A0565|14 22|patients
P08394862A0565|33 44|CMV disease
P08394862A0565|48 53|group
P08394862A0565|56 63|patient
P08394862A0565|74 87|CMV hepatitis
P08395004A0141|4 11|ability
P08395004A0141|15 29|spt2 mutations
P08395004A0141|62 74|interference
P08395004A0141|89 129|delta promoter insertion his-4-912 delta
P08395004A0141|149 157|increase
P08395004A0141|171 187|HIS4 mRNA levels
P08395004A0558|8 20|localization
P08395004A0558|25 54|protein sequence similarities
P08395004A0558|74 91|SPT2/SIN1 protein
P08395004A0558|137 149|protein HMG1
P08395010T0000|31 37|heptad
P08395010T0000|41 56|thyroid hormone
P08395010T0000|70 84|acid receptors
P08395010T0000|102 111|responses
P08395010T0000|125 136|heterodimer
P08395010T0000|145 164|homodimer formation
P08395014A1364|8 20|interactions
P08395014A1364|29 33|BCK2
P08395014A1364|44 62|pathway components
P08395014A1364|78 92|BCK2 functions
P08395014A1364|105 119|pathway branch
P08395014A1364|125 129|PPZ1
P08395014A1364|134 138|PPZ2
P08395654T0000|14 20|factor
P08395654T0000|42 50|receptor
P08395654T0000|66 76|expression
P08395654T0000|84 102|rat aromatase gene
P08395654T0000|114 121|tissues
P08395681A0388|24 35|differences
P08395681A0388|54 58|HPV5
P08395681A0388|63 71|HPV8 E7s
P08395681A0388|84 92|HPV16 E7
P08395681A0388|116 118|E7
P08395681A0388|124 138|reading frames
P08395681A0388|187 197|activities
P08395681A0388|203 218|binding ability
P08395681A0388|228 236|products
P08395681A0388|242 264|retinoblastoma protein
P08395681A0388|266 268|RB
P08395681A0388|280 304|complementation activity
P08395681A0388|324 345|adenovirus E1A mutant
P08396120A0690|4 33|rhaB transcription start site
P08396120A0690|68 73|start
P08396120A0690|77 88|translation
P08396261A0388|8 13|lines
P08396261A0388|17 25|evidence
P08396261A0388|48 65|growth inhibition
P08396261A0388|82 94|PKA subunits
P08396261A0388|99 103|cAMP
P08396261A0388|114 123|phenotype
P08396261A0388|140 144|cAMP
P08396261A0388|171 177|strain
P08396261A0388|195 211|cyclase activity
P08396261A0388|221 232|growth rate
P08396261A0388|242 255|transformants
P08396261A0388|281 285|cAMP
P08396261A0388|308 314|growth
P08396261A0388|337 344|RI cDNA
P08396261A0388|369 376|RI cDNA
P08396261A0388|388 398|RI protein
P08396261A0388|412 424|cAMP binding
P08396261A0388|457 466|phenotype
P08396261A0388|486 490|BL21
P08396261A0388|491 494|DE3
P08396261A0388|496 501|cells
P08396261A0388|527 542|C alpha protein
P08396657A0452|0 3|Liu
P08396657A0452|5 7|B.
P08396667T0000|0 7|BCR-ABL
P08396667T0000|18 27|oncogenes
P08396667T0000|44 52|patterns
P08396667T0000|63 71|lymphoma
P08396667T0000|92 110|lymphocyte subsets
P08396713A0305|6 17|experiments
P08396713A0305|48 52|form
P08396713A0305|60 68|receptor
P08396713A0305|91 99|extracts
P08396713A0305|103 108|cells
P08396713A0305|122 157|2,3,7,8-tetrachlorodibenzo-p-dioxin
P08396713A0305|159 163|TCDD
P08396713A0305|178 197|Ah receptor protein
P08396713A0305|202 206|ARNT
P08396713A0305|226 244|heat shock protein
P08396749A1112a|0 15|LDL cholesterol
P08396749A1112a|62 68|mmol/l
P08396749A1112a|77 82|weeks
P08396749A1112a|86 97|simvastatin
P08396749A1112a|99 100|P
P08396749A1112a|115 120|apo B
P08396749A1112a|156 161|mg/dl
P08396749A1112a|163 164|P
P08396749A1112b|0 15|LDL cholesterol
P08396749A1112b|62 68|mmol/l
P08396749A1112b|77 82|weeks
P08396749A1112b|86 97|simvastatin
P08396749A1112b|99 100|P
P08396749A1112b|115 120|apo B
P08396749A1112b|156 161|mg/dl
P08396749A1112b|163 164|P
P08396913A1379|14 21|element
P08396913A1379|39 43|part
P08396913A1379|68 72|cell
P08396913A1379|87 97|expression
P08396913A1379|105 113|DGK gene
P08397123T0000|10 18|activity
P08397123T0000|47 54|element
P08397123T0000|68 104|corticotropin-releasing hormone gene
P08397123T0000|130 138|features
P08397123T0000|160 171|transcripts
P08399970T0000|6 33|bioencapsulation technology
P08399970T0000|48 58|inoculants
P08400240A0166|10 31|hypersensitivity site
P08400240A0166|35 38|HS2
P08400240A0166|49 69|locus control region
P08400240A0166|71 74|LCR
P08400240A0166|83 100|gamma-globin gene
P08400240A0166|102 110|A gamma*
P08400240A0166|145 155|transcript
P08400240A0166|192 209|gamma-globin mRNA
P08400928A0318|0 13|INTERVENTIONS
P08400928A0318|15 23|Patients
P08400928A0318|37 46|treatment
P08400928A0318|52 89|levodopa/dopa decarboxylase inhibitor
P08400928A0318|97 100|arm
P08400928A0318|105 148|levodopa/decarboxylase inhibitor/selegiline
P08400928A0318|152 163|combination
P08400928A0318|165 168|arm
P08400928A0318|176 189|bromocriptine
P08400928A0318|191 194|arm
P08401570A0828|27 40|binding sites
P08401570A0828|45 69|transcription factor Sp1
P08401570A0828|95 104|sequences
P08401570A0828|142 151|enhancers
P08401570A0828|163 168|sites
P08401570A0828|173 194|transcription factors
P08401614A0187|7 11|bean
P08401614A0187|29 35|family
P08401614A0187|39 44|genes
P08401614A0187|54 57|PAL
P08401614A0187|75 80|genes
P08401614A0187|82 86|PAL2
P08401614A0187|91 95|PAL3
P08401614A0187|151 161|mRNA level
P08401614A0187|165 177|bean tissues
P08403245A1234|0 28|Plasma thromboxane B2 levels
P08403245A1234|42 47|group
P08403245A1234|83 90|piglets
P08403804A0754|28 47|regression analysis
P08403804A0754|57 66|magnesium
P08403804A0754|96 120|cyclosporin trough level
P08403804A0754|131 142|cholesterol
P08403804A0754|154 170|serum creatinine
P08403804A0754|172 176|time
P08403804A0754|183 193|transplant
P08403804A0754|201 205|dose
P08403804A0754|209 220|cyclosporin
P08405433A0000|23 36|growth factor
P08405433A0000|41 47|IGF-II
P08405433A0000|49 53|gene
P08405433A0000|68 77|promoters
P08405433A0000|79 81|P1
P08405433A0000|83 85|P2
P08405433A0000|87 89|P3
P08405433A0000|94 96|P4
P08406004A0691|23 42|transfection assays
P08406004A0691|44 48|PU.1
P08406004A0691|65 84|reporter constructs
P08406004A0691|100 114|JB cis-element
P08406004A0691|124 134|activation
P08406004A0691|181 189|sequence
P08406004A0691|212 219|portion
P08406004A0691|223 227|PU.1
P08406352A0172|0 13|Army veterans
P08406352A0172|27 40|fever vaccine
P08406352A0172|59 76|hepatitis B virus
P08406352A0172|89 97|controls
P08406352A0172|121 126|study
P08406352A0172|137 145|veterans
P08406352A0172|166 175|carcinoma
P08406352A0172|179 205|Veterans Affairs hospitals
P08406352A0172|219 227|controls
P08406352A0172|233 240|respect
P08406352A0172|244 251|receipt
P08406352A0172|268 275|vaccine
P08406419A0155|39 49|antibodies
P08406419A0155|53 70|hepatitis C virus
P08406419A0155|92 99|testing
P08406419A0155|101 105|RIBA
P08406419A0155|109 137|Ortho Diagnostic Systems Inc
P08406419A0155|139 147|Westwood
P08406419A0155|149 151|MA
P08406497A0000|0 7|Defects
P08406497A0000|11 20|fibrillin
P08406497A0000|22 26|FBN1
P08406497A0000|31 53|glycoprotein component
P08406497A0000|75 86|microfibril
P08406497A0000|94 109|Marfan syndrome
P08407784A0850|21 25|recJ
P08407784A0850|27 34|strains
P08407784A0850|36 50|srjA mutations
P08407784A0850|96 106|phenotypes
P08408194T0000|15 20|roles
P08408194T0000|28 49|membrane-cytoskeleton
P08408194T0000|54 62|cadherin
P08408194T0000|82 90|adhesion
P08408194T0000|115 117|Na
P08408194T0000|119 120|K
P08408194T0000|124 144|ATPase distributions
P08408194T0000|158 167|epithelia
P08408825A0000|9 28|lupus erythematosus
P08408825A0000|59 73|autoantibodies
P08408825A0000|82 84|Ro
P08408825A0000|89 100|La antigens
P08408841A0281|8 21|abnormalities
P08408841A0281|41 52|mutagenesis
P08408841A0281|73 86|abnormalities
P08408841A0281|103 112|mutations
P08408963A0048|10 12|L.
P08409284A0262|10 20|absorption
P08409284A0262|24 35|amino acids
P08409284A0262|43 54|NBB carrier
P08409284A0262|68 79|amino acids
P08409284A0262|86 87|Y
P08409284A0262|89 95|system
P08409284A0262|109 120|amino acids
P08409284A0262|131 142|PHE carrier
P08409284A0262|191 196|stage
P08409284A0262|207 216|diarrhoea
P08409284A0262|224 231|cholera
P08409593A0357|3 7|CFDN
P08409593A0357|9 13|AMPC
P08409593A0357|18 21|MNZ
P08409593A0357|52 60|activity
P08409593A0357|69 78|H. pylori
P08409593A0357|96 100|AMPC
P08409593A0357|130 138|activity
P08409593A0357|150 154|time
P08410042T0000|18 25|disease
P08410042T0000|42 59|dura mater grafts
P08410042T0000|61 67|report
P08410042T0000|75 80|cases
P08410097A0356|7 21|mean intensity
P08410097A0356|25 30|CLTPA
P08410097A0356|58 85|regression coefficient beta
P08410097A0356|94 95|p
P08410097A0356|124 137|oxygen uptake
P08410097A0356|139 143|beta
P08410097A0356|152 153|p
P08410097A0356|192 209|plasma fibrinogen
P08410097A0356|243 253|covariates
P08411024T0000|11 17|people
P08411024T0000|40 46|option
P08411024T0000|58 82|fibrosis carrier testing
P08411276A0302|2 9|patient
P08411276A0302|20 31|PIC patient
P08411276A0302|54 63|mechanism
P08411276A0302|67 73|injury
P08411276A0302|84 90|coding
P08411276A0302|102 124|Trauma Score variables
P08411276A0302|126 150|Glascow Coma Scale score
P08411276A0302|161 175|blood pressure
P08411276A0302|189 193|rate
P08411276A0302|211 214|age
P08411276A0302|221 246|Severity Characterization
P08411276A0302|250 256|Trauma
P08411276A0302|259 264|ASCOT
P08411276A0302|310 311|A
P08411276A0302|313 314|B
P08411276A0302|320 321|C
P08411276A0302|327 343|ASCOT components
P08411276A0302|356 364|injuries
P08412120A0839|0 4|Skin
P08412120A0839|9 19|bowel TPO2
P08412120A0839|32 35|DO2
P08412120A0839|52 53|P
P08412620A0688|2 8|region
P08412620A0688|27 29|bp
P08412620A0688|48 73|transcription start point
P08412620A0688|77 81|virB
P08412620A0688|125 135|activation
P08412620A0688|144 152|promoter
P08412620A0688|156 160|VirF
P08412662A0333|19 25|cosmid
P08412662A0333|37 40|DNA
P08412662A0333|65 69|site
P08412662A0333|73 93|transposon insertion
P08412662A0333|97 103|257DH4
P08412662A0333|123 126|Tn5
P08412662A0333|137 154|kb EcoRI fragment
P08412665A0000|4 15|scr regulon
P08412665A0000|19 25|pUR400
P08412665A0000|56 67|scr regulon
P08412665A0000|71 81|Klebsiella
P08412665A0000|93 100|KAY2026
P08412665A0000|146 155|repressor
P08412665A0000|157 161|ScrR
P08413186A0077|23 33|mechanisms
P08413186A0077|51 61|regulation
P08413186A0077|138 145|factors
P08413186A0077|157 167|expression
P08413186A0077|195 210|reductase genes
P08413186A0077|236 243|enzymes
P08413186A0077|251 258|pathway
P08413186A1199|4 13|Ntl1 gene
P08413186A1199|37 41|copy
P08413186A1199|57 83|N. plumbaginifolia species
P08413205A0733|10 34|transfection experiments
P08413205A0733|49 63|Pax-8 isoforms
P08413205A0733|70 71|b
P08413205A0733|81 82|c
P08413205A0733|87 88|d
P08413205A0733|109 122|transcription
P08413205A0733|130 138|promoter
P08413205A0733|154 160|copies
P08413205A0733|180 200|recognition sequence
P08413209A0159|19 24|third
P08413209A0159|32 39|protein
P08413209A0159|71 91|motif characteristic
P08413209A0159|107 115|proteins
P08413215A0327|21 28|ability
P08413215A0327|40 59|NF-kappa B subunits
P08413215A0327|85 98|transcription
P08413215A0327|109 122|IL-8 promoter
P08413223A0847|14 20|copies
P08413223A0847|28 53|IL-1 beta NF-kappa B site
P08413223A0847|92 97|virus
P08413223A0847|101 109|promoter
P08413223A0847|116 123|element
P08413223A0847|144 157|phorbol ester
P08413223A0847|191 206|gene expression
P08413239A0490|34 45|sequence CA
P08413239A0490|47 48|N
P08413239A0490|49 60|3-10AGTNNAA
P08413239A0490|75 84|plant Pol
P08413239A0490|97 110|U snRNA genes
P08413239A0490|136 149|end formation
P08413239A0490|153 167|U2 transcripts
P08413239A0490|188 198|vertebrate
P08413239A0490|202 205|box
P08413239A0490|229 237|mutation
P08413260A1437|6 13|results
P08413260A1437|28 38|Rb protein
P08413260A1437|64 73|component
P08413260A1437|74 75|s
P08413260A1437|84 88|cell
P08413260A1437|106 115|machinery
P08413260A1437|123 131|G2 phase
P08413274A0452|0 4|MDBP
P08413274A0452|10 14|HeLa
P08413274A0452|19 29|Raji cells
P08413274A0452|49 58|complexes
P08413274A0452|64 86|X-box oligonucleotides
P08413274A0452|141 151|MDBP sites
P08413291A1473|11 15|mice
P08413291A1473|30 53|rat TnI-CAT fusion gene
P08413291A1473|68 76|reporter
P08413291A1473|106 112|muscle
P08414410A0270|0 7|METHODS
P08414410A0270|27 31|eyes
P08414410A0270|57 61|eyes
P08414410A0270|81 87|fields
P08414410A0270|110 114|eyes
P08414410A0270|133 146|field defects
P08414410A0270|196 204|measures
P08414410A0270|219 225|damage
P08414410A0270|239 244|nerve
P08414410A0270|249 266|nerve fiber layer
P08414502A0244|20 30|hypothesis
P08414502A0244|63 72|regulator
P08414502A0244|84 95|p53 protein
P08414502A0244|102 105|DNA
P08414502A0244|120 133|transcription
P08414502A0244|145 154|promoters
P08415637A0000|4 27|ADP-ribosylation factor
P08415637A0000|29 32|ARF
P08415637A0000|34 40|family
P08415637A0000|56 67|subfamilies
P08415637A0000|75 90|RAS superfamily
P08415637A0000|108 114|weight
P08415637A0000|127 135|proteins
P08415637A0000|137 147|G proteins
P08415643A0555|4 11|E1 gene
P08415643A0555|40 46|intron
P08415643A0555|54 58|gene
P08415643A0555|63 67|RCC1
P08415643A0555|71 78|protein
P08415643A0555|94 99|onset
P08415643A0555|103 110|mitosis
P08415712A1153|8 30|Southern blot analysis
P08415712A1153|35 53|chromosome mapping
P08415712A1153|66 71|GPRK6
P08415712A1153|106 111|genes
P08415712A1153|123 134|chromosomes
P08415712A1153|182 186|GPRK
P08415712A1153|204 228|Huntington disease locus
P08415712A1153|232 242|chromosome
P08416952A0956|10 26|labeling studies
P08416952A0956|48 61|co-expression
P08416952A0956|65 71|nmt72p
P08416952A0956|85 103|protein substrates
P08416952A0956|107 112|Nmt1p
P08416952A0956|151 156|Leu99
P08416952A0956|163 175|substitution
P08416952A0956|185 194|reduction
P08416952A0956|202 211|acylation
P08416952A0956|232 250|protein substrates
P08416977A0892|6 17|CTD kinases
P08416977A0892|30 35|CTDK1
P08416977A0892|40 45|CTDK2
P08416977A0892|67 81|chromatography
P08416977A0892|85 92|Mono Q.
P08417117A0592|9 13|mRNA
P08417117A0592|29 31|kb
P08417117A0592|56 65|abundance
P08417330A0149|34 51|promoter fragment
P08417330A0149|53 63|oligo31/32
P08417330A0149|81 104|heat shock inducibility
P08417330A0149|125 148|CYC1-lacZ reporter gene
P08417330A0149|167 169|N.
P08417331A0745|4 12|sequence
P08417331A0745|20 29|HIR1 gene
P08417331A0745|49 56|protein
P08417331A0745|68 75|repeats
P08417331A0745|81 86|motif
P08417331A0745|100 114|G beta subunit
P08417331A0745|126 136|transducin
P08417331A0745|146 151|yeast
P08417331A0745|168 177|repressor
P08417331A0745|179 183|Tup1
P08417349A1633|13 17|data
P08417349A1633|31 42|replication
P08417349A1633|57 66|templates
P08417349A1633|116 127|replication
P08417349A1633|139 156|mutation fixation
P08418183A0000|12 19|factors
P08418183A0000|53 65|transmission
P08418183A0000|75 110|T cell leukemia/lymphoma virus type
P08418183A0000|114 120|HTLV-I
P08418183A0000|135 142|couples
P08418183A0000|159 180|Miyazaki Cohort Study
P08418183A0000|189 197|November
P08418183A0000|207 212|April
P08418183A0000|235 242|husband
P08418183A0000|264 265|H
P08418183A0000|268 272|wife
P08418183A0000|287 288|W
P08418183A0000|295 296|H
P08418183A0000|298 299|W
P08418183A0000|305 306|H
P08418183A0000|308 309|W
P08418183A0000|320 321|H
P08418183A0000|323 324|W
P08419318A1695|0 4|Biol
P08419333A0126|20 30|expression
P08419333A0126|39 56|DNA repair enzyme
P08419333A0126|101 106|clone
P08419338A0273|0 2|L.
P08419338A0273|4 10|Stange
P08419338A0273|12 14|G.
P08419338A0273|16 25|Markovich
P08419338A0273|27 29|D.
P08419338A0273|31 36|Biber
P08419338A0273|38 40|J.
P08419338A0273|42 48|Testar
P08419338A0273|50 52|X.
P08419338A0273|54 61|Zorzano
P08419338A0273|63 65|A.
P08419338A0273|67 74|Palacin
P08419338A0273|76 78|M.
P08419338A0273|84 89|Murer
P08419338A0273|91 93|H.
P08419376A0357|4 23|nucleotide sequence
P08419376A0357|31 35|gene
P08419376A0357|47 58|polypeptide
P08419376A0357|66 77|amino acids
P08419376A0357|84 87|kDa
P08419376A0357|125 132|domains
P08420230A0544|0 5|SAECG
P08420230A0544|7 23|echocardiography
P08420230A0544|28 48|thallium-201 imaging
P08420230A0544|77 82|month
P08420230A0544|99 110|angioplasty
P08420571A1880|17 22|PACE4
P08420571A1880|27 30|PC4
P08421295A0365|5 20|fusion proteins
P08421295A0365|42 51|complexes
P08421295A0365|65 75|DNA duplex
P08421295A0365|90 94|CTGT
P08421295A0365|98 122|4ACAG consensus sequence
P08421295A0365|130 144|LexA repressor
P08421687A0397|4 27|selenocysteine residues
P08421823A1041|0 11|CONCLUSIONS
P08421823A1041|18 38|protein S deficiency
P08421823A1041|68 76|patients
P08421823A1041|90 97|absence
P08421823A1041|127 136|condition
P08421897A0000|16 22|decade
P08421897A0000|34 39|types
P08421897A0000|65 74|sequences
P08421897A0000|106 112|genome
P08421897A0000|128 152|stringency hybridization
P08421897A0000|163 173|DNA probes
P08421897A0000|200 223|animal retrovirus genes
P08421910A0599|7 17|components
P08421910A0599|27 36|complexes
P08421910A0599|52 57|TRBPs
P08421910A0599|59 62|p30
P08421910A0599|64 67|p37
P08421910A0599|69 72|p46
P08421910A0599|74 77|p50
P08421910A0599|83 86|p56
P08421910A0599|120 127|TAR RNA
P08421910A0599|149 171|uv cross-linking assay
P08422975A1205|23 32|necessity
P08422975A1205|37 44|editing
P08422975A1205|48 74|kinetoplastid mitochondria
P08422975A1205|82 91|formation
P08422975A1205|108 113|mRNAs
P08423831A0523|4 7|use
P08423831A0523|16 21|model
P08423831A0523|73 79|issues
P08423831A0523|95 103|diseases
P08423831A0523|139 143|sets
P08423831A0523|147 157|parameters
P08425050A0898|22 28|repeat
P08425050A0898|46 50|rpeA
P08425050A0898|61 68|repeats
P08425050A0898|97 107|PE operons
P08425050A0898|121 125|date
P08425050A0898|140 148|sequence
P08425221A0000|32 47|tyrosine kinase
P08425221A0000|56 59|BPK
P08425221A0000|61 85|B cell progenitor kinase
P08425221A0000|114 120|stages
P08425221A0000|128 137|B lineage
P08425221A0000|153 158|cells
P08427501A0221|6 17|differences
P08427501A0221|30 36|groups
P08427501A0221|74 89|enzyme activity
P08427501A0221|107 122|enzyme activity
P08427501A0221|173 179|polyps
P08427501A0221|194 199|types
P08427501A0221|210 216|polyps
P08428722A1123|20 28|analysis
P08428722A1123|34 43|variables
P08428722A1123|79 87|survival
P08428722A1123|89 114|blood urea nitrogen level
P08428722A1123|116 154|serum aspartate aminotransferase level
P08428722A1123|197 208|peritonitis
P08428722A1123|210 213|age
P08428722A1123|226 231|score
P08428722A1123|236 241|ileus
P08428750T0000|0 12|Localization
P08428750T0000|31 35|gene
P08428750T0000|63 74|protein CLP
P08428750T0000|84 104|chromosome 10p13-ter
P08428907A0653|13 25|stage larvae
P08428907A0653|31 45|OBP transcript
P08428907A0653|108 111|RNA
P08428940A1763|9 15|mutant
P08428940A1763|49 56|hexamer
P08428940A1763|60 62|PR
P08428940A1763|86 95|occupancy
P08428940A1763|104 108|MerR
P08428940A1763|113 127|RNA polymerase
P08428940A1763|141 147|result
P08428940A1763|179 189|initiation
P08428940A1763|193 202|merR mRNA
P08428952A0399|9 18|L-plastin
P08428952A0399|42 47|types
P08428952A0399|67 72|cells
P08428952A0399|92 98|origin
P08428952A0399|119 129|expression
P08428952A0399|154 167|tumorigenesis
P08428952A0399|177 184|tissues
P08428952A1957|20 28|evidence
P08428952A1957|34 41|fimbrin
P08428952A1957|62 77|plastin isoform
P08428952A1957|118 124|levels
P08428952A1957|138 147|intestine
P08428953A1718|5 13|promoter
P08428953A1718|44 54|expression
P08428953A1718|62 89|reporter beta-galactosidase
P08428953A1718|98 107|frequency
P08428953A1718|123 131|colonies
P08428953A1718|147 152|cells
P08428953A1718|166 175|L-plastin
P08428953A1718|195 203|contrast
P08428953A1718|210 218|promoter
P08428953A1718|257 265|colonies
P08428953A1718|276 287|fibroblasts
P08428953A1718|311 320|frequency
P08428953A1718|337 347|activation
P08428953A1718|363 371|colonies
P08428953A1718|401 412|fibroblasts
P08428953A1718|435 455|L-plastin expression
P08428965A1868|4 13|half-life
P08428965A1868|35 58|CBP/tk binding activity
P08428965A1868|91 93|h.
P08428965A1868|94 102|ABSTRACT
P08428965A1868|120 125|WORDS
P08429019A0735|4 9|DNase
P08429019A0735|12 21|footprint
P08429019A0735|41 56|silencer region
P08429019A0735|80 86|repeat
P08429019A0735|107 112|motif
P08429019A0735|114 121|epsilon
P08429019A0735|135 137|bp
P08429019A0735|145 151|shares
P08429019A0735|159 164|bases
P08429019A0735|174 199|GATA-1 consensus sequence
P08429019A2022|13 23|competitor
P08429019A2022|39 61|YY1 consensus sequence
P08429019A2022|75 92|protein B binding
P08429019A2022|102 112|competitor
P08429019A2022|134 164|yeast ABF-1 consensus sequence
P08429019A2022|174 182|ABSTRACT
P08429019A2022|200 205|WORDS
P08429020A0495|4 8|gene
P08429020A0495|24 29|exons
P08429020A0495|38 45|introns
P08429020A0495|57 66|kilobases
P08429020A0495|70 73|DNA
P08429020A0495|95 108|reading frame
P08429020A0495|113 125|glycoprotein
P08429020A0495|158 162|exon
P08429568A0000|0 18|Rhizobium meliloti
P08429568A0000|25 41|plasmid pRmeGR4b
P08429568A0000|54 90|nodulation competitiveness locus nfe
P08429568A0000|111 132|nodulation efficiency
P08429568A0000|149 156|ability
P08429568A0000|160 170|strain GR4
P08429568A0000|174 187|alfalfa roots
P08430087A0467|13 20|ability
P08430087A0467|36 40|beta
P08430087A0467|48 60|gamma chains
P08430087A0467|96 102|assays
P08430087A0467|106 125|beta gamma activity
P08430087A0467|143 160|membrane extracts
P08430087A0467|177 186|fractions
P08430087A0467|201 210|Sf9 cells
P08430095A0161|5 11|report
P08430095A0161|26 40|identification
P08430095A0161|46 50|gene
P08430095A0161|62 70|function
P08430095A0161|72 76|SMD1
P08430095A0161|104 109|PRP38
P08430095A0913|6 10|data
P08430095A0913|21 26|Smd1p
P08430095A0913|41 50|component
P08430095A0913|67 85|splicing apparatus
P08430095A0913|92 98|factor
P08430095A0913|102 118|snRNA maturation
P08430095A0913|123 132|stability
P08431100A0108|5 10|study
P08431100A0108|39 56|motor performance
P08431100A0108|91 99|children
P08431100A0108|112 117|years
P08431100A0108|128 132|loss
P08431100A0108|136 149|consciousness
P08431100A0108|166 171|hours
P08431100A0108|186 200|children group
P08431100A0108|213 216|age
P08431100A0108|221 224|sex
P08432137A0000|16 26|parameters
P08432137A0000|35 54|adenosine deaminase
P08432137A0000|56 60|PADA
P08432137A0000|80 88|patients
P08432137A0000|95 115|PADA/serum ADA ratio
P08432137A0000|117 123|P/SADA
P08432137A0000|129 134|cases
P08432137A0000|145 153|lysozyme
P08432137A0000|155 159|PLYS
P08432137A0000|165 170|cases
P08432137A0000|177 197|PLYS/serum LYS ratio
P08432137A0000|199 205|P/SLYS
P08432137A0000|211 216|cases
P08432137A0000|231 247|interferon gamma
P08432137A0000|249 252|IFN
P08432137A0000|258 263|cases
P08432137A0000|281 288|ability
P08432137A0000|326 335|effusions
P08432137A0000|341 347|others
P08432526A0580|6 11|exons
P08432526A0580|43 59|sequencing cDNAs
P08432526A0580|72 111|polymerase chain reaction amplification
P08432526A0580|117 140|fibroblast cDNA library
P08432696A1117|0 8|Deletion
P08432696A1117|16 25|apeA gene
P08432696A1117|50 58|deletion
P08432696A1117|68 79|proteinases
P08432696A1117|81 89|protease
P08432696A1117|97 113|aminopeptidase N
P08432696A1117|133 139|effect
P08432696A1117|143 154|cell growth
P08432696A1117|170 175|media
P08435755A0938|3 13|Experiment
P08435755A0938|16 40|scopolamine hydrobromide
P08435755A0938|54 59|mg/kg
P08435755A0938|85 86|h
P08435755A0938|110 121|stimulation
P08435755A0938|133 136|rat
P08435755A0938|148 163|stage-3 seizure
P08435755A1078|0 3|PNT
P08435755A1078|5 8|ADD
P08435755A1078|13 16|BSS
P08435755A1078|32 37|stage
P08435755A1078|41 49|kindling
P08435755A1078|51 64|kindling rate
P08435755A1078|73 80|stage-3
P08435755A1078|88 96|seizures
P08435755A1078|98 116|seizure parameters
P08435755A1078|130 137|stage-3
P08435755A1078|179 185|values
P08435755A1078|213 218|group
P08435794A0658|0 11|CONCLUSIONS
P08435885A0787|21 32|correlation
P08435885A0787|41 72|pyridinium cross-link excretion
P08435885A0787|77 107|thyroid hormone concentrations
P08437521A0000|0 9|Mutations
P08437521A0000|47 55|residues
P08437521A0000|81 90|activator
P08437521A0000|106 115|areA gene
P08437521A0000|127 157|nitrogen metabolite repression
P08437521A0000|173 181|nidulans
P08437521A0000|215 222|ability
P08437521A0000|230 242|areA product
P08437521A0000|255 265|expression
P08437521A0000|274 279|genes
P08437521A0000|286 298|areA control
P08437737A0100|0 15|Naval personnel
P08437737A0100|27 36|standards
P08437737A0100|41 44|%BF
P08437737A0100|74 78|duty
P08438584A0524|5 22|promoter activity
P08438584A0524|44 52|promoter
P08438584A0524|60 62|C1
P08438584A0524|67 74|C2 ORFs
P08438584A0524|76 86|C1-C2 gene
P08438584A0524|100 108|promoter
P08438584A0524|116 122|V1 ORF
P08438584T0000|4 12|activity
P08438584T0000|20 41|coat protein promoter
P08438584T0000|61 73|mosaic virus
P08438584T0000|101 120|C1-C2 gene products
P08439564A0883|4 33|amino acid sequence alignment
P08439564A0883|37 39|TC
P08439564A0883|62 82|Cbl binding proteins
P08439564A0883|84 87|rat
P08439564A0883|98 104|factor
P08439564A0883|112 128|transcobalamin I
P08439564A0883|133 152|porcine haptocorrin
P08439564A0883|170 171|%
P08439564A0883|180 188|homology
P08439597A0000|11 24|communication
P08439597A0000|66 84|enzyme immunoassay
P08439597A0000|86 90|FEIA
P08439597A0000|124 141|fluoroimmunoassay
P08439597A0000|150 163|determination
P08439597A0000|167 178|thyrotropin
P08439597A0000|188 199|blood spots
P08439597A0176|4 14|evaluation
P08439597A0176|51 63|study design
P08439597A0176|77 90|blood samples
P08439597A0176|102 119|screening centres
P08440238T0000|2 8|region
P08440238T0000|16 26|C-terminus
P08440238T0000|30 40|adenovirus
P08440238T0000|45 56|E1a protein
P08440238T0000|73 84|association
P08440238T0000|101 115|phosphoprotein
P08440238T0000|147 157|modulation
P08440238T0000|161 168|T24-ras
P08440238T0000|178 192|transformation
P08440238T0000|194 207|tumorigenesis
P08440238T0000|212 222|metastasis
P08440688A1509|6 13|studies
P08440688A1509|36 43|G alpha
P08440688A1509|46 51|genes
P08440688A1509|81 94|LLC-PK1 cells
P08440688A1509|103 109|growth
P08440688A1509|111 126|differentiation
P08440688A1509|132 147|hormone signals
P08440720A1404|0 10|Constructs
P08440720A1404|38 48|PfCPK cDNA
P08440720A1404|99 104|level
P08440720A1404|138 145|protein
P08441379A0912|20 36|proIL-1 beta cap
P08441379A0912|51 57|region
P08441379A0912|98 110|proIL-1 beta
P08441379A0912|126 131|virus
P08441379A0912|135 152|enhancer elements
P08441379A0912|184 193|monocytes
P08441379A0912|202 212|HeLa cells
P08441379A0912|251 271|IL-1 beta expression
P08441394A1297|11 17|PC-PLC
P08441394A1297|23 32|component
P08441394A1297|38 65|signal transduction pathway
P08441394A1297|77 90|transcription
P08441394A1297|94 99|c-fos
P08441394A1297|104 108|junB
P08441394A1297|132 137|c-myc
P08441394A1297|160 169|PKC-delta
P08441394A1297|174 188|Ras activation
P08441411A1260|22 33|splenocytes
P08441411A1260|35 51|Gfi-1 expression
P08441411A1260|73 74|h
P08441411A1260|81 92|stimulation
P08441411A1260|115 121|levels
P08441411A1260|131 132|h
P08441411A1260|185 191|events
P08441411A1260|212 223|interaction
P08441411A1260|227 231|IL-2
P08441411A1260|241 249|receptor
P08441411A1260|270 280|transition
P08441411A1260|290 292|G1
P08441411A1260|300 307|S phase
P08441411A1260|315 325|cell cycle
P08441423A0145|39 43|GCD6
P08441423A0145|48 58|GCD7 genes
P08441423A0145|80 88|products
P08441423A0145|113 129|GCN4 translation
P08441423A0145|150 160|conditions
P08441869A0334|4 21|plateau MO2 value
P08441869A0334|55 63|relation
P08442384A0430|35 42|protein
P08442384A0430|50 61|amino acids
P08442384A0430|80 93|reading frame
P08442384A0430|95 99|uORF
P08442384A0430|115 121|leader
P08442384A0430|152 170|amino acid peptide
P08442384T0000|4 28|SCH9 protein kinase mRNA
P08442384T0000|48 54|leader
P08442384T0000|73 86|reading frame
P08443122A0657|3 11|contrast
P08443122A0657|15 22|T cells
P08443122A0657|27 60|fibroblasts PILOT gene expression
P08443122A0657|79 85|signal
P08443122A0657|87 90|PMA
P08443122A0657|115 118|CyA
P08443339A1374|14 26|localization
P08443339A1374|30 33|GUS
P08443339A1374|43 60|promoter function
P08443339A1374|64 78|leaf epidermis
P08443339A1374|80 89|mesophyll
P08443339A1374|103 110|bundles
P08443339A1374|119 125|cortex
P08443339A1374|139 147|cylinder
P08443339A1374|155 159|root
P08443340A0522|3 8|order
P08443340A0522|34 53|expression patterns
P08443340A0522|80 96|promoter regions
P08443340A0522|122 136|glucanase gene
P08443340A0522|144 162|beta-glucuronidase
P08443340A0522|164 167|GUS
P08443340A0522|169 182|reporter gene
P08443340A0522|196 206|expression
P08443340A0522|216 226|constructs
P08443340A0522|241 255|tobacco plants
P08443341A0384|0 22|Southern blot analysis
P08443341A0384|29 35|probes
P08443341A0384|48 56|portions
P08443341A0384|76 87|B. napus MA
P08443341A0384|92 106|MB cDNA clones
P08443341A0384|119 138|MA type myrosinases
P08443341A0384|170 175|genes
P08443341A0384|183 202|MB type myrosinases
P08443341A0384|231 236|genes
P08443341A0384|240 248|B. napus
P08444184A0245|0 9|Sudomoina
P08444184A0245|11 13|A.
P08444344A0000|0 12|Zinc fingers
P08444344A0000|14 16|Zf
P08444344A0000|42 47|motif
P08444344A0000|83 91|proteins
P08444345A0403|19 23|EFIA
P08444345A0403|26 36|amino acid
P08444345A0403|38 40|aa
P08444345A0403|42 50|sequence
P08444345A0403|56 57|%
P08444345A0403|71 79|rat EFIA
P08444345A0403|87 88|%
P08444345A0403|108 120|EFIA/DbpB/YB
P08444345A0403|123 136|family member
P08444345A0403|149 158|protein B
P08444345A0403|160 164|DbpB
P08445299T0000|0 6|Effect
P08445299T0000|19 31|insufflation
P08445299T0000|35 47|deferoxamine
P08445299T0000|57 71|ozone toxicity
P08445299T0000|75 79|rats
P08445655A1009|0 12|Localization
P08445655A1009|20 35|insertion locus
P08445655A1009|43 55|yeast genome
P08445655A1009|60 83|complementation studies
P08445655A1009|144 153|mutations
P08445729A0657|0 11|Replacement
P08445729A0657|19 34|spacer sequence
P08445729A0657|51 55|ARMs
P08445729A0657|71 78|stretch
P08445729A0657|82 90|sequence
P08445729A0657|104 115|RNA binding
P08445792A0469|0 4|Type
P08445792A0469|42 47|forms
P08445792A0469|49 52|IIA
P08445792A0469|57 60|IIB
P08445792A0469|98 105|species
P08445792A0469|123 129|stages
P08445792A0469|142 149|species
P08446579A0784|12 39|transcription factor Gal-ER
P08446579A0784|89 93|cell
P08446579A0784|108 117|variation
P08446579A0784|139 156|activating domain
P08446579A0784|164 188|herpesvirus protein VP16
P08446579A0784|198 208|C terminus
P08446579A1210|14 22|fos gene
P08446579A1210|54 60|levels
P08446579A1210|72 74|hr
P08446579A1210|78 95|estrogen addition
P08447005T0001|0 11|Elimination
P08447005T0001|27 55|influenzae type b meningitis
P08447005T0001|62 74|introduction
P08447005T0001|78 89|vaccination
P08449133A0578|0 14|Endosonography
P08449133A0578|35 50|tumor extension
P08449133A0578|58 67|T2 tumors
P08449133A0578|72 81|T3 tumors
P08449133A0578|93 102|T4 tumors
P08449943A0225|15 20|study
P08449943A0225|46 55|mechanism
P08449943A0225|59 65|action
P08449943A0225|69 78|8-Cl-cAMP
P08449943A0225|86 96|regulation
P08449943A0225|106 121|kinase isozymes
P08449943A0225|125 130|HL-60
P08449943A0225|151 165|leukemia cells
P08449978A0000|0 8|Analysis
P08449978A0000|12 33|cell cycle regulation
P08449978A0000|49 54|yeast
P08449978A0000|116 130|protein kinase
P08449978A0000|132 137|Cdc28
P08449978A0000|149 156|changes
P08449978A0000|160 168|activity
P08449978A0000|181 191|cell cycle
P08449978A0000|221 227|groups
P08449978A0000|231 238|cyclins
P08449978A0000|268 273|times
P08449986A0455|12 18|clones
P08449986A0455|44 49|cDNAs
P08449986A0455|54 63|MMI alpha
P08449986A0455|83 94|mouse brain
P08450015A0175|4 10|method
P08450015A0175|32 41|isolation
P08450015A0175|45 55|oxiracetam
P08450015A0175|69 77|standard
P08450015A0175|83 89|plasma
P08450015A0175|93 115|solid-phase extraction
P08450015A0175|129 138|formation
P08450015A0175|148 178|n-propyl carbamate derivatives
P08451187A0267|28 39|differences
P08451187A0267|60 73|ars sequences
P08451331T0000|0 8|Pathways
P08451331T0000|31 36|bulbs
P08451331T0000|71 83|hypothalamus
P08451331T0000|112 122|aggression
P08451331T0000|126 130|mice
P08453101A0128|0 16|Pokeweed mitogen
P08453101A0128|18 21|PWM
P08453101A0128|59 78|c-jun messenger RNA
P08453101A0128|80 84|mRNA
P08453101A0128|86 92|levels
P08453101A0128|96 103|T cells
P08453950A0498|10 27|seizure induction
P08453950A0498|29 33|MABP
P08453950A0498|51 56|mm Hg
P08453950A0498|61 70|brain pHi
P08453950A0498|103 106|min
P08453950A0498|128 133|level
P08453950A0498|140 141|h
P08453950A0498|143 144|P
P08454077A0956|3 11|contrast
P08454077A0956|13 17|rats
P08454077A0956|28 35|U74500A
P08454077A0956|39 58|mg/kg i.v. infusion
P08454077A0956|73 76|min
P08454077A0956|86 103|revascularisation
P08454077A0956|124 128|GMBF
P08454077A0956|140 151|reperfusion
P08454077A0956|153 155|PI
P08454077A0956|159 162|min
P08454077A0956|186 189|min
P08454077A0956|213 216|min
P08454077A0956|236 237|p
P08454077A0956|249 257|controls
P08454077A0956|262 269|normals
P08454077A0956|285 299|muscle salvage
P08454077A0956|301 304|GMV
P08454077A0956|308 309|%
P08454077A0956|328 335|muscles
P08454077A0956|337 338|p
P08454077A0956|350 358|controls
P08454077A0956|377 379|NS
P08454077A0956|385 392|normals
P08454077A0956|399 410|h ischaemia
P08454077A0956|413 421|ABSTRACT
P08454077A0956|439 444|WORDS
P08454591A0692|0 10|Sequencing
P08454591A0692|29 37|fragment
P08454591A0692|57 63|region
P08454591A0692|71 80|TSG6 gene
P08454591A0692|106 120|CAAT sequences
P08454591A0692|130 154|transcription start site
P08454591A1322|4 10|region
P08454591A1322|24 36|inducibility
P08454591A1322|40 44|IL-1
P08454591A1322|48 51|TNF
P08454591A1322|53 62|positions
P08454591A1322|95 108|binding sites
P08454591A1322|113 118|IRF-1
P08454591A1322|127 131|AP-1
P08454591A1322|137 144|NF-IL-6
P08454858A0285|0 8|Ig-alpha
P08454858A0285|13 20|Ig-beta
P08454858A0285|50 59|structure
P08454858A0285|71 82|amino acids
P08454858A0285|102 111|associate
P08454858A0285|129 138|effectors
P08454858A0285|185 204|signal transduction
P08455598A0000|8 15|mutants
P08455598A0000|63 76|alpha * cells
P08455598A0000|88 111|a/alpha aar1-6 genotype
P08455598A0000|124 144|alpha mating ability
P08455598A0000|156 170|mating ability
P08455598A0000|176 182|result
P08455598A0000|188 194|defect
P08455598A0000|198 206|a1-alpha
P08455598A0000|209 219|repression
P08455611A0000|26 37|interaction
P08455611A0000|62 66|zeta
P08455611A0000|69 84|globin promoter
P08455611A0000|93 105|alpha globin
P08455611A0000|117 124|element
P08455611A0000|126 131|HS-40
P08455611A0000|144 146|kb
P08455611A0000|163 167|zeta
P08455611A0000|170 181|globin gene
P08455611A0154|26 42|expression assay
P08455611A0154|48 53|HS-40
P08455611A0154|78 86|enhancer
P08455611A0154|102 106|zeta
P08455611A0154|109 133|globin promoter activity
P08455611A0154|137 147|K562 cells
P08455611A0154|162 171|cell line
P08455611A0154|198 204|origin
P08455623A0630|8 15|results
P08455623A0630|35 47|23S pre-rRNA
P08455623A0630|67 74|species
P08455623A0630|87 96|depletion
P08455623A0630|135 148|proteins NOP1
P08455623A0630|153 157|GAR1
P08455623A0630|168 173|snr10
P08455623A0630|181 187|strain
P08455629A0335|0 9|Breitbart
P08455629A0335|11 13|L.
P08456378A0134|5 10|study
P08456378A0134|25 36|feasibility
P08456378A0134|60 76|lymphangiography
P08456378A0134|95 104|technique
P08456378A0134|117 122|model
P08456879A0000|0 9|OBJECTIVE
P08456879A0000|15 22|purpose
P08456879A0000|57 71|concentrations
P08456879A0000|75 89|serum cotinine
P08456879A0000|117 122|blood
P08457205A0240|9 28|amino acid sequence
P08457205A0240|61 68|protein
P08457205A0240|88 107|% sequence identity
P08457205A0240|113 122|sequences
P08457205A0240|144 151|G alpha
P08457205A0240|159 166|G alpha
P08457205A0240|169 174|cDNAs
P08457291A0170|0 9|Estradiol
P08457291A0170|29 39|expression
P08457291A0170|51 66|proto-oncogenes
P08457291A0170|116 123|regions
P08457291A0170|140 154|c-fos oncogene
P08458660A0855|0 8|Air lead
P08458660A0855|43 51|variable
P08458849A0364|17 27|regulation
P08458849A0364|31 49|flaN transcription
P08458849A0364|71 76|sigma
P08458849A0364|80 88|promoter
P08458849A0364|97 109|ftr elements
P08458849A0364|136 160|transcription start site
P08458849A0364|169 173|ftr2
P08458849A0364|179 183|+120
P08458849A0364|185 189|ftr3
P08458906A0827|2 14|micrograms/l
P08458906A0827|31 36|urine
P08458906A0827|74 81|persons
P08459012T0000|8 15|dimelia
P08459012T0000|21 31|deficiency
P08459012T0000|39 44|tibia
P08459465A0257|17 22|study
P08459465A0257|45 64|energy expenditures
P08459465A0257|71 79|patients
P08459465A0257|95 106|calorimetry
P08459465A0257|134 152|energy expenditure
P08459465A0257|186 194|equation
P08459465A0257|216 234|energy expenditure
P08459465A0257|254 278|energy expenditure times
P08459465A0257|283 298|activity factor
P08459465A0257|306 319|stress factor
P08460270A0205|24 34|infections
P08460270A0205|47 53|larvae
P08460346A0350|71 76|study
P08460918A0252|0 5|Group
P08460918A0252|40 48|patients
P08460918A0252|50 55|group
P08460918A0252|96 104|patients
P08460918A0252|123 133|impairment
P08460918A0252|146 155|bilirubin
P08460918A0252|160 173|mumol liter-1
P08460918A0252|175 195|alkaline phosphatase
P08460918A0252|201 211|IU liter-1
P08460918A0252|213 241|gamma-glutamyltranspeptidase
P08460918A0252|247 257|IU liter-1
P08460918A0252|260 265|group
P08460918A0252|319 327|patients
P08460918A0252|358 376|hyperbilirubinemia
P08460918A0252|383 396|mumol liter-1
P08461946A0386|20 26|change
P08461946A0386|33 44|improvement
P08461946A0386|60 68|findings
P08461946A0386|70 79|t1/2 time
P08461946A0386|87 101|split function
P08461946A0386|109 117|patients
P08461946A0386|121 122|%
P08461981A0882|15 19|need
P08461981A0882|27 34|animals
P08461981A0882|48 54|months
P08461981A0882|63 68|study
P08461981A0882|80 102|regeneration phenomena
P08461981A0882|121 125|rats
P08463284A1531|8 12|beta
P08463284A1531|16 19|PKC
P08463284A1531|26 40|p34cdc2 kinase
P08463284A1531|75 81|lamina
P08463284A1531|93 102|stability
P08463284A1531|110 120|cell cycle
P08463320A1219|8 42|copper-phenanthroline footprinting
P08463320A1219|57 89|gel shift assembly intermediates
P08463320A1219|123 129|G4oric
P08463320A1219|145 158|SSB tetramers
P08463320A1219|187 195|addition
P08463320A1219|204 217|SSB tetramers
P08463320A1219|229 238|formation
P08463320A1219|251 260|structure
P08463485T0000|0 7|Effects
P08463485T0000|24 42|endotoxin infusion
P08463485T0000|62 78|oxytocin release
P08464056A0000|0 6|Finger
P08464056A0000|27 42|finger proteins
P08464056A0000|44 52|FAX-ZFPs
P08464056A0000|67 76|subfamily
P08464056A0000|89 103|C2H2 type ZFPs
P08464056A0000|107 121|Xenopus laevis
P08464056A0510|8 16|evidence
P08464056A0510|33 45|organization
P08464056A0510|49 76|FAX-ZFP transcription units
P08464056A0510|92 114|Southern blot analysis
P08464056A0510|132 153|restriction fragments
P08464056A0510|178 203|field gel electrophoresis
P08464056A0510|220 233|hybridization
P08464056A0510|244 255|chromosomes
P08464924A0243|2 10|rat cDNA
P08464924A0243|24 29|eIF-5
P08464924A0243|114 127|eIF-5 protein
P08466864A0878|11 19|analyses
P08466864A0878|42 52|importance
P08466864A0878|56 65|sequences
P08466864A0878|81 91|bp segment
P08466864A0878|123 126|AMP
P08466864A0878|138 161|element binding protein
P08466864A0878|163 167|CREB
P08466864A0878|169 181|binding site
P08466864A0878|186 194|TGF-beta
P08466864A0878|201 219|PMA responsiveness
P08466864A0878|233 237|PU-1
P08466864A0878|242 259|Sp1 binding sites
P08466864A0878|270 287|promoter activity
P08468320A0941|7 9|J.
P08468475A1280|19 41|internalization assays
P08468475A1280|63 73|YT-1 cells
P08468475A1280|79 96|IL-2R alpha chain
P08468475A1280|143 161|IL-2R beta subunit
P08468475A1280|178 189|IL-2R alpha
P08468475A1280|220 243|F42A-IL-2R beta complex
P08468475A1280|260 273|alpha-subunit
P08468475A1280|300 308|affinity
P08468475A1280|316 337|F42A binding reaction
P08469831T0001|21 29|dynamics
P08469831T0001|33 49|prostaglandin E1
P08469831T0001|57 68|nicardipine
P08469831T0001|89 98|reactions
P08469831T0001|106 111|hyper
P08469831T0001|129 134|state
P08469831T0001|145 150|shock
P08469831T0001|156 165|rat model
P08470021A0195|16 26|prevalence
P08470021A0195|30 44|IgG antibodies
P08470021A0195|53 70|Trypanosoma cruzi
P08470021A0195|82 94|blood donors
P08470021A0195|102 120|Instituto Nacional
P08470021A0195|124 135|Cardiologia
P08470021A0195|137 151|Ignacio Chavez
P08470021A0195|156 167|Mexico City
P08470895A1617|0 11|Examination
P08470895A1617|29 37|sequence
P08470895A1617|48 63|mRNA start site
P08470895A1617|75 83|TATA box
P08470895A1617|103 121|enhancer sequences
P08471241T0000|15 24|synthesis
P08471241T0000|46 53|removal
P08471241T0000|57 61|milk
P08471241T0000|75 80|women
P08471629A0816|0 15|Pseudosubstrate
P08471629A0816|41 51|C-terminus
P08471629A0816|68 80|PKC isotypes
P08471629A0816|92 100|beta-PKC
P08471629A0816|109 122|nPKC activity
P08471629A0816|136 148|Histone IIIS
P08471629A0816|152 159|peptide
P08471629A0816|170 179|substrate
P08471796A1654|15 22|results
P08471796A1654|30 35|model
P08471796A1654|44 54|regulation
P08471796A1654|66 81|gene expression
P08471796A1654|85 99|A. caulinodans
P08472750A0999|7 23|oxide inhalation
P08472750A0999|54 66|hypertension
P08472750A0999|70 93|porcine endotoxin shock
P08472750A0999|116 127|oxygenation
P08472750A0999|132 134|pH
P08472750A0999|149 160|attenuation
P08472750A0999|176 186|activation
P08473731A0149|0 1|B
P08473731A0149|16 20|mb-1
P08473731A0149|25 34|B29 genes
P08473731A0149|46 67|alpha/beta components
P08473731A0149|90 97|complex
P08473731A0149|108 112|sIgM
P08473731A0149|114 121|B cells
P08473967T0000|0 10|Bipolarity
P08473967T0000|14 33|Jungian type theory
P08473967T0000|42 69|Myers-Briggs Type Indicator
P08474438A0000|2 9|variety
P08474438A0000|21 39|ribonucleoproteins
P08474438A0000|88 102|RNA polymerase
P08474438A0000|106 117|transcripts
P08474438A0000|166 190|RNA processing reactions
P08474438A0000|202 226|pre-mRNA polyadenylation
P08474438A0000|231 239|splicing
P08474438A0000|269 283|mRNA transport
P08474439A0877|0 9|Mutations
P08474439A0877|19 24|sites
P08474439A0877|37 44|effects
P08474439A0877|48 54|muscle
P08474439A0877|70 75|cells
P08474439A0877|89 102|site mutation
P08474439A0877|120 126|effect
P08474439A0877|144 156|muscle types
P08474439A0877|158 167|mutations
P08474439A0877|175 179|MEF1
P08474439A0877|187 192|E-box
P08474439A0877|194 198|site
P08474439A0877|226 236|expression
P08474439A0877|249 255|muscle
P08474439A0877|261 270|mutations
P08474439A0877|278 287|CArG site
P08474439A0877|315 325|expression
P08474439A0877|337 343|muscle
P08474456A1041|10 31|transfection analysis
P08474456A1041|43 52|mutations
P08474456A1041|80 86|region
P08474456A1041|113 116|Ets
P08474456A1041|130 149|LyF-1 binding sites
P08474456A1041|166 177|D' activity
P08474464A0348|21 33|relationship
P08474464A0348|41 43|TR
P08474464A0348|45 52|Rev-Erb
P08474464A0348|69 85|TR binding sites
P08475104A0341|28 44|promoter element
P08475104A0341|86 101|G1-S activation
P08475104A0341|115 131|thymidine kinase
P08475104A0341|133 136|htk
P08475104A0341|138 146|promoter
P08475104A0341|168 173|cells
P08475104A0341|188 194|target
P08475104A0341|198 206|cyclin A
P08475104A0341|215 232|p33cdk2 complexes
P08476087A0814|17 27|influences
P08476087A0814|57 62|range
P08476087A0814|74 83|pressures
P08476087A0814|107 111|mmHg
P08476854A0097|0 5|DNase
P08476854A0097|8 20|footprinting
P08476854A0097|26 35|rat liver
P08476854A0097|44 52|extracts
P08476854A0097|88 95|domains
P08476854A0097|103 105|P1
P08476854A0097|114 116|P7
P08476854A0097|126 148|base pair DNA fragment
P08476854A0097|150 160|base pairs
P08479742A0985|30 34|part
P08479742A0985|44 51|ability
P08479742A0985|65 68|p53
P08479742A0985|80 98|cell proliferation
P08479742A0985|132 141|processes
P08481004A0321|8 13|clone
P08481004A0321|34 46|endonuclease
P08482539A0913|0 22|Northern blot analysis
P08482539A0913|41 44|RNA
P08482539A0913|60 64|xylP
P08482539A0913|82 92|transcript
P08482539A0913|113 118|xylan
P08483412A0000|4 8|nifJ
P08483412A0000|13 27|nifH promoters
P08483412A0000|31 41|Klebsiella
P08483412A0000|81 86|sigma
P08483412A0000|100 109|promoters
P08483412A0000|147 159|NifA protein
P08483479A1056|6 10|data
P08483479A1056|21 24|PTH
P08483479A1056|29 33|cAMP
P08483479A1056|46 72|collagen promoter activity
P08483479A1056|76 85|calvariae
P08483479A1056|102 106|mice
P08483479A1056|128 133|alpha
P08483479A1056|139 156|collagen promoter
P08483479A1056|173 193|elements down-stream
P08483479A1056|202 211|kilobases
P08483479A1056|225 228|PTH
P08483479A1056|233 248|cAMP repression
P08483479A1056|252 276|collagen gene expression
P08483479A1056|280 284|bone
P08484514A1536|28 38|isoflurane
P08484514A1536|51 73|baseline vein diameter
P08484514A1536|81 92|stimulation
P08484689T0000|0 10|Prevalence
P08484689T0000|25 34|arthritis
P08484689T0000|50 56|factor
P08484689T0000|60 65|women
P08484689T0000|67 75|evidence
P08484689T0000|90 97|decline
P08484891A0000|31 43|conditioning
P08484891A0000|55 59|rats
P08484891A0000|102 109|changes
P08484891A0000|127 131|bulb
P08484891A0000|140 148|evidence
P08484891A0000|175 183|circuits
P08484891A0000|224 232|memories
P08485317A0000|4 22|fission yeast dsk1
P08485317A0000|24 28|gene
P08485317A0000|42 52|suppressor
P08485317A0000|72 84|dis1 mutants
P08485317A0000|108 122|protein kinase
P08486035T0000|0 7|Closure
P08486035T0000|15 39|patent ductus arteriosus
P08486035T0000|47 55|Ligaclip
P08486035T0000|66 81|minithoracotomy
P08486276A0419|0 19|Sequence comparison
P08486276A0419|43 46|ORF
P08486276A0419|53 69|protein database
P08486276A0419|98 120|% aa sequence homology
P08486276A0419|134 147|transmembrane
P08486276A0419|149 151|TM
P08486276A0419|153 161|proteins
P08486276A0419|188 203|chloramphenicol
P08486276A0419|205 207|Cm
P08486276A0419|213 225|tetracycline
P08486276A0419|227 229|Tc
P08486276A0419|231 241|resistance
P08486276A0419|266 281|symport protein
P08486705A0181|4 14|yeast gene
P08486705A0181|28 33|eIF-5
P08486705A0181|46 50|TIF5
P08486705A0181|136 149|eIF-5 protein
P08488700A0283|4 14|strategies
P08488700A0283|24 35|hepatitis B
P08488700A0283|40 51|hepatitis D
P08488700A0283|101 113|immunization
P08488700A0283|135 143|exposure
P08488700A0283|157 162|blood
P08488700A0283|166 183|blood derivatives
P08488700A0283|188 197|education
P08488700A0283|213 222|awareness
P08488700A0283|228 239|hepatitis B
P08488700A0283|266 273|disease
P08490002A0620|0 6|Xylose
P08490002A0620|33 41|polymers
P08490002A0620|72 81|cellulose
P08490002A0620|91 97|breads
P08491124A0517|14 26|construction
P08491124A0517|34 50|mouth protectors
P08491124A0517|77 81|need
P08491124A0517|86 101|instrumentation
P08491124A0517|110 115|costs
P08491124A0517|124 133|materials
P08491124A0517|164 180|mouth protectors
P08491383A0154|4 17|alpha-subunit
P08491383A0154|47 50|DNA
P08491383A1291|21 34|alpha-subunit
P08491383A1291|59 66|protein
P08491383A1291|78 99|transcription factors
P08491383A1291|147 166|interaction domains
P08491683A0651|6 14|patients
P08491683A0651|28 36|patients
P08491683A0651|60 68|patients
P08491683A0651|95 109|adenocarcinoma
P08491683A0651|117 125|prostate
P08492164T0000|12 24|burst firing
P08492164T0000|28 31|cat
P08492164T0000|49 55|cortex
P08492164T0000|57 60|age
P08492164T0000|65 81|depth dependence
P08492164T0000|90 96|effect
P08492164T0000|107 127|interaction measures
P08492290A0306|31 37|method
P08492290A0306|50 56|medium
P08492290A0306|66 77|strength mu
P08492290A0306|89 108|stability constants
P08492290A0306|110 118|log beta
P08492290A0306|132 140|log beta
P08495786A0085|0 23|Cryopreservation straws
P08495786A0085|36 41|media
P08495786A0085|78 85|surface
P08495786A0085|104 109|donor
P08496157A0000|4 14|bcl-2 gene
P08496157A0000|53 61|proteins
P08496157A0000|88 102|carboxyl tails
P08496157A0000|129 147|splicing mechanism
P08496184A0772|16 29|reading frame
P08496184A0772|37 42|clone
P08496184A0772|54 57|min
P08496184A0772|73 83|chromosome
P08496184A0772|104 112|sequence
P08496184A0772|123 139|type counterpart
P08496185A0484|11 18|cloning
P08496185A0484|23 51|nucleotide sequence analysis
P08496185A0484|59 61|S.
P08496185A0484|68 89|adenylate kinase gene
P08496185A0484|91 95|adk1
P08496185A0484|115 121|region
P08496185A0484|129 140|nucleotides
P08496475T0000|0 13|Calcification
P08496475T0000|30 43|Streptococcus
P08496475T0000|51 66|Corynebacterium
P08496475T0000|68 80|Bacterionema
P08496475T0000|82 93|matruchotii
P08496599A0310|5 11|result
P08496599A0310|27 35|splicing
P08496599A0310|41 49|BGP gene
P08496599A0310|94 106|mRNA species
P08496601A1153|2 12|comparison
P08496601A1153|20 29|promoters
P08496601A1153|34 46|muMIP-1 beta
P08496601A1153|51 64|muMIP-1 alpha
P08496601A1153|85 97|CK-1 element
P08496601A1153|113 131|expression studies
P08496601A1153|135 138|RAW
P08496601A1153|145 156|macrophages
P08496601A1153|171 180|fragments
P08496601A1153|195 207|muMIP-1 beta
P08496601A1153|215 228|muMIP-1 alpha
P08496601A1153|232 240|promoter
P08496601A1153|258 308|growth hormone reporter gene link LPS-inducibility
P08496601A1153|320 337|promoter segments
P08496601A1153|375 398|consensus CK-1 sequence
P08496848A0692|19 39|contrast differences
P08496848A0692|61 74|FSE sequences
P08496848A0692|109 123|SE counterpart
P08497190T0079|0 17|Sequence analysis
P08497190T0079|22 36|identification
P08497190T0079|44 47|hyp
P08497190T0079|59 66|mutants
P08497248A0000|4 8|gene
P08497248A0000|22 30|receptor
P08497248A0000|35 45|macrophage
P08497248A0000|65 71|factor
P08497248A0000|75 80|CSF-1
P08497248A0000|87 106|c-fms protooncogene
P08497248A0000|168 178|phagocytes
P08497248A0000|183 195|trophoblasts
P08497259A0452|4 9|level
P08497259A0452|17 38|SUP4A53T61 transcript
P08497259A0452|67 80|tap1-1 mutant
P08497259A0452|98 102|type
P08497269A0999|5 24|sequence similarity
P08497269A0999|36 47|possibility
P08497269A0999|53 57|GCN1
P08497269A0999|73 82|ribosomes
P08497269A0999|86 100|tRNA molecules
P08497269A0999|105 114|functions
P08497269A0999|118 129|conjunction
P08497269A0999|135 139|GCN2
P08497269A0999|164 175|tRNA levels
P08497269A0999|187 194|process
P08497269A0999|198 220|translation elongation
P08497273T0000|0 5|NF-HB
P08497273T0000|7 11|BSAP
P08497273T0000|18 27|repressor
P08497273T0000|42 56|immunoglobulin
P08497273T0000|72 86|alpha enhancer
P08497273T0000|96 102|stages
P08497273T0000|106 128|B-cell differentiation
P08497280A0266|10 20|regulation
P08497280A0266|24 28|SWI4
P08497280A0266|52 74|cell cycle progression
P08497280A0266|98 101|cis
P08497280A0266|120 130|regulators
P08497280A0266|134 152|SWI4 transcription
P08497280A1397|39 46|pathway
P08497280A1397|66 84|SWI4 transcription
P08497280A1397|92 99|absence
P08497280A1397|103 107|SWI6
P08497280T0000|35 43|elements
P08497280T0000|52 70|SWI4 transcription
P08497280T0000|83 93|cell cycle
P08498570A1118|3 13|conclusion
P08498570A1118|15 22|changes
P08498570A1118|26 51|carotid sinus stimulation
P08498570A1118|59 69|blood flow
P08498570A1118|77 85|hindlimb
P08498570A1118|94 101|changes
P08498570A1118|110 115|Pcrit
P08498570A1118|120 122|Ra
P08499376A0000|10 13|PRK
P08499376A0000|49 63|predictability
P08499376A0000|81 92|corrections
P08499903A0883|6 14|patients
P08499903A0883|20 29|deletions
P08499903A0883|44 50|origin
P08499903A0883|54 62|deletion
P08499916A0000|4 15|COL7A1 gene
P08499916A0000|31 48|type VII collagen
P08499916A0000|75 89|candidate gene
P08499916A0000|131 136|forms
P08499916A0000|151 172|epidermolysis bullosa
P08500524A0424|9 14|study
P08500524A0424|33 43|gamma gene
P08500524A0424|77 81|exon
P08500524A0424|104 120|splicing signals
P08500524A0424|143 162|intron organization
P08500938A0408|17 22|grade
P08500938A0408|27 31|BGCT
P08500938A0408|73 81|excision
P08500938A0408|105 113|surfaces
P08500938A0408|118 122|part
P08500938A0408|130 140|metaphysis
P08501030A0456|16 25|induction
P08501030A0456|35 55|.5 operon expression
P08501030A0456|85 89|narL
P08501030A0456|95 102|strains
P08501030A0456|104 108|M.H.
P08501678A0498|9 18|knowledge
P08501678A0498|42 53|development
P08501678A0498|70 97|immunoprophylactic strategy
P08501678A0498|114 125|Hib disease
P08503348A0226|4 32|HMG CoA reductase inhibitors
P08503348A0226|77 83|agents
P08504707A0376|4 12|etiology
P08504707A0376|14 23|pathology
P08504707A0376|25 33|brain CT
P08504707A0376|39 47|features
P08504707A0376|58 72|manifestations
P08504707A0376|77 86|treatment
P08504707A0376|96 105|accidents
P08504928T0000|18 31|TFIID subunit
P08504928T0000|46 53|homolog
P08504928T0000|67 90|cell cycle gene product
P08504928T0000|113 124|DNA binding
P08504928T0000|132 136|TATA
P08504928T0000|149 156|subunit
P08504928T0000|160 165|TFIID
P08504932A0123|14 20|aspect
P08504932A0123|24 46|GATA factor expression
P08504932A0123|63 76|GATA proteins
P08504932A0123|122 138|site specificity
P08504932A0123|169 174|cells
P08504933A0000|0 5|Pit-1
P08504933A0000|27 44|POU domain factor
P08504933A0000|64 74|appearance
P08504933A0000|84 99|cell phenotypes
P08504933A0000|126 131|gland
P08505075A0236|0 14|Maximum number
P08505075A0236|18 25|strains
P08505075A0236|31 32|%
P08505075A0236|52 72|S. bareilly serotype
P08505075A0236|106 107|%
P08505075A0236|122 130|S. typhi
P08505075A0236|136 137|%
P08505312A0285|0 4|Biol
P08505340T0000|0 16|Characterization
P08505340T0000|30 40|regulation
P08505340T0000|48 56|promoter
P08505340T0000|64 103|rat prostaglandin endoperoxide synthase
P08505340T0000|106 110|gene
P08505340T0000|114 129|granulosa cells
P08505495A0253|4 13|retention
P08505495A0253|17 25|75SeHCAT
P08505605A0461|0 23|Patient characteristics
P08505605A0461|45 51|wounds
P08505605A0461|63 70|patient
P08505605A0461|75 96|wound characteristics
P08505605A0461|115 121|extent
P08505605A0461|125 132|healing
P08505605A0461|137 141|time
P08505605A0461|155 162|healing
P08506317A0000|0 7|Members
P08506317A0000|15 27|C/EBP family
P08506317A0000|31 51|basic-leucine zipper
P08506317A0000|53 57|bZip
P08506317A0000|59 80|transcription factors
P08506317A0000|86 98|heterodimers
P08506317A0000|115 123|CAAT box
P08506317A0000|151 166|enhancer motifs
P08506384A0146|13 18|cells
P08506384A0146|20 35|phosphorylation
P08506384A0146|39 50|eIF-2 alpha
P08506384A0146|64 72|activity
P08506384A0146|76 82|eIF-2B
P08506384A0146|88 111|GDP-GTP exchange factor
P08506384A0146|116 121|eIF-2
P08507921A1021|3 13|conclusion
P08507921A1021|21 33|observations
P08507921A1021|52 66|stratification
P08507921A1021|76 87|MI patients
P08507921A1021|91 107|plasma ANF level
P08507921A1021|133 139|method
P08507921A1021|155 164|prognosis
P08507921A1021|185 196|individuals
P08507921A1021|205 209|risk
P08507921A1021|221 226|death
P08508774A0242|0 8|Analysis
P08508774A0242|16 23|binding
P08508774A0242|27 30|Lrp
P08508774A0242|36 39|set
P08508774A0242|63 76|DNA fragments
P08508774A0242|87 93|region
P08508774A0242|109 112|Lrp
P08508774A0242|121 124|DNA
P08508778A0112|0 13|Yeast mutants
P08508778A0112|35 44|NOP1 gene
P08508778A0112|74 85|fibrillarin
P08508778A0112|94 105|temperature
P08508778A0112|120 126|growth
P08508778A0112|152 162|processing
P08508861A0294|4 12|patients
P08508861A0294|31 40|ischaemia
P08508861A0294|59 65|groups
P08508861A0294|73 78|basis
P08508861A0294|86 92|change
P08508861A0294|96 120|lactate extraction ratio
P08508861A0294|128 145|balloon inflation
P08509051A0316|16 24|patients
P08509051A0316|40 54|mortality rate
P08509051A0316|60 61|%
P08509333A0843|9 16|protein
P08509333A0843|43 60|membrane fraction
P08509333A0843|77 86|minicells
P08509333A0843|98 106|plasmids
P08509333A0843|116 125|ftsN gene
P08509333A0843|143 147|FtsN
P08509333A0843|154 170|membrane protein
P08509335T0000|0 4|SSG1
P08509335T0000|8 12|gene
P08509335T0000|45 63|1,3-beta-glucanase
P08509419A0785|0 10|Expression
P08509419A0785|19 26|protein
P08509419A0785|56 64|tyrosine
P08509419A0785|89 100|suppression
P08509419A0785|110 115|yeast
P08509419A0785|128 142|TyrRS activity
P08509430A0372|19 34|complementation
P08509430A0372|58 64|mutant
P08509430A0372|68 81|Chlamydomonas
P08509430A0372|83 90|CC-2341
P08509430A0372|92 102|ac-u-g-2.3
P08509430A0372|117 136|frameshift mutation
P08509430A0372|144 153|psaB gene
P08509430A0372|159 168|selection
P08509430A0372|187 200|transformants
P08509430A0372|212 218|medium
P08510320A0000|12 19|strains
P08510320A0000|68 72|MRSA
P08510320A0000|121 135|concentrations
P08510320A0000|137 141|MICs
P08510320A0000|148 153|total
P08510320A0000|174 180|agents
P08510320A0000|191 200|arbekacin
P08510320A0000|202 205|ABK
P08510320A1249|45 50|MRSAs
P08510320A1249|64 69|Japan
P08510320A1249|98 108|resistance
P08510320A1249|117 122|drugs
P08510320A1249|165 175|resistance
P08510320A1249|184 196|beta-lactams
P08510647A1347|0 4|Beg2
P08510647A1347|9 13|Beg1
P08510647A1347|59 68|variation
P08510647A1347|72 79|storage
P08510647A1347|83 105|utilization properties
P08510647A1347|116 132|barley globulins
P08510924A0490|40 55|transactivation
P08510924A0490|69 83|HSP70 promoter
P08510924A0490|87 99|Myb proteins
P08511994A0000|36 41|carps
P08511994A0000|69 81|ichthiomycin
P08511994A0000|85 99|concentrations
P08511994A0000|115 129|micrograms/dm3
P08512728A0991|0 7|RESULTS
P08512728A0991|35 46|differences
P08512728A0991|69 74|group
P08512728A0991|99 105|number
P08512728A0991|109 117|patients
P08512728A0991|141 153|fibrillation
P08512728A0991|159 169|conduction
P08512728A0991|177 194|accessory pathway
P08512728A0991|199 201|RR
P08512728A0991|213 217|msec
P08512728A0991|237 238|p
P08513025A0000|15 21|effect
P08513025A0000|34 43|thickness
P08513025A0000|51 62|correlation
P08513025A0000|71 76|serum
P08513025A0000|83 98|bilirubin level
P08513025A0000|118 127|bilirubin
P08513025A0000|129 132|TcB
P08513025A0000|134 142|readings
P08514757A1100|5 18|immunophilins
P08514757A1100|38 43|roles
P08514757A1100|47 64|receptor assembly
P08514757A1100|89 97|category
P08514757A1100|101 107|ligand
P08514757A1100|131 141|modulators
P08514757A1100|145 161|protein function
P08514766A0732|4 19|GTPase activity
P08514766A0732|23 30|CDC42Ce
P08514766A0732|65 76|n-chimaerin
P08514766A0732|98 105|protein
P08514766A0732|122 130|p21 rac1
P08515619A0184|0 19|Tl-201 uptake ratio
P08515619A0184|33 42|ventricle
P08515619A0184|65 70|ratio
P08515619A0184|80 86|counts
P08515619A0184|100 109|ventricle
P08515619A0184|113 119|counts
P08515619A0184|140 144|dose
P08515619A0184|148 154|Tl-201
P08515619A0184|170 174|COPD
P08515619A0184|200 209|emphysema
P08515619A0184|214 225|B type COPD
P08515619A0184|229 251|Burrows classification
P08515619A0184|260 268|controls
P08515776A0971|21 27|domain
P08515776A0971|57 64|regions
P08515776A0971|99 105|region
P08516301A0080|5 9|gene
P08516301A0080|19 21|kb
P08516301A0080|46 51|exons
P08516301A0080|61 68|introns
P08516308A0669|14 17|RAD
P08516308A0669|19 24|cells
P08516308A0669|44 57|microcolonies
P08516308A0669|64 69|cells
P08516308A0669|109 114|cells
P08516324A0000|22 35|translocation
P08516324A0000|59 72|Ewing sarcoma
P08516324A0000|103 108|tumor
P08516324A0000|131 139|molecule
P08516324A0000|175 182|portion
P08516324A0000|190 198|EWS gene
P08516324A0000|236 242|domain
P08516324A0000|258 267|FLI1 gene
P08517737A0889|6 14|findings
P08517737A0889|30 35|range
P08517737A0889|58 68|conditions
P08517737A0889|91 104|water systems
P08517737A0889|126 137|populations
P08517737A0889|141 149|bacteria
P08518797T0000|9 27|liver glycogenosis
P08518797T0000|29 41|localization
P08518797T0000|46 55|isolation
P08518797T0000|61 75|candidate gene
P08519621A0150|5 15|conclusion
P08519621A0150|32 44|observations
P08519621A0150|64 71|changes
P08519621A0150|100 106|stages
P08519621A0150|110 117|illness
P08519621A0150|149 160|association
P08519621A0150|182 190|bacteria
P08519621A0150|198 205|pharynx
P08519621A0150|227 232|tract
P08519862T0001|0 11|Measurement
P08519862T0001|24 38|IgM antibodies
P08519862T0001|60 63|kit
P08520646A0000|0 23|Embryo coculture system
P08520646A0000|57 67|mechanisms
P08520646A0000|83 91|decrease
P08520646A0000|95 104|fertility
P08520646A0000|110 115|aging
P08521414A1384|6 16|cell lines
P08521414A1384|27 38|methylation
P08521414A1384|46 56|CpG island
P08521414A1384|79 83|exon
P08521414A1384|87 95|p16INK4A
P08521414A1384|119 125|levels
P08521414A1384|145 149|mRNA
P08521414A1384|182 186|exon
P08521414A1384|188 195|E1 beta
P08521414A1384|215 225|cell lines
P08521414A1384|239 253|p16INK4A locus
P08521717A0126|20 28|reaction
P08521717A0126|30 40|PAP method
P08521717A0126|51 60|antiserum
P08521717A0126|64 70|Factor
P08521717A0126|91 99|antibody
P08521717A0126|136 144|biopsies
P08521717A0126|159 165|Factor
P08521717A0126|171 179|activity
P08521717A0126|199 210|endothelium
P08521717A0126|228 237|insertion
P08521717A0126|241 251|LNG-IUD-20
P08521780A0485|0 10|Umweltchem
P08522175A0306|0 5|Egd1p
P08522175A0306|29 34|BTF3b
P08522175A0306|63 75|beta subunit
P08522175A0306|128 135|complex
P08522175A0306|137 140|NAC
P08522175A0306|188 203|protein sorting
P08522175A0306|208 221|translocation
P08522175A0306|223 231|Wiedmann
P08522175A0306|240 246|Nature
P08522511A1250|9 12|PLB
P08522511A1250|28 42|lyase activity
P08522511A1250|46 48|pH
P08522511A1578|16 23|regions
P08522511A1578|32 36|pelA
P08522511A1578|41 45|pelB
P08522511A1578|80 103|beta-glucuronidase gene
P08522511A1578|124 126|F.
P08522511A1578|134 139|f. sp
P08522511A1578|141 145|pisi
P08522511A1578|151 180|beta-glucuronidase activities
P08522511A1578|188 201|transformants
P08522530A1342|5 14|nifA mRNA
P08522530A1342|24 30|points
P08522530A1342|46 62|primer extension
P08522530A1342|86 96|transcript
P08522530A1342|97 98|s
P08522530A1342|112 114|bp
P08522530A1342|129 138|anaerobox
P08522530A1342|162 172|transcript
P08522530A1342|185 187|bp
P08522530A1342|202 207|sigma
P08522530A1342|211 214|box
P08523031A0737|24 28|data
P08523031A0737|60 64|time
P08523031A0737|68 73|onset
P08523031A0737|85 93|seizures
P08523031A0737|115 121|stroke
P08523031A0737|126 136|recurrence
P08523545T0000|10 29|papillomavirus type
P08523545T0000|33 43|E7 protein
P08523545T0000|56 71|adenovirus type
P08523545T0000|74 77|E1A
P08523545T0000|103 118|transactivation
P08523545T0000|122 137|adenovirus type
P08523545T0000|146 151|genes
P08523545T0000|166 169|ATF
P08523545T0000|174 200|Oct-1 DNA binding activity
P08523566A1106|13 22|detergent
P08523566A1106|27 41|% Nonidet P-40
P08523566A1106|62 73|interaction
P08523566A1106|110 116|nature
P08523566A1106|124 135|interaction
P08524036A0747|12 24|expectations
P08524036A0747|52 57|level
P08524036A0747|61 70|variation
P08524036A0747|78 84|stripe
P08524036A0747|87 102|enhancer region
P08524036A0747|114 133|point substitutions
P08524036A0747|138 157|insertion/deletions
P08524036A0747|169 174|sites
P08524036A0747|193 198|level
P08524036A0747|202 211|variation
P08524036A0747|235 242|regions
P08524229T0000|0 11|Degradation
P08524229T0000|19 37|soybean ribulose-1
P08524229T0000|40 83|bisphosphate carboxylase small-subunit mRNA
P08524229T0000|85 89|SRS4
P08524229T0000|122 130|cleavage
P08524235A0695|0 7|Cloning
P08524235A0695|12 22|sequencing
P08524235A0695|37 41|dMax
P08524235A0695|53 61|deletion
P08524235A0695|81 87|region
P08524235A0695|92 97|helix
P08524235A0695|108 112|loop
P08524235A0695|137 143|region
P08524235A0695|161 167|result
P08524235A0695|183 191|splicing
P08524235A0695|195 202|max RNA
P08524241A0212|19 28|induction
P08524241A0212|32 37|HSP82
P08524241A0212|72 81|IME1-IME2
P08524241A0212|98 105|cascade
P08524260A0835|4 20|domain structure
P08524260A0835|31 37|LTBP-2
P08524260A0835|75 81|LTBP-2
P08524260A0835|97 105|examples
P08524260A0835|130 136|growth
P08524260A0835|149 156|repeats
P08524260A0835|179 197|consensus sequence
P08524260A0835|202 217|calcium binding
P08524260A0835|235 243|examples
P08524260A0835|258 264|motifs
P08524260A0835|283 293|fibrillins
P08524260A0835|298 304|LTBP-1
P08524267A1022|11 21|expression
P08524267A1022|61 83|prothymosin alpha gene
P08524267A1022|91 99|reporter
P08524267A1022|122 132|repertoire
P08524267A1022|148 153|genes
P08524267A1022|165 168|myc
P08524267A1022|211 222|myc mutants
P08524272T0000|13 23|regulation
P08524272T0000|31 41|alpha/beta
P08524272T0000|64 80|Jak/Stat pathway
P08524272T0000|88 91|SH2
P08524272T0000|110 137|tyrosine phosphatase SHPTP1
P08524284A0309|18 27|isolation
P08524284A0309|32 42|expression
P08524284A0309|46 51|cDNAs
P08524284A0309|61 70|PTF gamma
P08524284A0309|75 84|PTF delta
P08524284A0309|108 115|studies
P08524284A0309|129 139|antibodies
P08524284A0309|166 177|PTF complex
P08524284A0309|181 194|HeLa extracts
P08524292A1022|0 7|Results
P08524292A1022|17 32|mechanism study
P08524292A1022|52 55|YY1
P08524292A1022|75 90|transactivation
P08524292A1022|110 113|AP1
P08524292A1022|133 140|protein
P08524292A1022|146 149|YY1
P08524292A1022|162 170|activity
P08524292A1022|174 185|DNA binding
P08524294A0652|4 8|skp1
P08524294A0652|10 14|gene
P08524314A0216|4 8|TEA1
P08524314A0216|10 31|Ty enhancer activator
P08524314A0216|33 46|gene sequence
P08524314A0216|58 65|protein
P08524314A0216|74 77|kDa
P08524314A0216|84 94|N terminus
P08524314A0216|106 118|zinc cluster
P08524314A0216|123 141|dimerization motif
P08524314A0216|167 173|family
P08524314A0216|189 197|proteins
P08525186A0288|0 8|Refugees
P08525186A0288|19 23|Lund
P08525186A0288|43 48|Chile
P08525186A0288|66 72|health
P08525186A0288|92 102|proportion
P08525186A0288|122 134|counterparts
P08525186A0288|144 154|odds ratio
P08526620A1344|5 10|study
P08526620A1344|26 36|importance
P08526620A1344|49 74|SC5b-9 complement complex
P08526620A1344|89 95|marker
P08526620A1344|103 113|evaluation
P08526620A1344|117 138|complement activation
P08526620A1344|162 168|bypass
P08528479A0000|0 18|Videonystagmoscopy
P08528479A0000|61 70|responses
P08528479A0000|89 95|system
P08528479A0000|101 111|population
P08528479A0000|115 123|patients
P08528479A0000|140 148|deficits
P08528796A1470|4 7|MCA
P08528796A1470|12 24|UA PI values
P08528796A1470|45 54|deviation
P08528796A1470|77 86|parameter
P08529098A0549|9 30|sequence similarities
P08529098A0549|41 42|%
P08529098A0549|63 68|yeast
P08529098A0549|83 91|proteins
P08529098A0549|93 97|SMF1
P08529098A0549|102 106|SMF2
P08529098A0549|146 153|domains
P08529098A0549|155 159|exon
P08529098A0549|182 195|transmembrane
P08529098A0549|205 211|domain
P08529098A0549|213 217|site
P08529098A0549|232 255|susceptibility mutation
P08529098A0549|261 265|exon
P08529098A0549|290 305|transport motif
P08529630A0840|30 44|P protein mRNA
P08529630A0840|62 67|level
P08529630A0840|71 76|roots
P08529654A0589|4 55|B. germanica cyclophilin amino acid sequence shares
P08529654A0589|58 68|% identity
P08529654A0589|88 107|cyclophilin isoform
P08529654A0589|138 143|Cyp-1
P08529662A0507|42 46|form
P08529662A0507|50 61|ERp57/GRP58
P08529662A0507|65 81|Western blotting
P08529662A0507|99 107|labeling
P08530105A0308|12 18|region
P08530105A0308|33 66|Langer-Giedion syndrome deletions
P08530105A0308|93 101|analysis
P08530105A0308|108 116|patients
P08530105A0308|136 139|map
P08530105A0308|143 151|analysis
P08530105A0308|157 165|patients
P08530105A0308|172 181|deletions
P08530105A0308|193 202|endpoints
P08530107A1003|42 52|expression
P08530107A1003|56 65|histidase
P08530107A1003|72 79|finding
P08530107A1003|94 117|histidase transcription
P08530107A1003|144 151|factors
P08530149A0689|0 10|Comparison
P08530149A0689|14 23|promoters
P08530149A0689|37 42|c-myc
P08530149A0689|58 76|consensus sequence
P08530149A0689|84 93|initiator
P08530149A0689|95 98|Inr
P08530149A0689|100 107|element
P08530149A0689|109 112|TCA
P08530149A0689|116 121|YYYNY
P08530342T0000|10 23|gp39 promoter
P08530345A0880|0 21|Transfection analyses
P08530345A0880|36 44|mutation
P08530345A0880|65 78|TGACCT motifs
P08530345A0880|82 92|truncation
P08530345A0880|107 114|HD PPRE
P08530345A0880|131 134|DR1
P08530345A0880|139 150|DR2 element
P08530345A0880|193 201|response
P08530345A0880|205 212|HD PPRE
P08530345A0880|216 240|peroxisome proliferators
P08530369A0099|4 8|site
P08530369A0099|12 31|autophosphorylation
P08530369A0099|35 41|Tyr397
P08530369A0099|67 101|consensus autophosphorylation site
P08530369A0099|111 138|Src family tyrosine kinases
P08530384A0559|21 32|interaction
P08530384A0559|67 74|binding
P08530384A0559|78 90|Oct proteins
P08530384A0559|94 97|DNA
P08530384A0559|108 131|resolution footprinting
P08530384A0559|147 158|interaction
P08530384A0559|172 179|binding
P08530384A0559|183 186|BOB
P08530384A0559|192 194|.1
P08530384A0559|198 202|Oct1
P08530384A0559|206 210|Oct2
P08530384A0559|230 241|interaction
P08530384A0559|247 250|DNA
P08530418A1182|14 18|data
P08530418A1182|36 55|TR2 orphan receptor
P08530418A1182|65 81|master regulator
P08530418A1182|100 110|activation
P08530418A1182|122 126|HREs
P08530418A1182|128 137|RARE beta
P08530418A1182|142 149|CRBPIIp
P08530418A1182|176 208|acid signal transduction pathway
P08530432A0093|8 14|series
P08530432A0093|25 33|proteins
P08530432A0093|57 64|domains
P08530432A0093|81 91|activation
P08530432A0093|95 105|repression
P08530503A1004|7 10|ARF
P08530503A1004|16 36|ARP immunoreactivity
P08530503A1004|53 69|plasma membranes
P08530503A1004|81 88|cytosol
P08530503A1004|105 117|3T3-L1 cells
P08531373A0470|44 52|erythema
P08531373A0470|67 85|skin manifestation
P08531373A0470|89 92|SjS
P08531373A0470|103 123|SS-A/SS-B antibodies
P08531669A0950|0 11|Competition
P08531669A0950|49 64|Central America
P08531669A0950|69 85|Caribean islands
P08531669A0950|91 95|kind
P08531669A0950|99 104|study
P08531669A0950|132 139|control
P08531669A0950|153 160|species
P08532516A0000|8 13|paper
P08532516A0000|26 36|properties
P08532516A0000|44 59|cdc10-C4 mutant
P08532516A0000|67 80|fission yeast
P08532536A0925|0 15|TIEG expression
P08532536A0925|19 29|hFOB cells
P08532536A0925|52 60|TGF-beta
P08532536A0925|65 69|bone
P08532536A0925|84 93|protein-2
P08532536A0925|95 100|BMP-2
P08532536A0925|119 128|induction
P08532536A0925|142 155|growth factor
P08532536A0925|157 160|EGF
P08532536A0925|170 179|induction
P08532536A0925|189 213|growth factors/cytokines
P08532967A0364|14 20|origin
P08532967A0364|72 79|therapy
P08533472A0777|14 30|protein products
P08533472A0777|34 44|ORFs N2417
P08533472A0777|49 54|N2403
P08533472A0777|63 75|similarities
P08533472A0777|81 88|domains
P08533472A0777|94 102|proteins
P08533472A0777|112 121|organisms
P08533472A0777|127 175|Candida maltosa cycloheximide-resistance protein
P08533472A0777|187 198|interleukin
P08533472A0777|216 222|factor
P08533472A0777|224 229|ILF-2
P08533473A0375|36 45|ADH1 gene
P08533473A0375|69 77|database
P08533473A0375|97 110|EST sequences
P08533757A0204|5 13|families
P08533757A0204|17 41|Ashkenazi Jewish descent
P08533757A0204|54 71|185delAG mutation
P08533757A0204|92 101|haplotype
P08533757A0204|123 130|markers
P08533757A0204|158 160|kb
P08533757A0204|164 169|BRCA1
P08534217A0402|4 12|subjects
P08534217A0402|26 33|regions
P08534217A0402|48 63|pollution level
P08534217A0402|74 77|FVC
P08534217A0402|82 93|FEV1 values
P08534217A0402|114 128|Viskovo region
P08534367A0984|0 6|PTP-S3
P08534367A0984|20 26|PTP-S4
P08534367A0984|39 47|deletion
P08534367A0984|54 65|amino acids
P08534367A0984|83 90|exon E1
P08534848A0188a|10 21|NR isoforms
P08534848A0188a|39 41|cv
P08534848A0188b|10 21|NR isoforms
P08534848A0188b|39 41|cv
P08534855A0000|4 25|Arabidopsis FAD7 gene
P08534855A0000|36 55|chloroplast omega-3
P08534855A0000|62 77|acid desaturase
P08534855A0000|97 109|desaturation
P08534855A0000|140 145|acids
P08535138A0857|32 42|leaf cells
P08535138A0857|66 79|cell division
P08535138A0857|83 92|treatment
P08535138A0857|98 112|plant hormones
P08535138A0857|114 134|cycMs4 transcription
P08535138A0857|158 163|onset
P08535138A0857|167 180|DNA synthesis
P08535537A0000|2 8|survey
P08535537A0000|41 52|backgrounds
P08535537A0000|79 93|drug treatment
P08535537A0000|107 119|hypertension
P08536694A0000|0 15|Protein kinases
P08536694A0000|29 34|roles
P08536694A0000|42 49|control
P08536694A0000|67 76|processes
P08537388A0825|31 40|deletions
P08537388A0825|65 73|promoter
P08537388A0825|116 124|activity
P08537388A0825|148 158|base pairs
P08537388A0825|162 168|WNT-5A
P08537388A0825|192 209|promoter activity
P08537403A0336|4 26|protein kinase domains
P08537403A0336|30 35|LIMK1
P08537403A0336|40 45|LIMK2
P08537403A0336|89 127|sequence motif Asp-Leu-Asn-Ser-His-Asn
P08537403A0336|141 144|VIB
P08537403A0336|164 170|insert
P08537403A0336|179 193|subdomains VII
P08537403A0336|198 202|VIII
P08538052A0000|20 30|cDNA clone
P08538052A0000|48 68|amino acids residues
P08538052A0000|86 93|protein
P08538052A0000|95 102|THZif-1
P08538052A0000|130 142|cDNA library
P08538052A0000|177 196|leukemia HL60 cells
P08538052A0000|212 239|oligodeoxynucleotide probes
P08538052A0000|265 285|amino acid sequences
P08538052A0000|297 305|peptides
P08538052A0000|335 342|protein
P08538052A0000|384 391|element
P08538052A0000|393 396|NHE
P08538052A0000|411 421|c-myc gene
P08538382A1012|0 14|Erythrocyte AA
P08538382A1012|18 24|FO+EPO
P08538382A1012|38 45|infants
P08538382A1012|69 75|breast
P08538382A1012|81 88|placebo
P08538382A1012|101 107|levels
P08538483A0207|12 32|consideration weight
P08538483A0207|46 53|changes
P08538483A0207|57 66|bone mass
P08538483A0207|68 73|total
P08538483A0207|75 80|TBBMC
P08538483A0207|95 120|body bone mineral content
P08538483A0207|141 146|women
P08538483A0207|160 173|GnRH agonists
P08538483A0207|180 186|months
P08538483A0207|191 204|endometriosis
P08538483A0207|208 219|leiomyomata
P08538702A0214|12 23|polypeptide
P08538702A0214|38 46|sequence
P08538702A0214|54 68|ABA-1 allergen
P08538702A0214|72 79|Ascaris
P08538702A0214|85 93|gp15/400
P08538702A0214|95 101|ladder
P08538702A0214|103 110|protein
P08538702A0214|114 127|Brugia malayi
P08538702A0214|129 143|Brugia pahangi
P08538702A0214|183 190|antigen
P08538702A0214|194 213|Dirofilaria immitis
P08541499A0306|8 27|transcript patterns
P08541499A0306|31 48|Epifagus plastids
P08541499A0306|92 107|tobacco operons
P08541793A0796|12 20|recovery
P08541793A0796|38 41|min
P08541793A0796|47 50|hrs
P08542026A0792|0 3|DAF
P08542026A0792|12 27|kD glycoprotein
P08542026A0792|39 49|complement
P08542026A0792|67 84|consensus repeats
P08542026A0792|86 90|SCRs
P08542026A0792|97 101|gene
P08542026A0792|120 130|regulation
P08542026A0792|134 155|complement activation
P08542026A0792|157 160|RCA
P08542026A0792|162 174|gene cluster
P08542026A0792|178 188|chromosome
P08542026A0792|207 209|kb
P08542026A0792|213 217|size
P08542027A1471|4 12|XS2 gene
P08542027A1471|49 59|expression
P08542027A1471|63 71|LU genes
P08542027A1471|92 102|expression
P08542027A1471|106 110|CD44
P08542746T0000|0 13|Diabetes care
P08542746T0000|17 26|guideline
P08542746T0000|34 44|facilities
P08542746T0000|88 97|standards
P08543173A0314|12 20|TATA box
P08543173A0314|48 60|start points
P08543173A0314|62 65|tsp
P08543173A0314|85 110|primer extension analysis
P08543275A0130|17 30|investigation
P08543275A0130|43 48|burst
P08543275A0130|52 70|pseudoterranovosis
P08543275A0130|79 83|area
P08543275A0130|119 127|presence
P08543275A0130|131 140|sea lions
P08543275A0130|167 180|Arctic region
P08543275A0130|211 220|Japan Sea
P08543275A0130|246 255|host fish
P08543595A1093|3 10|summary
P08543595A1093|16 26|efficacies
P08543595A1093|39 50|carboplatin
P08543595A1093|68 80|radiotherapy
P08543810A0000|24 29|genes
P08543810A0000|57 69|coelomocytes
P08543810A0000|100 106|clones
P08543810A0000|140 152|cDNA library
P08543810A0000|166 169|set
P08543810A0000|183 196|sequence tags
P08543810A0000|198 202|ESTs
P08544820T0000|0 16|Characterization
P08544820T0000|23 54|EcR/USP heterodimer target site
P08544820T0000|69 92|ecdysone responsiveness
P08544820T0000|111 121|Lsp-2 gene
P08545502A0914|6 11|SPECT
P08545502A0914|36 39|PET
P08545502A0914|48 63|activation task
P08546707T0000|16 26|activation
P08546707T0000|34 55|chicken lysozyme gene
P08546707T0000|59 72|NF-kappa Bp65
P08546707T0000|74 78|RelA
P08546707T0000|84 89|c-Rel
P08546707T0000|102 115|NF-kappa Bp50
P08547205A1060|4 11|results
P08547205A1060|42 58|agents alinidine
P08547205A1060|63 74|zatebradine
P08547205A1060|103 111|efficacy
P08547205A1060|120 123|SVT
P08547205A1060|159 169|infarction
P08547205A1060|183 187|dogs
P08548291A1059|19 29|activation
P08548291A1059|33 38|SAPKs
P08548291A1059|50 59|formation
P08548291A1059|75 82|complex
P08548291A1059|94 99|Elk-1
P08548291A1059|101 122|serum response factor
P08548291A1059|131 153|serum response element
P08548291A1059|184 197|transcription
P08549706T0000|15 42|hepatitis B virus infection
P08549706T0000|61 71|drug users
P08549706T0000|75 82|Iceland
P08549859A1604|4 8|gene
P08549859A1604|34 38|odds
P08549859A1604|52 65|chromosome 3p
P08549859A1604|69 117|Centre d'Etude du Polymorphisme Humain pedigrees
P08550425A1401|15 23|subunits
P08550425A1401|59 62|POR
P08550425A1401|81 89|archaeon
P08550425A1401|91 113|Halobacterium halobium
P08550425A1401|117 127|% identity
P08550460A0374|27 31|gene
P08550460A0374|44 48|pilP
P08550460A0374|57 59|bp
P08550460A0374|98 115|protein precursor
P08550460A0374|140 176|membrane lipoprotein leader sequence
P08550461A0284|0 6|Cheung
P08550461A0284|11 13|S.
P08550462A0815|0 8|Upstream
P08550462A0815|16 24|dra gene
P08550462A0815|33 46|reading frame
P08550462A0815|54 65|amino acids
P08550467A0863|17 27|regulation
P08550467A0863|31 35|scrB
P08550467A0863|55 63|deletion
P08550467A0863|69 71|bp
P08550467A0863|89 97|sequence
P08550467A0863|99 101|OB
P08550467A0863|112 121|positions
P08550467A0863|150 154|scrB
P08550467A0863|171 181|start site
P08550470A1021|12 16|CheW
P08550470A1021|39 47|coupling
P08550470A1021|55 64|receptors
P08550470A1021|72 83|kinase CheA
P08550476A0610|4 12|promoter
P08550476A0610|26 30|gene
P08550476A0610|32 36|epiF
P08550476A0610|55 77|activator protein EpiQ
P08550476A0610|106 114|sequence
P08550476A0610|130 147|EpiQ binding site
P08550476A0610|155 168|epiA promoter
P08550476A0610|197 201|EpiQ
P08550564T0000|0 14|CXC chemokines
P08550564T0000|30 34|sets
P08550564T0000|38 62|selectivity determinants
P08550564T0000|135 142|domains
P08550564T0000|152 177|interleukin-8 receptor B.
P08551572A0155|0 21|Oligodeoxynucleotides
P08551572A0155|49 79|translation initiation regions
P08551572A0155|83 87|ICP4
P08551572A0155|92 102|pp38 mRNAs
P08551572A0155|113 126|proliferation
P08551572A0155|130 140|MSB1 cells
P08551572A0155|149 158|MDCC-CU91
P08551572A0155|160 164|CU91
P08551572A0155|166 187|reticuloendotheliosis
P08551572A0155|206 211|cells
P08551577A0000|11 22|replication
P08551577A0000|39 46|portion
P08551577A0000|62 73|transcripts
P08551577A0000|98 101|DNA
P08551577A0000|125 129|mRNA
P08551577A0000|138 154|envelope protein
P08551577A0000|162 180|Rous sarcoma virus
P08551577A0000|184 192|src mRNA
P08552042A1497|8 12|case
P08552042A1497|17 23|degree
P08552042A1497|27 47|promoter methylation
P08552042A1497|85 92|borders
P08552042A1497|122 131|reduction
P08552042A1497|148 152|poly
P08552042A1497|153 154|A
P08552042A1497|157 168|mRNA levels
P08552042A1497|183 188|state
P08552042A1497|213 220|meiosis
P08552042A1497|225 237|reactivation
P08552042A1497|253 264|generations
P08552045A0973|10 29|consensus sequences
P08552045A0973|34 56|phosphatase regulation
P08552045A0973|64 75|GCACGTGGG-3
P08552045A0973|84 95|GCACGTTTT-3
P08552045A0973|119 136|binding sequences
P08552045A0973|145 158|Cpflp protein
P08552045A0973|172 185|transcription
P08552045A0973|193 198|genes
P08552045A0973|202 225|methionine biosynthesis
P08552045A0973|234 253|centromere function
P08552082A0480|37 43|region
P08552082A0480|47 50|CAP
P08552082A0480|72 83|SH3 domains
P08552082A0480|95 103|proteins
P08552082A0480|119 124|yeast
P08552082A0480|142 155|protein Abp1p
P08552086A0150|39 65|vitamin D response element
P08552086A0150|67 71|VDRE
P08552086A0150|80 88|promoter
P08552086A0150|92 97|c-fos
P08552092A1678|3 11|addition
P08552092A1678|15 30|protein binding
P08552092A1678|34 43|sequences
P08552092A1678|72 82|regulation
P08552092A1678|86 99|transcription
P08552092A1678|109 121|footprinting
P08552092A1678|136 151|promoter region
P08552092A1678|171 185|protein factor
P08552092A1678|223 229|intron
P08552092A1678|237 246|rep3 gene
P08552093A0657|0 15|Differentiation
P08552093A0657|48 58|expression
P08552093A0657|79 84|forms
P08552093A0657|88 96|alpha i2
P08552093A0657|100 105|alpha
P08552093A0657|120 131|selectivity
P08552093A0657|140 149|Gq family
P08552093A0657|153 163|G proteins
P08552095A0686|27 31|role
P08552095A0686|35 48|transcription
P08552095A0686|50 55|Paf1p
P08552095A0686|76 83|nucleus
P08552095A0758|17 27|abundances
P08552095A0758|36 53|yeast transcripts
P08552095A0758|80 84|paf1
P08552095A0758|92 99|strains
P08552095A0758|120 125|genes
P08552095A0758|132 142|expression
P08552095A0758|158 162|PAF1
P08552095A1115|0 5|Paf1p
P08552095A1115|63 73|regulation
P08552095A1115|77 84|subsets
P08552095A1115|88 99|yeast genes
P08552096A0151|18 38|suppression strategy
P08552096A0151|61 71|yeast gene
P08552096A0151|73 77|UBS1
P08552096A0151|94 104|expression
P08552096A0151|132 150|cell cycle defects
P08552096A0151|167 182|cdc34 mutations
P08552387A0000|10 26|characterization
P08552387A0000|40 48|melanoma
P08552387A0000|57 62|parts
P08552387A0000|71 77|tissue
P08552387A0000|84 96|cell sarcoma
P08552387A0000|110 111|t
P08552387A0000|119 143|chromosome translocation
P08552387A0000|153 159|fusion
P08552387A0000|163 166|EWS
P08552387A0000|190 207|factor gene ATF-1
P08552643A0261|0 6|Clones
P08552643A0261|22 25|DBD
P08552643A0261|56 65|phenotype
P08552643A0261|95 103|activity
P08552643A0261|122 138|stomatitis virus
P08552643A0261|140 143|VSV
P08552643A0261|145 154|infection
P08552643A0261|160 173|IFN treatment
P08552670A0665|0 4|Abp1
P08552670A0665|38 43|sites
P08552670A0665|47 50|ARS
P08552670A0665|67 83|DNA polymer poly
P08552670A0665|84 85|d
P08552670A0665|86 89|A.T
P08552670T0000|0 14|Identification
P08552670T0000|16 28|purification
P08552670T0000|44 51|cloning
P08552670T0000|97 104|protein
P08552670T0000|112 125|fission yeast
P08553580A0102|13 26|reading frame
P08553580A0102|28 32|ORF2
P08553580A0102|46 54|function
P08553580A0102|74 86|FIV isolates
P08554069A0743|4 11|patient
P08554069A0743|46 54|mutation
P08554069A0743|80 81|G
P08554069A0743|84 98|T transversion
P08554069A0743|110 130|acceptor splice site
P08554069A0743|139 145|intron
P08554069A0743|152 156|exon
P08554069A0743|178 190|RNA splicing
P08554540A1480|6 13|regions
P08554540A1480|31 61|HIT protein similarity regions
P08554723A0187|13 17|rats
P08554723A0187|63 75|acid lesions
P08554723A0187|83 86|PBN
P08554723A0187|88 92|PBNx
P08554723A0187|149 152|CTA
P08554723A0187|156 165|l-alanine
P08554723A0187|171 172|M
P08554723A0187|191 206|sodium appetite
P08554723A0187|217 237|furosemide treatment
P08554723A0187|252 258|access
P08554723A0187|262 268|sodium
P08554723A0187|279 283|chow
P08555076A0333|10 24|Amphotericin-B
P08555076A0333|39 47|patients
P08555076A0333|68 75|mycosis
P08555076A0333|90 99|infection
P08555076A0333|105 116|Aspergillus
P08555076A0333|118 119|n
P08555076A0333|129 136|Candida
P08555076A0333|138 139|n
P08555168A0390|0 3|Mg2
P08555168A0390|9 12|Mn2
P08555168A0390|34 39|sites
P08555168A0390|70 78|affinity
P08555289A0207|9 25|storm indicators
P08555289A0207|43 51|medicine
P08555289A0207|56 66|geophysics
P08555289A0207|83 91|purposes
P08555446A0000|11 25|tobacco plants
P08555446A0000|27 32|ppa-1
P08555446A0000|77 92|pyrophosphatase
P08555446A0000|104 121|35S CaMV promoter
P08555446A0000|138 144|levels
P08555446A0000|156 162|sugars
P08555446A0000|172 178|leaves
P08555498A0427|6 11|LAF-4
P08555498A0427|36 41|genes
P08555498A0427|45 50|mouse
P08555498A0427|55 62|chicken
P08555498A0427|87 98|gene family
P08555498A0427|132 152|vertebrate evolution
P08555597A0808|0 9|Hb levels
P08555597A0808|29 31|Hb
P08555597A0808|49 53|g/dl
P08555597A0808|75 81|months
P08555753A0591|0 3|CBT
P08555753A0591|20 30|comparison
P08555753A0591|40 54|Wisconsin Card
P08555753A0591|63 67|Test
P08555753A0591|93 108|activation task
P08555753A0591|124 136|neuroimaging
P08555753A0591|152 157|lobes
P08556707A1390|6 10|data
P08556707A1390|34 40|218leu
P08556707A1390|56 80|transactivation activity
P08556707A1390|86 98|p53 promoter
P08556707A1390|102 107|yeast
P08556707A1390|125 137|temperatures
P08556707A1390|167 179|p53 function
P08556707A1390|187 195|presence
P08556707A1390|208 214|allele
P08556707A1390|218 230|SNU-C5 cells
P08558187A0403|0 6|Cycles
P08558187A0403|29 34|weeks
P08561607A1443|8 13|class
P08561607A1443|24 34|infections
P08561607A1443|45 60|transplantation
P08561893A0100|17 21|deal
P08561893A0100|51 58|factors
P08561893A0100|68 86|gene transcription
P08561893A0100|91 120|E-box DNA consensus sequences
P08561893A0100|122 129|studies
P08561893A0100|138 153|factor function
P08561893A0100|164 174|eukaryotes
P08561893A0100|207 215|presence
P08561893A0100|228 242|family members
P08561897A0604|0 8|Mobility
P08561897A0604|13 30|supershift assays
P08561897A0604|70 76|factor
P08561897A0604|78 81|USF
P08561897A0604|87 90|Sp1
P08561897A0604|110 118|elements
P08561897A0604|123 146|competition experiments
P08561897A0604|162 170|CREB/ATF
P08561897A0604|175 179|AP-1
P08561897A0604|192 207|CRE/TRE element
P08562688A0968|0 8|Upstream
P08562688A0968|37 46|sequences
P08562688A0968|54 62|isolates
P08562688A0968|78 84|length
P08562688A0968|89 97|sequence
P08563483A0094|9 14|cases
P08563483A0094|50 62|gonadotropin
P08563483A0094|64 67|hCG
P08563483A0094|69 75|levels
P08563483A0094|91 101|TSH levels
P08563483A0094|115 118|hCG
P08563483A0094|135 143|activity
P08564488A1359|5 22|fibrinogen levels
P08564488A1359|39 43|risk
P08564488A1359|62 72|thrombosis
P08564588A1318|0 21|Strontium chloride Sr
P08564588A1318|52 60|analysis
P08564588A1318|90 113|management expenditures
P08564588A1318|123 131|ABSTRACT
P08564588A1318|149 154|WORDS
P08565330A1783|27 35|features
P08565330A1783|55 62|control
P08565330A1783|74 81|control
P08565330A1783|93 103|expression
P08565548A0196|5 10|study
P08565548A0196|40 49|potential
P08565548A0196|53 65|silicone gel
P08565548A0196|98 106|collagen
P08565548A0196|111 114|BII
P08565548A0196|132 144|silicone gel
P08565548A0196|154 161|DA rats
P08566747A0756|0 3|SBF
P08566747A0756|17 25|promoter
P08566747A0756|39 49|activation
P08566747A0756|53 66|transcription
P08566747A0756|75 77|G1
P08566747A0756|95 111|Cln/Cdc28 kinase
P08566747A0756|126 133|ability
P08566747A0756|154 157|SBF
P08566747A0756|170 183|transcription
P08566751A0455|28 36|question
P08566751A0455|45 65|vertebrate Hox genes
P08566751A0455|86 93|control
P08566751A0455|119 128|sequences
P08566751A0455|148 156|function
P08566751A0455|171 180|Hox genes
P08566751A0788|5 13|approach
P08566751A0788|21 28|gHoxb-1
P08566751A0788|70 77|context
P08566751A0788|87 90|lab
P08566754A0783|8 28|splice site sequence
P08566754A0783|55 70|polyadenylation
P08566754A0783|98 100|U1
P08566754A0783|115 133|ribonucleoproteins
P08566754A0783|135 141|snRNPs
P08566754A0783|159 190|splicing factor/splicing factor
P08566754A0783|194 201|ASF/SF2
P08566756A0752|5 13|analysis
P08566756A0752|28 31|SAP
P08566756A0752|62 80|SF3a/SF3b subunits
P08566756A0752|82 96|UV cross-links
P08566756A0752|100 108|pre-mRNA
P08566756A0752|128 134|region
P08566756A0752|151 154|BPS
P08566773A1023|16 20|CTS1
P08566773A1023|25 29|CTS2
P08566773A1023|33 35|Ci
P08566773A1023|40 47|members
P08566773A1023|64 71|classes
P08566773A1023|82 92|chitinases
P08566773A1023|97 108|observation
P08566773A1023|146 152|fungus
P08567556A0000|13 24|consumption
P08567556A0000|48 52|MbO2
P08567556A0000|54 60|stores
P08567556A0000|64 76|seal muscles
P08567556A0000|102 114|seal muscles
P08567556A0000|122 144|laboratory simulations
P08567556A0000|148 154|diving
P08567556A0000|174 181|feature
P08567556A0000|192 204|field diving
P08567556A0000|214 226|measurements
P08567556A0000|230 240|heart rate
P08567556A0000|245 263|lactate production
P08567556A0000|276 287|differences
P08567556A0000|306 321|diving response
P08567556A0000|340 349|immersion
P08567683A0401|10 19|purH cDNA
P08567683A0401|28 38|base pairs
P08567683A0401|42 48|length
P08567683A0401|74 89|acid polypeptic
P08567683A0401|91 93|Mr
P08567717T0000|29 68|spindle pole body duplication gene MPS1
P08567717T0000|72 76|part
P08567717T0000|90 100|checkpoint
P08567847A1005|7 14|opinion
P08567847A1005|20 33|SM-CMA system
P08567847A1005|51 63|shortcomings
P08567847A1005|71 85|user-interface
P08567847A1005|110 120|instrument
P08567847A1005|125 136|examination
P08567847A1005|146 159|semen samples
P08567847A1005|176 184|features
P08569443A0123|4 11|purpose
P08569443A0123|19 24|study
P08569443A0123|66 77|differences
P08569443A0123|81 83|T1
P08569443A0123|88 90|T2
P08569443A0123|99 105|tumors
P08569443A0123|119 130|consequence
P08569443A0123|134 145|differences
P08569443A0123|164 170|volume
P08569443A0123|192 203|compartment
P08569680A0636|9 21|areA product
P08569680A0636|59 66|residue
P08569680A0636|91 95|GATA
P08569680A0636|110 116|domain
P08569680A0636|133 141|function
P08569684A0000|0 16|Oligonucleotides
P08569684A0000|34 39|basis
P08569684A0000|62 90|amino acid sequence segments
P08569684A0000|112 118|domain
P08569684A0000|133 149|protein kinase C
P08569684A0000|151 154|PKC
P08569684A0000|156 164|proteins
P08569684A0000|179 186|primers
P08569684A0000|191 217|polymerase chain reactions
P08569684A0000|250 262|DNA fragment
P08569684A0000|284 309|fungus Trichoderma reesei
P08570615T0000|0 10|Disruption
P08570615T0000|14 20|RB/E2F
P08570615T0000|23 34|interaction
P08570615T0000|45 60|point mutations
P08570615T0000|64 69|E2F-1
P08570615T0000|79 92|S-phase entry
P08570615T0000|97 106|apoptosis
P08572616A0000|9 13|loss
P08572616A0000|17 40|differentiation markers
P08572616A0000|74 83|neoplasms
P08573083A0645|5 11|region
P08573083A0645|23 28|motif
P08573083A0645|42 50|identity
P08573083A0645|60 72|binding site
P08573083A0645|92 112|transcription factor
P08573083A0645|134 140|factor
P08573083A0645|142 145|USF
P08573083A0645|173 189|insulin promoter
P08573637A0434|4 10|method
P08573637A0434|50 63|determination
P08573637A0434|67 78|paracetamol
P08573637A0434|97 109|formulations
P08573637A0434|125 131|fluids
P08574414A1037|6 13|primers
P08574414A1037|24 35|PCR product
P08574414A1037|56 62|length
P08574414A1037|75 94|Xanthomonas species
P08574414A1037|99 108|pathovars
P08574583A0658|4 15|Clb5 kinase
P08574583A0658|32 39|S phase
P08574583A0658|76 82|arrest
P08574583A0658|86 91|cells
P08574583A0658|108 114|strain
P08574583A0658|124 132|activity
P08574583A0658|153 164|sim mutants
P08575609A0526|4 13|C/D ratio
P08575609A0526|44 49|cases
P08575609A0526|54 58|eyes
P08575609A0526|69 75|values
P08575609A0526|107 111|eyes
P08575609A0526|117 118|%
P08575609A0526|126 134|patients
P08575614A0264|0 12|Rad6 mutants
P08575614A0264|46 55|phenotype
P08575614A0264|73 80|protein
P08575614A0264|84 87|DNA
P08575614A0264|103 114|mutagenesis
P08575614A0264|116 138|postreplication repair
P08575614A0264|140 150|repression
P08575614A0264|154 172|retrotransposition
P08575614A0264|178 189|sporulation
P08575618A1138|0 23|RNase protection assays
P08575618A1138|35 46|correlation
P08575618A1138|59 65|levels
P08575618A1138|69 75|dorsal
P08575618A1138|88 103|skin expression
P08575618A1138|109 145|pigmentation/phaeomelanin phenotypes
P08575754T0000|10 17|cloning
P08575754T0000|19 37|expression pattern
P08575754T0000|55 67|localization
P08575754T0000|77 89|CDKN2D/INK4d
P08575754T0000|94 103|inhibitor
P08575754T0000|107 113|cyclin
P08575754T0000|126 133|kinases
P08576042A0765|0 14|Overproduction
P08576042A0765|18 30|HrcA protein
P08576042A0765|45 49|copy
P08576042A0765|53 57|hrcA
P08576042A0765|73 80|plasmid
P08576042A0765|82 87|phrcA
P08576042A0765|93 104|B. subtilis
P08576042A0765|119 137|delta hrcA strains
P08576042A0765|148 168|heat shock induction
P08576042A0765|176 180|dnaK
P08576042A0765|185 197|groE operons
P08576042A0765|205 210|level
P08576042A0765|214 227|transcription
P08576042A0765|271 278|amounts
P08576042A0765|282 286|mRNA
P08576042A0765|296 307|temperature
P08576131A0151|24 31|cloning
P08576131A0151|47 63|characterization
P08576131A0151|67 80|USF2 isoforms
P08576131A0151|108 115|subunit
P08576131A0151|117 122|USF2a
P08576131A0151|141 148|subunit
P08576131A0151|150 155|USF2b
P08576131A0151|183 191|splicing
P08576131A0685|17 35|heterodimerization
P08576131A0685|39 51|USF subunits
P08576131A0685|95 106|association
P08576131A0685|123 131|subunits
P08576131A0685|148 160|USF proteins
P08576179A0126|10 13|PKR
P08576179A0126|29 34|dimer
P08576179A0126|69 98|translation initiation factor
P08576179A0126|101 114|alpha subunit
P08576179A0126|116 127|cIF-2 alpha
P08576179A0126|140 168|polypeptide chain initiation
P08576245A0000|0 5|GRP78
P08576245A0000|19 28|chaperone
P08576245A0000|58 67|reticulum
P08576245A0000|93 100|protein
P08576245A0000|113 129|stress responses
P08576245A0000|143 150|glucose
P08576245A0000|169 176|calcium
P08576245A0000|198 222|glycoprotein trafficking
P08576262A0160|4 17|IL-8 receptor
P08576262A0160|23 60|seven-transmembrane spanning receptor
P08576262A0160|96 106|G proteins
P08576262A0160|117 119|Gi
P08576262A0160|124 127|G16
P08576546A0975|12 18|series
P08576546A0975|22 33|experiments
P08576546A0975|39 47|efficacy
P08576546A0975|51 61|PDC/HDC Ac
P08576546A0975|104 118|dose regiments
P08580083A0259|28 40|significance
P08580083A0259|44 47|Fyn
P08580083A0259|55 65|expression
P08580083A0259|75 84|promoters
P08580083A0259|103 124|Fyn-expression vector
P08580083A0259|141 157|reporter plasmid
P08580083A0259|173 211|chloramphenicol acetyltransferase gene
P08580083A0259|222 229|HIV LTR
P08580083A0259|243 254|T cell line
P08580083A0259|256 262|Jurkat
P08580671A0137|50 55|trial
P08580671A0137|59 69|metoprolol
P08580671A0137|83 95|beta-blocker
P08580671A0137|100 110|prevention
P08580671A0137|131 139|bleeding
P08580671A0137|152 164|hypertension
P08580671A0137|184 192|patients
P08580671A0137|198 211|liver disease
P08580671A0137|242 250|bleeding
P08581174A0472|24 32|analysis
P08581174A0472|50 62|qutA mutants
P08581174A0472|82 91|mutations
P08581174A0472|101 104|map
P08581174A0472|127 131|half
P08581174A0472|147 159|QUTA protein
P08582143A0614|6 13|studies
P08582143A0614|44 48|test
P08582143A0614|89 113|cephalosporin substrates
P08582143A0614|123 133|nitrocefin
P08582143A0614|138 140|S1
P08582143A0614|169 194|beta-lactamase production
P08582143A0614|211 218|species
P08582633T0000|0 11|Suppressors
P08582633T0000|25 34|silencing
P08582633T0000|38 43|yeast
P08582633T0000|45 52|effects
P08582633T0000|72 82|repression
P08582633T0000|90 99|HMR locus
P08582633T0000|101 112|cell growth
P08582633T0000|117 135|telomere structure
P08583783A0870|9 12|ANP
P08583783A0870|40 50|filtration
P08583783A0870|59 63|calf
P08583783A0870|65 75|filtration
P08583783A0870|93 96|ANP
P08583846A0121|7 17|literature
P08583846A0121|37 55|beta-2 transferrin
P08583846A0121|87 93|marker
P08583846A0121|98 107|perilymph
P08583846A0807|13 43|methodology beta-2 transferrin
P08583846A0807|86 92|marker
P08583846A0807|97 106|perilymph
P08583846A0807|124 131|setting
P08584026A0115|4 15|hIGF-I gene
P08584026A0115|24 33|promoters
P08584026A0115|35 37|P1
P08584026A0115|42 44|P2
P08584035A0740|0 25|Gel mobility shift assays
P08584035A0740|63 71|proteins
P08584035A0740|102 120|binding properties
P08584035A0740|133 140|ability
P08584035A0740|155 171|beta I-A element
P08584035A0740|200 209|complexes
P08584035A0740|211 213|R1
P08584035A0740|217 219|R4
P08584074A0000|11 19|patients
P08584074A0000|36 41|years
P08584074A0000|44 50|months
P08584074A0000|58 63|years
P08584074A0000|109 122|lobe epilepsy
P08584074A0000|124 127|TLE
P08584074A0000|153 159|period
P08584074A0000|166 172|months
P08584074A0000|176 198|Bethel Epilepsy Center
P08584530A0545|12 24|correlations
P08584530A0545|41 45|FEV1
P08584530A0545|68 74|values
P08584530A0545|78 81|Raw
P08584530A0545|83 88|MEF50
P08584530A0545|93 98|MEF25
P08584530A0545|144 155|differences
P08584530A0545|164 176|test results
P08585324A0467|34 43|SSC1 gene
P08585324A0467|45 50|Smith
P08585324A0823|5 11|region
P08585324A0823|28 32|gene
P08585324A0823|55 64|precursor
P08585324A0823|71 78|remnant
P08585324A0823|84 95|tau element
P08585639T0000|13 21|exposure
P08585639T0000|25 42|hepatitis B virus
P08585639T0000|53 75|immunodeficiency virus
P08585639T0000|91 104|risk analysis
P08585883A0381|0 6|Hybrid
P08585883A0381|14 18|mice
P08585883A0381|20 31|C57BL x CBA
P08585883A0381|50 63|breeder males
P08585883A0381|65 69|CD-1
P08585883A0381|75 86|LNG pellets
P08585883A0381|105 108|day
P08585883A0381|116 119|day
P08585883A0381|129 145|copulation plugs
P08585883A0381|164 167|day
P08585883A0381|173 176|day
P08585883A0381|197 203|period
P08585957A0101|5 9|gene
P08585957A0101|29 49|transcription factor
P08585957A0101|55 62|regions
P08585957A0101|66 74|homology
P08585957A0101|92 100|proteins
P08585957A0101|115 127|zinc fingers
P08585957A0101|138 145|domains
P08585957A0101|174 186|gene product
P08585957A0101|197 204|AT-hook
P08585957A0101|218 223|motif
P08585957A0101|232 255|mobility group proteins
P08585994A0567|6 22|reference probes
P08585994A0567|35 44|standards
P08585994A0567|63 85|ost transcription unit
P08585994A0567|120 138|band interval 89A1
P08585994A0567|154 157|arm
P08585994A0567|171 181|chromosome
P08585994A0567|213 250|segmentation gene expression patterns
P08585994A0567|258 264|embryo
P08586643A0951|25 31|enzyme
P08586643A0951|51 70|phosphoryl transfer
P08586643A0951|76 79|ATP
P08586643A0951|83 86|UMP
P08586643A0951|91 94|CMP
P08586874T0000|0 7|Studies
P08586874T0000|15 25|life cycle
P08586874T0000|29 47|Haplorchis pumilio
P08586874T0000|49 54|Looss
P08586874T0000|62 67|Looss
P08586874T0000|93 106|redescription
P08586874T0000|127 133|stages
P08587075T0000|11 25|microaneurysms
P08587075T0000|31 36|cases
P08587075T0000|40 57|hepatitis B virus
P08587075T0000|66 86|polyarteritis nodosa
P08588852A0236|21 30|pregnancy
P08588852A0236|48 55|studies
P08588852A0236|68 73|fetus
P08588852A0236|86 90|week
P08588852A0236|94 103|gestation
P08588852A0236|120 132|micrognathia
P08588852A0236|149 155|thumbs
P08588852A0236|165 169|toes
P08588852A0236|181 187|tibiae
P08589315A1029|19 32|survival rate
P08589315A1029|38 39|%
P08589315A1029|41 49|survival
P08589315A1029|87 88|%
P08589315A1029|114 120|groups
P08589315A1029|122 142|tumor lysis syndrome
P08589315A1029|156 175|lupus erythematosus
P08589315A1029|181 189|patients
P08589315A1029|199 200|%
P08589315A1029|220 228|syndrome
P08589315A1029|234 242|patients
P08589315A1029|246 247|%
P08589358A0235|12 20|units/kg
P08589358A0235|42 56|erythropoietin
P08589358A0235|58 63|rhEPO
P08589358A0235|92 97|times
P08589358A0235|100 104|week
P08589358A0235|111 116|weeks
P08589358A0841|9 16|regimen
P08589358A0841|20 34|erythropoietin
P08589358A0841|56 61|donor
P08589358A0841|64 68|need
P08589358A0841|91 108|blood transfusion
P08589358A0841|127 136|Hb levels
P08589358A0841|152 162|milligrams
P08589735A0577|9 19|constructs
P08589735A0577|21 35|GUS expression
P08589735A0577|50 66|promoter regions
P08589735A0577|84 117|Arabidopsis alcohol dehydrogenase
P08589735A0577|119 123|Adh1
P08589735A0577|126 141|maize ubiquitin
P08589735A0577|143 147|Ubi1
P08589735A0577|150 160|rice actin
P08589735A0577|162 166|Act1
P08589735A0577|172 186|CaMV 35S genes
P08590465A0773|4 16|organization
P08590465A0773|21 31|regulation
P08590465A0773|50 52|S.
P08590465A0773|59 76|URA1 gene product
P08590465A0773|119 136|URA2 gene product
P08591700A0972|4 24|mean body mass index
P08591700A0972|26 29|BMI
P08591700A0972|48 53|kg/m2
P08591700A0972|71 76|kg/m2
P08591700A0972|80 85|women
P08591700A0972|90 93|men
P08592590A0822|6 14|findings
P08592590A0822|32 54|haemodialysis patients
P08592590A0822|68 79|hepatitis C
P08592590A0822|96 116|interferon treatment
P08592590A0822|138 146|response
P08592590A0822|169 179|proportion
P08592590A0822|183 191|patients
P08592713T0001|10 21|enantiomers
P08592713T0001|25 30|drugs
P08593813A0967|9 17|analysis
P08593813A0967|47 51|germ
P08593813A0967|66 75|Sp1 mRNAs
P08593813A0967|112 122|efficiency
P08593813A0967|140 150|transcript
P08595012A0817|3 15|nondiabetics
P08595012A0817|20 28|response
P08595012A0817|32 37|tcPO2
P08595012A0817|49 52|LDF
P08595012A0817|75 81|values
P08595012A0817|85 89|rest
P08595184A0407|5 10|study
P08595184A0407|23 32|estimator
P08595184A0407|63 70|effects
P08595184A0407|86 98|correlations
P08595184A0407|114 130|field potentials
P08595184A0407|132 136|LFPs
P08595414A0000|4 12|assembly
P08595414A0000|16 24|sequence
P08595414A0000|57 61|maps
P08595414A0000|66 78|construction
P08595414A0000|104 111|contigs
P08595414A0000|137 150|model genomes
P08595414A0000|169 182|determination
P08595414A0000|190 196|extent
P08595414A0000|225 231|clones
P08595414A0000|258 269|orientation
P08595627A1513|5 12|opening
P08595627A1513|16 20|KATP
P08595627A1513|33 43|inhibition
P08595627A1513|51 58|channel
P08595627A1513|82 94|consequences
P08595627A1513|107 116|occlusion
P08595627A1513|128 140|KATP opening
P08595627A1513|172 174|VF
P08595627A1513|209 211|VF
P08595658A0961|4 17|DNA sequences
P08595658A0961|36 43|termini
P08595658A0961|52 60|homology
P08595658A0961|64 100|plant mitochondrial-processing sites
P08595658A0961|128 132|ends
P08595658A0961|164 178|RNA processing
P08595836T0000|7 16|shrinkage
P08595836T0000|32 39|changes
P08595836T0000|58 71|glass ionomer
P08595836T0000|84 93|materials
P08595878A0201|24 32|evidence
P08595878A0201|49 63|PP2A functions
P08595878A0201|78 82|Ras1
P08595878A0201|100 124|receptor tyrosine kinase
P08595878A0201|126 129|RTK
P08595878A0201|131 158|signal transduction pathway
P08595878A0201|174 200|R7 photoreceptor cell fate
P08595878A0201|219 233|Drosophila eye
P08597108A0642|0 5|QBMDs
P08597108A0642|13 21|% change
P08597108A0642|25 33|response
P08597108A0642|35 41|QBMD05
P08597108A0642|65 72|average
P08597108A0642|97 102|NOAEL
P08597177T0000|0 7|Effects
P08597177T0000|20 29|exposures
P08597177T0000|33 50|hydrogen sulphide
P08597177T0000|54 57|rat
P08597177T0000|70 73|EEG
P08597596A0135|4 8|gene
P08597596A0135|32 40|cassette
P08597596A0135|42 57|ABC transporter
P08597636A0000|10 15|motif
P08597636A0000|32 38|family
P08597636A0000|42 47|genes
P08597636A0000|65 73|features
P08597636A0000|78 97|expression patterns
P08597636A0000|112 123|involvement
P08597636A0000|141 156|gene regulation
P08598051T0000|10 18|analysis
P08598051T0000|30 49|schizosaccharomyces
P08598051T0000|56 60|gene
P08598051T0000|76 98|RNP consensus-sequence
P08598051T0000|111 118|domains
P08598359X0000|11 25|treatment time
P08598359X0000|27 37|field size
P08598359X0000|43 69|treatment energy influence
P08598359X0000|76 83|control
P08598359X0000|87 92|T1-T2
P08598359X0000|102 117|cell carcinomas
P08598359X0000|133 139|larynx
P08598359X0000|141 148|PURPOSE
P08598359X0000|162 171|treatment
P08598359X0000|176 183|patient
P08598359X0000|203 210|factors
P08598359X0000|236 243|control
P08598359X0000|251 260|treatment
P08598359X0000|264 269|T1-T2
P08598359X0000|279 293|cell carcinoma
P08598359X0000|309 315|larynx
P08598449A0784|3 11|contrast
P08598449A0784|19 28|signaling
P08598449A0784|42 63|surface Ig engagement
P08598449A0784|67 80|B lymphocytes
P08598449A0784|82 95|CD38 ligation
P08598449A0784|121 145|tyrosine phosphorylation
P08598449A0784|162 190|protein tyrosine kinases lyn
P08598449A0784|192 195|fyn
P08598449A0784|201 204|btk
P08598449A0784|212 215|vav
P08598449A0784|243 250|protein
P08598449A0784|281 288|changes
P08598449A0784|302 305|CA2
P08598449A0784|307 321|concentrations
P08599945T0000|0 9|Mutations
P08599945T0000|17 31|alpha-amanitin
P08599945T0000|42 48|domain
P08599945T0000|64 71|subunit
P08599945T0000|75 95|yeast RNA polymerase
P08599945T0000|116 128|RNA cleavage
P08599945T0000|149 160|transitions
P08599946A0999|4 12|evidence
P08599946A0999|46 57|p40 complex
P08599946A0999|63 88|ribonucleoprotein complex
P08599946A0999|100 108|L1Hs RNA
P08599946A0999|109 110|s
P08599946A0999|137 149|interactions
P08599946A0999|171 181|structures
P08599946A0999|199 219|example coiled-coils
P08599946A0999|238 245|complex
P08600028A1129|4 8|data
P08600028A1129|22 38|trans-activation
P08600028A1129|60 75|intron enhancer
P08600028A1129|90 100|reflection
P08600028A1129|121 131|properties
P08600028A1129|139 150|Myc protein
P08600048T0000|17 31|conjunctivitis
P08600048T0000|42 69|bone marrow transplantation
P08600048T0000|110 115|study
P08600048T0000|123 127|case
P08601283A0875|3 7|view
P08601283A0875|15 23|presence
P08601283A0875|27 41|SECIS elements
P08601283A0875|54 68|reading frames
P08601283A0875|70 74|ORFs
P08601283A0875|89 103|selenoproteins
P08601283A0875|120 127|effects
P08601283A0875|135 139|type
P08601283A0875|142 152|deiodinase
P08601283A0875|170 173|ORF
P08601283A0875|183 196|SECIS element
P08601283A0875|239 253|SECIS function
P08601284A0000|28 34|spacer
P08601284A0000|36 39|ETS
P08601284A0000|41 47|region
P08601284A0000|55 63|pre-rRNA
P08601284A0000|103 111|sequence
P08601284A0000|120 122|bp
P08601284A0000|134 149|complementarity
P08601284A0000|157 166|U3 snoRNA
P08601490A0659|6 13|animals
P08601616A0726|5 19|spindle defect
P08601616A0726|23 35|pds1 mutants
P08601616A0726|73 77|step
P08601616A0726|101 114|G1/S boundary
P08601616A0726|125 129|time
P08601616A0726|133 149|spindle assembly
P08601806A0875|6 10|data
P08601806A0875|24 29|RPF-1
P08601806A0875|64 69|steps
P08601806A0875|77 92|differentiation
P08601806A0875|96 104|amacrine
P08601806A0875|109 123|ganglion cells
P08602169A0484|7 19|point mutant
P08602169A0484|39 45|repair
P08602169A0484|49 61|endonuclease
P08602169A0484|66 70|site
P08602169A0484|85 89|type
P08602169A0484|99 106|removal
P08602169A0484|110 114|CPDs
P08602169A0484|122 131|MAT alpha
P08602169A0484|136 150|HML alpha loci
P08602608A1056|27 32|cases
P08602608A1056|38 50|performances
P08602608A1056|58 64|CD3500
P08602608A1056|73 77|STKS
P08602608A1056|145 164|reference procedure
P08603921A1346|17 36|Spc110p truncations
P08603921A1346|49 72|calmodulin binding site
P08603921A1346|85 91|growth
P08603921A1346|125 129|cell
P08603921A1346|145 151|manner
P08604338A0198|5 14|EWS-FLI-1
P08604338A0198|19 33|FLI-1 proteins
P08604338A0198|46 67|transcription factors
P08604338A0198|94 107|ets sequences
P08604338A0198|113 122|ets boxes
P08604338A0198|135 152|promoter elements
P08604338A0885|3 31|electromobility shift assays
P08604338A0885|33 50|EWS-FLI-1 binding
P08604338A0885|58 61|SRE
P08604338A0885|83 90|absence
P08604338A0885|94 97|SRF
P08604338A0885|110 117|binding
P08604338A0885|121 126|FLI-1
P08604338A0885|155 166|interaction
P08604338A0885|172 175|DNA
P08604338A0885|183 187|step
P08604338A0885|209 226|complex formation
P08604338A0885|230 235|FLI-1
P08604708A1086|11 18|studies
P08604708A1086|56 75|cellulose dialyzers
P08604708A1086|105 121|blood flow rates
P08604708A1086|128 135|minutes
P08604708A1086|146 152|change
P08604708A1086|156 159|BTG
P08605302A1770|0 15|DNA methylation
P08605302A1770|57 72|deoxyadenosines
P08605302A1770|84 95|GATC motifs
P08605302A1770|114 118|exon
P08605302A1770|146 152|intron
P08605302A1770|160 174|rice CatA gene
P08605302A1770|212 234|CatA promoter activity
P08605302A1770|263 268|assay
P08605324A0434|10 13|LTR
P08605324A0434|30 38|promoter
P08605326A0772|12 23|cDNA clones
P08605705A0676|3 13|conclusion
P08605705A0676|15 28|IgM class CIC
P08605705A0676|48 51|CIC
P08605705A0676|61 72|hepatitis A
P08605705A0676|93 109|disease activity
P08605931A0777|0 15|Epitope mapping
P08605931A0777|42 48|clones
P08605931A0777|82 96|epitope domain
P08605931A0777|123 132|RNP motif
P08605931A0777|140 151|U1A protein
P08606267A0740|0 9|Variables
P08606267A0740|25 31|number
P08606267A0740|50 56|events
P08606267A0740|58 62|data
P08606267A0740|79 95|exercise testing
P08606267A0740|135 147|registration
P08606267A0740|166 176|evaluation
P08606267A0740|180 216|Tc-99m 2-methoxy isobutyl isonitrile
P08606267A0740|218 222|MIBI
P08606267A0740|224 229|scans
P08606267A0740|244 253|variables
P08608126A0811|7 13|length
P08608126A0811|27 31|acid
P08608126A0811|47 63|binding affinity
P08608126A0811|86 90|acid
P08608126A0811|111 112|K
P08608126A0811|113 114|d
P08608126A0811|132 134|nM
P08608126A0811|140 152|medium-chain
P08608126A0811|163 167|acid
P08608126A0811|179 190|short-chain
P08608126A0811|201 205|acid
P08608126A0811|212 218|lipids
P08608222T0000|32 38|region
P08608222T0000|48 59|granulocyte
P08608222T0000|79 94|factor receptor
P08608222T0000|111 116|STAT3
P08608222T0000|125 150|STAT1 homodimer formation
P08608447A0806|33 50|codon recognition
P08608447A0806|58 73|TPI transcripts
P08608447A0806|80 85|place
P08608447A0806|104 112|splicing
P08608448A0353|14 22|residues
P08608448A0353|49 65|dimethylsulphate
P08608448A0353|70 78|kethoxal
P08608448A0353|82 89|regions
P08608448A0353|145 160|structure model
P08608448A0353|167 172|S RNA
P08608448A0353|188 198|reactivity
P08608448A0353|216 224|residues
P08608448A0353|237 242|loops
P08610272A0265|19 33|investigations
P08610272A0265|64 72|approach
P08610272A0265|83 90|control
P08610272A0265|104 112|duration
P08610272A0265|116 140|maintenance chemotherapy
P08610272A0265|159 163|role
P08610272A0265|176 194|response modifiers
P08610272A0265|199 213|growth factors
P08610272A0265|239 246|outcome
P08610272A0265|251 259|patients
P08610272A0265|270 277|disease
P08610328A0228|0 7|SUMMARY
P08610328A0228|11 17|REVIEW
P08610328A0228|34 42|criteria
P08610328A0228|58 65|studies
P08610328A0228|93 104|experiences
P08610328A0228|115 122|studies
P08610328A0228|144 149|world
P08610582A0150|11 19|patients
P08610582A0150|33 40|lesions
P08610582A0150|55 63|CT scans
P08610582A0150|94 104|MR imaging
P08610582A0150|112 114|T.
P08611280A0820|12 19|volumes
P08611280A0820|60 68|subjects
P08611280A0820|89 95|cm3/m2
P08611280A0820|108 114|cm3/m2
P08611280A0820|116 117|p
P08611280A0820|129 134|onset
P08611280A0820|145 152|systole
P08611280A0820|163 169|cm3/m2
P08611280A0820|182 188|cm3/m2
P08611280A0820|190 191|p
P08611280A0820|220 226|cm3/m2
P08611280A0820|238 244|cm3/m2
P08611280A0820|246 247|p
P08612852A0553|0 7|RESULTS
P08612852A0553|15 34|plasma IGF-I levels
P08612852A0553|46 61|body mass index
P08612852A0553|63 66|BMI
P08612852A0553|94 102|patients
P08612852A0553|119 127|controls
P08614403A0557|21 27|levels
P08614403A0557|31 50|Rev-erbA alpha mRNA
P08614403A0557|63 78|C2C12 myoblasts
P08614403A0557|111 116|cells
P08614403A0557|164 172|myotubes
P08614403A0989|29 57|GAL4-REV-erbA alpha chimeras
P08614403A0989|76 78|AB
P08614403A0989|80 86|region
P08614403A0989|101 102|E
P08614403A0989|104 110|region
P08614403A0989|121 134|transcription
P08614403A0989|138 160|GAL4 response elements
P08614403A0989|168 176|presence
P08614403A0989|180 189|8-Br-cAMP
P08614403A0989|216 222|domain
P08614403A0989|224 227|LBD
P08614403A0989|264 272|silencer
P08614410A0000|4 24|alpha T3-1 cell line
P08614410A0000|44 65|gonadotroph cell line
P08614410A0000|88 99|oncogenesis
P08614410A0000|114 118|mice
P08614410A0000|138 148|regulation
P08614410A0000|156 190|glycoprotein hormone alpha-subunit
P08614410A0000|194 201|activin
P08615012A0627|0 14|Cotransfection
P08615012A0627|24 32|ie1 gene
P08615012A0627|56 64|increase
P08615012A0627|72 78|amount
P08615012A0627|90 97|enzymes
P08615012A0627|127 132|cells
P08615025A1214|13 26|glycosylation
P08615025A1214|30 33|Env
P08615025A1214|48 55|mutants
P08615025A1214|94 117|glycosylation phenotype
P08615025A1214|131 141|quantities
P08615025A1214|145 148|Env
P08615025A1214|176 192|immunoreactivity
P08615025A1214|196 198|V3
P08615025A1214|218 223|gp160
P08615025A1214|253 258|gp120
P08615025A1214|263 267|gp41
P08615025A1214|274 277|Env
P08615025A1214|297 310|cell membrane
P08615025A1214|325 330|gp120
P08615025A1214|337 340|CD4
P08615025A1214|351 364|membrane gp41
P08615025A1214|384 399|membrane fusion
P08615025A1214|405 408|CD4
P08615025A1214|410 415|cells
P08615183T0000|0 7|Effects
P08615183T0000|26 37|pallidotomy
P08615183T0000|41 50|Parkinson
P08615183T0000|53 60|disease
P08616743T0000|7 12|trail
P08616743T0000|16 19|Dr.
P08617216A0584|23 27|DnaJ
P08617216A0584|47 51|DnaK
P08617216A0584|64 71|protein
P08617216A0584|73 77|GrpE
P08617216A0584|82 91|refolding
P08617216A0584|110 120|luciferase
P08617237A0489|18 30|phosphoforms
P08617237A0489|34 39|STAT5
P08617237A0489|64 87|DNA binding specificity
P08617237A0489|92 102|reactivity
P08617237A0489|108 132|tyrosine phosphopeptides
P08617237A0489|163 175|localization
P08617238A0334|0 13|TNF Treatment
P08617238A0334|17 21|cell
P08617238A0334|36 58|p38 MAP kinase pathway
P08617238A0334|85 100|phosphorylation
P08617238A0334|104 118|p38 MAP kinase
P08617238A0334|127 137|activation
P08617238A0334|145 178|substrate protein MAPKAP kinase-2
P08617238A0334|203 218|phosphorylation
P08617238A0334|226 244|heat shock protein
P08617238A0334|249 254|hsp27
P08617243A0336|25 32|protein
P08617243A0336|57 65|extracts
P08617243A0336|96 100|site
P08617243A0336|116 122|region
P08617311A0979|19 38|sequence similarity
P08617311A0979|51 65|membrane exons
P08617311A0979|75 79|mIgY
P08617311A0979|94 98|mIgG
P08617311A0979|103 106|IgE
P08617311A0979|132 142|similarity
P08617311A0979|148 160|Xenopus mIgY
P08617800A0150|0 7|Control
P08617800A0150|11 24|transcription
P08617800A0150|32 43|erbB-2 gene
P08617800A0150|60 71|determinant
P08617800A0150|75 94|receptor expression
P08617800A0675|0 5|DNase
P08617800A0675|8 20|footprinting
P08617800A0675|41 62|mobility shift assays
P08617800A0675|77 80|PBP
P08617800A0675|94 103|half-site
P08617800A0675|112 122|palindrome
P08617800A0675|132 164|core recognition sequence TGGGAG
P08617802A0993|6 13|results
P08617802A0993|31 40|sequences
P08617802A0993|48 66|SH2/SH3/SH2 region
P08617802A0993|70 78|p120 GAP
P08617802A0993|111 119|activity
P08617802A0993|127 130|Ras
P08618433A0000|24 49|growth factor FLT3 ligand
P08618433A0000|51 53|FL
P08618433A0000|70 76|ligand
P08618433A0000|85 89|FLT3
P08618433A0000|91 115|tyrosine kinase receptor
P08618433A0000|117 118|R
P08618433A0000|141 146|FLK-2
P08618433A0000|151 156|STK-1
P08618433A1720|3 11|contrast
P08618433A1720|29 39|expression
P08618433A1720|47 55|receptor
P08618433A1720|57 70|FL expression
P08618433A1720|93 94|%
P08618433A1720|110 120|cell types
P08618433A1720|124 143|leukemia cell lines
P08618433A1720|167 180|cell lineages
P08618864A0754|8 16|analysis
P08618864A0754|25 31|domain
P08618864A0754|44 55|mutagenesis
P08618864A0754|69 73|core
P08618864A0754|100 108|residues
P08618864A0754|129 137|activity
P08618882A0343|0 8|Analysis
P08618882A0343|12 29|RAR alpha mutants
P08618882A0343|33 53|transfection studies
P08618882A0343|71 89|DNA binding domain
P08618882A0343|108 118|inhibition
P08618882A0343|122 136|BZLF1 activity
P08619866A0000|12 42|serum hepatocyte growth factor
P08619866A0000|44 47|HGF
P08619866A0000|52 60|patients
P08619866A0000|83 93|infarction
P08619866A0000|95 110|angina pectoris
P08619866A0000|122 136|heart diseases
P08619910A0000|11 20|mechanism
P08619910A0000|37 51|motor symptoms
P08619910A0000|59 67|rigidity
P08619910A0000|69 75|tremor
P08619910A0000|80 88|akinesia
P08619910A0000|104 110|result
P08619910A0000|128 147|dopamine deficiency
P08619910A0000|179 191|observations
P08619910A0000|199 205|effect
P08619910A0000|238 247|treatment
P08619910A0000|255 262|disease
P08619910A0000|266 274|relation
P08619910A0000|300 308|findings
P08619910A0000|331 350|nigra zona compacta
P08619910A0000|352 355|SNc
P08620003T0000|0 16|Protein splicing
P08620003T0000|18 26|evidence
P08620003T0000|34 56|N-O acyl rearrangement
P08620003T0000|72 76|step
P08620003T0000|84 100|splicing process
P08620856A1172|3 12|agreement
P08620856A1172|24 28|data
P08620856A1172|30 54|western blot experiments
P08620856A1172|64 72|antibody
P08620856A1172|111 118|portion
P08620856A1172|126 145|mouse c-kit protein
P08620856A1172|160 171|polypeptide
P08620856A1172|180 184|size
P08620856A1172|207 220|reading frame
P08620856A1172|247 257|c-kit cDNA
P08620856A1172|285 291|stages
P08620856A1172|295 310|spermatogenesis
P08620856A1172|329 340|spermatozoa
P08620889A0771|22 25|G+C
P08620889A0771|32 39|element
P08620889A0771|47 66|aldolase C promoter
P08620889A0771|75 88|transcription
P08620889A0771|127 132|cells
P08621017A1186|0 8|LY290181
P08621017A1186|28 51|uPA promoter activation
P08621017A1186|64 71|phorbol
P08621017A1186|89 96|binding
P08621017A1186|108 116|proteins
P08621017A1186|124 135|uPA PEA3/12
P08621017A1186|138 169|tetradecanoylphorbol 13-acetate
P08621017A1186|181 188|element
P08621017A1186|190 193|TRE
P08621384A0935|0 9|Treatment
P08621384A0935|13 26|keratinocytes
P08621384A0935|57 79|growth factor receptor
P08621384A0935|81 85|EGFR
P08621384A0935|92 100|TGFalpha
P08621384A0935|114 127|growth factor
P08621384A0935|134 137|min
P08621384A0935|146 179|PKCdelta tyrosine phosphorylation
P08621420A1166|18 23|bands
P08621420A1166|44 52|antibody
P08621420A1166|56 59|p50
P08621420A1166|69 79|antibodies
P08621420A1166|83 86|p65
P08621420A1166|96 114|NF-kappaB proteins
P08621420A1166|122 128|effect
P08621448A0862|28 31|DNA
P08621448A0862|33 37|cDNA
P08621448A0862|39 44|clone
P08621448A0862|53 78|RL95-2 expression library
P08621448A0862|96 98|C1
P08621448A0862|112 119|protein
P08621451A0552|0 4|Biol
P08621453A0815|3 11|addition
P08621453A0815|34 44|antibodies
P08621453A0815|64 69|80K-H
P08621453A0815|75 87|cell lysates
P08621453A0815|127 138|fibroblasts
P08621542A0535|10 25|protein kinases
P08621542A0535|27 32|c-Jun
P08621542A0535|46 53|kinases
P08621542A0535|55 59|JNKs
P08621542A0535|78 93|protein kinases
P08621542A0535|117 126|TNF-alpha
P08621542A0535|128 132|IL-1
P08621542A0535|138 156|CD28 costimulation
P08621628A1233|6 13|hGRbeta
P08621628A1233|59 68|inhibitor
P08621628A1233|72 89|hGRalpha activity
P08621659A0189|0 4|Gas6
P08621659A0189|30 40|Gla domain
P08621659A0189|68 74|growth
P08621659A0189|87 94|repeats
P08621659A0189|116 117|G
P08621659A0189|119 126|domains
P08621661A1035|5 22|P5CDh cDNA clones
P08621661A1035|46 56|transcript
P08621661A1035|60 74|Northern blots
P08621661A1035|93 100|tissues
P08621661A1035|122 126|cDNA
P08621661A1035|158 164|intron
P08621661A1035|192 202|transcript
P08621664A1430|0 14|Polymerization
P08621664A1430|18 41|neurofilament L protein
P08621664A1430|68 83|phosphorylation
P08621664A1430|87 110|neurofilament L protein
P08621664A1430|114 117|PKN
P08621714A0361|4 11|protein
P08621714A0361|37 52|disulfide bonds
P08621714A0361|64 75|thiol group
P08621714A0361|79 84|Cys25
P08621719A0000|7 13|others
P08621719A0000|41 69|c-cbl proto-oncogene product
P08621719A0000|93 100|targets
P08621719A0000|104 128|tyrosine phosphorylation
P08621719A0000|134 161|T cell receptor stimulation
P08621719A0568|14 22|fraction
P08621719A0568|26 29|Cbl
P08621719A0568|65 69|Grb2
P08621719A0568|79 90|interaction
P08621719A0568|107 123|Grb2 SH3 domains
P08621730T0000|3 24|AP-1 binding sequence
P08621730T0000|42 52|regulation
P08621730T0000|66 72|alpha2
P08621730T0000|73 74|I
P08621730T0000|76 84|collagen
P08621730T0000|86 92|COL1A2
P08621730T0000|94 111|promoter activity
P08621730T0000|128 146|growth factor-beta
P08622030A0667|15 26|differences
P08622030A0667|51 61|age groups
P08622030A0667|65 89|baseline characteristics
P08622030A0667|101 119|treatment protocol
P08622030A0667|121 139|performance status
P08622030A0667|145 172|serum lactate dehydrogenase
P08622030A0667|174 177|LDH
P08622030A0667|179 184|level
P08622070A0889|9 17|patients
P08622070A0889|22 23|%
P08622070A0889|31 33|CA
P08622070A0889|38 46|response
P08622070A0889|54 58|time
P08622070A0889|71 82|progression
P08622596A0189|4 7|men
P08622596A0189|35 39|diet
P08622596A0189|43 47|home
P08622596A0189|70 73|fat
P08622596A0189|89 92|fat
P08622596A0189|99 103|week
P08622645A1026|17 20|VDR
P08622645A1026|39 49|vitamin D3
P08622645A1026|67 79|RA induction
P08622645A1026|103 110|element
P08622668A1155|6 13|results
P08622668A1155|50 58|function
P08622668A1155|62 68|U6 RNA
P08622668A1155|74 84|modulation
P08622668A1155|90 129|phosphorylation-dephosphorylation cycle
P08622668A1155|133 149|C1 hnRNP protein
P08622668A1155|170 186|binding affinity
P08622668A1155|195 202|protein
P08622668A1155|207 215|pre-mRNA
P08622675A0587|0 9|Inclusion
P08622675A0587|26 36|N terminus
P08622675A0587|66 73|protein
P08622675A0587|97 107|similarity
P08622675A0587|124 136|factor Lef-1
P08622698T0000|20 26|Notch1
P08622698T0000|58 63|genes
P08622698T0000|69 78|mechanism
P08622698T0000|111 122|virus EBNA2
P08622887A1026|16 37|mobility shift assays
P08622887A1026|39 44|EMSAs
P08622887A1026|61 103|glucocorticoid receptor DNA binding domain
P08622887A1026|105 108|DBD
P08622887A1026|133 138|GRE-2
P08622887A1026|146 152|motifs
P08622887A1026|167 170|DBD
P08622887A1026|175 214|oligonucleotide competition experiments
P08622887A1026|253 263|affinities
P08622887A1026|268 271|DBD
P08622893A0000|10 19|subfamily
P08622893A0000|23 48|receptor tyrosine kinases
P08622893A0000|50 54|RTKs
P08622893A0000|66 69|EPH
P08622893A0000|77 86|prototype
P08622893A0000|99 104|roles
P08622893A0000|122 135|communication
P08622893A0000|160 171|development
P08622893A0000|193 212|signalling pathways
P08622893A0000|230 236|family
P08623554A1058|11 18|protein
P08623554A1058|48 57|infection
P08623554A1058|61 67|plants
P08624445A0257|35 54|sequencing analysis
P08624445A0257|62 91|cytosine methylation patterns
P08624445A0257|99 124|transposase binding sites
P08624445A0257|137 139|Ac
P08624445A0257|152 157|wx-m9
P08624445A0257|159 168|Ac allele
P08624445A0257|176 178|Ac
P08624445A0257|200 210|tenth exon
P08624445A0257|223 227|gene
P08625806A0263|0 7|Krox-20
P08625806A0263|11 27|zinc finger gene
P08625806A0263|52 59|pattern
P08625806A0263|63 73|expression
P08625806A0263|77 79|r3
P08625806A0263|84 86|r5
P08625806A0263|126 137|maintenance
P08625806A0263|141 154|mouse embryos
P08625900T0000|10 19|adenylate
P08625900T0000|39 50|polypeptide
P08625900T0000|61 88|prolactin promoter activity
P08625900T0000|95 109|protein kinase
P08625900T0000|121 128|pathway
P08625900T0000|172 179|pathway
P08625900T0000|214 221|hormone
P08625924A0411|0 10|Clones 33F
P08625924A0411|15 18|34B
P08625924A0411|37 55|aromatase proteins
P08625924A0411|63 74|amino acids
P08625924A0411|92 96|size
P08625924A0411|116 144|polyadenylation signal usage
P08625924A0411|167 172|mRNAs
P08625987A1086|10 38|bone marrow cells expression
P08625987A1086|47 58|VpreB genes
P08625987A1086|75 87|pro-B/pre-BI
P08625987A1086|106 111|cells
P08625987A1086|123 126|RNA
P08625987A1086|134 146|state levels
P08625987A1086|213 220|B cells
P08626065A0000|39 56|Bacillus subtilis
P08626065A0000|58 60|Bs
P08626065A0000|62 74|DNA fragment
P08626065A0000|95 99|nrdA
P08626065A0000|104 114|citB genes
P08626065A0000|128 135|degrees
P08626065A0000|143 153|chromosome
P08626290T0000|0 21|Aeromonas salmonicida
P08626290T0000|36 41|genes
P08626290T0000|51 59|homologs
P08626290T0000|79 95|membrane protein
P08626290T0000|97 101|OmpA
P08626313A1037|0 10|Expression
P08626313A1037|14 17|Msp
P08626313A1037|55 63|msp gene
P08626325A0543|3 12|agreement
P08626325A0543|36 40|data
P08626325A0543|61 65|UmuD
P08626325A0543|70 74|UmuD
P08626325A0543|98 108|homodimers
P08626325A0543|110 119|UmuD-UmuD
P08626325A0543|124 128|UmuD
P08626325A0543|130 134|UmuD
P08626325A0543|143 154|heterodimer
P08626325A0543|156 165|UmuD-UmuD
P08626437A0332|0 10|Lyn kinase
P08626437A0332|35 42|lysates
P08626437A0332|57 60|BCP
P08626437A0332|86 111|glutathione S-transferase
P08626437A0332|113 116|GST
P08626437A0332|118 128|Lyn fusion
P08626437A0332|170 177|p34cdc2
P08626437A0332|181 189|tyrosine
P08626493A1468|0 9|Mutations
P08626493A1468|27 33|region
P08626493A1468|37 40|CR2
P08626493A1468|45 48|E1A
P08626493A1468|66 73|binding
P08626493A1468|77 80|E1A
P08626493A1468|88 115|retinoblastoma gene product
P08626493A1468|117 120|pRb
P08626493A1468|143 154|stimulation
P08626493A1468|158 171|transcription
P08626493A1468|181 195|PEPCK promoter
P08626493A1468|227 235|type E1A
P08626529A0000|6 20|autoantibodies
P08626529A0000|28 35|Sjogren
P08626529A0000|38 54|syndrome patient
P08626529A0000|107 123|membrane protein
P08626529A0000|154 158|face
P08626529A0000|179 183|Kooy
P08626529A0000|185 187|J.
P08626529A0000|189 192|Toh
P08626529A0000|194 196|B.
P08626529A0799|28 35|regions
P08626529A0799|37 48|amino acids
P08626529A0799|69 73|p230
P08626529A0799|95 104|frequency
P08626529A0799|108 122|heptad repeats
P08626529A0799|124 138|characteristic
P08626529A0799|142 155|alpha-helices
P08626529A0799|186 196|structures
P08626529A0799|198 202|p230
P08626529A0799|221 240|sequence ESLALEELEL
P08626529A0799|242 253|amino acids
P08626529A0799|266 271|motif
P08626529A0799|285 298|granin family
P08626529A0799|309 317|proteins
P08626529A0799|339 347|granules
P08626529A0799|351 371|neuroendocrine cells
P08626539T0000|0 19|Binding specificity
P08626539T0000|24 34|modulation
P08626539T0000|42 66|ApoA-I promoter activity
P08626539T0000|70 74|homo
P08626539T0000|80 92|heterodimers
P08626539T0000|104 113|receptors
P08626540A1007|42 56|concentrations
P08626540A1007|61 69|turnover
P08626540A1007|98 106|ceramide
P08626540A1007|108 124|glucosylceramide
P08626540A1007|130 146|lactosylceramide
P08626596A0000|17 25|evidence
P08626596A0000|55 69|protein kinase
P08626596A0000|71 75|AMPK
P08626596A0000|85 89|role
P08626596A0000|104 109|cells
P08626596A0000|115 123|stresses
P08626596A0000|135 148|ATP depletion
P08626596A0000|193 201|pathways
P08626610A0931|16 27|suppression
P08626610A0931|31 39|cleavage
P08626610A0931|43 50|SREBP-1
P08626610A0931|106 112|region
P08626610A0931|114 121|residue
P08626610A0931|134 147|COOH terminus
P08626610A0931|170 175|forms
P08626610A0931|181 187|result
P08626610A0931|203 211|splicing
P08626612A1040|0 2|Am
P08626667A1372|0 28|EMSA competition experiments
P08626667A1372|41 50|mutations
P08626667A1372|69 76|repeats
P08626667A1372|99 106|binding
P08626667A1372|122 130|proteins
P08626667A1372|147 167|type oligonucleotide
P08626667A1517|0 13|Transcription
P08626667A1517|23 31|promoter
P08626667A1517|62 69|repeats
P08626667A1517|113 123|conclusion
P08626667A1517|135 151|motifs functions
P08626667A1517|171 190|GPT gene expression
P08626698A0989|21 29|increase
P08626698A0989|33 46|ERK3 activity
P08626698A0989|55 76|PKC beta transfectant
P08626698A0989|90 109|immunoprecipitation
P08626698A0989|136 144|antibody
P08626698A0989|171 191|complex kinase assay
P08626698A0989|201 217|gel kinase assay
P08626777A0537|0 17|Sequence analysis
P08626777A0537|33 48|Col2a1 enhancer
P08626777A0537|66 81|sequence motifs
P08626777A0537|93 99|motifs
P08626777A0537|130 136|region
P08626777A0537|144 161|link protein gene
P08626777A0537|171 185|cartilage gene
P08626785A0674|19 29|activation
P08626785A0674|37 69|tissue transglutaminase promoter
P08626785A0674|108 114|region
P08626785A0674|126 135|sequences
P08626785A0674|179 218|mouse tissue transglutaminase promoters
P08626785A0674|232 238|region
P08626785A0674|263 293|pair retinoid response element
P08626785A0674|295 302|mTGRRE1
P08626785A0674|305 312|mTGRRE1
P08626785A0674|328 353|hexanucleotide half-sites
P08626785A0674|397 410|DR7/DR5 motif
P08626785A0674|426 429|RAR
P08626785A0674|430 446|RXR heterodimers
P08626785A0674|451 465|RXR homodimers
P08626809A0729|15 19|pPKR
P08626809A0729|63 68|Ser51
P08626809A0729|84 102|eIF-2alpha peptide
P08626809A0729|110 124|characteristic
P08626809A0729|132 156|eIF-2alpha kinase family
P08627354A0000|11 20|synapsins
P08627354A0000|34 40|family
P08627354A0000|53 61|proteins
P08627354A0000|86 96|regulation
P08627354A0000|100 124|neurotransmitter release
P08627649A0734|16 37|mobility shift assays
P08627649A0734|50 58|extracts
P08627649A0734|64 75|FREJ4 cells
P08627649A0734|89 96|binding
P08627649A0734|102 108|member
P08627649A0734|109 110|s
P08627649A0734|119 129|Ets family
P08627649A0734|133 154|transcription factors
P08627649A0734|162 168|P4 EBS
P08627649A0734|185 196|interaction
P08627649A0734|204 211|members
P08627649A0734|219 229|Sp1 family
P08627649A0734|231 234|Sp1
P08627649A0734|239 242|Sp3
P08627649A0734|262 268|GC box
P08627667A0132|0 5|ZEBRA
P08627667A0132|19 39|AP-1 bZip activators
P08627667A0132|49 54|c-Fos
P08627667A0132|84 91|domains
P08627667A0132|115 128|specificities
P08627688A1520|5 11|result
P08627688A1520|34 38|I299
P08627688A1520|66 74|activity
P08627719A0784|0 28|UV cross-linking experiments
P08627719A0784|47 60|HSV infection
P08627719A0784|77 84|binding
P08627719A0784|88 103|protein factors
P08627719A0784|126 135|component
P08627719A0784|139 166|cleavage stimulation factor
P08627719A0784|168 172|CstF
P08627719A0784|178 182|poly
P08627719A0784|183 184|A
P08627719A0784|186 195|site RNAs
P08627719A0784|201 212|virus genes
P08627719A0784|229 236|classes
P08627719A0784|260 267|binding
P08627719A0784|277 287|expression
P08627719A0784|291 295|IE63
P08628251A1455|0 7|CM-ACO3
P08628251A1455|24 31|flowers
P08628251A1455|65 72|stimuli
P08628254A0665|24 40|Jun/eb1 chimeras
P08628254A0665|52 67|transactivators
P08628254A0665|71 80|AP1 sites
P08628254A0665|114 122|c-Ha-Ras
P08628254A0665|133 137|foci
P08628255A0932|16 26|HeLa cells
P08628255A0932|28 38|expression
P08628255A0932|42 61|luciferase activity
P08628255A0932|81 90|beginning
P08628255A0932|94 107|DNA synthesis
P08628255A0932|133 141|presence
P08628255A0932|160 164|site
P08628255A0932|172 186|H2A.1 promoter
P08628260A0895|20 40|transfection studies
P08628260A0895|44 55|HepG2 cells
P08628260A0895|76 84|deletion
P08628260A0895|92 98|factor
P08628260A0895|104 122|promoter sequences
P08628260A0895|133 143|nucleotide
P08628260A0895|148 155|results
P08628260A0895|183 191|increase
P08628260A0895|195 212|promoter activity
P08628284A0181|17 38|yeast reporter strain
P08628284A0181|54 63|lacZ gene
P08628284A0181|74 81|control
P08628284A0181|89 102|CYC1 promoter
P08628284A0181|125 131|copies
P08628284A0181|135 140|TRE-1
P08628302A0683|3 10|hnRNP K
P08628302A0683|16 36|transcription factor
P08628302A0683|43 55|interactions
P08628302A0683|65 79|RNA polymerase
P08628302A0683|83 106|transcription apparatus
P08628681A0364|32 39|kb mRNA
P08628681A0364|57 71|Northern blots
P08628681A0364|75 85|oocyte RNA
P08628681A0364|96 109|X.laevis cDNA
P08628681A0821|0 21|Sequence conservation
P08628681A0821|38 46|residues
P08628681A0821|71 78|centers
P08628681A0821|86 89|exo
P08628681A0821|94 105|pol domains
P08628681A0821|120 134|DNA polymerase
P08629348A0237|31 38|history
P08629348A0237|48 50|BI
P08629348A0237|93 100|changes
P08629348A0237|159 168|processes
P08629348A0237|184 189|cysts
P08629348A0237|235 243|epilepsy
P08629348A0237|245 258|hydrocephalus
P08630542A1421|6 14|findings
P08630542A1421|32 40|increase
P08630542A1421|44 45|V
P08630542A1421|65 76|consequence
P08630542A1421|84 92|increase
P08630542A1421|96 97|Q
P08630542A1421|115 123|response
P08630542A1421|131 140|procedure
P08630548A0000|8 17|cytokines
P08630548A0000|33 39|degree
P08630548A0000|52 62|regulation
P08630548A0000|85 92|potency
P08630548A0000|100 113|interleukin-1
P08630548A0000|115 119|IL-1
P08630548A0000|122 149|tumor necrosis factor-alpha
P08630548A0000|151 160|TNF-alpha
P08630583A1056|3 5|pH
P08630583A1056|10 12|Hb
P08630583A1056|42 53|CO2 content
P08630583A1056|59 65|effect
P08630583A1056|69 70|Q
P08630599A0534|3 13|difference
P08630599A0534|17 46|elastin peptide concentration
P08630599A0534|82 90|patients
P08630599A0534|103 111|subjects
P08630599A0534|113 117|mean
P08630599A0534|122 124|SD
P08630599A0534|141 154|micrograms/ml
P08630599A0534|158 166|patients
P08630599A0534|188 201|micrograms/ml
P08630599A0534|205 214|policemen
P08630599A0534|233 246|micrograms/ml
P08630599A0534|250 261|coal miners
P08631667A0851|0 14|Identification
P08631667A0851|23 29|region
P08631667A0851|45 53|tmk gene
P08631667A0851|82 97|complementation
P08631667A0851|103 120|yeast dTMP kinase
P08631667A0851|143 149|mutant
P08631667A0851|166 178|enzyme assay
P08631667A0851|198 213|kinase activity
P08631667A0851|217 230|cell extracts
P08631667A0851|245 248|use
P08631667A0851|270 278|plasmids
P08631685A0000|15 19|gene
P08631685A0000|24 30|copper
P08631685A0000|60 77|monoamine oxidase
P08631685A0000|79 83|maoA
P08631685A0000|100 118|amine oxidase gene
P08631685A0000|145 148|min
P08631685A0000|173 183|chromosome
P08631760A0609|5 16|interaction
P08631760A0609|36 46|SH2 domain
P08631760A0609|50 53|Crk
P08631760A0609|82 96|phosphopeptide
P08631760A0609|112 133|Crk-SH2 binding motif
P08631797A0982|16 22|ErbB-2
P08631797A0982|38 54|receptor subunit
P08631797A0982|60 84|tyrosine phosphorylation
P08631797A0982|120 127|ligands
P08631797A0982|163 169|effect
P08631797A0982|173 176|NDF
P08631797A0982|180 191|EGF binding
P08631817T0000|0 14|Identification
P08631817T0000|20 29|consensus
P08631817T0000|47 74|kinase phosphorylation site
P08631817T0000|97 101|form
P08631817T0000|111 156|deoxyuridine triphosphate nucleotidohydrolase
P08631820A0755|4 8|cDNA
P08631820A0755|30 39|FPS1 gene
P08631820A0755|67 82|complementation
P08631820A0755|95 107|yeast strain
P08631820A0755|121 133|FPS activity
P08631820A0755|135 143|Delourme
P08631820A0755|145 147|D.
P08631820A0755|149 157|Lacroute
P08631820A0755|159 161|F.
P08631820A0755|167 172|Karst
P08631820A0755|174 176|F.
P08631822A0677|13 30|plasmin fragments
P08631822A0677|34 38|VEGF
P08631822A0677|58 65|respect
P08631822A0677|69 84|heparin binding
P08631822A0677|86 97|interaction
P08631822A0677|111 125|VEGF receptors
P08631822A0677|131 138|ability
P08631822A0677|162 178|cell mitogenesis
P08631908A0224|0 7|VDR/RXR
P08631908A0224|26 31|VDREs
P08631908A0224|39 42|DR4
P08631908A0224|47 50|DR5
P08631908A0224|77 97|mobility shift assay
P08631934A0000|4 11|members
P08631934A0000|19 29|Myb family
P08631934A0000|33 54|transcription factors
P08631934A0000|70 78|homology
P08631934A0000|98 104|domain
P08631934A0000|131 135|site
P08631934A0000|137 140|MBS
P08631934A0000|142 150|sequence
P08631934A0000|152 154|YG
P08631934A0000|155 158|A/G
P08631934A0000|159 160|C
P08631934A0000|161 166|A/C/G
P08631934A0000|167 170|GTT
P08631934A0000|171 174|G/A
P08631944A0663|3 11|contrast
P08631944A0663|22 29|isoform
P08631944A0663|45 62|C epsilon4 domain
P08631944A0663|86 93|M2 exon
P08631944A0663|95 105|IgE grande
P08631944A0663|127 142|J558L cell line
P08631944A0663|189 193|cell
P08631944A0663|209 219|regulation
P08631944A0663|223 232|secretion
P08631958T0000|6 21|cytomegalovirus
P08631958T0000|38 57|protein IE2 tethers
P08631958T0000|76 93|repression domain
P08631958T0000|97 100|p53
P08632009A1067|4 15|specificity
P08632009A1067|19 25|action
P08632009A1067|29 49|C/EBP family members
P08632009A1067|74 89|characteristics
P08632009A1067|98 104|factor
P08632009A1067|120 139|expression profiles
P08632009A1067|145 167|DNA binding affinities
P08632009A1067|173 182|cofactors
P08632009A1067|198 206|addition
P08632009A1067|214 239|DNA binding specificities
P08632015A0879|4 14|antibodies
P08632015A0879|42 55|transcription
P08632015A0879|59 88|DNA polymerase alpha promoter
P08632015A1226|19 27|analysis
P08632015A1226|45 53|presence
P08632015A1226|57 73|DREF polypeptide
P08632015A1226|77 83|nuclei
P08632015A1226|109 123|division cycle
P08632015A1226|149 161|accumulation
P08632015A1226|165 169|DREF
P08632015A1226|210 220|expression
P08632015A1226|224 227|DNA
P08632015A1226|248 253|genes
P08632015A1226|263 276|DRE sequences
P08632018A0587|2 14|DNA fragment
P08632018A0587|30 41|nucleotides
P08632018A0587|71 77|region
P08632018A0587|85 96|UGT1A1 gene
P08632018A0587|112 124|MC induction
P08632463A1508|5 11|result
P08632463A1508|25 33|argument
P08632463A1508|43 47|beta
P08632463A1508|49 56|subunit
P08632463A1508|76 80|role
P08632463A1508|100 108|progress
P08632463A1508|112 136|transcription elongation
P08632779A0351|4 15|XPG regions
P08632779A0351|30 33|NLS
P08632779A0351|35 45|amino acid
P08632779A0351|47 49|AA
P08632779A0351|64 69|NLS-B
P08632779A0351|71 73|AA
P08632779A0351|89 94|NLS-C
P08632779A0351|96 98|AA
P08632779A0351|157 165|beta-gal
P08632779A0351|183 184|%
P08632779A0351|193 200|nucleus
P08632779A0351|204 214|HeLa cells
P08633855A1064|4 13|lacS gene
P08633855A1064|31 67|E. coli-Streptococcus shuttle vector
P08633855A1064|96 120|lacS deletion derivative
P08633855A1064|124 139|S. thermophilus
P08633855A1064|161 167|strain
P08633855A1064|179 185|NZ6091
P08634290A0000|4 10|genome
P08634290A0000|18 30|retroviruses
P08634290A0000|57 61|RNAs
P08634290A0000|97 100|end
P08634357A0527|4 23|extraction recovery
P08634357A0527|27 41|Amphotericin B
P08634357A0527|65 70|fluid
P08634357A0527|88 89|%
P08634357A0527|113 118|range
P08634420A1784|0 10|HuEpo-R Ab
P08634420A1784|42 58|UT-7 cell growth
P08634420A1784|76 81|cells
P08634420A1784|85 90|clone
P08634420A1784|115 122|muEpo-R
P08634420A1784|147 170|UT-7 cell proliferation
P08634423A0498|4 13|frequency
P08634423A0498|17 29|integrations
P08634423A0498|42 55|transcription
P08634423A0498|63 72|lacZ gene
P08634423A0498|96 97|%
P08634423A0498|105 117|integrations
P08634423A0498|130 131|%
P08634423A0498|154 169|differentiation
P08634423A0498|173 182|32D cells
P08634423A0498|191 202|neutrophils
P08634697A1155|4 12|sequence
P08634697A1155|26 31|cDNAs
P08634697A1155|52 60|reagents
P08634697A1155|78 88|expression
P08634697A1155|92 97|Brca1
P08634697A1155|105 110|mouse
P08634697A1155|132 142|importance
P08634697A1155|175 182|domains
P08635771A0000|2 7|study
P08635771A0000|37 43|ONLINE
P08635771A0000|48 68|EMIT II immunoassays
P08635771A0000|74 112|gas chromatographic/mass spectrometric
P08635771A0000|114 119|GC/MS
P08635771A0000|121 129|analysis
P08635771A0000|133 157|methaqualone metabolites
P08635771A0000|161 166|urine
P08635771A0000|173 180|samples
P08635771A0000|206 211|study
P08636031A1413|0 11|Interaction
P08636031A1413|19 32|Fur repressor
P08636031A1413|47 55|fragment
P08636031A1413|73 86|pvdS promoter
P08636031A1413|119 138|Fur titration assay
P08636031A1413|165 192|gel retardation experiments
P08636031A1413|219 234|Fur preparation
P08636124A0410|5 12|protein
P08636124A0410|29 33|cDNA
P08636124A0410|56 63|p150TSP
P08636124A0410|97 111|phosphoprotein
P08636124A0410|146 153|nucleus
P08636124A0410|181 190|evolution
P08636149A0220|12 21|receptors
P08636149A0220|44 56|cell surface
P08636149A0220|67 74|insulin
P08636149A0220|114 133|autophosphorylation
P08636149A0220|137 145|response
P08636149A0220|149 156|insulin
P08636211A0983|0 7|EMBO J.
P08636428A1363|20 27|results
P08636428A1363|71 98|smooth muscle proliferation
P08636428A1363|135 145|expression
P08636428A1363|171 179|mitogens
P08637006A0000|0 13|Transcription
P08637006A0000|19 29|adenovirus
P08637006A0000|39 47|promoter
P08637006A0000|74 79|array
P08637006A0000|99 107|elements
P08637006A0000|134 142|TBP site
P08637006A0000|148 157|E2F sites
P08637006A0000|181 192|orientation
P08637006A0000|224 232|ATF site
P08637711A1121|32 36|IL-6
P08637711A1121|37 53|interferon gamma
P08637711A1121|55 64|IFN gamma
P08637711A1121|66 82|response element
P08637711A1121|90 104|IRF-1 promoter
P08637711A1121|106 112|IR/IRF
P08637711A1121|147 151|site
P08637711A1121|177 181|site
P08637711A1121|207 224|binding complexes
P08637711A1121|236 247|JRE-IL6-BCs
P08637717A0817|9 16|peptide
P08637717A0817|18 29|amino acids
P08637717A0817|54 66|p21-activity
P08637717A0817|77 84|peptide
P08637717A0817|104 111|ability
P08637717A0817|115 118|p21
P08637717A0817|136 149|cyclin E/Cdk2
P08637717A1231|2 13|p21 peptide
P08637717A1231|23 34|amino acids
P08637717A1231|61 65|PCNA
P08637717A1231|71 91|filter binding assay
P08637717A1231|101 108|peptide
P08637717A1231|132 152|p21-PCNA interaction
P08638435A0522|0 7|Results
P08638435A0522|30 51|agar diffusion method
P08638435A0522|56 73|Y. enterocolitica
P08638435A0522|83 102|inhibition activity
P08638435A0522|121 134|A. hydrophila
P08639310A0548|0 3|OND
P08639310A0548|6 17|mg tid days
P08639310A0548|29 44|mg tid prn days
P08639310A0548|73 84|mg qds days
P08639310A0548|96 99|MCP
P08639310A0548|127 134|mg i.v.
P08639310A0548|142 144|CT
P08639310A0548|149 152|MCP
P08639310A0548|156 163|mg p.r.
P08639310A0548|178 179|h
P08639521A1032|12 22|properties
P08639521A1032|31 47|protein fragment
P08639521A1032|112 118|models
P08639521A1032|132 138|motion
P08639561T0000|0 9|Adduction
P08639561T0000|23 34|N-ras codon
P08639561T0000|38 46|sequence
P08639561T0000|57 59|7S
P08639561T0000|61 62|R
P08639561T0000|64 65|R
P08639561T0000|68 69|S
P08639561T0000|75 86|dihydroxy-9
P08639561T0000|90 97|epoxy-7
P08639561T0000|105 120|tetrahydrobenzo
P08639561T0000|124 130|pyrene
P08639561T0000|143 153|refinement
P08639561T0000|174 178|SRSR
P08639561T0000|190 192|7S
P08639561T0000|194 195|R
P08639561T0000|197 198|S
P08639561T0000|201 202|R
P08639561T0000|222 237|tetrahydrobenzo
P08639561T0000|240 247|pyrenyl
P08639561T0000|253 273|deoxyadenosyl adduct
P08639561T0000|279 285|1H NMR
P08639742T0000|0 9|Isolation
P08639742T0000|13 16|PCR
P08639742T0000|22 32|cDNA clone
P08639742T0000|38 48|pea petals
P08639742T0000|54 64|similarity
P08639742T0000|68 75|petunia
P08639742T0000|80 106|wheat zinc finger proteins
P08639837A0268|5 13|fragment
P08639837A0268|44 51|factors
P08639837A0268|72 78|GATA-1
P08639837A0268|83 90|members
P08639837A0268|98 108|Ets family
P08640866A0473|0 8|Exposure
P08640866A0473|23 36|blood T cells
P08640866A0473|48 56|subjects
P08640866A0473|60 63|PHA
P08640866A0473|100 110|antibodies
P08640866A0473|128 137|increases
P08640866A0473|141 145|MAPK
P08640866A0473|150 153|MEK
P08640866A0473|164 172|activity
P08641705A0986|16 28|observations
P08641705A0986|39 53|heterozygosity
P08641705A0986|61 62|A
P08641705A0986|67 77|G mutation
P08641705A0986|81 91|codon beta
P08641705A0986|109 117|deletion
P08641705A0986|140 150|Hbs Lepore
P08641705A0986|154 159|Kenya
P08641705A0986|166 194|beta-globin gene duplication
P08641705A0986|200 205|point
P08641705A0986|226 237|inheritance
P08641705A0986|241 254|Hb Costa Rica
P08642282A1009|18 29|description
P08642282A1009|38 47|knowledge
P08642282A1009|63 71|elements
P08642282A1009|85 95|expression
P08642282A1009|101 105|gene
P08642282A1009|117 119|B7
P08642282A1009|134 142|molecule
P08642285A1548|0 18|DNA-STAT complexes
P08642285A1548|60 70|cell lines
P08642285A1548|101 111|antibodies
P08642285A1548|120 125|STAT1
P08642285A1548|130 135|STAT5
P08642313A0770|37 46|cell line
P08642313A0770|48 54|TAN-1C
P08642313A0770|65 70|kappa
P08642313A0770|83 98|transactivation
P08642313A0770|112 132|reporter gene assays
P08642313A0770|138 145|fashion
P08642313A0770|182 189|protein
P08642313A0770|191 196|Bcl-3
P08642313T0000|0 6|T cell
P08642313T0000|64 79|Notch homologue
P08642313T0000|84 91|I kappa
P08642313T0000|99 107|activity
P08642313T0000|146 169|factor-kappa B proteins
P08642313T0000|173 180|T cells
P08642693T0000|0 22|Polyprotein processing
P08642693T0000|26 43|Southampton virus
P08642693T0000|45 59|identification
P08642693T0000|71 94|protease cleavage sites
P08642693T0000|107 118|mutagenesis
P08643111A0855|14 17|LL2
P08643111A0855|19 23|hLL2
P08643111A0855|40 45|chain
P08643111A0855|55 75|region glycosylation
P08643111A0855|87 105|immunoreactivities
P08643111A0855|147 150|LL2
P08643111A0855|152 156|cLL2
P08643111A0855|210 220|properties
P08643111A0855|243 254|counterpart
P08643111A0855|288 304|oligosaccharides
P08643111A0855|314 318|mLL2
P08643111A0855|341 356|antigen binding
P08643382A0752|23 38|transit peptide
P08643382A0752|53 59|region
P08643382A0752|69 73|poly
P08643382A0752|74 75|A
P08643382A0752|77 81|tail
P08643382A0752|95 105|cDNA clone
P08643382A0752|126 145|chloroplast protein
P08643513A0361|0 17|Deletion analysis
P08643513A0361|21 24|rOC
P08643513A0361|50 78|acetyltransferase constructs
P08643513A0361|114 122|sequence
P08643513A0361|143 151|promoter
P08643513A0361|166 168|nt
P08643513A0361|187 188|%
P08643513A0361|196 201|level
P08643513A0361|205 232|osteocalcin gene expression
P08643557A0259|17 25|question
P08643557A0259|33 45|HOX proteins
P08643557A0259|65 69|sets
P08643557A0259|73 85|target genes
P08643578A0000|0 9|RAS2val19
P08643578A0000|32 36|form
P08643578A0000|65 69|Ras2
P08643578A0000|99 105|growth
P08643578A0000|110 120|expression
P08643578A0000|142 153|reporter FG
P08643578A0000|154 157|TyA
P08643578A0000|160 164|lacZ
P08643578A0000|189 217|mating pathway reporter FUS1
P08643578A0000|219 223|lacZ
P08643578A0532|14 38|Rho family protein Cdc42
P08643578A0532|66 75|G protein
P08643578A0532|94 103|regulator
P08643578A0532|119 125|growth
P08643578A0532|130 132|FG
P08643578A0532|133 136|TyA
P08643578A0532|139 154|lacZ expression
P08643633A1187|5 22|immunoprecipitate
P08643633A1187|35 42|complex
P08643633A1187|46 48|N1
P08643633A1187|49 56|deltaEC
P08643633A1187|62 66|CBF1
P08643646A0479|5 11|region
P08643646A0479|21 25|verA
P08643646A0479|40 44|gene
P08643646A0479|84 96|biosynthesis
P08643646A0479|131 142|transcripts
P08643646A0479|154 158|size
P08643646A0479|175 177|kb
P08643646A0479|232 242|conditions
P08643682A0268|12 25|localizations
P08643682A0268|43 50|CBFbeta
P08643682A0268|59 87|CBFbeta-SMMHC fusion protein
P08643682A0268|107 125|immunofluorescence
P08643682A0268|129 142|NIH 3T3 cells
P08643682A0268|173 187|fusion protein
P08643759A0338|16 21|phase
P08643759A0338|51 72|personality variables
P08643759A0338|83 88|group
P08644734A0404|14 23|isolation
P08644734A0404|33 38|cDNAs
P08644734A0404|86 107|segment-polarity gene
P08645214A1052|17 21|BL21
P08645214A1052|23 26|DE3
P08645214A1052|27 32|plysS
P08645214A1052|59 66|plasmid
P08645214A1052|82 106|catalase-peroxidase gene
P08645214A1052|125 131|amount
P08645214A1052|135 143|proteins
P08645214A1052|164 172|SDS/PAGE
P08645214A1052|189 195|enzyme
P08645219A1377|0 3|Ca2
P08645219A1377|15 18|Zn2
P08645219A1377|20 27|binding
P08645219A1377|31 40|S100 beta
P08645219A1377|77 82|MRP14
P08645219A1377|104 107|Zn2
P08645219A1377|109 121|binding site
P08645219A1377|167 170|Ca2
P08645219A1377|172 187|binding domains
P08647086A0622|0 4|Cdk2
P08647086A0622|14 21|complex
P08647086A0622|27 36|cyclin D1
P08647086A0622|45 51|system
P08647086A0720|4 26|Cdk2-cyclin-D1 complex
P08647086A0720|60 70|substrates
P08647086A0720|80 90|H1 histone
P08647086A0720|92 95|pRB
P08647086A0720|97 101|SV40
P08647086A0720|108 117|T antigen
P08647086A0720|119 122|p53
P08647086A0720|124 129|E2F-1
P08647086A0720|135 146|preparation
P08647086A0720|158 166|proteins
P08647086A0720|172 182|HeLa cells
P08647086A0720|187 195|contrast
P08647086A0720|197 210|Cdk2-cyclin-E
P08647086A0720|215 228|Cdk2-cyclin-A
P08647086A0720|250 258|proteins
P08647086T0000|17 25|kinase-2
P08647086T0000|27 31|Cdk2
P08647086T0000|51 58|complex
P08647086T0000|64 73|cyclin D1
P08647086T0000|80 84|Cdk2
P08647086T0000|101 110|cyclin D1
P08647086T0000|136 149|Cdk7-cyclin-H
P08647091A0592|16 22|clones
P08647091A0592|46 56|Adh-2 gene
P08647091A0592|74 79|exons
P08647091A0592|91 97|region
P08647091A0592|108 117|placement
P08647091A0592|121 128|introns
P08647091A0592|171 180|ADH genes
P08647264T0000|0 8|Ligation
P08647264T0000|12 16|CD40
P08647264T0000|39 55|lymphoma B cells
P08647264T0000|61 78|calcium ionophore
P08647264T0000|84 91|antigen
P08647264T0000|111 120|apoptosis
P08647264T0000|135 145|activation
P08647264T0000|153 181|cysteine protease CPP32/Yama
P08647264T0000|186 194|cleavage
P08647264T0000|202 216|substrate PARP
P08647434A1124|6 15|T antigen
P08647434A1124|44 54|antibodies
P08647434A1124|73 76|TBP
P08647434A1124|89 92|TBP
P08647434A1124|94 98|hTAF
P08647434A1124|107 111|hTAF
P08647434A1124|124 128|hTAF
P08647434A1124|143 153|conditions
P08647434A1124|160 170|holo-TFIID
P08647451A0663|0 27|Northern blot hybridization
P08647451A0663|46 53|HEP-COP
P08647451A0663|78 83|range
P08647451A0663|109 116|tissues
P08647802A0000|20 37|signaling protein
P08647802A0000|89 100|arrangement
P08647802A0000|104 123|SH3-SH2-SH3 domains
P08647802A0000|127 131|Grb2
P08647822T0000|9 13|role
P08647822T0000|18 24|sterol
P08647822T0000|36 59|element binding protein
P08647822T0000|63 73|activation
P08647822T0000|104 112|coenzyme
P08647822T0000|115 129|reductase gene
P08647884A0547|34 43|reticulum
P08647884A0547|62 71|MHC class
P08647884A0547|74 83|molecules
P08647884A0547|110 119|transport
P08647884A0547|127 139|cell surface
P08648408A0792|9 12|PHT
P08648408A0792|17 27|CSA groups
P08648408A0792|43 53|Hyp levels
P08648408A0792|87 93|PHT-GO
P08648408A0792|95 100|group
P08648408A0792|113 119|CSA-GO
P08648408A0792|121 126|group
P08648665A0956|10 23|LE6 deletions
P08648665A0956|48 73|transformation efficiency
P08648665A0956|99 104|cells
P08648665A0956|142 145|LE6
P08648665A1320|0 15|ORF E8 colinear
P08648665A1320|21 27|ORF E6
P08648665A1320|66 73|protein
P08648665A1320|93 100|segment
P08648665A1320|120 125|cells
P08648665A1320|147 161|pZipNeo vector
P08648726A0713|0 7|Cloning
P08648726A0713|22 32|ZI domains
P08648726A0713|55 63|promoter
P08648726A0713|86 89|ZIA
P08648726A0713|91 94|ZIC
P08648726A0713|100 111|ZID domains
P08648726A0713|125 135|ZIB domain
P08648726A0713|141 144|TPA
P08649372A0501|0 17|Clb2/Cdc28 kinase
P08649372A0501|42 52|repression
P08649372A0501|68 74|factor
P08649372A0501|91 99|activity
P08649372A0501|103 105|G2
P08649372A0501|110 117|M phase
P08649372A0755|4 20|carboxy terminus
P08649372A0755|24 28|Mbp1
P08649372A0755|47 58|interaction
P08649372A0755|64 68|Swi6
P08649372A0755|78 94|carboxy terminus
P08649372A0755|98 102|Swi6
P08649372A0755|119 130|interaction
P08649372A0755|136 140|Mbp1
P08649373T0000|25 37|cis elements
P08649373T0000|68 77|chromatin
P08649373T0000|91 101|c-myc gene
P08649386A1032|6 29|UASH consensus sequence
P08649386A1032|59 67|analysis
P08649386A1032|86 100|consensus Abf1
P08649386A1032|109 113|site
P08649389A0000|36 52|CTCF cDNA clones
P08649389A0000|114 125|factor CTCF
P08649389A0000|163 170|protein
P08649389A0000|184 194|% identity
P08649389A0000|219 239|amino acid sequences
P08649389A0692|11 19|analysis
P08649389A0692|39 56|CTCF binding site
P08649389A0692|61 97|transient-cotransfection experiments
P08649389A0692|115 119|CTCF
P08649389A0692|141 150|repressor
P08649389A0692|164 174|c-myc gene
P08649393A0000|2 34|chromosome transmission fidelity
P08649393A0000|36 39|ctf
P08649393A0000|41 47|mutant
P08649393A0000|49 53|s138
P08649393A0000|105 115|centromere
P08649393A0000|117 120|CEN
P08649393A0000|138 159|readthrough phenotype
P08649393A0000|182 203|kinetochore integrity
P08649403A0963|4 17|growth defect
P08649403A0963|23 32|reg1 reg2
P08649403A0963|40 46|mutant
P08649403A0963|83 91|mutation
P08649403A0963|112 126|protein kinase
P08649405T0000|0 3|Sp1
P08649405T0000|14 19|sites
P08649405T0000|27 41|CD11c promoter
P08649405T0000|74 79|cells
P08649405T0000|100 103|AP1
P08649405T0000|116 129|transcription
P08649424A0000|0 10|Expression
P08649424A0000|18 48|phenylalanine hydroxylase gene
P08649424A0000|52 58|livers
P08649424A0000|63 70|kidneys
P08649424A0000|74 81|rodents
P08649424A0000|98 103|birth
P08649424A0000|122 137|glucocorticoids
P08649424A0000|149 152|AMP
P08649424A0000|160 165|liver
P08649425A0373|18 20|bp
P08649425A0373|28 36|enhancer
P08649425A0373|55 59|core
P08649425A0373|68 73|DNase
P08649425A0373|100 118|B-cell development
P08649425T0000|28 47|chromatin structure
P08649425T0000|55 81|mouse immunoglobulin kappa
P08649425T0000|85 93|enhancer
P08649427A0689|19 33|identification
P08649427A0689|39 43|cDNA
P08649427A0689|63 69|member
P08649427A0689|95 102|protein
P08649427A0689|104 107|GAP
P08649427A0689|109 115|family
P08649427A0689|119 136|GTPase regulators
P08649428A1227|8 13|study
P08649428A1227|43 53|regulation
P08649428A1227|61 70|synthesis
P08649428A1227|78 100|c-mos oncogene product
P08649428A1227|129 139|activation
P08649428A1227|143 147|Cdc2
P08649440T0000|4 17|heterogeneity
P08649440T0000|28 32|IgG2
P08649440T0000|34 38|VIII
P08649773A1374|4 11|ability
P08649773A1374|15 20|BCL-6
P08649773A1374|54 63|repressor
P08649773A1374|86 93|ability
P08649773A1374|107 120|B lymphocytes
P08649773A1374|138 151|cell lymphoma
P08649841A0956|17 21|uORF
P08649841A0956|54 69|Kozak sequences
P08649841A0956|94 102|promoter
P08649841A0956|108 112|SV40
P08649841A0956|119 136|CAT reporter gene
P08649841A0956|156 166|inhibition
P08649841A0956|170 192|CAT protein production
P08649841A0956|203 211|decrease
P08649841A0956|215 223|CAT mRNA
P08650818A0000|12 18|spread
P08650818A0000|78 84|strain
P08650818A0000|86 90|MRSA
P08650818A0000|105 113|patients
P08650818A0000|148 152|ward
P08650818A0000|156 161|spite
P08650818A0000|165 174|isolation
P08650818A0000|229 236|arrival
P08650818A0000|244 252|hospital
P08650818A0000|260 278|Mediterranean area
P08651853A0607|16 25|sclerosis
P08651853A0607|63 67|loss
P08651853A0607|83 90|gliosis
P08651853A0607|108 124|CA1/prosubiculum
P08651853A0607|129 137|patients
P08651853A0607|142 143|%
P08651853A0607|161 174|dentate gyrus
P08651853A0607|179 187|patients
P08651853A0607|191 192|%
P08651853A0607|206 216|CA4 region
P08651853A0607|221 229|patients
P08651853A0607|233 234|%
P08651853T0000|16 25|sclerosis
P08652081A1953|22 28|events
P08652081A1953|74 84|toxicities
P08652081A1953|94 105|hypotension
P08652081A1953|111 115|IL-1
P08652081A1953|124 132|headache
P08652081A1953|136 145|skin rash
P08652081A1953|151 155|IL-3
P08652081A1953|167 177|congestion
P08652081A1953|197 204|lesions
P08652081A1953|210 214|IL-4
P08654200A0274|20 37|resonance imaging
P08654200A0274|60 72|liver volume
P08654200A0274|101 109|patients
P08654200A0274|128 137|clearance
P08654200A0274|147 163|model substrates
P08654200A0274|165 174|lorazepam
P08654200A0274|181 186|mg/kg
P08654200A0274|189 199|antipyrine
P08654200A0274|204 209|mg/kg
P08654200A0274|216 227|indocyanine
P08654200A0274|235 238|ICG
P08654200A0274|244 249|mg/kg
P08654375A0544|13 21|analysis
P08654375A0544|37 43|region
P08654375A0544|53 64|amino acids
P08654375A0544|66 77|amino acids
P08654375A0544|92 102|N-terminus
P08654375A0544|106 110|Bob1
P08654375A0544|149 171|DNA binding POU domain
P08654375A0544|175 180|Oct-1
P08654375A0544|184 189|Oct-2
P08654390A0000|0 14|Heme oxygenase
P08654390A0000|33 39|enzyme
P08654390A0000|43 58|heme catabolism
P08654390A0000|72 76|heme
P08654390A0000|85 95|biliverdin
P08654390A0000|97 101|iron
P08654390A0000|107 122|carbon monoxide
P08654435A0540|12 18|analog
P08654435A0540|22 32|wortmannin
P08654435A0540|34 38|WM12
P08654435A0540|71 86|Erk2 activation
P08654435A0540|92 102|wortmannin
P08654435A0540|110 116|effect
P08654435A0540|124 132|activity
P08654435A0540|136 140|Erk2
P08654435A0540|177 183|assays
P08654946A0475|4 6|aa
P08654946A0475|8 14|shares
P08654946A0475|17 27|% identity
P08654946A0475|47 53|region
P08654946A0475|57 76|Xenopus laevis FGF3
P08654946A0475|83 93|% identity
P08654946A0475|103 110|product
P08654946A0475|147 151|gene
P08654946A0986|4 29|transcription start point
P08654946A0986|46 54|promoter
P08654946A0986|73 90|mouse promoter P3
P08654946A0986|119 125|region
P08654946A0986|129 137|sequence
P08654972A0000|0 7|Defects
P08654972A0000|42 44|Sp
P08654972A0000|46 50|cell
P08654972A0000|69 74|genes
P08654972A0000|87 109|cell cycle progression
P08654983A0000|17 44|signal recognition particle
P08654983A0000|46 49|SRP
P08654983A0000|51 63|SRP receptor
P08654983A0000|65 68|Srb
P08654983A0000|70 76|system
P08654983A0000|80 97|Bacillus subtilis
P08654983A0000|99 101|Bs
P08654983A0000|118 129|Bs srb gene
P08654983A0000|147 156|homologue
P08654983A0000|174 200|SRP receptor alpha-subunit
P08654983A0000|202 207|Oguro
P08654983A0000|216 223|DNA Res
P08655497A0000|8 12|gene
P08655497A0000|24 27|cmr
P08655497A0000|50 53|min
P08655497A0000|78 89|K-12 genome
P08655497A0000|112 122|resistance
P08655497A0000|126 141|chloramphenicol
P08655497A0000|181 187|vector
P08655555A0772|3 11|addition
P08655555A0772|16 25|deletions
P08655555A0772|46 48|bp
P08655555A0772|65 90|transcription start point
P08655555A0772|115 134|% promoter activity
P08655555A0772|160 167|hexamer
P08655555A0772|190 207|promoter activity
P08655555A1368|4 16|DNA sequence
P08655555A1368|52 59|hexamer
P08655555A1368|74 83|TGn motif
P08655555A1368|113 119|region
P08655555A1368|135 144|promoters
P08656672A0678|12 35|ufo mRNA overexpression
P08656672A0678|73 92|leukemia cell lines
P08656672A0678|135 144|subclones
P08656672A0678|152 183|cervix carcinoma cell line HeLa
P08657135A1444|23 30|studies
P08657135A1444|36 40|CKII
P08657135A1444|63 72|regulator
P08657135A1444|76 86|myogenesis
P08657135A1444|101 121|E protein homodimers
P08657135A1444|138 149|muscle gene
P08657135A1444|161 169|elements
P08657150A1049|4 8|role
P08657150A1049|21 31|regulators
P08657150A1049|40 44|NCE3
P08657150A1049|82 91|SIN5 gene
P08657150A1049|112 132|promoter specificity
P08657150A1049|147 157|activators
P08657157A0000|16 26|regulators
P08657157A0000|41 51|POU domain
P08657157A0000|64 69|motif
P08657157A0000|108 117|complexes
P08657157A0000|135 145|POU domain
P08657157A0000|170 181|recognition
P08657157A0000|193 218|octamer sequence elements
P08657183A0145|9 15|strand
P08657183A0145|26 32|repair
P08657183A0145|36 49|DNA fragments
P08657183A0145|68 73|genes
P08657183A0145|75 79|DHFR
P08657183A0145|95 99|gene
P08657183A0145|112 116|DHFR
P08657918A0360|0 9|MATERIALS
P08657918A0360|14 21|METHODS
P08657918A0360|23 45|Coronal 3D GRE imaging
P08657918A0360|87 102|dorsal portions
P08657918A0360|110 113|SLL
P08657918A0360|120 128|patients
P08657918A0360|161 164|SLL
P08657918A0360|187 193|wrists
P08657918A0360|212 215|SLL
P08657918A0360|228 238|dissection
P08659545A0000|6 12|effort
P08659545A0000|34 48|transcript map
P08659545A0000|58 68|chromosome
P08659545A0000|80 93|understanding
P08659545A0000|101 116|pathophysiology
P08659545A0000|120 127|trisomy
P08659545A0000|145 158|exon trapping
P08659545A0000|171 180|fragments
P08659545A0000|184 194|chromosome
P08659545A0000|198 203|genes
P08660733X0000|12 23|populations
P08660733X0000|32 37|aphid
P08660733X0000|61 72|Puerto Rico
P08660733X0000|76 81|April
P08660748X0000|4 9|model
P08660748X0000|23 30|essence
P08660748X0000|48 56|dynamics
P08660748X0000|79 90|predictions
P08660748X0000|94 113|population patterns
P08660866A0504|13 22|positions
P08660866A0504|38 41|Brd
P08660866A0504|50 64|loss phenotype
P08660866A0504|89 96|progeny
P08660866A0504|115 119|SOPs
P08660866A0504|148 155|neurons
P08660866A0504|160 168|thecogen
P08660866A0504|170 176|sheath
P08660866A0504|178 183|cells
P08660866A0504|199 208|trichogen
P08660866A0504|210 215|shaft
P08660866A0504|221 229|tormogen
P08660866A0504|231 237|socket
P08660866A0504|239 244|cells
P08660892A1044|16 24|blockade
P08660892A1044|41 57|co-transfections
P08660892A1044|73 94|SRF expression vector
P08660892A1044|123 133|expression
P08660892A1044|152 159|factors
P08660892A1044|169 173|MyoD
P08660892A1044|178 184|Mef-2C
P08660998A0851|4 19|mMIWC1 promoter
P08660998A0851|49 53|TATA
P08660998A0851|55 59|CAAT
P08660998A0851|61 65|GATA
P08660998A0851|71 84|AP-2 elements
P08660998A0851|86 102|primer extension
P08660998A0851|112 142|mMIWC transcription initiation
P08660998A0851|150 152|bp
P08660998A0851|171 177|mMIWC1
P08660998A0851|192 207|initiation site
P08661007T0000|6 17|MN/CA9 gene
P08661007T0000|27 33|member
P08661007T0000|50 66|anhydrase family
P08661007T0000|68 77|structure
P08661007T0000|82 86|exon
P08661007T0000|90 118|protein domain relationships
P08661100A0285|16 28|distribution
P08661100A0285|32 37|Cdebp
P08661100A0285|80 88|App gene
P08661100A0285|96 103|regions
P08661100A0285|127 134|domains
P08661100A0285|153 162|structure
P08661100A0285|176 181|parts
P08661101A0396|0 21|DNA sequence analysis
P08661101A0396|39 43|gene
P08661101A0396|54 61|protein
P08661101A0396|83 91|rat CRP1
P08661104A0687|4 8|gene
P08661104A0687|50 54|mRNA
P08661104A0687|81 94|cells/tissues
P08661104A0687|105 113|prostate
P08661104A0687|115 119|lung
P08661104A0687|121 126|liver
P08661104A0687|132 137|colon
P08661114A0564|14 21|domains
P08661114A0564|36 53|sequence homology
P08661114A0564|65 68|SIM
P08661114A0564|88 96|proteins
P08661116A0963|0 17|Promoter activity
P08661116A0963|30 40|cell lines
P08661116A0963|61 67|levels
P08661116A0963|82 89|D3 mRNA
P08661116A0963|107 129|Northern blot analyses
P08661116A0963|170 178|promoter
P08661116A0963|201 203|bp
P08661119A0085|27 53|EP4 receptor gene sequence
P08661119A0085|73 82|structure
P08661119A0085|95 104|EP4R cDNA
P08661119A0085|133 150|blood lymphocytes
P08661613A0691|5 10|users
P08661613A0691|38 57|management measures
P08661613A0691|65 70|users
P08661613A0691|86 94|response
P08661613A0691|98 107|education
P08661613A0691|135 140|group
P08661613A0691|166 188|enforcement activities
P08662193A0404|15 36|activation subdomains
P08662193A0404|62 68|region
P08662193A0404|88 93|yeast
P08662193A0404|132 138|region
P08662193A0404|142 146|NIT4
P08662499A0484|4 9|front
P08662499A0484|11 12|F
P08662499A0484|14 25|interaction
P08662499A0484|54 57|end
P08662499A0484|61 64|RNA
P08662617A2051|20 24|data
P08662617A2051|39 42|HIP
P08662617A2051|79 86|protein
P08662617A2051|104 111|surface
P08662617A2051|128 145|uterine epithelia
P08662617A2051|169 179|cell lines
P08662789A0673|18 22|gene
P08662789A0673|45 64|GenBankTM data base
P08662789A0673|68 86|sequence alignment
P08662789A0673|98 104|RPS30A
P08662852A1297|4 12|location
P08662852A1297|25 29|GRK2
P08662852A1297|34 60|GRK5 phosphoacceptor sites
P08662852A1297|76 93|carboxyl terminus
P08662852A1297|101 108|beta2AR
P08662852A1297|148 163|phosphorylation
P08662852A1297|167 176|rhodopsin
P08662928A1153|5 15|regulation
P08662928A1153|62 72|expression
P08662928A1153|76 89|STAT proteins
P08662928T0000|0 9|Receptors
P08662928T0000|14 25|interleukin
P08662928T0000|27 29|IL
P08662928T0000|48 57|cytokines
P08662928T0000|70 90|signaling mechanisms
P08662928T0000|104 117|transcription
P08662928T0000|126 148|IL-6 response elements
P08662936A0428|26 51|FR-19 amino acid sequence
P08662936A0428|83 84|%
P08662936A0428|93 101|identity
P08662936A0428|105 119|chicken TEF-1A
P08662936A0428|121 132|mouse TEF-1
P08662936A0428|138 143|mouse
P08662936A0428|154 157|TEA
P08662936A0428|176 182|factor
P08662980A0762|5 15|phenomenon
P08662980A0762|32 43|DNA binding
P08662980A0762|65 73|receptor
P08662980A0762|154 158|form
P08662980A0762|178 186|receptor
P08662980A0762|220 226|effect
P08663000A0000|4 12|receptor
P08663000A0000|17 27|hyaluronan
P08663000A0000|37 45|motility
P08663000A0000|47 52|RHAMM
P08663000A0000|54 69|gene expression
P08663000A0000|94 107|fibrosarcomas
P08663000A0000|132 151|growth factor-beta1
P08663000A0000|153 162|TGF-beta1
P08663120T0000|10 15|Raf-1
P08663120T0000|26 39|p70 S6 kinase
P08663120T0000|64 71|protein
P08663120T0000|91 98|pathway
P08663127A0697|11 19|analysis
P08663127A0697|23 27|KCC1
P08663127A0697|49 57|homology
P08663127A0697|61 65|NKCC
P08663127A0697|94 101|domains
P08663127A0697|125 129|loop
P08663127A0697|154 173|glycosylation sites
P08663127A0697|191 192|N
P08663127A0697|209 216|regions
P08663141T0000|13 24|DNA element
P08663141T0000|41 49|TATA box
P08663141T0000|54 83|transcription initiation site
P08663141T0000|99 107|response
P08663141T0000|122 131|sequences
P08663141T0000|141 161|angiotensinogen gene
P08663172A0311|5 12|protein
P08663172A0311|32 46|amino terminus
P08663172A0311|72 79|protein
P08663219A0246|4 12|promoter
P08663219A0246|20 34|rat PGS-2 gene
P08663219A0246|46 50|CAAT
P08663219A0246|68 90|protein consensus site
P08663219A0246|92 100|CAAT box
P08663219A0246|119 139|hormone inducibility
P08663219A0246|145 150|PGS-2
P08663219A0246|151 168|CAT reporter gene
P08663219A0246|192 204|E-box region
P08663310A0157|9 12|SRF
P08663310A0157|40 49|regulator
P08663310A0157|53 60|members
P08663310A0157|66 71|class
P08663310A0157|84 98|response genes
P08663310A0157|122 127|genes
P08663310A0157|129 133|IEGs
P08663310A0157|192 203|cell growth
P08663310A0157|208 223|differentiation
P08663326A0000|28 42|DmpR activator
P08663326A0000|53 66|transcription
P08663326A0000|74 84|dmp operon
P08663326A0000|102 109|enzymes
P08663326A0000|114 124|catabolism
P08663326A0000|129 135|methyl
P08663326A0000|136 143|phenols
P08663392A0215|8 13|study
P08663392A0215|40 49|DSG3 gene
P08663392A0215|83 93|regulation
P08663392A0215|101 111|expression
P08664229T0000|9 19|evaluation
P08664229T0000|27 44|Allergan Humphrey
P08664229T0000|49 62|autorefractor
P08664229T0000|71 98|Nidek AR-1000 autorefractor
P08664347A0923|0 4|None
P08664347A0923|17 48|proprotein processing proteases
P08664347A0923|87 94|pro-LPH
P08664347A0923|150 160|maturation
P08664347A0923|169 175|enzyme
P08664462A1404|6 13|changes
P08664462A1404|25 31|result
P08664462A1404|47 51|hand
P08664462A1404|66 77|sensitivity
P08664462A1404|99 111|transmission
P08664462A1404|129 149|muscle contractility
P08664462A1404|168 172|hand
P08664462A1404|178 184|result
P08664462A1404|198 214|plasma clearance
P08664462A1404|222 233|hypothermia
P08664667A0093|9 14|Delhi
P08664667A0093|22 27|India
P08665853A0228|33 38|cells
P08665853A0228|74 87|ErbB proteins
P08665853A0228|97 109|combinations
P08665853A0228|125 131|ErbB-3
P08665853A0228|160 168|activity
P08665853A0228|178 184|ErbB-1
P08665853A0228|189 195|ErbB-2
P08665853A0228|244 252|activity
P08666102A0820|0 4|ZIOS
P08666102A0820|58 65|methods
P08666102A0820|71 74|Ptc
P08666102A0820|116 120|FEV1
P08666238T0000|10 32|translation initiation
P08666238T0000|36 44|ribosome
P08666238T0000|93 98|cells
P08666241A0930|40 46|region
P08666241A0930|54 67|24p3 promoter
P08666241A0930|85 103|Dex responsiveness
P08666383A1252|6 14|findings
P08666383A1252|35 47|cDNA mapping
P08666383A1252|54 66|fluorescence
P08666383A1252|75 88|hybridization
P08666383A1252|120 128|approach
P08666383A1252|136 146|definition
P08666383A1252|164 167|map
P08666383A1252|181 187|genome
P08666398T0000|0 3|YAC
P08666398T0000|8 22|cosmid contigs
P08666398T0000|36 50|Batten disease
P08666398T0000|52 56|CLN3
P08666398T0000|58 64|region
P08666398T0000|68 81|16p12.1-p11.2
P08666404A0311|0 9|Isolation
P08666404A0311|32 36|cDNA
P08666404A0311|56 74|brain cDNA library
P08666404A0311|86 122|protein serine-threonine phosphatase
P08666404A0311|130 153|tetratricopeptide motif
P08666404A0311|181 186|PPP5C
P08666404A0311|188 191|PP5
P08666404A0311|218 225|rat PPT
P08666913A0000|0 5|Ly-49
P08666913A0000|11 22|family type
P08666913A0000|26 48|transmembrane proteins
P08666913A0000|62 74|gene cluster
P08666913A0000|85 95|chromosome
P08668124A0744|4 14|Dox-A2 ORF
P08668124A0744|29 42|TDH3 promoter
P08668124A0744|60 69|phenotype
P08668124A0744|75 81|strain
P08668124A0744|94 98|sun2
P08668142A1048|4 16|introduction
P08668142A1048|20 25|hARF4
P08668142A1048|33 38|cells
P08668142A1048|54 61|balance
P08668142A1048|104 115|Sec7p pools
P08668158A0765|4 8|data
P08668158A0765|35 40|Rpm1r
P08668158A0765|65 75|substrates
P08668158A0765|77 81|tRNA
P08668158A0765|92 99|tRNAPro
P08668158A0765|108 116|promoter
P08668158A0765|141 145|tRNA
P08668158A0765|152 156|gene
P08668158A0765|176 183|portion
P08668158A0765|214 222|promoter
P08668158A0765|244 248|tRNA
P08668158A0765|255 259|gene
P08668158A0765|264 268|RPM1
P08668158A1252|13 20|strains
P08668158A1252|33 43|RPM1 genes
P08668158A1252|60 75|precursor Rpm1r
P08668158A1252|93 102|mutations
P08668158A1252|113 117|gene
P08668158A1252|138 156|biogenesis defects
P08668190A1364|9 26|membrane vesicles
P08668190A1364|32 44|hum1 mutants
P08668190A1364|54 57|Ca2
P08668190A1364|59 60|H
P08668190A1364|62 79|antiport activity
P08668190A1364|100 105|Hum1p
P08668190A1364|120 128|exchange
P08668190A1364|132 135|Ca2
P08668190A1364|141 142|H
P08668190A1364|155 160|yeast
P08668190A1364|170 178|membrane
P08668201A1059|9 20|mutagenesis
P08668201A1059|28 35|element
P08668201A1059|57 74|sequence boundary
P08668201A1059|107 115|activity
P08668201A1059|123 135|MATalpha1 IE
P08668201A1059|166 171|codon
P08668201A1059|179 186|element
P08668201A1059|200 208|interval
P08668203A1230|0 3|FTF
P08668203A1230|40 48|pancreas
P08668203A1230|63 88|differentiation functions
P08668203A1230|103 114|sublineages
P08668203A1230|127 131|SF-1
P08668203A1230|149 156|tissues
P08668209A0406|0 6|Merlie
P08668209A0406|8 31|Cold Spring Harbor Symp
P08668210A0000|12 20|evidence
P08668210A0000|41 45|role
P08668210A0000|54 64|activation
P08668210A0000|72 77|Raf-1
P08668210A0000|100 122|protein kinase pathway
P08668210A0000|149 163|transformation
P08669274T0000|11 29|chain ossification
P08669274T0000|31 37|choice
P08669274T0000|54 62|approach
P08669676A1644|4 13|incidence
P08669676A1644|25 30|death
P08669676A1644|40 45|group
P08669676A1644|48 57|Q wave MI
P08669676A1644|59 67|propofol
P08669676A1644|69 70|n
P08669676A1644|76 85|midazolam
P08669676A1644|87 88|n
P08669676A1644|94 95|P
P08669676A1644|112 121|Q wave MI
P08669676A1644|123 131|propofol
P08669676A1644|133 134|n
P08669676A1644|141 150|midazolam
P08669676A1644|152 153|n
P08669676A1644|160 161|P
P08669676A1644|193 209|treatment groups
P08670556A0425|5 15|micromol/1
P08670556A0425|17 18|p
P08670556A0425|29 33|area
P08670556A0425|44 75|plasma concentration-time curve
P08670556A0425|92 104|infinity AUC
P08670556A0425|107 117|0-infinity
P08670853A0000|0 17|Cluster formation
P08670853A0000|21 31|E-cadherin
P08670853A0000|39 51|cell surface
P08670853A0000|79 89|importance
P08670853A0000|104 112|adhesion
P08670910A0156|0 16|DNA polymerase E
P08670910A0156|18 28|DNA ligase
P08670910A0156|39 42|DNA
P08670910A0156|62 84|endonuclease co-purify
P08670910A0156|99 118|polypeptide complex
P08672242A0517|9 33|reporter gene constructs
P08672242A0517|61 70|sequences
P08672242A0517|78 89|P1 promoter
P08672242A0517|106 113|regions
P08672242A0517|132 142|expression
P08673026T0000|4 20|factor structure
P08673026T0000|25 36|schizotypal
P08673026T0000|38 44|traits
P08673026T0000|54 71|replication study
P08675026A0420|62 75|sequence tags
P08675026A0420|77 80|EST
P08675026A0420|93 101|function
P08675026A0420|107 129|Caenorhabditis elegans
P08675026A0420|131 143|Oryza sativa
P08675026A0420|148 152|Homo
P08675395A0751|0 7|RESULTS
P08675395A0751|22 27|model
P08675395A0751|60 63|fit
P08675395A0751|71 90|acuity outcome data
P08675608T0000|0 7|Outcome
P08675608T0000|29 43|hypothyroidism
P08675763A0788|0 13|Mean increase
P08675763A0788|17 35|milk protein yield
P08675763A0788|43 46|g/d
P08675763A0788|52 55|Met
P08675763A0788|61 64|Lys
P08675763A0788|75 83|increase
P08675763A0788|92 107|protein content
P08675763A0788|116 120|g/kg
P08675763A0788|124 128|milk
P08675769A0158|10 15|rates
P08675769A0158|65 73|measures
P08675769A0158|91 101|efficiency
P08675769A0158|111 126|conception rate
P08675769A0158|131 143|calving rate
P08675769A0158|200 204|rate
P08675769A0158|228 237|fertility
P08675769A0158|243 247|bull
P08675769A0158|255 266|performance
P08675769A0158|273 286|AI technician
P08675821A0657|12 16|EMPD
P08675821A0657|30 41|glans penis
P08675821A0657|54 58|area
P08675821A0657|62 68|search
P08675821A0657|82 92|malignancy
P08676266A0838|4 15|mean values
P08676266A0838|19 36|protease activity
P08676266A0838|70 81|test groups
P08676266A0838|94 107|control group
P08676266A0838|111 119|baseline
P08676383A0518|5 18|half molecule
P08676383A0518|33 51|disulfide linkages
P08676383A0518|61 73|cis peptides
P08676454A0731|21 24|Pra
P08676454A0731|26 28|N0
P08676454A0731|33 35|Nb
P08676454A0731|41 46|ICP35
P08676454A0731|48 53|ICP35
P08676454A0731|74 83|B capsids
P08676454A0731|110 120|precursors
P08676454A0731|131 138|virions
P08676456A0879|11 29|VP16-Tat construct
P08676456A0879|45 62|leucine mutations
P08676456A0879|83 102|AP-1 responsiveness
P08676456A0879|106 116|comparison
P08676456A0879|134 156|VP16 activation domain
P08676495A0129|16 27|splice site
P08676495A0129|40 50|nucleotide
P08676495A0129|52 54|nt
P08676495A0129|78 88|processing
P08676495A0129|97 112|BPV-1 pre-mRNAs
P08676495A0129|134 144|C127 cells
P08676495A0129|174 179|times
P08676495A0129|205 210|warts
P08676858A0309|10 17|cloning
P08676858A0309|22 38|characterization
P08676858A0309|42 55|S-RNase genes
P08676858A0309|65 72|species
P08676858A0309|76 84|Rosaceae
P08676858A0309|86 91|apple
P08676858A0309|93 110|Malus x domestica
P08676858A0309|125 129|pear
P08676858A0309|131 145|Pyrus serotina
P08676858A0309|170 179|sequences
P08676858A0309|221 227|RNases
P08676858A1084|15 19|tree
P08676858A1084|23 30|members
P08676858A1084|38 60|T2/S-RNase superfamily
P08676858A1084|64 70|plants
P08677443A0238|5 27|Hoosier Oncology Group
P08677443A0238|39 44|study
P08677443A0238|73 86|SCLC patients
P08677443A0238|88 91|VIP
P08677443A0238|133 139|regard
P08677443A0238|150 154|time
P08677443A0238|158 169|progression
P08677443A0238|181 187|months
P08677443A0238|197 211|survival times
P08677443A0238|223 229|months
P08677443A0238|250 264|survival rates
P08677443A0238|268 269|%
P08677443A0238|273 274|%
P08677443A0238|280 281|%
P08677443A0238|285 286|%
P08677678A0258|18 32|administration
P08677678A0258|36 63|immunomodulator neurotropin
P08677678A0258|65 68|NSP
P08677678A0258|93 106|consolidation
P08677678A0258|111 120|retention
P08677678A0258|124 131|feeding
P08677678A0258|136 154|avoidance behavior
P08677678A0258|184 194|mechanisms
P08677678A0258|203 212|phenomena
P08678959A0640|0 22|Sestamibi scintigraphy
P08678959A0640|40 48|patients
P08678959A0640|74 89|ultrasonography
P08678959A0640|93 94|%
P08679131T0000|7 14|allergy
P08679131T0000|25 43|hypersensitivities
P08680702A0548|20 29|lethality
P08680702A0548|49 60|dysfunction
P08680702A0548|76 81|group
P08680702A0548|85 89|Days
P08680702A0548|121 128|animals
P08680702A0548|148 159|differences
P08680702A0548|178 182|cart
P08680702A0548|193 199|Vo2DIR
P08680702A0548|201 210|ml/kg/min
P08680702A0548|212 215|Day
P08680702A0548|237 238|p
P08680702A0548|247 250|Day
P08680702A0548|272 273|p
P08680702A0548|314 322|catheter
P08680702A0548|335 343|Vo2INDIR
P08680702A0548|345 354|ml/kg/min
P08680702A0548|356 359|Day
P08680702A0548|381 382|p
P08680702A0548|391 394|Day
P08680702A0548|416 417|p
P08680706A0889|8 9|h
P08680706A0889|13 24|reperfusion
P08680706A0889|26 40|PO2/FlO2 ratio
P08680706A0889|81 88|Therapy
P08680706A0889|101 106|mm Hg
P08680706A0889|120 139|Recipient Instilled
P08680706A0889|152 157|mm Hg
P08680706A0889|163 177|Control groups
P08680706A0889|189 194|mm Hg
P08680706A0889|215 221|values
P08680706A0889|225 243|Donor Aerosol dogs
P08680706A0889|256 261|mm Hg
P08682155A0902|4 30|euglobulin clot lysis time
P08682155A0902|58 65|smokers
P08682155A0902|78 89|non-smokers
P08682155A0902|116 126|situations
P08682155A0902|136 147|differences
P08682317A0900|0 15|HS inducibility
P08682317A0900|29 32|HSE
P08682317A0900|52 77|HS transcription factor-1
P08682317A0900|78 83|HSF-1
P08682317A0900|96 104|extracts
P08682317A0900|119 124|cells
P08682317A0900|136 138|HS
P08682868A0738|13 28|DSK2-1 mutation
P08682868A0738|48 55|residue
P08682868A0738|63 68|Dsk2p
P08682868A0738|84 90|domain
P08682868A0738|105 116|differences
P08682868A0738|120 125|Dsk2p
P08682868A0738|129 145|Cdc31p stability
P08683106A0374|9 13|IL-2
P08683106A0374|18 27|IFN-alpha
P08683106A0374|38 49|STAT1 alpha
P08683106A0374|54 59|STAT5
P08683106A0374|61 65|IL-2
P08683106A0374|90 95|STAT5
P08683106A0374|103 112|IFN-alpha
P08683106A0374|137 148|STAT1 alpha
P08683108A0965|21 35|interpretation
P08683108A0965|49 53|CREB
P08683108A0965|69 98|transcription factor proteins
P08683108A0965|109 113|junB
P08683108A0965|123 127|site
P08683108A0965|173 177|site
P08683108A1501|20 27|results
P08683108A1501|41 51|components
P08683108A1501|59 93|protein kinase A signaling pathway
P08683108A1501|111 114|mIg
P08683108A1501|125 143|junB transcription
P08683983A0785|4 11|complex
P08683983A0785|28 37|D protein
P08683983A0785|108 122|leukemia cells
P08683983A1163|4 11|results
P08683983A1163|24 37|participation
P08683983A1163|41 47|intron
P08683983A1163|69 79|regulation
P08683983A1163|87 97|c-myb gene
P08683983A1163|102 107|mouse
P08683983A1163|165 175|mechanisms
P08683983A1163|179 189|activation
P08683983A1163|212 227|differentiation
P08683983A1163|241 260|cell growth control
P08684522A0415|0 29|Immunofluorescence microscopy
P08684522A0415|49 59|deposition
P08684522A0415|82 90|matrices
P08684522A0415|94 98|type
P08684522A0415|102 110|collagen
P08684522A0415|115 122|laminin
P08684522A0415|139 143|wall
P08684742A0000|0 9|OBJECTIVE
P08684742A0000|22 45|pregnancy complications
P08684742A0000|49 54|women
P08684742A0000|70 83|amniocentesis
P08684742A0000|93 98|weeks
P08684742A0000|123 136|amniocentesis
P08684742A0000|146 151|weeks
P08684742A0000|153 162|gestation
P08686381A0527|6 10|ORFs
P08686381A0527|12 23|9765orfR002
P08686381A0527|25 36|9765orfR011
P08686381A0527|41 52|9765orfR013
P08686381A0527|113 142|polyadenylate binding protein
P08686381A0527|183 190|protein
P08686381A0527|198 201|BCR
P08686381A0527|205 211|region
P08686381A0527|217 230|transcription
P08686381A0527|242 254|protein Swi3
P08688190A0000|8 26|flavone glucosides
P08688190A0000|28 59|nevadensin 5-O-beta-D-glucoside
P08688190A0000|64 94|nevadensin 5-O-beta-D-glucosyl
P08688190A0000|101 117|beta-D-glucoside
P08688190A0000|154 159|parts
P08688190A0000|163 185|Lysionotus pauciflorus
P08688556A0242|14 24|laboratory
P08688556A0242|37 43|screen
P08688556A0242|75 86|suppressors
P08688556A0242|110 117|strains
P08688556A0242|121 129|clathrin
P08688556A0242|152 157|yeast
P08688556A0242|159 162|Chc
P08688556A0242|165 171|scd1-i
P08688556A0242|176 185|viability
P08689520T0000|0 19|Reproductive period
P08689520T0000|28 40|water intake
P08689520T0000|69 74|goats
P08690118A0845|13 32|regression analysis
P08690118A0845|40 53|manual method
P08690118A0845|55 65|percentage
P08690118A0845|73 83|morphology
P08690118A0845|89 93|IVOS
P08690118A0845|119 129|predictors
P08690118A0845|133 146|fertilization
P08690198A0346|0 7|METHODS
P08690198A0346|9 13|Rats
P08690198A0346|47 55|infusion
P08690198A0346|69 73|diet
P08690198A0346|82 97|supplementation
P08690198A0346|101 108|oatbase
P08690198A0346|110 136|Lactobacillus reuteri R2LC
P08690198A0346|142 169|Lactobacillus plantarum DSM
P08690198A0346|193 205|fermentation
P08690198A0346|216 225|beginning
P08690198A0346|233 238|study
P08691106A0733|9 19|D8 binding
P08691106A0733|36 55|nuclease protection
P08691106A0733|61 71|lactotroph
P08691106A0733|101 105|cell
P08691106A0733|114 121|protein
P08691962T0000|8 12|role
P08691962T0000|27 36|diagnosis
P08691962T0000|40 47|Whipple
P08691962T0000|50 57|disease
P08691962T0000|74 79|blood
P08691962T0000|92 97|cells
P08692885A0663|4 11|ability
P08692885A0663|15 18|A20
P08692885A0663|28 48|NF-kappaB activation
P08692885A0663|78 96|zinc finger domain
P08692892A0330|4 11|Pro-258
P08692892A0330|14 17|Leu
P08692892A0330|19 24|P258L
P08692892A0330|26 34|mutation
P08692892A0330|55 73|receptor signaling
P08692892A0330|105 106|%
P08692892A0330|114 127|maximum level
P08692892A0330|150 155|cells
P08692892A0330|172 184|alpha-factor
P08692924A0328|11 23|DNA sequence
P08692924A0328|41 48|ability
P08692924A0328|69 74|BCL-6
P08692924A0328|103 108|BCL-6
P08692924A0328|135 144|complexes
P08692924A0328|156 164|extracts
P08692924A0328|178 190|B-cell lines
P08697728A1199|15 20|value
P08697728A1199|35 39|flag
P08697728A1199|48 49|%
P08698756A1240|0 11|CONCLUSIONS
P08698756A1240|17 25|findings
P08698756A1240|39 52|pre-treatment
P08698756A1240|58 70|coenzyme Q10
P08698756A1240|93 97|role
P08698756A1240|122 132|procedures
P08698756A1240|160 165|cross
P08698756A1240|194 200|degree
P08698756A1240|217 223|damage
P08700531A1420|8 20|chromosome X
P08700531A1420|58 69|alterations
P08700531A1420|91 104|hamster cells
P08700531A1420|120 140|chemical carcinogens
P08700531A1420|155 162|viruses
P08700531A1420|168 180|localization
P08700531A1420|188 197|cph locus
P08700531A1420|206 216|chromosome
P08700531A1420|230 236|notion
P08700531A1420|246 258|cph oncogene
P08700531A1420|267 271|role
P08700531A1420|289 299|conversion
P08700531A1420|326 345|hamster fibroblasts
P08702517A0000|5 11|screen
P08702517A0000|16 21|genes
P08702517A0000|71 78|B6SUtA1
P08702517A0000|87 107|progenitor cell line
P08702543A0000|0 4|Gap1
P08702543A0000|5 10|IP4BP
P08702543A0000|22 28|member
P08702543A0000|32 35|Ras
P08702543A0000|54 62|proteins
P08702543A0000|98 132|inositol 1,3,4,5-tetrakisphosphate
P08702543A0000|134 137|IP4
P08702543A0000|139 154|binding protein
P08702543A0000|156 162|Cullen
P08702543A0000|164 166|P.
P08702556A0000|28 40|purification
P08702556A0000|67 83|acid phosphatase
P08702556A0000|85 88|PAP
P08702556A0000|99 123|porcine thymus membranes
P08702556A0000|125 130|Kanoh
P08702556A0000|132 134|H.
P08702556A0000|136 140|Imai
P08702556A0000|142 147|S.-i.
P08702556A0000|149 155|Yamada
P08702556A0000|157 159|K.
P08702556A0000|164 170|Sakane
P08702556A0000|172 174|F.
P08702556A0000|181 183|J.
P08702633A0164|4 13|mechanism
P08702633A0164|23 33|Gbetagamma
P08702633A0164|51 60|increases
P08702633A0164|64 88|tyrosine phosphorylation
P08702633A0164|96 115|Shc adapter protein
P08702633A0164|117 120|Shc
P08702633A0164|121 143|Grb2 complex formation
P08702633A0164|149 160|recruitment
P08702633A0164|164 211|Ras guanine nucleotide exchange factor activity
P08702644A0499|2 6|cDNA
P08702644A0499|37 38|%
P08702644A0499|42 46|apoB
P08702644A0499|48 54|apoB17
P08702644A0499|71 75|cDNA
P08702644A0499|99 110|amino acids
P08702644A0499|133 139|factor
P08702644A0499|141 144|DAF
P08702644A0499|166 172|signal
P08702644A0499|177 223|glycosylphosphatidylinositol anchor attachment
P08702728A1325|40 43|Shc
P08702728A1325|47 52|Y317F
P08702728A1325|60 63|Shc
P08702728A1325|69 79|HIRc cells
P08702756A0000|10 20|GTPase Rho
P08702756A0000|52 61|functions
P08702756A0000|78 100|actin-myosin filaments
P08702756A0000|109 120|cytokinesis
P08702756A0000|122 135|cell motility
P08702756A0000|148 166|muscle contraction
P08702807A0964|12 22|activation
P08702807A0964|31 48|signaling pathway
P08702807A0964|52 62|expression
P08702807A0964|90 94|MKK1
P08702807A0964|125 152|cyclin D1 promoter activity
P08702807A0964|157 185|cyclin D1 protein expression
P08702807A0964|192 198|growth
P08702807A0964|218 224|manner
P08702826A0870|22 31|insertion
P08702826A0870|39 61|GSTP1 silencer element
P08702826A0870|80 88|activity
P08702826A0870|107 115|promoter
P08702826A0870|119 129|MCF7 cells
P08702845A0000|3 8|order
P08702845A0000|33 39|motifs
P08702845A0000|61 69|affinity
P08702845A0000|74 85|recognition
P08702845A0000|100 120|dopamine transporter
P08702845A0000|122 125|DAT
P08702845A0000|141 143|3H
P08702845A0000|144 168|dopamine uptake kinetics
P08702845A0000|174 176|3H
P08702845A0000|177 204|CFT binding characteristics
P08702845A0000|208 219|COS-7 cells
P08702845A0000|250 254|DATs
P08702845A0000|268 281|COOH terminus
P08702936A0168|3 21|expression library
P08702936A0168|71 76|cDNAs
P08702936A0168|123 128|blood
P08702936A0168|141 146|cells
P08702936A0168|164 170|signal
P08702936A0168|188 196|CD4 cDNA
P08702936A0168|216 236|virus shuttle vector
P08702936A0984|25 29|TARC
P08702936A0984|52 64|T cell lines
P08702936A0984|80 87|T cells
P08702936A0984|99 108|monocytes
P08702936A0984|112 124|granulocytes
P08703005A0645|15 23|elements
P08703005A0645|37 54|promoter activity
P08703005A0645|71 76|sites
P08703005A0645|81 106|transcription factors Sp1
P08703005A0645|111 119|alphaCbf
P08703005A0645|130 135|CCAAT
P08703005A0645|148 155|protein
P08703010A0905|43 50|element
P08703010A0905|56 64|E1 E-box
P08703010A0905|81 103|GAP-43 promoter region
P08703010A0905|155 165|expression
P08703010A0905|173 184|GAP-43 gene
P08703010A0905|218 226|proteins
P08703010A0905|239 243|site
P08703908A1814|18 26|findings
P08703908A1814|44 48|SF-1
P08703908A1814|61 65|role
P08703908A1814|111 121|expression
P08703908A1814|129 138|StAR gene
P08703959A0659|34 51|proton resonances
P08703959A0659|75 82|segment
P08703959A0659|102 113|lesion site
P08703959A0659|144 154|assignment
P08703959A0659|163 176|sugar protons
P08703959A0659|184 194|C7 residue
P08703959A0659|202 210|spectrum
P08703959A0659|218 231|adduct duplex
P08704124A0420|21 30|fragments
P08704124A0420|32 38|CPK3-8
P08704124A0420|60 67|bp cDNA
P08704124A0420|69 77|VrCDPK-1
P08704124A0420|86 119|Vigna radiata lambda gt11 library
P08704240A1111|12 22|TF-1 cells
P08704240A1111|32 38|GM-CSF
P08704240A1111|46 56|starvation
P08704240A1111|58 78|CREB phosphorylation
P08704240A1111|95 102|minutes
P08704240A1111|109 128|PIXY321 stimulation
P08705056T0000|0 18|Workplace violence
P08705056T0000|20 26|nurses
P08705056T0000|30 34|risk
P08706368A1024|0 7|RESULTS
P08706368A1024|13 34|LV maximum brightness
P08706368A1024|39 43|area
P08706368A1024|54 59|curve
P08706368A1024|88 100|correlations
P08706368A1024|102 103|p
P08706368A1024|124 128|FIO2
P08706368A1024|148 158|brightness
P08706368A1024|189 200|correlation
P08706368A1024|202 203|p
P08706662A1125|4 11|results
P08706662A1125|32 39|absence
P08706662A1125|43 62|perforin expression
P08706662A1125|80 85|cells
P08706662A1125|104 115|suppression
P08706662A1125|123 132|induction
P08706662A1125|174 186|factor NF-P2
P08706731A1303|41 53|similarities
P08706731A1303|71 90|expression patterns
P08706731A1303|94 105|Ypr10 genes
P08706731A1303|110 128|ribonuclease genes
P08706731A1303|167 186|sequence similarity
P08706731A1303|194 214|ginseng ribonuclease
P08706731A1303|228 238|hypothesis
P08706731A1303|244 265|ribonuclease function
P08706731A1303|270 284|PR-10 proteins
P08706731A1303|299 309|prediction
P08706731A1303|333 338|roles
P08707424A0709|4 14|expression
P08707424A0709|18 31|ERV3 env mRNA
P08707424A0709|86 96|expression
P08707424A0709|118 124|stages
P08707424A0709|138 149|development
P08707516A0194|8 17|estimates
P08707516A0194|39 45|people
P08707516A0194|60 67|receipt
P08707516A0194|77 81|need
P08707516A0194|92 109|handicap services
P08707825A0063|37 49|muscle cells
P08707825A0063|53 70|Northern blotting
P08707825A0063|95 103|analysis
P08707825A0063|130 140|smoothelin
P08707825A0063|158 177|muscle cDNA library
P08707825A0063|211 223|antibody R4A
P08707825A0063|241 245|cDNA
P08707825A0063|253 260|protein
P08707840A0753|17 36|electron microscopy
P08707840A0753|52 59|p58/p45
P08707840A0753|64 67|p54
P08707840A0753|90 95|sides
P08707840A0753|111 123|pore complex
P08707840A0753|130 133|p62
P08707846A2308|33 39|uptake
P08707846A2308|62 70|receptor
P08707846A2308|96 110|ubiquitination
P08707846A2308|128 151|receptor ubiquitination
P08707846A2308|189 200|endocytosis
P08707846A2308|208 225|a-factor receptor
P08707846A2308|257 268|endocytosis
P08707922A0334|0 30|Transcription initiation sites
P08707922A0334|38 41|rat
P08707922A0334|45 49|beta
P08707922A0334|52 60|III beta
P08707922A0334|66 85|O beta-globin genes
P08707922A0334|111 121|base pairs
P08707922A0334|123 125|bp
P08707922A0334|146 174|translation initiation codon
P08707922A0334|176 179|ATG
P08707922A0334|190 194|gene
P08707922A0334|198 223|primer extension analysis
P08708984T0000|12 19|process
P08708984T0000|31 43|indomethacin
P08708984T0000|63 69|lesion
P08708984T0000|73 76|rat
P08709224T0000|13 18|virus
P08709224T0000|27 34|protein
P08709224T0000|38 43|EBNA2
P08709224T0000|56 65|component
P08709224T0000|79 94|SNF-SWI complex
P08709224T0000|96 106|hSNF5/Ini1
P08709245A1521|4 11|studies
P08709245A1521|30 41|possibility
P08709245A1521|51 66|phosphorylation
P08709245A1521|70 75|Ser-2
P08709245A1521|77 84|Ser-123
P08709245A1521|89 96|Ser-210
P08709245A1521|102 107|roles
P08709245A1521|115 141|trans-suppression activity
P08709245A1521|155 159|HDAg
P08709245A1521|168 176|assembly
P08709245A1521|197 210|HDAg particle
P08709245A1521|231 240|transport
P08709245A1521|244 249|HDAgs
P08709251A0000|11 24|recombination
P08709251A0000|37 59|Autographa californica
P08709251A0000|68 86|polyhedrosis virus
P08709251A0000|88 93|AcNPV
P08709251A0000|95 101|genome
P08709251A0000|121 133|DNA fragment
P08709251A0000|160 177|DNA helicase gene
P08709251A0000|181 187|Bombyx
P08709251A0000|201 219|polyhedrosis virus
P08709251A0000|230 239|eh2-AcNPV
P08709251A0000|264 276|AcNPV mutant
P08709251A0000|278 280|S.
P08709637A1471|4 8|data
P08709637A1471|35 53|IL-7R alpha chains
P08709637A1471|83 93|activation
P08709637A1471|97 101|JAKs
P08709637A1471|106 111|STATs
P08709637A1471|129 133|role
P08709637A1471|151 160|signaling
P08709637A1471|164 181|precursor B cells
P08709831A0599|17 24|potency
P08709831A0599|28 39|Dacarbacine
P08709831A0599|47 56|treatment
P08709831A0599|70 76|tumors
P08710151A0782|31 36|value
P08710151A0782|44 48|cost
P08710151A0782|53 60|episode
P08710151A0782|64 70|pnx s.
P08710151A0782|74 81|class A
P08710151A0782|98 99|%
P08710151A0782|112 119|class B
P08710151A0782|128 132|cost
P08710151A0782|137 144|patient
P08710151A0782|148 155|class A
P08710151A0782|182 190|class B.
P08710371A0000|26 37|interaction
P08710371A0000|61 76|polyomavirus BK
P08710371A0000|78 81|BKV
P08710371A0000|109 120|protein p53
P08710371A0000|139 146|biology
P08710371A0000|155 160|virus
P08710371A0000|196 206|mechanisms
P08710371A0000|210 229|p53 transactivation
P08710371A0499|0 9|Site S-II
P08710371A0499|26 37|bp sequence
P08710371A0499|60 83|consensus binding sites
P08710371A0499|95 115|base pair mismatches
P08710371A0499|134 152|base pair deletion
P08710377A0577|0 3|Cbl
P08710377A0577|38 49|SH3 domains
P08710377A0577|53 57|Grb2
P08710377A0577|66 76|preference
P08710377A0577|100 106|domain
P08710377A0577|123 126|way
P08710377A0577|140 143|Shc
P08710377A0577|149 164|BCR stimulation
P08710504A0995|0 10|Activation
P08710504A0995|23 28|Cat8p
P08710504A0995|59 70|cat1 mutant
P08711631A0989|0 9|Treatment
P08711631A0989|29 39|prednisone
P08711631A0989|44 60|cyclophosphamide
P08712799A0123|8 16|attempts
P08712799A0123|25 32|smoking
P08713933A0606|0 21|Laboratory evaluation
P08713933A0606|38 50|neuroimaging
P08713933A0606|69 80|obstruction
P08713933A0606|104 112|drainage
P08716757T0001|0 24|Microcomputer management
P08716757T0001|36 53|hepatitis B virus
P08716757T0001|67 75|patients
P08717391A0466|6 12|fusion
P08717391A0466|20 30|N-terminus
P08717391A0466|42 48|linker
P08717391A0466|59 66|surface
P08717391A0466|84 90|fusion
P08717391A0466|98 108|N-terminus
P08717391A0466|120 130|C-terminus
P08717391A0466|151 168|particle assembly
P08717391A0466|194 206|antigenicity
P08717391A0466|211 225|immunogenicity
P08717391A0466|229 234|HBcAg
P08717559A0223|13 19|dosage
P08717559A0223|65 69|ages
P08717559A0223|75 82|ampoule
P08717559A0223|98 108|micrograms
P08719155A0105|29 36|cloning
P08719155A0105|60 68|molecule
P08719155A0105|74 87|P. falciparum
P08719155A0105|105 113|sequence
P08719155A0105|129 141|similarities
P08719155A0105|160 176|surface molecule
P08719155A0105|182 192|Plasmodium
P08719155A0105|237 244|protein
P08719155A0105|246 250|TRAP
P08719155A0105|269 275|extent
P08719155A0105|286 302|circumsporozoite
P08719155A0105|304 306|CS
P08719155A0105|308 315|protein
P08719156A0953|13 20|introns
P08719156A0953|32 36|gene
P08719156A0953|68 81|reading frame
P08719156A0953|104 111|protein
P08719697A0221|0 7|METHODS
P08719697A0221|9 12|DSF
P08719697A0221|34 37|eye
P08719697A0221|59 61|CF
P08719697A0221|76 79|eye
P08719697A0221|93 101|subjects
P08719697A0221|112 120|patients
P08719697A0221|126 129|KCS
P08719832A0397|4 14|experience
P08719832A0397|30 48|rhinotomy approach
P08719832A0397|68 75|surgery
P08719832A0397|79 89|acromegaly
P08720407A1386|0 10|CONCLUSION
P08720407A1386|16 23|results
P08720407A1386|48 52|site
P08720407A1386|63 78|disc herniation
P08720407A1386|93 102|cytokines
P08720407A1386|111 130|interleukin-1 alpha
P08720407A1386|161 188|prostaglandin E2 production
P08721526A0000|28 37|allergens
P08721526A0000|59 67|children
P08721526A0000|79 90|pet animals
P08721989A1012|4 11|results
P08721989A1012|50 57|domains
P08721989A1012|67 85|cytokine receptors
P08721989A1012|104 122|signaling pathways
P08721989A1012|135 143|evidence
P08721989A1012|149 155|beta c
P08721989A1012|160 179|IL-2R beta function
P08721989A1012|194 211|signal transducer
P08721999A0432|3 11|addition
P08721999A0432|33 41|features
P08721999A0432|79 89|snoRNA U14
P08721999A0727|0 3|U24
P08721999A0727|24 26|nt
P08721999A0727|32 49|complementarities
P08721999A0727|72 77|tract
P08721999A0727|81 89|28S rRNA
P08722011A0103|5 12|complex
P08722011A0103|30 43|GTPase domain
P08722011A0103|57 69|subunit rRNA
P08722011A0103|87 99|binding site
P08722011A0103|107 114|protein
P08722011A0103|135 146|counterpart
P08722011A0103|173 184|protein L15
P08722011A0103|199 210|protein L12
P08722568A1001|0 20|Chromatin repression
P08722568A1001|30 47|replacement genes
P08722568A1001|105 115|expression
P08722568A1001|119 147|replacement H3 histone genes
P08722568A1001|151 157|plants
P08723352A0084|5 15|transition
P08723352A0084|72 79|kinases
P08723352A0084|81 85|cdks
P08723352A0084|109 116|product
P08723352A0084|124 161|retinoblastoma tumour suppressor gene
P08723352A0084|163 166|pRb
P08723365T0000|9 21|relationship
P08723365T0000|30 46|hyperinsulinemia
P08723365T0000|62 73|hypertrophy
P08723365T0000|77 92|nephrosclerosis
P08723883A0823|0 21|Blood GSH-Px activity
P08723883A0823|42 59|spectrophotometer
P08723883A0823|69 81|modification
P08723883A0823|108 113|assay
P08723883A1684|4 18|concentrations
P08723883A1684|22 42|vitamin A precursors
P08723883A1684|47 56|vitamin E
P08723883A1684|64 67|hay
P08723883A1684|109 115|levels
P08723883A1684|120 126|llamas
P08723883A1684|132 143|alfalfa hay
P08723883A1684|177 183|source
P08723883A1684|187 195|vitamins
P08723883A1684|202 203|E
P08723883A1684|212 219|species
P08726024A0244|6 10|cats
P08726024A0244|25 34|H. pylori
P08726024A0244|52 57|study
P08726024A0532|26 29|PCR
P08726024A0532|35 42|primers
P08726024A0532|67 74|product
P08726024A0532|80 88|majority
P08726024A0532|92 96|cats
P08726024A0532|108 118|weeks p.t.
P08726024A0532|131 144|fluid samples
P08726024A0532|169 178|H. pylori
P08726024A0532|198 202|cats
P08726024A0532|208 218|weeks p.t.
P08726024A0532|230 236|plaque
P08726024A0532|260 269|H. pylori
P08726247A0175|23 44|concentration changes
P08726247A0175|50 62|measurements
P08726247A0175|72 83|attenuation
P08726247A0175|97 108|path length
P08727192A0000|0 12|STUDY DESIGN
P08727992A0570|14 23|injection
P08727992A0570|27 37|PGF2 alpha
P08727992A0570|39 46|heifers
P08727992A0570|74 79|signs
P08727992A0570|83 89|estrus
P08727992A0570|111 114|min
P08728040T0000|13 23|activation
P08728040T0000|62 68|kinase
P08728040T0000|70 80|Jun kinase
P08728040T0000|85 111|Janus kinase-Stat pathways
P08728040T0000|115 127|oncostatin M
P08728040T0000|138 162|fibroblast growth factor
P08728040T0000|179 185|Kaposi
P08728040T0000|188 201|sarcoma cells
P08730470A0000|17 26|agreement
P08730470A0000|36 53|hepatitis C virus
P08730470A0000|101 105|data
P08730470A0000|115 127|transmission
P08730470A0000|133 140|mothers
P08730470A0000|144 150|babies
P08730470A0000|178 195|household contact
P08731155A0499|4 9|weeks
P08731155A0499|16 30|reconstruction
P08731155A0499|49 55|nerves
P08731155A0499|81 87|nerves
P08731222A0000|4 16|distribution
P08731222A0000|21 33|organization
P08731222A0000|37 48|projections
P08731222A0000|74 85|enlargement
P08731222A0000|89 120|subnucleus reticularis dorsalis
P08731222A0000|122 125|SRD
P08731222A0000|148 163|Cuneate nucleus
P08731222A0000|165 167|Cu
P08731222A0000|169 173|area
P08731222A0000|193 196|rat
P08731222A0000|206 221|microinjections
P08731222A0000|225 259|Phaseolus vulgaris leucoagglutinin
P08731222A0000|261 266|PHA-L
P08731222A0000|283 290|laminae
P08731222A0000|302 310|C7 level
P08731511A0625|4 10|levels
P08731511A0625|14 24|fibrinogen
P08731511A0625|36 48|antithrombin
P08731511A0625|54 59|ATIII
P08731511A0625|65 81|heparin cofactor
P08731511A0625|86 90|HCII
P08731511A0625|92 102|activities
P08731511A0625|143 150|animals
P08732665A0000|0 13|Amplification
P08732665A0000|18 32|overexpression
P08732665A0000|40 53|c-erbB-2 gene
P08732665A0000|57 63|21MT-2
P08732665A0000|68 74|21MT-1
P08732665A0000|81 103|breast carcinoma cells
P08732665A0000|138 144|levels
P08732665A0000|187 197|p185erbB-2
P08732665A0000|246 259|growth factor
P08732665A0000|261 264|IGF
P08732665A0000|293 306|growth factor
P08732665A0000|308 311|EGF
P08732665A0000|313 325|independence
P08732665A0000|329 336|culture
P08733123A0000|29 38|dystrophy
P08733123A0000|40 44|FSHD
P08733123A0000|86 94|disorder
P08733123A0000|124 132|weakness
P08733123A0000|136 143|muscles
P08733123A0000|151 155|face
P08733123A0000|157 165|shoulder
P08733123A0000|176 179|arm
P08733123A0951|11 21|chromosome
P08733123A0951|24 39|FRG1 transcript
P08733123A0951|48 50|bp
P08733123A0951|54 60|length
P08733123A0951|79 84|exons
P08733123A0951|109 116|protein
P08733123A0951|124 143|amino acid residues
P08733874A0000|0 8|Patients
P08733874A0000|28 41|thyroidectomy
P08733874A0000|46 63|thyroid carcinoma
P08733874A0000|92 99|periods
P08733874A0000|118 132|hypothyroidism
P08733874A0000|136 147|preparation
P08733874A0000|152 156|131I
P08733874A0000|163 176|body scanning
P08733874A0000|181 192|measurement
P08733874A0000|196 204|serum TG
P08733881A0343|5 29|thyroid function testing
P08733881A0343|69 76|samples
P08733881A0343|89 99|TSH values
P08733881A0343|112 120|subjects
P08733881A0343|135 145|TSH levels
P08734538A0613|11 21|experiment
P08734538A0613|23 32|crossover
P08734538A0613|55 63|textures
P08734538A0613|121 129|textures
P08734538A0613|142 144|AM
P08738510A0254|13 29|tumor FDG-uptake
P08738510A0254|31 38|Q-MRGlu
P08738510A0254|61 67|cortex
P08738510A0254|76 87|meningiomas
P08739209A0700|0 11|Zatebradine
P08739209A0700|53 57|rate
P08739209A0700|81 86|ratio
P08739209A0700|106 117|arrhythmias
P08739209A0700|148 156|ligation
P08739209A0700|160 161|h
P08739209A0700|172 180|ligation
P08739209A0700|194 198|dogs
P08739260T0000|0 5|Catha
P08739260T0000|16 21|plant
P08739260T0000|31 50|amphetamine effects
P08740416A0239|14 21|protein
P08740416A0239|23 28|Seb1p
P08740416A0239|45 56|amino acids
P08740416A0239|102 108|region
P08740416A0239|116 126|C-terminus
P08740416A0239|145 160|signal sequence
P08740416A0919|4 18|SEB1 homologue
P08740416A0919|34 38|SEB2
P08740416A0919|50 57|protein
P08740416A0919|60 61|%
P08740416A0919|75 80|Seb1p
P08741206A1551|30 39|afferents
P08741206A1551|60 68|settings
P08741206A1551|106 118|vasodilation
P08741206A1551|123 134|hypotension
P08741280A0374|6 10|ones
P08741280A0374|27 31|size
P08741280A0374|44 48|lobe
P08741280A0374|59 63|ones
P08741280A0374|94 100|length
P08741280A0374|113 117|lobe
P08742135A0000|0 9|Fragments
P08742135A0000|14 21|analogs
P08742135A0000|29 41|hormone ACTH
P08742135A0000|83 89|effect
P08742135A0000|97 104|outcome
P08742135A0000|108 119|head injury
P08742135A0000|136 142|levels
P08742135A0000|146 160|corticosterone
P08742135A0000|162 164|CS
P08742385A0211|18 24|causes
P08742385A0211|32 42|meningitis
P08742385A0211|72 80|drainage
P08742385A0211|86 87|%
P08742385A0211|113 114|%
P08742385A0211|120 131|head injury
P08742385A0211|139 140|%
P08745669A0000|10 18|patients
P08745669A0000|65 73|lymphoma
P08745669A0000|92 100|lymphoma
P08745669A0000|110 117|Hodgkin
P08745669A0000|120 127|disease
P08745669A0000|170 177|regimen
P08745669A0000|179 190|cisplatinum
P08745669A0000|192 202|methyl GAG
P08745669A0000|204 214|bleomocyin
P08745669A0000|216 234|methyl prednisolon
P08746605A0377|20 23|use
P08746605A0377|27 41|ACE inhibitors
P08746605A0377|47 56|incidence
P08746605A0377|73 80|effects
P08746605A0377|108 120|pancreatitis
P08746981A0154|5 15|treatments
P08746981A0154|20 24|diet
P08746981A0154|62 82|mg probiotic/kg food
P08747078T0000|9 16|aspirin
P08747078T0000|31 42|miscarriage
P08747343A0790|0 13|Protein films
P08747343A0790|53 61|profiles
P08747343A0790|73 78|films
P08747343A0790|93 102|materials
P08748033A0874|13 17|cpxA
P08748033A0874|19 28|mutations
P08748033A0874|42 50|toxicity
P08748033A0874|68 92|LamB-LacZ hybrid protein
P08748033A0874|111 118|effects
P08748033A0874|126 135|cytoplasm
P08748033A0874|154 158|DegP
P08749393A0783|4 17|PI3K_68D cDNA
P08749393A0783|28 35|protein
P08749393A0783|43 46|kDa
P08749393A0783|60 69|sequences
P08749393A0783|92 109|p110 PI 3-kinases
P08749393A0783|113 133|p85 adaptor proteins
P08749393A0783|179 187|sequence
P08749393A0783|209 220|SH3 domains
P08749393A0783|245 254|C2 domain
P08749394A0874|9 28|interaction studies
P08749394A0874|36 44|proteins
P08749394A0874|54 79|glutathione-S-transferase
P08749394A0874|93 104|RBP-J kappa
P08749394A0874|109 111|Su
P08749394A0874|112 113|H
P08749394A0874|136 149|RAM23 regions
P08749394A0874|153 165|mouse Notch1
P08749394A0874|170 186|Drosophila Notch
P08750173A0000|0 12|AIMS/METHODS
P08750173A0000|34 49|system function
P08750173A0000|66 75|clearance
P08750173A0000|93 101|bacteria
P08750173A0000|126 138|liver injury
P08750173A0000|150 165|D-galactosamine
P08750173A0000|169 173|rats
P08750173A0000|206 229|% liver resection model
P08750190A0000|4 14|laboratory
P08750190A0000|19 25|others
P08750190A0000|49 57|splicing
P08750190A0000|71 76|exons
P08750190A0000|105 109|site
P08750190A0000|146 156|generation
P08750190A0000|160 172|CD44 variant
P08750190A0000|174 179|CD44v
P08750190A0000|181 189|isoforms
P08750702A0183|0 12|Study groups
P08750702A0183|18 25|control
P08750702A0183|82 97|blockers WB4101
P08750702A0183|103 113|mg/kg i.v.
P08750702A0183|118 138|chloroethylclonidine
P08750702A0183|144 154|mg/kg i.v.
P08751635A0135|28 34|damage
P08751635A0135|48 52|loss
P08751635A0135|56 81|hippocampus subfields CA1
P08751635A0135|83 86|CA3
P08751635A0135|92 97|hilus
P08752714A0000|4 14|occurrence
P08752714A0000|27 37|malignancy
P08752714A0000|57 65|patients
P08752714A0000|83 95|malignancies
P08752714A0000|122 132|department
P08752714A0000|152 157|years
P08754777A1214|4 9|upTRE
P08754777A1214|21 35|T3R homodimers
P08754777A1214|45 65|T3R-RXR heterodimers
P08754777A1214|75 80|dnTRE
P08754777A1214|86 88|T3
P08754777A1214|114 133|heterodimer binding
P08754777A1214|141 143|dn
P08754777A1214|157 162|upTRE
P08754802T0000|16 23|control
P08754802T0000|37 41|gene
P08754802T0000|73 94|acid oxidation enzyme
P08754802T0000|109 113|mice
P08754802T0000|115 119|role
P08754802T0000|132 141|receptors
P08754802T0000|163 181|adipose expression
P08754827A0231|0 6|Hoeben
P08754827A0231|8 12|F.J.
P08754834A1097|15 24|fragments
P08754834A1097|42 59|response elements
P08754834A1097|83 101|transcription unit
P08754834A1097|131 138|NN-84AG
P08754834A1097|161 167|detail
P08754840A0793|10 34|glucan synthase activity
P08754840A0793|58 63|Rho1p
P08754840A0793|98 114|deltabem4 mutant
P08754852A0960|3 25|gel retardation assays
P08754852A0960|30 33|RCS
P08754852A0960|48 55|protein
P08754852A0960|84 91|protein
P08754852A0960|110 119|RCS cells
P08754852A0960|132 144|chondrocytes
P08754852A0960|162 170|sequence
P08754852A0960|182 188|18-mer
P08755898A0339|4 11|classes
P08755898A0339|27 36|pathogens
P08755898A0339|45 64|Bs2 host resistance
P08755898A0339|88 95|fitness
P08755898A0339|137 143|avrBs2
P08756332A0000|0 7|Members
P08756332A0000|15 28|Ras subfamily
P08756332A0000|50 58|proteins
P08756332A0000|103 110|variety
P08756332A0000|123 141|effector molecules
P08756332A0000|154 174|protein kinase c-Raf
P08756332A0000|196 230|guanine nucleotide exchange factor
P08756332A0000|232 239|Ral-GEF
P08756433A0282|10 26|characterization
P08756433A0282|34 49|promoter region
P08756433A0282|83 91|elements
P08756433A0282|139 149|expression
P08756433A0282|157 167|MAP1B gene
P08756556A0406|4 8|cDNA
P08756556A0406|26 33|protein
P08756556A0406|41 52|amino acids
P08756556A0406|75 95|acid signal sequence
P08756597A0854|0 7|Mutants
P08756597A0854|47 58|% reduction
P08756597A0854|66 71|level
P08756597A0854|75 84|psaB mRNA
P08756609A0498|12 31|amino acid sequence
P08756609A0498|69 74|range
P08756609A0498|78 88|eukaryotes
P08756609A0498|90 101|vertebrates
P08756609A0498|103 116|invertebrates
P08756609A0498|118 123|fungi
P08756609A0498|125 131|plants
P08756609A0498|136 144|protozoa
P08756609A0498|160 164|gene
P08756617A1204|0 4|Biol
P08756636T0000|13 22|mutations
P08756636T0000|30 49|yeast Rad51 protein
P08756636T0000|60 73|relationships
P08756636T0000|83 96|Srs2 helicase
P08756642A0230|0 11|Alterations
P08756642A0230|28 36|interval
P08756642A0230|64 78|myelodysplasia
P08756642A0230|91 99|leukemia
P08756712A0227|9 16|studies
P08756712A0227|45 55|amino acid
P08756712A0227|64 71|subunit
P08756712A0227|75 78|RPA
P08756712A0227|80 83|RPA
P08756712A0227|134 141|domains
P08757265A0466|0 7|Neurons
P08757265A0466|25 27|mV
P08757265A0466|56 63|effects
P08757943A0876|5 9|site
P08757943A0876|29 36|element
P08757943A0876|61 86|thymidine kinase promoter
P08757943A0876|108 120|inducibility
P08759870A1128|4 10|extent
P08759870A1128|18 40|fbpA operator sequence
P08759870A1128|45 47|bp
P08759870A1128|68 89|footprinting analysis
P08759870A1128|109 116|binding
P08759870A1128|124 144|Fur repressor dimers
P08760286A0696|15 25|similarity
P08760286A0696|34 37|Vav
P08760286A0696|48 83|guanine nucleotide exchange factors
P08760286A0696|106 114|proteins
P08760286A0696|141 155|identification
P08760286A0696|171 177|routes
P08760286A0696|191 198|members
P08760286A0696|206 209|Ras
P08760286A0696|214 224|Rho family
P08760286A0696|228 235|GTPases
P08760286A0696|268 272|MAPK
P08760286A0696|276 279|JNK
P08760286A0696|295 305|components
P08760286A0696|313 335|Vav signaling pathways
P08760776A1559|0 10|CONCLUSION
P08760776A1559|24 33|treatment
P08760776A1559|47 69|fluticasone propionate
P08760776A1559|73 83|micrograms
P08760776A1559|91 101|micrograms
P08760776A1559|140 152|theophylline
P08760776A1559|160 169|treatment
P08760776A1559|190 196|asthma
P08760872A0696|4 11|results
P08760872A0696|22 27|model
P08760872A0696|39 42|E2F
P08760872A0696|61 71|repression
P08760872A0696|93 99|stages
P08760872A0696|107 117|cell cycle
P08760872A0696|154 166|CHR elements
P08760889A0170|4 14|cDNA clone
P08760889A0170|40 45|probe
P08760889A0170|77 82|clone
P08760889A0170|92 96|H2A1
P08760889A0531|0 10|Comparison
P08760889A0531|26 46|amino acid sequences
P08760889A0531|52 69|protein sequences
P08760889A0531|87 91|H2As
P08760889A0531|118 129|differences
P08760889A0531|149 154|total
P08760889A0531|162 173|amino acids
P08760889A0531|178 182|H2A1
P08760889A0531|192 203|amino acids
P08760889A0531|208 212|H2A2
P08760889A0531|233 238|genes
P08760889A0531|256 266|divergence
P08760889A0531|280 287|species
P08761169T0000|17 28|dysfunction
P08761169T0000|34 39|child
P08761169T0000|54 60|damage
P08761480A0331|0 11|Interaction
P08761480A0331|56 69|splice region
P08761480A0331|73 79|RPDE-6
P08761480A0331|88 100|PDE4A splice
P08761480A0331|109 116|RPDE-39
P08761480A0331|137 143|RPDE-6
P08761480A0331|159 169|N-terminus
P08761480A0331|196 205|v-Src-SH3
P08761480A0331|207 215|met26RD1
P08761480A0331|223 226|RD1
P08761480A0331|230 233|rat
P08761480A0331|246 249|PDE
P08761480A0331|277 290|splice region
P08761480A0331|325 334|v-Src-SH3
P08761480A0331|344 355|association
P08761480A0331|359 365|RPDE-6
P08761480A0331|370 379|v-Src-SH3
P08761480A0331|397 411|fusion protein
P08761480A0331|439 452|splice region
P08762021A0156|29 37|measures
P08762021A0156|53 64|performance
P08762021A0156|135 142|rabbits
P08762172A0178|6 24|strain differences
P08762172A0178|44 53|variables
P08762172A0178|74 84|proportion
P08762172A0178|98 103|males
P08762172A0178|109 113|time
P08762172A0178|140 143|box
P08762172A0178|153 159|number
P08762172A0178|163 174|transitions
P08762172A0178|204 209|boxes
P08762472A0000|4 10|effect
P08762472A0000|14 40|ligustrazine hydrochloride
P08762472A0000|42 45|LTH
P08762472A0000|71 90|artery hypertension
P08762472A0000|117 124|studies
P08763207A0402|10 24|oxidation peak
P08763207A0402|33 40|product
P08763207A0402|60 65|media
P08763207A0402|74 75|V
P08763207A0402|102 105|DPV
P08763207A0402|127 139|accumulation
P08763207A0402|143 154|clenbuterol
P08763207A0402|178 181|CPE
P08763311A0189|0 13|Phenylephrine
P08763311A0189|24 54|alpha-1 adrenoreceptor agonist
P08763311A0189|88 104|vasoconstriction
P08763311A0189|120 132|hypertension
P08763311A0189|165 176|bradycardia
P08763925A0588|4 14|expression
P08763925A0588|32 37|genes
P08763925A0588|54 58|unit
P08763925A0588|60 66|c-gvpD
P08763925A0588|71 77|c-gvpE
P08763925A0588|101 113|Western blot
P08763925A0588|115 125|immunoblot
P08763925A0588|127 135|analyses
P08763925A0588|142 150|antisera
P08763925A0588|172 180|proteins
P08763953A0805|4 8|unit
P08763953A0805|17 21|traA
P08763953A0805|23 27|traF
P08763953A0805|33 37|traB
P08763953A0805|64 68|traC
P08763953A0805|70 74|traD
P08763953A0805|80 84|traG
P08764015A0284|0 2|A.
P08764136A0000|6 12|effort
P08764136A0000|24 29|genes
P08764136A0000|50 60|expression
P08764136A0000|68 78|mRNA level
P08764136A0000|96 110|transformation
P08764136A0000|139 144|cells
P08764136A0000|146 150|MECs
P08764136A0000|178 191|hybridization
P08764136A0000|207 221|MEC strain 76N
P08764136A0000|275 281|76R-30
P08766049A0000|0 11|CASE REPORT
P08766049A0000|41 60|corneal perforation
P08766049A0000|75 83|reaction
P08766049A0000|96 103|chamber
P08766049A0000|107 114|patient
P08766049A0000|166 175|injection
P08766049A0000|183 185|ml
P08766049A0000|189 191|mg
P08766049A0000|193 201|Amikacin
P08766049A0000|210 212|ml
P08766049A0000|216 218|mg
P08766049A0000|220 230|Vancomycin
P08766781A0322|12 18|period
P08766781A0322|37 45|increase
P08766781A0322|49 59|hematocrit
P08766781A0322|68 69|%
P08766781A0322|75 76|%
P08766781A0322|89 91|Hb
P08766781A0322|110 114|g/dl
P08768374A0765|4 8|P-wr
P08768374A0765|13 32|P-rr cDNA sequences
P08768374A0765|62 69|regions
P08768377A1387|12 24|hcf109 locus
P08768377A1387|41 49|distance
P08768377A1387|56 68|centimorgans
P08768377A1387|78 96|phytochrome C gene
P08768377A1387|112 128|characterization
P08768377A1387|143 150|cloning
P08769132A0000|10 28|MSH-2 gene product
P08769132A0000|34 40|member
P08769132A0000|63 69|family
P08769132A0000|73 81|proteins
P08769132A0000|121 136|mismatch repair
P08769132A0000|138 144|hMSH-2
P08769132A0000|189 193|MutS
P08769132A0000|222 227|MSH-1
P08769132A0000|232 246|MSH-2 proteins
P08769132A0000|277 280|DNA
P08769132A0000|288 293|sites
P08769132A0000|308 323|base mismatches
P08769132A0000|328 337|deletions
P08769132A0000|341 351|insertions
P08769132A0000|360 370|base pairs
P08769132A0000|372 378|hMSH-2
P08769132A0000|429 435|cancer
P08769132A0000|437 442|HNPCC
P08769132A0000|444 466|tumor suppressor genes
P08769132A0000|486 501|chromosome 2p16
P08769409A0114|48 58|expression
P08769409A0114|66 74|RAR beta
P08769409A0114|77 81|gene
P08769409A0114|85 98|mouse embryos
P08769409A0114|133 138|level
P08769409A0114|162 176|reading frames
P08769409A0114|178 183|uORFs
P08769409A0114|208 214|region
P08769409A0114|216 222|Zimmer
P08769409A0114|224 226|A.
P08769409A0114|228 232|A.M.
P08769566A0000|30 34|cDNA
P08769566A0000|41 61|transcription factor
P08769566A0000|77 82|Zfhep
P08769566A0000|84 107|zinc finger homeodomain
P08769566A0000|125 132|protein
P08769566A0000|158 177|zinc finger domains
P08769566A0000|179 182|ZD1
P08769566A0000|187 190|ZD2
P08769566A0000|212 215|DNA
P08769566A0000|223 234|homeodomain
P08769568A0949|4 13|structure
P08769568A0949|23 28|genes
P08769568A0949|47 55|ancestor
P08769568A0949|72 82|PLA2 genes
P08770021T0000|10 26|PTHRP production
P08770021T0000|32 56|tyrosine kinase oncogene
P08770021T0000|58 65|Tpr-Met
P08770021T0000|67 71|role
P08770021T0000|79 100|Ras signaling pathway
P08770896A1121|20 29|secretion
P08770896A1121|35 41|IGF-II
P08770896A1121|45 49|xz97
P08770896A1121|54 63|G11 cells
P08770896A1121|95 101|medium
P08770896A1121|136 143|species
P08770896A1121|149 154|appMr
P08770896A1121|159 162|17K
P08770896A1121|167 170|14K
P08770920A1220|15 27|coexpression
P08770920A1220|88 93|IDX-1
P08770920A1220|101 109|proteins
P08770920A1220|137 142|IDX-1
P08770920A1220|183 194|enhancement
P08770920A1220|198 213|transactivation
P08770920A1220|237 260|TAAT-1 element reporter
P08770981A0328|4 12|patients
P08770981A0328|26 47|von Willebrand factor
P08770981A0328|49 52|vWF
P08770981A0328|54 67|fragmentation
P08770981A0328|109 115|weight
P08770981A0328|144 164|weight vWF multimers
P08770981A0328|172 183|circulation
P08771781A0103|6 13|attempt
P08771781A0103|52 58|region
P08771781A0103|71 78|oleosin
P08771781A0103|97 110|reading frame
P08771781A0103|112 117|ORFII
P08771781A0103|122 136|Brassica napus
P08771781A0103|138 140|L.
P08771781A0103|157 165|promoter
P08771781A0103|196 201|ORFII
P08771781A0103|203 214|cDNA clones
P08771781A0103|256 273|leaf cDNA library
P08771781A1103|4 22|ORFII gene product
P08771781A1103|42 53|chloroplast
P08771781A1103|89 93|data
P08771781A1103|109 117|presence
P08771781A1103|121 134|PMSR activity
P08771781A1103|142 153|chloroplast
P08771787T0000|0 16|Characterization
P08771787T0000|20 23|LRP
P08771787T0000|40 46|repeat
P08771787T0000|48 51|LRR
P08771787T0000|53 60|protein
P08771787T0000|66 79|tomato plants
P08771787T0000|105 117|pathogenesis
P08774732A0271|16 19|Sp1
P08774732A0271|24 34|zif268/egr
P08774732A0271|56 61|motif
P08774732A0271|63 85|gel retardation assays
P08775674A0000|0 10|OBJECTIVES
P08775674A0000|16 19|aim
P08775674A0000|27 32|study
P08775674A0000|61 76|characteristics
P08775674A0000|78 87|treatment
P08775674A0000|92 99|outcome
P08775674A0000|107 115|patients
P08775674A0000|121 138|hydatidiform mole
P08776735A0000|25 31|kidney
P08776735A0000|36 41|cells
P08776735A0000|62 85|type rat LH/CG receptor
P08776735A0000|87 91|rLHR
P08776735A0000|96 105|receptors
P08776735A0000|122 127|tails
P08776735A0000|141 149|residues
P08776735A0000|179 188|rLHR-t653
P08776735A0000|190 199|rLHR-t631
P08776735A0000|205 214|rLHR-t628
P08776735A0000|239 249|importance
P08776735A0000|258 264|region
P08776735A0000|272 282|regulation
P08776735A0000|295 309|responsiveness
P08776748T0000|8 23|P300 amplitudes
P08776748T0000|26 32|marker
P08776748T0000|37 50|schizophrenia
P08776792A0626|0 5|Sleep
P08776792A0626|47 51|days
P08776792A0626|58 63|hours
P08776793A0811|4 12|patients
P08776793A0811|35 40|males
P08776901A0000|0 19|Chloroplast mutator
P08776901A0000|21 24|chm
P08776901A0000|29 40|Arabidopsis
P08776901A0000|64 72|mutation
P08776901A0000|101 112|variegation
P08776901A0000|116 122|leaves
P08776901A0000|159 166|fashion
P08777374A1471|7 21|concentrations
P08777374A1471|63 77|concentrations
P08777374A1471|101 110|exposures
P08777374A1471|157 171|concentrations
P08778265A0422|21 33|test battery
P08778265A0422|62 76|Wisconsin card
P08778265A0422|85 89|test
P08778265A0422|91 113|Street completion test
P08778265A0422|115 126|Stroop test
P08778265A0422|139 145|memory
P08778265A0422|156 160|test
P08778265A0422|175 191|recognition test
P08778700A0476|16 20|case
P08778700A0476|36 42|rarity
P08778700A0476|63 74|involvement
P08778700A0476|91 95|ARVD
P08780339A0142|16 28|single-blind
P08780339A0142|31 32|x
P08780339A0142|35 53|Latin-square study
P08780339A0142|59 70|corrections
P08780339A0142|79 96|carryover effects
P08780339A0142|101 106|males
P08780339A0142|114 121|females
P08780339A0142|131 142|supplements
P08780339A0142|154 161|glucose
P08780339A0142|175 181|starch
P08780339A0142|183 185|RS
P08780339A0142|209 219|cornstarch
P08780339A0142|221 224|RS2
P08780339A0142|259 269|cornstarch
P08780339A0142|271 274|RS3
P08781119A0723|16 22|region
P08781119A0723|30 50|mouse Met-ase-1 gene
P08781119A0723|76 83|regions
P08781119A0723|87 95|identity
P08781119A0723|117 123|region
P08781119A0723|131 149|rat Met-ase-1 gene
P08781144A1520|5 8|18F
P08781144A1520|9 19|FMISO TMRR
P08781144A1520|54 59|index
P08781144A1520|74 88|tumour hypoxia
P08781144A1520|92 95|NPC
P08783180A0000|9 16|methods
P08783180A0000|95 104|fruit bat
P08783180A0000|106 128|Carollia perspicillata
P08783180A0000|166 173|setting
P08783666A0957|3 11|addition
P08783666A0957|17 21|time
P08783666A0957|25 36|engraftment
P08783666A0957|70 84|amifostine arm
P08783666A0957|93 100|cohorts
P08784787A0383|14 31|thrombin receptor
P08784787A0383|33 37|PAR2
P08784787A0383|62 73|hexapeptide
P08784787A0383|104 119|ligand sequence
P08784787A0383|135 152|receptor cleavage
P08787110A0981|17 21|CPET
P08787110A0981|34 47|investigation
P08787110A0981|55 65|management
P08787110A0981|69 77|patients
P08787110A0981|99 106|disease
P08787110A0981|141 155|investigations
P08787110A0981|179 198|function laboratory
P08789441A0339|6 18|fluorescence
P08789441A0339|27 40|hybridization
P08789441A0339|70 80|breakpoint
P08789441A0339|86 93|patient
P08789441A0339|111 115|CMPD
P08789441A0339|120 132|sex reversal
P08789441A0339|171 172|t
P08789441A0339|180 193|translocation
P08789441A0339|213 227|cosmid markers
P08789441A0339|245 251|region
P08790288A0068|27 36|isolation
P08790288A0068|40 45|cDNAs
P08790288A0068|51 58|spinach
P08790288A0068|60 77|Spinacia oleracea
P08790288A0068|83 89|barley
P08790288A0068|91 109|Hordeum vulgare cv
P08790291A1022|4 8|data
P08790291A1022|27 31|work
P08790291A1022|46 50|thi1
P08790291A1022|75 95|DNA damage tolerance
P08790291A1022|99 110|plant cells
P08790387A0299|7 21|rat rnu allele
P08790387A0299|40 57|nonsense mutation
P08790387A0299|61 65|exon
P08790387A0299|75 83|whn gene
P08792217A1407|8 16|increase
P08792217A1407|48 65|TIMP-2 mRNA level
P08792217A1407|88 94|result
P08792217A1407|101 114|up-regulation
P08792217A1407|118 128|germ cells
P08792217A1407|137 147|germ cells
P08792217A1407|172 177|cells
P08792217A1407|198 206|increase
P08792217A1407|222 226|cell
P08792217A1407|240 257|TIMP-2 mRNA level
P08793029A0246|0 7|Control
P08793029A0246|15 19|rats
P08793029A0246|62 68|groups
P08793693A0237|0 6|DESIGN
P08793693A0237|26 31|study
P08794254A2957|7 10|SPK
P08794254A2957|15 27|PTA category
P08794254A2957|41 48|therapy
P08794254A2957|75 79|risk
P08794254A2957|83 93|graft loss
P08794326A0405|43 50|element
P08794326A0405|63 66|TRE
P08794326A0405|68 70|GP
P08794326A0405|85 88|end
P08794326A0405|96 104|gag gene
P08794326A0405|123 131|pol gene
P08794326A0405|135 140|SFV-1
P08794339A1162|13 20|binding
P08794339A1162|24 27|IE2
P08794339A1162|64 68|CREB
P08794339A1162|72 81|deltaCREB
P08794339A1162|94 97|IE2
P08794339A1162|111 120|complexes
P08794339A1162|126 130|p300
P08794339A1162|152 159|protein
P08794339A1162|161 164|CBP
P08794339A1162|176 180|turn
P08794339A1162|189 193|CREB
P08794339A1162|211 227|adaptor proteins
P08794339A1162|232 245|CREB function
P08794348A1067|13 34|complementation assay
P08794348A1067|60 63|NIa
P08794348A1067|76 81|trans
P08794348A1067|125 132|genomes
P08794348A1067|150 162|NIa proteins
P08794363A0259|7 12|basis
P08794363A0259|20 24|bZIP
P08794363A0259|36 44|homology
P08794363A0259|46 49|meq
P08794363A0259|70 76|member
P08794363A0259|84 103|jun-fos gene family
P08794363A0259|124 130|origin
P08794547A0648|4 8|rCBF
P08794547A0648|13 23|vasomotion
P08794547A0648|41 64|laser-doppler fluxmetry
P08794547A1403|15 22|vessels
P08794547A1403|56 63|vessels
P08794547A1403|85 88|SAH
P08794601A0000|11 22|combination
P08794601A0000|26 36|nizatidine
P08794601A0000|38 52|clarithromycin
P08794601A0000|58 76|bismuth subcitrate
P08794601A0000|92 110|ulcer healing rate
P08794601A0000|116 117|%
P08794601A0000|125 151|H. pylori eradication rate
P08794601A0000|157 158|%
P08794869A0274|8 13|lines
P08794869A0274|17 25|evidence
P08794869A0274|54 62|PKC-zeta
P08794869A0274|71 75|role
P08794869A0274|79 84|alpha
P08794869A0274|87 111|integrin gene expression
P08795304T0000|0 21|Plasma thrombomodulin
P08795304T0000|25 31|marker
P08795304T0000|50 63|complications
P08795304T0000|67 84|diabetes mellitus
P08797362T0037|0 6|Update
P08797362T0037|8 18|diphtheria
P08797362T0037|53 59|states
P08797362T0037|74 78|USSR
P08797362T0037|80 87|January
P08798420A0207|4 20|characterization
P08798420A0207|28 43|promoter region
P08798420A0207|85 93|elements
P08798420A0207|114 131|AP-1 binding site
P08798420A0207|136 139|TRE
P08798420A0207|144 163|PRDII/kappaB domain
P08798420A0207|171 179|CAAT box
P08798420A0207|200 210|activation
P08798420A0207|214 218|pp60
P08798420A0207|222 225|src
P08798443A0660|0 6|Serine
P08798443A0660|48 58|cell lines
P08798443A0660|64 76|substitution
P08798443A0660|80 86|serine
P08798443A0660|94 101|alanine
P08798443A0660|103 108|S528A
P08798443A0660|135 142|ability
P08798443A0660|146 149|Myb
P08798443A0660|179 187|promoter
P08798443A0660|204 210|copies
P08798443A0660|218 224|mim-1A
P08798443A0660|240 247|element
P08798443A0660|262 280|herpes tk promoter
P08798443A1218|4 15|DNA binding
P08798443A1218|20 46|multimerization activities
P08798443A1218|50 55|c-Myb
P08798443A1218|87 105|S528A substitution
P08798443A1218|123 138|phosphorylation
P08798443A1218|142 148|serine
P08798443A1218|169 175|effect
P08798443A1218|183 221|transcription transactivating activity
P08798443A1218|225 230|c-Myb
P08798443A1218|245 257|interactions
P08798443A1218|269 277|proteins
P08798512A1197|4 10|amount
P08798512A1197|20 27|factors
P08798512A1197|43 52|GEO cells
P08798512A1197|66 76|u-PAR gene
P08798610A0843|0 4|PIP2
P08798610A0843|29 65|phosphatidylcholine carrier vesicles
P08798610A0843|88 95|guanine
P08798610A0843|116 120|form
P08798610A0843|124 131|Cdc42Hs
P08798610A0843|160 164|form
P08798610A0843|184 191|protein
P08798610A0843|223 230|Cdc42Hs
P08798610A0843|269 284|Dbl oncoprotein
P08798635A0870|9 19|spleen GAP
P08798635A0870|32 42|hydrolysis
P08798635A0870|46 49|GTP
P08798635A0870|71 75|ARF1
P08798635A0870|77 81|ARF3
P08798635A0870|83 87|ARF5
P08798635A0870|93 97|ARF6
P08798635A0870|102 108|effect
P08798635A0870|125 139|myristoylation
P08798641A0400|0 4|Biol
P08798643T0000|32 38|domain
P08798643T0000|57 76|transforming region
P08798643T0000|80 83|Cbl
P08798643T0000|124 130|ZAP-70
P08798643T0000|134 141|T cells
P08798648A1816|0 7|Cys-757
P08798648A1816|20 25|Fe4S4
P08798648A1816|44 50|domain
P08798648A1816|76 91|enzyme activity
P08798700A0134|4 17|transcription
P08798700A0134|61 69|response
P08798700A0134|73 79|oxygen
P08798700A0134|83 98|heme deficiency
P08798700A0134|103 107|part
P08798700A0134|116 122|relief
P08798700A0134|126 136|repression
P08798700A0134|148 153|Rox1p
P08798700A0134|161 165|part
P08798700A0134|169 179|activation
P08798700A0134|204 223|activation sequence
P08798700A0134|225 228|UAS
P08798762A1279|16 23|results
P08798762A1279|58 66|activity
P08798762A1279|70 82|Cut proteins
P08798762A1279|99 102|PKC
P08798782A0976|0 3|Lck
P08798782A0976|48 51|SH2
P08798782A0976|56 67|SH3 domains
P08798893A0611|13 21|freezing
P08798893A0611|29 37|presence
P08798893A0611|48 59|lactalbumin
P08798893A0611|79 90|maintenance
P08798893A0611|107 116|viability
P08798893A0611|128 146|CCCD heterogeneity
P08798893A0611|150 157|respect
P08798893A0611|167 172|cells
P08801403T0001|20 28|effusion
P08801403T0001|32 49|presentation form
P08801403T0001|62 69|myeloma
P08803710A0701|10 19|survivals
P08803710A0701|35 36|%
P08803710A0701|42 43|%
P08803710A0701|49 50|%
P08803710A0701|56 57|%
P08803710A0701|65 66|%
P08803710A0701|71 77|stages
P08803710A0701|90 93|IVA
P08803710A0701|98 101|IVB
P08803845A0665|4 12|presence
P08803845A0665|56 64|clusters
P08803845A0665|79 84|cells
P08803845A0665|127 131|line
P08803845A0665|135 144|insertion
P08803845A0665|148 154|lesion
P08803845A0665|173 180|attempt
P08803845A0665|201 209|excision
P08804012A0662|12 22|categories
P08804012A0662|30 33|SIP
P08804012A0662|63 67|work
P08804012A0662|69 79|recreation
P08804012A0662|84 92|pastimes
P08804012A0662|94 109|home management
P08804012A0662|115 120|sleep
P08804012A0662|125 129|rest
P08804389A0893|0 22|Northern blot analysis
P08804389A0893|48 53|probe
P08804389A0893|70 95|Xanthomonas campestris pv
P08804389A0893|97 108|translucens
P08804389A0893|120 128|increase
P08804389A0893|140 146|levels
P08804389A0893|150 159|Ltp4 mRNA
P08804389A0893|188 190|pv
P08804389A0893|192 200|japonica
P08804389A0893|210 218|decrease
P08805338A1061|9 19|disruption
P08805338A1061|27 36|OGG1 gene
P08805338A1061|40 45|yeast
P08805338A1061|64 92|OG glycosylase/lyase protein
P08805338A1061|112 116|Ogg2
P08805338A1061|137 141|Ogg1
P08805338A1061|176 178|OG
P08805338A1061|179 181|G.
P08805824A1155|17 20|use
P08805824A1155|24 33|zero-loss
P08805824A1155|47 58|combination
P08805824A1155|64 93|exit wavefront reconstruction
P08805824A1155|141 148|effects
P08805824A1155|183 193|scattering
P08805824A1155|198 208|microscope
P08805824A1155|219 235|lens aberrations
P08805824A1155|248 257|technique
P08806491A0542|0 11|Transcripts
P08806491A0542|21 28|ODV-E18
P08806491A0542|33 41|ODV-EC27
P08806491A0542|66 77|TAAG motifs
P08806491A0542|83 94|transcripts
P08806491A0542|127 134|hr p.i.
P08806693A0584|3 8|order
P08806693A0584|28 37|sequences
P08806693A0584|45 60|GATA-1 promoter
P08806693A0584|77 87|activation
P08806693A0584|95 99|ME26
P08806693A0584|106 113|protein
P08806693A0584|123 132|deletions
P08806693A0584|140 148|promoter
P08806693A0584|169 197|luciferase expression vector
P08806693A0584|215 223|activity
P08806693A0584|227 244|mouse fibroblasts
P08806693A0584|267 273|GATA-1
P08806817A0244|0 17|Sequence analysis
P08806817A0244|42 47|clone
P08806817A0244|66 84|DNA binding domain
P08806817A0244|93 108|orphan receptor
P08806817A0244|141 153|TR2 receptor
P08806817A0716|8 25|DNA hybridization
P08806817A0716|40 46|SpSHR2
P08806817A0716|64 68|gene
P08806817A0716|76 96|S. purpuratus genome
P08807245A0843|7 27|retrospective review
P08807245A0843|55 56|%
P08807245A0843|64 74|undercalls
P08807288T0000|0 9|Isolation
P08807288T0000|14 28|identification
P08807288T0000|32 37|genes
P08807288T0000|64 79|ADH2 expression
P08807408A0524|0 7|METHODS
P08807408A0524|12 19|RESULTS
P08807408A0524|35 40|woman
P08807408A0524|56 58|AV
P08807408A0524|75 86|tachycardia
P08807408A0524|116 123|pathway
P08807408A0524|125 140|AV modification
P08807408A0524|155 181|radiofrequency application
P08808120A0774|0 8|Patients
P08808120A0774|18 29|probability
P08808120A0774|40 57|aluminum overload
P08808120A0774|59 76|serum iron levels
P08808120A0774|82 94|micrograms/L
P08808120A0774|99 102|DAI
P08808120A0774|109 121|micrograms/L
P08808120A0774|148 154|values
P08808120A0774|158 168|serum iron
P08808120A0774|170 197|iron transferrin saturation
P08808120A0774|203 224|serum ferritin levels
P08808120A0774|245 253|patients
P08808120A0774|266 277|probability
P08808120A0774|288 305|aluminum overload
P08808120A0774|307 328|serum aluminum levels
P08808120A0774|334 346|micrograms/L
P08808120A0774|351 354|DAI
P08808120A0774|361 373|micrograms/L
P08808275A1193|13 30|RAD23 equivalents
P08808275A1193|57 66|evolution
P08808275A1193|82 87|genes
P08808275A1193|121 130|phenotype
P08808275A1193|140 157|yeast counterpart
P08808707A0631|0 9|Ha-RasV12
P08808707A0631|24 32|proteins
P08808707A0631|70 76|kinase
P08808707A0631|78 81|ERK
P08808707A0631|108 122|protein kinase
P08808707A0631|124 128|SAPK
P08808707A0631|133 136|Jun
P08808707A0631|148 154|kinase
P08808707A0631|156 159|JNK
P08808707A0631|161 169|cascades
P08808707A0631|209 224|gene expression
P08808756A0587|0 17|Sequence analysis
P08808756A0587|52 56|cDNA
P08808756A0587|78 81|RNA
P08808756A0587|108 113|cells
P08808756A0587|131 139|presence
P08808756A0587|162 170|products
P08808756A0587|203 208|bases
P08808756A0587|224 236|accumulation
P08808756A0587|250 254|mRNA
P08808924A0326|4 22|hydropathy profile
P08808924A0326|52 57|spans
P08808924A0326|76 90|amino terminus
P08808924A0326|112 120|residues
P08808924A0326|142 150|presence
P08808924A0326|182 186|L-61
P08808924A0326|190 194|F-97
P08808924A0326|205 214|proximity
P08808924A0326|249 256|segment
P08808924A0326|260 264|ProW
P08808927A0417|9 16|HindIII
P08808927A0417|25 33|fragment
P08808927A0417|47 56|vspA gene
P08808927A0417|62 75|M. bovis PG45
P08808939A0000|0 28|Carbon catabolite repression
P08808939A0000|36 46|gnt operon
P08808939A0000|50 67|Bacillus subtilis
P08808939A0000|87 118|catabolite control protein CcpA
P08808939A0000|126 129|HPr
P08808939A0000|133 155|phosphocarrier protein
P08808939A0000|163 188|phosphotransferase system
P08809680T0000|0 9|Melatonin
P08809680T0000|14 25|seasonality
P08809680T0000|39 42|gap
P08810040A0955|13 19|screen
P08810040A0955|28 32|loss
P08810040A0955|62 81|target locus marker
P08810040A0955|102 113|replacement
P08810040A0955|124 133|frequency
P08810040A0955|138 139|%
P08810278A0682|42 49|protein
P08810278A0682|60 67|BCR/ABL
P08810278A0682|80 95|CRKL-SH2 domain
P08810278A0682|99 103|p130
P08810278A0682|104 107|CAS
P08810278A0682|110 114|p130
P08810278A0682|115 118|CAS
P08810278A0682|136 144|tyrosine
P08810278A0682|180 184|CRKL
P08810278A0682|188 217|BCR/ABL expressing cell lines
P08810278A0682|225 232|samples
P08810278A0682|247 250|CML
P08810278A0682|255 267|ALL patients
P08810278A0682|280 287|samples
P08810278A0682|293 301|controls
P08810323A0735|15 35|polyglutamine motifs
P08810323A0735|69 76|regions
P08812012T0000|4 11|effects
P08812012T0000|26 36|variations
P08812012T0000|52 66|Stroop effects
P08812020A0597|11 21|experiment
P08812020A0597|25 36|Chessmaster
P08812020A0597|61 67|number
P08812020A0597|71 77|boards
P08812020A0597|114 115|%
P08812020A0597|124 132|accuracy
P08812020A0597|167 173|pieces
P08812106T0000|0 9|PCNA mRNA
P08812106T0000|18 21|UTR
P08812106T0000|42 54|crescent RNA
P08812106T0000|84 88|eggs
P08812106T0000|93 100|embryos
P08812490A0000|9 19|cDNA clone
P08812490A0000|30 34|hKID
P08812490A0000|36 53|gene symbol AQP2L
P08812490A0000|60 68|homology
P08812490A0000|76 86|aquaporins
P08812490A0000|113 132|kidney cDNA library
P08812490A0542|0 26|PCR/Southern blot analysis
P08812490A0542|36 47|kidney cDNA
P08812490A0542|54 61|primers
P08812490A0542|75 79|hKID
P08812490A0542|87 95|sequence
P08812490A0542|105 115|expression
P08812490A0542|133 137|mRNA
P08812490A0542|148 159|transcripts
P08812490A0542|173 177|exon
P08812490A0542|192 196|exon
P08812490A0542|199 208|deletions
P08812490A1509|9 26|sequence homology
P08812490A1509|44 53|structure
P08812490A1509|81 85|loci
P08812490A1509|89 93|hKID
P08812490A1509|95 98|MIP
P08812490A1509|104 109|AQP-2
P08812490A1509|120 143|MIP family gene cluster
P08812490A1509|147 169|chromosome locus 12q13
P08813766A0605|10 13|ORF
P08813766A0605|26 36|transcript
P08813766A0605|44 46|kb
P08813766A0605|61 68|protein
P08813766A0605|76 84|residues
P08813766A0605|105 110|match
P08813766A0605|118 136|consensus sequence
P08813766A0605|142 165|C2H2 zinc finger domain
P08813766A0605|186 194|homology
P08813766A0605|200 211|yeast Mig1p
P08813766A0605|216 221|Cre-A
P08813766A0605|227 238|Aspergillus
P08813766A0605|240 250|Emericella
P08813900A1088|7 14|phytase
P08813900A1088|19 21|nP
P08813900A1088|35 46|orderliness
P08813900A1088|50 61|development
P08813900A1088|63 77|mineralization
P08813900A1088|82 93|arrangement
P08813900A1088|97 106|cartilage
P08813900A1088|111 121|bone cells
P08813900A1088|142 149|effects
P08813900A1088|153 165|P deficiency
P08813900A1088|196 205|structure
P08813900A1088|213 219|tibias
P08814651A0000|4 14|importance
P08814651A0000|27 34|factors
P08814651A0000|42 50|presence
P08814651A0000|55 63|severity
P08814651A0000|67 91|ethanol withdrawal signs
P08814651A0000|99 102|rat
P08814651A0000|124 136|rating scale
P08814651A0000|138 144|tremor
P08814651A0000|167 176|paradigms
P08816052A0238|0 4|Data
P08816052A0238|19 26|brevity
P08816052A0238|34 42|WISC-III
P08816052A0238|49 53|form
P08816052A0238|80 88|validity
P08816052A0238|101 107|K-FAST
P08816052A0238|116 169|Kaufman Short Neuropsychological Assessment Procedure
P08816052A0238|171 177|K-SNAP
P08816438A0316|13 21|analysis
P08816438A0316|25 43|plasmid loss rates
P08816438A0316|47 63|cdc28-1N strains
P08816438A0316|73 81|plasmids
P08816438A0316|96 115|replication origins
P08816438A0316|132 138|defect
P08816438A0316|153 168|DNA replication
P08816438A0316|190 212|plasmid loss phenotype
P08816443A1674|24 33|ROK alpha
P08816443A1674|60 74|reorganization
P08816443A1674|82 94|cytoskeleton
P08816443A1674|105 106|N
P08816443A1674|111 120|C termini
P08816443A1674|153 163|regulators
P08816443A1674|186 199|kinase domain
P08816443A1674|206 214|activity
P08816443A1674|230 239|formation
P08816443A1674|243 256|stress fibers
P08816443A1674|267 285|adhesion complexes
P08816452A0936|6 14|findings
P08816452A0936|36 55|tissue distribution
P08816452A0936|59 62|p54
P08816452A0936|90 97|protein
P08816452A0936|117 127|regulation
P08816452A0936|143 151|splicing
P08816452A0936|157 163|tissue
P08816452A0936|189 195|manner
P08816453A0000|4 13|elevation
P08816453A0000|24 27|AMP
P08816453A0000|29 33|cAMP
P08816453A0000|35 41|levels
P08816453A0000|49 53|cell
P08816453A0000|72 80|activity
P08816453A0000|88 100|Raf-1 kinase
P08816459A0090|3 21|interaction screen
P08816459A0090|31 48|repression domain
P08816459A0090|56 78|orphan receptor RevErb
P08816459A0090|90 95|N-CoR
P08816459A0090|101 112|corepressor
P08816459A0090|117 141|thyroid hormone receptor
P08816459A0090|143 145|TR
P08816459A0090|160 173|acid receptor
P08816459A0090|175 178|RAR
P08816460A1769|6 13|results
P08816460A1769|28 38|inhibition
P08816460A1769|42 63|Jun kinase activation
P08816460A1769|90 108|Ras transformation
P08816460A1769|121 129|presence
P08816460A1769|143 148|Erk-2
P08816461A0892|4 12|analysis
P08816461A0892|27 32|Upf1p
P08816461A0892|54 61|protein
P08816461A0892|77 87|activities
P08816461A0892|104 117|mRNA turnover
P08816461A0892|122 142|nonsense suppression
P08816472T0000|0 14|Identification
P08816472T0000|18 22|Ste4
P08816472T0000|38 47|regulator
P08816472T0000|51 55|Byr2
P08816472T0000|70 86|response pathway
P08816482A0234|20 28|variants
P08816482A0234|32 37|Stat5
P08816482A0234|39 45|Stat5a
P08816482A0234|50 56|Stat5b
P08816482A0234|82 87|genes
P08816483A0869|0 9|Mutations
P08816483A0869|19 23|loci
P08816483A0869|25 29|SIC1
P08816483A0869|31 35|SWI5
P08816483A0869|41 45|RIC3
P08816498A0000|4 33|serine/threonine kinase Raf-1
P08816498A0000|58 62|Rats
P08816498A0000|68 95|signal transduction cascade
P08816498A0000|122 129|stimuli
P08816498A0000|139 154|plasma membrane
P08816498A0000|162 169|nucleus
P08816504T0000|17 23|growth
P08816504T0000|41 51|activation
P08816504T0000|55 84|phosphatidylinositol 3-kinase
P08816504T0000|101 117|receptor binding
P08816504T0000|143 151|proteins
P08816504T0000|168 180|Ras activity
P08816507A1125|13 32|cotransfections E1A
P08816507A1125|50 58|activity
P08816507A1125|66 78|p53 promoter
P08816507A1125|89 94|level
P08816507A1125|96 103|12S E1A
P08816507A1125|134 141|13S E1A
P08816507A1125|150 158|activity
P08816507A1125|164 167|YY1
P08816507A1125|191 198|element
P08816507A1125|222 223|%
P08816507A1125|232 241|induction
P08816759A0000|4 28|retinoid Z receptor beta
P08816759A0000|30 38|RZR beta
P08816759A0000|44 59|orphan receptor
P08816759A0000|66 72|member
P08816759A0000|89 102|acid receptor
P08816759A0000|104 107|RAR
P08816759A0000|109 133|thyroid hormone receptor
P08816759A0000|135 137|TR
P08816759A0000|139 148|subfamily
P08816759A0000|160 169|receptors
P08816792A0000|14 28|protein kinase
P08816792A0000|30 36|DNA-PK
P08816792A0000|66 73|protein
P08816792A0000|75 77|Ku
P08816792A0000|101 108|subunit
P08816792A0000|110 118|DNA-PKcs
P08817323A0714|16 33|sequence identity
P08817323A0714|59 62|end
P08817323A0714|70 83|DXS6673E gene
P08817323A0714|102 115|sequence tags
P08817323A0714|117 121|ESTs
P08817323A0714|142 145|end
P08817323A0714|153 166|DXS6673E gene
P08817323A0714|179 183|EST.
P08817324A1070|0 10|Sequencing
P08817324A1070|18 21|16p
P08817324A1070|27 55|Xq28 duplication breakpoints
P08817324A1070|73 81|presence
P08817324A1070|116 140|CAGGG pentamer sequences
P08817324A1070|156 175|paralogy boundaries
P08818436A0557|27 35|analysis
P08818436A0557|48 51|age
P08818436A0557|53 59|gender
P08818436A0557|76 83|history
P08818436A0557|102 110|diseases
P08818436A0557|119 125|gender
P08818436A0557|164 169|death
P08818718A1229|41 50|injection
P08818718A1229|70 76|vector
P08818718A1229|99 108|liposomes
P08818718A1229|124 128|mice
P08818718A1229|130 138|delivery
P08818718A1229|142 146|MDR1
P08818718A1229|151 159|GC cDNAs
P08818718A1229|184 190|organs
P08820324A1699|4 10|limits
P08820324A1699|14 23|agreement
P08820324A1699|32 35|DBS
P08820324A1699|40 53|TOF responses
P08820642A0173|20 29|hrpZ gene
P08820642A0173|47 53|operon
P08820642A0173|72 104|Hrp secretion pathway components
P08820642A0173|112 116|part
P08820642A0173|135 142|cluster
P08820642A0173|146 155|hrp genes
P08820642A0173|167 180|cosmid pHIR11
P08820642A0173|206 214|bacteria
P08820642A0173|279 281|HR
P08820642A0173|285 292|tobacco
P08820648A0123|12 20|presence
P08820648A0123|39 63|ribonucleotide reductase
P08820648A0123|83 89|enzyme
P08820648A0123|118 124|growth
P08820648A0123|132 136|cell
P08820648A0123|161 168|mutants
P08820648A0123|177 184|species
P08820648A0123|207 215|presence
P08820648A0123|219 225|oxygen
P08822208A1364|16 23|results
P08822208A1364|49 57|isoforms
P08822208A1364|73 82|responses
P08822208A1364|99 110|differences
P08822208A1364|120 130|regulation
P08822399A0518|13 20|factors
P08822399A0518|33 42|attitudes
P08822399A0518|54 68|susceptibility
P08822399A0518|72 81|pregnancy
P08822399A0518|97 104|factors
P08823163T0000|16 25|structure
P08823163T0000|33 59|diphtheria toxin repressor
P08823163T0000|75 81|cobalt
P08823163T0000|86 95|manganese
P08823163T0000|122 128|domain
P08823163T0000|153 157|role
P08823163T0000|161 170|phosphate
P08823163T0000|174 188|co-corepressor
P08823187A1020|0 9|Titration
P08823187A1020|27 43|porcine proteins
P08823187A1020|92 112|membrane dipeptidase
P08823187A1020|151 166|disulfide bonds
P08823260A1161|0 4|FEV1
P08823260A1161|35 43|patients
P08823260A1161|69 73|GVHD
P08823260A1161|104 112|patients
P08823260A1161|146 155|infection
P08823646A1012|0 14|Administration
P08823646A1012|18 28|adrenaline
P08823646A1012|49 63|overestimation
P08823646A1012|71 75|SaO2
P08823646A1012|90 102|measurements
P08823709A0220|0 7|Therapy
P08823709A0220|21 33|modification
P08823709A0220|38 65|triglyceride lowering drugs
P08823709A0220|78 88|resolution
P08823709A0220|92 100|symptoms
P08823709A0220|105 112|parotid
P08823709A0220|129 136|patient
P08824201A0270|0 8|Chernoff
P08824201A0270|24 35|publication
P08824585A0260|23 37|protein kinase
P08824585A0260|60 77|progenitor kinase
P08824585A0260|81 85|HPK1
P08824585A0260|137 142|cells
P08824585A0260|160 176|progenitor cells
P08824798A0761|6 23|ESP1/CRP2 protein
P08824798A0761|32 43|LIM domains
P08824798A0761|54 60|shares
P08824798A0761|65 66|%
P08824798A0761|79 80|%
P08824798A0761|91 99|residues
P08824798A0761|125 132|protein
P08824798A0761|134 137|CRP
P08824798A0761|143 151|rat CRIP
P08824800A0808|4 13|fragments
P08824800A0808|50 77|agarose gel electrophoresis
P08824805A0832|15 30|exon boundaries
P08824805A0832|49 59|boundaries
P08824805A0832|74 81|domains
P08824805A0832|89 100|p55 protein
P08824881A0133|0 15|Linkage studies
P08824881A0133|27 46|locus heterogeneity
P08824881A0133|56 64|TSC gene
P08824881A0133|75 90|chromosome 9q34
P08824881A0133|107 114|16p13.3
P08824884A0000|16 26|expression
P08824884A0000|34 40|folate
P08824884A0000|59 63|site
P08824884A0000|65 70|FRAXE
P08824884A0000|86 95|expansion
P08824884A0000|101 111|GCC repeat
P08824884A0000|124 128|Xq28
P08824884A0000|142 154|X chromosome
P08824884A0000|185 189|form
P08824884A0000|200 208|handicap
P08825087A0213|0 21|DNA sequence analysis
P08825087A0213|32 54|bp BamHI-ClaI fragment
P08825087A0213|80 94|reading frames
P08825087A0213|96 100|ORFs
P08825087A0213|127 138|orientation
P08825178A0071|12 32|inpatient experience
P08825178A0071|37 48|individuals
P08825178A0071|66 68|TB
P08825178A0071|91 101|acceptance
P08825178A0071|109 122|participation
P08825178A0071|134 141|TB care
P08825554A0000|0 15|Tristetraprolin
P08825554A0000|17 20|TTP
P08825554A0000|29 38|prototype
P08825554A0000|44 49|group
P08825554A0000|63 84|transcription factors
P08825554A0000|118 135|CCCH zinc fingers
P08825556A0522|5 12|element
P08825556A0522|21 28|CREsp-a
P08825556A0522|30 38|TGACCTCA
P08825556A0522|56 66|nucleotide
P08825556A0522|86 89|CRE
P08825556A0522|91 97|CREpal
P08825556A0522|99 107|TGACGTCA
P08825556A0522|133 137|CREB
P08825556A0522|143 152|homodimer
P08825633A0304|0 8|Analysis
P08825633A0304|26 29|DNA
P08825633A0304|52 60|sequence
P08825633A0304|73 81|homology
P08825633A0304|91 98|G alpha
P08825633A0304|101 105|cDNA
P08825636T0000|25 34|structure
P08825636T0000|55 65|gene NFKB1
P08825636T0000|85 89|p105
P08825636T0000|94 106|p50 proteins
P08825636T0000|110 142|transcription factors NF-kappa B
P08825636T0000|147 162|I kappa B-gamma
P08825636T0000|164 176|implications
P08825636T0000|181 189|NF-kappa
P08825636T0000|201 220|signal transduction
P08825639A0827|12 30|Alu repeat element
P08825639A0827|58 65|repeats
P08825639A0827|93 99|region
P08825639A0827|127 135|cap site
P08827783A0499|4 8|ewes
P08827783A0499|26 34|normoxia
P08827783A0499|40 50|monitoring
P08827783A0499|71 73|h.
P08828142A0000|7 23|leukemia viruses
P08828142A0000|25 30|FeLVs
P08828142A0000|65 81|oncoretroviruses
P08828142A0000|98 109|cat species
P08828142A0000|151 163|environments
P08828152A1238|0 10|Comparison
P08828152A1238|18 38|amino acid sequences
P08828152A1238|46 63|RPO1 polypeptides
P08828152A1238|67 71|IIV6
P08828152A1238|73 77|LCDV
P08828152A1238|83 88|MCV-1
P08828152A1238|147 155|proteins
P08828152A1238|165 176|differences
P08828152A1238|180 201|amino acid similarity
P08828152A1238|219 232|relationships
P08828152A1825|4 8|RPO1
P08828152A1825|12 16|LCDV
P08828152A1825|35 45|similarity
P08828152A1825|53 57|RPO1
P08828152A1825|61 65|IIV6
P08828152A1825|88 98|similarity
P08828152A1825|117 128|polymerases
P08828152A1825|173 180|subunit
P08828857A2423|4 7|use
P08828857A2423|19 27|GE cells
P08828857A2423|64 70|system
P08828857A2423|83 88|study
P08828857A2423|96 105|endocrine
P08828857A2423|107 116|paracrine
P08828857A2423|132 139|factors
P08828857A2423|163 178|gene expression
P08828857A2423|186 195|pregnancy
P08829393A0083|13 30|dipole estimation
P08829393A0083|34 40|spikes
P08829393A0083|45 59|SEP components
P08829393A0083|73 81|patients
P08831364A1252|5 14|verapamil
P08831364A1252|19 30|propranolol
P08831364A1252|52 59|effects
P08831364A1252|65 74|adenosine
P08831364A1252|89 91|AV
P08831364A1252|98 113|conduction time
P08831364A1252|129 138|verapamil
P08831364A1252|154 158|dose
P08831364A1252|162 171|adenosine
P08831364A1252|192 194|AV
P08831364A1252|201 206|block
P08832146A0959|9 12|CBD
P08832146A0959|43 68|bone alkaline phosphatase
P08832146A0959|70 71|r
P08832146A0959|81 82|p
P08832146A0959|102 105|PTH
P08832146A0959|107 108|r
P08832146A0959|118 119|p
P08833153A0628|3 11|addition
P08833153A0628|15 25|comparison
P08833153A0628|33 53|hCHLR gene sequences
P08833153A0628|69 78|databases
P08833153A0628|102 109|portion
P08833153A0628|119 124|genes
P08833153A0628|136 141|exons
P08833153A0628|166 173|domains
P08833153A0628|199 205|region
P08833153A0628|215 223|proteins
P08833153A0628|248 252|part
P08833153A0628|281 296|repeat sequence
P08833153A0628|317 328|chromosomes
P08833653A0304|22 55|LIM domain homeobox protein isl-1
P08833653A0304|70 89|rat amylin promoter
P08833653A0304|98 108|fibroblast
P08833653A0304|113 129|islet cell lines
P08833653A0783|9 14|isl-1
P08833653A0783|33 40|insulin
P08833653A0783|45 74|amylin gene promoter elements
P08833653A0783|91 100|sequences
P08833653A0783|116 127|differences
P08833653A0783|162 172|properties
P08833653A0783|213 221|promoter
P08833653A0783|243 247|InR1
P08833653A0783|249 263|G9 islet cells
P08835393A2829|24 32|pathways
P08835393A2829|51 77|signal transduction events
P08835393A2829|85 105|calcium mobilization
P08835393A2829|111 137|promoter response elements
P08835393A2829|145 148|SRE
P08835895A1292|4 13|CD4 count
P08835895A1292|23 32|remission
P08835895A1292|59 75|immunodeficiency
P08835895A1292|86 90|risk
P08835895A1292|108 117|infection
P08835969A0000|20 31|laparoscopy
P08835969A0000|65 74|reference
P08835969A0000|82 91|diagnosis
P08835969A0000|103 112|pregnancy
P08835969A0000|114 116|EP
P08835969A0000|119 122|use
P08835969A0000|154 164|sonography
P08835969A0000|169 180|conjunction
P08835969A0000|198 210|serum assays
P08835969A0000|218 230|beta subunit
P08835969A0000|250 262|gonadotropin
P08835969A0000|264 272|beta-hCG
P08835969A0000|282 291|detection
P08835969A0000|315 318|EPs
P08836032T0000|0 15|Bifunctionality
P08836032T0000|23 29|AcMNPV
P08836032T0000|41 56|region sequence
P08836032T0000|58 61|hr1
P08836032T0000|64 72|enhancer
P08836032T0000|77 90|ori functions
P08836032T0000|106 127|sequence requirements
P08836172A1382|0 3|RVR
P08836172A1382|5 9|loss
P08836172A1382|13 21|function
P08836172A1382|23 30|studies
P08836172A1382|47 62|over-expression
P08836172A1382|86 97|RVR delta E
P08836172A1382|120 126|levels
P08836172A1382|130 142|p21Cip1/Waf1
P08836172A1382|147 161|myogenin mRNAs
P08836172A1382|168 184|serum withdrawal
P08836740A1025|8 12|CES1
P08836740A1025|17 21|CES4
P08836740A1025|39 50|cell growth
P08836740A1025|65 80|deletion mutant
P08837503A0392|10 23|repeat motifs
P08837503A0392|67 74|pattern
P08837503A0392|83 89|domain
P08837503A0392|111 118|SbHRGP3
P08837503A0392|136 141|group
P08837503A0392|145 153|proteins
P08837503A0392|165 178|repeat motifs
P08837503A0392|195 201|groups
P08837503A0392|205 220|dicot extensins
P08837746A0951|6 9|use
P08837746A0951|31 45|BrAAP activity
P08837746A0951|63 74|postproline
P08837746A0951|81 103|postglutamate cleavage
P08837746A0951|132 143|specificity
P08838144A0107|26 38|significance
P08838144A0107|48 58|subdomains
P08838144A0107|62 73|PRL binding
P08838144A0107|78 97|signal transduction
P08838144A0107|99 115|deletion mutants
P08838144A0107|119 142|S1 or/and S2 subdomains
P08838148A1218|22 31|cell line
P08838148A1218|47 65|mouse TRH receptor
P08838148A1218|85 97|transfection
P08838148A1218|118 123|cells
P08838148A1218|136 154|L channel activity
P08838314A0129|26 36|expression
P08838314A0129|41 51|regulation
P08838314A0129|59 63|V1aR
P08838314A0129|93 108|characteristics
P08838314A0129|110 127|tissue expression
P08838314A0129|141 153|localization
P08838314A0129|168 175|mapping
P08838314A0129|189 198|V1aR gene
P08838314A0129|200 206|AVPR1A
P08838585A0968|20 29|structure
P08838585A0968|45 63|backbone deviation
P08838585A0968|86 93|ras-p21
P08838805T0000|8 20|organization
P08838805T0000|34 51|beta-catenin gene
P08838805T0000|53 59|CTNNB1
P08839498A0507|35 47|distribution
P08839498A0507|56 67|tissue mass
P08839498A0507|75 80|trunk
P08839498A0507|85 89|legs
P08839498A0507|137 143|stages
P08839498A0507|158 170|distribution
P08839498A0507|174 177|fat
P08839832A0729|20 33|CD30v protein
P08839832A0729|66 72|region
P08839832A0729|120 127|domains
P08839832A1220|13 28|phosphorylation
P08839832A1220|36 49|CD30v protein
P08839832A1220|79 87|labeling
P08839832A1220|94 97|32P
P08839911A0716|4 5|%
P08839911A0716|9 15|cycles
P08840501A0345|19 28|discovery
P08840501A0345|52 56|gene
P08840501A0345|65 73|organism
P08840501A0345|95 99|ACT4
P08840506A0544|11 15|ORFs
P08840506A0544|50 54|ones
P08840506A0544|92 97|G2850
P08840997A0765|0 10|MVR typing
P08840997A0765|26 33|alleles
P08840997A0765|84 93|sequences
P08840997A0765|124 135|resemblance
P08840997A0765|157 164|alleles
P08842143A0000|0 14|Plasmid pAL618
P08842143A0000|36 48|determinants
P08842143A0000|53 62|H2 uptake
P08842143A0000|64 67|hup
P08842143A0000|98 100|bv
P08842143A0000|102 108|viciae
P08842143A0000|122 129|cluster
P08842143A0000|136 141|genes
P08843411A0801|4 11|classes
P08843411A0801|24 33|receptors
P08843411A0801|85 95|activation
P08843411A0801|100 112|dimerization
P08843411A0801|173 183|activation
P08843412A0543|32 52|40-amino acid region
P08843412A0543|64 68|LBDs
P08843412A0543|72 75|RXR
P08843412A0543|77 80|RAR
P08843412A0543|82 84|TR
P08843412A0543|90 107|chicken ovalbumin
P08843412A0543|117 146|promoter transcription factor
P08843412A0543|180 188|identity
P08843412A0543|210 221|interaction
P08843412A0543|244 255|DNA binding
P08843419A1290|0 3|OKA
P08843419A1290|8 19|calyculin A
P08843419A1290|36 41|OCFRE
P08843419A1290|54 66|interactions
P08843419A1290|110 122|interactions
P08844448A0000|55 70|crossover study
P08844448A0000|99 109|volunteers
P08844448A0000|129 134|years
P08844448A0000|138 141|age
P08844448A0000|157 163|effect
P08844448A0000|167 175|orlistat
P08844448A0000|196 212|lipase inhibitor
P08844448A0000|238 248|absorption
P08844448A0000|276 290|weight control
P08844448A0000|294 301|obesity
P08844448A0000|310 320|absorption
P08844448A0000|324 332|vitamins
P08844448A0000|339 341|E.
P08844577A0000|0 10|Tilmicosin
P08844577A0000|22 31|macrolide
P08844577A0000|67 70|use
P08844577A0000|85 93|medicine
P08844712A0000|0 6|Effect
P08844712A0000|18 23|oxide
P08844712A0000|25 28|N2O
P08844712A0000|55 56|A
P08844712A0000|62 72|C-reflexes
P08844712A0000|120 124|rats
P08844712A0000|143 159|alpha-chloralose
P08844712A0000|164 172|urethane
P08845378A0368|0 26|Restriction enzyme mapping
P08845378A0368|31 48|Southern analysis
P08845378A0368|82 92|MZF-1 gene
P08845378A0368|110 114|gene
P08846775A0110|7 14|absence
P08846775A0110|18 22|Swi4
P08846775A0110|27 46|Swi6 cell viability
P08846775A0110|87 97|expression
P08846775A0110|105 114|G1 cyclin
P08846775A0110|124 129|genes
P08846775A0110|131 135|CLN1
P08846775A0110|139 143|CLN2
P08847138A0609|4 19|detection ratio
P08847138A0609|30 34|ages
P08847138A0609|85 90|years
P08847138A0609|94 97|age
P08847403T0000|9 16|embryos
P08847403T0000|32 40|patients
P08847403T0000|52 55|IVF
P08847723A2351|0 12|IMPLICATIONS
P08847723A2351|30 34|size
P08847723A2351|43 48|study
P08847723A2351|57 70|inconsistency
P08847723A2351|74 81|results
P08847723A2351|108 115|studies
P08847723A2351|127 133|cancer
P08847723A2351|158 170|associations
P08847723A2351|172 184|replications
P08847723A2351|194 202|findings
P08848013A1469|17 25|TATA box
P08848013A1469|29 39|promoter B
P08848013A1469|63 67|role
P08848013A1469|71 88|promoter activity
P08848013A1469|98 106|TATA box
P08848013A1469|110 121|promoter A.
P08848052A0733|6 16|properties
P08848052A0733|31 35|Gle1
P08848052A0733|42 59|RNA-export factor
P08848052A0733|69 72|Rev
P08848052A0733|91 101|RNA export
P08848052A0733|119 127|function
P08848052A0733|131 135|Gle1
P08849208A1022|0 8|Demispan
P08849208A1022|40 47|measure
P08849208A1022|51 58|stature
P08849569A0615|4 14|techniques
P08849569A0615|24 42|assay coefficients
P08849569A0615|46 55|variation
P08849569A0615|105 112|pattern
P08849569A0615|116 124|cortisol
P08849778A0226|18 38|toeprinting analyses
P08849778A0226|42 51|repA mRNA
P08849778A0226|55 65|plasmid R1
P08849778A0226|84 90|duplex
P08849778A0226|110 113|RNA
P08849778A0226|115 119|CopA
P08849778A0598|9 13|work
P08849778A0598|26 30|repA
P08849778A0598|32 49|initiator protein
P08849778A0598|51 61|expression
P08849778A0598|71 74|tap
P08849778A0598|76 90|leader peptide
P08849778A0598|92 103|translation
P08849834A0000|2 8|system
P08849834A0000|35 51|volume flow rate
P08849834A0000|55 60|blood
P08849834A0000|66 72|vessel
P08849834A0000|104 137|colour Doppler ultrasound imaging
P08850585A0602|4 21|enzyme activities
P08850585A0602|44 52|elements
P08850585A0602|60 75|pathophysiology
P08850585A0602|86 92|caries
P08850585A0602|122 139|virulence factors
P08851337A1092|0 13|Tonsillectomy
P08851337A1092|30 35|means
P08851337A1092|39 50|prophylaxis
P08851337A1092|73 82|infection
P08851337A1092|95 110|angina patients
P08851434A0383|8 12|mice
P08851434A0383|18 43|fat/water intensity ratio
P08851434A0383|65 69|half
P08851434A0383|85 89|mice
P08853303A0431|16 26|parameters
P08853303A0431|43 49|values
P08853303A0431|63 73|literature
P08853303A0431|113 115|IA
P08853303A0431|117 137|bolus MMC injections
P08853303A0431|139 143|Tmax
P08853303A0431|150 153|min
P08853303A0431|168 177|beginning
P08853303A0431|181 193|MMC infusion
P08853303A0431|195 198|Vss
P08853303A0431|206 210|1/kg
P08853303A0431|212 214|C1
P08853303A0431|221 227|ml/min
P08853303A0431|228 230|kg
P08853303A0431|232 242|T1/2 alpha
P08853303A0431|249 252|min
P08853303A0431|254 263|T1/2 beta
P08853303A0431|271 274|min
P08853893A0158|8 13|study
P08853893A0158|43 56|E2F complexes
P08853893A0158|109 120|fibroblasts
P08854459A0000|5 10|paper
P08854459A0000|20 28|overview
P08854459A0000|43 50|pattern
P08854459A0000|54 64|casualties
P08854459A0000|68 79|earthquakes
P08854459A0000|115 121|period
P08854459A0000|129 138|September
P08854459A0000|150 158|February
P08854844A0637|16 23|finding
P08854844A0637|27 44|non-visualization
P08854844A0637|52 54|GB
P08854844A0637|60 76|h post injection
P08854844A0637|84 93|criterion
P08854844A0637|102 111|diagnosis
P08854844A0637|115 117|AC
P08854844A0637|134 142|accuracy
P08854844A0637|156 157|%
P08855804A1528|6 13|results
P08855804A1528|48 53|study
P08855804A1528|78 81|men
P08855804A1528|105 108|SLT
P08855804A1528|111 113|mg
P08855804A1528|120 125|times
P08855804A1528|138 144|months
P08856077T0000|12 22|processing
P08856077T0000|30 63|tryptophanyl-tRNA synthetase mRNA
P08856077T0000|94 99|cells
P08856132T0000|0 8|Evidence
P08856132T0000|27 31|role
P08856132T0000|53 66|kinin release
P08856132T0000|74 85|development
P08856132T0000|120 128|abortion
P08858211A0694|5 17|GAP activity
P08858211A0694|34 58|3T3-L1 adipocyte lysates
P08858211A0694|91 101|hydrolysis
P08858211A0694|110 119|alpha-32P
P08858211A0694|120 123|GTP
P08858211A0694|133 141|GST-Rab4
P08858211A0694|148 157|alpha-32P
P08858211A0694|158 161|GDP
P08858268A1307|0 10|CONCLUSION
P08858268A1307|27 36|treatment
P08858268A1307|55 63|response
P08858268A1307|72 82|cilazapril
P08858268A1307|134 145|improvement
P08858268A1307|149 157|patients
P08858268A1307|163 166|CHF
P08858268A1307|170 173|CLZ
P08858268A1307|218 225|effects
P08858463A0853|21 34|AIDS patients
P08858463A0853|40 54|cryptococcosis
P08858463A0853|56 65|tolerance
P08858463A0853|69 76|ILd-AmB
P08858463A0853|107 113|dosage
P08858463A0853|131 136|mg/kg
P08858463A0853|157 162|mg/kg
P08858463A0853|169 175|dosage
P08858463A0853|212 216|rate
P08858463A0853|220 234|nephrotoxicity
P08861955A0927|31 36|motif
P08861955A0927|52 66|amino-terminus
P08861955A0927|70 74|p619
P08861955A0927|86 113|guanine nucleotide exchange
P08861955A0927|117 121|ARF1
P08861955A0927|129 136|members
P08861955A0927|152 164|Rab proteins
P08861955A0927|189 209|GTP binding proteins
P08861955A0927|218 221|Ran
P08861955A0927|225 231|R-Ras2
P08861955A0927|232 236|TC21
P08861963A0375b|18 33|RNA polymerases
P08861963A0375b|49 70|mutant alpha subunits
P08861963A0375b|95 103|response
P08861963A0375b|107 131|transcription activation
P08861963A0375b|135 143|cAMP-CRP
P08861963A0375b|152 169|rrnBP1 UP element
P08861963T0000|0 40|Transcription factor recognition surface
P08861963T0000|48 76|RNA polymerase alpha subunit
P08861963T0000|92 99|contact
P08861963T0000|109 129|DNA enhancer element
P08862522A0690|21 31|similarity
P08862522A0690|37 45|cdc28-P8
P08862522A0690|75 85|precursors
P08862522A0690|105 116|temperature
P08862743A0603|2 10|decrease
P08862743A0603|14 28|erythrocyte Mn
P08862743A0603|34 37|age
P08862743A0603|52 58|nmol/L
P08862743A0603|71 72|p
P08863824A0509|0 7|Cloning
P08863824A0509|12 29|sequence analyses
P08863824A0509|48 52|cDNA
P08863824A0509|66 74|deletion
P08863824A0509|82 88|region
P08863824A0509|134 138|loop
P08863824A0509|154 174|transmembrane domain
P08863824A0509|182 190|5-HT2C-R
P08864061A0000|0 10|Expression
P08864061A0000|14 35|thymidine kinase gene
P08864061A0000|60 65|cells
P08864061A0000|74 84|cell cycle
P08864219A0178|23 37|concentrations
P08864219A0178|39 43|MICs
P08864219A0178|48 60|ketoconazole
P08864219A0178|62 72|miconazole
P08864219A0178|74 86|itraconazole
P08864219A0178|88 99|fluconazole
P08864219A0178|105 119|amphotericin B
P08864219A0178|157 170|inoculum size
P08864219A0178|190 200|techniques
P08866485A0125|6 14|bacteria
P08866485A0125|27 42|export proteins
P08866485A0125|63 75|interactions
P08866485A0125|95 99|cell
P08866485A0125|111 120|molecules
P08866485A0125|124 129|order
P08866485A0125|151 160|functions
P08866485A0125|168 173|cells
P08867519A0557|4 14|elevations
P08867519A0557|27 31|LDEE
P08867519A0557|38 42|s.c.
P08867519A0557|86 100|administration
P08867519A0557|123 130|periods
P08868473A1287|15 18|p28
P08868473A1287|43 47|role
P08868473A1287|75 84|cleavages
P08868473A1287|111 122|development
P08868473A1287|146 150|type
P08868473A1287|154 164|cell cycle
P08868660A0087|9 12|aim
P08868660A0087|20 32|contribution
P08868660A0087|49 54|arena
P08868660A0087|59 69|discussion
P08868660A0087|77 89|Rivista dell
P08868660A0087|90 100|Infermiere
P08868660A0087|137 145|research
P08868660A0087|169 178|strengths
P08868660A0087|183 190|novelty
P08868660A0087|195 205|weaknesses
P08868660A0087|213 235|hypothesis formulation
P08868660A0087|237 244|methods
P08868660A0087|249 260|instruments
P08868660A0087|267 277|discussion
P08868660A0087|281 288|results
P08868954A0648|32 39|effects
P08868954A0648|60 65|drugs
P08868954A0648|101 107|agents
P08868954A0648|114 133|calcium antagonists
P08868954A0648|142 153|angiotensin
P08868954A0648|165 182|enzyme inhibitors
P08868954A0648|198 210|hemodynamics
P08869358A0121|11 18|viruses
P08869358A0121|48 58|strategies
P08869358A0121|73 82|apoptosis
P08869358A0121|101 106|cells
P08869358A0121|127 134|T cells
P08869763A0378|43 52|phenomena
P08869763A0378|56 64|response
P08869763A0378|68 76|morphine
P08869763A0378|97 108|differences
P08869763A0378|112 122|expression
P08869763A0378|127 138|sensitivity
P08869763A0378|154 171|receptor subtypes
P08869763A0378|175 183|migraine
P08869825A0000|9 16|studies
P08869825A0000|57 71|monooxygenases
P08869825A0000|73 76|FMO
P08869825A0000|113 119|manner
P08870266A0651|22 34|observations
P08870266A0651|67 78|amino acids
P08870266A0651|98 112|NodO secretion
P08870266A0651|126 132|region
P08870266A0651|150 156|domain
P08870266A0651|175 195|secretion efficiency
P08871542A1352|18 27|potential
P08871542A1352|50 60|mechanisms
P08871542A1352|76 84|evidence
P08871542A1352|104 107|Mtx
P08871542A1352|116 124|promoter
P08871542A1352|155 176|Thbs3 gene expression
P08871567A0000|0 13|MSSP proteins
P08871567A0000|44 51|binding
P08871567A0000|67 74|element
P08871567A0000|78 83|c-myc
P08871567A0629|0 4|Gene
P08871635A0000|0 23|B cell antigen receptor
P08871635A0000|25 28|BCR
P08871635A0000|38 47|apoptosis
P08871635A0000|55 84|WEHI-231 B lymphoma cell line
P08871635A0000|114 118|CD40
P08872162A0884|5 12|alleles
P08872162A0884|67 70|CD4
P08872162A0884|72 75|CD8
P08872162A0884|77 91|T cell subsets
P08872671A0573|4 9|model
P08872671A0573|29 54|blood flow shunt fraction
P08872671A0573|56 61|Qs/QT
P08872671A0573|90 96|oxygen
P08872671A0573|107 130|amplitude perturbations
P08872671A0573|158 161|air
P08872671A0573|192 197|blood
P08872671A0573|217 226|equations
P08873063A0493|12 31|amino acid sequence
P08873063A0493|35 41|LvUSF2
P08873063A0493|65 71|LvUSF1
P08873063A0493|86 95|amino end
P08873063A0875|0 14|ECM disruption
P08873063A0875|18 36|Lytechinus embryos
P08873063A0875|55 59|drop
P08873063A0875|63 90|USF RNA accumulation levels
P08873063A0875|110 111|%
P08873063A0875|115 130|control embryos
P08873063A0875|138 166|LpS1 RNA accumulation levels
P08873063A0875|189 190|%
P08873159A0791|20 28|patients
P08873159A0791|32 37|group
P08873159A0791|62 74|chemotherapy
P08874399A0277|6 10|days
P08874399A0277|21 33|intervention
P08874399A0277|54 62|tensions
P08874399A0277|105 108|Ca2
P08874399A0277|110 123|concentration
P08874399A0277|126 128|Ca
P08874399A0277|129 130|o
P08874399A0277|140 146|groups
P08874399A0277|153 155|B.
P08874631A1133|0 14|Discrimination
P08874631A1133|23 28|HIV-1
P08874631A1133|33 38|HIV-2
P08874631A1133|46 54|evidence
P08874631A1133|63 71|presence
P08874631A1133|75 80|HIV-1
P08876167A0322|34 41|subunit
P08876167A0322|46 52|HiNF-D
P08876167A0717|4 10|HiNF-D
P08876167A0717|12 19|CDP/cut
P08876167A0717|21 28|complex
P08876167A0717|38 49|H4 promoter
P08876167A0717|73 83|antibodies
P08876167A0717|92 99|CDP/cut
P08876167A0717|104 107|pRB
P08876167A0717|116 120|p107
P08876167A0717|142 149|complex
P08876167A0717|168 176|promoter
P08876167A0717|178 187|gp91-phox
P08876167A0717|206 209|CDP
P08876167A0717|214 229|p107 antibodies
P08876701A0177|30 42|UmuC-homolog
P08876701A0177|44 48|DinB
P08877103A0081|13 23|regulation
P08877103A0081|27 42|mdr2 expression
P08877103A0081|48 56|promoter
P08877103A0081|64 73|mdr2 gene
P08877103A0081|128 137|cell line
P08877103A0081|139 146|J7.V2-1
P08877818A0184|4 17|amplification
P08877818A0184|41 48|primers
P08877818A0184|69 92|TRH progenitor sequence
P08877818A0184|94 109|Lys/Arg-Arg-Gln
P08877818A0184|110 125|His-Pro-Gly-Lys
P08877818A0184|126 133|Arg-Arg
P08878019A0357|27 32|cells
P08878019A0357|46 55|sinusoids
P08878019A0357|63 74|lymph nodes
P08878019A0357|141 146|tumor
P08878019A0357|155 159|case
P08878037A0000|4 13|gene ccpA
P08878037A0000|27 58|catabolite control protein CcpA
P08878044A1390|3 23|InlC deletion mutant
P08878044A1390|38 47|virulence
P08878044A1390|78 89|mouse model
P08878044A1390|109 120|replication
P08878044A1390|128 134|mutant
P08878044A1390|138 144|Caco-2
P08878044A1390|149 159|J774 cells
P08878044A1390|212 218|strain
P08878045A0606|10 23|N-Nus complex
P08878045A0606|48 56|contacts
P08878045A0606|66 69|CTD
P08878045A0606|77 90|alpha subunit
P08878045A0606|94 108|RNA polymerase
P08878045A0606|118 123|group
P08878045A0606|138 146|proteins
P08878045A0606|163 173|initiation
P08878045A0606|177 190|transcription
P08878573A1370|0 14|Administration
P08878573A1370|18 22|RIFA
P08878573A1370|30 39|mg/kg/day
P08878573A1370|43 54|combination
P08878573A1370|60 63|ATO
P08878573A1370|71 80|mg/kg/day
P08878573A1370|102 114|prolongation
P08878573A1370|118 126|survival
P08878573A1370|150 154|mice
P08878573A1370|169 172|ATO
P08878573A1370|176 180|RIFA
P08879080A0265|11 16|ACOAs
P08879080A0265|32 37|order
P08879080A0265|53 56|fit
P08879080A0265|64 69|model
P08879080A0265|77 81|data
P08879080A0265|85 98|path analysis
P08879080A0265|104 114|LISREL VII
P08879237A0744|13 29|initiation sites
P08879237A0744|48 56|sequence
P08879237A0744|75 99|consensus promoter motif
P08879237A0744|118 128|CRTA motif
P08879237A0744|136 137|R
P08879237A0744|146 147|G
P08879237A0744|156 174|rice mitochondrion
P08880405A1170|0 9|Selection
P08880405A1170|16 22|SC EPD
P08880405A1170|58 67|selection
P08880405A1170|80 83|age
P08880405A1170|87 94|puberty
P08880405A1170|98 107|daughters
P08881036A0351|15 18|PCR
P08881036A0351|22 32|VL element
P08881036A0351|47 50|CL2
P08881542T0000|0 38|Sodium polystyrene sulfonate treatment
P08881542T0000|43 59|lithium toxicity
P08881542T0000|61 68|effects
P08881542T0000|72 102|serum potassium concentrations
P08882492A0000|14 34|homeodomain proteins
P08882492A0000|46 55|Hox genes
P08882492A0000|74 78|role
P08882492A0000|92 103|development
P08882492A0000|128 134|queues
P08882492A0000|162 172|identities
P08882492A0000|199 203|axis
P08882492A0000|218 227|organisms
P08882710A0000|0 10|Interferon
P08882710A0000|22 33|gene factor
P08882710A0000|37 42|ISGF3
P08882710A0000|58 78|transcription factor
P08882710A0000|92 101|treatment
P08882710A0000|105 110|cells
P08882710A0000|116 132|interferon-alpha
P08882710A0000|137 141|beta
P08882710A0000|143 147|type
P08882710A0000|150 154|IFNs
P08884273A1413|4 20|TYAC/P1 resource
P08884273A1413|33 37|STSs
P08884273A1413|43 56|polymorphisms
P08884273A1413|80 88|resource
P08884273A1413|100 107|studies
P08884273A1413|111 129|telomere structure
P08884273A1413|134 142|function
P08884273A1413|149 154|means
P08884273A1413|180 195|map integration
P08884273A1413|200 207|closure
P08884757A0653|13 23|statistics
P08884757A0653|33 37|item
P08884757A0653|63 73|Impression
P08884757A0653|75 78|CGI
P08884757A0653|91 96|score
P08884757A0653|104 110|Sandoz
P08884757A0653|120 140|Assessment Geriatric
P08884757A0653|142 146|SCAG
P08884757A0653|148 153|scale
P08884757A0653|178 182|help
P08884757A0653|191 196|nurse
P08884757A0653|199 205|rating
P08884757A0653|219 227|patients
P08884757A0653|229 273|Beurteilungsskala fur geriatrische Patienten
P08884757A0653|275 278|BGP
P08884757A0653|294 299|score
P08884757A0653|323 339|Performance Test
P08884757A0653|341 357|Syndrom-Kurztest
P08884757A0653|359 362|SKT
P08885270A0428|6 13|mutants
P08885270A0428|49 55|strain
P08885270A0428|57 61|PAO1
P08886845A1274|33 50|myogenin promoter
P08886845A1274|52 60|presence
P08886845A1274|80 86|copies
P08886845A1274|100 107|vectors
P08886845A1274|121 140|expression activity
P08886845A1274|144 152|myotubes
P08886845A1274|220 229|myoblasts
P08887643A1167|33 40|signals
P08887643A1167|47 57|activation
P08887643A1167|61 64|Ras
P08887643A1167|69 73|TC21
P08887643A1167|89 114|TC21 controls cell growth
P08887643A1167|155 173|signaling pathways
P08887647T0000|0 18|Fission yeast mal2
P08887647T0000|36 58|chromosome segregation
P08887652A0341|0 9|Selection
P08887652A0341|23 33|expression
P08887652A0341|51 63|DNA fragment
P08887652A0341|106 112|region
P08887652A0341|137 144|segment
P08887652A0341|164 177|reading frame
P08887652A0341|187 192|frame
P08887652A0341|212 243|hygromycin B phosphotransferase
P08887652A0341|255 259|gene
P08887652A0341|261 266|con10
P08887652A0341|269 272|hph
P08887659A0753|0 9|Mutations
P08887659A0753|29 34|sites
P08887659A0753|36 42|serine
P08887659A0753|51 60|threonine
P08887659A0753|82 88|effect
P08887661A0138|0 5|IRF-1
P08887661A0138|32 41|activator
P08887661A0138|49 54|IRF-2
P08887661A0138|65 74|repressor
P08887661A1061|3 11|contrast
P08887661A1061|13 27|cotransfection
P08887661A1061|31 36|TFIIB
P08887661A1061|41 46|IRF-1
P08887661A1061|52 65|NIH 3T3 cells
P08887661A1061|95 105|repression
P08887661A1061|109 128|promoter activation
P08887661A1061|164 170|manner
P08887667A0992|4 15|requirement
P08887667A0992|19 43|Tyr-19 dephosphorylation
P08887667A0992|48 64|spindle assembly
P08887667A0992|88 98|conditions
P08887667A0992|108 125|spindle formation
P08887667A0992|144 151|mitosis
P08887667A0992|173 184|involvement
P08887667A0992|188 204|Cdc28/Clb kinase
P08887667A0992|208 222|SPB separation
P08887674A0630|2 8|subset
P08887674A0630|18 44|DMP1 recognition sequences
P08887674A0630|58 80|GGA trinucleotide core
P08887674A0630|117 125|elements
P08887674A0920|8 16|settings
P08887674A0920|46 52|cyclin
P08887674A0920|65 72|kinases
P08887674A0920|110 118|activity
P08887674A0920|158 168|mechanisms
P08887678A0000|0 10|Expression
P08887678A0000|31 42|protein Bax
P08887678A0000|53 60|control
P08887678A0000|66 80|GAL10 promoter
P08887678A0000|141 151|cell death
P08890537A0355|5 14|technique
P08890537A0355|34 42|patients
P08890537A0355|61 70|bone cyst
P08891131A0000|0 28|Enterococcus faecium strains
P08891131A0000|48 71|glycopeptide resistance
P08891131A0000|89 107|enrichment culture
P08891131A0000|117 127|intestines
P08891131A0000|132 137|feces
P08891131A0000|156 163|species
P08891131A0000|172 178|horses
P08891131A0000|183 187|dogs
P08891131A0000|190 191|%
P08891131A0000|203 211|chickens
P08891131A0000|214 215|%
P08891131A0000|231 235|pigs
P08891131A0000|238 239|%
P08891337A0614|19 25|region
P08891337A0614|29 32|E1A
P08891337A0614|62 77|weight proteins
P08891337A0614|111 131|coactivator function
P08891337A0614|135 139|p300
P08891337A0614|159 180|cAMP response element
P08891337A0614|182 185|CRE
P08891337A0614|187 202|binding protein
P08891341A0724|10 29|transfection assays
P08891341A0724|36 60|reporter gene constructs
P08891341A0724|80 87|lengths
P08891341A0724|104 113|sequences
P08891341A0724|132 140|sequence
P08891341A0724|149 160|between-247
P08891341A0724|169 171|bp
P08891341A0724|194 204|expression
P08891341A0724|212 225|reporter gene
P08891341A0724|244 254|cell lines
P08891345A0684|19 37|UTR characteristic
P08891345A0684|57 67|c-mos mRNA
P08891345A0684|87 98|translation
P08891345A0684|115 126|translation
P08891345A0684|130 141|transcripts
P08891345A0684|159 162|UTR
P08891345A0684|176 192|beta-globin mRNA
P08891345A0684|229 234|uORFs
P08891346A1217|26 32|effect
P08891346A1217|45 63|isoform expression
P08891346A1217|65 77|NIH3T3 cells
P08891346A1217|113 130|expression vector
P08891346A1217|142 146|cDNA
P08891346A1217|151 156|FGF8a
P08891346A1217|158 163|FGF8b
P08891346A1217|168 173|FGF8e
P08891474A0667|6 14|findings
P08891474A0667|32 38|F-wave
P08891474A0667|58 68|motoneuron
P08891474A0667|82 106|depolarization threshold
P08891474A0667|142 154|nerve fibers
P08891474A0667|169 178|threshold
P08891474A0667|182 196|depolarization
P08892755A0186|3 11|addition
P08892755A0186|13 22|carp JAK1
P08892755A0186|36 53|sequence homology
P08892755A0186|67 71|JAK1
P08892755A0186|97 100|JH2
P08892755A0186|106 112|kinase
P08892755A0186|114 117|JH1
P08892755A0186|119 126|domains
P08892755A0186|144 154|% identity
P08892755A0981|10 22|DNA fragment
P08892755A0981|50 83|chloramphenicol acetyltransferase
P08892755A0981|85 88|CAT
P08892755A0981|90 103|reporter gene
P08892755A0981|127 144|carp CF cell line
P08892755A0981|165 174|synthesis
P08892755A0981|178 188|CAT enzyme
P08892755A0981|192 197|times
P08892755A0981|237 247|pCAT-Basic
P08892757T0000|10 17|cloning
P08892757T0000|21 26|Elk-3
P08892757T0000|34 40|member
P08892757T0000|48 58|Ets family
P08892757T0000|76 95|mouse embryogenesis
P08892757T0000|100 108|analysis
P08892757T0000|132 151|repression activity
P08892859A0563|13 20|example
P08892859A0563|60 69|cell line
P08892859A0563|71 73|T9
P08892859A0563|91 97|levels
P08892859A0563|113 126|C-MYB protein
P08892859A0563|132 138|result
P08892859A0563|142 157|RAV integration
P08892859A0563|169 181|c-myb allele
P08893779A0229|23 59|digitorum longus muscle tendon units
P08893779A0229|84 90|values
P08893779A0229|95 99|load
P08893779A0229|103 110|failure
P08893779A0229|112 113|p
P08893779A0229|123 129|energy
P08893779A0229|142 149|failure
P08893779A0229|151 152|p
P08893779A0229|166 172|strain
P08893779A0229|176 183|failure
P08893779A0229|185 186|p
P08893779A0229|244 252|location
P08893779A0229|254 255|p
P08893779A0229|294 303|interface
P08893779A0229|358 366|junction
P08893779A0229|379 384|units
P08893822A0560|0 17|Northern analysis
P08893822A0560|32 42|PWP2H cDNA
P08893822A0560|72 82|transcript
P08893822A0560|124 131|tissues
P08894144A0330|47 51|rats
P08894144A0330|93 97|days
P08894144A0330|103 119|CsA vehicle p.o.
P08894144A0330|125 138|FB vehicle sc
P08894144A0330|144 147|CsA
P08894144A0330|152 157|mg/kg
P08894144A0330|159 163|p.o.
P08894144A0330|169 182|FB vehicle sc
P08894144A0330|188 204|CsA vehicle p.o.
P08894144A0330|210 212|FB
P08894144A0330|218 223|mg/kg
P08894144A0330|225 227|sc
P08894144A0330|237 240|CsA
P08894144A0330|245 250|mg/kg
P08894144A0330|252 256|p.o.
P08894144A0330|262 264|FB
P08894144A0330|270 275|mg/kg
P08894144A0330|277 279|sc
P08894144A1173|0 3|CsA
P08894144A1173|31 44|bone turnover
P08894826A0228|0 11|Individuals
P08894826A0228|26 40|GUM Department
P08894826A0228|48 63|Royal Infirmary
P08894826A0228|67 76|Edinburgh
P08894826A0228|108 117|diagnosis
P08894826A0228|121 134|HIV infection
P08894826A0228|144 149|warts
P08894826A0228|159 165|herpes
P08894826A0228|188 197|infection
P08894826A0228|199 203|NSGI
P08894826A0228|206 216|gonorrhoea
P08894826A0228|221 229|syphilis
P08894826A0228|251 256|study
P08895522T0000|10 20|activation
P08895522T0000|28 50|tyrosine kinase domain
P08895522T0000|64 82|trk proto-oncogene
P08895522T0000|86 92|fusion
P08895522T0000|98 120|cell adhesion molecule
P08895579A0583|0 17|Northern blotting
P08895579A0583|30 34|MDMX
P08895579A0583|41 45|MDM2
P08895579A0583|67 74|tissues
P08895579A0583|100 105|mRNAs
P08895579A0583|110 114|MDMX
P08895997A0336|0 7|Physiol
P08896272A0000|4 23|nucleotide sequence
P08896272A0000|34 36|bp
P08896272A0000|49 52|arm
P08896272A0000|56 66|chromosome
P08896280A0860|41 47|levels
P08896280A0860|51 55|IME1
P08896280A0860|60 69|IME2 mRNA
P08896280A0860|90 96|result
P08896280A0860|140 155|acid metabolism
P08896280A0860|170 185|yvh1 disruption
P08896402A0587|8 18|FL protein
P08896402A0587|52 61|cell line
P08896402A0587|83 85|kD
P08896402A0587|118 130|glycoprotein
P08896402A0587|147 158|kD subunits
P08896402A0587|179 181|kD
P08896402A0587|185 186|N
P08896402A0587|201 207|sugars
P08896473A0282|4 13|objective
P08896473A0282|22 27|study
P08896473A0282|47 56|influence
P08896473A0282|60 64|HHCA
P08896473A0282|87 94|factors
P08896473A0282|104 115|development
P08896473A0282|119 122|VGS
P08896590T0000|8 13|exons
P08896590T0000|17 27|adenovirus
P08896590T0000|33 37|RNAs
P08896590T0000|54 59|snRNP
P08896590T0000|82 88|domain
P08896795A0166|6 11|Spurr
P08896795A0166|14 19|resin
P08896795A0166|34 40|medium
P08896795A0166|65 74|specimens
P08896795A0166|80 93|oil immersion
P08896795A0166|104 108|lens
P08896795A0166|121 124|use
P08896795A0166|128 138|coverslips
P08896795A0166|151 162|air bubbles
P08896795A0166|172 180|specimen
P08896804A0000|12 17|study
P08896804A0000|31 46|dose dependence
P08896804A0000|51 70|time course effects
P08896804A0000|78 92|benzodiazepine
P08896804A0000|94 97|BDZ
P08896804A0000|115 122|agonist
P08896804A0000|124 133|RO19-4603
P08896804A0000|146 151|mg/kg
P08896804A0000|167 178|combination
P08896804A0000|188 223|BDZ receptor antagonists flumazenil
P08896804A0000|225 227|ZK
P08896804A0000|239 242|CGS
P08896804A0000|252 257|mg/kg
P08896804A0000|279 297|alcohol-preferring
P08896804A0000|299 300|P
P08896804A0000|302 306|rats
P08896804A0000|329 340|choice test
P08896804A0000|349 356|ethanol
P08896804A0000|358 362|EtOH
P08896804A0000|367 372|% v/v
P08896804A0000|391 400|saccharin
P08896804A0000|408 413|% g/v
P08896804A0000|415 423|solution
P08897663T0000|11 16|Tower
P08897663T0000|20 25|Babel
P08897663T0000|29 41|nomenclature
P08897663T0000|46 57|suicidology
P08897721A0000|0 9|Infection
P08897721A0000|15 24|Neisseria
P08897721A0000|38 45|group B
P08897721A0000|106 111|group
P08897721A0000|114 128|polysaccharide
P08897721A0000|139 148|immunogen
P08898336A0268|0 25|RNase protection analysis
P08898336A0268|33 47|rRNA fragments
P08898336A0268|54 59|genes
P08898336A0268|82 90|evidence
P08898336A0268|111 121|transcript
P08898336A0268|133 142|sequences
P08898336A0268|180 184|RNAs
P08898365A0274|0 5|Rss1p
P08898365A0274|32 39|protein
P08898365A0274|47 58|amino acids
P08898365A0274|109 115|domain
P08898365A0274|147 161|pore complexes
P08898365A0274|163 167|NPCs
P08898365A0274|180 189|cytoplasm
P08898866A0458|23 50|serine phosphorylation site
P08898866A0458|87 104|expression system
P08898866A0458|119 126|annexin
P08898866A0458|140 146|series
P08898866A0458|150 157|annexin
P08898866A0458|161 168|mutants
P08898866A0458|185 198|substitutions
P08898866A0458|214 229|serine residues
P08898866A0458|256 262|domain
P08898893A0202|4 14|PAI-2 gene
P08898893A0202|49 54|genes
P08898893A0202|95 140|phorbol ester phorbol 12-myristate 13-acetate
P08898893A0202|142 145|PMA
P08898893A0202|155 176|phosphatase inhibitor
P08898893A0202|186 190|acid
P08898893A0202|200 220|HT-1080 fibrosarcoma
P08898893A0202|225 230|U-937
P08898893A0202|243 248|cells
P08899719A0318|10 17|contigs
P08899719A0318|28 33|total
P08899719A0318|46 60|reading frames
P08899719A0318|62 66|ORFs
P08899719A0318|86 93|operons
P08899719A0318|98 102|ORFs
P08899719A0318|139 148|certainty
P08900164A0188|0 2|T.
P08900164A0188|4 9|Patel
P08900164A0188|11 13|S.
P08900190A0430|0 14|Growth factors
P08900190A0430|26 36|expression
P08900190A0430|60 98|gene products MAP kinase phosphatase-1
P08900190A0430|100 105|MKP-1
P08900190A0430|108 113|c-Fos
P08900190A0430|118 123|c-Jun
P08900296A0000|4 17|up-regulation
P08900296A0000|21 31|E-selectin
P08900296A0000|44 62|adhesion molecules
P08900296A0000|70 81|endothelium
P08900296A0000|99 104|event
P08900296A0000|112 121|mediation
P08900296A0000|142 150|response
P08901135A1132|4 16|NIT2 protein
P08901135A1132|33 39|nuclei
P08901135A1132|85 93|fraction
P08901135A1132|97 102|cells
P08901135A1132|116 137|nitrogen derepression
P08901135A1132|141 160|nitrogen repression
P08901135A1132|190 196|import
P08901135A1132|200 204|NIT2
P08901635A0000|3 8|spite
P08901635A0000|17 23|effort
P08901635A0000|28 31|one
P08901635A0000|82 88|enzyme
P08901635A0000|89 90|s
P08901635A0000|108 117|synthesis
P08901635A0000|121 130|cellulose
P08901635A0000|142 159|cell wall polymer
P08901635A0000|163 169|plants
P08901658A0498|9 18|responses
P08901658A0498|31 40|hyperemia
P08901658A0498|47 60|flow increase
P08901658A0498|94 102|dilation
P08901658A0498|122 141|glyceryl trinitrate
P08901658A0498|143 146|GTN
P08901658A0498|172 180|dilation
P08902214A1486|12 18|period
P08902214A1486|20 34|administration
P08902214A1486|59 62|PRL
P08902214A1486|89 99|activation
P08902214A1486|101 108|binding
P08902214A1486|117 129|Stat factors
P08902548A0144|16 30|administration
P08902548A0144|34 55|L-5-hydroxytryptophan
P08902548A0144|57 64|L-5-HTP
P08902548A0144|69 74|doses
P08902548A0144|88 93|mg/kg
P08902548A0144|116 126|defecation
P08902548A0144|130 134|mice
P08902641A0930|7 18|VA-SMV mode
P08902641A0930|24 34|connection
P08902641A0930|56 64|conduits
P08902641A0930|74 81|LV apex
P08902641A0930|83 89|inflow
P08902641A0930|108 113|aorta
P08902641A0930|115 122|outflow
P08902641A0930|125 126|n
P08902641A0930|143 146|DAo
P08902641A0930|148 149|n
P08902847A1946|4 12|evidence
P08902847A1946|16 23|support
P08902847A1946|53 57|fact
P08902847A1946|67 75|affinity
P08902847A1946|79 90|interaction
P08902847A1946|107 115|subunits
P08902847A1946|155 174|order rate constant
P08902847A1946|178 187|hCG alpha
P08902847A1946|190 194|beta
P08902847A1946|196 198|km
P08902847A1946|214 219|min-1
P08902847A1946|224 226|pH
P08902847A1946|237 246|degrees C
P08902847A1946|260 265|order
P08902847A1946|269 278|magnitude
P08902847A1946|299 304|rehCG
P08902847A1946|306 308|kw
P08902847A1946|324 329|min-1
P08902988A0258|0 15|Factor V Leiden
P08902988A0258|29 37|disorder
P08902988A0258|67 71|risk
P08902988A0258|82 92|thrombosis
P08903339A0264|18 31|determination
P08903339A0264|58 67|structure
P08903339A0264|74 77|RNA
P08903339A0264|91 102|spliceosome
P08905819A0531|4 12|majority
P08905819A0531|20 25|cases
P08905819A0531|31 34|0-I
P08905819A0531|38 54|0-III components
P08905819A0531|60 62|sm
P08905819A0531|64 70|cancer
P08906056A1290|6 14|patients
P08906056A1290|56 64|function
P08906056A1290|81 87|status
P08906056A1290|121 127|degree
P08906056A1290|131 154|health care utilization
P08906139A2935|5 16|observation
P08906139A2935|35 45|monitoring
P08906139A2935|49 56|calcium
P08906139A2935|61 88|alkaline phosphatase values
P08906139A2935|102 113|adjustments
P08906139A2935|117 133|vitamin D intake
P08906139A2935|139 149|fortifiers
P08906139A2935|172 179|periods
P08909546A0810|19 23|PEA2
P08909546A0810|65 72|pattern
P08909546A0810|101 108|protein
P08909546A0810|138 144|domain
P08910292T0000|0 9|Signaling
P08910292T0000|37 50|proteins Rac1
P08910292T0000|55 60|Cdc42
P08910292T0000|68 73|c-Jun
P08910292T0000|109 131|protein kinase pathway
P08910373A0315|0 18|Percent identities
P08910373A0315|26 35|mouse PP2
P08910373A0315|39 47|mouse Y1
P08910373A0315|49 61|mouse Y4/PP1
P08910373A0315|72 84|Y2 receptors
P08910550A0501|30 41|observation
P08910550A0501|47 58|CBF binding
P08910550A0501|66 75|78C1 site
P08910550A0501|91 95|EGTA
P08910550A0501|100 104|EDTA
P08910550A0501|121 137|cation chelators
P08910550A0501|175 188|transcription
P08910567A2269|10 23|gene fragment
P08910567A2269|47 77|rat liver glucokinase promoter
P08910567A2269|102 110|enhancer
P08910567A2269|118 148|hepatocyte transfection system
P08912232A0260|12 16|role
P08912232A0260|20 22|ML
P08912232A0260|45 49|axis
P08912232A0260|63 71|children
P08912232A0260|76 80|boys
P08912232A0260|88 93|girls
P08912807A0411|23 36|deer receptor
P08912807A0411|63 79|tyrosine residue
P08912807A0411|101 107|domain
P08912807A0411|146 156|activation
P08912807A0411|164 184|beta-casein promoter
P08913186A0431|5 11|report
P08913186A0431|29 37|evidence
P08913186A0431|46 51|riMLF
P08913186A0431|59 66|control
P08913186A0431|70 78|downgaze
P08913186A0431|86 96|synkinesis
P08913186A0431|119 130|development
P08913186A0431|138 170|convergence retraction nystagmus
P08913387A1010|0 9|Rifabutin
P08913387A1010|26 34|efficacy
P08913387A1010|60 66|agents
P08913974A0533|12 19|percent
P08913974A0533|27 30|EPs
P08913974A0533|49 50|%
P08913974A0533|58 63|tubes
P08913974A0533|90 97|changes
P08913974A0533|117 128|salpingitis
P08913974A0533|134 135|%
P08913974A0533|152 163|salpingitis
P08913974A0533|167 168|%
P08913974A0533|177 183|others
P08914388A1645|4 14|assessment
P08914388A1645|23 24|H
P08914388A1645|34 40|medium
P08914388A1645|55 61|author
P08914388A1645|86 96|activities
P08914388A1645|105 112|CS-940*
P08914388A1645|117 129|sparfloxacin
P08914388A1645|131 135|SPFX
P08914388A1645|150 158|AM-1155*
P08914388A1645|160 173|ciprofloxacin
P08914388A1645|175 179|CPFX
P08914388A1645|182 194|levofloxacin
P08914388A1645|196 200|LVFX
P08914388A1645|203 213|OPC-17116*
P08914388A1645|215 221|NM-394
P08914388A1645|226 234|sequence
P08914522A0118|4 14|STE20 gene
P08914522A0118|27 41|protein kinase
P08914522A0118|55 84|pheromone signal transduction
P08914522A0118|128 134|screen
P08914522A0118|156 167|suppressors
P08914522A0118|190 205|G beta mutation
P08914532A0598|5 11|enzyme
P08914532A0598|45 72|endohydrolase isoenzyme X-I
P08915051T0000|9 26|resonance imaging
P08915051T0000|43 52|arthritis
P08915508A0000|0 7|Moloney
P08915508A0000|15 29|leukemia virus
P08915508A0000|31 35|MMLV
P08915508A0000|71 78|vectors
P08915508A0000|121 124|Tat
P08915508A0000|126 141|trans-activator
P08915508A0000|145 158|transcription
P08915508A0000|170 180|expression
P08915508A0000|189 209|hammerhead ribozymes
P08915508A0000|244 253|sequences
P08915508A0000|265 278|group antigen
P08915508A0000|280 283|Gag
P08915508A0000|286 294|protease
P08915508A0000|310 323|transcriptase
P08915508A0000|325 327|RT
P08915508A0000|330 333|tat
P08915508A0000|339 347|envelope
P08915508A0000|349 352|Env
P08915508A0000|354 368|coding regions
P08915508A0000|378 407|immunodeficiency virus type-1
P08915508A0000|409 414|HIV-1
P08915508A0000|416 419|RNA
P08915559A0366|0 21|REM sleep deprivation
P08915559A0366|46 64|platform technique
P08916928A0950|9 16|ligands
P08916928A0950|51 57|effect
P08916928A0950|80 82|3H
P08916928A0950|83 106|thymidine incorporation
P08916928A0950|110 119|PAE cells
P08916928A0950|135 154|PDGF beta-receptors
P08916960A0350|19 35|biopsy specimens
P08916960A0350|47 55|patients
P08916960A0350|61 63|FL
P08916960A0350|78 89|alterations
P08916960A0350|108 118|bcl-2 gene
P08916960A0350|126 136|breakpoint
P08916960A0350|146 159|reading frame
P08916960A0350|161 164|ORF
P08916960A0350|166 173|regions
P08916960A1331|13 18|cases
P08916960A1331|28 30|FL
P08916960A1331|35 44|DLL cells
P08916960A1331|52 63|alterations
P08916960A1331|67 87|bcl-2 gene sequences
P08916960A1331|95 112|breakpoint region
P08916960A1331|130 142|conservation
P08916960A1331|150 160|bcl-2 gene
P08916960A1331|173 174|t
P08916960A1331|183 196|translocation
P08916960A1331|213 227|transformation
P08916960A1331|235 243|FL cells
P08917270A0229|0 10|BACKGROUND
P08917270A0229|33 35|QT
P08917270A0229|37 40|QTc
P08917270A0229|42 50|interval
P08917270A0229|58 66|exercise
P08917270A0229|86 92|marker
P08917270A0229|106 113|disease
P08917270A0229|130 139|substrate
P08917270A0229|153 164|QT syndrome
P08917435A0481|13 17|role
P08917435A0481|21 26|c-Jun
P08917435A0481|31 36|c-Fos
P08917435A0481|65 78|transcription
P08917435A0481|86 96|PAI-1 gene
P08917435A0481|120 127|finding
P08917435A0481|143 148|c-jun
P08917435A0481|153 180|c-fos oligodeoxynucleotides
P08917435A0481|228 243|PAI-1 synthesis
P08917449A0000|20 26|factor
P08917449A0000|28 31|LIF
P08917449A0000|38 50|neuropoietin
P08917449A0000|72 87|differentiation
P08917449A0000|96 104|survival
P08917449A0000|113 123|cell types
P08917449A0000|153 164|populations
P08917696A0485|15 24|mechanism
P08917696A0485|28 46|fos/jun activation
P08917696A0485|50 54|TCDD
P08917696A0485|84 98|mobility shift
P08917696A0485|113 130|expression assays
P08917696A0485|134 158|reporter gene constructs
P08917696A0485|170 187|response elements
P08917696A0485|192 229|12-O-tetradecanoyl-phorbol-13-acetate
P08917696A0485|231 234|TRE
P08917696A0485|237 242|serum
P08917696A0485|244 247|SRE
P08917696A0485|250 254|cAMP
P08917696A0485|256 259|CRE
P08917696A0485|275 287|hydrocarbons
P08917696A0485|289 293|AhRE
P08917696A0485|304 307|fos
P08917696A0485|312 321|jun genes
P08917696A0485|343 358|luciferase gene
P08917696A0485|369 376|control
P08917696A0485|384 388|SV40
P08917696A0485|397 405|promoter
P08918456A0455|12 20|sequence
P08918456A0455|25 36|interaction
P08918456A0455|42 44|mu
P08918456A0455|56 60|AP-2
P08918456A0455|65 73|tyrosine
P08918456A0455|80 86|anchor
P08918456A0455|99 107|arginine
P08918456A0455|111 121|position Y
P08918456A0455|130 137|leucine
P08918456A0455|141 151|position Y
P08918464A0225|19 24|Ba/F3
P08918464A0225|31 36|cells
P08918464A0225|38 45|BaF/STK
P08918464A0225|71 77|growth
P08918464A0225|87 90|STK
P08918464A0225|107 135|mouse erythroleukaemia cells
P08918464A0225|137 140|MEL
P08918464A0225|142 145|STK
P08918464A0225|169 178|apoptosis
P08918810A0967|9 14|DNase
P08918810A0967|17 29|footprinting
P08918810A0967|42 52|OxyR-C199S
P08918810A0967|63 67|Pmom
P08918810A0967|96 102|strand
P08918810A0967|118 151|protection pattern characteristic
P08918810A0967|173 177|OxyR
P08918885A0811|0 4|Kss1
P08918885A0811|29 44|GST-Dig1 fusion
P08918885A0811|52 59|absence
P08918885A0811|73 86|yeast protein
P08918885A1087|3 11|contrast
P08918885A1087|13 28|dig1 dig2 cells
P08918885A1087|51 62|agar medium
P08918885A1087|74 89|dig1 dig2 ste12
P08918885A1087|97 103|mutant
P08918885A1087|130 134|Dig1
P08918885A1087|139 143|Dig2
P08918885A1087|152 156|role
P08918885A1087|195 209|growth pathway
P08918918T0000|10 20|activation
P08918918T0000|28 46|HIV-1 LTR promoter
P08918918T0000|60 71|Tat protein
P08918918T0000|102 118|trans-activation
P08918918T0000|128 132|cell
P08918934A0424|0 10|Comparison
P08918934A0424|18 27|sequences
P08918934A0424|35 55|xFxFG repeat regions
P08918934A0424|59 62|p62
P08918934A0424|67 72|Nsplp
P08918934A0424|88 92|NTF2
P08918934A0424|152 156|core
P08918934A0424|166 173|repeats
P08918934A0424|210 217|linkers
P08919289A0402|18 24|report
P08919289A0402|43 52|resection
P08919289A0402|58 61|MFH
P08919289A0402|96 102|tissue
P08919289A0402|135 144|vena cava
P08919907A0763|10 20|expression
P08919907A0763|24 29|VSF-1
P08919907A0763|33 44|protoplasts
P08919907A0763|56 60|vs-1
P08919907A0763|71 81|activation
P08919907A0763|108 116|promoter
P08919986A1262|11 15|mind
P08919986A1262|28 33|range
P08919986A1262|37 40|age
P08919986A1262|45 52|dosages
P08919986A1262|54 64|advantages
P08919986A1262|69 82|disadvantages
P08919986A1262|90 94|drug
P08919986A1262|137 144|results
P08919986A1262|173 183|literature
P08920499A0164|0 25|Blood sampling procedures
P08921387A1182|0 8|Analysis
P08921387A1182|16 20|cDNA
P08921387A1182|41 55|splicing event
P08921387A1182|66 70|EZH1
P08921387A1182|93 102|gene GPR2
P08921387A1182|128 137|mechanism
P08921387A1182|156 168|EZH1 protein
P08921387A1182|197 203|domain
P08921667A0294|17 31|input function
P08921667A0294|44 49|value
P08921667A0294|53 72|distribution volume
P08921667A0294|74 76|Vd
P08921667A0294|91 107|rCBF measurement
P08921667A0294|116 122|method
P08921667A0294|156 161|study
P08921667A0294|176 186|volunteers
P08921865A1293|39 41|ss
P08921865A1293|43 60|DNA binding motif
P08921865A1293|86 104|terminase proteins
P08921865A1293|108 115|T4 gp17
P08921865A1293|161 174|ssDNA regions
P08921865A1293|206 211|T4DNA
P08922344A1539|41 49|subjects
P08922344A1539|56 60|acid
P08922344A1539|65 81|xanthine oxidase
P08922344A1539|99 110|association
P08922344A1539|116 130|blood pressure
P08922344A1539|160 167|factors
P08922344A1539|194 199|cause
P08922344A1539|203 209|effect
P08922344A1539|213 225|hypertension
P08922384A0466|0 14|Immunoblotting
P08922384A0466|40 48|proteins
P08922384A0466|69 81|08L antibody
P08922384A0466|96 107|08L epitope
P08922384A0466|115 127|carboxyl end
P08922384A0466|135 142|protein
P08922385A0622|36 46|inhibition
P08922385A0622|72 83|proteolysis
P08922385A0622|91 118|beta-galactosidase tetramer
P08922385A0622|126 140|fusion subunit
P08922385A0622|145 151|detour
P08922385A0622|159 167|tetramer
P08922385A0622|175 183|lysosome
P08922390A0361|12 17|study
P08922390A0361|30 38|vinculin
P08922390A0361|60 67|domains
P08922390A0361|71 79|paxillin
P08922390A0361|109 117|paxillin
P08922390A0361|124 132|adhesion
P08922390A0361|143 148|motif
P08922390A0793|6 10|data
P08922390A0793|27 35|presence
P08922390A0793|48 60|binding site
P08922390A0793|65 73|vinculin
P08922390A0793|100 105|sites
P08922390A0793|110 113|FAK
P08922390A0793|151 158|stretch
P08922390A0793|166 177|amino acids
P08922390A2076|6 10|data
P08922390A2076|28 36|paxillin
P08922390A2076|56 65|adhesions
P08922390A2076|81 93|interactions
P08922390A2076|99 107|vinculin
P08922390A2076|115 118|FAK
P08922390A2076|156 169|demonstration
P08922390A2076|173 184|LIM domains
P08922390A2076|210 221|determinant
P08922390A2076|225 232|protein
P08922390A2076|245 257|localization
P08922390A2076|267 276|adhesions
P08922391A0304|28 37|structure
P08922391A0304|52 60|entirety
P08922391A0304|69 80|PDZ repeats
P08922391A0304|90 96|PDZ1-2
P08922391A0304|111 118|protein
P08922391A0304|131 135|site
P08922488A0187|8 14|agents
P08922488A0187|35 44|treatment
P08922488A0187|74 81|effects
P08923258A0353|0 7|Jerseys
P08923258A0353|27 44|Cu concentrations
P08923258A0353|54 63|Holsteins
P08923258A0353|67 68|d
P08923460A0565|0 11|RUSH-1 beta
P08923460A0565|34 41|version
P08923460A0565|45 57|RUSH-1 alpha
P08923460A0565|88 96|splicing
P08923460A0565|108 112|exon
P08923460A0565|137 144|cloning
P08923469A1391|6 13|results
P08923469A1391|55 63|polarity
P08923469A1391|67 90|RXR heterodimer binding
P08923469A1391|104 129|hormone response elements
P08923469A1391|140 143|VDR
P08923469A1391|163 175|half-element
P08923470A0458|0 22|PPAR gamma mRNA levels
P08923470A0458|41 42|%
P08923470A0458|50 72|nM TNF alpha treatment
P08923470A0458|80 82|h.
P08924211A0941|0 5|Exons
P08924211A0941|42 48|region
P08924211A0941|73 79|region
P08924211A0941|109 114|types
P08924211A0941|118 121|PST
P08924211A0941|125 134|AST cDNAs
P08924381T0000|0 13|Growth factor
P08924381T0000|46 53|regimen
P08924381T0000|66 88|breast cancer patients
P08925545T0001|12 26|erythropoietin
P08925545T0001|28 35|r-HuEPO
P08925545T0001|44 53|treatment
P08925545T0001|57 63|anemia
P08925545T0001|76 83|myeloma
P08927169A0178|21 30|infection
P08927169A0178|36 45|body lice
P08927169A0178|64 69|times
P08927169A0178|76 84|patients
P08927169A0178|92 98|clinic
P08927169A0178|103 111|homeless
P08927169A0178|119 143|Community Health Service
P08927169A0178|147 154|Utrecht
P08927612T0000|11 24|p53 mutations
P08927612T0000|46 60|adenocarcinoma
P08927841A0053|16 20|data
P08927841A0053|56 61|death
P08927841A0053|88 96|activity
P08927841A0053|120 130|occurrence
P08929089A0231|13 23|ratio M/Pc
P08929089A0231|42 47|index
P08929089A0231|94 100|demand
P08929563T0000|0 18|Rat liver catalase
P08929563T0000|32 43|peroxisomes
P08929563T0000|62 84|tripeptide Ala-Asn-Leu
P08929563T0000|106 123|Ser-Lys-Leu motif
P08931388A0806|4 24|mobility shift assay
P08931388A0806|35 37|bp
P08931388A0806|51 59|fragment
P08931388A0806|73 80|extract
P08931388A0806|103 109|sample
P08931388A0806|131 135|band
P08931388A0806|167 173|sample
P08931991A1026|6 10|data
P08931991A1026|26 34|evidence
P08931991A1026|40 43|E2F
P08931991A1026|62 82|transcription factor
P08931991A1026|102 112|regulation
P08931991A1026|126 143|myosin expression
P08932363A0807|9 23|E1A N-terminus
P08932363A0807|37 47|competitor
P08932363A0807|51 73|squelshing experiments
P08932363A0807|99 109|activation
P08932363A0807|113 121|E2F1/DP1
P08932363A0807|134 144|E1A mutant
P08932363A0807|153 172|CBP binding ability
P08932385T0000|6 18|Maf proteins
P08932385T0000|43 80|transcription factor TCF11/Nrf1/LCR-F
P08933487A0325|13 27|occasion water
P08933487A0325|29 30|W
P08933487A0325|60 63|run
P08933640A0000|4 10|effect
P08933640A0000|23 32|ingestion
P08933640A0000|48 75|energy sweetener erythritol
P08933640A0000|96 99|KBL
P08933640A0000|100 109|JW strain
P08933640A0000|119 126|rabbits
P08934533A0784|19 28|mutations
P08934533A0784|39 48|structure
P08934533A0784|52 56|junB
P08934533A0784|69 72|DNA
P08934533A0784|80 89|chromatin
P08934540A0673|4 11|nm23-H1
P08934540A0673|12 24|nm23-H2 gene
P08934540A0673|41 55|activity ratio
P08934540A0673|80 89|cell line
P08935931A0787|0 10|CONCLUSION
P08935931A0787|24 47|diazepam administration
P08935931A0787|55 58|EGD
P08935931A0787|82 86|fall
P08935931A0787|90 94|SpO2
P08935931A0787|106 115|procedure
P08935931A0787|154 164|monitoring
P08935931A0787|168 172|SpO2
P08935931A0787|195 198|EGD
P08935991A0844|4 33|nucleotide sequence alignment
P08935991A0844|42 47|mouse
P08935991A0844|58 60|CA
P08935991A0844|64 69|shows
P08935991A0844|72 82|% identity
P08935991A0844|97 103|region
P08935991A0844|131 141|boundaries
P08935991A0844|168 173|sizes
P08935991A0844|181 188|introns
P08936128A0611|0 11|Discordance
P08936128A0611|19 33|cost dimension
P08936128A0611|61 65|G Hb
P08936128A0611|94 101|control
P08936128A0611|115 127|disagreement
P08936640A0105|0 12|DATA SOURCES
P08936640A0105|28 35|studies
P08936640A0105|37 53|research studies
P08936640A0105|55 70|review articles
P08936640A0105|76 94|government reports
P08936640A0105|109 121|epidemiology
P08936640A0105|125 136|lung cancer
P08937112A0561|0 7|RESULTS
P08937112A0561|13 29|age distribution
P08937112A0561|43 48|years
P08937112A0561|54 58|mean
P08937112A0561|68 73|years
P08937631A1223|13 20|changes
P08937631A1223|41 56|cell involution
P08937631A1223|61 71|hemorrhage
P08937631A1223|102 108|period
P08937631A1223|137 146|relevance
P08937631A1223|154 164|remodeling
P08937631A1223|180 191|vasculature
P08937981A0840|13 26|co-expression
P08937981A0840|35 38|p46
P08937981A0840|43 55|p54 subunits
P08937981A0840|89 101|distribution
P08937981A0840|105 108|p46
P08937981A0840|123 126|p46
P08937981A0840|152 159|nucleus
P08937981A0840|178 181|p54
P08937989A1365|4 11|results
P08937989A1365|44 45|N
P08937989A1365|62 69|regions
P08937989A1365|73 78|talin
P08937989A1365|84 89|actin
P08937989A1365|95 105|properties
P08937989A1365|119 126|regions
P08937989A1365|134 141|protein
P08938418A0099|0 4|Merr
P08938418A0099|7 21|embryo library
P08938420A0862|4 16|accumulation
P08938420A0862|25 29|LHA4
P08938420A0862|34 44|LHA2 mRNAs
P08938420A0862|63 71|addition
P08938420A0862|85 91|sugars
P08938420A0862|101 110|induction
P08938420A0862|138 150|sugar uptake
P08938420A0862|155 165|metabolism
P08938420A0862|175 183|mannitol
P08938420A0862|188 205|3-O-methylglucose
P08938420A0862|223 240|mRNA accumulation
P08939891A0285|10 15|yeast
P08939891A0285|27 33|screen
P08939891A0285|50 53|NRE
P08939891A0285|67 70|DNA
P08939891A0285|74 78|bait
P08939891A0285|96 101|clone
P08939891A0285|122 125|Nrl
P08939966A0816|7 11|rate
P08939966A0816|15 32|protein synthesis
P08939966A0816|55 68|embryogenesis
P08939966A0816|70 76|levels
P08939966A0816|80 85|SEC-1
P08939966A0816|102 114|mRNA decline
P08940132A1120|6 14|findings
P08940132A1120|28 46|fodrin proteolysis
P08940132A1120|71 79|activity
P08940132A1120|102 111|proteases
P08940132A1120|126 137|sensitivity
P08940132A1120|141 149|DEVD-CHO
P08940132A1120|169 181|contribution
P08940132A1120|187 192|CPP32
P08940132A1120|210 218|protease
P08940132A1120|239 244|CPP32
P08940132A1120|248 267|DEVD-CHO inhibition
P08940134A0705|3 6|3Y1
P08940134A0705|11 14|3Y1
P08940134A0705|33 44|fibroblasts
P08940134A0705|70 75|PTP1B
P08940134A0705|88 89|%
P08940134A0705|99 103|p130
P08940134A0705|104 107|Cas
P08940134A0705|109 120|co-sediment
P08940134A0705|126 135|membranes
P08940134A0705|170 179|reticulum
P08940298A0962|10 18|residues
P08940298A0962|30 38|delta419
P08940298A0962|58 69|AF-2 domain
P08940298A0962|79 98|vitamin D3 receptor
P08940298A0962|106 123|estrogen receptor
P08940298A0962|137 145|receptor
P08940298A0962|184 192|activity
P08942999T0000|10 29|G-to-A substitution
P08942999T0000|42 47|codon
P08942999T0000|51 56|SREBP
P08942999T0000|77 84|protein
P08942999T0000|99 109|resistance
P08942999T0000|134 158|hamster ovary cell lines
P08943032A0000|21 34|tet-repressor
P08943032A0000|36 40|TetR
P08943032A0000|42 57|operator system
P08943032A0000|80 89|variation
P08943032A0000|97 102|yeast
P08943032A0000|114 119|assay
P08943032A0000|129 140|disruptions
P08943032A0000|160 172|interactions
P08943032A0000|205 214|selection
P08943354A0295|7 14|studies
P08943354A0295|35 40|SHP-1
P08943354A0295|55 63|function
P08943354A0295|67 94|Jak family tyrosine kinases
P08943354A0295|125 136|association
P08943354A0295|146 157|Tyk2 kinase
P08943354A0295|166 186|hyperphosphorylation
P08943354A0295|190 201|Jak kinases
P08943354A0295|209 224|motheaten cells
P08943354A0295|246 251|SHP-1
P08943928A1137|0 14|Administration
P08943928A1137|27 31|dose
P08943928A1137|35 42|vaccine
P08943928A1137|54 62|outbreak
P08943934A0604|8 17|Theriault
P08943934A0604|28 40|improvements
P08943934A0604|54 62|exposure
P08943934A0604|113 121|findings
P08944755A0211|0 4|Biol
P08945479T0000|11 16|basis
P08945479T0000|21 31|activation
P08945479T0000|41 62|lymphocyte kinase Lck
P08945479T0000|68 92|tyrosine phosphorylation
P08945810T0001|10 20|morphology
P08945810T0001|38 42|bulb
P08945810T0001|46 49|man
P08945810T0001|72 79|mammals
P08946166A0568|11 18|results
P08946166A0568|43 46|ORF
P08946166A0568|54 63|FRDS gene
P08946668A0077|0 5|FK506
P08946668A0077|42 55|cyclosporin A
P08946668A0077|70 85|organ rejection
P08946668A0077|93 101|toxicity
P08947028A0992|6 13|results
P08947028A0992|27 32|Rho1p
P08947028A0992|56 70|reorganization
P08947028A0992|88 93|Bni1p
P08947028A0992|98 103|Pkc1p
P08948440A0628|4 26|ERH expression profile
P08948440A0628|50 53|An3
P08948440A0628|78 95|animal hemisphere
P08948440A0628|99 106|oocytes
P08948440A0628|142 148|embryo
P08950144A0172|0 8|Waves N1
P08950144A0172|10 12|P3
P08950144A0172|17 20|CNV
P08950144A0172|44 56|CNV paradigm
P08950144A0172|69 87|reaction time task
P08950144A0172|118 126|interval
P08950144A0172|128 131|ISI
P08950144A0172|138 141|sec
P08950352A0525|45 52|samples
P08950352A0525|76 81|areas
P08950352A0525|106 111|rates
P08950352A0525|130 134|ones
P08950352A0525|149 153|area
P08950352A0525|174 186|significance
P08950352A0525|188 189|p
P08950352A0525|211 215|test
P08951815A0465|0 10|Regulation
P08951815A0465|14 18|ASN1
P08951815A0465|23 38|ASN2 expression
P08951815A0465|57 69|lacZ fusions
P08951815A0465|79 84|genes
P08951815A0465|110 115|times
P08951815A0465|138 145|absence
P08951815A0465|153 182|transcription activator Gcn4p
P08952483A0207|19 27|features
P08952483A0207|36 56|polypeptide fragment
P08952483A0207|66 95|hamster lysyl-tRNA synthetase
P08952483A0207|133 141|assembly
P08952483A0207|150 156|enzyme
P08952483A0207|168 191|multisynthetase complex
P08952796A0743|17 22|years
P08952796A0743|29 36|relapse
P08952965A1182|0 10|Comparison
P08952965A1182|18 28|proportion
P08952965A1182|47 49|pN
P08952965A1182|67 69|pS
P08952965A1182|71 84|substitutions
P08952965A1182|99 103|site
P08952965A1182|111 118|tamarin
P08952965A1182|128 140|region genes
P08952965A1182|156 165|reduction
P08952965A1182|169 171|pN
P08952965A1182|179 196|framework regions
P08952965A1182|211 213|pN
P08952965A1182|230 249|MHC contact regions
P08952965A1182|251 255|CDR1
P08952965A1182|260 264|CDR2
P08953340A0000|4 11|effects
P08953340A0000|20 35|vanadyl sulfate
P08953340A0000|37 42|VOSO4
P08953340A0000|49 58|mg/kg/day
P08953340A0000|63 76|anthropometry
P08953340A0000|78 94|body composition
P08953340A0000|100 111|performance
P08953340A0000|177 182|trial
P08953340A0000|193 219|weight-training volunteers
P08954725A1175|9 20|development
P08954725A1175|22 37|Tbx6 expression
P08954725A1175|76 84|mesoderm
P08954725A1175|96 104|tail bud
P08954725A1175|125 131|streak
P08954725A1175|139 145|source
P08954725A1175|149 157|mesoderm
P08955071T0000|0 10|Disruption
P08955071T0000|14 36|re-replication control
P08955071T0000|40 54|overexpression
P08955071T0000|64 68|ORC1
P08955071T0000|72 85|fission yeast
P08955111A0989|4 11|results
P08955111A0989|33 41|promoter
P08955111A0989|46 62|enhancer regions
P08955111A0989|123 140|promoter activity
P08955111A0989|154 180|activin betaA subunit gene
P08955136A0606|35 46|PIP5KIalpha
P08955136A0606|57 71|PIP5K activity
P08955136A0606|110 127|PIP5KI antibodies
P08955159A0000|6 21|acid ceramidase
P08955159A0000|24 26|AC
P08955159A0000|28 60|N-acylsphingosine amidohydrolase
P08955159A0000|62 64|EC
P08955189A1198|12 31|NheI/BglII promoter
P08955189A1198|42 58|PMA inducibility
P08955189A1198|70 75|cells
P08955189A1198|107 114|element
P08955189A1198|129 132|Sp1
P08955189A1198|137 164|EGR-1 transcription factors
P08955306A0224|0 8|Northern
P08955306A0224|10 13|RNA
P08955306A0224|15 28|blot analyses
P08955306A0224|48 57|cdh genes
P08955306A0224|76 84|subunits
P08955306A0224|97 110|reading frame
P08955306A0224|112 116|ORF1
P08955306A0224|131 139|function
P08955306A0224|165 171|growth
P08955306A0224|175 182|acetate
P08955402A0288|4 11|classes
P08955402A0288|15 24|mutations
P08955402A0288|74 80|region
P08955402A0288|84 88|HOL1
P08955402A0288|105 112|ability
P08955402A0288|124 134|histidinol
P08955402A0288|156 165|mutations
P08955402A0288|188 205|HOL1-1 background
P08955402A0288|222 232|expression
P08955402A0288|240 252|Hol1 protein
P08955928A0390|0 6|Damage
P08955928A0390|14 17|BBB
P08955928A0390|32 45|extravasation
P08955928A0390|49 59|Evans Blue
P08955928A0390|61 63|EB
P08955928A0390|115 116|h
P08955928A0390|123 128|onset
P08955928A0390|132 136|MCAo
P08958137A0534|0 26|Lipid hydroperoxide levels
P08958137A0534|30 36|plasma
P08958137A0534|41 44|LDL
P08958137A0534|79 84|study
P08958720A1204|9 15|degree
P08958720A1204|19 27|exercise
P08958720A1204|41 45|mPAP
P08958720A1204|62 65|SVI
P08958720A1204|77 79|HR
P08958720A1204|99 101|CO
P08958720A1204|106 109|VO2
P08959062A0372|12 16|case
P08959062A0372|20 30|vasculitis
P08959062A0372|75 84|discovery
P08959062A0372|100 113|immunodeficit
P08959062A0372|122 125|EBV
P08959062A0372|138 145|Purtilo
P08959062A0372|148 156|syndrome
P08959117A0708|41 48|changes
P08959117A0708|69 79|hypoxaemia
P08959117A0708|102 109|disease
P08959117A0708|125 135|influences
P08959117A0708|155 166|ICU setting
P08959117A0708|172 184|measurements
P08959117A0708|232 247|reference group
P08959117A0708|249 252|REF
P08959117A0708|289 299|hypoxaemia
P08959778A0292|26 37|differences
P08959778A0292|41 55|graft survival
P08959778A0292|64 70|groups
P08959778A0292|82 96|graft function
P08959778A0292|98 101|EGF
P08959778A0292|107 110|DGF
P08959778A0292|128 144|transplantations
P08959778A0292|148 166|retransplantations
P08960827A1169|6 13|results
P08960827A1169|33 42|GG motifs
P08960827A1169|76 89|transcription
P08960827A1169|103 115|insulin gene
P08960827A1169|119 130|association
P08960827A1169|140 147|binding
P08960827A1169|181 187|factor
P08961873T0000|17 38|coproporphyrin levels
P08961873T0000|42 50|patients
P08961873T0000|63 80|hepatitis C virus
P08961873T0000|103 125|immunodeficiency virus
P08962614A0000|4 17|determination
P08962614A0000|21 37|immunoglobulin E
P08962614A0000|39 42|IgE
P08962614A0000|44 54|antibodies
P08962614A0000|73 89|laboratory tests
P08962614A0000|94 110|skin-prick tests
P08962614A0000|129 149|challenge procedures
P08962614A0000|186 197|individuals
P08962614A0000|204 222|outcome predictors
P08962614A0000|233 241|children
P08964067A0188|0 10|Thrombosis
P08964067A0188|24 28|vein
P08964067A0188|63 70|failure
P08964172A0221|0 6|Filter
P08964172A0221|11 38|cytocentrifuge preparations
P08964172A0221|46 51|urine
P08964172A0221|73 78|cases
P08964172A0221|108 118|aggregates
P08964172A0221|129 140|tumor cells
P08964172A0221|160 170|background
P08967870A0000|12 21|protocols
P08967870A0000|25 48|postmortem examinations
P08967870A0000|54 72|Moscow hospitals N
P08967963A1735|4 20|promoter segment
P08967963A1735|59 84|rat glioma cell line C6B4
P08967963A1735|90 93|rat
P08967963A1735|108 125|cell line RSMT-A5
P08967963A1735|135 138|rat
P08967963A1735|150 172|beta cell line RIN-5AH
P08967963A1735|217 232|alpha2c-AR gene
P08969495A0256|4 14|sequencing
P08969495A0256|41 56|mutation ts-A13
P08969495A0256|75 87|nrdE cistron
P08969495A0256|97 106|lethality
P08969495A0256|122 131|mutations
P08969495A0256|157 163|region
P08969495A0256|167 171|nrdE
P08969495A0256|176 180|nrdF
P08969495A0256|209 213|role
P08969495A0256|222 227|locus
P08969777A0771|23 29|scores
P08969777A0771|53 64|differences
P08969777A0771|68 76|patients
P08969777A0771|108 134|serum 25-OHD concentration
P08969777A0771|159 165|degree
P08969777A0771|169 178|paralysis
P08970352A0880|6 10|data
P08970352A0880|30 33|use
P08970352A0880|37 40|LDD
P08970352A0880|51 55|risk
P08970352A0880|59 70|progression
P08970352A0880|74 78|MSOF
P08970352A0880|82 88|sepsis
P08970951A0823|29 35|levels
P08970951A0823|48 59|hepatitis B
P08970951A0823|62 69|antigen
P08970951A0823|98 104|levels
P08970951A0823|108 112|core
P08970951A0823|117 129|Pol proteins
P08970951A0823|146 167|HBV DNA intermediates
P08970979A1246|3 11|contrast
P08970979A1246|13 21|extracts
P08970979A1246|36 43|virions
P08970979A1246|67 72|level
P08970979A1246|76 89|transcription
P08970979A1246|108 116|template
P08970979A1246|137 145|promoter
P08970984A0765|4 18|SCMV SNE sites
P08970984A0765|49 80|core recognition binding motifs
P08970984A0765|85 88|SRF
P08970984A0765|90 102|Rel/NFkappaB
P08970984A0765|104 107|ETS
P08970984A0765|113 144|YY1 class transcription factors
P08970984A0765|175 180|serum
P08970984A0765|184 211|tumor necrosis factor alpha
P08970991A0747|5 21|serum withdrawal
P08970991A0747|40 51|temperature
P08970991A0747|66 75|apoptosis
P08970991A0747|99 100|%
P08970991A0747|108 113|cells
P08971009A0860|19 26|problem
P08971009A0860|46 54|strategy
P08971009A0860|97 102|sites
P08971009A0860|114 122|sequence
P08971009A0860|165 169|loci
P08971009A0860|185 196|DNA genomes
P08971721A1314|7 12|basis
P08971721A1314|28 35|studies
P08971721A1314|60 66|domain
P08971721A1314|70 74|HspA
P08971721A1314|110 116|domain
P08971835A1057|3 8|Group
P08971835A1057|12 16|dogs
P08971835A1057|31 40|alpha-MSH
P08971835A1057|53 64|reperfusion
P08971835A1057|66 71|BAEPs
P08971835A1057|109 110|%
P08971835A1057|124 132|Group II
P08971835A1057|149 167|reperfusion period
P08972182A0000|4 16|Fas receptor
P08972182A0000|28 46|signalling cascade
P08972182A0000|71 81|cell death
P08972182A0000|83 92|apoptosis
P08972182A0000|101 106|hours
P08972182A0000|110 132|receptor cross-linking
P08972182A0527|0 3|Fas
P08972182A0527|30 33|ICE
P08972182A0527|35 48|interleukin-1
P08972182A0527|65 71|enzyme
P08972182A0527|73 89|family proteases
P08972182A0527|100 109|apoptosis
P08972182A0527|115 122|studies
P08972182A0527|137 170|cowpox ICE inhibitor protein CrmA
P08972182A0527|186 221|tetrapeptide ICE inhibitor YVAD-CMK
P08972182A0527|231 269|tripeptide pan-ICE inhibitor Z-VAD-FMK
P08972211A0059|14 24|expression
P08972211A0059|43 47|gene
P08972211A0059|72 76|mice
P08972211A0059|94 103|transgene
P08972211A0059|119 121|kb
P08972211A0059|137 145|sequence
P08972211A0059|149 151|kb
P08972211A0059|167 175|sequence
P08972211A0059|218 227|enhancers
P08972211A0059|266 270|gene
P08972232A0365|8 14|report
P08972232A0365|36 41|hGCN5
P08972232A0365|53 56|HAT
P08972232A0365|74 95|substrate specificity
P08972232A0365|99 104|yGCN5
P08973185T0061|4 10|effect
P08973185T0061|18 36|arginine mutations
P08973185T0061|50 65|phosphorylation
P08973185T0061|70 84|AAC expression
P08973527A0000|14 18|DNAs
P08973527A0000|36 48|coat protein
P08973527A0000|69 76|regions
P08973527A0000|80 102|Agropyron mosaic virus
P08973527A0000|104 108|AgMV
P08973527A0000|114 134|Hordeum mosaic virus
P08973527A0000|136 140|HoMV
P08973630A0923|8 13|cases
P08973630A0923|30 44|Rac activation
P08973630A0923|56 70|Rho activation
P08973630A0923|91 107|Cdc42 activation
P08973630A0923|117 131|Rac activation
P08973630A0923|173 180|changes
P08973917A0632|8 13|cDNAs
P08973917A0632|41 50|PWP2 gene
P08973917T0000|0 9|Isolation
P08973917T0000|22 31|structure
P08973917T0000|43 50|homolog
P08973917T0000|58 63|yeast
P08973917T0000|73 91|tryptophan protein
P08973917T0000|95 99|PWP2
P08973917T0000|101 113|gene mapping
P08973917T0000|117 124|21q22.3
P08974103A0451|0 8|Patterns
P08974103A0451|20 32|combinations
P08974103A0451|56 74|laboratory results
P08974103A0451|93 103|likelihood
P08974103A0451|107 110|PEM
P08974103A0451|119 124|all-2
P08974103A0451|134 141|pattern
P08974135A0052|19 27|thiamine
P08974135A0052|29 39|vitamin B1
P08974135A0052|41 51|deficiency
P08974135A0052|90 100|stomatitis
P08974135A0052|113 130|vitamin B1 levels
P08974135A0052|137 145|patients
P08974135A0052|170 180|stomatitis
P08974135A0052|191 198|members
P08974135A0052|204 217|control group
P08975532T0001|0 14|Liver injuries
P08975713A0454|15 27|cDNA library
P08975713A0454|35 40|probe
P08975713A0454|54 63|sequences
P08975713A0454|82 98|p53p2 start site
P08975713A0454|135 139|cDNA
P08975713A0454|158 162|mRNA
P08975713A0454|208 222|p53p2 promoter
P08976253A0637|30 41|correlation
P08976253A0637|50 55|serum
P08976253A0637|68 85|plasma PSA levels
P08977013A0788|4 16|implications
P08977013A0788|21 30|estimates
P08977013A0788|43 56|magnification
P08977013A0788|70 81|differences
P08977013A0788|89 104|specializations
P08977013A0788|108 114|foveal
P08977013A0788|130 136|vision
P08977235A0134|0 5|G-CSF
P08977235A0134|35 44|molecules
P08977235A0134|60 64|JAK1
P08977235A0134|69 81|JAK2 kinases
P08977235A0134|90 116|STAT transcription factors
P08977235A0588|0 7|Mutants
P08977235A0588|20 37|tyrosine residues
P08977235A0588|57 63|domain
P08977235A0588|79 86|ability
P08977235A0588|99 104|STAT5
P08977235A0588|109 114|STAT1
P08977235A0588|135 140|STAT3
P08977235A0588|156 161|STAT5
P08977235A0588|166 182|STAT1 activation
P08977235A0588|200 233|receptor tyrosine phosphorylation
P08977401A0227|4 17|RI alpha gene
P08977401A0227|45 50|exons
P08977401A0227|62 69|lengths
P08977401A0227|84 91|introns
P08977401A0227|104 108|gene
P08977401A0227|117 123|length
P08977401A0227|139 141|kb
P08977401A0227|154 161|cloning
P08977401A0227|177 196|RI alpha pseudogene
P08977401A0227|217 223|region
P08977401A0227|263 271|RI alpha
P08977401A0227|286 289|RNA
P08977401A0227|309 322|RI alpha gene
P08977401A0227|341 353|leader exons
P08977401A0227|361 365|rise
P08977401A0227|389 403|messenger RNAs
P08977401A0227|405 410|mRNAs
P08978690A0262|17 26|Rad3/Mec1
P08978690A0262|49 56|protein
P08978690A0262|87 112|DNA structure checkpoints
P08978690A0262|121 140|yeast model systems
P08978817A0620|3 11|addition
P08978817A0620|20 27|mutants
P08978817A0620|40 50|dim1-delta
P08978817A0620|54 60|dim2-1
P08978817A0620|69 95|endocytosis mutants end4-1
P08978817A0620|99 105|act1-1
P08978817A0620|126 140|growth defects
P08978817A0620|162 179|DIM gene products
P08978817A0620|223 230|pathway
P08978996A0000|4 18|identification
P08978996A0000|26 43|hepatitis C virus
P08978996A0000|57 62|cause
P08978996A0000|66 79|liver disease
P08978996A0000|88 105|dialysis patients
P08978996A0000|113 132|transplant patients
P08978996A0000|145 154|attention
P08978996A0000|162 174|epidemiology
P08978996A0000|183 189|impact
P08978996A0000|204 213|infection
P08978996A0000|223 237|patient groups
P08979089A1197|7 19|transfection
P08979089A1197|27 44|BL cell line Raji
P08979089A1197|50 60|constructs
P08979089A1197|72 95|core promoter mutations
P08979089A1197|124 132|Sp1 site
P08979089A1197|141 149|TATA box
P08979089A1197|172 182|activation
P08979089A1197|186 197|promoter P1
P08979089A1197|205 223|Ig kappa enhancers
P08979828A1561|18 30|interactions
P08979828A1561|54 62|behavior
P08980413A0500|4 7|P13
P08980413A0500|12 15|N22
P08980413A0500|19 25|ppSEPs
P08980413A0500|30 57|phase reversal relationship
P08980413A0500|67 69|P2
P08980413A0500|74 76|N2
P08980413A0500|95 98|PES
P08980522A0280|4 8|cDNA
P08980522A0280|12 16|cpm7
P08980522A0280|43 50|protein
P08980522A0280|59 62|kDa
P08980533A1160|24 30|region
P08980533A1160|34 39|ENBP1
P08980533A1160|53 61|homology
P08980533A1160|67 74|protein
P08980533A1160|80 83|rat
P08980533A1160|118 131|testis tissue
P08980536A1196|4 16|conservation
P08980536A1196|29 34|G-box
P08980536A1196|39 44|H-box
P08980536A1196|58 71|CHS promoters
P08980536A1196|89 99|importance
P08980536A1196|114 120|motifs
P08980819A0193|0 9|Mortality
P08980819A0193|22 27|ranch
P08980819A0193|77 83|groups
P08980819A0193|87 94|turkeys
P08980819A0193|109 113|toms
P08980819A0193|123 128|birds
P08980819A0193|134 139|birds
P08980819A0193|163 168|event
P08980819A0193|188 200|insemination
P08981371A2049a|13 25|PIP2 content
P08981371A2049a|39 50|kDa protein
P08981371A2049a|77 92|CSF-1 treatment
P08981371A2049b|13 25|PIP2 content
P08981371A2049b|39 50|kDa protein
P08981371A2049b|77 92|CSF-1 treatment
P08985109A1285|38 44|margin
P08985109A1285|49 53|apex
P08985109A1285|67 72|crest
P08985109A1285|97 103|aspect
P08985109A1285|115 119|cone
P08985115A1571|10 24|identification
P08985115A1571|39 53|37LRP/p40 gene
P08985115A1571|72 77|study
P08985115A1571|92 96|step
P08985115A1571|108 117|isolation
P08985115A1571|145 149|gene
P08985115A1571|158 171|understanding
P08985115A1571|189 199|mechanisms
P08985115A1571|216 229|up-regulation
P08985115A1571|237 247|expression
P08985115A1571|255 269|tumor invasion
P08985115A1571|274 284|metastasis
P08985122A0501|4 19|promoter region
P08985122A0501|21 23|P1
P08985122A0501|51 56|group
P08985122A0501|60 90|transcription initiation sites
P08985122A0501|104 108|TATA
P08985122A0501|113 123|CAAT boxes
P08985122A0501|141 154|binding sites
P08985122A0501|163 187|transcription factor SP1
P08985122A0501|215 216|G
P08985122A0501|226 232|domain
P08985122A0501|238 248|CpG island
P08985122A0501|273 282|promoters
P08985122A0501|324 329|genes
P08985415A1096|4 28|STAT-1 signaling pathway
P08985415A1096|51 60|mechanism
P08985415A1096|65 75|activation
P08985415A1096|83 91|CAEV LTR
P08985415A1096|95 104|IFN-gamma
P08985415A1096|108 117|monocytes
P08986190A0927|0 11|Reperfusion
P08986190A0927|31 40|reduction
P08986190A0927|44 62|lactate production
P08986190A0927|81 89|increase
P08986190A0927|93 104|LDH release
P08986214A0000|37 45|response
P08986214A0000|49 57|patients
P08986214A0000|73 86|liver disease
P08986214A0000|88 92|sera
P08986214A0000|102 110|patients
P08986214A0000|133 142|hepatitis
P08986214A0000|150 159|cirrhosis
P08986214A0000|178 202|hepatocyte growth factor
P08986214A0000|204 207|HGF
P08986214A0000|213 230|alpha-fetoprotein
P08986214A0000|232 235|AFP
P08986228A0000|0 8|Children
P08986228A0000|37 44|mothers
P08986228A0000|79 86|effects
P08986228A0000|122 135|malformations
P08986692A0306|0 12|INTERVENTION
P08986692A0306|13 14|S
P08986692A0306|28 49|hemostasis parameters
P08986692A0306|74 82|patients
P08986692A0306|94 100|IVF-ET
P08986770A0268|20 30|expression
P08986770A0268|38 58|I-POU/tI-POU message
P08986770A0268|92 97|phase
P08986770A0268|112 123|development
P08986770A0268|129 134|I-POU
P08986770A0268|152 166|splice variant
P08986812A1214|17 20|p53
P08986812A1214|26 37|delta proAE
P08986812A1214|45 49|cDNA
P08986812A1214|77 82|tumor
P08986812A1214|91 101|cell lines
P08986812A1214|133 140|effects
P08987009A0400|4 11|patient
P08987009A0400|14 18|role
P08987009A0400|37 50|prerequisites
P08987009A0400|65 72|freedom
P08987009A0400|100 113|psychoanalyst
P08987225A0675|16 27|risk factor
P08987225A0675|67 84|hepatitis C cases
P08987225A0675|91 98|history
P08987225A0675|112 120|drug use
P08987225A0675|135 145|proportion
P08987225A0675|149 154|cases
P08987225A0675|165 172|history
P08987225A0675|190 192|NT
P08987225A0675|198 201|ACT
P08987225A0675|206 216|Queensland
P08988257A1256|0 9|Silencing
P08988257A1256|29 37|creation
P08988257A1256|43 51|telomere
P08988257A1256|58 60|kb
P08988257A1256|70 88|reporter construct
P08988257A1256|96 105|insertion
P08988257A1256|113 115|bp
P08988257A1256|119 124|yeast
P08988257A1256|135 150|repeat sequence
P08988257A1256|159 163|site
P08988257A1256|184 194|truncation
P08988913A0821|3 11|contrast
P08988913A0821|35 41|models
P08988913A0821|43 53|provisions
P08988913A0821|75 83|turnover
P08988913A0821|95 111|folate excretion
P08988913A0821|144 153|excretion
P08988913A0821|168 177|processes
P08989025A0359|22 25|Ca2
P08989025A0359|27 35|channels
P08989025A0359|37 40|VOC
P08989025A0359|58 68|nifedipine
P08989025A0359|70 79|midazolam
P08989025A0359|84 98|concentrations
P08989025A0359|111 117|microM
P08989025A0359|152 161|responses
P08989763A0605|8 17|artifacts
P08989763A0605|48 61|visualization
P08989763A0605|69 78|diaphragm
P08990168A0688|9 27|p48 gene induction
P08990168A0688|44 49|STAT1
P08990168A0688|54 58|JAK1
P08990168A0688|70 75|STAT1
P08990168A0688|93 97|GATE
P08990194A0000|4 12|syndrome
P08990194A0000|16 26|resistance
P08990194A0000|30 45|thyroid hormone
P08990194A0000|75 80|serum
P08990194A0000|86 102|thyroid hormones
P08990194A0000|104 111|failure
P08990194A0000|134 155|thyrotropin secretion
P08990194A0000|181 195|refractoriness
P08990194A0000|199 213|hormone action
P08990397A1437|27 34|mutants
P08990397A1437|63 74|photosystem
P08990397A1437|85 88|H13
P08990397A1437|103 111|evidence
P08990397A1437|132 146|RNA processing
P08992115A0199|4 15|progression
P08992115A0199|25 35|bronchitis
P08992115A0199|64 84|blood concentrations
P08992115A0199|88 108|acute-phase proteins
P08992115A0199|110 124|KKS activation
P08992115A0199|132 137|blood
P08992115A0199|147 156|serotonin
P08992115A0199|161 180|lactic acid content
P08992115A0199|188 193|humor
P08992115A0199|223 226|air
P08993393A0498|25 37|implications
P08993393A0498|47 55|findings
P08993393A0498|65 75|physiology
P08993393A0498|91 104|hPACAP-R gene
P08993393T0000|13 22|signaling
P08993393T0000|43 58|gene activation
P08993393T0000|67 82|splice variants
P08993393T0000|106 115|adenylate
P08993393T0000|135 155|polypeptide receptor
P08993393T0000|157 165|hPACAP-R
P08993831A0000|16 34|muscle development
P08993831A0000|46 51|types
P08993831A0000|55 68|muscle fibers
P08993831A0000|108 120|combinations
P08993831A0000|140 153|gene products
P08993836A0699|17 24|results
P08993836A0699|30 37|respect
P08993836A0699|61 70|induction
P08993836A0699|78 94|HNF-3 alpha gene
P08993836A0699|110 120|epithelium
P08993836A0699|128 141|embryogenesis
P08994825A0000|0 10|BACKGROUND
P08994825A0000|12 19|Mitosis
P08994825A0000|36 39|MPF
P08994825A0000|41 51|maturation
P08994825A0000|62 68|factor
P08994825A0000|82 86|form
P08994825A0000|90 116|Cdc2/28-cyclin B complexes
P08994832A0782|8 18|expression
P08994832A0782|22 27|Apo-3
P08994832A0782|31 37|HEK293
P08994832A0782|41 51|HeLa cells
P08994832A0782|67 76|apoptosis
P08994968A0926|14 17|arm
P08994968A0926|28 35|subunit
P08994968A0926|74 80|domain
P08994968A0926|96 103|subunit
P08994968A0926|126 130|ring
P08994968A0926|134 138|NADP
P08995054A0618|0 10|Similarity
P08995054A0618|35 54|zinc knuckle region
P08995054A0618|58 64|region
P08995054A0618|83 92|gag genes
P08995054A0618|123 136|retroelements
P08995054A1368|0 2|D.
P08995054A1368|16 21|HeT-A
P08995054A1368|29 38|sequences
P08995054A1368|58 64|region
P08995054A1368|70 90|insertions/deletions
P08995054A1368|99 105|codons
P08995054A1368|115 133|nucleotide changes
P08995410A0000|11 28|initiation factor
P08995410A0000|32 36|eIF3
P08995410A0000|62 69|complex
P08995410A0000|98 105|complex
P08995410A0000|107 117|eIF2 x GTP
P08995410A0000|120 124|tRNA
P08995410A0000|125 128|Met
P08995410A0000|144 156|mRNA binding
P08995410A0000|167 168|S
P08995410A0000|179 186|subunit
P08995410A0000|188 192|eIF3
P08995410A0000|213 229|ribosome subunit
P08995410A0000|247 253|factor
P08995410A1109|4 8|data
P08995410A1109|33 40|Hershey
P08995410A1109|45 55|co-workers
P08995410A1109|80 84|eIF3
P08995410A1109|112 120|subunits
P08995410A1109|122 126|p170
P08995410A1109|128 132|p116
P08995410A1109|134 139|hPrt1
P08995410A1109|142 146|p110
P08995410A1109|148 151|p66
P08995410A1109|153 156|p48
P08995410A1109|158 161|p47
P08995410A1109|163 166|p44
P08995410A1109|168 171|p40
P08995410A1109|173 176|p36
P08995410A1109|182 185|p35
P08995614T0000|0 14|Identification
P08995614T0000|31 38|element
P08995614T0000|46 51|class
P08995614T0000|60 100|histocompatibility complex gene promoter
P08995614T0000|115 125|activation
P08995614T0000|140 149|sequences
P08995652A0812|4 11|results
P08995652A0812|43 50|capsids
P08995652A0812|129 140|amino acids
P08995652A0812|142 156|UL80.5 protein
P08995652A0812|197 208|amino acids
P08995652A0812|216 230|UL80.5 protein
P08995652A0812|268 279|amino acids
P08995652A0812|287 301|UL26.5 protein
P08995652A0812|310 317|capsids
P08995652A0812|339 350|interaction
P08995652A0812|358 372|UL80.5 protein
P08995652A0812|378 381|VP5
P08995652A0812|402 410|assembly
P08995652A0812|421 428|capsids
P08995652A0812|455 463|sequence
P08995652A0812|479 490|amino acids
P08995652A0812|498 512|UL80.5 protein
P08995652A0812|530 543|RRIFVA ALNKLE
P08995652A0812|547 559|RRIFVAAMMKLE
P08995652A0812|566 582|self-interaction
P08995652A0812|590 607|scaffold proteins
P08995652A0812|623 634|sequences N
P08995652A0812|651 675|maturation cleavage site
P08995652A0812|689 695|UL26.5
P08995652A0812|700 715|UL80.5 proteins
P08995652A0812|741 760|scaffold structures
P08995659A0563|15 38|region splice junctions
P08995659A0563|46 50|MSRs
P08995659A0563|80 89|infection
P08995659A0563|109 136|sequencing RNA-PCR products
P08995659A0563|152 159|primers
P08995659A0563|178 191|splice region
P08995681A0518|5 10|ICP27
P08995681A0518|49 54|forms
P08995681A0518|58 62|ICP4
P08995681A0518|66 73|protein
P08996730A1146|0 4|Lack
P08996730A1146|19 23|data
P08996730A1146|27 49|vibration measurements
P08996730A1146|54 74|employment durations
P08996730A1146|86 97|uncertainty
P08996730A1146|105 115|variations
P08996730A1146|119 134|tool conditions
P08996730A1146|136 150|grinder wheels
P08996730A1146|170 182|difficulties
P08996730A1146|186 197|measurement
P08997490A1127|0 12|C/EBP beta V
P08997490A1127|44 50|subset
P08997490A1127|54 65|C/EBP sites
P08997490A1127|80 89|DBP sites
P08997490A1127|99 115|oligonucleotides
P08997490A1127|139 147|contexts
P08997490A1127|155 162|albumin
P08997490A1127|167 200|cholesterol hydroxylase promoters
P08997532A0116|9 12|IgG
P08997532A0116|23 26|IgE
P08997532A0116|37 56|IgE immunoglobulins
P08997532A0116|65 73|Toxocara
P08997532A0116|100 108|antigens
P08997532A0116|110 113|TES
P08997532A0116|138 153|ELISA technique
P08998115A0114|0 23|SUMMARY BACKGROUND DATA
P08998115A0114|25 38|Melanoma care
P08998115A0114|84 89|years
P08998115A0114|99 110|controversy
P08998115A0114|123 145|lymph node dissections
P08998115A0114|154 161|disease
P08999414A0819|4 15|differences
P08999414A0819|22 31|subgenera
P08999414A0819|39 56|genus Dermacentor
P08999857A0801|13 18|E-box
P08999857A0801|26 33|context
P08999857A0801|53 59|region
P08999857A0801|97 108|enhancement
P08999857A0801|128 136|activity
P08999857A0801|144 150|alpha1
P08999857A0801|151 152|I
P08999857A0801|154 176|collagen gene promoter
P08999882T0000|0 10|Expression
P08999882T0000|23 29|traits
P08999882T0000|44 54|beta cells
P09000049A1341|16 19|Mnt
P09000049A1341|20 23|Max
P09000049A1341|29 38|complexes
P09000049A1341|69 72|Myc
P09000049A1341|73 87|Max activities
P09000049A1341|104 122|cell proliferation
P09000108A0330|4 25|transcription product
P09000108A0330|33 40|kb mRNA
P09000108A0330|65 69|site
P09000108A0330|81 90|consensus
P09000108A0330|102 125|polyadenylation signals
P09000108A0330|141 143|bp
P09000108A0330|162 191|translation termination codon
P09000108A0330|196 200|CG30
P09000146T0000|11 18|changes
P09000146T0000|35 39|type
P09000146T0000|52 63|c-src genes
P09000146T0000|84 104|sequence alterations
P09000589A0000|4 14|resurgence
P09000589A0000|33 40|malaria
P09000589A0000|58 68|evaluation
P09000589A0000|89 95|agents
P09000632A2341|7 18|p51 subunit
P09000632A2341|24 41|Cys181 side-chain
P09000632A2341|67 76|direction
P09000632A2341|84 101|Tyr181 side-chain
P09000632A2341|119 126|complex
P09001213A1111|20 39|level transcription
P09001213A1111|50 54|gene
P09001213A1111|82 97|chromosome ends
P09001213A1111|101 114|P. falciparum
P09001213A1111|187 203|expression sites
P09001213A1111|208 217|var genes
P09001245A0187|0 6|NUP145
P09001245A0187|69 75|screen
P09001313A0000|0 10|Prevalence
P09001313A0000|31 40|breathing
P09001313A0000|42 45|SDB
P09001313A0000|85 90|women
P09001667A0312|7 12|cases
P09001667A0312|17 28|antigenemia
P09001667A0312|63 83|day post-vaccination
P09001828A0222|2 7|total
P09001828A0222|16 19|men
P09001828A0222|34 39|years
P09001828A0222|74 78|time
P09001828A0222|82 92|physicians
P09001828A0222|103 106|BPH
P09001828A0222|140 149|treatment
P09001828A0222|171 176|study
P09002648A0202|0 5|BCL-2
P09002648A0202|10 19|inhibitor
P09002648A0202|23 32|apoptosis
P09002648A0202|43 50|variety
P09002648A0202|54 64|cell types
P09002648A0202|120 130|cell death
P09002672A0439|9 20|translation
P09002672A0439|28 38|mTRF1 cDNA
P09002672A0439|56 67|kDa protein
P09002672A0439|89 102|repeat arrays
P09002672A0439|104 109|mTRF1
P09002672A0439|129 149|sequence specificity
P09002672A0439|153 158|hTRF1
P09002672A0439|171 177|arrays
P09002672A0439|181 195|TTAGGG repeats
P09002672A0439|201 218|binding substrate
P09002672A0439|224 230|TTAGGC
P09002672A0439|235 249|TTGGGG repeats
P09003001A1593|27 30|E12
P09003001A1593|36 43|protein
P09003001A1593|87 94|factors
P09003001A1909|4 18|E-box sequence
P09003001A1909|26 38|SE2 fragment
P09003001A1909|46 66|transferrin promoter
P09003001A1909|71 77|CATCTG
P09003001A1909|97 107|gel shifts
P09003001A1909|115 139|consensus E-box elements
P09003001A1909|141 147|CANNTG
P09003311A0478|9 21|DNA fragment
P09003311A0478|60 70|porin gene
P09003311A0478|78 83|porCa
P09003311A0478|102 109|regions
P09003312A0740|12 19|AT-PHH1
P09003312A0740|30 37|AT-PHH1
P09003312A0740|42 61|AT-PHH1 delta C-513
P09003312A0740|97 101|size
P09003312A0740|115 131|photolyase genes
P09003312A0740|133 138|cDNAs
P09003312A0740|177 182|yeast
P09003312A0740|204 211|mutants
P09003312A0740|242 247|light
P09003410A0000|10 22|p100 protein
P09003410A0000|52 63|coactivator
P09003410A0000|84 89|virus
P09003410A0000|98 105|antigen
P09003462A0792|18 32|mutation sites
P09003462A0792|34 37|S61
P09003462A0792|39 42|SL1
P09003462A0792|44 47|S29
P09003462A0792|49 53|SL11
P09003462A0792|55 60|SL196
P09003462A0792|65 70|SL126
P09003462A0792|90 101|nrdB intron
P09003462A0792|114 127|self-splicing
P09003463A0198|5 11|report
P09003463A0198|25 34|isolation
P09003463A0198|39 55|characterization
P09003463A0198|75 81|region
P09003463A0198|87 89|kb
P09003463A0198|95 99|exon
P09003463A0198|115 129|RII alpha gene
P09003617A0000|2 8|cohort
P09003617A0000|20 28|children
P09003617A0000|50 56|months
P09003617A0000|63 68|years
P09003617A0000|72 75|age
P09004304A0000|4 7|aim
P09004304A0000|16 21|study
P09004304A0000|40 55|reproducibility
P09004304A0000|61 67|number
P09004304A0000|82 99|clearance methods
P09004304A0000|106 133|chromium-51 ethylenediamine
P09004304A0000|146 150|acid
P09004304A0000|152 161|51Cr-EDTA
P09004304A0000|202 224|blood sample technique
P09004504A0000|12 21|structure
P09004504A0000|32 47|bp DNA fragment
P09004504A0000|60 68|pla gene
P09004504A0000|79 100|plasminogen activator
P09004504A0000|110 116|origin
P09004504A0000|120 131|replication
P09004504A0000|149 179|Yersinia pestis plasmid pYP358
P09004987T0001|0 23|Serotonin concentration
P09004987T0001|31 36|blood
P09004987T0001|40 48|patients
P09004987T0001|66 71|fever
P09004987T0001|83 91|syndrome
P09005273A0322|0 21|MAIN OUTCOME MEASURES
P09005273A0322|23 35|Associations
P09005273A0322|39 45|factor
P09005273A0322|63 72|syndromes
P09005273A0322|78 90|risk factors
P09005273A0322|95 116|chemical interactions
P09005273A0322|130 151|butyrylcholinesterase
P09005273A0322|156 182|neuropathy target esterase
P09005273A1558|0 10|CONCLUSION
P09005273A1558|17 34|Gulf War veterans
P09005273A1558|72 81|syndromes
P09005273A1558|95 103|exposure
P09005273A1558|107 119|combinations
P09005273A1558|123 132|chemicals
P09005273A1558|146 167|butyrylcholinesterase
P09005273A1558|172 198|neuropathy target esterase
P09005609A0299|0 19|Control examination
P09005609A0299|41 44|end
P09005609A0299|53 59|period
P09005836A0977|3 14|correlation
P09005836A0977|27 30|age
P09005836A0977|38 44|horses
P09005836A0977|53 67|antibody level
P09005979A0841|4 12|GHR mRNA
P09005979A0841|13 28|GHBP mRNA ratio
P09005979A0841|76 91|differentiation
P09006007A0997|4 11|results
P09006007A0997|61 70|UGA codon
P09006007A0997|99 109|conditions
P09006007A0997|131 143|SelB protein
P09006007A0997|183 194|specificity
P09006007A0997|212 223|interaction
P09006007A0997|238 251|compatibility
P09006007A0997|270 277|complex
P09006007A0997|287 295|ribosome
P09006010A0527|4 28|linker-peptide insertion
P09006010A0527|36 51|RsaA C terminus
P09006010A0527|53 63|amino acid
P09006010A0527|76 82|effect
P09006010A0527|86 104|S-layer biogenesis
P09006010A0527|121 131|amino acid
P09006010A0527|147 156|secretion
P09006010A0527|164 171|protein
P09006010A0527|189 193|RsaA
P09006010A0527|206 222|secretion signal
P09006010A0527|229 230|C
P09006010A0527|243 253|amino acid
P09006010A0527|277 287|amino acid
P09006022A0252|20 33|gene products
P09006022A0252|39 48|cvaA gene
P09006022A0252|87 94|control
P09006022A0252|98 124|T7 RNA polymerase promoter
P09006051A1162|0 4|PrpB
P09006051A1162|12 20|homology
P09006051A1162|24 68|carboxyphosphonoenolpyruvate phosphonomutase
P09006051A1162|110 117|homolog
P09006051A1162|125 156|carnation Dianthus caryophyllus
P09006051A1162|158 162|PrpC
P09006051A1162|186 194|archaeal
P09006051A1162|209 226|citrate synthases
P09006051A1162|228 232|PrpD
P09006051A1162|240 248|homology
P09006051A1162|252 257|yeast
P09006051A1162|262 288|Bacillus subtilis proteins
P09006051A1162|300 308|function
P09006051A1162|310 314|PrpE
P09006051A1162|322 330|homology
P09006051A1162|334 363|acetyl coenzyme A synthetases
P09006555A0738|0 21|MAIN OUTCOME MEASURES
P09006555A0738|46 58|hemodynamics
P09006555A0738|69 92|blood gas determination
P09006555A0738|110 124|lavage protein
P09006555A0738|129 147|neutrophil content
P09006555A0738|149 173|neutrophil oxidant burst
P09006555A0738|175 203|lung myeloperoxidase content
P09006555A0738|209 226|scanning electron
P09006555A0738|240 247|studies
P09006902A0370|19 23|cDNA
P09006902A0370|39 44|MEKK3
P09006910A0000|19 29|mechanisms
P09006910A0000|62 69|control
P09006910A0000|73 92|retinoid X receptor
P09006910A0000|94 97|RXR
P09006910A0000|99 114|gene expression
P09006910A0000|132 138|region
P09006910A0000|152 169|RXRgamma2 isoform
P09006914A0812|0 3|JNK
P09006914A0812|8 11|p38
P09006914A0812|46 53|nucleus
P09006914A0812|69 74|c-JUN
P09006914A0812|79 84|ATF-2
P09006914A0812|109 112|JNK
P09006914A0812|117 120|p38
P09006914A1127|4 11|effects
P09006914A1127|36 41|forms
P09006914A1127|49 74|JNK/p38 signaling pathway
P09006914A1127|92 102|activation
P09006914A1127|112 119|kinases
P09006914A1127|153 179|E-selectin gene expression
P09006935A0590|0 3|Sp1
P09006935A0590|14 24|CTC repeat
P09006935A0590|33 41|affinity
P09006935A0590|43 45|KD
P09006935A0590|53 55|nM
P09006935A0590|81 97|consensus GC box
P09006936T0000|0 14|Identification
P09006936T0000|22 28|region
P09006936T0000|46 53|protein
P09006936T0000|84 90|domain
P09006936T0000|94 114|glycoprotein IBalpha
P09008301A0193|7 19|enzyme forms
P09008301A0193|59 78|autoprocessing site
P09008301A0193|116 123|protein
P09008301A0193|147 154|studies
P09009208A0337|4 10|primer
P09009208A0337|29 37|cleavage
P09009208A0337|58 63|bases
P09009208A0337|81 89|Tf1 mRNA
P09010223A0667|35 39|ELK1
P09010223A0667|41 46|SAP1a
P09010223A0667|48 52|FLI1
P09010223A0667|54 62|EWS-FLI1
P09010223A0667|64 68|ETS1
P09010223A0667|70 74|ETS2
P09010223A0667|76 80|PEA3
P09010223A0667|85 98|PU.1 proteins
P09010223A0667|116 125|complexes
P09010223A0667|131 134|SRF
P09010223A0667|142 151|Egr1 SREI
P09010223A1850|5 13|R-domain
P09010223A1850|31 42|interaction
P09010223A1850|48 51|SRF
P09010223A1850|65 74|mechanism
P09010223A1850|99 103|FLI1
P09010223A1850|108 116|EWS-FLI1
P09010223A1850|143 151|function
P09010223A1850|162 187|ETS transcription factors
P09010223A1850|195 205|regulation
P09010223A1850|213 222|Egr1 gene
P09011591A0309|10 16|number
P09011591A0309|20 29|specimens
P09011591A0309|46 56|nonsmokers
P09011591A0309|64 71|smokers
P09011744A0790|23 32|locations
P09011744A0790|45 75|NMDA receptor channel subunits
P09011744A0790|81 88|epsilon
P09011744A0790|92 98|Grin2a
P09011744A0790|101 108|epsilon
P09011744A0790|112 118|Grin2b
P09011744A0790|121 128|epsilon
P09011744A0790|132 138|Grin2c
P09011744A0790|141 148|epsilon
P09011744A0790|152 158|Grin2d
P09011744A0790|164 168|zeta
P09011744A0790|172 177|Grinl
P09011744A0790|179 187|subunits
P09011744A0790|228 251|backcross mapping panel
P09011744A0790|265 272|crosses
P09011744A0790|278 288|C57BL/6JxM
P09011744A0790|290 297|spretus
P09011744A0790|299 310|F1xC57BL/6J
P09011744A0790|312 316|mice
P09011745T0000|5 12|cloning
P09011745T0000|16 27|chick brain
P09011745T0000|80 94|acid receptors
P09011745T0000|103 115|conservation
P09011745T0000|119 128|structure
P09011745T0000|130 138|function
P09011745T0000|164 173|processes
P09011745T0000|189 198|receptors
P09012405A0785|17 22|TTD-A
P09012405A0785|27 39|XP-D defects
P09012405A0785|60 68|subunits
P09012405A0785|72 77|TFIIH
P09012405A0785|87 107|transcription factor
P09012405A0785|122 130|function
P09012405A0785|134 144|DNA repair
P09012636A0723|0 10|Adjustment
P09012636A0723|15 18|age
P09012636A0723|26 37|cholesterol
P09012636A0723|39 54|HDL cholesterol
P09012636A0723|56 69|triglycerides
P09012636A0723|79 86|smoking
P09012636A0723|101 109|pressure
P09012636A0723|131 142|association
P09012636A0723|151 161|fibrinogen
P09012636A0723|166 181|atherosclerosis
P09013499A0198|3 13|Experiment
P09013499A0198|17 21|pups
P09013499A0198|43 52|injection
P09013499A0198|75 122|N-methyl-D-aspartate receptor antagonist MK-801
P09013499A0198|128 133|mg/kg
P09013499A0198|151 154|min
P09013499A0198|183 195|conditioning
P09013499A0198|207 211|time
P09013499A0198|233 237|odor
P09013499A0198|258 266|controls
P09013760A0000|0 11|Cholesterol
P09013760A0000|23 47|cleavage cytochrome P450
P09013760A0000|49 55|CYP11A
P09013760A0000|57 64|P450scc
P09013760A0000|66 81|gene expression
P09013760A0000|98 111|gonadotropins
P09013760A0000|116 120|cAMP
P09013760A0000|128 133|ovary
P09013760A0000|141 145|ACTH
P09013760A0000|150 154|cAMP
P09013760A0000|175 180|cells
P09015543A0210|13 21|solution
P09015543A0210|39 46|forearm
P09015543A0210|52 56|flap
P09015757T0000|11 19|analysis
P09015757T0000|24 40|characterization
P09015757T0000|44 50|tissue
P09015757T0000|75 85|expression
P09015757T0000|99 116|bone sialoprotein
P09015757T0000|118 121|BSP
P09015757T0000|123 127|gene
P09015799T0000|0 19|Serotonin receptors
P09015799T0000|23 38|suicide victims
P09015799T0000|50 60|depression
P09016566A0655|22 27|motif
P09016566A0655|54 60|number
P09016566A0655|74 83|BiP mRNAs
P09017443A0734|17 30|marker screen
P09017443A0734|55 65|occurrence
P09017443A0734|79 87|syndrome
P09017443A0734|102 108|effect
P09017443A0734|112 119|regimen
P09017443A0734|141 155|stratification
P09017443A0734|157 158|p
P09018122A1389|4 13|detection
P09018122A1389|17 32|ORF-1 sequences
P09018122A1389|42 48|tumors
P09018122A1389|60 65|proof
P09018122A1389|79 91|prerequisite
P09018122A1389|113 117|role
P09018122A1389|121 138|tumor development
P09018133A0244|13 21|analysis
P09018133A0244|27 35|evidence
P09018133A0244|61 73|relationship
P09018133A0244|82 88|PhHV-1
P09018133A0244|93 100|members
P09018133A0244|108 128|Varicellovirus genus
P09018133A0244|136 155|alpha-Herpesvirinae
P09018133A0244|166 177|herpesvirus
P09019302A0600|8 14|method
P09019302A0600|16 19|PLP
P09019302A0600|23 29|plasma
P09019302A0600|58 69|sensitivity
P09019302A0600|76 90|derivatization
P09019302A0600|96 112|sodium bisulfite
P09019302A0600|127 132|phase
P09020138A0833|5 9|HEF1
P09020138A0833|14 17|Cas
P09020138A0833|32 39|complex
P09020138A0833|57 65|adhesion
P09020138A0833|72 87|tyrosine kinase
P09020138A0833|89 94|RAFTK
P09020138A0833|106 114|tyrosine
P09020138A0833|140 161|adapter molecule CrkL
P09020169A0552|0 4|SIM1
P09020169A0552|9 13|SIM2
P09020169A0552|26 36|homodimers
P09020169A0552|68 71|AHR
P09020172A0964|0 9|Complexes
P09020172A0964|13 19|qTBP42
P09020172A0964|44 50|strand
P09020172A0964|64 67|DNA
P09020172A0964|88 93|forms
P09020172A0964|114 120|strand
P09020172A0964|134 159|nM dissociation constants
P09020172A0964|161 163|Kd
P09020172A0964|173 182|complexes
P09020172A0964|214 217|DNA
P09020172A0964|244 253|Kd values
P09020856A0560|14 20|effect
P09020856A0560|32 36|TIS1
P09020856A0560|70 82|MCK promoter
P09021684A1418|13 17|data
P09021684A1418|45 53|proteins
P09021684A1418|90 97|nucleus
P09021684A1418|129 148|repressor functions
P09021684A1418|167 181|NF-kappa B2p52
P09021684A1418|204 228|transactivation activity
P09022040A0263|8 28|L-plastin expression
P09022040A0263|70 76|humans
P09022040A0263|81 88|rodents
P09022040A0263|116 126|mechanisms
P09022040A0263|146 161|gene expression
P09022040A0263|182 187|cells
P09022040A0263|239 247|function
P09022040A0263|252 272|nucleotide sequences
P09022040A0263|297 321|L-plastin gene promoters
P09022632T0000|42 49|surgery
P09023197T0000|4 15|dnaK operon
P09023197T0000|19 36|Bacillus subtilis
P09023378A0959|10 20|expression
P09023378A0959|24 28|CBF1
P09023378A0959|32 37|yeast
P09023378A0959|60 73|transcription
P09023378A0959|77 91|reporter genes
P09023378A0959|107 119|C-repeat/DRE
P09023378A0959|135 153|activator sequence
P09023378A0959|169 177|versions
P09023378A0959|185 196|DNA element
P09024039A0247|10 13|ASA
P09024039A0247|23 29|status
P09024039A0247|44 52|patients
P09024039A0247|66 73|variety
P09024039A0247|83 84|h
P09024039A0247|94 104|procedures
P09024039A0247|140 143|CCA
P09024039A0247|149 159|desflurane
P09024039A0247|163 173|isoflurane
P09024039A0247|179 190|ventilation
P09024097A0000|0 9|OBJECTIVE
P09024097A0000|15 19|goal
P09024097A0000|64 69|women
P09024097A0000|84 88|rate
P09024097A0000|100 113|complications
P09024097A0000|120 130|postpartum
P09024097A0000|137 145|ligation
P09024793A1325|7 43|electrophoresis mobility shift assay
P09024793A1325|58 66|extracts
P09024793A1325|83 88|cells
P09024793A1325|90 94|MyoD
P09024793A1325|99 107|myogenin
P09024793A1325|127 132|E-box
P09024793A1325|140 155|enhancer region
P09024793A1325|163 171|MCK gene
P09024793A1325|184 192|presence
P09024793A1325|196 201|BMP-2
P09024805A0905b|15 33|promoter construct
P09024805A0905b|51 58|repeats
P09024805A0905b|64 82|consensus Sp1 site
P09024805A0905b|112 116|copy
P09024805A0905b|124 127|ZII
P09024805A0905b|129 133|CREB
P09024805A0905b|135 138|AP1
P09024805A0905b|140 147|element
P09024805A0905b|157 171|BZLF1 promoter
P09024805A0905b|186 206|beta-globin TATA box
P09024805A0905b|218 244|phorbol ester inducibility
P09025122A0374|11 22|experiments
P09025122A0374|43 48|tasks
P09025122A0374|71 78|aspects
P09025122A0374|86 95|COWA task
P09025122A0374|141 152|performance
P09025549A0000|11 16|nurse
P09025549A0000|42 47|level
P09025549A0000|51 61|competence
P09025549A0000|95 108|practitioners
P09025549A0000|116 121|field
P09025549A0000|123 160|Vancouver sex therapist Bianca Rucker
P09025549A0000|190 197|network
P09025549A0000|201 211|colleagues
P09025549A0000|216 223|mentors
P09025549A0000|235 241|fields
P09025549A0000|250 254|home
P09025549A0000|270 279|continent
P09027346A1957|9 25|antibody binding
P09027346A1957|29 38|site IIIa
P09027346A1957|46 68|hCG-ectodomain complex
P09027346A1957|106 109|mAb
P09027346A1957|129 136|peptide
P09027346A1957|159 163|exon
P09027346A1957|165 169|pE x
P09027346A1957|180 183|LHR
P09027506T0000|0 12|cDNA cloning
P09027506T0000|14 33|expression analysis
P09027506T0000|51 63|localization
P09027506T0000|69 73|gene
P09027506T0000|84 92|homology
P09027506T0000|96 105|wheat eIF
P09027506T0000|107 110|iso
P09027506T0000|111 113|4F
P09027506T0000|128 134|eIF-4G
P09028089A0183|38 50|hypertension
P09028089A0183|78 88|blood flow
P09028089A0183|109 132|transplantation surgery
P09028308A0590|12 20|patients
P09028308A0590|34 37|AZQ
P09028308A0590|42 55|mitroxantrone
P09028308A0590|78 101|bone marrow suppression
P09028308A0590|129 136|cohorts
P09028308A0590|155 160|G-CSF
P09028308A0590|164 177|micrograms/kg
P09028308A0590|193 196|day
P09028308A0590|203 213|completion
P09028308A0590|227 232|cycle
P09028308A0590|236 248|chemotherapy
P09028942A0000|48 54|factor
P09028942A0000|56 63|hGM-CSF
P09028942A0000|77 80|set
P09028942A0000|84 89|genes
P09028942A0000|98 103|c-fos
P09028942A0000|105 108|jun
P09028942A0000|110 113|myc
P09028942A0000|125 145|growth response gene
P09028942A0000|149 154|egr-1
P09028998A0143|3 8|order
P09028998A0143|35 42|control
P09028998A0143|73 80|outcome
P09028998A0143|86 92|amount
P09028998A0143|96 109|breast tissue
P09028998A0143|134 137|BCT
P09029091A0881|36 60|tyrosine phosphorylation
P09029091A0881|64 85|phospholipase C gamma
P09029091A0881|110 122|Jurkat cells
P09029091A0881|138 152|A2/HCP chimera
P09029104A0226|9 14|IGLL1
P09029104A0226|16 20|gene
P09029104A0226|39 46|lineage
P09029104A0226|69 75|manner
P09029159A0000|4 14|interferon
P09029159A0000|16 19|IFN
P09029159A0000|45 48|RNA
P09029159A0000|50 55|dsRNA
P09029159A0000|67 89|Ser/Thr protein kinase
P09029159A0000|91 94|PKR
P09029159A0000|104 108|role
P09029159A0000|148 155|effects
P09029159A0000|159 162|IFN
P09029713A1120|14 18|data
P09029713A1120|47 54|control
P09029713A1120|62 69|amounts
P09029713A1120|77 91|activator SF-1
P09029713A1120|100 117|repressor COUP-TF
P09029713A1120|149 162|transcription
P09029956T0000|7 16|relations
P09029956T0000|25 35|management
P09029956T0000|49 68|structure formation
P09030581A0990|18 29|COS-7 cells
P09030581A0990|31 36|MKP-4
P09030581A0990|44 54|activation
P09030581A0990|58 69|MAP kinases
P09030581A0990|79 94|selectivity ERK
P09030581A0990|97 100|p38
P09030581A0990|103 111|JNK/SAPK
P09030688A0435|3 15|rlf2 mutants
P09030688A0435|27 36|chromatin
P09030688A0435|61 70|silencing
P09030688A0435|86 104|Rap1p localization
P09030781A0734|5 12|kinases
P09030781A0734|48 59|roscovitine
P09030781A0734|61 74|cdc2/cyclin B
P09030781A0734|76 89|cdk2/cyclin A
P09030781A0734|91 104|cdk2/cyclin E
P09030781A0734|109 117|cdk5/p35
P09030781A0734|152 163|IC50 values
P09030781A0734|190 196|microM
P09030781A0734|213 227|cdk4/cyclin D1
P09030781A0734|232 246|cdk6/cyclin D2
P09030781A0734|276 287|roscovitine
P09030781A0734|289 293|IC50
P09030781A0734|300 306|microM
P09031639A0474|10 17|kb cDNA
P09031639A0474|35 48|reading frame
P09031639A0474|50 53|ORF
P09031639A0474|62 64|bp
P09031639A0474|76 87|polypeptide
P09031639A0474|95 106|amino acids
P09031639A0474|108 110|aa
P09031639A0474|138 146|position
P09031639A0474|148 156|position
P09031639A0474|176 188|U1-C protein
P09032233T0000|0 11|Interaction
P09032233T0000|15 20|Ets-1
P09032233T0000|29 58|POU-homeodomain protein GHF-1
P09032233T0000|59 64|Pit-1
P09032233T0000|98 113|gene expression
P09032248A0239|9 14|Pho85
P09032248A0239|36 45|viability
P09032248A0239|47 76|Pcl1,2-Pho85 kinase complexes
P09032248A0239|98 103|Start
P09032248A0239|111 118|absence
P09032248A0239|122 142|Cln1,2-Cdc28 kinases
P09032250A0257|10 15|yeast
P09032250A0257|27 33|system
P09032250A0257|37 43|screen
P09032250A0257|48 56|proteins
P09032250A0257|77 81|Tax1
P09032250A0257|99 108|B subunit
P09032250A0257|116 142|CCAAT binding protein NF-Y
P09032250A0257|150 167|HeLa cDNA library
P09032254A0724|0 17|Enhancer activity
P09032254A0724|36 45|AP-1 site
P09032254A0724|65 74|sequences
P09032258A0395|0 7|Studies
P09032258A0395|14 31|HLA-DR-B7-1-LFA-3
P09032258A0395|39 52|transfectants
P09032258A0395|83 109|NF-AT DNA binding activity
P09032258A0395|138 156|B7-1 costimulation
P09032259A0150|13 23|activation
P09032259A0150|27 31|Rac1
P09032259A0150|36 40|RhoA
P09032259A0150|60 74|transformation
P09032259A0150|78 91|NIH 3T3 cells
P09032259A0150|103 112|functions
P09032259A0150|138 156|Ras transformation
P09032259A0972|13 28|Rac1 activation
P09032259A0972|32 35|JNK
P09032259A0972|39 42|SRF
P09032259A0972|47 56|induction
P09032259A0972|60 72|lamellipodia
P09032259A0972|115 141|Rac1 transforming activity
P09032267A0850|0 14|Overexpression
P09032267A0850|22 45|bZip interaction domain
P09032267A0850|49 52|CBP
P09032267A0850|89 99|cross talk
P09032267A0850|108 110|TR
P09032267A0850|115 123|p45/NF-E
P09032275A1133|16 22|domain
P09032275A1133|67 87|AHC deletion mutants
P09032275A1133|101 105|date
P09032304T0000|0 14|Identification
P09032304T0000|38 60|transactivation domain
P09032304T0000|68 88|herpes simplex virus
P09032304T0000|100 112|protein ICP4
P09032328A0650|0 14|DNA sequencing
P09032328A0650|26 33|segment
P09032328A0650|49 65|gammaherpesvirus
P09032328A0650|76 81|locus
P09032328A0650|83 87|DL-B
P09032328A0650|97 102|ORF11
P09032328A0650|107 112|ORF17
P09032328A0650|126 134|presence
P09032328A0650|149 153|ORFs
P09032328A0650|169 182|gene products
P09032328A0650|203 211|proteins
P09034337A0251|0 7|Studies
P09034337A0251|21 26|cells
P09034337A0251|43 52|induction
P09034337A0251|67 75|tyrosine
P09034337A0251|80 83|Y15
P09034337A0251|85 100|phosphorylation
P09034337A0251|104 111|p34cdc2
P09034337A0251|121 129|response
P09034337A0251|133 143|DNA damage
P09035307A0000|21 25|case
P09035307A0000|43 46|man
P09035307A0000|87 94|adenoma
P09035307A0000|111 155|99mTc-methoxyisobutylisonitrile scintigraphy
P09035307A0000|157 167|99mTc-MIBI
P09035612T0000|8 26|endothelin release
P09035612T0000|31 43|infarct size
P09035612T0000|56 66|blood flow
P09035612T0000|84 92|function
P09035612T0000|103 113|infarction
P09035612T0000|118 129|reperfusion
P09036529A0343|4 10|workup
P09036529A0343|20 30|skin tests
P09036529A0343|40 52|microgram/ml
P09036529A0343|54 63|Pharmacia
P09036529A0343|66 77|measurement
P09036529A0343|90 99|serum IgE
P09036529A0343|105 113|RAST-CAP
P09036529A0343|115 124|Pharmacia
P09036529A0343|131 135|CAST
P09036529A0343|147 161|concentrations
P09036529A0343|165 168|bee
P09036529A0343|170 184|Apis mellifera
P09036529A0343|190 194|wasp
P09036529A0343|196 208|Vespula spec
P09036529A0343|211 216|venom
P09036529A0343|218 229|Aquagen ALK
P09037032T0000|4 17|proliferation
P09037032T0000|45 50|P2P-R
P09037032T0000|52 56|gene
P09037032T0000|62 69|domains
P09037032T0000|101 130|ribonucleoprotein association
P09037032T0000|135 146|Rb1 binding
P09037032T0000|163 173|expression
P09037032T0000|190 205|differentiation
P09037064A0183|7 18|application
P09037064A0183|34 53|canarypox ALVAC/HIV
P09037064A0183|56 63|vectors
P09037064A0183|67 85|vaccine immunogens
P09037064A0183|89 94|HIV-1
P09037064A0183|108 118|volunteers
P09037064A0183|132 145|CTL responses
P09037064A0183|163 169|number
P09037064A0183|173 182|vaccinees
P09037163A1652|4 13|relevance
P09037163A1652|23 31|elements
P09037163A1652|56 65|induction
P09037163A1652|69 89|gpc4 gene expression
P09038166A0818|0 9|Exons A1a
P09038166A0818|14 17|A1b
P09038166A0818|68 74|intron
P09038192A0846|15 24|inhibitor
P09038192A0846|26 34|PD098059
P09038192A0846|37 43|Dudley
P09038192A0846|45 47|D.
P09038202A1951|6 10|data
P09038202A1951|23 27|idea
P09038202A1951|37 56|repression activity
P09038202A1951|60 69|NRSF/REST
P09038202A1951|87 94|species
P09038202A1951|98 106|promoter
P09038202A1951|142 150|proteins
P09038202A1951|170 179|promoters
P09039744T0000|21 29|analysis
P09039744T0000|33 55|electro-encephalograms
P09039744T0000|69 82|sinc function
P09040011A1316|3 10|summary
P09040011A1316|12 15|p56
P09040011A1316|16 19|lck
P09040011A1316|21 29|activity
P09040011A1316|41 56|G1/S transition
P09040011A1316|69 80|thymoblasts
P09040011A1316|95 109|cell viability
P09040011A1316|114 126|transduction
P09040011A1316|143 161|activation signals
P09040011A1316|176 186|components
P09040011A1316|194 214|Ras/Raf/MAPK pathway
P09041123A0195|13 19|action
P09041123A0195|36 42|ligand
P09041123A0195|70 77|factors
P09041123A0195|131 140|responses
P09041123A0195|162 169|complex
P09042078A0202|21 24|MBF
P09042078A0202|28 36|incisors
P09042078A0202|45 54|direction
P09042078A0202|64 74|dimensions
P09042078A0202|89 101|jaw openings
P09042078A0202|109 117|subjects
P09042269A1007|6 14|findings
P09042269A1007|54 66|chemotherapy
P09042269A1007|108 114|cancer
P09042683A0492|4 21|FBF questionnaire
P09042683A0492|63 79|symptoms profile
P09042683A0492|99 107|disorder
P09042683A0492|146 154|disorder
P09042683A0492|159 172|schizophrenia
P09042755T0000|16 35|sigma factor sigmaB
P09042755T0000|62 72|regulation
P09042755T0000|80 91|sigB operon
P09042755T0000|95 103|response
P09042755T0000|107 119|growth phase
P09042755T0000|124 134|heat shock
P09042911A0626|8 25|promoter elements
P09042911A0626|40 54|glucocorticoid
P09042911A0626|74 84|regulation
P09042911A0626|99 104|liver
P09042911A0626|141 151|expression
P09042911A0626|187 195|sequence
P09043534A1600|22 31|decreases
P09043534A1600|39 53|alkalinization
P09043534A1600|70 77|minutes
P09043768A0139|20 31|biokinetics
P09043768A0139|35 38|BLM
P09043768A0139|52 62|indium-111
P09043768A0139|64 70|In-111
P09045636A0789|0 17|CD3 cross-linking
P09045636A0789|26 50|tyrosine phosphorylation
P09045636A0789|54 59|Sam68
P09045636A0789|74 81|T cells
P09045805A0945|18 28|expression
P09045805A0945|36 50|acoABCD operon
P09045805A0945|84 96|acoK mutants
P09045805A0945|112 119|plasmid
P09045805A0945|139 143|acoK
P09045805A0945|158 182|transactivating function
P09045805A0945|190 202|gene product
P09045842T0000|0 9|Mutations
P09045842T0000|17 22|alpha
P09045842T0000|36 44|subunits
P09045842T0000|48 62|RNA polymerase
P09045842T0000|70 80|expression
P09045842T0000|88 98|mer operon
P09045919A1250|27 35|evidence
P09045919A1250|44 53|existence
P09045919A1250|60 69|activator
P09045919A1250|71 74|NFE
P09045919A1250|85 96|combination
P09045919A1250|106 109|p50
P09045919A1250|114 128|c-Rel proteins
P09045919A1250|134 138|part
P09045919A1250|146 176|transcription factor machinery
P09045919A1250|195 212|enhancer activity
P09045919A1250|227 234|control
P09045919A1250|242 251|IgH locus
P09045919A1250|260 284|B lymphocyte development
P09046013A0000|20 28|efficacy
P09046013A0000|71 94|calcium channel blocker
P09046013A0000|96 103|SNX-111
P09046013A0000|149 153|rats
P09046013A0000|170 173|min
P09046013A0000|192 200|ischemia
P09046013A0000|214 222|ligation
P09046013A0000|243 257|carotid artery
P09046013A0000|272 281|occlusion
P09046013A0000|311 317|artery
P09046090T0000|4 9|genes
P09046090T0000|23 52|transcription factor yTAFII60
P09046090T0000|58 70|G4p1 protein
P09046090T0000|86 105|glucose transporter
P09046090T0000|130 145|kb DNA fragment
P09046090T0000|158 161|arm
P09046090T0000|190 204|chromosome VII
P09046186A0189|4 13|protector
P09046186A0189|36 49|fall distance
P09046186A0189|54 62|fracture
P09046186A0189|70 80|trochanter
P09046384A0403|0 23|Marinol/marijuana usage
P09046384A0403|54 57|CD4
P09046384A0403|59 65|counts
P09046384A0403|79 93|amylase levels
P09046384A0403|105 117|DDI subgroup
P09047252A0209|0 7|METHODS
P09047252A0209|21 29|patients
P09047252A0209|63 72|resection
P09047252A0209|77 80|HCC
P09047252A0209|104 114|AFP levels
P09047252A0209|125 130|ng/ml
P09047252A0209|155 160|study
P09047344A0000|19 26|peptide
P09047344A0000|28 31|CBP
P09047344A0000|36 43|peptide
P09047344A0000|50 61|amino acids
P09047344A0000|75 88|muscle myosin
P09047344A0000|95 107|chain kinase
P09047344A0000|109 113|MLCK
P09047344A0000|125 135|calmodulin
P09047344A0000|151 159|affinity
P09048617A0648|22 26|type
P09048617A0648|30 54|tyrosine kinase receptor
P09048617A0648|91 97|nature
P09048617A0648|105 116|cAMP effect
P09049198A0289|8 15|insight
P09049198A0289|34 45|involvement
P09049198A0289|49 52|p21
P09049198A0289|56 73|liver cell growth
P09049198A0289|79 89|expression
P09049198A0289|94 104|regulation
P09049198A0289|112 120|p21 gene
P09049198A0289|145 151|models
P09049198A0289|155 173|liver regeneration
P09049198A0289|178 187|specimens
P09049198A0289|197 211|liver diseases
P09049270A0488|0 22|Northern blot analysis
P09049270A0488|26 30|LeMT
P09049270A0488|31 32|A
P09049270A0488|38 42|LeMT
P09049270A0488|43 44|B
P09049270A0488|58 69|transcripts
P09049270A0488|86 91|genes
P09049270A0488|114 120|leaves
P09049270A0488|126 131|roots
P09049270A0488|135 148|tomato plants
P09049270A0488|163 171|addition
P09049270A0488|181 191|metal ions
P09049270A0488|195 209|characteristic
P09049270A0488|213 217|type
P09049270A0488|221 224|MTs
P09049304A1193|3 26|co-transfection studies
P09049304A1193|31 35|AP-2
P09049304A1193|47 70|Egr-1 expression vector
P09049304A1193|81 103|VPF/VEGF transcription
P09049304A1193|126 138|AP-2 protein
P09049304A1193|168 171|TGF
P09049304A1193|186 210|VPF/VEGF gene expression
P09049306A0830|4 12|HBP gene
P09049306A0830|34 39|exons
P09049306A0830|54 56|kb
P09049306A0830|70 73|arm
P09049306A0830|77 87|chromosome
P09049313A0116|8 17|instances
P09049313A0116|50 60|expression
P09049313A0116|80 89|proteases
P09049313A0116|108 116|cleavage
P09049313A0116|120 143|initiation factor eIF4G
P09050689A0685|21 29|ablation
P09050689A0685|44 49|SnET2
P09050689A0685|76 90|administration
P09050689A0685|102 111|treatment
P09050689A0685|119 123|J/cm
P09050689A0685|127 132|hours
P09050847A0180|7 12|class
P09050847A0180|34 51|TBP-TAF complexes
P09050847A0180|71 77|murine
P09050847A0180|88 93|class
P09050847A0180|105 147|transcription initiation factor TIF-IB/SL1
P09050847A0180|170 181|selectivity
P09050847A0180|201 209|promoter
P09050849A0000|0 11|Cytohesin-1
P09050849A0000|15 22|protein
P09050849A0000|35 40|cells
P09050849A0000|55 61|system
P09050849A0000|95 102|homolog
P09050849A0000|135 152|Sec7 gene product
P09050849A0000|174 191|protein transport
P09050849A1459|8 14|regard
P09050849A1459|66 73|ARF-GEP
P09050849A1459|95 101|domain
P09050861A0903|20 34|identification
P09050861A0903|38 41|DEK
P09050861A0903|57 68|pets factor
P09050867A0542|6 14|elements
P09050867A0542|26 38|binding site
P09050867A0542|43 56|Krox proteins
P09050867A0542|74 80|factor
P09050867A0542|87 100|octamer motif
P09050867A0542|112 136|POU-homeodomain proteins
P09050867A0542|150 168|TN control element
P09051656A0390|0 14|Tissue samples
P09051656A0390|41 45|rats
P09051656A0390|78 88|withdrawal
P09051656A0390|107 128|day morphine infusion
P09051656A0390|132 136|sham
P09051656A0390|153 161|subjects
P09053309A1103|24 47|floor plate development
P09053309A1103|51 62|oep mutants
P09053309A1103|84 91|absence
P09053309A1103|99 122|floor plate inducer shh
P09053494A0612|0 7|RESULTS
P09053494A0612|13 20|medians
P09053494A0612|38 42|CD34
P09053494A0612|44 55|cell yields
P09053494A0612|60 68|patients
P09053494A0612|82 92|paclitaxel
P09053494A0612|98 100|CY
P09053494A0612|102 104|CE
P09053494A0612|110 113|CEP
P09053494A0612|119 124|G-CSF
P09053494A0612|160 162|kg
P09053494A0612|205 207|kg
P09053494A0612|215 230|reference group
P09053494A0612|245 247|CY
P09053494A0612|253 258|G-CSF
P09053494A0612|260 261|P
P09053835A0865|10 22|p53 activity
P09053835A0865|34 36|OP
P09053835A0865|60 68|p53 mRNA
P09053835A0865|76 90|protein levels
P09053973A1252|0 10|CONCLUSION
P09053973A1252|20 34|administration
P09053973A1252|38 49|misoprostol
P09053973A1252|89 95|effect
P09053973A1252|109 117|patients
P09053973A1252|123 130|ascites
P09055221A0288|4 13|intensity
P09055221A0288|21 26|SSTEs
P09055221A0288|33 38|order
P09055221A0288|42 51|magnitude
P09055221A0288|76 80|MSEs
P09055221A0288|100 115|signal contrast
P09055221A0288|124 131|effects
P09056761A0000|14 19|cells
P09056761A0000|31 42|termination
P09056761A0000|46 57|translation
P09056761A0000|70 76|codons
P09056761A0000|104 109|cause
P09056761A0000|115 122|variety
P09056761A0000|146 152|events
P09056761A0000|170 180|mRNA decay
P09056761A0000|188 197|cytoplasm
P09056761A0000|205 212|nucleus
P09056761A0000|222 243|splice site selection
P09056761A0000|249 253|exon
P09057325A0177|4 10|region
P09057325A0177|14 26|plasmid pCM2
P09057325A0177|40 65|pathogenicity locus pat-1
P09057325A0177|80 97|deletion analysis
P09057325A0177|102 125|complementation studies
P09057325A0177|138 161|Bg/II/SmaI DNA fragment
P09057648A0422|10 24|cotransfection
P09057648A0422|28 36|tat cDNA
P09057648A0422|40 57|sense orientation
P09057648A0422|59 64|tat/S
P09057648A0422|83 90|plasmid
P09057648A0422|106 120|c-fos promoter
P09057648A0422|122 125|FC3
P09057648A0422|148 153|front
P09057648A0422|171 204|chloramphenicol acetyltransferase
P09057648A0422|206 209|CAT
P09057648A0422|211 215|gene
P09057648A0422|239 251|CAT activity
P09057648A0422|255 267|Jurkat cells
P09057648A0422|285 293|addition
P09057648A0422|299 300|%
P09057648A0422|307 317|calf serum
P09057648A0422|319 322|FCS
P09057648A0422|329 361|micrograms/mL phytohemagglutinin
P09057648A0422|374 405|mol/L phorbol myristate acetate
P09057648A0422|407 410|PMA
P09057648A0422|416 426|U937 cells
P09057648A0422|442 447|% FCS
P09057648A0422|458 467|mol/L PMA
P09057703A1389|0 15|Snail mortality
P09057703A1389|49 69|treatment conditions
P09057840A0946|16 23|protein
P09057840A0946|40 51|homogeneity
P09057840A0946|56 59|NH4
P09057840A0946|60 78|2SO4-precipitation
P09057840A0946|83 106|affinity chromatography
P09057840A0946|113 126|AMP-Sepharose
P09057841T0000|0 12|Derepression
P09057841T0000|16 31|gene expression
P09057841T0000|60 66|region
P09057841T0000|74 95|isocitrate lyase gene
P09057841T0000|99 117|Candida tropicalis
P09057841T0000|159 167|pathways
P09058002T0000|18 22|task
P09058002T0000|49 60|lobe damage
P09058250A0128|9 22|complications
P09058250A0128|46 54|analysis
P09058250A0128|58 60|NO
P09058250A0128|65 68|NO2
P09058250A0128|94 101|therapy
P09058323A1287|4 11|results
P09058323A1287|29 41|cis elements
P09058323A1287|65 70|alpha
P09058323A1287|77 81|beta
P09058323A1287|91 98|regions
P09058323A1287|130 134|part
P09058323A1287|153 165|CNS patterns
P09058323A1287|169 173|beta
P09058323A1287|177 182|alpha
P09058323A1287|190 195|alpha
P09058323A1287|198 216|gene transcription
P09058373A0670|0 28|RNase protection experiments
P09058373A0670|43 51|presence
P09058373A0670|59 75|GHR1-279 variant
P09058373A0670|79 89|IM-9 cells
P09058373A0670|100 105|liver
P09058373A1620|11 16|tests
P09058373A1620|25 38|reporter gene
P09058373A1620|65 73|elements
P09058373A1620|108 112|form
P09058373A1620|158 166|function
P09058373A1620|186 194|receptor
P09058378A1134|22 46|glucocorticoid receptors
P09058378A1134|62 86|transactivation function
P09058378A1134|90 93|p53
P09058378A1134|101 116|transrepression
P09058378A1134|120 123|p53
P09059039A0850|0 11|99mTc-HMPAO
P09059039A0850|35 46|territories
P09059039A0850|54 57|ACA
P09059039A0850|62 65|MCA
P09059039A0850|77 85|patients
P09059039A0850|122 130|infusion
P09059039A0850|134 144|papaverine
P09059039A0850|154 164|C4 segment
P09059039A0850|198 207|territory
P09059039A0850|215 218|ACA
P09059039A0850|227 235|patients
P09059039A0850|272 280|infusion
P09059039A0850|284 294|papaverine
P09059039A0850|304 314|C1 segment
P09059039A0850|320 326|ml/min
P09060045A0576|11 26|review analyses
P09060045A0576|33 45|interactions
P09060045A0576|67 75|settings
P09060045A0576|101 118|endotoxin release
P09060444A0557|5 21|promoter segment
P09060444A0557|34 44|expression
P09060444A0557|50 74|luciferase reporter gene
P09060444A0557|113 123|initiation
P09060444A0557|131 139|reporter
P09060444A0557|161 179|EGF-responsiveness
P09060444A0557|214 218|gene
P09060622A1679|18 24|report
P09060622A1679|54 68|alphavirus RNA
P09060622A1679|79 83|poly
P09060622A1679|84 85|A
P09060622A1679|87 91|tail
P09060622A1679|105 114|infection
P09060622A1679|151 157|genome
P09060623A0961|10 20|coreceptor
P09060623A0961|53 62|SIV entry
P09060676A1634|6 13|changes
P09060676A1634|17 37|virus entry features
P09060676A1634|52 65|coronaviruses
P09060676A1634|88 98|properties
P09060971A0982|0 7|RESULTS
P09060971A0982|15 20|women
P09060971A0982|38 45|decline
P09060971A0982|49 52|BMD
P09060971A0982|79 84|sites
P09060971A0982|141 148|decline
P09060971A0982|169 173|neck
P09060971A0982|182 189|g/cm2/y
P09060971A0982|191 192|p
P09060971A0982|225 235|trochanter
P09060971A0982|243 246|hip
P09060971A0982|255 262|g/cm2/y
P09060971A0982|264 265|p
P09061697A0629|14 15|%
P09061697A0629|17 25|patients
P09061697A0629|48 51|MBq
P09061697A0629|55 58|mCi
P09061697A0629|60 77|99Tcm-tetrofosmin
P09061697A0629|81 85|rest
P09061697A0629|97 98|h
P09061697A0629|112 115|MBq
P09061697A0629|120 123|mCi
P09061697A0629|132 138|stress
P09061697A0629|146 158|day protocol
P09061697A0629|175 176|%
P09061697A0629|178 186|patients
P09061697A0629|191 195|rest
P09061697A0629|200 222|stress imaging studies
P09061697A0629|239 243|days
P09061697A0629|261 264|MBq
P09061697A0629|269 272|mCi
P09061697A0629|274 278|dose
P09061697A0629|282 299|99Tcm-tetrofosmin
P09061697A0629|308 316|occasion
P09061697A0629|324 336|day protocol
P09061697T0000|11 23|SPET imaging
P09061697T0000|29 46|99Tcm-tetrofosmin
P09061697T0000|59 67|practice
P09061697T0000|69 79|comparison
P09061697T0000|87 90|day
P09061697T0000|99 119|day imaging protocol
P09061698A0177|0 13|99Tcm-DMP-HSA
P09061698A0177|41 50|behaviour
P09061698A0177|76 87|blood cells
P09061698A0177|89 93|RBCs
P09061698A0177|131 149|reference standard
P09061698A0177|154 171|blood pool agents
P09062130A0116|0 6|Relief
P09062130A0116|12 26|autoinhibition
P09062130A0116|55 63|increase
P09062130A0116|67 68|V
P09062130A0116|69 72|max
P09062130A0116|98 121|N-SH2 domain engagement
P09062130A0116|136 157|phosphotyrosyl ligand
P09062130A0116|166 174|deletion
P09062130A0116|182 193|SH2 domains
P09062130A0116|217 230|PTPase domain
P09064659A1055|44 51|homolog
P09064659A1055|55 65|yeast UPF1
P09064659A1055|69 76|protein
P09064659A1055|92 98|levels
P09064659A1055|102 115|nonsense mRNA
P09064659A1055|146 153|protein
P09064659A1055|160 165|HUPF1
P09064659A1055|177 184|homolog
P09064659A1055|188 192|UPF1
P09064868T0001|2 14|miracle cure
P09064868T0001|23 31|solution
P09065170A0853|4 12|addition
P09065170A0853|16 26|zidovudine
P09065170A0853|50 58|transfer
P09065463A1012|0 19|DNA strand exchange
P09065463A1012|33 46|Rad51 protein
P09065463A1012|77 80|RPA
P09065690A0463|0 5|Ume6p
P09065690A0463|31 41|expression
P09065690A0463|59 64|genes
P09065690A0463|76 91|CAR1 expression
P09065690A0463|102 110|sequence
P09065690A0463|118 121|URS
P09065690A0463|128 136|function
P09065690A0463|140 161|nitrogen availability
P09065768A0862|11 16|class
P09065768A0862|20 24|cDNA
P09065768A0862|44 57|kb transcript
P09065768A0862|115 127|lactase mRNA
P09067577A0307|3 13|cell lines
P09067577A0307|29 36|BCR/ABL
P09067577A0307|38 42|CRKL
P09067577A0307|47 55|tyrosine
P09067577A0307|78 81|CRK
P09067577A0721|17 22|cells
P09067577A0721|36 44|proteins
P09067577A0721|65 69|CRKL
P09067577A0721|85 88|C3G
P09067577A0721|90 93|SOS
P09067577A0721|98 103|c-ABL
P09068989T0000|0 6|Effect
P09068989T0000|10 28|Azadirachta indica
P09068989T0000|44 56|leaf extract
P09068989T0000|79 85|system
P09071308A0376|0 7|RESULTS
P09071308A0376|17 26|opacities
P09071308A0376|52 64|distribution
P09071308A0376|87 94|finding
P09071308A0376|110 111|%
P09071308A0376|123 124|%
P09071308A0376|129 137|patients
P09071308A0376|143 146|MTB
P09071308A0376|151 155|NTMB
P09071407T0000|12 20|oxytocin
P09071407T0000|29 40|guinea pigs
P09071407T0000|64 76|cohabitation
P09071407T0000|94 103|condition
P09072361A0357|24 32|fraction
P09072361A0357|34 39|SHRSP
P09072361A0357|49 57|decrease
P09072361A0357|61 70|magnesium
P09072361A0357|79 86|tissues
P09072361A0357|94 103|elevation
P09072361A0357|111 118|calcium
P09072361A0357|122 137|magnesium ratio
P09072361A0357|167 170|WKY
P09072361A0357|175 180|SHRSR
P09073074T0000|10 23|transcription
P09073074T0000|36 53|FGFR-3 psuedogene
P09073074T0000|67 79|developement
P09073582A0444|11 17|report
P09073582A0444|42 61|BglII-SmaI fragment
P09073582A0444|69 81|SSO activity
P09073582A0444|83 87|ori2
P09073582A0444|89 96|Kataoka
P09073582A0444|105 108|Mol
P09074508A0397|10 19|CD38 gene
P09074508A0397|34 39|exons
P09074508A0397|65 67|kb
P09074508A0397|81 87|genome
P09075739A0827|0 4|Type
P09075739A0827|8 22|splice pattern
P09075739A0827|35 42|exon U3
P09075739A0827|47 48|S
P09075739A0827|67 73|kidney
P09075739A0827|78 83|ovary
P09076336A0281|0 13|GH deficiency
P09076336A0281|56 65|diagnosis
P09076336A0281|90 103|constellation
P09076336A0281|129 137|findings
P09076336A0281|155 163|spectrum
P09076336A0281|180 194|GH sufficiency
P09076336A0281|205 217|GH secretion
P09077076A0219|9 17|CRP test
P09077108A0458|19 25|period
P09077108A0458|27 38|pleocytosis
P09077108A0458|64 70|levels
P09077108A0458|74 77|IgG
P09077108A0458|79 83|IL-6
P09077108A0458|85 94|TNF-alpha
P09077108A0458|100 104|PGE2
P09077108A0458|126 131|fluid
P09077437T0000|0 22|Recognition mechanisms
P09077437T0000|43 49|origin
P09077437T0000|53 61|phage f1
P09077437T0000|82 96|RNA polymerase
P09077438A0076|4 11|minimum
P09077438A0076|26 34|subunits
P09077438A0076|39 52|RNA synthesis
P09079625A0935|0 10|Syndecan-4
P09079625A0935|22 40|adhesion component
P09079625A0935|51 62|interaction
P09079625A0935|81 84|PKC
P09079625A0935|101 109|activity
P09079625A0935|113 118|sites
P09079625A0935|130 139|adhesions
P09079638A0883|4 16|3ASubE cells
P09079638A0883|28 33|CXCR2
P09079638A0883|39 47|mutation
P09079638A0883|51 58|Ser-346
P09079638A0883|78 85|alanine
P09079638A0883|95 103|mutation
P09079638A0883|116 122|serine
P09079638A0883|131 137|domain
P09079638A0883|172 180|response
P09079638A0883|184 190|ligand
P09079638A0883|204 205|%
P09079638A0883|241 257|ligand challenge
P09079650A0136|0 7|Members
P09079650A0136|15 26|MAPK family
P09079650A0136|53 69|response kinases
P09079650A0136|71 75|ERKs
P09079650A0136|79 85|p42/44
P09079650A0136|86 90|MAPK
P09079650A0136|98 103|c-Jun
P09079650A0136|119 126|kinases
P09079650A0136|128 132|JNKs
P09079650A0136|143 150|p38/Hog
P09079650A0136|153 168|protein kinases
P09079689A0472|0 4|MOP5
P09079689A0472|34 44|PAS domain
P09079689A0472|60 70|C terminus
P09079689A0472|96 100|cDNA
P09079689A0472|117 123|domain
P09079689A0472|145 158|reading frame
P09079817A0928|12 25|NO production
P09079817A0928|35 40|cells
P09079817A0928|65 71|levels
P09079817A0928|75 79|mRNA
P09079817A0928|93 106|NO synthetase
P09079878A0000|9 11|kb
P09079878A0000|19 51|Lactobacillus sake plasmid pCIM1
P09079878A0000|106 120|reading frames
P09079878A0000|122 126|ORFs
P09079878A0000|144 148|lasA
P09079878A0000|177 179|S.
P09079902A0713|9 12|Pra
P09079902A0713|56 71|pyruvate kinase
P09079902A0713|73 75|Pk
P09079902A0713|78 80|Pk
P09079902A0713|85 88|Pra
P09079902A0713|100 107|complex
P09079902A0713|129 132|Ndk
P09079902A0713|134 136|Pk
P09079902A0713|142 145|Pra
P09079902A0713|163 165|Pk
P09079902A0713|179 187|affinity
P09079902A0713|193 196|Pra
P09079902A0713|211 218|complex
P09079902A0713|235 238|Ndk
P09079904A0995|11 26|iron regulation
P09079904A0995|28 43|sodA expression
P09079904A0995|60 67|changes
P09079904A0995|71 83|DNA topology
P09079904A0995|95 108|coumermycin A
P09079904A0995|131 140|virulence
P09079904A0995|152 162|Bvg system
P09079915T0000|10 26|characterization
P09079915T0000|59 74|motility operon
P09079915T0000|99 125|consensus sigma70 promoter
P09079928A0525|0 14|M. leprae OxyR
P09079928A0525|54 61|binding
P09079928A0525|69 78|oxyR-ahpC
P09079928A0525|90 96|region
P09079928A0525|100 109|M. leprae
P09079928A1319|4 16|binding site
P09079928A1319|21 25|OxyR
P09079928A1319|37 43|P1oxyR
P09079928A1319|79 84|loops
P09079928A1319|97 107|expression
P09079928A1319|111 115|oxyR
P09079928A1319|127 135|bacteria
P09079928A1319|140 154|characteristic
P09079928A1319|162 178|LysR superfamily
P09080250A0212|15 20|study
P09080250A0212|61 85|p15E cDNA gene fragments
P09080250A0212|99 104|means
P09080250A0212|108 133|polymerase chain reaction
P09080250A0212|135 138|PCR
P09080250A0212|155 159|P815
P09080250A0212|178 187|P815/DTIC
P09080250A0212|189 201|tumour cells
P09080517A0215|12 20|patients
P09081389A1088|0 5|Grade
P09081389A1088|10 19|mucositis
P09081389A1088|37 38|%
P09081389A1088|46 52|cycles
P09081392A0174|36 52|salvage regimens
P09082335A0730|0 4|None
P09082335A0730|22 36|manifestations
P09082335A0730|69 74|means
P09083291A1378|6 15|TGF-beta1
P09083291A1378|51 61|expression
P09083291A1378|66 75|abundance
P09083291A1378|79 97|G1 phase cyclin D1
P09083291A1378|102 106|cdks
P09083291A1378|118 121|MCs
P09083291A1378|135 147|cyclin E-cdk
P09083291A1378|150 158|activity
P09083291A1378|193 208|phosphorylation
P09083291A1378|213 225|inactivation
P09083291A1378|229 232|pRb
P09083291A1378|236 244|G1 phase
P09083291A1378|249 259|transition
P09083291A1378|263 270|S phase
P09083345A0851|13 18|range
P09083345A0851|22 28|values
P09083345A0851|59 63|need
P09083345A0851|79 88|districts
P09083345A0851|106 112|values
P09083345A0851|116 121|SYPLR
P09083345A0851|127 134|respect
P09083345A0851|142 161|inter-relationships
P09083345A0851|187 202|characteristics
P09083345A0851|204 212|duration
P09083345A0851|216 224|symptoms
P09083345A0851|235 247|presentation
P09083345A0851|252 270|treatment efficacy
P09083563A0971|14 21|lesions
P09083563A0971|52 65|surface layer
P09083563A0971|70 91|leptomeningeal tissue
P09083563A0971|106 123|arachnoid vessels
P09083563A0971|168 173|fluid
P09083563A0971|208 214|toxins
P09083563A0971|242 247|fluid
P09083563A0971|255 264|B. cereus
P09084174A0667|5 13|fragment
P09084174A0667|42 53|nucleotides
P09084174A0667|57 61|leuB
P09084174A0667|90 103|dehydrogenase
P09084174A0667|105 108|asd
P09084174A0667|119 160|aspartate-beta-semialdehyde dehydrogenase
P09084174A0667|162 165|Asd
P09084174A0667|172 176|orfA
P09084174A0667|184 191|product
P09084174A0667|199 209|similarity
P09084174A0667|217 229|Asd proteins
P09084174A0667|235 245|Vibrio spp
P09084176A0601|16 24|activity
P09084176A0601|41 64|slot-blot hybridization
P09084176A0601|83 86|RNA
P09084176A0601|101 105|lacZ
P09084176A0601|107 126|M. smegmatis clones
P09084227A0833|0 11|Hovenitin I
P09084227A0833|20 30|ampelopsin
P09084227A0833|61 72|ingredients
P09084227A0833|87 96|fractions
P09084227A0833|115 123|medicine
P09084227A0833|158 166|activity
P09084227A0833|190 207|muscle relaxation
P09084227A0833|211 215|rats
P09084621A0374|0 13|Movement time
P09084621A0374|28 43|characteristics
P09084621A0374|76 85|magnitude
P09084621A0374|98 108|blood flow
P09084621A0374|121 126|areas
P09084621A0374|130 158|brain activity proportionate
P09084621A0374|162 166|task
P09084621A0374|171 189|movement variables
P09084621A2567|0 5|Areas
P09084621A2567|33 37|rCBF
P09084621A2567|66 78|motor cortex
P09084621A2567|99 105|sulcus
P09084621A2567|116 123|caudate
P09085842A0181|7 14|studies
P09085842A0181|42 50|U1 snRNP
P09085842A0181|74 85|splice site
P09085842A0181|89 117|protein/protein interactions
P09085842A0181|135 142|domains
P09085842A0181|150 164|U1-70K protein
P09085842A0181|169 176|SF2/ASF
P09085842A1559|29 40|27K protein
P09085842A1559|94 122|protein/protein interactions
P09085842A1559|146 167|phosphorylation state
P09085842A1559|183 200|pre-mRNA splicing
P09086268A0611|9 11|P7
P09086268A0611|36 45|particles
P09086268A0611|54 56|P7
P09086268A0611|61 70|particles
P09086268A0611|84 86|P2
P09086268A0611|88 102|RNA polymerase
P09086268A0611|108 110|P7
P09087430A1046|18 29|U1A peptide
P09087430A1046|50 53|BSA
P09087430A1046|75 78|PAP
P09088371T0000|0 13|Plasma levels
P09088371T0000|17 26|protein C
P09088371T0000|28 37|protein S
P09088371T0000|43 55|antithrombin
P09088371T0000|63 71|patients
P09088371T0000|90 101|haemorrhage
P09088416A0000|31 37|branch
P09088416A0000|55 64|occlusion
P09088416A0000|66 73|IBRBRAO
P09088416A0000|85 93|syndrome
P09088416A0000|111 129|migraine headaches
P09088416A0000|131 139|tinnitus
P09088416A0000|141 148|vertigo
P09088416A0000|150 162|hearing loss
P09088416A0000|178 184|branch
P09088416A0000|193 209|artery occlusion
P09088416A0000|221 229|etiology
P09088737T0000|23 45|thickness measurements
P09088737T0000|66 76|microscopy
P09088737T0000|95 99|CMTF
P09089093A0373|0 9|Sequences
P09089093A0373|38 46|CA genes
P09089093A0373|79 96|enhancer elements
P09089653A0615|12 20|plasmids
P09089653A0615|47 49|nt
P09089653A0615|53 56|UTR
P09089653A0615|60 64|exon
P09089653A0615|78 88|nt segment
P09089653A0615|104 112|sequence
P09089653A0615|124 143|luciferase activity
P09089653A0615|154 159|times
P09089653A0615|187 202|control plasmid
P09089653A1112|0 8|Analysis
P09089653A1112|25 37|interactions
P09089653A1112|50 70|DNase-I footprinting
P09089653A1112|90 96|region
P09089653A1112|100 110|protection
P09089653A1112|126 128|nt
P09090050A0419|31 45|sugar carriers
P09090050A0419|58 63|mouse
P09090054A0186|25 29|loci
P09090054A0186|62 67|genes
P09090054A0186|73 82|regulator
P09090054A0186|84 92|permease
P09090054A0186|97 114|alpha-glucosidase
P09090054A0186|130 134|gene
P09090054A0186|156 178|alpha-glucosidase gene
P09090054A0186|193 197|MAL1
P09090054A0186|220 227|cluster
P09090054A0186|237 242|genes
P09090592A0175|9 16|methods
P09090592A0175|30 37|control
P09090592A0175|42 63|activation fMR images
P09090592A0175|102 107|error
P09090592A0175|180 191|orientation
P09091010A1003|6 11|women
P09091010A1003|53 61|cytology
P09091010A1003|85 92|disease
P09091125A0161|20 25|cells
P09091125A0161|54 62|activity
P09091125A0161|66 74|alkaline
P09091125A0161|79 96|acid phosphatases
P09091125A0161|105 120|NBT-test values
P09091403T0001|0 8|Analysis
P09091403T0001|23 36|DNA sequences
P09091403T0001|54 60|intron
P09091403T0001|68 73|mouse
P09091403T0001|84 94|mts1 genes
P09091403T0001|104 108|site
P09091403T0001|113 131|microsatellite DNA
P09092493A0861|4 15|integration
P09092493A0861|23 31|VIP CyRE
P09092493A0861|39 47|Jak-Stat
P09092493A0861|52 75|AP-1 signaling pathways
P09092493A0861|100 108|proteins
P09092493A0861|129 138|mechanism
P09092493A0861|143 147|cell
P09092493A0861|171 180|signaling
P09092580A1354|6 13|studies
P09092580A1354|27 38|involvement
P09092580A1354|46 64|MAP kinase pathway
P09092580A1354|72 82|activation
P09092580A1354|96 101|cells
P09092580A1354|109 123|transmigration
P09092580A1354|140 145|sites
P09092636A0802|4 11|results
P09092636A0802|48 62|rad54-3 allele
P09092636A0802|78 91|recombination
P09092636A0802|118 142|DYZ3 satellite sequences
P09092636A0802|180 184|DYZ5
P09092636A0802|206 215|YAC clone
P09092675A0283|2 20|P22 R17 derivative
P09092675A0283|29 39|OcRNA site
P09092675A0283|41 48|P22 R17
P09092675A0283|50 51|A
P09092675A0283|56 57|U
P09092675A0283|89 98|infection
P09092675A0283|108 115|strains
P09093867T0000|13 30|Ac/Ds transposons
P09093867T0000|32 41|formation
P09093867T0000|43 52|structure
P09093867T0000|57 61|fate
P09094093A0578|5 9|site
P09094093A0578|31 39|TATA box
P09094093A0578|56 61|cells
P09094315A0541|8 13|study
P09094315A0541|36 46|regulation
P09094315A0541|56 64|activity
P09094315A0541|68 79|cyclin-Cdks
P09094671A1192|0 32|Candidate tumor suppressor genes
P09094671A1192|34 38|Mts1
P09094671A1192|40 48|p16INK4a
P09094671A1192|54 58|Mts2
P09094671A1192|60 68|p15INK4b
P09094671A1192|96 102|region
P09094671A1192|111 133|Southern blot analysis
P09094671A1192|149 158|deletions
P09094671A1192|183 187|gene
P09096229T0000|0 15|Excision repair
P09096229T0000|23 28|level
P09096229T0000|36 46|nucleotide
P09096229T0000|79 88|MFA2 gene
P09096229T0000|90 97|mapping
P09096229T0000|116 122|repair
P09096229T0000|142 148|strand
P09096229T0000|168 182|identification
P09096229T0000|201 206|rad16
P09096229T0000|240 257|control sequences
P09096234T0000|21 32|interaction
P09096234T0000|41 49|subunits
P09096234T0000|64 88|DNA sequence specificity
P09096234T0000|90 118|operator site discrimination
P09096234T0000|122 147|phage lambda cI repressor
P09096958A0000|24 29|panel
P09096958A0000|46 56|antibodies
P09096958A0000|78 92|platelet talin
P09096958A0000|96 112|Western blotting
P09096958A0000|121 134|precipitation
P09096958A0000|140 158|immunofluorescence
P09096958A0000|175 191|antibodies TA205
P09096958A0000|196 200|TD77
P09096958A0000|209 228|actin stress fibers
P09096958A0000|239 248|adhesions
P09096958A0000|262 275|cell motility
P09096958A0000|306 317|fibroblasts
P09098066A0119|5 10|locus
P09098066A0119|34 37|kbp
P09098066A0119|47 52|genes
P09098066A0119|86 99|proteins HMW1
P09098066A0119|104 108|HMW3
P09098066A0119|118 128|insertions
P09098066A0119|147 151|loss
P09098066A0119|161 169|proteins
P09098066A0119|205 214|phenotype
P09098066A0119|230 241|designation
P09098066A0119|266 271|locus
P09098066A0119|273 276|crl
P09098899A0000|0 9|Coliphage
P09098899A0000|14 15|B
P09098899A0000|30 42|acid protein
P09098899A0000|60 70|Ogr family
P09098899A0000|84 105|transcription factors
P09098899A0000|125 130|phage
P09098899A0000|186 203|zinc-finger motif
P09098899A0435|4 26|UV absorption spectrum
P09098899A0435|38 46|shoulder
P09098899A0435|54 56|nm
P09098899A0435|58 72|characteristic
P09098899A0435|76 83|CysS-Cd
P09098899A0435|104 131|charge-transfer transitions
P09098899A0435|141 174|difference absorption coefficient
P09098899A0435|181 194|acidification
P09098899A0435|196 209|delta epsilon
P09098899A0435|218 227|mM-1 cm-1
P09098899A0435|243 251|presence
P09098899A0435|257 259|Cd
P09098899A0435|260 265|Cys-S
P09098899A0435|268 274|center
P09099683A0000|0 21|Diacylglycerol kinase
P09099683A0000|23 26|DGK
P09099683A0000|39 45|levels
P09099683A0000|56 80|messenger diacylglycerol
P09099683A0000|84 89|cells
P09099683A0000|122 131|messenger
P09099683A0000|146 150|acid
P09099702A0000|31 38|cloning
P09099702A0000|46 50|germ
P09099702A0000|74 99|orphan receptor germ cell
P09099702A0000|108 114|factor
P09099702A0000|116 120|GCNF
P09099702A0000|122 125|RTR
P09099702A0692|13 21|sequence
P09099702A0692|29 36|conRTRE
P09099702A0692|60 64|RTRE
P09099702A0692|81 86|P2-RE
P09099702A0692|116 122|region
P09099702A0692|130 145|mouse protamine
P09099702A0692|148 152|gene
P09099702A0692|187 192|stage
P09099702A0692|196 211|spermatogenesis
P09099702A0692|215 218|RTR
P09099743A0585|19 31|purification
P09099743A0585|47 51|form
P09099743A0585|80 88|particle
P09099743A0585|103 110|mRNP3+4
P09099743A0585|131 143|polypeptides
P09099743A0585|168 180|polypeptides
P09099743A0585|194 197|kDa
P09099743A0585|204 211|doublet
P09099743A0585|223 226|kDa
P09099743A0585|245 254|nucleolin
P09099745A1446|7 16|complexes
P09099745A1446|46 52|weight
P09099745A1446|67 76|complexes
P09099745A1446|112 115|p21
P09099745A1446|120 123|p27
P09099745A1446|139 143|Cdk2
P09099745A1446|159 168|threonine
P09099745A1446|173 188|phosphorylation
P09099745A1446|208 217|mechanism
P09099745A1446|221 231|activation
P09099745A1446|235 248|cyclin E-Cdk2
P09099745A1446|272 297|CDK inhibitor association
P09099745A1446|333 348|phosphorylation
P09099745A1446|352 356|Cdk2
P09100202A0000|7 12|Class
P09100202A0000|19 38|Class II recessions
P09100202A0000|45 53|patients
P09100202A0000|108 130|tissue graft procedure
P09101085A0686|4 15|derivatives
P09101085A0686|34 44|cell lines
P09101085A0686|62 72|expression
P09101085A0686|80 95|p27Kip1 protein
P09101085A0686|100 110|inhibition
P09101085A0686|114 125|cell growth
P09101910A0394|18 27|mortality
P09101910A0394|35 43|patients
P09101910A0394|51 52|%
P09101910A0394|58 67|mortality
P09101910A0394|71 79|patients
P09101910A0394|94 99|years
P09101910A0394|107 108|%
P09102113A0739|14 30|failure patients
P09102113A0739|67 73|causes
P09102113A0739|83 92|frequency
P09102113A0739|106 113|disease
P09102113A0739|130 135|death
P09102113A0739|157 158|%
P09103382T0000|8 23|FIGO definition
P09103382T0000|36 51|cancer stage IA
P09103382T0000|55 63|critique
P09104816A0610|4 10|effect
P09104816A0610|14 17|Vpu
P09104816A0610|21 26|class
P09104816A0610|29 39|biogenesis
P09104816A0610|61 67|detail
P09104816A0610|103 117|vaccinia virus
P09104816A0610|119 121|VV
P09105042A1497|5 10|study
P09105042A1497|30 39|phenotype
P09105042A1497|43 64|myofibrillar disarray
P09105042A1497|73 85|HCM patients
P09105042A1497|119 128|mutations
P09105042A1497|160 167|failure
P09105042A1497|182 188|myosin
P09105042A1497|195 208|chain protein
P09105042A1497|237 247|sarcomeres
P09105042A1497|279 285|effect
P09105042A1497|322 328|stress
P09105042A1497|342 359|beta MHC function
P09105363A0636|20 26|plasma
P09105363A0636|34 55|emission spectroscopy
P09105363A0636|83 110|tissue silicon measurements
P09105530A0000|3 14|egg protein
P09105530A0000|16 24|lysozyme
P09105530A0000|74 92|cheese preparation
P09106057A0000|2 8|method
P09106057A0000|30 43|determination
P09106057A0000|50 58|N-methyl
P09106057A0000|60 69|N-ethyl-8
P09106057A0000|73 92|anhydroerythromycin
P09106057A0000|111 116|EM523
P09106057A0000|135 146|metabolites
P09106057A0000|156 162|plasma
P09106057A0000|167 172|urine
P09106057A0000|222 236|chromatography
P09106057A0000|238 242|HPLC
P09106057A0000|249 266|chemiluminescence
P09106057A0000|268 270|CL
P09106057A0000|272 281|detection
P09108029A0399|27 35|activity
P09108029A0399|39 56|activator protein
P09108029A0399|60 64|AP-1
P09108029A0399|83 100|DNA repair enzyme
P09108029A0399|102 114|redox factor
P09108029A0399|118 123|Ref-1
P09108029A0399|150 167|DNA repair enzyme
P09108029A0399|169 184|AP endonuclease
P09108038A1128|10 20|LRR domain
P09108038A1128|40 46|domain
P09108038A1128|48 55|Acan125
P09108038A1128|64 84|C. elegans homologue
P09108038A1128|100 106|family
P09108038A1128|123 139|binding proteins
P09108207A0306|13 26|participation
P09108207A0306|49 73|oropharyngeal irritation
P09108279A0431|4 12|capacity
P09108279A0431|23 29|8-OxoG
P09108279A0431|61 69|extracts
P09108279A0431|87 99|ogg1 strains
P09108279A0431|108 126|34mer DNA fragment
P09108279A0431|147 161|8-OxoG residue
P09108279A0431|176 184|cytosine
P09108279A0431|186 194|8-OxoG/C
P09108279A0431|201 210|substrate
P09108451A0160|0 7|Results
P09108451A0160|27 39|laboratories
P09108451A0160|60 66|UCN-01
P09108451A0160|88 109|G1-phase accumulation
P09108451A0160|127 143|tumor cell lines
P09110176A0890|0 8|Northern
P09110176A0890|13 28|RT-PCR analysis
P09110176A0890|32 48|Ube3a expression
P09110176A0890|52 65|mouse tissues
P09110176A0890|71 78|animals
P09110176A0890|116 122|disomy
P09110176A0890|172 182|expression
P09110176A0890|203 210|animals
P09110176A0890|235 243|evidence
P09110176A0890|266 276|expression
P09110176A0890|287 292|locus
P09111004A0732|16 23|effects
P09111004A0732|44 55|Xaa residue
P09111004A0732|68 101|phosphorylation motif Thr-Xaa-Tyr
P09111004A0732|117 123|length
P09111004A0732|127 166|L12 influence p38 substrate specificity
P09111004A0732|181 187|length
P09111004A0732|191 194|L12
P09111004A0732|209 213|role
P09111004A0732|229 248|autophosphorylation
P09111048X0000|25 40|mRNA transcript
P09111048X0000|76 97|nitric-oxide synthase
P09111048X0000|99 113|mRNA diversity
P09111048X0000|133 138|theme
P09111048X0000|151 172|nitric-oxide synthase
P09111048X0000|174 178|nNOS
P09111048X0000|180 195|gene expression
P09111048X0000|207 220|cells/tissues
P09111059A0327|23 29|domain
P09111059A0327|35 46|homeodomain
P09111059A0327|87 98|specificity
P09111059A0327|102 105|DNA
P09111309A0674|0 14|Cotransfection
P09111309A0674|18 23|Ets-2
P09111309A0674|28 31|p44
P09111309A0674|50 57|protein
P09111309A0674|59 62|MAP
P09111309A0674|64 89|kinase expression vectors
P09111309A0674|111 137|HB-EGF promoter activation
P09111309A0674|141 149|response
P09111309A0674|153 163|deltaRaf-1
P09111309A0674|164 166|ER
P09111314A0970|0 9|Cyclin D1
P09111314A0970|38 42|cdk4
P09111314A0970|60 81|184A1L5R cell lysates
P09111314A1243|4 14|importance
P09111314A1243|36 46|regulation
P09111314A1243|50 58|p15INK4B
P09111314A1243|62 70|TGF-beta
P09111314A1243|92 103|observation
P09111314A1243|131 139|184A1L5R
P09111314A1243|154 168|p15 transcript
P09111314A1243|180 196|p15INK4B protein
P09111314A1243|244 269|cyclin D1-cdk association
P09111314A1243|274 291|kinase activation
P09111331A0119|4 16|Rlm1 protein
P09111331A0119|20 26|member
P09111331A0119|34 49|MADS box family
P09111331A0119|53 74|transcription factors
P09111331A0119|76 85|functions
P09111331A0119|100 104|Mpk1
P09111331A0119|112 119|pathway
P09111340A0240|23 31|elements
P09111340A0240|44 54|c-myc mRNA
P09111340A0240|59 73|downregulation
P09111340A0240|81 91|myogenesis
P09111340A0240|115 126|C2C12 cells
P09111340A0240|139 148|myc genes
P09111340A0240|161 166|genes
P09111340A0240|184 197|myc sequences
P09111340A0240|222 238|beta-globin gene
P09111340A0240|259 292|chloramphenicol acetyltransferase
P09111340A0240|294 297|CAT
P09111340A0240|299 303|gene
P09111367A1098|13 24|experiments
P09111367A1098|30 33|32D
P09111367A1098|56 65|p53 cells
P09111367A1098|89 105|tal-1 expression
P09111367A1098|124 135|temperature
P09111367A1098|167 173|effect
P09111367A1098|198 207|apoptosis
P09111367A1098|219 224|tal-1
P09111367A1098|239 245|effect
P09111367A1098|261 270|integrity
P09111367A1098|278 300|cell cycle checkpoints
P09111367A1098|308 317|host cell
P09111367A1098|335 340|c-myc
P09111367A1098|351 360|oncogenes
P09111367A1098|362 367|tal-1
P09111367A1098|375 386|experiments
P09111367A1098|409 422|tal-1 effects
P09111367A1098|468 494|heterodimerization domains
P09111367A1098|506 518|N-terminally
P09111367A1098|529 542|tal-1 variant
P09111367A1098|544 546|M3
P09111367A1098|561 566|T-ALL
P09111367A1098|577 582|cells
P09111367A1098|594 601|effects
P09111367A1098|619 626|protein
P09111863A0743|4 14|likelihood
P09111863A0743|29 35|region
P09111863A0743|39 48|deletions
P09111863A0743|65 81|tumor suppressor
P09111863A0743|106 117|coincidence
P09111863A0743|126 132|region
P09111863A0743|140 159|chromosome fragment
P09111863A0743|172 186|tumorigenicity
P09111863A0743|192 204|introduction
P09111863A0743|208 219|tumor cells
P09112400A1155|12 20|activity
P09112400A1155|46 54|addition
P09112400A1155|58 67|forskolin
P09112400A1155|88 93|cells
P09112589A0078|32 39|pattern
P09114972A1366|5 14|induction
P09114972A1366|18 21|SOS
P09114972A1366|23 32|viability
P09115242A0934|24 34|supershift
P09115242A0934|40 66|promoter deletion analyses
P09115242A0934|79 83|role
P09115242A0934|111 123|protein-beta
P09115242A0934|125 135|C/EBP-beta
P09115242A0934|137 149|binding site
P09115242A0934|188 201|transcription
P09115242A0934|205 218|collagenase-1
P09115242A0934|232 237|cells
P09115247A2069|0 25|11-Aminoundecanoyl-SK-NH2
P09115247A2069|30 55|11-aminoundecanoyl-SH-NH2
P09115247A2069|80 94|alkyl backbone
P09115247A2069|123 131|distance
P09115247A2069|146 154|elements
P09115247A2069|168 179|recognition
P09115247A2069|194 200|enzyme
P09115247A2069|219 223|site
P09115247A2069|249 260|amino group
P09115247A2069|264 277|beta-hydroxyl
P09115247A2069|286 305|epsilon-amino group
P09115247A2069|312 321|imidazole
P09115265A1160|22 33|CCCC module
P09115265A1160|77 83|domain
P09115265A1160|101 128|transcription factor GATA-1
P09115279A0345|0 20|Cdc2 co-precipitates
P09115279A0345|26 30|Pch1
P09115279A0345|34 36|S.
P09115279A0345|43 55|cell lysates
P09115279A0345|66 70|Cdc2
P09115279A0345|102 109|partner
P09115279A0345|115 126|Pch1 kinase
P09115357A0073|26 35|mechanism
P09115357A0073|45 57|availability
P09115357A0073|74 80|assays
P09115357A0073|96 124|immunoglobulin hypermutation
P09115357A0073|147 158|development
P09115357A0073|162 177|culture systems
P09115357A0073|182 203|hypermutating B cells
P09115357A0073|219 228|screening
P09115357A0073|233 244|individuals
P09115357A0073|262 269|process
P09115365A0000|0 10|Expression
P09115365A0000|24 42|heat shock protein
P09115365A0000|46 50|gene
P09115365A0000|52 57|hsp70
P09115365A0000|81 86|kinds
P09115365A0000|90 96|stress
P09115365A0000|104 113|oncogenes
P09115395A0478|9 17|proteins
P09115395A0478|79 86|mitosis
P09115395A0478|88 110|epithelial-microtubule
P09115395A0478|122 133|protein-115
P09115395A0478|135 140|Oct91
P09115395A0478|142 166|Elongation factor 1gamma
P09115395A0478|168 172|BRG1
P09115395A0478|187 199|protein L18A
P09115395A0478|222 230|proteins
P09115395A0478|250 255|roles
P09115395A0478|259 266|mitosis
P09115395A0478|268 290|epithelial-microtubule
P09115395A0478|302 313|protein-115
P09115395A0478|341 345|Cdc5
P09115395A0478|347 370|innercentrosome protein
P09115395A0478|372 376|BRG1
P09115395A0478|385 401|RNA helicase WM6
P09115395A0478|428 449|transcription factors
P09115395A0478|451 455|BRG1
P09115395A0478|466 482|co-factor 2alpha
P09115395A0478|484 489|Oct91
P09115395A0478|491 493|S.
P09115395A0478|500 504|Cdc5
P09115395A0478|506 511|HoxD1
P09115395A0478|513 517|Sox3
P09115395A0478|519 524|Vent2
P09115395A0478|534 542|isoforms
P09115395A0478|546 551|Xbr1b
P09115989A0993|25 33|location
P09115989A0993|35 55|psoralen cross-links
P09115989A0993|75 80|steps
P09115989A0993|88 106|initiation process
P09117345A0945|0 10|Activation
P09117345A0945|14 19|alpha
P09117345A0945|22 26|beta
P09117345A0945|34 40|TS2/16
P09117345A0945|67 78|protrusions
P09117345A0945|83 97|cell migration
P09117345A0945|121 128|pattern
P09117345A0945|132 147|phosphorylation
P09118196A0281|0 11|Performance
P09118196A0281|39 53|National Adult
P09118196A0281|76 82|NART-R
P09118196A0281|92 110|Vocabulary subtest
P09118196A0281|120 161|Wechsler Adult Intelligence Scale-Revised
P09118196A0281|163 169|WAIS-R
P09118196A0281|185 197|correlations
P09118196A0281|203 208|level
P09118196A0281|212 221|education
P09118664A1734|0 12|L-canavanine
P09118664A1734|26 35|inhibitor
P09118664A1734|60 74|oxide synthase
P09118664A1734|104 120|filling pressure
P09118664A1734|147 153|return
P09118664A1734|167 177|conditions
P09118704A0771|0 7|RESULTS
P09118704A0771|19 27|patients
P09118704A0771|52 64|chemotherapy
P09118704A0771|69 74|G-CSF
P09118704A0771|83 84|%
P09118704A0771|88 109|% confidence interval
P09118704A0771|111 113|CI
P09118704A0771|128 129|%
P09118704A0771|176 194|bleomycin toxicity
P09119031A1036|14 40|holoenzyme RNA polymerases
P09119031A1036|77 84|mutants
P09119031A1036|104 123|core RNA polymerase
P09119031A1036|125 140|alpha2beta beta
P09119031A1036|178 186|activity
P09119031A1036|190 200|comparison
P09119031A1036|208 214|enzyme
P09119031A1036|236 248|sigma factor
P09119112A1350|6 10|data
P09119112A1350|33 38|model
P09119112A1350|48 54|GATA-5
P09119112A1350|109 117|function
P09119112A1350|135 140|heart
P09119112A1350|145 149|lung
P09119391A0870|11 19|sequence
P09119391A0870|30 37|protein
P09119391A0870|45 56|amino acids
P09119391A0870|109 125|protein sequence
P09119391A0870|135 140|GPT-1
P09121424A0296|38 50|Swi3 homolog
P09121424A0296|52 56|Swh3
P09121424A0296|70 78|evidence
P09121424A0296|103 110|complex
P09121424A0296|123 130|homolog
P09121424A0296|132 136|Sthl
P09121430A0132|0 3|Shc
P09121430A0132|37 51|protein kinase
P09121430A0132|53 57|MAPK
P09121430A0132|77 84|complex
P09121430A0132|90 94|Grb2
P09121430A0132|117 125|tyrosine
P09121430A0132|127 128|Y
P09121430A0132|130 137|residue
P09121430A1075|3 11|contrast
P09121430A1075|13 26|Y239/240F Shc
P09121430A1075|36 45|Y317F Shc
P09121430A1075|71 84|c-myc message
P09121432A0000|4 15|Ras guanine
P09121432A0000|35 42|protein
P09121432A0000|68 74|switch
P09121432A0000|78 88|signalling
P09121432A0000|120 127|kinases
P09121433A0463|13 17|Rlm1
P09121433A0463|22 26|Smp1
P09121433A0463|57 70|specificities
P09121433A0463|72 76|Rlm1
P09121433A0463|97 108|specificity
P09121433A0463|112 116|MEF2
P09121433A0463|118 121|CTA
P09121433A0463|122 125|T/A
P09121433A0463|126 130|4TAG
P09121433A0463|138 142|SMP1
P09121433A0463|165 183|consensus sequence
P09121433A0463|185 192|ACTACTA
P09121433A0463|193 196|T/A
P09121433A0463|197 201|4TAG
P09121435A1183|0 7|Domains
P09121435A1183|20 21|B
P09121435A1183|39 47|assembly
P09121435A1183|55 73|TFIIIB-DNA complex
P09121435A1183|92 112|protein footprinting
P09121452A0538|0 25|Domain switch experiments
P09121452A0538|38 57|C/EBP beta proteins
P09121452A0538|80 94|leucine zipper
P09121452A0538|102 119|activation domain
P09121452A0538|123 134|C/EBP alpha
P09121452A0538|163 175|2D5 promoter
P09121452A0538|231 239|promoter
P09121452A0538|264 274|C/EBP site
P09121454A1328|12 22|phenotypes
P09121454A1328|26 30|bur6
P09121454A1328|35 39|bur3
P09121454A1328|41 45|mot1
P09121454A1328|47 56|mutations
P09121454A1328|70 75|Bur6p
P09121454A1328|80 85|Mot1p
P09121454A1328|119 128|functions
P09121454A1328|147 155|activity
P09121454A1328|171 194|transcription machinery
P09121476T0000|0 5|PRH75
P09121476T0000|31 37|member
P09121476T0000|45 68|DEAD-box protein family
P09121476T0000|81 87|plants
P09121774A0611|6 16|activities
P09121774A0611|38 49|stimulation
P09121774A0611|53 64|cell growth
P09121774A0611|90 97|members
P09121774A0611|105 122|MAP kinase family
P09121774T0000|2 6|role
P09121774T0000|21 31|GTPase Rac
P09121774T0000|35 47|polyomavirus
P09121774T0000|74 84|activation
P09121774T0000|92 114|serum response element
P09121774T0000|122 141|cell transformation
P09121998A0663|14 20|curves
P09121998A0663|38 44|region
P09121998A0663|48 56|interest
P09121998A0663|74 84|subjection
P09121998A0663|111 121|procedures
P09121998A0663|140 144|mean
P09121998A0663|153 165|transit time
P09121998A0663|167 170|MTT
P09121998A0663|183 191|fraction
P09121998A0663|199 208|test meal
P09121998A0663|225 232|stomach
P09121998A0663|242 245|min
P09121998A0663|247 250|F90
P09122168A1427|5 10|study
P09122168A1427|29 42|demonstration
P09122168A1427|48 52|role
P09122168A1427|57 68|G betagamma
P09122168A1427|105 118|translocation
P09122168A1427|122 126|GRK2
P09122168A1427|131 135|GRK3
P09122168A1427|158 164|system
P09122168A1427|182 201|isoform specificity
P09122168A1427|209 220|interaction
P09122168A1427|230 240|components
P09122176A0970|4 11|results
P09122176A0970|38 48|repression
P09122176A0970|56 65|hMGP gene
P09122176A0970|76 83|binding
P09122176A0970|96 103|RAR/RXR
P09122176A0970|124 143|RA response element
P09122198A0478|0 15|Point mutations
P09122198A0478|28 45|tyrosine residues
P09122198A0478|65 71|domain
P09122198A0478|79 87|receptor
P09122198A0478|126 137|conclusions
P09122215A0335|20 26|method
P09122215A0335|91 100|mutations
P09122215A0335|108 112|gene
P09122215A0335|116 124|interest
P09123055T0000|15 21|injury
P09123055T0000|29 41|preservation
P09123055T0000|51 57|livers
P09123055T0000|63 65|UW
P09123055T0000|70 82|HTK solution
P09123787A0486|35 44|responses
P09123787A0486|67 78|R1 response
P09123787A0486|86 122|orbicularis oculi muscle ipsilateral
P09123787A0486|130 134|side
P09123787A0486|138 149|stimulation
P09123787A0486|168 176|response
P09123787A0486|190 192|R2
P09123787A0486|211 213|Rc
P09123787A0486|228 239|R3 response
P09123787A0486|260 284|orbicularis oculi muscle
P09124054A1164|4 13|prognosis
P09124054A1164|23 31|patients
P09124054A1164|45 50|ABSCT
P09124054A1164|92 100|patients
P09124054A1164|127 134|therapy
P09126487A1399|7 10|Hum
P09126622A0466|4 21|pigment intensity
P09126622A0466|40 48|colonies
P09126622A0466|53 64|appressoria
P09126622A0466|68 85|CAL transformants
P09126622A0466|119 123|type
P09128730A0000|9 24|decarboxylation
P09128730A0000|28 45|Malonomonas rubra
P09128730A0000|59 68|formation
P09128730A0000|72 81|malonyl-S
P09128730A0000|83 103|acyl-carrier protein
P09128730A0000|110 118|acetyl-S
P09128730A0000|120 140|acyl-carrier protein
P09128730A0000|146 154|malonate
P09128730A0000|156 172|carboxyltransfer
P09128730A0000|178 192|biotin protein
P09128730A0000|201 216|decarboxylation
P09128730A0000|236 247|delta mu Na
P09128730A0000|249 259|generation
P09129147A0644|4 24|Jem peptide sequence
P09129147A0644|34 48|leucine-zipper
P09129147A0644|63 68|motif
P09129147A0644|82 90|homology
P09129147A0644|94 101|Fos/Jun
P09129147A0644|106 123|ATF/CREB proteins
P09129147A0644|145 166|phosphorylation sites
P09130595A0478|19 26|cloning
P09130595A0478|34 41|protein
P09130595A0478|56 69|enhancer site
P09130700A0676|8 15|support
P09130700A0676|29 40|interaction
P09130700A0676|44 49|Tub4p
P09130700A0676|51 57|Spc98p
P09130700A0676|62 68|Spc97p
P09130700A0676|84 92|toxicity
P09130700A0676|103 123|SPC97 overexpression
P09130700A0676|147 164|co-overexpression
P09130700A0676|168 172|TUB4
P09130700A0676|176 181|SPC98
P09130718A0497|0 9|Sequences
P09130718A0497|36 46|expression
P09130718A0497|50 54|sid1
P09130718A0497|79 88|bp region
P09130718A0497|109 111|kb
P09130718A0497|128 131|ATG
P09130720A0417|10 16|screen
P09130720A0417|28 35|mutants
P09130720A0417|43 61|branch site region
P09130720A0417|77 86|positions
P09130720A0417|104 120|TACTAAC sequence
P09130720A0417|139 157|intron recognition
P09131139T0000|0 11|Implication
P09131139T0000|15 18|PAF
P09131139T0000|23 38|acetylhydrolase
P09131139T0000|40 46|PAF-AH
P09131139T0000|48 56|activity
P09131139T0000|72 79|disease
P09132011A0298|0 10|Comparison
P09132011A0298|18 30|p50 sequence
P09132011A0298|47 55|proteins
P09132011A0298|67 77|% homology
P09132011A0298|111 118|protein
P09132011A0298|125 135|% homology
P09132011A0298|141 178|Drosophila cell cycle control protein
P09132011A0298|180 183|cdc
P09132057A0559|2 13|polypeptide
P09132057A0559|29 32|NTS
P09132057A0559|41 54|reading frame
P09132057A0559|59 78|sequence similarity
P09132057A0559|96 102|domain
P09132057A0559|114 138|receptor protein kinases
P09132057A0559|144 150|plants
P09132057A0559|165 183|S-receptor kinases
P09132057A0559|202 211|rejection
P09132057A0559|215 226|self-pollen
P09132057A0559|230 246|Brassica species
P09132057A0559|255 271|Pto gene product
P09132057A0559|275 281|tomato
P09132057A0559|296 306|resistance
P09132057A0559|322 330|pathogen
P09132061A0828|4 7|atp
P09132061A0828|14 17|atp
P09132061A0828|20 25|types
P09132061A0828|29 43|cDNA sequences
P09132061A0828|91 105|isoperoxidases
P09132061A0828|133 143|peroxidase
P09132061A0828|153 157|ESTs
P09133122A0656|11 22|information
P09133122A0656|51 60|sequences
P09133122A0656|76 91|video sequences
P09133122A0656|93 107|x-ray analysis
P09133122A0656|109 119|angiograms
P09133122A0656|148 155|program
P09135066A0653|42 46|Mek1
P09135066A0653|62 69|p96h2bk
P09135066A0653|77 84|absence
P09135066A0653|98 101|Ras
P09135149A0000|34 42|activity
P09135149A0000|67 77|Cdc2/Cdc13
P09135149A0000|95 101|kinase
P09135149A0000|118 122|Wee1
P09135149A0000|127 148|Mik1 tyrosine kinases
P09135149A0000|167 172|Cdc25
P09135149A0000|177 203|Pyp3 tyrosine phosphatases
P09135772T0000|9 17|response
P09135772T0000|40 46|roller
P09135772T0000|72 77|foods
P09135772T0000|88 96|subjects
P09135928A0912|14 20|mmol/l
P09135928A0912|22 23|P
P09135928A0912|46 58|BP responses
P09135928A0912|74 88|norepinephrine
P09135928A0912|93 104|angiotensin
P09135928A0912|137 150|glibenclamide
P09135928A0912|159 168|metformin
P09135928A0912|170 171|P
P09135928A0912|183 184|P
P09136015A0529|4 14|sequencing
P09136015A0529|27 33|copies
P09136015A0529|66 73|cluster
P09136015A0529|93 100|pattern
P09136015A0529|104 119|diversification
P09136080A1469|4 11|results
P09136080A1469|26 41|DNA methylation
P09136080A1469|43 62|chromatin structure
P09136080A1469|68 83|transactivation
P09136080A1469|90 98|Sp1 site
P09136080A1469|135 145|expression
P09136080A1469|169 176|lineage
P09136080A1469|186 190|gene
P09138076A1099|3 28|gel mobility shift assays
P09138076A1099|30 37|factors
P09138076A1099|57 65|extracts
P09138076A1099|94 104|osteoblast
P09138076A1099|114 136|oligonucleotide probes
P09138076A1099|152 157|E-box
P09138076A1099|164 169|E-box
P09138076A1099|172 180|elements
P09138492A0806|0 15|Laboratory exam
P09138492A0806|17 20|IDR
P09138492A0806|28 38|tuberculin
P09138492A0806|58 75|chest radiography
P09138492A0806|98 112|calcifications
P09138492A0806|114 122|ORL exam
P09138492A0806|131 136|tumor
P09138492A0806|144 148|foot
P09138492A0806|156 166|epiglottis
P09138492A0806|191 195|exam
P09138492A0806|221 241|epidermoid carcinoma
P09139665A0784|22 36|PhLP complexes
P09139665A0784|63 73|Gbetagamma
P09139694A0789|0 9|CTF1alpha
P09139694A0789|73 83|palindrome
P09139694A0789|86 98|DNA fragment
P09139694A0789|110 120|palindrome
P09139694A0789|133 143|palindrome
P09139694A0789|146 159|DNA fragments
P09139694A0789|181 188|binding
P09139694A0789|192 201|CTF1alpha
P09139694A0789|205 215|palindrome
P09139721A0183|0 9|Cyclin G2
P09139721A0183|44 50|system
P09139721A0183|69 87|tolerance subjects
P09139721A0183|102 113|lymphocytes
P09139721A0183|126 135|selection
P09139721A0183|147 155|deletion
P09139721A0183|160 169|apoptosis
P09139737A0000|19 27|protease
P09139737A0000|38 45|release
P09139737A0000|66 74|segments
P09139737A0000|78 84|sterol
P09139737A0000|112 120|proteins
P09139737A0000|122 128|SREBPs
P09139737A0000|135 149|cell membranes
P09139737A0000|186 193|nucleus
P09139737A0000|211 224|transcription
P09139737A0000|228 233|genes
P09139737A0000|250 256|uptake
P09139737A0000|261 270|synthesis
P09139737A0000|274 285|cholesterol
P09139737A0000|296 301|acids
P09139892A1150|24 28|orfX
P09139892A1150|33 46|vfr promoters
P09139892A1150|78 89|orientation
P09139892A1150|119 130|orientation
P09139892A1150|138 142|dorf
P09139892A1150|147 160|crp promoters
P09139910A0350|0 17|Sequence analysis
P09139910A0350|28 40|PCR products
P09139910A0350|55 63|presence
P09139910A0350|91 104|DNA fragments
P09139910A0350|138 142|nifV
P09139910A0350|162 168|probes
P09139910A0350|187 207|clone XbaI fragments
P09139910A0350|215 218|kbp
P09139910A0350|220 225|pOST4
P09139910A0350|235 238|kbp
P09139910A0350|240 245|pOST2
P09139910A1572|3 11|contrast
P09139910A1572|17 32|Anabaena strain
P09139910A1572|38 47|leuA gene
P09139910A1572|71 84|nifV mutation
P09139910A1572|88 93|R229I
P09140079A2528|9 15|effect
P09140079A2528|40 43|TRs
P09140079A2528|53 56|TRE
P09140474T0000|3 16|leishmaniasis
P09140474T0000|32 38|island
P09140474T0000|42 49|Minorca
P09140474T0000|51 56|Spain
P09140474T0000|76 80|case
P09140474T0000|97 102|years
P09140474T0000|106 113|Minorca
P09142146A0887|0 7|RESULTS
P09142146A0887|23 35|PAF blockade
P09142146A0887|46 55|mortality
P09142146A0887|62 68|trauma
P09142146A0887|78 94|WEB-2086 animals
P09142146A0887|109 124|vehicle animals
P09142146A0887|126 127|p
P09142146A0887|158 163|index
P09142146A0887|171 179|delivery
P09142146A0887|186 191|hours
P09142146A0887|193 194|p
P09143328A1002|5 12|finding
P09143328A1002|26 33|example
P09143328A1002|37 48|utilization
P09143328A1002|69 88|dinucleotide primer
P09143328A1002|95 109|RNA polymerase
P09143465A0838|5 7|T1
P09143465A0838|12 26|dual-T1 images
P09143465A0838|55 68|image quality
P09143465A0838|70 72|IQ
P09143465A0838|90 95|scale
P09144165A0614|5 10|model
P09144165A0614|26 33|complex
P09144165A0614|39 46|segment
P09144165A0614|50 54|NFAT
P09144165A0614|63 67|AP-1
P09144165A0614|75 92|Rel insert region
P09144165A0614|94 97|RIR
P09144165A0614|102 109|feature
P09144165A0614|134 150|hypervariability
P09144165A0614|154 158|size
P09144165A0614|166 174|sequence
P09144165A0614|183 190|members
P09144165A0614|198 229|Rel transcription factor family
P09144165A1275|26 34|NFAT RIR
P09144165A1275|59 63|role
P09144165A1275|67 82|DNA recognition
P09144165A1275|99 106|binding
P09144165A1275|110 143|AP-1 family transcription factors
P09144195A1051|10 21|association
P09144195A1051|25 38|PS1 fragments
P09144195A1051|64 70|cycles
P09144195A1051|74 107|phosphorylation/dephosphorylation
P09144195A1051|115 122|PS1 CTF
P09144770A0906|5 14|conformer
P09144770A0906|26 30|Type
P09144770A0906|33 42|beta-turn
P09144770A0906|73 81|contacts
P09144770A0906|91 113|FKBP12 binding surface
P09144958A0047|5 12|protein
P09144958A0047|27 33|region
P09144958A0047|41 49|promoter
P09144958A0047|56 67|Arabidopsis
P09144958A0047|85 113|chlorophyll a/b protein gene
P09144958A0047|115 120|Lhcb1
P09144958A0047|151 161|regulation
P09144958A0047|165 176|phytochrome
P09146027A0809|2 9|patient
P09146027A0809|13 20|Group B
P09146027A0809|32 43|athetoid CP
P09146027A0809|49 59|spasticity
P09146027A0809|87 92|trunk
P09146027A0809|97 101|neck
P09146071T0001|9 17|movement
P09146071T0001|36 40|limb
P09146071T0001|46 50|case
P09146071T0001|64 82|pontine hemorrhage
P09147420A0623|34 46|HCMV IE1/IE2
P09147420A0623|79 88|HIV-1 LTR
P09147420T0000|0 3|TAR
P09147420T0000|24 39|transactivation
P09147420T0000|43 46|HIV
P09147420T0000|61 67|repeat
P09147420T0000|75 86|Tat protein
P09147420T0000|94 102|presence
P09147420T0000|112 135|cytomegalovirus IE1/IE2
P09147788A0458|12 33|chain enzyme activity
P09147832A0174|0 8|Children
P09147832A0174|11 22|temperament
P09147832A0174|36 49|socialization
P09147832A0174|53 57|Time
P09147832A0174|61 62|n
P09147832A0174|79 84|years
P09147832A0174|102 112|predictors
P09147832A0174|123 133|conscience
P09147832A0174|182 190|measures
P09148770A0977|9 12|Csk
P09148770A0977|41 56|phosphoproteins
P09148770A0977|98 112|Csk SH2 domain
P09148903A1715|10 17|studies
P09148903A1715|43 53|activation
P09148903A1715|57 75|HIV-1 LTR activity
P09148903A1715|105 118|translocation
P09148903A1715|126 156|NF-kappaB transcription factor
P09148903A1715|179 214|IkappaBalpha serine phosphorylation
P09148903A1715|219 230|degradation
P09148903A1715|284 291|pathway
P09148929A0372|4 6|P1
P09148929A0372|15 20|clone
P09148929A0372|40 57|plasmid subclones
P09148929A0372|105 117|organization
P09148929A0372|125 135|Ctpct gene
P09148935A0805|14 32|c-Src PTK activity
P09148935A0805|54 73|type FAK expression
P09148935A0805|97 107|activation
P09148935A0805|111 115|ERK2
P09148935A0805|131 141|expression
P09148935A0805|149 182|c-Src binding site Phe-397 mutant
P09148935A0805|186 189|FAK
P09149825A0151|16 22|cement
P09149825A0151|24 38|4-META/MMA-TBB
P09149825A0151|46 51|resin
P09149825A0151|83 93|properties
P09149825A0151|99 110|bone cement
P09149929A0750|25 36|predictions
P09149929A0750|56 64|children
P09149929A0750|79 86|control
P09149929A0750|92 104|homesickness
P09149929A0750|109 119|separation
P09149929A0750|148 155|control
P09150334A0559|5 11|sample
P09150334A0559|78 81|min
P09150334A0559|88 96|sampling
P09150566A0316|19 23|role
P09150566A0316|27 33|grains
P09150566A0316|41 50|formation
P09150566A0316|54 71|complex molecules
P09150566A0316|98 104|clouds
P09150595A0225|9 18|elicitors
P09150595A0225|41 49|reaction
P09150595A0225|51 53|HR
P09150595A0225|67 82|E. chrysanthemi
P09150595A0225|84 93|HarpinEch
P09150595A0225|99 111|E. amylovora
P09150595A0225|113 121|HarpinEa
P09150595A0225|143 150|protein
P09150595A0225|178 193|signal sequence
P09150595A0225|240 246|domain
P09150595T0000|10 26|characterization
P09150595T0000|31 41|expression
P09150595T0000|49 80|Erwinia carotovora hrpNEcc gene
P09150595T0000|99 107|elicitor
P09150595T0000|130 138|reaction
P09150728A0596|4 8|mRNA
P09150728A0596|19 23|gene
P09150728A0596|32 36|HES1
P09150728A0596|84 89|heart
P09150728A0596|103 109|muscle
P09150774A0616|0 10|Anesthesia
P09150774A0616|31 41|isoflurane
P09150774A0616|43 46|ISO
P09150774A0616|48 51|N2O
P09150774A0616|56 66|inhalation
P09151152A0174|24 42|protein C activity
P09151152A0174|63 64|p
P09151152A0174|120 132|hemodialysis
P09151152A0174|139 147|factor X
P09151152A0174|152 162|factor VII
P09151152A0174|174 175|p
P09151152A0174|184 185|p
P09151152A0174|202 216|heparinization
P09151152A0174|231 237|amount
P09151152A0174|241 258|serum lipoprotein
P09151376A0000|13 17|case
P09151376A0000|21 25|type
P09151376A0000|29 53|hyperbetalipoproteinemia
P09151376A0000|59 66|patient
P09151376A0000|73 82|diagnosis
P09151376A0000|174 183|arthritis
P09151376A0000|194 198|gout
P09151806A1125|6 10|data
P09151806A1125|19 27|evidence
P09151806A1125|44 47|LAT
P09151806A1125|54 60|intron
P09151806A1125|68 81|mLAT pre-mRNA
P09151806A1125|96 108|branch point
P09151828A0919|12 31|amino acid residues
P09151828A0919|52 70|9ORF1 polypeptides
P09151828A0919|103 110|regions
P09151828A0919|126 132|region
P09151828A0919|136 144|residues
P09151828A0919|156 162|region
P09151828A0919|167 175|residues
P09151828A0919|202 208|region
P09151828A0919|214 222|residues
P09151837A0723|8 27|protein interaction
P09151837A0723|59 92|coimmunoprecipitation experiments
P09151837A0723|152 166|fusion protein
P09151837A0723|170 181|combination
P09151837A0723|188 191|35S
P09151837A0723|211 216|Rep78
P09151837A0723|251 283|transcription-translation system
P09151925A0479|4 9|C-LIP
P09151925A0479|33 44|transcather
P09151925A0479|54 66|embolization
P09151925A0479|68 71|TAE
P09151925A0479|73 78|C-LIP
P09151925A0479|91 105|gelatin sponge
P09151925A0479|124 149|ethanol injection therapy
P09151925A0479|151 155|PEIT
P09152656A0149|9 17|patients
P09152656A0149|23 55|New York Heart Association class
P09152656A0149|70 83|heart failure
P09152656A0149|128 133|study
P09153010A0499|9 19|advantages
P09153010A0499|33 41|analysis
P09153010A0499|57 68|acquisition
P09153010A0499|77 81|MUPs
P09153010A0499|100 110|collection
P09153010A0499|122 126|MUPs
P09153010A0499|144 148|site
P09153010A0499|154 165|possibility
P09153010A0499|190 204|threshold MUPs
P09153010A0499|215 219|bias
P09153010A0499|227 236|selection
P09153010A0499|240 244|MUPs
P09153010A0499|257 272|reproducibility
P09153010A0499|280 287|results
P09153010A0499|308 324|reference values
P09153010A0499|349 361|laboratories
P09153319A0844|35 44|triplexes
P09153319A0844|85 92|ethanol
P09153319A0844|112 117|water
P09153319A1332|0 24|Transfection experiments
P09153319A1332|41 50|triplexes
P09153319A1332|58 74|reporter plasmid
P09153319A1332|90 116|collagen promoter sequence
P09153319A1332|136 146|inhibition
P09153319A1332|150 163|transcription
P09153319A1332|185 213|control phosphorothioate ODN
P09153348A0647|9 17|increase
P09153348A0647|21 31|plasma TBG
P09153348A0647|38 43|shift
P09153348A0647|57 65|androgen
P09153348A0647|70 105|mineralocorticoid steroid secretion
P09153348A0647|114 132|cortisol secretion
P09153348A0647|150 157|markers
P09153348A0647|162 173|progression
P09153348A0647|181 188|disease
P09153348A0647|192 200|patients
P09153348A0647|206 219|HIV-infection
P09153795A0298|11 18|studies
P09153795A0298|23 27|RDFS
P09153795A0298|38 46|evidence
P09153795A0298|50 61|reliability
P09153795A0298|66 74|validity
P09154283A0307|0 11|Latanoprost
P09154283A0307|35 44|reduction
P09154283A0307|60 68|pressure
P09154283A0307|70 73|IOP
P09154283A0307|88 99|combination
P09154283A0307|105 112|timolol
P09154283A0307|114 125|pilocarpine
P09154283A0307|127 140|acetazolamide
P09154283A0307|145 155|dipivefrin
P09154621A1475|6 13|results
P09154621A1475|35 58|safflower phospholipids
P09154621A1475|77 87|ingredient
P09154621A1475|91 97|layers
P09154621A1475|111 130|liver triglycerides
P09154621A1475|135 152|serum cholesterol
P09154621A1475|173 180|effects
P09154795A0628|14 24|techniques
P09154795A0628|58 66|analysis
P09154795A0628|98 117|DNA polymerase beta
P09154795A0628|119 127|beta-pol
P09154795A0628|129 142|gene promoter
P09154797A0777|10 30|spermidine transport
P09154797A0777|34 38|stk2
P09154797A0777|40 52|lacZ mutants
P09154797A0777|89 97|affinity
P09154797A0777|116 120|Vmax
P09154797A0777|142 148|strain
P09154819A0501|10 24|overexpression
P09154819A0501|28 33|c-Jun
P09154819A0501|42 63|tenascin-C expression
P09154819A0501|75 78|REF
P09154819A0501|86 91|FR3T3
P09154819A0501|108 128|fibroblast cell line
P09154822T0000|0 10|Inhibition
P09154822T0000|18 30|Raf-1 kinase
P09154822T0000|41 53|AMP agonists
P09154822T0000|61 70|apoptosis
P09154822T0000|92 97|cells
P09154827A0158|9 16|studies
P09154827A0158|39 56|hamster cell line
P09154827A0158|58 62|ts13
P09154827A0158|71 85|point mutation
P09154827A0158|93 96|TAF
P09154827A0158|100 108|250/CCG1
P09154827A0158|110 113|TAF
P09154827A0158|122 126|gene
P09154827A0158|155 165|expression
P09154827A0158|171 177|subset
P09154827A0158|181 186|genes
P09154827A0158|191 198|arrests
P09154827A0158|207 209|G1
P09154827A0158|218 228|degrees C.
P09155015A0140|22 42|protein kinase MEKK1
P09155015A0140|54 78|reporter gene expression
P09155015A0140|107 113|factor
P09155015A0140|115 118|ANF
P09155015A0140|120 128|promoter
P09155015A0140|140 146|marker
P09155015A0140|180 191|hypertrophy
P09155024A0955|0 14|Overexpression
P09155024A0955|18 22|EFG1
P09155024A0955|26 37|C. albicans
P09155024A0955|68 74|growth
P09155024A0955|82 86|form
P09155024A0955|99 111|pseudohyphae
P09155024A0955|115 121|liquid
P09155024A0955|135 140|media
P09156883A0294|9 19|parameters
P09156883A0294|21 31|heart rate
P09156883A0294|33 35|HR
P09156883A0294|47 61|blood pressure
P09156883A0294|63 66|ABP
P09156883A0294|84 94|saturation
P09156883A0294|96 100|SaO2
P09156883A0294|115 127|pulsoximetry
P09156883A0294|153 162|procedure
P09157100A0583|16 23|signing
P09157100A0583|62 65|SIB
P09157100A0583|93 103|extinction
P09157337A0545|4 11|husband
P09157337A0545|34 41|couples
P09157337A0545|58 67|hepatitis
P09157337A0545|84 92|etiology
P09157337A0545|99 121|Infectology Department
P09157337A0545|127 132|years
P09157760A0000|34 42|analysis
P09157760A0000|75 88|peculiarities
P09157760A0000|92 99|Meynart
P09157760A0000|102 109|nucleus
P09157760A0000|133 137|part
P09157760A0000|153 160|nucleus
P09157760A0000|164 172|thalamus
P09157760A0000|206 217|individuals
P09159111A0437|20 28|proposal
P09159111A0437|54 63|dichroism
P09159111A0437|65 67|CD
P09159111A0437|73 88|NMR experiments
P09159111A0437|96 106|Skn domain
P09159111A0437|126 134|proteins
P09159160A0000|11 18|cloning
P09159160A0000|44 53|sequences
P09159160A0000|76 81|genes
P09159160A0000|107 115|diseases
P09159183A0119|0 5|Genes
P09159183A0119|10 37|ocs element binding factors
P09159183A0119|39 43|OBFs
P09159183A0119|70 75|class
P09159183A0119|79 106|basic-region leucine zipper
P09159183A0119|108 112|bZIP
P09159183A0119|114 135|transcription factors
P09159183A0119|161 167|number
P09159183A0119|171 177|plants
P09160361A0858|11 20|mortality
P09160361A0858|28 37|CPB group
P09160361A0858|54 59|group
P09160361A0858|67 68|%
P09160361A0858|76 77|%
P09160361A0858|133 134|p
P09160881A0491|23 47|co-precipitation studies
P09160881A0491|53 58|yeast
P09160881A0491|70 76|screen
P09160881A0491|109 121|interactions
P09162084A0956|5 16|association
P09162084A0956|43 57|Src-SH2 domain
P09162084A0956|67 74|PECAM-1
P09162084A0956|100 127|GST-Src-SH2 affinity matrix
P09162092A0675|0 24|MKK3 autophosphorylation
P09162092A0675|29 39|activation
P09162092A0675|43 46|p38
P09162092A0675|75 87|coexpression
P09162092A0675|91 95|MKK3
P09162092A0675|101 106|MEKK3
P09162092A0675|121 126|MEKK2
P09162097A0776|25 41|MAdCAM-1 variant
P09162097A0776|68 72|exon
P09162097A0776|88 100|mucin domain
P09162097A0776|118 136|leukocyte adhesion
P09162097A0776|140 146|LPAM-1
P09162097A0776|155 163|adhesion
P09162097A0776|181 189|receptor
P09162097A0776|191 201|L-selectin
P09162097A1258|3 10|summary
P09162097A1258|16 20|data
P09162097A1258|66 79|MAdCAM-1 cDNA
P09162097A1258|109 118|homologue
P09162097A1258|122 136|mouse MAdCAM-1
P09162097A1258|152 167|dissimilarities
P09162097A1258|175 183|MAdCAM-1
P09162097A1258|195 205|structures
P09163332A0275|29 49|mutagenesis approach
P09163332A0275|69 72|Xaa
P09163332A0275|77 84|hydroxy
P09163332A0275|86 93|Ser/Thr
P09163332A0275|95 114|amino acid residues
P09163332A0275|118 125|sequons
P09163332A0275|155 165|efficiency
P09164543A0219|0 8|MATERIAL
P09164543A0219|13 20|METHODS
P09164543A0219|26 33|authors
P09164543A0219|46 53|persons
P09164543A0219|76 83|surgery
P09164543A0219|93 98|years
P09164543A0219|105 111|months
P09164543A0219|118 122|mean
P09164543A0219|148 156|vagotomy
P09164543A0219|189 197|vagotomy
P09164543A0219|218 226|drainage
P09164856A0980|5 11|region
P09164856A0980|45 57|TATA element
P09164856A0980|75 88|transcription
P09164856A0980|96 112|glutaminase gene
P09164856A0980|138 146|promoter
P09165004A1700|0 12|SRE activity
P09165004A1700|35 45|activation
P09165004A1700|49 64|phosphorylation
P09165004A1700|78 92|complex factor
P09165004A1700|121 136|complex factors
P09165004A1700|140 145|Elk-1
P09165035A0842|0 35|Serum alkaline phosphatase activity
P09165035A0842|37 59|bone mass measurements
P09165035A0842|66 78|energy x-ray
P09165035A0842|94 102|analysis
P09165035A0842|106 121|mineral density
P09165035A0842|138 152|testing values
P09165035A0842|156 165|vertebrae
P09165035A0842|170 176|femora
P09165035A0842|185 186|D
P09165035A0842|191 198|animals
P09165035A0842|243 244|D
P09165035A0842|249 256|animals
P09165039A0728|4 19|monkey LHR cDNA
P09165039A0728|35 36|%
P09165039A0728|45 62|sequence homology
P09165039A0728|88 97|LHR cDNAs
P09165039A1372|3 13|conclusion
P09165039A1372|15 34|marmoset monkey LHR
P09165039A1372|53 61|sequence
P09165039A1372|79 83|exon
P09165039A1372|94 102|LHR gene
P09165039A1372|122 129|species
P09165118A0311|9 16|mutants
P09165118A0311|18 34|VA motor neurons
P09165118A0311|46 53|pattern
P09165118A0311|66 71|input
P09165118A0311|107 119|sister cells
P09165118A0311|125 141|VB motor neurons
P09165118A0311|147 151|loss
P09165118A0311|162 167|input
P09165118A0311|175 178|VAs
P09165118A0311|211 226|movement defect
P09167421A0234|14 25|irradiation
P09167421A0234|49 67|microSelectron HDR
P09167421A0234|81 87|device
P09167421A0234|105 107|Gy
P09167421A0234|127 136|fractions
P09168083A0987|3 10|patient
P09168083A0987|14 19|group
P09168083A0987|32 35|HAT
P09168083A0987|37 38|P
P09168083A0987|54 59|group
P09168134A0858|0 19|Sequence comparison
P09168134A0858|32 52|kb promoter sequence
P09168134A0858|62 71|promoters
P09168134A0858|79 88|Sm-E gene
P09168134A0858|93 107|U1 snRNA genes
P09168134A0858|136 142|motifs
P09168134A0858|160 165|genes
P09168134A0858|179 195|snRNP components
P09168218A0216|0 7|METHODS
P09168218A0216|13 22|responses
P09168218A0216|40 45|woman
P09168218A0216|68 86|pain syndrome type
P09168218A0216|109 118|dystrophy
P09168218A0216|133 138|grill
P09168218A0216|180 194|ganglion block
P09168511A0640|26 32|number
P09168511A0640|36 48|developments
P09168511A0640|72 75|use
P09168511A0640|91 109|steroid budesonide
P09168511A0640|119 132|dexamethasone
P09168511A0640|153 161|argument
P09168511A0640|172 180|steroids
P09168623A0614|2 6|xylE
P09168623A0614|23 29|fusion
P09168623A0614|46 59|mxbD promoter
P09168623A0614|77 87|expression
P09168623A0614|101 106|cells
P09168623A0614|116 126|one-carbon
P09168623A0614|128 130|C1
P09168623A0614|132 141|compounds
P09168623A0614|160 170|expression
P09168623A0614|174 179|cells
P09168623A0614|189 198|succinate
P09168879A0219|19 28|Sf9 cells
P09168879A0219|35 59|transcription initiation
P09168879A0219|95 105|TAAG sites
P09168879A0219|136 146|TAAG sites
P09168892A1016|0 8|Mutation
P09168892A1016|12 23|nucleotides
P09168892A1016|40 44|AP-1
P09168892A1016|58 66|elements
P09168892A1016|74 80|effect
P09168892A1016|84 100|trans-activation
P09169127A0371|10 19|proximity
P09169127A0371|31 60|neuropeptide Y receptor genes
P09169127A0371|100 122|gene duplication event
P09169127A0371|138 144|intron
P09169127A0371|169 177|sequence
P09169127A0371|185 192|y1 gene
P09169127A0371|227 235|sequence
P09169127A0371|247 254|y5 gene
P09169127A0371|288 296|sequence
P09169127A0371|341 345|exon
P09169127A0371|354 361|y1 gene
P09169420A0000|14 40|phosphoinositide 3-kinases
P09169420A0000|42 47|PI3Ks
P09169420A0000|49 58|p110alpha
P09169420A0000|60 64|beta
P09169420A0000|70 93|delta form heterodimers
P09169420A0000|99 111|Src homology
P09169420A0000|115 118|SH2
P09169420A0000|138 146|adaptors
P09169420A0000|155 163|p85alpha
P09169420A0000|167 170|p55
P09169420A0000|171 174|PIK
P09169475A0272|7 14|studies
P09169475A0272|46 52|region
P09169475A0272|66 76|gp130 gene
P09169475A0272|98 128|transcription initiation sites
P09169475A0772|0 12|Localization
P09169475A0772|20 45|cytokine response element
P09169475A0772|52 69|deletion analysis
P09169475A0772|88 99|mutagenesis
P09169475A0772|122 134|binding site
P09169475A0772|149 163|STAT complexes
P09169593T0000|0 18|Insulin regulation
P09169593T0000|40 61|protein kinase kinase
P09169593T0000|63 66|MEK
P09169593T0000|87 101|protein kinase
P09169593T0000|106 119|casein kinase
P09169593T0000|127 139|cell nucleus
P09169593T0000|152 156|role
P09169593T0000|164 174|regulation
P09169593T0000|178 193|gene expression
P09169852A0235|0 10|Sequencing
P09169852A0235|24 37|pag-3 alleles
P09169852A0235|68 75|alleles
P09169852A0235|85 102|nonsense mutation
P09169852A0235|114 126|zinc fingers
P09169852A0235|133 150|missense mutation
P09169852A0235|165 176|zinc finger
P09169852A0235|205 214|histidine
P09169852A0235|220 228|tyrosine
P09169853A0000|0 5|Pax-3
P09169853A0000|23 36|homeobox gene
P09169853A0000|75 81|dorsal
P09169853A0000|103 107|tube
P09170159A0348|34 39|cells
P09170159A0348|65 80|marker proteins
P09170159A0348|89 99|tyrosinase
P09170159A0348|123 130|protein
P09170159A0721|6 15|mutations
P09170159A0721|28 34|codons
P09170159A0721|38 42|exon
P09170159A0721|99 107|proteins
P09170159A0721|116 123|HLH-Zip
P09170159A0721|127 140|Zip structure
P09171038A0219|8 12|case
P09171038A0219|16 23|Sjogren
P09171038A0219|26 34|syndrome
P09171038A0219|95 105|complaints
P09171038A0219|121 130|treatment
P09171038A0219|134 141|Sjogren
P09171038A0219|144 152|patients
P09171081T0000|0 7|Cloning
P09171081T0000|12 28|characterization
P09171081T0000|34 38|cDNA
P09171081T0000|69 83|RNA polymerase
P09171081T0000|100 123|plant Chenopodium album
P09171235A0851|11 25|overexpression
P09171235A0851|40 53|concentration
P09171235A0851|57 65|COUP-TFI
P09171235A0851|75 91|COUP-TFI delta35
P09171235A0851|109 127|silencing activity
P09171235A0851|146 152|TRbeta
P09171239A1118|10 21|amino acids
P09171239A1118|26 30|part
P09171239A1118|49 54|helix
P09171239A1118|94 111|hormone receptors
P09171239A1118|129 140|core domain
P09171239A1118|165 189|transactivation function
P09171239A1118|191 195|AF-2
P09171239A2146|31 37|ligand
P09171239A2146|53 57|acid
P09171239A2146|66 73|binding
P09171239A2146|77 82|SRC-1
P09171239A2146|90 103|RXR component
P09171239A2146|121 132|heterodimer
P09171363A0149|3 11|ciliates
P09171363A0149|18 28|mechanisms
P09171389A0549|13 23|occurrence
P09171389A0549|35 56|transcription signals
P09171389A0549|64 91|Thermus pyr promoter region
P09171389A0549|103 133|amino acid sequence identities
P09171389A0549|143 144|%
P09171389A0549|154 166|Thermus PyrR
P09171389A0549|175 200|PyrR attenuation proteins
P09171389A0549|208 220|Bacillus sp.
P09171389A0549|246 255|mechanism
P09171389A0549|282 293|attenuation
P09171389A0549|305 324|pyr gene expression
P09171389A0549|328 335|Thermus
P09171468T0000|0 5|Diver
P09171468T0000|18 27|responses
P09171468T0000|56 75|breathing apparatus
P09171969A1165|0 11|Measurement
P09171969A1165|19 23|time
P09171969A1165|36 39|VO2
P09171969A1165|44 56|oxygen pulse
P09171969A1165|73 91|work rate exercise
P09171969A1165|121 131|evaluation
P09171969A1165|139 154|training effect
P09171969A1165|158 166|patients
P09171969A1165|172 176|COPD
P09172312T0000|0 16|Characterization
P09172312T0000|20 30|CR1 repeat
P09172312T0000|38 49|PCR markers
P09172312T0000|66 80|chicken genome
P09172414A0000|58 62|HPLC
P09172414A0000|64 70|method
P09172414A0000|79 92|determination
P09172414A0000|96 115|cocaine metabolites
P09172414A0000|137 142|serum
P09172414A0000|147 162|liver esterases
P09172641A0181|11 18|studies
P09172641A0181|27 35|evidence
P09172641A0181|44 47|end
P09172641A0181|70 81|side chains
P09172641A0181|85 94|subdomain
P09172641A0181|113 121|contacts
P09172641A0181|131 142|nucleotides
P09172812A0660|21 32|fludarabine
P09172812A0660|52 57|agent
P09172812A0660|61 64|CLL
P09173733A0404|16 26|techniques
P09173733A0404|30 41|EA analysis
P09173733A0404|59 64|study
P09173733A0404|74 96|Fourier transformation
P09173733A0404|98 101|FFT
P09173733A0404|106 108|EA
P09173733A0404|120 124|band
P09173733A0404|157 163|method
P09173733A0404|180 189|expansion
P09173733A0404|197 207|EEG curves
P09173733A0404|234 239|shape
P09173733A0404|244 259|factor analysis
P09173733A0404|267 269|EA
P09173733A0404|279 288|densities
P09174049A1788|15 49|p34CDC2 histone H1 kinase activity
P09174049A1788|97 107|cell lines
P09174049A1788|128 132|role
P09174049A1788|142 149|protein
P09174049A1788|171 181|cell death
P09175708A1526|6 11|PRL-R
P09175708A1526|56 63|regions
P09175708A1526|78 86|receptor
P09175708A1526|100 111|possibility
P09175708A1526|125 133|fragment
P09175708A1526|187 194|nucleus
P09175858A1449|10 20|B-S mutant
P09175858A1449|66 72|GAPDHs
P09175858A1449|109 116|effects
P09175858A1449|153 163|inspection
P09175858A1449|185 195|structures
P09175858A1449|219 226|account
P09175858A1449|269 275|mutant
P09175858A1449|289 294|GAPDH
P09176340A1194|0 13|Transcription
P09176340A1194|23 28|genes
P09176340A1194|50 53|gut
P09176340A1194|58 62|lung
P09176340A1194|70 78|freezing
P09176340A1194|84 95|mRNA levels
P09176340A1194|105 112|tissues
P09176340A1194|132 137|liver
P09176837A0211|0 17|Computer software
P09176837A0211|37 41|CSAO
P09176837A0211|70 75|PN Ca
P09176837A0211|76 88|P solubility
P09176837A0211|103 107|data
P09176837A0211|130 132|Ca
P09176837A0211|137 153|P administration
P09177169A0935|10 17|chimera
P09177169A0935|45 51|halves
P09177169A0935|59 67|molecule
P09177169A0935|102 110|bacteria
P09177857A0000|4 14|conditions
P09177857A0000|29 45|titanium dioxide
P09177857A0000|55 88|substrates titanium tetrachloride
P09177857A0000|93 99|oxygen
P09177857A0000|142 147|steel
P09177857A0000|155 159|type
P09177857A0000|172 178|plasma
P09177857A0000|188 221|chemical vapour deposition method
P09178269A0107|8 13|genes
P09178491A0262|16 23|regions
P09178491A0262|36 62|preS2/S gene transcription
P09178491A0262|70 85|HBV adw subtype
P09178491A0262|100 108|TATA box
P09178491A0262|124 141|initiator element
P09178494A1123|59 66|regions
P09178494A1123|76 84|patterns
P09178494A1123|88 92|stem
P09178494A1123|97 112|loop structures
P09178494A1123|142 154|flaviviruses
P09178494A1123|178 187|selection
P09178494A1123|192 204|preservation
P09178494A1123|218 221|RNA
P09178494A1123|232 242|structures
P09178494A1123|284 291|control
P09178494A1123|296 307|replication
P09178752A0574|0 3|EGF
P09178752A0574|22 27|means
P09178752A0574|31 58|transactivation domain AF-1
P09178752A0574|68 72|cAMP
P09178752A0574|82 109|transactivation domain AF-2
P09178752A0574|117 119|ER
P09180687A0096|19 25|region
P09180687A0096|29 33|SulA
P09180687A0096|55 65|inhibition
P09180687A0096|69 82|cell division
P09180687A0096|101 107|series
P09180687A0096|137 146|deletions
P09180687A0096|150 154|SulA
P09180687A0096|161 167|series
P09180687A0096|171 199|alanine substitution mutants
P09181130A1067|20 27|Krox-20
P09181130A1067|42 55|recombination
P09181130A1067|59 67|ES cells
P09181130A1067|94 102|mutation
P09181130A1067|116 124|deletion
P09181130A1067|128 130|r3
P09181130A1067|135 137|r5
P09181130A1587a|38 46|analysis
P09181130A1587a|68 79|populations
P09181130A1587a|96 104|mutation
P09181130A1587a|120 125|light
P09181130A1587a|133 137|role
P09181130A1587a|141 148|Krox-20
P09181130A1587a|156 168|segmentation
P09181130A1587a|194 206|consequences
P09181130A1587a|214 226|inactivation
P09182281A0197|37 50|Cyclosporin A
P09182281A0197|91 95|drug
P09182527A0443|20 24|role
P09182527A0443|28 46|p53 ubiquitination
P09182527A0443|48 54|mE6-AP
P09182527A0443|77 84|nucleus
P09182527A0443|89 96|cytosol
P09182527A0443|104 110|Nedd-4
P09182527A0443|133 140|cytosol
P09182707A0254|0 3|SPP
P09182707A0254|27 51|tyrosine phosphorylation
P09182707A0254|61 76|adhesion kinase
P09182707A0254|78 82|p125
P09182707A0254|83 86|FAK
P09182707A0254|102 117|tyrosine kinase
P09182707A0254|142 151|adhesions
P09182707A0254|188 204|protein paxillin
P09182990A0245|34 40|allele
P09182990A0245|44 49|SUP45
P09182990A0245|51 58|sup45-2
P09182990A0245|66 77|combination
P09182990A0245|102 112|approaches
P09182990A0245|138 145|product
P09182990A0245|153 163|SUP45 gene
P09182990A0245|165 171|Sup45p
P09182990A0245|175 179|eRF1
P09182990A0245|186 192|factor
P09182990A0245|206 229|translation termination
P09182990A0245|233 238|yeast
P09183145T0001|0 10|Evaluation
P09183145T0001|25 34|perfusion
P09183145T0001|56 61|SPECT
P09183145T0001|123 134|angioplasty
P09183145T0001|156 166|infarction
P09183406A0637|22 38|thrombocytopenia
P09183406A0637|47 53|HPA-3a
P09183406A0637|55 59|Baka
P09183406A0637|61 76|incompatibility
P09185183A0089|35 40|years
P09185183A0089|44 47|age
P09185183A0089|70 79|worsening
P09185183A0089|83 98|motor abilities
P09185183T0000|0 7|Merosin
P09185183T0000|37 46|dystrophy
P09185183T0000|59 69|deficiency
P09185183T0000|71 79|epilepsy
P09185183T0000|84 95|MRI changes
P09185183T0000|118 124|matter
P09185586A0000|16 21|mRNAs
P09185586A0000|43 60|scanning ribosome
P09185586A0000|62 71|mechanism
P09185645T0000|0 10|Comparison
P09185645T0000|14 48|Tc-99m sestamibi perfusion imaging
P09185645T0000|53 69|echocardiography
P09185645T0000|79 98|arbutamine infusion
P09185645T0000|107 116|detection
P09185645T0000|129 143|artery disease
P09186056A0514|16 30|overexpression
P09186056A0514|39 46|protein
P09186056A0514|50 61|C2C12 cells
P09186056A0514|74 87|transcription
P09186056A0514|93 105|CAT-reporter
P09186056A0514|122 130|E12/MyoD
P09186056A0514|138 146|enhancer
P09186430A0341|44 52|albinism
P09186507A0882|53 61|sequence
P09186507A0882|96 109|cDNA sequence
P09186507A0882|133 143|CpG island
P09186507A0882|151 155|TATA
P09186507A0882|160 170|CAAT boxes
P09186507A0882|192 203|G+C content
P09186507A0882|222 239|CpG dinucleotides
P09186507A0882|279 283|site
P09186507A0882|331 335|gene
P09187136A0000|0 6|SSeCKS
P09187136A0000|19 24|essex
P09187136A0000|42 68|protein kinase C substrate
P09187136A0000|74 84|expression
P09187136A0000|115 118|src
P09187136A0000|147 158|fibroblasts
P09187136A0000|193 204|fibroblasts
P09187136A0000|206 208|X.
P09187277A0118|0 4|Type
P09187277A0118|7 32|position-vestibular-pause
P09187277A0118|34 39|PVP I
P09187277A0118|62 65|V I
P09187277A0118|67 74|neurons
P09187277A0118|97 103|number
P09187277A0118|113 117|type
P09187277A0118|124 128|type
P09187277A0118|152 159|neurons
P09187371A0450|20 32|mRNA species
P09187371A0450|56 61|heart
P09187371A0450|78 85|species
P09187371A0450|103 108|heart
P09187371A0450|110 116|kidney
P09187371A0450|121 126|brain
P09187371A0450|148 154|muscle
P09187371A0450|158 163|liver
P09187637A1199|0 18|Taurine deficiency
P09187637A1199|47 56|amplitude
P09187637A1199|60 63|OP1
P09187637A1199|68 71|OP4
P09188094A0934|19 23|mcs4
P09188094A0934|25 30|cells
P09188094A0934|48 58|activation
P09188094A0934|62 66|Spc1
P09188094A0934|70 78|response
P09188094A0934|90 95|forms
P09188094A0934|99 105|stress
P09188699A1388|13 30|rat SP-A isoforms
P09188699A1388|91 103|SP-A species
P09188699A1388|117 130|SDS-PAGE gels
P09188863A0954|12 20|splicing
P09188863A0954|24 30|CDC25B
P09188863A0954|63 70|control
P09188863A0954|74 92|cell proliferation
P09189783A0000|5 18|investigation
P09189783A0000|79 87|feedings
P09189783A0000|103 115|carbohydrate
P09189783A0000|117 120|CHO
P09189783A0000|144 149|bolus
P09189783A0000|164 177|blood glucose
P09189783A0000|182 199|insulin responses
P09189783A0000|207 211|rest
P09189783A0000|216 224|exercise
P09189896A0611|4 12|findings
P09189896A0611|26 37|ERP effects
P09189896A0611|50 66|memory processes
P09189896A0611|113 125|instructions
P09190202A0166|5 17|coat protein
P09190202A0166|30 35|Sar1p
P09190202A0166|41 63|Sec23p protein complex
P09190202A0166|75 81|Sec23p
P09190202A0166|86 92|Sec24p
P09190202A0166|102 124|Sec13p protein complex
P09190202A0166|136 142|Sec13p
P09190202A0166|163 170|protein
P09190202A0166|172 176|p150
P09190821A0707|57 63|change
P09190821A0707|67 75|position
P09190821A0707|81 86|P243L
P09190940A0127|0 9|Induction
P09190940A0127|31 51|germline transcripts
P09190940A0127|77 90|switch region
P09190940A0127|95 108|recombination
P09190940A0127|113 122|switching
P09191052A0850|10 13|PCE
P09191052A0850|22 39|Pbx dimer partner
P09191052A0850|60 65|Class
P09191052A0850|68 80|Hox proteins
P09192732A1384|30 37|portion
P09192732A1384|45 54|homologue
P09192732A1384|91 99|membrane
P09192732A1384|126 130|part
P09192769T0000|10 17|cloning
P09192769T0000|22 38|characterization
P09192769T0000|44 48|cDNA
P09192769T0000|50 56|CHEMR1
P09192769T0000|69 87|chemokine receptor
P09192769T0000|95 103|homology
P09192769T0000|117 139|C-C chemokine receptor
P09192769T0000|141 146|CCR-4
P09192786T0000|0 12|Organization
P09192786T0000|26 33|LU gene
P09192786T0000|48 53|basis
P09192786T0000|61 63|Lu
P09192786T0000|67 69|Lu
P09192786T0000|70 71|b
P09192786T0000|73 97|blood group polymorphism
P09192842A0988|26 33|hybrids
P09192842A0988|38 51|FISH analysis
P09192842A0988|57 66|PE-2 gene
P09192842A0988|89 107|chromosome 19q13.2
P09192842A0988|111 117|region
P09192842A0988|130 144|translocations
P09192842A0988|149 158|deletions
P09192842A0988|162 171|leukemias
P09192842A0988|190 196|tumors
P09192842A0988|225 235|ETS factor
P09192842A0988|247 251|role
P09192842A0988|255 269|carcinogenesis
P09192998A0356|19 26|enzymes
P09192998A0356|58 68|terminator
P09192998A0356|72 78|T7 DNA
P09192998A0356|80 81|T
P09192998A0356|82 85|phi
P09192998A0356|92 99|rrnB T2
P09192998A0356|138 155|termination sites
P09192998A0356|159 166|rrnB T1
P09192998A0356|199 202|PTH
P09192998A0356|207 217|CJ signals
P09193072A0199|12 16|data
P09193072A0199|34 44|transgenes
P09193072A0199|62 71|nucleolus
P09193077A0000|17 21|unit
P09193077A0000|25 29|LRU1
P09193077A0000|90 100|activation
P09193077A0000|108 125|chalcone synthase
P09193077A0000|127 130|CHS
P09193077A0000|140 148|promoter
P09193077A0000|152 172|Petroselinum crispum
P09193080A0904|0 19|Sequence divergence
P09193080A0904|48 55|regions
P09193080A0904|73 83|definition
P09193080A0904|101 107|probes
P09193671A0347|11 16|state
P09193671A0347|34 44|hydrolysis
P09193671A0347|54 57|GTP
P09193671A0347|78 85|ARF-GDP
P09194250A0708|31 43|World Summit
P09194250A0708|48 56|Children
P09194250A0708|70 86|mortality target
P09194250A0708|95 99|year
P09194250A0708|120 127|targets
P09194250A0708|151 163|inequalities
P09194250A0708|178 187|mortality
P09195923A0125|4 16|immunophilin
P09195923A0125|38 43|FK506
P09195923A0125|48 75|cyclosporin A-binding class
P09195923A0125|86 91|hsp90
P09195923A0125|100 124|tetratricopeptide repeat
P09195923A0125|126 129|TPR
P09195923A0125|131 137|domain
P09195923A0125|153 177|receptor heterocomplexes
P09195923A0125|205 217|immunophilin
P09195923A0125|243 249|region
P09195923A0125|253 258|hsp90
P09197241A0770|12 23|macrophages
P09197241A0770|25 32|absence
P09197241A0770|36 40|CD45
P09197241A0770|52 72|hyperphosphorylation
P09197241A0770|77 92|hyperactivation
P09197241A0770|96 102|p56/59
P09197241A0770|103 106|hck
P09197241A0770|112 118|p53/56
P09197241A0770|119 122|lyn
P09197241A0770|136 139|p58
P09197241A0770|140 145|c-fgr
P09197342T0000|0 9|Secretion
P09197342T0000|13 17|milk
P09197342T0000|37 45|transfer
P09197342T0000|61 65|oils
P09197342T0000|67 78|Lipiodol UF
P09197342T0000|83 90|Oriodol
P09197342T0000|95 102|rabbits
P09197408A0126|0 10|Sequencing
P09197408A0126|18 27|facB gene
P09197408A0126|55 62|protein
P09197408A0126|101 103|Zn
P09197408A0126|107 112|2Cys6
P09197408A0126|117 124|C6 zinc
P09197408A0126|136 143|cluster
P09197408A0126|148 159|DNA binding
P09197408A0126|161 168|leucine
P09197408A0126|181 201|heptad repeat motifs
P09197408A0126|250 257|regions
P09197408A0126|277 285|function
P09197408A0126|319 328|activator
P09199167A0942|0 14|Overexpression
P09199167A0942|18 23|Sed5p
P09199167A0942|32 38|growth
P09199167A0942|46 53|absence
P09199167A0942|57 62|Vti1p
P09199286A0086|11 17|region
P09199286A0086|21 25|mkh1
P09199286A0086|55 59|exon
P09199286A0086|88 95|protein
P09199292A0536|27 38|association
P09199292A0536|42 46|p107
P09199292A0536|50 54|p130
P09199292A0536|67 80|cyclin E-cdk2
P09199292A0536|84 97|cyclin A-cdk2
P09199292A0536|110 120|activities
P09199292A0536|130 137|kinases
P09199318A1147|13 17|p150
P09199318A1147|29 43|actin gelation
P09199318A1147|72 92|muscle alpha-actinin
P09199322T0000|0 12|Denaturation
P09199322T0000|27 32|virus
P09199322T0000|36 42|origin
P09199322T0000|46 57|replication
P09199322T0000|76 98|replication protein A.
P09199327A1250|5 11|effect
P09199327A1250|35 43|EM motif
P09199327A1250|69 78|construct
P09199327A1250|129 153|transactivation function
P09199327A1250|161 170|TEF-1-Max
P09199327A1250|183 190|complex
P09199327A1250|211 218|binding
P09199327A1250|226 233|complex
P09199327A1250|241 249|EM motif
P09199328T0000|15 23|residues
P09199328T0000|39 45|region
P09199328T0000|49 53|VP16
P09199328T0000|68 73|Oct-1
P09199328T0000|75 78|HCF
P09199328T0000|84 87|DNA
P09199348A0156|7 11|view
P09199348A0156|43 59|U14 interactions
P09199348A0156|73 79|domain
P09199348A0156|93 101|activity
P09199348A0156|130 138|U14 RNAs
P09199348A0156|144 152|Y domain
P09199348A0156|197 205|analysis
P09199353A1924|15 22|results
P09199353A1924|35 40|Cdc68
P09199353A1924|66 75|regulator
P09199353A1924|79 98|chromatin structure
P09199353A1924|118 134|polymerase alpha
P09199353A1924|159 167|proteins
P09199353A1924|176 182|access
P09199353A1924|190 198|template
P09199353A1924|205 212|origins
P09199353A1924|216 227|replication
P09199413A0518|14 27|inoculum size
P09199413A0518|65 74|CFU/mouse
P09199413A0518|79 80|%
P09199413A0518|104 111|animals
P09199413A0518|126 130|days
P09199626A0613|6 11|cases
P09199626A0613|16 17|%
P09199626A0613|22 28|change
P09199626A0613|32 37|stage
P09199932A1357|0 31|Promoter recognition algorithms
P09199932A1357|53 70|promoter elements
P09199932A1357|82 92|CpG island
P09199932A1357|117 120|ATM
P09199932A1357|125 139|E14/NPAT genes
P09199932A1357|153 161|evidence
P09199932A1357|184 196|ATM promoter
P09199932A1357|212 218|intron
P09199932A1357|263 267|exon
P09199970A1101|20 24|pMCP
P09199970A1101|37 50|transmembrane
P09199970A1101|67 74|domains
P09199970A1101|79 85|factor
P09199970A1101|88 105|cofactor activity
P09199970A1101|109 121|C3b cleavage
P09199970A1101|197 200|MCP
P09200029A0211|28 33|signs
P09200029A0211|59 66|setting
P09200029A0211|76 85|diagnosis
P09200029A0211|109 117|features
P09200029A0211|126 149|bone marrow examination
P09200498T0000|8 13|zones
P09200498T0000|18 37|muscle coactivation
P09200498T0000|46 53|control
P09200498T0000|66 75|stability
P09200530A0411|0 6|Liquid
P09200530A0411|23 33|separation
P09200530A0411|52 64|Zorbax RX C8
P09200530A0411|76 82|column
P09200530A0411|89 105|gradient elution
P09200811T0000|11 24|plasmid pDHL1
P09200811T0000|62 69|protein
P09200811T0000|95 123|pGKL1-plasmid DNA polymerase
P09201946A0000|28 47|helicase activities
P09201946A0000|72 108|transcription termination factor rho
P09201946A0000|146 159|RNA molecules
P09201946A0000|181 200|nucleotide residues
P09201946A0000|204 210|length
P09201946A0000|232 237|trp t
P09201946A0000|253 273|termination sequence
P09201980A0910|4 18|p20-CGGBP gene
P09201980A0910|38 45|mammals
P09201980A0910|59 67|homology
P09201980A0910|86 93|species
P09202147A0866|4 8|data
P09202147A0866|30 35|yeast
P09202147A0866|40 46|plants
P09202147A0866|57 66|subfamily
P09202147A0866|70 73|UBC
P09202147A0866|118 129|degradation
P09202147A0866|142 150|proteins
P09202147A0866|154 160|result
P09202147A0866|164 170|stress
P09202669A0614|4 10|pWP-19
P09202669A0614|28 31|AAV
P09202669A0614|50 57|repeats
P09202669A0614|62 73|integration
P09202669A0614|78 89|replication
P09202669A0614|98 127|herpes virus thymidine kinase
P09202669A0614|144 148|gene
P09202669A0614|153 172|neomycin resistance
P09202669A0614|174 178|neoR
P09202669A1530|34 54|gene transfer system
P09202669A1530|63 80|rat preproinsulin
P09202669A1530|84 88|gene
P09202859A0091|4 16|serum levels
P09202859A0091|20 30|beta-human
P09202859A0091|41 53|gonadotropin
P09202859A0091|55 58|HCG
P09202859A0091|74 94|alkaline phosphatase
P09202859A0091|96 100|PLAP
P09203585A0660|11 18|feature
P09203585A0660|38 48|H19 allele
P09203585A0660|56 66|occurrence
P09203585A0660|81 88|imprint
P09203585A0660|100 124|neo replacement cassette
P09203586A1197|20 31|recruitment
P09203586A1197|41 50|T antigen
P09203586A1197|58 71|rRNA promoter
P09203586A1197|75 78|SL1
P09203586A1197|101 105|step
P09203586A1197|113 131|activation process
P09203731A0497|12 36|International Commission
P09203731A0497|45 58|Certification
P09203731A0497|62 73|Eradication
P09203731A0497|77 102|Poliomyelitis Eradication
P09203731A0497|104 109|ICCPE
P09203731A0497|134 166|Pan American Health Organization
P09203731A0497|194 206|transmission
P09204566T0000|26 34|analysis
P09204566T0000|46 52|copies
P09204566T0000|60 74|fixNOQP operon
P09204566T0000|78 113|Rhizobium leguminosarum strain VF39
P09204570A0110|5 10|study
P09204570A0110|27 40|MADS box gene
P09204570A0110|42 47|nmhC5
P09204570A0110|66 70|nmh7
P09204570A0110|72 74|J.
P09205113A0587|5 8|E14
P09205113A0587|10 15|TG3B1
P09205113A0587|28 40|ES cell line
P09205113A0587|59 71|mouse genome
P09205113A0587|82 91|HPRT gene
P09205113A0587|97 113|selection marker
P09205113A0587|122 134|transmission
P09205113A0587|145 154|frequency
P09205113A0587|164 179|mouse germ line
P09205677A0577|0 4|Lung
P09205677A0577|22 28|damage
P09205677A0577|40 50|indicators
P09205677A0577|59 66|outcome
P09205677A0577|87 94|disease
P09205965A1249|4 11|results
P09205965A1249|41 52|micturition
P09205965A1249|70 85|bladder filling
P09205965A1249|90 96|L-dopa
P09205965A1249|119 126|pathway
P09205965A1249|133 145|transmission
P09205965A1249|168 196|spinal alpha 1-adrenoceptors
P09206230A0000|0 9|OBJECTIVE
P09206230A0000|16 21|study
P09206230A0000|57 62|cause
P09206230A0000|66 76|asthenopia
P09206230A0000|84 95|astigmatism
P09206968A0000|0 11|Disturbance
P09206968A0000|15 27|regeneration
P09206968A0000|54 63|condition
P09206968A0000|81 87|damage
P09206968A0000|91 105|tunica propria
P09206968A0000|110 114|loss
P09206968A0000|122 130|function
P09206968A0000|139 146|support
P09206968A0000|161 172|homeostasis
P09208214A0572|0 19|Sternocleidomastoid
P09208214A0572|21 25|neck
P09208214A0572|36 43|muscles
P09208214A0572|77 82|cases
P09208930T0000|0 14|Identification
P09208930T0000|27 32|genes
P09208930T0000|57 74|interleukin-1beta
P09208930T0000|86 97|enzyme gene
P09208930T0000|129 138|proteases
P09209031A0350|22 28|region
P09209031A0350|58 82|serine carboxypeptidases
P09209312A0968|4 17|RNA construct
P09209312A0968|41 52|nucleotides
P09209312A0968|54 56|nt
P09209312A0968|63 65|nt
P09209312A0968|73 75|nt
P09209312A0968|103 110|complex
P09209312A0968|120 123|RNA
P09209312A0968|147 158|nucleotides
P09209312A0968|164 166|nt
P09209312A0968|174 176|nt
P09209372A0345|25 30|AML1a
P09209372A0345|52 59|effects
P09209372A0345|81 90|regulator
P09209372A0345|130 140|activation
P09209372A0345|144 149|AML1b
P09209372A0345|160 165|AML1a
P09209372A0345|186 194|affinity
P09209372A0345|216 221|AML1b
P09209406A1021|42 49|regions
P09209406A1021|55 90|guanine nucleotide exchange factors
P09209406A1021|112 120|proteins
P09209406A1021|128 138|c-cbl gene
P09209438A0994|15 22|ATL-16T
P09209438A0994|31 38|extract
P09209438A0994|61 67|GATA-4
P09209438A0994|93 100|protein
P09209438A0994|133 140|complex
P09209438A0994|154 163|GATA site
P09210012A0000|4 10|impact
P09210012A0000|21 28|support
P09210012A0000|36 49|relationships
P09210012A0000|62 69|couples
P09210478A0000|45 53|factor-1
P09210478A0000|55 60|HIF-1
P09210478A0000|77 87|expression
P09210478A0000|99 105|number
P09210478A0000|126 131|genes
P09211354A0000|0 13|Stromelysin-1
P09211354A0000|15 41|matrix metalloproteinase-3
P09211354A0000|43 48|MMP-3
P09211354A0000|67 80|endopeptidase
P09211354A0000|114 119|cells
P09211354A0000|123 136|organ tissues
P09211605A0478|0 6|Tendon
P09211605A0478|20 26|degree
P09211605A0478|30 43|extensibility
P09211675A0392|0 12|Surveillance
P09211675A0392|17 29|preeclampsia
P09211675A0392|47 56|personnel
P09211675A0392|84 95|assignments
P09211675A0392|116 128|measurements
P09211675A0392|132 146|blood pressure
P09211675A0392|159 176|protein excretion
P09211675A0392|209 215|visits
P09211675A0392|217 226|protocols
P09211675A0392|248 260|measurements
P09211675A0392|272 287|hospitalization
P09211675A0392|292 300|delivery
P09211675A0392|306 313|reviews
P09211675A0392|325 332|records
P09211675A0392|348 365|outpatient visits
P09211675A0392|374 390|hospitalizations
P09211913A0000|0 25|Aryl hydrocarbon receptor
P09211913A0000|34 46|translocator
P09211913A0000|48 52|ARNT
P09211913A0000|59 68|component
P09211913A0000|76 97|transcription factors
P09211913A0000|99 124|aryl hydrocarbon receptor
P09211913A0000|126 129|AhR
P09211913A0000|153 159|factor
P09211913A0000|189 201|target genes
P09211913A0000|211 217|CYP1A1
P09211913A0000|222 236|erythropoietin
P09211913A0000|241 249|response
P09211913A0000|273 285|hydrocarbons
P09211913A0000|300 313|concentration
P09211934A0722|0 5|DNase
P09211934A0722|8 26|footprint analysis
P09211934A0722|50 56|region
P09211981A0526|16 24|evidence
P09211981A0526|30 34|gar2
P09211981A0526|67 70|p13
P09211981A0526|71 75|suc1
P09211981A0526|93 99|kinase
P09211981A0526|131 139|extracts
P09211981A0526|154 158|cell
P09211981A0526|175 183|activity
P09211981A0526|207 210|p34
P09211981A0526|211 215|cdc2
P09211981A0526|216 222|kinase
P09212059A1356|24 59|metal affinity chromatography assay
P09212059A1356|61 77|self-association
P09212059A1356|81 85|PR-A
P09212059A1356|138 143|DhLBD
P09212059A1356|147 162|hLBD constructs
P09212059A1856|12 19|results
P09212059A1856|28 33|paper
P09212059A1856|58 68|conclusion
P09212059A1856|96 99|LBD
P09212059A1856|132 147|PR dimerization
P09212059A1856|166 173|regions
P09212059A1856|189 194|hinge
P09212059A1856|214 223|sequences
P09212059A1856|269 285|homodimerization
P09212059A1856|289 291|PR
P09212063A0425|32 39|A-phage
P09212063A0425|44 57|cosmid clones
P09212063A0425|83 85|kb
P09212063A0425|95 98|DNA
P09212063A0425|124 132|VDR gene
P09214274T0001|11 20|carcinoma
P09214274T0001|34 42|approach
P09214274T0001|46 54|patients
P09214274T0001|76 96|metastasis resection
P09215525A0581|23 30|effects
P09215525A0581|34 44|cell cycle
P09215525A0581|50 57|changes
P09215525A0581|61 77|E2F/DP complexes
P09215525A0581|82 90|activity
P09215525A0581|110 124|C2C12 myocytes
P09215891A0000|4 12|products
P09215891A0000|45 49|CIN1
P09215891A0000|51 55|CIN2
P09215891A0000|60 70|CIN4 genes
P09215891A0000|101 108|pathway
P09215891A0000|129 149|microtubule function
P09216017A0621|0 10|Vitrectomy
P09216017A0621|35 46|risk factor
P09216017A0621|60 65|holes
P09216936T0000|8 17|editorial
P09216936T0000|40 47|effects
P09216936T0000|51 59|exercise
P09216936T0000|63 76|leptin levels
P09216936T0000|80 86|humans
P09218436A0443|5 14|promoters
P09218436A0443|22 30|TATA box
P09218436A0443|36 40|Pint
P09218436A0443|56 67|MED-1 class
P09218436A0443|71 80|promoters
P09218436A0443|97 110|transcription
P09218436A0443|123 128|sites
P09218459A0000|0 21|Serum response factor
P09218459A0000|23 26|SRF
P09218459A0000|31 37|member
P09218459A0000|52 58|family
P09218459A0000|74 82|proteins
P09218459A0000|124 144|transcription factor
P09218459A0000|168 174|growth
P09218459A0000|193 198|genes
P09218520A0075|18 25|studies
P09218520A0075|38 66|candidate signal transducers
P09218520A0075|101 107|domain
P09218520A0075|109 111|cd
P09218520A0075|120 125|IL-1R
P09218599A0184|8 13|study
P09218599A0184|37 47|mechanisms
P09218599A0184|89 96|effects
P09218599A0184|100 104|IL-4
P09218775A0000|23 30|strains
P09218775A0000|41 49|patients
P09218775A0000|62 70|fibrosis
P09218775A0000|72 74|CF
P09218775A0000|93 102|phenotype
P09218775A0000|110 124|overproduction
P09218775A0000|128 136|alginate
P09218775A1229|0 8|Activity
P09218775A1229|12 17|palgD
P09218775A1229|25 36|cysB mutant
P09218775A1229|41 44|CHA
P09218775A1229|67 77|strain PAO
P09218775A1229|98 101|use
P09218775A1229|123 139|algD-xylE fusion
P09219526A0383|21 32|specificity
P09219526A0383|40 54|cDNA construct
P09219526A0383|75 86|observation
P09219526A0383|96 113|peptide sequences
P09219526A0383|178 186|fragment
P09219526A0383|216 222|region
P09220158A0537|17 24|protein
P09220158A0537|62 72|processing
P09220158A0537|97 105|sequence
P09220158A0537|109 120|amino acids
P09220158A0537|135 140|ORF-2
P09220158A0537|146 175|baculovirus expression vector
P09220158A0537|204 209|virus
P09220158A0537|220 229|Sf9 cells
P09220177A0564|4 20|CPK-MB isoenzyme
P09220177A0564|31 50|percentage increase
P09220177A0564|60 63|CPK
P09220177A0564|77 78|%
P09220177A0564|106 107|h
P09220177A0564|118 123|shock
P09220177A0564|144 150|number
P09220177A0564|154 162|attempts
P09220177A0564|166 179|cardioversion
P09222057A0176|0 5|Serum
P09222057A0176|21 35|dialysis fluid
P09222057A0176|37 40|PDF
P09222057A0176|61 66|assay
P09222057A0176|82 88|course
P09222057A0176|96 101|study
P09222057A0176|112 116|days
P09222115A0545|0 7|Results
P09222115A0545|20 30|hypothesis
P09222115A0545|71 77|factor
P09222115A0545|110 122|binding site
P09222115A0545|157 180|response characteristic
P09222115A0545|184 188|pups
P09222115A0545|206 211|phase
P09222115A0545|215 224|isolation
P09222115A0545|234 246|surroundings
P09223042A0000|0 5|Liver
P09223042A0000|15 27|blood volume
P09223042A0000|29 33|LRBV
P09223042A0000|57 71|disease states
P09223042A0000|84 89|drugs
P09223122A0774|9 28|matter NAA/mI ratio
P09223122A0774|55 61|groups
P09223229A0565|29 39|mb-1 genes
P09223229A0565|48 54|region
P09223229A0565|69 78|mb-1 gene
P09223229A0565|88 96|TATA box
P09223475A0898|0 40|Chloramphenicol acetyltransferase assays
P09223475A0898|55 62|ability
P09223475A0898|66 70|IE86
P09223475A0898|82 90|activity
P09223475A0898|100 104|HCMV
P09223475A0898|114 122|promoter
P09223475A0898|139 143|HCMV
P09223475A0898|150 158|promoter
P09223475A0898|174 179|class
P09223475A0898|183 187|RNAs
P09223475A0898|216 225|integrity
P09223475A0898|233 245|IE86 protein
P09223479A1193|0 6|ORF M1
P09223479A1193|20 28|homology
P09223479A1193|32 48|poxvirus serpins
P09223479A1193|56 63|ORF M11
P09223479A1193|84 91|homolog
P09223479A1193|106 115|molecules
P09223479A1193|133 151|gammaherpesviruses
P09223479A1193|153 157|gene
P09223479A1193|164 167|HVS
P09223479A1193|172 176|KSHV
P09223479A1193|185 195|BHRF1 gene
P09223479A1193|199 202|EBV
P09223506T0000|0 34|Transcription factor binding sites
P09223506T0000|59 86|immunodeficiency virus type
P09223506T0000|89 113|transcription start site
P09223506T0000|132 149|virus infectivity
P09223647T0000|0 17|Crystal structure
P09223647T0000|24 32|oligomer
P09223647T0000|48 56|zymogens
P09223647T0000|82 90|analysis
P09223647T0000|113 120|complex
P09223647T0000|125 137|implications
P09223647T0000|148 158|activation
P09223667A0139|18 30|transfection
P09223667A0139|34 57|NIH3T3 fibroblast cells
P09223667A0139|62 87|gel mobility shift assays
P09223667A0139|104 116|binding site
P09223667A0139|142 148|region
P09223667A0139|163 165|bp
P09223667A0139|175 199|transcription start site
P09223667A0139|213 227|CTCCC sequence
P09223880A1147|21 36|injection speed
P09223880A1147|43 52|.2 ml.s-1
P09223880A1147|77 87|anesthesia
P09224655T0000|12 20|splicing
P09224655T0000|24 29|ClC-6
P09224655T0000|33 39|member
P09224655T0000|47 74|CIC chloride-channel family
P09224655T0000|76 87|transcripts
P09224655T0000|114 122|isoforms
P09224655T0000|137 143|ClC-6c
P09224811A0000|12 17|study
P09224811A0000|49 62|transcription
P09224811A0000|70 75|NADPH
P09224811A0000|76 106|cytochrome P450 oxidoreductase
P09224811A0000|108 113|P450R
P09224811A0000|115 119|gene
P09224811A0000|140 147|thyroid
P09224811A0000|157 163|status
P09224811A0000|171 177|animal
P09224811A0000|230 238|pathways
P09224811A0000|282 298|P450R mRNA level
P09225151T0000|4 12|behavior
P09225151T0000|26 31|types
P09225151T0000|35 58|polytetrafluoroethylene
P09225151T0000|60 64|PTFE
P09225151T0000|66 76|prostheses
P09225151T0000|95 111|scarring process
P09225151T0000|125 137|wall defects
P09225506A0462|4 17|control group
P09225506A0462|48 54|levels
P09225506A0462|58 77|coagulation factors
P09225506A0462|82 83|V
P09225506A0462|88 92|VIII
P09225506A0462|110 121|index group
P09225682A0579|4 13|frequency
P09225682A0579|35 50|antibody titers
P09225682A0579|73 90|syndrome patients
P09225682A0579|96 99|PEN
P09225682A0579|103 111|isolates
P09225682A0579|155 163|syndrome
P09225682A0579|168 174|Fisher
P09225682A0579|177 194|syndrome patients
P09225682A0579|203 206|PEN
P09225682A0579|210 218|isolates
P09225686A0683|13 37|radiofrequency lesioning
P09225686A0683|45 54|hamartoma
P09225686A0683|67 84|seizure remission
P09225686A0683|93 106|complications
P09225686A0683|110 116|months
P09225686A0683|123 130|surgery
P09225998A0000|0 36|NF-kappa B/Rel transcription factors
P09225998A0000|56 66|activation
P09225998A0000|79 84|genes
P09225998A0000|104 127|regulation/inflammation
P09225998A0000|138 147|cytokines
P09225998A0000|149 171|cell surface receptors
P09225998A0000|173 191|adhesion molecules
P09225998A0000|203 217|phase proteins
P09226113A0857|29 48|source water sample
P09226113A0857|54 62|borehole
P09226113A0857|90 98|borehole
P09226345A0436|14 25|food intake
P09226345A0436|35 42|% group
P09226345A0436|64 73|ACT group
P09226345A0436|75 76|p
P09226345A0436|110 111|p
P09226345A0436|129 138|SEP group
P09226345A0436|155 162|amounts
P09226345A0436|179 180|%
P09226345A0436|190 201|requirement
P09227099A0106|14 23|technique
P09227099A0106|36 48|modification
P09227099A0106|54 72|bar superstructure
P09227099A0106|91 101|advantages
P09227099A0106|105 116|convenience
P09227099A0106|118 126|security
P09227099A0106|196 206|angulation
P09227099A0106|210 218|implants
P09227099A0106|227 235|accuracy
P09227332A1798|3 10|summary
P09227332A1798|12 15|DDC
P09227332A1798|24 33|receptors
P09227332A1798|46 51|panel
P09227332A1798|55 64|cytokines
P09227332A1798|71 80|receptors
P09227332A1798|85 94|cytokines
P09227332A1798|101 108|effects
P09227332A1798|112 114|DC
P09227799A0254|30 34|tool
P09227799A0254|55 67|surveillance
P09227799A0254|84 94|comparison
P09227799A0254|123 128|tests
P09227799A0254|130 147|stool examination
P09227799A0254|149 154|ELISA
P09227799A0254|168 179|egg antigen
P09227799A0254|181 184|SEA
P09227799A0254|205 220|precipitin test
P09227799A0254|222 226|COPT
P09228042A0109|20 49|dermatan sulfate proteoglycan
P09228042A0109|51 60|epiphycan
P09228042A0109|67 74|decorin
P09228042A0109|79 87|biglycan
P09228042A0109|110 120|extraction
P09228042A0109|137 157|epiphyseal cartilage
P09228042A0109|182 194|ion-exchange
P09228042A0109|196 210|gel permeation
P09228042A0109|229 232|Zn2
P09228042A0109|234 241|chelate
P09228042A0109|258 263|steps
P09228092A1779|6 14|analyses
P09228092A1779|36 52|dUTPase isoforms
P09228092A1779|77 81|gene
P09228092A1779|104 115|transcripts
P09228092A1779|136 139|use
P09228092A1779|158 163|exons
P09228202A0581|14 51|5-HT3 receptor antagonists ramosetron
P09228202A0581|53 58|YM060
P09228202A0581|61 66|YM114
P09228202A0581|68 75|KAE-393
P09228202A0581|78 89|granisetron
P09228202A0581|94 105|ondansetron
P09228202A0581|127 137|benzamides
P09228202A0581|139 166|5-HT4 receptor agonist/5-HT
P09228202A0581|168 188|receptor antagonists
P09228202A0581|190 209|cisapride mosapride
P09228202A0581|214 222|SC-53116
P09228202A0581|257 265|emptying
P09228202A0581|276 280|rats
P09229420A0158|0 13|Re-evaluation
P09229420A0158|21 36|biopsy specimen
P09229420A0158|52 55|hip
P09229420A0158|69 73|time
P09229420A0158|89 98|operation
P09229420A0158|106 111|areas
P09229420A0158|115 129|chondrosarcoma
P09229420A0158|145 155|background
P09229420A0158|168 182|chondromatosis
P09229595A0618|4 19|corneal buttons
P09229595A0618|59 67|electron
P09229595A0618|80 87|studies
P09230129A0039|22 33|homogeneity
P09230129A0039|43 50|% yield
P09230129A0039|54 77|affinity chromatography
P09230129A0039|88 101|DNA-cellulose
P09230129A0039|107 113|purity
P09230129A0039|127 138|preparation
P09230129A0039|155 163|SDS/PAGE
P09230129A0039|165 169|lack
P09230129A0039|173 186|contamination
P09230129A0039|196 205|nucleases
P09230129A0039|210 220|production
P09230129A0039|239 247|antibody
P09230129A0039|260 266|enzyme
P09230216T0000|18 34|glycosylase maps
P09230216T0000|38 58|chromosome 12q22-q24
P09230216T0000|64 70|region
P09230216T0000|79 83|loss
P09230216T0000|87 101|heterozygosity
P09230216T0000|113 119|cancer
P09230307A0329|0 3|FOG
P09230307A0329|24 30|GATA-1
P09230307A0329|48 59|development
P09230307A0329|96 101|cells
P09230384A0725|9 14|times
P09230384A0725|18 27|detection
P09230384A0725|35 47|mycobacteria
P09230384A0725|53 59|BACTEC
P09230384A0725|65 67|MB
P09230384A0725|72 78|BACTEC
P09230384A0725|83 85|TB
P09230384A0725|114 118|days
P09230384A1056|11 17|BACTEC
P09230384A1056|23 32|MB system
P09230384A1056|64 73|specimens
P09230384A1056|133 141|recovery
P09230384A1056|145 157|mycobacteria
P09230384A1056|172 181|specimens
P09230384A1056|210 215|sites
P09230894A0422|22 29|KmMig1p
P09230945A0089|18 27|deformity
P09230945A0089|66 70|slip
P09230986A0000|0 22|Autoimmune neutropenia
P09230986A0000|24 27|AIN
P09230986A0000|43 48|cause
P09230986A0000|60 71|neutropenia
P09230986A0000|95 103|children
P09232593A0946|5 11|regard
P09232593A0946|34 52|expression pattern
P09232593A0946|56 66|DJ protein
P09232593A0946|87 99|repeat units
P09232593A0946|120 125|roles
P09233487A1386|7 15|analysis
P09233487A1386|29 45|outcome measures
P09233487A1386|49 60|performance
P09233487A1386|106 113|benefit
P09233487A1386|117 130|ear selection
P09233487A1386|141 150|Prom-EABR
P09233772A0136|5 12|protein
P09233772A0136|25 29|p532
P09233772A0136|63 69|weight
P09233772A0136|71 77|EMBO J
P09233772A0136|124 131|domains
P09233772A0136|146 153|regions
P09233772A0136|172 179|repeats
P09233772A0136|202 227|cell cycle regulator RCC1
P09233772A0136|231 265|guanine nucleotide exchange factor
P09233772A0136|292 303|protein Ran
P09233772A0136|323 330|domains
P09233772A0136|353 365|beta subunit
P09233772A0136|384 394|G proteins
P09233772A0136|411 428|SH3 binding sites
P09233772A0136|441 455|leucine-zipper
P09233772A0136|479 505|HECT domain characteristic
P09233772A0136|509 537|E3 ubiquitin-protein ligases
P09233801A1180|10 22|L45 sequence
P09233801A1180|31 48|kinase subdomains
P09233801A1180|56 57|V
P09233801A1180|68 91|TGF-beta responsiveness
P09233801A1180|99 103|type
P09233801A1180|106 114|receptor
P09233809A0381|8 19|mouse lines
P09233809A0381|46 60|Hnf3g-lacZ YAC
P09233809A0381|85 89|copy
P09233809A0381|132 142|expression
P09233809A0381|161 163|kb
P09233809A0381|171 182|Hnf3g locus
P09233809A0381|195 203|elements
P09233809A0381|221 231|regulation
P09233809A0381|235 240|Hnf3g
P09233809A0815|24 34|transgenes
P09233809A0815|39 53|gene targeting
P09233809A0815|72 88|Hnf3g gene locus
P09233809A0815|135 141|region
P09233809A0815|149 153|gene
P09233809A0815|192 216|reporter gene expression
P09233809A0815|220 225|liver
P09233809A0815|227 235|pancreas
P09233809A0815|237 244|stomach
P09233809A0815|255 264|intestine
P09233811A0072|5 15|regulation
P09233811A0072|29 45|HMG-box proteins
P09233811A0072|62 88|Ste11 transcription factor
P09233811A0072|97 98|M
P09233811A0072|116 131|protein Mat1-Mc
P09234677A0770|24 34|hypothesis
P09234677A0770|50 61|transcripts
P09234677A0770|66 74|proteins
P09234677A0770|101 112|transcripts
P09234677A0770|136 147|respiration
P09234690A0242|0 8|Upstream
P09234690A0242|20 29|sequences
P09234690A0242|31 35|UASs
P09234690A0242|73 78|genes
P09234690A0242|141 145|PREs
P09234690A0242|158 161|PRE
P09234690A0242|175 187|binding site
P09234690A0242|201 208|protein
P09234696A0238|10 33|protein kinase cascades
P09234696A0238|76 83|protein
P09234696A0238|85 88|MAP
P09234696A0238|90 97|kinases
P09234703A0192|0 3|JNK
P09234703A0192|49 63|G proteins Rac
P09234703A0192|68 73|Cdc42
P09234713A0754|8 13|study
P09234713A0754|30 36|notion
P09234713A0754|64 67|PCR
P09234713A0754|82 91|formation
P09234713A0754|120 124|gene
P09234713A0754|126 129|RAG
P09234713A0754|141 161|double-strand breaks
P09234713A0754|163 167|DSBs
P09234713A0754|172 176|RSSs
P09234713A0754|183 190|Ddelta3
P09234713A0754|201 208|Jdelta1
P09234717A0000|7 14|studies
P09234717A0000|38 41|Cbl
P09234717A0000|55 70|protein product
P09234717A0000|78 98|c-cbl proto-oncogene
P09234717A0000|112 121|substrate
P09234717A0000|127 133|number
P09234717A0000|154 170|tyrosine kinases
P09234717A0000|175 190|forms complexes
P09234717A0000|196 199|SH3
P09234717A0000|204 207|SH2
P09234717A0000|226 234|proteins
P09234717A0000|252 256|role
P09234717A0000|260 279|signal transduction
P09234720A1015|42 45|MEK
P09234720A1015|47 53|MEK-2E
P09234720A1015|59 64|v-Src
P09234720A1015|114 125|H19-7 cells
P09234720A1015|127 139|coexpression
P09234720A1015|168 171|MEK
P09234720A1015|176 181|v-Src
P09234720A1015|190 207|neurite outgrowth
P09234723A0846|5 14|mechanism
P09234723A0846|21 29|contrast
P09234723A0846|39 44|cases
P09234723A0846|48 67|splicing regulation
P09234723A0846|71 74|PTB
P09234723A0846|89 96|protein
P09234723A0846|111 122|splice site
P09234725A1892|37 52|transactivation
P09234725A1892|59 78|interaction surface
P09234725A1892|107 122|transrepression
P09234725A1892|126 139|AP-1 activity
P09234727A0770|9 23|fusion protein
P09234727A0770|34 47|transcription
P09234727A0770|53 66|reporter gene
P09234727A0770|79 87|promoter
P09234727A0770|115 127|DNA elements
P09234736A0999|8 30|hybridization analysis
P09234736A0999|40 50|rat tissue
P09234736A0999|64 75|correlation
P09234736A0999|86 93|pattern
P09234736A0999|113 121|drm mRNA
P09234736A0999|192 197|cells
P09234736A0999|207 214|neurons
P09234736A0999|216 220|type
P09234736A0999|223 233|lung cells
P09234736A0999|239 251|goblet cells
P09234743A0475|17 25|proteins
P09234743A0475|48 52|pair
P09234743A0475|67 79|alpha-globin
P09234743A0475|82 85|UTR
P09234743A0475|140 141|C
P09234743A0475|143 159|binding proteins
P09234743A0475|167 180|alpha-complex
P09235073A0000|4 9|years
P09235073A0000|16 22|months
P09235073A0000|34 41|patient
P09235073A0000|52 61|diagnosis
P09235073A0000|65 80|Weaver syndrome
P09235424A1200|11 19|measures
P09235424A1200|28 34|nurses
P09235424A1200|53 57|ABPM
P09235424A1200|62 67|women
P09235424A1200|89 95|effect
P09235618A0000|5 11|series
P09235618A0000|15 23|patients
P09235618A0000|29 43|neuroinfection
P09235618A0000|45 57|Lyme disease
P09235618A0000|59 82|Guillain Barre syndrome
P09235618A0000|84 99|demyelinization
P09235618A0000|125 133|epilepsy
P09235618A0000|173 183|antibodies
P09235618A0000|187 190|IgG
P09235618A0000|195 207|IgM subtypes
P09235618A0000|237 244|factors
P09235618A0000|246 252|member
P09235618A0000|256 268|thrombocytes
P09235618A0000|270 288|sedimentation rate
P09235618A0000|292 304|erythrocytes
P09235995A0339|1 6|1996a
P09235995A0339|8 20|Biochemistry
P09235998A0788|12 31|membrane expression
P09235998A0788|35 40|alpha
P09235998A0788|45 58|beta subunits
P09235998A0788|75 86|cholesterol
P09235998A0788|91 109|17-ketocholesterol
P09235998A0788|133 150|HMG-CoA reductase
P09236118A1455|4 11|results
P09236118A1455|25 28|Lrp
P09236118A1455|57 61|site
P09236118A1455|104 110|groove
P09236118A1455|118 128|DNA target
P09236118A1455|150 156|dimers
P09236118A1455|174 179|sites
P09236118A1455|190 222|nucleoprotein activation complex
P09236224A0939|10 20|activation
P09236224A0939|24 38|p21 expression
P09236224A0939|74 81|feature
P09236224A0939|89 97|activity
P09236224A0939|101 104|NGF
P09236224A0939|125 143|PC12 growth arrest
P09236224A0939|151 166|differentiation
P09236441A0639|17 25|patients
P09236441A0639|36 46|recordings
P09236441A0639|50 53|ECG
P09236441A0639|77 94|oxygen saturation
P09236441A0639|96 100|SaO2
P09236441A0639|107 118|respiration
P09236441A0639|158 167|breathing
P09236656A0124|21 31|cell count
P09236656A0124|49 57|baseline
P09236656A0124|74 75|L
P09236656A0124|77 79|SD
P09236656A0124|101 102|L
P09236656A0124|104 106|SD
P09236656A0124|115 118|day
P09237695A0000|28 33|study
P09237695A0000|66 76|indicators
P09237695A0000|93 108|virus infection
P09237862A0782|20 24|eyes
P09237862A0782|45 54|reduction
P09237862A0782|77 84|absence
P09237862A0782|99 105|nerves
P09237862A0782|113 117|iris
P09238467A0763|6 13|lesions
P09238467A0763|32 43|propranolol
P09238467A0763|47 59|phentolamine
P09238850A0785|13 17|ICER
P09238850A0785|59 67|promoter
P09238850A0785|87 100|feedback loop
P09238850A2042|15 26|oscillation
P09238850A2042|55 60|clock
P09238850A2042|93 100|nucleus
P09238850A2042|102 105|SCN
P09238860A0175|21 28|nucleus
P09238860A0175|36 41|cells
P09238860A0175|113 155|AMP response element binding proteins CREB
P09238860A0175|160 168|CREM tau
P09238860A0175|174 180|manner
P09238860A0175|194 211|protein kinase A.
P09238860A1974|6 11|cells
P09238860A1974|33 40|signals
P09238860A1974|58 62|CREB
P09238860A1974|101 123|cytokine Interleukin-2
P09238860A1974|125 129|IL-2
P09238860A1974|134 142|response
P09238860A1974|146 152|agents
P09238860A1974|165 173|increase
P09238860A1974|188 191|Ca2
P09238860A1974|209 226|protein kinase C.
P09239635A0477|14 18|dogs
P09239635A0477|27 36|serum IgG
P09239635A0477|49 54|mg/ml
P09239635A0477|71 81|littermate
P09239635A0477|99 108|serum IgA
P09239635A0477|124 129|mg/ml
P09241092A1108|0 11|CONCLUSIONS
P09241092A1108|13 22|Valproate
P09241092A1108|46 61|glucuronidation
P09241092A1108|65 81|carbamazepine-10
P09241092A1108|85 95|trans-diol
P09241092A1108|128 138|conversion
P09241092A1108|142 158|carbamazepine-10
P09241092A1108|162 169|epoxide
P09241092A1108|178 199|trans-diol derivative
P09241092A1108|242 250|reaction
P09241232A0653|4 16|Ogg1 protein
P09241232A0653|39 49|DNA duplex
P09241232A0653|68 75|AP site
P09241232A0653|97 105|cytosine
P09241232A0653|107 111|AP/C
P09241232A1154|2 20|consensus sequence
P09241232A1154|50 64|lysine residue
P09241232A1154|66 70|K120
P09241232A1154|74 86|endonuclease
P09241232A1154|94 98|K241
P09241232A1154|102 106|Ogg1
P09242375A1313|15 23|findings
P09242375A1313|41 56|mutations E768D
P09242375A1313|61 66|V804L
P09242375A1313|71 97|gain-of-function mutations
P09242375A1313|122 133|RET isoform
P09242375A1313|138 146|capacity
P09242375A1313|169 175|effect
P09242375A1313|192 201|mutations
P09242375A1313|238 243|MEN2A
P09242375A1313|248 263|MEN2B mutations
P09242499A0505|0 10|Volunteers
P09242499A0505|36 41|backs
P09242499A0505|60 62|UV
P09242499A0505|75 76|d
P09242499A0505|83 94|application
P09242499A0505|102 112|sunscreens
P09242499A0505|123 134|base lotion
P09242499A0505|148 153|sites
P09242506A1033|0 3|E2F
P09242506A1033|23 30|complex
P09242506A1033|45 63|E2F family members
P09242506A1033|74 85|DP proteins
P09242551A0653|0 10|EBER1 mRNA
P09242551A0653|25 31|marker
P09242551A0653|41 48|latency
P09242551A0653|70 79|PEL cases
P09242551A0653|99 105|levels
P09242551A0653|126 134|controls
P09242551A0653|142 158|EBER1 expression
P09242551A0653|178 184|subset
P09242551A0653|188 202|lymphoma cells
P09243267A0401|0 7|METHODS
P09243267A0401|28 36|patients
P09243267A0401|46 55|diagnosis
P09243267A0401|68 82|cell carcinoma
P09243267A0401|95 101|cavity
P09243267A0401|125 134|treatment
P09243267A0401|138 164|Roswell Park Cancer Center
P09243267A0401|166 170|RPCI
P09243385A1314|11 14|use
P09243385A1314|18 31|presaturation
P09243385A1314|62 76|motion studies
P09243385A1314|88 104|PC velocity data
P09243505A1194|3 11|addition
P09243505A1194|29 40|experiments
P09243505A1194|73 85|MADS domains
P09243505A1194|91 96|dimer
P09243505A1194|150 161|specificity
P09243505A1194|169 176|complex
P09243505A1194|186 195|sequences
P09243505A1194|229 235|region
P09243505A1194|243 254|MADS domain
P09243505A1194|268 273|cases
P09243505A1194|305 316|specificity
P09243505A1194|324 332|proteins
P09243587A0000|0 18|PURPOSE/OBJECTIVES
P09243587A0000|35 43|question
P09243587A0000|80 89|pregnancy
P09243587A0000|91 95|FFTP
P09243587A0000|114 127|breast cancer
P09243587A0000|140 152|interruption
P09243587A0000|160 169|pregnancy
P09243587A0000|186 223|abortion increases breast cancer risk
P09243840A0663|12 19|studies
P09243840A0663|42 53|week period
P09243840A0663|73 81|HLA-DQA1
P09243840A0663|99 102|DNA
P09243840A0663|106 118|autopsy room
P09243840A0663|132 157|DNA Laboratory structures
P09244100A0194|11 15|rats
P09244100A0194|39 45|groups
P09244282A1371|0 11|Mutagenesis
P09244282A1371|19 23|pecT
P09244282A1371|35 41|region
P09244282A1371|55 63|presence
P09244282A1371|71 76|sites
P09244282A1371|86 96|insertions
P09244282A1371|112 127|pec-1 phenotype
P09244350A0000|0 5|BRCA1
P09244350A0000|18 24|breast
P09244350A0000|37 63|cancer susceptibility gene
P09244350A0000|80 95|phosphoproteins
P09244350A0000|113 130|tumor suppressors
P09244350A0000|140 159|breast cancer cells
P09244430A0693|16 28|splice sites
P09244430A0693|46 61|adducin isoform
P09244430A0693|63 69|beta-3
P09244430A0693|87 92|donor
P09244430A0693|97 111|acceptor sites
P09244430A0693|119 124|exons
P09246343T0000|0 11|Proteinuria
P09246343T0000|23 26|man
P09246585T0000|7 15|blockade
P09246585T0000|31 42|cancer pain
P09247645A0000|30 37|alleles
P09247645A0000|41 45|SEC3
P09247645A0000|67 76|SEC genes
P09247645A0000|103 109|fusion
P09247645A0000|134 142|vesicles
P09247645A0000|150 165|plasma membrane
P09247645A0000|214 220|screen
P09247645A0000|257 264|mutants
P09247645A0000|300 306|sec4-8
P09248639A0152|5 17|cell strains
P09248639A0152|34 45|fibroblasts
P09248639A0152|75 82|samples
P09248639A0152|91 104|blister fluid
P09248639A0152|113 119|effect
P09248639A0152|138 142|rate
P09248639A0152|146 157|contraction
P09248639A0152|175 185|fibroblast
P09248639A0152|196 213|collagen lattices
P09248639A0152|215 219|FPCL
P09249039A0124|26 33|enzymes
P09249039A0124|76 83|control
P09249039A0124|87 93|growth
P09249039A0124|95 110|differentiation
P09249039A0124|121 131|metabolism
P09249039A0124|135 146|vertebrates
P09249070A0989|0 4|Cell
P09249710A0331|26 30|sera
P09249710A0331|69 108|plaque reduction neutralization testing
P09250554A0402|0 8|Patients
P09250554A0402|25 37|diltiazem CD
P09250554A0402|42 44|mg
P09250554A0402|48 64|placebo once/day
P09250554A0402|68 79|combination
P09250554A0402|106 113|therapy
P09251843A0189|18 29|hyperplasia
P09251843A0189|46 51|cases
P09251843A0189|55 60|cases
P09251843A0189|90 101|hyperplasia
P09251843A0189|105 114|Castleman
P09251843A0189|117 124|disease
P09251843A0189|144 155|hyperplasia
P09251843A0189|180 188|lymphoma
P09251843A0189|207 212|cases
P09251843A0189|228 236|lymphoma
P09251843A0189|270 275|cases
P09252397A0081|27 39|repair rates
P09252397A0081|43 72|cyclobutane pyrimidine dimers
P09252397A0081|76 97|nucleotide resolution
P09252397A0081|114 122|JUN gene
P09252397A0081|133 144|fibroblasts
P09252397A0081|170 176|repair
P09252397A0081|180 189|sequences
P09252397A0081|199 228|transcription initiation site
P09252397A0081|238 244|repair
P09252397A0081|255 263|promoter
P09252406A0511|0 8|Tyrosine
P09252406A0511|37 49|binding site
P09252406A0511|58 62|Grb2
P09252406A0511|67 87|Shc adaptor proteins
P09252406A0511|93 104|p85 subunit
P09252406A0511|108 128|phosphatidylinositol
P09252406A0511|132 138|kinase
P09252406A0511|140 160|phospholipase Cgamma
P09252406A0511|168 179|phosphatase
P09252406A0511|181 185|SHP2
P09252879A0470|19 32|HRCT findings
P09252879A0470|51 59|features
P09252879A0470|71 80|functions
P09252879A0470|85 102|methacholine PC20
P09252879A0470|104 109|PC20M
P09252879A0470|138 150|significance
P09254678A0106|0 8|Gtx mRNA
P09254678A0106|24 32|parallel
P09254678A0106|42 46|RNAs
P09254678A0106|77 85|proteins
P09254678A0106|110 117|protein
P09254678A0106|119 122|MBP
P09254678A0106|129 148|proteolipid protein
P09254678A0106|150 153|PLP
P09254678A0106|172 189|brain development
P09254678A0106|191 199|Gtx mRNA
P09254678A0106|213 221|parallel
P09254678A0106|227 230|MBP
P09254678A0106|235 244|PLP mRNAs
P09254678A0106|252 258|brains
P09254678A0106|279 283|rats
P09254678A0106|298 312|point mutation
P09254678A0106|320 328|PLP gene
P09254709T0000|0 8|Contacts
P09254709T0000|17 45|Bacillus subtilis catabolite
P09254709T0000|57 69|protein CcpA
P09254709T0000|74 90|amyO target site
P09255349A0836|24 30|GTPase
P09255349A0836|42 50|proteins
P09255349A0836|62 66|IRA1
P09255349A0836|71 75|IRA2
P09256973A0455|4 6|E2
P09256973A0455|13 16|cat
P09256973A0455|37 42|group
P09256973A0455|44 45|G
P09256973A0455|57 59|G2
P09256973A0455|61 63|mg
P09256973A0455|67 82|itraconazole/kg
P09256973A0455|84 92|capsules
P09256973A0455|112 117|weeks
P09256973A0673|0 7|RESULTS
P09256973A0673|13 15|E1
P09256973A0673|17 55|itraconazole plasma drug concentration
P09256973A0673|72 76|time
P09256973A0673|86 90|dose
P09256973A0673|108 121|micrograms/ml
P09256973A0673|132 146|residence time
P09256973A0673|148 151|MRT
P09256973A0673|167 172|hours
P09257651T0000|10 21|U4/U6 snRNP
P09257651T0000|38 51|90kD proteins
P09257651T0000|92 120|yeast splicing factors Prp4p
P09257651T0000|125 130|Prp3p
P09257887A0457|0 5|G-CSF
P09257887A0457|21 24|day
P09257887A0457|35 40|cycle
P09257887A0457|44 57|microg/kg/day
P09257887A0457|79 82|day
P09257887A0457|99 108|apheresis
P09257887A0457|126 142|neutrophil count
P09258439A1001|9 26|expression system
P09258439A1001|58 63|forms
P09258439A1001|67 73|SsEF-2
P09258439A1001|86 97|mutagenesis
P09258439A1001|119 123|gene
P09258606A0822|0 9|Crosstalk
P09258606A0822|20 28|pathways
P09258606A0822|50 55|forms
P09258606A0822|59 65|stress
P09258606A0822|88 99|development
P09258606A0822|105 115|malignancy
P09259052A0568|0 17|Supershift assays
P09259052A0568|25 28|Jun
P09259052A0568|33 43|Fos family
P09259052A0568|60 70|antibodies
P09259052A0568|84 101|protein complexes
P09259052A0568|112 123|AtT-20 cell
P09259052A0568|132 140|extracts
P09259052A0568|154 169|c-jun AP-1 site
P09259052A0568|188 206|Jun family members
P09259052A0568|208 212|JunD
P09259052A0568|214 218|JunB
P09259052A0568|224 228|cJun
P09259313A0950|4 12|majority
P09259313A0950|16 34|PI kinase activity
P09259313A0950|71 86|PRL stimulation
P09259315A0809|0 8|Mutation
P09259315A0809|12 16|Enh4
P09259315A0809|43 51|enhanson
P09259315A0809|59 66|context
P09259315A0809|81 89|enhancer
P09259315A0809|101 118|silencer activity
P09259315A0809|137 153|GT-IIC enhansons
P09259315A0809|171 204|CSEn enhancer/silencer activities
P09259315A0809|208 212|BeWo
P09259315A0809|217 225|GC cells
P09259320A0830|22 36|chromatography
P09259320A0830|38 49|discordance
P09259320A0830|62 69|pattern
P09259320A0830|73 88|O-glycosylation
P09259320A0830|92 96|SSBP
P09259320A0830|101 105|DSBP
P09259328A0440|0 28|Deletion mapping experiments
P09259328A0440|49 58|sequences
P09259328A0440|77 85|activity
P09259328A0440|89 100|MSC-1 cells
P09259328A0440|126 128|bp
P09259328A0440|136 146|start site
P09259328A0440|170 177|regions
P09259328A0440|206 225|luciferase activity
P09259328A0440|236 238|bp
P09259328A0440|247 249|bp
P09259328A0440|256 258|bp
P09259328A0440|267 269|bp
P09259328A0440|280 282|bp
P09259328A0440|290 297|regions
P09261155A0833|17 19|PH
P09261155A0833|24 35|PTB domains
P09261155A0833|70 71|%
P09261155A0833|101 128|insulin receptor substrates
P09261155A0833|142 147|IRS-1
P09261155A0833|149 154|IRS-2
P09261155A0833|160 165|IRS-3
P09261178T0000|4 9|mouse
P09261178T0000|41 47|kinase
P09261178T0000|50 54|gene
P09261184A0170|19 46|gel mobility shift analysis
P09261184A0170|51 73|supershift experiments
P09261184A0170|75 80|FIRE1
P09261184A0170|140 144|NF-Y
P09261200T0001|0 10|MR imaging
P09261200T0001|24 37|head injuries
P09261200T0001|44 59|FLAIR technique
P09261397A0509|0 27|Gag protein sequence motifs
P09261397A0509|35 44|NC domain
P09261397A0509|62 69|viruses
P09261397A0509|96 116|genome encapsidation
P09261397A0509|138 142|FeFV
P09263010T0000|0 9|Induction
P09263010T0000|13 29|B cell apoptosis
P09263010T0000|50 54|CD23
P09263010T0000|59 62|sIg
P09263010T0000|81 91|regulation
P09263010T0000|95 100|c-myc
P09263010T0000|121 126|bcl-2
P09263094A0799|0 12|MEASUREMENTS
P09263094A0799|17 29|MAIN RESULTS
P09263094A0799|31 45|Lung elastance
P09263094A0799|47 49|EL
P09263094A0799|55 65|resistance
P09263094A0799|67 69|RL
P09263094A0799|92 104|measurements
P09263094A0799|108 123|airway pressure
P09263094A0799|136 144|pressure
P09263094A0799|150 161|airway flow
P09263094A0799|194 198|dogs
P09263094A0799|239 259|mean airway pressure
P09263094A0799|266 271|cmH2O
P09263094A0799|282 287|range
P09263094A0799|291 312|breathing frequencies
P09263094A0799|325 327|Hz
P09263094A0799|331 340|intervals
P09263094A0799|359 366|volumes
P09263094A0799|393 395|mL
P09263856A0563|28 34|models
P09263856A0563|43 46|Gla
P09263856A0563|51 64|EGF-1 modules
P09263856A0563|74 76|PS
P09263856A0563|95 106|prothrombin
P09263856A0563|111 119|factor X
P09263856A0563|133 143|structures
P09264466A0947|4 16|Cut9 subunit
P09264466A0947|35 41|target
P09264466A0947|57 60|APC
P09264466A0947|72 80|function
P09264466A0947|105 117|interactions
P09264466A0947|122 137|phosphorylation
P09265534A0455|4 8|dose
P09265534A0455|16 39|Gy/20 fractions/5 weeks
P09265642A0668|25 32|pathway
P09265642A0668|40 47|vacuole
P09265642A0668|78 85|pathway
P09265642A0668|87 102|internalization
P09265642A0668|113 121|membrane
P09265642A0668|132 141|marker FM
P09265642A0668|166 177|sop mutants
P09265932A0575|8 13|women
P09265932A0575|28 30|mg
P09265932A0575|37 48|bupivacaine
P09265932A0575|66 75|injection
P09265932A0575|83 98|L2-3 interspace
P09267306A0381|24 28|case
P09267306A0381|43 54|measurement
P09267306A0381|58 63|apo B
P09267306A0381|89 97|standard
P09267306A0381|101 121|laboratory precision
P09267306A0381|126 137|reliability
P09267306A0381|162 174|introduction
P09267306A0381|187 199|laboratories
P09267431A0000|4 23|soybean cDNA clones
P09267431A0000|25 30|SPK-3
P09267431A0000|35 40|SPK-4
P09267431A0000|60 75|protein kinases
P09267439A0000|0 5|Genes
P09267439A0000|23 38|ras superfamily
P09267439A0000|83 91|proteins
P09267439A0000|126 133|variety
P09267439A0000|137 146|organisms
P09267542A0126|0 10|Naltrexone
P09267542A0126|45 49|Food
P09267542A0126|54 73|Drug Administration
P09267542A0126|82 91|treatment
P09267542A0126|95 113|alcohol dependence
P09268298T0000|0 20|Ent-kaurene synthase
P09268298T0000|30 53|fungus Phaeosphaeria sp
P09268387A0293|8 14|report
P09268387A0293|61 64|ELL
P09268387A0293|76 83|domains
P09268387A0293|100 111|interaction
P09268387A0293|117 131|RNA polymerase
P09268387A0293|151 169|elongation complex
P09268578A0225|14 28|cDNA sequences
P09268578A0225|60 67|message
P09268578A0225|88 93|death
P09268578A0225|95 98|mud
P09268631A0316|4 12|position
P09268631A0316|14 39|transcription orientation
P09268631A0316|55 61|status
P09268631A0316|69 74|genes
P09268631A0316|96 101|Igf2r
P09268638A0332|30 56|chromosome walking studies
P09268638A0332|71 77|D8S260
P09268638A0332|89 95|D8S285
P09268652A0116|20 39|zinc finger protein
P09268652A0116|41 50|dsRBP-ZFa
P09268652A0116|77 95|expression library
P09268652A0116|101 106|dsRNA
P09268661A1405|4 11|results
P09268661A1405|30 42|retroplasmid
P09268661A1405|51 64|transcriptase
P09268661A1405|97 111|cDNA synthesis
P09268661A1405|132 144|CCA sequence
P09269879A0266|6 16|absorption
P09269879A0266|34 49|bioavailability
P09269879A0266|56 57|%
P09269879A0266|67 69|iv
P09269879A0266|80 100|elimination profiles
P09269900A1035|16 23|results
P09269900A1035|37 48|EGF/Ras/Raf
P09269900A1035|57 70|transcription
P09269900A1035|84 94|activation
P09269900A1035|98 108|ATF3/c-Jun
P09269900A1035|130 136|factor
P09269900A1035|146 150|JunD
P09269900A1035|161 170|repressor
P09269900A1035|179 187|response
P09271393A1333|16 20|data
P09271393A1333|31 36|model
P09271393A1333|46 61|Tax anchors CBP
P09271393A1333|69 84|HTLV-1 promoter
P09271393A1333|114 124|activation
P09271393A1333|159 169|activities
P09271393A1333|184 194|remodeling
P09271393A1333|199 210|recruitment
P09271393A1333|226 249|transcription machinery
P09271394A0558|0 5|DNase
P09271394A0558|39 51|footprinting
P09271394A0558|55 77|MURA-Mu1 TIR complexes
P09271394A0558|92 96|MURA
P09271394A0558|138 144|region
P09271394A0558|152 155|TIR
P09271394A0558|159 162|Mu1
P09271397A1596|21 26|model
P09271397A1596|40 49|construct
P09271397A1596|74 80|copies
P09271397A1596|95 118|LDL receptor SREBP site
P09271397A1596|138 146|Sp1 site
P09271397A1596|208 215|fashion
P09271400A0475|8 14|assays
P09271400A0475|27 44|promoter activity
P09271400A0475|53 61|sequence
P09271400A0475|89 96|control
P09271400A0475|100 115|E2F2 expression
P09271400A0475|125 143|growth stimulation
P09271417A0585|13 18|mouse
P09271417A0585|20 29|ERR alpha
P09271417A0585|58 64|kidney
P09271417A0585|66 71|heart
P09271417A0585|83 93|adipocytes
P09271417A0585|95 102|tissues
P09271417A0585|141 146|acids
P09271417A1011|4 8|MCAD
P09271417A1011|17 42|receptor response element
P09271417A1011|46 52|NRRE-1
P09271417A1011|78 87|ERR alpha
P09271417A1011|101 112|COS-7 cells
P09271496T0000|0 16|Mapping features
P09271496T0000|20 35|HIV-1 integrase
P09271496T0000|50 55|sites
P09271496T0000|69 89|target DNA molecules
P09271496T0000|114 121|complex
P09271496T0000|125 144|photo-cross-linking
P09272108A1295a|0 8|Analysis
P09272108A1295a|28 34|region
P09272108A1295a|42 46|gene
P09272108A1295a|65 73|presence
P09272108A1295a|86 90|TATA
P09272108A1295a|95 109|CAAT sequences
P09272108A1295b|0 8|Analysis
P09272108A1295b|28 34|region
P09272108A1295b|42 46|gene
P09272108A1295b|65 73|presence
P09272108A1295b|86 90|TATA
P09272108A1295b|95 109|CAAT sequences
P09272138A1153|13 21|response
P09272138A1153|23 25|CR
P09272138A1153|27 31|rate
P09272138A1153|38 39|%
P09272138A1153|47 51|CODE
P09272138A1153|57 70|rhG-CSF group
P09272138A1153|77 78|%
P09272138A1153|86 90|CODE
P09272138A1153|97 102|group
P09272138A1153|115 123|survival
P09272138A1153|138 143|weeks
P09272138A1153|168 174|groups
P09272138A1153|176 177|P
P09275159T0000|22 42|ribonucleoprotein A1
P09275159T0000|81 87|region
P09275159T0000|91 116|mouse hepatitis virus RNA
P09275164A0000|4 25|m7GpppN cap structure
P09275164A0000|40 44|mRNA
P09275164A0000|93 99|action
P09275164A0000|109 116|enzymes
P09275164A0000|118 136|RNA triphosphatase
P09275164A0000|138 161|RNA guanylyltransferase
P09275164A0000|167 170|RNA
P09275164A0000|172 181|guanine-7
P09275164A0000|183 200|methyltransferase
P09275990A0938|13 17|part
P09275990A0938|25 30|study
P09275990A0938|44 56|mutagenicity
P09275990A0938|73 84|TA98 strain
P09275990A0938|103 113|activation
P09275990A0938|142 165|mutagenicity prevalence
P09275990A0938|169 175|diesel
P09276882A0479|4 12|addition
P09276882A0479|16 23|culture
P09276882A0479|31 33|CC
P09276882A0479|38 40|CC
P09276882A0479|41 55|SW by-products
P09276882A0479|68 77|pH values
P09276882A0479|85 86|P
P09276882A0479|114 121|culture
P09276882A0479|125 128|Day
P09276882A0479|143 167|% carbohydrate treatment
P09276882A0479|190 192|pH
P09276882A0479|205 219|% carbohydrate
P09277472A1070|24 29|edema
P09277472A1070|57 66|mechanism
P09277472A1070|80 91|dysfunction
P09277472A1070|98 107|DC shocks
P09277629A0268|4 15|experiments
P09277629A0268|17 18|N
P09277629A0268|62 68|nature
P09277629A0268|72 88|ERP negativities
P09277629A0268|107 118|memory task
P09277629A0268|146 157|memory task
P09278441A0163|0 4|Biol
P09278441A1160|4 11|pattern
P09278441A1160|16 22|timing
P09278441A1160|26 46|CARP mRNA expression
P09278441A1160|68 78|expression
P09278441A1160|86 92|tongue
P09278441A1160|101 105|days
P09278441A1160|135 139|Nkx2
P09278441A1160|142 145|Csx
P09278441A1160|158 165|homolog
P09278441A1160|169 175|tinman
P09278441A1160|205 209|gene
P09278441A1160|234 245|development
P09278441A1777|0 14|Overexpression
P09278441A1777|18 22|CARP
P09278441A1777|26 40|cardiomyocytes
P09278441A1777|60 70|troponin C
P09278441A1777|94 114|factor transcription
P09278445T0000|0 21|Substrate specificity
P09278445T0000|29 43|RNase activity
P09278445T0000|47 67|yeast RNA polymerase
P09278450A1338|16 37|mobility shift assays
P09278450A1338|42 65|competition experiments
P09278450A1338|78 84|site A
P09278450A1338|105 116|NF1 protein
P09278454A1261|0 11|Examination
P09278454A1261|19 37|MMP-2 RE1 sequence
P09278454A1261|61 75|Y-box sequence
P09278454A1261|77 89|CTGCTGGGCAAG
P09278454A1261|139 143|YB-1
P09278454A1261|147 183|DMS protection footprinting analysis
P09278475A0465|7 12|scs32
P09278475A0465|43 55|ts phenotype
P09278475A0465|87 100|Ino-phenotype
P09278475A0465|104 112|rpo26-31
P09278494A0762|3 11|contrast
P09278494A0762|18 21|Sp1
P09278494A0762|26 38|ETS proteins
P09278494A0762|72 89|promoter activity
P09278494A0762|97 113|Surf-1 direction
P09278758A1636|0 10|CONCLUSION
P09278758A1636|12 24|Patients wit
P09278758A1636|45 57|neck disease
P09278758A1636|59 63|N1-3
P09278758A1636|79 87|evidence
P09278758A1636|108 115|disease
P09278758A1636|131 137|spread
P09278758A1636|166 177|lymph nodes
P09278758A1636|193 197|risk
P09278758A1636|212 219|failure
P09278758A1636|231 236|sites
P09279379A0310|23 29|pBR322
P09279379A0310|47 51|acid
P09279379A0310|53 56|DNA
P09279379A0310|58 67|sequences
P09279379A0310|97 103|region
P09279379A0310|112 118|spacer
P09279379A0310|130 136|spacer
P09279379A0310|144 160|H2B histone gene
P09279889A1124|0 4|Area
P09279889A1124|15 19|drug
P09279889A1124|39 45|curves
P09279889A1124|47 57|AUC0-24 hr
P09279889A1124|63 66|MTX
P09279889A1124|86 88|ng
P09279889A1124|100 104|PG-2
P09279889A1124|106 113|% Azone
P09279889A1124|118 122|PG-7
P09279889A1124|124 139|% Azone systems
P09280747A0195|4 15|combination
P09280747A0195|19 44|hydralazine hydrochloride
P09280747A0195|49 69|isosorbide dinitrate
P09280747A0195|84 92|survival
P09280747A0195|105 115|comparison
P09280747A0195|124 132|regimens
P09280747A0195|142 150|evidence
P09280747A0195|173 179|effect
P09280747A0195|197 211|ACE inhibitors
P09282329A0527|11 21|mechanisms
P09282329A0527|34 46|interactions
P09282329A0527|50 54|Site
P09282329A0527|69 76|factors
P09282329A0527|87 113|cell cycle control element
P09282329A0527|142 154|determinants
P09282329A0527|174 184|regulation
P09282329A0527|192 213|G1/S phase transition
P09282329A0527|217 223|FDC-P1
P09282329A0527|238 254|progenitor cells
P09282911A0277|4 8|goal
P09282911A0277|17 22|study
P09282911A0277|48 61|cell cultures
P09282911A0277|75 90|RC3/neurogranin
P09282911A0277|131 133|T3
P09282911A0277|154 163|mechanism
P09282911A0277|167 177|regulation
P09282985A0961|11 22|differences
P09282985A0961|31 36|males
P09282985A0961|38 39|p
P09282985A0961|64 79|characteristics
P09283828A0484|16 25|responses
P09283828A0484|56 60|cues
P09285715A1257|18 22|data
P09285715A1257|43 46|Rev
P09285715A1257|61 75|export pathway
P09285715A1257|105 109|RNAs
P09285715A1257|114 116|5S
P09285715A1257|127 130|RNA
P09285715A1257|136 139|CTE
P09285715A1257|188 195|factors
P09285715A1257|228 239|mRNA export
P09285789A0712|6 9|Duo
P09285789A0712|21 55|guanine nucleotide exchange factor
P09285789A0712|57 60|GEF
P09285789A0712|62 68|domain
P09285789A0712|107 126|pleckstrin homology
P09285789A0712|128 130|PH
P09285789A0712|132 138|domain
P09285789A0712|157 169|repeat units
P09286115T0000|0 3|S2F
P09286115T0000|34 40|factor
P09286115T0000|70 77|element
P09286115T0000|111 121|RPL21 gene
P09286981A0147|0 4|ArgR
P09286981A0147|23 28|dimer
P09286981A0147|42 50|subunits
P09286981A0147|74 78|mass
P09286981A0147|89 91|Da
P09287036A0457|0 28|Plasma leptin concentrations
P09287036A0457|44 49|women
P09287036A0457|55 58|men
P09287036A0457|75 85|adjustment
P09287036A0457|90 101|differences
P09287036A0457|109 113|mass
P09287036A0457|124 129|ng/ml
P09287036A0457|134 139|women
P09287352A0930|16 23|effects
P09287352A0930|27 42|STAT activation
P09287352A0930|52 68|SHP-1 expression
P09287352A0930|95 105|activation
P09287352A0930|131 153|protein kinase pathway
P09287352A0930|155 165|expression
P09287352A0930|169 174|SHP-1
P09287352A0930|176 179|Cys
P09287352A0930|184 187|Ser
P09287352A0930|199 207|activity
P09287352A0930|211 214|MEK
P09287352A0930|234 235|%
P09287352A0930|245 255|expression
P09287352A0930|259 264|SHP-1
P09287352A0930|295 305|% increase
P09287362A0589|5 16|interaction
P09287362A0589|30 40|SH3 region
P09287362A0589|44 47|p50
P09287362A0589|48 51|csk
P09287362A0589|72 78|region
P09287362A0589|80 97|PPPLPERTPESFVLADM
P09287362A0589|121 127|region
P09287362A0589|131 139|PTP-PEST
P09288848A0780|14 16|Gy
P09288848A0780|18 30|HbO2 changes
P09288916T0000|10 20|expression
P09288916T0000|76 90|acid hydrolase
P09288916T0000|98 104|meprin
P09288916T0000|106 111|alpha
P09288916T0000|116 129|beta subunits
P09288916T0000|133 144|Madin-Darby
P09288916T0000|152 164|kidney cells
P09290207A0731|25 37|derepression
P09290207A0731|52 68|mating type loci
P09290571A0420|9 17|patients
P09290571A0420|43 46|VTs
P09290571A0420|80 85|study
P09290571A0420|87 90|EPS
P09290571A0420|96 99|VTs
P09290571A0420|107 115|patients
P09290571A0799|4 16|cycle length
P09290571A0799|28 30|VT
P09290571A0799|32 33|n
P09290571A0799|39 42|VTs
P09290571A0799|59 63|msec
P09291077T0000|10 25|hyperammonaemia
P09291077T0000|45 57|shepherd dog
P09291098A0452|28 39|kb mRNA V-1
P09291098A0452|52 67|kb GGT mRNA V-2
P09291098A0452|89 97|splicing
P09291098A0452|114 124|transcript
P09291098A0452|147 155|promoter
P09291098A0452|163 175|rat GGT gene
P09291098T0000|18 26|promoter
P09291098T0000|36 81|gamma-glutamyl transpeptidase gene expression
P09291098T0000|102 105|rat
P09291098T0000|118 129|liver cells
P09292499A0887|6 21|repressor sites
P09292499A0887|26 36|pyrimidine
P09292499A0887|65 101|polypyrimidine tract binding protein
P09292499A0887|103 106|PTB
P09292499A0887|111 115|HeLa
P09292499A0887|124 132|extracts
P09292499A0887|150 184|UV crosslinking/competition assays
P09293006A1412|11 21|expression
P09293006A1412|25 29|lipA
P09293006A1412|33 44|S. lividans
P09293006A1412|50 54|gene
P09293006A1412|85 99|aphII promoter
P09294139A0729|16 36|core homology region
P09294139A0729|48 62|HS12 enhancers
P09294139A0729|83 84|%
P09294139A0729|109 116|homolog
P09294139A0729|137 143|motifs
P09294139A0729|188 196|function
P09294139A0729|211 219|enhancer
P09294139A0729|232 240|segments
P09294139A0729|249 270|sequence conservation
P09294139A0729|283 294|possibility
P09294139A0729|333 339|motifs
P09294161A0650|3 11|contrast
P09294161A0650|29 36|protein
P09294161A0650|38 48|expression
P09294161A0650|52 61|p45 NF-E2
P09294161A0650|75 92|activation domain
P09294161A0650|99 104|NF-E2
P09294161A0650|110 119|cell line
P09294161A0650|156 169|transcription
P09294161A0650|183 189|assays
P09294161A1103|6 14|findings
P09294161A1103|37 46|mechanism
P09294161A1103|58 69|recruitment
P09294161A1103|91 98|regions
P09294161A1103|106 117|globin loci
P09294161A1103|136 145|promoters
P09294262A0885|4 19|promoter region
P09294262A0885|30 48|consensus TATA box
P09294262A0885|65 70|CCAAT
P09294262A0885|75 85|CreA boxes
P09294262A0885|115 121|stress
P09294262A0885|144 154|regulation
P09294262A0885|165 174|promoters
P09294422A1223|8 25|cysteine residues
P09294422A1223|53 59|region
P09294422A1223|83 92|formation
P09294422A1223|98 114|disulfide bridge
P09294422A1223|135 153|activation process
P09294422A1223|171 179|activity
P09294422A1376|4 12|por gene
P09294422A1376|47 51|time
P09294422A1376|153 165|tac promoter
P09294422A1376|184 194|production
P09294422A1376|198 201|POR
P09294422A1376|216 220|form
P09294452A2107|20 28|operator
P09294452A2107|63 72|reduction
P09294452A2107|76 98|reporter enzyme levels
P09294453A0949|4 15|ORF3 mutant
P09294453A0949|33 39|levels
P09294453A0949|43 51|tabtoxin
P09294453A0949|69 73|ORF3
P09294453A0949|85 89|role
P09294453A0949|93 114|T beta L biosynthesis
P09294471A1198|8 18|Cox models
P09294471A1198|27 36|CD4 count
P09294471A1198|40 50|150/microL
P09294471A1198|63 73|200/microL
P09294471A1198|89 91|I0
P09294471A1198|96 98|I1
P09294471A1198|120 125|model
P09294471A1198|138 141|fit
P09294471A1198|158 162|data
P09296251A0163|23 30|reports
P09296251A0163|50 56|number
P09296251A0163|60 68|patients
P09296251A0163|81 85|data
P09297698A0933|6 17|transcripts
P09297698A0933|33 37|ends
P09297698A0933|48 60|UbCRBP mRNAs
P09297698A0933|77 83|UbCRBP
P09297698A0933|107 113|region
P09297698A0933|133 141|distance
P09297698A0933|154 166|enolase gene
P09299696A1074|4 16|distribution
P09299696A1074|20 34|cryptosporidia
P09299696A1074|42 51|intestine
P09299696A1074|56 62|number
P09299696A1074|66 80|cryptosporidia
P09299696A1074|91 97|villus
P09299696A1074|111 114|DPI
P09299696A1074|148 164|characterization
P09299696A1074|172 181|infection
P09299696A1074|185 189|kids
P09299696A1074|195 200|model
P09299696A1074|218 235|cryptosporidiosis
P09300323A1182|5 11|result
P09300323A1182|46 62|blood flow ratio
P09300323A1182|64 72|ENDO/EPI
P09300323A1182|110 126|control stenosis
P09300323A1182|150 153|ITF
P09300323A1182|181 185|i.v.
P09300323A1182|214 217|NTG
P09300697A0000|0 11|Proteasomes
P09300697A0000|33 41|protease
P09300697A0000|58 68|generation
P09300697A0000|72 80|peptides
P09300697A0000|94 103|MHC class
P09300697A0000|106 115|molecules
P09300698A1219|3 10|support
P09300698A1219|19 33|interpretation
P09300698A1219|54 58|MQ9b
P09300698A1219|125 133|peptides
P09301114A0573|0 9|Takahashi
P09301114A0573|11 13|H.
P09301350A0946|4 24|sputum interleukin-8
P09301350A0946|53 80|treatment median difference
P09301350A0946|88 93|pg/ml
P09301350A0946|97 118|% confidence interval
P09301350A0946|120 122|CI
P09301350A0946|134 139|pg/ml
P09301350A0946|144 150|favour
P09301350A0946|154 161|placebo
P09301350A0946|181 196|expiratory flow
P09301350A0946|202 203|%
P09301350A0946|210 211|%
P09301350A0946|236 244|capacity
P09301350A0946|259 262|sex
P09301350A0946|267 273|height
P09301350A0946|289 306|percentage points
P09301350A0946|308 310|pp
P09301350A0946|315 319|% CI
P09301350A0946|328 330|pp
P09301350A0946|332 357|mean treatment difference
P09301350A0946|361 367|favour
P09301350A0946|371 378|placebo
P09303437A0875|18 26|deletion
P09303437A0875|30 33|Fp1
P09303437A0875|41 52|hCRBP1 gene
P09303437A0875|71 83|CAT activity
P09303437A0875|123 131|function
P09303437A0875|148 155|element
P09303437A0875|161 170|insertion
P09303437A0875|187 190|p12
P09303437A0875|197 205|promoter
P09303437A0875|240 251|stimulation
P09303437A0875|255 274|CAT gene expression
P09303635A0000|0 7|Gaucher
P09303635A0000|10 17|disease
P09303635A0000|38 46|disorder
P09303635A0000|68 72|lack
P09303635A0000|100 106|enzyme
P09304123A0079|6 19|discoloration
P09304123A0079|48 52|ways
P09304123A0079|70 85|tooth structure
P09304123A0079|123 129|manner
P09304123A0079|133 138|order
P09304123A0079|161 165|bulk
P09304123A0079|190 198|material
P09305592A0000|21 49|translocation characteristic
P09305592A0000|53 56|CML
P09305592A0000|76 88|bcr/abl gene
P09305592A0000|105 119|fusion protein
P09305592A0000|121 132|p210bcr/abl
P09305631A0770|0 14|Overexpression
P09305631A0770|18 23|BAG-1
P09305631A0770|47 57|cell lines
P09305631A0770|63 67|heat
P09305631A0770|82 92|cell death
P09305755A0540|16 22|region
P09305755A0540|42 55|binding sites
P09305755A0540|73 80|protein
P09305755A0540|82 85|Sp1
P09305755A0540|95 101|factor
P09305755A0540|105 108|NF1
P09305755A0540|111 135|CAAT-box binding protein
P09305755A0540|137 142|C/EBP
P09305755A0540|145 155|hepatocyte
P09305755A0540|164 171|factors
P09305755A0540|181 185|HNF1
P09305755A0540|187 191|HNF5
P09305755A0540|197 215|activator proteins
P09305755A0540|225 228|AP1
P09305755A0540|230 233|AP2
P09305870A0894|4 27|recognition specificity
P09305870A0894|35 49|p55 PDZ domain
P09305870A0894|88 99|PDZ domains
P09305870A0894|103 107|hDlg
P09305870A0894|115 135|lymphocyte homologue
P09305870A0894|154 159|discs
P09305870A0894|166 182|tumor suppressor
P09305870A0894|212 218|domain
P09305870A0894|222 236|glycophorin C.
P09305944A0621|17 32|RanGAP activity
P09305944A0621|38 44|series
P09305944A0621|72 96|rna1p mutant derivatives
P09305944A0621|129 137|sequence
P09305944A0621|156 162|domain
P09305944A0621|171 185|yeast proteins
P09305944A0621|231 245|GTP hydrolysis
P09307065A0553|7 14|absence
P09307065A0553|18 27|MHC class
P09307065A0553|49 56|D10 TCR
P09307065A0553|88 102|enterotoxin C2
P09307065A0553|111 127|association rate
P09307065A0553|150 151|M
P09307065A0553|156 159|sec
P09307065A0553|170 187|dissociation rate
P09307065A0553|211 214|sec
P09307065A0553|229 250|dissociation constant
P09307065A0553|258 264|microM
P09307312A0172|0 8|Evidence
P09307312A0172|23 29|shifts
P09307312A0172|52 61|responses
P09307312A0172|74 86|nerve fibers
P09307312A0172|97 109|microphonics
P09307312A0172|119 128|responses
P09307312A0172|138 148|hair cells
P09307312A0172|164 169|cells
P09307312A0172|177 184|cochlea
P09307312A0172|208 239|membrane vibration measurements
P09307312A0172|275 279|data
P09308234A0225|0 3|Mnt
P09308234A0225|4 17|Max complexes
P09308234A0225|58 68|activation
P09308234A0225|83 91|promoter
P09308738A1216|7 20|United States
P09308738A1216|29 32|HES
P09308738A1216|123 125|MW
P09308738A1216|141 149|decrease
P09308738A1216|153 193|factor VIII/von Willebrand factor levels
P09309457A0680|0 6|Assays
P09309457A0680|16 27|cholesterol
P09309457A0680|43 46|HDL
P09309457A0680|48 52|HDL2
P09309457A0680|54 57|LDL
P09309457A0680|59 72|triglycerides
P09309457A0680|74 86|endothelin-1
P09309457A0680|88 99|lipoprotein
P09309457A0680|105 114|estradiol
P09309457A0680|119 122|FSH
P09309457A0680|145 153|baseline
P09309457A0680|171 174|ERT
P09309457A0680|187 193|months
P09309457A0680|197 200|ERT
P09310836A1019|11 18|repeats
P09310836A1019|26 35|P element
P09310836A1019|50 63|SV40 promoter
P09310836A1019|77 108|phorbol 12-myristate 13-acetate
P09310836A1019|130 138|elements
P09311164A0245|24 33|density J
P09311164A0245|59 65|volume
P09311164A0245|81 91|motor unit
P09311568A0595|4 23|cleavage dipeptides
P09311568A0595|27 45|C1YVV NIa protease
P09311568A0595|50 51|Q
P09311568A0595|52 53|E
P09311568A0595|55 56|S
P09311568A0595|57 58|A
P09311568A0595|59 60|G
P09311796A0218|16 23|studies
P09311796A0218|41 51|activation
P09311796A0218|80 93|IEP86 binding
P09311796A0218|106 130|TATA-box binding protein
P09311796A0218|132 135|TBP
P09311796A0218|145 165|transcription factor
P09311808A0341|38 49|p4 molecule
P09311810A0814|9 21|accumulation
P09311810A0814|25 42|cyclin D3 protein
P09311810A0814|46 56|Vero cells
P09311810A0814|74 96|alpha0 deletion mutant
P09311810A0814|129 134|cells
P09311810A0814|159 164|virus
P09311810A0814|182 187|virus
P09311810A0814|209 225|alpha0 sequences
P09311835A0147|38 54|characterization
P09311835A0147|62 72|T antigens
P09311835A0147|90 102|SV40 mutants
P09311835A0147|153 161|residues
P09311835A0147|181 199|ATP binding pocket
P09312025A0373|6 13|effects
P09312025A0373|32 45|co-expression
P09312025A0373|66 74|PKC zeta
P09312025A0373|79 89|inhibition
P09312025A0373|93 136|phosphatidylinositol 3-kinase p85alpha-p110
P09312025A0373|140 150|wortmannin
P09312025A0373|152 160|LY294002
P09312025A0373|185 191|mutant
P09312025A0373|195 203|p85alpha
P09312025T0000|0 22|Protein phosphatase 2A
P09312025T0000|37 46|regulator
P09312025T0000|50 81|protein kinase C zeta signaling
P09312025T0000|94 98|SV40
P09312025T0000|105 106|t
P09312025T0000|118 129|cell growth
P09312025T0000|134 154|NF-kappaB activation
P09312028A0975|19 32|RXRalphaF318A
P09312028A0975|46 54|activity
P09312028A0975|72 84|heterodimers
P09312028A0975|92 100|presence
P09312028A0975|104 110|BMS614
P09312028A0975|124 133|integrity
P09312028A0975|142 145|RXR
P09312028A0975|150 166|RAR AF-2 domains
P09312032A0165|6 13|introns
P09312032A0165|34 46|snoRNA genes
P09312032A0165|57 67|processing
P09312032A0165|92 99|release
P09312032A0165|107 113|snoRNA
P09312032A0165|130 144|intron lariats
P09312087A0000|7 14|studies
P09312087A0000|35 49|Src homology-2
P09312087A0000|51 54|SH2
P09312087A0000|91 102|phosphatase
P09312087A0000|104 109|SHP-2
P09312087A0000|143 149|domain
P09312087A0000|153 160|PECAM-1
P09312087A0000|206 226|platelet aggregation
P09312087A0000|230 237|process
P09312087A0000|262 266|part
P09312087A0000|286 301|phosphopeptides
P09312087A0000|335 341|domain
P09312087A0000|345 352|PECAM-1
P09312087A0000|366 391|tyrosine residues Tyr-663
P09312087A0000|395 402|Tyr-686
P09313755A0816|15 25|clustering
P09313755A0816|35 49|risk variables
P09313755A0816|61 68|factors
P09314306A0571|0 15|Supplementation
P09314306A0571|33 39|pl-ALB
P09314306A0571|52 56|g/dL
P09314487T0000|0 9|Detection
P09314487T0000|22 48|Mycobacterium tuberculosis
P09314487T0000|52 66|air filtration
P09314487T0000|71 96|polymerase chain reaction
P09314537A1600|6 14|findings
P09314537A1600|25 30|EBP50
P09314537A1600|61 82|ezrin binding protein
P09314554A0149|41 52|translation
P09314554A0149|75 78|AUG
P09314554A0149|97 110|reading frame
P09314554A0149|158 170|presentation
P09314554A0149|182 190|epitopes
P09314554A0149|208 222|reading frames
P09314554A0149|234 272|influenza A PR/8/34 nucleoprotein gene
P09314570A0153|5 11|family
P09314570A0153|15 23|proteins
P09314570A0153|38 44|motifs
P09314570A0153|67 81|gene promoters
P09314570A0153|105 115|activation
P09314570A0153|119 129|repression
P09314570A0153|149 159|activities
P09315631A1064|0 8|Deletion
P09315631A1064|16 25|POR2 gene
P09315631A1064|50 59|phenotype
P09315631A1064|67 73|yeasts
P09315631A1064|79 88|deletions
P09315631A1064|101 105|POR1
P09315631A1064|110 120|POR2 genes
P09315631A1064|153 161|glycerol
P09315631A1064|168 177|degrees C
P09315631A1064|203 213|delta por1
P09315631A1064|221 228|mutants
P09315632A1137|23 34|observation
P09315632A1137|40 50|expression
P09315632A1137|73 92|FGFR3 kinase domain
P09315632A1137|130 141|fibroblasts
P09315632A1137|156 169|dysregulation
P09315632A1137|173 178|FGFR3
P09315632A1137|207 211|role
P09315632A1137|221 230|neoplasia
P09315633A0333|12 31|amino acid sequence
P09315633A0333|39 43|gene
P09315633A0333|60 68|homology
P09315633A0333|76 86|interferon
P09315633A0333|98 105|factors
P09315633A0333|107 111|IRFs
P09315651T0000|0 11|Involvement
P09315651T0000|15 19|AP-2
P09315651T0000|23 33|regulation
P09315651T0000|41 52|R-FABP gene
P09315651T0000|71 83|chick retina
P09315678A0278|9 14|Cbf5p
P09315678A0278|73 76|rat
P09315678A0278|87 100|protein NAP57
P09315678A0278|134 141|Nopp140
P09315678A0278|206 215|shuttling
P09315678A0278|217 219|U.
P09316937A0133|21 29|organism
P09316937A0133|63 76|discrepancies
P09316937A0133|89 94|Vitek
P09316937A0133|99 129|API 20E identification systems
P09317131A0000|0 2|Ig
P09317131A0000|9 30|chain class switching
P09317131A0000|46 55|cytokines
P09317131A0000|65 78|transcription
P09317131A0000|97 105|CH genes
P09317131A1332|14 18|data
P09317131A1332|36 69|NF kappa B2 nucleoprotein complex
P09317131A1332|99 104|STAT6
P09317131A1332|131 141|activation
P09317131A1332|155 172|IgE germline gene
P09317757T0000|0 8|EXERCISE
P09317757T0000|28 73|CHRISTMAS ISLAND RED CRAB GECARCOIDEA NATALIS
P09317757T0000|76 86|ENERGETICS
P09317757T0000|90 100|LOCOMOTION
P09317830T0000|15 29|SONG FREQUENCY
P09317830T0000|33 40|CICADAS
P09321406T0000|4 30|pheromone response pathway
P09321406T0000|41 54|transcription
P09321406T0000|58 78|Ty5 retrotransposons
P09321406T0000|101 110|chromatin
P09321657A0439|8 13|study
P09321657A0439|33 42|mutations
P09321657A0439|66 74|elements
P09321657A0439|82 96|cox3 promoters
P09321657A0439|121 133|core element
P09321657A0439|151 173|cox3 promoter activity
P09321657A0439|184 201|element mutations
P09321657A0439|220 226|effect
P09321930A0567|23 45|tumor suppressor genes
P09321930A0567|53 56|p53
P09321930A0567|58 61|DCC
P09321930A0567|63 66|APC
P09321930A0567|68 71|MCC
P09321930A0567|73 78|BRCA1
P09321930A0567|84 93|WAF1/CIP1
P09321930A0567|125 136|frequencies
P09321930A0567|149 159|mechanisms
P09321930A0567|167 171|loss
P09321930A0567|175 189|heterozygosity
P09321930A0567|191 194|LOH
P09321930A0567|197 201|loss
P09321930A0567|205 215|expression
P09321930A0567|217 220|LOE
P09321930A0567|223 231|mutation
P09321930A0567|237 249|inactivation
P09321930A0567|262 277|binding protein
P09322738A0510|21 25|gene
P09322738A0510|27 34|rpoCHIS
P09322738A0510|70 76|allele
P09322738A0510|84 94|chromosome
P09322738A0510|98 111|S. coelicolor
P09322738A0510|116 127|S. lividans
P09322872A0745|12 20|deletion
P09322872A0745|34 41|TK gene
P09322872A0745|43 52|selection
P09322872A0745|58 69|gancyclovir
P09322872A0745|78 83|cells
P09322872A0745|105 118|recombination
P09323366A0000|4 24|malate synthase gene
P09323366A0000|26 30|MLS1
P09323366A0000|39 44|yeast
P09323366A0000|108 121|carbon source
P09323366A0000|129 142|growth medium
P09323366A0299|3 20|deletion analysis
P09323366A0299|28 47|MLS1 control region
P09323366A0299|67 72|sites
P09323366A0299|74 78|UAS1
P09323366A0299|83 87|UAS2
P09323366A0299|116 128|derepression
P09323366A0299|136 140|gene
P09323612A0374|0 4|Lack
P09323612A0374|31 38|studies
P09323612A0374|42 69|sleep electroencephalograms
P09323612A0374|71 74|EEG
P09323612A0374|85 88|use
P09323612A0374|92 102|medication
P09323612A0374|107 115|children
P09323612A0374|135 144|dysphasia
P09323612A0374|167 187|treatment strategies
P09323612A0374|191 199|children
P09323612A0374|226 232|speech
P09323612A0374|237 255|language disorders
P09324720A0317|9 14|meals
P09324720A0317|22 27|times
P09324720A0317|39 50|tablespoons
P09324720A0317|54 60|Alzoon
P09324878A0952|33 37|wall
P09324878A0952|44 66|ultrasound examination
P09324878A0952|97 106|diagnosis
P09324878A0952|135 152|type B dissection
P09324922T0065|0 20|Fermentation process
P09324922T0065|27 42|supplementation
P09324922T0065|71 84|acid bacteria
P09324922T0065|96 100|acid
P09324988X0000|0 10|Substrates
P09324988X0000|23 26|p21
P09324988X0000|28 31|ras
P09324988X0000|33 41|proteins
P09324988X0000|51 57|lamins
P09324988X0000|65 71|series
P09324988X0000|83 91|proteins
P09325022A0192|0 7|Ovaries
P09325022A0192|14 21|animals
P09325022A0192|26 31|group
P09325022A0192|40 47|studies
P09325022A0192|51 60|CD-1 mice
P09325022A0192|67 72|study
P09325022A0192|81 84|C3H
P09325022A0192|89 101|C57BL/6 mice
P09325022A0192|131 137|microm
P09325135A0737|11 25|fusion protein
P09325135A0737|59 60|%
P09325135A0737|87 94|protein
P09325273A1240|6 13|results
P09325273A1240|27 32|UBP41
P09325273A1240|55 59|role
P09325273A1240|67 76|recycling
P09325273A1240|80 89|ubiquitin
P09325273A1240|93 103|hydrolysis
P09325273A1240|116 137|poly-ubiquitin chains
P09325273A1240|155 161|action
P09325273A1240|168 180|S proteasome
P09325273A1240|203 221|protein substrates
P09325273A1240|241 251|production
P09325273A1240|260 269|ubiquitin
P09325273A1240|282 303|poly-ubiquitin chains
P09325273A1240|329 337|proteins
P09325273A1240|343 368|ubiquitin fusion proteins
P09325278A0458|2 27|data base homology search
P09325278A0458|56 79|ER1 amino acid sequence
P09325278A0458|95 102|regions
P09325278A0458|106 116|similarity
P09325278A0458|124 127|rat
P09325278A0458|138 146|proteins
P09325278A0458|184 188|gene
P09325278A0458|190 194|mta1
P09325278A0458|204 211|regions
P09325278A0458|215 225|similarity
P09325278A0458|233 264|Caenorhabditis elegans sequence
P09325278A0458|284 288|mta1
P09325284A0469|14 18|cDNA
P09325284A0469|40 52|acid protein
P09325284A0469|55 56|%
P09325284A0469|76 92|progelatinase B.
P09325322A1293|4 14|inhibition
P09325322A1293|28 31|Ca2
P09325322A1293|49 57|decrease
P09325322A1293|61 74|cooperativity
P09325322A1293|84 89|shift
P09325322A1293|93 97|EC50
P09325322A1293|112 132|InsP3 concentrations
P09326163A0942|0 7|RESULTS
P09326163A0942|26 41|mortality ratio
P09326163A0942|43 46|SMR
P09326163A0942|66 75|neoplasms
P09326163A0942|86 90|% CI
P09326246A0567|0 17|Sequence analysis
P09326246A0567|26 32|region
P09326246A0567|68 76|elements
P09326246A0567|82 90|deletion
P09326246A0567|119 125|levels
P09326246A0567|129 148|luciferase activity
P09326246A0567|161 180|bp reporter plasmid
P09326263A0410|8 12|RACE
P09326263A0410|25 42|transcription-PCR
P09326263A0410|44 50|RT-PCR
P09326263A0410|52 65|methodologies
P09326263A0410|83 92|sequences
P09326263A0410|98 103|brain
P09326263A0410|108 116|placenta
P09326263A0410|132 140|material
P09326263A0410|181 186|exons
P09326263A0410|225 229|exon
P09326263A0410|231 233|1A
P09326263A0410|263 267|exon
P09326263A0410|269 271|1B
P09326317A0372|18 23|study
P09326317A0372|33 51|mutation screening
P09326317A0372|84 88|EXT1
P09326317A0372|93 103|EXT2 genes
P09326317A0372|117 133|linkage analysis
P09326727T0000|4 17|regurgitation
P09326727T0000|36 46|injections
P09327881T0000|0 41|Positron emission tomography radioligands
P09327881T0000|46 67|dopamine transporters
P09327881T0000|72 79|studies
P09327881T0000|102 110|primates
P09328341A1449|0 11|Attenuation
P09328341A1449|21 41|vit A2 consensus ERE
P09328341A1449|74 85|DNA binding
P09328341A1449|93 120|TR alpha DNA binding mutant
P09328341A1449|159 174|transactivation
P09328343A0181|0 10|Expression
P09328343A0181|21 28|element
P09328343A0181|59 74|protein complex
P09328343A0181|107 110|E2A
P09328343A0181|128 136|proteins
P09328343A0181|157 164|members
P09328343A0181|177 183|family
P09328349A1679|10 19|CCAAT box
P09328349A1679|45 60|characteristics
P09328349A1679|86 96|expression
P09328349A1679|104 122|alpha-subunit gene
P09328349A1679|126 138|trophoblasts
P09328476A0068|0 11|U4/U6 snRNP
P09328476A0068|51 68|ribonucleoprotein
P09328476A0068|70 75|snRNP
P09328476A0068|77 86|particles
P09328476A0068|88 90|U1
P09328476A0068|92 94|U2
P09328476A0068|96 98|U5
P09328476A0068|103 108|U4/U6
P09328476A0068|125 136|spliceosome
P09328476A0374|0 6|Hprp3p
P09328476A0374|15 26|kDa protein
P09328476A0374|80 101|splicing factor Prp3p
P09328824A0000|21 31|properties
P09328824A0000|50 65|v-erbA oncogene
P09328824A0000|84 91|version
P09328824A0000|99 131|chicken thyroid hormone receptor
P09328824A0000|133 135|TR
P09328824A0000|137 142|alpha
P09328824A0000|192 202|repression
P09328824A0000|224 229|roles
P09328824A0000|233 235|TR
P09328824A0000|249 263|acid receptors
P09328833A0588|21 25|cDNA
P09328833A0588|31 33|kb
P09328833A0588|39 42|HET
P09328833A0588|51 69|MCF-7 cDNA library
P09331119A0659|16 21|grade
P09331119A0659|24 32|toxicity
P09331119A0659|37 48|neutropenia
P09331119A0659|50 66|thrombocytopenia
P09331119A0659|72 84|parasthesias
P09331119A0659|101 102|%
P09331119A0659|106 112|cycles
P09331864A0230|0 20|Serum concentrations
P09331864A0230|24 26|E2
P09331864A0230|31 35|TBOH
P09331864A0230|53 54|d
P09331864A0230|120 127|heifers
P09331864A0230|155 165|treatments
P09331864A0230|170 177|control
P09331864A0230|182 185|MGA
P09331864A0230|190 192|mg
P09331864A0230|197 203|heifer
P09331864A0230|214 223|Revalor-H
P09331864A0230|229 235|mg TBA
P09331864A0230|241 246|mg E2
P09331864A0230|252 261|Revalor-H
P09331864A0230|264 267|MGA
P09331864A0230|272 282|Finaplix-H
P09331864A0230|288 294|mg TBA
P09331864A0230|304 314|Finaplix-H
P09331864A0230|317 320|MGA
P09331864A0848|0 23|Serum E2 concentrations
P09331864A0848|69 70|d
P09331864A0848|84 92|controls
P09331864A0848|97 100|MGA
P09331864A0848|116 124|controls
P09331864A0848|133 136|MGA
P09333018A0000|0 10|Interferon
P09333018A0000|22 28|Factor
P09333018A0000|30 33|IRF
P09333018A0000|76 82|growth
P09333018A0000|115 135|transcription factor
P09333026A0397|12 21|structure
P09333026A0397|25 28|brk
P09333026A0397|43 48|exons
P09333026A0397|56 66|boundaries
P09333026A0397|104 122|PTK family members
P09333026A0397|169 179|divergence
P09333026A0851|33 43|expression
P09333026A0851|49 55|tumour
P09333026A0851|64 72|brk cDNA
P09333026A0851|76 81|mouse
P09333026A0851|92 103|fibroblasts
P09333026A0851|133 138|cells
P09333026A0851|148 157|anchorage
P09333026A0851|170 176|growth
P09333026A0851|222 230|response
P09333026A0851|244 257|growth factor
P09333168A0310|0 22|Anti-hepatitis A virus
P09333168A0310|24 27|HAV
P09333168A0310|29 34|titer
P09333168A0310|41 52|vaccination
P09333168A0310|105 108|men
P09333231T0018|4 9|skull
P09333231T0018|21 28|species
P09334264A0540|14 30|calf thymus CstF
P09334264A0540|62 66|form
P09334264A0540|81 88|subunit
P09334264A0540|106 110|mass
P09334264A0540|117 120|kDa
P09334330A0252|5 14|mutations
P09334330A0252|18 23|daf-3
P09334330A0252|33 42|mutations
P09334330A0252|46 51|genes
P09334330A0252|66 81|TGF-beta signal
P09334330A0252|87 96|receptors
P09334330A0252|113 146|Smad signal transduction proteins
P09334330A0252|148 153|daf-3
P09334330A0252|164 176|Smad protein
P09334330A0252|219 223|DPC4
P09334330A0252|253 264|development
P09334330A0252|280 287|tissues
P09334330A0252|314 331|dauer development
P09334331A0910|4 11|results
P09334331A0910|22 33|possibility
P09334331A0910|54 75|EGF receptor DER/Egfr
P09334331A0910|93 102|EMA cells
P09334331A0910|118 126|receptor
P09334331A0910|131 135|Vein
P09334475A0327|0 8|PATIENTS
P09334475A0327|13 20|METHODS
P09334475A0327|41 49|patients
P09334475A0327|67 84|National Registry
P09334475A0327|105 115|Infarction
P09334475A0327|132 142|resolution
P09334475A0327|146 156|chest pain
P09334475A0327|164 181|segment elevation
P09334475A0327|189 190|%
P09334475A0327|211 214|min
P09334475A0327|223 230|CK rise
P09334475A0327|240 241|h
P09334475A0327|246 262|T wave inversion
P09334475A0327|266 273|infarct
P09334475A0327|282 285|EKG
P09334475A0327|312 313|h
P09334475A0327|320 332|thrombolysis
P09335267A0142|15 31|operon structure
P09335267A0142|40 48|organism
P09335267A0142|62 69|methods
P09335267A0142|90 101|mutagenesis
P09335267A0142|110 114|risk
P09335267A0142|136 143|effects
P09335267A0142|158 163|genes
P09335267A0142|186 195|mutations
P09335267A0142|213 219|genome
P09335298A0529|30 43|parCBA operon
P09335298A0529|54 81|plasmid partitioning system
P09335298A0529|83 85|M.
P09335298A1227|17 26|insertion
P09335298A1227|34 48|ColE1 cer site
P09335298A1227|58 69|RK2 plasmid
P09335298A1227|90 96|region
P09335298A1227|121 128|plasmid
P09335298A1227|136 150|MC1061K strain
P09335298A1227|172 200|multimer resolution activity
P09335298A1227|212 218|parCBA
P09335298A1227|256 278|stabilization activity
P09335298A1227|297 303|operon
P09335298A2129|15 20|basis
P09335298A2129|38 49|differences
P09335298A2129|71 78|killing
P09335298A2129|103 110|strains
P09335298A2129|112 133|transformation assays
P09335298A2129|177 190|sensitivities
P09335298A2129|198 205|strains
P09335298A2129|213 231|ParE toxin protein
P09335608T0000|16 24|elements
P09335608T0000|38 47|sequences
P09335608T0000|69 77|splicing
P09335608T0000|96 102|myosin
P09335608T0000|109 130|chain gene transcript
P09335619A0583|0 28|Nucleotide sequence analysis
P09335619A0583|32 33|R
P09335619A0583|47 59|similarities
P09335619A0583|67 77|R1 plasmid
P09335619A0583|107 118|maize races
P09335619A0583|124 136|RU cytoplasm
P09335619A0583|145 155|M1 plasmid
P09335619A0583|169 175|source
P09335619A0583|179 182|Zea
P09335619A0583|193 201|teosinte
P09335619A0583|210 214|atp9
P09335619A0583|229 233|gene
P09335619A0583|254 262|sequence
P09335619A0583|278 284|region
P09335619A0583|295 306|orf221 gene
P09336455A0000|21 29|kinetics
P09336455A0000|37 45|recovery
P09336455A0000|49 63|mRNA synthesis
P09336455A0000|81 86|GAL10
P09336455A0000|91 101|RNR3 genes
P09336455A0000|108 116|exposure
P09336455A0000|120 131|yeast cells
P09336455A0000|135 146|ultraviolet
P09336455A0000|148 150|UV
P09336455A0000|152 161|radiation
P09337861T0000|0 7|Cloning
P09337861T0000|19 44|phosphoinositide 3-kinase
P09337861T0000|52 61|C2 domain
P09337861T0000|84 95|sensitivity
P09337861T0000|103 123|inhibitor wortmannin
P09338414A0430|0 8|Ea value
P09338414A0430|31 36|ratio
P09338414A0430|77 85|pressure
P09338414A0430|87 91|ESAP
P09338414A0430|96 109|stroke volume
P09338414A0430|111 125|thermodilution
P09339900A0939|11 19|analysis
P09339900A0939|23 40|promoter activity
P09339900A0939|60 66|region
P09339900A0939|70 79|cyclin D2
P09339900A0939|99 105|region
P09339900A0939|133 138|C/EBP
P09339900A0939|140 144|PEA3
P09339900A0939|146 149|AP2
P09339900A0939|151 155|NF-Y
P09339900A0939|157 162|c-Myc
P09339900A0939|168 171|Sp1
P09339900A0939|209 217|activity
P09339900A0939|222 232|expression
P09339900A0939|236 245|cyclin D2
P09340641T0001|0 6|Effect
P09340641T0001|10 17|alcohol
P09340641T0001|39 53|nCPAP pressure
P09341139A0690|3 11|contrast
P09341139A0690|13 28|resensitization
P09341139A0690|57 71|beta2AR mutant
P09341139A0690|73 78|Y326A
P09341139A0690|112 126|overexpression
P09341139A0690|137 141|GRK2
P09341139A0690|145 158|beta-arrestin
P09341158A0167|4 17|medium chains
P09341158A0167|27 36|complexes
P09341158A0167|38 41|mu1
P09341158A0167|46 49|mu2
P09341158A0167|79 84|types
P09341158A0167|88 99|interaction
P09341158A0167|101 109|assembly
P09341158A0167|119 124|beta1
P09341158A0167|129 141|beta2 chains
P09341158A0167|163 172|complexes
P09341158A0167|177 188|recognition
P09341158A0167|207 222|sorting signals
P09341182A0605|69 83|BTB/POZ domain
P09341182A0605|89 93|PLZF
P09341182A0605|95 107|PLZF-BTB/POZ
P09341192T0000|8 13|shock
P09341192T0000|25 44|GLUT4 translocation
P09341192T0000|48 64|3T3L1 adipocytes
P09341192T0000|76 99|tyrosine kinase pathway
P09341193A0362|19 22|Sp1
P09341193A0362|24 27|Sp3
P09341193A0362|33 43|NGFI-A/Egr
P09341193A0362|69 90|transcription factors
P09341193A0362|102 106|TRE1
P09341193A0362|121 139|Tax responsiveness
P09343208A1405|15 22|segment
P09343208A1405|60 71|copy number
P09343208A1405|75 80|genes
P09343208A1405|92 101|segment W
P09343208A1405|139 151|organization
P09343208A1405|155 159|PDVs
P09343208A1405|197 206|functions
P09343208A1405|215 220|virus
P09343208A1405|249 260|association
P09343208A1405|276 281|wasps
P09343210A1112|13 21|deletion
P09343210A1112|26 43|mutation analyses
P09343210A1112|51 66|VCAM-1 promoter
P09343210A1112|82 126|chloramphenicol acetyltransferase constructs
P09343210A1112|141 144|Tax
P09343210A1112|170 185|VCAM-1 promoter
P09343210A1112|194 209|NF-kappaB sites
P09343210A1112|221 223|bp
P09343210A1112|243 263|VCAM-1 gene promoter
P09343210A1112|318 328|expression
P09343210A1112|337 354|adhesion molecule
P09343222A0415|4 7|AGM
P09343222A0415|12 41|NIH/Swiss mouse CCR5 proteins
P09343222A0415|58 59|%
P09343222A0415|68 69|%
P09343222A0415|93 100|protein
P09343398A1193|0 12|Processivity
P09343398A1193|16 29|DNA synthesis
P09343398A1193|44 54|holoenzyme
P09343398A1193|66 73|pcna-79
P09343398A1193|92 96|poly
P09343398A1193|97 99|dA
P09343398A1193|109 111|dT
P09343398A1193|155 163|template
P09343398A1193|179 188|structure
P09343426A0456|0 30|Alanine substitution mutations
P09343426A0456|38 59|Zta activation domain
P09343426A0456|80 87|ability
P09343426A0456|91 94|Zta
P09343426A0456|112 123|D-A complex
P09343432A0209|4 7|Scm
P09343432A0209|12 23|ph proteins
P09343432A0209|32 47|homology domain
P09343432A0209|55 65|% identity
P09343432A0209|73 79|length
P09343432A0209|86 97|amino acids
P09343432A0209|110 120|SPM domain
P09343432A0209|158 167|C termini
P09343433A0000|34 39|genes
P09343433A0000|55 69|RNA polymerase
P09343433A0000|74 78|RNAP
P09343433A0000|107 125|effect variegation
P09343433A0000|144 159|yeast telomeres
P09343433A0360|10 20|rad6-delta
P09343433A0360|29 38|silencing
P09343433A0360|63 67|RNAP
P09343433A0360|83 93|genes URA3
P09343433A0360|98 102|ADE2
P09343982A0890|4 13|amplitude
P09343982A0890|17 38|detrusor contractions
P09343982A0890|56 61|hours
P09343982A0890|84 94|difference
P09343982A0890|112 120|controls
P09344650A0967|17 37|transmembrane domain
P09344650A0967|39 47|Casr-rs2
P09344650A0967|52 60|Casr-rs3
P09344650A0967|67 68|%
P09344650A0967|82 90|Casr-rs1
P09345037A0886|10 15|roles
P09345037A0886|57 76|trans-factor GATA-1
P09345037A0886|91 120|progenitor cell proliferation
P09345495A0000|0 22|PET activation studies
P09345495A0000|59 73|brain function
P09346238T0000|6 14|proteins
P09346238T0000|19 28|receptors
P09346238T0000|57 67|substrates
P09346238T0000|75 103|SCF ubiquitin-ligase complex
P09346621A1181|7 14|context
P09346621A1181|18 42|liver allograft shortage
P09346621A1181|48 55|results
P09346621A1181|72 75|ELT
P09346621A1181|103 111|patients
P09346621A1181|125 132|failure
P09346621A1181|148 151|OSF
P09346621A1181|159 168|APACHE II
P09346925A0660|4 15|SH3 domains
P09346925A0660|19 23|Grb2
P09346925A0660|64 70|motifs
P09346925A0660|78 87|HPK1 tail
P09346925A0660|140 147|binding
P09346925A0660|151 155|Grb2
P09346925A0660|159 163|HPK1
P09346925A0660|179 189|Cos1 cells
P09346935A0459|15 23|analysis
P09346935A0459|28 57|coimmunoprecipitation studies
P09346935A0459|79 84|ZNF74
P09346935A0459|104 122|zinc finger domain
P09346935A0459|161 168|subunit
P09346935A0459|172 186|RNA polymerase
P09346935A0459|191 198|pol IIo
P09346935A0459|236 240|form
P09346935A0927|6 27|ZNF74 sublocalization
P09346935A0927|39 46|domains
P09346935A0927|59 86|pre-mRNA maturating factors
P09346935A0927|92 112|RNA binding activity
P09346935A0927|146 157|interaction
P09346935A0927|167 174|pol IIo
P09346935A0927|178 182|form
P09346935A0927|190 204|RNA polymerase
P09346935A0927|239 254|mRNA processing
P09346935A0927|266 270|role
P09346935A0927|280 286|member
P09346935A0927|294 325|KRAB multifinger protein family
P09346935A0927|329 343|RNA processing
P09346938A1680|0 33|Ki-ras4BVal-12 transfectant cells
P09346938A1680|60 74|protein levels
P09346938A1680|92 121|cysteine protease cathepsin B
P09346938A1680|146 173|cathepsin B mRNA expression
P09346953A0000|13 17|rate
P09346953A0000|35 63|heparan sulfate proteoglycan
P09346953A0000|65 72|HSPGact
P09346953A0000|74 84|generation
P09346953A0000|106 111|level
P09346953A0000|149 157|activity
P09346953A0000|159 184|HSact conversion activity
P09346953A0000|237 288|heparan sulfate D-glucosaminyl 3-O-sulfotransferase
P09346953A0000|290 295|3-OST
P09346953A0000|298 305|Shworak
P09346953A0000|307 309|N.
P09348226A0852|15 18|EGF
P09348226A0852|28 35|insulin
P09348226A0852|48 72|tyrosine phosphorylation
P09348226A0852|76 81|c-cbl
P09348226A0852|90 101|association
P09348226A0852|107 113|Crk-II
P09348931T0000|3 6|end
P09348931T0000|14 21|lottery
P09349501A0196|41 48|portion
P09349501A0196|76 88|MLL products
P09349501A0196|104 112|MLL-LTG9
P09349501A0196|117 126|MLL-LTG19
P09349501A0196|145 151|nuclei
P09349501A0196|209 213|role
P09349501A0196|217 231|leukemogenesis
P09349967A0653|4 11|results
P09349967A0653|29 36|pattern
P09349967A0653|40 52|blood supply
P09349967A0653|83 95|organisation
P09349967A0653|106 119|lamellar bone
P09351242A0719|0 9|Induction
P09351242A0719|13 38|AtP5CS1 mRNA accumulation
P09351242A0719|55 64|seedlings
P09351242A0719|109 117|response
P09351242A0719|131 145|ABA signalling
P09351242A0719|171 184|cycloheximide
P09351242A0719|207 217|deficiency
P09351242A0719|221 237|ABA biosynthesis
P09351242A0719|245 268|aba1 Arabidopsis mutant
P09351823A0414|21 35|MAPK functions
P09351823A0414|47 57|maturation
P09351823A0414|85 89|eggs
P09351823A0414|127 138|development
P09352016A1110|8 22|AF G-CSF level
P09352016A1110|30 32|pg
P09352016A1110|34 36|ml
P09352016A1110|58 67|predictor
P09352016A1110|71 74|CAM
P09352127A0953|11 22|correlation
P09352127A0953|31 46|serum myoglobin
P09352127A0953|51 72|CA III concentrations
P09352127A0953|74 76|rs
P09352127A0953|86 87|P
P09352127A0953|126 134|patients
P09352127A0953|154 161|failure
P09353247A0922|17 43|over-replication phenotype
P09353247A0922|68 76|p65cdc18
P09353247A0922|111 130|cyclin/CDK activity
P09353247A0922|140 149|inhibitor
P09353247A0922|153 169|over-replication
P09353255A0159|0 5|Rip1p
P09353255A0159|46 60|pore complexes
P09353255A0159|94 115|FG-nucleoporin family
P09353255A0159|119 132|pore proteins
P09353296A0510|4 15|CNXA domain
P09353296A0510|34 50|amino acid level
P09353296A0510|75 92|moaA gene product
P09353296A0510|100 104|CNXC
P09353296A0510|131 143|moaC product
P09353296A0510|163 171|products
P09353296A0510|193 201|cistrons
P09353304A0732|0 9|Deletions
P09353304A0732|27 34|regions
P09353304A0732|43 64|membrane localization
P09353304A0732|68 73|Tiam1
P09353304A0732|78 95|membrane ruffling
P09353328A0736|21 27|kinase
P09353328A0736|38 44|domain
P09353328A0736|75 82|zippers
P09353328A0736|109 117|homology
P09353328A0736|129 137|proteins
P09353343A0919|0 14|RNA polymerase
P09353343A0919|18 28|inhibition
P09353343A0919|43 50|binding
P09353343A0919|59 72|AUBP activity
P09353343A0919|78 82|poly
P09353343A0919|83 84|U
P09353343A0919|86 95|Sepharose
P09353343A0919|111 119|hnRNP A1
P09353343A0919|135 151|hnRNP A1 binding
P09353343T0000|0 10|Modulation
P09353343T0000|14 44|AUUUA response element binding
P09353343T0000|70 90|ribonucleoprotein A1
P09353343T0000|100 113|T lymphocytes
P09354349A0338|13 19|slides
P09354349A0338|27 33|biopsy
P09354349A0338|42 49|patient
P09354349A0338|118 124|Giemsa
P09354349A0338|126 128|MG
P09354349A0338|135 149|Warthin-Starry
P09354349A0338|151 153|WS
P09354349A0338|183 189|method
P09354349A0338|191 194|IMM
P09354349A0338|222 241|H. pylori antiserum
P09354349A0338|243 252|DAKO B471
P09354644A0124|6 18|biosynthesis
P09354644A0124|39 49|precursors
P09354644A0124|74 101|beta1,6-GlcNAc transferases
P09354644A0124|103 108|IGnT6
P09354644A0124|110 116|GlcNAc
P09354644A0124|120 123|Gal
P09354676A1714|6 14|findings
P09354676A1714|33 34|t
P09354676A1714|42 47|p16.3
P09354676A1714|49 52|q32
P09354676A1714|96 109|translocation
P09354676A1714|113 115|MM
P09354676A1714|138 148|FGFR3 gene
P09354676A1714|160 166|target
P09354676A1714|175 186|abnormality
P09354676A1714|210 223|tumorigenesis
P09354676A1714|227 229|MM
P09354684A1158|3 11|addition
P09354684A1158|13 21|mutation
P09354684A1158|29 37|Sp1 site
P09354684A1158|65 82|promoter activity
P09354757A1444|0 19|Amino acid residues
P09354757A1444|23 27|beta
P09354757A1444|32 39|alpha A
P09354757A1444|42 49|alpha B
P09354757A1444|60 64|loop
P09354757A1444|76 82|His539
P09354757A1444|90 104|RNase H domain
P09354757A1444|123 136|primer strand
P09354757A1444|144 149|dsDNA
P09356645A0672|17 24|patient
P09356645A0672|32 39|sarcoma
P09356645A0672|68 77|procedure
P09356645A0672|90 107|nerve enlargement
P09358045A0000|9 29|length cDNA sequence
P09358045A0000|35 39|Type
P09358045A0000|55 73|growth factor-beta
P09358045A0000|75 83|TGF-beta
P09358045A0000|85 93|receptor
P09358045A0000|140 163|nematode Brugia pahangi
P09358055A0590|5 13|sequence
P09358055A0590|24 32|homology
P09358055A0590|62 78|promoter element
P09358055A0590|80 84|Enh2
P09358055A0590|101 104|LTR
P09358055A0590|108 113|mouse
P09358055A0590|130 141|A-particles
P09358069T0000|0 18|Codon optimization
P09358069T0000|34 44|expression
P09358069T0000|54 68|erythropoietin
P09358069T0000|70 73|EPO
P09358069T0000|88 93|cells
P09358837T0000|12 16|rise
P09358837T0000|28 42|albumin levels
P09358837T0000|49 58|treatment
P09358837T0000|72 84|hypertension
P09359844A0674|2 3|%
P09359844A0674|13 28|HSL transcripts
P09359844A0674|51 61|adipocytes
P09359887A1168|20 24|data
P09359887A1168|38 51|Rat7p/Nup159p
P09359887A1168|75 78|NPC
P09359887A1168|103 109|region
P09359887A1168|123 132|sequences
P09360422A0135|5 10|group
P09360422A0135|17 25|patients
P09360422A0135|44 58|arteriopathies
P09360422A0135|72 77|limbs
P09360422A0135|82 95|plasma levels
P09360422A0135|99 113|thrombomodulin
P09360422A0135|115 117|TM
P09360422A0135|120 139|betathromboglobulin
P09360422A0135|141 148|beta-TG
P09360422A0135|151 158|D-dimer
P09360422A0135|160 162|DD
P09360422A0135|168 199|plasminogen activator-inhibitor
P09360422A0135|201 206|pAI-1
P09360422A0135|243 249|values
P09360422A0135|275 285|volunteers
P09360953A1057|6 14|residues
P09360953A1057|16 22|Ile244
P09360953A1057|44 47|end
P09360953A1057|65 70|helix
P09360953A1057|78 84|Tyr318
P09360953A1057|106 113|portion
P09360953A1057|131 135|loop
P09360953A1057|155 158|Leu
P09360953A1057|163 166|Ile
P09360953A1057|174 188|PTH-1 receptor
P09360956A0840|31 46|phosphorylation
P09360956A0840|57 61|zeta
P09360956A0840|69 82|CKIalpha site
P09360956A0840|84 91|Thr-233
P09360956A0840|118 125|binding
P09360956A0840|129 134|c-Raf
P09360956A0840|173 192|signal transduction
P09360993T0000|0 24|Mouse mast cell protease
P09360993T0000|36 42|member
P09360993T0000|50 60|chromosome
P09360993T0000|64 70|family
P09360993T0000|74 90|serine proteases
P09360993T0000|132 142|mast cells
P09361007A0922|2 7|DNase
P09361007A0922|25 29|site
P09361007A0922|67 87|pair enhancer region
P09362105X0422|20 30|resistance
P09362105X0422|32 35|PVR
P09362105X0422|46 54|% O2-PVR
P09362105X0422|64 72|% O2/PVR
P09362105X0422|82 83|%
P09362105X0422|126 142|vasoconstriction
P09362105X0422|144 147|HPV
P09362473A1540|14 21|results
P09362473A1540|32 38|tinman
P09362473A1540|59 64|array
P09362473A1540|77 94|enhancer elements
P09362473A1540|151 157|inputs
P09362473A1540|188 197|activator
P09362473A1540|202 225|repressor binding sites
P09362473A1540|249 257|enhancer
P09362473A1540|274 288|twist activity
P09362473A1540|301 306|areas
P09362473A1540|318 341|twist expression domain
P09362480A0452|11 27|cysteine triplet
P09362480A0452|45 54|sequences
P09362480A0452|58 68|TB domains
P09362480A0452|101 105|core
P09362480A0452|114 124|C-terminus
P09362499A0000|4 15|Fis protein
P09362499A0000|40 53|DNA inversion
P09362499A0000|69 75|family
P09362499A0000|79 93|DNA invertases
P09362499A0000|137 145|enhancer
P09363759A0000|0 20|Protein phosphatases
P09363759A0000|37 41|role
P09363759A0000|49 59|regulation
P09363759A0000|78 88|cell cycle
P09363759A0000|93 112|signal transduction
P09364211A0319|4 8|cell
P09364211A0319|25 49|transcription factor E2F
P09364211A0319|72 75|DNA
P09364211A0319|81 88|binding
P09364440A2206|4 9|study
P09364440A2206|35 44|structure
P09364440A2206|52 69|FSH receptor gene
P09364440A2206|80 86|motifs
P09364440A2206|99 107|coupling
P09364440A2206|121 130|effectors
P09364750T0000|16 26|regulation
P09364750T0000|30 35|SUP35
P09364750T0000|40 45|SUP45
P09365201A2018|6 13|studies
P09365201A2018|27 32|basis
P09365201A2018|49 65|characterization
P09365201A2018|84 93|mechanism
P09365201A2018|97 117|aromatase expression
P09365201A2018|127 140|breast cancer
P09365201A2018|145 149|ASCs
P09365272T0000|0 7|Xenopus
P09365272T0000|20 27|protein
P09365272T0000|41 53|interactions
P09365272T0000|58 65|effects
P09365272T0000|77 85|assembly
P09365272T0000|89 109|Xenopus egg extracts
P09365431A0314|20 31|combination
P09365431A0314|35 50|benzodiazepines
P09365431A0314|59 103|acetylcholinesterase inhibitor physostigmine
P09366456A0234|0 7|METHODS
P09366456A0234|15 31|muscle paralysis
P09366456A0234|58 68|anesthesia
P09366456A0234|74 79|group
P09366456A0234|89 96|persons
P09366456A0234|98 99|n
P09366456A0234|105 120|body mass index
P09366456A0234|131 133|kg
P09366456A0234|148 153|group
P09366456A0234|166 173|persons
P09366456A0234|175 176|n
P09366456A0234|182 196|body mas index
P09366456A0234|207 209|kg
P09366517A0835|0 3|PKA
P09366517A0835|19 22|WT1
P09366517A0835|26 33|Ser-365
P09366517A0835|38 45|Ser-393
P09366517A0835|81 86|sites
P09366517A0835|97 112|phosphorylation
P09366517A0835|139 147|activity
P09366517A0835|151 154|WT1
P09366517A1828|4 12|findings
P09366517A1828|31 39|evidence
P09366517A1828|49 57|function
P09366517A1828|61 64|WT1
P09366517A1828|89 104|phosphorylation
P09366628T0000|0 2|Re
P09366628T0000|19 28|direction
P09366628T0000|32 41|causality
P09366628T0000|61 68|studies
P09367288A0115|9 12|aim
P09367288A0115|42 50|decrease
P09367288A0115|68 84|unit rest length
P09367288A0115|107 121|immobilisation
P09367288A0115|137 145|position
P09367288A0115|171 182|adaptations
P09367288A0115|190 196|muscle
P09367288A0115|200 206|tendon
P09367392A0567|4 12|presence
P09367392A0567|30 38|sequence
P09367392A0567|42 53|nucleotides
P09367392A0567|74 77|end
P09367392A0567|81 85|RNA3
P09367392A0567|95 115|template recognition
P09367392A0567|119 123|RdRp
P09367392A0567|137 149|accumulation
P09367392A0567|153 157|RNA3
P09367392A0567|179 185|levels
P09367426A1354|26 30|role
P09367426A1354|34 36|hh
P09367426A1354|52 60|polarity
P09367426A1354|82 99|compartment cells
P09367426A1354|117 131|interpretation
P09367426A1354|159 171|polarization
P09367676A0275|0 26|Restriction enzyme mapping
P09367676A0275|28 38|subcloning
P09367676A0275|44 67|DNA sequencing analysis
P09367676A0275|83 95|phage lambda
P09367676A0275|100 109|P1 clones
P09367676A0275|124 129|exons
P09367676A0275|150 163|mouse TS mRNA
P09367676A0275|188 190|kb
P09367676A0275|199 202|DNA
P09367676A1115|0 21|Transfection analyses
P09367676A1115|41 51|expression
P09367676A1115|55 61|Tbxas1
P09367676A1115|115 123|sequence
P09367676A1115|156 164|elements
P09368006A1332|4 11|results
P09368006A1332|20 25|study
P09368006A1332|39 57|NF-kappaB activity
P09368006A1332|82 93|interaction
P09368006A1332|103 113|cell cycle
P09368006A1332|125 132|protein
P09368006A1332|134 139|E2F-1
P09368014A0740|4 21|lysozyme FEF site
P09368014A0740|45 47|PU
P09368026A0000|0 11|Osteocalcin
P09368026A0000|13 15|OC
P09368026A0000|22 28|matrix
P09368026A0000|45 52|protein
P09368026A0000|66 77|osteoblasts
P09368026A0000|82 94|odontoblasts
P09368026A0000|106 120|mineralization
P09368026A0435|8 13|study
P09368026A0435|30 37|effects
P09368026A0435|41 56|Msx2 expression
P09368026A0435|60 82|OC promoter activation
P09368026A0435|84 103|luciferase reporter
P09368026A0435|108 116|FGF2/FSK
P09368026A0435|121 131|calcitriol
P09368026A0435|135 155|MC3T3-E1 osteoblasts
P09368057A1083|19 27|proteins
P09368057A1083|48 60|SRF activity
P09368057A1083|66 84|repressor activity
P09368057A1083|113 120|element
P09368057A1083|164 174|inhibition
P09368057A1083|178 189|SRF binding
P09368058A0969|32 57|phosphopeptide comigrates
P09368058A0969|85 99|phosphopeptide
P09368058A0969|168 171|CAK
P09368058A0969|210 214|site
P09368097T0000|4 7|pen
P09368100A1354|4 16|mHIF-1 alpha
P09368100A1354|28 32|gene
P09368100A1354|51 56|exons
P09368190A1053|42 50|sequence
P09368190A1053|68 72|EMSA
P09368190A1053|76 95|DNA binding pattern
P09368190A1053|130 138|exposure
P09368190A1053|142 151|IFN-gamma
P09368190A1053|187 198|stimulation
P09368190A1053|209 218|IFN-alpha
P09368190A1053|223 232|IFN-gamma
P09368419A0000|3 14|Arabidopsis
P09368419A0000|20 29|induction
P09368419A0000|58 62|gene
P09368419A0000|64 68|rd22
P09368419A0000|94 98|acid
P09368419A0000|100 103|ABA
P09368419A0000|118 138|protein biosynthesis
P09368419A0000|157 172|gene expression
P09368419A0628|2 6|cDNA
P09368419A0628|30 49|DNA binding protein
P09368419A0628|66 94|DNA-ligand binding screening
P09368419A0628|112 118|region
P09368419A0628|124 129|probe
P09368419A0628|146 153|rd22BP1
P09368760A0665|6 10|PDK1
P09368760A0665|32 65|Drosophila protein kinase DSTPK61
P09368760A0665|100 110|regulation
P09368760A0665|114 133|sex differentiation
P09368760A0665|135 144|oogenesis
P09368760A0665|149 164|spermatogenesis
P09369450A1358|22 29|effects
P09369450A1358|33 42|HNF-1beta
P09369450A1358|51 53|GR
P09369450A1358|82 99|promoter activity
P09369450A1358|135 145|HNF-1 site
P09369450A1358|154 157|GRE
P09369450A1358|205 217|interactions
P09369450A1358|230 251|transcription factors
P09369450A1358|283 306|transcription machinery
P09369450A1358|312 340|steroid receptor coactivator
P09369451A0693|11 19|analysis
P09369451A0693|39 43|AP-1
P09369451A0693|49 57|sequence
P09369451A0693|70 80|TGAATCATCA
P09369451A0693|98 121|myocyte enhancer factor
P09369451A0693|123 126|MEF
P09369451A0693|135 143|sequence
P09369451A0693|156 169|TTAAAAATAAAAA
P09369451A0693|184 190|region
P09369451A0693|213 224|OP-1 effect
P09369453A0273|18 25|members
P09369453A0273|33 45|Bcl-2 family
P09369453A0273|47 50|BAD
P09369453A0273|52 62|Bcl-xL/Bcl
P09369453A0273|76 90|death promoter
P09369453A0273|95 109|death enhancer
P09369453A0273|129 149|transmembrane domain
P09369453A0273|191 199|membrane
P09369453A0273|212 220|envelope
P09369482A0690|0 21|Electromobility shift
P09369482A0690|26 47|cotransfection assays
P09369482A0690|66 75|HNF1alpha
P09369482A0690|85 89|HNF4
P09369482A0690|112 116|site
P09369482A0690|136 158|G6Pase gene expression
P09370276A0781|8 21|reading frame
P09370276A0781|30 32|bp
P09370276A0781|48 66|amino acid protein
P09370307A0093|17 27|AACA motif
P09370307A0093|61 70|regulator
P09370307A0093|83 90|tissues
P09370307A0093|101 111|similarity
P09370307A0093|119 137|barley gibberellin
P09370307A0093|149 156|element
P09370307A0093|180 200|DNA binding proteins
P09371431A1172|0 13|Strain CFN037
P09371431A1172|20 34|R. etli mutant
P09371431A1172|55 71|Tn5mob insertion
P09371431A1172|79 94|promoter region
P09371431A1172|102 122|thiCOGE gene cluster
P09371431T0000|0 10|Expression
P09371431T0000|35 40|genes
P09371431T0000|42 49|thiCOGE
P09371431T0000|55 65|production
P09371431T0000|79 100|terminal oxidase cbb3
P09371431T0000|104 118|Rhizobium etli
P09371455A0000|31 37|region
P09371455A0000|49 62|lipase operon
P09371455A0000|106 121|metalloprotease
P09371455A0000|125 143|Vibrio cholerae O1
P09371564A0713|17 23|amount
P09371564A0713|27 31|tRNA
P09371564A0713|32 36|3Lys
P09371564A0713|65 68|RNA
P09371564A0713|80 87|viruses
P09371564A0713|145 150|virus
P09371566A1384|5 12|protein
P09371566A1384|32 36|HeLa
P09371566A1384|45 53|extracts
P09371566A1384|58 71|S100 extracts
P09371566A1384|91 111|protein preparations
P09371566A1384|154 161|protein
P09371596T0000|13 23|regulation
P09371596T0000|31 36|pre-C
P09371596T0000|52 61|promoters
P09371596T0000|71 88|hepatitis B virus
P09371596T0000|92 99|members
P09371596T0000|115 135|receptor superfamily
P09371612A1964|0 4|Acad
P09371622A0779|0 8|Chimeras
P09371622A0779|20 32|IE1 peptides
P09371622A0779|56 69|transcription
P09371622A0779|83 91|promoter
P09371622A0779|102 124|lac operator sequences
P09371626A1345|4 11|results
P09371626A1345|15 31|replicase assays
P09371626A1345|54 57|VP2
P09371626A1345|71 79|deletion
P09371626A1345|99 105|domain
P09371626A1345|134 138|role
P09371626A1345|143 146|VP2
P09371626A1345|150 161|replication
P09371626A1345|179 186|protein
P09371626A1345|189 196|ability
P09371626A1345|209 222|mRNA template
P09371626A1345|240 249|synthesis
P09371657A0165|28 53|alanine cluster mutations
P09371657A0165|55 58|R77
P09371657A0165|62 63|A
P09371657A0165|65 69|R77A
P09371657A0165|71 75|K79A
P09371657A0165|80 91|E192A-E194A
P09371657A0165|127 151|triphosphatase component
P09371698A1254|0 12|Transfection
P09371698A1254|16 21|HepG2
P09371698A1254|26 39|SK-N-MC cells
P09371698A1254|45 55|constructs
P09371698A1254|90 99|fragments
P09371698A1254|114 124|definition
P09371698A1254|142 162|bp promoter fragment
P09371698A1254|178 193|pseudo-TATA box
P09371698A1254|223 228|sites
P09371731A0627|5 12|inserts
P09371731A0627|35 45|homologues
P09371731A0627|49 67|eIF-2alpha kinases
P09372287A0296|16 26|electrodes
P09372287A0296|89 94|tract
P09372287A0296|96 100|LVST
P09372287A0296|129 134|tract
P09372287A0296|136 140|MVST
P09372287A0296|149 159|C1 segment
P09372287A0296|178 185|pathway
P09372287A0296|189 194|axons
P09372451T0000|0 8|Epitopes
P09372451T0000|43 53|antibodies
P09372451T0000|91 97|domain
P09372451T0000|105 118|integrin beta
P09372451T0000|121 128|subunit
P09372908A1068|27 36|Sex Combs
P09372908A1068|87 96|mechanism
P09372908A1068|119 134|gene repression
P09372908A1068|148 157|inclusion
P09372908A1068|161 177|Polycomb protein
P09372908A1068|185 192|complex
P09372908A1068|196 200|PREs
P09372908A1068|217 226|silencing
P09372924A0758|18 33|rhHR23 proteins
P09372924A0758|56 66|NER system
P09372924A0758|95 103|proteins
P09372924A0758|123 134|involvement
P09372924A0758|138 152|hHR23 proteins
P09372924A0758|160 179|DNA repair reaction
P09372924A0758|184 195|interaction
P09372924A0758|201 204|XPC
P09372937T0000|4 9|yeast
P09372937T0000|17 52|information regulator Sir4p anchors
P09372937T0000|57 76|partitions plasmids
P09372950A1283|6 13|results
P09372950A1283|57 66|structure
P09372950A1283|77 86|sequences
P09372950A1283|95 100|sides
P09372950A1283|115 128|cleavage site
P09372950A1283|139 149|processing
P09372950A1283|159 165|U2 RNA
P09372960A0456|0 17|Polysome analyses
P09372960A0456|45 58|fal1-1 mutant
P09372960A0456|80 86|strain
P09372960A0456|96 104|decrease
P09372960A0456|112 118|number
P09372960A0456|122 125|40S
P09372960A0456|136 144|subunits
P09372968A0532|0 17|Sequence analysis
P09372968A0532|43 54|cDNA clones
P09372968A0532|58 63|Dlc-1
P09372968A0532|67 75|sequence
P09372968A0532|106 113|homolog
P09372968A0532|131 137|dynein
P09372968A0532|150 157|protein
P09372968A0996|16 20|HeLa
P09372968A0996|29 34|cells
P09372968A0996|65 77|kappaB alpha
P09372968A0996|129 134|Dlc-1
P09373140A0000|4 20|mouse M-lysozyme
P09373140A0000|32 40|enhancer
P09373140A0000|86 92|levels
P09373140A0000|96 111|gene regulation
P09373155T0000|0 14|Identification
P09373155T0000|18 24|dynein
P09373155T0000|31 42|chain genes
P09373155T0000|66 78|mouse testis
P09373155T0000|92 104|localization
P09373155T0000|120 131|dynein gene
P09373651A0255|7 14|cassava
P09373651A0255|35 45|glycosides
P09373651A0255|47 57|processing
P09373651A0255|78 97|acetone cyanohydrin
P09373651A0255|102 118|hydrogen cyanide
P09374082A0504|13 22|mechanism
P09374082A0504|26 39|effect states
P09374082A0504|50 62|2-ethylhexyl
P09374082A0504|64 73|phthalate
P09374082A0504|75 79|MEHP
P09374082A0504|94 112|hydrolysis product
P09374082A0504|116 120|DEHP
P09374082A0504|142 156|prostaglandins
P09374082A0504|158 160|PG
P09374082A0504|162 165|PGD
P09374082A0504|170 176|9alpha
P09374082A0504|179 187|betaPGF2
P09374082A0504|193 202|PGF2alpha
P09374082A0504|208 220|thromboxanes
P09374082A0504|228 233|lungs
P09374082A0504|258 262|risk
P09374082A0504|275 287|inflammation
P09374082A0504|295 302|airways
P09374082A0504|315 329|characteristic
P09374082A0504|333 339|asthma
P09374541A0277|12 33|protein binding sites
P09374541T0000|13 23|protection
P09374541T0000|27 52|E2F recognition sequences
P09374541T0000|66 91|thymidine kinase promoter
P09374541T0000|99 121|cell cycle progression
P09376325A0167|0 10|Comparison
P09376325A0167|22 30|sequence
P09376325A0167|46 54|ph locus
P09376325A0167|117 136|transcription units
P09376626A0737|0 9|Radiation
P09376626A0737|24 30|levels
P09376626A0737|34 36|T4
P09376626A0737|41 43|T3
P09376626A0737|46 47|h
P09376626A0737|55 56|h
P09376626A0737|60 67|group C
P09376626A0737|72 79|group A
P09376626A0737|86 87|h
P09376626A0737|92 99|group B
P09376626A0737|106 120|h postexposure
P09376782A0328|21 31|experience
P09376782A0328|43 46|MMT
P09376782A0328|55 63|practice
P09376782A0328|69 86|hepatitis C virus
P09376782A0328|88 91|HCV
P09376782A0328|93 102|infection
P09377355A0362|4 10|author
P09377355A0362|34 38|data
P09377355A0362|48 53|study
P09377355A0362|70 78|features
P09377355A0362|97 106|disorders
P09377355A0362|124 135|impairement
P09377355A0362|148 151|use
P09377355A0362|173 178|tools
P09377374A0000|8 13|paper
P09377374A0000|15 31|characterization
P09377374A0000|69 77|features
P09377374A0000|81 92|VH B course
P09377374A0000|105 115|background
P09377374A0000|119 129|narcomania
P09379301A2036|4 11|microns
P09379301A2036|16 32|A. microcephalum
P09379301A2036|41 48|microns
P09379301A2036|53 61|A. wedli
P09379301A2036|74 80|testes
P09379301A2036|85 95|proglottis
P09380504A1255|4 14|ZnF20 cDNA
P09380504A1255|38 49|transcripts
P09380504A1255|55 79|thyroid cancer cell line
P09380504A1255|96 98|kb
P09380504A1255|121 144|cycloheximide treatment
P09380504A1255|160 161|h
P09380504A1255|168 176|addition
P09380504A1255|180 194|actinomycin D.
P09380507A0514|0 25|Glutathione S-transferase
P09380507A0514|27 30|GST
P09380507A0514|32 35|E2F
P09380507A0514|40 62|GST-DP fusion proteins
P09380507A0514|111 120|E2F sites
P09380507A0514|128 162|DNA polymerase alpha gene promoter
P09380697T0000|4 10|sterol
P09380697T0000|35 44|sequences
P09380697T0000|53 66|up-regulation
P09380697T0000|70 97|caveolin gene transcription
P09380697T0000|101 109|response
P09380697T0000|117 136|density lipoprotein
P09380697T0000|142 153|cholesterol
P09380707A0714|23 32|LAZ3/BCL6
P09380707A0714|42 46|SMRT
P09380707A0714|79 87|proteins
P09380707A0714|121 125|dots
P09381261A0970|0 11|CONCLUSIONS
P09381261A0970|32 42|EPO levels
P09381261A0970|47 54|mothers
P09381261A0970|59 67|newborns
P09381261A0970|76 80|area
P09381261A0970|120 124|ones
P09381950A0209|0 9|Ischaemia
P09381950A0209|31 40|flow rate
P09381950A0209|48 56|mL min-1
P09381950A0209|64 67|min
P09381950A0209|101 112|reperfusion
P09382498A0618|11 15|MCTs
P09382498A0618|29 38|electrode
P09382498A0618|42 44|cm
P09382498A0618|48 52|size
P09382498A0618|84 88|area
P09382498A0618|96 101|tumor
P09382498A0618|113 117|MCTs
P09382498A0618|129 138|electrode
P09382498A0618|142 144|cm
P09382498A0618|148 152|size
P09382498A0618|198 202|area
P09382498A0618|210 215|tumor
P09382850A0000|0 10|BACKGROUND
P09382850A0000|12 31|Checkpoint pathways
P09382850A0000|51 62|progression
P09382850A0000|70 75|event
P09382850A0000|79 90|DNA lesions
P09382886A1061|7 12|proof
P09382886A1061|48 57|apoptosis
P09382886A1061|61 64|PKD
P09382886A1061|90 93|p53
P09382886A1061|121 128|matings
P09382886A1061|137 140|SBM
P09382886A1061|145 148|p53
P09382886A1061|154 158|mice
P09382924A0131|12 20|evidence
P09382924A0131|42 53|stimulation
P09382924A0131|59 75|interferon-gamma
P09382924A0131|77 86|IFN-gamma
P09382924A0131|105 113|subunits
P09382924A0131|126 130|LMP2
P09382924A0131|132 136|LMP7
P09382924A0131|142 148|PSMB10
P09382924A0131|176 190|20S proteasome
P09382924A0131|232 240|subunits
P09382924A0131|252 257|PSMB6
P09382924A0131|259 264|PSMB5
P09382924A0131|270 275|PSMB7
P09383156A0691|10 34|RNase E cleavage product
P09383156A0691|44 50|pSok-6
P09383156A0691|75 103|polynucleotide phosphorylase
P09383156A0691|105 111|PNPase
P09383188A0654|5 15|difference
P09383188A0654|42 47|match
P09383188A0654|55 72|ARG box consensus
P09383188A0654|80 81|O
P09383188A0654|82 86|rocD
P09383188A0654|88 92|site
P09385169T0000|4 8|AONE
P09385169T0000|11 18|experts
P09385169T0000|29 52|productivity indicators
P09386074A0694|4 8|pigs
P09386074A0694|34 48|LV dysfunction
P09386074A0694|61 81|LV ejection fraction
P09386074A0694|90 91|%
P09387333T0001|4 12|progress
P09387333T0001|30 38|research
P09387333T0001|59 66|nucleus
P09387999A1053|4 14|amplitudes
P09387999A1053|18 23|DPOAE
P09387999A1053|52 58|extent
P09387999A1053|69 85|hair cell losses
P09387999A1053|124 128|ears
P09388198A1396|4 8|data
P09388198A1396|17 25|evidence
P09388198A1396|37 64|signal transduction pathway
P09388198A1396|80 83|JNK
P09388198A1396|85 88|ERK
P09388198A1396|94 108|p38 MAP kinase
P09388198A1396|131 140|induction
P09388198A1396|144 148|rhoB
P09388198A1396|162 168|stress
P09388198A1396|196 210|autoregulation
P09388198A1396|214 218|rhoB
P09388199A0948|6 12|effort
P09388199A0948|25 32|domains
P09388199A0948|36 40|FadR
P09388199A0948|54 65|DNA binding
P09388199A0948|67 79|dimerization
P09388199A0948|85 99|ligand binding
P09388199A0948|110 125|protein fusions
P09388199A0948|138 156|DNA binding domain
P09388199A0948|160 164|LexA
P09388199A0948|179 186|regions
P09388199A0948|190 194|FadR
P09388200A0639|0 10|Inhibition
P09388200A0639|34 43|titration
P09388200A0639|55 76|transcription factors
P09388200A0639|85 104|MDM2 overexpression
P09388200A0639|114 119|c-fos
P09388200A0639|137 146|promoters
P09388200A0639|165 178|transcription
P09388201A1027|3 5|PU
P09388201A1027|10 12|PD
P09388201A1027|34 38|TATA
P09388201A1027|42 53|CAAT motifs
P09388246A0903|27 66|electron microscopy immunocytochemistry
P09388246A0903|72 83|amphiphysin
P09388246A0903|106 111|nerve
P09388246A0903|121 131|cytomatrix
P09388246A0903|175 188|intermediates
P09388271A1243|4 18|mobility shift
P09388271A1243|36 44|proteins
P09388271A1243|61 70|treatment
P09388271A1243|76 86|inhibitors
P09388271A1243|90 93|PKC
P09388271A1243|115 122|protein
P09388271A1243|159 172|kinase kinase
P09389137A0763|4 16|prescription
P09389137A0763|21 29|apoplexy
P09389137A0763|39 43|C1-7
P09389137A0763|45 49|T1-9
P09389137A0763|54 58|L2-4
P09389198A0363|11 20|aftermath
P09389198A0363|24 34|excitation
P09389198A0363|42 46|skin
P09389198A0363|59 64|nerve
P09389198A0363|75 86|arithmetics
P09389198A0363|93 106|A delta units
P09389198A0363|133 138|state
P09389198A0363|165 174|threshold
P09389492A0520|13 20|fashion
P09389492A0520|40 45|cells
P09389492A0520|47 52|serum
P09389492A0520|69 77|response
P09389492A0520|81 94|dexamethasone
P09389492A0520|106 112|effect
P09389492A0520|116 123|phorbol
P09389492A0520|141 149|activity
P09389666A0538|6 20|Hex expression
P09389666A0538|62 87|anteroposterior asymmetry
P09389666A0538|95 107|mouse embryo
P09389666A0538|147 151|axis
P09389666A0538|159 165|embryo
P09389666A0538|180 190|conversion
P09389666A0538|210 219|asymmetry
P09389666A0538|249 265|endoderm lineage
P09389669A1009|6 9|dpp
P09389669A1009|14 17|omb
P09389669A1009|31 51|dorsal leg cell fate
P09389669A1009|92 106|leg disc cells
P09389982A1383|0 11|CONCLUSIONS
P09389982A1383|19 33|INR correction
P09389982A1383|67 74|methods
P09389982A1383|90 107|log reference INR
P09389982A1383|121 137|prothrombin time
P09389982A1383|148 167|regression analysis
P09390125A0379|0 7|RESULTS
P09390125A0379|21 24|FNF
P09390125A0379|42 43|%
P09390125A0379|56 57|%
P09390125A0379|63 64|%
P09390125A0379|69 70|%
P09390125A0379|78 79|%
P09390125A0379|95 103|quarters
P09390183A1027|0 21|Western blot analysis
P09390183A1027|40 47|tissues
P09390183A1027|59 79|NMT peptide antibody
P09390183A1027|124 128|band
P09390183A1027|156 160|mass
P09390183A1027|172 175|kDa
P09390183A1027|183 190|tissues
P09391173A0811|0 25|Transcription start sites
P09391173A0811|33 53|plastid ACCase genes
P09391173A0811|86 97|cDNA clones
P09391173A0811|113 117|RACE
P09391173A0811|125 138|amplification
P09391173A0811|142 151|cDNA ends
P09392979T0000|26 40|histoplasmosis
P09392979T0000|44 57|San Francisco
P09392979T0000|59 69|California
P09393706A1171|6 9|Fis
P09393706A1171|47 56|activator
P09393706A1171|68 76|promoter
P09393717A1517|6 18|observations
P09393717A1517|34 41|support
P09393717A1517|50 54|idea
P09393717A1517|60 70|expression
P09393717A1517|81 85|tRNA
P09393717A1517|99 116|mutator phenotype
P09393717A1517|149 158|phenotype
P09393717A1517|171 175|mutA
P09393717A1517|180 190|mutC cells
P09393771A1659|0 18|TNF-alpha exposure
P09393771A1659|38 46|activity
P09393771A1659|70 78|proteins
P09393771A1659|99 101|Mr
P09393771A1659|128 135|protein
P09393875A0873|28 42|papillomavirus
P09393875A0873|48 53|mRNAs
P09393875A0873|85 91|copies
P09393875A0873|99 111|virus genome
P09393875A0873|132 137|cells
P09393875A0873|156 167|c-fos mRNAs
P09393875A0873|195 202|factors
P09393875A0873|238 256|Fos protein levels
P09393875A0873|266 280|papillomavirus
P09393875A0873|290 295|cells
P09393966A0190|20 23|IgH
P09393966A0190|33 45|region genes
P09393966A0190|47 50|CHA
P09393966A0190|55 58|CHB
P09394650A0121|4 7|aim
P09394650A0121|16 21|study
P09394650A0121|79 90|lymph nodes
P09394650A0121|122 124|US
P09395456A0424|13 17|role
P09395456A0424|27 39|chain motifs
P09395456A0424|43 64|substrate recognition
P09395456A0424|75 83|variants
P09395456A0424|106 124|proenteropeptidase
P09395456A0424|159 179|transmembrane domain
P09395456A0424|187 201|signal peptide
P09395470A0294|0 12|CKbeta4GT-II
P09395470A0294|38 42|type
P09395470A0294|46 72|transmembrane glycoprotein
P09395470A0294|79 82|kDa
P09395470A0294|112 131|glycosylation sites
P09395525A0395|47 54|protein
P09395525A0395|56 61|C/EBP
P09395525A0395|63 68|delta
P09395525A0395|80 89|component
P09395525A0395|123 130|complex
P09395525A0395|141 145|HS3D
P09395525A0395|160 170|C/EBPdelta
P09395525A0395|186 200|IGF-I promoter
P09395525A0395|216 220|site
P09396402A0264|0 8|PATIENTS
P09396402A0264|13 20|METHODS
P09396402A0264|22 36|Semen analyses
P09396402A0264|58 66|patients
P09396402A0264|72 78|stages
P09396402A0264|85 87|HD
P09396402A0264|114 126|chemotherapy
P09396402A0264|141 152|sperm count
P09396402A0264|172 179|effects
P09396402A0264|193 205|radiotherapy
P09396402A0264|227 239|chemotherapy
P09396427A1488|10 17|absence
P09396427A1488|30 52|infarct-zone viability
P09396427A1488|67 75|patients
P09396427A1488|117 125|dilation
P09396427A1488|143 146|AMI
P09396427A1488|195 203|geometry
P09396437A0878|7 17|BMI cutoff
P09396437A0878|38 50|NE spillover
P09396437A0878|57 58|%
P09396437A0878|78 86|subjects
P09396437A0878|115 123|subjects
P09396437A0878|125 126|P
P09396722A0185|4 8|gene
P09396722A0185|10 15|ApxII
P09396722A0185|45 76|ascorbate peroxidase isoenzymes
P09396722A0185|98 110|organization
P09396722A0185|118 122|gene
P09396796A1173|20 30|conclusion
P09396796A1173|36 41|CDF-1
P09396796A1173|52 69|E2F family member
P09396796A1173|74 80|points
P09396796A1173|93 104|differences
P09396796A1173|112 133|cell cycle regulation
P09396796A1173|137 142|CDF-1
P09396796A1173|147 150|E2F
P09396823T0000|17 23|domain
P09396823T0000|44 58|DNA polymerase
P09396823T0000|71 74|DNA
P09396823T0000|82 105|RNA exonuclease domains
P09397261A0940|0 20|Interleukin-1 levels
P09397261A0940|49 55|course
P09397723T0001|0 22|Responsibility matters
P09397723T0001|45 52|council
P09398267A0440|0 22|Southern blot analysis
P09398267A0440|56 59|DNA
P09398267A0440|73 97|chick embryo fibroblasts
P09398267A0440|99 102|CEF
P09398267A0440|119 123|MEK2
P09398267A0440|141 145|gene
P09398267A0440|165 172|species
P09398332A0732|0 9|Sequences
P09398332A0732|23 34|interaction
P09398332A0732|38 41|mu2
P09398332A0732|46 52|CTLA-4
P09398332A0732|71 79|residues
P09398332A0732|81 89|161TTGVY
P09398332A0732|93 99|CTLA-4
P09398332A0732|106 114|sequence
P09398332A0732|176 193|SH2 binding motif
P09398332A0732|195 202|165YVKM
P09398332A0732|216 232|CTLA-4 signaling
P09398598A0256|43 56|hamster ovary
P09398598A0256|58 61|CHO
P09398598A0256|63 72|cell line
P09398598A0256|93 105|CD4 fragment
P09398598A0256|142 149|domains
P09398598A0256|174 183|molecules
P09398598A0256|205 214|multimers
P09398855A0438|0 6|SCID V
P09398855A0438|7 8|D
P09398855A0438|9 24|J recombination
P09398855A0438|50 63|T-lymphocytes
P09398855A0438|87 93|agents
P09398855A0438|95 112|gamma-irradiation
P09398855A0438|117 126|bieomycin
P09398855A0438|138 146|mutation
P09398855A0438|154 162|p53 gene
P09398855A0438|205 224|DNA repair activity
P09398855A0438|228 236|response
P09398855A0438|240 250|DNA damage
P09398855A0438|265 274|apoptosis
P09398855A0438|282 289|absence
P09398855A0438|293 296|p53
P09400613A0594|0 12|Coexpression
P09400613A0594|16 25|mouse PKR
P09400613A0594|40 44|Gal4
P09400613A0594|57 70|domain fusion
P09400613A0594|113 116|PKR
P09400613A0594|124 136|K296R mutant
P09400613A0594|170 173|PKR
P09400613A0594|180 190|K64E/K296R
P09400613A0594|219 228|mouse PKR
P09400613A0594|253 287|PKR-Gal4 activation domain fusions
P09400613A0594|300 310|activation
P09400613A0594|318 322|HIS3
P09400613A0594|327 341|lacZ reporters
P09400613A1209|6 35|GST-PKR fusion chromatography
P09400613A1209|53 64|interaction
P09400613A1209|77 82|mouse
P09400613A1209|93 105|PKR homologs
P09400738A1046|29 37|response
P09400738A1046|71 83|instillation
P09400738A1046|87 91|ufCB
P09400738A1046|107 122|CB instillation
P09402029A1632|29 41|strain H37Ra
P09402029A1632|54 67|hybridization
P09402029A1632|83 89|probes
P09402029A1632|113 118|genes
P09402029A1632|160 166|strain
P09402029A1632|193 205|copy numbers
P09402029A1632|242 254|strain H37Rv
P09402088A2250|6 13|defects
P09402088A2250|17 22|doubt
P09402088A2250|46 59|configuration
P09402088A2250|81 91|processing
P09402088A2250|99 117|AVP gene precursor
P09402139A1121|0 12|Similarities
P09402139A1121|25 33|hIGFBP-1
P09402139A1121|38 64|phosphoenolpyruvate kinase
P09402139A1121|66 71|PEPCK
P09402139A1121|73 82|promoters
P09402139A1121|94 101|regions
P09402139A1121|113 120|insulin
P09402139A1121|122 136|glucocorticoid
P09402139A1121|173 182|responses
P09402139A1121|217 227|hypothesis
P09402139A1121|233 240|IGFBP-1
P09402139A1121|256 266|regulation
P09402139A1121|270 288|glucose metabolism
P09403059A0209|12 18|repeat
P09403059A0209|39 51|DNA elements
P09403059A0209|65 70|LINES
P09403059A0209|72 77|SINES
P09403059A0209|79 115|medium reiteration frequency repeats
P09403059A0209|139 146|element
P09404725A0644|6 10|days
P09404725A0644|15 21|amount
P09404725A0644|25 37|gangliosides
P09404725A0644|62 69|females
P09404725A0644|78 83|males
P09404725A0644|103 112|exception
P09405195A0320|14 24|constructs
P09405195A0320|53 58|locus
P09405195A0320|73 86|recombination
P09405195A0320|105 114|sequences
P09405195A0320|128 137|stretches
P09405195A0320|160 163|DNA
P09405195A0320|172 187|intron excision
P09405195A0320|226 229|DNA
P09405195A0320|247 260|recombination
P09405380A0800|4 13|existence
P09405380A0800|27 37|categories
P09405380A0800|41 48|strains
P09405380A0800|70 76|system
P09405380A0800|90 100|properties
P09405380A0800|129 139|retrovirus
P09405536A0777|11 33|conditioning procedure
P09405536A0777|39 46|C-fiber
P09405536A0777|104 111|fashion
P09405536A0777|136 143|animals
P09405536A0777|155 166|application
P09405536A0777|186 206|conditioning stimuli
P09405536A0777|224 233|magnitude
P09405536A0777|241 250|responses
P09405536A0777|261 268|plateau
P09405685A0113|23 55|DNA binding transcription factor
P09405685A0113|57 60|p53
P09405685A0113|91 106|consensus motif
P09405685A0113|110 117|PuPuPuC
P09405685A0113|118 121|A/T
P09405685A0113|124 127|T/A
P09405685A0113|128 142|GPyPyPyPuPuPuC
P09405685A0113|143 146|A/T
P09405685A0113|148 151|T/A
P09405685A0113|152 161|GPyPyPy-3
P09407026A0426|0 13|TSA treatment
P09407026A0426|49 72|enhancer factor binding
P09407026A0426|80 91|positioning
P09407026A0426|95 100|nuc-1
P09407026A0426|108 116|majority
P09407026A0426|124 143|chromatin templates
P09407026A0426|160 179|protein acetylation
P09407026A0426|184 204|chromatin remodeling
P09407026A0426|221 226|steps
P09407026A0426|274 283|templates
P09407026A0426|293 303|remodeling
P09407026A0426|307 312|nuc-1
P09407026A0426|333 340|factors
P09407031A0557|5 14|UV damage
P09407031A0557|16 20|Crb2
P09407031A0557|86 92|timing
P09407031A0557|96 111|phosphorylation
P09407031A0557|115 126|Chk1 kinase
P09407031A0557|158 173|Cdc2 activation
P09407031A0974|19 33|overexpression
P09407031A0974|37 41|Chk1
P09407031A0974|57 67|phenotypes
P09407031A0974|71 75|cut5
P09407031A0974|80 92|crb2 mutants
P09407036T0000|0 11|Tcn1p/Crz1p
P09407036T0000|37 57|transcription factor
P09407036T0000|88 103|gene expression
P09407090T0000|0 9|Structure
P09407090T0000|14 26|localization
P09407090T0000|40 44|gene
P09407090T0000|54 63|SR-BI/CLA
P09407642A0305|18 31|gel technique
P09407642A0305|45 50|assay
P09407642A0305|55 73|antibody detection
P09407642A0305|78 92|identification
P09408516T0000|0 9|Stability
P09408516T0000|13 26|pyrimethamine
P09408516T0000|39 57|dosage formulation
P09408516T0000|75 81|months
P09408796A0648|9 28|regression analyses
P09408796A0648|43 84|WAIS-R factor scores Verbal Comprehension
P09408796A0648|89 96|Freedom
P09408796A0648|102 117|Distractibility
P09408796A0648|140 141|%
P09408796A0648|149 157|variance
P09408796A0648|161 166|WMS-R
P09408796A0648|171 183|CVLT indices
P09409416A0111|16 24|arteries
P09409416A0111|60 68|approach
P09409416A0111|78 81|MHz
P09409416A0111|89 107|Doppler instrument
P09409416A0111|109 121|TC-2 64B EME
P09409774A0214|15 20|level
P09409774A0214|26 35|sequences
P09409774A0214|43 50|members
P09409774A0214|59 65|family
P09409774A0214|83 104|rat Rattus norvegicus
P09409774A0214|110 120|VCSA1 gene
P09409774A0214|151 167|polypeptide SMR1
P09409774A0214|177 187|VCSB1 gene
P09409774A0214|218 229|polypeptide
P09409821T0000|29 39|RAD30 gene
P09409821T0000|43 52|homologue
P09409821T0000|73 77|dinB
P09409821T0000|82 86|umuC
P09409821T0000|91 101|DNA damage
P09409821T0000|116 125|functions
P09409821T0000|148 180|postreplication repair mechanism
P09411459A0729|18 28|experiment
P09411459A0729|42 55|deletion task
P09411459A0729|75 86|puppet game
P09411459A0729|97 108|pretraining
P09411459A0729|113 122|selection
P09411459A0729|126 140|vowel deletion
P09411459A0729|165 170|level
P09411459A0729|174 181|success
P09411459A0729|202 210|children
P09411459A0729|228 241|CVCC material
P09412079T0001|0 12|Diet therapy
P09412079T0001|18 30|soy proteins
P09412079T0001|43 57|stomach ulcers
P09413375A1486|3 15|ICU patients
P09413375A1486|21 24|LIS
P09413375A1486|54 58|rise
P09413375A1486|62 72|IL-6 level
P09413375A1486|95 99|rise
P09413375A1486|103 124|plasma concentrations
P09413375A1486|128 137|cytokines
P09414074A0827|0 19|Resistance training
P09414074A0827|31 42|power curve
P09414074A0827|57 66|direction
P09414074A0827|76 88|measurements
P09414074A0827|118 123|loads
P09414074A0827|143 148|power
P09414074A0827|187 203|performance task
P09414074A0827|213 216|SSP
P09414287A0637|0 16|Gel-shift assays
P09414287A0637|32 49|Sp1 binding sites
P09414287A0637|62 69|element
P09414319A1442|0 6|Y15170
P09414319A1442|8 14|Surf-2
P09414319A1442|16 22|Surf-4
P09414319A1442|25 31|Y15171
P09414319A1442|33 39|Surf-3
P09414319A1442|41 47|Surf-1
P09414319A1442|49 55|Surf-6
P09414319A1442|62 68|Y15172
P09414319A1442|70 76|Surf-5
P09415711A1348|0 18|Gel mobility shift
P09415711A1348|35 41|assays
P09415711A1348|48 53|liver
P09415711A1348|62 70|extracts
P09415711A1348|83 92|rat liver
P09415711A1348|96 110|DDT1MF-2 cells
P09415711A1348|133 136|CRE
P09415711A1348|144 160|alpha 1B-AR gene
P09415711A1348|167 186|CRE binding protein
P09416467A0959|6 13|results
P09416467A0959|49 54|model
P09416467A0959|56 70|ACE inhibitors
P09416467A0959|81 92|arrhythmias
P09416467A0959|103 123|ischemia-reperfusion
P09416467A0959|141 158|scavenging action
P09416467A0959|168 173|drugs
P09416467A0959|209 213|role
P09416467A0959|234 240|effect
P09416898A1798|4 15|mean values
P09416898A1798|35 45|components
P09416898A1798|82 95|ARVD patients
P09416898A1798|108 116|subjects
P09417082A0127|13 30|signaling cascade
P09417082A0127|47 65|urokinase receptor
P09417108A0000|11 24|Htf9-a/RanBP1
P09417108A0000|29 41|Htf9-c genes
P09417108A0000|94 102|promoter
P09417493A0823|3 13|accordance
P09417493A0823|28 39|improvement
P09417493A0823|51 59|decrease
P09417493A0823|63 84|laboratory indicators
P09417493A0823|88 100|inflammation
P09417493A0823|113 120|protein
P09417493A0823|122 139|alpha 2-globuline
P09417493A0823|141 157|prostaglandin E2
P09417870A0105|33 42|depletion
P09417870A0105|46 62|protein kinase C
P09417870A0105|76 85|treatment
P09417870A0105|89 113|B16 mouse melanoma cells
P09417870A0105|119 137|phorbol dibutyrate
P09417870A0105|139 143|PDBu
P09417870A0105|155 159|cell
P09417870A0105|178 191|melanogenesis
P09417928A0980|0 11|Replacement
P09417928A0980|15 23|residues
P09417928A0980|27 36|positions
P09417928A0980|41 50|His128Asn
P09417928A0980|56 58|+2
P09417928A0980|60 69|Gln155Lys
P09417928A0980|78 93|reading helices
P09417928A0980|97 104|fingers
P09417928A0980|138 145|binding
P09417941A1287|4 22|disulphide bridges
P09417941A1287|51 73|spermadhesin molecules
P09417941A1287|83 94|CUB domains
P09417941A1287|106 113|loop LA
P09417941A1287|118 129|strand beta
P09417941A1287|136 144|loops LE
P09417941A1287|149 151|LG
P09417941A1287|179 184|edges
P09417941A1287|197 201|face
P09417941A1287|209 215|domain
P09418040T0000|0 12|Mg-chelatase
P09418040T0000|16 23|tobacco
P09418040T0000|25 39|identification
P09418040T0000|45 64|Chl D cDNA sequence
P09418040T0000|82 89|subunit
P09418040T0000|91 99|analysis
P09418040T0000|107 118|interaction
P09418040T0000|132 140|subunits
P09418040T0000|150 155|yeast
P09418040T0000|167 173|system
P09418040T0000|179 193|reconstitution
P09418040T0000|201 216|enzyme activity
P09418040T0000|220 233|co-expression
P09418040T0000|249 254|CHL D
P09418040T0000|256 261|CHL H
P09418040T0000|266 272|CHL I.
P09418057A0684|4 9|R-EST
P09418057A0684|27 35|sequence
P09418057A0684|55 64|locations
P09418861A0623|16 25|structure
P09418861A0623|51 56|motif
P09418861A0623|77 93|protein kinase C
P09418861A0623|98 109|n-chimaerin
P09418861A0623|125 151|pleckstrin homology domain
P09418871A0620|4 15|interaction
P09418871A0620|24 27|DDB
P09418871A0620|32 36|E2F1
P09418871A0620|61 94|coimmunoprecipitation experiments
P09418882A0760|14 24|antibodies
P09418882A0760|60 67|version
P09418882A0760|71 77|Prp42p
P09418882A0760|103 111|U1 snRNA
P09418882A0760|117 131|yeast extracts
P09418905A1396|6 13|results
P09418905A1396|31 39|addition
P09418905A1396|57 67|activation
P09418905A1396|71 74|Ras
P09418905A1396|96 110|DAG production
P09418905A1396|127 130|EGF
P09418905A1396|149 162|S-phase entry
P09418905A1396|167 182|gene expression
P09418905A1396|201 211|activation
P09418905A1396|215 218|PKC
P09419415A0236|8 13|study
P09419415A0236|31 46|STAT activation
P09419415A0236|52 57|panel
P09419415A0236|68 89|fibroblast cell lines
P09419415A0236|126 138|oncoproteins
P09419421A0385|20 25|cells
P09419421A0385|31 38|binding
P09419421A0385|42 50|NF-Y/CBF
P09419421A0385|54 58|TKC1
P09419421A0385|91 98|plateau
P09419421A0385|106 113|S phase
P09419680A1112|0 10|CONCLUSION
P09419680A1112|19 31|animal model
P09419680A1112|45 63|barrier disruption
P09419680A1112|93 100|finding
P09419680A1112|104 119|single-fraction
P09419680A1112|131 149|irradiation injury
P09420219A0284|18 31|investigation
P09420219A0284|35 45|parameters
P09420219A0284|68 74|export
P09420219A0284|98 103|cells
P09420219A0284|135 154|beta-actin minigene
P09420219A0284|165 172|control
P09420219A0284|205 222|enhancer-promoter
P09420219A0284|226 231|mouse
P09420219A0284|240 251|tumor virus
P09420219A0284|284 287|end
P09420219A0284|295 310|adenovirus type
P09420219A0284|314 317|Ad5
P09420219A0284|319 325|genome
P09420220A0070|0 4|Cell
P09420220A0070|32 44|interactions
P09420220A0070|87 97|expression
P09420220A0070|105 109|HCMV
P09420220A0070|137 141|gene
P09420220A0070|143 145|J.
P09420234A0654|0 9|MpB GroEL
P09420234A0654|24 43|sequence similarity
P09420234A0654|47 48|%
P09420234A0654|72 77|GroEL
P09420234A0654|88 95|members
P09420234A0654|103 123|chaperonin-60 family
P09420239A1937|13 22|mutations
P09420239A1937|82 92|elongation
P09420239A1937|100 102|TM
P09420239A1937|107 127|Nef coding sequences
P09420239A1937|129 136|changes
P09420239A1937|140 156|RNA splice donor
P09420239A1937|161 175|acceptor sites
P09420239A1937|177 191|TATA box sites
P09420239A1937|197 206|Sp1 sites
P09420239A1937|217 224|changes
P09420239A1937|232 241|V2 region
P09420239A1937|245 247|SU
P09420239A1937|261 293|consensus neutralization epitope
P09420239A1937|317 336|glycosylation sites
P09420239A1937|340 342|SU
P09420251A1363|0 2|C.
P09420252A0092|28 34|repeat
P09420252A0092|36 39|LTR
P09420252A0092|41 49|promoter
P09420252A0092|67 77|expression
P09420252A0092|102 110|proteins
P09420252A0092|134 142|promoter
P09420252A0092|167 170|end
P09420252A0092|178 186|env gene
P09420252A0092|201 211|expression
P09420252A0092|225 243|auxiliary proteins
P09420269A0000|7 10|end
P09420269A0000|26 29|RNA
P09420269A0000|33 46|rubella virus
P09420269A0000|48 51|RUB
P09420269A0000|79 81|nt
P09420269A0000|99 105|leader
P09420269A0000|107 116|ss-leader
P09420269A0000|146 155|structure
P09420269A0000|162 164|SL
P09420269A0000|167 169|nt
P09420269A0000|185 195|complement
P09420269A0000|215 218|end
P09420269A0000|239 242|RNA
P09420269A0000|249 251|SL
P09420269A0000|288 296|promoter
P09420269A0000|301 310|synthesis
P09420269A0000|327 334|strands
P09420275A0682|19 31|requirements
P09420275A0682|36 48|CBF2 binding
P09420275A0682|67 73|series
P09420275A0682|77 93|oligonucleotides
P09420275A0682|110 132|transversion mutations
P09420275A0682|161 174|core sequence
P09420275A0682|196 205|sequences
P09420275A1111|3 11|addition
P09420275A1111|17 27|affinities
P09420275A1111|31 35|CBF2
P09420275A1111|55 60|LMP-1
P09420275A1111|62 67|LMP-2
P09420275A1111|73 87|CD23 promoters
P09420671A1190|0 11|CONCLUSIONS
P09420671A1190|28 34|uptake
P09420671A1190|38 53|99mTc sestamibi
P09420671A1190|64 72|subjects
P09420671A1190|77 85|patients
P09420671A1190|100 114|artery disease
P09420671A1190|135 143|exercise
P09420671A1190|145 157|dipyridamole
P09420671A1190|163 179|adenosine stress
P09421507A0000|7 21|protein family
P09421507A0000|64 81|pre-mRNA splicing
P09421507A0000|144 153|organisms
P09421508A0696|19 27|activity
P09421508A0696|31 36|TCF11
P09421508A0696|59 63|site
P09421508A0696|87 95|presence
P09421508A0696|99 103|MafG
P09421508A0696|130 148|transfection assay
P09421511A0827|16 27|comparisons
P09421511A0827|49 58|evolution
P09421511A0827|69 95|RNA-polymerase specificity
P09421511A0827|99 128|telomerase RNA-gene promoters
P09421511A0827|153 161|position
P09421511A0827|169 186|template sequence
P09421511A0827|194 208|telomerase RNA
P09421516A1516|0 13|Deadenylation
P09421516A1516|18 23|decay
P09421516A1516|27 43|beta-globin mRNA
P09421516A1516|47 57|K562 cells
P09421516A1516|96 109|NIH 3T3 cells
P09421516A1516|141 150|stability
P09421516A1516|161 177|beta-globin mRNA
P09421516A1516|181 191|K562 cells
P09421516A1516|220 238|deadenylation step
P09421521T0000|0 27|Holliday junction resolvase
P09421521T0000|71 92|endonuclease activity
P09421521T0000|100 119|CCE1 homologue YDC2
P09422351A0000|0 3|Ca2
P09422351A0000|26 40|protein kinase
P09422351A0000|45 49|CaMK
P09422351A0000|75 106|serine/threonine protein kinase
P09422351A0000|122 134|ion channels
P09422351A0000|146 153|enzymes
P09422351A0000|168 176|proteins
P09422351A0000|191 212|transcription factors
P09422727A0196|42 50|TGACGTGA
P09422727A0196|52 69|promoter sequence
P09422727A0196|76 110|protein kinase A signaling pathway
P09422727A0196|132 141|induction
P09422727A0196|147 157|activation
P09422727A0196|166 185|CRE binding protein
P09422727A0196|187 191|CREB
P09422727A0196|208 230|transcription factor-2
P09422727A0196|232 237|ATF-2
P09422727A0196|264 271|process
P09423123A0000|0 4|IVOX
P09423123A0000|21 28|acronym
P09423123A0000|47 57|oxygenator
P09423310A0251|0 19|Histopathologically
P09423310A0251|30 42|lymphangioma
P09423310A0251|86 94|features
P09423310A0251|123 132|stainings
P09423310A0251|136 140|CD34
P09423310A0251|145 151|Factor
P09423310A0251|165 172|antigen
P09423310A0251|202 211|reactions
P09423310A0251|227 232|cells
P09423310A0251|240 245|cysts
P09423856A1098|0 19|Protease activities
P09423856A1098|23 31|cultures
P09423856A1098|53 60|strains
P09423856A1098|82 89|species
P09423856A1098|113 119|masses
P09423856A1098|144 147|kDa
P09423856A1098|178 188|processing
P09423856A1098|203 209|result
P09423856A1098|213 228|autoproteolysis
P09423856A1098|245 258|peptide bonds
P09423856A1098|277 282|parts
P09423856A1098|290 299|molecules
P09423968A0039|4 13|mechanism
P09423968A0039|30 39|analgesia
P09423968A0039|74 85|interaction
P09423968A0039|143 150|systems
P09423968A0039|152 159|defense
P09423968A0039|166 170|pain
P09423968A0039|204 210|course
P09423968A0039|214 221|defense
P09423968A0039|226 237|nociception
P09423968A0039|245 254|processes
P09423968A0039|282 290|ontogeny
P09423968A0039|294 298|rats
P09424012A1774|12 34|field placement errors
P09424012A1774|40 48|patients
P09424012A1774|68 80|mm distances
P09424012A1774|113 122|isocenter
P09424012A1774|145 152|patient
P09424012A1774|162 168|degree
P09424012A1774|180 185|error
P09424012A1774|226 232|errors
P09425036A0649|3 11|addition
P09425036A0649|38 45|version
P09425036A0649|53 70|Src family member
P09425036A0649|72 75|Lck
P09425036A0649|86 97|cell kinase
P09425036A0649|144 157|Csk substrate
P09425038A0752|0 2|A.
P09425038A0752|4 9|Swift
P09425038A0752|11 13|A.
P09425676A0000|9 19|mechanisms
P09425676A0000|31 48|stimulus-response
P09425676A0000|50 53|S-R
P09425676A0000|55 67|associations
P09425676A0000|71 94|S-R compatibility tasks
P09425676A0000|116 127|experiments
P09425676A0000|133 140|monkeys
P09426068A0826|4 24|c-myc/TGF-alpha HCCs
P09426068A0826|74 84|expression
P09426068A0826|88 97|TGF-alpha
P09426068A0826|121 126|index
P09426068A0826|130 138|contrast
P09426068A0826|147 153|levels
P09426068A0826|157 166|apoptosis
P09426068A0826|183 190|tissues
P09426068A0826|195 205|c-myc HCCs
P09426143A1358|20 24|data
P09426143A1358|55 62|effects
P09426143A1358|66 69|CRP
P09426143A1358|74 78|KdgR
P09426143A1358|86 96|expression
P09426143A1358|104 122|pectinolysis genes
P09426143A1358|142 152|mechanisms
P09426143A1358|171 182|competition
P09426143A1358|199 209|regulators
P09426143A1358|225 234|repressor
P09426143A1358|239 253|RNA polymerase
P09426143A1358|262 272|occupation
P09426143A1358|285 295|DNA region
P09426143A1358|303 315|target genes
P09426183A0000|15 35|Rel/NF-kappaB family
P09426183A0000|39 71|vertebrate transcription factors
P09426183A0000|84 90|number
P09426183A0000|128 136|proteins
P09426183A0000|147 150|DNA
P09426183A0000|154 160|dimers
P09426183A0000|171 179|activity
P09426183A0000|208 216|location
P09426239A0386|4 14|cglIM gene
P09426239A0386|42 48|operon
P09426239A0386|68 76|addition
P09426239A0386|82 87|genes
P09426239A0386|114 133|restriction enzymes
P09426595T0000|21 30|reductase
P09426595T0000|35 61|saccharopine dehydrogenase
P09426595T0000|67 87|Arabidopsis thaliana
P09426595T0000|89 108|nucleotide sequence
P09426595T0000|113 129|characterization
P09426907A0391|4 11|purpose
P09426907A0391|20 33|investigation
P09426907A0391|56 67|formulation
P09426907A0391|71 90|silver sulfadiazine
P09426907A0391|96 101|water
P09426907A0391|110 113|gel
P09426907A0391|115 124|poloxamer
P09426958A0110|4 15|study goals
P09426958A0110|46 51|clone
P09426958A0110|61 66|CO-Ag
P09426958A0110|81 101|corneal cDNA library
P09426958A0110|122 127|clone
P09427544A0000|4 12|pel gene
P09427544A0000|21 33|Amycolata sp
P09427544A0000|46 59|pectate lyase
P09427544A0000|61 63|EC
P09427544A0000|89 97|activity
P09427544A0000|118 129|DNA library
P09427544A0000|155 159|TK24
P09427551A0501|4 8|gene
P09427551A0501|22 27|exons
P09427551A0501|49 59|kb introns
P09427551A0501|97 107|chromosome
P09427551A0501|113 129|linkage analysis
P09427627A0802|3 18|Xenopus embryos
P09427627A0802|35 56|PDGF receptor protein
P09427627A0802|69 78|formation
P09427627A0802|82 90|mesoderm
P09427627A0802|108 116|explants
P09427627A0802|140 146|manner
P09427627A0930|12 19|variant
P09427627A0930|27 34|protein
P09427627A0930|55 75|transphosphorylation
P09427627A0930|119 122|p70
P09427627A0930|123 126|S6k
P09427627A0930|131 141|MAP kinase
P09427627A0930|152 161|treatment
P09427627A0930|167 173|FK1012
P09427627T0000|15 22|control
P09427627T0000|26 33|insulin
P09427627T0000|38 61|PDGF receptor signaling
P09427627T0000|70 74|role
P09427627T0000|78 97|membrane attachment
P09427844A0739|25 36|dAK subunit
P09427844A0739|70 81|association
P09427844A0739|89 92|dGK
P09427844A0739|96 107|dCK subunit
P09427844A0739|156 162|affect
P09427844A0739|166 170|dGuo
P09427844A0739|174 178|dCyd
P09427844A0739|201 208|subunit
P09428389A1805|0 11|CONCLUSIONS
P09428389A1805|27 31|dose
P09428389A1805|35 47|bicalutamide
P09428389A1805|76 87|combination
P09428389A1805|96 101|agent
P09428389A1805|113 119|LHRH-A
P09428389A1805|133 151|serum testosterone
P09428389A1805|164 169|doses
P09428389A1805|173 185|bicalutamide
P09428389A1805|209 213|drug
P09428389A1805|226 237|monotherapy
P09428787A0138|10 15|clone
P09428787A0138|49 51|kb
P09428787A0138|71 77|region
P09428787A0138|92 96|exon
P09428787A0138|104 131|p69/71 2-5A synthetase gene
P09428799A0897|13 17|gene
P09428799A0897|58 63|genes
P09428799A0897|88 95|enzymes
P09428799A0897|101 125|intron/exon organization
P09428799A0897|165 172|P450scc
P09429913A0528|0 7|RESULTS
P09429913A0528|24 32|question
P09429913A0528|40 48|benefits
P09429913A0528|100 107|studies
P09429913A0528|124 132|efficacy
P09429913A0528|137 141|EMDR
P09429913A0528|152 161|disorders
P09429913A0528|191 199|disorder
P09430461A0742|16 21|study
P09430461A0742|27 38|defect size
P09430461A0742|48 61|BMIPP imaging
P09430461A0742|103 111|infarcts
P09430461A0742|113 114|p
P09430461A0742|153 162|risk area
P09430461A0742|175 200|contrast ventriculography
P09430461A0742|202 203|r
P09430461A0742|212 213|p
P09430461A0742|224 234|CONCLUSION
P09430461A0742|258 262|data
P09430461A0742|288 293|group
P09430461A0742|297 305|patients
P09430461A0742|332 345|BMIPP imaging
P09430461A0742|367 381|quantification
P09430461A0742|385 396|defect size
P09430461A0742|400 405|means
P09430461A0742|418 437|threshold technique
P09430461A0742|459 464|phase
P09430461A0742|474 487|determination
P09430461A0742|495 501|amount
P09430461A0742|505 515|myocardium
P09430461A0742|519 523|risk
P09430461A0742|547 557|infarction
P09430661A0796|10 24|overexpression
P09430661A0796|35 50|EphB1 receptors
P09430661A0796|52 57|Y594F
P09430661A0796|67 82|Nck recruitment
P09430661A0796|86 91|EphB1
P09430661A0796|115 129|JNK activation
P09430661A0796|143 168|cell attachment responses
P09430668A0172a|4 12|promoter
P09430668A0172a|17 33|HMG-CoA synthase
P09430668A0172a|55 60|sites
P09430668A0172a|69 75|sterol
P09430668A0172a|103 111|proteins
P09430668A0172a|113 119|SREBPs
P09430730A0374|0 2|S.
P09430730A0374|8 14|Walter
P09430730A0374|16 18|P.
P09431812A0576|25 27|Hh
P09431812A0576|32 39|Patched
P09431812A0576|41 44|Ptc
P09431812A0576|64 80|Ci binding sites
P09431812A0576|97 102|level
P09431812A0576|135 145|activation
P09431812A0576|149 157|S2 cells
P09431828A1472|23 31|increase
P09431828A1472|35 52|cyclosporine DR/C
P09431828A1472|53 62|SS trough
P09431828A1472|71 76|l h-1
P09431828A1472|91 96|l h-1
P09431828A1472|112 117|range
P09432752A0109|0 8|Patients
P09432752A0109|19 28|relatives
P09432752A0109|76 99|treatment possibilities
P09432752A0109|120 126|moment
P09432752A0109|137 148|application
P09432752A0109|166 173|patient
P09434160A0767|8 15|PTPases
P09434160A0767|62 84|bone marrow stem cells
P09434160A2078|0 10|Expression
P09434160A2078|14 19|PTPRO
P09434160A2078|47 51|CD34
P09434160A2078|53 70|bone marrow cells
P09434160A2078|105 115|stem cells
P09434185A0902|4 16|organization
P09434185A0902|20 30|SPP1 genes
P09434185A0902|47 58|replication
P09434185A0902|60 73|DNA packaging
P09434185A0902|78 101|phage assembly proteins
P09434185A0902|116 128|organization
P09434185A0902|132 137|genes
P09434185A0902|152 159|regions
P09434185A0902|197 207|DNA phages
P09434979A0790|4 11|results
P09434979A0790|48 62|photon fluence
P09434979A0790|80 94|photon fluence
P09434979A0790|112 122|collimator
P09434979A0790|142 148|filter
P09434979A0790|155 156|%
P09434979A0790|159 160|%
P09434979A0790|168 177|isocenter
P09434979A0790|193 194|%
P09434979A0790|229 235|filter
P09435056A0128|22 28|domain
P09435056A0128|32 44|pediocin AcH
P09435056A0128|46 49|Lys
P09435056A0128|55 58|Cys
P09435056A0128|96 105|machinery
P09435056A0128|126 135|periplasm
P09435056A0128|146 150|form
P09435056A0128|165 170|frame
P09435056A0128|178 191|COOH terminus
P09435056A0128|209 216|protein
P09435056A0128|233 240|protein
P09435056A0128|242 245|MBP
P09435116A0437|0 7|Isomers
P09435116A0437|41 51|MS-MS data
P09435116A0437|59 97|trofluoroacetyl-biphenylol derivatives
P09435789A0961a|9 14|RAD17
P09435789A0961a|16 21|RAD24
P09435789A0961a|26 30|MEC3
P09435789A0961a|52 69|cell cycle arrest
P09435789A0961a|75 82|S phase
P09435789A0961a|99 110|hydroxyurea
P09435789A0961a|112 114|HU
P09435789A0961a|143 152|viability
P09435789A0961a|156 167|yeast cells
P09435789A0961a|181 189|presence
P09435789A0961a|193 195|HU
P09435789A0961a|240 246|repair
P09435789A0961a|261 271|DNA damage
P09435806T0001|9 14|value
P09435806T0001|22 32|estimation
P09435806T0001|36 51|growth kinetics
P09435806T0001|71 89|cancer recurrences
P09435806T0001|93 98|CA125
P09435806T0001|108 112|time
P09436657A0303|5 11|review
P09436657A0303|35 42|disease
P09436657A0303|55 63|pathways
P09436657A0303|67 81|carcinogenesis
P09436657A0303|97 101|ways
P09436657A0303|129 141|risk factors
P09436657A0303|168 173|basis
P09436657A0303|186 195|knowledge
P09436706A0168|4 11|patient
P09436706A0168|43 65|sperm injection cycles
P09436706A0168|89 100|spermatozoa
P09436706A0168|121 131|pharmacist
P09436706A0168|134 141|mistake
P09436706A0168|151 162|stimulation
P09436706A0168|184 195|combination
P09436706A0168|211 250|gonadotrophin-releasing hormone agonist
P09436706A0168|252 268|leuprolide depot
P09436706A0168|274 288|gonadotrophins
P09436795A0350|0 20|Protein C deficiency
P09436795A0350|24 44|protein S deficiency
P09436795A0350|69 80|risk factor
P09436795A0350|88 89|%
P09436795A0350|93 101|patients
P09436795A0350|111 112|%
P09436795A0350|116 124|patients
P09436795A0350|153 161|children
P09436989A1011|11 19|addition
P09436989A1011|30 34|part
P09436989A1011|53 61|function
P09436989A1011|70 77|mitosis
P09436989A1011|79 83|MOB1
P09436989A1011|102 127|cell cycle reset function
P09436989A1011|146 156|initiation
P09436989A1011|164 193|spindle pole body duplication
P09437001A0769|3 11|contrast
P09437001A0769|13 27|overproduction
P09437001A0769|31 36|Der3p
P09437001A0769|52 66|sec61-2 strain
P09437001A0769|85 96|temperature
P09437001A0769|103 113|degrees C.
P09438165A0405|7 15|baseline
P09438165A0405|17 22|day-8
P09438165A0405|24 33|PC levels
P09438165A0405|44 45|%
P09438165A0405|77 85|patients
P09438165A0405|93 97|time
P09438165A0405|101 118|VOD manifestation
P09438165A0405|122 125|day
P09438165A0405|160 161|%
P09438427A0727|15 19|role
P09438427A0727|28 39|CE2 element
P09438427A0727|54 70|Hoxa1 expression
P09438427A0727|91 95|mice
P09438427A0727|127 165|Hoxa1 beta-galactosidase reporter gene
P09438427A0727|182 190|mutation
P09438427A0727|198 209|CE2 element
P09438427T0000|26 33|element
P09438427T0000|51 57|somite
P09438427T0000|83 93|expression
P09438427T0000|101 111|Hoxa1 gene
P09440166A0857|0 7|RESULTS
P09440166A0857|20 40|cDNA insert sequence
P09440166A0857|49 60|nucleotides
P09440166A0857|64 70|length
P09440166A0857|86 90|mRNA
P09440166A0857|98 104|region
P09440166A0857|110 121|nucleotides
P09440166A0857|145 151|region
P09440166A0857|156 167|nucleotides
P09440166A0857|191 197|region
P09440166A0857|204 208|poly
P09440166A0857|209 210|A
P09440166A0857|212 216|tail
P09440616A0422|14 19|phase
P09440616A0422|24 34|activities
P09441664A0377|47 67|transcription factor
P09441664A0377|69 74|HNF-6
P09441664A0377|98 126|HNF-3 beta promoter activity
P09441664A0377|162 168|region
P09441664A0377|201 206|genes
P09441746A0546|2 12|cDNA clone
P09441746A0546|60 64|gene
P09441746A0546|66 71|GPR39
P09442017A0435|7 14|Science
P09442024A0236|0 2|P.
P09442024A0236|4 10|Peyron
P09442024A0236|12 14|J.
P09442024A0708|2 17|hybridoma clone
P09442024A0708|19 22|7H1
P09442024A0708|43 49|fusion
P09442024A0708|58 67|CEMLAI/NP
P09442024A0708|88 110|fibroblasts MRC5 cells
P09442024A0708|131 138|amounts
P09442024A0708|142 145|P47
P09442024A0708|170 184|Jacalin lectin
P09442024A0708|199 208|O-glycans
P09442031A0586|5 16|information
P09442031A0586|32 42|estimation
P09442031A0586|50 54|size
P09442031A0586|79 86|subunit
P09442031A0586|101 107|series
P09442031A0586|132 156|TSHR ectodomain variants
P09442031A0586|158 178|places cleavage Site
P09442031A0586|188 196|vicinity
P09442031A0586|225 232|residue
P09442072A0716|9 14|DNase
P09442072A0716|17 29|footprinting
P09442072A0716|53 59|region
P09442072A0716|67 75|promoter
P09442072A0716|90 94|Hepa
P09442072A0716|99 103|cell
P09442072A0716|112 119|extract
P09442072A0716|137 146|footprint
P09442072A0716|152 158|region
P09442072A0716|187 189|bp
P09442072A0716|204 213|fVII gene
P09442072A0716|231 244|liver factors
P09442072A0716|264 270|region
P09442072A0716|278 281|DNA
P09442080A0856|13 26|binding assay
P09442080A0856|33 43|IM-9 cells
P09442080A0856|49 55|source
P09442080A0856|59 64|SHP-1
P09442080A0856|69 74|SHP-2
P09442080A0856|93 104|association
P09442080A0856|108 113|SHP-2
P09442080A0856|123 128|SHP-1
P09442080A0856|137 169|glutathione S-transferase fusion
P09442080A0856|184 187|GHR
P09442080A0856|200 215|domain residues
P09442080A0856|241 247|fusion
P09442172A0908|22 25|FSH
P09442172A0908|30 33|age
P09442172A0908|85 103|gonadotrophin dose
P09442172A0908|117 123|number
P09442172A0908|127 134|oocytes
P09442172A0908|149 163|pregnancy rate
P09443948A0000|14 19|study
P09443948A0000|76 85|technique
P09443948A0000|87 90|EIT
P09443948A0000|110 119|diagnosis
P09443948A0000|129 143|trichinellosis
P09443948A0000|161 184|immunofluorescence test
P09443948A0000|186 189|IIF
P09443948A0000|202 206|sera
P09443948A0000|212 221|outbreaks
P09443948A0000|231 245|trichinellosis
P09443948A0000|249 258|Argentina
P09443972A1145|4 11|results
P09443972A1145|22 26|GKLF
P09443972A1145|50 70|transcription factor
P09443972A1145|90 100|regulation
P09443972A1145|104 114|expression
P09443972A1145|129 134|genes
P09443973A1028|0 4|CES4
P09443973A1028|20 27|plasmid
P09443973A1028|51 60|tif1-A79V
P09443978A0262|32 37|cells
P09443978A0262|73 76|Sp1
P09443978A0262|99 112|transcription
P09443978A0262|128 137|promoters
P09443978A0262|149 159|TATA boxes
P09443978A0262|174 183|promoters
P09443978A0262|200 209|initiator
P09443978A0262|223 231|TATA box
P09444316A0388|21 26|signs
P09444316A0388|50 58|toxicity
P09444316A0388|80 82|F0
P09444316A0388|87 97|F1 animals
P09444316A0388|108 111|sex
P09445056A0215|31 53|chemical cross-linking
P09445056A0215|59 62|bis
P09445056A0215|63 80|sulfosuccinimidyl
P09445056A0215|81 89|suberate
P09445056A0215|91 94|BS3
P09445056A0215|115 127|architecture
P09445056A0215|135 148|gp41 oligomer
P09445488A0230|6 12|effort
P09445488A0230|29 47|USH1C disease gene
P09445488A0230|69 75|region
P09445488A0230|90 97|markers
P09445488A0230|101 106|yeast
P09445488A0230|118 129|chromosomes
P09445488A0230|131 135|YACs
P09445488A0230|145 156|combination
P09445488A0230|160 179|STS content mapping
P09445488A0230|184 205|Alu-PCR hybridization
P09445488A1169|0 19|PowerBLAST analysis
P09445488A1169|35 43|clusters
P09445488A1169|57 70|sequence tags
P09445488A1169|72 76|ESTs
P09445488A1169|89 94|genes
P09445488A1169|96 99|BIR
P09445488A1169|101 105|SUR1
P09445488A1169|133 139|region
P09445488A1169|185 194|gene NEFA
P09445488A1169|196 210|DNA binding/EF
P09446600A0260|2 16|fusion protein
P09446600A0260|29 47|beta-galactosidase
P09446600A0260|64 67|Ahr
P09446600A0260|90 99|cytoplasm
P09446600A0260|107 114|nucleus
P09446600A0260|137 143|manner
P09446616A0780|0 14|Reconstitution
P09446616A0780|18 32|Raf-1 activity
P09446616A0780|56 62|kinase
P09446616A0780|70 74|Jak1
P09446616A0780|83 93|cell lines
P09446815A1021|3 11|addition
P09446815A1021|35 41|region
P09446815A1021|72 74|bp
P09447917A0000|4 14|hypothesis
P09447917A0000|18 25|Geisler
P09447917A0000|27 36|Brain Res
P09447962A0452|11 21|transcript
P09447962A0452|23 29|rhis4l
P09447962A1027|21 35|interpretation
P09447962A1027|46 50|form
P09447962A1027|54 58|XRN1
P09447962A1027|82 93|exonuclease
P09447962A1027|127 137|suppressor
P09447962A1027|157 166|half-life
P09447962A1027|170 180|rhis4 mRNA
P09447962A1027|203 211|increase
P09447962A1027|228 239|mRNA levels
P09447962A1027|266 281|HIS4 mRNA level
P09447963A0223|0 4|Sip1
P09447963A0223|33 39|virtue
P09447963A0223|47 58|interaction
P09447963A0223|64 68|SC35
P09447963A0223|72 87|splicing factor
P09447963A0223|98 104|family
P09447973A0168|25 32|reports
P09447973A0168|34 42|addition
P09447973A0168|48 69|myristoylation signal
P09447973A0168|73 78|mSos1
P09447973A0168|80 87|MyrSos1
P09447973A0168|118 131|NIH 3T3 cells
P09447973A0168|136 144|deletion
P09447973A0168|152 167|mSos C terminus
P09447973A0168|169 183|MyrSos1-deltaC
P09447973A0168|213 221|activity
P09447979A1430|5 14|mutations
P09447979A1430|51 60|phenotype
P09447979A1430|64 77|sequestration
P09447979A1430|85 119|guanine nucleotide exchange factor
P09447979A1430|121 125|GNEF
P09447994A0000|8 15|studies
P09447994A0000|59 65|region
P09447994A0000|69 74|c-fos
P09447994A0000|102 110|elements
P09447994A0000|129 132|AMP
P09447994A0000|134 138|cAMP
P09447994A0000|140 157|response elements
P09447994A0000|159 163|CREs
P09447994A0000|187 206|c-fos transcription
P09447994A0000|210 218|response
P09447994A0000|224 231|variety
P09447994A0000|249 256|stimuli
P09448268A0186|17 23|kinase
P09448268A0186|25 28|Nlk
P09448268A0186|47 54|homolog
P09448268A0186|79 82|nmo
P09448268A0186|84 88|gene
P09448574A0964|4 12|findings
P09448574A0964|35 38|FDG
P09448574A0964|56 61|RACLO
P09448574A0964|90 98|measures
P09448574A0964|111 119|function
P09448574A0964|148 156|patients
P09448574A0964|171 185|system atrophy
P09449018T0000|0 21|Childhood misbehavior
P09449018T0000|30 34|risk
P09449018T0000|48 56|drug use
P09450932A0142|8 16|analysis
P09450932A0142|45 56|subpathways
P09450932A0142|64 89|DNA structure checkpoints
P09450932A0142|116 122|arrest
P09450932A0142|126 139|DNA synthesis
P09451003A0894|6 24|Esigma54 promoters
P09451003A0894|43 46|CRP
P09451003A0894|50 57|protein
P09451003A0894|71 89|sigma54 activators
P09451003A0894|99 109|repression
P09451003A0894|132 138|result
P09451003A0894|145 156|interaction
P09451003A0894|165 173|Esigma54
P09451003A0894|182 198|CRP-cAMP complex
P09451016A1037|0 6|GlcNAc
P09451016A1037|12 44|GlcNAc2-PP-Dolichol biosynthesis
P09451016A1037|87 96|membranes
P09451016A1037|102 107|cells
P09451016A1037|134 141|plasmid
P09451016A1037|155 162|glucose
P09451016A1037|180 193|transcription
P09451016A1037|212 216|gene
P09451857T0001|0 13|Demonstration
P09451857T0001|17 31|tissue lesions
P09451857T0001|52 61|injection
P09451857T0001|65 78|determination
P09451857T0001|82 97|creatine kinase
P09451857T0001|101 106|blood
P09452421A1042|0 10|Antibodies
P09452421A1042|26 36|GST mSH2-B
P09452421A1042|59 66|protein
P09452421A1042|73 76|kDa
P09452421A1042|120 123|Tyr
P09452444A0000|0 13|Interleukin-6
P09452444A0000|15 19|IL-6
P09452444A0000|38 46|cytokine
P09452444A0000|93 102|responses
P09452444A0000|110 125|phase reactions
P09452444A0000|131 144|hematopoiesis
P09452444A0450|5 13|analysis
P09452444A0450|25 33|deletion
P09452444A0450|52 60|variants
P09452444A0450|74 92|IL-6 gene promoter
P09452444A0450|106 119|reporter gene
P09452444A0450|158 179|transcription factors
P09453537A0863|5 11|region
P09453537A0863|33 43|CCAATC box
P09453537A0863|59 69|complement
P09453537A0863|82 90|GC boxes
P09453537A0863|100 117|recognition sites
P09453537A0863|122 125|SP1
P09453689A0000|4 11|purpose
P09453689A0000|49 53|S4-5
P09453689A0000|55 68|pin sensation
P09453689A0000|70 73|PPS
P09453689A0000|79 94|bulbocavernosus
P09453689A0000|96 100|S2-4
P09453689A0000|110 113|BCR
P09453689A0000|136 147|cord injury
P09453689A0000|149 152|SCI
P09453689A0000|172 197|bladder function recovery
P09454719A0181|12 23|termination
P09454719A0181|38 49|transcripts
P09454719A0181|60 77|LTR R/U5 junction
P09454719A0181|118 147|AAUAAA polyadenylation signal
P09454719A0181|173 179|effect
P09454719A0181|196 228|polyadenylation signal sequences
P09454719A0181|236 246|properties
P09454719A0181|281 287|vector
P09454735A1782|0 6|Levels
P09454735A1782|14 35|MEK inhibitor PD98059
P09454735A1782|59 70|mitogenesis
P09454735A1782|75 101|MAP kinase phosphorylation
P09454735A1782|134 154|adhesion disassembly
P09454735A1782|159 172|cell motility
P09455695A0762|0 10|ALT levels
P09455695A0762|14 24|responders
P09455695A0762|43 44|%
P09455695A0762|49 59|AST levels
P09455695A0762|78 79|%
P09455695A0762|89 94|weeks
P09455695A0762|98 117|vitamin E treatment
P09456312A1064|32 38|domain
P09456312A1064|42 49|RanGAP1
P09456312A1064|85 104|localization signal
P09458021A1373|4 5|%
P09458021A1373|7 8|P
P09458021A1373|24 27|MMF
P09458021A1373|39 49|AZA groups
P09458030A0192|4 9|study
P09458030A0192|42 48|effect
P09458030A0192|52 55|MMF
P09458030A0192|67 90|bone mineral metabolism
P09459241A0707|0 4|Pao2
P09459241A0707|33 36|kPa
P09459241A0707|49 54|mm Hg
P09459241A0707|72 75|kPa
P09459241A0707|88 93|mm Hg
P09459241A0707|96 97|P
P09459685T0001|8 22|configurations
P09459685T0001|39 53|stress factors
P09459685T0001|85 93|children
P09459685T0001|98 109|adolescents
P09459835A0297|5 9|cats
P09459835A0297|19 23|PMEA
P09459835A0297|29 35|dosage
P09459835A0297|42 59|mg/kg body weight
P09459835A0297|66 70|cats
P09459835A0297|80 85|FPMPA
P09459835A0297|91 97|dosage
P09459835A0297|104 121|mg/kg body weight
P09460171T0000|0 10|Resistance
P09460171T0000|14 29|thyroid hormone
P09460171T0000|31 43|implications
P09460171T0000|67 75|research
P09460171T0000|83 90|effects
P09460171T0000|94 120|thyroid hormone disruptors
P09461594A0000|17 25|evidence
P09461594A0000|31 39|exposure
P09461594A0000|43 64|DT40 lymphoma B cells
P09461594A0000|72 78|energy
P09461594A0000|95 100|field
P09461594A0000|102 105|EMF
P09461594A0000|120 128|tyrosine
P09461594A0000|146 156|activation
P09461594A0000|160 181|phospholipase Cgamma2
P09461594A0000|183 193|PLC-gamma2
P09461594A0000|216 246|inositol phospholipid turnover
P09463174A0670|27 34|results
P09463174A0670|50 58|patients
P09463174A0670|90 96|period
P09463174A0670|103 109|months
P09463380A1050|10 17|xTAK1KN
P09463380A1050|34 44|expression
P09463380A1050|56 77|mesoderm marker genes
P09463380A1050|89 94|Smad1
P09463560A0124|0 8|PATIENTS
P09463560A0124|13 19|METHOD
P09463560A0124|36 44|patients
P09463964A0243|4 9|assay
P09463964A0243|29 34|range
P09463964A0243|46 60|micrograms l-1
P09463964A0243|80 88|antibody
P09463964A0243|109 123|micrograms l-1
P09463964A0243|130 136|mg l-1
P09463964A0243|166 175|antiserum
P09463991T0000|13 18|audit
P09464248A0289|12 20|TATA box
P09464525T0000|0 10|Expression
P09464525T0000|15 31|characterization
P09464525T0000|60 62|Fv
P09464525T0000|67 79|Fv fragments
P09464525T0000|95 98|set
P09464525T0000|112 122|antibodies
P09465035A1032|11 20|inhibitor
P09465035A1032|21 22|s
P09465035A1032|60 68|fraction
P09465035A1032|86 87|L
P09465035A1032|88 93|alpha
P09465035A1032|95 103|activity
P09465783A0449|0 20|Platelet aggregation
P09465783A0449|24 32|response
P09465783A0449|39 61|micrograms collagen/ml
P09465783A0449|79 87|parallel
P09465783A0449|94 103|treatment
P09465783A0449|109 112|ASA
P09466267A1192|6 18|himA mutants
P09466267A1192|38 41|IHF
P09466267A1192|50 54|role
P09466267A1192|82 92|regulation
P09466267A1192|96 116|dmsA-lacZ expression
P09466931T0000|0 13|Cross-talking
P09466931T0000|39 48|receptors
P09466931T0000|68 84|response element
P09466931T0000|92 96|ng-1
P09466931T0000|101 121|ng-2 intermolt genes
P09467044A0973|16 41|breast tumor relapse rate
P09467044A0973|66 70|PALP
P09467044A0973|75 87|MGDET groups
P09467707T0000|0 19|Sibling aggregation
P09467707T0000|45 68|lipoprotein cholesterol
P09467707T0000|73 90|apolipoproteins B
P09467707T0000|95 105|A-I levels
P09467707T0000|125 133|children
P09467707T0000|139 159|Bogalusa Heart Study
P09467900A0701|4 18|CAPLC1 protein
P09467900A0701|49 57|features
P09467900A0701|77 84|stretch
P09467900A0701|94 113|amino acid residues
P09467900A0701|125 133|X domain
P09467900A0701|156 166|N-terminus
P09467900A0701|204 214|EF-hand Ca
P09467900A0701|219 233|binding domain
P09467955A0468|5 15|hypothesis
P09467955A0468|39 49|occurrence
P09467955A0468|53 71|PEA3 binding sites
P09467955A0468|79 92|PEA3 promoter
P09467955A0468|106 113|ability
P09467955A0468|117 121|PEA3
P09467955A0468|144 152|promoter
P09468386A0594|0 5|Pet-1
P09468386A0594|33 41|PEA3 ETS
P09468386A0594|54 59|motif
P09468386A0594|77 90|transcription
P09468386A0594|104 123|promoter constructs
P09468386A0594|147 153|manner
P09468509A0463|4 11|protein
P09468509A0463|25 35|F2771 cDNA
P09468509A0463|51 60|COS cells
P09468509A0463|81 90|cytoplasm
P09468514A1065|0 17|Northern analysis
P09468514A1065|41 51|expression
P09468514A1065|55 61|tissue
P09468514A1065|75 85|expression
P09468514A1065|93 98|heart
P09468515A0621|17 25|deletion
P09468515A0621|33 48|promoter region
P09468515A0621|52 62|nucleotide
P09468515A0621|93 110|SF-1 binding site
P09468515A0621|131 138|ability
P09468515A0621|163 167|SF-1
P09469415A1337|4 15|observation
P09469415A1337|21 28|beta 2m
P09469415A1337|54 61|peptide
P09469415A1337|85 106|CTL target structures
P09469415A1337|127 140|possibilities
P09469415A1337|157 166|induction
P09469415A1337|187 200|CTL responses
P09469415A1337|211 227|DNA immunization
P09469415A1337|231 240|injection
P09469415A1337|272 279|beta 2m
P09469820A0151|4 9|mRNAs
P09469820A0151|19 24|genes
P09469820A0151|51 60|YAP1 uORF
P09469820A0151|71 81|YAP2 uORF1
P09469820A0151|86 91|uORF2
P09469820A0151|107 121|reading frames
P09469820A0151|137 147|modulation
P09469820A0151|168 174|events
P09469820A0151|198 204|region
P09469820A0151|209 212|UTR
P09469820A0151|235 242|control
P09469820A0151|255 266|translation
P09469820A0151|279 289|mRNA decay
P09469833A0533|27 33|nature
P09469833A0533|41 57|site specificity
P09469833A0533|60 63|set
P09469833A0533|67 83|deletion mutants
P09469833A0533|95 106|bp sequence
P09469933A1060|7 14|tissues
P09469933A1060|30 35|brain
P09469933A1060|41 48|message
P09469933A1060|53 61|CLIP-170
P09469933A1060|94 100|Restin
P09471984A0000|0 10|BACKGROUND
P09471984A0000|12 21|Chemicals
P09471984A0000|59 66|ability
P09471984A0000|85 103|contact dermatitis
P09472038T0000|13 25|polarization
P09472038T0000|29 36|T cells
P09472038T0000|56 70|immunoreceptor
P09472038T0000|86 96|activation
P09472038T0000|113 122|mechanism
P09472608A0253|26 33|ability
P09472608A0253|50 62|protein YB-1
P09472608A0253|75 88|transcription
P09472608A0253|96 110|HIV-1 promoter
P09472608A0253|133 142|cell line
P09472608A0253|144 150|U-87MG
P09472608A0253|164 173|cell line
P09472608A0253|175 182|SK-N-MC
P09472608A0253|197 202|cells
P09472608A0253|204 210|Jurkat
P09472608A0253|215 233|transfection assay
P09472616A1004|18 29|amino acids
P09472616A1004|47 54|regions
P09472616A1004|58 59|B
P09472616A1004|64 65|C
P09472616A1004|69 72|VP7
P09472616A1004|119 127|lineages
P09473040A1303a|11 20|alcR gene
P09473040A1303a|54 83|siderophore system activities
P09473040A1303a|91 98|mutants
P09473040A1303b|11 20|alcR gene
P09473040A1303b|54 83|siderophore system activities
P09473040A1303b|91 98|mutants
P09473317X2131|0 9|Copyright
P09473317X2131|15 29|Academic Press
P09473483A0953|41 45|care
P09473483A0953|89 99|Rev mutant
P09473483A0953|138 145|therapy
P09473483A0953|154 169|HIV-I infection
P09473483A0953|174 185|individuals
P09473483A0953|205 210|HIV-I
P09473483A0953|215 221|HTLV-1
P09473755A0318|0 8|PATIENTS
P09473755A0318|13 20|METHODS
P09473755A0318|30 37|January
P09473755A0318|47 51|June
P09473755A0318|60 63|St.
P09474001A0825|4 13|frequency
P09474001A0825|17 20|SPs
P09474001A0825|54 60|groups
P09474001A0825|99 107|patients
P09474001A0825|122 127|MMFCV
P09474001A0825|129 130|p
P09474001A0825|146 150|arms
P09474001A0825|165 170|MMFCV
P09474001A0825|181 182|%
P09474001A0825|191 193|SP
P09474648A0298|16 23|P-SAECG
P09474648A0298|31 35|time
P09474648A0298|40 56|frequency domain
P09474648A0298|63 71|patients
P09474648A0298|77 80|Paf
P09474648A0298|88 96|controls
P09475378A1449|20 59|transcription-polymerase chain reaction
P09475378A1449|64 77|HPLC analysis
P09475378A1449|90 101|RUSH-1alpha
P09475378A1449|132 146|splice variant
P09475724T0000|0 4|TOR2
P09475724T0000|8 12|part
P09475724T0000|28 46|signaling pathways
P09475724T0000|60 71|cell growth
P09475898T0000|14 27|amnioinfusion
P09476399A0141|11 19|division
P09476399A0141|31 45|tea plantation
P09476399A0141|49 54|Kandy
P09476520A1326|7 13|models
P09476520A1326|29 40|interaction
P09476520A1326|79 87|profiles
P09476520A1326|115 125|antibodies
P09476520A1326|134 141|hybrids
P09476520A1326|152 162|complexity
P09476520A1326|177 186|existence
P09476520A1326|207 220|heterogeneity
P09476520A1326|230 239|molecules
P09477316A0140|3 8|order
P09477316A0140|25 32|pathway
P09477316A0140|47 65|Hox gene induction
P09477316A0140|98 116|Hox gene regulator
P09477316A0140|122 165|leucine zipper transcription factor MafB/Kr
P09477316A0140|226 233|signals
P09478921A0126|0 10|Substrates
P09478921A0126|15 19|p210
P09478921A0126|20 27|bcr-abl
P09478921A0126|62 74|pathogenesis
P09478921A0126|78 81|CML
P09478971A1896|0 19|Reporter constructs
P09478971A1896|43 49|manner
P09478971A1896|73 77|role
P09478971A1896|85 88|AhR
P09478971A1896|129 139|expression
P09478971A1896|143 149|Cyp1B1
P09478971A1896|153 177|mouse embryo fibroblasts
P09478976A0718|0 20|Transfection studies
P09478976A0718|41 49|deletion
P09478976A0718|53 62|sequences
P09478976A0718|97 107|start site
P09478976A0718|134 137|OSM
P09478976A0718|144 153|induction
P09478976T0000|0 12|Oncostatin M
P09478976T0000|24 29|c-Fos
P09478976T0000|69 81|AP-1 element
P09478976T0000|93 109|tissue inhibitor
P09478976T0000|113 141|metalloproteinase-1 promoter
P09479498A0000|29 45|RING-finger gene
P09479498A0000|47 51|RNF4
P09479498A0000|83 90|protein
P09480831A0272|28 37|mechanism
P09480831A0272|50 65|gene expression
P09480831A0272|78 86|elements
P09480831A0272|102 108|region
P09480831A0272|112 119|AM gene
P09480831A0272|161 166|cells
P09480831A0272|168 172|HAEC
P09480843A0848|18 24|region
P09480843A0848|32 43|transcripts
P09480843A0848|62 77|triplet repeats
P09480843A0848|79 82|GCT
P09480843A0848|84 91|alanine
P09480843A0848|96 106|nucleotide
P09480843A0848|167 175|rat RL14
P09480929T0000|8 12|FasR
P09480929T0000|28 34|domain
P09480929T0000|47 57|production
P09480929T0000|68 74|fusion
P09480929T0000|102 110|proteins
P09480929T0000|121 151|baculovirus/insect cell system
P09481826T0000|0 7|Control
P09481826T0000|17 31|liver syndrome
P09481826T0000|37 48|Jersey herd
P09481826T0000|54 60|change
P09481826T0000|64 68|diet
P09481826T0000|77 80|use
P09481826T0000|103 116|somatotrophin
P09482107A0551|4 14|inhibition
P09482107A0551|18 33|focus formation
P09482107A0551|50 58|presence
P09482107A0551|62 65|C3G
P09482107A0551|87 94|effects
P09482107A0551|98 112|cell viability
P09482107A0551|132 141|C3G cells
P09482107A0551|161 169|survival
P09482107A0551|174 186|growth rates
P09482107A0551|204 216|NIH3T3 cells
P09482107A0551|220 225|cells
P09482107A0551|243 257|plasmid vector
P09482902A0423|0 8|C.D2-Chr
P09482902A0423|20 27|strains
P09482902A0423|38 51|DBA/2 alleles
P09482902A0423|72 83|Pctr1 locus
P09482902A0423|94 99|DBA/2
P09482902A0423|112 119|alleles
P09482902A0423|127 151|CDK4/CDK6 inhibitors p16
P09482902A0423|156 159|p15
P09482902A0942|28 33|DBA/2
P09482902A0942|35 38|p16
P09482902A0942|45 50|A134C
P09482902A0942|55 60|G232A
P09482902A0942|77 85|variants
P09482902A0942|89 92|p16
P09482902A0942|119 126|ability
P09482902A0942|142 150|activity
P09482902A0942|154 168|cyclin D2/CDK4
P09482902A0942|172 185|kinase assays
P09482902A0942|191 213|retinoblastoma protein
P09482902A0942|252 258|allele
P09482902A0942|278 282|role
P09482902A0942|298 312|susceptibility
P09482902A0942|316 327|BALB/c mice
P09482902A0942|332 354|plasmacytoma induction
P09482902A0942|364 367|p16
P09482902A0942|368 373|INK4a
P09482902A0942|387 396|candidate
P09482902A0942|405 416|Pctr1 locus
P09483596A0626|26 36|difference
P09483596A0626|55 65|conditions
P09483596A0626|73 79|minute
P09483596A0626|88 99|excellent/5
P09483596A0626|112 131|suxamethonium group
P09483596A0626|139 150|excellent/3
P09483596A0626|163 179|rocuronium group
P09484463T0000|0 7|Cloning
P09484463T0000|12 22|expression
P09484463T0000|30 35|genes
P09484463T0000|59 67|proteins
P09484463T0000|73 80|tobacco
P09484781A1233|20 31|association
P09484781A1233|37 62|D3 phosphatidylinositides
P09484781A1233|89 99|activation
P09484781A1233|103 110|PKB/Akt
P09485308A1165|4 14|FMN moiety
P09485308A1165|28 34|3Fe-4S
P09485308A1165|36 43|cluster
P09485308A1165|51 58|subunit
P09485308A1165|90 98|reaction
P09485790T0000|0 26|Alison Bell Memorial Award
P09486035A0051|0 7|METHODS
P09486035A0051|11 28|population survey
P09486035A0051|54 65|individuals
P09486035A0051|81 91|prevalence
P09486035A0051|109 115|causes
P09486035A0051|119 128|blindness
P09486035A0051|132 139|Lebanon
P09486531A0638|7 20|organogenesis
P09486531A0638|22 38|HFH-8 expression
P09486531A0638|66 74|mesoderm
P09486531A0638|84 94|apposition
P09486531A0638|102 114|gut endoderm
P09486531A0638|129 133|role
P09486531A0638|160 169|induction
P09486531A0638|173 177|lung
P09486531A0638|182 199|gut morphogenesis
P09486890A0234|9 20|laparoscopy
P09486890A0234|41 54|inoperability
P09486890A0234|62 67|cases
P09486890A0234|71 87|carcinoma spread
P09486890A0234|91 96|areas
P09486890A0234|128 141|visualization
P09487130A0383|3 13|difference
P09487130A0383|17 32|telomere length
P09487130A0383|45 52|mutants
P09487130A0383|69 79|regulation
P09487130A0383|83 87|Cdc2
P09487130A0383|109 127|DNA repair mutants
P09487130A0383|157 166|telomeres
P09487130A0383|185 189|type
P09487590A0657|4 17|mean duration
P09487590A0657|21 32|pain relief
P09487590A0657|41 46|weeks
P09487841A0132|4 8|ESEM
P09487841A0132|35 38|SEM
P09487841A0132|50 68|sample preparation
P09487841A0132|104 111|changes
P09488441A0615|0 3|Sp1
P09488441A0615|17 30|transcription
P09488441A0615|39 53|immunoglobulin
P09488441A0615|66 74|enhancer
P09488441A0615|78 113|P-selectin promoter NF-kappaB sites
P09488441A0615|115 129|p50 homodimers
P09488441A0615|138 141|Sp1
P09488441A0615|151 170|P-selectin promoter
P09488441A0615|182 198|site competition
P09488441A0615|243 253|expression
P09488441A0615|261 268|concert
P09488441A0615|274 279|Bcl-3
P09488441A0615|291 301|expression
P09488466A0695|7 15|fragment
P09488466A0695|55 59|mRNA
P09488466A0695|75 86|actinomycin
P09488466A0695|97 102|cells
P09488466A0695|117 147|precursor-product relationship
P09488486A0000|4 8|TATA
P09488486A0000|21 28|protein
P09488486A0000|30 33|TBP
P09488486A0000|54 58|role
P09488486A0000|62 75|transcription
P09488486A0000|108 123|RNA polymerases
P09488486A0000|125 136|polymerases
P09488486A0000|138 141|Pol
P09488486A0000|154 157|III
P09488486A0906|16 19|TBP
P09488486A0906|21 26|R231E
P09488486A0906|29 34|R235E
P09488486A0906|37 42|R239S
P09488486A0906|64 72|activity
P09488486A0906|77 110|yeast U6 snRNA gene transcription
P09488486A0906|138 141|Pol
P09488486A0906|151 164|transcription
P09488491A0000|0 12|E2F activity
P09488491A0000|29 33|part
P09488491A0000|41 62|retinoblastoma family
P09488491A0000|66 91|tumor suppressor proteins
P09488713A0886|28 38|inhibition
P09488713A0886|42 57|Site-1 cleavage
P09488713A0886|91 105|overexpression
P09488713A0886|121 125|SCAP
P09488725A0904|32 40|identity
P09488725A0904|44 47|SFD
P09488725A0904|73 85|polypeptides
P09488725T0000|10 26|characterization
P09488725T0000|49 57|subunits
P09488725T0000|81 92|proton pump
P09489670A1157|3 14|C. albicans
P09489670A1157|16 20|HST6
P09489670A1157|57 63|levels
P09489670A1157|81 91|cell types
P09489670A1157|102 107|yeast
P09489670A1157|109 115|hyphae
P09489670A1157|155 173|HST6 transcription
P09489670A1157|207 212|yeast
P09489670A1157|281 289|function
P09489670A1157|298 315|Hst6p transporter
P09489670A1157|319 330|C. albicans
P09490676A0800|13 20|binding
P09490676A0800|36 39|Myb
P09490676A0800|44 57|Ets-2 protein
P09490676A0800|67 76|fragments
P09490676A0800|103 109|excess
P09490676A0800|129 150|oligodeoxynucleotides
P09490676A0800|190 193|Myb
P09490676A0800|210 215|sites
P09490727A1041|5 28|structure interconnects
P09490727A1041|38 46|triplets
P09490727A1041|60 66|bodies
P09490727A1041|89 96|bundles
P09490727A1041|124 133|apparatus
P09491074A0104|29 38|mechanism
P09491074A0104|55 65|expression
P09491074A0104|73 84|temperature
P09491074A0104|90 105|promoter region
P09492038A0352|15 20|study
P09492038A0352|26 31|roles
P09492038A0352|59 67|elements
P09492038A0352|90 96|region
P09492038A0352|106 110|exon
P09492038A0352|113 130|promoter activity
P09492038A0352|152 163|mutagenesis
P09492038A0352|188 202|binding assays
P09494078A1362|8 22|5HT5A receptor
P09494078A1362|27 35|addition
P09494078A1362|39 48|yohimbine
P09494078A1362|83 89|effect
P09495283A0000|17 30|reporter gene
P09495283A0000|32 40|beta-gal
P09495283A0000|42 52|expression
P09495283A0000|71 103|heat shock transcription factors
P09495283A0000|113 117|HSF1
P09495283A0000|122 126|HSF2
P09495283A0000|131 141|HeLa cells
P09495283A0000|149 154|yeast
P09495771A0379|10 22|fluorescence
P09495771A0379|46 51|cells
P09495771A0379|73 93|midcell constriction
P09495771A0379|111 115|FtsK
P09495771A0379|157 162|stage
P09495771A0379|166 175|septation
P09498553A0702|3 11|TATA box
P09498553A0702|38 53|promoter region
P09498553A0702|68 76|GC boxes
P09498553A0702|99 108|cap sites
P09498553A0702|158 164|nature
P09498553A0702|168 178|CYP51 gene
P09498553A0702|187 196|existence
P09498553A0702|213 243|transcription initiation sites
P09498553T0000|28 35|studies
P09498553T0000|39 45|sterol
P09498553T0000|61 65|P450
P09498553T0000|67 72|CYP51
P09498553T0000|94 112|P450 monooxygenase
P09498553T0000|114 116|I.
P09498769A0095|4 22|expression pattern
P09498769A0095|26 40|representative
P09498769A0095|49 50|B
P09498769A0095|65 73|proteins
P09498769A0095|99 117|B cell development
P09498769A0095|122 132|activation
P09498769A0095|162 169|B cells
P09498769A0095|203 215|plasma cells
P09499031A0000|19 33|gene junctions
P09499031A0000|47 63|stomatitis virus
P09499031A0000|65 68|VSV
P09499031A0000|88 105|sequence elements
P09499031A0000|129 144|polyadenylation
P09499031A0000|149 174|transcription termination
P09499031A0000|187 197|transcript
P09499031A0000|209 221|reinitiation
P09499031A0000|225 238|transcription
P09499031A0000|253 263|transcript
P09499048A1003|18 31|virus progeny
P09499048A1003|81 86|cells
P09499048A1003|104 106|gK
P09499048A1003|124 132|function
P09499048A1003|140 157|replication cycle
P09499061A0000|0 8|Cleavage
P09499061A0000|13 16|DNA
P09499061A0000|25 34|reactions
P09499061A0000|57 84|immunodeficiency virus type
P09499061A0000|88 93|HIV-1
P09499061A0000|95 104|integrase
P09499061A0000|143 152|insertion
P09499061A0000|156 165|HIV-1 DNA
P09499061A0000|175 186|host genome
P09499254A1309|4 15|DSF regimen
P09499254A1309|44 52|activity
P09499254A1309|56 64|patients
P09499254A1309|96 116|islet-cell carcinoma
P09499254A1309|122 139|patient tolerance
P09499254A1309|147 154|regimen
P09499254A1309|193 206|investigation
P09501093A0071|0 10|Activation
P09501093A0071|18 25|mitogen
P09501093A0071|36 43|protein
P09501093A0071|45 48|MAP
P09501093A0071|50 56|kinase
P09501093A0071|70 81|consequence
P09501093A0071|85 99|Ras activation
P09501093A0071|116 120|role
P09501093A0071|134 157|Ras signal transduction
P09501169A0000|0 26|Histone acetylation levels
P09501169A0000|30 35|cells
P09501169A0000|58 69|equilibrium
P09501169A0000|88 106|histone acetylases
P09501169A0000|111 123|deacetylases
P09501982A1178|0 11|CONCLUSIONS
P09501982A1178|13 18|XCoe2
P09501982A1178|38 42|role
P09501982A1178|66 73|cascade
P09501982A1178|97 104|neurons
P09501982A1178|108 123|Xenopus embryos
P09501982A1178|140 162|Delta-Notch signalling
P09501982A1178|164 169|XCoe2
P09501982A1178|199 208|potential
P09501982A1178|221 237|progenitor cells
P09501982A1178|251 259|X-ngnr-1
P09501982A1178|274 284|transition
P09501982A1178|300 310|competence
P09501982A1178|328 338|commitment
P09501982A1178|351 355|fate
P09501982A1178|382 397|differentiation
P09501982A1178|412 430|XNeuroD expression
P09502627A0705|0 7|RESULTS
P09502627A0705|9 17|Patients
P09502627A0705|21 28|Group A
P09502627A0705|42 51|incidence
P09502627A0705|70 95|wall motion abnormalities
P09502627A0705|97 98|p
P09502627A0705|124 140|ventriculography
P09502627A0705|151 163|infarct area
P09502627A0705|188 215|peak creatine kinase levels
P09502627A0705|218 219|p
P09502627A0705|257 274|ejection fraction
P09502627A0705|276 280|LVEF
P09502627A0705|285 303|hospital discharge
P09502627A0705|305 306|p
P09502627A0705|330 338|Group B.
P09502720A0214|0 19|CyIIa transcription
P09502720A0214|73 86|specification
P09502720A0214|106 113|domains
P09502720T0000|29 52|cell type specification
P09502720T0000|71 78|element
P09502720T0000|92 110|complex expression
P09502720T0000|118 128|CyIIa gene
P09502720T0000|132 150|sea urchin embryos
P09503017A1021|16 24|evidence
P09503017A1021|36 41|HYAL1
P09503017A1021|77 81|gene
P09503017A1021|105 111|others
P09503017A1021|117 134|chromosome 3p21.3
P09503017A1021|186 211|lung carcinoma cell lines
P09503526A0614|3 11|patients
P09503526A0614|17 24|myalgia
P09503526A0614|26 33|Raynaud
P09503526A0614|36 44|syndrome
P09503526A0614|46 61|skin vasculitis
P09503526A0614|75 103|diseases WFAg concentrations
P09503526A0614|124 132|patients
P09504423A0114|13 23|expression
P09504423A0114|31 42|4E-BP1 gene
P09504423A0114|84 88|gene
P09504423A0114|124 128|BL21
P09504423A0114|129 132|DE3
P09504423A0114|140 151|fusion gene
P09504423A0114|161 186|glutathione-S-transferase
P09504423A0114|188 191|GST
P09504423A0114|193 197|gene
P09504423A0114|218 236|gene fusion vector
P09504423A0114|238 247|pGEX-4T-2
P09504423A0114|267 280|gene sequence
P09504423A0114|292 305|cleavage site
P09504423A0114|321 329|protease
P09504423A0114|331 345|alpha-thrombin
P09504514T0000|11 21|comparison
P09504514T0000|25 33|addition
P09504514T0000|48 75|bone-marrow transplantation
P09504514T0000|89 101|chemotherapy
P09504514T0000|120 129|leukaemia
P09504514T0000|139 148|remission
P09504514T0000|150 157|results
P09504514T0000|161 168|MRC AML
P09504514T0000|172 177|trial
P09504553T0000|12 15|use
P09504553T0000|19 27|cannabis
P09504906A0099|0 8|Analysis
P09504906A0099|23 33|revertants
P09504906A0099|50 58|function
P09504906A0099|74 84|amino acid
P09504906A0099|105 121|cysteine residue
P09504906A0099|141 147|domain
P09504906A0099|151 156|Hap1p
P09505135A0182|18 25|stimuli
P09505135A0182|49 56|stimuli
P09505135A0182|70 77|targets
P09505733A0246|2 8|review
P09505733A0246|12 19|studies
P09505733A0246|52 57|shows
P09505733A0246|85 92|factors
P09505733A0246|122 130|distress
P09505733A0246|157 168|limitations
P09505733A0246|174 179|group
P09505733A0246|183 191|patients
P09506439A2179|0 9|PKC-gamma
P09506439A2179|35 48|keratinocytes
P09506439A2179|74 89|gene expression
P09506439A2179|111 117|manner
P09506439A2179|140 150|SVHK cells
P09506959T0000|0 14|Identification
P09506959T0000|19 35|characterization
P09506959T0000|60 69|complexes
P09506959T0000|81 88|members
P09506959T0000|96 115|Myc/Max/Mad network
P09506959T0000|135 145|regulators
P09506962A1000|33 42|targeting
P09506962A1000|46 53|calpain
P09506962A1000|65 75|proteasome
P09506962A1000|106 114|elements
P09506962A1000|118 121|YY1
P09506983A0304|0 7|Primers
P09506983A0304|23 29|rounds
P09506983A0304|33 37|RACE
P09506983A0304|64 68|ends
P09506983A0304|82 95|RACE products
P09506990T0000|6 18|ZFM1 protein
P09506990T0000|40 49|repressor
P09506990T0000|74 105|transcription activation domain
P09506990T0000|124 141|activator protein
P09507032A1144|18 34|CSF1R/IRDelta960
P09507032A1144|59 67|CSF1R/IR
P09507032A1144|81 97|CSF-1 protection
P09507032A1144|101 106|cells
P09507032A1144|134 143|apoptosis
P09508119A0498|0 11|CONCLUSIONS
P09508119A0498|34 46|presentation
P09508119A0498|54 58|case
P09508119A0498|71 78|Gardner
P09508119A0498|81 89|syndrome
P09508377A0863|6 13|results
P09508377A0863|40 54|UV sensitivity
P09508377A0863|79 91|phaeomelanin
P09508377A0863|100 116|eumelanin levels
P09508377A0863|122 127|point
P09508377A0863|135 163|eumelanin/phaeomelanin ratio
P09508377A0863|175 193|chemical parameter
P09508377A0863|228 239|individuals
P09508377A0863|248 252|risk
P09508377A0863|257 268|skin cancer
P09508377A0863|273 281|melanoma
P09508511A0588|3 10|ferrets
P09508511A0588|35 46|H. mustelae
P09508511A0588|57 61|dose
P09508511A0588|66 71|mg/kg
P09508511A0588|77 79|os
P09508511A0588|84 96|fluorofamide
P09508511A0588|128 134|urease
P09508775A0293|29 36|pathway
P09508775A0293|89 114|protein kinase activation
P09508775A0293|132 138|growth
P09508775A0293|156 164|pathways
P09508775A0293|172 177|level
P09508775A0293|185 195|expression
P09508775A0293|207 243|protooncogenes/transcription factors
P09509226A1235|0 11|CONCLUSIONS
P09509226A1235|13 16|Use
P09509226A1235|30 36|method
P09509226A1235|59 68|reduction
P09509226A1235|76 89|time patients
P09509226A1235|106 109|ICU
P09509226A1235|117 125|transfer
P09509226A1235|137 141|unit
P09509226A1235|146 153|savings
P09509226A1235|157 169|nursing time
P09509226A1235|183 190|methods
P09509226A1235|228 236|outcomes
P09510189A0192|35 47|organization
P09510189A0192|68 77|CD58 gene
P09510189A0192|107 116|kilobases
P09510189A0192|118 120|kb
P09510189A0192|137 140|DNA
P09510398A1138|4 16|risk factors
P09510398A1138|21 30|hematuria
P09510398A1138|34 42|patients
P09510398A1138|54 66|hypouricemia
P09510398A1138|75 84|elevation
P09510398A1138|96 115|urate concentration
P09510398A1138|124 132|subtypes
P09510398A1138|136 140|Post
P09510398A1138|145 154|Secretion
P09510582A0157|23 31|patients
P09510582A0157|46 50|DCBM
P09510582A0157|101 103|mg
P09510582A0157|105 111|geG-25
P09510582A0157|117 120|geG
P09510582A0157|125 127|mg
P09510582A0157|129 135|geG-50
P09510582A0157|141 144|HBB
P09510582A0157|148 150|mg
P09510582A0157|164 169|agent
P09510925A0389|7 32|haemoglobin concentration
P09510925A0389|34 36|Hb
P09510925A0389|55 61|g dL-1
P09510925A0389|85 96|week course
P09510925A0389|108 116|sulphate
P09511724A0483|7 12|cells
P09511724A0483|18 30|accumulation
P09511724A0483|39 57|Dsg protein levels
P09511724A0483|67 74|calcium
P09511724A0483|103 110|calcium
P09511724A0483|122 124|mM
P09511724A0483|126 131|media
P09511760A0221|9 36|restriction enzyme analysis
P09511760A0221|38 52|Southern blots
P09511760A0221|54 88|polymerase chain reaction analysis
P09511760A0221|93 107|DNA sequencing
P09511760A0221|153 159|clones
P09511760A0221|186 196|cHO-1 gene
P09511760A0221|226 228|kb
P09511760A0221|245 252|regions
P09511760A0221|261 265|ends
P09512416A0460|0 7|RESULTS
P09512416A0460|15 26|information
P09512416A0460|34 48|dbEST database
P09512416A0460|62 75|sequence tags
P09512416A0460|92 117|Arabidopsis thaliana gene
P09512416A0460|119 123|GCR1
P09512416A0460|140 147|protein
P09512416A0460|187 194|domains
P09512416A0460|205 213|features
P09512416A0460|232 245|7TM receptors
P09512550T0000|0 3|E1A
P09512550T0000|14 49|apolipoprotein AI enhancer activity
P09512550T0000|53 64|liver cells
P09512550T0000|75 78|pRb
P09512550T0000|100 107|pathway
P09512559T0000|21 31|expression
P09512559T0000|43 87|nerve growth factor-luciferase reporter gene
P09512559T0000|100 105|yeast
P09512559T0000|117 134|chromosome vector
P09513759A0716|0 18|Calcitriol therapy
P09513759A0716|41 49|decrease
P09513759A0716|53 70|serum iPTH levels
P09514156A1147|0 11|Alterations
P09514156A1147|15 20|DNase
P09514156A1147|23 33|reactivity
P09514156A1147|53 67|element region
P09514156A1147|81 83|GC
P09514156A1147|96 105|complexes
P09514156A1147|136 142|manner
P09514156A1147|153 161|promoter
P09514156A1147|199 204|state
P09514159A0562|15 44|hormone-coding gene promoters
P09514159A0562|62 66|Ptx1
P09514260A1083|19 26|inteins
P09514260A1083|51 64|pseudo intein
P09514260A1083|71 78|results
P09514260A1083|97 109|architecture
P09514260A1083|114 121|inteins
P09514260A1083|137 143|origin
P09514260A1083|148 160|relationship
P09514260A1083|170 186|protein families
P09514260A1083|219 227|findings
P09514260A1083|246 251|roles
P09514260A1083|255 263|intein N
P09514260A1083|265 266|C
P09514260A1083|272 281|EN motifs
P09514272A0482|0 12|Purification
P09514272A0482|16 20|MvaT
P09514272A0482|38 50|polypeptides
P09514272A0482|76 80|mass
P09514272A0482|84 87|kDa
P09514272A0482|95 98|kDa
P09514272A0482|111 114|P15
P09514272A0482|119 122|P16
P09514962A0841|0 4|M-66
P09514962A0841|27 34|protein
P09514962A0841|46 50|MMTV
P09514962A0841|59 74|T-cell lymphoma
P09514962A0841|76 80|EL-4
P09515031A1020|6 13|results
P09515031A1020|28 37|TGF-betaf
P09515031A1020|54 63|c-fos SRE
P09515031A1020|77 80|PKC
P09515031A1020|93 109|SRF binding site
P09515032A1230|0 6|RT-PCR
P09515032A1230|22 30|p21 mRNA
P09515032A1230|117 123|stages
P09515032A1230|168 173|stage
P09515665T0000|0 11|Ganciclovir
P09515665T0000|16 34|foscarnet efficacy
P09515665T0000|51 72|CMV polyradiculopathy
P09515858A0000|0 10|BACKGROUND
P09515858A0000|12 21|Defensins
P09515858A0000|43 62|neutrophil peptides
P09515858A0000|82 90|peptides
P09515858A0000|106 124|azurophil granules
P09515858A0000|128 139|neutrophils
P09515921A1662|16 24|mutation
P09515921A1662|34 53|pca gene expression
P09515921A1662|73 81|promoter
P09515921A1662|90 100|pca operon
P09515924A0104|9 10|g
P09515924A0104|14 19|cells
P09515924A0104|35 37|mg
P09515924A0104|41 52|PDH complex
P09515924A0104|69 77|activity
P09515924A0104|86 90|U/mg
P09515924A0104|94 101|protein
P09515924A0553|4 7|PDH
P09515924A0553|25 30|genes
P09515924A0553|50 75|hybridization experiments
P09515924A0553|80 97|sequence analysis
P09515924A0553|114 126|gene regions
P09515924A0553|134 140|genome
P09515924A0553|144 154|Z. mobilis
P09516472A0292|34 42|elements
P09516472A0292|77 87|TATA motif
P09516472A0292|102 123|Id4 promoter activity
P09517646A0149|0 12|Azithromycin
P09517646A0149|22 42|generation macrolide
P09517646A0149|81 97|pharmacokinetics
P09517646A0149|132 137|agent
P09517646A0149|161 176|pylori regimens
P09517989A0476|4 9|study
P09517989A0476|23 29|people
P09517989A0476|47 50|CMV
P09517989A0476|55 58|HIV
P09517989A0476|78 87|CD4 count
P09517989A0476|111 118|cells/l
P09518383A0000|0 10|BACKGROUND
P09518383A0000|15 25|OBJECTIVES
P09518383A0000|52 60|diseases
P09518383A0000|62 65|STD
P09518383A0000|67 82|control program
P09518383A0000|94 105|sex workers
P09518383A0000|107 110|FSW
P09518383A0000|115 119|Lima
P09518383A0000|121 125|Peru
P09518383A0000|157 162|tests
P09518383A0000|167 175|syphilis
P09518383A0000|189 195|smears
P09518383A0000|200 209|gonococci
P09518383A0000|219 229|medication
P09518383A0000|234 237|STD
P09518383A0000|241 248|condoms
P09518808T0000|0 22|National certification
P09518808T0000|32 41|component
P09518808T0000|45 62|quality assurance
P09519757A0482|15 24|mutations
P09519757A0482|26 31|D811N
P09519757A0482|35 39|exon
P09519757A0482|47 52|R835C
P09519757A0482|56 60|exon
P09519757A0482|113 117|fold
P09519757A0482|119 122|NBF
P09519757A0482|150 156|region
P09519757A0482|160 164|SUR1
P09519757A0482|173 180|patient
P09519757A0482|192 205|heterozygotes
P09519828A0809|10 27|VP16-E2 molecules
P09519828A0809|81 91|activation
P09519828A0809|99 117|BPV-4 LCR promoter
P09519828A0809|137 162|E2 transactivation domain
P09519830A0282|3 8|order
P09519830A0282|34 38|role
P09519830A0282|58 67|silencing
P09519830A0282|86 101|HSV-1 infection
P09519830A0282|115 122|viruses
P09519830A0282|167 172|ICP34
P09519830A0282|175 184|promoters
P09519830A0282|201 211|expression
P09519830A0282|217 264|chloramphenicol acetyltransferase reporter gene
P09519830A0282|288 309|thymidine kinase gene
P09519830A0282|323 329|genome
P09520398A0124|6 13|changes
P09520398A0124|41 49|increase
P09520398A0124|57 75|acetylation levels
P09520398A0124|88 101|core histones
P09521907A0190|26 29|otd
P09521907A0190|42 51|Otx genes
P09521907A0190|76 81|terms
P09521907A0190|85 104|expression patterns
P09521907A0190|116 126|phenotypes
P09521909A0081|0 20|APETALA3 transcripts
P09521909A0081|58 64|region
P09521909A0081|92 97|petal
P09521909A0081|102 118|stamen primordia
P09521909A0081|124 134|expression
P09521909A0081|157 163|region
P09521909A0081|182 193|development
P09521909A0081|203 209|organs
P09521913A0400|18 27|mutations
P09521913A0400|35 43|60A gene
P09521913A0400|83 89|factor
P09522297A0744|0 10|Cell lines
P09522297A0744|56 62|tumors
P09522297A0744|71 75|mice
P09522297A0744|91 99|analysis
P09522297A0744|107 116|karyotype
P09522979T0000|22 33|fibronectin
P09522979T0000|41 51|prediction
P09522979T0000|55 69|preterm labour
P09522979T0000|84 94|population
P09523478A0572|3 11|addition
P09523478A0572|13 16|IgM
P09523478A0572|34 42|children
P09523478A0572|59 72|toxoplasmosis
P09523478A0572|76 84|subjects
P09523478A0572|100 112|reactivation
P09523551A0367|5 13|variants
P09523551A0367|46 54|topology
P09523551A0367|75 76|G
P09523551A0367|93 102|receptors
P09524122A0336|15 21|allele
P09524122A0336|25 29|GPA2
P09524122A0336|46 52|growth
P09524122A0336|58 64|strain
P09524122A0336|78 87|RAS genes
P09524222A0769|4 17|COOH-terminus
P09524222A0769|30 37|isoform
P09524222A0769|58 62|beta
P09524222A0769|77 87|amino acid
P09524222A0769|100 108|sequence
P09524222A0769|138 148|cell alpha
P09524222A0769|167 175|subunits
P09524222A0769|213 219|region
P09524222A0769|223 229|MARCKS
P09524222A0769|245 256|actin-cross
P09524222A0769|265 272|protein
P09524222A0769|286 302|protein kinase C
P09524222A0769|307 325|calcium/calmodulin
P09524222A0769|327 341|beta 4-adducin
P09524222A0769|376 401|calmodulin binding domain
P09524222A1113|0 12|PCR analysis
P09524222A1113|37 57|beta-adducin isoform
P09524222A1113|80 85|brain
P09524222A1113|90 95|liver
P09524222A1113|97 108|bone marrow
P09524222A1113|114 118|NT-2
P09524222A1113|137 142|cells
P09524222A1113|181 188|tissues
P09524229A0000|4 14|gene lac-1
P09524229A0000|29 43|enzyme laccase
P09524229A0000|76 82|number
P09524229A0000|86 91|genes
P09524229A0000|99 121|chestnut blight fungus
P09524229A0000|123 147|Cryphonectria parasitica
P09524229A0000|171 182|hypoviruses
P09524229A0000|186 191|group
P09524229A0000|217 228|mycoviruses
P09524229A0000|230 235|lac-1
P09524229A0000|297 311|concentrations
P09524229A0000|333 356|inhibitor cycloheximide
P09524229A0000|358 361|CHX
P09524229A0000|392 406|cyclosporin A.
P09524250A0767|14 22|elements
P09524250A0767|47 50|AP1
P09524259A0301|4 22|hp55 gamma protein
P09524259A0301|61 66|IGFIR
P09524259A0301|100 115|mutant receptor
P09524259A0301|117 127|hp55 gamma
P09524259A0301|152 168|insulin receptor
P09524259A0301|170 172|IR
P09524259A0301|181 186|yeast
P09524259A0301|198 204|system
P09524267A1023|4 17|plant protein
P09524267A1023|47 54|domains
P09524267A1023|74 82|proteins
P09524267A1023|102 121|localization signal
P09524267A1023|135 141|domain
P09524267A1023|146 161|helicase motifs
P09524267A1023|200 204|part
P09524267A1023|212 239|RNA transcription apparatus
P09524267A1023|252 278|nucleotide excision repair
P09524267A1023|282 293|plant cells
P09524273A0205|5 10|paper
P09524273A0205|33 45|organization
P09524273A0205|49 61|mouse gC1qBP
P09524273A0205|70 86|characterization
P09524273A0205|106 112|region
P09524276A0939|0 13|LysR proteins
P09524276A0939|42 48|urease
P09524276A0939|52 72|Klebsiella aerogenes
P09524276A0939|74 77|NAC
P09524276A0939|84 92|catalase
P09524276A0939|114 118|OxyR
P09524276A0939|152 172|bacterium protection
P09524276A0939|192 198|damage
P09525105A0298|28 38|activities
P09525105A0298|53 60|extract
P09525105A0298|64 80|Buddleia cordata
P09525105A0298|99 116|glycoside linarin
P09525598A0325|0 10|Regulation
P09525598A0325|18 28|Raf kinase
P09525598A0325|32 39|T cells
P09525598A0325|53 61|findings
P09525598A0325|69 76|variety
P09525598A0325|80 90|cell lines
P09525598A0325|110 116|domain
P09525598A0325|120 123|Raf
P09525598A0325|125 128|Raf
P09525598A0325|129 140|delta26-303
P09525598A0325|152 160|activity
P09525888A1482|12 23|FLAP clones
P09525888A1482|45 50|mouse
P09525888A1482|60 79|muscle cDNA library
P09525891T0000|0 7|Members
P09525891T0000|15 20|meis1
P09525891T0000|25 57|pbx homeodomain protein families
P09525891T0000|95 103|sequence
P09525891T0000|105 109|CRS1
P09525891T0000|123 128|CYP17
P09527921A1178|31 40|complexes
P09527921A1178|44 63|electron microscopy
P09527921A1178|92 96|site
P09527921A1178|100 115|WDV Rep protein
P09527921A1178|127 139|core element
P09527921A1178|184 186|bp
P09527921A1178|205 220|initiation site
P09527921A1178|234 244|start site
P09527921A1178|269 282|transcription
P09527921A1178|291 299|TATA box
P09528758T0000|0 5|Rex-1
P09528758T0000|9 13|gene
P09528758T0000|25 45|transcription factor
P09528758T0000|69 75|embryo
P09528758T0000|94 99|Oct-3
P09528758T0000|106 119|Oct-6 binding
P09528758T0000|126 138|octamer site
P09528758T0000|151 158|protein
P09528758T0000|160 165|Rox-1
P09528758T0000|190 194|site
P09528766A0915|9 19|inhibition
P09528766A0915|32 39|ERK/RSK
P09528766A0915|48 65|p38/MAPKAP kinase
P09528766A0915|68 76|pathways
P09528766A0915|110 138|CREB Ser-133 phosphorylation
P09528768A0000|0 5|Cells
P09528768A0000|21 33|accumulation
P09528768A0000|46 54|proteins
P09528768A0000|74 83|reticulum
P09528768A0000|85 87|ER
P09528768A0000|107 120|transcription
P09528768A0000|128 133|genes
P09528768A0000|155 173|chaperone proteins
P09528770A1379|29 56|protein kinase cAPK pathway
P09528770A1379|70 82|UAS activity
P09528770A1379|86 90|IREu
P09528770A1379|98 106|presence
P09528770A1379|110 117|glucose
P09528770A1379|130 143|carbon source
P09528770A1379|171 187|activators Msn2p
P09528770A1379|192 197|Msn4p
P09528770A1379|210 222|UAS activity
P09528770A1379|231 237|repeat
P09528770A1379|245 253|presence
P09528770A1379|257 264|acetate
P09528784A0000|4 8|mei4
P09528784A0000|10 14|gene
P09528784A0000|22 35|fission yeast
P09528784A0000|87 102|complementation
P09528792A0000|12 20|splicing
P09528792A0000|24 57|fibroblast growth factor receptor
P09528792A0000|61 67|FGF-R2
P09528792A0000|75 82|example
P09528792A0000|115 123|splicing
P09528792A0000|133 143|exons IIIb
P09528792A0000|148 152|IIIc
P09528792A0000|190 196|manner
P09528792A0000|210 220|cell types
P09528858A0205|8 13|cases
P09528858A0205|28 39|methylation
P09528858A0205|43 47|CpGs
P09528858A0205|69 76|regions
P09528858A0205|88 99|suppression
P09528858A0205|103 116|gene activity
P09528950A0716|12 21|fragments
P09528950A0716|49 73|luciferase reporter gene
P09528987A1348|0 23|Cotransfection analyses
P09528987A1348|31 65|T/EBP promoter-reporter constructs
P09528987A1348|73 96|T/EBP expression vector
P09528987A1348|108 119|HepG2 cells
P09528987A1348|142 147|T/EBP
P09528987A1348|164 178|autoregulation
P09528987A1348|215 218|rat
P09528987A1348|229 250|T/EBP gene expression
P09529156A1238|0 8|Deletion
P09529156A1238|25 37|Ser residues
P09529156A1238|53 71|PKC consensus site
P09529156A1238|79 92|receptor tail
P09529156A1238|109 129|phorbol 12-myristate
P09529156A1238|149 164|desensitization
P09529156A1238|170 171|%
P09529216A0644|0 13|Flap survival
P09529216A0644|29 40|development
P09529216A0644|52 58|number
P09529216A0644|71 82|connections
P09529216A0644|91 98|vessels
P09529216A0644|116 123|pedicle
P09529216A0644|147 154|vessels
P09529649A0307|0 9|Jean Klig
P09529649A0307|25 35|literature
P09529649A0307|60 75|tract infection
P09529649A0307|79 87|children
P09529721A0000|10 20|indicators
P09529721A0000|47 62|classifications
P09529721A0000|81 93|malnutrition
P09529721A0000|101 111|guidelines
P09529721A0000|127 137|management
P09529721A0000|141 158|childhood illness
P09529721A0000|167 179|malnutrition
P09529721A0000|206 214|referral
P09529721A0000|218 226|hospital
P09529721A0000|241 247|weight
P09529721A0000|273 283|assessment
P09529721A0000|297 308|counselling
P09529721A0000|313 322|follow-up
P09530251A0766|0 4|SNAC
P09530251A0766|8 11|PBS
P09530251A0766|32 33|h
P09530251A0766|48 51|min
P09530251A0766|59 67|ischemia
P09530251A0766|98 106|duration
P09530251A0766|110 121|reperfusion
P09531538A0983|12 23|requirement
P09531538A0983|47 64|splicing activity
P09531538A0983|79 96|dU2AF38 RS domain
P09531549A0658|9 24|binding studies
P09531549A0658|31 50|GST fusion proteins
P09531549A0658|55 69|yeast extracts
P09531549A0658|95 100|sites
P09531549A0658|104 111|yAP180A
P09531549A0658|116 121|Pan1p
P09531549A0658|126 134|clathrin
P09531549A0658|136 151|yAP180 proteins
P09531549A0658|156 161|Pan1p
P09531549A0658|168 173|actin
P09531549A0658|198 205|patches
P09531549A0658|216 231|plasma membrane
P09531559A1153|9 26|affinity analyses
P09531559A1153|64 71|protein
P09531559A1153|96 100|ZO-1
P09531559A1153|121 127|domain
P09531559A1153|131 139|occludin
P09531559A1153|154 158|ZO-2
P09533030T0000|0 12|Cytochrome b
P09533030T0000|22 29|complex
P09533030T0000|55 69|oxidoreductase
P09533030T0000|72 84|cDNA cloning
P09533030T0000|92 102|components
P09533030T0000|106 124|liver mitochondria
P09533030T0000|129 150|chromosome assignment
P09533030T0000|158 163|genes
P09533030T0000|179 183|SDHC
P09533030T0000|196 200|SDHD
P09533030T0000|202 210|subunits
P09533030T0000|214 218|1q21
P09533030T0000|223 228|11q23
P09533109A0449|11 19|decrease
P09533109A0449|23 35|theophylline
P09533109A0449|38 44|volume
P09533109A0449|48 60|distribution
P09533109A0449|66 70|days
P09533109A0449|99 113|administration
P09533109A0449|117 128|chloroquine
P09533109A0449|193 205|significance
P09533109A0449|207 208|p
P09535082A0537|4 12|addition
P09535082A0537|33 40|extract
P09535082A0537|70 85|protein binding
P09535082A0537|103 119|target sequences
P09535082A0537|127 134|absence
P09535082A0537|138 142|PrfA
P09535082A0537|160 167|complex
P09535082A0537|169 173|CIII
P09535082A0537|189 193|PrfA
P09535082A0537|206 208|bp
P09535082A0537|213 225|DNA fragment
P09535082A0537|261 268|complex
P09535082A0537|270 272|CI
P09535579A1105|20 31|assumptions
P09535579A1105|55 61|uptake
P09535579A1105|88 102|interpretation
P09535579A1105|106 124|energy expenditure
P09535579A1105|132 136|EPOC
P09535579A1105|140 141|l
P09535579A1105|156 158|kJ
P09535833A0228|14 33|amino acid sequence
P09535833A0228|37 43|m-Staf
P09535833A0228|76 80|Staf
P09535833A0228|90 128|selenocysteine tRNA gene transcription
P09535833A0228|140 146|factor
P09535833A0228|150 164|Xenopus laevis
P09535835A0279|0 6|ROCK-I
P09535835A0279|8 16|Kinectin
P09535835A0279|22 27|mDia2
P09535835A0279|46 56|type forms
P09535835A0279|65 69|RhoA
P09535835A0279|74 79|Cdc42
P09535835A0279|99 105|manner
P09535851A0591|12 20|isoforms
P09535851A0591|26 38|beta isoform
P09535851A0591|56 66|Vmax value
P09535851A0591|75 81|PtdIns
P09535851A0591|84 101|P kinase activity
P09535851A0591|110 123|gamma isoform
P09535851A0591|168 172|acid
P09535892A0000|4 16|beta subunit
P09535892A0000|39 49|G proteins
P09535892A0000|65 72|signals
P09535892A0000|84 99|plasma membrane
P09535892A0000|146 153|segment
P09535892A0000|182 187|units
P09535892A0000|195 197|WD
P09535892A0000|199 206|Trp-Asp
P09535892A0000|208 215|repeats
P09535892A0000|250 258|proteins
P09535908A0321|29 41|LNX messages
P09535908A0321|61 69|proteins
P09535908A0321|95 101|masses
P09535908A0321|108 111|kDa
P09535908A0321|113 116|LNX
P09535908A0321|125 128|kDa
P09535908A0321|130 135|LNX-b
P09536028A0945|3 11|contrast
P09536028A0945|17 35|contractile action
P09536028A0945|51 55|acid
P09536028A0945|72 94|cyclooxygenase product
P09536028A0945|113 125|contractions
P09536028A0945|141 143|TF
P09536028A0945|148 151|EGF
P09536028A0945|183 214|signal pathway probe inhibitors
P09536440A0000|7 14|studies
P09536440A0000|44 52|myosin V
P09536440A0000|94 99|motor
P09536440A0000|122 130|movement
P09536901A0362|14 22|occasion
P09536901A0362|27 29|T1
P09536901A0362|43 45|T2
P09536901A0362|55 63|sagittal
P09536901A0362|68 70|T2
P09536901A0362|86 95|sequences
P09536901A0362|119 127|relation
P09536901A0362|143 153|assessment
P09537295A0951|21 31|start site
P09537295A0951|50 52|bp
P09537295A0951|75 79|site
P09537295A0951|94 133|transcriptase-polymerase chain reaction
P09537295A0951|147 157|P1 primers
P09537295A0951|159 173|primer walking
P09537295A0951|176 192|primer extension
P09537295A0951|198 210|cDNA cloning
P09537295T0000|0 8|Analysis
P09537295T0000|12 20|promoter
P09537295T0000|25 33|androgen
P09537295T0000|45 54|sequences
P09537295T0000|76 89|transcription
P09537295T0000|97 100|rat
P09537295T0000|118 130|protein gene
P09537361A0149|4 19|iron dependence
P09537361A0149|23 36|transcription
P09537361A0149|41 51|expression
P09537361A0149|55 59|cvaA
P09537361A0149|77 106|transporter accessory protein
P09537361A0149|112 115|cvi
P09537361A0149|130 156|colicin V immunity protein
P09537361A0149|177 187|conditions
P09537361A0149|191 202|iron excess
P09537361A0149|206 215|depletion
P09537375A0198|5 25|gntR deletion mutant
P09537375A0198|31 41|expression
P09537375A0198|59 63|gntT
P09537375A0198|65 76|lacZ fusion
P09537375A0198|124 128|GntR
P09537375A0198|145 154|regulator
P09537375A0198|158 162|gntT
P09537378A1227|17 25|deletion
P09537378A1227|29 32|bcp
P09537378A1227|42 52|chromosome
P09537378A1227|60 66|effect
P09537378A1227|70 89|gcv-lacZ expression
P09537651A0366|9 14|sites
P09537651A0366|16 20|PEA3
P09537651A0366|25 29|STAT
P09537651A0366|58 67|induction
P09537651A0366|71 76|v-src
P09537651A0366|100 108|elements
P09537651A0366|131 140|induction
P09537651A0366|148 187|phorbol ester phorbol myristate acetate
P09537651A0366|189 192|PMA
P09538156A0130|0 13|BRCA1 protein
P09538156A0130|41 58|zinc finger motif
P09538156A0130|89 95|region
P09538220A0000|29 35|region
P09538220A0000|37 40|mrr
P09538220A0000|62 69|tRNAPhe
P09538220A0000|74 87|tRNAPro genes
P09538220A0000|105 108|DNA
P09538220A0000|110 115|mtDNA
P09538220A0000|134 144|regulation
P09538220A0000|148 159|replication
P09538220A0000|164 177|transcription
P09538220A0000|199 205|genome
P09538258A0200|8 14|report
P09538258A0200|35 44|mechanism
P09538258A0200|56 70|Ras activation
P09538258A0200|76 87|stimulation
P09538258A0200|101 106|types
P09538258A0200|110 119|receptors
P09538258A0200|137 142|cells
P09539421A0970|6 18|Sir proteins
P09539421A0970|24 33|K. lactis
P09539421A0970|39 44|roles
P09539421A0970|53 62|silencing
P09539421A0970|67 94|telomere length maintenance
P09539421A0970|128 134|themes
P09539721A0599|28 32|DnaA
P09539721A0599|49 61|beta subunit
P09539721A0599|65 79|RNA polymerase
P09539721A0599|87 97|activation
P09539721A0599|105 116|pR promoter
P09539746A0781|0 10|Expression
P09539746A0781|14 20|Bcl-XL
P09539746A0781|35 46|association
P09539746A0781|50 56|Apaf-1
P09539746A0781|62 71|caspase-9
P09539746A0781|85 90|cells
P09539779A0621|20 33|hybridization
P09539779A0621|43 56|mouse embryos
P09539779A0621|69 73|days
P09539779A0621|94 101|pattern
P09539779A0621|105 120|Arp1 expression
P09539779A0621|152 162|expression
P09539779A0621|166 170|All1
P09540062A0755|6 13|mutants
P09540062A0755|30 37|ability
P09540062A0755|58 62|Site
P09540062A0755|74 82|proteins
P09540062A0755|115 122|ability
P09540062A0755|133 135|H4
P09540062A0755|152 160|activity
P09540062A0755|176 209|H4 promoter/CAT fusion constructs
P09540062A0755|223 233|cell types
P09541280A0404|10 20|plasma IgE
P09541280A0404|47 54|NC mice
P09541280A0404|60 69|treatment
P09541280A0404|75 89|FK506 ointment
P09541280A0404|102 118|plasma IgE level
P09541636T0000|0 23|Creatine kinase release
P09541636T0000|38 57|artery embolization
P09541636T0000|61 69|patients
P09541636T0000|85 91|tumors
P09541721A0894|20 41|ischemia/angiotension
P09541721A0894|53 62|AHF model
P09541721A0894|64 67|NIC
P09541721A0894|109 117|pressure
P09541721A0894|119 124|LVEDP
P09543227A0815|0 7|Group A
P09543227A0815|20 25|years
P09543227A0815|40 48|patients
P09543227A0815|61 73|risk factors
P09543227A0815|75 76|B
P09543227A0815|89 94|years
P09543227A0815|109 121|risk factors
P09543227A0815|127 128|C
P09543227A0815|141 146|years
P09543227A0815|169 181|risk factors
P09544987A1583|28 38|RU486-PR-B
P09544987A1583|65 69|NCoR
P09544991A0483|0 12|PRL receptor
P09544991A0483|28 33|SHP-2
P09544991A0483|47 67|tyrosine phosphatase
P09544991A0750|22 28|mutant
P09544991A0750|32 37|SHP-2
P09544991A0750|63 72|induction
P09544991A0750|76 100|tyrosine phosphorylation
P09544991A0750|117 125|activity
P09544991A0750|129 137|m-Stat5a
P09544991A0750|139 147|m-Stat5b
P09544991A0750|175 183|deletion
P09544991A0750|192 208|m-Stat5adelta749
P09544991A0750|225 250|transactivation potential
P09544991A0750|254 262|m-Stat5a
P09544991A0750|267 275|m-Stat5b
P09545146A0884|0 11|CONCLUSIONS
P09545146A0884|39 43|data
P09545146A0884|66 75|estimates
P09545146A0884|79 86|changes
P09545146A0884|90 98|CBZ Cl/F
P09545146A0884|106 118|comedication
P09545146A0884|138 146|decrease
P09545146A0884|150 154|Cl/F
P09545146A0884|167 187|regression equations
P09545146A0884|209 223|concentrations
P09545146A0884|238 252|validation set
P09545293A0590|0 5|Sites
P09545293A0590|17 24|lumican
P09545293A0590|29 38|keratocan
P09545293A0590|59 67|location
P09545312A1197|4 16|observations
P09545312A1197|30 37|members
P09545312A1197|45 57|HMG-I family
P09545312A1197|76 80|role
P09545312A1197|98 111|transcription
P09545312A1197|127 133|effect
P09545312A1197|177 188|interaction
P09545323T0000|14 22|assembly
P09545323T0000|36 43|complex
P09545323T0000|60 72|DNA mismatch
P09545323T0000|81 96|yeast MSH2-MSH6
P09545323T0000|101 128|MLH1-PMS1 protein complexes
P09545332A0137|0 8|Mutation
P09545332A0137|24 30|Tyr497
P09545332A0137|34 37|Phe
P09545332A0137|49 73|tyrosine phosphorylation
P09545332A0137|81 107|insulin receptor substrate
P09545332A0137|111 115|IRS1
P09545332A0137|132 145|proliferation
P09545332A0137|149 157|response
P09545332A0137|161 165|IL-4
P09545353A1071|33 48|kappaB elements
P09545353A1071|63 121|activating transcription factor/cAMP response element site
P09545353A1071|147 152|sites
P09545353A1071|160 175|E-selectin gene
P09545353A1071|198 207|TNF-alpha
P09545353A1071|226 236|expression
P09545638A0330a|35 64|yeast hnRNP methyltransferase
P09545638A0330a|66 70|HMT1
P09545638A0330b|35 64|yeast hnRNP methyltransferase
P09545638A0330b|66 70|HMT1
P09545638A0836|12 27|HRMT1L2 protein
P09545638A0836|76 102|methyltransferase activity
P09545638A1181|13 18|roles
P09545638A1181|22 29|HRMT1L1
P09545638A1181|34 41|HRMT1L2
P09545638A1181|51 58|disease
P09545638T0000|0 14|Identification
P09545638T0000|19 35|characterization
P09545638T0000|58 85|arginine methyltransferases
P09545638T0000|87 94|HRMT1L1
P09545638T0000|99 106|HRMT1L2
P09546424A1550|29 47|PDGF beta-receptor
P09546424A1550|70 82|Crk proteins
P09547311A1394|13 25|interactions
P09547311A1394|61 71|E-cadherin
P09547311A1394|80 87|chimera
P09547311A1394|103 113|E-cadherin
P09547311A1394|128 134|domain
P09547311A1394|143 153|desmoglein
P09547311A1394|170 176|domain
P09547311A1394|195 203|evidence
P09547311A1394|237 249|interactions
P09547311A1394|253 263|E-cadherin
P09547311A1394|278 285|domains
P09547349A0000|4 76|ether phospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine
P09547349A0000|78 88|ET-18-OCH3
P09547349A0000|90 100|edelfosine
P09547349A0000|114 121|inducer
P09547349A0000|125 134|apoptosis
P09547349A0000|144 155|tumor cells
P09548481A0000|3 11|addition
P09548481A0000|42 50|promoter
P09548481A0000|52 54|P1
P09548481A0000|73 82|existence
P09548481A0000|95 103|promoter
P09548481A0000|118 133|IL-5Ralpha gene
P09549179A0774|0 12|Serum levels
P09549179A0774|16 28|testosterone
P09549179A0774|56 63|changes
P09549179A0774|67 75|exposure
P09549179A0774|79 80|p
P09549179A0774|81 82|p
P09549179A0774|84 87|DDE
P09549179A0774|98 108|conditions
P09549179A0774|117 122|study
P09549398A1463|8 17|agreement
P09549398A1463|26 63|rest/postnitroglycerin technetium-99m
P09549398A1463|76 88|SPET studies
P09549398A1463|93 112|rest/redistribution
P09549398A1463|116 158|rest/reinjection thallium-201 SPET studies
P09549398A1463|174 182|presence
P09549398A1463|197 206|viability
P09549398A1463|214 215|%
P09549398A1463|222 223|%
P09549632A1189|6 9|use
P09549632A1189|24 35|sensitivity
P09549632A1189|41 42|%
P09549632A1189|49 60|specificity
P09549632A1189|66 67|%
P09549632A1189|73 79|regard
P09549632A1189|83 97|predictability
P09549632A1189|101 111|ALT levels
P09549632A1189|134 139|trial
P09549660A0782|22 31|data sets
P09549660A0782|39 47|subjects
P09549660A0782|85 98|data scenario
P09549783T0000|8 16|accuracy
P09549783T0000|56 64|saccades
P09549783T0000|82 90|patients
P09550591A0454|11 20|treatment
P09550591A0454|52 67|airway pressure
P09550591A0454|81 86|cmH2O
P09550591A0454|94 98|days
P09550591A0454|120 128|decrease
P09550591A0454|137 151|blood pressure
P09550591A0454|155 159|OSAS
P09550919A0365|5 9|data
P09550919A0365|41 47|manner
P09550919A0365|53 61|response
P09550919A0365|77 86|adenosine
P09550919A0365|89 91|mg
P09550919A0365|95 97|mg
P09550919A0365|101 103|mg
P09550919A0365|111 113|mg
P09550919A0365|124 132|episodes
P09550919A0365|136 140|PSVT
P09550919A0365|148 156|episodes
P09550919A0365|160 161|%
P09550919A0365|167 175|episodes
P09550919A0365|179 180|%
P09550919A0365|186 194|episodes
P09550919A0365|198 199|%
P09550919A0365|208 216|episodes
P09550919A0365|220 221|%
P09551096A0108|0 4|RNAs
P09551096A0108|28 38|components
P09551096A0108|57 65|subunits
P09551096A0108|99 106|factors
P09551096A0108|114 132|particle formation
P09551182A0212|9 28|retinoid signalling
P09551182A0212|32 49|zebrafish embryos
P09551182A0212|72 78|method
P09551182A0212|100 109|retinoids
P09551182A0212|121 128|embryos
P09551182A0212|138 152|fusion protein
P09551182A0212|160 166|ligand
P09551182A0212|177 199|transactivation domain
P09551182A0212|214 227|acid receptor
P09551182A0212|247 265|DNA binding domain
P09551938A0318|31 38|factors
P09551938A0318|91 109|CCR5 gene promoter
P09551972A1033|0 12|Fluorescence
P09551972A1033|21 34|hybridization
P09551972A1033|38 55|metaphase spreads
P09551972A1033|59 69|chromosome
P09551972A1033|84 113|hybrid cell line 706-B6 clone
P09551972A1033|118 123|CL-17
P09551972A1033|130 143|cosmid c101F1
P09551972A1033|161 171|gene close
P09551972A1033|179 187|telomere
P09551972A1033|191 197|8q24.3
P09552469A0225|4 15|interaction
P09552469A0225|24 33|piroxicam
P09552469A0225|38 47|poloxamer
P09552469A0225|63 83|x-ray diffractometry
P09552469A0225|85 88|XRD
P09552469A0225|101 103|IR
P09552469A0225|105 117|spectroscopy
P09552469A0225|143 151|analysis
P09552469A0225|153 156|DTA
P09552469A0225|171 181|dispersion
P09552469A0225|210 217|mixture
P09553040A0651|0 13|Cell survival
P09553040A0651|17 20|Epo
P09553040A0651|37 47|activation
P09553040A0651|63 81|signaling pathways
P09553040A0651|92 103|PI-3 kinase
P09553040A0651|105 114|PLC-gamma
P09553040A0651|116 119|Ras
P09553040A0651|123 128|Stats
P09553134A0596|25 42|neurite outgrowth
P09553134A0596|63 102|tyrosine kinase inhibitors herbimycin A
P09553134A0596|107 110|PP1
P09553143A0729|11 27|ZAP-70 substrate
P09553143A0729|29 35|SLP-76
P09553143A0729|51 65|Erk activation
P09553143A0729|114 126|Jurkat cells
P09553143A0729|139 149|P116 cells
P09553143A0729|156 165|treatment
P09553143A0729|171 175|H2O2
P09553686A0000|20 28|patterns
P09553686A0000|32 41|estradiol
P09553686A0000|43 46|CAS
P09553686A0000|63 70|estrone
P09553686A0000|72 75|CAS
P09553686A0000|109 114|women
P09553686A0000|138 147|menopause
P09553686A0000|159 170|application
P09553686A0000|180 189|estradiol
P09553686A0000|202 207|patch
P09553686A0000|220 226|matrix
P09553686A0000|239 259|absorption enhancers
P09553686A0000|286 298|applications
P09553686A0000|304 308|days
P09553686A0000|330 338|patch 7D
P09555046A1617|4 11|results
P09555046A1617|34 45|base change
P09555046A1617|53 83|branchpoint consensus sequence
P09555046A1617|90 96|intron
P09555046A1617|113 120|disease
P09555046A1617|135 143|sequence
P09555046A1617|167 174|mammals
P09556557A1238|24 31|regions
P09556561A0671|10 23|H/ACA snoRNAs
P09556561A0671|40 45|Gar1p
P09556561A0671|75 80|group
P09556561A0671|84 91|snoRNAs
P09556561A0671|118 123|yeast
P09556561A0671|137 143|guides
P09556561A0671|148 171|pseudouridine synthesis
P09556561A0671|190 198|molecule
P09556566A0174|12 30|vitamin D receptor
P09556566A0174|32 35|VDR
P09556566A0174|54 74|acid Xalpha receptor
P09556566A0174|76 84|RXRalpha
P09556566A0174|99 120|T cell line MT2 cells
P09556573A1062|8 15|studies
P09556573A1062|38 54|PPARalpha ligand
P09556573A1062|57 58|S
P09556573A1062|84 88|acid
P09556573A1062|111 122|interaction
P09556573A1062|126 135|PPARalpha
P09556573A1062|145 165|co-activator RIP-140
P09556573A1062|184 195|interaction
P09556573A1062|199 208|PPARalpha
P09556573A1062|231 235|SMRT
P09556861A1018|21 31|literature
P09556861A1018|37 47|mechanisms
P09556861A1018|64 72|toxicity
P09556861A1018|76 78|OA
P09556861A1018|100 107|effects
P09556861A1018|113 123|inhibition
P09556861A1018|141 152|respiration
P09556861A1018|171 180|depletion
P09556861A1018|184 187|ATP
P09556861A1018|193 203|inhibition
P09556861A1018|207 222|tRNA-synthetase
P09556861A1018|248 265|protein synthesis
P09556861A1018|284 302|lipid peroxidation
P09557678A0140|38 48|expression
P09557678A0140|63 82|papillomavirus type
P09557678A0140|86 90|BPV1
P09557678A0140|92 102|E2 protein
P09557678A0140|106 110|HeLa
P09557678A0140|115 119|HT-3
P09557678A0140|129 149|carcinoma cell lines
P09557678A0140|175 188|proliferation
P09557678A0140|212 236|G1/S phase growth arrest
P09557682A0490|14 22|isoforms
P09557682A0490|24 35|hGli2 alpha
P09557682A0490|37 41|beta
P09557682A0490|43 48|gamma
P09557682A0490|54 59|delta
P09557682A0490|75 87|combinations
P09557682A0490|119 128|splicings
P09557682A0490|142 150|isoforms
P09557682A0490|167 176|DNA motif
P09557682A0490|178 183|TRE2S
P09557682A0490|192 195|LTR
P09557708A1426|0 23|Specialized actin tails
P09557708A1426|36 49|IEV particles
P09557708A1426|57 66|periphery
P09557708A1426|84 94|microvilli
P09557708A1426|130 135|cells
P09557708A1426|152 157|cells
P09557708A1426|172 181|vA33delta
P09557912A0699|11 14|IOP
P09557912A0699|25 27|SD
P09557912A0699|33 37|mmHg
P09557912A0699|47 56|induction
P09557912A0699|60 70|anesthesia
P09557912A0699|78 80|SD
P09557912A0699|86 90|mmHg
P09557912A0699|97 101|loss
P09557912A0699|105 112|eyelash
P09557912A0699|130 139|injection
P09557912A0699|143 156|methohexitone
P09557912A0699|164 166|SD
P09557912A0699|172 176|mmHg
P09557912A0699|183 192|cessation
P09557912A0699|196 217|muscle fasciculations
P09557912A0699|229 242|suxamethonium
P09557912A0699|250 252|SD
P09557912A0699|258 262|mmHg
P09557912A0699|269 278|cessation
P09557912A0699|282 292|convulsion
P09557912A0699|303 305|SD
P09557912A0699|311 315|mmHg
P09557912A0699|326 336|resumption
P09557912A0699|360 371|respiration
P09560221A0282|2 6|cDNA
P09560221A0282|8 14|cak1At
P09560221A0282|49 61|CAK mutation
P09560221A0282|73 78|yeast
P09560221A0282|107 131|fission yeast CAK mutant
P09560221A0282|133 139|cak1At
P09560221A0282|150 157|protein
P09560221A0282|169 180|animal CAKs
P09560325A1285|19 32|modifications
P09560325A1285|41 54|glycosylation
P09560325A1285|59 74|phosphorylation
P09560325A1285|106 118|explanations
P09560325A1285|127 148|protein heterogeneity
P09560390A0771|3 11|addition
P09560390A0771|25 43|checkpoint control
P09560390A0771|45 59|overexpression
P09560390A0771|63 67|sum1
P09560390A0771|89 108|cell cycle response
P09560390A0771|120 126|stress
P09560430A0000|0 4|Ime1
P09560430A0000|21 25|role
P09560430A0000|33 43|initiation
P09560430A0000|47 54|meiosis
P09560430A0000|58 65|a/alpha
P09560430A0000|74 79|cells
P09561560A0579|0 15|Rhesus macaques
P09561560A0579|20 31|BALB/c mice
P09561560A0579|52 80|Mengo virus SIV recombinants
P09561560A0579|99 112|CTL responses
P09561560A0579|125 142|SIV gene products
P09561560A0579|161 181|HIV-Nef recombinants
P09561560A0579|197 209|CTL response
P09561560A0579|213 217|mice
P09561560A0579|233 249|HIV1 Nef peptide
P09561560A0579|259 268|positions
P09561616A0142|0 12|Deltamethrin
P09561616A0142|48 55|surface
P09561616A0142|72 83|% mortality
P09561616A0142|91 110|culicifacies adults
P09561616A0142|120 125|weeks
P09561616A0142|159 163|dose
P09561616A0142|170 175|mg/m2
P09562398A0848|0 17|Trichloroethylene
P09562398A0848|22 26|turn
P09562398A0848|42 45|AUC
P09562398A0848|57 59|.4
P09562398A0848|92 94|.4
P09562398A0848|137 143|values
P09562398A0848|148 156|n-hexane
P09562398A0848|172 174|.1
P09562398A0848|206 208|.9
P09562558T0000|0 18|Solution structure
P09562558T0000|26 31|IRF-2
P09562558T0000|44 50|domain
P09562558T0000|60 68|subgroup
P09562558T0000|100 106|family
P09564860A2139|3 11|contrast
P09564860A2139|13 40|receptor/G protein coupling
P09564860A2139|64 74|expression
P09564860A2139|78 93|loop 3i domains
P09564860A2139|111 120|receptors
P09564860A2139|132 133|G
P09564860A2139|134 137|i/o
P09564860A2139|139 147|proteins
P09564860A2139|189 198|receptors
P09564860A2315|6 10|data
P09564860A2315|49 53|loop
P09564860A2315|61 71|rat GnRH-R
P09564860A2315|87 97|receptor G
P09564860A2315|98 102|q/11
P09564860A2315|104 120|protein coupling
P09564860A2315|128 139|selectivity
P09564860A2315|152 155|GGH
P09564860A2315|161 170|cell line
P09564860A2315|177 181|loop
P09564860A2315|202 221|signal transduction
P09564860A2315|243 261|Gs protein pathway
P09564917A0900|10 16|levels
P09564917A0900|20 38|alpha2-antiplasmin
P09564917A0900|65 76|mediastinum
P09564917A0900|95 99|U/mL
P09564917A0900|101 102|p
P09565576T0000|12 18|domain
P09565576T0000|33 53|DNA topoisomerase I.
P09565584A0770|2 9|cluster
P09565584A0770|19 30|amino acids
P09565584A0770|32 36|KKKR
P09565584A0770|66 75|sequences
P09565584A0770|104 108|exon
P09565584A0770|132 136|exon
P09565584A0770|170 179|targeting
P09565584A0770|186 187|H
P09565584A0770|222 242|mutagenesis analysis
P09565606A0520|25 34|structure
P09565606A0520|51 54|end
P09565606A0520|58 62|repY
P09565606A0520|86 93|rCGCC-3
P09565606A0520|95 103|sequence
P09565606A0520|112 116|repZ
P09565606A0520|134 138|site
P09566731A0458|10 15|genes
P09566731A0458|54 60|region
P09566731A0458|70 94|chromosome 16p12.1-p11.2
P09566731A0458|110 126|mouse chromosome
P09566731A0458|145 157|cell hybrids
P09566731A0458|169 175|clones
P09566871A0343|3 15|fus3 mutants
P09566871A0343|21 27|levels
P09566871A0343|31 38|Ty1 RNA
P09566871A0343|40 57|protein synthesis
P09566871A0343|75 85|processing
P09566871A0343|124 136|FUS3 strains
P09566871A0343|154 160|levels
P09566871A0343|164 167|TyA
P09566871A0343|169 178|integrase
P09566871A0343|192 214|transcriptase proteins
P09566871A0343|219 227|Ty1 cDNA
P09566871T0000|18 28|regulation
P09566871T0000|32 54|Ty1 retrotransposition
P09566871T0000|76 95|protein kinase Fus3
P09566876A0000|12 36|transcription factor IIA
P09566876A0000|38 43|TFIIA
P09566876A0000|64 84|TATA binding protein
P09566876A0000|86 89|TBP
P09566876A0000|95 107|promoter DNA
P09566876A0000|119 143|transcription activation
P09566882A0693|6 14|function
P09566882A0693|38 42|Pho2
P09566882A0693|50 58|promoter
P09566882A0693|84 91|binding
P09566882A0693|95 99|Pho4
P09566882A0693|114 118|Pho2
P09566918A1115|0 12|Substitution
P09566918A1115|20 33|Ser-Thr sites
P09566918A1115|58 61|Asp
P09566918A1115|96 100|form
P09566918A1115|104 109|IRF-3
P09566918A1115|143 152|activator
P09566918A1115|156 165|promoters
P09566918A1115|177 188|PRDI-PRDIII
P09566918A1115|192 196|ISRE
P09566918A1115|208 216|elements
P09568445T0000|10 16|angina
P09568445T0000|44 54|infarction
P09568445T0000|83 103|contractile recovery
P09568445T0000|110 122|thrombolysis
P09568549A0188|8 13|study
P09568549A0188|19 25|effect
P09568549A0188|35 49|administration
P09568549A0188|61 66|doses
P09568549A0188|70 79|malathion
P09568549A0188|100 106|routes
P09568549A0188|110 114|mice
P09568549A0188|119 123|rats
P09568549A0188|127 139|serum levels
P09568549A0188|143 152|histamine
P09570030T0000|6 24|growth retardation
P09570030T0000|30 35|cause
P09570030T0000|56 67|development
P09570107A0355|11 28|PCDFs/PCDDs ratio
P09570107A0355|32 35|ESP
P09570107A0355|63 69|boiler
P09570133A0474|3 11|addition
P09570133A0474|27 39|interactions
P09570133A0474|57 69|interactions
P09570133A0474|75 91|partner proteins
P09570133A0474|109 114|roles
P09570133A0474|139 147|proteins
P09570133A0474|160 169|promoters
P09570944T0000|0 12|Localization
P09570944T0000|19 24|exons
P09570944T0000|30 40|YAC contig
P09570944T0000|54 56|Mb
P09570944T0000|78 100|resistance gene region
P09570944T0000|110 127|chromosome 7q21.1
P09570952A0000|25 37|organization
P09570952A0000|52 56|gene
P09570952A0000|66 75|M-protein
P09570952A0000|90 97|protein
P09570952A0000|112 122|myofibrils
P09571563A0000|0 7|PURPOSE
P09571563A0000|25 39|image analysis
P09571563A0000|47 53|cornea
P09571563A0000|73 84|keratectomy
P09571563A0000|86 89|PRK
P09571563A0000|132 145|determination
P09571563A0000|149 156|changes
P09571563A0000|164 173|condition
P09571563A0000|181 187|cornea
P09572428A0526|0 4|Mean
P09572428A0526|7 35|SD serum VEGF concentrations
P09572428A0526|63 64|P
P09572428A0526|77 82|women
P09572428A0526|88 91|PCO
P09572428A0526|96 100|PCOS
P09572428A0526|127 132|ng/ml
P09572428A0526|161 166|women
P09572428A0526|179 186|ovaries
P09572428A0526|198 203|ng/ml
P09572491A1044|18 23|cells
P09572491A1044|34 51|missense mutation
P09572491A1044|59 67|p53 gene
P09572491A1044|71 76|codon
P09572491A1044|82 85|p53
P09572491A1044|111 118|alanine
P09572491A1044|123 130|glycine
P09572511A0148|8 17|algorithm
P09572511A0148|26 33|RBI-MAP
P09572511A0148|60 65|block
P09572511A0148|76 78|EM
P09572511A0148|80 86|RBI-EM
P09572511A0148|88 97|algorithm
P09572965A1235|8 11|ORF
P09572965A1235|13 17|ORF5
P09572965A1235|25 33|homology
P09572965A1235|39 48|gene agrB
P09572965A1235|102 111|mechanism
P09572965A1235|115 125|regulation
P09572965A1235|133 152|virulence phenotype
P09572965A1235|161 168|species
P09572990A0630|3 14|association
P09572990A0630|23 27|hSIE
P09572990A0630|32 38|Stat-3
P09572990A0630|45 59|MHC-I ligation
P09572990A0630|103 109|Stat-3
P09572990A0630|123 131|extracts
P09572990A0630|150 160|hSIE probe
P09572990A0630|180 187|agarose
P09573187T0000|16 26|repression
P09573187T0000|49 63|regulator CatR
P09573187T0000|82 95|binding sites
P09573202A0900|35 41|levels
P09573202A0900|49 62|alpha subunit
P09573202A0900|81 93|substitution
P09573202A0900|97 104|glycine
P09573202A0900|122 134|acid residue
P09573202A0900|138 146|position
P09573202A0900|170 176|domain
P09573244A0523|10 22|mRNA species
P09573244A0523|52 78|polyadenylation site usage
P09573374A0687|6 28|Southern blot analysis
P09573374A0687|33 52|restriction mapping
P09573374A0687|64 67|YAC
P09573374A0687|69 74|yeast
P09573374A0687|86 96|chromosome
P09573374A0687|102 115|cosmid clones
P09573374A0687|138 146|RIL gene
P09573374A0687|155 157|kb
P09573374A0687|175 184|IRF1 gene
P09573374A0687|215 224|structure
P09573378A0761|0 3|U73
P09573378A0761|13 14|C
P09573378A0761|16 17|D
P09573378A0761|22 30|D' boxes
P09573378A0761|61 76|complementarity
P09573378A0761|98 101|RNA
P09573884A0392|20 28|position
P09573884A0392|30 35|S-N-B
P09573884A0392|40 47|S-N-Pog
P09573884A0392|84 93|retrusive
P09573884A0392|97 102|Class
P09573884A0392|125 130|Class
P09573884A0392|133 141|subjects
P09574799A1072|0 15|Echinostomiasis
P09574799A1072|47 54|factors
P09574799A1072|63 70|poverty
P09574799A1072|72 84|malnutrition
P09574799A1072|119 125|market
P09574799A1072|129 133|lack
P09574799A1072|148 163|food inspection
P09574799A1072|186 196|sanitation
P09574799A1072|204 217|helminthiases
P09574799A1072|242 252|conditions
P09575143A1189|4 16|localization
P09575143A1189|20 26|ZAP-70
P09575143A1189|34 45|cell cortex
P09575143A1189|78 86|activity
P09575143A1189|90 108|SRC-family kinases
P09575143A1189|133 140|ability
P09575143A1189|158 172|immunoreceptor
P09575143A1189|188 205|activation motifs
P09575143A1189|213 216|TCR
P09575187A1558|11 15|role
P09575187A1558|20 29|NF-kappaB
P09575187A1558|44 53|apoptosis
P09575187A1558|65 83|ER calcium release
P09575187A1558|104 108|data
P09575187A1558|122 131|sAPPalpha
P09575187A1558|162 171|apoptosis
P09575187A1558|176 182|effect
P09575187A1558|194 210|kappaB decoy DNA
P09575217A0000|5 23|cytokine receptors
P09575217A0000|31 61|Janus protein tyrosine kinases
P09575217A0000|63 67|Jaks
P09575217A0000|73 91|signal transducers
P09575217A0000|96 106|activators
P09575217A0000|110 123|transcription
P09575217A0000|125 130|Stats
P09575217A0000|144 153|signaling
P09575217A0971|16 30|R618K mutation
P09575217A0971|38 54|Stat5 SH2 domain
P09575217A0971|69 84|phosphorylation
P09575217A0971|88 92|Jak2
P09575217A0971|100 108|deletion
P09575217A0971|116 126|C terminus
P09575217A0971|134 160|Stat5 hyperphosphorylation
P09576230T0000|4 10|effect
P09576230T0000|21 45|oxide synthase inhibitor
P09576230T0000|49 67|reperfusion injury
P09576230T0000|75 80|brain
P09576230T0000|111 117|arrest
P09576915A0269|14 27|recombination
P09576915A0269|31 34|HMR
P09576915A0269|55 60|rings
P09576915A0269|77 78|E
P09576915A0269|85 94|silencers
P09577365A0747|3 17|angiodysplasia
P09577365A0747|27 34|vessels
P09577365A0747|42 48|mucosa
P09577365A0747|74 87|collagen type
P09577365A0747|112 119|vessels
P09577365A0747|127 136|submucosa
P09577365A0747|154 161|vessels
P09577365A0747|179 184|cases
P09577365A0747|193 201|staining
P09577365A0747|209 214|level
P09577365A0747|222 240|muscularis mucosae
P09577395A0000|46 49|VOR
P09577395A0000|54 62|response
P09577395A0000|72 80|impulses
P09577395A0000|83 88|brief
P09577395A0000|144 154|degrees/s2
P09577395A0000|157 170|low-amplitude
P09577395A0000|178 185|degrees
P09577395A0000|192 201|rotations
P09578042A0363|34 42|patterns
P09578042A0363|70 85|seizure outcome
P09578042A0363|98 107|SEEG/ECoG
P09578042A0363|121 126|group
P09578042A0363|130 138|patients
P09578042A0363|153 166|lobe epilepsy
P09578042A0363|168 171|TLE
P09578570A0200|8 13|study
P09578570A0200|35 39|gene
P09578570A0200|44 53|protein Z
P09578570A0200|59 71|organization
P09578570A0200|76 85|structure
P09578570A0200|107 118|combination
P09578570A0200|122 139|PCR amplification
P09578570A0200|143 156|leukocyte DNA
P09578570A0200|161 170|isolation
P09578570A0200|174 186|phage clones
P09578570A0200|208 215|library
P09579602A1720|6 19|modifications
P09579602A1720|52 67|reproducibility
P09579602A1720|71 90|CD34 determinations
P09579602A1720|102 111|reduction
P09579602A1720|115 130|sample handling
P09579602A1720|135 146|calculation
P09579602A1720|150 157|results
P09579789A0974|12 19|results
P09579789A0974|37 41|rats
P09579789A0974|64 72|remnants
P09579789A0974|90 94|bulb
P09579789A0974|109 116|variety
P09579789A0974|120 134|odor detection
P09579789A0974|139 159|discrimination tasks
P09579789A0974|189 197|controls
P09579808A0000|0 10|UDP-GlcNAc
P09579808A0000|11 37|alpha-6-D-mannoside beta-1
P09579808A0000|40 71|N-acetylglucosaminyltransferase
P09579808A0000|76 79|GnT
P09579808A0000|84 86|EC
P09579808A0000|126 134|assembly
P09579808A0000|157 164|glycans
P09580062A0100|6 14|patients
P09580062A0100|48 64|cyclophosphamide
P09580062A0100|69 77|steroids
P09580062A0100|116 130|cyclosporine A
P09580062A0100|137 141|dose
P09580062A0100|147 156|mg/kg/day
P09580563A0331|14 33|amino acid sequence
P09580563A0331|41 42|%
P09580563A0331|72 78|dynein
P09580563A0331|85 90|chain
P09580563A0331|94 111|Neurospora crassa
P09580563A0331|117 118|%
P09580563A0331|152 160|nidulans
P09580563A0331|169 170|%
P09580700A0841|4 26|DNA binding activities
P09580700A0841|40 62|repressor preparations
P09580700A0841|82 91|fragments
P09580700A0841|103 107|CIRs
P09580700A0841|109 118|CIR3-CIR6
P09580700A0841|145 151|region
P09580700A0841|155 164|templates
P09580700A0841|169 174|DNase
P09580700A0841|177 189|footprinting
P09581552A1323|10 19|modelling
P09581552A1323|39 61|tetramerization domain
P09581552A1323|79 85|bundle
P09581552A1323|101 113|interactions
P09581552A1323|142 153|amino acids
P09581775A0185|15 20|study
P09581775A0185|68 86|NF-kappaB activity
P09581775A0185|130 134|U937
P09581775A0185|136 143|U9-IIIB
P09581775A0185|162 169|PLB-985
P09581775A0185|171 179|PLB-IIIB
P09581775A0185|181 186|cells
P09581775A0185|205 214|signaling
P09581834A2578|22 29|results
P09581834A2578|43 52|silymarin
P09581834A2578|89 95|effect
P09581834A2578|104 107|PCA
P09581834A2578|122 128|effect
P09581834A2578|150 160|impairment
P09581834A2578|183 200|signaling pathway
P09581834A2578|202 211|induction
P09581834A2578|215 220|CDKIs
P09581834A2578|238 247|G1 arrest
P09581872A0000|14 20|tissue
P09581872A0000|22 36|cell structure
P09581872A0000|52 56|type
P09581872A0000|59 78|collagen expression
P09582267A0326|15 23|function
P09582267A0326|50 54|Siah
P09582267A0326|56 64|proteins
P09582267A0326|66 85|expression plasmids
P09582267A0326|95 102|Siah-1A
P09582267A0326|152 157|cells
P09582267A0326|162 184|GM701 fibroblast cells
P09582267A0326|199 212|growth arrest
P09582267A0326|221 230|induction
P09582267A0326|234 243|apoptosis
P09582306T0000|2 16|point mutation
P09582306T0000|20 27|Galphao
P09582306T0000|32 40|Galphai1
P09582306T0000|48 59|interaction
P09582306T0000|65 74|regulator
P09582306T0000|78 106|G protein signaling proteins
P09582308A1165|41 50|formation
P09582308A1165|71 81|homodimers
P09582308A1165|95 104|formation
P09582308A1165|108 112|homo
P09582308A1165|118 130|heterodimers
P09582326A0151|0 2|N.
P09582326A0151|8 15|Fanning
P09582326A0151|17 19|E.
P09582327A0295|30 39|GH3 cells
P09582327A0295|61 83|rat GnRH receptor cDNA
P09582327A0295|85 91|GGH3-1
P09582327A0295|93 98|cells
P09582327A0295|112 122|expression
P09582327A0295|142 153|fusion gene
P09582327A0295|170 180|base pairs
P09582327A0295|184 199|rat LHbeta gene
P09582327A0295|212 220|sequence
P09582327A0295|237 247|base pairs
P09582327A0295|271 277|region
P09582327A0295|289 308|luciferase reporter
P09582327A0295|317 326|LHbetaLUC
P09582327A0295|345 357|GnRH agonist
P09582327A0295|373 384|stimulation
P09582327A0295|388 396|activity
P09582331A0506|16 22|region
P09582331A0506|29 39|nucleotide
P09582331A0506|63 67|TATA
P09582331A0506|81 91|CAAT boxes
P09582331A0506|103 109|GATA-1
P09582331A0506|110 113|SP1
P09582331A0506|155 163|elements
P09582343A0000|34 47|cell line SX9
P09582343A0000|61 85|carcinoma cell line FM3A
P09582350A0165|3 11|patients
P09582350A0165|17 50|type IA maple syrup urine disease
P09582350A0165|56 71|E1alpha subunit
P09582350A0165|102 106|loss
P09582350A0165|110 112|E1
P09582350A0165|132 154|ketoacid dehydrogenase
P09582350A0165|165 175|activities
P09582635A0523|0 7|Results
P09582635A0523|24 42|mean bond strength
P09582635A0523|46 62|H.T.V. specimens
P09582635A0523|88 94|kg/cm2
P09582635A0523|106 124|mean bond strength
P09582635A0523|128 144|R.T.V. specimens
P09582635A0523|170 176|kg/cm2
P09582953A0000|0 10|OBJECTIVES
P09582953A0000|23 46|coagulation factor VIII
P09582953A0000|47 56|coagulant
P09582953A0000|58 64|F.VIII
P09582953A0000|65 66|C
P09582953A0000|72 93|C1-esterase inhibitor
P09582953A0000|95 101|C1-INH
P09582953A0000|126 155|acute-phase reactant proteins
P09582953A0000|160 183|coagulation factors VII
P09582953A0000|185 190|F.VII
P09582953A0000|197 199|F.
P09582953A0000|208 209|X
P09582953A0000|211 214|F.X
P09582953A0000|217 236|hemostasis proteins
P09582953A0000|260 280|acute-phase response
P09582953A0000|294 304|population
P09582953A0000|308 314|horses
P09582953A0000|320 325|colic
P09582953A0000|330 354|hemostasis abnormalities
P09582953A0000|389 396|changes
P09582953A1097|0 7|RESULTS
P09582953A1097|9 15|Horses
P09582953A1097|21 26|colic
P09582953A1097|52 76|fibrinogen concentration
P09582953A1097|86 95|alpha 2AP
P09582953A1097|100 120|protein C activities
P09582953A1097|133 135|PT
P09582953A1097|140 144|APTT
P09582953A1097|162 168|horses
P09582953A1670|4 8|data
P09582953A1670|22 33|plasminogen
P09582953A1670|35 44|alpha 2AP
P09582953A1670|50 56|C1-INH
P09582953A1670|86 106|acute-phase proteins
P09583201A0759|0 4|None
P09583201A0759|12 20|patients
P09583208A0171|7 16|elevation
P09583208A0171|20 35|creatine kinase
P09583208A0171|55 68|serum albumin
P09583208A0171|70 84|immunoglobulin
P09583208A0171|90 100|complement
P09583592A0263|0 6|DESIGN
P09583592A0263|11 18|METHODS
P09583592A0263|20 30|Case study
P09583823A0238|0 7|METHODS
P09583823A0238|11 16|total
P09583823A0238|23 27|pigs
P09583823A0238|47 55|ligation
P09583823A0238|73 81|arteries
P09583823A0238|83 99|infarction group
P09583823A0238|101 102|n
P09583823A0238|112 116|TMLR
P09583823A0238|137 141|wall
P09583823A0238|150 157|holmium
P09583823A0238|158 182|yttrium-aluminium garnet
P09583823A0238|184 186|Ho
P09583823A0238|187 190|YAG
P09583823A0238|192 197|laser
P09583823A0238|199 210|laser group
P09583823A0238|212 213|n
P09583823A0238|250 255|group
P09583823A0238|257 258|n
P09584165T0000|0 5|RACK1
P09584165T0000|9 17|receptor
P09584165T0000|32 40|C kinase
P09584165T0000|47 54|homolog
P09584165T0000|62 74|beta subunit
P09584165T0000|78 88|G proteins
P09584165T0000|99 107|activity
P09584165T0000|111 131|src tyrosine kinases
P09584165T0000|136 142|growth
P09584165T0000|146 159|NIH 3T3 cells
P09584179A0673|0 17|Peptide sequences
P09584179A0673|25 48|zinc finger protein Ttk
P09584179A0673|57 83|transcription factor Adf-1
P09584180A0701|24 37|reporter gene
P09584180A0701|90 95|Stat6
P09584180A0701|100 118|NF-kappaB proteins
P09584180A0701|138 161|I.29mu B lymphoma cells
P09584194A0000|0 4|HEF1
P09584194A0000|6 10|p130
P09584194A0000|11 14|Cas
P09584194A0000|21 28|Efs/Sin
P09584194A0000|42 48|family
P09584194A0000|64 80|docking proteins
P09584194A0000|127 137|regulation
P09584194A0000|141 154|cell adhesion
P09584194A1305|3 10|support
P09584194A1305|16 20|role
P09584194A1305|28 35|spindle
P09584194A1305|48 65|library screening
P09584194A1305|71 75|HEF1
P09584194A1305|97 104|homolog
P09584194A1305|112 116|G2/M
P09584194A1305|136 149|protein Dim1p
P09584194A1305|164 174|interactor
P09584194A1305|182 188|region
P09584194A1305|192 196|HEF1
P09584194A1305|212 215|p55
P09584194A1305|216 220|HEF1
P09585253A1147|4 8|data
P09585253A1147|21 31|activation
P09585253A1147|39 54|raf-ERK pathway
P09585253A1147|62 72|activation
P09585253A1147|76 89|TF expression
P09585253A1147|93 115|breast carcinoma cells
P09585253A1147|148 158|activation
P09585253A1147|167 174|pathway
P09585253A1147|189 202|TF expression
P09585253A1147|206 222|MDA-MB-231 cells
P09585540A0440|25 31|enzyme
P09585540A0440|61 69|dialysis
P09585540A0440|101 126|agent 1,10-phenanthroline
P09586285A0551|4 12|patients
P09586285A0551|26 56|H. influenza type b meningitis
P09586285A0551|74 79|years
P09586832A0229|4 9|lines
P09586832A0229|69 78|receptors
P09587549T0001|11 18|seizure
P09587549T0001|28 37|treatment
P09587549T0001|43 59|interferon alpha
P09587549T0001|78 89|hepatitis C
P09588228A0370|23 38|anticytokeratin
P09588228A0370|42 50|antibody
P09588228A0370|67 75|staining
P09588228A0370|111 122|MPM tissues
P09590294A0453|8 15|studies
P09590294A0453|46 60|identification
P09590294A0453|72 82|components
P09590294A0453|90 103|Notch pathway
P09590540A0513|4 13|bZP2 cDNA
P09590540A0513|24 26|nt
P09590540A0513|32 34|kb
P09590540A0513|47 56|sequences
P09590540A0513|79 94|signal sequence
P09590540A0513|128 134|domain
P09590540A0513|140 143|PCR
P09590540A0513|158 167|Sac1-Sal1
P09590540A0513|179 187|fragment
P09590540A0513|198 203|frame
P09590540A0513|222 233|T5 promoter
P09590540A0513|244 264|lac operator control
P09590540A0513|270 283|pQE-30 vector
P09591221A0137|0 16|Control subjects
P09591221A0137|25 35|potentials
P09591221A0137|37 40|EPs
P09591221A0137|75 85|positivity
P09591221A0137|100 108|ms range
P09591221A0137|110 112|P1
P09591221A0137|139 143|site
P09592125A0000|0 5|Class
P09592125A0000|8 29|alpha1,2-mannosidases
P09592125A0000|48 52|role
P09592125A0000|60 71|elaboration
P09592125A0000|75 82|complex
P09592125A0000|87 95|hybrid N
P09592125A0000|97 104|glycans
P09592125A0000|118 123|cells
P09592168T0000|11 19|features
P09592168T0000|35 53|DNA binding domain
P09592168T0000|55 63|M98-F219
P09592168T0000|74 112|nucleotide excision repair protein XPA
P09592208A0470|14 23|qualities
P09592208A0470|29 33|book
P09592208A0470|36 46|importance
P09592208A0470|59 63|fact
P09592208A0470|108 120|construction
P09592208A0470|140 144|data
P09592208A0470|165 178|possibilities
P09592208A0470|215 225|statistics
P09592219A0652|4 11|results
P09592219A0652|25 38|effectiveness
P09592219A0652|58 70|intervention
P09593302A1165|16 28|implications
P09593302A1165|41 59|non-responsiveness
P09593302A1165|86 94|A-domain
P09593302A1165|121 128|ability
P09593302A1165|137 143|phenol
P09594299A0468|0 7|RESULTS
P09594299A0468|20 25|index
P09594299A0468|62 66|time
P09594299A0468|104 108|year
P09594299A0468|119 128|reduction
P09594299A0468|146 157|dislocation
P09594299A0468|165 168|hip
P09595496A0000|25 31|levels
P09595496A0000|35 47|endothelin-1
P09595496A0000|49 53|ET-1
P09595496A0000|88 93|fluid
P09595496A0000|97 105|patients
P09595496A0000|125 132|surgery
P09596536A0219|34 54|knee loading changes
P09596536A0219|65 80|ACL transection
P09596536A0219|108 130|cartilage degeneration
P09596542A0542|17 25|surfaces
P09596542A0542|38 54|cartilage matrix
P09596542A0542|106 110|core
P09596638T0000|12 19|mapping
P09596638T0000|27 50|Brassica S locus region
P09596638T0000|59 67|homeolog
P09596638T0000|71 82|Arabidopsis
P09596738T0000|0 5|Roles
P09596738T0000|13 29|Candida albicans
P09596738T0000|48 70|protein kinase homolog
P09596738T0000|72 77|Cek1p
P09596738T0000|89 100|development
P09596738T0000|114 125|candidiasis
P09598205A0430|12 20|reaction
P09598205A0430|24 39|monosaccharides
P09598205A0430|48 61|disaccharides
P09598205A0430|67 79|beta-alanine
P09598205A0430|96 105|formation
P09598205A0430|109 115|maltol
P09598894A0732|8 16|subjects
P09598894A0732|18 25|markers
P09598894A0732|29 43|bone formation
P09598894A0732|48 58|resorption
P09599102A1191|0 8|Analysis
P09599102A1191|14 26|Mac1p mutant
P09599102A1191|28 38|refractile
P09599102A1191|60 70|repression
P09599102A1191|78 80|Cu
P09599102A1191|81 82|I
P09599102A1191|84 99|transport genes
P09599102A1191|120 127|pattern
P09599102A1191|131 146|CUP1 expression
P09599102A1191|151 169|copper sensitivity
P09599664A0881|4 18|DNA sequencing
P09599664A0881|38 44|clones
P09599664A0881|58 68|expression
P09599664A0881|72 81|RXR alpha
P09599664A0881|86 94|RXR beta
P09599724A0193|20 26|sample
P09599724A0193|40 49|employees
P09599724A0193|57 63|cohort
P09599724A0193|67 92|phenoxy herbicide workers
P09599724A0193|130 134|PCDD
P09599724A0193|139 153|PCDF congeners
P09599724A0193|157 169|blood lipids
P09599724A0193|184 190|extent
P09599724A0193|199 203|PCDD
P09599724A0193|208 221|PCDF exposure
P09599724A0193|230 236|cohort
P09599724A0193|254 262|exposure
P09599724A0193|291 306|cancer findings
P09599724A0193|320 326|cohort
P09599897A0000|17 36|laboratory features
P09599897A0000|43 51|children
P09599897A0000|57 81|Henoch-Schonlein purpura
P09599897A0000|83 86|HSP
P09599897A0000|129 141|associations
P09599897A0000|154 172|laboratory indices
P09599897A0000|190 200|blood cell
P09599897A0000|202 205|WBC
P09599897A0000|215 220|serum
P09599897A0000|232 239|protein
P09599897A0000|241 244|CRP
P09599897A0000|246 252|levels
P09599897A0000|254 262|platelet
P09599897A0000|264 267|PLT
P09599897A0000|294 308|manifestations
P09599897A0000|318 321|HSP
P09601007A0223|11 20|community
P09601007A0223|31 35|data
P09601007A0223|61 68|changes
P09601007A0223|72 89|CO2 concentration
P09601007A0223|103 120|coral reef waters
P09601007A0223|140 149|processes
P09601007A0223|179 193|photosynthesis
P09601007A0223|195 206|respiration
P09601007A0223|208 221|calcification
P09601007A0223|227 244|CaCO3 dissolution
P09601510A0215|3 11|contrast
P09601510A0215|27 39|retroviruses
P09601510A0215|45 57|FV pol genes
P09601510A0215|84 95|transcripts
P09601516A0695|0 12|Substitution
P09601516A0695|34 42|residues
P09601516A0695|56 64|residues
P09601516A0695|72 76|PEP1
P09601516A0695|89 104|fusion activity
P09601516A0695|112 121|S protein
P09601516A0695|140 150|processing
P09601516A0695|155 173|surface expression
P09601921A0000|0 11|Tributyltin
P09601921A0000|20 38|breakdown products
P09601921A0000|50 61|di-butyltin
P09601921A0000|82 93|water birds
P09601921A0000|109 119|Lake Huron
P09601921A0000|125 136|Great Lakes
P09601921A0000|154 167|United States
P09601921A0000|177 187|west coast
P09601921A0000|191 207|British Columbia
P09601921A0000|209 215|Canada
P09601940A0280|16 22|region
P09601940A0280|30 38|CD1 gene
P09601940A0280|53 67|binding motifs
P09601940A0280|95 116|transcription factors
P09601940A0280|118 126|NF-IL2-A
P09601940A0280|131 137|NF-IL6
P09602124A0127|0 7|Fregnac
P09602124A0127|9 11|M.
P09603345A1257|0 7|GLRaV-2
P09603345A1257|20 33|closterovirus
P09603345A1257|60 79|genome organization
P09603345A1257|87 98|type member
P09603345A1257|106 111|group
P09603345A1257|113 116|BYV
P09603345A1257|175 181|member
P09603345A1257|189 208|genus Closterovirus
P09604052A0166|25 29|data
P09604052A0166|51 64|control group
P09604052A0166|92 97|women
P09604052A0166|109 115|sample
P09604052A0166|123 128|women
P09604052A0166|134 148|wrist fracture
P09605137A0677|9 19|expression
P09605137A0677|23 28|c-Jun
P09605137A0677|33 36|p65
P09605137A0677|54 67|transcription
P09605137A0677|71 84|IL-2 promoter
P09605137A0677|104 123|reporter constructs
P09605137A0677|132 137|LFA-3
P09605137A0677|161 173|Jurkat cells
P09605930A1428|10 17|results
P09605930A1428|37 50|transfections
P09605930A1428|55 76|mobility shift assays
P09605930A1428|103 118|rat hepatocytes
P09605930A1428|143 151|ALS gene
P09605934A0801|5 19|E box sequence
P09605934A0801|21 27|CACGTG
P09605934A0801|49 64|binding element
P09605934A0801|69 72|USF
P09605934A0801|95 101|factor
P09605934A0801|106 112|member
P09605934A0801|137 143|family
P09605934A0801|147 168|transcription factors
P09606633A0523|0 23|Interferon beta therapy
P09606633A0523|47 52|weeks
P09606924T0000|0 6|Liquid
P09606924T0000|23 29|method
P09606924T0000|34 42|analysis
P09606924T0000|46 78|all-rac-alpha-tocopheryl acetate
P09606924T0000|83 100|retinyl palmitate
P09606924T0000|115 129|infant formula
P09606924T0000|136 165|matrix solid-phase dispersion
P09609342A0000|23 28|types
P09609342A0000|32 43|turbo pumps
P09609342A0000|59 63|pump
P09609342A0000|65 68|CFP
P09609342A0000|79 88|flow pump
P09609342A0000|90 93|MFP
P09609342A0000|109 118|flow pump
P09609342A0000|120 123|AFP
P09609342A0000|154 165|performance
P09609705A0895|0 11|Examination
P09609705A0895|33 62|bc1 complex crystal structure
P09609705A0895|64 69|Zhang
P09609705A0895|71 73|Z.
P09609705A0895|75 80|Huang
P09609705A0895|82 84|L.
P09609705A0895|86 97|Shulmeister
P09609705A0895|99 101|V.
P09609720A0357|23 32|fragments
P09609720A0357|46 47|N
P09609720A0357|64 70|halves
P09609720A0357|78 86|nuclease
P09609720A0357|119 128|proteases
P09609720A0357|146 153|protein
P09609720A0357|166 172|region
P09610755A1731|4 27|side-to-side difference
P09610755A1731|61 64|EXT
P09610755A1731|68 77|degrees/s
P09610755A1731|85 94|degrees/s
P09610755A1731|96 97|p
P09611016A0652|0 10|CONCLUSION
P09611016A0652|15 20|women
P09611016A0652|54 64|management
P09611016A0652|68 73|grade
P09611016A0652|76 84|prolapse
P09611016A0652|119 126|pessary
P09611016A0652|132 141|placement
P09611016A0652|149 158|pessaries
P09611229A1664|4 11|ability
P09611229A1664|24 34|expression
P09611229A1664|38 42|FAS1
P09611229A1664|46 71|nmt1-451Dino2 Delta cells
P09611229A1664|85 94|existence
P09611229A1664|106 126|transcription factor
P09611229A1664|131 138|factors
P09611229A1664|146 165|expression/activity
P09611229A1664|198 204|levels
P09611229A1664|217 242|protein N-myristoy-lation
P09611234A0098|0 18|Rev-erbAalpha/beta
P09611234A0098|21 26|Mxi-1
P09611234A0098|31 52|Mad bHLH-zip proteins
P09611234A0098|61 78|oncoproteins PLZF
P09611234A0098|83 92|LAZ3/BCL6
P09611234A0098|112 130|corepressors N-CoR
P09611234A0098|135 139|SMRT
P09611877A0455|15 23|isolates
P09611877A0455|27 30|CSF
P09611877A0455|61 65|ECHO
P09611877A0455|74 78|ECHO
P09611877A0455|89 93|ECHO
P09612351A0386|13 21|evidence
P09612351A0386|40 51|oscillation
P09612351A0386|63 71|ULF band
P09612775A0726|4 20|ParaSight-F test
P09612775A0726|47 67|serum antigen levels
P09612775A0726|74 83|treatment
P09612775A0726|90 98|patients
P09613574A0905|25 32|protein
P09613574A0905|53 68|enzyme activity
P09613574A0905|83 91|transfer
P09613574A0905|96 98|3H
P09613574A0905|99 112|methyl groups
P09613574A0905|122 135|substrate DNA
P09613574A0905|143 155|MGMT protein
P09613574A0905|161 169|activity
P09613574A0905|199 208|degrees C
P09613574A0905|225 228|min
P09613946A0194|2 28|deproteinization procedure
P09613946A0194|63 78|HPLC separation
P09613946A0194|95 102|mm I.D.
P09614065A0966|0 11|Elimination
P09614065A0966|29 37|response
P09614065A0966|60 68|mutation
P09614065A0966|77 86|sequences
P09614065A0966|104 112|presence
P09614065A0966|126 130|EpRE
P09614065A0966|144 153|AP-1 site
P09614065A0966|171 180|induction
P09614106T0000|11 19|mobility
P09614106T0000|31 40|sequences
P09614106T0000|58 71|pair enhancer
P09614106T0000|79 90|Col2a1 gene
P09614106T0000|127 137|expression
P09617765A0174|4 12|sequence
P09617765A0174|30 43|reading frame
P09617765A0174|52 54|nt
P09617765A0174|74 80|strand
P09617765A0174|100 106|region
P09617765A0174|115 117|nt
P09617765A0174|127 131|poly
P09617765A0174|132 133|A
P09617765A0174|135 139|tail
P09617807A0929|15 23|analysis
P09617807A0929|39 59|transcriptase domain
P09617807A0929|94 104|assessment
P09617807A0929|110 117|Cyclops
P09617807A0929|123 126|pea
P09617807A0929|138 145|element
P09617807A0929|163 175|relationship
P09617807A0929|215 223|elements
P09617807A0929|229 235|plants
P09618150A0127|17 22|doses
P09618150A0127|44 59|growth factor I
P09618150A0127|61 66|IGF-I
P09618150A0127|71 78|insulin
P09618150A0127|109 123|dibutyryl cAMP
P09618150A0127|125 131|dbcAMP
P09618150A0127|147 175|UCP1 gene transcription rate
P09618150A0127|179 180|h
P09618150A0127|191 213|UCP1 mRNA accumulation
P09618150A0127|217 218|h
P09618150A0127|235 241|effect
P09618150A0127|251 259|increase
P09618150A0127|274 283|treatment
P09618150A0127|291 293|h.
P09618150A1464|3 11|addition
P09618150A1464|13 20|insulin
P09618150A1464|29 54|AP-1 DNA binding activity
P09618150A1464|61 67|effect
P09618150A1464|99 107|presence
P09618150A1464|111 126|MEK-1 inhibitor
P09618164A0709|17 18|O
P09618164A0709|20 47|methyl oligoribonucleotides
P09618164A0709|51 57|OMeRNA
P09618164A0709|81 87|nuclei
P09618164A0709|99 112|mdx myoblasts
P09618164A0709|116 123|culture
P09618475A0747|8 16|deletion
P09618475A0747|36 41|motif
P09618475A0747|49 64|down-regulation
P09618475A0747|99 107|function
P09618475A0747|111 115|Nrd1
P09618481T0000|0 10|Regulation
P09618481T0000|24 46|p21/WAF1/Cip1 promoter
P09618481T0000|58 63|cells
P09618481T0000|78 90|interactions
P09618481T0000|99 102|Sp1
P09618481T0000|107 126|Smad family members
P09619631A0344|0 7|RESULTS
P09619631A0344|23 38|C. elegans cDNA
P09619631A0344|54 61|protein
P09619631A0344|126 138|p120 Ras-GAP
P09619777A1583|9 26|base ketoconazole
P09619777A1583|43 54|dissolution
P09619777A1583|69 80|formulation
P09619777A1583|102 107|Fluid
P09619777A1583|116 122|pepsin
P09619777A1583|124 129|SGFsp
P09619777A1583|141 148|minutes
P09619777A1583|152 165|% dissolution
P09619777A1583|171 176|hours
P09619777A1583|187 192|state
P09619777A1583|217 227|conditions
P09619777A1583|238 251|% dissolution
P09619777A1583|257 262|hours
P09619777A1583|276 292|state conditions
P09620273A0189|3 10|mammals
P09620273A0189|16 26|Rb protein
P09620273A0189|62 69|cyclins
P09620273A0189|84 102|cell proliferation
P09620273A0189|106 113|binding
P09620273A0189|129 154|E2F transcription factors
P09620606A0000|3 11|addition
P09620606A0000|19 26|signals
P09620606A0000|39 47|ligation
P09620606A0000|55 58|TCR
P09620606A0000|60 67|T cells
P09620606A0000|100 107|signals
P09620873A1710|14 25|observation
P09620873A1710|38 67|luteal HSP-27 phosphorylation
P09620873A1710|85 94|pregnancy
P09620873A1710|101 110|PKC-delta
P09620873A1710|156 174|PKC family members
P09620873A1710|189 216|sHSP phosphorylation events
P09620955A0370|21 30|structure
P09620955A0370|39 50|leader mRNA
P09620955A0370|64 77|program Mfold
P09620955A0370|84 95|combination
P09620955A0370|119 128|deletions
P09620955A0370|171 181|lac operon
P09621062A0810|4 14|importance
P09621062A0810|24 29|sites
P09621062A0810|50 60|activation
P09621062A0810|90 101|mutagenesis
P09621062A0810|114 140|promoter function analysis
P09621062A0810|148 155|mutants
P09621062A0810|163 212|chloramphenicol acetyltransferase reporter system
P09621372A0369|8 25|blood examination
P09621372A0369|33 45|leukocytosis
P09621372A0369|47 63|thrombocytopenia
P09621372A0369|74 77|CRP
P09621372A0369|103 110|enzymes
P09621893A0000|9 16|studies
P09621893A0000|54 63|increases
P09621893A0000|68 82|responsiveness
P09621893A0000|95 115|alpha2-adrenoceptors
P09622055A0207|4 11|members
P09622055A0207|19 29|Cbl family
P09622055A0207|57 64|mammals
P09622055A0207|66 71|c-Cbl
P09622055A0207|76 81|Cbl-b
P09622055A0207|91 101|C. elegans
P09622055A0207|103 108|Sli-1
P09622055A0207|133 138|D-Cbl
P09622121A0525|9 19|antibodies
P09622121A0525|40 47|binding
P09622121A0525|51 54|PTB
P09622121A0525|58 61|RNA
P09622121A0525|88 116|supershift RNA-PTB complexes
P09622121T0000|4 7|use
P09622121T0000|11 21|antibodies
P09622121T0000|29 65|polypyrimidine tract binding protein
P09622121T0000|67 70|PTB
P09622121T0000|87 105|protein components
P09622121T0000|145 154|pre-mRNAs
P09622121T0000|172 185|branch points
P09623830A0000|16 19|use
P09623830A0000|23 38|botulinum toxin
P09623830A0000|40 45|Botox
P09623830A0000|64 74|popularity
P09625762A0426|10 25|oncoprotein E1A
P09625762A0426|50 65|transactivation
P09625762A0426|86 92|manner
P09625807A0000|20 24|mRNA
P09625807A0000|38 52|display method
P09625807A0000|76 81|mRNAs
P09625807A0000|134 147|cell cultures
P09625807A0000|172 192|carcinoma cell lines
P09626662A1076|8 19|experiments
P09626662A1076|25 27|TR
P09626662A1076|45 53|affinity
P09626662A1076|57 63|RIP140
P09626662A1076|71 82|RXR subunit
P09626662A1076|112 119|partner
P09626662A1076|127 145|TR/RXR heterodimer
P09626662A1076|175 181|ligand
P09627285A0160|0 7|SETTING
P09627285A0160|9 19|University
P09627285A0160|45 68|care infertility center
P09627285A0554|0 6|RESULT
P09627285A0554|7 8|S
P09627285A0554|14 22|patients
P09627285A0554|37 47|FSH levels
P09627285A0554|51 60|cycle day
P09627285A0554|70 82|oocyte yield
P09627285A0554|121 127|number
P09627285A0554|131 138|ampules
P09627285A0554|142 145|hMG
P09627598A0384|0 7|RESULTS
P09627598A0384|16 24|patients
P09627598A0384|36 37|%
P09627598A0384|64 70|values
P09627598A0384|86 99|preponderance
P09627598A0384|107 116|OVAR test
P09627598A0384|120 127|measure
P09627598A0384|131 155|otolith system imbalance
P09627598A0384|179 187|subjects
P09628375A0700|7 22|ePTFE specimens
P09628375A0700|24 39|tissue coverage
P09628419A0812|20 24|Wing
P09628419A0812|29 48|Kristofferson model
P09628419A0812|54 63|durations
P09628419A0812|78 82|ISIs
P09628821A1194|22 38|KG1a EST dataset
P09628821A1194|43 53|candidates
P09628821A1194|68 73|genes
P09628821A1194|88 93|roles
P09628821A1194|127 138|progression
P09628821A1194|143 161|lineage commitment
P09628890A0455|13 22|following
P09628890A0455|33 42|mutations
P09628890A0455|64 86|carbohydrate structure
P09628890A0455|106 115|HA trimer
P09629449A0540|4 11|results
P09629449A0540|22 36|ROS production
P09629449A0540|47 58|spermatozoa
P09629449A0540|89 102|concentration
P09629449A0540|106 118|PMN elastase
P09629449A0540|127 133|number
P09629449A0540|172 177|cells
P09630245A0102|0 14|Yeast U1 snRNP
P09630245A0102|62 73|counterpart
P09630245A0102|99 110|differences
P09630245A0102|119 124|yeast
P09630245A0102|129 136|metazoa
P09630245A0102|146 161|splicing events
P09630245A0903|0 14|Yeast U1 snRNP
P09630245A0903|47 55|proteins
P09630245A0903|73 92|snRNP core proteins
P09630245A0903|100 110|homologues
P09630245A0903|118 129|metazoan U1
P09630245A0903|145 153|proteins
P09630245A0903|178 195|U1 snRNP proteins
P09631366A0951|16 21|cycle
P09631366A0951|26 31|cases
P09631366A0951|48 58|dose level
P09631366A0951|77 82|cycle
P09631366A0951|87 92|cases
P09631366A0951|109 119|dose level
P09632217A0477|11 32|antagonist naltrexone
P09632217A0477|43 48|mg/kg
P09632217A0477|81 97|stimulus effects
P09632217A0477|101 107|heroin
P09632217A0477|113 123|naltrexone
P09632217A0477|127 132|doses
P09632217A0477|142 147|mg/kg
P09632217A0477|155 161|effect
P09632217A0477|184 200|stimulus effects
P09632217A0477|204 211|cocaine
P09632637A0361|8 13|study
P09632637A0361|43 58|cell regulation
P09632637A0361|62 83|M6P/IGFIIR expression
P09632637A0361|99 132|M6P/IGFIIR mRNA transcript levels
P09632637A0361|155 160|cells
P09632637A0361|166 170|rats
P09632637A0361|182 202|carbon tetrachloride
P09632637A0361|204 208|CCl4
P09632637A0361|231 240|stimulant
P09632709A0464|4 14|cDNA clone
P09632709A0464|26 33|NCoA-62
P09632709A0464|56 63|protein
P09632709A0464|90 94|BX42
P09632709A0464|130 137|protein
P09632709A0464|170 185|gene expression
P09632734A0081|23 31|proteins
P09632734A0081|51 57|region
P09632734A0081|81 98|sequence homology
P09632734A0081|104 109|group
P09632734A0081|113 138|GDP/GTP exchange proteins
P09632734A0081|147 158|Rab3 family
P09632734A0081|168 188|GTP binding proteins
P09632734A0943|8 22|p82 expression
P09632734A0943|30 36|effect
P09632734A0943|40 55|ERK2 activation
P09632734A0943|59 63|p126
P09632734A0943|65 68|p70
P09632734A0943|95 103|activity
P09632785A0000|4 33|pre-mRNA splicing factor U2AF
P09632785A0000|35 37|U2
P09632785A0000|52 78|ribonucleoprotein particle
P09632785A0000|80 85|snRNP
P09632785A0000|97 103|factor
P09632785A0000|122 126|role
P09632785A0000|133 154|splice site selection
P09633171A0321|4 12|brackets
P09633171A0321|57 65|incisors
P09633171A0321|78 85|storage
P09633171A0321|89 98|tap water
P09633171A0321|102 118|room temperature
P09633171A0321|126 131|hours
P09633171A0321|168 178|shear mode
P09633171A0321|197 212|testing machine
P09633274A0000|0 17|Exercise training
P09633274A0000|59 68|treatment
P09633274A0000|72 94|heart failure patients
P09633630A0740|4 10|growth
P09633630A0740|14 17|Aer
P09633630A0740|19 29|hydrophila
P09633630A0740|51 66|lettuce extract
P09633630A0740|98 99|%
P09633630A0740|101 104|v/v
P09633630A0740|106 109|BMC
P09633630A0740|126 128|Ps
P09633630A0740|130 141|fluorescens
P09633630A0740|177 178|%
P09633630A0740|180 183|v/v
P09633630A0740|185 188|BMC
P09633879A0246|19 29|compliance
P09633879A0246|43 53|resurgence
P09633879A0246|57 78|serum ferritin levels
P09633879A0246|95 103|patients
P09633879A0246|112 119|veteran
P09633879A0246|121 126|group
P09633879A0246|137 142|years
P09633879A0246|146 148|L1
P09635149A1148|0 10|Hematocrit
P09635149A1148|15 19|PaO2
P09635276A1608|0 10|Regulation
P09635276A1608|14 41|myosin phosphatase activity
P09635276A1608|51 58|changes
P09635276A1608|62 82|subunit interactions
P09635276A1608|103 113|mechanisms
P09636119T0000|21 30|generator
P09636119T0000|69 74|plant
P09636119T0000|80 87|pulleys
P09636358A0000|21 28|VAI RNA
P09636358A0000|32 42|adenovirus
P09636358A0000|72 75|RNA
P09636358A0000|111 122|translation
P09636358A0000|145 150|mRNAs
P09636358A0000|159 164|times
P09636358A0000|171 180|infection
P09636670T0000|0 9|Structure
P09636670T0000|17 21|gene
P09636670T0000|58 78|kinase inhibitor p18
P09636670T0000|94 102|analysis
P09636670T0000|106 119|breast cancer
P09636708A0460|4 16|YccA protein
P09636708A0460|63 69|manner
P09636708A0460|104 110|YccA11
P09636708A0460|118 125|protein
P09636708A0460|141 160|amino acid residues
P09636708A0460|199 205|domain
P09636708A0460|229 240|degradation
P09637689A0150|10 14|type
P09637689A0150|24 42|activator proteins
P09637689A0150|56 59|DNA
P09637689A0150|82 96|RNA polymerase
P09637689A0150|98 102|RNAP
P09637689A0150|104 114|holoenzyme
P09637689A0150|143 154|recruitment
P09637689A0150|162 166|RNAP
P09637689A0150|174 182|promoter
P09638342T0000|12 16|role
P09638342T0000|21 23|L1
P09638342T0000|43 47|link
P09638342T0000|65 73|adhesion
P09638342T0000|78 108|membrane cytoskeleton assembly
P09638485A0111|12 19|benzene
P09638485A0111|37 41|acid
P09638485A0111|43 48|tt-MA
P09638485A0111|54 93|leukocyte alkaline phosphatase activity
P09638485A0111|95 99|LAPA
P09638485A0111|125 138|car mechanics
P09638485A0111|143 162|road tanker drivers
P09638485A0111|182 189|workers
P09638650A0169|27 33|region
P09638650A0169|35 38|NCR
P09638650A0169|46 57|nucleotides
P09638650A0169|69 83|reading frames
P09638650A0169|85 89|ORFs
P09638650A0169|111 119|proteins
P09638650A0169|125 126|M
P09638650A0169|127 128|r
P09638650A0169|134 137|kDa
P09638650A0169|152 166|RNA polymerase
P09638650A0169|168 172|ORF1
P09638650A0169|178 198|kDa movement protein
P09638650A0169|202 206|ORF2
P09638650A0169|212 232|kDa movement protein
P09638650A0169|236 240|ORF3
P09638650A0169|246 266|kDa movement protein
P09638650A0169|270 274|ORF4
P09638650A0169|280 296|kDa coat protein
P09638650A0169|298 302|OFR5
P09638650A0169|314 317|NCR
P09638650A0169|324 335|nucleotides
P09638793A1446|28 40|hemodilution
P09638793A1446|42 45|Hct
P09638793A1446|47 48|%
P09638793A1446|50 61|superiority
P09638793A1446|65 70|LV MC
P09638793A1446|75 77|LV
P09638793A1446|88 98|properties
P09638793A1446|126 137|oxygenation
P09638793A1446|155 179|i.v. perflubron emulsion
P09638793A1446|196 203|carrier
P09639074A0707|0 3|Sp1
P09639074A0707|12 24|Sp3 isoforms
P09639074A0707|63 75|constituents
P09639074A0707|91 100|complexes
P09639074A0707|136 140|site
P09639410A3282|6 11|genes
P09639410A3282|38 45|targets
P09639410A3282|66 76|strategies
P09639558A0957|36 46|haemolysis
P09639558A0957|55 58|IgG
P09639558A0957|79 91|erythrocytes
P09639565A0225|46 63|enhancer activity
P09639565A0225|77 82|cells
P09639565A0225|111 124|SV40 promoter
P09640162A0242|11 18|patient
P09640162A0242|50 64|growth hormone
P09640162A0242|69 78|treatment
P09640162A0242|82 107|growth hormone deficiency
P09640162A0242|130 148|ventricle teratoma
P09640162A0242|160 162|yr
P09640802A0467|43 55|consequences
P09640802A0467|71 75|flap
P09640802A0467|95 108|possibilities
P09640802A0467|116 127|flap choice
P09641167A1359|0 10|CONCLUSION
P09641167A1359|12 21|TNF alpha
P09641167A1359|23 31|TGF beta
P09641167A1359|33 37|PDGF
P09641167A1359|42 50|IL-1beta
P09641167A1359|61 81|LDLr gene expression
P09641167A1359|143 161|gene transcription
P09642042A0646|0 18|Binding affinities
P09642042A0646|32 47|nucleotide mono
P09642042A0646|58 71|triphosphates
P09642042A0646|93 100|analogs
P09642042A0646|119 140|beta-phosphate moiety
P09642042A0646|157 174|substrate binding
P09642200A0956|47 51|size
P09642200A0956|59 71|proteolipids
P09642200A0956|77 99|M. thermoautotrophicum
P09642200A0956|104 117|M. jannaschii
P09642200A0956|133 137|ahaK
P09642200A0956|216 224|membrane
P09642200A0956|247 263|chemical natures
P09642200A0956|267 273|lipids
P09642200A0956|279 286|archaea
P09642200A0956|291 299|bacteria
P09642214A0244|8 14|report
P09642214A0244|30 34|role
P09642214A0244|55 72|phosphatase SHP-2
P09642214A0244|90 100|activation
P09642214A0244|122 136|protein kinase
P09642214A0244|138 142|MAPK
P09642214A0244|162 175|SHP-2 mutants
P09642214A0244|179 190|COS-7 cells
P09642227A0000|0 12|Osteoadherin
P09642227A0000|37 54|bone proteoglycan
P09642227A0000|66 81|keratan sulfate
P09642238A0532|0 6|Intron
P09642238A0532|46 63|enhancer activity
P09642238A1285|4 10|intron
P09642238A1285|13 28|enhancer region
P09642238A1285|50 56|GATA-1
P09642238A1285|71 74|Sp1
P09642238A1285|78 105|transactivation experiments
P09642238A1285|109 120|COS-1 cells
P09642238A1285|136 147|involvement
P09642238A1285|161 172|Sp1 protein
P09642238A1285|210 216|factor
P09642276A0881|4 12|cleavage
P09642276A0881|16 19|Fak
P09642276A0881|23 31|caspases
P09642276A0881|59 63|role
P09642276A0881|71 80|execution
P09642276A0881|88 103|suicide program
P09642276A0881|136 144|function
P09642276A0881|148 151|Fak
P09642764A0469|14 18|mass
P09642764A0469|38 50|QCM response
P09642764A0469|63 81|Sauerbrey equation
P09642764A0469|90 94|mass
P09642764A0469|117 123|thanks
P09642764A0469|144 154|techniques
P09642764A0469|163 167|case
P09642764A0469|181 186|assay
P09642764A0469|217 221|mass
P09642764A0469|256 259|QCM
P09643153T0000|1 10|Treatment
P09643153T0000|20 22|T1
P09643153T0000|29 47|T2N breast cancers
P09643546A0436|0 24|Transcription initiation
P09643546A0436|81 89|promoter
P09643546A0436|115 120|cells
P09643546A0436|143 160|stress conditions
P09643548A0000|4 9|genes
P09643548A0000|20 26|2Fe-2S
P09643548A0000|39 50|ferredoxins
P09643548A0000|83 119|cyanobacterium Synechocystis PCC6803
P09645576A0148|0 3|RNA
P09645576A0148|7 12|GBV-C
P09645576A0148|35 36|%
P09645576A0148|38 46|patients
P09645576A0148|54 57|BMT
P09645942A1164|8 12|pool
P09645942A1164|16 41|Dsg-plakoglobin complexes
P09645942A1164|56 58|8S
P09645942A1164|79 92|stoichiometry
P09645961A1158|4 11|results
P09645961A1158|30 37|binding
P09645961A1158|41 49|CBF/NF-Y
P09645961A1158|66 75|CCAAT box
P09645961A1158|111 121|activation
P09645961A1158|129 138|nTPH gene
P09647233A0336|3 14|macrophages
P09647233A0336|30 51|HIV-1 gene expression
P09647233A0336|67 71|part
P09647233A0336|75 82|binding
P09647233A0336|86 96|NF-kappa B
P09647233A0336|117 130|binding sites
P09647233A0336|164 170|repeat
P09647233A0336|172 175|LTR
P09647240A0000|4 13|influence
P09647240A0000|17 20|p53
P09647240A0000|43 70|Janus kinase-STAT signaling
P09647240A0000|97 122|hepatoma Hep3B cell lines
P09647240A0000|186 199|Val135 mutant
P09647240A0000|203 206|p53
P09649069A0490|39 59|laryngeal parameters
P09649069A0490|113 125|examinations
P09649265A1575|0 11|CONCLUSIONS
P09649265A1575|29 33|sets
P09649265A1575|49 59|ultrasound
P09649265A1575|75 83|biopsies
P09649265A1575|91 99|prostate
P09649265A1575|122 134|office visit
P09649265A1575|162 177|biopsy strategy
P09649265A1575|182 185|men
P09649265A1575|229 240|examination
P09649265A1575|257 266|serum PSA
P09649315A0943|0 11|Examination
P09649315A0943|32 41|resonance
P09649315A0943|43 46|NMR
P09649315A0943|48 55|spectra
P09649315A0943|61 67|series
P09649315A0943|94 113|MIP-1 beta variants
P09649315A0943|133 141|proteins
P09649315A0943|152 157|range
P09649315A0943|161 168|ability
P09649426A0636|15 27|PKA activity
P09649426A0636|48 54|strain
P09649426A0636|63 68|Msn2p
P09649426A0636|73 87|Msn4p activity
P09649437A1140|31 43|interactions
P09649437A1140|52 58|C/EBPs
P09649437A1140|72 90|Ets family members
P09649437A1140|106 112|GATA-1
P09649437A1140|132 164|eosinophil lineage determination
P09649438A0182|18 56|transcription elongation factor P-TEFb
P09649438A0182|72 83|CDK9 kinase
P09649438A0182|85 93|cyclin T
P09649438A0182|115 122|factors
P09649438A0182|156 159|Tat
P09649438A0182|171 185|Tat activation
P09649438A0182|189 193|HeLa
P09649438A0182|202 209|extract
P09649438A0182|222 228|P-TEFb
P09649501A0358|29 36|repeats
P09649501A0358|44 69|HSF1 trimerization domain
P09649501A0358|77 82|yeast
P09649501A0358|94 119|protein interaction assay
P09649501A0358|132 165|heat shock factor binding protein
P09649501A0358|169 174|HSBP1
P09649501A0358|211 218|protein
P09649501A0358|246 252|arrays
P09649501A0358|268 275|repeats
P09649501A0358|299 318|HSF1 heptad repeats
P09649537A0000|12 23|cDNA clones
P09649537A0000|42 70|yeast GCN2 eIF-2alpha kinase
P09649537A0000|72 77|yGCN2
P09650180A1130|12 25|recombination
P09650180A1130|42 49|voltage
P09650180A1130|57 58|V
P09650180A1130|73 74|%
P09650180A1130|79 89|dose-rates
P09650180A1130|106 115|mGy min-1
P09650186A1043|8 14|number
P09650186A1043|24 33|positives
P09650186A1043|53 59|scheme
P09650186A1043|82 93|radiologist
P09650186A1043|115 122|regions
P09650275T0000|29 47|weapons convention
P09650275T0000|52 64|implications
P09650275T0000|91 113|biotechnology industry
P09650299A0000|0 5|VirD2
P09650299A0000|24 58|Agrobacterium tumefaciens proteins
P09650299A0000|77 87|processing
P09650299A0000|92 100|transfer
P09650299A1334|22 26|data
P09650299A1334|45 50|VirD2
P09650299A1334|57 63|domain
P09650299A1334|97 108|integration
P09650403A0868|4 16|DHEAS levels
P09650403A0868|24 30|stages
P09650403A0868|44 47|BMD
P09650403A0868|91 96|group
P09650403A0868|109 112|BMD
P09650789A0185|0 11|Orientation
P09650789A0185|27 38|spin system
P09650789A0185|68 84|Overhauser shift
P09650789A0185|102 115|energy levels
P09650789A0185|136 142|degree
P09650789A0185|154 165|orientation
P09651321A0000|0 10|Cystatin A
P09651321A0000|14 43|cysteine proteinase inhibitor
P09651321A0000|59 77|precursor proteins
P09651321A0000|91 104|cell envelope
P09651321A0000|108 121|keratinocytes
P09651321A0000|155 160|stage
P09651321A0000|164 192|keratinocyte differentiation
P09651367T0000|2 6|role
P09651367T0000|11 17|RalGDS
P09651367T0000|30 42|Ras effector
P09651367T0000|63 73|inhibition
P09651367T0000|86 96|myogenesis
P09651375T0000|0 6|GTPase
P09651375T0000|18 29|specificity
P09651375T0000|33 38|RGS12
P09651375T0000|43 62|binding specificity
P09651375T0000|91 94|PDZ
P09651375T0000|96 102|PSD-95
P09651375T0000|103 109|Dlg/ZO
P09651375T0000|113 119|domain
P09651383A0967|9 18|mutations
P09651383A0967|26 44|HNF-4 binding site
P09651383A0967|48 60|element CIIB
P09651383A0967|65 75|inhibition
P09651383A0967|79 94|HNF-4 synthesis
P09651383A0967|98 109|HepG2 cells
P09651383A0967|123 139|HNF-4 constructs
P09651383A0967|154 178|apoCII promoter activity
P09651383A0967|187 188|%
P09651383A0967|196 203|control
P09651383A0967|221 226|HNF-4
P09651383A0967|241 250|regulator
P09651383A0967|258 269|apoCII gene
P09652736A1205|3 11|addition
P09652736A1205|26 31|E2F-1
P09652736A1205|42 51|apoptosis
P09652736A1205|55 58|p53
P09652736A1205|62 74|tumour cells
P09652736A1205|87 91|p300
P09652736A1205|119 131|co-activator
P09652736A1205|140 158|E2F/DP heterodimer
P09652736A1205|183 191|activity
P09652736A1205|195 200|E2F-1
P09652737A1244|25 33|analysis
P09652737A1244|49 75|Fos family member proteins
P09652737A1244|87 92|Fra-1
P09652737A1244|97 102|Fra-2
P09652737A1244|118 129|progression
P09652737A1244|137 144|changes
P09652737A1244|158 184|Jun family member proteins
P09652737A1244|218 222|AP-1
P09652737A1244|223 242|DNA binding complex
P09652742A0455|38 41|p53
P09652742A0455|88 94|glands
P09652742A0455|110 116|tumors
P09652742A0455|145 151|strain
P09653182A1298|6 10|data
P09653182A1298|34 44|virus RNAs
P09653182A1298|46 50|BSMV
P09653182A1298|65 78|primer donors
P09653182A1298|83 92|MStV mRNA
P09653182A1298|111 124|transcription
P09653182A1298|144 150|plants
P09653641A0471|6 14|isoforms
P09653641A0471|65 76|start codon
P09653648A0445|0 10|Comparison
P09653648A0445|14 18|cDNA
P09653648A0445|31 40|sequences
P09653648A0445|56 67|ZNF189 gene
P09653648A0445|91 93|kb
P09653648A0445|130 135|exons
P09653648A0445|150 158|end exon
P09653648A0445|183 201|zinc finger domain
P09653648A0445|226 232|region
P09653745A0180|0 7|Malaria
P09653745A0180|50 55|1940s
P09653745A0180|66 79|paper queries
P09653745A0180|93 102|reduction
P09653745A0180|118 134|control projects
P09653745A0180|142 150|thirties
P09653745A0180|177 185|projects
P09653745A0180|198 203|model
P09653745A0180|231 236|world
P09653745A0180|244 251|malaria
P09653745A0180|265 278|problem today
P09655248A0000|4 21|gp330/Megalin/LRP
P09655248A0000|24 31|protein
P09655248A0000|59 91|lipoprotein receptor gene family
P09655248A0000|136 144|receptor
P09655248A0000|153 159|uptake
P09655248A0000|163 175|lipoproteins
P09655248A0000|191 198|ligands
P09655916A0415|7 28|DNA recognition helix
P09655916A0415|32 38|finger
P09655916A0415|57 60|Arg
P09655916A0415|64 72|position
P09655916A0415|88 92|side
P09655916A0415|124 133|histidine
P09655916A0415|152 155|Leu
P09655916A0415|159 162|Gln
P09656414A0220|0 6|Dosage
P09656414A0220|15 20|cases
P09656414A0220|29 33|g/m2
P09656485A0351|16 22|copies
P09656485A0351|31 39|elements
P09656485A0351|65 86|restriction digestion
P09657003T0000|13 26|relationships
P09657003T0000|56 71|RNA polymerases
P09657003T0000|110 113|RNA
P09657003T0000|127 145|elm disease fungus
P09657003T0000|147 167|Ophiostoma novo-ulmi
P09657003T0000|178 185|viruses
P09657003T0000|201 205|RNAs
P09657003T0000|217 228|Arabidopsis
P09657003T0000|243 249|genome
P09658104T0000|0 4|Role
P09658104T0000|12 48|transcription start site core region
P09658104T0000|53 77|transcription factor YY1
P09658104T0000|81 99|Rous sarcoma virus
P09658104T0000|114 138|repeat promoter activity
P09658122T0000|0 13|Fowlpox virus
P09658122T0000|35 43|homologs
P09658122T0000|56 66|alpha-SNAP
P09658122T0000|68 72|PC-1
P09658122T0000|94 101|homolog
P09658122T0000|116 132|nematode protein
P09658403A1207|0 8|Addition
P09658403A1207|12 15|Rap
P09658403A1207|19 23|KN62
P09658403A1207|30 38|exposure
P09658403A1207|42 47|cells
P09658403A1207|51 75|progesterone agonist Org
P09658403A1207|88 94|effect
P09658403A1207|98 107|induction
P09658403A1207|111 123|CAT activity
P09658405A0000|4 14|Dax-1 gene
P09658405A0000|25 32|protein
P09658405A0000|65 72|members
P09658405A0000|80 86|orphan
P09658405A0000|95 115|receptor superfamily
P09658769A0058|32 44|IFN alpha-2b
P09658769A0058|55 64|diagnosis
P09658769A0058|76 88|hepatitis C.
P09660823A0934|9 32|Ser/Thr phosphorylation
P09660823A0934|47 60|molecules Akt
P09660823A0934|65 78|p70 S6 kinase
P09660836A0983|13 23|evaluation
P09660836A0983|38 52|state kinetics
P09660836A0983|56 70|MEK inhibition
P09660836A0983|80 89|compounds
P09660836A0983|103 108|U0126
P09660836A0983|143 151|affinity
P09660836A0983|156 169|deltaN3-S218E
P09660836A0983|170 179|S222D MEK
P09660836A0983|190 198|PD098059
P09660838A0920|0 10|Regulation
P09660838A0920|17 26|degrees C
P09660838A0920|52 58|action
P09660838A0920|68 91|protein kinase cascades
P09660838A0920|105 109|HSF1
P09660838A0920|118 133|phosphorylation
P09660838A0920|137 152|serine residues
P09660838A0920|187 193|growth
P09660838A0920|213 232|heat shock response
P09661676T0000|9 20|implication
P09661676T0000|24 38|protein levels
P09661676T0000|42 46|IL-5
P09661676T0000|58 64|sputum
P09661676T0000|78 86|patients
P09662339A0744|9 14|cells
P09662339A0744|28 38|transition
P09662339A0744|66 75|induction
P09662339A0744|92 100|activity
P09662339A0744|122 132|expression
P09662339A0744|136 145|CD44 mRNA
P09662339A0744|150 157|protein
P09662443A0402|47 59|organization
P09662443A0402|78 88|expression
P09662443A0402|96 116|caveolin gene family
P09663062A0175|0 22|Tensile bond strengths
P09663062A0175|31 36|resin
P09663062A0175|58 64|dentin
P09663062A0175|71 77|dentin
P09663062A0175|87 94|systems
P09663062A0175|96 118|Clearfil Liner Bond II
P09663062A0175|120 122|LB
P09663062A0175|127 151|Scotchbond Multi-Purpose
P09663062A0175|153 155|MP
P09663062A0175|157 172|bonding systems
P09663062A0175|188 195|scatter
P09663062A0175|202 210|students
P09663062A0175|215 223|dentists
P09664033A1204|5 17|distribution
P09664033A1204|49 58|precursor
P09664033A1204|80 89|nucleolus
P09664033A1204|119 126|snoRNAs
P09664033A1204|141 147|import
P09664033A1204|151 169|processing pathway
P09664033A1204|186 192|bodies
P09665361T0000|12 19|therapy
P09665361T0000|24 39|thyroid nodules
P09665503A0526|22 32|volunteers
P09665503A0526|47 52|study
P09665720A0325|7 14|absence
P09665720A0325|18 21|Mg2
P09665720A0325|38 54|exonuclease site
P09665720A0325|74 89|polymerase site
P09665720A0325|94 104|possession
P09665720A0325|112 127|primer terminus
P09665720A1145|21 24|Mg2
P09665720A1145|26 39|binding sites
P09665720A1145|56 71|primer terminus
P09665720A1145|90 106|exonuclease site
P09665720A1145|133 143|polymerase
P09665720A1145|151 155|site
P09666103A0496|4 19|missense allele
P09666103A0496|21 26|P236S
P09666103A0496|42 46|loss
P09666103A0496|50 58|function
P09666103A0496|65 73|degreesC
P09666103A0496|83 99|missense alleles
P09666103A0496|101 106|L173F
P09666103A0496|108 113|E225K
P09666103A0496|115 120|S269L
P09666103A0496|125 130|E274K
P09666103A0496|149 160|temperature
P09666103A0496|171 180|phenotype
P09666114A0389|11 19|analysis
P09666114A0389|41 47|region
P09666114A0389|65 79|c-met promoter
P09666114A0389|86 90|TATA
P09666114A0389|94 107|CAAT elements
P09666114A0389|134 145|G-C content
P09666114A0389|159 176|Sp1 binding sites
P09667482A0978|4 10|report
P09667482A0978|35 47|contribution
P09667482A0978|51 65|stress factors
P09667482A0978|73 80|context
P09667482A0978|84 91|therapy
P09667482A0978|114 121|disease
P09667482A0978|131 138|results
P09667482A0978|176 183|context
P09667482A0978|189 223|stress system disorder perspective
P09667795A0000|6 18|pancreatitis
P09667795A0000|48 56|disorder
P09668063A0274|25 29|role
P09668063A0274|33 45|Ets proteins
P09668063A0274|49 67|Ras transformation
P09668063A0274|94 101|effects
P09668063A0274|125 132|variety
P09668063A0274|136 151|Ets2 constructs
P09668063A0274|171 177|NIH3T3
P09668063A0274|179 181|DT
P09668063A0274|183 188|cells
P09668096A0806|13 17|site
P09668096A0806|49 59|preference
P09668096A0806|72 80|partners
P09668098A0868|22 37|FGF-BP promoter
P09668098A0868|56 73|deletion analysis
P09668098A0868|79 82|TPA
P09668098A0868|94 102|elements
P09668098A0868|139 149|base pairs
P09668098A0868|166 190|transcription start site
P09668108A1017|0 12|Manipulation
P09668108A1017|20 41|checkpoint regulators
P09668108A1017|54 71|cell cycle arrest
P09668108A1017|76 85|apoptosis
P09668108A1017|111 119|strategy
P09668108A1017|123 137|cancer therapy
P09668119A0496|16 37|mobility shift assays
P09668119A0496|68 83|protein binding
P09668119A0496|107 122|point mutations
P09668119A0496|143 162|binding nucleotides
P09668119A0496|198 203|bases
P09668119A0496|224 231|CTCCT-3
P09669641A0425|15 23|accuracy
P09669641A0425|27 37|serum PE-1
P09669641A0425|60 67|amylase
P09670034A0340|20 25|Ddc1p
P09670034A0340|60 65|Mec3p
P09670034A0340|76 87|interaction
P09670034A0340|97 103|Rad17p
P09670912T0000|18 26|seizures
P09670943T0000|0 23|B cell antigen receptor
P09670943T0000|25 28|BCR
P09670943T0000|39 48|formation
P09670943T0000|54 73|SHP-2-pp120 complex
P09670943T0000|82 92|inhibition
P09670943T0000|96 125|Fc gamma RIIB1-BCR coligation
P09671313A0334|0 5|Chem.
P09671313A0334|33 45|MT Hartsough
P09671313A0334|54 56|J.
P09671464A0316|9 13|SNF1
P09671464A0316|24 31|meiosis
P09671464A0316|50 55|steps
P09671464A0316|79 86|glucose
P09671464A0316|104 111|glucose
P09671464A0316|119 126|meiosis
P09671464A0316|141 145|Snf1
P09671496A0557|24 28|role
P09671496A0557|32 37|c-Cbl
P09671496A0557|41 52|development
P09671496A0557|57 68|homeostasis
P09671496A0557|72 76|mice
P09671496A0557|89 99|disruption
P09671496A0557|107 118|c-Cbl locus
P09671496A0557|136 140|mice
P09671496A0557|187 197|appearance
P09671576A0900|34 42|endoderm
P09671576A0900|61 81|streak morphogenesis
P09671579A1168|16 24|noi/pax2
P09671579A1168|54 73|signaling processes
P09671579A1168|83 93|integrator
P09671579A1168|116 136|boundary development
P09671791T0000|19 29|activation
P09671791T0000|50 72|growth factor receptor
P09671791T0000|88 100|intermediate
P09671791T0000|148 156|activity
P09671791T0000|160 167|L cells
P09673037A0358|0 7|METHODS
P09673037A0358|18 25|changes
P09673037A0358|36 47|bone marrow
P09673037A0358|103 131|reticulin fiber impregnation
P09673037A0358|133 139|method
P09673037A0358|143 149|Gomori
P09673436A0898|22 26|rats
P09673436A0898|28 40|ANP infusion
P09673436A0898|56 65|increases
P09673436A0898|69 85|sodium excretion
P09673436A0898|87 91|FENA
P09673436A0898|127 128|%
P09673436A0898|130 131|P
P09673436A0898|140 141|n
P09673436A0898|159 167|infusion
P09673436A0898|169 173|FENA
P09673436A0898|209 210|%
P09673436A0898|212 213|n
P09673436A0898|232 242|hypocapnia
P09675154A0690|40 48|families
P09675154A0690|54 60|GSD-Ib
P09675154A0690|84 93|mutations
P09675154A0690|125 134|insertion
P09675154A0690|138 152|point mutation
P09675154A0690|162 191|consensus splicing donor site
P09675154A0690|199 216|missense mutation
P09675154A0690|218 223|W118R
P09675896A0959|0 7|Removal
P09675896A0959|15 30|carboxyl region
P09675896A0959|64 74|activation
P09676349A0000|3 10|Level A
P09676349A0000|29 40|correlation
P09676349A0000|73 93|release theophylline
P09676349A0000|95 98|CAS
P09676349A0000|108 119|preparation
P09676349A0000|121 134|Bronchoretard
P09676349A0000|142 155|investigation
P09676419A0158|0 6|METHOD
P09676419A0158|23 31|children
P09676419A0158|44 50|months
P09676419A0158|57 62|years
P09676419A0158|86 91|study
P09676419A0158|108 122|questionnaires
P09676419A0158|126 133|patient
P09676419A0158|138 154|family histories
P09676419A0158|168 183|screening tests
P09676419A0158|208 217|allergens
P09676419A0158|219 226|CAP SX1
P09676419A0158|233 246|determination
P09676419A0158|256 278|serum immunoglobulin E
P09676419A0158|280 283|IgE
P09676419A0158|307 316|serum IgE
P09676419A0158|320 344|solid-phase immunoassays
P09677330A0584|29 46|linker region LR1
P09677330A0584|60 64|UCR1
P09677330A0584|69 73|UCR2
P09677330A0584|93 98|exons
P09677330A0584|108 111|LR2
P09677330A0584|125 129|UCR2
P09677330A0584|147 151|unit
P09677330A0584|176 180|exon
P09677405A0856|0 18|Pol32Delta strains
P09677405A0856|28 40|antimutators
P09677405A0856|78 89|mutagenesis
P09677410A1059|12 16|time
P09677410A1059|22 29|results
P09677410A1059|44 47|p53
P09677410A1059|66 70|role
P09677410A1059|79 82|HBV
P09677410A1059|119 136|HBV core promoter
P09677410A1059|160 168|enhancer
P09677410A1059|176 179|HBx
P09677410A1059|222 230|function
P09677410A1059|234 237|p53
P09678579A0768|8 15|insight
P09678579A0768|25 35|expression
P09678579A0768|43 53|AtCP1 gene
P09678579A0768|64 77|blot analysis
P09678837A0736|4 7|aim
P09678837A0736|15 20|study
P09678837A0736|42 56|responsiveness
P09678837A0736|60 78|bronchoprovocation
P09678837A0736|84 96|methacholine
P09678837A0736|100 108|subjects
P09678837A0736|125 133|rhinitis
P09678837A0736|156 169|pollen season
P09678837A0736|181 190|serum IgE
P09678837A0736|195 212|blood eosinophils
P09679066A1352|6 13|results
P09679066A1352|32 45|demonstration
P09679066A1352|57 64|protein
P09679066A1352|79 87|splicing
P09679066A1352|100 109|pre-mRNAs
P09679750A0304|19 28|potential
P09679750A0304|33 64|prostate cancer chemoprevention
P09679750A0304|102 107|drugs
P09679750A0304|109 135|cyclo-oxygenase inhibitors
P09679750A0304|137 143|NSAIDs
P09679750A0304|165 174|attention
P09680994A0169|5 10|study
P09680994A0169|23 32|isolation
P09680994A0169|38 53|P. hybrida gene
P09680994A0169|55 60|jaf13
P09680994A0169|96 103|protein
P09680994A0169|117 122|basis
P09680994A0169|126 143|sequence homology
P09680994A0169|148 169|intron/exon structure
P09680994A0169|186 207|P. hybrida orthologue
P09680994A0169|215 230|Z. mays r genes
P09681822A0520|10 29|c-erbB3 transcripts
P09681822A0520|70 77|tissues
P09682897A0218|18 23|years
P09682897A0218|38 44|search
P09682897A0218|58 76|electrocardiograms
P09682897A0218|104 115|QRS changes
P09682897A0218|142 156|injury pattern
P09683576A0542|21 34|cleavage site
P09683576A0542|61 76|protease domain
P09683576A0542|78 93|Gln2526-Asp2527
P09683576A0542|106 116|processing
P09685021A0127|0 7|METHODS
P09685021A0127|9 44|Millipore ultrafiltration membranes
P09685021A0127|64 74|pore sizes
P09685021A0127|88 113|model lenticule materials
P09685021A0127|126 145|membrane pore sizes
P09685021A0127|155 161|microm
P09685021A0127|168 174|microm
P09685021A0127|182 188|microm
P09685021A0127|194 211|surface roughness
P09685021A0127|234 239|order
P09685021A0127|244 253|membranes
P09685021A0127|278 283|layer
P09685021A0127|287 297|collagen I
P09685021A0127|326 332|pocket
P09685021A0127|349 355|cornea
P09685021A0127|365 369|cats
P09685021A0127|409 415|extent
P09685021A0127|419 436|epithelialization
P09685021A0127|445 456|persistence
P09685021A0127|471 481|attachment
P09685226A0000|4 8|role
P09685226A0000|12 22|calcitonin
P09685226A0000|34 42|agonists
P09685226A0000|62 74|cAMP pathway
P09685226A0000|90 103|transcription
P09685226A0000|145 152|protein
P09685226A0000|154 159|PTHrP
P09685226A0000|161 165|gene
P09685226A0000|194 215|lung cancer cell line
P09685226A0000|217 220|BEN
P09685346A0419|4 15|combination
P09685346A0419|19 24|Pitx2
P09685346A0419|37 56|homeodomain protein
P09685346A0419|58 63|Pit-1
P09685346A0419|95 105|activation
P09685346A0419|113 131|prolactin promoter
P09685346A0419|135 154|transfection assays
P09686344T0000|30 38|spectrum
P09686344T0000|42 79|ornithine transcarbamylase deficiency
P09686603A0124|26 30|role
P09686603A0124|45 53|elements
P09686603A0124|74 84|mechanisms
P09686603A0124|126 134|promoter
P09686603A0124|147 166|germline expression
P09686603A0124|170 192|TCR beta gene segments
P09687498A1173|4 11|results
P09687498A1173|37 41|role
P09687498A1173|49 58|mutations
P09687498A1173|70 76|v-erbA
P09687498A1173|83 91|oncogene
P09687498A1173|107 113|c-ErbA
P09687498A1173|115 122|TRalpha
P09687498A1173|155 167|conformation
P09687498A1173|190 204|overexpression
P09687511A1091|0 14|Downregulation
P09687511A1091|18 32|FUS expression
P09687511A1091|55 67|32Dcl3 cells
P09687511A1091|88 99|suppression
P09687511A1091|103 109|growth
P09687511A1091|129 145|colony formation
P09687511A1091|147 158|restoration
P09687511A1091|189 204|differentiation
P09687511A1091|229 238|potential
P09687514A0521|8 13|study
P09687514A0521|49 69|transcription system
P09687514A0521|106 114|proteins
P09687514A0521|147 156|complexes
P09688264A1029|5 14|repressor
P09688264A1029|46 49|spi
P09688264A1029|57 76|UTR silencer action
P09688264A1029|106 121|rat hepatocytes
P09689047A0253|2 14|prerequisite
P09689047A0253|23 32|synthesis
P09689047A0253|47 62|glycoconjugates
P09689047A0253|80 105|sugar-nucleotide cytidine
P09689047A0253|109 122|monophosphate
P09689047A0253|142 146|acid
P09689047A0253|148 158|CMP-Neu5Ac
P09689047A0253|178 187|substrate
P09689047A0253|192 216|Golgi sialyltransferases
P09689919A1192|17 26|PEDF cDNA
P09689919A1192|81 98|PEDF glycoprotein
P09691031A1050|13 18|model
P09691031A1050|28 41|Sro7 function
P09691031A1050|61 70|targeting
P09691031A1050|78 93|myosin proteins
P09691031A1050|113 121|pathways
P09691037A0355|9 18|sequences
P09691037A0355|35 44|insertion
P09691037A0355|58 65|strains
P09691037A0355|69 78|N. crassa
P09691037A0355|89 107|Neurospora species
P09692965A0904|5 13|cysteine
P09692965A0904|37 44|helices
P09692965A0904|71 79|patterns
P09692965A0904|91 99|exposure
P09692965A0904|104 110|burial
P09693035T0000|6 10|ULK1
P09693035T0000|20 43|serine/threonine kinase
P09693035T0000|55 68|UNC-51 kinase
P09693035T0000|72 94|Caenorhabditis elegans
P09693035T0000|96 108|cDNA cloning
P09693035T0000|110 120|expression
P09693035T0000|138 148|assignment
P09693134A0782|30 37|markers
P09693134A0782|79 86|domains
P09693134A0782|92 103|neuroblasts
P09693134A0782|118 129|neuroblasts
P09693134A0782|147 150|DER
P09693134A0782|158 165|embryos
P09693134A0782|183 201|column neuroblasts
P09693134A0782|226 244|column neuroblasts
P09693134A0782|259 269|identities
P09693134A0782|294 302|position
P09693134A0782|322 333|neuroblasts
P09693306T0000|21 31|potentials
P09693306T0000|35 43|patients
P09693306T0000|60 71|schwannomas
P09694034A0713|6 13|results
P09694034A0713|19 28|clozapine
P09694034A0713|45 47|LI
P09694034A0713|64 78|antipsychotics
P09694034A0713|101 105|mode
P09694034A0713|109 115|action
P09694034A0713|146 151|value
P09694034A0713|155 157|LI
P09694034A0713|163 173|test model
P09694034A0713|206 215|potential
P09694034A0713|225 230|drugs
P09694514A0000|4 41|complement C3a anaphylatoxin receptor
P09694514A0000|43 47|C3aR
P09694514A0000|74 83|G-protein
P09694514A0000|92 116|chemoattractant receptor
P09694514A0000|137 155|C3a peptide ligand
P09694514A0000|183 192|responses
P09694514A0000|204 221|histamine release
P09694514A0000|227 237|mast cells
P09694514A0000|246 264|muscle contraction
P09694514A0000|283 292|migration
P09694514A0000|296 307|eosinophils
P09694599A1355|0 11|CONCLUSIONS
P09694599A1355|25 35|elevations
P09694599A1355|39 48|IL-1alpha
P09694599A1355|53 61|IL-1beta
P09694599A1355|71 79|patients
P09694599A1355|95 103|cystitis
P09694599A1355|120 129|hematuria
P09694725A0500|11 17|assays
P09694725A0500|67 74|element
P09694725A0500|76 81|LILRE
P09694725A0500|83 98|oligonucleotide
P09694725A0500|102 129|gamma interferon activation
P09694725A0500|140 144|site
P09694725A0500|174 191|IL-1beta promoter
P09694860A0498|15 21|region
P09694860A0498|44 50|domain
P09694860A0498|75 81|region
P09694860A0498|91 99|homology
P09694860A0498|123 130|protein
P09694869A0932|3 11|addition
P09694869A0932|20 27|support
P09694869A0932|43 47|role
P09694869A0932|51 56|STATs
P09694869A0932|64 74|activation
P09694869A0932|82 94|p21 promoter
P09694869A0932|96 110|overexpression
P09694869A0932|114 119|Stat3
P09694869A0932|136 151|cytokine effect
P09694869A0932|159 171|p21 promoter
P09694869A0932|201 206|Stat3
P09694869A0932|213 221|mutation
P09694869A0932|229 250|STAT response element
P09694869A0932|258 266|promoter
P09694869A0932|294 309|cytokine effect
P09694897T0000|26 62|ribonucleoprotein C protein tetramer
P09694897T0000|69 71|U1
P09694897T0000|73 75|U2
P09694897T0000|81 90|U6 snRNAs
P09694897T0000|108 135|affinity RNA binding domain
P09694897T0000|151 156|motif
P09695194T0000|7 17|comparison
P09695194T0000|32 43|proportions
P09695194T0000|58 62|data
P09696164A0000|18 24|system
P09696164A0000|33 42|detection
P09696164A0000|53 74|infant death syndrome
P09696164A0000|76 80|SIDS
P09696819A0450|14 21|mutants
P09696819A0450|44 46|gE
P09696819A0450|54 62|vaccinia
P09696819A0450|75 88|vTF7-3 system
P09696819A0450|98 107|formation
P09696819A0450|124 133|reticulum
P09696819A0450|135 137|ER
P09696819A0450|148 157|transport
P09696819A0450|183 190|complex
P09698457A0778|18 22|mice
P09698457A0778|35 50|Cux/CDPDeltaCR1
P09698457A0778|62 71|phenotype
P09698457A0778|95 104|vibrissae
P09698457A0778|114 118|hair
P09698457A0976|11 18|protein
P09698457A0976|33 39|levels
P09698457A0976|95 114|tissue distribution
P09698457A0976|128 135|protein
P09698457A0976|166 174|affinity
P09698457A0976|185 201|target sequences
P09698457A0976|213 216|DNA
P09698457A0976|239 243|date
P09698457A0976|262 272|cut repeat
P09698457A0976|277 284|binding
P09698512A0296|0 7|METHODS
P09698512A0296|63 84|transplant recipients
P09700644T0000|4 12|spectrum
P09700644T0000|31 50|brain abnormalities
P09700644T0000|58 69|measurement
P09700644T0000|92 102|correlates
P09701609A0116|4 14|laboratory
P09701609A0116|58 73|orphan proteins
P09701609A0116|75 81|PhLOP1
P09701609A0116|86 92|PhLOP2
P09701609A0116|108 115|ability
P09701609A0116|133 143|Gbetagamma
P09701616A0108|8 47|transcriptase-polymerase chain reaction
P09701616A0108|49 55|RT-PCR
P09701616A0108|77 85|eyestalk
P09701616A0108|100 103|DNA
P09701616A0108|111 140|sand shrimp Metapenaeus ensis
P09701821A1108|3 11|contrast
P09701821A1108|13 26|transcription
P09701821A1108|43 51|opuE P-1
P09701821A1108|53 60|sigma A
P09701821A1108|70 80|proportion
P09701821A1108|97 107|osmolarity
P09701821A1108|135 141|levels
P09701895A0119|22 30|children
P09701895A0119|38 49|months-3 yr
P09701895A0119|71 77|period
P09701895A0119|85 89|year
P09701895A0119|105 115|prevalence
P09701895A0119|131 138|anaemia
P09703021A0000|3 10|insects
P09703021A0000|12 47|arylalkylamine N-acetyltransferases
P09703021A0000|49 55|AANATs
P09703021A0000|103 112|processes
P09703021A0000|124 138|sclerotization
P09703021A0000|140 152|inactivation
P09703021A0000|164 181|neurotransmitters
P09703021A0000|203 211|function
P09703021A0000|215 226|vertebrates
P09703021A0000|228 237|catalysis
P09703021A0000|259 263|step
P09703021A0000|267 289|melatonin biosynthesis
P09703213A0280|3 14|experiments
P09703213A0280|24 41|D1 antagonist SCH
P09703213A0280|71 81|depression
P09703213A0280|112 124|facilitation
P09703276A2346|6 13|results
P09703276A2346|29 42|hydroquinones
P09703276A2346|51 63|mutagenicity
P09703276A2346|68 83|carcinogenicity
P09703816A0139|0 5|IA-CT
P09703816A0139|11 20|cisplatin
P09703816A0139|24 26|mg
P09703816A0139|31 42|doxorubicin
P09703816A0139|46 48|mg
P09703816A0139|73 84|shot method
P09703816A0139|107 121|iliac arteries
P09704006A0224|0 10|Arnt3 mRNA
P09704006A0224|28 33|brain
P09704006A0224|44 50|muscle
P09704006A0224|61 68|embryos
P09704006A0224|74 83|P19 cells
P09704006A0224|106 110|acid
P09704296T0000|34 41|purpura
P09704296T0000|60 71|serum level
P09704296T0000|75 91|immunoglobulin E
P09704296T0000|96 108|eosinophilia
P09704296T0000|123 130|patient
P09704569T0000|12 21|structure
P09704569T0000|38 46|location
P09704569T0000|60 79|TR2 orphan receptor
P09704569T0000|83 89|member
P09704569T0000|97 125|steroid receptor superfamily
P09704857T0000|0 11|Correlation
P09704857T0000|15 29|skin disorders
P09704857T0000|35 49|CD4 lymphocyte
P09704857T0000|60 68|patients
P09704857T0000|74 82|HIV/AIDS
P09704927A0479|6 12|shares
P09704927A0479|25 33|homology
P09704927A0479|39 43|E2Fs
P09704927A0479|71 82|DNA binding
P09704927A0479|84 102|heterodimerization
P09704927A0479|114 125|box domains
P09705258A0837|4 20|IE13.1 cell line
P09705258A0837|58 63|virus
P09705258A0837|78 84|copies
P09705258A0837|95 99|gene
P09705258A0837|117 126|insertion
P09705258A0837|151 160|lacZ gene
P09705324A0213|0 5|DNase
P09705324A0213|8 20|footprinting
P09705324A0213|41 64|mobility shift analyses
P09705324A0213|78 88|hepatocyte
P09705324A0213|97 105|factor-1
P09705324A0213|107 111|HNF1
P09705324A0213|143 150|protein
P09705324A0213|152 157|C/EBP
P09705324A0213|168 177|consensus
P09705324A0213|190 223|thyroid hormone response elements
P09705324A0213|245 255|base pairs
P09705324A0213|257 259|bp
P09705324A0213|268 285|promoter sequence
P09705324A0213|289 296|rat Std
P09705324A1602|12 19|studies
P09705324A1602|23 48|rat Std promoter function
P09705324A1602|67 71|HNF1
P09705324A1602|76 81|C/EBP
P09705324A1602|102 119|liver specificity
P09705324A1602|127 139|rat Std gene
P09705324A1602|157 167|repression
P09705324A1602|175 179|gene
P09705324A1602|193 201|presence
P09705324A1602|216 221|OCT-1
P09705324A1602|226 240|C/EBP elements
P09705324A1602|249 258|positions
P09705324A1602|284 286|AR
P09705324A1602|321 327|effect
P09705324A1602|363 375|interference
P09705324A1602|379 384|OCT-1
P09705324A1602|389 394|C/EBP
P09705324A1602|424 442|DNA-AR interaction
P09705352A0879|9 13|Hsk1
P09705352A0879|33 38|Cdc19
P09705352A0879|40 44|Mcm2
P09705352A0879|46 53|subunit
P09705352A0879|72 114|minichromosome maintenance protein complex
P09705352A0879|129 142|fission yeast
P09705497A0227|4 19|yeast MMS2 gene
P09705497A0227|38 45|ability
P09705497A0227|64 99|methyl methanesulfonate sensitivity
P09705497A0227|107 120|mms2-1 mutant
P09705497A0227|159 186|DNA post-replication repair
P09705564T0000|0 10|Expression
P09705564T0000|24 43|papillomavirus type
P09705564T0000|47 58|E5A protein
P09705564T0000|68 72|E1E4
P09705564T0000|73 86|E5 transcript
P09706565A1072|0 10|Anesthesia
P09706565A1072|16 19|M/K
P09706565A1072|44 47|min
P09706565A1072|51 65|immobilization
P09706565A1072|71 82|atipamezole
P09706643A0206|30 35|agent
P09706643A0206|43 50|disease
P09707498A0262|0 21|MK-801 administration
P09707498A0262|45 53|response
P09707498A0262|57 72|seizure latency
P09707577A1047|3 11|contrast
P09707577A1047|17 29|distribution
P09707577A1047|43 50|markers
P09708450A0648|0 8|Toxicity
P09708450A0648|32 38|period
P09708450A0648|66 77|study group
P09708450A0648|107 114|control
P09708450A0648|138 145|regimen
P09708450A0648|154 159|G-CSF
P09708565A0000|4 11|purpose
P09708565A0000|20 27|article
P09708565A0000|46 53|factors
P09708565A0000|70 79|selection
P09708565A0000|83 93|antibodies
P09708565A0000|95 108|radionuclides
P09708565A0000|122 129|methods
P09708565A0000|137 148|development
P09708565A0000|152 170|radioimmunotherapy
P09708565A0000|172 175|RIT
P09708565A0000|195 203|lymphoma
P09708565A0000|205 208|NHL
P09708565A0000|233 243|study site
P09708565A0000|252 270|multicenter trials
P09708565A0000|275 292|commercialization
P09710131A0374|5 12|methods
P09710131A0374|50 59|distances
P09710131A0374|61 89|image intensifier tube modes
P09710131A0374|94 115|laser printer formats
P09710582A0535|4 10|effect
P09710582A0535|14 17|Rho
P09710582A0535|21 25|AP-1
P09710582A0535|66 88|protein kinase pathway
P09710582A0535|113 116|MEK
P09710582A0535|123 136|MEK inhibitor
P09710582A0535|138 145|PD98059
P09710582A0535|174 187|AP-1 activity
P09710589A1111|14 25|mutagenesis
P09710589A1111|29 37|residues
P09710589A1111|46 52|domain
P09710589A1111|54 58|R82A
P09710589A1111|60 64|K85A
P09710589A1111|66 70|K88A
P09710589A1111|76 80|V89A
P09710589A1111|94 102|proteins
P09710589A1111|142 152|HTLV-1 LTR
P09710591A0981|0 9|Mutations
P09710591A0981|21 31|C terminus
P09710591A0981|35 40|c-fos
P09710591A0981|44 59|serine residues
P09710591A0981|69 92|phosphorylation targets
P09710591A0981|97 111|growth factors
P09710591A0981|116 126|MAP kinase
P09710591A0981|147 162|transactivation
P09710591A0981|167 185|block potentiation
P09710591A0981|189 199|MAP kinase
P09710599A0310|14 19|cells
P09710599A0310|21 26|ets-2
P09710599A0310|33 38|CSF-1
P09710599A0310|55 68|response gene
P09710599A0310|89 94|ets-2
P09710599A0310|121 122|h
P09710599A0310|140 150|expression
P09710599A0310|154 167|ets-2 protein
P09710599T0000|11 21|activation
P09710599T0000|43 62|protein kinases p42
P09710599T0000|67 70|p44
P09710599T0000|75 96|ets-2 phosphorylation
P09710599T0000|100 108|response
P09710599T0000|131 137|factor
P09710599T0000|146 155|signaling
P09710614T0000|0 14|Identification
P09710614T0000|33 41|sequence
P09710614T0000|49 52|CD2
P09710614T0000|65 71|domain
P09710614T0000|85 95|regulation
P09710614T0000|117 125|adhesion
P09710614T0000|130 140|activation
P09710614T0000|144 169|phosphoinositide 3-kinase
P09710615T0000|0 5|Vam7p
P09710615T0000|22 30|molecule
P09710615T0000|36 41|Vam3p
P09710615T0000|45 61|syntaxin homolog
P09710615T0000|63 71|function
P09710615T0000|84 89|yeast
P09710615T0000|99 118|protein trafficking
P09710621A0598|20 31|possibility
P09710621A0598|62 68|series
P09710621A0598|72 94|cysteine substitutions
P09710621A0598|102 126|Neu juxtamembrane domain
P09710621A0598|130 135|order
P09710621A0598|145 157|dimerization
P09710621A0598|166 172|series
P09710621A0598|176 189|interreceptor
P09710641A0000|41 46|Pax-6
P09710641A0000|57 63|domain
P09710641A0000|65 67|PD
P09710641A0000|69 80|homeodomain
P09710641A0000|82 84|HD
P09710641A0000|86 106|transcription factor
P09710641A0000|120 135|eye development
P09710641A0000|156 166|activation
P09710641A0000|174 180|alphaB
P09710641A0000|183 189|alphaA
P09710641A0000|192 198|delta1
P09710641A0000|205 226|zeta-crystallin genes
P09710641A0000|234 238|lens
P09712037A0470|0 15|Tctex-1 binding
P09712037A0470|38 49|amino acids
P09712037A0470|53 56|Fyn
P09712037A0470|61 70|integrity
P09712037A0470|78 93|lysine residues
P09712037A0470|106 114|sequence
P09712037A0470|162 178|Fyn interactions
P09712037A0470|188 202|immunoreceptor
P09712037A0470|218 235|activation motifs
P09712037A0470|237 242|ITAMs
P09712037A0470|247 270|lymphocyte Ag receptors
P09712297T0000|4 37|prothrombin gene G20210A mutation
P09712297T0000|66 74|patients
P09712297T0000|85 100|vein thrombosis
P09712297T0000|113 124|individuals
P09712644T0000|16 26|regulation
P09712644T0000|34 44|GluR2 gene
P09712644T0000|62 72|expression
P09712644T0000|83 92|promoters
P09712644T0000|109 117|elements
P09712859A1110|4 11|binding
P09712859A1110|15 21|NF-ATp
P09712859A1110|36 42|NF-AT4
P09712859A1110|52 60|enhancer
P09712859A1110|100 109|infection
P09712859A1110|130 143|blood T-cells
P09712898A0911|6 11|TRAF2
P09712898A0911|22 26|SAPK
P09712898A0911|31 45|p38 activation
P09712898A0911|70 85|protein kinases
P09712898A0911|87 90|GCK
P09712898A0911|95 98|RIP
P09712898T0000|0 31|Tumor necrosis factor signaling
P09712898T0000|52 66|protein kinase
P09712898T0000|68 72|SAPK
P09712898T0000|74 77|Jun
P09712898T0000|91 97|kinase
P09712898T0000|99 102|JNK
P09712898T0000|108 111|p38
P09712915A0672|4 12|activity
P09712915A0672|28 36|promoter
P09712915A0672|69 80|combination
P09712915A0672|88 98|activities
P09712915A0672|106 131|transcription factors Sp1
P09712915A0672|133 136|Sp3
P09712915A0672|142 146|NF-Y
P09712919A0307|7 14|studies
P09712919A0307|33 39|report
P09712919A0307|66 83|signaling pathway
P09712919A0307|84 85|s
P09712919A0307|112 127|CREB activation
P09712919A0307|138 145|T cells
P09713584A1193|0 11|Respondents
P09713584A1193|29 43|spouse/partner
P09713584A1193|89 99|BMI status
P09713584A1193|105 111|people
P09713584A1193|129 135|groups
P09713990T0000|0 9|Isolation
P09713990T0000|21 37|TP53 target gene
P09713990T0000|45 67|colon cancer cell line
P09713990T0000|106 128|TP53 expression system
P09713996A0262|0 14|Overexpression
P09713996A0262|18 22|MDR1
P09713996A0262|53 60|cancers
P09713996A0262|70 84|patient tumors
P09713996A0262|92 102|cell lines
P09713996A0262|119 126|variety
P09713996A0262|147 153|agents
P09713996T0000|26 42|characterization
P09713996T0000|65 79|rearrangements
P09713996T0000|95 115|drug resistance gene
P09713996T0000|117 136|MDR1/P-glycoprotein
P09713996T0000|155 165|cell lines
P09713996T0000|170 178|patients
P09713996T0000|184 188|drug
P09713996T0000|200 203|ALL
P09714109A0000|0 10|BACKGROUND
P09714109A0000|42 49|smoking
P09714109A0000|60 74|blood pressure
P09714109A0000|88 94|muscle
P09714109A0000|107 121|nerve activity
P09714109A0000|123 126|SNA
P09714109A0785|9 32|blood pressure increase
P09714109A0785|36 44|response
P09714109A0785|48 55|smoking
P09714109A0785|85 93|infusion
P09714109A0785|116 124|increase
P09714109A0785|128 138|muscle SNA
P09714835A0345|11 17|report
P09714835A0345|19 37|carboxypeptidase D
P09714835A0345|39 42|CPD
P09714835A0345|121 139|carboxypeptidase E
P09714835A0345|141 144|CPE
P09714835A0345|151 157|enzyme
P09714835A0345|169 184|characteristics
P09714835A0345|200 210|duck gp180
P09714835A0345|212 216|Song
P09714835A0345|218 220|L.
P09714835A0345|222 229|Fricker
P09714835A0345|231 235|L.D.
P09715278A1079|0 12|RA-treatment
P09715278A1079|22 35|transfectants
P09715278A1079|77 87|maturation
P09715278A1079|89 96|changes
P09715278A1079|113 118|genes
P09715278A1079|126 146|G1 cell cycle arrest
P09715278A1079|152 158|manner
P09715278A1079|179 191|NT2/D1 cells
P09715278A1526|4 18|histopathology
P09715278A1526|23 41|neovascularization
P09715278A1526|77 93|xenograft tumors
P09715278A1526|107 127|FGF4 over-expressing
P09715278A1526|135 156|control transfectants
P09715384A0235|12 19|vessels
P09715384A0235|28 36|diameter
P09715384A0235|44 46|mm
P09715384A0235|48 58|treatments
P09715384A0235|72 77|J/cm2
P09715384A0235|90 97|results
P09715384A0235|110 111|%
P09715384A0235|130 137|vessels
P09715384A0235|146 148|mm
P09715384A0235|161 162|%
P09716095T0000|0 15|Pressure ulcers
P09716179A0974|0 20|RXR-gamma expression
P09716179A0974|42 51|reduction
P09716179A0974|55 61|levels
P09716179A0974|79 84|genes
P09716179A0974|116 146|kinase inhibitors p21Cip1/WAF1
P09716179A0974|151 158|p27Kip1
P09716179A0974|183 187|cdc2
P09716179A0974|192 212|cdk2 kinase activity
P09716179A0974|217 235|RB phosphorylation
P09716183A1036|0 3|TBP
P09716183A1036|38 46|extracts
P09716183A1036|50 60|U937 cells
P09716183A1036|99 103|ERK2
P09716183A1036|109 130|phosphorylation sites
P09716183A1036|146 172|ERK kinase consensus sites
P09716183A1036|180 183|TBP
P09716183A1036|199 205|domain
P09716435A1004|11 21|CR/PP diet
P09716435A1004|31 42|HS subjects
P09716435A1004|75 79|rise
P09716435A1004|83 93|depression
P09716435A1004|95 102|decline
P09716435A1004|106 112|vigour
P09716435A1004|117 135|cortisol elevation
P09716435A1004|163 173|PR/CP diet
P09717246A0526|10 13|ILC
P09717246A0526|18 29|ILVF values
P09717246A0526|56 69|exposure time
P09717246A0526|75 89|rate constants
P09717246A0526|116 121|day-1
P09717246A0526|131 143|lipid weight
P09717246A0526|149 152|ILC
P09717246A0526|170 175|day-1
P09717246A0526|180 184|ILVF
P09717835A0941|6 23|sequence analyses
P09717835A0941|37 43|xIRS-u
P09717835A0941|55 61|member
P09717835A0941|69 79|IRS family
P09717835A0941|94 109|Xenopus homolog
P09717835A0941|125 131|member
P09717887A0239|12 17|study
P09717887A0239|39 47|equation
P09717887A0239|60 67|VO2peak
P09717887A0239|91 108|occlusive disease
P09717887A0239|110 114|PAOD
P09717887A0239|116 124|patients
P09717887A0239|143 155|claudication
P09717887A0239|185 195|predictors
P09717887A0239|199 206|VO2peak
P09717887A0239|215 225|population
P09718372T0000|0 8|Evidence
P09718372T0000|40 47|pathway
P09718372T0000|64 70|stress
P09718372T0000|81 101|Sty1/Spc1 MAP kinase
P09718372T0000|105 118|fission yeast
P09718671A0000|16 28|Injury Scale
P09718671A0000|30 33|AIS
P09718671A0000|36 57|Injury Severity Scale
P09718671A0000|62 79|TRISS methodology
P09718671A0000|112 118|system
P09718671A0000|127 135|analysis
P09718671A0000|139 147|injuries
P09718671A0000|160 168|patients
P09719636A1134|5 15|hypothesis
P09719636A1134|42 51|mutations
P09719636A1134|73 88|histidine pairs
P09719636A1134|94 111|H382-X2-H385 pair
P09719636A1134|117 134|H411-X2-H414 pair
P09719636A1134|143 160|H430-X5-H436 pair
P09719636A1134|198 204|region
P09719636A1134|214 224|C terminus
P09719636A1134|228 232|gp17
P09721207A0637|16 24|analysis
P09721207A0637|31 36|exons
P09721207A0637|66 72|region
P09721207A0637|83 93|Chromosome
P09721207A0637|123 137|vacillans gene
P09721798A1734|13 20|percent
P09721798A1734|24 32|children
P09721798A1734|55 65|transplant
P09721798A1734|70 83|HCV hepatitis
P09721798A1734|105 115|recurrence
P09721798A1734|128 141|liver failure
P09721798A1734|146 151|death
P09722043A2070|14 24|TPN groups
P09722043A2070|41 49|increase
P09722043A2070|53 63|activities
P09722043A2070|67 72|liver
P09722043A2070|83 90|enzymes
P09722161A3065|0 10|Regulation
P09722161A3065|24 30|growth
P09722161A3065|45 54|targeting
P09722161A3065|72 85|Igf2/Mpr gene
P09722508A0953|34 48|Galpha11 Q209L
P09722508A0953|60 86|Src family kinase activity
P09722508A0953|99 123|tyrosine phosphorylation
P09722508A0953|135 143|proteins
P09722508A0953|147 160|HEK-293 cells
P09722766A0706|4 24|micturition pressure
P09722766A0706|64 73|injection
P09722766A0706|79 84|BUP-4
P09722766A0706|115 119|rats
P09723896A0000|0 10|Peroxisome
P09723896A0000|34 43|receptors
P09723896A0000|45 49|PPAR
P09723896A0000|60 73|transcription
P09723896A0000|97 107|peroxisome
P09723896A0000|130 138|elements
P09723896A0000|140 144|PPRE
P09723896A0000|154 172|heterodimerization
P09723896A0000|197 210|acid receptor
P09723896A0000|212 215|RXR
P09724654A0761|36 43|origins
P09724654A0761|62 68|timing
P09724654A0761|78 89|recruitment
P09724654A0761|96 107|Mcm protein
P09724654A0761|120 126|timing
P09724654A0761|130 133|RPA
P09724654A0761|136 147|recruitment
P09724654A1120|13 21|presence
P09724654A1120|32 38|S-CDKs
P09724654A1120|43 52|Dbf4/Cdc7
P09724654A1120|54 58|Mcms
P09724654A1120|68 75|origins
P09724654A1120|103 110|loading
P09724654A1120|114 117|RPA
P09724754A0173|0 8|Tyrosine
P09724754A0173|24 29|STATs
P09724754A0173|64 71|nucleus
P09724754A0173|93 98|genes
P09724763T0000|14 26|substitution
P09724763T0000|30 63|abalone sperm fertilization genes
P09724763T0000|72 84|substitution
P09724763T0000|88 95|introns
P09724763T0000|114 117|DNA
P09724772A0840|0 22|Gel retardation assays
P09724772A0840|47 56|complexes
P09724772A0840|74 95|zia operator-promoter
P09724772A0840|100 116|ZiaR-DNA binding
P09724772A0840|133 142|treatment
P09724772A0840|150 164|metal-chelator
P09725292A1473|0 10|CONCLUSION
P09725292A1473|50 58|criteria
P09725292A1473|80 85|liver
P09725292A1473|97 99|CT
P09725651A0077|13 17|RTPS
P09725651A0077|44 61|Microsoft Windows
P09725651A0077|67 78|environment
P09725651A0077|90 98|versions
P09725651A0077|105 114|computers
P09725651A0077|136 154|Pentium processors
P09725854A1060|19 29|similarity
P09725854A1060|53 59|action
P09725854A1060|67 72|genes
P09725854A1060|94 105|differences
P09725854A1060|118 136|IS1112C Rf3 allele
P09725854A1060|153 160|alleles
P09725854A1060|164 180|maintainer lines
P09725854A1060|188 198|capability
P09725854A1060|216 222|orf107
P09725854A1060|227 255|urf209 processing activities
P09726201T0000|0 5|JCAHO
P09726201T0000|14 28|interpretation
P09726979T0000|10 17|cloning
P09726979T0000|33 49|characterization
P09726979T0000|60 78|sphingosine kinase
P09726987T0000|8 45|SPT3-TAFII31-GCN5-L acetylase complex
P09726987T0000|60 84|transcription factor IID
P09726988A0275|0 6|Oleate
P09726988A0275|28 34|levels
P09726988A0275|38 50|M-CPT I mRNA
P09726991T0000|0 7|Mapping
P09726991T0000|15 33|DNA binding domain
P09726991T0000|59 84|transcription factor Mac1
P09727045A0817|10 19|mechanism
P09727045A0817|40 50|activation
P09727045A0817|55 66|cooperation
P09727045A0817|70 79|receptors
P09727045A0817|101 105|HREs
P09727045A0817|136 144|presence
P09727045A0817|157 170|AR N terminus
P09727045A0817|175 196|ligand binding domain
P09727046A0000|43 50|protein
P09727046A0000|52 58|HS2NF5
P09727046A0000|94 100|region
P09727046A0000|123 127|site
P09727046A0000|131 134|HS2
P09727046A0000|149 181|beta-globin locus control region
P09727046A0000|183 186|LCR
P09727046A0000|189 192|Lam
P09727046A0000|194 196|L.
P09727046A0784|4 13|CBF1 site
P09727046A0784|21 24|HS2
P09727046A0784|38 43|sites
P09727046A0784|62 72|regulators
P09727046A0784|81 87|GATA-1
P09727046A0784|89 94|NF-E2
P09727046A0784|100 104|TAL1
P09729481A0000|4 47|rat branched-chain-2-oxo-acid dehydrogenase
P09729481A0000|49 53|BCOD
P09729481A0000|55 66|kinase mRNA
P09729481A0000|99 107|promoter
P09729481A0000|125 134|sequences
P09729481A0000|152 169|Sp1 binding sites
P09729481A0000|179 203|transcription start site
P09729481A1177|0 15|Co-transfection
P09729481A1177|23 45|Sp1 expression plasmid
P09729481A1177|58 76|promoter construct
P09729481A1177|93 108|Schneider cells
P09729481A1177|123 126|Sp1
P09729481A1177|146 152|kinase
P09729481A1177|159 176|promoter activity
P09729481A1177|209 213|site
P09729481A1177|225 231|region
P09730413A0642|11 25|investigations
P09730413A0642|62 66|role
P09730413A0642|80 89|treatment
P09730413A0642|115 126|TME surgery
P09730413A0642|147 163|treatment option
P09730413A0642|168 179|Stage T1-T3
P09730413A0642|187 194|cancers
P09731354A0963|17 26|degrees C
P09731354A0963|33 34|%
P09731354A0963|43 58|surface density
P09731354A0963|62 72|NH2 groups
P09731354A0963|83 90|maximum
P09731354A0963|97 99|hr
P09731354A0963|142 144|hr
P09731513A1090|22 29|results
P09731513A1090|47 58|cooperation
P09731513A1090|62 93|transcription factors NF-kappaB
P09731513A1090|98 102|AP-1
P09731513A1090|120 135|transactivation
P09731513A1090|139 148|IL-8 gene
P09731513A1090|152 162|HTLV-I Tax
P09731704A0000|5 10|study
P09731704A0000|36 43|effects
P09731704A0000|55 78|estrogen receptor-alpha
P09731704A0000|80 87|ERalpha
P09731704A0000|89 96|isoform
P09731704A0000|100 108|estrogen
P09731704A0000|110 112|E2
P09731704A0000|123 138|gene activation
P09731704A0000|142 166|U2-OS osteosarcoma cells
P09731704A1472|0 12|Transfection
P09731704A1472|27 34|amounts
P09731704A1472|38 69|delta5ERalpha expression vector
P09731704A1472|76 83|ERalpha
P09731704A1472|85 93|OS cells
P09731704A1472|106 118|potentiation
P09731704A1472|136 151|ERELuc activity
P09731704A1472|185 191|manner
P09731705A2126|0 7|Studies
P09731705A2126|18 23|yeast
P09731705A2126|35 41|system
P09731705A2126|63 71|evidence
P09731705A2126|80 89|formation
P09731705A2126|95 101|VDR-TR
P09731705A2126|118 129|interaction
P09733493A0493|4 11|results
P09733493A0493|46 56|standpoint
P09733493A0493|58 67|melatonin
P09733493A0493|90 107|hydroxyl radicals
P09733493A0493|116 122|vacuum
P09733493A0493|138 146|solution
P09733647A1960|5 13|sequence
P09733647A1960|15 50|Thr-Gly-X-X-Gly-Asp-Gly-Lys-Ile-Phe
P09733647A1960|58 62|part
P09733647A1960|70 76|B-loop
P09733647A1960|104 111|variety
P09733647A1960|115 124|organisms
P09733647A1960|138 146|bacteria
P09733647A1960|148 153|algae
P09733647A1960|158 172|archeabacteria
P09733794A1323|23 30|changes
P09733794A1323|34 39|Bcl-2
P09733794A1323|57 65|proteins
P09733794A1323|67 72|Bcl-x
P09733794A1323|74 77|Bax
P09733794A1323|91 98|control
P09733794A1323|120 125|cells
P09733794A1323|142 151|treatment
P09733794A1323|157 159|Tg
P09733815T0000|0 8|Tyrosine
P09733815T0000|23 42|membrane protein 2A
P09733815T0000|60 91|protein tyrosine kinase loading
P09733815T0000|96 106|regulation
P09733815T0000|123 136|virus latency
P09733854A0198|24 34|transcript
P09733854A0198|52 59|latency
P09733854A0198|84 86|LR
P09733854A0198|88 91|RNA
P09734808A0000|11 26|test efficiency
P09734808A0000|66 90|contrast/color card test
P09734808A0000|116 129|test stimulus
P09734808A0000|147 153|number
P09734808A0000|157 164|stimuli
P09734808A0000|186 192|phases
P09735286A0599|4 10|defect
P09735286A0599|20 28|proteins
P09735286A0599|69 72|Mn2
P09735286A0599|82 94|Mu B protein
P09735286A0599|102 110|presence
P09735286A0599|114 117|ATP
P09735286A0599|122 132|target DNA
P09735366A1180|6 33|homology cloning techniques
P09735366A1180|51 66|mouse homologue
P09735366A1180|70 71|E
P09735366A1180|72 74|Pc
P09735366A1180|84 88|Epc1
P09735366A1180|92 105|yeast protein
P09735366A1180|119 123|EPL1
P09735366A1180|151 155|ESTs
P09735366A1180|161 183|Caenorhabditis elegans
P09735366A1180|185 189|mice
P09735366A1180|194 200|humans
P09735368A0636|22 24|m8
P09735368A0636|28 31|UTR
P09735368A0636|49 61|accumulation
P09735368A0636|78 89|transcripts
P09735368A0636|102 110|activity
P09735368A0636|129 144|K box sequences
P09735371A0227|41 60|homeodomain protein
P09735371A0227|76 86|production
P09735371A0227|94 105|touch cells
P09735371A0227|113 118|mec-3
P09735371A0227|138 157|homeodomain protein
P09735371A0227|173 188|differentiation
P09735371A0227|196 207|touch cells
P09736239A0436|14 34|resuscitation period
P09736239A0436|50 59|aspartate
P09736239A0436|64 88|glutamate concentrations
P09736239A0436|105 113|striatum
P09736239A0436|144 157|resuscitation
P09736239A0436|159 160|p
P09736239A0436|173 174|p
P09736239A0436|210 223|resuscitation
P09736239A0436|231 232|%
P09736239A0436|242 243|%
P09736239A0436|275 287|accumulation
P09736239A0436|298 310|excitotoxins
P09736239A0436|329 342|resuscitation
P09736697A0783|0 10|Expression
P09736697A0783|36 40|MEK1
P09736697A0783|46 52|kinase
P09736697A0783|68 72|ERKs
P09736697A0783|77 91|overexpression
P09736697A0783|95 99|ERK2
P09736697A0783|109 113|JNK1
P09736697A0783|125 141|Stat3 activation
P09736697A1107|0 4|MEKs
P09736697A1107|9 13|ERKs
P09736697A1107|24 39|IL-6 activation
P09736697A1107|43 48|Stat3
P09736697A1107|61 69|mutation
P09736697A1107|73 83|serine-727
P09736697A1107|95 99|site
P09736697A1107|104 126|serine phosphorylation
P09736697A1107|139 149|inhibition
P09736697A1107|163 168|Stat3
P09736697A1107|184 202|Janus kinases Jak1
P09736697A1107|207 211|Jak2
P09736697A1107|224 229|Stat3
P09736697A1107|256 263|pathway
P09736715A0729|13 33|phosphatidylinositol
P09736715A0729|40 53|trisphosphate
P09736715A0729|82 90|activity
P09736715A0729|94 97|ILK
P09736715A0729|115 123|addition
P09736715A0729|125 133|membrane
P09736715A0729|166 168|Pi
P09736715A0729|171 172|K
P09736715A0729|183 186|ILK
P09736770A0351|0 12|Transfection
P09736770A0351|26 41|binding studies
P09736770A0351|60 65|HEFT1
P09736770A0351|68 76|promoter
P09736770A0351|89 97|activity
P09736770A0351|109 115|GC box
P09736770A0351|129 132|Sp1
P09736770A0351|136 139|Sp3
P09737453A0557|0 6|Plasma
P09737453A0557|48 50|SD
P09737453A0557|52 56|days
P09737453A0557|58 65|surgery
P09737453A0557|70 84|IgG antibodies
P09737453A0557|92 99|complex
P09737453A0557|120 126|factor
P09737453A0557|190 195|assay
P09737453A0557|197 202|ELISA
P09737921T0000|0 17|Genome plasticity
P09737921T0000|32 48|tail fiber locus
P09737921T0000|63 76|bacteriophage
P09737921T0000|78 91|recombination
P09737921T0000|110 122|motifs swaps
P09737921T0000|131 142|specificity
P09738010A0305|4 16|FAS promoter
P09738010A0305|37 44|insulin
P09738010A0305|66 91|insulin response sequence
P09738010A0305|106 117|E-box motif
P09738010A0305|129 147|base pair position
P09738087A0583|4 10|effect
P09738087A0583|26 36|predictors
P09738087A0583|40 48|survival
P09738087A0583|67 87|Cox regression model
P09738087A0583|93 103|adjustment
P09738087A0583|117 126|illnesses
P09738693T0000|0 7|Effects
P09738693T0000|11 18|rhG-CSF
P09738693T0000|22 42|neutrophil functions
P09738693T0000|47 55|survival
P09738693T0000|59 65|sepsis
P09738693T0000|83 87|rats
P09739401A0000|0 9|OBJECTIVE
P09739401A0000|15 22|purpose
P09739401A0000|31 38|article
P09739401A0000|52 71|balance instruments
P09739401A0000|101 106|years
P09739401A0000|131 137|clinic
P09739401A0000|141 157|home environment
P09739913A0194|0 11|CASE REPORT
P09739913A0194|38 49|skin defect
P09739913A0194|77 82|trunk
P09741391A0581|33 41|body box
P09741391A0581|43 53|PenH units
P09741391A0581|64 69|Pause
P09741391A0581|80 86|effort
P09741391A0581|90 99|breathing
P09741391A0581|126 131|pause
P09741391A0581|140 151|inspiration
P09741391A0581|156 166|expiration
P09741783A0000|0 11|Anastrozole
P09741783A0000|25 44|aromatase inhibitor
P09741783A0000|67 85|survival advantage
P09741783A0000|101 108|acetate
P09741783A0000|128 133|women
P09741783A0000|148 161|breast cancer
P09742129A0491|0 2|W.
P09743128A0969|0 7|Moritta
P09743128A0969|22 29|Bis-GMA
P09743233A0526|0 8|Mutation
P09743233A0526|23 27|AP-1
P09743233A0526|35 48|ets component
P09743233A0526|57 61|site
P09743233A0526|77 94|promoter activity
P09743233A0526|98 102|SMCs
P09743720A0268|0 7|ANIMALS
P09743720A0268|15 19|dogs
P09743720A0268|46 48|DM
P09744095A1016|21 28|mutants
P09744095A1016|36 50|shy2-1D mutant
P09744095A1016|82 93|mutants hy2
P09744095A1016|95 98|hy3
P09744095A1016|99 105|phyB-1
P09744095A1016|111 117|fre1-1
P09744095A1016|118 126|phyA-201
P09744095A1016|160 168|response
P09744095A1016|172 180|darkness
P09744095A1016|195 204|hypocotyl
P09744095A1016|215 233|inflorescence stem
P09744095A1016|247 263|level expression
P09744095A1016|271 279|CAB gene
P09744095A1016|289 296|shy2-1D
P09744095A1016|304 310|mutant
P09745797A0943|25 41|underpredictions
P09745797A0943|45 49|pain
P09745797A0943|68 78|disruption
P09745797A0943|90 95|tasks
P09745797A0943|114 120|impact
P09747651A0000|0 14|Laser ablation
P09747651A0000|50 57|measure
P09747651A0000|80 89|emphysema
P09747873T0000|19 40|adapter protein GRB10
P09747873T0000|56 63|BCR-ABL
P09748261A0000|45 65|acyl-CoA synthetases
P09748261A0000|73 97|acid activation proteins
P09748261A0000|99 104|Faaps
P09748286A0000|41 49|enhancer
P09748286A0000|63 71|leukemia
P09748286A0000|83 98|factor receptor
P09748286A0000|100 104|LIFR
P09748286A0000|106 110|gene
P09748286A0000|133 149|characterization
P09748286A0000|166 179|pair enhancer
P09748286A0000|193 204|nucleotides
P09748513X1360|0 9|Copyright
P09748513X1360|15 36|Elsevier Science B.V.
P09748669A0414|10 14|time
P09748669A0414|33 42|dichotomy
P09748669A0414|51 53|AD
P09748669A0414|58 61|VaD
P09749533A0764|0 5|Clone
P09749533A0764|15 22|homolog
P09749533A0764|26 34|CONSTANS
P09749533A0764|47 51|gene
P09749533A0764|80 94|flowering time
P09749533A0764|98 109|Arabidopsis
P09749988A0000|0 7|Badcock
P09749988A0000|12 22|Westheimer
P09749988A0000|32 38|Vision
P09749988A0000|46 50|3-11
P09749988A0000|86 90|line
P09749988A0000|106 111|zones
P09749988A0000|115 125|attraction
P09749988A0000|130 139|repulsion
P09749988A0000|146 151|study
P09749988A0000|166 173|results
P09749988A0000|228 235|extents
P09749988A0000|243 257|repulsion zone
P09749988A0000|283 290|contour
P09749988A0000|301 310|repulsion
P09750325A0000|4 11|effects
P09750325A0000|20 45|intensity light emissions
P09750325A0000|74 102|power energization technique
P09750325A0000|104 108|PPET
P09750325A0000|118 126|survival
P09750325A0000|140 151|populations
P09750325A0000|191 199|serotype
P09750325A0000|205 207|H7
P09750325A0000|213 235|Listeria monocytogenes
P09750325A0000|237 248|serotype 4b
P09750540A0000|9 29|chemical sensitivity
P09750540A0000|31 34|MCS
P09750540A0000|41 49|syndrome
P09750540A0000|68 76|symptoms
P09750540A0000|109 126|chemical exposure
P09751061A0000|0 19|POU-domain proteins
P09751061A0000|52 64|factor Pit-1
P09751061A0000|70 77|members
P09751061A0000|85 103|homeodomain family
P09751061A0000|107 115|proteins
P09751061A0000|139 150|development
P09751061A0000|155 166|homeostasis
P09751061A0000|196 204|response
P09751061A0000|208 236|signal-transduction pathways
P09751061A0000|271 281|expression
P09751061A0000|294 299|genes
P09751114A0967|21 25|MyoD
P09751114A0967|47 52|cells
P09751114A0967|62 64|E1
P09751114A0967|88 94|vector
P09751114A1987|6 13|results
P09751114A1987|27 33|Thr115
P09751114A1987|56 60|role
P09751114A1987|68 78|regulation
P09751114A1987|82 95|MyoD function
P09751114A1987|102 112|conditions
P09751114A1987|121 132|mitogenesis
P09751166A1460|18 25|results
P09751166A1460|43 46|CRE
P09751166A1460|51 59|Sp1 site
P09751166A1460|89 105|TH transcription
P09751166A1460|111 119|promoter
P09751166A1460|138 144|manner
P09751458A0845|0 20|desmethyltrimebutine
P09753241A0524|11 23|examinations
P09753241A0524|42 52|blood cell
P09753241A0524|54 57|WBC
P09753241A0524|71 77|assays
P09753241A0524|81 105|myeloperoxidase activity
P09753241A0524|107 110|MPO
P09753241A0524|115 126|homogenates
P09753241A0524|130 142|colon mucosa
P09753241A0524|168 172|week
P09753241A0524|175 186|% DSS model
P09753241A0524|198 203|weeks
P09753241A0524|206 217|% DSS model
P09753730A0881|0 16|T7 transcription
P09753730A0881|59 65|levels
P09753730A0881|82 92|expression
P09753730A0881|106 109|use
P09753730A0881|113 131|promoter mutations
P09753769A0362|4 11|primers
P09753769A0362|28 32|sets
P09753769A0362|36 52|oligonucleotides
P09753769A0362|72 92|amino acid sequences
P09753769A0362|100 114|PBAN precursor
P09753774A1642|0 6|Plants
P09753774A1642|38 47|construct
P09753774A1642|64 87|oligofructans 1-kestose
P09753774A1642|89 92|GF2
P09753774A1642|95 106|1,1-nystose
P09753774A1642|108 111|GF3
P09753774A1642|117 139|1,1,1-fructosylnystose
P09753774A1642|141 144|GF4
P09753774A2246|13 23|comparison
P09753774A2246|41 61|amino acid sequences
P09753774A2246|65 70|1-sst
P09753774A2246|75 80|1-fft
P09753774A2246|101 134|plant fructosyl transferase genes
P09753774A2246|159 178|plant fructan genes
P09753774A2246|197 218|plant invertase genes
P09753775A0734|9 13|ICK1
P09753775A0734|29 32|ABA
P09753775A0734|49 63|ICK1 induction
P09753775A0734|76 84|decrease
P09753775A0734|98 124|histone H1 kinase activity
P09754571A0169|9 19|transcript
P09754571A0169|49 69|display amplicon 3G1
P09754571A0169|107 127|RAG1 mRNA expression
P09754571A0169|145 155|cell lines
P09754571A1257|4 14|hBRAG gene
P09754571A1257|41 44|arm
P09754571A1257|48 58|chromosome
P09754571A1257|63 68|10q26
P09755191A0553|21 27|swa5-1
P09755191A0553|59 65|allele
P09755191A0553|73 81|clathrin
P09755191A0553|88 98|chain gene
P09755191A0553|100 106|chc1-5
P09755191A0553|125 144|frameshift mutation
P09755191A0553|157 160|end
P09755191A0553|168 172|CHC1
P09755191A0553|178 191|reading frame
P09755199A0373|33 40|lesions
P09755199A0373|49 52|Scm
P09755199A0373|60 67|alleles
P09755199A0373|95 107|requirements
P09755199A0373|121 128|domains
P09755199A0559|32 45|Scm mutations
P09755199A0559|67 77|mbt repeat
P09755199A0559|93 106|PcG mutations
P09755199A0559|129 132|Scm
P09755199A0559|138 145|alleles
P09755478A0366|0 17|Northern analysis
P09755478A0366|41 51|expression
P09755478A0366|59 69|transcript
P09755478A0366|73 81|diapause
P09755478A0366|119 125|larvae
P09755478A0366|136 152|trace expression
P09755478A0366|170 175|pupae
P09756687A0981|12 28|characterization
P09756687A0981|33 43|discussion
P09756687A0981|64 69|setup
P09756687A0981|80 94|rate constants
P09756687A0981|146 152|values
P09756895A0322|8 13|locus
P09756895A0322|17 23|chCTCF
P09756895A0322|56 60|exon
P09756895A0322|89 94|exons
P09756895A0322|105 111|intron
P09757012A0942|4 12|presence
P09757012A0942|16 19|PDZ
P09757012A0942|24 35|SAM domains
P09757012A0942|43 54|KS5 protein
P09757012A0942|95 102|adaptor
P09757012A0942|127 138|information
P09757012A0942|144 171|signal transduction pathway
P09759180A0000|0 10|BACKGROUND
P09759180A0000|12 28|Fluoroquinolones
P09759180A0000|30 32|FQ
P09759180A0000|57 65|children
P09759180A0000|81 85|risk
P09759180A0000|89 105|cartilage damage
P09759691A1051|3 11|analyses
P09759691A1051|17 24|control
P09759691A1051|38 47|variables
P09759691A1051|58 62|risk
P09759691A1051|67 83|microalbuminuria
P09759691A1051|93 110|albumin excretion
P09759691A1051|119 129|microg/min
P09759691A1051|134 137|men
P09759691A1051|142 147|women
P09759691A1051|189 194|mm Hg
P09759691A1051|205 207|SD
P09759691A1051|218 232|blood pressure
P09759691A1051|268 276|1.0-mmol
P09759691A1051|277 278|L
P09759691A1051|283 288|mg/dL
P09759691A1051|297 321|plasma cholesterol level
P09759691A1051|356 363|smokers
P09759691A1051|367 377|nonsmokers
P09759691A1051|419 424|kg/m2
P09759691A1051|432 447|body mass index
P09759865A0673|15 23|IL-1beta
P09759865A0673|28 37|TNF-alpha
P09759865A0673|59 66|binding
P09759865A0673|74 90|Rel proteins p50
P09759865A0673|95 98|p65
P09759865A0673|105 140|NF-kappaB consensus oligonucleotide
P09759865A0673|144 160|gel shift assays
P09759865A0673|182 193|degradation
P09759865A0673|197 206|inhibitor
P09759865A0673|210 225|NF-kappaB-alpha
P09759865A0673|227 240|IkappaB-alpha
P09759865A0673|249 258|cytoplasm
P09759865A0673|262 276|myofibroblasts
P09759865A0673|283 291|IL-1beta
P09759865A0673|304 315|PDGF-Ralpha
P09760243A0970|0 15|Cotransfections
P09760243A0970|21 26|ATF-2
P09760243A0970|31 56|HNF-4 expression plasmids
P09760243A0970|78 93|transactivation
P09760243A0970|101 117|apoCIII promoter
P09760341T0000|0 26|Phosphocreatine hydrolysis
P09760341T0000|45 53|exercise
P09760341T0000|59 65|effect
P09760341T0000|69 73|FIO2
P09761711A0000|0 20|Pseudocontact shifts
P09761711A0000|62 69|average
P09761711A0000|85 93|coupling
P09761711A0000|111 119|electron
P09761711A0000|124 130|nuclei
P09761711A0000|139 147|presence
P09761711A0000|160 185|susceptibility anisotropy
P09761723A0226|0 6|GETS-1
P09761723A0226|28 35|tissues
P09761723A0226|56 62|retina
P09761723A0226|67 72|brain
P09761791A0489|4 15|interaction
P09761791A0489|19 25|U1-70K
P09761791A0489|35 47|SRZ proteins
P09761791A0489|86 104|blot overlay assay
P09763421A1199|10 20|phenotypes
P09763421A1199|36 61|Fab1p kinase inactivation
P09763421A1199|92 98|growth
P09763421A1199|109 130|acidification defects
P09763421A1199|145 154|increases
P09763421A1199|167 171|size
P09763446A0000|6 13|GTPases
P09763446A0000|21 35|Ypt/Rab family
P09763446A0000|56 66|regulation
P09763446A0000|80 89|transport
P09763446A1234|4 7|GEF
P09763446A1234|12 26|GAP activities
P09763446A1234|31 36|Ypt1p
P09763446A1234|70 79|fractions
P09763470A0000|0 25|Dopamine beta-hydroxylase
P09763470A0000|27 30|DBH
P09763470A0000|46 56|conversion
P09763470A0000|60 68|dopamine
P09763470A0000|72 85|noradrenaline
P09763470A0000|147 154|neurons
P09763470A0000|159 179|neuroendocrine cells
P09763470A1756|19 24|study
P09763470A1756|47 51|role
P09763470A1756|55 61|Phox2a
P09763470A1756|88 97|synergism
P09763470A1756|109 130|transcription factors
P09763470A1756|138 142|CREB
P09763470A1756|144 147|AP2
P09763470A1756|153 156|Sp1
P09763470A1756|177 187|activation
P09763470A1756|195 203|DBH gene
P09763522A2545|18 26|antibody
P09763522A2545|35 42|N-SMase
P09763522A2545|56 62|Ox-LDL
P09763522A2545|86 95|apoptosis
P09763522A2545|136 143|studies
P09763522A2545|147 156|apoptosis
P09763522A2545|173 180|animals
P09763607A0521|23 34|Ngo strains
P09763607A0521|42 57|phosphorylation
P09763607A0521|62 72|activation
P09763607A0521|76 79|JNK
P09763607A0521|91 101|p38 kinase
P09764741A0092|8 13|beams
P09764741A0092|40 48|elements
P09764741A0092|56 79|cell division machinery
P09764741A0092|95 102|beating
P09764741A0092|106 112|hearts
P09764741A0092|127 132|basis
P09765261A0000|10 16|T cell
P09765261A0000|30 45|retrovirus type
P09765261A0000|49 55|HTLV-I
P09765261A0000|57 72|trans-activator
P09765261A0000|74 77|Tax
P09765261A0000|111 138|basic-domain/leucine-zipper
P09765261A0000|140 144|bZip
P09765261A0000|146 153|protein
P09765261A0000|155 192|cAMP response element binding protein
P09765261A0000|194 198|CREB
P09765261A0000|235 242|element
P09765261A0000|281 293|pair repeats
P09765261A0000|307 333|cAMP response element core
P09765261A0000|354 363|sequences
P09765271A1108|5 13|sequence
P09765271A1108|37 62|insulin response sequence
P09765271A1108|87 93|region
P09765271A1108|103 108|genes
P09765271A1108|133 140|insulin
P09765271A1108|164 197|phosphoenolpyruvate carboxykinase
P09765271A1108|199 224|tyrosine aminotransferase
P09765271A1108|243 249|growth
P09765271A1108|265 272|protein
P09765277A0000|24 51|glucose transporter isoform
P09765277A0000|55 59|Glut
P09765277A0000|126 133|neurons
P09765277A0000|138 150|trophoblasts
P09765285A0998|22 31|half-site
P09765285A0998|39 64|consensus sequence AGGTCA
P09765285A0998|66 73|IRper-1
P09765285A0998|85 92|binding
P09765285A0998|96 101|AaEcR
P09765285A0998|102 107|AaUSP
P09765285A0998|121 128|IRhsp-1
P09765285A0998|146 150|time
P09765285A0998|164 174|stringency
P09765285A0998|182 207|spacer length requirement
P09765285A0998|214 221|IRper-0
P09765285A0998|225 232|IRper-5
P09765285A0998|252 259|binding
P09765285A1763|4 10|levels
P09765285A1763|14 29|transactivation
P09765285A1763|65 83|binding affinities
P09765285A1763|91 108|response elements
P09765285A1763|110 117|IRper-1
P09765285A1763|120 124|DR-4
P09765285A1763|127 134|IRhsp-1
P09765372A0669|9 16|density
P09765372A0669|31 37|spines
P09765372A0669|51 55|half
P09765372A0669|63 67|body
P09765372A0669|76 88|distribution
P09765372A0669|92 96|type
P09765372A0669|100 108|papillae
P09765372A0669|112 126|dorsal surface
P09765372A0669|166 176|C. armatus
P09765388T0000|0 12|Inactivation
P09765388T0000|16 19|p53
P09765388T0000|28 31|p73
P09765388T0000|35 50|adenovirus type
P09765388T0000|53 56|E1B
P09765388T0000|75 77|E4
P09765388T0000|92 104|oncoproteins
P09765394A0000|17 41|virus transactivator Zta
P09765394A0000|57 72|gene expression
P09765394A0000|94 105|replication
P09765394A0000|119 125|origin
P09765394A0000|127 133|oriLyt
P09765394A1590|0 14|Cotransfection
P09765394A1590|39 47|proteins
P09765394A1590|90 107|activation domain
P09765394A1590|130 145|superactivation
P09765394A1590|149 163|CAT expression
P09765411A0991|0 20|Sequence comparisons
P09765411A0991|47 51|S27a
P09765411A0991|60 69|ubiquitin
P09765411A0991|77 86|sequences
P09765411A0991|100 106|genome
P09765411A0991|110 116|CP Rit
P09765411A0991|149 153|mRNA
P09765411A0991|165 179|hybrid protein
P09765411A0991|189 222|structure NH2-ubiquitin-S27a-COOH
P09765466A0231|0 2|J.
P09765754A1727|12 17|trend
P09765754A1727|25 32|studies
P09765754A1727|43 46|PVI
P09767504A1371|16 20|dose
P09767504A1371|27 32|mg/kg
P09767504A1371|56 69|concentration
P09767504A1371|79 80|h
P09767504A1371|84 98|administration
P09767504A1371|127 129|h.
P09767575A0657|5 11|domain
P09767575A0657|41 45|edge
P09767575A0657|53 64|SD sequence
P09767575A0657|83 99|ribosome binding
P09767575A0657|131 137|region
P09767575A0657|141 147|domain
P09767593A0130|9 13|YopH
P09767593A0130|33 36|PTP
P09767593A0130|66 72|subset
P09767593A0130|100 108|proteins
P09767593A0130|112 122|host cells
P09767593A0130|134 141|p130Cas
P09767687T0000|13 21|position
P09767687T0000|29 40|Phacotaceae
P09767687T0000|52 69|Chlamydophyceaeas
P09767687T0000|82 90|analysis
P09767687T0000|94 102|18S rDNA
P09767687T0000|107 121|rbcL sequences
P09769209A0100|17 24|studies
P09769209A0100|36 46|conclusion
P09769209A0100|72 81|induction
P09769209A0100|85 107|nasF operon expression
P09769209A0100|143 168|antitermination mechanism
P09769910A1700|4 14|activation
P09769910A1700|19 25|injury
P09769910A1700|41 46|cells
P09769910A1700|58 61|TNF
P09769910A1700|88 97|cytokines
P09769910A1700|121 128|effects
P09769910A1700|138 147|mediators
P09770241A0000|2 11|technique
P09770241A0000|24 31|imaging
P09770241A0000|39 45|animal
P09770241A0000|56 68|brain cortex
P09770241A0000|95 101|system
P09770378A0641|0 11|EGFR levels
P09770415A0139|25 32|THOV NP
P09770415A0139|44 49|motif
P09770415A0139|51 66|KRxxxxxxxxxKTKK
P09770415A0139|71 91|amino acid positions
P09770415A0139|146 165|localization signal
P09770415A0139|167 170|NLS
P09770493A0499|3 7|PP2A
P09770493A0499|17 22|range
P09770493A0499|35 44|functions
P09770493A0499|55 76|cell cycle regulation
P09770493A0499|81 104|cell fate determination
P09770493A0499|143 150|embryos
P09770493A0499|174 190|postimplantation
P09770493A0499|209 212|day
P09770686A0484|18 29|risk factor
P09770686A0484|48 60|hypertension
P09771555A0499|4 11|results
P09771555A0499|26 51|anthraquinone sennoside B
P09771555A0499|56 61|rhein
P09771967A1052|13 21|LB1 gene
P09771967A1052|32 48|chromosome 13q14
P09771967A1052|52 58|region
P09771967A1052|99 109|breakpoint
P09771967A1052|113 117|DLBL
P09771985A0238|3 11|subjects
P09771985A0238|17 24|repatch
P09771985A0238|35 56|ethylmercury chloride
P09771985A0238|58 64|EtHgCl
P09771985A0238|73 82|solutions
P09771985A0238|94 100|EtHgCl
P09771985A0238|112 122|L-cysteine
P09771985A0238|127 138|glutathione
P09773975A1873|10 24|AT1A receptors
P09773975A1873|47 66|hamster ovary cells
P09773975A1873|95 113|Ang II stimulation
P09773975A1873|115 119|t1/2
P09773975A1873|124 127|min
P09773975A1873|137 142|level
P09773975A1873|146 161|internalization
P09773975A1873|163 167|Ymax
P09773975A1873|173 174|%
P09773975A1873|191 200|receptors
P09773975A1873|224 237|substitutions
P09773975A1873|239 244|T332E
P09773975A1873|246 250|t1/2
P09773975A1873|255 258|min
P09773975A1873|260 264|Ymax
P09773975A1873|269 270|%
P09773975A1873|272 277|S335D
P09773975A1873|279 283|t1/2
P09773975A1873|288 291|min
P09773975A1873|293 297|Ymax
P09773975A1873|302 303|%
P09773975A1873|305 310|T336E
P09773975A1873|312 316|t1/2
P09773975A1873|321 324|min
P09773975A1873|326 330|Ymax
P09773975A1873|335 336|%
P09773975A1873|338 343|S338D
P09773975A1873|345 349|t1/2
P09773975A1873|354 357|min
P09773975A1873|359 363|Ymax
P09773975A1873|368 369|%
P09773981A0415b|14 37|glucocorticoid receptor
P09773981A0415b|46 53|complex
P09773981A0415b|59 64|Stat5
P09773981A0415b|109 118|induction
P09774403A0107|0 2|T.
P09774403A0107|4 12|Mahasneh
P09774403A0107|14 16|A.
P09774403A0107|22 26|Cote
P09774403A0107|28 30|G.
P09774444A0351|22 29|portion
P09774444A0351|33 37|UKLF
P09774444A0351|53 65|zinc fingers
P09774444A0351|73 87|Cys2-His2 type
P09774444A0351|114 125|CACCC motif
P09774444A0351|133 153|beta-globin promoter
P09774444A0351|165 189|Sp1 recognition sequence
P09774450A0000|30 42|mouse enzyme
P09774450A0000|50 78|gamma-glutamyl leukotrienase
P09774450A0000|80 83|GGL
P09774450A0000|99 113|leukotriene C4
P09774450A0000|115 119|LTC4
P09774450A0000|124 138|leukotriene D4
P09774450A0000|140 144|LTD4
P09774484T0000|0 18|UGA codon position
P09774484T0000|31 41|efficiency
P09774484T0000|45 73|selenocysteine incorporation
P09774484T0000|79 103|glutathione peroxidase-1
P09774641A0824|0 9|Forskolin
P09774641A0824|54 64|expression
P09774641A0824|68 76|cyclin D
P09774641A0824|81 96|phosphorylation
P09774641A0824|104 131|retinoblastoma gene product
P09774662A0958|4 16|ARF promoter
P09774662A0958|59 74|E2F1 expression
P09774662A0958|101 108|results
P09774662A0958|116 125|RNA level
P09776293A0777|0 7|RESULTS
P09776293A0777|13 20|binding
P09776293A0777|24 31|99mTc d
P09776293A0777|33 40|1-HMPAO
P09776293A0777|50 58|placenta
P09776293A0777|75 76|%
P09776293A0777|84 85|%
P09776293A0777|93 94|%
P09776293A0777|102 103|%
P09776293A0777|110 112|ml
P09776293A0777|122 130|solution
P09776360A0620|0 2|CM
P09776360A0620|23 39|binding activity
P09776360A0620|43 68|transcription factor AP-1
P09776360A1781|0 9|NF-kappaB
P09776360A1781|49 57|activity
P09776360A1781|71 74|NOS
P09776360A1781|78 86|promoter
P09776360A1781|123 131|effector
P09776360A1781|135 137|CM
P09776360A1781|141 152|DLD-1 cells
P09777477A0000|0 9|Observers
P09777477A0000|15 27|brain injury
P09777477A0000|32 52|control participants
P09777477A0000|65 79|vigilance task
P09777477A0000|116 122|whiffs
P09777477A0000|136 139|air
P09777477A0000|143 146|air
P09777477A0000|160 170|peppermint
P09777600A0000|20 26|method
P09777600A0000|31 40|l-menthol
P09777600A0000|68 82|chromatography
P09777600A0000|112 120|detector
P09777999A0796|0 7|RESULTS
P09777999A0796|21 26|index
P09777999A0796|62 74|PaCO2 levels
P09777999A0796|76 86|hypocapnia
P09777999A0796|91 92|%
P09777999A0796|94 105|hypercapnia
P09777999A0796|109 110|%
P09778006A0718|16 29|baseline Vmca
P09778006A0718|43 51|pressure
P09778006A0718|55 69|carbon dioxide
P09778006A0718|82 87|blood
P09778006A0718|89 94|PaCO2
P09778006A0718|112 116|mmHg
P09778006A0718|118 122|mean
P09778006A0718|127 129|SD
P09778006A0718|132 144|measurements
P09778006A0718|164 168|PaCO
P09778006A0718|185 189|mmHg
P09778006A0718|199 224|carbon dioxide reactivity
P09778006A0718|235 240|value
P09778006A0718|242 244|cm
P09778006A0718|247 248|s
P09778006A0718|255 259|mmHg
P09778006A0718|274 279|value
P09778006A0718|281 291|percentage
P09778006A0718|295 313|baseline Vmca/mmHg
P09778068A1129|13 34|Cox survival analysis
P09778068A1129|46 57|baseline EF
P09778068A1129|67 68|%
P09778068A1129|70 78|presence
P09778068A1129|101 114|regurgitation
P09778068A1129|128 136|ablation
P09778068A1129|142 149|failure
P09778068A1129|178 189|performance
P09778068A1129|195 200|month
P09778068A1129|207 215|ablation
P09778068A1129|240 250|predictors
P09778068A1129|254 259|death
P09778191A0000|24 30|method
P09778191A0000|35 45|estimation
P09778191A0000|58 61|CBF
P09778191A0000|63 67|rCBF
P09778191A0000|89 105|reserve capacity
P09778191A0000|126 131|basis
P09778191A0000|135 140|means
P09778191A0000|161 178|resonance imaging
P09778191A0000|180 183|MRI
P09778197A0415|0 27|Cost-effectiveness analysis
P09778197A0415|48 53|means
P09778197A0415|76 97|health care resources
P09778197A0415|114 124|comparison
P09778197A0415|132 137|costs
P09778197A0415|156 163|therapy
P09778197A0415|180 187|therapy
P09778197A0415|193 229|beta-hydroxy-beta-methylglutaryl-CoA
P09778197A0415|231 241|coenzyme A
P09778197A0415|243 263|reductase inhibitors
P09778197A0415|265 272|statins
P09778197A0415|284 289|costs
P09778197A0415|293 308|atherosclerosis
P09778197A0415|345 356|cholesterol
P09780002A0996|9 15|E2FBP1
P09780002A0996|26 48|transactivation domain
P09780002A0996|64 67|E2F
P09780002A0996|83 96|transcription
P09780002A0996|100 111|cooperation
P09780002A0996|117 122|E2F-1
P09780228A0122|0 10|Sequencing
P09780228A0122|22 33|DNA segment
P09780228A0122|41 59|FK506 gene cluster
P09780228A0613|14 31|domain structures
P09780228A0613|35 39|FkbB
P09780228A0613|44 48|FkbC
P09780228A0613|74 78|FkbA
P09780228A0613|95 114|fatty-acid-synthase
P09780228A0613|115 118|FAS
P09780228A0613|125 132|domains
P09780228A0613|147 154|modules
P09780336A0771|0 8|Analysis
P09780336A0771|12 32|Msy2 mRNA expression
P09780336A0771|58 70|mouse testes
P09780336A0771|88 99|populations
P09780336A0771|103 113|germ cells
P09780336A0771|131 141|expression
P09780336A0771|157 173|round spermatids
P09780336A0771|177 186|cell type
P09780336A0771|201 208|amounts
P09780336A0771|219 247|messenger ribonucleoproteins
P09781761A0384|5 21|Ho Chi Minh City
P09781761A0384|37 44|culture
P09781761A0384|49 68|latex agglutination
P09781761A0384|72 77|blood
P09781761A0384|93 98|fluid
P09781761A0384|100 105|urine
P09781761A0384|118 123|fluid
P09781871A0404|0 18|Glycogen synthesis
P09781871A0404|23 33|catabolism
P09781871A0404|35 50|gluconeogenesis
P09781871A0404|52 62|glycolysis
P09781871A0404|64 72|motility
P09781871A0404|74 97|cell surface properties
P09781871A0404|102 111|adherence
P09781871A0404|129 133|csrA
P09781871A0404|165 175|production
P09781871A0404|196 213|virulence factors
P09781871A0404|219 224|plant
P09781871A0404|240 262|response elicitor HrpN
P09781871A0404|263 266|Ecc
P09781871A0404|302 313|metabolites
P09781871A0404|331 335|rsmA
P09781871A0404|339 357|Erwinia carotovora
P09781874A1061|4 19|cwg2-1 mutation
P09781874A1061|40 47|guanine
P09781874A1061|51 71|adenine substitution
P09781874A1061|75 85|nucleotide
P09781874A1061|104 110|region
P09781874A1061|128 140|change A202T
P09781874A1061|148 153|cwg2p
P09784063A0621|0 17|Deletion analysis
P09784063A0621|46 52|domain
P09784063A0621|61 69|promoter
P09784063A0621|82 113|ORF5/deltaX transcript promoter
P09784063A0621|125 136|nucleotides
P09784192A1027|12 19|peptide
P09784192A1027|20 31|MBP fusions
P09784192A1027|57 82|surface plasmon resonance
P09784245T0000|23 32|protein C
P09784245T0000|34 40|MyBP-C
P09784245T0000|43 57|identification
P09784245T0000|61 77|protein kinase A
P09784245T0000|82 120|protein kinase C phosphorylation sites
P09785114A1026|12 15|PND
P09785114A1026|45 56|CORT levels
P09785114A1026|71 77|groups
P09786197A0322|0 8|Analysis
P09786197A0322|24 36|DNA sequence
P09786197A0322|67 87|transposon insertion
P09786197A0322|108 122|reading frames
P09786197A0322|135 139|csrR
P09786197A0322|144 148|csrS
P09786197A0322|166 185|sequence similarity
P09786197A0322|224 231|systems
P09786404A0541|10 23|aggregates/ml
P09786404A0541|29 32|rpm
P09786404A0541|34 35|P
P09786926A0095|27 33|region
P09786926A0095|41 69|fatty-acid synthase promoter
P09786926A0095|113 127|overexpression
P09786926A0095|135 154|fatty-acid synthase
P09786926A0095|156 159|FAS
P09786926A0095|161 165|gene
P09786926A0095|196 204|activity
P09786926A0095|223 231|promoter
P09786926A0095|254 257|rat
P09786926A0095|262 267|cells
P09786926A1372|24 39|binding studies
P09786926A1372|56 62|SREBP2
P09786926A1372|84 103|ADD1/SREBP1 binding
P09786926A1372|113 119|sterol
P09786926A1372|131 138|element
P09786926A1372|140 143|SRE
P09786926A1372|145 149|site
P09786932A1042|6 11|IRF-7
P09786932A1042|32 42|similarity
P09786932A1042|46 51|IRF-3
P09786932A1042|79 89|expression
P09786932A1042|93 98|IRF-7
P09786932A1042|111 116|cells
P09786932A1042|122 131|cell type
P09786932A1042|147 151|IFNA
P09786932A1042|167 172|IRF-7
P09786932A1042|193 197|role
P09786932A1042|216 236|IFNA gene expression
P09786949A0114|0 2|J.
P09787323A0000|0 7|PURPOSE
P09787323A0000|13 31|role interleukin-6
P09787323A0000|33 37|IL-6
P09787323A0000|46 55|treatment
P09787323A0000|70 87|thrombocytopenias
P09788739A1096|26 39|serine kinase
P09788739A1096|76 84|molecule
P09788739A1096|90 107|signaling cascade
P09788739A1096|124 131|variety
P09788739A1096|144 153|responses
P09788739A1096|157 183|MDA231 breast cancer cells
P09789025A0149|0 7|Galphaq
P09789025A0149|9 17|Galpha12
P09789025A0149|23 31|Galpha13
P09789025A0149|41 48|Galphai
P09789025A0149|59 62|SRF
P09789025A0149|71 75|RhoA
P09789795A0607|22 30|subjects
P09789795A0607|43 44|A
P09789795A0607|50 63|noradrenaline
P09789795A0607|65 67|NA
P09789795A0607|69 83|concentrations
P09790499A0545|0 22|Northern blot analyses
P09790499A0545|37 53|hBub1 mRNA level
P09790499A0545|81 88|tissues
P09790499A0545|92 97|cells
P09790499A0545|118 123|index
P09790767A0372|36 55|sequence tag clones
P09790767A0372|73 79|contig
P09790767A0372|89 99|chromosome
P09790767A0372|103 111|band q31
P09790768A0621|0 11|Htra2-beta3
P09790768A0621|72 77|brain
P09790768A0621|79 91|liver testis
P09790768A0621|107 113|kidney
P09790771A0956|0 18|Gng3lg transcripts
P09790771A0956|38 45|variety
P09790771A0956|49 56|tissues
P09790771A0956|72 77|brain
P09790771A0956|82 88|testes
P09790771A1032|23 38|backcross panel
P09790771A1032|58 62|Gng3
P09790771A1032|67 73|Gng3lg
P09790771A1032|86 91|locus
P09790771A1032|95 105|chromosome
P09790986A0689|28 36|antibody
P09790986A0689|49 89|glutathione S-transferase fusion protein
P09790986A0689|121 132|amino acids
P09790986A0689|142 148|NRAMP2
P09792439T0000|0 10|Inhibition
P09792439T0000|18 47|apolipoprotein B mRNA editing
P09792439T0000|66 82|hnRNP C1 protein
P09792439T0000|87 106|40S hnRNP complexes
P09792627A0441|0 5|SRC-1
P09792627A0441|41 51|repression
P09792627A0441|55 66|GR activity
P09792630A1127|12 20|sequence
P09792630A1127|37 66|transcription start site CTCA
P09792630A1127|67 69|+1
P09792630A1127|70 74|TTCC
P09792630A1127|94 108|consensus CTCA
P09792630A1127|109 111|+1
P09792630A1127|112 116|NTCT
P09792630A1127|118 119|N
P09792630A1127|127 137|nucleoside
P09792630A1127|146 163|initiator element
P09792630A1127|182 209|deoxynucleotidyltransferase
P09792630A1127|216 222|number
P09792630A1127|249 254|genes
P09792682A0713|6 13|results
P09792682A0713|38 44|number
P09792682A0713|48 57|subunit c
P09792682A0713|61 63|F0
P09792702A0754|0 10|Expression
P09792702A0754|34 40|mutant
P09792702A0754|44 48|JNK1
P09792702A0754|65 72|glucose
P09792702A0754|93 108|JNK1 activation
P09792702A0754|120 141|HSP70 gene expression
P09792714A1408|4 15|interaction
P09792714A1408|19 23|AF-1
P09792714A1408|29 37|proteins
P09792714A1408|61 66|steps
P09792714A1408|70 83|transcription
P09792714A1408|98 107|mechanism
P09792714A1408|124 134|activation
P09792714A1408|138 153|gene expression
P09792714A1408|157 161|AF-1
P09794414T0000|4 8|role
P09794414T0000|12 38|protein kinase C signaling
P09794414T0000|52 69|DRA transcription
P09794795A0183|0 14|Ligand binding
P09794795A0183|22 38|receptor complex
P09794795A0183|48 72|tyrosine phosphorylation
P09794795A0183|77 87|activation
P09794795A0183|91 104|Janus kinases
P09794795A0183|106 109|Jak
P09794795A0183|112 127|phosphorylation
P09794795A0183|135 167|signal transducing subunit gp130
P09794795A0183|181 192|recruitment
P09794795A0183|197 212|phosphorylation
P09794795A0183|220 237|signal transducer
P09794795A0183|242 251|activator
P09794795A0183|255 282|transcription factors STAT3
P09794795A0183|287 292|STAT1
P09794795A0183|301 320|src homology domain
P09794795A0183|322 325|SH2
P09794795A0183|338 366|protein tyrosine phosphatase
P09794795A0183|368 372|SHP2
P09795130A0742|18 26|increase
P09795130A0742|30 38|distance
P09795130A0742|73 79|effect
P09795130A0742|83 105|translation efficiency
P09795170A0774|20 40|polyadenylation site
P09795170A0774|65 68|TGA
P09795170A0774|74 79|codon
P09795170A0774|104 122|kb transcript size
P09795213A0129|0 13|RBP56 protein
P09795213A0129|31 39|hTAFII68
P09795213A0129|77 84|protein
P09795213A0129|96 102|factor
P09795213A0129|104 107|TAF
P09795213A0129|116 130|sub-population
P09795213A0129|134 149|TFIID complexes
P09795213A0129|151 164|Bertolotti A.
P09795213A0129|166 170|Lutz
P09795213A0129|172 174|Y.
P09795213A0129|176 181|Heard
P09795213A0129|183 187|D.J.
P09795213A0129|189 196|Chambon
P09795213A0129|198 200|P.
P09795213A0129|202 206|Tora
P09795213A0129|208 210|L.
P09795213A0129|218 226|hTAFII68
P09795213A0129|254 261|protein
P09795213A0129|267 275|homology
P09795213A0129|283 309|proto-oncoproteins TLS/FUS
P09795213A0129|314 317|EWS
P09795213A0129|342 347|TFIID
P09795213A0129|352 366|RNA polymerase
P09795341A0806|19 39|mobility shift assay
P09795341A0806|74 90|binding property
P09795341A0806|94 97|TR2
P09795341A0806|116 123|isoform
P09797189A0559|13 27|shift analysis
P09797189A0559|55 66|CCAAT motif
P09797456A0000|0 10|BACKGROUND
P09797456A0000|16 36|c-myc proto-oncogene
P09797456A0000|68 73|roles
P09797456A0000|77 95|cell proliferation
P09797456A0000|97 112|differentiation
P09797456A0000|114 128|transformation
P09797456A0000|133 142|apoptosis
P09797456A0883|0 5|AMY-1
P09797456A0883|27 36|cytoplasm
P09797456A0883|40 45|cells
P09797456A0883|57 62|c-myc
P09797456A0883|70 76|levels
P09797456A0883|89 96|nucleus
P09797456A0883|104 109|cells
P09797456A0883|120 136|c-myc expression
P09797456A0883|164 169|cells
P09798068A0290|0 7|RESULTS
P09798068A0290|37 41|cDNA
P09798068A0290|55 68|reading frame
P09798068A0290|77 79|bp
P09798068A0290|109 116|protein
P09798068A0290|124 135|amino acids
P09798068A0290|163 173|% homology
P09798068A0290|183 186|rat
P09798068A0290|206 212|acid B
P09798068A0290|214 219|GABAB
P09798068A0290|221 229|receptor
P09798100A0705|3 6|Day
P09798100A0705|14 20|CIDR-B
P09798100A0705|41 64|micrograms cloprostenol
P09798100A0705|75 77|IM
P09798263T0000|20 30|properties
P09798263T0000|39 65|serotonin receptor ligands
P09798263T0000|70 97|calcium channel antagonists
P09798263T0000|123 136|swimming test
P09798263T0000|140 144|mice
P09799086A0725|18 34|hotspot mutation
P09799086A0725|48 55|patient
P09799086A0725|59 70|frame shift
P09799086A0725|83 105|G nucleotide insertion
P09799086A0725|122 128|repeat
P09799086A0725|136 138|Gs
P09799086A0725|142 151|HPRT exon
P09799086A0725|199 210|LN patients
P09799237A0624|14 21|embryos
P09799237A0624|46 65|gastrulation defect
P09799237A0624|88 92|term
P09799362A0507|32 40|features
P09799362A0507|65 82|abbreviation AZF1
P09799362A0507|100 119|Zinc Finger protein
P09799362A1463|0 15|Over-expression
P09799362A1463|19 24|Azf1p
P09799362A1463|32 42|yeast cell
P09799362A1463|66 82|expression level
P09799362A1463|104 130|transcription factor Mtf1p
P09799362A1463|152 161|influence
P09799362A1463|165 170|Azf1p
P09799362A1463|178 189|suppression
P09799362A1463|219 240|RNA polymerase mutant
P09799634A0161|20 34|computer model
P09799634A0161|53 59|domain
P09799634A0161|71 80|repressor
P09799634A0161|94 111|crystal structure
P09799634A0161|130 134|UmuD
P09799634A0161|136 143|protein
P09799793T0000|12 22|sequencing
P09799793T0000|30 37|regions
P09799793T0000|47 62|chromosome 7q22
P09799793T0000|64 72|analysis
P09799793T0000|80 82|kb
P09799793T0000|94 102|sequence
P09799793T0000|114 117|EPO
P09799793T0000|122 132|CUTL1 loci
P09799793T0000|144 149|genes
P09800187A0100|8 13|Trp53
P09800187A0100|19 32|mouse homolog
P09800187A0100|42 46|TP53
P09800187A0100|64 67|Tk1
P09800187A0100|71 81|chromosome
P09800187A0100|124 133|responses
P09800187A0100|144 152|exposure
P09800187A0100|156 175|DNA damaging agents
P09800187A0100|209 229|mouse lymphoma cells
P09800187A0100|237 246|mutations
P09800187A0100|250 255|Trp53
P09801156A0220|13 22|fragments
P09801156A0220|41 69|amino acid sequence homology
P09801156A0220|84 92|ecdysone
P09801156A0220|103 111|gene E75
P09801333A0174|16 22|N gene
P09801333A0174|40 53|reading frame
P09801333A0174|86 96|PRRS virus
P09801333A0174|98 102|PA-8
P09802206A1058|9 26|sequence homology
P09802206A1058|32 37|genes
P09802206A1058|57 60|TEF
P09802206A1058|71 108|translation elongation factor-1 alpha
P09802206A1058|113 117|RPS7
P09802206A1058|138 148|protein S7
P09802902A0225|30 34|ARNO
P09802902A0225|52 67|plasma membrane
P09802902A0225|102 126|ARF6 nucleotide exchange
P09803081T0000|6 15|pathology
P09803081T0000|30 37|outcome
P09803081T0000|41 54|childhood SLE
P09804779A0000|0 21|Transcription factors
P09804779A0000|29 40|Stat family
P09804779A0000|59 74|protein kinases
P09804779A1163|20 28|pathways
P09804779A1163|38 66|Stat5 serine phosphorylation
P09804779A1163|209 215|Stat5a
P09804836A0000|36 43|protein
P09804836A0000|86 94|response
P09804836A0000|98 124|mouse BAC1.2F5 macrophages
P09804836A0000|128 155|colony stimulating factor-1
P09804836A0000|157 162|CSF-1
P09804836A0000|165 169|pp37
P09804836A0000|202 210|fraction
P09804836A0000|223 224|P
P09804836A0000|226 249|affinity chromatography
P09804836A0000|251 280|size exclusion chromatography
P09804836A0000|286 288|C4
P09804836A0000|297 302|phase
P09804836A0000|308 316|pressure
P09804836A0000|324 338|chromatography
P09805052A0119|0 4|Dose
P09805052A0119|11 13|ig
P09805052A0119|41 47|scheme
P09805052A0119|62 68|months
P09805052A0119|72 77|order
P09805052A0119|91 105|immunogenicity
P09805052A0119|143 149|months
P09805052A0119|166 170|dose
P09805977A0143|22 26|data
P09805977A0143|70 76|origin
P09805977A0143|86 96|sperm fall
P09805977A0143|157 162|class
P09805977A0143|166 176|substances
P09805977A0143|182 195|xenoestrogens
P09806516A1212|5 16|association
P09806516A1212|51 59|patients
P09806516A1212|87 97|recurrence
P09806516A1689|0 10|CONCLUSION
P09806516A1689|18 25|control
P09806516A1689|43 48|Preop
P09806516A1689|52 60|patients
P09806516A1689|93 100|disease
P09806516A1689|111 117|Postop
P09806516A1689|121 129|patients
P09806516A1689|173 181|excision
P09806546A1270|4 15|interaction
P09806546A1270|21 25|RFX5
P09806546A1270|30 35|RFXAP
P09806546A1270|53 60|binding
P09806546A1270|68 79|RFX complex
P09806546A1270|83 99|MHC-II promoters
P09806826A0244|30 36|defect
P09806826A0244|40 47|RIIIS/J
P09806826A0244|58 67|mouse Chr
P09806826A0244|90 99|Vwf locus
P09806826A0244|103 106|Chr
P09806826A1773|6 10|data
P09806826A1773|31 43|localization
P09806826A1773|53 65|disease loci
P09806826A1773|81 87|region
P09806826A1773|103 107|gene
P09806826A1773|133 141|syndrome
P09806826A1773|155 160|locus
P09806826A1773|165 179|susceptibility
P09806826A1773|203 214|lung injury
P09806830X1174|0 9|Copyright
P09806830X1174|15 29|Academic Press
P09806857A0854|8 21|reading frame
P09806857A0854|33 40|protein
P09806857A0854|65 75|similarity
P09806857A0854|79 89|invertases
P09806857A0854|94 104|resolvases
P09806857A0854|145 162|Pac25I R-M operon
P09806858T0000|0 14|Identification
P09806858T0000|24 28|gene
P09806858T0000|50 62|plasmid pLS1
P09806858T0000|68 77|rnaI gene
P09806919A0447|8 11|usp
P09806919A0447|38 51|instar larvae
P09806919A0447|102 111|responses
P09806919A0447|119 133|ecdysone pulse
P09806919A0447|148 166|puparium formation
P09807755A0146|24 30|supply
P09807755A0146|52 61|viability
P09807755A0146|67 78|muscle flap
P09808155A0813|0 11|Examination
P09808155A0813|15 18|DNA
P09808155A0813|19 44|protein binding complexes
P09808155A0813|58 66|analysis
P09808155A0813|90 97|factors
P09808155A0813|142 147|cells
P09808155A0813|161 173|DNA fragment
P09808155A0813|194 196|bp
P09808216A0000|0 10|BACKGROUND
P09808216A0000|12 19|Studies
P09808216A0000|28 31|men
P09808216A0000|42 52|regulation
P09808216A0000|56 62|energy
P09808216A0000|64 66|EB
P09808216A0000|76 83|balance
P09808216A0000|85 87|FB
P09808216A0000|96 108|manipulation
P09808216A0000|120 126|ratios
P09808366A0828|6 14|apneusis
P09808366A0828|44 54|conditions
P09808366A0828|71 76|apnea
P09808366A0828|105 122|KA microinjection
P09808366A0828|130 134|side
P09808366A0828|142 149|VRG-Apa
P09808366A0828|153 160|animals
P09808441A0320|14 22|analysis
P09808441A0320|65 74|melanomas
P09808441A0320|90 101|singularity
P09808441A0320|109 113|case
P09808441A0320|132 141|character
P09808441A0320|149 157|melanoma
P09808441A0320|163 176|lymphotropism
P09808441A0320|185 196|coexistence
P09808441A0320|218 232|cell carcinoma
P09810087A0379|0 7|RESULTS
P09810087A0379|21 35|seroconversion
P09810087A0379|53 61|presence
P09810087A0379|65 69|type
P09810087A0379|72 92|herpes simplex virus
P09810087A0379|94 99|HSV I
P09810087A0379|109 114|acids
P09810087A0379|142 147|humor
P09811695A1146|6 13|results
P09811695A1146|28 47|HIV-1 Gag sequences
P09811695A1146|84 94|processing
P09811695A1146|102 125|MuLV TM Env protein p15
P09811695A1146|126 127|E
P09811718A0979a|6 13|results
P09811718A0979a|37 48|association
P09811718A0979a|52 55|SIV
P09811718A0979a|60 69|HIV-2 nef
P09811718A0979a|79 88|HIV-1 nef
P09811718A0979a|95 102|TCRzeta
P09811730A1396|0 16|Competition EMSA
P09811730A1396|67 75|proteins
P09811730A1396|86 97|KCS element
P09811730A1396|111 139|KCS protein binding activity
P09811730A1396|156 173|promoter activity
P09811730A1396|191 218|transfection reporter assay
P09811730T0000|0 9|Mechanism
P09811730T0000|13 30|interferon action
P09811730T0000|32 46|identification
P09811730T0000|60 69|positions
P09811730T0000|100 111|KCS element
P09811730T0000|141 151|activation
P09811730T0000|173 196|protein kinase pkr gene
P09813041A1122|0 2|GH
P09813041A1122|23 38|phosphorylation
P09813041A1122|42 52|activation
P09813041A1122|56 59|Jun
P09813041A1122|71 77|kinase
P09813041A1122|88 98|conditions
P09813063T0000|0 10|Expression
P09813063T0000|29 52|phospholipase D homolog
P09813063T0000|82 93|development
P09813063T0000|101 110|forebrain
P09813093A0624|15 21|effect
P09813093A0624|34 41|YCL024W
P09813093A0624|62 73|combination
P09813093A0624|79 87|deletion
P09813093A0624|91 95|GIN4
P09813098A0521|0 10|Paralemmin
P09813098A0521|43 47|mRNA
P09813098A0521|125 131|manner
P09813110A0982|12 31|amino acid sequence
P09813110A0982|35 40|CBP90
P09813110A0982|60 70|similarity
P09813110A0982|84 91|protein
P09813110A0982|119 125|domain
P09813110A0982|144 150|region
P09813203T0000|4 10|effect
P09813203T0000|26 46|serine substitutions
P09813203T0000|54 61|V3 loop
P09813203T0000|65 85|HIV-1 gp120 IIIB/LAI
P09813203T0000|93 107|immunogenicity
P09813203T0000|115 131|envelope protein
P09813207A0434|0 32|Transcription start site mapping
P09813207A0434|48 56|presence
P09813207A0434|90 100|transcript
P09813207A0434|116 126|TAAG motif
P09813207A0434|143 154|nucleotides
P09813207A0434|192 202|transcript
P09813207A0434|222 232|TTGT motif
P09813207A0434|244 255|nucleotides
P09813207A0434|272 280|TATA box
P09813207A0434|289 300|nucleotides
P09813207A0434|307 314|respect
P09813207A0434|325 328|ATG
P09813207A0434|332 336|lef2
P09813254A0000|17 31|oligoadenylate
P09813254A0000|33 37|2-5A
P09813254A0000|39 50|synthetases
P09813254A0000|55 62|members
P09813254A0000|68 85|family interferon
P09813254A0000|87 90|IFN
P09813254A0000|113 121|proteins
P09813259A1097|4 12|findings
P09813259A1097|42 50|blockade
P09813259A1097|69 80|sensitivity
P09813259A1097|106 112|injury
P09813259A1097|121 124|GBP
P09813259A1097|129 132|IBG
P09813635A0678|6 16|striations
P09813635A0678|32 39|contact
P09813635A0678|58 62|edge
P09813635A0678|76 82|canine
P09813635A0678|91 93|P3
P09813635A0678|125 132|complex
P09814637A1214|4 18|PbrO2 readings
P09814637A1214|54 70|microhemorrhages
P09814637A1214|88 90|CT
P09814637A1214|94 97|MRI
P09814905A0598|4 16|consequences
P09814905A0598|30 46|swine production
P09814905A0598|54 65|environment
P09814905A0598|79 88|solutions
P09814905A0598|92 97|means
P09814905A0598|101 110|nutrition
P09815578A1245|5 10|study
P09815578A1245|29 39|alteration
P09815578A1245|43 48|CDKN2
P09815578A1245|85 98|abnormalities
P09815578A1245|102 117|prostate cancer
P09815578A1245|140 163|prostate carcinogenesis
P09815948A1065|20 30|parameters
P09815948A1065|58 68|toxicities
P09815948A1065|78 82|area
P09815948A1065|93 98|curve
P09815948A1065|103 120|peak plasma level
P09817131A0296|15 32|SF-36 survey form
P09817131A0296|63 82|translation process
P09817190A0074|13 16|use
P09817190A0074|20 33|cyclosporin A
P09817190A0074|66 76|prevalence
P09817190A0074|80 92|hypertension
P09817190A0074|96 124|kidney transplant recipients
P09817373A0000|0 7|PURPOSE
P09817373A0000|26 33|effects
P09817373A0000|37 57|hypercholesterolemia
P09817373A0000|114 127|insufficiency
P09817373A0000|149 160|muscle tone
P09817373A0000|169 183|oxide synthase
P09817373A0000|185 188|NOS
P09817373A0000|190 198|activity
P09817373A0000|214 230|tissue synthesis
P09817373A0000|234 257|constrictor eicosanoids
P09817601T0000|0 16|Characterization
P09817601T0000|35 42|regions
P09817601T0000|56 65|aromatase
P09817601T0000|67 75|P450arom
P09817601T0000|77 81|gene
P09817601T0000|112 122|expression
P09819038A0448|12 17|FVIIa
P09819038A0448|36 49|infusion pump
P09819038A0448|62 66|days
P09819038A0448|70 86|room temperature
P09819038A0448|98 99|h
P09819038A0448|103 119|body temperature
P09819110A0703|0 14|CD4 lymphocyte
P09819110A0703|25 36|load levels
P09819110A0703|58 66|response
P09819110A0703|70 81|ARV therapy
P09819110A0703|89 96|time LD
P09819216A0220|7 19|Biochemistry
P09819288A0578|0 6|Levels
P09819288A0578|10 19|serum IgE
P09819288A0578|53 56|IgE
P09819288A0578|77 83|height
P09819288A0578|88 91|end
P09819288A0578|99 105|season
P09819377A1209|2 10|mutation
P09819377A1209|21 32|C2U4 repeat
P09819377A1209|40 57|underaccumulation
P09819377A1209|61 67|snR13F
P09819377A1209|77 86|mutations
P09819377A1209|97 108|C2U4 repeat
P09819377A1209|119 131|accumulation
P09819377A1209|145 149|RNAs
P09819377A1209|177 182|range
P09819391A1123|34 38|Arfs
P09819391A1123|43 59|tyrosine kinases
P09819391A1123|83 94|cell growth
P09819391A1123|112 124|organization
P09819391A1123|126 131|ASAP1
P09819391A1123|149 175|membrane remodeling events
P09819391A1123|187 196|processes
P09819411A0897|3 8|DNase
P09819411A0897|11 29|footprint analysis
P09819411A0897|37 48|PNR element
P09819411A0897|52 62|palindrome
P09819411A0897|96 101|sites
P09819411A0897|103 115|CTTCCCTGGAAG
P09819414A1103|14 20|nexins
P09819414A1103|51 58|isoform
P09819414A1103|66 81|leptin receptor
P09819414A1103|109 124|medium isoforms
P09819421A0000|0 12|Cyclophilins
P09819421A0000|43 53|isomerases
P09819421A0000|110 123|cyclosporin A
P09819421A0000|125 128|CsA
P09819422A0768|9 38|protein retention experiments
P09819422A0768|48 69|Hsp90 heterocomplexes
P09819422A0768|100 115|coprecipitation
P09819422A0768|119 123|Cns1
P09819430A0000|16 23|GTPases
P09819430A0000|49 57|proteins
P09819430A0000|64 69|cycle
P09819430A0000|100 104|form
P09819430A0000|129 134|state
P09819440A0000|12 25|transcription
P09819440A0000|38 45|factors
P09819440A0000|69 90|transcription factors
P09819440A0000|98 113|RNA polymerases
P09819440A0000|119 126|variety
P09819440A0000|130 134|ways
P09819440A0783|11 14|RMP
P09819440A0783|71 75|RPB5
P09819440A0783|79 93|RNA polymerase
P09819440A0783|107 112|cells
P09819507A0000|8 13|study
P09819507A0000|15 22|rabbits
P09819507A0000|57 71|wound reaction
P09819507A0000|77 82|Dexon
P09819507A0000|86 91|nylon
P09819507A0000|112 116|flap
P09819507A0000|136 140|days
P09819507A0000|147 169|trabeculectomy surgery
P09819507A0000|190 193|use
P09819507A0000|197 208|mitomycin-C
P09820163A0565|4 11|mapping
P09820163A0565|31 48|Southern blotting
P09820163A0565|53 73|restriction analysis
P09820205A0000|4 18|zona pellucida
P09820205A0000|20 22|ZP
P09820205A0000|43 53|glycocalyx
P09820205A0000|73 79|oocyte
P09820205A0000|117 135|gamete interaction
P09820611T0000|12 15|use
P09820611T0000|43 51|infusion
P09820611T0000|73 87|erythropoietin
P09820611T0000|104 115|predialysis
P09820611T0000|123 131|patients
P09820611T0000|146 157|nephropathy
P09820621A0067|22 38|thyroid function
P09820621A0067|53 60|changes
P09820621A0067|64 82|energy expenditure
P09820621A0067|87 103|body composition
P09820621A0067|118 127|influence
P09820621A0067|131 144|leptin levels
P09821978A1255|16 24|deficits
P09821978A1255|43 50|animals
P09821978A1255|64 70|MK-801
P09821978A1255|78 80|SE
P09822602A0237|29 38|mechanism
P09822602A0237|42 52|activation
P09822602A0237|56 66|HIF-1alpha
P09822602A0237|83 90|process
P09822602A0237|132 138|import
P09822602A0237|143 153|activation
P09822602A0237|155 167|derepression
P09822602A0237|176 198|transactivation domain
P09822602A0237|213 224|recruitment
P09822602A0237|245 252|protein
P09822602A0237|254 257|CBP
P09822602A0237|259 275|p300 coactivator
P09822602A1172|32 38|import
P09822602A1172|43 58|transactivation
P09822602A1172|62 73|recruitment
P09822602A1172|77 80|CBP
P09822602A1172|146 151|roles
P09822602A1172|155 174|signal transduction
P09822602A1172|178 188|HIF-1alpha
P09822647A0000|4 23|rat aldolase C gene
P09822647A0000|45 51|enzyme
P09822647A0000|80 85|brain
P09822652A1118|14 20|effect
P09822652A1118|24 45|HCK promoter activity
P09822652A1118|67 81|concentrations
P09822652A1118|85 88|Sp1
P09822661T0073|16 22|domain
P09822661T0073|27 46|amino acid residues
P09822661T0073|59 74|quinone binding
P09822685A0596|8 16|analyses
P09822685A0596|22 30|antisera
P09822685A0596|46 64|Lu-ECAM-1 peptides
P09822685A0596|90 96|region
P09822685A0596|119 132|reading frame
P09822685A0596|163 176|size proteins
P09822690A0000|10 24|sperm motility
P09822690A0000|43 50|cascade
P09822690A0000|69 99|protein phosphorylation events
P09822690A0000|112 129|protein kinase A.
P09822825A0141|8 13|paper
P09822825A0141|34 38|BAP2
P09822825A0141|44 54|expression
P09822825A0141|62 71|BAP3 gene
P09822825A0141|107 115|addition
P09822825A0141|134 145|amino acids
P09822825A0141|153 159|medium
P09823014T0000|0 6|Effect
P09823014T0000|30 38|products
P09823014T0000|52 64|carbohydrate
P09823014T0000|69 72|fat
P09823014T0000|76 83|indices
P09823014T0000|87 99|carbohydrate
P09823014T0000|104 120|lipid metabolism
P09823014T0000|124 132|patients
P09823014T0000|138 143|NIDDM
P09823561T0001|18 31|MALT lymphoma
P09823561T0001|36 59|helicobacter heilmannii
P09823561T0001|61 84|Gastrospirillum hominis
P09823775A1122|6 13|studies
P09823775A1122|26 30|view
P09823775A1122|36 41|HMG I
P09823775A1122|42 43|Y
P09823775A1122|61 69|cofactor
P09823775A1122|74 97|HLA-DRA gene activation
P09823775A1122|101 107|Oct-2A
P09823775A1122|120 128|insights
P09823775A1122|138 147|mechanism
P09823775A1122|151 157|action
P09824001A1665|3 11|contrast
P09824001A1665|49 59|predictors
P09824001A1665|63 71|survival
P09824001A1665|73 76|vWF
P09824001A1665|77 79|Ag
P09824001A1665|106 116|techniques
P09824021A1263|0 10|CONCLUSION
P09824021A1263|39 47|features
P09824021A1263|51 58|disease
P09824021A1263|108 116|response
P09824021A1263|128 138|NO therapy
P09824021A1263|149 159|parameters
P09824158A1336|13 39|BCL-6 POZ domain mutations
P09824158A1336|57 68|interaction
P09824158A1336|74 79|N-CoR
P09824158A1336|84 88|SMRT
P09824158A1336|107 120|transcription
P09826434T0000|8 24|characterization
P09826434T0000|39 43|site
P09826434T0000|50 81|platelet cAMP phosphodiesterase
P09826434T0000|83 88|PDE3A
P09826434T0000|107 118|mutagenesis
P09826658A0691|5 18|core sequence
P09826658A0691|65 76|nucleotides
P09826658A0691|104 115|suppression
P09826658A0691|131 139|assembly
P09826658A0691|144 152|splicing
P09826658A0691|156 171|BPV-1 pre-mRNAs
P09826778A0943|0 15|Over-expression
P09826778A0943|23 36|cofactor p300
P09826778A0943|59 70|coactivator
P09826778A0943|88 101|transcription
P09826778A0943|114 124|repression
P09826778A0943|128 135|COUP-TF
P09827446T0001|20 29|hepatitis
P09827446T0001|34 47|C4 deficiency
P09827724A1362|3 12|mutations
P09827724A1362|38 46|adenomas
P09827878A0091|6 28|glutathione peroxidase
P09827878A0091|30 33|GPX
P09827878A0091|39 59|superoxide dismutase
P09827878A0091|61 64|SOD
P09827878A0091|85 89|role
P09827878A0091|93 104|erythrocyte
P09827878A0091|119 126|defence
P09827878A0091|168 176|activity
P09827878A0091|203 210|workers
P09827993A0000|11 32|nucleocapsid proteins
P09827993A0000|34 38|NCPs
P09827993A0000|54 74|zinc finger proteins
P09827993A0000|88 117|virion RNA binding activities
P09827993A0000|134 153|retrovirus assembly
P09827993A0000|166 183|RNA encapsidation
P09828137A0000|30 34|rad1
P09828137A0000|36 70|cell cycle checkpoint control gene
P09828137A0000|87 94|S-phase
P09828137A0000|99 110|G2/M arrest
P09828137A0000|114 122|response
P09828137A0000|131 141|DNA damage
P09828137A0000|157 172|DNA replication
P09829836A0000|32 43|progression
P09829836A0000|67 77|cell cycle
P09829836A0000|95 107|oscillations
P09829836A0000|115 123|activity
P09829836A0000|127 133|cyclin
P09829836A0000|145 152|kinases
P09829836A0000|154 158|CDKs
P09829836A0815|17 27|selections
P09829836A0815|32 42|inhibition
P09829836A0815|46 65|cyclin/CDK function
P09829836A0815|111 127|yeast LEU2 genes
P09829843A0119|37 44|factors
P09829843A0119|46 49|CSF
P09829843A0119|86 94|practice
P09829843A0119|120 128|measures
P09829843A0119|149 158|incidence
P09829843A0119|173 186|complications
P09829843A0119|190 198|patients
P09829843A0119|204 210|cancer
P09829843A0119|215 226|neutropenia
P09829843A0819|4 14|injections
P09829843A0819|18 21|CSF
P09829843A0819|43 53|initiation
P09829843A0819|57 68|neutropenia
P09829843A0819|93 103|occurrence
P09829843A0819|119 138|neutrophil recovery
P09829843A0819|140 150|rHu GM-CSF
P09829843A0819|155 164|rHu G-CSF
P09829843A0819|201 209|microg m
P09829843A0819|214 217|day
P09829843A0819|228 237|microg kg
P09829843A0819|242 245|day
P09829843A0819|250 255|level
P09829843A0819|299 315|neutrophil count
P09829843A0819|320 339|neutrophil function
P09829843A0819|369 393|chemiluminescence system
P09829916T0000|0 10|Expression
P09829916T0000|14 18|lacZ
P09829916T0000|28 36|promoter
P09829916T0000|65 71|operon
P09829916T0000|84 91|vectors
P09829916T0000|105 109|W205
P09829916T0000|118 124|fusion
P09832099A0000|40 51|wall motion
P09832099A0000|59 66|systole
P09832099A0000|70 78|patients
P09832099A0000|104 113|tetralogy
P09832099A0000|117 123|Fallot
P09832099A0000|125 128|TOF
P09832099A0000|136 157|color kinesis imaging
P09832436A0738|0 15|RT-PCR analysis
P09832436A0738|28 33|PLP-H
P09832436A0738|45 50|PLP-C
P09832436A0738|55 60|PLP-D
P09832436A0738|82 93|rat strains
P09832436A0738|120 133|PLP diversity
P09832436A0738|155 166|differences
P09832436T0000|10 17|cloning
P09832436T0000|22 38|characterization
P09832436T0000|48 54|member
P09832436T0000|62 65|rat
P09832436T0000|76 85|prolactin
P09832436T0000|87 90|PRL
P09832436T0000|92 98|family
P09832436T0000|109 119|protein H.
P09832504A0596|32 43|interaction
P09832504A0596|52 55|Tat
P09832504A0596|60 66|hCycT1
P09832504A0596|76 80|zinc
P09832504A0596|102 119|cysteine residues
P09832504A0596|128 136|proteins
P09832505A0903|28 45|activation target
P09832505A0903|57 66|activator
P09832505A0903|68 73|Oct-1
P09832505A0903|100 121|transcription complex
P09832511A0269|13 25|neurogenesis
P09832511A0269|27 38|Vnd protein
P09832511A0269|64 84|column neuroectoderm
P09832511A0269|89 100|neuroblasts
P09832511A0269|136 143|pattern
P09832511A0269|147 154|neurons
P09832518A0615|4 21|repression domain
P09832518A0615|45 58|Cdc68 protein
P09832518A0615|97 105|sequence
P09832518A0615|113 118|Cdc68
P09832518A0615|130 137|homolog
P09832518A0615|147 152|yeast
P09832518A0615|167 173|lactis
P09832518A0615|181 198|database searches
P09833610A0626|4 13|exodomain
P09833610A0626|33 49|affinity hormone
P09833610A0626|58 62|site
P09833610A0626|105 111|signal
P09833740A1112|0 27|Pyrrolidine dithiocarbamate
P09833740A1112|54 63|inhibitor
P09833740A1112|77 80|LTR
P09833740A1112|96 114|cytokine responses
P09833740A1112|123 125|U1
P09833740A1112|130 141|ACH-2 cells
P09833740A1112|198 207|mechanism
P09833740A1112|217 227|cell types
P09833740A1112|252 257|modes
P09833740A1112|261 277|provirus latency
P09834070A0793|25 35|activation
P09834070A0793|39 43|ERK2
P09834070A0793|60 67|absence
P09834070A0793|71 78|changes
P09834070A0793|96 99|Ca2
P09834070A0793|125 135|inhibition
P09834070A0793|139 164|protein kinase C activity
P09834070A0793|191 198|pathway
P09834070A0793|208 212|CD19
P09834070A0793|223 238|B cell function
P09834521A0000|17 29|hydatid cyst
P09834521A0000|45 49|site
P09835615A0574|12 20|analysis
P09835615A0574|34 37|KS1
P09835615A0574|51 58|protein
P09835615A0574|90 107|repressor domains
P09835615A0574|109 111|R1
P09835615A0574|116 118|R2
P09836881A0441|13 22|BCH group
P09836881A0441|45 62|motor performance
P09836881A0441|70 94|Bruininks-Oseretsky Test
P09836881A0441|98 115|Motor Proficiency
P09836881A0441|117 126|Bruininks
P09837714A1068|4 11|results
P09837714A1068|22 33|possibility
P09837714A1068|39 41|pH
P09837714A1068|69 82|modifications
P09837714A1068|86 91|DdRPA
P09837714A1068|108 114|events
P09837714A1068|125 143|cell proliferation
P09837714A1068|155 170|differentiation
P09837714A1068|174 187|Dictyostelium
P09837715A0581|36 42|amount
P09837715A0581|58 61|DNA
P09837715A0581|67 72|level
P09837715A0581|76 109|chloramphenicol acetyltransferase
P09837715A0581|111 114|CAT
P09837715A0581|116 120|mRNA
P09837715A0581|152 157|cells
P09837715A0581|171 176|HIV-1
P09837715A0581|189 203|leukemia virus
P09837715A0581|205 208|MLV
P09837715A0581|210 242|SL3-3 LTR-CAT reporter construct
P09837824A0419|14 30|telSMN mutations
P09837824A0419|65 76|individuals
P09837824A0419|96 100|copy
P09837824A0419|104 110|telSMN
P09837824A0419|130 150|frameshift mutations
P09837824A0419|152 160|800ins11
P09837824A0419|165 173|542delGT
P09837824A0419|185 203|missense mutations
P09837824A0419|205 208|A2G
P09837824A0419|210 215|S262I
P09837824A0419|221 226|T274I
P09837907A0857|4 12|decrease
P09837907A0857|16 29|TNF receptors
P09837907A0857|33 37|IL-4
P09837907A0857|57 72|down-regulation
P09837907A0857|88 98|activities
P09837907A0857|110 122|cytotoxicity
P09837907A0857|124 144|caspase-3 activation
P09837907A0857|146 155|NF-kappaB
P09837907A0857|160 175|AP-1 activation
P09837907A0857|181 186|c-Jun
P09837907A0857|198 214|kinase induction
P09837913A0000|0 4|Type
P09837913A0000|7 17|deiodinase
P09837913A0000|19 21|D2
P09837913A0000|40 52|deiodination
P09837913A0000|56 65|thyroxine
P09837913A0000|81 97|triiodothyronine
P09837913A0419|45 64|sequence tag clones
P09837913A0419|102 105|UTR
P09837913A0419|119 121|D2
P09837913A0419|123 126|hD2
P09837913A0419|128 132|cDNA
P09837914A0844|0 4|Biol
P09837920A0222|41 53|requirements
P09837920A0222|58 70|consequences
P09837920A0222|85 100|phosphorylation
P09837920A0222|109 120|interaction
P09837920A0222|129 134|c-Jun
P09837920A0222|139 142|JNK
P09837933T0000|0 6|P-CIP1
P09837933T0000|16 23|protein
P09837933T0000|58 64|domain
P09837933T0000|68 83|peptidylglycine
P09837933T0000|100 113|monooxygenase
P09837933T0000|134 143|endosomes
P09837945A0820|0 18|Immunolocalization
P09837945A0820|22 27|Sop1p
P09837945A0820|51 63|distribution
P09837945A0820|68 94|cell fractionation studies
P09837945A0820|121 129|fraction
P09837945A0820|133 138|Sop1p
P09837945A0820|171 179|fraction
P09837945A0820|197 205|material
P09837978T0093|10 20|activation
P09837978T0093|24 29|c-Jun
P09837978T0093|65 79|protein kinase
P09837978T0093|81 89|JNK/SAPK
P09838122A0489|31 51|coding cDNA sequence
P09838122A0489|59 74|mouse homologue
P09838122A0489|78 82|MPP3
P09840822A0462|4 10|method
P09840822A0462|27 34|tagging
P09840822A0462|55 62|concern
P09840822A0462|80 110|magnetization transfer effects
P09840928A0884|31 34|Dlk
P09840928A0884|50 66|core histones H3
P09840928A0884|68 71|H2A
P09840928A0884|76 78|H4
P09840928A0884|92 102|substrates
P09840928A0884|118 128|histone H3
P09840928A0884|132 145|kinase assays
P09840928A0884|159 167|extracts
P09840932A0365|8 13|study
P09840932A0365|25 33|evidence
P09840932A0365|39 44|B-Myb
P09840932A0365|71 77|target
P09840932A0365|82 95|cyclin A/Cdk2
P09840934A0435|8 14|Ha-Ras
P09840934A0435|16 20|G12V
P09840934A0435|22 26|T35S
P09840934A0435|29 41|Ha-RasV12S35
P09840934A0435|64 86|Rafl signaling pathway
P09840934A0435|92 98|Ha-Ras
P09840934A0435|99 103|G12V
P09840934A0435|105 109|E37G
P09840934A0435|112 124|Ha-RasV12G37
P09840934A0435|148 162|RalGDS pathway
P09840934A0435|189 196|effects
P09840934A0435|218 227|apoptosis
P09840934A0435|239 244|cells
P09840943A0144|31 37|cyclin
P09840943A0144|39 48|cyclin E2
P09840943A0144|76 84|homology
P09840943A0144|88 97|cyclin E.
P09842517A0497|8 18|experience
P09842517A0497|32 42|technology
P09842517A0497|58 66|SieScape
P09842517A0497|94 101|methods
P09842517A0497|110 112|CT
P09842517A0497|117 120|MRI
P09843378A0187|4 24|dopamine D4 receptor
P09843378A0187|65 74|receptors
P09843378A0187|100 119|SH3 binding domains
P09843412A0130|36 40|form
P09843412A0130|44 49|Abeta
P09843412A0130|51 58|Abeta42
P09843412A0130|73 80|species
P09843412A0130|127 129|AD
P09843572A0944|5 10|model
P09843572A0944|27 38|experiments
P09843572A0944|52 67|Cdr2 associates
P09843572A0944|99 105|domain
P09843572A0944|109 113|Wee1
P09843572A0944|117 129|cell lysates
P09843572A0944|149 153|Wee1
P09843577A0000|26 31|cells
P09843577A0000|52 63|deprivation
P09843577A0000|76 98|G2/M cell size control
P09843944A0976|0 8|A-tracts
P09843944A0976|58 65|hexamer
P09843944A0976|90 94|turn
P09843944A0976|152 171|UP element function
P09844106A0835|5 20|phosphorylation
P09844106A0835|36 45|adherence
P09844106A0835|49 52|FLG
P09844106A0835|58 63|cells
P09844106A0835|67 78|fibronectin
P09844106A0835|86 89|ST2
P09844106A0835|98 103|cells
P09844921A0000|0 3|Raf
P09844921A0000|13 44|serine-threonine protein kinase
P09844921A0000|71 83|transmission
P09844921A0000|87 93|growth
P09844921A0000|114 138|differentiation messages
P09845043A0000|4 25|US National Institute
P09845043A0000|29 42|Alcohol Abuse
P09845043A0000|47 57|Alcoholism
P09845043A0000|59 64|NIAAA
P09845043A0000|81 86|forms
P09845043A0000|102 110|drinking
P09845043A0000|121 134|alcohol abuse
P09845043A0000|151 158|problem
P09845043A0000|165 183|alcohol dependence
P09845043A0000|201 209|disorder
P09845043A0000|236 245|component
P09845662A0085|0 8|Collagen
P09845662A0085|32 36|skin
P09845662A0085|46 50|lack
P09845662A0085|54 58|type
P09845662A0085|63 71|collagen
P09845662A0085|90 95|means
P09845662A0085|99 113|sodium dodecyl
P09845662A0085|137 156|gel electrophoresis
P09845662A0085|158 166|SDS-PAGE
P09845856A0560|0 7|RESULTS
P09845856A0560|27 33|period
P09845856A0560|63 77|ulcer diseases
P09846033A0488|0 7|RESULTS
P09846033A0488|21 28|changes
P09846033A0488|34 46|pretreatment
P09846033A0488|50 63|posttreatment
P09846033A0488|79 80|p
P09846482A0441|3 7|turn
P09846482A0441|9 17|assembly
P09846482A0441|26 33|complex
P09846482A0441|57 67|activation
P09846482A0441|89 103|protein kinase
P09846482A0441|122 142|actin polymerization
P09846927A0227|4 7|tip
P09846927A0227|15 21|button
P09846927A0227|31 42|perforation
P09846927A0227|60 72|stomach wall
P09846927A0227|85 90|death
P09847371A0000|0 22|Jembrana disease virus
P09847371A0000|24 27|JDV
P09847371A0000|58 68|lentivirus
P09847371A0000|107 129|immunodeficiency virus
P09847371A0000|131 134|BIV
P09847397A0935|16 17|%
P09847397A0935|25 33|residues
P09847397A0935|64 73|sequences
P09847397A0935|89 96|viruses
P09847397A0935|111 128|response elements
P09847397A0935|133 148|glucocorticoids
P09847397A0935|177 188|CCAAT boxes
P09847397A0935|217 227|TATA boxes
P09848653A0597|0 5|Nhp2p
P09848653A0597|24 31|protein
P09848653A0597|50 56|family
P09848653A0597|81 89|proteins
P09849421A0332|5 11|survey
P09849421A0332|44 54|Norwegians
P09849421A0332|64 69|years
P09849421A0332|73 76|age
P09849421A0332|103 115|Organization
P09849421A0332|120 128|Research
P09849421A0332|133 142|Treatment
P09849421A0332|146 165|Cancer Core Quality
P09849421A0332|169 187|Life Questionnaire
P09849421A0332|189 202|EORTC QLQ-C30
P09849421A0332|211 215|mail
P09849722A0797|7 19|presentation
P09849722A0797|36 47|expressions
P09849722A0797|63 78|signal increase
P09849722A0797|114 129|cingulate gyrus
P09849722A0797|151 165|cingulate gyri
P09849722A0797|182 188|cortex
P09849722A0797|213 218|gyrus
P09849722A0797|220 233|brain regions
P09849722A0797|276 300|emotion processing tasks
P09849961A0387|0 15|Down-regulation
P09849961A0387|19 24|IRS-1
P09849961A0387|42 64|serine phosphorylation
P09849961A0387|78 98|PI 3-kinase activity
P09849961A0387|124 139|differentiation
P09849961A0387|153 158|IRS-1
P09849961A0387|227 245|myoblast cell line
P09849965A0000|5 10|study
P09849965A0000|45 51|system
P09849965A0000|67 71|role
P09849965A0000|75 81|ligand
P09849965A0000|89 101|dimerization
P09849965A0000|111 132|progesterone receptor
P09849965A0000|134 137|hPR
P09851614A0109|18 26|features
P09851614A0109|77 84|regions
P09851614A0109|86 89|UTR
P09851614A0109|96 107|nucleotides
P09851614A0109|109 112|nts
P09851614A0109|132 139|absence
P09851614A0109|146 160|cap structures
P09851614A0109|170 175|mRNAs
P09851700A0000|4 8|gene
P09851700A0000|24 57|tissue-type plasminogen activator
P09851700A0000|59 63|t-PA
P09851700A0000|102 108|manner
P09851988A0085|9 17|presence
P09851988A0085|21 29|arginine
P09851988A0085|34 46|anaerobiosis
P09851988A0085|69 78|induction
P09851988A0085|86 93|pathway
P09852005A1287|0 11|Competition
P09852005A1287|28 59|MADS box consensus binding site
P09852005A1287|69 77|promoter
P09852005A1287|130 139|gene PEP1
P09852005A1287|141 145|SAP1
P09852005A1287|161 192|MADS box consensus binding site
P09852005A1287|197 218|serum response factor
P09852005A1287|254 263|complexes
P09852005A1287|291 303|OP4 sequence
P09852068A0150b|10 14|SHBG
P09852068A0150b|24 32|promoter
P09852068A0150b|49 54|DNase
P09852068A0150b|57 69|footprinting
P09852068A0150b|90 102|significance
P09852068A0150b|120 127|regions
P09852068A0150b|129 136|FP1-FP6
P09852068A0150b|158 166|promoter
P09852068A0150b|188 214|HepG2 hepatoblastoma cells
P09852109A1475|9 20|translation
P09852109A1475|42 58|profile analysis
P09852109A1475|74 87|transcripts C
P09852109A1475|92 93|E
P09852109A1475|137 149|efficiencies
P09852109A1475|194 206|transcript D
P09852109A1475|240 247|regions
P09852109A1475|255 259|role
P09852109A1475|277 284|control
P09852136A0174|21 29|mutation
P09852136A0174|31 36|Ser36
P09852136A0174|41 44|Asn
P09852136A0174|56 62|domain
P09852136A0174|66 70|p190
P09852136A0174|90 97|ability
P09852136A0174|106 124|guanine nucleotide
P09852136A0174|145 158|hemagglutinin
P09852136A0174|160 162|HA
P09852136A0174|171 178|protein
P09852136A0174|182 191|COS cells
P09852136A0507|0 17|Wild type HA-p190
P09852136A0507|28 37|phenotype
P09852136A0507|49 54|cells
P09852136A0507|73 83|extensions
P09852136A0507|110 122|Rho function
P09852136A0507|139 155|ADP-ribosylation
P09852752A0950|34 44|vasculitis
P09852752A0950|66 78|complication
P09852752A0950|82 84|RA
P09854034A0536|26 34|promoter
P09854034A0536|44 55|G+C content
P09854034A0536|61 68|exon 1b
P09854034A0536|109 121|mRNA species
P09855111A0905|27 41|overexpression
P09855111A0905|63 70|domains
P09855111A0905|113 123|regulation
P09855111A0905|127 143|SREBP processing
P09855111A0905|161 171|disruption
P09855111A0905|211 221|regulation
P09855111A0905|233 238|genes
P09855111A0905|244 255|mRNA levels
P09855111A0905|287 297|coenzyme A
P09855111A0905|299 306|HMG CoA
P09855111A0905|308 316|synthase
P09855111A0905|330 340|cell lines
P09855111A0905|378 384|manner
P09856397A0099|0 17|Dry matter intake
P09856397A0099|28 52|nutrient digestibilities
P09856397A0099|54 78|serum chemistry profiles
P09856397A0099|80 107|sphingolipid concentrations
P09856397A0099|113 124|persistency
P09856397A0099|128 131|FB1
P09856397A0099|135 142|tissues
P09856732A0114|12 19|studies
P09856732A0114|90 96|effect
P09856732A0114|100 109|lidocaine
P09857038A1374|0 2|E.
P09857038A1374|4 9|Scott
P09857038A1374|11 13|J.
P09857197A0289|0 5|Yap1p
P09857197A0289|37 48|crm1 mutant
P09857197A0289|54 59|Crm1p
P09857197A0289|79 94|export sequence
P09857197A0289|96 99|NES
P09857197A0289|106 114|sequence
P09857197A0289|118 123|Yap1p
P09857197A0289|131 139|presence
P09857197A0289|143 149|RanGTP
P09857265A0669|0 11|Mean intake
P09857265A0669|15 24|vitamin A
P09857265A0669|49 58|mg RE/day
P09857265A0669|63 66|men
P09857265A0669|71 76|women
P09857265A0669|96 109|contributions
P09857265A0669|113 117|meat
P09857265A0669|119 123|fats
P09857265A0669|128 132|oils
P09857265A0669|134 144|vegetables
P09857265A0669|149 163|dairy products
P09857265A0669|173 179|intake
P09857265A0669|187 188|%
P09857265A0669|192 193|%
P09857265A0669|197 198|%
P09857265A0669|206 207|%
P09858094A0583|10 19|amplitude
P09858094A0583|39 49|potentials
P09858094A0583|51 53|O1
P09858094A0583|57 59|O3
P09858094A0583|60 62|O4
P09858094A0583|117 123|period
P09858531A1017|13 33|RING1 overexpression
P09858531A1017|54 64|expression
P09858531A1017|72 93|proto-oncogenes c-jun
P09858531A1017|98 103|c-fos
P09858571T0000|4 19|yeast RER2 gene
P09858571T0000|47 87|reticulum protein localization mutations
P09858571T0000|97 118|cis-prenyltransferase
P09858571T0000|126 132|enzyme
P09858571T0000|136 154|dolichol synthesis
P09858572A0000|4 29|yeast retrotransposon Ty5
P09858572A0000|61 68|regions
P09858572A0000|79 88|chromatin
P09858577A1186|4 8|loss
P09858577A1186|12 16|SKO1
P09858577A1186|37 52|ENA1 expression
P09858577A1186|58 69|hog1 mutant
P09858577A1186|107 125|stress sensitivity
P09858577A1186|138 143|Sko1p
P09858577A1186|160 168|effector
P09858577A1186|176 187|HOG pathway
P09858581A0183|9 19|expression
P09858581A0183|52 56|gene
P09858581A0183|58 64|SPP381
P09858581A0183|93 99|growth
P09858581A0183|104 120|splicing defects
P09858581A0183|149 151|Ts
P09858581A0183|160 167|prp38-1
P09858588A1046|36 40|form
P09858588A1046|44 47|p68
P09858588A1046|68 73|cells
P09858588A1046|77 81|G1/S
P09858588A1046|102 107|cells
P09858588A1046|116 120|G2/M
P09858593A0334|19 39|amino acid sequences
P09858593A0334|57 78|Xenopus NeuroD1/BETA2
P09858593A0334|102 125|insulin gene expression
P09858593A0334|138 150|neurogenesis
P09858599A0392|5 25|NUP98-HOXA9 chimeras
P09858599A0392|38 57|NIH 3T3 fibroblasts
P09858599A0392|68 82|transformation
P09858599A0392|96 109|HOXA9 domains
P09858599A0392|114 125|DNA binding
P09858599A0392|130 145|PBX interaction
P09858619A0356|7 14|studies
P09858619A0356|35 39|Y319
P09858619A0356|65 80|ZAP-70 function
P09858713A1174|22 26|data
P09858713A1174|51 54|Pan
P09858713A1174|59 62|CiD
P09858713A1174|86 89|Arm
P09858713A1174|116 128|transduction
P09858713A1174|136 145|Wg signal
P09858713A1174|162 165|ciD
P09858713A1174|168 175|animals
P09858713A1174|194 205|enhancement
P09858713A1174|213 238|gain-of-function activity
P09858713A1174|242 245|CiD
P09858713A1174|260 267|mutants
P09858714A1171|8 11|ORF
P09858714A1171|13 18|dda.2
P09858714A1171|35 39|modA
P09858714A1171|44 47|dda
P09858714A1171|49 75|shares sequence similarity
P09858714A1171|81 88|sigma70
P09858714A1171|105 108|srd
P09858745A1350|4 12|location
P09858745A1350|20 23|IBS
P09858745A1350|35 39|catB
P09858745A1350|51 55|gene
P09858745A1350|61 74|cooperativity
P09858745A1350|87 107|footprinting studies
P09858745A1350|120 127|studies
P09858745A1350|145 148|IBS
P09858745A1350|169 180|interaction
P09858745A1350|184 188|CatR
P09858745A1350|207 220|binding sites
P09858745A1350|252 255|DNA
P09858745A2033|9 29|transcription assays
P09858745A2033|61 73|intermediate
P09858745A2033|75 83|fumarate
P09858745A2033|124 133|formation
P09858745A2033|141 156|clcA transcript
P09858883A1106|0 16|BIAcore analysis
P09858883A1106|24 28|Kaff
P09858883A1106|45 48|M-1
P09858883A1106|57 64|binding
P09858883A1106|68 72|N-A3
P09858883A1106|76 81|T84.1
P09858883A1106|99 102|M-1
P09858883A1106|111 118|binding
P09858883A1106|122 126|N-A3
P09858883A1106|130 133|T84
P09860979A0521|0 10|Expression
P09860979A0521|14 18|p130
P09860979A0521|19 22|Cas
P09860979A0521|25 28|Cas
P09860979A0521|39 54|binding protein
P09860979A0521|63 77|Crk SH2-domain
P09860979A0521|92 106|JNK activation
P09860979A0521|147 150|Crk
P09861099A1011|9 21|correlations
P09861099A1011|44 56|measurements
P09861099A1011|61 75|protein intake
P09861099A1011|77 78|r
P09861099A1011|85 86|P
P09861099A1011|95 108|energy intake
P09861099A1011|110 111|r
P09861099A1011|118 119|P
P09861099A1011|140 151|differences
P09861099A1011|159 165|g/kg/d
P09861099A1011|167 169|SD
P09861099A1011|179 190|kcal/kg/day
P09861099A1011|192 194|SD
P09861365A0000|4 9|Og4C3
P09861365A0000|38 43|assay
P09861365A0000|45 50|ELISA
P09861365A0000|95 102|antigen
P09861365A0000|111 117|microL
P09861365A0000|121 126|serum
P09862343A0225|17 35|gp200-MR6 ligation
P09862343A0225|51 55|IL-4
P09862343A0225|104 113|influence
P09862343A0225|132 138|system
P09862343A0225|148 161|up-regulation
P09862343A0225|180 189|molecules
P09862343A0225|193 206|B lymphocytes
P09862481A0000|4 18|Mig1 repressor
P09862481A0000|24 43|zinc finger protein
P09862481A0000|58 76|glucose repression
P09862481A0000|80 85|yeast
P09862496A0187|0 8|Ethylene
P09862496A0187|24 41|endosperm rupture
P09862496A0187|57 77|betaGLU I expression
P09862496A0187|128 135|pattern
P09862496A0187|139 159|betaGLU I expression
P09863624A0629|4 14|divergence
P09863624A0629|26 35|structure
P09863624A0629|48 58|sheep CRF1
P09863624A0629|83 88|CRF1s
P09863624A0629|133 138|amino
P09863624A0629|148 154|domain
P09863624A0629|162 170|receptor
P09863624A0629|191 199|residues
P09863624A0629|201 206|ovine
P09863624A0629|216 220|CRF1
P09863624A2301|16 40|receptor internalization
P09863624A2301|60 67|percent
P09863624A2301|71 76|total
P09863624A2301|78 82|125I
P09863624A2301|84 93|Tyr0-oCRF
P09863624A2301|130 138|fraction
P09863624A2301|154 157|Cos
P09863624A2301|160 165|cells
P09863624A2301|182 186|time
P09863624A2301|193 196|min
P09863624A2301|203 212|degrees C
P09863624A2301|245 250|oCRF1
P09863720T0000|30 37|disease
P09863720T0000|47 52|onset
P09863720T0000|57 77|protein S deficiency
P09864141A0528|15 20|Stat3
P09864141A0528|25 34|Stat3beta
P09864141A0528|40 48|affinity
P09864141A0528|64 79|phosphopeptides
P09864141A0528|91 95|Y704
P09864141A0528|100 104|Y744
P09864141A0528|134 151|peptide analogues
P09864141A0528|158 173|phosphopeptides
P09864141A0528|185 189|Y729
P09864141A0528|194 198|Y764
P09864335A1226|20 27|results
P09864335A1226|46 55|FCR1 gene
P09864335A1226|78 87|regulator
P09864335A1226|91 106|drug resistance
P09864335A1226|110 121|C. albicans
P09864335A1226|147 155|evidence
P09864335A1226|161 175|FCZ resistance
P09864335A1226|196 208|inactivation
P09864335A1226|225 231|factor
P09864335A1226|240 245|Fcr1p
P09864689A1408|6 14|findings
P09864689A1408|33 38|MYO/M
P09864689A1408|59 71|washout rate
P09864689A1408|86 92|effect
P09864689A1408|96 105|treatment
P09864689A1408|109 122|heart failure
P09864689A1408|130 133|DCM
P09865775A0162|5 10|study
P09865775A0162|42 50|couplers
P09865775A0162|61 70|placement
P09865775A0162|82 87|ALGO2
P09865775A0162|103 113|properties
P09866068A1058|0 11|CONCLUSIONS
P09866068A1058|13 25|Pretreatment
P09866068A1058|31 34|OCs
P09866068A1058|54 65|suppression
P09866068A1058|90 95|phase
P09866068A1058|114 128|cyst formation
P09866068A1058|150 156|effect
P09866068A1058|182 193|recruitment
P09866068A1058|197 212|pregnancy rates
P09867159A1444|5 11|regard
P09867159A1444|27 43|threshold values
P09867159A1444|45 56|sensitivity
P09867159A1444|61 72|specificity
P09867159A1444|81 82|%
P09867159A1444|85 86|%
P09867159A1444|93 94|%
P09867159A1444|97 98|%
P09867159A1444|104 111|FDG PET
P09867159A1444|127 128|%
P09867159A1444|131 132|%
P09867159A1444|139 140|%
P09867159A1444|143 144|%
P09867253A0229|5 19|c-Jun activity
P09867253A0229|36 41|c-Fos
P09867253A0229|51 67|protooncoprotein
P09867253A0229|91 96|c-Jun
P09867253A0229|109 134|transcription factor AP-1
P09867855T0000|0 19|Dorsal root ganglia
P09867855T0000|36 53|promoter activity
P09867855T0000|61 117|rabbit beta-galactoside alpha1,2-fucosyltransferase gene
P09868412A1628|0 10|CONCLUSION
P09868412A1628|16 21|study
P09868412A1628|43 51|body BMD
P09868412A1628|64 72|neck BMD
P09868412A1628|106 117|study group
P09868412A1628|148 157|exercises
P09868412A1628|174 182|subjects
P09868412A1628|188 205|swimming exercise
P09868412A1628|213 219|effect
P09868412A1628|223 226|BMD
P09868412A1628|245 253|swimming
P09868412A1628|277 285|exercise
P09868412A1628|316 324|shoulder
P09868412A1628|336 356|grip muscle strength
P09869297A1807|14 19|roles
P09869297A1807|33 36|CE1
P09869297A1807|41 53|CE2 elements
P09869297A1807|68 89|Hoxb1 gene expression
P09869297A1807|97 108|development
P09869356A0926|0 8|CAL gain
P09869356A0926|31 33|mm
P09869356A0926|37 38|%
P09869356A0926|46 53|defects
P09869356A0926|62 70|CAL gain
P09869356A0926|79 81|mm
P09869400A0203|0 11|Comparisons
P09869400A0203|29 36|germins
P09869400A0203|53 61|proteins
P09869400A0203|82 109|Arabidopsis GLP subfamilies
P09869400A0203|126 138|wheat germin
P09869528T0000|5 13|fixation
P09869528T0000|17 21|dogs
P09869528T0000|36 45|RF energy
P09871353A0174|32 40|evidence
P09871353A0174|44 69|A. salmonicida infections
P09871353A0174|84 96|furunculosis
P09871353A0174|118 122|fish
P09871353A0174|131 135|loch
P09872326A0566|41 49|CBF/cdc2
P09872326A0566|68 71|CBF
P09872326A0566|104 122|heat shock protein
P09872326A0566|126 134|promoter
P09872337A0000|17 27|absorption
P09872337A0000|31 42|clindamycin
P09872337A0000|71 81|volunteers
P09872337A0000|111 122|clindamycin
P09872337A0000|124 129|% w/v
P09872337A0000|131 140|tretinoin
P09872337A0000|147 152|% w/v
P09872337A0000|154 158|gels
P09872337A0000|171 198|clindamycin phosphate ester
P09872337A0000|203 218|clindamycin HCl
P09872337A0000|248 276|clindamycin phosphate lotion
P09872337A0000|279 292|% clindamycin
P09872337A0000|294 303|Dalacin T
P09872832A1262|4 22|BAL concentrations
P09872832A1262|35 44|cytokines
P09872832A1262|86 91|lungs
P09872832A1262|107 120|interleukin-6
P09872832A1262|122 126|IL-6
P09872832A1262|129 133|IL-8
P09872832A1262|135 140|IL-12
P09872832A1262|142 169|tumor necrosis factor-alpha
P09872832A1262|171 180|TNF-alpha
P09872832A1262|187 203|interferon gamma
P09872832A1262|205 214|IFN-gamma
P09872832A1262|235 246|differences
P09872832A1262|248 249|p
P09873060A0901|0 24|Phosphorylation analyses
P09873060A0901|40 50|inhibition
P09873060A0901|54 59|ERK-1
P09873060A0901|94 109|phosphorylation
P09873060A0901|113 117|JunD
P09873060A0901|122 126|FosB
P09873291A0620|8 16|analysis
P09873291A0620|20 28|variance
P09873291A0620|69 84|knowledge score
P09873291A0620|100 114|patient groups
P09874803A0000|21 52|bacterium group A Streptococcus
P09874803A0000|79 96|cysteine protease
P09874803A0000|122 132|exotoxin B
P09874803A0000|134 138|SpeB
P09874803A0000|160 176|virulence factor
P09874803A0000|190 206|disease episodes
P09875541A0210|4 17|orbitofrontal
P09875541A0210|47 51|part
P09875541A0210|59 80|dorsal premotor areas
P09875541A0210|133 151|hand movement task
P09875541A0210|153 157|SELF
P09876794T0000|0 9|Improving
P09876794T0000|14 27|evidence base
P09876794T0000|32 43|anaesthesia
P09877417A0704|0 17|Plasma CCK levels
P09877417A0704|45 54|intervals
P09878256A0000|4 35|peroxisome biogenesis disorders
P09878256A0000|37 41|PBDs
P09878256A0000|49 52|set
P09878256A0000|71 79|diseases
P09878256A0000|119 131|deficiencies
P09878256A0000|145 158|abnormalities
P09878256A0000|167 178|retardation
P09878256A0000|194 199|death
P09878437A0967|11 15|site
P09878437A0967|36 47|triad Asp53
P09878437A0967|53 57|site
P09878437A0967|61 76|phosphorylation
P09878437A0967|79 84|Asp10
P09878437A0967|89 93|Glu9
P09878542A1151|22 30|findings
P09878542A1151|64 73|silencing
P09878542A1151|88 91|VDR
P09878542A1151|115 131|osteopontin VDRE
P09879766A0402|3 8|PAV-3
P09879766A0402|14 24|E1A region
P09879766A0402|56 65|map units
P09880029A0703|13 32|MDV genome products
P09880029A0703|48 51|Rep
P09880029A0703|69 77|proteins
P09880029A0703|99 100|%
P09880029A0703|102 121|amino acid identity
P09880029A0703|147 161|FBNYV proteins
P09880029A0703|181 193|Rep proteins
P09880029A0703|205 211|MDV-C2
P09880029A0703|216 218|C3
P09880029A0703|227 228|%
P09880029A0703|237 238|%
P09880029A0703|269 276|SCSV-C2
P09880029A0703|281 283|C6
P09880103A0387|0 3|MPO
P09880103A0387|23 31|mCi 125I
P09880103A0387|37 46|technique
P09880103A0387|50 63|self-labeling
P09880103A0387|71 79|presence
P09880103A0387|90 109|M hydrogen peroxide
P09880327A0322|19 26|variety
P09880327A0322|57 65|proteins
P09880327A0322|77 88|yeast Uso1p
P09880327A0322|103 110|protein
P09880327A0322|123 130|docking
P09880327A0322|164 172|vesicles
P09880512A1251|4 8|data
P09880512A1251|23 27|Bmp2
P09880512A1251|73 82|receptors
P09880512A1251|87 90|Sp1
P09880513A1013|5 13|proteins
P09880513A1013|62 69|tubulin
P09880543A0570|0 4|HEED
P09880543A0570|26 36|MA protein
P09880543A0570|76 87|yeast cells
P09880544A0693|14 36|DT-40 lymphoma B-cells
P09880544A0693|77 87|disruption
P09880544A0693|95 103|btk gene
P09880544A0693|118 140|recombination knockout
P09880544A0693|151 160|apoptosis
P09880544A0693|167 179|Fas ligation
P09880544A0693|195 206|DT-40 cells
P09880544A0693|224 235|DT-40 cells
P09880544A0693|271 279|btk gene
P09881666A0535|2 7|motif
P09881666A0535|9 17|TGATGTCA
P09881666A0535|35 44|CREB site
P09881666A0535|66 75|AP-1 site
P09881666A0535|95 98|ER2
P09881692A0094|39 47|variants
P09881692A0094|49 51|b4
P09881692A0094|53 55|b5
P09881692A0094|57 59|b6
P09881692A0094|64 66|b9
P09881692A0094|120 138|Ckappa1 gene locus
P09881692A1109|14 19|order
P09881692A1109|45 50|genes
P09881692A1109|78 94|oligonucleotides
P09881692A1109|99 101|b5
P09881692A1109|103 105|b6
P09881692A1109|110 112|b9
P09881692A1109|116 126|probe DNAs
P09881692A1109|148 150|T.
P09881692A1109|167 174|rabbits
P09881692A1109|178 195|Southern blotting
P09882303A1413|0 5|TRAF2
P09882303A1413|33 38|TRADD
P09882303A1413|44 54|expression
P09882303A1413|89 110|deletion TRAF2 mutant
P09882303A1413|155 169|JNK activation
P09882303A1413|177 182|cells
P09882303A1984|6 10|data
P09882303A1984|28 32|role
P09882303A1984|37 42|TRADD
P09882303A1984|47 52|TRAF2
P09882303A1984|56 70|JNK activation
P09882303A1984|88 92|LMP1
P09882303A1984|102 123|signalling mechanisms
P09882303A1984|136 160|TNF receptor/CD40 family
P09882303A1984|187 197|activities
P09882303T0000|34 50|membrane protein
P09882303T0000|67 78|JNK pathway
P09882303T0000|99 109|C terminus
P09882303T0000|116 125|mechanism
P09882303T0000|136 141|TRADD
P09882303T0000|146 151|TRAF2
P09882321A0948|3 11|contrast
P09882321A0948|37 42|cells
P09882321A0948|54 60|EBNA-3
P09882321A0948|80 88|increase
P09882321A0948|92 117|EBNA-3 protein expression
P09882321A0948|135 146|EBNA-3 gene
P09882321A0948|159 170|EBNA-3 cDNA
P09882334A0822|16 24|passages
P09882334A0822|34 45|lamb kidney
P09882334A0822|47 50|FLK
P09882334A0822|52 57|cells
P09882334A0822|82 91|infection
P09882334A0822|97 100|BLV
P09882334A0822|118 130|transfection
P09882334A0822|145 153|mutation
P09882334A0822|166 182|tyrosine residue
P09882334A0822|201 206|motif
P09882334A0822|232 243|propagation
P09882334A0822|251 256|virus
P09882337A0000|0 22|Varicella-zoster virus
P09882337A0000|24 27|VZV
P09882337A0000|29 44|glycoprotein gI
P09882337A0000|50 54|type
P09882337A0000|57 83|transmembrane glycoprotein
P09882337A0000|97 106|component
P09882337A0000|128 130|gE
P09882337A0000|131 153|gI Fc receptor complex
P09882348A0611|8 11|end
P09882348A0611|29 51|phosphorylation status
P09882348A0611|67 92|tyrosine kinase substrate
P09882348A0611|111 130|Shc adapter protein
P09882348A0611|135 146|fibroblasts
P09882348A0611|168 176|oncogene
P09882451A0195|6 11|genes
P09882451A0195|57 63|mutant
P09882451A0195|88 107|ferrochelatase gene
P09882451A0195|109 114|HEM15
P09882451A0195|142 152|phenotypes
P09882451A0195|160 173|transformants
P09882489A0451|8 13|study
P09882489A0451|15 23|evidence
P09882489A0451|76 91|mef2 expression
P09882489A0451|119 124|array
P09882489A0451|150 157|modules
P09882489A0451|199 206|signals
P09882499A0231|30 46|mouse technology
P09882499A0231|87 95|elements
P09882499A0231|128 138|expression
P09882499A0231|142 146|Pax6
P09882593A0996|14 24|experiment
P09882593A0996|35 49|nickel isotope
P09882593A0996|51 55|61Ni
P09882593A0996|70 84|drinking water
P09882593A0996|109 114|women
P09882593A0996|134 142|controls
P09882593A0996|149 155|groups
P09882593A0996|173 184|hand eczema
P09882593A0996|192 206|pompholyx type
P09882638A0235|7 13|tissue
P09882638A0235|26 41|collagen fibers
P09882638A0235|49 65|tunica albuginea
P09882638A0235|77 86|expansion
P09882638A0235|94 102|erection
P09883639A0000|0 6|Number
P09883639A0000|10 18|patients
P09883639A0000|48 60|mycobacteria
P09883639A0000|62 65|NTM
P09883639A0000|102 107|years
P09884232A0286|0 10|Comparison
P09884232A0286|18 27|sequences
P09884232A0286|31 35|attP
P09884232A0286|37 41|attB
P09884232A0286|64 78|junctions attL
P09884232A0286|83 87|attR
P09884232A0286|100 102|bp
P09884232A0286|110 123|core sequence
P09884232A0286|131 144|recombination
P09884232A0286|151 156|place
P09884232A0286|170 173|end
P09884232A0286|181 195|integrase gene
P09884275T0000|0 26|Interferon-alpha treatment
P09884275T0000|65 73|disorder
P09884275T0000|77 87|recipients
P09884275T0000|97 114|organ transplants
P09884747A0477|14 21|testing
P09884747A0477|43 58|brewery workers
P09884747A0477|68 86|control volunteers
P09884747A0477|93 111|skin prick testing
P09884747A0477|123 129|barley
P09884747A0477|135 149|yeast antigens
P09884747A0477|183 192|allergens
P09884747A0477|219 235|serum IgE levels
P09885431A0000|0 9|OBJECTIVE
P09885431A0000|27 35|accuracy
P09885431A0000|57 62|crown
P09885431A0000|67 86|bridge restorations
P09885431A0000|102 105|mix
P09885431A0000|117 125|silicone
P09885431A0000|138 158|impression materials
P09885431A0000|175 180|types
P09885431A0000|184 194|stock tray
P09886602A0000|0 10|OBJECTIVES
P09886602A0000|26 33|ability
P09886602A0000|37 49|pretreatment
P09886602A0000|87 94|antigen
P09886602A0000|96 99|PSA
P09886602A0000|101 113|measurements
P09886602A0000|124 135|tumor stage
P09886602A0000|137 148|tumor grade
P09886602A0000|150 161|Gleason sum
P09886602A0000|163 167|race
P09886602A0000|169 172|age
P09886602A0000|178 192|radiation dose
P09886602A0000|208 218|recurrence
P09886602A0000|222 237|prostate cancer
P09886602A0000|257 279|beam radiation therapy
P09886602A0000|281 284|XRT
P09886602A0000|296 308|introduction
P09886602A0000|312 315|PSA
P09886602A0000|321 333|tumor marker
P09886602A0000|350 361|care center
P09886843A0339|30 34|gene
P09886843A0339|45 51|target
P09886843A0339|55 70|thyroid hormone
P09886843A0339|106 114|elements
P09886843A0339|118 122|NRGN
P09886843A0339|138 147|fragments
P09886843A0339|167 171|gene
P09886850A0145|20 28|activity
P09886850A0145|32 41|PPARgamma
P09886850A0145|69 83|ligand binding
P09886850A0145|112 127|phosphorylation
P09886850A0145|144 169|MEK/ERK signaling pathway
P09887544A0000|0 10|BACKGROUND
P09887544A0000|12 20|Diazepam
P09887544A0000|33 53|benzodiazepine group
P09887544A0000|57 70|tranquilizers
P09887544A0000|97 101|drug
P09887544A0000|106 114|sedation
P09887544A0000|123 129|relief
P09887544A0000|133 140|anxiety
P09887544A0000|148 157|treatment
P09887544A0000|161 169|epilepsy
P09888711A0781|0 22|Bioplastique granuloma
P09888711A0781|63 69|spaces
P09888711A0781|81 85|size
P09888711A0781|142 148|bodies
P09888711A0781|157 175|Artecoll granuloma
P09888711A0781|191 205|round vacuoles
P09888711A0781|226 230|size
P09888711A0781|235 240|shape
P09888711A0781|251 256|round
P09888711A0781|321 327|bodies
P09888994A0858|20 24|gene
P09888994A0858|62 80|mesoderm formation
P09888994A0858|85 98|somitogenesis
P09888994A0858|108 114|embryo
P09889202T0000|19 27|analysis
P09889202T0000|49 62|domain Zalpha
P09889202T0000|66 96|dsRNA adenosine deaminase type
P09889202T0000|107 117|similarity
P09889202T0000|126 131|alpha
P09889202T0000|134 138|beta
P09889202T0000|140 146|family
P09889202T0000|167 175|proteins
P09889306A0321|3 11|addition
P09889306A0321|17 27|regulation
P09889306A0321|31 53|Glvr-1 gene expression
P09889306A0321|73 85|applications
P09889306A0321|89 101|gene therapy
P09889306A0321|120 127|vectors
P09889306A0321|144 180|ape leukemia virus envelope proteins
P09889306A0321|194 207|gene delivery
P09889306A0321|223 233|cell types
P09890778T0000|0 13|Carbohydrates
P09890778T0000|18 33|glycoconjugates
P09890778T0000|46 53|methods
P09891009T0000|10 17|cloning
P09891009T0000|21 44|mouse glycolate oxidase
P09891046A0269|10 16|manner
P09891046A0269|28 31|PKR
P09891046A0269|41 52|cell growth
P09891046A0269|65 74|apoptosis
P09891046A0269|84 94|disruption
P09891046A0269|105 118|PKR signaling
P09891046A0269|142 153|cell growth
P09891046A0554|24 35|protein L18
P09891046A0554|39 50|interaction
P09891046A0554|56 59|PKR
P09891049A0761|0 10|Processing
P09891049A0761|32 41|precursor
P09891049A0761|51 60|nucleases
P09891049A0761|78 93|rRNA processing
P09891049A0761|101 106|Rnt1p
P09891049A0761|111 116|Rat1p
P09891061A0373|30 40|regulators
P09891061A0373|52 60|fragment
P09891061A0373|68 81|SpHE promoter
P09891061A0373|112 120|elements
P09891061A0373|149 153|bait
P09891061A0373|183 194|cis element
P09891061A1240|27 31|SpHE
P09891061A1240|48 57|regulator
P09891061A1240|63 69|timing
P09891061A1240|73 95|SpEts4 gene expression
P09891061A1240|119 129|expression
P09891061A1240|133 137|SpHE
P09891061A1240|156 175|sea urchin blastula
P09891065A1493|27 41|SRE activation
P09891065A1493|75 82|mutants
P09891065A1493|86 95|PKC-alpha
P09891065A1493|99 110|PKC-epsilon
P09891085A0815|15 20|cells
P09891085A0815|40 47|defects
P09891085A0815|66 71|cells
P09891085A0815|102 116|27S precursors
P09891092A1000|28 32|site
P09891092A1000|37 46|stem-loop
P09891092A1000|51 61|structures
P09891092A1000|91 104|end formation
P09891707A0000|15 23|subtypes
P09891707A0000|27 46|spondyloarthropathy
P09891707A0000|48 51|SpA
P09892017A2151|8 19|experiments
P09892017A2151|62 66|role
P09892017A2151|70 74|ELE1
P09892017A2151|86 106|receptor functioning
P09892021A0712|0 14|Overexpression
P09892021A0712|18 22|PTTG
P09892021A0712|38 51|NIH 3T3 cells
P09892021A0712|68 78|expression
P09892021A0712|83 92|secretion
P09892021A0712|102 126|fibroblast growth factor
P09892021A0712|146 151|tumor
P09892021A0712|170 176|factor
P09892422A1096|30 43|tissue sheath
P09892422A1096|75 86|contraction
P09892422A1096|94 104|myocardium
P09892422A1096|127 133|spread
P09892422A1096|137 147|conduction
P09892422A1096|166 178|transmission
P09892422A1096|186 193|impulse
P09892422A1096|206 217|termination
P09892422A1096|225 239|purkinje fibre
P09892642A0172|0 2|E1
P09892642A0172|6 18|DNA helicase
P09892642A0172|42 56|HPV E2 protein
P09892642A0172|74 85|replication
P09892662A0334|19 39|mutant alpha subunit
P09892662A0334|87 97|activation
P09892662A0334|101 103|Gs
P09892662A0334|121 130|regulator
P09892662A0334|143 150|cyclase
P09892736A0343|9 15|search
P09892736A0343|36 42|region
P09892736A0343|46 55|CDED/LIOR
P09892736A0343|72 84|% similarity
P09892736A0343|96 104|proteins
P09892736A0343|116 135|signal transduction
P09892736A0343|140 156|cell replication
P09892736A0343|166 170|ORC1
P09892736A0343|175 178|KSR
P09893060A0767|0 22|Northern blot analysis
P09893060A0767|51 61|expression
P09893060A0767|69 71|kb
P09893262A1272|16 23|variety
P09893262A1272|38 45|schemes
P09893262A1272|81 92|restriction
P09893262A1272|96 114|TGF-beta responses
P09893913A0656|0 9|Induction
P09893913A0656|13 24|anaesthesia
P09893913A0656|43 51|fentanyl
P09893913A0656|55 68|micrograms/kg
P09893913A0656|71 82|thiopentone
P09893913A0656|86 91|mg/kg
P09893913A0656|94 104|atracurium
P09893913A0656|110 115|mg/kg
P09894962T0000|2 12|comparison
P09894962T0000|29 36|profile
P09894962T0000|50 63|malformations
P09894962T0000|99 112|malformations
P09895323T0000|23 28|roles
P09895323T0000|32 40|kreisler
P09895323T0000|44 54|regulation
P09895323T0000|73 78|Hoxa3
P09895323T0000|83 94|Hoxb3 genes
P09897032T0000|29 41|self-pulsing
P09897032T0000|57 66|resonator
P09900679T0000|0 16|Wave cybernetics
P09900679T0000|27 32|model
P09900679T0000|87 96|phenomena
P09903722T0000|0 20|Autoionization rates
P09903722T0000|25 38|energy levels
P09903722T0000|42 52|triplet nf
P09903722T0000|58 72|Rydberg states
P09903722T0000|76 78|H2
P09904139T0000|14 22|approach
P09904139T0000|41 50|operators
P09911328T0000|9 17|approach
P09911328T0000|21 31|scattering
P09911328T0000|53 60|problem
P09913308T0000|11 17|lasing
P09913308T0000|26 28|nm
P09913308T0000|40 47|Ti ions
P09913308T0000|61 62|J
P09913308T0000|66 72|energy
P09913308T0000|89 101|laser pulses
P09914156A1496|18 25|regions
P09914156A1496|33 41|promoter
P09914156A1496|66 72|series
P09914156A1496|76 106|tenascin-C promoter constructs
P09914156A1496|115 124|deletions
P09914156A1496|170 187|promoter activity
P09914156A1496|215 227|pair element
P09914156A1496|249 251|bp
P09914156A1496|268 282|RNA start site
P09914500A0000|8 22|factor kappa B
P09914500A0000|24 33|NF-kappaB
P09914500A0000|51 71|transcription factor
P09914500A0000|80 85|genes
P09914500A0000|111 119|proteins
P09914500A0000|153 176|cytokines interleukin-1
P09914500A0000|181 202|tumor necrosis factor
P09914500A0000|204 207|TNF
P09914500A0000|208 213|alpha
P09914500A0000|241 251|conditions
P09914518A1217|15 26|enhancement
P09914518A1217|46 56|activation
P09914518A1217|60 68|COUP-TFI
P09914518A1217|95 124|AF-1 transactivation function
P09914518A1217|128 130|ER
P09914518A1217|158 166|presence
P09914518A1217|170 172|E2
P09914518A1217|176 194|4-hydroxytamoxifen
P09914518A1217|203 206|ICI
P09914525A0890|12 15|Ffh
P09914525A0890|30 35|point
P09914525A0890|39 41|tm
P09914525A0890|47 55|degreesC
P09915118T0000|11 26|naris occlusion
P09915118T0000|35 48|rat accessory
P09915118T0000|59 63|bulb
P09915798A1077|5 11|region
P09915798A1077|15 20|hsp90
P09915798A1077|46 64|chaperone activity
P09915798A1077|79 104|hsp90 dimerization domain
P09915798A1077|130 138|elements
P09915798A1077|153 181|steroid receptor interaction
P09915860A0000|4 12|promoter
P09915860A0000|20 39|rat pgp2/mdr1b gene
P09915860A0000|54 60|region
P09915860A0000|62 68|pgp2GC
P09915860A0000|98 107|mdr genes
P09915860A0000|124 142|consensus Sp1 site
P09915860A0119|0 3|Sp1
P09915860A0119|6 10|role
P09915860A0119|14 29|transactivation
P09915860A0119|37 56|pgp2/mdr1b promoter
P09915860A0119|82 97|Schneider cells
P09916786A0811|0 12|Measurements
P09916786A0811|22 42|bone mineral density
P09916786A0811|57 62|spine
P09916786A0811|76 81|femur
P09916786A0811|98 118|X-ray absorptiometry
P09916786A0811|136 143|markers
P09916786A0811|147 162|bone remodeling
P09916786A0811|164 169|serum
P09916786A0811|184 204|alkaline phosphatase
P09916786A0811|208 219|immunoassay
P09916786A0811|224 247|urine deoxypyridinoline
P09916786A0811|272 286|chromatography
P09916809A0405|6 9|MGP
P09916809A0405|44 50|matrix
P09916809A0405|52 55|ECM
P09916809A0405|57 64|protein
P09916809A0405|98 105|protein
P09916809A0405|118 146|transmembrane signal peptide
P09917064T0000|5 10|roles
P09917064T0000|14 17|p82
P09917064T0000|23 40|clam CPEB homolog
P09917064T0000|57 72|polyadenylation
P09917064T0000|91 98|masking
P09917387T0000|4 18|RNA polymerase
P09917387T0000|34 47|factor TFIIIB
P09917387T0000|58 66|DNA bend
P09917387T0000|79 87|TATA box
P09917387T0000|112 122|start site
P09917389A1239|4 11|pattern
P09917389A1239|15 32|RNase E digestion
P09917389A1239|36 47|finP305 RNA
P09917389A1239|62 66|FinP
P09917389A1239|72 80|GST-FinO
P09917389A1239|97 108|finP305 RNA
P09917389A1239|114 122|cleavage
P09917391A0380|0 25|Transcription readthrough
P09917391A0380|44 51|repeats
P09917391A0380|63 69|effect
P09917391A0380|78 83|event
P09917555T0001|0 8|Analysis
P09917555T0001|26 53|growth factor prescriptions
P09917555T0001|67 81|cancer centers
P09918096A0520|14 18|case
P09918096A0520|33 37|cyst
P09918715A0304|0 4|MotA
P09918715A0304|18 30|DNA sequence
P09918715A0304|34 42|MotA box
P09918715A0304|57 65|position
P09918715A1158|16 20|MotA
P09918715A1158|25 29|AsiA
P09918715A1158|67 71|TAFs
P09918715A1158|73 93|TATA binding protein
P09918715A1158|95 98|TBP
P09918715A1158|111 118|factors
P09918715A1158|126 133|binding
P09918715A1158|137 148|TBP results
P09918715A1158|152 165|transcription
P09918715A1158|175 198|core promoter sequences
P09918720A0998|4 17|S229A variant
P09918720A0998|43 48|bases
P09918720A0998|87 91|base
P09918720A0998|117 123|pocket
P09918720A0998|141 147|Ser229
P09918720A0998|161 168|contact
P09918720A0998|184 191|adenine
P09918842A0184|9 21|conservation
P09918842A0184|32 40|terminus
P09918842A0184|60 66|region
P09918842A0184|79 87|assembly
P09918842A0184|91 99|proteins
P09918842A0184|117 127|initiation
P09918842A0184|131 146|RNA replication
P09920539A0272|4 16|stimulations
P09920539A0272|42 48|GnRH-a
P09920539A0272|62 65|day
P09920539A0272|79 87|protocol
P09920539A0272|95 119|gonadotropin stimulation
P09920775A0075|4 12|sequence
P09920775A0075|24 26|bp
P09920775A0075|43 67|transcription start site
P09920775A0075|94 118|reporter gene expression
P09920775A0075|147 162|differentiation
P09920775A0075|166 175|P19 cells
P09920882A0287|0 4|Chem
P09920896A1230|15 26|differences
P09920896A1230|60 73|type peptides
P09920896A1230|110 122|substitution
P09920896A1230|137 144|protein
P09920896A1230|155 165|disruption
P09920896A1230|194 204|structures
P09920903A1045|6 13|results
P09920903A1045|31 41|c-met gene
P09920903A1045|52 58|target
P09920903A1045|62 81|p53 gene regulation
P09920930A0521|0 8|C3 toxin
P09920930A0521|30 43|RhoA function
P09920930A0521|65 68|SRE
P09920930A0521|69 81|Luc activity
P09920930A0521|94 100|effect
P09920930A0521|119 135|c-Fos expression
P09920930A0959|9 17|C3 toxin
P09920930A0959|30 41|combination
P09920930A0959|47 61|growth factors
P09920930A0959|80 84|AP-1
P09920930A0959|85 97|Luc activity
P09920930A0959|139 149|activation
P09920930A0959|153 157|AP-1
P09920930A0959|158 161|Luc
P09920930A0959|174 182|response
P09920930A0959|186 200|co-stimulation
P09920930A0959|206 220|growth factors
P09920930A0959|225 235|Ro-31-8220
P09920982A0253|4 7|aim
P09920982A0253|23 28|study
P09920982A0253|62 76|susceptibility
P09920982A0253|112 118|agents
P09920982A0253|125 132|strains
P09920982A0253|136 138|P.
P09920982A0253|159 171|acne lesions
P09920982A0253|195 214|Rap ID ANA II panel
P09921179T0001|4 8|role
P09921179T0001|27 43|echocardiography
P09921179T0001|47 54|surgery
P09921179T0001|62 67|heart
P09921179T0001|78 85|vessels
P09922230A1482|20 27|results
P09922230A1482|45 49|CAP1
P09922230A1482|75 85|resistance
P09922230A1482|100 115|stress response
P09922230A1482|119 130|C. albicans
P09922856A0459|0 10|Trinipatch
P09922856A0459|57 62|patch
P09922856A0459|71 90|absorption promoter
P09922856A0459|108 122|dose-strengths
P09922856A0459|126 133|mg/24 h
P09922856A0459|141 148|mg/24 h
P09922856A0459|153 176|Laboratoires Synthelabo
P09923245A0482|4 8|RMRI
P09923245A0482|24 46|interrater reliability
P09923245A0482|83 91|patients
P09924675A0412|13 18|point
P09924675A0412|26 39|consideration
P09924675A0412|49 60|conceptions
P09924675A0412|76 81|ICIDH
P09924675A0412|113 121|mainstay
P09924675A0412|127 132|model
P09924675A0412|137 148|diagnostics
P09924675A0412|152 166|rehabilitation
P09924675A0412|205 220|characteristics
P09924675A0412|239 246|process
P09924675A0412|260 265|basis
P09924675A0412|270 282|intervention
P09924987A0000|0 8|Pokeweed
P09924987A0000|19 26|protein
P09924987A0000|28 31|PAP
P09924987A0000|38 58|Phytolacca americana
P09924987A0000|80 93|N-glycosidase
P09924987A0000|103 119|adenine residues
P09924987A0000|121 126|A4324
P09924987A0000|130 138|28S rRNA
P09924987A0000|143 148|A2660
P09924987A0000|152 160|23S rRNA
P09924987A0000|174 183|ribosomes
P09924987A0000|192 202|eukaryotes
P09924987A0000|207 218|prokaryotes
P09925120A0074|0 9|OBJECTIVE
P09925120A0074|16 29|meta-analysis
P09925120A0074|47 53|trials
P09925120A0074|105 111|effect
P09925120A0074|129 135|fibers
P09925372A0458|16 20|ZFPs
P09925372A0458|30 38|ZFP cDNA
P09925372A0458|45 49|HFHZ
P09925372A0458|63 72|heart ZFP
P09925372A0458|79 96|sequence homology
P09925372A0458|121 124|box
P09925372A0458|126 130|KRAB
P09925372A1063|20 30|expression
P09925372A1063|44 49|heart
P09925372A1063|68 73|heart
P09925372A1063|88 97|HFHZ mRNA
P09925372A1063|122 129|process
P09925372A1063|133 144|development
P09925777A1195|14 31|affinity hnRNP A1
P09925777A1195|40 44|site
P09925777A1195|67 87|beta-globin reporter
P09925777A1195|89 92|Rev
P09925777A1195|130 136|levels
P09925777A1195|150 155|mRNAs
P09925777A1195|161 162|%
P09927193A0107|3 7|date
P09927193A0107|18 26|proteins
P09927193A0107|28 32|PLZF
P09927193A0107|37 42|LAZ-3
P09927193A0107|43 48|BCL-6
P09927193A0107|74 85|oncogenesis
P09927449A0421|0 14|Overexpression
P09927449A0421|18 22|POG1
P09927449A0421|53 62|G1 arrest
P09927449A0421|83 93|repression
P09927449A0421|101 105|CLN1
P09927449A0421|110 120|CLN2 genes
P09927570A0507|17 31|RNU2 fragility
P09927570A0507|50 62|transfection
P09927570A0507|71 88|expression vector
P09927570A0507|98 106|Ad12 E1B
P09927570A0507|110 113|kDa
P09927570A0507|134 143|E1 vector
P09927570A0507|157 168|E1 products
P09927570A0507|172 184|E1A proteins
P09927570A0507|201 204|E1B
P09927570A0507|208 211|kDa
P09927570A0507|219 231|kDa proteins
P09927585A0796|0 33|Competitionsupershift EMSA assays
P09927585A0796|57 65|proteins
P09927585A0796|83 110|bandshift complex formation
P09927585A0796|116 119|KCS
P09927585A0796|152 162|factor Sp1
P09927589T0000|0 10|Similarity
P09927589T0000|14 25|DNA binding
P09927589T0000|46 56|regulation
P09927589T0000|60 88|Caenorhabditis elegans MAB-3
P09927589T0000|117 120|DSX
P09927589T0000|130 142|conservation
P09927589T0000|146 149|sex
P09927589T0000|162 172|mechanisms
P09929088A0000|0 7|CONTEXT
P09929088A0000|9 17|ThinPrep
P09929088A0000|19 26|AutoPap
P09929088A0000|32 38|Papnet
P09929088A0000|49 61|technologies
P09929088A0000|80 91|sensitivity
P09929088A0000|96 100|cost
P09929088A0000|113 129|cancer screening
P09929811A0000|0 11|Experiments
P09929811A0000|26 30|cats
P09929811A0000|53 64|derivatives
P09929811A0000|107 117|properties
P09929811A0000|142 148|agents
P09929811A0000|162 168|CM-251
P09929811A0000|170 176|CM-266
P09929811A0000|182 188|CM-345
P09929811A0000|201 210|mean rise
P09929811A0000|214 221|segment
P09929811A0000|237 242|leads
P09929811A0000|261 272|electrogram
P09929811A0000|286 295|occlusion
P09929811A0000|323 329|branch
P09929811A0000|351 357|artery
P09931118A1072|12 18|p42/44
P09931118A1072|27 38|JNK pathway
P09931118A1072|59 65|action
P09931118A1072|69 77|IL-1beta
P09931191A0434|3 11|protocol
P09931191A0434|31 39|subjects
P09931191A0434|50 53|Con
P09931191A0434|58 71|Ecc arm curls
P09931191A0434|75 82|fatigue
P09931191A0434|109 124|muscle ischemia
P09931191A0434|144 154|resistance
P09931191A0434|161 169|protocol
P09931216A0566|0 7|Airflow
P09931216A0566|44 51|turbine
P09931216A0566|58 63|45-ft
P09931216A0566|70 75|cable
P09931216A0566|106 112|module
P09931252A1055|5 14|mutations
P09931252A1055|22 46|amino acid substitutions
P09931252A1055|60 72|coat protein
P09931252A1055|102 111|abilities
P09931252A1055|135 154|scaffolding protein
P09931391A0944|9 17|recovery
P09931391A0944|21 35|liver function
P09931391A0944|47 54|surgery
P09931435A0357|14 25|transcripts
P09931435A0357|47 52|exons
P09931435A0357|54 58|exon
P09931435A0357|65 70|ZIS-2
P09931435A0357|85 90|ZIS-1
P09931435A0357|105 109|exon
P09931435A0357|119 123|exon
P09931435A0357|128 133|ZIS-1
P09931435A0357|147 151|size
P09931435A0357|178 181|UTR
P09932288A0378|0 10|Expression
P09932288A0378|25 29|gene
P09932288A0378|31 34|XT3
P09932288A0378|71 77|kidney
P09932288A0378|91 99|sequence
P09932288A0378|126 138|cDNA library
P09933428A0351|0 9|IFN-gamma
P09933428A0351|37 39|TB
P09933428A0351|67 75|controls
P09933428A0351|104 113|treatment
P09933641A0241|15 24|sequences
P09933641A0241|51 64|amplification
P09933641A0241|68 77|cDNA ends
P09933641A0241|85 93|analysis
P09933641A0241|100 104|NHE5
P09933641A0241|113 118|clone
P09933641A0241|139 148|sequences
P09933641A0241|175 188|amplification
P09933641A0241|192 201|cDNA ends
P09933848A1008|6 20|alloantibodies
P09933848A1008|43 51|analysis
P09933848A1008|64 68|role
P09933848A1008|72 76|drug
P09933848A1008|89 103|autoantibodies
P09934611A1054|5 15|dependence
P09934611A1054|53 59|extent
P09934611A1054|72 83|min LVdP/dt
P09934611A1054|87 91|mean
P09934611A1054|99 107|pressure
P09935377T0108|0 5|Genoa
P09935377T0108|7 12|Italy
P09935377T0108|20 26|August
P09936001T0000|11 20|structure
P09936001T0000|24 29|delta
P09936001T0000|31 40|plutonium
P09936001T0000|55 57|Al
P09936001T0000|59 61|Ga
P09936001T0000|67 80|Sc impurities
P09936001T0000|84 89|delta
P09936001T0000|91 100|plutonium
P09938097T0000|14 22|transfer
P09938097T0000|27 63|photoluminescence undulation spectra
P09938097T0000|68 77|acceptors
P09938097T0000|81 85|ZnTe
P09940132T0000|8 14|theory
P09940132T0000|43 65|charge-transfer solids
P09940132T0000|76 86|properties
P09943651T0000|9 14|modes
P09943651T0000|20 27|soliton
P09944066T0073|0 2|II
P09945838T0000|18 37|matching conditions
P09945838T0000|42 46|GaAs
P09945838T0000|48 50|Al
P09945838T0000|51 53|Ga
P09945838T0000|57 72|heterojunctions
P09947191T0000|0 31|Neutron scattering measurements
P09947191T0000|44 53|exponents
P09947191T0000|57 64|CsMnBr3
P09947191T0000|68 70|Z2
P09947191T0000|79 94|antiferromagnet
P09949160A0600|14 28|32D Epo1 cells
P09949160A0600|44 49|level
P09949160A0600|53 61|bulk PKC
P09949160A0600|72 80|activity
P09949160A0600|93 103|expression
P09949160A0600|107 114|epsilon
P09949160A0600|119 135|eta PKC isoforms
P09949160A0600|165 177|upregulation
P09949160A0600|195 203|isoforms
P09949160A0600|212 217|betaI
P09949160A0600|224 234|readdition
P09949160A0600|238 241|Epo
P09949160A0600|245 251|growth
P09949160A0600|267 272|cells
P09949178A0264|8 18|expression
P09949178A0264|39 52|interleukin-6
P09949178A0264|54 58|IL-6
P09949178A0264|67 73|factor
P09949178A0264|90 96|growth
P09949178A0264|102 112|pre-B-cell
P09949178A0264|121 125|line
P09949178A0264|127 132|1A9-M
P09949312A0524|0 7|Airflow
P09949312A0524|20 29|dust trap
P09949312A0524|52 63|vacuum pump
P09950213A1660|38 50|goblet cells
P09950213A1660|52 59|TbetaRI
P09950213A1660|64 72|TbetaRII
P09950213A1660|116 124|TGF-beta
P09950213A1660|137 150|participation
P09950213A1660|154 163|TbetaRIII
P09950394A0336|4 11|history
P09950394A0336|15 23|exposure
P09950394A0336|28 52|carboxyhemoglobin levels
P09950394A0336|70 79|physician
P09950394A0336|88 97|diagnosis
P09952378A0529|4 14|odds ratio
P09952378A0529|19 22|CHD
P09952378A0529|35 56|% confidence interval
P09952378A0529|86 96|serostatus
P09952378A0529|109 123|IgG antibodies
P09952378A0529|130 140|adjustment
P09952378A0529|145 155|covariates
P09952425A0893|8 13|group
P09952425A0893|17 21|HIPP
P09952425A0893|40 47|animals
P09952425A0893|63 68|tasks
P09952425A0893|79 85|lesion
P09952425A0893|101 112|impairments
P09952425A0893|120 124|type
P09952425A0893|175 185|structures
P09952425A0893|204 210|lesion
P09952425A0893|226 230|role
P09952425A0893|238 249|hippocampus
P09952425A0893|258 264|degree
P09959737T0000|4 8|case
P09959737T0000|13 22|neutrinos
P09959737T0000|28 36|SN 1987A
P09961326T0000|11 23|fluctuations
P09961326T0000|43 52|interface
P09961326T0000|65 71|models
P09961682T0000|0 5|Model
P09961682T0000|24 32|dynamics
P09961682T0000|36 53|stick-slip motion
P09964171T0000|0 3|NMR
P09964171T0000|17 22|atoms
P09964171T0000|44 50|medium
P09964171T0000|58 66|presence
P09964171T0000|92 97|field
P09964770T0000|0 14|Microstructure
P09964770T0000|19 31|conductivity
P09964770T0000|48 67|laminate composites
P09965234T0000|12 26|heat transport
P09965234T0000|34 52|octylcyanobiphenyl
P09965234T0000|54 57|8CB
P09965234T0000|59 73|liquid crystal
P09965909T0000|7 15|approach
P09965909T0000|23 28|study
P09965909T0000|32 53|soliton perturbations
P09971776A0838|0 9|Mutations
P09971776A0838|25 39|CD4 regulation
P09971776A0838|50 58|residues
P09971776A0838|91 98|binding
P09971776A0838|102 105|Nef
P09971776A0838|114 122|receptor
P09971776A0838|132 135|W57
P09971776A0838|140 143|L58
P09971776A0838|176 191|dileucine motif
P09971776A0838|209 218|dipeptide
P09971776A0838|237 243|region
P09971776A0838|251 258|protein
P09971790A0856|8 17|mutations
P09971790A0856|32 44|endonuclease
P09971790A0856|49 68|helicase activities
P09971790A0856|88 117|amino-terminal-charge cluster
P09971790A0856|125 132|protein
P09971790A0856|134 148|D40A-D42A-D44A
P09971790A0856|166 198|AAV hairpin DNA binding activity
P09971806A1585|10 15|cycle
P09971806A1585|19 23|KSHV
P09971806A1585|52 59|control
P09971806A1585|67 80|KSHV/Rta gene
P09971806A1585|109 127|tumor pathogenesis
P09971815A2094|48 71|candidate latency genes
P09971815A2094|82 91|gammaHV68
P09971815A2094|98 108|expression
P09971815A2094|112 117|genes
P09971815A2094|125 132|latency
P09971815A2094|163 169|organs
P09971815A2094|196 212|latency programs
P09971815A2094|238 243|sites
P09971815A2094|247 254|latency
P09971815A2094|266 273|regions
P09971815A2094|287 293|genome
P09971815A2094|295 307|v-bcl-2 gene
P09971815A2094|309 319|v-GCR gene
P09971815A2094|325 329|gene
P09971815A2094|357 364|latency
P09971815A2094|375 384|gammaHV68
P09971815A2094|397 415|gammaherpesviruses
P09971822A1542|6 10|data
P09971822A1542|33 37|role
P09971822A1542|42 44|U1
P09971822A1542|61 80|splicing inhibition
P09973351A1522|23 39|DcuS-DcuR system
P09973351A1522|61 71|substrates
P09973607A0254|21 35|identification
P09973607A0254|40 56|characterization
P09973607A0254|68 80|Sp100 splice
P09973607A0254|89 97|proteins
P09973607A0254|116 125|existence
P09973607A0254|129 140|elucidation
P09973607A0254|151 154|end
P09973607A0254|162 172|Sp100 gene
P09974642T0000|0 9|Crossover
P09974642T0000|26 30|heat
P09974642T0000|41 48|magnets
P09974642T0000|79 87|dynamics
P09976626T0000|0 7|Erratum
P09976626T0000|9 16|Absence
P09976626T0000|20 37|precursor effects
P09976626T0000|60 74|transformation
P09976626T0000|87 94|crystal
P09976626T0000|98 106|Li metal
P09980944T0000|0 19|Interplane coupling
P09980944T0000|27 53|superconductor Y2Ba4Cu7O15
P09980944T0000|69 82|NQR spin-echo
P09980944T0000|90 99|resonance
P09982923T0000|11 20|structure
P09982923T0000|33 38|NiSi2
P09982923T0000|42 53|CoSi2 layer
P09982923T0000|57 64|bulk Si
P09983871T0000|0 19|Raman investigation
P09983871T0000|23 46|YBa2-xLaxCu3O7 ceramics
P09984526T0000|0 7|Effects
P09984526T0000|11 24|point defects
P09984526T0000|28 46|lattice parameters
P09984526T0000|50 64|semiconductors
P09985302T0000|8 25|electron dynamics
P09985302T0000|62 69|antidot
P09986796A1761|9 18|deletions
P09986796A1761|26 27|C
P09986796A1761|46 57|amino acids
P09986796A1761|79 86|effects
P09987176A0260|6 12|months
P09987176A0260|31 42|vaccination
P09987176A0260|48 57|vaccinees
P09987176A0260|78 87|follow-up
P09987176A0260|109 115|levels
P09987176A0260|119 127|anti-HAV
P09987634A1265|15 18|PRK
P09987634A1265|24 29|weeks
P09987634A1265|33 36|age
P09987634A1265|46 57|retreatment
P09987634A1265|82 92|regression
P09987634A1265|100 110|PRK effect
P09987961A0093|10 17|lesions
P09987961A0093|40 52|angiomatosis
P09987961A0093|54 66|vasculopathy
P09987961A0093|72 85|proliferation
P09987961A0093|89 101|synoviocytes
P09987961A0093|106 117|fibroblasts
P09988682T0033|10 17|cloning
P09988682T0033|27 31|cDNA
P09988682T0033|49 88|beta1,6-N-acetylglucosaminyltransferase
P09988682T0033|97 101|core
P09988682T0033|108 112|core
P09988767A1496|14 39|mouse back-cross analysis
P09988767A1496|55 59|loci
P09988767A1496|64 80|mouse 3Ost genes
P09988767A1496|94 105|assignments
P09988767A1496|129 136|isologs
P09988767A1496|159 173|identification
P09988767A1496|200 212|site markers
P09988850A0000|4 10|Scales
P09988850A0000|24 34|Impairment
P09988850A0000|60 67|Records
P09988850A0000|69 76|SCIRFIR
P09988850A0000|81 88|battery
P09988850A0000|112 139|dementia rating instruments
P09988850A0000|159 166|records
P09988850A0000|212 234|schizophrenia patients
P09988850A0000|244 251|purpose
P09988850A0000|296 302|course
P09988850A0000|316 322|change
P09988850A0000|326 339|schizophrenia
P09988850A0000|369 386|autopsy materials
P09989334A0964|29 47|processing signals
P09989334A0964|55 65|transcript
P09989334A0964|77 95|donor splice sites
P09989334A0964|104 124|polyadenylation site
P09989334A0964|156 162|intron
P09989339A0968|19 22|use
P09989339A0968|30 37|product
P09989339A0968|41 53|brain weight
P09989339A0968|58 67|clearance
P09990057T0000|0 13|Recombination
P09990057T0000|18 31|transcription
P09990057T0000|50 52|Ig
P09990057T0000|59 70|chain locus
P09990057T0000|90 92|Ig
P09990057T0000|99 104|chain
P09990057T0000|114 134|enhancer core region
P09990057T0000|142 149|absence
P09990057T0000|157 182|matrix attachment regions
P09990060A0803|13 19|motifs
P09990060A0803|24 28|part
P09990060A0803|65 86|dyad symmetry element
P09990060A0803|124 137|IL-2 enhancer
P09990060A0803|146 159|CD18 promoter
P09990060A0937|3 10|concert
P09990060A0937|20 57|coactivator CREB binding protein/p300
P09990060A0937|80 89|GABPalpha
P09990060A0937|95 102|binding
P09990060A0937|106 115|GABPalpha
P09990060A0937|121 125|beta
P09990060A0937|133 154|dyad symmetry element
P09990060A0937|168 177|induction
P09990060A0937|181 195|IL-16 promoter
P09990060A0937|199 206|T cells
P09990315A0205|0 3|TPO
P09990315A0205|31 35|ERK1
P09990315A0205|37 41|ERK2
P09990315A0205|46 62|protein kinase C
P09990315A0205|64 67|PKC
P09990315A0205|78 81|TPO
P09990315A0205|118 128|activation
P09990315A0205|132 136|ERKs
P09990315A0205|154 162|agonists
P09990315A0205|173 181|thrombin
P09990315A0205|186 200|phorbol esters
P09990315A0205|224 238|PKC activation
P09990315A0205|248 256|agonists
P09990507A0000|0 10|BACKGROUND
P09990507A0000|39 58|proteolysis pathway
P09990507A0000|62 78|ubiquitin ligase
P09990507A0000|80 82|E3
P09990507A0000|113 124|selectivity
P09990507A0000|129 135|timing
P09990507A0000|139 150|degradation
P09990507A0763|0 11|CONCLUSIONS
P09990507A0763|13 30|Fission yeast SCF
P09990507A0763|46 50|Pop1
P09990507A0763|55 59|Pop2
P09990507A0763|115 139|F-box/WD-repeat proteins
P09994942T0000|4 15|NMR studies
P09994942T0000|37 53|antiferromagnets
P09995847T0000|0 26|Optical-absorption spectra
P09995847T0000|42 55|energy levels
P09995847T0000|61 86|transition line strengths
P09995847T0000|90 97|holmium
P09995847T0000|110 113|Na3
P09995897T0000|0 11|Observation
P09995897T0000|23 35|interactions
P09995897T0000|44 55|Pb0 defects
P09995897T0000|69 86|Si/SiO2 interface
P09999256T0000|20 26|theory
P09999256T0000|41 60|transport phenomena
P09999742T0000|0 3|NH3
P09999742T0000|8 22|NO interaction
P09999742T0000|28 30|Si
P09999742T0000|44 52|surfaces
P10000253T0000|0 15|Chirality-glass
P10000253T0000|20 43|spin-glass correlations
P10000253T0000|79 87|XY model
P10001333T0038|0 15|Echo modulation
P10001333T0038|19 22|Pr3
P10001333T0038|24 29|YAlO3
P10001541T0000|0 10|Mechanisms
P10001541T0000|28 36|emission
P10001541T0000|66 73|silicon
P10002245T0000|21 33|conductivity
P10002245T0000|41 51|CuO chains
P10002245T0000|71 80|YBa2Cu3O7
P10002245T0000|82 95|delta crystal
P10006319T0000|0 18|Surface spin waves
P10006319T0000|24 46|Heisenberg ferrimagnet
P10006319T0000|65 75|anisotropy
P10007469T0000|19 26|librons
P10007469T0000|31 38|phonons
P10007469T0000|54 57|C60
P10007564T0000|22 30|geometry
P10007564T0000|46 55|structure
P10007564T0000|61 62|W
P10007564T0000|68 75|surface
P10008261T0000|0 22|Temperature dependence
P10008261T0000|30 40|sublattice
P10008261T0000|53 66|magnetization
P10008261T0000|70 79|YBa2Cu3O6
P10009565T0000|0 22|GW Gamma approximation
P10009565T0000|27 49|electron self-energies
P10009565T0000|53 67|semiconductors
P10009565T0000|72 82|insulators
P10013227T0000|0 21|Precision measurement
P10013227T0000|29 54|pion mass difference m pi
P10013227T0000|57 61|m pi
P10019841T0000|8 15|gravity
P10019841T0000|41 46|order
P10019841T0000|63 71|approach
P10021333A0674|8 19|experiments
P10021333A0674|26 33|mutants
P10021333A0674|59 64|bruno
P10021333A0674|85 96|interaction
P10021333A0674|111 116|genes
P10021350A0093|15 20|model
P10021350A0093|35 41|signal
P10021350A0093|53 75|Armadillo/beta-catenin
P10021350A0093|103 109|nuclei
P10021350A0093|120 143|TCF/LEF family proteins
P10021350A0093|163 184|transcription factors
P10021350A0093|200 213|transcription
P10021350A0093|217 229|Wingless/Wnt
P10021350A0093|241 246|genes
P10022032A0000|3 10|support
P10022032A0000|35 42|studies
P10022032A0000|48 70|vasodilator nicorandil
P10022032A0000|72 75|NIC
P10022032A0000|115 147|receptor antagonists propranolol
P10022032A0000|158 166|atenolol
P10022032A0000|168 171|ATN
P10022032A0000|186 219|calcium channel blocker diltiazem
P10022032A0000|221 224|DTZ
P10022032A0000|280 292|interactions
P10022210A0620|0 7|Factors
P10022210A0620|20 36|direct-immersion
P10022210A0620|38 40|DI
P10022210A0620|42 54|SPME process
P10022850A0929|3 11|contrast
P10022850A0929|31 39|fragment
P10022850A0929|55 66|C/H1 domain
P10022850A0929|86 98|coactivation
P10022850A0929|102 119|Zta transcription
P10022850A0929|130 151|reactivation function
P10022858A0985|3 11|addition
P10022858A0985|22 48|splicing enhancer sequence
P10022858A0985|65 74|selection
P10022858A0985|106 113|protein
P10022867A1069a|0 11|Elimination
P10022867A1069a|15 19|ETH1
P10022867A1069a|23 35|apn1 strains
P10022867A1069a|63 77|mutation rates
P10022867A1069a|113 117|type
P10022867A1069a|135 144|reversion
P10022867A1069a|148 155|adenine
P10022867A1069a|159 177|lysine prototrophy
P10022867A1069b|0 11|Elimination
P10022867A1069b|15 19|ETH1
P10022867A1069b|23 35|apn1 strains
P10022867A1069b|63 77|mutation rates
P10022867A1069b|113 117|type
P10022867A1069b|135 144|reversion
P10022867A1069b|148 155|adenine
P10022867A1069b|159 177|lysine prototrophy
P10022875A1265|6 10|data
P10022875A1265|30 43|Ras effectors
P10022875A1265|65 76|PI 3-kinase
P10022875A1265|109 112|Pak
P10022880A0000|10 39|Ras GTPase-activating protein
P10022880A0000|41 44|GAP
P10022880A0000|47 59|p120 Ras-GAP
P10022880A0000|91 104|downregulator
P10022880A0000|109 117|effector
P10022880A0000|121 133|Ras proteins
P10022880A0000|151 155|role
P10022880A0000|172 200|signal transduction pathways
P10022905A0446|6 19|mog-1 alleles
P10022905A0446|38 49|stop codons
P10022905A0446|76 83|alleles
P10022905A0446|98 115|missense mutation
P10022905A0446|149 157|activity
P10022905A0446|159 169|mog-1 mRNA
P10022905A0446|191 200|germ line
P10022905A0446|213 220|tissues
P10022921A0608|20 29|SIN3 gene
P10022921A0608|59 63|pst1
P10022921A0608|84 98|cell viability
P10022925A0870|4 25|Nmd3 protein sequence
P10022925A0870|64 70|motifs
P10022925A0870|80 88|function
P10022978A1261|4 16|distribution
P10022978A1261|32 39|repeats
P10022978A1261|53 65|organization
P10022978A1261|105 112|regions
P10022978A1261|122 126|base
P10022978A1261|140 155|chromosome arms
P10024383T0000|0 10|Calcitonin
P10024383T0000|52 64|hyperostosis
P10024383T0000|80 90|osteopenia
P10024383T0000|118 123|mouse
P10024383T0000|125 132|twy/twy
P10024498A0783|31 37|assays
P10024498A0783|57 64|HNF-3 X
P10024498A0783|69 76|Y sites
P10024498A0783|100 105|sites
P10024498A0783|129 139|HNF-3alpha
P10024498A0783|144 153|HNF-3beta
P10024882A0541|3 11|addition
P10024882A0541|31 35|cdk7
P10024882A0541|75 81|domain
P10024882A0541|83 86|CTD
P10024882A0541|91 98|RNA pol
P10024882A0541|109 116|absence
P10024882A0541|120 136|promoter opening
P10025050A1052|4 11|therapy
P10025050A1052|31 41|antagonist
P10025050A1052|76 85|therapies
P10025050A1052|91 101|omeprazole
P10025050A1052|105 117|lansoprazole
P10025506A0079|3 9|humans
P10025506A0079|33 49|plastin isoforms
P10025506A1078|3 7|TATA
P10025506A1078|11 23|Inr sequence
P10026146A0680|4 14|inhibition
P10026146A0680|22 37|RIalpha subunit
P10026146A0680|53 61|addition
P10026146A0680|75 89|concentrations
P10026146A0680|93 97|cAMP
P10026146A0680|99 101|Ka
P10026146A0680|107 109|nM
P10026146A0680|136 140|PrKX
P10026146A0680|153 157|type
P10026146A0680|175 189|protein kinase
P10026146A0680|217 236|cAMP concentrations
P10026146A0680|246 256|holoenzyme
P10026146A0680|266 280|Calpha subunit
P10026146A0680|299 313|protein kinase
P10026211A0136|0 8|Proteins
P10026211A0136|27 36|PEPCK CRE
P10026211A0136|61 68|protein
P10026211A0136|70 74|CREB
P10026211A0136|80 87|members
P10026211A0136|118 125|protein
P10026211A0136|127 132|C/EBP
P10026211A0136|134 140|family
P10026211A0543|5 14|construct
P10026211A0543|23 37|pDeltaCREC/EBP
P10026211A0543|45 55|C/EBPalpha
P10026211A0543|60 64|beta
P10026211A0543|73 77|CREB
P10026211A0543|112 135|glucocorticoid response
P10026211A0543|170 194|H4IIE rat hepatoma cells
P10026229A0950|3 11|addition
P10026229A0950|22 33|mutagenesis
P10026229A0950|42 51|Engrailed
P10026229A0950|56 66|Pbx1 sites
P10026229A0950|101 106|sites
P10026229A0950|147 158|enhancement
P10026229A0950|186 194|fragment
P10026275A0549|18 36|structure elements
P10026784A0331|9 17|evidence
P10026784A0331|41 50|functions
P10026784A0331|58 64|family
P10026784A0331|68 89|transcription factors
P10026784A0331|111 132|POU DNA binding motif
P10026784A0331|140 145|roles
P10026784A0331|159 170|development
P10026784A0929|28 39|DNA binding
P10026784A0929|43 75|POU domain transcription factors
P10026784A0929|115 130|POU-homeodomain
P10026784A2166|7 20|Oct-1 crystal
P10026784A2166|39 45|domain
P10026784A2166|59 73|GCAT half-site
P10026784A2166|99 107|sequence
P10026784A2166|126 131|Pit-1
P10026784A2166|145 151|domain
P10026784A2166|153 157|GTAT
P10026784A2166|178 184|strand
P10026824A0309|22 30|analysis
P10026824A0309|34 57|V1a/V2 hybrid receptors
P10026824A0309|95 99|loop
P10026824A0309|107 119|V1a receptor
P10026824A0309|161 169|coupling
P10026824A0309|173 178|Gq/11
P10026824A0309|212 216|loop
P10026824A0309|224 235|V2 receptor
P10026824A0309|267 275|coupling
P10026824A0309|279 281|Gs
P10027498A0536|11 21|end points
P10027498A0536|51 56|death
P10027498A0536|89 101|U.S. program
P10027498A0536|122 123|p
P10027904A0768|61 67|region
P10029337A0406|4 20|fatigue exercise
P10029337A0406|44 71|blood lactate concentration
P10029337A0406|79 81|SD
P10029337A0406|87 91|mmol
P10029337A0406|94 95|l
P10029337A0406|108 116|increase
P10029337A0406|120 141|serum creatine kinase
P10029337A0406|143 145|CK
P10029337A0406|147 155|activity
P10029337A0406|169 173|days
P10029337A0406|180 182|SD
P10029337A0406|188 189|U
P10029337A0406|192 193|l
P10029860A0605|19 26|aspects
P10029860A0605|51 61|categories
P10029860A0605|66 70|type
P10029860A0605|104 111|filling
P10029917A0366|0 7|Results
P10029917A0366|30 38|presence
P10029917A0366|42 56|myofibroblasts
P10029917A0366|82 86|case
P10029917A0366|90 94|case
P10029917A0366|128 150|muscle cell dispersion
P10029917A0366|195 215|portal vein branches
P10031854T0000|0 22|New Langevin equations
P10031854T0000|80 83|top
P10032519T0000|10 21|corrections
P10032519T0000|25 35|beta decay
P10032519T0000|44 55|possibility
P10032519T0000|68 78|generation
P10032581T0000|17 46|grazing-incidence diffraction
P10032581T0000|50 61|synchrotron
P10032581T0000|64 73|radiation
P10033973T0000|12 20|exchange
P10033973T0000|24 29|atoms
P10033973T0000|38 43|traps
P10033973T0000|55 71|Bose condensates
P10034615T0000|0 23|Structure determination
P10034615T0000|59 73|reconstruction
P10034615T0000|78 79|x
P10034615T0000|83 87|H/Ni
P10035841T0000|9 17|trapping
P10035841T0000|43 51|hydrogen
P10036181A0603|0 13|Northern blot
P10036181A0603|26 48|hybridization analyses
P10036181A0603|58 80|GPR34 mRNA transcripts
P10036181A0603|102 119|rat brain regions
P10036191A0000|4 22|microphthalmia-TFE
P10036191A0000|24 27|MiT
P10036191A0000|29 38|subfamily
P10036191A0000|65 79|leucine zipper
P10036191A0000|81 89|bHLH-ZIP
P10036191A0000|91 112|transcription factors
P10036191A0000|124 128|TFE3
P10036191A0000|130 134|TFEB
P10036191A0000|136 140|TFEC
P10036191A0000|146 150|Mitf
P10036191A0000|179 189|regulation
P10036191A0000|209 224|gene expression
P10036191A0000|236 249|cell lineages
P10037004A0000|12 20|patients
P10037004A0000|31 36|years
P10037004A0000|62 70|leukemia
P10037004A0000|72 75|ALL
P10037004A0000|96 107|bone marrow
P10037004A0000|109 111|BM
P10037004A0000|113 120|relapse
P10037004A0000|149 156|therapy
P10037004A0000|197 202|study
P10037378A0176|4 17|dorsal nerves
P10037378A0176|25 30|penis
P10037378A0176|66 75|lidocaine
P10037460A0221|7 12|brain
P10037460A0221|25 34|receptors
P10037460A0221|43 48|motor
P10037460A0221|53 68|memory function
P10037460A0221|72 83|interaction
P10037460A0221|95 115|ligand acetylcholine
P10037576T0000|20 28|necrosis
P10037576T0000|35 41|iodine
P10037576T0000|48 67|plaque radiotherapy
P10037576T0000|87 95|melanoma
P10037681A0494|11 22|interaction
P10037681A0494|26 29|ARF
P10037681A0494|34 43|PKC-alpha
P10037681A0494|49 53|PLD1
P10037681A0494|89 97|fragment
P10037681A0494|107 111|PLD1
P10037681A0494|122 124|D4
P10037681A0494|154 160|mutant
P10037681A0494|164 168|RhoA
P10037681A0494|170 180|RhoAVal-14
P10037774A0366|8 13|study
P10037774A0366|35 63|signal transduction pathways
P10037774A0366|96 114|LDLR transcription
P10041728T0000|0 21|Vacuum Rabi splitting
P10041728T0000|27 34|feature
P10041728T0000|38 62|linear-dispersion theory
P10041728T0000|64 72|Analysis
P10041728T0000|90 102|observations
P10043466T0000|14 21|effects
P10043466T0000|46 54|kinetics
P10043466T0000|58 66|excitons
P10043466T0000|70 91|polydiacetylene 4BCMU
P10044519T0000|5 14|reduction
P10044519T0000|28 33|flows
P10044519T0000|37 45|polymers
P10046849T0000|6 11|scale
P10046849T0000|23 45|structure calculations
P10047970T0013|8 24|world literature
P10049357A0608|6 13|results
P10049357A0608|24 27|Ski
P10049357A0608|33 42|component
P10049357A0608|50 62|HDAC complex
P10049357A0608|72 75|Ski
P10049357A0608|112 122|repression
P10049357A0608|140 147|complex
P10049359A1073|12 15|unr
P10049359A1073|54 57|PTB
P10049359A1073|71 82|translation
P10049359A1073|100 115|rhinovirus IRES
P10049742T0000|0 8|Analysis
P10049742T0000|16 42|consensus binding sequence
P10049742T0000|63 69|domain
P10049742T0000|73 76|ZF5
P10049775T0000|0 7|Mapping
P10049775T0000|39 61|Anion Channel isoforms
P10049912T0000|0 14|Identification
P10049912T0000|18 25|RNase T
P10049912T0000|41 51|suppressor
P10049912T0000|59 73|UV sensitivity
P10049912T0000|104 130|DNA exonuclease deficiency
P10050883A0967|0 10|Inhibition
P10050883A0967|14 43|phosphatidylinositol-3 kinase
P10050883A0967|71 77|effect
P10050883A0967|81 97|p53 conformation
P10050883A0967|134 140|effect
P10050883A0967|157 166|viability
P10051030A1080|3 13|difference
P10051030A1080|17 27|percentage
P10051030A1080|31 36|males
P10051030A1080|40 56|semen production
P10051030A1080|75 82|strains
P10051030A1080|84 93|CP levels
P10051030A1080|106 114|regimens
P10051400A0000|4 12|Lp mouse
P10051400A0000|31 36|model
P10051400A0000|65 76|tube defect
P10051400A0000|78 81|NTD
P10051400A0000|84 103|cranio-rachischisis
P10051488A1293|8 16|analysis
P10051488A1293|20 47|AP-1 DNA binding activities
P10051488A1293|64 71|culture
P10051488A1293|82 86|HSCs
P10051488A1293|98 107|discovery
P10051488A1293|116 139|mobility AP-1 complexes
P10051488A1293|141 147|HMAP-1
P10051488A1610|0 9|Mutations
P10051488A1610|17 26|AP-1 site
P10051488A1610|34 49|TIMP-1 promoter
P10051488A1610|65 74|formation
P10051488A1610|78 84|HMAP-1
P10051488A1610|96 102|% loss
P10051488A1610|106 114|activity
P10051488A1610|140 144|HSCs
P10052371A0171|0 12|STUDY DESIGN
P10052371A0171|23 46|immunoglobulin A levels
P10052371A0171|61 69|subjects
P10052371A0171|91 100|occasions
P10052371A0171|119 126|subject
P10052371A0171|137 144|smoking
P10052371A0171|156 160|days
P10052371A0171|167 176|cessation
P10052371A0171|180 187|smoking
P10052371A0171|208 211|day
P10052371A0171|218 227|cessation
P10052878A0135|16 31|set-up accuracy
P10052878A0135|36 51|reproducibility
P10053852T0000|0 4|Role
P10053852T0000|8 10|g2
P10053852T0000|27 36|Schwinger
P10053852T0000|41 72|Gerasimov-Drell-Hearn sum rules
P10054976T0000|0 12|Spectroscopy
P10054976T0000|25 29|ions
P10054976T0000|52 62|detachment
P10054976T0000|68 89|Raman coupling regime
P10055173T0000|0 22|Band structure effects
P10055173T0000|26 46|transport properties
P10055173T0000|62 75|quasicrystals
P10059496T0000|9 29|transmission spectra
P10059496T0000|37 52|Penrose lattice
P10063122T0000|0 25|Two-Channel Kondo Lattice
P10063122T0000|41 46|Metal
P10063739A0601|26 55|esophageal sphincter pressure
P10063739A0601|75 86|study group
P10063739A0601|88 92|mean
P10063739A0601|94 96|SD
P10063739A0601|109 113|mmHg
P10063739A0601|119 127|controls
P10063739A0601|140 144|mmHg
P10063739A0601|151 159|pressure
P10063739A0601|185 188|EVS
P10063739A0601|192 195|EVL
P10064604A0824|0 4|CPDs
P10064604A0824|20 25|sites
P10064604A0824|49 55|TFIIIA
P10064604A0824|80 86|repair
P10065176A0657|13 23|difference
P10065176A0657|31 54|hormone receptor status
P10065176A0657|67 72|cases
P10065176A0657|81 102|lymph node metastases
P10065176A0657|112 133|lymph node metastases
P10065176A0657|152 167|macrometastases
P10065684A0916|13 17|hand
P10065684A0916|19 27|subjects
P10065684A0916|33 45|air trapping
P10065684A0916|56 62|volume
P10065684A0916|64 66|RV
P10065684A0916|74 87|lung capacity
P10065684A0916|89 92|TLC
P10065684A0916|97 98|%
P10065684A0916|128 129|n
P10065684A0916|130 133|mit
P10065684A0916|167 178|mt x microm
P10065684A0916|184 185|p
P10065684A0916|204 214|sarcomeres
P10065684A0916|216 217|L
P10065684A0916|218 221|sar
P10065684A0916|229 237|subjects
P10065684A0916|262 273|abnormality
P10065684A0916|302 308|microm
P10065684A0916|310 311|p
P10066790A0497|0 14|Gel filtration
P10066790A0497|16 38|sedimentation velocity
P10066790A0497|44 75|immunoprecipitation experiments
P10066790A0497|90 95|beta4
P10066790A0497|101 110|component
P10066790A0497|129 136|complex
P10066790A0497|138 142|AP-4
P10066790A0497|167 185|sigma4 polypeptide
P10066790A0497|205 229|adaptor subunit homologs
P10066790A0497|236 239|mu4
P10066790A0497|241 248|mu-ARP2
P10066790A0497|254 261|epsilon
P10066798A0391|0 6|Cyclin
P10066798A0391|21 36|kinase activity
P10066798A0391|41 55|protein levels
P10066798A0391|82 88|tumors
P10066798A0391|109 125|tumor virus-pp60
P10066798A0391|126 135|c-src527F
P10066798A0391|148 152|mice
P10066815T0000|4 7|SH2
P10066815T0000|26 34|inositol
P10066815T0000|38 49|phosphatase
P10066815T0000|51 55|SHIP
P10066815T0000|70 81|p85 subunit
P10066815T0000|85 110|phosphoinositide 3-kinase
P10066815T0000|140 150|inhibition
P10066815T0000|154 179|B cell receptor signaling
P10068040A0136|17 29|mouse genome
P10068040A0136|44 50|copies
P10068040A0136|58 68|ubc-9 gene
P10068418A1194|3 11|increase
P10068418A1194|15 35|bone mineral density
P10068418A1194|43 48|spine
P10068418A1194|56 59|hip
P10068418A1194|71 75|body
P10068418A1194|99 109|raloxifene
P10068418A1194|151 159|estrogen
P10068418A1194|163 182|alendronate therapy
P10068446A0124|18 25|studies
P10068446A0124|37 45|presence
P10068446A0124|49 61|thiol agents
P10068446A0124|69 85|PKC preparations
P10068446A0124|101 109|reaction
P10068446A0124|113 116|BPO
P10068446A0124|135 152|cysteine residues
P10068446A0124|156 159|PKC
P10068637A1320|15 23|Csx/Nkx2
P10068674A0644|42 46|form
P10068674A0644|50 57|Lyp RNA
P10068674A0644|59 63|Lyp2
P10068834A0713|4 9|costs
P10068834A0713|15 17|DM
P10068834A0713|31 33|PE
P10068834A0713|35 37|DM
P10068834A0713|51 53|VR
P10068834A0713|58 60|DM
P10068834A0713|73 76|MR.
P10069815A0285|15 23|evidence
P10069815A0285|52 63|interaction
P10069815A0285|72 76|Doa4
P10069815A0285|85 95|proteasome
P10070158A0573|12 27|splicing events
P10070158A0573|63 77|cassette exons
P10070158A0573|128 148|transmembrane domain
P10071205A0833|14 19|genes
P10071205A0833|49 52|ORF
P10071205A0833|60 64|STA2
P10071205A0833|93 103|AUG codons
P10071205A0833|120 127|cistron
P10071212A0399|22 38|O. australiensis
P10071761A2374|3 11|addition
P10071761A2374|13 20|mapping
P10071761A2374|28 43|promoter region
P10071761A2374|52 66|identification
P10071761A2374|79 87|promoter
P10071761A2374|99 108|sequences
P10071761A2374|121 128|insight
P10071761A2374|154 164|regulation
P10071761A2374|168 183|UCP2 expression
P10071761A2374|202 208|anyone
P10071761A2374|232 239|factors
P10071806A0377|4 8|rate
P10071806A0377|12 25|resectability
P10071806A0377|44 52|survival
P10072205A0167|3 8|order
P10072205A0167|36 48|distribution
P10072205A0167|52 54|ML
P10072205A0167|59 72|MAP estimates
P10072205A0167|85 95|conditions
P10072205A0167|109 128|point approximation
P10072205A0167|132 146|density values
P10072205A0167|166 178|distribution
P10072205A0167|187 196|estimates
P10072774A0537|0 6|RT-PCR
P10072774A0537|58 81|oligonucleotide primers
P10072774A0537|89 110|ligand binding domain
P10072774A0537|112 115|LBD
P10072774A0537|126 148|beta integrin subunits
P10072774A0537|153 161|Bge cDNA
P10073899A0740|11 31|culture failure rate
P10073899A0740|43 47|cent
P10073899A0740|64 67|EAF
P10073899A0740|90 94|cent
P10073899A0740|101 104|CVS
P10073940A0335|8 18|expression
P10073940A0335|22 28|d-axin
P10073940A0335|48 57|signaling
P10073947A1110|18 29|differences
P10073947A1110|33 38|FVIIa
P10073947A1110|43 48|PAI-1
P10074135T0000|33 41|elements
P10074135T0000|55 64|synthesis
P10074135T0000|68 74|barley
P10074135T0000|82 93|dwarf virus
P10074135T0000|105 109|RNA1
P10074282A0236|13 17|side
P10074282A0236|35 39|ring
P10074282A0236|58 63|L-NNA
P10074282A0236|65 87|NO-synthesis inhibitor
P10074282A0236|92 106|methylene blue
P10074282A0236|116 133|cGMPase inhibitor
P10074282A0236|140 147|changes
P10074425A0729|14 26|inactivation
P10074425A0729|34 55|cyclin E-Cdk2 complex
P10074425A0729|59 67|response
P10074425A0729|71 89|mitogen starvation
P10074425A0729|109 113|MEFs
P10074425A0729|137 145|deletion
P10074425A0729|153 161|p27 gene
P10074520T0000|0 14|Identification
P10074520T0000|19 35|characterization
P10074520T0000|39 45|IS2404
P10074520T0000|50 56|IS2606
P10074520T0000|80 89|sequences
P10074520T0000|94 103|detection
P10074520T0000|107 129|Mycobacterium ulcerans
P10074520T0000|133 136|PCR
P10074903A0915|22 29|results
P10074903A0915|54 65|possibility
P10074903A0915|71 83|p202 protein
P10074903A0915|103 135|cell growth retardation activity
P10074903A0915|143 147|IFNs
P10074903A0915|161 165|part
P10074903A0915|181 199|p21 protein levels
P10074921A1169|8 15|results
P10074921A1169|42 72|HepG2 hepatoblastoma cell line
P10074921A1169|85 88|p53
P10075415A1178|8 18|sequencing
P10075415A1178|26 32|region
P10075415A1178|47 54|ORF-Pto
P10075415A1178|64 72|homology
P10075415A1178|80 91|ru/AB genes
P10075415A1178|105 118|UV resistance
P10075415A1178|125 138|plasmid pPSR1
P10076007A0656|4 8|MSY2
P10076007A0656|20 26|kinase
P10076007A0656|34 47|casein kinase
P10076007A0656|55 61|kinase
P10076007A0656|88 95|mRNP3+4
P10076007A0656|99 106|oocytes
P10076007A0656|131 137|kinase
P10077188A1172|33 38|genes
P10077188A1172|62 74|biosynthesis
P10077188A1172|86 91|acids
P10077188A1172|96 104|proteins
P10077188A1172|119 124|genes
P10077188A1172|163 173|heat shock
P10077188A1172|206 215|synthesis
P10077188A1172|219 223|mRNA
P10077188A1172|228 235|protein
P10077533A0976|6 10|data
P10077533A0976|33 38|tools
P10077533A0976|53 67|identification
P10077533A0976|75 78|MKS
P10077533A0976|87 96|MUL genes
P10078734A0480|13 27|recovery curve
P10078734A0480|47 58|stimulation
P10078734A0480|73 78|nerve
P10078734A0480|86 91|elbow
P10078734A0480|96 105|recording
P10078734A0480|115 136|flexor carpi radialis
P10078876A0000|4 11|origins
P10078876A0000|31 38|changes
P10078876A0000|64 72|activity
P10078876A0000|82 89|signals
P10078876A0000|112 136|rat somatosensory cortex
P10078876A0000|150 157|imaging
P10078876A0000|159 181|microspectrophotometry
P10078876A0000|201 210|flowmetry
P10078876A0000|224 231|changes
P10078876A0000|241 265|hemoglobin concentration
P10078876A0000|270 281|oxygenation
P10079173A0000|25 33|proteins
P10079173A0000|57 79|RNA recognition motifs
P10079173A0000|81 85|RRMs
P10080436T0000|0 10|Comparison
P10080436T0000|14 25|frequencies
P10080436T0000|36 48|fibrillation
P10080436T0000|64 77|artery bypass
P10080436T0000|108 111|use
P10080436T0000|131 137|bypass
P10080875A0772|4 11|results
P10080875A0772|15 34|supershift analysis
P10080875A0772|50 60|antibodies
P10080875A0772|69 90|transcription factors
P10080875A0772|119 128|complexes
P10080875A0772|143 167|NF-kappaB components p50
P10080875A0772|172 175|p65
P10080875A0772|203 221|NF-kappaB proteins
P10080875A0772|223 226|p52
P10080875A0772|228 233|c-Rel
P10080875A0772|235 240|Rel B
P10080875A0772|243 256|AP-1 proteins
P10080875A0772|258 263|c-Fos
P10080875A0772|265 270|C-Jun
P10080875A0772|273 277|CREB
P10080875A0772|281 290|C/EBPbeta
P10080875A0772|292 298|NF-IL6
P10080901A0271|2 5|set
P10080901A0271|9 17|peptides
P10080901A0271|50 58|elements
P10080901A0271|72 81|structure
P10080901A0271|110 116|domain
P10080901A0271|134 144|protein L9
P10082137A0262|4 11|results
P10082137A0262|24 33|IFN-gamma
P10082137A0262|55 67|accumulation
P10082137A0262|71 81|interferon
P10082137A0262|92 98|factor
P10082137A0262|100 103|IRF
P10082137A0262|107 111|mRNA
P10082137A0262|154 164|inhibition
P10082137A0262|168 174|alpha1
P10082137A0262|175 176|I
P10082137A0262|178 205|procollagen mRNA expression
P10082137A0262|209 225|skin fibroblasts
P10082137A0262|249 255|donors
P10082554T0000|11 18|domains
P10082554T0000|22 52|c-myc promoter binding protein
P10082554T0000|83 93|repression
P10082554T0000|98 120|cell growth regulation
P10082570A0440|30 40|gene UBP43
P10082573A1015|6 13|results
P10082573A1015|38 48|hypothesis
P10082573A1015|54 57|HS2
P10082573A1015|59 62|HS3
P10082573A1015|68 71|HS4
P10082573A1015|98 102|unit
P10082573A1015|121 146|globin gene transcription
P10082573A1015|152 163|holocomplex
P10082573A1015|210 219|formation
P10082573A1015|225 230|DNase
P10082573A1015|248 259|holocomplex
P10082573A1015|309 334|globin gene transcription
P10082585A0512|31 38|factors
P10082585A0512|51 65|rDNA silencing
P10082585A0512|90 96|screen
P10082585A0512|117 126|mutations
P10082585A0512|143 153|expression
P10082585A0512|157 171|reporter genes
P10082585A0512|194 198|rDNA
P10084294A0219|23 27|need
P10084294A0219|32 36|iron
P10084294A0219|69 80|progenitors
P10084294A0219|103 117|serum ferritin
P10084294A0219|122 151|transferrin saturation levels
P10084294A0219|182 194|microg/liter
P10084294A0219|201 202|%
P10085088A0918|6 13|results
P10085088A0918|32 43|p33 subunit
P10085088A0918|47 51|eIF3
P10085088A0918|71 75|role
P10085088A0918|83 99|initiation phase
P10085088A0918|103 120|protein synthesis
P10085088A0918|146 152|domain
P10085088A0918|177 185|activity
P10085120A0000|8 13|study
P10085120A0000|28 46|signaling pathways
P10085120A0000|71 78|therapy
P10085120A0000|80 83|PDT
P10085120A0000|90 99|hypericin
P10085140A1004|6 13|results
P10085140A1004|28 33|ATF-2
P10085140A1004|50 54|role
P10085140A1004|58 76|TGF-beta signaling
P10085140A1004|107 113|target
P10085140A1004|122 126|Smad
P10085140A1004|131 144|TAK1 pathways
P10085383A1367|4 9|WORDS
P10085383A1367|11 20|Melaleuca
P10085383A1367|22 37|Lake Okeechobee
P10085383A1367|39 52|Littoral zone
P10085383A1367|54 65|Water level
P10085383A1367|67 86|Regulation schedule
P10085505A1184|13 17|peak
P10085505A1184|31 35|vein
P10085505A1184|66 70|peak
P10085505A1184|87 92|cases
P10085605A0239|0 9|Specimens
P10085605A0239|27 44|alpha-fetoprotein
P10085605A0239|59 66|estriol
P10085605A0239|73 82|alpha hCG
P10085605A0239|94 97|hCG
P10085697T0000|0 45|FASEB Federal Funding Consensus Conference FY
P10086544A0504|14 18|data
P10086544A0504|36 43|arrival
P10086544A0504|61 70|care unit
P10086544A0504|89 94|hours
P10086544A0504|101 112|termination
P10086544A0504|116 119|CPB
P10086544A0504|121 131|heart rate
P10086544A0504|133 147|blood pressure
P10086544A0504|161 169|pressure
P10086544A0504|190 212|temperature difference
P10086544A0504|238 266|oxygen saturation difference
P10086544A0504|268 280|urine output
P10086544A0504|282 298|serum creatinine
P10086544A0504|300 307|lactate
P10086544A0504|312 338|neutrophil elastase levels
P10086544A0504|344 351|Doppler
P10086544A0504|370 377|factors
P10086544A0504|389 397|fraction
P10086544A0504|402 413|preejection
P10086544A0504|438 451|ejection time
P10086544A0504|468 473|doses
P10086544A0504|477 491|catecholamines
P10086544A0504|493 504|epinephrine
P10086544A0504|507 516|enoximone
P10086544A0504|522 532|furosemide
P10086725A0000|0 9|MDS1/EVI1
P10086725A0000|22 32|chromosome
P10086725A0000|35 43|band q26
P10086725A0000|79 102|transcription activator
P10086725A0000|140 145|cells
P10086725A0000|178 185|tissues
P10087213A0878|0 8|Analysis
P10087213A0878|16 33|protein sequences
P10087213A0878|47 57|replicases
P10087213A0878|98 136|H. pylori plasmid replication proteins
P10087213A0878|151 160|formation
P10087213A0878|175 180|class
P10087213A0878|184 210|H. pylori plasmid proteins
P10087549A0720|4 13|JTc delta
P10087549A0720|30 36|groups
P10087549A0720|61 70|JTc delta
P10087549A0720|78 86|VT group
P10087549A0720|94 96|ms
P10087549A0720|104 106|ms
P10087549A0720|112 121|JTc delta
P10087549A0720|129 138|PVC group
P10087549A0720|146 150|msec
P10087549A0720|158 162|msec
P10087549A0720|172 181|JTc delta
P10087549A0720|189 202|control group
P10087549A0720|210 212|ms
P10087549A0720|220 223|ms.
P10087993A0782|3 11|contrast
P10087993A0782|13 21|deletion
P10087993A0782|38 45|portion
P10087993A0782|53 67|delta promoter
P10087993A0782|85 93|decrease
P10087993A0782|97 107|expression
P10087993A1352|14 25|mutagenesis
P10087993A1352|37 42|sites
P10087993A1352|51 73|repressor proteins BP1
P10087993A1352|78 81|BP2
P10087993A1352|98 105|portion
P10087993A1352|113 129|beta globin gene
P10087993A1352|139 145|region
P10087993A1352|164 172|increase
P10087993A1352|176 193|promoter activity
P10090125A0750|18 44|alpha1 antagonist prazosin
P10090125A0750|68 69|M
P10090125A0750|75 85|relaxation
P10090146T0000|13 23|expression
P10090146T0000|27 36|AP-2alpha
P10090146T0000|41 49|AP-2beta
P10090146T0000|68 80|chick retina
P10090146T0000|82 92|repression
P10090146T0000|96 120|R-FABP promoter activity
P10090146T0000|124 128|AP-2
P10090535A1194|4 13|algorithm
P10090535A1194|27 29|TG
P10090535A1194|42 43|%
P10090535A1194|45 49|apoB
P10090535A1194|61 62|%
P10090535A1194|68 70|Lp
P10090535A1194|86 87|%
P10090535A1194|111 117|groups
P10090943A1426|9 14|value
P10090943A1426|22 27|CD79b
P10090943A1426|35 40|CD79b
P10090943A1426|60 65|ratio
P10090943A1426|84 86|SD
P10090943A1426|97 103|donors
P10090943A1426|122 124|SD
P10090943A1426|128 133|B-CLL
P10090943A1426|135 136|P
P10090943A1976|10 17|B cells
P10090943A1976|36 43|variant
P10090943A1976|49 58|mechanism
P10090943A1976|62 67|CD79b
P10090943A1976|88 98|regulation
P10090943A1976|117 133|activation stage
P10090943A1976|148 154|B cell
P10090943A1976|166 171|B-CLL
P10091594A0284|15 22|studies
P10091594A0284|43 64|structure predictions
P10091594A0284|66 68|CD
P10091594A0284|73 89|NMR spectroscopy
P10091594A0284|104 116|ELISA assays
P10091594A0284|149 159|propensity
P10091594A0284|167 174|epitope
P10091594A0284|179 194|helix formation
P10091594A0284|213 224|recognition
P10091594A0284|228 237|anti-K159
P10091619A0104|0 6|Schwab
P10091619A0104|11 29|England ADL scores
P10091619A0104|43 48|state
P10091619A0104|68 69|%
P10091619A0104|86 91|state
P10091619A0104|96 102|scores
P10091619A0104|116 117|%
P10092132A0285|11 16|gains
P10092132A0285|18 22|HLGs
P10092132A0285|38 57|gene amplifications
P10092132A0285|77 82|11q13
P10092132A0285|90 95|cases
P10092132A0285|108 112|case
P10092132A0285|148 150|.2
P10092132A0285|152 159|7q21-22
P10092132A0285|161 168|11p11.2
P10092132A0285|170 180|12p11.2-12
P10092132A0285|186 191|13q34
P10092847A0455|5 12|respect
P10092847A0455|20 32|distribution
P10092847A0455|43 47|MREs
P10092847A0455|57 72|promoter region
P10092847A0455|78 90|hMT-IIA gene
P10092847A0455|121 149|mouse metallothionein-I gene
P10092847A0455|167 182|MRE arrangement
P10092847A0455|203 209|factor
P10092847A0455|214 230|metal regulation
P10092856A0798|4 8|cDNA
P10092856A0798|61 68|control
P10092856A0798|76 81|yeast
P10092856A0798|89 117|phosphate isomerase promoter
P10094314A0935|19 32|RNA sequences
P10094314A0935|57 81|zinc knuckle 9G8 variant
P10094314A0935|112 117|SRp20
P10094314A0935|122 131|agreement
P10094314A0935|141 145|fact
P10094314A0935|155 158|RBD
P10094314A0935|162 165|9G8
P10094314A0935|170 175|SRp20
P10094396A0000|0 16|Topoisomerase II
P10094396A0000|28 34|target
P10094396A0000|42 70|protein kinase casein kinase
P10094396A0000|74 80|PK CK2
P10094701A0000|7 11|work
P10094701A0000|20 30|laboratory
P10094701A0000|50 54|gene
P10094701A0000|66 80|acetate kinase
P10094701A0000|82 86|ackA
P10094701A0000|91 113|Sinorhizobium meliloti
P10094701A0000|133 141|response
P10094701A0000|145 165|phosphate limitation
P10095059A1003|4 11|numbers
P10095059A1003|21 41|nucleotide positions
P10095059A1003|59 75|HIV-1 transcript
P10095061A0592|0 17|Sequence analysis
P10095061A0592|36 48|MEMA protein
P10095061A0592|73 76|kDa
P10095061A0592|86 92|domain
P10095061A0592|101 108|serines
P10095061A0592|111 114|DRS
P10095061A0592|116 123|protein
P10095061A0592|146 157|nucleoplasm
P10095061A0592|186 196|structures
P10095062A0558|29 38|structure
P10095062A0558|52 78|topoisomerase IIalpha gene
P10095062A0558|101 106|exons
P10095062A0558|121 123|kb
P10096469T0000|13 23|modulation
P10096469T0000|41 49|activity
P10096469T0000|53 62|cat motor
P10096469T0000|72 79|neurons
P10096573A0207|9 16|studies
P10096573A0207|72 78|factor
P10096573A0207|80 82|NF
P10096573A0207|84 108|kappaB consensus element
P10096573A0207|140 146|region
P10096573A0207|154 173|MGSA/GRO-alpha gene
P10096573A0207|181 183|bp
P10097120T0000|3 7|exon
P10097120T0000|22 31|transport
P10097120T0000|44 48|mRNA
P10097932A0915|17 25|patients
P10097932A0915|58 62|UAER
P10097932A0915|68 75|mg/24 h
P10097932A0915|77 78|n
P10097932A0915|88 104|microalbuminuria
P10097932A0915|142 150|patients
P10097932A0915|162 166|UAER
P10097932A0915|173 180|mg/24 h
P10097932A0915|190 195|years
P10097932A0915|199 208|follow-up
P10098601A1320|11 19|analysis
P10098601A1320|35 38|DNA
P10098601A1320|51 56|JEG-3
P10098601A1320|65 73|proteins
P10098601A1320|85 89|site
P10098601A1320|128 141|SF-1 sequence
P10098744A0630|3 11|contrast
P10098744A0630|16 22|change
P10098744A0630|43 52|phenotype
P10098744A0630|69 75|clones
P10098744A0630|82 89|respect
P10098744A0630|114 124|parameters
P10098744A0630|126 144|proliferation rate
P10098744A0630|148 157|monolayer
P10098744A0630|159 175|serum-dependence
P10098744A0630|180 193|proliferation
P10098744A0630|197 205|survival
P10098744A0630|207 221|tumorigenicity
P10098744A0630|232 242|morphology
P10098744A0630|263 286|differentiation markers
P10099247A1051|7 17|reactor pH
P10099247A1051|40 54|retention time
P10099247A1051|61 65|days
P10099247A1051|76 84|presence
P10099247A1051|102 116|SRB population
P10099247A1051|124 132|inoculum
P10099247A1051|161 165|time
P10099247A1051|197 200|SRB
P10099247A1051|215 217|MB
P10099576A0666|14 20|valves
P10099576A0666|26 29|aim
P10099576A0666|50 56|effect
P10099576A0666|60 65|shear
P10099576A0666|71 80|parameter
P10099576A0666|102 110|geometry
P10099576A0666|118 123|valve
P10099576A0666|141 151|conditions
P10100605A0392|24 29|burst
P10100605A0392|78 92|transformation
P10100605A0392|96 112|dihydrorhodamine
P10100605A0392|140 149|rhodamine
P10100605A0392|158 172|flow cytometry
P10101159A0742|2 10|mutation
P10101159A0742|25 34|SOC1 gene
P10101159A0742|68 77|mutations
P10101159A0742|92 107|cbp1 ts alleles
P10101159A0742|141 146|mRNAs
P10101198A0632|2 28|deletion mutation analysis
P10101198A0632|48 55|protein
P10101198A0632|86 92|region
P10101198A0632|105 120|leucine zippers
P10101198A0632|143 150|binding
P10101198A0946|2 17|database search
P10101198A0946|57 65|homology
P10101198A0946|68 73|match
P10101198A0946|103 135|transcription termination factor
P10101198A0946|137 142|mTERF
P10101198A0946|147 154|protein
P10101198A0946|171 174|DNA
P10101198A0946|180 187|monomer
P10101198A0946|207 222|leucine zippers
P10101198A0946|246 258|interactions
P10101744A0917|7 13|trials
P10101744A0917|15 32|antigen challenge
P10101744A0917|44 45|h
P10101744A0917|61 70|treatment
P10102000A1206|13 21|patients
P10102000A1206|42 54|ERA-II group
P10102000A1206|68 81|ERA-III group
P10102000A1206|96 110|mortality rate
P10102000A1206|117 118|%
P10102136A0220|20 23|PSA
P10102136A0220|47 58|cyst fluids
P10102136A0220|74 75|%
P10102136A0220|86 90|sera
P10102136A0646|0 4|Type
P10102136A0646|7 12|cysts
P10102136A0646|26 27|K
P10102136A0646|30 32|Na
P10102136A0646|34 39|ratio
P10102136A0646|67 70|PSA
P10102136A0646|76 80|Type
P10102136A0646|84 89|cysts
P10102627A0217|13 33|DNA binding activity
P10102627A0217|35 57|AP-1 reporter activity
P10102627A0217|82 87|cells
P10103002A0705|9 29|N-glycosylation site
P10103002A0705|41 53|chicken gp42
P10103002A0705|91 99|proteins
P10103002A0705|101 122|carbohydrate analysis
P10103002A0705|126 130|gp42
P10103002A0705|144 152|presence
P10103002A0705|166 183|type glycan chain
P10103002A0705|192 196|site
P10103057A0251|21 33|optimization
P10103057A0251|38 54|characterization
P10103057A0251|72 80|fragment
P10103057A0251|97 108|Runt domain
P10103057A0251|112 116|AML1
P10103057A0251|151 158|studies
P10119827T0000|0 14|Judge OKs docs
P10119827T0000|16 19|bid
P10119827T0000|24 40|Chicago hospital
P10120952T0000|0 5|HANYS
P10120952T0000|30 53|gall bladder guidelines
P10125354T0000|0 13|Groups dicker
P10125354T0000|18 30|price breaks
P10125354T0000|45 48|gas
P10132730T0000|9 20|CareNetwork
P10132730T0000|26 30|pact
P10132730T0000|44 57|teacher union
P10132730T0000|61 65|Wis.
P10134977T0000|0 5|JCAHO
P10134977T0000|15 24|hospitals
P10134977T0000|26 34|patience
P10146207A0223|0 15|Ultrasonography
P10146207A0223|50 60|evaluation
P10146207A0223|71 82|cord injury
P10153759A0360|0 4|UPMC
P10153759A0360|21 33|organization
P10153759A0360|54 76|NHBC organ procurement
P10171173A0955|11 19|concerns
P10171173A0955|30 35|blood
P10171173A0955|69 76|disease
P10171173A0955|98 117|deficiency syndrome
P10171173A0955|122 127|non-A
P10171173A0955|135 144|hepatitis
P10171173A0955|173 188|research effort
P10171173A0955|208 218|hemorrhage
P10171173A0955|246 252|bypass
P10171173A0955|273 284|circulation
P10181397A0641|14 20|trends
P10181397A0641|24 33|fertility
P10181397A0641|35 57|life expectancy ratios
P10181397A0641|63 81|gender differences
P10181397A0641|91 100|countries
P10181397A0641|119 129|population
P10181397A0641|137 150|United States
P10184191T0045|0 6|Holger
P10187317T0000|0 8|Hospital
P10187317T0000|24 40|AHERF physicians
P10187798A1098|0 14|Overexpression
P10187798A1098|25 30|DAP-1
P10187798A1098|34 41|sentrin
P10187798A1098|49 58|apoptosis
P10187798A1098|76 101|L929 fibroblast cell line
P10187798A1098|128 150|osteosarcoma cell line
P10187798A1098|152 156|U2OS
P10187842A1155|11 19|contrast
P10187842A1155|23 33|PPARgamma2
P10187842A1155|95 99|site
P10187842A1155|105 110|motif
P10187842A1155|141 146|sites
P10187842A1155|164 173|PPARalpha
P10187864A1372|6 13|results
P10187864A1372|22 26|KCC3
P10187864A1372|36 42|member
P10187864A1372|50 60|KCC family
P10187864A1372|84 94|regulation
P10187864A1372|100 104|KCC1
P10190324A0000|21 33|elastin gene
P10190324A0000|38 47|mutations
P10190324A0000|85 93|stenosis
P10190324A0000|95 99|SVAS
P10190324A0000|139 147|families
P10190324A0000|177 181|SVAS
P10191090A0000|15 25|expression
P10191090A0000|33 42|PAX3 gene
P10191090A0000|71 82|development
P10192134A1088|0 8|25-OH-D3
P10192134A1088|41 47|health
P10192134A1088|64 73|use level
P10192134A1088|80 98|micrograms/kg feed
P10192134A1088|114 124|vitamin D3
P10192134A1088|128 142|turkey rations
P10192432A0214|2 6|list
P10192432A0214|13 18|names
P10192432A0214|27 34|disease
P10192432A0214|53 61|criteria
P10192432A0214|81 96|Consensus Panel
P10192432A0214|111 118|experts
P10192432A0214|138 143|order
P10192432A0214|164 172|core set
P10192432A0214|176 184|criteria
P10192638T0000|0 24|Methanesulfonyl fluoride
P10192638T0000|26 29|MSF
P10192638T0000|67 72|study
P10192638T0000|76 82|safety
P10192638T0000|87 95|efficacy
P10192638T0000|103 112|treatment
P10192638T0000|123 131|dementia
P10192638T0000|139 153|Alzheimer type
P10193950A0478|0 7|METHODS
P10193950A0478|17 23|August
P10193950A0478|33 37|June
P10193950A0478|48 51|men
P10193950A0478|66 68|T2
P10193950A0478|72 74|T3
P10193950A0478|87 90|TNM
P10193950A0478|92 110|prostate carcinoma
P10193950A0478|112 116|bone
P10193950A0478|149 153|risk
P10193950A0478|157 179|lymph node involvement
P10193950A0478|207 216|pendetide
P10193950A0478|231 254|staging lymphadenectomy
P10194225A1132|10 15|wheel
P10194225A1132|65 72|alanine
P10194225A1132|76 89|pyruvate Gneo
P10194225A1132|102 113|glycerol Ra
P10194230A0817|18 25|surgery
P10194230A0817|27 41|dialysate PGE2
P10194230A0817|46 70|adenosine concentrations
P10194230A0817|104 106|nM
P10194451A0000|31 43|relationship
P10194451A0000|65 69|p210
P10194451A0000|70 77|bcr/abl
P10194451A0000|79 111|protein tyrosine kinase activity
P10194451A0000|116 130|manifestations
P10194451A0000|168 176|leukemia
P10194451A0000|178 181|CML
P10194451A0000|191 200|expansion
P10194451A0000|209 213|goal
P10194451A0000|238 253|p210 substrates
P10194451A0000|265 282|chronic-phase CML
P10194451A0000|297 313|progenitor cells
P10194762A0648|9 22|precipitation
P10194762A0648|30 70|glutathione-S-transferase-fusion protein
P10194762A0648|97 119|transactivation domain
P10194762A0648|123 129|STAT5a
P10194762A0648|150 161|association
P10194762A0648|165 171|ERK1/2
P10194762A0648|181 195|fusion protein
P10194762A0648|226 232|serine
P10194762A0648|240 246|STAT5a
P10194762A0648|262 269|alanine
P10194769A0146|9 16|element
P10194769A0146|18 20|1P
P10194769A0146|38 43|clone
P10194769A0146|51 54|rat
P10194769A0146|65 88|cDNA expression library
P10194769A0146|97 122|417-amino acid WD protein
P10194769A0146|135 139|PREB
P10194769A0146|141 144|PRL
P10194769A0146|156 171|element binding
P10194769A0146|173 180|protein
P10195425T0000|0 16|Characterization
P10195425T0000|24 50|transcription factor MTF-1
P10195425T0000|69 79|pufferfish
P10195425T0000|81 94|Fugu rubripes
P10195425T0000|117 129|conservation
P10195425T0000|139 160|metal stress response
P10195690A0000|4 14|peroxisome
P10195690A0000|38 47|receptors
P10195690A0000|49 54|PPARs
P10195690A0000|60 67|members
P10195690A0000|83 111|hormone receptor superfamily
P10195697A0456|9 23|F-SRC-1 mutant
P10195697A0456|48 54|domain
P10195697A0456|71 89|enhancing activity
P10196127A1059|14 18|site
P10196127A1059|26 35|S1 pocket
P10196127A1059|69 77|residues
P10196127A1059|97 117|pyroglutamyl residue
P10196248A0482|22 32|TTV genome
P10196248A0482|51 59|sequence
P10196248A0482|67 69|nt
P10196248A0482|71 73|nt
P10196248A0482|129 133|arms
P10196248A0482|160 167|stretch
P10196248A0482|169 179|GC content
P10196248A0482|185 186|%
P10196248A0482|190 192|nt
P10196266A0000|10 29|mouse Mus castaneus
P10196266A0000|46 55|infection
P10196266A0000|74 98|mink cell focus-inducing
P10196266A0000|100 103|MCF
P10196266A0000|105 113|subgroup
P10196266A0000|124 140|leukemia viruses
P10196266A0000|142 147|MuLVs
P10196316A0715|17 25|function
P10196316A0715|29 35|VZV gK
P10196316A0715|39 51|virus growth
P10196316A0715|55 61|series
P10196316A0715|65 84|gK deletion mutants
P10196316A0715|107 110|VZV
P10196316A0715|118 121|DNA
P10196316A0715|139 149|Oka strain
P10196318T0000|0 26|CCAAT displacement protein
P10196318T0000|67 86|papillomavirus type
P10196318T0000|89 91|E6
P10196318T0000|93 95|E7
P10196318T0000|101 113|E1 promoters
P10196597A0510|12 20|findings
P10196597A0510|38 45|studies
P10196597A0510|80 95|characteristics
P10196597A0510|99 112|drink drivers
P10197763A0580|30 39|mutations
P10197763A0580|54 74|AMP response element
P10197763A0580|92 118|nerve growth factor effect
P10197763A0580|125 126|%
P10197985A0145|9 33|RNase H protection assay
P10197985A0145|56 72|oligonucleotides
P10197985A0145|87 98|recognition
P10197985A0145|124 126|ss
P10197985A0145|132 152|branchpoint sequence
P10197985A0145|154 157|BPS
P10197985A0145|159 167|elements
P10197985A0145|171 174|U11
P10197985A0145|179 189|U12 snRNPs
P10197985A0145|221 234|cooperativity
P10197985A0145|251 256|sites
P10197985A0145|264 282|pre-mRNA substrate
P10197985A0145|297 314|complex formation
P10198003A1505|0 8|Analysis
P10198003A1505|12 16|lacZ
P10198003A1505|33 40|fusions
P10198003A1505|69 74|sites
P10198003A1505|97 107|expression
P10198003A1505|111 115|rsmB
P10198056A0000|16 37|cell surface proteins
P10198056A0000|58 71|lipid bilayer
P10198056A0000|80 108|glycosylphosphatidylinositol
P10198056A0000|110 113|GPI
P10198061A0339|17 29|import assay
P10198061A0339|31 43|beta-catenin
P10198061A0339|70 77|nucleus
P10198061A0339|100 108|addition
P10198061A0339|112 119|cytosol
P10198061A0339|121 124|Ran
P10198061A0339|129 136|ATP/GTP
P10199539A1353|24 31|hypoxia
P10199539A1353|42 53|correlation
P10199539A1353|72 75|cyt
P10199539A1353|78 96|a3 oxidation level
P10199539A1353|101 104|VO2
P10199539A1353|134 141|hypoxia
P10199539A1353|143 145|r2
P10200473A0171|24 33|regulator
P10200473A0171|42 49|process
P10200473A0171|57 64|Usurpin
P10200473A0171|87 94|aliases
P10200473A0171|99 106|Usurpin
P10200473A0171|115 119|CASH
P10200473A0171|121 127|Casper
P10200473A0171|129 134|CLARP
P10200473A0171|136 143|FLAME-1
P10200473A0171|145 149|FLIP
P10200473A0171|151 158|I-FLICE
P10200473A0171|163 167|MRIT
P10201468A0297|0 14|Plasma glucose
P10201468A0297|31 38|insulin
P10201468A0297|40 43|IRI
P10201468A0297|46 55|C-peptide
P10201468A0297|57 65|glucagon
P10201468A0297|71 83|GLP-1 levels
P10201468A0297|92 102|time point
P10201468A0297|110 114|OGTT
P10202006A0546|17 24|product
P10202006A0546|31 45|fusion protein
P10202006A0546|53 61|B domain
P10202006A0546|80 89|protein A
P10202006A0546|91 94|SPA
P10202006A1266|0 14|Polypyrimidine
P10202006A1266|19 32|ssDNA binding
P10202006A1266|49 58|VH domain
P10202006A1266|94 96|Ab
P10202006A1266|111 119|activity
P10202006A1266|131 145|autoantibodies
P10202006A1266|177 184|binding
P10202006A1266|190 196|ligand
P10202006A1266|209 224|polypyrimidines
P10202006A1266|236 240|role
P10202006A1266|244 260|B cell selection
P10202006A1266|268 280|immunization
P10202006A1266|286 291|Z-DNA
P10203611T0000|0 56|Technetium-99m methylene diphosphonate scintimammography
P10203611T0000|61 71|evaluation
P10203611T0000|84 97|breast masses
P10205099A0377|0 13|INTERVENTIONS
P10205099A0377|15 29|Study patients
P10205099A0377|71 77|groups
P10205099A0377|96 107|terbinafine
P10205099A0377|112 114|mg
P10205099A0377|117 120|day
P10205099A0377|134 139|weeks
P10205099A0377|141 151|groups T12
P10205099A0377|156 159|T16
P10205099A0377|164 176|itraconazole
P10205099A0377|181 183|mg
P10205099A0377|186 189|day
P10205099A0377|196 200|week
P10205099A0377|212 217|weeks
P10205099A0377|231 236|weeks
P10205099A0377|238 247|groups I3
P10205099A0377|252 254|I4
P10205176A0000|8 17|receptors
P10205176A0000|19 22|NRs
P10205176A0000|56 71|transregulators
P10205176A0000|94 105|yeast cells
P10205176A0000|133 141|features
P10205176A0000|161 168|control
P10205176A0000|200 209|evolution
P10205176A0704|44 50|domain
P10205176A0704|52 56|PSU1
P10205176A0704|70 83|transcription
P10205588A0000|0 9|OBJECTIVE
P10205588A0000|38 46|patients
P10205588A0000|52 61|arthritis
P10205588A0000|68 77|infection
P10205588A0000|99 111|streptococci
P10205588A0000|115 133|Lancefield group A
P10205588A0000|135 143|beta HSA
P10205588A0000|151 159|emphasis
P10205588A0000|172 187|characteristics
P10205588A0000|204 212|features
P10205933A0699|0 8|Bacteria
P10205933A0699|26 39|labyrinthitis
P10205933A0699|69 72|ear
P10205933A0699|87 106|Treponemas Pallidum
P10205933A0699|110 121|spirochaete
P10205933A0699|135 143|syphilis
P10205933A0699|172 183|spirochaete
P10205933A0699|196 208|Lyme Disease
P10206152A1024|18 28|expression
P10206152A1024|36 43|protein
P10206152A1024|48 55|maximum
P10206152A1024|59 66|mitosis
P10206152A1024|71 78|minimum
P10206152A1024|82 84|G1
P10206152A1024|112 122|expression
P10206152A1024|130 143|messenger RNA
P10206698A2041|6 14|findings
P10206698A2041|49 60|mutagenesis
P10206698A2041|73 81|approach
P10206698A2041|104 109|genes
P10206698A2041|130 137|ability
P10206698A2041|160 165|tract
P10206959A0368|0 6|Pathol
P10207041A0065|15 25|cell cycle
P10207041A0065|41 45|part
P10207041A0065|62 75|transcription
P10207041A0065|79 91|cyclin genes
P10207041A0065|99 115|protein products
P10207041A0065|176 183|kinases
P10207049A0693|4 13|GAC1 gene
P10207049A0693|37 44|subunit
P10207049A0693|51 55|type
P10207049A0693|58 101|serine/threonine phosphoprotein phosphatase
P10207049A0693|103 107|Glc7
P10207049A1001|4 11|results
P10207049A1001|33 49|Glc7 phosphatase
P10207049A1001|58 62|Gac1
P10207049A1001|74 86|subunit play
P10207049A1001|96 101|roles
P10207049A1001|105 119|HSF activation
P10207049A1001|123 141|CUP1 transcription
P10207087A0956|0 3|MEF
P10207087A0956|8 13|AML1B
P10207087A0956|48 59|interleukin
P10207087A0956|62 94|promoter reporter gene construct
P10207087A0956|104 123|activating activity
P10207087A0956|127 130|MEF
P10207087A0956|150 153|MEF
P10207087A0956|175 183|AML1/ETO
P10207090A0801|21 29|presence
P10207090A0801|37 40|GRR
P10207090A0801|65 76|degradation
P10207090A0801|80 83|p50
P10207090A0801|105 113|molecule
P10207092A0924|5 20|phosphorylation
P10207092A0924|85 108|protein kinase activity
P10207092A0924|118 136|sea urchin nucleus
P10207115A0389|34 39|level
P10207115A0389|43 46|p21
P10207115A0389|95 104|mechanism
P10208865A1246|28 47|osteoclast cultures
P10208865A1246|49 56|mrIhh-N
P10208865A1246|81 90|formation
P10208865A1246|94 109|resorption pits
P10208865A1246|113 127|dentine slices
P10208893A0839|13 20|results
P10208893A0839|44 53|genotypes
P10208893A0839|70 89|WAD goat population
P10209021A0212|14 23|mechanism
P10209021A0212|33 38|Gle2p
P10209021A0212|61 81|interaction function
P10209021A0212|85 96|mRNA export
P10209031A0832|4 20|Fyn NH2 terminus
P10209031A0832|58 69|interaction
P10209031A0832|75 79|zeta
P10209031A0832|89 99|Fyn kinase
P10209031A0832|104 115|SH2 domains
P10209031A0832|141 156|phosphorylation
P10209031A0832|160 179|zeta ITAM tyrosines
P10209031A0832|195 221|zeta ITAM phosphotyrosines
P10209119A0076|11 16|yeast
P10209119A0076|22 35|protein Skp1p
P10209119A0076|55 68|member Cdc53p
P10209119A0076|78 107|F-box/WD-repeat protein Cdc4p
P10209119A0076|117 150|SCFCdc4p ubiquitin ligase complex
P10209119A0076|187 193|kinase
P10209119A0076|195 198|Cdk
P10209119A0076|200 215|inhibitor Sic1p
P10209119A0076|220 231|proteolysis
P10209119A0594|59 71|similarities
P10209119A0594|77 81|pop1
P10209119A0594|86 96|pop2 genes
P10209119A0594|129 148|deletion phenotypes
P10209119A0594|226 235|functions
P10209119A0594|239 250|proteolysis
P10209759T0000|0 16|Antithrombin III
P10209759T0000|29 32|min
P10209759T0000|49 76|ischemia reperfusion injury
P10209759T0000|80 84|rats
P10210952A0261|3 13|retrospect
P10210952A0261|19 28|diagnoses
P10210952A0261|63 71|criteria
P10211329A0457|6 18|observations
P10211329A0457|31 43|serum lipase
P10211329A0457|48 56|serum CA
P10211329A0457|65 72|Sjogren
P10211329A0457|75 83|syndrome
P10211329A0457|92 100|evidence
P10211329A0457|104 114|malignancy
P10211329A0457|138 149|involvement
P10211329A0457|158 166|disorder
P10211422T0000|6 18|pancreatitis
P10211422T0000|24 36|complication
P10211422T0000|40 60|polyarteritis nodosa
P10211919A0846|22 33|improvement
P10211919A0846|35 36|p
P10211919A0846|52 68|sertraline group
P10211919A0846|98 101|end
P10211919A0846|105 109|week
P10211919A0846|119 125|Y-BOCS
P10211919A0846|134 155|CGI Improvement scale
P10211919A0846|168 171|end
P10211919A0846|175 180|weeks
P10211919A0846|211 215|NIMH
P10211919A0846|220 238|CGI Severity scale
P10212278A0387|17 32|protein kinases
P10212278A0387|55 71|c-jun expression
P10212278A0387|97 117|protein kinase/c-Jun
P10212278A0387|129 143|protein kinase
P10212278A0387|145 153|SAPK/JNK
P10212278A0387|159 170|p38 members
P10212278A0387|196 210|protein kinase
P10212278A0387|212 216|MAPK
P10212278A0387|218 229|superfamily
P10212278A0387|243 252|molecules
P10212284A0000|13 26|growth factor
P10212284A0000|28 31|TGF
P10212284A0000|33 38|beta1
P10212284A0000|61 78|matrix deposition
P10212284A0000|83 96|proliferation
P10212284A0000|112 117|cells
P10212332T0000|0 18|Chronotherapeutics
P10212332T0000|37 44|disease
P10212426A1067|0 5|Group
P10212426A1067|19 28|functions
P10212426A1067|33 42|listeners
P10212426A1067|48 60|hearing loss
P10212426A1067|75 83|decrease
P10212426A1067|87 98|performance
P10212426A1067|114 120|values
P10212426A1067|124 129|delta
P10212426A1067|149 154|study
P10212969A0470|0 12|Uroflowmetry
P10212969A0470|24 31|dysuria
P10212969A0470|86 94|subjects
P10214610A0900|14 23|variation
P10214610A0900|39 50|percentiles
P10214610A0900|66 69|age
P10215485A0837|12 24|correlations
P10215485A0837|40 46|status
P10215485A0837|78 95|State Examination
P10215485A0837|100 105|NA/mI
P10215485A0837|107 112|mI/Cr
P10215485A0837|117 119|NA
P10215594A1728|0 8|Glucagon
P10215594A1728|22 34|LUC activity
P10215594A1728|58 62|CRE1
P10215594A1728|67 77|CRE2 sites
P10215594A1728|93 102|induction
P10215594A1728|111 115|CRE1
P10215594A1728|118 122|CRE2
P10215594A1728|123 143|2SV40-LUC constructs
P10215594A1728|176 179|pO2
P10215608A0161|8 13|study
P10215608A0161|29 38|isolation
P10215608A0161|43 59|characterization
P10215608A0161|74 83|rat GSTA3
P10215608A0161|85 93|rGST Yc1
P10215608A0161|95 107|subunit gene
P10215803T0000|39 47|infusion
P10215803T0000|51 68|calcium gluconate
P10215811A0635|8 15|control
P10215811A0635|19 27|bleeding
P10215811A0635|44 55|eradication
P10215811A0635|77 85|sessions
P10215811A0635|91 94|EVL
P10215850A0754|35 47|organization
P10215850A0754|61 71|TrxR2 gene
P10215850A0754|94 99|exons
P10215850A0754|118 120|kb
P10215850A0754|142 154|localization
P10215850A0754|158 174|position 22q11.2
P10216052A0105|4 8|aims
P10216052A0105|17 22|study
P10216052A0105|54 63|frequency
P10216052A0105|67 71|self
P10216052A0105|88 98|disability
P10216052A0105|108 113|tasks
P10216052A0105|127 144|glaucoma patients
P10216052A0105|161 174|interrelation
P10216052A0105|183 195|disabilities
P10216052A0105|202 217|factor analysis
P10216052A0105|232 240|relation
P10216052A0105|266 276|difficulty
P10216052A0105|283 290|measure
P10216052A0105|298 306|severity
P10216052A0105|317 327|field loss
P10216052A0105|342 350|glaucoma
P10216052A0105|360 368|subgroup
P10216052A0105|372 381|questions
P10216052A0105|399 407|validity
P10216052A0105|412 423|reliability
P10216052A0105|432 440|subgroup
P10216052A0105|444 453|questions
P10216052A1682|17 25|validity
P10216052A1682|38 44|subset
P10216052A1682|48 57|questions
P10216052A1682|87 88|r
P10216052A1682|96 97|p
P10216052A1682|112 123|correlation
P10216052A1682|134 141|measure
P10216052A1682|149 157|severity
P10216052A1682|178 188|field loss
P10216052A1682|202 207|score
P10216052A1682|215 224|variables
P10216052A1682|237 245|glaucoma
P10216052A1682|255 263|subgroup
P10216052A1682|267 276|questions
P10216161A1530|0 19|Sequence comparison
P10216161A1530|23 37|cytochromes bd
P10216161A1530|48 56|homologs
P10216161A1530|70 79|organisms
P10216161A1530|102 110|proteins
P10216161A1530|138 149|subfamilies
P10216161A1530|169 173|type
P10216161A1530|192 194|bd
P10216161A1530|225 229|type
P10216161A1530|244 272|B. stearothermophilus enzyme
P10216161A1530|301 305|type
P10217683A0509|0 22|Canalith repositioning
P10217683A0509|30 38|mainstay
P10217683A0509|42 51|treatment
P10218109T0000|0 18|Solution structure
P10218109T0000|23 32|mechanism
P10218109T0000|40 65|MutT pyrophosphohydrolase
P10218200A0534|6 10|eyes
P10218200A0534|47 57|micrograms
P10218200A0534|73 101|tissue plasminogen activator
P10218200A0534|132 135|hrs
P10218357A0486|0 7|RESULTS
P10218357A0486|12 23|CONCLUSIONS
P10218357A0486|25 31|Brandt
P10218357A0486|41 51|cuff-tubes
P10218357A0486|53 55|G2
P10218357A0486|90 98|increase
P10218357A0486|102 115|cuff-pressure
P10218357A0486|123 134|anaesthesia
P10218357A0486|140 143|N2O
P10219091A0246|32 41|gene CTL1
P10219091A0246|51 57|enzyme
P10220275A0694|4 11|binding
P10220275A0694|15 25|PH domains
P10220275A0694|29 39|Gbetagamma
P10220275A0694|57 70|preincubation
P10220275A0694|74 84|Gbetagamma
P10220275A0694|126 130|form
P10220275A0694|134 141|Gialpha
P10220364A0087|6 16|afterglows
P10220364A0087|35 45|supernovae
P10220364A0087|71 81|hypernovae
P10221467T0000|13 25|pericarditis
P10221467T0000|46 53|disease
P10221467T0000|70 94|dopamine agonist therapy
P10221467T0000|96 107|cabergoline
P10221467T0000|113 122|Parkinson
P10221467T0000|125 132|disease
P10221820A0902|13 17|type
P10221820A0902|21 25|APBD
P10221820A0902|56 59|AMT
P10221820A0902|92 102|clinicians
P10221820A0902|133 144|coexistence
P10221820A0902|148 152|APBD
P10221820A0902|157 160|AMT
P10223338A1601|3 11|addition
P10223338A1601|56 70|fusion protein
P10223338A1601|85 94|HIV-2 gag
P10223338A1601|100 110|V3 domains
P10223338A1601|114 123|HIV-1IIIB
P10223338A1601|125 132|HIV-1MN
P10223338A1601|134 142|HIV-1SF2
P10223338A1601|147 154|HIV-1RF
P10223338A2186|4 11|results
P10223338A2186|26 37|V3 peptides
P10223338A2186|53 59|clades
P10223338A2186|63 68|HIV-1
P10223338A2186|80 89|HIV-2 gag
P10223338A2186|117 133|HIV/AIDS vaccine
P10223498A0479|0 8|Efficacy
P10223498A0479|27 36|responses
P10223498A0479|52 59|ability
P10223498A0479|74 82|erection
P10223498A0479|88 96|question
P10223498A0479|100 107|ability
P10223498A0479|123 131|erection
P10223498A0479|140 167|15-item International Index
P10223498A0479|171 188|Erectile Function
P10223498A0479|190 194|IIEF
P10224244T0000|0 8|Evidence
P10224244T0000|17 28|involvement
P10224244T0000|36 57|Glc7-Reg1 phosphatase
P10224244T0000|66 82|Snf1-Snf4 kinase
P10224244T0000|90 100|regulation
P10224244T0000|104 122|INO1 transcription
P10224257A0079|3 11|XO males
P10224257A0079|17 28|her-1 mRNAs
P10224257A0079|30 36|her-1a
P10224257A0079|41 47|her-1b
P10224257A0079|83 92|promoters
P10224257A0079|94 96|P1
P10224257A0079|125 131|region
P10224257A0079|137 139|P2
P10224257A0079|169 175|intron
P10224289T0000|0 9|Induction
P10224289T0000|13 34|Fas ligand expression
P10224289T0000|38 41|HIV
P10224289T0000|55 66|interaction
P10224289T0000|70 73|Nef
P10224289T0000|83 109|T cell receptor zeta chain
P10224293A0000|0 38|Receptor protein tyrosine phosphatases
P10224293A0000|40 45|RPTPs
P10224293A0000|58 64|family
P10224293A0000|68 76|proteins
P10224293A0000|104 123|phosphatase domains
P10224293A0000|131 141|ectodomain
P10224293A0000|171 177|motifs
P10224293A2021|25 38|brain regions
P10224293A2021|53 58|basis
P10224293A2021|70 77|studies
P10224293A2021|81 100|RPTP-kappa function
P10224513A0240|14 23|stressors
P10224513A0240|35 46|arithmetics
P10224513A0240|48 60|speech tasks
P10224513A0240|66 77|Stroop test
P10224513A0240|79 96|videogame playing
P10224513A0240|98 103|films
P10224513A0240|107 117|videotapes
P10224513A0240|122 132|interviews
P10224758A0202|4 17|control group
P10224758A0202|29 47|afterbirth samples
P10224758A0202|77 88|pregnancies
P10225279A0450|25 29|gene
P10225279A0450|42 51|MDV2 UL54
P10225279A0450|56 66|UL55 genes
P10225279A0450|72 80|homology
P10225279A0450|94 97|ORF
P10225279A0450|99 104|ORF-1
P10225279A0450|116 132|herpesvirus type
P10225279A0450|153 157|gene
P10225279A0450|172 190|pseudorabies virus
P10225945A0436|3 11|contrast
P10225945A0436|17 21|loss
P10225945A0436|25 38|MAD2 staining
P10225945A0436|42 49|meiosis
P10225945A0436|82 104|microtubule attachment
P10225945A0436|131 138|measure
P10225945A0436|142 149|tension
P10225945A0436|155 163|distance
P10225945A0436|193 205|kinetochores
P10225945A0436|210 217|meiosis
P10226029A0905|14 19|cells
P10226029A0905|25 34|PH domain
P10226029A0905|38 45|Akt/PKB
P10226029A0905|59 64|sites
P10226029A0905|94 101|contact
P10226029A0905|123 131|contacts
P10226029A0905|145 152|absence
P10226029A0905|156 161|serum
P10226074A0637|31 38|regions
P10226074A0637|63 68|exons
P10226074A0637|79 101|translation start site
P10226074A0637|127 131|exon
P10226838A1011|4 12|motility
P10226838A1011|16 21|sperm
P10226838A1011|57 67|electrodes
P10226838A1011|90 101|stimulation
P10226838A1011|106 109|60s
P10226838A1011|137 143|energy
P10228009A0600|0 9|Induction
P10228009A0600|17 30|CINC promoter
P10228009A0600|34 39|IL-17
P10228009A0600|43 54|IEC-6 cells
P10228009A0600|59 62|TNF
P10228009A0600|83 91|factor-6
P10228009A0600|93 98|TRAF6
P10228009A0600|109 114|TRAF2
P10228155A1293|0 7|SCFFWD1
P10228155A1293|28 45|tumor development
P10228155A1293|50 61|suppression
P10228155A1293|70 80|regulation
P10228155A1293|84 114|beta-catenin protein stability
P10228157T0000|18 44|spindle checkpoint pathway
P10228157T0000|59 71|Dbf2p kinase
P10228157T0000|83 88|yeast
P10228561A0539|24 36|organization
P10228561A0539|40 59|DNA polymerase beta
P10228561A0539|75 83|residues
P10228561A0539|91 98|contact
P10228561A0539|104 118|DNA phosphates
P10228561A0539|142 149|modules
P10228795A0842|0 7|RESULTS
P10228795A0842|21 27|nerves
P10228795A0842|55 65|regulation
P10228795A0842|77 92|nerve responses
P10228795A0842|96 99|EFS
P10228795A0842|114 117|IAS
P10229084A0000|16 35|gel electrophoresis
P10229084A0000|51 69|immunoprecipitates
P10229084A0000|114 127|T lymphocytes
P10229084A0000|144 158|identification
P10229084A0000|176 191|protein complex
P10229084A0000|231 234|Fyn
P10229084A0000|258 273|phosphoproteins
P10229084A0000|275 279|pp43
P10229084A0000|281 285|pp72
P10229084A0000|287 291|pp85
P10229084A0000|297 325|protein tyrosine kinase Pyk2
P10229084A0000|362 378|adaptor proteins
P10229084A0000|380 386|SKAP55
P10229084A0000|391 399|SLAP-130
P10229668A0190|19 32|cdc33 mutants
P10229668A0190|48 50|G1
P10229668A0560|2 16|cdc33-1 strain
P10229668A0560|42 47|Cln3p
P10229668A0560|49 56|Cln3-1p
P10229668A0560|63 74|hybrid UBI4
P10229668A0560|78 87|CLN3 mRNA
P10229668A0560|95 106|translation
P10229668A0560|126 136|dependence
P10229668A0560|140 145|eIF4E
P10229668A0560|172 182|cell cycle
P10229682A1151|11 17|motifs
P10229682A1151|22 37|gene expression
P10229682A1151|86 94|sequence
P10229682A1151|96 107|kappaB site
P10229682A1151|160 168|sequence
P10229682A1151|170 182|NF-IL-6 site
P10229682A1151|225 231|region
P10231026A0253|4 18|gene structure
P10231026A0253|22 26|Elk1
P10231026A0253|38 40|kb
P10231026A0253|63 68|exons
P10231026A0253|77 84|introns
P10231454A0731|6 19|serum calcium
P10231454A0731|36 41|mg/dl
P10231454A0731|59 66|calcium
P10231454A0731|83 88|mg/dl
P10231454A0731|90 100|phosphorus
P10231454A0731|113 118|mg/dl
P10231454A0731|124 144|alkaline phosphatase
P10231454A0731|158 165|U/liter
P10231485A0342|0 17|Sequence analysis
P10231485A0342|32 36|TtrA
P10231485A0342|48 91|molybdopterin guanine dinucleotide cofactor
P10231485A0342|99 105|4Fe-4S
P10231485A0342|107 114|cluster
P10231485A0342|121 125|TtrB
P10231485A0342|138 144|4Fe-4S
P10231485A0342|146 154|clusters
P10231485A0342|165 169|TtrC
P10231485A0342|185 201|membrane protein
P10231485A0342|215 236|quinol oxidation site
P10231513T0000|14 25|differences
P10231513T0000|29 57|granulation tissue formation
P10231513T0000|75 80|study
P10231513T0000|88 91|rat
P10231581A1125|14 25|mutagenesis
P10231581A1125|51 60|SP1 sites
P10231581A1125|73 77|exon
P10231581A1125|123 140|promoter activity
P10231862A1117|19 26|infants
P10231862A1117|75 80|acids
P10231862A1117|106 110|week
P10231862A1117|114 118|life
P10231862A1117|128 140|contribution
P10231862A1117|155 164|synthesis
P10231862A1117|178 184|plasma
P10231862A1117|212 216|pool
P10232078A0552|0 8|Ischemia
P10232078A0552|13 24|reperfusion
P10232078A0552|48 55|release
P10232078A0552|59 76|6-keto-PGF1 alpha
P10232078A0552|81 85|TXB2
P10232600T0000|18 25|antigen
P10232600T0000|27 30|PSA
P10232600T0000|67 77|expression
P10232600T0000|81 104|sodium iodide symporter
P10232600T0000|108 134|prostate cancer cell lines
P10232872A0081|40 42|CD
P10232872A0081|60 68|subgroup
P10232872A0081|83 93|population
P10233147A0218|0 5|Ras2p
P10233147A0218|25 31|growth
P10233147A0218|63 81|signaling pathways
P10233147A0218|87 105|filamentation MAPK
P10233147A0218|107 125|Cdc42p/Ste20p/MAPK
P10233147A0218|127 134|cascade
P10233147A0218|157 171|protein kinase
P10233147A0218|173 187|Cyr1p/cAMP/PKA
P10233147A0218|189 196|pathway
P10233885A0899|21 31|prediction
P10233885A0899|33 46|transfections
P10233885A0899|70 86|cell line Jurkat
P10233885A0899|114 124|activation
P10233885A0899|132 146|mim-1 promoter
P10233885A0899|154 157|p32
P10233885A0899|162 174|p30 isoforms
P10233946A0000|9 13|work
P10233946A0000|29 50|spleen necrosis virus
P10233946A0000|52 55|SNV
P10233946A0000|71 78|repeats
P10233946A0000|80 84|LTRs
P10233946A0000|145 155|expression
P10233946A0000|166 184|leukemia virus RNA
P10233946A0000|202 212|hypothesis
P10233946A0000|218 225|SNV RNA
P10233946A0000|248 255|element
P10233946A0000|294 302|proteins
P10234698A0728|33 40|effects
P10234698A0728|44 59|CNS development
P10234698A0728|63 69|number
P10234698A0728|73 87|animal studies
P10234698A0728|104 116|pretreatment
P10234698A0728|122 137|corticosteroids
P10234698A0728|163 168|brain
P10234698A0728|191 197|injury
P10234698A0728|224 233|treatment
P10235265A0197|7 16|mechanism
P10235265A0197|64 70|system
P10235265A0197|97 118|proteolysis machinery
P10235265A0197|142 145|Clb
P10235265A0197|147 161|cyclin subunit
P10236651T0000|0 10|Predictors
P10236651T0000|14 21|success
P10236651T0000|25 40|pharmacy school
P10236651T0000|42 46|PCAT
P10236651T0000|57 75|admission criteria
P10240361T0000|9 15|survey
P10240361T0000|35 50|dissatisfaction
P10240361T0000|57 67|physicians
P10243927A0000|5 11|series
P10243927A0000|29 39|fire tests
P10243927A0000|41 54|investigators
P10243927A0000|62 84|IIT Research Institute
P10243927A0000|115 127|door control
P10243927A0000|135 139|room
P10243927A0000|143 154|fire origin
P10243927A0000|184 190|spread
P10243927A0000|200 205|smoke
P10243927A0000|210 215|gases
P10271171A0458|7 12|LATCH
P10271171A0458|28 33|shift
P10271171A0458|37 51|identification
P10271171A0458|59 66|library
P10271171A0458|82 86|unit
P10271171A0458|105 120|resource center
P10281637A0000|0 9|Reporting
P10281637A0000|21 27|events
P10281637A0000|54 60|trials
P10281637A0000|80 85|drugs
P10281637A0000|91 98|complex
P10281637A0000|117 122|issue
P10304090T0000|0 21|Medicare SNF benefits
P10308312A0203|8 13|paper
P10308312A0203|27 33|status
P10308312A0203|41 54|understanding
P10308312A0203|62 84|interaction mechanisms
P10308312A0203|88 98|ultrasound
P10308312A0203|115 120|media
P10308312A0203|129 136|factors
P10308312A0203|170 177|effects
P10318806A0000|0 7|Members
P10318806A0000|15 22|mitogen
P10318806A0000|33 40|protein
P10318806A0000|42 45|MAP
P10318806A0000|47 60|kinase family
P10318806A0000|93 99|kinase
P10318806A0000|118 134|protein kinase-1
P10318806A0000|135 140|c-Jun
P10318806A0000|154 160|kinase
P10318806A0000|166 169|p38
P10318806A0000|183 191|elements
P10318806A0000|211 217|signal
P10318806A0000|231 245|growth factors
P10318806A0000|247 256|cytokines
P10318806A0000|272 278|agents
P10318806A0476|15 20|study
P10318806A0476|58 62|role
P10318806A0476|76 87|MAP kinases
P10318806A0476|114 123|responses
P10318806A0918|0 8|Analyses
P10318806A0918|12 20|tyrosine
P10318806A0918|37 51|PDGF receptors
P10318806A0918|62 74|Src homology
P10318806A0918|95 103|proteins
P10318806A0918|114 132|Src family kinases
P10318806A0918|134 163|phosphatidylinositol 3-kinase
P10318806A0918|187 194|protein
P10318806A0918|198 201|Ras
P10318806A0918|207 219|Src homology
P10318806A0918|240 257|phosphatase SHP-2
P10318806A0918|259 280|phospholipase C-gamma
P10318806A0918|286 289|Crk
P10318806A0918|310 314|role
P10318806A0918|345 355|activation
P10318806A0918|359 362|p38
P10318859A0535|18 27|calpeptin
P10318859A0535|37 58|tyrosine phosphatases
P10318859A0535|70 94|tyrosine phosphorylation
P10318859A0535|111 119|paxillin
P10318900A0637|29 36|studies
P10318900A0637|43 66|electron cryomicroscopy
P10318900A0637|83 90|binding
P10318900A0637|98 101|Fab
P10318900A0637|103 109|8H2/G5
P10318900A0637|131 143|conformation
P10318900A0637|151 157|capsid
P10318900A0637|167 177|efficiency
P10318900A0637|181 196|mRNA production
P10318900A0637|239 247|particle
P10318918A0824|20 28|analysis
P10318918A0824|32 36|NS5A
P10318918A0824|62 68|region
P10318918A0824|87 92|motif
P10318918A0824|124 137|HCV genotypes
P10319320A1022|22 30|findings
P10319320A1022|41 49|16K hPRL
P10319320A1022|76 90|Ras activation
P10319320A1022|97 107|antagonism
P10319320A1022|153 162|mechanism
P10319320A1022|171 178|control
P10319320A1022|182 194|angiogenesis
P10319327A1237|0 8|Analysis
P10319327A1237|12 57|SRE oligonucleotide gel mobility shift assays
P10319327A1237|71 79|extracts
P10319327A1237|93 98|cells
P10319327A1237|116 124|presence
P10319327A1237|137 140|SRF
P10319327A1237|177 192|protein E12/E47
P10319955A0941|14 25|differences
P10319955A0941|34 49|occlusion rates
P10319955A0941|57 61|chi2
P10319955A0941|63 73|chi-square
P10319955A0941|75 79|test
P10319955A0941|97 108|differences
P10319955A0941|127 128|P
P10320177A0487|0 29|Baseline electrocorticography
P10320177A0487|39 46|surface
P10320177A0487|63 67|lobe
P10320177A0487|72 98|depth electrode recordings
P10320177A0487|106 114|amygdala
P10320177A0487|119 130|hippocampus
P10320177A0487|161 164|min
P10320177A0487|168 177|recording
P10320177A0487|199 218|i.v. administration
P10320177A0487|227 237|alfentanil
P10320177A0487|241 250|microg/kg
P10320177A0487|255 263|fentanyl
P10320177A0487|267 276|microg/kg
P10320480A0451|22 28|system
P10320480A0451|60 64|role
P10320480A0451|80 90|C-terminus
P10320480A0451|98 110|beta subunit
P10320480A0451|122 136|RNA polymerase
P10320579A1831|16 20|FlgN
P10320579A1831|25 29|FliT
P10320579A1831|53 73|flagellar chaperones
P10320579A1831|87 102|oligomerization
P10320579A1831|110 114|HAPs
P10320579A1831|143 150|domains
P10320579A1831|158 164|export
P10321158T0000|0 4|Post
P10321158T0000|9 25|core fabrication
P10321158T0000|40 46|canals
P10321158T0000|54 63|cast post
P10321158T0000|68 72|core
P10321158T0000|93 98|dowel
P10322022A0263|0 6|Rep63A
P10322022A0263|12 23|amino acids
P10322022A0263|25 27|aa
P10322022A0263|54 57|ORF
P10322022A0263|76 86|similarity
P10322022A0263|90 100|% identity
P10322022A0263|109 129|replication proteins
P10322022A0263|135 152|plasmids pAMbeta1
P10322022A0263|154 160|pIP501
P10322022A0263|166 174|pSM19035
P10322022A0263|196 210|pAW63 replicon
P10322022A0263|226 241|pAMbeta1 family
P10322022A0263|277 285|plasmids
P10322629A0198|19 26|cloning
P10322629A0198|31 47|characterization
P10322629A0198|51 64|Xenopus Pax-5
P10322629A0198|69 74|Pax-8
P10322629A0198|80 91|orthologues
P10322629A0198|99 104|Pax-2
P10322629A0198|109 120|gene family
P10323225A0244|0 9|Km values
P10323225A0244|14 22|ammonium
P10323225A0244|24 38|2-oxoglutarate
P10323225A0244|40 44|NADH
P10323225A0244|46 55|glutamate
P10323225A0244|60 63|NAD
P10323225A0244|101 103|mM
P10323463T0000a|0 16|Interferon-alpha
P10323463T0000a|66 80|manifestations
P10323463T0000a|93 99|effect
P10323463T0000a|143 151|activity
P10323463T0000b|0 16|Interferon-alpha
P10323463T0000b|66 80|manifestations
P10323463T0000b|93 99|effect
P10323463T0000b|143 151|activity
P10323863A0852|3 11|addition
P10323863A0852|37 47|production
P10323863A0852|70 80|telomerase
P10323863A0852|92 98|factor
P10323863A0852|102 128|rabbit reticulocyte lysate
P10323863A0852|143 169|ribonucleoprotein assembly
P10325413A1211|13 20|binding
P10325413A1211|24 29|c-Abl
P10325413A1211|33 73|DNA containing 5-methylcytosine residues
P10325413A1211|103 113|propensity
P10325413A1211|128 133|helix
P10325413A1211|185 194|reduction
P10325413A1211|202 206|base
P10325413A1211|216 227|interaction
P10326221A0531|11 19|mutation
P10326221A0531|27 35|children
P10326221A0531|43 53|amputation
P10326221A0531|57 61|legs
P10326221A0531|77 86|fulminans
P10326654A0351|13 30|pilot experiments
P10326654A0351|56 65|durations
P10326654A0351|84 92|ischemia
P10326654A0351|115 122|minutes
P10326654A0351|128 137|durations
P10326654A0351|166 171|study
P10326654A0351|176 183|minutes
P10326654A0351|185 190|group
P10326654A0351|216 228|fibrillation
P10326654A0351|230 232|VF
P10326654A0351|254 258|form
P10326654A0351|262 273|arrhythmias
P10326654A0351|282 289|minutes
P10326654A0351|291 296|group
P10326654A0351|314 324|prevalence
P10326654A0351|328 330|VF
P10326654A0351|368 378|difference
P10326654A0351|386 394|duration
P10326654A0351|398 406|ischemia
P10326856T0000|14 36|pancreaticojejunostomy
P10326856T0000|56 75|purse-string device
P10327051A0688|32 63|Stress-Activated-Protein-Kinase
P10327051A0688|65 69|SAPK
P10327051A0688|71 83|target sites
P10327051A0688|87 91|ATF2
P10327051A0688|93 98|Thr69
P10327051A0688|103 108|Thr71
P10327051A0688|134 143|formation
P10327051A0688|151 163|p300/CBP-ATF
P10327051A0688|178 185|complex
P10328351A0443|0 13|Blood samples
P10328351A0443|46 68|supplementation period
P10328351A0443|75 76|d
P10328351A0443|89 90|d
P10329135A1326|6 13|results
P10329135A1326|41 53|presequences
P10329135A1326|72 80|mt-hsp70
P10329135A1326|111 125|protein import
P10329566A0610|7 15|terminus
P10329566A0610|23 29|genome
P10329566A0610|71 80|structure
P10329566A0610|92 108|valine anticodon
P10329566A0610|124 133|structure
P10329566A0610|142 152|pseudoknot
P10329566A0610|160 174|aminoacyl stem
P10329566A0610|178 185|feature
P10329566A0610|201 207|genera
P10329566A0610|211 223|tetraviruses
P10329574A1733|0 2|O.
P10329574A1733|13 18|RNA-7
P10329574A1733|63 66|RNA
P10329574A1733|95 98|RNA
P10329574A1733|113 126|OnuMV4-Ld RNA
P10329574A1733|148 157|deletions
P10329586A0414|9 13|gene
P10329586A0414|15 26|fibronectin
P10329586A0414|28 30|FN
P10329586A0414|72 85|LNCaP-r cells
P10329586A0414|123 137|overexpression
P10329586A0414|141 143|FN
P10329586A0414|147 162|prostate cancer
P10329625A0715|22 38|cell surface CD4
P10329625A0715|41 44|CD8
P10329625A0715|47 50|CD3
P10329625A0715|54 59|cells
P10329625A0715|76 85|TCR genes
P10329625A0715|154 159|cells
P10329625A0715|166 170|FTOC
P10329736A0681|28 33|yeast
P10329736A0681|45 51|system
P10329736A0681|53 58|mIRS3
P10329736A0681|81 92|p85 subunit
P10329736A0681|96 125|phosphatidylinositol 3-kinase
P10329736A1106|0 19|Insulin stimulation
P10329736A1106|33 44|association
P10329736A1106|48 53|mIRS3
P10329736A1106|59 62|p85
P10329736A1106|64 68|SHP2
P10329736A1106|70 73|Nck
P10329736A1106|79 82|Shc
P10330134A0765|4 19|mRNA expression
P10330134A0765|23 27|RFX1
P10330134A0765|29 33|RFX2
P10330134A0765|39 43|RFX3
P10330134A0765|78 107|transient-transfection assays
P10330134A0765|122 139|RFX binding sites
P10330134A0765|143 148|front
P10330134A0765|160 168|promoter
P10330134A0765|197 203|tissue
P10330134A0765|226 232|manner
P10330146A0730|7 11|case
P10330146A0730|32 38|intron
P10330146A0730|40 50|repression
P10330146A0730|54 75|luciferase expression
P10330146A0730|109 118|sequences
P10330146A0730|126 147|luciferase expression
P10330146A0730|165 173|deletion
P10330146A0730|183 188|sites
P10330159A1258|6 9|VDR
P10330159A1258|38 48|components
P10330159A1258|62 72|activation
P10330159A1258|81 98|promoter/enhancer
P10330159A1258|117 122|NFAT1
P10330159A1258|152 156|site
P10330159A1258|189 196|Jun-Fos
P10330159A1258|204 207|DNA
P10330168A0135|29 36|kinases
P10330168A0135|42 50|cyclin B
P10330168A0135|52 55|Clb
P10330168A0135|74 80|kinase
P10330168A0135|82 92|Cdk/Cdc28p
P10330168A0135|98 103|Cdc7p
P10330168A0135|131 143|factor Dbf4p
P10330168A0135|166 168|G1
P10330168A0135|181 196|DNA replication
P10330396A0387|4 25|RanQ69L preincubation
P10330396A0387|35 47|accumulation
P10330396A0387|51 55|CRM1
P10330396A0387|75 84|periphery
P10330396A0387|100 112|pore complex
P10330396A0387|114 117|NPC
P10330396A0387|122 133|association
P10330396A0387|143 154|p62 complex
P10330396A0387|159 169|Can/Nup214
P10331276A0298|11 19|elements
P10331276A0298|40 49|structure
P10331646A0595|3 11|contrast
P10331646A0595|25 44|amino acid sequence
P10331646A0595|57 63|family
P10331646A0595|65 69|ART5
P10331646A0595|74 86|transferases
P10331646A0595|107 121|lymphoma cells
P10331646A0595|144 153|abundance
P10331646A0595|157 163|testis
P10331646A0595|188 202|amino terminus
P10331646A0595|222 237|signal sequence
P10331646A0595|263 278|signal sequence
P10331646A0595|286 303|carboxyl terminus
P10331646A0595|325 332|protein
P10331646A0595|349 355|export
P10331730A0504|0 7|RESULTS
P10331730A0504|14 18|year
P10331730A0504|33 34|%
P10331730A0504|38 43|cases
P10331730A0504|52 60|Sardinia
P10331730A0504|82 83|%
P10331730A0504|97 105|patients
P10331730A0504|126 138|study period
P10331730A0504|175 182|centres
P10331875A0523|5 20|dimer interface
P10331875A0523|72 83|specificity
P10331875A0523|88 96|affinity
P10331875A0523|113 117|form
P10331875A0523|121 124|HSF
P10331875A0523|152 165|cooperativity
P10331875A0523|183 190|trimers
P10332733A0000|4 24|paramyxovirus fusion
P10332733A0000|26 27|F
P10332733A0000|29 36|protein
P10332733A0000|46 61|membrane fusion
P10333481A1102|14 31|deletion analysis
P10333481A1102|39 43|UCP2
P10333481A1102|58 68|constructs
P10333481A1102|96 102|region
P10333481A1102|118 135|promoter activity
P10333481A1102|156 158|nt
P10333481A1102|191 199|enhancer
P10333481A1102|223 225|bp
P10333481A1102|236 251|promoter region
P10333526A0459|4 14|hTERT gene
P10333526A0459|61 66|exons
P10333529A0277|5 17|betaAPP mRNA
P10333529A0277|22 34|Abeta levels
P10333529A0277|52 59|trisomy
P10334888A0960|3 16|reperfusion B
P10334888A0960|36 41|group
P10334888A0960|69 77|increase
P10334888A0960|81 100|IL-8 concentrations
P10334888A0960|113 116|min
P10334888A0960|129 141|nondiabetics
P10336495A0547|5 15|repression
P10336495A0547|29 37|agonists
P10336495A0547|48 56|receptor
P10336495A0547|84 95|interaction
P10336495A0547|104 108|NCoR
P10336495A0547|113 122|PPARalpha
P10336495A0547|123 131|RXRalpha
P10336495A0547|146 155|complexes
P10336495A0547|169 174|cells
P10339552A0361|15 20|study
P10339552A0361|35 45|SRm160/300
P10339552A0361|76 79|ESE
P10339552A0361|95 103|splicing
P10339552A0361|109 117|pre-mRNA
P10339552A0361|156 160|gene
P10339566A0602|0 6|Spc42p
P10339566A0602|32 41|component
P10339566A0602|59 73|SPB subcomplex
P10339566A0602|85 97|Spc94p/Nud1p
P10339566A0602|99 105|Cnm67p
P10339566A0602|111 117|Spc42p
P10340447A0424|12 24|coefficients
P10340447A0424|28 39|correlation
P10340447A0424|71 74|QMF
P10340447A0424|83 93|QIT system
P10340883A1266|11 13|OS
P10340883A1266|18 28|stage IIIB
P10340883A1266|37 38|%
P10340883A1266|55 56|%
P10340883A1266|61 66|stage
P10341219A0481|13 36|heparin lyase treatment
P10341219A0481|40 48|extracts
P10341219A0481|52 57|cells
P10341219A0481|81 98|YD-repeat protein
P10341219A0481|113 120|protein
P10341219A0481|141 156|mass aggregates
P10342511A0909|4 15|coefficient
P10342511A0909|19 32|determination
P10342511A0909|34 36|r2
P10342511A0909|51 57|scores
P10342536A0954|6 19|determination
P10342536A0954|27 42|protein content
P10342536A0954|50 58|formulae
P10342536A0954|73 84|information
P10342536A0954|86 106|RAST/EAST inhibition
P10342536A0954|123 126|cow
P10342536A0954|129 133|milk
P10342536A0954|172 184|whey formula
P10342536A0954|207 226|whey/casein formula
P10342536A0954|228 253|soy/pork collagen formula
P10342536A0954|263 281|amino acid formula
P10342829A0236|3 8|light
P10342829A0236|16 26|importance
P10342829A0236|30 35|GnRHR
P10342829A0236|51 61|mechanisms
P10342829A0236|93 103|regulation
P10342829A0236|117 122|GnRHR
P10342829A0236|124 130|hGnRHR
P10342829A0236|132 136|gene
P10342829A0236|150 155|issue
P10342829A0236|179 191|reproduction
P10342829A1370|12 33|mobility shift assays
P10342829A1370|47 56|alphaT3-1
P10342829A1370|65 72|extract
P10342829A1370|88 100|SF-1 protein
P10342829A1370|124 128|SF-1
P10342829A1370|172 183|GSE element
P10343189A0911|0 5|Grade
P10343189A0911|8 17|mucositis
P10343189A0911|36 43|patient
P10344736A0796|0 22|CDK4 kinase activities
P10344736A0796|52 58|levels
P10344736A0796|66 87|CDK inhibitor p21Cip1
P10344736A0796|99 123|cyclin E immunocomplexes
P10347144A0516|25 32|protein
P10347144A0516|50 68|baculovirus system
P10347144A0516|98 102|size
P10347144A0516|106 109|kDa
P10347144A0516|130 138|sequence
P10347144A0516|142 147|AVQGP
P10347197A0502|0 9|Induction
P10347197A0502|17 35|urokinase promoter
P10347197A0502|39 45|HGF/SF
P10347197A0502|54 66|Met receptor
P10347197A0502|82 95|co-expression
P10347197A0502|119 123|Grb2
P10347197A0502|128 153|Sos1 expression construct
P10347203A0832|0 22|Serine phosphorylation
P10347203A0832|26 31|STAT3
P10347203A0832|56 78|somatostatin treatment
P10347203A0832|100 115|pertussis toxin
P10347203A0832|119 121|PD
P10347203A0832|158 167|increases
P10347203A0832|171 184|proliferation
P10347220A1477|61 66|yeast
P10347220A1477|75 84|apparatus
P10347220A1477|100 103|RNA
P10347220A1477|107 121|triphosphatase
P10347220A1477|123 128|Cet1p
P10347220A1477|131 154|RNA guanylyltransferase
P10347220A1477|156 161|Ceg1p
P10347220A1477|168 173|Abd1p
P10347220A1477|231 240|apparatus
P10347220A1477|270 310|triphosphatase-guanylyltransferase Mce1p
P10347220A1477|319 341|methyltransferase Hcm1
P10347220A1477|350 352|p.
P10347839A0434|4 15|IC50 values
P10347839A0434|20 23|rat
P10347839A0434|28 31|dog
P10347839A0434|40 47|bladder
P10347839A0434|66 67|M
P10347839A0434|85 86|M
P10348859A0292|30 43|binding sites
P10348859A0292|58 72|MerR homodimer
P10348859A0292|88 90|Hg
P10348859A0292|95 98|ion
P10348859A0292|110 115|Cys82
P10348859A0292|125 132|monomer
P10348859A0292|137 143|Cys117
P10348859A0292|148 154|Cys126
P10349084T0000|4 13|influence
P10349084T0000|30 50|virus seropositivity
P10349084T0000|58 66|efficacy
P10349084T0000|89 97|globulin
P10349084T0000|101 109|children
P10349084T0000|139 146|purpura
P10349443A0358|4 11|results
P10349443A0358|19 22|lab
P10349443A0358|27 38|field tests
P10349443A0358|52 58|levels
P10349443A0358|62 73|infestation
P10349443A0358|77 83|larvae
P10349443A0358|89 95|values
P10349443A0358|118 119|%
P10349443A0358|137 138|%
P10350027A0942|0 11|Amisulpride
P10350027A0942|16 18|mg
P10350027A0942|39 46|effects
P10350027A0942|50 61|psychomotor
P10350027A0942|102 113|performance
P10350027A0942|127 130|day
P10350454A0000|0 4|MutY
P10350454A0000|23 34|glycosylase
P10350454A0000|40 51|specificity
P10350454A0000|56 66|mismatches
P10350454A0000|77 89|8-oxoguanine
P10350454A0000|91 93|oG
P10350454A0000|100 107|guanine
P10350454A0000|109 112|G.A
P10350484A0346|4 12|kinetics
P10350484A0346|16 31|kinase activity
P10350484A0346|45 54|complexes
P10350484A0346|67 71|CheA
P10350484A0346|105 115|% decrease
P10350484A0346|123 125|KM
P10350484A0346|130 133|ATP
P10350484A0346|149 157|increase
P10350484A0346|165 169|Vmax
P10350638A0000|0 7|Latexin
P10350638A0000|11 39|carboxypeptidase A inhibitor
P10350638A0000|59 63|cell
P10350638A0000|78 84|manner
P10350638A0000|124 131|systems
P10350638A0000|139 142|rat
P10353073A0118|0 19|Regression analyses
P10353073A0118|33 37|risk
P10353073A0118|55 62|factors
P10353880A0257|64 71|infants
P10353880A0257|89 95|births
P10353880A0257|102 111|diagnosis
P10353880A0257|115 118|HSV
P10353880A0257|120 121|P
P10355085A1119|0 7|Subsets
P10355085A1119|11 19|patients
P10355085A1119|52 60|severity
P10355085A1119|64 70|trauma
P10355085A1119|72 75|ISS
P10355085A1119|124 138|injury pattern
P10355085A1119|144 153|survivors
P10355085A1119|161 173|nonsurvivors
P10355536A0172|11 14|age
P10355536A0172|22 27|years
P10355536A0172|29 34|range
P10355536A0172|41 46|years
P10355910A0369|14 23|follow-up
P10355910A0369|27 30|age
P10355910A0369|33 38|years
P10357751A0866|13 18|group
P10357751A0866|31 39|children
P10357751A0866|59 64|score
P10357751A0866|74 80|weight
P10357751A0866|89 92|FFM
P10357751A0866|140 144|risk
P10357751A0866|148 153|death
P10357751A0866|164 168|risk
P10357751A0866|172 176|% CI
P10357751A0866|243 251|children
P10357751A0866|269 276|disease
P10357751A0866|301 306|score
P10357751A0866|311 317|weight
P10357751A0866|365 369|risk
P10358031A0303|3 11|addition
P10358031A0303|19 24|cells
P10358031A0303|57 63|nuclei
P10358031A0303|80 90|G2/M delay
P10358031A0303|102 110|division
P10358031A0303|122 128|defect
P10358031A0303|132 143|cytokinesis
P10358031A0303|151 166|cell separation
P10358075A0984|0 5|DAF16
P10358075A0984|23 32|component
P10358075A0984|38 55|signaling pathway
P10358075A0984|115 125|homologues
P10358075A0984|133 144|insulin/IGF
P10358075A0984|147 155|receptor
P10358075A0984|157 172|PtdIns 3-kinase
P10358075A0984|177 180|PKB
P10358079A0391|9 28|neu differentiation
P10358079A0391|44 56|heterodimers
P10358079A0391|60 65|ErbB2
P10358079A0391|70 75|ErbB4
P10358079A0391|86 91|Stat5
P10358080A1114|9 23|linker regions
P10358080A1114|27 48|transcription factors
P10358080A1114|71 94|DNA binding specificity
P10358080A1114|100 107|studies
P10358080A1114|131 142|HSF1 linker
P10358080A1114|152 156|role
P10358080A1114|172 196|HSF1 binding preferences
P10358080A1114|223 234|determinant
P10358080A1114|253 284|HSF1 monomer-trimer equilibrium
P10358080T0000|0 10|Modulation
P10358080T0000|20 51|heat shock factor trimerization
P10358080T0000|59 72|linker domain
P10358083A0263|16 24|analyses
P10358083A0263|64 72|F9 cells
P10358083A0263|77 93|characterization
P10358083A0263|109 118|complexes
P10358083A0263|148 170|sequence motifs GTGACT
P10358083A0263|171 172|C
P10358083A0263|175 180|ATTGT
P10358083A0263|186 190|GATA
P10358083A0263|202 222|transcription factor
P10358083A0263|231 236|sites
P10358138A0672|6 13|results
P10358138A0672|31 40|phenotype
P10358138A0672|44 47|XLP
P10358138A0672|74 83|signaling
P10358138A0672|101 105|SLAM
P10358138A0672|122 144|cell surface molecules
P10358138A0672|158 161|SAP
P10358138A0672|167 192|signaling adaptor protein
P10359014A1077|22 49|Fra-2 phosphorylation sites
P10359014A1077|53 57|MAPK
P10359014A1077|67 76|threonine
P10359014A1077|87 102|serine residues
P10359014A1077|124 130|region
P10359014A1077|134 139|means
P10359014A1077|157 168|mutagenesis
P10359014A1077|189 207|threonine residues
P10359014A1077|233 237|MAPK
P10359575A0317|53 62|FcalphaRI
P10359575A0317|75 78|IgA
P10359575A0317|80 84|hIgA
P10359575A0317|101 105|IgG2
P10359575A0317|107 112|bIgG2
P10359575A0317|123 133|bFcgamma2R
P10359575A0317|140 145|bIgG2
P10359575A0317|154 158|hIgA
P10359603A0430|0 5|Vac1p
P10359603A0430|28 50|Sec1p homologue Vps45p
P10359663A0425|34 40|system
P10359663A0425|63 70|regions
P10359663A0425|74 81|oIFNtau
P10359663A0425|99 104|front
P10359663A0425|115 120|virus
P10359663A0425|125 129|SV40
P10359663A0425|131 139|promoter
P10359663A0425|145 152|regions
P10359663A0425|161 166|bases
P10359663A0425|210 225|enhancer region
P10359663A0425|239 271|oIFNtau-SV40-CAT transactivation
P10359663A1280|3 26|co-transfection studies
P10359663A1280|32 42|expression
P10359663A1280|46 51|c-Jun
P10359663A1280|57 62|c-Fos
P10359663A1280|76 91|transactivation
P10359663A1280|95 106|oIFNtau-CAT
P10359663A1280|115 125|expression
P10359663A1280|129 135|GATA-1
P10359663A1280|137 143|GATA-2
P10359663A1280|147 153|GATA-3
P10359664A0579|18 23|sites
P10359664A0579|45 51|MARCKS
P10359664A0579|70 88|lysyl endoprotease
P10359664A0579|105 121|electrospray MS.
P10359673A0000|4 19|yeast LPD1 gene
P10359673A0000|29 52|lipoamide dehydrogenase
P10359673A0000|79 86|control
P10359673A0000|90 113|amino acid biosynthesis
P10359673A0000|130 155|GCN4 transcription factor
P10359792A0610|20 27|defects
P10359792A0610|40 52|Rpd3 mutants
P10359792A0610|90 97|Groucho
P10359792A0610|102 128|dCtBP corepressor proteins
P10359792A0610|164 175|recruitment
P10359792A0610|179 199|histone deacetylases
P10360454A0916|13 38|serum TNF-a concentration
P10360454A0916|66 74|patients
P10360454A0916|85 99|pentoxifylline
P10360454A0916|117 122|pg/ml
P10360454A0916|128 133|month
P10360454A0916|144 149|pg/ml
P10360454A0916|151 152|p
P10360454A0916|177 190|control group
P10360839A1338|3 11|addition
P10360839A1338|30 40|expression
P10360839A1338|55 62|members
P10360839A1338|70 79|subfamily
P10360839A1338|83 105|KRAB zinc finger genes
P10360839A1338|146 159|cell lineages
P10360947A1113|10 35|fluorescence spectroscopy
P10360947A1113|49 58|dichroism
P10360947A1113|79 86|binding
P10360947A1113|90 93|Ca2
P10360947A1113|98 103|ALG-2
P10360947A1113|139 146|changes
P10360947A1113|185 192|domains
P10360947A1113|200 207|protein
P10361038A0281|27 36|locations
P10361038A0281|44 53|promoters
P10361038A0281|81 94|protein genes
P10362652A0350|5 14|carbachol
P10362652A0350|20 26|microM
P10362652A0350|32 35|EGF
P10362652A0350|40 42|nM
P10362652A0350|52 66|Ras activation
P10362652A1456|18 21|Sos
P10362652A1456|37 58|carbachol stimulation
P10362652A1456|62 69|HA-ERK2
P10362652A1456|100 106|effect
P10362652A1456|110 113|EGF
P10362652A1456|119 120|%
P10362897A0545|0 7|RESULTS
P10362897A0545|24 31|passage
P10362897A0545|35 43|contrast
P10362897A0545|67 74|amounts
P10362897A0545|90 99|intensity
P10362897A0545|107 121|Doppler signal
P10362897A0545|145 153|duration
P10362897A0545|162 168|effect
P10363517A0401|8 13|paper
P10363517A0401|20 27|lesions
P10363517A0401|35 40|cases
P10363517A0401|59 74|ultrasonography
P10364076A0429|6 13|regions
P10364076A0429|31 36|E-box
P10364076A0429|59 72|repeat motifs
P10364076A0429|82 89|SREBP-1
P10364076A0429|105 115|affinities
P10364159A0813|17 26|questions
P10364159A0813|42 59|FRAP/mTOR protein
P10364159A0813|66 93|FRAP/mTOR immunoprecipitate
P10364159A0813|120 133|kinase assays
P10364159A0813|151 157|4E-BP1
P10364163A0092|0 3|Hrs
P10364163A0092|10 14|FYVE
P10364163A0092|22 40|zinc finger domain
P10364163A0092|67 87|phosphatidylinositol
P10364163A0092|91 100|phosphate
P10364163A0092|129 137|proteins
P10364163A0092|160 167|traffic
P10364202A0646|4 16|coexpression
P10364202A0646|32 53|expression constructs
P10364202A0646|63 66|DBP
P10364202A0646|79 94|leukemia factor
P10364202A0646|118 126|increase
P10364202A0646|130 140|activation
P10364202A0646|157 181|GAL4-DBP fusion proteins
P10364202A0646|198 209|involvement
P10364202A0646|225 236|coactivator
P10364202A0646|245 252|process
P10364314A0919|6 16|subgenomes
P10364314A0919|41 52|nucleotides
P10364314A0919|73 77|part
P10364314A0919|85 93|NS2 gene
P10364319A0109|0 2|Cp
P10364319A0109|24 32|promoter
P10364319A0109|37 57|EBNA mRNA initiation
P10364319A0109|78 84|EBNA3C
P10364319A0109|126 138|control loop
P10364425A0610|6 17|indications
P10364425A0610|33 43|signalling
P10364425A0610|51 58|absence
P10364425A0610|62 70|tyrosine
P10364425A0610|107 117|activation
P10364425A0610|121 126|STAT3
P10364523A0826|5 18|exon trapping
P10364523A0826|52 57|exons
P10364523A0826|67 77|YAC 946E12
P10364523A0826|93 99|region
P10364523A0826|138 144|contig
P10364523A0826|152 160|vicinity
P10364523A0826|168 179|breakpoints
P10364523T0000|11 46|dysplasia translocation breakpoints
P10364523T0000|68 70|Mb
P10364523T0000|83 87|SOX9
P10364523T0000|89 97|evidence
P10364523T0000|114 128|control region
P10365883A1355|16 31|characteristics
P10365883A1355|35 47|VRE patients
P10365883A1355|66 80|vancomycin use
P10365883A1355|120 129|infection
P10365883A1355|131 142|coinfection
P10365883A1355|164 173|pathogens
P10365883A1355|197 206|infection
P10366446A0893|14 20|domain
P10366446A0893|52 59|protein
P10366446A0893|83 100|interaction motif
P10366446A0893|105 112|FLI LRR
P10366503A0812|0 18|Binding affinities
P10366503A0812|40 46|phages
P10366503A0812|68 77|retention
P10366503A0812|87 93|phages
P10366503A0812|99 106|His-tag
P10366503A0812|119 130|gp17 column
P10366503A0812|139 161|co-immunoprecipitation
P10366503A0812|176 185|terminase
P10366503A0812|209 215|nature
P10366503A0812|230 237|protein
P10366503A0812|242 269|terminase interaction sites
P10366503A1506|13 22|terminase
P10366503A1506|54 58|gp20
P10366503A1506|66 73|peptide
P10366503A1506|86 94|antibody
P10366503A1506|114 121|peptide
P10366503A1506|140 146|access
P10366503A1506|164 173|structure
P10366503A1506|195 206|association
P10366503A1506|210 214|gp20
P10366503A1506|219 223|gp17
P10366503A1506|246 263|terminase regions
P10366503A1506|275 281|portal
P10366503A1506|289 306|packasome complex
P10366559A0605|4 18|hybrid viruses
P10366559A0605|52 58|levels
P10366559A0605|71 77|plants
P10366559A0605|94 101|virions
P10366722T0000|0 4|cDNA
P10366722T0000|20 32|organization
P10366722T0000|40 50|gene Pole1
P10366722T0000|59 87|mouse DNA polymerase epsilon
P10366722T0000|98 105|subunit
P10367240A1354|13 29|cryopreservation
P10367240A1354|33 44|spermatozoa
P10367240A1354|50 56|medium
P10367240A1354|76 78|SP
P10367240A1354|94 104|substances
P10367240A1354|131 145|cryoprotection
P10367240A1354|149 160|spermatozoa
P10367240A1354|184 208|fertilization procedures
P10367240A1354|242 257|sperm injection
P10367385A0000|25 31|method
P10367385A0000|49 57|analysis
P10367385A0000|61 74|beta-carotene
P10367385A0000|86 90|food
P10367460A0191|4 19|FCMS conditions
P10367460A0191|39 49|kW maximum
P10367460A0191|61 78|power consumption
P10367460A0191|84 111|V maximum capacitor voltage
P10367460A0191|117 129|microseconds
P10367460A0191|146 158|microseconds
P10367460A0191|164 168|time
P10367460A0191|180 192|Hz frequency
P10367646A0569|7 16|hemolysis
P10367646A0569|55 62|changes
P10367646A0569|70 81|mean values
P10367646A0569|95 103|analytes
P10367646A0569|107 115|addition
P10367646A0569|133 142|increases
P10367646A0569|144 168|alanine aminotransferase
P10367646A0569|170 177|calcium
P10367646A0569|183 198|serum globulins
P10367646A0569|200 201|P
P10367646A0569|215 222|albumin
P10367646A0569|233 240|protein
P10367646A0569|242 243|P
P10369418A0644|0 4|EMSA
P10369418A0644|24 32|extracts
P10369418A0644|51 62|stimulation
P10369418A0644|68 73|CD40L
P10369418A0644|89 98|induction
P10369418A0644|102 121|NF-kappaB complexes
P10369418A0644|153 168|NF-kappaB sites
P10369418A0644|196 199|p50
P10369418A0644|204 208|RelB
P10369418A0644|227 232|c-Rel
P10369418A0644|237 240|p65
P10369625A0942|8 18|monitoring
P10369625A0942|22 25|ODA
P10369757A0000|10 31|transcription factors
P10369757A0000|44 63|arginine metabolism
P10369757A0000|88 105|Bacillus subtilis
P10369757A0000|107 111|ArgR
P10369757A0000|116 120|AhrC
P10369757A0000|162 170|proteins
P10369757A0000|181 182|l
P10369757A0000|215 224|complexes
P10369757A0000|247 260|transcription
P10369757A0000|281 286|genes
P10369757A0000|306 319|transcription
P10369757A0000|333 338|genes
P10369757A0000|340 344|AhrC
P10369757A0000|367 391|plasmid dimer resolution
P10369775A0178|12 29|protein fragments
P10369775A0178|41 63|residues Arg183-His267
P10369775A0178|77 79|ER
P10369775A0178|84 106|residues Lys438-Gln520
P10369775A0178|114 120|rat GR
P10369926A0251|4 8|exon
P10369926A0251|9 25|intron structure
P10369926A0251|29 40|chicken IL8
P10369926A0251|85 88|IL8
P10369926A0251|137 156|CXC chemokine genes
P10369965A0000|4 16|Aa-Pri2 gene
P10369965A0000|48 75|basidiocarp differentiation
P10369965A0000|83 109|mushroom Agrocybe aegerita
P10370675A0649|9 15|causes
P10370675A0649|19 32|liver disease
P10370675A0649|40 48|patients
P10370675A0649|54 57|HCC
P10370675A0649|63 80|hepatitis C virus
P10370675A0649|82 85|HCV
P10370675A0649|90 91|%
P10370675A0649|94 107|alcohol abuse
P10370675A0649|111 112|%
P10370675A0649|123 134|combination
P10370675A0649|138 141|HCV
P10370675A0649|146 159|alcohol abuse
P10370675A0649|163 164|%
P10370778A0000|10 30|aromatase inhibitors
P10370778A0000|55 60|phase
P10370778A0000|65 75|evaluation
P10370778A0000|79 88|treatment
P10370778A0000|103 116|breast cancer
P10370778A0000|136 141|women
P10370778A0000|148 155|disease
P10370778A0000|179 196|tamoxifen therapy
P10370778A0000|198 209|anastrozole
P10370778A0000|211 219|ARIMIDEX
P10370778A0000|221 227|Zeneca
P10370778A0000|230 239|letrozole
P10370778A0000|241 247|FEMARA
P10370778A0000|249 257|Novartis
P10370778A0000|263 271|vorozole
P10370778A0000|273 280|RIVIZOR
P10370778A0000|282 289|Janssen
P10371097A0963|0 11|CONCLUSIONS
P10371097A0963|13 22|Turbutest
P10371097A0963|37 41|tool
P10371097A0963|55 63|patients
P10371097A0963|65 73|training
P10371097A0963|84 98|identification
P10371097A0963|103 114|improvement
P10371097A0963|132 152|inhalation technique
P10371097A0963|158 168|Turbuhaler
P10372627A0530|9 17|injuries
P10372627A0530|23 28|cases
P10372627A0530|34 43|snowboard
P10372627A0530|60 65|cases
P10373029A0204|12 23|artery/vein
P10373029A0204|32 38|soleus
P10373029A0204|43 64|gastrocnemius muscles
P10373029A0204|101 111|volunteers
P10373507A0680|0 9|SRFDelta5
P10373507A0680|69 75|mutant
P10373507A0680|111 122|alpha-actin
P10373507A0680|132 143|alpha-actin
P10373507A0680|152 163|alpha-actin
P10373507A0680|165 174|SM22alpha
P10373507A0680|180 223|SRF promoter-luciferase reporter activities
P10373523A0924|14 19|media
P10373523A0924|21 27|p50E4F
P10373523A0924|52 61|apoptosis
P10374632A0818|4 11|potency
P10374632A0818|19 25|effect
P10374632A0818|29 32|Nim
P10374632A0818|38 45|mg.kg-1
P10374632A0818|75 78|NBP
P10374632A0818|83 90|mg.kg-1
P10374632A0897|0 10|CONCLUSION
P10374632A0897|12 29|NBP pre-treatment
P10374632A0897|70 74|rCBF
P10374632A0897|78 86|striatum
P10374632A0897|90 100|RMCAO rats
P10375107A1138|0 11|Progression
P10375107A1138|29 41|chemotherapy
P10375107A1138|82 90|survival
P10375107A1138|95 103|patients
P10375107A1138|109 119|metastasis
P10375638A0859|0 9|Mutations
P10375638A0859|23 27|UTR1
P10375638A0859|37 53|NRF-1 expression
P10375638A0859|74 78|mRNA
P10375638A0859|93 103|efficiency
P10375638A0859|119 124|cells
P10375638A0859|144 162|translation system
P10375640A0153|23 42|nucleotide sequence
P10375640A0153|50 54|cDNA
P10375640A0153|56 61|CBS-1
P10375640A0153|79 92|reading frame
P10375640A0153|111 122|amino acids
P10375640A0153|141 147|weight
P10375640A0153|155 158|kDa
P10375694T0000|39 50|input zones
P10375694T0000|77 87|motor area
P10375694T0000|103 109|monkey
P10375694T0000|111 121|comparison
P10375694T0000|131 142|input zones
P10375694T0000|166 176|motor area
P10375718A0000|6 30|fibroblast growth factor
P10375718A0000|32 36|bFGF
P10375718A0000|63 75|angiogenesis
P10375718A0000|87 100|animal models
P10375718A0000|110 117|methods
P10375718A0000|121 135|administration
P10376065A0881|5 12|filters
P10376065A0881|36 45|elevation
P10376065A0881|62 70|pressure
P10376065A0881|72 78|median
P10376065A0881|92 97|mm Hg
P10376065A0881|99 100|n
P10376065A0881|115 128|spring filter
P10376065A0881|133 144|RF02 filter
P10376446A0000|11 16|women
P10376446A0000|18 21|age
P10376446A0000|28 33|years
P10376446A0000|59 65|2-hour
P10376446A0000|68 74|method
P10376446A0000|86 89|leg
P10376446A0000|98 101|PLR
P10376446A0000|118 120|FP
P10376446A0000|126 132|luteal
P10376446A0000|134 136|LP
P10376446A0000|138 144|phases
P10376446A0000|165 170|cycle
P10376873A0706|6 12|sgRNA2
P10376873A0706|36 39|UTR
P10376874A0759|24 31|defects
P10376874A0759|39 60|eRF1-eRF3 interaction
P10376874A0759|98 111|protein eRF3C
P10376874A0759|136 149|eRF1 proteins
P10376874A0759|178 185|protein
P10376874A0759|205 212|support
P10376874A0759|221 229|presence
P10376874A0759|246 257|interaction
P10376877A0611|0 7|Removal
P10376877A0611|36 44|segments
P10376877A0611|65 69|half
P10376877A0611|96 105|formation
P10376877A0611|112 119|Ss rRNA
P10376877A0611|138 142|part
P10376877A0611|161 167|region
P10376877A0611|175 182|protein
P10376877A0611|199 209|production
P10376877A0611|213 221|18S rRNA
P10376991A0977|0 3|Ras
P10376991A0977|31 39|tegument
P10377345A0740|0 5|Green
P10377345A0740|33 40|UNC-49B
P10377345A0740|45 61|UNC-49C subunits
P10377345A0740|81 93|muscle cells
P10377345A0740|126 133|regions
P10377438A0647|15 22|protein
P10377438A0647|24 28|UBC9
P10377438A0647|58 61|TEL
P10378989A0000|4 7|aim
P10378989A0000|16 21|study
P10378989A0000|57 64|reports
P10378989A0000|86 100|drug reactions
P10378989A0000|122 130|patients
P10378989A0000|140 145|years
P10378989A0000|149 152|age
P10378989A0000|157 163|Sicily
P10378989A0000|165 170|Italy
P10378989A0000|183 189|period
P10378989A0000|197 204|January
P10378989A0000|216 224|December
P10379547A0000|0 9|Molecules
P10379547A0000|13 16|NH3
P10379547A0000|52 61|radiation
P10379547A0000|63 68|MASER
P10379899A0446|10 18|findings
P10379899A0446|26 33|studies
P10379899A0446|77 84|signals
P10379899A0446|108 117|follicles
P10379899A0446|130 154|theca cell layer markers
P10379942A0956|30 38|residues
P10379942A0956|89 93|part
P10379942A0956|101 118|MDV2 UL10 protein
P10379942T0000|0 14|Identification
P10379942T0000|19 28|structure
P10379942T0000|36 41|Marek
P10379942T0000|44 66|disease virus serotype
P10379942T0000|69 88|glycoprotein M gene
P10379942T0000|90 100|comparison
P10379942T0000|106 126|glycoprotein M genes
P10379942T0000|130 150|Herpesviridae family
P10380232A0000|0 9|OBJECTIVE
P10380232A0000|24 51|cost-effectiveness analysis
P10380232A0000|53 56|CEA
P10380232A0000|88 110|regimen-chlorpromazine
P10380232A0000|113 126|dexamethasone
P10380232A0000|128 135|CPM-DEX
P10380232A0000|144 181|5-HT3 receptor antagonist-tropisetron
P10380232A0000|183 187|TROP
P10380232A0000|197 204|control
P10380232A0000|214 220|emesis
P10380232A0000|250 262|chemotherapy
P10380232A0000|266 274|children
P10380232A0000|301 313|perspectives
P10380232A0000|315 323|hospital
P10380232A0000|328 336|patients
P10380659A0545|0 13|Baseline data
P10380659A0545|36 42|adults
P10380800A0194|2 12|comparison
P10380800A0194|20 30|nucleotide
P10380800A0194|43 63|amino acid sequences
P10380800A0194|71 83|core regions
P10380800A0194|105 127|RNA polymerase domains
P10380800A0194|149 155|dsRNAs
P10380800A0194|177 183|dsRNAs
P10380800A0194|227 237|host plant
P10380800A0194|252 260|ancestor
P10380878A0542|21 32|possibility
P10380878A0542|44 50|region
P10380878A0542|54 58|Bin1
P10380878A0542|87 106|repression function
P10380878A0542|110 113|DNA
P10380878A0542|136 155|histone deacetylase
P10380890A0619|12 21|sequences
P10380890A0619|102 104|IR
P10381257A0000|21 28|protein
P10381257A0000|30 37|metaxin
P10381257A0000|53 62|component
P10381257A0000|68 93|preprotein import complex
P10381257A0000|107 115|membrane
P10381257A0000|133 146|mitochondrion
P10381377T0000|10 17|cloning
P10381377T0000|21 24|rat
P10381377T0000|40 60|inositol phosphatase
P10381377T0000|64 69|SHIP2
P10381377T0000|79 83|role
P10381377T0000|91 101|regulation
P10381377T0000|105 122|insulin signaling
P10381570A1355|0 4|Slp1
P10381570A1355|15 28|transcription
P10381570A1355|38 50|binding site
P10381570A1355|54 65|yeast cells
P10381570A1355|87 91|role
P10381570A1355|104 113|repressor
P10381570A1355|117 128|ftz stripes
P10381570A1355|132 151|interstripe regions
P10381570A1355|164 170|stages
P10381570A1355|174 187|embryogenesis
P10383764A1809|4 11|results
P10383764A1809|21 28|studies
P10383764A1809|39 44|model
P10383764A1809|54 66|VirB4 dimers
P10383764A1809|70 83|homomultimers
P10383764A1809|106 117|information
P10383764A1809|126 134|assembly
P10383764A1809|140 161|transenvelope channel
P10383764A1809|190 202|DNA transfer
P10383764A1809|229 237|activity
P10383764A1809|271 278|channel
P10383764A1809|294 308|export machine
P10383966A0000|4 31|penicillin binding proteins
P10383966A0000|33 37|PBPs
P10383966A0000|62 75|peptidoglycan
P10383966A0000|92 101|component
P10383966A0000|119 128|cell wall
P10384129A0000|0 9|TCR alpha
P10384129A0000|11 15|TCRA
P10384129A0000|17 27|expression
P10384129A0000|44 55|RNA samples
P10384129A0000|61 65|PBMC
P10384129A0000|79 90|populations
P10384129A0000|94 97|CD4
P10384129A0000|100 103|CD8
P10384129A0000|113 120|T cells
P10384129A0000|137 148|individuals
P10385384A0654|8 15|results
P10385384A0654|35 42|xylitol
P10385384A0654|47 56|activator
P10385384A0654|64 89|pentose phosphate pathway
P10385395A0000|9 28|density lipoprotein
P10385395A0000|30 33|HDL
P10385395A0000|35 43|receptor
P10385395A0000|57 63|uptake
P10385395A0000|67 78|cholesterol
P10385395A0000|83 101|cholesteryl esters
P10385395A0000|103 113|substrates
P10385395A0000|118 133|steroidogenesis
P10385395A0000|143 155|HDL particle
P10385395A0000|171 176|gland
P10385395A0000|181 187|gonads
P10385915A1341|0 7|D3S1261
P10385915A1341|45 55|MITF locus
P10385915A1341|63 70|D3S2465
P10385915A1341|75 82|D3S1766
P10385915A1341|100 105|locus
P10385915A1341|120 122|cM
P10385915A1341|131 139|distance
P10385915A1341|145 149|side
P10388670A1976|4 15|percentages
P10388670A1976|19 27|recovery
P10388670A1976|43 55|storage time
P10388670A1976|70 78|addition
P10388670A1976|82 92|dispersant
P10388670A1976|116 123|storage
P10388670A1976|154 162|adhesion
P10390158A1150|0 15|Point mutations
P10390158A1150|23 27|site
P10390158A1150|44 57|Pit-1 binding
P10390158A1150|81 103|tiGH promoter activity
P10390538T0000|23 42|zinc-finger protein
P10390538T0000|67 76|sequences
P10391075A0000|20 32|autopsy case
P10391075A0000|62 71|sclerosis
P10391075A0000|116 127|brain tumor
P10391075A0000|131 143|MRI findings
P10391246A0756|13 18|MOM-4
P10391246A0756|23 27|TAK1
P10391246A0756|41 49|proteins
P10391246A0756|69 86|kinase activities
P10391277A0000|0 10|BACKGROUND
P10391277A0000|16 24|MAZE-III
P10391277A0000|41 50|treatment
P10391277A0000|54 60|choice
P10391277A0000|93 105|fibrillation
P10391903T0000|0 4|Gab2
P10391903T0000|12 31|pleckstrin homology
P10391903T0000|50 65|adapter protein
P10391903T0000|84 93|signaling
P10391903T0000|99 109|ERK kinase
P10391903T0000|113 118|Elk-1
P10392266A0111|4 12|presence
P10392266A0111|26 35|xanthomas
P10392266A0111|48 66|serum lipid levels
P10392266A0111|101 109|activity
P10392266A0111|128 142|immunoglobulin
P10392669A0935|6 13|attempt
P10392669A0935|28 37|incidence
P10392669A0935|72 79|lesions
P10392669A0935|95 105|approaches
P10392669A0935|130 133|use
P10392669A0935|141 175|prostaglandin analogue misoprostol
P10392669A0935|199 203|drug
P10392669A0935|252 262|prevention
P10392669A0935|301 307|ulcers
P10392669A0935|318 327|reduction
P10392669A0935|362 375|complications
P10392669A0935|382 415|histamine H2 receptor antagonists
P10392669A0935|417 431|H2 antagonists
P10392669A0935|439 449|ranitidine
P10392669A0935|451 461|cimetidine
P10392669A0935|466 476|famotidine
P10392669A0935|502 512|prevention
P10392669A0935|539 545|ulcers
P10392669A0935|558 572|term treatment
P10392669A0935|589 599|prevention
P10392669A0935|625 631|ulcers
P10392669A0935|639 661|proton pump inhibitors
P10392669A0935|667 677|omeprazole
P10392669A0935|683 695|pantoprazole
P10392669A0935|703 711|efficacy
P10392669A0935|743 749|ulcers
P10392669A0935|791 805|barrier agents
P10392669A0935|855 874|prophylactic agents
P10392669A0935|900 911|gastropathy
P10392710A1000|0 15|Lung mesenchyme
P10392710A1000|29 37|compleat
P10392710A1000|39 46|inducer
P10392710A1000|50 68|lung morphogenesis
P10392710A1000|90 112|peptide growth factors
P10392900A1020|4 14|activation
P10392900A1020|22 34|HIV promoter
P10392900A1020|56 68|localization
P10392900A1020|72 77|c-Abl
P10392900A1020|117 141|tyrosine phosphorylation
P10392900A1020|145 159|RNA polymerase
P10392903A0000|11 36|papillomavirus E2 protein
P10392903A0000|53 66|proliferation
P10392903A0000|70 80|HT-3 cells
P10392903A0000|106 125|carcinoma cell line
P10392903A0000|154 173|papillomavirus type
P10392903A0000|177 180|DNA
P10392903A0889|0 16|E2 point mutants
P10392903A0889|35 46|cell growth
P10392903A0889|63 69|cdc25A
P10392903A0889|74 91|cdc25B expression
P10392903A0889|105 138|cell cycle inhibitors hydroxyurea
P10392903A0889|143 151|mimosine
P10392914A0000|0 18|BACKGROUND/PURPOSE
P10392914A0000|30 41|arrangement
P10392914A0000|68 72|duct
P10392914A0000|74 79|AAPBD
P10392914A0000|122 132|dilatation
P10392914A0000|172 188|tract malignancy
P10393192A0792|0 24|Neurospora crassa CYT-18
P10393192A0792|48 52|trap
P10393192A0792|57 71|intron mutants
P10393192A0792|97 103|defect
P10393197A0543|0 4|DDP1
P10393197A0543|23 38|heterochromatin
P10393197A0543|42 59|interphase nuclei
P10393197A0543|70 81|neuroblasts
P10393201A0654|25 42|DNA repair system
P10393201A0654|54 73|DNA polymerase beta
P10393201A0654|78 98|DNA ligase III-XRCC1
P10393201A0654|138 150|base residue
P10393201A0654|170 175|break
P10393201A0654|192 200|addition
P10393201A0654|208 219|exonuclease
P10393251A0283|4 13|PAC clone
P10393251A0283|22 33|insert size
P10393251A0283|37 42|120kb
P10393251A0283|70 90|restriction analysis
P10393251T0000|0 8|Sequence
P10393251T0000|12 23|10q24 locus
P10393251T0000|40 54|HOX11 oncogene
P10393251T0000|69 78|gene HUG1
P10393251T0000|94 109|T-ALL cell line
P10393422A0476|9 11|kb
P10393422A0476|24 29|LAMB2
P10393422A0476|41 45|gene
P10393422A0476|95 105|pseudogene
P10393422A0476|107 113|LAMB2L
P10393910A0705|14 25|mutagenesis
P10393910A0705|33 43|R2 protein
P10393910A0705|64 72|evidence
P10393910A0705|83 88|motif
P10393910A0705|97 101|part
P10393910A0705|116 120|site
P10393910A0705|128 140|endonuclease
P10393910A0705|157 164|element
P10393969A0000|13 29|cell protein no.
P10393969A0000|33 37|ICP0
P10393969A0000|42 62|herpes simplex virus
P10393969A0000|82 96|transactivator
P10393969A0000|118 128|expression
P10393969A0000|132 137|genes
P10393969A0000|155 160|cells
P10393969A0000|164 173|infection
P10393969A0000|177 189|transfection
P10394116T0000|0 17|Wrist measurement
P10394116T0000|21 35|blood pressure
P10394116T0000|51 58|remarks
P10394116T0000|62 74|oscillometry
P10394900A1166|15 25|expression
P10394900A1166|29 35|leaves
P10394900A1166|49 57|presence
P10394900A1166|64 79|enhancer region
P10394900A1166|89 113|cauliflower mosaic virus
P10394900A1166|115 119|CaMV
P10394900A1166|121 133|35S promoter
P10394919A1058|8 15|element
P10394919A1058|45 54|amplitude
P10394919A1058|62 73|oscillation
P10395199A0792|5 9|scFv
P10395199A0792|32 39|control
P10395199A0792|43 54|experiments
P10395199A0792|78 82|scFv
P10395199A0792|84 93|Y259 scFv
P10395199A0792|134 145|mAb Y13-259
P10395199A0792|159 170|Ras pathway
P10395199A0792|191 207|tumor regression
P10395199A0792|218 229|mouse model
P10395199A0792|231 237|Cochet
P10395199A0792|239 241|O.
P10395199A0792|243 253|Kenigsberg
P10395199A0792|255 257|M.
P10395199A0792|259 267|Delumeau
P10395199A0792|269 271|I.
P10395199A0792|273 285|Virone-Oddos
P10395199A0792|287 289|A.
P10395199A0792|291 297|Multon
P10395199A0792|299 303|M.C.
P10395199A0792|305 312|Fridman
P10395199A0792|314 318|W.H.
P10395199A0792|320 333|Schweighoffer
P10395199A0792|335 337|F.
P10395199A0792|339 347|Teillaud
P10395199A0792|349 353|J.L.
P10395199A0792|355 361|Tocque
P10395199A0792|363 365|B.
P10395283A0960|13 24|competition
P10395283A0960|33 42|activin A
P10395283A0960|47 51|OP-1
P10395283A0960|56 68|availability
P10395283A0960|72 77|Smad4
P10395283A0960|99 112|concentration
P10395283A0960|128 145|signal transducer
P10395283A0960|201 210|responses
P10395378A1198|4 8|data
P10395378A1198|64 88|HA envelope glycoprotein
P10395378A1198|99 106|ligands
P10395378A1198|129 132|end
P10395378A1198|155 170|fusion activity
P10395827A1297|22 47|parallel beta helix model
P10395827A1297|61 65|coil
P10395827A1297|92 104|beta strands
P10395827A1297|117 136|parallel beta sheet
P10395908A0236|42 49|protein
P10395908A0236|87 94|regions
P10395908A0236|104 135|amino acid motif characteristic
P10395908A0236|143 153|R7G family
P10395908A0236|157 166|G-protein
P10395908A0236|190 199|receptors
P10395911A0288|0 16|Characterisation
P10395911A0288|24 55|chicken apolipoprotein A-I gene
P10395911A0288|68 74|region
P10395920A1424|6 13|results
P10395920A1424|27 34|members
P10395920A1424|42 52|ATF family
P10395920A1424|99 109|regulation
P10395920A1424|117 125|KGF gene
P10395920A1424|129 137|response
P10395920A1424|155 162|stimuli
P10395920A1424|175 178|CRE
P10395920A1424|190 197|element
P10396343A0754|17 27|proportion
P10396343A0754|31 44|blood samples
P10396343A0754|59 65|sample
P10396343A0754|73 77|rest
P10396343A0754|85 93|suspects
P10396343A0754|135 138|DNA
P10396343A0754|142 145|PCR
P10396343A0754|151 152|%
P10396343A0754|157 172|T. b. gambiense
P10396343A0754|181 182|%
P10396343A0754|187 204|T. b. rhodesiense
P10396343T0000|15 25|evaluation
P10396343T0000|33 37|card
P10396343T0000|47 65|agglutination test
P10396343T0000|70 85|trypanosomiasis
P10396343T0000|87 101|TrypTect CIATT
P10396793A0815|0 7|Results
P10396793A0815|12 15|men
P10396793A0815|36 42|drinks
P10396793A0815|47 50|day
P10396793A0815|71 90|dependence criteria
P10396793A0815|105 115|reductions
P10396793A0815|123 133|prevalence
P10396793A0815|146 156|indicators
P10396793A0815|160 178|alcohol dependence
P10396793A0815|199 200|%
P10396793A0815|207 208|%
P10397257A1142|0 11|Mutagenesis
P10397257A1142|19 35|CDE/CHR elements
P10397257A1142|40 49|Sp1 sites
P10397257A1142|58 64|region
P10397257A1142|78 89|combination
P10397257A1142|115 123|activity
P10397257A1142|132 133|%
P10397257A1142|160 165|cells
P10397257A1142|180 202|cell cycle periodicity
P10397257A1142|224 229|cells
P10398286A0678|6 13|Scheffe
P10398286A0678|16 25|procedure
P10398286A0678|32 44|illustration
P10398286A0678|46 57|comparisons
P10398286A0678|76 95|sample size methods
P10398286A0678|135 141|nature
P10398286A0678|145 148|S2p
P10398682A0365|4 21|crystal structure
P10398682A0365|29 38|VP16 core
P10398682A0365|68 78|resolution
P10399136A0389|0 7|Ozagrel
P10399136A0389|9 19|ifenprodil
P10399136A0389|21 32|cinnarizine
P10399136A0389|37 44|dilazep
P10399136A0389|70 84|pentoxifylline
P10399136A0389|99 103|rCBF
P10399136A0389|111 114|HPC
P10400032A0304|11 17|method
P10400032A0304|48 57|vena cava
P10400032A0304|76 87|hypotension
P10400032A0304|119 129|management
P10400593A1084|3 11|contrast
P10400593A1084|13 18|PvirE
P10400593A1084|22 46|Plac promoter constructs
P10400593A1084|66 71|VirE2
P10400593A1084|80 85|virE1
P10400593A1084|107 112|virE2
P10400712A0000|7 26|parainfluenza virus
P10400712A0000|30 33|SV5
P10400712A0000|40 49|prototype
P10400712A0000|57 79|Paramyxoviridae family
P10400712A0000|111 122|RNA viruses
P10400712A0577|19 28|functions
P10400712A0577|32 34|GE
P10400712A0577|36 38|IG
P10400712A0577|44 56|GS sequences
P10400712A0577|60 73|transcription
P10400712A0577|90 98|plasmids
P10400712A0577|110 115|cDNAs
P10400712A0577|135 145|SV5 genome
P10400712A0577|159 182|gene junction sequences
P10400712A0577|184 186|GE
P10400712A0577|188 190|IG
P10400712A0577|196 208|GS sequences
P10400712A0577|230 257|hemagglutinin-neuraminidase
P10400712A0577|259 261|HN
P10400712A0577|271 281|polymerase
P10400712A0577|283 284|L
P10400712A0577|286 291|genes
P10400712A0577|315 336|counterpart sequences
P10400712A0577|348 362|gene junctions
P10400757A0000|0 5|CXCR4
P10400757A0000|11 29|chemokine receptor
P10400757A0000|36 46|coreceptor
P10400757A0000|71 73|X4
P10400757A0000|92 96|R5X4
P10400757A0000|104 131|immunodeficiency virus type
P10400757A0000|135 140|HIV-1
P10400757A0000|142 150|isolates
P10400757A1498|6 10|data
P10400757A1498|34 40|detail
P10400757A1498|45 50|CXCR4
P10400757A1498|62 74|requirements
P10400757A1498|98 111|HIV-1 strains
P10400757A1498|136 155|mutagenesis efforts
P10400757A1498|185 192|domains
P10400757A1498|196 201|CXCR4
P10400757A1498|218 223|HIV-1
P10400757A1498|237 251|fusion process
P10400760A0663|4 11|results
P10400760A0663|21 29|analyses
P10400760A0663|48 58|proteinase
P10400760A0663|70 99|amino acid residues E960-A961
P10400760A0663|101 112|E1071-S1072
P10400760A0663|114 125|E1345-T1346
P10400760A0663|131 142|E1419-G1420
P10400760A0663|157 176|cleavage efficiency
P10400774A0240|0 2|y.
P10400785A0912|0 2|SM
P10400785A0912|53 63|components
P10400785A0912|71 74|CRM
P10400785A0912|77 91|export pathway
P10400785A0912|113 123|GTPase Ran
P10400785A0912|132 154|nucleoporin CAN/Nup214
P10400794T0000|0 14|Identification
P10400794T0000|28 32|gene
P10400794T0000|38 44|Kaposi
P10400794T0000|66 77|herpesvirus
P10400794T0000|89 96|protein
P10400794T0000|102 114|similarities
P10400794T0000|125 142|membrane proteins
P10400794T0000|149 151|2A
P10400794T0000|168 173|virus
P10402022A0432|9 15|clicks
P10402022A0432|32 36|rate
P10402022A0432|43 44|s
P10402467T0000|0 6|Myosin
P10402467T0000|13 25|chain kinase
P10402467T0000|50 57|Ras/ERK
P10402467T0000|69 78|migration
P10402467T0000|97 108|plasminogen
P10402467T0000|130 135|cells
P10402467T0000|161 167|manner
P10403575A1401|4 14|inhibition
P10403575A1401|18 41|StAR gene transcription
P10403575A1401|45 50|DAX-1
P10403575A1401|79 92|transcription
P10403575A1401|97 98|%
P10403575A1401|102 116|control levels
P10403690A0000|28 33|study
P10403690A0000|39 47|patients
P10403690A0000|72 88|cell lung cancer
P10403690A0000|90 95|NSCLC
P10403690A0000|97 107|stage IIIb
P10403690A0000|119 142|ECOG performance status
P10403690A0000|144 146|PS
P10403690A0000|214 218|care
P10403690A0000|220 223|BSC
P10403690A0000|239 243|care
P10403690A0000|249 273|combination chemotherapy
P10403690A0000|275 286|IEP regimen
P10403690A0000|288 298|ifosfamide
P10403690A0000|301 306|gm/m2
P10403690A0000|315 334|mesna uroprotection
P10403690A0000|336 346|epirubicin
P10403690A0000|350 355|mg/m2
P10403690A0000|362 365|day
P10403690A0000|372 381|cisplatin
P10403690A0000|385 390|mg/m2
P10403690A0000|397 400|day
P10403690A0000|407 418|MVP regimen
P10403690A0000|420 431|mitomycin-C
P10403690A0000|434 439|mg/m2
P10403690A0000|441 450|cisplatin
P10403690A0000|455 460|mg/m2
P10403690A0000|467 470|day
P10403690A0000|474 485|vinblastine
P10403690A0000|488 493|mg/m2
P10403690A0000|500 504|days
P10403839A0140|6 26|sequence information
P10403839A0140|38 43|BMAL1
P10403839A0140|45 51|hBMAL1
P10403839A0140|53 58|cDNAs
P10403839A0140|86 96|laboratory
P10403839A0140|133 138|cDNAs
P10403839A0140|154 169|splice variants
P10403839A0140|177 188|mouse BMAL1
P10403839A0140|190 196|mBMAL1
P10403839A0140|198 202|gene
P10403839A1459|0 10|Comparison
P10403839A1459|20 41|bHLH/PAS family genes
P10403839A1459|60 86|intron/exon splice pattern
P10403839A1459|90 96|mBMAL1
P10403839A1459|130 134|mAhr
P10403839A1459|156 161|BMAL1
P10403839A1459|166 169|Ahr
P10403839A1459|189 197|subclass
P10403839A1459|242 246|gene
P10405635A0374|20 30|activities
P10405635A0374|50 58|promoter
P10405635A0374|86 105|deletion constructs
P10405635A0374|181 186|cells
P10406047A1244|35 46|differences
P10406047A1244|70 78|capacity
P10406047A1244|92 98|weight
P10406047A1244|102 108|height
P10406047A1244|114 124|compliance
P10406047A1244|144 150|system
P10406047A1244|164 170|weight
P10406047A1244|174 185|lung volume
P10406047A1244|193 204|ILD infants
P10406047A1244|229 237|controls
P10406047A1244|241 248|infants
P10406047A1244|257 261|PPHN
P10406047A1244|285 289|PFTs
P10406047A1244|334 347|lung function
P10406047A1244|356 365|age group
P10406122T0000|23 30|element
P10406122T0000|38 50|LTR promoter
P10406122T0000|58 86|tobacco retrotransposon Tto1
P10406122T0000|102 116|responsiveness
P10406122T0000|120 134|tissue culture
P10406122T0000|146 162|methyl jasmonate
P10406122T0000|174 183|elicitors
P10406459A0000|8 13|study
P10406459A0000|48 61|growth factor
P10406459A0000|63 67|PDGF
P10406459A0000|70 104|12-O-tetradecanoyl-phorbol-acetate
P10406459A0000|106 109|TPA
P10406459A0000|116 125|forskolin
P10406459A0000|134 138|CREB
P10406459A0000|172 179|protein
P10406459A0000|181 204|Ser-133 phosphorylation
P10406459A0000|221 230|magnitude
P10406459A0000|235 243|kinetics
P10406459A0000|247 260|NIH 3T3 cells
P10406462A1127|17 25|evidence
P10406462A1127|41 45|role
P10406462A1127|49 54|SRC-1
P10406462A1127|79 89|activation
P10406462A1127|93 105|OR1/RXRalpha
P10406464A0687|3 11|contrast
P10406464A0687|13 36|mTRAP100 coprecipitates
P10406464A0687|58 67|component
P10406464A0687|75 87|TRAP complex
P10406464A0687|89 96|TRAP220
P10406464A0687|114 125|contacts TR
P10406464A0687|134 152|vitamin D receptor
P10406464A0687|175 181|manner
P10406465A0589|5 13|sequence
P10406465A0589|27 30|VDR
P10406465A0589|35 59|vitamin D responsiveness
P10406465A0589|78 86|promoter
P10406466A0000|35 44|receptors
P10406466A0000|51 75|thyroid hormone receptor
P10406466A0000|86 99|acid receptor
P10406466A0000|117 126|receptors
P10406843A1265|0 10|Expression
P10406843A1265|14 28|GlcNAc-TI mRNA
P10406843A1265|32 39|tobacco
P10406843A1265|66 72|RT-PCR
P10406954A0715|0 24|Chemical stability tests
P10406954A0715|43 54|mutagenesis
P10406954A0715|66 82|amino acids H219
P10406954A0715|87 90|D63
P10406954A0715|94 98|RegS
P10406954A0715|103 107|RegR
P10406954A0715|145 153|residues
P10407184A0149|3 17|overexpression
P10407184A0149|25 37|betaAPP gene
P10407184A0149|49 54|areas
P10407184A0149|62 70|AD brain
P10407184A0149|109 115|factor
P10407184A0149|123 137|neuropathology
P10407184A0149|141 143|AD
P10407184A0520|15 22|studies
P10407184A0520|28 44|promoter regions
P10407184A0520|73 86|reporter gene
P10407184A0520|88 122|chloramphenicol acetyl transferase
P10407184A0520|124 127|CAT
P10407184A0520|134 143|phbetaE-B
P10407184A0520|150 157|plasmid
P10407184A0520|183 184|h
P10407184A0520|186 201|promoter region
P10407184A0520|228 231|URE
P10407184A0520|242 252|prhbetaE-B
P10407184A0520|259 266|plasmid
P10407184A0520|285 291|rhesus
P10407184A0520|293 295|rh
P10407184A0520|297 312|promoter region
P10407184A0520|323 326|URE
P10407184A0520|345 354|bp region
P10407184A0520|362 379|hbetaAPP promoter
P10407269A0000a|7 9|bp
P10407269A0000a|24 27|DNA
P10407269A0000a|44 57|markers cdc18
P10407269A0000a|62 67|cdc14
P10407269A0000a|81 84|arm
P10407269A0000a|88 112|fission yeast chromosome
P10407269A0000a|138 142|part
P10407269A0000a|150 164|European Union
P10407269A0000a|191 216|genome sequencing project
P10407269A0000b|7 9|bp
P10407269A0000b|24 27|DNA
P10407269A0000b|44 57|markers cdc18
P10407269A0000b|62 67|cdc14
P10407269A0000b|81 84|arm
P10407269A0000b|88 112|fission yeast chromosome
P10407269A0000b|138 142|part
P10407269A0000b|150 164|European Union
P10407269A0000b|191 216|genome sequencing project
P10407985A0574|0 5|G-CSF
P10407985A0574|11 21|micrograms
P10407985A0574|38 42|s.c.
P10407985A0574|65 71|GM-CSF
P10407985A0574|77 92|micrograms s.c.
P10407985A0574|117 123|cycles
P10409656A1016|0 14|Overexpression
P10409656A1016|18 27|H411 cDNA
P10409656A1016|35 38|RAW
P10409656A1016|45 65|macrophage cell line
P10409656A1016|88 99|growth rate
P10409656A1016|117 127|expression
P10409656A1016|131 135|H411
P10409656A1016|139 143|part
P10409656A1016|165 178|cell response
P10409656A1016|182 185|LPS
P10409699A0292|16 35|sequence tag clones
P10409699A0292|55 74|sequence similarity
P10409699A0292|92 97|yeast
P10409699A0292|125 137|mannosidases
P10409699A0292|159 172|coding region
P10409699A0292|189 208|mannosidase homolog
P10409699A0292|227 238|combination
P10409699A0292|251 264|amplification
P10409699A0292|268 277|cDNA ends
P10409699A0292|289 314|polymerase chain reaction
P10409699A0292|336 340|cDNA
P10409724A1021|0 10|Activation
P10409724A1021|14 20|ERK1/2
P10409724A1021|40 49|induction
P10409724A1021|73 87|response genes
P10409730A0597|4 17|transcription
P10409730A0597|26 34|RP genes
P10409730A0597|55 74|Rap1p binding sites
P10409730A0597|87 89|bp
P10409730A0597|108 118|initiation
P10409730A0597|122 135|transcription
P10409741A0382|30 37|alleles
P10409741A0382|41 45|CDC4
P10409741A0382|47 54|cdc4-10
P10409741A0382|56 63|cdc4-11
P10409741A0382|69 76|cdc4-16
P10409741A0382|105 120|division defect
P10409741A0382|124 137|cdc20-1 cells
P10409749T0000|0 4|Role
P10409749T0000|18 27|structure
P10409749T0000|31 45|discrimination
P10409749T0000|81 91|activators
P10409755A1846|3 10|summary
P10409755A1846|12 14|Ca
P10409755A1846|29 39|activation
P10409755A1846|43 56|NO production
P10409755A1846|66 75|apoptosis
P10409755A1846|82 93|TG exposure
P10409755A1846|97 109|JT/Neo cells
P10411139A0887|0 12|Accumulation
P10411139A0887|20 32|U4/U6 duplex
P10411139A0887|49 63|overexpression
P10411139A0887|77 83|Prp44p
P10411139A1344|4 11|results
P10411139A1344|62 69|results
P10411139A1344|88 92|role
P10411139A1344|97 103|Prp44p
P10411139A1344|124 135|U4/U6 helix
P10411140A0499|26 29|RNA
P10411140A0499|50 66|RNase E cleavage
P10411140A0499|88 94|region
P10411140A0499|102 107|mRNAs
P10411140A0499|120 130|terminator
P10411160T0000|4 13|mysteries
P10411160T0000|28 39|variability
P10411160T0000|55 76|skin cancer incidence
P10413604A0063|47 54|kinases
P10413604A0063|56 60|PKAs
P10413604A0063|82 88|growth
P10413604A0063|123 132|mechanism
P10413604A0063|157 170|DNA synthesis
P10413607A0085|33 41|contrast
P10413607A0085|65 81|matrix molecules
P10413607A0085|101 112|collagen VI
P10413607A0085|114 117|CVI
P10413607A0085|133 146|DNA synthesis
P10413607A0085|170 180|cell types
P10413607A0085|226 245|signal transduction
P10413662A0193|39 64|pMJ101 replication region
P10413662A0193|94 98|pJM1
P10413662A0193|102 109|plasmid
P10413662A0193|125 148|iron acquisition system
P10413662A0193|166 175|virulence
P10413662A0193|179 193|V. anguillarum
P10413662A0193|217 225|pathogen
P10413662A0193|238 247|vibriosis
P10413676A0000|0 3|FAK
P10413676A0000|17 22|sites
P10413676A0000|26 68|transmembrane integrin receptor clustering
P10413676A0000|99 115|signaling events
P10413676A0595|0 10|Expression
P10413676A0595|22 33|FAK mutants
P10413676A0595|41 44|FAK
P10413676A0595|46 51|cells
P10413676A0595|64 83|FAK kinase activity
P10413676A0595|89 96|Tyr-397
P10413676A0595|97 107|SH2 domain
P10413676A0595|116 120|site
P10413676A0595|149 167|SH3 binding region
P10413676A0595|175 178|FAK
P10413676A0595|190 196|domain
P10413676A0595|251 254|FAK
P10413676A0595|256 270|cell migration
P10413676A0595|274 276|FN
P10413676A0595|292 308|paxillin binding
P10413676A0595|312 315|FAK
P10413676A1193|23 29|effect
P10413676A1193|33 37|FRNK
P10413676A1193|56 70|point mutation
P10413676A1193|72 80|Leu-1034
P10413676A1193|84 87|Ser
P10413676A1193|105 122|FRNK localization
P10413676A1193|132 145|contact sites
P10414451A0093|16 24|patients
P10414451A0093|26 29|age
P10414451A0093|34 36|yr
P10414451A0093|58 61|DVT
P10414451A0093|88 96|presence
P10414451A0093|100 110|resistance
P10414451A0093|124 133|protein C
P10414451A0093|135 140|APC-R
P10414451A0093|143 162|lupus anticoagulant
P10414451A0093|164 166|LA
P10414451A0093|185 195|antibodies
P10414451A0093|200 212|deficiencies
P10414451A0093|216 225|protein C
P10414451A0093|227 236|protein S
P10414451A0093|238 254|ATIII activities
P10416429A0221|0 6|DESIGN
P10416429A0221|8 18|Comparison
P10416429A0221|22 28|number
P10416429A0221|32 37|women
P10416429A0221|43 46|PKU
P10416429A0221|58 63|years
P10416429A0221|71 87|NSW PKU database
P10416429A0221|98 104|number
P10416429A0221|120 126|number
P10416429A0221|140 155|population data
P10416558A0000|0 7|PURPOSE
P10416558A0000|13 21|purposes
P10416558A0000|37 42|study
P10416558A0000|62 69|effects
P10416558A0000|81 91|laboratory
P10416558A0000|106 122|exercise program
P10416558A0000|142 150|function
P10416558A0000|152 166|CD4 cell count
P10416558A0000|191 204|health status
P10416558A0000|245 256|individuals
P10416558A0000|258 259|N
P10416558A0000|284 290|degree
P10416558A0000|304 310|health
P10416558A0000|331 347|exercise relapse
P10417331A1008|4 10|enzyme
P10417331A1008|28 36|activity
P10417331A1008|50 61|mM pantoate
P10417331A1008|63 64|k
P10417331A1008|65 68|cat
P10417331A1008|75 76|s
P10417331A1008|89 91|pH
P10417703A1326|22 29|results
P10417703A1326|51 53|RP
P10417703A1326|64 78|20S proteasome
P10417703A1326|129 139|eukaryotes
P10417703A1326|162 180|plant RPT subunits
P10417703A1326|193 211|yeast counterparts
P10417703A1326|232 241|functions
P10419006A0378|14 22|evidence
P10419006A0378|38 66|estrogen replacement therapy
P10419006A0378|73 82|menopause
P10419006A0378|93 111|breast cancer risk
P10419521A0136|3 11|addition
P10419521A0136|19 38|elongation activity
P10419521A0136|40 43|ELL
P10419521A0136|61 65|type
P10419521A0136|69 83|RNA polymerase
P10419521A0136|87 105|interaction domain
P10419521A0136|136 155|polymerase activity
P10419521A0136|177 190|transcription
P10422291A0572|2 11|diagnosis
P10422291A0572|15 25|IgA lambda
P10422291A0572|35 42|myeloma
P10422291A0572|59 70|involvement
P10422342A0535|4 20|radiation burden
P10422342A0535|41 49|majority
P10422342A0535|53 65|examinations
P10422342A0535|77 85|medicine
P10422342A0535|113 117|dose
P10422342A0535|141 157|radiation burden
P10422342A0535|177 189|examinations
P10422342A0535|202 216|administration
P10422342A0535|220 232|preparations
P10422342A0535|238 242|131I
P10422342A0535|244 249|201Tl
P10422342A0535|251 255|67Ga
P10422342A0535|260 265|111In
P10422468A0524|13 17|risk
P10422468A0524|21 33|malformation
P10422468A0524|37 45|children
P10422468A0524|57 61|ICSI
P10422468A0524|101 105|risk
P10422468A0524|126 139|abnormalities
P10422468A0524|143 147|case
P10422468A0524|151 154|NOA
P10422468A0524|168 172|rate
P10422468A0524|176 190|sex chromosome
P10422468A0524|195 209|microdeletions
P10422468A0524|217 229|Y chromosome
P10422468A0524|238 242|case
P10422468A0524|257 259|OA
P10422468A0524|261 270|mutations
P10422468A0524|285 298|fibrosis gene
P10423156A0265|0 13|TaV particles
P10423156A0265|29 36|density
P10423156A0265|46 51|g/cm3
P10423156A0265|55 59|CsCl
P10423156A0265|79 94|capsid proteins
P10423156A0265|107 110|kDa
P10423193A1309|0 10|CONCLUSION
P10423193A1309|18 25|results
P10423193A1309|64 75|involvement
P10423193A1309|115 125|neuropathy
P10423193A1309|140 143|CTS
P10423292A0782|13 15|bp
P10423292A0782|25 31|region
P10423292A0782|35 40|Spam1
P10423292A0782|86 106|transcription factor
P10423292A0782|115 120|sites
P10423292A0782|133 136|CRE
P10423292A0782|154 161|element
P10425094A1006|13 23|relaxivity
P10425094A1006|31 38|complex
P10425094A1006|48 49|s
P10425094A1006|54 56|mM
P10425445T0000|0 9|Structure
P10425445T0000|14 24|expression
P10425445T0000|32 97|mouse growth hormone receptor/growth hormone binding protein gene
P10426450A1458|10 18|recovery
P10426450A1458|22 24|SA
P10426450A1458|34 46|liver/spleen
P10426450A1458|61 67|tonsil
P10426450A1458|71 85|contact poults
P10426450A1458|90 92|SG
P10426450A1458|98 112|contact chicks
P10426450A1458|126 129|ILK
P10426450A1458|184 198|contact poults
P10426450A1458|203 209|chicks
P10426878A0367|4 11|results
P10426878A0367|19 31|ISIS-2 trial
P10426878A0367|40 44|data
P10426878A0367|67 76|Trialists
P10426878A0367|78 91|Collaboration
P10426878A0367|107 114|aspirin
P10426878A0367|131 139|patients
P10426878A0367|162 172|infarction
P10426878A0367|191 201|prevention
P10427654A0000|5 10|study
P10427654A0000|39 43|role
P10427654A0000|69 80|laparoscopy
P10427654A0000|101 108|staging
P10427654A0000|112 120|patients
P10427654A0000|126 140|adenocarcinoma
P10427654A0000|148 157|esophagus
P10427654A0000|167 173|cancer
P10427654A0000|189 195|cancer
P10427654A0000|223 230|surgery
P10428091A0322|5 11|report
P10428091A0322|36 40|MMRs
P10428091A0322|79 90|disparities
P10428091A0322|103 112|mortality
P10428091A0322|137 142|women
P10428294A0227|0 25|Preheparin LPL mass level
P10428294A0227|58 69|individuals
P10428294A0227|84 89|years
P10428294A0227|104 107|men
P10428294A0227|112 117|women
P10428759A0743|2 10|decrease
P10428759A0743|30 54|receptor kinase activity
P10428759A0743|93 102|receptors
P10428811A0628|0 5|Cat-1
P10428811A0628|46 61|binding partner
P10428811A0628|86 101|receptor kinase
P10428811A0628|103 110|betaARK
P10428811A0628|114 119|GRK-2
P10428811A0628|154 162|activity
P10428811A1067|0 12|Cat proteins
P10428811A1067|62 67|cells
P10428811A1067|83 102|adhesion kinase Fak
P10428811A1067|107 110|Src
P10428862A0834|0 31|Immunoprecipitation experiments
P10428862A0834|52 62|antibodies
P10428862A0834|75 86|interaction
P10428862A0834|106 110|DokR
P10428862A0834|125 132|protein
P10428862A0834|183 194|BaF/3 cells
P10429184A0000|0 9|Expansins
P10429184A0000|16 22|family
P10429184A0000|26 34|proteins
P10429184A0000|59 68|extension
P10429184A0000|81 97|plant cell walls
P10429184A0000|135 144|mechanism
P10429740A0000|5 11|review
P10429740A0000|36 44|evidence
P10429740A0000|64 73|therapies
P10429740A0000|87 101|bowel syndrome
P10429740A0000|103 106|IBS
P10429946A0473|15 21|region
P10429946A0473|29 34|alpha
P10429946A0473|37 38|V
P10429946A0473|40 53|collagen gene
P10429946A0473|73 81|fragment
P10429946A0473|96 98|bp
P10429946A0473|108 116|promoter
P10429946A0473|125 127|bp
P10429946A0473|131 135|exon
P10429946A0473|138 147|sequences
P10429946A0473|178 186|elements
P10429946A0988|13 21|addition
P10429946A0988|25 73|B-Myb-glutathionine S-transferase fusion protein
P10429946A0988|84 101|complex formation
P10430421T0000|0 19|APOE-epsilon4 count
P10430421T0000|29 32|age
P10430421T0000|38 48|prevalence
P10430421T0000|52 64|AD increases
P10430421T0000|85 103|Cache County Study
P10430580A0000|0 6|Repair
P10430580A0000|10 30|double-strand breaks
P10430580A0000|32 36|DSBs
P10430580A0000|53 56|DNA
P10430580A0000|74 85|end-joining
P10430580A0000|87 91|NHEJ
P10430580A0000|126 131|yeast
P10430583A0000|6 21|DNA repair gene
P10430583A0000|58 66|homology
P10430583A0000|70 74|RecA
P10430883A0000|22 27|cells
P10430883A0000|41 46|gland
P10430883A0000|54 59|cells
P10430883A0000|61 68|Brunner
P10430883A0000|71 77|glands
P10430883A0000|89 95|glands
P10430883A0000|118 123|tract
P10430883A0000|140 145|ducts
P10430883A0000|165 175|metaplasia
P10430883A0000|208 213|class
P10430883A0000|218 223|mucin
P10430883A0000|250 253|Con
P10430883A0000|256 264|staining
P10430883A0000|287 296|oxidation
P10430883A0000|298 326|sodium borohydride reduction
P10430883A0000|328 333|Con A
P10430883A0000|339 370|horseradish peroxidase reaction
P10430886A0838|15 22|mutants
P10430886A0838|51 55|TraR
P10430886A0838|87 102|heteromultimers
P10430886A0838|122 131|activator
P10430890A1059|6 15|elongin C
P10430890A1059|43 51|solution
P10430890A1059|90 104|rearrangements
P10430890A1059|110 117|binding
P10430890A1059|135 151|partner proteins
P10430944A1298|4 8|data
P10430944A1298|20 38|JAK/STAT signaling
P10430944A1298|45 49|role
P10430944A1298|68 80|malignancies
P10430980A0465|14 17|men
P10430980A0465|26 31|women
P10433729A1559|0 2|A.
P10433729A1559|4 10|Bowers
P10433729A1559|12 15|K.E
P10433729A1559|21 29|Matthews
P10433729A1559|31 33|C.
P10433970A0279|0 6|Spfkh1
P10433970A0279|34 47|reading frame
P10433970A0279|66 84|DNA binding domain
P10433970A0279|94 113|localization signal
P10433970A0279|118 140|transactivation domain
P10435595A0203|14 23|mechanism
P10435595A0203|40 56|trans-activation
P10436016A0337|0 14|Gel filtration
P10436016A0337|19 50|co-immunoprecipitation analyses
P10436016A0337|63 68|Mad2p
P10436016A0337|101 129|spindle checkpoint component
P10436016A0337|131 136|Mad1p
P10437043A0164|0 7|METHODS
P10437043A0164|23 28|cases
P10437043A0164|34 36|SS
P10437043A0164|51 59|biopsies
P10438540A1185|36 50|domain mutants
P10438540A1185|60 62|Cd
P10438540A1185|67 76|tolerance
P10438540A1185|91 97|strain
P10438540A1185|102 120|transport activity
P10438540A1185|128 135|protein
P10438593A0000|10 39|immunodeficiency virus type-1
P10438593A0000|41 46|HIV-1
P10438593A0000|48 59|Tat protein
P10438593A0000|70 83|transcription
P10438593A0000|99 126|RNA polymerase processivity
P10438607A0330|13 18|SEBPs
P10438607A0330|20 25|SEBP2
P10438607A0330|47 54|product
P10438607A0330|71 85|gene fork head
P10438627A0885|0 17|Identity elements
P10438627A0885|21 25|tRNA
P10438627A0885|30 34|mono
P10438627A0885|54 63|reactions
P10438627A0885|83 90|pfTrm1p
P10438627A0885|122 136|T7 transcripts
P10438627A0885|143 151|variants
P10438627A0885|155 159|tRNA
P10438627A0885|160 163|Asp
P10438627A0885|168 172|tRNA
P10438627A0885|173 176|Phe
P10438627A0885|182 187|yeast
P10438924A1009|22 27|cells
P10438924A1009|29 32|Akt
P10438924A1009|68 118|serine/threonine kinase glycogen synthase kinase-3
P10438924A1009|120 125|GSK-3
P10438924T0000|4 27|B cell antigen receptor
P10438924T0000|42 45|Akt
P10438924T0000|47 63|protein kinase B
P10438924T0000|65 109|glycogen synthase kinase-3 signaling pathway
P10438924T0000|114 143|phosphatidylinositol 3-kinase
P10438941A1197|6 26|recombination events
P10438941A1197|58 59|B
P10438941A1197|64 76|T cell lines
P10438941A1197|97 117|switch recombination
P10438941A1197|138 143|genes
P10438950A0580|0 4|IL-1
P10438950A0580|9 46|TNF increase AND-34 transcript levels
P10438950A0580|84 89|nurse
P10438950A0580|95 116|fibroblast cell lines
P10439040A0658|18 28|role eIF4E
P10439040A0658|43 59|c-myc expression
P10439040A0658|65 70|c-myc
P10439040A0658|87 93|region
P10439040A0658|95 98|UTR
P10439040A0658|122 135|CAT reporters
P10439040A0658|165 175|constructs
P10440923A0684|0 8|Analysis
P10440923A0684|12 31|cell cycle proteins
P10440923A0684|47 48|h
P10440923A0684|52 72|lovastatin treatment
P10440923A0684|80 93|control cells
P10440923A0684|104 113|elevation
P10440923A0684|121 127|levels
P10440923A0684|152 172|kinase inhibitor p27
P10440923A0684|173 177|kip1
P10440923A0684|180 190|inhibition
P10440923A0684|199 207|cyclin E
P10440923A0684|213 219|cyclin
P10440923A0684|232 247|kinase activity
P10440923A0684|263 269|levels
P10440923A0684|293 315|retinoblastoma protein
P10440923A0684|317 320|pRb
P10441243A0443|0 7|RESULTS
P10441243A0443|21 42|leptin concentrations
P10441243A0443|81 86|ng/ml
P10441243A0443|98 106|subjects
P10441449X1212|0 9|Copyright
P10441449X1212|15 29|Academic Press
P10441483A0454|0 22|Oligonucleotide probes
P10441483A0454|61 75|EpRE sequences
P10441483A0454|115 123|analyses
P10441483A0454|136 144|proteins
P10441506A0098|0 7|PKNbeta
P10441506A0098|17 34|sequence homology
P10441506A0098|40 48|PKNalpha
P10441506A0098|70 73|PKN
P10441506A0098|93 100|repeats
P10441506A0098|112 117|amino
P10441506A0098|128 134|region
P10441506A0098|140 154|leucine-zipper
P10441506A0098|160 169|sequences
P10441506A0098|171 184|CZ region/HR1
P10441506A0098|222 228|domain
P10441506A0098|255 273|amino acid stretch
P10441506A0098|275 287|D region/HR2
P10441506A0098|306 319|CZ region/HR1
P10441506A0098|338 344|domain
P10442493A0815|3 11|baseline
P10442493A0815|13 25|serum levels
P10442493A0815|29 37|lycopene
P10442493A0815|42 46|FLOP
P10442493A0815|72 82|serum FLOP
P10442493A0815|117 143|plasma cyclosporine levels
P10442493A0815|145 146|r
P10442493A0815|156 157|p
P10443990A0000|0 10|BACKGROUND
P10443990A0000|20 39|alcohol consumption
P10443990A0000|83 94|bone health
P10444597A0586|25 34|induction
P10444597A0586|38 44|stress
P10444597A0586|48 58|heat shock
P10444597A0586|65 69|salt
P10444597A0586|74 81|ethanol
P10444597A0586|83 93|conditions
P10444597A0586|111 122|mRNA export
P10444597A0586|135 140|Npl3p
P10444597A0586|168 175|nucleus
P10444813A0448|16 22|relief
P10444813A0448|27 37|inhibition
P10444813A0448|45 51|growth
P10444813A0448|59 82|metastases interferon-a
P10444813A0448|87 109|somatostatin analogues
P10445161A1565|3 10|summary
P10445161A1565|49 54|study
P10445161A1565|81 84|ppm
P10445161A1565|105 116|weight gain
P10445161A1565|127 131|rats
P10445161A1565|147 167|organ weight changes
P10445161A1565|176 181|sexes
P10445161A1565|190 193|ppm
P10445506A0073|30 35|sperm
P10445506A0073|44 49|times
P10445506A0073|65 76|body length
P10445945T0000|0 19|John leonard dawson
P10446131A0132|0 19|PDGF A-chain levels
P10446131A0132|50 69|smooth muscle cells
P10446131A0132|71 75|SMCs
P10446131A0132|88 92|ATII
P10446149A0809|29 34|yeast
P10446149A0809|46 51|assay
P10446149A0809|66 79|Ras effectors
P10446149A0809|91 98|c-Raf-1
P10446149A0809|100 105|A-Raf
P10446149A0809|107 112|B-Raf
P10446149A0809|114 144|phosphoinositol-3 kinase delta
P10446149A0809|146 152|RalGDS
P10446149A0809|158 162|Rin1
P10446206A0000|0 16|Deletion mapping
P10446206A0000|30 42|presenilin-1
P10446206A0000|44 47|PS1
P10446206A0000|49 57|promoter
P10446206A0000|85 93|fragment
P10446206A0000|115 123|relation
P10446206A0000|131 155|transcription start site
P10446206A0000|171 176|study
P10446206A0000|192 213|neuroblastoma SK-N-SH
P10446206A0000|218 238|hepatoma HepG2 cells
P10446833T0000|17 28|oxygenation
P10446833T0000|33 41|shunting
P10446833T0000|45 51|sepsis
P10446833T0000|56 61|shock
P10446910A0147|0 8|Analysis
P10446910A0147|16 34|E2F1 gene promoter
P10446910A0147|63 69|region
P10446910A0147|87 104|E2-responsiveness
P10446910A0147|118 137|transfection assays
P10446910A0147|154 180|deletion/mutation analysis
P10446910A0147|252 257|sites
P10446910A0147|276 291|transactivation
P10446910A0147|295 297|E2
P10446912A0883|7 13|course
P10446912A0883|35 45|mechanisms
P10446912A0883|55 58|OF5
P10446912A0883|63 66|OF3
P10446912A0883|77 98|CYP11A1 transcription
P10446912A0883|114 117|OF5
P10446912A0883|122 125|OF3
P10446912A0883|132 135|Sp1
P10446912A0883|140 143|Sp3
P10446912A0883|147 158|JEG-3 cells
P10446998A0375|3 11|contrast
P10446998A0375|17 32|differentiation
P10446998A0375|63 68|cells
P10446998A0375|96 110|responsiveness
P10446998A0375|114 118|junB
P10446998A0375|122 140|c-fos inducibility
P10446998A0955|0 25|Adipocyte differentiation
P10446998A0955|44 49|cells
P10446998A0955|78 85|ability
P10446998A0955|89 92|SRF
P10446998A0955|108 116|junB SRE
P10446998A0955|122 131|c-fos SRE
P10446998A0955|143 147|SREs
P10446998A0955|166 180|mobility shift
P10446998A0955|185 206|gel supershift assays
P10446998A0955|230 257|DNA binding characteristics
P10446998A0955|273 285|protein SP-1
P10446998T0000|0 14|Transformation
P10446998T0000|46 56|inhibition
P10446998T0000|60 94|serum response factor interactions
P10446998T0000|100 123|serum response elements
P10447593A0144|4 15|core enzyme
P10447593A0144|42 59|bacteriophages T3
P10447593A0144|61 63|T7
P10447593A0144|68 71|SP6
P10447593A0144|84 102|specificity factor
P10447593A0144|109 121|similarities
P10447593A0144|137 150|sigma factors
P10447597A1004|4 17|Cr.psbA-4 ORF
P10447597A1004|36 41|motif
P10447597A1004|58 71|GIY-YIG motif
P10448036A0748|4 15|interaction
P10448036A0748|19 24|zf4-6
P10448036A0748|44 49|S RNA
P10448036A0748|89 113|competitor concentration
P10448036A0748|127 132|zf4-7
P10448036A0748|135 152|S RNA interaction
P10448036A0748|170 176|finger
P10448036A0748|203 211|affinity
P10448036A0748|216 227|specificity
P10448036A0748|236 243|protein
P10448036A0748|244 259|RNA interaction
P10448095A0865|4 29|STAT protein accumulation
P10448095A0865|45 61|C/EBP expression
P10448095A0865|103 113|conversion
P10448095A0865|117 128|fibroblasts
P10448095A0865|132 142|adipocytes
P10448095A0865|161 179|expression profile
P10448095A0865|218 228|adipocytes
P10448285A1035|11 20|durations
P10448285A1035|25 33|response
P10448285A1035|38 51|survival time
P10448285A1035|64 69|phase
P10448285A1035|73 78|trial
P10448285A1035|88 94|months
P10448285A1035|103 109|months
P10448440T0020|4 8|role
P10448440T0020|24 34|psychiatry
P10448440T0020|39 61|understanding patients
P10448440T0020|75 88|schizophrenia
P10448440T0020|99 119|personality disorder
P10448902A0921|23 30|enzymes
P10448902A0921|32 40|catalase
P10448902A0921|42 64|glutathione peroxidase
P10448902A0921|69 89|superoxide dismutase
P10448902A0921|110 114|rats
P10448902A0921|154 158|rats
P10449072A0560|11 15|goal
P10449072A0560|49 60|arrangement
P10449072A0560|68 71|GPi
P10449072A0560|75 77|PD
P10449899A0881|14 21|results
P10449899A0881|59 68|PERV copy
P10449899A0881|73 89|integration site
P10450815A0180|12 25|investigation
P10450815A0180|41 51|population
P10450815A0180|74 85|individuals
P10450815A0180|93 102|age range
P10450815A0180|109 114|years
P10450815A0180|147 159|relationship
P10450815A0180|168 183|tobacco smoking
P10450815A0180|202 210|calculus
P10450815A0180|224 231|account
P10450815A0180|253 260|factors
P10450815A0180|269 272|age
P10450815A0180|274 280|gender
P10450815A0180|287 294|hygiene
P10450815A0180|308 320|inflammation
P10451209A0000|0 9|OBJECTIVE
P10451209A0000|32 46|administration
P10451209A0000|50 61|misoprostol
P10451209A0000|79 89|hemorrhage
P10451209A0000|101 105|dogs
P10451209A0000|124 129|doses
P10451209A0000|133 168|methylprednisolone sodium succinate
P10451209A0000|170 174|MPSS
P10452306A0502|0 8|Patients
P10452306A0502|35 46|MIBG uptake
P10452306A0502|60 88|norepinephrine concentration
P10452306A0502|90 94|LVEF
P10452306A0502|96 104|peak Vo2
P10452306A0502|106 111|x-ray
P10452306A0502|127 132|ratio
P10452306A0502|134 140|M-mode
P10452306A0502|167 175|diameter
P10452306A0502|192 224|heart catheterization parameters
P10452951A0000|8 25|hormone receptors
P10452951A0000|27 30|NRs
P10452951A0000|53 74|transcription factors
P10452951A0000|97 106|functions
P10452951A0000|115 122|species
P10452991A0331|6 11|cells
P10452991A0331|33 58|influenza virus particles
P10452991A0331|81 94|T cell clones
P10453006A0000|0 10|Sequencing
P10453006A0000|14 23|zebrafish
P10453006A0000|25 36|Danio rerio
P10453006A0000|59 69|chromosome
P10453006A0000|74 76|P1
P10453006A0000|88 98|chromosome
P10453006A0000|107 122|clone fragments
P10453006A0000|130 141|cDNA clones
P10453006A0000|157 171|identification
P10453006A0000|184 188|loci
P10453006A0000|200 213|beta subunits
P10453006A0000|217 228|proteasomes
P10453006A0000|230 234|PSMB
P10453006A0478|3 11|addition
P10453006A0478|15 25|homologues
P10453006A0478|39 50|genes PSMB5
P10453006A0478|59 64|PSMB9
P10453006A0478|74 79|genes
P10453006A0478|81 87|PSMB11
P10453006A0478|92 98|PSMB12
P10453006A0478|159 164|genes
P10453006A0478|168 174|humans
P10453248A0094|11 15|Udry
P10453248A0094|28 39|perspective
P10453248A0094|101 107|models
P10453248A0094|146 155|behaviour
P10453371A0640|0 6|Weight
P10453371A0640|11 26|height z-scores
P10453371A0640|62 74|BMD z-scores
P10453721A0445|10 27|sampling strategy
P10453721A0445|57 87|parameter estimation algorithm
P10453721A0445|96 100|part
P10453721A0445|108 133|ADAPT II software package
P10454533A0859|0 11|Interaction
P10454533A0859|15 18|HRI
P10454533A0859|24 29|Hsc70
P10454533A0859|51 65|transformation
P10454533A0859|69 72|HRI
P10454533A0859|81 97|Hsc70 antagonist
P10454533A0859|108 112|acid
P10454533A0859|138 141|HRI
P10454533A0859|166 178|conformation
P10454540A0392|4 28|amino acid changes D206A
P10454540A0392|33 38|D208A
P10454540A0392|60 71|combination
P10454540A0392|76 96|exonuclease activity
P10454550A0960|22 30|evidence
P10454550A0960|50 54|Reg1
P10454550A0960|68 72|Glc7
P10454550A0960|84 94|substrates
P10454550A0960|107 126|Snf1 kinase complex
P10454557A0000|15 20|yeast
P10454557A0000|48 59|replicators
P10454557A0000|85 95|chromosome
P10454557A0000|124 132|sequence
P10454557A0000|134 137|ARS
P10454557A0000|139 147|elements
P10454557A0000|165 175|chromosome
P10454557A0000|189 193|ARSs
P10454557A0000|228 242|HML locus show
P10454557A0000|246 273|replication origin activity
P10454557A0975|6 13|results
P10454557A0975|36 51|HML ARS cluster
P10454557A0975|53 59|ARS303
P10454557A0975|61 67|ARS320
P10454557A0975|73 79|ARS302
P10454557A0975|82 92|inactivity
P10454557A0975|96 103|origins
P10454557A0975|144 153|silencing
P10454557A0975|167 174|origins
P10454557A0975|179 188|silencers
P10454557A0975|199 202|cis
P10454557A0975|221 231|components
P10454561A0594|15 20|study
P10454561A0594|42 52|expression
P10454561A0594|56 71|TD-IkappaBalpha
P10454561A0594|80 124|phorbol myristate acetate-phytohemagglutinin
P10454561A0594|128 149|tumor necrosis factor
P10454561A0594|164 195|IkappaBalpha gene transcription
P10454561A0594|210 240|NF-kappaB DNA binding activity
P10454561A0594|275 288|sequestration
P10454561A0594|292 296|RelA
P10454561A0594|297 300|p65
P10454561A0594|305 320|TD-IkappaBalpha
P10454568A0815|13 29|Grb10 expression
P10454568A0815|35 39|cDNA
P10454568A0815|77 94|expression system
P10454568A0815|106 113|PDGF-BB
P10454568A0815|116 121|IGF-I
P10454568A0815|127 134|insulin
P10454568A0815|154 167|growth factor
P10454568A0815|169 172|EGF
P10454568A0815|182 195|DNA synthesis
P10454568A0815|202 210|ecdysone
P10454568A0815|227 234|fashion
P10454570A0846|4 12|analysis
P10454570A0846|47 70|protein kinase pathways
P10454570A0846|99 117|protein kinase-Jun
P10454570A0846|129 146|kinase activation
P10454570A0846|165 180|phosphorylation
P10454570A0846|184 189|ATF-2
P10454570A0846|191 196|c-Jun
P10454570A0846|202 206|JunD
P10454570A0846|237 241|IL-1
P10454570A0846|274 283|induction
P10454570A0846|324 330|kinase
P10454570A0846|334 339|ERK-1
P10454570A0846|345 361|ERK-2 activation
P10454570A0846|381 384|TPA
P10454570A0846|416 427|stimulation
P10454570A0846|435 447|uPA enhancer
P10455087A1400|0 11|CONCLUSIONS
P10455087A1400|24 35|individuals
P10455087A1400|43 67|body insulin sensitivity
P10455087A1400|112 121|threshold
P10455143T0000|0 21|Interdomain signaling
P10455143T0000|38 46|fragment
P10455143T0000|60 83|glucocorticoid receptor
P10455183A0530|3 11|contrast
P10455183A0530|17 22|xtRNA
P10455183A0530|23 26|Sec
P10455183A0530|28 32|gene
P10455183A0530|43 50|binding
P10455183A0530|64 81|Staf zinc fingers
P10455183A0530|91 96|Oct-1
P10455183A0530|126 134|capacity
P10455183A0930|20 27|results
P10455183A0930|55 66|utilization
P10455183A0930|70 86|Staf zinc finger
P10455183A0930|116 127|determinant
P10455183A0930|151 171|activation mechanism
P10455183A0930|180 192|Xenopus tRNA
P10455183A0930|193 196|Sec
P10455183A0930|208 222|U6 snRNA genes
P10455189A0104|3 10|B cells
P10455189A0104|12 16|HEF1
P10455189A0104|63 72|mechanism
P10455189A0104|94 111|integrin ligation
P10455189A0427|23 47|tyrosine phosphorylation
P10455189A0427|51 55|HEF1
P10455189A0427|71 75|time
P10455189A0427|96 102|manner
P10457075A1198|0 40|Independent protrudor muscle stimulation
P10457075A1198|51 53|VI
P10457075A1198|54 57|max
P10457075A1198|64 72|increase
P10457075A1198|76 77|%
P10457075A1198|79 80|P
P10457075A1198|105 110|Pcrit
P10457075A1198|126 128|Rn
P10457075A1198|130 143|peak decrease
P10457075A1198|150 151|%
P10457075A1198|153 154|P
P10458905A0000|14 26|construction
P10458905A0000|69 89|YAC/BAC clone contig
P10458905A0000|93 101|8p22-p23
P10458907A0543|10 16|RAD30B
P10458907A0543|21 50|mouse Rad30b mRNA transcripts
P10458907A0543|62 77|repair proteins
P10458907A0543|107 113|testis
P10458914A0674|0 8|Analysis
P10458914A0674|16 31|mouse STAP gene
P10458914A0674|58 65|library
P10458914A0674|84 93|STAP gene
P10458914A0674|102 108|region
P10458914A0674|120 122|kb
P10458914A0674|143 148|exons
P10459809A1262|10 29|matrix distribution
P10459809A1262|43 55|cell density
P10459809A1262|77 84|biofilm
P10460015A0465|9 15|months
P10460015A0465|19 28|treatment
P10460015A0465|49 57|estrogen
P10460015A0465|68 74|height
P10460015A0465|79 85|weight
P10460015A0465|93 104|improvement
P10460015A0465|116 136|bone mineral density
P10460015A0465|141 149|bone age
P10460171A0842|0 21|Viscosity experiments
P10460171A0842|39 63|fragment kinase reaction
P10460171A0842|86 94|chemical
P10460171A0842|96 115|phosphoryl transfer
P10460171A0842|117 121|step
P10460171A0842|136 140|rate
P10460172A0823|0 22|Velocity sedimentation
P10460172A0823|24 37|cross-linking
P10460172A0823|43 71|immunoprecipitation analyses
P10460172A0823|97 106|rat brain
P10460172A0823|135 151|kDa polypeptides
P10460172A0823|166 181|heterotetramers
P10463057A0534|9 26|expression levels
P10463057A0534|44 52|plasmids
P10463242A0316|3 6|EEG
P10463242A0316|24 29|waves
P10463242A0316|50 56|region
P10464185T0000|10 26|characterization
P10464185T0000|53 86|polysaccharide biosynthesis genes
P10464185T0000|90 122|Streptococcus agalactiae type Ia
P10464250A0275|7 15|FASEB J.
P10464291A0597|0 8|IL-1beta
P10464291A0597|13 18|ng/ml
P10464291A0597|47 57|PDGFalphaR
P10464291A0597|85 98|protein delta
P10464291A0597|100 110|C/EBPdelta
P10464291A0597|112 123|mRNA levels
P10464291A0597|129 133|time
P10464291A0597|144 150|manner
P10464302A1109b|4 15|recruitment
P10464302A1109b|49 53|p185
P10464302A1109b|54 57|neu
P10464302A1109b|87 103|pathway proteins
P10464302A1109b|135 151|interaction site
P10464302A1109b|172 177|model
P10464302A1109b|198 206|assembly
P10464302A1109b|224 231|pathway
P10464302A1109b|241 253|transmission
P10464302A1109b|257 277|growth factor signal
P10464302A1109b|285 297|cytoskeleton
P10464310A0218|10 34|tyrosine phosphorylation
P10464310A0218|38 41|Crk
P10464310A0218|45 62|fibroblast growth
P10464310A0218|95 100|cells
P10464310A0218|122 152|juxtamembrane tyrosine residue
P10464310A0218|160 166|FGFR-1
P10464310A0218|174 188|Crk SH2 domain
P10464310A0218|202 208|FGFR-1
P10464310A0218|228 235|Tyr-463
P10464310A0218|255 272|complex formation
P10464310A0218|281 284|Crk
P10464310A0218|289 295|FGFR-1
P10466306A0000|21 51|Technetium-99m sestamibi SPECT
P10466306A0000|64 73|technique
P10466306A0000|96 105|perfusion
P10466306A0000|110 118|function
P10466825T0000|0 4|Role
P10466825T0000|28 34|region
P10466825T0000|38 58|baculovirus p10 mRNA
P10466825T0000|73 83|expression
P10466825T0000|95 100|genes
P10467004A0116|4 14|intron RNA
P10467004A0116|32 43|nucleotides
P10467004A0116|81 90|structure
P10467004A0116|113 128|sequence motifs
P10467004A0116|146 153|introns
P10467004A0116|155 161|Michel
P10467004A0683|4 10|intron
P10467004A0683|25 33|splicing
P10467004A0683|46 50|fact
P10467004A0683|65 74|EBS1/IBS1
P10467004A0683|83 108|EBS2/IBS2 sequence motifs
P10467004A0683|146 154|splicing
P10467004A0683|183 185|bp
P10467403A0000|4 36|Trk/Nerve Growth Factor receptor
P10467403A0000|56 66|activation
P10467403A0000|72 78|number
P10467403A0000|96 114|signaling proteins
P10467403A0000|126 155|phosphatidylinositol 3-kinase
P10467403A0000|157 168|PI 3-kinase
P10467465T0000|4 15|controversy
P10467465T0000|19 39|significance testing
P10467465T0000|41 55|misconceptions
P10467465T0000|60 72|alternatives
P10468033T0000|0 15|Chemical uptake
P10468033T0000|27 42|stratum corneum
P10468033T0000|82 90|solvents
P10468585A0980|5 16|DNA binding
P10468585A0980|34 45|enhancement
P10468585A0980|86 105|amino acid residues
P10468585A0980|136 143|portion
P10468585A0980|147 152|Hap46
P10468585A0980|177 194|hsp70 interaction
P10469140A0336|19 27|function
P10469140A0336|60 65|sites
P10469140A0336|81 86|PAI-2
P10469140A0336|96 104|promoter
P10469140A0336|109 123|responsiveness
P10469140A0336|127 135|TNFalpha
P10469140A0336|142 199|chloramphenicol acetyl transferase reporter gene deletion
P10469140A0336|204 221|mutation analyses
P10469174A0678|11 28|sequence analysis
P10469174A0678|33 49|NMR measurements
P10469174A0678|69 77|fragment
P10469174A0678|112 120|residues
P10469174A0678|124 128|MBF1
P10469174A0678|167 173|domain
P10469174A0678|177 181|MBF1
P10469174A0678|183 190|MBF1CTD
P10469656T0000|16 24|response
P10469656T0000|57 71|gene induction
P10469656T0000|100 119|MAP kinase cascades
P10469656T0000|121 125|MSK1
P10469656T0000|141 155|histone H3/HMG
P10469656T0000|159 165|kinase
P10470220A1011|4 15|arrangement
P10470220A1011|25 38|cutoff-levels
P10470220A1011|50 61|sensitivity
P10470220A1011|67 68|%
P10470220A1011|74 85|specificity
P10470220A1011|91 92|%
P10470220A1011|97 109|Protein S100
P10470220A1011|127 130|RIA
P10470220A1011|141 152|sensitivity
P10470220A1011|158 159|%
P10470220A1011|165 176|specificity
P10470220A1011|182 183|%
P10470220A1011|201 204|LIA
P10471587A0239|9 16|strains
P10471587A0239|20 34|C. trachomatis
P10471587A0239|38 55|triplicate assays
P10471587A0239|70 83|RT-PCR method
P10471587A0239|134 143|technique
P10471587A0239|158 172|antimicrobials
P10471587A0239|196 200|MICs
P10471587A0239|215 221|RT-PCR
P10471587A0239|252 264|erythromycin
P10471587A0239|289 300|amoxicillin
P10471696A0734|5 12|alleles
P10471696A0734|16 20|SAS4
P10471696A0734|25 29|SAS5
P10471696A0734|43 47|role
P10471696A0734|55 73|Abf1p binding site
P10471696A0734|81 95|HMR-E silencer
P10471696A0734|108 112|role
P10471696A0734|120 123|ACS
P10471696A0734|127 145|Rap1p binding site
P10471721A0141|17 25|analysis
P10471721A0141|48 55|S locus
P10471721A0141|99 104|genes
P10471721A0141|112 115|SLG
P10471721A0141|117 120|SRK
P10471721A0141|146 159|pollen S gene
P10471721A0141|160 161|s
P10471721A0141|181 186|genes
P10471743A0000|2 6|cDNA
P10471743A0000|27 30|RNA
P10471743A0000|38 50|DNA helicase
P10471743A0000|74 109|Arabidopsis thaliana cDNA libraries
P10471746A1102|9 13|MyoD
P10471746A1102|28 44|tryptophan motif
P10471746A1102|54 74|chromatin remodeling
P10471746A1102|82 99|Myogenin promoter
P10471746A1102|116 138|Myogenin transcription
P10472314A0717|0 7|RESULTS
P10472314A0717|13 20|Periods
P10472314A0717|24 27|TTP
P10472314A0717|31 35|PUNP
P10472314A0717|53 56|men
P10472314A0717|68 73|women
P10472836A0189|0 11|Feed intake
P10472836A0189|16 24|BW gains
P10472836A0189|41 42|P
P10472836A0189|62 72|treatments
P10472836A0189|84 86|M.
P10473589A0189|4 14|N terminus
P10473589A0189|18 22|beta
P10473589A0189|27 30|kDa
P10473589A0189|47 52|alpha
P10473589A0189|62 78|integrase domain
P10473589A0189|95 105|C terminus
P10473589A0189|110 113|kDa
P10473598A0691|0 6|Skn-1a
P10473598A0691|30 36|region
P10473598A0691|53 76|transactivation ability
P10473598A0691|98 106|promoter
P10473598A0691|137 152|transactivation
P10473598A0691|163 169|Skn-1a
P10473598A0691|173 191|competition assays
P10473623A0081|9 24|Xenopus embryos
P10473623A0081|43 76|growth factor-beta member activin
P10473623A0081|89 99|gene Mix.2
P10473623A0081|119 128|formation
P10473623A0081|147 154|complex
P10473623A0081|175 181|factor
P10473623A0081|183 186|ARF
P10474898A0629|28 37|structure
P10474898A0629|55 64|synthesis
P10474898A0629|72 88|CMT1A-REP repeat
P10474898A0629|110 123|hybridization
P10474898A0629|125 129|FISH
P10474898A0629|131 139|analysis
P10474898A0629|167 173|assays
P10474898A0629|197 203|series
P10474898A0629|207 215|primates
P10475610A1289|0 5|Natl.
P10475972A0269|7 11|face
P10475972A0269|19 27|outbreak
P10475972A0269|41 46|delay
P10475972A0269|54 65|vaccination
P10475972A0269|83 89|deaths
P10476970A0542|26 33|isoform
P10476970A0542|37 41|Rapl
P10476970A0542|60 67|protein
P10476970A0542|76 85|rap1GAPII
P10476970A0542|113 127|alpha-subunits
P10476970A0542|135 136|G
P10476970A0542|140 146|family
P10476970A0542|165 175|G-proteins
P10477545T0000|4 14|B-oligomer
P10477545T0000|18 33|pertussis toxin
P10477545T0000|46 67|CC chemokine receptor
P10477545T0000|81 86|entry
P10477545T0000|99 112|HIV-1 strains
P10477583A0000a|18 36|B cell Ag receptor
P10477583A0000a|38 41|BCR
P10477583A0000a|54 66|Fc receptors
P10477583A0000a|71 74|IgG
P10477583A0000a|76 86|Fc gamma R
P10477583A0000a|105 116|progression
P10477583A0000a|122 131|mechanism
P10477583A0000b|18 36|B cell Ag receptor
P10477583A0000b|38 41|BCR
P10477583A0000b|54 66|Fc receptors
P10477583A0000b|71 74|IgG
P10477583A0000b|76 86|Fc gamma R
P10477583A0000b|105 116|progression
P10477583A0000b|122 131|mechanism
P10477597A0126|0 5|TRAF2
P10477597A0126|18 27|activator
P10477597A0126|40 63|serine/threonine kinase
P10477597A0126|80 93|center kinase
P10477597A0126|103 107|GCKR
P10477597A0126|129 133|KHS1
P10477597A0126|150 160|activation
P10477597A0126|168 180|SAPK pathway
P10477599T0000|25 32|element
P10477599T0000|43 52|C motif-1
P10477599T0000|53 74|lymphotactin promoter
P10477599T0000|80 84|site
P10477599T0000|127 139|interactions
P10477599T0000|158 164|factor
P10477599T0000|178 184|T cell
P10477620A0580|17 48|NF-kappa B DNA binding activity
P10477620A0580|50 54|RelA
P10477620A0580|63 76|translocation
P10477620A0580|78 105|I kappa B alpha degradation
P10477620A0580|107 123|I kappa B serine
P10477620A0580|127 142|phosphorylation
P10477620A0580|148 164|I kappa B kinase
P10477620A0580|166 169|IKK
P10477620A0580|171 179|activity
P10477620A0580|196 214|curcumin treatment
P10477748A1076|2 9|portion
P10477748A1076|13 17|p193
P10477748A1076|58 65|spindle
P10478275A1230|9 15|issues
P10478275A1230|24 28|need
P10478275A1230|42 48|number
P10478275A1230|66 76|mechanisms
P10478275A1230|106 110|diet
P10478275A1230|141 145|risk
P10478275A1230|164 169|foods
P10478275A1230|189 199|technology
P10478275A1230|221 229|contrast
P10478844A1604|0 14|Cotransfection
P10478844A1604|22 33|coactivator
P10478844A1604|47 54|protein
P10478844A1604|84 94|repression
P10478844A1604|98 109|PPARalphawt
P10478844A1604|113 124|PPARalphatr
P10478844A1604|164 170|effect
P10478844A1604|174 185|PPARalphatr
P10478844A1604|206 217|competition
P10478844A1604|232 244|coactivators
P10478848A0331|0 4|SF-1
P10478848A0331|33 43|AF1 domain
P10479025A0528|16 25|locations
P10479025A0528|29 36|sources
P10479025A0528|46 64|TF-MUSIC algorithm
P10479025A0528|83 96|target region
P10479025A0528|104 115|spectrogram
P10479025A0528|137 146|responses
P10479382A1098|17 24|results
P10479382A1098|28 33|terms
P10479382A1098|41 50|influence
P10479382A1098|56 60|time
P10479382A1098|77 88|constraints
P10479382A1098|105 125|development patterns
P10479382A1098|130 137|fitness
P10479492A0000|0 9|OBJECTIVE
P10479492A0000|16 28|Surveillance
P10479492A0000|30 42|Epidemiology
P10479492A0000|48 59|End Results
P10479492A0000|61 65|SEER
P10479492A0000|67 71|data
P10479492A0000|88 89|%
P10479492A0000|97 110|survival rate
P10479492A0000|115 153|corpus uteri adenocarcinoma FIGO stage
P10480937A0000|8 42|Drosophila A kinase anchor protein
P10480937A0000|55 78|A kinase anchor protein
P10480937A0000|84 92|DAKAP200
P10480937A0000|162 169|signals
P10480937A0000|181 185|cAMP
P10480937A0000|187 189|Ca
P10480937A0000|199 213|diacylglycerol
P10480937A0000|215 217|Li
P10480937A0000|219 221|Z.
P10480937A0000|223 228|Rossi
P10480937A0000|230 232|E.
P10482516A1158|9 30|transcription results
P10482516A1158|53 72|structure functions
P10482516A1158|80 101|attenuation mechanism
P10482516A1158|109 117|deletion
P10482516A1158|125 134|stem-loop
P10482516A1158|145 153|increase
P10482516A1158|157 182|transcription readthrough
P10482516T0000|5 18|RNA stem-loop
P10482516T0000|39 74|transcription attenuation mechanism
P10482516T0000|89 99|expression
P10482516T0000|107 141|Bacillus subtilis trpEDCFBA operon
P10482565A0469|28 37|mutations
P10482565A0469|59 66|effects
P10482565A0469|93 99|fusion
P10482620A1009|33 46|transcription
P10482620A1009|56 60|MMTV
P10482620A1009|64 67|LTR
P10482620A1009|92 99|absence
P10482620A1009|103 109|Stat5a
P10482620A1009|113 133|transcription factor
P10482620A1009|184 197|transcription
P10482620A1009|207 215|MMTV LTR
P10483124T0000|0 8|Regional
P10483124T0000|21 32|mutagenesis
P10483124T0000|45 50|genes
P10483124T0000|58 78|CIC5F11/CIC2B9 locus
P10483124T0000|82 113|Arabidopsis thaliana chromosome
P10483124T0000|126 142|Ac/Ds transposon
P10483124T0000|146 157|combination
P10483124T0000|167 187|cDNA scanning method
P10483945A0641|0 7|RESULTS
P10483945A0641|9 24|CK-MB elevation
P10483945A0641|45 53|patients
P10483945A0641|59 60|%
P10483945A0641|68 72|1-3x
P10483945A0641|80 81|%
P10483945A0641|83 87|3-5x
P10483945A0641|94 95|%
P10483945A0641|101 103|5x
P10483945A0641|117 118|%
P10483945A0641|122 130|patients
P10484695A0791|6 24|NART-R performance
P10484695A0791|44 52|estimate
P10484695A0791|56 67|baseline IQ
P10484695A0791|72 80|patients
P10484695A0791|97 106|disorders
P10484695A0791|122 141|language impairment
P10484818A0292|10 15|areas
P10484818A0292|40 45|means
P10484818A0292|49 75|cross-correlation analysis
P10485353T0000|8 37|Haemophilus influenzae type b
P10485353T0000|47 72|polysaccharide antibodies
P10485353T0000|80 87|infants
P10485353T0000|92 100|children
P10485353T0000|106 117|West Africa
P10485353T0000|119 131|Burkina-Faso
P10485353T0000|137 143|France
P10485353T0000|163 173|serosurvey
P10485470A0242|8 13|study
P10485470A0242|29 32|Sp1
P10485470A0242|37 40|Sp3
P10485470A0242|50 57|factors
P10485470A0242|73 82|Sp1 sites
P10485470A0242|90 112|p21/WAF1/Cip1 promoter
P10485470A0242|116 126|MG63 cells
P10485470A0242|151 172|mobility shift assays
P10485470A0242|189 202|TSA treatment
P10485470A0242|224 242|binding activities
P10485585A0175|0 7|Galoyan
P10485585A0175|27 34|results
P10485585A0175|42 51|discovery
P10485585A0175|68 81|neurohormones
P10486210A0126|13 23|regulation
P10486210A0126|31 41|expression
P10486210A0126|53 76|aldehyde reductase gene
P10486210A0126|81 89|promoter
P10487040A0453|20 28|staining
P10487040A0453|34 39|MIB-1
P10487040A0453|44 58|p53 antibodies
P10487040A0453|74 75|%
P10487040A0453|90 98|reaction
P10487217A0735|4 11|C2C-Prx
P10487217A0735|28 38|preprotein
P10487217A0735|46 57|amino acids
P10487217A0735|102 108|signal
P10487217A0735|115 126|amino acids
P10487217A0735|134 144|N-terminus
P10487307A0768|19 35|surgery patients
P10487307A0768|64 78|hydrocortisone
P10487307A0768|83 85|mg
P10487307A0768|89 96|placebo
P10487307A0768|121 126|order
P10487744T0000|17 31|sorting signal
P10487744T0000|39 53|beta2 integrin
P10487744T0000|66 72|domain
P10487744T0000|86 95|recycling
P10487744T0000|103 118|plasma membrane
P10487744T0000|156 165|migration
P10487753A0788|4 13|injection
P10487753A0788|17 30|XDRP1 protein
P10487753A0788|47 59|Xenopus eggs
P10487753A0788|78 91|cell division
P10487759A0630|17 32|Xenopus embryos
P10487759A0630|58 67|integrity
P10487759A0630|81 90|sequences
P10487759A0630|124 134|expression
P10487759A0630|140 145|Xbra2
P10487759A0630|162 175|reporter gene
P10487760A0336|3 8|order
P10487760A0336|12 18|screen
P10487760A0336|28 37|cofactors
P10487760A0336|81 87|mutant
P10487760A0336|91 104|Xenopus MEF2D
P10487760A0336|110 115|yeast
P10487760A0336|127 133|screen
P10487762A0252|0 4|NuA4
P10487762A0252|31 35|mass
P10487762A0252|43 46|MDa
P10487921A0132|0 18|ATF1 transcription
P10487921A0132|64 69|acids
P10487921A0132|74 80|oxygen
P10487953A0765|4 12|patients
P10487953A0765|28 34|tumors
P10487953A0765|44 61|S-phase fractions
P10487953A0765|89 98|specimens
P10487953A0765|110 114|time
P10487953A0765|129 138|operation
P10488087A0340|0 8|Mutation
P10488087A0340|26 31|sites
P10488087A0340|33 36|TBE
P10488087A0340|53 64|combination
P10488087A0340|100 108|activity
P10488087A0340|112 116|SP-A
P10488087A0340|142 170|acetyltransferase constructs
P10488087A0340|182 201|SP-A gene sequences
P10488088T0000|13 28|growth factor-I
P10488088T0000|37 51|bcl-2 promoter
P10488088T0000|64 84|transcription factor
P10488088T0000|115 122|protein
P10488129T0058|0 9|Synthesis
P10488129T0058|23 26|RNA
P10488129T0058|31 32|S
P10488129T0058|49 56|binding
P10488129T0058|60 73|E2F complexes
P10488129T0058|77 83|intron
P10488147A1176|0 14|Identification
P10488147A1176|18 27|eotaxin-3
P10488147A1176|53 66|understanding
P10488147A1176|74 81|control
P10488147A1176|85 107|eosinophil trafficking
P10488147A1176|143 152|phenomena
P10488148A0111|0 9|NF-kappaB
P10488148A0111|27 31|role
P10488148A0111|35 45|activation
P10488148A0111|49 70|HIV-1 gene expression
P10488148A0111|74 83|cytokines
P10488148A0111|94 101|stimuli
P10488148A0111|111 139|signal transduction pathways
P10488148A0111|158 164|switch
P10488148A0111|191 200|infection
P10488148A1267|6 13|studies
P10488148A1267|27 31|MAPK
P10488148A1267|52 56|AP-1
P10488148A1267|98 109|interaction
P10488148A1267|113 117|AP-1
P10488148A1267|123 132|NF-kappaB
P10488148A1267|149 156|complex
P10488148A1267|197 206|HIV-1 LTR
P10488148T0000|0 37|ERK MAP kinase links cytokine signals
P10488148T0000|41 51|activation
P10488148T0000|62 77|HIV-1 infection
P10488148T0000|107 118|interaction
P10488148T0000|122 126|AP-1
P10488148T0000|131 140|NF-kappaB
P10488337T0000|26 35|chaperone
P10488337T0000|51 63|dimerization
P10488337T0000|65 76|DNA binding
P10488337T0000|98 106|activity
P10488337T0000|110 123|bZIP proteins
P10488875A0000|9 24|differentiation
P10488875A0000|28 36|patients
P10488875A0000|65 70|palsy
P10488875A0000|72 74|CP
P10488875A0000|91 102|toe walking
P10488875A0000|104 107|ITW
P10489680A0927|0 11|Sputum IL-8
P10489680A0927|16 19|MPO
P10489680A0927|55 58|BPT
P10489680A0927|67 70|TDI
P10489680A0927|76 93|grain dust-asthma
P10489680A0927|95 96|P
P10489822T0000|0 11|Montelukast
P10489822T0000|20 26|airway
P10489822T0000|40 52|inflammation
P10489822T0000|56 62|asthma
P10489822T0000|89 94|trial
P10490065T0000|0 9|Treatment
P10490065T0000|22 28|angina
P10490065T0000|30 34|role
P10490065T0000|53 60|therapy
P10490604A0601|26 37|kinase-dead
P10490604A0601|56 61|forms
P10490604A0601|65 68|Fyn
P10490604A0601|70 73|Lck
P10490604A0601|79 95|ZAP-70 block 70Z
P10490604A0601|109 124|NFAT activation
P10490609A0413|0 13|Substitutions
P10490609A0413|17 23|region
P10490609A0413|41 50|sequences
P10490609A0413|75 83|sequence
P10490609A0413|95 102|repeats
P10490609A0413|132 140|adenines
P10490609A0413|144 152|thymines
P10490609A0413|162 174|interruption
P10490609A0413|178 185|guanine
P10490609A0413|189 197|cytosine
P10490609A0413|220 232|ARS activity
P10490639A0000|29 34|PHO85
P10490639A0000|62 76|protein kinase
P10490639A0000|78 81|Cdk
P10490639A0000|93 100|subunit
P10490639A0000|126 131|roles
P10490639A0000|159 170|association
P10490639A0000|186 201|cyclin partners
P10490639A0000|203 207|Pcls
P10490662A0431|0 7|Mutants
P10490662A0431|18 30|lace alleles
P10490662A0431|46 52|adults
P10490662A0431|76 88|morphologies
P10490662A0431|96 106|appendages
P10490662A0431|108 120|compound eye
P10490662A0819|3 7|fact
P10490662A0819|9 21|SPT activity
P10490662A0819|29 32|fly
P10490662A0819|59 63|Lace
P10490662A0819|97 105|antibody
P10490816A0000|0 9|Mutations
P10490816A0000|17 25|RET gene
P10490816A0000|38 62|receptor tyrosine kinase
P10490816A0000|104 127|cancer syndromes MEN 2A
P10490816A0000|132 138|MEN 2B
P10490822A1167|6 13|results
P10490822A1167|24 33|targeting
P10490822A1167|37 44|Ras-GAP
P10490822A1167|80 88|approach
P10490826T0000|0 4|EB-1
P10490826T0000|8 48|tyrosine kinase signal transduction gene
P10490826T0000|88 89|t
P10490826T0000|96 102|subset
P10490826T0000|112 115|ALL
P10490826T0000|131 151|oncoprotein E2a-Pbx1
P10490835T0000|0 23|Protein kinase A-Ialpha
P10490835T0000|51 61|inhibition
P10490835T0000|73 91|cancer cell growth
P10490835T0000|93 102|crosstalk
P10490835T0000|108 141|tyrosine kinase signaling pathway
P10490843A0159|0 4|BCL6
P10490843A0159|15 36|POZ/Zn finger protein
P10490843A0159|40 49|structure
P10490843A0159|99 109|regulators
P10490843A0159|125 132|protein
P10490843A0159|167 177|malignancy
P10490843A0159|179 183|PLZF
P10490955T0000|0 4|Beta
P10490955T0000|7 15|integrin
P10490955T0000|43 54|stimulation
P10490955T0000|58 82|T lymphoma cell adhesion
P10490955T0000|105 129|protein kinase signaling
P10490955T0000|133 149|thrombospondin-1
P10490955T0000|154 179|thrombospondin-1 peptides
P10491133A0365|0 10|Optical CD
P10491133A0365|29 46|activity analyses
P10491133A0365|68 78|reactivity
P10491133A0365|82 93|HO isozymes
P10491133A0365|99 109|NO species
P10491133A0365|122 131|NO donors
P10491187T0000|4 29|phosphotransferase system
P10491187T0000|31 34|PTS
P10491187T0000|63 77|identification
P10491187T0000|94 102|analysis
P10491187T0000|108 144|histidine phosphocarrier protein HPr
P10491187T0000|160 169|gene ptsH
P10491213A0263|0 20|Serum concentrations
P10491213A0263|24 28|bone
P10491213A0263|38 58|alkaline phosphatase
P10491213A0263|60 64|BALP
P10491213A0263|70 81|osteocalcin
P10491213A0263|83 99|bone Gla protein
P10491213A0263|101 104|BGP
P10491213A0263|115 121|levels
P10491213A0263|125 137|pyridinoline
P10491213A0263|139 142|Pyr
P10491213A0263|148 165|deoxypyridinoline
P10491213A0263|167 171|Dpyr
P10491213A0263|186 196|tomography
P10491213A0263|198 200|CT
P10491213A0263|202 214|measurements
P10491213A0263|238 243|areas
P10491213A0263|251 260|vertebrae
P10491213A0263|269 275|femurs
P10491213A0263|290 297|density
P10491213A0263|312 316|bone
P10491213A0263|324 333|vertebrae
P10491213A0263|343 349|volume
P10491213A0263|358 374|material density
P10491213A0263|387 391|bone
P10491213A0263|399 405|femurs
P10491213A0263|429 433|boys
P10491213A0263|442 447|girls
P10491213A0263|449 453|ages
P10491213A0263|459 464|years
P10492127A0914|11 16|study
P10492127A0914|30 44|administration
P10492127A0914|48 58|devazepide
P10492127A0914|71 108|cholecystokinin-A receptor antagonist
P10492127A0914|115 119|dose
P10492127A0914|127 135|mg/kg/hr
P10492127A0914|149 152|min
P10492127A0914|173 186|saline intake
P10492127A0914|207 209|hr
P10492169A0939|5 12|cluster
P10492169A0939|52 56|ESTs
P10492169A0939|65 70|genes
P10492169A0939|93 109|plasma protein-A
P10492169A0939|111 117|PAPP-A
P10492169A0939|131 135|gene
P10492169A0939|155 162|EST-YD1
P10493203T0000|11 16|value
P10493203T0000|22 46|treadmill exercise score
P10493203T0000|62 70|patients
P10493203T0000|93 106|abnormalities
P10493203T0000|118 121|ECG
P10493575T0000|11 18|changes
P10493575T0000|26 36|C-terminus
P10493575T0000|40 43|Ca2
P10493575T0000|51 60|rat S100B
P10493575T0000|62 71|beta beta
P10493575T0000|91 98|peptide
P10493575T0000|138 144|domain
P10493575T0000|148 151|p53
P10493580A1126|16 21|Gly84
P10493580A1126|25 29|part
P10493580A1126|45 58|oxyanion hole
P10493580A1126|76 89|stabilization
P10493580A1126|97 113|transition state
P10493580A1126|129 136|C group
P10493580A1126|144 166|esterase/lipase family
P10493876A0000|4 22|solution structure
P10493876A0000|30 36|adduct
P10493876A0000|63 70|bonding
P10493876A0000|78 90|fjord region
P10493876A0000|96 99|11S
P10493876A0000|101 104|12R
P10493876A0000|106 109|13R
P10493876A0000|111 114|14S
P10493876A0000|116 128|stereoisomer
P10493876A0000|144 156|dihydroxy-13
P10493876A0000|160 168|epoxy-11
P10493876A0000|195 196|g
P10493876A0000|197 205|chrysene
P10493876A0000|218 219|B
P10493876A0000|220 221|g
P10493876A0000|222 225|CDE
P10493876A0000|244 245|N
P10493876A0000|248 259|amino group
P10493876A0000|275 286|residue dA6
P10493876A0000|305 315|trans-anti
P10493876A0000|318 319|B
P10493876A0000|320 321|g
P10493876A0000|322 323|C
P10493876A0000|324 327|dA6
P10493876A0000|341 349|opposite
P10493876A0000|352 372|thymine residue dT17
P10493876A0000|380 402|DNA sequence context d
P10493876A0000|403 417|C1-T2-C3-T4-C5
P10493876A0000|419 420|B
P10493876A0000|421 422|g
P10493876A0000|423 424|C
P10493876A0000|425 444|A6-C7-T8-T9-C10-C11
P10493876A0000|447 448|d
P10493876A0000|449 484|G12-G13-A14-A15-G16-T17-G18-A19-G20
P10493876A0000|489 496|A21-G22
P10493876A0000|511 512|B
P10493876A0000|513 514|g
P10493876A0000|515 516|C
P10493876A0000|517 519|dA
P10493876A0000|521 523|dT
P10493876A0000|531 537|duplex
P10493876A0000|574 585|information
P10493876A0000|599 607|NMR data
P10493876A0000|611 622|combination
P10493876A0000|638 646|dynamics
P10493876A0000|648 650|MD
P10493876A0000|652 664|calculations
P10495573A0365|6 16|sildenafil
P10495573A0365|29 35|market
P10495573A0365|55 60|place
P10495573A0365|64 68|MUSE
P10495573A0365|100 107|studies
P10495573A0365|120 127|results
P10495573A0365|132 142|sildenafil
P10495573A0365|148 152|MUSE
P10495573A0365|156 157|%
P10495573A0365|163 164|%
P10495573A0365|173 179|course
P10495573A0365|194 204|acceptance
P10496161A0503|0 16|Serum antibodies
P10496161A0503|45 46|%
P10496161A0503|63 74|guinea pigs
P10496161A0503|88 91|WPI
P10496161A0503|96 100|rats
P10496161A0503|114 117|WPI
P10496284A0115|27 35|episodes
P10496284A0115|37 48|CSF protein
P10496284A0115|53 69|immunoglobulin G
P10496284A0115|71 74|IgG
P10496284A0115|76 82|levels
P10496284A0115|118 127|IgG index
P10496284A0115|131 149|IgG synthesis rate
P10496303A1968|0 11|CONCLUSIONS
P10496303A1968|19 26|results
P10496303A1968|53 67|valganciclovir
P10496303A1968|80 89|exposures
P10496303A1968|93 104|ganciclovir
P10496303A1968|106 111|AUC24
P10496303A1968|156 167|ganciclovir
P10496303A1968|171 176|mg/kg
P10496388A1956a|11 23|nonperfusion
P10496388A1956a|48 55|vessels
P10496388A1956a|67 71|dose
P10496388A1956a|79 84|J/cm2
P10496388A1956a|103 109|events
P10496388A1956a|118 125|concern
P10496388A1956b|11 23|nonperfusion
P10496388A1956b|48 55|vessels
P10496388A1956b|67 71|dose
P10496388A1956b|79 84|J/cm2
P10496388A1956b|103 109|events
P10496388A1956b|118 125|concern
P10496553A1004|4 16|healing rate
P10496553A1004|33 41|patients
P10496553A1004|49 56|percent
P10496553A1004|66 71|weeks
P10496553A1004|80 87|percent
P10496553A1004|97 102|weeks
P10496553A1004|122 129|figures
P10496553A1004|134 142|patients
P10496553A1004|157 182|immunodeficiency syndrome
P10496553A1004|197 204|percent
P10497117A0358|4 10|P mRNA
P10497117A0358|33 36|ORF
P10497117A0358|45 54|V protein
P10497117A0358|99 102|ORF
P10497199A0559|10 16|screen
P10497199A0559|20 25|yeast
P10497199A0559|77 91|factor binding
P10497199A0559|99 103|GlRE
P10497199A0559|114 131|chicken ovalbumin
P10497199A0559|164 170|factor
P10497199A0559|175 184|COUP-TFII
P10497262A0000|31 35|gene
P10497262A0000|44 49|trans
P10497262A0000|64 72|U5 snRNA
P10497262A0000|82 124|trypanosomatid species Leptomonas seymouri
P10497262A0000|132 157|U5 RNA affinity selection
P10497262A0000|162 174|cDNA cloning
P10497800A0000|4 10|MMPI-A
P10497800A0000|12 19|Butcher
P10497800A0000|50 54|MMPI
P10497800A0000|56 64|Hathaway
P10497800A0000|67 75|McKinley
P10497800A0000|106 114|anorexia
P10497800A0000|119 126|bulimia
P10497874A0925|13 17|hand
P10497874A0925|19 40|phosphatidyl inositol
P10497874A0925|45 57|bisphosphate
P10497874A0925|59 63|PIP2
P10497874A0925|65 75|hydrolysis
P10497874A0925|92 107|phosphorylation
P10497874A0925|111 127|tyrosine residue
P10497874A0925|135 153|PLC-gamma1 isozyme
P10498616A0157|2 13|G22V mutant
P10498616A0157|17 22|M-Ras
P10498616A0157|57 67|expression
P10498616A0157|74 87|interleukin-3
P10498616A0157|89 93|IL-3
P10498616A0157|105 138|mast cell/megakaryocyte cell line
P10498616A0157|161 169|survival
P10498616A0157|177 184|absence
P10498616A0157|188 192|IL-3
P10498616A0157|204 210|growth
P10498616A0157|214 218|IL-4
P10498616A0157|233 250|expression levels
P10498616A0157|274 280|growth
P10498616A1280|10 15|M-Ras
P10498616A1280|22 44|Caenorhabditis elegans
P10498616A1280|56 63|exhibit
P10498616A1280|85 93|features
P10498616A1280|127 137|activation
P10498616A1280|153 168|signaling paths
P10498616A1280|186 194|parallel
P10498616A1280|218 225|p21 Ras
P10498706A1219|20 24|data
P10498706A1219|38 42|PecS
P10498706A1219|54 58|pelD
P10498706A1219|63 78|pelE expression
P10498706A1219|108 117|repressor
P10498706A1219|123 127|KdgR
P10498717A1048|6 18|observations
P10498717A1048|34 38|RsmC
P10498717A1048|60 78|rsmB transcription
P10498717A1048|102 117|RsmA production
P10499121A0542|21 38|hearing aid users
P10499121A0542|55 74|Class D instruments
P10499121A0542|80 97|input compression
P10499121A0542|114 118|time
P10499121A0542|128 138|enrollment
P10499121A0542|147 152|study
P10499357A0439|0 12|SCOB testing
P10499357A0439|32 39|animals
P10499357A0439|64 69|ratio
P10499357A0439|71 73|FR
P10499357A0439|81 89|interval
P10499357A0439|91 93|FI
P10499357A0439|95 103|schedule
P10499357A0439|105 109|FR20
P10499357A0439|110 115|FI120
P10499357A0439|146 154|exposure
P10499357A0439|179 187|behavior
P10499357A0439|193 197|data
P10499357A0439|203 208|Weeks
P10499357A0439|245 253|evidence
P10499357A0439|257 270|neurotoxicity
P10501034A0839|0 30|Ribonuclease protection assays
P10501034A0839|45 49|hmg1
P10501034A0839|54 58|hmg2
P10501034A0839|134 140|manner
P10501034A0839|148 161|morphogenesis
P10501034A0839|198 212|pigment glands
P10501034A0839|216 223|embryos
P10501656A1415|13 23|expression
P10501656A1415|41 63|Northern blot analysis
P10501656A1415|94 110|tumor cell lines
P10501936T0000|0 12|Inactivation
P10501936T0000|20 37|Neurospora crassa
P10501936T0000|58 80|membrane protein TOM70
P10501936T0000|99 113|point mutation
P10501936T0000|115 118|RIP
P10501936T0000|127 134|defects
P10501936T0000|152 166|protein import
P10501936T0000|171 181|morphology
P10501965A0879|8 13|genes
P10501965A0879|33 38|units
P10501965A0879|73 76|end
P10501965A0879|90 99|s6 kinase
P10501965A0879|101 105|Rsk3
P10501965A0879|147 152|genes
P10501965A0879|158 163|Gpr31
P10501965A0879|189 198|G-protein
P10501965A0879|207 215|receptor
P10501969A1329|4 11|results
P10501969A1329|25 31|GATA-5
P10501969A1329|61 68|targets
P10501969A1329|78 84|GATA-4
P10501969A1329|145 158|cardiogenesis
P10502216A0289|5 10|study
P10502216A0289|39 47|efficacy
P10502216A0289|51 60|efegatran
P10502216A0289|66 79|streptokinase
P10502216A0289|87 94|heparin
P10502216A0289|112 140|tissue plasminogen activator
P10502216A0289|142 145|TPA
P10502216A0289|159 170|reperfusion
P10502216A0289|180 182|MI
P10502402A0129|23 28|TRAIL
P10502402A0129|83 102|mouse T lymphocytes
P10502402A0129|116 127|possibility
P10502402A0129|133 138|TRAIL
P10502402A0129|160 161|T
P10502402A0129|176 188|cytotoxicity
P10502402A0129|203 213|regulation
P10502402A0533|2 7|panel
P10502402A0533|25 35|inhibitors
P10502402A0533|64 92|signal transduction pathways
P10502402A0533|105 125|TRAIL gene induction
P10502402A0533|136 159|T lymphocyte activation
P10502434A0367|5 13|February
P10502434A0367|22 28|August
P10502434A0367|39 47|patients
P10502434A0367|65 74|carcinoma
P10502434A0367|132 151|vault brachytherapy
P10502434A0367|173 182|treatment
P10502434A0604|7 15|patients
P10502434A0604|20 30|stage IBG3
P10502434A0604|39 43|ICG1
P10502434A0604|51 55|ICG2
P10502434A0604|67 79|ICG3 disease
P10502522A0000|10 26|provirus genomes
P10502522A0000|36 62|T-cell leukemia virus type
P10502522A0000|92 103|lymphocytes
P10502522A0000|118 129|individuals
P10502522A0000|146 156|cell lines
P10503540A0602|2 7|total
P10503540A0602|15 27|primer pairs
P10503540A0602|47 63|banding patterns
P10503540A0602|72 73|%
P10503540A0602|106 113|alleles
P10503540A0602|124 143|polyacrylamide gels
P10503812A1450|2 12|population
P10503812A1450|29 34|study
P10503812A1450|38 49|cyclosporin
P10503812A1450|53 78|organ transplant patients
P10503812A1450|98 118|allograft recipients
P10503812A1450|128 133|years
P10503812A1450|137 140|age
P10503812A1450|159 162|age
P10503812A1450|191 219|cyclosporin pharmacokinetics
P10504332A0701|0 22|Immunofluoresence data
P10504332A0701|63 71|receptor
P10504332A0701|93 96|RAP
P10504332A0701|115 122|markers
P10504332A0701|140 147|pathway
P10504332A0701|161 166|cells
P10504332A0701|192 200|receptor
P10504332A0701|202 218|RAP fluorescence
P10504332A0701|247 254|markers
P10505694A0000|0 14|Interleukin-12
P10505694A0000|16 21|IL-12
P10505694A0000|28 36|cytokine
P10505694A0000|60 65|blood
P10505694A0000|78 83|cells
P10505694A0000|85 89|PBMC
P10505694A0000|103 119|interferon-gamma
P10505694A0000|121 130|IFN-gamma
P10505694A0000|132 142|production
P10505694A0000|147 158|enhancement
P10505694A0000|176 188|cytotoxicity
P10505694A0739|0 16|IL-12 production
P10505694A0739|37 54|C3a concentration
P10505694A0739|71 77|outlet
P10505694A0739|81 93|hemodialyzer
P10505694A0739|103 106|min
P10505694A0739|110 118|dialysis
P10505694A0739|120 121|r
P10505694A0739|130 131|P
P10506143A0610|3 13|HeLa cells
P10506143A0610|19 44|JNKK2-JNK1 fusion protein
P10506143A0610|64 76|JNK activity
P10506143A0610|112 116|JNK1
P10506143A0610|135 142|stimuli
P10506143A0610|147 157|activators
P10506143A0610|169 172|EGF
P10506143A0610|174 183|TNF-alpha
P10506143A0610|185 195|anisomycin
P10506143A0610|197 211|UV irradiation
P10506143A0610|213 218|MEKK1
P10506143A0610|230 255|GTP binding proteins Rac1
P10506143A0610|260 267|Cdc42Hs
P10506160A0297|0 2|J.
P10508522A1598|4 11|results
P10508522A1598|22 34|TGF-beta RII
P10508522A1598|47 53|target
P10508522A1598|57 65|EWS-FLI1
P10509768A1118|4 13|reduction
P10509768A1118|33 45|acids intake
P10509768A1118|68 73|group
P10509768A1118|94 100|mmol/l
P10509768A1118|105 106|%
P10509768A1118|108 117|reduction
P10509768A1118|127 150|serum cholesterol level
P10510295A0606|13 46|ethanol repression autoregulation
P10510295A0606|48 51|ERA
P10510295A0606|65 74|TA repeat
P10510295A0606|76 79|TAB
P10510295A0606|81 98|repressor element
P10510295A0606|125 140|promoter region
P10510295A0606|148 157|GLK1 gene
P10510379A0105|10 30|transcription factor
P10510379A0105|39 46|process
P10510379A0105|50 55|STAT6
P10510379A0105|83 94|DNA element
P10510379A0105|100 119|cytokine activation
P10511216A0654|0 11|CONCLUSIONS
P10511216A0654|42 46|kink
P10511216A0654|63 68|cause
P10511554T0000|41 57|polymorphism map
P10511554T0000|66 100|clone Caenorhabditis elegans cdf-1
P10512699A0364|5 14|machinery
P10512699A0364|36 45|structure
P10512699A0364|47 60|SECIS element
P10512699A0364|92 96|mRNA
P10512699A0364|108 132|selenocysteine insertion
P10512699A0364|140 148|position
P10512699A0364|155 159|opal
P10512699A0364|161 164|UGA
P10512699A0364|166 171|codon
P10512699A0364|193 204|termination
P10512699A0364|208 219|translation
P10512699T0000|11 21|expression
P10512699T0000|71 96|rat thioredoxin reductase
P10512699T0000|107 119|gene fusions
P10512699T0000|151 165|SECIS elements
P10512699T0000|170 183|co-expression
P10512699T0000|193 197|selA
P10512699T0000|199 203|selB
P10512699T0000|208 218|selC genes
P10512857A0000|3 16|Wnt signaling
P10512857A0000|18 30|beta-catenin
P10512857A0000|35 46|plakoglobin
P10512857A0000|57 64|signals
P10512857A0000|72 79|nucleus
P10512857A0000|88 100|interactions
P10512857A0000|115 136|transcription factors
P10512882A0137|0 8|Assembly
P10512882A0137|14 21|complex
P10512882A0137|30 33|FAK
P10512882A0137|38 49|Src kinases
P10512882A0137|88 100|localization
P10512882A0137|119 127|activity
P10512882A0137|131 138|members
P10512882A0137|146 156|Src family
P10512882A0137|160 167|kinases
P10513756A0584|4 7|EPV
P10513756A0584|26 30|bias
P10513756A0584|42 43|%
P10513756A0584|67 84|8-predictor model
P10513756A0584|119 138|selection criterion
P10513756A0584|149 154|alpha
P10513922A1237|4 9|study
P10513922A1237|40 49|increases
P10513922A1237|57 63|number
P10513922A1237|85 91|fibers
P10513922A1237|105 116|repair site
P10513922A1237|120 130|comparison
P10513922A1237|159 165|groups
P10513922A1237|167 168|p
P10514493A0199|25 40|differentiation
P10514493A0199|44 71|N1E-115 neuroblastoma cells
P10514493A0199|91 101|expression
P10514493A0199|120 130|Ntr-1 gene
P10514493A0199|135 149|reporter genes
P10514493A0199|160 184|NTR-1 promoter sequences
P10514808T0000|9 19|dysplasias
P10514808T0000|21 29|genetics
P10514808T0000|35 50|epileptogenesis
P10516011A0471|7 11|work
P10516011A0471|35 50|peptide mapping
P10516011A0471|52 69|mass spectrometry
P10516011A0471|89 100|mutagenesis
P10516011A0471|117 121|sets
P10516011A0471|125 150|pAP phosphorylation sites
P10516026A0270|5 16|HERV-K type
P10516026A0270|25 31|clones
P10516072A0146|0 4|Duch
P10516072A0146|10 12|F.
P10516738A0925|7 18|time-points
P10516738A0925|25 33|patients
P10516738A0925|40 41|%
P10516738A0925|58 73|irbesartan/HCTZ
P10516878T0000|0 12|Modification
P10516878T0000|16 45|dopamine D2 receptor activity
P10516878T0000|49 58|pergolide
P10516878T0000|62 71|Parkinson
P10516878T0000|74 81|disease
P10516878T0000|94 99|study
P10516878T0000|103 106|PET
P10517666A1069|14 27|binding sites
P10517666A1069|37 39|GR
P10517666A1069|44 63|AP-1 nucleoproteins
P10517666A1069|92 100|elements
P10517666A1069|112 116|nGRE
P10517672A1417|15 23|fragment
P10517672A1417|40 76|alpha1-globin promoter-CAT construct
P10517672A1417|100 126|CCAAT transcription factor
P10517672A1417|130 134|CTF1
P10517672A1417|136 139|NF1
P10517672A1417|145 182|Drosophila Schneider SL2 insect cells
P10517672A1417|204 212|proteins
P10517672A1417|214 230|trans-activation
P10517672A1417|234 246|CAT activity
P10517675A0809|0 21|Western blot analysis
P10517675A0809|51 59|increase
P10517675A0809|63 83|p21WAF1/CIP1 protein
P10517675A0809|93 107|protein levels
P10517675A0809|119 125|member
P10517675A0809|150 173|kinase inhibitor family
P10517675A0809|175 182|p27kip1
P10518496A0952|0 11|Aggregation
P10518496A0952|41 51|stem cells
P10518496A0952|78 85|embryos
P10518496A0952|134 141|tissues
P10518496A0952|151 177|periimplantation lethality
P10518496A0952|189 200|development
P10518496A0952|222 235|organogenesis
P10518502T0000|0 5|nos-1
P10518502T0000|10 15|nos-2
P10518502T0000|21 26|genes
P10518502T0000|76 97|germ cell development
P10518502T0000|102 110|survival
P10518502T0000|114 136|Caenorhabditis elegans
P10518561A0261|18 28|regulators
P10518561A0261|32 50|Tec family kinases
P10518561A0261|120 129|effectors
P10518561A0261|139 146|enzymes
P10518561A0885|10 25|phosphorylation
P10518561A0885|29 34|BRDG1
P10518561A0885|38 41|Tec
P10518561A0885|55 57|PH
P10518561A0885|62 73|SH2 domains
P10518561A0885|89 102|kinase domain
P10518822A1037|0 10|CONCLUSION
P10518822A1037|18 26|findings
P10518822A1037|38 45|eotaxin
P10518822A1037|90 96|asthma
P10518822A1037|112 121|biomarker
P10518822A1037|126 134|activity
P10518822A1037|142 169|CCR3 receptor ligand system
P10518822A1037|203 209|asthma
P10518937A0572|4 23|expression analysis
P10518937A0572|31 42|KlHIS4 gene
P10518937A0572|49 69|phosphate starvation
P10518937A0572|78 92|adenine supply
P10518937A0572|104 111|factors
P10518937A0572|121 125|Bas1
P10518937A0572|129 133|Bas2
P10518937A0572|157 164|control
P10518937A0572|197 200|way
P10518937A0572|204 213|K. lactis
P10518956A0137|6 29|thyroid hormone changes
P10518956A0137|49 53|part
P10518956A0137|57 66|cytokines
P10518956A0137|89 98|mediators
P10518956A0137|114 119|level
P10518956A0137|127 139|hypothalamus
P10518956A0137|154 159|gland
P10518956A0137|165 178|thyroid gland
P10518956A0137|196 213|deiodinase system
P10518956A1212|0 8|ESS type
P10518956A1212|17 20|FT3
P10518956A1212|29 32|FT4
P10518956A1212|37 40|TSH
P10518956A1212|70 74|form
P10520800A0307|0 7|METHODS
P10520800A0307|35 43|patients
P10520800A0307|49 53|HOCM
P10520800A0307|58 61|men
P10520800A0307|69 72|age
P10520800A0307|83 88|years
P10520800A0307|114 123|reduction
P10520800A0307|130 146|echocardiography
P10520800A0307|151 168|electrocardiogram
P10520800A0307|170 173|ECG
P10521345A0202|18 22|data
P10521345A0202|32 46|Laurentian Fan
P10521345A0202|58 63|proxy
P10521345A0202|68 91|sea surface temperature
P10521345A0202|105 131|surface slope waters north
P10521345A0202|139 150|Gulf Stream
P10521345A0202|189 196|Ice Age
P10521345A0202|217 226|centuries
P10521345A0202|243 249|notion
P10521345A0202|275 281|system
P10521443A0486|5 11|effect
P10521443A0486|25 38|IR activation
P10521443A0486|65 76|IR mutation
P10521443A0486|80 89|tyrosines
P10521443A0486|113 133|NF-kappaB activation
P10521443A0486|160 174|overexpression
P10521443A0486|196 209|IkappaB-alpha
P10521443A0486|210 216|A32/36
P10521443A0486|234 248|overexpression
P10521443A0486|256 279|NF-kappaB c-Rel subunit
P10521447A0606|4 10|factor
P10521447A0606|22 23|B
P10521447A0606|57 72|sequence TGTGGT
P10521447A0606|76 86|core motif
P10521447A0606|101 108|members
P10521447A0606|116 156|AML/CBFalpha transcription factor family
P10521447A1190|13 27|overexpression
P10521447A1190|31 45|AML3/CBFalpha1
P10521447A1190|63 82|AML1-ETO repression
P10521450A0437|12 26|Akt activation
P10521450A0437|30 33|Lyn
P10521450A0437|36 39|Syk
P10521450A0437|59 69|DT40 cells
P10521450A0437|74 81|B cells
P10521450A0437|87 90|Lyn
P10521450A0437|96 100|mice
P10521509A0000|0 10|Regulators
P10521509A0000|14 33|G protein signaling
P10521509A0000|35 38|RGS
P10521509A0000|40 48|proteins
P10521509A0000|62 65|DEP
P10521509A0000|79 85|EGL-10
P10521509A0000|87 97|pleckstrin
P10521509A0000|103 106|GGL
P10521509A0000|108 123|G protein gamma
P10521509A0000|138 145|domains
P10521509A0000|153 162|subfamily
P10521509A0000|191 208|RGS proteins RGS6
P10521509A0000|210 214|RGS7
P10521509A0000|216 220|RGS9
P10521509A0000|226 231|RGS11
P10521544T0000|0 7|Cloning
P10521544T0000|12 22|expression
P10521544T0000|43 64|alpha 1,2-mannosidase
P10521544T0000|76 87|Man9GlcNAc2
P10521544T0000|91 111|Man8GlcNAc2 isomer B
P10521544T0000|128 140|biosynthesis
P10521796A0872|4 7|ORs
P10521796A0872|11 13|GC
P10521796A0872|28 31|age
P10521796A0872|36 39|sex
P10521796A0872|74 92|baseline diagnoses
P10521796A0872|119 129|metaplasia
P10521796A0872|131 133|IM
P10521796A0872|165 167|IM
P10521796A0872|176 185|dysplasia
P10521796A0872|187 190|DYS
P10521796A0872|195 197|IM
P10521796A0872|213 220|atrophy
P10521796A0872|225 241|neck hyperplasia
P10521796A0872|287 290|DYS
P10521796A0872|309 317|subjects
P10521796A0872|335 344|gastritis
P10521796A0872|346 348|SG
P10521796A0872|370 379|gastritis
P10521796A0872|381 384|CAG
P10521796A0872|389 397|baseline
P10523319A0209|20 25|Dbp5p
P10523319A0209|30 35|Rat7p
P10523319A0209|69 76|domains
P10523520A0986|10 24|nematode genes
P10523520A0986|38 46|homologs
P10523520A0986|50 62|Hh molecules
P10523520A0986|72 77|phyla
P10523634A1404|2 8|subset
P10523634A1404|12 21|mutations
P10523634A1404|29 48|Psi synthase domain
P10523634A1404|57 68|association
P10523634A1404|84 98|Cbf5p proteins
P10523634A1404|113 130|box H/ACA snoRNAs
P10523634A1404|173 179|domain
P10523634A1404|202 213|interaction
P10523640A0367|13 32|Src tyrosine kinase
P10523640A0367|54 75|Stat3 phosphorylation
P10523640A0367|79 87|tyrosine
P10523640A0367|89 99|activation
P10523640A0367|118 133|gene regulation
P10523640A0367|148 156|tyrosine
P10523640A0367|161 183|serine phosphorylation
P10523640A0367|187 192|Stat3
P10523647A0000|4 29|transcription factor CHOP
P10523647A0000|31 36|C/EBP
P10523647A0000|48 55|protein
P10523647A0000|65 77|bZIP protein
P10523647A0000|91 98|variety
P10523647A0000|102 109|stimuli
P10523647A0000|130 146|stress responses
P10523647A0000|176 187|cell growth
P10523647A0000|214 224|cell death
P10523647A1001|6 10|CHOP
P10523647A1001|48 57|regulator
P10523647A1001|61 79|C/EBP target genes
P10523647A1001|107 119|AP-1 factors
P10523647A1001|134 151|AP-1 target genes
P10523663A0404|5 10|motif
P10523663A0404|47 72|homeobox activator DEAF-1
P10523663A0404|97 102|group
P10523663A0404|131 141|modulators
P10523674A0000|0 9|RNase MRP
P10523674A0000|15 49|ribonucleoprotein endoribonuclease
P10523674A0000|78 83|roles
P10523674A0000|106 121|DNA replication
P10523674A0000|137 154|S rRNA processing
P10524258A0286|21 31|regulation
P10524258A0286|39 50|FGFR-1 gene
P10524258A0286|52 57|cek-1
P10524258A0286|77 85|cultures
P10524258A0286|89 108|immunocytochemistry
P10524258A0286|113 135|Northern blot analysis
P10524258T0000|0 10|Regulation
P10524258T0000|20 53|fibroblast growth factor receptor
P10524258T0000|57 63|FGFR-1
P10524258T0000|65 80|gene expression
P10524258T0000|97 119|muscle differentiation
P10525413A1408|4 21|backbone dynamics
P10525413A1408|25 33|residues
P10525413A1408|56 60|part
P10525413A1408|64 68|CRP2
P10525413A1408|69 73|LIM2
P10525413A1408|74 79|R122A
P10525413A1408|126 144|N NMR spectroscopy
P10526670A0236|0 3|Rac
P10526670A0236|11 20|uncapping
P10526670A0236|24 39|actin filaments
P10526670A0236|41 48|F-actin
P10526670A0236|57 66|plus-ends
P10526670A0236|76 96|phosphatidylinositol
P10526670A0236|101 113|bisphosphate
P10526670A0236|115 119|PIP2
P10526670A0236|145 162|membrane ruffling
P10526670A1828|20 31|ICE/caspase
P10526670A1828|34 43|inhibitor
P10526670A1828|51 56|N1445
P10526670A1828|93 102|apoptosis
P10526670A1828|119 122|PKB
P10526670A1828|161 172|suppression
P10526670A1828|176 194|Ras transformation
P10527106A0384|0 9|OBJECTIVE
P10527106A0384|24 37|preponderance
P10527106A0384|41 49|findings
P10527106A0384|56 63|support
P10527106A0384|131 138|deficit
P10527106A0384|142 146|need
P10527106A0384|168 177|depiction
P10527106A0384|185 192|deficit
P10527158T0000|4 12|AL-R8 SI
P10527158T0000|23 51|generation staging container
P10527158T0000|56 70|plutonium pits
P10527158T0000|78 96|USDOE Pantex Plant
P10527180A0869|0 7|RESULTS
P10527180A0869|9 16|Factors
P10527180A0869|48 49|P
P10527180A0869|65 69|risk
P10527180A0869|73 90|treatment failure
P10527180A0869|96 99|Cox
P10527180A0869|113 121|analysis
P10527180A0869|131 134|age
P10527180A0869|149 154|years
P10527180A0869|165 171|hazard
P10527180A0869|181 202|% confidence interval
P10527180A0869|204 206|CI
P10527180A0869|221 248|Karnofsky performance score
P10527180A0869|261 262|%
P10527180A0869|272 276|% CI
P10527180A0869|290 297|absence
P10527180A0869|301 318|hormone receptors
P10527180A0869|328 332|% CI
P10527180A0869|352 355|use
P10527180A0869|368 380|chemotherapy
P10527180A0869|390 394|% CI
P10527180A0869|429 446|survival interval
P10527180A0869|462 471|treatment
P10527180A0869|491 497|months
P10527180A0869|507 511|% CI
P10527180A0869|525 535|metastases
P10527180A0869|543 548|liver
P10527180A0869|558 562|% CI
P10527180A0869|594 600|system
P10527180A0869|610 614|% CI
P10527180A0869|627 650|approaches significance
P10527180A0869|661 667|tissue
P10527180A0869|669 673|bone
P10527180A0869|678 682|lung
P10527180A0869|694 699|sites
P10527180A0869|714 721|disease
P10527180A0869|731 735|% CI
P10527180A0869|764 772|response
P10527180A0869|785 793|response
P10527180A0869|811 823|chemotherapy
P10527180A0869|833 837|% CI
P10527426A0521|4 8|form
P10527426A0521|16 36|SBEI gene transcript
P10527426A0521|51 58|kernels
P10527426A0521|73 98|exon I+II+III combination
P10527426A0521|109 112|end
P10527426A0521|128 133|forms
P10527426A0521|146 155|inclusion
P10527426A0521|159 165|intron
P10527426A0521|171 180|exclusion
P10527426A0521|184 188|exon
P10527426A0521|192 201|sequences
P10527475A0643|3 5|PC
P10527475A0643|12 17|MNGCs
P10527475A0643|35 45|inclusions
P10527475A0643|50 57|grooves
P10528035A1102|3 10|percent
P10528035A1102|12 13|P
P10528035A1102|36 49|normalization
P10528035A1102|53 90|serum alanine aminotransferase levels
P10528035A1102|95 102|percent
P10529198A0068|25 31|domain
P10529198A0068|72 87|homologues p140
P10529198A0068|88 95|ras-GRF
P10529198A0068|101 104|Sos
P10529354A0375|4 14|proteasome
P10529354A0375|26 33|complex
P10529354A0375|65 75|structures
P10529354A0375|81 84|20S
P10529354A0375|89 92|19S
P10529354A0375|93 98|PA700
P10529354A0375|103 116|P28 complexes
P10529354A0375|143 156|26S particles
P10531334A0525|3 9|assays
P10531334A0525|24 31|enzymes
P10531334A0525|51 60|PTPS-S19A
P10531334A0525|76 85|substrate
P10531334A0525|109 123|protein kinase
P10531334A0525|125 128|cGK
P10531334A0525|130 134|type
P10531340A1275|0 2|R.
P10531340A1275|4 15|Fleischmann
P10531340A1275|17 19|R.
P10531340A1275|21 27|Venter
P10531340A1275|29 31|J.
P10531342A0348|15 21|domain
P10531342A0348|42 45|kDa
P10531342A0348|68 86|amino acid repeats
P10531342A0348|102 110|homology
P10531342A0348|114 148|promastigote surface glycoproteins
P10531342A0348|156 173|psa2/gp46 complex
P10531342A1111|3 11|contrast
P10531342A1111|40 60|proteophosphoglycans
P10531342A1111|66 83|ppg1 gene product
P10531342A1111|148 173|promastigote cell surface
P10531360A0958|16 25|infection
P10531360A0958|33 38|cells
P10531360A0958|58 67|construct
P10531360A0958|105 114|induction
P10531360A0958|118 127|VEGF mRNA
P10531360A0958|134 144|conditions
P10531360A0958|156 163|hypoxia
P10531446A0203|0 10|Neuregulin
P10531446A0203|22 27|ErbB2
P10531446A0203|29 34|ErbB3
P10531446A0203|40 45|ErbB4
P10531446A0203|47 54|members
P10531446A0203|62 73|ErbB family
P10531446A0203|77 102|receptor tyrosine kinases
P10532354A1374|4 11|results
P10532354A1374|25 30|Anu2p
P10532354A1374|38 53|yeast homologue
P10532354A1374|67 78|epsilon-COP
P10532354A1374|94 106|accumulation
P10532354A1374|114 125|ER membrane
P10532354A1374|138 146|blockage
P10532354A1374|160 185|protein transport pathway
P10532354A1374|195 205|alteration
P10532354A1374|217 227|morphology
P10532354A1374|243 254|yeast cells
P10532805A0792|3 13|PC12 cells
P10532805A0792|15 34|nerve growth factor
P10532805A0792|52 67|differentiation
P10532805A0792|82 92|expression
P10532805A0792|96 101|nrg-1
P10532805A1084|5 21|PC12 cell mutant
P10532805A1084|43 68|protein kinase A activity
P10532805A1084|70 72|AB
P10532805A1084|104 110|agents
P10532805A1084|140 150|nrg-1 mRNA
P10533066A0758|0 14|TSC1 mutations
P10533066A0758|36 45|mutations
P10533066A0758|52 62|insertions
P10533066A0758|74 90|splice mutations
P10533066A1197|7 15|patients
P10533066A1197|24 37|abnormalities
P10533066A1197|45 48|PTT
P10533066A1197|71 89|missense mutations
P10533066A1197|103 107|TSC2
P10534048A0297|10 19|algorithm
P10534048A0297|21 29|FOREPROJ
P10534048A0297|49 69|projection algorithm
P10534048A0297|82 93|calculation
P10534048A0297|105 135|attenuation correction factors
P10534048A0297|137 140|ACF
P10534048A0297|182 194|transmission
P10534048A0297|234 249|attenuation map
P10534048A0297|284 294|projection
P10534402A0126|15 19|cDNA
P10534402A0126|32 35|DNA
P10534402A0126|42 52|mouse gene
P10534402A0126|64 71|protein
P10534402A0126|89 108|sequence similarity
P10534402A0126|122 129|domains
P10534402A0126|139 147|proteins
P10534402A0126|155 168|Spo11p family
P10534402A0659|0 6|RT-PCR
P10534402A0659|19 41|hybridization analyses
P10534402A0659|47 58|time course
P10534402A0659|71 89|testis development
P10534402A0659|104 120|Spo11 expression
P10534402A0659|145 153|Prophase
P10534402A0659|170 185|pachytene stage
P10534402A0659|203 215|accumulation
P10534402A0659|219 223|mRNA
P10534402A0659|236 251|pachytene stage
P10534691A0542|0 7|Animals
P10534691A0542|20 25|death
P10534691A0542|28 33|weeks
P10534691A0542|48 54|grafts
P10534691A0542|111 118|culture
P10534691A0542|143 153|procedures
P10534691A0542|158 166|evidence
P10534691A0542|170 179|infection
P10535715A0268|4 7|RMR
P10535715A0268|35 40|phase
P10535715A0268|66 67|F
P10535715A0268|111 118|kJ/24 h
P10535715A0268|128 134|luteal
P10535715A0268|141 148|kJ/24 h
P10535715A0268|150 156|phases
P10536125A0093|0 11|Oseltamivir
P10536125A0093|13 19|GS4104
P10536125A0093|63 70|prodrug
P10536125A0093|74 80|GS4071
P10536125A0093|105 114|inhibitor
P10536125A0093|118 147|influenzavirus neuraminidases
P10536369A0662|3 28|gel mobility shift assays
P10536369A0662|42 50|evidence
P10536369A0662|55 85|VDR-TR heterodimer interaction
P10536369A0662|102 109|element
P10536369A1280|13 23|importance
P10536369A1280|37 47|mechanisms
P10536369A1280|62 70|response
P10536369A1280|88 94|manner
P10536788A0931|9 10|d
P10536788A0931|14 25|overfeeding
P10536788A0931|35 46|PL profiles
P10536788A0931|73 79|breeds
P10536788A0931|103 117|control livers
P10536788A0931|138 140|PL
P10536788A0931|157 158|%
P10536788A0931|168 170|PL
P10540015A0664|0 13|C-SP duration
P10540015A0664|43 55|ALS patients
P10540015A0664|68 76|controls
P10540015A0664|84 105|stimulation intensity
P10540015A0664|126 139|MEP threshold
P10540015A0664|155 156|%
P10540292A1179|6 10|data
P10540292A1179|25 44|spv virulence genes
P10540292A1179|78 86|regulons
P10540292A1179|94 98|cell
P10540292A1179|112 123|possibility
P10540292A1179|129 143|spv expression
P10540292A1179|165 173|response
P10540292A1179|200 206|inputs
P10540553A0980|10 19|synthesis
P10540553A0980|23 26|PNA
P10540553A0980|34 39|cells
P10540553A0980|57 61|wall
P10540553A0980|97 105|activity
P10540553A0980|115 124|synthesis
P10540553A0980|128 131|DNA
P10540553A0980|153 160|ability
P10540553A0980|165 178|proliferation
P10540553A0980|180 184|i.g.
P10540553A0980|190 196|growth
P10540915A0697|9 21|transsection
P10540915A0697|42 50|ligation
P10540915A0697|52 57|TL&PL
P10540915A0697|70 79|reduction
P10540915A0697|87 88|%
P10540915A0697|90 94|n.s.
P10541432A0185|17 30|erbB proteins
P10541432A0185|49 62|growth factor
P10541432A0185|64 67|EGF
P10541432A0185|77 101|tyrosine phosphorylation
P10541432A0185|116 128|Shc proteins
P10541432A0185|182 201|ERK MAPK activities
P10541432A0185|211 229|glioblastoma cells
P10541432A0185|246 265|ERK MAPK activities
P10541550A0487|6 24|immunolocalization
P10541550A0487|42 46|ACE3
P10541550A0487|57 72|chorion element
P10541550A0487|87 98|information
P10541550A0487|119 132|amplification
P10541550A0487|142 160|DmORC localization
P10541550A0487|164 178|follicle cells
P10541865A1301|22 34|co-deletions
P10541865A1301|38 44|CDKN2A
P10541865A1301|49 55|CDKN2B
P10541865A1301|68 77|mutations
P10541865A1301|99 110|transcripts
P10541865A1301|148 154|tumors
P10542237A0357|26 34|explants
P10542237A0357|64 68|mice
P10542237A0357|92 100|response
P10542237A0357|117 124|stimuli
P10542237A0357|134 152|lipopolysaccharide
P10542237A0357|154 157|LPS
P10542237A0357|189 203|IL-6 secretion
P10542249A0415|0 18|Albumin expression
P10542249A0415|40 45|liver
P10542249A0415|51 62|combination
P10542249A0415|81 102|transcription factors
P10542249A0415|111 115|CAAT
P10542249A0415|133 140|protein
P10542249A0415|142 147|C/EBP
P10542249A0415|148 153|alpha
P10542249A0415|158 167|C/EBPbeta
P10542260A0832|4 15|requirement
P10542260A0832|32 40|activity
P10542260A0832|49 54|FVIIa
P10542260A0832|59 62|FXa
P10542260A0832|96 105|receptors
P10542269A0000|0 20|Amyloid beta-protein
P10542269A0000|22 27|Abeta
P10542269A0000|41 52|constituent
P10542269A0000|56 71|amyloid fibrils
P10542269A0000|88 95|plaques
P10542269A0000|109 116|vessels
P10542269A0000|120 129|Alzheimer
P10542269A0000|132 139|disease
P10542269A0000|141 143|AD
P10542269A0000|163 174|proteolysis
P10542269A0000|184 214|beta-amyloid precursor protein
P10542269A0000|216 219|APP
P10542274A1376|18 28|activation
P10542274A1376|32 48|protein kinase A
P10542274A1376|50 53|PKA
P10542274A1376|55 64|signaling
P10542274A1376|96 125|caveolin-1 protein expression
P10542274A1376|130 147|promoter activity
P10542277A0000|4 18|importin alpha
P10542277A0000|19 35|beta heterodimer
P10542277A0000|53 59|import
P10542277A0000|63 71|proteins
P10542277A0000|101 121|localization signals
P10542281A0382|14 19|G1-G2
P10542281A0382|34 44|hyaluronan
P10542281A0382|49 61|link protein
P10542281A0382|102 107|motif
P10542281A0382|112 124|proteoglycan
P10542281A0382|132 144|repeat loops
P10542281A0382|152 161|G1 domain
P10542281A2021|4 11|results
P10542281A2021|29 37|presence
P10542281A2021|41 48|absence
P10542281A2021|59 74|keratan sulfate
P10542281A2021|85 90|G1-G2
P10542281A2021|111 119|activity
P10542281A2021|123 134|atrolysin C
P10542281A2021|150 155|sites
P10543270A1054|8 28|i.v. steroid therapy
P10543270A1054|31 36|NOexh
P10543270A1054|67 75|recovery
P10543270A1054|88 91|ppb
P10543270A1054|93 94|p
P10543270A1054|108 117|discharge
P10543270A1054|130 133|ppb
P10543270A1054|135 136|p
P10543727A0282|20 25|sites
P10543727A0282|38 59|transcription factors
P10543727A0282|65 72|example
P10543727A0282|99 111|binding site
P10543727A0282|116 151|rel/NF-kappaB transcription factors
P10543727A0282|162 165|end
P10543727A0282|171 176|H2TF1
P10543727A0282|180 195|kappaB1 element
P10543727A0282|212 223|kappaB site
P10543727A0282|229 244|kappaB2 element
P10543727A0282|295 308|H2TF1 element
P10543727A0282|336 344|p65/relA
P10543727A0282|358 368|HLA system
P10543727A0282|383 387|AP-1
P10543727A0282|388 412|ATF recognition sequence
P10543727A0282|423 426|end
P10543727A0282|428 435|EnA-TRE
P10543728A0358|16 19|E1A
P10543728A0358|22 35|cHa-ras cells
P10543728A0358|79 101|DNA binding activities
P10543728A0358|105 109|AP-1
P10543728A0358|114 122|contrast
P10543728A0358|141 146|cells
P10543728A0358|155 164|E1A cells
P10543730A0000|4 9|yeast
P10543730A0000|17 36|cyclin Ume3p/Srb11p
P10543730A0000|62 68|kinase
P10543730A0000|70 73|Cdk
P10543730A0000|75 80|Ume5p
P10543730A0000|107 117|repression
P10543730A0000|121 126|genes
P10543730A0000|143 158|stress response
P10543730A0000|162 169|meiosis
P10543949A0686|19 21|S1
P10543949A0686|23 39|specificity site
P10543949A0686|73 79|cavity
P10544037A0617|0 4|FZD4
P10544037A0617|22 26|FZD9
P10544037A0617|31 36|FZD10
P10544037A0617|50 69|amino acid identity
P10544037A0617|85 89|FZD4
P10544037A0617|93 97|FZD9
P10544037A0617|103 104|%
P10544037A0617|106 110|FZD4
P10544037A0617|114 119|FZD10
P10544037A0617|125 126|%
P10544037A0617|128 132|FZD9
P10544037A0617|136 141|FZD10
P10544037A0617|147 148|%
P10544088A0308|4 13|NF-kappaB
P10544088A0308|25 43|reporter construct
P10544088A0308|46 51|PRDII
P10544088A0308|56 59|CAT
P10544088A0308|81 94|transcription
P10544088A0308|110 119|NF-kappaB
P10544088A0308|133 136|Tat
P10544089A1208|4 19|RNA transcripts
P10544089A1208|52 58|sgRNAs
P10544089A1208|62 68|TMV U1
P10544089A1208|73 78|crTMV
P10544089A1208|97 114|hairpin structure
P10544089A1208|116 117|H
P10544089A1208|143 147|IRES
P10544089A1208|148 150|MP
P10544089A1208|162 164|MP
P10544089A1208|172 174|CR
P10544089A1208|176 183|MP-CP-3
P10544089A1208|184 187|UTR
P10544089A1208|195 197|MP
P10544089A1208|202 204|U1
P10544089A1208|206 213|MP-CP-3
P10544089A1208|214 217|UTR
P10544089A1208|245 252|MP gene
P10544113A0293|0 29|EIAV LTR sequence variability
P10544113A0293|60 67|portion
P10544113A0293|75 83|enhancer
P10544113A0293|95 105|U3 segment
P10544113A0293|113 116|LTR
P10545192T0000|0 41|Phosphatidylinositol 3-kinase requirement
P10545192T0000|45 55|activation
P10545192T0000|63 72|ras/C-raf
P10545192T0000|75 82|MEK/ERK
P10545192T0000|87 90|p70
P10545192T0000|91 94|s6k
P10545192T0000|96 113|signaling cascade
P10545192T0000|137 158|agent vanadyl sulfate
P10545248A0567|4 8|core
P10545248A0567|17 25|enhancer
P10545248A0567|64 77|binding sites
P10545248A0567|86 112|homeodomain protein Tinman
P10545248A0567|114 117|Tin
P10545248A0567|175 190|muscle lineages
P10545281A0836|4 11|example
P10545281A0836|13 25|introduction
P10545281A0836|45 71|purification tag sequences
P10545281A0836|92 105|coding region
P10545281A0836|130 143|bop gene mRNA
P10545281A0836|148 168|protein accumulation
P10548434A1549|26 33|ability
P10548434A1549|37 44|polyoma
P10548434A1549|52 62|T antigens
P10548434A1549|96 111|differentiation
P10548434A1549|131 134|ERK
P10548434A1549|144 151|JNK/SPK
P10548434A1549|155 168|p38 signaling
P10548622A0906|31 36|block
P10548622A0906|42 52|lignocaine
P10548622A0906|71 82|conjunction
P10548622A0906|88 111|i.v. sedation/analgesia
P10548622A0906|119 133|egg collection
P10548622A0906|169 174|route
P10548622A0906|181 200|ultrasound guidance
P10548622A0906|202 207|TUGOR
P10548622A0906|223 227|pain
P10548622A0906|235 244|procedure
P10548722A0099|4 8|loci
P10548722A0099|24 36|organization
P10548722A0099|49 53|H1.8
P10548722A0099|71 85|TcP2beta genes
P10548722A0099|141 149|sequence
P10548722A0099|157 161|SIRE
P10548722A0099|193 200|element
P10548722A0099|245 249|gene
P10549354A1782|2 12|proportion
P10549354A1782|16 19|APC
P10549354A1782|30 46|colon carcinomas
P10549354A1782|51 60|melanomas
P10549354A1782|96 101|Tcf-4
P10549354A1782|102 124|beta-catenin complexes
P10549354A1782|130 136|result
P10549354A1782|149 158|mutations
P10549354A1782|166 176|N terminus
P10549354A1782|180 192|beta-catenin
P10549354A1782|223 237|downregulation
P10549354A1782|241 244|APC
P10549354A1782|246 255|GSK3 beta
P10549354A1782|261 275|Axin/Conductin
P10549354A2371|8 18|mechanisms
P10549354A2371|30 42|deregulation
P10549354A2371|46 70|Tcf target gene activity
P10549354A2371|100 108|melanoma
P10549354A2371|119 124|forms
P10549354A2371|128 134|cancer
P10549912A0136|5 11|report
P10549912A0136|24 31|patient
P10549912A0136|74 84|infarction
P10549912A0136|117 127|infarction
P10549912A0136|154 158|lead
P10549912A0136|162 179|segment elevation
P10549912A0136|181 186|V1-V4
P10549912A0136|202 206|loss
P10549912A0136|238 246|branches
P10549912A0136|265 276|angioplasty
P10549912A0136|299 305|artery
P10550139A0191|0 8|PATIENTS
P10550139A0191|13 20|METHODS
P10550139A0191|49 62|prostatectomy
P10550139A0191|64 85|bone marrow aspirates
P10550139A0191|96 101|sides
P10550139A0191|115 120|crest
P10550139A0191|141 149|patients
P10550571A0000|0 7|PURPOSE
P10550571A0000|18 25|WR-2721
P10550571A0000|48 55|studies
P10550571A0000|72 85|plasma levels
P10550571A0000|89 97|patients
P10550571A0000|123 132|compounds
P10550571A0000|138 142|none
P10550571A0000|156 163|effects
P10550571A0000|167 174|WR-2721
P10550571A0000|189 195|thiols
P10550574A1038|5 11|regard
P10550574A1038|30 40|toxicities
P10550574A1038|42 50|diarrhea
P10550574A1038|52 61|infection
P10550574A1038|75 101|serum alkaline phosphatase
P10550574A1038|105 110|grade
P10550574A1038|139 140|%
P10550574A1038|144 150|cycles
P10551788A0229|0 6|LHbeta
P10551788A0229|33 50|gonadotrope cells
P10551788A0229|55 61|CGbeta
P10551788A0229|88 105|trophoblast cells
P10551796T0000|0 10|Regulation
P10551796T0000|14 33|HIV-1 transcription
P10551816A0162|6 12|LTBP-1
P10551816A0162|44 49|forms
P10551848A0000|14 19|study
P10551848A0000|21 27|Kimura
P10551848A0000|29 31|Y.
P10551848A0000|33 45|Kurzydlowski
P10551848A0000|47 49|K.
P10551848A0000|51 55|Tada
P10551848A0000|57 59|M.
P10551848A0000|65 74|MacLennan
P10551848A0000|76 78|D.
P10551867A0350|20 39|amino acid residues
P10551867A0350|53 73|9-kilobase pair mRNA
P10551867A0350|83 98|splice variants
P10551867A0350|131 149|rat cDNA libraries
P10551879T0000|21 43|protein kinase binding
P10551879T0000|47 74|A-kinase anchoring proteins
P10551879T0000|78 90|living cells
P10551879T0000|94 132|fluorescence resonance energy transfer
P10551879T0000|154 177|protein fusion proteins
P10552357A1936|0 11|CONCLUSIONS
P10552357A1936|16 24|addition
P10552357A1936|32 43|superiority
P10552357A1936|72 84|microspheres
P10552357A1936|99 111|microspheres
P10552357A1936|116 132|LV opacification
P10552357A1936|138 146|efficacy
P10552357A1936|150 154|OCTA
P10552357A1936|192 203|LV function
P10552357A1936|235 242|effects
P10552357A1936|251 263|echogenicity
P10552357A1936|269 272|AIR
P10553551A0000|0 20|Factor XI deficiency
P10553551A0000|51 59|disorder
P10553551A0000|84 91|pathway
P10553959A0812|4 19|Ishasha samples
P10553959A0812|27 32|range
P10553959A0812|60 66|levels
P10554946A0082|21 26|SERMS
P10554946A0082|28 46|clomiphene citrate
P10554946A0082|51 60|tamoxifen
P10554946A0082|102 107|drugs
P10554946A0082|111 121|raloxifene
P10554946A0082|126 134|faslodex
P10554946A0082|141 149|emphasis
P10554946A0082|161 168|actions
P10554946A0082|172 178|breast
P10554946A0082|180 186|uterus
P10554946A0082|188 192|bone
P10554946A0082|197 203|lipids
P10555079A0254|0 2|Ti
P10555079A0254|28 38|morphology
P10555285A1065|5 17|organization
P10555285A1065|32 50|duplication events
P10555285A1065|83 105|FUT3-FUT5-FUT6 cluster
P10555285A1065|176 185|mechanism
P10555285A1065|233 247|globin cluster
P10555964A0778|0 2|S.
P10555964A0778|4 7|Kim
P10555964A0778|9 11|S.
P10556028A0292|4 14|cop region
P10556028A0292|30 36|region
P10556028A0292|40 63|plasmid incompatibility
P10556028A0292|65 68|inc
P10556028A0292|95 104|structure
P10556028A0292|110 123|repA promoter
P10556028A0292|125 129|Prep
P10556028A0292|155 173|RepA binding sites
P10556028A0292|175 179|BD-1
P10556028A0292|184 188|BD-2
P10556029A0852|0 13|WA constructs
P10556029A0852|44 55|topoisomers
P10556029A0852|61 81|cyclization kinetics
P10556029A0852|97 112|interconversion
P10556029A0852|116 126|precursors
P10556029A0852|138 149|topoisomers
P10556033A0000|4 22|RFX protein family
P10556033A0000|32 39|members
P10556033A0000|45 50|yeast
P10556033A0000|54 60|humans
P10556033A0000|99 106|systems
P10556033A0000|132 138|domain
P10556033A0000|166 172|region
P10556044A0913|0 7|Binding
P10556044A0913|11 22|sulphatides
P10556044A0913|31 58|alpha-dystroglycan receptor
P10556044A0913|103 113|LG modules
P10556046A0328|62 79|signaling pathway
P10556046A0328|103 107|side
P10556046A0328|115 129|Xenopus embryo
P10556063A0092|6 13|kinases
P10556063A0092|30 39|subfamily
P10556063A0092|55 68|Trk subfamily
P10556089A0901|4 8|data
P10556089A0901|23 28|etr-1
P10556089A0901|46 64|muscle development
P10556089A0901|68 78|C. elegans
P10556089A0901|101 105|role
P10556089A0901|130 140|processing
P10556089A0901|149 165|muscle component
P10556089A0901|198 210|conservation
P10556089A0901|214 227|gene function
P10556089A0901|239 245|CUG-bp
P10556145A1034|0 10|Gentamicin
P10556145A1034|20 23|DPI
P10556145A1034|28 31|SVN
P10556145A1034|60 78|sputum Psa density
P10556145A1034|80 81|p
P10556145A1034|105 110|order
P10556145A1034|114 123|magnitude
P10556263A1035|0 11|CONCLUSIONS
P10556263A1035|25 30|value
P10556263A1035|44 49|space
P10556263A1035|89 91|AC
P10556263A1035|98 103|space
P10556595A0391|3 11|analysis
P10556595A0391|15 23|sequence
P10556595A0391|38 47|recN gene
P10556595A0391|59 60|G
P10556595A0391|61 62|C
P10556595A0391|66 67|T
P10556595A0391|70 82|transversion
P10556595A0391|95 98|end
P10556595A0391|113 119|region
P10556751A0758|17 21|view
P10556751A0758|39 57|transmission rates
P10556751A0758|61 64|HGV
P10556751A0758|73 77|lack
P10556751A0758|91 103|immunization
P10556751A0758|105 108|HGV
P10556751A0758|156 162|hazard
P10556751A0758|186 191|staff
P10557008T0000|0 9|Detection
P10557008T0000|13 22|poisoning
P10557008T0000|26 32|Impila
P10557008T0000|60 66|mother
P10557008T0000|71 76|child
P10557072A0127|30 35|mouse
P10557072A0127|46 51|cDNAs
P10557072A0127|73 79|kinase
P10557072A0127|81 85|ULK1
P10557072A0418|0 4|ULKs
P10557072A0418|9 15|UNC-51
P10557072A0418|32 48|domain structure
P10557072A0418|70 83|kinase domain
P10557072A0418|95 109|proline/serine
P10557072A0418|116 118|PS
P10557072A0418|120 126|domain
P10557072A0418|152 153|C
P10557072A0418|155 161|domain
P10557072A1218|6 13|results
P10557072A1218|27 31|ULK2
P10557072A1218|76 93|signaling pathway
P10557072A1218|107 112|cells
P10557308A0000|0 18|Connector enhancer
P10557308A0000|22 25|KSR
P10557308A0000|27 30|CNK
P10557308A0000|49 56|protein
P10557308A0000|70 83|RAS signaling
P10559207A0207|11 20|organisms
P10559207A0207|26 41|ATP sulfurylase
P10559207A0207|46 66|APS kinase reactions
P10559207A0207|93 100|enzymes
P10559207A0207|125 130|genes
P10559207A0207|150 156|fusion
P10559207A0207|169 174|genes
P10559207A0207|186 192|course
P10559207A0207|196 205|evolution
P10559207A0207|233 239|enzyme
P10559303A0000|13 18|virus
P10559303A0000|20 23|EBV
P10559303A0000|32 48|membrane protein
P10559303A0000|52 56|LMP1
P10559303A0000|88 102|transformation
P10559303A0000|114 127|B lymphocytes
P10559320A0080|19 23|half
P10559320A0080|27 29|1a
P10559320A0080|43 50|homolog
P10559320A0080|54 64|alphavirus
P10559320A0080|79 91|protein nsP1
P10559320A0080|136 140|RNAs
P10559324A0716|24 26|Ad
P10559324A0716|38 50|Ad5 E4orf6/7
P10559324A0716|59 68|apoptosis
P10559324A0716|72 81|rat cells
P10559324A0716|128 130|Ad
P10559364A0846|3 7|HCMV
P10559364A0846|8 13|Towne
P10559364A0846|24 32|HF cells
P10559364A0846|45 46|h
P10559364A0846|48 51|IE2
P10559364A0846|91 119|DNA replication compartments
P10559364A0846|135 165|polymerase processivity factor
P10559364A0846|167 171|UL44
P10559364A0846|194 213|DNA binding protein
P10559364A0846|215 218|SSB
P10559364A0846|220 224|UL57
P10559364A0846|231 258|UL112-113 accessory protein
P10559364A0846|283 300|bromodeoxyuridine
P10559364A0846|302 306|BrdU
P10560014A0000|26 47|heart vascularization
P10560014A0000|72 89|angioarchitecture
P10560014A0000|108 114|system
P10560014A0000|147 157|myocardium
P10560997A1072|0 10|CONCLUSION
P10560997A1072|11 12|S
P10560997A1072|33 42|LH levels
P10560997A1072|59 65|method
P10560997A1072|82 91|ovulation
P10561095A2141|9 20|reoperation
P10561095A2141|40 47|disease
P10561095A2141|49 54|group
P10561095A2141|83 100|calcitonin levels
P10561095A2141|131 140|incidence
P10561095A2141|154 172|hypoparathyroidism
P10561153A0225|13 17|case
P10561153A0225|21 30|carcinoma
P10561153A0225|38 44|breast
P10561153A0225|74 77|SSc
P10561153A0225|135 142|failure
P10561153A0225|153 158|month
P10561251A0000|0 7|PURPOSE
P10561251A0000|38 46|survival
P10561251A0000|48 51|DFS
P10561251A0000|65 73|survival
P10561251A0000|75 77|OS
P10561251A0000|91 98|factors
P10561251A0000|122 131|mortality
P10561251A0000|135 140|women
P10561251A0000|146 156|stage IIIB
P10561251A0000|170 183|breast cancer
P10561251A0000|185 188|IBC
P10561251A0000|212 228|modality therapy
P10561251A0000|230 233|CMT
P10561251A0000|249 261|chemotherapy
P10561251A0000|263 267|HDCT
P10561251A0000|285 310|stem-cell transplantation
P10561460A0615|4 21|GPI anchor moiety
P10561460A0615|64 69|level
P10561460A0615|77 88|polypeptide
P10561460A0615|108 112|cDNA
P10561460A0615|137 151|signal peptide
P10561460A0615|156 176|GPI signal sequences
P10561546A0000|41 48|protein
P10561546A0000|90 98|antibody
P10561546A0000|137 156|localization signal
P10561546A0000|160 181|NF-kappaB p65 subunit
P10562418A0238|18 24|events
P10562418A0238|48 53|cells
P10562456T0000|11 18|regions
P10562456T0000|26 34|promoter
P10562456T0000|45 51|intron
P10562456T0000|59 78|growth hormone gene
P10562456T0000|82 95|rainbow trout
P10562456T0000|97 109|Oncorhynchus
P10562456T0000|117 124|walbaum
P10562495A0188|14 23|SFV genes
P10562495A0188|29 37|homologs
P10562495A0188|55 71|Chordopoxvirinae
P10562495A0188|77 87|SFV genome
P10562495A0188|100 104|gene
P10562495A0188|122 132|production
P10562495A0188|160 165|virus
P10563212A0514|24 43|SF-36 questionnaire
P10563212A0514|54 57|QoL
P10563212A0514|123 131|controls
P10563605A0773|12 17|trend
P10563605A0773|28 39|association
P10563605A0773|48 52|IENF
P10563605A0773|63 68|nerve
P10563605A0773|82 97|fiber densities
P10563605A0773|99 100|r
P10563605A0773|109 110|p
P10563789A1951|3 11|addition
P10563789A1951|13 18|media
P10563789A1951|30 50|F beta alpha/CG beta
P10563789A1951|91 93|CG
P10563789A1951|98 111|FSH receptors
P10563836A1234|3 11|contrast
P10563836A1234|13 34|AP-2 binding activity
P10563836A1234|64 74|T47D cells
P10563836A1234|80 93|Western blots
P10563836A1234|114 133|AP-2 protein levels
P10563836A1234|143 148|cells
P10564231A0315|0 11|N. van Hoek
P10564231A0315|17 19|M.
P10564280A0140|52 59|protein
P10564280A0140|61 68|YT521-B
P10564280A0140|131 169|component scaffold attachment factor B
P10564280A0140|186 199|Src substrate
P10564280A0140|218 225|mitosis
P10564280A0140|227 232|Sam68
P10564472A0853|6 13|mutants
P10564472A0853|46 57|TraR fusion
P10564472A0853|76 82|system
P10564474T0000|10 20|homologues
P10564474T0000|56 66|expression
P10564474T0000|74 101|outer-membrane protein OprH
P10564474T0000|106 128|polymyxin B resistance
P10564479A0384|0 8|Deletion
P10564479A0384|12 16|fdsR
P10564479A0384|44 50|effect
P10564479A0384|54 58|FdsR
P10564479A0384|66 76|fds operon
P10564479A0384|106 115|activator
P10564479A0384|123 131|presence
P10564479A0384|135 142|formate
P10564479A0384|149 158|repressor
P10564479A0384|166 173|absence
P10564479A0384|177 184|formate
P10564484A0859|5 15|constructs
P10564484A0859|31 43|binding site
P10564484A0859|51 55|gene
P10564484A0859|69 77|promoter
P10564484A0859|128 140|requirements
P10564484A0859|147 155|function
P10564484A0859|180 184|site
P10564484A0859|194 202|promoter
P10564495A0444|3 11|addition
P10564495A0444|23 35|Opa proteins
P10564495A0444|39 43|C751
P10564495A0444|65 75|HeLa cells
P10564495A0444|93 97|cDNA
P10564495A0444|128 135|antigen
P10564495A0444|137 140|CEA
P10564495A0444|142 147|CD66e
P10564495A0444|150 158|subgroup
P10564495A0444|166 177|CD66 family
P10564495A0444|197 204|tropism
P10564495A0444|209 213|CGM1
P10564495A0444|216 221|CD66d
P10564495A0444|227 230|NCA
P10564495A0444|232 237|CD66c
P10564495A0444|250 255|cells
P10564593A0428|0 4|FISH
P10564593A0428|19 29|chromosome
P10564593A0428|32 37|paint
P10564593A0428|60 74|rearrangements
P10564593A0428|85 95|chromosome
P10564593A0428|101 115|MCF-7 AdVp3000
P10564593A0428|120 128|MCF-7 MX
P10564593A0428|136 144|S1-M1-80
P10564593A0428|180 193|translocation
P10564593A1618|4 12|MXR gene
P10564593A1618|23 39|half-transporter
P10564593A1618|48 55|absence
P10564593A1618|71 79|evidence
P10564593A1618|83 98|coamplification
P10564593A1618|108 115|regions
P10564593A1618|132 139|partner
P10564593A1618|182 202|MXR half-transporter
P10564593A1618|228 242|drug transport
P10564939A0981|4 10|effect
P10564939A0981|14 21|smoking
P10564939A0981|47 52|study
P10564939A0981|62 66|data
P10566630A0371|0 5|Serum
P10566630A0371|19 34|growth factor I
P10566630A0371|36 41|IGF-I
P10566630A0371|43 51|SD score
P10566630A0371|84 87|men
P10566630A0371|92 97|women
P10566630A0371|134 140|months
P10566630A0371|164 170|months
P10566862A0000|0 10|BACKGROUND
P10566862A0000|12 23|Measurement
P10566862A0000|27 39|stereoacuity
P10566862A0000|51 60|distances
P10566862A0000|83 107|depth stereoacuity tests
P10566862A0000|127 137|evaluation
P10566862A0000|141 149|patients
P10566862A0000|165 174|imbalance
P10566862A0000|178 188|strabismus
P10567430A0785|11 18|studies
P10567430A0785|40 52|brain Galpha
P10567430A0785|53 57|q/11
P10567430A0785|92 101|construct
P10567430A0785|105 109|GRK2
P10567430A0785|120 127|binding
P10567430A0785|131 137|Galpha
P10567430A0785|138 142|q/11
P10567430A0785|145 151|Galpha
P10567430A0785|152 153|s
P10567430A0785|156 162|Galpha
P10567430A0785|170 176|Galpha
P10567430A0785|198 208|constructs
P10567430A0785|212 216|GRK5
P10567430A0785|220 224|GRK6
P10567524T0000|4 25|elm1 kinase functions
P10567524T0000|39 56|signaling network
P10567524T0000|68 73|yeast
P10567533A0818|8 21|transcription
P10567533A0818|23 25|RT
P10567533A0818|27 39|PCR products
P10567533A0818|77 84|primers
P10567533A0818|112 118|motifs
P10567533A0818|130 146|tyrosine kinases
P10567538A1028|3 11|addition
P10567538A1028|17 43|acetyltransferase activity
P10567538A1028|47 51|p300
P10567538A1028|107 126|activation function
P10567538A1028|134 137|CH3
P10567538A1028|157 163|region
P10567581A0119|27 32|HNF-3
P10567581A0119|33 62|fork head homolog-11B protein
P10567581A0119|64 71|HFH-11B
P10567581A0119|87 94|Trident
P10567581A0119|99 102|Win
P10567581A0119|109 122|family member
P10567581A0119|148 174|head transcription factors
P10567581A0119|195 200|liver
P10567581A0119|205 215|expression
P10567581A0119|240 256|hepatocyte entry
P10567581A0119|262 277|DNA replication
P10567581A0119|279 286|S phase
P10567582A1334|7 12|mouse
P10567582A1334|14 19|CtBP1
P10567582A1334|38 44|embryo
P10567582A1334|59 64|CtBP2
P10567582A1334|92 105|embryogenesis
P10567589A1268|13 22|functions
P10567589A1268|26 31|Pmt3p
P10567589A1268|76 84|proteins
P10567589A1268|102 119|Pmt3p conjugation
P10568275A0679|4 8|role
P10568275A0679|12 21|transport
P10568275A0679|25 32|sea ice
P10568275A0679|42 50|Kara Sea
P10568275A0679|60 72|Arctic Ocean
P10568275A0679|97 105|subgroup
P10568275A0679|109 115|GEOMAR
P10568455A0000|31 40|injection
P10568455A0000|44 73|slow-release estradiol-17beta
P10568455A0000|75 79|SRE2
P10568455A0000|94 109|pseudopregnancy
P10568455A0000|113 118|gilts
P10568455A0000|131 140|PGF2alpha
P10568455A0000|159 172|corpora lutea
P10568455A0000|174 176|CL
P10568455A0000|181 196|pseudopregnancy
P10568728A1445|4 9|level
P10568728A1445|13 34|serum creatine kinase
P10568728A1445|60 64|days
P10568728A1445|71 76|ESWIB
P10568728A1445|100 104|week
P10568744A0728|23 28|sites
P10568744A0728|45 54|promoters
P10568744A0728|79 84|genes
P10568744A0728|99 104|sites
P10568744A0728|135 139|role
P10568744A0728|159 168|direction
P10568744A0728|172 193|mating type switching
P10570262A0000|0 10|Activation
P10570262A0000|14 21|T cells
P10570262A0000|30 33|TCR
P10570262A0000|58 67|receptors
P10570262A0000|79 85|number
P10570262A0000|89 107|signaling cascades
P10570996A1213|15 23|analysis
P10570996A1213|33 43|TK domains
P10570996A1213|55 64|sequences
P10570996A1213|92 105|scavenger RTK
P10570996A1213|111 118|domains
P10570996A1213|132 141|signature
P10570996A1213|150 158|TK class
P10570996A1213|162 171|receptors
P10570996A1213|220 227|insulin
P10570996A1213|245 254|receptors
P10571047A1009|8 11|7SL
P10571047A1009|25 34|sequences
P10571047A1009|58 65|spacers
P10571047A1009|101 118|HindIII fragments
P10571047A1009|140 142|kb
P10571474A0571|0 7|Results
P10571474A0571|23 29|stress
P10571474A0571|39 42|CA3
P10571474A0571|53 60|atrophy
P10571474A0571|65 75|tianeptine
P10572087A0326|19 34|binding partner
P10572087A0326|51 73|anemia group C protein
P10572087A0326|75 80|FANCC
P10572087A0326|85 90|yeast
P10572087A0326|102 111|screening
P10572130A1623|6 13|results
P10572130A1623|32 56|transcription activators
P10572130A1623|94 102|subunits
P10572130A1623|106 120|RNA polymerase
P10572130A1623|137 141|role
P10572130A1623|145 154|formation
P10572130A1623|165 177|DNA geometry
P10572131A0000|0 18|Klebsiella oxytoca
P10572131A0000|63 70|enzymes
P10572131A0000|86 102|nasFEDCBA operon
P10572866A0481|7 16|hemolysis
P10572866A0481|41 54|plasma values
P10572866A0481|58 67|potassium
P10572866A0481|69 79|phosphorus
P10572866A0481|87 94|protein
P10572866A0481|100 126|aspartate aminotransferase
P10573781A0631|0 7|Studies
P10573781A0631|31 42|involvement
P10573781A0631|55 59|loci
P10573781A0631|71 82|chromosomes
P10573781A0631|87 93|excess
P10573781A0631|100 111|chromosomes
P10574913A1108|38 62|receptor phosphorylation
P10574913A1108|87 96|processes
P10574913A1108|105 120|Src recruitment
P10574913A1108|143 158|internalization
P10574913A1108|197 211|ERK activation
P10574913A1108|251 265|ERK activation
P10574929A0583|21 34|fractionation
P10574929A0583|47 61|P-CIP2 protein
P10574982A1075|0 16|Supershift EMSAs
P10574982A1075|54 62|factor-1
P10574982A1075|71 76|USF-1
P10574982A1075|90 94|part
P10574982A1075|104 113|complexes
P10574992A0901|12 23|E1A binding
P10574992A0901|32 40|p300/CBP
P10574992A0901|55 63|increase
P10574992A0901|67 87|PARP enzyme activity
P10574992A0901|108 133|cell death susceptibility
P10574992A0901|137 148|irradiation
P10574992A0901|191 231|PARP chemical inhibitor 3-aminobenzamide
P10575231A0355|0 8|Analysis
P10575231A0355|24 30|region
P10575231A0355|55 64|Cdc6 gene
P10575231A0355|84 89|exons
P10575231A0355|96 103|introns
P10575545A0147|18 23|CACCC
P10575545A0147|28 39|CAAT motifs
P10575642T0000|0 15|Skin pH changes
P10575642T0000|32 45|iontophoresis
P10576177A0308|5 16|distinction
P10576177A0308|44 53|diagnosis
P10576177A0308|81 86|range
P10576177A0308|90 99|prognoses
P10576177A0308|125 136|implication
P10576545A0926|4 16|availability
P10576545A0926|38 51|DNA cassettes
P10576545A0926|73 90|D1A gene promoter
P10576545A0926|131 141|expression
P10576545A0926|145 155|transgenes
P10578528A0730|23 31|location
P10578528A0730|37 42|focus
P10578528A0730|57 60|EEG
P10578528A0730|80 89|character
P10578528A0730|94 107|manifestation
P10578528A0730|145 159|symptomatology
P10579331A1225|4 11|results
P10579331A1225|21 28|studies
P10579331A1225|50 81|rat HDL receptor SR-BI promoter
P10579331A1225|95 119|sterol response elements
P10579331A1225|121 125|pSRE
P10579331A1225|130 134|dSRE
P10579331A1225|150 158|SREBP-1a
P10579331A1225|181 194|transcription
P10579331A1225|203 207|gene
P10579722T0000|0 15|Phosphorylation
P10579722T0000|34 41|subunit
P10579722T0000|43 46|MBS
P10579722T0000|51 69|myosin phosphatase
P10579722T0000|73 83|Rho-kinase
P10580071A0436|9 17|patients
P10580071A0436|51 55|list
P10580071A0436|60 75|transplantation
P10580071A0436|119 129|transplant
P10580438A0508|19 39|mobility shift assay
P10580438A0508|41 45|EMSA
P10580438A0508|53 76|GLUT4 repressor element
P10580438A0508|78 82|G4RE
P10580438A0508|103 108|bands
P10580438A0508|122 130|extracts
P10580438A0508|136 149|preadipocytes
P10580438A0508|164 174|adipocytes
P10582831T0000|0 9|Syndromes
P10582831T0000|26 40|redistribution
P10582831T0000|55 68|complications
P10582831T0000|85 93|patients
P10584138T0001|0 14|Cytoprotection
P10584138T0001|20 30|amifostine
P10584138T0001|34 46|radiotherapy
P10584138T0001|50 68|radio-chemotherapy
P10584138T0001|72 76|head
P10584138T0001|81 92|neck tumors
P10584704A0913|20 28|staining
P10584704A0913|46 51|S-100
P10584704A0913|61 66|cases
P10584704A0913|89 95|HMB-45
P10584704A0913|104 105|%
P10584704A0913|131 142|cytokeratin
P10584704A0913|152 157|cases
P10584704A0913|174 182|melanoma
P10584704A0913|199 204|block
P10584704A0913|220 228|sections
P10585311A0494|0 8|Patients
P10585311A0494|14 19|types
P10585311A0494|30 34|MPGN
P10585311A0494|53 56|age
P10585311A0494|69 74|onset
P10585311A0494|76 79|age
P10585311A0494|83 92|diagnosis
P10585311A0494|97 105|interval
P10585311A0494|120 125|onset
P10585311A0494|129 137|symptoms
P10585311A0494|141 150|diagnosis
P10585311A0494|152 158|biopsy
P10585311A1542|17 30|abnormalities
P10585311A1542|67 75|patients
P10585311A1542|81 85|type
P10585311A1542|95 99|type
P10585311A1542|102 106|MPGN
P10585417A1412|16 27|differences
P10585417A1412|31 40|signaling
P10585417A1412|45 62|tissue expression
P10585417A1412|99 103|PRLr
P10585417A1412|126 130|PRLr
P10585417A1412|148 156|function
P10585440A0204|43 56|FAK homologue
P10585440A0204|58 64|DFak56
P10585440A0204|80 88|band 56D
P10585440A0204|102 105|arm
P10585440A0204|120 130|chromosome
P10585453A1029|12 23|Pit-1 sites
P10585453A1029|31 50|hGH-N gene promoter
P10585453A1029|77 92|gene activation
P10585453A1029|108 112|data
P10585453A1029|165 169|role
P10585453A1029|174 179|Pit-1
P10585453A1029|187 194|hGH LCR
P10585463A0859|12 32|prenylcysteine lyase
P10585463A0859|51 84|baculovirus-Sf9 expression system
P10585480A0157|28 38|SH3 domain
P10585480A0157|48 51|Sos
P10585480A0157|55 89|guanine nucleotide exchange factor
P10585480A0157|94 97|Ras
P10585480A0157|102 105|Rac
P10585480A0265|0 15|Point mutations
P10585480A0265|29 39|SH3 domain
P10585480A0265|66 77|interaction
P10585491A0945|3 28|gel mobility shift assays
P10585491A0945|34 50|binding activity
P10585491A0945|54 57|CBF
P10585491A0945|75 97|AtpC promoter sequence
P10585491A0945|124 132|extracts
P10585491A0945|138 144|tissue
P10585491A0945|154 176|AtpC expression levels
P10585491A0945|183 191|extracts
P10585491A0945|225 234|seedlings
P10585491A0945|249 265|binding activity
P10585491A0945|286 294|extracts
P10585491A0945|300 307|tissues
P10585491A0945|318 340|AtpC expression levels
P10585491A0945|347 355|extracts
P10585491A0945|373 382|seedlings
P10585491A0945|397 406|seedlings
P10585491A0945|420 429|cytokinin
P10585808A0000|0 29|Mycoplasma hominis infections
P10585808A0000|69 76|methods
P10585808A0000|91 100|detection
P10586074A0129|9 16|purpose
P10586074A0129|28 34|series
P10586074A0129|38 56|plasmid constructs
P10586074A0129|76 81|forms
P10586074A0129|89 112|envelope glycoprotein E
P10586074A0129|120 130|flavivirus
P10586074A0129|142 160|encephalitis virus
P10586107A0160|29 34|types
P10586107A0160|49 70|transduction pathways
P10586107A0160|85 107|cell surface receptors
P10586115A0477|54 63|cytokines
P10586115A0477|74 83|IL-1alpha
P10586115A0477|85 93|IL-1beta
P10586115A0477|95 104|TNF-alpha
P10586115A0477|109 113|IL-6
P10586115A0477|120 124|IL-6
P10586115A0477|155 161|PKCeta
P10586115A0477|174 179|cells
P10586115A0477|203 210|inducer
P10586115A0477|233 241|cultures
P10586115A0477|245 250|% FCS
P10586626A0607|14 22|diseases
P10586626A0607|42 48|matter
P10586626A0607|90 98|presence
P10586626A0607|123 134|involvement
P10586626A0607|138 146|patients
P10586626A0607|152 156|ADEM
P10587460A0302|22 41|VDRE binding domain
P10587460A0302|52 55|VDR
P10587460A0302|57 61|hVDR
P10587460A0302|66 72|series
P10587460A0302|99 111|hVDR mutants
P10587460A0302|113 121|Delta134
P10587460A0302|123 131|Delta113
P10587460A0302|133 141|Delta102
P10587460A0302|143 150|Delta90
P10587460A0302|152 159|Delta84
P10587460A0302|161 168|Delta80
P10587460A0302|174 181|Delta60
P10587460A0302|214 222|bacteria
P10587461A0341|18 27|mechanism
P10587461A0341|29 37|contacts
P10587461A0341|47 56|anticodon
P10587461A0341|70 79|formation
P10587461A0341|92 108|transition state
P10587461A0341|114 118|site
P10587576A0596|6 10|REPs
P10587576A0596|15 23|clusters
P10587576A0596|38 42|loci
P10587576A0596|55 57|kb
P10587576A0596|62 68|harbor
P10587576A0596|83 87|ESTs
P10587576A0596|105 121|SH3GL pseudogene
P10588946A0432|16 23|minimum
P10588946A0432|50 58|proteins
P10588946A0432|71 76|ORP-1
P10588946A0432|80 85|ORP-6
P10589562A1208|3 7|part
P10589562A1208|13 19|result
P10589562A1208|27 36|inability
P10589562A1208|69 81|BB resonator
P10589562A1208|100 121|RF power requirements
P10589711A1228|3 11|addition
P10589711A1228|13 28|narZ expression
P10589711A1228|82 93|Madin-Darby
P10589711A1228|101 107|kidney
P10589711A1228|119 124|cells
P10589711A1228|154 166|salts medium
P10589711A1228|213 219|milieu
P10590092A0124|9 19|mechanisms
P10590092A0124|31 52|HIV-1 gene expression
P10590092A0124|60 63|CNS
P10590368X0000|11 24|trachelectomy
P10590368X0000|32 43|alternative
P10590368X0000|55 67|hysterectomy
P10590368X0000|72 80|patients
P10590368X0000|86 106|stage IA-B carcinoma
P10590368X0000|114 120|cervix
P10590368X0000|122 132|BACKGROUND
P10590368X0000|138 147|prognosis
P10590368X0000|164 174|lymph node
P10590368X0000|191 206|stage carcinoma
P10590368X0000|214 220|cervix
P10590368X0000|247 261|survival rates
P10590368X0000|277 278|%
P10591633A0138|6 11|event
P10591633A0138|20 27|process
P10591633A0138|45 56|recognition
P10591633A0138|64 79|target membrane
P10591633A0138|87 94|vesicle
P10591633A0138|111 115|view
P10591633A0138|124 150|SNARE protein interactions
P10591633A0138|173 177|role
P10591633A0138|196 207|recognition
P10591633A0138|215 230|membrane fusion
P10591933A0798|16 20|Type
P10591933A0798|23 36|configuration
P10591933A0798|60 66|values
P10591933A0798|90 95|angle
P10591933A0798|100 108|coracoid
P10591933A0798|179 187|distance
P10591976A0317|0 12|Measurements
P10591976A0317|20 28|LWS p.a.
P10591976A0317|31 38|LWS lat
P10591976A0317|47 51|Ward
P10591976A0317|54 62|triangle
P10591976A0317|78 83|total
P10591976A0317|91 99|patients
P10591990A0178|2 7|group
P10591990A0178|14 20|DSM-IV
P10591990A0178|44 55|in-patients
P10591990A0178|76 81|times
P10591990A0178|92 96|SAPS
P10591990A0178|98 102|SANS
P10591990A0178|104 108|BPRS
P10591990A0178|113 116|PAS
P10592791A0370|3 13|conclusion
P10592791A0370|19 28|TECRA kit
P10592791A0370|67 69|SE
P10592791A0370|80 87|strains
P10592791A0370|94 102|SET-RPLA
P10592791A0370|107 122|RIDASCREEN kits
P10592791A0370|156 169|investigation
P10592791A0370|173 181|SE types
P10592791A0370|191 195|lack
P10592791A0370|199 206|ability
P10592791A0370|231 235|time
P10592791A0370|249 256|testing
P10592791A0370|262 274|SET-RPLA kit
P10592791A0370|284 294|background
P10592791A0370|306 320|RIDASCREEN kit
P10592791A0370|376 391|test procedures
P10592791A0370|400 404|lack
P10592791A0370|408 415|ability
P10592791A0370|439 451|practicality
P10592791A0370|455 466|SET-EIA kit
P10592791A0370|470 479|screening
P10592791A0370|500 517|research purposes
P10592791T0001|0 10|Comparison
P10592791T0001|14 30|immunoassay kits
P10592791T0001|35 44|detection
P10592791T0001|63 75|enterotoxins
P10592824A1157|17 26|frequency
P10592824A1157|38 47|infection
P10592824A1157|66 71|rates
P10592824A1157|75 87|JEV antibody
P10592824A1157|119 123|dose
P10592824A1157|127 134|vaccine
P10592824A1157|153 154|%
P10592824A1157|170 171|%
P10592824A1157|183 184|%
P10592824A1157|198 199|%
P10592824A1157|212 220|children
P10592824A1157|246 250|dose
P10592824A1157|254 265|JE vaccines
P10592824A1157|281 282|P
P10592824A1157|292 302|Chi-square
P10592824A1157|307 317|trend test
P10593939A0747|50 73|interaction experiments
P10593939A0747|90 102|SR33 protein
P10593939A0747|134 146|SR45 protein
P10593939A0747|170 177|members
P10593939A0747|179 184|SRZ21
P10593939A0747|189 194|SRZ22
P10593939A0747|206 212|family
P10593939A0747|249 260|Arabidopsis
P10593939A0747|273 278|U-70K
P10593950A1113|3 10|summary
P10593950A1113|12 15|WT1
P10593950A1113|37 39|dT
P10593950A1113|41 55|chromatography
P10593950A1113|64 70|U2AF65
P10593950A1113|76 78|U5
P10593950A1113|108 120|protein p116
P10593950A1113|125 133|hnRNP A1
P10594130A0652|15 21|hearts
P10594130A0652|47 54|infants
P10594130A0652|70 77|degrees
P10594130A0652|90 98|staining
P10594239A0614|0 9|Tih1 maps
P10594239A0614|20 29|mouse Chr
P10594239A0614|42 50|Chr 1q31
P10594239A0614|64 71|regions
P10594239A0614|92 100|evidence
P10594239A0614|124 132|contrast
P10594239A0614|136 139|Ipl
P10594239A0614|141 145|Tih1
P10594239A0614|186 193|alleles
P10594239T0000|8 18|pleckstrin
P10594239T0000|36 47|gene family
P10594239T0000|59 68|Ipl/Tssc3
P10594239T0000|70 76|TDAG51
P10594239T0000|82 86|Tih1
P10594239T0000|104 114|expression
P10594239T0000|128 136|location
P10594903A0000|4 13|potential
P10594903A0000|34 47|nanoparticles
P10594903A0000|49 52|RNP
P10594903A0000|111 121|substances
P10594903A0000|134 151|warfare agents GA
P10594903A0000|153 155|GB
P10594903A0000|157 159|HD
P10594903A0000|164 166|VX
P10594903A0000|197 207|laboratory
P10595315A0344|28 35|effects
P10595315A0344|53 63|parameters
P10595315A0344|75 81|status
P10595315A0344|87 98|blood gases
P10596955A1032|23 39|failure patients
P10596955A1032|44 52|troponin
P10596955A1032|64 72|microg/l
P10596955A1032|79 91|Axsym method
P10596955A1032|102 108|levels
P10596955A1032|122 130|microg/l
P10596955A1032|137 143|Immuno
P10597222A1371|27 30|p27
P10597222A1371|52 60|molecule
P10597222A1371|64 78|HMBA signaling
P10597222A1371|106 109|p21
P10597223A0339|22 36|Ras-expression
P10597223A0339|61 71|activation
P10597223A0339|75 78|p21
P10597223A0339|101 107|region
P10597223A0339|111 123|p21 promoter
P10597223A0339|131 133|bp
P10597223A0339|150 179|transcription initiation site
P10597223A0339|191 204|binding sites
P10597223A0339|220 241|transcription factors
P10597232A0000|4 26|RET/PTC3 rearrangement
P10597232A0000|40 46|fusion
P10597232A0000|54 58|ELE1
P10597232A0000|63 72|RET genes
P10597232A0000|144 162|thyroid carcinomas
P10597317A1156|0 9|Apoptosis
P10597317A1156|19 24|cells
P10597317A1156|49 64|co-transfection
P10597317A1156|68 71|JBD
P10597317A1156|76 80|LMP1
P10597317A1156|88 96|addition
P10597317A1156|113 125|HD-MyZ cells
P10597317A1156|151 157|masses
P10597317A1156|198 208|inhibition
P10597317A1156|212 215|JNK
P10597317A1156|230 239|apoptosis
P10597317A1156|243 247|LMP1
P10597317A1156|256 264|RS cells
P10598101A0000|3 11|addition
P10598101A0000|19 39|bZIP protein Opaque2
P10598101A0000|62 77|maize endosperm
P10598101A0000|86 94|proteins
P10598101A0000|117 120|box
P10598101A0000|127 150|kDa zein gene promoters
P10598101A0754|4 19|mEmBP-1 protein
P10598101A0754|33 46|transcription
P10598101A0754|64 72|promoter
P10598101A0754|86 94|pentamer
P10598101A0754|105 109|site
P10598101A0754|113 124|yeast cells
P10598101A0754|158 171|transcription
P10598101A0754|180 197|kDa zein promoter
P10598101A0754|213 229|expression assay
P10598101A0754|245 266|maize endosperm cells
P10598316A1534|0 3|GHB
P10598316A1534|7 9|CB
P10598316A1534|11 14|HMB
P10598316A1534|41 51|substances
P10599013A0505|14 20|deaths
P10599727A1567|10 12|GH
P10599727A1567|17 43|estrogen treatment regimen
P10599727A1567|50 55|girls
P10599727A1567|61 63|TS
P10599727A1567|98 108|conformity
P10599727A1567|128 133|peers
P10600171A1066|28 42|responsiveness
P10600171A1066|46 52|CYP3A2
P10600171A1066|60 66|result
P10600171A1066|83 90|binding
P10600171A1066|94 101|COUP-TF
P10600171A1066|109 128|CYP3A2 DexRE-1 site
P10600171A1432|7 14|CYP3A23
P10600171A1432|21 29|activity
P10600171A1432|54 59|E-box
P10600171A1432|63 72|3A23SiteA
P10600171A1432|93 97|USF1
P10600171A1432|112 152|bHLH/leucine zipper transcription factor
P10601280A0674|34 41|element
P10601280A0674|70 91|ST3 promoter activity
P10601280A0674|120 130|activation
P10601290A0742|18 23|basis
P10601290A0742|42 64|cell surface stability
P10601290A0742|89 96|peptide
P10601290A0742|119 130|differences
P10601290A0742|134 152|T cell recognition
P10601290A0742|161 164|I1Y
P10601290A0742|169 172|I1F
P10601290A0742|192 216|x-ray crystal structures
P10601290A0742|228 233|class
P10601290A0742|236 257|MHC-peptide complexes
P10601335A0892|0 14|Redistribution
P10601335A0892|18 29|mannosidase
P10601335A0892|53 58|cells
P10601335A0892|75 85|degrees C.
P10601344A1653|3 11|addition
P10601344A1653|31 46|activity assays
P10601344A1653|60 67|GTPases
P10601344A1653|86 96|expression
P10601344A1653|100 106|beta1A
P10601344A1653|108 114|beta1D
P10601344A1653|119 130|IL2R-beta1A
P10601344A1653|134 138|GE11
P10601344A1653|142 152|GD25 cells
P10601344A1653|162 172|activation
P10601344A1653|181 185|RhoA
P10601344A1653|190 194|Rac1
P10601344A1653|207 212|Cdc42
P10601410A0977|3 13|conclusion
P10601410A0977|19 23|data
P10601410A0977|41 45|role
P10601410A0977|50 54|IVIg
P10601410A0977|62 75|remyelination
P10601410A0977|95 112|sclerosis lesions
P10601410A0977|136 151|conduction time
P10601606A0152|4 24|rhabdomyosarcoma R1H
P10601606A0152|46 51|flank
P10601606A0152|60 72|WAG/Rij rats
P10601606A0152|96 97|h
P10601606A0152|104 113|degrees C
P10601606A0152|120 130|degrees C.
P10601747A0482|21 34|control words
P10601747A0482|85 94|anomalies
P10601747A0482|112 123|N400 effect
P10601747A0482|155 159|msec
P10601747A0482|166 176|word onset
P10602419A1253|18 25|effects
P10602502A0422|9 20|Tob protein
P10602502A0422|22 26|Tob2
P10602502A0422|37 59|cell cycle progression
P10602502A0422|69 74|G0/G1
P10602502A0422|78 86|S phases
P10602507A0652|15 23|increase
P10602507A0652|27 36|cyclin D1
P10602507A0652|41 44|p21
P10602507A0652|53 59|effect
P10602507A0652|104 112|activity
P10602507A0652|116 130|cyclin D1/cdk4
P10602507A0652|132 135|p53
P10602507A0652|159 174|CSF-1 induction
P10602507A0652|178 181|p21
P10602507A0652|218 232|p53 expression
P10602516A0182|3 11|addition
P10602516A0182|13 16|SLK
P10602516A0182|31 39|homology
P10602516A0182|43 54|microtubule
P10602516A0182|78 85|protein
P10602516A0182|87 92|M-NAP
P10602516A0182|98 104|AT1-46
P10602516A0182|122 130|function
P10602838A0127|8 13|study
P10602838A0127|17 25|patients
P10602838A0127|30 37|females
P10602838A0127|44 49|males
P10603349A1667|4 29|signalling molecules Wnt1
P10603349A1667|40 48|hedgehog
P10603349A1667|68 78|activation
P10603349A1667|82 86|Myf5
P10603349A1667|99 115|progenitor cells
P10603349A1667|123 129|somite
P10603349A1667|156 165|viscinity
P10603349A1667|173 195|Myf5 expression domain
P10603349A1667|203 216|mesencephalon
P10604246A0523|0 12|STUDY DESIGN
P10604246A0523|17 24|METHODS
P10604246A0523|28 33|study
P10604246A0523|63 73|collection
P10604246A0523|77 82|PBPCs
P10604246A0523|96 102|device
P10604246A0523|108 116|AutoPBSC
P10604246A0523|118 125|version
P10604246A0523|127 128|V
P10604246A0523|138 157|AutoPBSC tubing set
P10604246A0523|178 181|MNC
P10604246A0523|195 199|cell
P10604246A0523|201 210|procedure
P10604246A0523|212 214|V4
P10604246A0523|228 243|cell tubing set
P10604246A0523|250 258|patients
P10604246A0523|271 277|donors
P10604583T0000|0 16|Albumin dialysis
P10604583T0000|28 35|removal
P10604583T0000|39 45|copper
P10604583T0000|51 58|patient
P10604583T0000|74 88|Wilson disease
P10604583T0000|116 137|liver transplantation
P10604583T0000|145 156|possibility
P10604583T0000|165 176|elimination
P10604583T0000|194 200|toxins
P10604945A0731|16 35|promoter constructs
P10604945A0731|56 65|Sp1 sites
P10604945A0731|92 99|ethanol
P10604945A0731|105 111|others
P10604945A0731|142 154|organization
P10604945A0731|171 186|promoter region
P10604945A0731|205 211|factor
P10604945A0731|230 246|ethanol response
P10606245A0906|0 14|Overexpression
P10606245A0906|18 25|CDP/cut
P10606245A0906|29 32|ROS
P10606245A0906|40 58|osteosarcoma cells
P10606245A0906|70 80|repression
P10606245A0906|84 104|OC promoter activity
P10606245A0906|111 121|repression
P10606245A0906|147 156|OC box I.
P10606272A1241|0 9|Injection
P10606272A1241|29 32|RNA
P10606272A1241|38 48|C. elegans
P10606272A1241|70 79|lethality
P10606272A1241|91 99|SF1 gene
P10606272A1241|125 130|yeast
P10606272A1241|156 164|metazoan
P10606515A0389|5 12|domains
P10606515A0389|40 51|DNA binding
P10606515A0389|73 94|acid receptor element
P10606515A0389|108 113|DNase
P10606515A0389|116 125|footprint
P10606515A0389|153 159|strand
P10606664A0000|0 21|Snail family proteins
P10606664A0000|26 37|zinc finger
P10606664A0000|54 64|regulators
P10606664A0000|116 121|roles
P10606664A0000|125 148|cell fate determination
P10607566A0880|21 28|finding
P10607566A0880|30 42|beta-catenin
P10607566A0880|72 83|RA receptor
P10607566A0880|85 88|RAR
P10607566A0880|114 120|manner
P10607566A0880|139 158|retinoid X receptor
P10607566A0880|160 163|RXR
P10607566A0880|170 173|RAR
P10607566A0880|188 191|TCF
P10607566A0880|196 216|beta-catenin binding
P10607899A0605|0 17|Sequence analysis
P10607899A0605|25 40|promoter region
P10607899A0605|51 59|TATA box
P10607899A0605|75 99|consensus binding motifs
P10607899A0605|104 107|Sp1
P10607899A0605|109 113|CREB
P10607899A0605|119 129|half sites
P10607899A0605|137 167|estrogen receptor binding site
P10607900T0000|0 25|Sak kinase gene structure
P10607900T0000|46 56|regulation
P10608053A0923|0 12|Thrombolysis
P10608053A0923|39 47|increase
P10608053A0923|51 68|platelet activity
P10608053A0923|82 88|values
P10608053A0923|108 112|hour
P10608053A0923|121 127|groups
P10608053A0923|140 145|IU/ml
P10608053A0923|149 154|Group
P10608053A0923|175 180|Group
P10608053A0923|184 185|p
P10608053A0923|191 209|001versus baseline
P10608053A0923|214 218|p NS
P10608053A0923|231 237|groups
P10608893A0727|11 16|Hp140
P10608893A0727|27 31|Hp55
P10608893A0727|38 41|DNA
P10608893A0727|56 64|strength
P10608893A0727|75 86|specificity
P10608893A0727|123 126|DNA
P10610716A1127|19 37|missense mutations
P10610716A1127|39 44|E138V
P10610716A1127|46 51|R254G
P10610716A1127|57 62|P362R
P10610716A1127|93 100|AC gene
P10610716A1127|106 117|FD patients
P10611225A1127|6 10|data
P10611225A1127|29 40|interaction
P10611225A1127|44 49|eIF4A
P10611225A1127|66 72|region
P10611225A1127|76 82|eIF4GI
P10611225A1127|100 111|translation
P10611225A1127|125 136|interaction
P10611225A1127|140 145|eIF4A
P10611225A1127|166 172|region
P10611225A1127|192 196|role
P10611228A1388|4 12|DAP5/p86
P10611228A1388|23 27|form
P10611228A1388|49 57|DAP5/p97
P10611228A1388|78 84|assays
P10611235A1927|27 31|step
P10611235A1927|40 45|model
P10611235A1927|53 63|activation
P10611235A1927|71 81|MAPK Fus3p
P10611235A1927|94 95|G
P10611235A1927|96 105|betagamma
P10611235A1927|117 131|relocalization
P10611235A1927|139 157|Ste5p-MAPK cascade
P10611235A1927|165 180|plasma membrane
P10611242A0541|21 28|finding
P10611242A0541|40 44|SAGA
P10611242A0541|54 65|TBP binding
P10611242A0541|73 86|HIS3 promoter
P10611242A0541|103 107|SAGA
P10611242A0541|116 120|Spt3
P10611242A0541|124 128|Spt8
P10611320A0816|73 81|CAK gene
P10611320A0816|83 87|CAK1
P10611320A0816|121 134|Cak1p protein
P10611320A0816|148 152|Cdk7
P10611353A0458|0 13|Northern blot
P10611353A0458|26 52|transcription-PCR analyses
P10611353A0458|62 74|mRNA samples
P10611353A0458|92 95|RNR
P10611353A0458|128 134|retina
P10611353A0458|141 152|transcripts
P10611353A0458|174 176|kb
P10611353A0458|196 198|kb
P10611353A0458|222 224|kb
P10611353A0458|228 250|Northern blot analysis
P10612044A1180|30 42|conservation
P10612044A1180|49 66|AP-4 binding site
P10612044A1180|78 89|nucleotides
P10612044A1180|106 135|transcription initiation site
P10612044A1180|144 153|Aal-rpL34
P10612044A1180|158 172|Aal-rpL8 genes
P10612505A1317|11 15|type
P10612505A1317|18 23|error
P10612505A1317|37 42|study
P10612505A1317|49 54|power
P10612505A1317|82 83|%
P10612505A1317|94 111|group differences
P10612505A1317|115 131|treatment effect
P10612505A1317|162 163|%
P10612505A1317|169 170|%
P10612773A1210|0 11|CONCLUSIONS
P10612773A1210|13 25|Serum levels
P10612773A1210|29 38|S-100beta
P10612773A1210|52 59|markers
P10612773A1210|83 91|outcomes
P10612773A1210|106 113|surgery
P10612805A0716|20 30|alteration
P10612805A0716|58 65|cancers
P10612918A0318|4 12|problems
P10612918A0318|52 58|screws
P10613816X0000|0 7|Statins
P10613816X0000|15 21|lipids
P10613816X0000|33 38|bones
P10613816X0000|49 56|statins
P10613816X0000|97 102|drugs
P10613816X0000|113 118|study
P10613816X0000|139 148|compounds
P10613816X0000|163 170|effects
P10613816X0000|174 178|bone
P10613816X0000|211 221|treatments
P10613816X0000|243 256|bone diseases
P10613816X0000|265 277|osteoporosis
P10613843A0107|16 24|products
P10613843A0107|36 54|duplication events
P10613843A0107|89 94|genes
P10613843A0107|122 124|Ca
P10613843A0107|129 141|ion channels
P10613863T0000|4 27|VirR response regulator
P10613863T0000|33 56|Clostridium perfringens
P10613863T0000|101 108|repeats
P10613863T0000|133 146|pfoA promoter
P10613874A0663|0 7|Cloning
P10613874A0663|12 22|sequencing
P10613874A0663|39 45|region
P10613874A0663|49 53|pepX
P10613874A0663|67 75|presence
P10613874A0663|83 87|ORFs
P10613874A0663|105 107|bp
P10613874A0663|145 153|proteins
P10613874A0663|164 172|homology
P10613874A0663|176 180|GlnR
P10613874A0663|185 198|GlnA proteins
P10614676A0000|0 9|Objective
P10614676A0000|35 44|thickness
P10614676A0000|53 62|incidence
P10614676A0000|74 82|bleeding
P10614676A0000|101 106|women
P10614676A0000|120 128|tibolone
P10614676A0000|133 135|mg
P10614676A0000|161 173|mg estradiol
P10614676A0000|180 205|mg norethisterone acetate
P10614676A0000|207 213|E+NETA
P10614676A0000|224 251|hormone replacement therapy
P10614857A0584|0 18|Leukocyte cultures
P10614857A0584|34 39|blood
P10614857A0584|60 68|children
P10614857A0584|74 80|months
P10614857A0584|84 87|age
P10614857A0584|104 110|yields
P10614857A0584|114 117|IFN
P10614857A0584|149 157|children
P10614857A0584|180 190|adenovirus
P10614857A0584|192 193|P
P10614857A0584|203 214|coronavirus
P10614857A0584|216 217|P
P10614857A0584|228 238|rhinovirus
P10614857A0584|240 241|P
P10616948A0998|7 19|BF ECT group
P10616948A0998|34 38|dose
P10616948A0998|90 113|seizure threshold level
P10617126A1005|13 21|analysis
P10617126A1005|47 51|loss
P10617126A1005|72 77|group
P10617126A1005|117 121|area
P10617126A1005|123 126|CA1
P10617126A1005|140 144|rats
P10617126A1005|156 169|dentate gyrus
P10617126A1005|186 190|area
P10617126A1005|192 195|CA1
P10617126A1005|200 203|CA3
P10617126A1005|220 224|rats
P10617126A1005|254 259|group
P10617144A0386|4 11|extents
P10617144A0386|15 30|phosphorylation
P10617144A0386|34 39|Ser44
P10617144A0386|44 49|Ser64
P10617144A0386|92 97|sites
P10617144A0386|119 120|%
P10617232A0393|0 13|Serum HBV-DNA
P10617232A0393|21 29|serology
P10617232A0393|35 48|liver enzymes
P10617232A0393|77 92|liver histology
P10617232A0393|121 130|treatment
P10617232A0393|137 145|patients
P10617613A1192|0 4|Chem
P10618645A0750|0 17|Maximum induction
P10618645A0750|21 25|AP-1
P10618645A0750|43 56|concentration
P10618645A0750|64 70|nmol/L
P10618645A0750|74 78|CalC
P10619062T0000|0 27|Haycocknema perplexum n. g.
P10619062T0000|29 34|n. sp
P10619169A0411|0 4|Rams
P10619169A0411|22 33|testis size
P10619169A0411|51 61|orchimetry
P10619169A0411|70 81|time period
P10619254A1055|0 14|Animal studies
P10619254A1055|27 44|beam equalization
P10619254A1055|98 111|image quality
P10619353T0000|0 4|Role
P10619353T0000|8 32|estrogen receptor ligand
P10619353T0000|37 71|estrogen response element sequence
P10619353T0000|75 86|interaction
P10619353T0000|92 109|chicken ovalbumin
P10619353T0000|119 148|promoter transcription factor
P10619353T0000|150 157|COUP-TF
P10620010A1155|0 10|CONCLUSION
P10620010A1155|15 19|Cdks
P10620010A1155|47 57|cell cycle
P10620010A1155|59 83|tyrosine phosphorylation
P10620010A1155|105 115|activation
P10620010A1155|119 125|kinase
P10620010A1155|139 154|phosphorylation
P10620010A1155|158 167|threonine
P10620010A1155|175 181|T-loop
P10620010A1155|199 209|activation
P10620335A0749|20 23|AHR
P10620335A0749|39 46|COUP-TF
P10620335A0749|62 72|CV-1 cells
P10620777A1399|0 8|AB004534
P10622574A0000|4 14|prevalence
P10622574A0000|18 35|hepatitis C virus
P10622574A0000|37 40|HCV
P10622574A0000|42 51|infection
P10622574A0000|73 82|childhood
P10622574A0000|98 114|prevalence rates
P10622574A0000|125 126|%
P10622574A0000|142 147|world
P10622576A0552|26 37|information
P10622576A0552|60 68|patients
P10622576A0552|79 84|means
P10622576A0552|88 98|prevention
P10622576A0552|112 121|attention
P10622576A0552|136 147|risk groups
P10622576A0552|159 171|drug abusers
P10623758A0947|7 14|latency
P10623758A0947|27 28|%
P10623758A0947|32 39|neurons
P10623758A0947|43 50|ganglia
P10623758A0947|70 77|footpad
P10623758A0947|88 106|beta-galactosidase
P10623758A0947|117 123|number
P10623758A0947|136 141|cells
P10623758A0947|176 182|months
P10623804A0808|18 26|approach
P10623804A0808|35 43|question
P10623804A0808|65 72|effects
P10623804A0808|98 102|SHIP
P10623804A0808|104 109|SHP-1
P10623804A0808|114 119|SHP-2
P10623804A0808|135 149|decoy proteins
P10623804A0808|153 177|Fc gamma RIIB1 signaling
P10624787A0432|36 45|functions
P10624787A0432|53 61|patients
P10624787A0432|74 75|P
P10624787A0432|117 132|blood pressures
P10624787A0432|134 135|P
P10624787A0432|146 147|P
P10624787A0432|170 174|case
P10624787A0432|178 182|Type
P10624787A0432|185 187|DM
P10624787A0432|203 218|body mass index
P10624787A0432|220 221|P
P10624787A0432|236 251|waist-hip ratio
P10624787A0432|253 254|P
P10625438A1429|7 14|tissues
P10625438A1429|29 40|transcripts
P10625438A1429|54 60|insert
P10625438A1429|70 82|bp insertion
P10625438A1429|86 92|repeat
P10625438A1429|124 134|conditions
P10625438A1429|148 155|% level
P10625438A1429|159 165|insert
P10625438A1429|177 187|transcript
P10625438A1429|238 253|control samples
P10625494A1059|6 13|results
P10625494A1059|28 39|CAAT-region
P10625494A1059|72 85|MDR1 promoter
P10625494A1059|89 103|HL60/VCR cells
P10625683A0091|5 14|receptors
P10625683A0091|23 47|protein tyrosine kinases
P10625683A0091|49 53|PTKs
P10625683A0091|63 78|phosphorylation
P10625683A0091|100 109|molecules
P10625683A0091|113 120|process
P10625683A0091|146 154|function
P10625683A0091|163 172|receptors
P10625721T0101|0 11|Hypothermia
P10625721T0101|26 32|Arrest
P10625721T0101|34 38|HACA
P10625721T0101|40 51|Study Group
P10627518A0544|16 22|effect
P10627518A0544|40 51|cooperation
P10627518A0544|91 94|sum
P10627518A0544|102 115|contributions
P10627518A0544|134 138|UTRs
P10627532A0739|25 26|R
P10627532A0739|31 32|Z
P10627532A0739|55 61|stress
P10627532A0739|80 87|protein
P10627532A0739|89 92|MAP
P10627532A0739|94 101|kinases
P10627532A0739|103 106|p38
P10627532A0739|111 114|JNK
P10627532A0739|129 144|phosphorylation
P10627532A0739|150 160|activation
P10627532A0739|178 203|transcription factor ATF2
P10627834A0178|4 6|US
P10627834A0178|18 27|cultivars
P10627834A0178|29 35|Tehama
P10627834A0178|40 44|Vina
P10627834A0178|73 82|cultivars
P10627834A0178|84 93|Esterhazy
P10627834A0178|100 104|G120
P10627834A0178|115 137|New Zealand selections
P10627834A0178|139 142|Rex
P10627834A0178|144 150|Dublin
P10627834A0178|153 158|Glory
P10627834A0178|160 166|Meyric
P10627834A0178|168 177|McKinster
P10627834A0178|179 186|Stanley
P10628490T0000|0 7|Anatomy
P10628490T0000|23 29|artery
P10628748A0344|9 19|activation
P10628748A0344|27 39|cAMP pathway
P10628748A0344|68 92|inhibin alpha expression
P10628748A0344|115 122|actions
P10628748A0344|126 130|SF-1
P10628748A0746|0 8|Deletion
P10628748A0746|27 38|mutagenesis
P10628748A0746|57 61|SF-1
P10628748A0746|73 80|element
P10628748A0746|82 92|TCA GGGCCA
P10628748A0746|130 151|cAMP-response element
P10628748A0746|153 156|CRE
P10628750A0298|31 35|APRE
P10628750A0298|41 49|cytokine
P10628750A0298|51 78|tumor necrosis factor-alpha
P10628750A0298|80 88|TNFalpha
P10628750A0298|102 110|enhancer
P10628750A0298|148 161|factor-kappaB
P10628750A0298|163 172|NF-kappaB
P10628750A0298|182 185|Rel
P10628750A0298|188 200|x NF-kappaB1
P10628750T0000|0 11|Angiotensin
P10628750T0000|31 37|factor
P10628750T0000|39 41|NF
P10628750T0000|43 59|kappaB1 isoforms
P10628750T0000|72 121|angiotensinogen gene acute-phase response element
P10628750T0000|143 150|pathway
P10628750T0000|155 175|NF-kappaB activation
P10628755A0000|10 17|ligands
P10628755A0000|66 71|cycle
P10628755A0000|85 97|GH secretion
P10628755A0000|122 153|orphan GH-secretagogue receptor
P10628755A0000|155 160|GHS-R
P10628971A0824|4 14|collection
P10628971A0824|18 25|mutants
P10628971A0824|37 40|TGN
P10628971A0824|49 56|defects
P10628971A0824|66 73|members
P10628971A0824|79 88|mutations
P10628971A0824|123 144|protein sorting genes
P10628971A0824|146 149|VPS
P10628971A0824|166 192|dynamin family member VPS1
P10628971A1165|12 20|spectrum
P10628971A1165|24 31|mutants
P10628971A1165|37 40|TGN
P10628971A1165|49 56|defects
P10628971A1165|61 69|isolates
P10628971A1165|75 84|mutations
P10628971A1165|92 101|following
P10628971A1165|103 107|RIC1
P10628971A1165|120 127|product
P10628971A1165|166 185|ribosome biogenesis
P10628971A1165|187 191|LUV1
P10628971A1165|204 211|product
P10628971A1165|236 243|vacuole
P10628971A1165|248 272|microtubule organization
P10628971A1165|278 283|INP53
P10628971A1165|314 350|inositol polyphosphate 5-phosphatase
P10629035A0827|11 23|strandedness
P10629035A0827|52 61|extension
P10629035A0827|76 82|strand
P10629035A0827|84 91|G tails
P10629035A0827|125 135|telomerase
P10629035A0827|153 171|cdc17/pol1 mutants
P10629035A0827|180 187|defects
P10629035A0827|216 225|synthesis
P10629176A0887|3 11|addition
P10629176A0887|13 19|CaMig1
P10629176A0887|36 45|complexes
P10629176A0887|55 66|URS1 region
P10629176A0887|88 97|FBP1 gene
P10629938A1352|22 34|distribution
P10629938A1352|42 58|GFP-POLO protein
P10629938A1352|66 78|compartments
P10629938A1352|94 103|apparatus
P10629938A1352|124 128|tool
P10629938A1352|140 147|studies
P10629938A1352|151 161|cell cycle
P10629938A1352|169 180|development
P10630471T0000|3 12|ASIC-chip
P10630471T0000|30 44|depth analysis
P10630471T0000|89 102|cell behavior
P10630630A0614|9 21|calphostin C
P10630630A0614|34 43|inhibitor
P10630630A0614|47 50|PKC
P10630630A0614|78 86|increase
P10630630A0614|90 105|CFI mRNA levels
P10633075A1111|10 13|IgG
P10633075A1111|25 38|Fab fragments
P10633075A1111|51 59|polymers
P10633075A1111|74 93|N-acetylglucosamine
P10633075A1111|101 107|effect
P10633499A1306|0 24|Arhythmacanthus Yamaguti
P10633499A1306|50 57|synonym
P10633499A1306|86 97|distinction
P10633499A1306|120 130|hook types
P10633499A1306|158 168|transition
P10633499A1306|202 207|hooks
P10634007A0202|14 18|case
P10634007A0202|22 44|acetaminophen overdose
P10634007A0202|72 84|hemodialysis
P10634007A0202|86 88|HD
P10634007A0202|94 97|NAC
P10634007A0202|112 124|intoxication
P10634007A0202|134 148|drug clearance
P10635209A0419|10 22|conditioning
P10635209A0419|33 37|coat
P10635209A0419|41 49|adhesive
P10637149A0806|18 33|G-A anastomosis
P10637149A0806|39 41|RD
P10637149A0806|43 45|CC
P10637149A0806|47 48|E
P10637149A0806|49 50|p
P10637149A0806|55 65|loop areas
P10637149A0806|100 103|REF
P10637149A0806|138 141|A-A
P10637230A0332|8 18|expression
P10637230A0332|22 27|c-myc
P10637230A0332|59 72|proliferation
P10637230A0332|87 92|cells
P10637230A0332|96 104|response
P10637230A0332|108 112|IFNs
P10637238A0291|0 46|Eastern Cooperative Oncology Group trial E3186
P10637238A0291|77 85|question
P10637337A0545|18 28|DNA repair
P10637337A0545|44 48|TFA1
P10637337A0545|61 70|mutations
P10638607A0000|6 14|articles
P10638607A0000|31 38|results
P10638607A0000|75 80|phase
P10638607A0000|83 89|trials
P10638607A0000|98 107|treatment
P10638607A0000|111 119|patients
P10638607A0000|141 148|N0-1 M0
P10638607A0000|150 160|esophageal
P10638607A0000|170 184|cell carcinoma
P10638607A0000|186 189|SCC
P10638607A0000|205 219|adenocarcinoma
P10639585A0157|0 7|Studies
P10639585A0157|11 30|MPO gene regulation
P10639585A0157|57 66|mechanism
P10639585A0157|98 113|differentiation
P10640683A0204|0 12|NDRF/NeuroD2
P10640683A0204|38 41|PKN
P10640683A0204|51 57|lysate
P10640683A0204|61 72|COS-7 cells
P10640683A0204|95 116|expression constructs
P10640683A0204|121 133|NDRF/NeuroD2
P10640683A0204|138 141|PKN
P10640683A0670|10 29|transfection assays
P10640683A0670|36 45|P19 cells
P10640683A0670|60 70|expression
P10640683A0670|74 86|NDRF/NeuroD2
P10640683A0670|101 116|transactivation
P10640683A0670|124 152|rat insulin promoter element
P10640683A0670|156 161|RIPE3
P10640683A0670|163 171|enhancer
P10640683A0670|209 222|co-expression
P10640683A0670|247 251|form
P10640683A0670|255 258|PKN
P10640683A0670|285 295|derivative
P10640683A0670|329 337|increase
P10640683A0670|363 376|transcription
P10640701T0000|21 26|sites
P10640701T0000|30 40|Engrailed2
P10640701T0000|65 75|initiation
P10640701T0000|104 114|expression
P10640734A0190|5 29|tyrosine phosphorylation
P10640734A0190|37 42|ITIMs
P10640734A0190|50 59|molecules
P10640734A0190|68 71|SH2
P10640734A0190|90 102|phosphatases
P10640734A0190|126 148|tyrosine phosphatase-1
P10640734A0190|173 186|cell activity
P10641037A1371|0 8|AF154055
P10641688A0341|0 9|Alignment
P10641688A0341|26 31|spine
P10641688A0341|43 56|abnormalities
P10641688A0341|62 74|disc changes
P10642524A0156|16 27|interaction
P10642524A0156|31 36|mSTI1
P10642524A0156|42 47|hsp70
P10642524A0156|52 57|hsp90
P10642524A0156|65 66|N
P10642524A0156|114 138|tetratricopeptide repeat
P10642524A0156|140 143|TPR
P10642524A0156|145 151|motifs
P10642524A0156|161 168|regions
P10642531A2322|0 23|Competition experiments
P10642531A2322|58 70|relationship
P10642531A2322|85 106|RGD recognition sites
P10642889A0393|0 17|Sequence analysis
P10642889A0393|46 52|region
P10642889A0393|69 78|ATG codon
P10642889A0393|110 118|TATA box
P10643313A0345|6 25|i.v. administration
P10643313A0345|33 49|mg acetazolamide
P10643313A0345|54 66|disinfection
P10643313A0345|74 85|conjunctiva
P10643313A0345|90 106|micrograms rt-PA
P10643313A0345|114 116|ml
P10643313A0345|118 121|BSS
P10643313A0345|131 137|ml SF6
P10644357A0935|6 13|results
P10644357A0935|27 30|VP1
P10644357A0935|66 73|nucleus
P10644357A0935|115 122|regions
P10644357A0935|138 141|VP2
P10644357A0935|146 149|VP3
P10644414T0000|13 23|expression
P10644414T0000|28 38|regulation
P10644414T0000|42 60|20-hydroxyecdysone
P10644414T0000|64 95|mosquito ultraspiracle isoforms
P10644753A0725|10 18|isoforms
P10644753A0725|43 67|antibody affinity column
P10644753A0725|80 87|sulfate
P10644753A0725|91 106|heparan sulfate
P10644753A0725|111 118|heparin
P10644753A0725|136 154|glycosaminoglycans
P10644760A0000|4 19|differentiation
P10644760A0000|24 35|maintenance
P10644760A0000|41 67|neurotransmitter phenotype
P10644760A0000|85 96|interaction
P10644760A0000|110 114|cues
P10644760A0000|138 147|machinery
P10644760A0956|0 8|Analysis
P10644760A0956|23 30|domains
P10644760A0956|34 38|Arix
P10644760A0956|61 78|activation domain
P10644760A0956|96 113|repression domain
P10645921A0000|0 10|BACKGROUND
P10645921A0000|29 40|hypertrophy
P10645921A0000|60 68|disorder
P10645921A0000|83 95|morphologies
P10645921A1320|13 23|predictors
P10645921A1320|40 50|remodeling
P10645921A1320|52 53|P
P10645921A1320|62 72|odds ratio
P10645921A1320|98 115|ejection fraction
P10645921A1320|119 121|SD
P10645921A1320|136 137|P
P10645921A1320|170 188|circumflex disease
P10645921A1320|190 191|P
P10645921A1320|200 210|odds ratio
P10646820T0000|4 8|case
P10646820T0000|28 43|lymphadenectomy
P10646820T0000|58 69|lymph nodes
P10646820T0000|95 107|hysterectomy
P10646820T0000|121 130|carcinoma
P10646863A0838|0 14|Overexpression
P10646863A0838|18 24|ICBP90
P10646863A0838|46 51|cells
P10646863A0838|72 82|expression
P10646863A0838|97 118|topoisomerase IIalpha
P10647177A0599|4 15|RNA aptamer
P10647177A0599|52 56|pair
P10647177A0599|69 75|bulges
P10647177A0599|105 109|fold
P10647177A0599|135 140|sites
P10647177A0599|162 166|base
P10647177A0599|174 183|formation
P10647633A1685|4 9|study
P10647633A1685|23 31|presence
P10647633A1685|49 58|sphincter
P10647633A1685|66 69|RSJ
P10647633A1685|98 105|passage
P10647633A1685|109 115|stools
P10647633A1685|133 138|colon
P10647633A1685|146 152|rectum
P10647817T0000|0 9|Isolation
P10647817T0000|13 18|cDNAs
P10647817T0000|28 34|gibbon
P10647817T0000|39 54|monkey platelet
P10647817T0000|59 84|T cell activation antigen
P10647817T0000|88 92|PTA1
P10647859A0000|38 44|effect
P10647859A0000|76 96|pressure ventilation
P10647859A0000|98 102|IPPV
P10647859A0000|119 127|activity
P10647859A0000|135 144|diaphragm
P10647859A0000|182 190|subjects
P10647859A0000|198 207|occasions
P10647859A0000|223 228|rates
P10647859A0000|246 255|breathing
P10647859A0000|257 259|QB
P10647859A0000|274 280|levels
P10647859A0000|292 300|pressure
P10647859A0000|302 307|Pappl
P10647859A0000|322 327|cmH2O
P10647859A0000|341 351|hypocapnia
P10647859A0000|353 354|P
P10647859A0000|355 358|CO2
P10647859A0000|385 393|eucapnia
P10647859A0000|395 398|CO2
P10647859A0000|417 420|gas
P10648020A0151|0 7|METHODS
P10648020A0151|9 30|Von Willebrand factor
P10648020A0151|32 35|vWF
P10648020A0151|58 94|factors tissue plasminogen activator
P10648020A0151|96 99|tPA
P10648020A0151|114 126|tPA capacity
P10648020A0151|132 163|plasminogen activator inhibitor
P10648020A0151|167 172|PAI-1
P10648020A0151|175 184|platelets
P10648020A0151|186 196|fibrinogen
P10648020A0151|215 222|markers
P10648020A0151|243 251|patients
P10648020A0151|277 279|RA
P10648211A0000|9 29|signaling properties
P10648211A0000|60 68|quantity
P10648211A0000|73 84|combination
P10648211A0000|88 100|ion channels
P10648489A1117|0 9|Treatment
P10648489A1117|36 40|dose
P10648489A1117|51 60|reduction
P10648489A1117|68 71|sum
P10648489A1117|78 96|segment depression
P10648489A1117|105 111|trough
P10648489A1117|116 135|peak concentrations
P10648619A0000|25 37|contribution
P10648619A0000|63 70|protein
P10648619A0000|72 75|TBP
P10648619A0000|77 94|TATA interactions
P10648619A0000|102 119|promoter activity
P10648619A0000|150 163|silkworm tRNA
P10648619A0000|164 165|C
P10648619A0000|167 170|Ala
P10648619A0000|172 176|gene
P10648619A0000|209 213|lack
P10648619A0000|225 246|interactions accounts
P10648619A0000|259 276|promoter activity
P10648619A0000|282 286|silk
P10648619A0000|302 306|tRNA
P10648619A0000|307 309|SG
P10648619A0000|311 314|Ala
P10648619A0000|316 320|gene
P10649449A0413|4 13|sequences
P10649449A0413|31 41|homologies
P10649449A0413|47 70|squalene synthase genes
P10649449A0413|75 82|enzymes
P10649449A0413|90 96|number
P10649449A0413|106 115|organisms
P10649449A0413|128 151|amino acid conservation
P10649449A0413|163 170|binding
P10649449A0413|185 192|domains
P10649456A1061|4 10|clones
P10649456A1061|15 22|strains
P10649456A1061|59 66|EUROFAN
P10649456A1061|75 87|stock centre
P10649456A1061|89 98|EUROSCARF
P10649456A1061|100 109|Frankfurt
P10649738A0953|4 12|episodes
P10649738A0953|16 27|peritonitis
P10649738A0953|47 54|patient
P10649738A0953|64 68|CAPD
P10649738A0953|72 81|episode/3
P10649738A0953|84 98|patient-months
P10650104X0284|0 9|Copyright
P10650104X0284|19 32|Royal College
P10650104X0284|36 48|Radiologists
P10650938T0000|4 21|estrogen receptor
P10650938T0000|23 25|ER
P10650938T0000|27 35|isoforms
P10650938T0000|51 72|estrogen dependencies
P10650938T0000|96 109|trout ER gene
P10650939A0789|0 9|Induction
P10650939A0789|26 38|coexpression
P10650939A0789|42 47|A-Fos
P10650939A0789|72 76|AP-1
P10650939A1542|14 17|SMC
P10650939A1542|24 32|isoforms
P10650939A1542|40 61|progesterone receptor
P10650939A1542|63 67|PR-B
P10650939A1542|72 76|PR-A
P10650939A1542|104 114|activation
P10650939A1542|118 127|PGDH-2368
P10650939A1542|128 132|luc3
P10650958A1315|0 9|Element B
P10650958A1315|40 50|% homology
P10650958A1315|56 79|consensus c-myb element
P10650958A1315|105 114|complexes
P10650958A1315|142 147|c-myb
P10650958A1315|171 191|mobility shift assay
P10651076T0000|5 15|resolution
P10651076T0000|25 35|tomography
P10651076T0000|43 48|lungs
P10651076T0000|52 60|patients
P10651076T0000|77 86|arthritis
P10651805A1600|7 19|transfection
P10651805A1600|52 64|carrier cDNA
P10651805A1600|70 96|mouse L1210 leukemia cells
P10651805A1600|108 127|folate accumulation
P10651805A1600|145 155|leucovorin
P10651805A1600|166 190|acid growth requirements
P10651805A1600|212 223|sensitivity
P10651805A1600|227 239|methotrexate
P10651805T0000|0 16|Characterization
P10651805T0000|75 82|carrier
P10651805T0000|94 113|folate accumulation
P10651805T0000|126 140|leukemia cells
P10652093A0139|0 8|Electron
P10652093A0139|35 43|analyses
P10652093A0139|62 73|A118 genome
P10652093A0139|129 139|collection
P10652093A0139|159 172|DNA molecules
P10652102A0620|25 31|dosage
P10652102A0620|45 49|Fus3
P10652102A0620|66 76|inhibition
P10652102A0620|85 102|Ty1 transposition
P10652102A0620|116 122|growth
P10652228A0759|14 24|activation
P10652228A0759|28 33|c-Jun
P10652228A0759|45 51|kinase
P10652228A0759|66 76|Rho family
P10652228A0759|89 97|proteins
P10652228A0759|121 124|Dbl
P10652324A0177|13 26|participation
P10652324A0177|30 46|collagen binding
P10652362A0933|16 20|data
P10652362A0933|38 55|carboxyl terminus
P10652362A0933|59 63|CFTR
P10652362A0933|90 112|internalization signal
P10652362A0933|147 167|adaptor complex AP-2
P10652362A0933|192 197|entry
P10652362A0933|201 205|CFTR
P10652362A0933|227 235|vesicles
P10652800A0984|4 27|insulin therapy regimen
P10652800A0984|47 56|evolution
P10652800A0984|64 72|patients
P10652800A0984|92 104|relationship
P10652800A0984|125 128|age
P10652800A0984|132 141|diagnosis
P10652800A0984|143 151|duration
P10652800A0984|155 163|diabetes
P10652800A0984|171 185|insulin dosage
P10652800A0984|199 206|control
P10652800A0984|211 217|height
P10652800A0984|221 224|BMI
P10653359A1297|0 10|Scmh1 maps
P10653359A1297|14 22|4D1-D2.1
P10653359A1297|26 30|mice
P10653400A0000|4 17|applicability
P10653400A0000|34 51|donor nephrectomy
P10653400A0000|53 56|LDN
P10653400A0000|93 98|donor
P10653550A1120|0 20|Hyaluronan treatment
P10653550A1120|32 51|collagen remodeling
P10653550A1120|70 76|region
P10653550A1120|107 115|meniscus
P10653550A1120|138 144|region
P10653693A0429|24 30|issues
P10653693A0429|72 76|KRAB
P10653693A0429|77 99|KAP-1-RBCC interaction
P10653693A0429|115 125|components
P10653693A0903|4 15|RING finger
P10653693A0903|17 23|B2 box
P10653693A0903|41 47|region
P10653693A0903|65 80|oligomerization
P10653693A0903|84 94|KAP-1-RBCC
P10653693A0903|99 111|KRAB binding
P10653693A0903|116 125|mutations
P10653693A0903|135 142|domains
P10653693A0903|173 182|functions
P10653697A0133|0 6|Actins
P10653697A0133|26 31|forms
P10653697A0133|46 56|processing
P10653697A0133|87 95|sequence
P10653733A0596|9 16|domains
P10653733A0596|56 64|peptides
P10654032A1133|0 4|JPEG
P10654032A1133|24 41|compression ratio
P10654032A1133|86 97|performance
P10655164A0546|40 53|uncertainties
P10655164A0546|83 95|Li abundance
P10655164A0546|121 127|limits
P10655164A0546|134 139|parl0
P10655164A0546|140 142|Li
P10655164A0546|147 152|solm0
P10655164A0546|153 154|H
P10655164A0546|159 164|parr0
P10655164A0546|165 166|p
P10655164A0546|181 187|x10-10
P10655230A0685|11 28|yeast counterpart
P10655230A0685|34 53|mouse GCN2 isoforms
P10655230A0685|76 85|sequences
P10655230A0685|104 110|kinase
P10655230A0685|121 127|domain
P10656154A0722|5 10|women
P10656154A0722|16 17|%
P10656154A0722|23 31|criteria
P10656154A0722|36 39|PMS
P10656161A0316|0 3|MBI
P10656161A0316|8 12|MMBI
P10656161A0316|28 39|Cmax values
P10656161A0316|82 87|serum
P10656161A0316|131 141|AUC values
P10656802A1724|13 22|insertion
P10656802A1724|30 61|cathepsin X amino acid sequence
P10656802A1724|113 117|site
P10657238A0541|0 24|Transfection experiments
P10657238A0541|59 65|region
P10657238A0541|88 98|mStaf gene
P10657238A0541|106 119|transcription
P10657238A0541|123 140|mouse NMuMG cells
P10657238A0541|152 161|construct
P10657238A0541|175 183|fragment
P10657238A0541|236 244|activity
P10657658A0165|8 15|studies
P10657658A0165|19 29|T-24 cells
P10657658A0165|48 60|HA fragments
P10657658A0165|74 105|I kappa B alpha phosphorylation
P10657658A0165|110 121|degradation
P10657658A0165|123 128|kappa
P10657658A0165|138 162|reporter gene expression
P10657658A0165|168 192|ICAM-1 promoter activity
P10657658A0165|199 207|NF-kappa
P10657658A0165|220 226|manner
P10657899A0685|0 12|Pretreatment
P10657899A0685|16 21|cells
P10657899A0685|25 35|mouse skin
P10657899A0685|51 67|oligonucleotides
P10657899A0685|71 78|PKCzeta
P10657899A0685|99 109|activation
P10657899A0685|113 117|AP-1
P10657899A0685|121 130|JB6 cells
P10657899A0685|172 176|mice
P10658425A1567|4 9|level
P10658425A1567|25 34|infection
P10658425A1567|41 42|%
P10658425A1567|62 66|dogs
P10658445A0208|0 7|METHODS
P10658445A0208|20 25|group
P10658445A0208|35 43|patients
P10658445A0208|84 108|PGE1 alpha-ciclodestrina
P10658445A0208|121 137|treatment cycles
P10658445A0208|142 146|year
P10658445A0208|157 163|latter
P10658445A0208|181 196|reference group
P10658445A0208|213 227|prostaglandins
P10658588A0304|0 28|Desmethylferrochloroquine 1a
P10658588A0304|33 60|didesmethylferrochloroquine
P10658588A0304|92 106|schizontocides
P10658588A0304|112 114|CQ
P10658588A0304|136 143|strains
P10658588A0304|145 148|HB3
P10658588A0304|153 156|Dd2
P10658588A0304|161 182|Plasmodium falciparum
P10660069A0819|4 22|rrd1,2delta mutant
P10660069A0819|48 60|inactivation
P10660069A0819|64 68|HOG1
P10660069A0819|72 76|PBS2
P10660069A0819|92 103|interaction
P10660069A0819|116 125|RRD genes
P10660069A0819|134 167|Hog1p signal transduction pathway
P10660304A0522|0 7|Members
P10660304A0522|15 29|JAK/Tyk family
P10660304A0522|33 49|tyrosine kinases
P10660304A0522|58 73|phosphorylation
P10660304A0522|77 82|STAT3
P10660304A0522|86 92|Tyr705
P10660304A0522|100 114|CNTF signaling
P10660304A0522|129 135|kinase
P10660304A0522|152 167|phosphorylation
P10660304A0522|171 183|STAT3 Tyr727
P10660304A0522|228 236|stimulus
P10660304A0522|254 261|context
P10660604A0748|9 25|CARbeta/RXRalpha
P10660604A0748|36 49|transcription
P10660604A0748|58 95|HD-PPRE luciferase reporter construct
P10660676A0000|0 17|Zebrafish cyclops
P10660676A0000|19 22|cyc
P10660676A0000|47 65|Growth Factor beta
P10660676A0000|67 74|TGFbeta
P10660676A0000|76 92|signaling factor
P10660676A0000|112 123|mouse Nodal
P10662550A0679|6 10|SOX8
P10662550A0679|21 35|candidate gene
P10662550A0679|63 84|retardation phenotype
P10662550A0679|93 108|ATR-16 patients
P10662614A0000|4 23|genome organization
P10662614A0000|48 73|wheat streak mosaic virus
P10662614A0000|75 79|WSMV
P10662614A0000|109 116|members
P10662614A0000|124 135|Potyviridae
P10662614A0000|153 160|genomes
P10662614A0000|188 214|amino acid dissimilarities
P10662614A0000|236 248|polyproteins
P10662614A0972|15 20|assay
P10662614A0972|58 63|genes
P10662614A0972|67 69|CI
P10662614A0972|71 77|HC-Pro
P10662614A0972|79 81|P1
P10662614A0972|83 85|P3
P10662614A0972|91 93|CP
P10662614A0972|115 127|interactions
P10663558T0000|19 31|light chains
P10663558T0000|46 74|basement membrane reactivity
P10663558T0000|92 96|mice
P10663558T0000|128 130|Ig
P10663558T0000|137 142|chain
P10664876A0000|0 10|Patch test
P10664876A0000|33 47|corticosteroid
P10664876A0000|57 65|patients
P10664876A0000|86 107|corticosteroid series
P10664876A0000|130 144|classification
P10664876A0000|148 172|corticosteroid molecules
P10664876A0000|181 187|groups
P10664876A0000|206 215|molecules
P10664876A0000|223 230|group A
P10664876A0000|232 251|hydrocortisone type
P10664876A0000|254 261|group B
P10664876A0000|263 273|acetonides
P10664876A0000|276 283|group C
P10664876A0000|285 307|betamethasone type-non
P10664876A0000|324 331|group D
P10664876A0000|333 339|esters
P10665308T0001|0 10|Mechanisms
P10665308T0001|14 27|tachyphylaxis
P10665308T0001|40 50|anesthesia
P10665308T0001|59 67|duration
P10665798A0598|3 11|increase
P10665798A0598|19 24|level
P10665798A0598|28 41|serum enzymes
P10665798A0598|51 73|aspartate transaminase
P10665798A0598|75 95|alkaline phosphatase
P10665798A0598|97 119|creatine phosphokinase
P10665798A0598|121 142|lactate dehydrogenase
P10665798A0598|149 176|D. russelli venom injection
P10665798A0598|180 191|albino rats
P10665798A0598|209 213|cell
P10665798A0598|217 230|tissue damage
P10665949A1131|12 23|farm budget
P10665949A1131|40 50|importance
P10665949A1131|76 83|lesions
P10665949A1131|89 96|feedlot
P10666222A0330|35 55|survivin cDNA clones
P10666222A0330|86 95|existence
P10666222A0330|110 127|survivin proteins
P10666238A1322|10 19|induction
P10666238A1322|23 34|E2F binding
P10666238A1322|42 56|E2F-1 promoter
P10666238A1322|64 68|E4-6
P10666238A1322|71 78|protein
P10666238A1322|113 128|transactivation
P10666238A1322|132 155|E2F-1 promoter activity
P10666253A1291|13 26|stabilization
P10666253A1291|34 41|hairpin
P10666253A1291|54 60|amount
P10666253A1291|64 75|tRNA primer
P10666253A1291|100 103|PBS
P10666509A0494|26 37|arrhythmias
P10666509A0494|62 73|zatebradine
P10666509A0494|78 96|propranolol groups
P10667597A0668|0 3|ZK7
P10667597A0668|8 19|HZF16 genes
P10667597A0668|37 52|splice variants
P10667597A0668|79 83|gene
P10668701A1311|0 10|CONCLUSION
P10668701A1311|12 20|Presence
P10668701A1311|24 37|APOE epsilon4
P10668701A1311|62 66|risk
P10668701A1311|71 79|dementia
P10668701A1311|84 86|AD
P10668701A1311|108 114|effect
P10668701A1311|118 130|dyslipidemia
P10668701A1311|135 148|atherogenesis
P10669319A1722|12 23|conclusions
P10669319A1722|58 64|number
P10669319A1722|68 76|patients
P10669319A1722|94 99|phase
P10669319A1722|103 108|trial
P10669594A0000|24 32|fimbrins
P10669594A0000|34 38|AgfA
P10669594A0000|43 47|SefA
P10669594A0000|77 91|fimbriae SEF17
P10669594A0000|96 101|SEF14
P10669594A0000|159 162|PT3
P10669594A0000|181 220|16-amino acid Leishmania T-cell epitope
P10669594A0000|238 258|metalloprotease gp63
P10669594A0969|10 18|contrast
P10669594A0969|22 26|AgfA
P10669594A0969|28 32|none
P10669594A0969|49 62|SefA proteins
P10669594A0969|96 104|fimbriae
P10669596A0430|11 17|growth
P10669596A0430|21 30|phage P22
P10669596A0430|87 95|presence
P10669596A0430|99 103|Abc2
P10669596A0430|140 145|level
P10669596A0430|163 180|nuclease activity
P10669596A0430|207 213|change
P10669596A0430|221 227|nature
P10669596A0430|245 269|RecBCD nuclease activity
P10669596A0430|293 299|enzyme
P10669633A0391|8 13|study
P10669633A0391|45 55|mechanisms
P10669633A0391|81 91|expression
P10669633A0391|99 109|flt-1 gene
P10669633A0391|121 131|activation
P10669633A0391|135 146|THP-1 cells
P10669736A0903|21 31|difference
P10669736A0903|35 38|CAT
P10669736A0903|59 70|transcripts
P10669736A0903|74 84|HeLa cells
P10669736A0903|118 127|abundance
P10669736A0903|131 134|PTB
P10669751T0000|27 60|protein kinase signaling pathways
P10669751T0000|73 88|cot oncoprotein
P10669751T0000|96 110|c-jun promoter
P10669751T0000|127 141|transformation
P10670358A0143|0 11|Dermatology
P10670358A0143|18 27|exception
P10671224A0254|15 20|study
P10671224A0254|57 66|mechanism
P10671224A0254|71 87|CD95L expression
P10671519A0641|0 25|Protein sequence analysis
P10671519A0641|39 50|MAN1 shares
P10671519A0641|72 78|domain
P10671519A0641|99 110|amino acids
P10671519A0641|130 140|LEM module
P10671519A0641|161 178|membrane proteins
P10671519A0641|197 208|polypeptide
P10671519A0641|215 221|emerin
P10671520T0000|10 17|cloning
P10671520T0000|35 40|I-mfa
P10671520T0000|59 66|protein
P10671520T0000|100 126|T-cell leukemia virus type
P10671520T0000|133 149|HIV-1 expression
P10671554A0492|12 32|amino acid sequences
P10671554A0492|52 58|bovine
P10671554A0492|63 76|porcine cDNAs
P10671554A0492|111 130|amino acid residues
P10671554A0492|174 182|sequence
P10671554A0492|197 214|Edman degradation
P10671606A0884|5 27|chemical shift imaging
P10671606A0884|33 49|signal intensity
P10671606A0884|80 86|images
P10671606A0884|106 107|%
P10671606A0884|109 117|patients
P10671606A0884|123 126|APA
P10671606A0884|151 152|%
P10671606A0884|154 162|patients
P10671606A0884|168 171|BAH
P10672433A0199|9 14|night
P10672433A0199|20 25|diary
P10672433A0199|49 60|measurement
P10672433A0199|64 71|bedtime
P10672433A0199|73 82|wake time
P10672433A0199|84 88|time
P10672433A0199|92 95|bed
P10672433A0199|97 100|TIB
P10672433A0199|109 119|efficiency
P10672433A0199|121 127|number
P10672433A0199|131 138|minutes
P10672433A0199|142 146|wake
P10672433A0199|153 164|sleep onset
P10672433A0199|166 170|WASO
P10672433A0199|173 182|alertness
P10672433A0199|186 195|awakening
P10672433A0199|201 211|percentage
P10672433A0199|215 222|morning
P10672433A0199|234 239|alarm
P10672433A0199|246 252|person
P10672899A0078|0 4|Acad
P10673335X0782|0 9|Copyright
P10673335X0782|15 29|Academic Press
P10673426A0168|13 14|R
P10673426A0168|16 22|domain
P10673426A0168|59 67|activity
P10673426A0168|92 93|T
P10673426A0168|95 101|domain
P10673426A0168|111 124|translocation
P10673426A0168|130 137|process
P10673426A0168|172 178|domain
P10673426A0168|203 211|receptor
P10673426A0168|219 223|site
P10673426A0168|231 243|cytotoxicity
P10674395A0262|37 47|expression
P10674395A0262|55 59|gene
P10674395A0262|81 93|neuropeptide
P10674395A0262|95 99|GnRH
P10674395A0262|141 144|GMP
P10674395A0262|146 150|cGMP
P10674395A0262|152 179|signal transduction pathway
P10674395A0262|203 217|protein kinase
P10674395A0262|262 277|cell line GT1-7
P10674484A0633|6 10|data
P10674484A0633|33 40|lesions
P10674484A0633|73 80|neurons
P10674484A0633|88 97|rat brain
P10674484A0633|121 131|perception
P10674484A0633|156 162|memory
P10675154T0000|8 15|potency
P10675154T0000|19 34|botulinum toxin
P10675331A0600|3 11|contrast
P10675331A0600|13 18|c-Src
P10675331A0600|32 45|isoproterenol
P10675331A0600|53 77|tyrosine phosphorylation
P10675331A0600|81 84|Shc
P10675331A0600|100 114|Erk activation
P10675331A0600|124 148|tyrosine phosphorylation
P10675331A0600|152 161|cortactin
P10675331A0600|165 170|Stat3
P10675610A0279|0 5|MSSPs
P10675610A0279|31 46|DNA replication
P10675610A0279|48 61|transcription
P10675610A0279|63 73|apopotosis
P10675610A0279|78 100|cell cycle progression
P10675610A0279|125 138|C-MYC protein
P10677214A1045|9 18|type MutT
P10677214A1045|27 31|E53D
P10677214A1045|36 48|E44D mutants
P10677214A1045|50 55|plots
P10677214A1045|59 62|log
P10677214A1045|63 64|k
P10677214A1045|65 68|cat
P10677214A1045|78 80|pH
P10677214A1045|102 107|slope
P10677214A1045|130 134|limb
P10677214A1045|146 150|hump
P10677214A1045|176 183|maximum
P10677214A1045|189 191|pH
P10677214A1045|208 215|plateau
P10677214A1045|235 237|pK
P10677214A1045|241 247|values
P10677214A1045|296 300|base
P10677214A1045|320 333|acid catalyst
P10677214A1045|374 381|MutT-Mg
P10677214A1045|386 393|dGTP-Mg
P10677214A1045|398 405|complex
P10677214A2842|11 18|changes
P10677214A2842|51 55|E44D
P10677214A2842|78 79|H
P10677214A2842|84 98|N HSQC spectra
P10677214A2842|127 139|loop I-helix
P10677214A2842|142 147|motif
P10677214A2842|165 171|Glu-44
P10677214A2842|194 205|site region
P10677297A0933|9 19|expression
P10677297A0933|58 66|nonsense
P10677297A0933|71 89|missense mutations
P10677297A0933|134 142|location
P10677297A0933|150 157|protein
P10677297A0933|170 175|cells
P10678144A0509|6 10|i.v.
P10678968A1096|0 8|Immunity
P10678968A1096|21 25|mice
P10678968A1096|33 46|I. scapularis
P10678968A1096|55 63|activity
P10678968A1096|73 79|summer
P10678968A1096|100 110|proportion
P10678968A1096|118 134|mouse population
P10678968A1096|152 169|E. phagocytophila
P10678968A1096|181 187|period
P10678968A1096|198 206|activity
P10678968A1096|220 226|season
P10679015A0216|13 17|view
P10679015A0216|27 34|studies
P10679015A0216|38 43|yeast
P10679015A0216|57 62|class
P10679015A0216|66 73|snoRNPs
P10679015A0216|98 101|set
P10679015A0216|105 113|proteins
P10679065A0711|0 17|BCR cross-linking
P10679065A0711|55 80|protein kinase-2 activity
P10679065A0711|85 91|enzyme
P10679065A0711|130 138|p38 MAPK
P10679065A0711|155 171|protein kinase-2
P10679065A0711|179 188|complexes
P10679065A0711|206 223|peptide substrate
P10679065A0711|239 250|CREB serine
P10679065A0711|255 276|phosphoacceptor motif
P10679065A1217|0 10|Activation
P10679065A1217|30 77|junB promoter/chloramphenicol acetyltransferase
P10679065A1217|79 82|CAT
P10679065A1217|84 97|reporter gene
P10679065A1217|105 108|BCR
P10679065A1217|129 137|SB203580
P10679190A0693|11 19|evidence
P10679190A0693|43 56|reading frame
P10679190A0693|58 62|uORF
P10679190A0693|78 89|translation
P10679190A0693|119 132|reading frame
P10679190A0693|134 138|mORF
P10679649A0311|0 7|METHODS
P10679649A0311|9 25|TBN measurements
P10679649A0311|54 65|outpatients
P10679649A0311|71 87|breast carcinoma
P10679649A0311|117 133|cyclophosphamide
P10679649A0311|135 147|methotrexate
P10679649A0311|153 167|5-fluorouracil
P10679649A0311|169 172|CMF
P10679649A0311|180 192|chemotherapy
P10679649A0311|194 204|median age
P10679649A0311|209 214|years
P10679649A0311|216 221|range
P10679649A0311|230 235|years
P10679781A1183|6 37|bp Glucocorticoid Response Unit
P10679781A1183|39 42|GRU
P10679781A1183|65 89|glucocorticoid induction
P10679781A1183|106 120|dibutyryl-cAMP
P10679781A1183|136 150|phorbol esters
P10679922A1110|11 20|mutations
P10679922A1110|46 53|samples
P10679922A1110|71 75|ING1
P10679922A1110|85 113|tumor suppressor gene target
P10679922A1110|117 121|head
P10679922A1110|126 137|neck cancer
P10681520A0525|0 8|Ras-GRF1
P10681520A0525|36 41|v-Src
P10681520A0525|93 105|GEF activity
P10681520A0525|113 116|Rac
P10681520A0525|126 129|Rho
P10681520A0525|134 139|Cdc42
P10681520A0525|183 193|Gbetagamma
P10681562A0263|15 36|PPARgamma antagonists
P10681562A0263|107 122|mutant receptor
P10681562A0263|144 160|PPARgamma action
P10681588A0899a|0 4|EMSA
P10681588A0899a|25 33|proteins
P10681588A0899a|39 43|PC12
P10681588A0899a|52 54|C6
P10681588A0899a|58 68|Rat2 cells
P10681588A0899a|78 81|CRE
P10681588A0899a|87 94|complex
P10681588A0899a|117 137|transcription factor
P10681588A0899a|139 142|ATF
P10681588A0899a|150 155|CCAAT
P10681588A0899a|173 185|protein beta
P10681588A0899a|198 202|PC12
P10681588A0899a|207 214|C6 cell
P10681588A0899a|223 231|extracts
P10681588A0899a|254 263|CCAAT-box
P10681588A0899a|269 276|complex
P10681588A0899a|296 305|factor Y.
P10681588A0899b|0 4|EMSA
P10681588A0899b|25 33|proteins
P10681588A0899b|39 43|PC12
P10681588A0899b|52 54|C6
P10681588A0899b|58 68|Rat2 cells
P10681588A0899b|78 81|CRE
P10681588A0899b|87 94|complex
P10681588A0899b|117 137|transcription factor
P10681588A0899b|139 142|ATF
P10681588A0899b|150 155|CCAAT
P10681588A0899b|173 185|protein beta
P10681588A0899b|198 202|PC12
P10681588A0899b|207 214|C6 cell
P10681588A0899b|223 231|extracts
P10681588A0899b|254 263|CCAAT-box
P10681588A0899b|269 276|complex
P10681588A0899b|296 305|factor Y.
P10681679A0220|8 18|resolution
P10681679A0220|32 39|portion
P10681679A0220|47 52|tumor
P10681679A0220|54 64|serial MRI
P10681679A0220|72 83|enlargement
P10681679A0220|97 107|tumor cyst
P10681679A0220|110 115|years
P10681679A0220|135 144|diagnosis
P10682570A0453|0 3|LPO
P10682570A0453|8 18|SOD levels
P10682570A0453|41 47|points
P10682570A0453|70 79|operation
P10683072T0000|22 33|tachycardia
P10683072T0000|53 64|prophylaxis
P10683072T0000|82 109|bolus interleukin-2 therapy
P10683072T0000|131 145|cell carcinoma
P10683244A0939|17 21|NBF1
P10683244A0939|22 31|R protein
P10683244A0939|37 49|NBF2 protein
P10683244A0939|57 64|mixture
P10683244A0939|76 84|proteins
P10683244A0939|134 153|sieve chomatography
P10683244A0939|159 166|mixture
P10683244A0939|202 206|NBF1
P10683244A0939|207 208|R
P10683244A0939|212 216|NBF2
P10683244A1860|20 31|experiments
P10683244A1860|49 53|CFTR
P10683244A1860|56 60|NBF1
P10683244A1860|61 69|R region
P10683244A1860|78 89|NBF2 domain
P10683244A1860|128 133|units
P10683244A1860|149 159|propensity
P10683244A1860|186 197|interaction
P10683244A1860|215 222|absence
P10683244A1860|232 243|nucleotides
P10683244A1860|267 282|phosphorylation
P10683244X2359|0 9|Copyright
P10683244X2359|15 29|Academic Press
P10683259A0774|0 20|Sulfhydryl titration
P10683259A0774|26 39|iodoacetamide
P10683259A0774|80 86|thiols
P10683259A0774|93 101|reaction
P10683259A0774|109 129|maleimide derivative
P10683259A0774|133 139|biotin
P10683259A0774|161 171|difference
P10683259A0774|188 190|pK
P10683259A0774|194 200|values
P10683259A0774|208 217|cysteines
P10683259A0774|229 245|splice junctions
P10683989A0251|13 29|oxide inhalation
P10683989A0251|35 42|results
P10683989A0251|59 68|increases
P10683989A0251|72 76|PaO2
P10683989A0251|81 85|SaO2
P10683989A0251|87 88|P
P10683989A0251|115 123|decrease
P10683989A0251|127 141|Qs/Q tau ratio
P10683989A0251|143 144|P
P10684069A0508|4 11|results
P10684069A0508|24 27|MIP
P10684069A0508|29 33|MMIF
P10684069A0508|35 38|FIC
P10684069A0508|40 45|Wimax
P10684069A0508|47 51|P0.1
P10684069A0508|56 74|minute ventilation
P10684069A0508|76 78|Vr
P10684069A0508|115 129|administration
P10684069A0508|133 149|methylphenidatum
P10684069A0508|154 167|aminophylline
P10684097A0175|18 20|SD
P10684097A0175|28 32|rats
P10684097A0175|65 71|groups
P10684097A0175|80 94|sham operation
P10684097A0175|106 117|ovariectomy
P10684097A0175|119 130|ovariectomy
P10684097A0175|150 167|ethinyl estradiol
P10684097A0175|187 191|g B.
P10684111A1411|30 37|variety
P10684111A1411|55 62|factors
P10684111A1411|75 79|pair
P10684111A1411|83 91|MAPK p44
P10684111A1411|96 104|MAPK p42
P10684111A1411|108 127|MAPK family members
P10684265T0000|9 21|modification
P10684265T0000|29 59|transactivator protein IE2-p86
P10684265T0000|69 84|cytomegalovirus
P10684265T0000|88 99|conjugation
P10684265T0000|128 143|proteins SUMO-1
P10684265T0000|148 154|hSMT3b
P10684304A1242|4 15|interaction
P10684304A1242|24 25|U
P10684304A1242|26 27|L
P10684534A0634|0 9|Protamine
P10684534A0634|14 27|heparin doses
P10684534A0634|35 38|sum
P10684534A0634|40 50|Sigma-dose
P10684534A0634|82 87|doses
P10684534A0634|103 117|clotting times
P10684646A0224|8 13|study
P10684646A0224|24 33|mechanism
P10684646A0224|72 78|growth
P10684646A0224|97 107|expression
P10684646A0224|111 119|caveolin
P10684660A1266|0 10|Comparison
P10684660A1266|18 23|plant
P10684660A1266|32 36|tRNA
P10684660A1266|40 57|processing enzyme
P10684660A1266|67 72|plant
P10684660A1266|110 120|activities
P10684660A1266|135 142|enzymes
P10684941A0722|4 15|requirement
P10684941A0722|22 37|complementarity
P10684941A0722|44 61|ligation reaction
P10684941A0722|79 86|results
P10684941A0722|94 107|nt insertions
P10684941A0722|132 136|side
P10684941A0722|144 148|nick
P10684967A0000|0 6|NKX2.1
P10684967A0000|12 18|member
P10684967A0000|26 36|NK2 family
P10684967A0000|63 84|transcription factors
P10684967A0000|100 110|disruption
P10684967A0000|114 119|mouse
P10684967A0000|135 142|absence
P10684967A0000|146 160|thyroid tissue
P10684967A0000|185 199|lung phenotype
P10687366A0000|0 22|National abortion laws
P10687366A0000|44 52|abortion
P10687366A0000|60 66|foetus
P10687366A0000|116 119|age
P10687366A0000|132 137|weeks
P10687855A1197|0 10|Expression
P10687855A1197|30 39|pituitary
P10687855A1197|65 70|cells
P10687855A1197|85 90|Zn-16
P10687855A1197|104 108|role
P10687855A1197|122 133|development
P10687855A1197|155 170|differentiation
P10687855T0000|0 47|Mouse growth hormone transcription factor Zn-16
P10687855T0000|66 75|structure
P10687855T0000|105 124|zinc finger domains
P10687855T0000|141 150|rat Zn-15
P10687862A1980|4 31|CCAAT core sequence mutants
P10687862A1980|46 50|CIII
P10687862A1980|55 61|CI/CII
P10687862A1980|97 114|promoter activity
P10687945A0000|0 11|Deglutition
P10687945A0000|44 51|infants
P10688639A1310|5 15|repression
P10688639A1310|37 57|PU.1 transactivation
P10688639A1310|61 73|PEST domains
P10688639A1310|100 115|p300 expression
P10688646A0535|23 33|K562 cells
P10688646A0535|65 82|HS-40 mutants cis
P10688646A0535|101 113|alpha-globin
P10688646A0535|130 149|hormone hybrid gene
P10688646A0535|175 187|footprinting
P10688646A0535|192 211|expression analysis
P10688660A0992|15 23|addition
P10688660A0992|36 39|CBP
P10688660A0992|55 63|extracts
P10688660A0992|67 77|T47D cells
P10688660A0992|98 110|progesterone
P10688660A0992|129 142|transcription
P10688660A0992|167 196|progesterone response element
P10688660A0992|198 201|PRE
P10688660A0992|210 231|reporter DNA template
P10688661A0237|12 27|binding protein
P10688661A0237|29 38|REST/NRSF
P10688661A0237|56 76|transcription factor
P10688661A0237|87 96|mutations
P10688661A0237|117 126|lethality
P10688661A0237|154 161|mutants
P10688661A0237|179 189|expression
P10688661A0237|209 214|genes
P10688663A0207|0 7|Removal
P10688663A0207|15 40|core histone tail domains
P10688663A0207|52 71|trypsin proteolysis
P10688663A0207|75 86|acetylation
P10688663A0207|94 112|core histone tails
P10688663A0207|141 151|inhibition
P10688663A0207|163 169|TFIIIA
P10688663A0207|218 221|DNA
P10688666A1010|13 22|mechanism
P10688666A1010|26 41|ASK1 activation
P10688666A1010|55 59|part
P10688666A1010|61 81|homo-oligomerization
P10690702A0065|0 7|OUTCOME
P10690702A0065|9 42|Acetylcholine receptor antibodies
P10690702A0065|60 74|electromyogram
P10690702A0065|94 103|diagnosis
P10690702A0065|107 124|myasthenia gravis
P10690725A1037|10 18|patients
P10690725A1037|29 33|PRFR
P10690866A0783|4 14|variations
P10690866A0783|39 45|shifts
P10690866A0783|49 75|TSH frequency distribution
P10690866A0783|79 86|mothers
P10690866A0783|91 99|neonates
P10691972T0000|0 16|Characterization
P10691972T0000|36 42|region
P10691972T0000|66 84|resistance protein
P10691972T0000|88 92|MRP2
P10691972T0000|94 98|gene
P10691972T0000|107 117|regulation
P10691972T0000|121 139|comparison withthe
P10691972T0000|150 168|resistance protein
P10691972T0000|172 176|MRP3
P10691972T0000|178 182|gene
P10692167A0364|16 25|mechanism
P10692167A0364|58 70|observations
P10692167A0364|74 85|M. synoviae
P10692374A1873|6 13|results
P10692374A1873|31 44|M. jannaschii
P10692374A1873|73 88|20S proteasomes
P10692374A1873|99 119|nucleotidase complex
P10692374A1873|128 131|PAN
P10692374A1873|164 174|hydrolysis
P10692374A1873|195 203|proteins
P10692374A1873|231 250|amino acid residues
P10692374A1873|254 257|PAN
P10692374A1873|295 303|reaction
P10692433A0000|4 28|transcription factor E2F
P10692433A0000|48 52|role
P10692433A0000|56 57|G
P10692433A0000|64 82|S phase transition
P10692433A0000|108 118|cell cycle
P10693246A0252|19 29|dissection
P10693246A0252|35 45|components
P10693246A0252|124 134|dissection
P10693246A0252|157 179|laryngeal nerve chains
P10693246A0252|193 204|mediastinum
P10693314A0521|11 19|patients
P10693314A0521|29 42|CK-MB results
P10693314A0521|66 67|%
P10693314A0521|69 77|patients
P10693314A0521|79 82|ECG
P10693314A0521|92 95|AMI
P10693314A0521|105 106|%
P10693314A0521|108 116|patients
P10694189A0469|4 10|effect
P10694189A0469|14 17|MIB
P10694189A0469|39 44|curve
P10694189A0469|67 80|noradrenaline
P10694210A0385|13 21|blockade
P10694210A0385|25 28|H1R
P10694210A0385|87 105|cingulate cortices
P10694210A0385|127 141|administration
P10694210A0385|145 163|d-chlorpheniramine
P10694210A0385|181 185|dose
P10694210A0385|189 191|mg
P10694210A0385|208 209|%
P10694210A0385|213 216|H1R
P10694210A0385|232 240|cortices
P10694511A0570|4 14|expression
P10694511A0570|22 26|yam8
P10694511A0570|30 34|cDNA
P10694511A0570|42 46|mid1
P10694511A0570|54 59|cells
P10694511A0570|89 98|phenotype
P10694511A0570|124 132|increase
P10694511A0570|136 138|Ca
P10694511A0570|143 158|uptake activity
P10694605A1327|19 34|infection rates
P10694605A1327|36 59|events/100 patient-days
P10694605A1327|112 123|double-lung
P10694605A1327|125 126|P
P10694605A1327|129 131|NS
P10694605A1327|138 144|months
P10694609A0309|19 29|compliance
P10694609A0309|49 58|induction
P10694609A0309|62 72|anesthesia
P10694609A0309|103 113|filtration
P10694609A0309|121 138|operating theater
P10694609A0309|142 146|hour
P10694609A0309|153 159|return
P10694609A0309|187 196|care unit
P10694609A0309|205 210|hours
P10694609A0309|221 230|operation
P10695685T0000|12 19|therapy
P10695685T0000|33 42|rationale
P10695685T0000|55 67|implications
P10695685T0000|82 94|consequences
P10696007A1325|12 23|correlation
P10696007A1325|32 53|C2-C3 disk morphology
P10696007A1325|88 96|response
P10698516T0000|0 3|KFC
P10698516T0000|18 24|kinase
P10698516T0000|54 64|capability
P10698516T0000|81 97|SAPK/JNK pathway
P10698937T0000|0 5|TIP30
P10698937T0000|23 38|kinase activity
P10698937T0000|52 65|up-regulation
P10698937T0000|71 77|subset
P10698937T0000|91 96|genes
P10698974A0951|25 35|STAG3 gene
P10698974A0951|48 54|region
P10698974A0951|58 68|chromosome
P10698974A0951|96 101|genes
P10698974A0951|157 161|gene
P10698974A0951|226 237|breakpoints
P10698974A0951|283 291|syndrome
P10698974A0951|293 296|WBS
P10698974A0951|298 306|deletion
P10699354A0557|0 13|Reaction time
P10699354A0557|15 17|RT
P10699354A0557|23 27|P300
P10699653A0967|3 13|experiment
P10699653A0967|20 24|rats
P10699653A0967|34 40|access
P10699653A0967|48 55|bottles
P10699653A0967|80 89|tap water
P10699653A0967|125 132|ethanol
P10699653A0967|135 136|%
P10699653A0967|143 150|sucrose
P10699653A0967|153 154|%
P10699653A0967|156 164|solution
P10699684A0661|13 18|Zelen
P10699684A0661|21 27|method
P10699684A0661|51 57|number
P10699684A0661|61 69|patients
P10699684A0661|91 97|groups
P10699684A0661|110 121|institution
P10699684A0661|123 125|M.
P10699896A0455|0 7|RESULTS
P10699896A0455|17 22|group
P10699896A0455|26 34|patients
P10699896A0455|41 47|gender
P10699896A0455|49 50|P
P10700262A0000|17 26|attention
P10700262A0000|44 53|interplay
P10700262A0000|74 89|control systems
P10700262A0000|102 118|brain structures
P10701534A0164|4 11|patient
P10701534A0164|37 57|low-frequency tremor
P10701534A0164|62 74|hemidystonia
P10701534A0164|90 101|head trauma
P10701534A0164|118 123|years
P10701534A0164|127 130|age
P10702241A0357|13 23|a1 isoform
P10702241A0357|53 58|brain
P10702241A0357|63 68|heart
P10702241A0357|70 72|a2
P10702241A0357|76 81|liver
P10702241A0357|86 92|kidney
P10702241A0357|98 100|a3
P10702241A0357|104 109|liver
P10702241A0357|111 115|lung
P10702241A0357|117 122|heart
P10702241A0357|124 129|brain
P10702241A0357|131 137|spleen
P10702241A0357|143 149|kidney
P10702253A0357|11 18|cloning
P10702253A0357|30 69|transcriptase-polymerase chain reaction
P10702253A0357|83 101|HIF-1alpha subunit
P10702253A0357|119 130|cDNA clones
P10702253A0357|165 173|splicing
P10702253A0357|181 196|HIF-1alpha gene
P10702285A0855|14 26|relationship
P10702285A0855|35 36|G
P10702285A0855|37 38|q
P10702285A0855|40 41|G
P10702285A0855|46 54|function
P10702285A0855|64 93|phosphatidylinositol 3-kinase
P10702285A0855|104 111|pathway
P10702285A0855|113 123|expression
P10702285A0855|150 153|p85
P10702285A0855|165 172|subunit
P10702285A0855|185 205|wortmannin treatment
P10702285A0855|243 244|G
P10702285A0855|245 246|q
P10702285A0855|265 289|GLUT4-EGFP translocation
P10702389A1148|11 13|BL
P10702389A1148|19 32|RB2/p130 gene
P10702389A1148|59 64|cases
P10702389A1148|74 81|protein
P10702389A1148|103 112|cytoplasm
P10702794A1495|16 20|data
P10702794A1495|30 34|ERK2
P10702794A1495|60 66|target
P10702794A1495|70 75|HePTP
P10702794A1495|102 107|model
P10702794A1495|117 122|HePTP
P10702794A1495|144 157|ERK2 activity
P10702794A1495|161 165|part
P10702794A1495|171 189|feedback mechanism
P10702926T0089|0 14|Cross-reaction
P10702926T0089|36 44|antibody
P10702926T0089|53 80|alpha beta T cell receptors
P10703633A0747|0 17|Strontium nitrate
P10703633A0747|38 42|acid
P10703633A0747|47 57|comparison
P10703633A0747|72 76|acid
P10703633A0747|94 95|p
P10703633A0747|116 124|duration
P10703633A0747|132 152|irritation sensation
P10703633A0747|170 174|mean
P10703633A0747|177 180|SEM
P10703633A0747|182 185|min
P10703633A0747|200 204|mean
P10703633A0747|207 210|SEM
P10703633A0747|212 215|min
P10703633A0747|236 237|p
P10703633A0747|256 270|mean magnitude
P10703633A0747|278 298|irritation sensation
P10703633A0747|306 317|time points
P10704196A1051|19 36|sulfhydryl groups
P10704196A1051|79 83|half
P10704196A1051|91 106|plasma membrane
P10704196A1051|140 145|model
P10704196A1051|161 165|side
P10704196A1051|173 180|helices
P10704283A0649a|0 8|Analysis
P10704283A0649a|14 16|Mb
P10704283A0649a|30 38|sequence
P10704283A0649a|48 54|region
P10704283A0649a|68 75|synteny
P10704283A0649a|85 104|chromosome 5q31-q33
P10704283A0649a|119 134|gene candidates
P10704283A0649a|159 164|genes
P10704283A0649a|178 204|IL-4 cytokine gene cluster
P10704285A0536|6 13|AP-2rep
P10704285A0536|29 48|reporter expression
P10704285A0536|80 98|AP-2alpha promoter
P10704285A0536|118 132|AP-2alpha gene
P10704285A0536|175 184|AP-2alpha
P10704338A0354|3 8|order
P10704338A0354|24 31|insight
P10704338A0354|41 45|role
P10704338A0354|68 74|domain
P10704338A0354|82 85|p24
P10704338A0354|86 88|CA
P10704338A0354|90 97|protein
P10704338A0354|111 122|replication
P10704338A0354|147 163|proline residues
P10704338A0354|181 186|turns
P10704338A0354|204 217|alpha-helices
P10704338A0354|229 232|p24
P10704338A0354|242 251|structure
P10704338A0354|271 286|leucine residue
P10704338A0354|288 300|P-position-L
P10704410T0000|0 17|Clb/Cdc28 kinases
P10704410T0000|34 40|export
P10704410T0000|48 85|replication initiator proteins Mcm2-7
P10704499A0682|15 28|PC12-E2 cells
P10704499A0682|47 56|treatment
P10704499A0682|62 72|antibodies
P10704499A0682|80 104|fibroblast growth factor
P10704499A0682|106 109|FGF
P10704499A0682|111 119|receptor
P10704499A0682|121 131|inhibitors
P10704499A0682|151 170|tyrosine kinase p59
P10704499A0682|171 174|fyn
P10704499A0682|177 180|PLC
P10704499A0682|182 185|PKC
P10704499A0682|190 193|MEK
P10704499A0682|201 210|activator
P10704499A0682|214 217|PKC
P10704499A0682|219 250|phorbol-12-myristate-13-acetate
P10704499A0682|252 255|PMA
P10704853T0000|0 17|Cooperative roles
P10704853T0000|21 35|Bozozok/Dharma
P10704853T0000|54 62|proteins
P10704853T0000|70 79|formation
P10704853T0000|87 103|dorsal organizer
P10704853T0000|107 116|zebrafish
P10704975A0479|0 18|Thiopentone sodium
P10704975A0479|45 48|min
P10704975A0479|72 75|min
P10704975A0479|82 90|exposure
P10704975A0479|94 99|NOC-5
P10704975A0479|157 170|neurotoxicity
P10704975A0479|185 193|controls
P10705380A0629|40 59|Xretpos transcripts
P10705380A0629|104 111|regions
P10705380A0629|127 141|UV-irradiation
P10705380A0629|146 166|BMP-4 overexpression
P10705380A0629|194 197|way
P10705380A0629|199 206|genesis
P10705783A0433|13 18|cases
P10705783A0433|31 41|neurectomy
P10705783A0433|45 53|chemical
P10705783A0433|65 80|labyrinthectomy
P10705783A0433|85 90|means
P10705783A0433|112 136|concentration gentamicin
P10705783A0433|141 146|mg/mL
P10706475A0644|33 37|DSPP
P10706475A0644|54 57|DSP
P10706475A0644|62 65|DPP
P10706513A0843|15 24|prognosis
P10706513A0843|33 44|% mortality
P10706513A0843|50 56|months
P10706513A0843|77 88|ventilation
P10706688A0376|14 27|TCR signaling
P10706688A0376|36 48|AP-1 binding
P10706688A0376|57 61|site
P10706688A0376|80 102|fasl promoter function
P10706688A0376|108 115|fashion
P10706688A0376|129 146|NF-kappaB binding
P10706736A1091|6 14|patients
P10706736A1091|31 39|melanoma
P10706736A1091|66 68|Ag
P10706736A1091|82 91|detection
P10706736A1091|95 98|CD8
P10706736A1091|100 107|T cells
P10706736A1091|130 135|HLA-A
P10706736A1091|167 175|epitopes
P10706887A0281|16 17|%
P10706887A0281|21 26|ALCLs
P10706887A0281|40 43|ALK
P10706887A0281|63 64|t
P10706887A0281|101 114|abnormalities
P10706887A0281|138 152|ALK expression
P10706887A1457|3 11|addition
P10706887A1457|22 31|decreases
P10706887A1457|35 39|ATIC
P10706887A1457|50 58|function
P10706887A1457|82 91|lymphomas
P10706887A1457|109 115|tumors
P10706887A1457|145 150|drugs
P10706887A1457|159 171|methotrexate
P10708243A0000|14 25|observation
P10708243A0000|50 60|antibodies
P10708243A0000|78 92|pregnancy loss
P10708243A0000|97 109|preeclampsia
P10708243A0000|115 119|role
P10708243A0000|138 148|antibodies
P10708424A0800|10 14|ions
P10708424A0800|46 65|autophosphorylation
P10708424A0800|69 74|BGLF4
P10708424A0800|80 89|magnesium
P10708424A0800|108 116|activity
P10708769A0433|4 8|Mif1
P10708769A0433|21 27|region
P10708769A0433|50 52|ER
P10708769A0433|71 78|element
P10708769A0433|103 112|induction
P10708769A0433|116 127|tunicamycin
P10709705T0000|6 32|point feature registration
P10709705T0000|46 57|information
P10710499A0000|0 12|Methysergide
P10710499A0000|18 38|serotonin antagonist
P10710499A0000|75 91|wound blood flow
P10710499A0000|96 111|edema formation
P10710742T0000|0 27|Serum leptin concentrations
P10710742T0000|31 36|women
P10710742T0000|44 75|gonadotropin stimulation cycles
P10710985T0000|8 16|families
P10710985T0000|25 38|work practice
P10710985T0000|44 52|families
P10710985T0000|60 81|strengths perspective
P10711674A0000|0 7|PURPOSE
P10711674A0000|51 57|family
P10711674A0000|83 88|Leber
P10711674A0000|100 109|amaurosis
P10711674A0000|111 114|LCA
P10711674A0000|116 119|MIM
P10711674A0000|133 144|keratoconus
P10712512A0506|0 6|Ste18p
P10712512A0506|27 42|plasma membrane
P10712512A0506|55 62|absence
P10712512A0506|66 77|prenylation
P10712512A0506|81 94|thioacylation
P10712599A0349|19 24|IRF-1
P10712599A0349|66 73|pathway
P10712618A0181|14 33|sequence comparison
P10712618A0181|48 73|Bacillus YM55-1 aspartase
P10712618A0181|83 93|% homology
P10712618A0181|99 126|Bacillus subtilis aspartase
P10712618A0181|133 134|%
P10712618A0181|185 195|aspartases
P10713083A0170|15 21|system
P10713083A0170|27 35|activity
P10713083A0170|39 43|TraR
P10713083A0170|95 99|TraM
P10713083A0560|25 30|assay
P10713083A0560|59 70|DNA binding
P10713083A0560|72 76|TraM
P10713083A0560|87 100|TraR function
P10713083A0560|122 142|transcription factor
P10713083A0560|160 180|DNA recognition site
P10713155A0151|18 40|IIIa pre-mRNA splicing
P10713155A0151|84 92|extracts
P10713155A0151|132 137|cells
P10713155A0151|139 144|Ad-NE
P10713155A0151|169 178|HeLa cell
P10713155A0151|187 195|extracts
P10713155A0151|197 204|HeLa-NE
P10713161A0985|0 12|Inactivation
P10713161A0985|16 20|Ulp2
P10713161A0985|45 49|ulp1
P10713161A0985|50 52|ts
P10713161A0985|54 61|defects
P10713161A0985|107 130|Smt3-protein conjugates
P10713161A0985|150 156|mutant
P10713175A1399|18 25|results
P10713175A1399|39 50|ARF binding
P10713175A1399|54 58|Mdm2
P10713175A1399|84 90|change
P10713175A1399|118 124|import
P10713175A1399|132 148|ARF-Mdm2 complex
P10713175A1399|167 184|cell cycle arrest
P10713176A0422|0 19|Cyclin A expression
P10713176A0422|46 51|cells
P10713176A0422|55 58|E2F
P10713176A0422|69 80|conjunction
P10713176A0422|90 116|pocket protein partners Rb
P10713176A0422|118 122|p107
P10713176A0422|128 132|p130
P10713176A0422|143 148|v-Jun
P10713176A0422|164 171|control
P10713176A0422|196 198|Rb
P10713176A0422|226 244|E2F-p107 complexes
P10713176A0422|262 280|mitogen withdrawal
P10713176A0885|0 21|D-cyclin-cdk activity
P10713176A0885|38 56|Rb phosphorylation
P10713176A0885|78 83|cells
P10713176A0885|99 109|expression
P10713176A0885|117 121|cdk4
P10713176A0885|141 154|inhibitor p16
P10713176A0885|155 160|INK4A
P10713176A0885|176 189|DNA synthesis
P10713176A0885|194 212|cell proliferation
P10713239A0988|0 10|CONCLUSION
P10713239A0988|25 34|mechanism
P10713239A0988|49 66|capsulorhexis rim
P10713239A0988|92 101|IOL optic
P10713453A0172|4 11|protein
P10713453A0172|47 59|antibody Q18
P10713453A0172|76 80|gene
P10713453A0172|92 95|57A
P10713453A0172|99 119|polytene chromosomes
P10713453A0172|152 158|Hrb57A
P10714985A1057|3 27|RNA boundary experiments
P10714985A1057|49 58|structure
P10714985A1057|71 77|number
P10714985A1057|82 85|G/U
P10714985A1057|86 96|AG repeats
P10714985A1057|126 148|leader RNA association
P10715322A0000|0 14|Gene silencing
P10715322A0000|40 53|DNA sequences
P10715322A0000|81 91|eukaryotes
P10715322A0000|103 109|plants
P10715325A0834|4 15|AtERF genes
P10715325A0834|49 57|ethylene
P10715325A0834|73 90|stress conditions
P10715325A0834|100 108|wounding
P10715325A0834|121 129|salinity
P10715325A0834|134 141|drought
P10715325A0834|147 168|ETHYLENE-INSENSITIVE2
P10715325A0834|170 174|EIN2
P10715325A0834|202 210|pathways
P10715602A0149|0 7|Animals
P10715602A0149|19 23|dose
P10715602A0149|27 40|dexamethasone
P10715602A0149|45 50|mg/kg
P10715602A0149|83 113|surfactant preparation Exosurf
P10715602A0149|120 133|phospholipids
P10715602A0149|145 155|surfactant
P10715602A0149|157 170|Wellcome GmbH
P10715602A0149|172 181|Burgwedel
P10715602A0149|183 190|Germany
P10715602A0149|198 203|rSP-C
P10715602A0149|210 220|surfactant
P10717612A0000|0 10|BACKGROUND
P10717612A0000|16 19|aim
P10717612A0000|28 33|study
P10717612A0000|55 69|response rates
P10717612A0000|74 82|toxicity
P10717612A0000|90 98|regimens
P10717612A0000|140 158|stimulating factor
P10717612A0000|160 166|GM-CSF
P10717612A0000|171 182|combination
P10717612A0000|188 201|interleukin-2
P10717612A0000|203 207|IL-2
P10717612A0000|216 225|treatment
P10717612A0000|229 237|patients
P10717612A0000|260 274|cell carcinoma
P10720434A0291|12 21|injection
P10720434A0291|35 40|mRNAs
P10720434A0291|62 71|sequences
P10720434A0291|88 98|repression
P10720434A0291|102 116|cyclin B1 mRNA
P10720434A0291|137 140|UTR
P10721698A1195|6 10|data
P10721698A1195|25 34|expansion
P10721698A1195|42 58|dodecamer repeat
P10721698A1195|83 91|promoter
P10721698A1195|95 99|CSTB
P10721698A1195|122 130|function
P10721698A1195|138 146|promoter
P10721698A1195|167 180|transcription
P10721698A1195|184 188|CSTB
P10721704A1155|24 36|organization
P10721704A1155|40 44|mHuA
P10721704A1155|81 88|members
P10721704A1155|96 107|Elav family
P10721704A1155|113 129|promoter element
P10721704A1155|160 177|sequence analysis
P10721704A1155|198 206|activity
P10721704A1155|221 231|cell types
P10721704X0000|0 8|Analysis
P10721704X0000|19 22|end
P10721704X0000|30 42|mouse Elavl1
P10721704X0000|44 48|mHuA
P10721704X0000|50 54|gene
P10721704X0000|92 99|element
P10721704X0000|104 112|evidence
P10721704X0000|135 147|organization
P10721704X0000|149 153|mHuA
P10721704X0000|155 161|Elavl1
P10721704X0000|193 199|family
P10721704X0000|203 208|genes
P10721704X0000|230 238|proteins
P10721704X0000|262 273|cell growth
P10721704X0000|278 291|proliferation
P10721704X0000|304 314|regulation
P10721704X0000|318 332|mRNA stability
P10721714A1087|16 37|mobility shift assays
P10721714A1087|52 55|Sp1
P10721714A1087|79 86|regions
P10721714A1087|103 111|promoter
P10721714A1087|123 131|Sp1 site
P10721714A1087|169 175|region
P10721717A0676|0 4|Fgd3
P10721717A0676|9 13|FGD1
P10721717A0676|27 33|degree
P10721717A0676|37 54|sequence identity
P10721717A0676|82 101|amino acid residues
P10721726T0000|10 17|cloning
P10721726T0000|21 49|mouse thioredoxin reductases
P10722063A0328|4 15|HPLC method
P10722063A0328|28 50|octadecylsilane column
P10722063A0328|57 66|degrees C
P10722063A0328|70 77|mixture
P10722063A0328|116 120|acid
P10722063A0328|133 136|v/v
P10722063A0328|148 153|phase
P10722063A0328|158 167|detection
P10722063A0328|175 177|nm
P10722509A0392|6 14|patients
P10722509A0392|28 30|mg
P10722509A0392|43 52|dipivoxil
P10722509A0392|57 59|kg
P10722509A0392|63 74|body weight
P10722509A0392|84 92|patients
P10722509A0392|106 108|mg
P10722509A0392|121 130|dipivoxil
P10722509A0392|135 137|kg
P10722661A0146|0 4|CYC2
P10722661A0146|22 29|protein
P10722661A0146|39 56|sequence identity
P10722661A0146|64 87|Neurospora crassa PREG1
P10722661A0146|110 122|PHO80 cyclin
P10722661A0406|16 20|CYC2
P10722661A0406|35 42|complex
P10722661A0406|70 81|trypanosome
P10722661A0406|95 102|kinases
P10722661A0406|104 108|CRKs
P10722661A0406|115 124|CYC2 gene
P10722661A0406|142 156|TY epitope tag
P10722661A0406|178 196|trypanosome genome
P10722661A0406|228 235|control
P10722737A1726|6 14|findings
P10722737A1726|28 39|involvement
P10722737A1726|43 46|Sp1
P10722737A1726|54 57|Inr
P10722737A1726|79 89|regulation
P10722737A1726|109 129|transcription factor
P10722737A1726|134 137|Sp1
P10722737A1726|159 169|regulation
P10722737A1726|177 180|LTC
P10722737A1726|183 189|S gene
P10722969A0510|15 23|progress
P10722969A0510|27 31|date
P10722969A0510|40 44|area
P10723723A0781|18 32|mouse promoter
P10723723A0781|45 51|copies
P10723723A0781|57 88|CT dinucleotide repeat sequence
P10723723A0781|115 117|bp
P10723723A0781|124 128|exon
P10723727A0713|18 24|region
P10723727A0713|37 43|intron
P10723727A0713|88 120|polyadenylation signal sequences
P10724436A0085|22 26|U3O8
P10724436A0085|36 55|reference materials
P10724436A0085|83 89|system
P10724483A0540|24 36|cAMP control
P10724483A0540|52 56|SRP1
P10724483A0540|61 72|HEM13 genes
P10724483A0540|96 107|HOG pathway
P10724519A1185|44 48|RNAs
P10724519A1185|77 85|elements
P10725017A0673|5 10|paper
P10725017A0673|40 48|approach
P10725017A0673|60 67|CEN ENV
P10725017A0673|84 98|specialisation
P10725017A0673|117 134|healthcare record
P10725017A0673|144 151|CEN ENV
P10725017A0673|170 200|Healthcare Record Architecture
P10725382A0398|0 17|Sequence analyses
P10725382A0398|21 25|sos2
P10725382A0398|33 40|alleles
P10725382A0398|83 89|domain
P10725382A0398|120 126|domain
P10725382A0398|130 134|SOS2
P10725433A0543|2 10|mutation
P10725433A0543|31 38|binding
P10725433A0543|48 55|factors
P10725433A0543|64 84|Wp reporter activity
P10725433A0543|101 113|B cell lines
P10725433A0543|125 133|mutation
P10725433A0543|153 157|site
P10725433A0543|163 172|consensus
P10725433A0543|186 194|sequence
P10725433A0543|215 232|promoter function
P10727247A0461|21 28|cloning
P10727247A0461|46 64|expression pattern
P10727247A0461|81 97|characterization
P10727247A0461|111 125|TEF-1 isoforms
P10727247A0461|127 136|TEF-1beta
P10727247A0461|141 151|TEF-1gamma
P10727413A1244|14 27|binding sites
P10727413A1244|47 54|factors
P10727413A1244|71 85|hamster CYP7A1
P10727413A1244|95 103|promoter
P10727413A1244|113 121|vicinity
P10727413A1244|144 151|species
P10727413A1244|177 181|unit
P10727413A1244|210 220|expression
P10727413A1244|225 243|tissue restriction
P10727413A1244|251 257|action
P10727413A1244|261 269|hormones
P10727413A1244|278 285|insulin
P10727426A1280|4 19|kinase activity
P10727426A1280|23 28|PfPK6
P10727426A1280|45 59|CDK inhibitors
P10727426A1280|68 78|olomoucine
P10727426A1280|83 94|roscovitine
P10727428A0000|9 12|MAP
P10727428A0000|32 39|protein
P10727428A0000|41 48|kinases
P10727428A0000|67 85|cell proliferation
P10727428A0000|90 105|differentiation
P10727428A0000|114 124|cell types
P10727428A0000|130 134|role
P10727428A0000|138 149|MAP kinases
P10727428A0000|161 172|hypertrophy
P10727433A0560|0 12|Transfection
P10727433A0560|20 45|CSF-1R expression plasmid
P10727433A0560|72 82|activation
P10727433A0560|90 108|signalling pathway
P10727433A0560|122 129|Ets/AP1
P10727433A0560|131 148|activator protein
P10727433A0560|152 159|element
P10727433A0560|167 179|uPA promoter
P10727433A0560|219 225|target
P10727433A0560|239 242|ras
P10727433A0560|247 272|protein kinase C pathways
P10727433T0000|0 10|Regulation
P10727433T0000|14 64|urokinase plasminogen activator gene transcription
P10727433T0000|72 78|RAW264
P10727433T0000|86 106|macrophage cell line
P10727433T0000|110 120|macrophage
P10727433T0000|140 146|factor
P10727433T0000|148 153|CSF-1
P10727433T0000|177 182|level
P10727433T0000|199 207|receptor
P10727511A0294|0 8|Molecule
P10727511A0294|9 10|s
P10727511A0294|33 41|cultures
P10727511A0294|61 70|induction
P10727511A0294|74 79|GLT-1
P10727511A0294|111 129|signaling pathways
P10727511A0294|145 155|regulation
P10727515A1202|0 12|Coactivation
P10727515A1202|40 41|G
P10727515A1202|42 43|q
P10727515A1202|53 62|receptors
P10727515A1202|85 93|receptor
P10727515A1202|110 122|stimulations
P10727515A1202|126 133|PLCbeta
P10727515A1202|143 152|responses
P10727515A1202|183 198|pertussis toxin
P10728945A0233|0 8|Patients
P10728945A0233|25 35|Integrilin
P10728945A0233|48 68|Platelet Aggregation
P10728945A0233|82 95|Thrombosis-II
P10728945A0233|97 106|IMPACT-II
P10728945A0233|108 113|trial
P10728986A0000|4 25|Wnt signaling pathway
P10728986A0000|57 75|animal development
P10728986A0000|87 106|cell fate decisions
P10729151A1160|5 13|mutation
P10729151A1160|38 44|HPV-11
P10729151A1160|83 102|reporter expression
P10729155A0653|20 31|MVMi capsid
P10729155A0653|38 46|sequence
P10729155A0653|57 68|carboxy end
P10729155A0653|88 101|beta-strand I
P10729155A0653|103 108|betaI
P10729155A0653|129 137|residues
P10729155A0653|173 177|face
P10729155A0653|202 209|subunit
P10729220A0000|19 23|IGF2
P10729220A0000|44 57|growth factor
P10729220A0000|66 75|H19 genes
P10729220A0000|121 126|mouse
P10729220A1569|15 26|methylation
P10729220A1569|63 73|disruption
P10729220A1569|77 80|H19
P10729220A1569|109 114|brain
P10729221A0798|4 14|comparison
P10729221A0798|22 41|expression patterns
P10729221A0798|55 73|Kv4 family members
P10729221A0798|80 99|subtype specificity
P10730292T0000|6 25|treatment mechanics
P10730292T0000|33 50|Class II division
P10730292T0000|53 65|malocclusion
P10730763A1491|12 15|use
P10730763A1491|23 55|Nottingham Eczema Severity Score
P10730763A1491|78 89|development
P10730763A1491|95 108|research tool
P10730763A1491|122 132|assessment
P10730763A1491|136 152|disease severity
P10730763A1491|191 198|studies
P10731411A0958|4 13|consensus
P10731411A0958|29 39|importance
P10731411A0958|43 51|residues
P10731411A0958|73 79|motifs
P10731411A0958|111 133|DEAD-box RNA helicases
P10731411A0958|165 175|importance
P10731411A0958|184 185|A
P10731411A0958|187 194|residue
P10731411A0958|207 211|DEAD
P10731411A0958|213 218|motif
P10731926A0775|0 16|Advanced adenoma
P10731926A0775|35 42|adenoma
P10731926A0775|58 60|mm
P10731926A0775|67 74|adenoma
P10731926A0775|82 86|size
P10731926A0775|100 109|component
P10731926A0775|122 131|dysplasia
P10731926A0775|144 153|carcinoma
P10732669A0510|13 19|assays
P10732669A0510|27 31|rice
P10732669A0510|52 57|cells
P10732669A0510|73 93|particle bombardment
P10732669A0510|121 127|Oshox1
P10732669A0510|162 170|activity
P10732669A0510|174 198|reporter gene constructs
P10732669A0510|213 233|HD-Zip binding sites
P10732669A1336|0 7|Results
P10732669A1336|22 28|assays
P10732669A1336|49 70|mobility shift assays
P10732669A1336|104 112|proteins
P10732669A1336|116 124|families
P10732669A1336|143 153|homodimers
P10732669A1336|163 175|heterodimers
P10732669A1336|192 200|proteins
P10732669A1336|213 219|family
P10733569A0364|16 20|HSFs
P10733569A0364|22 26|HSF1
P10733569A0364|62 72|regulation
P10733569A0364|93 115|stress gene expression
P10733569A0364|129 137|function
P10733569A0364|141 145|HSF2
P10733569A0364|149 164|stress response
P10733581A1391|25 35|expression
P10733581A1391|62 65|Raf
P10733581A1391|70 80|V12N38 Ras
P10733581A1391|108 112|loss
P10733581A1391|116 130|TTF-1 activity
P10733591A0146|27 34|targets
P10733591A0146|46 56|remodeling
P10733591A0146|64 82|actin cytoskeleton
P10733591A0146|84 94|activation
P10733591A0146|98 101|p70
P10733591A0146|102 104|S6
P10733591A0146|106 112|kinase
P10733591A0146|117 122|c-jun
P10733591A0146|134 140|kinase
P10733591A0146|142 145|JNK
P10733591A0146|152 162|regulation
P10733591A0146|166 179|transcription
P10733591A0146|184 202|cell proliferation
P10733591A0533|0 10|Expression
P10733591A0533|24 37|Cdc42 results
P10733591A0533|45 58|translocation
P10733591A0533|62 71|PKClambda
P10733591A0533|81 88|nucleus
P10733591A0533|98 105|cytosol
P10733591A0533|111 116|Cdc42
P10733591A0533|121 130|PKClambda
P10733591A0533|149 164|plasma membrane
P10733591A0533|176 185|cytoplasm
P10733880X1783|0 9|Copyright
P10733880X1783|15 29|Academic Press
P10734312A0503|22 38|Shc localization
P10734312A0503|42 56|membrane rafts
P10734312A0503|83 95|Shc function
P10734312A0503|114 125|Shc chimera
P10734312A0503|141 172|Ras membrane localization motif
P10734312A0503|180 190|C-terminus
P10735272A0649|0 17|Southern blotting
P10735272A0649|29 70|strand conformation polymorphism analyses
P10735272A0649|99 110|alterations
P10735272A0649|119 123|gene
P10735272A0649|127 134|gliomas
P10735272A0649|139 153|RT-PCR studies
P10735272A0649|161 171|expression
P10735272A0649|175 192|glioma cell lines
P10735272A0649|210 215|ANOVA
P10735272A0649|227 270|chromosome 19q glioma tumor suppressor gene
P10735848A1440|0 4|RegA
P10735848A1440|36 45|regulator
P10735848A1440|49 68|tol-oprL expression
P10736161T0000|0 8|Enzyme I
P10736161T0000|16 35|phosphoenolpyruvate
P10736161T0000|36 67|sugar phosphotransferase system
P10736223A1227|15 19|data
P10736223A1227|38 51|transcription
P10736223A1227|55 59|prgX
P10736223A1227|82 93|Qa promoter
P10736223A1227|97 101|prgQ
P10736223A1227|107 111|PrgX
P10736223A1227|130 143|transcription
P10736223A1227|180 191|readthrough
P10736223A1227|206 220|mRNA stability
P10737366A0280|55 59|PTFL
P10737366A0280|86 95|threshold
P10737366A0280|111 118|stimuli
P10737366A0280|126 139|formalin test
P10737366A0280|143 147|rats
P10738139A0681|10 17|mimicry
P10738139A0681|27 35|cytokine
P10738139A0681|40 71|cytokine response pathway genes
P10738139A0681|75 79|KSHV
P10739408A0896|0 18|Family environment
P10739408A0896|36 45|influence
P10739408A0896|63 76|relationships
P10739408A0896|78 91|substance use
P10739408A0896|104 111|support
P10739671A0136|3 40|electrophoresis mobility shift assays
P10739671A0136|47 53|probes
P10739671A0136|81 89|segments
P10739671A0136|112 124|c-myb intron
P10739671A0136|127 153|transcription pause region
P10739671A0136|166 174|extracts
P10739671A0136|188 199|leukemia HL
P10739671A0136|207 220|fibroblast WI
P10739671A0136|224 229|cells
P10739671A0136|272 279|complex
P10739671A0136|294 302|fragment
P10739671A0136|314 327|binding sites
P10739671A0136|336 346|interferon
P10739671A0136|358 365|factors
P10739671A0136|367 371|IRFs
P10739671A0136|381 389|proteins
P10740602A0141|0 12|STUDY DESIGN
P10740602A0141|14 36|Fine needle aspiration
P10740602A0141|47 53|smears
P10740602A0141|62 67|cases
P10740602A0141|88 97|carcinoma
P10740602A0141|99 102|ILC
P10740602A0141|107 113|breast
P10740602A0141|157 165|analysis
P10741850A0452|0 30|Electrophile Response Elements
P10741850A0452|32 37|EpREs
P10741850A0452|63 72|sequences
P10741850A0452|85 89|GCSh
P10741850A0452|94 112|GCSl subunit genes
P10741850A0452|161 175|gene induction
P10741850A0452|197 205|exposure
P10741947T0000|6 15|technique
P10741947T0000|40 48|stenosis
P10741947T0000|63 66|LAD
P10741947T0000|75 83|hemoclip
P10742114A0486|0 4|Dll3
P10742114A0486|37 42|mouse
P10742114A0486|50 55|pudgy
P10742114A0486|57 59|pu
P10742114A0486|72 79|variety
P10742114A0486|98 105|defects
P10742114A0486|117 130|SD phenotypes
P10742216A0555|0 8|Schlegel
P10742216A0555|10 12|J.
P10743608A1154|0 17|TbRAB31 behaviour
P10743608A1154|46 56|cell cycle
P10743608A1154|58 65|TbRAB31
P10743608A1154|97 106|structure
P10743608A1154|137 144|mitosis
P10743608A1154|162 176|daughter cells
P10743608A1154|193 199|manner
P10743608A1154|215 219|body
P10743608A1154|224 235|kinetoplast
P10743608A1154|252 263|involvement
P10743608A1154|267 279|microtubules
P10743719A0223|10 12|dg
P10743719A0223|17 26|rejection
P10743719A0223|48 57|rejection
P10743719A0223|73 83|management
P10743719A0223|95 99|risk
P10743719A0223|123 144|rejection nephropathy
P10744026A0000|0 10|Invertases
P10744026A0000|35 44|breakdown
P10744026A0000|48 55|sucrose
P10744026A0000|59 67|fructose
P10744026A0000|72 79|glucose
P10744749A0315|29 39|mechanisms
P10744749A0315|61 71|inhibition
P10744749A0315|89 95|effect
P10744749A0315|119 127|activity
P10744749A0315|144 156|MyoD protein
P10744749A0315|178 186|paradigm
P10744749A0315|195 202|factors
P10744749T0000|10 16|T cell
P10744749T0000|39 49|virus type
P10744749T0000|52 63|Tax protein
P10744749T0000|89 102|transcription
P10744749T0000|137 147|KIX domain
P10744749T0000|151 155|p300
P10744974T0000|0 15|Phosphorylation
P10744974T0000|20 50|spindle pole body localization
P10744974T0000|58 64|Cdc15p
P10744974T0000|84 98|protein kinase
P10744974T0000|110 115|yeast
P10745563A0409|15 26|hyperplasia
P10745563A0409|42 55|complications
P10745563A0409|116 127|gold stents
P10745563A0409|150 158|capacity
P10745563A0409|164 169|steel
P10745563A0409|197 212|neo-endothelium
P10747053A1102|4 14|cell cycle
P10747053A1102|35 42|defects
P10747053A1102|53 58|taf17
P10747053A1102|59 65|slm7-1
P10747053A1102|91 95|role
P10747053A1102|99 102|TAF
P10747053A1102|111 121|modulators
P10747053A1102|141 151|activation
P10747053A1102|170 174|role
P10747053A1102|179 184|TAF17
P10747053A1102|199 209|activation
P10747053A1102|213 216|SBF
P10747053A1102|221 224|MBF
P10747099A0507|24 30|kinase
P10747099A0507|32 35|ERK
P10747099A0507|37 47|activation
P10747099A0507|62 70|coupling
P10747099A0507|78 99|adaptor proteins p130
P10747099A0507|115 124|substrate
P10747099A0507|126 129|CAS
P10747099A0507|135 142|c-CrkII
P10747099A0507|144 147|Crk
P10747099A0507|172 180|pathways
P10747099A0507|193 206|cell invasion
P10747099A0507|219 224|cells
P10747099A0507|230 239|apoptosis
P10747099A0507|263 278|collagen matrix
P10747782A0390|0 11|Proteolysis
P10747782A0390|15 19|Mbp1
P10747782A0390|24 28|Swi4
P10747782A0390|41 50|complexes
P10747782A0390|68 74|extent
P10747782A0390|84 93|sequences
P10747782A0390|121 130|molecules
P10747782A0390|159 179|DNA binding activity
P10747782A0390|196 208|core domains
P10747879A0607|4 13|evolution
P10747879A0607|21 25|CCR5
P10747879A0607|41 47|region
P10747879A0607|64 77|reading frame
P10747879A0607|105 112|domains
P10747879A0607|125 138|reading frame
P10747890A1096|6 13|results
P10747890A1096|28 35|residue
P10747890A1096|53 67|protein sensor
P10747890A1096|86 105|groove interactions
P10747890A1096|127 149|base pair interactions
P10747890A1096|171 178|lesions
P10747987A0658|16 23|enzymes
P10747987A0658|33 41|monomers
P10748054T0048|2 9|pathway
P10748054T0048|14 24|regulation
P10748054T0048|28 48|B lymphocyte antigen
P10748054T0048|66 78|calcium flux
P10748113A0187|25 36|RIM protein
P10748113A0187|45 49|RIM2
P10748113A0187|80 84|RIM1
P10748113A0187|117 122|brain
P10748125A0000|0 11|Inhibitor-1
P10748125A0000|13 16|I-1
P10748125A0000|22 33|inhibitor-2
P10748125A0000|35 38|I-2
P10748125A0000|60 64|type
P10748125A0000|67 104|protein serine/threonine phosphatases
P10748125A0000|106 109|PP1
P10748164A1284|0 18|Scanning mutations
P10748164A1284|34 44|AC element
P10748164A1284|61 70|induction
P10748164A1284|113 118|sites
P10748164A1284|134 141|factors
P10748164A1284|145 147|AC
P10748164A1284|162 168|probes
P10748164A1284|193 200|factors
P10748175A0000|4 14|substrates
P10748175A0000|19 35|glycan synthesis
P10748175A0000|43 48|lumen
P10748175A0000|56 61|Golgi
P10748175A0000|77 83|sugars
P10748175A0000|118 125|cytosol
P10748175A0000|153 165|transporters
P10748194T0000|9 18|targeting
P10748194T0000|39 61|density protein PSD-95
P10748194T0000|91 109|trafficking signal
P10748204A0238|7 9|J.
P10748672A0130|0 5|Bites
P10748672A0130|13 20|species
P10748672A0130|24 30|adders
P10748672A0130|32 44|Vipera aspis
P10748672A0130|49 61|Vipera berus
P10748672A0130|110 117|failure
P10749145T0000|29 42|PCPH proteins
P10749145T0000|58 80|diphosphatase activity
P10749145T0000|94 105|oncoprotein
P10749145T0000|122 125|Ras
P10749145T0000|171 182|kinase ERK1
P10749166A0991|6 13|results
P10749166A0991|49 54|genes
P10749166A0991|85 96|arrangement
P10749166A0991|135 146|B. henselae
P10749166A0991|171 179|bacteria
P10749166A0991|188 202|A. tumefaciens
P10749849A0000|13 22|mechanism
P10749849A0000|36 56|tumor suppressor p53
P10749849A0000|75 84|stability
P10749849A0000|98 115|cell cycle arrest
P10749849A0000|124 134|activation
P10749849A0000|159 179|kinase inhibitor p21
P10749849A0000|180 189|WAF1/Cip1
P10749849A0000|191 195|gene
P10749932A0000|0 8|Paxillin
P10749932A0000|20 36|adaptor molecule
P10749932A0000|40 58|integrin signaling
P10750020A0843|6 30|growth factor activation
P10750020A0843|34 36|ER
P10750020A0843|49 64|transactivation
P10750020A0843|68 82|ER/Sp1 binding
P10750020A0843|94 99|sites
P10750020A0843|123 130|pathway
P10750020A0843|154 163|ER action
P10750021A0728|13 21|analysis
P10750021A0728|25 62|deletion promoter-reporter constructs
P10750021A0728|84 92|activity
P10750021A0728|96 98|P2
P10750021A0728|123 129|region
P10750021A0728|133 135|P2
P10750524A0724|0 7|RESULTS
P10750524A0724|18 28|thresholds
P10750524A0724|58 63|tests
P10750524A0724|87 97|proportion
P10750524A0724|103 106|age
P10750524A0724|139 144|group
P10750524A0724|146 147|p
P10751398A1135|3 11|addition
P10751398A1135|17 30|transcription
P10751398A1135|34 49|c-IAP2 promoter
P10751398A1135|81 85|CD40
P10751398A1135|102 107|virus
P10751398A1135|115 131|membrane protein
P10752450A0288|2 9|variety
P10752450A0288|43 60|fluoride products
P10752450A0288|83 108|fluoride delivery systems
P10752450A0288|135 141|market
P10752475A1376|6 13|studies
P10752475A1376|38 64|signal-transduction events
P10752475A1376|81 90|apoptosis
P10752475A1376|104 111|B cells
P10752475A1376|137 145|ligation
P10752475A1376|149 153|CD20
P10752475A1376|167 177|antibodies
P10752475A1376|185 193|presence
P10752475A1376|220 225|cells
P10752475A1376|239 243|goat
P10752475A1376|250 258|mouse Ig
P10752475A1376|260 270|antibodies
P10752475A1376|303 320|tumor regressions
P10752475A1376|333 345|mouse models
P10752475A1376|359 365|trials
P10752807A1598|0 10|CONCLUSION
P10752807A1598|12 21|Treatment
P10752807A1598|25 31|sepsis
P10752807A1598|61 85|factor antagonist BB-882
P10752807A1598|96 105|advantage
P10752807A1598|111 118|placebo
P10752807A1598|122 130|survival
P10752807A1598|144 150|status
P10752807A1598|164 172|function
P10752807A1598|177 197|organ failure scores
P10753553T0000|0 9|Phenazone
P10753553T0000|44 50|effect
P10753553T0000|54 63|lidocaine
P10753553T0000|67 71|mice
P10754312A0798|4 14|solubility
P10754312A0798|34 42|proteins
P10756007A0575|20 33|RBE sequences
P10756007A0575|64 73|locations
P10756007A0575|87 93|genome
P10756007A1512|0 11|EM analysis
P10756007A1512|47 54|complex
P10756007A1512|69 85|ch-19 target DNA
P10756020A0571|4 11|protein
P10756020A0571|41 65|vaccinia virus particles
P10756020A0571|75 84|membranes
P10756020A0571|108 115|virions
P10756020A0571|140 159|electron microscopy
P10756020A0571|172 177|cells
P10756032A0599|8 37|dimethyl sulfate footprinting
P10756032A0599|45 62|cyclin E promoter
P10756032A0599|80 87|regions
P10756032A0599|91 101|protection
P10756032A0599|106 122|hypersensitivity
P10756032A0599|152 157|cells
P10756094A0671|2 7|total
P10756094A0671|15 19|STSs
P10756094A0671|32 40|interval
P10756094A0671|46 48|Mb
P10756094A0671|68 85|marker resolution
P10756094A0671|114 116|kb
P10756100A0457|12 20|mutation
P10756100A0457|28 42|amino-terminus
P10756100A0457|46 49|IB1
P10756100A0457|70 78|diabetes
P10756225A1464|0 10|CONCLUSION
P10756225A1464|24 25|%
P10756225A1464|29 37|patients
P10756225A1464|53 61|rhinitis
P10756225A1464|66 69|CRS
P10756225A1464|91 98|surgery
P10756225A1464|102 110|response
P10756225A1464|141 146|cells
P10756225A1464|158 167|IL-5 mRNA
P10756225A1464|175 190|ethmoid sinuses
P10757975A0509|0 4|Biol
P10757983A0733|7 12|basis
P10757983A0733|16 20|size
P10757983A0733|26 38|CRS sequence
P10757983A0733|76 90|identification
P10757983A0733|96 115|zinc finger protein
P10757983A0733|117 127|Adx factor
P10757983A0733|166 185|zinc finger protein
P10757983A0733|189 211|mouse ZBP-89 homologue
P10758289A0141|0 7|METHODS
P10758289A0141|25 38|muscle fibres
P10758289A0141|69 83|finger flexors
P10758289A0141|114 127|pisiform bone
P10758289A0141|144 153|specimens
P10758489A0206|22 31|isolation
P10758489A0206|35 39|ICK2
P10758489A0206|73 80|Cdc2aAt
P10758489A0206|104 107|CDK
P10758489A0206|113 124|Arabidopsis
P10758489A0206|126 133|Cdc2bAt
P10758726T0000|9 15|impact
P10758726T0000|32 44|arrangements
P10759693A0201|0 7|METHODS
P10759693A0201|26 36|odds ratio
P10759693A0201|38 40|OR
P10759693A0201|48 55|measure
P10759693A0201|72 76|risk
P10759693A0201|109 120|interaction
P10759693A0201|136 139|use
P10759693A0201|159 169|antagonist
P10759693A0201|171 181|cimetidine
P10759693A0201|215 232|agents ranitidine
P10759693A0201|234 244|famotidine
P10759693A0201|249 259|nizatidine
P10759693A0201|263 268|users
P10759693A0201|273 281|nonusers
P10759693A0201|285 293|warfarin
P10759693A0201|295 304|phenytoin
P10759693A0201|309 321|theophylline
P10760109A1050|4 14|prevalence
P10760109A1050|18 30|malnutrition
P10760109A1050|37 38|%
P10760109A1050|49 57|patients
P10760109A1050|66 69|CVD
P10760109A1050|102 103|%
P10760109A1050|105 106|P
P10760109A1050|126 134|patients
P10760109A1050|140 143|CVD
P10760109A1050|164 168|tHcy
P10760109A1050|170 174|SAlb
P10760109A1050|176 188|plasma IGF-1
P10760109A1050|190 206|serum creatinine
P10760109A1050|208 211|SCr
P10760109A1050|218 234|blood hemoglobin
P10760132A1169|4 8|data
P10760132A1169|40 51|temperature
P10760132A1169|72 77|level
P10760132A1169|85 104|protein prenylation
P10760132A1169|133 153|vesicle polarization
P10760169A1142|22 26|pair
P10760169A1142|30 40|CreA sites
P10760169A1142|68 98|transcription initiation sites
P10760950A1133|11 27|staining pattern
P10760950A1133|36 46|N-utrophin
P10760950A1133|111 130|actin stress fibers
P10761263A1108|5 14|Newcastle
P10761263A1108|16 21|model
P10761263A1108|41 50|Hotelling
P10761263A1108|53 65|T2 statistic
P10761263A1108|122 134|displacement
P10761263A1108|145 162|prostate patients
P10762254A0954|4 7|MMA
P10762254A0954|9 12|DMA
P10762254A0954|18 40|TMA methyltransferases
P10762254A0954|49 57|homologs
P10762254A0954|77 103|MMA methyltransferase gene
P10762254A0954|109 114|genes
P10762254A0954|128 131|DMA
P10762254A0954|136 158|TMA methyltransferases
P10762254A0954|190 201|amber codon
P10762348A0269|6 21|phosphorylation
P10762348A0269|23 36|STAT proteins
P10762348A0269|62 69|nucleus
P10762348A0269|98 106|activity
P10763823A0824|0 14|Overexpression
P10763823A0824|18 23|mcl-1
P10763823A0824|57 66|apoptosis
P10763823A0824|74 86|transfection
P10763823A0824|92 97|mcl-1
P10763823A0824|108 115|plasmid
P10763823A0824|123 133|cell death
P10763827A1158|24 43|senescence pathways
P10763827A1158|61 69|response
P10763827A1158|75 87|ras oncogene
P10763827A1158|89 101|inactivation
P10763827A1158|105 123|TGFbeta1 secretion
P10763827A1158|127 135|response
P10763827A1158|163 181|senescence program
P10764150A0000|8 13|study
P10764150A0000|19 28|abilities
P10764150A0000|61 66|forms
P10764150A0000|80 91|Raf kinases
P10764150A0000|108 127|cytokine dependency
P10764150A0000|131 143|FDC-P1 cells
P10764574A0718|0 11|Application
P10764574A0718|19 25|method
P10764574A0718|46 49|set
P10764574A0718|62 67|genes
P10764574A0718|73 93|Arabidopsis thaliana
P10764574A0718|113 124|improvement
P10764574A0718|128 147|prediction accuracy
P10764574A0718|177 194|alignment methods
P10764729A1846|13 26|cDNA sequence
P10764729A1846|36 50|betaV spectrin
P10764729A1846|69 76|GenBank
P10764729A1846|77 79|TM
P10764729A1846|84 100|accession number
P10764760T0000|0 15|Transactivation
P10764760T0000|39 44|HIV-1
P10764760T0000|59 66|repeats
P10764760T0000|74 95|JNK signaling pathway
P10764802A1258|6 10|data
P10764802A1258|37 43|domain
P10764802A1258|47 50|p57
P10764802A1258|51 55|Kip2
P10764802A1258|84 100|Cip/Kip proteins
P10764802A1258|135 146|interaction
P10764802A1258|181 190|mechanism
P10764802A1258|224 232|activity
P10764802A1258|247 250|p57
P10764802A1258|251 255|Kip2
P10764802A1258|257 271|family members
P10764802A1258|299 314|differentiation
P10764970A1009|4 8|mode
P10764970A1009|12 22|resistance
P10764970A1009|26 51|quinupristin/dalfopristin
P10764970A1009|87 90|PCR
P10764970A1009|103 108|cases
P10764970A1009|124 133|existence
P10764970A1009|161 169|isolates
P10764970A1009|181 193|introduction
P10764970A1009|216 221|class
P10764970A1009|242 250|practice
P10765095A0308|5 10|study
P10765095A0308|38 51|PRL secretion
P10765095A0308|66 90|prostate cancer patients
P10765095A0308|105 115|conditions
P10765095A0308|123 131|response
P10765095A0308|135 141|L-Dopa
P10765095A0308|146 160|metoclopramide
P10765095A0308|225 230|tests
P10765095A0308|235 248|PRL secretion
P10766246A0000|0 27|Integrin adhesion receptors
P10766246A0000|38 45|signals
P10766246A0000|67 81|cell functions
P10766246A0000|100 110|regulation
P10766246A0000|114 129|gene expression
P10766246A0000|139 152|proliferation
P10766246A0000|154 169|differentiation
P10766246A0000|174 182|survival
P10766493T0000|0 13|Recombination
P10766493T0000|15 26|replication
P10766493T0000|28 34|repair
P10766493T0000|41 51|complexity
P10766493T0000|55 62|harmony
P10766556T0000|4 24|somatoform conundrum
P10766556T0000|28 36|question
P10766556T0000|52 58|valves
P10767091A0133|16 26|ultrasound
P10767091A0133|28 32|IOUS
P10767091A0133|61 68|attempt
P10767091A0133|87 99|difficulties
P10767091A0133|139 145|nature
P10767091A0133|147 169|inter-user variability
P10767091A0133|175 193|image obliteration
P10767091A0133|223 233|techniques
P10767251A1046|0 11|CONCLUSIONS
P10767251A1046|29 34|study
P10767251A1046|46 54|Vivostat
P10767251A1046|62 69|sealant
P10767251A1046|97 108|air leakage
P10767251A1046|121 136|lung resections
P10767251A1046|140 144|pigs
P10767251A1046|171 180|pressures
P10767338T0000|14 21|disease
P10767338T0000|35 44|mutations
P10767338T0000|48 54|ATP2C1
P10767338T0000|72 74|Ca
P10767338T0000|79 83|pump
P10767553A0100|0 3|Hex
P10767553A0100|35 40|liver
P10767553A0100|77 103|helix transcription factor
P10767553A0100|105 115|Hepatocyte
P10767553A0100|124 136|Factor 3beta
P10767553A0100|138 146|HNF3beta
P10767560A0105|6 15|extension
P10767560A0105|34 50|characterization
P10767560A0105|70 82|organization
P10767560A0105|90 104|mouse Pkr gene
P10767560A0105|149 174|mouse Pkr promoter region
P10767560A0105|202 215|transcription
P10769144A0000|4 7|CRE
P10769144A0000|12 22|TGACGTCA-3
P10769144A0000|51 69|consensus sequence
P10769144A0000|78 89|cis-element
P10769144A0000|118 133|gene expression
P10770041A0731|0 13|Kidney length
P10770041A0731|51 56|right
P10770041A0731|76 88|kidney width
P10770041A0731|99 108|thickness
P10770041A0731|113 117|size
P10770041A0731|123 124|p
P10770065A0264|13 18|stage
P10770065A0264|26 32|T1N0M0
P10770065A0264|39 62|S2 sleeve segmentectomy
P10770065A0264|68 89|lymph node dissection
P10770065A0264|91 92|R
P10770065A0264|95 96|b
P10770471T0000|0 11|Benztropine
P10770471T0000|36 48|night sweats
P10771528T0036|2 7|cause
P10771528T0036|11 19|increase
P10771528T0036|23 43|alkaline phosphatase
P10771528T0036|47 55|children
P10771709A0291|4 14|physicians
P10771709A0291|18 24|charge
P10771709A0291|32 40|patients
P10771709A0291|46 54|evidence
P10771709A0291|64 71|Q fever
P10771709A0291|73 87|seroconversion
P10771709A0291|95 103|presence
P10771709A0291|107 110|IgM
P10771709A0291|123 130|Q fever
P10771709A0291|142 149|disease
P10771709A0291|157 175|IgG antibody titer
P10771709A0291|179 186|phase I
P10771709A0291|190 207|Coxiella burnetii
P10771709A0291|245 258|questionnaire
P10772856X1492|0 9|Copyright
P10772856X1492|15 29|Academic Press
P10772977A0222|19 27|movement
P10772977A0222|31 44|PVX CP mutant
P10772977A0222|65 85|Nicotiana tabacum cv
P10773351A0672|0 9|Induction
P10773351A0672|13 28|CD86 expression
P10773351A0672|32 43|stimulation
P10773351A0672|47 57|U937 cells
P10773351A0672|63 72|IFN-gamma
P10773351A0672|86 94|presence
P10773351A0672|113 116|GAS
P10773351A0672|118 150|gamma-interferon activation site
P10773351A0672|152 160|elements
P10773455A1268|43 48|sites
P10773455A1268|79 85|region
P10773455A1268|113 115|bp
P10773455A1268|123 143|mouse ALAS2 promoter
P10773455A1268|179 189|activation
P10773455A1268|216 231|differentiation
P10773455A1268|235 244|MEL cells
P10773455A1268|261 271|importance
P10773455A1268|296 307|specificity
P10773455A1268|315 320|ALAS2
P10773455A1268|337 347|activation
P10773458A0000|0 7|SNAP-23
P10773458A0000|27 31|role
P10773458A0000|39 49|regulation
P10773458A0000|53 72|vesicle trafficking
P10773458A0000|86 91|cells
P10773667A0351|4 14|HMG domain
P10773667A0351|23 37|HMG20 proteins
P10773667A0351|65 76|yeast NHP6A
P10773667A0351|80 81|%
P10773667A0351|87 88|%
P10773951A0000|0 3|IgM
P10773951A0000|8 11|IgG
P10773951A0000|17 18|A
P10773951A0000|28 45|B antibody status
P10773951A0000|63 78|O group mothers
P10773951A0000|92 108|O group husbands
P10775038A0142|6 13|attempt
P10775038A0142|28 43|Wee1 regulation
P10775038A0142|51 61|cell cycle
P10775038A0142|63 68|yeast
P10775038A0142|80 89|screening
P10775038A0142|124 131|protein
P10775038A0142|132 133|s
P10775267A0363|11 23|transduction
P10775267A0363|27 30|T/T
P10775267A0363|31 32|L
P10775267A0363|76 83|disease
P10775267A0363|96 118|bone marrow transplant
P10775267A0363|120 123|BMT
P10775267A0363|125 130|model
P10775267A0363|140 143|T/T
P10775267A0363|144 145|F
P10775267A0363|156 168|long-latency
P10775267A0363|170 180|pre-B-cell
P10775267A0363|195 203|lymphoma
P10775585A0754|0 14|Ab-MLV strains
P10775585A0754|26 32|P70/S2
P10775585A0754|53 66|NIH 3T3 cells
P10775585A0754|102 110|capacity
P10775585A0754|122 138|signaling events
P10775585A0754|191 198|protein
P10775585A0754|200 203|MAP
P10775585A0754|205 219|kinase pathway
P10775623A0120|4 15|codon usage
P10775623A0120|47 50|gag
P10775623A0120|52 55|pol
P10775623A0120|61 70|env genes
P10777217A0536|4 23|p53-homolog p73beta
P10777217A0536|43 56|PIG3 promoter
P10777217A0536|65 73|contrast
P10777217A0536|77 80|p53
P10777217A0536|99 105|domain
P10777217A0536|109 116|p73beta
P10777217A0536|118 126|residues
P10777217A0536|165 178|PIG3 promoter
P10777499A0883|0 7|Results
P10777499A0883|23 29|assays
P10777499A0883|42 49|mutants
P10777499A0883|66 69|DE1
P10777499A0883|79 86|signals
P10777499A0883|92 104|phytochromes
P10777499A0883|111 112|B
P10777499A0883|138 145|element
P10777499A0883|175 182|element
P10777586A1022|0 22|Co-immunoprecipitation
P10777586A1022|27 54|DNA affinity chromatography
P10777586A1022|66 69|Sp1
P10777586A1022|91 97|ZBP-89
P10777586A1022|116 132|silencer element
P10777586A1022|156 163|complex
P10777586A1022|170 178|mobility
P10777586A1022|223 227|HeLa
P10777586A1022|236 243|extract
P10777586A1022|247 264|band shift assays
P10777669A0582|4 15|ZNF274 gene
P10777669A0582|36 49|marker RP S28
P10777669A0582|65 89|chromosome 19qter region
P10777669A0582|94 104|RH mapping
P10778740A1493|15 31|Cdk2 truncations
P10778740A1493|71 78|strains
P10778740A1493|102 110|activity
P10778740A1493|118 123|pho85
P10778740A1493|131 137|region
P10778740A1493|167 172|pho85
P10778740A1493|174 178|HIS3
P10778740A1493|191 196|locus
P10778757A0000|32 38|nature
P10778757A0000|57 63|mutant
P10778757A0000|65 71|mn1-89
P10778757A0000|94 100|allele
P10778757A0000|108 118|Miniature1
P10778757A0000|120 123|Mn1
P10778757A0000|125 135|seed locus
P10778757A0000|165 184|cell wall invertase
P10778757A0000|186 191|INCW2
P10779313A1842|33 41|myocytes
P10779313A1842|49 64|Xenopus oocytes
P10779313A1842|82 93|stimulation
P10779313A1842|121 134|GIRK channels
P10779313A1842|141 148|pathway
P10779313A1842|177 192|phosphorylation
P10779313A1842|209 213|beta
P10779313A1842|216 218|AR
P10779329T0000|0 4|Slap
P10779329T0000|26 29|Src
P10779329T0000|40 48|function
P10779329T0000|81 104|cell morphology changes
P10779352T0000|0 14|Identification
P10779352T0000|26 38|E2F3 product
P10779352T0000|50 59|mechanism
P10779352T0000|76 87|specificity
P10779352T0000|91 101|repression
P10779352T0000|105 116|Rb proteins
P10779508A0452|3 8|DNase
P10779508A0452|11 43|footprinting protection analysis
P10779508A0452|50 54|SFRE
P10779508A0452|59 70|ERE regions
P10779508A0452|89 139|glutathione S-transferase-ERRalpha1 fusion protein
P10779508A0897|19 30|coactivator
P10779508A0897|32 37|SRC1a
P10779508A0897|41 46|GRIP1
P10779508A0897|99 107|activity
P10779508T0000|0 8|Estrogen
P10779508T0000|26 40|receptor alpha
P10779508T0000|58 69|coactivator
P10779508T0000|103 129|estrogen response elements
P10779508T0000|143 159|lactoferrin gene
P10780018A0539|19 25|models
P10780018A0539|33 40|effects
P10780018A0539|44 49|aging
P10780018A0539|58 71|response time
P10780518A1270|4 11|effects
P10780518A1270|21 30|mutations
P10780518A1270|34 50|protein function
P10780518A1270|67 78|examination
P10780764A0722|11 17|levels
P10780764A0722|21 30|particles
P10780764A0722|38 39|%
P10780764A0722|60 69|diameters
P10780764A0722|77 81|PM10
P10780764A0722|91 97|microm
P10780764A0722|99 102|PM2
P10780764A0722|116 121|range
P10780764A0722|139 144|range
P10780764A0722|159 164|x m-3
P10780883T0000|0 6|Kaposi
P10780883T0000|28 39|herpesvirus
P10780883T0000|46 56|interferon
P10780883T0000|68 74|factor
P10780883T0000|83 93|resistance
P10780883T0000|119 125|effect
P10780883T0000|129 145|interferon-alpha
P10781109T0000|31 43|interference
P10781109T0000|63 66|RNA
P10781109T0000|70 90|Arabidopsis thaliana
P10781423A0993|0 10|Comparison
P10781423A0993|14 23|sequences
P10781423A0993|40 42|bp
P10781423A0993|54 77|consensus binding sites
P10781423A0993|86 149|homeodomain transcription factor thyroid transcription factor-1
P10781423A0993|151 156|TTF-1
P10781541A1063|26 35|sequences
P10781541A1063|59 65|region
P10781541A1063|74 83|promoters
P10781541A1063|115 119|role
P10781541A1063|130 139|sequences
P10781541A1063|158 168|regulation
P10781541A1063|172 185|transcription
P10781541A1063|197 206|promoters
P10781552A0000|0 6|Purple
P10781552A0000|22 30|bacteria
P10781552A0000|66 72|energy
P10781552A0000|86 93|sources
P10781552A0000|105 119|photosynthesis
P10781552A0000|121 132|respiration
P10781552A0000|138 139|H
P10781552A0000|143 152|oxidation
P10781604A0827|3 11|analysis
P10781604A0827|25 33|peptides
P10781604A0827|53 65|CTD sequence
P10781604A0827|107 121|Rsp5 WW domain
P10781604A0827|123 131|Rsp5 WW2
P10781604A0827|149 154|yeast
P10781604A0827|166 172|assays
P10781611A1023|13 17|bone
P10781611A1023|33 44|macrophages
P10781611A1023|64 68|mice
P10781611A1023|98 108|efficiency
P10781611A1023|112 122|comparison
P10781611A1023|130 141|macrophages
P10781611A1023|157 161|mice
P10781990A0455|12 15|MRI
P10781990A0455|42 45|day
P10781990A0455|85 105|hyperintense lesions
P10781990A0455|113 128|globus pallidus
P10782640A0444|4 10|method
P10782640A0444|35 55|aberration constants
P10782640A0444|61 84|CM300 FEG/UT microscope
P10782640A0444|90 100|correction
P10782640A0444|119 130|astigmatism
P10782989A0575|4 15|interaction
P10782989A0575|39 47|presence
P10782989A0575|78 96|DNA binding domain
P10782989A0575|104 124|amino acid sequences
P10782989A0575|137 155|DNA binding domain
P10782989A0575|173 184|amino acids
P10784367A0133|0 6|METHOD
P10784367A0133|12 18|sample
P10784367A0133|22 30|subjects
P10784367A0133|50 86|Suffolk County Mental Health Project
P10784367A0133|117 122|study
P10784367A0133|145 153|subjects
P10784367A0133|169 178|disorders
P10784367A0133|192 197|study
P10784367A0133|209 217|patients
P10784367A0133|237 246|disorders
P10784393A0000|0 16|Marrow dysplasia
P10784393A0000|28 42|characteristic
P10784393A0000|46 54|patients
P10784393A0000|76 84|syndrome
P10784393A0000|86 89|MDS
P10784393A0000|103 119|marrow blastosis
P10784393A0000|121 130|cytopenia
P10784393A0000|147 156|anomalies
P10785294A0720|28 41|inlays/onlays
P10785294A0720|65 77|restorations
P10785294A0720|109 113|ones
P10785294A0720|133 148|resin composite
P10785668A0000|4 10|plants
P10785668A0000|22 28|attack
P10785668A0000|36 41|range
P10785668A0000|45 55|herbivores
P10785668A0000|60 69|pathogens
P10785668A0000|96 101|field
P10785668A0000|109 116|subject
P10785668A0000|133 141|research
P10785668A0000|160 170|biologists
P10785668A0000|175 185|ecologists
P10785880A0947|0 10|CONCLUSION
P10785880A0947|16 27|probability
P10785880A0947|47 60|complications
P10785880A0947|90 98|patients
P10785880A0947|107 112|class
P10785880A0947|115 129|HELLP syndrome
P10786671A0182|18 22|step
P10786671A0182|27 46|telomerase activity
P10786671A0182|63 73|expression
P10786671A0182|91 98|subunit
P10786671A0182|106 112|enzyme
P10786671A0182|135 145|telomerase
P10786671A0182|154 167|transcriptase
P10786671A0182|169 174|hTERT
P10786671A0182|176 180|gene
P10786742A0670|7 20|control group
P10786742A0670|22 38|platelet markers
P10786742A0670|51 52|h
P10786742A0670|59 66|surgery
P10787437A1616|13 20|element
P10787437A1616|37 61|transcription start site
P10787437A1616|82 87|SRE-1
P10787804T0000|0 4|AMDA
P10787804T0000|11 16|paper
P10787804T0000|28 32|ways
P10787804T0000|59 63|care
P10787804T0000|67 71|SNFs
P10788320A1034|6 14|proteins
P10788320A1034|26 38|TPR elements
P10788320A1034|90 102|interactions
P10788320A1034|124 137|102kD protein
P10788320A1034|159 168|tri-snRNP
P10788320A1034|183 185|U5
P10788320A1034|190 202|U4/U6 snRNPs
P10788320A1034|226 235|particles
P10788476A0891|0 10|Antibodies
P10788476A0891|39 46|portion
P10788476A0891|50 77|Sec31A co-precipitate Sec13
P10788476A0891|90 108|ER-Golgi transport
P10788476A0891|143 163|stomatitis G protein
P10788476A0891|181 191|cell assay
P10788480T0000|0 10|Regulation
P10788480T0000|56 85|protein gene expression links
P10788480T0000|112 127|DNA replication
P10788480T0000|131 141|drosophila
P10790390X0000|22 32|complexity
P10790390X0000|40 80|position effect variegation modifier mod
P10790390X0000|81 85|mdg4
P10790390X0000|102 105|mod
P10790390X0000|106 110|mdg4
P10790390X0000|127 128|E
P10790390X0000|129 132|var
P10790390X0000|133 138|3-93D
P10790390X0000|157 164|variety
P10790390X0000|168 177|processes
P10790390X0000|187 201|gene silencing
P10790390X0000|205 232|position effect variegation
P10790390X0000|234 237|PEV
P10790390X0000|244 251|control
P10790390X0000|255 280|gypsy insulator sequences
P10790390X0000|282 292|regulation
P10790390X0000|305 320|gene expression
P10790390X0000|337 347|cell death
P10791251A0110|25 30|kinds
P10791251A0110|41 47|things
P10791251A0110|59 68|functions
P10791251A0110|90 96|humans
P10791819A0771|5 13|tendency
P10791819A0771|42 64|nucleotide composition
P10791819A0771|72 88|asparagus genome
P10791819A0771|123 132|selection
P10791819A0771|146 152|codons
P10791901A0609|0 12|Transduction
P10791901A0609|35 49|cell line K562
P10791901A0609|68 90|MRP1-PG13 supernatants
P10791901A0609|114 123|MRP1 gene
P10791901A0609|143 144|%
P10791901A0609|148 165|target K562 cells
P10791901A0609|231 239|presence
P10791901A0609|259 273|concentrations
P10791901A0609|277 286|etoposide
P10792583A0000|0 10|Regulation
P10792583A0000|24 49|vasopressin V1b receptors
P10792583A0000|67 71|role
P10792583A0000|116 123|hormone
P10792583A0000|125 129|ACTH
P10792583A0000|131 140|secretion
P10792583A0000|148 158|adaptation
P10792583A0000|162 168|stress
P10792718T0000|0 14|Identification
P10792718T0000|21 35|AfsA homologue
P10792718T0000|37 41|BarX
P10792718T0000|88 97|regulator
P10792718T0000|110 136|autoregulator biosynthesis
P10792718T0000|138 164|virginiamycin biosynthesis
P10792718T0000|169 196|virginiamycin M1 resistance
P10793143A1533|32 43|DNA binding
P10793143A1533|68 77|Abf1 ARS1
P10793143A1533|90 98|activity
P10793143A1533|104 111|results
P10793143A1533|125 129|Cdc6
P10793143A1533|142 150|activity
P10793143A1533|170 174|role
P10793143A1533|182 192|initiation
P10793143A1533|196 211|DNA replication
P10793991A0569|19 28|longevity
P10793991A0569|36 39|Web
P10793991A0569|41 56|TIE researchers
P10793991A0569|79 87|position
P10793991A0569|99 105|trends
P10793991A0569|109 121|telemedicine
P10794405A0000|15 20|study
P10794405A0000|24 32|peptides
P10794405A0000|59 66|domains
P10794405A0000|70 80|histone H1
P10794405A0000|104 108|step
P10794405A0000|120 133|understanding
P10794405A0000|141 149|function
P10794405A0000|153 155|H1
P10794405A0000|159 168|chromatin
P10794936A0241|4 18|recovery rates
P10794936A0241|27 34|MB/BacT
P10794936A0241|36 40|MGIT
P10794936A0241|56 61|media
P10794936A0241|87 88|%
P10794936A0241|112 124|mycobacteria
P10794936A0241|130 144|recovery rates
P10794936A0241|170 171|%
P10794936A0241|191 214|M. tuberculosis complex
P10794936A0241|246 247|%
P10794936A0241|286 298|mycobacteria
P10795098A0253|9 19|vasculitis
P10795098A0253|33 38|Crohn
P10795098A0253|41 48|disease
P10795098A0253|73 83|phenomenon
P10796465A0373|0 18|SELECTION CRITERIA
P10796465A0373|55 61|trials
P10796465A0373|68 79|acupuncture
P10796465A0373|89 95|asthma
P10796465A0373|112 120|symptoms
P10796486A0817|0 18|SELECTION CRITERIA
P10796486A0817|31 37|trials
P10796486A0817|48 56|children
P10796486A0817|79 86|therapy
P10796486A0817|103 109|family
P10796486A0817|113 124|conjunction
P10796486A0817|130 147|asthma medication
P10796486A0817|154 162|children
P10796486A0817|170 187|asthma medication
P10797125A0000|12 22|hypothesis
P10797125A0000|47 56|increases
P10797125A0000|68 84|core temperature
P10797125A0000|93 119|core temperature threshold
P10797125A0000|124 138|sweating onset
P10797125A0000|159 167|estrogen
P10797125A0000|186 191|women
P10797125A0000|202 204|yr
P10797125A0000|212 226|degrees C rest
P10797125A0000|238 241|min
P10797125A0000|245 260|passive heating
P10797125A0000|265 274|degrees C
P10797125A0000|291 294|min
P10797125A0000|298 306|exercise
P10797125A0000|313 323|degrees C.
P10797586A0402|4 10|models
P10797586A0402|41 49|response
P10797586A0402|53 65|disturbances
P10797586A0402|82 88|signal
P10797586A0402|98 105|bladder
P10798607A1359|4 8|data
P10798607A1359|35 42|killing
P10798607A1359|46 58|meningococci
P10798607A1359|89 94|assay
P10798607A1359|100 121|antibody titer levels
P10798607A1359|144 152|immunity
P10798607A1359|182 190|patients
P10799501A1391|6 13|studies
P10799501A1391|36 45|component
P10799501A1391|58 69|environment
P10799501A1391|86 101|SPRK activation
P10799501A1391|105 110|Cdc42
P10799576A0196|0 2|M.
P10799590A0431|0 6|Jkappa
P10799590A0431|19 24|sites
P10799590A0431|52 62|activation
P10799590A0431|77 92|EBNA-3C protein
P10799590A0431|108 114|Jkappa
P10799590A0431|125 138|transcription
P10799590A0431|167 174|EBNA-3C
P10799590A0431|192 199|EBNA-3C
P10799590A0431|213 226|transcription
P10799590A0431|237 246|mechanism
P10799590A0431|270 276|Jkappa
P10799595A1454|11 14|YY1
P10799595A1454|19 22|CDP
P10799595A1454|45 55|regulators
P10799595A1454|87 104|HPV-6 E1 promoter
P10799595A1454|121 135|HPV life cycle
P10799863T0000|11 19|cleavage
P10799863T0000|23 40|metallopeptidases
P10799863T0000|45 56|proteasomes
P10799863T0000|83 100|HIV-1 ENV epitope
P10799863T0000|116 125|MHC class
P10799863T0000|128 148|antigen presentation
P10799879T0000|0 7|Cloning
P10799879T0000|12 28|characterization
P10799879T0000|38 41|Lnk
P10799879T0000|46 61|adaptor protein
P10799879T0000|67 86|pleckstrin homology
P10799879T0000|91 103|Src homology
P10799879T0000|106 113|domains
P10799879T0000|131 148|T cell activation
P10801244A0578|0 15|Vancomycin data
P10801244A0578|66 71|model
P10801244A0578|77 80|use
P10801244A0578|84 101|NONMEM population
P10801244A0578|118 126|software
P10801330A1714|9 12|Cas
P10801330A1714|31 38|cytosol
P10801330A1714|43 74|membrane cytoskeleton fractions
P10801330A1714|90 95|state
P10801330A1714|127 147|platelet aggregation
P10801330A1714|154 157|FAK
P10801330A1714|191 199|fraction
P10801482A0968|18 21|p65
P10801482A0968|37 44|targets
P10801482A0968|63 71|affinity
P10801482A0968|91 99|residues
P10801482A0968|114 119|roles
P10801482A0968|141 155|kappaB targets
P10801809T0000|16 26|regulation
P10801809T0000|34 53|yeast PHO8 promoter
P10801809T0000|57 67|comparison
P10801809T0000|87 100|PHO5 promoter
P10801860A0000|4 11|Siglecs
P10801860A0000|18 27|subfamily
P10801860A0000|38 45|lectins
P10801860A0000|47 82|immunoglobulin superfamily proteins
P10801860A0000|93 99|sugars
P10801860A0000|136 141|acids
P10802669A1434|4 8|data
P10802669A1434|31 42|explanation
P10802669A1434|51 61|similarity
P10802669A1434|65 74|phenotype
P10802669A1434|83 86|A-T
P10802669A1434|91 94|NBS
P10802909A0478|0 11|PATIENTS OR
P10802909A0478|18 30|PARTICIPANTS
P10802909A0478|39 47|children
P10802909A0478|56 64|criteria
P10804379T0001|0 6|Update
P10804379T0001|25 35|infections
P10804379T0001|39 50|hepatitis C
P10804379T0001|52 55|HIV
P10804379T0001|60 75|cytomegalovirus
P10805286A0233|15 20|study
P10805286A0233|39 51|cis-elements
P10805286A0233|65 73|PCI gene
P10805286A0233|87 97|expression
P10805286A0233|122 131|cell line
P10805286A0233|133 144|HepG2 cells
P10805286A0233|165 188|rat PCI mRNA expression
P10805286A0233|210 216|effect
P10805286A0233|220 228|androgen
P10805286A0233|232 235|rat
P10805286A0233|249 256|tissues
P10805286A0914|7 12|study
P10805286A0914|16 35|PCI mRNA expression
P10805286A0914|56 62|organs
P10805286A0914|80 92|rat PCI cDNA
P10805286A0914|116 122|effect
P10805286A0914|126 134|androgen
P10805286A0914|142 161|PCI mRNA expression
P10805390A0340|18 29|performance
P10805390A0340|31 43|measurements
P10805390A0340|47 64|photoluminescence
P10805390A0340|68 96|GaAs/AlGaAs heterostructures
P10805729A0987|4 17|stoichiometry
P10805729A0987|25 34|complexes
P10805729A0987|68 76|C strand
P10805729A0987|95 99|DDP1
P10805729A0987|120 130|KH domains
P10805729A0987|179 200|acid binding surfaces
P10805737T0000|11 19|analysis
P10805737T0000|33 62|translation initiation factor
P10805737T0000|66 70|eIF5
P10805737T0000|73 77|role
P10805737T0000|81 92|interaction
P10805737T0000|105 117|beta subunit
P10805737T0000|121 125|eIF2
P10805737T0000|130 134|eIF5
P10805737T0000|138 151|eIF5 function
P10805738A0799|5 13|evidence
P10805738A0799|29 32|p38
P10805738A0799|39 48|activator
P10805738A0799|52 56|MyoD
P10805738A0799|62 81|p38 kinase activity
P10805738A0799|102 112|expression
P10805738A0799|132 137|genes
P10805738A0799|153 162|induction
P10805738A0799|166 169|p38
P10805738A0799|201 209|activity
P10805738A0799|215 239|Gal4-MyoD fusion protein
P10805738A0799|261 271|activation
P10805738A0799|296 305|reporters
P10805738A0799|309 313|MyoD
P10805738A0799|349 359|conversion
P10805738A0799|374 379|mouse
P10805738A0799|390 401|fibroblasts
P10805738A0799|415 423|p38alpha
P10805738A0799|429 436|embryos
P10805739A0343|5 13|activity
P10805739A0343|31 48|complex formation
P10805739A0343|64 78|eIF2B subunits
P10805739A0640|4 12|analysis
P10805739A0640|16 34|nonsense mutations
P10805739A0640|54 64|C terminus
P10805739A0640|68 80|eIF2Bepsilon
P10805739A0640|82 90|residues
P10805739A0640|134 142|activity
P10805739A0640|147 158|interaction
P10805739A0640|164 168|eIF2
P10805747A0633|3 11|contrast
P10805747A0633|13 22|mutations
P10805747A0633|61 68|kinases
P10805747A0633|87 92|Hsl1p
P10805747A0633|97 102|Kcc4p
P10805747A0633|126 132|effect
P10805747A0633|136 155|septin organization
P10805823A1920|0 11|CONCLUSIONS
P10805823A1920|25 31|pacing
P10805823A1920|48 55|benefit
P10805823A1920|73 79|pacing
P10805823A1920|88 98|prevention
P10805823A1920|102 108|stroke
P10805823A1920|112 117|death
P10805823A1920|140 146|causes
P10807900A0933|6 20|non-cirrhotics
P10807900A0933|22 26|lack
P10807900A0933|37 55|vein visualisation
P10807900A0933|64 77|% sensitivity
P10807900A0933|81 94|% specificity
P10807900A0933|98 99|%
P10807900A0933|120 125|value
P10807900A0933|133 134|%
P10807900A0933|155 160|value
P10807900A0933|168 177|diagnosis
P10807900A0933|203 215|hypertension
P10807903A0362|0 5|D5/D1
P10807903A0362|6 8|CT
P10807903A0362|13 19|D5/D1D
P10807903A0362|20 22|CT
P10807903A0362|24 49|tail substitution mutants
P10807903A0362|62 72|rank order
P10807903A0362|76 83|potency
P10807903A0362|88 106|agonist affinities
P10807903A0362|142 154|D1 receptors
P10807903A0362|175 189|ligand binding
P10807903A0362|214 238|cAMP accumulation assays
P10807903A0362|259 271|D1 receptors
P10807903A0362|281 297|exhibit receptor
P10807903A0362|311 319|activity
P10807903A0362|323 337|responsiveness
P10807903A0362|349 357|agonists
P10809233A0606|0 8|Modeling
P10809233A0606|42 49|surface
P10809233A0606|61 68|absence
P10809233A0606|72 75|H12
P10809233A0606|86 94|residues
P10809233A0606|100 102|H3
P10809233A0606|104 108|loop
P10809233A0606|114 116|H4
P10809233A0606|122 125|H11
P10810083A1283|21 32|kinase gene
P10810083A1283|67 84|zinc finger motif
P10810294A0730|0 15|Stat activation
P10810294A0730|19 27|response
P10810294A0730|31 33|GH
P10810294A0730|38 42|IL-6
P10810294A0730|61 84|reporter gene induction
P10810745A0677|0 8|HFA 134a
P10810745A0677|23 31|tendency
P10810745A0677|43 51|moisture
P10810745A0677|61 72|environment
P10810745A0677|82 85|HFA
P10811079A0555|0 7|RESULTS
P10811079A0555|18 34|color perception
P10811079A0555|50 51|%
P10811079A0555|59 76|epilepsy patients
P10811079A0555|90 112|vigabatrin monotherapy
P10811079A0555|119 120|%
P10811079A0555|128 145|epilepsy patients
P10811079A0555|159 184|carbamazepine monotherapy
P10811079A1277|7 26|SPP2 screening test
P10811079A1277|34 40|plates
P10811079A1277|63 69|groups
P10811804A0000|18 25|protein
P10811804A0000|27 30|MAP
P10811804A0000|32 52|kinase phosphatase-3
P10811804A0000|54 59|MKP-3
P10811804A0000|71 94|specificity phosphatase
P10811804A0000|143 149|kinase
P10811804A0000|151 154|ERK
P10811804A0000|156 167|MAP kinases
P10811804A0800|35 43|peptides
P10811804A0800|57 70|docking sites
P10811804A0800|82 105|target substrates Elk-1
P10811804A0800|110 113|p90
P10811804A0800|114 117|rsk
P10811804A0800|141 151|activation
P10811804A0800|155 160|MKP-3
P10811908A0938|0 27|HPLC phosphopeptide mapping
P10811908A0938|29 50|amino acid sequencing
P10811908A0938|70 81|mutagenesis
P10811908A0938|98 102|NCLK
P10811908A0938|118 121|Ser
P10811908A0938|129 132|I-1
P10812294X0000|16 20|diet
P10812294X0000|34 37|SBF
P10812294X0000|49 60|feed intake
P10812294X0000|90 93|SBF
P10812294X0000|115 121|ponies
P10812294X0000|142 152|ingredient
P10814989T0000|0 27|Hepatitis C virus infection
P10814989T0000|52 60|diseases
P10814989T0000|64 70|France
P10814989T0000|83 88|study
P10815410A0000|11 17|system
P10815410A0000|49 70|neuroendocrine system
P10815410A0000|94 103|increases
P10815410A0000|107 116|cytokines
P10815410A0000|125 129|IL-1
P10815410A0000|131 135|IL-6
P10815410A0000|140 143|TNF
P10815410A0000|158 165|effects
P10815410A0000|189 195|system
P10815807A1271|27 40|transcription
P10815807A1271|61 75|c-Myb promoter
P10815807A1271|100 106|HTLV-I
P10815807A1271|119 131|T-cell lines
P10817754T0000|0 3|H19
P10817754T0000|8 12|Igf2
P10817754T0000|25 35|expression
P10817754T0000|65 69|ways
P10817754T0000|82 85|cis
P10817754T0000|104 110|region
P10817754T0000|123 126|H19
P10819327T0000|0 17|C. elegans KLP-11
P10819327T0000|18 23|OSM-3
P10819327T0000|24 29|KAP-1
P10819327T0000|31 40|orthologs
P10819327T0000|48 69|sea urchin kinesin-II
P10819327T0000|75 114|mouse KIF3A/KIFB/KAP3 kinesin complexes
P10820829T0000|0 10|Flavonoids
P10820829T0000|16 36|Brosimum acutifolium
P10820904A0000|0 10|BACKGROUND
P10820904A0000|20 34|encephalopathy
P10820904A0000|57 65|syndrome
P10820904A0000|88 101|liver failure
P10820904A0000|123 136|liver disease
P10820904A0000|156 167|anastomosis
P10821836A0842|24 37|S transcripts
P10821836A0842|74 93|sense S transcripts
P10822117A1386|12 22|adjustment
P10822117A1386|52 57|model
P10822117A1386|83 95|observations
P10822117A1386|114 125|information
P10822117A1386|135 149|subject-models
P10823630A1124|13 21|presence
P10823630A1124|25 35|effacement
P10823630A1124|78 87|parameter
P10823630A1124|119 129|prediction
P10823837A1213|4 8|data
P10823837A1213|33 37|idea
P10823837A1213|43 60|YLL031c transfers
P10823837A1213|65 86|ethanolaminephosphate
P10823837A1213|116 123|mannose
P10823837A1213|134 139|group
P10823837A1213|155 171|GPI lipid anchor
P10823837A1213|175 183|proteins
P10823837A1213|193 198|Mcd4p
P10823837A1213|203 239|Gpi7p transfer ethanolaminephosphate
P10823837A1213|249 257|alpha1-4
P10823837A1213|279 287|mannoses
P10823837A1213|295 305|GPI anchor
P10823961A0664|4 14|C terminus
P10823961A0664|18 22|TRBP
P10823961A0664|32 40|CBP/p300
P10823961A0664|45 52|DRIP130
P10823961A0664|56 65|component
P10823961A0664|73 94|DRIP/TRAP/ARC complex
P10823961A0664|116 120|TRBP
P10823961A0664|134 147|transcription
P10823961A0664|151 156|means
P10823961A0664|165 177|interactions
P10824485A0393|4 12|patients
P10824485A0393|46 53|disease
P10824485A0393|67 70|CD4
P10824485A0393|72 91|T lymphocyte counts
P10824485A0393|114 118|AIDS
P10824485A0393|128 137|illnesses
P10824958A1109|18 24|energy
P10824958A1109|35 38|PAB
P10824958A1109|47 50|use
P10824958A1109|68 70|CO
P10824958A1109|83 85|PF
P10824958A1109|96 100|PSHL
P10824958A1109|104 120|broiler breeders
P10824958A1109|139 141|wk
P10824958A1109|145 148|age
P10825000A1245|4 28|gene amplification model
P10825000A1245|32 40|Coquelle
P10825200T0000|0 9|Hierarchy
P10825200T0000|13 37|protein tyrosine kinases
P10825200T0000|41 54|interleukin-2
P10825200T0000|56 60|IL-2
P10825200T0000|62 71|signaling
P10825200T0000|73 83|activation
P10825200T0000|87 90|syk
P10825200T0000|102 106|Jak3
P10825200T0000|125 128|Syk
P10825200T0000|133 136|Lck
P10825200T0000|167 182|STAT activation
P10825293T0000|12 18|dimers
P10825293T0000|22 43|N-cadherin-Fc chimera
P10825293T0000|68 90|cell contact formation
P10825293T0000|92 104|contribution
P10825293T0000|139 146|signals
P10825294A0473|13 24|OC promoter
P10825294A0473|43 53|C terminus
P10825294A0473|64 70|manner
P10825294A0473|76 79|MDR
P10825294A0473|81 84|LTR
P10825294A0473|89 102|BSP promoters
P10825294A0473|135 145|mechanisms
P10825294A0473|186 200|AML C terminus
P10825294A0473|245 263|pentapeptide VWRPY
P10826861A0000|15 38|immunoglobulin products
P10826861A0000|42 62|plasma cell neoplasm
P10826861A0000|82 89|variety
P10826861A0000|93 107|manifestations
P10826861A0000|118 132|hyperviscosity
P10826861A0000|134 145|amyloidosis
P10826861A0000|147 163|cryoglobulinemia
P10826861A0000|165 175|neuropathy
P10826861A0000|187 194|failure
P10826946A1198|0 13|Investigation
P10826946A1198|32 37|basis
P10826946A1198|45 56|interaction
P10826946A1198|71 74|Igs
P10826946A1198|79 84|gp120
P10826946A1198|106 115|gp120 SAg
P10826946A1198|141 147|subset
P10826946A1198|157 158|V
P10826946A1198|159 160|H
P10826946A1198|164 167|Igs
P10827885T0059|33 38|trial
P10827952A0158|23 31|TAFII250
P10827952A0158|45 52|subunit
P10827952A0158|56 61|TFIID
P10827952A0158|83 102|bromodomain modules
P10827952A0158|148 167|histone H4 peptides
P10828022A0877|0 20|Endostatin treatment
P10828022A0877|28 35|minutes
P10828022A0877|42 47|hours
P10828022A0877|56 80|tyrosine phosphorylation
P10828022A0877|84 87|Shb
P10828022A0877|92 101|formation
P10828022A0877|118 127|complexes
P10828319A0342|11 18|analogs
P10828319A0342|22 32|vitamin D3
P10828319A0342|61 67|number
P10828319A0342|71 77|trials
P10828319A0342|86 97|improvement
P10828319A0342|101 110|psoriasis
P10828591A0080|4 14|transcript
P10828591A0080|53 66|cDNA sequence
P10828591A0080|74 80|course
P10828591A0080|99 113|transcript map
P10828591A0080|121 127|region
P10828591A0080|136 152|markers D11S1765
P10828591A0080|157 168|uteroglobin
P10828591A0080|192 196|gene
P10828591A0080|210 217|disease
P10828751A2258|9 18|challenge
P10828751A2258|27 33|future
P10828751A2258|46 56|management
P10828751A2258|60 68|patients
P10828751A2258|102 111|treatment
P10829973T0000|0 27|Iodine deficiency disorders
P10829973T0000|31 41|Bangladesh
P10830395A0408|4 21|network evolution
P10830395A0408|44 52|approach
P10830395A0408|66 77|Flory model
P10831972A0744|0 7|RESULTS
P10831972A0744|17 28|CD23 levels
P10831972A0744|58 63|women
P10831972A0744|69 82|endometriosis
P10831972A0744|90 99|treatment
P10831972A0744|119 127|controls
P10831972A1091|0 10|CONCLUSION
P10831972A1091|16 24|findings
P10831972A1091|38 51|endometriosis
P10831972A1091|70 81|CD23 levels
P10831972A1091|119 126|danazol
P10831972A1091|130 158|leuprolide acetate injection
P10833461A0603|16 20|gene
P10833461A0603|24 27|P-1
P10833461A0603|39 49|chromosome
P10833461A0603|51 54|PAC
P10833461A0603|56 63|library
P10833461A0603|89 108|length UGT2B7 probe
P10833461A0603|115 120|clone
P10833461A0603|142 144|kb
P10833461A0603|148 154|length
P10833486A0598|0 3|Age
P10833486A0598|11 16|years
P10833486A0598|18 28|odds ratio
P10833486A0598|30 32|OR
P10833486A0598|42 45|BMI
P10833486A0598|53 57|kg/m
P10833486A0598|62 64|OR
P10833486A0598|72 85|triglycerides
P10833486A0598|94 100|mmol/L
P10833486A0598|102 104|OR
P10833486A0598|114 138|alanine aminotransferase
P10833486A0598|140 143|ALT
P10833486A0598|149 151|2N
P10833486A0598|153 155|OR
P10833486A0598|204 212|fibrosis
P10834707A1533|25 32|amounts
P10834707A1533|36 62|platelet activating factor
P10834707A1533|84 91|sorbent
P10834707A1533|110 124|treatment time
P10834781A0693|21 26|group
P10834781A0693|60 75|residence times
P10834781A0693|77 81|MRTs
P10834781A0693|93 109|plasma clearance
P10834781A0693|113 122|lidocaine
P10834781A0693|134 140|period
P10834781A0693|165 170|group
P10834781A0693|172 173|P
P10835355A0225|23 47|zinc finger protein Gis1
P10835355A0225|75 85|suppressor
P10835355A0225|93 110|rim15Delta defect
P10835355A0225|114 122|nutrient
P10835355A0225|158 170|derepression
P10835355A0225|174 178|SSA3
P10835485A0941|15 18|SH3
P10835485A0941|20 27|segment
P10835485A0941|35 48|linker domain
P10835485A0941|53 61|contrast
P10835485A0941|86 103|sequence identity
P10835485A0941|119 138|amino acid residues
P10835485A0941|147 154|factors
P10835485A0941|159 165|cattle
P10835485A0941|178 183|mouse
P10835732A0911|3 14|differences
P10835732A0911|24 42|cholesterol levels
P10835732A0911|65 73|mapuches
P10835732A0911|78 85|aymaras
P10836542A0363|8 9|%
P10836542A0363|23 34|UV exposure
P10836542A0363|54 67|UV-A waveband
P10836542A0363|77 79|nm
P10836786A0516|29 33|role
P10836786A0516|41 53|RNA subunits
P10836786A0516|57 72|enzyme function
P10836786A0516|77 98|substrate specificity
P10836786A0516|115 133|hairpin structures
P10836786A0516|135 139|MRP3
P10836786A0516|144 146|P3
P10836786A0516|156 169|RNase MRP RNA
P10836786A0516|174 185|RNase P RNA
P10837126A1004|6 11|genes
P10837126A1004|29 40|pMesogenin1
P10837126A1004|44 50|Xwnt-8
P10837126A1004|54 70|signaling factor
P10837126A1004|94 104|repertoire
P10837126A1004|108 120|marker genes
P10837126A1004|144 153|phenotype
P10838139A1447|16 28|Ha-ras codon
P10838139A1447|32 41|mutations
P10838139A1447|80 86|tumors
P10838399A0525|15 22|PET FDG
P10838399A0525|39 53|lung infection
P10838399A0525|68 80|bone disease
P10838399A0525|86 109|reconstruction artifact
P10838531A0675|0 12|Tumor stages
P10838531A0675|18 21|IIB
P10838531A0675|23 28|T3 N0
P10838531A0675|35 36|%
P10838531A0675|38 42|IIIA
P10838531A0675|48 49|%
P10838531A0675|55 59|IIIB
P10838531A0675|65 66|%
P10838531A0675|70 78|patients
P10839470A1148|11 21|comparison
P10839470A1148|25 46|percentage reductions
P10839470A1148|50 60|heart rate
P10839470A1148|64 70|supine
P10839470A1148|84 92|exercise
P10839470A1148|105 121|measure analysis
P10839470A1148|133 139|Malays
P10839470A1148|169 175|change
P10839470A1148|201 202|p
P10839547A0978|20 25|model
P10839547A0978|27 39|CTCF binding
P10839547A0978|56 71|DNA methylation
P10839593A0000|0 9|OBJECTIVE
P10839593A0000|28 36|efficacy
P10839593A0000|41 47|safety
P10839593A0000|51 65|amphotericin B
P10839593A0000|71 81|suspension
P10839593A0000|83 87|ABOS
P10839593A0000|97 106|treatment
P10839593A0000|110 121|fluconazole
P10839593A0000|138 149|candidiasis
P10839593A0000|153 160|persons
P10839593A0000|166 179|HIV infection
P10840001A0188|0 21|Mucin gene expression
P10840001A0188|70 78|diseases
P10840001A0188|94 101|cancers
P10840001A0188|126 131|tract
P10841537A0669|26 33|regions
P10841537A0669|37 41|RPB5
P10841537A0669|60 72|interactions
P10841537A0669|130 140|structures
P10841593A0780|4 9|model
P10841593A0780|32 43|% reduction
P10841593A0780|47 68|cigarette consumption
P10841593A0780|92 104|availability
P10841593A0780|108 124|nicotine patches
P10841601T0000|0 11|Paper alert
P10843716A0406|4 18|tryptase locus
P10843716A0406|61 72|pseudogenes
P10843716A0406|84 90|mastin
P10843716A0406|94 98|gene
P10843716A0406|112 116|dogs
P10843716A0406|128 134|humans
P10843810A0802|13 17|part
P10843810A0802|40 45|clone
P10843810A0802|64 72|homology
P10843810A0802|79 83|exon
P10843810A0802|97 117|tyrosine phosphatase
P10843810A0802|120 124|gene
P10843810A0802|161 170|direction
P10843810A0802|196 199|LTR
P10845522A0000|0 9|OBJECTIVE
P10845522A0000|16 21|study
P10845522A0000|59 64|roles
P10845522A0000|68 101|99mTc-sestamibi scintimammography
P10845522A0000|106 116|sonography
P10845522A0000|124 134|evaluation
P10845522A0000|138 152|breast lesions
P10845522A0000|193 204|mammography
P10845522A0000|217 228|examination
P10846054A0573|11 19|analyses
P10846054A0573|46 52|codons
P10846054A0573|83 86|RNA
P10846054A0573|89 93|ORFs
P10846054A0573|109 121|accumulation
P10846054A0573|125 141|progeny LIYV RNA
P10846054A0573|147 150|RNA
P10846054A0573|170 173|RNA
P10846054A0573|192 200|proteins
P10846054A0573|215 235|LIYV RNA replication
P10846069T0000|0 4|Role
P10846069T0000|8 10|NH
P10846069T0000|33 40|domains
P10846069T0000|48 57|P protein
P10846069T0000|67 91|parainfluenza virus type
P10846069T0000|97 110|transcription
P10846069T0000|115 126|replication
P10848605T0000|0 15|Phosphorylation
P10848605T0000|19 36|tyrosine residues
P10848605T0000|44 57|kinase domain
P10848605T0000|62 82|juxtamembrane region
P10848605T0000|122 132|activities
P10848605T0000|136 149|Eph receptors
P10848848A0413|0 7|RESULTS
P10848848A0413|9 17|Fournier
P10848848A0413|20 28|gangrene
P10848993A0000|8 22|DNA sequencing
P10848993A0000|30 38|vicinity
P10848993A0000|42 71|methylmalonyl-CoA mutase gene
P10848993A0000|73 78|mutAB
P10848993A0000|87 96|rifamycin
P10848993A0000|110 140|Amycolatopsis mediterranei U32
P10848993A0000|155 160|clone
P10848993A0000|162 170|sequence
P10848993A0000|187 191|gene
P10848993A0000|209 240|serine/threonine protein kinase
P10848993A0000|242 245|amk
P10850329A0248|0 4|IL-2
P10850329A0248|31 40|treatment
P10850329A0248|59 70|combination
P10850329A0248|76 88|chemotherapy
P10850329A0248|92 102|biotherapy
P10850329A0248|110 120|management
P10850329A0248|135 143|melanoma
P10850329A0248|165 179|cell carcinoma
P10850453A0713|10 20|expression
P10850453A0713|34 40|Ha-Ras
P10850453A0713|62 67|Raf-1
P10850453A0713|92 98|effect
P10850453A0713|102 111|TGF-beta1
P10850453A0713|115 122|TSU-Pr1
P10850453A0713|132 152|TGF-beta1 inhibition
P10850453A0713|156 161|DU145
P10850453A0713|178 189|stimulation
P10850453A0713|193 215|V12Ha-Ras transfection
P10850453A1292|20 24|data
P10850453A1292|38 57|prostate carcinomas
P10850453A1292|67 94|Ras/MAPK pathway activation
P10850453A1292|118 134|growth advantage
P10850453A1292|148 168|TGF-beta1 production
P10850719A0680|0 14|Vbeta segments
P10850719A0680|31 52|DJbeta rearrangements
P10850719A0680|79 84|Vbeta
P10850719A0680|88 93|Jbeta
P10850719A0680|117 130|compatibility
P10850719A0680|134 147|Vbeta 23-RSSs
P10850719A0680|152 164|Jbeta12-RSSs
P10850849A0730|9 23|administration
P10850849A0730|25 38|AUC0-infinity
P10850849A0730|59 72|microg x h/ml
P10850849A0730|74 82|t1/2beta
P10850849A0730|102 107|hours
P10850849A0730|109 130|maximum concentration
P10850849A0730|132 136|Cmax
P10850849A0730|157 166|microg/ml
P10850849A0730|168 172|time
P10850849A0730|176 180|Cmax
P10850849A0730|199 204|hours
P10850849A0730|211 226|absorption time
P10850849A0730|245 250|hours
P10850849A0730|256 271|bioavailability
P10850849A0730|287 288|%
P10850942A0989|3 13|experiment
P10850942A0989|20 30|difference
P10850942A0989|42 50|emptying
P10850942A0989|56 65|% peptone
P10850942A0989|71 80|% glucose
P10850942A0989|99 103|rats
P10850942A0989|114 117|TPN
P10850942A0989|151 160|nutrition
P10850942A0989|174 178|days
P10850997A1016|3 11|contrast
P10850997A1016|13 17|H-NS
P10850997A1016|27 37|regulation
P10850997A1016|59 66|absence
P10850997A1016|70 73|Fur
P10851089A1248|6 9|SAG
P10851089A1248|29 51|cell cycle progression
P10851089A1248|55 60|yeast
P10851089A1248|74 88|ubiquitination
P10851089A1248|93 104|degradation
P10851089A1248|108 118|cell cycle
P10851089A1248|130 138|proteins
P10851267A0000|0 3|E2F
P10851267A0000|12 32|transcription factor
P10851267A0000|48 70|cell cycle progression
P10851267A0000|76 83|S-phase
P10851745A0624|16 23|fatigue
P10851745A0624|34 39|moods
P10851745A0624|54 60|health
P10851745A0624|62 67|sleep
P10851745A0624|69 75|safety
P10851745A0624|89 97|capacity
P10852221A0422|23 32|treatment
P10852221A0422|40 45|graft
P10852221A0422|79 85|period
P10852221A0422|103 110|surgery
P10852221A0422|127 133|effect
P10852221A0422|141 149|survival
P10852221A0422|174 181|neurons
P10852460A0170|4 17|relationships
P10852460A0170|24 44|blood concentrations
P10852460A0170|48 64|thyroid hormones
P10852460A0170|69 77|selenium
P10852460A0170|79 83|zinc
P10852460A0170|85 92|retinol
P10852460A0170|98 114|alpha-tocopherol
P10852460A0170|142 150|Northern
P10852460A0170|170 178|subjects
P10852460A0170|180 189|age range
P10852460A0170|198 200|yr
P10852460A0170|219 227|criteria
P10852460A0170|235 251|SENIEUR protocol
P10852485A0477|8 14|Spring
P10852485A0477|16 18|CS
P10852485A0477|33 39|Q gene
P10852485A0477|54 78|chromosome deletion line
P10852485A0477|82 84|CS
P10852485A0477|94 96|q5
P10852485A0477|112 113|%
P10852485A0477|117 120|5AL
P10852485A0477|135 141|Q gene
P10852953A0000|0 14|Investigations
P10852953A0000|33 39|slices
P10852953A0000|83 89|bursts
P10852953A0000|105 121|field potentials
P10852953A0000|129 150|gamma frequency range
P10852953A0000|158 160|Hz
P10852953A0000|187 198|oscillation
P10852953A0000|206 210|beta
P10852953A0000|213 218|range
P10852953A0000|226 228|Hz
P10853059X0751|0 9|Karger AG
P10853059X0751|11 16|Basel
P10853778A0316|7 25|surgery bone cysts
P10853778A0316|53 64|bone grafts
P10853850A1103|8 12|LTE4
P10853850A1103|34 44|challenges
P10853850A1103|49 53|rise
P10853850A1103|97 119|inhalation provocation
P10853850A1103|121 122|p
P10854004A0788|6 9|FVR
P10854004A0788|41 42|%
P10854004A0788|46 49|ERT
P10854004A0788|54 57|HRT
P10854004A0788|63 76|FVR responses
P10854004A0788|80 93|noradrenaline
P10854004A0788|95 106|angiotensin
P10854004A0788|111 124|acetylcholine
P10854004A0788|129 142|nitroprusside
P10854699A0424|6 18|FGF-AS cDNAs
P10854699A0424|50 61|FGF-AS mRNA
P10854699A0424|82 97|splice variants
P10854699A0424|106 110|exon
P10854699A0424|116 121|exons
P10854699A0424|137 152|FGF-AS sequence
P10855690A0870|22 29|results
P10855690A0870|44 54|MAP kinase
P10855690A0870|70 84|hPL-B enhancer
P10855690A0870|109 116|pathway
P10855793A1418|0 16|Characterization
P10855793A1418|32 36|TNRs
P10855793A1418|61 66|genes
P10855793A1418|93 97|cord
P10855793A1418|123 137|identification
P10855793A1418|145 155|candidates
P10855793A1418|160 165|genes
P10855793A1418|196 205|disorders
P10855796A1160|17 42|RNA hybridization studies
P10855796A1160|68 75|pattern
P10855796A1160|79 100|EphA8 gene expression
P10855796A1160|127 133|region
P10855796A1160|146 152|tectum
P10855796A1160|170 181|development
P10856298A0798|0 12|Transfection
P10856298A0798|16 21|cDNAs
P10856298A0798|39 46|enzymes
P10856298A0798|70 89|hamster ovary cells
P10856298A0798|109 114|level
P10856298A0798|125 131|growth
P10856298A0798|143 148|T339I
P10856298A0798|166 172|growth
P10856298A0798|178 183|level
P10856298A0798|220 226|enzyme
P10856491A0178|0 7|SETTING
P10856491A0178|9 19|University
P10856491A0178|23 41|Paris VII hospital
P10856491A0178|42 49|Patient
P10856491A0178|50 51|s
P10856491A0178|59 64|women
P10856491A0178|69 81|embolization
P10856491A0178|98 103|myoma
P10856491A0178|113 124|pregnancies
P10856805T0000|0 33|Improving fissure sealant quality
P10856805T0000|46 57|preparation
P10856805T0000|70 75|level
P10857215A0000|4 26|Menopause-Rating-Scale
P10857215A0000|28 33|MRS I
P10857215A0000|56 64|practice
P10857215A0806|4 10|MRS II
P10857215A0806|39 47|standard
P10857215A0806|54 64|instrument
P10857215A0806|85 95|population
P10857262A0186|4 11|protein
P10857262A0186|27 42|fruA transcript
P10857262A0186|70 72|D.
P10857262A0186|86 100|type A protein
P10857262A0186|119 122|BTB
P10857262A0186|147 153|domain
P10857262A0186|175 180|exons
P10857262A0186|200 201|%
P10857751A0304|3 11|addition
P10857751A0304|17 31|mouse ortholog
P10857751A0304|33 47|Mharp/Smarcal1
P10857751A0304|69 100|Caenorhabditis elegans ortholog
P10857751A0304|102 108|CEHARP
P10857751A0304|132 148|GenBank database
P10858355A0920|0 12|Sparfloxacin
P10858355A0920|17 30|clinafloxacin
P10858355A0920|54 81|Enterococcus faecium SF2149
P10858355A0920|86 113|Enterococcus faecalis WH245
P10858988A0786|0 3|ECP
P10858988A0786|8 23|tryptase levels
P10858988A0786|27 32|serum
P10858988A0786|78 87|challenge
P10860131A0847|0 17|Tolterodine users
P10860131A0847|27 32|times
P10860131A0847|82 86|drug
P10860131A0847|88 90|RR
P10860131A0847|98 102|% CI
P10860196A0876|20 27|program
P10860196A0876|33 38|costs
P10860196A0876|76 80|year
P10860196A0876|108 113|years
P10860752A1601|4 12|presence
P10860752A1601|32 35|RNA
P10860752A1601|37 51|binding domain
P10860752A1601|63 72|mechanism
P10860752A1601|90 104|autoregulation
P10860752A1601|108 149|bacteriophage T4 DNA polymerase synthesis
P10860752A1601|172 176|mRNA
P10860827A0399|0 8|Deletion
P10860827A0399|24 32|analyses
P10860827A0399|70 78|elements
P10860827A0399|87 93|region
P10860827A0399|117 132|CSX1 expression
P10860827A0399|136 150|cardiomyocytes
P10860846A0480|11 18|studies
P10860846A0480|38 46|mutation
P10860846A0480|54 77|AP2 core binding region
P10860846A0480|89 115|cotransfection experiments
P10860846A0480|125 146|AP2 expression vector
P10860846A0480|161 164|AP2
P10860846A0480|185 189|role
P10860846A0480|197 223|HGF gene promoter activity
P10861080A0433|17 25|transfer
P10861080A0433|29 41|IkappaBalpha
P10861080A0433|43 70|IkappaBalpha overexpression
P10861080A0433|77 87|production
P10861080A0433|91 100|TNF-alpha
P10861080A0433|118 121|GBS
P10861080A0433|146 147|%
P10861086A0259|3 29|reconstitution experiments
P10861086A0259|52 62|expression
P10861086A0259|70 73|RAW
P10861086A0259|80 89|cell line
P10861086A0259|104 114|Src kinase
P10861086A0259|116 119|Csk
P10861086A0259|164 184|gain-of-function Csk
P10861086A0259|199 207|Fc gamma
P10861086A0259|219 228|signaling
P10861086A0259|243 255|phagocytosis
P10861086A0259|278 284|manner
P10861086A0904|3 11|contrast
P10861086A0904|27 36|construct
P10861086A0904|38 43|a-Src
P10861086A0904|89 98|membranes
P10861086A0904|122 128|series
P10861086A0904|132 154|phagocytosis signaling
P10861906A0999|4 24|delta srb10 mutation
P10861906A0999|48 65|transcript levels
P10861906A0999|86 91|genes
P10861906A0999|99 103|IME1
P10861906A0999|108 112|IME2
P10861906A0999|118 126|mutation
P10861906A0999|140 156|transcript level
P10861906A0999|160 164|IME1
P10861906A0999|185 189|IME2
P10861906A0999|212 219|defects
P10861906A0999|234 247|DNA synthesis
P10861906A0999|252 259|meiosis
P10861906A1479|33 43|conditions
P10861906A1479|48 55|meiosis
P10861906A1479|76 93|transcript levels
P10861906A1479|97 102|KIN28
P10861906A1479|107 111|CCL1
P10861906A1479|123 142|nitrogen starvation
P10861906A1479|178 190|alkalization
P10861906A1479|194 200|medium
P10861909A0502|4 15|pJR vectors
P10861909A0502|57 63|marker
P10861909A0502|90 93|LEU
P10861909A0502|96 100|gene
P10861909A0502|120 122|S.
P10861909A0502|135 139|gene
P10861909A0502|144 146|S.
P10861909A0502|153 157|ura4
P10861909A0502|163 167|his3
P10861909A0502|169 174|genes
P10861909A0502|206 219|nmt1 promoter
P10861909A0502|221 223|3X
P10861909A0502|225 228|41X
P10861909A0502|233 236|81X
P10861909A0502|274 298|transcription efficiency
P10861909A0502|336 348|cloning site
P10861909A0502|371 376|sites
P10861909A0502|386 403|restriction sites
P10862289A0289|1 4|GUT
P10862289A0289|5 9|Sera
P10862289A0289|16 23|montoux
P10862289A0289|41 47|adults
P10862289A0289|49 56|age/sex
P10862289A0289|80 87|control
P10862289A0289|101 104|IgG
P10862289A0289|110 116|bodies
P10862289A0289|120 131|A60 antigen
P10863048A0000|4 10|effect
P10863048A0000|41 53|cord lesions
P10863048A0000|77 85|activity
P10863048A0000|117 125|stimulus
P10863048A0000|138 148|distension
P10863048A0000|150 153|CRD
P10863048A0000|158 162|mmHg
P10863048A0000|167 168|s
P10863048A0000|212 216|rats
P10863352T0001|0 14|Franz Schubert
P10863352T0001|20 24|life
P10863352T0001|26 31|music
P10863352T0001|36 44|diseases
P10864271A0504|4 11|results
P10864271A0504|29 33|role
P10864271A0504|37 51|S. argyrostoma
P10864271A0504|59 72|dissemination
P10864271A0504|76 94|Trichinella larvae
P10864271A0504|98 104|nature
P10864271A0504|119 129|comparison
P10864271A0504|137 141|role
P10864271A0504|152 159|mammals
P10864271A0504|165 174|scavenger
P10864271A0504|193 201|behavior
P10864496A0401|4 36|equilibrium dissociation binding
P10864496A0401|54 65|interaction
P10864496A0401|69 73|TnrA
P10864496A0401|83 106|nrgAB promoter fragment
P10864496A0401|115 117|nM
P10864496A0401|128 138|conditions
P10864641A1400|6 13|results
P10864641A1400|31 40|N-glycans
P10864641A1400|71 75|site
P10864641A1400|83 94|HA molecule
P10864641A1400|106 116|regulators
P10864641A1400|120 142|influenza virus growth
P10864641A1400|153 159|glycan
P10864641A1400|163 169|Asn149
P10864641A1400|197 203|Asn123
P10864989A0484|0 7|RESULTS
P10864989A0484|13 25|introduction
P10864989A0484|33 37|PAIP
P10864989A0484|65 66|p
P10864989A0484|74 83|reduction
P10864989A0484|101 105|WBCs
P10864989A0484|107 113|median
P10864989A0484|132 139|numbers
P10864989A0484|150 153|FIP
P10864989A0484|155 161|median
P10864989A0484|196 215|separation efficacy
P10864989A0484|219 220|%
P10864989A0484|226 241|separation time
P10865422A0138|20 34|serum ferritin
P10865422A0138|36 38|SF
P10865422A0138|41 51|hemoglobin
P10865422A0138|53 55|Hb
P10865422A0138|57 62|level
P10865422A0138|86 95|histories
P10865422A0138|99 108|donations
P10865422A0138|113 133|iron supplementation
P10865838A0000|21 34|growth factor
P10865838A0000|36 40|VEGF
P10865838A0000|52 59|agonist
P10865838A0000|86 91|cells
P10865838A0000|102 111|migration
P10865838A0000|116 124|division
P10865838A0000|149 154|cells
P10865940A0000|16 49|agent pyrrolidine dithiocarbamate
P10865940A0000|51 55|PDTC
P10865940A0000|95 100|cells
P10865940A0000|102 104|EC
P10865940A0000|160 180|NF-kappaB activation
P10866323A0666|23 30|effects
P10866323A0666|34 56|SIE-1 hypermethylation
P10866323A0666|60 77|p21WAF1 induction
P10866323A0666|81 96|STAT activation
P10866677A1839|0 3|Phd
P10866677A1839|28 36|peptides
P10866677A1839|63 68|mouse
P10866677A1839|99 107|extracts
P10866689A0295|7 10|pRb
P10866689A0295|14 30|SAOS-2 cell line
P10866689A0295|62 78|reporter plasmid
P10866689A0295|94 112|tal-1 binding site
P10866689A0295|114 117|pRb
P10866689A0295|147 155|activity
P10866689A0295|159 173|tal-1-E12-Lmo2
P10866689A0295|178 207|tal-1-E12-Lmo2-Ldb1 complexes
P10866689A0295|226 247|tal-1-E12 heterodimer
P10866886A1277|5 11|effect
P10866886A1277|28 39|conjunction
P10866886A1277|45 54|oxycodone
P10866886A1277|72 91|mu-receptor agonist
P10867199A0230|3 11|contrast
P10867199A0230|33 41|criteria
P10867199A0230|51 55|data
P10867199A0230|78 85|studies
P10867199A0230|101 106|level
P10867199A0230|127 131|EPVs
P10867199A0230|152 165|insect orders
P10867496T0001|0 17|Neurofibromatosis
P10867496T0001|25 31|breast
P10867496T0001|37 44|patient
P10867496T0001|50 75|Morbus von Recklinghausen
P10868488A0921|17 23|period
P10868488A0921|29 33|rate
P10868488A0921|37 47|aggression
P10868488A0921|86 104|testosterone level
P10869076A1384|6 13|results
P10869076A1384|26 36|hypothesis
P10869076A1384|49 57|presence
P10869076A1384|61 71|tryptophan
P10869076A1384|76 84|ribosome
P10869076A1384|97 101|tnaC
P10869076A1384|109 112|Rho
P10869076A1384|115 121|access
P10869076A1384|129 133|boxA
P10869076A1384|138 147|rut sites
P10869076A1384|168 193|transcription termination
P10869465A1054|8 21|hybridization
P10869465A1054|41 51|RNA probes
P10869465A1054|74 92|expression changes
P10869465A1054|106 112|clones
P10869465A1054|131 138|changes
P10869465A1054|151 167|germ cell stages
P10869465A1054|185 195|cell types
P10869465A1054|197 204|Sertoli
P10869465A1054|235 240|cells
P10870043A0621|4 18|administration
P10870043A0621|26 38|GnRH agonist
P10870043A0621|51 71|bone mineral density
P10870043A0621|85 90|femur
P10870043A0621|98 99|%
P10870043A0621|115 128|control group
P10870391T0034|0 10|Prevention
P10870391T0034|25 34|diagnosis
P10870391T0034|39 46|therapy
P10870391T0034|50 65|travel diarrhea
P10871045A1221|5 10|study
P10871045A1221|22 31|C/EBPbeta
P10871045A1221|51 64|C/EBP isoform
P10871045A1221|84 98|stellate cells
P10871045A1221|118 135|C/EBPbeta protein
P10871045A1221|140 157|C/EBPbeta binding
P10871045A1221|172 190|C/EBP binding site
P10871045A1221|198 206|promoter
P10871045A1221|231 237|effect
P10871045A1221|241 253|acetaldehyde
P10871347A0477|0 17|Mutation analysis
P10871347A0477|40 52|motif TCCCCT
P10871347A0477|69 86|PyRo1 interaction
P10871379A0261|8 12|VP16
P10871379A0261|18 42|transactivation function
P10871379A0261|46 51|Luman
P10871379A0261|73 76|HCF
P10871412A0369|21 27|rounds
P10871412A0369|31 40|selection
P10871412A0369|44 65|focus formation assay
P10871412A0369|82 90|ribozyme
P10871412A0369|92 97|Rz007
P10871615A0368|0 2|G.
P10871615A0368|8 12|Hyde
P10871615A0368|14 16|C.
P10871842A0988|4 11|results
P10871842A0988|25 46|proteasome inhibition
P10871842A0988|56 68|upregulation
P10871842A0988|81 88|members
P10871842A0988|92 121|transcription factor families
P10871842A0988|143 158|stress response
P10871842A0988|163 176|proliferation
P10872473A2286|4 18|ATR-X syndrome
P10872473A2286|32 41|mutations
P10872473A2286|49 57|XH2 gene
P10872473A2286|74 86|X chromosome
P10872473A2286|88 94|Xq13.3
P10872473A2286|125 131|factor
P10872473A2286|148 163|gene expression
P10872535A0000|0 4|AIMS
P10872535A0000|22 26|role
P10872535A0000|58 65|factors
P10872535A0000|85 97|birthweights
P10872535A0000|101 106|twins
P10872535A0000|122 136|susceptibility
P10872535A0000|140 148|diabetes
P10872535A0000|177 186|responses
P10872535A0000|199 221|glucose tolerance test
P10872535A0000|223 227|OGTT
P10872535A0000|253 264|association
P10872535A0000|280 303|birthweight differences
P10872535A0000|318 331|abnormalities
P10872535A0000|341 345|life
P10872756A1325|3 13|NASCIS III
P10872756A1325|17 40|randomization imbalance
P10872756A1325|84 90|number
P10872756A1325|94 102|patients
P10872756A1325|111 124|motor deficit
P10872756A1325|143 149|chance
P10872756A1325|154 162|recovery
P10872756A1325|177 195|dose control group
P10872827A0000|0 18|Penicillin acylase
P10872827A0000|20 22|PA
P10872827A0000|46 55|ATCC11105
P10872827A0000|73 84|heterodimer
P10872827A0000|104 107|kDa
P10872827A0000|114 121|subunit
P10872827A0000|131 134|kDa
P10872827A0000|141 148|subunit
P10872831A0000|19 31|sequence tag
P10872831A0000|33 36|EST
P10872831A0000|46 54|homology
P10872831A0000|60 83|erythropoietin receptor
P10872831A0000|85 89|EPOR
P10872831A0000|113 125|EST database
P10872851A0714|9 12|LCx
P10872851A0714|53 64|tachycardia
P10872851A0714|87 90|AoP
P10872851A0714|92 93|P
P10872851A0714|125 127|SV
P10872851A0714|129 130|P
P10872851A0714|143 148|LVEDP
P10872851A0714|164 165|P
P10873158A0000|0 10|Activation
P10873158A0000|22 28|factor
P10873158A0000|30 32|NF
P10873158A0000|34 40|kappaB
P10873158A0000|72 87|gene expression
P10873158A0000|97 103|airway
P10873158A0000|115 120|cells
P10873158A0000|148 154|stress
P10873286X0000|0 13|GAP JUNCTIONS
P10873286X0000|21 26|BRAIN
P10873286X0000|28 35|PREFACE
P10873386A0000|52 62|mouse gene
P10873386A0000|71 81|C2 subunit
P10873386A0000|89 103|20S proteasome
P10873387A0816|29 33|gene
P10873387A0816|42 45|end
P10873387A0816|53 70|Cacna1f gene maps
P10873387A0816|80 82|kb
P10873387A0816|93 96|end
P10873387A0816|104 128|mouse synaptophysin gene
P10873387A0816|134 140|region
P10873387A0816|156 160|Xp11
P10873388A0623|15 28|Rhotekin cDNA
P10873388A0623|34 39|probe
P10873388A0623|41 63|Northern hybridization
P10873388A0623|87 97|transcript
P10873388A0623|122 127|level
P10873388A0623|131 139|prostate
P10873388A0623|156 161|level
P10873388A0623|174 181|tissues
P10873388A0623|221 226|liver
P10873388A0623|231 243|lung tissues
P10874044A0647|11 24|co-expression
P10874044A0647|48 54|mutant
P10874044A0647|58 66|p38alpha
P10874044A0647|79 83|ERK1
P10874044A0647|85 89|ERK2
P10874044A0647|91 95|JNK1
P10874044A0647|100 104|JNK2
P10874044A0647|140 156|pE1-luc activity
P10874151A0000|0 10|BACKGROUND
P10874151A0000|12 36|Gamma knife radiosurgery
P10874151A0000|38 41|GKR
P10874151A0000|67 78|alternative
P10874151A0000|82 89|surgery
P10874151A0000|107 114|lesions
P10878398A0542|16 24|patients
P10878398A0542|26 29|Epo
P10878398A0542|42 47|group
P10878398A0542|49 62|leptin levels
P10878398A0542|106 119|CAPD patients
P10878398A0542|121 124|Epo
P10878398A0542|137 142|group
P10878606A0876|35 45|structures
P10878606A0876|64 70|organs
P10878606A0876|111 123|interactions
P10878675A1278|0 10|CONCLUSION
P10878675A1278|34 53|antagonist idazoxan
P10878675A1278|92 100|activity
P10878675A1278|109 127|energy expenditure
P10878675A1278|137 145|subjects
P10878944A0000|9 42|diphtheria toxin polymer particle
P10878944A0000|54 59|agent
P10878944A0000|76 85|DiaMed AG
P10878944A0000|87 98|Switzerland
P10878944A0000|129 139|laboratory
P10878944A0000|143 152|Institute
P10878944A0000|156 176|Childhood Infections
P10878944A0000|180 183|St.
P10880486A0790|35 44|mutations
P10880486A0790|92 98|zipper
P10880486A0790|99 102|Ebr
P10880486A0790|117 127|RhoA locus
P10880702A0966|15 22|results
P10880702A0966|46 54|exposure
P10880702A0966|58 69|amphetamine
P10880702A0966|73 84|apomorphine
P10880702A0966|117 126|component
P10880702A0966|130 143|sensitization
P10880702A0966|147 158|amphetamine
P10880702A0966|195 203|behavior
P10881275T0000|12 29|serum IgM binding
P10881275T0000|33 48|GM1 ganglioside
P10881275T0000|61 69|practice
P10882163A1077|0 19|Objective responses
P10882163A1077|37 44|studies
P10882163A1077|70 73|use
P10882163A1077|77 87|exemestane
P10882163A1077|94 101|failure
P10882163A1077|105 122|aminoglutethimide
P10882163A1077|126 127|%
P10882163A1077|133 143|exemestane
P10882163A1077|148 154|mg/day
P10882163A1077|178 198|aromatase inhibitors
P10882163A1077|203 204|%
P10882163A1077|210 220|exemestane
P10882163A1077|224 230|mg/day
P10882213A0163|0 6|Topics
P10882213A0163|30 34|data
P10882213A0163|50 61|association
P10882213A0163|65 73|myositis
P10882213A0163|79 85|cancer
P10882213A0163|106 117|evaluations
P10882213A0163|122 132|malignancy
P10882213A0163|138 154|myositis patient
P10882213A0163|159 167|approach
P10882213A0163|175 185|assessment
P10882213A0163|189 197|patients
P10882213A0163|203 232|dermatomyositis sine myositis
P10882213A0163|238 248|usefulness
P10882213A0163|292 307|classifications
P10882213A0163|311 321|discussion
P10882213A0163|333 342|childhood
P10882213A0163|353 361|myositis
P10882213A0163|388 396|entities
P10882213A0163|400 406|review
P10882213A0163|427 434|factors
P10882213A0163|463 473|management
P10882213A0163|477 494|myositis patients
P10882213A0163|504 514|approaches
P10882213A0163|525 536|limitations
P10882213A0163|551 567|disease activity
P10882213A0163|572 578|damage
P10882462T0000|4 11|science
P10882462T0000|15 33|tissue engineering
P10882850A0000|0 12|Endonuclease
P10882850A0000|18 21|Nth
P10882850A0000|48 63|DNA glycosylase
P10882850A0000|82 89|removal
P10882850A0000|102 126|pyrimidine base residues
P10882850A0000|132 135|DNA
P10884978A0633|4 12|duration
P10884978A0633|25 34|hyperemia
P10884978A0633|50 55|aging
P10884978A0633|65 75|difference
P10884978A0633|84 89|males
P10884978A0633|94 101|females
P10884978A0633|129 132|age
P10885708T0000|9 27|bile duct blockage
P10885708T0000|29 34|entry
P10885708T0000|52 57|agent
P10885708T0000|79 86|abscess
P10885731A0915|18 23|study
P10885731A0915|37 43|impact
P10885731A0915|47 67|synthesis conditions
P10885731A0915|71 83|block length
P10885731A0915|88 101|crystallinity
P10885731A0915|111 117|impact
P10885731A0915|143 156|crystallinity
P10885731A0915|161 171|solubility
P10885731A0915|179 187|polymers
P10885750A0236|48 56|function
P10885750A0236|60 66|CREB-2
P10885750A0236|80 91|development
P10885750A0236|95 111|organ physiology
P10886067A0520|10 18|diameter
P10886067A0520|27 36|thickness
P10886067A0520|44 49|rotor
P10886067A0520|57 59|mm
P10886067A0520|66 68|mm
P10887912A0740|9 13|MVBF
P10887912A0740|22 42|maximum EMG activity
P10887912A0740|56 64|masseter
P10887912A0740|87 105|temporalis muscles
P10887912A0740|142 153|muscle pain
P10887912A0740|163 175|subjects bit
P10887912A0740|191 195|side
P10887921A0718|0 11|CONCLUSIONS
P10887921A0718|24 32|relation
P10887921A0718|40 50|topography
P10887921A0718|66 77|field areas
P10887921A0718|90 94|SWAP
P10887921A0718|131 139|rim area
P10887921A0718|158 162|role
P10887921A0718|170 179|diagnosis
P10887921A0718|184 193|follow-up
P10887921A0718|207 215|glaucoma
P10888570A0678|10 19|alkaloids
P10888570A0678|37 41|peel
P10888570A0678|45 52|Atzimba
P10888570A0678|54 59|Lopez
P10888570A0678|61 69|Marciana
P10888570A0678|71 79|Montsama
P10888570A0678|81 86|Murca
P10888570A0678|92 98|Puebla
P10888570A0678|118 124|limits
P10888570A0678|141 152|food safety
P10889399A0243|4 26|detection success rate
P10889399A0243|56 63|markers
P10889399A0243|75 78|MEK
P10890911A0470|21 26|Smad3
P10890911A0470|57 71|HMG box domain
P10890911A0470|75 79|LEF1
P10890911A0470|89 96|TGFbeta
P10890911A0470|101 113|Wnt pathways
P10890911A0470|136 149|transcription
P10890911A0470|157 183|Xenopus homeobox gene twin
P10890911A0470|185 189|Xtwn
P10891093A0000|4 26|transmembrane topology
P10891093A0000|30 32|Na
P10891093A0000|36 37|H
P10891093A0000|41 55|exchanger NHE3
P10891093A0000|88 113|transcription/translation
P10891093A0000|121 126|types
P10891093A0000|130 144|fusion vectors
P10891093A0000|162 191|membrane insertion properties
P10891093A0000|195 209|cDNA sequences
P10891093A0000|228 241|NHE3 membrane
P10891093A0000|251 258|domains
P10891093A0000|260 264|msds
P10891266A0421|0 5|ACE-2
P10891266A0421|24 34|C terminus
P10891266A0421|38 44|H type
P10891286A0000|0 7|Members
P10891286A0000|15 27|titin/myosin
P10891286A0000|34 53|chain kinase family
P10891286A0000|72 76|role
P10891286A0000|84 96|organization
P10891286A0000|104 129|actin/myosin cytoskeleton
P10891286A0000|155 163|assembly
P10891286A0000|168 176|function
P10891399A1185|18 28|activation
P10891399A1185|32 39|c-fosER
P10891399A1185|65 75|inhibition
P10891399A1185|79 82|p21
P10891399A1185|83 92|Cip1/WAF1
P10891399A1185|131 140|AP-1 site
P10891399A1185|165 169|role
P10891399A1185|174 179|c-fos
P10891399A1185|192 199|control
P10891399A1185|203 213|cell cycle
P10891399A1185|225 230|genes
P10891441A0871|15 41|pTyr317 Shc phosphopeptide
P10891441A0871|65 69|Grb2
P10891441A0871|71 75|Sos1
P10891441A0871|77 81|SHIP
P10891441A0871|91 102|p85 subunit
P10891441A0871|106 126|phosphatidylinositol
P10891441A0871|130 136|kinase
P10891441A0871|142 152|mast cells
P10891441A0871|174 191|mass spectrometry
P10891489A0152|19 29|expression
P10891489A0152|37 53|HMG-I/Y proteins
P10891489A0152|82 95|proliferation
P10891489A0152|108 122|transformation
P10891489A0152|142 149|cancers
P10891489A0152|155 159|role
P10891489A0152|169 177|proteins
P10891489A0152|185 197|pathogenesis
P10891489A0152|201 211|malignancy
P10891632A0435|4 37|naltrexone/lofexidine combination
P10891632A0435|71 81|resolution
P10891632A0435|96 115|withdrawal syndrome
P10891632A0435|145 163|treatment schedule
P10891632A0435|185 194|increases
P10891632A0435|198 217|withdrawal symptoms
P10891632A0435|233 245|side-effects
P10892300A0268|10 18|symptoms
P10892300A0268|31 41|calcinosis
P10892300A0268|56 61|March
P10892300A0268|85 89|cows
P10892300A0268|100 123|locomotor abnormalities
P10892823A1040|0 9|Screening
P10892823A1040|11 21|counseling
P10892823A1040|27 36|treatment
P10892823A1040|41 48|alcohol
P10892823A1040|61 69|drug use
P10892823A1040|90 100|components
P10892823A1040|118 126|HBP care
P10893243T0000|16 26|regulation
P10893243T0000|34 39|mouse
P10893243T0000|50 100|chaperonin subunit gene Ccta/t-complex polypeptide
P10893243T0000|106 144|selenocysteine tRNA gene transcription
P10893243T0000|156 190|factor family zinc finger proteins
P10893258T0000|13 29|protein response
P10893258T0000|49 56|aspects
P10893258T0000|74 101|membrane protein biogenesis
P10893258T0000|118 143|reticulum quality control
P10894149T0000|0 4|PNRC
P10894149T0000|29 37|receptor
P10894149T0000|51 58|protein
P10894149T0000|90 100|activation
P10894149T0000|121 130|receptors
P10894149T0000|141 161|orphan receptors SF1
P10894149T0000|177 183|factor
P10894149T0000|191 200|ERRalpha1
P10894149T0000|202 210|estrogen
P10894149T0000|219 235|receptor alpha-1
P10894816A0836|0 7|Studies
P10894816A0836|16 32|reporter plasmid
P10894816A0836|81 88|element
P10894816A0836|90 93|SRE
P10894816A0836|128 136|response
P10894816A0836|140 144|IL-6
P10894886A0375|26 32|subset
P10894886A0375|36 42|tumors
P10894886A0375|61 68|changes
P10894886A0375|78 83|genes
P10895417A0000|33 36|EPI
P10895417A0000|38 46|delivery
P10895417A0000|50 58|morphine
P10895417A0000|90 99|liposomes
P10895417A0000|101 130|DepoFoam drug delivery system
P10895417A0000|153 162|clearance
P10895417A0000|166 174|morphine
P10895417A0000|191 200|analgesia
P10895417A0669|10 19|EPI-C0401
P10895417A0669|29 35|saline
P10895417A0669|39 55|DepoFoam vehicle
P10895417A0669|84 86|hr
P10895417A0669|101 117|food consumption
P10895417A0669|119 126|arousal
P10895417A0669|128 148|hindlimb muscle tone
P10895417A0669|154 170|body temperature
P10895851A0696|0 18|Bailey Instruments
P10895851A0696|23 45|Owen Mumford filaments
P10895851A0696|77 78|%
P10895851A0696|102 103|g
P10895851A0696|110 112|g.
P10896008A0531|0 12|PARTICIPANTS
P10896008A0531|26 32|sample
P10896008A0531|47 58|outpatients
P10896008A0531|75 80|motor
P10896008A0531|93 103|neuropathy
P10896008A0531|105 109|type
P10896008A0531|113 114|n
P10896008A0531|139 148|dystrophy
P10896008A0531|150 151|n
P10896008A0531|175 183|controls
P10896008A0531|185 186|n
P10896859A0000|4 10|effect
P10896859A0000|14 31|water deprivation
P10896859A0000|39 40|h
P10896859A0000|50 62|Na excretion
P10896859A0000|94 97|ADX
P10896859A0000|99 104|sheep
P10896859A0000|142 150|infusion
P10896859A0000|154 165|aldosterone
P10896859A0000|170 178|cortisol
P10896859A0000|193 206|steroid sheep
P10896859A0838|22 27|cause
P10896859A0838|57 69|Na retention
P10897233A1057|0 10|CONCLUSION
P10897233A1057|22 27|fever
P10897233A1057|35 48|Nazareth area
P10897973T0001|0 27|Antithrombin III deficiency
P10897973T0001|34 44|substitute
P10897973T0001|51 58|heparin
P10897973T0001|60 74|Thrombosis ABC
P10897973T0001|83 87|role
P10897973T0001|91 103|antithrombin
P10898795A0527|9 14|class
P10898795A0527|24 44|histone deacetylases
P10898795A0527|46 51|HDACs
P10898795A0527|75 79|BCoR
P10898795A0527|97 101|BCoR
P10898795A0527|134 141|classes
P10898795A0527|145 150|HDACs
P10899128A0661|18 25|example
P10899128A0661|42 70|transcription factor complex
P10899128A0661|89 97|MADS-box
P10899128A0661|104 120|forkhead protein
P10899128A0661|143 155|implications
P10899128A0661|164 174|regulation
P10899128A0661|188 203|gene expression
P10899142A0000|20 28|Berkeley
P10899142A0000|40 63|Genome Project database
P10899142A0000|69 78|sequences
P10899142A0000|137 138|G
P10899142A0000|155 163|receptor
P10899142A0000|165 168|LGR
P10899142A0000|187 193|DLGR-1
P10899142A0000|219 223|gene
P10899142A0000|240 243|LGR
P10899142A0000|245 251|DLGR-2
P10899142A0000|268 272|cDNA
P10900129A0138|0 18|Degenerate primers
P10900129A0138|50 57|regions
P10900129A0138|67 82|CYP3A sequences
P10900129A0138|105 112|RT-PCRs
P10900269A0396|5 10|cells
P10900269A0396|35 39|TFOs
P10900269A0396|68 83|polypurine site
P10900269A0396|109 117|TK genes
P10900269A0396|119 132|recombination
P10900269A0396|149 160|frequencies
P10900269A0396|168 173|range
P10900269A0396|178 179|%
P10900269A0396|202 212|background
P10901133A0381|0 16|Methyllevamisole
P10901133A0381|42 50|standard
P10902348A0566|0 17|Resistance ratios
P10902348A0566|32 45|field strains
P10902348A0566|58 68|comparison
P10902348A0566|78 87|R5 strain
P10902348A0566|124 135|application
P10902348A0566|164 180|glass jar method
P10903440A0515|5 16|transcripts
P10903440A0515|30 36|TSGF-2
P10903440A0515|53 58|ovary
P10903440A0515|63 77|testes tissues
P10903440A0515|81 87|adults
P10903440A0515|102 109|puparia
P10903440A0515|125 129|gene
P10903440A0515|175 181|stages
P10903495A0533|5 26|gel retardation assay
P10903495A0533|33 38|HepG2
P10903495A0533|47 55|extracts
P10903495A0533|73 81|sequence
P10903495A0533|115 119|band
P10903583T0000|0 11|Reliability
P10903583T0000|24 29|range
P10903583T0000|33 39|motion
P10903583T0000|50 56|OSI CA
P10903583T0000|62 83|spine motion analyser
P10903583T0000|116 124|subjects
P10903733A0540|0 33|Coimmunoprecipitation experiments
P10903733A0540|59 64|cells
P10903733A0540|77 81|BCMA
P10903733A0540|114 120|factor
P10903733A0540|122 126|TRAF
P10903733A0540|131 136|TRAF2
P10903733A0540|142 164|TRAF3 adaptor proteins
P10903837A1208|10 19|RINX gene
P10903837A1208|33 41|ortholog
P10903837A1208|49 67|goldfish Vsx1 gene
P10903837A1208|87 91|VSX1
P10903837A1208|105 132|Gene Nomenclature Committee
P10903843A0447|16 28|localization
P10903843A0447|39 49|chromosome
P10903843A0447|67 74|cluster
P10903843A0447|88 93|genes
P10903843A0447|131 136|Tapa1
P10903843A0447|141 152|Kcnq1 genes
P10903877A0879|0 10|Activation
P10903877A0879|14 17|PKA
P10903877A0879|36 39|AMP
P10903877A0879|43 52|forskolin
P10903877A0879|58 68|inhibition
P10903877A0879|72 75|PKC
P10903877A0879|79 91|calphostin C
P10903877A0879|119 127|decrease
P10903877A0879|131 143|3TP activity
P10903877A0879|164 183|ERK kinase activity
P10903877A0879|187 191|CRAC
P10904191A0000|12 17|study
P10904191A0000|47 58|sensitivity
P10904191A0000|63 74|specificity
P10904191A0000|78 84|AMP CT
P10904191A0000|86 108|Gen-Probe Incorporated
P10904191A0000|110 119|San Diego
P10904191A0000|121 123|CA
P10904191A0000|125 128|USA
P10904191A0000|144 153|specimens
P10904191A0000|177 185|patients
P10904191A0000|199 209|void urine
P10904191A0000|211 214|FVU
P10904191A0000|216 225|specimens
P10904191A0000|244 252|patients
P10905349A0329|0 6|Mus81p
P10905349A0329|19 27|homology
P10905349A0329|33 39|motifs
P10905349A0329|53 81|XPF endonuclease superfamily
P10905349A0609|14 22|analysis
P10905349A0609|37 43|Rad54p
P10905349A0609|48 54|Mus81p
P10905349A0609|66 73|pathway
P10905349A0609|82 88|repair
P10905349A0609|96 105|tolerance
P10905349A0609|121 131|DNA damage
P10905352A0000|11 24|plasmid pCLU1
P10905352A0000|34 39|yeast
P10905352A0000|54 60|lactis
P10905352A0000|88 97|cytoplasm
P10905352A0000|108 111|aid
P10905352A0000|119 125|helper
P10905352A0000|133 146|plasmid pGKL2
P10905352A0000|163 170|protein
P10905352A0000|172 174|TP
P10905352A0000|181 187|primer
P10906176A0000|15 18|ETn
P10906176A0000|26 36|transposon
P10906176A0000|38 44|family
P10906176A0000|48 57|sequences
P10906176A0000|87 94|mutagen
P10906176A0000|103 115|mouse genome
P10906317A0351|26 35|variables
P10906317A0351|54 63|hemifield
P10906317A0351|65 69|left
P10906317A0351|73 78|right
P10906317A0351|88 98|proportion
P10906317A0351|102 108|trials
P10906317A0351|121 126|shift
P10906317A0351|139 148|hemifield
P10906317A0351|152 153|%
P10906317A0351|159 160|%
P10906999T0000|4 15|measurement
P10906999T0000|19 21|NO
P10906999T0000|36 43|systems
P10906999T0000|50 67|chemiluminescence
P10907348A0508|12 24|examinations
P10907348A0508|47 57|metabolism
P10907348A0508|67 71|ions
P10907348A0508|76 94|PTH concentrations
P10907348A0508|98 109|blood serum
P10907348A0508|119 127|activity
P10907348A0508|131 145|bone isoenzyme
P10907348A0508|149 151|AP
P10907971A0806|0 12|Atorvastatin
P10907971A0806|41 68|HMG-CoA reductase inhibitor
P10907971T0000|17 27|assessment
P10907971T0000|31 66|HMG-CoA reductase inhibitor therapy
P10907971T0000|71 79|analysis
P10907971T0000|93 105|CURVES study
P10908317A1459|24 33|E domains
P10908317A1459|47 56|receptors
P10908317A1459|82 93|replacement
P10908317A1459|102 108|domain
P10908317A1459|112 116|rtER
P10908317A1459|130 141|counterpart
P10908317A1459|161 182|estradiol sensitivity
P10908317A1459|190 198|increase
P10908317A1459|206 215|magnitude
P10908317A1459|219 234|transactivation
P10908364A0000|0 5|G-DNA
P10908364A0000|25 38|DNA structure
P10908364A0000|72 77|roles
P10908462A3159|4 17|effectiveness
P10908462A3159|21 24|NRT
P10908462A3159|66 75|intensity
P10908462A3159|90 97|support
P10908462A3159|114 120|smoker
P10908478A0717|0 18|SELECTION CRITERIA
P10908478A0717|35 41|trials
P10908478A0717|48 54|adults
P10908478A0717|60 73|schizophrenia
P10908478A0717|85 94|illnesses
P10908478A0717|114 124|quetiapine
P10908478A0717|126 133|placebo
P10908478A0717|155 160|drugs
P10908478A0717|191 199|outcomes
P10908822A0519|1 2|%
P10908822A0519|6 10|% CI
P10908822A0519|19 22|.3%
P10909973A1508|3 11|contrast
P10909973A1508|17 23|action
P10909973A1508|27 32|GLP-1
P10909973A1508|40 43|CRE
P10909973A1508|63 77|cotransfection
P10909973A1508|83 90|M1-CREB
P10909973A1508|95 102|isoform
P10909973A1508|116 140|consensus serine residue
P10909973A1508|152 161|substrate
P10909973A1508|179 194|phosphorylation
P10910073A0876|12 29|PDGFbetaR fusions
P10910073A0876|59 67|splicing
P10910073A0876|80 84|exon
P10910073A0876|93 97|gene
P10910073A0876|121 134|amplification
P10910073A0876|138 142|cDNA
P10910073A0876|148 151|PCR
P10910073A0876|155 166|patient RNA
P10910439A1196|0 11|CONCLUSIONS
P10910439A1196|26 38|hypertension
P10910439A1196|48 60|protein load
P10910439A1196|71 79|decrease
P10910439A1196|83 86|GFR
P10910439A1196|129 138|treatment
P10910908A0767|5 12|finding
P10910908A0767|32 59|PI3K-Akt activation pathway
P10910908A0767|71 75|role
P10910908A0767|97 103|effect
P10910908A0767|107 110|EPO
P10913094A0424|5 18|DNA fragments
P10913094A0424|83 87|AdpA
P10913094A0424|105 111|cycles
P10913094A0424|117 146|gel mobility shift-PCR method
P10913172A0442|37 42|motif
P10913172A0442|60 74|Rad24 function
P10913172A0442|101 107|lysine
P10913172A0442|113 120|residue
P10913172A0442|129 134|motif
P10913276A0510|35 41|domain
P10913276A0510|45 49|SOS1
P10913276A0510|69 80|interaction
P10913276A0510|90 111|PLC-gamma1 SH3 domain
P10913276A0684|15 33|expression studies
P10913276A0684|65 75|SH3 domain
P10913276A0684|79 89|PLC-gamma1
P10913276A0684|111 122|association
P10913276A0684|128 132|SOS1
P10913304A0894|13 22|Ets mRNAs
P10913304A0894|40 44|Ets2
P10913304A0894|46 50|Fli1
P10913304A0894|52 61|GABPalpha
P10913304A0894|63 67|SAP1
P10913304A0894|69 73|Elk1
P10913304A0894|79 82|PE1
P10913304A1180|4 17|kb transcript
P10913304A1180|36 41|brain
P10913304A1180|74 85|kDa protein
P10913304A1180|101 108|protein
P10913304A1180|139 149|Ets domain
P10913304A1180|153 156|PE1
P10913304A1180|180 186|domain
P10913304A1180|203 211|homology
P10913304A1180|222 225|ERF
P10915728A0216|16 24|patients
P10915728A0216|30 39|cirrhosis
P10915728A0216|65 71|groups
P10915728A0216|76 84|patients
P10915728A0216|108 113|units
P10915728A0216|125 133|IFN-beta
P10915728A0216|142 146|week
P10915728A0216|154 160|months
P10915728A0216|168 176|patients
P10915728A0216|185 196|IFN therapy
P10915780A1063|0 20|Wnt-1 overexpression
P10915780A1063|43 48|cells
P10915780A1063|57 71|cyclin D1 mRNA
P10915780A1063|85 99|overexpression
P10915780A1063|103 108|Wnt-1
P10915780A1063|124 129|gland
P10915780A1063|144 148|mice
P10915780A1063|164 176|ILK activity
P10915780A1063|181 197|cyclin D1 levels
P10917402T0000|24 38|administration
P10917402T0000|42 55|amitriptyline
P10917402T0000|59 67|patients
P10917402T0000|79 89|depression
P10918059A0569|0 8|Deletion
P10918059A0569|16 26|RVH domain
P10918059A0569|39 43|loss
P10918059A0569|47 49|Ca
P10918059A0569|64 74|activation
P10918164A0878|9 28|regression analysis
P10918164A0878|43 53|physicians
P10918164A0878|63 68|times
P10918164A0878|96 103|lesions
P10918164A0878|113 115|mm
P10918164A0878|144 153|detectors
P10918164A0878|157 178|% confidence interval
P10918164A0878|182 186|% CI
P10918164A0878|199 200|P
P10918440T0000|0 31|Erythema exsudativum multiforme
P10918440T0000|43 54|granulocyte
P10918440T0000|74 80|factor
P10918440T0000|109 130|blood stem cell donor
P10918572A0794|0 3|VaI
P10918572A0794|8 12|VaII
P10918572A0794|40 45|ErbB2
P10918572A0794|60 65|ErbB1
P10918572A0794|67 72|ErbB3
P10918572A0794|77 82|ErbB4
P10918572A1547|6 18|interactions
P10918572A1547|22 24|WT
P10918572A1547|37 46|TGF-alpha
P10918572A1547|56 61|ErbBs
P10918572A1547|76 92|ErbB2 activation
P10918572A1547|128 140|consequences
P10918572A1547|170 190|TGF-alpha precursors
P10918572A1547|215 229|ErbB signaling
P10918596A0000|33 47|p53 C-terminus
P10918596A0000|64 68|role
P10918596A0000|88 96|activity
P10918596A0000|114 122|molecule
P10918599A0071|3 11|contrast
P10918599A0071|27 32|E2F-3
P10918599A0071|65 78|G1/S boundary
P10918599A0071|80 86|E2F-3B
P10918599A0071|114 124|cell cycle
P10918599A0071|135 141|levels
P10918599A0071|145 147|GO
P10918599A0071|176 178|Rb
P10918612A0000|4 28|transcription factor Jun
P10918612A0000|30 35|c-Jun
P10918612A0000|79 93|growth signals
P10918612A0000|117 125|patterns
P10918612A0000|129 144|gene expression
P10918943T0000|14 22|toxicity
P10918943T0000|30 35|class
P10918943T0000|55 71|agent almokalant
P10918943T0000|75 79|mice
P10918948A0110|5 13|compound
P10918948A0110|36 46|metabolite
P10918948A0110|50 61|trimebutine
P10918948A0110|66 74|Debridat
P10918948A0110|76 79|CAS
P10918948A0110|137 145|diseases
P10919971A0606|3 11|addition
P10919971A0606|19 25|effect
P10919971A0606|44 63|neutrophil response
P10919971A0606|77 85|exercise
P10919971A0606|87 96|vitamin E
P10919971A0606|114 122|increase
P10919971A0606|138 162|creatine kinase activity
P10919971A0606|202 215|muscle repair
P10920186A0528|17 26|formation
P10920186A0528|40 49|templates
P10920186A0528|59 71|fusion point
P10920186A0528|88 98|transcript
P10920186A0528|106 110|loop
P10920186A0528|119 122|use
P10920186A0528|126 137|MLL primers
P10920186A0528|151 154|PCR
P10920906A0759|0 10|CONCLUSION
P10920906A0759|16 23|authors
P10920906A0759|51 61|management
P10920906A0759|73 76|STS
P10920906A0759|119 125|margin
P10920906A0759|138 140|cm
P10921197A0179|0 12|Measurements
P10921197A0179|49 75|treatment planning systems
P10921197A0179|87 91|VO5B
P10921197A0179|96 113|ADAC Pinnacle3 V4
P10921197A0179|115 117|b.
P10924061A0588|0 10|Activation
P10924061A0588|41 44|min
P10924061A0588|52 53|h
P10924061A0588|60 69|treatment
P10925159A1353|8 14|MARTA1
P10925159A1353|46 53|lysates
P10925159A1353|89 98|fractions
P10925159A1353|115 123|extracts
P10925159A1353|125 131|MARTA2
P10925159A1353|173 194|salt-wash preparation
P10925207A0634|15 20|exons
P10925207A0634|37 50|kb transcript
P10925207A0634|125 132|regions
P10925207A0634|134 138|UTRs
P10926776A0731|12 25|PDP1 isoforms
P10926776A0731|40 52|substitution
P10926776A0731|56 65|insertion
P10926776A0731|69 80|amino acids
P10926776A0731|114 121|protein
P10928179A0101|12 21|technique
P10928179A0101|43 54|examination
P10928179A0101|58 78|sentinel lymph nodes
P10928179A0101|80 84|SLNs
P10928179A0101|101 107|debate
P10928337A0590|8 18|correction
P10928337A0590|22 28|anemia
P10928337A0590|52 66|erythropoietin
P10928337A0590|99 103|mass
P10928337A0590|108 114|volume
P10928477A0764|5 10|study
P10928477A0764|33 49|PFA-100 analyzer
P10928477A0764|86 103|platelet function
P10928477A0764|121 137|platelet defects
P10928477A0764|149 161|shear stress
P10928477A0764|173 192|patient populations
P10930526A0174|35 42|cloning
P10930526A0174|48 61|PL scramblase
P10930526A0174|72 80|HuPLSCR1
P10930526A0174|86 98|mouse origin
P10931524A0313|26 34|activity
P10931524A0313|38 41|Gtx
P10931524A0313|87 95|sequence
P10931524A0313|126 131|assay
P10931927A0655|9 24|oligomer duplex
P10931927A0655|28 29|A
P10931927A0655|30 36|GGGTTA
P10931927A0655|48 54|TAACCC
P10931927A0655|58 61|T-3
P10931927A0655|68 83|template-primer
P10931927A0655|107 122|Klenow fragment
P10931927A0655|143 157|DNA polymerase
P10931927A0655|164 167|HIV
P10931927A0655|176 189|transcriptase
P10931927A0655|203 225|telomere DNA sequences
P10931927A0655|242 250|products
P10931927A0655|268 272|size
P10931927A0655|280 292|template DNA
P10931950A0869|0 4|Cdk2
P10931950A0869|9 13|MAPK
P10931950A0869|42 55|tumor lysates
P10931950A0869|93 96|p27
P10931950A0869|109 121|T187A mutant
P10931960A0630|4 8|loss
P10931960A0630|12 31|avirulence activity
P10931960A0630|43 52|mutations
P10931960A0630|83 100|activation domain
P10931960A0630|117 125|addition
P10931960A0630|133 150|activation domain
P10931960A0630|160 174|herpes simplex
P10931960A0630|181 193|protein VP16
P10932196A0359|0 9|Mutations
P10932196A0359|17 26|RP2 locus
P10932196A0359|30 36|Xp11.3
P10932196A0359|66 67|%
P10932196A0359|71 84|XLRP patients
P10932196A0359|104 119|linkage studies
P10932329A0597|4 9|limit
P10932329A0597|22 27|cecum
P10932329A0597|46 51|colon
P10932329A0597|81 108|sulcus cecocolicus dorsalis
P10932329A0597|113 122|ventralis
P10932527A0947|14 16|HD
P10932527A0947|27 34|healing
P10932527A0947|68 85|epithelialization
P10932527A0947|108 120|inflammation
P10932527T0000|4 17|effectiveness
P10932527T0000|25 50|haemodialysate Solcoseryl
P10932527T0000|72 85|wound healing
P10932527T0000|89 95|horses
P10932527T0000|100 106|ponies
P10932679A0049|25 33|evidence
P10932679A0049|39 55|diet composition
P10932679A0049|85 89|role
P10932679A0049|97 107|absorption
P10932679A0049|111 122|expenditure
P10932679A0049|126 132|energy
P10932679A0049|159 163|role
P10932679A0049|167 178|food intake
P10933154A1118|6 14|findings
P10933154A1118|37 45|analysis
P10933154A1118|76 93|donor transplants
P10933154A1118|108 117|rejection
P10933728A1398|6 13|results
P10933728A1398|43 47|role
P10933728A1398|52 56|CBF2
P10933728A1398|70 91|EBNA2 transactivation
P10933728A1398|111 129|hnRNP protein AUF1
P10933728A1398|141 150|component
P10933728A1398|154 158|CBF2
P10933728A1398|182 190|evidence
P10933728A1398|207 215|sequence
P10933728A1398|229 249|CBF1 binding element
P10933728A1398|273 287|responsiveness
P10933728A1398|291 296|EBNA2
P10933732A0000|4 10|genome
P10933732A0000|24 35|herpesvirus
P10933732A0000|39 44|HHV-8
P10933732A0000|57 64|cluster
P10933732A0000|73 87|reading frames
P10933732A0000|89 93|ORFs
P10933732A0000|104 112|proteins
P10933732A0000|118 126|homology
P10933732A0000|143 164|transcription factors
P10933732A0000|172 182|interferon
P10933732A0000|194 200|factor
P10933732A0000|202 205|IRF
P10933732A0000|207 213|family
P10934073A1433|14 25|limitations
P10934073A1433|30 43|CHIME monitor
P10934073A1433|56 67|opportunity
P10934073A1433|92 96|data
P10934073A1433|127 131|home
P10934310A0698|0 14|DATA SYNTHESIS
P10934310A0698|30 40|ultrasound
P10934310A0698|85 95|weaknesses
P10934310A0698|108 119|angiography
P10934640A1114|0 12|TB bone area
P10934640A1114|14 15|p
P10934640A1114|26 32|height
P10934640A1114|34 35|p
P10934640A1114|45 50|years
P10934640A1114|62 68|colony
P10934640A1114|70 71|p
P10934640A1114|85 91|menses
P10934640A1114|93 94|p
P10934640A1114|113 119|TB BMC
P10934751T0001|0 14|CREST syndrome
P10934751T0001|36 48|significance
P10935488A1033|0 12|Troglitazone
P10935488A1033|40 61|PPARgamma target gene
P10935488A1033|65 74|T24 cells
P10935488A1033|97 117|acid binding protein
P10935488A1033|119 125|A-FABP
P10935488A1033|132 142|expression
P10935488A1033|168 198|bladder cancer differentiation
P10935880A1049|0 7|Viruses
P10935880A1049|29 34|lungs
P10935880A1049|43 48|PI-3V
P10935880A1049|57 70|NCP BVDV type
P10935880A1049|90 96|BVHV-1
P10935880A1049|101 105|BVDV
P10936051T0000|4 9|RS447
P10936051T0000|16 29|megasatellite
P10936051T0000|48 56|sequence
P10936051T0000|90 96|enzyme
P10936051T0000|115 123|promoter
P10936920A0105|9 19|experience
P10936920A0105|35 39|cues
P10936920A0105|54 62|elements
P10936920A0105|70 80|generation
P10936920A0105|97 107|prediction
P10938102A0265|21 27|effect
P10938102A0265|43 50|targets
P10938102A0265|54 81|NS1 influenza virus protein
P10938102A0265|97 116|translation factors
P10938102A1359|45 49|data
P10938102A1359|60 65|model
P10938102A1359|72 75|NS1
P10938102A1359|85 91|eIF4GI
P10938102A1359|128 134|region
P10938102A1359|139 142|UTR
P10938102A1359|157 161|mRNA
P10938102A1359|193 204|translation
P10938102A1359|212 238|influenza virus messengers
P10938102T0000|11 44|translation initiation factor 4GI
P10938102T0000|59 65|target
P10938102T0000|70 81|NS1 protein
P10938102T0000|99 108|activator
P10938102T0000|112 127|influenza virus
P10938105A0000|0 8|Splicing
P10938105A0000|34 38|exon
P10938105A0000|46 79|fibroblast growth factor receptor
P10938105A0000|82 86|gene
P10938105A0000|122 135|sequence IAS1
P10938105A0000|177 188|splice site
P10938109A1361|15 20|cells
P10938109A1361|22 29|PKCbeta
P10938109A1361|61 65|role
P10938109A1361|79 86|insulin
P10938109A1361|95 98|EGF
P10938109A1361|108 121|growth factor
P10938109A1361|132 139|signals
P10938113A0388|57 70|isoforms Vav2
P10938113A0388|75 79|Vav3
P10938113A0388|134 141|classes
P10938113A0388|145 154|receptors
P10938113A0388|184 196|Vav isoforms
P10938113A0388|226 236|activities
P10938120A1093|16 26|regulation
P10938120A1093|30 54|fbp1 promoter constructs
P10938120A1093|71 75|UAS1
P10938120A1093|79 83|UAS2
P10938120A1093|102 105|PKA
P10938120A1093|110 125|MAPK regulation
P10938120A1093|146 151|sites
P10938130A0338|0 5|X-ray
P10938130A0338|23 27|data
P10938130A0338|42 61|PLZF BTB/POZ domain
P10938130A0338|80 89|homodimer
P10938130A0338|107 116|interface
P10938135A0259|4 11|ability
P10938135A0259|15 19|SMRT
P10938135A0259|44 65|transcription factors
P10938135A0259|89 99|repression
P10938135A0259|125 135|activation
P10938135A0259|139 173|tyrosine kinase signaling pathways
P10938135A0259|217 239|growth factor receptor
P10938556A0248|3 11|addition
P10938556A0248|34 38|rats
P10938556A0248|48 55|neurons
P10938556A0248|66 71|cells
P10938556A0248|88 98|ventricles
P10939030A0986|4 15|differences
P10939030A0986|45 60|response rate p
P10939030A0986|70 75|power
P10939030A0986|81 82|p
P10939030A0986|93 94|%
P10939030A0986|100 110|survival p
P10939030A0986|123 128|grade
P10939030A0986|132 150|granulocytopenia p
P10939030A0986|174 187|neutropenia p
P10939785A0540|0 8|Patients
P10939785A0540|35 44|treatment
P10939785A0540|54 79|ACE inhibitor perindopril
P10939785A0540|98 108|indapamide
P10939785A0540|136 146|indication
P10939785A0540|154 170|contraindication
P10939785A0540|174 183|treatment
P10939785A0540|213 220|placebo
P10939785A0540|221 222|s
P10940413A1153|4 11|results
P10940413A1153|43 49|effect
P10940413A1153|74 83|stiffness
P10940413A1153|88 116|stress concentration effects
P10940413A1153|140 148|strength
P10940413A1153|159 163|bone
P10940413A1153|184 190|defect
P10940553A0912|6 13|regions
P10940553A0912|48 66|tissue-specificity
P10940553A0912|85 95|regulation
P10940553A0912|110 134|hPer1 gene transcription
P10940557A1687|23 30|CF1/USP
P10940557A1687|35 81|Broad Complex Z2 transcription factor elements
P10940557A1687|109 116|regions
P10940557A1687|120 123|MIH
P10940557A1687|134 139|genes
P10940562A0379|0 17|Sequence analysis
P10940562A0379|52 62|oasA2 gene
P10940562A0379|76 86|pseudogene
P10940562T0000|23 39|characterization
P10940562T0000|47 62|oas gene family
P10940562T0000|72 86|O-acetylserine
P10940562T0000|88 93|thiol
P10940562T0000|95 101|lyases
P10940562T0000|103 110|enzymes
P10940562T0000|132 136|step
P10940562T0000|140 161|cysteine biosynthesis
P10940562T0000|165 185|Arabidopsis thaliana
P10940892A0573|23 42|susceptibility loci
P10940892A0573|47 57|vasculitis
P10940892A0573|73 83|chromosome
P10940892A0573|85 88|Chr
P10940892A0573|95 102|D4Mit89
P10940892A0573|107 115|D4Mit147
P10940892A0573|124 133|progenies
P10942587A0981|7 16|treatment
P10942587A0981|22 43|phosphorylation state
P10942587A0981|47 49|Rb
P10942587A0981|82 86|form
P10942587A0981|88 92|mRNA
P10942587A0981|101 116|HPV E6/E7 genes
P10942587A0981|149 156|changes
P10942587A0981|164 174|E7 protein
P10942587A0981|210 216|levels
P10942587A0981|220 222|Rb
P10942587A0981|255 265|antibodies
P10942599A1298|8 24|characterization
P10942599A1298|43 62|Hoxa-1 target genes
P10942599A1298|91 100|functions
P10942599A1298|108 122|Hoxa-1 protein
P10942599A1298|130 155|differentiation processes
P10942599A1298|175 188|embryogenesis
P10943891A1062|4 11|ability
P10943891A1062|15 29|U6-U57 mutants
P10943891A1062|47 55|fidelity
P10943891A1062|64 75|branch site
P10943891A1062|83 106|splice site recognition
P10943891A1062|126 136|nucleotide
P10943891A1062|160 169|formation
P10943891A1062|184 188|site
P10943891A1062|189 190|s
P10943891A1062|199 210|spliceosome
P10944466A0451|23 32|structure
P10944466A0451|40 51|WNT-2B gene
P10945010T0001|4 8|role
P10945010T0001|12 24|daunorubicin
P10945010T0001|28 45|induction therapy
P10945010T0001|70 78|leukemia
P10945781A0412|12 29|Aeromonas strains
P10945781A0412|41 58|V cholerae non-O1
P10945781A0412|77 97|enterotoxin activity
P10946303A0000|0 9|TNF-alpha
P10946303A0000|20 24|dose
P10946303A0000|45 53|increase
P10946303A0000|57 73|cyclooxygenase-2
P10946303A0000|75 80|COX-2
P10946303A0000|82 92|expression
P10946303A0000|97 111|PGE2 formation
P10946303A0000|121 129|NCI-H292
P10946303A0000|141 146|cells
P10947274A0839|4 16|therapy time
P10947274A0839|32 35|NCS
P10947274A0839|48 52|dose
P10947274A0839|62 69|RBE-cGy
P10947274A0839|77 82|times
P10947274A0839|95 100|157Gd
P10947274A0839|120 123|10B
P10947840A0762|0 4|Mis3
P10947840A0762|23 32|formation
P10947840A0762|36 52|18S ribosome RNA
P10947840A0762|79 84|level
P10947840A0762|88 96|proteins
P10947840A0762|114 122|coupling
P10950398T0100|0 21|Losartan Intervention
P10950398T0100|26 34|Endpoint
P10950415A0866|0 10|CONCLUSION
P10950415A0866|12 22|Vitrectomy
P10950415A0866|36 46|hemorrhage
P10950415A0866|50 65|Terson syndrome
P10950415A0866|90 99|procedure
P10950415A0866|132 143|improvement
P10950415A0866|147 153|vision
P10950924A0393|0 3|RNA
P10950924A0393|12 25|hybridization
P10950924A0393|29 43|brain sections
P10950924A0393|60 67|embryos
P10950924A0393|86 94|labeling
P10950924A0393|109 114|areas
P10950924A0393|131 137|cortex
P10950935A0111|14 26|manipulation
P10950935A0111|44 53|sequences
P10950935A0111|70 76|method
P10950935A0111|108 110|P1
P10950935A0111|122 133|chromosomes
P10950935A0111|135 139|PACs
P10950935A0111|146 151|yeast
P10950935A0111|163 174|chromosomes
P10950935A0111|176 180|YACs
P10951579A1238|6 23|gamma-irradiation
P10951579A1238|29 37|majority
P10951579A1238|41 49|F9 cells
P10951579A1238|58 67|apoptosis
P10951579A1238|82 88|wt-p53
P10951579A1238|96 104|triggers
P10951579A1238|119 134|gene expression
P10951579A1238|138 141|DNA
P10951579A1238|150 155|cells
P10951848A0230|0 12|Mobilization
P10951848A0230|18 34|cyclophosphamide
P10951848A0230|58 76|stimulating factor
P10951848A0230|94 99|terms
P10951848A0230|103 107|CD34
P10951848A0230|109 119|cell shift
P10951848A0230|134 139|blood
P10951848A0230|153 170|quality autograft
P10951848A0230|201 209|recovery
P10951848A0230|216 232|megachemotherapy
P10952828A2638|43 52|resonance
P10952828A2638|70 79|technique
P10952828A2638|84 90|volume
P10952828A2638|95 123|ejection fraction estimation
P10952828A2638|127 149|heart failure patients
P10952828A2638|166 177|3D approach
P10952828A2638|196 206|ventricles
P10952828A2638|220 233|image quality
P10954093A0000|13 27|DNA transposon
P10954093A0000|29 32|Pat
P10954093A0000|56 63|genomes
P10954093A0000|85 92|strains
P10954093A0000|112 137|fungus Podospora anserina
P10954525A1161|13 21|presence
P10954525A1161|25 28|Tax
P10954525A1161|45 51|extent
P10954525A1161|68 75|profile
P10954525A1161|79 87|proteins
P10954525A1161|96 101|TRE-2
P10954564A1262|37 43|domain
P10954564A1262|51 54|ORF
P10954564A1262|58 65|protein
P10954564A1262|86 98|gene product
P10954564A1262|125 128|ORF
P10954913A0152|21 31|cDNA clone
P10954913A0152|38 62|Atlantic halibut Mx gene
P10954913A0152|83 101|liver cDNA library
P10955313A0000|0 6|PLUS-3
P10955313A0000|24 32|protocol
P10955313A0000|44 50|speech
P10955313A0000|65 73|children
P10955913A0827|5 11|HIT II
P10955913A0827|26 33|heparin
P10955913A0827|60 68|heparins
P10955998A1124|12 22|efficiency
P10955998A1124|30 50|glycosylase activity
P10955998A1124|82 89|ability
P10955998A1124|93 103|S120K MutY
P10955998A1124|115 128|DNA mutations
P10958271A0365|0 7|METHODS
P10958271A0365|12 19|RESULTS
P10958271A0365|61 73|measurements
P10958271A0365|94 111|ejection fraction
P10958271A0365|113 117|LVEF
P10958271A0365|123 130|volumes
P10958271A0365|156 166|Technetium
P10958271A0365|172 177|Tc99m
P10958271A0365|179 194|perfusion SPECT
P10958271A0365|200 242|equilibrium radionuclide angiocardiography
P10958271A0365|244 248|ERNA
P10958271A0365|256 264|patients
P10958271A0365|273 283|assessment
P10958271A0365|296 304|function
P10958271A0365|310 326|echocardiography
P10958271A0365|333 341|patients
P10958456A0529|6 11|cDNAs
P10958456A0529|28 34|length
P10958456A0529|71 78|regions
P10958456A0529|87 89|bp
P10958456A0529|93 95|Cp
P10958456A0529|96 98|F6
P10958456A0529|106 108|bp
P10958456A0529|112 114|Cp
P10958456A0529|115 118|F10
P10958456A0529|148 170|polyadenylation signal
P10958673A0142|19 28|signaling
P10958673A0142|52 68|protein response
P10958673A0142|70 73|UPR
P10958673A0142|106 132|ER stress response element
P10958673A0142|134 138|ERSE
P10958673A0142|143 150|mammals
P10958688A0265|2 28|Y. lipolytica Kar2p mutant
P10958688A0265|56 67|interaction
P10958688A0265|76 88|Sls1p mutant
P10958688A0265|110 121|interaction
P10958688A0265|127 132|Sls1p
P10958688A0265|142 152|nucleotide
P10958688A0265|160 172|conformation
P10958698A0280|51 62|mutagenesis
P10958698A0280|70 86|Cse4p N terminus
P10958698A0280|102 110|function
P10958698A0485|4 11|spacing
P10958698A0485|40 46|domain
P10958698A0485|48 51|END
P10958698A0485|69 72|HFD
P10958698A0485|122 128|effect
P10958698A0485|132 146|Cse4p function
P10959676A0200|4 9|bases
P10959676A0200|18 28|comparison
P10959838A0153|3 16|invertebrates
P10959838A0153|18 22|Fhit
P10959838A0153|39 53|fusion protein
P10959838A0153|59 62|Nit
P10959838A0153|66 72|member
P10959838A0153|80 101|nitrilase superfamily
P10961046A0342|0 15|Platelet counts
P10961046A0342|20 28|function
P10961046A0342|40 50|fibrinogen
P10961046A0342|55 76|von Willebrand factor
P10961046A0342|78 81|vWF
P10961046A0342|83 89|levels
P10961046A0342|114 120|sample
P10961585A0273|4 18|manifestations
P10961585A0273|44 60|thrombocytopenia
P10961585A0273|81 90|hemolysis
P10962564A0883|2 31|beta2 RARE reporter construct
P10962564A0883|69 78|cytosines
P10962564A0883|86 98|sense strand
P10962564A0883|116 123|thymine
P10962564A0883|141 145|loss
P10962564A0883|149 157|activity
P10962564A0883|194 200|manner
P10962593A0580|18 26|AFP rate
P10962738A0000|0 13|Consciousness
P10962738A0000|32 41|attention
P10962738A0000|51 57|memory
P10962738A0000|62 72|perception
P10962881A0900|0 11|Multiparity
P10962881A0900|29 35|effect
P10962881A0900|51 55|risk
P10962881A0900|59 63|% CI
P10963577T0016|0 7|Picture
P10963577T0016|12 17|smell
P10963735A0193|4 7|aim
P10963735A0193|15 20|study
P10963735A0193|41 46|level
P10963735A0193|60 66|stress
P10963735A0193|78 86|controls
P10963735A0193|88 91|CTL
P10963735A0193|107 110|CRF
P10963735A0193|115 126|HD patients
P10963735A0193|167 183|dialysis session
P10963735A0193|221 252|polyacrylonitrile membrane AN69
P10963735A0651|9 26|plasma parameters
P10963735A0651|35 44|vitamin E
P10963735A0651|46 51|thiol
P10963735A0651|61 72|acid levels
P10964833A1696|15 27|participants
P10964833A1696|32 33|%
P10964833A1696|49 53|POAG
P10964833A1696|105 106|%
P10964833A1696|141 144|IOP
P10964833A1696|158 162|mmHg
P10964995A2152|41 48|concern
P10964995A2152|54 59|women
P10964995A2152|65 67|ER
P10964995A2152|71 78|cancers
P10964995A2152|124 133|treatment
P10964995A2152|141 147|tumors
P10964995A2152|165 170|HER-2
P10965135A0735|0 17|Promoter activity
P10965135A0735|52 66|cotransfection
P10965135A0735|79 82|ras
P10965135A0735|86 99|mos oncogenes
P10965135A0735|105 124|oncogene inhibition
P10965135A0735|154 162|activity
P10965135A0735|178 183|cells
P10965135A0735|206 223|MAP kinase kinase
P10965135A0735|225 228|MKK
P10965135A0735|230 247|inhibitor PD98059
P10965135A1207|4 11|results
P10965135A1207|30 40|expression
P10965135A1207|44 52|Cktsf1b1
P10965135A1207|56 60|gene
P10965135A1207|83 94|development
P10965135A1207|99 118|cell transformation
P10965135A1207|136 146|MKK levels
P10965135A1207|181 211|transcription factor complexes
P10965830A0305|0 13|INTERVENTIONS
P10965830A0305|28 38|tissue PO2
P10965830A0305|43 56|PCO2 tensions
P10965830A0305|83 91|patients
P10965830A0305|109 118|fasciitis
P10965830A0305|134 144|volunteers
P10965830A0305|178 188|conditions
P10965905A1618|19 33|Akt activation
P10965905A1618|67 72|cells
P10965905A1618|85 98|concentration
P10965905A1618|102 110|LY294002
P10965905A1618|118 126|findings
P10965905A1618|145 167|wortmannin sensitivity
P10965905A1618|224 245|MAP kinase activation
P10965905A1618|262 270|activity
P10965905A1618|303 309|target
P10965905A1618|310 311|s
P10965905A1618|316 324|addition
P10965905A1618|328 332|PI3K
P10965905A1618|336 345|mediation
P10965905A1618|360 381|MAP kinase activation
P10965905A1618|391 396|cells
P10965905T0000|0 16|Insulin receptor
P10965905T0000|38 49|enhancement
P10965905T0000|53 59|growth
P10965905T0000|94 119|protein kinase activation
P10967361A0000|20 37|resonance imaging
P10967361A0000|39 43|fMRI
P10967361A0000|90 104|brain function
P10967361A0000|128 135|feature
P10967361A0000|153 163|resolution
P10967531A1025|24 29|aorta
P10967531A1025|54 59|edema
P10967531A1025|67 81|fibre necrosis
P10967531A1025|87 95|adhesion
P10967531A1025|99 109|leucocytes
P10967531A1025|119 137|muscle fibre areas
P10967531A1025|164 170|microm
P10967531A1025|178 182|type
P10967531A1025|205 211|microm
P10967531A1025|219 223|type
P10967890A1120|4 11|results
P10967890A1120|30 42|relationship
P10967890A1120|51 64|comprehension
P10967890A1120|69 79|production
P10967890A1120|106 112|stages
P10967890A1120|116 127|development
P10970048A0352|18 26|increase
P10970048A0352|34 42|RH level
P10970048A0352|62 68|values
P10970048A0352|76 82|orders
P10970048A0352|86 95|magnitude
P10970048A0352|97 109|contrariwise
P10970048A0352|115 129|voltage values
P10970048A0352|150 155|times
P10970048A0352|161 165|drop
P10970048A0352|173 175|RH
P10972688A1272|13 22|follow-up
P10972688A1272|49 59|difference
P10972688A1272|67 76|incidence
P10972688A1272|80 96|hospitalizations
P10972894A0488|8 17|libraries
P10972894A0488|40 48|cultures
P10972894A0488|62 68|format
P10972894A0488|113 121|colonies
P10972894A0488|126 132|plates
P10972894A0488|143 150|library
P10972894A0488|173 180|library
P10972894A0488|200 207|library
P10972980A0295|11 21|cell lines
P10972980A0295|23 27|mTOR
P10972980A0295|46 53|targets
P10972980A0295|74 94|phosphatidylinositol
P10972980A0295|96 98|PI
P10972980A0295|100 108|3-kinase
P10972980A0295|110 127|protein kinases A
P10972980A0295|129 130|B
P10972980A0295|136 137|C
P10972980A0295|154 164|G-proteins
P10972980A0295|186 192|kinase
P10972980A0295|196 203|calcium
P10972980A0295|219 230|amino acids
P10972990A0196|21 32|protein p53
P10972990A0196|68 77|stability
P10972990A0526|0 10|Abrogation
P10972990A0526|14 26|p53 function
P10972990A0526|30 32|E6
P10972990A0526|48 56|increase
P10972990A0526|76 96|mutation frequencies
P10972990A0526|117 133|thymidine kinase
P10972990A0526|135 137|TK
P10972990A0526|139 144|locus
P10972990A0526|171 210|hypoxanthine phosphoribosyl transferase
P10972990A0526|212 216|HPRT
P10972990A0526|218 223|locus
P10972990A0966|12 20|analysis
P10972990A0966|24 35|LOH mutants
P10972990A0966|39 58|chromosome painting
P10972990A0966|71 77|mosaic
P10972990A0966|93 104|aberrations
P10972990A0966|115 125|chromosome
P10972990A0966|147 167|chromosome deletions
P10972990A0966|169 183|amplifications
P10972990A0966|198 212|translocations
P10972990A0966|250 256|mutant
P10972990A1518|6 13|results
P10972990A1518|24 29|model
P10972990A1518|39 50|p53 protein
P10972990A1518|70 81|maintenance
P10972990A1518|93 102|integrity
P10972990A1518|127 133|repair
P10973151A0883|4 14|importance
P10973151A0883|43 50|profile
P10973151A0883|54 69|schistosomiasis
P10973151A0883|77 82|State
P10973151A0883|86 96|Pernambuco
P10973151A0883|111 115|fact
P10973151A0883|162 174|interference
P10973151A0883|182 193|environment
P10973385A1423|3 11|patients
P10973385A1423|17 21|type
P10973385A1423|25 31|tumors
P10973385A1423|37 44|pattern
P10973385A1423|58 64|spread
P10973385A1423|119 128|curvature
P10973385A1423|147 159|artery nodes
P10973385A1423|161 174|esophagectomy
P10973385A1423|186 202|survival benefit
P10973385A1423|217 228|gastrectomy
P10973385A1423|238 246|patients
P10973400A0664|0 7|RESULTS
P10973400A0664|24 35|deformation
P10973400A0664|49 60|artery flow
P10973400A0664|78 103|flexion-distraction Stage
P10973400A0664|106 114|injuries
P10973400A0664|138 143|range
P10973400A0664|156 163|flexion
P10974541A0389|14 31|K562 cDNA library
P10974541A0389|53 64|transcripts
P10974541A0389|66 71|MZF1B
P10974541A0389|76 81|MZF1C
P10975465A0134|10 26|cDNA clone NFBD1
P10975465A0134|50 58|KIAA0170
P10975465A0134|76 83|protein
P10975465A0134|90 101|amino acids
P10975465A0134|105 111|length
P10975465A0134|134 138|mass
P10975465A0134|147 148|D
P10975465A0134|164 176|BRCT domains
P10975465A0134|184 200|carboxy terminus
P10975465A0134|202 221|amino acid residues
P10976413A0514|0 7|RESULTS
P10976413A0514|23 32|FSH level
P10976413A0514|48 57|FSH level
P10976413A0514|95 105|predictors
P10976413A0514|109 120|IVF success
P10976413A0514|134 141|patient
P10976413A0514|149 152|day
P10976413A0514|155 164|FSH level
P10976413A0514|172 178|mIU/ml
P10976413A0514|195 198|day
P10976413A0514|202 211|FSH level
P10976413A0514|219 225|mIU/ml
P10976413A0514|250 259|pregnancy
P10980416T0000|12 30|hormone regulation
P10980416T0000|34 51|bone sialoprotein
P10980416T0000|53 56|BSP
P10980416T0000|58 76|gene transcription
P10980416T0000|118 140|transcription factor-1
P10980416T0000|142 147|Pit-1
P10980416T0000|149 154|motif
P10980416T0000|162 183|rat BSP gene promoter
P10981094A0779|7 22|target BP goals
P10981094A0779|42 54|Sixth Report
P10981094A0779|64 88|Joint National Committee
P10981094A0779|90 96|JNC VI
P10981094A0779|115 122|premise
P10981094A0779|132 141|intensity
P10981094A0779|145 154|treatment
P10981094A0779|183 192|magnitude
P10981094A0779|196 213|pretreatment risk
P10982076A0000|35 54|morbidity recording
P10982076A0000|73 80|illness
P10982076A0000|82 85|ILI
P10982076A0000|104 112|sampling
P10982076A0000|141 146|value
P10982076A0000|170 180|indicators
P10982076A0000|196 214|influenza activity
P10982143A0346|4 10|muskox
P10982143A0346|20 31|host record
P10982143A0346|36 45|T. gondii
P10982391A0425|14 25|NPF repeats
P10982391A0425|29 36|leucine
P10982391A0425|44 50|repeat
P10982391A0425|71 79|residues
P10982391A0425|116 118|WW
P10982391A0425|134 138|site
P10982391A0425|157 163|domain
P10982391A0425|188 201|membrane core
P10982391A0425|227 246|transmembrane spans
P10982391A0425|269 277|segments
P10982391A0425|324 332|elements
P10982825A0363|23 33|difference
P10982825A0363|48 56|presence
P10982825A0363|62 79|Mot3 binding site
P10982825A0363|83 86|OpA
P10983344A0000|4 11|article
P10983344A0000|27 37|diagnosing
P10983344A0000|42 52|correction
P10983344A0000|67 75|ischemia
P10983344A0000|83 92|intestine
P10983857A0923|8 19|application
P10983857A0923|23 31|NCX-4016
P10983857A0923|56 68|PD reduction
P10983857A0923|81 82|H
P10983857A0923|84 88|loss
P10983857A0923|112 121|hyperemia
P10983857A0923|139 145|damage
P10983857A0923|153 160|stomach
P10983857A0923|193 197|rats
P10983979T0000|11 22|recognition
P10983979T0000|29 40|splice site
P10983979T0000|44 49|U4/U6
P10983979T0000|50 62|U5 tri-snRNP
P10983979T0000|93 97|step
P10983979T0000|107 127|spliceosome assembly
P10984122A0911|3 10|control
P10984122A0911|16 21|cells
P10984122A0911|44 56|DNA mixtures
P10984122A0911|68 81|vector mU6-C1
P10984122A0911|85 91|mU6-C2
P10987280A0604|4 23|amino acid sequence
P10987280A0604|27 39|matrilysin-2
P10987280A0604|56 73|threonine residue
P10987280A0604|101 105|site
P10987280A0604|142 149|feature
P10987280A0604|153 163|matrilysin
P10987301A0332|8 14|regard
P10987301A0332|71 72|G
P10987301A0332|89 97|receptor
P10987301A0332|99 103|GPCR
P10987301A0332|120 126|Kaposi
P10987301A0332|148 160|herpes virus
P10987301A0332|162 166|KSHV
P10987301A0332|174 186|herpes virus
P10987301A0332|217 229|angiogenesis
P10987301A0332|248 257|secretion
P10987301A0332|282 295|growth factor
P10987301A0332|297 301|VEGF
P10987301A0332|330 340|stimulator
P10987301A0332|356 363|mitogen
P10987301A0332|372 383|development
P10987301A0332|387 393|Kaposi
P10987301A0332|396 403|sarcoma
P10989777A1286|12 20|subgroup
P10989777A1286|24 31|clients
P10989777A1286|52 55|URD
P10989777A1286|80 85|study
P10989777A1286|103 113|assignment
P10989777A1286|161 166|group
P10991383A0289|7 14|lattice
P10991383A0289|18 19|%
P10991383A0289|27 32|sites
P10991383A0289|49 50|%
P10991383A0289|58 63|atoms
P10991383A0289|82 88|energy
P10991383A0289|98 106|sublevel
P10991383A0289|114 115|%
P10991383A0289|134 136|3D
P10991383A0289|149 154|state
P10991648T0000|45 59|half syndromes
P10992299A0745|22 29|members
P10992299A0745|36 51|gene expression
P10992299A0745|70 83|tumorigenesis
P10992299A0745|85 100|PI12 expression
P10992299A0745|135 154|tumor brain tissues
P10992299A0745|166 189|brain cancer cell lines
P10992299A0745|191 198|U-87 MG
P10992299A0745|203 205|H4
P10992983T0000|15 23|relation
P10992983T0000|39 50|orientation
P10992983T0000|55 66|penile size
P10992983T0000|72 74|A.
P10993773A0717|5 10|slope
P10993773A0717|52 64|min ischemia
P10993773A0717|80 91|microm/mmHg
P10993773A0717|113 127|control values
P10993773A0717|154 164|myocardium
P10993773A0717|171 183|min ischemia
P10993773A0717|199 210|microm/mmHg
P10993787A0369|13 16|MAP
P10993787A0369|21 34|MSNA increase
P10993787A0369|42 45|SHG
P10993787A0369|51 61|transition
P10993787A0369|67 70|SHG
P10993787A0369|74 77|PHI
P10993787A0369|110 119|reduction
P10993787A0369|123 126|MAP
P10993787A0369|141 150|elevation
P10993787A0369|154 158|MSNA
P10993787A0369|173 183|separation
P10993787A0369|193 200|factors
P10995121A0569|0 8|Analysis
P10995121A0569|12 44|Standard Reference Material 1846
P10995121A0569|46 60|Infant Formula
P10995121A0569|74 79|value
P10995121A0569|98 113|mg vitamin K/kg
P10995121A0569|115 116|K
P10995121A0569|120 122|K1
P10995121A0569|126 127|n
P10995121A0569|141 152|coefficient
P10995121A0569|156 165|variation
P10995751A0093|57 69|protein-beta
P10995751A0093|71 81|C/EBP-beta
P10995751A0093|91 109|gene transcription
P10995751A0093|126 146|IFN response element
P10995751A0093|194 201|element
P10997330A0361|0 22|Northern blot analysis
P10997330A0361|45 55|STORP gene
P10997330A0361|73 80|pattern
P10997330A0361|84 94|expression
P10997330A0361|118 126|PML gene
P10997863A0753|7 19|TLE patients
P10997863A0753|24 27|NAA
P10997863A0753|33 39|ratios
P10997863A0753|60 73|seizure focus
P10997863A0753|88 100|FLE patients
P10997863A0753|137 150|seizure focus
P10997904A1258|4 18|Spo0F residues
P10997904A1258|45 50|patch
P10997904A1258|75 94|response regulators
P10997904A1258|115 122|binding
P10997904A1258|153 161|residues
P10997904A1258|181 212|response regulator-kinase pairs
P10998679A0500|16 23|factors
P10998679A0500|35 38|wth
P10998679A0500|47 54|illness
P10998679A0500|65 74|prognoses
P10998679A0500|101 109|scenario
P10998679A0500|158 162|pain
P10999205A0607|24 34|resolution
P10999205A0607|55 63|interest
P10999205A0607|91 95|area
P10999205A0607|117 120|VOI
P10999205A0607|131 142|acquisition
P10999205A0607|163 170|spectra
P10999301A0000|13 23|evaluation
P10999301A0000|43 53|parameters
P10999301A0000|70 75|order
P10999301A0000|85 93|scanning
P10999301A0000|113 123|microscope
P10999301A0000|125 129|SNOM
P10999301A0000|131 141|technology
P10999301A0000|149 154|study
P10999301A0000|158 167|magnetism
P10999301A0000|186 191|scale
P10999369A0192|18 27|amplitude
P10999369A0192|51 61|potentials
P10999369A0192|63 72|amplitude
P10999369A0192|80 90|N2/P2 peak
P10999369A0192|119 125|microV
P10999369A0192|131 133|mA
P10999369A0192|150 156|microV
P10999369A0192|163 165|mA
P11000203A0752|6 15|mutations
P11000203A0752|19 24|K-Rev
P11000203A0752|58 68|properties
P11000203A0752|106 116|RNA export
P11000203A0752|126 139|K-Rev mutants
P11000203A0752|164 168|type
P11000203A0752|210 220|activities
P11000203A0752|252 262|RNA export
P11000250A0200|0 5|LMP-1
P11000250A0200|25 40|plasma membrane
P11000250A0200|57 61|TRAF
P11000250A0200|63 68|TRADD
P11000250A0200|74 87|JAK molecules
P11000250A0200|100 109|NF-kappaB
P11000250A0200|112 116|AP-1
P11000250A0200|138 146|pathways
P11000250A0200|155 159|CD40
P11000266T0000|0 14|Identification
P11000266T0000|21 29|enhancer
P11000266T0000|49 57|promoter
P11000266T0000|71 77|intron
P11000266T0000|85 107|alpha-fetoprotein gene
P11000521A0588|23 41|signaling pathways
P11000521A0588|78 92|transformation
P11000521A0588|115 127|NIH3T3 cells
P11000521A0588|168 183|phosphorylation
P11000521A0588|187 215|insulin receptor substrate-2
P11000521A0588|217 222|IRS-2
P11000521A0588|241 251|activation
P11000521A0588|255 284|phosphatidylinositol 3-kinase
P11000521A0588|286 297|PI 3-kinase
P11000521A0588|303 319|protein kinase B
P11000521A0588|321 328|PKB/AKT
P11002236A0328|0 7|METHODS
P11002236A0328|24 29|study
P11002236A0328|34 41|authors
P11002236A0328|54 63|PPB cases
P11002236A0328|80 100|retrospective search
P11002236A0328|125 137|Associations
P11002236A0328|142 162|Pediatric Hematology
P11002236A0328|167 183|Oncology centers
P11003471A1149|13 21|analysis
P11003471A1149|38 52|ToLCV isolates
P11003471A1149|58 67|Bangalore
P11003471A1149|81 86|group
P11003471A1149|90 97|viruses
P11003471A1149|131 136|India
P11003641A0811|27 38|motif KEFGK
P11003641A0811|46 51|RAP74
P11003641A0811|53 58|Tfg1p
P11003641A0811|60 67|subunit
P11003641A0811|71 76|TFIIF
P11003641A0811|108 118|phenotypes
P11003641A0811|130 139|fcp1 tfg1
P11003641A0811|147 154|mutants
P11003641A0811|169 176|ability
P11003641A0811|180 185|Fcp1p
P11003641A0811|198 211|transcription
P11003641A0811|250 258|promoter
P11003652A0961|6 13|results
P11003652A0961|27 33|Cdc42p
P11003652A0961|40 44|fact
P11003652A0961|58 76|pheromone response
P11003652A0961|86 97|interaction
P11003652A0961|107 117|PAK Ste20p
P11003652A0961|139 143|role
P11003653A0198|0 8|Deletion
P11003653A0198|38 42|site
P11003653A0198|52 59|complex
P11003653A0198|73 100|beta-globin locus construct
P11003653A0198|126 131|gamma
P11003653A0198|136 157|beta-globin switching
P11003653A0198|172 176|mice
P11003653A0198|198 209|PYR complex
P11003653A0198|233 239|switch
P11003669A0000|4 11|product
P11003669A0000|15 23|rat gene
P11003669A0000|67 74|protein
P11003669A0000|91 97|screen
P11003669A0000|112 132|ErbB-2 juxtamembrane
P11003669A0000|137 151|kinase domains
P11003669A0000|155 159|bait
P11003805A0443|0 7|Studies
P11003805A0443|25 29|DGOR
P11003805A0443|38 49|acid reflux
P11003805A0443|64 72|symptoms
P11003805A0443|84 95|acid reflux
P11003805A0443|141 153|oesophagitis
P11003807A0303|0 8|Symptoms
P11003807A0303|51 63|oesophagitis
P11003807A0303|79 87|symptoms
P11003807A0303|121 139|oesophageal damage
P11004369A0000|0 9|OBJECTIVE
P11004369A0000|27 39|relationship
P11004369A0000|48 58|blood flow
P11004369A0000|66 71|tumor
P11004369A0000|84 108|color Doppler ultrasound
P11004369A0000|110 129|microvessel density
P11004369A0000|156 176|growth factor levels
P11004369A0000|192 201|carcinoma
P11005808A1082|6 13|results
P11005808A1082|26 29|Ras
P11005808A1082|51 70|ERK MAPK activation
P11005808A1082|81 95|cell viability
P11005808A1082|106 116|heat shock
P11005831A0242|6 11|cDNAs
P11005831A0242|27 41|leucine zipper
P11005831A0242|43 47|bZIP
P11005831A0242|49 53|type
P11005831A0242|67 75|proteins
P11005831A0242|103 108|yeast
P11005831A0242|120 126|system
P11005831A0242|147 152|AREB1
P11005831A0242|154 159|AREB2
P11005831A0242|165 170|AREB3
P11005831A0242|187 210|element binding protein
P11006283A1180|12 20|AROM-p64
P11006283A1180|36 43|binding
P11006283A1180|63 66|DNA
P11006283A1180|71 75|poly
P11006283A1180|76 77|A
P11006283A1180|79 91|homopolymers
P11006283A1180|113 120|protein
P11006283A1180|134 138|role
P11006283A1180|142 168|mRNA maturation/metabolism
P11006284T0000|21 31|kinase fer
P11006284T0000|58 67|complexes
P11006284T0000|79 107|insulin receptor substrate-1
P11006284T0000|112 141|phosphatidylinositol 3-kinase
P11006331A0319|13 22|phenotype
P11006331A0319|30 45|allotetraploids
P11006331A0319|84 97|abnormalities
P11007509A1271|7 22|PMR target area
P11007509A1271|49 53|area
P11007509A1271|57 68|improvement
P11007509A1271|92 104|flow reserve
P11007509A1271|115 128|wall segments
P11007509A1271|175 191|stress perfusion
P11007777A0813|0 8|Analysis
P11007777A0813|12 34|intron/exon boundaries
P11007777A0813|50 60|BAC clones
P11007777A0813|78 85|junctin
P11007777A0813|87 95|junctate
P11007777A0813|101 126|aspartyl beta-hydroxylase
P11007777A0813|151 159|splicing
P11007777A0813|172 176|gene
P11007949A1395|25 45|inactivation mutants
P11007949A1395|49 53|PTEN
P11007949A1395|65 66|%
P11007949A1395|74 79|forms
P11007949A1395|89 95|tumors
P11007949A1607|30 38|activity
P11007949A1607|42 45|ILK
P11007949A1607|76 80|PTEN
P11007949A1607|88 93|cells
P11007954A0170|4 17|growth factor
P11007954A0170|33 40|protein
P11007954A0170|44 48|Grb2
P11007954A0170|50 57|adaptor
P11007954A0170|78 81|Sos
P11007954A0170|83 86|Son
P11007954A0170|106 121|exchange factor
P11007954A0170|125 128|Ras
P11007954A0170|142 148|signal
P11007954A0170|160 168|tyrosine
P11007954A0170|186 194|receptor
P11007954A0170|198 201|Ras
P11007954A0170|216 219|Sos
P11007954A0170|227 235|membrane
P11007954A0170|246 256|activation
P11007954A0170|260 263|Ras
P11007961A0930|0 9|Mutations
P11007961A0930|13 18|genes
P11007961A0930|28 43|PR65/A subunits
P11007961A0930|92 99|cancers
P11007961A0930|108 122|PP2A inhibitor
P11007961A0930|131 141|fostriecin
P11007961A0930|176 180|drug
P11007968A0255|9 16|purpose
P11007968A0255|20 27|segment
P11007968A0255|31 34|dxr
P11007968A0255|93 96|DNA
P11007968A0255|101 104|PCR
P11007968A0255|111 127|oligonucleotides
P11007968A0255|142 149|regions
P11008139T0000|11 19|learning
P11008139T0000|26 53|pattern discrimination task
P11008420A0580|4 12|detector
P11008420A0580|21 30|advantage
P11008420A0580|50 68|segment deviations
P11008420A0580|85 100|complex changes
P11008420A0580|127 143|characterization
P11008420A0580|170 176|events
P11011139A0000|36 53|SIN4 gene product
P11011139A0000|59 68|component
P11011139A0000|74 90|mediator complex
P11011139A0000|107 121|RNA polymerase
P11011139A0000|134 141|studies
P11011139A0000|154 165|involvement
P11011139A0000|169 173|Sin4
P11011139A0000|181 191|alteration
P11011139A0000|208 227|chromatin structure
P11012568A0192|16 32|hypersensitivity
P11012568A0192|36 46|ACTH drive
P11012568A0192|50 57|obesity
P11012671A0576|3 11|addition
P11012671A0576|42 46|site
P11012671A0576|58 78|Gadd45gamma promoter
P11012671A0576|85 94|C/EBPbeta
P11012671A0576|99 109|C/EBPdelta
P11012671A0576|156 176|mobility shift assay
P11012671A0576|178 182|EMSA
P11012671A0576|188 210|reporter gene analysis
P11012680A0676|0 14|Src activation
P11012680A0676|26 30|FGF1
P11012680A0676|50 60|SH2 domain
P11012680A0676|64 67|Src
P11012680A0676|72 75|PP2
P11012680A0676|88 97|inhibitor
P11012680A0676|101 104|Src
P11012680A1020|4 7|use
P11012680A1020|15 23|PLCgamma
P11012680A1020|35 42|peptide
P11012680A1020|44 52|neomycin
P11012680A1020|61 86|calcium chelator BAPTA-AM
P11012680A1020|90 97|oocytes
P11012680A1020|109 114|FGFR1
P11012680A1020|122 133|stimulation
P11012680A1020|137 144|PDGF-BB
P11012680A1020|148 155|oocytes
P11012680A1020|167 178|PDGFR-FGFR1
P11012680A1020|194 215|PLCgamma binding site
P11012680A1020|227 231|GVBD
P11012680A1020|236 256|ERK2 phosphorylation
P11013079A0927|9 34|transcription start sites
P11013079A0927|52 77|primer extension analysis
P11013079A0927|85 95|mouse gene
P11013079A0927|101 124|transfection constructs
P11013079A0927|152 160|promoter
P11013079A0927|187 195|activity
P11013079A0927|222 235|SV40 promoter
P11014197A0339|9 28|inhibitor scaffolds
P11014197A0339|70 80|inhibitors
P11014197A0339|96 103|kinases
P11014197A0339|123 134|subfamilies
P11014213A1019|21 32|interaction
P11014213A1019|36 44|arsenite
P11014213A1019|70 76|domain
P11014213A1019|88 107|receptor activation
P11014213A1019|109 120|COS-1 cells
P11014213A1019|170 186|receptors GAL-ER
P11014213A1019|223 229|domain
P11014213A1019|233 240|ERalpha
P11014213A1019|261 267|domain
P11014213A1019|275 300|transcription factor GAL4
P11014213A1019|324 341|CAT reporter gene
P11014215A1092|18 34|deletion studies
P11014215A1092|64 76|DNA fragment
P11014215A1092|109 131|translation start site
P11014215A1092|152 158|region
P11014215A1092|172 182|GnRHR gene
P11014215A1092|226 241|down-regulation
P11014215A1092|251 274|GnRHR promoter activity
P11014465A0479|9 12|day
P11014465A0479|16 25|diagnosis
P11014465A0479|45 58|echodensities
P11014465A0479|71 75|days
P11014465A0479|77 82|range
P11014465A0479|88 92|days
P11014465A0479|109 112|PVL
P11014465A0479|122 126|days
P11014465A0479|128 133|range
P11014465A0479|139 143|days
P11014821T0000|4 25|LAMMER protein kinase
P11014821T0000|41 50|Doa locus
P11014821T0000|54 64|Drosophila
P11014821T0000|97 111|germline cells
P11014821T0000|161 169|isoforms
P11014821T0000|181 192|development
P11015197A0310|19 27|cysteine
P11015197A0310|38 42|time
P11015197A0310|59 67|residues
P11015197A0310|82 85|TMS
P11015197A0310|87 90|TM4
P11015200A0156|7 9|J.
P11016014A0181|0 10|HYPOTHESIS
P11016014A0181|16 19|aim
P11016014A0181|28 33|study
P11016014A0181|67 81|susceptibility
P11016014A0181|85 99|apolipoprotein
P11016014A0181|113 125|lipoproteins
P11016014A0181|142 148|status
P11016014A0181|152 160|patients
P11016014A0181|181 190|syndromes
P11016014A0181|210 225|angina pectoris
P11016724A0536|3 10|group B
P11016724A0536|14 17|MBq
P11016724A0536|25 31|microL
P11016724A0536|35 56|99mTc-HSA nanocolloid
P11016724A0536|100 101|h
P11016724A0536|109 116|surgery
P11016724A0536|122 130|aliquots
P11016737A0275|26 33|outcome
P11016737A0275|73 79|status
P11016850A0423|12 24|DNA fragment
P11016850A0423|49 53|part
P11016850A0423|59 66|protein
P11016850A0423|84 94|similarity
P11016850A0423|98 105|members
P11016850A0423|113 124|LysR family
P11016850A0423|144 154|regulators
P11016850A0423|156 161|LTTRs
P11016954A0438|0 4|AGO1
P11016954A0438|19 24|QDE-2
P11016954A0438|51 56|RDE-1
P11016954A0438|70 74|RNAi
P11017876A0787|14 34|localization studies
P11017876A0787|45 51|mDAP-3
P11017876A0787|52 71|EGFP fusion protein
P11017876A0787|73 91|cell fractionation
P11017876A0787|96 127|protease protection experiments
P11017876A0787|138 144|mDAP-3
P11017876A0787|166 172|matrix
P11018028A0263|25 36|involvement
P11018028A0263|55 69|protein kinase
P11018028A0263|71 74|PKA
P11018028A0263|83 98|phosphorylation
P11018028A0263|102 109|CDC25Mm
P11018028A0263|113 124|fibroblasts
P11018028A0263|145 151|RasGEF
P11018028A0263|166 177|mouse brain
P11018028A0263|191 200|membranes
P11018264A0397|0 33|Reporter gene expression analyses
P11018264A0397|53 67|WASP promoters
P11018264A0397|78 84|levels
P11018264A0397|88 98|expression
P11018264A0397|126 136|cell lines
P11019257A0159|13 20|3T1-3T2
P11019257A0159|45 51|effect
P11019257A0159|59 69|line shape
P11019257A0159|84 94|decay rate
P11019257A0159|98 106|emission
P11019257A0159|116 125|3T2 state
P11019257A0159|139 145|extent
P11019257A0159|182 191|magnitude
P11019257A0159|210 221|distortions
P11020375A0134|2 7|total
P11020375A0134|25 44|Ross broiler chicks
P11020375A0134|64 80|treatment groups
P11020375A0134|109 116|control
P11020375A0134|118 121|CLI
P11020375A0134|126 130|g kg
P11020375A0134|134 138|diet
P11020375A0134|144 149|parts
P11020375A0134|163 166|ppb
P11020375A0134|168 170|AF
P11020375A0134|175 181|ppb AF
P11020375A0134|187 190|CLI
P11020375A0134|196 202|ppb AF
P11020375A0134|208 214|ppb AF
P11020375A0134|220 223|CLI
P11020375A0134|233 237|days
P11023074A1105|4 8|cost
P11023074A1105|13 17|test
P11023074A1105|41 43|CC
P11023074A1105|45 49|kEIA
P11023074A1105|54 59|PACE2
P11023832A1038|17 24|results
P11023832A1038|42 52|KG1a cells
P11023832A1038|54 62|TNFalpha
P11023832A1038|89 95|PC-PLC
P11023832A1038|100 103|PLD
P11023832A1038|111 125|lipid products
P11023832A1038|138 142|turn
P11023832A1038|161 175|protein kinase
P11023832A1038|177 187|MAP kinase
P11023832A1038|193 213|NF-kappaB signalling
P11023853A0188|27 45|weather conditions
P11023853A0188|69 80|budget data
P11023853A0188|96 101|birds
P11023853A0188|106 121|laboratory data
P11023853A0188|143 147|rate
P11023853A0188|175 185|laboratory
P11023853A0188|187 190|TAL
P11023853A0188|192 201|estimates
P11023853A0188|211 229|energy expenditure
P11023853A0188|231 234|DEE
P11023853A0188|244 253|partition
P11023853A0188|258 265|verdins
P11023853A0188|267 280|energy budget
P11023853A0188|304 312|activity
P11023853A0188|323 333|components
P11023934A0855|0 3|L/H
P11023934A0855|11 14|chi
P11023934A0855|24 25|P
P11023934A0855|52 67|filling pattern
P11023934A0855|69 72|chi
P11023934A0855|81 82|P
P11023934A0855|107 117|predictors
P11023934A0855|121 127|events
P11024026A0133|9 20|selectivity
P11024026A0133|24 33|arrestins
P11024026A0133|65 69|form
P11024026A0133|73 81|receptor
P11024026A0133|103 110|binding
P11024026A0133|115 127|dissociation
P11024036A0984|22 33|fibroblasts
P11024036A0984|41 70|C/EBP alpha expression vector
P11024036A0984|72 96|reporter gene expression
P11024036A0984|136 146|constructs
P11024047A0626|0 10|Expression
P11024047A0626|34 39|Smad2
P11024047A0626|66 71|level
P11024047A0626|75 103|luciferase reporter activity
P11024047A0626|121 130|treatment
P11024182A0781|7 13|alpha1
P11024182A0781|14 15|I
P11024182A0781|17 30|collagen mRNA
P11024182A0781|53 62|reduction
P11024182A0781|68 70|AR
P11024182A0781|74 76|IR
P11024182A0781|100 122|pHbetaAPr-1-neo vector
P11024182A0781|141 142|%
P11024182A0781|160 169|reduction
P11024182A0781|182 190|ribozyme
P11024182A0781|214 217|pCI
P11024182A0781|218 228|neo vector
P11024300A1579|0 6|Nature
P11024300A1579|30 50|amino acid sequences
P11024300A1579|54 71|peptide fragments
P11024300A1579|88 99|polypeptide
P11024300A1579|111 118|complex
P11024300A1579|122 130|proteins
P11024300A1579|143 162|chromatin structure
P11024300A1579|164 167|ARC
P11024300A1579|186 194|portions
P11024300A1579|215 228|reading frame
P11024300A1579|232 242|TIG-1 mRNA
P11025367A1009|0 13|Abnormalities
P11025367A1009|17 39|plasma cholecystokinin
P11025367A1009|62 70|patients
P11025367A1009|92 100|emptying
P11027027A0061|3 20|Sunset Yellow FCF
P11027027A0061|51 83|chromatography/mass spectrometry
P11027027A0061|85 90|LC/MS
P11027027A0061|97 120|electrospray ionization
P11027267A0752|0 8|Polysome
P11027267A0752|13 35|40S ribosome fractions
P11027267A0752|67 78|krr1 mutant
P11027267A0752|98 103|cells
P11027274A1682|34 45|PI 3-kinase
P11027274A1682|56 64|activity
P11027274A1682|82 89|extents
P11027274A1682|126 135|structure
P11027274A1682|144 151|isoform
P11027280A0536|0 10|Cam kinase
P11027280A0536|30 45|phosphorylation
P11027280A0536|49 54|Smad2
P11027280A0536|59 64|Smad4
P11027280A0536|82 88|extent
P11027280A0536|90 95|Smad3
P11027289A0000|28 38|suppressor
P11027289A0000|48 52|gene
P11027289A0000|57 58|s
P11027289A0000|94 113|RNA binding protein
P11027289A0000|115 117|SU
P11027289A0000|118 119|S
P11027289A0000|148 164|RNA accumulation
P11027289A0000|177 184|alleles
P11027289A0000|194 199|genes
P11027289A0000|210 231|transposon insertions
P11027289A0000|254 260|region
P11027289A0321|5 11|result
P11027289A0321|47 53|motifs
P11027289A0321|55 59|ARM1
P11027289A0321|64 68|ARM2
P11027289A0321|87 107|RNA binding activity
P11027289A0321|111 113|SU
P11027289A0321|114 115|S
P11027294A0483|5 16|interaction
P11027294A0483|30 64|histone acetyltransferase activity
P11027294A0483|68 72|p300
P11027294A0483|95 104|reduction
P11027294A0483|120 139|histone acetylation
P11027294A0483|144 154|alteration
P11027294A0483|158 177|chromatin structure
P11027724A0335|12 19|BRI1-KD
P11027724A0335|42 48|serine
P11027724A0335|50 53|Ser
P11027724A0335|59 68|threonine
P11027724A0335|70 73|Thr
P11027724A0335|75 83|residues
P11027724A0335|89 94|p-Ser
P11027833A0362|0 13|Flow cytomery
P11027833A0362|27 46|cell cycle analysis
P11028131A1374|8 16|research
P11028131A1374|39 64|measure treatment effects
P11028131A1374|66 78|modification
P11028131A1374|82 84|MS
P11028131A1374|93 100|history
P11028131A1374|119 124|costs
P11028131A1374|128 139|IFN beta-1b
P11028131A1374|143 147|RRMS
P11028131T0000|0 18|Cost-effectiveness
P11028131T0000|22 40|interferon beta-1b
P11028131T0000|61 93|sclerosis disability progression
P11028944A1020|9 13|Cmax
P11028944A1020|18 28|AUC values
P11028944A1020|67 71|dose
P11029045A0000|0 15|Hyperactivation
P11029045A0000|19 23|Cdc2
P11029045A0000|27 40|fission yeast
P11029045A0000|48 53|cells
P11029045A0000|84 91|mitosis
P11029045A0000|107 118|catastrophe
P11029262T0000|0 5|Diary
P11029458A0000|0 5|Cells
P11029458A0000|23 31|response
P11029458A0000|57 64|stimuli
P11029459A0000|13 32|growth factor-beta1
P11029459A0000|34 43|TGF-beta1
P11029459A0000|58 74|tumor suppressor
P11029459A0000|80 94|tumor promoter
P11029459A0000|112 127|characteristics
P11029459A0000|145 149|cell
P11029467T0000|22 29|peptide
P11029467T0000|44 53|adenylate
P11029467T0000|73 84|polypeptide
P11029467T0000|101 113|factor-kappa
P11029467T0000|126 141|gene activation
P11029467T0000|154 160|levels
P11029467T0000|184 199|cell line THP-1
P11029656A0640|0 3|Mn2
P11029656A0640|24 40|junction binding
P11029656A0640|54 64|activities
P11029656A0640|79 87|proteins
P11029700A0295|6 8|Pt
P11029700A0295|9 13|cycH
P11029700A0295|20 22|Os
P11029700A0295|23 27|cycH
P11029700A0295|52 59|tissues
P11029700A0295|74 85|transcripts
P11029700A0295|121 126|cells
P11029700A0746|32 37|assay
P11029700A0746|50 52|Os
P11029700A0746|53 57|CycH
P11029700A0746|82 84|R2
P11029700A0746|102 111|rice CDKs
P11029704A0378|13 21|analysis
P11029704A0378|28 48|particle bombardment
P11029704A0378|52 73|tobacco leaf sections
P11029704A0378|77 85|tetramer
P11029704A0378|93 103|distB ABRE
P11029704A0378|130 137|element
P11029704A0378|148 163|transactivation
P11029704A0378|167 171|ABI3
P11029704A0378|191 199|response
P11029704A0378|203 206|ABA
P11029704A0378|218 226|tetramer
P11029704A0378|244 256|RY/G complex
P11029704A0378|269 279|RY repeats
P11029704A0378|286 291|G-box
P11029704A0378|323 338|transactivation
P11029704A0378|342 346|ABI3
P11030066A0142|23 37|manifestations
P11030066A0142|41 53|brain injury
P11030066A0142|63 69|babies
P11030066A0142|82 96|motor deficits
P11030476A0685|0 6|Spores
P11030476A0685|12 31|Rhizopus stolonifer
P11030476A0685|60 65|water
P11030476A0685|77 86|spores/mL
P11030744A0763|0 14|Overexpression
P11030744A0763|18 24|Trdpm1
P11030744A0763|30 34|dpm1
P11030744A0763|39 48|his7/dpm1
P11030744A0763|52 54|S.
P11030744A0763|89 97|increase
P11030744A0763|110 131|DPM synthase activity
P11031252A0646|4 13|LMW FGF-2
P11031252A0646|31 49|PKC epsilon levels
P11031252A0646|66 74|contrast
P11031252A0646|79 90|HMW isoform
P11031252A0646|110 115|level
P11031252A0646|124 135|PKC isotype
P11031252A0646|170 176|amount
P11031252A0646|180 189|PKC delta
P11031366T0001|0 19|Helicobacter pylori
P11031366T0001|24 40|stomach diseases
P11031366T0001|55 60|point
P11031366T0001|64 68|view
P11031773A0174|9 16|purpose
P11031773A0174|31 35|test
P11031773A0174|37 46|capsaicin
P11031773A0174|51 72|formalin induced-pain
P11031773A0174|76 80|mice
P11032599T0000|15 30|recommendations
P11032599T0000|39 42|use
P11032599T0000|79 86|factors
P11032599T0000|113 132|practice guidelines
P11032677A0230|10 18|findings
P11032677A0230|32 44|pancreatitis
P11032677A0230|68 73|plugs
P11032677A0230|120 129|steatitis
P11032677A0230|144 152|myopathy
P11032677A0230|165 172|atrophy
P11032677A0230|174 185|candidiasis
P11032677A0230|212 221|glossitis
P11034392A1072|20 24|data
P11034392A1072|48 65|survival pathways
P11034392A1072|89 97|receptor
P11034392A1072|107 120|NF-kappaB/Rel
P11034392A1072|125 130|PI-3K
P11034392A1072|160 173|proliferation
P11034547A0674|10 14|Arix
P11034547A0674|19 25|NBPhox
P11034547A0674|47 56|multimers
P11034547A0674|81 88|binding
P11034547A0674|96 99|DB1
P11034547A0674|111 118|element
P11034547A0674|139 168|homeodomain recognition sites
P11034547A1355|22 27|study
P11034547A1355|33 37|Arix
P11034547A1355|42 48|NBPhox
P11034547A1355|118 128|properties
P11034547A1355|136 148|DBH promoter
P11034933A0389|0 7|METHODS
P11034933A0389|12 19|RESULTS
P11034933A0389|21 28|Studies
P11034933A0389|59 76|guinea pig hearts
P11034933A0389|119 131|prolongation
P11034933A0389|143 157|repolarization
P11034933A0389|165 183|nmol/L domperidone
P11035037A0183|21 28|segment
P11035037A0183|32 44|yeast TAF145
P11035037A0183|46 53|yTAF145
P11035037A0183|64 67|TBP
P11035037A0183|89 101|TBP function
P11035867A0000|0 9|OBJECTIVE
P11035867A0000|35 46|performance
P11035867A0000|70 98|wrist blood pressure monitor
P11035867A0000|100 121|Braun PrecisionSensor
P11035867A0000|123 133|Braun GmbH
P11035867A0000|135 143|Kronberg
P11035867A0000|145 152|Germany
P11035867A0000|172 202|ANSI/AAMI SP10-1992 guidelines
P11035867A0000|223 227|data
P11035867A0000|246 255|selection
P11035867A0000|263 272|algorithm
P11035867A0000|290 311|blood pressure values
P11035867A0000|335 356|blood pressure curves
P11036786A0628|14 21|results
P11036786A0628|39 50|experiments
P11036786A0628|58 72|target animals
P11036786A0628|88 112|Drinking Water Standards
P11036786A0628|117 124|Animals
P11036938A1162|3 11|increase
P11036938A1162|28 38|expression
P11036938A1162|62 76|erbB receptors
P11036938A1162|110 122|augmentation
P11036938A1162|134 151|steroid secretion
P11036938A1162|176 179|day
P11036938A1162|206 211|surge
P11036938A1162|215 228|gonadotropins
P11036939A2149|0 3|Dsh
P11036939A2149|34 42|pathways
P11036939A2149|48 59|Wnt pathway
P11036939A2149|64 87|planar polarity pathway
P11037759T0000|0 15|Catch-up growth
P11037759T0000|33 43|dimensions
P11037759T0000|54 68|administration
P11037759T0000|91 108|agent vincristine
P11037759T0000|118 122|rats
P11037823A1134|0 11|CONCLUSIONS
P11037823A1134|13 30|LSCC malformation
P11037823A1134|49 66|ear malformations
P11037823A1134|92 100|aqueduct
P11037823A1134|120 128|deafness
P11037823A1134|144 150|gusher
P11037823A1134|175 178|CHL
P11037823A1134|180 184|SNHL
P11037823A1134|196 203|hearing
P11038042A0948|0 10|Escalation
P11038042A0948|18 23|mg/m2
P11038042A0948|55 77|blood cell nadir count
P11038042A0948|96 97|l
P11038042A0948|102 122|platelet nadir count
P11038118A0000|0 14|Methyl formate
P11038118A0000|56 67|oligoesters
P11038118A0000|76 87|fabrication
P11038118A0000|91 103|microspheres
P11038118A0000|129 142|serum albumin
P11038118A0000|144 147|BSA
P11038317A0000|32 40|proteins
P11038317A0000|48 61|RAB subfamily
P11038317A0000|81 89|elements
P11038317A0000|97 106|machinery
P11038317A0000|121 137|membrane traffic
P11038317A0000|152 157|cells
P11038366A1322|13 17|loss
P11038366A1322|21 32|methylation
P11038366A1322|58 69|association
P11038366A1322|81 86|yeast
P11038366A1322|94 101|subunit
P11038366A1322|103 108|Rts1p
P11038366A1417|6 17|methylation
P11038366A1417|21 27|Pph21p
P11038366A1417|45 54|formation
P11038366A1417|58 62|PP2A
P11038366A1417|84 93|complexes
P11038366A1417|117 130|PP2A function
P11039341A0180|4 11|purpose
P11039341A0180|20 25|study
P11039341A0180|54 69|characteristics
P11039341A0180|86 93|mapping
P11039341A0180|113 123|components
P11039341A0180|138 141|ICA
P11039341A0180|185 189|task
P11039780A0770|4 11|authors
P11039780A0770|33 40|studies
P11039780A0770|81 94|animal models
P11039780A0770|98 112|osteoarthritis
P11039780A0770|119 131|gene therapy
P11039780A0770|148 156|overview
P11039780A0770|168 178|strategies
P11039780A0770|187 198|development
P11039780A0770|202 214|gene therapy
P11039780A0770|218 242|osteoarthritis treatment
P11039780A0770|250 256|future
P11040101A1180|16 23|results
P11040101A1180|38 47|IL-1 beta
P11040101A1180|56 76|VEGF gene expression
P11040101A1180|126 132|levels
P11040101A1180|138 147|IL-1 beta
P11040101A1180|155 163|p38 MAPK
P11040101A1180|168 182|JNK signalings
P11040101A1180|193 197|turn
P11040101A1180|212 225|transcription
P11040101A1180|233 242|VEGF gene
P11040101A1180|263 268|sites
P11040219A0548|0 7|Binding
P11040219A0548|11 15|NusA
P11040219A0548|19 22|RNA
P11040219A0548|30 38|presence
P11040219A0548|42 47|alpha
P11040219A0548|51 52|N
P11040219A0548|80 98|S1 homology region
P11040219A0548|141 145|NusA
P11041308A0156|4 12|subjects
P11041308A0156|35 40|basis
P11041308A0156|44 50|DSM-IV
P11041308A0156|64 81|gambling criteria
P11041308A0156|108 115|Version
P11041308A0156|119 145|South Oaks Gambling Screen
P11041308A0156|147 151|SOGS
P11042197A0386|0 3|Lys
P11042197A0386|13 16|Arg
P11042197A0386|52 55|end
P11042197A0386|59 61|HD
P11042197A0386|81 93|dimerization
P11042199A0572|0 9|Elevation
P11042199A0572|27 29|Ca
P11042199A0572|34 40|levels
P11042199A0572|67 76|treatment
P11042199A0572|102 109|protein
P11042199A0572|111 121|nifedipine
P11042199A0572|123 128|MK801
P11042199A0572|130 137|removal
P11042199A0572|141 143|Ca
P11042199A0572|157 163|medium
P11042199A0572|168 178|dantrolene
P11042199A0572|201 218|calcium elevation
P11042199A0572|237 247|activation
P11042199A0572|251 255|CREB
P11042204A0186|12 17|study
P11042204A0186|29 49|phosphatidylinositol
P11042204A0186|69 90|p38 kinase activation
P11042204A0186|101 120|Akt phosphorylation
P11042204A0186|125 133|activity
P11042204A0186|143 154|neutrophils
P11042703A0875|5 9|BFDS
P11042703A0875|27 36|reference
P11042703A0875|38 50|W/A Z scores
P11042703A0875|78 88|increments
P11042703A0875|95 100|birth
P11042703A0875|104 109|girls
P11042703A0875|116 118|mo
P11042703A0875|122 126|boys
P11043469A0440|15 31|border sequences
P11043469A0440|76 85|T-regions
P11043469A0440|106 114|T-region
P11043469A0440|118 126|pTiChry5
P11043469A0440|135 142|T-right
P11043469A0440|144 146|TR
P11043469A0440|162 172|production
P11043469A0440|180 193|Amadoriopines
P11044097A0422|27 30|HMG
P11044097A0422|83 88|sites
P11044097A0422|113 133|transcription factor
P11044097A0422|142 147|sites
P11044097T0000|20 27|protein
P11044097T0000|43 50|binding
P11044097T0000|54 75|transcription factors
P11044097T0000|83 92|U5 region
P11044097T0000|106 133|immunodeficiency virus type
P11044097T0000|145 153|promoter
P11044105A0616|19 26|element
P11044105A0616|35 54|splicing suppressor
P11044105A0616|58 62|ESS1
P11044105A0616|75 78|use
P11044105A0616|86 88|nt
P11044105A0616|97 108|splice site
P11045180A1892|0 11|Leptinaemia
P11045180A1892|55 77|blood pressure reading
P11045180A1892|87 92|stage
P11045180A1892|96 108|hypertension
P11045180A1892|130 144|classification
P11045607A0239|3 16|RACE analysis
P11045607A0239|36 65|transcription initiation site
P11045607A0239|70 72|bp
P11045607A0239|105 115|start site
P11046146A1202|6 23|diamide treatment
P11046146A1202|35 43|extracts
P11046146A1202|65 72|binding
P11046146A1202|76 88|NFI proteins
P11046146A1202|98 106|addition
P11046146A1202|117 131|concentrations
P11046146A1202|135 149|dithiothreitol
P11046146A1202|161 169|extracts
P11046146A1202|186 191|cells
P11046146A1202|201 216|NFI-DNA binding
P11046146A1202|220 226|levels
P11046146A1202|230 238|extracts
P11046146A1202|254 259|cells
P11046148A0716|0 5|LMP2A
P11046148A0716|15 18|Lyn
P11046148A0716|23 41|Syk ubiquitination
P11046148A0716|55 62|fashion
P11046148A0716|83 91|activity
P11046148A0716|95 115|Nedd4 family members
P11046148A0716|136 151|destabilization
P11046148A0716|159 178|Lyn tyrosine kinase
P11046153A1052|22 31|apoptosis
P11046153A1052|69 79|expression
P11046153A1052|87 103|p300 coactivator
P11046517A0619|4 11|results
P11046517A0619|40 41|Z
P11046517A0619|62 63|Z
P11048832A0271|0 6|Fisher
P11048832A0271|15 19|test
P11048832A0271|23 30|Pearson
P11048832A0271|33 42|chi2 test
P11048832A0271|69 77|analysis
P11049241A0659|0 7|RESULTS
P11049241A0659|25 30|group
P11049241A0659|32 57|serum PP14 concentrations
P11049241A0659|88 90|ET
P11049241A0659|110 120|difference
P11049241A0659|142 147|group
P11049241A0659|168 173|group
P11049241A0659|189 193|days
P11049241A0659|204 206|ET
P11049241A0659|208 209|p
P11049889A1271|0 19|Thromboelastography
P11049889A1271|25 29|test
P11049889A1271|72 78|degree
P11049889A1271|82 97|anticoagulation
P11049889A1271|124 138|weight heparin
P11050084A0000|5 15|expression
P11050084A0000|23 33|peroxisome
P11050084A0000|57 71|receptor alpha
P11050084A0000|73 82|PPARalpha
P11050084A0000|105 108|fat
P11050084A0000|148 156|capacity
P11050084A0000|160 175|lipid oxidation
P11050084A0888|17 24|element
P11050084A0888|31 40|PPARalpha
P11050084A0888|45 54|PPARgamma
P11050084A0888|70 76|nuclei
P11050168A1185|6 13|results
P11050168A1185|29 37|evidence
P11050168A1185|55 69|susceptibility
P11050168A1185|95 105|mRNA decay
P11050168A1185|138 146|affinity
P11050168A1185|164 171|protein
P11050168A1185|187 209|stability determinants
P11051364A0890|0 7|RESULTS
P11051364A0890|23 24|%
P11051364A0890|26 34|patients
P11051364A0890|39 42|PHG
P11051364A0890|51 58|group A
P11051364A0890|70 71|%
P11051364A0890|83 86|PHG
P11051364A0890|93 113|variceal eradication
P11051364A0890|115 122|group B
P11051370A1906|0 8|Response
P11051370A1906|39 48|Americans
P11051370A1906|64 76|HCV genotype
P11053009A0000|0 7|Aspirin
P11053009A0000|22 28|ulcers
P11053009A0000|71 85|cyclooxygenase
P11053009A0000|87 90|COX
P11053009A0000|92 100|activity
P11053009A0000|105 128|prostaglandin synthesis
P11053263A0200|2 7|total
P11053263A0200|16 22|clones
P11053263A0200|50 60|sequencing
P11053263A0200|68 71|end
P11053370A0708|0 10|Expression
P11053370A0708|16 30|hybrid protein
P11053370A0708|69 73|half
P11053370A0708|77 81|UhpB
P11053370A0708|91 116|glutathione S-transferase
P11053370A0708|118 121|GST
P11053370A0708|144 157|Uhp signaling
P11054011A1685|0 11|CONCLUSIONS
P11054011A1685|43 52|treatment
P11054011A1685|56 60|MSGT
P11054011A1685|81 101|locoregional control
P11054011A1685|105 106|%
P11054011A1685|114 115|%
P11054011A1685|124 132|survival
P11054011A1685|138 144|series
P11054011A1685|148 156|patients
P11054011A1685|172 191|oncology department
P11054011A1685|205 213|hospital
P11054011A1685|217 222|Quito
P11054011A1685|224 231|Ecuador
P11054341A0599|0 7|RESULTS
P11054341A0599|9 26|Glaucoma suspects
P11054341A0599|49 55|groups
P11054341A0599|75 79|SWAP
P11054341A0599|94 98|risk
P11054341A0599|105 123|SWAP abnormalities
P11054341A0599|133 137|risk
P11054341A0599|151 162|SWAP result
P11054539A0114|4 8|gene
P11054539A0114|32 37|exons
P11054539A0114|53 60|introns
P11054539A0114|75 88|reading frame
P11054539A0114|106 116|base pairs
P11054539A0114|118 120|bp
P11054539A0114|144 155|polypeptide
P11054539A0114|164 183|amino acid residues
P11054565A0654|9 20|p190-B exon
P11054565A0654|32 36|exon
P11054565A0654|40 46|p190-A
P11054565A0654|71 73|kb
P11054565A0654|77 83|length
P11054565A0654|104 110|GTPase
P11054565A0654|122 129|domains
P11054565A0654|131 139|residues
P11054565A0654|171 181|GAP domain
P11054565A0654|201 213|conservation
P11054565A0654|225 234|structure
P11054565A0654|247 257|p190 genes
P11054571A0230|17 27|teneurin-1
P11054571A0230|29 33|TEN1
P11054571A0230|35 39|gene
P11054571A0230|62 72|PAC clones
P11054571A0230|86 90|part
P11054571A0230|110 120|locus Xq25
P11054970A0282|4 26|plexiform neurofibroma
P11054970A0282|50 63|neurofibromas
P11054970A0282|86 89|NF1
P11055513A0564|11 19|lookback
P11055513A0564|25 33|patients
P11055513A0564|47 52|blood
P11055513A0564|77 88|hepatitis C
P11055513A0564|112 119|testing
P11055786A0306|13 22|algorithm
P11055786A0306|43 48|steps
P11056007A0224|25 36|amino acids
P11056007A0224|40 47|FVVLNLQ
P11056007A0224|60 67|stretch
P11056007A0224|77 85|sequence
P11056007A0224|104 107|Gln
P11056007A0224|117 120|Phe
P11056007A0224|137 140|SET
P11056007A0224|142 150|Suvar3-9
P11056007A0224|152 169|Enhancer-of-zeste
P11056007A0224|171 180|Trithorax
P11056007A0224|194 200|domain
P11056007A0224|202 205|SID
P11056007A0224|210 214|rMTM
P11056019A0926|0 4|MED1
P11056019A0926|16 36|glycosylase activity
P11056019A0926|54 60|adduct
P11056019A0926|63 64|N
P11056019A0926|68 82|ethenocytosine
P11056019A0926|86 96|metabolite
P11056019A0926|100 114|vinyl chloride
P11056019A0926|119 134|ethyl carbamate
P11058008A0159|14 23|instances
P11058008A0159|33 46|flap necrosis
P11058008A0159|60 65|flaps
P11058008A0159|73 86|tip ischaemia
P11058119A0957|6 13|results
P11058119A0957|27 31|XAB1
P11058119A0957|55 61|GTPase
P11058119A0957|82 94|localization
P11058119A0957|98 101|XPA
P11058120A0256|13 20|factors
P11058120A0256|22 27|IRF-2
P11058120A0256|69 80|counterpart
P11058120A0256|84 89|IRF-1
P11058120A0256|105 114|potential
P11058132A0264|16 20|CDSs
P11058132A0264|25 42|% match sequences
P11058132A0264|46 54|proteins
P11058132A0264|69 86|Bacillus subtilis
P11058132A0264|95 96|%
P11058132A0264|121 131|comparison
P11058132A0264|141 149|proteins
P11058132A0264|161 170|organisms
P11058132A0264|182 192|B.subtilis
P11058406A0447|18 21|SLN
P11058406A0447|35 39|i.v.
P11058406A0447|59 75|circulation time
P11058406A0447|92 96|i.v.
P11058406A0447|110 129|tobramycin solution
P11059492A0376|0 9|Bacteriol
P11059777A0813|9 25|deoxynucleotidyl
P11059777A0813|47 71|nick end labeling assays
P11059777A0813|95 105|activation
P11059777A0813|113 128|PAX3 repressors
P11059777A0813|147 156|apoptosis
P11059777A0813|178 193|down-regulation
P11059777A0813|197 202|BCL-X
P11059777A0813|203 204|L
P11059777A0813|206 216|expression
P11059786A0682|0 22|VEGF promoter activity
P11059786A0682|36 49|transfections
P11059786A0682|101 111|inhibition
P11059786A0682|115 119|EGFR
P11059786A0682|121 124|Ras
P11059786A0682|129 149|phosphatidylinositol
P11059786A0682|153 159|kinase
P11059786A0682|161 163|PI
P11059786A0682|167 173|kinase
P11059786T0000|10 32|growth factor receptor
P11059786T0000|85 109|growth factor expression
P11059786T0000|119 137|glioblastoma cells
P11059786T0000|144 151|pathway
P11059786T0000|162 182|phosphatidylinositol
P11059786T0000|186 192|kinase
P11059786T0000|227 234|hypoxia
P11062047A1208|6 11|IHHNV
P11062047A1208|34 46|densoviruses
P11062047A1208|54 75|genus Brevidensovirus
P11062047A1208|83 102|family Parvoviridae
P11062047A1208|144 181|virus Penaeus stylirostris densovirus
P11062047A1208|183 189|PstDNV
P11062067A0000|17 31|protein kinase
P11062067A0000|35 40|SAPK1
P11062067A0000|55 60|c-Jun
P11062067A0000|72 78|kinase
P11062067A0000|80 83|JNK
P11062067A0000|115 123|response
P11062067A0000|144 153|cytokines
P11062067A0000|166 174|stresses
P11062068T0000|10 20|activation
P11062068T0000|42 49|protein
P11062068T0000|51 54|MAP
P11062068T0000|56 76|kinase phosphatase-1
P11062068T0000|91 105|p38 MAP kinase
P11062068T0000|116 120|role
P11062068T0000|128 131|p38
P11062068T0000|143 149|domain
P11062068T0000|166 176|regulation
P11062257A0977|10 29|class C-Vps complex
P11062257A0977|47 56|reactions
P11062257A0977|68 75|docking
P11062257A0977|80 86|fusion
P11062257A0977|90 98|vesicles
P11062257A0977|108 115|vacuole
P11062257A0977|158 169|specificity
P11062257A0977|174 184|efficiency
P11062257A0977|193 210|transport process
P11062274T0000|52 80|tissue plasminogen activator
P11062274T0000|99 105|stroke
P11062705A0658|28 32|role
P11062705A0658|51 56|ATF-2
P11062705A0658|68 84|cancer cell line
P11063127A0000|0 19|Signal transduction
P11063127A0000|24 34|modulation
P11063127A0000|38 53|phosphorylation
P11063127A0000|70 80|inhibition
P11063127A0000|84 103|protein phosphatase
P11063127A0000|105 107|PP
P11063127A0000|118 122|PP2A
P11063127A0000|141 145|role
P11063127A0000|157 161|acid
P11063127A0000|163 165|OA
P11063127A0000|176 183|effects
P11063169T0000|0 17|Botulinum toxin A
P11063169T0000|25 34|treatment
P11063169T0000|57 66|foot drop
P11063169T0000|92 100|outcomes
P11063252A0437|0 6|Exon A
P11063252A0437|34 36|kb
P11063252A0437|47 73|HSL translation start site
P11063742A0000|0 9|NF-kappaB
P11063742A0000|31 51|transcription factor
P11063742A0000|87 93|stress
P11063742A0000|105 113|chemical
P11063742A0000|129 139|reductants
P11064829T0058|0 27|Cardiovascular risk factors
P11064829T0058|49 58|treatment
P11066245T0000|26 43|compliance review
P11066245T0000|55 63|mistakes
P11066245T0000|72 76|SNFs
P11067797A1306|0 11|CONCLUSIONS
P11067797A1306|13 28|EBCT technology
P11067797A1306|55 65|evaluation
P11067797A1306|102 110|function
P11067797A1306|123 133|assessment
P11067797A1306|151 166|BV distribution
P11067797A1306|191 201|components
P11067928A0532|10 14|mAbs
P11067928A0532|29 30|V
P11067928A0532|31 32|H
P11067928A0532|38 39|J
P11067928A0532|40 41|H
P11067928A0532|43 56|gene segments
P11067928A0532|72 73|D
P11067928A0532|75 81|Vkappa
P11067928A0532|87 99|Jkappa genes
P11069011A0224|0 15|SSF experiments
P11069011A0224|48 59|bioreactors
P11069011A0224|75 78|CO2
P11069011A0224|100 105|traps
P11069011A0224|120 127|mixture
P11069011A0224|147 156|materials
P11069011A0224|176 185|pesticide
P11069075T0000|0 16|Characterization
P11069075T0000|22 59|Xenopus laevis CXC chemokine receptor
P11069075T0000|63 75|implications
P11069075T0000|94 110|cell development
P11069075T0000|118 135|vertebrate embryo
P11069223A0593|0 8|Patients
P11069223A0593|30 35|liver
P11069223A0593|48 64|marrow functions
P11069307A0546|0 10|Inhibition
P11069307A0546|14 30|RNA2 translation
P11069307A0546|54 60|effect
P11069307A0546|81 92|translation
P11069307A0546|96 107|translation
P11069307A0546|111 114|BMV
P11069307A0546|128 149|replication factor 1a
P11069307A0546|174 177|p20
P11069307A0546|190 200|antagonist
P11069307A0546|204 217|DED1 function
P11069307A0546|221 232|translation
P11069756A2618|0 13|Abbreviations
P11069756A2618|15 18|CAS
P11069756A2618|35 44|substrate
P11069756A2618|46 48|CH
P11069756A2618|68 74|domain
P11069756A2618|76 79|CSK
P11069756A2618|92 102|SRC kinase
P11069756A2618|104 106|E6
P11069756A2618|108 133|Papillomavirus E6 protein
P11069756A2618|135 138|FAK
P11069756A2618|146 161|adhesion kinase
P11069756A2618|163 166|GIT
P11069756A2618|168 182|GRK interacter
P11069756A2618|184 188|GPCR
P11069756A2618|223 231|receptor
P11069756A2618|233 236|GRK
P11069756A2618|238 271|G-protein-coupled-receptor kinase
P11069756A2618|273 277|MAPK
P11069756A2618|297 311|protein kinase
P11069756A2618|313 316|ERK
P11069756A2618|318 321|p38
P11069756A2618|323 326|JNK
P11069756A2618|329 332|PAK
P11069756A2618|348 354|kinase
P11069756A2618|356 359|PBS
P11069756A2618|378 387|subdomain
P11069756A2618|389 392|PIX
P11069756A2618|410 425|exchange factor
P11069756A2618|427 430|PKL
P11069756A2618|432 454|paxillin kinase linker
P11069756A2618|456 460|POR1
P11069756A2618|462 469|partner
P11069756A2618|473 476|Rac
P11069756A2618|478 480|PS
P11069756A2618|482 495|phosphoserine
P11069756A2618|497 499|PT
P11069756A2618|501 517|phosphothreonine
P11069756A2618|519 521|PY
P11069756A2618|523 538|phosphotyrosine
P11069756A2618|540 543|RTK
P11069756A2618|545 583|growth factor receptor tyrosine kinase
P11069756A2618|585 587|SH
P11069756A2618|602 608|domain
P11069788A0531|28 30|SB
P11069788A0531|54 62|patients
P11069788A0531|82 97|difference PEEP
P11069788A0531|107 110|Pga
P11069788A0531|118 123|decay
P11069788A0531|125 129|mean
P11069788A0531|134 136|SD
P11069788A0531|150 154|cm H
P11069788A0531|157 158|O
P11069788A0531|181 185|PEEP
P11069788A0531|189 196|dyn ref
P11069788A0531|210 214|cm H
P11069788A0531|217 218|O
P11069791A0226|16 24|subjects
P11069791A0226|49 52|IPT
P11069791A0226|58 62|dose
P11069791A0226|70 72|mg
P11069791A0226|92 94|mo
P11069791A0226|96 105|Regimen A
P11069791A0226|133 136|IPT
P11069791A0226|141 143|mg
P11069791A0226|163 165|mo
P11069791A0226|167 176|Regimen B
P11069791A0226|208 211|IPT
P11069791A0226|216 218|mg
P11069791A0226|231 233|mo
P11069791A0226|235 244|Regimen C
P11069825A0530|15 20|cases
P11069825A0530|24 36|tuberculosis
P11069825A0530|58 60|yr
P11069825A0530|64 73|follow-up
P11069825A0530|88 97|incidence
P11069897A1112|6 13|results
P11069897A1112|29 35|BACH1t
P11069897A1112|45 50|BACH1
P11069897A1112|58 65|nucleus
P11069897A1112|74 77|BTB
P11069897A1112|94 105|interaction
P11069999A1602|4 11|U17/U16
P11069999A1602|20 23|U16
P11069999A1602|25 38|gene products
P11069999A1602|58 65|HIV LTR
P11070007A0136|0 13|Transcription
P11070007A0136|25 35|EBNA genes
P11070007A0136|85 92|B cells
P11070007A0136|117 126|promoters
P11070007A0136|128 130|Cp
P11070007A0136|135 137|Wp
P11070007A0136|161 164|end
P11070007A0136|178 184|genome
P11070056A0704|4 20|Cili-2 sequences
P11070056A0704|29 39|similarity
P11070056A0704|47 60|RNaseH domain
P11070056A0704|64 72|Lian-Aa1
P11070056A0704|76 84|mosquito
P11070056A0704|93 108|retrotransposon
P11070078A1153|13 21|response
P11070078A1153|49 52|p53
P11070078A1153|57 85|Rb tumor suppressor pathways
P11070078A1153|100 110|HeLa cells
P11070078A1153|120 130|repression
P11070078A1153|134 140|HPV E6
P11070078A1153|145 147|E7
P11070078A1153|164 172|pathways
P11070078A1153|187 194|fashion
P11070078A1153|206 212|growth
P11070078A1153|224 231|signals
P11070078A1153|239 244|cells
P11071651A1308|38 45|pathway
P11071651A1308|66 81|differentiation
P11071651A1308|105 123|retinoid induction
P11071651A1308|127 145|FR-beta expression
P11071789T0000|22 33|dose levels
P11071789T0000|37 51|ACE inhibitors
P11071789T0000|63 76|heart failure
P11071852A0297|23 29|SOCS-3
P11071852A0297|48 53|IGFIR
P11071852A0297|71 77|SOCS-3
P11071852A0297|114 128|chain reaction
P11071852A0297|149 160|muscle mRNA
P11071924A0588|2 9|protein
P11071924A0588|22 25|SH2
P11071924A0588|30 49|RING finger domains
P11071924A0588|57 65|activity
P11071924A0588|82 89|protein
P11071924A0588|99 102|SH2
P11071924A0588|107 126|RING finger domains
P11071924A0588|130 135|SLI-1
P11071924A0588|163 170|domains
P11071924A0588|174 179|c-Cbl
P11071924A0588|184 192|activity
P11071974A0155|16 23|effects
P11071974A0155|27 30|HRT
P11071974A0155|40 47|factors
P11071974A0155|67 74|disease
P11071974A0155|76 80|ESRD
P11071974A0155|82 90|patients
P11071974A0155|109 116|changes
P11071974A0155|120 133|lipid profile
P11071974A0155|135 146|coagulation
P11071974A0155|151 171|fibrinolysis markers
P11071974A0155|177 203|plasma homocysteine levels
P11071974A0155|210 219|treatment
P11072155A0764|29 40|correlation
P11072155A0764|49 57|TGF beta
P11072155A0764|60 66|levels
P11072155A0764|78 99|cell radiosensitivity
P11072155A0764|101 115|lymphocyte SF2
P11072388T0000|6 17|feasibility
P11072388T0000|22 28|safety
P11072388T0000|34 60|smoking reduction strategy
P11072388T0000|65 72|smokers
P11072388T0000|78 91|schizophrenia
P11073163A0131|28 39|degradation
P11073163A0131|43 51|proteins
P11073163A0131|65 83|cell cycle control
P11073163A0131|94 98|role
P11073163A0131|106 116|proteasome
P11073163A0131|132 150|cell proliferation
P11073163A0131|155 168|cell survival
P11073218A0800|10 20|nucleotide
P11073218A0800|62 70|U.G pair
P11073218A0800|95 101|region
P11073539A0866|11 19|analysis
P11073539A0866|34 40|desmin
P11073539A0866|44 48|SW13
P11073539A0866|50 53|vim
P11073539A0866|56 61|cells
P11073539A0866|69 80|aggregation
P11073539A0866|100 106|clumps
P11073539A0866|126 134|material
P11073539A0866|160 169|cytoplasm
P11073870A0375|0 8|Patients
P11073870A0375|14 21|lesions
P11073870A0375|36 39|PRC
P11073870A0375|56 59|PHC
P11073870A0375|65 73|patients
P11073870A0375|79 86|lesions
P11073870A0375|102 105|PRC
P11073870A0375|110 113|PHC
P11073870A0375|128 138|oculomotor
P11073870A0375|147 160|response task
P11073870A0375|187 200|memory delays
P11073870A0375|213 215|s.
P11073919A0631|3 11|addition
P11073919A0631|16 35|amino acid residues
P11073919A0631|37 40|K69
P11073919A0631|42 45|D88
P11073919A0631|47 50|E94
P11073919A0631|52 56|D134
P11073919A0631|58 62|R154
P11073919A0631|64 68|K169
P11073919A0631|70 74|H197
P11073919A0631|76 80|D233
P11073919A0631|82 86|G235
P11073919A0631|88 92|G236
P11073919A0631|94 98|G237
P11073919A0631|100 104|F238
P11073919A0631|106 110|E274
P11073919A0631|112 116|G276
P11073919A0631|118 122|R277
P11073919A0631|124 128|Y278
P11073919A0631|130 134|K294
P11073919A0631|136 140|Y323
P11073919A0631|142 146|Y331
P11073919A0631|148 152|D332
P11073919A0631|154 158|C360
P11073919A0631|160 164|D361
P11073919A0631|166 170|D364
P11073919A0631|172 176|G387
P11073919A0631|178 182|Y389
P11073919A0631|188 192|F397
P11073919A0631|194 213|mouse ODC numbering
P11073919A0631|251 260|formation
P11073919A0631|296 302|domain
P11073919A0631|329 335|domain
P11073919A0631|343 362|dimer stabilization
P11073919A0631|383 387|ODCs
P11073919A0631|412 430|S. ruminantium LDC
P11073954A0337|4 13|Psc2 cDNA
P11073954A0337|32 45|reading frame
P11073954A0337|60 79|CP2 family proteins
P11074003A0741|4 11|results
P11074003A0741|26 29|Shh
P11074003A0741|50 57|cycling
P11074003A0741|85 90|CGNPs
P11074210A0623|4 15|QT interval
P11074210A0623|39 49|components
P11074210A0623|57 84|insulin resistance syndrome
P11074210A0623|96 98|BP
P11074210A0623|103 122|insulin sensitivity
P11075678A0298|4 15|wavenumbers
P11075678A0298|44 49|modes
P11075678A0298|53 62|vibration
P11075678A0298|89 92|DFT
P11075678A0298|94 101|B3LYP/6
P11075678A0298|104 105|G
P11075678A0298|109 122|approximation
P11075678A0298|133 142|agreement
P11075678A0298|161 167|values
P11075678A0298|209 220|force field
P11075929A1657|4 8|data
P11075929A1657|24 32|evidence
P11075929A1657|38 42|ThlA
P11075929A1657|62 72|metabolism
P11075929A1657|81 85|acid
P11075929A1657|98 107|formation
P11075929A1657|135 143|function
P11075929A1657|147 151|ThlB
P11075944A0691|3 11|addition
P11075944A0691|13 17|npm3
P11075944A0691|53 57|fgf8
P11075944A0691|61 75|MMTV insertion
P11075944A0691|100 109|androgens
P11075944A0691|113 123|SC-3 cells
P11076860A0872|0 11|Experiments
P11076860A0872|32 40|proteins
P11076860A0872|51 56|UEV1A
P11076860A0872|70 77|protein
P11076860A0872|92 95|Kua
P11076860A0872|100 107|Kua-UEV
P11076860A0872|132 142|structures
P11076860A0872|164 174|Kua domain
P11076860A0872|202 214|localization
P11076860A0872|218 225|Kua-UEV
P11078726X0000|15 30|phosphorylation
P11078726X0000|40 43|p53
P11078726X0000|47 53|Ser315
P11078726X0000|79 92|transcription
P11078726X0000|94 114|p53 protein activity
P11078726X0000|120 140|transcription factor
P11078726X0000|169 179|antibodies
P11078726X0000|227 233|domain
P11078726X0000|259 266|enzymes
P11078726X0000|284 290|domain
P11078726X0000|302 306|role
P11078726X0000|336 351|gene expression
P11080796A0883|27 36|cell line
P11080796A0883|43 53|expression
P11080796A0883|61 64|IKK
P11080796A0883|76 83|protein
P11080796A0883|85 93|IKKgamma
P11080796A1277|4 28|Tax/IKKgamma interaction
P11080796A1277|47 50|Tax
P11080796A1277|58 61|IKK
P11080796A1277|72 80|subunits
P11080796A1277|82 90|IKKalpha
P11080796A1277|95 102|IKKbeta
P11080796A1277|113 124|recruitment
P11080796A1277|152 161|mechanism
P11080796A1277|171 174|Tax
P11080796A1277|190 198|activity
P11080796A1277|202 205|IKK
P11081962T0000|12 16|AFLP
P11081962T0000|44 47|map
P11081962T0000|59 64|Avena
P11082185A0415|3 11|addition
P11082185A0415|35 39|type
P11082185A0415|54 60|domain
P11082185A0415|82 93|amino acids
P11082185A0415|97 102|IRF-1
P11082185A0415|147 155|activity
P11082587X0000|0 7|Effects
P11082587X0000|32 41|smoothing
P11082587X0000|56 76|brillouin scattering
P11082587X0000|105 116|model limit
P11082587X0000|121 130|influence
P11082587X0000|134 154|laser beam smoothing
P11082587X0000|169 193|Brillouin backscattering
P11082587X0000|195 199|SBBS
P11082587X0000|232 237|limit
P11082587X0000|261 271|spot model
P11082715X0001|13 26|determination
P11082715X0001|30 42|theophylline
P11082715X0001|51 62|metabolites
P11082715X0001|66 70|HPLC
P11082715X0001|79 90|performance
P11082715X0001|98 112|chromatography
P11082715X0001|114 118|HPLC
P11082715X0001|120 126|method
P11082715X0001|167 180|determination
P11082715X0001|184 196|theophylline
P11082715X0001|205 216|metabolites
P11082715X0001|223 231|caffeine
P11082715X0001|240 251|metabolites
P11083154A0881|4 9|males
P11083154A0881|25 40|test conditions
P11083154A0881|45 62|oxygen uptake VO2
P11083154A0881|64 74|heart rate
P11083154A0881|76 97|minute ventilation VE
P11083154A0881|109 117|exertion
P11083154A0881|129 138|shrinkage
P11083358A1071|0 10|CONCLUSION
P11083358A1071|12 15|SPT
P11083358A1071|36 39|WST
P11083358A1071|59 67|patients
P11083358A1071|83 93|aspiration
P11083432A0332|8 14|groups
P11083432A0332|34 41|control
P11083432A0332|43 44|n
P11083432A0332|55 59|FK-1
P11083432A0332|61 62|n
P11083432A0332|72 76|FK-3
P11083432A0332|78 79|n
P11083868A0386|0 11|DNA binding
P11083868A0386|16 41|glutathione S-transferase
P11083868A0386|52 58|assays
P11083868A0386|76 83|binding
P11083868A0386|93 98|Elk-1
P11083868A0386|129 151|transactivation domain
P11084022A1178|14 28|ALK7 signaling
P11084022A1178|51 57|change
P11084022A1178|61 76|cell morphology
P11084022A1178|94 109|cell flattening
P11084022A1178|114 125|elaboration
P11084022A1178|142 156|cell processes
P11084334A0590|4 17|swa2-1 allele
P11084334A0590|46 52|screen
P11084334A0590|63 77|point mutation
P11084334A0590|85 109|tetratricopeptide repeat
P11084334A0590|111 114|TPR
P11084334A0590|116 122|domain
P11084334A0590|126 131|motif
P11084334A0590|145 152|auxilin
P11084334A0590|172 180|proteins
P11084334A0590|192 203|interaction
P11084334A0590|220 228|proteins
P11084556T0000|0 11|Association
P11084556T0000|15 21|stress
P11084556T0000|29 37|delivery
P11084556T0000|53 60|numbers
P11084556T0000|74 79|cells
P11084556T0000|98 114|progenitor cells
P11084556T0000|128 138|cord blood
P11084649A0497|18 25|embryos
P11084649A0497|31 41|expression
P11084649A0497|60 64|side
P11084649A0497|72 78|embryo
P11084649A0497|86 88|E6
P11084649A0497|99 104|onset
P11084649A0497|108 120|gastrulation
P11084649A0497|122 132|expression
P11084649A0497|149 157|epiblast
P11084649A0497|168 176|endoderm
P11084649A0497|186 194|mesoderm
P11084649A0497|214 220|streak
P11085267A0562|0 14|Transformation
P11085267A0562|22 35|sconC3 mutant
P11085267A0562|41 46|sconB
P11085267A0562|71 80|phenotype
P11085600A0123|4 11|authors
P11085600A0123|48 54|inputs
P11085600A0123|73 79|cortex
P11085600A0123|94 100|region
P11085600A0123|160 171|information
P11086872A0000|0 9|Influence
P11086872A0000|13 26|oil emulsions
P11086872A0000|31 39|diphenyl
P11086872A0000|75 82|changes
P11086872A0000|86 97|Kagzi limes
P11086872A0000|99 118|Citrus aurantifolia
P11087141A0977|9 17|analysis
P11087141A0977|21 27|alpha1
P11087141A0977|29 43|GT transcripts
P11087141A0977|75 92|splicing patterns
P11087141A0977|116 122|region
P11087141A0977|127 130|UTR
P11087141A0977|136 144|evidence
P11087141A0977|155 172|splicing activity
P11087141A0977|206 212|manner
P11088635A0200|10 41|Kubo-Martin-Schwinger condition
P11088635A0200|60 68|coupling
P11088635A0200|74 82|computer
P11088635A0200|104 110|source
P11088635A0200|141 155|usage patterns
P11088635A0200|163 169|system
P11089911A1267|19 28|sequences
P11089911A1267|52 59|regions
P11089911A1267|90 103|transcription
P11089911A1267|111 129|retrotransposition
P11089911A1267|137 150|ATLN elements
P11090172A0612|4 15|time course
P11090172A0612|19 35|RNA1 replication
P11090172A0612|40 54|RNA3 synthesis
P11090172A0612|66 71|yeast
P11090172A0612|91 96|yeast
P11090172A0612|122 136|FHV virion RNA
P11090272A1240|4 17|transcription
P11090272A1240|34 42|splicing
P11090272A1240|52 56|ORL1
P11090272A1240|61 65|GAIP
P11090762A0527|0 7|RESULTS
P11090762A0527|18 24|effect
P11090762A0527|28 39|muscle pain
P11090762A0527|65 76|stimulation
P11090762A0527|113 121|increase
P11090762A0527|125 130|delta
P11090762A0527|136 138|Hz
P11090762A0527|140 145|power
P11090762A0527|153 160|alpha-1
P11090762A0527|167 169|Hz
P11090762A0527|171 185|power increase
P11090762A0527|209 223|parietal locus
P11092770A0238|4 14|extraction
P11092770A0238|83 90|class C
P11092770A0238|96 105|predictor
P11092770A0238|123 133|extraction
P11092770A0238|135 146|specificity
P11092770A0238|153 154|%
P11092770A0238|159 170|sensitivity
P11092770A0238|184 185|%
P11092809A0823|3 11|addition
P11092809A0823|17 24|results
P11092809A0823|35 39|ERKs
P11092809A0823|44 49|PI3Ks
P11092809A0823|75 83|ectoderm
P11092809A0823|89 97|mesoderm
P11092850A1023|9 40|16S rRNA gene sequence analysis
P11092850A1023|49 56|species
P11092850A1023|68 77|tuf genes
P11092850A1023|96 104|ancestor
P11092850A1023|120 127|species
P11092850A1023|144 148|copy
P11092850A1023|180 187|lineage
P11092850A1023|207 215|ancestor
P11092886A0341|14 42|protein kinase A stimulation
P11092886A0341|51 60|CREMalpha
P11092886A0341|77 84|complex
P11092886A0341|92 100|promoter
P11092886A0341|108 141|phosphoenolpyruvate carboxykinase
P11092886A0341|143 148|PEPCK
P11092886A0341|150 154|gene
P11093745A0563|17 26|HNF3 site
P11093745A0563|36 46|apposition
P11093745A0563|52 64|NF1/CTF site
P11093745A0563|109 116|element
P11094066A0505|21 31|regulation
P11094066A0505|47 57|modulation
P11094066A0505|65 102|forkhead transcription factor FKHR-L1
P11094066A0505|108 112|IL-3
P11094066A0505|123 139|FKHR-L1 activity
P11094066A0505|160 166|manner
P11094066A1194|22 34|observations
P11094066A1194|49 59|inhibition
P11094066A1194|63 66|p27
P11094066A1194|67 71|KIP1
P11094066A1194|73 86|transcription
P11094066A1194|108 131|FKHR-L1 phosphorylation
P11094066A1194|149 158|mechanism
P11094066A1194|191 199|survival
P11094066A1194|204 217|proliferation
P11094072A0842|0 5|DNase
P11094072A0842|16 28|footprinting
P11094072A0842|47 57|c-Myb site
P11094072A0842|91 98|fashion
P11094072A1234|17 22|c-Myb
P11094072A1234|37 51|RAG-2 promoter
P11094072A1234|55 62|T cells
P11094072A1234|82 97|consensus c-Myb
P11094072A1234|106 110|site
P11094073A0000|24 30|member
P11094073A0000|38 57|Vav family proteins
P11094073A0000|59 63|Vav3
P11094073A0000|89 125|Ros receptor protein tyrosine kinase
P11094073A0000|127 131|RPTK
P11094073A0000|145 152|protein
P11094073A0000|156 161|yeast
P11094073A0000|173 182|screening
P11094075A0257|31 43|reexpression
P11094075A0257|51 64|r-PTPeta gene
P11094075A0257|85 102|rat thyroid cells
P11094075A0257|118 130|retroviruses
P11094075A0257|144 149|v-mos
P11094075A0257|154 172|v-ras-Ki oncogenes
P11094075A0257|200 209|phenotype
P11094087T0000|8 18|expression
P11094087T0000|22 26|Rnd3
P11094087T0000|46 60|transformation
P11094087T0000|85 90|cells
P11094087T0000|137 151|kinase pathway
P11094091A0000|4 12|activity
P11094091A0000|20 45|transcription factor CREB
P11094091A0000|76 83|stimuli
P11094091A0000|103 118|phosphorylation
P11094091A0000|133 147|serine residue
P11094091A0000|149 155|Ser133
P11094109A0600|0 7|RESULTS
P11094109A0600|17 20|age
P11094109A0600|24 37|symptom onset
P11094109A0600|47 52|years
P11094590A0617|8 14|fields
P11094590A0617|39 51|relationship
P11094590A0617|74 82|presence
P11094590A0617|86 94|bacteria
P11094590A0617|98 111|Gram staining
P11094590A0617|126 135|diagnosis
P11094590A0617|139 142|VAP
P11094590A0617|148 151|PSB
P11094590A0617|156 159|PTC
P11094590A0617|174 185|sensitivity
P11094590A0617|195 196|%
P11094590A0617|198 209|specificity
P11094590A0617|220 221|%
P11094590A0617|243 248|value
P11094590A0617|259 260|%
P11094590A0617|282 287|value
P11094590A0617|297 298|%
P11095248A0423|21 29|proteins
P11095248A0423|31 36|XFGF3
P11095248A0423|66 68|Mr
P11095248A0423|76 88|glycoprotein
P11095248A0423|90 94|gp31
P11095248A0423|124 132|cleavage
P11095248A0423|172 179|product
P11095248A0423|181 185|gp27
P11095248A1523|25 32|Xenopus
P11095248A1523|47 52|FGF3s
P11095248A1523|72 84|prerequisite
P11095248A1523|107 115|activity
P11095981A0254|26 38|cis-elements
P11095981A0254|52 63|replication
P11095981A0254|79 90|bp promoter
P11095981A0254|123 131|plasmids
P11095981A0254|149 158|mutations
P11095981A0254|163 172|deletions
P11096662T0000|0 9|Tranilast
P11096662T0000|17 24|Therapy
P11096662T0000|37 51|Artery Disease
P11097040A0000|4 14|objectives
P11097040A0000|30 35|study
P11097040A0000|57 64|effects
P11097040A0000|75 80|Equex
P11097040A0000|86 99|TRIS-extender
P11097040A0000|114 119|semen
P11097040A0000|130 135|steps
P11097040A0000|137 145|freezing
P11097040A0000|161 168|methods
P11097040A0000|183 188|rates
P11097040A0000|198 210|interactions
P11097040A0000|225 235|treatments
P11097040A0000|254 262|survival
P11097040A0000|266 281|dog spermatozoa
P11097040A0000|288 298|degrees C.
P11097079A0525|5 10|study
P11097079A0525|43 53|validation
P11097079A0525|61 70|clinician
P11097079A0525|77 87|NIMH-LCM-p
P11098217A0674|4 14|Aie1 locus
P11098217A0674|29 52|mouse chromosome 7A2-A3
P11098217A0674|76 89|hybridization
P11098420A0175|12 21|disorders
P11098420A0175|25 33|children
P11098420A0175|38 49|adolescents
P11098420A0175|69 78|morbidity
P11098420A0175|87 98|development
P11098420A0175|124 133|mortality
P11098420A0175|137 144|suicide
P11099377T0000|10 17|cloning
P11099377T0000|22 32|expression
P11099377T0000|42 54|UDP-d-Xylose
P11099377T0000|55 106|proteoglycan core protein beta-d-xylosyltransferase
P11099377T0000|121 134|isoform XT-II
P11100515A0282|0 14|Thyrotoxicosis
P11100515A0282|22 32|amiodarone
P11100515A0282|104 113|potential
P11100515A0282|117 131|thyrotoxicosis
P11100515A0282|162 168|effect
P11100515A0282|175 196|amiodarone withdrawal
P11101008A0649|0 15|Chaperones/HSPs
P11101008A0649|36 41|roles
P11101008A0649|49 69|cell cycle processes
P11101847A0159|10 20|signalling
P11101847A0159|24 28|E2F1
P11101847A0159|57 70|stabilization
P11101847A0159|75 85|activation
P11101847A0159|93 114|tumour suppressor p53
P11101847A0159|116 120|refs
P11102367A1170|5 10|study
P11102367A1170|29 40|conclusions
P11102367A1170|51 59|identity
P11102367A1170|63 71|proteins
P11102367A1170|89 100|development
P11102367A1170|116 122|system
P11102367A1170|126 136|Drosophila
P11102367A1170|153 160|example
P11102367A1170|176 184|approach
P11102367A1170|204 209|masse
P11102367A1170|228 237|mutations
P11102367A1170|260 267|screens
P11102458A0000|16 30|identification
P11102458A0000|43 59|characterization
P11102458A0000|63 75|neurobeachin
P11102458A0000|107 114|protein
P11102458A0000|122 125|kDa
P11102458A0000|155 159|site
P11102458A0000|161 162|K
P11102458A0000|163 164|d
P11102458A0000|170 172|nm
P11102458A0000|182 186|type
P11102458A0000|201 208|subunit
P11102458A0000|212 228|protein kinase A
P11102458A0000|230 237|PKA RII
P11103472A0802|0 8|Children
P11103472A0802|14 17|ADD
P11103472A0802|47 62|CNV-1 amplitude
P11103472A0802|69 74|trend
P11103472A0802|93 98|CNV-1
P11103472A0802|103 108|CNV-2
P11103472A0802|119 129|amplitudes
P11103601T0025|6 11|UMDNJ
P11103792A0755|0 14|Overexpression
P11103792A0755|18 23|c-Myc
P11103792A0755|50 55|mouse
P11103792A0755|66 71|cells
P11103792A0755|81 90|apoptosis
P11103792A0755|129 137|presence
P11103792A0755|141 147|growth
P11103792A0755|166 171|serum
P11103792A0755|187 196|apoptosis
P11103792A0755|224 232|bax-null
P11103792A0755|264 269|mouse
P11103792A0755|280 291|fibroblasts
P11105129T0000|14 28|Susceptibility
P11105129T0000|32 42|Klebsiella
P11105129T0000|54 96|Producing Extended-Spectrum beta-lactamase
P11105129T0000|98 102|ESBL
P11105129T0000|116 125|Hospitals
P11105129T0000|129 135|Brazil
P11105716A0782|0 10|CONCLUSION
P11105716A0782|16 23|results
P11105716A0782|37 56|AIF peak saturation
P11105716A0782|91 96|error
P11105716A0782|104 117|determination
P11105716A0782|121 124|CBV
P11105716A0782|129 139|CBF values
P11105716A0782|177 184|account
P11105716A0782|215 235|MR perfusion studies
P11105717A0123|0 7|METHODS
P11105717A0123|9 11|T2
P11105717A0123|55 61|images
P11105717A0123|103 128|susceptibility difference
P11105717A0123|165 175|hemoglobin
P11105717A0123|183 194|vasculature
P11105717A0123|199 215|microvasculature
P11106216A0918|7 20|COPD patients
P11106216A0918|26 37|variability
P11106216A0918|52 55|Rrs
P11106216A0918|59 60|%
P11106216A0918|87 94|FOT Rrs
P11106216A0918|98 99|%
P11106428A0635|12 15|end
P11106428A0635|39 47|proteins
P11106428A0635|74 80|domain
P11106428A0635|84 89|FAP-1
P11106428A0635|106 117|amino acids
P11106428A0635|135 139|form
P11106428A0635|141 148|Cys2408
P11106428A0635|151 154|Ser
P11106428A0635|165 190|glutathione-S-transferase
P11106428A0635|192 195|GST
P11106667A1061|6 13|Pet111p
P11106667A1061|30 35|roles
P11106667A1061|44 65|membrane localization
P11106667A1061|70 80|regulation
P11106667A1061|84 99|Cox2p synthesis
P11106667A1061|107 119|mitochondria
P11106668A0875|13 25|transfection
P11106668A0875|29 34|cells
P11106668A0875|44 62|spacer-RING domain
P11106668A0875|98 106|function
P11106668A0875|125 135|BIR domain
P11106668A0875|139 145|c-IAP1
P11106668A0875|158 167|apoptosis
P11107637X0001|4 17|determination
P11107637X0001|32 38|bounds
P11107637X0001|42 60|blood serum lipids
P11107637X0001|64 73|titration
P11107637X0001|79 84|ozone
P11107637X0001|90 105|pathophysiology
P11107637X0001|121 133|significance
P11107637X0001|143 150|article
P11107637X0001|155 161|method
P11107637X0001|165 175|definition
P11107637X0001|186 193|binders
P11107637X0001|197 203|lipids
P11107637X0001|207 218|blood serum
P11107637X0001|222 230|patients
P11107637X0001|246 254|diseases
P11107637X0001|265 280|atherosclerosis
P11107637X0001|294 307|heart disease
P11107637X0001|314 327|use titration
P11107637X0001|331 336|ozone
P11108151A0560|0 3|Ang
P11108151A0560|15 31|fibronectin mRNA
P11108151A0560|52 66|PKC inhibitors
P11108151A0560|70 83|PKC depletion
P11108151A0560|102 112|inhibition
P11108151A0560|116 130|EGF-R function
P11108151A0560|154 166|EGF-R mutant
P11108151A0560|171 188|tyrphostin AG1478
P11108151A0560|199 208|induction
P11108151A0560|212 228|fibronectin mRNA
P11108374A1466|0 6|Acoust
P11108523A0326|0 12|Video images
P11108523A0326|20 28|nostrils
P11108523A0326|65 69|area
P11108523A0326|71 80|perimeter
P11108523A0326|82 90|centroid
P11108523A0326|102 106|axis
P11108523A0326|108 115|moments
P11108523A0326|142 146|axes
P11108523A0326|148 151|I11
P11108523A0326|153 156|I22
P11108523A0326|159 169|anisometry
P11108523A0326|171 180|bulkiness
P11108523A0326|198 216|internostril angle
P11108523A0326|233 238|angle
P11108548A0710|0 18|MS characteristics
P11108548A0710|22 31|coumarins
P11108548A0710|33 42|psoralens
P11108548A0710|64 72|flavones
P11108548A0710|88 109|substitution patterns
P11108548A0710|133 138|basis
P11108548A0710|146 154|response
P11108548A0710|173 187|APcI interface
P11108616A0000|0 10|Young fish
P11108616A0000|12 35|Oreochromis mossambicus
P11108616A0000|53 65|microgravity
P11108616A0000|73 74|g
P11108616A0000|88 92|days
P11108616A0000|100 121|space missions STS-55
P11108616A0000|126 132|STS-84
P11108616A0000|140 152|hypergravity
P11108616A0000|154 156|hg
P11108616A0000|164 168|days
P11108720A0124|0 4|S6K2
P11108720A0124|29 33|S6K1
P11108720A0124|41 52|core kinase
P11108720A0124|57 63|linker
P11108720A0124|75 82|domains
P11108720A0124|100 104|S6K1
P11108720A0124|112 113|N
P11108720A0124|130 137|regions
P11108720A0124|184 191|nucleus
P11108720A0124|224 243|localization signal
P11108720A0124|254 258|S6K2
P11108720A1130|0 12|Pretreatment
P11108720A1130|16 21|cells
P11108720A1130|88 101|kinase kinase
P11108720A1130|103 106|MEK
P11108720A1130|108 123|inhibitor U0126
P11108720A1130|134 149|S6K2 activation
P11108720A1130|163 169|extent
P11108720A1130|175 179|S6K1
P11108839A0401|0 7|T cells
P11108839A0401|20 28|isoforms
P11108839A0401|32 36|S6k1
P11108839A0401|43 46|kDa
P11108839A0401|59 65|kinase
P11108839A0401|76 87|kDa isoform
P11108839A0401|115 127|localisation
P11110040A0000|0 10|Ketanserin
P11110040A0000|26 30|drug
P11110040A0000|36 61|5-HT2 receptor antagonism
P11110040A0000|92 100|infusion
P11110040A0000|110 124|% w/v solution
P11110040A0000|128 135|corneal
P11110040A0000|148 160|applications
P11110040A0000|193 201|pressure
P11110040A0000|212 217|times
P11110040A0000|223 231|activity
P11110040A0000|241 251|metabolite
P11110040A0000|253 265|ketanserinol
P11110528A0414|22 24|2D
P11110528A0414|31 39|sequence
P11110528A0414|45 62|velocity encoding
P11110528A0414|83 92|direction
P11110528A0414|109 115|region
P11110528A0414|129 137|velocity
P11110528A0414|148 152|cm/s
P11111051A0051|31 36|Tip60
P11111051A0051|41 66|histone acetyltransferase
P11111051A0051|68 71|HAT
P11111051A0051|73 81|activity
P11112417A1126|4 8|data
P11112417A1126|28 45|MLSN1 transcripts
P11112417A1126|126 140|melanoma cells
P11112417A1126|159 175|MLSN1 expression
P11112417A1126|200 205|level
P11112417A1126|214 227|transcription
P11112417A1126|232 247|mRNA processing
P11112438X0847|0 9|Copyright
P11112438X0847|15 29|Academic Press
P11112700A1936|0 7|Plectin
P11112700A1936|12 23|desmoplakin
P11112700A1936|44 51|domains
P11112700A1936|61 70|C-termini
P11112700A1936|122 128|domain
P11112700A1936|132 139|plectin
P11112700A1936|149 160|desmoplakin
P11112700A1936|174 177|MTs
P11112700T0000|0 16|Characterization
P11112700T0000|24 50|microtubule binding domain
P11112700T0000|54 91|microtubule actin crosslinking factor
P11112700T0000|93 97|MACF
P11112700T0000|100 114|identification
P11112700T0000|126 131|group
P11112700T0000|135 146|microtubule
P11112700T0000|158 166|proteins
P11112790A0989|6 13|results
P11112790A0989|31 42|involvement
P11112790A0989|57 65|elements
P11112790A0989|73 76|UPR
P11113179A0541|16 24|contrast
P11113179A0541|28 32|SRC1
P11113179A0541|41 48|binding
P11113179A0541|52 55|CBP
P11113179A0541|63 80|estrogen receptor
P11113179A0541|106 120|SRC1 functions
P11113179A0541|137 144|adaptor
P11113179A0541|156 159|CBP
P11113179A0541|164 168|p300
P11113179A1020|14 23|construct
P11113179A1020|41 49|residues
P11113179A1020|86 98|LXXLL motifs
P11113179A1020|107 117|AD1 region
P11113179A1020|121 125|SRC1
P11113179A1020|143 163|coactivator activity
P11113179A1020|171 177|assays
P11113199A0800|6 9|MEK
P11113199A0800|32 38|anchor
P11113199A0800|47 51|ERKs
P11113199A0800|57 61|lack
P11113199A0800|67 82|MEK interaction
P11113199A0800|116 128|localization
P11113199A0800|132 155|ERK2-Delta19-25 mutants
P11113199A0800|173 178|cells
P11113201A1114|0 4|Pmt2
P11113201A1114|10 16|member
P11113201A1114|22 40|six-protein family
P11113201A1114|44 49|yeast
P11113201A1114|75 79|step
P11113201A1114|83 98|O mannosylation
P11113201A1114|102 117|target proteins
P11113546A0728|6 13|samples
P11113546A0728|36 45|beginning
P11113546A0728|50 53|end
P11113546A0728|62 74|trial period
P11113546A0728|114 127|nematode eggs
P11113546A0728|132 144|Giardia cyst
P11113692A0169|4 7|aim
P11113692A0169|16 21|study
P11113692A0169|43 55|risk factors
P11113692A0169|60 70|background
P11113692A0169|80 91|retinopathy
P11113692A0169|93 96|BDR
P11113692A0169|102 105|PDR
P11113692A0169|132 140|patients
P11113692A0169|158 162|type
P11113692A0169|165 173|diabetes
P11113692A0169|194 199|years
P11113692A0169|203 206|age
P11113692A0169|208 216|mean age
P11113692A0169|226 240|blood pressure
P11113692A0169|244 249|entry
P11113692A0169|257 262|mm Hg
P11113822A0999|10 19|quadrants
P11113822A0999|36 44|controls
P11113822A0999|90 102|jaw pathoses
P11113823A0197|5 10|cases
P11113823A0197|23 37|chondromatosis
P11114294A0075|9 16|studies
P11114294A0075|54 91|cytokines tumor necrosis factor alpha
P11114294A0075|96 112|interferon gamma
P11114294A0075|124 134|expression
P11114294A0075|149 193|fibrosis transmembrane conductance regulator
P11114294A0075|195 199|CFTR
P11114294A0075|201 205|gene
P11114294A0075|207 211|CFTR
P11114294A0075|216 221|HT-29
P11114294A0075|226 235|T84 cells
P11114521A0282|0 10|Regulation
P11114521A0282|14 18|RhoA
P11114521A0282|43 51|adhesion
P11114521A0282|66 71|cells
P11114521A0282|98 112|cell spreading
P11114521A0282|117 126|migration
P11114718A0349|16 33|mouse fibroblasts
P11114718A0349|56 61|v-Src
P11114718A0349|67 71|mRNA
P11114718A0349|76 90|protein levels
P11114718A0349|94 97|p21
P11114718A0349|99 108|WAF1/CIP1
P11114718A0349|111 120|cyclin D1
P11114718A0349|126 134|cyclin E
P11114924A0808|0 4|ORFA
P11114924A0808|9 13|ccdA
P11114924A0808|65 90|primer extension analysis
P11116084A0000|0 12|Mouse Impact
P11116084A0000|39 43|gene
P11116084A0000|81 88|protein
P11116084A0000|100 108|function
P11116131A0863|6 11|cells
P11116131A0863|21 24|P2Y
P11116131A0863|29 33|mRNA
P11116131A0863|41 48|culture
P11116148A0741|0 20|Coexpression studies
P11116148A0741|35 42|insulin
P11116148A0741|47 50|PKB
P11116148A0741|60 75|transactivation
P11116148A0741|79 88|C/EBPbeta
P11116148A0741|98 108|C/EBPalpha
P11116148A0741|130 153|transactivation domains
P11116148A0741|157 166|C/EBPbeta
P11117263A0570|25 32|species
P11117263A0570|41 56|Ids3 expression
P11117263A0570|91 96|roots
P11117263A0570|100 110|H. vulgare
P11117263A0570|122 129|cereale
P11117263A0570|171 175|acid
P11117263A0570|177 180|DMA
P11117263A0570|201 205|acid
P11117263A0570|207 209|MA
P11117263A0570|236 240|acid
P11117263A0570|242 248|epiHMA
P11117263A0570|250 260|H. vulgare
P11117263A0570|285 289|acid
P11117263A0570|291 294|HMA
P11117263A0570|296 306|S. cereale
P11117523A0650|3 11|contrast
P11117523A0650|18 37|COUP-TFI expression
P11117523A0650|59 74|differentiation
P11117523A0650|78 87|P19 cells
P11117523A0650|101 103|RA
P11117523A0650|118 131|cell cultures
P11117523A0650|140 147|neurons
P11117826A0788|8 11|PET
P11117826A0788|35 47|pretreatment
P11117826A0788|52 72|follow-up evaluation
P11117826A0788|78 81|use
P11117826A0788|98 101|PET
P11117826A0788|111 119|patients
P11117826A0788|143 153|comparison
P11117826A0788|177 181|data
P11117826A0788|207 211|data
P11118062A1691|27 32|model
P11118062A1691|38 50|localization
P11118062A1691|58 66|mutation
P11118062A1691|74 84|K-ras gene
P11118062A1691|112 117|level
P11118062A1691|121 135|aggressiveness
P11118062A1691|156 165|phenotype
P11118438A0411|22 31|isolation
P11118438A0411|35 41|MdPin1
P11118438A0411|45 59|Pin1 homologue
P11118438A0411|69 88|plant species apple
P11118438A0411|90 105|Malus domestica
P11118438A0411|162 183|substrate specificity
P11118438A0411|208 215|juglone
P11118438A0411|236 240|case
P11118438A0411|245 249|Pin1
P11118440T0000|13 24|association
P11118440T0000|28 36|products
P11118440T0000|40 63|alternative transcripts
P11118440T0000|71 102|candidate tumor suppressor ING1
P11118440T0000|112 123|mSin3/HDAC1
P11118440T0000|140 159|corepressor complex
P11118619A0835|16 20|data
P11118619A0835|44 47|TAg
P11118619A0835|52 58|models
P11118619A0835|60 91|host cell transcription factors
P11118619A0835|121 130|infection
P11118619A0835|154 159|event
P11118619A0835|189 203|transformation
P11118712A1296|5 25|sensitivity analysis
P11118712A1296|52 58|limits
P11118712A1296|66 74|accuracy
P11118712A1296|97 101|test
P11118712A1296|117 127|estimation
P11118712A1296|140 155|herd prevalence
P11118712A1296|174 191|confidence limits
P11118712A1296|205 220|within-herd PTB
P11118712A1296|226 236|prevalence
P11118712A1296|254 260|reason
P11118712A1296|278 294|herd specificity
P11118712A1296|299 304|herds
P11118712A1296|323 332|herd size
P11119611A0428|0 6|ORFK10
P11119611A0428|19 26|protein
P11119611A0428|55 62|antigen
P11119611A0428|66 71|LANA2
P11119611A0428|124 131|tissues
P11119611A0428|143 146|PEL
P11119611A0428|151 153|CD
P11119611A0428|162 172|KS lesions
P11120441A1193|17 26|believers
P11120441A1193|70 80|activation
P11120441A1193|105 114|asymmetry
P11120441A1193|129 139|complexity
P11121043A0074|3 10|Xenopus
P11121043A0074|12 16|BMPs
P11121043A0074|34 42|inducers
P11121043A0074|64 74|regulators
P11121043A0074|78 90|neurogenesis
P11121118A0075|22 30|variants
P11121118A0075|49 62|GAF sequences
P11121118A0075|81 87|region
P11121118T0000|8 20|organization
P11121118T0000|34 63|phosphodiesterase PDE11A gene
P11121397A0587|12 20|findings
P11121397A0587|39 52|rib-2 protein
P11121397A0587|66 106|alpha1,4-N-acetylglucosaminyltransferase
P11121397A0587|136 146|initiation
P11121397A0587|151 161|elongation
P11121397A0587|165 180|heparan sulfate
P11121434A0915|0 10|Inhibition
P11121434A0915|18 33|Mek/Erk pathway
P11121434A0915|37 51|Rat1/ras cells
P11121434A0915|63 76|Mek inhibitor
P11121434A0915|78 85|PD98059
P11121434A0915|121 129|recovery
P11121434A0915|170 174|HR12
P11121490A0000|4 42|transcription factor CHOP/GADD153 gene
P11121490A0000|66 72|stress
P11121490A0000|102 111|apoptosis
P11122381A0908|0 8|Addition
P11122381A0908|46 54|peptides
P11122381A0908|86 95|tyrosines
P11122381A0908|105 123|GM-CSF stimulation
P11122381A0908|147 157|activation
P11122381A0908|161 166|STAT5
P11122588A0549|0 21|MAIN OUTCOME MEASURES
P11122588A0549|23 40|Percentage change
P11122588A0549|63 68|index
P11122588A0549|70 73|AHI
P11122588A0549|75 87|apnea events
P11122588A0549|90 105|hypopnea events
P11122588A0549|110 114|hour
P11122588A0549|118 123|sleep
P11122588A0549|129 133|odds
P11122588A0549|167 170|SDB
P11122588A0549|186 189|AHI
P11122588A0549|199 205|events
P11122588A0549|210 214|hour
P11122588A0549|218 223|sleep
P11122588A0549|231 238|respect
P11122588A0549|252 258|weight
P11123054T0000|25 34|syndromes
P11123089A0362|5 12|article
P11123089A0362|28 39|information
P11123089A0362|47 56|frequency
P11123089A0362|58 73|characteristics
P11123089A0362|99 109|mechanisms
P11123089A0362|117 129|vasculitides
P11123089A0362|143 151|patients
P11123089A0362|177 192|tissue diseases
P11123316T0000|0 20|Tec kinase signaling
P11123316T0000|24 31|T cells
P11123316T0000|48 77|phosphatidylinositol 3-kinase
P11123316T0000|86 116|Tec pleckstrin homology domain
P11123701A0442|8 16|evidence
P11123701A0442|26 30|type
P11123701A0442|34 37|DNA
P11123701A0442|77 85|coupling
P11123701A0442|116 126|activities
P11123701A0442|130 139|promoters
P11123701A0442|164 178|DNA constructs
P11123701A0442|198 219|transcription complex
P11123701A0442|260 274|DNA supercoils
P11123701A0442|296 305|diffusion
P11123701A0442|321 331|DNA duplex
P11123912A0306|4 13|structure
P11123912A0306|26 36|SH2 domain
P11123912A0306|70 73|SH2
P11123912A0306|113 120|peptide
P11123912A0306|134 146|polyomavirus
P11123912A0306|154 163|T antigen
P11123912A0306|165 167|MT
P11124024A1098|33 38|sites
P11124024A1098|43 60|protein complexes
P11124024A1098|64 74|palindrome
P11124024A1098|85 91|repeat
P11124024A1098|99 111|C+T sequence
P11124024A1098|138 149|GAGA motifs
P11124024A1098|169 175|strand
P11124902X1337|0 9|Copyright
P11124902X1337|15 29|Academic Press
P11125151T0000|0 19|Nucleotide sequence
P11125151T0000|21 40|genome organization
P11125151T0000|58 66|analysis
P11125151T0000|70 88|pineapple mealybug
P11125151T0000|105 112|virus-2
P11125363A0525|0 8|Patients
P11125363A0525|19 42|pretreatment cystoscopy
P11125363A0525|56 69|tumor mapping
P11125363A0525|96 98|mg
P11125363A0525|101 103|m.
P11125363A0525|105 114|cisplatin
P11125363A0525|118 121|day
P11125363A0525|130 132|gm
P11125363A0525|134 136|m.
P11125363A0525|145 159|5-fluorouracil
P11125363A0525|163 167|days
P11125363A0525|190 202|radiotherapy
P11125411A0857|16 24|patients
P11125411A0857|35 46|laparoscopy
P11125411A0857|109 115|testes
P11125411A0857|132 138|testis
P11125411A0857|155 160|canal
P11125872A0133|5 15|philosophy
P11125872A0133|39 50|compound RP
P11125872A0133|69 86|phosphodiesterase
P11125872A0133|90 99|inhibitor
P11125872A0133|145 153|delivery
P11125872A0133|181 187|routes
P11125872A0133|191 205|administration
P11126275A1068|10 16|levels
P11126275A1068|20 52|anticardiolipin immunoglobulin G
P11126275A1068|68 76|bleeding
P11126353A0582|0 7|RESULTS
P11126353A0582|9 19|Prevalence
P11126353A0582|23 30|obesity
P11126353A0582|32 39|BMI SDS
P11126353A0582|51 52|%
P11126353A0582|56 65|diagnosis
P11126353A0582|86 87|%
P11126353A0582|91 93|3y
P11126806A0206|11 19|sequelae
P11126806A0206|27 54|antiphospholipid-antibodies
P11126806A0206|85 96|circulation
P11127161T0000|0 9|Bupropion
P11127161T0000|17 34|smoking cessation
P11127200A1024|38 42|AP-1
P11127200A1024|59 67|activity
P11127200A1024|71 74|ROS
P11127200A1024|82 87|cells
P11127200A1024|109 135|AP-1 transcription factors
P11127200A1024|145 154|TGF-beta1
P11127200A1024|176 186|expression
P11127200A1024|195 201|alpha1
P11127200A1024|203 218|collagen I gene
P11127200A1024|250 260|expression
P11127200A1024|280 287|hormone
P11127200A1024|289 292|PTH
P11127200A1024|306 313|peptide
P11127200A1024|315 320|PTHrP
P11127200A1024|322 330|receptor
P11127250A1111|0 2|PM
P11127250A1111|12 17|mg/kg
P11127250A1111|40 44|dose
P11127250A1111|48 50|SB
P11127250A1111|58 62|days
P11127250A1111|101 103|SB
P11127250A1111|125 129|cure
P11127250A1111|134 142|patients
P11127250A1111|148 150|VL
P11127250A1111|154 159|Bihar
P11127250A1111|161 166|India
P11127955X0001|9 16|therapy
P11127955X0001|21 33|colon cancer
P11127955X0001|35 42|Surgery
P11127955X0001|81 87|number
P11127955X0001|108 121|colon cancers
P11128312A1238|23 34|differences
P11128312A1238|36 37|p
P11128312A1238|56 64|fracture
P11128312A1238|81 87|groups
P11128312A1238|101 110|femur BMD
P11128312A1238|114 115|%
P11128312A1238|129 132|BMD
P11128312A1238|147 153|radius
P11128312A1238|156 157|%
P11128312A1238|176 185|dimension
P11128312A1238|193 204|radiographs
P11128312A1238|206 209|FD2
P11128312A1238|213 214|%
P11128925A0000|0 10|BACKGROUND
P11128925A0000|16 19|aim
P11128925A0000|28 33|study
P11128925A0000|63 76|interleukin-6
P11128925A0000|78 82|IL-6
P11128925A0000|84 90|levels
P11128925A0000|114 119|fluid
P11128925A0000|121 124|GCF
P11128925A0000|151 159|findings
P11128925A0000|163 171|patients
P11128925A0000|188 197|arthritis
P11128925A0000|199 201|RA
P11128925A0000|213 226|periodontitis
P11128925A0000|228 230|AP
P11129515A0000|30 35|trial
P11129515A0000|40 48|efficacy
P11129515A0000|55 86|Vitex agnus castus L extract Ze
P11129515A0000|114 122|patients
P11129515A0000|142 150|syndrome
P11129515A0000|152 155|PMS
P11129724A0904|0 7|Studies
P11129724A0904|36 42|source
P11129724A0904|46 59|contamination
P11129724A0904|74 78|role
P11129724A0904|100 104|milk
P11129724A0904|112 124|transmission
P11129724A0904|128 132|MRSA
P11129724A0904|136 144|neonates
P11131321T0000|0 7|Effects
P11131321T0000|11 28|Trypanosoma vivax
P11131321T0000|32 41|pregnancy
P11131321T0000|45 58|Yankasa sheep
P11131321T0000|67 74|results
P11131321T0000|78 107|homidum chloride chemotherapy
P11131634A0955|0 10|NF kappa B
P11131634A0955|43 49|extent
P11131634A0955|53 64|roscovitine
P11131634A0955|75 80|cells
P11131634A0955|89 97|Y8 cells
P11132063A0250|13 32|treatment exposures
P11132063A0250|47 57|population
P11132063A0250|95 102|effects
P11132063A0250|112 121|cirrhosis
P11132063A0250|135 146|hepatitis C
P11132063A0250|183 197|cardiomyopathy
P11132063A0250|221 228|effects
P11132063A0250|248 259|dysfunction
P11132148A0162|4 12|presence
P11132148A0162|31 39|residues
P11132148A0162|62 77|promoter region
P11132148A0162|113 122|HLA class
P11132148A0162|125 129|loci
P11132195A0000|12 18|number
P11132195A0000|22 32|parameters
P11132195A0000|47 62|Volterra series
P11132195A0000|91 97|length
P11132195A0000|105 111|memory
P11132195A0000|120 125|order
P11132195A0000|133 145|nonlinearity
P11132195A0000|147 154|methods
P11132195A0000|177 183|models
P11132195A0000|189 201|measurements
P11132195A0000|205 222|input/output data
P11132195A0000|248 255|systems
P11132195A0000|278 286|memories
P11132790A0609|13 19|method
P11132790A0609|50 55|score
P11132790A0609|63 66|S-B
P11132790A0609|79 87|subtests
P11132790A0609|99 104|score
P11132790A0609|180 193|risk children
P11133741A0617|0 4|NiCl
P11133741A0617|16 31|MCP-1 synthesis
P11133741A0617|41 51|activation
P11133741A0617|55 64|NF-kappaB
P11133741A0617|71 79|mutation
P11133741A0617|101 106|sites
P11133741A0617|114 122|promoter
P11133741A0617|144 148|loss
P11133741A0617|162 179|promoter activity
P11133830A0174|0 10|Engagement
P11133830A0174|20 23|CD2
P11133830A0174|37 42|pairs
P11133830A0174|55 58|mAb
P11133830A0174|67 91|tyrosine phosphorylation
P11133830A0174|97 103|number
P11133830A0174|121 129|proteins
P11133830A0174|146 164|kDa phosphoprotein
P11133830A0174|189 209|proto-oncogene c-Cbl
P11133927T0000|0 8|Validity
P11133927T0000|12 28|NIR spectroscopy
P11133927T0000|58 64|muscle
P11133927T0000|85 89|rate
P11133927T0000|93 101|exercise
P11133986A0350|9 16|studies
P11133986A0350|58 79|transcription factors
P11133986A0350|90 94|PU.1
P11133986A0350|99 123|PU.1 interaction partner
P11133986A0350|125 128|PIP
P11133986A0350|130 138|function
P11133986A0350|160 165|c-Fos
P11133986A0350|171 176|c-Jun
P11133986A0350|194 201|kappaE3
P11133986A0350|203 211|enhancer
P11133986A0350|215 224|3T3 cells
P11134033A0000|11 22|int-6 locus
P11134033A0000|49 65|integration site
P11134033A0000|69 74|mouse
P11134033A0000|83 96|tumor viruses
P11134033A0000|117 130|eIF3e subunit
P11134033A0000|134 168|translation initiation factor eIF3
P11134033A0639|3 16|int6 deletion
P11134033A0639|18 27|int6Delta
P11134033A0639|29 35|mutant
P11134033A0639|74 80|medium
P11134351A1405|14 20|MIP-2A
P11134351A1405|33 44|cell growth
P11134351A1405|56 60|role
P11134351A1405|64 69|MBP-1
P11134508A0317|23 29|plants
P11134508A0317|55 69|Arabidopsis HD
P11134508A0317|71 76|AtHD1
P11134508A0317|78 82|gene
P11134822A0629|12 13|P
P11134822A0629|29 49|accelerations/30 min
P11137296A0923|5 35|transcription initiation sites
P11137296A0923|72 75|RNA
P11137296A0923|98 111|amplification
P11137296A0923|115 124|cDNA ends
P11137296A0923|126 134|RLM-RACE
P11137296A0923|156 158|bp
P11137296A0923|168 196|translation initiation codon
P11137296A0923|205 231|transcription-PCR analysis
P11137296A0923|246 251|PFK-A
P11137296A0923|253 258|PFK-B
P11137296A0923|263 274|PFK-C genes
P11137296A0923|298 311|mouse tissues
P11137296A0923|331 337|levels
P11137296A1216|0 10|PFK-A mRNA
P11137296A1216|48 55|tissues
P11137296A1216|70 75|PFK-B
P11137296A1216|80 91|PFK-C genes
P11137367A0297|12 31|Toshiba IIDR system
P11137367A0297|57 72|X-ray TV system
P11137367A0297|87 92|image
P11137367A0297|102 109|circuit
P11137551A0437|9 16|sardine
P11137551A0437|25 29|acid
P11137551A0437|46 52|levels
P11137551A0437|88 93|limit
P11138009A1032|3 11|addition
P11138009A1032|31 40|mutations
P11138009A1032|42 53|Delta M1281
P11138009A1032|58 63|IVS51
P11138009A1032|65 66|G
P11138009A1032|84 96|USH1 patient
P11138231T0000|0 7|Closeup
P11138231T0000|11 19|resource
P11138231T0000|24 30|nurses
P11138694A0000|1 4|18F
P11138694A0000|11 33|fluorobenzyltrozamicol
P11138694A0000|35 38|FBT
P11138694A0000|82 107|acetylcholine transporter
P11138694A0000|139 145|neuron
P11138694A0000|188 194|ligand
P11138694A0000|203 208|study
P11138694A0000|233 240|density
P11138694A0000|254 261|ganglia
P11138694A0000|267 270|PET
P11139148A0421|24 31|protein
P11139148A0421|44 53|homologue
P11139148A0421|57 62|SAF-A
P11139148A0421|107 111|MARs
P11139148A0421|153 161|activity
P11139148A0421|185 194|fractions
P11139336A0257|14 26|associations
P11139336A0257|37 52|INCENP behavior
P11139336A0257|60 67|mitosis
P11139469A0402|0 6|Ang II
P11139469A0402|29 52|Ang2 mRNA accumulations
P11139469A0402|71 75|Ang1
P11139469A0402|79 94|Tie2 expression
P11139469A0402|119 146|protein kinase C inhibitors
P11139469A0402|168 170|Ca
P11139469A0402|185 191|agents
P11139473A0696|0 17|Promoter analysis
P11139473A0696|40 48|sequence
P11139473A0696|62 71|consensus
P11139473A0696|88 95|element
P11139473A0696|97 100|CRE
P11139473A0696|125 139|SMemb promoter
P11139473A0696|157 175|Hex responsiveness
P11139567A1440|0 25|LH/CG receptor activation
P11139567A1440|29 33|ARNO
P11139567A1440|53 63|activation
P11139567A1440|67 96|phosphatidylinositol 3-kinase
P11139567A1440|98 109|PI 3-kinase
P11139567A1440|117 146|G protein beta gamma subunits
P11139605A0811|0 17|Deletion analysis
P11139605A0811|43 51|sequence
P11139605A0811|93 110|promoter activity
P11139605A0811|115 130|auto-activation
P11139605A0811|151 172|mobility shift assays
P11139605A0811|188 199|interaction
P11139605A0811|203 209|C/EBPs
P11139605A0811|214 217|Sp1
P11139605A0811|226 232|region
P11139974A0762|0 11|Termination
P11139974A0762|23 25|VT
P11139974A0762|39 46|attempt
P11139974A0762|67 76|BV pacing
P11139974A0762|82 83|%
P11139974A0762|92 101|RV pacing
P11139974A0762|107 108|%
P11140472A0497|15 22|results
P11140472A0497|31 40|algorithm
P11140472A0497|50 57|results
P11140472A0497|82 92|algorithms
P11140472A0497|106 115|algorithm
P11140472A0497|120 131|monochannel
P11140472A0497|147 152|noise
P11140472A0497|169 178|algorithm
P11140472A0497|205 210|noise
P11140472A0497|237 254|cases improvement
P11141003T0000|0 7|Changes
P11141003T0000|11 29|stimulation levels
P11141003T0000|35 39|time
P11141003T0000|43 50|nucleus
P11141003T0000|54 62|cochlear
P11141003T0000|71 76|users
P11142380A0389|0 8|Nuclease
P11142380A0389|40 51|mutagenesis
P11142380A0389|77 79|TE
P11142380A0389|81 86|TE105
P11142380A0389|116 125|structure
P11142380A0389|142 149|helices
P11142380A0389|179 186|regions
P11143384A0267|0 9|Tele-Talk
P11143384A0267|24 34|capability
P11143384A0267|38 47|operating
P11143384A0267|56 77|conference situations
P11143384A0267|84 100|microphone input
P11145562A0000|9 17|decrease
P11145562A0000|25 29|type
P11145562A0000|45 58|growth factor
P11145562A0000|60 63|IGF
P11145562A0000|65 73|receptor
P11145562A0000|75 81|IGF-IR
P11145562A0000|93 101|prostate
P11145562A0000|113 118|cells
P11145562A0000|126 140|transformation
P11145562A0000|175 180|state
P11145562A0468|4 17|P69 cell line
P11145562A0468|33 48|immortalization
P11145562A0468|66 74|prostate
P11145562A0468|86 91|cells
P11145562A0468|113 122|T antigen
P11145563A0202|32 45|StAR promoter
P11145563A0202|63 69|sterol
P11145563A0202|97 105|proteins
P11145563A0202|107 113|SREBPs
P11145563A0303|0 10|Expression
P11145563A0303|14 22|SREBP-1a
P11145563A0303|34 56|StAR promoter activity
P11145563A0303|64 71|context
P11145563A0303|75 86|COS-1 cells
P11145563A0303|97 119|granulosa-lutein cells
P11145566A0000|25 45|lipoprotein receptor
P11145566A0000|47 52|HDL-R
P11145566A0000|63 70|element
P11145566A0000|74 97|cholesterol homeostasis
P11145566A0000|126 132|target
P11145566A0000|158 163|drugs
P11145566A0000|168 181|understanding
P11145566A0000|185 201|HDL-R regulation
P11145571A0788|15 28|gene factor-3
P11145571A0788|33 49|STAT1 homodimers
P11145571A0788|85 101|response element
P11145571A0788|103 107|ISRE
P11145571A0788|129 137|sequence
P11145571A0788|139 142|GAS
P11145571A0788|144 151|element
P11145590A0217|40 50|mechanisms
P11145590A0217|54 70|TGF-beta1 action
P11145590A0217|74 87|thyroglobulin
P11145590A0217|89 91|TG
P11145590A0217|93 108|gene expression
P11145590A0217|125 134|attention
P11145590A0217|138 158|TGF-beta1 regulation
P11145590A0217|179 200|transcription factors
P11145717A0936|22 28|lysine
P11145717A0936|30 31|K
P11145717A0936|56 68|TPO fragment
P11145717A0936|89 99|sequencing
P11145717A0936|117 121|K713
P11145743A0170|28 38|regulation
P11145743A0170|48 53|genes
P11145743A0170|57 70|thyroid cells
P11145743A0170|76 82|effect
P11145743A0170|86 114|thyroid transcription factor
P11145743A0170|118 123|TTF-1
P11145743A0170|158 165|protein
P11145743A0170|169 174|Pax-8
P11145743A0170|199 207|activity
P11145743A0170|215 235|deiodinase promoters
P11145813A0668|0 19|Regional blood blow
P11145813A0668|36 41|means
P11145813A0668|45 57|microspheres
P11145813A0668|72 79|regions
P11145813A0668|87 89|C6
P11145813A0668|91 94|T11
P11145813A0668|100 112|L6 vertebrae
P11145887A1393|0 10|Activation
P11145887A1393|14 27|transcription
P11145887A1393|40 49|AP-1 site
P11145887A1393|53 65|Jurkat cells
P11145887A1393|69 73|JunD
P11145887A1393|81 86|Fra-2
P11145887A1393|97 102|c-Jun
P11145887A1393|104 108|JunB
P11145887A1393|114 130|c-Fos activation
P11145887A1393|157 162|level
P11145887A1393|193 196|Tax
P11145955A0189|4 13|mechanism
P11145955A0189|34 57|estrogen receptor alpha
P11145955A0189|59 66|ERalpha
P11145955A0189|78 88|activation
P11145955A0189|92 107|gene expression
P11145955A0189|120 123|SRE
P11145955A0189|153 161|analysis
P11145955A0189|169 177|promoter
P11145955A0189|179 187|analysis
P11145955A0189|209 223|protein kinase
P11145955A0189|225 229|MAPK
P11145955A0189|231 249|pathway activation
P11145955A0189|253 255|E2
P11145955A0189|274 293|growth factor alpha
P11145955A0189|295 304|TGF-alpha
P11145955A0189|320 327|control
P11146961T0000|0 19|Perfusion technique
P11146961T0000|59 72|artery bypass
P11146961T0000|74 80|PADCAB
P11148042A1258|9 17|mixtures
P11148042A1258|22 24|LA
P11148042A1258|46 55|chain PEs
P11148042A1258|90 100|variations
P11148042A1258|113 134|peptide immiscibility
P11148042A1258|146 164|gel state bilayers
P11148589A1124|0 11|CONCLUSIONS
P11148589A1124|27 49|immunization practices
P11148589A1124|55 62|authors
P11148589A1124|101 126|Pacific Islander children
P11148589A1124|141 160|United States today
P11148589A1124|187 190|HBV
P11148589A1124|198 204|future
P11148589A1124|233 255|liver carcinoma deaths
P11149472A1257|12 34|NP/NMP4/CIZ expression
P11149472A1257|38 48|osteocytes
P11149472A1257|50 61|osteoblasts
P11149472A1257|67 79|chondrocytes
P11149472A1257|83 91|rat bone
P11150114T0000|0 9|Chlamydia
P11150114T0000|23 29|cancer
P11150114T0000|38 49|association
P11150315A0226|8 16|approach
P11150315A0226|47 78|transcription factor activities
P11150315A0226|133 142|signaling
P11150315A0226|157 179|oligonucleotide clones
P11150315A0226|187 210|DNA recognition library
P11150315A0226|231 251|DNA binding proteins
P11150315A0226|257 261|PC12
P11150315A0226|270 278|extracts
P11150315A0844|0 3|NGF
P11150315A0844|41 60|ERK phosphorylation
P11150315A0844|66 69|EGF
P11150315A0844|96 103|reports
P11150315A1126|0 3|NGF
P11150315A1126|13 16|EGF
P11150315A1126|37 42|bands
P11150315A1126|76 81|Fra-2
P11150439A0701|0 18|Energy expenditure
P11150439A0701|55 63|infusion
P11150439A0701|67 70|NaH
P11150439A0701|74 76|CO
P11150439A0701|82 88|breath
P11150439A0701|93 95|CO
P11150439A0701|99 123|enrichment determination
P11150439A0701|127 158|isotope ratio mass spectroscopy
P11150439A0701|168 179|application
P11150439A0701|194 213|regression equation
P11151826T0000|0 8|Workload
P11151826T0000|10 14|UAPs
P11152070A0573|4 13|actA gene
P11152070A0573|37 41|copy
P11152070A0573|49 55|genome
P11152070A0573|59 73|A. chrysogenum
P11152070A0573|83 99|expression level
P11152070A0573|113 117|pcbC
P11152070A0573|122 141|cefEF cephalosporin
P11152070A0573|155 160|genes
P11152070A0573|180 206|cephalosporin fermentation
P11152070A0573|232 242|transcript
P11152081A0413|10 20|mmol SDS/l
P11152081A0413|38 48|inhibition
P11152081A0413|52 65|acidification
P11152081A0413|67 87|metal solubilization
P11152081A0413|92 108|sulfur oxidation
P11152283A0223|25 29|role
P11152283A0223|33 36|NGF
P11152283A0223|51 69|gene transcription
P11152283A0223|73 77|PC12
P11152283A0223|82 93|INS-1 cells
P11152283A0223|98 103|order
P11152283A0223|141 146|genes
P11152344A0416|5 12|animals
P11152344A0416|31 38|animals
P11152344A0416|51 58|animals
P11152344A0416|76 90|arachnoid scar
P11152344A0416|94 99|C1-C2
P11152344A0416|123 132|placement
P11152344A0416|159 165|sponge
P11152344A0416|183 190|surface
P11152344A0416|205 209|cord
P11152451A0529|4 33|Schistosoma mansoni homologue
P11152451A0529|35 42|SmSmad2
P11152451A0529|65 73|bacteria
P11152451A0529|79 102|Sj26-GST fusion protein
P11152451A0529|130 140|antibodies
P11152451A1580|6 10|data
P11152451A1580|29 36|SmSmad2
P11152451A1580|53 69|TGF-beta signals
P11152451A1580|73 84|interaction
P11152451A1580|90 100|receptor I
P11152451A1580|162 169|nucleus
P11152451A1580|193 218|target gene transcription
P11152451A1580|254 269|TGF-beta effect
P11152521A0181|19 35|protein products
P11152521A0181|76 94|expression vectors
P11152521A0181|109 128|ORF40/41 transcript
P11152521A0181|157 166|component
P11152521A0181|202 208|intron
P11152963A0000|0 10|Expression
P11152963A0000|18 30|src homology
P11152963A0000|34 37|SH3
P11152963A0000|74 84|astrocytes
P11152963A0000|86 90|SETA
P11152963A0000|92 96|gene
P11152963A0000|116 140|astrocyte transformation
P11152963A0000|144 151|culture
P11152963A0000|156 162|tumors
P11152963A0000|176 181|brain
P11153302A0000|0 24|Naltrexone hydrochloride
P11153302A0000|40 66|opioid receptor antagonist
P11153302A0000|84 91|efforts
P11153302A0000|116 130|detoxification
P11154491A0322|0 7|METHODS
P11154491A0322|42 50|patients
P11154491A0322|57 60|age
P11154491A0322|64 69|years
P11154491A0322|93 99|masses
P11154491A0322|113 115|CT
P11154491A0322|127 134|EUS-FNA
P11154491A0322|159 172|echoendoscope
P11154491A0322|186 193|needles
P11155096A0222|0 7|METHODS
P11155096A0222|9 23|Thyroid status
P11155096A0222|40 48|baseline
P11155096A0222|68 78|assessment
P11155096A0222|82 98|serum antibodies
P11155096A0222|102 120|thyroid peroxidase
P11155096A0222|122 129|TPO-Abs
P11155096A0222|145 150|IU/ml
P11155096A0222|153 169|serum TSH levels
P11155096A0222|180 183|TSH
P11155096A0222|211 215|mU/l
P11155096A0222|218 239|serum thyroxin levels
P11155096A0222|241 243|T4
P11156303A1098|34 42|shunting
P11156303A1098|81 92|alternative
P11156303A1098|107 115|drainage
P11156303A1098|119 127|children
P11156303A1098|149 158|adhesions
P11156303A1098|169 176|history
P11156303A1098|198 207|infection
P11156413T0000|0 10|Derivation
P11156413T0000|23 39|characterization
P11156413T0000|45 50|mouse
P11156413T0000|59 74|tumor cell line
P11156413T0000|88 100|polyomavirus
P11156413T0000|108 117|T antigen
P11156413T0000|119 126|utility
P11156413T0000|134 145|development
P11156413T0000|155 174|cancer therapeutics
P11156484A0223|0 12|TBARS levels
P11156484A0223|39 53|capacity assay
P11156484A0223|58 69|AFR release
P11156484A0223|82 90|electron
P11156484A0223|104 113|resonance
P11156484A0223|115 118|EPR
P11156484A0223|145 154|existence
P11156484A0223|168 174|stress
P11156484A0223|178 186|diabetes
P11156618T0000|11 21|comparison
P11156618T0000|35 49|mouse SCL loci
P11156618T0000|61 68|regions
P11156618T0000|72 83|sensitivity
P11156618T0000|87 112|restriction endonucleases
P11156618T0000|139 144|peaks
P11156618T0000|168 177|sequences
P11156789A1669|20 31|observation
P11156789A1669|48 54|causes
P11156789A1669|73 86|CSF pulsation
P11156789A1669|90 98|children
P11156789A1669|108 123|motion artifact
P11156789A1669|125 132|changes
P11156789A1669|145 165|oxygen concentration
P11156789A1669|179 187|propofol
P11156789A1669|219 225|oxygen
P11156789A1669|252 259|changes
P11156789A1669|263 281|CSF protein levels
P11156789A1669|293 309|propofol binding
P11156789A1669|313 321|proteins
P11156789A1669|326 332|uptake
P11156789A1669|338 341|CSF
P11157035A1405|4 13|utilities
P11157035A1405|30 35|study
P11157035A1405|79 93|determinations
P11157035A1405|106 112|trials
P11157035A1405|125 137|IFN alpha-2b
P11157035A1405|157 164|benefit
P11157035A1405|168 175|therapy
P11157334A1107|0 9|Serum PTH
P11157334A1107|36 44|WL group
P11157334A1107|60 68|WM group
P11157334A1107|70 71|P
P11157763T0000|0 9|Structure
P11157763T0000|17 30|EMAPII domain
P11157763T0000|40 73|aminoacyl-tRNA synthetase complex
P11157763T0000|95 108|dimer mimicry
P11157774A0789|12 25|dSLBP alleles
P11157774A0789|42 53|development
P11157774A0789|71 80|sterility
P11157784A0141|14 24|DGCR6 gene
P11157784A0141|28 44|chromosome 22q11
P11157784A0141|58 69|copy repeat
P11157784A0141|78 82|sc11
P11157784A0141|111 115|copy
P11157784A0141|123 127|gene
P11157784A0141|129 135|DGCR6L
P11157784A0141|158 163|locus
P11157784A0141|172 176|sc11
P11157784A0141|178 180|b.
P11157879A0192|0 7|METHODS
P11157879A0192|13 20|passive
P11157879A0192|32 41|transport
P11157879A0192|45 56|fluorescein
P11157879A0192|69 72|BRB
P11157879A0192|101 112|fluorometry
P11158236A0000|0 19|Nerve growth factor
P11158236A0000|21 24|NGF
P11158236A0000|39 43|acid
P11158236A0000|45 47|RA
P11158236A0000|65 72|actions
P11158236A0000|76 86|PC12 cells
P11158288T0000|0 11|Recruitment
P11158288T0000|18 32|RNA polymerase
P11158288T0000|36 43|complex
P11158288T0000|76 93|activation domain
P11158288T0000|97 101|CREB
P11158288T0000|120 140|CREB phosphorylation
P11158290A0728|4 10|region
P11158290A0728|27 34|serines
P11158290A0728|67 82|destruction box
P11158290A0728|86 98|IkappaBalpha
P11158290A0728|101 105|beta
P11158290A0728|112 119|epsilon
P11158295A0158|5 13|function
P11158295A0158|36 49|kinase domain
P11158295A0158|53 56|Csk
P11158295A0158|71 83|Src homology
P11158295A0158|87 90|SH3
P11158295A0158|96 107|SH2 regions
P11158310A0993|28 32|ERSF
P11158310A0993|43 47|NF-Y
P11158310A0993|52 61|ATF6alpha
P11158310A0993|69 73|beta
P11158310A0993|100 104|ERSE
P11158310A0993|140 143|UPR
P11158324A1073|13 23|phenotypes
P11158324A1073|60 70|disruption
P11158324A1073|91 112|lipoprotein secretion
P11158324A1073|130 140|expression
P11158324A1073|144 149|genes
P11158324A1073|159 175|apolipoprotein B
P11158324A1073|191 220|triglyceride transfer protein
P11158324A1073|230 238|increase
P11158324A1073|250 268|cholesterol uptake
P11158324A1073|286 296|expression
P11158324A1073|323 343|lipoprotein receptor
P11158324A1073|345 366|scavenger receptor BI
P11158324A1073|380 388|decrease
P11158324A1073|392 408|bile acid uptake
P11158324A1073|416 421|liver
P11158324A1073|429 444|down-regulation
P11158324A1073|470 534|bile acid transporters sodium taurocholate cotransporter protein
P11158324A1073|547 572|anion transporter protein
P11158326A1032|6 13|effects
P11158326A1032|33 38|SHIP2
P11158326A1032|52 60|mutation
P11158326A1032|68 78|SH2 domain
P11158326A1032|80 84|R47G
P11158337A0000|39 49|expression
P11158337A0000|57 70|GnRH receptor
P11158337A0000|72 78|GnRH-R
P11158337A0000|80 84|gene
P11158337A0000|110 131|transcription factors
P11158337A0000|168 174|GnRH-R
P11158337A0000|186 194|sequence
P11158337A0000|196 200|GRAS
P11158337A0000|207 226|activator protein-1
P11158337A0000|228 232|AP-1
P11158337A0000|234 241|element
P11158337A0000|265 273|factor-1
P11158337A0000|275 279|SF-1
P11158337A0000|281 293|binding site
P11158456A0223|0 7|METHODS
P11158456A0223|22 31|interview
P11158456A0223|54 58|time
P11158456A0223|70 82|consultation
P11158456A0223|108 117|intervals
P11158456A0223|128 132|type
P11158456A0223|136 139|BHS
P11158456A0223|141 150|frequency
P11158456A0223|154 160|spells
P11158456A0223|173 183|phenomenon
P11158456A0223|185 193|sequelae
P11158456A0223|195 209|family history
P11158456A0223|215 218|age
P11158456A0223|222 233|termination
P11158456A0223|237 243|spells
P11159081A1155|9 14|cases
P11159081A1155|20 21|%
P11159081A1155|28 38|MR imaging
P11159081A1155|84 89|tumor
P11159081A1155|107 113|seroma
P11159081A1155|117 127|reexcision
P11159363A1251|0 11|Methylation
P11159363A1251|20 37|cytosine residues
P11159363A1251|45 56|E2F element
P11159363A1251|59 60|m
P11159363A1251|61 63|CG
P11159363A1251|64 65|m
P11159363A1251|66 68|CG
P11159363A1251|122 129|complex
P11160096A1067|6 15|mutations
P11160096A1067|44 59|fliF background
P11160096A1067|75 84|phenotype
P11160280A1275|27 37|expression
P11160280A1275|41 46|IRF-1
P11160280A1275|55 62|binding
P11160280A1275|70 81|IRF element
P11160307A0394|5 13|molecule
P11160307A0394|15 24|wH22xeGFP
P11160307A0394|74 81|mAb H22
P11160307A0394|87 91|eGFP
P11160307A0394|128 131|end
P11160307A0394|140 150|CH3 domain
P11160307A0394|152 161|wH22xeGFP
P11160307A0394|194 200|region
P11160307A0394|208 214|Fc end
P11160307A0394|254 260|region
P11160307A0394|268 271|Fab
P11160307A0394|300 309|FcgammaRI
P11160656A0000|0 10|Inactivity
P11160656A0000|24 39|cytomegalovirus
P11160656A0000|41 45|HCMV
P11160656A0000|80 86|region
P11160656A0000|88 93|MIERR
P11160656A0000|117 125|promoter
P11160656A0000|127 135|enhancer
P11160656A0000|144 150|region
P11160656A0000|156 165|modulator
P11160656A0000|180 184|lack
P11160656A0000|188 204|HCMV replication
P11160656A0000|226 231|cells
P11160656A0000|259 269|cell types
P11160656A0000|297 313|NTera2 carcinoma
P11160656A0000|315 318|NT2
P11160656A0000|320 325|cells
P11160683A1220|5 16|interaction
P11160683A1220|38 57|C/EBP dimer binding
P11160683A1220|70 80|C/EBP site
P11160683A1220|99 117|CREB-1 recruitment
P11160683A1220|121 135|ATF/CREB sites
P11160683A1220|161 165|CREB
P11160688A1726|14 20|events
P11160688A1726|47 56|structure
P11160688A1726|71 80|cyclin D3
P11160688A1726|91 104|translocation
P11160688A1726|108 112|ICP0
P11160688A1726|120 129|cytoplasm
P11160721A0932|10 23|transfections
P11160721A0932|45 53|mutation
P11160721A0932|55 59|556M
P11160721A0932|71 93|TBLV enhancer activity
P11160721A0932|128 140|T-cell lines
P11160732A0464|0 13|Vector stocks
P11160732A0464|25 42|envelope proteins
P11160732A0464|64 77|SIVmac clones
P11160732A0464|87 96|SIVmac239
P11160732A0464|98 117|T-lymphocyte tropic
P11160732A0464|131 140|SIVmac316
P11160732A0464|142 159|macrophage tropic
P11160732A0464|177 187|SIVmac1A11
P11160732A1199|13 24|PCR studies
P11160732A1199|40 49|synthesis
P11160732A1199|54 63|transport
P11160732A1199|67 77|vector DNA
P11160732A1199|87 94|nucleus
P11160732A1199|112 123|macrophages
P11160732A1199|142 147|clone
P11160732A1199|160 171|pseudotypes
P11160732A1199|193 204|restriction
P11160732A1199|209 228|SIVmac239 infection
P11160732A1199|246 259|transcription
P11160732A1199|272 278|import
P11160732A1199|288 291|DNA
P11160738A1414|26 35|functions
P11160738A1414|39 45|vIRF-2
P11160738A1414|68 81|establishment
P11160738A1414|105 114|infection
P11160742A0696|5 6|Z
P11160742A0696|11 23|R expression
P11160742A0696|36 50|PML dispersion
P11160742A0696|67 72|cells
P11160860A0662|19 27|activity
P11160860A0662|31 45|IkappaB kinase
P11160860A0662|47 55|IKK-beta
P11160860A0662|83 87|role
P11160860A0662|91 111|NF-kappaB activation
P11160860A0662|120 143|IkappaB phosphorylation
P11160860A0662|188 193|cells
P11160860A0662|207 235|IkappaBalpha phosphorylation
P11160896A0713|0 26|Immunofluorescence studies
P11160896A0713|30 44|C2C12 myotubes
P11160896A0713|55 60|Smad2
P11160896A0713|65 82|MEF2A co-localise
P11160896A0713|90 97|nucleus
P11160896A0713|114 122|myotubes
P11160896A0713|130 145|differentiation
P11160902A0962|16 20|TFOs
P11160902A0962|45 54|potential
P11160902A0962|84 94|expression
P11160902A0962|98 125|c-sis/PDGF-B proto-oncogene
P11160902A0962|148 156|settings
P11160902A0962|176 186|expression
P11160902A0962|195 199|gene
P11160929T0000|6 15|evolution
P11160929T0000|35 39|site
P11160929T0000|43 52|LAGLIDADG
P11160929T0000|60 73|endonucleases
P11161455A1286|0 22|Southern blot analysis
P11161455A1286|34 37|DNA
P11161455A1286|51 63|cell hybrids
P11161455A1286|101 110|cDNA maps
P11161455A1286|114 124|chromosome
P11161720X1294|0 9|Copyright
P11161720X1294|15 29|Academic Press
P11161793A1033|4 12|presence
P11161793A1033|26 43|receptor isoforms
P11161793A1033|55 62|species
P11161793A1033|83 91|proteins
P11161793A1033|122 127|roles
P11161793A1033|142 155|EGFR activity
P11161816A0851|19 31|similarities
P11161816A0851|41 60|endophilin proteins
P11161816A0851|78 86|sequence
P11161816A0851|94 107|SH3GLB family
P11161816A0851|129 133|fold
P11161816A0851|158 162|mode
P11161816A0851|166 172|action
P11162278A0629|7 15|rotation
P11162278A0629|26 33|figures
P11162278A0629|45 55|activation
P11162278A0629|86 92|lobule
P11162278A0629|122 127|gyrus
P11162576A0213|21 35|identification
P11162576A0213|59 70|alternative
P11162576A0213|77 82|exons
P11162576A0213|99 107|promoter
P11162576A0213|121 131|PDE5A gene
P11162666A0442|4 31|glucose/insulin stimulation
P11162666A0442|53 61|addition
P11162666A0442|87 92|acids
P11162936A2727|15 26|development
P11162936A2727|30 37|ligands
P11162936A2727|65 74|estrogens
P11162936A2727|78 91|antiestrogens
P11162936A2727|96 103|ERalpha
P11162936A2727|107 113|ERbeta
P11162936A2727|137 155|tissue selectivity
P11162936A2727|165 171|agents
P11162936A2727|187 214|hormone replacement therapy
P11162936A2727|223 232|treatment
P11162936A2727|237 247|prevention
P11162936A2727|251 264|breast cancer
P11163932A0000|12 17|tests
P11163932A0000|27 35|specimen
P11163932A0000|43 78|roman garden snail Helix pomatia L.
P11163932A0000|97 102|order
P11163932A0000|126 143|thermopreferendum
P11163932A0000|152 161|pulmonate
P11163932A0000|192 203|temperature
P11163932A0000|211 221|substratum
P11163932A0000|234 249|air temperature
P11163968A0152|15 19|work
P11163968A0152|34 50|genome sequences
P11163968A0152|54 75|Pyrococcus horikoshii
P11163968A0152|80 97|Pyrococcus abyssi
P11163968A0152|103 110|species
P11163968A0152|116 121|genus
P11163968A0152|143 151|archaeon
P11163968A0152|153 168|archaebacterium
P11163968A0152|201 221|genome polymorphisms
P11163968A0152|234 272|restriction-modification gene homologs
P11164078A0833|5 17|animal model
P11164078A0833|21 29|dystonia
P11164078A0833|46 51|model
P11164078A0833|55 58|NAD
P11164078A0833|62 65|man
P11164078A0833|75 84|viewpoint
P11164078A0833|88 106|treatment-response
P11166478T0000|33 48|antinociception
P11166478T0000|54 59|mouse
P11166478T0000|69 79|pain model
P11166863A0167|14 15|%
P11166863A0167|20 24|% CI
P11166863A0167|31 32|%
P11166863A0167|34 42|patients
P11166863A0167|61 66|grade
P11166863A0167|75 83|toxicity
P11166863A0167|85 89|RTOG
P11167019A1249|4 8|TATA
P11167019A1249|10 15|motif
P11167019A1249|47 56|GABPalpha
P11167019A1249|60 95|ATPsynCF6 transcription start sites
P11167111A0957|21 45|lung function parameters
P11167111A0957|73 83|recipients
P11167111A0957|87 90|LPD
P11167111A0957|101 107|grafts
P11167111A0957|110 115|weeks
P11167111A0957|122 124|TX
P11167778T0000|9 32|antithrombin deficiency
P11167778T0000|36 42|sepsis
P11168366A0569|3 11|addition
P11168366A0569|40 48|fragment
P11168366A0569|79 88|sequences
P11168366A0569|102 110|GGT mRNA
P11168366A0569|114 125|HepG2 cells
P11168422A0248|7 13|Nature
P11168422A0248|50 69|metal fluoride ions
P11168422A0248|79 88|phosphate
P11168422A0248|112 117|sites
P11168422A0248|125 137|iron protein
P11168422A0248|139 142|Kp2
P11168446T0000|10 34|erythropoietin synthesis
P11168446T0000|38 46|patients
P11168446T0000|65 78|heart failure
P11168446T0000|93 104|alterations
P11168446T0000|114 127|haemodynamics
P11168588T0000|0 10|Expression
P11168588T0000|14 39|herpes simplex virus type
P11168588T0000|42 45|US3
P11168588T0000|58 75|Cdc42/Rac pathway
P11168588T0000|91 96|c-Jun
P11168588T0000|108 125|kinase activation
P11169080T0000|13 22|education
P11169080T0000|41 50|ignorance
P11169080T0000|52 55|Bok
P11169080T0000|58 61|Law
P11169113A0555|21 25|role
P11169113A0555|29 32|p16
P11169113A0555|38 50|phi29 mutant
P11169113A0555|77 85|mutation
P11169113A0555|89 93|gene
P11169149A0097|19 28|knowledge
P11169149A0097|30 35|SNTCS
P11170476A1546|18 27|stability
P11170476A1546|31 38|peptide
P11170476A1546|40 54|gp96 complexes
P11170476A1546|63 73|plasticity
P11170476A1546|97 103|pocket
P11170476A1546|125 130|relay
P11170476A1546|142 150|peptides
P11170476A1546|154 157|MHC
P11170476A1546|171 180|molecules
P11170476A1546|195 206|recognition
P11171118A0836|14 21|binding
P11171118A0836|25 29|NF-1
P11171118A0836|33 38|PSE-B
P11171118A0836|51 56|PSE-A
P11171118A0836|75 86|competition
P11171118A0836|102 114|interactions
P11171118A0836|124 141|NF-1 DNA elements
P11171118A0836|146 156|antibodies
P11171320A0894|0 12|Coexpression
P11171320A0894|20 24|p120
P11171320A0894|25 28|ctn
P11171320A0894|30 37|protein
P11171320A0894|57 65|deletion
P11171320A0894|99 129|tyrosine phosphorylation sites
P11171320A0894|138 145|protein
P11171320A0894|160 183|amino acid substitution
P11171320A0894|185 193|tyrosine
P11171320A0894|204 217|phenylalanine
P11171320A0894|234 242|increase
P11171320A0894|250 261|aggregation
P11171320A0894|283 285|EL
P11171320A0894|290 304|EalphaCL cells
P11172610A0508|13 16|p73
P11172610A0508|49 55|number
P11172610A0508|78 87|promoters
P11172944A0548|0 7|RESULTS
P11172944A0548|19 27|patients
P11172944A0548|35 40|Grade
P11172944A0548|43 54|pneumonitis
P11172944A0548|67 72|Grade
P11172944A0548|75 86|pneumonitis
P11172944A0826|3 11|contrast
P11172944A0826|45 56|correlation
P11172944A0826|65 80|plasma TNFalpha
P11172944A0826|85 106|radiation pneumonitis
P11175333A0336|21 45|co-precipitation methods
P11175333A0336|74 82|proteins
P11176098A0342|0 7|METHODS
P11176098A0342|17 21|pigs
P11176098A0342|60 72|shock groups
P11176290T0000|0 14|Identification
P11176290T0000|28 41|vein stenosis
P11176290T0000|48 71|radiofrequency ablation
P11176290T0000|83 95|fibrillation
P11176290T0000|102 105|MRI
P11177538A0655|0 16|Tumor cell lines
P11177538A0655|34 37|MOI
P11177538A0655|49 53|days
P11177538A0655|64 90|% gene transfer efficiency
P11177686A0243|0 9|Treatment
P11177686A0243|45 52|options
P11177686A0243|67 74|therapy
P11177686A0243|130 138|dilation
P11178248A1042|38 58|screening techniques
P11178248A1042|62 67|terms
P11178248A1042|71 82|sensitivity
P11178248A1042|84 94|efficiency
P11178248A1042|99 109|occurrence
P11178248A1042|119 128|positives
P11178696A0301|7 16|US images
P11178696A0301|94 95|s
P11178696A0301|114 123|injection
P11178696A0301|129 130|g
P11178696A0301|134 148|contrast agent
P11178696A0301|181 186|PD US
P11178765A0642|19 26|effects
P11178765A0642|51 55|acid
P11178765A0642|61 72|development
P11178765A0642|86 96|metastasis
P11178765A0642|116 136|mouse adenocarcinoma
P11178765A0642|147 152|colon
P11178765A0642|156 161|cells
P11179272T0000|0 15|Cytomegalovirus
P11179272T0000|17 26|Chlamydia
P11179272T0000|43 77|Helicobacter pylori IgG antibodies
P11179272T0000|82 92|restenosis
P11179272T0000|105 117|implantation
P11179272T0000|153 169|ultrasound study
P11179400T0000|0 9|Responses
P11179400T0000|25 52|carotid body chemoreceptors
P11179400T0000|62 66|rats
P11179664T0000|0 12|Architecture
P11179664T0000|17 24|anatomy
P11179664T0000|40 45|locus
P11179664T0000|85 116|transcription factor RUNX1/AML1
P11179668A0869|34 42|proteins
P11179668A0869|63 74|PLTP family
P11179687A0280|8 13|paper
P11179687A0280|18 26|tyrosine
P11179687A0280|45 52|enzymes
P11179687A0280|75 87|phosphatases
P11179687A0280|89 93|PTPs
P11179687A0280|138 149|subfamilies
P11179687A0280|163 167|PTPs
P11179687A0280|176 189|receptor PTPs
P11179687A0280|191 196|RPTPs
P11179687A1118|24 32|metazoan
P11179687A1118|34 40|module
P11179687A1118|62 72|disulphide
P11179687A1118|81 91|Ig members
P11179687A1118|133 139|member
P11179687A1118|148 153|group
P11179689A0000|4 19|Sox gene family
P11179689A0000|21 24|Sry
P11179689A0000|30 42|HMG box gene
P11179689A0000|76 88|DNA sequence
P11179689A0000|100 106|domain
P11179689A0000|127 138|amino acids
P11179689A0000|164 172|sequence
P11179689A0000|182 193|DNA binding
P11179956A1818|12 19|results
P11179956A1818|60 67|effects
P11179956A1818|86 92|domain
P11179956A1818|96 114|nucleotide binding
P11179956A1818|143 155|interactions
P11179956A1818|176 183|domains
P11179956A1818|209 225|proton transport
P11180027A1306|12 22|parameters
P11180027A1306|38 41|M6G
P11180027A1306|68 78|depression
P11180027A1306|84 92|morphine
P11180255A0776|23 32|arguments
P11180255A0776|41 54|improbability
P11180255A0776|69 76|effects
P11180255A0776|80 95|UHF frequencies
P11180255A0776|105 114|mechanism
P11180255A0776|145 151|energy
P11180255A0776|157 161|time
P11180255A0776|166 171|space
P11180688A0000|14 35|maximum oxygen uptake
P11180688A0000|37 38|V
P11180688A0000|42 45|max
P11180688A0000|50 59|Hong Kong
P11180688A0000|68 76|children
P11180688A0000|96 107|association
P11180688A0000|125 134|illnesses
P11180688A0000|164 176|Fitness Test
P11180688A0000|178 181|MFT
P11180688A0000|191 198|shuttle
P11180688A0000|203 207|test
P11180688A0000|218 232|schoolchildren
P11180688A0000|251 256|years
P11181516A0119|16 61|deletion insulin promoter-reporter constructs
P11181516A0119|75 88|transfections
P11181516A0119|99 115|INS-1 beta-cells
P11181516A0119|153 160|regions
P11181516A0119|172 194|rat insulin I promoter
P11181516A0119|229 237|elements
P11181516A0119|243 245|E2
P11181516A0119|251 255|Flat
P11181516A0119|257 262|A2/A3
P11181525T0000|4 21|androgen receptor
P11181525T0000|23 25|AR
P11181525T0000|27 41|amino-terminus
P11181525T0000|68 78|regulation
P11181525T0000|82 100|AR gene expression
P11181525T0000|115 123|enhancer
P11181531A0464|8 17|mechanism
P11181531A0464|27 36|estrogens
P11181531A0464|45 57|osteoporosis
P11181531A0464|70 80|repression
P11181531A0464|84 97|transcription
P11181531A0464|101 124|NF-kappa B target genes
P11181531A0464|160 183|cytokines interleukin-6
P11181531A0464|188 201|interleukin-1
P11181548A0214|45 52|element
P11181548A0214|53 54|s
P11181548A0214|72 78|tissue
P11181548A0214|81 87|region
P11181548A0214|108 118|expression
P11181548A0214|126 138|mE-RABP gene
P11181548A0214|149 161|DNA fragment
P11181564A0733|7 12|mouse
P11181564A0733|19 24|genes
P11181564A0733|48 58|region 8E1
P11181564A0733|62 72|chromosome
P11181995A1093|0 8|Analysis
P11181995A1093|16 31|genome sequence
P11181995A1093|65 76|transcripts
P11181995A1093|118 126|evidence
P11181995A1093|190 195|genes
P11181995A1093|201 214|mouse matches
P11181995A1093|240 248|evidence
P11182520A0889|18 26|genotype
P11182520A0889|49 60|restriction
P11182520A0889|74 79|assay
P11182746A0872|16 24|patients
P11182746A0872|41 47|levels
P11182746A0872|64 76|drug therapy
P11185475T0034|3 10|Caveman
P11187016T0000|11 17|models
P11187016T0000|26 46|A-bomb survivor data
P11187016T0000|48 60|implications
P11187016T0000|78 88|mechanisms
P11188971A0000|22 29|surgery
P11188971A0000|34 43|Parkinson
P11188971A0000|46 53|disease
P11188971A0000|55 57|PD
P11188971A0000|70 80|discussion
P11188971A0000|96 107|methodology
P11188971A0000|122 128|target
P11188993A0298|0 7|Corneal
P11188993A0298|35 41|biopsy
P11188993A0298|84 94|evaluation
P11188993A0298|109 120|acid-Schiff
P11188993A0298|122 128|Giemsa
P11188993A0298|134 140|Gomori
P11188993A0298|143 168|methenamine silver stains
P11189314A1000|6 13|results
P11189314A1000|28 32|BACM
P11189314A1000|77 84|effects
P11189314A1000|90 94|GLCM
P11191208A0000|10 20|resistance
P11191208A0000|73 87|overexpression
P11191208A0000|91 96|genes
P11191208A0000|112 133|membrane efflux pumps
P11191208A0000|145 157|facilitators
P11191208A0000|166 199|ABC binding cassette transporters
P11191208A0000|211 218|control
P11191208A0000|226 250|transcription regulators
P11191208A0000|266 270|PDR1
P11191208A0000|275 285|PDR3 genes
P11191365A0682|0 14|Susceptibility
P11191365A0682|35 46|arrhythmias
P11191365A0682|67 76|diabetics
P11191365A0682|86 87|%
P11191365A0682|100 106|hearts
P11191365A0682|129 140|tachycardia
P11191365A0682|142 144|VT
P11191365A0682|153 154|%
P11191365A0682|165 173|episodes
P11191365A0682|189 201|fibrillation
P11191365A0682|203 205|VF
P11191365A0682|222 224|VT
P11191365A0682|229 230|%
P11191365A0682|235 237|VF
P11191365A0682|241 242|%
P11191365A0682|264 266|VF
P11191365A0682|270 271|%
P11191365A0682|280 293|non-diabetics
P11191365A0682|295 296|P
P11193045A1193|2 9|picture
P11193045A1193|32 40|gradient
P11193045A1193|44 52|function
P11193045A1193|59 62|p53
P11193045A1193|64 67|p73
P11193045A1193|69 72|p63
P11193045A1193|86 103|tumor suppression
P11193045A1193|107 118|development
P11193666A1269|30 39|outbreaks
P11193666A1269|43 66|Babesia carrier animals
P11193666A1269|98 102|herd
P11193704A0000|18 33|pleuropneumonia
P11193704A0000|45 51|threat
P11193704A0000|56 62|cattle
P11193704A0000|66 72|Africa
P11194101A0532|0 19|Baseline BMD values
P11194101A0532|70 75|group
P11194101A0532|92 98|others
P11194101A0532|106 111|level
P11194101A0532|122 127|spine
P11194101A0532|145 149|view
P11194101A0532|221 227|g x cm
P11194101A0532|233 234|P
P11194101A0532|282 293|user groups
P11194101A0532|335 339|bone
P11194101A0532|370 375|femur
P11194147A1496|4 16|distribution
P11194147A1496|24 40|rice cultivation
P11194147A1496|44 53|Sri Lanka
P11194147A1496|77 90|HIDD villages
P11194183A0866|4 12|increase
P11194183A0866|16 22|number
P11194183A0866|35 40|hairs
P11194183A0866|63 68|hairs
P11194183A0866|82 88|microm
P11194183A0866|92 100|diameter
P11194183A0866|120 124|area
P11194183A0866|130 139|cm square
P11194183A0866|147 155|cm2 area
P11194183A0866|164 194|procyanidin B-2 group subjects
P11194183A0866|213 218|trial
P11194183A0866|262 292|placebo control group subjects
P11194183A0866|294 309|procyanidin B-2
P11194183A0866|326 330|mean
P11194183A0866|335 337|SD
P11194183A0866|344 347|cm2
P11194183A0866|349 356|placebo
P11194183A0866|374 378|mean
P11194183A0866|383 385|SD
P11194183A0866|392 395|cm2
P11194183A0866|397 398|P
P11194183A0866|418 424|t test
P11195338A0494|8 18|expression
P11195338A0494|42 52|Lg3 allele
P11195338A0494|78 87|phenotype
P11195401A1030|5 22|plasma AVP levels
P11195401A1030|43 48|cases
P11195401A1030|62 67|SSRIs
P11195401A1030|78 91|AVP secretion
P11195401A1030|109 114|SIADH
P11196191A1789|9 36|T47D breast carcinoma cells
P11196191A1789|38 42|IL-6
P11196191A1789|51 58|synergy
P11196191A1789|64 95|EGF receptor autocrine activity
P11196191A1789|118 136|MAPK/PI3K pathways
P11196199T0000|6 15|homologue
P11196199T0000|19 40|yeast Rad23 protein A
P11196199T0000|83 98|element binding
P11196199T0000|100 104|CREB
P11196199T0000|106 121|binding protein
P11196199T0000|155 163|activity
P11196199T0000|167 170|p53
P11196340A1046|18 25|methods
P11196340A1046|27 41|identification
P11196340A1046|50 58|antigens
P11196340A1046|79 90|variability
P11196340A1046|113 127|aescin analogs
P11196340A1046|143 151|validity
P11197288A0855|5 13|patients
P11197288A0855|24 37|metronidazole
P11197288A0855|68 75|strains
P11197288A0855|104 108|rate
P11197288A0855|130 138|regimens
P11197328T0000|0 7|Binding
P11197328T0000|11 15|cell
P11197328T0000|38 46|proteins
P11197328T0000|66 72|region
P11197328T0000|76 121|maize C4 phosphoenolpyruvate carboxylase gene
P11197328T0000|147 160|transcription
P11197328T0000|164 179|mesophyll cells
P11197549A0748|0 7|RESULTS
P11197549A0748|20 40|stabilization period
P11197549A0748|42 47|PaCO2
P11197549A0748|49 53|mean
P11197549A0748|58 60|SD
P11197549A0748|75 80|mm Hg
P11197549A0748|85 96|arrhythmias
P11197926A0000|0 10|BACKGROUND
P11197926A0000|21 28|studies
P11197926A0000|79 87|versions
P11197926A0000|95 123|General Health Questionnaire
P11197926A0000|125 128|GHQ
P11197926A0000|151 158|effects
P11197926A0000|198 203|times
P11197926A0000|215 224|intervals
P11198053T0000|6 13|effects
P11198053T0000|17 19|LI
P11198053T0000|25 32|extract
P11198053T0000|36 56|Hypericum perforatum
P11198053T0000|58 65|St John
P11198053T0000|68 72|wort
P11198053T0000|89 101|constituents
P11198053T0000|120 129|responses
P11198053T0000|137 140|rat
P11198289T0000|10 29|serum ceruloplasmin
P11198289T0000|34 47|copper levels
P11198289T0000|60 68|dystonia
P11198385A0000|25 38|algerae Vavra
P11198385A0000|74 80|larvae
P11198385A0000|85 91|adults
P11198385A0000|97 114|laboratory colony
P11198385A0000|118 134|Culex pipiens L.
P11198385A0000|151 170|Gharbia Governorate
P11198424T0000|10 17|cloning
P11198424T0000|22 38|characterization
P11198424T0000|42 47|OsPSK
P11198424T0000|51 55|gene
P11198424T0000|67 76|precursor
P11198424T0000|81 101|phytosulfokine-alpha
P11198424T0000|116 139|rice cell proliferation
P11200568A0830|0 5|Blood
P11200568A0830|11 15|dams
P11200568A0830|39 50|inoculation
P11200568A0830|58 62|time
P11200568A0830|66 74|necropsy
P11200568A0830|79 90|measurement
P11200568A0830|94 97|IgM
P11200568A0830|102 116|IgG antibodies
P11200568A0830|120 131|M. pulmonis
P11201250A0849|0 24|Plasma DHE concentration
P11201250A0849|47 52|ng/ml
P11201250A0849|63 74|application
P11201250A0849|82 90|PSA tape
P11201250A0849|108 112|skin
P11201250A0849|125 128|rat
P11202434T0000|7 31|amino acid substitutions
P11202434T0000|56 62|domain
P11202434T0000|76 77|C
P11202434T0000|78 99|palmitoyl-CoA binding
P11202434T0000|103 108|ACBP2
P11202434T0000|113 124|Arabidopsis
P11202434T0000|142 149|protein
P11202434T0000|155 170|ankyrin repeats
P11202705A1112|0 12|Implications
P11202705A1112|16 29|biomonitoring
P11202705A1112|46 67|accumulation patterns
P11202705A1112|97 104|tissues
P11202705A1112|108 126|Posidonia oceanica
P11203702A1307|6 12|Xlim-1
P11203702A1307|54 71|activation domain
P11203702A1307|114 120|domain
P11203702A1307|124 133|CT239-403
P11203702A1307|167 176|mechanism
P11203702A1307|210 218|activity
P11203702A1307|222 228|Xlim-1
P11203702A1307|236 245|organizer
P11204897A0797|15 19|time
P11204897A0797|24 34|absorption
P11204897A0797|36 48|participants
P11204897A0797|61 82|bridge simulator task
P11207216A0296|11 22|PGHS-2 cDNA
P11207216A0296|39 50|combination
P11207216A0296|87 101|chain reaction
P11207216A0296|106 128|cDNA library screening
P11207216A0719|4 14|regulation
P11207216A0719|18 29|PGHS-2 mRNA
P11207216A0719|34 41|protein
P11207216A0719|65 73|cultures
P11207216A0719|100 105|cells
P11207216A0719|122 153|phorbol 12-myristate 13-acetate
P11207216A0719|155 158|PMA
P11207216A0719|164 166|nM
P11207261A1421|11 19|analysis
P11207261A1421|45 62|DT40 B cell lines
P11207261A1421|100 131|Fc gamma RIIB1-PECAM-1 receptor
P11207261A1421|159 171|Src homology
P11207261A1421|192 204|phosphatases
P11207261A1421|206 211|SHP-1
P11207261A1421|216 221|SHP-2
P11207261A1421|289 299|regulation
P11207261A1421|305 315|coligation
P11207261A1421|319 330|BCR complex
P11207261A1421|347 355|receptor
P11207269A0745|15 18|mAb
P11207269A0745|53 63|properties
P11207269A0745|72 85|p95 component
P11207282A0729|20 30|expression
P11207282A0729|58 62|form
P11207282A0729|66 80|chicken Notch1
P11207282A0729|84 90|Notch2
P11207282A0729|96 107|B cell line
P11207282A0729|121 136|down-regulation
P11207282A0729|140 162|surface IgM expression
P11207282A0729|192 201|reduction
P11207282A0729|205 225|IgH gene transcripts
P11207288A0897|0 13|Substitutions
P11207288A0897|21 24|YFV
P11207288A0897|36 42|region
P11207288A0897|44 47|ABR
P11207288A0897|93 101|residues
P11207288A0897|125 132|binding
P11207288A0897|136 146|peptide-Ag
P11207288A0897|154 172|class Ia molecules
P11207308A0999|11 19|curcumin
P11207308A0999|21 38|diferuloylmethane
P11207308A0999|62 67|agent
P11207308A0999|95 116|STAT1 phosphorylation
P11207308A0999|130 138|activity
P11207308A0999|142 147|STAT1
P11207308A0999|153 158|c-Jun
P11207308A0999|170 187|kinase activation
P11207308A0999|206 210|JAK1
P11207308A0999|212 216|JAK2
P11207308A0999|218 222|JAK3
P11207308A0999|224 230|ERK1/2
P11207308A0999|236 255|p38 phosphorylation
P11207609A0994|3 11|contrast
P11207609A0994|17 24|failure
P11207609A0994|32 42|QKTT motif
P11207609A0994|47 52|TGN46
P11207609A0994|65 69|tail
P11207609A0994|93 108|ER localization
P11207609A0994|122 151|stomatitis virus glycoprotein
P11207609A0994|153 157|VSVG
P11207609A0994|159 167|chimeras
P11207609A0994|171 175|HeLa
P11207609A0994|180 189|NRK cells
P11207609A0994|217 228|differences
P11207609A0994|248 259|trafficking
P11208017A0070|2 12|cDNA clone
P11208017A0070|22 51|C2H2-type zinc finger protein
P11208017A0070|53 59|SCOF-1
P11208017A0070|79 86|soybean
P11208814A0673|20 31|specificity
P11208814A0673|49 60|interaction
P11208814A0673|64 75|DmCKIIalpha
P11208814A0673|92 100|proteins
P11208814A0673|102 120|sequence alignment
P11208814A0673|140 142|m5
P11208814A0673|144 146|m7
P11208814A0673|152 154|m8
P11208814A0673|165 179|consensus site
P11208814A0673|184 199|phosphorylation
P11208814A0673|203 207|CKII
P11208814A0673|217 226|subdomain
P11208814A0673|249 257|proteins
P11209100A0069|25 35|properties
P11209100A0069|44 48|data
P11209100A0069|63 66|PMN
P11209100A0069|96 103|effects
P11209100A0069|107 118|stimulation
P11209100A0069|123 130|release
P11209100A0069|134 154|cytokine antagonists
P11209100A0069|163 196|interleukin-1 receptor antagonist
P11209100A0069|198 204|IL-1ra
P11209814A0243|4 11|purpose
P11209814A0243|20 33|investigation
P11209814A0243|65 80|characteristics
P11209814A0243|96 110|tissue capsule
P11209814A0243|130 142|implantation
P11209814A0243|146 172|aluminum calcium phosphate
P11209814A0243|174 179|ALCAP
P11209814A0243|185 199|hydroxyapetite
P11209814A0243|201 203|HA
P11209814A0243|205 216|bioceramics
P11210401A0000|0 23|Sevelamer hydrochloride
P11210401A0000|25 32|Renagel
P11210401A0000|69 76|polymer
P11210401A0000|94 103|treatment
P11210401A0000|107 124|hyperphosphatemia
P11210401A0000|134 142|patients
P11210401A0000|153 165|hemodialysis
P11210401A0544|20 28|profiles
P11210401A0544|32 39|digoxin
P11210401A0544|44 52|warfarin
P11210401A0544|104 118|administration
P11210401A0544|122 131|sevelamer
P11210839A0282|7 25|PO3 administration
P11210839A0282|37 41|half
P11210839A0282|47 48|%
P11210839A0282|57 65|patients
P11210839A0282|103 108|drugs
P11210839A0282|110 121|ethambutole
P11210839A0282|126 137|ethionamide
P11210839A0282|141 152|ethambutole
P11210839A0282|157 169|oprofloxacin
P11210988T0000|4 12|survival
P11210988T0000|30 38|patients
P11210988T0000|62 77|prostate cancer
P11211759A0165|0 8|Patients
P11211759A0165|31 36|group
P11211759A0165|38 53|Control group A
P11211759A0165|65 74|hot-water
P11211759A0165|87 93|system
P11211759A0165|107 114|group B
P11211759A0165|126 147|transtracheal heating
P11211759A0165|152 173|humidification system
P11211759A0165|177 192|ANAMED HUMITUBE
P11211759A0165|218 234|cancer operation
P11211936A1490|12 16|data
P11211936A1490|47 57|expression
P11211936A1490|61 65|blr1
P11211936A1490|76 93|JNK/SAPK activity
P11211936A1490|99 102|JNK
P11211936A1490|104 119|SAPK activation
P11211936A1490|162 177|differentiation
P11211936A1490|182 195|growth arrest
P11212249A0993|4 11|effects
P11212249A0993|31 40|receptors
P11212249A0993|62 72|antagonism
P11212249A0993|76 93|activator protein
P11212249A0993|97 101|AP-1
P11212249A0993|103 111|activity
P11212327A1564|7 14|studies
P11212327A1564|30 44|rat adipocytes
P11212327A1564|72 85|PIG compounds
P11212327A1564|95 126|IRS1/3 tyrosine phosphorylation
P11212327A1564|130 143|p59Lyn kinase
P11212327A1564|151 155|site
P11212327A1564|159 169|cross-talk
P11212327A1564|184 194|regulation
P11212327A1564|207 218|interaction
P11212327A1564|224 232|caveolin
P11212327A1564|260 263|PIG
P11213342A0492|0 7|RESULTS
P11213342A0492|13 27|parameters SF2
P11213342A0492|40 50|efficiency
P11213342A0492|85 96|test period
P11214177A1125|13 18|sense
P11214177A1125|50 57|nt RNAs
P11214177A1125|76 82|satRNA
P11214177A1125|121 130|satellite
P11214354A1104|7 14|animals
P11214354A1104|41 42|p
P11214354A1104|51 57|levels
P11214354A1104|72 90|lipid peroxidation
P11214354A1104|102 103|p
P11214354A1104|112 126|protein thiols
P11214354A1104|137 140|I-R
P11214354A1104|157 168|CON animals
P11215622A0949|0 8|Grippers
P11215622A0949|40 53|force sensors
P11215622A0949|72 78|strain
P11216247T0000|4 9|child
P11218739A0811|0 10|Transition
P11218739A0811|19 20|P
P11218739A0811|26 32|H-BPPV
P11218739A0811|48 53|cases
P11220166A0616|16 23|effects
P11220166A0616|40 51|stimulation
P11220166A0616|59 76|motor performance
P11220166A0616|89 96|aspects
P11220166A0616|110 120|processing
P11220166A0616|133 142|existence
P11220166A0616|154 166|interactions
P11220166A0616|196 220|brain dopamine receptors
P11220166A0616|229 241|intervention
P11220166A0616|281 293|cortex loops
P11220166A0616|297 302|motor
P11220166A0616|317 326|behaviour
P11220306A0911|0 6|HexA71
P11220306A0911|26 30|RpoS
P11220306A0911|39 45|levels
P11220306A0911|66 78|sigma factor
P11220306A0911|97 101|HexA
P11220306A0911|122 126|HexA
P11220306A0911|128 134|strain
P11220306A1753|9 15|copies
P11220306A1753|19 23|rsmB
P11220306A1753|25 28|DNA
P11220306A1753|43 47|hand
P11220306A1753|69 79|production
P11220306A1753|106 113|effects
P11220306A1753|131 135|copy
P11220306A1753|139 143|hexA
P11220486A0686|1 2|%
P11220486A0686|8 13|IL-12
P11220486A0686|19 20|%
P11220487T0000|11 17|review
P11220487T0000|32 37|tests
P11220487T0000|50 64|trichomoniasis
P11220857T0000|0 4|CHAP
P11220857T0000|13 23|Department
P11220857T0000|27 43|Veterans Affairs
P11221836A0981|23 29|fusion
P11221836A0981|57 64|vaccine
P11221836A0981|91 98|potency
P11221836A0981|144 150|tumors
P11221845A0295|27 45|methylation status
P11221845A0295|61 66|liver
P11221845A0295|71 83|liver tumors
P11221845A0295|87 103|SV40 T/t antigen
P11221845A0295|115 119|mice
P11221845A0295|121 131|MT-D2 mice
P11221845A0295|139 159|Restriction Landmark
P11221845A0295|168 176|Scanning
P11221845A0295|181 192|Methylation
P11221845A0295|194 200|RLGS-M
P11221845A0295|225 235|loci/spots
P11221845A0295|281 293|liver tumors
P11221845A0800|4 20|Genescan program
P11221845A0800|39 52|reading frame
P11221845A0800|77 81|gene
P11221845A0800|98 107|B236 spot
P11221845A0800|132 154|493-amino acid protein
P11221845A0800|170 190|SNAG repressor motif
P11221845A0800|211 217|region
P11221845A0800|227 255|C2H2-type zinc finger motifs
P11221845A0800|277 281|half
P11221845A1370|0 22|Northern blot analysis
P11221845A1370|37 40|mlt
P11221845A1370|68 73|brain
P11221845A1370|75 81|spleen
P11221845A1370|83 91|stom ach
P11221845A1370|97 102|liver
P11221845A1713|0 9|Treatment
P11221845A1713|13 26|N18TG-2 cells
P11221845A1713|48 53|agent
P11221845A1713|55 74|5-aza-deoxycytidine
P11221845A1713|91 101|expression
P11221845A1713|105 108|mlt
P11221845A1713|132 142|repression
P11221845A1713|146 149|mlt
P11221845A1713|171 182|methylation
P11221845A1713|189 192|mlt
P11221845A1713|206 217|target gene
P11221845A1713|238 249|methylation
P11221845A1713|257 276|liver tumorigenesis
P11221845A1713|290 304|SV40 T antigen
P11222387A1497|21 29|compound
P11222387A1497|37 46|mechanism
P11222387A1497|50 56|action
P11222387A1497|79 109|ABL tyrosine kinase inhibition
P11222387A1497|111 123|FTI SCH66336
P11222387A1497|130 137|promise
P11222387A1497|146 155|treatment
P11222387A1497|175 183|leukemia
P11222639A1273|6 13|results
P11222639A1273|35 39|role
P11222639A1273|44 60|tyrosine residue
P11222639A1273|73 83|regulation
P11222639A1273|87 101|L1 endocytosis
P11222720A1699|17 21|RPMS
P11222720A1699|41 50|regulator
P11222720A1699|54 59|EBNA2
P11222720A1699|64 78|Notch activity
P11222720A1699|91 103|interactions
P11222720A1699|129 148|corepressor complex
P11223131A0000|0 17|Folate metabolism
P11223131A0000|31 69|malaria parasite Plasmodium falciparum
P11223131A0000|86 94|activity
P11223131A0000|99 110|cell growth
P11223131A0000|115 126|replication
P11223131A0000|136 142|target
P11223131A0000|159 164|class
P11223131A0000|180 186|agents
P11223131A0000|201 204|use
P11223153A0533|4 14|BFA System
P11223153A0533|23 32|text file
P11223153A0533|38 43|flows
P11223153A0533|71 92|microsphere technique
P11223153A0533|98 108|constructs
P11223153A0533|113 125|lung anatomy
P11223153A0533|142 148|pixels
P11223153A0533|161 166|flows
P11223153A0533|174 186|color schema
P11223164A0000|0 9|Retinoids
P11223164A0000|29 34|onset
P11223164A0000|38 53|differentiation
P11223164A0000|55 64|apoptosis
P11223164A0000|73 83|inhibition
P11223164A0000|87 93|growth
P11223164A0000|104 111|variety
P11223164A0000|136 141|cells
P11223186A1095|0 15|Transactivation
P11223186A1095|19 55|oIFNtau enhancer-reporter constructs
P11223186A1095|89 96|regions
P11223186A1095|108 117|AP-1 site
P11223186A1095|119 123|GATA
P11223186A1095|129 137|sequence
P11223186A1095|142 146|site
P11223186A1095|147 148|s
P11223199A0751|6 13|results
P11223199A0751|28 38|evaluation
P11223199A0751|42 50|exposure
P11223199A0751|54 64|S. neurona
P11223199A0751|68 79|WB analysis
P11223199A0751|83 88|serum
P11223199A0751|116 122|horses
P11223240A0655|11 34|Menin1 gene transcripts
P11223240A0655|51 72|polyadenylation sites
P11223240A0655|99 107|messages
P11223246A0359|0 17|Sequence analysis
P11223246A0359|33 54|RBP21 shares homology
P11223246A0359|89 97|proteins
P11223246A0359|117 128|motif LxCxE
P11223246A0359|147 153|region
P11223255A1034|3 11|addition
P11223255A1034|17 43|consensus amino acid motif
P11223255A1034|48 81|serine threonine receptor kinases
P11223256A1212|51 57|region
P11223256A1212|65 79|pea 33RNP gene
P11223257A0404|0 6|OsBBPI
P11223257A0404|42 60|rice seedling leaf
P11223257A0404|64 72|response
P11223257A0404|100 104|acid
P11223257A0404|106 108|JA
P11223257A0404|126 148|protein phosphatase 2A
P11223257A0404|150 154|PP2A
P11223257A0404|156 166|inhibitors
P11223257A0404|168 179|cantharidin
P11223257A0404|181 183|CN
P11223257A0404|189 198|endothall
P11223257A0404|200 202|EN
P11223257A0404|210 220|light/dark
P11223257A0404|223 227|time
P11223257A0404|248 254|manner
P11223257A0404|261 270|induction
P11223257A0404|299 312|cycloheximide
P11223257A0404|314 317|CHX
P11223257A0404|333 344|requirement
P11223257A0404|357 374|protein synthesis
P11223257A0404|382 391|induction
P11223938X1218|0 9|Copyright
P11223938X1218|15 25|John Wiley
P11223938X1218|28 32|Sons
P11223938X1218|34 38|Ltd.
P11224226A0000|4 11|effects
P11224226A0000|15 31|chlordiazepoxide
P11224226A0000|41 46|mg/kg
P11224226A0000|56 87|benzodiazepine receptor agonist
P11224226A0000|93 103|bretazenil
P11224226A0000|113 118|mg/kg
P11224226A0000|131 162|benzodiazepine receptor agonist
P11224226A0000|211 219|paradigm
P11226228A0899|9 17|plasmids
P11226228A0899|31 36|yeast
P11226228A0899|43 47|gene
P11226752A0750|13 33|tissue culture cells
P11226752A0750|35 49|overexpression
P11226752A0750|69 90|mouse deltex homologs
P11226752A0750|122 130|activity
P11226752A0750|134 137|E47
P11226752A0750|171 178|protein
P11226752A0750|185 191|manner
P11226752A0750|203 214|suppression
P11226752A0750|231 235|form
P11226752A0750|245 251|Notch1
P11226752A0750|261 265|DTX1
P11227039A0953|12 17|women
P11227039A0953|35 38|BMI
P11227039A0953|40 41|P
P11227039A0953|54 57|PBF
P11227039A0953|59 60|P
P11227039A0953|83 88|primi
P11227039A0953|106 112|groups
P11227182A1475|4 11|authors
P11227182A1475|43 55|correlations
P11227182A1475|64 74|parameters
P11227182A1475|82 88|lipids
P11227182A1475|92 103|bone marrow
P11227182A1475|108 121|leptin levels
P11227182A1475|125 130|serum
P11227182A1475|135 146|bone marrow
P11227484T0000|13 26|determination
P11227484T0000|30 43|methylmercury
P11227484T0000|50 73|ion-association complex
P11227484T0000|79 90|rhodamine B
P11227484T0000|98 106|presence
P11227484T0000|110 116|iodide
P11228700T0000|4 12|position
P11228700T0000|20 27|analyst
P11228700T0000|31 37|expert
P11228700T0000|39 48|yesterday
P11228700T0000|53 58|today
P11230145A0732|4 11|results
P11230145A0732|37 41|role
P11230145A0732|49 59|Notch-CBF1
P11230145A0732|60 88|RBP-Jkappa signaling pathway
P11230145A0732|92 111|cell fate decisions
P11230145A0732|138 146|pathways
P11230145A0732|156 167|replication
P11230145A0732|182 192|conversion
P11230169A0480|14 20|method
P11230169A0480|31 60|chromatin immunoprecipitation
P11230169A0480|73 92|array hybridization
P11230169A0480|137 147|DNA domain
P11230169A0480|184 196|20p12 region
P11230169A0480|203 209|invdup
P11230169A0480|211 214|20p
P11230169A0480|222 239|marker chromosome
P11230534A0688|14 19|total
P11230534A0688|26 40|DEAH helicases
P11230534A0688|55 62|species
P11230889A1151|4 9|cases
P11230889A1151|30 45|arm lymphoedema
P11230889A1151|76 88|improvements
P11230889A1151|92 102|arm volume
P11230889A1151|119 125|months
P11230889A1151|132 141|treatment
P11230889A1151|147 151|HBO2
P11231287A0158|4 15|sensitivity
P11231287A0158|25 52|neuroblastoma cells SK-N-SH
P11231287A0158|64 73|apoptosis
P11231287A0158|85 97|thapsigargin
P11232947A1451|13 34|lymph node dissection
P11232947A1451|38 55|radiation therapy
P11232947A1451|69 74|chain
P11232947A1451|94 104|recurrence
P11232947A1451|146 154|survival
P11233643A0000|24 27|use
P11233643A0000|49 53|acid
P11233643A0000|55 58|ALA
P11233643A0000|68 82|protoporphyrin
P11233643A0000|87 91|PPIX
P11233643A0000|110 117|therapy
P11233643A0000|119 122|PDT
P11233643A0000|142 149|maximum
P11233643A0000|165 173|ALA dose
P11233643A0000|178 183|mg/kg
P11234223A1451|16 27|antibiotics
P11234223A1451|37 43|groups
P11234223A1451|74 82|activity
P11234223A1451|110 115|class
P11234223A1451|119 130|antibiotics
P11234223A1451|152 159|killing
P11234223A1451|168 171|AMK
P11234223A1451|173 176|IPM
P11234223A1451|181 185|PAPM
P11234223A1451|200 203|CAZ
P11234223A1451|205 209|MEPM
P11234223A1451|231 238|killing
P11235335T0000|9 12|HIV
P11235777A0878|3 14|Klinefelter
P11235777A0878|17 25|syndrome
P11235777A0878|27 32|47XXY
P11235777A0878|35 60|serum testosterone levels
P11235777A0878|78 81|end
P11235777A0878|96 101|range
P11235777A0878|106 132|dihydrotestosterone levels
P11235817A0000|4 37|histamine H1 receptor antagonists
P11235817A0000|39 53|antihistamines
P11235817A0000|72 77|class
P11235817A0000|81 92|medications
P11235817A0000|106 112|relief
P11235817A0000|123 131|symptoms
P11235817A0000|164 174|conditions
P11235817A0000|188 196|children
P11235817A0000|201 207|adults
P11236056A0374|0 10|Conclusion
P11236056A0374|16 18|Lp
P11236056A0374|22 28|levels
P11236056A0374|38 46|children
P11237038A0889|2 8|subset
P11237038A0889|12 20|patients
P11237038A0889|22 23|n
P11237038A0889|51 72|pressure flow studies
P11237038A0889|110 114|HIFU
P11237038A0889|123 150|bladder outflow obstruction
P11237491A0000|0 4|AIMS
P11237491A0000|21 29|baseline
P11237491A0000|50 62|fluctuations
P11237491A0000|70 88|tumour markers CEA
P11237491A0000|90 92|CA
P11237491A0000|100 102|CA
P11237491A0000|110 118|patients
P11237491A0000|141 147|cancer
P11237491A0000|165 175|hypothesis
P11237491A0000|181 201|serum concentrations
P11237491A0000|222 234|fluctuations
P11237491A0000|258 272|concentrations
P11237491A0000|288 299|individuals
P11237598A0962|27 36|framework
P11237598A0962|46 53|enzymes
P11237598A0962|68 78|structures
P11237598A0962|99 108|evolution
P11237598A0962|131 140|mechanism
P11238105A0959|0 5|Cells
P11238105A0959|17 31|alpha subunits
P11238105A0959|53 59|domain
P11238105A0959|61 67|term-3
P11238105A0959|102 109|alpha-2
P11238105A0959|117 123|domain
P11238105A0959|150 157|ability
P11238105A0959|169 193|tyrosine phosphorylation
P11238105A0959|197 202|Jak-2
P11238105A0959|211 221|substrates
P11238105A0959|240 244|CD86
P11238375A0617|14 18|RhoA
P11238375A0617|41 55|kinase cascade
P11238375A0617|71 81|activation
P11238375A0617|85 89|ERK6
P11238375A0617|91 100|p38 gamma
P11238375A0617|125 131|member
P11238375A0617|139 149|p38 family
P11238375A0617|153 158|MAPKs
P11238402A0191|37 47|mechanisms
P11238402A0191|68 91|DAN/TIR gene expression
P11238405A0817|3 10|strains
P11238405A0817|19 24|tup11
P11238405A0817|29 34|tup12
P11238405A0817|40 49|atf1-pcr1
P11238405A0817|66 75|activator
P11238405A0817|104 108|role
P11238405A0817|112 132|fbp1-lacZ expression
P11238405A0817|143 168|spc1 MAPK phosphorylation
P11238405A0817|172 176|atf1
P11238405A0817|208 218|activation
P11238447A0524|9 24|binding studies
P11238447A0524|42 48|eIF-5A
P11238447A0524|75 86|interaction
P11238447A0524|90 97|Rev-NES
P11238447A0524|103 117|CRM1/exportin1
P11238447A0524|127 133|eIF-5A
P11238447A0524|153 176|nucleoporins CAN/nup214
P11238447A0524|178 184|nup153
P11238447A0524|186 191|nup98
P11238447A0524|197 202|nup62
P11238586A0000|11 18|studies
P11238586A0000|35 40|class
P11238586A0000|49 75|histocompatibility complex
P11238586A0000|77 80|MHC
P11238586A0000|110 125|T cell receptor
P11238586A0000|127 130|TCR
P11238586A0000|132 143|alpha/betas
P11238586A0000|158 166|contacts
P11238586A0000|176 182|alpha1
P11238586A0000|187 201|alpha2 helices
P11238586A0000|209 212|MHC
P11238586A0000|259 271|interactions
P11238586A0000|297 304|binding
P11238882A0157|29 33|eIF6
P11238882A0157|72 76|gene
P11238884A0892|0 4|Mice
P11238884A0892|24 36|dlg mutation
P11238884A0892|45 63|growth retardation
P11238884A0892|67 72|utero
P11238884A0892|79 89|hypoplasia
P11238884A0892|97 107|premaxilla
P11238884A0892|112 120|mandible
P11238884A0892|129 134|cleft
P11238884A0892|145 151|palate
P11238916A0838|12 19|complex
P11238916A0838|31 38|PTP phi
P11238916A0838|40 48|paxillin
P11238916A0838|76 91|tyrosine kinase
P11238916A0838|93 97|Pyk2
P11238916A0838|130 148|macrophage lysates
P11238916A0838|168 174|domain
P11238916A0838|178 185|PTP phi
P11238916A0838|204 212|paxillin
P11238916A0838|217 221|Pyk2
P11238947A0636|9 20|base change
P11238947A0636|22 25|A8G
P11238947A0636|37 45|sequence
P11238947A0636|54 70|hnRNP A2 binding
P11238947A0636|83 87|case
P11238947A0636|91 97|A2RE-2
P11238947A0636|108 121|RNA transport
P11239184A1340|0 18|Baseline variables
P11239184A1340|35 37|CD
P11239184A1340|63 66|use
P11239184A1340|80 87|aspirin
P11239184A1340|101 110|incidence
P11239184A1340|120 130|CT changes
P11239184A1340|134 139|edema
P11239184A1340|143 154|mass effect
P11239184A1340|180 191|artery sign
P11239529A0981|0 8|IL-1beta
P11239529A0981|37 49|endometrioma
P11239529A0981|58 65|lesions
P11239529A0981|75 88|localizations
P11240600A0523|11 23|drug history
P11240600A0523|53 59|amount
P11240600A0523|64 72|duration
P11240600A0523|76 90|VGB medication
P11241166A0677|7 15|analysis
P11241166A0677|19 34|gene expression
P11241166A0677|53 65|FA treatment
P11241166A0677|83 91|decrease
P11241166A0677|99 105|amount
P11241166A0677|109 124|leptin receptor
P11241166A0677|126 130|Ob-R
P11241166A0677|132 136|mRNA
P11241166A0677|145 153|increase
P11241166A0677|170 180|regulators
P11241166A0677|184 199|STAT signalling
P11241166A0677|201 206|SOCS3
P11241166A0677|208 219|suppressors
P11241166A0677|223 242|cytokine signalling
P11241166A0677|247 255|cytokine
P11241166A0677|266 274|sequence
P11241166A0677|276 279|CIS
P11241215A0566|11 20|receptors
P11241215A0566|33 41|sBMPR-IA
P11241215A0566|61 76|fusion proteins
P11241215A0566|82 93|thioredoxin
P11241215A0566|142 147|phase
P11241215A0566|153 164|performance
P11241215A0566|172 186|chromatography
P11241215A0566|188 195|RP-HPLC
P11241215A0566|203 212|digestion
P11241215A0566|218 230|enterokinase
P11241243A0693|4 11|authors
P11241243A0693|38 46|analysis
P11241243A0693|50 59|pathology
P11241243A0693|65 79|quantification
P11241243A0693|87 97|percentage
P11241243A0693|118 127|component
P11241243A0693|129 134|% PSC
P11241243A0693|140 154|p53 expression
P11241332A0393|9 16|purpose
P11241332A0393|63 81|fixation strengths
P11241332A0393|89 99|variations
P11241332A0393|117 136|bone anchor designs
P11241332A0393|147 153|anchor
P11241332A0393|160 172|screw anchor
P11241332A0393|205 210|foams
P11241332A0393|229 233|bone
P11241332A0393|250 259|densities
P11241356T0000|13 28|phosphorylation
P11241356T0000|41 53|localization
P11241356T0000|57 62|Smad3
P11241356T0000|93 120|collagen gene transcription
P11241356T0000|142 156|stellate cells
P11241672T0000|0 7|Cloning
P11241672T0000|12 28|characterization
P11241672T0000|36 47|murine beta
P11241672T0000|51 73|integrin gene promoter
P11241672T0000|75 89|identification
P11241672T0000|96 109|interleukin-4
P11241672T0000|121 128|element
P11241672T0000|133 143|regulation
P11241672T0000|147 153|STAT-6
P11243306A0961|0 11|CONCLUSIONS
P11243306A0961|26 32|levels
P11243306A0961|36 52|oxLDL antibodies
P11243306A0961|80 92|hypertension
P11243306A0961|117 131|artery disease
P11243306A0961|150 158|presence
P11243306A0961|162 174|hypertension
P11243306A0961|202 208|levels
P11243336A0000|12 19|MD-55-2
P11243336A0000|34 38|film
P11243336A0000|83 95|applications
P11243336A0000|128 151|brachytherapy dosimetry
P11243494A0833|0 7|RESULTS
P11243494A0833|18 22|days
P11243494A0833|28 34|groups
P11243494A0833|62 68|heroin
P11243494A0833|75 78|CRF
P11243494A0833|82 87|rates
P11243494A0833|116 127|performance
P11243777A0000|11 25|CCAAT elements
P11243777A0000|61 77|promoter regions
P11243980A0510|12 20|patients
P11243980A0510|35 51|PET examinations
P11243980A0510|63 81|staging procedures
P11244568A0506|4 10|Gap69C
P11244568A0506|28 32|gene
P11244568A0506|58 62|mRNA
P11244568A0506|74 85|development
P11244568A0506|95 101|amount
P11244568A0506|118 124|larvae
P11244733A0782|0 5|Cases
P11244733A0782|9 20|lung cancer
P11244733A0782|41 51|metastasis
P11244733A0782|96 101|death
P11245986T0000|31 38|protein
P11245986T0000|58 86|rat aldolase B gene promoter
P11246679A0000|0 9|OBJECTIVE
P11246679A0000|30 41|association
P11246679A0000|70 81|heart block
P11246679A0000|83 87|CCHB
P11246679A0000|96 101|fetus
P11246679A0000|112 119|disease
P11246887A0000|5 10|study
P11246887A0000|24 28|role
P11246887A0000|32 58|cholesteryl ester transfer
P11246887A0000|60 63|CET
P11246887A0000|66 100|cholesteryl ester transfer protein
P11246887A0000|102 106|CETP
P11246887A0000|108 116|activity
P11246887A0000|135 151|transfer protein
P11246887A0000|153 157|PLTP
P11246887A0000|159 167|activity
P11246887A0000|185 195|prevalence
P11246887A0000|208 228|artery calcification
P11246887A0000|230 233|CAC
P11246887A0000|247 255|subjects
P11246887A0000|282 290|subjects
P11246887A0000|302 306|loss
P11246887A0000|314 328|sex difference
P11246887A0000|332 335|CAC
P11246887A0000|339 347|diabetes
P11247663A1447|4 12|families
P11247663A1447|29 40|inheritance
P11247663A1447|44 57|DNAH9 alleles
P11247663A1447|70 81|individuals
P11248463A0187|4 16|blood levels
P11248463A0187|20 27|lactate
P11248463A0187|29 37|pyruvate
P11248463A0187|42 53|amino acids
P11248626T0000|0 8|Efficacy
P11248626T0000|29 37|Cavermap
P11248626T0000|48 56|location
P11248626T0000|61 69|function
P11248626T0000|83 89|nerves
P11248626T0000|105 118|prostatectomy
P11248626T0000|142 152|evaluation
P11248626T0000|168 176|surgeons
P11250196A0455|16 27|domain fold
P11250196A0455|39 43|pair
P11250196A0455|47 68|calcium binding sites
P11250196A0455|125 164|betagamma-crystallin fold family member
P11250196A0455|166 176|Protein S.
P11250942A0626|11 19|analyses
P11250942A0626|23 26|VDR
P11250942A0626|42 47|GRIP1
P11250942A0626|52 56|RAC3
P11250942A0626|76 99|VDR activation function
P11250942A0626|101 105|AF-2
P11250942A0626|107 113|domain
P11250942A0626|128 139|interaction
P11250942A0626|175 182|regions
P11250942A0626|190 193|VDR
P11251083T0000|0 9|Mechanism
P11251083T0000|28 35|control
P11251083T0000|39 54|cell morphology
P11251083T0000|59 72|S phase entry
P11251083T0000|86 99|growth factor
P11251083T0000|118 137|MEK/ERK activations
P11251104A0526|4 14|expression
P11251104A0526|18 31|alpha-amylase
P11251104A0526|61 87|transcription factor GAMyb
P11251104A0526|116 119|GA.
P11251252A0494|0 19|3D image-processing
P11251252A0494|39 54|ultrasound data
P11251252A0494|89 95|planes
P11251252A0494|97 109|section mode
P11251252A0494|127 135|3D views
P11251252A0494|147 151|mode
P11251276A0793|10 18|patients
P11251276A0793|32 39|surgery
P11251697T0000|7 37|superoxide scavenging activity
P11251697T0000|72 77|drugs
P11251697T0000|79 92|determination
P11251697T0000|96 119|electron spin resonance
P11251697T0000|130 146|spin trap method
P11251951A0000|0 10|BACKGROUND
P11251951A0000|12 22|Dermoscopy
P11251951A0000|40 49|technique
P11251951A0000|80 88|accuracy
P11251951A0000|102 114|skin lesions
P11251951A0000|143 152|diagnosis
P11251951A0000|156 164|patients
P11251951A0000|180 188|melanoma
P11251951A0000|198 202|CMIS
P11251951A0000|223 231|melanoma
P11254134A0648|10 14|PTax
P11254134A0648|32 53|background activities
P11254134A0648|59 62|PTF
P11254134A0648|84 92|sequence
P11254134A0648|121 127|region
P11254134A0648|142 159|background levels
P11254504A0766|13 28|promoter region
P11254504A0766|71 79|elements
P11254504A0766|88 91|Sp1
P11254504A0766|99 116|growth response-1
P11254504A0766|118 137|activator protein-2
P11254504A0766|139 143|MyoD
P11254504A0766|145 149|p300
P11254504A0766|159 172|factor-kappaB
P11254504A0766|182 203|zinc finger protein-1
P11254504A0766|220 228|homeobox
P11254504A0766|230 233|Cdx
P11254504A0766|235 241|gene A
P11254504A0766|247 274|Cdx protein-2 binding sites
P11254713A1029|10 21|interaction
P11254713A1029|25 28|Tat
P11254713A1029|38 48|components
P11254713A1029|57 64|rel/AP1
P11254713A1029|77 84|complex
P11254713A1029|130 141|alterations
P11254713A1029|150 157|complex
P11254713A1029|161 171|activation
P11254713A1029|199 207|decrease
P11254713A1029|211 234|IL-2 gene transcription
P11254864T0000|25 34|treatment
P11254864T0000|38 51|breast cancer
P11255035A0331|13 29|progenitor cells
P11255035A0331|37 42|brain
P11255035A0331|44 65|SVZa progenitor cells
P11255035A0331|75 83|capacity
P11255035A0331|130 139|phenotype
P11255252A0961|10 22|ER3 sequence
P11255252A0961|26 29|DNA
P11255252A0961|72 79|FXR HRE
P11255252A0961|121 135|yeast extracts
P11255423A0211|0 9|OBJECTIVE
P11255423A0211|28 39|association
P11255423A0211|54 62|symptoms
P11255423A0211|80 89|mortality
P11255423A0211|94 101|decline
P11255423A0211|105 119|CD4 lymphocyte
P11255423A0211|133 138|women
P11255423A0211|144 147|HIV
P11256845A0340|12 20|analysis
P11256845A0340|27 31|West
P11256845A0340|35 69|Scotland Coronary Prevention Study
P11256845A0340|71 78|WOSCOPS
P11256845A0340|80 88|findings
P11256845A0340|104 120|statin treatment
P11256845A0340|146 152|events
P11256845A0340|164 172|patients
P11256845A0340|178 188|population
P11256845A0340|208 215|WOSCOPS
P11256845A0340|228 229|%
P11256845A0340|237 241|risk
P11256845A0340|262 267|event
P11256845A0340|285 289|cost
P11256845A0340|321 327|pounds
P11256944A1144|25 30|forms
P11256944A1144|34 38|ATF6
P11256944A1144|47 63|G13 gene product
P11256944A1144|94 107|point mutants
P11256944A1144|126 152|ER stress response element
P11256944A1144|185 194|ER stress
P11256962A0233|0 17|Sequence analysis
P11256962A0233|39 50|differences
P11256962A0233|66 72|region
P11256962A0233|80 97|beta subunit gene
P11256962A0233|120 127|regions
P11256962A0233|146 170|GlyR alpha subunit genes
P11256962A0233|199 203|exon
P11256962A0233|205 209|exon
P11256962A0233|254 261|portion
P11256962A0233|269 283|GlyR beta mRNA
P11257870A0000|12 17|study
P11257870A0000|47 56|potential
P11257870A0000|62 68|hybrid
P11257870A0000|80 87|reactor
P11257870A0000|109 115|filter
P11257870A0000|117 119|TF
P11257870A0000|135 149|sludge process
P11257870A0000|151 154|ASP
P11257870A0000|166 176|wastewater
P11257870A0000|188 205|trichloroethylene
P11257870A0000|207 210|TCE
P11257870A0000|223 234|temperature
P11257870A0000|258 272|retention time
P11257870A0000|274 277|HRT
P11258906A0743|3 32|DNA strand exchange reactions
P11258906A0743|39 55|oligonucleotides
P11258906A0743|71 75|Rec2
P11258906A0743|88 100|pairing bias
P11258906A0743|126 130|RecA
P11259347A0000|10 22|observations
P11259347A0000|48 58|literature
P11259347A0000|79 84|clues
P11259347A0000|99 109|variations
P11259347A0000|113 119|humans
P11259347A0000|121 128|ability
P11259347A0000|147 156|chemicals
P11259503A0212|0 19|Forskolin treatment
P11259503A0212|24 30|microM
P11259503A0212|51 56|cells
P11259503A0212|66 67|h
P11259503A0212|86 96|luciferase
P11259593A1094|0 8|Analysis
P11259593A1094|12 27|ace2Delta cells
P11259593A1094|41 46|Ace2p
P11259593A1094|63 78|cell separation
P11259593A1094|101 107|growth
P11260468A1179|4 11|results
P11260468A1179|37 40|AR1
P11260468A1179|66 77|CAP subunit
P11260468A1179|95 114|papBA transcription
P11260468A1179|127 134|absence
P11260468A1179|155 167|protein H-NS
P11260662X0000|0 2|A.
P11260662X0000|4 11|Slatkin
P11260662X0000|13 15|D.
P11263622A0683|0 7|RESULTS
P11263622A0683|23 34|correlation
P11263622A0683|36 37|p
P11263622A0683|69 83|wall thickness
P11263622A0683|88 104|vessel wall area
P11263622A0683|113 116|MRI
P11263622A0683|121 135|histopathology
P11263622A0683|137 138|r
P11263622A0683|150 151|r
P11263664A1085|4 8|data
P11263664A1085|23 27|SIP1
P11263664A1085|51 71|XBra gene expression
P11263664A1085|79 87|mesoderm
P11263664T0000|0 4|SIP1
P11263664T0000|6 30|Smad interacting protein
P11263664T0000|38 46|deltaEF1
P11263664T0000|65 88|enhancer binding factor
P11263664T0000|131 141|repressors
P11264176A0181|0 5|B-myb
P11264176A0181|23 38|G1/S transition
P11264176A0181|86 108|cyclin A2/cdk2 complex
P11264177T0000|0 19|Nucleotide sequence
P11264177T0000|21 38|transcription map
P11264177T0000|44 61|mutation analysis
P11264177T0000|69 74|13q14
P11264177T0000|87 93|region
P11264177T0000|105 111|B-cell
P11264177T0000|132 140|leukemia
P11264182A0000|6 32|T-cell leukemia virus type
P11264182A0000|36 42|HTLV-I
P11264182A0000|44 47|Tax
P11264182A0000|76 85|regulator
P11264182A0000|133 138|genes
P11264182A0000|183 197|leukemogenesis
P11264182A0000|207 222|T-cell leukemia
P11264372T0000|0 12|Requirements
P11264372T0000|41 54|translocation
P11264372T0000|58 79|infected-cell protein
P11264372T0000|85 105|herpes simplex virus
P11264375A0000|10 25|cytomegalovirus
P11264375A0000|27 31|HCMV
P11264375A0000|55 66|protein IE2
P11264375A0000|80 94|phosphoprotein
P11264375A0000|124 133|regulator
P11264375A0000|159 169|infections
P11264561A0167|0 9|OBJECTIVE
P11264561A0167|32 36|RSTD
P11264561A0167|55 62|anatomy
P11264561A0167|85 94|occlusion
P11265853A0000|4 11|Novacor
P11265853A0000|29 42|Assist System
P11265853A0000|44 48|LVAS
P11265853A0000|51 63|Novacor Corp
P11265853A0000|65 72|Oakland
P11265853A0000|74 76|CA
P11265853A0000|154 167|configuration
P11266184A0000|0 8|Atheroma
P11266184A0000|31 52|signal intensity area
P11266184A0000|70 84|time-of-flight
P11266184A0000|86 89|TOF
P11266184A0000|100 109|resonance
P11266184A0000|111 113|MR
P11266184A0000|115 121|images
P11266184A0000|131 141|components
P11266184A0000|155 173|signal intensities
P11266184A0000|177 186|spin-echo
P11266184A0000|188 190|SE
P11266184A0000|192 198|images
P11266194A0743|0 4|Body
P11266194A0743|9 21|distribution
P11266194A0743|59 69|tomography
P11266227A0295|4 14|flux rates
P11266227A0295|18 29|p-toluidine
P11266227A0295|47 55|pH value
P11266227A0295|63 77|donor solution
P11266540A0328|39 61|Groucho family members
P11266540A0328|72 79|ability
P11266540A0328|121 143|Tcf/Lef family members
P11266558A1470|31 52|transcription extract
P11266558A1470|64 80|binding activity
P11266558A1470|106 123|initiator element
P11266558A1470|152 177|recruiting RNA polymerase
P11266558A1470|188 208|SL RNA gene promoter
P11266615A0258|4 11|protein
P11266615A0258|37 44|domains
P11266615A0258|72 85|linker region
P11266615A0258|92 111|amino acid residues
P11267679A0102|8 25|bp EcoRI fragment
P11267679A0102|49 71|Southern hybridization
P11267679A0102|89 102|reading frame
P11267679A0102|119 126|protein
P11267679A0102|134 145|amino acids
P11268459A0167|25 30|study
P11268459A0167|46 58|relationship
P11268459A0167|71 90|DOX binding ability
P11268459A0167|92 95|%DB
P11268459A0167|116 124|response
P11268459A0167|126 130|rate
P11268459A0167|134 142|decrease
P11268459A0167|146 158|tumor volume
P11268459A0167|177 190|tissue tumors
P11268459A0167|210 222|chemotherapy
P11268459A0167|227 236|prognosis
P11268887A1174|9 27|misinterpretations
P11268887A1174|37 53|reference values
P11268887A1174|76 90|preadolescents
P11268887A1174|106 112|regard
P11268887A1174|116 119|FVC
P11268887A1174|124 128|FEV1
P11271297T0000|0 14|Nephrotoxicity
P11271297T0000|32 53|liver transplantation
P11271297T0000|57 70|cyclosporin A
P11271297T0000|75 77|FK
P11271297T0000|90 98|patients
P11273995A1148|29 37|subjects
P11273995A1148|46 58|TOF patients
P11273995A1148|107 117|velocities
P11273995A1148|142 157|relaxation time
P11274109A0129|0 7|Acetoin
P11274109A0129|29 37|bacteria
P11274109A0129|56 61|phase
P11274109A0129|73 87|carbon sources
P11274149A0625|11 19|analysis
P11274149A0625|36 41|U-box
P11274149A0625|52 63|RING finger
P11274149A0625|73 81|proteins
P11274149A0625|102 107|basis
P11274149A0625|116 127|interaction
P11274149A0625|133 143|E2 enzymes
P11274179A0610|10 17|studies
P11274179A0610|25 38|Rac/Cdc42/Pak
P11274179A0610|44 50|module
P11274179A0610|63 68|Raf-1
P11274179A0610|80 90|activation
P11274179A0610|106 116|disruption
P11274184A0000|0 4|Nrf2
P11274184A0000|15 25|expression
P11274184A0000|29 34|genes
P11274184A0000|44 51|enzymes
P11274184A0000|57 68|antioxidant
P11274184A0000|75 91|heme oxygenase-1
P11274184A0000|93 97|HO-1
P11274184A0000|114 128|detoxification
P11274184A1068|6 13|results
P11274184A1068|28 32|ATF4
P11274184A1068|53 57|CdCl
P11274184A1068|69 79|expression
P11274184A1068|87 96|ho-1 gene
P11274184A1068|116 122|manner
P11274184A1068|141 148|complex
P11274184A1068|154 158|Nrf2
P11274357A0724|13 17|hand
P11274357A0724|26 40|overexpression
P11274357A0724|53 57|type
P11274357A0724|90 96|mutant
P11274357A0724|100 106|nm23H1
P11274357A0724|132 137|forms
P11274357A0724|141 145|Rac1
P11274357A0724|147 152|Cdc42
P11274357A0724|158 162|RhoA
P11274357A0724|182 187|forms
P11274357A0724|204 242|nucleoside diphosphate kinase activity
P11274357A0724|248 254|nm23H1
P11274357A0724|302 306|form
P11274357A0724|316 323|GTPases
P11274368A0469|5 11|effect
P11274368A0469|32 39|absence
P11274368A0469|51 68|protein synthesis
P11274368A0469|92 120|histone deacetylase activity
P11274368A0818|0 8|Deletion
P11274368A0818|26 43|initiator element
P11274368A0818|60 70|repression
P11274368A0818|78 90|p21 promoter
P11274368A0818|94 99|c-Myc
P11274563T0000|6 17|lung volume
P11274563T0000|19 29|estimation
P11274563T0000|33 35|MR
P11274563T0000|52 59|results
P11275986A0091|7 20|gene products
P11275986A0091|22 24|E6
P11275986A0091|50 78|p53 tumor suppressor protein
P11275986A0091|113 124|degradation
P11276426A0501|3 8|mouse
P11276426A0501|10 15|Mmip1
P11276426A0501|17 27|Mad member
P11276426A0501|40 47|protein
P11276426A0501|60 65|share
P11276426A0501|68 87|% sequence identity
P11276426A0501|96 104|products
P11276426A0501|117 121|gene
P11277913T0000|3 10|element
P11277913T0000|38 44|region
P11277913T0000|54 64|Hsp70 mRNA
P11277913T0000|89 97|enhancer
P11277913T0000|101 117|mRNA translation
P11278286A0456|18 23|cells
P11278286A0456|37 39|MR
P11278286A0456|41 43|GR
P11278286A0456|49 65|5-HT1A receptors
P11278286A0456|67 75|deletion
P11278286A0456|79 91|inactivation
P11278286A0456|99 103|nGRE
P11278286A0456|114 117|GRE
P11278286A0456|139 149|regulation
P11278286A0456|157 167|rat 5-HT1A
P11278286A0456|184 193|promoters
P11278286A0456|197 212|corticosteroids
P11278286A0456|226 235|inclusion
P11278286A0456|269 279|inhibition
P11278286A0456|298 306|promoter
P11278286A1083|40 50|inhibition
P11278286A1083|67 72|MR/GR
P11278286A1083|76 87|combination
P11278286A1083|97 99|MR
P11278286A1083|103 105|GR
P11278290A1220|8 13|Smad2
P11278290A1220|44 52|TGF-beta
P11278290A1220|81 91|activation
P11278290A1220|95 109|Agc expression
P11278290A1220|123 128|cells
P11278290A1220|130 146|Smad2 activation
P11278290A1220|189 194|level
P11278290A1220|198 212|Agc expression
P11278310A1516|35 41|mutant
P11278310A1516|69 90|caspase-3 stimulation
P11278310A1516|110 118|decrease
P11278310A1516|122 133|cell number
P11278390A0632|8 54|transcriptase-polymerase chain reaction assays
P11278390A0632|67 77|PKRDeltaE7
P11278390A0632|102 107|range
P11278390A0632|117 124|tissues
P11278390A0632|137 143|levels
P11278400A0668|31 41|cell lines
P11278400A0668|66 72|number
P11278400A0668|76 79|POU
P11278400A0668|81 92|OCT binding
P11278400A0668|94 114|homeodomain proteins
P11278400A0668|143 163|mobility shift assay
P11278440A0095|0 3|SV1
P11278440A0095|19 30|acid insert
P11278440A0095|38 61|S1 transmembrane domain
P11278440A0095|82 84|S1
P11278440A0095|93 107|hydrophobicity
P11278440A0095|123 135|S0-S1 linker
P11278461A0637|11 21|antibodies
P11278461A0637|45 49|part
P11278461A0637|51 62|amino acids
P11278461A0637|90 94|part
P11278461A0637|96 107|amino acids
P11278461A0637|120 152|rainbow trout HIF-1alpha protein
P11278461A0637|164 177|rainbow trout
P11278461A0637|182 215|chinook salmon HIF-1alpha protein
P11278461A0637|219 240|Western blot analysis
P11278488T0000|4 20|v-Src SH3 domain
P11278488T0000|35 39|cell
P11278488T0000|61 72|association
P11278488T0000|84 99|adhesion kinase
P11278521A0849|10 30|pair oligonucleotide
P11278521A0849|47 54|nonamer
P11278521A0849|63 76|up-regulation
P11278521A0849|80 87|hypoxia
P11278521A0849|92 102|inhibition
P11278521A0849|124 129|acids
P11278521A0849|169 177|promoter
P11278521A0849|183 206|lacZ reporter construct
P11278563A0917|0 17|Deletion analyses
P11278563A0917|47 58|amino acids
P11278563A0917|62 67|Grb14
P11278563A0917|72 87|ankyrin repeats
P11278563A0917|97 106|tankyrase
P11278563A0917|127 138|interaction
P11278583A0873|0 11|Mutagenesis
P11278583A0873|15 19|SNT1
P11278583A0873|20 23|IRS
P11278583A0873|24 26|CX
P11278583A0873|44 51|classes
P11278583A0873|55 70|effector motifs
P11278583A0873|78 81|SNT
P11278583A0873|110 124|ERK activation
P11278583A0873|138 153|differentiation
P11278583A0873|163 185|phosphotyrosine motifs
P11278583A0873|199 210|recruitment
P11278583A0873|214 218|Grb2
P11278583A0873|227 249|phosphotyrosine motifs
P11278583A0873|263 274|recruitment
P11278583A0873|278 282|Shp2
P11278583A0873|304 309|motif
P11278583A0873|347 350|Sos
P11278594A0618|21 31|propeptide
P11278594A0618|40 47|chimera
P11278594A0618|71 76|MIC-1
P11278594A0618|80 100|TGF-beta1 propeptide
P11278594A0618|113 122|secretion
P11278594A0618|153 160|chimera
P11278594A0618|184 195|interaction
P11278594A0618|214 230|MIC-1 propeptide
P11278594A0618|242 249|peptide
P11278604A0300|25 34|N-glycans
P11278604A0300|56 62|5Lec20
P11278604A0300|114 121|species
P11278604A0300|136 145|CHO cells
P11278604A0300|151 170|Lec20 cell extracts
P11278604A0300|194 201|ability
P11278604A0300|214 217|Gal
P11278604A0300|240 249|acceptors
P11278610A0902|18 26|SOCS box
P11278610A0902|43 51|Cullin-2
P11278610A0902|65 79|ubiquitination
P11278610A0902|83 91|TEL-JAK2
P11278671T0000|16 30|Bcl-2 homology
P11278671T0000|45 59|splice variant
P11278671T0000|63 66|Bak
P11278671T0000|88 95|neurons
P11278671T0000|131 136|cells
P11278713A1054|24 30|region
P11278713A1054|44 48|exon
P11278713A1054|67 71|site
P11278713A1054|89 109|instability elements
P11278713A1054|128 139|transcripts
P11278713A1054|166 191|coding region determinant
P11278819A0565|0 19|Sequence comparison
P11278819A0565|24 39|binding studies
P11278819A0565|66 71|sites
P11278819A0565|83 89|intron
P11278819A0565|114 130|mouse IRBP genes
P11278819A0565|148 161|half sequence
P11278819A0565|179 191|core element
P11278819A0565|196 208|MOK2 binding
P11278848A1316|13 21|SB203580
P11278848A1316|44 54|activation
P11278848A1316|58 61|Sp1
P11278848A1316|78 95|promoter activity
P11278848A1316|99 104|cells
P11278848A1316|124 131|plasmid
P11278848A1316|147 169|Sp1 consensus sequence
P11278855A0205|17 28|interaction
P11278855A0205|37 40|TLS
P11278855A0205|45 48|p65
P11278855A0205|66 71|assay
P11278855A0205|90 122|coimmunoprecipitation experiment
P11278855A0205|135 147|Western blot
P11278855A0205|164 168|cell
P11278870A0123|0 8|Analysis
P11278870A0123|23 30|regions
P11278870A0123|38 46|promoter
P11278870A0123|54 58|ctr4
P11278870A0123|62 85|copper transporter gene
P11278870A0123|89 102|fission yeast
P11278870A0123|141 149|identity
P11278870A0123|182 189|element
P11278870A0123|191 195|CuSE
P11278870A0123|225 250|transcription factor Cuf1
P11278928A1634|20 24|data
P11278928A1634|38 52|mRNA structure
P11278928A1634|80 86|effect
P11278928A1634|90 104|mRNA structure
P11278928A1634|108 119|translation
P11278928A1634|137 158|C/EBPepsilon isoforms
P11278928A1634|160 163|p32
P11278928A1634|168 171|p30
P11279038A0194|0 12|WRN helicase
P11279038A0194|32 46|DNA structures
P11279038A0194|79 82|DNA
P11279038A0194|88 106|Holliday junctions
P11279086A1350|6 10|data
P11279086A1350|24 33|ADAM-TS12
P11279086A1350|43 48|roles
P11279086A1350|62 67|cells
P11279086A1350|81 92|development
P11279086A1350|99 114|tumor processes
P11279086A1350|139 147|activity
P11279086A1350|156 164|molecule
P11279086A1350|189 199|regulation
P11279086A1350|203 216|cell adhesion
P11279108T0000|0 7|Binding
P11279108T0000|11 32|serum response factor
P11279108T0000|36 54|CArG box sequences
P11279108T0000|99 114|gene expression
P11279108T0000|134 146|muscle cells
P11279207A0904|16 23|results
P11279207A0904|33 37|HPK1
P11279207A0904|47 56|component
P11279207A0904|60 73|TCR signaling
P11279217A0273|0 4|Biol
P11279324A0710|4 8|size
P11279324A0710|16 23|infarct
P11279324A0710|49 64|creatine kinase
P11279324A0710|74 80|method
P11279385A3917|24 33|technique
P11279385A3917|67 73|M mode
P11279385A3917|87 89|2D
P11279385A3917|103 110|Doppler
P11279385A3917|134 141|ability
P11279385A3917|168 176|pathways
P11279385A3917|189 199|conduction
P11279385A3917|221 227|method
P11279720A0844|0 18|SELECTION CRITERIA
P11279720A0844|42 48|trials
P11279720A0844|52 63|cabergoline
P11279720A0844|71 78|placebo
P11279720A0844|82 90|patients
P11279720A0844|107 116|diagnosis
P11279720A0844|131 140|Parkinson
P11279720A0844|143 150|disease
P11279720A0844|165 178|complications
P11279720A0844|182 198|levodopa therapy
P11280495A1330|0 11|CONCLUSIONS
P11280495A1330|61 70|PD fluids
P11280495A1330|94 103|formation
P11280495A1330|107 122|Amadori albumin
P11280495A1330|127 131|AGEs
P11280799A1025|3 11|contrast
P11280799A1025|23 32|PTHrP1-34
P11280799A1025|42 50|peptides
P11280799A1025|80 95|IL-8 production
P11280799A1025|126 136|antibodies
P11280799A1025|157 167|production
P11280799A1025|171 175|IL-8
P11280799A1025|191 196|PTHrP
P11281201T0000|14 21|effects
P11281268A0000|19 35|arginine kinases
P11281268A0000|37 40|AKs
P11281268A0000|75 80|times
P11281268A0000|98 107|evolution
P11281268A0000|111 129|phosphagen kinases
P11281268A0000|131 134|AKs
P11281268A0000|154 189|sea anemone Anthopleurura japonicus
P11281268A0000|203 235|clam Pseudocardium sachalinensis
P11282029A0075|4 9|mouse
P11282029A0075|27 40|growth factor
P11282029A0075|42 46|PDGF
P11282029A0075|48 70|beta-receptor promoter
P11282029A0075|82 93|CCAAT motif
P11282029A0075|99 103|NF-Y
P11282029A0075|123 127|role
P11282029A0075|135 148|transcription
P11282088A0837|0 12|Baseline MBF
P11282088A0837|16 23|females
P11282088A0837|43 44|P
P11282088A0837|67 72|males
P11282394A0841|16 28|VH/VL-chains
P11282394A0841|69 89|antigen reactivities
P11282394A0841|100 104|mAbs
P11282394A0841|127 145|cross-reactivities
P11282395A0530|37 52|RAG1/2 proteins
P11282395A0530|64 76|DNA hairpins
P11282395A0530|100 108|activity
P11282395A0530|134 149|protein complex
P11282395A0530|157 193|DNA repair proteins Nbs1/Mre11/Rad50
P11282395A1073|3 11|addition
P11282395A1073|43 54|differences
P11282395A1073|58 72|CDR3 sequences
P11282395A1073|87 97|Ig lambdaL
P11282395A1073|102 124|kappaL chain gene loci
P11282395A1073|148 165|blood lymphocytes
P11282395A1073|172 183|NBS patient
P11282395A1073|199 210|individuals
P11282433T0000|0 5|Phase
P11282433T0000|9 14|study
P11282433T0000|18 28|paclitaxel
P11282433T0000|38 47|etoposide
P11282433T0000|51 59|patients
P11282433T0000|106 122|cell lung cancer
P11282761A0531|5 20|supplementation
P11282761A0531|24 34|L-arginine
P11282761A0531|59 78|plasma L-citrulline
P11282761A0531|96 107|enhancement
P11282761A0531|111 124|NO production
P11283010A0701|5 15|activation
P11283010A0701|36 46|CGS 12066A
P11283014A0921|4 11|results
P11283014A0921|25 29|WASP
P11283014A0921|40 53|transcription
P11283014A0921|64 79|TCR stimulation
P11283014A0921|85 91|manner
P11283014A0921|119 123|role
P11283014A0921|143 163|actin polymerization
P11283168A0738|27 32|lines
P11283168A0738|64 74|expression
P11283168A0738|82 90|Gus gene
P11283168A0738|111 120|endosperm
P11283168A0738|128 143|mid-development
P11283168A0738|166 167|d
P11283168A0738|174 182|anthesis
P11283256A0258|32 36|MRCK
P11283256A0258|69 78|complexes
P11283354A0548|6 10|data
P11283354A0548|30 37|pathway
P11283354A0548|57 78|histone modifications
P11283354A0548|92 104|histone code
P11283354A0548|135 146|inheritance
P11283354A0548|150 174|heterochromatin assembly
P11285054A0781|0 19|Regression analyses
P11285054A0781|32 56|SOREMP dream occurrences
P11285054A0781|91 97|amount
P11285054A0781|101 110|REM sleep
P11285054A0781|118 141|NREMP dream occurrences
P11285054A0781|158 166|arousals
P11285054A0781|172 182|NREM sleep
P11285235A0466|9 14|TRPS1
P11285235A0466|67 77|activation
P11285235A0466|96 108|GATA factors
P11285329A0682|7 11|% CI
P11285329A0682|22 32|micromol/L
P11285329A0682|39 44|women
P11285329A0682|46 47|P
P11286833A0959|6 14|patients
P11286833A0959|35 41|cycles
P11286833A0959|45 59|5-fluorouracil
P11286833A0959|64 74|leucovorin
P11286833A0959|78 102|maintenance chemotherapy
P11286833A0959|103 110|RESULTS
P11286833A0959|119 124|males
P11286833A0959|132 139|females
P11286833A0959|154 157|age
P11286833A0959|164 169|years
P11286833A0959|171 176|range
P11286833A0959|184 189|years
P11287555A1057|4 19|Delta6CCI virus
P11287555A1057|48 68|replication capacity
P11287555A1057|82 96|infectiousness
P11287555A1057|101 108|CEMx174
P11287555A1057|113 122|MT4 cells
P11287578A1311|0 9|Secretion
P11287578A1311|13 26|interleukin-8
P11287578A1311|28 34|RANTES
P11287578A1311|36 46|macrophage
P11287578A1311|60 74|protein 1alpha
P11287578A1311|111 118|protein
P11287578A1311|153 166|keratinocytes
P11287578A1311|170 172|E6
P11287579A1084|8 14|mutant
P11287579A1084|16 21|T255A
P11287579A1084|32 39|ability
P11287579A1084|48 54|E4orf6
P11287579A1084|80 100|late-gene expression
P11287611A0802|7 16|PPARgamma
P11287611A0802|46 53|15d-PGJ
P11287611A0802|61 64|PGD
P11287611A0802|82 89|ligands
P11287611A0802|91 99|BRL49653
P11287611A0802|104 116|troglitazone
P11287611A0802|141 151|expression
P11287611A0802|159 173|cyclin D1 gene
P11287623A0286|82 88|kinase
P11287623A0286|90 93|ERK
P11287623A0286|95 112|signaling pathway
P11287623A0286|142 152|expression
P11287623A0286|167 184|integrin subunits
P11287623A0286|190 197|variety
P11287623A0286|211 227|mouse cell lines
P11287654A0150|0 4|PABP
P11287654A0150|18 25|protein
P11287654A0150|60 67|domains
P11287654A0150|85 95|C terminus
P11288208A0712|0 8|Children
P11288208A0712|41 57|tract infections
P11288208A0712|61 64|PCP
P11288208A0712|79 84|rates
P11288208A0712|88 95|decline
P11288208A0712|99 114|CD4 cell counts
P11288208A0712|134 140|months
P11288208A0712|144 148|life
P11288930A0000|17 24|effects
P11288930A0000|32 46|administration
P11288930A0000|81 85|acid
P11288930A0000|87 91|MCPA
P11288930A0000|96 100|rats
P11288930A0000|128 139|generations
P11288930A0000|155 161|mating
P11288930A0000|174 180|mating
P11288930A0000|185 194|gestation
P11288930A0000|199 208|lactation
P11289135A0975|0 10|Coexposure
P11289135A0975|14 16|FP
P11289135A0975|66 76|activation
P11289135A0975|102 116|protein kinase
P11289135A0975|155 177|protein kinase cascade
P11289135A0975|184 197|PMA treatment
P11289135A0975|208 218|disruption
P11289135A0975|227 234|pathway
P11289135A0975|260 281|protein kinase kinase
P11289135A0975|284 299|inhibitor U0126
P11289135A0975|316 328|potentiation
P11289135A0975|332 341|apoptosis
P11289149A0658|10 21|EWS protein
P11289149A0658|33 46|transcription
P11289149A0658|77 99|transactivation domain
P11289149A0658|107 115|cofactor
P11289149A0658|129 136|protein
P11289149A0658|138 141|CBP
P11290415A0288|15 20|study
P11290415A0288|45 66|ICBP90 gene structure
P11290415A0288|70 79|screening
P11290415A0288|91 99|placenta
P11290415A0288|108 115|library
P11290415A0288|120 132|PCR analysis
P11290906T0000|11 23|accumulation
P11290906T0000|27 39|Tl-201 SPECT
P11290906T0000|73 83|infarction
P11291552A0156|0 7|METHODS
P11291552A0156|13 21|patients
P11291552A0156|52 55|MFH
P11292335A0852|22 29|dnaE173
P11292335A0852|40 56|mutator mutation
P11292335A0852|70 91|sequence substitution
P11292335A0852|115 125|frameshift
P11292335A0852|147 156|frequency
P11292335A0852|173 192|frameshift mutation
P11292839A0531|4 17|transcription
P11292839A0531|30 33|pol
P11292839A0531|56 63|factors
P11292839A0531|71 78|U6 gene
P11292839A0531|94 103|exception
P11292839A0531|122 130|TATA-box
P11292839A0531|139 148|construct
P11292839A0531|184 191|protein
P11292839A0531|193 196|TBP
P11292839A0531|198 204|mutant
P11292839A0531|206 213|TBP-DR2
P11292839A0531|228 231|TBP
P11292839A0531|243 248|TBPwt
P11292844A0081|0 3|HSF
P11292844A0081|10 13|DNA
P11292844A0081|19 25|trimer
P11292844A0081|42 49|trimers
P11292844A0081|59 62|DNA
P11294895A0292|29 34|spo20
P11294895A0292|38 50|gene product
P11294895A0292|106 111|Sec14
P11294895A0292|123 160|phosphatidylinositol transfer protein
P11294895A0292|172 177|yeast
P11295470A0954|13 21|evidence
P11295470A0954|25 47|linkage disequilibrium
P11295470A0954|72 76|site
P11295470A0954|84 90|B cell
P11295470A0954|100 108|promoter
P11295470A0954|129 132|UTR
P11295523A0218|6 13|numbers
P11295523A0218|49 58|mid-1970s
P11295760A1374|0 23|Specimen mass reduction
P11295760A1374|39 49|irradiance
P11295760A1374|63 64|%
P11295760A1374|80 84|mass
P11295760A1374|95 99|W/cm
P11296288A1107|3 11|addition
P11296288A1107|21 31|derivative
P11296288A1107|35 43|pCMVJS21
P11296288A1107|45 60|pCMVJS21DeltaGP
P11296288A1107|75 78|gag
P11296288A1107|80 83|pol
P11296288A1107|89 94|orf-x
P11296288A1107|103 112|sequences
P11296288A1107|148 152|foci
P11296442A0565|3 13|conclusion
P11296442A0565|15 24|tube size
P11296442A0565|38 42|Cole
P11296442A0565|45 52|formula
P11296442A0565|102 111|tube size
P11296442A0565|134 144|anesthesia
P11296442A0565|175 182|formula
P11296442A0565|199 208|tube size
P11297419A0894|3 8|F222W
P11297419A0894|9 23|W21F rGST A1-1
P11297419A0894|56 74|fluorescence probe
P11297419A0894|78 85|changes
P11297419A0894|93 104|environment
P11297419A0894|123 130|residue
P11297514A0218|14 27|hos1 mutation
P11297514A0218|44 53|induction
P11297514A0218|61 86|CBF transcription factors
P11297514A0218|94 105|temperature
P11297514A0218|153 158|genes
P11297545A0948|7 19|transfection
P11297545A0948|29 38|CHOP cDNA
P11297545A0948|52 67|carcinoma cells
P11297545A0948|86 90|CHOP
P11297545A0948|111 119|mediator
P11297545A0948|138 149|mitogenesis
P11297545A0948|174 184|protection
P11297545A0948|190 199|apoptosis
P11297545A0948|212 215|hGH
P11297545A0948|221 224|p38
P11297545A0948|240 246|manner
P11297866A0484|3 11|contrast
P11297866A0484|21 33|I. argentina
P11297866A0484|38 49|I. theezans
P11297866A0484|62 68|effect
P11297866A0484|72 74|BF
P11297866A0484|89 99|propulsion
P11298326A0677|2 12|comparison
P11298326A0677|31 43|Vkappa genes
P11298326A0677|62 71|selection
P11298326A0677|107 114|regions
P11298326A0677|133 138|genes
P11298326A0677|142 157|point mutations
P11301189A1396|3 11|contrast
P11301189A1396|28 38|expression
P11301189A1396|42 45|p19
P11301189A1396|46 51|INK4d
P11301189A1396|106 121|B-lineage cells
P11302072A0508|4 11|results
P11302072A0508|32 43|stimulation
P11302072A0508|53 64|performance
P11302072A0508|72 90|Boston Naming Test
P11302072A0508|97 123|Word List Recognition Task
P11302072A0508|134 146|intervention
P11302072A0508|183 195|significance
P11302566A1318|19 29|flattening
P11302566A1318|55 84|dopamine receptor sensitivity
P11302566A1318|89 108|psychomotor slowing
P11302704T0000|0 20|Homo-oligomerisation
P11302704T0000|33 45|localisation
P11302704T0000|49 74|mouse histone deacetylase
P11303027A0954|6 10|data
P11303027A0954|28 35|network
P11303027A0954|39 51|interactions
P11303027A0954|60 67|GTPases
P11303027A0954|75 85|ARF family
P11303027A0954|96 105|effectors
P11303027A0954|119 128|potential
P11303027A0954|133 143|cross-talk
P11303638A0559|5 23|NEU overexpression
P11303638A0559|31 38|control
P11303638A0559|56 57|%
P11303638A0559|63 64|%
P11303638A0559|66 67|p
P11303890A0996|7 11|time
P11303890A0996|37 42|doses
P11303890A0996|51 57|values
P11303890A0996|79 87|microg/l
P11305129T0000|0 7|Effects
P11305129T0000|13 25|booster dose
P11305129T0000|29 43|tetanus toxoid
P11305129T0000|68 75|courses
P11305129T0000|79 90|vaccination
P11305129T0000|92 104|implications
P11305129T0000|112 115|use
P11305129T0000|126 134|globulin
P11306101A0000|6 21|RACE techniques
P11306101A0000|62 75|hamster liver
P11306101A0000|99 113|dehydrogenases
P11306101A0000|145 153|alcohols
P11306101A0000|163 186|17beta-hydroxy-steroids
P11306101A0000|191 213|3alpha-hydroxysteroids
P11306463A0383|2 10|mutation
P11306463A0383|18 26|C domain
P11306463A0383|30 32|Rb
P11306463A0383|34 39|L901Q
P11306463A0383|87 110|cdk4/D1 phosphorylation
P11306463A0383|127 135|C domain
P11306511A1476|3 14|association
P11306511A1476|44 54|expression
P11306511A1476|98 108|mdm2 mRNAs
P11306511A1476|115 119|lack
P11306511A1476|123 144|progesterone receptor
P11306845A0168|13 24|examination
P11306845A0168|42 49|changes
P11306845A0168|64 81|blister formation
P11306845A0168|96 109|keratinocytes
P11308851A0333|17 34|response function
P11308851A0333|63 67|GSER
P11308851A0333|93 108|frequency range
P11308851A0333|127 146|material parameters
P11308851A0333|159 163|bead
P11308851A0333|172 179|network
P11308877A0213|35 40|input
P11308877A0213|46 49|map
P11308877A0213|67 75|relation
P11308877A0213|84 96|input phases
P11308877A0213|112 127|discharge times
P11308877A0213|173 206|orientation preserving circle map
P11309077A0953|5 12|strains
P11309077A0953|30 34|Camp
P11309077A0953|36 42|jejuni
P11309077A0953|50 56|jejuni
P11309077A0953|86 90|ones
P11309077A0953|94 104|biotype I.
P11309373A0783|0 8|Analysis
P11309373A0783|12 22|mCTR mRNAs
P11309373A0783|63 72|promoters
P11309373A0783|78 82|rise
P11309373A0783|101 114|mCTR isoforms
P11309373A0783|125 131|region
P11309373A0783|139 143|gene
P11309373A0783|173 180|regions
P11309373A0783|199 206|lengths
P11309389A0273|31 42|proteolysis
P11309389A0273|77 122|phorbol ester phorbol 12-myristate 13-acetate
P11309389A0273|124 127|PMA
P11309389A0273|144 168|metalloprotease activity
P11309389A0273|193 197|GHBP
P11309389A0273|224 227|GHR
P11309389A0273|254 268|domain remnant
P11309389A0273|288 303|down-regulation
P11309389A0273|307 320|GHR abundance
P11309389A0273|325 337|GH signaling
P11309400T0000|0 7|Effects
P11309400T0000|14 36|terminus modifications
P11309400T0000|40 44|mRNA
P11309400T0000|56 61|decay
P11309400T0000|78 95|protein synthesis
P11309677A0000|35 42|battery
P11309677A0000|66 74|veterans
P11309677A0000|80 96|Gulf War Illness
P11309677A0000|98 101|GWI
P11309677A0000|127 134|fatigue
P11309677A0000|136 140|GV-F
P11309677A0000|157 165|veterans
P11309677A0000|167 171|GV-H
P11309678A0489|8 34|transcription-PCR analysis
P11309678A0489|38 42|mRNA
P11309678A0489|48 56|patients
P11309678A0489|87 96|mutations
P11309678A0489|117 125|splicing
P11310937A0548|0 7|RESULTS
P11310937A0548|18 27|mortality
P11310937A0548|56 60|time
P11310937A0548|67 73|months
P11310937A0548|107 114|tertile
P11310937A0548|119 122|CRP
P11310937A0548|127 131|IL-6
P11310937A0548|167 174|tertile
P11310937A0548|179 189|fibrinogen
P11310937A0548|194 203|TNF-alpha
P11310937A0548|242 250|tertiles
P11311153T0000|4 16|relationship
P11311153T0000|24 48|factor V Leiden mutation
P11311153T0000|74 86|polymorphism
P11311153T0000|94 105|angiotensin
P11311153T0000|117 123|enzyme
P11311153T0000|141 162|thromboembolic events
P11311153T0000|185 197|arthroplasty
P11311464A0362|6 15|disorders
P11311464A0362|33 37|pain
P11311464A0362|39 56|saddle anesthesia
P11311464A0362|68 76|sciatica
P11311464A0362|83 97|motor weakness
P11311464A0362|111 122|extremities
P11311464A0362|134 144|paraplegia
P11311464A0362|150 169|bladder dysfunction
P11311480A0079|6 18|nerve biopsy
P11311480A0079|49 60|perineurium
P11311480A0079|71 82|alterations
P11311480A0079|101 118|cell infiltration
P11311480A0079|126 137|perineurium
P11311480A0079|154 158|loss
P11311480A0079|189 195|fibers
P11311550A0253|27 37|regulation
P11311550A0253|45 59|rat eIF4E gene
P11311550A0253|65 67|kB
P11311550A0253|75 100|rat eIF4E promoter region
P11311550A0253|120 132|contribution
P11311550A0253|145 153|elements
P11311550A0253|168 181|transcription
P11311550A0253|208 216|cultures
P11311550A0253|220 235|rat cardiocytes
P11311550A0253|252 253|C
P11311550A0253|256 257|C
P11311550A0253|262 280|myoblast cell line
P11311563A0423|10 19|CCAAT box
P11311563A0423|53 71|promoter construct
P11311563A0423|73 85|OA induction
P11311563A0423|113 122|CCAAT box
P11311687A0231|4 10|JHRLSS
P11311687A0231|34 41|studies
P11311687A0231|52 64|RLS severity
P11311687A0231|107 115|relation
P11311687A0231|126 134|measures
P11311687A0231|142 151|morbidity
P11311687A0231|168 171|RLS
P11311909A0938|17 21|case
P11311909A0938|27 35|aneurysm
P11311909A0938|65 68|end
P11311909A0938|87 102|A1 fenestration
P11311980A1049|0 4|GABA
P11311980A1049|5 6|B
P11311980A1049|7 10|R1g
P11311980A1049|33 38|brain
P11311980A1049|54 61|tissues
P11312108A2853|0 4|Raes
P11312108A2853|6 8|P.
P11312120A1311|0 28|NF-kappaB pathway activation
P11312120A1311|43 57|transformation
P11312120A1311|71 77|number
P11312120A1311|91 100|oncogenes
P11312120A1311|112 119|Bcr/Abl
P11312120A1311|121 124|Ras
P11312120A1311|129 132|Rac
P11312120A1311|173 182|potential
P11312326A0169|10 13|rev
P11312326A0169|33 41|HIV type
P11312326A0169|45 50|HIV-1
P11312326A0169|62 67|clone
P11312326A0169|71 98|complementation experiments
P11312326A0169|114 120|method
P11312326A0169|135 144|isolation
P11312326A0169|179 187|elements
P11312326A0169|207 213|genome
P11312326A0169|231 237|rescue
P11312326A0169|241 258|virus replication
P11312584X1846|0 9|Copyright
P11312584X1846|15 29|Academic Press
P11313249T0000|27 36|zebrafish
P11313249T0000|60 67|protein
P11313249T0000|98 115|activation domain
P11313342A0224|29 50|alanine substitutions
P11313342A0224|65 86|center cleft residues
P11313342A0224|112 124|depurinating
P11313342A0224|129 137|ribosome
P11313342A0224|149 157|activity
P11313342A0224|161 164|PAP
P11313386A0704|0 21|SH2D1A protein levels
P11313386A0704|42 60|CD40 cross-linking
P11313386A0704|83 107|B cell receptor ligation
P11313398A0687|0 22|Cross-linking FcalphaR
P11313398A0687|26 33|wt-ITAM
P11313398A0687|37 51|IIA-ITAM cells
P11313398A0687|73 75|PI
P11313398A0687|95 105|activation
P11313398A0687|109 117|PKBalpha
P11313946A0449|0 8|RPM/RGL3
P11313946A0449|19 23|AF-6
P11313946A0449|28 33|Nore1
P11313946A0449|85 90|M-Ras
P11313946A0449|95 102|p21 Ras
P11313946T0000|18 26|effector
P11313946T0000|30 35|M-Ras
P11313946T0000|40 47|p21 Ras
P11313946T0000|69 72|p21
P11313946T0000|86 100|gene induction
P11313946T0000|105 116|cell growth
P11313961A1323|4 8|mice
P11313961A1323|66 72|tumors
P11313961A1323|85 88|age
P11313961A1323|93 101|contrast
P11313961A1323|116 119|p53
P11313961A1323|126 133|strains
P11313961A1323|151 159|p53 gene
P11314030A1264|4 11|results
P11314030A1264|40 46|region
P11314030A1264|50 53|Crk
P11314030A1264|83 91|elements
P11314030A1264|111 114|Abl
P11314030A1264|119 122|FAK
P11314030A1264|133 148|signal pathways
P11314030A1264|163 171|paradigm
P11314030A1264|194 200|region
P11314030A1264|208 211|SH3
P11314030A1264|230 240|SH3 domain
P11314046A0000|0 7|Cyclins
P11314046A0000|31 43|determinants
P11314046A0000|55 77|cell cycle progression
P11314373T0000|15 19|care
P11314373T0000|27 34|formula
P11314373T0000|46 53|problem
P11314428A0651|29 36|ability
P11314428A0651|44 58|hydroxyapatite
P11314428A0651|66 73|sockets
P11314428A0651|98 110|significance
P11314428A0651|122 146|months width differences
P11314428A0651|162 168|region
P11314428A0651|170 171|P
P11314428A0651|181 184|LHS
P11314428A0651|190 191|P
P11314428A0651|201 204|RHS
P11315633A0920|4 17|cleavage site
P11315633A0920|26 29|VPg
P11315633A0920|34 37|RNA
P11315633A0920|48 62|RNA polymerase
P11315633A0920|83 92|E445-T446
P11315633A0920|106 134|amino acid sequence analysis
P11315633A0920|142 153|polyprotein
P11315633A0920|169 182|sobemoviruses
P11316127A0485|4 10|%SVend
P11316127A0485|14 19|HCM-I
P11316127A0485|64 70|values
P11316127A0485|78 84|HCM-II
P11316127A0485|89 103|Control groups
P11317256A0361|11 19|isolates
P11317256A0361|23 37|S. intermedius
P11317256A0361|47 55|isolates
P11317256A0361|59 74|S. constellatus
P11317256A0361|87 88|%
P11317256A0361|101 113|S. anginosus
P11317256A0361|136 143|abscess
P11318363A0085|0 6|DESIGN
P11318363A0085|22 27|study
P11318608A0669|6 34|brain cDNA library screening
P11318608A0669|48 61|amplification
P11318608A0669|65 69|cDNA
P11318608A0669|95 105|DENTT cDNA
P11318608A0669|133 146|reading frame
P11318608A0669|183 190|protein
P11318608A0669|219 239|localization signals
P11318608A0669|241 245|NLSs
P11318608A0669|267 274|regions
P11318608A1155|0 12|Transfection
P11318608A1155|28 57|DENTT NLS deletion constructs
P11318608A1155|80 85|NLS-1
P11318608A1155|109 118|nucleolus
P11319098A0164|6 11|genes
P11319098A0164|21 38|tryptophanyl tRNA
P11319098A0164|44 78|protein translocase component SecE
P11319098A0164|99 111|protein NusG
P11319098A0164|131 143|proteins L11
P11319098A0164|148 150|L1
P11319098A0164|154 162|addition
P11319098A0164|166 170|PkwR
P11319098A0164|194 201|protein
P11319098A0164|209 225|LacI-GalR family
P11319880A1108|0 9|Rapamycin
P11319880A1108|11 30|FRAP/mTOR inhibitor
P11319880A1108|40 62|4E-BP1 phosphorylation
P11319880A1108|73 85|predominance
P11319880A1108|93 98|alpha
P11319880A1108|120 124|band
P11321187A0355|31 42|MS patients
P11321187A0355|48 49|%
P11321187A0355|70 79|synthesis
P11321187A0355|83 85|C.
P11321187A0355|106 109|IgG
P11321187A0355|142 150|controls
P11321187A0355|155 156|%
P11323411A0505|0 25|Far Western blot analysis
P11323411A0505|52 63|SH2 domains
P11323411A0505|67 71|SHP2
P11323411A0505|80 84|Gab1
P11323411A0505|99 110|orientation
P11323411A0505|125 137|N-SH2 domain
P11323411A0505|147 162|phosphotyrosine
P11323411A0505|164 167|Tyr
P11323411A0505|168 169|P
P11323411A0505|184 196|C-SH2 domain
P11323411A0505|206 209|Tyr
P11323411A0505|210 211|P
P11323419T0000|10 17|cloning
P11323419T0000|27 34|mapping
P11323419T0000|40 50|expression
P11323419T0000|67 84|blood group alpha
P11323419T0000|90 114|fucosyltransferase genes
P11323419T0000|143 167|mouse uterine epithelium
P11323419T0000|189 194|tract
P11323716A0413|4 15|UBA domains
P11323716A0413|19 24|RAD23
P11323716A0413|29 33|DDI1
P11323716A0413|57 69|interactions
P11324516A0159|30 44|administration
P11324516A0159|46 50|i.t.
P11324516A0159|55 83|D2 receptor agonist LY171555
P11324516A0159|87 121|D1/D2 receptor agonist apomorphine
P11324516A0159|132 146|pain threshold
P11324516A0159|157 176|potentiating effect
P11324516A0159|180 182|AA
P11325195A0661|4 6|R2
P11325195A0661|15 18|MFI
P11325195A0661|39 45|muscle
P11325195A0661|68 72|lamb
P11325195A0661|77 93|pork longissimus
P11325391A0498|10 15|doses
P11325391A0498|19 32|d-amphetamine
P11325391A0498|69 79|saline key
P11325391A0498|91 100|schedules
P11325685A1624|12 33|L-carnitine treatment
P11325685A1624|44 75|plasma carnitine concentrations
P11325685A1624|103 110|fatigue
P11325685A1624|132 139|decline
P11325685A1624|148 165|exercise capacity
P11325685A1624|169 190|hemodialysis patients
P11325944A0511|9 19|expression
P11325944A0511|35 39|UhpB
P11325944A0511|56 70|hybrid protein
P11325944A0511|72 78|GST-Bc
P11325944A0511|89 114|glutathione S-transferase
P11325944A0511|116 119|GST
P11325944A0511|157 164|portion
P11325944A0511|168 172|UhpB
P11325944A0511|194 202|blockage
P11325944A0511|206 221|uhpT expression
P11325944A0511|227 230|uhp
P11325944A0511|234 240|strain
P11327292A0190|12 20|location
P11327292A0190|34 46|malformation
P11327292A0190|68 72|risk
P11327292A0190|86 90|loss
P11327292A0190|98 104|vision
P11327698A0191|18 21|PKC
P11327698A0191|26 48|p44/p42MAPK signalings
P11327698A0191|95 104|IGF-II P4
P11327698A0191|121 129|activity
P11327698A0191|140 154|PKC activation
P11327698A0191|158 161|PMA
P11327698A0191|165 186|PKC expression vector
P11327698A0191|197 216|Sp1 phosphorylation
P11327698A0191|221 232|P4 activity
P11327698A0191|252 263|HepG2 cells
P11327698A0191|270 284|PKC inhibition
P11327698A0191|288 308|PKC inhibitor Go6976
P11327698A0191|317 336|Sp1 phosphorylation
P11327698A0191|338 349|P4 activity
P11327698A0191|355 366|IGF-II mRNA
P11327698A0191|386 397|HepG2 cells
P11327698A0191|413 423|inhibition
P11327698A0191|427 441|MEK activation
P11327698A0191|445 450|U0126
P11327698A0191|459 478|Sp1 phosphorylation
P11327698A0191|480 491|P4 activity
P11327698A0191|496 507|IGF-II mRNA
P11327698A0191|527 538|HepG2 cells
P11327858A0087|18 28|mechanisms
P11327858A0087|30 33|Arf
P11327858A0087|47 63|oncoprotein Hdm2
P11327858A0087|76 85|regulator
P11327858A0087|89 92|p53
P11328699A0000|30 39|test mice
P11328699A0000|58 62|time
P11328699A0000|72 77|close
P11328699A0000|85 89|wall
P11328699A0000|97 106|container
P11328699A0000|145 159|test situation
P11328853A0644|0 11|Examination
P11328853A0644|23 48|promoter deletion mutants
P11328853A0644|64 68|SF-1
P11328853A0644|95 110|promoter region
P11328853A0644|124 142|promoter sequences
P11331589A0113|4 15|MSL complex
P11331589A0113|49 66|male X chromosome
P11331589A0113|83 93|expression
P11331596A0710|0 4|Prrp
P11331596A0710|33 44|EVH1 domain
P11331596A0710|48 52|Mena
P11331596A0710|87 94|protein
P11331604A0267|0 5|Srb10
P11331604A0267|25 34|regulator
P11331604A0267|38 52|Gcn4 stability
P11331604A0267|66 81|phosphorylation
P11331604A0267|86 94|turnover
P11331604A0267|98 102|Gcn4
P11331604A0267|121 134|srb10 mutants
P11331613A0827|11 18|effects
P11331613A0827|22 35|pVHL function
P11331613A0827|58 67|mutations
P11331613A0827|80 88|subclass
P11333263A0240|6 12|intron
P11333263A0240|20 30|base pairs
P11333263A0240|48 54|middle
P11333263A0240|78 93|leader sequence
P11333263A0240|132 149|promoter activity
P11333268A1521|14 22|analysis
P11333268A1521|44 56|interactions
P11333268A1521|60 63|Sos
P11333268A1521|73 79|switch
P11333268A1521|86 92|switch
P11333268A1521|95 102|regions
P11333268A1521|106 109|Ras
P11333268A1521|135 147|consequences
P11333268A1521|153 164|interaction
P11333268A1521|170 176|switch
P11333268A1521|192 201|anchoring
P11333268A1521|205 208|Ras
P11333268A1521|212 215|Sos
P11333268A1521|229 240|interaction
P11333268A1521|246 252|switch
P11333268A1521|264 274|disruption
P11333268A1521|301 305|site
P11333268A1521|310 326|GDP dissociation
P11334124A0903|13 26|dose-response
P11334124A0903|56 64|increase
P11334124A0903|68 72|FEV1
P11334124A0903|81 82|h
P11334124A0903|84 92|AUC0-6 h
P11334124A0903|103 107|FEV1
P11334124A0903|119 129|dose range
P11334124A0903|146 154|Respimat
P11335116A1099|0 21|Bandshift experiments
P11335116A1099|39 45|BmHR3A
P11335116A1099|68 72|RORE
P11335116A1099|96 128|Orphan receptor Response Element
P11335116A1099|135 144|sequences
P11335116A1099|152 161|promoters
P11335116A1099|170 175|genes
P11335116A1099|202 206|role
P11335116A1099|211 217|BmHR3A
P11335116A1099|236 246|expression
P11335116A1099|250 260|BmGATAbeta
P11335116A1099|265 274|ESP genes
P11335116A1099|282 296|vitellogenesis
P11335710A0320|44 49|phase
P11335710A0320|53 67|Erk activation
P11336211A0132|14 20|method
P11336211A0132|33 42|Bengtsson
P11336211A0132|44 48|Appl
P11336698A0075|18 22|Rsc3
P11336698A0075|27 32|Rsc30
P11336698A0075|42 52|components
P11336698A0075|70 97|yeast remodeler RSC complex
P11337859A0651|4 7|COD
P11337859A0651|12 26|color removals
P11337859A0651|49 50|%
P11337859A0651|56 61|FeCl3
P11337859A0651|78 89|coagulation
P11337859A0651|91 98|dosages
P11337859A0651|111 122|coagulation
P11337859A0651|144 149|mol/L
P11337859A0651|180 220|hydrogen peroxide oxidation pretreatment
P11337859A0651|226 237|H2O2 dosage
P11337859A0651|246 251|mol/L
P11340048A0432|26 37|correlation
P11340048A0432|50 64|flux densities
P11340048A0432|95 102|sensors
P11340048A0432|116 127|differences
P11340048A0432|135 149|flux densities
P11340048A0432|173 180|sensors
P11340080A0096|13 21|proteins
P11340080A0096|34 54|checkpoint signaling
P11340080A0096|56 60|Rad1
P11340080A0096|62 66|Hus1
P11340080A0096|72 76|Rad9
P11340080A0096|109 128|immunoprecipitation
P11340080A0096|133 138|yeast
P11340080A0096|150 157|studies
P11340085A0211|13 23|hypothesis
P11340085A0211|54 61|regions
P11340085A0211|117 129|coactivators
P11340085A0211|147 166|amino acid sequence
P11340085A0211|170 180|C/EBPalpha
P11340085A0211|196 203|species
P11340085A0211|205 209|frog
P11340085A0211|257 264|regions
P11340085A0211|266 273|CR1-CR4
P11340085A0211|286 308|transactivation domain
P11340516A0509|0 9|Tolerance
P11340516A0509|13 19|ADAL-2
P11340516A0509|43 56|Vicryl suture
P11340516A0509|61 70|tolerance
P11340516A0509|74 80|ADAL-2
P11340516A0509|105 114|Tisuacryl
P11340525A0737|7 15|patients
P11340525A0737|24 31|regimen
P11340525A0737|44 60|study end points
P11340525A0737|74 75|%
P11340525A0737|85 94|regimen A
P11340525A0737|108 109|%
P11340525A0737|119 128|regimen B
P11340525A0737|146 147|%
P11340525A0737|157 166|regimen C
P11340525A0737|175 202|treatment success criterion
P11341349T0000|6 16|indicators
P11341349T0000|24 30|effect
P11341349T0000|36 67|breast cancer screening program
P11341349T0000|83 88|women
P11341405A0146|7 17|POPULATION
P11341405A0146|19 22|MCB
P11341405A0146|30 47|racing Greyhounds
P11341405A0146|65 72|reasons
P11341405A0146|86 103|MCB abnormalities
P11341405A1154|0 11|CONCLUSIONS
P11341405A1154|25 34|RELEVANCE
P11341405A1154|55 64|thickness
P11341405A1154|79 89|properties
P11341405A1154|98 104|MCB-IV
P11341405A1154|110 111|V
P11341405A1154|115 125|Greyhounds
P11341405A1154|149 157|turnover
P11341405A1154|162 173|orientation
P11341405A1154|177 184|osteons
P11341405A1154|192 208|dorsal quadrants
P11341405A1154|217 220|MCB
P11341405A1154|249 258|responses
P11341405A1154|293 300|loading
P11341405A1154|306 312|result
P11341405A1154|316 322|racing
P11341405A1154|335 341|tracks
P11341828A0744|30 40|D-peptides
P11341828A0744|73 79|domain
P11341828A0744|94 103|molecules
P11342479A0430|0 7|METHODS
P11342479A0430|12 19|RESULTS
P11342479A0430|21 41|Palmaz-Schatz stents
P11342479A0430|63 73|paclitaxel
P11342479A0430|94 109|microgram/stent
P11342479A0430|114 123|immersion
P11342479A0430|137 147|paclitaxel
P11342479A0430|152 163|evaporation
P11344530A0320|0 11|Percentages
P11344530A0320|15 23|recovery
P11344530A0320|28 36|overload
P11344530A0320|41 55|dilution tests
P11344530A0320|79 80|%
P11345435A0199|21 35|RNA subdomains
P11345435A0199|48 50|P3
P11345435A0199|107 119|localization
P11345445A0533|13 22|OECD soil
P11345445A0533|33 42|Cd levels
P11345445A0533|77 94|Cd concentrations
P11345445A0533|108 119|springtails
P11345445A0533|146 152|levels
P11345445A0533|156 158|Cu
P11345445A0533|163 165|Zn
P11345445A0533|187 201|concentrations
P11347201X0001|0 18|Nutritional status
P11347201X0001|22 28|adults
P11347201X0001|62 66|diet
P11347201X0001|68 78|BACKGROUND
P11347201X0001|80 90|Plant food
P11347201X0001|97 108|vitamin B12
P11347201X0001|110 119|vitamin D
P11347201X0001|131 134|n-3
P11347201X0001|157 162|acids
P11348318A0940|19 26|adjunct
P11348318A0940|30 41|mammography
P11348318A0940|51 59|patients
P11348318A0940|88 95|breasts
P11348318A0940|104 120|characterization
P11348318A0940|133 139|masses
P11349796A0950|0 12|Measurements
P11349796A0950|57 65|exposure
P11349796A0950|67 69|D0
P11349796A0950|79 83|days
P11349796A0950|101 112|measurement
P11349796A0950|114 116|D3
P11349796A0950|132 136|days
P11349796A0950|144 147|D30
P11350038A0459|16 24|evidence
P11350038A0459|41 45|half
P11350038A0459|47 51|Stem
P11350038A0459|84 98|stem structure
P11350038A0459|112 119|hY RNAs
P11350038A0459|142 146|role
P11350038A0459|154 168|export process
P11350165A1606|0 7|Changes
P11350165A1606|15 26|DB sequence
P11350165A1606|60 74|stem structure
P11350165A1606|90 96|losses
P11350165A1606|100 122|translation efficiency
P11350175A0173|27 34|members
P11350175A0173|43 57|protein family
P11350175A0173|78 87|isomerase
P11350175A0173|92 110|chaperone activity
P11350812A0829|0 10|Inhibition
P11350812A0829|18 41|Raf-1 target ERK kinase
P11350812A0829|43 46|MEK
P11350812A0829|79 87|Rp-cAMPS
P11350812A0829|105 119|ERK activation
P11350812A0829|121 146|caldesmon phosphorylation
P11350812A0829|152 174|stress fiber formation
P11350957A0457|0 10|PACAP mRNA
P11350957A0457|46 53|tissues
P11350957A0457|70 75|cells
P11350957A0457|77 82|PACAP
P11350957A0457|114 123|cytoplasm
P11350982A0560|26 34|evidence
P11350982A0560|43 54|involvement
P11350982A0560|58 79|GCN1-GCN2 interaction
P11350982A0560|83 93|activation
P11350982A0560|97 101|GCN2
P11352423A0084|11 23|forearm flap
P11352423A0084|67 75|arm flap
P11352423A0084|87 91|flap
P11352423A0084|95 101|choice
P11352423A0084|113 123|situations
P11352663A0138|3 13|comparison
P11352663A0138|33 42|Ad5 cells
P11352663A0138|44 49|class
P11352663A0138|52 62|expression
P11352663A0138|89 96|binding
P11352663A0138|100 107|COUP-TF
P11352663A0138|119 126|binding
P11352663A0138|130 139|NF-kappaB
P11352671A0492|6 17|application
P11352671A0492|29 37|genetics
P11352671A0492|57 74|nucleotide change
P11352671A0492|76 79|UCU
P11352671A0492|83 86|ACU
P11352671A0492|131 135|site
P11352671A0492|143 149|V gene
P11352671A0492|169 179|hPIV2 cDNA
P11352671A0492|215 222|viruses
P11352671A0492|224 230|rPIV2V
P11352671A0492|244 248|cDNA
P11353392A1127|4 14|frameshift
P11353392A1127|28 33|ADEx2
P11353392A1127|67 82|coding sequence
P11353392A1127|113 126|ASIP mutation
P11353770A0085|25 33|activity
P11353770A0085|58 60|S3
P11353770A0085|79 101|N-glycosylase activity
P11353770A0085|110 117|removal
P11353770A0085|121 142|8-oxoguanine residues
P11353770A0085|146 149|DNA
P11353770A0085|171 176|sites
P11353770A0085|186 192|places
P11353774A0255|19 28|isolation
P11353774A0255|33 49|characterization
P11353774A0255|57 75|forkhead homologue
P11353774A0255|79 95|rhabdomyosarcoma
P11353774A0255|97 101|FKHR
P11353774A0255|125 131|member
P11353774A0255|139 149|hepatocyte
P11353774A0255|158 175|factor 3/forkhead
P11353774A0255|185 196|gene family
P11353774A0255|211 227|hormone receptor
P11353774A0255|229 231|NR
P11353774A0255|246 253|protein
P11354406A1373|13 36|CSF outflow conductance
P11354406A1373|67 77|compliance
P11354406A1373|112 124|ICP waveform
P11354975A0850|6 13|species
P11354975A0850|17 28|Euspondylus
P11354975A0850|53 59|female
P11354975A0850|76 85|bromeliad
P11354975A0850|98 105|El Humo
P11354975A0850|107 112|Sucre
P11354975A0850|127 136|Venezuela
P11355576A1125|4 11|cyclins
P11355576A1125|37 40|CDK
P11355576A1125|57 72|phosphorylation
P11355576A1125|83 93|inhibition
P11355576A1125|102 126|tumor suppressor protein
P11355576A1125|128 131|pRb
P11355576A1125|133 156|pRb controls commitment
P11355576A1125|178 180|G1
P11355576A1125|184 191|S phase
P11355576A1125|205 209|part
P11355576A1125|228 236|activity
P11355576A1125|244 269|E2F transcription factors
P11355576A1125|287 305|cell proliferation
P11355615A0766|11 20|education
P11355615A0766|25 33|research
P11355615A0766|63 72|direction
P11355615A0766|77 89|intervention
P11355615A0766|94 107|incorporation
P11355615A0766|113 121|practice
P11355668T0000|14 26|vasculopathy
P11355668T0000|41 52|hemorrhages
P11355668T0000|56 72|porcine neonates
P11355668T0000|91 98|porcine
P11355668T0000|128 142|syndrome virus
P11356214A0794|4 14|difference
P11356214A0794|18 26|hardness
P11356214A0794|32 36|time
P11356214A0794|50 59|specimens
P11356214A0794|79 106|Knoop hardness measurements
P11356214A0794|135 143|surfaces
P11356214A0794|147 162|resin specimens
P11356214A0794|173 184|Teflon mold
P11356214A0794|194 204|dimensions
P11356214A0794|212 218|cavity
P11356214A0794|231 237|dentin
P11356716A0372|17 22|clone
P11356716A0372|33 42|sequences
P11356716A0372|64 78|GHS-R variants
P11356835A0000|48 55|network
P11356835A0000|72 79|control
P11356835A0000|99 103|cell
P11356835A0000|120 127|amounts
P11356835A0000|131 149|protein precursors
P11356835A0000|157 178|amino acid starvation
P11356853A0429|3 13|Ka13 cells
P11356853A0429|15 19|CoCl
P11356853A0429|34 44|expression
P11356853A0429|50 74|luciferase reporter gene
P11356853A0429|85 92|control
P11356853A0429|110 134|pair mouse ho-1 promoter
P11356853A0429|136 144|pHO15luc
P11356853A0554|0 17|Mutation analyses
P11356853A0554|51 60|sequences
P11356853A0554|84 92|elements
P11356853A0554|94 99|StREs
P11356853A0873|0 7|Members
P11356853A0873|15 31|AP-1 superfamily
P11356853A0873|35 63|basic-leucine zipper factors
P11356853A0873|76 80|StRE
P11357063A0138|0 12|Descriptions
P11357063A0138|21 26|locus
P11357063A0138|39 49|comparison
P11357063A0138|95 103|features
P11357063A0138|113 120|species
P11357063A0138|133 137|loci
P11357063A0138|170 184|LH/CGbeta gene
P11357063A0138|201 233|LHbeta-CGbeta gene cluster locus
P11357063A1053|9 18|consensus
P11357063A1053|29 40|LHbeta gene
P11357063A1053|58 64|region
P11357063A1053|72 88|gpLH/CGbeta gene
P11357063A1053|107 120|TATA sequence
P11357063A1053|124 126|bp
P11357063A1053|143 166|translation start codon
P11358801A1046|19 29|situations
P11358801A1046|43 49|breaks
P11358801A1046|51 66|NHEJ deficiency
P11358801A1046|84 98|rearrangements
P11358801A1046|103 112|agreement
P11358801A1046|130 137|studies
P11358958A0878|0 10|Expression
P11358958A0878|20 25|RACK1
P11358958A0878|60 77|growth inhibition
P11358958A0878|81 85|HF7c
P11358958A0878|105 116|tumor cells
P11358958A0878|134 143|apoptosis
P11358962A0344|0 5|Foxp1
P11358962A0344|10 15|Foxp2
P11358962A0344|38 44|levels
P11358962A0344|52 56|lung
P11358962A0344|69 72|E12
P11358962A0344|78 95|mouse development
P11358962A0344|101 117|Foxp2 expression
P11358962A0344|136 153|airway epithelium
P11359568T0000|10 18|analysis
P11359568T0000|26 50|pRA2 partitioning region
P11359568T0000|52 56|ParB
P11359568T0000|71 90|parAB transcription
P11359568T0000|103 124|nucleoprotein complex
P11359568T0000|134 156|plasmid partition site
P11359568T0000|158 162|parS
P11359827T0000|30 46|characterization
P11359827T0000|74 83|exotoxins
P11359827T0000|90 91|J
P11359827T0000|93 98|SPE-I
P11359827T0000|103 108|SPE-J
P11359907A0099|8 27|dozen HIF-1 targets
P11359907A0099|53 57|gene
P11359907A0099|88 101|growth factor
P11359907A0099|103 107|VEGF
P11360190A0178|28 31|Tax
P11360190A0178|40 62|cell cycle progression
P11360190A0178|68 79|G0/G1 phase
P11360190A0178|83 84|S
P11360190A0178|89 100|G2/M phases
P11360190A0178|110 125|T-cell line Kit
P11360190A0178|130 135|cells
P11361338A0093|5 10|yeast
P11361338A0093|23 38|matrix proteins
P11361338A0093|49 53|type
P11361338A0093|78 94|targeting signal
P11361338A0093|96 100|PTS1
P11361338A0093|120 134|tripeptide SKL
P11361338A0447|10 26|PEX5-TPR domains
P11361338A0447|39 46|tobacco
P11361338A0447|52 60|nematode
P11361338A0447|91 96|yeast
P11361338A0447|103 112|construct
P11361338A0447|125 140|Pex5p chimaeras
P11361493T0000|0 5|HIV-1
P11361493T0000|10 38|hepatitis B virus infections
P11361493T0000|42 53|adolescents
P11361493T0000|64 83|security institutes
P11361493T0000|87 99|Buenos Aires
P11367523A1684|0 26|Immunofixation experiments
P11367523A1684|30 33|C4A
P11367523A1684|38 41|C4B
P11367523A1684|59 68|allotypes
P11367523A1684|80 87|classes
P11367523A1684|91 99|proteins
P11367523A2624|9 21|C4B proteins
P11367523A2624|51 56|genes
P11367523A2624|84 98|concentrations
P11367523A2624|120 129|C4A genes
P11368363A0129|7 13|course
P11368363A0129|31 52|transcription factors
P11368363A0129|83 98|myeloperoxidase
P11368363A0129|100 103|MPO
P11368363A0129|105 113|promoter
P11368363A0129|132 136|time
P11368363A0129|164 168|cDNA
P11368363A0129|181 184|DNA
P11368363A0129|195 199|HBP1
P11368363A0129|201 227|HMG-Box containing protein
P11368363A0129|234 240|member
P11368363A0129|253 267|mobility group
P11368363A0129|295 303|proteins
P11368363A1103|10 26|protein sequence
P11368363A1103|59 65|domain
P11368363A1103|90 98|rat HBP1
P11368363A1103|109 117|homology
P11368363A1103|127 137|activation
P11368363A1103|142 159|repressor domains
P11368363A1103|191 202|rat protein
P11368787A0180|0 8|Promoter
P11368787A0180|25 33|activity
P11368787A0180|63 70|portion
P11368787A0180|84 99|annexin A5 gene
P11368787A0180|106 108|bp
P11368787A0180|166 192|transcription start points
P11368901A0327|3 11|contrast
P11368901A0327|26 31|mouse
P11368901A0327|37 45|proteins
P11368901A0327|58 69|repeat unit
P11368901A0327|97 104|portion
P11368911T0000|10 24|identification
P11368911T0000|28 33|smg-4
P11368911T0000|48 65|mRNA surveillance
P11368911T0000|69 79|C. elegans
P11368914T0071|22 27|exons
P11368914T0071|39 63|complement C3 gene locus
P11368914T0071|87 90|end
P11368914T0071|104 107|ORF
P11368914T0071|118 125|control
P11368914T0071|145 153|promoter
P11369066A1210|0 11|CONCLUSIONS
P11369066A1210|20 23|MMF
P11369066A1210|42 56|corticosteroid
P11369066A1210|74 79|cream
P11369066A1210|141 146|cream
P11369066A1210|171 191|radiation dermatitis
P11369106A0428|7 15|advances
P11369106A0428|41 47|sulfur
P11369106A0428|53 59|result
P11369106A0428|74 86|interactions
P11369106A0428|91 115|transformation processes
P11369106A0428|135 144|food webs
P11369410A0949|10 20|hypothesis
P11369410A0949|42 47|sense
P11369410A0949|53 73|stimulus differences
P11369410A0949|87 96|behaviour
P11369410A0949|137 147|processing
P11369410A0949|158 170|participants
P11369453A1083|13 21|increase
P11369453A1083|25 40|protein binding
P11369453A1083|51 58|element
P11369453A1083|70 87|peptide treatment
P11369700A0074|0 3|CSR
P11369700A0074|34 48|chain isotypes
P11369700A0074|52 61|cytokines
P11369700A0074|66 83|B cell activators
P11369700A0074|96 109|transcription
P11369700A0074|136 144|germline
P11369700A0074|146 148|GL
P11369700A0074|151 152|C
P11369700A0074|153 154|H
P11369700A0074|156 168|region genes
P11369700A0616|8 18|manuscript
P11369700A0616|50 59|Ets sites
P11369700A0616|67 90|mouse GL alpha promoter
P11369700A0616|100 127|transcription factors Elf-1
P11369700A0616|132 136|PU.1
P11369700A0616|154 158|site
P11369700A0616|176 186|expression
P11369700A0616|192 216|luciferase reporter gene
P11369700A0616|231 248|GL alpha promoter
P11369759A0605|0 4|Cell
P11370174A0447|9 31|serum creatinine level
P11370174A0447|66 72|months
P11370174A0447|79 89|withdrawal
P11370174A0447|93 96|MMF
P11371115A0962|4 14|proportion
P11371115A0962|22 30|biopsies
P11371115A0962|60 71|HBs antigen
P11371115A0962|80 81|%
P11371115A0962|107 110|MGN
P11371115A0962|114 126|MPGN pattern
P11371160A0193|19 30|nucleotides
P11371160A0193|45 61|base-pair C1-G72
P11371160A0193|66 88|discriminator base A73
P11371160A0193|96 101|amino
P11371160A0193|116 122|branch
P11371160A0193|130 138|molecule
P11371160A0854|5 11|domain
P11371160A0854|34 48|anticodon loop
P11371160A0854|56 64|tyrosine
P11371160A0854|75 79|acts
P11371160A0854|86 92|anchor
P11371160A0854|97 114|TyrRS interaction
P11371160A0854|135 145|efficiency
P11371160A0854|149 161|tyrosylation
P11371343A0125|19 29|cell cycle
P11371343A0125|31 39|separase
P11371343A0125|85 92|protein
P11371343A0125|100 107|securin
P11371417A0744|11 22|ventilation
P11371417A0744|26 39|control lungs
P11371417A0744|53 63|% decrease
P11371417A0744|67 83|chord compliance
P11371417A0744|88 96|increase
P11371417A0744|100 118|lung lavage levels
P11371417A0744|122 143|tumor necrosis factor
P11371417A0744|145 148|TNF
P11371417A0744|150 155|alpha
P11371417A0744|169 174|pg/ml
P11371417A0744|177 188|interleukin
P11371417A0744|190 192|IL
P11371417A0744|195 199|beta
P11371417A0744|213 218|pg/ml
P11371417A0744|225 235|macrophage
P11371417A0744|249 258|protein-2
P11371417A0744|260 265|MIP-2
P11371417A0744|280 285|pg/ml
P11371417A0744|308 314|levels
P11371417A0744|318 327|cytokines
P11371417A0744|340 359|preventilation data
P11371417A0744|368 374|change
P11371417A0744|378 388|percentage
P11371417A0744|409 419|aggregates
P11371417A0744|421 423|LA
P11372882A1143|9 10|p
P11372882A1143|11 12|p
P11372882A1143|13 16|DDE
P11372882A1143|21 36|beta-HCH levels
P11372882A1143|71 77|levels
P11372882A1143|83 89|levels
P11372882A1143|93 97|PCBs
P11372959A1447|9 28|regression analysis
P11372959A1447|71 78|factors
P11372959A1447|91 100|abundance
P11372959A1447|113 118|sites
P11372959A1447|131 143|relationship
P11372959A1447|145 160|R2 coefficients
P11372959A1447|172 188|habitat category
P11372959A1447|206 207|%
P11372959A1447|215 224|variation
P11372959A1447|228 242|tick abundance
P11373277A0812|3 10|summary
P11373277A0812|44 59|oncoprotein E1A
P11373277A0812|70 83|transcription
P11373277A0812|104 118|AP-2alpha gene
P11373277A0812|123 129|effect
P11373277A0812|160 172|derepression
P11373277A0812|180 198|AP-2alpha promoter
P11373277A0812|202 213|interaction
P11373277A0812|217 220|E1A
P11373277A0812|238 255|corepressor CtBP1
P11374051A0437|11 18|factors
P11374051A0437|36 39|age
P11374051A0437|53 56|use
P11374051A0437|60 75|corticosteroids
P11374051A0437|79 93|anticoagulants
P11374051A0437|101 120|ulcer complications
P11374051A0437|135 143|diseases
P11374051A0437|169 173|risk
P11374051A0437|177 185|bleeding
P11374559A0103|0 12|SERS spectra
P11374559A0103|30 48|vacuum evaporation
P11374559A0103|53 60|casting
P11374559A0103|64 69|p-NTP
P11374559A0103|82 94|island films
P11374559A0103|110 136|colloidal silver solutions
P11374866X0914|0 9|Copyright
P11374866X0914|15 29|Academic Press
P11375392T0000|4 17|core promoter
P11375392T0000|27 48|thioredoxin reductase
P11375392T0000|52 59|cloning
P11375392T0000|77 85|activity
P11375392T0000|91 96|Oct-1
P11375392T0000|98 101|Sp1
P11375392T0000|107 118|Sp3 binding
P11375392T0000|146 154|promoter
P11375392T0000|189 193|gene
P11376007A0584|42 46|loss
P11376007A0584|54 77|protein kinase activity
P11376007A0584|81 87|DNA-PK
P11376007A0584|107 115|addition
P11376007A0584|142 149|subunit
P11376007A0584|160 179|protein phosphatase
P11376007A0584|185 207|protein phosphatase 2A
P11376007A0584|209 213|PP2A
P11376007A0584|229 241|reactivation
P11376007A0584|267 296|protein phosphatase inhibitor
P11376007A0584|298 309|microcystin
P11376119A0346|10 14|exon
P11376119A0346|16 23|exon 1A
P11376119A0346|66 72|region
P11376119A0346|80 91|GHR 1A mRNA
P11376119A0346|103 105|bp
P11376119A0346|120 124|exon
P11376119A0346|134 142|GHR gene
P11376134A1506|6 17|corrections
P11376134A1506|33 42|sequences
P11376134A1506|68 88|transcription factor
P11376134A1506|97 102|sites
P11376165T0000|0 3|FLP
P11376165T0000|8 32|Cre recombinase function
P11376165T0000|36 51|Xenopus embryos
P11376279A0000|2 8|method
P11376279A0000|53 62|resonance
P11376279A0000|64 66|MR
P11376279A0000|68 79|angiography
P11376279A0000|93 104|extremities
P11376279A0000|120 138|volume acquisition
P11376687A0344|9 32|nucleotide polymorphism
P11376687A0344|34 37|SNP
P11376687A0344|42 46|exon
P11376687A0344|84 87|SNP
P11376687A0344|89 100|GTG83/ATG83
P11376687A0344|146 149|AUG
P11376687A0344|160 170|MTH1 mRNAs
P11376687A0344|191 207|MTH1 polypeptide
P11376687A0344|209 212|p26
P11376687A0344|256 272|targeting signal
P11376946A0000|13 20|studies
P11376946A0000|37 42|SHP-1
P11376946A0000|46 49|SH2
P11376946A0000|85 96|phosphatase
P11376946A0000|123 128|cells
P11376946A0000|146 154|lineages
P11376946A0000|191 196|cells
P11376946A0000|207 214|control
P11376946A0000|249 257|promoter
P11376946A0000|259 261|P1
P11377975A0898|30 40|COS1 cells
P11377975A0898|63 82|proteinase activity
P11377975A0898|106 116|substrates
P11377975A0898|141 151|conditions
P11377975A0898|160 165|study
P11378898A0164|0 4|ORF1
P11378898A0164|11 13|bp
P11378898A0164|15 28|EMBL databank
P11378898A0164|30 43|Accession No.
P11379106A0372|7 15|meantime
P11379106A0372|52 78|deammonification processes
P11379106A0372|95 99|flow
P11379106A0372|111 122|pilot plant
P11380028A0000|4 11|purpose
P11380028A0000|20 25|study
P11380028A0000|53 60|methods
P11380028A0000|65 75|estimation
P11380028A0000|79 92|Technetium Tc
P11380028A0000|98 103|99mTc
P11380028A0000|105 114|pentetate
P11380028A0000|119 137|orthoiodohippurate
P11380028A0000|145 153|131I-OIH
P11380028A0000|155 171|plasma clearance
P11380028A0000|175 179|dogs
P11380028A0000|184 188|cats
P11380028A0000|202 215|blood samples
P11380370A0000|2 9|patient
P11380370A0000|28 40|skin lesions
P11380370A0000|52 58|Kaposi
P11380370A0000|61 68|sarcoma
P11380370A0000|70 72|KS
P11380837A1505|0 13|Interventions
P11380837A1505|38 47|mediators
P11380837A1505|52 61|processes
P11380837A1505|132 137|costs
P11380837A1505|150 168|access dysfunction
P11381094A0797|3 11|addition
P11381094A0797|13 19|stonin
P11381094A0797|35 46|C2B domains
P11381094A0797|50 64|synaptotagmins
P11382701A0688|13 24|transection
P11382701A0688|38 49|vasopressin
P11382701A0688|68 76|response
P11382701A0688|89 93|rise
P11382701A0688|97 124|plasma sodium concentration
P11382948A0793|3 13|conclusion
P11382948A0793|30 38|MRI data
P11382948A0793|68 96|tumor microvessel properties
P11382948A0793|105 124|breast cancer model
P11382948A0793|140 152|permeability
P11382948A0793|171 176|USPIO
P11382948A0793|208 219|tumor grade
P11383860A0661|4 10|images
P11383860A0661|47 56|excretion
P11383860A0661|60 79|99mTc ciprofloxacin
P11383860A0661|100 105|brain
P11383860A0661|107 111|lung
P11383860A0661|116 134|bone marrow uptake
P11383860A0661|143 155|liver uptake
P11383860A0661|160 169|excretion
P11384225A0634|8 11|end
P11384225A0634|16 35|expression cassette
P11384225A0634|54 58|gene
P11384225A0634|83 90|protein
P11384225A0634|92 95|GFP
P11384225A0634|115 118|end
P11384225A0634|160 169|sequences
P11384229A1669|13 26|N63S mutation
P11384229A1669|44 58|VP5 background
P11384229A1669|73 84|interaction
P11384229A1669|103 130|beta-galactosidase activity
P11384229A1669|137 143|factor
P11384229A1669|170 182|PR7 mutation
P11384576A1132|3 11|addition
P11384576A1132|20 31|vision loss
P11384576A1132|49 59|interferon
P11384576A1132|79 90|retinopathy
P11384880A0719|4 13|mechanism
P11384880A0719|21 30|induction
P11384880A0719|34 48|3beta-HSD type
P11384880A0719|51 66|gene expression
P11384880A0719|96 103|ZR-75-1
P11384880A0719|110 129|breast cancer cells
P11385840A1684|14 27|RTC algorithm
P11385840A1684|42 59|wastewater system
P11385840A1684|79 89|parameters
P11385840A1684|134 155|optimization routines
P11387208T0000|0 37|SKP1-SnRK protein kinase interactions
P11387208T0000|58 65|binding
P11387208T0000|71 97|plant SCF ubiquitin ligase
P11387351A0092|0 8|PATIENTS
P11387351A0092|13 20|METHODS
P11387351A0092|30 34|June
P11387351A0092|44 52|December
P11387351A0092|90 119|analog 2-chlorodeoxyadenosine
P11387351A0092|121 126|2-CDA
P11387351A0092|134 142|children
P11387351A0092|156 159|AML
P11387351A0092|167 175|children
P11387351A0092|191 194|AML
P11387351A0092|214 222|syndrome
P11387351A0092|224 227|MDS
P11387940A0647|4 12|severity
P11387940A0647|27 34|changes
P11387940A0647|54 63|magnitude
P11387940A0647|67 77|percussion
P11387950X0001|13 18|study
P11387950X0001|22 33|ta chengchi
P11387950X0001|39 48|decoction
P11387950X0001|63 74|lung injury
P11387950X0001|100 112|pancreatitis
P11387950X0001|118 128|objectives
P11387950X0001|136 141|study
P11387950X0001|166 173|changes
P11387950X0001|177 199|leukocyte adhesiveness
P11387950X0001|204 225|tumor necrosis factor
P11387950X0001|227 230|TNF
P11387950X0001|245 250|stage
P11387950X0001|272 284|pancreatitis
P11387950X0001|286 289|ANP
P11387950X0001|315 323|relation
P11387950X0001|333 340|changes
P11387950X0001|344 355|lung injury
P11387950X0001|359 362|ANP
P11387950X0001|396 402|effect
P11387950X0001|406 417|ta chengchi
P11387950X0001|423 432|Decoction
P11387950X0001|436 454|leukocyte adhesion
P11387950X0001|459 472|TNF secretion
P11389077A0000|2 9|variety
P11389077A0000|31 49|signaling pathways
P11389077A0000|109 119|regulators
P11389085A0290|0 8|TT cells
P11389085A0290|18 31|MTC cell line
P11389085A0290|43 58|MEN 2A type RET
P11389085A0290|93 97|RelA
P11389085A0290|98 101|p65
P11389085A0290|110 117|nucleus
P11389085A1032|0 10|Inhibition
P11389085A1032|27 45|NF-kappaB activity
P11389085A1032|57 67|cell death
P11389085A1032|71 79|TT cells
P11389085A1032|91 106|focus formation
P11389085A1032|128 133|forms
P11389085A1032|137 140|RET
P11389085A1032|144 157|NIH 3T3 cells
P11390395A1018|14 31|HMGI-C expression
P11390395A1018|74 84|repression
P11390395A1018|104 119|transactivation
P11390581A1203|10 17|finding
P11390581A1203|25 39|identification
P11390581A1203|53 61|sequence
P11390581A1203|77 86|Cp region
P11390581A1203|166 174|activity
P11390581A1203|182 190|promoter
P11390650A0562|11 29|deletion mutations
P11390650A0562|71 77|domain
P11390650A0562|102 108|region
P11390650A0562|112 118|SLP-76
P11390650A0562|145 155|P-1 domain
P11390663A1400|9 18|profiling
P11390663A1400|24 33|gcn4Delta
P11390663A1400|66 93|induction pathway operating
P11390663A1400|102 120|Gcn4p target genes
P11390663A1400|142 147|cells
P11390684A1170|0 8|Evidence
P11390684A1170|16 38|Northern hybridization
P11390684A1170|54 69|jadM expression
P11390684A1170|89 110|jadomycin B synthesis
P11391303A0807|6 9|LHR
P11391303A0807|11 16|R-LHR
P11391303A0807|36 49|interobserver
P11391303A0807|54 83|intraobserver reproducibility
P11391303A1023|0 11|CONCLUSIONS
P11391303A1023|17 28|methodology
P11391303A1023|32 47|LHR measurement
P11391303A1023|86 98|contribution
P11391303A1023|102 131|Tl-201 lung uptake evaluation
P11391531A1157|0 8|Mutation
P11391531A1157|16 30|NF-kappaB site
P11391531A1157|38 52|Mdr1b promoter
P11391531A1157|66 75|induction
P11391531A1157|79 88|TNF-alpha
P11391793A0856|25 35|complexity
P11391793A0856|51 57|region
P11391793A0856|71 77|tumors
P11391793A0856|103 106|map
P11391793A0856|120 123|SRO
P11391793A0856|152 165|bacteriophage
P11391793A0856|188 198|chromosome
P11391793A0856|200 203|PAC
P11391793A0856|205 211|clones
P11392306T0000|7 15|teaching
P11392306T0000|17 23|design
P11392306T0000|28 38|techniques
P11392772A0182|4 15|application
P11392772A0182|23 36|biotechnology
P11392772A0182|44 50|plants
P11392772A0182|55 64|treatment
P11392772A0182|72 92|surface storm waters
P11392772A0182|113 126|zone Telychka
P11392772A0182|134 138|city
P11392772A0182|142 146|Kyiv
P11392772A0182|163 170|content
P11392772A0182|174 183|petroleum
P11392772A0182|187 192|water
P11392772A0182|208 215|Dnieper
P11392772A0182|248 253|times
P11393463A0274|0 4|Data
P11393463A0274|40 55|student samples
P11393463A0274|71 76|group
P11393463A0274|78 79|n
P11393463A0274|100 121|NEO-PI-R self-ratings
P11393463A0274|127 136|occasions
P11393463A0274|165 173|interval
P11393463A0274|181 196|informant group
P11393463A0274|198 199|n
P11393463A0274|220 227|ratings
P11393463A0274|242 249|friends
P11393463A0274|253 262|relatives
P11393463A0274|268 277|occasions
P11393463A0274|295 309|month interval
P11393791A1153|0 22|Northern blot analysis
P11393791A1153|26 30|RNAs
P11393791A1153|38 44|number
P11393791A1153|48 61|mouse tissues
P11393791A1153|75 80|Atp6i
P11393791A1153|111 122|osteoclasts
P11393791A1153|145 155|expression
P11393791A1153|195 220|polymerase chain reaction
P11393791A1153|222 228|RT-PCR
P11393791A1153|230 235|assay
P11393791A1153|260 268|analysis
P11395469A1373|8 16|mutation
P11395469A1373|33 39|motifs
P11395469A1373|66 76|regulation
P11395469A1373|80 84|sid1
P11395469A1373|111 121|regulation
P11395469A1373|125 129|sid2
P11395469A1373|133 137|iron
P11396685A0477|14 21|results
P11396685A0477|32 35|DTD
P11396685A0477|97 103|amount
P11396685A0477|107 113|sample
P11396685A0477|132 134|mg
P11396685A0477|162 173|information
P11396685A0477|189 195|groups
P11396685A0477|199 208|compounds
P11396685A0477|220 227|cheeses
P11397652A0381|0 10|Guidelines
P11397652A0381|36 48|spiral assay
P11397652A0381|80 92|test methods
P11397652A0381|116 123|variety
P11397652A0381|137 149|difficulties
P11397652A0381|170 189|sample availability
P11397652A0381|191 207|sample viscosity
P11397652A0381|211 221|volatility
P11397652A0381|223 227|etc.
P11398134A1565|3 13|conclusion
P11398134A1565|15 22|obesity
P11398134A1565|24 38|alcohol intake
P11398134A1565|59 68|disorders
P11398134A1565|103 113|predictors
P11398134A1565|122 133|development
P11398134A1565|137 150|hyperuricemia
P11398899A1183|0 4|Fans
P11398899A1183|8 15|tunnels
P11398899A1183|25 32|windows
P11398899A1183|48 57|locations
P11398899A1183|89 99|likelihood
P11398899A1183|108 126|PH3 concentrations
P11398899A1183|139 144|areas
P11399064T0000|0 14|Autoregulation
P11399064T0000|33 41|pathways
P11399064T0000|53 88|CCAAT/enhancer binding protein beta
P11399064T0000|90 100|C/EBP beta
P11399064T0000|102 115|transcription
P11399834T0000|10 14|case
P11399834T0000|18 36|HCV seroconversion
P11399834T0000|40 48|Portugal
P11399834T0000|59 71|introduction
P11399834T0000|75 92|HCV NAT screening
P11400644A0435|5 15|reflection
P11400644A0435|19 32|uncertainties
P11400644A0435|40 49|estimates
P11400644A0435|65 72|sources
P11400644A0435|83 94|percentiles
P11400644A0435|98 113|PCDD/F releases
P11400644A0435|140 149|g I-TEQ/y
P11401105T0000|0 10|Gabapentin
P11401105T0000|29 38|myoclonus
P11401105T0000|42 57|cancer patients
P11401611A1703|0 11|CONCLUSIONS
P11401611A1703|17 30|meta-analysis
P11401611A1703|56 62|trials
P11401611A1703|66 69|HRT
P11401611A1703|104 113|reduction
P11401611A1703|130 139|fractures
P11402674T0000|0 32|Newcastle disease antibody titre
P11402674T0000|49 76|serum calcium concentration
P11403173A0192|2 7|total
P11403173A0192|14 22|patients
P11403173A0192|38 51|brain tumours
P11403663A0359|4 8|lift
P11403663A0359|22 26|drag
P11403663A0359|38 46|bearings
P11403663A0359|63 71|impeller
P11403663A0359|90 101|predictions
P11403663A0359|111 121|2-D theory
P11403719A1257|4 11|results
P11403719A1257|26 30|Gab1
P11403719A1257|50 57|control
P11403719A1257|61 77|egr-1 expression
P11403719A1257|91 98|insulin
P11404010A0235|13 22|triplexes
P11404010A0235|37 43|length
P11404010A0235|51 57|repeat
P11404016A1922|4 16|co-existence
P11404016A1922|20 30|TE domains
P11404016A1922|46 50|PKSs
P11404016A1922|99 102|TEs
P11404016A1922|104 110|TE IIs
P11404016A1922|136 142|number
P11404016A1922|154 164|polyketide
P11404016A1922|183 200|peptide synthases
P11404016A1922|202 206|NRPS
P11404019A0532|11 24|understanding
P11404019A0532|32 49|mGSTM2 regulation
P11404019A0532|88 103|promoter region
P11404312A0660|13 22|pmol/24 h
P11404312A0660|24 25|P
P11406007A0292|0 18|SELECTION CRITERIA
P11406007A0292|46 52|trials
P11406007A0292|63 67|IUSs
P11406007A0292|79 84|forms
P11406007A0292|99 113|contraceptives
P11406007A0292|146 154|outcomes
P11406007A0292|158 163|women
P11406007A0292|180 185|years
P11406025A0204|0 10|OBJECTIVES
P11406025A0204|16 25|objective
P11406025A0204|34 40|review
P11406025A0204|60 73|effectiveness
P11406025A0204|75 81|safety
P11406025A0204|86 99|acceptability
P11406025A0204|107 116|diaphragm
P11406025A0204|134 144|spermicide
P11406277A0598|12 22|hypothesis
P11406277A0598|34 42|elements
P11406277A0598|60 77|promoter activity
P11406277A0598|95 123|reporter expression activity
P11406277A0598|127 135|segments
P11406277A0598|147 156|mutations
P11406277A0598|166 174|elements
P11406277A0598|180 188|activity
P11406277A0598|196 224|parent Hlx promoter sequence
P11406642A0792|16 21|cases
P11406642A0792|23 33|expression
P11406642A0792|52 57|genes
P11407289A1507|0 11|CONCLUSIONS
P11407289A1507|43 53|anesthesia
P11407289A1507|85 94|BIS index
P11407289A1507|183 189|agents
P11407448A0815|4 11|results
P11407448A0815|59 67|patients
P11407448A0815|84 111|jejunum flap reconstruction
P11407448A0815|143 166|tract voice restoration
P11407448A0815|200 216|voice prosthesis
P11407448A0815|256 264|puncture
P11407448A0815|289 304|speech training
P11407650A0661|0 13|Hypercalcemia
P11407650A0661|39 62|serum PTH concentration
P11407650A0661|82 101|hyperparathyroidism
P11407650A0661|117 128|BC patients
P11407650A0661|131 132|%
P11407650A0661|141 145|none
P11407650A0661|157 162|women
P11407650A0661|166 174|patients
P11407650A0661|180 194|thyroid cancer
P11408099A0518|25 37|correlations
P11408099A0518|61 66|weeks
P11408099A0518|70 79|pregnancy
P11408099A0518|84 93|Se levels
P11408099A0518|97 103|kidney
P11408099A0518|105 106|r
P11408099A0518|114 115|P
P11408099A0518|127 132|heart
P11408099A0518|134 135|r
P11408099A0518|143 144|P
P11408338A1686|5 10|study
P11408338A1686|25 28|PSP
P11408338A1686|110 118|majority
P11408338A1686|122 127|cases
P11408338A1686|158 170|neurologists
P11408575A0000|29 34|entry
P11408575A0000|40 47|mitosis
P11408575A0000|57 67|activation
P11408575A0000|92 104|kinase Cdc28
P11408575A0000|112 120|cyclin B
P11408575A0000|122 125|Clb
P11408575A0000|138 142|form
P11408591A0000|20 30|production
P11408591A0000|34 44|hyaluronan
P11408591A0000|46 48|HA
P11408591A0000|58 64|effect
P11408591A0000|68 81|cell motility
P11408591A0000|85 90|cells
P11408591A0000|106 119|v-src mutants
P11408604A1440|4 11|results
P11408604A1440|26 27|D
P11408604A1440|35 36|D
P11408604A1440|37 39|2L
P11408604A1440|41 50|receptors
P11408604A1440|64 82|ERK kinase cascade
P11408604A1440|103 112|signaling
P11408604A1440|120 133|PDGF receptor
P11408604A1440|162 172|activation
P11408604A1440|176 182|ERK1/2
P11408604A1440|186 194|pathways
P11408604A1440|216 240|receptor tyrosine kinase
P11408774X0893|0 9|Karger AG
P11408774X0893|11 16|Basel
P11409425A0000|15 29|plasma samples
P11409425A0000|39 47|patients
P11409425A0000|55 73|National Institute
P11409425A0000|90 98|Diseases
P11409425A0000|103 109|Stroke
P11409425A0000|111 116|NINDS
P11409425A0000|118 146|tissue plasminogen activator
P11409425A0000|148 152|t-PA
P11409425A0000|154 166|Stroke Trial
P11409425A0000|182 194|relationship
P11409425A0000|206 220|apolipoprotein
P11409425A0000|222 225|Apo
P11409425A0000|227 229|E2
P11409425A0000|236 252|Apo E4 phenotype
P11409425A0000|269 276|outcome
P11409425A0000|279 285|months
P11409425A0000|292 298|stroke
P11409425A0000|304 308|risk
P11409425A0000|326 336|hemorrhage
P11409425A0000|346 354|response
P11409425A0000|370 382|t-PA therapy
P11410110A0190|0 4|NIRS
P11410110A0190|35 46|measurement
P11410110A0190|50 58|muscle O
P11410110A0190|62 73|consumption
P11410110A0190|75 77|mV
P11410110A0190|78 79|O
P11410110A0190|88 106|forearm blood flow
P11410110A0190|108 111|FBF
P11410110A0190|127 135|subjects
P11410563A0363|21 27|factor
P11410563A0363|31 35|risk
P11410563A0363|60 79|regression analysis
P11410563A0363|91 94|age
P11410563A0363|96 113|body surface area
P11410563A0363|115 125|valve size
P11410563A0363|127 151|shop order fracture rate
P11410563A0363|157 177|manufacturing period
P11410563A0363|181 193|risk factors
P11410563A0363|198 201|OSF
P11410664A0963|8 14|report
P11410664A0963|20 29|technique
P11410664A0963|51 83|breast carcinoma MDA-MB231 cells
P11410664A0963|105 108|MPG
P11410664A0963|112 117|order
P11410664A0963|136 149|up-regulation
P11410664A0963|165 169|step
P11410664A0963|173 176|BER
P11410664A0963|188 196|activity
P11410664A0963|215 218|BER
P11410664A0963|220 225|hOGG1
P11410664A0963|230 237|APE/ref
P11410664A0963|251 259|reversal
P11410664A0963|261 265|MGMT
P11410664A0963|267 284|repair activities
P11410679A0000|14 24|alteration
P11410679A0000|32 38|genome
P11410679A0000|45 60|Cre recombinase
P11410679A0000|75 88|rearrangement
P11410679A0000|92 97|genes
P11410679A0000|109 134|LOX recognition sequences
P11410679A0000|152 155|use
P11410679A0000|180 190|constructs
P11410679A0000|216 219|cre
P11410679A0000|249 253|gene
P11410679A0000|257 265|interest
P11410679A0000|277 286|LOX sites
P11411198A0711|11 17|cancer
P11411198A0711|61 75|Ashkenazi Jews
P11411198A0711|106 110|risk
P11411198A0711|139 153|stomach cancer
P11411198A0711|173 181|lymphoma
P11411623T0000|0 9|Influence
P11411623T0000|13 32|compression therapy
P11411623T0000|36 44|symptoms
P11411623T0000|60 73|tissue injury
P11411623T0000|97 105|exercise
P11411961A0735|0 26|Keratoconjunctivitis sicca
P11411961A0735|57 69|complication
P11411961A0735|78 86|children
P11411961A0735|92 95|JRA
P11411961A0735|143 150|battery
P11411961A0735|154 159|tests
P11413148A0573|0 16|STAT5A mutations
P11413148A0573|24 36|Src homology
P11413148A0573|40 43|SH2
P11413148A0573|49 60|SH3 domains
P11413148A0573|92 116|tyrosine phosphorylation
P11413277A1121|3 13|conclusion
P11413277A1121|23 35|chemotherapy
P11413277A1121|50 58|dose MTX
P11413277A1121|63 68|ara-C
P11413277A1121|92 97|PCNSL
P11413310A0148|0 6|RANTES
P11413310A0148|23 33|activation
P11413310A0148|44 50|T-cell
P11413310A0148|91 103|CC chemokine
P11413310A0148|133 142|monocytes
P11413310A0148|144 155|lymphocytes
P11413310A0148|161 172|eosinophils
P11413310A0148|178 188|cell types
P11413310A0148|204 208|lung
P11413310A0148|222 232|infiltrate
P11413310A0148|244 257|RSV infection
P11413319A0000|0 14|Reovirus mRNAs
P11413319A0000|49 59|host cells
P11413319A0000|72 79|absence
P11413319A0000|101 106|tails
P11413641A0373|0 8|Analyses
P11413641A0373|23 36|scale matters
P11413641A0373|58 64|effect
P11413641A0373|68 80|quadrat area
P11413760A0000|0 10|Myasthenia
P11413760A0000|35 42|disease
P11413760A0000|62 72|production
P11413760A0000|76 86|antibodies
P11413760A0000|99 112|ACh receptors
P11413760A0000|134 141|synapse
P11414754X1099|0 9|Copyright
P11414754X1099|15 29|Academic Press
P11415633A1253|23 33|force data
P11415633A1253|37 42|input
P11415633A1253|66 71|model
P11415633A1253|96 107|compression
P11415952A0369|0 6|Angina
P11415952A0369|8 9|Q
P11415952A0369|11 22|persistence
P11415952A0369|37 49|associations
P11415952A0369|75 85|infarction
P11415952A0369|97 103|angina
P11415952A0369|105 131|electrocardiogram ischemia
P11415952A0369|163 183|heart disease events
P11415952A0369|189 191|Q5
P11415958A0000|12 18|decade
P11415958A0000|45 53|advances
P11415958A0000|61 64|use
P11415958A0000|77 88|methodology
P11415958A0000|93 101|analysis
P11415958A0000|119 123|data
P11415958A0000|158 168|advantages
P11415958A0000|185 193|approach
P11416012A1982|38 47|mediation
P11416012A1982|51 53|LH
P11416012A1982|56 68|contribution
P11416012A1982|90 95|drive
P11416012A1982|101 113|LDL receptor
P11416012A1982|128 130|bp
P11416012A1982|132 148|reporter plasmid
P11416012A1982|188 226|rabbit muscle protein kinase inhibitor
P11416012A1982|228 231|PKI
P11416012A1982|233 241|minigene
P11416012A1982|274 296|sarcoma virus promoter
P11416012A2511|30 34|role
P11416012A2511|42 72|insulin/IGF-I effector pathway
P11416012A2511|94 105|stimulation
P11416012A2511|109 141|LDL receptor promoter expression
P11416012A2511|172 177|cells
P11416012A2511|201 204|min
P11416012A2511|223 233|inhibitors
P11416012A2511|237 265|phophatidylinositol 3-kinase
P11416012A2511|267 277|wortmannin
P11416012A2511|283 285|nM
P11416012A2511|291 293|LY
P11416012A2511|305 311|microM
P11416012A2511|338 359|protein kinase kinase
P11416012A2511|361 363|PD
P11416012A2511|374 380|microM
P11416012A2511|383 388|U0126
P11416012A2511|393 399|microM
P11416012A2511|409 415|latter
P11416012A2511|427 437|derivative
P11416012A2511|439 444|U0124
P11416012A2511|449 455|microM
P11416012T0000|26 36|activation
P11416012T0000|48 81|density lipoprotein receptor gene
P11416012T0000|85 92|insulin
P11416012T0000|109 116|hormone
P11416012T0000|129 136|porcine
P11416012T0000|154 159|cells
P11416012T0000|170 181|convergence
P11416012T0000|185 199|protein kinase
P11416012T0000|203 232|phosphatidylinositol 3-kinase
P11416012T0000|256 289|protein kinase signaling pathways
P11416132A1351|6 13|studies
P11416132A1351|45 56|recognition
P11416132A1351|64 71|bxd PRE
P11416132A1351|75 76|d
P11416132A1351|77 79|GA
P11416132A1351|81 82|n
P11416132A1351|84 109|repeat binding activities
P11416132A1351|133 142|silencing
P11416144A1324|4 12|findings
P11416144A1324|25 38|understanding
P11416144A1324|46 52|ZBP-89
P11416144A1324|63 81|cell proliferation
P11416144A1324|102 111|mechanism
P11416144A1324|125 136|p53 protein
P11416260A0000|15 21|method
P11416260A0000|47 52|point
P11416260A0000|67 75|activity
P11416260A0000|108 116|patients
P11416260A0000|172 185|data analysis
P11416393A0000|5 15|modalities
P11416393A0000|36 46|approaches
P11416393A0000|78 100|lifestyle modification
P11416393A0000|105 112|control
P11416393A0000|125 149|blood pressure elevation
P11416393A0000|154 170|weight reduction
P11416393A0000|180 191|body weight
P11416393A0000|210 214|risk
P11416393A0000|218 230|hypertension
P11416393A0000|265 274|morbidity
P11416393A0000|279 288|mortality
P11416393A0000|301 319|sodium restriction
P11416393A0000|335 336|g
P11416393A0000|339 342|day
P11416393A0000|352 361|assurance
P11416393A0000|394 402|pressure
P11416393A0000|431 437|dosage
P11416393A0000|442 449|numbers
P11416393A0000|481 486|drugs
P11416393A0000|491 501|moderation
P11416393A0000|505 524|alcohol consumption
P11416393A0000|540 545|ounce
P11416393A0000|548 551|day
P11416393A0000|575 591|exercise program
P11416393A0000|600 609|cessation
P11416393A0000|613 632|tobacco consumption
P11416650T0000|18 30|Hypertension
P11416650T0000|35 41|Update
P11416737T0000|0 5|Ga-67
P11416737T0000|10 29|Tl-201 scintigraphy
P11416737T0000|48 60|plasmacytoma
P11416737T0000|64 75|case report
P11416879A1589|9 27|blood gas tensions
P11416879A1589|52 69|ventilation modes
P11418130A0499|24 38|loxP sequences
P11418130A0499|74 87|recombination
P11418662A0917|15 22|portion
P11418662A0917|26 31|Notch
P11418662A0917|32 34|IC
P11418662A0917|46 61|p50 DNA binding
P11418662A0917|95 106|p50 subunit
P11418662A0917|112 115|p65
P11418662A0917|119 128|NF-kappaB
P11419938T0000|15 22|changes
P11419938T0000|37 62|uptake regulation protein
P11419938T0000|68 84|metal activation
P11419938T0000|89 100|DNA binding
P11419938T0000|108 116|evidence
P11419938T0000|131 141|homologies
P11419938T0000|151 177|diphtheria toxin repressor
P11420612A0303|5 15|complement
P11420612A0303|31 38|mapping
P11420612A0303|43 61|sequencing efforts
P11420612A0303|106 110|maps
P11420612A0303|115 128|sequence data
P11420612A0303|142 149|regions
P11420612A0303|153 161|interest
P11422200A0000|0 11|Granulocyte
P11422200A0000|31 37|factor
P11422200A0000|39 44|G-CSF
P11422200A0000|46 60|administration
P11422200A0000|99 117|defence mechanisms
P11422200A0000|126 135|infection
P11422200A0000|149 157|microbes
P11422757A0737|6 17|individuals
P11422757A0737|28 35|changes
P11422757A0737|66 76|ACR levels
P11422757A0737|80 88|baseline
P11423991A1393|10 16|screen
P11423991A1393|27 38|p53 mutants
P11423991A1393|42 47|yeast
P11423991A1393|67 79|p53 variants
P11423991A1393|113 116|p53
P11423991A1393|136 145|responses
P11423991A1393|174 190|cancer therapies
P11424992A0712|33 42|diagnoses
P11424992A0712|111 119|criteria
P11425076A0364|49 54|flows
P11425076A0364|60 66|result
P11425076A0364|75 80|alpha
P11425076A0364|109 115|values
P11425076A0364|123 138|Reynolds number
P11425076A0364|165 172|inertia
P11425076A0364|194 221|perturbation theory results
P11425076A0364|225 235|comparison
P11425076A0364|253 264|integration
P11425076A0364|277 282|model
P11425877A1026|0 5|Cells
P11425877A1026|14 18|p116
P11425877A1026|38 44|defect
P11425877A1026|52 61|formation
P11425877A1026|86 96|structures
P11425877A1026|112 121|reduction
P11425877A1026|129 133|rate
P11425877A1026|137 160|fluid phase pinocytosis
P11425877A1026|176 184|decrease
P11425877A1026|192 202|efficiency
P11425877A1026|218 229|aggregation
P11425877A1026|237 245|decrease
P11425877A1026|258 273|F-actin content
P11427329A1077|4 12|validity
P11427329A1077|20 25|FPS-R
P11427329A1077|67 79|correlations
P11427329A1077|89 92|VAS
P11427329A1077|94 95|r
P11427329A1077|102 103|N
P11427329A1077|116 119|CAS
P11427329A1077|121 122|r
P11427329A1077|129 130|N
P11427329A1077|152 158|sample
P11427611A0000|4 18|susceptibility
P11427611A0000|34 43|fumigatus
P11427611A0000|47 60|mulundocandin
P11427611A0000|83 91|compound
P11427611A0000|114 120|agents
P11427611A0000|141 159|National Committee
P11427611A0000|173 193|Laboratory Standards
P11427611A0000|195 200|NCCLS
P11427611A0000|202 214|M38-P method
P11427611A0000|263 275|phenyl-amino
P11427611A0000|276 284|carbonyl
P11427611A0000|287 310|H-tetrazolium hydroxide
P11427611A0000|312 315|XTT
P11427611A0000|336 341|assay
P11427611A0000|347 360|determination
P11427611A0000|376 387|alterations
P11427611A0000|391 401|microscopy
P11428276A0352|4 7|Van
P11428276A0352|12 17|Hoeve
P11428276A0352|20 36|syndrome lesions
P11428276A0352|69 81|calcium salt
P11428276A0352|95 103|increase
P11428276A0352|107 117|phosphates
P11428283A0228|14 20|infant
P11428283A0228|48 55|stridor
P11428283A0228|78 86|distress
P11428435A0446|0 6|DESIGN
P11428435A0446|24 36|chart review
P11428435A0446|46 54|patients
P11428435A0446|75 85|procedures
P11428435A0446|93 107|period January
P11428435A0446|116 124|December
P11428487T0000|10 20|vein varix
P11428487T0000|24 35|association
P11428487T0000|61 74|vein stenosis
P11428897A0318|12 23|experiments
P11428897A0318|40 44|CopG
P11428897A0318|78 88|target DNA
P11428897A0318|96 103|protein
P11428897A0318|104 114|DNA ratios
P11428897A0318|151 156|turns
P11428897A0318|169 173|face
P11428897A0318|188 193|helix
P11428897A0318|202 212|directions
P11428897A0318|231 237|repeat
P11428897A0318|259 263|CopG
P11428897A0318|272 278|target
P11429702A0917|42 52|conditions
P11429702A0917|54 60|KMS-11
P11429702A0917|65 76|OPM-2 cells
P11429702A0917|97 103|levels
P11429702A0917|122 135|FGFR3 mutants
P11429702A0917|162 172|activation
P11429702A0917|180 185|Y373C
P11429702A0917|190 205|K650E receptors
P11429702A0917|211 219|addition
P11429702A0917|227 238|aFGF ligand
P11429702A0917|261 266|level
P11429702A0917|270 294|receptor phosphorylation
P11430042A0000|1 7|figure
P11430042A0000|13 17|text
P11430042A0000|23 47|Stille coupling reaction
P11430042A0000|98 115|tetrafluoroborate
P11430042A0000|117 125|BMIM BF4
P11430042A0000|153 159|liquid
P11430042A0000|161 165|RTIL
P11430976X0000|8 14|issues
P11430976X0000|30 42|biosynthesis
P11430976X0000|46 69|woody plant biopolymers
P11430976X0000|82 92|substances
P11431348A0000|0 12|Interactions
P11431348A0000|25 52|checkpoint abrogator UCN-01
P11431348A0000|81 91|inhibitors
P11431348A0000|117 131|protein kinase
P11431348A0000|133 137|MAPK
P11431348A0000|139 145|kinase
P11431348A0000|147 150|MEK
P11431348A0000|152 164|MAPK pathway
P11431348A0000|189 196|variety
P11431348A0000|206 225|leukemia cell lines
P11431472A0540|4 20|affinity binding
P11431472A0540|24 33|Rab6A-GTP
P11431472A0540|53 54|K
P11431472A0540|55 56|d
P11431472A0540|63 69|microm
P11431472A0540|80 85|Rab1B
P11431472A0540|105 106|A
P11431857A0186|4 12|students
P11431857A0186|30 45|urine screening
P11431857A0186|67 71|time
P11431857A0186|90 104|urine analysis
P11431857A0186|114 118|days
P11431857A0186|149 163|urine analysis
P11432112A0000|0 7|PURPOSE
P11432112A0000|13 22|objective
P11432112A0000|31 36|study
P11432112A0000|57 72|embryo cleavage
P11432112A0000|74 77|FEC
P11432112A0000|85 86|h
P11432112A0000|110 125|sperm injection
P11432112A0000|127 131|ICSI
P11432112A0000|138 147|parameter
P11432112A0000|156 180|embryo selection process
P11432748T0000|0 10|Regulation
P11432748T0000|14 49|laminin beta2 chain gene expression
P11432748T0000|59 76|cancer cell lines
P11432776A0421|0 8|Northern
P11432776A0421|13 34|Western blot analyses
P11432776A0421|53 58|Graf2
P11432776A0421|83 90|tissues
P11432776A0421|109 119|expression
P11432776A0421|132 138|muscle
P11433014A0683|44 50|fusion
P11433014A0683|54 70|core histone H2A
P11433014A0683|74 77|H2B
P11433014A0683|95 99|tail
P11433014A0683|109 112|MCB
P11433014A0683|162 169|protein
P11433018A0756|6 10|data
P11433018A0756|38 45|binding
P11433018A0756|49 54|Nhp2p
P11433018A0756|58 71|H/ACA snoRNAs
P11433018A0756|92 100|assembly
P11433018A0756|104 117|H/ACA snoRNPs
P11433018A0756|136 145|stability
P11433018A0756|163 173|components
P11433024A0260|0 10|Telomerase
P11433024A0260|16 41|ribonucleoprotein complex
P11433024A0260|69 72|DNA
P11433024A0260|78 89|chromosomes
P11433024A0260|100 113|RNA component
P11433024A0260|117 125|template
P11433379A0000|0 3|SIT
P11433379A0000|36 51|adaptor protein
P11433379A0000|92 107|adaptor protein
P11433379A0000|131 142|lymphocytes
P11434084A0508|15 26|patients DD
P11434084A0508|50 66|microlatex tests
P11434084A0508|85 92|d-dimer
P11435428A0000|10 31|acetyl-CoA synthetase
P11435428A0000|33 39|AceCS1
P11435428A0000|51 58|acetate
P11435428A0000|73 78|cells
P11435428A0000|84 94|acetyl-CoA
P11435428A0000|99 114|lipid synthesis
P11435517A0396|6 21|digestibilities
P11435517A0396|25 27|DM
P11435517A0396|29 31|OM
P11435517A0396|33 35|CP
P11435517A0396|51 56|fiber
P11435517A0396|58 61|TDF
P11435517A0396|78 84|energy
P11435517A0396|86 88|GE
P11435517A0396|102 103|P
P11435517A0396|116 120|dogs
P11435517A0396|125 130|diets
P11435517A0396|155 160|fiber
P11435517A0396|175 179|dogs
P11435517A0396|188 200|control diet
P11435560A1322|15 19|data
P11435560A1322|35 47|HFV R region
P11435560A1322|60 67|nucleus
P11435560A1322|94 98|fate
P11435560A1322|102 117|target HFV mRNA
P11435578A0760|6 10|TxRE
P11435578A0760|41 49|elements
P11435578A0760|51 54|CRE
P11435578A0760|79 87|TGACGTCA
P11435578A0760|89 98|consensus
P11435578A0760|140 146|strain
P11435578A0760|153 161|AGACGTCA
P11435578A0760|163 171|TGACGGCA
P11435578A0760|173 181|TGACCTCA
P11435578A2231|23 37|reconstitution
P11435578A2231|43 56|consensus CRE
P11435578A2231|75 84|enhancers
P11435578A2231|95 102|binding
P11435578A2231|106 123|CREB/ATF proteins
P11435578A2231|144 154|repression
P11435578A2231|171 184|transcription
P11435605A0587|14 25|mutagenesis
P11435605A0587|29 32|CAR
P11435605A0587|47 65|CAR residues Leu73
P11435605A0587|70 76|Lys121
P11435605A0587|84 90|Lys123
P11435605A0587|104 120|contact residues
P11435605A0587|127 132|Tyr80
P11435605A0587|137 142|Tyr83
P11435605A0587|178 197|binding interaction
P11435605A0587|207 210|Ad5
P11435605A0587|212 215|Ad9
P11435605A0587|217 221|Ad12
P11435605A0587|227 244|Ad41L fiber knobs
P11435688A0262|5 14|subfamily
P11435688A0262|18 23|genes
P11435688A0262|54 60|domain
P11435688A0262|68 78|N-terminus
P11435688A0262|103 106|set
P11435688A0262|110 132|transmembrane segments
P11435983T0000|0 9|Tolerance
P11435983T0000|19 34|transplantation
P11435983T0000|52 63|bone marrow
P11435983T0000|87 96|follow-up
P11437439A0201|4 21|promoter activity
P11437439A0201|38 44|region
P11437439A0201|77 83|subset
P11437439A0201|87 101|prestalk cells
P11437660A1219|0 12|Substitution
P11437660A1219|16 31|serine residues
P11437660A1219|39 49|C-terminus
P11437660A1219|65 69|loss
P11437660A1219|73 94|phosphorylation sites
P11437660A1219|122 128|effect
P11437660A1219|132 145|transcription
P11437660A1219|150 161|replication
P11438651A1365|6 31|replication fork movement
P11438651A1365|37 40|HML
P11438651A1365|60 66|origin
P11438651A1365|90 112|replication initiation
P11438651A1365|137 142|Orc2p
P11438651A1365|146 155|component
P11438651A1365|163 184|replication initiator
P11438654A1237|6 14|findings
P11438654A1237|32 44|adapter Gab1
P11438654A1237|58 73|c-Met signaling
P11438654A1237|82 86|PI3K
P11438654A1237|99 131|c-Akt/Pak1 cell survival pathway
P11438666A0555|23 36|mouse protein
P11438666A0555|38 41|TAF
P11438666A0555|64 67|HFD
P11438666A0555|74 91|plant homeodomain
P11438666A0555|93 96|PHD
P11438666A0555|98 104|finger
P11438666A0555|131 150|immunoprecipitation
P11438666A0555|169 184|TFIID component
P11438838A0788|10 19|inhibitor
P11438838A0788|33 42|TAR decoy
P11438838A0788|58 60|U6
P11438838A0788|75 87|RNA promoter
P11438838A0788|89 93|U6-P
P11439343A0785|3 11|contrast
P11439343A0785|15 19|MPc3
P11439343A0785|21 25|data
P11439343A0785|44 58|Pc protein M33
P11439343A0785|82 85|AF9
P11441163T0000|0 10|Foreigners
P11441311X0001|10 17|results
P11441311X0001|23 30|MACOP-B
P11441311X0001|35 52|radiation therapy
P11441311X0001|68 77|lymphomas
P11441311X0001|79 89|BACKGROUND
P11441311X0001|101 108|results
P11441311X0001|132 153|chemotherapy regimens
P11441311X0001|169 176|factors
P11441311X0001|194 203|lymphomas
P11441311X0001|205 208|NHL
P11441952A0414|6 10|days
P11441952A0414|12 13|D
P11441952A0414|24 30|months
P11441952A0414|52 56|rats
P11441952A0414|83 93|percentage
P11441952A0414|97 106|avoidance
P11441952A0414|112 120|controls
P11441952A0414|140 150|difference
P11441952A0414|166 181|months post-TBI
P11441952A0414|183 184|b
P11441952A0414|194 208|avoidance test
P11441952A0414|215 219|test
P11441952A0414|245 248|TBI
P11441974A0320|7 10|end
P11441974A0320|19 22|day
P11441974A0320|26 35|migration
P11441974A0320|50 63|hemolymph PO2
P11441974A0320|83 86|kPa
P11441974A0320|96 106|hemocyanin
P11441974A0320|149 156|reserve
P11441974A0320|189 197|mmol x l
P11443509A0293|0 6|DESIGN
P11443509A0293|20 32|cohort study
P11443509A0293|43 44|y
P11443509A0293|55 61|period
P11443509A0293|67 88|First National Health
P11443509A0293|93 111|Examination Survey
P11443509A0293|113 119|NHANES
P11443509A0293|147 152|Study
P11443509A0293|154 159|NHEFS
P11443999A0573|0 22|Mean Hg concentrations
P11443999A0573|30 36|livers
P11443999A0573|40 44|mice
P11443999A0573|53 58|sites
P11443999A0573|62 73|Isle Royale
P11443999A0573|103 104|P
P11443999A0573|118 135|Hg concentrations
P11443999A0573|155 174|government agencies
P11443999A0573|201 212|consumption
P11444762A0373|25 34|proposals
P11444762A0373|55 63|analysis
P11444762A0373|67 71|data
P11444762A0373|91 96|onset
P11444762A0373|100 106|action
P11445008A0816|4 9|assay
P11445008A0816|38 48|comparison
P11445008A0816|61 83|FGFR expression levels
P11445008A0816|106 114|RNA pool
P11445008A0816|134 150|RNA pool samples
P11447490A0598|4 10|amount
P11447490A0598|22 30|effusion
P11447490A0598|49 54|fluid
P11447490A0598|79 89|assessment
P11448051A0093|4 10|system
P11448051A0093|62 84|intestine transit time
P11448051A0093|116 120|core
P11448051A0093|145 151|matrix
P11448051A0093|175 180|agent
P11448051A0093|182 186|NaCl
P11448051A0093|188 196|mannitol
P11448051A0093|202 207|Emdex
P11448051A0093|222 229|polymer
P11448051A0093|231 245|Eudragit RS100
P11449014A0000|0 15|STUDY OBJECTIVE
P11449014A0000|22 27|study
P11449014A0000|60 67|aspects
P11449014A0000|83 90|quality
P11449014A0000|124 130|trials
P11449014A0000|132 136|CCTs
P11449014A0000|141 149|relation
P11449014A0000|157 170|participation
P11449014A0000|177 207|epidemiologist/biostatistician
P11449014A0000|209 212|E/B
P11450490A0565|46 52|acuity
P11450490A0565|62 82|range hand motions/0
P11450490A0565|110 115|lines
P11450490A0565|170 176|acuity
P11450490A0565|186 191|range
P11450490A0565|204 205|P
P11450776T0000|7 11|case
P11450776T0000|23 28|group
P11450776T0000|45 56|peritonitis
P11451447A0205|0 5|Gimpl
P11451447A0205|7 9|F.
P11451682A0190|12 24|chemotherapy
P11451682A0190|28 30|AE
P11451682A0190|47 61|administration
P11451682A0190|65 100|benzimidazole carbamate derivatives
P11451682A0190|110 121|mebendazole
P11451682A0190|126 137|albendazole
P11451995T0000|27 35|analysis
P11451995T0000|64 70|Ste14p
P11451995T0000|81 87|member
P11451995T0000|95 146|isoprenylcysteine carboxyl methyltransferase family
P11454004T0000|9 19|regulation
P11454004T0000|32 41|promoters
P11454004T0000|49 52|rat
P11454004T0000|67 106|glycerol-3-phosphate dehydrogenase gene
P11454004T0000|108 122|identification
P11454004T0000|136 160|hormone-response element
P11454004T0000|179 190|promoter B.
P11454190A0000|0 15|BACKGROUND/AIMS
P11454190A0000|17 28|Hepatitis C
P11454190A0000|46 65|fatty liver disease
P11454190A0000|67 71|NAFL
P11454190A0000|97 102|forms
P11454190A0000|106 119|liver disease
P11454190A0000|127 140|United States
P11454239A0478|12 20|Analysis
P11454239A0478|30 35|ANOVA
P11454239A0478|41 87|Pearson Product Moment Correlation Coefficient
P11454239A0478|89 118|Principal Components Analysis
P11454239A0478|123 153|Discriminant Function Analysis
P11454239A0478|162 173|calculation
P11454239A0478|177 185|Cronbach
P11454239A0478|188 193|alpha
P11454239A0478|195 200|alpha
P11454239A0478|202 209|RESULTS
P11454239A0478|216 227|Sensitivity
P11454239A0478|232 243|specificity
P11454239A0478|267 276|Chronbach
P11454239A0478|279 284|alpha
P11454239A0478|299 304|scale
P11454703A0000|4 14|telomerase
P11454703A0000|27 34|complex
P11454703A0000|51 62|maintenance
P11454703A0000|76 79|DNA
P11454703A0000|83 98|chromosome ends
P11454703A0000|150 155|cells
P11454703A0000|201 216|immortalization
P11454703A0000|228 241|tumorigenesis
P11456259A0142|4 9|titer
P11456259A0142|13 49|TSH binding inhibitor immunoglobulin
P11456259A0142|51 55|TBII
P11456259A0142|76 77|%
P11456259A0142|89 101|presentation
P11456259A0142|115 116|%
P11456259A0142|122 127|weeks
P11457139A0604|4 11|results
P11457139A0604|22 25|CVN
P11457139A0604|65 77|affinity Man
P11457139A0604|80 86|GlcNAc
P11457139A0604|98 109|D1D3 isomer
P11457139A0604|113 116|Man
P11457139A0604|119 125|GlcNAc
P11459048A0485|33 46|uncertainties
P11459048A0485|54 60|models
P11459048A0485|74 81|planets
P11459048A0485|93 103|atmosphere
P11459048A0485|109 114|Venus
P11459048A0485|157 172|rotation states
P11459304T0078|0 21|Enantiomer separation
P11459304T0078|25 36|venlafaxine
P11459304T0078|41 63|O-desmethylvenlafaxine
P11459304T0078|73 79|plasma
P11459794A1172|0 12|TE-671 cells
P11459794A1172|40 61|cAMP response element
P11459794A1172|69 79|constructs
P11459794A1172|112 120|activity
P11459794A1172|128 144|GnRH-II promoter
P11459960A1109|39 49|components
P11459960A1109|55 59|heat
P11459960A1109|81 92|heat labile
P11459962A0785|32 37|genes
P11459962A0785|45 50|Rad52
P11459962A0785|67 81|repair pathway
P11459962A0785|103 111|survival
P11459962A0785|115 134|rad27 Delta strains
P11459962A0785|158 167|degrees C
P11459962A0785|173 187|semipermissive
P11459962A0785|192 201|degrees C
P11459962A0785|203 215|temperatures
P11459962A0785|220 226|growth
P11460035A0548|12 16|case
P11460035A0548|23 41|hydroxychloroquine
P11460035A0548|43 56|carbamazepine
P11460035A0548|61 72|fluvoxamine
P11460035A0548|86 98|imputability
P11461595A0000|19 36|reaction kinetics
P11461595A0000|56 65|particles
P11461595A0000|71 78|inertia
P11461595A0000|88 104|coalescence type
P11461595A0000|108 116|reaction
P11461595A0000|118 121|B+B
P11461595A0000|124 125|B
P11461595A0000|164 169|flows
P11462004A0886|4 8|role
P11462004A0886|16 23|Vp1 DBD
P11462004A0886|31 40|infection
P11462004A0886|68 77|advantage
P11462004A0886|81 84|NLS
P11462004A0886|96 111|complementation
P11462004A0886|113 115|N.
P11462004A1500|33 37|Vp1s
P11462004A1500|77 84|nucleus
P11462004A1500|92 95|Vp2
P11462004A1500|100 103|Vp3
P11462004A1500|137 141|NLS1
P11462004A1500|162 168|signal
P11462004A1500|189 201|localization
P11462004A1500|205 208|Vp1
P11462024A0306|0 3|Zhu
P11462024A0306|5 7|V.
P11462952A1040|8 22|gastrin levels
P11462952A1040|31 36|range
P11462952A1040|45 49|mU/L
P11462952A1040|69 73|mU/L
P11462952A1040|82 86|mean
P11462952A1040|94 98|mU/L
P11463359A0167|23 40|phorbol ester PMA
P11463359A0167|93 103|expression
P11463359A0167|109 124|luciferase gene
P11463359A0167|135 142|control
P11463359A0167|150 165|G6Pase promoter
P11463359A0167|193 213|H4IIE hepatoma cells
P11463834A0606|8 28|deletion mutagenesis
P11463834A0606|42 53|amino acids
P11463834A0606|70 73|CBP
P11463834A0606|106 112|region
P11463834A0606|116 119|CR2
P11463834A0606|137 143|region
P11463834A0606|148 163|Tax interaction
P11464997A0566|5 14|knowledge
P11464997A0566|29 38|diagnosis
P11464997A0566|43 52|treatment
P11464997A0566|60 67|patient
P11464997A0566|72 82|counseling
P11464997A0566|99 105|family
P11465518A0000|0 10|BACKGROUND
P11465518A0000|32 40|interest
P11465518A0000|48 52|part
P11465518A0000|56 69|investigators
P11465518A0000|78 84|public
P11465518A0000|105 109|ways
P11465518A0000|131 141|treatments
P11465518A0000|195 206|individuals
P11465518A0000|222 227|risks
P11465655A0439|12 16|week
P11465655A0439|38 57|antagonist atenolol
P11465655A0439|82 86|dose
P11465655A0439|93 99|mg/day
P11465655A0439|119 125|mg/day
P11465655A0439|135 139|week
P11465844T0000|0 4|Lack
P11465844T0000|8 19|association
P11465844T0000|28 45|Kawasaki syndrome
P11465844T0000|50 59|infection
P11465844T0000|65 83|Rickettsia conorii
P11465844T0000|85 101|Rickettsia typhi
P11465844T0000|103 120|Coxiella burnetii
P11465844T0000|124 154|Ehrlichia phagocytophila group
P11466227A1665|4 12|presence
P11466227A1665|16 24|AS-oligo
P11466227A1665|40 46|effect
P11466227A1665|67 77|activation
P11466227A1665|85 87|EB
P11466227A1665|89 106|mTf-CAT construct
P11466227A1665|133 143|activation
P11467349A0452|22 26|task
P11467349A0452|45 53|measures
P11467349A0452|57 68|ISF glucose
P11468958A0122|14 21|results
P11468958A0122|36 51|policy analysis
P11468958A0122|76 85|decisions
P11468958A0122|94 100|recall
P11468958A0122|104 109|blood
P11468958A0122|117 122|donor
P11468958A0122|136 139|CJD
P11468958A0122|153 161|decision
P11468958A0122|171 180|donations
P11468958A0122|186 197|individuals
P11468958A0122|213 227|travel history
P11468958A0122|235 237|UK
P11468958A0122|267 275|concerns
P11468958A0122|295 298|CJD
P11469701A0377|10 18|approach
P11469701A0377|22 44|insulin administration
P11469701A0377|87 102|insulin therapy
P11469701A0377|104 109|CIIIT
P11469701A0377|120 127|insulin
P11469701A0377|143 150|fashion
P11469701A0377|178 199|insulin concentration
P11469701A0377|214 218|vein
P11469737A1791|3 8|visit
P11469737A1791|27 31|test
P11469737A1791|48 72|muscle function recovery
P11469737A1791|80 81|%
P11469737A1791|87 88|%
P11469737A1791|107 111|test
P11469737A1791|131 139|recovery
P11469853A0702|15 21|system
P11469853A0702|26 42|domain shuffling
P11469853A0702|60 68|function
P11469853A0702|72 82|C1 domains
P11469853A0702|94 104|Raf kinase
P11469853A0702|109 120|rat PKC eta
P11469853A0702|124 129|yeast
P11469853A1053|19 23|data
P11469853A1053|35 43|evidence
P11469853A1053|49 60|interaction
P11469853A1053|74 80|GTPase
P11469853A1053|104 112|function
P11469853A1053|120 129|C1 domain
P11469853A1053|133 138|yeast
P11469926T0000|0 29|Breast cancer risk assessment
P11469926T0000|51 63|crystal ball
P11469970A0873|0 8|Patients
P11469970A0873|14 18|type
P11469970A0873|23 26|SOD
P11469970A0873|45 57|hyperalgesia
P11469970A0873|61 66|trial
P11469970A0873|70 85|antidepressants
P11469970A0873|103 108|trial
P11469970A0873|114 139|botulinum toxin injection
P11469970A0873|149 156|ampulla
P11469970A0873|212 219|therapy
P11470914A0305|4 12|activity
P11470914A0305|16 20|Rac1
P11470914A0305|30 49|STAT3 translocation
P11470914A0305|57 64|nucleus
P11470914A0305|97 112|gene expression
P11471077A0382|0 7|RESULTS
P11471077A0382|33 39|amount
P11471077A0382|43 52|variation
P11471077A0382|65 72|results
P11471077A0382|76 80|TRA1
P11471077A0382|85 89|TRA2
P11471077A0382|106 113|results
P11471077A0382|122 125|TRA
P11471077A0382|149 155|survey
P11471231A0964|3 11|addition
P11471231A0964|19 27|patients
P11471231A0964|67 78|differences
P11471231A0964|115 123|spectrum
P11471231A0964|187 197|procedures
P11472523A0535|0 10|CONCLUSION
P11472523A0535|12 29|Extrusion cooking
P11472523A0535|51 63|inactivation
P11472523A0535|67 70|DON
P11472523A0535|89 94|value
P11472523A0535|99 103|AFB1
P11472523A0535|113 127|metabisulphite
P11472696A0387|4 15|differences
P11472696A0387|23 28|CPIgG
P11472696A0387|30 33|CRP
P11472696A0387|39 56|fibrinogen levels
P11472696A0387|60 68|patients
P11472696A0387|93 96|ACS
P11473254A0000|0 4|NaeI
P11473254A0000|14 30|DNA endonuclease
P11473254A0000|38 51|topoisomerase
P11473254A0000|56 78|recombinase activities
P11473254A0000|86 97|Lys residue
P11473254A0000|117 120|Leu
P11473261A0587|0 4|Mss4
P11473261A0587|43 77|guanine nucleotide exchange factor
P11473261A0587|79 82|GEF
P11474642A1451|4 14|decrements
P11474642A1451|34 44|resistance
P11474642A1451|56 69|hexamethonium
P11474642A1451|74 82|mm Hg ml
P11474642A1451|87 90|min
P11474642A1451|108 115|control
P11478627A0573|4 25|desirability function
P11478627A0573|42 48|search
P11478627A0573|62 69|optimum
P11478627A0573|71 72|D
P11478627A0573|78 80|Y1
P11478627A0573|82 84|Y2
P11478627A0573|91 93|Yn
P11478627A0573|103 117|transformation
P11478627A0573|134 142|property
P11478627A0573|162 167|scale
P11478627A0573|177 186|criterion
P11479104A0446|52 60|antibody
P11479104A0446|90 98|criteria
P11479104A0446|112 131|lupus erythematosis
P11479104A0446|133 143|CONCLUSION
P11479104A0446|149 157|presence
P11479104A0446|178 185|disease
P11479104A0446|191 196|woman
P11479104A0446|202 205|POF
P11479104A0446|230 239|clinician
P11479104A0446|280 285|cause
P11479501A0744|0 7|RESULTS
P11479501A0744|35 47|distribution
P11479501A0744|57 68|coefficient
P11479501A0744|72 81|variation
P11479501A0744|83 92|SD/mean x
P11479501A0744|96 97|%
P11479501A0744|113 124|valve sizes
P11479501A0744|140 141|%
P11479501A0744|147 148|%
P11479501A0744|156 177|St Jude Medical valve
P11479501A0744|189 190|%
P11479501A0744|196 197|%
P11479501A0744|205 221|Omnicarbon valve
P11480490A0443|33 38|signs
P11480490A0443|67 75|blockade
P11480490A0443|79 80|I
P11480490A0443|81 83|Kr
P11480490A0443|85 92|current
P11480490A0443|113 123|occurrence
P11480490A0443|127 137|arrhythmia
P11480497T0000|0 7|Effects
P11480497T0000|25 38|JP-8 jet fuel
P11480497T0000|71 78|battery
P11480497T0000|84 92|learning
P11480497T0000|97 103|memory
P11480497T0000|111 114|rat
P11480555A0928|4 14|production
P11480555A0928|18 26|ceramide
P11480555A0928|44 51|fixture
P11480555A0928|66 76|cell death
P11481625A0202|27 35|subjects
P11481625A0202|87 90|TIW
P11481625A0202|92 115|interferon alfa-2b dose
P11481625A0202|119 122|MIU
P11481625A0202|144 146|QW
P11481625A0202|148 169|peginterferon alfa-2b
P11481625A0202|188 197|microg/kg
P11484028T0000|3 17|cross purposes
P11484578A1132|0 10|CONCLUSION
P11484578A1132|25 36|differences
P11484578A1132|44 60|measurement data
P11484578A1132|79 85|method
P11484578A1132|97 113|measurement data
P11484578A1132|122 128|object
P11484578A1132|166 180|design program
P11486032A1261|10 31|transcription factors
P11486032A1261|71 78|protein
P11486032A1261|85 90|RUNX1
P11486032A1261|124 131|E2A-HLF
P11486141A0424|5 12|factors
P11486141A0424|42 49|outcome
P11486141A0424|53 61|students
P11486141A0424|84 89|power
P11486141A0424|99 112|meta analysis
P11486141A0424|150 157|sources
P11486141A0424|161 166|error
P11486399A0000|4 15|combination
P11486399A0000|19 29|ifosfamide
P11486399A0000|31 41|epirubicin
P11486399A0000|46 55|etoposide
P11486399A0000|57 60|IEV
P11486399A0000|78 93|salvage regimen
P11486399A0000|118 125|disease
P11486476A0147|14 19|trial
P11486476A0147|61 76|characteristics
P11486476A0147|80 88|patients
P11486476A0147|94 104|chest pain
P11486476A0147|110 115|value
P11486476A0147|127 145|markers troponin T
P11486476A0147|147 156|myoglobin
P11486476A0147|161 171|CK-MB mass
P11486476A0147|214 224|chest pain
P11486476A0147|234 244|proportion
P11486476A0147|248 256|patients
P11486476A0147|262 265|ACS
P11486476A0147|280 287|markers
P11486476A0147|316 327|information
P11486476A0147|331 340|admission
P11486476A1512|8 26|markers troponin T
P11486476A1512|28 38|CK-MB mass
P11486476A1512|43 52|myoglobin
P11486476A1512|86 95|diagnosis
P11486476A1512|99 109|chest pain
P11486476A1512|125 128|ECG
P11489597A0379|3 14|termination
P11489597A0379|16 18|gd
P11489597A0379|43 50|females
P11489597A0379|65 70|group
P11489597A0379|100 106|status
P11489597A0379|123 130|outcome
P11489597A0379|137 144|fetuses
P11489597A0379|196 209|malformations
P11489597A0561|13 18|death
P11489597A0561|28 39|body weight
P11489597A0561|53 64|weight gain
P11489597A0561|88 92|dose
P11489597A0561|104 119|pregnancy rates
P11489597A0561|134 135|%
P11489597A0561|145 150|group
P11490862A0141|15 26|development
P11490862A0141|30 53|bladder neck suspension
P11490862A0141|67 81|Stamey-Pereyra
P11490862A0141|87 90|use
P11490862A0141|104 116|bone anchors
P11490862A0141|139 146|support
P11494391A0579|4 11|results
P11494391A0579|32 33|%
P11494391A0579|49 71|artery-alone ALT graft
P11494391A0579|93 102|structure
P11494391A0579|123 128|month
P11494391A0579|150 164|bile secretion
P11495833T0000|15 21|impact
P11495833T0000|46 51|means
P11495833T0000|78 83|model
P11495833T0000|104 114|properties
P11495920A0504|9 22|pair mismatch
P11495920A0504|48 54|region
P11495920A0504|62 73|CYP3A4 gene
P11495920A0504|108 125|enhancer activity
P11496495A0000|4 11|authors
P11496495A0000|20 28|analysis
P11496495A0000|50 60|conditions
P11496495A0000|74 87|possibilities
P11496495A0000|116 120|care
P11496495A0000|124 132|children
P11496617A0301|0 7|METHODS
P11496617A0301|12 18|female
P11496617A0301|31 39|patients
P11496617A0301|51 66|thyroid surgery
P11496617A0301|170 177|regimes
P11496617A0301|182 195|mg dolasetron
P11496617A0301|212 219|minutes
P11496617A0301|229 238|induction
P11496617A0301|242 253|anaesthesia
P11496617A0301|255 260|group
P11496617A0301|270 283|mg dolasetron
P11496617A0301|311 320|induction
P11496617A0301|324 335|anaesthesia
P11496617A0301|337 342|group
P11496617A0301|353 359|mg DHB
P11496617A0301|387 396|induction
P11496617A0301|400 411|anaesthesia
P11496617A0301|413 418|group
P11496617A0301|427 434|placebo
P11496617A0301|436 441|group
P11498795A0716|10 21|progression
P11498795A0716|40 48|G1-phase
P11498795A0716|71 86|phosphorylation
P11498795A0716|94 104|RB protein
P11498795A0716|120 125|delay
P11498795A0716|135 153|S phase transition
P11500377A0518|3 10|mammals
P11500377A0518|32 42|repressors
P11500377A0518|50 61|Wnt pathway
P11500512A0000|10 20|ABCG1 gene
P11500512A0000|31 37|member
P11500512A0000|57 65|cassette
P11500512A0000|67 70|ABC
P11500512A0000|72 83|superfamily
P11500512A0000|87 107|transporter proteins
P11500512A0000|135 146|macrophages
P11500512A0000|166 176|oxysterols
P11500571A0976|17 27|expression
P11500571A0976|31 50|NtmybAS transcripts
P11500571A0976|61 67|pollen
P11500571A0976|69 86|gPAL1 transcripts
P11500571A0976|110 116|pollen
P11500913A1238|0 13|C/EBPbeta LIP
P11500913A1238|29 39|HC11 cells
P11500913A1238|56 72|beta-casein mRNA
P11500913A1238|93 120|cell differentiation marker
P11500913A1238|125 133|response
P11500913A1238|148 156|hormones
P11502738A1457|10 17|effects
P11502738A1457|37 47|inhibitors
P11502738A1457|70 77|mutants
P11502738A1457|109 118|bp region
P11502738A1457|126 144|cyclin D1 promoter
P11502758A0869|6 14|findings
P11502758A0869|51 55|role
P11502758A0869|60 65|LAD-1
P11502758A0869|77 91|FGFR signaling
P11502778A0941|18 21|men
P11502778A0941|40 56|estradiol levels
P11502778A0941|67 73|median
P11502778A0941|78 88|pmol/liter
P11502778A0941|93 98|pg/ml
P11502778A0941|126 131|rates
P11502778A0941|135 144|bone loss
P11502778A0941|149 155|levels
P11502778A0941|159 182|bone resorption markers
P11502778A0941|188 191|men
P11502778A0941|210 226|estradiol levels
P11502778A0941|236 246|pmol/liter
P11504545A0393|0 11|Competition
P11504545A0393|28 42|mobility shift
P11504545A0393|47 65|immunoshift assays
P11504545A0393|81 92|NF1 factors
P11504545A0393|112 120|extracts
P11504545A0393|124 128|HeLa
P11504545A0393|133 143|CV-1 cells
P11504545A0393|156 163|BKV-MLP
P11504709A0981|5 10|study
P11504709A0981|39 49|expression
P11504709A0981|53 61|response
P11504709A0981|72 75|PMA
P11504709A0981|79 82|TPO
P11504709A0981|107 115|Ets site
P11504709A0981|132 140|promoter
P11504709A0981|144 148|GPIX
P11504709A0981|184 194|activation
P11504709A0981|234 240|kinase
P11505407A0461|0 7|RESULTS
P11505407A0461|22 30|fragment
P11505407A0461|47 55|activity
P11505407A0461|59 64|EpCAM
P11505407A0461|74 79|cells
P11505407A0461|115 142|tumor necrosis factor alpha
P11505407A0461|144 152|TNFalpha
P11509266A0955|3 6|Cox
P11509266A0955|20 53|hazards regression adenocarcinoma
P11509266A0955|55 56|P
P11509266A0955|69 80|development
P11509266A0955|84 87|BPF
P11509266A0955|89 90|P
P11509266A0955|105 108|age
P11509266A0955|110 111|P
P11509266A0955|142 147|stage
P11509266A0955|149 150|P
P11509266A0955|182 192|predictors
P11509266A0955|196 204|survival
P11509615T0000|0 29|Phosphatidylinositol 3-kinase
P11509615T0000|65 85|T cell proliferation
P11509615T0000|102 115|IL-2 receptor
P11509673A0574|14 27|transfectants
P11509673A0574|29 38|BM3 cells
P11509673A0574|70 89|P450 AA epoxygenase
P11509673A0574|91 99|F87V BM3
P11509673A0574|160 164|acid
P11509673A0574|173 182|14,15-EET
P11509673A0574|184 186|AA
P11509673A0574|202 211|apoptosis
P11509673A0574|250 259|apoptosis
P11511544T0000|4 15|loop domain
P11511544T0000|19 50|heat shock transcription factor
P11511544T0000|74 85|specificity
P11511544T0000|90 99|responses
P11511544T0000|103 114|heat stress
P11512925A0000|0 18|EXAFS measurements
P11512925A0000|35 39|edge
P11512925A0000|79 85|alloys
P11512925A0000|100 104|time
P11512925A0000|130 139|structure
P11512925A0000|149 156|Ge atom
P11513121T0000|12 17|study
P11513121T0000|22 37|robustness test
P11513121T0000|41 51|QSAR model
P11513121T0000|61 88|quantum chemical parameters
P11513121T0000|104 107|BCF
P11513121T0000|144 153|compounds
P11513121T0000|155 160|PCOCs
P11513180A1257|11 16|cases
P11513180A1257|30 39|polyposis
P11513180A1257|41 45|none
P11513180A1257|68 70|CT
P11513180A1257|109 114|bowel
P11513579A0372|21 27|system
P11513579A0372|56 60|Rac1
P11513579A0372|88 95|Rho-GDI
P11513579A0372|125 129|role
P11513579A0372|150 161|interaction
P11513579A0372|165 182|complex formation
P11516890A0236|28 44|cytochrome P-450
P11516890A0236|46 49|CYP
P11516890A0236|51 57|system
P11516890A0236|59 70|venlafaxine
P11516890A0236|80 87|CYP 2D6
P11516890A0236|92 95|3A4
P11516890A0236|112 118|extent
P11516890A0236|131 136|SSRIs
P11517190A0352|0 8|Analysis
P11517190A0352|16 33|promoter sequence
P11517190A0352|47 55|presence
P11517190A0352|83 93|start site
P11517190A0352|107 115|TATA box
P11517190A0352|129 132|cis
P11517190A0352|144 152|elements
P11517190A0352|176 186|expression
P11517190A0352|214 221|element
P11517190T0000|15 23|promoter
P11517190T0000|31 48|rat ER alpha gene
P11517190T0000|79 92|transcription
P11517190T0000|106 114|receptor
P11517269A0472|0 5|Pitx2
P11517269A0472|28 50|differentiation defect
P11517269A0472|77 90|axon guidance
P11517269A0472|106 116|phenotypes
P11517269A0472|127 134|mutants
P11517269A0472|154 160|degree
P11517269A0472|175 187|conservation
P11517269A0472|225 230|genes
P11517399A0858|4 12|patterns
P11517399A0858|22 26|mRNA
P11517399A0858|31 49|protein expression
P11517399A0858|65 72|mutants
P11517399A0858|110 118|mutation
P11517399A0858|126 127|T
P11517399A0858|134 147|acceptor site
P11517399A0858|164 175|utilization
P11517399A0858|187 199|splice sites
P11517399A0858|208 218|generation
P11517399A0858|226 227|T
P11517399A0858|229 236|species
P11517445A0221|10 15|cases
P11517445A0221|19 26|cholera
P11517445A0221|42 56|V. cholerae O1
P11518505A0107|73 80|tissues
P11518505A0107|85 91|organs
P11518868A0559|30 37|history
P11518868A0559|51 64|risk behavior
P11518868A0559|76 85|knowledge
P11518868A0559|93 110|hepatitis C virus
P11518868A0559|116 149|healthcare provider communication
P11519466A0196|13 17|diet
P11519466A0196|43 49|impact
P11520436A0705|6 17|BALB/c mice
P11520436A0705|52 58|strain
P11520436A0705|62 66|mice
P11520436A0705|78 85|studies
P11520436A0705|102 112|connection
P11520436A0705|121 130|infection
P11520436A0705|136 144|T. canis
P11520436A0705|158 164|asthma
P11521191A0000|45 60|12S E1A protein
P11521191A0000|75 97|phosphorylation status
P11521191A0000|101 105|p130
P11521191A0000|110 114|p107
P11521191A0000|132 139|changes
P11521191A0000|147 157|cell cycle
P11521191A0000|168 183|phosphorylation
P11521191A0000|191 213|retinoblastoma protein
P11522431A0673|4 14|prevalence
P11522431A0673|18 36|tobacco dependence
P11522431A0673|64 79|ICD-10 criteria
P11522431A0673|112 123|individuals
P11522431A0673|129 130|%
P11522431A0673|140 151|nondrinkers
P11522431A0673|162 170|drinkers
P11522431A0673|176 177|%
P11522584A0882|8 16|myalgias
P11522584A0882|39 47|patients
P11522584A0882|69 79|MMF lesion
P11522584A0882|91 104|muscle biopsy
P11522584A0882|106 107|P
P11522626A1374|22 32|regulation
P11522626A1374|36 37|G
P11522626A1374|41 59|gene transcription
P11522626A1374|94 104|activation
P11522626A1374|112 120|Mek-Erk1
P11522626A1374|123 130|pathway
P11522626A1374|134 152|estrogen receptors
P11522658A0086|29 50|ErbB1/ErbB2 signaling
P11522658A0086|71 78|process
P11522658A0086|92 122|ErbB kinase inhibitor AG1478in
P11522658A0086|139 145|BT-474
P11522658A0086|150 156|SKBR-3
P11522658A0086|163 182|breast cancer cells
P11522658A0870|22 37|phosphorylation
P11522658A0870|41 44|p27
P11522658A0870|48 52|MAPK
P11522658A0870|66 75|stability
P11522658A0870|79 82|p27
P11522658A0870|112 116|Cdk2
P11522658A0870|125 138|stoichiometry
P11522658A0870|157 172|kinase activity
P11523446A0523|0 3|ICA
P11523446A0523|11 29|reference solution
P11523446A0523|51 53|LC
P11523446A0523|58 72|time-of-flight
P11523446A0523|74 77|TOF
P11523446A0523|79 81|MS
P11523446A0523|100 102|LC
P11523446A0523|120 138|nitrogen detection
P11523446A0523|140 147|LC-CLND
P11524015A0937|7 17|expression
P11524015A0937|21 27|BZAP45
P11524015A0937|48 59|H4 promoter
P11524015A0937|61 63|nt
P11524015A0937|76 102|CAT reporter gene activity
P11524815A0753|6 19|control rates
P11524815A0753|27 28|%
P11524815A0753|44 55|lung cancer
P11524815A0753|59 60|%
P11524815A0753|73 84|lung cancer
P11524815A0753|91 92|%
P11524815A0753|97 99|T1
P11524815A0753|101 112|2N0M0 cases
P11524823X0001|0 7|Utility
P11524823X0001|11 23|OAE screener
P11524823X0001|25 28|GSI
P11524823X0001|41 51|evaluation
P11524823X0001|55 73|distortion product
P11524823X0001|86 95|emissions
P11524823X0001|101 108|purpose
P11524823X0001|117 122|study
P11524823X0001|146 153|ability
P11524823X0001|161 177|OAE screener GSI
P11524823X0001|196 212|cochlea function
P11524823X0001|216 224|neonates
P11524823X0001|226 233|infants
P11524823X0001|238 244|adults
P11525102A0970|8 14|sample
P11525102A0970|29 36|reviews
P11525102A0970|48 64|ACP Journal Club
P11525102A0970|66 67|n
P11525102A0970|80 95|PubMed strategy
P11525102A0970|107 118|sensitivity
P11525102A0970|124 125|%
P11525102A0970|127 129|CI
P11525102A0970|133 134|%
P11525102A0970|140 141|%
P11525486A0350|16 25|CaCO3-CO2
P11525486A0350|26 28|N2
P11525486A0350|38 46|solution
P11525486A0350|75 77|pH
P11525640A0560|0 10|Inhibition
P11525640A0560|14 18|JNK1
P11525640A0560|23 44|ERK kinase activities
P11525640A0560|55 65|expression
P11525640A0560|98 102|JNK1
P11525640A0560|109 118|treatment
P11525640A0560|136 154|chemical inhibitor
P11525640A0560|158 161|ERK
P11525640A0560|163 171|PD098059
P11525640A0560|201 213|UV induction
P11525640A0560|221 236|GADD45 promoter
P11528127A1402|7 17|GC content
P11528127A1402|23 24|%
P11528127A1402|33 40|segment
P11528127A1402|71 73|H1
P11528127A1402|89 96|segment
P11528127A1402|100 104|% GC
P11528127A1402|117 121|% GC
P11528127A1402|125 130|mouse
P11528127A1402|145 150|L1/L2
P11528253X1211|0 9|Copyright
P11528253X1211|15 17|S.
P11528500A0571|3 11|mutation
P11528500A0571|19 27|NRL gene
P11528500A0571|56 64|families
P11529914T0000|0 9|NF-kappaB
P11529914T0000|29 39|regulation
P11529914T0000|43 48|CD154
P11529914T0000|50 61|CD40 ligand
P11529914T0000|63 73|expression
P11529914T0000|91 98|T cells
P11530684A0667|6 18|nerve injury
P11530684A0667|36 45|responses
P11530684A0667|54 58|type
P11530684A0667|61 68|neurons
P11530684A0667|90 98|C-fibers
P11530684A0667|103 132|drive NK1-receptor mechanisms
P11530684A0667|143 160|pain transmission
P11530684A0667|196 203|changes
P11530684A0667|207 211|type
P11530684A0667|215 219|ones
P11530684A0667|241 249|C-fibers
P11530684A0667|254 284|drive NMDA receptor-mechanisms
P11530684A0667|292 296|type
P11530684A0667|301 305|ones
P11530684A0667|349 357|A-fibers
P11530684A0667|363 393|drive NMDA-receptor mechanisms
P11530829A0000|5 12|article
P11530829A0000|25 31|design
P11530829A0000|36 47|development
P11530829A0000|54 67|ECG simulator
P11530829A0000|81 84|use
P11530829A0000|92 99|testing
P11530829A0000|101 112|calibration
P11530829A0000|117 128|maintenance
P11530829A0000|153 162|equipment
P11532556A0000|22 41|angioencephalopathy
P11532556A0000|43 47|SDAE
P11532556A0000|69 76|disease
P11532556A0000|88 96|etiology
P11532556A0000|115 122|thalami
P11532856A1175|0 5|Third
P11532856A1175|29 33|data
P11532856A1175|35 51|N-acetylcysteine
P11532856A1175|76 82|effect
P11532856A1175|86 89|HGF
P11532856A1175|93 117|stress kinase activities
P11532856A1175|125 139|p42/44 mitogen
P11532856A1175|150 156|kinase
P11532856A1175|158 162|MAPK
P11532856A1175|194 205|involvement
P11532856A1175|226 232|kinase
P11532856A1175|234 237|JNK
P11532856A1175|243 251|p38 MAPK
P11532856A1175|255 271|HIF-1 activation
P11533238A1137|0 8|Mutation
P11533238A1137|16 31|octamer element
P11533238A1137|63 70|ability
P11533238A1137|74 79|HDAC1
P11533238A1137|90 100|repression
P11533238A1137|114 141|HLA-DRA promoter activation
P11533340A1285|25 35|difference
P11533340A1285|53 59|scores
P11533340A1285|71 77|months
P11533340A1285|88 99|PDF infants
P11533340A1285|121 136|point advantage
P11533340A1285|140 165|Bayley motor score scales
P11533863A0125|14 18|case
P11533863A0125|23 34|restoration
P11533863A0125|57 64|routine
P11533863A0125|80 94|presupposition
P11533863A0125|111 118|therapy
P11534132A0219|14 28|search engines
P11534132A0219|58 65|results
P11534132A0219|71 77|domain
P11534132A0219|87 94|experts
P11534900A0000|24 36|combinations
P11534900A0000|54 86|molluscicides Azadirachta indica
P11534900A0000|91 109|Cedrus deodara oil
P11534900A0000|115 133|synergists MGK-264
P11534900A0000|135 153|piperonyl butoxide
P11534900A0000|155 157|PB
P11534900A0000|163 175|fruit powder
P11534900A0000|179 192|Embelia ribes
P11534900A0000|215 232|Lymnaea acuminata
P11535014A1157|15 22|results
P11535014A1157|48 60|seizure type
P11535014A1157|64 67|TLE
P11535014A1157|79 88|frequency
P11535014A1157|92 99|seizure
P11535014A1157|126 145|precipitate factors
P11535014A1157|159 168|latencies
P11535014A1157|172 176|P300
P11535014A1157|194 202|patients
P11535140T0000|13 21|findings
P11535140T0000|25 34|pregnancy
P11535532A0189|21 33|enzyme DUB-2
P11535532A0189|48 56|response
P11535532A0189|60 64|IL-2
P11535532A0189|80 88|function
P11535832A0586|4 11|isoform
P11535832A0586|24 30|HDAC9a
P11535832A0586|39 41|aa
P11535832A0586|57 67|C terminus
P11535832A0586|73 78|HDAC9
P11536063A0178|10 21|embolectomy
P11536063A0178|26 46|lung transplantation
P11536063A0178|60 71|indications
P11536063A0178|80 83|use
P11536063A0178|87 105|heart-lung-machine
P11538437A0568|8 18|conditions
P11538437A0568|42 51|reactions
P11538437A0568|72 74|N2
P11538437A0568|75 76|A
P11538437A0568|80 82|N2
P11538437A0568|83 84|A
P11538437A0568|90 92|N2
P11538437A0568|93 94|C
P11538437A0568|95 96|B
P11538437A0568|97 98|V
P11538437A0568|103 105|N2
P11538437A0568|106 107|X
P11538437A0568|110 112|N2
P11538437A0568|113 114|A
P11538437A0568|118 120|N2
P11538437A0568|121 122|X
P11538437A0568|123 124|V
P11538437A0568|132 134|N2
P11538437A0568|135 136|X
P11538437A0568|140 142|N2
P11538437A0568|143 144|B
P11538437A0568|145 146|V
P11538437A0568|157 175|N2 post-discharges
P11538437A0568|180 182|N2
P11538437A0568|183 184|A
P11538437A0568|188 191|CH4
P11538437A0568|196 204|products
P11538437A0568|206 207|C
P11538437A0568|210 211|N
P11538437A0568|214 216|M2
P11538437A0568|221 223|CN
P11538437A0568|224 225|B
P11538437A0568|226 227|V
P11538437A0568|232 234|M2
P11538437A0568|236 238|N2
P11538437A0568|239 240|X
P11538437A0568|241 242|V
P11538437A0568|248 250|CN
P11538437A0568|255 257|N2
P11538437A0568|258 259|X
P11538437A0568|263 265|CN
P11538437A0568|266 267|B
P11538437A0568|268 269|A
P11538437A0568|270 271|V
P11538437A0568|282 303|% CH4 post-discharges
P11539522A0612|4 19|NAUSICAA system
P11539522A0612|33 42|knowledge
P11539522A0612|46 57|LET spectra
P11539522A0612|72 76|time
P11539522A0612|80 95|space dosimetry
P11540991A0127|3 8|order
P11540991A0127|27 34|effects
P11540991A0127|36 41|tests
P11540991A0127|64 100|NASA MSFC Neutral Buoyancy Simulator
P11540991A0127|109 120|NASA KC-135
P11540991A0127|134 140|flight
P11540991A0127|149 154|space
P11540991A0127|164 176|EASE program
P11540991A0127|188 217|Shuttle Atlantis mission 61-B
P11542677A0411|5 12|article
P11542677A0411|42 57|Generic Systems
P11542677A0411|82 94|alternatives
P11542677A0411|98 124|composting facility design
P11542677A0411|129 136|control
P11542780A0086|28 37|detectors
P11542780A0086|39 42|TLD
P11542780A0086|74 86|contribution
P11542780A0086|105 130|energy transfer component
P11542780A0086|132 135|LET
P11542780A0086|141 155|keV/micrometer
P11542780A0086|177 192|track detectors
P11542780A0086|194 198|PNTD
P11542780A0086|220 234|energy tranfer
P11542780A0086|236 239|LET
P11542780A0086|241 250|component
P11543154T0000|0 9|Responses
P11543154T0000|13 24|TLD Mg2SiO4
P11543154T0000|25 27|Tb
P11543154T0000|54 59|glass
P11543154T0000|77 86|particles
P11543154T0000|91 106|space radiation
P11543317A0203|13 17|dose
P11543317A0203|34 45|combination
P11543317A0203|65 74|detectors
P11543317A0203|96 105|dosemeter
P11543317A0203|109 116|Mg2SiO4
P11543317A0203|118 120|Tb
P11543317A0203|122 126|TDMS
P11543317A0203|148 162|track detector
P11543317A0203|164 168|PNTD
P11543662A0562|11 15|gstC
P11543662A0562|17 24|mutants
P11543662A0562|54 58|half
P11543662A0562|62 63|C
P11543662A0562|78 84|defect
P11543662A0562|92 99|ability
P11543662A0562|108 117|L protein
P11545594A1556|29 40|Myb domains
P11545594A1556|74 82|function
P11545594A1556|91 101|Myb domain
P11545594A1556|117 136|amino acid residues
P11545594A1556|161 168|surface
P11545594A1556|177 184|protein
P11547819A0532|0 7|METHODS
P11547819A0532|9 20|Experiments
P11547819A0532|37 45|catheter
P11547819A0532|79 87|catheter
P11547819A0532|102 113|measurement
P11547819A0532|121 144|laser output beam sizes
P11547819A0532|149 160|divergences
P11547819A0532|166 176|evaluation
P11547819A0532|192 209|matter generation
P11547819A0532|217 225|ablation
P11547819A0532|245 251|tissue
P11547819A0532|257 268|measurement
P11547819A0532|272 291|ablation hole sizes
P11547819A0532|296 320|tissue penetration rates
P11547819A0532|342 353|examination
P11547819A0532|379 397|vessel wall injury
P11548027A0163|2 10|proposal
P11548027A0163|17 39|performance indicators
P11548027A0163|68 74|groups
P11548027A0163|112 122|indicators
P11548027A0163|136 146|indicators
P11548027A0163|148 153|water
P11548027A0163|158 184|service quality indicators
P11548027A0163|186 206|personnel indicators
P11548027A0163|220 230|indicators
P11550795A2583|0 14|Overexpression
P11550795A2583|18 26|RORgamma
P11550795A2583|53 59|T cell
P11550795A2583|78 87|apoptosis
P11550795A2583|91 108|T cell hybridomas
P11550795A2583|128 137|induction
P11550795A2583|141 151|Fas-ligand
P11550795A2583|156 167|interleukin
P11552058A0235|5 8|ICP
P11552058A0235|26 32|values
P11552058A0235|38 43|mm Hg
P11552058A0235|45 55|herniation
P11552058A0235|86 90|days
P11552058A0833|6 15|therapies
P11552058A0833|57 72|saline solution
P11552058A0833|74 78|THAM
P11552058A0833|80 112|Tris-hydroxy-methyl-aminomethane
P11552058A0833|114 120|buffer
P11552058A0833|136 148|barbiturates
P11552724A0527|0 11|CONCLUSIONS
P11552724A0527|32 36|IVUS
P11552724A0527|60 70|blood flow
P11552724A0527|82 94|vessel lumen
P11552724A0527|142 149|disease
P11552724A0527|163 173|blood flow
P11552724A0527|217 230|interventions
P11552724A0527|234 242|patients
P11552724A0527|254 261|failure
P11552724A0527|265 272|allergy
P11552724A0527|287 290|use
P11552724A0527|294 308|contrast media
P11552922A0361|0 16|CYP2C19 genotype
P11552922A0361|39 112|polymerase chain reaction-restriction fragment length polymorphism method
P11553091A1472|4 11|results
P11553091A1472|48 57|diagnosis
P11553091A1472|71 83|relationship
P11553091A1472|124 134|correction
P11553091A1472|138 143|Class
P11553091A1472|153 165|relationship
P11553704A0674|8 12|data
P11553704A0674|62 72|EGFR-CD533
P11553704A0674|94 101|Ras N17
P11553704A0674|121 136|MAPK activation
P11554469A1386|6 14|analyses
P11554469A1386|27 35|question
P11554469A1386|52 62|CesA genes
P11554469A1386|70 89|cellulose synthases
P11554469A1386|123 130|members
P11554469A1386|182 191|synthases
P11554469A1386|195 201|plants
P11554566A0668|4 22|hatcher incubators
P11554566A0668|31 40|companies
P11554566A0668|135 144|company A
P11554566A0668|180 190|company B.
P11554566A0833|8 23|companies sites
P11554566A0833|74 79|Tr104
P11554566A0833|125 134|locations
P11554727A0890|4 24|mutation experiments
P11554727A0890|55 63|sequence
P11554727A0890|72 82|repression
P11554727A0890|86 89|PTH
P11554727A0890|97 111|GGGGGAGGGGAG-3
P11554727A0890|128 133|PTHSR
P11555516A0639|8 14|output
P11555516A0639|28 37|threshold
P11555516A0639|39 43|COAT
P11555516A0639|56 61|L/min
P11555516A0639|75 87|cutoff value
P11555516A0639|125 139|artery disease
P11555516A0639|150 154|risk
P11555669A0464|0 10|Experience
P11555669A0464|28 36|sections
P11555669A0464|55 72|Vrinnevi Hospital
P11555669A0983|13 16|mix
P11555669A0983|24 32|sections
P11555669A0983|37 44|samples
P11555669A0983|49 56|tissues
P11555669A0983|61 67|stains
P11555669A0983|89 94|pairs
P11556809A2085|36 51|enzyme activity
P11556809A2085|83 102|5-epi-aristolochene
P11556809A2085|107 123|1-deoxycapsidiol
P11556809A2085|127 136|capsidiol
P11556809A2085|167 173|notion
P11556809A2085|184 195|P450 enzyme
P11556809A2085|211 225|hydroxylations
P11556809A2085|233 254|hydrocarbon substrate
P11557127A0991|3 13|conclusion
P11557127A0991|15 19|NF-Y
P11557127A0991|24 41|Sp1 binding sites
P11557127A0991|58 62|role
P11557127A0991|76 86|expression
P11557127A0991|94 107|rat mrp2 gene
P11557127A0991|125 134|MRP2 gene
P11559366T0000|30 40|inhibition
P11559366T0000|48 84|plasminogen activator inhibitor type
P11559366T0000|87 91|gene
P11559547T0000|16 26|regulation
P11559547T0000|53 82|pS2 breast cancer marker gene
P11559547T0000|90 100|ERR family
P11559547T0000|119 128|receptors
P11559564A0459|0 6|NB-506
P11559564A0459|31 39|capacity
P11559564A0459|43 56|topoisomerase
P11559564A0459|97 112|splicing factor
P11559564A0459|127 142|splicing factor
P11559564A0459|144 151|SF2/ASF
P11559789A0314|20 24|work
P11559789A0314|54 59|virus
P11559789A0314|75 98|ASF/SF2 splicing factor
P11559789A0314|106 118|progesterone
P11559789A0314|140 153|gene cassette
P11559789A0314|174 181|ASF/SF2
P11559789A0314|213 218|level
P11559789A0314|230 248|producer cell line
P11559789A0314|262 269|absence
P11559789A0314|273 280|inducer
P11559821A1315|0 18|DNA binding assays
P11559821A1315|33 45|interference
P11559821A1315|49 52|p30
P11559821A1315|66 74|assembly
P11559821A1315|78 91|CREB-Tax-p300
P11559821A1315|92 95|CBP
P11559821A1315|109 118|complexes
P11559821A1315|128 151|repeat oligonucleotides
P11560292A0557|32 41|structure
P11560292A0557|45 57|domain model
P11560292A0557|60 73|prototype DSS
P11560292A0557|78 101|dipslide urine cultures
P11560509T0000|0 15|DNA recognition
P11560509T0000|19 34|F factor TraI36
P11560509T0000|61 68|binding
P11560509T0000|88 91|DNA
P11560990A0272|0 18|E47 protein levels
P11560990A0272|71 76|stage
P11560990A0272|87 92|point
P11560990A0272|126 132|levels
P11560990A0272|169 179|transition
P11560990A0272|203 208|stage
P11560992A0000|9 28|specificity kinases
P11560992A0000|47 61|protein kinase
P11560992A0000|63 67|MAPK
P11560992A0000|69 75|kinase
P11560992A0000|77 80|MKK
P11560992A0000|87 91|MKK4
P11560992A0000|105 114|molecules
P11560992A0000|146 160|stress kinases
P11560992A0000|178 193|protein kinases
P11560992A0000|195 200|SAPKs
P11560992A0000|202 207|c-Jun
P11560992A0000|219 226|kinases
P11560992A0000|228 232|JNKs
P11560992A0000|237 245|response
P11560992A0000|276 283|stimuli
P11560992A0651|0 19|SAPK/JNK activation
P11560992A0651|52 59|absence
P11560992A0651|63 67|MKK7
P11560992A0651|81 91|expression
P11560992A0651|95 99|MKK4
P11560992A0651|128 132|mkk7
P11560992A0651|138 153|mast cell lines
P11560992A0651|159 174|phosphorylation
P11560992A0651|178 182|MKK4
P11560992A0651|204 212|response
P11560992A0651|225 239|stress stimuli
P11560992A1184|6 10|MKK7
P11560992A1184|40 49|regulator
P11560992A1184|68 87|SAPK/JNK activation
P11560992A1184|91 101|mast cells
P11560992A1184|106 110|MKK7
P11560992A1184|132 145|growth factor
P11560992A1184|150 157|antigen
P11560992A1184|174 187|proliferation
P11560992A1184|205 210|cells
P11561623A0897|10 45|copepod Pseudonychocamptus proximus
P11561623A0897|79 92|Tisbe furcata
P11561623A0897|96 108|sand filters
P11561623A0897|120 124|fall
P11561623A0897|167 175|increase
P11561623A0897|190 197|biomass
P11561623A0897|213 219|spring
P11561626A0197|24 33|solutions
P11561626A0197|37 43|TMT-55
P11561626A0197|53 62|solutions
P11561626A0197|87 91|zinc
P11561626A0197|93 100|cadmium
P11561626A0197|110 115|salts
P11561626A0197|141 147|Zn-TMT
P11561626A0197|176 182|Cd-TMT
P11561626A0197|198 204|Pb-TMT
P11561626A0197|207 209|M3
P11561626A0197|210 216|S3C3N3
P11561626A0197|219 223|nH2O
P11561626A0197|231 232|M
P11561626A0197|233 236|Cd2
P11561626A0197|239 242|Pb2
P11561626A0197|249 252|Zn2
P11561626A0197|258 259|n
P11561626A0197|314 317|air
P11562278A0169|22 27|genes
P11562278A0169|44 57|G1 regulation
P11562278A0169|88 92|role
P11562278A0169|96 109|proliferation
P11562278A0169|111 126|differentiation
P11562278A0169|141 155|transformation
P11562278A0169|171 181|cell death
P11562278A0169|183 192|apoptosis
P11562870A0892|4 15|probability
P11562870A0892|19 28|treatment
P11562870A0892|34 45|lamotrigine
P11562870A0892|71 77|months
P11562870A0892|84 85|%
P11562870A0892|98 104|months
P11562870A0892|107 108|%
P11562870A0892|123 128|years
P11562870A0892|131 132|%
P11564871A1184|6 13|results
P11564871A1184|27 35|presence
P11564871A1184|52 73|transcription systems
P11564871A1184|90 100|eukaryotes
P11564871A1184|113 120|insight
P11564871A1184|139 143|need
P11564871A1184|148 151|TBP
P11564871A1184|165 169|Pols
P11564871A1184|179 189|eukaryotes
P11564871A1184|200 204|lack
P11564871A1184|208 221|TATA elements
P11564871A1184|231 240|promoters
P11564893A1068|16 22|change
P11564893A1068|26 38|conformation
P11564893A1068|44 50|repair
P11564893A1068|58 68|6RG lesion
P11564893A1068|70 74|MGMT
P11564893A1068|91 108|DNA repair factor
P11564893A1068|114 137|transcription regulator
P11564893A1068|139 145|R-MGMT
P11564893A1068|161 165|cell
P11564893A1068|169 174|sense
P11564893A1068|186 193|respond
P11564893A1068|197 205|mutagens
P11565747A1020|0 4|Data
P11565747A1020|19 34|splicing assays
P11565747A1020|36 51|UV crosslinking
P11565747A1020|68 91|competition experiments
P11565747A1020|111 122|correlation
P11565747A1020|135 153|binding affinities
P11565747A1020|157 160|PSI
P11565747A1020|169 184|SELEX sequences
P11565747A1020|195 202|ability
P11565747A1020|215 223|splicing
P11565747A1020|227 241|P element IVS3
P11566874T0000|8 20|motor domain
P11566874T0000|38 44|dynein
P11566948A1217|16 31|nephrosclerosis
P11566948A1217|33 40|therapy
P11566948A1217|55 59|ACEI
P11566948A1217|72 83|combination
P11566948A1217|110 119|incidence
P11566948A1217|129 135|events
P11566961A0472|0 21|Body weight reduction
P11566961A0472|32 51|insulin sensitivity
P11566961A0472|70 83|blood glucose
P11566961A0472|88 110|blood pressure control
P11566996A1391|21 25|uvrA
P11566996A1391|34 68|nucleotide excision repair pathway
P11566996A1391|89 95|repair
P11566996A1391|112 122|DNA damage
P11566996A1391|158 168|adaptation
P11566996A1391|172 181|S. mutans
P11566996A1391|189 192|pH.
P11568988A0960|9 25|regression model
P11568988A0960|41 48|changes
P11568988A0960|56 60|WCXR
P11568988A0960|70 74|time
P11568988A0960|93 100|culture
P11568988A0960|105 119|antibody titer
P11568988A0960|124 135|Pa elastase
P11569800T0000|0 23|Temperature measurement
P11569800T0000|40 47|systems
P11569900A0660|0 14|APC-resistance
P11569900A0660|48 54|method
P11569900A0660|65 76|sensitivity
P11569900A0660|81 92|specificity
P11569900A0660|101 125|factor V Leiden mutation
P11569949A2087|0 5|Zarix
P11569949A2087|15 33|patient enrollment
P11569949A2087|55 60|sites
P11569949A2087|73 79|Spring
P11570735A1097|0 7|RESULTS
P11570735A1097|13 21|subjects
P11570735A1097|39 53|feedback group
P11570735A1097|82 86|peak
P11570735A1097|96 117|ground reaction force
P11570735A1097|136 146|conditions
P11570735A1097|167 176|reduction
P11570735A1097|208 217|reduction
P11570735A1097|275 282|control
P11570735A1097|286 301|feedback groups
P11570820T0000|5 18|casein kinase
P11570820T0000|21 29|isoforms
P11570820T0000|69 76|nucleus
P11570820T0000|81 90|cytoplasm
P11572377T0000|0 3|Use
P11572377T0000|20 32|lithotripter
P11572377T0000|73 89|cavitation field
P11572388A0000|5 10|paper
P11572388A0000|25 32|results
P11572388A0000|47 52|study
P11572388A0000|60 71|application
P11572388A0000|82 112|solvation energy relationships
P11572388A0000|114 119|LSERs
P11572388A0000|128 138|prediction
P11572388A0000|160 169|compounds
P11572388A0000|212 216|RPLC
P11572388A0000|218 236|method development
P11572467A0658|9 19|blood clot
P11572467A0658|46 52|cavity
P11572467A0658|67 76|injection
P11572467A0658|80 84|t-PA
P11572467A0658|97 108|plasminogen
P11572467A0658|112 119|plasmin
P11572467A0658|135 139|clot
P11572467T0000|0 10|Management
P11572467T0000|47 57|hemorrhage
P11572467T0000|63 91|tissue plasminogen activator
P11572467T0000|93 97|t-PA
P11572467T0000|103 109|volume
P11572467T0000|134 143|exchanger
P11573771T0000|0 6|Effect
P11573771T0000|10 25|heat treatments
P11573771T0000|33 44|meltability
P11573771T0000|48 55|cheeses
P11573891A0525|0 7|RESULTS
P11573891A0525|19 23|cent
P11573891A0525|35 44|Americans
P11573891A0525|59 78|community outbreaks
P11573891A0525|84 87|TST
P11573891A0525|116 117|%
P11573891A0525|121 127|whites
P11573891A0525|149 158|exposures
P11574088A1687|4 8|mean
P11574088A1687|17 21|time
P11574088A1687|37 56|pancreas transplant
P11574088A1687|65 69|days
P11574088A1687|74 77|SPK
P11574088A1687|86 90|days
P11574088A1687|95 109|PAK recipients
P11574088A1687|111 112|P
P11574105A0727|0 8|Patients
P11574105A0727|14 28|antibody peaks
P11574105A0727|60 68|increase
P11574105A0727|72 86|antibody titer
P11574105A0727|110 124|antibody titer
P11574105A0727|134 140|course
P11574105A0727|144 147|GBS
P11574105A0727|160 177|disability scores
P11574105A0727|199 204|weeks
P11574105A0727|208 211|GBS
P11574105A0727|233 240|outcome
P11574105A0727|251 254|IgG
P11574105A0727|269 287|IgM antibody peaks
P11574105A0727|300 306|damage
P11574105A0727|318 336|IgM antibody peaks
P11574105A0727|351 359|patients
P11574105A0727|373 388|antibody titers
P11575109A0214|10 18|baseline
P11575109A0214|28 39|examination
P11575109A0214|64 71|therapy
P11575109A0214|76 84|patients
P11575109A0214|107 114|surgery
P11575109A0214|134 140|grafts
P11575109A0214|145 154|treatment
P11575109A0214|180 187|gingiva
P11575977A1133|9 17|patients
P11575977A1133|32 51|office hypertension
P11575977A1133|86 99|complications
P11576158A1371|7 19|TVD-patients
P11576158A1371|33 48|skin blood flow
P11576158A1371|88 96|controls
P11576776T0081|15 21|moduli
P11576776T0081|25 51|microcrystalline cellulose
P11577094A1226|6 14|findings
P11577094A1226|45 49|WT-1
P11577094A1226|50 63|HSAL2 pathway
P11577094A1226|75 79|role
P11577094A1226|83 94|development
P11577094A1226|99 112|hematopoiesis
P11578685A0077|0 6|ICAM-1
P11578685A0077|28 37|predictor
P11578685A0077|45 50|onset
P11578685A0077|54 56|GO
P11579100T0000|0 23|Phosphotyrosyl peptides
P11579100T0000|45 65|DNA binding activity
P11579100T0000|67 82|gene regulation
P11579100T0000|88 107|cell transformation
P11580173A0181|0 19|Plane wave geometry
P11580173A0181|48 51|use
P11580173A0181|60 67|results
P11580173A0181|76 80|work
P11580173A0181|118 134|P3 approximation
P11580173A0181|151 159|geometry
P11580173A0181|179 184|paper
P11580301A1161|4 13|diagnosis
P11580301A1161|17 30|HCV arthritis
P11580301A1161|34 42|patients
P11580301A1161|68 74|factor
P11580301A1161|100 113|polyarthritis
P11580757A0304|0 7|METHODS
P11580757A0304|40 53|TFCD patients
P11580757A0304|68 75|surgery
P11580757A0304|92 100|epilepsy
P11580757A0304|110 113|aim
P11580757A0304|139 148|resonance
P11580757A0304|150 152|MR
P11580757A0304|165 171|lesion
P11580757A0304|197 201|zone
P11580757A0304|243 253|recordings
P11580941A0815|0 7|RESULTS
P11580941A0815|19 30|examination
P11580941A0815|37 45|UPDRS II
P11580941A0815|50 60|III scores
P11580941A0815|79 80|%
P11580941A0815|85 96|stimulation
P11580941A0815|102 109|therapy
P11580941A0815|116 120|mean
P11580941A0815|123 134|% reduction
P11580941A0815|148 152|time
P11583428A0191|3 6|Exp
P11583621A0301|27 34|stimuli
P11583621A0301|46 56|expression
P11583621A0301|79 87|cleavage
P11583621A0301|91 95|hTAF
P11583621A0301|102 107|delta
P11583621A0301|109 113|hTAF
P11583621A0301|120 125|delta
P11583621A0301|134 138|hTAF
P11583621A0301|165 172|complex
P11583621A0301|181 185|hTAF
P11583880T0000|13 28|aneurysm repair
P11583880T0000|38 56|AneuRx stent-graft
P11584107T0000|20 28|diseases
P11584107T0000|43 49|origin
P11584107T0000|54 64|assessment
P11584107T0000|78 83|field
P11584328A0532|0 17|Drug interactions
P11584328A0532|39 44|drugs
P11584328A0532|71 88|CYP450 isoenzymes
P11584328A0532|92 99|statins
P11585856A0285|0 7|METHODS
P11585856A0285|33 40|benefit
P11585856A0285|60 62|RR
P11585856A0285|75 77|AC
P11585856A0285|86 106|scanning line source
P11585856A0285|112 130|scatter correction
P11585856A0285|132 154|photon energy recovery
P11585856A0285|156 159|PER
P11585856A0285|185 199|backprojection
P11586096A0699|11 22|differences
P11586096A0699|26 49|patient characteristics
P11586096A0699|51 71|control measurements
P11586096A0699|98 104|muscle
P11586096A0699|112 120|patients
P11587514A0758|13 32|abi1-1 gene product
P11587514A0758|40 46|effect
P11587514A0758|54 69|ABA suppression
P11587514A0758|89 107|alpha-amylase gene
P11587980A1039|3 11|children
P11587980A1039|48 57|maneuvers
P11587980A1039|59 60|n
P11587980A1039|68 71|FOT
P11587980A1039|73 81|contrary
P11587980A1039|89 110|interrupter technique
P11587980A1039|133 141|subgroup
P11587980A1039|151 159|children
P11587980A1039|170 187|resistance values
P11587980A1039|191 199|baseline
P11587980A1039|232 247|bronchodilation
P11589568A0744|11 16|yeast
P11589568A0744|30 49|checkpoint response
P11589568A0744|63 76|proteins Mad1
P11589568A0744|84 88|Bub1
P11589568A0744|93 97|Bub3
P11589568A0744|116 128|counterparts
P11589568A0744|152 164|kinetochores
P11589779T0000|0 6|HTLV-1
P11589779T0000|17 25|Th2 type
P11589779T0000|36 44|response
P11589779T0000|48 56|patients
P11589779T0000|62 78|strongyloidiasis
P11590364A1056|13 34|beta5L splice variant
P11590364A1056|57 63|retina
P11592315A0325|0 9|PROCEDURE
P11592315A0325|11 19|Cannulas
P11592315A0325|63 67|body
P11592315A0325|80 86|antrum
P11592315A0325|95 99|calf
P11592532A0188|0 7|METHODS
P11592532A0188|9 38|Humphrey Field Analyzer model
P11592532A0188|44 47|HFA
P11592532A0188|51 58|program
P11592532A0188|85 92|degrees
P11592532A0188|97 109|degrees grid
P11592532A0188|151 157|method
P11593394A0000|13 31|growth factor-beta
P11593394A0000|33 41|TGF-beta
P11593394A0000|51 64|growth arrest
P11593394A0000|68 73|cells
P11593394A0000|83 93|regulation
P11593394A0000|101 111|activities
P11593394A0000|120 121|D
P11593394A0000|134 157|cyclin kinase complexes
P11593394A0000|198 208|regulation
P11593394A0000|212 215|p15
P11593394A0000|216 221|Ink4b
P11593394A0000|227 230|p27
P11593394A0000|231 235|Kip1
P11593394A0000|237 261|cyclin kinase inhibitors
P11595170A0582|0 9|Alignment
P11595170A0582|23 28|cDNAs
P11595170A0582|36 41|NR5A2
P11595170A0582|43 47|hB1F
P11595170A0582|49 53|gene
P11595170A0582|71 79|sequence
P11595170A0582|96 107|delineation
P11595170A0582|126 138|organization
P11595170A0582|161 163|kb
P11595170A0582|186 191|exons
P11595170A0582|213 220|introns
P11595176T0000|12 21|structure
P11595176T0000|35 45|SPEC1 gene
P11595176T0000|62 70|splicing
P11595176T0000|75 99|close promoter proximity
P11595176T0000|107 130|AF1q translocation gene
P11595478A1014|0 2|Hp
P11595478A1014|12 21|relatives
P11595478A1014|33 39|cancer
P11595478A1014|62 72|prevalence
P11595478A1014|76 83|atrophy
P11595478A1014|100 113|Hp negativity
P11595478A1014|122 138|cancer relatives
P11595813A0633|11 21|metabolism
P11595813A0633|25 34|androgens
P11595813A0633|41 46|place
P11595813A0633|58 63|areas
P11595813A0633|89 93|unit
P11595813A0633|117 128|differences
P11595813A0633|136 146|activities
P11595813A0633|150 159|aromatase
P11595813A0633|161 177|5alpha-reductase
P11595813A0633|196 204|presence
P11595813A0633|212 230|androgen receptors
P11595840A0000|4 10|uptake
P11595840A0000|26 44|fluorodeoxyglucose
P11595840A0000|46 54|F-18 FDG
P11595840A0000|71 76|tumor
P11595840A0000|92 111|blood glucose level
P11596104A0614|0 22|Northern blot analysis
P11596104A0614|39 45|PARNAs
P11596104A0614|73 79|signal
P11596104A0614|101 110|kilobases
P11596104A0614|112 114|kb
P11596104A0614|131 141|cell lines
P11596838A1357|5 13|analysis
P11596838A1357|27 30|use
P11596838A1357|34 56|fluticasone propionate
P11596838A1357|60 66|microg
P11596838A1357|93 102|treatment
P11596838A1357|106 114|patients
P11596838A1357|131 137|asthma
P11596838A1357|175 188|beta2-agonist
P11597185A0477|35 49|metapopulation
P11597185A0477|58 64|models
P11597185A0477|69 89|computer simulations
P11597185A0477|143 150|regimes
P11597185A0477|154 177|metapopulation dynamics
P11597936A0570|6 18|CAD patients
P11597936A0570|51 59|patients
P11597936A0570|64 67|age
P11597936A0570|74 79|years
P11597936A0570|82 90|baseline
P11597936A0570|95 114|density lipoprotein
P11597936A0570|121 126|mg/dL
P11597936A0570|133 146|triglycerides
P11597936A0570|154 159|mg/dL
P11597936A0570|212 217|drugs
P11597936A0570|235 243|controls
P11599079A1040|18 34|orifice voltages
P11599079A1040|49 60|instruments
P11599079A1040|75 76|V
P11599079A1040|78 81|API
P11599079A1040|98 99|V
P11599079A1040|101 104|API
P11599079A1040|125 126|V
P11599079A1040|128 131|API
P11599797A0732|0 7|RESULTS
P11599797A0732|17 21|gene
P11599840A0813|4 10|moduli
P11599840A0813|14 24|elasticity
P11599840A0813|47 53|matter
P11599840A0813|69 72|kPa
P11599840A0813|74 78|mean
P11599840A0813|92 101|deviation
P11599840A0813|117 120|kPa
P11599840A0813|134 141|section
P11599840A0813|151 154|kPa
P11599840A0813|169 172|kPa
P11599840A0813|188 195|section
P11599840A0813|211 214|kPa
P11599840A0813|229 232|kPa
P11599840A0813|249 256|section
P11600252A0795|4 6|LA
P11600252A0795|38 42|data
P11600252A0795|74 80|series
P11600252A0795|131 137|change
P11600252A0795|141 150|mortality
P11600314A0000|15 27|polarography
P11600314A0000|45 50|pulse
P11600314A0000|65 72|methods
P11600314A0000|137 145|analysis
P11600314A0000|149 159|vitamin B1
P11600314A0000|161 163|B2
P11600314A0000|168 170|B6
P11600365A0471|22 31|organisms
P11600365A0471|33 39|E-4767
P11600365A0471|44 50|E-5065
P11600365A0471|106 118|tosufloxacin
P11600365A0471|152 171|reference compounds
P11600467A1436|35 45|alteration
P11600467A1436|66 78|permeability
P11602353A0770|15 25|HNF-3 beta
P11602353A0770|27 32|HFH-1
P11602353A0770|34 39|HFH-2
P11602353A0770|41 46|HFH-3
P11602353A0770|48 53|C/EBP
P11602353A0770|59 69|C/EBP beta
P11602353A0770|124 143|expression profiles
P11602353A0770|151 155|gene
P11603271T0001|9 16|vertigo
P11603271T0001|21 38|vertigo syndromes
P11604152A0526|4 8|MABP
P11604152A0526|13 26|MCBFV signals
P11604152A0526|32 40|bandpass
P11604152A0526|76 81|range
P11604152A0526|83 86|VLF
P11604152A0526|99 101|Hz
P11604152A0526|104 123|low-frequency range
P11604152A0526|125 127|LF
P11604152A0526|139 141|Hz
P11604152A0526|162 167|range
P11604152A0526|169 171|HF
P11604152A0526|183 185|Hz
P11604152A0526|203 206|CCF
P11604152A0526|215 222|purpose
P11604152A0526|239 245|effect
P11604152A0526|259 269|bandwidths
P11604152A0526|287 296|mean CCFs
P11605207T0001|0 9|Treatment
P11605207T0001|22 35|heart disease
P11605598A0785|0 11|Hepatitis B
P11605598A0785|16 38|C seroprevalence rates
P11605598A0785|55 66|adolescents
P11605598A0785|80 87|El Paso
P11605598A0785|110 124|US populations
P11605598A0785|146 153|climate
P11605598A0785|158 177|prevention programs
P11606538A1002|10 19|insertion
P11606538A1002|33 38|genes
P11606538A1002|40 43|Nrk
P11606538A1002|63 87|receptor tyrosine kinase
P11606538A1002|93 96|Tpp
P11606538A1002|114 128|neuropeptidase
P11614398T0000|11 17|people
P11614398T0000|38 45|aspects
P11614398T0000|49 58|Mormonism
P11639485A0478|12 16|work
P11639485A0478|78 82|Urdu
P11639485A0478|93 102|languages
P11639485A0478|111 118|benefit
P11639485A0478|134 146|day students
P11639485A0478|151 159|scholars
P11642687T0000|0 10|Comparison
P11642687T0000|21 38|language versions
P11642687T0000|46 52|QWB-SA
P11642687T0000|57 62|SF-36
P11642687T0000|74 82|outcomes
P11642687T0000|87 95|patients
P11642687T0000|101 117|prostate disease
P11653491T0000|13 19|action
P11653491T0000|24 37|DNA violation
P11669281A0653|11 23|cytotoxicity
P11669281A0653|36 47|antibiotics
P11669281A0653|70 78|evidence
P11669281A0653|82 93|competition
P11669281A0653|97 106|synergism
P11669476A0346|17 25|cytokine
P11669476A0346|27 54|tumor necrosis factor-alpha
P11669476A0346|56 65|TNF-alpha
P11669476A0346|90 97|tissues
P11669476A0346|107 115|subjects
P11669476A0346|148 152|role
P11669476A0346|165 183|insulin resistance
P11675912A0131|10 17|alcohol
P11675912A0131|34 38|week
P11675912A0131|71 82|preparation
P11675912A0131|95 102|aspirin
P11675912A0131|107 120|acetaminophen
P11675912A0131|126 137|alleviation
P11675912A0131|141 150|headaches
P11676899A0704|19 31|risk factors
P11676899A0704|65 70|virus
P11676899A0704|83 96|mononucleosis
P11676899A0704|126 142|immunodeficiency
P11676899A0704|160 168|exposure
P11676899A0704|174 187|wood industry
P11677363A0775|19 26|finding
P11677363A0775|46 56|IMT values
P11677363A0775|78 83|h SBP
P11677363A0775|87 89|PP
P11677363A0775|99 108|deviation
P11677363A0775|110 111|P
P11677363A0775|124 131|measure
P11677363A0775|143 146|SBP
P11677363A0775|150 164|PP variability
P11677839A0876|4 14|difference
P11677839A0876|27 35|patients
P11677839A0876|44 52|controls
P11677839A0876|84 85|p
P11678437A0000|4 10|effect
P11678437A0000|20 32|oil spillage
P11678437A0000|36 42|growth
P11678437A0000|44 56|productivity
P11678437A0000|61 76|nutrient uptake
P11678437A0000|80 85|maize
P11678437A0000|87 98|Zea mays L.
P11678437A0000|118 132|pot experiment
P11678437A0000|150 165|manifold sample
P11678437A0000|171 200|petroleum development company
P11678437A0000|223 230|gravity
P11679441A0429|0 14|NO metabolites
P11679441A0429|38 49|measurement
P11679441A0429|53 68|nitrate/nitrite
P11679441A0429|70 73|NOx
P11679441A0429|75 99|micromol/mmol creatinine
P11679441A0429|112 135|guanosine monophosphate
P11679441A0429|137 141|cGMP
P11679441A0429|143 163|nmol/mmol creatinine
P11679441A0429|168 174|plasma
P11679441A0429|179 184|urine
P11680835A0756|17 25|analysis
P11680835A0756|40 45|costs
P11680835A0756|50 57|patient
P11680835A0756|83 87|acid
P11680835A0756|101 112|pamidronate
P11683558A0446|4 8|diet
P11683558A0446|12 20|migrants
P11683558A0446|43 57|macronutrients
P11683558A0446|73 87|micronutrients
P11683558A0446|89 100|differences
P11683558A0446|124 128|diet
P11684665A0000|0 24|C. elegans embryogenesis
P11684665A0000|51 59|sequence
P11684665A0000|74 88|cell divisions
P11684665A0000|139 157|nematode body plan
P11685047A0301|23 29|method
P11685047A0301|49 68|thrombin inhibition
P11685047A0301|77 93|substrate S-2238
P11685284X0000|1 13|Diabetologia
P11685284X0000|25 30|Suppl
P11685284X0000|35 42|B37-B44
P11686239A0464|16 24|sequence
P11686239A0464|32 39|3B gene
P11686239A0464|57 58|T
P11686239A0464|82 85|G/C
P11686239A0464|91 100|stretches
P11686239A0464|149 168|sequence similarity
P11686239A0464|176 183|G boxes
P11686239A0464|234 253|Dictyostelium genes
P11686378A0326|21 28|reactor
P11686378A0326|61 70|discharge
P11686378A0326|80 84|LD50
P11686378A0326|91 97|values
P11686378A0326|132 146|concentrations
P11686378A0326|154 159|range
P11686378A0326|180 193|E coli/cfu mL
P11686378A0326|246 254|Pn decay
P11686378A0326|280 288|colonies
P11686378A0326|304 314|phenomenon
P11686378A0326|330 335|cells
P11686378A0326|369 376|numbers
P11686378A0326|387 392|cells
P11686378A0326|400 403|EHD
P11687083A0218|0 10|OBJECTIVES
P11687083A0218|16 25|objective
P11687083A0218|34 40|review
P11687083A0218|59 66|effects
P11687083A0218|70 100|prophylactic prostaglandin use
P11687083A0218|114 119|stage
P11687083A0218|123 129|labour
P11687180A3209|12 16|term
P11687180A3209|18 27|questions
P11687180A3209|68 75|rHu EPO
P11687180A3209|83 89|speeds
P11687180A3209|96 102|delays
P11687180A3209|107 112|onset
P11687180A3209|116 124|dialysis
P11687352A0215|0 7|METHODS
P11687352A0215|28 34|review
P11687352A0215|50 54|eyes
P11687352A0215|64 69|LASIK
P11687352A0215|78 87|September
P11687352A0215|97 106|September
P11687517A1619|3 8|ISREs
P11687517A1619|36 50|mouse promoter
P11687737A0000|0 10|BACKGROUND
P11687737A0000|21 34|heart disease
P11687737A0000|50 55|cause
P11687737A0000|59 68|morbidity
P11687737A0000|73 82|mortality
P11687737A0000|89 98|diabetics
P11687737A0000|143 146|age
P11687869A0000|14 19|woman
P11687869A0000|36 43|colitis
P11687869A0000|67 78|sarcoidosis
P11689217T0000|0 34|Cholesteryl ester transfer protein
P11689217T0000|39 54|atherosclerosis
P11689217T0000|67 75|subjects
P11689217T0000|79 84|study
P11689217T0000|103 114|angiography
P11691585A1174|16 37|mobility shift assays
P11691585A1174|42 71|coimmunoprecipitation studies
P11691585A1174|85 89|homo
P11691585A1174|95 113|heterodimerization
P11691585A1174|129 149|cKrox family members
P11691585T0000|4 22|hcKrox gene family
P11691585T0000|56 68|matrix genes
P11692004A1200|2 8|review
P11692004A1200|16 26|literature
P11692004A1200|63 70|studies
P11692004A1200|108 120|relationship
P11692004A1200|129 132|NF1
P11692004A1200|150 159|aneurysms
P11693461A1649|6 22|utilisation data
P11693461A1649|36 46|drug costs
P11693461A1649|54 59|range
P11693461A1649|64 66|US
P11693461A1649|79 81|US
P11693461A1649|96 111|TNF antagonists
P11693461A1649|116 118|RA
P11693461A1649|133 143|population
P11695481A0310|10 20|conditions
P11695481A0310|26 43|combination O3/UV
P11695481A0310|64 80|degradation rate
P11695481A0310|93 102|ozonation
P11697760A0000|5 10|study
P11697760A0000|32 37|boron
P11697760A0000|56 63|ability
P11697760A0000|67 83|17beta-estradiol
P11697760A0000|85 87|E2
P11697760A0000|104 111|hormone
P11697760A0000|113 116|PTH
P11697760A0000|129 141|bone quality
P11697760A0000|160 168|OVX rats
P11703464A0560|24 37|subjects rCBF
P11703464A0560|51 58|regions
P11703464A0560|116 124|circuits
P11703464A0560|128 136|response
P11703464A0560|154 160|reward
P11703464A0560|177 190|reinforcement
P11703558A0000|0 11|Doxorubicin
P11703558A0000|13 16|DOX
P11703558A0000|43 52|treatment
P11703558A0000|80 86|tumors
P11704380A1608|4 14|event rate
P11704380A1608|18 26|patients
P11704380A1608|40 48|Irr-rMFP
P11704380A1608|52 60|Un-nrMFP
P11704380A1608|107 115|Rev-rMFP
P11704380A1608|119 128|Sta-nrMFP
P11704829A0312|0 25|Subtraction hybridization
P11704829A0312|37 61|melanoma differentiation
P11704829A0312|73 79|gene-7
P11704829A0312|81 86|mda-7
P11704829A0312|94 98|gene
P11704829A0312|134 141|changes
P11704829A0312|151 165|melanoma cells
P11705093A2016|11 31|vitamin D3 analogues
P11705093A2016|65 71|effect
P11706668A0000|0 10|Hydrocoele
P11706668A0000|24 27|men
P11706668A0000|60 65|areas
P11706668A0000|71 80|treatment
P11706668A0000|113 125|intervention
P11706949T0000|0 14|Growth hormone
P11706949T0000|32 57|growth factor I receptors
P11706949T0000|83 88|joint
P11706949T0000|96 99|rat
P11707977A0750|13 17|hand
P11707977A0750|36 52|infusion therapy
P11707977A0750|66 74|survival
P11707977A0750|78 89|H3 patients
P11708032A0183|3 11|addition
P11708032A0183|57 65|infusion
P11708032A0183|69 81|levoforinate
P11708032A0183|83 87|l-LV
P11708032A0183|93 95|mg
P11708032A0183|100 114|5-fluorouracil
P11708032A0183|116 120|5-FU
P11708032A0183|126 128|mg
P11708032A0183|159 169|metastases
P11708032A0183|196 199|day
P11708032A0183|214 225|medications
P11708032A0183|252 257|hours
P11708032A0183|273 285|infuser pump
P11708362A0889|4 18|astronaut crew
P11708362A0889|32 39|payload
P11708362A0889|58 67|operation
P11708431A0904|10 18|patients
P11708431A0904|23 35|introduction
P11708431A0904|50 58|category
P11708431A0904|69 83|oligoarthritis
P11708431A0904|87 92|onset
P11708431A0904|139 153|patient groups
P11708761A1388|29 35|number
P11708761A1388|39 48|arguments
P11708761A1388|63 66|use
P11708761A1388|70 84|ACE inhibitors
P11708761A1388|99 107|patients
P11708761A1388|113 130|diabetes mellitus
P11709561T0000|0 5|Phase
P11709561T0000|9 14|trial
P11709561T0000|29 31|D2
P11709561T0000|44 56|antibody 3F8
P11709561T0000|103 109|factor
P11709561T0000|114 127|neuroblastoma
P11709890T0000|0 11|Hepatitis A
P11709890T0000|21 33|food handler
P11709890T0000|40 48|Edmonton
P11709890T0000|50 57|Alberta
P11709890T0000|65 78|food facility
P11709890T0000|87 115|health protection strategies
P11710233T0000|0 9|Hydrogels
P11710233T0000|14 32|tissue engineering
P11710685A0994a|16 22|subset
P11710685A0994a|26 31|ASCUS
P11710685A0994a|44 59|ASCUS/SIL ratio
P11710685A0994a|98 109|sensitivity
P11710685A0994a|117 134|Papanicolaou test
P11710685A0994b|16 22|subset
P11710685A0994b|26 31|ASCUS
P11710685A0994b|44 59|ASCUS/SIL ratio
P11710685A0994b|98 109|sensitivity
P11710685A0994b|117 134|Papanicolaou test
P11711701A0602|12 31|medicine physicians
P11711701A0602|56 64|findings
P11711701A0602|91 97|images
P11711701A0602|110 140|Tc-99m MIBI image combinations
P11711701A0602|147 154|minutes
P11711701A0602|165 172|minutes
P11711701A0602|179 184|hours
P11711701A0602|189 196|minutes
P11711701A0602|203 208|hours
P11711701A0602|217 224|minutes
P11711701A0602|237 242|hours
P11711701A0602|277 306|pertechnetate thyroid imaging
P11714429X0000|3 14|clopidogrel
P11714429X0000|27 34|aspirin
P11714429X0000|48 58|prevention
P11714429X0000|71 78|disease
P11714429X0000|84 95|cornerstone
P11714429X0000|108 116|evidence
P11714429X0000|133 141|efficacy
P11714429X0000|145 160|thienopyridines
P11714429X0000|162 173|clopidogrel
P11714429X0000|175 186|ticlopidine
P11714429X0000|195 202|aspirin
P11714429X0000|220 230|prevention
P11714429X0000|243 250|disease
P11714429X0000|258 269|Clopidogrel
P11714429X0000|277 284|Aspirin
P11714429X0000|288 296|Patients
P11714429X0000|300 304|Risk
P11714429X0000|318 330|Events trial
P11715079A1016|20 34|proprioception
P11715079A1016|64 78|efference copy
P11715079A1016|86 97|development
P11715079A1016|105 113|response
P11715079A1016|117 130|perturbations
P11715079A1016|154 164|mismatches
P11715079A1016|173 197|eye movement information
P11715079A1016|224 231|command
P11715079A1016|247 253|motion
P11715079A1016|261 264|eye
P11715079A1016|298 304|organs
P11716043A0380|27 35|patients
P11716043A0380|46 53|surgery
P11716043A0380|66 69|PTC
P11716043A0380|77 87|Department
P11716043A0380|91 98|Surgery
P11716043A0380|100 136|Helsinki University Central Hospital
P11716441A0585|0 3|ISS
P11716441A0585|18 28|physiology
P11716441A0585|41 58|health evaluation
P11716441A0585|60 66|APACHE
P11716441A0585|85 94|admission
P11718197A1282|4 13|procedure
P11722993A0276|0 12|Paul Monagle
P11722993A0276|27 39|epidemiology
P11722993A0276|52 62|thrombosis
P11722993A0276|94 100|system
P11722993A0276|129 138|locations
P11722993A0276|164 169|utero
P11723500X0000|30 45|characteristics
P11723500X0000|58 72|cell carcinoma
P11723500X0000|85 91|cavity
P11723500X0000|95 100|women
P11723500X0000|102 112|BACKGROUND
P11723500X0000|123 137|cell carcinoma
P11723500X0000|139 142|SCC
P11723500X0000|156 162|cavity
P11723500X0000|189 199|population
P11723511A0780|22 26|risk
P11723511A0780|34 39|drugs
P11723511A0780|48 49|%
P11723511A0780|63 78|category A risk
P11723511A0780|91 92|%
P11723511A0780|97 107|category B
P11723511A0780|120 121|%
P11723511A0780|126 136|category C
P11723511A0780|146 147|%
P11723511A0780|152 162|category D
P11723511A0780|175 176|%
P11723511A0780|181 192|category X.
P11723675A1022|4 12|severity
P11723675A1022|25 31|course
P11723675A1022|49 54|means
P11723675A1022|58 68|SOFA score
P11723675A1022|70 77|group A
P11723675A1022|85 93|.3 point
P11723675A1022|95 102|group B
P11723675A1022|115 120|point
P11723675A1022|122 129|group C
P11723675A1022|135 137|.3
P11723675A1022|142 147|point
P11723675A1022|153 168|APACHE II score
P11723675A1022|170 177|group A
P11723675A1022|190 195|point
P11723675A1022|197 204|group B
P11723675A1022|219 224|point
P11723675A1022|226 233|group C
P11723675A1022|241 243|.2
P11723675A1022|249 254|point
P11723928A0294|4 11|process
P11723928A0294|36 53|river reclamation
P11723928A0294|57 72|Yangpu District
P11723928A0294|76 89|Shanghai City
P11723928A0294|91 96|China
P11724510T0000|9 19|principles
P11724510T0000|35 44|apheresis
P11726022A0909|6 13|results
P11726022A0909|37 46|estimates
P11726022A0909|50 61|penetration
P11726022A0909|80 92|calculations
P11726022A0909|101 105|root
P11726022A0909|109 126|time calculations
P11726022A0909|166 171|model
P11726068A0539|0 4|Rind
P11726068A0539|14 19|study
P11726068A0539|27 38|conclusions
P11726068A0539|74 78|data
P11726164A0215|9 16|concern
P11726164A0215|20 35|food processors
P11726164A0215|55 68|cross-contact
P11726164A0215|72 85|food products
P11726164A0215|102 110|residues
P11726164A0215|163 172|reactions
P11726164A0215|189 201|food allergy
P11726262A0692|0 25|Lactate accumulation peak
P11726262A0692|44 59|supplementation
P11726262A0692|61 64|HMB
P11726262A0692|78 80|mM
P11726262A0692|82 85|LEU
P11726262A0692|99 101|mM
P11726262A0692|103 106|CON
P11726262A0692|120 122|mM
P11726413A1756|14 23|clearance
P11726413A1756|42 49|infants
P11726413A1756|56 64|contrast
P11726413A1756|74 81|opioids
P11726574A1304|6 13|results
P11726574A1304|29 36|changes
P11726574A1304|44 64|baseline assumptions
P11726574A1304|72 77|model
P11727073A0842|0 10|CONCLUSION
P11727073A0842|16 24|training
P11727073A0842|28 35|novices
P11727073A0842|42 56|MIST-VR yields
P11727073A0842|70 77|changes
P11727073A0842|81 86|skill
P11727073A0842|126 130|task
P11727073A0842|154 161|results
P11727073A0842|189 197|training
P11727209A0502|4 12|patients
P11727209A0502|23 31|families
P11727209A0502|75 86|examination
P11727209A0502|98 102|test
P11727209A0502|107 118|orthostasia
P11728771A0187|44 52|reaction
P11728771A0187|61 78|contrast material
P11730182A0984|38 49|correlation
P11730182A0984|86 99|pollen levels
P11730182A0984|103 115|Philadelphia
P11730182A0984|123 134|Cherry Hill
P11730182A0984|136 140|Acer
P11730182A0984|142 143|r
P11730182A0984|144 145|p
P11730182A0984|156 163|Quercus
P11730182A0984|165 166|r
P11730182A0984|167 168|p
P11730182A0984|179 185|Betula
P11730182A0984|187 188|r
P11730182A0984|189 190|p
P11730182A0984|201 206|Pinus
P11730182A0984|208 209|r
P11730182A0984|210 211|p
P11730182A0984|222 234|Cupressaceae
P11730182A0984|236 237|r
P11730182A0984|238 239|p
P11730182A0984|250 257|Poaceae
P11730182A0984|259 260|r
P11730182A0984|261 262|p
P11730182A0984|273 281|Ambrosia
P11730182A0984|283 284|r
P11730182A0984|285 286|p
P11730182A0984|301 306|Rumex
P11730182A0984|308 309|r
P11730182A0984|310 311|p
P11730182A0984|322 323|P
P11730262A0874|22 27|study
P11730262A0874|34 53|etidronate/fluoride
P11730262A0874|75 87|osteoporosis
P11730262A0874|104 115|pilot study
P11730262A0874|122 125|men
P11730262A0874|158 170|osteoporosis
P11730262A0874|189 199|etidronate
P11730262A0874|207 211|days
P11730262A0874|224 232|fluoride
P11730262A0874|238 255|calcium/vitamin D
P11730262A0874|263 267|days
P11730712A0416|0 18|Treadmill training
P11730712A0416|34 39|weeks
P11730712A0416|55 70|infarction size
P11730712A0416|75 80|edema
P11730712A0416|91 104|MCA occlusion
P11730712A0416|106 107|P
P11732088A0471|3 8|order
P11732088A0471|40 48|readings
P11732088A0471|70 89|sphincter manometry
P11732088A0471|110 118|secretin
P11732088A0471|141 151|ultrasound
P11732088A0471|153 158|SSEUS
P11732088A0471|189 197|response
P11732088A0471|215 221|method
P11732088A0471|248 257|diagnosis
P11732417A0571|12 39|percentage positivity value
P11732417A0571|116 129|serum samples
P11732417A0571|146 155|reference
P11732417A0571|163 174|sample data
P11732417A0571|194 203|ELISA kit
P11736254A0000|3 11|analysis
P11736254A0000|19 27|dynamics
P11736254A0000|61 67|models
P11736254A0000|91 98|glasses
P11736254A0000|115 127|partitioning
P11736254A0000|147 156|landscape
P11736254A0000|169 179|structures
P11736792A0204|10 23|semen samples
P11736792A0204|46 51|study
P11736792A0204|72 74|G1
P11736792A0204|96 98|G2
P11736792A0204|109 143|World Health Organization criteria
P11736792A0204|156 166|morphology
P11736792A0204|208 216|criteria
P11737056A0680|8 17|timepoint
P11737056A0680|24 34|leucocytes
P11737056A0680|42 44|ME
P11737056A0680|49 58|ET mucosa
P11737056A0680|76 80|BrdU
P11737056A0680|99 100|%
P11737056A0680|112 119|subsets
P11737158A1517|18 23|areas
P11737158A1517|37 45|Wernicke
P11737158A1517|52 66|fusiform gyrus
P11737158A1517|68 78|Broca BA44
P11737158A1517|94 99|gyrus
P11737158A1517|126 138|computations
P11737158A1517|158 165|contact
P11737158A1517|191 201|dimensions
P11737900A0700|12 23|correlation
P11737900A0700|32 42|plasma COP
P11737900A0700|47 58|body weight
P11737900A0700|71 74|age
P11737900A0700|76 78|r2
P11737900A0700|87 88|P
P11738404A0120|6 25|chemical structures
P11738404A0120|47 52|alpha
P11738404A0120|55 92|alpha-diacetoxy-8 beta-isobutanoyloxy
P11738404A0120|96 115|alpha-benzoyloxy-13
P11738404A0120|117 129|alpha-methyl
P11738404A0120|130 148|butanoyloxy-4 beta
P11738404A0120|152 189|beta-dihydroxy-beta-dihydroagarofuran
P11738404A0120|197 202|alpha
P11738404A0120|205 227|alpha-diacetoxy-8 beta
P11738404A0120|229 233|beta
P11738404A0120|235 251|furancarbonyloxy
P11738404A0120|255 296|alpha-benzoyloxy-13-isobutanoyloxy-4 beta
P11738404A0120|300 337|beta-dihydroxy-beta-dihydroagarofuran
P11738404A0120|348 353|alpha
P11738404A0120|357 361|beta
P11738404A0120|365 444|alpha,13-tetraacetoxy-9 alpha-benzoyloxy-2 alpha-hydroxy-beta-dihydroagarofuran
P11738404A0120|459 471|analyses NMR
P11738404A0120|476 478|MS
P11738404A0120|488 492|data
P11740571A0114|5 11|toxins
P11740571A0114|17 21|dose
P11740571A0114|45 52|maximum
P11740571A0114|65 78|concentration
P11740571A0114|89 97|activity
P11740571A0114|101 123|glutathione peroxidase
P11740571A0114|127 139|brain tissue
P11740571A0114|151 158|toluene
P11740571A0114|169 196|chemiluminescence intensity
P11740571A0114|216 226|activation
P11740571A0114|243 252|processes
P11740806X0810|0 16|Saunders Company
P11741259A1233|4 15|performance
P11741259A1233|32 41|particles
P11741259A1233|65 72|ability
P11741259A1233|88 92|drug
P11741259A1233|118 122|part
P11741259A1233|130 139|intestine
P11741259A1233|168 172|form
P11741554T0000|0 10|Comparison
P11741554T0000|27 48|lipoprotein particles
P11741554T0000|67 72|women
P11741554T0000|99 113|artery disease
P11741554T0000|121 124|men
P11741554T0000|139 153|artery disease
P11742432A0798|8 15|results
P11742432A0798|37 43|trials
P11742432A0798|61 69|efficacy
P11742432A0798|84 99|MAC prophylaxis
P11742432A0798|103 111|patients
P11742432A0798|134 145|combination
P11742432A0798|161 168|therapy
P11742432A0798|188 197|incidence
P11742432A0798|231 243|colonization
P11742432A0798|263 268|tract
P11742432A0798|277 282|trial
P11742432A0798|296 311|discontinuation
P11742432A0798|315 336|macrolide prophylaxis
P11742432A0798|344 357|AIDS patients
P11742432A0798|364 374|CD4 counts
P11742432A0798|396 408|cells/microL
P11743360A2491|6 12|stress
P11743360A2491|18 22|rats
P11743360A2491|42 53|mean amount
P11743360A2491|57 61|IL-6
P11743360A2491|78 83|urine
P11743360A2491|91 92|%
P11743360A2491|133 135|pg
P11743360A2491|137 139|ml
P11743612A1179|0 8|Patients
P11743612A1179|14 16|CF
P11743612A1179|21 35|meconium ileus
P11743612A1179|65 71|status
P11743612A1179|75 84|diagnosis
P11743612A1179|97 110|survival rate
P11743612A1179|135 148|CF population
P11744290T0045|1 10|Cactaceae
P11744290T0045|12 24|waste matter
P11744953A0878|0 12|Skin cancers
P11744953A0878|43 48|tract
P11744953A0878|66 72|system
P11744953A0878|95 107|age patients
P11752821A1365|0 10|CONCLUSION
P11752821A1365|12 15|MMF
P11752821A1365|21 26|g/day
P11752821A1365|53 58|signs
P11752821A1365|76 95|Adamantiades-Behcet
P11752821A1365|98 105|disease
P11755894A0466|7 16|treatment
P11755894A0466|33 41|patients
P11755894A0466|56 63|surgery
P11755894A0466|77 84|opioids
P11755894A0466|95 99|pain
P11755894A0466|106 109|ADL
P11755894A0466|122 124|mg
P11755894A0466|139 149|management
P11755894A0466|167 172|ileus
P11755894A0466|174 177|POI
P11755894A0466|197 201|time
P11755894A0466|220 234|bowel function
P11755894A0466|252 265|hospital stay
P11760398A0553|0 7|METHODS
P11760398A0553|25 33|patients
P11760398A0553|39 41|BS
P11760398A0553|50 58|patients
P11760398A0553|86 96|conditions
P11760398A0553|119 127|presence
P11760398A0553|131 138|absence
P11760398A0553|146 154|features
P11760398A0553|158 160|BS
P11760398A0553|164 169|means
P11760398A0553|184 188|form
P11760398A0553|226 238|ISG criteria
P11760796A0698|0 8|Evidence
P11760796A0698|23 38|PHACES syndrome
P11760796A0698|55 66|association
P11760796A0698|78 90|phakomatosis
P11760796A0698|100 107|studies
P11760796A0698|128 133|light
P11760796A0698|156 166|background
P11761601A0133|2 18|computer program
P11761601A0133|20 30|ACCESS-IAQ
P11761601A0133|61 76|airflow pattern
P11761601A0133|82 94|time history
P11761601A0133|102 128|contaminant concentrations
P11761601A0133|145 149|zone
P11761601A0133|159 179|inhalation exposures
P11763176A0918|19 27|decrease
P11763176A0918|31 52|antithrombin activity
P11763176A0918|80 91|experiments
P11763176A0918|100 110|experiment
P11763176A0918|146 147|%
P11764062A0000|4 34|Penn State Worry Questionnaire
P11764062A0000|39 47|Children
P11764062A0000|49 55|PSWQ-C
P11764062A0000|70 95|self-report questionnaire
P11764062A0000|124 132|tendency
P11764062A0000|136 144|children
P11764062A0000|201 206|worry
P11764062A0000|208 216|Chorpita
P11764062A0000|225 230|Behav
P11764226A0798|0 14|Classification
P11764226A0798|32 45|ILAR criteria
P11764226A0798|66 74|patients
P11764226A0798|80 88|patients
P11764226A0798|95 111|disease duration
P11764226A0798|121 127|months
P11764226A0798|165 179|EULAR criteria
P11765448A0588|10 26|X-ray projection
P11765448A0588|48 56|patients
P11766747A0000|39 45|review
P11766747A0000|54 62|patients
P11766747A0000|85 93|teratoma
P11768467A0000|0 23|Pyrethroid insecticides
P11768467A0000|43 54|agriculture
P11768467A0000|67 77|households
P11769229A0357|4 23|sorption mechanisms
P11769229A0357|37 47|adsorption
P11769229A0357|51 60|partition
P11769229A0357|68 75|process
P11769229A0357|91 99|sorption
P11771979A1141|34 45|variability
P11771979A1141|49 60|LDF signals
P11771979A1141|87 96|microflow
P11771979A1141|112 117|range
P11771979A1141|132 139|methods
P11771979A1141|153 159|organs
P11771979A1141|161 164|LDF
P11771979A1141|181 188|mapping
P11771979A1141|237 250|heterogeneity
P11771979A1141|274 285|vasculature
P11773168A0915|19 27|survival
P11773168A0915|29 31|OS
P11773168A0915|54 62|survival
P11773168A0915|64 67|PFS
P11773168A0915|69 74|rates
P11773168A0915|84 85|%
P11773168A0915|94 95|%
P11773168A0915|100 105|arm A
P11773168A0915|114 115|%
P11773168A0915|124 125|%
P11773168A0915|130 135|arm B
P11773168A0915|137 138|P
P11773168A0915|149 150|P
P11773921A0397|0 7|METHODS
P11773921A0397|9 30|P-selectin expression
P11773921A0397|67 76|platelets
P11773921A0397|81 85|flow
P11773921A0397|121 132|clopidogrel
P11773921A0397|141 145|dose
P11773921A0397|167 171|days
P11773921A0397|178 186|patients
P11773921A0397|201 215|artery disease
P11773921A0397|220 228|patients
P11773921A0397|232 237|group
P11773921A0397|253 255|mg
P11773921A0397|259 270|clopidogrel
P11773921A0397|283 295|implantation
P11773921A0397|303 311|patients
P11773921A0397|315 320|group
P11773921A0397|350 361|clopidogrel
P11773921A0397|370 374|dose
P11773921A0397|395 399|dose
P11773921A0397|406 408|mg
P11773921A0397|412 423|clopidogrel
P11773921A0397|433 439|groups
P11775180A0379|21 32|exploration
P11775180A0379|49 55|survey
P11775180A0379|63 84|gamma-detecting probe
P11775301A0797|3 9|effect
P11775301A0797|17 29|intervention
P11775301A0797|33 50|depression scores
P11776922A0830|13 22|sclerosis
P11776922A0830|27 37|resorption
P11776922A0830|45 55|skull base
P11776922A0830|59 64|cases
P11776922A0830|68 73|group
P11776922A0830|76 83|lesions
P11776922A0830|90 95|group
P11776922A0830|99 106|lesions
P11777575A0363|4 12|quantity
P11777575A0363|21 31|population
P11777575A0363|36 46|bulgaricus
P11777575A0363|48 63|S. thermophilus
P11777575A0363|91 97|pellet
P11777575A0363|101 105|PyMS
P11777575A0363|115 119|data
P11777575A0363|155 163|networks
P11777575A0363|165 169|ANNs
P11777632A1678|0 2|AF
P11777632A1678|38 45|pattern
P11777632A1678|49 59|expression
P11777632A1678|104 113|component
P11777632A1678|128 134|breast
P11777632A1678|146 153|lesions
P11777632A1678|177 181|loss
P11777632A1678|185 198|AF expression
P11777632A1678|233 246|breast cancer
P11777632A1678|259 265|stroma
P11778044A0000|16 49|probability density distributions
P11778044A0000|74 84|properties
P11778044A0000|92 106|climate system
P11778044A0000|125 148|fingerprinting approach
P11778044A0000|160 171|simulations
P11778044A0000|191 215|complexity climate model
P11778044A0000|236 247|diagnostics
P11778044A0000|258 278|climate observations
P11778804A0179|0 9|Frequency
P11778804A0179|20 26|curves
P11778804A0179|49 55|method
P11778804A0179|72 75|FDT
P11781615A0000|26 33|disease
P11781615A0000|35 40|cGVHD
P11781615A0000|53 65|complication
P11781615A0000|94 114|cell transplantation
P11782218A0349|12 26|white-on-white
P11782218A0349|28 31|W-W
P11782218A0349|33 42|perimetry
P11782218A0349|44 48|SWAP
P11782218A0349|83 94|variability
P11782218A0349|115 125|estimation
P11782218A0349|129 138|threshold
P11782218A0349|147 163|media absorption
P11782218A0349|175 195|examination duration
P11782218A0349|214 229|learning effect
P11783457A0000|0 13|Preservatives
P11783457A0000|31 40|component
P11783457A0000|55 67|preparations
P11783457A0000|93 101|activity
P11783457A0000|109 115|bottle
P11783457A0000|131 144|decomposition
P11783457A0000|155 159|drug
P11785085X0001|12 20|analysis
P11785085X0001|32 42|techniques
P11785085X0001|56 64|drainage
P11785085X0001|68 76|patients
P11785085X0001|102 113|prostatitis
P11785085X0001|119 127|efficacy
P11785085X0001|141 149|drainage
P11785085X0001|170 187|vacuum aspiration
P11785085X0001|189 202|Introl-4 unit
P11785085X0001|220 238|pneumovibromassage
P11785085X0001|240 248|PVM-R-01
P11785085X0001|271 279|patients
P11785085X0001|305 316|prostatitis
P11785827A0986|4 11|results
P11785827A0986|29 37|relation
P11785827A0986|52 58|models
P11785827A0986|68 79|propagation
P11785827A0986|84 94|physiology
P11785827A0986|138 149|degradation
P11785827A0986|159 165|forest
P11785827A0986|182 200|selection pressure
P11785827A0986|205 221|transmissibility
P11785827A0986|231 244|communication
P11786248A1162|0 11|Consumption
P11786248A1162|16 25|% sucrose
P11786248A1162|58 65|lesions
P11786248A1162|73 77|PPTg
P11786248A1162|83 87|PPTg
P11786248A1162|97 101|rats
P11786248A1162|132 133|%
P11786248A1162|140 149|% sucrose
P11786248A1162|155 168|sham controls
P11786945A0958|10 17|freedom
P11786945A0958|35 46|arrhythmias
P11786945A0958|57 66|follow-up
P11786945A0958|83 84|%
P11786945A0958|88 95|group A
P11787041A0167|7 18|development
P11787322X0001|0 9|Influence
P11787322X0001|23 30|methods
P11787322X0001|34 55|chemical disinfection
P11787322X0001|72 82|properties
P11787322X0001|86 90|type
P11787322X0001|98 106|V gypsum
P11787322X0001|121 132|instruments
P11787322X0001|137 146|materials
P11787322X0001|166 180|prosthodontics
P11787322X0001|190 195|stone
P11787322X0001|210 221|impressions
P11787322X0001|237 244|records
P11787322X0001|276 286|literature
P11787322X0001|291 299|vehicles
P11787322X0001|303 315|transmission
P11787322X0001|330 338|diseases
P11787720A1313|14 18|milk
P11787720A1313|38 46|decrease
P11787720A1313|59 63|acid
P11787720A1313|65 68|C18
P11787720A1313|70 72|n6
P11787720A1313|78 79|%
P11787720A1313|91 92|P
P11787720A1313|118 122|acid
P11787720A1313|124 127|C20
P11787720A1313|129 131|n6
P11787720A1313|137 138|%
P11787720A1313|140 141|P
P11787746A0374|0 10|Vitrectomy
P11787746A0374|15 22|removal
P11787746A0374|35 49|lens fragments
P11787746A0374|71 77|acuity
P11787746A0374|100 108|glaucoma
P11787746A0374|116 124|majority
P11787746A0374|128 136|patients
P11789206A1182|0 11|CONCLUSIONS
P11789206A1182|17 26|mechanism
P11789206A1182|30 34|MIRI
P11789206A1182|38 51|Qi deficiency
P11789206A1182|56 68|blood stasis
P11789206A1182|72 75|TCM
P11789206A1182|90 100|principles
P11789206A1182|121 123|Qi
P11789206A1182|141 153|blood stasis
P11789216T0001|0 7|Effects
P11789216T0001|22 39|blood circulation
P11789216T0001|50 62|blood stasis
P11789216T0001|66 80|barrier action
P11789216T0001|92 96|wall
P11789216T0001|117 126|gastritis
P11790897T0000|10 18|patterns
P11790897T0000|22 28|nipple
P11790897T0000|38 44|fluids
P11790897T0000|57 66|SELDI-TOF
P11790897T0000|68 77|potential
P11790897T0000|86 96|biomarkers
P11790897T0000|111 120|diagnosis
P11790897T0000|124 137|breast cancer
P11791292A0193|17 27|laboratory
P11791292A0193|41 52|application
P11791292A0193|63 70|network
P11791292A0193|85 92|problem
P11791571T0000|2 53|high-efficiency cross-flow micronebulizer interface
P11791571T0000|68 83|electrophoresis
P11791571T0000|108 132|plasma mass spectrometry
P11791585A0287|4 14|electrodes
P11791585A0287|68 71|use
P11791585A0287|145 152|surface
P11791853A0532|17 24|results
P11791853A0532|41 77|coagulation-electrooxidation process
P11791853A0532|107 112|color
P11791853A0532|121 124|COD
P11791853A0532|148 158|wastewater
P11792586A0290|7 14|loading
P11792586A0290|18 22|bone
P11792586A0290|43 51|activity
P11792586A0290|65 74|formation
P11792586A0290|78 89|microcracks
P11792586A0290|101 114|tissue matrix
P11792586A0290|126 130|bone
P11793172A0545|19 26|surface
P11793172A0545|34 41|PE head
P11793172A0545|63 67|time
P11793172A0545|74 77|THA
P11793172A0545|87 107|friction coefficient
P11793172A0545|160 167|PE head
P11793614A0000|0 9|OBJECTIVE
P11793614A0000|28 32|lack
P11793614A0000|36 42|effect
P11793614A0000|59 73|concentrations
P11793614A0000|77 87|cilomilast
P11793614A0000|100 117|phosphodiesterase
P11793614A0000|120 129|inhibitor
P11793614A0000|138 147|treatment
P11793614A0000|181 188|disease
P11793614A0000|210 225|anticoagulation
P11796977T0000|0 8|Postdocs
P11796977T0000|14 22|hardship
P11796977T0000|30 45|mainland Europe
P11800119A0814|4 20|design principle
P11800119A0814|40 54|vibration mode
P11800586A1090|12 21|DPPD gene
P11800586A1090|56 63|bacilli
P11800586A1090|71 78|results
P11800586A1090|97 105|molecule
P11800586A1090|127 131|tool
P11800586A1090|152 161|diagnosis
P11800586A1090|165 177|tuberculosis
P11800878T0000|0 15|Dynamic imaging
P11800878T0000|27 41|wave functions
P11800878T0000|47 73|ultrashort UV laser pulses
P11801459T0000|0 8|Efficacy
P11801459T0000|13 19|safety
P11801459T0000|23 30|aspirin
P11801459T0000|48 58|management
P11801459T0000|62 78|atherothrombosis
P11802580A0000|4 38|General Practice Research Database
P11802580A0000|40 44|GPRD
P11802580A0000|53 58|world
P11802580A0000|69 90|computerized database
P11802580A0000|118 133|patient records
P11802580A0000|147 155|practice
P11802580A0000|179 199|health research tool
P11802601A0107|5 10|paper
P11802601A0107|23 30|results
P11802601A0107|36 52|laboratory study
P11802601A0107|56 64|aldicarb
P11802601A0107|78 89|metabolites
P11802601A0107|91 107|aldicarb sulfone
P11802601A0107|112 130|aldicarb sulfoxide
P11803325A0868|9 25|DC cardioversion
P11803325A0868|46 55|HBS group
P11803325A0868|67 69|DC
P11803325A0868|77 86|CBC group
P11803325A0868|99 101|DC
P11803325A0868|109 118|GIK group
P11804081A0552|6 12|August
P11804081A0552|23 27|ENRP
P11804081A0552|53 57|tons
P11804081A0552|61 63|TP
P11804081A0552|102 112|Everglades
P11804100A0365a|22 35|disappearance
P11804100A0365a|39 43|BOD5
P11804100A0365a|48 53|NH3-N
P11804100A0365a|94 102|kinetics
P11804100A0365a|112 120|kinetics
P11804100A0365a|124 134|TP removal
P11804100A0365b|22 35|disappearance
P11804100A0365b|39 43|BOD5
P11804100A0365b|48 53|NH3-N
P11804100A0365b|94 102|kinetics
P11804100A0365b|112 120|kinetics
P11804100A0365b|124 134|TP removal
P11804510A0730|0 6|Losses
P11804510A0730|10 23|dichlofluanid
P11804510A0730|27 28|%
P11804510A0730|31 43|chlozolinate
P11804510A0730|47 48|%
P11804510A0730|55 66|etridiazole
P11804510A0730|70 71|%
P11804510A0730|118 128|processing
P11804510A0730|132 138|apples
P11804510A0730|175 181|levels
P11804510A0730|197 198|%
P11804510A0730|227 237|processing
P11806132A0253|4 16|TB incidence
P11806132A0253|25 30|AIRIN
P11806132A0253|32 36|area
P11806132A0253|52 65|% TB patients
P11806132A0253|94 98|rate
P11810685A0147|21 46|displacement distribution
P11810685A0147|67 70|MRI
P11810685A0147|89 101|displacement
P11810685A0147|115 116|r
P11810685A0147|126 141|long-wavelength
P11810685A0147|155 156|q
P11810685A0147|158 164|limits
P11810685A0147|177 179|3D
P11810685A0147|189 214|displacement distribution
P11810685A0147|226 232|DT-MRI
P11811743A0800|4 13|procedure
P11811743A0800|30 39|retention
P11811743A0800|69 81|Class III FI
P11811743A0800|87 93|manner
P11811743A0800|117 124|patient
P11811743A0800|133 142|clinician
P11811825A0972|4 11|results
P11811825A0972|28 56|cross-validation experiments
P11811825A0972|75 82|average
P11811825A0972|88 94|system
P11811825A0972|109 120|specificity
P11811825A0972|158 175|sensitivity level
P11815644A0081|13 28|characteristics
P11815644A0081|38 43|calls
P11815644A0081|55 62|species
P11815644A0081|66 69|bat
P11815644A0081|75 85|variations
P11815644A0081|104 110|timing
P11815644A0081|115 123|patterns
P11815644A0081|139 157|muscle recruitment
P11815644A0081|165 177|echolocation
P11816458A0319|13 21|Examples
P11816458A0319|26 38|Explanations
P11816458A0319|42 50|APA Form
P11816458A0319|63 74|help system
P11816458A0319|80 88|examples
P11816458A0319|104 112|sections
P11816458A0319|118 132|review article
P11816458A0319|134 149|journal article
P11816458A0319|163 173|experiment
P11816458A0319|178 193|journal article
P11816458A0319|215 226|experiments
P11816779A0343|4 16|drug packets
P11816779A0343|27 41|acetyl aspirin
P11816779A0343|43 56|acetaminophen
P11816779A0343|61 76|chloramphenicol
P11818675X0897|0 9|Karger AG
P11818675X0897|11 16|Basel
P11819326A0000|0 3|AIM
P11819326A0000|22 26|role
P11819326A0000|42 48|status
P11819326A0000|62 70|patients
P11819326A0000|103 117|encephalopathy
P11819326A0000|119 122|PSE
P11819326A0000|124 131|METHODS
P11819326A0000|156 164|patients
P11819326A0000|170 179|cirrhosis
P11819326A0000|188 191|PSE
P11819326A0000|248 258|volunteers
P11821098A0269|0 20|MAIN OUTCOME MEASURE
P11821098A0269|21 22|S
P11821098A0269|25 37|Serum levels
P11821098A0269|41 44|FSH
P11821098A0269|46 48|LH
P11821098A0269|54 63|inhibin A
P11821098A0269|68 70|B.
P11822790A0907|4 12|instance
P11822790A0907|22 31|SIP score
P11822790A0907|49 56|patient
P11822790A0907|64 65|%
P11822790A0907|88 95|example
P11822790A0907|112 117|score
P11822790A0907|125 141|study population
P11822790A0907|175 176|%
P11822790A0907|197 202|items
P11822790A0907|215 226|improvement
P11822790A0907|234 255|reproducibility noise
P11822811A0319|0 5|Group
P11822811A0319|26 33|Collies
P11822811A0319|61 86|microg/kg ivermectin p.o.
P11822811A0319|113 117|VMTH
P11822811A0319|120 125|hours
P11822811A0319|132 144|intoxication
P11824701A0894|0 8|Patients
P11824701A0894|34 39|event
P11824701A0894|56 60|Type
P11824701A0894|63 80|behavior patterns
P11824701A0894|92 106|Bortner scores
P11824701A0894|112 120|patients
P11824701A0894|149 154|event
P11824801A0661|15 27|continuation
P11824801A0661|35 53|interferon therapy
P11824801A0661|61 69|presence
P11824801A0661|92 104|exacerbation
P11824801A0661|108 119|sarcoidosis
P11824801A0661|137 145|minority
P11824801A0661|149 157|patients
P11824801A0661|175 192|organ involvement
P11825801A1212|27 36|mortality
P11825801A1212|63 72|follow-up
P11825801A1212|79 85|months
P11826141T0000|12 19|effects
P11826141T0000|23 45|lidocaine inactivation
P11826141T0000|53 60|rostral
P11826141T0000|84 92|amygdala
P11826141T0000|100 111|maintenance
P11826141T0000|116 129|reinstatement
P11826141T0000|149 157|behavior
P11826141T0000|161 165|rats
P11828186A0239|4 14|population
P11828186A0239|38 41|men
P11828186A0239|51 56|women
P11828186A0239|68 73|years
P11828186A0239|92 105|heart disease
P11828186A0239|115 131|CRP measurements
P11828186A0239|139 160|Third National Health
P11828186A0239|165 193|Nutrition Examination Survey
P11828186A0239|195 205|NHANES III
P11830544A0335|0 9|Herceptin
P11830544A0335|32 37|HER-2
P11830544A0335|38 49|neu antigen
P11830544A0335|66 70|size
P11830544A0335|75 77|nm
P11830544A0335|86 93|1B4M-Gd
P11830544A0335|137 150|WIBC-9 tumors
P11830544A0335|176 195|control MC-5 tumors
P11830544A0335|222 234|angiogenesis
P11831512A0468|12 16|pigs
P11831512A0468|45 46|d
P11831512A0468|50 53|age
P11831512A0468|92 102|treatments
P11831512A0468|107 114|control
P11831512A0468|120 127|lactose
P11831512A0468|135 154|carbohydrate source
P11831512A0468|159 166|lactose
P11831512A0468|177 181|gram
P11831512A0468|186 190|gram
P11831512A0468|197 200|CSS
P11831512A0468|202 221|dextrose equivalent
P11831512A0468|223 225|DE
P11831512A0468|239 246|lactose
P11831512A0468|261 266|DE-42
P11832019A0668|0 11|CONCLUSIONS
P11832019A0668|13 17|AMVT
P11832019A0668|51 68|emergency disease
P11833863A0987|13 23|difference
P11833863A0987|27 41|apnea duration
P11833863A0987|54 60|supine
P11833863A0987|71 80|positions
P11834476A1187|22 34|animal model
P11834476A1187|54 62|ischemia
P11834476A1187|72 83|transfusion
P11834476A1187|94 97|min
P11834476A1187|104 112|ischemia
P11834476A1187|138 160|hemoglobin transfusion
P11834476A1187|173 189|oxygen transport
P11834476A1187|206 212|cortex
P11834476A1187|222 230|increase
P11834476A1187|274 284|protection
P11835109A0000|48 57|awareness
P11835109A0000|65 75|importance
P11835109A0000|106 113|quality
P11835109A0000|117 121|life
P11835109A0000|123 127|HRQL
P11835109A0000|132 140|patients
P11835109A0000|166 175|disorders
P11835109A0000|197 203|trials
P11836046A0549|51 53|mg
P11836046A0549|57 74|calcium carbonate
P11836046A0549|80 82|mg
P11836046A0549|96 103|calcium
P11836046A0549|112 115|end
P11836046A0549|121 125|meal
P11836046A0549|132 137|times
P11836046A0549|140 143|day
P11836046A0549|145 152|group A
P11836046A0549|154 155|n
P11836046A0549|163 180|calcium carbonate
P11836046A0549|193 199|manner
P11836046A0549|211 217|mg/day
P11836046A0549|239 247|estrogen
P11836046A0549|254 277|mg medrogestone acetate
P11836046A0549|283 286|day
P11836046A0549|297 302|month
P11836046A0549|304 311|group B
P11836046A0549|313 314|n
P11836303A0518|0 8|TNFalpha
P11836303A0518|13 24|IL-6 levels
P11836303A0518|48 68|culture supernatants
P11836303A1191|16 21|study
P11836303A1191|53 64|disturbance
P11836303A1191|86 92|change
P11836303A1191|96 112|cytokine biology
P11836303A1191|162 167|stage
P11837409A0584|24 51|National Longitudinal Study
P11837409A0584|55 72|Adolescent Health
P11837409A0584|80 87|measure
P11837409A0584|102 116|symptomatology
P11837409A0584|135 143|interval
P11838058A0084|0 7|METHODS
P11838058A0084|11 16|cases
P11838058A0084|46 62|tissue expansion
P11838058A0084|64 68|CITE
P11838058A0084|76 81|cases
P11838058A0084|116 132|tissue expansion
P11838058A0084|134 138|CPTE
P11838058A0084|160 165|study
P11838102T0001|0 7|Wegener
P11838102T0001|10 24|granulomatosis
P11840365A0949|24 30|effect
P11840365A0949|34 44|hematocrit
P11840365A0949|52 72|General Health scale
P11840365A0949|80 85|SF-36
P11840365A0949|87 88|P
P11842037A0327|18 28|precisions
P11842037A0327|37 62|% urine-plasma difference
P11842037A0327|86 91|value
P11842728X0001|20 35|schistosomiasis
P11842728X0001|37 51|Schistosomosis
P11842728X0001|66 74|diseases
P11842728X0001|85 97|blood flukes
P11842728X0001|105 122|Schistosoma genus
P11843252A0907|9 22|response rate
P11843252A0907|29 30|%
P11843252A0907|34 55|% confidence interval
P11843252A0907|59 63|% CI
P11843252A0907|67 68|%
P11843252A0907|71 72|%
P11843252A0907|97 105|survival
P11843252A0907|113 119|months
P11844591A0329|22 31|parameter
P11844591A0329|38 43|angle
P11844591A0329|55 66|peak torque
P11844591A0329|68 71|APT
P11844812A0915|17 28|ng/mL model
P11844812A0915|34 37|AUC
P11844812A0915|45 58|ANN ROC curve
P11844812A0915|93 97|AUCs
P11844812A0915|102 112|percentage
P11844812A0915|121 124|PSA
P11844812A0915|126 127|P
P11844812A0915|137 143|PSA-TZ
P11844812A0915|145 146|P
P11844812A0915|160 171|PSA density
P11844812A0915|182 197|prostate volume
P11844812A0915|199 200|P
P11845547A0449|10 20|treatments
P11845547A0449|29 39|dobutamine
P11845547A0449|41 64|KATP channel activators
P11845547A0449|70 86|21-aminosteroids
P11846167A0000|0 8|Selenium
P11846167A0000|25 32|element
P11846167A0000|37 43|humans
P11846167A0000|45 52|animals
P11846167A0000|62 69|species
P11846167A0000|73 87|microorganisms
P11846187A0894|4 23|GT-foreign-pictures
P11846187A0894|40 48|judgment
P11846187A0894|58 66|subjects
P11846187A0894|94 117|permeability directions
P11847580T0000|14 27|cholecystitis
P11847580T0000|41 49|findings
P11849417A0900|0 3|Age
P11849417A0900|30 36|groups
P11849417A0900|67 74|RESULTS
P11849417A0900|83 93|initiation
P11849417A0900|97 117|dialysis PD patients
P11849417A0900|139 144|years
P11849417A0900|154 155|P
P11849417A0900|171 182|HD patients
P11849796A0452|0 7|RESULTS
P11849796A0452|13 24|target dose
P11849796A0452|47 53|3D-CRT
P11849796A0452|58 68|IMRT plans
P11849796A0452|79 91|improvements
P11849796A0452|122 133|IMRT fields
P11851941A0372|37 56|serumalbumin method
P11851941A0372|70 82|blood volume
P11851941A0372|89 102|haemodilution
P11851941A0372|134 145|haemoglobin
P11851941A0372|150 160|comparison
P11851941A0372|168 186|reference solution
P11851941A0372|190 209|hydroxyethyl starch
P11851941A0372|211 214|HES
P11852907A0871|4 34|equilibrium phosphorus content
P11852907A0871|36 40|EPC0
P11852907A0871|45 57|surface soil
P11852907A0871|88 99|SRP content
P11852907A0871|103 117|drainage water
P11852907A0871|126 130|farm
P11852907A0871|136 141|order
P11852907A0871|145 154|magnitude
P11853943A0122|14 24|prediction
P11853943A0122|40 49|algorithm
P11853943A0122|54 77|R-R interval estimation
P11858256A0102|21 29|research
P11858256A0102|34 45|explanation
P11858256A0102|54 60|effect
P11858548A0241|4 13|structure
P11858548A0241|40 45|study
P11858548A0241|53 57|mono
P11858548A0241|77 88|NMR spectra
P11858548A0241|93 110|mass spectrometry
P11858635A0896|34 42|property
P11858635A0896|46 57|QSAR models
P11858635A0896|74 94|LOO cross-validation
P11859400A0229|16 24|efficacy
P11859400A0229|29 34|costs
P11859400A0229|38 50|valacyclovir
P11859400A0229|65 81|HSV reactivation
P11859400A0229|88 91|HSV
P11859400A0229|116 147|progenitor cell transplantation
P11859400A0229|149 153|APCT
P11859400A0229|155 163|patients
P11859400A0229|180 188|controls
P11859400A0229|209 218|acyclovir
P11859400A0229|225 240|HSV prophylaxis
P11859943A0150|4 10|adults
P11859943A0150|25 43|outpatient clinics
P11859943A0150|64 72|hospital
P11859943A0150|90 94|days
P11859943A0150|118 146|General Health Questionnaire
P11860097A1695|0 4|Data
P11860097A1695|8 22|prosthesis use
P11860097A1695|61 66|study
P11860097A1695|107 114|outcome
P11860097A1695|119 135|prosthesis users
P11860097A1695|140 149|non-users
P11860723A0182|2 13|mail survey
P11860723A0182|17 32|Georgia members
P11860723A0182|40 56|American College
P11860723A0182|60 73|Obstetricians
P11860723A0182|78 91|Gynecologists
P11860876A0409|0 15|HIV-1 C subtype
P11860876A0409|19 23|IDUs
P11860876A0409|42 43|%
P11861092A0730|7 14|plateau
P11861092A0730|18 29|enhancement
P11861092A0730|52 58|lesion
P11861092A0730|67 74|patient
P11861092A0730|118 132|scanning modes
P11861092A0730|151 156|scale
P11861092A0730|158 161|FGS
P11861092A0730|176 190|colour Doppler
P11861092A0730|192 195|FCD
P11861092A0730|210 223|power Doppler
P11861092A0730|225 228|FPD
P11861092A0730|252 257|scale
P11861092A0730|259 262|HGS
P11861092A0730|275 289|inversion mode
P11861092A0730|291 294|Pim
P11861092A0730|305 320|HDI5000 scanner
P11861092A0730|325 335|C5-2 probe
P11861092A0730|337 340|ATL
P11861092A0730|342 349|Bothell
P11861092A0730|351 353|WA
P11862350T0000|14 19|study
P11862350T0000|27 34|effects
P11862350T0000|38 51|carbamazepine
P11862350T0000|60 95|NMDA receptor antagonist remacemide
P11862350T0000|99 112|road tracking
P11862350T0000|131 142|performance
P11862350T0000|153 160|traffic
P11863811A0259|26 40|Nusselt number
P11863811A0259|59 60|%
P11863811A0259|70 75|range
P11863811A0259|79 81|Pr
P11863811A0259|97 107|experiment
P11864173T0000|19 28|pathogens
P11864173T0000|32 38|causes
P11864173T0000|42 46|type
P11864173T0000|55 68|exacerbations
P11864173T0000|80 90|bronchitis
P11865218A0069|0 9|Treatment
P11865218A0069|19 28|condition
P11865218A0069|44 47|use
P11865218A0069|53 66|wax softening
P11865218A0069|81 86|agent
P11866130A0419|3 11|addition
P11866130A0419|13 23|benzocaine
P11866130A0419|28 44|2-phenoxyethanol
P11866130A0419|55 74|complement activity
P11866130A0419|79 91|phagocytosis
P11866130A0419|99 104|MS222
P11866130A0419|109 128|quinaldine sulphate
P11867388A0502|4 6|EC
P11867388A0502|15 26|suppression
P11867388A0502|40 46|memory
P11867388A0502|52 65|concentration
P11867388A0502|77 83|memory
P11867388A0502|89 90|%
P11867388A0502|95 112|fear conditioning
P11867388A0502|116 123|context
P11867388A0502|132 133|%
P11867388A0502|149 150|%
P11867388A0502|152 156|mean
P11867388A0502|168 171|SEM
P11867388A0502|182 199|fear conditioning
P11867388A0502|203 207|tone
P11867388A0502|216 217|%
P11867388A0502|233 234|%
P11867388A0502|237 238|P
P11870646A0668|4 11|utility
P11870646A0668|20 28|analyses
P11870646A0668|36 42|design
P11870646A0668|46 79|ceramic/substrate bilayer systems
P11870646A0668|92 102|resistance
P11870646A0668|127 133|damage
P11872359A0000|26 44|insulin resistance
P11872359A0000|46 48|IR
P11872359A0000|62 69|cluster
P11872359A0000|88 95|disease
P11872359A0000|97 100|CVD
P11872359A0000|102 114|risk factors
P11872359A0000|141 149|syndrome
P11872359A0000|152 155|CVD
P11872359A0000|169 174|cause
P11872359A0000|188 197|mortality
P11872359A0000|215 226|Australians
P11872570T0000|0 8|Dementia
P11872570T0000|29 32|NHS
P11872570T0000|44 48|care
P11873003X0000|0 15|HIV-1 infection
P11873003X0000|25 31|Africa
P11873003X0000|44 54|difference
P11873003X0000|65 69|time
P11873003X0000|73 77|AIDS
P11873003X0000|82 90|survival
P11873003X0000|128 137|countries
P11873003X0000|139 149|OBJECTIVES
P11873003X0000|167 184|progression times
P11873003X0000|188 203|HIV-1 infection
P11873003X0000|209 223|seroconversion
P11873003X0000|227 231|AIDS
P11873003X0000|239 244|death
P11873003X0000|250 254|time
P11873003X0000|277 281|AIDS
P11873003X0000|285 290|death
P11873003X0000|300 306|Uganda
P11874637A0212|4 7|use
P11874637A0212|40 47|therapy
P11874637A0212|49 54|HAART
P11874637A0212|84 96|improvements
P11874637A0212|104 113|treatment
P11874637A0212|117 130|HIV infection
P11874637A0212|144 152|decrease
P11874637A0212|160 169|incidence
P11874637A0212|174 182|severity
P11874637A0212|210 229|deficiency syndrome
P11874637A0212|231 235|AIDS
P11874637A0212|245 257|malignancies
P11875695A0718|0 4|Time
P11875695A0718|8 19|progression
P11875695A0718|26 32|months
P11875695A0718|38 44|months
P11875695A0718|60 68|survival
P11875695A0718|74 86|registration
P11875695A0718|94 100|months
P11875695A0718|104 108|% CI
P11875695A0718|114 120|months
P11876937A0261|0 7|Heparin
P11876